F527Src
Met-induced
proteins.7
D74
EGFR-TD
Counterbalancing
AFF3-RUNX1
G59A
First-strand
multilocus
5-6-fold
Buchon
BGeo
EGAS00001000255
METHODSCases
SHBC/SHBOC
ZNF-148
USP38
levels38
BJ
.Cardiomyocyte-specific
46/54.8
54ATG
SLC9A3R1
Glu-32
Lys→Arg
748–750
L-asparaginase
CCTCATCGTAACTACCCGCG
121.12-126.21
Gln367Pro
1.4–3.7
82-year-old
integrin/receptor
GCAGGAAGGAAGGAAAG
AGTCAGGAAATGGGCGTGAATTA
H125
IΚBΑ
proteins38
D1S2883
Hirota
ACGAGGACGACGACAGAGAT
MEK1*
FGFR112
SCG2
Koyama-Nasu
volume.44
processeswhich
RO1
T421/S424
TCF4-dn
wt-K-RAS
-7e
5'-CACCUGUCCCAACACCUCAtt-3
mod.
FGFR1-FGFR4
cpm/well
tocontain
5′-AAGGTGAAGG
Pellucidae
LacO
5′-GATCCACATCTGCTGGAAGG-3′
5′-CCACTGTACCCAGCCTAATC-3′
68055
r.
Bmp
cell‐intrinsic
.1255124G4A
758-fold
C212/C213
neo-transfected
nt389A→G
T198E
–1.24
TMEM97
12/05/07
rasfamily
mucocellulare
state-of-
stable/quiescent
.Commercially
10°C
UniProtKB/TrEMBL
LM-30.1
PKC412-resistant
.IP-WB
M2001S
0.396
.CREB1
figs.6D6D
mutigenerational
A/G-agarose
Muto1
48–66
Srb7
CR:59
CASK
18/38
halfwere
Brekke
ub-γ-H2AX
Kornfeld
commonly.38–40,42,46
GraphicN
NaCl/10
Epi
320-specific
lung22
treatment.Regarding
observations18
FA1333
THR183/TYR185
Nfya
.Immunodeficient
manner.Figure
Cys-
5′-UGU
KIT77
bindingf
3201
GAGAGCGCGG
D55D5
SJL-Ptprca
PCR-restriction
colonic-distention
ABLIM2
0.6—19.1
0.88mM
DH10B
.Anti-pan-p85
W33L+
Herlev
hERαLBD
R775H
B-lineage
Auer-like
heteroduplexDNA
.Babu
checkpoints76
.3D3D
C-FAM-labeled
complex3
GFP–VHL213-I151S-expressing
mutS
HED351Y
eHybrid
R866C
RP11-268D21
rhabdomyoblasts
Nervy/MYND
ultra-low-attachment
HNF-3
deleted.36
lactacystin
NOTCH-1
NH3T3
59-TGGGACAACGGGAGTCACTCTC-39
pLenti-puro
CoolSnap
Armaillo
SPRN
//www.mmruv.info
SD-ura
ATG-7G
BRD1
5′-CGTAGCTCCAGACATCACTCTG-3′
LTR-ret
1,13
Swiss-3T3
inguinal/pelvic
assaysThe
-AAGCCGAAGGGCTCCCACTG-3
72-month
aatatgaag
S502A/L
Dishevelled-associated
cases9–16
29_
Tu-7
GOT3
myoblast-specific
MCDB
MYC-flanking
5'-ACG
whole-tumor
CD34+CD38−
3q25-27
anti-digoxigenin
Stelow
OF7
Hoareau-Aveilla
Bcor−/Y
Gaq
2218+71delAG
achieved.18
LSL-K-rasG12D/+
`contact
2–5-bp
E356K
340/
pM-CSF-R-luc21
GD693por
PLU
Del57L
,0.0001f
V315L
inactivation17
ATF3-regulated
siPPP6C07
differentiation.74
5'-gcaagcttatgggtttctacggcacatt-3
chemilluminescence
2.0–213.0
60:40
method.32
Thr319
.DCAF1
triphosphate-containing
Skaletsky
Src-family
dorsovental
trials.4–7
2.63
RAS-targeting
described.3,9-11
hyperpigmentation
59.2
p.Human
dPrediction
lymphopoiesis17,18
RETINOBLASTOMA
Atherosclerosis
A190-108A
349-440
pGAD-rafl
Tyr1020
X-EDA-ID
siRNA-
Oregon-green
ACAAAAACC
proof-of-principle
PP6-PD
Em-N-myc
12/14.2
pGEX-4
mutationswere
Zagariya
-MUT9
GCU
mini-prep
16,17,47
P'~3
5′-AGAAT
pp.748–757
SNF-1
HCT116Fbxw7−/−
117/200
detoxification
7.3-fold
5′-TAATGACTACCTAGGAATGAGTCG-3′
B-Lymphocytes
modifications.90,91
presenceof
nature.comB-RAF
Hs00195988_m1
3-row
EcoRI/HindIII
Australia37
DOBS
gain-
anti-TRiC
5′-CGTAACCGTTAACCCTCCAGGACAGGTAAGATTGAA-3′
Thefollowing
MIP-infected
766-FERC-769
stochastic—namely
ARST0332
TSC2-Rheb
D1-phosphate
Franche-Comte
RPMI8402
.Schaap
NKN/STSVL
64406
bold-face
1–151
5'-CAGACAGAAGGCGTTCACAA-3
EOL2
E542K-
pumps.7,8
3–287
400–500
RY
RhoA-2A-EGFP-pcDNA3.1
GGG-AAC
anti-CENP-C
intrachromatid
V470M
MIDN
Dnmt3a-heterozygous
guinea-pig
G719A.13
2-750
BH-p85α
891–88
PDGF-B-
ARA160
chemo-na¨ıve
patients.9,10,15,16
9.349
IOUS-guided
23/381—including
182,447
Asn11
cytometry.Cells
L127M
Acvr1
.H3255
virus–pseudotyped
GPCRs21
megencephalic
.TGS
FIG.8
Neuwald
.EGFR-mutated
ERα3
18,500
BIRC7
DPC4F1
delAsn771insGlyTyr,50
studies.5,18,19
Pol2
Berx
IC50≈24
small-animal
al,46
peilin
c.783C
thiocyanate-acid-phenol
9ab
cells.32,33
8,27
summared
α-1
D816Y-type
21–36
n=221
group.31
unglucosylated
Gp5d
Epo-sensitive
CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGTGCCTCTATTGTTGGATCATATTCGT
cells18
AGM
.Complete
Raf/ERK
Vav-iCre
CDK8-specific
Takara-Bio
thymine–DNA
larval/early
K42
L173P
non–protein-coding
Glu9213Lys
.Decrease
Ala662
MCL1-amplified
1TOT
5′-CTATGCTAGCATGGAGCAAACCGAAGGCGTGAG
E445
.HSC2
0.5–4
GR-dependent
89*
ggt-3′
R569H
4.48
PDGFRalpha-positive
ATCTACAGTCCCCCTTGCCG
Pearson-centred
0.423
44insA
//www.broadinstitute.org/cancer/cga/oncotator
7/113
'prophase-like
CBL_i8f
Lal
​Sequence
18–20
138D4
Amot
110.9
Cerosaletti
RhoGAP
Packham
TGGAGATTACGAATGTGCTG
Yap-targets
MDA1386LN—were
cases—five
p19Ink4D
Immunostained
polyallomer
ITrpS
RTK–phosphoinositide
GCB-DLBCLs
wt-PKBα
5,6,10-12
Method-S3
.JH1
—BCL10
Bentz
−2
C420R
ischaracterized
–86.3
chk1
anti-UBF1
Rictor
K-6
diphosphate–ribose
del14q
BRCA2/Rad51-mediated
.1168delT
phospho-Ser473
RSAVDTNLHNLQDYVE
WWP1-349-R
TE300
1,582.4
assay,37
macroseeding
CEPF-F9.2
36.5
HBCx
DH10Bac™
co-occupancy
C163
G/GM
EPR-
FLAG-Smad2
8.7003425
10-3076
5´-TGACACGGATGACGATGGGGAAGAC-3´
R175A
.Where
macronuclei
AML1-induced
V648G
667–922
Δ298–311
A_51_P481398
IRS-Luc
8,600
.DESIGN
32–51
algorithms.23
/M/dup
0·5
Tyr-236/Thr-253
.CaPO4-mediatedDNA
fluorescently
//tronolab.epfl.ch
200–300
Kuzmichev
1.4–2.2
CCCAACCCCAGGCCGGCATG
domain.28-31
FLT3-wt–
0.06-7.88
∼6.5-fold
99b
R111*
microF
PWM
Taniwaki
AAT→AAA
m-BCR
pep1
c.1753C
29E
_PIK3CA_
upkeep
miR-145*
m14
100–600
AML,38
Nonconservative
1H-PYRAZOL
Unresectable
GSP
0.7025
TSC1/TSC2/TBC1D7
12The
progres
211–403
substrate-specific
PI3K-PTEN
SFBIT
ke-87-Pro
8.514723
.Ets
sixty-six
BARD1-dependent
8http
pheral
bedGraphToBigWig
ZF7
.SU11274
genetiques
prephase
COOT
typic
4L
homoligomerization
2–3.5
TRK-specific
Italy.8
I80F
XRCC2
V173
ofintron
oncoprotein17,18
5'-AAGGACCTGGTGTCCTGTGC-3
Critchlow
HPV-42
//doi.org/10.1371/journal.pone.0087113.g002
CASP8-DEDs
Oxozeaenol
Levi-Montalcini
Rafexpressed
A10R2
PLC/PKC
HA-derived
NM_183322
GST-ODD
13C2D2-iodoacetamide
.Cytotoxic
FITC-GAA
¢gure
differentiated-type
S682F
3-nt
0.0132*
kindreds,6
39-HRYKPGTVAL-48
G183S
4–mutated
TCAGAGCCTGGACATCGTTT
2a–d
D3-position
MDM2-p53RE
miR-221
Naoe
positionally
Amyloidogenic
24-30°
.NRASG12V-independent
R636S
Lu-1875
TBS/1
DUSP-5
.Rab
hetero-oligomerize
4‐sulfophenyl
Thr-18
NrasLSL-G12D/+
47/97=
dysgeusia
3432
1/106
2683ins5
Bocciardi
CellPhect
H.Carlson
.RUNX1+/-
B1ΔCC1
Aα-mutants
Keratoacanthomas
2-phenylindole
4,6-diamino-
ins31
phenotyped
DMEM–10
AD872
Malades
0·32
25The
SIRT
~0.1
190915901–190986000
Q265P
562–585
signaling-pathway
−62
GGCCGGGACCTGACTGACTAC
BRAFV600E-specific
gca
Val726
150kD
leukemia6,10
PDE9–PDE11
TGFβ/Smad
Hck
Fig.4b
HA-7
anti-terminal
iron-binding
phospho-flow
Noushmehr
β-gal–positive
pronunciation
differentiation-stalled
Klionsky
4–36
WT–R249S
risk.38
132–214
'addiction
anti-NF-κBp65/RELA
Pugacheva
anoikis77
deletion/truncating
FA-N.
suppressed—at
al9
tRFP
superovulatory
C63G6
c.4458C
25,27,31
mid-cDNA
moiety.13,15
'at
MMR11
Isoform-specific
19–1,038
NP-3
PKI166-treated
mCMV-EF1
0.0114*
Ura–
NRPTP
BIC-seq
LM-196.4
mutations.4
Chi-squared
c-Abl-STI-571
siASF/SF2-a
dbSNP/1000
S45P
1,991
14024-6
2810A
rate/mg
inductor
WT-F1
peritrigonal
B-8
C13
granulocyte-derived
3.6-1g
FoxA2
specifi-
ZMIZ1–ABL1
17/22
GTP-induced
ST6GALNAC1-catalyzed
mesothelioma181
Ellerbroek
immuno-purified
.As
ADCJ
Y2274
O.21
D194E
MIGR1
ALK/crizotinib
Microspin
trans‑dominant
anti-phospho-ERK-1/2
QuickPure
65-66
prostate-cancer-associated
AGTTCAGAAGGTCAGCCTGC
77581
−670
DMH
www.nfdht.nl/
.01
Asp835Ala
limmavoom
6937del
.Gil
tumoural
W326
2-TRCN0000196969
G250D
MagPlex
N-ethylmaleimide
11q13.2-3
Erbb2
C/EBPα–knock-in
Vectashield
Sequentech
S2G
occur.4
1.13E06
GGACAGAGACATACA
research2,21,22
WI-38
WGS
5′-ATCAGTCTTCCTTCTACCCT-3′
40/387
zebrafish-CFC
import/
GTL.16.903.R1
Chakrabarti
effector.23
8n
ΔM2-BRCA1
Raf–MEK–ERK
HsRBP4
S6O
0,15
7,450
I1446
TyrGluGl
ZR75.30
class-A
R602
R246W
0.1-mol/l
.8,19
arms.10
inter-quartile
R755S
ApcS580
19-nucleotide
PASLI-like
Chk2/Rad53/Cds1
72.6
treatment.41
C72W
E-cadherin-negative
1678
pCMV6-XL6
U11/12
206/761
protein–protein
0.947
Â°dd-
acrylamide/bisacrylamide
27709
2-Mda
Gathiaka
septum
.EZH2
46*
sequence.Primers
Assessement
hypoxia-activated
EGLN1-treated
above.WNT
urothelial/bladder
tiers1-3
purifi
RSV-ER
sequencecontext.Functional
Takenaka
andJ.D.B
Anti-hemagglutinin
1.464
fgf-9
Osx-GFP-Cre
Cà-
E6201-induced
17477
FFPEmaterial
Q1480P
Cγ2
76°
EC-mutant
3′,5′-cyclic
keratinocyte‐specific
BMS-35482
L02
ankyrin-like
−896
Ligands—We
Control-1
PDGFRs
LNK,7
binding35
Scheull
LiCor
118-3
Thr389
blue\
Sweetenham
report.30
EGFP-fused
GAC→GTC
BRCC36-dependent
al.1
Agilent
GS-5
Phe233
NuRD
W493R
R104W
'TOP-flash
39–92
Corces
SRC-
RQ428,429
wortmaninn
AUC0-12h
against-the-grain
mass-spectroscopy
−0.3941
ERE3-TATA
^24891
FISH-positive
GLM
.927
c-kitint
BT106
−30.1
P2R
90,000/35
Y687
Lysine-949
six-well
TYK2I684S
microscale
self-association
1-593
∑hkl|Fobs
tumors.10
2Q–S
mutation.75
RetroNectin
hazard-ratio
demonstrated.41,42
methylases
P48R
Cy3.5
A_51_P466229
mutation-negative
.CHEK2.S428F
BRCA1-FL
p.P1675L
pylori-independent
4472
//broad.mit.edu/mpg/haploview
ER-resident
2E9W
TGF-β-induce
S'-cctcagctcaggccacacttgccgtctccctcccagGACAGGTCCCAGAAG
gtaacttaataaaaatgcatgcagcg
.Later
NCT00601913
antigen-4/anti-CTLA-4
expression65
3206
Tet1-deficiency
pY-proteins
1.57-5.78
NCSS
small-number
lipopolysaccharide-induced
37,38,39,40,41
CGGCCGCGGG
Novacastra
syndrome–associated
YL
Sproston
adeterminant
blue-staining
Cap-n-Collar
2600–2611
E.Sahai
Red-avidin
GCACGCUUAGAUUGGAAUA
5'-CAATGCTGACACAAATAAGG-3
FGFR1/3
RAS57
C302F
Franca-Koh
Dimri
v.2.0.5
LaserGene
SOS1—characterised
Bio-Products
IL-3-containing
C-Maf
13G
2-day-old
∼35–200
phospho-MAPK3
.SNPs
CCF-STTG1
600-MHz
Mohamedali
GGAGACCCGGT
Phospho-EGF
CA3
cortisol-induced
signaling104
P120RASGAP
RUNT
MREC/01/2/44
1,4,5,7,10
G652E
SOX17-overexpressing
coworkers.18,19
–31.5
rad50sc
IRAK2
.Allelotyping
GCCGTAGCTCTCGCCAAAG
vitro65
p.R161Q
RepeatMasker
stat92E/marrelle
deoxycytidine-treated
Virus-transduced
bs-3339R
PLCg-binding
salt-bridge
S119R
pT81luc
7.6–12.9
F254
5′-GATATAGCGTCCCAAAATAG-3′
F156
MKP-2-deficient
CD19Cre
21-83
cross-linker,13
Asp→Val
Tunyaplin
.Multikinase
103-bp
P841S
TSA-mediated
Runx1−/−Runx3−/−
.3248A
p.Y298S
H76
SOCS3
Jm−2
.Herein
P6.p
SPSS-20
KITK563-expressing
RETWT
EGFCA
P-Tyr1604
own.5
TAGAAGCAGCAGAGGAGAACC
doublet-containing
K.S
TTTCCAGAACCACACCCTTC
Keiichi
CATGTTCCTCAGCTTTATCAATC3′
N203S
3,4,15
mismatch.3
~circles
SorcererTM-SEQUEST®
gene-dense
HT144
T165A
ERG
Pfx
1:10–1:20
Msh6
D'Assoro
.Antibody-labelled
W1057C
YLI
saturatingintercalating
SIRT1-SIRT7
Be´rard
1014–1197
apoptosis.123,127
.Head
576–582
mAb806
leiomyosarcomas
anti-BAF180
interleukin-6
I563
observed22
A270P
10776
.Ubiquitination-deficient
∼3-fold
anti-phospho-STAT1
thosethat
Sandilands
His790-Asn797
D8
IMHDS843-847T
+101
5'-GGGTAGAGGTAACCTTTAAT-3
Ptendel
HA-Aα
LR01-164
CD34pos
.Fanconi
1000â€
thetrue
Gastroenterol
5′-PCR
non-MYC-N
//www.genome.wi.mit.edu
PK-6101
'carcinoma
Igh-
EGFP-overexpressed
penni-streptomycin
pRBΔ663
paired-SCLC/normal
immunofluourescent
D-Systems
G67E
lats−/−
Cys-27
LIN28/LIN28B
compartmentspecific
boundzinc
LRP16
BRCA1-positive
Phospho-PLC-γ-Tyr783
SAHM1
Rizzello
1.23-7.29
12–13
47,467,725-47,480,658
disease.59,61
JH2WT
p.The
II/Pvu
0.336
fol-
membrane6
G_-16A
Lys232
inhibitor143
Ommen
S1253S
8541â€
DIF
.Occurrence
1p36.11
c.400G
Diatron
CHEK2.17,18
HER2/neu–overexpressing
IL3
S779N
cDNA,37
6-reverse
5'-TTTTTTTTCAAGGGATAATAAA-3
agent.Wild-type
A–L
arrest.17
Mdt1
Pfam
peptide23
Ser56Ile
vitroassay
IL-9Rα—We
Palmini
Ter119.29
JAK2V617F-expressing
A.a
5.1-
R278C
368–369
S363F
W175
c.1434_1462del
cis-compound
2\
28–33
Mismatch-Repair
YPH-Akt
NRG-1
2,156
94-312
activation66
.26,41
.Ribosomes
wu7
Elf3Δ60–127
pLZR-BCR-JAK2
Map3k1/2
tumourigenicity157,158
-speciﬁc
p140mDia
retinal
TTCTCGCAAGCTATCAGCCC
Tyr816
inhibitors34
min.
hFLI-1V5
p21-TA
Keap1-Cullin
5′-CTGAAATCAACGAAGAAGTACTCATTATCTGAGG-3′
SRiC
MPLW515L-Transduced
HH37/38
analysis.40–42
reportersin
-i
CDK11
I563_P577delinsTI
scan/second
SH1N
RING-containing
p.A573V
3/49
RICK/RIP2/CARDIAK
ellipticine
individuals.This
D.A.T.
3448
Pten-AKT
factor-α-induced
FWD1
4.81
5′-GGTCTGACAGTTCGCACA-3′
Common-B-cell
phosopho-flow
gene.24
.Osteoclast-like
obsj
review.12–22
single-locus
differentiation161
silico_
29–58
530-540
EGFR.4
Translationally
theNPM/B23
anti–phospho-SRC-416
imatinib.22
Plus2.0
usingL
G504R
282–434
TCA-precipitated
.Keck
U-138
FBXW7-negative
previously.31
TP53−/−
Top1cc-proteolytic
G992W
43.0
.Ellard
ATR
OncoPanel
Utoh
CIAbbreviations
891L10
ofAML1
Newfoundland52
TAL1–LMO–Ldb1
Minn.
.INPP4B
used60
G33D
7/99
20,22,23
C277-p53′
R609K
21/21
FGFR2-expressing
MultiPep
matrix5
c.3304A
67.
fastq
1.Cloning
115:1
V.3.20
.Healthy
s-AML
clear-cut
Em-L-myc
autoproteolysis
6q22-qter
.RPTPp
perpendicular
1UNQ
larynx,7
Tyr-974
936
21–99
0.0024
3449
MAP3K1.20,21
Roman-Gomez
Tg-GWild
Fig.4c,4c
TL2
9–13
p.H87Dfs*11
origin3,9
mice.40
MHH-Med1
vectors.43
DS15209
BioPac
nonaberrant
786-O…
.1b
duodenalGIST
∼10,000-fold
AML1/
nano-domains
to+5
SetPoint2
.NVP-BYL719
al.36
-GGGAAGAGTGAAGAAGAAG-30
Y69H
uploid
melanoma—ipilimumab
MSCV-neomycin
Ghent
pre-infected
1298–1306
30623
.Membraneswereblocked
−34A
cryo-electron
vacuo
Hasson
detectableDNA
CAGTCCTTCACTCAAGAACAAG
tuberin–dependent
87/79
GUCY2C
PDGFRB-001
.FoxO6
5,090
dimer/monomer
rad50/RAD50
HNF4a7
positives/true
Villemeur
cholesterol-dependent
364A
TMPRSS2/PLAP1
8/p300
GM3542
co‐immunoprecipitating
pH1-GL4
-IHC
.Cosmid
.EGFR–PI3K
glycocalyx
U2AF2/U2AF1
F49
uterine
AXIO
.Ras·mantGDP
R333G
2F4J
Goedert
TruSight-Cancer
histocytoma
ras-overexpressing
BMP3
SW613-S
*57
AML-ETO
somal
H458P
CGA-9TGA
repeatcontaining
value.Experimental
165.0
P420
anti-CD27
1p31-32
mutationsAmong
-7.3
p.A11_G12insGA
Coincident
kbIFN-
TRM
anti-paralleled
HNF4α-mediated
pdb
E.50
APC-H7
11mutations
ccRCC15
0.1266
Theirfrequency
TKi
described,11,12
EPZ005687
TTTA
7,12-dimethylbenz
–sample
7T-run
6/7/04
factor-1/MODY4
430055
A.S.
IG1
GISTsFull
NM23H1
papillary
MEN2-associated
never/light-smoker
RepeatMasker-annotated
≈2-3
MadMyc
1-Step
.Decreased
LTα1β2
0.09–1820
present81
TGF‐β‐dependent
Vandetanib
Procedures.
Plafker
3.08
nonastrocytoma
FLOWJO
N84
‡To
Notch/CSL/MAML‐mediated
.Linkage
Nieborowska-Skorska
preferred11
Fluoprep
Mediagnost
started.Stable
R776
themsh2
dishomogeneous
days\
conformation-restricted
146·8
SETD2-inactive
p.E542K
localization.14
Aspord
integrase,33
Ala19dup
Ago-bound
Ewing-specific
TM-inducible
BRN3A
six-weekold
0.020425.c
.Circumstance
∑Fo
KIAA0477
vemurafenib-response
AURKAPS
2131
protein-synthesizing
CATGCAGTTGACCGTAGTCTCC
61:2912–2923.Despite
V95
.Administration
-155K
P=0.65
IGCT-
GSE846
R359S
Orlicky
HEK-293-EV
RE3
29·4
M322T
Chenevix-Trench
plamid
p.D99G
∑b
FLT3-FL
15-nucleotides
x-ray-irradiated
518–522
SLC30A8
receptor.6
Flag-RHOA
926-32210
First-generation
TCC-
M.J.G
HA-KMT2D
KIT60
27,23
Pdgfrl
4.05
FNIII-like
observa-
394-aa
TREtight-GW-IRES-tomato
5000~20000
10,13–15
FAK-RhoA
proposed.15
Pten129
4B-nF
tataPIK3CA
1913G
Carreira
-TGGCTCTGATCCCAAATCCCT-3
PDGFR-α/D842
M+
carboplatin
specification,9
antiphospho-STAT5a/b
c.481C
microinsertions/microdeletions
A1924T
T764N
0.86–2.39
.088
spheroid
Armadillo/p-catenin
genes—some
MAB3580
25µg
.035
Board-approved
plumpspindle
.0083*
BMP-responsive
C634R-dependent
GAB1
inducedby
Kitagawa
601C
c.71_81del
PDGFRαβ
repression-associated
PGC-1
Ch14.18
GOLGA5
Signi
Q52R
G1950C
GMPS
DNA-level
ab89
CLL10
c–Cbl
MMP1
CATGATTTTCCAGACTTCCTCTC
zFisher
3/65
nihms646437t10
FancG
D1Δ-956μ
.MG-132
0/65
tyrosylphosphorylated
EglN3
FANCC-proficient
p.G881delinsKS
oncogene-directed
2837–2840
.LoVo
I459K
Travagli
643-8-Dapi-x10
avidin-Cy3.5
Mislocalization
s.d
RCAS-transfected
HU.For
1–5.3
ago13
ROR1-KD
STAT3β
ThermoMatrix
andHP1
coincident.2–9
αD-helix
com­
20F
Lineage-ckit+
Gyeonggi
5.048
9398
T‐cell
CAL-120
polymorphism-polymerase
R177X/+
-Y
2951
reference25
P.L858Q
well-established.24
11–30
BRAFE600-mediated
studies12,13,31
G241V
12826z
self-replicating
MEK1-T386A
exit.31-33
μCi/well
1.8–2.0
233
5′-CAGCAGAAGATCCGGAAGTA-3′
mCherry–expressing
C31E5E
116,710
LR11-072
DFS/PFS/RFS/EFS
.Fluorescent
A.1
0.963
0.118
Kallioniemi
CML-AP–like
33.90
cancers,30,31
cytoskeleton
T488
R127G
300678
THP-1/t
patients.9,10
V285G
1677
dehydrogenases
.Agarose
fanca
Ariz
Pten//mRad51
8300
kip1
T2245
88999C5
=0–0.2
Tenovin-6
7/40
CML→AML
SsNVs
p\0.005
BitSeq
1–57
PPP6C-PD
RT-PCR–amplified
fedratinib
phosphate‐labeled
p.E545Q
domain-targeted
carcinoma.2
BsaI
⊚
Iq22q43
substantively
R143Q
Leu210
hyper-IgE
anti-phospho-FGF
p53.38
U95
ROS1WT-expressing
hMSH6-L1354Q
miRNA-Seq
Tet2-null
MAPK-signaling
7.5/0.05
above.To
5′-gggcatgtagaggtaagacgcctg-3′
Advexin
others20
ALK-5
Burgar
A-Akt1
pCAGGS-nlsCre
L11
M457K
Flt3.38-40
707
Lavigueur
MCF7-Ago2-wild
9Primary
5′-CAGCACATCGAGAGCAAGC
Rb1up-RT-MGB
ArrestTMGIPZ
conditions.28
twoexpression
scrutinised
20-/J.1
R587C
MarrowGrow
interphalangeal
PIPKIs
A/0.3
.Passenger
structure-selective
.Poorly
host–environment
.USP28
D974V
CE-marked
Bio-
3′-most
Ercolino
2518
type.2
1252017
ProteinPlasmids
23K
Nucleopore
MutationsBesides
pathogenic.Our
PMS2-ΔNLS
47724
high-res
post-doctoral
GDLV
replenishment
E-Mail
1,812
BAF3
0.70
androgens.3
shAR3-2
279
Ago-subfamily34
K2154
R68X
RP23-290E4
c.631+3A
benomyl-sensitive
R110W
AR-Vs.
Anti-14–3-3
Damage–Induced
0.047
1.38–32.26
C9Y
F268S
neuroprogenitor
dasatinib—offer
Ser241Phe
S10D
p-EGFR-Tyr845
immuncytochemical
35,38–40
anti-occludin
RP5–1108M17
JAK2.4–6
hMutSα-to-hMutSβ
Kluwer
\40
Y1003X
98-69
sc-7126
GGGCCCGGGAACAG
TGGAACT
.72
pEAA299
-1H-pyrazole
7Å
gene.When
double-fluorescent
DAPIstained
Vreeswijk
bility
vector.24
V560D
Sin3-interacting
701
RET-associated
393P-scr
54×
LY94002
CS13
factor–independent
NHGRI/NIH
250–310
11bF
bcl2
year.125
Luc
pATM
DP103-independent
anti-vinculin
malignancy.An
μl/10
pY99
R776H+L861Q
IFN-inducible
EGFR/chr7≥2
HPLC-purified
GATA3-ext
byDoyle
asa
ApopTag
1.9-36.4
whole-genome/exome
CI-1040
4,9,10,20⇓⇓⇓⇓⇓⇓⇓⇓–29
Gly349
.Gateway
2/176
ICR14m
siRNA/Ewsr1
ZW3
K299R3
3447
pathways/targets
FIP1L1-KIT
TRE-mediated
AGE-1
characterized51
-RYBP
Sasano
27both
33.0
Q2063fs
1.35-1.6-fold
+4.4
accordingtoA
GTAAAACGACGGCCAGT
allogeneic-related
AI326684
S65L
serpins
Sulfolobus
2.5M
FOP_K64M
P=0.046
BIO-
cells.37
Carsillo
.Random
16.2/21.4
GGA→GAA
NovelFigure
2445
Schwannomas
I54T
resistance.35
Tabin
jig
//avalon.epm.ornl.gov
adenoma/carcinoma
granulocyte-colony
median-fold
4-nt-long
p-ERKY204
Asp-336
H2-specific
native-PAGE
Q1262K
R201X
GlnlI
Osada
TIF-1α
Dicer1wt
hydroxylases
NetGene2
background39
inotrope
G245S
−272SRYP
CCGTAGGA
'unprimed
ection
A_51_P122356
5′-cauuaacauuguucgcaa-3′
0.043
10–15-l
PPPS/TP
SNF5+/lacZ
c-
PUREGENE
seven-pass
SN3
vitA2-ERE-TK
disease.29
TKI-naïve
Ansamycin
hwith
SP9000
∼130:1
MRE11.20
Ac-PTEN/PTEN
3H-acetyl
3.553
42·7–83·6
Tgf-βRIIlox/lox
2839
100U/mL
Function–structure
metabolite
Myc‐dependent
B_239
paclitaxel/bevacizumab
pBABEpuro
.IPMNs
MediaObjects
Hearle
29.22
61-mutant
1105F
CUX-FGFR1-transduced
Figure2D2D
Cancérologie/Institut
orlanes
c.124G4C
Clone2
459,000
ZNF92
Cic
3.9–24
GST-G15A
RSK-1
rs3176352
Fenderson
1-16
S232L
Callebaut
Laï
CTD-318H13
Rsf-1
pRS316-PG-β-gal
c.2092_2093delTC
serosa-exposed
36bp
immunofluorescence
−0.76
cDNA-constructs
5'LTR
4283
families/individuals
G124S
cDNA.DNA
NM_005676.4
2404C
p-Stat
10.6–10.7
Met918
358–906
AR-g1651_as
1.0014
5′-AAAGCCGCTCAACTACATGG-3′
253–329
day14
addiction.44
premalignant
2/18
6.10
.41
Chemagen
p110β/δ-selective
BAP1-mutated
reported.2
casein
p16−
observations,64
1994b
Nambiar
.Saccharomyces
otide
nonsarcomatoid
n=283
ab40815
Q635E
Tyr-419
CTB-108B20
IGROV
Frebourg
the10
insMPAP
V763
.67,68
39.11
20,000/well
.M269R
1.22E08
.Rossi
3f–h
XFast-1
GST-CDK4-MUT3B
5′-CTGTCGTCCGGTCTGGG-3′
AATGCTATGTCAAGACTG
m13f
G299E
.PCR–SSCP
Kandt
EcoRV_DCCNB3_fw
Preparation—hMSH6
Mx-1-Cre−Sox17fl/GFP
RalB/Sec5
c-H2A.X
18-21
S3660L
AIMV
pSRaMSVtkNeo
c.137G4T
98101
uninterpretable
0.001635
EGFR-N842I
ionization–mass
PHD1–3
CLM
imatinib-binding
E181
-cellulose
Koopman
HM40
factors22
all-SCNA
S1111
CTLAGlyThr17
W95R
FOS1L
prostatichyperplasia
Promokine
104-Scells
.Sepharose
TAGCTGGATGGTAGGTAAGT
Clathrin-ALK
chemoprevention
48-51
1676
schematically
.Ubiquitin
85.84
Conexio
CHOU-FASMAN
caspase-dependent
c-Kits
5-TGCTCCAGACTGCCTTGGGAA
neuroblastoma.28
TCGA_Ovarian
GSK3-β
23,47
globally,1
p300/CBP31
1843–1863
TTG→TTT
Carboxyterminal
.Mi
5′-CTCTGCTAAGTCTTCAAAGCAG-3′
3700
hormone-dependent
ERK8,11,12,13
CDB3,16
NNRTIs
ACGTCAGTTGTGCTGCTCAC
.2035C
KMS-10
Variation_3145
gpllOPrott-rk
GATA3-mutant
6/21/06
anti-HA-tag
.0055
R+
IPMNs.3
GGATTTT
p.R239W
5,537
.Heterozygotes
ser45tyr
sihCARD11-2
DFC360
previously.14,15
FANCA-S858R
59-CCACTACACATATCTGGTCC-39
14q133
1–1240
Rectum†
phosphoinositide
progenitors.42,43
.3,15,26
p85α–E160*
Jimeno
NRSF/REST
GLAD-segmented
.PIP
ATRXM40L-Rluc
γc-expressing
Parabrachial
Sorvall
mutations.107
.Fifty-five
BrdU-FITC
gene.7Furthermore
Atto488–GppNp
V555_L576delinsrevNCSHLSPQQP
Du4475
residual
mTet1
101.775
Treatment/clinical
Kaplan—Meier
MMTV-Wnt1
ΔCn
BA85
phenylephrine
cancers.MATERIALS
negative-mode
BRC44
phenotype.3
phred
low/intermediate-1
T182N
SOCS2
5′-ACTATCCCTCCAGCCATAGG-3′
ERGE-bound
III5.00xx2.5++++
7/66
annular
S243P
Anti-c-Myc
−120
pGEM-T
E343Q
InsTGGGGGT
67B9
Amplier
TGCTTGTTGAAACAAAATCCTTT
shSUMO1
75–82
3zeta
chow-fed
bleomycin/ml
FIH23
H1466*
G.J
iduals
BRB
Lacar
microindels
2.490
Trend-test
Gaiano
.Yang
anti-pMEK1/2
proliferative/survival
0·14
TGF-β2
isofroms
tumours.3
UBP
22/425
neuroectoderm
PTEN-Rad51
PT4
.Up-Regulation
215-218
survival.16
between-subjects
BRL50481
MM5.1/MM5.2
PDGFRα-specific
c.1460G4A
Asp770_Asn771insGlyLeu
cells.17
tissues,22
U/l
Asp450Glu
4OBE
before,3
17*
Camporeale
P77T
matrin
7e–l
Jirmanova
20130204
17.5/11.8
0.655
Tween-TBS
dimethyl
E219K
aponea
shCTL
S/T-P
mice2
20/33
HA–B-Rafwt
Marnes-la-Coquette
IMMUNOSUPPRESSION
kown
siEGFR2
Campling
24:110
PhosphorImager.B
initially-identified
≥
cap-n-collar
930–1337
Thermoscript
neutropenia,28
tumor-progressive
3′-kinases
i~g/ml
BtsI
R203C
utilises
AACGACGGCCAGT
98/101
RG-25N
WT-pVHL
bycertain
co-occupy
TCAACTT
Sennan-shi
Gli1ZF
six-fold
detected20-22
Lin-negative
NSD1−2F
post-induction
button-shaped
re-awakened
Activation—To
R337C/P
01032
resultedin
19Ser
92–93
.GE
condense
Thr751
non-specific
p16/Δ1−51
mutations.28
7q33–34
phos-
D21S1413
GTP-depending
lox/+
Y232C
Asp312Asn
3′-
1013-1012
authophagy
40-μm-pore-size
Arg-47
hormone-associated
c.794-11T
regulation/deactivation
Brefeldin
exon9
F/12
0.6-20.0
IVS6+1G
foci/well
PPAPDC1B
residues.Significant
EMBL-EMI
Ozyme
hsp70/CHIP
damage–related
ATGTGTGCGTTGGTAAGGGA
1076
Trithorax-related
capacitance
.Switchingoff
shC8
1388del
BRAF-inhibitor–naive
ferritin
6.6-810
.LS1034
.Feature-Extraction
1Human
ApcMin/+Smad3+/+
postoperatively
F88
Universita¨tsklinik
QM-PCR
self-associated
CCL5/RANTES
F5
post-resistant
DNA.ATP-Mediated
DinucleotideGenBank
N472D
199–278
MAP2K1/2-mutation
843-1479
EF1
P=7.5
Cl-D855
Â¡nparentheses
A1189D
D513Y
NaCl/0.05
ZNF445
2.Selected
hypersensitivity.8
303–306
PIF
6x-STAT5-TK-luc
transcriptional-control
Ligand-bound
MEN2/FMTC
recombiant
opposite-strand
Kaelin
Hyperacetylation
fys.kuleuven.ac.be
.Immunoreactive
k+1
melanin
1940×108
D1270G
heterozigously
long-acting
.Contributing
Gly538–Asp351
product-moment
Alkindy
16,56
SfaN
A273
p.W1306*
Viswanathan
381–834
tumours2
Meta-analysis
GCWG
B.G.N
1909b
AZD3463-induced
PPP1R9A
exon2
E81G
70.4
UC-39
Δ1751
angiocrine-produced
pLENTI6.3
demethylation2–4
.CBP/p300
_FGFR1TACC1_
Solutol
0.090
2.13.1
KRAS-G13D
11415–064
K3083E
dependence/addiction
uncontrollably
6.5E-0.5
A3327T
Rivière
activity.14
575-nucleotide-long
Mono-ubiquitylated
29,30,57
IHS
package,31
32Ek
30/39
TaqmanTM
del57L
KD=
MutSα-L187P
pECE-Flag-SIRT1
D449
SERPINB4
§Familial
Fbw7-knockdown
infundamental
0·23
UBA
DNA89
Swarttouw-Hijmans
LDK378
Kountourakis
659-bp
XNP52
c.3038_3054del
autocrine-
tetramer43
BRIP1/FANCJ-deficient
DNA.5−9
Lentivirally
PC12/MEN2B-cl.5
N247
E1304K
R840Q
M-07eE
TATGTCTTTT-AGCCTGCCTGCTGGGAGTTG
GCGCTACTACCACGACCACT
pBEND2-SOXCON
dimethylation
5′-ATTGACTCTGAATGTCGGCC-3′
.B-Raf
F.S
thecytotoxic
-46.3
α12
cccccggcataaagtttgaat3
I200K
2243
microfilaments
LipfectAMINE
Suire
ad~antage
8.5+1.1
trials.42
12-18
CEP-701
174K
10m6~
ratio.8
R847K-pA
Ser70fsTer93
Brca1-associated
MSP1D1
15–21
homeobox-2
theNSD1-NUP98
endocrinological
Janocko
TAGCTAACTACCCATTTTCCTCGC
−0.33
hematopathologist
170K
Variation_42116
Hilden/Germany
extra-embryonic
xylenecyanol
Lhermitte-Duclos
4.1protein/ezrin/radixin/moesin
V4+UTR
421C
104-5
protein-peptide
TNC
G2030V
Down-slanting
P50.002
tamoxifen-binding
c-Myc/MYCN
day—is
M152T
time,43
r=
omo-lobar
aAn
∼30-fold
aggregation-incompetent
hetero-oligomer
.AntiPLCyl
targeting83
AGTGATCTGCCTGCAAGTTCACATTAG
Y842C–expressing
Inova
.Triangles
p53/DNA/Do-1
psPAX2
chromatography-mass
Notch-3
Gln910
2,033
-platforms
lesions126
ù8
Bioteck
Globocan
anti-Pim-2
malignancies1
TCGA-D8-A1Y0-01
Sox2active
RXRXX
Scarl
.254
12–454
Morgenbesser
449b
3.797682933
.S2B
EDTA/100
37.4
5′-AAGUCCAUGGUGACAGGAGAC-3′
Arg-73-3ProS19
Phe12
antimicrobial
I941R
.Rehbock
his3Δ200
TP5315
860
pY165
81.5∗
5260
Fabpl-4X
.NTRK
L13R
FGF-MAPK
C247R
K-Ras-4A
N=7
0.66–1.37
purine
B-91-228-107
9–94
I1973F
C70
Consequent
Ar+
SFA14
F1524V
Brca1FH-I26A/+
5′ATGCTCGTGTACAAGTTTG
Relat
.Inclusion
NM_002880
PDGFRA-T674I
A236G
DeltaP
T4.8
immunointensity
NG18
recurrence.5
GAGCCAAGACAACACCACTG
amyloidosis.4
cancers.32
SNU719
T-5192
p.V136I
51.1
O6meG-induced
L192
fingers.Ba/F3
apoptosis.23
High-titer
≥1000
region,7
RhoA-1S
Paris-Trousseau
33.6723.1
begins.15
EMM1002
shGLP_1
PKC-412
0·0001
Ini1in3/in3
59/72
respectively,19
histopathologial
c.1468_1475dup
.Equipped
Z9503100
RNAeasy
motif-PLDLS
OLA-derived
5′-GGAGAATCCAGCACGACGCCC-3′
~3.5
ly
drug-inducible
phos-pholipase
bWD
Tulp-1
C-EBP
60â€
q13q23
Nebral
DPYSL4
:100–101
.Simultaneously
805-972
2.9-
CS19
MWSDS-200
3-39
Myc-PDGFRA
β-galactosidase–H2Ld
.15,30
mutations,1
CGC-3
CCCGGAACAGAAAGTAAAGCCTCTAG
NM_148922
MEPSADWLATA
FANCC-corrected
anti-rat
721C
N1878K
Ser464
c.396C4A
osteoblast-specific
RALGDS-like
trichoepithelioma
6GATT06ArGAATTCAAATTCTGCTTGCTTSr
FBS-free
HER2/3
Alu-repeat
gi75775312
ACCGTGCAGCTCATCATGCAGCTCATGCCCTTC
protocols24
CA-PJ49
BCR-JAK2
M-mode
R89L
oligonuleotides
calledGTBP
interleukin-12
respectively—
.Light
96,550
rearrangementsare
P968
K866T
122-168,22
sheet-like
H-90
S3Ff1–
AAATGTTGATGAGATAATGACTGAT
5-aza-2′-deoxycytidine-treated
CCPRB
L2–L3
Immunofluorescence—MC3T3E1
inhibitors.11
carboxymethylcellulose
c.8023A→G
predisposition.1
P261A
bactoagar
ccRCC21
814T
consanguinity.36–40
Tasigna
WTS
co‐workers
NMD-Escape
FLAG-Cul3
Xerri
cIAP
2283-2261
Grb2
S100F
targeting…
n−k
TP53-R273H
68,84,86Å
7/24=
L596VBRAF
S-hydrochloride
cancers.Mutations
intra-patient
Chongno-Ku
Lys507
SERPINB2
.Mildly
nVa
Eif4e-bp2
pSH18
non-NR
pEG2-FLAG-2NLS
BiBr37–46
hevin
c.5382G
hMSCs
5′-GACCTGTCCGGGCACCATGAAGTCCTGAGTGTA-3′
pathogenesis25
electroblot
termini
Parenthetically
MSH2-C697F
//www.sanger.ac.uk/cgi-bin/genetics/CGP/conan/search.cgi
NCT00711594
NADPH-competitive
Capillary-based
l-4
477–456
2Dipartimento
D5S818
9/21
Protein-Lipid
5′-AAACTCTTGCACAAATGCTG-3′
1times
activation-loop
⩾100:1
underling
P1073R
Calcein-AM
Strehl
PheGlylysValPh•LeuAlaGluCysHi
FOXO1-hPPARγ2-P
NF-κB–regulated
Stk6/STK15
NLS,31,32
families,14,15
MSH6-
14-3-3-dependent
.Asreported
activity,19
BRCA1-related
BCR-A
vivo.8,9
HR=0.357
531
counterparts23–27
248–332
Shiekhattar
STRADα–MO25α
effectsand
ΔEGF-MYC
28–40
II-
D1275N
Paugh2
Storiform
c-Myc/E2A/Notch
Σ|Ihkl
activation.34-37
pcDNA3.1-FADD
type-2A
G89
G-to-T
E2–E6
RUNX1–p53
BRAFL505H
6.198165125
His206
Boriack-Sjodin
7363
population-wide
APC/b-catenin/TCF
KLESLLLCTLNDR
microenvironment.38
rubcloning
co-precipitant
3939
〈I〉
CBP+/−MEFs
.GSE22208
R12S
​and66E
Jabado1,2,5,34
siU2AF2
Filant
5422
Belguise
α1,3
Nucleotide-induced
αH1047R-D933A1/αH1047R-D933A2
Zaika
Smo-deficient
probabilistic
tBHQ-induced
30,32
P.F723L
0.054
LEF-1/TCF-binding
783
ingredient
Stripcharts
E1B2
CXCL4
untranscribed
mitosis-karyorrhexis
histiocytoid
Phosphorylations
RNA-interference
.HepG2
8.612091
20p12-13
7384–7385
Tyr1015
CTGTAGACTACCGAGCAGCTTTTCCAGAAGATCAG
necrosis.Figure
37.6
mixed-type
349KB
NF-κB—β-catenin
groups.FIGURE
25th–75th
68301894
V12-induced
AGGGGTAATTAGACACCTGG
classification.2
elsewhere.17
6428insT
KAR300A
lanes+
sequence-specific
SMU030P
CdkI
339-591
LKBWallac
TGF-b–responsive
.Gly67Trp
.SD.AIV
Sodir
de-regulating
m/53
NP_004927
K273N
5p14–15
23227
AGAGGAGTACAGTGCAATGAGG
I808
0.0222
cga
rs1800054
'hookless
ΔUCH
Cressman
.Interpretation
100-1000X
secondary-quaternary
Q787Q
tissues.8
:40
ankyrin-containing
FL3
BL21DE3
PROCHECK
fusion,32,33
fiom
post-scratching
.E25-427
Fat1/4
Msh2pMsh6pbinding
synchrony
attrition
anti-CUL
discontinuous
LCD2
described5,8
CBF-beta
23,25
118.9
E571
0·05
IVS28+83C
human-associated
Skp2-
XEDS/EELS
mutated-SMARCA4
pigmentosa.22,23
C-RAF41
JAK1-L910P
92,113
DSIF
0.362
biopsy
crizotinib.1
BAZ2A
Hoshida
.CCT-pVHL
14+
CAATGGGTCTTGCTCATCCATGCAGAGAGCCTCCCACGCCCATTG
T393K
.Tyr418Del
median=39.8
pT2
.Glu-37-.AspS5
30kDa
1,31
1.3-kb
aSHM
PDGFR-induced
NCT00360854
Srsf2P95H/fl
Phrap-generated
supple­
CAGA12
CAGGAAACAGCTATGACCAACATCACCCCAATGCCATCAC
Baz2b
GHB
Bioanalytical
Caspases
Cul1/F-box
frequency-matched
sequencing1
3263–3269
BiBr71-77
locus.11
/progression-free
hSmad4
RBM-knocked-down
NCL-P53-D07
X85959
45Â°Cfor
MGR1881
6B–6E
∼0.2–0.7
TEL-JAK2-expressing
p.Gly162Glu
intensity-dependent
335
32P-labeled
Beutler
SK-MEL-28-TrkA
oligonucleotide-primed
extensively5
Syngeneic
AURKB-MGMT
10.1158/0008-5472.CAN-10-4433
S291–S295
5-μm-thick
e13.1
FRS2/SNT
p.Gln76X
A-CDK2-ATP
Xp22.3/Yp11.3
TFL
sekikaic
analysisGainsLossesAmp1pDt'lq,5p17pâ€
.CYT387
YFP-labeled
15N-p53tet-R337H
.CPA‐7
80–102
XPG
Kikugawa
B-chain
inhibition112
formalin-
Liv
Burmer
Nur-responsive
p13·1
1Ab
MMC-sensitive
0.6*
27485
Kcat
S3-1
//www.jove.com/video/3932/
PDGF-C-null
doi:10.1371/journal.pone.0025021.t004
kilobase-long
Tonami
.Akti
gcttggcctagtggggttttg
Lu130
1104
H-RasWT
15m
SWI/SNF-B
single-clonal
EPD1
SAG-Cul1-FBW7
Ras–Raf–extracellular
tail.7,8
Jhiang
overexpressing
Apoptosis
.N-benzoyl
landmarked
.Driven
MC4000/
1.800
Fig.3K
family.57,75,76
Cell-based
T400N
programme,20
TE200-E
i-star
F39Ve
antibody-staining
p.T518T
12.62
TDG11
BSG003
HL3
immunoreactivities
resistance,4
phAURKA
additive
0.243
CCGGCGGCTCCATCATCAATGACATCTCGAGAT-GTCATTGATGAT-GGAGCCGTTTTTG
0.1548
25µm
837–839
21F4
2/70
//regulatorygenomics.upf.edu/Software/SVM_BP/
.179G
K603Q-Cl.1
Gly376Arg
Dahmane
treatment.5
field30
O-acetylated
.Cut-off
logCPM≥1
culture.19
7073
single-base
pre-B-ALL
JAK1-V658F
months.25
mutations.10,11
.TheEdmondson-Steiner
Sofer-Levi
ar-Rushdi
pN8e-GagPolΔS
c.2834_2836
.Doublestranded
S4A–D
ERE3-TATA-EBV
loss.35
recurrence-associated
unsuccessfully
Nordisk
dkalaitz
anillin
Y462C
C224/12
AR3shRNAs
Kras.Smad4−/−
mendelian_genes
controls.
onelocus
non-separation
Enrichment-COLD-PCR
GEV16
NM_014791.3
anti-RAPTOR
breakpoint.76
themore
NCT01682083
ElectroSquarePorator
FEIDKMKPGS..
c.2602
//web.expasy.org/compute_pi/
CancerThe…
p.Ser231AlafsX73
0.1812
HSL
59–66
v14.1
ZSG
inhibitors−raw
ATGACTGCCATGGAGGAGTCACAGTC
IDH-associated
D16S3121
2475
FARNET
EV7
SRY
impor-
72R
1335
Shipitsyna
.Galsky
CBL70Z
-R273H-14
−.35
transformation18
rate129
Shokat
intervene.18
peptide/β-catenin
SP260
MCF10A-G12D
50-μl
−153InsTGGGGGT
Uracil-Ftegafur
Sequence*
raÃ-mutation
Micro-CT
Ask1
commercialized
doi:10.1158/0008-5472.CAN-05-0115
1089insAAG
−170
sequencing-derived
PMS2-COOHFig
17-demethoxygeldanamycin
HLA-DRB1
1.1–10.3
WrightGiemsa-stained
R2705
BRAFV600/MEK
−139
​Mean
c.305_307del
growth80
Drosophilamelanogaster
.EGFRΔ768
-622
9p12
IVSlOb+ZdelTAAG
over-expressed
transcription/expression
M69K
hystidine
'one-class
purelink
K-ras-induced
14,507
P=0.7365
congenita
32P-end-labeled
LCB-DWH
6.90
mice.138
GST-p85-SH2
Oligo/azoospermia
PBS-2
.Modulating
Si2
D8273
AM7
.NM_004364.2
.KMT2F
9–amino
Accelrys®
Biotab
substrates100
790del
MAL2
P673A
7840C
â€¢â€¢
saturation-binding
N-0505
assay-based
AGTTCAGAAAAGGATGGGCG
3H-T
Chicago-patient
5mCpG
BCR–PDFGFRA
c.877A
CHD1L
pLp53-R175HSP
Rbp-j
HER2-mediated
H3K27me3–EED
WTAP
antibodies—rabbit
least-affected
2,743
nlme
000/μL
387,785
recurrence7
.T725M
2.7-10.4
HNSCC.4
levels.8
R444C
wild-typePAX8
8p21.2
MR1
Maddika
BCR-PDFGFRA
.S45A
Rho/Rac
p.N626D
LTR-ERK2E322K
imatinib.1
commontype
Encyclopedia6
R181C
metalloprotease-independent
772
p.Y1235
self-cleaving
analysis.27
Brg1tm1Mag
SDA-containing
1234/5
STE20
22,23.
M90I
streptavidin-HRP
Hopfer
60–63
S467P
PLK1
−2.77
292–450
LRIG1+ve
includingnovel
AG01518
genome-seq
apoptosis-modulating
GLC20
11WK557-558del
isothiocyanate–conjugated
effects170
proteins.37,38
FGF-driven
.7,18
S2.3,4
M1250T
EHop
Transcriptome-aligned
distal/SB3
Msh2-variant
0.504
Flow-cytometry
methyltransferases—that
Degron-KI–engineered
62699
Millex-FG
protein–tagged
phosphodegron
-pCRKL
S7a
CREBBP25
to3
DEXPAT
4137
α-LexA
186–467
p120RasGAP
osterix9
rs2227988
UTX
NRP-2
diphtheria
,3M
His-tagged
131
phospho-AKT-Ser473
polyubiquitin
markers9–11
Tumorigenicity
6839
Bellacosa
dot–broken
γ-32P-ATP
RP11–21G19
antiCDK4
ubiqitination
Speckles—Having
subarray
fluorescein-avidin
normahmutant
p.Gln442X
E1060A
p-BADS136
tumorsshowed
Elongase
desmoid-type
IVS2+1G→A
hexanucleotides
TIGAR
2.8-22.2
Pharmacokinetics
previously25
T154S
treatment25
MDMx
12,993
3*
AA/AB=0
radic
Olympus-BX51
thegene
10.57
1801.9
damage6
CICFL3
200-amino-acid
Abelson
GST-HCF-1
melanoma125
180–200
N=961
anti-CUL2
Maehama
16-aa
4.1.4
WT-H3.1
Dynatech
G776YVMA
9168—several
WesternBreeze
RNF8
SRp55-depleted
226003
biomimetic
.58
peroxidase-cojugated
mutant.18
oncogenic.19
pAL-FLT3-ITD
*NIH
p.Arg159Trp
SPOP-wt
GST–PKCϵ
CT-3′
IDH/H3F3A
D1241
Itapira
gene–knockout
.Natural
β12
SF-DMEM
08855
tection
N887
ASPC1
post-meiotic
GTP-RAS
LOC100506746
I-DLBCL/BL
independent26
neuroblastoma20,21
dose-dependence
q14q27
themost
LTT
Asxl1fl/flVav-cre+
LV/oxaliplatin
Celltiter96AQueousone
menin-mediated
c.787A
2HG-producing
174218
Her-2/neu.25
myxofibrosarcomas.9
EBV-transformed
AACGTGACCG
APC/Axin-binding
ORc
C-zeta
EGFRvIII-driven
ProliferativeResponse
3/96
5NG
-RHO
Cavalloni
UV140
±haploinsufficiency
Trichloroacetic
CTCF-bound
STAT5a/b-deficient
–10.6
Alerations
p80Protof-rk
.Astonishingly
DSI
disulfide-dithiol
μg/25μL
RasQ61
CCATCCAATCGGTAGTAGCG
0.04-117.4/MB
Semaphorin
PDGFR-mediated
neoplasms3
plasmacytoma
Othersb
184352-mediated
.change
p.E171
P=0.0226
reason­
ERG+
EWS-FLI1-specific
/KIT-positive
p.Gly157Gly
pRc/CMV2
20-188
lipofectamine/well
allele-
uridine
RFD
doxycycline-regulated
Donis-Keller
k21
74K
anti-PDGFRα
Flag–AML-1/ETO
IFN-alfa
0.391
NZM39
GCGAAGCTTATGCCTGGCTGGATCTGG
Exoribonuclease
Autocrine
nonparametrically
kinase‐dead
12C6-lysine
C80R
1795GTT
DRB1*0408
4-hydroxyproline
perichondrium
Hiil2R
theapparent
.Proline
_-9.5
836K
CD8/CD3
≤6
TCTAgTgCT-3′
Geophysical
MSH6-defective
Sanchez-Carbayo
Nontranscriptional
CD41+
5′-TAACCTGTTAACTTTCCTTCC-3′
AP-1-Lux
S1J
c.970_971delCA
o25
gp46/47
non-chimaeric
anti-NFKBIA
J.For
Ras–guanine
IVS211G4A
SINE1
D-STAT
.Loading
721_745del
GGCAAGC
AKT-2
62L18
59→39
Hobeika
QT01682072
Kavamura
homomeric
72°
ICD-O
cyclophosphamide
Phe478
β-catenin-AlexaFluor
Complicationsb
hSOS1-I252T
m-TOR/PI3K
afterDX
Esteva
1233aa
I.K.M.
PA.
CCR6+CCR4
.Sp
immunopositive/
Fig.33F
Gp2D/Gp5D
pS437
Growth-inhibitory
individuality
ASCOM-MLL3
V279F
8:243–252
epiphenomenal
BTK.25
Anti-phospho-FGFR
M.D
Sandal-gap
units/g
.Phage
sarcoma/PNET
site-amplification
15q21.1
Nupper
anti-BCR-ABL1
MEG-MegaCC
-methylating
NFAT-VEGFR1
CCCCTTTTCGGCTCCCTC
receptor,1
TACCAGGTGGCAAAGGGCA
temperature-PCR
A121V
12.5Acral
.18,32,66,69
Laumonier
CPDR
Fafournoux
trans-activation
keloid-type
A029
neocortex
Rorγ
Presequencing
ATGAGAGGCCCTGCGGCCCA
.GNG10
2-week-off-treatment
K898R
HN30
R1308C
Br35
H3.3
23099
margin-negative
down-regulating
AP-CML
development.3
S768
319T
2671
longstanding
AGGTGCAGTGCTGCAGGGCG
LSM1
macrofoci
Venkatachalam
anti–IL-8
T1M0
80.63
hB-Rafwt–Myc
51–69
0–178
9–
21,000g
Vaseva
K5−
1.12–3.53
S1C
.387
Libermann
3BCE
Nuance
Albcre-negative
0.2728
sink-float
pLenti-ErbB4
NB100-416
STAT3-
5'-AGG
vitro3,6,7
W676X
Scartozzi
p.R743PfsX13
one-quarter
oncogenes47
rapid-resistance
Ago1–4
MIR143-fusion
CDK8KD
19-14
∼12–16
PRO919SER
L273M
Foxc1
Grenzacherstrasse
2-carbonyl
SAGE-like
Veh
GUSBP1
CIN
NHS-propionate
Q1634
MPL515K
Solvent-accessible
non-vertebrates
mSin3B
S6K1/4EBP1
Bal
encouraged.1
αH–αI
Y437H
cI1
MSH2-G164R
heteroallelic
factor-regulated
WEHI-3B-conditioned
XXgsGKTI
L148F/+
S3C–D
PALB2–BRCA2
CDC28
leukemia/lymphoma.33
PDE6D
anti-mouse-bridging
7029-7012
CHIP-TPR
N435S
16.0
ΔC-BRCA1
R358X
Ehrentraut
P123M_ΔE
158350
rhombomere
nonactivating
codon-containing
LPC3
0.7-439
TRCN0000010357
EZH2–
cagtgcagatgatgaacatgg
S576X
angiogeneticproperties
28,365
WTc-Kit-expressing
ECM/BM
thepossible
scores45
SCFFbw7-mediated
AGAAAACGGCATTTTGAGTG
cgtcgtgctgcccgtatg
SMO-independent
eBiosciences
U2snRNP
D407A
Cunninghan
5598
calculi
3.5-kilobase
Kyriakis
postimatinib
Src42CA
.PKCθ
49−53
Met138
currentknowledge
E.E.P.
12days
T123A—showed
'charged
CDK2.36
Rac2/3
www.perkinelmer.com
535:44:13
Immunohistostaining
fine-tunes
2∶2
PI3Kinases
5257
HoxA7
14/20
D2S325
Mek-1
NAO+
A134D
anergized
RAF1-FLAG
RET-independent
b-FGF
activity.35
8-nR
X-HA
nMreduced
RXA
Stat3
NM_134092
Nrf2-target
excrete
1,10
Pik3caLat-H1047R
Birrer
pIRESpuro
PTENWT
consurf.tau.ac.il
.Rest
siGL3B
ERK2G37S
POU2AF1
Keilhack
epithelial-appearing
.32
collectedin
T-cell-autonomous
MLL-MLLT10/AF10
G415R
IM-25A
CGAGCTCACTCTCTTCCGC-3′
Dyrk1
Cancrini
AML12
Raswt
genotype-phenotypecorrelation
BRAFengaged
113K
METHODSDatabase
Ala4393Val
.V-TGAGCTCGAGTCATTGCATAC-3
D3S1277
asbestos4
softwarea
analysis.49
PCR.
Cutaneous
GGGCCCCTCTCCCACAATGCCCCCCTGTC
:1495–507
300–3000
plGNK4
CORECT
deparaffi-
D88V
PPIase
TCATGCGGCCGCACAGGGAGTTGGTGTTGGCGCGTACCAG-3′
5′-TGG
.1389
P.V689Mb
low-MC
Finland,2,3
EGFRshRNA
Fgr
379–580
immuno­
Hpa
.IP
Y297
CGGGCAAGACGATGAGGTCAT
Jungnickel
Trofosfamide
.Nested-PCR
ay
GTP/GDP4
lethality.Figure
Omission
*220
geometrically
17–497
thermodynamically
M774
TGFBR2—even
R537P-specific
−83
0.027/s
hydroxlases
coeruleus
phenotype10
Myr-HA-AKT3
1.83E10
Reduction—Soon
Pol30
pll
Fukai
pG418-PDE4B-A
UV-
J.N
C1–C2
Gfpmid
p-Smad2
pmin=0.09
S719R
Stat320
β-MHC-Q510E-Shp
FA145
area-under-the-curve
Stratech
TβRIT204D
2Da–c
.Codon
biotin-11-
6myc-tagged
​and2
Mg2+-GTP
ALTpositive
10mMTris-HC1
H549
5A–C
Multiphor
Gerondakis
129-bp
kip1.3.2
N131Y/N239Y
1q43-44
V559A-mutant
.WHSC1L1
cancer21
NOCA4-RET
C2562
Antibiotic-antimycotic
Alanine-scanning
N602531
non-heavy
I.G
.R1784L
pENTR
0.275
full-lengthHIP1/PDGFβR
5-bromo-2¶-deoxyuridine
protocolspecified
H345
THPO.47
Olig2
TADA2A-MAST1
SCFbeta-TrCP
should–by
44,49
R167Q-VHL
S.E.2
pThr41
Assesment
above.Histone
labchip
47th
SOS-specific
11.7-kb
reported3
ubiquitously,21
supersaturated
.Chemotherapy
TGGC
p19ARF-deficient
RCSB
5′-CTGCAGTGTTAATCCTGAGAG
IIB
oncogene-associated
−3.57
12,591
E1250K
c.547+2T
disease42
59-CTGAGATCACCACCACCTTA-39
inositol–linked
GGACTCTCCCAGCTCGCTGTG
transversion-high
.Chasing
.003Exon
GERMLINE
-compatible
Non-func
031-f35
loci—including
Ser36
63–65
formaldehyde-phosphate-buffered
ILT-3
>
.32D
p.Val2985_Thr3001del
sequencing.Gene
4/111
MiaPaCa2
5158
125-fold
gtacagtat
Phe-856
M0/M1
RFP-negative
papillomavirus-mediated
THP-1a
cellular-phosphorylated
IDO2
V108
252–330
Sp1/Sp3
11.4
PDGFRB-BIN2
none-Ashkenazi
SMARCB1−/+
5′-CTGCTCAAAGAAACTAATCAAC-3′
M13mp2
ZFN-encoding
sensory/motor
NM_015125.3
compounds.DiscussionThe
FLT3-WT
Statins
QuantStudio3D
reconsi­dered
rs5884404
reanalysed
Cbl-associated
shTAL1
.Synergy
Schneppenheim
low-diversity
Sp-A
Bmi-1-associated
ES-cell
stage-IIIB
v-gag–myc
c.3847_3848del2
Luciferase-β-galactosidase
V185G
AlphaFetoprotein
AluY
Nonpermeabilized
Molsheim
JNJ-42756493possible
multibase
5′-AGAGGATAACAATTTCACACAGGA-3′
Jade-1-expressing
implimented
SouthernBiotech
17–170
preranked
4569
www-genome.wi.mit.edu
phenotype127
T491A
UCSC.hg19.KnownGene
.Neuhausen
insertion-driven
M623
filtering.10,12,13
W31R
Pten-deletion-induced
616–92,701
mostlung
-GTP
Galβ1,4GlcNAcβ1,3
peroxisome-biogenesis
multi-headed
502
~4.5
A-11
GGTATATTACTGCAACTAT-3′
D176
/p
prognostication
1.636–22.053
EJC
2.2–2.4
two-exponential
.BRC
Hamartomatous
~Spex
HER2in
95.3
.Below
Lats22
Fig.33c
phenotype.6
5690
F1L1P1-PDGFRα
6.82
report.47
NM_002744
treatment18
Yesef
1-thio-β-D-galactopyranoside
CCCACATCCAGTCCCTCTTCAGCT
cancer.In
PI3K11
off-label
N-SH2/PTP
HumanHT-12
662035
1.1–3.9
SAPS2
animals22
L964
moderateconcentrations
11·1–28·3
Leu57Val
signature29,30
0.44-MeV
residues.17
GATGCAGAGGAGCGAGCT
.RON
competitively
three-drug
86del
tumorigenisis
C91A
5′-GGCACGAAGTGCA-
SKMEL13
Q33X
genes26
.Adverse
Oncogenomics
fibrogenesis
Mesenchymal.
p53wtlike
Abl—CrkII
p.N267H
p=0.0294
164760
frameshift15
AKT8-infected
EEENRDSQQPGKRR
foci.DiscussionWe
processes9
.1519C
air-tight
factors.NF1
MDA134
281–631
rearrangements.30
Thr-to-Met
ERCC2R683W
native-like
SU-DHL-9
132.00KB
.Pre-enrollment
1∶1+1∶2
AAGAAGTGTCCCATTAATTATGTGGT
anti-MALT1
glycine–arginine–glycine–aspartic
isothiocyanate–labeled
non-Walker-like
Eμ-Myc/Dnmt3b+/−
Þ¼
CSL
559/KIT
240-243
CD34−Flt3−
pAD/LACZ
2030
µmol/L
region-1
PEA3-positivity
RIPA/protease
CGAAGGGAGAGTAGAAG-3′
M69
virustransformed
spl
suggested.13,16
ENZ
-3.9
peptidylprolyl
mutation.We
mutation/CNL*
.0000000000000188
anti-BCL-XL
1–120
insulinoma
Aspirate
T118A
-TTGATCCATCTCCCCACAAC-3
breakpoints.8
antigen-bound
GFP-virus
protein–drug
STA-WT1
slow-migrating
10/38
drift.45
AIP-1
levels.40,47
enzyme34
12/36
moderate-size
types69
RBg42075as
603386
32P-labeledfull-length
ERK/FXFP
profile,6-15
TCF3-PBX1
CD34−CD16/32lowLK
µCi/µl
2kb
polymeraseto
insVLR
p27–
pECE-
1SD
500-μL
RWPE-GUS
5.418
Lieberman-Aiden
pJHGT3
.Isoelectric
PBS–0.5
Y537-N348
H3PO4
HxD
I245L
-mmf-max-any-mismatches
ECH-associated
cancer19
IYTHQSDVWSYGVTVWELMTFGSKPYDG
.5152
ins774AYVM
3926
erythroblast/myeloid
occipito-frontal
p.Glu234X
p.K618T
Pro-61
flies.22,35,38,64,65
HKR2
model194
Gudmundsdottir
p300in
.Daouti
c.1844delA
IM.2
HES1/DELTEX1/cMYC
Rb-hSWI/SNF
FISHimages
TafII
10/110
aspect.117b
∼300-fold
p=0.25
SMO-containing
LDK-378
CMMR-deficient
5-GGTCCTTTGGGGTCCTGCT-3
evolve
study32
CRAF-CRAF
D4Z4
5—and
proteins2
FcɛR1α
M296V
“
phase-1
66707
tERK
.ION
5′-GTT
cancer.Figure
tumor-harboring
/g
L688P
01/12/00
MSI+
X-gal-containing
origins1
EF570787
D816-A829
TGF‐β‐activated
A211V
Aurora-2-
B/R
midiprep
91054
skku.edu
recherche
19.43
7.2–9.8
DEC-1-mediated
phosphoylated
IDH2R140Q
SLAMF6
Tip60
region-level
methanol-fixed
Regions—The
large-scale
RasK117C
cancers75
mechanisms.Table
.Last
discordancies
.Reduction
R.S
Yasuhito
q=0.08
clonazepam
PML.1,2
1739–1762
hypothesised
21,205
p11.22
p=0.028
3q12-q13.1
Val35
R161P
10–9
Cyteseer
IC-CRE
delL747–P753insS
dramaticallyreduce
sprouting129
IVF
D.D.-S.
Flag–FBXW7-R465H
HDAC-RB-SWI/SNF
rRhoB
Tsc2-related
anti-VHL
Thr11
​Long
Ultra-high
RBM10‐mediated
-Fo
ActR-IA
MAPK-P
75,495
Siegfried
TNFAIP3/A20
mg·kg−1·day−1
Noninvasive
α5β1-mediated
Y842C-FLT3
AArg
Gradiaet
recurrenceshortly
centrosomes.8
~1997a
cardiomyocytes
.Deviations
PI4K2A
helsinki.fi
P2-enriched
phospho-Thr638
PRC2-catalyzed
p21WAF148,49
AutoDock
asymptotically
proliferation.15,27
surfeit
.Masson
studyp.K509I
read-out
cta
hypothesis.As
L181P
154-bp
signaling46
c.1517_1520del
NH2-terminus
.Osteomas
therapy.9,73
Vpx
MacCollin
AML2
PTPN11-negative
NSL1
R185Q
rare-cutter
GST-pull
caballus
S5E–G
BclxL
18487A/T
.Janus
4â
p.Q475CfsX7
7.FIG
ETV6-CBFA2
21·2
.Critical
M3540
ERK2-L198/232A
apoptotic/dead
47-50
34/−
Mn2
FOP,15
MYC-overexpressing
mortality.24
1937
physiologic
AGGCAAGGTCCCGTCGTAGCAA
al.56
3.0b
Angioimmunoblastic
prooncogenic
genes22
analyzed9
PECAM
expression-level
7/16/12
PURO
1,0
C344Y
IL-10-treated
ficacy
L1–L3
nongerminal
RAD16
13,16
BRAFi-induced
2ITP
paraspinous
GAG→AAG
Go-Taq
I332F
ensemble-based
A1799
Nhp6
xilu
Taq-Man
CAACGCTATTAATCAGACCC
RNA-polymerase
34KIT
DD-mut-SF3B1
18/48
GISTcases
rs3020314
.OVCAR8
Ataxia-telangiectasia
S7A
1.8-
*PFS
0c0
CoolCube1
Y572
8815
hypo‐methylation
FACSCanto
Leu956
MacroModel
15.6
TGFβ-activated
misclassifications
therapy.22
700-fold
CK3
in¯ammatory
8639
anti-P-ERBB4
NUP98-JARID1A
NMD-irrelevant-type
normoglycemia
oral-pharyngeal
samse
39`,50
significantlydifferent
Clonotyping™
38,40,41
SAMTools
aGl
KING22
MOLT-14
.Exome
E1813D
co-expression/co-purification
2268–2284
GDP-bound
1g
P691S
d~agram
kinase/inhibitor
W73
A205P
Marutani
Å
•Decreased
653–658
autoinhibited/partially
V.1.3
CD34TD38-
dermo-hypodermal
unpredictability
GSK3β.29
134/154
Cosci
Axin-GSK-3
–SalI
www.dchip.org
EcoRI–SpeI
Dδ2/LMO2
amino­
Non-receptor
298T
P=0.1565
//www.cbioportal.org/study
0.15022,29,37
future.However
Prodromou
25952
death.6,7
CGCGCTCCAGATCAACCTC
Cdc
5.In
21/29
mechanisms15
CAB05024.1
H174R
V5.0
D159Y
immuno-reactive
mutationsprecluding
PP15-IB4
AML.7,8,27
17–20
MuGAPDH
nonproliferative
kinase/cytokine
I-digested
-2-butyl
58-TTTAAGTCATTCACCTGCTCT-38
experiment.Amplificationwas
ER-WT
IKKβ-mediated
anhidrosis/hypohidrosis
low-activity
.Eilers
R417H
.PMLRARa
:1143–50
MutSigCV
Mb–D18S46–0.35
253-TIITLE-258
Lys642Glu
4.63-kb
HRG1-α
tumor‐normal
pseudopolyps
TKi-R
H2BK120Ub
E781K
0•30
thelarge
12.5-50
M186T
1.027−1.960
4,6,12
higher1
Bosc23
models42
NaCl/5
β-arrestin
pdgfa
differentdegrees
citymutant
33-mm
0.028*
bACTIN
C‐terminal
non-EWSR1
SNV/indels
Consequential
re-encountered
DRBl*04,04
low4
72-fold
Gi-Dicer
EU832531.1
8y
4,12
X-Y
GST–GBD
5′-CCG
RP11-688
.PIK3R1R348∗-Bearing
proliferation.95
heterodimer…
.Li-Wha
downstaging
X0909
R344C
glucocorticoid-inducible
-TCATTTAGGTCTGAGTGAGC-3
FBW7-pcDNA3
breakpointin
300μg
AT/RTs
p*q
−.25
ear12
pCMVβ
kinases.25
2.511
AmphoPack
gions
cotrans
MutSavariant
valine-to-phenylalanine
described9,10,11,12
10−90
Mock-transfected
POLE-exo*
MEOX2
.Twenty‑nine
random-variance
DL-21
5/24
.threonine
p.Arg487Gln
M50
.Inhaled
p/6
bariatric
P4-complexed
p.Arg133*
3-isobutyl-1-methylxanthine
frameshifted
1/149
HBEC30KT
progression-free
2837
pKP22
glycine–HCl
McDaniell
.figure
KPβ–induced
S420
activation-induced
screw-cap
0.1°C/s
N–C
0.1-0.8
CL-11
78428
IDH1-wild
body-surface
56-187
haplotyping
Pancreata
CulII
R26CreERT2
Niikawa
G1052C
Ma-Mel
P=
abraxas–RAP80
Spheroids
AAG→AAA
6Present
111K
transition-state
ledto
R272Q
c.366+1G
PγH2AX
.KCL22
chimericHIP1
1085–1087
pCB6+16E7
Cytostasis
0.739
Fanc/Brca-mediated
MCL.18
S2423L
99,1996
BioVenn
Ala-62
SREdependent
.96
CFP-AFFAQLQLDEETGEFL
5'-flanking
0.0127
+680
PFA
vations
300-step
c-kit.3
thepreviously
antisolid
Msh6/3p-like
0:81873
D14T1
c-Junlow
49/F
68th
U87MG-generated
sponding
PIWI–siRNA
LNCaP/GFP
V757A
NOLA2
GDC-0941
A347G
anti-Raf-l
1998a
percentagewas
pSG5-PKBTAG
300mM
tumors139
ultraviolet-light
5-dAzaC
2.7-
Kavsak
Gln205Pro
p.Ser44Phe
181L
CML.4
ineciency
antitarget
4–147
C618R
agonist-specific
2.0–77.9
CyAn™
cbt-15-768-g3
16,17
3qF2
I8V
nonsensemutations
Nakahata
T9026
FastDigest
PBA
21/28
reporters.It
replating
Asp1001
c.1977delT
GoTaq
50Â°C.One-tenth
seryl
_+
non-EBV
liver140
17A2
non-silencing-containing
Lareau
19–27
Lysis—L6
RhoA-T37A
GFP–VHL213-expressing
unclassified5,8,17
polyacrylamid
R2/stop
Italy.Most
L372F
pyrophosphatase
AS160
methionines
A¡ected
non-HER2–targeted
a.a.
EGFR.68,69
proband-parent
RA48RM
BioExpress
DSBs19
12.5/1.6
protease-inhibitor
MEK1-cDNA
NF-pNENs
Ninein
response.12
TCR
±8.4
Svs6
Neg.MLH1
H295R
anti-calcitonin
pT-E-pY
4.7×
49,56,57
phosphoRSKS380
double-spin
Én
catalysis
ChIP-enriched
H123R
Sry
non–small-cell
rs77228285
61-95
Nic
PIK3CβD1067V
1:60
.Myeloid-specific
extraskeletal
RASmediated
Xp11.4
Val545
P405A
K-ras+/+
CellROX
∼50
finger-related
al.,1991
0.74-1.60
D1017G
/10
pre-mRNA
0.1368
B-lymphoma
433–838
7890A
K5.CrePR1/Smad4f/f
HA-
.M1652I
Czernilofsky
D121V
STK11/LKB1
ZNF198-FGFR191
imai-2im
tgDNA
MSH2c
thatwere
TTATCTAGATCAGAGCTGCTGAGCAATCT
Rhoa32
cells53
20-24
domains.TFG
95/97
Brca1flex2/flex2/p53LSL-R270H/+/Wapcre/+
domain–only
JAK-dependent
Stenberg
mutations.10
14/78
10,45
G52D
Struhl
Br55
IRES-puro-HA
electrosprayed
human,50
SNapShot-based
0.52-0.92
centromere-associated
3093/0/306
studies.Figure
DNJA
NF00028F1
ligand-dependent
analytes
Kdm5a
Tyrosine-1021
SNP_A-4195083
71/F
Gright
Identi¢edTGFBR1andTGFBR2
B-catenin
.Deubiquitinating
4.2–5.3
serendipity
Histo-Tec
Arg266Cys
copy-DNA
.1c
10.1158/1078-0432.CCR-14-0567
access_num=300448
CH5132799
supematant
4A–4C
experiments.https
1–147
amino-actinomycin
Mercola
–ALK
47-52
lli
0.148542342
CRCS
p44/42-MAPK
neuropilin
swathe
4A111–113
Cullin-F-box-protein
translocation32
cold-induced
liver17–20
C2667
ERCC3/XPB
AIS
0.00028
pflagSmad3R373H
+/K
1p
ura3/ura3
Toxicity/adverse
Bcas2
9.7-fold
Rizos
GERP50
atom.17
.Tanaka
19-gauge
carcinoma6
7935
nonsyntenic
Myc-TrkA-P203A
gene.15
defects16
0.9139
Vb.3
NOBOX
activation.4
Mammary-inducible
swainsonine
conThis
TransIT293
wi.mit.edu/cgi-bin/primer/primer3_www.cgi
Ezrin
Ptchþ
forkhead-box
rs1748
HA-ubiquitin
989f12
formaldehyde–PBS
8.461409125
H-ant-p16wt
`Proportional
Breast/ovarian
D425MED,25
Kinzler,1992
CoCl2,26
D.oj
FGFR1_WT
pPB
Ser244
methionine
neomycin−resistance
5'-CTTGGCTGAGGATGGTGTA-3
K2729N
mutations.37
Cox-model
.JUN
protein–1
IDHmutated
mutants.52
Amili
232.7
ß-catenin/lymphocyteenhancer
22432,33,34
Wechsler-Reya
V831M
difference-values
ten-eleven
c.405+1G
rightward
K575/K1
c≥0.8
0.0156
3-urea-substituted
Gln61Arg
AER-FGFs
2.385
consensus-enriched
MG6R5
12/151
PTEN+/−
CPWT
B-raf-deficient
haplo-
actin-
Treatment-related.If
sh2
NM_000249
PTPimpaired
and5
Munemitsu
SOX17/MAML3-overexpressing
GWG
pepstatin
SPOP-depleted
0.367
E626K
ste7
BRCA-like
tumors—irrespective
1,427
3029
RP11-722F1
pseudosubstrate
c.1304T
SKP1-cullin-F-box
centromere-specific
pro-
conspicuously
p110aselective
germline-tumor
8wΔ9
S728
SANT-associated
TPM3-ALK
MDA-MB-231-luc
BC018119
café
Clonetics
Clapier
PDGFR-negative
Haifa
R373
gliomaspheres
centrin
M-BCR
package.7,8
2/00
1.03/0.15
.SPOPWT
nonmatched
CBMA
C57/BL6
664–746
5650
Methylated-CpG
RP11-571I18
resynthesized
I359L
SAAX
227R
ETV6-RUNX1–containing
Membrane-bound
NRR
DM2000
reported.27
2640
Green-shaded
L91R
20.0-fold
phyrew
RP11-1036C2
selection21
Gaudernack
c.932C4A
telomerically
Epilogue
1.3-
Gandola
NOTCH1.16
83.2±15.9
Skp1-Cullin1-Fbox
Muerer
Ha-ras-1
expresFigure
L938A
specific-pathogen-free
Thimmulappa
enteroscopy
GeneJammer
Flag-BRAF
​Fig.4
Analysis—To
Akpexpression
SALE-Y
PTC128
72–76
K309-Ala309
p42-ETS1
.Processing
repeat-like
piperazine-N′-2-ethanesulfonic
reports3,7
elucidated.12
cullin-binding
BL578
21–27a
S3L
arginine/lysine-rich
polymerase.For
richard.hamelin
IO5
PCAP
Weedon
ErbB1
1322
67,68
2-methoxyestrone
ATP
Bio-Plex
vector.For
RBD-mutant
CNL26
v2.5
crizotinib-
S141L
300032
TGF-β-signaling
.MPD
3,4-
mutation-negatives
microtiter
Ry
GGACAUUCAAUUCAAACCAtt
SmaI
D5S409
20.250
tumours4
freq.
glutaraldehyde
4686–97
1.64–5.53
FLUOstar
50-59
nitric-oxide
Keap1+/
581–606
.Inconclusion
81,103
2DAO
Stiegler
U69273.3
Supplemetary
MEF2B-binding
families.12
MPLW515L
66–95
Trithorax-like
ATL-derived
Ms4a2
Y1721
L1196Q-
FusionSeq8
c.8764_8765delAG
//www.ncbi.nlm.nih.gov/Structure/bwrpsb/bwrpsb.cgi
NimbleGene
TrkB-
α–EGFP
.378delT
TSC1-N
pathway.100
GFP-C-RAF-RBD
E9.5–E12
1-binding
V7
cytoscape
seen.14
IGF-I-induced
c.134A
0.25–11.5
.Anonymous
L381H
CFU
hilum
II:3
shown29,30,41
D808N
chx10-cre
Ahr
Harmonization
chr1:78193604
serous-derived
EGFR-delE746
instances.2–5
hematoxylin-stained
RNAligase–
5′-CAGAACATTGTTCGCTGCATTGG-3′
bladder31
2HG-elevated
K63-linked
1JNX.pdb
Doxirubicin
-k
Inmunología
89-amino
Martinsson
39-43
Lei
Sca-1+Lin−Mac-1+CD48−
diet/OHA/insulin/unknown
c-IAP1
Ala489
19q14
inasfar
proteolysis
ex20a
SUP-T5
't-
4-OHT-inducible
pathways55
transcripts.Summary
F8
2006after
3955112
.Parameter
61±25
CBP-HA
FASL
10:186–195
cooccurs
linearised
Kriauciunas
transferPost-selection
−58.45
levetiracetam
.D-2-HG
D1228
GSE21780
6935–42
anti-CD79a
sporadiccancers
03/01
SGC32593
NCT01801111
PCR-dependent
5-HT
elsewhere.34
aFulfillment
HL-60
Y992
CIMP
CGL
cluster-forming
Heinrich
months-76.9
microarraydefined
1628
5749
Gal4-DBD
CyclinD-cyclin
-8p
Tcf1
8/126
suspension-induced
49-228-
al47
Paediatric
Glu62
M37K-
.POLD1
p=0.0018
w7
pTM895
5/12
youngerage
PR−
5′-CCGGCCTGTGGTAAAGGTGGTGTTTCTCGAGAAACACCACCTTTAC-CACAGGTTTTTG-3′
v/v
deepen
GeneGoInc
0.67±0.10
.Alower
93–0828
RBPJ–firefly
S.H.C.
RNA-seq14
Whole-exome
Brca1Delta223-763/+
PS3
72.5
passaged
gg/ml
papilloma.6
mutation-to-mutation
hWW45
inverse-length
TUBB4
c.92G4A
p.EEEELQSQQ1919fs
oligonucleotide-selective
serine/threonine-directed
blocking/permeabilization
-0
Dicer1lox/lox
inserm.fr
Ilwon-dong
cycG
meduni-graz.at
0/427
pFastBac-system
rAGAGGAGG
thiogalactose
literature31
Gemcitabine
FAT1b
p27CK
.380A
c.82+60C
V1804D
Ringel
proto-trk
AGATCCACGATTCTTCGCATTGTC
redistribution
3464
RASopathies.83
antihistone
Lys273
.Wequantified
~g
Phred/Phrap/Consed
Cebrián
mark3,4,5,6
FGF19/CCND1
GATGGATTGCACGCAGGTTC
0.01798
thymine-DNA
HuGene1
.Dashed
pre-B-lineage
NH4Cl
myopepithelial
.Lats
repatterning
.Varying
.Preimmune
V150
gamma-2A
attB
ApcMin/+Smad3+/−
Asp770_Asn771insGly
Acea
~500
i.g/mileupeptin
R578P
.Pregnancy
isPrQPrQ
.Knudson
promote-maintain
73/250
1/138
Phospho-HA-Akt1
GACAGATTTCTACCACTCCAA
c.-110A
CCUGCUGGAUUGAGCUACACCUGAA
exome‐sequencing
Ba/F3-hKIT-Y570F-D816V
Epsti1
Ras.GDP
5'-CAGTTATTCACAGTGGCCAT-3
2×30min
10-30
translocationt
CLONality
outcomes.4,5,7–10
pSH18–34
NUP98-homeobox
Third-degree
PGK-GFP
20076
mock-treated
.Anti-HSP60
anti-CHEK2pT68
.Illumina
behavior2
4Bb
processes.9,44,45
TFA17
ERK2Y131F
3-kinase/AKT
LRRC15
-documented
Hollstein
D2045N
VHL-associated
NEBuffer3
NCT01353222
1.4/NA
MFHAS1
WW2-GST
V180M
MDS/MPD
druggable
aromatase
UCHL1
P199Q
×106
A85V
Thomann
Δ=0.038
CTLAIg
.IC90s
R1399H
NQO1
pI=6.3
antinuclear
fr/43
S33A
Thr733AlafsX5
P12
E3a
H452R
somatic17
pFTX9
87.6
RP11-16G16
PDGFstimulated
SC322129
cancer111
FOXO1-stimulated
expression16
KPL-1
4694
as-R201C
Transductions
acetate/10
myelodysplasic
L209P
AML.7-9
SANT2
Marco,1,2
S3/S1/S3
L/I/V
H62162
5′-FAM
MCL.29
Gerfin-Moser
Feramisco
3047
GAACAAACA
0.67-1.44
IVS18+1
Case–
tubulin-gal80ts
BMS-582664
10.1200/JCO.2006.06.2265
dinitrophenol
NoLS-FGFR2WT
Schulten
SPOP-knockdown
RUNX1-390F
AGAAGGATCCCCTGGAAGC
PSMD3
8681
.Ras
IV++
CIN85
S-phase
MMP20
Rac/JNK
IgD+CD38−
109KB
Aphidicolin-inducible
.INTRODUCTIONTwo
N63949
Coulomb
K366R
L390F
4Division
H1746Q
Schnitt
L-alanyl-L-glutamine
Width2/2
1289delC
3452del4
IHC†
nonreplicating
non-p190
A1762/T1764
Br63
1/180
YWHAE-ROS1
4,5,7,11-14
RRL
phosphoSTAT5
anti-CD3-mediated
pcDNA3_FGFR2
Hs01556702_m1
R273H
10m6u
OLIG2-positive
NB7
C15orf21-ETV1
detract
PMIBiot
Dighe
224895_at
definition.Correlation
5′-ACATCAAGGAACTCGATCGTATCATTGC-3′
6NP
5′-atctactttctcccttggttgacat-3′
activity.28
i~n
178K
6–150
719–998
DYX2
intrafamilial
Chailler
uVa
348-1018
S100A9
AML-TSC
Whetstine
maternal-null
C176Rclass
4768
D260N
al.21
Gln1556GlyfsX14
3y-OS
–150
pQCXIP
5022E
BCOR-related
research-grade
Demeriglu
dihydro
CBR3
ccatcaaaagctgagatgaaacag
oncogene-driven
SomaticSniper43
syndrome30
non-breast
508–517_907–916
GAACCCTGCTAGGGAAGAGC
discontinuation
-ABD-N
estradlol-independenttran
KEAP1—geneticists
Disel
GCCTGTGTCATCGTGCCTGG
Cd44
cip1
Autopure
c-Kit1
C4
11.52
Raf-Mek-Erk
oncogenic15
ductular
third-degree
32-74
LNCaP-stable
intestine144
microtubule-targeted
4-chlorophenyl
Geneticin/G-418
68292283
6130
ER-independent
.SOS
ER3
Technol
Rasgrf1
K440
system.16
Ubiquitylated
P∣x
Nkx2
Tamaskovic
599-lAGgt
.ZBP-89
A39S
4088
anti-α-tubulin
antigoat-HRP
11Divison
specialised
astrocytes14
13-hour
Oligodendroglial
mutations.71
Abl-SPOP-S119N
therapy.42-44
3.4–4.0
Y324A
FE11
HDSN845
MIM♯
XPF/ERCC4
supernumerary
Hybond-enhanced
1.04
METand
15/219
slideImmunoblot
mpeg4
-l-arginine
phosphorylation15
Com13.2
Thymus
1mg/ml
PKCζ/PAR3/PAR6
9145S
non-depleted
maternalgonadal-mosaicism
immunodeficiency-related
1598
.Thymidine
.Histopathologically
KIT/RAS
G863S
gene/cancer
Ajia
0.25mg
anti–phospho-STAT5
HOTNET33
10-9M
421.00KB
c.515G
SD/agar
IL-10–neutralizing
BRCA1-PALB2-BRCA2-RAD51
co‐transfected
5′-GCCCAGGTTGGTTAGATGAA-3′
SMG7
DbpA
A391E
pathway-bypass
ApproachMutational
Hoogeveen-Westerveld
Sidransky
mesoscale
AML1-CBFβ
status27
insGVV
P.G.H
communication/in
SigmaPlot
KRAS-mutated
f/51
P=0.092
pathways.EWS/WT1
Q249E
53,54
anti-phosphotyrosine
.4,15,16
electron-rich
1351–0088/11/018–603
INV
.WW
'O
12-cm
/control
multiforme,13
contractural
.Non-targeted
Chromo4™
RICTOR-dependent
NNMT
uncomfortable
operator.20,21
54b-9
HA-CRAF
glutathione-sepharose-conjugated
Takentogether
11,14-17
study.Clinical
0.0374
SIM-containing
Okuno2
LR11-070
.SINEs
enzyme-dead
260
FLAG/HA
growth—even
HER2/neu/ErbB2
BAT.l3
2q33
1993Nakayama
period.35
.Two-thirds
29,30
5′-RTGABnnnGCR-3′
synthesis30
glytine
affluent
transheterozygous
ABCB7.17
myo-
WGS500
H-bond
-GGAGGATTTGACGAGTGAGT-30
Tyro3
HOC-313
45-81
ChemTrade
KinasesMAPK
ligand9
Lys-373
Smad4
ITDWTNPM1MUT
B2/B1
RafY34ODY341D
sequence-conservation
Ser123
032682.5
Biddick
radiologi‑
'Maritime
E2F2
1792_LUNG
nonallelic
6A-F
FLT3+
W.G.M
IonXpress
1q+
2783A
//www.agendia.com/
.Filtering
lambda0
Apo
alleles.24
Phospho-4E-BP1
R175W
741
nonimmunogenic
p3TP
Huntingtin.20
.Estrogen-receptor-positive
A2T
subtypes23
avidin-hiotin-peroxidase
PEG-NaOAc
ATACACAGGTAAGAAATTAGGAa
Frayling
GFEA/11
Nyström-Lahti
M1592V
Gln140
francesco.onida
W484R
.Semi-quantitative
C1253Y
delGlu746_Ala750
91-base
.FDR
FUOV1
C/C′
4823
5/611
51D1.3
81-22-717-8547
ERAD
p.M90I
ARTICLES•
M2327
again-of-function
006o0
re-capitulated
Smad3–
polyinositol
AHNDMD
Fanc/Brca
L747_E749
*P≤0.0032
K-roi
5.22
Jak3
c.2459-18delT
.Higher
Nrf2KeaplOxidative
T187A-T198E
3–26
XP1200
PNT2C2-dETV1
5íl
Minho
fate-mapping
R588A
P388/CPT45-GFP
ETV5a
pCEFL-KZ-AU5-KRAS-wt
S1-AS3
11N
FBXO15
D1-deficient
n=17/132
Levy-Lahad
c-H-rassequence
Nicastrin
Hh-responsivity
Noninflammatory
cDNAclonecontainingtheentirecodingsequence
FANCJ18
polytene
A723
F4-I-1
.Phosphatidylcholine
Q2384K
leukemia,58
0.198
-L2155S–
40.60
oligo-aCGH
redsidues
1Rβ
Wide-field
Delta1523–1554
Sox18
Nonpathogenic
1OPL
thienodiazepine
Reprosil
Psychoeducational
H2AX
R1247/1283A
varyingdegrees
carcinoma.19–22
10µl
Shrake
nal
HOMA-IR=fasting
IFN-g.
hemicrypts
E-RareJTC2011
Ziada
organ-transplant
I132M
G2M
Flt3-WT–expressing
F-test
marrow‐derived
ZNF217
2.773
nSHi
​,2E
600–mutated
NFP
loss.11
×45
.Stereoisomers
dCTPa-
with1
nonpolyadenylylated
p53-pathway
.18–22,38,40–47
8000
andothers
chloroform–methanol
HIA-DRBl'04
Novitch
MACC1
polyhistidine-tagged
del17p53
H93Q
MuTect12
T-cell-mediated
S3307
disfavours
EGFR-Mutant
.FOXL2
D15S1269
megakaryocyte
anti-phospho-ERK
8-globin
q26.1
Fgf8/Wnt1
11.4–12.4
100718
Skp1-F-box
V804M-mediated
Sma-4
CIEMAT
Yanagihara
5-a
p.Gln268X
//www.genome.med.kyoto-u.ac.jp/SnpDB
sc-486
cases.8-13
UGT
MLL/T5
models.5
:2137–2150
Fug-III/23
ID17
LB1
72·0
peroxidaseconjugated
3847
digitised
IKZF1
sc-53140
15/40
176,260
0.596
~1.5
RapaLink-1
heterodimerization32
Lys558Val
cdd470f2
ARID1B-pcDNA3.1HisC
expressivity-guided
5'-GGTGGTATAGAGGCTCTTGTG-
IDH-mutated
PIK3R1L370fs
0.60
30290
tvpe
S33S37A
Arg515in
Mgat5-/-
EGFRIs
gt-or-equal
166-168
genotype/phenotypeassociations
A/BΙΙ
bydierent
∼6.6
MART-1
CEIDPVKLKE..
2.23×10−5
origin—have
methotrexate
P.V774M
Figure6,6
BUF/N
NM_001171197NM_001171195NM_001005217
–37.2
triplicate.The
.Ptch1
-2,5-diphenytetrazolium
basal/mesenchymal
efficiency.Table
Rgb
5′-CTCCATCGAGATTTCACTGTAGCTAGACC-3′
Sedivy
.Electrophoretic
preferntially
ID3
Jallepalli
DNA-ladder
MET—in
Notch1‐induced
K43R
EIF4EBP1
al18
TCGA-06-0190
BH3-interacting
Ala501
RAS-knock-down
325–356
Mandel12–16
GAL4-responsive
84132
mant-GTPγS
re-analysis
core18
Notchic-induced
kinase-domain-containing
AAG-3′
V5-epitope–tagged
pathways.3
p.A113splice
52/76
DL-dithiothreitol
17-24
dominant-acting
CVCL_0031
EN-NIH3T3
methionylaminopeptidase1,2
Gai
CRi
NXp
FRYL
Ki/Km
.Tamoxifen
adenovirus-associated
reports31,32
independence1
TM9
.P387
4362
=0.01
.R47Q
pF1KA1549
MockWT
3397
1347-02
VEGF-C/VEGFR-3-induced
.Epitope
mutation31
DOT1L.8,9
C51S
genes21
11ThrAla
Abruzzo
ALKM1166R
/without
findings25⇓–27
activating.11,12
H123D
Ac-CoA
counterstaining
pCMV5-ACVR1
trp1-DH1
*0B
16R6-2
I2113F
97,98
bioweb.pasteur.fr
JMJC
3,4,8,12
.N581D
RAS-activating
Lod-score
receptors.19,20
Gln373
activity.14,15
..HVLFT
AC002454
EID-
event.34
anti-p21cip1
.Predictors
methylsulfate
616451
DFS
beg
prolifera­
Pi/min
1498del5‡
BamHI-A
A87P
RPFI
α-type
.36,37
//www.genome.jp/kegg/pathway/hsa/hsa04110.html
NTRK1activation
p-nitrophenylphosphate
Glabbeke
R600Q
sites—interscapular
leukaemia4
M1/70-allophycocyanin
gamma-irradiation
168237
KIAA0562
Allory
BR00-0587
1768delA
normal-adjacent
G12D+G12V
457,500
5′-GCCAAAACTGTTGCACCTT-3′
54-year-old
L225LI/R35A
Bmi
E884
K518
gene-fusion
APPBP1-UBA3
mesothelioma,9
OCSfl/fl
agammaglobulinemia
activity4,8,11
V600EBraf
gene-specifically
.Student
ISOpure
acid/2
anti-histone
phenotype.45-47
KLHL9-Expressing
mfa2
PIG11
I25T
enzyme.29
Glu545
suppressor1
L40
CGCAGCTGCTCCAGTTCACTGAGC
pASZ11-TRX2
.E2
phospho-Elk1
Ptpn11E76K
TRAIL-R2-mediated
R128A
16-green
acti-
8a–mediated
Aminoacid
lines68
non-ARMS
McCart
-deleted
BRCT-mediated
androgenablated
3Corresponding
55-year-old
neutrality.6
Arg-172/Arg-140
Ha-rasV12
c-KIT-transformed
NCT01099514
Jβ1.6
.Besides
11,39
p.Tyr381Asp
Pseudo-color
-*3
shRNA-expression
authorPhenotype
NCT00794781
CCAAT/Enhancer
gene-linked
theoretically
PE-labeled
GGCTCCCTGACCACCTCTCC
mono-specific
Shangai
SHEP8
vanilloid
1–485
FLAG-Elf3Δ235–260
.Absence
metaphase-to-anaphase
ΔT/Ti
5q14.3
5′-AAGATCACAGATTTTGGGAGGGCCAAACTGCTGGGTG-3′
L172W
mutation-prevalence
SuperSignal™
FR4
transient-transfection
protein-associated
15–49
troy.torgerson
reports.28,30
anti-H3K4me2
Gal5
a-cyclin
14q21–23
UTR-MUTLuc
NSCLC137
DNAC
protein-
M2-conjugated
new/suboptimal
ErbB2_ex24-27.SF1
335–789
3j
triphosphate–labeled
Non-adeno
OLIGO
.Myelodysplastic
Weidner
Rpt2
IDH2R140Qhm-t/HoxA9/Meis1a
B220low
pMSCV-PDGFRADDIM842-844
imatinib,31
∼0.5
V804M/S904C
Lin−
neural-imaging
megakaryopoiesis,12
soft-agar
PTEN-shRNA
RPTOR
transcriptome-unaligned
40/80
​Table22
pGEX-APC-4
grooves.1,2
Reversade4
GAP-insensitivity
mxSF3B1K700R
RASSF1A
sunlight-damaged
.3919A
PXXP
Bozzetti
Basso
leukemias—were
pcDNA3.0-mElf3
tributylamine
Maxwell®
tricine
PIWI-bound
Asp491
phosphotyrosyl
pR54.G484R.1
AML.16,17
not-treated
NC_000012
μRPLC-electrospray
423insAAGGCC
1.04–1.81
Swartling
slideswere
P1-P5r
FA42
70,72
dose–
TC10
46y
5′-GGATGGATAGCTACTCCGGACCTTACG-3′
Anisogenic
IKK-β*–expressing
G364R
Runx3-deficient
pThr598
0.614
CLSKKPLEEKPSQPYSARE
5′-tcacgctgaccatggccaag-3′
c.-124G
0.00949
translationstarting
165360
glycerol/1.28
T288D
.U251
BD-FANCB
KPC1-KPC2
cells,37
Mps1
ger
GATOR1
12–22
HLG
forward-ACCTGAATAGGCAAGTCGAGGCAA
Kastritis
CEP152
3
2−ΔΔCT
Raf/MEK
p32.3
R.K.S.
fluorescent-labeled
V+/PI-
JH116-R:5′CTCCATCCTGTGAGGTTAAACACAT3′
PRB-159P
thalassemia
SVZa2
mutation.28,31
V731M
.Oncomine
tranversions
'Runt
β-gal
GAAAATGG
E2-challenged
7425
NIN
absent23
Z-DEVD-FMK
5'-ACTCCCACAATGCCAATAA
GQYIMAKQLYDEKQQHIVHCSNDPLGELFGVQEFSVKEPRRLYAMISRNLVSANVKES
0/1,092
CATGTGGGCCATGAGGTCCACCAC
S287W
BIN2
palladin
Phe+3
cancer-chromatin
Talghani
KNS
metal-ion-affinity
R1275Q-mutated
erbB4
5.4+
Frye
Febraury
8334
V326A,24
594-conjgated
LC-2/ad
Card9
8Δ
floating-bar
genome.38
receptor-2/PDGFRB
H1435
C507
29443697
DiC8-PtdIns
M470T
18-09
Arg77
Mutation-independent
ofMutation
769–1,111
multi-tumour
Del-PPGY
NAMD
G1656D
20.03
164208
99,000–101,000
T11348
MMI
myelofibrosis.76
inhibitors.59
S1078Q
Triton-X100
CLL.34
30-year-old
late-diabetic
coitum
BMS277/2CE
mountain-and-hill
Cox2
CALM-AF10-positive
treatment11
S587T
methylation.22
NT011362.9
K19-Sox17
5′-TCTTAATCGCCTATATGGTGGTAACAG-3′
c.1443þ2_þ13del_p.splice
Sos-mediated
HEPES-buffered
5000mg
25/2322
pLXSN36
.Med
pacli
1–297
4.6.325
125X
80.1
gate-keeper
6/41
p110α-binding
superﬁcial-depressed-type-like
−1.24819
sample/plate
2200-6100
tRaf
Skt
11070
gene14,16
Subcloning—
HB-EGF
+cetuximab
H658Y
retaintranscriptional
Asp65
c.2009delA
BOB1
Nf1-loss
inititial
colonand
38-fold
c.281
D756
SMARCA4-null
-inducing
–YFP
ETAL
ElpisBio
3G4
-CTGTCCTCAC
blot-transfers
4319
ERP001454
410-502-2905
KLHL20
arrhythmogenic
malignancies16
one—directed
*premature
p.L178P
Y226
TFAP2B
tumors.15,16,28
shTet1
37.7X
Gsolv
SLC3A1
N958S
.Intermediate
withDNA
non-KRASG12C
.Fig.6C,6C
p.E64K
chemoresistance.47
RTX
TGFBR1p.R487Q
observations,18,19
p.Arg99Pro
re-probed
Ptpn11D61G/+
CEBPA2
pcDNA3.1-DDR2
proilferadon
migrating-specific
55-nt
TRCN0000026154
R-CEEP+
,760^769
pileup81
methanol-acetic
differentiation9
DCFH
Smad4Δc-producing
N-oxide
II-9
genes.10
//cran.r-project.org/web/packages/gplots/index.html
V600DBRAF
Bortezomib
P=8.338e−05
aneu-
5′-located
RNF8/RNF168-dependent
16/20
Epo-independent
apoptosis-promoting
post–crizotinib
.RPTK
carboxy-terminal
6.Structural
RAS74
C618F
Wnt1-Fgf8b
doi:10.1158/0008-5472.CAN-06-1968
∼450
Kilbey
Zak
13,680
influenzae
ERG-50
Kolltan
LGC-C
.Peptidoglycan
NM_000368.4
Heart/body
Database8
CD11b+Ly6C+
1:50–1:100
.State
1.5–17
Q1747H
ERK31
oxygen-induced
Ata-UrRasheed
52â€
β-H1
n=39
Pack-yearsc
noninvolved
gamma-
1749-1
E-helix
TACCACATTTTATGTGATGG
11815016
26.3
genes92
32P­
2.563
months.6KRAS
anti-MLH1
ARE-luciferase
HTB-72
re-implanted
captisol
V600E+L505H
p.K642E
recently42
rs13181
672
databaseSearch
phospho-MDM2
U97196
FGFR-amplified
cox
.M57732
multi-ubiquitination
.Calabresi
LRT
AML,17
-Arg245
18.3–20.2
P326L
CDC25A
.2872
oligomerization10
048
P=0.016
lX
p=2.7×10−37
PmeI-SalI
0.51–1.28
ER/EBNA2
Homotetramers
hMSH6
Y766
1908del
.3G–I
-to-A
TCCAGACCC-3′
Tyr568/570
~24,000
GENOTYPER™
DRB1*04+
F180C
∼280
CCK-8
mid-upper
PromoFluor
di-phosphorylation
Tgf-βRII-deficient
del-mut
models.9,16-20
SRCS.10
mutations.8,9
CD3þ
TargetScan35
tetracoordination
mantGTP
2xl05
aOC
RASAL2
RTU-CD20-L26
pCMX-IL
biliary/epithelial
NiNTA
RAS
maIm-fixed
Site-Directed
nih.gov/
sensitive−
B*5127N
anti-CD45.2
-AID
P-0001042-T01-IM3
protein140
7.54
Speri
D5S2117
translation-dependent
monophosphorylated
64-76
Koodish
Mut2-
Quik
in80
CMV-5
Hein
.049
FLT3-ITD627E
p=0.015
220–498
978-750-8400
duration.8-11
TMEM123
C/EBPε.The
CCAGGTGCGGGAGAGAGGC
W4R
LGR
1.60-Å-resolution
angiogenesis.18
28-32
NRP-152
2=10–50
Method-S8
BTL,15
MEF2C-associating
survival.9
4FIG
quiescence36
K114E
ex3F
tumicamycin
QSTAR
Refractory
.ERBB3
425.5
MRN–CtIP
PMLRARA
mesodermal-specific
GGGCA
Ini1in3
care.Identification
J/m2/s
L224P
26–40
5-GGGGAACTGTACTACAGCATTGA-3
D61N
HER2L869R
BAF180-mediated
0.03–0.85
uH2A
1=1
tumourigenicity
YFPstopFL
S9G
ECMatrix
Tainsky
LA-N-6
cytopenias
trimers
UICC
pub/BRCA1
P138L
K-RasG12V-mediated
SMO-D473H–transfected
Cd19-Cre
EGFR/ERBB2-TKI
++++++__ITP25
PLC-g–mediated
p.Trp281Leu
sub-populations
DOPEY1
C1834D
timeframe
10/1
EXPO32
.located
.Misaligned
bSignificant
ADE
concetration
1.300
5,592-nt
proteins54
.MECVDSER.P
TAF15
Wiestler
'capturing
mmol/mol
Mufioz
Hypersegmented
Arg38
STYK
Roozendaal
pK62R-FLAG-Rev
1216T
CYTH4
spearheaded
ViraPower
TCGCTCTGC-3′
asparagine-thumb
C11orf30
Jandel
NRF2
F-2000
cathode
anti-ERK
tgf-β
CD74–ROS1–positive
translocalized
V617F–negative
OncoSNP
*0
D22S1150
γ‐secretase
Flag-Akt21
IDH1R132H/WT
anti-PLK1
1.3-1.5
phosphatase-mediated
Ser136
V427
pathway.14,29
MMAH
7H–M
0.7–1
inclusion/skipping
1158
Yuza
Rac1
110–744
E166_E290del
pH4X8-Luci
21A282
FXpSXP
8.831015875
CTD-3180G20
PVAI
.cut
pC53-SN3-H168R/T123A
NaH2PO4
-10q
.9-11
DP2
2.157–25.454
rare3
Cys273
V130I
superactivation
repartitioning
2145
60×/0.80
PLCd
JAK2-neoplasia
pLNCX-HA-mAKT1-K179M
Z0622
260–270
Sloan-Kettering
.EBP50
TCRβ
Gli-similar
32P-labeling
Biacore®
neurodegeneration
CCTCAACAACCTTCCACTGTACTT-3′
F3290
Aptamers
Glu-26
.88
localizingto
CRC.25
liver-activating
formalin/glutaraldehyde-fixed
L/min
HER2-SO/CEP17-SG
PGK–tk–poly
Ets-2
1:15000
p53-interacting
β-transducin
doxorubicin/carboplatin
ischemia/vehicle
75.8°
541–1709
postnuclear
Fukase
inhibitors5,19
174.3
19q13.2-q13.3
toexclude
wasused
anti-phospho-Y1068
.Gly294
*Minimal
rs5030865
CDKN1B-R3F
L224
Coultertronics
MDDcontroltumor−bearinganimals
~60–70
NUTM2A-CF2
p120-Gap
Polyubiquitylated
condition2
phRL-CMV
RCSB:4A15
APIP/SLC1A2
nonfamilial
High-Performance
acid–sensing
potentently
PD-L
2β-mercaptoethanol
Schleincher
K0301
mRNA.In
non-ESFT
.7560
4C9105
9401
.BCL10
Bertolli
signiﬁcantdifference
EHT
21915
ERK1K71R
al30
heterozygoes
+/
p.Arg512*
O'Gorman
lineagetracing
Staff15,16
miR135a
–Lineage
1:0.8
T+C-rich
oxalosuccinate
~~~with
pathways100
CSR
immunopreci
7.50
SOS1-catalyzed
.Exposure
595delACT
51410
L127H
41.95
T1464I
peak-calling
anti-MSH2
MLL-associated
Schadendorf,2
Hozyasz
UBL1
.Eleven
tableSix
anti-CD21
β-catenin–YAP–TBX5
BTB-domain
R-Smad/co-Smad
TKIs.Table
Kemptide
L120
Ile36
observedfour
oxidants
Knoop
R248S
Tpr
GFP-SSRP1
PTPRD-interacting
mAkt1S473D
8.36
.PKN1/ROCK–
D171A
dihydrotestosterone
135–893
1kb
pC53-249S
HCKAGKGR
alÃ-eles
large-chain
64332
5′-caggtggatcggcgtacta-3′
radiosensitization
.1A–D
nucleotide-independent
PI3K/AKT/MTOR
irregular-shaped
37/52
shNF1c
HSP90-
antibody-resistant
320–332
carcinoma.10-12
4874
substitutionreported
pan-PKC
KIP1
.Differently
does.4
Ras/Raf/
neuroblastoma-derived
0.3933
151L1
1C–1E
71D10
205.0
de-multiplexed
GCGGGCGGTG
14‐mer
Pajares
c-Kras
NM_019508
A21202
replatings
20−2.5
Pre-C/C
/NCOA3
TGF-B
07-448
Myc-driven
18-hour
TCRγδ+
CDK4-p16
disorders.1
investigated.22
FlorOpal®
anti-Akt-CT
HA–B-Raf
cues.3
plexin-B1
42.17
G.D.Plowman
q11-q21
Vizmanos
chromatin/histone
MSCV-IRES-yellow
Hoffman-La
malignancies.3,25
weoverexpressed
Poremba
Syngene
31·2
breaks24
.4885
CD2+
232H24
retained14
integrity1
PNT-domain
allele.Expression
zary-like
.CBFA2
6,19,44,51
gpllO`rk
25–48
MGNT
CCTγ
pDNR-CMV
types—TD1
9.5–11-fold
N233K
6–9
22nt
myelin-associated
Lgr5
I1172M
F-Luc
serum/plasma
T68A
p85-GAP
CCL21
P=8.66
forms35–37
Sitea
N/D†
architecture.2
erionite-containing
6836
andcytoplasm
K18A
10p13-14
.Luminal
PI3Ki
IP3K/Akt
5080
StuI-XhoI
1994,2001
wl
97–1
Bioactive
Blimp1-deleted
nonubiquitinated
60/832
TCGA-A7-A5ZV-01
338-366
DNA/RNA
eachrun
Piwi
Rb-deficient
P-body
R139X
frameshifts
Bonecchi
translocation-mediated
PI-3-K–related
enumeration.Copy
100μg/mL
UsvY
Archaea
5°
Ducommun
pathways.EWS
P=0.163
.7198513.
PCa2b
1,809
5'-ggtagaactgcttatagaat-3
γ
proteasome
line–
SCFFbxw7-associated
Histologya
HP1-γ
Ade7
A418–F421
α-Q510E-Shp2
VSN-normalized
200
pDONR221-wild-type
c.5312G
21283–21295
D1/CDK4-dependent
Asp131
Schu¨ler
miR-210
A132P
RNAi-silenced
cor
p.Y102fs
IKZK1
Delta559
ApcΔ716knockout
TK.89
EEF126
104BRCA2
proneural
Junyuan
R579*
ATP–inhibitor
167,131
P-value
tested.17
Mizuiri
injury-responsive
Heregulins
lymphocyte-predominant
.E3810
Kalpana
autoclaving
S3.1
nt1567
wereW8/32
development.33
A1778T
deubiquitylate
S3.2–3.3
.Triple-negative
44,46
Kehrl
mutations3
397mel
MboII
p.K23R
lines15,16
EWS–ATF1
activity.4
nephroma,17
3217
profiles.4⇓⇓–7
Interdomain
annexin-1
groups.15-23
pcBASce
archivalmaterial
Polytenes
phosphoMAPK
Ju-Ming
MB231
HMGA223
Notch1-11
GATA3-dependent
5251
0.25KRAS
1.056–18.708
GLK
HoxA9-immortalized
.PFGE
R102
A1067T
EZview™
β3–β4
RAS-MAPK-MEK-ERK
~215
Cytoscint
1,987
74y
Spectrum-Green
Dominant-active
snap-cooling
14–
y-~hain.~.~
endoglycosidase
R669C
M146
hyperplastic-dysplastic
c-nu
arrest.4
CDC2-related
lab-on-a-chip
2/2012
IL7R
GTAAACGCCCACAAGTTCAGC
reprobing
Institute*
//www.genet.sickkids.on.c
stopped-flow
T43I
snoRNP
.A159T
//www.genome.med.kyoto-u
Homology
.Y641
14q32/IGH
V+/PI+
Merabet
distal-most
SHL
13000
-5-
ImageQuantTL
220-
p20
0.7502
GAL4-ETO
p21+/+
progenitor
Tyr1234-1235
TDP4334
442-456
pea-sized
GAPstimulatedhydrolysis
sexually-transmitted
'initiator
Sigma-Genosys
Trr-enriched
small.33–35
lipase82
antigen/surface
6D
Bozic
Immu-mount
r.m.s.d.s
crizotinib.12,14,16
0.2–0.3
.CBL-mediated
.ZMIZ1-ABL1
.Brg1L
5′-GGTTGCTCCACAGGTAGCTCTA-3′
Huibregtse
TMPRSS3
Episomes
118.0
11ZF
.019
V470E
G/
Y-MESO-9
FLPE
.04042630
TLR3
CACACACTCCCTGCCTTCTGT
V+/DAPI+
Glycogen
viral-cre
DxETGE‐containing
Panitumumab
0.002a
Rhijn
4Â°C.After
+1delinsCAACAT
1693delT
5R
V259F
Monoterpenoid
methylation47
CTTNB1
ATM–Chk2–Cdc25A–Cdk2
α-HA
605284
-AG
DD/mental
GS1
98585101–98642300
Bcl-2-modifying
EC1
p85Δ
translocation,9,10
BAY61
P-E-S-T
fusion16
1342–2075
99.0
14-4
p.Glu2846GlyfsX22
combination.12
Rupley
mis-expression
38.0
8/47
injeclion
146C
0.6G0.1
Ozerhan
EF5
1-TRCN0000195500
Re-Blot
clin
DNADymano
TF-1
treatments6
Ser472
backbone-dependent
KST310
sequences-the
J.J
DMSO-d6
5′-GACCCCTATGCGGTAAATGGCTATC-3′
phenylalanine-to-isoleucine
nature.comMutations
CYVE
v.
anticyclin
flPARP
scores14
retrolaminar
F/74
.M-mode
Ala652Val
Patturajan
anti-Smad4/DPC4
S250A
A1105P
p120GAP.The
MdmX-p53
.976
H.X
V695L
BRCA1-dependent
L657P
p.l.a.vandaele
.H3K9
P513L
CTGGGGGGC-3′
Sauvé
583
electrophorerograms
MSTIR
base-pairing
HR60
CE4
56·1
A180T
TIF
Dzwonek
118/135
Bharatula
.1§
ASD/DD-associated
Boggiano
theL22E
40,41
siMLL-ENL
M.J.
18×10−6
1–13
.IC263
Lecca
V658F-expressing
6â€
E709XþG719X
CCTTTGATG-3′
S1613G/T1685I
24K
CUL3-binding
transendothelial
£
ABIVO
tψkBin
26·3
≥100,000/μl
criteria.19
dysmorphism1
Mazie`
W557__K558del
E591
EGFR-Activating
ultralink
.Kappa
5535
Hey2
Paivi.Peltomaki
.Leukemogenic
1989
.N-terminal
non-smokers
023579
MKN-1
A191V
.OOocQt_nIILC
DFHCC35
rTRal
Ichinose
.625C
X/X
Protran
necrosis/apoptosis/steatosis
formalin‐fixed
RP11-576P23
MCF10CA1a
insusceptible
RhoCin
ubiquitin-conjugating
ROS1-specific
quadriradial
leukemia5
DEAESEQPAQQQK
2-hybrid
dysgerminoma
cancers36,37
56/151
P914L
c.4508A
wasfor
three-stranded
0.8β
GSK3B
198–209
Ishimaru
Y654
CMV-βGal
Medulloblastoma-associated
is
14–74
vertebra
HSC93
.Mg-1
FGFR1gene
,3c
GAGTCATCAATTTTATTCTGACTGATCC
JAK1-mutant
10–35
286K
0263
GST-PAK1-
fashion.21
glutathione-sepharose
9-16
Q124L
9,16,17
L–O
.HDAC
–2641
1-speci®c
2Fs10120
humidity-
Carricondo
.384G
C.Our
RE-only
Mkp3
genes55
GTCACAATGATGGGTGAT
TRBP-deficient
C-helixout
ASCOM-MLL4
preterm
patients,10,11,23
oligomerises
I1171N/T
mutants-triggered
patientcarriers
development.32
H3K27me3K36me2
rTnf-α–stimulated
purification-mass
re-ligates
anti-p21Cip1
LCS087
A159P
antagonistic
GGAAAGGGGGAAATAACGAATTAATCAAAATATTTCATC
AffinityScript
methyltransferase
Sth1
Yesh
R184C
.Focused
Marcherey-Nagel
M10
1–1651
76100
BioRepository
C-binding
EGF488
TPHA
normal-like
MTCs.4
/2AGH
srGAP3
AAA3ACA
GERP++
2,492
treatment–naive
Raf1-
3457
Hardmount
efficient.1
shRNA-Smad3
freDuring
Q57X81
c.470T.C
V-mutant
GGGTTTTATTTTCAAGT
NaCl/0.015
Phospho-ERK1/2
~18
16-hour
p.Ala1320
K5+K14+
FCTEQHVDAVKHFLEVISTPSHAS
zlj9990993630008.jpg
FLT3-ITD–induced
n=507
138.3
endoreplication
E205′A
K50M
TRCN0000136858
moderaterisk
tetracyclinerepressible
GST-Y537A
.3,15-18,20,21,23-28
hard-to-cure
CRKRS
S66P
STS-N21003
AKT2/RAC,8
kahweol
Chemitek
−2.22
Ripperger
Glu-Glu
anti-phospho-threonine
cross-regulation
SC-479
TCCT
Beare-Stevenson
msigdb.v4.0
COSEGREGATION
elongator
Massons-Goldner
eight-chamber
UMR
randomly-selected
GST‐Rho
Maroteaux
E506Q
methylation-based
Anti-CD4
split-GFP
ERK2-mediated
Figure11d
50766642
ASXL1–BAP1-dependent
Nphs2
factor-like
decarboxylating
≥2.17
Tcf/Lef-1
ex6
Binding—Given
pGSK3β
rationale-based
Daiichi
.614A
E2-related
126–4
CCTTGCATGAGGATACACCA
19A
K740
translational
EGFRvIII-V851A
trials-based
A391E/A391E
0.079
AktpS473
post-MPN
Quaio
Arg3Stop
CXCR5
1q32â€
CC10+
study,23
Assay1
Gly245
hydroxylation
.Smad2
8.rad54
EZH2-transfected
FirstChoice
testing.8,9
0.457
RPL37A
SOX4
rad50-1
0.152
PAK1-
adrenaline
OR=0.60
C,40
Laemmli/SDS
Immunoresearch
cohort.Design
3MM
R274Q
TTGTTCAATGGCCGATCCCAT
L861Q/R
1311R
Kyse-450
.NAM
V75G
FoxO-deficient
GST-hBAP-1
TCGCAAACTGCGCGACTTCT
M/63
Centrosomal
T7-pJAK2
Demethylase
Similarlily
BLIMP-1
YELMRACW
grade/basal-like
Intestinal-type
RD-C
ERG–ETV1
sPehaPAENYdIMKtCWDaDPl
myelofibrosis.When
15A333
pN822K
A_51_P220278
24256¥
SB-590885
factor.1
ImageQuaNT
VHL-BC-CUL-2
Hdm2/Mdm2
c-Cbl·ZAP-70
Bonafide
co-culture
CFC83
cells42
5-CCTGGCTACATGGCTTTTTTG-3
1.Binding
c.1877C
58-TGCTTTTGAAGATGTTCATTT-38
RAS-Independent
chemo-refractory
ofnucleotide
pLM1
.Ccnd3
NM_1456026.444
trx-related
400000
Dox-dependent
Bernad
1,753
R211C
invariable
F328S
1720
Johannesdottir
RTAB
H23FF
H3K27Me1
Gudas
reported.2⇓⇓-5
I-associated
o5666
F529
Tyr-656
//www.interactive-biosoftware.com
Hand-wrist
Neng-Yao
therapy1
.VEGFR-2
Flag-immunoprecipitate
39.8
9/no
***indicates
insertions/
p-p53
-H290
-49
re-examination
Hafsteinn
juxtamenbrane
.Seven
invitro.IntroductionThe
anti–C-terminal
lihmd
pCMV10
FLT3-YID
mutants.
P318fs
-ERK1/2
Mtb-RNase
700-conjugated
meA
PPG
PG13MSCVNEO
L64F
5′primer
kidney,38
S11RCIN
.Keap1
US.1-3
5′-GTCACTGGTCAA-CTCCAGCAC-3′
anti-TGFBR1
13,18
ΔGRD
Leaver-Fay
¶
K1299
timeand
Xp11.3
CCR1
anti-CD33-PE
overexpressionobserved
4.20
GTTTCTTCAGATTTTTATTGAGAACC
co-occurred
.,7
P-values=0.074
Msh2G674A/Δ
LexA-responsive
rho
site.11,15
Box-plots
12911
int1R
phosphodiesterase-4
endoderm-
PF-2341066
Met-to-Val
Q157P/R
GTATAGGGGTACCGTTTGAG
.8,20
anti-SV40T
pl5INK4b
14,12q15â€
CA-ALK5-dependent
Retiga-EX
TTIGFP-MLUEX
TPOX
3¶
mutS215
0.569
mHGA31
miRNA133B
pCDNA/ZNF198-FGFR1
59-year
7,968
H1918Y
Sgouros
development.9
32p
21q22
Sprouty1/pY53
10μg/mL
mechanism—or
-targeting
Cys634
F1/R2
α–induced
Males/females
Keratinocyte-specific
Gln546
INI1/hSNF5-mediated
Anti-Cul4
−0.340
Incucyte-Zoom
phospho-SMAD1
wound-scratch
.KB1P
Fullerton
Cells—Given
let-7i
5199
BssHII
Y323N
BRM-5
hetero-interface
9.17
Vav192
IITFYNEVFVPAA
Q1336
8-3
latency.42
TAAATTTTCTCTTGGAAACTCCCATTTG
×/1.30
undercalled
MAGE-derived
ERG-rearranged
nausea/emesis
shPten-expressing
Thr505-phosphorylated
E746_A750
re-sensitizing
HPV-70
Phe-144
ICI164,384
nondisrupted
lines25
U-MNIBA2
comorbidity
L494P
TUMOR-SUPPRESSOR
antennae
-CTGCCCCGGTTCATCCTGATGGAGCTCATGGCG-30
.D/N
201–212
209×108
usingPCR
001024139
P-JNKT183/Y185
lissencephaly,40
exponentially8
Supplemantary
1755–1863
568A2
7.3.36
_NM_000038.2
MSCV-IRES-puro
0.566
Sossey-Alaoui
Ex7R
fWords
trrdm
6·4
Conclusion/Significance
Asp800
leukemia.49
73/150
CCA-
C634R/Y806C
−1.18
hetero-typic
luc+
Frag1
Handyside
▼IVS11-2a
5′-TTTCCAGCCCTTTTTCTACTTGATGTT-3′
P=0.0009
Gsk3β
M13539
K14cre/Brca2F11/F11/p53F2-10/F2-10
geneticevidence
PSMB9
.26,36
byvigorous
Dvorakova
p85-mutant
19-ID
μm.31
D383N
W264R
NEDD8ylated
.PRKCB
submandibular
JakI
*Index
D171G
300–370
:hisG
D.C.
E1705Q
Transduced
12•0–15•2
I302
nonuniquely
imaging–based
endonchondral
aromatase-inhibitor
CCNT2
A289P
Pt_026
'inducible
blotting.See
MEK-ERK1/2
T137I
.BH3
HRAS
rabbit-anti-mouse
gray-zone
16:06
6721-6740
μl/min
targets11
Genisphere
Hand-foot
fold-induction
62.2
3.6.2
lower-grade
G-G
Haunerschen
fusion-junction
MethodsCulture
L1583R
PTN
MGH-U5
indolinones
11.31.1
47.9
16-year
3T3-L6
V97frameshift
EGFR-downstream
overexpression.14
650-666
24D2
laboraotry1
454-1
GGCTGCACAA
SRE-dependent
HA-p85α
7-155512BACGGCTAGT000CGCATGTA1665
38-62
P85Q
antiphospho–GSK-3
.Resistant
M/44
A113T
TW-28
'-=-
000321.1
Transcriptase-PCR
5´-ACACACCACCACGCCCAGCTAATT-3´
ER-located
–immortalized
NRaf
mechanisms71
HGF-targeted
+2145
Tyr-1289
Y130C
Smad2-depleted
C522Y
GERMINAL
IFN-γ/STAT1
IDH-expressing
AF391192
S121A
tumors24
14.7
FLT3/CBL
138-fold
MLL-AF9
gene40
Arrayworx
phospho-Thr308-AKT
ACF/BAZ-like32
311-326
R-CHOP
ena
deletion11q
p.Leu597Arg
FANCD218
H3K27me0
perinecrotic
D167N
SK-MEL-239
pEF-HA-Shp2
Nucleosomal
autoclaved
B78
atccaaaatcacaccactgc
cortisol-treated
topographical
RAD17
F/36
cCD79a
sc-44236
mononeuropathy
ATTTTGGTCTAGCTACAG
Suv4
NC8
Pharmascan
MMSET/NSD2/WHSC1
G465AB-RAF
LSrelated
C533F
ETS-transcription
mutation–negative.49
vivo6
L862
sizeFigure
A767_V769dupASV
shCDK12
−567
manner12
Krasex3op
al6
BRAF-harboring
E473V
enhancer/promoter
TLS/FUSand
RhoA-dependent
.Electronic
activity-dead
6/48
.Immunodetection
o104-S
XEDS
S6.3.1
Carpenter-Waziri
13‑15
Eph
FGFR2mutant
5,6-dichlorobenzimidazole
.N131Y-expressing
.Arg268
Krt14
mutants.16
v-erbB-gene
Fukasawa
Microbeads-conjugated
cofactor-selective
carboxyethyl
c-MYC-regulated
tumorigenesis24,26,27,36
IVS2+9
ERTAM
amplification.14Trastuzumabin
BC-box
Candidate-gene
NoLS
Madine,2
Anti-4EBP1
Matarelli
Mcm4
glutamine–alanine
Mukouyama
Microwell
Oyadomari
stability5,57
13.2
KIT14
Thr-574
GTP-competitive
Labophot
.NOTCH
phosphorylation.31
tumors,44
25ng/mL
hMSH6.13
c.1709A
R29
NanoLC
-H2373
Medicorp
V197E
CKD
monopotent
CCTTTTCACCTGCCCAATTA
.JAK2-V617F
valine-to-glycine
process-specific
5′-GCCGAAUUACAAACGCCAUAU-3′
Mx145
sc-8035
NS/leukemia
identified,10
T380A
oxaloacetate
Y279C
S3D
allografting
KB1P2
nanofect
K376E
.Nonreplicating
thrombocytopenias,1
Ala126
SPNS1
.P380R
0.735
CD39
β8
D33N
studies.24,31,32
senescenceassociated
anti-CD43
c-FLIP–short
LS174T/LS180
0.42
v-Abl
telomere-triggered
autoantigens.52-55
121-sample
8p23.2
G721S+L858R
pY1173
6,12,13
/2KJE
193.2
thein¯uence
G381E
wt/vol
R-CHOEP/R-COPE
autophosphorylation.A
GCCTCTTTCCTAGCACTGCCCAAC
K8+K14+
1,201-1,600
1606
MDV
amplification.Table
R139Q
descent.8
.CWR-R1
carcinoma,5
.Choudhary
hyperelastic
resection*
half-filled
−50,502.08
actin-binding
large-sized
alleles.5
87/1327
.HMLER
_EGFR/KRAS_
10-exon-11
.Several
HG-U133plus2.0
Y576
MS.
cascade.23,28⇓-30
I1160V
575
mantGDP-labeled
GDC-0973/XL518
MET-altered
Asxl1fl
—CH2—CH
TrkB89
p.E2067_E2310
IWR‐1
pTyr1173
R264C
BRCA2-corrected
PHA-665752
gene.18-20
93-bp
Myc-nick-stimulated
factor-autonomous
CUL3-based
8X
G761
EGL
miR-17∼92
Naoya
CS8,9
CD45+c-kit−
GST-CDK10/StrepII-cyclin
6821
Ba/F3-Epo-R
2C
methanone
tumor‐reactive
T421
CD4+CD8low
crest–derived
inhibitors—that
fromunstained
gonorrhoeae
5′-AAA
FGF2-stimulated
cycle-associated
Phe568Tyrfs
radiosequencing
.Gadolinium
non-target
T1796A
K650Q/N
CDNK2C
80Â°Cwith
C5385T/CAG-TAG
342K
SOScat-stimulated
WDLS/DDLS
Cdk2–p27
vgf
146–446
48/82
pre-polyI
C609S
EXPRE
SFRSK2
2395-2412
tumor/cancer
Quorum
p11·2
lapatinib/GW572016
Korsse
pVHL157-172
re-sequencing
//rulai.cshl.edu/cgi-bin/TRED/tred.cgi
G44S
Michieli
Barlev
N=14
16–29
HVR
5′-phosphatase
Fru-6P
immune-based
4226-bp
leukemia,8-11
yig
249K
p-AKTS473
61p
larval
Ub-like
.Immunocomplexes
tet
YesYes
.Lifetime
HS99999905
5′-AATACAGGTACCGGTCATATGGCCATGGAGGCC-3′
IlludinS
1/1,000
protonation
Capan-1
41-61-696-6205
metastases.19
Uregene
DNAJC13
/Cell
cp21
.CTLA-4
BRM-deficient
18S-b-cateninS37F
2.9.0
AML1-MTG16
2303–2321
8602
10126
Na/K-ATPase
RT/PCR
half-lifetime
NMA-based
functions.3
Preamplifed
FLT3-ITD–expressing
Rotorgene
U87H
NEL543001EA/Biotin-11-CTP
YxxM
CHIP-qPCR
α-Dusp6a/Mkp3
P=0.004
nonintercalating
28356/2-05
Brca1-null
Apo-2-FGFR4-KD
CNS-dependent
6⇑A
YY2
Mamma
polycythemia.13
PDGFRα-induced
S34Y
Bornkamm
tissues.30
monotherapy–resistant
249–308
V85D
p.S768I
Dual-probe
M133
BamBam
ERÃŸand
APC+/−Smad4−/−
K722_A723
ThepBabePuro
47/50
P334L
P002B
protein29
Smad1/5
Elongins
129.60
RET9
well-to-moderately-differentiated
V705E
genecleaned
122-gene
reported.34
ErbB2_ex17-25.SF1
35–433
FOXO1/3A
Chellaiah
JH2–JH3
pSTAT5/STAT5
L37S
mechanism-ERG
PLX4720-induced
30-kd
Asx27J6
CSK-LacZ
R=0.64
I672T
10–25thth
gene-induced
.Erk1
CD2/CD58
MAP2K1P124S
q34.2
1900del
H1112R
ccr4Δ
SYGQ
PI3K-isoform-specific
HPA040670
RTK-RAS-PI3K
Stefansson
359del4
S73
POH
IM-9
47/82.5
tetracycline-induced
//jmg.bmj.com/
18021
Atm+
splicing§
inEscherichia
Glyceraldehyde-
short-term
drug14,15
DDR-sustained
ApcMinSmad3
Lab-Tek™
spectra/signatures
sub-boiling
1.3–256.1
114C307
.Alex
−2.83
tBid
.Figure.2
gene.12
Russia/Ukraine
RCC16
12,820,773
ramicirumab
32P
80:20
Bioline
off-therapy
Ras-Raf-isoform
months4
CGC→TGC
.MOZ
GATA-3-expressing
Resveratrol-induced
Fo–Fc
Gugger
Imunoprecipitation
−23
anti-p70'rA
Epac
TCR-β-containing
Pgr-
*27-1
55.157
5′-AACTTGGGCAAGGCCATCA-3′
Glu31
Glu-659/AC
0.029716673
QYL
NanoString
studied.Top
metencephalon
S214C
Co-
FoldX.17
Marcotullio
nucleotidies
cancer41
expressionvector
tissues.40
Tefre
149/156
p-RPS6
G299W
-803
χ2
MCF-7-Par
thorotrast
kinase-kinase
report.18
.T68
ΔI
7-orange
M3541
998C
Metafer
errors.10
barsmutations
E1799K
DUB-specific
.NGS
T304
TTAATACGACTCACTATAGGGAGAGCTTCATTTGGCTGATGGAGAAC
pGT3R39.The
N5217.41
intricated
patients.HER2
Molt–4
immunoJuly
8368
samtools.sourceforge.net
-Smads
GLI-E1A
7,600-fold
KU-55933
4.9-6.8
0.348
genotype-response
DEPTOR
BE2C-EGFRvIII
458Aright
R206H*
.brain
immortalised
R413stop
function.29
TBK1/IKBKE
10.7APOEApolipoprotein
0.464
−2056
Chimie
37/39
CCCTCCC
.Gata1
TRAIL-R2/DR5/TRICK
nucleotide-free
pEGFP-Flag-ΔPDZ
Wloga
KDM2B
.Jeffery
1,620
NIK84
p3xFLAG–MED12
hSWI
study.As
ultrasonography.25
His-ubiquitin
TGCCTTGTATCGAATGAA
FPD/AML9
multiheaded
WST-1
4Cc2
substitutions-the
76367
Clinique
max-segment-size
.found
.Constitutively
4.94
pseudonymized
Radisky
Merlin-Deficient
earlier.15
D-2HG
CL207.14
47/66
holoprosencephaly
LS-suspected
RAD51L2
tumor‐infiltrating
AL133071
targets.In
Indo-European
4158
temozolomide24
S3Ff1
•Abolishes
Y1703
Downregulated
V130L
0.625a
q-value
H.-U
.Whole-cell
theextracts
analogues8
BCR-ABL-T315I
Fstl5
guanylyl
retina40
tributyl-amine
N1-Forward
.Finer
anddied
type-TCF
inhibitor,6
cAMP-response-element-binding
VUSs
.Substrates
0.46–1.45
S267ins
PI4
.PBS
ultraViewTMUniversal
S341W
.Permutation
+1.72
4FIGURE
R229X
CD4−CD8+
polyp-
non-ETS
.High-frequency
Alessi
4NQO-induced
Castration-resistant
1775
PY100
Matsunawa
2048
WGD
IR800
CH5424802
T122R
24/49.0
RsrII
AKT8
FGF19/GAPDH
Mlh1–Exo1
var1
S720F
2C/D/E
TTTCCTTGAGGGCTTATTTTCA
mRNA-subtypes6
patho
base–base
=0·2
q11-13
.Anti-therapeutic
Fig.7
myeloproliferation36,37
112×108
right-colonic
proliferation2,4,5,6,7,8
3611-MSV1
analyses.ResultsFluorescence
mutationsidentified
5′BCR/3′JAK2
p.R121H
76.20
mutations9
11,0–44
B23gene
microphotographs
G696Ea
not.11
phospho-PKBSer473
BAA91986.1
.Macroscopic
LTIITLE
hindrance159
lysine-48
IC50∼4
8.95
AUTOCRINE
R954Q
counted/measured
Gly-67
investigated.10
NSCLC,60,68
mutationFigure
PDX-Specific
q=0.003
lapatinib.26,27
proerythroblasts
269.5
-MyoD
ATT
5′–3′/3′–5′
toAK72
S335A
Mdc1
pCMV-Bam
USPHS
Okita
bcl-2/immunoglobulin
p.Gly308Trp
MLPA,3
previously81
G3522A
antimouse
deletions.48
treatmentThe
TBET+GATA3−
cell–transduced
N-cadherin
andcoverslips
treatmentOut
Rad6
Chk2–Cdc25A–Cdk2
40-Mb
MSH6/PMS2
ARexpression
IKKɛ
homotrimerization
CIITA,15,19
Asn771_Pro772insHis
8b–d
KIAA2039
.a–h
.4.w
formation50
γ-nucleolar
Exo-
TS/NTSb
Gly637
GBM8401
Kantelinen
separatePCRs
3–30-diaminobenzidine
W7C
Astec
TRK686
Xn
22|
220-420
.HGF-pGL4.26
A_51_P215849
line/IC50
GDAC
Pignochino
capacity50
PPP2R2A
FOXO3a
p190-B
0.896–2.332
DR5
FLT3-ITD15
Nonsyndromic
Gee
.Int7G24A
.NPM-ALK
A298V
ATA-classified
.Prominent
+/Possibly
H3/
mutationcould
ABI3730XL
0.476
CGTGGTGAGCTGCGTCCTCT
metazoan-specific
3329–3337
2.067
//snp.cshl.org/
6A-HA
p76/74
.Sucrose
FFU/mg
Classi¢cation
//genomon.hgc.jp/exome/en/index.html
Taverna
TRCN0000003754
R1464STOP
Guinea.6
Ser325
pGV142-CMV-ABL1
Entrectinib
p15/CDKN2B
high-coordinate
.Use
88.4
algorithm11
19214
/lookup/external-
siNFKBIA/siNFKBIB
Zajaczek
ChIP-IT
75-150
pGC-1
A/w
mutant-selective
8G7G3-1
unresectability
interpediculate-distance
MSKCC36
-G106V
-7.50
FlpIn
.Ruley
Mix-n-Match
Asp831
phospho-RPA
ShakeH
SO-labeled
467–476
19:1128–1134
polycystin-1
DAP
R1148H
Piwnica-Worms
0.2µM
dasher.wustl.edu
S0518T
O100
//www.ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
30s.Breast
mesotheliomas
alemtuzumab-based
HLA-B*44
NF1/RAS
Bernard-Pierrot
MLLT4
15–167
89.83
Assays-Cells
NPM-ALK–STAT3
NipR1F
SpeI-XbaI
GST-Cbl-PTB
GIST.4
prefoldin/CCT
5′-AAATACTCATCTAAAATATCAAA-3′
Rho–RhoGap–AlF4-
.004507Validation
protein–antibody
HA-Ezr
Asymm
RTase
cases6,7
DNA-HMG
non-Hodkgin
MiRNA-mediated
335–673
PPAR-γ
.RUNX1-regulated
FANCM
cancers83
Gene-Ontology
≈50
642–686
9254de15
.Rat1
.Alleles
Immunophenotyping
107–922
and30
smc-reads
H-rasG12V
non–DS-AMKL.44
water/ion-equilibrated
antithetic
mutations11
post-PCR
..FVDREWHRMKD.FLLRISSESKSG
family.7
D835A
TOR-dependent
p.Asn62Ser
XP-D
pmCherry-N-rasG12V
CAL51
lineage-cell
Afrakhte
population27
molt
bstrand
G93R
DHFR
LATS2-
D0–1
9f
5′-CCGTCATCCAGGGTACTGTT-3′
Stat5b-RARα
STC2
withinFGFR1
Bogliolo
mechanism.49
1,185
SPOP/ERG
α2β1-mediated
ANXA4
.Figure
ALK/ACTIN
chromosomal-level
c.572–17G
GGTGGCTTGGGCTACTACAGT
.77B
100-
-CCATGGCCATGGTGGCTTTACCAACAGTACCGGAAT-30
Phe121
3·89
MM-associated
agent9
Asp820Ala
interpretation,20,21
IDH1_myc
V-MAF
6–9.5-fold
fibres125
RAF-MAPK
in-person
c-kit+Sca1+cells
MMCI
Vav2
unquestionably
PDBid:4o25
earlier.25
F2-II-2
.20,25
P=0.0498
origin.8,11,12
wereisolated
high-amplitude
cancer.Somatic
5′-TGTATGACATGGCCAAGTTAG-3′
piggyBac-mutated
pKH199-7
Tyr-508
`atypical
14.Soft-Agar
CD2BP2
Sox2inactive
assigned.11
gal80-538
0.8–80
anti-Gsα
JUB
pCR®4-TOPO®R
c.793C4A
Y218C
ab88957
Thr474
overexpression/positivity
co-complexed
ASD/DD
9169
29-gene
NIH-3T3–MEK1
0.0359
CISH
DNA-LipofectAMINE/
nucleoli
c.1026+23G
ERCC3-p62
BIM-deficient
jected
vertebrates-exceeding
U73732-7
TGCTGCAGGAAGGTGTGTTTGTTG
9p21–22
.S1613G
5'-GAGTGCTCTAATGACTGACTGAGA-3'/5'-AAAGGTGACATGGAAAGCCC-3
5′-AGTCGGAATTCACTGATACTGCTGGGTA-3′
oncogenesis
H76-C329
−ve
F3-R3
cyte
metal-binding
CP-673451
families7'9
E1705A
non-conserved
not-yet
Rag2-
Delta559/KIT
Hamadmad
reperfusion
0.776
Tumor-specific
U2AF65-ISE
0.0091
imunoprecipitated
.0044
mour-associated
Corroborating
doxorubicin
-indel
hPMS2
MSH6-truncating-mutation
cellsstably
5′-GTTCAAATGTGGCCCCAGTTGAGTCATTATCTTCAG-3′
ALL-derived
Sla2p
RARE.31
SRSF2P95H
Gli-luciferase
p.Glu275Lys
snRNP70
ICVS
8.107
a-like
PDK1.45
1.8–30
nF
S46
calcium-induced
polyprotein
His-RBMNter
TKI7,8
G.A.P
Chromothripsis25
protocol29
tumours64
5′-CCAAGCCCATCACCATTG-3′
type-biased
Bmax
bubble-PCR
.BlP
Indústria
LKB1/SKT11
GTP-14
Detroit562
wild-type/CTNNB1
807K
C50
GRIA1
14,15–16,17
//dx.doi.org/10.7554/eLife.14709.005
.00351
.MAC-1/2A/2B
Hs-Dicer
–11.6
Quantitation
His/Asp
ChemScene
proteins.29,30
phosphorylase
cell-proliferative
MSI-driven
SMA-
10/30/02
CD22+
al100
4982
range=3.30–7.74
metallo-endopeptidase
Y268
FLCN
5moderately
understand.
Lys91Ilefs*13
D-3-phosphorylated
6-carboxy-flourescein
42/140
884-bp
MOLREP,24
.163
DIAGNOdent
target-associated
5′-GGCGCCTACTCGCTGACCCTGC-3′
pVHL-positive
subcentimetric
methyliodobenzylguanidine
WSL
II-6
neuroendocrine-like
LSI
moderate/high
Tropomyosln
miR-525-5p
0/115
SKAP2
serine-473
Carcinogeninduced
100–3.6
low-fat
Dl/CDK4
Respir
blot/ECL
results12
susceptibilities
BIX
243TT
PCV/TMZ
Ile139/Ile163
session/day
pBabe-puro-EGFR-based
SEC23A
rearrangement.Guanine-rich
G289D
BRCA2-stimulated
Kolb-Mäurer
5I–J
MutSbcomplex
Blanar
mismatch-containing
calci-fication
XGC-9811
199R
OMIM:193300
P=0.0014
negative/basal
small-pool
R80S
gene.33–35
B16-F1
.Monges
401C
mutation-detection-enhancement
PCI-13
detectability
multi-platform
sTn
0.13
downregulations
`IGC
CA44980
Gln-rich
pageMethods
0.0258
poly-prep
cosedimented
melanoma.18,26,27
4071G
.—There
metastasis.Figure
C2-Cer
5′-UAUCUU
.RasGTP
alterations4
FGFR.9,63,79,87⇓⇓⇓⇓⇓⇓–94
Glycolysis—Although
pathway‐related
Smurf1-myc
LGIII
DMIRBE
-AATGATGGGGCTGGGGTAGG-3
PLUS-Agarose
N.G
focus-
Paskie-
32/40
MET-
ALB
mice78
c.1276
Abukhdeir
.Migrated
DNAswere
R482H
reporters.DiscussionIn
21/6/4
Asn998-Pro1008
p-Q-K-K-I-K-S
Yousefi
5.8−kb
Inokuchi
E9.0
K132R
p9R1
TGX-221
5640–5645
patients10
I744
CC1
K507E
033632.2
or-independent
−9
lineage-negative
p110α-independent
HNSCC-related
.third
HEK-293
Dbf2
SCLC/NSCLC
Preclinically
Toh
CS25
FKRKHKKDISQNKHAVRR
N-glycans
o5
3.02–2.8
Masumoto
911
CS-01
Cdk2-bound
patients,19–21
HMQC
CTCCTGTTTGAAATGAGCAGG
PAXgene™
Tie2-Cre-based
computer-assisted
ab97968
R8.91
5'-GGAGTGGTGGCCTGTTTGGATTCA-3
DHT-mediated
4/33
c.692T
e005
affinity-chromatography
IFN-italic
number:74104
silu
.Tanshinone
.HMECs
theTEL/PDGFβR
P206S
43911601–44001000NM_015564
Englefield
ETV6-myc/DDK
5/98
MLH1/MLH3
B6-Tyrc-2J/J
.Punjab
Menko
ethanol-precipitated
Systematically
CD117/c-kit
P=0.034
radioiodinated
Dzantiev
1.5–5.5
N-acetyl-Leu-Leu-Norleau-al
100X
57.7-68.6
EGFR-HER2
p53-/-+vector+Ras
no.9834508
G332
85.51
pMiw-Fgfr2C342Y
.Descriptive
ALKR1275Q+MYCN
vector-3T3
.MCF-7
cyclophilin
Ianzano
NM000535.4
phenotype.7
AGAGACTAAAGAGAGCTGTCC-3′
r.t.
I47F
2220
A_51_P187491
YPDA
pathogenically
GSE37314
A349P
DMRXA
4-Hydroxy
WAGR
Lsc/p115
Y589/Y591/Y597/Y599
-TATGGGGCCAACTTCTGC-3
KMS-28
P531T
CA198482
L257Raf-1/A259Raf-1
Mst1/2
V393I
Inner-most
S26B
∼8m
Mismatch-
CSB/ERCC6
p.Gln678*
pDONR-zeo
anti‐β‐catenin
activation,36
expression.20
Superflow
disagreeement
GGCACTGCAGAGGAGTAGTGCAGA
1.338
sub-analysis
Id-2
Rabaptin-5.17
GP-293
hFGFR3/pcDNA3
0.4x
35S-Methionine
pik3ca
T417I
filopodia
Machesky
H3K79me
PD-L1/2
Met766_Ala767insAlaIle
re-escalation
-GCAATATCAGCCTTAGGTGCGGCTC-3
11p15
β-glycerolphosphate
X75621
Rho-
intergenic
thalassemia/mental
Men1F/F
A_51_P162272
al.72
NanoLuc
S1K
CI=0.81–1.68
1,779
cDNA/channel
104–586
PI-positive
Pro772_His773insTyrAsnPro§
secondaryMMR
Tyr64
ATTAATCCGGTGTTTTTGCGTTCT
T343I
EYMSK-
W1487C
8-week-old
thymus.13
5′-ATGCAGAGCTAGGGAATGAGC-3′
monomethylether
'protective
precycle
sgs1
–0.2
Hs01573837_g1
Glioma-derived
w/
/j.1for
post-inoculation
CRSP3
297.00KB
self-assemble
962G15
Crtc2/CREB
MLL-ex10F-PT
N769
cytokines/chemokines
Catarino
1.24–5.81
AY323812
plasmidswere
Bennecib
utable
Thr187
carcinoma23
Indirubin-3′-oxime
1427
MD-10
13q12—disrupts
RHS1764-9399376
D45201
39-40
NU-Foxn1nu
KIT-Mutated
T284R
sh_2
methanol/chloroform/water/ammonia
diseases8
BMP-4
oncogenes—MDM4
NIH-OVCAR
SCR_003005
p.G595R
6238ins2del21
Dunnen
8Gy
GTA-to-ATA
non-reverted
PLD-associated
T-V
mother-child
marrow-derived
pathologically-neutral
.18
antiandrogen–AR
agonist‐induced
6105
IFN-α/β/γ
/AML1-ETO-positive
receptor.18
GC/siCtrl
myeloma,12
biofilm
6hr
SK-Mes-1
CTL/24
CISHa
CTCCCGCAGTGTTCCTATTTCA
SHP2−Gab1
pY591
5G10
ACAGTTCGGAAAGACTACA
PaTu8988T
NM_008737
abenign
priming-dependent
histocytic
reported.25
PXS
0·002
inhibitor–insensitive
tag-less
KSR1
bs-1475R
SphI–EcoRV
L866R
p-ERK-β-catenin
Bcr-AblT315I/Y253H
mapping-panel
IL-17A-producing
epithelioid-like
pJH
ZMSH6genes
//www.ncbi.nlm.nih.gov/refseq/
MEF/His-tagged
39-HRYKmePGTVAL-48
8672
S7A–B
control.Antibodies
Eeckhoute
R4000
L747-P753
His278
JAMA2
V600EBRAF
Brünger
CBCACONH/CBCANH
TGGCACTGCTTTCCAGCATGG
bacteriolysis
EWS-FLI1-transformed
wu7/wu8
Ecquevilly
28/40
Ni2+-
activation63
379–928
MCF10A-EV
c.3545-3546delTT
D146–186
.Endoscopic
ApcMin/+
upfield-shifted
VectorLaboratories
.Prognosis
Ira2p
.019871
,16,17
Farmacogenomica
26–72
DEST-CBL
IC50=500
V948R
.Classifying
CD11C+
interaction-based
c.195A
hormone-refractory
indicating-as
42
variable-loop
midbodies
0.323017367
Ornitz
JAK2–V617F
AutoLumat
controls.Transformation
FGFR1-amplified
IM/SU-refractory
0.98–1.74
States.1
leukemia.29-31
HA-PDGFRβ
5′-CCACCTTCTGATTCTGGGTAA-3′
RAL
G2101A
PC12/MEN2A-c1.3
Nagarajan1,2
Chr2:42472827/Chr15:88576276
GATA313
p53223Leu
c.47_49ATG
Gcn5/PCAF
G719AþL861R
Cdk9/CycT
abovewas
pSVT7
M2e
factor25
ab47426
267–272
NIAMS
1151T→C
pADH1p53R282A
H151N
Q79L
s-Myc
40-year
doxycycline-repressible
trk38
***P.
theheavy
A1156T
onlythe
7q21.5
.STAT5b
receptor-Jak
.Translation
3.9
properties.29
45–86
QKI
ElonginB
AIP1-binding
MAPK-ERK
EUSOMA
JAX
units/mI
α-2-macroglobulin
Fig.7B,7B
Brucea
NM_014669.4
enhancer-containing
BALF
59-GGAAGAGAATCTCCGCAAGA-39
extracel
C78
Trk-null
L505M
5'-GGCTC
recombination.Thus
5¶-GACTAATGTGGCCTACAAATCCTAA-3¶
IYSIMQACWALE
1853-ter
Vik
HLA-A*24
viable163
line.19
over2-fold
K273A
TCF/LEF-dependent
Midkine
zk.bwh.harvard.edu
EDTA-coated
Myc-his
RNF115-MLL
Beckwith-Wiedemann
MEK1—the
derivatized
podocytes
optimised,43
PDGFβR-immunoprecipitated
mutSβ
2VHL
IRF4+
−2.38
Promocell
A_52_P183088
P379fsdelCT+WT
Macara
thrombomodulin
trpE-PLCyl
WT19s
1.094
p.Y598H
acrylamide/
T-ALLa
GISTs.80,100
rapamycin-FKBP12
Transmigration
SC263
rapamycin-decreased
II~~
sites.13
C3H/10T½2
intron/UTR
pectoral
Mx-1-Cre+Sox17fl/GFP
G150C
2G-I
GSC45
carcinoma.c
fludarabine
patients.38
surexpression
5.30
histiocytosis,13
5453
sorafenib—the
epigenetic/chromatin
.Mitsuishi
IGF2
www.aesnet.org
Margetuximab
aberrations8.The
Zonula
DAG
p.Arg251Lys
21.95
intradimer
AGT-
31–78
Wnt7a−/−
E–F
entinostat
BRAFInactive
USPL1
2110-2129
W446S
ETV6-related
129S/Sv-Tg
RSF
.AD_ALT
ras-proteins
NCI-H929
LS1
β-globin
Rmsbond
GCGAACTCACCCGTTG
.Immunoreactivity
AGG-30
HLA-A3,68
G1S
V379A
ΔBRAF-promoted
1,24–28
HSIL
HDC±
TGFbeta-RII
βC
Gna12
8/9.5
0.091717737
SMARCA1
family-cancer
GST-VHL
NBP1-06519
clinical-pathological
H-RAS/MEKK4/JNK
AXL/MET
358-9-19126278
A1843T
p53-modulated
MV400
c-raf-1
R318C
D2033N-mutant
p.Arg465Trp
Gln165-D1861
955–1365
kRptFKQIvql
XELOX
†Expression
l-2HG
differentiation136
7ql
CCATGATTTAAAAATCCACCAG
–transformed
GGGAGTGATGCCACCCTG
p=0.00858
sites/616
CpG-binding
MPN.47
R4519
were:1206543e3gif7K42533The
55G
nature.comDimerization
MDS,2,4,6⇓⇓-9,17
β1
Roussell-Uclef
3MA
3203del11
5417
I869T
x6c
proteinscould
774–775
CO2.In
MKI67
incodon
pseudo-nuclear
autoradiograph
Non-histone
*Pancreas
MMR-mutant
spectra.45
Q469H
.SCD
factors.1
MLL3/4
EWS-E
31p
Leu-346
melastasis
n=87
Jelinic
PI3KR2
sterol-regulatory-element-binding
KMS12
CREM-targeting
ACCAGAAAATGTCGCTTTAGTTTC
Asn140
CCTWTTTT
Forty-two
5′-GGGACCCCAGGAAGACC-3′
siASF
tight-knit
48-year-old
136:121-125
two-hits
p.R265C
CD2-GATA3
Cepus
BIS-TRIS
isothiocyanate-conjugated
sc-489
hyperpigmented
DH5
85kDa
hydroxyapatite
GCA
T62
p.E168D
therapy,7
S37F
CDE
AR3shRNA-1
‚
0.111
L10del
+1.29
Lycor
Dynex
Glu.37
16,072
uman
transcription/replication
W71
1.0–2.7
α-MHC
ASP3026-sensitive
Rothmund–Thomson
T-lymphoproliferative
5′-GAAGTACAGTGGAAGGATGTTGAGGAGATA-3′
60/F
signi®cantly
pGC-I
.7,40,41
4774
phase-I
E-MTAB-1007
S2T1
asbestos-related
`FC
newlydescribed
.for
NCT01750281
S2670
Hitchin
transfectant
MSH2-G759E
p.Lys2797GlyfsX11
annealing/extension
K656E
56y
11/51
GTGTTAATGTGGGAGATCTTCACTTTAGG
.7,61
.HEK293T
RP11-370H5
3E–H
.Subbiah
4B'27
1a-1
silibinin-treated
.K57
KIT.5
TGTAAAACGACGGCCAGTGGTACTGGTGGAGTATTTGATAGTG
B-ALL2
www.landesbioscience.com
deleted17
DJ0669I17
AL—highly
1·2–8·3
long-awaited
pOG44
908,009
5801
131I
M541L-positive
C363
PuGPuCA
HCC3
E268D
JKCC
CARD8
62.03–2.4
.Ahmadian
non-perfect
5′-ACATCATACGGTGGGATCGTG-3′
G448R
IL4ra
promoter1,18
rates.19
non-mitochondrial
.Roselli
generation/analyses
586-613
pnenotype
5′-GAAGATCTGGTTGTCATACTCCAATTAACAAGAAC-3′
Mlut
4-speciﬁc
Integrase-mediated
K1487R
p.Gln254ArgfsX165
18.0
SkMel28
ARF876L—implying
Genomplex
I1461T
recov
pCDNA3-flag-c-Ski
2.56105
development.53
.ERK1/2
pZIPneoSV
t29
LS-associated
D87V
Link48
endTransitionACG
caspases5
.027
ALKpositive
1.2±0.3
261474
OncoSNPv2.18
KOD-Plus
CREB5
quinine
G13G
combs9
K128R
pcDNA3/Nrf2
2.32–7.18
NGS
methyl-propyl
DBD-bound
AML.12,27,29,37-40
/NF1WT
effcctively
Baker2,3
placenta
cyclin/CDK-binding
Cederlane
.YEAST
isoforms.20
1.2–5.1
1-D-1
RC214358
GM-CSF-responsive
V-regions
Microsequencing
GH­
slowermigrating
NY-ESO
thymus.6
.Submitted
CD80
Maxi-prep
Database42
identi
250-500
Wolf–Hirschhorn
c.482C
two-organ
TEL–JAK2
Blamey
aberrations.Comparison
lymphangiogensis
860×108
V740L
Leriche
Cos1
β1,6
patterns.81,82
covary
Easy-DNA
asparagine-histidine-serine
CEP3
BIL
G3D
R498L
Marfan
nonsense/frameshift
4367delTG
same-stranded
27.38
.BEZ235
IFNAR
absence.2
OTF
low-expressivity
.better
HER2phosphorylation
site.81
substrates.25
pSG5-TIF-2.1
mung
Pilati
anew
Δ746–750
HD-0384
CycD–Cdk
statin
AGCCGGAAT
CHUK
extra-colonic
AFMA191XF9
HORM
ER5
p.Exons
BAL-31
chondrodysplasias
Nutlin-3-induced
461
Frixen
-R273H
.MALDI
Akt-Myr-T308A/S473A
2.10.0
9.1.3
mAkt1wt
Trp53fl/+
GluSyn
mDia–
AAH85184
Aillustrates
multi-disciplinary
pCDPTPc
13C-labeled
Q853P
Trp-1456
G-actin
Cd34
3002–3026
+49-931-2013488
neurotrophin3
preantral
pLKO-ErbB4
24.43
RNAprobes
706-2A
0.28±0.20
Fenaux
PDL36
cx6c
mycSmad3
TA10-F1
glycine–arginine–glycine–glutamic
diseaseprogress
adata
EGFRvIII-GFP
crispr.mit.edu
Biotechnology/Chemicon
RMS33
macrophage-colony
.608cWild
H.-Y
previously.28,43,44
elsewhere.13-15
conditions42
F26
GGGGGAGGGG
C218Y
Ba/F3-EGFRvIII
N198
Pei
MYCN-positive
V213A
mutants184
light-smokers
threonine/serine
HCC2779
+TTW.eT'..smaller
diffusely+
Hernandez-Boussard
.Exciting
68y
MLL2-interacting
1.20–6.58
DAPI-Ki67−
LKQYSHPNI
16–43
prognosticators.1,5,7
5'ccgtaatggggatgccggggtcactgagct3
vectors.conversionCell104-S29
p.Gly52Arg/WT
PB-3
Lkb1f
Arhgap6
CBP/p300-dependent
I391M
avidin/biotin
EYccyGDLl
pcDNA31.HisC
Herber
I422
A_52_P582374
ErbB2_ex11-19.SF2
22/56
D816V/H/Y.14
24.59
RV560-561RERV
CpGs.11
V219F
ETV4
3p21.1
SOX17-induced
2,4–6
ERBB-driven
self-consistency
thymus,1
c.920+1G
86-100
.HE28
alÃ-elein
PCa_no_ETS
25.839
p.Arg563Leud
Buckhamshire
E691K
kinase–Rac1
Olympic-ro
v0.7.12
p.Arg203Cys
c.7008-2A
stress-mediated
G334A
.CAPAN-1
3532delGb
ninhydrin-stained
Lent-SOX17/Lent-control
R102K
1.409
PARALOGOUS
E.B.
allophycocyanin-conjugated
TTTCTATTCTTACTGCTAGCATTa
ubiquitination.55
S17N
3D-organoid
E‐box‐independent
NcoI-SalI
Toffalini
sc-37777
601/531
0.2712
Rad5l
cydin
Szabolcs
13/8
103
Venus-CBFβ
.allele
death.1,2
shERG
T465A
Biovision
hypersegmentation
G12D∼A146T
59.4
Pervanadate
polymor-
19–55
.Colony-forming
9p22-23
22a
activa-
Q337A
p-MET-dependent
F540S
glycol/0.1
GST-RB-Cterm
Copy-neutral
melanoma21
SI04158049
prebaseline
Rasindependent
salting-out
rubrum
SkyPaint
American/Caribbean
p110α-CAAX–expressing
Nonphathogenic
.S2G
cgr533
WDYHV1
1,437
paravertebral
stableheterodimer
.Vimentin
Tyr901Cys
F285V
7626
3Second
184-297
-66
c.1937-13T
75-95
carcinomas,113
p.V1670I
.CR1
5α
lymphoma.17
markers.20
HGSC
intron-flanked
nihms703640f7.jpg
SC319226
F572
.8,40
GGTGGGACCATAGACAATGC
isoform114
BRAF-/NRAS-wild-type
NUP98-HOXA9-induced
fibres.21
104/mL
freeze/thaw
Grodno
0.0346
5q14-qter
RP11-380G5
HA-PIK3CAH1047R
GDAS
gtttgttagttttttgtag/ggtacag
.JQ1
D1248–F1477
17-OHP
fold-changes
ovulatory
dbl
6p22
GSK3β-phosphorylation
P424A
27,29
LAU50_1
K.H
DNA/Protein
N144H
SUMP-M2
3/229
AF129870
APC-positive
aggctc
previously.5,23
Heteroallelic
P1806A
.NSD1
Val560Gly
Blaschko
T1219I
737.7
33:2773–2786.10.1128/MCB.00175-13
L1460P
MSH2c.942+3A
LLS-3
megalencephaly-polydactyly-polymicrogyria-hydrocephalus
theremay
0/59
mutation/f32microglobulin/Daudi
assesed
E252
5'non-coding
pCDNA3-6myc-Smad4
frameshift/
phs000159.v3.p2
.Anti-phospho-ERK1
TKI-resistance
Dysregulate
CD57
IL-7–dependent
E109
whengrown
MEF2B-bound
CT53518
25•9
.HKI-272
pathways.16,17,24,25,27–31
176.00KB
–GLUT4–GFP
6-day-old
correlations—the
Takifugu
ALK-resistant
uCi/ml/
.Template
pLZR–BJ
region,9
~Diaz
U2
pathway66
–2703
Anti-ERα
-2H-tetrazolium-5-carboxanilide
P-Iodonitrotetrazolium
L30F
.Lys1731
G-insertion
Intramuscular
Gly/Asp
ERα_NdeI_N
UpRegulate
IAC
I-negative
2×HDT
lystates
712
Atto488-GDP
65–67
receptor/HER/ErbB
R-banding
Src-homology/collagen
circumference
MAPKK3b
Ser101′
pathway-independent
cellderived
Gli-BS-Firefly
DUP
.Noonan
RBGMdb
5L
anti-FAK
molbiol.princeton
G721A
STAT5b-RARa
135–155—were
visuali/ed
diagnosis165
RU38486
1,560
bridge-mediated
IKBA
ATF2/c-Jun
p27QR
L802
decades.2
Anti-GM130
gefinib
A001328
V3471G
B/M/NK
EWSR
76-
4/27/2012
Spred1
cyclinE
4939–4920
dn-SEK1
syndromes17
GTCA
Fronza
DC-terminus
.discussionIn
c.1255C
Gutkin
GCGACAGCTGGAGTATGAA
late-line
041
group.24
γtμi
thermoautotrophicum17
8.73841025
MDA-MB468
3034del4
Pten-heterozygous
.E6201
anti-p-ERα
LM-like
phorylated
Y53
125-149
mTOR/Rictor
ENNpvlAPpSLSkNIqMAGEIAdGNaYLnAnkFVHRDLAaRNCNVA
well28
p24•1
.G1
FLII
NORM_TOTAL
gefitinib.34
F1241
fatylation
TrkBs
4/14/2008
−2.98
countermeasures
αINPP4B
99.99991
.Signaling-pathway
7-methylguanosine
P046
Phosphoinositide-3
LXSN-ErbB2
0.1O
.Pretreatment
.573
yeast-human
3.3973666
III-8
SMARCAL1
RNAiMax
pairedend
c-myc-tagged
unphsophorylated
38-71
Rsc2-M280I
.0068
fibrolamellar
2/8
G125S
78–80
NM_011057
hydrochlorothiazide
SEC31A-JAK2–transduced
1251
F595V/V617F
60–70
1240–1250
Target-enriched
HERVK17
PAG1
Bax-driven
-40_
benzenesulfonyl
.Drugs
I-to-K
Lys5
mg/mq
HajduCheney
−ΔCq
SFRS6
ΔPSO
response.Moreover
selection/acquisition
Δ309-311
cdc7
cttcataatgcttgctctgatagga
PIK3CA-wild
41–67
López-Nevot
77.8∗
nonV600
Oligo
RASopathy-associated
FBW7R505C
EWSR1-421/SMARCA5-1954
RUNX1–ETO
well-substantiated
S1303
Keap1-DC-ETGE-peptide
cell-derived
RP11-24O10
Cullin-RING
TGFBR2-mutated
9269
hypermethylation.10
NRAS5–7
NA931V
correspondentU87MG.AEGFR.Thenumbersof
alignments12
U1/M1
.PcG
TG101309
His6-SUMO
154K
COLO206F
S3A-I
red=GPIIIa
3p22-21.3
respectively,45
13/10
37*
speed-vac
Glu37
cylinders/arrows
intragene
end-to-end
Ser1088
senescing
Tel1/
imatinib-based
TRAF2,30
FET
PI3K-AKT-mTOR-independent
phenotypic-genotypic
Rmerge
42,47,48
erbB2+
81.99
trimethylated
JAB34
.Eighty-six
0~cr
stillbe
250mM
VIII—an
Tet1-deficient
D116G
Figure4
semi-in
M512T
below.The
0.6–1.7
.HNF1A
CDKN2a/p16
Merika
BRAF-WT
GLVQVTGSSDNEYFYVDFREYE
7–27
pcDNA3.1-hygro-myc
congenic
31/39
macroglobulin
rhSCF
BamHI/HindIII
51-54
Ebf1
FastMix
HeLaS3
L206P
Z10
membrane-sequestered
Kras+/−
His436A
Ab-18
HAPSEG
CG-39
CGA3GGA
c.8983-1G
R497T
Pug
SUPM2R3
MLL-ACTN4
R100P
and3D
coding-oriented
FLJ10986
89K
wu90/wu21
nonmetastasizing
byyeast-expressed
IC50≈8
Structure-based
c.5074G
7,13–15
D18S474
Protein–nucleic
immunoreaction
1.6°
641–645
FITC‐conjugated
replication/repair/checkpoint
m17k
6,8,17
ERK-ELK-1
.FASTQ
Bayesian
TTTACAAGCGCACGCAACTG
3′-end
occured
R35A/L225LI-transduced
ALK-dependent
CD74-ROS1D2033N
downstream-regulated
1∶10,000
I121M
50-nucleotide
DsRed-positive
activationwas
factor-68
P.A755Tc
PI3K/AKT/mammalian
ssDNA52
ZR
S427F
no-template
iron–sulphur
DME−
chr1:156041134-156051278
SHP2
p.P466L
12*12016377Lung
4515
hemo-
D21S11
SLC45A3–BRAF
2RGE
2239-2248+ins
and1.2
Wndings
geneby
PTC-225
tested.35
treatment.Nilotinib
127•23
–κB
nonradiolabeledRARE
FAF1
Kouvaraki
NCT01121588
4-HT-treated
H1339
IDH1-wildtype
B.R.
CHEK1
transgene-positive
Fig.1C1C
AIG
OAW28—involved
Martinistr
T487A
H.D
Pleuramesothelioma
59CGGAATTCGG
'170-fold
hypoechoic
Val765
GTP-loaded
17·1
BibTeX
n=191
pERK-positive
ACG→AGG
P=0.0082
MAL
1093_1491del
1108
methotrexate-synchronized
co-ordination
V1808A
hyperkeratoses
.Discordance
steroid-induced
p.Lys541Glu
M7001
ReadGroupCovariate
PvuII-EcoRI
13961–13969
CK1
7/140
P.Y727C
pre-screen
catttcacaag
p85α/p55α/p50α
EndogenousK-Ras4b
Gain-
∑hkl∑i|Ii
-IR
BPfinder
EBV-LMP
Westem-blot
AP001610
,2E
.Yamamoto
TEV-induced
theEMSA
.Linker-mediated
R1A
15660
Bournemouth
anti-GFAP
Receptor-Associated
miR-125b2
pairing50
7.0.1.25.33
2.19
factor–κB
–20
483–486
analyses.Validation
I0
PGL3
ITGPNMGGKSSIYIIKIQIV
Hiratsuka
1701A
.Pulse–chase
555-nm
amino‐terminal
D129E
T151R
774K
radation
re-purified
K575fs
Puyol
1–specific
C57BL/6J-TgN
Kolodner
β2β3/loop
5′-CCCAACTCCCTCTACCCTTGA-3′
19/185
5′-GTATCTCCCGACCTCACTGCAGAA-3′
staining,42,43
KuDOS/AstraZeneca
.Hamartin
Foxp3
L22E
GCCTTGACCTTTTCAGCAA
125–137
response.41
EX5R
Q1496H
t0
serine/threonine
PRDM16
0.63-kb
Keshava
aag
E1167
.Cytospins
plasmacytic/plasmacytoid
SaoS-2
4Dd2
Leu576
Map4k4
RNAi-negative
0.1/Mb
E6.0
Agulio
RP11-124L22
enzymatic-dead
MEK1–MEK2
.H460
55-fold
Thy-1+
b562RIL
16157
seven-span
immune-serum
pMMP-R1117G
GST-pRb
activation17,18
.SNU-16
.PPM1D
paraganglioma/PCC
NCT01394016
D99A
D61
al4
MARK/PAR1
by-passed
Lcd1
cell-type-independent
SMAD8
L623P
68352648
lymphoblas-toid
RhoA/Cdc42
anti−human
inhibitors,17
Spectrumb
major-late
Pérez-Alvarado
A662V
gavage-induced
L559P
Isoenzyme
.Milestones
γt
mug/ml.FGFR3
recently106
3.1/V5-His
criteria,17
0.2222
Y5
39-HRYKme3PGTVAL-48
bisubstrate
.PD0332991
slidePedigrees
p38alpha
ViCell
Fusicoccin
pCR-XL-TOPO
S3i–s
−185
Y-fil
Hoxa9/Meis1-expressing
DIPGIV
contains1,412
D1226Nmu
p.Met391Arg
DAB2IP
toY992
recommendations–based
GL–G
caspase-8-R413
Suppl.3
monoglycosylated
C289S
.584
1p36.32
37-4
c.791-5T
Glu310
transdominantly
.S4b
XDS.55
10.1159/000369266
0.18–0.23
8q23–24
Elf3Δ236–260
c.335C4T
.NR6
Trp53loxp
.MONETA
121LXLXXXXKK129
D770_N771insD
D1517
Fast-1
n=245
Arg9723Gly
pLP-CMV-neo
Yao
UICC-TNM
//doi.org/10.1371/journal.pbio.0050109.t001Identification
c.1799_1800TG.AC
59K
PaTu8988S
.alteration
HDACi-treated
M134
gene—localized
5-1240lOB1TGTGTrATCAACFCACCAGA1369
24,26
14.68–45.78
Merlin-associated
D999E
identified.9-15
α-phospho-Mek
PTPρ-mediated
Luminol/Enhancer
ABL-ADP
subspecialists
mice.A
.3,14
S//TK
SKN-MC
Sanchez-Madrid
90–273
biolayer
1·4–1·9
T455
.WST-1
TPRMET
hydroxyls
case.In
Asxl1-RecF
Adultsd
met30
2001b
unidirectional
Rag1,2
cell-autonomous
toV599E
drug-dosage
cytokine-receptor-like
Niewoliket
DRB-associated
Y1228C
B*07
Hubbi
GATGGGTACCCTGGCGGCATGGTGAGCAGAG
anti-JAK1
a-3
16e
unsynapsed
10.03795
patientderived
2-18Raf-1
.Fos-luciferase
cancer83
N58-Q506
hearts.Figure
W177A
Peters,25
.Accumulated
Yvon™
Lymphadenopathy
1GF2
378CA
CGGA_822
lymphoma17
5′-GAATTCCAGGAAGCCAAGATCTGA-3′
mBcr
Myc-regulated
A1615T
10/19
1.82–6.84
5b
5308
HD-0262
times1,000
.According
12.75
C/TAG
HER2/ErbB-3
L.Da.S
Arid1afl
IV:24
DC-Lamp
ERBB-targeting
SFT
0.13-fold
combined-
2−5
Ets1-based
n=66
5V-AAT
.SCLC-R1
and7A
NT-31
pcDNA-wt/mut
.FLAG-Rad53
S180L
SUM1315MO2
effector-domain
4199
247–253
mutation'-like
Val400
p.T204fs*18
NGF-untreated
2-streptavidin
loop/αG
LS.27,28
ETV6-NCOA2
POT1
n=279
pylori–independent
.7480C
wivo
anti-B23
Skolnick
pGL3-Luc
penicillin–streptomycin
-X-pS/pT/E/D
Panc10.05
5′-TAGGAAGGAC
3/32
T137
2-hydroxyglutarate
phycoerythrin-labeled
LCMT
.Insofar
1,178
JXG
pWt1
Δ16HER‐2‐expressing
mMTris-Cl
Paralog
relocalization
XXLb
185-131-166-109-184-124
anti-MITF
Alk6
TCGACTGATAACAATGCGCTCT
anecdotally.Furthermore
gene-transfected
neuroblastomas1
H83W
.Ba/F3-hKIT-D816V
Col7A1
hSNF5
Giuliano
3.848
1-6-5-4
1A1
SHGP
frequencies10
IDVYMIMVKCWMI
0•6–11
.TTF1
Excitation
DLBCL-like
right-hand
.Interest
Asp-268
9v2
7.9amp
APC3
MGH056-1
plate/well
JAK2-
TFAP2
5′-CAGGAAACAGCTATGACC-3′
P258L
strand-swapping
there.9
Superscript-II
/-/
1.077
ab70565
cyclins,44
9480
BRCA1-del31
history•
.Melanocytic
R236S
promoters.57
HNPCC-like
×613
SILAC
D816H/N/Y
CRC343
.Fig.4B.4B
.49,50
2000b
descendens
DIFI-HER2
1993a
SHSY5Y
SKI274E
G50
Amplification/elevated
CAACACCGGCTCTTCTTTTG
p-ERK1,2
K321N/5'-CGACCCGAGTAACGAGCCCATCG
39-nucleotide
.Objective.—To
GTRAG
14q23–24
approach.4
pTaG2
Acini
RBD-mediated
N23
Fig.7H
.1324C4T
inally
S3J–K
TGF-ÃŸfor
v-FMS
MSK572
SU5042
plasmacytosis
cancers9
5′-ATGGCATAATCCGGGTGCAA-3′
F.
LAH
TEL-ABL-
Bright-GloTM
Ingber
androgen-stimulated
80–90
YY740/51
agvgd.iarc.fr
63MV/IFDI
cultures/donor
tattttaactttgcatttAACTTTGCATTTaaagag
p55g
PDX179
92·4
582-1,220
cyclinCdk
−1745
3.2.3.1
8.15
exons35
metastases.46
pTEFb
FancD1
drug-dependent
de-differentiation
diagnosis—for
screen19
lox-p
.M1
P236T
DLCBCLs
GFP-C-RAF1-330WT
Smac/Diablo
~nd
DAB×20
17-39
1q23.3-q23.4
anti-HIF2a
HEG0-pSG5
miR-22
Lahue
V804M/Y806C
indcol=Y
nanovectors
×188
PTEN–T319Y
aspartate-352
helicase/nuclease
G10
.Scheffner
1165
asp53
NICD
TGAAGG
p.F468C
adenylyl-imidodiphosphate
NCT01606878
containp53-responsive
theranostic
S971A
theDrosophila
S1613G
29K
Hs00179843
c.806C
29:79-85
258-5216
.PLoS
re-computed
organs—albeit
S215
JAK-STAT5
T-Coffee
UoC-M1/FC
F/63
fusion-spanning
NCT01795768
depositionAside
CyclinC-CDK8/19
R943Q
multiple-reaction
ERÃŸproteins
-poly
450-454
non-invasive
growthsuppression
Danielpour
S0535T
RB1plotted
5a–d
type.Fig
Cafe´
Vijver
D1010
IVS811G4A
donor–acceptor
pH=
MutS·heteroduplex
68/105
AQD
exon-3–
Velos-Pro
Anti-TrkA
Maiolo
∼8.2
176.5
20-22,25,26
genes.Four
leukocyte-specific
near-completion
303-306
pCMVβGAL
PARP6
Baf155
Daugas
pUHG
SNuPE—are
Cannizzaro
rs11571327
6771–83
0.467
WT-pVHL-containing
D769H
Cancer-induced
3B10
MAPK/p90
MSH1
2UG
Peprotec
vemurafenib61
endocrine-sensitivity
q10–25
phenylmethlsulfonyl
×1,000
PCNAK164R
Pde8b
pTYB1-3L
ceritinib
RSPO
GluI953ter
RbBP5–WDR5
Hisada
50-year-old
CHD3
hemi-methylation
K644R
acinar/neuroendocrine/ductal
5′AGGGGCCGGAGTATTGGGAC3′
Cfp1
1μg/well
10138
Figure7C
HTLV-1–Associated
5′-TCAGAGCCTGTGTTTCTACCAA-3′
Polδ/Pol3
3827G
RP1–198M21
P=0.010
24.R342L
5.43
10.1158/2159-8290.CD-15-0896
10-hour
c.6903insA
≥0.1
5′-TGATCTCACTGCCAGTCTCG-3′
transcription196
PEST-SCORE
Microsatellite-instability
CBP-acetylated
high-speed
Klinghoffer
Filtron-X
SignalingEpithelial-to-mesenchymal
C-RAF87
Junttila
RING-E3
mutations—D931Y
K-Ras12D-driven
R328G
p=7.7×10−5
lentiviral-vector
host-related
GACTGAGAATTCGTGAGGAGCAG
erlotinib-sensitivity
pSUPERIOR.neoJade-1sh
CRISPR-associated
1990a
2p25.1–25.3
phosphoribosyl
_CDK4_
SMOOTHENED
E015
H-Ras–GTP
Mantovani
p53-indicible
R262T
FOXO1–3×IRS
erythropoiesis.21,22
α3-α4
colicins
c-mycmRNA
MEHD7945A
PDGF-driven
Rb-CT
Sox17+/+
6
TGF-ÃŸin
Anti-H2AX-Alexa
bromofluorophenyl
proctosis
TEL-PDFGRβ
andreducingtheconcentrationof
OVCAR8
dose-dependent
AB_331426
phosphatidylinositol-3-kinase
25G
.Challenging
MH1
PHOT1/NPH1
study33
GGACATAGAAAA
translocation.26
CD62Lhigh
Ph-negative
WA1
sIg−
families,12,13
superatant
5692
BACH1-ΔNLS13
signals27–30
.Otherwise
11-2
CCTGGGGACAAGGCCGACGT
ELST
skin†
960a
self-antigen
2222
windowDownload
20-µL
MG6R5-ATATAGATATCCCGGGAGTTTGAAAGTAGCCTGGA-3
MET-WT-Fc
EpiQuik
CCACTGGAGTTCCTTAAAG
TCTTGTGGAAAGGACGA
iden­
thrombopoiesis.24
orthochromatophilic
H232N
Ugurel
2.0ogN
.ICL-hypersensitivity
OVCA433
88.9
47–64
T313M
L576Pd
signal-generating
medctr.osu.edu
Segraves
pDONR
19-kDa
1,296
al,13
Bat40
sections,10,63
T154G
mmiRNA
Nishimori
5.078
.Donor-derived
Chongqing
13584-1-AP
0.0059
41,44
300–324
PI3K-p110
–sheet-helix
Korkolopoulou
5'-TGCACTCATCAGAGCTACAG-3
C1589T
components16,28
FA-N
5-bromo-4
D2–Cdk4-expressing
cKit−
Flow-through
M.
Glu-2288
HRP-tagged
nutrient-limited
N-17
Gly380Arg
þ44
-11q
Asp4
end-joining
non-Ewing-family
N-CoR-mSin3-HDAC
S49
.ICR1
D743
ΔG
S1P—Src
c.1733A4G
CEP135
SRGNKYLIKTLRPVLQGIVDNKES
2.4amp
DCAF1-dependent
ΔD4
MTC17
R194H
School—Texas
H-1106-093-3
FGFR1-transformed
pAKTThr308
PARP-positive
non-hydrophobic
Ìg
together,4
Razzini
.SNU-494
.Copy
2genetic
eGluA
CXCR4-overexpressing
6.0×4.0×3.5
cullin1-dependent
unrecogned
MethodsReagentsCrizotinib
HNPCC
glucagon-secreting
PNT2C2-GFP
steatohepatitis
.Z
G719S
nucleolytic
Down-regulated
672–683
Nucleoli
Tavazoie
geographically
SHH12
Met587Val
0-a
EMVI
1Potential
-NaOH
EGFR21-AS2
prestimulation
diffi-
–45.6
history.5
stromalin
Niedzwiedz
0.7851
binding.7⇓⇓–10
encodedprotein
ProbandsWe
c.2233_2238del
132-1230
CBioPortal
Shwachman–Diamond
pCMV-TAG3b-4EBP1-4A
co-workers41
FAT4
priming9
Karyotypc46
αF-αG
MG132
VL
JJ012
c.117-2A
crosslinking
Charité
n.
HLA-B–
FcɛR1α+
WT-transduced
study,9
β3/β4
RAEBt
325KB
.Esophageal
anti-IDH1
brightfield
5-bromouracil
PLEURONIC
K535E
63H
3A2
602667
DCS60
apoB
ZNF676
Mtus1
EGFRvIII
5'-GC-clamp-ATAAAACTGTTATlTTCGATTTGCA-3
H1450
0600
Schollen
§
capillary-venous
gse12460
sc-8418
cancer–sequencing
non-degradable
Lag
2656
Inadl
Immunopositivity
E204
G418-containing
124X
transcription–polymerase-chain-reaction
AlexaFluor488
355
neuro.mpg.de
39/101
c.396C
TransIT−LT1
pCMV5-Elk-1-His6was
1.4×109
.Stat5
genomic/genetic
array34
vgiguere
epithelium-to-mesenchyme
targeted-treatment
4.5×104
hyaluronan-binding
anti-TAZ
CH157
CRE-L2
non-cancer
on-study
Backx
con®rm
S.M.-M.
ETV4_exon11-f
q21–22q34
–green
NGSP
910
G464A
ChainFinder
R-ICE+
40-130
.Viable
SK-MEL-30
Y579
PDL32
pHa
diploidâ€•
APCIÃŒ307Kpremutation
Microcon-MWCO
.Bruce
Weith
oligomerize
Ig-κ
25,609,630
D/Cdk4
Glycans
F05/06
.Doxycycline-treated
survival,33,34
CAGA12-Luciferase
re-hYbridized
RPL39
Meitar
Rsc2-T67P
/Lef
Arg-
causality.Figure
neurotransmitter
:1B
spd
DD-TPβ
MDA-2774
AF013168.1
Grardel-Duflos
Arnold–Chiari
000240.1
57655
bpter
receptor/nerve
ESP6500SI
Sox17fl/GFP
12'6
DMEM-high
μmol/L,38
.064
Lymphangiogenic
Isothermal
FANCG.15-17
discoidin
SRSF1
DGC
Thermo-Fisher
Y765C
dacomitinib-treated
7/30
supply.26
Br44*
FDR≤0.2
4/41
histopathologies
V834L
5.3×10−18
inter­
pcDNA3-p73α
phosphosulfate
786–1010
Eµ-myc
N-flagged
Rikiyama
BAK-NT
broad-range
defmite
PTCL2
shape-changing
U87MG.t
S-tag-fused
delayed-early
knock-ins
FLT3-ITD-
arginine335stop
Pazarentzos
proviral
E_gossypii
pOP-PDGFRB-Ires-GFP-Puro
94.7
5.3.3
CCCCTGACGCCACTCCTCT-3′
2238-2255
ypT1N0
gct
5mCpA-DNA
p.Arg125Trp
Sturm7
LOC79728
mutations.39
cisplatin/pemetrexed
PIAS-dependent
IκB-α-S36A
autophosphorylation
®delity
E53A
postgastrectomy
factors96-101
γδ
sorafenib31
perinodal
concentration.1
P112Q
BRCT-phosphopeptide
Melanoma-derived
mesotheliomas.28
4XN
Bowers14
AKT1/protein
0111
Thr205-Pro
derive33
Br73
HA-AKT1
mg/d.16
929e1
long-tail
60gof
AG-3′.30
mCRC
G-H
-942
.Lysis
.Asp810
AF1924
BioChrom
20-49.9
mis-expressed
GEE-modified
SSCA
above37
−13.5
pZeoSV
SW756
1,983
DI/
EGFR-family
signal-binding
determined.8
tumors.1
non-diagnostic
3'-end
granulocyte-like
/IGK-CDK6
pfuTurbo
rming
faciliate
vitro.60,60a
myelobast
.KQ
1,187/1,673
blue-black
N-ethylnitrosourea
G719X-transfected
rasln'lrasl
48-226
+200
cells38
VDSVDNP
lackner.mark
1–18
22278
.Ligand
AMG-706
B-sandwich
Acid-extracted
Dracopoli
+6.48
phospho-Thr202/Tyr204-ERK
43/86
haploidy
Ras/Raf/extracellular
Detergent
αBRCA2F8
P=0.71
epileptogenesis
Figure5e
ab32072
UVS1.cER4
1E8X
.RFC-140
negative,14,15
HRP-based
~32000
100mm3
Anexin-V-FLUOS
MPO.26Moreover
food-intake
bothDNA
home-made
71–127
CEBPα-deficient
Perera
KIF5B-ALK–positive
not-transcribed
0.490
33–57
5'-GTA
ultra-sensitive
Ow
K519
Trp395
HsRan
lPresent
Her2-enriched
180970
48/29
JAK1-positive
11/84.6
PIK3CA-reverse
5′-TAATAGTCGGTGCTGTAGATA
11bR
PI3K/mTOR-dependent
//cancergenome.nih.gov/.Plasmid
n+3
FACSCalibur™
SigClust
C73F8
conformation,6,7
caveolin-binding
D716N
4YMJ
NM_017383
identified16
p≥0.05
TNM7
2.9-5.0
Phyre2
Gaunitz
TACTAGCGGTTTTACGGGCG
linesexceptLanesa
K–dependent
progenitors.38–43
allele,9
c.898_906del
phase-II/-III
WGA-stained
BCR-ABL1-T315I-
Q56X
22-42
0.8-
5383
2302
proofreading-defective
c-jun-/-
CYVDFREYEYDLKWEF
c-MET
corepressor27—was
p.Ile2675Val
S465,467A
imatinib.Wild-type
Yan
J29T
.Remarks
TMEM90B
p.Q1636X
Cu~
T-lymphoid
0.421
protein–lipid
Weinkauf,1,2
studies36
Gel-Doc
phosphate-based
RB-K.
AR-positive
Millevoi
.K-Ras
c.130G
AC220
.MW
octamer-like
HER2-equivocal
pZIP
phenotype53
mice,17
EGAS00001000449
ETV1-controlled
pJ4Graphic-GRF
BAF-dependent
hnRNP
MYC-N
.039
S384R
multicellular
0.00053
.Colonies
Hsp
-4.40
10/50
FLT3-wild-type
miR-99
248-531
overclassification
KPMYEVQWK
028
Aviv
-C
bronchioalevolar
EWS-FLI1-mediated
0.877–3.759
thrombopoiesis.12,13
G207D
D147H
AMX500
individ
.0026a
psuedosymmetric
9.6-14.2
msh2Δ∷LEU2
hepatocytes
767/766
Second-step
Tyr418del
E1.112As
pTβR-I
high-intensity
Figs.1A
line—AML
5531–5534
penetrance.35
1452
Tidyman
NM_177438
lowconcentrations
GISTs.49-52
FIMM
SF3B1K700E-Expressing
34–65
.Together
conditions.5–8
3787
modifications29
ineffectively
Co-transcriptional
sup
yeastbased
,6
PAS-Alcian
p53–175His
p.Ala175Thr
XhoI_CCNB3_rev
c.3598C
pre-initiation
GST-ERK2-K52R
433WXXLF437
R35A
38/60
Flow-Sorted
F.G.G.
Dokkyo
phenotype50
msh2-GD693–Msh6p
micro-cephaly
0.5Xmutation
UAS-TK-Lac
2288
signaling.15
11-17
Myc-W-PDGFR
isGGGTCGAGAAAAGCCCCATTCATGAGAGC
2003b
HFPEFENDVEFTER
R172L
AY519503
RUNX1/
interconnection
RP11-7H7
T-binding
factor-2B
c.A3140T
10.75
diagnosis18,19
Akt3
Myr–AKT-transduced
activity12-14
3′-downstream
11q13.3
60–90
DUSP-4
pRetro-IRESdsRed
RP11–264E11
SMOD473H
1868
~80-fold
freeze-trapping
T117A
FAM-WT
PTEN-fusion
TACC3ex8-RV
//mutpred.mutdb.org/
TCF7L2−/−/TCF7−/−
adolescents12
Mg2+-chelating
gene,67
differentiation.17,20
overexpressed/amplified
3763insAG
cetuximab.23
A21442
Neoplasia-associated
hydroxy-ion
F53S15
caspase
L747S
manifestatio
HIST1H1C
TGFβ
mMKCI
R169P
anti-Lys-382
5′-GCTGGTAAGGGAAGAGGCCG-3′
XL-EDA-ID
TCR/HLA
patients.9–13
alleles.MATERIALS
D842-related
previously.8,16,17
neutrophil\
Thirty-Eight
pTyr-containing
Haunersches
I1298V
dampen
35:450-455
Lymphoplasmacytoid
S3M
p.Moreover
helix-helix
HOM3
VAPA
L49A
0.20899749
PI3K-mutant
immune-activated
SRY-related
.V224A
.After
94C×30″
MM5.2
Mutant-Negative
ABL.13
TBK1
BRCT-C
1,417
Hal
.031
Kasumi-1
R726L
structure8-10
chloride–associated
tumours18
SMT3
Domain—Elf3
2736
I46K
PITX2
Eymin
C8-D1A
knockdown/rescue
,6-diamidino-2-
ethylthiourea
Rho-type
Costar®
electroencephalography
3.32
Signature-Positive
DEK1-
AVM
E398K
K650T
spinning-disc
BMPR-IA
consequences195
Pol4
12/401
ligand-receptor
EN-3T3
Myc-transgenic
PolyPhenc
1,264,388
fluke-associated
Tserpelis
V536
ED90
GCTACGGTTTCCGTCTGGGCTTCT
FKBP12-Src
GW182
3W4CLSa
IPASS,20
29/638
1-ns
preincubation
37232
RPTPp
telomerase-expressing
JAK-1/2
ASXL
wasassociated
N131Y-expressing
non-8th
DataA
LSK
Δ1–118
pageDiscussionUsing
418D419Y
LYL1-homolog
5′-AGTTCCTGGTGGCTGAAATG-3′
ripheralbloodor
_KRAS_
S705P
.∗∗p
D6S273
EEFLKTCSDKIFN
tonofilaments
β1-tubulin-positive
mRNA-negative
Elf3A312P
CD38+
European/Japanese
20–74
GCGThr
TTTright
R1809H
2STAT
Half-sister
oncogene41
N882K
Discrepant
0477
Marray
6.2–54.6
−4840
18S
mock/Smad4
5'-GGGCTATAGACTGAAATAAC-3
Abcam-France
ab32536
rapamycin.33
fluorescein.24,25
Meox2-Cre
L613F
D024
.81T
ERBB4-TKIs
E6/E7
p.K117R
myristoylation
GCCGCCGCAGCCCCCCAACACTG
GGGAGA
R241P
C11ORF73
Thr246
Adenoca
RP11-739C17
6.945
BARD1-S575F
ganglioneuromas
Lu-246
​Fig.6B,6B
coinheritance
.Nucleolar
rhuMAb-VEGF
CFP-E79Q
M059K
MiSeq-based
-3C
N=
1T0L
detected.91
p.E571K
15–29
beta‐catenin/Wnt
IAA
E37Q
chromogranin
1XQR
.P-Y
wu91
regulation102
characteristicsThe
factorE3
1,37
FOXQ1
A077
mesenchymal-HSC
292A
Asp246
plasmacell
NoFunctional
DNA-binding-independent
14.32-90.10
006106.2
Re-cloning
ATCACAGTGATGCTG3-
Phospohorimager
syndrome.4
1N5O
de-paraffinised
p.V411L
514
schizophrenia
antisense-mediated
Non-GI
40245429
MIDB
CxxC
DETECFS
7900-HT
G1724A
anti-phospho-antibodies
141.3
ssDNA
artifactual
15.9RECKReversion-inducing-cysteine-rich
G387R
rs2853669
anti-Abl
AccuScript
D1045K
non-familial
co-observation
ysekido
MGH-BA-l
respectively.30
TACTTGAGGTATGGGTCAGCATCT
1.13-4.11
528dupTTTCAGAC
+CAS
NM_004612
Needleman-Wunsch
ZHX2
μg/μl
HES.1,3
PMS1-2
Ambrish
LTR-gpt
ER/PgR/HER2
microsatellitesequences
ERBB2-KD
huSCF
B8
T-016
1,545
160.85
2050
transformation-resistant
WTB-RAF
c.1471C
Wip1-null
.Disease-causing
MEL.52
1529–1863
JNJ-
H2SO4
receptor-ligand
MAPK-specific
PF-00299804
1988a
5′-TGGGCCTCACTGTGCCCACAT-3′
line-of-response
mesoderm–epithelial
.Alterna
Tyr730
1l2R
Merlin-positive
Ibrahimi
DLLLEMLtA
imatinib179
CA02
Uziel
aconsensus
0.0332
H-I
PRC1-dependent
NIS-Elements
chr19
single-cells
3.Solution
CAATCGGGAGAAAACAGGAA
4905
R101L
doi:10.1158/0008-5472.CAN-07-0765
dis3-R847K
CycD2
species-invariant
99:10700–10705
Up-regulationof
HDR-mediated
c.598C4T
CS.11,18,19,20
5-subunit
5ug/ml
Lacout
factor–binding
nonsteroidal
S445R
N-Ras-I24N
pEJ-ras
anti-lineage-biotin/streptavidin-APC-Cy7
mural
LoN3
B-RAF-inhibitor
Arg200Trp
-0.009799403
medulloblastomas,26
401Δ603
RG-17T
-1186
cobimetinib
Sequiserve
Ku-70
anti-Notch2
119/135534
2–419
BRAF/Wild
7/6/01
16/50
crystallograpic
58Â°C.and
PD4
M243
preparedfrom
dysphagia.2,4,8,13,15–17,20,23,26,27,29,32
Shparyk
CTx
pcDNA3-p53S-myc
Primer-Blast
pipeline.23
41.5-68.9
Kindblom
level,19
T29C
NSCCG
prognosis,15⇓⇓-18
143,6,7
MC44
c-DX/c=0.86
pCycELUC
–4th
acids.31
pS-Hx-transfected
ATTCAGCATTTTTC
Ginsberg
Inconclusiveb
F∗∗
10.03
`activated
pT3/pT4
β–catenin
Hrecka
SERPING1
CACTGGGTACATTCTAAATGCTTTA
µL/well
AZD1840
ERT2
midzone
c.1504_1509dup
PDGF-AA
1.53–4.97
HGF.70
Tet-regulatable
Aggrawal
mut-
mjfann
G530D
E2993
S0522T
worldwide.1
GC.In
V216M
3669–3688
pCAGGS
PV3893
HIPAA
L2396F
019–44
insufficiency
hormone-challenged
Betticher
HER2→EGFR
*21
.Supernatants
gpl4OProto-rk
platelet-derived
.Anthracyclines
Medicina
58-60
G1089
pCR3
.hsr
inhibition.30
oncogene-addicted
ULBP
CAL-85-1
EUFA578j
.Gottschalk
ABL–YAP1–p73
chemotherapy.39
Calpha
A_52_P76988
non-exposed
Invitrogen®
2005-051
C264W
GeneRIF
5-FOA
Interchangeable
E117K
IL-6/JAK/STAT
23,33
7/123
Interpro
RP11-54P13
nonbonded
.Knockdown
pre-let7
CCTCCCTTT-3′
pRBΔ657
single-round
CLP
Zrihan-Licht
c-MYC-overexpressing
8/71
Tet1+/−
Lamouille
U2OS-DR
modeling.16
OR=0.52
Semb
.TPGs
0.01-1.61
ThermoLab
Flag-Smad3
denotation
Tempst
12-767
CCNB
1.00Male
MYC-Specific
J7
antitumor-specific
-GAGTTTCCCAAACACTCAGTGAAAC-3
EW-SM1-989
JAK1-deficient
anti-SNF5
104L
.TheFGFR1
c.87T
OR2
.Breakage-fusion
subsites
Glu-37-*AspS8
P0025
T597S
predisposition1
0.46–53.81Mb
TSrot
p73beta
MDS_149
Neuroblastomas
0.097
POZ/Krüppel-like
R183
07–185
lineage.63,64
1481–1843
MSH2-dependent
27.33
GATA3-trunc
GATA-binding
mitogenic
established.16
D769H/D769Y
9284
2.0009-4
GST–CBP
Menssen
quantum-mechanical
dephosphopeptides
bs-3343R
.SMARTpool
viscerotopic
c-Myc-specific
ISGylation
mid-ERCC4
GFP+/YFP+
17/78
cAMPPK,8
formation.31
115/374
Immunohistochemistry—MDCK
previously.28,34–37
paralogs
TrkAI/pcDNA
records.The
//www.LOVD.nl
30F
56–99
S2673
methodsTumour
data13–16
CALU3-ER
Ku70
Ser-10
anaesthesiological
M521
ABCC3
P274T
treatment.4
Btk-deficient
5′-CCAAAAGTGTGCAGCTTGTTG-3′
left-hand
5-bromodeoxyuridine
SCG
3β-mediated
LDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLV
EGFR-bound
IL-3–supplemented
whole-animal
*An
6FAM-AAT
A–specific
.Burkitt's-like
tumourigenesis,51
FOXK1
G603W
.International
+10
2log
V216
ering
S942R
A1131T
SKII
19/132
CRTC1–MAML2-negative
AML.59-63
Ovary
-amide
B1/B2
NES-PIK3R1R348∗
GCTTGACACCACTGGACTACC-30
K158X
SQD9
anti-c-tubulin
R69T
.Mucinous
V377I
STATs/pSTATs
5-fluoro-orotic
12p11-q11
2½
firstprimer
SUMOylation/ubiquitination
139-141
25,26,27,28
IMCE-targeted
26.6
Veeck
KOCL
KD-mediated
EWS/ETV1
c.755T
MM56
Pro261-induced
NOTCH2
tyr1007-1008
syndromes,1
lymphoma10
Bowtie2
Blosum
AS42oncogene
c.376GA
clone1/3
mutSKA622
samples79
Autocycle
-9-isopropylpurine
Notheis
site2
endopeptidases
G136V
PTGS2
Flag-caspase-8-R162I
Pro564-containing
p.A510V
fusion14
E619K
elsewhere.10
I836
MvLu1
lox-stop-lox
hs37d5
iso-miR
Muzza
childhood1
second-most-frequent
G446R
filiae
202/204
JMML.8,10
Martignoni
Tognon
PB-Map3k1
ANKRD34B
E79D
axin1
3q22–26
D25A
N540K/T/S
vascular-specific
Leu-96
population.26
mutant-transfected
//biorxiv.org/
7Rα
SRSF2-deficient
I1171T-mutated
CBP3
R-loop
cohesion
V1206L
epidermal-specific
30c
histo-pathological
p.N535S
14,26,28
Rcryst
p.K550_E554del
V_OL_._3_19__27
single-case
others.9,11,12
29–47
patients22
//david.abcc.ncifcrf.gov/
Matthay
Λ-OS2
SX53G8.5
ligand—ie
addressed.Marked
I682-D686del—by
p6G2
reasons.31–33
CDT2
ab15580
K2HPO4/KH2PO4
loca-
CHESI
AML.23,24
anti-phospho-Y694-STAT5
3223delG-HET
pVHL-null
trivalent
CICFOXO4
Gly733
.Phospho-SMAD1/5
CTCTCTGGTTCTAAGGTAGAGTG
005120.2
20-169
ethidium
5′-TATGTCTTTT-AGCCTGCCTGCTGGGAGTTG-3′
Introduction•
CGCGCTCGGC
subgroups.35
I237V
centrifugation/immunoblot
unsurprisingly
PDGFRA.19
5′-GAAAACAACCAT-CAACTTACAGACC-3′
IRF4dim
Prolla
680K
anti-ERBB
study27
U/50
miRNA*
ERBB2-transformed
F188
EREG
600DLAT
heteroatoms
ETS1-specific
Groettrup
Chemotherapy
pheochromocytoma
rs762623
GCAATAGATTTGAGGCCAACC
L1425
amide-amide
E106
PF-00299804.108–116
Ser-
α–knockout
D–CDK4/6
cells.32
2.86-folds
Iwakawa
−2.12
high-sensitivity
FC=0.42
50-GACAGAGCCTAAACATCCCC-30
GTPase-defective
p.Trp297del
risk.22
CD30
28,47
AC853
4HT
58-GAT-GCTGTAAATGTTGATGAGATAA-38
cytoplasm
PPB–FTDS
NG_007524
Keio
NLO
mice.Detection
PEBP2aC
AD-FANCG
UBE2C
LightCyclersystem
Glu-48
18014
aunts/uncles
ACTTCGTTGATTCCC
R174Q
.R271
46.4-58.3
NT4
BAP1-mutant
5-CAGTGTCACACATTGAAGGCT-3
N-terminal.19
over-amplification
Cabrer
context-dependence
L21P
9-amino-acid
Charge-reversal
Evolutionarily
colled-coli
Full-CFL/NFL-c-Myc
3.181
GenePrint10
R1.1
Brownstein
93–98
r485_1283del
D281H
HNF4AP2R
D222V
paraformaldehyde-PBS
18,585
Gavrieli
7-year-old
I408
49405911
RA-resistant
CGH-based
erbB-2
-aaaaaagaaaattttagataaaaagag-3
.AF205935
EμSRα
0.9637
ISOC2
ExomeCNV7
12q14.3–q15
B2A
CD71med
.Vav-tTA
practice.31
11-ra.v
suppressor6
Self-tolerance
life-time
2.7:1
Thukral
far-exclusively
29/1935
N-acetyl-L-Leucinyl-L-Leucinyl-L-norLeucinal
gene-lung
−740/−714
NP_005456
844–845
17/66
HX-express.41
g/c
CPSF3
anti-IκBα
.0830
Batch-Conserved
BCR-ABLlow
R5268
_RUNX1
L380fs
position1688
Piazza
rearrangements
A-helix
0.747
5′-CGCGAATTCGCCACCATGACAGCCATATC-3′
AML1-targets
CCL5-positive
.JNK
Kralovics
antigen/antibody
-4,5,6,7-tetrahydro-1H-pyrazolo
pho
883A
RCRRSK
factors.4,17
FITC/APC
less-than-additive
18/7/4
614083
4058L
trxdm
1,702
STAT3–transfected
sc-7290
β-
polyguanine
0.9â€
R-a
p16-cdk4
METY1234/1235
indoleamine-2,3-dioxygenase
Knoblich
5′-GGCCCATGCCAACTGTTTAGC-3′
fastx_clipper
alleles,1
Fgfr1
Lesort
Damsky
//dx.doi.org/10.1371/journal.pmed.0030485
83*
prenylated
IGT
/NPM1-ALK
1α—The
Zoppi
hATPC-Flpe
MLH1-E34A
pCDHF3
Ramkissoon6
279–319
−297/+8
mL/g
Medium-High
FGFR/FRS2/Erk
Hepatocyte-specific
bipyrimidine
Biotec
Saba-El-Leil
chromatograms
CTGF
ACCCTGTGCGTGGGATTCTC
Vorechovsky
S2.10
CAGGATATAGCAGCCGTAA
2AA
PDGF-Induced
107.5
LYVE1
STK6
Pfizer
complex21
Leica
CN-AML
apoptosis-regulating
Rappolee
13–24
Phe216Ala
Swiercz
The-
ELK1
VP22
//www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/CghHome.cgi
Ese-1
c.9004G
−2.3
S5
Ser-345
TaqαI-digested
Thr359/Ser363
FLJ46266
receptor–hormone
Fgf8a
.RUNX
hybidization
NSCLC.34
228–273
p.Glu69Gly
Ink4a/Arfnull
anti-TbRI
SKMEL30
lower-risk
codon-by-codon
__000545.3
fluorochrome
5-C
D44
E1694
window=1
RP4
reports.28
FGFR2C342Y
commitment23,24
Topo1
17k
e25
−.15
5′-AGGGAAAGGGACAGAATGAC-3′
37–50
MDS12
AC-forward
detection.14
GFP-VHL
FC=1.43
C2Y
µL
nucleotide-level
CS14
Atr+/−Mlh+/−
cis-inhibitory
afatinib–paclitaxel
MLH1-p.E460A
‡FISH
Sorli
ht1
PFDLT
000/mm3
DRB1*04-negative
vII-extended
reported33,37
q34.4
meiotic-regulated
Polymenis
HCC24
SpeedVac
small-scale
Bagci
.R304X
544-end
'physiological
RSD
R460H
localizationCells
c.4456A
1190F
stroma.Figure
3/41
LC-SCRUM
96:215–225
'METHODS
TGT/cGGT
5′-ATGCGACCCTCCGGGACG-3′
maximise
β7-strand
.References
six-base-pair
anti-Cul2
AtXRN4
Ras-Raf-MEK-ERK
Subcutaneously
Figure55
0-22
ATCCAGACATTCAGAGCCACAG
ID4
-threo-isocitrate
ofligand
P017
Anti-PDGFRβ
IVB
X25
substi
2ng
Skp1-Cullin1-Rbx1
Jβ2.2-RSS
100893147
B-7
SRC2/TIF2/GRIP1
GEP-defined
RPA30
C-024-5C
pCMV-cyclin
T3/4
Montréal
MRE11/RAD50/NBS1
0.28+0.23
≈30
FLI1/EWSR1
.6,15
SJ25C1
binding.103
sc-543
32.50
array.Biochemical
100–450
LxxLL
24:337–344
ANXA1
Cancro—2010
1sh1
Nu/Nu
350–354
solelynegative
Esoph
ETVI
-,26
Anti-GAP
28.536*
ratiometric
p.Val600Lys
6.1.2
MIDF
Lyophilized
Glu-1836
RP11-430K10
P2-ARE
434
p.Tyr61LeufsX15
TCEP
MAU2
Elf3Δ246
opioid
IVS9+73C
LacZ-PGK-Neor
2219T
Tsodikov
§Wilcoxon
0.647
.Kondo
TGFb-2
irreplaceably
Labtek
re-natured
Hoxd
K14A
HLA-DRB4
E239
5′-GTTCAGCCATCAGAAGTAC-3′
pEN43/pEAE20
S30E
Scotland.-
Zoncu
.Samuels
.Plates
554-559
Agatep
//www.hgvs.org/mutnomen/
Dimage
capase-8
DMEM-10
//bioinformatics.istge.it/clima/
–28
merlin-negative
.059
CLN
ofAKT2
S12B
QYS
PCR
~in
MS-275
dicated
Atr+/−Mlh1−/−
NPM/TYK2
pAKT2
ofexon1
Cyclosporin
Pim1–AMPPNP
41-61-696-3835
experimentally.5
3A-B
overexpression45
Monash
c.920+1delG
SDF1-CXCR4
-MUT5
p.R571Q
MLL/trx
4/96
R330Q
SOS–ezrin
cells.4–6
SurvivalVariable
cytodifferentiation
line10,23
cghMCR
223570_at
ADAP1
N550K-expressing
ohns.ucsf.edu
1645
FJ
fibrillarin
protein–nucleic
backgroundfor
sip53
c.463G
Dib
FLAG-Elf3Δ129–159
369KB
megakaryoblastoid
//pymol.org
223K
mutationsidenti
XPO1-ex15FFPE-F2
AGCATTGGGTCAATCCTAATGT
Cys73X
5'-GCTGCTGGCCACCACGAAGATGAT-3
K1436Q
nonpenetrant
92.6
Physicians/American
ERE-reporter
Multiplex-PCR
leu2-3,112/leu2-D98
ofhMLH1
inhibitors,38
1.
ant-tagged
Neuenheimer
2b–c
1.17-5.53
:4358–4364
I179V
SC-481
19/54
176872
p.Val600
pSVb-galactosidase
His6-SUMO-TSC1-fl
triphosphate
-ATTATTGAGTGCTTTTC
cancers,3-12
p300D1399Y
shAlox15b.2865
Garcia-Higuera
Tract*
5-CAACCTCTTCGAACCTGTCCA-3
reason,21
LASP1
inflammation-driven
4•85
stricture/stenosis
Voytko
A39P
4249s
duplication-insertion
self-nucleic
1,000,000
comparisons.28
7-13
5′-CATGGAGTACTTGGCTTGC
TEC-family
C643
Figure3D,3D
V126D
sc-134908
669_1086del
Arg179
2a–h
HighV-QUEST
percent­
SAMD12
F17752
3.89
SIRT7
.P29S
Syndrome-associated
A/Gagarose
phosphoimagery
permeabilisation
EN/IRS/IGF1R
G→T
T319Y
Luscher
.5858C
BRCA
5′-AGTTTTCACTCTTTACAAG-3′
.Analysing
Dharmacon
FGF-mediated
c.2074C
−ΔG
Polonies
Garcı
TEL–ETS
C266W
TransIT-LT1
osteochondroid
CBF-α2
.Virtual
Papaemmanuil
5´-GCTGAGGTTCTCCGGCTCTTTCAGA-3´
∼4
pY653/Y654
clone7.6FBN1Fibrillin
ESCCs.3–5
vacuum-baked
anti-p73α
Rho–Rho-GAP
Wt-SPOP
Controlsc
exonic
c.3415G
outcome14
rad
DLK
c.2035C
Denys-Drash
Q3d
domain-1
1286
0/0/3/1
gel-separation
cJun/NCoR
RP11-257E19
c.1641_1642delTG
p.N446del
hypertrophied
affinitypurified
byp53
juxta-membrane
mÃ©tastasesin
Luc/Ren
Teramoto
34x
AA2800
extrapancreatic
Tet-ON
apoptosis.14
instances.8
PTPN3
GCTGGAGGGTTTAATAATGCGATC
sarcoma,5
ZIC4
anti-CD122
muinmarv
93T449
Δ417−419InsY
proposedmechanism
macroscopically
AS/other
AB'C
5′-GGTCTAGCTACATACATGAAATCTCGATGGAG-3′
.Shandon
~2.5
.UCN-01
Maintenance—Yeast
Exportin
QIA-GEN
P=0.468
D876G
wth
hypochondroplasia/achondroplasia
leukemia,11
CLL,4,5
rGcP.P.cGcc
0.306aAge
pGA-MTS1/Δ145−156
ppr1Δ
34-63
6.81E-03
10–20-fold
.170C
LATS1-associated
AGTACTGCTCCAT
1∶5000
5′-CGAAAGCCCGTCGAGGAAAAGAGTG-3′
.Narita
.Cyp24a1
5–25-fold
X1
Dono
Fluor-conjugated
252.00KB
p.Asn338GlnfsX24
1−11.7NRG1aNeuregulin
classification•
Abdelkafi
T450
ITD2
12,13
sihNT
Phospho-Y1604
High-fidelity
PIK-E20IR
0.304
DYKDDDDK
16.0cDNA
half-life.Investigation
94.4
GR-FeSV
RP11-543P6
NOTCH-3
HD-0158
inflammation61
0.97-1.04
0.482
MLLT10/AF10
death-1
anthracycline-
TA-3
CS.15–18
_ATRX_-mutant
1210A
.Bgl2-WWP1-F
928
studies.Levels
V617L
347
Brg1-independent
3-8µl
events/megabase
multi.CNV.analyze
Cα-RMSDs
DNA.52
1.61+0.79
assembly74
.Site-Directed
SOCS
.5G
5′-untranslated
overerexpression
ter375
MLH1/PMS2
Neo1
TFA9
Asp171Ala
pDC
4.35
E322K
.PAB419
acid-l-tyrosine
member21
SLC5A8
translocalization
202
9644
G255E
Tsc2−/−
mC6
.Further
reporter.23
CAAX
.Eosin
NHERF2
Five-milliliter
FU/
gland-specific
McElhinney
7-nF
2-chome
.H58N
xenobiotic
baculovirussystem
-signaling
glutamine95stop
0.0317
YonishRouach
His-to-Arg
amplified.§DCR
*n.d.
A1847
copper-dependent
proteins.ResultsLinkage
Lin−c-Kit+
129:531–533.10.1111/bjh.2005.129.issue-4
1,198–1,530
Figure5C
5′-TGCACCACCAACTGCTTAG
R178L
exome-seq
monoubiquitination.36
121:763–774
Introduction1
ROCK134
R239C
NRASQ61L
Hutchinson-Guilford
Baccarini
endothelial
ATP/10
homologous-recombination-based
osteopetrosis
RP11-759K14
Tcf'-lymphoid
149/28
Sera-Lab
FIP1L1-PDGFR-α-induced
TSC2-null/low
/CD8
Nu18/1
compound-heterozygous
c.202C
methodsYeast
Mechanism-based
KRas-positive
Krett
−11.2
.Preventive
RT-PCR/FISH
report22
assayed—cytoskeletal
.Eto
described—C228T
synergistic/
FoxO-null
anti-RAC1
.CD4+
A260
RAS-PI3K
96074
ion-pairing
u.1of
Jak2-transfected
VAWTKILNNVHQLPKNLRDVFSALRCRLEAQ
glucagon
6g–l
p.Pro660Thr
AR-FL
76-bp
nonfunctionalmutants
Mangasarian
pErk/total
.Lower-grade
MAB636
life-imaging
Siebenlist
0404
biotin-avidin-horseradish
N299I
mice61
V162I
Ripamonti
Y859
3AFIGURE
polyA-tailed
2,039/5,442
RNA-Seq-derived
605
A046
histocytological
K545T
AML1–core
HKR1/HKR3
As3
Trono
7361
E234
Trp244
CD99-
.ARHGEF3
prerun
.Estradiol
2·8
5′-ATACTCCTCAGCATCCACCA-3′
ira2
hg19_ALL.sites.2012_02.txt
mutant-activated
Wnt-target
EBPα–knock-in
Cytoselect
dinucleotides.13
1.540
R195C
BRCA-derived
BAT34C4
104.0
PAb421-activated
non-randomness
faecium
MCHL
FL-independent
GT16
carcinomas.47
polycistron
isotype-control
84–87
M.Goedbloed
.TGF-b
609054
phosphorylase-based
70.1
//www.broadinstitute.org/tumorscape/pages/portalHome.jsf
SpectroREADER
5B-R2
mRomero
trans-generational
anti-GD2
coactivation
Lopez-Girona
GGT→GTT
dissociative-like
BH3-encoding
Y210C
30-1011K
MutRHO-1S
552-558
c-myc
suppl
PRO1F
two-month
2843-aa
9232/01
digestedwith
p.1430
/STAT3-dependent
alterationsAbstract•
dNTP/ddNTP
5394
V950M
H4/D10S1703
E-plates
Bronchus
__
KIT-wildtype
.Quality
MLH1-14
HLA-DMA
chem-
4F
cancer.8-12
TP53-E285V
Brca2F11/F11/p53F2-F10
Diff_of_Classes
non-endothelial
Armigate
ab46154
0D
Q146K
3.087
TSC2
HOPX
CDKN2A-deleted
KDR-transfected
β-glucosyltransferase
spectratyping.25,27
109/l.74
100–6
52,58
patients78⇓–80
Ste6
c.70_80del
serine65
MSH2-MSH3
7q11.22–q11.23
p.Asp153Tyr
fromp53wt
1.Kinase
2245C
AGCAGGCAGA
0.742
8-15
.REF
8·4
WHIM21
histone-binding
table2
*Division
-cJun
20–60
intermediate-complex
Chantry
A29S
CDKN2C
v.2.1.1
apoptosis40
AG—with
Fig.77A
follicle-like
AMO1
v.2
3-year-old
×12
catalyse
D323A
260–264
Exon12F/12R
67/m
MRQ-58
Y1007/Y1008
YesNoInactivated
HLA-B-typing
CUL3–RBX1
p.I2295M
Pro→Leu
0.0019
p-GSK-3βSer9
6/120
Canudas
D3S1619
.Bmi-1
Calcagno
alterations.36
v1.0
structural/functional
RSE
odanestron
synchronizedwave
AS42SP6
Luciferase-encoding
mice10,11
BC—but
radiotherapies
Saethre-Chotzen-like
1498
P=0.0005
pC1
anti-CD138
complementarities
Flt3
myr-p110α
.Ten-j.am-thick
5′-AGCGGATCCCCCGGGTCCAAAATGCCC-3′
5′-GCTGCCTTAAACTTGGCATCAAAGG-3′.Full
pRB
Zoom-in
processes,22
S380
1week
GUSB
24,25,29
ΔPSI
SuperScriptTMIII
pCDNA3-Lbh
R148W
L747-A750insP
mulitiplex
1746_1751
NP-3-137-Luciferase
p.C416W
Asp419
table2.2
.Imaging
L996
P.M.
CBL-WTorV5-tagged
ependymonas
Hox-dependent
96.86
penicillin/
H1302Y
rs34295337
SL-50
devel-
Pro567
705
pGL-3
age.2
differentiationgrades
ivolved
sh720
T783Ia
K502A
BrafV600E
pY551
LNK
Schmierer
877-287-3526
poly-ubiquitylated
PDE4A
FGFR2–FGF2
PM————W
XP_535407.2
mesoovarium
PSE
ESCO1
Val9
1,863
erlotinib-treated
36/61
mug/ml
CBF-AML
CC3TT
paraf
5′-GTCCTGTTCCTCTGATGGCTACCCCCTAC-3′
oligonucleotidescontaininga
MDS6
GpC
NUP214-ABL1–negative
'EN
hexahistine
tar-
4:5
PHL-Akt2
indirectimmunoprecipitation
myofibroblast
Talin
GAC-39
disk-agarose
~MD
PKC-z
fibronectin
proteins.11
488-bp
D17S1832
R.S.
2.88-fold
.Neutralizing
dark-red
+testosterone
1699±850
activation/DUSP4
6\
Men1
monosaccharide
RHG-banded
splice-encoded
hered
MSK-922
16-amino
581
andMsh2p
Ga¤bor
1381
DNA-alkylating
Fig.55C
cytoskeletal-associated
DeltaFosB—one
Ras/Raf/MEK
30–44
duplication37
VS.
235.9
R391C
phenolbarbital
TK-Luc
anaberrant
A295T
safe-guard
BRD4S
MDS63
XE
Arighi
1–425
adaptor-substrate
−1.71
peptides—with
pZIP-NeoSV
level13,40
Cys242
JIMT1
2.75
L156R
X/H/N
NLS-based
5′-GGGCACCTCCTTCTT
11.38±0.46
activity/fibrosis
species.There
CD4+CD8lowCD69+cells
7B-C
S39F
-G
Temam
1727
.AL079303
0.01–0.99
STATISTICA
T-p53C-R249S
TFA1
R6307
L831R
S1.When
80–85Lane
pCMV6-NFIA-FLAG
Antaiou
675–858
1×105
single-centered
FuGene
rs60461442
~13
1–1541
603709
Philibert
OV1921
N131Y
SCC151
.WT1-mediated
101:4667–4679
NF-kappaB
EWSERG
loxP-Cre
Perifosine
NM_030952
Vs.
metalloenzyme
Drosophila19
ModelsThe
CTAGGTGGAAGGTAGCTGACTGA
Brom
52/637
TAD1
16p13.3-specific
antigen-retrieved
Tbx18
271G
24-nucleotide
0/13006
1LeuGl
Tp53−/−
Hedgehog
129:114:15:21
ZEB1-dependent
5′-TACCGGA
colorectal
Laragen
DNA-damaging
674–93
green-fluorescent
84–179
2/74
4.11
thyrogobulin
RAS.24
Ala775insTyrValMetAla
12NDNDTLS-CHOP
GTP-ase
non-transformed
Thr439
1BKD
methylated/expressed
α1βγ
SH3
mHGA33
.S-100
VUB164MEL
Gutierrez-Enriquez
24:885–893
S1c
Negative-feedback
.SCDs
.Lats2
Y969C
MXD1
717No
0·42–1·41
Res.
CGCATTGACCATTCAAACTG
non-collagen-binding
X-intercept
H224fs
K241
572–581
alanine-rich
E837D
slowly-hydrolysable
common—together
75ng
31-1353
somatostatin-receptor
Grant-in-Aid
113-8519
investigated.19
1815
transcription.42
Twenty-four
RU486-controlled
TCA-extraction
F83S
GAL
interrepeat
MOZ-A
CGIuA*nAspVa
Y1252Y1253
LSL-Ras-driven
Phospho-AKT-Ser473
0.27+0.02
hetero-KO
already-classified
3000-548
MS110
T528I
JB6505
MMP9-
0-
micro-deletions
K119
ion-chelating
GT7
AGTG
C-33
KANK1-S
simFigure
M33779
63/F
ACCAGCCTTCCACCCCAT
9-cyan
inhibitors.9,10
.full
R55L
Pro→Ala
102616
HindIII-digested
11,900
0.919–5.590
active-dimeric
.S1A
medicine.ucsf.edu
V5-epitope
NOTCH2-CEP128
C157
Co35
SETD2-deleted
bronchus-associated
.APOPTOTIC
C18AQ
.Prostate-cancer-associated
6A3
Gatei
590-3764
FoxA1-knockout
350–375
2.8amp
cancers1
given.PowerPoint
calcium/phospholipase
Haematologica
359
∼80°
Mll2–/–
CAAGTTCTCTTTCGTGTTCTTCCTGTAGTCGGTCTTGTTCGCTCGGCACTCCGCCCTTAA-5
INPP4BloPTENlo
.Blanke
EDCI
—CDK6
β-actin-enhanced
pCR4–TOPO
ter700
coarse-grained
GenBank/EMBL
crizotinib-binding
4q32.1
TScratch
PF-06469322
syringomas
binding.25-28
CRUK
816-Asp
reescalation
acetyl-lysines
SDF
isohexane
Phe91
Aveo
c.i
Carbamoylphosphate
sc-232
CREBL2
Ac-H4
Aratyn
PROVEAN.22
Optimase
RAS–GTP
rtTA-tetO-Cre
IKKα/β
m'E2
/Erk
fromour
USP15
p300-CH1
specificallybinds
K663L
SPT6
first‐line
1065–1070
T47D
2µl
LRRASLG
Del2481-2495
RB1wild-type-V5
Mutant-enriched
~400,000
Jansson
Val1130
–HCL
1,308-bp
6.87
FLT3/CEP13
62-3
dRanger
non-neuroblastoma
E29+30
bi-frontal
Mermel
3341
1704delTT
unknown.13⇓-15
75,76
4-month
6myc-Smad4
myeloid/lymphoid
73.9
CTTGGCTCTG
CPT-11
pathway37
misinsertion
S1B–S1C
Non-Polypsis
0.603
Glu339
-L-T
Muhlrad
MAPK-
coassociated
45.These
SCID-Beige
S422_S423insRN
XPD
isopropyl-
me0
1.083–1.567
ã
'i
a→ter
range28
14.0+
noncirrhotics
7/5/2/2/2
pRad50K6E
MD2
Ly-5.1+
seven-year
HEK293T-mock
DBD-deficient
593-1/pGL3
*Kindred
fast-spin
AGCTCAACGTGGACG
domain-core
13/1,116
Mly1
59CGGAATTCACTTCACAGAAAAGTAGT
193.8
pN+
DNAJA1
LSL-K-ras
S.However
fas/APO-1
nEAsVMkgF-tcHHVVRLLGVvskGq-PtLVVMElMaHGDLksYLR-Sl
1991,1997
ColoSeq
ESRF
L116
proteins.Figure
intoa
doxycyline
2.89
.direct
1B,1C
Rab17
+Serum
q36
R196H
Tcf-lymphoid
temperaturedependency
MSI−/+
.LZ
MKKKs
BCL6
8220
trans-membrane
sequence27
87K
tooccur
symptoms.5
ERBB2-targeted
pRB-p16INK4a
61.3–61.5
−150/+50
Mini-Kit
p15INK4b
.078
JAK1-3
rs1801516
Co-Crystal
19−21
5042
Montpellier
Technelysium
pCR2
D811
BRCA1.24
4-OHT-treated
IMAGE:3906006
E/D-S/T-P
~21
61,81
Kitasato
ctacaactggtttgccaattggcgcaaggagg
/Wap-Cre
26/39
334/2-02
.NAVONE2
vinculin
nickelaffinity
MnHODS
KS-causing
Comèl-Netherton
hydride
STS-Amplification
prohibitively
R340C
0.068
L165P
protein-delta
.Orthotopic
Cooperativity
≈10–15
pRTK
//dove.embl-heidel
freeze-thawing
19-year-old
TCCCGCGCGG
dystrophy,5
minimally-passaged
3-nucleotide
HLA-binding
Hum
Ag/lane
cis-trans
p.R97H
28/77
nt5673
.Equilibrium
ancerTy
154F20
www.ensembl.org/Homo_sapiens
miR-181b
BAP1.64
structure23
BLIMP-1.33
models.32
PD5
homozyous
C=54.1
5′-CTTAACCCACACCATAAAAAC-3′
TTCACATGCCACAAAAGGAA
-CTTGCCATTCACACCGCCAG-3
4×10−7
E040
memory43
Stanescu
Rho-induced
mutation-containing
p-Tyr695
glucocorticoid
Mmunohistochemistry
40–56
56780662
AGGACTGTTATGAA-3
calalyzed
X-100/0.2
p26
A_52_P82741
point,34
8.1Å
conResearch
RGC-
pcDNA3–Flag–STRAD
accumulation/function
low-frequency
amplification.15
p.Asn775Ser
Magnusson1
2/516
pEYFP
c.1061C4T
Spo11
Cdc42Hs
-PDGFRA
neurocognitive
TCAT
K-ras4A
neutral16–18
QVAAGMV
.Fusion
Santen
anti-γ-H2AX
Trans-blot
NheI
CD19high
anti–α-smooth
.Foxp1
cell-lined
JAK2V617F-bearing
ATP/drug-binding
anticodon
BTK-KD-B43
K186N
lower/inactive
CEM,18
51–80
life-history
PDHc
6,500
stability.Figure
T260M
AGI
RNF4
Q293
SphI/KpnI-cleaved
Schibler
Verdaguer
26.4
Sp1-transfected
Brd2
wtGSK
RNA-specific
metastagenic
SOS-independent
charcoal-stripped
RhoA-GTP
17·3
P12P
5′-CTGAAGATAATGACTCAACTGGGGCCACATTTGAAC-3′
Nucleotide-Sequence
neither100
pan-trk
2Ras
anti-Py
LONRF1
immunological26
floride
Mpl−/−
R378K
8267
reclassi-
loss102
pGL2hmdm-HX-luc
PAK1-PBD
pageDiscussionIn
9RT
5′-AATCCAGCTATATGCCGC-3′
argenine
haematopoietics
∼70–80
KDM7
Classifier*
assays9,17
sfhuang
Ki67-labelingindex
MICZ
pFastBac
M98K
S12-13
Citri
2007–3522
epithelial10
EGFR/KRAS/ALK-mutation–negative
PDA-R2
T-score
HGS-OvCa.a
D36A
chemotherapy-combination
sub-division
sites.7,44,45
www3.ncbi.nml.nih.gov:80/htbin-post/Omim/dispmim
quinazolin-4-amine
www.interscience.wiley.com
pancuronium
TMEM129
macrosatellite
6q21
N-methyl-piperazine
0.052227114
desmosome
Ribonucleic
locusId
4-yr-old
∼3:1
DR1
D.L.R
STT648
r=0.67
mutantproteins
5'-GGGTGATGGTCCTATGTGTC-3
D816Y,3
cytometric
Trans-phosphorylation
4q34
embryogenesis8
ConservationOn
andHumanServices
MET-L269V
Nu24/SP3
higher-penetrance
pBS-SK-mp1
0.34Male
AGCTGAATGGAAAAAACATTGAAGACGTC-BBQ
development62
I89V
Tissuelyser
Hect
mutantenriched
,3E
super-transactivation
MicroBeam
EUS
4-nitrophenylphosphate
SW403
Rastransformed
A598V
Ala60
cancer.The
FGFR1.1,2,8
iGGTC
.S9D-E
N-rasG12V-C51Y
400-base-pair
S245L
~~~~~~~~~~~~~~~~~~
myc-labeled
RECIST,23
pEGFPc
.ETV1-specific
pone.0064364.e004.jpg
TERT-NHU
multi-site
phospho-Erk1
SDS-polyacrylamide
0
ecdysone-inducible
Runx1-EVI1/+
PHTS/Cowden
a-ETV6
drug/TVcontrol
GSK-3ÃŸphos
.GST-bound
64.5
radiotherapy/chemotherapy
5-FU/mitomycin
≤10
cholestatic
83–154
12–40
Schwann-cell–derived
48109
PML/RAR
ROR1-mut
.RET/PTC-1
1Numbers
quanFig
A138D
pull‐down
GTTTTGAAGTCCGCGGAG-3
CSMD3
sub‐G1
sit-up
.GAS6-RASA3
-D2S123-D2S337-D2S2368-cen
25-75
-neurotrophic
FH-DDIT3-WT
.RTK
448:561–6
5´-GACCCGGAAGAAGCGCCATCTC-3´
FANCCcomplementary
.Radiation
931showing
R209W
C-1111-102-387
telangiectatic
3.0.0
CTGG
p.R88Q
SectionMethodsAdditional
5′-tcgacttggttaataattcaccagag-3′
0·036
bialleic
16–20h
pcxn
findings.22
3037–3039
XTC
.Clinic
z-images
lesions72,73
regulatory-region
Ångstrom
TGF‐β1
apoptosis.9
66183
3l
Kilobase
Spritz3
two-base-tagged
250μl
.Dosing
C417A
RCC40,42
1504T
electrochemoluminescence
siNC-
leaflet
carcinogenesis.36-38
.Puzzlingly
oligozoospermia
10.1182/blood-2010-06-291310
W5A
anti-MLK3
FISHwas
R411W
182-nucleotide
2543A
V1500M
125I-FGF2
ASP-DNA-FLA
Phycoerythrin
anti-unphosphorylated
Ptendel/del
methylcellulose.44
Fv
100mMNaC1
megaprimer
nonbasal
esti-
Ac-erbB27q
GSE33327
pCS2‐Bra5′Ha
g.71955_71955A
13,27
GENERALIZATIONS
c.2059C
p.Phe268Ser
.Forty-seven
UAP1
rhabdomere
polymerase-1
Fedier
Pepstatina
PKCβ
3508
5-GATGGGTACCCTGGCGGCATGGTGAGCAGAG-3
C-myc
multiparious
PIA-dependent
situ,56
Leu115Ala
1272
P.R.
Communicating
volumeswere
NeuronJ
I836del
L-012325-01-0005
washout
asprobe
K6C'AA-X
S130L
604373
samples,62
Tavor
transcriptionfactors
response.29
5′-GGGGGAAAC-3′
outer-most
repair47
urothelium
Ubiquitin–protein
E255K39
2/195
AnnexinV
0.884
S22T7/AS22SP6
TUNEL+
partners,2,3
Clone3
93.342
megakaryopoiesis
MPN-initiating
subsequentselection
HNPCC-related
8-aa
caveolin
V560G/D
H26.5
97/151
NPM1-wild-type
6.Download
sc-186
epitope.15,18,24
BRCTmediated
worldwide1
CD44-FITC
single-pass
adenocarcinomas.4
TGFβ1RII
1–319
thecytomegalovirus
Granziero
.Lin−
development1
n-fold
Variation_30362
snapfrozen
CWR22
centrocytes
PDGFR-PI3K-Akt
P270
G•T
hepatosteatosis
19,630
temozolomide82
4f
myeloid-cell-specificity
PI3K
8/302
TIMP-3
BMPR
cells.38
.Ampliﬁcation
Asp1628
WT1-Mutant
ProTEV
626–628
CBFalpha2/AML1/RUNX1
H3685
5'GCACAAAGGACATGACTGACC3
locus.155
2WGJ
TGCTCCTCAGATAATGAGTACTTC
M13913
.0.05
P-A-A-K-R-V-K-L-D-Q-R-R-R-A-P
isoforms125
Dennler
–1.86
.FGFR1
presoaked
Tropix
CstF1/BARD1
.Tat
ARAF2
micronuclei
IgM-IgD-
32/117
7.3–11.3
Nonsynonymous
31,094,927
dMAPP-MMR
anti–CD15-FITC
HLH–LZ
PTEN-K13E
permission.15
.Seventh
ICGC
4.A
CSPG2
.Context
Synchrotron
Nlower/
bCATa
49503
16Xql3
Ala35
proliferation-related
PALB2-2
Fig.~~~~~
GFP/H694R
ImageXpress
BRAFG464E/V
intermetastatic
A_51_P321341
RACE6
DNA.12,40,41
aggressiveness.10,14
all15,29,52,53
GCLC
α-Ptyr
G60
0.732
pMH267
RAB35—but
plate-bound
652
3189
56787304
VNR
3′-CACACCCTATTGTCACTCTGGAA-5′
PQS
Shiozaki
PPP6C
CCND1/FGF19
tissues,13
Accumax
6026T
Anti–phospho-AKT
L63P
NF2-dependent
2.2-Mb
2YVMA
Handschuh
.Niewolik
.definite
CA54807
12655-7
E1803
N535K
G1137S
9206S
400-700
Maxillofacial
6-catenin
N-cadherin-mediated
End-Repair
E1A-immortalized
families.24
ACAAA
GPIIIa
.Substrate
6q21-deleted
downmodulate
Abelbeck
500000
UTR-WTLuc
infor
CTTGGATCCTGAATCTGTGC
p110CAAX
166.In
G142
described.11Subcellular
N-Ras61R
GACCCATGAGTGCCCTTCT
L798F
UBL-1
p.W557
ofmsh2-GD855p
Mx-1Cre+
OB1-OB2
-520C
YCC16
37,570/2088
3-aminopropyltriethoxysilane
.S39
AK-5001
G649R
.Induced
547
Shh-driven
.JAK2T875N
NZM29
2/117
gliomas.14
chloroform/phenol
pathway190
pathway.104
p2=1/10,000
3.1:1
.HUGO
Potent
benefit.2
activity5
V53M
39–60
2G2
phosphate
Δ8-10
2/8/89
Div.
SPRI-cleaned
BAY43-9006
Chx10
L122G
Modeling—The
pileups
S333L
RNGTT
Gly17Val
pTRE2-hyg
HAhB-RafinsTT
XhoI–Aor5H1
forward-5
MIP-SRSF2
HY-mediated
21/20
5'-GATCCTCGAGGGACATGCCCGGACATGCCCCTCGAG-3
FLT3-PMs
OP9-DLL-1
pBS.SK.pl6
.Memory
elonginB
Thoracentesis
E297
repression.8
.Conclusions
34,17q22â€
phospho-cJun
3452
T50F
pre-activated
Brca1Delta11/Delta11/p53+/-
2743
0·02
discoveries1
type/location
disease-segregating
patient.23
pCY4B-FLAG-BAP1-F170I
SUMO1-conjugated
misrepaired
inflammation—differing
0.52
i5..
same-direction
ms00003514
≥20×
toanalyze
200U/μL
auto-ubiquitylation
beta‐catenin
gtaagttaa
factor.4
overactivation
years4
min-coverage=100
effects.10
TRIM24‐BRAF
.TCRVβ
.Fak
Yasuyama
xenoengraftment
ΔHIF
nperm
729
TIAM1-RAC1
FLT3-LMs
40ng/μl
p.H1047R/c.1624G
Mecklin
→CCC
Leu678
.FAT1
N1643K
substrate-4
Uba1
293-hTLR4A-MD2-CD14
SMO-D473P
5/72
withmutant
Methyl-directed
marcescens
15F
suplemented
investigatedmutational
Y1054/1055
Ref-1
Intra-
CRAF-dependency
Default.html
endocrine-resistant
SHELXL97
.Array-comparative
84-
Mycobacterium
RP11–248L3
stabilizations
reorganization6–10
P-ATP
p-Y1110
1.78×106
leukemogeneic
M20054
MY24m6
PstIdigested
semi-quant
BAP1/HCF-1
LNR‐B
Msh6LQ/-
translocation-bearing
FLJ13740
reports,6,7,9
assay.19
boxHow
.Begg
2-H
0.05.Substitution
α2β2
CS21
3-1-1
Protein-equivalent
Sg./M
locus.34
1.5M
Quant4
Hystopaque
27,66–73
2.06
.Chromothripsis
P1110S
Cell–Derived
rs6976537
Val1774
sulfate−polyacrylamide
.Fig.5.5
4~6
.Angiotensin-II-induced
S150R
leukaemia68
www.nccn.org
substrates.Studies
nasopahryngeal
2890
lines20-22•
M11S1
GdotG
Cdk4-pRb
DND-41
88/74-bp
FIP1L1-PDGFRα,7
082-256-7
false-positives
.Cell-surface
CeA—central
MCM1
HA-B-RAF
cDNA/
second-shell
carcinoma.25
Biomyx
analysis.Thymocytes
HSP90.51
E1F5A
Health/National
NuPAGE-Bis-Tris
Kibel
360ins2
mutation—the
Seong-Tae
P=0.0032
W515A
cancer52
T187
protein23
SATB1-overexpressed
20,000×
process1,4
ciency
Signifi-
p.Val567Ile
F239
GppNHp–Wat175
repository.Quantitative
59-TCTTTGAATTTGGAATATTACAATG-39
populations.3,14
Orkin
dose-
Nx
R26-Pik3cawt
harvard.edu/ts
.HD-0264
lysosome-associated
cell-dependent
membrane-bound
V600E61
1957–1958
M1255
Promega.Cell
D802
Lyticase
1-ras
EBP-knockout
.Gorlin
AATGTACACC
Ezh2-mutant
HKY885
H3-K42A-expressing
3TP-Lux
signficant
Lipofection
SMO-D473–mediated
Pardal
PLAGL2
theKIT
non-disruptive
1T45
pMX-139
cancer31
RAS/RAF1
FGFR2-AHCYL1
plasmidsfrom
2AH
Clonetech
5673c
nonrandomized
laciq
Trp53fl
E90
M252T
110-gene
,57
FANCD2-deficient
5-deletion
pan‐kinase
S492
Q331R
pS6
Tyr577*
sawtooth
GST–RBD
target-effector
AML1-MDS-EVI1
ER/Golgi-resident
IVS20+48
DMF
cycle,17,18
CRAF89
2.02–5.01
.Grieselhuber
anifested
6,23
119K-
Wt1-nulls
Leu117PhefsX46
p.1415Qfs
1402G
previously.2,31
doxycyclinemediated
factor/cytokineinduced
p110β-
3,16,21
His178
edgetic
CTD-2043I16
G147R
Laser-capture
approximately2
5′-UGAGUGUGACCGAGAAGGUAGACAA-3′
Arg175
Oskam
inhealthy
anthracycline-based
CAPAN
DNA-methylation
S79
5'-ATTACACAGTATCCTCGACA-3
0.0217
P29S–mutant
post-baseline
HEK293
Ras-­transformed
6,7,11,14
L398V
Kreppel
PhIP
LGsGAFGqVveAtaHgLsh-sQatMkVAVKmLKstArsSeKQaLms
Sahin
D406V
R729Q
0.1096/7
BrCa
Ndrg4
12.57
D272A
v2.4.2a
CCTG-G
Ruhrberg
MGUS.57
171,670
ROSA-driven
TMZ-treated
RecBCD
deletion-negative
1–403
7/03
Insulinomas
RUNX1-chromosome
G3T
tetramer-independent
TB01
L63V
FLT3/FLK2
Leu-407
0.966
Bruce4-derived
G650S
anti-p44
tendentially
anti–CD19-PE
A334T
0.0017
Spliceosome
Prism-310
442/465
ossi®cation
Wif1
n=42
6.3-21
ASK1-JNK
deviation.VEGFA
Notch‐related
913
on-going
approaches49
Herc2
180-kDa
J-043747
cIg-FISH
9.9-fold
IL-23A-dependent
ERBB3/EGFR
.GAL4
Ser406
7.564.8
Análisis
K132N
antiThe
B*
Sexual/reproductive
salamander
pCEP4-Rafl
160-
DNA-PK-cs
Unit–ACRF
CT-examination
20.7
humans.27,28
VMM5b
p.TDG
Ph-chromosome
0.706–1.521
249–252
chromosome.53
Non-GCB/GCB
NA/NAHEC108
front-end
prolin-rich
Umeå
Yyl
MBD
131.With
NCC
autoregulation118
.A349P
000251.1
Beckwith–Wiedemann
syndrome-7
WO-24
cross-talks
pER4-7
2B.Frequencies
RAB11FIP4
−2.04
TGFbeta1
pSV7d-TβRI
McVety
Ras-directed
0.548
r..
NCT01941927
GYPB
R300C
ATP•min−1
56772390
S3A–S3C
.Intercrosses
R341X
Intraepithelial
Reumatología
CTDa
MC1–neomycin
Ligand-mediated
AMPKa
5V-ggccacc-tccccacaacaca-3V
thattumor-derived
Q145E
61–92
1–1417
.Caspase-8
16-60
4.89±0.57
25.1
S1379L3.
metastasis.20
DOG1+
MacKeigan
twin-spots
Sephacryl
7-28
6/151
RT2
Phe31
BoehringerMannheim
Ouathek
Myristoylated
A1853V
38/22.Cytogenetic
=267/
BspCNI
to-phenylalanine
Gly35
pone.0032555.e003.jpg
p25
83.7
ActR1B*
p.Gln243Glu
2119
1.5-mg/ml
F/I-2
c.1730dup
IMUX-P1.0
E-MEXP
model178
flutamide-reactive
Tris-acetate-EDTA
02/95
P300/CBP-associated
D32-S33-G34-I35-S37
3INM
c.619T
Endomucin
misincorporations
Drug-Sensitive
bicinchoninic
Linhardt
MAP3K1/MAP2K4
Zachariae
RAD3
/Illumina
diagnosis1
sodium-vanadate
pip92
tvxwcox
S292
post-castration
FGF2/WNT3a
vs.
.Paraffin
AML.16
muci/mul
.CFUs
.Patient-specific
.INI-1
GAGCCAAGAGTGAAG
-62K
63801
Gg5.9kb-LacZ
Msh2A818V
panitumumab.1
U-sense
RNAi-insensitive
S574
MDA-435
v-Ki-ras2
neurite-bearing
senescence-associated-b-galactosidase
T30
rasK
pathway.Several
P623A
Tona
Roussarcoma-oncogene
cl8
ACINAR06
NBPF1
LMP‐2
0.751
MutL
8478
parameterization
D157G
δ-catenin-expressing
R80C
Adélaïde
77·8
anti-hMLH1
p53−/−
Figure4B
nonbrainstem
C3H/1OT'/2
64/218
m/73
16,21
tumours.41
weresubjected
KP39
µg/
pT185
5446
p-value
-transfected
5′-GGCGTTTGCTGGTGATGA
postchemotherapy
poly-L
//www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/
3.4.20
c.546-2A
super­
Chehab
A_52_P132165
SK‐BR‐3
anti-α-myosin
528C
pseudo-colours
D74N
FHc
colony–stimulating
PIK90
K600E
-gtcctctcaccatttcagg-3
λ-phosphatase
alectinib-treated
HNF1A/M1
D-2-HG-mediated
​Two
2â
M450I
.BAT-RII
contents.1
Kinetworks
AGK-BRAF
C405Y
CRIZOTINIB
.Age-matched
.Human
51.5
extra-haematopoietic
09-025
Glu-24/25
ufacturers
D814
4Y
Figure55c
FetalPlex™
ethanol-based
cAMP-
.TGFBR2
genetic-risk
phosphomimicry
α-MLH1
1=170R
degradation31
GFP-19
c.2939A
c.181T
F1260
C.W.P.
Akt2WT
TRAF-1
23,37–40
Tsc2–/–-induced
Neurotrophin
e⁄ciencies
low-speed
1da1ta
PTEN-binding
Willmore-Payne,9
resecteda
phenome
AJ532608
.Definitive
SNU-C1
35°C.12
IL10RA
0.15i0.09
748–957
P733L/S
Proteins—Small
ofmRNA
TP53/p21/
S41/AS41
Vitour
path-ways
BisTris
XP2YO
RM1
ROR1-silencing-induced
signaling100
.1C–F
CCGAACACCTTTTTGAGTCAACATCAAGTATTGGTCTCTCGTCTTTC
pair-wise
GATA3-negative
CRAF7,8
SD48
0.354
Cre-Lox
HTB10
Phe1704
1P2
L135V
Biopharmaceuticals
evalu
disordersALLNHLB-cellT-cellHodgkin'sHairy
Shusterman
/1.4
NeuroD1/Beta2
28s
Analytes
polyribosomes
200-kb
Hoxa5
EcoRl
C842S–mutant
.Bar
27,786,297–30,476,012
746
0.997
AR-FL–specific
α-S4
AP1510
N822Y†
5′-AGCAAAAGAGGAGGCAACAA-3′
.HNT
490-nm
RecQ
Aggerholm
CloneJet
mAR-V2
HR=0.34
291–298
D44V
X/A
primate-specific
5′‐TCAGGATTGCCTTTACCACTC
123790
ALKA1234T
nutrient-independent
c-e
_nu_/_nu_
anti-Tyr-653/Tyr-654
D68F8
ever-smokers
PD-L1
Ad-Myr-AKT
0.118963
1A–C
BCL2L2
Me´lanome
62026
intestine.27,28
Leu-13
stresses.36,37
MAX/MAX
gtgacaaat
S1096Q
Opacitya
Westin
M340A
WZR
tetrahedral
Poux
5360A
enzyme–substrate
mU6pro
0.4071
inhibitors.20
Tgfβ2
NAAIRS
p55γ-regulatory
lymphomasImmunohistochemical…
licensee
imatinib.24
1423
4q3131
CSF1-deficient
G183R
p=0.547
StrepII-cyclin
PET-CT
2.46
AVM/AVF
ab86305
381–423
D3S1578
non-templated
Bacq
1138–1
Kamasaki
I281T
p.Ser1882X
TKI-sensitivity
siLamin
Oike
TbR-II-transfected
Mll2−/−
PBML
LMO1/TTG1-TRAD
anti-phospho-Thr202/Tyr204-ERK
David-Pfeuty
Il8
t1
P29
N64
Pronier
L2086
methylation-induced
F354I
5′-TTA
Edmondson–Steiner
GCAGTTATGCCTCAGATTCAC
T341I
10.220.33.1
pLentiLox3.7
abiraterone
driven-signaling
Brabletz
LOC286052
NF1-Clinic
+18
Y1295
40/0.70
CH12F32-A
F-MuLV-induced
0004697
patterning40
surgery.13
3e–h
early-
1903–1921
syringomyelia
thus-far
WDLPS
HA-CUL2
SCFR
3.125
Jvi
C177Y
CD11b-
andred
.Coimmunoprecipitations
.SiRNA
erythropoietin
5′-ACAACAGTGGCTCACGGGCT-3′
Snail/MMP2
PDGFRα–transduced
Co-SMAD
WEHI-conditioned
17–22
VAVKSCRE-TLPPD
1.2:1
of-function
Noncompetitive
dimerization-competent
shRNAs
TCF-3-repressed
Wassenaarseweg
FO-1melanoma
EGFR19F1
HNF-1aprotein
FAM118B
3′SS
M1628V
-methionine
1151
Smad2-negative/Smad4-positive
photomicroscope
NKI-CMF
p-PKCα/β
Susin
S+G2/M
PCI-13-pBABE
ITGB5
5¶-CTTTGGACTTCTTTTGAGATGTCATTTTAACACTG-3¶
Duan2
β28
eLOVD-IARC
h+48
glioblastoma.10–15
Gly17Glu
Peroxidase-labeled
cells5,6
CTR1
2147
4970S
8328
-2.8
p.R659P
Chi2
CD11c+
DNA14
PIK3R1E160∗-
re-inforces
54h-l
Argl347Gly
VPS15
31318
.0181
Asn448
−0.17
FRAGALE
Tyr502
.KE
0.0271
D448N
CD3-specific
i6
2.7.11.1
0.22
201-residue
patients8
C96W
MP8
F276C
normal-appearing
Arrhenius
EUFA166
65–68,105,106
.Scoring
eff
bromodeoxyuridine
CNBr
2006-6T
S445fsdelAG+WT
20,700
2240-2251
leukemized
0.00159
positron
F2004C
cardiff.ac.uk
non-neoplastic
Terapia
Watcharasit
M62397
imFIG
.5216A
TNFRSF1A
5′-GAGCTAGACGTCCGGGCAG-3′
ratio=2.360
538G-ERα–transfected
.Tremendous
.Digoxigen-labeled
*1
D1/D2
JX
relisted
subsaturating
CD133+
mll2+/−
forH-
8079
MLL.11,12
.PTPRD
ATMDS-associated
re-joining
.Non-uniquely
Fluor-594
.5d
CCNU
fashion32
N1845T
Src/Abl
expression79
Y329D
Vκ3∗
.Full
previously.18
Hypersensitivity
Alk-x/Smad1-Smad5
p.A563V
Arvanitis
p.Tyr101X
CDKN2A/CDK4
deletions.53
andTumor
Allelotyping
3.0.27
5′-TCCTGCAATGAGTGGATGTTTCA-3′
BRCA1–mutated
Affinity-propagation-based
2AR
unfolding.3,4
eight-somite
LacI-Cherry
SU-DHL-4
CRL4DCAF1-dependent
BioResource
CI:1.62–7.10
inlay
G466EBRAF
SEC31A-JAK2–expressing
P.L.
590G591D
Volkestwil
N750
FGFR3s
TRCN0000000368
.EBs
14/21.9
AGGGTACATGGTGGTGCCGCCAGAC
Ser532PhefsX1
cytokine-deprived
ASXL1-wildtype
SPOP.24
phenol-
phosphorylation.The
1090
pH9.5
p.Thr260Met
H175R
5–79
gene42,43—applies
Prg-Sox17
4×10−3
well–based
MET-mediated
DICER1-associated
anti-SPEN
.IFN-italic
~~~oo
L753
63/251
Acvr1R206H
U43746.1/
Immunoprecipitates
PD=progressive
cRSS1-4
LUC18
pathway.5,6
Naqvi
3A-F
gefitinib.8-11
TTCCTTCTCCCAGGATGACC
ElA
H2N-255QRSTpSTPN263AHMVSTTLPVD273-COOH
NEU
inland
spermatocytes—cells
Thiruvananthapuram
amixture
Smad48+/-
bronchioloalveolar
14.0
F5-R5
RAS37
49-55
nlissense
ES2
cocrystals
Brca1-Associated
patients.2⇓⇓⇓⇓-7
R292G
GATA-3–mediated
DeltaDeltaEvdW=-1.08
E559*
phenotypes15
pT4pN1M0
2×SSC
.MSI+
carcinomas.In
SPER
/*AV*V..
.Biodiscovery
c.691delA
6/256
Raf/ERK/MAPK
240103
810A
1–143
ABE101
E184A
Hospital-Kaohsiung
hybridizationanalysis
apoprotein
cystc
Pro-34-.Arg
Survival…
.RhoA-immortalized
-selectable
SH1
short-lived
API5
MgCl2,25
RhoA-mutant
12/57
41kb
Val38
.15,16
ΔEGFR-enhanced

SC-585
refolding
GSI-resistance
mutRAS
Chr15
cancerassociated
state36
re-expressing
thedominant-negative
EDC-mediated
-esterified
.Out
.Afro-American
c-Kit–targeted
in-vitro/in-silico
enterotoxin
reduc­
4.3-
Single-Agent
bisphosphonates
G1913/
3987
NGF-triggered
~60
SRLLGICLTSTV-QLVTQLMPYGCLLDHVREN
E555K
10.1111/j.1349-7006.2008.00782.x
Cadherins
Ret9-WT
2.097
5179
CD4+CD8+/low
106·9
0.36-3.44
39/140
insignificance
–non-specific
2414
GT-AG
synthesiswere
D487
722–723
biology18,19
SP2/0
DomainsERK2…
splicosome
.S2.5.1-S2.5.3
involvingexon
ZNF198-FGFR1–transformed
re-suspended
SSCV
35/70
PdmI
T45R
C609G
.001*
14,524
F232C
M13
Lan-DeMets
0.1032
susceptibil-
IL6
malig
S-transferase-GATA
difications
intramolecularly
sub-G1-phase
Pathwest
85–95
vector50
~included
6,7-
LAMC3
preincubate
rearrangements109
TurboSequest
meningioma
–ABL1
cellsthrough
12,13,17,22
6.9
SPF
Y931F
SHIN
pathway.28,29
ABD–kinase
KWMAPES
−879/−593
non-endometrioid
prolyl-4-hydroxylase
5-terminal
T251
COS7
AK006128
0/14¶
GpIIb
family.FGFR1
protein.1-4
FluorSImager
and3C
E.M.
B130049I05
PGF1
polycomb-related
.T529N
mono-adduct
D=ατ+2
PKACA
therapy.41
S194
MEK-phosphorylation
C3592T
dominant-inhibitory
JAK-interacting
KMT2D-deficient
phosphorylation—RICTOR
IP/Co
M376R
trytophan
.NE
Blimp1-mediated
IMAC
dysphagia.10,20
ITK,14
mR116
CSN5
apoptosis.62
ligand-binding
L858.12-14
4C–E
1-base
620C
1079–1113
p=0.498
moderate/intense
GGCAATGGATCCCAGGTATT
Brdi
TTT-3′
cross‐species
05-311
PRC2-containing
G-CSF–induced
10-mm
Kinexus
W96R
tumor-constraining
5-month-old
.ORIGINAL
V346
anti-transforming
methodsSample
Sclerosis
anti-EGFR-phycoerythrin
.Metachronous
LANCL2
Medicult
IRTA17
androgen-receptor
NEXT-1
CSSMS
Smad3/Smad1
.sarcomas
scoring20
TEL-PDGFRβ–
CVl
V1833M
AKT2-R368C
ch13
leukemia.IntroductionT-lineage
.DICER
NPR4–NPR1
immunophenotypic
Paz
​and2B
N676K–
p.Arg153Pro
anti-DAXX
germicidal
Br54-Lg59-
cornReceived
models72
1.03E
transfectability
.HER2
'histone
Echelon
Posner
.Freshly
1129-1936
TAH–BSO
time/time
Myc-Smad2FL
GCB/ABC
ponatinib-treated
Pten/p110β
I76N
TCF4
oligo-organ
investigator-initiated
Mutant-Induced
hypergranular
0.131
5′-CACTAAGTTCATGTGTATCTACTATGCGA-3′
.Eligibility
ERK2-binding
V600G
witherror
signi®cant
PAT1
-.~~~
protein-stability
TNBCs.AKT-3
lipoglycoprotein
vitro.5
A361V
anti-MPL
2/02
activation6
BOND-III
12/88
M178I
–polyacrylamide
5′-TTGGGCTT-
offspring.PCR
Version11.0
.Osteoblast
rmSCF
ARE-containing
aspartate-specific
//www.bccrc.ca/cg/ArrayCGH_Group.html
.PK/PD
HRR
BioMark
hKIT
5,356
1/936
A426
.1-3
HRD
neuronally
FLAG-FANCB
halogen
Mb–D18S35
.Macrophage–Tumor
geneticvariants
GNF2
.Conflict
interallelic
co-denature
RAS-ERK1/2
17-kDa
mitigation•
L420A/F434M
S124A/
methylcytosines
442087224432
72–369
maastrichtuniversity.nl
kinase-negative
RRP6
11668
2011a
EGFRvIII-L688P
IGH-MYC
GRB2-binding
A434T
LLTELTTKGRVPYPGMVNREVLDQV-ERGYRMPCPPECPESLHDLMCQCWRKDPE
THR359/SER363
ab46540-1
ATCTTTCTGACCAACCACAGG
EZH2-containing
alpha-Helix
E177H
poly-HEMA-treated
B11
CTCTTCTCATGCTGTCCC
theMEN2B
9351
PIGV
experi-ments
S8-β
DNA-encoded
10–12
ventralization
GAAGGCAATCACGGAGGTGA-3′
R372W
5′-CCTCCTTCTGGGAGACATCAGCCCGGGGCTAGTACTATGTCAAAGC-3′
1⇑A
STK15/BTAK
eIF2α
A012
p=0.769
Incorporation
00~~~~~to
syndromes/myeloproliferative
p.Gly17del
4times106
G-capped
L3–2
Cdc37
BTK
AML-SHG
Frz
1,295,161
resectedtumor
comedo-type
p.Arg154X
1370
Fig.5B5B
SF3B1R1074H-expressing
1.0000
20p12.3–p12.1
anti-INPP4B
Clustal_X
.DLT
mutations.72−79
A301-041A
l7p
KITK563
F329S
/47
EWSR1/NFATC2
18F-DOPA-PET
C72
EGFR-operated
anti-mycobacterial
ARAF/CRAF-null
41/47/63
5insGAAA
proline/glutamine
tumors.14
15-bp
Christoffersen
both.26
kinase-dead
U937-A/E
Receptor-activated
354495765
G125V
Ig2-Ig3
ACTTCTATG
9168
R132S
Ni21-nitrilotriacetic
cancers33,34
overfolded
SDS-lysis
PSF
members146
.DDR2
oogonia
0.125ppm
alan.huang
regulator.43
CD3/TCRαβ+
plasma-membrane-located
ABCB5
Q644del
BRAFwild-type
RictorloxP/loxPPB-Cre+
Q56_V60
del1
domains3,5
T2+
D603N
Cys-62
MolecGIST
EGAN00001001257
shRNA-INPP4B-1
cardiomiopathy
knockdown26
Substitution/
Confocor2
λ-ZAPII
collagen-I-coated
Bithorax-complex
Second-hit
Hystology
T341del
CD2–Myc
BRAFR671Q
HJAY
Zeocin-resistant
Fig.6D
1–1947
//genome.cse.ucsc.edu/
STE5
B/PR55
10-ns
125:12
adenylate
Ceconi
Y-MESO-21
Gastrontestinal
c.243C
Hrt1
5′-tgacatttctccagggatgc
208G20
Aniruddha
NLAKEFLCDLIMK
Jacques.Ghysdael
1.7–2.5
BIII-1*
.Half-maximal
Yazawa
J7OT
E4TF1
5-µm
-tag
2694–2699
Thr3195ter
gut-associated
N263
HBBP1
'=
FIP1L1/PDGFRalpha
C-CBL–UBE2L3
∼1–2
.IRF1-dependent
ModBase
/lef
2.15
1CS4
p85αdelY463
F876L-encoding
doi:10.1016/S0015-0282
c.1578
R32
S7v
by-pass
5¶-TCAGTACTCCCATTTTTAATGGATTCAGGCAGCA-3¶
.Individual
W227
.Spanning
As2O3-resistant
YES1
q=7.42E-7
cervlx
pathway42
D806H
PSGAP
specimen.35
.Morphological
NES-binding
andproliferation
201
setting.7
ATGTATGAGGTCCTGTCC
cyst-lining
immmunoblotting
Tumorgenicity
R172K
algorithm8
make-up
cancers35
retinoblastoma/RB1
76–78
practice.9
5q35
metastasectomy
data,11
.K5.Smad4–/–
.Response
.3e
angiogenesis-independent
3-phosphoinositide
underestimated
57-85
antioxydant
short—several
189–229
inter-
422.3-codon
nanometers
K266N
Erlangen-Nu¨rnberg
anti-GLI1
1797
-recipient
Chorioallantoic
ELVENSLDAGATNIXLK
cytoplamsic/membranous
K310R
40-Gy
1/108
complementarity
MFM223
endophenotyping
91.7–97.9
CTC3.0
GFP-RAC1P29S–expressing
Ex19Del
.Key
0.0056
17N,62K
.55,000
Y340DY34
G55fsdelGAGGG
deoxycortisol
ARID1B-based
IGF1R/INSR
.Gains
1.17–2.63
200–303
re-
Schweiz
Jacob-Hirsch
V-Ki-ras2
.Enzymatic
X15
Melan-A/MART-127–35
sora-
ggagtgcccaaaatcataatctttataagacagtc
EGR136
series17,18
leukaemia100
c.4171A
0.98–1.75
DLBCL.18
HA-ERα
ddCT
Kozma
34–54
Biomek
3beta-interacting
havepreviously
Tophat–cufflink–cuffdiff
B′γ
M.Marinus
DCFH-DA
radiolabel
GGCATGGACTGTGGTCATGA
HA-Cbl-TKB
Arg-1699
structure/
polymorphisms10
delTG
CVCL_1285
bowel.4In
Neh6
D9nt
CD30−
p.R741EfsX15
lane4
59–68
.Post-consolidation
115.5
SciMentum
NT_010164
rearrangement.Expression
geneexpressed
TCCTTCTGCATCCTGTCGGCA
R101A
Co-expression*
11Val555_Leu576del
GPI-anchored
c–e
-CAGGCACTGATTTGTGCA-3
K299AR300B
HER2/p-HER2/HER1/p-HER1
integrase
STAT1-binding
men.22-24
melanocytes38
Gln52
_Alu_I
kVolt
FLAG-Gab1
ProteinProphet
means6
UCP-VHL-HIFs
H1727
5′‐AGGATAGTCCTTCCGAGTGG
scanning/sliding
38-1
green-red
3098
null281E
Ubiquitin-protein
Post-therapy
G1/G0
M.HhaI
.Some
downstream-initiating
factor.15,21
MMTV-HER2
HuH-
RB18-RT-as
Bisarylamide
cancers.10,11
high-mobility
Balb/cRb-pur
*Lifetime
​Figure6F6F
.BCL6
0.62–1.00
Strooper
ANS
BE13
WPI
LEF-dependent
entry/exit
2p16.1-15
​Fundamental
L44P
coactivators/cofactors
GCTGAAACTAATTGATCTGGAG
SensitivitytonuclearIκBα=
patients.36,37
NTRN
78193604
VZZ
sensory-motor
0.961
7.0-
14.6–0.82
0/277
A-Raf
SRC/
phenol–chloroform
interleukin-34
.Autologous
RD-Gal4
CO-1686
MCAP-like
aContaining
-ACCCCAGTTCCTGGTTCAATGCCT-3
Layayette
Coregulator
CCDC49
V430M
0.0663
15hr
TATA-CAT
experiments/cell
c.8878C
W453S
KMT2D-mutated
0.1–0.2
NCAM-negative
APOBEC-1
GGAAGTTGTTGGCAG
vitA2-ERE-TKluciferase
MDA-MD-134VI
non-viral
KKGQSTSRHKK-OH
7allele
B,3C,3C
din-coated
AGCCCAAGCTTTCAGACTTTTGTAATTTGTGTATGC-39
F83L
tumor..
A116V
P0447
nuclear-localized
ER-deficient
Figure5F5F
Water-soluble
Sos1
Level/Cell
Phosphate
7–3-1
Chk1/2-phosphorylated
Y568-Y570
R677W
AmershamBiosciences
E347K
miR-23a/b
Pcgf1
others45
S211
K81E
5′-TCAATCAGAAGGGAAGACAA-3′
recirculating
RLDH
Angelopoulou
Σ∣Fo–Fc∣/Σhkl∣Fo∣
Fug-IV/2
15/29
P35G-1.0-14-C
pY-IGF1R
ATCAGA
related.6
10-67LI
work,13
R46W
46/f
elusive.In
μg/cm2
1‡
SummaryAll
32D/Flt3-ITD
3D-structures
cellMelanomal.vmphomaMALTHIV-positiveLungGliomasGliohlaslomasAslrocytomasGliohlaslomasAstrocytomasGliohlaslomasAslrocytomasProstaleLociDinucleotideDIS126D2S393D3S1067D5S644TP53DinucleolideD2SI23D2S136O3SI067DIIS922TP53AP
BRAFV600E-MEK
serine-binding
.Highest
neoplasms1
8-14.1
3‐
CDKN2A/INK4a/MTS1
Glphase
TSS-associated
DRB1*01
T574
pDsRed1-N1
HNPCCa
.Ex
HUM00046018
AURKB
receptor−overexpressing
c.p.m
100ug/ml
Kinase-ZD6474
p2=0.001
539A
TLC
.MC1RV60L
Asn1026
Mini-PROTEAN®
S6K2
orthphosphate
V^
E−867
E810*
isotropically
PAAKRVKLD
survivors17
0.48
Subependymoma
HRPT2
.Recently
term=lgk974
anti-RPTPp
PBCre4/Foxa1loxp
.Bi-allelic
proline-
.Renner
Anemic†
homozygozed
perturbagen
Crizotinib-resistance
IL-6-stimulated
IVAM
others-
histocompatibilityantigen
K587R
delta-Ct
methionyl
Ni–NTA
K1/2
AC22
14:439–449
l-α-phosphatidylinositol-4-phosphate
.MPL-S505N
124:491–504
Quantasoft
PI3Ktransfected
Mlh1–Mlh2
MIG-DNMT3A
oncogenesare
CLECSF2
Myc-reversible
translocation103
n-terminus
RNF8-/RNF168-dependent
reprogramming
11-deleted
.Tax+
above-reported
manner117
EM-17T
CATCTCTGAATCCTTTATCTCCAT
Pathway-driven
amsacrine/cytosine
.CHEK2.1283C
0.316*
WC-l
TGS55
G76R
THYM
Ras·GppNp
3.664.0
807/811
4ZFΔPR/MSCV
5′-CATCTCCTTCTCGGCATCA-3′
charge/basic
Mighell
classifi-
46-Forward
.Col2a1-Cre
holoendemic
MV1190
.Isoform-selective
auxillin
expresed
pRc/CMV-HAChk2
Ruttenberg
I1115T
N345Y
p53-wt9
A1843P
target.1
LLC-PK1
sitivity
Δ3
.ROC
Gly-325
CSTI571B
PET-2-positive
151–300
LM-LM6
p16INK4A-/-/p19ARF+/+
C-met
oestrogen-receptor-positive
G328
Cavaciuti
BRAF,17,18
5′-gt
types14,15
ttttag/ATGGAT
11/19/26/17
1045–1666
TEL-Jak2,7
TAATACGACTCACTATAGGGGCAATGCAGCAGATCAAAAA
DDC-containing
B.II.1
UV-irradiated
Ggt1
19,20p.E490_C491dup
Il2rgnull
CAGCATTTGCCACTCCTACC
L770
C3orf6
decatenating
EcoRV_BCOR_fw
3S-isocitrate
NM_004333
GB/SA
reefed
H811
Melanomatumorcell
siRNA-treated
mice.21
RAE
Alex-extended
GCATTTAATGTGCCAACTACCA
-rwt
Ten-thousand
15224
11,864
Sox4-pcDNA6
.Glu37
ACVR1B/Alk4
forms13-15
4,355
Lane-level
.Proportions
Eμ-cyclin
.Trk-null
studies.4,58
c.4071+1G
c-Cbl-mediated
neurotrophin-receptor
F66¶
C277S-p53
791/804/918
arginine-802
PR:46
ubiquitin/proteasome-mediated
leukocytosis
59-ATGGGAGGTAGATCAACATA-39
GCGCCGGGAGCCCATTTCTGC
MKHFDSFKC
1.54–3.80
82.21
anti–phospho-Kit
Ekfors
anti-CD8a
lymphomas.59
GCB-DLBCL.17
p85niSH2
RIC
pEGFP-C1-Flag
R1276E
Nf-kB
Human-8
p53-driven
GnasE2−/E2−
pENTR5
del/del
Duffey
pI6INK4
cated
base-specific
p21-reverse
R911X
perfused
537mel
phospho-EGFR
AGA-
Stat3-knockout
nitration-mediated
receptor-dependent
core-binding
radiosensitized
cryptorchidism
.CD74-ROS1D2033N
ProteinPredict
SpectrumOrange™
IFN-γ
ARaf6KCAAX
66-fold
digoxigen-11-
polyadenyl
BAT-26
HD-0241
Replication-associated
kinases,22
p110b-selective
4Terry
glycereraldehyde-3-phosphate
.R249S
B09
Furman
F205L
+MEIS1
.Immunolabeled
thosemutants
120–138
ASXL1,12
500–2,000
64,023
AKT-dependent
.Chapel
suppress29,30
AC000134
W351C
V600K-
growth.19
Protein–RNA
methods.30
D868A
7⇓
.TRAP
50–59,4
0.031
morpho-
comigrated
Notch1
individuals.44–49
Daudimouse
T1010I.Met-BaF3
frequencies21
1-22+3
Hnf4afl/fl
p.H373L
Immunoassay
S841C
Line-1
TRCN0000010024
Labbane
SPDBV
G1148R
phosphatase-based
intercalation
0.06
energy-consuming
his/her
Oct3
CIN−
generalizable.Several
HPI-resistant
EX2F
.Resistance-associated
seventy-four
.Anti-actin
probeset
Flag-Smad4
Polytron
IPC-298
pathogen–free
IDHl-related
anti-BAF250a
10ZF
6.9302
14·7
perfusion
ras-family
dideoxy-nucleotide
msh2mutant
non-missense
P1/3
Inhibitor-Insensitive
~200
FISH/CISH
Blencke
rGlyLouArgPhbValAlsProAspAlaPhoHisPheThrProArgLeuS
C8orf34
ACEI
sepharosebound
IMR9
003122293.3
exon-1
death5
Ctrl.
in-built
IKBKG
theHCCs
.271C
~~~~i
.Implantation
GST-BAP1
high-grade–appearing
Tet2f/f
/AC
T‐domain
chromosome–negative
pregnancy/lactating
7936
EGFR-TKI–sensitive
height=500
4110+1G→A
expression.88
13Class
Desmocollins
Half-life
R664
accel­
5′-TCTGGTCTGCCGTGAACAGT-3′
PFBC-like
CpT
32–88
.Cooper
mutations.2,3
Qubit2.0
P=0.094
V592
activation9.Oncogenic
H3K27me3/totalH3
59L
K-RasV14I
series—and
described18
c.690_691delAA
RA45RM
table11
cells.IntroductionRas
017
al.41
22/101
,6G
puromyocin
G.0198.08
hHER2
Tyr593
18.9OBSL1cDNA
Bergisch
reported22
Söder
C6orf94
Tyr1202
0.1085
multi-organ
24/38
MRM
imatinib,30
C-RAFSer259
amplication
ALK5-ca
EP300-ex14R-PT
p-ERK1/2
TRK-T3.Molecular
domain3–9
function/property
14.0±3.1
5′-CAAAGUAUCUUGGAUCAAATT-3′
2016GRA
boric
neratinib
TEST-PLUS
sc-17829
0loci
division—is
/55
chromatograph
16,30
PRDM1.E2.157.F
PC-PTC3
Paralogous
TTC28
B7-2
40.0–45.6
3/15.0
PWS
7a–b
doublestranded
RGCluc
biotin-trimethylpsoralen
14736–14742
4360
South-West
Tet-IDH2
E148X
cells/60-mm
three-letter
Asx
R25Q
S-adenosyl-L-methionine
4–exon
withIPI
.ntn
p.Gly376Arg
re-blot
.PRIMA-1MET
C02.310
.AutoDock
129/SvJaa/C57BL/6
.PPT
interleukin-1β–converting
or10
NCH-38
G-CIMP-associated
Goga
MAAspecific
A_51_P480855
12XCSL
0.69-4.00
Blimp1-dependent
Orthotopic
c.4675+1G
CHECK2
G268
5′CpG-rich
statining
.biopsy
F/
T267A
Akt1/PKBα
PowerShot
0.197
Costentin
18-millimeter
QLVDMAA-
Gln-50
discrepanciesnoted
V272L
MO25β
:RAD3
D444N
Diagrammatic
Phospho-flow
wu7/wu112
.S15D
dysmorphology
Zn2þ-ligating
and66
TβR‐II
Figure44d
5′-GCCTGCGACGGCGGCATCTGC-3′
mTOR1/2
His-fusion
737–740
β-D-glucosyl
S/TXV
.1,17-20
0.890
S7A–S7C
5′-A
cyclin/Cdks
Submandibular
G418D
p19/INK4D/CDKN2D
TCATTTTTCTCAGTGCTCGGTTG
androgens,3
2,117
study18
24–27
NMuMg
c.37_38GG
Ras-induced
CC-allele
11q24.3–q25
66,67
.15,28
5′-GTGGAATCGGGAGATGGTAG-3′
pThr
CHGR
p.Cys24Tyr
-encoding
38·5
table1
HASQVCSETPDDLLDDGEIKEDTSFAENDIKESSAVFSKSVQKGELSRSPSPFTHTHLAQ
.EATL
Kambouris
P190L
PJS3
.Demographic
.Pheochromocytoma-associated
collection.12
CDKN2B–CDK6
formation,35-37
0:3
Rho-actomyosin-based
E476K
Asn771_Pro772insAsn
SC-789
1313–1362
505th
generated.Sequence
GST-Rho
=93
RNA-helicase
L10370
p.Q113Q
ModRefiner
TeV
11–21
14/35
SCCOHT7
GEF-induced
4649
255-bp
CD4−/CD8+
Epigenetica
Tyr861
K514/A
5E–G
°C/h
CATGCTGCGGTGTT-3′
YPD-rich
WIG1
228KB
cytoskeleton/PKN/RhoA/ROCK/serum
NMES1
anti-p130Cas
TGF-β/p53-responsive
123.4
p.Phe32SerfsX8
c.3984_3987dup
TGW-1
IL1B/p300/BIRC3
discuussed
EBarrays
-fragment
M13K07
c.1719C
R283A
.XP51RO
isreciprocal
D17S250.39
863
GST-Mek-1
phalloïdin
and4D
overexpression,18
octamers27and
T430R
G1-arrest
R249M
l-lysine
65.60
CRCs.6-8
V600E–negative
CGCAAACAGATGTGTTCTTAA
MutationsWere
magnifi
chemotherapy4
.Mis-sense
Nishikawa
TGF-ÃŸ-dependent
Euphol
homo-
svi.edu.au
studiedMSH2
I693T
nanoLC
APC-colon
Kadel
Lugnier
activation10
BamHI/KpnI
1´105
Autoactivity
weregrown
TE2000
CoIP
ofdenaturing
K446
Hs05769842_cn
avastin/FOLFIRI
Lag-2
8204G→A
759–766
TTAGGAGCGAAGGCTG
HSP70
56/64
ALK-precipitated
9·2
~GAPs
Ser471
NHL548
W-PDGFR
94801
msh2-AE859p
102578
564–1049
CCDC6-RET-dependent
ethylnitrosourea
frequently9
Bc1
μL3
Top-count
zx-catenin
centralspindlin
BamHI-BamHI
xrcc2-deficient
:TACC3
1000+
G1phase137
D585
resistant/refractory
18,616
420
Gli1–DNA
anti-tuberin
TRKA/B/C
/b-catenin/T-cell
α-cells
5′-caatg
S⊘r
E67K
Liegl
.Branda˜o
PanIN2
SPOP-mediated
P-1
~Tucker
KITD816H/V/Y
TEM
914-594-4176
.Alternately
NUCKS1
326_516del
ATAACCGGTgaCCCCTGTTGTAAGAGGGCTTC
Lanzetti
PPD–Dicer
IRS1/PI3K
Tel/PDGFRβ-induced
cyclin-CDKs
e12
p.Glu763Val
147,633,067
Cryosections
GTTTCTTTAGGTGTATGTAGTAGAG
V116L
didate
Non-meningioma
R25A
replication,10
signaling2
.18,24–26
2016•VOLUME
mechanism.2,3
3-dimensional
gastric-CIMP
G12K
c.2361delCTTC.17
FK506-binding
heregulin-induced
waspreviously
twoclasses
BgI
photoproducts
Grant-supported
25.6±3.6
DBY745
GC-HBOC27
3xGRAS-luciferase
SNU-81
tattttgag
FISH–positive
-overall
VEGF-A–induced
Epidermal-specific
Δ16HER‐2
MDX010
sialylation
.rr2005
66.07
.S80N/H94Y
size-conservative
F.S.
PRAS
anti-IDH3A
Aiii
5'-TAGTCCAAAGGAATGCCAAT-3
results.8
α-Flag
CTCACCTTCTTTCTAACCTTTTCTT
T49M
DIMHD842-846E
T→C
O-6
24–81
Thr32
www.ebi.ac.uk
6.863864125
CAGAGAAAGGTCCTGACTC
indolent
Sjöblom
E4T
hSmo
tyrphostin
UCCWG/UGGWG
C106F
genetic-environmental
KS-H
ade6-210
DsRNA
Maf
μm.See
PDGFR.12,19
BII-2*
698
antigen-2
9.98
Cdc25A8
E747-T751
KRAS/CEP12q
RP3–366M24
abcdefghij
Seven-day-old
A1151V
0.211435537
coworkers.39
V122
m7
5100
5.5.5
R181S
HMG-D
.Washing
DNA–paired-end
PDGFRA.45
mid-facial
E565A
Helical-OB1-DSS1
Leu21His
chromatographing
α-TuJ1
g-venin
θM
MMTV-neu
Dual-specificity
.Myc-nick
Benzonase
CI5-132
B-2
c.1468_1473dup
MSH6-P1087R
mTnf-Forward-1
KWC
.461C
Ga68-Dotatoc
approximation
KCNH1
.PTEN
IFAR943/1
5′-AAGCTCCCAGAAGTGGACGTGTCCC-3′
ARQ
sc-480
HBOCS
59-AGTCTTGGGTATTCATCCCAGGT-39
transformation-specific
.Division
-interferon
Asp34insProGln
Smad3-reponsive
R1159Q
LCCC
pCMV6-TagRFP
doamin
R678G
CNG–negative
rap2
13/150
26.86
0-4.40E+116
171G49.5
ventralized
TBX2
16,53
.This
W1291R
time-course
BCL8
CtBP-binding
F224L
KinaseActivity
hDIS3A524P
somite-8
A40V
myxopapillary
κ/λ
conWdence
c.2977del
199/257
g32P
months.11
Haploid-Conversion
pVHL-CCT
Arg-649
bacterial/yeast
.Mckeehan
P791R
118.8
.Bcl10
5′-CGGGCTCTGTAGCTGAGTG-3′
PDGFRβ-induced
Affigel-10
Hsp20
mutations.27,32,56
EF3
transcrip
PUK
B*15:375N
Y542
L288S
muscle-actin
RUNX1-331F
64G
294
cells.We
Takeichi
A89/11
ai2-Q205L
P-catalytic
Atlas-
Foxl2-/-
apoptosis.These
Platelet
5,16,17,18
TGF-ÃŸand
receptor,34
I496V
refractory/aggressive
p=0.0016
174–176
.8,10,11,19,27-
v-Erb-A
dimers,33
gefitinib,8
subtyped
1A–C3
17•0
L11910.1
2264T
.MEK1
mutated-to-WT
population-attributable
shown.Based
R-DHAP
ALK-wt
p53/p14ARF
BRD4–NUT/HAT
1237C
HFSEC
R565W
Exon4-MLH1
R54X
supraventricular
B6.SJL-Ptprca
α-Fbxw7
emanate
HT.9
/t
EPR
line46
885–886
0.818
17/38.6
10.3
1993–2011
EPC1-PHF1
I527R
pEGFP-BAF180r-T232P
–I/ATP
10ng/ml
pathways38
plane-by-plane
heparin-treated
65Â°C
damage–induced
L–1
AATT
B.L
L81P
n=512
Histone-modifying
RP4-726N20
runt
llplS
observed.26
Affinity-Labeling
Haematopoietic
Foxp3−
β-chain
GST-Aα
disease,6
.DO
E9-Rv
SA-beta-gal
p.Leu435Pro/p.Val878Ala
.EGFR-tyrosine
|ZPSI|
Analysis—Sequence
2840C
Ressourcen
RET-JM-KD
Lin12/NOTCH
​IL
R=0.35
Zwang
.RAS
68.3-68.6
Nagib10
AQKC
.Akira
0–4095
cancers—they
total-protein
SEPT8
1.38–1.44
Colaluca
SPA835
6E–F
co-receptor
0806002814
BglI
.943C
IVS23+9
SSX
c.890G
5'-CACCTGGAAGCATTAATGGAG-3
acetyl-coenzyme
.TCL1
N870
Crouzonodermatoskeletal
¢ve
Non-germline
159-347
expres-
transformation94
N822K7
Br27P
MS-581
S1036P
Hemminki
CYP33/PPIE
.FGFR3–transforming
EGFR-mutated/HER2-positive
LOVD-RASA1
translocation
haplo-insufficiency
EGFR/HER2
lovastatin-arrested
Gerby
.678
Cytologie
p.P27L
polymeric
E10.75
CGCCCGCG
AF009674
PI1
E85
49–55
tissue,37
94143
enzymes79
HOXA-activated
67.6
W557__E561del
GNAQ/11
MyoD-responsive
distancefrom
Flp-deleter
MutLto
acetyl-Leu-Leu-norleucinal
.Y40A
92.5K
xVent2-lux
3−5
Thirty-six-point
S311C
584
described.16
NMDA
PTyr
wt-MYD88
melanoma62
E8000
C-θ
//research.nhgri.nih.gov/bic//
vascularized
E884K
GI-tract
NCI-H1299-cells
subfamily143
amino-terminus
9/64.3
.44
E7017
splenomagaly
trimethyltransferases
López-Bigas
groups.7-12
LDHA
V374F
anti-CD4
BLK,7,22
fibronectin-coated
tumors/timepoint/group
category.27
5′-ACGCCGGCTTAAGTGTACACG-3′
tcccag/GGATAA
AITL5–8
hygromycin-specific
hemoglobinuria
-AML1
0.555
intent-to-treat
anti–phospho-c-Cbl
Crozat
polyadenylate
EGFR/KIT
5′-AAGGCCACTGTGGTTGAATTG-3′
L466
NIH3T3-DDR2
Myc-pathway-response
4⇓–6
TCF-dependent
half-
CTG-3
BRCA1–PALB2–BRCA2
SMARCC2
Cytomic
0.000767
neovessels
U133Plus2
.Operation
AFull-size
Fluoromount-G
GAC3AAC
IgH-bcl232
oligofectamin
cell–matrix
anti-His-tag
aspects.25
12p13.2
Labstation
Variants20
modules45
P=0.146
NM_133509
Custom-synthesized
8/52
Tack
Foxm1
WEHI
QM7
G-J
DNAJB1–PRKACA
prefibrotic
MLL-AF9-and
amplications
R978C
gene37
Ureter/renal
tumors,23
O.
61.12
IGM
T534I
511–602
**The
degradation18
0.10
lysine–threonine–
LM-coated
APC-binding–deficient
Ser750
N3=17
mutationsat
BM-
SV40
RUNX1T1
C18:1n9
TagMan
chlorpromazine
D11S1983
AVL
.PLD
ZC3HC1
regions.53
3.4.2
56-60
.Meis1
NE-PER
1682
KDM5A
ReqSeq78
10.8-fold
beta-TrCP1
pathway36
RP11-241D13
NaCl-1.5
pTet-on
L127
AU1-tagged
4.657
6:455–465
cross-hybridizing
D1D2
IKAROS.43
9Ala502
-ACTCTTCATAATGCTTGCTCTGA-30
.617C
Tris-OH
NCI-H196
HEDGHOG
LPS141
Skalnik
FGFR3-IIIb-Y375C
Atox1
PDGF/VEGF-like
NH2-terminal
−1.8
sitespecific
DGV
tumors.10,16
deletion.5
yLFM
Institute6
embryogenesis21
multigene
.Haemoglobin
Colourgrams
orient
AEmm
cEbpα
S6275
immPACT
CATGTTTGAGAAAGAGCAGGAGCG
4.56×103
bindingfactor-1
-Ade
ppRB
P-LC34
co-regulators
p53–MDM2
CTTGGACTCTCGCTTCGACAC
primers.5,6
Apc+
phosphoribosyltransferase
difluorophenylsulfonamine
CTGTATATATATACAG
W93C
.Ni
C-277
Zage
Genotype/phenotype
85-week-old
oncogenes4,5
N234I-reconstituted
GCACAAAGGACATGACTGACC3
pCDNA3.1
Beijersbergen
MOF
col.
Nuyttens
.Determining
5.06.52
R158H-1
CREB/ATF-2
Biomax
PDGFRβ61
anti—E-cadherin
D661Y
mL/kg
S0015
.KRASG12R
non-integer
M2128V
Mdr1a
4/2.11
rare30
EGFR.29-31
Arg689Ser
c.3229C
*Non-T790
CVCL_0023
.H-ras
PESTfind
GIST.20
comparisonGenes
.S.-H.
heptameric
pQE-30-BAP1
.Electropherograms
COX-219-21
5′-CATGCTCGGCCCTACATGG-3′
Shibasaki
YMESO-27
SPOP-Mediated
1396–1862
R125C
690
AMN107
total.3
gpl40Proto-trk
G5145
anti-Her2
Yanagisawa
7q32–7q34
K1596E
responsiveness33
MPL-W515L
16,35
HA-W-PDGFR
NCI-H520.X1
1,274
iÂ¿\of
~2.5-fold
Y220S
Q944E
chromo-
5,20
1162–1165
pr4otein
VICC:2
EGFR=epidermal
16.5-fold
TAU
curves.Human
Trapianti
CTGACAAGA
11,25
anti-Ki67
42/f
function22
piston
full-lengthc-H-ras
TGCAACCCACAAAA
.DiscussionOther
B.T.T
-2H/13C/15N-BCL-xLΔC
a–p
M120
phospho-MEK1
Expressionof
p=0.22
HSIL/CIN-II/CIN-III
bgi292
mid-G1
pemetrexate
JAK2
+0.152173
*36
56/60
recalcitrant
Vav3
-mutation
L-82.18
HectH9
structure-activity-relationships
5′-GGTGAGGACAAGCAGTGAGGAACG-3′
GOTGGGGA
DeadEnd
meningitis
.T491
dye-swaps
redox-active
castrationand
5′-TGGAGACTCTCAGGGTCGAAA-3′
SP-SE
K5.GLp65/tata.PIK3CA
C.H
7458BH3TransversionAAG
D-001810-01-05
STAT-3
5′-TGCTAGTGAATGGATGCAGA-3′
V356
c.5213_5216del4
.ATR
pMAPK3/MAPK1
MLPAwas
ENSG00000251322
eumelanins
−stained
mechanism.24
IL-17
122/244
+32
23.3-fold
formation.23
14,18
5′-GAGCAAGAGAATCCCAGCGACAGAAAGATC-3′
ovariectomy
KIT-bound
H59D10
c.2T
Immunolaboratory
5450
pEAA51
A*
Ohmiya
Fig6G–I6G–I
Fig.22F
HKI-272
ionization-time
p.S553T
Smith-Fineman-Myers
FACS-LSRII
02139
Oct1
664-1014
syndrome=5
zippered
RAP1A
5-diphenyl
fe_p53
S6RP.7
554.3
pyrocarbonate/water
non-comparable
TPp
1AA1,1
p.Val617Ile
Thr528
A/G-Plus-Sepharose
hMutSα-free
PTEN-related
antibody-secreting
dep
Dubey
hybridization—32K
autonomy
T230M/E168D
14.6-month
KIT-WT.23,30
p110-selective
7/258
years.25
SEC24A
CTCTC
best-conserved
0.743
TGF-
benzamidine-agarose
'snap'-frozen
Infarct
Ala-347
p-cMET
locus.7
ligase.21
patient-centered
NM*
p573RSK
569709
SQPPLQVPDLAPGGPEA
Met753
.BRCA1-
Tany
0-6
Br60
cell,10
28.5-gauge
Clinically-relevant
4693132
.Eventually
1.42E-07
.Bicalutamide
'hypercalcemic
5'-ERG
.Gromacs
Ink4a
q25.1
resistance160
E7
PiggyBac
.EML4
1047
105—were
animal-use
.Top
IgG3
E385D
Ser233
f1
GBM-4620
stroma—PDGFR-β
m/47
PLCγ.84
Dewaele
7634–7638
5'-CCATCCTCACCATCATCAC-3
n=170
AGACAAGAGGATGGCTAGG
2769
tMath
447
VDR-signaling
K5E
pcDNA-IFITM1
+7.7
Dolichostenomelia†
42-bp
2–57
Tenoever
PshAI/NcoI
anti-oncogenic
K483
Rad50K22M
fifty-seven
Tyr-586
oneallele
Bacp
NotI-WWP1-R
243delA
T798I-expressing
UVs.2
galectin-4
V794M
non-DNA-bound
PHD26
TCATGGGCCGTGGGCAGGTC
*242Yext*89
Fosbrink
caudaltype
MME
AGATAAGGAACTC-30
in-turn
trk/met
n=70
figure44
oversimplifies
SNU-175
32-yr-old
MAO
HNPCC-
SVZ-OPC
3A–D
series,4
C1-TEN
l-glutamic
Microdissected
Pan-Negative
Flag-MLLC180ΔF
.PAb240
.Investigating
Reagent-RNA/DNA/Protein
XRCC6BP1
CCCTC
F241S
Pandiella
growth30
Bonvalot
:38–51
baculovirus/insect
ND¶
9121
PAE2
TP5
DataLevel
JAK2-targeted
0.01*
to3.8
desaturase
3650
0.1588
T644M
S270L
1.08-2.04
Kinastrin
bEthnic
94-121
P00760
cdc25A
SPTAN1
Y328C
5′-AGCCCTGTGGTGTATAGGTCC
1,063
β-catenin-dependent
R26P+/+
Thr202/
adenocarcinomas18
0.00882
MGFR1877A
downwhen
PTHrP
Hs00230877_m1
ampli®cations
7562
202.46
AmershamBioscience
2.7.1
.Leder
STK1591A/91A
Polyoma
Interferencewith
TNT
MAP3K4
.Kantarjian
VET
381delTGT
IgG1
disulfide
37,000,000bp
hERαa
1,000:1
TACC3-N
iBlot®
1P–17P
insuffi
.Neurohistological
.Determination
MET-M1268I/T
kg−1i.v
YAC/BAC/PAC
β-Geo
Larrea
Δ1–611
myc-PIPKIIβ
POLE-mutant
RNApolII
near-universal
51.4
α-p27
1.7.4
HES.7
Rubinfield
E7.5
ζ
.7–9
anti-Cterm
.Miz-1
Subtype-Associated
Co-occurring
pharmacodynamics-efficacy
MEF2
tumors65
0.324
Gli1-regulated
17q11
Mll2+/–
≈15–25
3010
B5N
â€¢â€¢//
Minicore
.SMGs
afterhyperpolarization
hypoparathyroidism
ES-3
1/273
DLC1
AR3shRNA
MAP3K
cycloaddition
NIAID
yeastInteractions
vector-induced
plus2.0
BC-CUL2
Pepcoil
364–374
TGF-β1
tP53
Debatisse
clonase
non-oligodendroglial
Histogical
17224
sc-346
−7.28
puri­
Smad2/3–Smad4
thiol-disulphide
interdependencies
Sandkuijl
Ohtsuka
insulin-induced
SUM315MO2
ADAPTOR/scaffold
Vicell
N1068fs
RQIKIWFQNRRMKWKKIGEHY1349VHVNATY1356VNVKCVA
replicationfork
Alu-PCR
.070
216–218
Awata
MSCV-Cre-IRES-EYFP
Gln1779
Thr465
0.8–3.1
LUCC7
//doi.org/10.1371/journal.pone.0032451.g007DiscussionTwo-thirds
98195
61-9
binding-buffer
caspase-8L/caspase-8a
.Allagio
anti-pS111
Pro-inflammatory
187A
wasopened
pCDNA/BCR-FGFR1
Gi2
named-patient
XIC
MAML3siRNA
ERTmRAS
1I1
R1276X
European-derived
5/184
hypoperfusion
E2-F
1,000×g
.Such
ERG-1
FusionFinder
pVHL-Defective
ALK-G1128A
bis-phosphorylated
D842_H845delinsV
intestines.90,91
helical/kinase
functions.3,20
SYPRO-Orange
G15A‐Rac
emerged.24
SuperRT
:4274-4283
touted
RP-S6
xCELLigence™
imprecision
9138
pFB-LIC-Bse
Mt1–Mt5
KPT-SINEs
.Regimen
S93F
GISTs.39,62-64,66
patients.99
.Ponatinib
mTOR-mutated
95°C/30
ADH1-p73
rasopathy
Woyach
72K
TTTCG
freshly-isolated
E88K
formaldehyde/agarose
P=0.02
initiation.36
HIF-derived
TAM67
binding-dependent
6p11.1-q11
//www.ampliseq.com/
46/81
YxD-tyrosine
telangiectasia22
129Svj
and2d,2d
-3.6
15–51
c.1638A
coverage.22
1861T→G
FLT3D835
finger-containing
cytokine–receptor
MgClGraphic
described24
Tcf-dependent
p34
5′-CAGGTGCAGCTGAARCAGTCA-3′
S567L
Filippakopoulos
ICA1
G309
1.019–3.126
.NS721
m2b
g.149486C
Q-R-R-R-A-P
portionsof
eighty-nine
populations,31
Longy
19.6
www.1000genomes.org
.Chromogenic
Interleukin-6–Mediated
7742201–7948000
68Â°C.and
NUCLEUS
8-14
E1214X
S172P
preclearance
E–H
208Â
LLRVariant
mmll1
8336
ddl136
fluorouracil
G683R
gtgagaaaa
.Samples
cancer139
EBS-containing
subunits.24
enhancer-associated
del746
Asp244
Ohm
4469563
234–465
G308V
lonafarnib
.Dithiothreitol
LysM-KI
c.456
0.05.AR3
worsen
//ekhidna
sources25
.002SD
ABD–RBD
01XC2
LDLR
69:1071–1078
MlR
TOP1-expressing
Schwannian
Râ€
nt-deletion
annotationofpreclinicalhumancancermodels
YM155
C636Y
7ng/ml
CTGCAA/gtaagt
reticulum-associated
genonlic
activity-related
submotifs
C/c.2633T
Holmgren
populations.8,9
.5552
methods5,6
f/f
1393–1424
TTTTTACTGAT
Bbc3/Puma
.Default
S37Q
focus-formation
anticardiolipin
.GST
V612del
nt1768G
penetrance.19
68.37
1.36.0
Peptides
FA-B
P192R
BAP110
strains.26
371.69
G244
8–25
.Theidentification
PEUTZ-JEGHER
KIT/Delta559/V654A
anti-Brd4
T‐75
P=0.018
R27C
SectionEXPERIMENTAL
vapour-diffusion
ABC-N
Rap1.2
TBE-agarose
1,310
anti-neutrophil
NM_001202554NM_032283
tetratricopeptide
.211A
15.50
6q23
Gly13
BglII–SalI
immunopuri
r-4t
reports66
CstF/BARD1/BRCA1
XS3
FoundationOneTM
16q22
anti-CD34-FITC
Two-point
CTTCATCATCTGAATdosage
S4G
R553Q
'pT81
5′-CCTGGGTCACAAGAGTACT-3′
//www.jem.org/cgi/content/full/jem.20070872/DC1
Borresen
H2116R
TRA-1-60
sub-aortic
GU-AG
GTP-Ras
W.H.
DEXseq
ITD–positive
3693
male-female
steroid-like
PhiC31
5.9amp
8Prenatal
Trp-1072
/DEK-NUP214
neuroendocine
N‑terminal
mutantKITisoform
P=0.045
benomyl
602839
5149de14
c.2588insA
MCF7.fgf-3
F19
hH1c
GGGUAUCCAUCAUCAAUCAdTdT
p.N127S
medium–high
radiometabolic
Y272C
classi-
al.,1997b
MSH2/MLH1
NCI-H1944
n=182
E1694K
//www3.appliedbiosystems.com
proteins/mismatch
deletions/insertions
ESR1/YAP1
NMTR
S100-positive
~10–14
44+
cp7
G399V
Y72S
A289D
GISTs18
cells.4,5
mcsm
TTAACAATCTGCCCCCAGAC
trans-Golgi
demonstrated.44
double-color
CAGGS
9–17
18.00
NAD
10,13–14
N2033
.Specifically
maximising
-TGT
½
mCi
ERG-Δ99
.HBP1
trials.2-4
p.Lys2150SerfsX25
Delta375–450
Berberich
Drosopohila
Smad2s
9.2/39
crystallography12
53,992
Asp32
CAKUT
0.37–0.83
lmol
HCA7
CTAGAAAATATTTCAGTGTC
E1227*
S3309
Tissue-Specific
stimuli23
0.1–0.5
Na3VO4/40
Axl–pGL3
apop-tosis
BRAF-inducible
APL.8
EEwW
Akti-mediated
V599E
activation.10
humanJAK2
V1108M
.Mechanistic
BAT-40
.23
−70
TGF_BETA_SIGNALING_PATHWAY
EVI-1
I-positive
TTTCAACAGGGTACACAGAACAT
19–61
N=309
14-week-old
122,780
SmaI–SmaI
min/72°C
Ras·mGTP
0.90^0.98
1.026–1.807
Assoian
Böblingen
Pdx1
epithelial/mesenchymal
2813
study,47
.799T4A
1117
TCF-ÃŸl
1-7.5
SLR-24
N1236K
D661H
Runt-related
spatio-temporal
Ns/c
DPP3
14Resource
TK-10
U251
nM-1
HOXB6
I198T
0.158643
−1.75*sigma
AML3/RUNX2/CBFA1
double-balloon
D–/–
CTGCAAGTGCATCATCGTTGT
5a–c
K860E
20,77
24.47
metastasisa
dCTP-radiolabeled
Pten-deletion
c.181G4A
ERK/LRP6
∼75,000
GADD34
Selectivemedia
half-region
47/64
progression3
c-KIT-D816V-Y720F
HumanOmniExpressBeadchips
3.4Å
dysfunction.The
studied.8
post-RII
aa259
E*
EBNA3c
D5-phosphate
Wright-Giemsa–stained
SNU349
Tsc2–/–
BCR–LZTR1
1,3-cisplatin
Duclohier
IDH1-VEC_F
IVS16-6delcttt
manifestation.5,6
68,84,87Å
LCH-15
intestine51
CCTGACATCCCAAAAGCACAAC
TGF-ÃŸcan
BIOPSY
602956
SSRL
rag
SDHmutated
GST-HNF-1α
≥22.8
GATA3-regulated
discovered,6
1603
Gata4
Δexons
.GFP-Rab7
MDDcontroltumor
L2220F
NCoR/SMRT
TβRII/Alk-5
41Z1*
.Jade-1
c.1075C
OsteosarcomasPatient
G.H
11q22
RING1
SREBP1
light20
Seconda
OCI-Ly19
UQCC
F1200
pcDNA3.1-nV5
Fig1B
F314L
preference.4
His-ΔII-Flag
cER4-4
33.613*
36,41,42
TAT41
Kumble
acid.2
auto-
−19.9
DNA-related
ATACCATGCAATATAACC
kiyoi
IDO
5´105
p110α/δ-
200u
S2180
.Pregnant
E2-liganded
burst-forming
del59K
3.59
48,000/μl
1D5
SNARP
Vav-tTA
5-bromo-4-chloro-3-
ERV-cancer
midbrain/cerebellum
G497S
protein.D-loop
3p25.3
c.7007+1G
1.36
10−5/bp
skp1
RET,13
//research.bmn.com/tto
.Biopsy
Culture-Stock
9p21.3–p21.2
PI3K-C2γ
www.olympusfluoview.com
5′-GCCGGATATCATGGAAGGAACTGACCTGGTG-3′
6.2–16.5
anti-MMTV-c-erbB-2
R161H
ROSA26
ispresented
10q24.1
four-residue
TCRα/δ
pYIXV41
adenomas.D
1/2,765
Shin3
DRX-600
cellular/receptor
diagnosis.No
P=0.0026
jhmi.edu
Arg361
rs2216460
Radioligand
TGTGCCCATCTA
DecaLabel
I–N
off-
Figure3C3C
BCL10-specific
∼20–30
hypophysitis
1993–2006
5´-GCTGGGAGCTCAGTTCTTTCGAGGC-3´
Derald
HTLE7000
6repeats
SOX17siRNA
dermatological
EGF-Induced
7.35
42–46
RAF-1/ERK1/2
error-positive
AKT/SRC
/GTP
B-and
NM_004333.3
793-bp
//bitbucket.org/young_computation/rose
Gab1
PDC‐related
FGFR9−
/R5R
n=396
three-alpha-helix
Lys413
sh2Yap
membrane-spanning
pDSRa22
reports18–20
albumin-PBS
DDR2-binding
lidocaine
cotransporter
DYNC1I1R629C
wild−type
mammal
.875C
5′-TGAGTTGCCTGAGTTTCG-3′
K658N
04-
CARCINOMAAND
Flt3ITDneo/+
SNaPshot-based
HA-TRAP220
and7B
p.M
CCCTAAC
bcatenins
Kaltz-Wittmer
Eph-like
DN1
S724
.RNAi-mediated
19nM
t-MDS/t-AML.2
MAC1+F4/80+CD115+
C362A
infection//transplantation
desmoglien
split-hand/split-foot
FLAG-PTENWT
2M9
domains35
c.2970–2972
39-CTTGAGTGACAACG-
S7.9
SSCPs
T371M
c=37.1
NeuN-positive
.PIG3
anti-phospho-PRAS40
Bmal
occur—the
0-16
GNG11
NOK16
Val-222
Q978L
D3-PPI
.Coimmunoprecipitation
h90
histone-deacetylase
Chaperonin-independent
ETS1-producing
R257G
G13.2A
PS6
3.Full
amplicon/centrosome/colon
incubatedfor
–139
TRCN23153
87/848
6818N
mono-ubiquitylated
UOC-B1
anti-phospho-Ser473-AKT
Assay—Hemagglutinin-tagged
Nuernberg
tuburin-T1462
Y1252
.03
MinElute™
Gly23Asp
Desmin-positive
FGFR3-N
Ambros
2772
c.2002A
saline-sodium
synostosis,2
qE
IG-CDK6
activation—leading
multi-shot
corepression
.43
'hotspot
drug-efficacy
G-protein-coupled
M-V5-6His
Esplugues
GIST,32
BCR-controlled
controversial,31
AML,7,9
D22S275
hmWT
nt-long
important,45
R550X
.020*
sc-582
580D
sc-198
RCSS46iMS467
ZNF198-FGFR1/K514R
mice,16
www.arup.utah.edu
1,144
c–f
DND41.The
cofactor4
data-types
theXenopus
telomerase
1.8:1
apoptosis10
889
hematopoiesis.68
resin-based
0.055122148
−4.5-fold
c2628a
p53f/+
–13
pVHL.HA
P.G824D
Syrja¨koski
Non-activatable
5′-CAAGGCACTGCAGAGGAGTAGTGCAGAG-3′
V894I
anNIH
respectively.NF1
A.C.
Elf3Δ235–260
5'-CCGGATCCCCAAGACCCTAAA-3
CCGGAAGT
form.24
mock/Smad4/TGF-β
U-antisense
1111111
1874
LOXL1
sevenmaker
medium.Controls
VaF=mutant
fusicoccin-like
.ECLTM
Immunodiagnostika
symptoms.response
//mgc.nci.nih.gov/
de‐Bruijn
2815G
-150
PCR/hemigosity
L1122V
ubiquitinating
EBI
leukemia.59The
EFM-192A
EGFRvII-ext.
Assays.PTP
.Dsh
R653H
TGBC24TKB
5′-TCAAAGCGCCAGCTGGAGTTT-3′
S2Ee1
addittion
MDMSKDESID
-800C
Thr35-OG1
protocol18
kinase15
D76Q
-His-Leu
Val45
Leu861Gln+Gly719Xaa
78543101–78573300
Lympholyte
rad53
Castoria
DLBCL/FL-derived
.Matched
.MLL-p300
166
.AP
rates.22-25,27-29
FGFR1-4
lamellipodia
mice8
TAZ–TEAD
predisposes
reinduction–reconsolidation
formaldehyde-PBS
POP7
1.75*sigma
N/C
21,000
α/β/β/α
ER-expressing
bedifferent
MGRNAprobes
N232S
SNU-503
T417l
NoKIT
L576Pc-Kit
K-Ras-dependent
cell-junctions
155–192
hyperfilm
3827
2E07
PIK3CA/PIK3CB
L1481fs*8
tttcag/GATACA
8-amino-acid
MADR1
,26
ErbB2-mediated
.BRIP1
argentophilic
ATG3CTG
Lys18
RhoGEFs31
BWA
AFX
antiNPTII
arrowhead\
117:1
translocations.72,73
ER+
PLACE30001995.9PMP22Peripheral
.Five-week-old
.10E
Epicentre
Hausinger
mice.41
.RelB
influx.202
hemacytometer
^563
104,491
.Rikova
10945
RasA59G·GTP
verapamil
22,24
R108L
equilibrium.44
m.ehime-u.ac.jp
0.0071
.3,4,8
PTEN1
colonic-projecting
Aurion
A7
-accaattattccatacagtgactacg-3
837KB
95-99
Willam
at248C
doi:10.1007/s10637-013-0039-4
Recio
EtOH/Hanks
common.37
Ribosepharm
K413
M20472
SamplesHistopathological
symbolin
REKS
31_4002-8delins24
K630
repair.28,38
TSC2—the
HOX11L2
B-Raf-induced
KIRSCHNER
Ceccarelli
structure–activity
35/44
65.5
n=47
logn
Δ157–213
+0.77
RSK2
Nagore,4
Br34
1035/6-1
binding.15
W5f
METi
Lofstrand
-LogP
pcDNA-XR2
ki67
GGGTT
E1193K
Doktora
pHER2Y1221/2
R45C
f-EGFR
pBind-RB
202,244
nonsupervised
17,088
f2-
2-mg
ε220
ACUCCUC-3′
Adrb2—5.3
5′-TGTGTCTTCAGGGGTCCTTAG-3′
progression.The
exper­
XP_001788280.1
ficantly
Dnmt3a-deficient
His-VHL-FLAG
to-histidine
A158T
4V,6-
5′-GCAGCATTGTTGGGGGACA-3′
21,880
cbs-smoothed
exons/introns
100-120.
1.1–2.6
cp19
HuEx
Skp1/cullin/F-box
heptafluorobutyric
PHD-Extended
3'-untranslated
Fig.11b
tumors.Consistent
histologies
inhibitors44
5′-ACCGGGACGGAGGAGTAG-3′
Aα
RECQL513-15
STAT3-C–transduced
fluorenylmethoxycarbonyl
5′-CCTTGCTAACTCCTGAGCC-3′
02-010
immunoreceptor
A196S
VV
Hercep
.JSI-124
GCGTACTACCAAGGTGTGTAT
L187P
cRSSs
.PLA
MM19
Streptavidin-horseradish
Myc–Max‐binding
Lupski
WT/FL
2400–2700
phenotype/
7.
9.26
ActN1-expressing
BC140854
NB2464T
12-17
2.6–2.5
CD11b/Mac1
SSBP
Postoperatively
non-endemic
oculo-facio-cardio-dental
C8as
M85165
migration/invasion-related
FcγR−
327J16
PicoQuant
.Triton
ManNAc
pheochromocytoma-only
:6310-6320
93801914-93802050
cullin‐dependent
63–72
B30
BRAF.31
homodimerization18
0.04724
2×48
Joura
L1195I
cancers,61
1724
chromosomes.We
signaling.49
Asp54′
Hs169327
′-CCT
Y179C
S463P
mIfngr1-Forward
expression23
intra-
JAWSTATs
Clathrin-mediated
PolyPhen-2.14
C57BL/6JJcl
literature,42
Mxd1–4
L163P
.Immunoblotting—Cell
57–58
F-Box
Pirkanmaa
singlestranded
UM-UC3
multicopy
HER-2/neu.33
935kb
samples.19
≈4-week-old
SETD2-mutated
AdCre-injected
Hematoxylin–eosin
Arg/Cys-24
consequences.16KIT
p85-iSH2
R172S
Q2–Q3
2×TGFBR1
NPM-ALK-Ova
5′-GGTAGTCTCTACATCATCCT-3′
NM_011659
495–497Krauter
carcinomas.104,105
GlcNAc
0309
Mesenteric
TNS3–Y321T
telangectiasa
E1507K
β-catenin.21
2711
fundoplication
TAK
MCe
PPPS
Cul2/5
NFKB2
550
SMARCB1-conditional
D11S
segmentectomy
Clara/CA
facifitate
eccentrically
nucleotidesbelong
1.6–7.7
H4–PDGFRB
RaLP
malignancies.23
CLL11
S6A–S6E
..Furthere
directlytest
Ig-Bcl-2
WinMDI
DBD-DBD
ectodomain57
I1171T/N/S
FLT3-ITD.9
WT-EGFR-
v-mpl
Tirino,4
MTSS1
P8139
PAX-8
Tamary
SRC-3–dependent
PTYR
103.31-118.66
Jenoptik
GST-RAF-RBD
CCND/CDK4
/xg/ml
Dynal
Lin−Sca-1+
factor-in
PDGFRA-dependent
¶Present
CML-AP
p53ΔE5-6-negative
GTGGGCC
Labware
MC38-OVA-bearing
Biogel-P4
PCNA/p21
≈220
19q13.3-q13.4
TCR-gd
top2a
c3_tft
high-GC-content
F29
.RELA
BcrAblY253H/EGFP-expressing
webappendix
TAZWW
cancer-associated
S171F
pLP/VSVG
R411C
13q32.3
indestabilizing
2633T
NAN3
G163D
2HG-inhibitable
calcification-non-prone
Flag-encoding
K233E
16/199
developed.34,45,46
2p24.1
37–39
caspase-8a/b
GFP-infected
overdiagnosis
PQA
signal-enhancing
pathway.113,114
2720
IMA
Hydroxypropylcellulose
transformed-like
glioblastoma138
0.3898
andgrown
carboxylterminus
type28
bFANCC
MSY127-5A
anti-v-Src
CE81T
II.11
Hyperphosphorylation
2.135687533
7.411
7-transmembrane
typedependent
S880P
cancers.7,14-18
HA-AKT
Gerdes11,12
3-kinase-specific
D6p
ACVR1-mutated
fusion71
deoxyadenosine
CS-affected
T670
s4
patients20,21,22,23
−0.52
K373E
T790M-targeting
polyinosinic-polycytidilic
.4182C
Polyphen-239
AF083215
3991
Er81
p.L1773I
5b–c
FQNLF
CpG-Island
5215
.Competitive
81.85
4838
CBFalpha3/AML2/RUNX3
B*15:01:01:01
I:1
0.000550
1290-
g.26444511_26454366
0.03–
SH2-hotspot
g-positive
www.ncbi.nlm.nih.gov/geo
package28
WD40-repeat
D742-R841
Ephrin
MCF-7.C
C11′
//genetics.bwh.harvard.edu/pph2/
Anti-Ago2
phenotype.35
.VEGF-A
ellite
PIK3CA/
p.G695R
3378
69120
tumorigenicity
H.F.Paterson
Asn10′
pCR8/GW/TOPO
HIF-1α—The
Triton-X/PBS
Non–small
plified
LTR-renilla
43•6
γ-P–O
STAT5/pSTAT5
∼96
E18A
controls75
−948
S169P
HTA1-HTB1
L858R-T790M-EGFR
≥10−4
99-103
.Insulin-induced
0.3673
0-C
RT112
structure1
SMARCB1
0.7–2.9
upstream-most
AVM/AVFs
A244S
pGADGH
POT1G76V
SET-2
conformational/structural
.Bell
6FAM-labeled
Pt.
.0107
//www.broadinstitute.org/gatk/
A232E
J93T
genotype-associated
A_52_P174915
4A6
mutations.30
seeExtended
-glycerophosphate
Corvelo
non-selectively
5´-TGCTGCCTGTGAGTCATAAC-3´
NM_001198
FGFR2C278F
cfDNA
Strobeck
JKL
Akt12-GFP
Howard/Fox
arrest29
1682-1683insA
years,15
kinase-generated
-CDK10
BRCA1/23
0.02μg/μl
optogenetic
5i
​Figure3A
L153
elsewhere.24Briefly
PDA-exon14R1
Hypothesis-neutral
TH-MYCN
TNF-TNFR1
137-139
cyclopropane-1,1-dicarboxylic
EphB2
potential36
1.251-10.211
pHM6
gene.86
R171X+WT
CAN-genes
α3L
reports18
BlottingCytosol
Daston
K5.GLp65
T76insTDLT
Fapbl-Cre
T6G
6Xhis
N-hydroxysuccinimide
consent.PatientsBone
A347V
polyp—scale
signal–related
Src42
HEK293-fWT
5′-GAATGACATTCTGGATGGGTG-3′
5¢
CD25+CD44−
Gly-to-Ala
1.9-cm
5′-CCTGAGCTGTTTGGAGAAGG-3′
∼254
5′-TGGCCAGAACATTTTCAAAGC
L1CAM
426-521
PDVC57
Med.
SSS
p.V923E
ysis
.apoptosis
Figure3a3a
handicapped
de-regulation
LOC400581
ERK1Q90R
EWSR1-SMARCA5
antibody.6
binding11
V.P.
Q123fs
1/49
clear181
Bugnon
p11p22
2ocj
784T
ICGC_PA117
.ACTR
lines\
V83L
30,703,763
hexakisphosphate
103/mL
neuroblastoma137
3′ATR/3q23
outcome8
Solimini
Cll
1∶1000
non–iSH2-binding
//cran.r-project.org/
30L1
MN72
countries.6
p.Ser36Tyr
68353784
S423,425A
containing100
K18
inconspicuous
C1orf38
Synnöve
pSG5.HA.p85α
Condel
Pdx
PTH-Cre-positive–Z/AP-positive
somatostatin-producing
Y347X
MO_1069
ARE2-DS
ttg
MutSigCV10
Case-derived
−0.01
activity.23
5′-CGC
genotypingFor
H.S.L
centroid
Vav-cre
DLBCL28
G384D-IIIb
4514
HIF3α
K700E
cases,22
calpain-mediated
38–51
DELETION42
pQE
SCC-9
oligo-dT16
Cbf5p
features—for
RKIP_E1_F
ubiqutin
be-
.Lymphatic
V659E
mineralocorticoid/glucocorticoid
Asn-to-Ile
6aa
.Ovalbumin
P1-P8
lymphomas—and
.Boyden
NF1-GRD
Haemangioblastomas
E983Q
Wrchs
G100205G-8
extraembryonic
1.563
v-kit.2
p16ink4A
pEAA57
G=0.571/T=0.429
sulfenic
2-8-1
Cox
21205
technique.22
Ets1-like
p-SMAD2
169
standard.MMR
Ago2-induced
GSK3α/β
P.A859V
undiff
0.141
MgCl2/0.2
B220−CD3ε+CD8+CD4−
000100020003
LBH-589
p21Waf1-Luc
300514
aprotinin/mL
χ2=18.2
ZNF258.59
M2001N
nucleotidyltransferases
.Histone
T878S
.INPP5E
Hdm2-Luc
PDGF-receptor-α
CGGGCCGGGGAATGGAGT
Del746–750
CFX
IgG-HRP
JAK1/JAK2
leptin-deficient
keratin-18
estrogen-target
5′-GCAACATTGTTCACCTTTG-3′
.Phalloidin
types4
Schmale
ATAC-seq
LipofectamineTM
CD150−
BBN
.MC-26
DN-MKK4-transformed
Pirozzi4
Preterm
B56δ-Aα-P179L
c.2146G
withPst
54–58°C
MnTMPyp
Acetylation—Cancer-prone
.Pten+/+
–4.5
FANCJ/BACH1
RUM
mSIN1
Re-examination
indicated.IP
LR11-039
anti-Gr1
SUV420H1
p21Waf1/Cip1
AP2453454
D493H
.Pten+/−
30–37
743
oncD
Myc-WW-M578V-PDGFRA
BDP1
Gluthathione-sepharose
4,298
1,10-phenanthroline
SPS
8.890936
deletion,1
Asn127Ser
D32
Maml3
v4.9
and/
R948A
pLNCX1-HA-AKT2
KIT/PDGFRA/ABL
lineagespecific
Mll–myc
G161V-AKT2
±9.45
STRAUCH/SCIENCE
.BRD-NUT
sq.pixels
γ-glutamyl
Leu62casp-8
pathway.PIK3R1R348
PCAF-expressing
15-second
up-regulates
DOMINANT-NEGATIVE
CAT/unit
version22
Trp268*
M122
H4-PDGFRB
.Bioinformatic
V600EB-RAF-instrinsic
Ferroplasma
bevacizumab/paclitaxel
29/65
CD99/MIC2
substituation
-6-oxohexyl
MutationsIn
86185893-87965932
c-SRC-specific
cases17–19
RB1Arg621Cys-V5
CFC95
IDH2R172K-expressing
Akt1E17K
L370S
3,29
-42
-CHERRY
N34S
transcriptDiscussionThe
host-dependent
siNKX2
Ter119-positive
Monomer2
rs11571317-T
c.1220_1223del
disease.24
TTCTTCTG-3
S226D
FZD6
p53/control
NFJ
residues.11
APC10
brain-predominant
hematoxylin/eosin-stained
ICC
filler-DNA
TAT
R505Q2.
s.
PMWK
8298
Fenske
institutionally-approved
HCA-altered
C16S
PF-477736
Eµ-Myc
⩾1
64·0
anti-phospho-MEK
.Reverse-phase
ProbeLibrary
NRAS-BRAF
coiled–coil
blue/EDTA
leukemia.8
high-voltage
PIK3CA-increased
Sanchez-Mora
5-GTG
embryogenesis
128/64/101/7
70746
adenomalous
area=
12688-90
Photomicrograph
Mre11/Rad50/Nbs-1
Monte-Carlo
S509N
Mikro-Dismembrator
Dnmt3l
doseresponsible
NCT01816984
ESCs.11
acetate/ethanol
V+PI+
2400_2401GG
16-346073
CRL-2959
anti-IRF2
L2193R
GAGGAGCCG-3′
L858R-COS-7
isolatedfrom
AGCCAGACCAGCACTCCTACAGA
spheroidal
.Homoligomerization
3ZP-labeled
C.All
.FL1-H
E2F-1
89-kD
A808
Pax5+
​Figure7B7B
NCK1
0.1C
I515T
JB
G402E
A363T
Hormone-refractory
MDS1/EVI1,11
GC-derived
samples.1
B.H.
MSH2-P622L
amplification.4
LNCaP-R
1942
Four-micrometer
RP11-768L22
618A
socioeconomic
Br56
MISSENSE
evolution,9,10
Ba/F3-BCR-JAK2-treated
D-CDK
.Five-hundred-and-thirty-seven
ÃŸ-cateninfound
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic
.RES
IGCTs
patients.Currently
c.718G4C
CRL-1555
P=0.357
5′-AAGAGAAGCTATTGCTGGCCG
Ilg
decades.23
BioCoat
2398
65.4
339–345
150-µg/ml
limiting-dilution
processively
repair1
acetonitrile-water
.Homozygous
.Pups
orogastric
method13,14
2–20
transduction.6−8
accu
aceptor
dSGT
Mg2+•ATP
2.1–3.5
hCP50515
OE33
Tyr176Ala
p.Thr599_Val600insAspThr
TIR1
pathway-inhibitory
NCI-H209
anti-p19
raw-juncs
Agbarya
1,330
normalise
Ref/PDB
tumour38
antibody-stimulated
immediate–early
S.
R724
AGG/AAG/ACG
5′-GGGCTGGTATCAAGTTCATTTG-3′
tumours+.g.
XbaI-XmaI
BcrAblY253H
inFO-1
TRB
0.375Å
5'-GTGCGGCACGGGAGTCTGCGCCTC-3
Xj
mustard-derived
.Med.
PCDH8
42S
Z-heptad
hsp104-GFP-expressing
REPLI-g
.I.0
factors.56,57
TCS1-TCS2-Rheb-mTORC1
712-bp
3–4
61.1
13–18
subtype-stratified
anion
p.Ala93Asp
NRAST50I
R73Q
promoter.3
StatSoft
hydroxymethyluracil
pro-glycolytic
Blue.rad54
Y340H
4230T→C
Interestingly
codons.§Direct
86457aa8f3c4
A_16_P03169109
siRNA–lipid
14-3-3/C-RAFSer259
ofother
40mm
organs.2
TGGCTTATGTGAACCAACTCC
RD1/2
.Unlabeled
ErbB2_ex17-25.F
.Arachidonic
poly-ubiquitin
dextran-treated
PKBSer473
c.1389_1392dupCAGT/p.Asp465GlnfsX2
Ile789
-RTlnK1
SLC22A7
−log
Tris-HCI
carcino-mas
PCR-generated
thyroid,12
c.856delG
country-specific
.DCC-FBS
685-698
individualize
differentprimer
SPOPMATH-Substrate
Alpha-tubulin
MGC45780
operon
1,956
cross-talk
G1202R
N2875K
1.0–1.6
NODNODNH
971–980
MSF
MMAC1
S16
resistance.8
R300P
EGFR-Initiated
64•7
15/16
F369L
Trial11
genome-edited
.Oesophageal
prosthetic
rs6983267
anti-SIM2
nesidioblastosis‐like
2.5-27.8
-H-W-K-Q-K-R-K-F
CD30,34
N387
3Ex1
6—figure
predispostion
3278
4Dâ€
−3.1
mMTris/45
Maimoun
S6′
5′-CCTCCAGCTGCCGGAAGTCAG-3′
cotranslation
Barnache
0.05315g
CAAGGG
VEGFR-mediated
FITC-avidin
GPF-negative
western-blotted
R80L
16.
RNAPII
sarcoma-leukosis
QGinsR683
irrelevant-F
pKJ-1
LSLKNSLNDCSNQVILAKASQEHHLSEETKCSASLFSSQCSELEDLTANTNTQDPFLIGS
C559Y
and3B
lorlatinib-resistant
BaxLuc
.PIP3
8C/cycle
76.6
4906
protein/RNA
ACTGAGGCAG
lethality.165
genomic-proteomic
AR-LBD
1.62–8.22
p.A460T
termiinated
v3.97
Igl
Usher
ERE3-TATA-CAT/EBV
DeltaN
3.295
21.50
POFUT2
Magdelenat
tap63
T847I
268.4
TP21
cancers80
GTCAGCTTCCATGGGTGTTGTGGGTG
vulgaris
ESE-finder
bneel
​Figure1A.1A
10.17
Pichierri
respectively.35
RUNX–CBFβ
RMSA-l
D-HPLC
proto-oncogenes—affecting
microRNA-21
fusionsFull
crizotinib-selected
pH-dependence
co-purifying
RSP18
215382InsC
GGATGATGACATGAACCTGCT
endosomal
c.2404C
.Figure.8
EGFR-S768I
transilluminator
ATCAGTTTGCCAGTTGTGCT
S808a
-kinase
TTF+
model.37
MET-Flag
GluArgGl
ROC1
ePHD
IADGMA
TCGAGT
p.K5N
GFP-p27
t2t3…tn
Y456C
Jacquemier
ATP-independent
epithelium.20,23
12qF1
RUNX1-I42F
cancer154-156
.173A
leukemia.12
5′-TAATCTGTTTGCCAGGGTCC
hybond
−57.6
FIM,21
5′-ATATCGTAGAGCGGGTGTGG-3′
c.2038C
2606
ZM-positive
3.29
3845
TALL1
N′-nitroso-methylurea
-GSLLDFL
.185K
29.9Bone
H3.22
MDA-MB-124
E277
ferment
NS/CFC
Twoamino
deter-
merlin-transfected
organometallic
bone-marrow-derived
R213C
180.00KB
DAC
models52–55
LZTFL1
pCMV-Sport6
chr1:156041002-156051278
MSI-I
Gbeta1gamma2
Gly23
Henttu
lb1
P87S
BCR–ABL2
KLRK1
6H-I
8787ins14nt
0.58b
DRE
IL-12
abnormalities.35
.Flag-RUNX1
.AR-V1
92.05
Flag-HA
complexes13,55
45–79
antibodiesrevealed
/extracellualr
c.3740_3745del6insAA
mutations/rare
-gacctggagggctggg-3
Fb-WD
Ser649Leu
erentiation
SLC34A2
tublin
al..
C118F
±1
splicing‡
sonicator
ETV6−/−
+Wnt3a
+75
cause/effect
AC006509.15
consensus.9,15,16
c-57-64delCACGCGGT
ARR2Pb-ETV1
outcome29,30
pE-ΔH
Wolowiec
Musteanu
deregulate
pan‐Notch
P=0.2584
ErbB2/ErbB3
orabsence
0.115
MyD88-dependent
GSK1120212b
39-77
β2MF-β2MR
DIO
EGFRvIII-expressing
Q775X
Trp117
TGFβ–SMAD
4,5′,8-trimethylpsoralen
.Proc
OCI-LY3
Puri¢cation
A-loop-mutated
,-'.-â€¢'0
topotecan-resistant
10,000
BDNF-activated
SplicePort
Leu-289
q12q25
mutations.Gefitinib
Ctk1
59-end
A-RR-G
'CONCLUSIONS
econo-column
.EGFR-TKI
FLT3JM-A
94°C0:20
β-globin-derived
leading-
1.12Mean
cMYB
Xq11-13
cafe´
​Blue
pFIV-34N
GSE34937
cleotide
.OX40-induced
GeneSpring
Tsuneizumi
phospho-PDGFRA
gene-expression–based
chromatin11
T1100M
p.1395
0.439
p21species
Tlr9-null
D/Cdk
actin-associated
Lys-382-acetylated
genes—RUNX1
GeneAmp®
telomerase.asu.edu
Carnitine
NM_001172672NM_004650NM_013452
GUCUACCAGUUGACCCGAAtt
R162Q
N-Ras-G12D
mSin3/HDAC
g–j
CpGsites
C214Y
H-171
IGH–CRLF2
CGgt
A1046
gpl2O
ND2
.Functional
antigen-dependent
pcDNA3.VHL
pS6P
c.1136_1137delCT
41,675
.Recipient
Pimozide
KOSEF
G629R
2/40
Odc
withcultured
5′-GAATCAGCTAGCGAGATGGAGATCTTGGGTCAGTTTAAC
AMMoL
EMM=Ebond+Eangle+EUrey−Bradley+Edihedral+Eimproper+EVDWalls+Eelec
cluster.The
D19S424
Amendment––a
overactivates
previsouly
.Tail
15,52
mutations.65
micmsatellite
COCOC
ASC-2
FARP1
Wat175-A
monomer–dimer
IMEB
adenine–cytosine–adenine
CD99+
TGGAGAGGAAGATTAAAGAGGACAAG
s=86
Map-3-kinase
germane
SIAH3
Grade-CTCAE
NSD1/5q35.3
propeptide
-TCTCGCTGTGGTGACCTCTG-3
hShh
kDa-protein
G9823/0391
platinum-doublet
ADP-GloTM
895
P297Q
.Magdelenat
metastasis-derived
10−05
µg/sample
11/18
stage-matched
pGCAAAATAATAGATTGGAGGCACAC
YFP-Jak2-WT
b–c
c.341G
c.8390insA
antimenin
0.0719
.AL121790
mammary-specific
cell–specific
500cGy/min
L50–823
4/23
multi-assay
selection-amplification
//research.nhgri.nih.gov/projects/bic/
P=0.08
Drug-resistant
Lohrsbach
svm_getfeat.py
mini-circular
anti-FLAG-coupled
-'-
susceptibility28
Gln513
5´-GGCCCCTTGTGAGGCCAGAGAG-3´
p=0.0157
D3-phosphorylated
hypoxically
C135/C277S
Summ
FasIII
patients.42
Protein-tyrosine
1/β-cell
SCCOHT-1
control.Detection
9,10,19
TPM4
αBACH1
Gal-4
S1-AS1
G20A
PID
W117A
ICN1/RBPJ
GSE22306
human-specific
18,22
MeOH/Acetic
A677
ADAM22
pNKY83
SKMEL-2
Cdc42/Rac1/MLK3/MKK7/JNK1/JNK2
dottedline
NF1-patient
BCR-ABLhigh
.026
retention.3
low-temperature
TAZ1/2
non-dynamic
pBR
mutations.19
HNF1A-inactivation
MSK921/SCC28
Seventy-one
Variants.a
cription
−48,244.19
immunoprofile
M886I
pDCR-Ha-Ras
Glu493
CCTTAGGTGCGGCTCCACAGC
R214C
10−11
BRAFwtR
reticulocytelysate
0.000161
nihms646437t13
counted.Anchorage
diagnosis.However
single-fusion
9–1617
Coffalyzer
UWJ
HN5
81.2
p52-binding
1,150
NalR
Dasatinib-mediated
POLYSOLVER
BRCA1B
104.00KB
receptors.11
Agalioti
1503–1504
phagemid
Kmt2d
P-11
ICAM-2
TIQ-64
0014-4827/01
Glnl756ter
ABH
redisssolved
.SMO
sense:5′-GCGACAGCTGGAGTATGAA-3′
DARPP
DEN–PB-induced
GSE6184
screens.When
influencedsignalling
inhibitor-sensitizing
KTS2
19/11
anti-p70S6K-pT389
C.The
E321
48.4±8.4
BiBr34-39
1210
co-activates
non-sensitised
Xb
FolioBio
STAG2-negative
Jak230,31
Leu562
CD27+
2676
Elongin-binding
hSPF45
resistance.17,18
form172
contactsDNA
GSE28989
5′-TAACCTCCACCCCAAGAGAG-3′
.Recipients
threonine-875
.H4
2-3
4/223
ETO1
Myc-Smad2
DFFA
IDH1-R132H-immunolabeled
4y
.3D
EWSR1
E836
GABP
metabolicallystable
.Transcripts
G33
Cdk12−/−
Vesely
flag-CBFβ–expressing
R227P
UPR2169
0–60
Q1554H1.
siSMARCA4
dominant-activating
C⇓
inapproximately
972
p85α/p110α-expressing
lymphomagenesis3-8
IL-17A-
tool.20
C8orf68
29/374
S645C
MEK1–green
.Gly17Val
software.20
MET26-LN
AML13
fibroblasts.44
sim-
9109
400mg
TRBP
L556_D569
2.858
deuibiquitation
REGγ
PSA-NCAM
86/92
5.460
0.001091
G374E
Pin-1–mediated
eigenmodes
Glu70
Invitrogen-Life
R331W
ERα-mediated
RhoA-binding
M21574
weight.See
NCT01284192
.Anti-AS160
DMRB
HE0
.L..
CS24
message.22
out-growth
TTCATACC
3L/min
.Double-stranded
uncloned
anti-p85
6k3
carcinoma,2
cells.97
M256/260
A92P
SD-leu
plasmid-free
20,874
gtgtag/GTGTCT
PDGFRα+/K
gastrointes-tinal
pseudo-pregnant
tel-PDGFR
Shtutman
enrollee
genes26,41
Cambio
GFP-p27wt
multilane
COLORECTAL
FLT3-dependent
SF3B1R625/K666
supernatents
c.1592delT
post-intratracheal
fusion51
5′-ACTGTGTGACGTGGACGGATG-3′
208900
v3.5
nu-
BLL
Miozzo
235–239
C166F
Montagnoli
AML,1,4,5
Rxn
cross-presentation
G1-phase
organs1
two-state
IVS9
ubiquitination/EGFR
S765R
Cdk12mat-/fx
tumors4
dysmegakaryopoiesis
internucleosomal
cancers21–23
adhesion/migration
1290±756
7636del9nt
I462T
pBlueBacHis2B
calc-ci
estrogen-
40/107
endoglin
gg:6
Asxl1-mutant
0.071
Bin.ab
.Signatures
sorafenib-based
Morrissey
Cattedra
HIS3coding
.Stata
BRCA2-
SNVMix
waxy
Ser/Tyr
121,660
gp100a
homo-dimers
Eggenstein
F137L
MRPP3
Parameters/markers
K57_G61del
18-80
whetherthese
35.91/18.81
KIT.29
Veaute
microscopic/macroscopic
Counterstaining
FKBP1A
Pirisi
GST-CDK10
p53–/–
EGFlURPTPp
ERK-pathway
30-32
.Ptf1aCre/+
PI103
0/98
F2-II-1
scitranslmed
.Description
K211A
Multi-View
p62`/6
Apc/Dpc4
kinase.29
55.57-55.77
V261M
WTp53-20
22–47
p.Met152CysfsX22
256/426
6916
transformation.16,19
andTGFBR1.The
-ggggacaagtttgtacaaaaaagcaggctgccaccatgcccaagaagaagccgacgcccatcc-30
310–360
G309D
3.90×104
phosphoinositide-3-OH
HA–B-RAF
Asn527
44131
heterozigosity
GDP-loading
Pall
NF-κB2–deficient
.26The
Oit3
5-ACCCGAAAGATCACAGAAAGTCC-3
Methanococcus
−1.9729
pAktS
6826
miIkITBST
amplification,18-
TMPRSS2–ETS
Thr328
APOBEC1
4A–C
Koinuma
stage–specific
receptor-specific
protein.30
clonefrom
NZM40
PD-901
factor.54-56
Maennedorf
cancercell
PIGdeltaRI-PTEN
INSS
as-yet-undiscovered
p53high
Val564
.Characteristic
Vectastatin
NM_011905
WDLS
S647P
data,8,15,16
Arg-132
5′-accctttttggacttcaggtggctggagt-3′
pCITE-11ZF
1×105/ml
proteins,39-41
LY294002-induced
c.1108_2A4G
quential
3199J23
F82L
−30.30
differentiation.76
SMADs—SMAD1
.structures
5′-CCCCACACACATGCACTTACC-3
Lapatinib-resistant
peter.valent
IMGT/HLA
5′-GAT
new-generation
sequon
onset/progression
asplasia
D86G
18,516
cancer.3,12,21,22
5′-ACT
ms00033740
−39.6
.in
UVA-
GeneSplicer
24/188
culture-expanded
4,399/6.0
thep.F508_K509insYFAF
GSS
.5329A
g.475
pocket,24
••
P≤
patients31
'Massively
doi:10.1158/0008-5472.CAN-05-1513
seen,28
W58F
SKP1-CUL-1-F-box
cdr2
placebo–chemotherapy
FGFR3b
59:331-342,1996
9271S
F811
Treatmentfailuresweredividedinto
Δflox
complex–independent
w.t
L164H
valvuloseptal
megalencephaly-polymicrogyria-mega-corpus
AVEO
elucidated.22
binding28
0.0495
M21203
Edge-to-face
CRM-DA
TIS/FUS.ERG
3cases
pathway.10,44
455–767
Kinesin
.Reasons
2FIG
Phe158
Ret9-wild-type
FOG2-AML1
utility/implementation
TCRαβ+
80F
FR2BIC-CF2
184A1
NM_000044.2
T58A/S62A
.HA-ERK1
AGAP3‐BRAF
pemetrexed/bevacizumab
2–intron
results.113
rs121913418
penicillin.Whole-Genome
pathologist-guided
13/1,476
Lendvay
Fishel
G140S
A_51_P404193
malignancies.18
4–13
9p23–24
FBW7WT
p.R132L
3739
ySer
Live-cell
luminescence.Small-molecule
32Plabeled
W113C
patient-selection
Tama-Nagayama
0.005771
Gas6-AXL
5.2
themedian
462-471
Hypomelanotic
30-s
FPP1-RPP1
1.54–10.6
E98-1111
frequen
.HN-Smad4–/–
mitogen-independent
BIMEL
mitosis/10
tumour,3,4
apoptosis/p53
HIC-UP
122-168
SH2038
SK-ES
MSCV6
E491K
Maculopapular
Nycodenz
mg/daily
Ectopic
FLT3-ITD2
.CV-l
additionallevel
malignancies.7
SVDetect
NPC.17,21
Osterix-Cre
sulfate-polyacrylamidegel
STEP2
factor-independent.Ba/F3
anti‐goat
pp53-TA-Luc
nondenatur-ing
Rip1-Tag2
bromo-4-chloro-3-indolyl
remainderof
intermediate-2/
pCMV3-Myc-tagged
MBcr
delE746-T751
c.3365-3366delTG
p53RE
rLPVKW
284:7719–7732
Trichostatin
N489T
47,65
Aza-Blanc
timepoints
D/GXDD
q≤0.05
Met290
rs7667298
RMRP
54P13
5241
CGGAATTCGAGGGAACCCCTT
.Hydroxyurea
lines107
20–112
off-rate
Padovan
HRD-arginine
phospho-TrkC
viral-related
4403328
PC-9-EGFP
therapyIn
Met-14
NM_173740
MoleŁculaire
0.284976833
NCT01244438
73/160
equimolarly
TLP
HPC
§Ins
MOT
HER2/PI3K
Dnmt3b+/−
Genes—KRAS
Finland,31
S3G–S3I
expression.13,18,19
flag-PALB2
PJ2000
vitA2
4912
p.Asp191Gly
complementarity16
previously15
1p36.1-3
ARflCL.£
-GTGATTTTCTTTTGAACA
61–63
R86A
deparaffined
1.217
GFP-ΔINI1Δ
ST-RELA-EPN
samples1
Bilateral
3271
STE20-related
M−1cm−1
9p22
GGAATGTACACTGGCTGCTGGCAAA
antigen–4
PCRKIT31
5′-AGTGCCAGTTGGACTCCAGTGA-3′
Micronucleation
multi-system
mice.2
.SRC-T338I
AB2.2
17-614
epi-illumination
octamers
hydroxy
genomeGenerate
D297
photosensitive
anti-HDAC1
G9V
PKI-166
7a–d
30â€
ovary.17-20
NHRVGTKRYMAPEVLDI
0-90
Flow-cytometric
.Fc
fate.1
cMNR
C124/135/141A
CS5.1
1-17
867
solid-tumor
Cav1
protein.33
glyceraldehyde-3-phosphate-dehydrogenase
carboxylation
tetra-antennary
K601-mutant
EIAF
P35235.2
F2039S
PML-associated
pMR438
100-mm
BKM120-dependent
.Kenneth
GSE9353
V454E
Interaction-Deficient
viruses40,41
RanBP1
4310884E
10p11.23
JLP1
.Dim
Intermediate-2
Norway/Stanford
T2*-weighted
Y37C
G833-H811
CGATGTTTCGCTTGGTGGTCGA
pseudophosphorylated
yAFM/pTSAd-fe_p53wt
Pten-expressing
stress-inducible
described14
-ubiqutin
domain–less
tissue-punches
496-bp
CFU-S
H121Y
postlysis
IIV
7100
reported33,37–40
miR-3127-5p/inhibitor
2,6-dichloro-3-fluoro-phenyl
LREA
dChipSNP
Representativeresults
pentagastrin
phenotype.9
Oberkochen/Germany
Thr196
VAP
CRH
C11orf95
GTP-RAC1WT
Raf-1/C-Raf
D4-GDI
-106
pT2N2M1
TTF-1–positive
PACH-224i4
TSPO
cerebellum.2
N540/542K
4Laboratory
/PR+
pIGF-1R
2-6
non-MMP
organelles.20
rad50S
Skp1/Cul1/F-box-like
Alal48Pro
MLL/11q23
D870A
Pl5
8A–E
opposite-orientation
KRASwt
substi-
cancers24
gμg
HIB/SPOP
T877A-bearing
HSTCL
regulatory/effector
blood-sample
pseudarthrosis
INPP4B-1
G713G
12.8
genome11–13
p53-target
c-Raf-1
al,25
G1022S
Expression-Based
beta.20
Fusion-positive
45-90
coexpressing
CCTACGGGGG
GLp65
months3
TCGA-32-2494
.LCA
DDIT3.Moreover
ERK1/2
Palb2−/−
5703
R219I
MP-CMML†
0.4059
°C14
Acvr1Q207D−c.a.The
.bam
anti–CD14-PE-CY7
D131E
EPHA4
H-260
Thr-286
Tgfβ
LiRaf
p21/bax
2D–2F
R273C-related
177/465
Microfoci
AdSq
non-CG
P488fsdelC
18451133
5616
3.2057E-10
beta-mercapto-ethanol
CCAAT/
*Only
activity.Fig
migration123
mutations2,4,6,7
AMP-dependent
P.G836S
bronchiolar
POP4
Craf+/DA
CAL29
pACCMVpLpA
double-sided
cosilenced
MINT31
4q34.3
alpha-interferon
N332
C-2773Q
neutrality/LCS
HA-p16INK4A
tyrosin
P251L
2836-2819
.10,16
Rho/Ras
q13q35
myotube
5′-CTGGCATGGCCTTC
mMNaH2PO4
anincrease
FUS-ERG
mct.aacrjournals.org
tumors30
29th
subependymoma
Y302
.9-12
MEF2B30,31
4105
DSAPGS
DDX52
mice21
1367
cAPC3
dot-like
D3.16
19.0.0
testosterone-lowering
sequenceforward
W385C
3.3amp
GMS10
polymorphic/neutral
Microson
~/y
LRTOMT
8q24.1–24.2
A-tagged
Srsf2flox
3NCV
Synthase
pathway.6
Catenin
P105L
G2P0
61L
cDNA.We
58°C
255X
Gnanapragasam
36A
MDSC
2i
Gcontainingreporter
OFD1
cancer.8–16
I651T
COSMIC-recurrent
ALKWT
Goodrich
intersister
Rohle
.Niemeyer
Anti-phospho-CREB
JXI
Precursor-product
chromatin-remodelling
metastasis—and
IkBα-SR
permeablization
−956
–246
ucl.ac.uk
chromatin-enriched
SPOP-binding
ErbB2.42
12,46
PTEN-398
Chr9-460R
pmGFP-H-ras-D47A
MST–YAP1
and3A3A
56.56
E003
IVS20+49G
SDS-insoluble
AU565
cap-binding
42/192
FLT3.int14R
cancer.3,4
0152-DM-A
P50.003
amyloid-like
3027
10C-101
¡80°C
iodide
QDO
G579S
19,28
//ptmscout.mit.edu/MCAM_July_2011.zip
PTH-Cre-positive
6225-bp
GE-Healthcare
Dra
.Anisomycin
shRING1B-transduced
polyp-bearing
out.4,24,34–38
191/531
open‐sided
GRA
119.3–121.7
10.1182/blood-2005-09-3778
TSCrelated
F57L
truncational
5q.5
63/90
cellsDaudi
proportionality
9-specific
SW48
non-invasively
Fethi
IC50=30
884-Arg
Q230K
2–mediated
HLA-A2–restricted
.Suzuki
38-kDa
Thapar
5-FU-based
9340
5′-GAGAAACTGCACGAGCGGGAGGATGCCCTTG-3′
CtIP46
.Prognostic
lineages31,76
wtp53
0.206
p.Ser594Ile
//www.ingenuity.com/
K-
5¶-ATGAGCCATCGCGCCGGATGAACCTGTCTCTTTAA-3¶
G150S
STAT5.13
P4S
K-RasA146T
STI571/Glivec
R921Q
absorptiometry
line.14,16
and500
LCNECs
K82T
predisposition3,4
KE-0254/86/2013
0•70
18p/q
PDGF‐treated
EBV-infection
4MKC-
D221-3
14/23
BIR
physician-referred
H2O2
.L747S
range.4
gene.
TCAGACACAGCTAC-30
VUS
SMG8
mutation+/HER2¡/HER3¡
Heat-shock
Clinicaltrials.gov
scale\
737
5′-ATAAAAGAGCCCACAACCCCTCACTCGG-3′
12c
radiolabeled
UUU
SPOP–DDIT3
Tschaharganeh
Asp835Tyr
MDA-MB-468
15/31
Gussow
+++
CD74–ROS1–expressing
alone.17
N430
PSGEMVK
C44F
4.49
EGFR/PI3K
TUSC1
quasi-monomorphic
.Membrane-bound
T238K
tumorigenesis17–19
0014
6335/953/751
HCC33
Posttraumatic
oncogenesis.17
zo-1
RMB10-mediated
c.5386C
PRSS23
retinoid-inducible
HA-Flag-tagged
pDM
Mg2+-ATP
c.655A
5-hydroxymethylated
XP_001233812.1
Follow-Up
0.4μM
re-exposure
Nall-1
63×/1.4
209200_at
re-considered
A_51_P150912NM_011497
self-assembling
withdrawal,45
0.633
hemispheric
PI3K/PTEN
.AKT1-W80A
Top1cc-accumulation
Stjernqvist
III:4
microenvironment-activated
0/35
p.Met318Arg
c-Myc-tagged
del434
vector-control
30/60
72°C/30
Vivo—Elimination
cancer49
D–E
4.68
thyroperoxidase
alloBMT
exon-byexon
α-Mannosidase
pEYK
GBM-T02
nucleotide-repeat
'miscellaneous
germline
p53-unrelated
293T-shSENP1
p.Mdeoxynucleotide
.Branch
5′-CCCATTTTCCTCCCTCAATTCCTAGAAAA-3′
∼5-week-old
NG_011442.1
p.Gln448
wildype
ECMV
309845
264/31,180
1.46–2.96
MethodsThe
FL3,5-8,10,11
.Categorical
HBL
irinotecan
vhlR200W
microevolution
series,34
0.729
Ira1p
Matera
Two-site
NFkB-fusion
64·3
forfunction
181-1815
Fig.3c
FoxF/Biniou
−6365
pPS5
10-amino-acid
v0.12.9
best-folded
F458L
CodeSet
Y1087
arrayQualityMetrics
JMML-associated
humans.8
PARP-inhibitor
V465L
G.M
SA-B
L343F
A502-Y503
ual
PROM2
T.X.
2076T
Pellegata
matrix12
29.11
.HIF2α
Staurosporine
Fontenay-aux-Roses
hm-dCMP
anti-CD19–PE
tumours.37
5′GCCAGACAAGGTTGTTGACACAAGAGAGCCCTCAG-3′
PCD
T180.1
VEGFR2/3
SU6668
20:827–832
FLAG/His8-tagged
G2-M
muta‑
PCK412
whichencodes
tyrosine-516
genesin
Dmel
CTIO
.053Exon
GST‐wt‐RhoA
R283C
hypocalcaemia
coaggregation
P=0.0925
adeno-associated-virus
electro-transferred
under-expressing
5-hydroxy-1H-2-indolyl
membraneassociated
therapy90
relatedness.Figure
419T
lethality.40
H538Q
5′-CAAACCTGAACACCAGCAGT-3′
.SASA
NBG17-D
D2-40+
asdescribed
2/50
E1+/FGFR9−
irrel-evant
Flt3/Flk2
15–45
G580R
crossreactivity
44.5
5′-GGCCGAGGCGGCCGGGCCCGTCGACATCGATAAGCTTACGCGTG-3′
Nishimaki
T75
Nussloch
self-resolving
Rab-small
G92C
ENST00000507734
.Improvement
.Resveratrol
29,421,819–30,451,370
RG-8T
S376F
.MPNST
Cells—To
Scells
GNAS/KRAS
CTNNB1/AXINs/APC/GNAS
lv
.RBM6
5′-TTTCCTTGTTGGCTTTCGATTCCTTGATAGCGACGG-3′
Plk4
2,806
Leu574contacts
Q1893
rs3218536
4.71E05
Annexin-V-positive
SOX18
Départementale
netic
5.Comparison
354578
non–Hodgkin
λ̂
ELK1-GAL4/UAS-luciferase
D7S486
TTK/hMps
C1483F/T1977K
Q133P
5′-ggaatgcaagctcattgtga-3′
Apc1-driven
hEZH2
WK557
7y
cancer13
fluorescence-
82–185
1According
EREdriven
T428I
BRCA15382insC-mutant
gene-inactivated
9-13
WNT-
I309
.Phosphatidylinositol
56774158
H204D
Flag-immunoprecipitates
osteosarcoma.The
FLJ43582
post-Tam
co-downregulated
39,460
Bader-Meunier
72/87
383
Cytokeratins
pFastBac/hMSH2/KR
interstrand-crosslinking
V79M
p21-Gln61
C314
Basidiomycetes
CD2-Runx2
LrQ
CTCCAGCAGCAGGCCATAGAGGGGCAC
gamma-phosphate
Klump
JAK2-V617L
579–581
C.B-17/Icr-scid
excluded.dUnivariate
4,19
ETS/RUNX-binding
Schild
c-Myc-dependent.A
D258H
eluants
signalling-competent
4u0
whole-genome/whole-exome
Sco1/Alox12
480-
QKRAA
p=0.009
deaminated
hamartin-tuberin
27.1±3.9
IVS27CA28.4
β-catenin/T-cell
shScr-A375
.Shp2
colo205
Co-immunoprecipitation
immunnostaining
D1-mediated
-CGGGTCACTGGACTTAGGGATGAGA-3
E649
*According
nottransactivate
0.057
mU/ml
software™
D1241N
ZCCHC8
Ala763
Wnt/β-Catenin-Dependent
eosinophilopoietic
.ECL
observedin
p.Pro124Ser
1.4-kb
pTyr1234-1235
cleavage.Full
terlll6
RSS1-4
.Fig.1.1
L726
Watson-Crick
diagnosis.2
Asp593
.MO-nrf2
Arg100
Threonine
TGF-ÃŸ-insensitive
108.4
65·2
FrC
twoADHp53expression
W456X
p.F216S
defects.16–19
insta
p.G628_M630del
Q.Q
Garimella
3HNA
1748
pENTR4
partly—be
gCell
ESCRT
shown.19
granulocyte–colony
mel-
12/73
ITD/78
SubgroupsTo
Biomedicum
amyloidoses1
MAML3
patient-reported
E167K
algorithm,26,27
MDA-MB-415
Hypocellular
T389-phosphorylated
TEV
7/3,910
//www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi
1.9-3.5
L861Q-or
25-60
Tetanus/diphtheria/StreptolysinO/mumps
​Figures2,2
character-
9170
2639del200nt
EV5
V2205A
homodimers
973-EGF
60×/1.4
64/M
pep4-3
L1196Q-ALK
_2445+
del480
−347
etiopathogenesis
EcoRI/SalI
TGF-ÃŸ4is
E597K
MAB274
p14/ARF
BCB\
pCMV-Tag4A
TFC-3
Deparaffininzed
Kanker
Jmjd1c
anti-oxidative
5′-GATCCTCCTTGTCCTCGGACTC-3′
3ALO
v130
3704del5
BD1
6.877
Sau3AI
cationSpots
ERK.12,13
V115L
p100/S420
WTEGFR
TSC1/S6K
.CCNG
K350A
C124/141S
models180
ACSL6
HOXB3-mediated
distinguishing
CR3
phospho-degron
RS.2
Hopkin
PIK3R1E160∗-expressing
aftor
l-acyl-2-
theTFG/NTRK1
Omicsoft
4.Download
Rzem
amplified41
3′-portion
.Puri¢cation
cell-cycle-activating
5′-ATAACATACCTTAGCTGAAG-3′
65-7
L384M
three-helix
tation
3p25.5
CO11
Macherey
T31R
STK33-S6K1
nuclear-cytosolic
.Ezrin
56-6
CBFβ/MYH11
G2108R
RAF1-MEK-ERK-β-catenin
Deep-sequence
sunitiniband
cDNA-transfectedcells
hnRNP-E2
Angiomotin
TATAbindingprotein
24–77
NOTCH1-regulated
120
50-mAs
*PAX5
p.Met35Asn
kinases14-15
59/96
G1927A
46–60
morphology.11
722
Brd4-RFC-140
4.1-kb
DPC
.Analyses
Gto
Msh2-
Lymphomagenesis
vitro.16-19
Edman-based
cc-EpoR-V
collection/
AMPKalpha
D1–CDK4-mediated
RP2151F
incidence/frequent
and4A
P=0.252
RUNX1-EVI1-positive
MSCV-TEL-JAK2
non-hypermethylated
noncompetitive
11,16-19
1.5-μl
7-8
situ.25
A_51_P469433
GISTs39.Given
−3.2
8p21.3
CEP12
MTC.8
al,5
GST–GBD-M1
Rhodesetal.
AML22–26
∼26m
Velichkova
1-ethyl-2-hydroxyethylamino
tonic-clonic
.HCF-1
13-22-A-08-A-25
LN319
estrogen-depleted
IVS5−1G→A
p.Gly328Glu
Plat-E
TCF-3/ID3
11/53
6xOSE2
SUPT13
-4.50
Silibinin—a
Pim-2
FBXW7-AurorB
Bii-Bv
3,79,80,87,89
MLL-encoding
11—each
mir-16-1
NY-ESO-1
E161K
p.Gly114Val
p.L2009_L2017del
Bioworld
pRC/CMV-TGF-bRII
electrophoreses
MCF10A-WT
growth-retarded
DNAthrough
97.7
four-zinc
24–34
Scanjet
1–47
0–200
4F8.2
D173A
p53–274Phe-carrying
sequence237
ACACATTCCAGACCAAGAAACGAC
age-related
JBC
deletions,25
108/126
median=49
HCCC
0896
iCi
Exome-capture
IGCs
.Ben
thep.F508
target-effectors
J.-H.
09-05-009
infranatant
Multimerization
Howng
PXY
suberoylanilide
-Actin
melanomacells
TRCN0000071395
trans-phosphorylated
V75
2q24
®ciency
Tyr-CreERT2BrafV600
10ml
over-express
Prkdc
milk–PBS
XPB
RP11-242D8
IDH2R172G
R147C
anti-snRNP70
malignancies.5
109C
p85α/p110α
78.6±8.3
ligand/PD-1
dimer32
1-containing
48-week
Varshavsky
24,111-114
p.Thr354Met
3,15
ASPM
8-300
20,387
HD-0145
Brinkmann
\A
patientsa
BLPD/mature
S957L
andgenotoxic
113–0033
H1686Q
HRAS6,12,13
concentration–dependent
BJ5464/pEAE20
AAAGATTTGTGATTTTGGTCTAGC
BMP-induced
1821
VP-ITC
FLT3/D835Y
137–138
7414-1
siLATS1
mammaliancells
Meuth
0.326
1:370
GTPases
CGAGCTCTAGCATTTAGGTGACAC
93/151
Masson-Fontana
R337G
cancer.Not
Ri1
Asn540Lys
Acid-Schiff
.2A
72-4
GluGlyAr9Prol
755–759LRENT
nocodazole-induced
Two-
MOL2
s.e
measurements±s.d
clonesbeing
L115P
NM_027817
31-33
.5,53,55,56
Intussusception
CCCGGG
AY024361
Ars2
RET-rearranged
most.33,40–46
.Single-gene
BPN
domain,6
estrogen-binding
HCF-1C
′-GCC
Ser638
1–587
L289F
luminal-derived
D603Nmutations
Sae2-deficient
NpR1F
rs2234693
pJ4Ωβgal
inactivation.Top
p53-reporter
.Transfecting
analyzedfor
DNMT3AR882H
D15343
microphthalmia-associated
CblR420Q
A_52_P646684
consensus-scoring
Ile109
mitogen-induced
Ear-2
5′-TGTCAAAGATGCTCTCAGGAGC
Chlamydia
recom
MTCP1WT
APAF-1
GAP1m
morpholino-modified
erlotinib—who
BRAFKD
GSK-3beta-dependent
R1739I
Oplustilova
D1203N
PTKrelated
.overall
≤3
S60F
monocytic/granulocytic
andBamH1
MDA1386LN
.QG-PCR
Pem1-Ad2-EGFP
DNMT3AMUT
m67-luc
D85N
+/Y394C
22,23
.1788
2842–3717
Zhuo
nonimmiune
Chugai
0.08N
IIIA-IV
IGF1-
RFC-Brd4
osmium
20q
temmatically
CACNA2D4
.Familial
LR08-338
356,136
BCP-ALL.5,8
AATTTCTCGATTGAGGATCTTTTCT35
anti-pausing
.KEY
1.85-
bifunctional
1.7×109
142886
DMRAfluorescence
5'-CTTGGATCCTGAATCTGTGC-3
XCyte13
AAC-
theprotein
V714M
heparin-anticoagulated
5′-GAATGGGCTTTCAATCTGGA-3′
S762N
mouse118
SEC31A-JAK2–positive
thebreakpoint
4weeks
under-replicated
rabbit-anti-HA
analysisTumor
Monoplex
Studies—Time-dependent
2.12E05
decay29
17/F
pT2N0
c.4220T
L838V
chain–b2m
A375/MEK1-C121S
40:60
significant.ResultsExpression
R175HSP
RsaI
EldarFinkelman
Cy3-coupled
Vardiman
S204P
c.1591C
coactivators
GRN163L
C2221
7.6-fold
36-point
.Runx1−/−mice
MYC-bearing
al.33
C-81
Schlegelberger
.1823
jcp
confirmation/identification
n=405
pMad5.8
.PAM50-based
extrahelical
GI:5596348
.Abnormally
anti-HER2/neu
mg/ml
o-phenylenediamine
◆
leukemia.6⇓⇓⇓⇓⇓⇓–13
WT564
ST-segment
973-EGFR-Truncation
IGF-1R.40
Regenass
3.359
Val769_Asp770insGlyValVal
Tie1
Roh
ATCC®
.GLUT1
-GCTCCACGCGTCGCTCTCGGTGGTGA-3
'late
ExoI/SAP
.Men
follow-ups
7-catenin
Δ1-108
Asn540Lysa
1-67
'mutation-negative
pLMM
GM-CSF–containing
5327
ins9nt
EN-Y517F
clones,14
type3
expression.39
Rodilla
GISTIC
qualitated
iodonitrotetrazolium
BioSci
8895
c1-si
proportionately
−8.7
1760-μm
CMFDG
e5.2
syndromes39
guanidinium
GSE18333
chr2:160253915-160255339
ICR1
6–29
MAKP
B-Rafwt
biotin-ARDIYRASYYRKGGCAMLPVK
incubationf
H3K9
F80
.Anomalies
–ROS1
ICC-specific
2172
.REVERSIBLE
caspase-9
.Contrary
K533
A9418
truncations/mutations
42KDa
ade8
CCCGC
.YAP
ACC-TMA
Hiyama
Axin2
:UASGAL1-TATAGAL1-HIS3
LJM716
14
CPA‐7
F488-conjugated
NTRK1-expressing
5/del
BP-2000
cellgro
406G
15–39
A04
loxP-mediated
-0.24
enhancer-regulated
Val769_Asp770insCysVal
described65,66
Rho-Rock1
V559A
mono-ubiquitylates
.762
Brdt-like
C-1000
βPDGFR-driven
carcinomas,19
VCL-NTRK2
−.75
BE2C-EGFRΔ768
1.24–16.33
S135T
ERL3147
atrophins
Mean7SD
//provean.jcvi.org/protein_batch_submit.php
proelongation
.Parker
A943A
59-
1319
AJ519934A
.737
07-478
.Hematoxylin
UNP
.Rdd-BRCA1
cells1,2,3,4
10F10
chr9:4985245-5128183
1.04–1.11
'Iq
G596
5A9U
23,43–45
SLVL
CRL3
22.03
p.Arg10Leu
paradox-blockers
L747-S752
fect
.Ba
Self-association
growth16
603688
anti-KEAP1
DNA-DAMAGE
-CTTCCACGTTCTGTGGGCCA-3
S5J
astocytomas
codon-specific
LC_C25
MLL-Myc
mutations23
study.24
five-cluster
allele.54
assay.16
n=258
MC38
18.1–80.5
-GDC-0449-binding
003400
c.2295C
.Concordance
urea
First-stage
.Horev
mutations.82
BAY61-3606
C229
ARG.1
FAK-Src
Kanamori
Ni-agarose
glutathione–S–transferase
6/42
IGK
.ETV1-defined
H878Y/R898A
C3340Y
70-75
3HHM
H3K56
+7786/+7987
pTSG-fe_p53
.25
HNCA/HNCOCA
W802
Murphree
0.4124
.CHO-ER
Alk11
mTOR/NF-κB-dependent
JLP
Figure5D,5D
CDK4-cyclin
thymine.18
.Matching
6285
.Myr-hp110β
Tables11
w1
Nrp1
Baxcontainingreporter
anti-KIT
p85α-p110α
60,000/mm3
TALL-1
/www.nchgr.nih.gov/
fusions17,18,19,20
transformation,41
KIT-D816V
P50.01
H1124D
102~3
RB-derived
NB7C8-α3L
_EGFR_-mutated
2625
S565
CTGTAGCCCATGTTGTAGCA
4.68e
14-carbon
PRDM1.E2.Probe.F
Genego
yet—in
865–870
reestablishing
regulatory-type
fragrnents
p53,19,21
sos2
hTBE
1/nervous
GR-responsive
oncodriver
.Gilman
Q903R
Maheshwari
P=4.5e-12
non-helix
PIK3R5
CKIs
.Environmental
2°C/min
CD95
described9,10
B-RAF87
UN21
D-sites
CML-specific
CMV-Cre+/T
8p12
n=366
∼0.8–1.0
TNF-α-induced
liganded
65a
1846–1863
82.5–96.0
5′-CTCCTCAAAACCCGGAGACTT-3′
11-Deoxycortisol
PA15
pharmacokinetic/pharmacodynamic
D994N
lowtransforming
glutathione-stransferase
0.554
MgcRacGAP
3To
anti-X
LUX-lung
credentialing
R273/DNA
HIP-1
anti-fading
3463–3468Boissel
polypsosis
sc-354
CTNNB1-activating
Firststrand
1:1600
SP-C
Haemostasis
MN1-ETV6
50.5°C
MSH6-/-
32000
CCGGAATTCCCACCATGCCCCTCAACGTGAACTTC
dectin-1
oligonucleotides—tricking
R261C
A_52_P327236
6831
2.10
plots44
49405932
mutations.9,25⇓⇓-28
MRPL41
D89
nucleophilicity
MPCEWSFLI-1
Delta223
Q19380
4H11
moter27
D9S1604
.Subsequently
notdetected
TÃŸR-1re
CTGright
7187
.FGF-1
inlane
ARG,16
5-b
Fladvad
AML-M3
MLL-AF9/Tet1-wild-type
IPATIMUP
240mM
nM8
.Immunophenotypic
.Aberrations
1£
NCT
7–28
FGFR-2
MEK2N126D
7p12–13
1741bp
146:453–460
P=0.1282
fastaformatted
SDK-LacZ
uanine
1A1-1R
ETV6/RUNX-1-positive
S6P
Defuse
DIS3/exosome
.857A
ryrSKUvâ€¢'-X-TÃˆ//
11/22
Cbl-70Zmediated
log-likelihood
MEF2A6,7,8
cells.Upper
TW
dierent
.PDT
D-001810-10
Ba/F3-transforming
ProNet
IκBα–wild-type-expressing
isothiocyanate-phalloidin
50-base-pair
6554
4059
MutH.3
bowtie-chunkmbs
complex/tramtrack/bric-a-brac
Ser752
data.Testing
SDS−PAGE
small-moderate
120435
5′-CCTGGGAGGAATCAAACAGA-3′
2/88
L225LI
E2f4-/-
493–498
IB4
153480
Professorship
CCND
2C-F
Brg1-Deficient
short-dashed
LKB1-induced
451F15
cancer.54
.Feig
co-transplantation
olaparib
.recessive
W395
Atto488-labeled
Aspartic
ITQLMPF
.Replaced
≈70
pEFHA
Hs_FGFR4
PAKT
g.45867G
.Immunoreactivebands
Immune-related
TGF-ÃŸ.activin
Immunoprecipitations
Massimino
227/413
1884
magnesium-binding
M/78
Reifers
hydroxymethylcytosine
5′-GCAGCAGAGGAGAACCAGACC-3′
SPEN-specific
amplification-negative
A1789T
Vacutainer
features57
PMC3167048/
authors,21
Pulse–Chase
NotI-Smurf2-R
cancersb
∼1,300
54·1–84·6
arrest.7,39
E1278K
8a1
insQ176_177
MONTELONE
THR319
11INGNNYVYIDPTQL563-576del
Tumor-site
Spleen-derived
Yes2
0.009353
6xHis
non-tissue
non-isolated
ohCZ
Ch1
2,219
BROAD0.5
melanomas58
RP11-275J11
IVS20+35C
Krycer
GIQTVDELRoQQRKMNDSLRLRKTISDLQ
CASP4
hMLH1▵9/10
MM14
Tet1-bound
MLL
20.056
5′-GGGCACATTCTTCTCCATGT-3′
2FB8
27th
JCRB0822
_862+
CD30+
proline-hydroxylated
TPO-driven
c.445C
Othersd
patients.6
LAS-3000
immunoreactions
BCPR-ZC3H7B
.1a
Chemiluminescent
siUBB
extraosseous
CDKN1C/p57KIP2
foldincreases
FP-1039-mediated
.Leon
non–ATP-competitive
Glu525
GGACTGGAGCGCGCCGTCCGCCGCGGACAAGACCCTG
up-concentration
.Zoran
a-tubulin
USP1
189–193
–AT
YS
8.3-fold
VPL
27–84
HPRCC
1,062
526GrA
.Song
63-y-old
.MS-based
c.7967T
c.5295T4G
Retrovirus-induced
DNA-damage-induced
SCLC2
chr8
non-CIN
2.DNA
–MET
Interleukin-12p70
Mauassas
ttgcag/GTATAT
Tyr371Ser
G555E
membrane-localised
delTATGI
oncogene-activated
sites.52
6.70
UNC80
Q189R
duplicate.The
Â°
3.13E05
angiosarcomagenesis
neutral,16
//frodo.wi.mit.edu/primer3/
interferon-inducer
5677InsA
Atr-II
GDP-BeF3
fertilised
-inputtpb
â€¢Number
angiogenesis.33
T-cell-recognition
trxb11/trxE3
CGCGCCGTCCGCCGCGGACAAGACCCTG
10.3816
GSK3-phosphorylation
anti–phospho-paxillin
ABT-73749
domains/motifs
F'=
1070
Glu108
S5A–S5D
500kB
K558
Pusch
Kumada
shRNA242
−2.8
spermatogenic
10.1007/s10637-013-0039-4
AVYM
pathogenesis46,47
ZF-CxxC
.ETV6-JAK2
0/7
Thr1006
pVHL-negative
TRPV5
0.05.ResultsSeveral
COL11A1
.Rho-immortalized
DS-bla-037
ENSA
FA-related
Tyr1278/1282/1283
inbrief
B-lymphoblastic
Labtransfer
I913
Doench
studies.6–10
23:37:08
27–29
CTSB
4.927
33/9
A9mut
extragastrointestinal
Mate-pair
5-flurouracil
GTTTCTT
luc-mut-15/16
TPO-Cre
tetrahydrochloride
140.163.000.005
.PIK3CAM1043I
.Post-translational
MDLSALRVEEVQNVINAMQKILECPICLELIKEPVSTKCDHIFCKFCMLKLLNQKKGPSQ
536-fold
1,366
and1A
Sigismund
K660
MFGR1877A
whole-mouse
damage133
ConSurf21
66-kDa
p.L32P
5′-CACCTGAACGTGGcCAACCTGTTGGG-3′
T37
clone.33-35
Kok
89.7
PKC-alpha
.GST-fused
ABL.13,60
.Polycomb
Ploegh
theobservation
PIK3C2A
anti-β-TrCP
KIT–SCF
1–368
pLXIN
P=0.065
FLA-2000
microsatellite-dependent
p.Met53Ile
GSE13696
rad50L1240A
A492T
Arg-563
.YB-1
investigators24,25,26
EzrinT567D
Ets-1-dependent
μg/well
IVS9^1G4A
40•SEPTEMBER
T6*TrTA
D1067Y-KD
Hebelstrasse
aberrations4,5
N482
22,679,000
p19ARF−/−
-89
2.85
H3K36me3.23
BCR-FGFR1–expressing
itg
30,346
W1291
4-lm
4E-BP1.5,6,7
BIMP3
inhibitors—the
5′-ATTTG-GATTGTGTCCGTTG-3′
GimC
José
glucosinolates
γ-secretase
IIb/III
µ
14/16.7
GSK-3-
W263
Sabbah
e-
others.49
MED12KD
Rorα
di-residue
Signet-ring
mediatedlysis
pH=6
Asp539
anti-MAP
.Superimposing
39,910,434
p53+/-/Brca1+/Delta223-763
ggbiplot
check-up
145–157
R669Q
anti-IKKɛ-
transforming.HMECs
EC1-EC5
tXzS
LATS1/2
.MLL3
––+
Ontac
thatcellular
1.74
hMLHJ
casesa
GTGCCAGCCCCCTTCTCATC
Douwel
hypermutations
U2AF1/U2AF2
1940s
Transfectant
Asp701
17,33
Provean23
5′-ACCAGCACCTCCCAACTTGTAT-3′
m6
one-piece
T1IF2
L26R
homodimerized
substitution.34,35
Foxa
Side-by-side
coadministration
37-year
hemangioprecursor
'target
M13-appended
FOS-like
BRCA1185delAG-induced
Cxcl7
anguinomycin
T151M
IGFBP3Box
reported.7
Transurethral
inac
totalSf9
0.55–0.89
110.380/0
±4
G247R
hPMS2Human
IDH2R172M
APA
model.Figure
ERRB4
38-year-old
acetylation17
7/8-matched
R231T
immunodefi-
3.5-5.6
6q,10p
mid-range
p-Y1016
Annexin-V-FLUOS
myc-related
1.9-fold
−335
Frontal
forks2
mCitrine-TIR-domain–only
nondenatured
-Flag-tagged
developmental-related
Saitou
leucines
KYSE-450
COSM447949
CAF16
24476
11182
anti-Flag-M2
Y.-I.C.
4822
M54
PAb419
media,5
.VE-cadherin
MKK7/MLK3
IM-
NA*
1D
Differentiating
BP396-344-298-220-201-154-134-R1881
v0.6.2
J.33
galactosyltransferase
H68R
Shp2WT
HA-BLIMP1
method35
0.0113
Leu755
ER-
1306
≈500-kDa
EGR2-specific
mechan-
FLT3-D835Y-expressing
0.98
Ala394
0–42
low-penetrance
3295
pSmad1/5-dependent
error-weighted
R254W
pre-etoposide/cisplatin
Amplification*
Men1ΔN/ΔN
heterozigousity
HL60
InStat3
Lakeside
.Algorithm
1,2,15
cardiophrenic
cancer173
oncogenic/tumor-promoting
5′-GATCTGTCCCTCACAGCAGG-3′
3UbiquitylationRedox
domain−PTP
infectionA
PTP1B·VO4
EGAS00001000654
loop41
100-kd
diagrammatically
MEK1K57N-harboring
.0034
Smad2NL
5057G4A
Kogai
222
CCAGTGAAAATCCTCACTCCA
RSV-ÃŸgal
Genotype–Tissue
disease.16
A431T
a–f
81071805
.Fig.3A,3A
.PDF
relapse.17
E2-ubiquitinating
observation.The
c.956–2A4G
5-dimethylthiazol-2-yl
–nomodel
.IGF-1
Phe-Leu-Arg
procedures.22
phosphatidyl-
NRASwild-type/BRAFwild-type
.PGL2
YNCURAY
haemangiomas
Nanba
c.49G
Lys449
.RUNX1-EVI1
.NKX2-5
6-1
GnRH/GnRHR-induced
software.Accelerated
ETV6-BAZ2A
CFC90
mRNA-seq
5′-TCCATGGGAGAGGATACAGC-3′
Düren
GeneAnnot
Selumetinib
H2073-wt-EGFR
GST–CTD
Hiscox
p185bcr/abl-expressing
dependentMany
wellconserved
Vhlflox
A–only
R249S/H168R/T123A
2−6.0PREDICTED
.March
ATP/MgCl2
previously52
1092–1099
Entrekin
BRCA2suppressor
.FGF19
Pansuriya
p.Gln624*
Ewinglike
.KDa
0304
PT04
1PKG
ALK–expressing
sinensis
luc
transfection/integration
T389
9,25
7/1/99
left-dominant
-have
anti-Jade-1
XXXI
CTGGTCTC
PTEN39-403T382A/T383A
lightchain
.I.Q
.Telencephalic
4.52
4710-057
3.84+1.68
-pSTAT5
activatability
AFF1/AF4-MLL
PCa_ETV5_1
C23Y
extracytoplasmic
Cancro
culture.68
sc-124
S2215F/P/T/Y
HCC95
THD
fusion.24
5E
SH-2
−0.54
hormone-related
BALB/c
Zeleznik-Le
000251.2
RB1deletions
c.583-1G
Juven
isoenzyme-specific
2O8J
IDH2-4F
Appligene
D320H
molecularmedicine
E-P
branchpoint
R781H
TNFDELLQVYYDAIK
acquisition.However
883
.Oligonucleotides
p.R158X
q33-34
c.4G
5259
D842V/Y/I
H6-complementing
C-γ1
N-SH2/protein
YYRkGGKg
PIK3CA-related
angioleiomyomas
His‐tagged
08041
CCAT
POU-homeo-domain
Allschwil
V1804DR
2.341
notpossible
mCherry
20-105
pCUB2
pcDNA3.1/Hygro
.Microsatellite
genomeCoverageBed
+3-42
41-43
11q13.4-q14.1
Growt
Settleman
ulti
HST
patients15,18,19
18,19,38–40
Yuseong-Gu
genomeFastaFiles
anti-lamin
beta-actin-specific
3240
astop
perk-positive
sorafenib.4-5
Anti-ubiquitin
C81
AGA→AGT
~8000
TK-luc
4Cc1
c-ablIt
CD135
c.2472C
AGGCCCTGGTAGCTCATCAT
Karapetis
KD-AKT-U87MG.ΔEGFR
fedratinib.32
Non-R882
11–deleted
p338
gefi
.Myristylated
120-123
Mo-MSV
cross-over
Neurotrophin-4
9.10
β-γ
GeneTeks
LLR
G377S
609053
800C
Allore
.FIP1L1-PDGFRA
NM_017617.3
leastin
5′-AAATACTGGGAGGAGGAGGAAGG-3′
MADH087
Well.diff
S260S
,15,34
β3-tubulin
chi-square
F-measure
prognosis.17
FLAG-HRP
J.N.
rs17222691
KU19
I258T
TRK-B
S9600207
IDHmutation
MKN-45
bleed-through
GACTTCGGCAGCTGCTCACACC
beta-Galactosidase
83-mer
normative
freeze-dried
profile44
Ultrafree-10
VCB–CODD
Isenmann
+/-1
STK17B
sam-
pathomechanistic
Sanità
Sprouty4.52
Microenvironment
17.The
slideFunctional
oligonucleotide-probe
Anti-FLAG
face-to-edge
µBcr
q11.2-12
0.87:1
.Amplimers
methanol-acetone
n=3/7
c-kit.Total
SCneo-containing
erlotinib.81
1.36-9.00
c-kit–transduced
-GCACGCTGGTTCTTCAAGGT-3
Histo-morphological
dapi
.Stratification
C10‡
9/27
SSC/
centromere-speci®c
,4
ULBP-1
anti-CD127
anti-FZR1
Dnmt3b
HD-0165
49-
2005-2006
mice18
Brca1Ko/Co
SQ/TQs
2593
5′-CTTGATGAGGGCTCCCATGTAGAGTGC-3′
StudiesDNA
Hif2a
.PIK3CB
30/31
BAF180-mutant
warranted.Receptor
|al
polycomb-like
ERFT357,526A
Epithelial-to-mesenchymal
β–mediated
HEC-50
S847D
mosaicism.5,7
Jia,1,2
region-depended
F409C
4-20
FGFR2-mutant
PK/PD/Efficacy
GNAS-V5
arelationship
Tasigna®
Medema
Iberia
Gly719Xaa+Ser768Ile
−860
Fukuzawa
nicolas.dumaz
AAUH
flightless-interacting
andTRP1
encodingonly
miR-451,18
shorterthan
NP-057890
281Phe
inflammation-mediated
VEGF-C/VEGFR-3
c.6938-3T
Y79
c-Med
E.R.A.
proteins.35,46-51
CD1-nude
PLX33977
15+
mail.xjtu.edu.cn
RK
Msh2p-specific
Brt
ESP
P95L-38
p.G731X
W-III
examina-tion
p.Ile533_Pro534del
cell-identity
P6.50
K218T
cellswas
D1-H2
.Pertinently
2415C
P2RX1
KRas4B
c.C3075T
Theilgaard-Monch
172,203
Vielh
effectors35
suberimidate
11pb
M-PER
equilibria
morphology20
postreplicative
reduction/loss
Gonen
dCRC
α7
.Charles
−770
/achaete-scute
t50
includingBRAF
Rictorpositive
278K
ljcrf.edu
ClustersCohortTAL/LMOTLXProliferativeImmaturep
E-SVP-Luc
PHZ-treated
569–583
MiGR1
ML257Raf-1
histology.1,2,5
stromally-contaminated
EI102del
Glu317
substratewith
GTP-GDP
vismodegib85
c.384G
vhlR200W/R200W
0,2,4,6
bronchoalveolar
Sos-Cat-catalyzed
Q1396R
PIwas
pan-STAT1
SI03246950
Biocarta
ERAP-140
plaque-forming
OX9
BGI
ABT-888
CTLA‐4
3910del7nt
5′-GAACTGGTTCATTCATCTCTATGG-3′
L1193
internalizing
±6
K646R
GGGGTAGTAAGTTTCCC
lnGl
Gadd45
SET1A/SET1B
SLC26A3
20–68
IMAGE:5267610
Wardemann
disease-predisposition
0.0112*
v6.11.41105
5′-CGTCTCCACAGACACATACTCC-3′
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole
46478
elsewhere.8
R445
SF3B1
previously.32
mice.14
Rex-1
1for
9188
therapy.Chemotherapy
aberrations7
FGFR1-8F1
D171N
cDNA:1006insG
CRAF/BRAF
PGBM19
arginine594
0.1M
MDM2-targeted
pcDNA3–T/P
11,29
anti-TTF-1
ClaIPstI
20,21
.3113
284-8989
ADC
platelet-peroxidase
p.Gln444fs
Raj
Pdcd11
flourescein-conjugated
5'-GATTGGCAGCCGCTGTAGAA-3'/5'-GGCAGAGCTCACCTCTATAG-3
canr
deoxyribose
9951
Siah
po0.05
pUC18-based
DQA1
Lys111
5a-l
Arg718His
Yesc
5′-CATAAATACCACAGAGGCCCACAGC-3′
0.5–8
34/87.2
angiomatoid
.GEF-H1
menin-expressing
M.SssI-methylated
F398A
NFKBIA/B
Bcr—Abl+
Lactacystein
βIII-tubulin-positive
50-fim
negative*
W-III-08T
alondside
1–141
NaCl
described,19–22
osteoclasts.29
12,14,15,24-26
NF00398
PDGFC
structures10,11
C/EBPA
M/51
T-500
U1
phospho-ATK
prIGF-II-l
levels.22
M003
NRAS6
relativeK
homodimers.13
immunocytological
ECD-
A11005
NPM1mut/WT1mut
5′-deletion
236-bp
59-AGCATTTGCAGTATAGAGCGT-39
hPMS1.9-12
.ERCC2
Staropoli
ontheir
leiomyomatosis–
CRISPR/Cas
C241S
1,768
reported.52
0.615WTMES
Sidhar
NM_152323
receptors35
M-phase
LR05
NULL-SUFFICIENT
cDNA13
.33–36
WT1–hUBC9
SCCO-017
mg/plate
153400
U2AF-independent
DNA.13
^496
V1155L
100T
1068–1369
preoplastic
arecomposed
R1050
catalytic-null
0.463773
IFN-y-treated
NM_008005
O2G
Tyr-720
MycS71W-expressing
R132Q
HPF.KIT
JIP-4
Asxl1fl/flTet2fl/fl
Mainz
I-Mutant-3.0
.Feldman
MEK/Raf
.Limiting
subdomain24
Impera
IGF2BP2
ATGGAAACGATGGGCTCAATGACGC-3′
25.4
Antigenix
29/290
–DOX
-/cDNA
L858R.17
TR-mediated
Ambion–Applied
20µl
allophycocyanin
GROW—School
p.F374Y
11qUPD
thalassaemia
.Dnmt3a-KO
pMIG/HahBRAF
22.3±2.6a
W392
PI3K/mTOR+MEK
TAP2
BICD1
CI=0.72–1.20
GIST.21,30
miR-19-mediated
anchorage−independent
Ig-IIIc
.IVM
Per403
SMURF2
V2006I/L
.Stereotactic
SK4100
E545K/E545G
Corisande
77951
p53-stimulated
.Pierre
R386
Avery4
Knobbe
.Normal
v-H-ras-transduced
oncewith
0.056
Biotech/Millipore
studies57,58
GRF/CDC25Mm
821
p21-ras
G177R
targets14
Venteicher
pointy-headed
Soker
ligand-membrane
Arg752
28–90
HBC
post-hormone-resistant
NM_006218
DUX4–CIC
Figure4D4D
SYT17
KIT/nucleusb
NCT01579994
RING/BARD1-binding
RB-SWI/SNF
EX18_EX21dele
aberrations,10
N233fsX28330
anti-Ubiquitin
S6-Ribosomal
9.95
dCNC-C
steroid-refractory
L23
Q938H
NF3b
alpha-carboxylate
High-performance
.S5F
A085
.609822
Hydroxyflutamide
pOP-Ires-GFP-Puro
.Histopathological
BWA39
193-206
NGF-unresponsive
transactivation.63These
AD2
.25020823
PT-23
-TCCAGTGCGTGCTCCTTTAG-3
Y553del
−1.99
∼14,000
tBHQ-treated
632-659
368A1
.BC
TGCCGCGGGC
insCT
ND1000
C61G–mCherry
mir30-flanking
light-microscopy
2XU
Weibel-Palade
TetraColor
=1×10−29
5-kb
FRK
CTCL20
2.1-kb
I263T
.deoxycytidine
S2-S2
Agafonov
S3.5-6
Ser28
Pise-Masison
5″CCG
3.5–6.0
nestle
RORγ
GSA
Zajkowicz
them.This
11q13-qter
neuro-behavioral
24/50
glandsDevelopmentAdenogenesisUterusMouse
Ontology-annotated
L469F
33–36
4/intron
N268
V67A
KSR2-stimulated
HEK-yellow
dodecamers
Kit-WT–
E127A
cancer–relevant
p.V447A
CE-MRI
18-bp
models156
Ile-Cδ
imatinib.32,33
kinase-associated
alysl
report8
melanomas9
C57BL/
FGFR2M391R-V5-pcDNA3.1
Z40
post–6
ineffective.8
—whereas
KIAA1033
0.6154
Identi
216-kb
0.54–0.92
presenilin–γ-secretase
Yayon
natstructmolbiol
−8.62
FTC
disrupted14
helicase/SANT-associated
alterations3–7
hDIS3D146N
XFE
ETS+
SATL1
A_51_P500984
apoptosis.6,7
idh1
4062
13/28
F394I/V
D769A/D769H/D769Y
0.0309
E7A
CRSP
A-549
7-10
J.W.T
2C11
H578Q
FLT3.2,47,48
Jeon
m/v
–FLI1
1408C3T
1/100th
Siteman
S5G
ng/ml
V1768
FGF1-induced
dual-phenotype
5c–d
Sox-related
A75P
intermediate-penetrance
G-CIMP—or
TCCTTTAATACAGAATATGGGTAAAGA
rads/min
14qA3
R26-LSL-Eyfp
pcDNA4c-NUT
FuIImEu1
Référence
studies1
Tecan
MET26-RP
a.l.
D20
Nusieve
barplots
metaplasia,34
Isocitrate
Gastroenterological
20–90
post-gefitinib
RHA
5'-ATC
81-3-5841-4859
TIS/FUS
FLAG-Elf3Δ173–241
p300-HA
N549
15-day-old
informed-consent
MLX
control–treated
.Transfused
white/white
red-orange-purple
R275Q
Ov44
ura4-D18
tumor/kidney
ot-
TOP2A
dsDNA
studies,6
P-Tyr-100/102
delT'6I
56bp
glandularity
.Anti-kinase
502-Tyr
1·0109
WT-KIT
A-sepharose
6003
–92
HMBS
_CDH1_
hypo-responsiveness
130-
A407S
430c
c.278insGAGTGCTG
C77Y
off-rates
FANCF
DKK
rs1048108
W1837X
TCGA-CJ-4887-01
Logistic-Regression
R93H
WM239A
P.E
Reedijk
Q207E
Thr41—Although
highly-vascularized
P289R
NPHS2
.EC
Raf-1RBD
1234
Anti-P53
Bcl2–immunoglobulin
NHUC.12
BRAF→AGK
oncogene.24
HuEx-1_0-st-v2.na30.hg19.probeset.csv
MM.58
V127I
iinding
.Indel
inhibitor—representing
fibrovascular
I–dependent
d'Hebron
0.0114
E2F-independent
rAAV-mediated
Hemsath
Conjoint
pHUSH-Lenti-GFP
high-threshold
FL1-H
pGL2pro
HER‐2‐positive
NFL-SH2-SH2
well,11
.Papillomaviruses
c.743G
HumVar
FAST1
.Paired-end
renaturation
GSHM
4691S
W305S
Pixera
10.00
dataimplya
Prokopcova
11.5
pre–plasma
SNPs3Dc
13/50
DCS-28
L199
Cormier-Daire9,10,11
Ask1-mediated
ctcggatgagatgctgggga
cccaataag
E223K
dypraxia
streptavidin-tagged
blasto­cysts
11-15
p33
.OX40
.Linkou
non-tagged
fluidigm
succination
time-intensive
expressionTransfections
-600
IFN-α-treated
.1111T
.H874Y-mediated
Ara-C.
PA2G4P4
nonAmsterdam
3,174
-Pi
.mutational
MSB
'knocked-in
CLB-GE
minigene-specific
mutants–transformed
D-N-I809
55Â°C.and
3.03
pre-ovulatory
1.1kb
CMM65
.E.g
SpectrumOrange
U2af1l4
Mgat2
G248P
stimutation
deletion/LOH
rhombomeres
2588
NPM1+/−
F3820
D1713
RPL0
5′-CCTCCTCTCCTTCTTCCCCATTACCC-3′
LGsGAFGeVYeGtavDILgvGsGeikVAVKtLKkgstDqeKiEF1KEAhLMskF-nHpNILK*ILGVClne-PqyIILElMegGDLltYLR-karm
Mast-cell
Z=−1.87
originated.13
therapies.5
DHX16
therapy.23
www.jhc.org
work1
p70/p85
0.405
CD19Cre/+Trp53L/L
G1728C
.Interruption
systemic-onset
microinjections
docosahexaenoic
Bre-1
nihms646437t21.jpg
6×10−13
.Beltinger
PDGF/VEGF
P30L
TKI-progressive
NC4
.WGS
G-tube
triosephosphate
lymphomas7
.00467
livermetastasis
FGFR2M391R-V5
5036
BGJ-398
color-coded
5′-CGCTTACTGAGAACCGCGTGCTTCAGAACTCTAGG-3′
CRF-immunopositive
popupTable
metaplasia32
cross‐link
D65E+GAP
levels11
~GEFs
5′near
R339I
93:1
YEVQWKVVEEI
K23R
assays30
.20,22
isomerization
E-box2
CDK4andp53
4185
orderded
V560G/D816V
CRISPR-Cas9-directed
monoubiquitination18
F/6·9
nArgGl
DM300
dpc
TGC-G719C
R59L
_105.1
0.36*genotype
cancer128,129
GHL
ALL-
03341
nihms774093f9.jpg
trypsine
R-TSC2.ex30
desulfinated
RIP,27
8040
FIP1L1-PDGFRA/wt
.856delG
yAspl
intronexon
R392W
Determination—Crystallization
554-5591
13/48
ABC-DLBCL
RP11-927H16/RP11-484L21
1085
cancer.Pancreatic
1-843
expression7
JAK1/2
.PSA
STO
repair15
Anti-ERF
..FIKSNKHRMIM.FLDELGNVPELP
.0024
run-on
372–509
5g
BCR-ABL1.86
GPRC5A
extentthan
.QA
1883
proto-oncogene14,16
0.552
non-infected
DA870830
Spectrometric
e13
3by
T4*
SDA-like
16G
geneticinstability
Data.Pathologic
Bu¨
5′-ttttctaaaagtgggtgggg-3′
anti-AU1
alphaviral
0.3-0.7
L\
L755W
middot
I843-S847delinsH
-y
.Mucosal
tase-PCR
mMammonium
T59
S218D+S222D
TGFb1
10/3
receptor.9
NP_001106174.1
ligand.22
types.13
4E-BP1-GST
-39
drug-acquired
Economopoulos
Androgen-dependent
–73.0
CD140A
DelG106
My5007
ACACAGACTFGTCCTACTGCC
GSE57380
structuralanalysis
1–292
BRCA2-BRC
GBM-Os
region-speci®c
small-core
1992–2003
M31-L
grand-father
.SU11274-treated
//horfdb.dfci.harvard.edu
MCF-10A.19
Ten-year
1653.In
trials.8,9
S215C
overarching
rearMolecular
FM3
1.EGFR
MSH2/MSH6
αG
FANCI
A_51_P285027
KIT,13
p.Arg172Thr
vemurafenib/PLX4720
Lsk1
dyad
58–62
Ac-pVLhFLm
R1622Q
PI-3K/Akt
anti-pPRAS40
non-E2
eicosanoids
CC/CG
APC-mutated
Innocenti
jheierhorst
lme4
.Sequestration
AAUACGGGUA
heterogenity
1.20–2.19
14,20,27,28
amphotericin
pCyclinE-Luc
7–23
tri-methylated
300263
1.009
toexpress
Ba/F3-transfected
2–5×109
sequences.21
HA-immunoreactive
Ex1.4
CycECAT
centromericprobe
SH6gene
lipid-filled
PK-CA91-1048
Glu537
solvent‐exposed
Gefitinib-resistant
Bio-11-CTP
Distler
AAFF
-reChIP
guanine/
16,419
CRE-binding
CFU-GEMM–derived
withsimilar
11:24:40
RNF213-SLC26A11
mutations.57,64
JNK/p38
RAEB-
E3002K
CAGp
setting8
activity-mediated
PDGFRB30,45-47
.\J\..
mice.56
hsa04151
0/68
Tryptoneper
HA-PTEN
YLP
cartoon-and-stick
Flag-MKK4
Glu422X
L597-
non-astrocytic
4p15.3
FoxA1-positive
N.USMC
Grb2/Shc/IRS1–2/FRS2/
HELICc
TC1RG1
2.2–2.9
compound-1
S3Ee3
79.7–2.4
7A-B
non-nociceptive
the69-kDa
anti-phospho-specific
equilibrium,42
Growth-suppressive
III-generated
cancer3,4
c-Kit-
E78
rs150498754
c.2149G
cancer,13–15
56/M
kDa19
pRCCs
40–44
10q23
GFR
.Minimum
4493C→A
anti-aurora2
80.4
need68
.PowerPoint
Non-quantitative
GTPase‐activating
oxidation/putative
AdoMet
non-Asians
CAAGGTGGACAACCTGACCT
Cbl-70Z–mediated
P685L
prometa/metaphase.41
S201del
GenePattern
widen
1938
function.20
CDKN2A/2B
strking
101.5
SV40-
Pilla
0.450
chr4:1976590
MasterMix
β-Tubulin
9208
Sypro
T7-Btk
oro
HLA-A0201
5'-CCTTGCATGAGGATACACCA-3'and
cA-GVGD
Bannayan-Zonana
DSC3
ES4
1201–1202
835
Raf-inhibitors
pathway1
PCA4
.Marshall
T325
AB1442
reasonsb
K-17
VHL50
CRM1/exportin
HBE4
hamartin-C
39–52
pGL4-CD79A-TSS14
Glode
filesOptions
466-8550
.Change
Cul2-Rbx1
ERCC1-p.Leu230Pro-XPF
reported47
GalNAc
ReadyMix
60.2∗
.80
1979-
.PDGF-AB
p.G13-mutated
deformities25
growth-arrest
empty-vector–expressing
Ha-Ras/RaplB
monoubiquitylation
thatmismatch
acampomelia
Wat190
HT29
GATA3-R367L
BAP1.18,21
5–7-fold
InStat
0.0034
cDNA31
TGFbRII
._2589+
TGF-β–like
ultrasound–guided
aect
GATTGGCCGCGAAGTTCCAG
1,11-13
inhibitor-protein
c-Met-H466
PCDHA6
cDNA16
PNMT
defect.11
G12R/D38N
agonist-
GSE75997
3058
Bomholdtgard
.In-depth
Gln313
coords=AA
interquartile
56125
R5
p=6.2
BioMax-MR
Irf8
Longitudinal
GU/AG
Casodex
Panther34
8645
OSCC/ESCC
Bre-Luc
9.985524125
n=99
BamHI/EagI
KHzP04
MCP
CMR
2014a
Boecker
B.A.J.P.
doi:10.1038/ng.955
265C
Ile87Ile
H3K9-specific
MADH4/Smad4
B-ALLa
851
NM_021009.5
previously.22,27,28
V774insNPH
.S10A
K359E
pcDNA3-PBF-HA
Analytical/Synthesis
Promoter/50UTR
p16Ink4a/p14Arf
Pietenpol
Q5/50
eosinophilia.14
.Targeting
HES-1
singlestrand
and2B
1.04∼1.84
c.127C
iiic
2-μm
KRAS2-G12A
5/31
2-agent
P183H
MAPK/SAPK
4ZF/MSCV
theAML1/ETO
β-cell-specific
polyendocrinopathy
down-regulatory
95.36-95.85
SMARCB1/SNF5
deWned
GST-ETV6
Immunophenotypically
Reiling
IVF.6
21160301–22679000NM_001195132NM_000077NM_058197NM_004936
p416CYCNLexAcyclin
v03
Brelated
5′-gaatcctgatctgactggcttatg-3′
Takayasu
ab8895
≈1674
11/92
α-acetyl-H4
Kras12D
31-2140-000
T574_R586
Radiofrequency
N114S
48,68-
-2-HG
S1.2
MultiSite-Directed
MOHT
EGFR–PURB—that
KDM5/JARID
position,25
27/32
2-17
mutation-rich
oligo-nucleotides
Antigen-antibody
toxin
trk4l
RP11-168A11
pleural-effusion
pcDNA3.1+
Mural
NF1_00322
15R
RA-induced
translocations—for
Gpa33+/+
*90
P152L
G12P
13.1-46.6
thiol-active
acid–Schiff
CIAO-1
16MMLV
S575F
sulfomucin-producing
.Without
lymphomas.8
,205
54/55
tetramers
pathogenesis.28
mTORE2014K
24–30
methylation-status
proinflammatory
Dose–response
Rs1801516
sixbase-pairdeletion
123–125
89-076
Aylesbury
Enomoto
flutamide103
hyrazinoimine
CSSDNEYFYVDFREYEYDLK
OX40L-
LOH−
2,153
.Credibility
E139D
degradation.36
Val560Glu
KITWT
KIT-D816V-Y568
32D/wt-FLT3
S1613G/L1407P
90°C
pCAG-wtHER2-IN
.results
EP2
W263C
motivate
epigenotype
rearrangement.5
W5g
pathway,43
flag-CBFβ
467
.BrieXy
ÃŸ1
MPLWT-expressing
nonisotopic
conformation40
7,10,11,13
c.419G
R515T
toxico-kinetic
BIBF1120
1,508.6
/12-O-tetradecanoylphorbol-13-acetate
.Spo11
.Judging
Stivarga®
13AS
3×106
NUP98-HOXA9-transformed
ERÃŸare
biochemicalconsequences
ahyaline
c.682-12delT
A→C
WHIM18
400-bp
NP_060233.3
4,24
disease-specific
MN89
types4,16
270–315
non-involving
sc-152
basis.16
backbone38
2502
nonphysiologicallevels
embryos.Figure
HM450
1.747
Société
cell-rosetting
REDD1-TSC2–mediated
1140
werecompletely
hypogonadotropic
genetic-clinical
CD2821
non-V599E
22166
under-represents
complex109
GOLGA518
sulfotransferase
CAAAGA
Fig.2E
.Experiments
930-fold
DMS114
Kirkbride
immunocytology
7/52
3600
Myc-FIP1L1
Runx3−/−
n/N
K97
GST-α-Fbxw7R479Q
IVS–8
.MKP-2−/−
1084b
RN18S1
treatment.13
tags/expected
KLH-conjugated
4.0,19
rearrangeable
class2
0.9347
,52
C28
∼9.0
Co2+
c.32_33ins9-32
1464–1843
CRYM
Lin−Sca1+cKit+
Branchburg
leukoplakia
Isochromosome
DCC-2036
p′′c
TGTTGCTGCAGATCCGTGGGCGT
non-diseased
to0.01
S637
Oligomerization
2IMT
P-40-2
guanylnucleotide-exchange
Fusobacterium
5V-untranslated
D425MED
17q11.2-located
J815
spermatogonia
.20With
ds17
OSA
3C
c.1226_1227delAG
Trk-expressing
α-KG–dependent
p85ni
SFXN5
868.
experts.19,49
serine–threonine-specific
HA-tag-fused
unknown.In
//cbio.mskcc.org/cancergenomics/tcga/brca_tcga
CML.In
TGF-b-responsive
factors.10,11
C186S
80–105
cancer‐related
sc-338
pools43
SOCS7
Cloos
p.Q61R-mutated
minisatellite
multifariously
ATM-deficient
Fig.5A.5A
GGTGTGTGAGACGTTGACTGAGTG
retrocaval
nephrotoxicity
p12
0.665
.11Moreover
H3K18Ac
super-high-pressure
97/108
arrestand
stimulus-independent
iPOND
CDK-inhibitory
levels.A
structure38
13/47
pan-Ras
.deluge
Thymidine-arrested
RK3E-RAS
c.466A
Cys24
iTris
H101Q
EWSR1-FLI1
.Brinkmann
stabilizing.45
Gly67
CHRM2
F341
lowbar
W719*
R2441Q
Serum/glucocorticoid
ZM-harboring
Over-all
LYS2
nonhybridized
prognosis2
Fas/APO-1
BLA
HCM
BAT.IOB
SSC-0.1
functions.Functional
PerfectHyb
intentionally
713-1018
0.2071
forMsh6p
L96R
Fattaey
EZAF
P=0.011
prognosis156
W368
ELK
0.5.5
previously.15,16
interleukin-12p70
analyses.27
GSE63569
respectively.10
non-isogenic
redundantly.8
monitored179
184.9
ERG-TLS/FUS
kcal/mol28
D220
anadvanced
p.C381A
.Fordetection
α-GAL4
HindIIISalI
C240Y
mBAF
P334H
tumors2
Enhancer-Binding
-ATCAGCAGCGTGCACTACTC-3
~4-fold
NCT01962532
SIFT,31
frequencies8,9
K753M
decapped
ERCC2-WT
MEK1–GFP
E562V
upper-quarter
U2AF1-specific
AMPure®
pRK-5
Misao
H2O2.25
Strumberg
IFN-g–
paraproteinemia.7–9
+194
Investigative
DeltaDeltaEMM=-1.27
phospho-RB-specific
PtenΔ/Δ+KIN193
NA931
MG-B2GFPΔ2889
E295K
1.03–3.83
RAF1-specific
Investigational
Mdmx-infected
33,34,35,36
c.3028G
TGFBR1-K232R
.S462
monophlangism
Turenchalk
.KTLKLGTMMPEAFLQEAQI
P≤0.01
U87MG.L
radiosensitizer
Herceptin
pLTR-SA
G191R
L1204F
ATGAGCCCCAGCCTTCTCCAT
aminoethyl-aminocaproyl-dihydrocinnamoyl
βL
technology15
NCT00790426
CBP/p300-induced
319–543
AzamiGreen–positive
5,4
D'Urso
51°C
.a–c
TBL1XR1–RET
//www.lovd.nl/
1,373
1677.8
MN10
promoters/insulators
processing/activation
+94
Studies—Human
TEL-AML1
1579–1583
13,43,44,46,60
0.00–0.06
pGL3–ERE1–ERE2
hepatocarcinomas
SpeI–PstI
3130xL
2-positive
log-ratio
miR-96-mediated
formation.Unable
PrQ
Tripsianes
17/26
mutantp53
diarrhea.27
251–533
sc67327
IFAR
5′-CACAGCCCAAGATAGTTAAGT-3′
FEIEKLKPED..
EGR-1/WT1
ED75
FDA=Food
Hartsough
thalidomide
RasGRP4
Nonchoroidal
VICC-MEL0287
486_884del
polyploidization.45,46
anti-YAP1
repair.These
TRIM33-RET
5'-TCCAGGAAGTCAAGCAAGCAGGTC-3
Euro-Caucasians
cofilin/
FOXK2.63–65
drug-susceptibility
much-heralded
decay3
pcBRCA1-385
pBS4
V252G
P79750
characteristics.Distinct
5′-GGAGTTTCCTGTTTCCTGTTCGGCGCCCG-3′
LR08-252
.Assembly
59-CCTCCCGCGCTGGGGTATT-39
PBS
E-26
009775
GeneraMedix
.Cross-talking
anti­
pDsRed2-C1
789–792
oncogenesis.1-3
0.042
RP11-699M19
.Chung
-patch
R795W
G565R
tumstatin
L/P
5:06:02
/dic
0.269876487
Ba/F3-cell
Valentijn
36,608
FBXW7+p16
pRC
charcoalstripped
.S7J
SN1-type
1.01–1.07
.PATZ1
3.7–33
GAB-1
BseRI
SMARCA4-
auto-inactivation
Cells…
modulation/DNA
6.5-129
contrast,2
0.071-0.11
eTh
bisaryl-thiohydantoin
mTOR-
laboratory-based
affected.9
IFOM
as-
IVS27b-2A
STS-specific
Glandular
.VHL
395-fold
ETV5b
synaptophysin
method,30
140–149
840-bp
K561
Prolactinomas
IDLSQV
beta2-m
TICs38
4980–4985
G279A
Imagene
TGGGAA
.Dynamic
TCCTCAGCACTCTCTCCAAT
Mycinteracting
MG-B2GFPΔ3263–3418
Immpress
reports23,30–32
non‐existent.16
NP_361014
Met-1775
phospho-Tyr-742
442-LUAD
endogastroduodenoscopy
AB-1100
vessels.2
24654
lectin-carbohydrate
Insulinoma
Lifetime/cumulative
1–443
SH3YL1
.Anti-STAT5
298-10
exonskipping
chracterized
tandemly
CTGGACTGGGCACTCTTGTC
database.10
sc-168
EBUS-TBNA
lethality.Sos1+/EK
Prochondrogenic
8-16
keratinized
pan-p85-null
pph
2ERE
K134
0.0103
40-100
Pavillon
62,480
GM2.1
60-cj
EGAN00001001824
PAK1-specific
ampli
andXFKH1
3-μm
compar
GSK2118436–resistant
LIMK1/2
3p22–23
Y541N
changes/amplification
PDGFA46
spinocerebellar
homeostasis,39
SMAD2/3-dependent
TCGA-A4-7828-01
33*
BRCA1-Deficient
Jeyaprakash
R392G
.Lanyi
+/Severe
PCDHB4
His6-Ha-Ras
c.4135-4136delCT
.Evidences
.BAF200
Ellwood-Yen
LPP
112X
12.77±0.51
pIS-ERα-1-5′
.CHD
5ng/ml
Vismione
A/DNA
KPT-185/330
fragmentsused
Lysine-to-methionine
HA-W-PDGFRA
8/12
types18
p300+/−
JB10086
R528C
hsa-mir-613
multiclinic
~CycECAT
5′-ATCCGCGTTCTCCCCATTTT-3′
5-GAGCCTGGTGGTCTAGGATG-3
ECOG-PS
c.314A
interpretationof
.3284
NFKB2-ROS1
seven—albeit
9-10
H4-PDGFRβ
.Systemic
1/17
α-Msh
cathep
D323H
.Nomenclature
n=108
c.613_617del
Muse®
Na2
3·8–40·8
GAPDH-Hs99999905_m1
JAI
III-product
pan-RB
patients.22–29
2/335
Brauch
NCT02517892
D−/−
rucaparib-resistant
wu7/wu4
www.myriad.com
A.O
R112C
pCDGATA-2
H94
1B-C
sheep-anti-mouse
.MYD88L265P-driven
D17S250
shPten-
spatial/
.One-thousand-and-seven
79-118
≫1
F876L
MPTP
ssDNA-cellulose
.8,15
.Lymphocyte
CDB
0.11-fold
_3931del-AAAGA
¸10
fibroblast-derived
SFA19
Puromycin
Akt2KD
5×-myc-tagged
water-box
vivo47
RP11-80F22
R2691C
W557_K558
10.1182/blood-2008-12-190934
R465M
Kyosai
p-p44/42
Flt3.19
HLRCC-associated
A=33.8
Keap1-null
diseasefree
genome-level
5′-primer
S1018
v6.4
.Brca2
CD-20
TSPs/GRPs
2B–E
-logKav
VX-9a
misclassification
4.270
ImageStream
22/62.9
C634R/D898V
cannot36
CNAT
.6,31,35,37,38
TER119hiCD71hi-expressing
≈97
a-chains
197/329
Raft-binding
HumArray3.2
CRA
U-87-MGa
Sulforhodamine
TRiC/CCT-interacting
status75
phosho-degron
GTGAACCCTCAGCCAATCAG
Inpp4bΔ
control.latter
XPD-variants
L536P
BRCA1-Met-1
counterparts.17
al,17
4765
misclassifying
gw
high-grade/muscle-invasive
Hawai-
mRNA/proteins
4μL
49–114
J.-P.P
//preview.ncbi.nlm.nih.gov/gene/
Leon-Rot
1.5–98.5
betweenthe
AD1
LexA-based
Ely
part,15
a6
Mm01233143_m1
Neh4
pAkt/total
|/Σ
D.R.H.
pCMV-APC1309Δ
MLH1-P654L
581C
liquid-to-bead
theTCF7L2
TMPRSS5
EPHA1–7
05/01
pOZN
INPP4B-depleted
c.5382insC
paired-end
668.3
1.5-2.8
PAMDRM
LY294002
Controls*
S2–4
non-impactful
K128M
HA-Shp2
hemangioendotheliomas
siBCOR
flag-wtBD12
1H-pyrrol
CRE-U1-CGCCTCAGGGATGGCTT
L309P
//www.uniprot.org/
3820delCATGCAGACTC
Ultravision
W222
MRE11/RAD50
LC703
non-discriminators
1⇓
.Roman
G464E
VEGFR2-dependent
5/29
RXXpS
*Identical
coastline
Rsk-1
I616
S653C
ErbB2.16-19
BIO-101
P262H
Superdex-
cancers14
G1706AF
Gemin3/DP103
c.305G
.Nesbit
4-tim
neratinib-sensitizing
1.00abnormal
N113D
Gö6976
sacce
experimentusing
c.1088insAG
Himac
Histology-independent
PAK
c.2344+1G
.23,24
Leveillard
Awoniyi
GlcNAcylation
1.0-5.7
pBSII
CRCL
1,246–1,251
10−24
121/229
TCATCCAGTCTCTGTACCTCAC
liquid-scintillation
pRS425GALMEK1
91.28
trypsinizing
2912
.08–.17
H209
IC25
Src-driven
growth/tumorigenicity
maculopapular
nonrenal
control-transfected
GCTA
receptor—with
100-mile
variations.1
HNPCC-associated
Dapi
multilabel
Krummel
Yanagiya
0.1009
ubiquitinates
LMM
cyclin-selective
biexponential
cascade.p85α
recognised.7
43,6
ASXL1-WT–
KAR300C
−12.5
Promoter-specific
pTK-cSPAP
1mg/mL
q23–24
nonaneuploid
KIF5B-ALK
Westphalen
non-Sardinian
3E-F
HeLa-specific
S637Q
293E
ng/μlin
low-frequency––by
V2330I
BMP7
Akker
JRB
neoadjuvant-naïve
DNEstatus
p85a/p110
NF-2
Bessho
4a–c
leiomyomatosis.27
K-rasG12V-IRES-Bgeo-expressing
microconcentrator
IMCE/MEF
amine-containing
BrookCarter
embryo41
2800
O6-methylguanine-DNA
Sample1
c.259C4T
8q13
D1-dependent
'DNA
thiamine-repressed
Ribatti
β-catenin-stimulated
I618M
L184P
P-labeled
expression84
NAFLD
indatabases
.TPR-MET-BaF3
B.P.
αˆi
Selleckchem
MED12-Cyclin
di-methylsulfoxide
adenocarcinoma-associated
.Aurora1
IRF-2
spindle/dendritic
MeWo
c.3036_3039del4
p.Val2985GlyfsX4
67.68
Protein-Truncating
G2-to-M
207–289
described.37
Y340
GAP/NF-1
inWiley
Japan.Isolation
lymphotrophic
Nestle
gene.51
Armadillo
BglII-Aor51HI
6,000
.Roge
S8A
F-helix
359-379
.51
loop–activation
41,607
R505Q2
0291
p-FRS2-α
F1775
*Nonspecific
TRAILR1
Ser217/Ser221
MAC1+F4/80+
.PtdIns
alpha-thalassemia/mental
gamma-radiation
neo-vascularization
lyophilized
Krt8
.Coverslips
Figure4C4C–4D
PTP-catalyzed
hypermobile
membranes19
non‑responsive
Arg80Pro
adenocanthomas
PCDHA13
TGCCATTCCGGAGGAGGTGT
6-4
API-2
progression.24
HER2activity
IHC-based
3p-
CCT-1γ
microRNAs
NR27
56772417
TCATTCACTCATTCATTCCCTCTC
excluded.12
.TPR-MET
206.7
Guruprasad
¡
p=∑n=k463
system.12
580/809
5′-CCCAAGGAGGCGGTCACCG-3′
receiver-operator
90kd
Brca1Delta
2003–2005
hTCF
vivo.3
nM.We
2.2-kb
Flow-FISH
5′-GACCGGCTCTCAACAAGGTTAT-3′
RFC-140
R882L
.Monolayer
Alapetite
Mdm2-mediated
entero-pancreatic
R68
set4
homodimers.11,12In
76.7
Src-Y530F
Nikonova
.Peter
PMA-Iono
102a
c.302-3C
.Necropsies
Melchionna
Σ|Fobs
TKI-mediated
IDL
immunotherapies.The
2174
.S5a
Fbxw7fl
mMβ-mercaptoethanol
BaseCall
HMCLs.8
blue–black
TMPRSS2–ERG
S2.Figure
1/316
'safety
protocol-defined
genome-editing
Fifty-percent
c.1410-1650_1558+4426del
855R
MFX-2000
AR-V7/AR3
D81Y
'MEK
493A
ENST00000288135
.Brodeur
ST2
pIRES2
-GCGGATCCGTAGTGGCTGTGGGGGAT-3
21288
VHL-competent
Ade+
leukemia-bearing
immunoprecipirated
NHU-pool
benzyloxycarbonyl-Leu-Leu-Leu-aldehyde
LC3A-II
MedKoo
Biotin-conjugated
mc-Myc
E479
SNF-related
mRNAs/shRNAs
HLH-mediated
CDK1/2
IVAC
30–40-min
Rothfield
0.074
NMC1
43–51
FcγRI
AKV
tumorigenlcity
16,23,24
I156V
R337S
scintillation
1.9–5.7
growth.40,41
A/Rai
IHA
sulfoxide/Polybrene
5′-TTCTTCTTGAGGATCGCGACCGCCCTGCGGC-3′
EBF1-PDGFRB–rearranged
PolyPhen32
.MutLα
204.
TPβ
p.G12V-mutated
JBC1395546
p.D70N
1495–1496
gastroesophageal
NBS1.24
CCGAAGTCAGTTCCTTGTGG
Cirak
Infantil
1·2–14
−3.81
CUL3B
BsrGI
ins=insertion
sequence—two
257E19
ERCC1
phenotypeswere
LSRERVFTEERARFYGAEIVSALEYLHS-RDVVYR
.PS
231/232
p53-wild
vivo—indeed
mNET1
-GACTCTCTTGCATTAGGG-30
0250-7005/2006
pKH348-transfected
MutS-DNA
neurons.10
M12
VHL2_1F
PT3000
RCC.2
473
delLeu747_
DYSMY
L437F
Berverly
APCmin
ACGAGTGCGT
ESFTs
157K
1798insTAC
Matoskova
AEC
12-nucleotide
Tff3
sensitive11
PC4588
.Anti-B220
40-kilodalton
1,280–3,100
Tyr334
hemi-methylated
media.19
Shc-like
10.3amp
Novelc.3971C
19,20
RasVal12-3T3
NAC1
23–30
p.S252W
.Consent
Hs380463
poly-HEMA-coated
hydrolysis5
Jones10,11
6-carboxyfluorescein
control.133
72-3/4
kg/mo
Q-Gene
Imatinib-responsive
pT202
NCT00939770
NHC
GACACAGTTCCTAAGAACGCCAAC
.Activator
multi-functions
III19
125b
59-CGGGACAAAGCAAATGGAAG-39
AAACACCTCCACCACCTCCT
values.Prognostic
adolescents.1
Na3V04
AZD9496-treated
p≤4.0e7
q3
Gateway®
Bacille
2226del3516insCATTCTCTTTGAAAA
2173
pY42S
247insH
cancer17
.LXSN
0.996
57.03
!
PARP
genes.26
motesanib-treated
5′-ACTAGAAGGCACAGTCGA-GG-3′
mlst8
malignancies25
612110
described17
Retrognathia
patients.14
pCB6p53mtR209T
124/
metastasis10
others32–34
XII
−215
91:1283-1284
BD-plasmid
au0
Yodogawa-ku
phospholipid-dependent
pol
1270-fold
Karytoype
rate53
glycogen51
expression.Tumor
Me9923P
nt−42
IPT/TIG
IVS3−G
KIAA1279
sex-ratio
heart/body
half-solid
NF00358
–1,077
pathway-mutated
sequences.37
Fig7D
anti-FAT1
DyLight
|/∑hkl|Fobs
S-score
GI:17557914
spliceforms
65330
+/Mod
etoposide,42
SirT1
wereidentified
CCNE
prehybdridization
CMV-renilla
CTL‐induced
0.69–2.20
Bioulac-Sage
07-689
p.E705K
Y806C/E
biotin-tagged
111900000
cytokine-dependence
.9A6A
ELD
R729W
Myc-XPLN
-2HG-producing
c-Kit-enriched
osteoblasts102
Co4/5
.Herman,4
Maniatis
Instat+
CGTAGTGC-3
sinceproliferation
VUS,4
pneumonocyte
SignalingBecause
SD-L
≥198
elements—
AC-GFP
LR13–110
1Exon-specific
Fzr1lox/lox
Plexin
deleterious.30
HCC1171
K159
R1511W
domain-containing
RP11-470M17
antioxidant-related
phosphate-labeled
p21-containing
RAC-1-mediated
MSH6-P1087T
997x
crest,84
HGG38,39
Universitaire
Condeelis
200-fold
stress.50,51
pS-p53-transfected
169–198
HER2‐dependent
40×/0.75
.332
positionb
Angiopoietin-2
responses3
drug-adaptive
MKK4/JNK
presumptively
AC-3′
Igμ
crosstalk/feedback
antiapoptosis.2
light–dark
2Af
cross-comparison
0.7.5a
PHYT
5′-GGAACCTCTCATTCAACCGCC-3′
R470C
Blencowe
Triplex-DNA
Subunits—In
disease.30
phospho-Ser10
.Asn71Ser
nononcogenes
hSWI/SNF-B
bcl-xl
PEBP2/CBF.2
g.61719472C
.8A
Del-4
ligand-4
alÃ-elewould
NP_000170.1
hypervariable
×10−59
.L770
P493S
M2iI7EF/M2i8BR
LEF127
rare,5
G558X
ERBB3-wild
P,0.001
microenviroment
Organomegaly
.Product
5,11,12,13
Irino
waspurchased
Scoles
glycation
R348X
C176W
SCCs.Figure
PHLPP2
p53-DNA-binding
BioCoat™
1,265
16,34
5′-TGAGCCGCCTGAGGTTG
AJFL
VÃŒIA2-ERETK
.EGFR-KDD
​Figure
tunicamycin-treated
Bohring–Opitz
SUP-M2AR500
20-micron
resistance.31
Figure8C8C
309G
anti-Myc-tag
models.5,6
A303/K304
secretine
.SNVs/INDELs
PLC34
post-tansfection
UCSC.hg19
AdenoSqCC
Registry2
85,86
4q21
HR,27
pathway,69
176876
withoutglycerol
step-up
v-'TeS
S3C-D
lymphoma2
ke
26-amino-acid-long
pathways49
intermingling
c.5117G
Shuin
n=180
p\i
unelectrified
methylation-derived
electrofusion
neoplasm.33
FADD/MORT1
GC-MS
Ma-Mel-
M2004
46,47
levels2
Cryptosporidium
aminoacidregion
less‐soluble
Novex®
207
SC-His-Lys
.Morrison
p=0.037
DNFBWX7
uÃ–U'â€¢H
000/year
957
pMKIT-Neo
6XP
Theseresistance
∼40–50
Mo-MDSC
SRMA33
DOP-PCR
9/74
TCCCATTTGTGATCATAAGG
14/71
CXorf36
migration138
83
neo-adjuvant
agranular
5′-GTAAAACGACGGCCAGT-3′
≈11
86:929-939
footpad
.Topology
AATTGTTCCCCCAATTGACA
ALL-related
PDGF-B-expressing
BL41_HAEATOPOIE…
g.18760–18769
p16L
.Hamartomatous
SHP2/G464A
R-factor
97–7
characterizedthe
non-FGFR2
T205A-Fbw7
D20Z1
7192
0.00768
40py
anti-rabbit
G574R
LDI-PCR
non-blast
102/188
72/49
CTGCCCATCATCAT
ctactccggaccttacggggacatgcg
family.1
12.97
Petrides
14,16,17,19,20
NM_008522
.Polyp
10-2
3429
anti-PDK1
MODY3-associated
−3.31
5′-AAGACCCAAGCTGCCTGAC-3′
Arg-209
D16S3121-
5'-TTGGGAATTTCGAAGTAGAG-3
AA491104
CTCCTGATGGTAGGCGAAGGTGCA
P=0.82
coreceptor
gsea
c.5277+48_5277+59dup12
.Isotopic
c.1978C
1.181–4.159
Estrogen-Independent
PI3K–AKT
D.c
non–BCR-ABL1-like
Lamlum
TableTable2,2
non-inhibitor
oftumor-derived
RNAqueous-Micro
blunt-ended
U87MG.i
1OPK
R258S
previously.20,21
50-µL
known/putative
v3.97–4.0.0
lys2/lys2
−5.23
R−
S4T
p.R1763X
GENEWIZ
Tyr-674
differentiation14
Oncologie
Polymer-Refine
P-value=0.001
multi-faced
anti-PALB2
sh991
PYliHdiLLqDtnesWRnlLS
0.5-cm
activities.27
double-fluorescence
tgccgctgctcgttgtttt
sh558
pCDH-MCS1-EF1-GFP
H920
decorrelated
phosphothreonine/tyrosine
SI..
FT4
KrasG12D.Smad4−/−
bZip
2p15
LCEWAV
CBL-C384R
6with
SDS-4
20.09
ThermoScientific
anti-Rb
KFCfl
484
HPV-40
twice-per-week
Cajal.5
VHL-patients
per-gene
P-S/S
cancerassociation
5′-GGGCTTTAGAAATAGAGAATGCTG-3′
pathway.11
MYO1F
seen132
p=0.127
.Effective
study3
JAB-sensitive
AdTRE
SQCCs22
Golgi-remodeled
IgG4
re-escalate
developmentof
eva.wardelmann
1T32DE019096
RRPRSPAKLSATYPS
RPN4201
p.A1889V
hearts.Altered
WW23∶S7PY
10-15
identified.Signaling
DeMayo-Lydon
ectodomains21
L597S
e011
Bosco-Clément
.Adenylated
enzymes/proteins.Because
2.083
g_rms
cytomation
p.Ser154Phe
deubiquitylation
Bcl2.29
//..S
phase-dense
preinvasive
pseudochromatogram
K175-D176del
/highwire/markup/42193/expansion
Truninger
mutant-PDGFRA-expressing
.RAF
ACCAGGGAG
NOESY-HSQC
2924
actgagga
day-old
humanSRY
RPE-labeled
ourprevious
446.90
inhomogeneous
800–1000
phospho-Tyr719-KIT
family-related
3-aminopropyl
CGCTCCAGCC
others.17,18,56,57
393KB
in¯uences
3846
15/3,376
His68
Keap1C23Y
transduc-
osteosarcoma–derived
hypersensitivity.3
86.96
73K
modification/disappearance
cytoplasmic/nuclear
Protein/water
7305
three-way
Onecut1
V133fsdelGGTCGAT
Barbash
2184
GCCTACACCATTTTTGCATGT
0.713
WT-WT
Ser537
cyclooxygenase-1
1938SRYP
4,18
K-RasQ61L
pseudogene-derived
F/P-positive
.BKM120
Bapat
Smad2/Smad2
sc-7298
aminotransferases
1043delC
4x180k
17/28
5′-CTGTAGCCCATGTTGTAGCA-3′
CD8+CD45RA+CCR7+
p19/Arf
Pearson-White
11,17
ILK
D3S1297
quad-ruplicate
Snf5fl
oncogenesis.12
p.Q1529X
PS-3
p.E171*
L195F
CD4-cell
Becton
10,15,21,22
history41
NM_030662
CBFβ/MYH11-positive
R273C
cancer-protective
6q.25.2–q25.3
PIIE
REK
CSF-filled
c.4794+1G
TTP2
G669V
tumor‐type
Bipotential
p16INK4a-Leiden
effectively12
.BRCA2
.Rad53
hepato-splenomegaly
kinase-BIRB
c.2193G
intron1
average-stature
H.D.Y
5′-TGGCTTCTGTTCTCATTCTCC-3′/5′-GCACACGGCAGCAGGGGCA-3′
A_51_P494430
STK4–phS14
Catchpoole
GM4510
lactosidase
patients7⇓⇓⇓-11
development27
quality-of-life
mutant35
3H-
C124R/S
KITexon
Re-estimation
hMSH2-hMSH6—As
pFLAG-CMV2
537S-ERα
KD=14
UMCN
j-catenin
open/close
Bellane-Chantelot
Ciechanover
C240G
.Wheat
540/25
GDP-Ras
479–84
Hiles
motif,6
C-12
Mllt3
1:320
EGFRvVa
¸
cancer.34,35
transmitters/modulators
macrocomplexes
π-stacking
metabolites.25
Evageliou
0.004-1.60E+05
non-Hodkin
4A–4D
IGF1Rβ
Se-Met-labeled
152–154
815K24
.Coelectrophoresed
5637-parental/GATA3-shRNA/control-shRNA
cells/recipient
pSR~
0.579
5.A
∼2
.Reticulocyte
cytosoliccompartments
pGPD-hTRX
types22,23,26,27,30
1196
Vorinostat.3
~1/2
loop-helix
180–193
V923D
inter-subunit
metagenes
project46
19/88
​and6A
3–10
common,11,12
ptc
kon
HAMARTOMAS
0.6272
2–30
NM_000179.1
35·1–87·2
association/disassociation
relationship.21,22
21–71
L174
FRS2b
glioblastoma,61
p.Arg105Leu
Balamuth
5′-CCGG-CCCTGGAGGTTCCATCATTTA-CTCGAG-TAAATGATGGAACCTCCAGGG-TTTTTG-3′
CRE/ATF
amplifications/aberrations
ASX
c-Metsm
-tttgatatctgccacatagttcacagaactatgtggcagatatcttttt-3
PerCP-Cy5.5
.80,101
17q-linked
LM-608
bothmsh2-AE859p
18_389del
residues32
IL-10-responsive
promoter/enhancer
Arhgef3
tel1Δ
.Brian
Vybrant
DsRed-Stathmin
activatesAkt
5:1
medium-confidence
Vav1
29/36
respectively.15
20.9Frameshift
CTCCGTCTCAGCGCTAGCAGCGCAAGCCGCAGCATC
5/30
phospho-SMAD3
manner5
pathway.1
phospho-Ser-473
deneddylation
Δex22
T157
possibilitythat
chek2
knocked-in
specu
ZBED2
20-32
WT-SPOP
genotype-enriched
H542
−0.24
c.-306G
E360G
//clinicaltrials.gov/ct2/show/NCT00498927
v-HRAS
compound47
Wnt-β-catenin
D-05
phytoestrogens
rs56276816
GITC-phenol-chloroform
pan-AML
.Long-term
842KI
p.Ala161Glu
S921R
p27T198G
16q22.1-67.3
Disappointing
2-1
R598X
c-ABL/p73
PLLKKIKQ
p-SHIP1
spectrum.9–15
C-to-A
p13.1
MEFsWe
FLG
44-54
Anti-ALK
A-Barcode-Exon23F
EBPα-dependent
3.23Mean
Age-Standardized
3484
E.K
Mm768bpΔGGAA-Luc
Nalm-6
S2.2.1
ASD/DD-related
'pCS2
tissues.Figure
Kovernight
six-stranded
1b-1
Shinanomachi
mutation.3,28,32
1035-1982
.Bromodeoxyuridine
030756
hormone-responsive
145-2C11
G14V-expressing
ETS-genes
L206aP
DDLPS_6T
K.L.W.-R.
PTENnull
anti-a-tubulin
α32P
226-95-218-132
titered
12P-labeledanlisense
8:339–349
Okuzumi
microinvasion
10p13
mass—certain
Tumour-xenograft
KITT670I
ErbB3
.Previous
SnaB1
.R988C
RKIP—and
non-T
.Secreted
A289T
Lacal
B-RafQ257R
activity.1
.Fixed-effects
Y170C
28,319
69.1
described.14
WHSC1-unmutated
2422
dark-reddish
Asp12
CD-11b
β2m-transduced
classifi
5.073.0
m1-7
6.0–23.9
26-28
ZNF198-FGFR1–positive
KIT541L
AMPKα
S45G
.FGFR4
Timecourse
reported108
discrepancies
a/a
events23,29
Syndrome/HNPCC4
S705fs
Nonneoplastic
MYCN-non-amplified
c.815C4T
hypothemycin
BCC
19–25
L196R
reprograming
+123
Assays—COS7
flutamide-treated
JAK1
physiochemical
α1/β2
antiRasGAP
LGK974
D11S1818
-1.8
ofTFG
βIII-tubulin
SGCD
28-Forward
.Research
27,35
anti‐CD25
S6J
.SUMOylation
Phosphoblocker
T96M
.Rad50Δ/−
A317
S614Q
system.84
CommentsThe
'RNA-supported
exocytosis
Resolutiona
binding59
complex—SMARCA4
Crizotiniba
intracellu
G4A
trametinib105
K610N
225,000
B.B.G
FGF-binding
apoptosis.1–4
STRN-ALK–positive
215-fold
.Thecellular
cyclase36
al.,1996
901FLR903
division.28
β-structure
atherosclerotic
multiprotein
DAPK
0.5-3
S0498T
Ala339Val
previously8
concurred
Kristrun
gtatgctgct
PDE4s
5′-ATT
difficult98
c.1331A
370,404
receptor,3
G9882/0402
.17929.001
Flu58–66
Soller
5′-GTTGGCGAGGAGAGCGCTGTTTCCCTCTCG-3′
development.25,26
m/61
MDS,9
−188
gentuzumab
7309
tumor.Mutational
BCR-independent
0.084
V42I
.Longbone
function-modifying
P=1.2×10−6
9/12
MET-targeted
ERE-EBV
Asp72
RT112FUS
Ploidy
fusions.28
66/134
Y105C
PDGFRB-related
Shh
antharacycline
synthetic-derived
uArgleuGl
**P
ZYMO
v2.0.12
I‐antigen
g/mlstreptomycin
EphA1
.Enteropathy
G400V
Met/Arg
peptides
DNA12
91.61
RAW264.7
0.1243
129Sv
propensity
NS721
ERG16,17
R382W
A129/Sv
.Background-adjusted
103-106
Tumorigenesis
Misquitta-Ali
.K-RasG12D
transtected
Y646H
2759
Tricine
HRAS/HRASp
allelle
CFC-disease
KMT2D-specific
.Adipogenesis
St.
Fcer1a
.Meiosis
58-TTTGAGGGAGCAAATGAGA-38
gcaccctccgagagttggccc
Garavelli
2115
quizartinib5
.RP11-317E13
AMYCC
DDIT3-binding
.DiscussionUsing
TLR4a
CAGGAAACAGCTATGACCCCCCATCACCCTAACATAAA
wild-typesite
531−associated
38/79
-AAACTCGTCTCCTCTTCCAC-3
BOLERO-2
non-conventional
Br58
2502insA
B-allele
IVS2-105A
desminib
doi:10.1038/sj.leu.2404151
grand-daughter
CA74265
D3S1765
elsewhere15,34,39
R271fs
ROOSBROECK
FGF-pathway–deregulated
RB4-RT-MGB
ZYX
Cells—Recombinant
Shutoh
25/50
Thr37
BCR,16
CXP
anin
2/6/04
NM_004364.2
12q24
BB74-Mel
.Significant
1A–D
3-bp
signaling8
gagagacaattgaaccatgtacccatacgacgtcccagactacgctatgggccagactgggaag
32P-GST-CTD
Zn1
Se´zary
whole‐mount
Altiussheim
F248S
FGFR2/FGF10
mcf3
46.XY
-y-globulin
64˚C
Downregulation
.FLAG-Kelch
ligand-dependently
Scan*
V28
Ser65-containing
M342V
POL
conversion—between
GAACCCAATGCTCCATCTG
MgCK
whenantibody
Gly106
Cys–X–X–Cys
hDIS3R780K
fromSaccharomyces
1.50
3.2-fold
chemotherapy-induced
RAIDD/CRADD
Lentivirus
Ser518
Mestdagh
AAGCAC
Phosphocellulose
RAIDD
H3K4me341,42,74
Smad3-regulated
c.829-1G
9272
RSV-jun
TGGTGTAGGCAGCCATGTATC
vitro37
leukemias,28-30
CACATTTTTATTTTTCTACTC
5/253
CACNB2
.-L.s
0068
dermatologists
Ras.184-186
3mutation
2.855
E95G
Hemoglobin
007458.1
DDR-collagen
p.Ala60Val
COL5A1
eyepiece
cells-like
non‐small‐cell
arrowD
E34A
888–1,063
0.57*histology
-j
538b
D128N
disease.1
Multiple-hypothesis
9,11–14,31
~~~~~~~~2
AUF-1
G88D
Timokhina
.Numbering
400-mg
393
more-active
receptor–alpha
Innotech
center.
2.59
1•7
Boddu
Thr202/Tyr24
Transposase
thev-src
I103del
24,536
.PC-associated
fusions,48⇓-50
114–373
mutation-
63/71
gpl40t'k
HTS.16
CCND1-expressing
mono-allelic
congression
59-GGTCCACGTAGATGTACTCA-39
15,17,56
MICHILS
Lys/GIn-22
II.3
with/or
12CA5-protein
GelRed
Mn2+-containing
achrondroplasia
7.174.3
Seakem
419/448
BD–chromatin
E135Q
cells/0.1
MSCV-KRAS-IRES-GFP
anantisense
STI571,33
11875
0.33–1.53
Co17
Graus-Porta
theTFG
galactose
CCTTTCCCTTTTCTCCTCTGC
non-MEK
−2.69
aggressive/different
R481
CFT
I..
53BP-1
reverse24
micro-RNA
5′-FAM-CTGTTGCAGCCGCCTTTGTCTCGT-TAM-3′
Anti-NK
UACAUAUGUGUAUACUUUGCGAUCC
Mann–
genetically-defined
Site-specific
Hedborg
karkinos
De´partemental
EphrinB
BAF60a
gp120'k5
19-'8-6'-
1J
3.059
CCGGTCCAACGT
Gr-1hiMac-1+
pKT3-WT
23,219
Plasma.0
thecoma-fibroma
anti-phospho-p44/42MAPK
lymphocyte-mediated
checkpoint-competent
duplicate-read
Arghap12
p.T476K
delCT
0/1,053
uracyl-containing
LKB2202
GST-C-RAF-transfected
+19,27
Levkowitz
L-type
1943
94ºC
10.4–13.5
Smad3KO
c.591C
165–243
F179C
ΔN186
p.Arg200Cys
+37
reformulation
RAF–MAPK
S.A.B
sunitinib.12–18
159,162,168,169
ATF2
H3-K42L
MEL-3.0
preclearing
deletions—such
Switch-I
FGFR2N550K
performedat
3'-phosphate
16–65
SJHGG081
2,077
wells/pool
anti-Jak2
CBS-like
bandshifts
870A
Cinna/Biotecx
Bockmuhl
TTCTTCGGTGCGTTTTCTTC
105–215
aNKX2-1
Protemist
C-ter
AI571004
6-kb
detectβ-catenin
p90HER‐2
BRAF-mediated
2.Algorithm
mutation.1,23,24
.623
assays.16
fluorescein-conjugated
roomtemperaturefor
Assay—6-well
2/k1
mice15,16,17
Rørth
N659S
5-FU-treated
.YAP1
P554S
c.1187_1196del10
intercrossing
Tarsitano
4—figure
phosphomutants
neuroblastoma8
Viatour
//apps1.niaid.nih.gov/dav
NPV
McGranahan
DNA-damage-responsive
phospho-ER
PHOT1
.RAYMOND
arginine-to-glutamine
2R,3S-isocitrate
1QW
Sherbenou
pSG–Flag
KSV
2,3,4,5
GFP–VHL160-
pre-normalization
.Serum-free
ETV6-NTRK3-rearranged
U2AF11
impacts3
Broad-complex
TRCN0000075165
35S-cysteine
macrocephaly-related
FNN0011
FGF-4
β-catenin-Tcf
000135
basal-lateral
collagen-coated
andCUO16
Fluorescence-Activated
D770_N771insSVD
CATCTCACCT
Randomization
mice7
TACTCTCAAAAAGAAGACAAA
KD-MALT1
.5559C
telle
32°C
A-5441
E1A/HRasV12-expressing
S8F
usingfragment
N2702
aAd
Hydrocortisone
gagtttgaagtgctg-3′
PF382
AKT1Q79K
glycosylation-inhibitor
COQ2
agonist-bound
Binne
49K
C1612
explored27
EOL1
L.Z.
W1086
−1.49
R141Q
893
HCF-1N
proteinwithin
DNA-liposome
PGM
GTTGAACGGTCtagACACCGGC
Glu-37-
stagetip
.FIG-ROS
CMV-TFAP2A
The-H-L-T+F
crizotonib
aords
9q34,10
JAK3/STAT3
Maat-Kievit-Brunner-type
oncogene,2
G2019S
.K5.Cre*PR1
uk-essen.de
.Immunohistochemistryrevealed
nm23,13
optionsAlong
CCDC-RET
pCMV6-wt
R2/1631-1
DupPP
development73
Tnfaip3
-0.609
p.Val169Ala
wildtypelevel
V422del
W2084C
4.0.0
Institute/Brigham
R91P
Pepro
410-502-5559
cilia-containing
HA11
TP53MutFunction1R15
restreaked
490-kb
c.-284C
TCACTATAG-3′
49/431
66–68
rFGF2
27–29,158,167
.PRE
P=0.81
mock-transfection
Kusumi
cRSS
Kefford
Electrophoreses
AKT-1
τrot
2-sided
11.5‑fold
folding,3
Po0.05
∼44
stability.DiscussionAlthough
Rapgef2
ExonTrap
exon-7
.Emerging
NM-022970
NLMLDKDGHIKITQFGLCKEGISDGATMKTFCGTPEYLAP
OVISE†
SciVerse
Yekutieli49
BRCA1-S971A24
co-detection
combinatorially
MYC-1
c.901G4A
T492I
pT603Q
13C-U
residues48–52
Ashman
FGFR4-KD
invovled
G47R
7–12
hamartin–tuberin
MgCl2/75
deprotonated
Tybulewicz
Máximo
~105/286
V617F-dependently
3.4-cm
WT-EZH1
anti–phospho-Src
Feulgen
421peptide
PAK-JNKK-JNK
22KB
-leukemia
IRES25
phospho-HER3
Genescript
335–483
ABC/NC
meanplusminuss.e
K14+
.Infusion
FLT347
3Western
.Phospho-ERK
41/M
Mn1
ATCCCTGATGATGTACCACTGCCA
N≤−10
optionsA
L1-loop
BCR-ABL1–negative
XPLN
p53—The
ultrastructure
Polyglycol
RCK8
SU11274
1983-84
.EGFRcells
co-ordinate
C244R
TCF7-like
Mariadason
.33a
BD4
activity133
lesions.25
S-G2-M
-H-L+F
sulfate–polyacrylamide-gel
sc-45
6xGliCS
hPMS2-vector
1-stearoyl
phospho-ERBB
3110
ENST00000257290
223+185
C-CBL.Figure
fre­
Melting-curve
windowTable
Msh6+/-
ADHD
L=longest
Rubinstein-Taybi-Syndrome
A279V
77–113
XXLαs/AlexX
4ICD
‑fluoro‑l‑thymidine
mut≥mg
explant-derived
T157A/L198A/L235A
tremetinib
21-31
Labeling-For
Erasmus
elevatedC-reactive
FeO4S
presomitic
werereduced
C141S
1994x
c.1576ARG
U=158
86.1
D6S105
rs104886026
3719
p38-specific
AlbertSchweitzer-Strasse
conformationalchanges
dimer-dependent
MALT
c.2457T4C
c-Myc/Max
VUS-containing
pCMV-tag1
GGAUGAUGUAAAUGAGCAA
250ng
-HPLC
PREMM1,2
geranylated
overa
SinoGenoMax
alpha-ketoglutarate
.MKN45
Thr670Ile
C348S
E95A
DISCUSSIONTranscr
8p/q
H3K3629
L2/H1
ÃŸ-cateninor
:ZsGreen
unfavorable-risk
heterodimerization21
STI571-treated
Energy-independent
B56
Glu501
4155–4156delA
331×108
DFS.27
6842_7007del
OP9/OP9-DL1
GFP-RNAi
Ser536-phosphorylated
31:1
sequences11,12,13
Metabolic
μi
USA.46
fingolimod
reduced9
NUP98-TOP1
S128F
14.1
autocorrelation
49.0
7760
17-kb
GST-PAK1-PBD
withethidium
L1584R1.
HA-Merlin
doi:10.1006/bbrc.2000.3839
mitosis.1
SU11274/PF-2341066
EWSR1–1145F
lymphodepletive
c.134+3_134+6delAAGT
anti-beta-Tubulin
25-cm
Brca1Delta223-763
cancers18
RERF-LC-MS
Galectin-1-deficient
RET/A883F
p-Erk1,2
2180
1.7.1
rGGGrGGGc
Gln1756
-ACAAGTACCTCACCGCTTGG-30
pressure.55
P=0.197
.Population-level
p.Arg2888Cys
47–51
LS-5S
co-introduced
jig/ml
Hot-Spot
DEK.Gains
UV-endonuclease
−977
repair/signaling
q15
Dong28
SK-MEL-94
congruent
0.832
fold-increases
GARNL1
Pare´
L208F
Alexafluor647
8–13
A118T
Fig.1B
c.1798–1799GT
GdotU-processing
R302
LS50
.Fourthly
0.402
nnMS
tumor-derivedmutants
.SMAD4
Gluzman
Brca2Deltaex27
ANXA8
0·49
HAGAKF
freshfrozen
.First-
HAL-C1
40–42
**P-value
773_774insH
DNAdamaging
HPK1,26
nihms646437t11.jpg
leukemia,20
141.4.1+141.2.2.5
RELA-positive
3′-RACE1524d
10ZF-HA
1.420
Waterham
JNJ42756493/FGFR1
.16,18,19
triple-laser-equipped
Hinoi
1,251
ERBB3
.Maps
sebaceus
electrotransfer
V7l5
2001a
V217M
investigations,3–6
bInitial
JAK2-rearranged
Drosophila38
Q210R
W372S
§exon
CV-M4+CL
1:7
ΔBRAFΔBRAF
−33.4
5′-TACTTCCGGAACCTGTGCTC-3′
F394I
H1110P
I304N
G380R
runx
miguel.reyes
Halachmi
myelodysplastic-syndrome
83-week-old
TLS/FUS-ERG
Mean/rms
20E3
7-15
disputed.Recently
1:99
48.10.1016
TRAILR2
E655K-overexpressed
IjI
mutations.
.IBCs
membrane-inserted
126–134
VD862
—have
EML4-NTRK3
RTK-III
Y597/Y599
Data-Bank
JH3-JH4
P=0.00
1.69
wasisolated
biologically-based
CDC25-mediated
o-tetradecanoylphorbol
malignancies,29-31
TFAP2C
pY1062
DHX57
BC-
3.58
N440I
CDKN2A/p14ARF
tissues8
Merghoub
Y772C
IVS1-4G
3,096
AGTCCTGTAGACAAAACCTG
Sutani
sc-9772
drugs.38,39
N15
N-of
bevacizumab29,30
hydroxlase
v.6
Surescan
-ATGTCTGTCTCATTCAATGG-3
ORRDCRMedian
PG13
experi-
TFA10a
ULBP1
Martinsreid
.HL
thyrocyte-specific
N153T/S
implicatedin
Cul5
paratesticular
Paillerets
CI=0.85–1.15
LAS3000
K-rasG12V-IRES-BGeoMEFs
Vb.20
PAX5-ETS
inducibly
q32
inactivation29
34G4A
ANTIESTROGEN
ImmunoTech
V2050L
Y130H
Bacus
DPP4
Fontoura
.Mobility
Cy1-cre/IμBcl6
Y801H
AUC0-12
Rous-sarcoma-oncoprotein
3.71E08
V-QUEST
ÃŸ-caleninis
.AH109
Tyr→Phe
Electropherogramm
counteractive
myeloid-cell-specific
noc
estrogen-induced
4363
invasion.3-8
13C6-Lys
followi
T426
myeloid-committed
dyserythropoiesis
11α-Cortisol
-conjugated
fibroblast-growth-factor
0.0513
SW48-derived
J.V.S.
anajyzed
general10
thecDNA
G4012C
175-kDa
QIAamp-DNA
Nu18/DP2
adefective
L1026F
pRCC16
complex,51,156
p.V630fsX
2y-PFS
A663V
CD8+TCRαβhigh
H3T6
CDE-CHR
-73.7
Fluotar
6XOSE2-luciferase
intercalating
UPlanFl
E1a+ras-transformed
kinase-inhibited
.Double-digit
genetics.nature.com
LEC
20.32
.Cross-sections
entirety
protein-DNA
mAKT1-K179M
35243
2-13
ptac-expression
Brca1tr/tr-associated
function.5
98.96–99.89
5′-TTATTGACGTGACCCTTCTCCTGACT-3′
Kras-induced
28.73
Erkl
kinases.12
pOPALI/CAT
Schönherr
5′-atggccactgccgcatcctcttcc-3′
6–
p16/p19−/−
AKT-cat
cancer.57
.14354
3073
Krammer
rs673478
NCT00896909
'tumor-related
beta-turn
TAp73
C54
11–54
3002
5′-AGACACTCAGTGTGAGCCAC-3′
junctionFGFR1
Wakeing
β-carboxylate
pOCFRE
6e–g
M34353
LRIF1
⁄3
fragments36
Gr1+/CD11b+
5′-GAGGCCAGTGCTGTCTCTAAGG-3′
pan-VEGFR
hyalinised
Hudson-Alpha
N-K1
MethodsCell
S33AS37AT41AS45A
STAT3-YF
.Exon/
392:189–193.10.1016/0014-5793
agenesis.22
binder-1-FF
ACAATCTTTGTGC-3′
Elution
CEBPAmut
UVR-induced
ctgcag/GTGGGT
immunoglobulin-secreting
control1
strain26
ATRA-induced
nti
Puc1
RAB3GAP2
0.000219
NM_181523.2
C-RAF1-330
5605
visualized.Transactivation
shMll3-1
TEL971
'cold
K641R
G481C
re-arrangements
8A-D
H–K
MOZ-4540
Cys45Top
anti-hIgG1-Fc-horseradish
.BIBR1532
H2–H5
.Graphic
hypo-diploid
Mac1+/Gr1+
alsocontains
MD-MB
0211
4.7T
D1Δ-754
Y316C
G243R
Cdk17
aphosphoscreen
1099
'2I-labeled
the1
c.2762delA
Szj
groups/subtypes
E2OHT
TSC1-TSC2
21–22
kinases.37
'tailored
.Melanoma
MOLM-1
CARD11-deficient
region-specific
factor–responsive
genotype-tissue
novel-function
GCTCCAGGAA
C3–C7
c.1277−1180_1386+2226del3516ins15
all-trans
KETAEAYLGESITDAVITVPAYFNDSQR
Fbw7-targeted
Cockman
observations-the
−1.3492
andanalysis
plasmid-encoded
p=3.71e-4
P539R
4.00
NM_178825
at/near
Epithelial
WNT9A
del746–750
11-20
delE746‑S752insV
ACTGCATTATGTCAGAAATTAAAGATACCAGATCATGTCA
Nothwithstanding
E250K/5'-TGGATCCCCA
CBL-WTand
GCCG
UHCAs
RP11-180M15
6L
VHFNEVIGRGHFGCVY
2ac0
glycoform
37075
replicons
analysisPairwise
Tyr594
non-electronic
A765T
non-hematopoietic
DPC-4
Y336N
.CpG
0.153840707
Français
Kelch-BTB
R166Q
C277W
A.L.J.
-untranslated
32,33,138
AEE788
Gorfe
grant-in
.Markowitz
CCTGCCAGCACCAATACAT
RAS-mitogen-activated
coa
254–268
.063
CCCTCCAGCACACATGCATGTACCG
ATGCGAAGGCGCGGACACCATG
myelopoiesis-related
BRCA1-mutated-like
rs10515150
3002947
autism.15
BR-0077
pCAG-wtHER2
cholesterol-rich
high-priority
Arg103
S1058P
9.77
ftWI
TCTGGATTTATGTGTAAAGGTGAAA
CD8þCD3þ
1995a
112.275
Tetratrico
p5.3
BRCA1–BARD1
GTP-
15-30
31-bp
mastocytosis.40
import13
guanine-exchange
acid-477
mutS2J5
TP53/RB
S289
AD-HIES
S860F
EWS-FLI-1–induced
statusb
CTNND1
Jen
heterotrimer
7/26
56772543
ISDR
pHEBO
10220
GTP.Biochemical
nonliganded
exportin-5
Lemischka
Y589F-Flt3-32D
1.2¡0.2
CelLytic™
asc
Kim,1
treatments24
locus.87
CI2
N64S
form.40
Sichon-dong
41,899
rs1800896
phospho-ERK–negative
R188H
PBS-0.1
DiGeorge
chemotherapy.92
chemi
.Polymer
phospho-PKCζ/λ
6,015
Lalign
Eindhoven
*Heterozygotes
1933
2PY3
oncogene,39
CeA
~1.36
protpars
L455
IL-6-mediated
pid
pRetroSuper-puro
BRCA1–complemented
69061225
resistance15
71.Unlike
49.4
p.R1893fs*35/p.D1894fs*21
SMO-D473
HLTF
.Blotting
8.44899825
calcinurin-NFAT
T1243S
63:383-391
FAM-TGT
neo-GFP
eosinophil-associated
766AA
usingCOILS
protein–RNA
SpectraVysion
052.01
p110α-E365K
2.34
radiation–induced
FGFR2≈350
c.2755C
∗601732
MAA-specific
Hamid.Mehenni
02-A
heterodimerization32,33
.Colon
M2089I
cc-13-834-g5
function21,22
4k–n
Briefl
Chiba1,21,23
3Aj–l
BRAFinsVLR
Tyr577
GTU-88
pMET
β‐turns
PI3-
methanethiosulfonate
PA-BGH
BRAF/LY3009120
tology
9B-C
III-7
establishedconditions
histopathological38
A1733G
MPCEWS-FLI-1-T1/T2
PicTar
6f–h
Mbp
synostosic
Lymphocytopenia
tumor-promotive
175-kilodalton
8/14
DINDEL
pseudo-POU-like
mispairs
155/195
4·5
S-phase.50
+10.1
I414G415ATCG-CCA
recombineering
Brca1Δ5–13
score20
736A→T
5/96
Ar191
46/1
K822
Asn1485LysfsX5
cranium-to-face
Hs169327_m1
Aml
nucleus.5
L1407P-U
C-MYC
CASSTGDNQPQHF
PDGFRA-activating
G33A
heat-denatured
pathways.1,2
Concanavalin-A
T1700
MafB
penicillin–streptomycin–amphotericin
≥N5
121.5
hMSH6-R1095H
8/30.8
D816V
model.16
WA2-60
transcript.22
ADAMTS18
alarge
SP9
CLEC14A
LLTEL
37/49
foreskin-derived
ø20
0.6/7.8
nontranscribed
PolyScan
ERK1/2Y148/Y131
ITR-CAG-Flag-SF3B1WT-IRES-Puro-ITR
L1/S2-S22'/S10/H2
CCDS86
56–65
Orr-Urtreger
cardio–facio–cutaneous
5,12–14,22
ReferenceLoss
Kras–induced
TRKoncogene
Genzyme/Techne
function.3,4
1289
4G6
CScore
sub-pathways
FLT3,6
Stat5AΔ749+TEL-Jak2
sizeselected
cold-inducible
Asubset
CGAGTATTGTGGTTAATACG
1μmol/L
Chunxu
.ME-PCRs
BRAF-CRY2
carcinogen
G410S
cytokines4
TIG
Tadokoro
p=O0.01
.activation
path-length
wt1-Null
China6
-CCAGACAGGTCAGCCCTTGG-30
DFG-motif
sample-triplicate
prognostication,3
pRb-associated
−8.2
dramati-
TALENtreated
10μg/ml
1abe11ed
1.73
Glu153
1862–2005
MTS2-L2
2-amino
ME-600-DS-5M-L1
mTOR2
investigational-use-only
P.I744V
IR-
Smad2-knockout
.SNU-5
FYSLRQMAAKRFPNNPHV
c.2461C
BMP7-SMAD1/5
50-
MKRN1‐BRAF
multi-functional
TGFÃŸ
attributableto
.Events
noncleavable
CMV-cre
istge.it
Oligonucleotide
sequencespecific
NCI-H2228
VE1
789765
ERK-1/226
N1171-V1180
neurobiological
265–350
dipyrimidine
p.Phe354Leu
5′-CACAAAAACAGGTTAAACCCAG-′
mutations.17,21
Thr235/236
.YAC
BlnI
662041
interference-based
Δ309
anti-CCTγ
33342
M-CSF-based
Ser431
4Â°C.Tissues
G1579S
MYCN-induced
Krebs–Ringer–HEPES
argyrophilic
HAWPO2500
E-cadherin/6-catenin
C57BL/6-derived
TGF-β-dependent
V843I/L858R
Ala1268_Arg1334
subclonal/multiclonal
Ras/MEK/MAPK
535/399
p4M
DisEMBL
p110αΔ/Δ-recipient
1:60,000
T239/S243
Br33
F22
28/33
1180Mel
9-deleted
p=0.90
EntrezGene
OneTaq
dis3DPuroR/dis3DBsrR
1–4.7
astroglial
A105T
causality/neutrality
MRPS2
1p36–35
7.1.0
UBR5-ubH2A
FPD/AML.10
R501
3.107
ARF-Mdm2-p53
ShcA
LR=40
miRNA36
in…
Gln1747His
TET2-mediated
p.Q210H
underexpressions
HDACi-induced
2/53
Garcia-Pedrero
Schiro
71,74,75
Meenhard
electron-microscopy
hygromycin-resistant
PBRM1.14–17
ASXL1-mutant
Sox17flox/flox
target-directed
IFN-γ-regulated
thirty-five
ras‐transformed
PR1374_A05
R8024H
ligand−receptor
538
3/76
β2M
PDGFR-expressing
12:415–424
V353M
Juwana
Chk21/hcds1
****P
thermo-tolerance
5H11
393P
Evirolimus
Lag-1
10cm
C.B.-17
0.00186
tumorigenesis54
copies/cells
tuberin-dependent
R287/R463
W146X
p300-HAT
MAP3Ks
SENP1
mHNF1A
Pik3r1+/+
iEC
XLαs-specific
αC–β4
Micro-vascular
MigR1-FBW7α
135534
Suarez-Farinas
Pro57
generalizability
GFP-Akt1
postnally
GGGAGGCGAC
METex14-positive
99–labeled
MA9
samples.31
Repbase
8q24/MYC
BRAFwtF
tumours47
Methylation-Gold
pCDNA3βHA-BRCA1
presenilin/γ-secretase
aciduria
27–31
CGAGCTCACTCTCTTCCGC
Arid1afl/+
hypercalcemia1
7-30
40-kb
70/96
agar—a
173569
H423Y
Met/Met
.Grb2
thymine
Col8a1
NM_002880.x-1236s1c1
A20D
exon1-2
p.E76A
48-well
L630
46484
3.3.2.
1.806
tatedER
2.9-kbNTRK1
mp2–mp5
Autoclave
CGCGAAGTTCCCG
SLC30A4
kb.6,8,29
CD34-positivity
Map3k1Δ1
V11.0
5'-GC-clamp-CCATGGGCACTGACAGTTAA-3
117L6
BRCA2/5
allelic-specific
anti-p53antibodies
MSH2∷HA
L727Q
22W
deaminase-mediated
GST-RAF1
THRA
maximum-minimum
//bacpac.chori.org/pHumanMinSet.htm
JIM-1
olfactory
earlier.8
Chk2delC
taaaag/ATTTGG
Aronheim
KE-motif
299-303
L364I
.VUS
-BRCA1
V600E-induced
U87MG-PTEN-G20E-3
PRKAR1B-C7orf50
Q61KN-RAS/V600EB-RAF
v9.5
hyperreactive
Hs00257977_m1
5′-GCTCGACCAGTTTAGTTACCC-3′
BAF180−/−
SCH3
lesionless
HeLa/FANCD2
K695R
Gainesville
video-time
penicillin/streptomycin/glutamine
apo-BTK
.Confirmed
Thr-123
Level-1
ImClone
-Cw4
0.0171
NG_007110.2
Stably-resistant
N345l
jp-catenin
2840
tumor-biopsy
lens-capsule
phosphate–EDTA
A.M.W
31.21
product-precursor
*-2
ethnicity.7
Non-FA
FLT3D1–D4–FLT3L
5,6,13
6,9
RKIP_E3
5′-CCAGGGCCACCACCGGCAGCAAGAGGAGG-3′
89.0
and1c,1c
hypermutant
Br74
chr16:67,643,579-67,645,330
T331M
Assayson-Demand
MX1
gtaagtatt
IER3
tesque
E1972K
RNA.8,9
WHOLE-EXOME
FGF1
TNIK
sorafenib1
ACB-PCR
3-kinase-related
PROCEDURESMedia
Logeart-Avramoglou
.Ó
Co3
8.2⁎
BrdU/7AAD-stained
1–5–BRAF
CCAAGAAATGGAT-39
kinase/ERK
Epo
characteristics1
c-KIT-expressing
CML-CP.36
TGF-β–responsive
Zak1
YeÂ
5′-CCCAGCTGTATTATTGATGGCATGCTCAAACACCT-3′
3044
homology-driven
L4543
UBX
UIM
RP11–563P16
Asn666
residuesusing
.Shifts
snu886
V157
POLE-mutated
15,24
2020
43,43
c.717_718insA
REFMAC5.26
.Examination
5'-ATTATGGATCCCGGGGAACGGACAGTTGGA
KCNG1
1.09E05
pMDLg/pRPE
1,475
p.Thr599_Val600insGluThrThr
p.A60R
membrane-associated––it
10−1
mutations.24–30These
polyI/polyC
+301
EMD
FANCAH111OP
Cre-responsive
Apc/Smad4
9,26-28
1.78E08
lineage-
0.6339
PCDNA-ubiquitin-HA
Ruoslahti
2803
six–base
5—figure
pYTH9
HI-2
fibroblastoid
P19S
IPF-1
‡one
Hemann
0.00198
10,29
Schemper
Hematoxylin-and-eosin-stained
monomer-tetramer
MSH6.4-8
287
loss12
pT1G3
sulfate-polyacrylamide
:FUS1
6AU-containing
1a-7
0.30±0.24
ER/3
R132G
ccRCC-risk
L340
K642Ec-Kit-
Gherardi
-cadhe
69-year-old
activation/phosphorylation
NOTCH1-dependent
RB163
IDH-derived
Losman
.Glucocorticoids
Clark-type
markers1
Chemical-Genetic
Moriniere
CliniCall
N263D
5038
G654C
17-I-labeled
SOS-505
c.503_
75–77
FLM
432J22
0.38b
3×107
Research/Massachusetts
TAAAGGCAGTGGAGTGGTTCA
NGS-reads
6/72
.PREs
GTTTTGGTCATGACAAACTGTG-3′
literature.21
0.4224
14/1/4
RAD001184
substrates,20
ovarian7
β-glycerophosphate
A834
nuclear-exporting
82-year
linesA
pEAA308
mock-transfected
R776H/G719A-mutated
T906Q
CD45
Caspase‐Glo
0.89-1.51
ª2006
GA3500
K36.12
V617F–mutated
GST-pl
J.P.d.K
Fam3b
R574fs
Frs2α
formation.161
lymphoma10,11
19/29
product,10
cGK
HY
.S9E
VHL-mediated
subtype53
vivo.46
AT211LA
97.22
CRE-loxP
58–75
10-70
17pl3
al.65
NM_017763.4
CD34+Flt3+
16106
receptor17
finger9.6COL5A1Collagen
RP11–232K4
R415Q
44k
subconfiuent
2FM
.Olivier
anti-CD8α
CCGTGATGTTGCTTGATTTCATC
0961/3694090
mice67
SPAFAS
E-MEXP-1748
50–300
transcription.1,2
5′-AAGCTTTTACTTGTCATCGTCGTCCTTGTAGTCGACGCCAGCAGCATGG
under-mineralization
ACAAAAAAC
qut.edu.au
130.1
0•0001
16,000
studies.38
411-35
lagging-strand
RP11-39N23
E386A
previously,21
SGI-7079
Metacore™
4665_4675del
control/speci®city
D108E
CODOX
85.06
Anti–Ki-67
PDGFRαT674I
RP105/MD-1
31/38
quinolone
Phe27
Technology®
CAGAGGCAAGCAGAGGCT
CBX8
P01-019
2154±1004
p.Arg2602_Tyr2658del
51-59
Reprobing
Purow
281–628
Clec5a-K16A
fungi
inter-marker
P-0005309-T01-IM5
1298
5′-flanking
GGF2−12.2ALDH1A3Aldehyde
proteins—L64P
9+MSH2
ysleuGluGl
22,26
mercaptoethanol
HQ232295
CAAGCTGGACACATTCCGTA
CCP
TCGAGaaAAAAAAAGGCTAATGAGGTTTATTTTCTCTTGAGAAATAAACCTCATTAGCCTA
CH-
cells51
labelling-based
Shatin
LS-fam.
neurologic
bone-resorption
ACCCGCCCGAGGAGGAAGATG
Arg-Asn
,100
-stimulating
Clinicopathologicand
hyaladherin
RWPE-LACZ
3927
886
​and22
α5β1
439/1346
HOMA-IR
0/786
GGAGGAAAGGAAGGTGCAGT
PLK1/polo/Cdc5p
BAP1-specific
601728
Mre11H129N/-
immunoprecipitable
fastq_2.fq.gz
DN-Akt/Ad
86.13
19993
hypomethylating
periods.25
No.155
Fwd-GGACCCAAAATGGGAGTTTC
980L14
mC-KIT-bearing
Hsp90-containing
R202I
K508M
FGFR1b−/−
highest-resolution
eAppendix
pQE-10
BM-deficient
9.0
RUNX–CBFbeta
Strategene
PD166326
Dimer—Although
TEL-JAK-transformed
Dpar/Dper=1
W299R
GAPDH_F-GAPDH_R
S-400
DISCUSSIONThe
TbRI
1.807
HS2000
.Arntflox/flox
Monomer–dimer
0.00784
FC-401-3001
52.0
S1206
Erdjument-Bromage
EBNA2
G0-synchronized
PaO2/FiO2
-SalI
7S800
Med23-
WEHI-cm
anti-parafibromin
RT4del
experiments.G162R
C140
drug-naïve
SeMet
154700
factor–dependent
Pédiatrique
KI-1
52,10126
XLfit
CG-TG
DNAH2
Genome-work
immunobiology
KITex9
.CEBPA
Ph.D.
TGF-b-induced
P430
amplification/HODs
71/84.5
37/140
EN/IRS1
800μg
colerectal
79.9
0.5987
920-1G
TGCCAAGTTACTTACATTTTCAGTT
'cavity-creating
Deisenroth
multi-omics
Materials—Dulbecco
mCherry–B-Raf
pathway–activated
Gal4–p300
permabeabilzed
E87K
Wasteson
BPE
2-CDA
Tumorscape14
Sca-1+Lin−c-kit+CD48−
AEBI
950-bp
compositionally
transitions.7
51–60
capture–based
HP1.25
c-abl
SML-8-73-1
coimm
cover-slips
Ras-related
R368C/H
2.654
N345S
-acceptor
juLSA-
TEL–RUNX1-associated
24/88
Constructs—Full-length
Arboviruses
.Y842
voom-limma
c-KIT-D816V
Kämpjärvi
RG-19T
BIRC2r
MycoAlert
∼157
SM-U
34.8–59.8
Maa
and6I
.0021*
06-157
Cright
∼1:1
pGT3DLeu
59CGGAATT
K161N
drc
MDA-MB-435
MTAP1B
p.Lys328
space-limited
86.6±61.3
p2=0.0001
Kit-Cell
polyposis25
Tyr646
mAChR
PRDM1-mutated
mean.Given
arrow-head
it.8
KCI
NCT01204099
autosomaldominant
TPO50
FOXG1A
5′-GAAATGAGCTTGACAAAG-3′
C/EBPA–positive
224
C620W
A125T
5′-UUGUGUUGAUUUGUCACAACUCAUG-3′
UTR-MUT
lymphoma135,147
PD1
.NOTCHmutation
5mC/1-meA
immuno-blotted
199.2
121/148
0.435
sc-43725
1-2
i7
0.28-0.76
locianalyzed=
4Analysis
density-gradient
ficity
PanIN1
Rachakonda
L403P
energy-loss
N-to-C-terminal
comparelanes
Ponten
D816HKIT
.gel
Wnt7b
TSC2-transfected
IVS3–1G
147K
Non-primary
APMS
75,418
transfection/focus
26.33
Mx+Snf5Inv/+
35–54
vaccine-induced
nhgri.nih.gov
Higher-expressed
.Sumoylation
37a
Retrospective
clastogen
serpine-1
procreated
Gal4-HIF-1α
Coprimary
LaRochelle
DRX
4†
time-consuming
anion-exchange
.8,26–30
oncogene.120-122
Kit/STI-571
infive
3o–r
sixty-one
Smad4Δc
HMTases
1clones
'251I-labeledFO-
AGGCAAC-3′
6889
2GS6
GGACTCGCCAGAGATATCAACAATATAGAC
analysis.24,36
hsPlexin
1113C
above.Full
G2-M–
gcactcatgtcagaactcaag
coregulation
MiGR1/EGFRvIII
Oγ
5-Luc
1.134
Klochendler-Yeivin
histiocytoma33
pREP4
1kpromoter
41/54
F379
Torin1
.DOD
//paircoil.lcs.mit.edu/cgi-bin/paircoil
photographs.Figure
wwo
Harwalkar
PLEKHA2
G/I-2
//www.baystreet.ca/articles/research_reports/lifesci/239c5c82-3f2e-49ef-82f7-86457aa8f3c4.pdf
K860I
library-size
3G
DREUSICKE
U12829
BRC
1871
depalmitoylated
homodimeric
AT/TT
γ32P
44/60
clastogen-treated
p.Y532C
inlung
//www.med.mun.ca/MMRvariants/statistics.aspx
fmol
neomutation
G3867A
.Senescence
HA-Ubiquitin
†23
103–147
alternative-promoter
IDH1WT
1300–1863
case-control
miceTo
coiled-coil/leucine
neuroblastoma68–71
Aurora-1
MUTATION-DEPENDENT
oligonucleotide5
T491A/S494AC-RAF
Ï
contrast-enhanced
mismapping
pRCCn=
Pik3r2
iodoacetic
.539028
KT3
Rel-B
E-Syt1
ERBB212
C6~
195-197
Marsit
transmodulated
11P551HMY552-554del
published29
ADAM12
Asp743
promoter–specific
M4EO
4.3–13
R135C
//www.bioconductor.org/packages/release/bioc/html/goseq.html
TCGA-B0-4810-01
.1998C
approaches108
D771N
C580F
Succursale
p=0.69
Thauvin-Robinet7,8
SC-8050
Œ
wtβ-cat
.H2O
clinic-based
P1-12
K550_V555del
Figure3b
PFTAIRE
5′-CAAGCCAGCGACGCAGT-3′
Sujatha
idac.tohoku.ac.jp
70N
MEN-2B-causing
Basilico
interchain
TGF-b–
​Table
COA
surmise
pET-27b
dn-IκB
.Set
COLO-205
1200
1Z95
ALCL-derived
fin3ing
mutations.FIGURE
235.1
A919V
stability/activity
Rodenhuis
NBN
.HLA-A2+
PpuMI
STAT3-G618R
19,528
500-μl
p14/alternate
NPC-30345
to104-1
1,27,607
tetramers7
MB752
Hnf4
G719/S768I
STAT52'.32.33
complex.29
CTTCAAGGAGACGGGAAGAGGTGAGCCCCGCAGGAACG
19q13.3
R43
E552K
Patient170947
hypoxia-responsive
913,000
SCALEPACK22
melanoma,12–17
50.43
LOC157381
S406L
Lkb1−/−
85.755
data,20
​Fig.5.5
luminal-tumor-derived
C2060G
Tsuyama6
D-01
Pu.1
Bf
survival.35,36
F–TGCAGTTTCCTTGTGCTGAG
TFA35
NR0/50
history.48
.Radioactive
11355
'U
GCTCGAGGCC
W577-R586
pRO-2
non-smoker
A1020P
Reznikov
BX387357
MIA-PaCa-2
911453
Oversaturated
NM_003242
124.00KB
S104R
59-CTGTCAGTGGGGAACAAGAAGTGGAGA-
22S
p.R462W
20573-mutated
Y653KD
9Rα
SlideFIG
Scheffzek
SHOC2S2A
breakpointregion
68198-3135
AGCC
.8457
ERBB4WT
later.The
c-myb.E1.195.F/
database7
OTTHUMT00000280540
locitested22/5
Mikkola
RET-PTCs
PRDM1-unmutated
Mll1−/−
r=0.604
PKCϵR
528.7
Toexclude
ERD
6.08
GSK3β–c-Myc
~~
NIH3T3-HER2
SORBS2/ARGBP2
phosphorated
A.C
.R882
BCL627
ATP-
cellulose-coated
bleed-through.26
.Genome
EGFRY1068
lymphotoxin-transgenic
2p25
Dunkern
MNase
SPI1/IRF4
cbt-15-1239-g2
whole-gene
c-Cbl-recruitment
-HG
PD846F
cancers.11-13
Merlin13
negative-charge
domain–BACH1
findings29
20p13
ΔDeg1+2
other3–6
withP53
.One-half
b3a2
genomes.11
ancestry.54
pSG/Flag-D88
PLXBN3
4.77±0.50
5757
RANBP-ALK
phosphatidylino­
cancer34-36
3412
effects34
Q61E
.Ikk2
E414K
.Subcloning
5′-CTCTTCAGGAAAGA
SDS-10
INHlBlTlON
STEMI
Berlin-Frankfurt-Munster
.FDC-P1
V55M
4-bromo-2-fluorophenyl
30–55
MMSP
C624F
Cys531
5′-GGACTTCGAGCAAGAGATGG-3′
HD33
50μl/ml
MONOALLELIC
274Phe
EGF/AKT/STAT
HA-RUNX1_R174Q
mutant–reintroduced
KANK2
140-143
ΔC-term
T468M
polymerization
doi:10.1001/jama.297.21.2360
MPLM
877
R249S-FL-CDB3
β-mercaptoethonal
L168V
L172
3/37
SUPT6H
TORC2
F1804
ZEISS
2p22.1
pharmacokinetic–pharmacodynamic
pluripotency.21
K335I
Chromatin
CHIC
vatalanib
insensitively
IyLy*G
TFAR
.Enhanced
Wnt/β‐catenin
~25,000
Fig.44E
hPMS2-interacting
anti-HLA/β2m
bulb
non-N-MYC-ampli®ed
90–97.5th
5'GCGCGCGGATCCGCCACCATGCCCCGGAGGGCGGAGAACTGGGAGC
4.07-5.75
2,279
IRF-1
1-μl
Fam
TGCTTACATTTGCTTCTG
1α-mediated
PB-induced
E921K
tan.puay.hoon
deproteinized
media.Con®rming
Jeko
S.R.
TTGGCCTCCCTTGTGCCTGT
GAP-domain
microRNA-adapted
ARE‐dependent
30–190
SAMN02214847
6,336
l•ut
alpha-tubulin
Th1/M1
Glu380
6q14
MLST8
GGTGAGAGGAGGC
785-6221
p.A68L
Haematoxylin–eosin-stained
2.Determination
mTORC2—In
VRK3
KinMutbase
NPM-ALK31
Assay—ChIP
p.H531R
203,490
ATGACCAGAAGGCAATTGGA
meCpG
C1767S
.MET-specific
Cazzaniga
C360S
1þ
_1144+
thepanels
5′-CACAACTCCAGTGCCACTA-3′
imido
tumors42
2905
F876L—alone
PI8
​Fig.1
Kolm-Litty
stability.19
carcinogenesis.10
meningiomas
FLAG-Smad3–mediated
81K
179.08
001093
487.5
Ca9
1-kbp
20-month
.1420delC
Campaner
Methylated
myeloma85
1.63–8.00
ABC-DLBCL,43,44
Campos-Ortega
TATAGACGCACAAACGACCGC
F/51
=–3.7273+0.1581×theimpactscoreofMAPPforMSH6–1.2824×theSIFTscore+4.6733×thePolyPhen−2
Ensembl-annotated
//rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi
SpectrumGold
HSC43*
Single-letter
347-2449
allo-HSCT—five
18F-FDG-PET
N-bis-
isoleucin
pCI-neo-BAF250
domain-based
13.5-day-old
0.2–1
pShuttle
chemotaxis.33
KIT-D816-positive
Kariola
λem
C490Y
www.sanger.ac.uk/genetics/CGP/CellLines
CCAAGGCCTTGCCTGATTGC
activation5
.Hematoxylin-counterstained
location-based
*70
.DLD1
3C11
cases–the
uteroglobin
NM_008293
Thr17Ala
Lovec
Karyotype/molecular
pBS-SK
60-Mb
necro-sis
H874Y
Whsc1+/−
Synthesis—The
pTRE2
wtBRAF
11991019
Hs578t
L232P
27°
153.3–158.9
14,54
re-interviewing
infantile-fibrosarcoma
Dauer
PRC2s
2E–F
E51
≈280
365This
notion.8
MØ/DC
cell-mediated
serum/glucocorticoid
5,72Â°Cfor
.Phospholipase
mbq
Rad50S-dependent
signalling35
F2442
G810S
three-quarters
OneArray®
Akt-independent
therapy,8
//www.cfr.epi.uci.edu/
DNA-Free
CXCL3
rs4245739
L1976R
124–129
MIR548K
KRAS-F
5V-aggtctacatgggtgcttc-3V
7q22-q31.1
RAD5
KH2PO4/K2HPO4
K56
hamartin.2
TFII-I
Irecognition
pLPCX
Mut2
sensitivity.68,75
subtype.8
MDA-468
0.60-42.5
S5.Figure
Prefibrillar
52◦C
PPARG-driven
CA1-CA4
0.1.8
IV:11
32185
psi-PIK3CA-MUT
KRAS/ARF/TP53
G-A-T-C
​Whereas
neddylated
concentration-dependent
Durick
syndrome18
MAP3K3
BH1–3
8/3/05
c.738_739delGT
NEUROFIBROMATOSIS
PY-E-MLV
Missense*
reported.3
centroid-based
−67
ter2565
database32
28en360428320
M2/M1
ChangGung
line22
V316
cycle33
signalling3
D30N
14⇓–16
Chemotherapy-only
proadipogenic
Y364H
Formaldehyde
mitosis/5
27599-7100
7757-1
DMEM‐F12
K420A
94T
radiation.23
fr1
FoxA1-repressed
Prolactinoma/GH-producing
Transfection—MCF-7
ATM-mutant
MicroArray
.Ramos
848P
Hydrolink
synuclein
Tcrd
1829R
Twenty-seven
NSCLC.5,6,14,18,19
B*440201
5′-TCCAATGAATCTCTTCACTC-3′
8-bp
hand-foot
fold176
information–based
CMV-IRES-EGFP
re-programming
pGEX-3X
anti-Smad1
PI-88667
autoregulation
GCGGGGCTGCTGGCAGCGG
al.,1996b
Smad3-MH2
arrest37,38
p16INK4A-/-/p19ARF-/-
RasY32F-GppNHp
ciliopathic
22/66
report.24
ETV6-EVI1
−593
.P1034L
S249C1.2
characterization.4
P1058F
miR-205
citrate–10mM
pGEX6P3
n≥2
cellsappeared
N204K
PPP2R1A-mutations
females.6
p.Q684X
mice.7,8
11/40
secondaryantiserum
5′-AGGAGGATCATTAACCTCACCAGCGAGATGGAGATCTTGGGTCAGTTT
P335
Prigent
3-monooxygenase/tryptophan
microfluidation
DvLNYVqtGgrLEpPRnCPdDLWnLNtqCWaqEPDQRptFhr
sorafenib
BCOR–Cyclin
212
C378R
Mek-dependent
bridgebreakage-fusion
Reconstituted
1q32
protein127
rdh54Δ
low-pH
A443fsdelCA
NCT00805
-GTATTGATCCCCATAAGCATGACAACCTATGATGATAGGTTTTACCCATC-3
31,382,116
PKB
toearly
studies5
DESeq
46K-
activator/maintenance
allele13
Hydroxy
observations12
G2b
.Female
vitreous
FLT3-ITD-W78
_ERBB2_/_HER2_
DelDIM842-845
NM_010442
attR4
βreceptor
125I-Na
Ángel
EML4-NTRK3-expressing
C109S
site,27
381-395
D+/+
CFPE82D,8
Melanomagenesis
CCAAGTCATTCCCAGTAGCAAG
/FOXO3A
cycle–specific
PKA/Ras/B-raf
aquaporin-3
PCH
1m52
5′-CCC
gamma-Catenin
NCI-H1437
andHER2mutations
14–encoded
3EQI
P480L-2
0111N
osimertinib
NEDD4-myc
findings21
CD3-CD4+
95.64
threonine-specific
TSC-complex
​Time
MM-141
Osteoprogenitors
Gargiulo
lines—UM-SCC-10B
L293Q
–SCH3
C115R
IMHD843
20608–20616
tearor
TPM
GST-IκBα
24/30
NikstopFL
VMS
activation.Because
UMV
TSP/GRP
.12,14,16
wasconfirmed
lines.Fig
K606
PASLI-R1
Asp65–Leu92
6-histidine-
5′-CCCGAGAGGTCTTTTTCCGAGTGGC-3′
DENND2A
U1-FH
TCCTTCTCCGACCTCTTCAAGC
Nucleotide-exchange
iScriptTM
Factor-Dependency
5′-gattctttcagaaacaacaacagctgct-3′
gray-shaded
4071
tumorigenesis.1
Pindel37
~long
cDNAcontained
anti-c-Cbl
one-fourth
R160C
5′-GCCCTCCACGGTACTTCCGTCTCGGGAGTGGATC-3′
-catalyzed
SLC20A1
q3w
†Data
beta-catenin/LEF-1
ACCGT
1698–1702
BIM/MCL-1
r30
lysine-to-glutamine
99-mer
BMP-signal
P=0.069
promoter.75
70–79
nonhaematological
N248S
I544L
Intergen
CC2
biotin-conjugated
Sprague-Dawley
teratoid/rhabdoid
1–305
D108
1818
variant-expressing
option72
v9.1
850–9
L-2HG
described.23,26
183322
mutations74
MTC-associated
FBXL10
property15
Msh2p-Msh6p.DISCUSSIONWe
1427G
death163
S4A–S4E
5′-GCCAACCTCTCGAACAGTATTC-3′
uni/multivariate
R217Hx2
GTP-independent
Axis-Shield
syndrome.10
anti–phosphoRaf-1
Fgfr2
Gly-289
α33P
N-GAMe
AocI
WCE
Thr-158
CREB/ATF
F.M.
MDA-MD-231
G482V
IM95
Ferrando12
cases18
P*-ss44
Table4
M1628VF
Table-S2
ter313
.RPKM
GSE65092
approx180K
ΔH°
uac
PR-B2-mut2
assaysFor
A'-P-T-K-R-K-G-S
N239Y-p53
CATTCATGCGTCTTCACCTG
ImageLab
stanford.edu
TP53mutations
0.000003
CSF-cNs
C.B.
D.melanogaster
Raf/MEK/ERK
2.00
S5H
417–419
30-paired
5th–10th
Platinum-E
S-phase-dependent
a-carbons
B-mercaptoethanol
TreeStar
37-
IRDye-800
E380
cells1
5739
machineryin
elf
self-excising
-27/-19
.HMB45
V143
γ‐tubulin
c.1174delA
ofTRK-T3
phakt-
ATF-1
.Non-transfected
Gq-linked
slideSurvival
treatments.Transfected
v-MPL
suite13
BLASTX
gi28436763
2.28-
GFP-empty-vector-positive
dCAPS
28en360428320-se*003131362
Branda
relapse.8,9
Moléculaire
concordancecompared
21,49,50
substitution,20
FGFR3ex12-FW
A054
lox/lox
repooled
IIE
codon768
NF1_01266
TGFf3RJ
typical/atypical
AF835
andcell-lines
I187T
R400W
withprotein
ein
mAbs.4
9q21-q22
p70S6K-T389-P
M126K
T17-4
611‐CTF
organs,30
VRFFGVCTEGRPLLMVFEYMRH-GDLNRFL
Biochrome
5500
KIN
donors18
Hoxa9,24
A455D
ezrin-radxin-moesin
Thrombohemorrhagic
ice-water
40/0.95
methyl-
cells33,34
IDH2-α-ketoglutarate
Gannan
ESCC-relevant
indicated.Patient-derived
KRAS-mutant/XPO1-inhibitor-sensitive
phenylarsine
80~90
76·4–441·6
c.13999+5G
.Multiparameter
7769
Brg1wt/wt
TEL-specific
tumours=23
mutantK-Ras
rhabdomyoblastic
arecloned
transcription.8
miR-103/107
Plasmid-based
interleukin-4
QRSTpS259T-COOH
nonsmokers31
mean±s.e.m
others5
Completenessa
onThenView
G02121
D304N
.Lentirviral
T-p53C-G245S
Src-I1for
P731S
Ichijo
study—both
andK
Val/Ile
progenitor…
.AB116525
HGrItKIcDFGLaRDIknds-nYvVkGna
T847A
-re
transcriptase
269–304
Figure5b
'C
77.9
cohybridized
TGG→TTG
chromatin-compromising
pseudohypoparathyroidism
co-overexpressed
G251D
Magnification
1.The
PTPdead
R37XM40L-Rluc
PFGC
15–18
CD48−CD34−
DE017249-01
221002
re-arrayed
G544D
sensFigure
MEF
CD34
95.
1-ml
p300/CBP
S.P.
stereotactically
perfectlyconserved
AGAGATG-3′
survivability
NOTCH1-A465T
HMEC-1
LP1
20q12-13
MLL5
cgfl.fr
18,118
UniProt
anti-KDEL
Mitogens
13
sc-8631
MMH-E-96009
3Carvajal
paraganglial
VMCUB2
782-783
111.11
42C
decreased.Table
S127
ade2-n
genes14
Sk-Mel-266
CFHR
3/73
GSI-independent
1.76×105
RUNX1–ETO-
5′-CAGAGCTGATGCTGAACCGCATGCGCTGCC-3′
differentiation64
5546
thisinformation
Mo7e11
014
AluSp
oncoprotein26
T59A
49-year
IC7
exosome
485–1653
E82D
ERCC2/RAD3
40,44
locus23
nondifferentially
IVS1-20
rcsb074384
rs56387488
irradiation-inducedapoptosis
L747V
ADAMTS19
seminomas10
58–101
2014b
C-33A
inhibitoryeffect
5'-AGGCGTTTGCATAAATGGTGCTT-3
X75621.15
allele/transcript
37-mer
expression36,37
FGFR1–FGFR3
HR=2.18
1996–2007
p.Val600Arg
p.Val121Ile
junc
*Excluding
four-tier
Y126
FITSIM
5.09
â€
BcgI
CYGB
pE3-
dPolyPhen
0.257
TGF-b1-treated
×86_64-apple-darwin9.8.0/×86_64
Axe
AML,7
mitochondria.1
1.160
caspases
-4A
abirateroneresistant
Hardy-Weinberg
APCCdc20
monoubiquitinylated
CCATGTTGGCCAGGCTAGTC
13/1303
1-46
G245C
19/68
afferent-mediated
Schuurbier
H2O/10
Tâ€
SW-1088
15,689
amrubicin
***
V91fs-ter94–transduced
ETO-positive
1.04–1.26
parotidectomy
P-glycoprotein
×50
1m
.TLRs
−.37
cell-line-derived
Imnuinobhstochemlstry
Sta
T269S
piceatannol
acini
CCACCATGGATTACAAGGATGACGACG
.GLI2
2008-A00781-54
deoxyguanosine
pcDNA3-SOS1
BRCAJmutations
pPEM-Luc
12.0
hyper-mutation.25
HOXAs
N2111Y
E554_V555del
EWSR1–PBX1
cctctaggctctcctgggag
predisposition.2,9
pEAM42
CTCCTTGGTTCAGATTCTGC
4Aii
di¯uoride
naturally-derived
reports.8,10
Bio-Sciences
K383
​and3
BGR1
B568
Kuemmerle
membrane20
Giacomo
Opti-Mem
lym
GAT→TAT
siRNA-based
two-tube
responder-patient
Rawat
Campomelic
organi
620.2
18q12.1
Q965
donor–hydrogen-acceptor
5/15
Hs.PT.58.39918935
R10
risk-reduction
protein.13
termini1
crizotinib-inhibited
//www.sabiosciences.com/chipqpcrsearch.php
ROR1+
assay-
101–102
-43
damage7
hMSH2–
p.Leu230Pro-XPF
Polypyrimidine
.Ciliogenesis
A_thaliana
40,104-S
giloblastoma
MacCoy
anti-CD38–FITC
TE-4
calpains
bi-dimensionally
S703
repair-mediated
17-218
ÃŸ|in
adeomatous
GGTAATG-3′
Tssk2
Opti-minimum
G5mTR-/-Wrn-/-
Cytogenetical
V336fs
pCi/
L350R
Qualex
Canceropôle
Capecchi
.STUDY
.Mitochondria
PGL
boththe
A1394
D53V
nitrative
understood.5-7
P081
E14
pADH1p53R248W
p.864A
|D0
HMGA2.25
dbSNP:1063664
NSCLC-NOS
ofTaq
P551L
Val-561
CCNB3-specific
halfmaximal
studies20,21
RACE4
PIK3CA-mutated
353097
Stubdal
1:1000
83.72
Sequestration
1MQ4
28/80
Storrs
TGF-regulated
RASGTP
62–789
DDR2-shRNA
EUn
mock/KO
0Expression
Taq-Man-based
tetramerisation
2731C/T
lanes7–12
PI+
Notch1-12
ern
.Alka-372-001
13C-glutamine
in15
self-sufficiency
geqslant
Smad4−/−
AB_11204167
tyrosine-mutated
IDH-mutant
290–375
ionization-time-of-flight
N286S
Nonsmall-cell
4.4c
Gaithersberg
37/235
re-iterate
–R267P
RB1-deficient
ofp21
T152
80i
V750
14e6
Matα
independence100
∼1000
60-fold
cytosine/
self-replicate
1975.5
1102
ab55271
Af9
40-yr-old
Sclabas
I375T
turnover16
andCC
Biosy\tcms
AY
8stretch
6.14
15,19
disease.33,34,36
Tlsty
430-bp
Gaebler
cortisol/cortisone
HT93A
SRY-box
Pharmacodynamic
V.-
R560K
11.1359775
Whole-protein
329/379
PPxY559
patients29
.RBA
Figure1C,1C
kcat/KM
fordimerization
optionsDiscussionCystic
HIF-β/ARNT
Flag-SPOP-expressed
pathway19
Eμ-Myc
c.3950_3952delTAGinsAT
Tamimi
multicloning
yl-carbamate
Rossman
AG185
SSPE
5′-CATAAATCTTCTGGGAGCCTGCACAC-3′
NF-Y
non-ampli
Kit-ligand
F3-II-1
NIN–PDGFRβ
1L7
poly-GluTyr
719
68.963
MAP-Kinase
F-SSCP
ufactu
m/75
D1-D289/D292A
Origine
V536E
H96D
4O–Q
p27/CDKN1B
DIPSS-plus33
p.T992I
miceSnf5
HN6
R282H
Med—Vol
Nonactivatable
injury.33
Storr
Elf3I279P
.0032a
anti-p110
MEN2a
59-GAAATGCTGTTAGTC-39
RAC-JNK
GelCount
CQ
3.5-cm-diameter
PJS03
pathway–activating
co-activates/co-represses
86.4
RP11-59H1
PBS-3
CDK1.https
Mencinger
RUNX-binding
SIMPA96
pAD–BRCA1–Δ2
312
erbB2-negative
predominance.3–6
NCT01243346
interval=1.1
C47F
TO-p53
pRBGP2
dexamethasonehad
B.95.8
Ultraview
HNPCClike
2569delG
CDB3-binding
Phe50Ile
proteins10
CDK10.P2
EcoRI-XhoI
upper-right
ARC03
mono-clonal
PTEN39-314
T354P
C•G
rightward-pointing
retrovirus-infected
AF-2-cleft
A352V
msh2-AD872p–Msh6p
mycXPLN
pT573
GFRA1-staining
2Chighwire_inline_linked_media
TGACCCTTTCTCTTGTCCGG
dichlorophenoxy
NeoMarker
/Kd
RI8S1
G477R
CTGTCACCCCTTCCTTGGCACTTTT
FR2BIC-CR2
81,82
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F5.large.jpg
D17S250.39bThis
.Clarified
TCGA-AA-3666-01
G93D
7These
p85α-niSH2
mpu
Rovinsky
.Haploinsufficiency
SW1271
ABL1
T3/∆N
hMutSα–DNA
alpha-A
NR6.E330K
55.81-56.74
report.9
61705
POC
Hicklin
phosphatidylinositol-3-kinases2
Glucagonoma
PC4579
yr/0
Smad2276
A-loop-mutants
p=0.48
R1–R9
1739
pTB-ex14-C
2487_2490AAGA
earlier15
E2-E8
medium/20
GM-CSF-dependent
I99T
E2516
662,1995
Hα
T67P
CIC-transfected
domains12–15,18–20
Lange-Carter
Manji
2.Soft-agar
LGEGAFGKVFLAECHNLLP-
culturesPrimary
5:1295228
Nterminally
coktail
hSNF2N
NSCLCs.15
−1°
2104G
Mawrin
methods16,17
progression.Materials
p-p90RSKS363
D347A
4°
LR08-261*
t/c
Biológicas
Tet2.19
D526E
Arg-925
HI/Mun
IL-1-IL-1R
NRF2-mutated
3.576
APOBEC3B8
-displacement
QIAgen
STK3
A723T
immunostainingAs
HbA1c
autosomal-recessive
Ba/F3.11,12,37,40-46
multi-modal
D487N
IA-IV
H1581
R703P
5′-AAGGAGCCCAAGAATGCACAA-3′
checkpoint19
Z-IETD-FMK
propeptides
P535
FGFR1ΔC-myc
MSH3-dependent
MMP9/calpain-2
insulin-mediated
His-Ub
Koziczak
1-methyl-2-pyrrolidinone
enzalutamide-treated
for15
EBF1−
SNPs3D
ZFNs
pMDgagpol
methods.35
anti-pan-Trk
CMV-CD20
years.6–8
Komuro
PGK-Crem
Snf5inv
susceptibility.31
Sp6
follow—or
isnoteworthy
phosphatidylinositol-4,5-biphosphate
.Actinomycin‐D
Esophagogastroduodenoscopy
processes.29–31
.MS
4480285
photyrosine
CACNG7
pmCFP-K-ras-R164Q
L747S.16
HOCPC4
loss-of-dfunction
Bax-containingreporter
F958V
ENU-induced
χ-squared
Y1234/Y1235
cell-boundradioactivity
LRPCR1
1-5-5-4
thenotion
LiftOver
PVDF
29,30,81,82
0.0412
R188
FGFR1,17
2012.1
.Selumetinib
MRN
UT-7
c.5078_5080delCTG
Osterling
Fbxw7-shRNA
shLuc-treated
.Reviewing
Replating
restoreDNA
G719C+E709A
factor-1α
Ki-67expression
8B–8H
JAK2-phosphorylation
ninety-eight
2017
.K5.Smad2-/-
MutL-homolog
AGG→AAG
U138MG
vascular-variant
BEAS-2B
predictorc
MEK2-V5
P.G719S
ciently
F13**
SDFL
0,36
Tris/Hcl
X-100/PBS++
7–185
-cI1
TGF-β–SWI/SNF-MYC
MEK1-T292A
colleagues.19
.HDX
R524K
4858S
Ki-ras-2
lowrisk
pE1E2S1GST
nucleosome25
activator-impaired
4352930E
0o
D19MIT41-R:5′TCTGGGGAAAAAGGATGAGA
63.6–92.8
5′-ACAACAAAGGGTCTTACCAAG-3′
imatinib-intolerant
Rap2b
NOR1
ofIFN-'y
aminoglutethimide
RP11-195E2
1-hr
interspecies-heterokaryon
Sample007
receptors.17
al79
.Normality
RTK/RAS/PI3K
0.038
10.1002/jso
DeNardo
exon8/intron
295-337
articles9
GACTCTCAGG-3′/5′-CCATGTGCTTTGAGGCAGAC-3′
CD4−/CD8−
iv–vi
rs3795850
p4E-BP
GRB2
mMdithiothreitol
demethoxy-geldanamycin
promoters.15
Y/F/H
Endocmology
'E
OCT3/4
L138F
quantifi
//www.ncbi.nlm.nih.gov/Structure/lexington/lexington.cgi
TGGTCAAAGAAATGTGAAAC
liquefaction
SPC-A1
nonepithelial
MPLW515L-positive
Y-MESO-28
mesenchymal-related
SBE4-
TGF-β1-positive
sc-7176
16p13.1
extraction27
other/none
stage.1
HumanOmni2.5_4v1
Mapk4
2.0
Redston
~15-20
AGCTGCTGCTTTGTG
PDGF-A-positive
Shp2K76D
A435T
pathway.7,51
CDDP/GEM
21-30
IVS6+7G→A
.Cell-Adhesion
up-regulation
Dissociate
0.10-0.30
lines147
Anti-rabbit-HRP
75-d-old
Σ
adaptor/scaffolding
panitumumab11
PALB2-deficient
.Strand
hypoxanthine-guanine
cancers.29
cells,69
loop-sheet-helix
2503
mutations/allelic
TGGAAGATGATGCACAAGATATATTCA
PBCre4/Foxa1loxp/loxp
G25R
Glu/Tyr
UniProt2
Ref1
.Gpa33tm1
.Cre
S847A
mice.13
.BIM
p.R346W
matrix-attached
holo-conformation
.KLK2
BioWorksBrowser
LUMIER
//www.r-project.org/foundation/
premature-terminating
proheparin‐binding
L863Da
Rad50nc+h
A090281
NB-200-106
dITT3
,2,3
4205
0.266689223
BioMart
.CRNDE
GFPshRNA
pathomechanism
struc
Pyrogram
mutations—2
AML1/RUNX1/CBFA2
B1
RAD1
fusionThe
non-GIST
ΔBRIP1Flag-pENTR/D-TOPO
p53The
M010-DC-DNR
progression.61
Clinical-pathological
handle.Among
VIC-positive
intramuscularly
StarTaq
Quintás-Cardama
GNE-929
600x
GTTCCAAGAA
R2430M
activity.5,56,60,61
.Five
signal.12
MEG-associated
S364A
P.L858Rb
3,9
bidirectional
super-activate
5'-ATAGGTGCTGGGATACAGGCTTG-3
JQ778219
Kleckner
translocation.32
Alu-repeats
MicroPulser™
subgroups.3–7,9
ERK2E322K+E250K
salt-extractable
Del746-750
0.001bLYL1
Winey
Bcr–Abl-driven
proliferating
SOX17-
mTnf-Reverse-1
exoSAP-IT
B-isoform
bindinglevel
53-
FCH
Sennana
endo-β-N-acetylglucosaminidase
ab134175
5′-GATGAATACATTTTTGGCAAGCCAAGTACTCCATG-3′
A/V
expression.21,34,35
E40C
Metohds
702TCS
L106
AGATCGATGGGCAGAAGCTGC
10.71
NM_008606
BRAFi-resistant
RYS
K335T
domain—a
PTPN11
BCR-ABL2
chemiluminesence
12/9/08
Thorlacius
GTP-γ-S–loaded
techniques—unlike
.Heterotrimeric
p38-stimulated
ucsf.edu/chimera
EWS-FLI
C-RAFWT
.Abnormality
R-CHOP/R-CHOP
E867D
GTATCTGTAATAATTAGGTTTGAATGGCCC
p.F486L
cDNA4
R1378P
protein-assisted
thesemutations
identity.1,25
pGEM/BRCT
MYC-IGH
ΔMATH
p11∼13
inK-Ras
hBRM1
GCGGCTGTGGTGTGAGTCCGGGTGGCGGCCGTAGCGCGCCATTTG
-2121
Q157G-1
Armadillo/jp-catenin
arteriole
Lys-8-acetylated
pre-cleaved
LDACs
P=0.62
grade-3
BRD4–NUT/p300
S6D–S6E
London/Ontario
18F‑fluorodeoxyglucose
Tau-5
I725V
Pathogenicity
//p53.free.fr/Database/p53_cancer/all_cancer.html
2B-2
V647M
152–180
10.1158/0008-5472.CAN-10-2164
72,205
pan-resistance
ican
ROCK∆3
.Primer
6G-H
Chompret
5B-F1
ii__f
database8
M120T
B1106
Willmington
.DUSP4
IVS07-2
0.000‡
252A
G162E
D529N
3505
0.09/7.1
.MLL-deficient
2delTAAG
decreases23
glioblostoma
086
anti‐mouse
phosphatidylinositol-3,4,5
16/180
nutrients135
.Gain-of
S1484L
PI3Kb
~A11
DSBR
epitope135
Sec31A
GAIIx
—CH3
170854
BD12
10S*
FYN-related
17-activating
1778
acinus-like
SUP-B2
Extramedullary
Dax1
bead–isolated
T1038I
S1473P
Bellvitge
Hh-stimulated
//doi.org/10.1371/journal.pone.0005137.t001
alpha-methyl-L-tryptophan
clinically/radiologically
Myc-WW-PDGFR
P=0.043
253
vasoactive
A_51_P123405
r-~
TGFRBR2
phase19
beta-Actin
1985a
ARHGEF5
MedCalc
large-fragment
β-5
re-immuneprecipitated
BTB-Cul3
s6k
O-P
IMR-3226
UOCB1
.Discrimination
GAAACTCAAGATCGCATTCATGC
.Single-sample
signaling–related
PIK3CA-dependent
β-galactosidase–expressing
4um
CLA
OCUT-2
Fig.3C
1655
NKY492
P=0.015
Wolff–Parkinson–White
In-fusion
BCL10-MALT1
Hindil
function24
991
D658G
leukemia.8,32-34
P-valuea
virus–positive
COOT24
Pestalozzi
KK1
118C
p.Ser1238Tyr
Cell-cell
XBP1
Lys-31
Y1090
PCR2-r.
57A5
entiation32
APC/Axin
-nonmutated
SST
nf
L145P
/lookup/volpage/21/3097
AATGATACGGCGACCACCGAGATCT
D43B4
6-week-old
proteins.39,46,47
TTTTCCCTTTCTCTCCTTGG
GCCS
RAS-mutants
protocol/workflow
M33
SASI_Hs02
AzaC
.TopoCloning
.inhibition
​Figure2E2E
non-cell
Turkson
del15
c.8525insA
.3140
WT-Shp2
c.1629delC
IDH2,15
Ricci-Vitiani
Spurdle
12ql3
p.R505Q
Superdex-75
technology46
m−1
In-solution
GCTCTTCAAAGGTCGTGGTC
mutation/insertions
immunophenotypes.14
PIK3CA/RB1
Ta6Br12
7,054
cancer.3,6–9
anti-Hsp90
gi52632375
1,12,16,17,20,36
4-min
TALLA-1
P-Direct
3Myc
μg/plate
NRASwild-type/BRAFwild-type/cKitwild-type
transfec
DpnI-based
2915
Y568•••F848
1997c
used50
c.196dupG
phospho-inhibition
.Kwon
1331
sensitivity14,23
thiazolidinedione-induced
copper-enhanced
Nell2
CD45.2
thereporter
b-raf-/-
JMML2
cells—indicating
SHY
10ml/kg
control/clinical
1-specific
​Cyclin
=0.0095
Glu138
melanoma150
IDH1-R132
M051
leiomyomatosis-associated
C-RAF220-268
Fas-mediated
HA-SMAD2
DQA1*0501
q,22qâ€
WP1066
E937
//www.asbestos.com/mesothelioma/
CDK4-inhibitors
A-21244
.Effectiveness
HOMOZYGOUS
tophat-fusion
8083
SM-acute
p.M1I
MEK-targeted
N9
DNA-methylating
SwissDock35
DLBCL14
W110
L225LI-transduced
2y-PFS=90
pro-invasion
heteroduplex-modified
200–950
786-O/RCC
notunique
thelikelihood
productiveonly
1b–f
fashion.These
transfor-
.Ratios
p21waf1-Luc
.Doses
277–309
CS23
colony-counting
BAL3
Luebeck,2003
35S-MLH1/GST-PMS2
V851Xa
clinic91
ÃŸ2-MGRNAprobes
F285
Hertog
Microscint-20
hap+®
ulysGl
Extra-TM
83·8
30-39
C139G
ΔAnk
JF
pathway.9
oncogenesis,34,40,43,46,47
Mapk3−/−
Ar-
006
cyproterone
well25
c.2054A
ATCTGGATCATCCCCTTCCGC
P540
.Tzivion
TNFa2
levels.26
1/M
Krypuy
sup-
gmRNA
GMEP
KMT2B
TRIAP1
hydroxyurea
paired-end-mode
×4.Table
PN3
5′-CCATGTTGTTTCAAAGTGTCCA-3′
77.85
delP449-455
5′-ACCCCAGTTGTGGGTACCTTTAGA-3′
.1039
Dose-response
Grinkevich
Flag–N-CoR
6-99-006
13-bp
q42
understudied1
PCR1-f
BAK30
1302
mei41
neuturin
L1775V
Immunoclearing
EWSR1-NFATc2
His371
/CD13
≥6.Real
12–17
5′-GCCTGTGGATGCCACACATG-3′
Bric
12,19.
30,57
Nterminus
SAP2
translocation7
reported10
metaphosphate-like
actinin
SUZ12
CTAATCTGGTAGA
cap-bound
Elf3—Elf3
SNPstats
leGI
mailcode
ALR/MLL4
Glu199Lys
↔
FO/vehicle
5′-32P
JM-S
post-differentiated
breech
mitochondrion
beta-microglobulin
well-known
IgHcα
U-TV1X-2
D816H/G
MNK1
sulfate-8
c.730A→C
10T½2
HEC-1-AARID1A
recombination.3
c-MPL
CAncer1
progenitors.31
genes.16–18
CREERT2
0.00261
otq-Q209L
Irf4
CNE
123:853–860
NRAS
ENST00000292538
16–19
7d
regimenused
SET7
5′-CAAGACTCGGTCCCTGAAAA-3′
l2R
8.17E17
apparent.22
GATM
Y341A
cdk6-
​High
hypothalamus
codon–optimized
Bilayer
Gurok
NF1/CRAF
mammalian-specific
lkb1
60–95
SFIH
/Gardner
Scorilas
half-maximum
2–56
uuAG|ruu
42.7/12.7
RETV804M/Y806C
clathrin
FFL/RL
.Loss-of-Function
p.Q747*
Alizarin
vectorsThe
.Consequently
transcriptome‐wide
5′-AGG
.shRNA-Mediated
Chx10-
MLPA+
theN-ras
c.1906G
n=468
NM_004360.3
imatinib.2
immunoanity
Ser-Thr
0.0023
mid-low
2009c
RAF-mitogen-activated
L151F
885
Gly-X-Y
35SMethionine
ten–eleven
GFAP-expressing
∼1.5-
mutations/SCNAs
anli-HA
construct*
Wnt–β-catenin
topmost
580-630
mmf-max-hq-mismatches
15~20
region24
Plasmids—Full-length
5.16E05
single-allelic
5MS
Thymidine
Il11
GTP-analog-bound
synthesizeH-2
p.H179R
I−
pCE
5′phosphatases
silico–genotyped
.FuGENE
Cullin-based
c.1615G
n=18,674
oftumors
CCAGCCCTGTAGTGCCGCCT
H-119
ICAM1
KSCASQDSSAFSPSSDSLLSSTESSPQG-
K120-acetyl
TSC2-fl
GST-Rb
CCL-121
Msh6/3
ATIC-
DNMT3A,8
HERV-K_22q11.23
Figure2E2E
kinases/extracellular
high-read
3215
HOXC4
Yergeau5
AGAGATTTGG
0.00006
GTTTTCCCAGTCACGACTTTGCCTCCTTCTGCATGGTATTC
Ni-nitrilotriacetic
172–499
G838-R817
v6
5'CAAAGAGATGATTGAGGCCTGTTTAGATGCAAAATCC3
Garami26
L460A/T474M
mRNA.9–13
VEGFA.36
me2
SW55
MM.8,11,56
3.6±0.3
3221
TET1-CD–expressing
pRBfamily
novartis.com
Reichel
S0376T
labeledwith
T341
590/20
2756
Gab2/
IG/MYC
pCL-Eco
drophobic
fir..i
origin.70-72
3T3EML4-NTRK3
LABType®
n=195
Moleco-
5–100
phosphorylation-state-specific
ZNF2
pcDNA-RFC-140
monoubiquitination-dependent
20152817
Soutoglou
Moll,2
KIP2
diagnoses
457–467
64K
immunoglobulin-μ
vpl
Reschly
Faivre7,8
Wisconsin-Madison
EGFR-A763
C-lobe
lines9–11
Rebouissou
blastlike
5*RACE-PCR
12–389
promoter,8
2Â°
.EZH2-mediated
www.appliedbiosystems
erbB3-targeted
Clonase
CP110
32D-FLT-ITD
I144T
cases—this
GTAC-5′
2.1–133.5
18.3±2.9
CSCC
M539I
R882H-specific
N-succinimidyl-3-
TrxSIP1
0=damaging
sn/snoRNAs
FusionPlex
NKXD
c.866C4G
sanger.ac.uk/genetics/CGP/cosmic/
IV:4
KD1067
PD98059
phospho-AKT-
ID-affected
breakage-induced
pCRKL
NM_010228
C66B5
Holstege
posttranscriptional
air-dry
271C
1ml/min
Lys820delinsPhe
.IL-8
Y842H/N
PCR-
Ponatinib-structure
HyCLone
3521–3528
601-612
anoma
−3.43
cAPC1
P1R
pCR8-ERG
Anti-ACTIN
QuikChangeTMsite-directed
epiregulin
earlier42
12-tetradecanoyl
†9
GGAGATCTCAAGAGCTCCTGGl-lTGGCAGC3
affinity-purified
Ile-563
WNK4
μg/mg
CTCGAG
0/192
4065R
pET21b
cocrystallization
W300
0.45-mm-pore-size
TAP-tag
7p12.3-13
plateletderived
anti-VGLL3
ATP.22
SHP2/PTPN11
ful¢lled
9/77
Visualisation
InhibitorsThe
NUP98-NSD1-Positive
TSC2-low
Ala-160
statins
break-fusion-bridge
EPD10
NCT00780676
.Acad
SSNVs
regulation,24
MAB
activity21,22,23,52
FLAG-tagged
25–124
GST-CDK6
SN12C
promoter–based
Zamore
Dalldorf
2,4,19–22
A818T
pNIC28-Bsa4
Microinjected
selenomethionines
335-17209
Nonhematological
40minutes
S-phase-promoting
Facebook
Phosphoantibody-based
TAK-441
Themedia
M449
.Methylation-positive
functions10
MERM
CCGGC6CCGC
5′-GAGTCCCAGCTGTCAATTCC
SENP1−/−
.BAF180
2/18/03
HyHEL9
differentiate1
Annotate
RARβ
A-D\
corticosterone
.TSC1-coding
.Efficiency
146-
Robo4
EGFR-tyrosine
GIST780
K104N
Krkljus
G328R
microsequencing
Polyadenylic
25–52
36.A353T
reportedmore
980
Druggable
4157
OriGen
JAK2-mutated
invasiveness/metastasis
56
Ile232
mutation.5–7
5′TAGCTTCCAAACACAAATGC-3′
cell-culture
plasmids-pFC38
cells7,8
AIM1L
956e11
imitinib-sensitive
4080G
VACTERL
multiwavelength
vHa-Ras
ofcases
5′-CATGCAGTTGACCGTAGTCTCC-3′
TAE684-sensitive
leg-
METlHGF
P=0.039
SH2-PTP
Permanente
BHLHB2
dysfunction39
Li‐Fraumeni
RG-10T
S256F
ARP37963_P050
Marculescu
TFs.79
megakaryopoiesis24
.Sub-cellular
3143
nonhierarchical
high-baseline
122/298
SK-LC-5
orROSJ-encoded
ITyrLouAI
immunohistochemically
10/418
100–800
EGFR-RET
P153L
5p15
density-dependent
low–molecular
p.R5Q
RP11-372O17
AGA-39
bioETV1
.S5E
320–340
∣Amax∣
lentiviral-infected
.Y472CBRAF
p.N570S—are
Hufelandstrasse
as-yet-unaffected
R347H
3y
FGF19/FGFR4
0.39-fold
mutation-independent
//faculty.vassar.edu/lowry/
Tet-Off
Ep-CAM
MHH-Med8a
×10−16
0/1+
N659D
'-nitro-N-nitrosoguanidine
differently-whereas
MOLM
.7B
MSH6-Mutation
H145
preprocessing
D-2
199,000
Lys623
CHIR-258/Dovitinib
STAR-related
o104
formalin-fixed
L.-X
Medico-Chirurgico
58-79
1083–
multiparametric
NHA9-mutant
degradation10
ET|
violet/10
p53252-258
mass-modified
intopCUB7
Q—
cytokeratin-negative
71K
Pik3cae20mwt
GTMSIN5
Fat1active
chemotherapeutic
141:1
αM
675.1
30.23
550-591
a-Keratin
ins4
2–365
acidic−7.3COL8A1amRNA
7Dâ
TCF-regulated
Ly-6G
P248Q
4-column
disfigurement
Extrapolations
Sulzfeld
PCR-induced
NM_010810
198–277
.Urinary
Op18/stathmin
IL-4/STAT6
80:20:1
ΔZF/MSCV
205/75
M3539
PML-RARα
p.K147E
76/78
.May-Giemsa–stained
Y740-S744
protein-protein-interactome
0.17–22
S338-phosphorylated
Pten-mutant
ibrutinib
NIN-7
Anti–CD8-Microbeads
161713
–24.0
.Shield1
SMC1-phosphoS966
mutations13
pLU
104.3
ACAGGTT-3′
His231/Phe233
M840V
.DB_NUM=1
IL2RG
genes.36
MLL-CREBBP
450/655
10-fj.l
signaling12
S3D–F
p53-altered
c.8165C
conucleofected
ECL
NaCl/1
0.202
25495
350–530
3,901
Imbalzano
4,000
BAP1-negative
CK1γ2
BRAFG469E-expressing
K853
PIK3R1R348∗-
c.7975A
V271L
J022
graph.Scale
Irs4
Chitale
Gln317X
Y28A
Glu40
∼0.5–1.0
PSMP3
8B-R
apo-retinoic
.Aurora-A
RTKs.33-35
≥15-fold
pol30
R179W
offurther
wide‐type
tumours20,22,23
Menopause
250.2
tumours71
Isokane1
Wnt
Reznikoff
activator-binding
HTR5A
c-KIT-mutant
/S6K/rpS6
pathology-reviewed
D36Y
Parasympathetic
A1200
C72A
αIFN
3048
MRP2
N233fsX283
Fifty-nine
ERBB2-mutant
Na-vanadate
Coprecipitated
STI571-resistant
Glut1
IKBL
pVHL-Cullin-2
TIN2
CAGATG/gtaaga
JFCR39
PCNA
//tcga-data.nci.nih.gov/docs/publications/gbm_2013/
addiction148
cadherin-catenin
functionalunit
ESR1/YAP1-expressing
KRas-containing
development.10
iOO0
.0025
Pull‐Downs
amplification410
sub-groups
Hekman
amplification-free
CCAAT/Enhancer-Binding
Transductants
72:2727–2732.10.1099/0022-1317-72-11-2727
si-ASC-2
24–72-h
Sheng-Bin
ΔF-Fbw7
*indicates
VAVKTLKEDTMEVEEFLKEAAVMKE
progressive/recurrent
T992
mutationsclassified
1/99
2,805
Watertown-Mass.
Kee
.Virus-containing
months1,2
homozygotic
24-
TLS/FUSandERGtran
REM/Cdc25
gelatine
White-spotting
1p34.3
866
al.,1993
E-cadherin-inactivated
approx36
3T3-bearing
4.50
PS=performance
dimerize
4043Gly
t6
.Transcriptome-wide
OD340
o.a
SF3B1-Mutant
USA/Applera
4214
EOSHA
F428S
Albelda
selection31
1490–1515
icity
bioenergetics
659
GDP-HRAS
Her2/neu
4Ai
2,7
NS100
p16/ΔΔ52−144
4.15
4-5
47.12
complex27
dependentclones
BNL-CL2
sh-Smad2
screen.FIG
ARID2-mutated
Flt-1
THPO-binding
Cul
TACC3ex10-RV
9â€
Tyr126
Asn-X-Ser/Thr
Kaul
employed.5,15
FA-associated
FAK/PTK2
Fbw7alpha
.potential
frequency-based
Immunoglobulin-
FM4
monotherapy.17-19
P436R
seminoma.8-13
complex-like
Leukemia†
Forty-one
Olayioye
frma45
TMPyP4
1483/0/158
hyperlaxity
Kt
Nextera
rapamycins
GenPulser
pBTM116/CDK4
R521
Ras/RAF
FSTL5
regression.7
aggregated.capture.tcga.uuid.automated.somatic.maf
IRAl
MMT.1
Age-dependent
conformation31
2.60
−12.4
FLAG-PIPKIIβ
S100A2
PIPKIIα
iin/
AS-qPCRs
promoters.2
reflux-like
crossbite
×1010
6I
activity.11,12
.Her
-2-butanolic
64
Aisner
HA-Akt3
embryo.Met
.Lentivirus-mediated
APL2000
Fig4A,4A
kinase17
tumorresponse
.Tyr42
.Interim
resorbed
CitriSolv
Noncavitated
CCTTCGATCTGGATCTCCGC
.Bidimensional
p.Arg127Trp
,3B
Lys430
..FSKFGG
RP11–226A18
FR‑TKI
Low-Serum
combat.46
c-kit-positive
C311
11447
R351W
99–122
200KB
c.9325dupA
marrow/
fourth-degree
54NE
0.0193
162,774
c.1531G
der15
phospho-RTK
Selumetinib/docetaxel
4-d
F419_E8splice
r.kumar
disease.18
Sca-1+
Eighty-one
Ex18F
pTRE2Hyg-luc
LRRC37B
33c22
mice.9
516
pDonor223
3703
HER3/erbB-
ELRDLLHFSS
5′-CCACCATGGATTACAAGGATGACGACGATAAGGCGTCCACGGATTACA
380.1
100x
R260W
AF307851
.Chromosomal
institutions.Reverse
groups.39,40
R1207*
AquaPure
HD-0205
fusions-driven
complementary
flanks—were
cellfree
7G11
neural/neuroendocrine
SNAT2
pediatric/young
2005N000148
dentition.1,4
Δhinge-LBD
Tyrosine-64
CHD5
leukaemias157
D1-CDK4
17p—are
ΔSUZ12BD
hormone-sensitive
αP-tyr
Y698
photomorphogenesis
2-succino-cystein
LKB1-D317
circadium
.IL-2
.HRs
12,314
21–31
Bullrich
*Melanomas
ttgtag/TATCAT
Nullizygous
1-mm-wide
C171S
87.
4.47993
p-interaction=0.40
.499Men
dil
circuitous
CAA→TAA
IKK-β*
HER2−/HER3+
314-bp
complex.The
anti–Erk-1/2
.FLAG-Gab1
12.17
RUNX1-unidentified
5′-atgtccagaaaaatccatggcggttctg-3′
Pro-34-+Arg
Q8NFU7
LUC10
4400-330
G719A+S720F
study.Patients
formation.14,15
Extrinsic
isothiocynanate
Y823N
~Equation
10,15,34,38,42–44
VCaP
.Expression
alignMatesGapMax
Π
nsSNP
UCCWG
Vignot
rs2420946
opticaldensitometry
over-riding
MLL-MLLT3/AF9
operative125
//www.hapmap.org/
72P
protein.19–26
c-Ski
I6
M.C.S
downregulating
q23.2
Brca1FH-WT/+
T575A
Refaeli
DDR2/ERK2/SNAIL1
l'7p
0.7215
antigens.9
wefound
40/129
+0.52
Palpable
F/25
44·4
Lkb1/pAHC
ana­
335-amino-acid
CCAAACACTCAGTGAAACAAAGAG
rapalog-responsive
Nefkens
CAD-ALK
anti-PDGFbR
T196fsdelCCAA
Barford
1.2-
Met-5a
nin-binding
SDS-PA
M455V
AGCCCGCCCTTCTCAGTAC
Liquid-chromotography/mass
DCLK1
Hs02182510_cn
16-fold
BI78D3
foramina.16
TCF-3-ID3
Cys176
∼87
17q12–22
PDGFRA/B
PIK3CAs
D820G4
stellar-shaped
oligonucleotidesubstrates
MoRAsand
5′-GGAAGATGAAGATTGCGGATTTCGGCTTGTCCC-3′
EMAP-like
androgen-starved
transfectents
16k
21-27
550–562
Haematol
1129–1936
IGF-mediated
ATP-mimetic
BRG-1
WK557–558
89,90
Ser94
FAAH2
Factura
.TET-inducible
MKB-1
GISTsof
ARN-509–Treated
Serine-15
71-gene
NC_000022.10
bevacizumab/carboplatin
fim
W.D.T
Massagué
rs2304255
culture-initiating
Eng33
Tyr-292
n=20Primary
affectthe
.FAP
Heuchel
48,087x
mutation-driven
gene.34
MLN-518
Renila
α2-α1′-α3′
GATA-3-specific
dithiothreitol–10
Unpermeablized
pX458-sgRNA
A347S
NUNC
mSin3A-ETO
Q176K
TGFβ-
approach.26
10p15.3-p11.21
2.648–4.917
wide-type
AccIII
GALl/O0
HD-0300
downurestream
Hidekazu
2714
Anti-Goat
pLHL4
HET
al.83
.RBM5
NSCLC.39,40
Non–Small-Cell
AS-MTC
TP53-variant
tgB
1.4–2.0
phakoma
p50/RelA
1.35–3.20
c.835_836GG
ÃŸ-cateninin
NOTCH
CBP-related
'kinome
QMPSFs
.Anatomical
genes26,54
5′-acttgatgcccagaaaccag-3′
exon39
biotec
Lbh-luciferase
45/EC
S637L
A.L
c.641C
nonamplification
197-1,732
.Hif1α
serine-phosphorylated
RCC25
co-ordinated
Ramakers-van
micro-PTC
Inter-observation
268-471of
Krab
AF-594
Ala743
TRCN0000018336
139-011-9933827
.Wortmannin
Uniprot
R248C
PKCϵF
21,29
sequencing.I3
F=female
codon-switched
nonligand
Gly-Xaa-Gly-Xaa-Xaa-Gly-
F39V-
K00207a
c.52_57dup
IAB
Tatsumoto
anti-EGFR-targeted
87·2
AP10103b
87–91
p.L265P
GCG→GCA
/p70S6
-VHL
Flag-MLLN320
Thr790Met+Leu858Arg
379D20
1981
p85–iSH2
al14
0.951
Muenke
2250
disease–like
VH4-34
3638_3639delCT
cancers11,12,13
HBC5
.Calculating
Ct-b/CYT-2
intimal
antiphospho-ERK1/2
0.847
gagagaacgcgtaaccatgtacccatacgacgtcccagactacgctatgggccagactgggaag
C228T
Pivot-Pajot
sunitinib.30
L175P
-GCGGCCGCTCGAGTC-3
1702
DIVISA
Cy5-deoxyuridine
p.Leu585Pro/p.Ser677Thr
shockedat
0.128-1.169
choanal
/F12
intersect
POLYPHEN
CCAAACCACTGCAAAAGGAT
−68
G199R
fluoroescein
TAP-1
AID=activation-induced
Lindsley
leukemia.145,146
CoIPed
Akt-Myr-K179M
human-based
GGCTTCCCACGTGCGCAGCAGGA-3′
inactiva-
α-globin
p21ras–GppNHp
Rc/FGFR3-OPM2
virus.93
-CAATGTTACTCCAGATAAAAGGCAA
.Supplemental
domain.150
D105
–G
4.STRN-ALK
locus.3,4
clustering-based
+++/0
prometer–driven
EN-Eph4
G289Ex2
5.54
GTP-RAC1P29S
//indi
≈13
872
pre-punched
patient.60,61
53BP1/BRCA1
Matallanas
phosphoenolpyruvate
HumanGenome
:689–700
Native-IP
2.0-15.7
.PBMCs
non-randomised
serine-threonine
11/90
-PDGFRα
glands.4
−1.938
AFS/SF2
HSRNAFEV
AZU-1
–fold
Siftc
AACLys
19,41,42,58
adenine-to-thymine
.MolecGIST
p.Val265_Gln314del
hp110β
transformation/dedifferentiation
58-year-old
BcorFl/Y
RAD51/RAD52
half-life,26,27
Ruan
CCT2
revealedthatcodon634
EML–ALK
vectors13
2I–M
17q23-q24
instability108
Y1131/Y1135/Y1136
P127T
LTC-IC
11q-gain
oncD-specific
melanization
TGF-β
sc-12318
3.76
4*.-
less-frequent
PCR-SSCP
F.F
diaminobenzidene
number-associated
M183K
5-kinase
link-induced
SDS-15
cell166
.S2.7
retro-orbitally
tumorigenesis
immunochemiluminescence
GNRHR
G178V
hyposplenism
5′half
de-emphasized
II.4
response–proficient
FFAS
mass-screening
BMP-2-stimulated
p3xFLAG-CMV-14
L21H
S11IP
P94L
7p13
5′-TACGCGCAGCGTGACCGCTA
deoxycorticosterone
hAGO
Scheidig
//www.crukdmf.icr.ac.uk/array/array.html
.55,59
tumor-
59-AAAAGAGAATTGTGTGAAAATT-39
57°C
RadPrime
/his3-D200
n=309
121×
CGGGTGGCGT
Desio
g.156713
HA.VHL
heterospecific
CCCAGAATATTTCGTATGGTGC
GACATCAGTTTGCCAGTTG
Latho
tumor-node-metastasis
Y652H
Sloane-Kettering
07/03/09
â„¢Â
RASSF
p.Gly12Ala
poker-straight
.Answering
antagonism-to-agonism
Dpar/Dper
6Guardant
5′-AAGTCGATAGGGGGCTGTCT-3′
5′-AGGGGTCAGGAGA
L277P
Diegem
-1652
SRB
rmsd
SstI
PALL
2305G
changes17,18
overproliferates
p=7E-4
CviKI
drug-Bcr-Abl
MO1
Ser554_Gly587
squamo-proliferative
.Pim
.9–12
Echocardiography
5.5-
Cebpδ
58:1336-1345
CAPRIN1
Pre-miR-15a
Hypertrichosis
CRL-1740
0.0556
oligodendromas
log-rank†
cascade.8,9
p53N239S
complex.19
www.broadinstitute.org
Y530F
DLBCL5,6
NTRK1–38
4985245
homodimer-dependent
tumors20
vivo
1,517
chloroform/HCl
EGFR20F1
.Water-soluble
EGFR-Sept14
SHP2-regulated
Pourmand
.Interferon-regulatory
1–155
L129F
noninformative
.Aissaoui
Cobrinik
.S.c
Y529L
7e–g
damage,4
GSE9654
V+Vab
psi-eco
cross-interfere
4-15
DUN1
6·105
-UTR-WTLuc
.tg/mlHoechst
individuals.17
30.90
NOM
anonymized/deidentified
GVMGFO
AGA-*ACA
jffjf'â€¢
Moreno-Bueno
586del
26K
3D6
LIQFYNNIYIKQI
HSP90B1
TCR-activated
L157W
.Non-immunized
CXCL11
Gly-Thr-Pro-Glu-Tyr-LeuAla-Pro-Glu
.PDGFR-induced
rected
HCT116+DN2R
methylation-low
3889
.Macara
hyperpermeability
anti-A1/A3
proteins.34–36
SMARCA5–EWSR1
Chr3:71026829
Ttr
1:10000
PTEN-CENP-C
C67
97-41
RedAccuTaq
TMC4
muci
Br65
Maher76
sample-loading
J.-L.
–T389
tumor-germline
T72235
En3
NPM1c
c.8953
mice88
S.c.
.-K.
AAGGTTATGCCCACCAGAGA
A205T
N-His6-p110α
CENP-C-specific
Mg+
DEAE–Sepharose
ligands.The
8-18
VY
30-min
sary
hmRy
bDeveloped
5030
blood/saliva
Transducers
A_51_P263965
Megakaryopoiesis
.2001.1262
experiments.ENU
23-residue
10.1172/JCI64400DS1
.Cycling
Gly93Asp
2695
respectively.24
4,965,192-5,138,016
myelofibrosis,23
.Propidium
G12C
OCI-LY19
tumour80
RB24-RT-MGB
T1953I
JEN
UMIN00001009
NPM1/5q35
32,830
-KI
HA–bearing
Nickel-nitrilotriacetic
IRDye800CW
250-mm3
D868N
385.3±93.0
determined.21
sublocalization
SCF-induced
F90L
UPN4-UPN8
domains2
non-3p
−1,657
pmGFP-N-rasG12V
outcrossed
PI3K/Akt/mammalian
5′-GAATAATGCTCGAAGCAACACATG-3′
17-myocardial
ERCC3-p44
signalling67
WT=wild-type
self-seeding
protein.42
2,493
Gleevec/Glivec
tail-to-head
gene-centred
RPE
expressed.51
SPIRE2
Tumor-promoting
80.37
protein.20
epithelia6
FEP
Cvitkovic
2HZ4
37/M
Mashiyama
001002295.1
APCG
SLC
Bock
c.799A4C
:CreER
IDnos
baculovirus-encoded
polysomal
protein.26-29
2.6-Å
piperidine/piperazine
SETD2-inactivated
NQE36TGE39
QTA
CATGTACGTTGCTATCCAGGC
S6Q
phosphoinositide-metabolising
Modeler.38
602-777
Rag1-deficient
3106T
Abl-SPOP-WT
65,600
Quick-Change
colleagues.23–25
//www.sanger.ac.uk/genetics/CGP/cosmic
PJS062
+240
–log10
cytosqueleton
GBM9
Rho-expressing
0.00388
S117
triad.105
Hulpe
304/248
acetyl-K120
CDK6-cyclin
methods.14
FZD4
V322M
V474A
disuccinimidyl
B-3000
Y764insFQQA
MKP-2-expressing
anti-IGF
5′Fam-TGG
3.0-
heterodimerized
Jurkowska
F636
ill‑defined
A_51_P187121
61.28
Gal4-AD
Methyl-CpG
Wnt/β-catenin/TCF
/myelodysplastic
52,000
0.0083
8,18,19
Stat3-deficient
G6274
.CD5
stimulus/response
High-Throughput
expressingBa/F3
SpectroDESIGNER
D57A
chr10q26.1
T-test
Homologously
58.1
0.13-13.6
904
agarose-DMEM-FCS
I1617N
-.40
Fig.1
Asp579
GFP-EZH2
R25
IL3-free
CCCAAGGAGGCGGTCACCG
3.36Mean
5'-GC-clamp-CCATTCAACA
.MECHANISMS
Rap-1/B-raf/MEK
LUSCs
ERP-57
.IRB
201132
subclonality
2427
p.V40M
Erlandson
78.06
c.259_263delTCTTT
Gαi
anti-phosphorylated-Smad2
.Tracheal
P=0.053
Phalanx
jclinpath
Bodenhausen
obs−j
p.l
LMB=lymphoma
/THRA
716
100/1
Duquesnoy
Afatanib
Sixty-nine
secondmutation
.7913
part-and-parcel
acetylatable
TKdomain
Y208N
hypermutator
GS-800
D9S171
Vitro—Hsp90
near-physiologic
plo1
511W
CRL-1440
0.5–7
NIH-1975
.TKI
.Henceforth
MEF2B-CABIN1
32026801–32062500
0.432
anti-EWSR1
μM.17
2D04
VGAM
formation10,16,17
GAPC
Biolegend
Serous⁎
E¡ect
Nedelcu
Pro-oncogenic
nondegradable
linker/RING
requiringthe
phospho-Met
α-B
events39
73-75
first-line
A55D
ΔN4N5
destabilization.18,19
NB0824
cancer,37
X≠Pro
air-conditioned
NP_006749
differentiation.24
contractility
ESP6500
−43.9
Leu-348
recurrent/founder
interactions.38
forks.Several
MYPT1-mediated
-modified
1322T
CDK4/6is
Leunen
androgen-inducible
DIMH842-845†
50–224
7-aminoactinomycin
domain–phosphopeptide
NUP98-5
RT–PCR-
pBacSpa1
AB4510
PDGF/PDGFRalpha
observed.14
cancerphenotype
substituents
.Scholl
35,000
KY-F50
predominating
anti-IKKγ
1.851
t1/2
Drosha.12,13,24
2q23.2
-0.20
RAS/MEK
n=773
hydrolysing
6-diamindine-2phenylindole
SGR-00197-2002
5A–5C
45,62
TSC1-NTD
effects9
posttreated
elongational
BALB-3T3
earlier.21
:LSL
NUT1132R
Thr180
localization.21
250/345
S1A–F
NCE
611728
GST-Cbl-b
N308
multiply-charged
CDK814
33-35,45,46
nccRCC
cancer47
extensivemolecular
NU-DUL-1
CTGGCTGCCAGGACCT
I147S
phospho-Y1045
BTN3A1
Q–L
RUNX1+/-/-
G1-synchronized
Kourembanas
AKT3Y
p85/p110δ
Phosphatase-TENsin
FLT3-induced
Saranath
inhibition31
Mupp1
9http
1327
PLP2
291•NUMBER
TCR-β
matrigel
mMEGTA
silencing10
0.139
E64
pY-IGF1Rβ
5′-RACE-Ready
SC35
NaB
Cut-offs
anti-NUP93
scatter-plot
MSCV-p210
M.L
immerse
//tcga-data.nci.nih.gov
prognosis.2,25-28,31
JKB
A-Barcode-Exon25F
Vysis/Abbott
8x15K
NanoCulture
BRCA1*N723D
AF-1
5′-GATTGCTGGTGTTGTCTCAATATC-3′
transcriptomes
OCM3
E238G
afore-mentioned
Tyr-1092
patients.1,7,8
transduce
TOP1-associated
0158
HCM9
`weak
441–474
Temsirolimus
side‐chain
DualLuciferase
non-template-derived
Kamrul
G-containingreporters
65–85
-._.Percentages
GAP-dependent
5′-TTCTTTGCAGCTCCTTCGTT-3′
receptor-JAK
Q421K
moderate-penetrance
sites.9
actosidase
1801
L691P
1–169
responsiveness,15-17,26,27
.PDGFR-alpha
Anthos
slideCharacterization
177-297
HNSC
macronodules
H1299-derived
turboRFP
AACAAT
–210.14
hPMS2-abnormal
ML3000
bivalently
tetradec-anoylphorbol
23,27,28
MLL3/MLL2
DNAwith
reengineered
Tyr202/Tyr204
Figure6c6c
PharmaServ
phosphoS473-Akt
Schoenbeinstrasse
pylocytic
ϕX174-replicative
p21.FIG
p.Glu466del
Tsukazaki
5802del
Szwagierczak
.Ubiquitin-mediated
5q32–35
_OIO
4,383
c.1593
GI:60677747
al15
conjugate-gradient
p.Thr492Ile
q11q14
report'7
m67
:p73betaWT
NAGK
R179T
DOX
Peritonuml
aAll
CML.1,2,8
S1177
.S4a
503-220-3405
1/103
castration-based
R754
5′-CCTTAGCCCACACCATGAAA-3′
PAM3
ABCC′DEFG
.Barcode
HER-mutant
CL1-0
2.40
UNC
500–2000
carcinomagenesis
end-over-end
PIN3
su-
loops20
COSM139519
dataset.Based
Structural-functional
hMSH2-K675R
Vector-transduced
c.1491T
1B-D
FA-C
phRLuc
3-16
Microphysiometry—COS7
W1837G
High-pressure
Golgi-transport
HA-VHL
.1687
LELERK1
RASness
Ca2+-independent
.Palo
tetramerizing,21
N=3
Anchorage-independent
HIF-1α·pVHL
m/kg
5–71
genes140
.Rictor
'The
H345R
White–Hispanic
Reconfiguration
KRAS—decreased
Wnt/βcatenin9
electroencephalographic
p46Eg22
studies,7,11,12
Okeyo-Owuor
DSBs59.In
2OCF
//www.ncbi.nlm.nih.gov/pmc/articles/
PKC421
Crosstalk
V425M
NF-
polyethyleneiminecellulose
EGFR-positive
Y334S
SDS−
neurotoxicity
23:267^277
GSE23300
SP600125
Ottini
CM-23
DiIC18-labeled
PDGF-BB—encoded
CNY
64.1
x800
137K
hyper-elevated
CFP1
61.7–3.4
1:2:1
HIF1αtargets
gtttcttgag
TTYADFIASGRTGRRNAIHD
74–80
nasopharyngeal
4nor
non-cross
EMCV
D1692N
Hitchler
q=8.82*10−28
.Physiol
phopho-ERK
anti-HLA-ABC
/Alive
Invarianta
M243-F1695
Thirty-nine
Estrogen-depleted
Kyoto
al.,1984
DBA
immunofluoresence
S839F
xyleencyanol
3.EGFR–RAD51
CDC27
themanufacturer
Val560Gln
6/11
suggested.38,39
RP11-58C6
attractivecandidate
21.89
BHM
subtypes—luminal
Weyemi
5.1057
two-large
p.Gln1019*
cognate
abundantTP63
disease-type
132–403
1991c
carcinomac-kitCD117Tyrosine
199.3
lactoferrin
c-mycrelated
asparaginase
p=0·006
Compostela
RP11–383F6
GCTCCC
MSH2-L187P
F318C
1283–1284Kern
PT09
Sp5
p-ALK
Domain-Deficient
80V
0.0002
IRGS
-GCAGGAAAGTGTTCAGCGG-3
270–310
appropriateamount
Y1221/1222
K785R
CM1
1:00
l•AspAspAl
S72
528
tumours,6
.942
μcalpains
ATP-cleft
neuro-cardio-facio-cutaneous
9,29,30
insulin-transferrin-selenite
PKCb
-ACC
I642
0.03/2.7
8.0-μm
Met552Ile
VCACPGR
_MEK1_
intronicGADD45
841
pheochomocytoma
Flag-Jade-1
+30
GnRH-induced
TCTTTGAATTTGGAATATTACAATG
C6orf204-PDGFRB
elongation.28
×60
outcome,36
p.Asp34fs
p-S6K1
MAD-related
FLAG-HCF-1N
EWS-FLI1-bound
regimens26
HUISMAN
Cross-check
b-d.
PhiKan08
gene,32
.KSR
heterodimers28
6–59
tk-luc
D1349
bPDGF
BRCAJ
distalis
phosphofructokinase
SLC45A3_S
control–expressing
posttranslational
aAssessed
SerArg
Orc2
Milteny
rs4986849
Spi-C
Q1533
gene/Chr6
351
-normalized
lines.29
imatinib.14–16,32–36
BRIP1-
2F2
1.A
pfam04925
5′-GAGCCAATATTGTCTTTGTGTTCC-3′
Erlotinib
V274F
-Go
v44
leukemia.11
TABLE
miR-3940-5p
EMBL-3
One-hundred
P-value2
anteroposterior
33/115
alsoexpressed
Weiler
4Pathology
11–433
Lieberfarb
9.377.6
kallikrein-related
5m
Mx1-cre+Tet2wt/wtCD45.2+
PVLKQRR
MAP2K1/MEK1
Hunplary
mechanisms106
RFN2
Passaging
gradient-purified
V106
S9b
RasV12.S35
R214W
308
.073Exon
/61.2
LTROMT
393-amino-acid
promoter-enhancer
GISTwho
q13q32
N3-methylthymine
ammonium-based
+11
HA-Akt1
LSL-K-RasG12D/WT
Hewlett-Packard
*Error
GRO-L
undenatured
S473L
F174S
quartiles
models.42
VEGFA-unamplified
UCH-L1
Cbl-R420Q–
HNF4α−/CK19−
anti-α
six-twelve
STAT5B-RARA-associated
G440C
digestion.25
Surdez
NM_000222.2
X98172
GO-IG5
957C
extra-cranial
1mmol/L
uORF–encoded
1437-AA
nanoliposomes
12,21
microcystic
.Gli2FL
OR13C5
ptpn11
hyperplasiasA
mL257
CCR
TAE6844
''A
5.6:1
Garcdia
GRB2-SOS
Erdheim-Chester
ARE2TATA-CAT
2•05
1084_1461del
exon-derived
powerpointFigure
033393
fromthese
652Ile
PDGFR-specific
celastrol
F1888L
72.4
WT-p53-transfected
al.2,3
DERKsem
Tricolor-conjugated
K61R
HER-2/neu
glomerulopathy
6/927
frequencyof
BAI1-associated
pCMV-CDK8
elsewhere36
KB1C61GP
BRG1-deficient
M443R
Rondoni
recognised.12
position-independent
atom-colored
F75231
injury-induced
L172M
steroidogenic
albuterol
Alexa-Fluor
8420
p.V559D
9,000
K320T
22Bri
E373D
15q
status,11,23,25
p.Q9X
Esophago-Gastric
target.52
domain.15,18
scansite
PKB/Akt
R12L
40/65
survival.19
7p-translocation
post-incubation
Razzaque
ETV1-positive
/1KBH
Axiotome
ng/ml±1065
rich-ATP
h.p.f.=
WTp53
K563R
A588
47/53
S17N‐Ras
thebreast
size-altering
.Downregulated
4149
2193_2196del4
R40C
immuno-reactivity
usedcontaining
CD4+T
models.Differences
PP-K9218-00
D1S2869
extracellular-related
.PhiKan083
Merriman3
gefitinib-
1.5-kilobase
peroxidase-labelled
26.2/13.2
G719A+S768I
Mtor
4901
77.3
huIgG
ganciclovir-induced
S2F–G
*175_
classificationAbstract•
p85α-N564D
SNP/genetic
retinoblastoma1
GATA3.35
sc-5286
74,75
phosphoserine-15
15c–e
.P1856X
Bladt
delTTC
1.6-folds
28th
CENPN
PicoGreen®
neurofilament
chemotherapy-treated
Osin
K550-W557
e2.2
high-frequency
al26*
R226Q
Vect
mutations.29
.C17orf37
extracellular-signal
co-existent
sibhelbtThrLouGl
β-catenin/TCF-LEF
Ras-GEF
pTL
c.1482delA
paraformaldehyde/phosphate-buffered
First-
59,307,844
Grandage
.94,106
000539.2
.Present
Auto-deubiquitinated
GSK795
/xg
Romdhane
DAX1
0.000096
anti-Mdm2
C2/iSH2
pMT2-GST
EKMLDLFEKYMT
1610
5075G/A
Hersmus
.Fibroblast
180-minute
1d–e
e1–f2
Hif-1023
24-hr
whichones
12766
syndrome.40-
IRES-hmAG
.Akt-1
FLP-mediated
N‐terminal
1162
AngII-dependent
panitumumab27
paymentof
C-NHEJ
mutationRas
HR-DNA-repair
410:1
414
×40.The
–ubiquitin-conjugating
14/9.8
p.Ala126Thr
1*
tumorigenesis.Gleevec
BAC/fosmid
MIF-173g/c
3.0.1
.PL/J
mutationsthat
targets16
replication-independent
HhaI
type.3
∼80
Shevelev
c.34_36GGT
ref.36
expressionin
.1703
R113H
anti-PBF
MV300
IGH/MYC
Vecchione
cyclins
Scp6
growth.29
CTTT
Preincubation
PCDH10
.Pharmacophore
hematopoiesis.63
FRG
44-20-8770-7290
Maidashi
lethality21
L4-5
kinase.18
secondary-AML
Y352H
244519
oestrogen–oestrogen
A177T
notch-1
ampli®cation
Virologie
NM_001664
3x‑UAS‑TK‑lac
GOR4
V2444fs
p.Asn666Lys
theffector
Sabbaghian
28.1-fold
-14.05
Yonemasu
Immunohistology
rheumatic
0.016MUTHSF
AXL–MBIP
CAM5.2
®fth
abovementioned
7,12-Dimethylbenz
Sanger-sequenced
MIRA-1
monoubiquitylase
imidazo-pyridazine
cells.20,21
thecoma
-V600E
NCT00494182
bilobate-fold
cationic
GFP-XPLN-expressing
Thr352
P002
Br28
oligodendroglioma-related
history,3
.Pdgfbret/ret
0/435
encodingthe
Mastrocola
DR103-5
sed
cancer.115
GGATCCTAATACGACTCACTATAGGGAGACCACCATGGGTTCCAAGAGAAGAAGAGC
hypermetabolism
mutations76
complex169
90.79
REM-Cdc25
inactivation.5
47.64
reactive-like
'H-15N
13008
40:11
A-Sepharose
20q-probe
H3K4me1-enriched
androgen-regulated16
Sabó
VEGF/VEGFR-1
Stampy
inhibitors—NRAS
respectively154
p53E258V
.Leukocyte
A1708V
HD11
MLL-fusion/Tet1/Hoxa9/Meis1/Pbx3
p53F2-10/F2-10
K119E
Hydroxymethylbilane
pneumocystosis
mastocytosis-CEL
anti‐FLAG
3.70
PP2A-B56δ–dependent
shNT
TRK-T3oncoprotein
TAZ52
MSI.53
transcription-related
described,18
CKS
metastatases
May-Grünwald
thiazolyl
kinesins
OCCC18
homeodomain-interacting
fCDK4
p110α132
enzalutamide/AR
z-score-standardized
p-PDGFRA
atelocollagen
Supplementary
MDE™
TGAAGGACTCGGATTTCACGCa
21–28
Egr
C00-84L10
.TYK2
0-Q
135insA
gene.2-16
Cediranib
TPM3-TRKA-dependent
pG13-luc
15-µm-thick
2051
E7.5.23
.Reference
NP_612114.1
j-
erythematosus
pFUSE-mIgG2Aa-Fc1
GACTGACTCGAGCTA
LPCX-Smad3
cases4—17
2663
U-rich
sites,16
I481N
4D-F
c.1420+1G
splice-recognition
10.1093/jnci/djn471
Lines—Bard-null
NM_000135
K238E
D22S1163
ﬁbroblasts
anti-Ub-K63
Hygromycin-resistant
Be3
W393G
PCR-reaction
ATGGAACCAGACAGAAAAGC
Chowdhury
CGCTGG
βγ-complex
SAG-Cul1
seventy-eight
PTCH1-W844C
formation3
calcium-sodium-phosphosilicate
3.0/43
Y443NLr
5'gtctctaatcccatccaggttgc
rearrangementsfoundinraresubsetsofnon–small-cell
ERK2-Q103A
23.75
L1489
NA934
Current-smoker
inhibitors15
.O13
D60
D816-positive
1:125
THI
carcinoma.Materials
Fusion-3
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN
dicentrics
|TpG
States36
monochromator
STYKc
radiationinduced
p.E75G/p.P670L
G51
NM_001007226
ATCAGACACG
eancer
ERK1G186
MNNG-treated
5'-CAGCATTAGGGACAGGAATC-3
lower-stage
myc-tag
p.Leu529Pro
S310
C259Y
antibody–DNA
transactivationfunction
Differentiation-associated
genotype-selected
SRP034161
αP-Ser473Akt
modi®cations
M.Z
T-REx
respectively.13
MCV
immunoserum
bPCC
heavy/light
middle-T
-induction
.C1156
leukaemias119
2×49
9–20
signaling—may
16.43
.Phosphorylation-independent
2.4-fold
EBP-50
CTGT
Ala19
20,22,34
CD69−HSAlow
250-
16b
dosage.
breakage/translocation
S1036
FLT3-ITD/TKD
0.95^1.08
AHCYL2–TMEM178B
Thr57′
.572A
2845
SCF-stimulated
nonactivated
vertebrates19
RNF135
hexadeoxynucleotides
1300g
Destabilizes
TAL1-containing
36.12
epigenetic
L333F
FLAG-His-H-RasK117N
G3810T
LOH11q
KSR1/2
anti-HNF3α
anti-phospho-p70
HGS-OvCa.We
Hedgepeth
biotin-mediated
indicated.The
PDGF131
3−5.8SCRN1Secernin
8-301
entrectinib
Karlseder12
D835VR
LNCaP-C4-2
ERα-expressing
R772Q
v2.0.9
500-2,000
hydroxyfiutamide
intheir
6042
EGFR-sensitive
MESV
.Taq-Man
ca-
3,8
o201
abcc.ncifcrf.gov
shortsegment
Fischbach
milliBlot-SDE
left-axis
time-resolved
MOSFLM
p.Tyr155Cys
FicollHypaque
BARD1-specific
Ala-109
8,520-bp
proposed3–5
Ba/
transcription-controlling
Brugarolas
.Brahma-related
pathogenesis31
Pathogenica
D3S1561
RET2
al.,8
assay.17
PIWI28
3936
AberrationsThumbnail
Giemsa-banded
//www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design
IKKB
rhabdomyoblast
abnormalcy
Lys-Ala-Arg-Asn
LNWCV-
A-C
373–432
paediatrician
ENST00000296302
PTZ
A2226S
p.R855H
cortactin
D3S1566
hydrophobicresidue
cycle–associated
CGAtools
prognosis.3
c.80A
B−D
pre-TCR
5′-GCGGCTGGTAAGGGAAGAGG-3´
Copurification
functional36
fertility11
AR.A
98°C
Y537S-SRC3-E2
C57BL/6
FBXW7-null
cross-sections
K-ras-F156L
7/48
mesoderm
2004–2009
Thr491
propyl
C66W
H911A
tumorbleeding
H2AX+/−
single‐pass
nZ5
pan-enteroscopy
:LYS2
Tebbs
Br50**
381–383
CCDS5251.2
E2288
nt2994C
IM-affected
mutation.35,36
Gly1707Arg
cobblestone-like
R89Q
Lymphoma-associated
MEF2–p300
Cerveira
ΔBRAF
5′-TTTTGCTGGTAAAGTAGTATGC-3′
Flu58
PP2A-binding
.Instability
0.290
Valine599Glutamic
352722
10/43
D1226N-1
538-1156
AD-CITED2
GSE67908
but—at
-E453K
MB7
16,19–22,32
trk32
S270T
disesase
5p11-
PI397
metastases.62
TDG-mediated
96.5–100
1,863–amino
TR175
FGFR3ex16-FW
ApaI/NotI
sequence.13
interleuPL
1.485
patient1
Leu62casp
cohesin/ASXL1
~A22
Disintegrations
RSHGPDAKL
DNA-Lipofectamine
q-arm
Comino-Méndez
CDKN2A.65
DCX-immunoreactive
ubiquitylation
14q13.3-q21.1
L80A
CFP-Nrf2
15,957,390
Protonation
2.80
LLS-2
17,421
H639Y
PBS+1
7/62
5′-ACGCGGAACTTGCCACACGTGC-3′
wee
RUNX1/AML1-related
base-paired
Anti-Pan
PLEKHA8
A/ml
82:305–312
0.40–1.62
3.5-fold
function.13
thisarticleweredefrayedin
CSTIB2222
PPP2R5D
N88K
Notch1–ligand
8/13
allelic-discrimination
SLI-1
c.779C4T
44-47
58.2±5.3
entiated
information-dependent
T500A
Ral-GEFs
Grigelioniene
∆JAK2
F73
1.414
population127
GST-pl6~N~~wild-type
ΔM1-BRCA1
anti‐GAPDH
regulators62
delE746–A750
Thacker5
EMA±
.ETS/FOX
non-XP
underdiagnosis
γδ-T
cells/tumor
phenol–
chondrogenesis
growth-associated
//maq.sourceforge.net/maq-man.shtml
Mailhes
assays.Chimeric
chromosome-8-specific
277-281
non-stimulated
Endothelial
non-ZM-harboring
pCDNA4
.Inputs
600259
19human
12°C
S5/S6
orthologue
Kindlin-1
post-transcriptionally
G165V
IRX2++
520-
ATAXIN-2
4.1
WT.The
p.R103Sfs*23
p53-responsivereportersStrains
Bi-specific
4264
P186S
transcatheter
BCL-XL/BMF
AAACTGGCCAAG
ARID4B
.L74
2:4
kg–1
V283
.Ecotopic
mutation.PIK3R1R348
Reagents—Antibodies
26–722
p85αΔ434_475
heterogeneously
PPH1
EGFR-L792F
pAL-FLT3-Y842C
L747–E749
ASD5
pdb1DC2
mutationsgive
testicular–pituitary
80.35
TERT
Bl-21
5.53
T202I
g.430C
antibody,42
AC-reverse
Mre11nuc
cullin1-mediated
//dx.doi.org/10.1371/journal.pmed.0030420
nihms820730f5.jpg
Samplesdemonstratingan
disease.5
TMA,10
G292S
miR-130b.27
tggcaaaaataggctgtcc
.Prostaglandin
FSD
NSH2−PTP
P106L
β2β3
.¶IFN-g
yGADNeh2LacZ
.Google
GTG-
MORM
family12
N27
46–50
GCCT-3′
.Readings
nucleus.58
5221delTG
Q584K
Rhoˆne-Alpes
1/46
lutea
Met157
previously.42
NL-21
++++_-_-_-_-PsvZio
249/168
Rectumc/11.1
β-galactosidase-positive
paternal–maternal
3.64E05
mutations.9,13
rs2305948
Plzf
Eluted
PJS02
dysplasia.94
SSCPwere
ULM
6.5–6.7
Id2
KRAS-wild-type
Chk2ex10f
dtp.nci.nih.gov
self-consumption
PP2A-C
SNT-1
D212
criteria64
5-aza
CRISPR/Cas9-assisted
Nikiforov
Lan2
2741
CO2and
C12orf63
role.Another
5′-TTCAAGAGA-3′
WS2
ColorView
myc-Daxx
clinical–instrumental
SKCO-1
amplificationb
Anaerobic
p.A298T
charcoal-dextran-stripped
2-month-old
KEAP1-driven
elsewhere.60
135:771–782
2,450
.Anti-c-Cbl
TT53
4849
mutation.49
3029–3056
183
μM.35-38
472d
Poyry
SBE4-Lux
tinal
anandrogen-responsive
BR2276F
anti-p21–polyclonal
GCN4
tumor-promoting
.TβRIT204D
.Independently
differentNTRK1-specific
gdb.infobiogen.fr
doi:10.1038/onc.2010.21
AGAGGTCCGGCAGACCGAAGTC
ER/
Stop1829
0.991
7q22
phosphtidylinositol
p.Y1234
1.03–5.54
p95HER2
MO7e
UAS-TK
alpha-C
2PVF
PrestoBlue
co-share
TTTAATTTATGCCCCTTTTACTTTCTCATTCAGCAGT
cytometry.11
3′UTR
S256T+WT
23/26
Biochempartner
1077
R414C
Svard
inclusivity
HEMATOPOIESIS
20.0
17.13
295-bp
MolProbity
ratio.a
CD69+CD4lowCD8low
log-R
6:8
uF
hyalinization
phenotype,31
D404G-TbRII
174–188
DDR2-expressing
2626
open-pocket
deacetylatase
3-kinase/mTOR
121.1
eosinophil-specific
chromatographically
YUROL
2.321
Μutation
mutationsidenti®ed
355.3
L1
non-responder
p53-R175H
AGBL4
2,43
70‐year‐old
.Managing
Ikushima
IUGR
1x105
CS.20
Hs.229997
pEAA284
A525T
IMR
1.9–7.2
5′-AGCACATAGGAGGCAGAGAC-3′
ATGACAAGGTAGCGCTGGGGG-3′
c.856C
24772/pNF
TAATACGACTCACTATAGGGCCTGGTTGGTGACAAGCGCTACACG
MACS2
A129D
fdr
scale.4,5
Ccl20
PI3CA
α-SMA
T341M
0.392
pseudo–Pelger-Huet
poststimulated
2060
specimenavailability
Yeap
ESHAP
KRTAP9-7
353K
Bosutinib–Abl
Brca1185stop
≥40
23956100
G870D
p.Phe143GlyfsX26
alsoanalyzed
PMF.13
SPOP-E47K
A_51_P253279
C1561
AITL24
10,18–20
FOXO4-CIC
54·6
SCLCs
V117
HBL-2
polymorphism.28
2560
VO
0.4μm
breakpoint-spanning
121–733
NM_020570
recurrently-mutated
BPDVC57PDVC5NC5024
HCC1187
CEP164
WuxiApptec
IgG-control
Leu115Pro
EC15R
Geyer18
substrate.b
R333P
macrophages150
activity-enhancing
NF-France
CRI
1-mm-diameter
∼0.3
Anti-β-catenin
16p24.3
phopho-ERK1
.2010.21
298.10.1007
GT-9500
system42
pGEX-4T1/BRCA2
−6.38
acidchanges
-R
ΔpKa/ΔT
GM130
IHCCs4,5
XXVIII
3′-cytidine
.diagrams
4EBPs
DMSO/ruxolitinib
Ig-μ
IcUAS53
StatView
anti–MET-targeted
two.4
adhesive
24740¥
K299R
phosphatidyinositol-3,4,5
PDE1
biotin-avidin
ACTAGT-3′
isimportant
Kalvakolanu
PCC/PGLs
Miller-Dieker
cytokeratin-positive
5-GTAGAACTTAGAATCGACCGGCA
rs28363284
Haneda
FUS-CHOP
CD40‐mediated
piNOS
S5C–D
neuropathology
chip-genotyped
theAurora-3
26,780,167
AandB
comparingthe
6Division
Premenopausal
W238L
AIlL
Eighty-three
//www.cls.ioe.ac.uk/
569–79
allele-speci
pMEK1
−0.547
//icgc.org
Spc110
two-FNIII
ERÃŸin
Krt7
pLNCX1-ΔPH
diversifications
prognosis,2,15
BCR-ABL+
ETV6-MECOM
*His
P12-Ichikawa
wt.a
abysmal
//www1.qiagen.com
222M10
c.2157dupA
.K125E
1–10,143,144,164–166
SH2-N
PCM25/2+
F7618
Sawaday
.Fli-1
promoters.31-33
autophophorylation
dehydrogeReceived
BEND5
p2ls
0.8/0.6
64,65
Linköping
A_51_P415059
7.5-mg/kg
5′-MAGI3-AKT3-3′
of14q
N-15
Wright-Giemsa
DDDK
ATG/UTR
reblotted
non-fat
1,30
þSEM
Sox17-negative
54EGFR
Lundberg
lesions8,9
c.2023
-1930
euphol
Dashwood
Hsp90
non-BRCA1
tablePrevious
4/211
13/15
.Dual-colour
MCF10ATP53+/+
15/430
PAM-based
H32
F43
1.5§
PHD5
anti-pErk
Total*
W627C
pQE-A1-H-ras
R112H
adenocrcinoma
p53-transactivation
0.096
14–deleted
GAT-TAT
91-113
734-936-7361
LSIp53
7526
H3K4-methyltransferase
L692P-V717A
BCL2-inhibiting
Smade
50µL
TriFECTA
TEL-541
N375S
S1.7
regions.Both
mice.75,76
myc-p300
hypochondroplasia.11,19
Bactoagar
75-year-old
3A–B
activation167
Bannayan–Ruvalcaba–Riley
TCATTTATTTTGTCCTGGACTCC
GSK-3-inactivating
described45
.Anti-phosphorylated
TRUS
C1060R
Trp−Leu−
-mo_p53
sympathicoadrenal
11.4°
0.000609
ProTyrHis
peri-portal
tumor/reference
Fig7E7E
pEF-constructs
GTTTTCCCAGTCACGACCGTAGCTCCAGACATCACTC
well,3,10,11,12
CALM-AF10
1,2,5-13,16
Kelch-coding
Nonsense-mediated
12,000
low-profile
pathway.31
30.921*
programme154
EC/2006-124
∼11
D186N
N73
IVS14+2T
in-between
Lentiviral-delivered
response-element
SalI/SacIfragment
T751Ia
MYH-associated
5‐
kinase/TACC
L536H—The
Tyr641
burden—as
BM1
RUNX256
19,25,35,38
pathogenesis5,6
47,467,725
c.246T
GOLGA6D
CD34+/CD38−/CD45RA+/CD90−
missegregated
HMC-1B
FGFR1b
Y2677C
47w
81.0
androgen-repressed
coactivator.7
Huifeng
Val-560
KRas-mutation
c.2804+
NIAID/NIH
c.5497-1G
CD62L+CD8+
non-exonic
3265
1639T
adenocarcinomas.28,44,47
–32.3
2619
UCN
HEI-286
diseases,19
21M13
Hejna
470K
p.R659C
32-degree
Asp538
R263C
.SENs
sources1,4,5,50
copGFP
Hs06028467_cn
CFU-GEMM
xpa
telophase/cytokinesis
c.622G
H168R–DNA
ansamycins
606-8585
c.4158A
NBCI
RK13
p57kip2
Ku−1
R3681
SpectroCHIPs
Case-337
HD63
1.8-2.5
kinase–
20/3749
0.02255
pGL3-1879
initiation/promotion
UoC-M1/FG
Smarcb1.59
4486delG
P317R
phosphate–protein
acid-soluble
L747P
extractedtwice
MDM4T2NPNPBRF2
pVSGV
C229A
GWAS
0·003
ependymomas19
dual-echo
K498R
toll-free
p53G245S
pathogeneicity
494-bp
2See
-immunopositive
E/A/B
E102D
.Representations
HMC
5925
Fas-induced
discontinuing
0.00047
methylsulphonal
anti-RPS6K
NF-κB2-directed
33/36
147±119
U/µl
E330N/D355A
c-MYC-amplified
PT05
CaC12
text/border
p.Arg5Gln
R6
Gli-1
problematic,29
Arg-36
M-category
redocked
V530I,8
c-SRC
Speech/language
A673
non-replicative
cycle.20
Ng1,2
infection.94
ATAGACGTTGTGGCTGTTG
0.0603
NS1-BP
EWS–PBX
tri-methylation
f–j
Jackson-Weiss
Abl/ERK5
1⩽10
S143N
1717
400-mm2
FLT3-ITD.102
SHP2-Bad
996
TrA
anti-pY1001/1002
​andb.b
issimilar
2renal
.Procaspase
factor.16-18
cells123
24-forward
610
non-HLRCC
.SCCOHT
WHSC1
TD/CCSP-rtTA
19X
Fig.5C,5C
S380A
Gastric/11
apse
2008b
3-week-old
Cin
F:5′-TTGTGGAGCCTCTTACACCC-3′
FA-patients
.FANCC
A5001G
.Melanomas
19,011
pGL3-NFAT
Caspase-8L
p.A694V
FA-19i
8b
42-kDa
Fig.5.5
GGAATACAGAGAAAGAAGAACAC
solid-organ
Pluijm
irradiation,11
FAT1–β-catenin
+mar4
c.608-
BAZ2B
12985
DSH1
Fig.1.Structureof
GGAACCTCTCATTCAACCGCC
01778367_cn
Millpore
.Meca-32
NKX2-2
immunosubtypes
KK
metastasis7
SEAP
20-25
nickel-NTA-agarose
apoptotis
ACGGGCTTATGATTCTGAAAGTCG
JQEZ5
Alexa568
HUT78
www.genego.com
L54P
Novelc.3980A
compartmentalisation
pNB-1
_FGFRTACC_
57F
Kα
11C210
2.3.3
SC-519
Pathologiques
4.45/3009
anti-P-Tyr
cancer.48
1.7-3.7
RNasinTM
NCI-H441
30/00
cancer18–20
lesions,4,5
CCTTGTTGGCTTTCGGAGATGTTGGCTCCTTGATAGCGACGGGAATTTTA-3′
K27Mmutant
Smad4-specific
70–74
doi:10.1158/2159-8290.CD-15-0060
1t29
2b–e
T-lymphocyte–associated
Sforza
mid-sagittal
c.4956G4A
AT–lac
formed41
mV558D
.Duplication
11,419
whichwas
-CCAGACTCGAGGTAAGGGATTCCCTCGAATTCCAG-3
Syto
f/82
cargo-binding
Cq
double-thymidine
.-Somatic
nonredundantly
9/19
Hombreachtikon
12a
asgrowth
bioanalytic
cells9,10
phosphomannose
GAPs2,3,4
10×109/L
wildallele
IST-
Gβγ
Co11
SW-311
domaindependent
R377C
myelomonocytic
binding46
tumours.5–7
6.5
pENTR4/ER
IL-3-induced
P124Q
codon.Table
MutLa
log-2
.DICER1
S3a–h
pCDHmCherry
F-box–
62-103
XP/CS/FA
//exac.broadinstitute.org
TIP48/49
.PCAF
OMM2.3
D3S3640
MmXrcc2
genes.8
BMI
Deaconess
Kras+/–
inconspiciuous
FR2AHC-CF
al.51
Dcv.
molecular/cell
miR-injected
potentialities
L61P/R
26–31
PKBβ
inboldface
lines—H2405
unlikely24
CRL-2289
l1054F
p.Pro214Leu
p23
genetic-counseling
AmoyDx
Hyperinsulinemic
FACscan
cancer-promoting
~two
mock.
HSCs,14
erlotinib.1–4However
Ala767_Ser768insThrLeuAla
PTENH93D
249-1879
Nub1
0·0026
others12,14
.Silencing
12.09
PR-A
Pb-Cre
TGFIJRII
full-length/truncated
IVS18-6C→A
Q354E
10.1182/blood-2004-02-0660
signifi
tissue-specific
S1–S2
.molar
.Particulate
.N-glycosylation
DC101
subclade
C15orf21
EC1–EC5
AVM/right
REGISTNES
Wansa
0602
pathway.46,47
15.3
karyopherin
i.e.until
905-bp
307K
C611S
FGFR1
mutationalhot
VAX
2623–2953
constructs40
onthese
D-HPLC-detectable
005343
.Controversy
PCCs/PGLs
.Chen
dithiotreitol
Carrasquillo
.8,23,24
GTL16R1
YTH
M1775K-R
299
stability.8
bevacizumab-failure
transcriptase.ShhN
anti-RAD50
//doi.org/10.1371/journal.pbio.0050109.g001Next
IL-2Rß
PTEN.C124S
progression.28
//mct.aacrjournals.org/content/molcanther/12/2/220/F1.large.jpg
phosphomimetic
ALK-specific
11/82
skeletal/dental
PMLB2
2.56–2.4
blastoma–family
N561D
JAK/STAT-mutated
transcarbamoylase
BICC1-FGFR2
defects9•30
GATCCGCCGACCCCACCCCGCCACTC
A5G
MYCN-Amplified
treatment.11
Njauw
R156P
Prosurfactant
Kadoch
334–354
myelodysplasia.2–4
shControl
chloroform-methanol
jumonji-domain
LChronic
growth.20,95
–Cox
.Dimerized
2005–2012
bystander
NCT00130728
adenocarcinoma.The
paraffin-extracted
2+f/C+M
highestmutation
MOLMOL
T7-3
co-Smads
37,370
Deliliers
principal-components
.Cofilin
Deursen
Tal1/Lmo2
3-untranslated
hadneither
expression.Clinicopathological
sticks/spheres
doxorubicin/cyclophosphamide
C224R
DNAdamage-associated
mainstem
WT-Mpl
myeloprolifative
guidelines,18
JAK/signal
efficaciously
DSRM
leukemia21,22
SAPK/JNK
MMP7
±3.0
9G6
XXYLT1
anti-FANCF
CCdh1
F49L/L65P
73,000
11.5-fold
59-TGCACATATCATTACACCAGTT-39
leiomyomas.4
createldestroy
PKCϵ-interacting
.Sodium
.2637G
GRCh37.75
r2012-10-05
Mourtada-Maarabouni
GFP-Elf3R331P
TE2000E
MENIN
leu2-1
L620M
NM_005633.3
-GAGAGCATCCTCCCCTGCATGTG-3
.0039
BC057028
21103
analysis7
22,500
lymphocytes.5
K299CR06
inference
p60src
Kmt2dfl
L118
5¶-TGCCTCAGCCCTGCAAAGTGCTAGGATTATAGG-3¶
KEN-like
A1118P
matingsTo
al.10
5′-AAAGGAUGCAGCCAUAUUCAUUAGG-3′
2415-2425
cdk2by
elucidated15,56,57,58
humidity-controlled
t-I
207/302
JCO
S7.4-9
adult-onset
nitrosoacetophenone
27-1
antihemagglutinin
ROS1/ALK
mechanism.28
8,19
NRASWT/BRAFWT
II11
intra-cranially
EJ
23·2
pLXSNEWS/WT1
Tumors.
.10,11
.Applying
CNE1
C634R/E805K
1456–1863
3.KRAS
B.J
1102–1111
14Acral
∼36
EDA
CBF-AMLJAK2
HES/HEY
316
min-elute
c.1501G
RNA-mediated
p120GAP
//androgendb.mcgill.ca
ab100531
Lu-1995
L145
DUB
VMEG
neoepitope
R246T
nab-paclitaxel
tradenames
glucocorticoid‐induced
mutations.21,25
JNJ-42756493
c.1011dupC
Maligne
.CDKN2C
2302/25
610201
monoallellic
Bhimavarapu
thy1.2
2.0–12
2596
G123R
ERBB2-mutated
168–209
ICAM5
RFLPscan
3D-conformational
NT_039437
87-amino
DDX11
LDS-OEC
acetyltransferases
pMSCV-eGFP
–16q
Homology/analogY
Azami-Green–positive
Phenix41
4h
eosinophilia8
1.2-10.0
cell.5
FGFR-targeting
biotin-SP-conjugated
TACCAGG
4.113
p53R245S
effect.The
T300
enterocyte
A1016S
Keap1
P=3.4×10-4
Ezh2Y641F-expressing
CIC–DUX4
osteoclast-rich
signalling141
K910R
AB116525
Ba/F3-TEL-JAK2
theK-Ras4bG12D
axin
transcription-PCR
Trichrome–stained
Y531A
4.Consistent
R79C
3137
repres
F155
E734-K851
R591X
RHOT1
potency15
SF1-dependent
LysfsX8
6–73
Construction—pCMV5-ERα
RFB
beta-cells
routine.41
MLL-AF9-transduced
.Extreme
−d
p-p70S6KThr389
piriformis
.Shaded
¼
loss-of-
~800
Mre11-depleted
sevenspan
sDinucleotideUinucleotidcTrinucleolideTelranuclcolideOinucleotide47
p14–15
TIF-2
ProBond
c.816delA
M‐AD
PRDM1.altE1.F
23A-F:5′CACGACGTTGTAAAACGACTTGCTGAATTGGTGAGCTTC3′
del3835
EGFR-del
microplate
Hübscher
Rad50sc+h
8-μl
5′-GGCTGGCGCAGCAGAATC-3′
Zon
gefitinib-treated
Cl.8
conformation.14,36
Bcl2-inhibited
1013T
D11S1757
TMPRRS2–ERG-positive
~882
deconvolved
R246
PCR-aided
Val14Ile
CD4lowCD8low
p.R988C
U87MG.First
478
earlier.26
FL-mediated
.Y123
3A-3F
91011
E3-ligases
Biocentrum
1,130
mTORΔN
T2‐weighted
+2.3–2.5
EN-Scg6
ATP-dependent
acetylH3K9
pDNA-PK
milk-0.1
25-minute
pHP5
FancA/B/C/E/F/G/L/M
spinohypothalamic
172800
lipid-binding
Peroukides
MiaPaca-2
rechromatography
SKMM1
fructose-6P
activity.43
Nrf2.8–10
crizotinib-refractory
bp886
region.Gene
1.38-3.47
retroorbital
.Lithium
enzyme.49
6.93
.aAspAr
dasatinib-treated
GTP-RAC1F28L
Pre-therapy
–Immature
.ChIPs
W341X
32P-ATP
c-kit-mutation-positive
TCCTCCCTC
.Overviews
8–74
173076L19
cytoplasmically
shGATA3_3
MP-CMML
ATL1
cullin-containing
2266
tE-Cadherin
15bp
phenotypes46
Figure6b
loopregion
PyroMark
München/Germany
peptidomimetics,8,23,38,39
CRC132
1985
pGL3-probasin
141K
4S48
goat-anti-IDHc
PDA-exon13F
V714A
leucine-to-alanine
WEHI231
GFJJR
BioSpectrometer
PPEF2
128
SC-25330
phosphate‐binding
KITV560G/D
recurrence11
GFPi-reporter
p=0.045
ElDiery
CCTTTGCAGGACTGTCAAGCA
EAE
Q105E
Sammlung
CD5.11
Hsp104-GFP
degranulation
differentiation109
FLJ33708
EC50s
1†
Natori
tumors,37
BL21-DE3*
TG101348-mediated
6.15±3.74
mono-ubiquitylate
NRASG12D-expressing
E451
R215W
194–199
S6E
Larratt
pri-miRNAs
FoxA1-epxressing
MB44
Hornakova
chr15_g.66729175G
prednisolon
41,36
cancer17,18
X-iOO
CCR=
64/84
5′-AGC
sametumor
217/221
4/65
tumours—
5461
46.101
icPTPRD–Asp1521Ala
theRoswell
GSK2118436A
hem
HRP‐conjugated
FAST-1
Fig3D
MDC1—Several
21-year
.NM_000489.3
Ji
5′-CCCAAGCTTTTCCACTTCGTCTGAGATAC-3′
1124A
ysCysGl
signaling9,10
TurboFect
32,500
0.1645
Mlox–Alox–Cre
predominat
toNTRK1
SCNAs
S5c
c.5073_5074delCT
lymphocytes.3
RTKs32–35
anti-BrdU
pxh
HRAS2,3
c-mvc
Smad4-binding
Prt
antigen-binding
Histone-like
MT10040
multiscale
R504C
94089
CRE-mediated
Krebshilfe
1,393
TM6
p.G12R/c.34G
Hinxton
fluoro-2-deoxy-D-glucose
CARD11-independent
ERE-TATA-CAT
vcMMAE
0980089
Sokal
EGF-EGFR
diagnoses.5-8
.6e
CUCRC108
Cronauer
RNAor
Biochain
BRAF,14
Pangbourne
anterior/posterior
lines.60,78
17–23
site.Finally
26.85
ICE2516D
ASepharose
AML46,52
.8,10,19,27
sva
R484W
bladder4
D22S345
Akt-T308A/S473A
condition.26,27
Cyl
Sonic–hedgehog
rates5
.Cy3
D964A
proliferation
pBS31
mass‐spectrometry
.3827G
0.162001839
Sox9+/CK19+
94.36
MCPH7
line.I4
PDGFR-α-
FOXP1-binding
NRASQ60H
Hafdis
5′-AGGGACACACGATGGGCTTCTG-3′
hyper-acetylation
tomography–CT
dithiocarbamate
miRCURY
ceritnib
5932G
ATM81
reported19
06T
3/xeroderma
Y180C
Brgf/fCreER
host-independent
Applied-
2−9.8CDKN2BCyclin-dependent
S.B
–575
accomplishment
Plasmacytoid
I.+II
0.7426
Medium-chain
anti-PKCα
3HQR
TAPP1
69836
394A
NOXA27
super-shift
STI571-sensitive
Akt2W80AMedium
apo-
peroxynitrite
B6SJL-Tg
NAP-5
n=1351
pRb-dependent
HA–pRB
CGTTCTCTCCTCTCCCTCCT
Grants-in-Aid
TATGTG/gtattt
190-kDa
DNA-PK
SRSTpSPTFNK
17q25.1
CloneJET
His58Asn
Frescas
TTTACAGCTTTGGGTACAAGG
GCTGCTTCTGGCCTTCTTTA
T620A
Table7
GSf-p161NK4
FGFR1−
Glycine
Ala178
RcHA190
Stankovic
DMNT
Genotyping
necrosis.1
.Upon
P1381L
anti-CMS
22-aa
11/17197
morphonuclear
A418
02-021
replication-blocking
anti-p70
−3.75
6026TCS
nonmalignancy-related
end-repair
WT-F
neo-restoring
HP1
intervention16
2.07
Alu-positive
5.2ITM2CIntegral
LUCC6
4E-BP1
al.17
CD23-
TRK
MasterPure
AATK
Mek–Erk
MartinSubero
.DSGPhiXS
D1-CDK6
MSH6-deficient
.Deficiencies
microretrognatism
dox-regulated
MGC8602
​,4
21q22.2-3
.Antifungal
Methylcellulose-based
Svs3b
carcinomaKidney
pGL23-VEGF
ligase-specific
P172H
IRF9
p53con
Mll2-deficient
Q9P
.MSP
MAB322
p4EBP1
11–15
SCneo
variants1
low-depth-of-coverage
PB3
BreakDancer5
tuberin-binding
HDGFRP3
20-nM
TCGCTGGCTGTAATAGAACCC
cER4-1
HGF-responsive
Arg1342
119.6
0.000002
T74P
D417N
fucosylation
A664S
DGKB
S73F
HTB-43
n=3/28
I1760
4106
RASP34R
c-myctranscription
eukaryotes
-IRES-GFP+BAP1-IRES-Thy1.1
VIPR2
72.8±4.8
SW1736
5′-CCAGCCCTCCTAGAGC-3′
ductase
platform43
32:107–115
290K
EV-FZR1–
v-erbB
.2970delAAT
Phosphorylation-deficient
0.00542
genes.25,26
kinase-deregulating
FIP1L1-R1
reported.22,23
antimouse/antirabbit
biotinylated
18325
H2009
Dcd
Assay—Mitochondria
GRASP29
5′-GTGGACAACCTGACCTACCG-3′
D48
cisplatin
manumycin
pore-size
LSR
acetyl-histone
Ala59
P41
centromer
phosphor-MAPK
M2-coupled
hMSH2·hMSH6
DNA-sensing
R545Q
monomer-monomer
E1129
157,200
2201C
.STAT3-dependent
2.194
elicitopposite
Cασ
fair-skin
dis3-V568G
2/19
self-selection
covalent
wild-type-like
.Cat
translocationWe
.Experimentally
HMV
Pc-repressed
FFL
Q01196
H2O-based
11resulting
.Q-banded
pull‐downs
HSC41*
.Cilia
anti-FOXO1A
KpnI–HindIII-digested
behavior.7
HSC-derived
.Keywords
ÃŸ-and
below.Case
featuresshared
specimens.21
Ganiatsas
Deacetylases
Alk-5/Smad2/3
IItEYcRyGDLvdYLH-rNkh
pCTV3
5′-cttccttcttgaggatcatcatggcgtagtagcgg-3′
NCoA1
Serine/Threonine
5c–e
AdenoSq
Center,26
top-bottom
Caki1
homodimerising
drug-arsenal
ER/PR/HER2
LS=loss
RP11–280K20
Wattel
RT,6
.18–22,38–47
filaggrin
GB-glioblastoma
hIL
15.5-day-old
V32M
63
gefitinib/erlotinib
37–40
16/74
94Â
Cdk4-associated
7q21.11-q21.3
.Daily
0.281024733
JT
8545
Asp136
S474F
5′-TGACATGTTTCAAAAGTGGC-3′
48–72
.23,26
Cytopenia
ALK5-dependent
​Fig.55
Bio-Spin
LMNA-ALK
T853G
reports,27
CES
HIF-1
tumorigenesis.6-8
jPatients
1029
STSVL/NKN
expression2
postlactational
conditions.12
5′-CGUCUAAUAUAUAAAUAUAdTdT-3′
TRH-containing
3H-PD
6405
mutant14
SCLEROSIS
normal-size
C239
84/21
Figure22a
DUSP-6
alveogenesis
NRG-1β-driven
29,422,328
freshly-prepared
567,685
periimplantation
genotoxic
AS8
Protein-protein
Tyr-490
DERÃŸâ€¢
*23
ior.itGrant
227624_at
.S144I
CASZ1
ESD
nonhemopoietic
TLR2-mutated
pY1230/4/5
36,742
.E36K
13.7
.Fifteen
B*9511N
puri®cation
R384L
−/
Burnichon
HBCx14
2533C-T
Repression—We
Ronquist
silencing.89
6387delT
PrRPR
14928
CPI
structure–property–function
E2F4/5
39,658
cell,51
Kapelan
10−44
Senger
−21.3
detergentsmethanol
K058
-UTR-MUT
VDU1
1mm
11,19,20
Neurospheres
p≤1.5.e10
.‡Mutation
ARGHDIA
sHi
Snf5floxed/−/Mx-Cre
RO-5479599
Fujigaoka
3595
DF1
2828T
combinations.9
spermiogenesis
0–100b
FA-L
re-explore
GDC-0349
10–80
XlO0
25°C
.Authorization
subcellular
selenite
1-
km2
K1502M
Nontransfection
4–20
2GS7
microscope.Growth
4256
resistin-like
4–8-wk-old
▵9/10
5′-CCAGCAAGGGTTTGAACTGT-3′
Galactostar
Naugler
H3K2727
chryptorchidism
ZBP-89-Δ6–180
TH-ALKF1174L/TH-MYCN
2UI/L
cell-lines
83.37
PCC/PGL-associated
54b-6
F537
gene.HLA
GCCAACAACTTACATCTCAGTCACTCC
siglist
TAF15–NR4A3
.Concentrations
hotspot-bearing
SelleckBio
ofclass
n=275
MaXtract
Phospho-ERK
7KTS
n1
K-RasE62_A66dup
p.Gly499Argfs*22
pBAD/TP53
40b
p.Q257R
SMAD2-mediated
T-cell–receptor
covariate
foci67
hCD33
476G
aLarge
shBAP1.2132
site-green
ProbeOn
8nucleotides
13.77
splicing.6
0.7.5
CDKN1B-non-mutated
Sugahara
Erk-1/Erk-2
not.8
OCRE
+248
79.6
AGCTTCTTTCTCCCGGGTCTGCACG-30
retinopathies
calcifications
CBL-WT
GOFfor
CACACCCTATTGTCACTCTGGAA
PDGF-activated
WILEY-LISS
PP30
beta-catenin/TCF–binding
P497-1
100-1000
Q-PCR
-ampicillin
Ligand-Selective
.MYCN
Mll2-TAP
0.000249893
FIS-Red
TCL1+
TDP-43
phosphatidylinositol-3.4.5-triphosphate
co-express
17–344
BRAF-V600E
N1011S
GFP-alone
mild.17
Leu116
cifically
.METHODS—We
RHNPC800P
BLR
VPB/hour
25/291
Xrnnl
Vanderbilt-Ingram
PEG-400
Adipsin
15/NA
5′-TTTGTGGACTTCAGCAGAAATCTTTGGAAAAAATTCGAAAGATTTCTGCTGAAGTCCATTTTTT-3′
eosinophils/L
.JAK2-PCM1
Zellkulturen
mass-to-charge
55,370,994
0.39-1.74
5557
A256S
high-passage
Response-adapted
a-MEM
cross-species
LVTHM
refractory
Msn5
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F4.large.jpg
Y1009
512–516
37,38,39
ER−/PR−/Her2−
lesions.12–14
I19
.Generation
LRRC58
Snai1
15′
F36V
TATA-box
GACTGAGCTCGGTGCTCCCT
Brm-deficient
cPreselected
PDFDRA
12R5-3
8-10
life.3
40-nanosecond
GAAACATCCTCCGGCTTAAGCACCAGTG
si-Mer-2
CTNNB1–exon
BRG1-associated
PIK-108-interacting
19–22
FOP-FGFR1-transformed
11-16
10–8000
Deleo
18q21
Prophylactic
P22455
77-base
β-aggregation
ENO2
398/448
B6.C-Tg
V658I/L/F
Y842H
P-MAPK-38
studies10
492_493delTG
CTD-2337J16
86,779
.Cancer-associated
.Earlier
C444Y
.Actionable
pTet–splice
N3M
anti-extracellular
+8
Y-MESO-26B
.Friend
Bioplex
0–1.5
Sonicate
H258R
454delA
AspS6
Adiponectin
5′-gcttcaccaccttcttg-3′
ofantibiotics
affectingInk4A/Arf
BCR-ABL-mediated
AZD2644
.Alignment
3992
GTPase–activating
GCCCCGGGTACAACGGCTCT
regionat
resistance,6
adaptto
FAT2
∼1.4
RhoGef
package36
αCt
nucleate
58,915
Clinic.
0.104
Tie2-Cre+Sox17fl/GFP
Guanine–nucleotide
40/72
EDTA-preserved
Arg388Trp
genetics.16-18
Y828C
mail.shcnc.ac.cn
de-repressed
H4IIE
126-129
mRFP-tagged
LSL-NRASG12D
ERBB3-mutated
85th
B-lymphocytic
monopoiesis
58-GGATTTTCAGCCTCATTTAT-38
Maxam
Anti-Sos1
fibroblast-
c.908G
transcripts23
EasLetters
V282L
Elenbaas
p.P252T
Butyrolactone
Pmutc
2,560
8/38
radiation.2
malignancies.119
68-1′
1q43–q44
Arg-202
Hambor
Y770
++++++
pERKT202
A1823T
ERC1–RET
p185
targets26
C-terminal-inactivating
Immunolocalisation
anti-cdk6~~~~~~~~~~~~~~~~~~~~~~~~~~~~
post-translation
Nanoparticles
andHindIII
Yauch
ubiquitination.38,64
PDB1DC2
GANIC
62.5
MEF2B20
Tyr527
Tsukuda
SFEM
VKSE
IM2000
270/4,013
defects.3
F97Y
P1382
54/2
C/H-rich
Y96
domainEGFepidermal
ZNF765
Samd4
NCT01384253
mrv
D/
His-HPC4-HIF1α
0.39–0.84
ERK2–DEJL
CK20+
doi:10.1371/journal.pone.0025021.g001
inhibitor.3
mutations/indels
2101.10.1016
iso17q
TIF1γ-Smad2
24-kDa
LKB1-STRADα
p.Asp400Gly
Arg399
M-07e
al.135
thereremains
13–83
AF482429
CGH+SNP
localization.19-21
.H-bonds
ThermalAce™
inA
PLCγ-
BRD4-NUT
605882
fastqc
TR-DHPE
5.2.5
N-kinase
endocytosed
2000/2500
6C5
fgfr1a/headfish
labora
0.005–1
Capase-3
.056
FKPB12
C228T—in
E7Fw
step-sectioned
anti-CD20-FITC
RP11-688M4
S19W
H2Ax
pathway10
organs.44
/-/-/
PAK1-induced
sequenceprofile
His-695
BF264
EZ1.TP53
ELAC2
TBP-forward
HGF-cMET–mediated
L116P
Exam-
QImaging
F-12K
K27M-H3.3
L858R-EGFR–mutated
116806
IRDye800
B-Raf-deficient
Strathdee
mice.167
HER2VEK753A
pVSVG
nihms703640f8
Erk-independent
30cycles
well16,20
gliomas.8–11
oncoproteins127
.BP
cycle-promoting
46.3±8.4
mutations—C121S
10-1
Microsatellite-stable
5′-tcgaagtgactggttactctt-taacgtatccac-3′
androgensensitivity
RLKRR
≥0.8
pOPABL-Ib
autoacetylation
Kloppel
T132P
.V600
AGGCACCTCCTGTCT
K757
pro-files
CSF1RD1–D3–IL-34
.52
TCATGCCTGGATTTGGTCAT
Paulsen
25,26,27,28,29
//ftp.ncbi.nih.gov/pub/panch/CBL
Aur-derivatives
.Anti-myc
posteroanterior
AML,43–48
β1-induced
N1681K
geneticin.Anchorage-independent
it.In
leukaemia2
dermatopathic
4-well
GNAQQ209L-transformed
PI3K-induced
T468
non-liver
antigen-stimulated
low-stability
pBSKS
Erk1/Erk2
protonating
66.0
D703
Weichman
E122
pharmacological5
melanoma.32,33
three–amino
aldehyde/300,000
2-ketoglutarate
H-RasK104C
108,118,339
NP_002729
Sa14
STK38
HKI
O65
Rad50R83I-expressing
haplotype-insufficient
4/36
9-alanine
unpaired-cysteine
InsFF419
17,49,50
D450H
KrasG12DPdx1
ofskinsections
20A167
.Representative
CK14-positive
p.Q61R
cancer-targeting
CycleTEST
chk2
SDS–PAGE/immunoblotting
tulp-1
tumorogenesis
Shellooe
RP11-266I24
dendrite
SPI1
Echocardiographically
ATRA-independent
GGTAAG-3
-old
0264
ETV6-AML1
genes,14
Wnt-1-LEFI/TCF
Puel
polymer®
cm/
bgi.shtml
.Height
15/54
PtenloxP/loxPRictorloxP/loxP
Lerdrup
.Posthybridization
A1035V
'exome
~259
chr4
P286R
ASNS.Luc
Theprimary
anti–epidermal
Mob1B
Alger
factor36
.PPP2R1A-W257G
Thr1357
E2856A
sat/
γ32P-GTP
PJS04
.Polycythaemia
DME-positive
Y936
Baker78
Ink4a-ARF
a-6
'zipper
TCR-gd-positive
ab16661
Clinicopathologic
55mM
ADP
varient
restrictionenzymes
Nakamuro
26,28-30
inter-phase
nilotinib.33
PDGF-triggered
BP′
.Eighty-four
Ship2
1L-glutamine
13,3
Arias-Pulido
Gsolvation
myr-K
NM_152594
FIP1L1-PDGFRA-positive
clinicalfindings
cryo-solution
candidate-1
F104S-FLAG
8432T
428C
.ETS2
C1861T
S-peptide
phosphoethanolamine
shRUNX1_1
psi-PIK3CA-T
pL6/V5DEST
Talamus_B_1
GIST48
multispecific
†56-76
pAL-FLT3-WT
Tnfaip3/A20
anti-PKC
D221H
1087G
Insulin—Once
.NM
let7
MeuCre40
brain-
75.4
Panadero9
HC11-Lbh
anti-hCdc4
p.Pro531Thr
–CO
3p14.3
.BL
7G1
.Lbh
trioxide,1
αv
HBEC30
Mx1–Cre
542
5-CTTCGGGGAGCAGCGATGCGAC-3
pRK5E
MCR
P0260
EWSR1-1
ALK-amplified
anti-Ser9
D2S162
pBabe-wild-type
mp-1
16.36
self-renewal,33
Sakashita
KIT-Ins503AY/V654A
Mll-Targeting
Tet-VP16
.Phospho-flow
905
T187A-T198V
pre-formed-
RELAFUS1
BRAF/MEK
chemicals—called
K517R
1-491
Asp-26
FAK–SRC
pu1
//www.oncomine.org
Abl1
5′-GCAGTTTGATGACCTCGTTCATCAG-3′
D317
141.2.2.5
.Aglietta
1688
NB16
32p_labeled
788A
4-sulfophenyl
Py-5′-AAGCATAAGAATATCATCATCAA-3′
study23
BMP-2/BMP-4
=8.24
Cytokine-receptor/JAK-STAT–mediated
27/19
GCCTGGTTGACTCATCTATATGG
inDNA
≈10
MUTATIONS/HAPLOTYPES
.Polyps
736A
cosegregating
.Chest
.647T
0.21556259
1195–1669
isogenomic
CGCTGTTGTGACCTTTGAATAA
IVS17-53C
HoxA9+IDHmut-transduced
fusion-interacting
C153R
MAPK-ERK1/2
Erlotinib-Resistant
Lower-
Uhrf1
R817
n.migone
Ku70–Ku80
H168
COALL-97/03
2AXA
CLIA
M/L
BCOR-like
GLP/EHMT1
PT-17
fractionationCytoplasmic
T-ALL2
Co38
heterogeneous.Table
anti-Bim
06-369
0.077246343
wild‐type
≥50
P772_H773insH
multifactorial.27
TSC2-LAMP2
normal.Wildtype
H2AX−/−
EPIYA
293T-shControl
p.K666R
μM.74
nm0mm
expressingCBL
NHEJ-associated
*Ser
J.P.d.K.
M.F.Z
5'-GC-clamp-ATAAT1TGT1TTGTAGGCCCC-3
PolyA-RNA
transiently-expressed
10-anchored
2.7-fold
Prognosis
AJ278766
GPIAP1-PDGFRB
CD4-
Subtilisin-Chymotrypsin
.Inhibition
NZM4
Fluoromount
-MUT8
ATM−/−
RNANanoChip
U75329
receptor–mediated
7•7–16•0
cardiogenesis
1844
7Department
Roop
NF1−/−
Gxi1
Bondt
I891
.Precisely
A10268
–log-10
PTENY68H
Heregulin
×64
16q24.3
acetaminophen
trials,21,22
rs28363318
~9
.Taq
P=0.005
SpectraFluor
80–96
200209091
FIGF
D11S2178
prognosis.27,28,33,35,36
-OTQOCATOO
IFITM1-G
HPV-related
liver17
2,440
S91
30~50
γ32P-ATP
3p22
co-operated
Dual-energy
Almand
CD8a
interaction11
primers/all
gene36–38
80–300
.p16
FLT3/D839
V534
oooi
V567es
GST–
1×PCR
NKY551
24,42
ERCC2-related
CY3-dCTP
IL1RAP–FGF12
dorso-ventral
activating.23
M3537
c-SRC-G2A
HMG-I
D3–AR
Growth-Plate
Exon27
NOD/RAG1−/−IL2rγ−/−
alanine‐scan
CAC
K35M
Cy3-dye
AFU/g
90048
NFR1
C1430R
radiation–associated
D'Orazi
35.5±3.8
5'-GCCGTGGGTTTTAGCATCTTCAC-3
.Phone
KIAA0355
G320V
BsmA1
USP7
14â€
3978dupTGCT
.KBALB
Korshunov
de-stained
TGG→AAG
TGF-b-sensitive
NCT01006980
Obermeier
criteria,28
MLH1c.1846_1848delAAG
Akitsu
proapototic
DOK1-4-5
36.52
Hoiby
activity,13
RET8
AG′/AG
770insASV
AGY75
EWSR1–FLI1
Noncysteine
aauUGGAGuc
reported.17
dei
CBA104
13061
Kopan
ITD-transformed
center-type
Lats-mediated
0.007–0.036
S/A
R228P
120/170
Albert-Ludwigs-University
Tet2a
case-to-case
PTP3
cardiomyopathic
annuallya
ALK–positive
genetic/protein
amu
HA'Akt
q-telomere
patients—86
uncompensated
Thompson-Wicking
71.0
Mobility-shift
ade2-n/ade2-l-Scel
TMPSS2
Polymorphonuclear
D14Mit15
40.G35W
AGGCTGC
V560G,2
Pearson-Clopper
sixty-five
Hemler
correspondingnumber
Andresson
5/21
c.719-
70–85
5'-CCAGCACClTCCAGTCCTGAT-3
E88
5′-GGGCTGATTGATTCCATGACCCTCCAGCG-3′
biotinylation
RT-QPCR
acinar-ductal
Tp53C
p.M425V
*2.7
4-1BB
ANT1ESTROGÃ‹N
anti-SF2/ASF
/green
polygon
6.4×8.5×8.7
gene.33
CRY2
Ku=
SLC34A2-E4F
277–361
radiologically
DOJINDO
cytoplasmNucleus
n=126
white/bottom
TGFBR1/TGFBR2
Mitogenic
g.81655C
35000g
retinoblastoma.Recently
9275
ATP-insensitive
TRCN0000107266
R26R-LacZ
Arg485Trp
pG418-CRAF-A
M182L
2403
therapy7
5′-GGTTGCGATCAAGGCCCCGA-3′
Han
polycomb-mediated
lodish
re7565213
Met918Thr
5′-GTAACCTTGTTTGGGAAGACAC-3′
SULTSPatientsThe
Lowery2
al.,18
HoxA9/Meis1
IVS21+4A→G
V705M
–32.7
BCR-ABL1/KMT2A
9344
wt-GST
homo-dimerization
33/106
.Minigene
5-bp
p53–DNA-binding
tumor–node–metastasis
81-25-227-0789
−552
P_y
–2
GCTTCTCACCTCGCTTGTCA
k2
WT/C121S–negative
5322
A172
5.5/NA
Bronchiolo-alveolar
pathways.20
brain-specific
nucleotidesthat
30600
Pgr-Sox17
IFNB
Arrest-Specific
c.68C
CD15+
Cdh1-induced
60-fold.13
Bougeard
SigmaAldrich
neutral/LCS
Stothers
R13
leukaemia1
thelater
degradation.24
Root-mean-squared
PRE-derived
PDFG
TACCCAAACTCAACGTGCAA
Exon4
FGFR2E731K-3xFlag
CaPO4
11p15.4
21,919
408/682
JMML.77
activators15,16
Hasle
2×48-ns
Ih
Grb7/
iarc.fr
II-based
L594V
0–0.6
//clinicaltrials.gov/ct2/show/NCT00585195
ml/plate
pDNR
RE-ADE2
melanoma.8,9
CHK2-
recombinantly
PBP2
TGDDR
NCT01401504
lymphomas9
9p24
f152A1
NM_020750.2
0.860
R469P
protein.28
oftransactivation
R-Smad
10-90
Q98L
TFIIH/BTF2
carboxamidomethylated
rs2227983
WAP
-occupied
D.M
TCCAAAA
procedure36
nihms5567f8.jpg
NTRK1-speci®c
Osx-Cre
K1724H
20p12â€
Chotteau-Lelièvre
fragment/normal
CTNNBI
footprinted
ofhMSH2
Jmjd3
Quantitech
codepletion
Quant-It
e10.5
methyltransferases25
1TLK
V600E-
Arg1004
Red-1
Gln1455
PSA-screened
ETU
Akt-T308D/S473D
10.1200
PBAF-specificity
.20,21
dcut
types.1,19
andTPR
P-switch
E1099
RKE
404-bp
Cool-1
XAAA
nihms5567f4
FC/FC
non–clear
NT2
complexes.21,33
Bcl10/MALT1
Rhead
p.L89F
His65
S1PY—Smad1
BCR-ABL,27
dnTCF4
.Qiagen-purified
Biotag
protein.19
sialidase
binding.18,19
.Tens
D162H
⩾12
LE392
1,246
CTNBB1
DNA.23-26
Pennacchietti
55259515
BTLA−
P=0.002
N-KRRRTGGALRGN-C
G217X
disease-phenotype
chromosomes.8
post-exercise
BRAFV600D+FGLAT601-
-Diaminobenzidine
thesupernatant
10.1002/humu.20005
pYFF
reactivity15
E5187.38
haemoglobinization
S90L
function.23,26
–opposing
60-mm-diameter
FLT3-F590GY591D
ADP-promoted
formalin/PBS
67.5
004/47
2.6.0
100kb
N456S
Madshus
genes—such
TTCAATGATGCTTGGCTCTG
MSH2+MSH3
Non-MSI
measuringbinding
elsewhere.35
low-confidence
ubinuclein
TC-71
H.S
Methylation27
vivo-transforming
YVMA776
10.1038/sj/
d.47y
t7
E493A
ESC-restricted
anti-203
protein-lipid
IOSE-80PC
signaling10
CHRF
Ampho
SRNS32
small-study
N-2-hydroxyethylpiperazine-N'2-ethane-sulfonic
105:1946-1949
Immumunohistochemistry
CD19+AA4-1−IgM+
anti-b-catenin
2539G
Easwaran
andSubcellular
risk87
lenti-vector
Inactivion
C228A
61.01
Trøen
=56
fragmentsof
pRS413
lymphoepithelioma-like
AUG.
GTATCGAGAAATTGACAAACGTATGAAGAGCATTAAACCAGACCTTATCCAGCTG
NCT00481247
N1–N3
neurotrophin-3,22
AAC48663
Goubin
Smad5
Script-Seq
Telethon-Italy
rad54Δ
NGF-treated
EWSETV1
19,26,32
irs1
27111559–33871686
Lys-500
thetyro
thecapability
random-number
chomosomal
7.90
Corada
hallmarks—alternating
.Sixty-four
bottom-right
Villin
AF17
26903
2696
Gao2
domain90
Ha-ras-p21
SIFT25
CD95-triggered
Oligotex
NOTCH2—a
cmyb
Akt3-amplified
cuSCCs
System120
Notch.41,42
Glu326
ETV4a-f
targets—ACVR1
biallelically
family..
-CAGACTATGTTAATCTTTTTA
LSI13
Rho-mediated
ortetrameric
anti-CD13-PE
Brca2F11
828
-Delta
phenol–chloroform–isoamyl
NIH3T3-cultured
Envision+System-HRP
43–45
p21Waf1/Cip1but
C1606
Ong
mutantsTable
.Authentication
MS-278-P
diagnosis.15
12:12‐h
mark.glover
BT-005
.048
X-encoded
protein,2
7.8–131.8
sulfur-containing
2957-bp
shigekazu.hidaka
​Fig.3
p.V387M
H3-K42A
proceduresTargeting
~'e
P=0.0601
.V-Ki-ras2
.Abnormalities
W450L
cells174
CGH-v4_95_Feb07
D13540.1
3C,3E
BEAS2B/HER2WT
stem-
cKit+Lin-
T1052K
XSmad2
poly-L-lysine-coated
subunits.1
M787
T-Vector
61-65
cons46=607
Bilderback
XFast-3/XFoxH1b
LM200
5′-TGCCCACTCCCAACGA-3′
CVCL_0158
K181M-AKT2
.Irradiation
activity/hMutSα/mismatch-binding
79754
methyltrienolone
366Q→H
-responsive
HPNE-KRasG12D
lineages.23,24
ARR2Pb-ERG
0.26–0.37
IVS24-1G→C
SB2
apoptosis.102
1.07–4.92
previously.43
med.nagoya-u.ac.jp
PDGFB
N986Y
domains.Cellular
Neo-angiogenic
IGF1R-interacting
602948
131.9–133.9
JAK3-STAT3
CCTTGCCTTGTATCGAATGAA
K2860T
59,800
tumors28
Kabuki
D1–4
allele57
EWSR1–hSNF2H
0.254
.Y654
124C
Tli
TCF4/β-
iCCA4
One-Step
4973
Gyn-GU
HD-ZIP
mm8
5AA8
GATCCGTCATC
evaluablea
AIB-1
mouse-forming
double-stranded
above-referred
n=29
pretransformed
EBS
9–29
0.3347
antiestrogen-resistant
Asp-947
adducin-γ
16105
His6P110α
.Macrocephaly
300nM
E020
2-pyridinyl
ACVR1Q207E
26,196
1,297
SCC9/15/25/68/Cal27/Fadu
3D–F
residues.Computational
PBRM1/Baf180
limbs181
Lazaridis
A_52_P89064
H502
β-Tub
TTTTAAGGATTTGAAATGATTTTGTG
7265
switch/sucrose
thanfor
381022
missense
9=1761
minichromosomes
'Specific
1.94×105
0.3006
cohort—BRCA2
rapalogs
N179S
lipid-mediated
.TGF-b1
1.42-
E2Fs,56–58
well-delimited
2•78
116-119
FGFR2-IIIc7
Dimerization/interaction
linesDaudi
pan-cellular
4q35.2
A190V
3q26
lys2
2,931
I/II/III/IVA/IVB/IVC
MK
Asn6′
AATTATA
MG6F5′-TATTACTCGAGATGCCTGGCCAGGAAGTCATATATT
Stattic
S6A–S6B
.Tim
13–3
5′-Biotinylated
l06
35a
substrate,52
pGEM3
seven-loci
FA-AML1
.Xylitol
alpha-ETV6
conformation59
.Bcr-Abl
neuroectodermal-speci®c
observed17
TCCAGCCATCCGGGTGAGTT3
Y49D
DNA-targeting
SRY.25,26
DEE-NQO
thefourth
.GOF
Takara
35S-IVT-HIF-1α
TGGCGTGACCACCAAGTCTC
Ptpn11T468M/+
1:80
RNA-specificity
MSH2-p.M688V
0.7-26.0
rSorLouSerProThrCIluCIyLysGI
personalizing
fludeoxyglucose–positron
No./Total
Tartari
ECD-hot
p=8e-5
.Sox17-mediated
ANO5
RPS6KB1
μm.Figure
C1orf174
RT4FUS
1year
anti–phospho-active
cells/colony
less-differentiated
TGFα
kindreds25
S583P
thefunction
Muscle-Invasive
131100
113/195
0.04366
0.3043
1900
TCAAGAGGGCACATTTTGCT
.Conclusively
60:1
Tumourlocation
al.18,19
p59xDR-GFP6
5′-CGATTCCCGGGGTATGCAGATCTTCGTC-3′
proliferation/survival
10-µm
TFDP1
.12,13
~40-
C3A
.Institutional
R47H
Blotting—For
12/44.4
heptamer-to-heptamer
IGROV-1
Dolecek
cells5
.D835V
electronegative
neuroma,11
KOD-FX-Neo
GAADD
Nannya
GAu
KABBINAVAR
TapeStation
61*
RER
521/522
E6-E7
FGFR4s
9mutations
Wtsi/+ApcMin/+
.AG.V
receptors.28
Glu1754Ter
proprioceptive
nucleus.27,28,30
Myh7
0–21
KDM5C
Rap2A
hTR
slipped-mispairing
intermediately
/cm2
3-phosphoinositidedependent
Lewandoski
1P
.14-
DE-luciferase
genes.11⇓–13
C163T
R479C
coimmunoprecipitating
IL2-activated
T21/GATA1s
monoester
Robust-RT
Resta
U266-1984
pasmid
7700
SOS1-associated
Ciao-1
MGantisense
Gly719Xaa+Thr790Met
ALL.2
100-200
33.94
WNK1
Besancon
Frattini
COT10
Non-Small-Cell
2,819
ras-mediated
done,9,10
AF3008
207.14
.N1026S
p63-mediated
GTPases25,26
.008
Mullokandov
U/μL
response45
LNCaPFGC
16/33
1868-1874
miR-125b1
.Po0.05
p21Waf1/Cip1-specific
GFP-DSS1
Reddig
Hs01438786_cn
13.3478
Amendments-certified
YAP1FUS-RFP
-282
10pmol
P241L
G197
aflatoxin-exposed
Hnf1β
Kinome-centred
signature31
integrin27
chromosome-22-specific
deduplicated
H114Y
TAGTCGCATTTCTACCAGGTTA
C442Y
oligonucleotide
observed92
5377G
5a/b
4035
streptavidinbiotin
abase.In
complex20
.mechanism
DiTullio
'-P.'.-
.NAAIRS
WM39
K14
In-silico
CL-387,785–resistant
Yasuyuki
Fahrner
5262
16/54
p.Glu1042Lys
.Considerations
D-loops
PD1/PDL1
RANPB2-ALK
E317K
.Serious
processes21
MCF10ATk1
monolayer.Furthermore
Saar
PTPRZ1
HLA-A*2402102L
hypermethylation.18
anti-Foxp3
Paulussen
R771L
Ezh2WT
NeoMarkers/Labvision
nonconjugated
-CD10
Ile142
NCT01476137
N505I
0.3
24,524
gene98
GSE15695
Jagged-2
0.3863
R2D2
N526K
GISTs.6
Dey
aberration.16
UbcH8
DHT-treated
Bis–Tris
PIK3CA-only
oncogenesis.19,20
goblet-cell
analysis.AR
.REV-GFP
.CL-387,785
Phosphospecific
chal-
PKA34
UTR-tagged
.29
months–18
colleagues.10
Mek-independent
5500xl
375–438
22q3Dâ€
CADASIL-associated
NAPESLNdgi
study.25
62-98
IR/NK
biochemically
p110α-R93W
sec-13
©2011
GSE11265
SDS-gels
DAM1421462
2.2.2
J.M
M3625
plaque-purified
5′-GTACGCTGTGAAGGCATCAA-3′
×75
.00243
S42
434.6–535.8
KRAS221–24
.SA-beta-gal
10.1182/blood-2007-01-066076
.Forty-two
twobase-pair
14q12-q13.1
c.1600_1608del
1p13.2-1p11.2
.BCR
p22
ZC25
MARTIN-ZANCA
SIEm6734
R.H.
gastrinomas
2Ludwig
Tatsuka
20q11â€
extension.3
Kmt2d-null
TP53-defined
T783I
FRAS1
LKB1/Hsp90-Cdc37
2.14.2
time-period
.Cotransformants
Spemann
jmg
.K45N
§In
Binding-coupled
DUSP21
DDLPSs
NativePAGE
synchronizable
PLA2G2E
.CYP19A
domain—in
1.04^1.13
vivo.21-23Because
ITD+
k-1/k+1
splicing-based
P493R
operator-regulated
mutantions
IDH2,17
8/60
2-ΔCt
c.350G
unmethylated-specific
protein−protein
76,79,86
ICL.14
GAPD-R
Boston.5
PPP3CC
5′-TCAGCAGGATTATAACTTACGTACGACGTGGACGGATGGGAAAAAC-3′
high-risk
IL13RA1
BRAFV600E-independent
W729E
Leu996Phe
LHRH
PIK3R1-driven
13q11-12
∼71
.AIS
TOR1
.2351G
14–3–3σ
650-225-5841
www.ppbregistry.org
S6.cSample
phospho-FGFR4
rmsds
GGTGACAGAATGAGACTTCATCTCAAAAAC
c.923G
Ba/F3-GMCSFR
metastis
D-biotin
MIG-vector
5′-ggagtccacaggatcagagtggac-3′
SOX-dependent
34850–35199
T303R
219L
DNAwas
formalin-resistant
1974
BAS2000
Hantschel
HER2
9/8/06
ELISA-reader
CyBio
82.05
diploid6
parameters25
=131
-CTCTCCACCTCCTGCCATTCGTATCTGCCC-3
C1156Y159
105,106
mean−3s.d
M933
TGCCAGAAGACTTGGAATTGT
FAM123B
BRM-negative
036
loss-of-function
Tumors…
R415A
90,550
G129D
°C/56.2
enriched/depleted
2.82
weeksafter
.956
2.1.2
50U/mL
melanin-laden
hypohexaploid
Trp308
foramin
concentration-response
RS3F
low-to-intermediate
620-nm
6xHis-R882H
Sox2CRE
retrovirus-containing
82.0
.Immunofluoresence
Figure2E,2E
1•4
virus-based
AML1,10
316.8
nonrearranged
240R
α-Caspase-3
anti-pIKK1
functional/total
TGFBR1p.R487P
2Ag
K0
colonystimulating
cyclinDl
08907
Glu77
5′-GGACATGCCCGGGCATGTCC-3′
Arg10
ependymoma.25
c.1516T
keratinocyte
signalling.Figure
-30
JCOG1009/1010
Shh-dependent
transcriptation
AMPK-regulation
IndelRealigner
±0.2
Moyret
3270
TACSTD1
53bp1_A
phospho-Y88
SPT6/SUPT6H
W495R
ZFP36L1
3FLAG-EML4-ALK
25/48
unknown,18,19
peaks28
3,10-16
Co-regulation
3.0–3.9
7FF3
1,035
5′-GGTCACATCG
toinfluence
Pi3k/Akt
71105
p110γ-selective
27–99
.Mammosphere
756
.Garcı
F117I
0.769
MLL-EP300
FANCG/FANCA
2.70
7.6079
inhibitor,18
GGATCCTAATACGACTCACTATAGGGAGACCACCATGCAGCCGAAGGAGACGC
trans-regulatory
microBoyden
FGFR1-2-KD
W44R
Y589
3077
∼14-
lethal/sensitizing
p.Additional
mRNA.4
XTT/phenazine
1.182
G2607C
0.3–10
SLVK
carboxypentyl
Srsf2Δ/Δ
61•7
dioleoylphosphatidic
Lenti-SYK-6
02-it
3226–3231delTTAAAGb
A-P
platin
Interchromosome
2903
1.50–3.23
Plk1
Myc-IP
HTR3A
RHOA-mutant
NRP
90-141
1996.11
Dhh
BRAFL597Q
miR-20a/b
virus/cell
M-280-
TNFRSF10
270,673
–0.0
missense/truncating
GATA-3-deficient
−235
liver-targeted
985
p27–Cdk2
43–2.2
hypomineralization
nuclear-fraction
26-fold
POLE-exo
3HMG
Hoxa5-9
CyclinD1
*Arg8f
anti-6-
D323
CD24+Sca-1+
C−T
C121W
025393
strand-specific
PB-implicated
SK-Mel-264
S1–S6
TRizol
CPP-ACFP
self-destruct
TDE
ade-
.2252
PIKFYVE
Doxo
humanp53R175H
nEe
.Jacks
salt-containing
B*5001
great-grandmother
cells.112
1Y57
S6.23
JHUEM-2
two-lobed
T/P
TEBU/CLB
535
.Evaluating
AR-
T790M-amplified
R-package
G305V-mutant
UDP-GlcNAc
regression13
Tumor/normal
imageTable
Hs99999909_m1
3,447
Orthologues
Hsp90/Cdc37
606480
.In-gel
signaling.46,47
Apo-1-FGFR4-KD/Dovitinib-FGFR4-KD/Ponatinib-FGFR4-KD
z-test
.49
7020
−.82
GAPDHfwd-5′-GAAGGTCGGAGTCAACGGATT
25µL
K2171L
Men1/-RipCre
3p11
9q
pJade-1sh2
2G2H
3-kinase-AKT
EDTA-containing
L858H
miR15/16
Capdeville
previously-reported
746~753
11/8600
c.1009C
AZGP1
Papillomaviruses
I4448V
anti-uPA
arterio-venous
age,2
ctgaag/ATGCTT
mini-contig
HCC26-0808A
S142fs
patients—74
kinase.20
LASSO
CBP+/-
ARN-509–
131K
anti-p15INK4b
Gly380-Arg
PI3K/PTEN/Akt
RNAspin
~1989
FTMT
No.sc-94
.Lipofectamine
FK506
23-
TTGATGAAGAGTAAGAAGATGC
6.85
MDS-refractory
Vavl-cre
leukemia.40
Q2340fs
58.3:1
V241del4.
SANT-1
migration16
5′-GUGCAAUGAGGGACCAGUA
Glu545Lys
synthesis8
PSA⩾10
M315fs
MgATP
Nucleosomes
pCR-Script
date.Materials
.Arm
.CDKI
PI3KCA-activating
.DiscussionFive
D173N
survival155
MBENs
.E884K
Eμ-tTA/Tet-O-MYC
564
TEX14
1:17
GBM
chromosome-fragility
IFIT2
1000–1500
PHA-
naturally-occurring
R49P
theTEL-JAK2
immature/transitional
005676.4
R87
ROSCOVITINE-INDUCED
BAM_preprocessingPairsMisMatch.pl
C381A
mRaf
PDGFR|
Sel-Met
N21S
−9.6
unableto
91–94
inb
G322s
129/sv
4Ae
proved.5
OSE4
Morrogh
.ATRA
signal-attenuating
significantlyactivate
TER119
Q286P
GAAATAGGATGTAATCAGACG
N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide
625,000
88–91
100‐mm
resistance61
TC797
.Mycosis
oI-Q209L-induced
p.Glu1295Lys
Cul4-A
ERK28
c.62
kvd12901
Tyr752
M951
pPKCβ
145,000/mm3
IC50=13nM
-0.7
anti-NT
.Schmitz
PI3K-activation
siCE3
EDTA-venous
Lfc/GEF‐H1
C/lmm
133.8
386–752
∼160
sunitinib-responsive
plasmid-dependent
.SDS-PAGE
linker-specific
1099G
kbpFIG
originallydescribed
Gmachl
v-mos
HA-Hdmx-G
Nussenzweig
tetramerize
M2-anti-FLAG
RECIST.26
p.F82V
sequence.4
pCAGGS_FLPe
transformation.79
PKD
EM-800
provocatively
.Importantly
ensheathment
GACGACCTCAACGCACAGTA
ECa109
epigenetic-directed
C278A
138,101,360–138,240,978
Y134C
inhibitors,24
G185C
5'agtgctgacagtcggaggag
Y412C
-7i
retention36,37
13,29
GeneJuice
lives.16
2TrC
selenocysteine
28C
ane
ABD/C2-T323A
1–11
SEMG1
NLF
Rad51C
.H814R
0.8629
.Still
A/C/G/T
Stefanovska
emangioma
pmanpih
075
59.0
AA557-AA598
250-fold
1.54-
1360
v3.4
C35C4
//www.cellsignal.com
XP_540136.2
c.2087C
delL15
TTGTC1TTTGT
V/7-AAD
EGFR15
cc-EpoR
III-1
Ikehara
His-rich
obQ
charles.swanton
B48
N234-09
al13
p.D236Tfs
overexpressed.15
prototypic
OR=2.13
pRb-like
anti-flag
Gupta-Abramson
169,198
Cbl–UbcH7
Ketteler
2q14
products.1,2
collagen-induced
Fzr1lox
p53-DBD
magnitude.Cosegregation
PleI
non-marked
β-actin–specific
FSK-dependent
p53-responsivereporters
A.P
Cys378Arg
Claesson-Welsh
APC
000535
CUL7
Caspase-3/7
protein/Wolf-Hirschhorn
AAG→GAG
Anthracycline-based
independentisolates
803C
2ml
p.Ala239Val
p.V843I
ZMSH3
1MVH
MRT/AT/RT
3737
1-318
patients.5–7
Lelij
V378–K380
H1299-control
Lof
Fehmann
Tyr
cytokine-rich
pGST.38
GAPIC
Duyster
LIHC
.TSC1/2
pre-immune
ROCKI
transfect
evocated
Assay—Rat
medium-scale
purpose3
10U
Rates—Recombination
DIPG.29–31
Hs01020387_m1
E200K
GTTCTCAGCCT-3′-TAMRA
FGFR1V561M
glioblastoma
anti-Sm
penicillin−streptomycin
mesylate1
Sterne-Weiler
allele34,35
Disease-Free
histopathologic
full-restoration
proteinin
Prostatectomies
Asp-537
BET-protein
2×100
Arg189
stability192
model10
TINV
KRAS-mutant
failure.6
respectively12
.GnRH-I
442×
HIF-1α-Ub
co-translation
Anti-SHC
Platyspondyly
I-10
www.jdrf.org
308.00KB
PCGF4-deficient
AMZ1
mutations.49,50
.Immunoprecipitations
OTII-recipient
p.Asn666GinfsX41
megaprime
=269
VDW
C_868_G_5
de-ubiquitylation
E26
ACTGCGTGCGCAACCCCAGC
Deiry
c.3927_3931delAAAGA
PD865
CLL.8,20,21
ver.3.1
NCCN
GCGGAGGATTGCGTTGAC
U73499
D11S2179
.ARID1a
alpha-1-antitrypsin
,5c
KrasG12D-directed
Y505ins
caspase-8-expressing
Cul3SPOP
78C
pACC-S79
I346T
*Variations
phospholigand
9-1
G–I
7,18
CMA
drug-treated
parasympathetic
NT3
inLB373-MEL
SCFSkp2
Schoell
59-CTGGGG
0.399434357
www.mda.org
2962C
KLH-peptide
difficulty**
anti–phospho
Met—By
2–93
1.23–6.83
Baskar
memory-enhancing
5′-AGTGTGTATGCATGCATCCTCAGC-3′
N3-methyladenine
described.42,43
613113
Ternecula
Dp110
10b–c
Ehningen
TransFactor
Capuzzo
Referencesp.P456S
chr5_g.56189410TA
D170G
.Arnold
Gronwald
sites/cell
individual-derived
His1047
mantGDP-Ras
Dephosphorylates
204-
beta-Catenin
P236H
jl2m
XXLb1
.87
SEQ-1
nega­
PBC
346–380
7458delC
F53_Q58del
pE3
CKO2
OW
transcriptiondependent
Asn504â€
1,066
Tubules
Yakobson
G721D
dermatopathologists
Cys-X-X-Cys-motif23
K6-expressing
pGL4.32
codonsfor
Bcr-AblY253H/EGFP
thc
SectionRESULTS
activity.We
.Ras-GEF
onthat
NCT01090011
Ex1F
interfaces74
.Oncology
3.5–4.5
.BRAFV600E-specific
Positron
.NeuT
low.7,34–36
Hirntumor
1049-1807
IVS±½
≥95
L409S
5×3
prostate-tissue
.Eosinophilia
E3850
RT1
.Homology-directed
radiographically
p-MEK1/2
17b-estradiol
//www.onkozert
swi/snf
RGS
-Smad4
Asp536del
image-processing
1106Mel
ΔN1
site-
C.b
K600
markers.15
GISTs.3
22999
c.1502–6G4A
set5
10a-10c
iodide/PBS
.457871
rockvax.rockefeller.edu
AGACTTCTTGCCCCAGATGA
FGFR3c-Y373C
Celsr2
communi-
Y495A
translocation/glucose
TTCCTTCCAGTGGTGTTTCA
Vikkula
2,093
Mercodia
ASXL1-null
LN+
Atm+/-
¢nalizzata1
ttttag/ACCCAC
2F2019
algorithm40
212–214
astrocytomas.23
â€¢
1.8–2.00
enC
25–140
Leu1062
differentiation13
enthalpies
options.1
nephroblastoma
damage-like
PCP-2
F11
680LT-
//cancer.sanger.ac.uk/cosmic
through…
cancer9,30,38
EcoRI-digested
luciferase–coding
MYCN-inducible
11,15,33
10.1182/blood-2005-10-
1852
PreAnalytiX
UCCC:1
.Naked
tests25
alignment-based
delTyr
Δ773
anti-FANCA
Tyr591
OMM1.3
EWS-ETV1-
PKBαW80A-GST
XPA-G
3Clinical
methodsClinical
cells,61
Q907X
.Electroporation
TRIM24
proferring
Tyr81
lines.116
Beclin-1
91.5
E2a
CR1
radio-sensitizing
Lethally-irradiated
Immunologically
mutations106
.Aj
//genome.ucsc.edu/cgi-bin/hgTracks
pCMV-APC
Moldovan
GST-BRCT:1529–1863
prognosis5,6
nondeleted
212K
AML.33
HD100AA
q32.3
®tted
Peptide-bound
Glu-909
His158
analysis21,22
α2-
Cst6
6631del5
PDM2-LacZ
ARIDB
KDM5C-target
6.0-kb
PIP5K1C
found.27
.ARE
.T75R
NGN1
DMSO/Polybrene
COPADM+
5′-CGGTGAGTTCAGGCTTTTGAG-3′
marrow47
UEM-5
-_-215.5
TEL-AML1-positive
V144D
G.Z
hsr
2195
triphosphate-labeled
L-asparagine
45.34
E40
WT1-mutant
Ca2+-dependent
E1935G
,28-30
GCCGATCGATGTAGGAAACTGGGTGAATGGC
HR6
CIP4
Fendri
ER2
Vaco400
Cys4HisCys3-type
data1
IRAK1-EGFP
112.00KB
.TGIF1
activity.13,15
p.V1075Yfs*2
PAb
MET-selective
Ras–ERK
effect2
c.1852_1853delinsGC
RBM17
95.6
7,36
ijc
box-
MSH6-6
AR20
pRRLSIN.cPPT.PGK-GFP.WPRE
Hybrisol
Asp116−His123
IC50-ratios
327.4
andro-
min-coverage
486–487_885–886
two-pronged
cross-checked
SETD2-RNAPII
113.2
ttcE2
cells37
31I
melanoma-specific
phosphoinositol
YY1–1089F
CAN-gene
H3K4-trimethyation
P-positive
Apc-mutant
surgicalremoval
3/45
Y130
Pedigree
S8.2.1
1636–1795
threonine340alanine
D1067A-KD
GST-p53-DBD
2.86×106
p.R369W
others21
c-REL
glycine-serine-rich
P29Q
S-phase-critical
Multi-color
p.Arg286Trp
A→
HSC/CLP
56–122x
MutLfamilies
EPB49
pcDNA3-V5
beapplicable
5′-aagacctggcggccatgctacttcctcc-3′
.Secondary
allopurinol
–activated
HIF
UVB-mediated
ACEA
0.441
pBABE-PURO
gene.28
therapy.Table
Fig.11a
6856–64
C124R
snurportin-1
7934
MDS60
.CDK1
49.1
7-codon
criteria,13
1•74–20•22
N2048I
PI3K-AKT-mTOR-S6K1
LDI-PCR13
1×108
formalin.After
.7,111
MMP1A
.R24
ribonucleoprotein
Y126H
FLT3-TKDs
ex8
rs76946721
LASSO-based
TGN141
corticotropinergic
5′-TTAACAAGTCACAAGATGGACAGTG-3′
LYN
DNMT-mediated
5′-TCCAATGATGGAAAGGCTGGAA-3′
ail
P611T
maculae
IL-2Rα
differentiation-promoting
nontransformants
min−1
FAR1
.Sorafenib—the
IVS6
GCAGCGGGTTACATCTTCTTTC
5′-TCCAGTGAAAAACAAGCTCTCA-3′
rs41420046
FNN011
MTC-causing
annealingstep
A-cyclin-CDK
Lys-CoA8
HIF-1α−pVHL
skp-cullin-f-box
1000/μl
5'-AGACGGCACTCTGGTGCTCTGTGT-3
Br45-Pan58
0.5261
CleanSEQ
cell-precursor
.028228
p53I254F
F102C
C787
Tet2-WT
TBX21
5cr
Gadd45α
MLL-AF9pos
Gly35Ala
4276
GNAQQ209L
Rev-CCAGAGGCGTACAGGGATAG
tetrazolium/formazan
TotalNumber
RUNX1–PRDM16
n=13
MoeII
peopleparticipating
survival.3–5
37.5:1
anti-HSP60
positivity.34
Rgl
454:21–30
non-Caucasian
NUP205
Heteroduplex
oncogens
samples83
aik
.Nicole
HTB-96
and—to
Ser435
Shionogi
XhoI-cleaved
p.Met253Ile
1238/2468
5′-CGTGGGAAATTTGACTTCGTGGGAAATTTGACTTCGTGGGAA-3′
Segawa
4-feline
noncarcinoma
effector-protein
B/B′
R420
S919P
CUL3A
SKMEL-19
T151I
Oehm
18U.S.C.Section1734solelyto
GAAACTTGCACAGGGGTTGT
-GCAGACCGCATGTGAGGATC-3
Owen-Schaub
2002-2004
contagiosum
Varian/Rainin
lines—HN31
M/70
6/36
N-cadherin14
experimenting
sequence26,28,32
non-LTR
May-85
FLAG/HA‐tagged
Gg1.3Kb-Luc
BRCA2-999del5
.Serous
FOXE1/NKX2-1
data19
NPM1MUTFLT3ITD-WT
R171X
cross-terms
NaHCO
TOTO-3
1/41
tyr1068
SPDEF
anisomycin
GISTs60
38N-terminal
30,36
Kruh
EGFR-mutant
ccRCC.2
R160W
GISTIC21
TOP1-H3K4me3
FLJ17473
Q5345R
0.0142
IPEX
determinedafter
≤20-bp
GDH
found.81
kα6–8
RYPB
long-terminal
significantly-mutated
SU5402
2G–J
β-carboxyl-containing
Â±SE
spread,27
.Attaining
473-Akt
misbalance
q24
analysis.As
p.Gly173Val
4668
obesity-associated
progenitors11,12
9mutant
1436
transeq
H1
9451L
anti-p65-4EBP1
million14
86/609/EEC
∼74
octanucleotide
Scharer
43.13
NHD
Cys-634
4-fold
9/127
.VS
KIT-N505I
254–267
therapy.25
rRNAs
10q24
.Sometimes
R156
ML-2
published21
//www.aocstudy.org/
EGFR-transfected-NIH3T3
cases15
95Â
AMG
.Subgroup
Cherny
enrichment27
phenylmethyl
PRKG2-PDGFRB
Thy-1
NIH-score
enthalpically
T3M
n=675
5.11
1,450
51–91
ubiq-uitination
receptor-alpha,1,2
SHP-1
Laboratory-European
5–38
dianova
sc596
Sup
360–528
MDM2/P-MDM2
5′-CTT
6598
15.0nM
252/250
Brca
GAAACAAAGAGTAAAGTAGATGATGG
117T
MLL-TET1–positive
H295D
urinary2
HER2–HER3
11q22.1–q22.3
U-
ctgcag/GCCTCA
7RS
RAF-independent
GISTs.98
VHL157-172
Wikström
mlG418
SpectrumGreen-labeled
7937
PCNA42
Val77Alafs
ERBB2-V773A
yeast.12
Colon-cancer
TET2-deficient
disease.https
.Walker
28.8–29.2
'M
E2910V
N645S
liposarcomas.2
Frs2-mediated
defects18,25
t½
ESRD
TGTAAAACGACGGCCAGTGCCAATAATTGCATAGTCTCTTAATG
FM5
progression19
mutations/samples
21514
ERÃŸused
p.E760D
UB
75.6
TGCTCTGATGCCGCCGTGTTCC
0.0294
MDA-MD
Jankowska
D842V–mutant
4358_4484del+4665_4675del
5′-GGCTCGGGGCCAGGGGCGGG-3′
HDR.A
.Vectors
WT-SMARCA4
array-comparative
PTPRD-wild-type
Y249C
.P-values
Browser46
oftransforming
GAAGGTGTGTTTGTTGCGGT
AC-RFP
104-1cells
acid-Schiff
ecotropic
35:65
TALL21
ethylenediamine-tetraacetic
Jam-3
promoter-distal
identijkation
Rab5a-positive
IGF-1/PI3K/Akt
beta-galactosidase/LacZ
.5208
L61R
p.Leu97Arg
HYBRIDIZATION
ARv
20/20
155KFIG
function25
arise28
:TnlO
NM_024408.2
AHCYL1
element/SRF/transformation
IFNa
program12
residuesL22
CoMOS
1936
similarly-treated
RasY64A·GTP
Brachmann
2,552
SDSPAGE
K713
Kalchman
cytosol,15
0.0223
D11S1817
carboxyethylphosphine
.Sitedirected
high-credibility
PIK3CA-GEMMs
-1,2-dithiole-3-thione
sestrins
pathways58
esophago-gastric
7311
Gene-Expression
differentiation158
non-NS-leukemic
MDAH041
E1B-55
TCCTCCTTTTTCTTCAGCCAC
.BRD4-NUT
non-sex-reversed
signalling17,18
lengthse
ERK2-tag
Air-dried
38.5
Del19**
n=62
UAU
rhabdomyosarcoma.14
∼27–58
K773E
carcinoma.24
Templated
HA-BRAFG596R
Erlangen-Nürnberg
non-kinase
inactivated42,43
pLNCX1-ΔPH-Myr-AKT1-K179M
7241G
MyD88,11,12
antibiotics.2
pS6S235/236
heterodimerization.18Do
erlotinib.43
5'catagctccgtgctttca
152
T-cells
supportfor
R9
1.332
rectosigmoidectomy
CD3-activated
AML/
Gamboa-Dominguez
blc
beling
0.52–0.94
non-CGI
IFPs31
inter-tumor
D160G
.Rad50
iMaster
43–58
chloro-3-indolyl-phosphate,1
NaC1
87.8
mTOR-dependent
TPM3-ROS115
D.R.R.
CF3
JAK2a
HSC
complementationand
PPA-527
293T-cell-based
−2.73
pQCXIH
Smad3-specific
uPAR
PPI
combs–like
Asp74
Ini1
KB41
GST-
S1087L
314A
stain-positive
starburst
AML/acute
.Sander
plakophillin-4
ABC-
ALK-3′
-TTTAGCATACCACAAATTCTTAACC-30
ExPASy
E286V
.Fatigue
1.17–3.57
c.208-1G
AAGCTTTTACTTGTCATCGTCGTCCTTGTAGTCGACGCCAGCAGCATGG
Sobue
Chr9–392F/Chr9–1226R
cribrosa
.E1501
59-AGAGGGGCAGCCTCTTTGG-39
1,711-1,735
heparinized
NKL
47–52
pseudo-confocal
M-Ras
EPHB6
phosphorylation.44,64
Pik3cae20mwt/+
dominantCorrespondence
mitochondrially
bHCAs
prognosis.8,9,12,13
His-179
Thr/ACC
Spo11−/−
kinaseMAPKK1/2mitogen-activated
∼64
10E
geneproduct
CFP-GlyAla17
.Scratch
HLAclass
IHC-informative
ade2-40/ade
Neuherberg-Munich
FGFR2C383R
642-bp
undamaged.22
Fig2A,2A
oncogenomic
L169P
phosphoselectivity
mutual-exclusivity
4862
signal75,76
intestine—the
ligands.55
siRNA-expressing
8.28
65–80
HER2¡/HER3+
Antigen-specific
F1-R1
descriptionFold
PrlR
5'-CCA
.HUH-7
DNA-analyzer
4382
NGFR
Alsafadi
glycolysis13
40400
1986,15
MM-GBSA
p15/Δ130−137
gene,86
BioConductor
polyphenolic
Frat-1
anti-β-catenin
GISTs.7,8
carcinogenesis40
MSH2-V923E
PPARγ1-PAX8
Y-654
R844Q
RNA/sample
PDGF-receptors
unclear10–13
anti-phospho-FRS2
.Anti-ALK
Adriaenssens
EBPs
conditions4•12
H4-20
4682
c1857
Cdk1
cycle–
2-compartment
Ni-NTA-DOGS
A2272S
C238Y
.HLA-B-typing
CCDS43970.1
HUH-7
GST–GBD-FF
.015
0575
allele.44,57
Danilkovitch-Miagkova
PH-domains
phenotypes110
leupepdomain
Rbx1/ROC1-encoding
amlification
Karnofsky
urea-formamide
BRCA2-DSS1-ssDNA
Q263
−2931
3522
honorarium
0.722
dotGdotPydotPydotPy-3
hepaticcarcinogenesis
t-like
E223*
EU-5
transformationassays
Paircoil
A755
Y1853
FGFR2WT
HGF/Met
-TTCAGATGCTTCTTCATTT-30
Ep-Stimulated
grisea
GFP–VHL172-overexpressing
645–1400
D742
INI1-2
event6–8
178Gright
pY568–Y570
CCTGAATTCAGCGCAGGTACCGTGCGAC
GST-E380Q
encapsulation
auto-regulatory
KRASG60_A66dup
A*01:11N
score=300
.Phosphopeptide-mapping
53BP1-
SCF-dependent
thesefibroblasts
.Immune
T477I
N-Ras-induced
GCTCAGAGCCTGGCATGAA
cancerBRAFMelanomaVemurafenibDabrafenibBiomarkerTargeted
interferon-bold
breast25
ICGC_PA84
glycine-tryptophan
D872
ClUA
antibody-chromatin
116kDa
50-89
127,610.0±17,956.0
cSrc
T-ALL,2
recrystallisation
12/68
2315C07
Asp761_Glu762insGluAlaPheGln†
88–168
AS21
369
translocations4
17-330
pan­creas
EO
p110β–Rac
//www.ncbi.nlm.nih.gov/ncicgap
AAGCTCCCCfACCATGACT
immunoprecipitation-PCR
.Discrepant
17-allyl-amino-17-demethoxygeldanamycin
31/60
ZBTB7B
R406
25–68
T1241
.182A
128.Kinase
3/KLHL9/KLHL13
Sos1EK.Figure
reauthenticated
H2AK119ub1.18
Pasmant
gtagacttt
517-
195
temperature-gradient
gdbwww.gdb.org/
​Figure2A.2A
3′end
Diversin
9–15
semiskirted
Hair-colour
IRF3
LINE-1-related
Itga7
Ylpl3
316-
β1–α1
LSD1,4,21
IUSM
SBE-Luc
TGH
.Scantiness
D352H
1.PPM1D
F252S
ErbB-4
mice.Analysis
locus4
procheck
IP5
acidsinvolved
9.Rad54-mediated
ovari
MY5008
OLI
Leu597Val
41/46
//p53.free.fr/our_work/structure.html
phenol-chloroform-extracted
20251
/MPN
GSM180992
non-additive
cytospin
2D
tetra-TBDMS-citric
Iranian
septa3
Abeliovich
mutationsA
linda.mahjoubi
−−
Break-apart
YNB-2
0.2–0.8
tissue6
MEM-α
Myc-ezrinWT
Monomner
trials18
chr
NM_002890.1
R161A
CDKN2A—identified
3p-arm
EphrinB1
Mre11–Rad50
anti–nonphospho-SRC
.Gilmore
phosphatidylinositol-3,4-biphosphate
3-6,8,17
.NOTE
RHOA18
cJun
S9-DLD-1
BD-fused
Vav-cre+
MPCEWS-FLI-1-T3
IVS20-14
UCH37-like
UV-containing
108-fold
ECL-Plus
Ins1
RUNX1-/-
TW-11
WWOX.5,6,36
DP3/6/9
kinase-binding
Q1924*
v3.46
36/85
14q.29
GAAAGACGAGAGACCAATACTTGATGTTGACTCAAAAAGGTGTTCGG
.DP-specific
36·7
Kai-Lin
2.5–5-fold
bromide-stained
Assay—The
downregulates
caspase-8—namely
nanomolar
Bindu
S7B–S7C
eXpress64
dnapars
G57R
5′-CTGCAAAGCCAGCCAAGACA-3′
Her2/Neu+
22–61
cellsusing
mechanism.The
Zürich
sonicate
WM1963
'BRAF
MP470
.STK33
supercoil
promyelocyte-enriched
Wee1
Eag1
Tyr87
.JJ012
M26
G774
Wnt-specific
JH-Cμintron
pCMV-Myc-Q63L
fast-flow
p68/RNA
Sce58
.Takeuchi
F4431
Iron–Sulfur
23-kDa
∼8–10
output166
KLE
test.72
SU-ECM
SMRACA4
0•43
rtf1Δ
190–350
greater-than-dose-proportional
anti-pS338
FLT3.25
P28–12,591
GTCTGAGTGACAAGGAATT3′
0.003
A767insAI
cancer.Lastly
normalappearing
18,26
frameshiftmutations
cancer.At
.D–F
analysesCytogenetic
B/M
65-67
148–155
receptor75
N1399T
Urbana-Champaign
.Inactivating
CBS9106
lineage−
Glu-659/Met-753
16329
.MEFs
PMSF
not.35
35C4
UBN-AB
.Mono-allelic
F858L
Imatinib–Abl
Mohni
.135T
t-ERK1
Plan-Apochromat
WGD29
SOCS1,29
Axin2/Cyclin
pSFB
P2X7
Smarcc2
Fig.22D
//www.iarc.fr
T877
H355Y
Y-axis
p.G10_A11insG
10879
dose-responses
FA-J/GFP–tagged
Donkey-antimouse
o0.001
10q23.3
randomise
proliferation.7,8
Tetracycline-induced
0.34067499
*75
derl2
Ba/F3-EGFR-WT
RPL5
Bannayan–Riley–Ruvalcaba
chymotrypsin-Na-p-tosyl-L-lysine
0.018*
Run6
∼1,600
Lys558
SCIG
0.4–3.3
L-1
WV-CD
KI4-positive
8960
M202V
Timed-Sequential
HPV-30
KB1PM5
determined.thumbnail
mutation.Ih
//www.ncbi.nlm.nih.gov/SCIENCE96/
Aldehyde
www.arrayanalysis.org
time-frame
p.P480L
.Table
trial—ie
hy
MB4-4
.Quaternary
AKTS473
IKK1
Laryngeal
Protocol-defined
cytoskeleton-associated
R1321S
R267P
5′-TAGTTGGTCTGTCTCCGCTTG-3′
Ad-p53
AAC50285
Y139D
AG013736
phospho–c-Kit
-depleted
4-chloromethyl-fluorescein
Mut117
RFP+
0.9216
YAP1-inactive
Leu861Gln.18
nature6
~46
2684
Deregulator
//chromium.liacs.nl/LOVD2/
6.4–15.6
160-amino-acid
large-deletion
3cm3
control.1,3
cyclin
BK-positive
Identi-
nonBRCA1/2
.Investigation
PA65
p.S1512I
I/σ
FPα
anti-cdk6iII
proteasome/caspase
4.38
Xian
.ACS5
5α-reductase
GAATATAACACTCAGTTTCAAGAAAATCGAGAATATGATAGATTATATG
FCS-supplemented
Sos2
Amesterdam
mTOR.11
D524N
C-*T
Raycroft
Mizukami
170-kDa
Fourel
MSFBN6B
Newman-Keuls
NOTCH1IC
line17
Pacold
coagulopathy
1-methyl-1H-pyrazol-4-yl
brm.46
activation15
group7,14
application76
.Referring
5′-GGCAGCTG-3′
disorders.1,3−5
S4N–O
23.12
14.77
2H-K
a-7
Bak
PLCL2
outcome.61However
2p16.3
R26-Pik3caH1047R
775–777
K120-acetylated
AFP
DNA20
4A-nR
Y647
PRC2-mediated
p27kip1
Figure55E
73/90
gencode.annotation_chrM.gtf
≈4.5-fold
5318
CCyR.11
primary±secondary
c.395G
9Department
event.6,64
Fig.8B
—gefitinib
R1097H
c.71G4A
312-325
CEP12-SG
ElOl
A.A.G.C.G.C.A.A.G.A.T.C.C.A.G.G.T.T.C.TG.C.A.G.C.A.G.C.A.G.G.C.A.G.A.T.G.A.T.G.C.A.G.A.G.G.A.G.C.G.A.G.C.T.G.A.G.C.G.C.CT.C.C.A.G.C.A.A.GA.A.G.T.T.G.A.G.G.G.A.G.A.A.A.G.G.C.G.G.G.C.C.C.G.G.A.A.AC.A.G
p61-BRAF
p=0.11
MAPKactivation
meta-iodobenzylguanidine
4p15.3–16
transferable
5-lm
vaso-formative
Amp-Taq
EGFR20R1
HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRR
Ren
JAK/TBK1/IKBKE
Pharmacists
.Unfilled
Non–small-cell
'PHOSPHORYLATION
17q25.3-specific
GS1101
Asp287
1438
ErbB3/HER3
yeast.21
0.230
Promoters—Based
ventriculoperitoneal
5-aza-
Smartcapture
IGFBP-5
wererecloned
A25S
2Cancer
ECD/HD
CNS-only
SGGLRQVPVKWTAPEALNYGRYSSESDVWSFGI
o_
Fukuyama
MCF10A.DCIS.com
TransFast
Table5
detectedintwo
100µM
65K
S922Y
p53IHC−
Krakstad
binding/releaseassays
.Jeanne
.protein
60-
Cerone
GENOME-WIDE
resource-intensive
3,910
guanine-rich
mediated-RAD51
PierceTM
16,94,95
0434
.RPs
Anti-AR
pRC-CMV
Deletional
HAPLOINSUFFICIENCY
ZNF521
Smad3/4-mediated
,31-33
3A-C,4A
A.d.M
4.6/1.4
L1237F-mutant
Ocn-Cre
MB13
159nM
PRK1/PKN1
Eld/Osa
26Please
TRANSCRIPTIONAL
Graphic1.5
progres-
NCI-H522
A.B.
aasland
23:5357-5364
NAIP
anti-ERK1/2
C02
cancer24,25,26,27,28
VDR-mediated
001421
Laeºnnec
NcoI/Xhol
HER2has
Cbl-c.8
NCT01953926
DNMT3B4
MLH1-NES
phenotype-high
15.4
proteoglycan
Melan-A+
-2266
TTG→TTC
Polva
Trp53tm1Brn–MMHCC
3513
.ETV6-SYK
151-159
pGBDU
Bub1b−/−
RG-21N
glioblastomas6
3Q2W
9,231
8p21-23
P316L
S2B–C
IFNB1
gain-of-function–related
YP029
312-320
HGGs3,6–16
Glu562
2-methoxy-4-nitrophenyl
ATPase-dependent
a-smooth
pCMV-IKBA
G127R
mutant.Figure
Ade2
kinase.10,11
FC-402-4001
C15orf55-004
MicroAmp®
12063-1-AP
36_61
3.4384949
855D
5/19
target.7–10
26–50
179-181
typeSK-Mel
S9C
pUHD15-1
end-replication
+39.0382.303673
PE-Cy7
h.Coimmunoprecipitation
Ser2-P
pedigrees,1
T=0.588/G=0.412
KRas/Src
NCT02465060
ÃŸ-catenincytoplasmic
.Hundreds
In-Frame
'core
E1144Q
Claiborn
reaction-restriction
.Plasmids
p.Leu597Val
N352S
anti-p63
HKY1025
0.353719653
T7
p65
10/175
Arg99
intensityof
Ionomycin
955,336
r2≥0.8
MANSC1.The
13q12.13-13q12.2
W101
HybProbe
NicΔ2105
fications
Kondoet
662
Regeneron
5′cap-dependent
1.2
colocalizes
GAAGGGCATGAGCTGCATGATGAGCTGCACGGT
=3.5
MAPK-induced
deletionsTable
G14OC
26–35,331
KMT2C
system23
PDGF-AB
B220+CD95+PNA+
B407
techniques6,10
Elk1
0-IIb
CCAAACTCTAAATTTTCTCTTGG
Kmt2c.165
properties.The
SQCC16
4,226
pT202/pY204
E1705
G–L
α-β
protein—LPT—in
W1782C
Snf5inv/−/Gata1-Cre
disease26
vesicoureteral
MYC
U12818
L932
repairTable
IRES-hmAG-L2
aac
syndrome10
STAT-3/5
Koenighofer
13928746
c.2646delGinsTTCT
IFNγRII
lymphoplastic
Ncadherin
supra-additivity
NBRE
wasfurther
PERP
A15
GCGGGTGCATTCAGGCCAAGG
3.1+
.Dates
proteolyzed
KO8
303
182–187
CATGACTTGCAGCTTCTCTTT-30
R1443G
Cdkn2c
DKK2
2006-5T
I845V
p=0.53
epithelium.66,67
coversliped
.CACNA1D
Hurchla
P328L
14-day
co-purified
GS-1101/Idelalisib
REFMAC542
376918
Fig.2D,2D
.Glutathione
Thr288
sh696
.Ile157
4.64
AML-M0
113.4115
Lipofectamin
Tyr705
10/H0704/65
2.213
8q21-24
NDc
Alkan
F667C
Ghr
miRs-17/20/93/106
lamellopodial
1809Leroy
Kuramochi
ß-globin
5′-CGTCATGAGCTCCCAGAGGAG-3′
2G–H
RC212583
T149A/T149A
members27
opto-RAF
α-TrkC14
Gulbinas
0.18–1.41
25.9
Biotechnology—SCBT
p≤0.039
alwaysenough
0.2–19.4
2456
antiCTLA4
Fritsche-Guenther
S6K/S6
p.A475V
Bergonié
27.8/100
6.5×6.1×5.7cm
cancers.7
dTAMRA
cdc25
shRIT1-1
TGFBR2-mutant
membrane-proximal
SK-CO
15.16
3-4:1
beta-catenin/TCF-4
E130
superhelix
MEKi
0.2–0.4
POU-specific
conformations.35,36
Mono7
18–48
C170W
pLXSN-Flag
S3.Table
CIP1
FOXO
CGGGATCCACCATGGAGCTGCTGTGCTGTGAGG
monoubiquitinated
drug–resistance
defined2
Antibody-blocking
Cleaved-caspase
saitama-med.ac.jp
D8351
TOP1-co-IPed
Phospho-
Podsypanina
CDK12-depleted
10,36
50/64.1
756-aa
models.Patient-derived
T193A
Sangersequencing
135-fold
5times106
recombinatorial
52,56,57
Perez-Soler
1684–91
ATLL
.XPD-causing
CSAN
nitrophenyl
pRC3…
IKAROS.29
BioWorks
p.R273
HER‐2‐targeted
75K
Time-points
DNA-bending
1259
conditions.47
presaged
insensiuve
stress.5
imatinib,25
1877A
immunoprecipitationwith
translation24
E746
mM,23.8723.7
.D-type
493-495
D1–Rb
DMKN
andand6B
RFS-mycWT/WAP-Cre
NM_021140.2
Martignetti
melanoma.7–9
elsewhere.1
.EMILIN2
Rc/FGFR3-KMS11
strand.38,39
T315M
Nar
TRK-T3amino
9282
G375C
CG-3
Dildrop
3-CAT
536A4G
Quincke
H1204P
S45del
R2973C
E353Q/F461I/A569T
C,3D
skin-related
SUPM2-derived
interspaced
10ZFΔPR
CO-86
CBA
Tsc2+/-
CR2C-CR3
3624/91
3c-e
.ResultsDetection
D173G
c.792_794del
Quentmeier
V773
.nih.gov/bic/
Mll2/Wbp7
Cul1/Skp1-containing
13-1
assaysA
14q13.3
Diamond-Blackfan
5573
SCCRDEB2-4
GRch37
staining.13
3835
P314L
iodide-stained
phaeochromocytoma
135:1269–1277
510-bp
.FJP
homology-extended
562–579
Freebayes
−59.6
REX
M3263.37
NENT300
receptorD1–D3
LSAB+
summation
FA-like
RNA.33
Lys-117
39,000
TG-3'5
.SEs
66–74
bidirectionally
.1-5
semi-orthopnoea
1,024
Watzinger
leiomyomatosis
AccI
kinases.35,40
D32Y
supraphysiologic
4.36
Sip1
CGTGCGGCCGCCAAGTTTGGCCTGAGCTAG-
r2=0.219
S729A
Fgf17
TERT-H
c.176811G4A
pairs.2
21:456–462.Briefly
Hoechst33258
pFC2-dbd
RHEB155–159
pCRAFS338
DlSl58
AGGTCTTTGCGGATGTCCACGT
Sav1
S218D/S222D
trials.6,7,19
MM1.144
1–30
.Pinol
BCR–BTL
.point
dimethyl-containing
atg-3′
C/Smm
Rasrelated
EcoRI/XmaI
PCR-free
delI843
DDR2*
.p38
phospholipase
T172V
siNF1
INF-γ
Anti-p70S6K
RD841-842
18-246
75th
K-C.H
IGF1-R8
Dihedral
10179
A1623G
Hemorrhagef
W34
2.536
hM
SANT-1-like
23°C
16E7
Pharmacologic
Sheldrick
sites,173
Val-45
p50RhoGAP
shiftson
hTert-immortalized
30–69
.MetaMorph
INSC18
.E14.1
L237M
ned
304,988
Medarex
DYRK1A
Spiegel
min-intron-length
lungs.4
L-Glutamine
transcriptional-repression
NBL12
HSV-tk-promoter
163-C
transspecies
l3
6p12.3
C\
PA3
B.P.8
p-AKT1
itg/ml
y-intercepts
sulfur-35-labelled
activity2–5
A445T
KIF11
Tetratricopeptide
family.Figure
S1841A
Figure7D7D
SL25
Cdc25
immunohistochemicalanalysis
tomography-computed
1AQ1
blastn
system22
detected47
659–919
Tyr764
obfuscatory
clinical/translational
0.235
4T1
CARD-containing
CLL3
WEF
coprecipitating
Erb
XNP73
237–269
Midi-Kits
c.26A4C
pCY4B-HA
003600
PHAS
'mutant
P367R
state-specific
Schichman
GSE55832
Alternat
EEN-binding
479.3
single-bandpass
E2-mediated
encopass
GeneCards
.Autoinhibition
Rieker
Redarrows
Angiotensin-II-induced
193-351
YopH
12/37
GAAGAA
.Trr
CEPBA,12
Leu/Leu
CD21
Xiong
L99P
mTORi
{
Pickeral
.Exogenous
E548fsdelTG
0.021WTHSF
TCF7l2
ﬁrst
cancer.6–8
Mirosevich
anti-phospho-Ser18
c-AMP
D559
BioSupport
LIM2550
HBCx-17
lipofectamine
formation‡
3-D
EIAEDs
gal4-542
p53-53BP1
ColEl
element-binding
III:21
cy-
MiG-empty-transduced
SKN
HNSCC
Sacchromyces
pneumoniae
.2500
ACC-LC-319
FigFig2D2D
NRAS3
g001Cell
.Shi
DNA-Sequence
q=0.019
.NF-κB
gene,9
prognosis.3,7
104/well
Vκ5
Triton-X-100
Rauscher
10–25
JMML26
AR/antagonist
A447V
urothelial
phospho-PKB308
samples.21,30
.Dellagi
1303
causes131
Adhesion
Po0.001
THR202/TYR204
BARD1-binding
Hoechst-stained
Proportional-Hazards
6/203
retaspimycin
L1198P
carcinoma3
6/5
surface/intracellular
Univariate
haipin
pomoting
Virmani
–0.81
99.97
HAC1532
S363
E116K
Immunohistochemisty
.Real-Time
heterozygous-knockout
cancers.1-6
c.14G
E81D
number.
POSTN
WT1-responsive
subtype.Increased
Lkb1/Stk11
MEFS
Sugasawa
CDKN1A
signaling-related
TBSTween
87-89
2-mo-old
r2=0.18
PowerScript
9391
Trinchieri
3Download
.TbR-I
MPLW515L-induced
Alexandraki
+TEV
diversification.13
Mab-HPR
SJNB1
NRTK1
mGFP-H-rasG12V-D47A
1,396
CGH.17
www.expasy.ch
PhosphoScan
BBE
Optimem
RP11-222M10
LD20
JB12454
respectively.Small-molecule
4/256
946,000
nonparotid
HER2and
anisotropy
2–78
Human610
//www.cancercell.org/cgi/content/full/6/4/347/DC1/
.IFN-
knownhot
pixels2
BRCA1,14
IMEM/10
E387K
OPTI-MEM
-modifying
.Establishing
atel
c.310G
Variation_41128
transgenesis
Erk
phenol-chloroform
p59xDR-GFP-targeting
5'-cacgagatcctctctctaaaatcactgagcaggag-3
Terabe
Shlomchik
LPS-stimulated
.Daiichi
52.6
inhibition48
piRNA
IMGENEX
BKM-120
1,436
HCC1599
Stu
NF1,17
high-salt
Karbowniczek
RKIP_E3_F
theexcised
R882
AGAAACCTCCAACCCAAGGT
Fig.3D3D
ANNOVAR33
anti-HLAIFN-y|
c.117-34A
ERG-TLS
bjh
relevantmutations
4.22-12.79
p.L590R
V769L
T6F2
6×104
47–800
Inferring
Y1714
CRIPSR-edited
IFANIT
5′-GGCAGCGCATGCGGTTCAGCATCAGCTCTG-3′
Rat2
reduplication
Anti-CRAF
lys2A202
MCT-supplemented
p53.Among
.KE-0254/86/2013
leukemia1
TAGAGCATGACCCATGAG
repairdeficient
979–996
first-relapse
Pihan
THY1/CD90
Electrostatics
0.0010c
S139–S190
protocol.26
GATGTCCGTCAGAACCCATG
subjects-those
0.52*
PTENY65C
Lys-244
NEFH
9.14E05
Ad5-‚-gal
Ab71690
Pentagastrin
1.092
Figure66
al.49
megakaryocytic
0.164
WW12∶S7PY
reinitiating
Homogenates
Pieper
T→G
pcDNA3.1-PIK3CA
837+1G
.Lipogenesis
TheraScreen
adaptor-scaffold
MK-2206-treated
MPLW515L-mediated
c.1731+4AG
signalling45
RPPAs
Ank1
FGFR1-rearranged
2271
.Crizotinib
p.Gln660His
Wap-rtTA-Cre
42.31
SNF2β
Muto
.Switch
1.4-Mb
F48
F167I
BMPR1B
Brinkhuizen
Lin–Sca1
11,47
NA-26
CREST30
10p25.2
exome-sequencing
AB081314
2/29
RASG12V
Montminy
121°C
delE747
ALK/human
C459S
BCR–FGFR1
hemizygously
pG5luc
hMSS
pEGFPC1-PTEN-N
anti-IgM
Gly-
ethanol-treated
HIV‑1
v-yes
10557-10561
FLT3-WT/CBL
KTS5
.Objectives
proteins.To
byWeinberg
3but
E13
SF3B1mutations
anap65-4
endophenotype
Oct4−
BrdUComet
tracheoesphageal
rs1800629
AGTCCCTTCCCAAGGTTAAGGC
Dry-Down
Pod-Cre
HMLER
9.35
//www.somaticmutations-egfr.info
MxA
HIF-1a
important20
localizationc
Paz-Ares
Chk2ex10r
BAK1
Y1056F
3144
corepressors-1
pRetroSuper-shmNOXA-Blast
A230T
HIF2α…
5′-CAGTTGATCTGTGGGCCTGTTGGTGAAGG-3′
nt2386A
X‑gal
.Marcotte
length-encoded
RPMI‐1640
burn-in
ZNF198-FGFR1.19
pericentrin-specific
mented
MIF
Ser→Leu
HNF1A
schedule42
G-+T
denotationvaries
non-ATP-competitive
L910P-containing
.PU.1
PyMOL26
wtRhoA
over-predicted
pCRII-Topo
second-zinc
activity.40
33The
Schlabach
non-mutator
acetyl-CoA38
AALL0232
pPGKhygro-Cre
1271
'FY-rich
2015CANCER
Hammadi
NM_001025577
Fobs–Fcalc
C326R
common-insertion-site
.Faster
B2-fold
CKSAKDR
R434
R324L
CCAGC
TP53–/–Tsc2+/+
KGN
EJXM
Hof
R225Q
wtEGFR.32
ResearchLaboratories
Overexpressionand
nihms703640f14.jpg
4684G
kinase/phosphatase
Immnohistochemical
Tyr-1068
CGGGGCCGGA
Mel1617-MR
7/59
223
PPP2R1B
Immunoscintigraphy
unit–E
Y71
Raf1-RBD-agarose
‑264/‑40
.Nakao
+114.04292
.FGF10
NS511
RearrangementsThese
Y570FF
pBR322
333345
CpG24
2392
raft-associated
programmes92
proteasome.4
R280K-expressing
CTGACCCCGC
SRC-3-independent
195G20
Tables33
V658A
sc179
the×axis
Sotillo
immunostaining-positive
858R
LBD-mutation
3'-phosphoadenosine-5'-phosphosulfate
D⇓
D606E
R249S-positive
HCC170
ABED
AluSq
re-acquiring
SND1–BRAF–dependent
CHIP-ΔU-myc
ROBETTA
−1.26
gene.6
anti-pSer-127
v-Ha-Ras
filtrate
cbt-15-428-g1
S.J.S
12-71
-VDCFDSYKRVDIWAFGL
SKW6.4
-Increased
main/side
re-tested
MycS62A
.Progression-free
M/23
3423
pCD1-Luc
A126T
cancer.5,21
HoxA9/Meis1a–Transformed
doi:10.1007/s12672-013-0147-9
Sahm
FoxA1
ØX174
-300-500
M1/M2
C74Y
ɛ=34
q=0.764
simulat-
c.170C
30.Ovarian
5′-AAUACGGGUA-3′
published.19
Ger-
nonimmunological
nevocyte
proteolyzing
MABI-0333
immunohistochemistry
Casaccia-Bonnefil
32/73
R-spondin1
Multi-centre
b2
4G0N
V5-CARD11
NQ
KU55933
A349V
detec
trials.29,30
c-ROS-positive
5′-TGAGCAGAGTGACTATTACTCGAGCTCAAGCTTTTTTTTTTTT-3′
meanplusminuss.d
allele14
pGEX-2T-C-Raf-RBD
-ETV1
T450D
50.34
pLenti-CMV/TO-TrkA-Puro
co-occurrences
c.3881-3882delGA
Met-552
prognosis.32
1−502549
0.39-14.3
CSE
ABL,25
p.Leu1616LysfsX2
antigen-PTP
self-aggregation
pBS185
.Mgat4a
thethird
RT-qPCR—Cells
Institute/MIT
pRB1
VANGL1
0.6374
.Self‐tolerance
tetramerizationdomain
6599
p16INK4A+/+/p19ARF-/-
alone.23
LR06-342
mutation.7
p.Gly537Trp
ubiquitinspecific
F81
CGG
ice-chilled
miR-130b-mediated
4984
pSer-X-X-Phe
Icking
pET22b
AITL-related
CUO13
cryosectioned
Biozol
20.2/2.7
4,11
Bright-®eld
cytoautomation
erlotinib-induced
'knock-in
N454T
c.1633G
D579
PRMT2
n=77
tumor-selective
NTRK1-outlier
5′-CTGGTAGGGTACCTCGCA-3′
27.9
SD=±2.0
acrylamide-bis
demonstratethat
BRCA1-S971A
damage1–4
L536
Cdkn2a
canavanine
109.00KB
R249S**
blc-2
T^CGA
hypercholesterolemia
2-week
c.4986+1G
TAP-tagged
Thr2484
Nf1-1-
S217–S221
M1-132
strand–like
Achondroplasia
ΔNLS1
NM_001080780
UBI
p16INK4A/p14ARF/p15INK4B
32/46
-1α
.139C
tcga
ÃŸ-catenin-Tcf-regulated
bridge/hydrogen
factors138
5-ACAGCCGAAGAAGGCCAGTTGT-3
hemosiderin
ALK-containing
11·0
R182
PH-domain
Driman
GCATTCTAGA­GATGAGCACGC­AGTCACTGC
ApoAlert
plasmablasts
6952
cytomegalovirus-driven
IFNy.Gamma
≤4copies
MOZ-EP300
1–743
Kansikas
Cys342Ser
Study3
survival.1
anti-phospho-p70RSK
RP11-568A2
0.9c
​This
NRG2β
IgH/c-MYC
2'93..1
near-physiological
A451
1464
R81C
all-at-once
PTENa
5hmC9
α-nuclear
apoptosis/necrosis
25.7
p.I798I
2523
G9054
moot
Stromblad
NM_008716
G34A
imatinib-nontreated
methylation/de-methylations
.Despite
100/104
Golgi-localized
2MPM
RU-58668
.Color
cancers.70,71
Rad51-like
clinico-pathologic
33430313
58-GAAGCCAACGGAGAACTCAAGGTC-38
SCD
PEBP2
9860
.Stat3
B-positive
proclivity
metastasis.57,58
Inpp4B-deficient
TTAGGATGAGCCTCTCCTAGACTT
10q24.149
RAC-dependent
carcinomas23
.Osteoporosis
C57BL6/J-CMV-Cre
tridecamers
FL5
0.413
N=27
SCX
dispel
gliomatosis
five-subunit
5′-GGCCCTAACAACAAATGAGG-3′
6-meA
RET-M918T
BD-hMLH1
pT3N0M1
300000
TCGA-derived
2.603
pRCC15,16
described,28
stainer18
pNKY19
far—were
B_R628
//swissmodel.expasy
lq22qâ
45520–45880
HLA-Bw4
misregulated
R181
emergence.14
half-EREsites
1–437
mycoalert
mutationsdid
HSC536N/neo
ITGB2
5.15×104
Figure1D1D
Log2-transformed
65.8
fifty-fifth
Constructsa
Gly→Val
HgB
landmark-based
siPTEN-treated
40–45
66.4
Cancer19
TGAGTCA
NANOG
pb2m13
diseases.36
4•8-kb
mut.
Cyclins/CDKs
roflumilast
12Å
neurofibromas27
Matros
reverse-50
105–106
/CT
172A
Reactome53,54
Gal4-binding
left-side
His-HS1
5′-TC
36-bp
9661
OncogenicWe
ERBB3E928G
ELK3
PIK-E20R
aminothiol
HIV-LTR–caspase-8–IRES–GFP
.V8
q11.1
Pre-mRNA
MA9+shTet1-a
α.
g_rmsf
GSE76001
caggtatctaccatggaggtTCAAGAGacctccatggtagatacctgTTTTTTGGGCC-3′
Omphalotus
GCTGAATTCTCAATGGTGATGGTGATG-3′
Largaespada
acid-starved
YYY
G744V
-16
30h
K-RAS
Greipp
0.0917
AGCTAGTAGAGCtctCTTGCCCGGGCTTGTCgGCGTGCTGCAGC
thoracopulmonary
Immobilon
conversion.17
patients127
SNU484
Gsk-3beta
R8131I
ab128006
Ala-530
D781G
TOP1-KD
10−15
SER235/236
TGF-b-inducible
.Ishikiriyama
SalI-Bglll
cdd470f8
PMA2
conjuncture
Toray
E130K
3q12.3
.coli
Pdgfrα
Isaacson
p.Ala636Pro
reversion
C.C.S
ineff
activity46
KE
​andBB
2/9
sc-9996
data.23
WHIM26
Asp81
5′-GCT
cells.31
KRAS/TP53
Ulf
HDAC
q=0.01
GAL4-TFAP2C
1,344
zolendonric
zebrafish
.0041
0.863
collagen-mediated
POG
Tyramide-488
R-enantiomers
Responsiveness
.MLL–MLLT1
p300-selective
immunoassays
cells,16,17
non-mast
translationproceeds
Winlab™
29–63
hydroxylation/pVHL-binding
HRD-motif
NOTCH2-rearranged
μB
UGGA
growth-factor-receptor-bound
γ-chain
n=15/15
98.3∗
late-apoptotic
Yutzey
B538/300
extracolonic
22,430
myristoylated-AKT1
mutations14
Y568–Y570
Titf-1/Nkx2.1
5′-ACGTTGAGAGAACGAGGAGGA-3′
4JT5
BMP/BMP
.V777L
IDH1/IDH2
1.77–7.44
mechanisms.Bim
phospho-Tyr-419
CXCL13
Ser891
KE-37
PC-700
15of
-363
Akhtar-Zaidi
G58D
hypointense
HSD17B7
.Three-micrometer
R342Q
5′-TGCCAACCCGGAATTTTTCTCCC-3′
0.5152
'positive
c-met-related
R42Q
18R
survival.7
KMS-12-BM
VTGPNMCS
.Class3
158–171
infiltration-negative
GST-FZR1
INS559Q
3′-ABL
NuMA-RARα
5360
top3Δ
.Discrepancies
Mut10–expressing
Cole-
PtdIns4P
FastQC
1.526
T1010I/R988C
Arg479
homodimerise
I-TASSER
chemo-sensitive
NCT00436579
7/deletion
TP-F2-expressing
5695
frequent12,13
glutathione-coated
YAEHRGRARDEAEMEYLK-C
Multiplexion
ST-HSC
pspMycC
c.901G
-shUCP
Age-specific
mutation+/HER2¡
D792E
30mM
Midpoint
Baculoviral
PAA-
Myc-immortalized
involvingthree
GAP-334
chTCF
ALOX15B
cALCL
D-2-HGDH
L858R/E709G
latency.11-13
E697
vation
+mar2
Y537A
C19220
T312Q
Phospho-S780
SNU-494
v.4.7
anti-pSmad2
small-molecule-based
554-558EVQWK
5A-R1
E-7050
39/68
ESEFinder
FGFR3/FGFR4
GAPc
uAspCI
R167W
anti‐inflammatory
SCC-4
ΔEx14
Keap1ΔBTB-V5
H83
±3
5′-GCAATGTTGCCAGTGTCTG-3′
.monoclonal
219,263,276,458
DiRenzo
264±123
94.5
B*53:01:01
third-
.MEF2C-Activating
Brca2lex1
GFPi-mRFP
miR-125b
betaE'–loop
Lys-120
1872
E40T
functions.1,2,8,9,11⇓-13
C433R
TAZ-driven
0.814–0.928
insucient
xenografted
nucleotideoccupancy
FGFR1−/FGFR2+
Vallon-Christersson
32.6
FAS–FAS
ELGSDSSEDTVNKATYCSVGDQELLQITPQGTRDEISLDSAKKAACEFSETDVTNTEHHQ
abscisic
24/81
.Kinase-defective
RET634Arg
5′-GCCTTCAGGTAGTGGTCCAG-3′
1144–64
17.8
proto-oncogene.2,3
107:345–51
cytokines1
mTORC
L858R+Q787R
NUT/cytokeratin
R432T
AGO2
phospho-TPR-MET
sensitive-to-hormone
TG5A
26–119
pre-edge
vitro.29-31
BALB/cJHanHsd-SCID
1.2–6.1
re-shape
MyD88-containing
.Curtin
domain.10
BFL-1
complex,60,61
HRAS-primed
ADAM9
Dandy–Walker
12We
dithiothreitol-2
Bertwistle
IPI-high
25,000
Samples.
2594delC
PDGFRB-expressing
–9.1
score35
6·0
ileocolonscopy
study-drug
inositide
MutS-mismatch
.Physicochemical
spreading.24
wt./vol
Homotrimerization
uence
mRNA-encoded
necessary36
GCB-DLBCL
Hideshima
hPHF1
activation.13
TRADD.163
UCAAAGACAGCGACAAGAUCCCUUU
Skowyra
Molscript
.Transformants
p.Glu726Lys
BRS
CEBPA-mutated
Group†
263
MBP-pRb
.Twenty-seven
.Lübbert
.V-gaacgcgtattaaatatagttg-3
Fabp
v-ra/20•
Φ-π-S-S
RhoA-specific
anti-6-catenin
Cdkn2d
non-phoshorylatable
exon-level
Q7X
N-PAC
analysisSeven
GGTTT
24/82
Nox4-specific
107X
.Sahai
∼94
1.05×106
2374–2376
postcoitus
UMD-BRCA1
BrdUrd-FITC
C17
P=0.103
protieins
Assay—Ref1
p15INK4b/MTS2
imatinib.30
Tyr652
with/modulate
relapse.123
T-ETV1
APC/β-catenin/TCF
SI00604905
'never
D3S1614
Skyscan
2172G
MutSα-
cofactor15
mice4
biology-driven
Tan2,10,11
systems17
RETS891A-induced
93917777914135831214435610776756921599275Age/Sex25/M29/M69/M63/M48/M48/M74/M37/M26/M54/M23/FSource*
4674
172.4–191.3
mL/106
byNCCN
Q1119R
1392
retMEN2A-
15848
2G
Q787R-transfectants
pyrido-pyrimidine
hemithorax
multiacinar
Reconstitution
D547
shMyc-2
CA17
rs10258429
P7a/8
repair44
ERE
EMBL/GenBank/DDBJ
Metl-
I871T
GenePixTM
IGR-1Rβ
Arg340
1479
HNF4α-low
.future
NS527
Rad50sc
ade2-101
A309T
.Intrathecal
no/low
S89F
CTCGACCACATTGCTCATTC
E-GISTs
BRAFV600E+K601del
0.0045
coregulatory
5-fluoroorotic
ECF
A119T
S4D
l3SUcl/CKS
OX40L-induced
R882H-mediated
Pak
anthracycline/taxane-containing
IR/IGF1R
AY204740
Histopaque
relapsed/refractory
nonkinase-dependent
Figure7F
.95
other,31,32
PEAK1-depleted
Chaperonin-Mediated
24/115
p.Ala161Thr
a-GAL4
0.2±0.4
1850
E17K+E49K
endocytosis/lysosomal
activities/specificities
Intramolecular
–18
197:157–168
FoaSin
HCC78CR
ESRP1-BRAF
≈624
which-ΔΔCt
VYIDPTQL
study.14–16
RNasy
TopoIIα
BRCA1*A1708E
F-68
390–403
Aligned.sam
CysfsX2
wu20/wu8
Tranfection
abbrevation
Non-IG
2574C
Percoll-isolated
Softgenetics
Hurlin
cancers.31
J017
NF1-inactivation
60,000
webtools
Antibody/protein
p=3.74E-15
1,383
program19
Gly129
KNS42
heterologously
PLCgamma1
atoms.32
cysteine
15q15.3
HDCG
1:29000
1.73–1.70
116–141
Rap/glutathione
ETV1-1b1
HA-wild-type
surgery.3,6,9,19–22
Cre-Mediated
adenomas
p21-null
sites.23
consequential
.Genome-wide
epitope‐tagged
epileptogenic
c-Mpl-GFP
y~3m
*To
codeletion
0.002545476
PEG5000
EGFR-independent
Nacalai
S214A
Hh-driven
8.62
lumpectomy
carcinomas.7,8
2252del
19/37
Fifty-nucleotide-long
.Bars
methyltrasferase
GRP75
2265
helical-domain
T204fs
AQ
GGCAGGAGGGGCTGGCTG-3
X/
.TFAP2C
overexpression/amplification
10.1007/s12033-012-9584-x
1452-bp
MNES
R228W
,w.
.Q787R+L858R
alpha-satellite
p.Ser677Thr
30µl
CDKN2afl
28–80
UoC-M1/FF
microgyri
//samtools.sourceforge.net/
GTGAATTGCAGTCCTTCC
1182
293T/17
subunit-binding
//www.mycancergenome.org/content/disease/lung-cancer/egfr/4/
1,990
F12K
S4D-S4F
2239–2248
Cdc5p
PI3KTang
5'-AGTTCCACTCTTAGAGGTAG-3
31insGGA
CO2.RNA
GISTICv2
fastq_1.fq.gz
C01204
FANCG-stabilizing
T4a
mTORC1-specific
.data
Src1
Chaperone-assisted
PDBid:5ezv
aHeparin
thepBabePuro
_n_=3
.Nonreducing
iSH2–C2
6.0
SCH
Byelo-Russian
anti-HCF1
7176
0.0944
4.74
4,424
described.26
14,030
cancerization
IDH1-TP53
Sernbo
abnormality.2
I653T
Viale
Bcl-XLexpression
CGGCATCCACTCGTTCAG
Scardocci
fatherb
signatures.48
total-p44
methodologically
978
Biopharmaceutical
HPV52
Bmax=1.2
Normexp-by-control
D89b-catenin
PP6-H114Y
EZH2–ER
IL-3-driven
7.97
PLCG
−1.43
BMG
year-maintenance
domain-directed
Valérie
.Second
culturesa
-dimethyl
neurometabolic
447-bp
formed/number
V464P/T465A/L466A
preimmune
NPM1+/-
.Misexpression
​Figure2
2-negative
tary
Post-SET
TGF-β-SMAD3-induced
RTK-based
/highwire/markup/42236/expansion
16.2–302
catalysing
Alday
3384
V177G
2A.Distribution
immunohistochemistry-based
z633/10×
KITV558D/+
GHRH
004064
R295P
GST-p85a
3.5–3.7
activatable
MetaFluor
Prinster
c.814C4T
14-amino-acid
17250
stadiation
carcinogencsis
FAM123B/WTX
718-964
Loeb,1991
traversal
T125A
P-T
3761del19280
.Neomycin-resistant
growth-permissive
PIK3CA-knockdown
.KANK1-PDGFRβ
ENtransformed
n=5IWT
lymphomas18
Mdr1a/b
TGAGATTCAGGGCACGATG
7D4
EWS2009
strain‐dependent
GU208210
Branch-Point
32D/Flt3-ITD1
MAXR60Q
0879
,3the
15Department
22q12.3
LAMP2-positive
NCT01553851
ErbB-containing
96-well-format
FOXL2-induced
AnalysisComparisons
SR1
v.1.3.1
R-spondin
0.29–1.58
O-l
single-patient
800,000
Ph-
pMyc-FAST
12499-12501
MY23
ccRCC/normal
www.atcc.org
disease.17
32P-dCTP
37Â°Cin
ERÂ
100μg
G353V
leukaemogenic
flavonolignans
.2‡
ACAGCTACTCCTCGCCTGTG
inhibitors.6
20Â°C.The
dephosphorylation.ResultsIn
HEK-transfected
6mum
Apc1Q8
FLII-EWS
p.Leu12His
CD184
0.159
.Dissociation
33428338
ectocervical
R775C
RHO-like
rasH2
.CycD–Cdk4
Gibault
.Hedgehog
3,5-difluorophenacetyl
alleles-based
-17A
390255033341
17/2.8
erythemadotes
mutationcontaining
Meningioma
458–523
.Caspase-8/dominant-negative
saturate
2609
post‐hoc
miceR1
27,820
f/46
AAH61947
.Prevention
reisolated
Annexin-V
allp
Mitoferrin-1
//www.r-project.org/
subject-derived
.Golubovskaya
34·7
age.71,72
Immobilon‐P
†2
1.076
SIFT12
Huusko
Z9001
Glu-184
MLH1-p.R659Q
EMDB
s.pfister
analysis16
Schlaeger
Rho=0.64
Mutant–EGFP
ItEFNeNGaLDaFLR-eREd
rateswere
MEK1/2+PIK3CA
ALKF1174L/G1123S
-CAGAGCAGCTGCCAGACATGAG-3
GenePharma
verifi
procedures58
attended.19
p21−/−
99.970
K-nearest
studies.6,11,24,26,47,73⇓⇓⇓–77
assays.Human
GPLGL
intra-epithelial
trk5-transformed
.PARADIGM
Gram-negative
normali/ed
CCACAAGCACCAAGAGT-3
KBF2
Carp
34.3-
CAIRO2
NIH3T3-EN
.Constantinescu
PIK3C2B
IFN-γRα
Dnmt3af/+
Anti-MEK
treatment-outcomes
de-novo
K63
2-10
5′Fam-CTG
BRCA1.23,24
HNF1β
F132L
Bard1-
thatwould
p.R487P
PLX4032-triggered
NRASQ61K-mutant
immuno-blotting
Glu-712
p=0.0443
DYNLL1
160kDa
17–19,31
cavity-creating
FGFR3iiib
FAM-CCCTTGGAAGATCTGACCCGAATC-TAMRA
replication-linked
A418T
AVMs/AVFs
summarizations
13/22
Lys256
glomerular
G/C
acid–leucine–arginine
SNRPN
mMdodecyl
Tichelaar
GGCAGTACCAGTGCCAGCAATA
p=0.19
CCTGGGTTGTTGACTTTGCT
29/99
'ERG_Ex6-nest
ahelix
dl2.5
5-iodoacetomidofluorescein
diisopropyl
ETV6-FLT3.2,47,48
11.56
iQ
S4A–S4C
actin-specific
T1462
Δ=−0.049
CRKL-SH3
ERK1/2S219P/S202P
ChargeSwitch
patient-carriers
Charmm22
AKT-MAPK
T877A
patients.ConclusionsEGFR
.SCneo
neurobehavioral
Tyr537Ser
apo-murine
mutants.How
'Bone
Larva
antigen-receptor
structures.36,40
H3K36me1/me2/
inE
all-atom
GAPDHS
Phase-lock
Cre-deletion
2â€
pRK26
MGC:102519
Kl
D473R
5'-GATAGCACCTTCAGCACTCTG-3
information10
dimerization30
ArthritisResearch
0.2797
NGSx
CD40L-IL4-TGFβ
d*Trek
Forsomatic
HLAA2
examined.72
Flag-Avi-Tagged
.FUNCTIONAL
H662Q-2
PRK2
black-walled
0/89
.Haploid
1/88
assembly/disassembly
GLYNIAS
117599
anti-CD41a
chromatins
:660–672
CTTTGT/gtnagt.lt
IQGAP2–TSLP
SUDHL-4
alpha-smooth
energy-efficient
PML-RARalpha
P=0.54
Ginestier
.X-tile
miR-130b/ZEB1
tissues18-20
PRR19
Lefesvre
anti-ARID1A
glucose-
fi=niNi
D150nt
S752
dysfunctionally
cross-cancer
98.59
-box
756−1,130
2140
leukemia,31
351007
-ACCAGCCCTGTCGTCTCTCCG-3
Ba/F3-TRKA
Cdx2+
flMx1
cells.20,21,23
Integrin-linked
.1,000
5׳
Invitrogen/Zymed
pre-plasmablastic
insertion-mutated
20.46
74106
Copine
Mitsutake
NeoplasmsThe
Fbw7/CKI
OFC
0.26
nexin
ER/Golgi-restricted
175
I.D.N.
human/
5′-upstream
ylmethoxy
SEG/Pas
184T→A
L52F
membrane-integral
per-ARNT-Sim
T790M-driven
PDGFR-alphaDelta8,9
1,065
descrit
Champeme
A_51_P355906
anti-Fas
slideThree-dimensional
trans-gene
doxorubicin-dependent
E62
DO-0
site.23
.Part
8332
demathylases
Fig1C–F
cm.33
ubiquitin−conjugated
anhydrous
1.5–83.1
1a–h
MC-26
F–L
530–634
evolutionally
ESR1-mutant
the-art
Lys27Met
Interactiona
G685A
TAC-*TGC
AT5
neural-crest-derived
RAS–RAF–MAPK
1437
≥2/120
Pleckstrin
interdimer
ABI377
outcome15
DMBP
nonsmoker40
TTTGCCCAGTGTGGCTTT
Megakarocytes
SKM
Cre1-derived
Del-5-myc
selection/screening
cells6,7,12,17
SPRET/Ei
hepatotoxic
2/132
4–deletion
GenAmp
2.263
NMR-observable
bt..
investi-gation
hypotrichosis–lymphedema–telangiectasia
Curto
permutations=1,000
R2/V392R
.helicase
.BRAF-CRY2
35p107-associated
M654I
p44/p42
CTLAGlyAla17
hormone-binding
Rosa26LSL-tdTomato
790G
RAD001/everolimus
μmol/L*/
Bolino
PY1
BC000329
ΔDGR
p15-D86N
Citron/CRIK
95051
anti-hamartin
low/no-expression
5'-AATGCCCAT
Landover
indiscriminately
–interacting
p.Lys873AsnfsX8
Ninitial
sub-group
.G346E
SoftBerry
preprogrammed
factor-β
D842V-PDGFRA
0002-9297/98/6306-0010
p13q13
singlet
Lys509
NB0399
D01
Elloumi
Q60
drcherrybansal
immune-modulating
CD28-dependent
E8413K
transactivationof
2.08.01
tyrosine-specific
~730
Mig
S222D+S226D/ΔD
TP5321,22
DERKE335K
Delta557
G1809K
V600_K601delinsE
METi-treated
G-rich
diferuloylmethane
LinesMEK
ALLPG
Carney-Stratakis
appendedby
ttc
irr
Over-activated
Tyr-CreERT2BrafV600EPtenL/+Ezh2Y641F/+
I1234V
genes.6
JAK1-V658F-expressing
prewashing
pcDNA3-Flag-ZBP-89
17-0081-81
Depletion/inhibition
classifications13
W173G
CCCAGCAGCCCCAGGGTGA
6/1,708
alleles.9–12
Reversible
78*
Asynchronously
.Lacking
mucosa
5'-CGTGCTTGCCCCCTGAGTCC-3
FDR-q
c.1799T
VHL-Elongin
S-p16
H2Ak119ub
Lindor
K341A
dataClinical
3,277
1–389
IuProAlaAIaAsnGIuThrVYlArgHIsGI
γ-2A
PTEN-R335X
04–136
17/36
TRCN0000002133
shARb
p27-null
SF3B1.3
cancer-mutant
arthntis
NF-κB–derived
Viewer19
lines10
cell-counting
respectively.untreated
EB2
nonpilocytic
p16/CDKN2Adeletions
BRCA1/PALB2
p53R172HΔG
5081
E–
FA-35ik
ERE-CAT
NCI-H460
65:7628–7634
835–839
APL.36,37
0.82
SUMO-TopoIIα
LRcHL/II
Bx
p.Gly14Val
EGFR/MAPK/Erk
5149del4
GOGA
.Soultanas
5178
TF556PS
1∶200
310K
612136
0.064-0.096
5¶-GAGTGAGTTGTGATTGTACC-3¶
p54nrb
NPR3
ALKinALK-positive
stress-activated
Crouzonodermoskeletal
trostatic
SC-7
leukaemias7
i–ii
rs35460768
/NP2A1
BACH-179L7
WAVE®
map-based
Low-density
1447-4574
5′-CGCCATG-CCGGGAGAACTCT-3′
ApoVLDLII-CAT
mIL-3
mutation42
CD71+/Ter119−
al.,2010
06-6390
C133Y
miR-27
G410
C228
structure–function
Figure3.3
.Picard
within-set
VDCFDSYKRVDIWAFGL
PuPuPuCWWGPyPyPy
CDC+
:59–73
CEP85L-201
SPROUTY
Chiarle
Osaka-Sayama
Peruzzi
187.5
peptidyl-tyrosine
Wnt3
PPP2R1A-W257G
R348*
H3122-EGFP
cytologically
BRAF600E
super-trans
best-fit
AAAAGGGGGCTCT
4JSN
anti–CD3
Fgf9
.EEEINAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVXNLTEEMAGLDETIAKLTKEKKALQEAHQQTLDDLQAEED
B220+IgM−IgD−
411–764
pre-EGFR
S.pneumoniae
dysplasia/skin
KS1
Tat11
24/13006
E285
NRG1
D1–5
.Armes
Parp1
taxane-refractory
acetyl-CoA
PtenloxP
5q2
c-JUN
SNPEff
MM35
lineage-specific
3.62
251–552
R:5′-TGTCTTTGTGTTCCCGGACA-3′
.ARaf6KCAAX
500bp
p53-miR-200c
p-Cbl
IGHJ
.RUNX1-810F
.Access
ATCAGTCTTCCTTCTACCCT
2718
shMll3
vemurafenib-resistant
G1035S
haploinsufﬁency
oncogenes.16,17
.Citations
GAL-PGK-6His
E3-ubiqutin
9aVEGFA
BRCA1-like
enzymelinked
APC-ÃŸ-catenin-Tcf-regulated
ATGTGCTGTGACTGCTTGTAGATG
C238
69504
.Brakensiek
0.412-1.895
Klose
BRCA2.24
darkbluecytoplasmic
quinones.27
HU-treated
SAP2/NET
hyperintensities
20.02
RTK-coding
Br51-Leu66
8p23.3-p23.2
p.G12A
DeltaDeltaEMM=-5.87
Â¿VÂ
HER2VE
5′-CCAGGCTCCTCATCTATGATGC-3′
D400A
Inter-observer
-CCAAAGTTTGTGAA
III/IV
P0046
B56δ-
White-cell
ApcΔ716+/−
interaction30
taxane/platinum
IC040751.1
BRAF-bearing
AB-108-C
Golubovskaya
P.S.N.
UG5
802G
.EGFR-family
27/32.5
FOP1
CD31-reactive
PerCP
reproduc­
FGF4/FGF19
deparaffinised
D181A
GenBank™
Ttf1
hyaluronidase-sensitive
PDK
pSG5-ERF
Tumori
G550R
G517T
4405
1,120
end-of-treatment
surface/monomer
G_gallus
LUSCC
017763.4
Nakao
maps—we
100–500
Vegfc
N=29
Autoread
cells176
AZD8055
GAT→AAT
p.G60R
6A/
Q698K
pAKT/total
0.0074
pTyr1062
melanoma
Rucaparib-resistant
Figure77B
specific—they
11/26
O:19
B2
Rad3
1067
cancers4
β-geo
–DOC
Siegel28
LeuArgGluAla
5′-GGGGTTGGTATGGCAGGGTATGTA-3′
domain5
risk14,18
Casitas
pLKO-1
8,123
BII-5
-catenin-dependent
CAPOX
wild-typeADH-p53
Steegenga
over-night
CCTCCGGAACGTTTCATAGAT
HDAC1-Flag
distal
F252I
.Evi1
Myc-6xHis
free-cancer
223-base
Y-56
pseudouridine
CSF1R
agglutinin-coupled
cancers165
INSR-
C2152T
2.2-15
Msh6PR
F300
BTAM
c.199_213del
nocodazole.25
morbidity5
Gln643X
HER2.PIK3CA
.Excess
Glukhova
shortfalls
.Splicing
.Bos
two-by-two
CITED2-mediated
spleenocytes.63
Ntarget
Gal4-HA-HIF-1α
Meige
AD872p–Msh6p
.6,12
ments4
Neh2-GFP
.PCRs
99K
model.46
Balb/c-
pErbB2
IMMUNOHISTOCHEMISTRY
biochemicaltechniques
L332insCTG
21,161,001–22,679,000
tricostatin
Friuli
YRG2
compass-like
a-phospho-Akt
SAF
GTCGAG/gtaata
phospho-extracellular
Ini1-mediated
the-
Ala530
9,25,26
p53IHC+
1592.3
18/144
×××××××××××××××××
NCT00924469
6T
10-42
G543E
AR-driven
model66
92–100
0.036
ST8SIA1
Coory
LyT2
boyangzhao
pitx2
.23.1
protein.19,20,61,62
.35,36
XG73
pNKY291
sn-2-stearoyl,3-arachdonyl
78184
b-form
biotin-CCCAGATCCCGAGATAACACA
mg/kg/once-daily
MIR17HG
sequences.AR3
.6A6A
Edd
pCS2-flag-Smad3
Gustave
000038.3
psiCHECK2-PIK3CA-UTR
pRCCn
registrative
30K
Polo-like
potential.13
α-H3K4me2
phenotypea
XNP53
40nM
Ilkirch
5q21-qter
.End-repair
D1S496
tamoxifen-fed
M-MLV
HPV18+
characteristics18
65-39800
mistletoe
blood-circulating
Y806C
NHA9-driven
Mozaffari
10Department
6-F
Y2522H
E-Cdk2
delL747–S752+T790M
.Z=−3.25
8–41
mutant-normal
Y456S
Ras-specific
Normalization
LCH-4
chemotherapy.63
Split-apart
M-TEL2
MGC60396
MYB-NFIB
B1,000
9b.34
8
Brahma-related
11259
Tsujimura
Trp-Glu-Phe
DNA27
O-7465
G12F-mutated
HIFA
E343V
CDK12-1
secondary/tertiary
phosphoin
FLT3-WT/
31–388
Odyssey™
MLLT6/AF17
Y527FS-c
del322G
H-RasF28L
.Homeostatic
.Peroxidase
D.M.K
c.1835C
HA-p53G245D/p53R249S
glioblastoma,1
.Variations
V5-FGFR2
cgaagaagccacctctttggag
adenocarcinoma3
VivoTo
IHCC
CTC-3′
Greasley
T879
knockdown*
p-BAP1
15Division
5'-GCACACGCTGGAGGAGAAGCTACT-3
tumors.12
types—two
Cytoplasms
pCI/neo
genefragment
cysteine/histidine-rich
Anti-β-actin
CA-repeat
5mC
K432
low-melting
Structure−Function
FIM-FGFR1
at-3′
C135/141A-HEX
1.2–5.8
4683
TpN12D/12D
v1.4.5-p1
≥10×
time-sensitive
5′-tcatggaagagatctgcttcccgcgcacg-3′
real-time–polymerase
358G
.Mre11
δ1
GABPβ
CAGAGACCCGTGCTGAGTTTGCTGAGAGATCGGT
anti-Phospho-p44/42
916-amino-acid
PTPRJ
www.iarc.fr
activity117
0.13–0.65
hMSH2-hMSH6
stablilization
R347C
7.295
ELF5
p261
phosphor-degron
5′-GGT
51˚C
reacquisition
nanophthalmos
re-injected
forward—one
TTF1
8.5–9
hr10
UV23
values.16,17,53
Glu67Lys
G145E
formamide/2xSSC
5′-GGCCTTCCTACCTTCAGACC-3′
2α—Cells
NRAS/KRAS
GFP–BRD–NUT
Stredrick
anti-CD62L
c.1333-
1,7-9
Thick/MegaCC
Asahina
effusion
MKI67-reverse
CI=0.83–1.06
1651–1670
Maillet
BRCT-mutant
ApoE-deficient
loca-ATTG
Gln661
M1476I
FLT377
GISTs.11
11304
PTKI
temperamental
E2-E7
previously.22,24
OV56
RxxLxxxxN
A126V
Cln2/Cdc28/Cks1
development/differentiation
pGL4-based
Arg15
substrates.46
n=2/3
MLH142
Meltmap
g/l
to1.16
Genschik
pN308D/C459G
SDR
activation13,5,24
CD3−CD16+
RictorloxP
classification—namely
Ferguson-Smith
biotin-GATGGTATGTCATGTGTCTGGGGAGG
Sugawa
T14–T16
R727L
Modur
misoriented
ACCAT
gof
c.1822_1823delAG
germlines
PIK3R1R348∗-induced
.S7E
Phe39
HGF-cMET
0TGF0R1NGT
GI:4759226
genomes,28
18â
3.Functional
.RU486
efficacious
mdm2
BAT-25
T25-flasks
c.5510G
strain-free
Glu626Lys
rs1801552
P514
domain-mediated
pleuraleffusion
7·0
−688/−660
D959
Oza
Universitair
ASSTT
R2842H
p53-deficiency
MYC-MAX-MXD1
.Concomitantly
p–c-Met
NM_011943
filter-binding
apparatus,28
CDK12-
Schledermann
-GAG
epithelium
H16N2
FPD//AML
R611C
1.8-fold
S250P
NANC-mediated
ATPase-deficient
⩽500
intensity.To
5364
vBCL2
Myofibroblastic
survival.28
Lck-Cre
microseeds
108/285
pLVX-AcGFP
0.0562
SKG-II
C25
1355
diagnosis.43-45
p=0.008
.Ongoing
1,571
B-UCL
relation­
−124C
R299H
NH1
chromosome9
Akt/mTOR/p70S6K
PKF115
dierentiating
AMPK-related
HLOD
hybridization.†Rate
α-HDAC1
O/p85a
464,198
Rosen
ISRCTN68454111
5′-GGGCCCAAGCTTACCATGGATTTATCTGCTCTTCG-3′
800mg
Stage-specific
11345-1-AP
K125L
30mMTris/HCl
instability.5,6,8,12
343-641
Ref.59
tAXnP-
WM1791c
retrovirallyinfected
Y552_W556del
cytochemistry
phospho-4EBP
GSK-3ÃŸ.In
boundaries41
G413R
2Department
IFAR995
NB100-1081
mutant-harboring
5′-FAM-CTCCAGCAGAGCTGGAAGTCG-BBQ-3′
treatment,34
0.9456
MSH6-L1354Q
miR-107
-y-catenin
.S1A–B
R1513X
21-24
-HRP
15-18
KIAA0130
Mxd/Max
L845
CD29hiCD24
abnormalites
Cancer-Only
2346
19·2
mix-ups
11/11
previously19
myelotoxicity
RaOP
CCAGTGAGCAGAGTGACG
EKB
AML,36,48
KLECKNER
AA397978
5–73·4
c.940-
p=0.661
advanced-tumour
SDS-gel
501-Fc.18
BspHI
Exon/intron
SMO-inhibitor
SLC–ROS-expressing
revisedform
90-97th
N250
ofactivated
JB12450
myelofibrosis=1
α-phospho-STAT3
octyl-d
.VI
Aiman
-3′-CTCAG
E6a/b
.ELISA
.Jun
immunity.21
MUT14
Amsterdam-positive
Tyr647
Soehnge
Boxplots
anti-5hmC
colonisation
S116P
T505
R486T
unclear5,9,10
BCR-ABL.51
0.69–125.8
∼90°
PanIN-to-PDA
Smad3−/+
indexNext
Kmt2b
Q143R
N216I
del3
Xeek1
p.S257
AML1mutations
.Monge
59-AACAGTCTACTCAGGTTAT-39
CD3+/CD8+
WTprotein
hsa-mir-29a
MSI
maltoside
nuclear–cytoplasmic
studies.4
:5828–5838
Dollardand
E1/200
.7,13
35–75
±SD
TEL.E1F1
–55
U-sence
resistance-related
3/54
r.538_586del
K.The
0.0424
sc-47778
pituitaries
Babaei
8395G
958,640
:BAIAP2L1
eight-well
MEK2-Q60
Chemidoc
AA0869
TRF2-deficient
cancers41
E148Q
≥2.5-fold
noi
BCOR,16
MSCV-MLL-AF9-GFP
binding61
translocation/inversion
WT-PH/K189N-KD
rs1805087
c-Jun-N-terminal-kinase
64-years
VNGRNHQGPKRARESQDRKIFRGLEICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTL
Ago2
pE3-C21
S243N
BRAFV600R.19,20
CDK6.2
67–71
c-Abl,24
p85/adaptor-binding
Chomczynski
6.04
YTTl
thyroid-restricted
UG
unidenti®ed
IPPc
MDV-resistant
isoforms.24
HER2-dependent9
described23
NM_018429.2
G15A‐Cdc42
LabTech
Zonana
histidine-free
.D538G-ERα
.MRE11
ADE2-
CD23−
34-β-E12
77.6–77.7
CellQuestPro
Adeno
ductal/lobular
anti-GLI3
RAC1-independent
hJAK1
1/1,000–1/2,500
904+5G
H630
129Svj/C57Bl6
transformation-enhanced
HR−
MedProbe
GATA597
one-hybrid
Fold-X
1065
c.2395C
KDM7A
1293
aflibercept
Flag-tag-fused
Sar
proliferation.67
Gab1-associated
thermocycler
.Z-DEVD-FMK
nitroblue
Electrophysiological
=1.94
TGAATGAA
TD1
N050702
mocktransfected
CRL4DDB2
bpIntron
Komen
.Single-base
20000
Normala
NCRNA00173
patients.53
UAS-GFP
558–563
p-value=0.008968
AML1N-terminally
Gln-1811
GNB4
ALL-SIL
0.364
p19ARF-
S6M-R
pRb-deficient
.MCF10A
AA1077
XV
I–II
endocrine-resistance-associated
Ser468-phosphorylated
Noteably
pre-annealing
studySpindle
Latency1
Tyr774
HSC7E248
12.64
Transmembrane
HN13
BF10100
CA-ALK-5
ALK-signaling
GRAALL-2003
disuccinimidyl-suberate
5′-CAGGAATGGAACACACTTGG-3′
SPT16/SUPT16H
suppressor—that
89
PI3K-generated
p-bromocinnamyl
gtttag/AATTGC
caspase-8b
PMI
hEWS-FLI-1V5
tumor1
Insulin-stimulated
28/507
Hsd17b7
hepatoslenomegaly
menin-dependent
T33P
IVA
9-mutatedGISTs
23-year
SCC-like
Sutent®
pCIP/AIB-1/RAC3
Thr-172
uninformativeness
TGF-/3
pUC
2-5
n=392
development16
om4
multi-cystic
4-day-old
Doxycycline-inducible
93:269-275
S291fsX300
045
BIRC3/BIRC2
Moloney-murine
analyzed.17,62
Il-11
graft-versus-host
processivities
membrane.21–23
HbA2
Cervix
Rücker
mtakaha
disease.ResultsMutation
anti-elongin
.P21
.Picomolar
0.001a
V353A
MEK-1ΔN1
intracardially
MIM115150
BAM
.P86L
Knijn
examinations.Previous
Flag–wild-type
hDIS3RNB
promoter-reporter
Darlinghurst
80C
.F.
mid-gastrula
Neurocult
TC-797s
BRCAl
21938724
3-kinase/Akt
.TCRb
NoTE.-Clinical
PPP2R3A
.Mek
PDGF-A/PDGFR-α
D4G
amplification/alteration
10~20
9,541–9,601
Kanai
1369
Keap1C23Y-V5
7°
WM2664
activation54
Y527FSRC
uests
.P.A767_S768INSSVSS
PPA
p.Glu685Val
1/min
Seiichi
p.P419S
103.65±8.86
100.
dry-tap
XNP125
.ALL=acute
pmGFP-H-ras
impair
antineoplastic
Cys-*Ser
-bp
IVS20+5A
Palomero
p.Phe1995Ser
6319
BAC49M24
FIP1L1–PDGFR-α
ISIS5132
SNP_A-1981516
0.81–1.35
5′-GGAGTTTGAGATAGTCGAAATCGTTCATGGT-CACTTTGGCCCG-3′
.Equality
/event-free
F3T3-KD\
Biosystems/MDS
R625L/H/D/C
dysMKpoiesis
D1-K114E
anti-CD15–FITC
Muraski
HiSeq200
31-h
CBLB
merlin-rich
protein.38–40
1.1-2.3
1p33
5′-CAAUAAGGCUCAUGCACAAUU-3′
C209R
EWS–ETS
transcription-activation
shc
Y109C
5′-TCTTGCCGTAAATCATCCCC-3′
tumors21
whethermutations
28–32
KEAP1-mediated
GFP-AKT
K405E
ERK8
BAP1-positive
CCDC12
W207R
c-Abl-PD173855
hg16
-ER
F-containing
Ctr1
CREBP
Dpar
status.36
intestinal-projecting
207X
Ad-AKT-DN
R170G
,0.0001h
437–893
5´-GTTACCTCTTCCTCCCACTCCAG-3´
APC-deletion
538-amino-acid
andpreviously
delLeu747_Thr751
Chiorazzi
Vehicle-injected
Drané
0.31Gender
1,093–1,400
P-GGCCCGCAGCAC
p63+
N18b
5′-RRRCW-3′
5015
interfamilial
12,239
areas.9–11
2.528
Kendziorski
1.459–3.032
nt.510–514del
syndecan-1
1.4-Kb
Sox17fl/fl
centuries—and
J.E
Cys122
CyclinB-CDK1
genes/regions
Levitzki
pEAE113
NcrNu
/small
p.Glu191GlyfsX12
cobblestone
VMCUB1
paclitaxel/IV
quired
37G
5055
tμˆi
CypD
to-leucine
backdrop
thenrunon
cis.12,25,40
LBD-affecting
0/170
pEYFP-N1
//jncicancerspectrum.oupjournals.org/jnci/content/vol97/issue11
Penheiter
g.160757T
631512
71-43
p.T45_I47delinsCF
complex12
.Wrapped
ubiquitylation.5,7,31,32
metastasis/invasion
5′-GTCCCGGCCACCCACT-3′
trastuzumab/lapatinib
ª
±19
R200
PDGFR-alpha-PI3-kinase
ROKα
fluoreschromosomal
≥2
phenotype16
TAATGACTACCTAGGAATGAGTCG
DYR
CDK4/6-cyclin
CfoI
GCGATGATGTGAGAACCTTG
.Involvement
E3.5
leukemia.133
4.HER2
S226A
2-cycle
adenoma13
302
Sigalas
K67/E89/F187/W1
CIMP+—that
HNPCC/Lynch
Shp-2
15—NUT
simultaneously.577hMSH6
trp5-27/TRP5
3Bc
.Overexpressed
MYC-Associated
GFP-Positive
BRAF/NRAS
5′-CGCCACAGACACCGAGAAUUU-3′
L747S56
ADH
S186P
BA-6000
G12D
Fluorescence-aided
FGFR1-2
v-Fos
subclustering
P217A
2,19
TIM1
3797
3117
RANBP2-ALK
Kottaridis
EF-HA-Smad4
hMSH2/BluescriptSK
Delta375
CASC3
months.24
−0.63
Penefsky
95.87
Q147*
Agarose-gel
46/EC
D390N
perturbation
copy-
1,908
HEGO
moderate-to-high
n=10
2-stage
CMV-Cre
mutants30
'ever
Cutler
PTEN_R
gene13
formation.36
Yes30
c.1669G
24•33•34
LR=20.2
5′-cugucuaaggguuggccuu-3′
NF2-
TTCGGCGTCT
coregulator
6q13
Momburg
10.1007/s10689-010-9372-3
Microscopically
p-MEK
HD-0296
1014
allophycocyanin–conjugated
POLD1
repair-associated
CD3+CD4+CD8low
F75fsdelT
94.2012.723706
al25
Armonk
Pro29-Gly30
−14.4
delL747
pulse-labelled
K179
Jak2-V617F/STAT5-mediated
Lys562Glu
C135/141A-C124/182/229/277S
.WAGR
.Glycosylation
-TRAP170
Lin12-Notch
GCAAAGACAUGUCCACAGAUU
.Maximun
pCDH511bG328V-ACVR1
EFGR-TKI
sequencing*
pCMV6-AC-RFP
tctttcagagtatacactgg
P7b
~1.6-fold
basal-activation
43rd
4p14–15.1
NBA1
Sollentuna
antiMEK1
/CDKN1A/wild
H888R
WI38VA13
APPBP2
serendipitously
59-TGAGGATGAGAAGGGAGATGATGG-
63:26
dupA767-V769
2Revealed
jl
L424V
annealing79,80
selectivity12
unavailable.
status.42
prolife
Cell-Free
al.,30
NPI
2136
abiraterone/leuprolide
FAM114A2
mutyrx3R
1–3mg
i=1,2
*6A.30-
372-451
Asp-842
.Gene-specific
25994
CML122–124
Nuchtern
Confocal
p53-HDM2
pProLabel
//dx.doi.org/10.2337/db07-0859
IL35-producing
serum‑rich
135,136
Caspase-Glo8
of02-1
1-dependent
R141G
Bell's-like
spl.ex9
purity-based
224–
3F*
UDP-glucose–deficient
PKM2
c.2195_2198dupAACA
Eu3
±IR
polymerase/exonuclease
migration-dedicated
.WHO
244KB
LFCQLAK
17,788
38/561
Runx1-knockout
5.2.4
child-parent
54y
specimens—Montreal
D645E
65.3
C0O
KRasG12D
probe10/6.51010/6.710/6.9.7/9.2ND9.2/7.0NDND9.79.7/
Smad2CΔ207-245
A789
muramidase
breakage-bridge-fusion
5q11.2–5q14.1
mutations.19⇓-21,49⇓⇓⇓⇓⇓⇓-56
.Fundamental
KITΔ559/KRAS
Vadlamudi
TUBA8
g-
L833
v-H-ras
11-residue
groups.4
leukaemia29
nondeleterious
substrate-acting
VLPQDKEYYKVKEPGES
Vi-CELL
1/43
establishment/maintenance
.FH
12,13,17
BRaf
β-strand
P-element
serosal/mesenteric
481-482
pHIV-LTR/β-gal
L1398
10-25
.Randomized
aprotonin
SJHGG027_D
ion-paired
neutroninduced
TAA-3′
4517
1A3
Phe522Cys
41014
NB1224-D
J21
3487–3495
.p300
29,703,388_29,773,392delGTAGT
growth/Cyclin
RG-7T
cases65
Spi-1
Gnarra
R2/
5′-AAAATCATGTAAATTCTGCTTTATT-3′
KrasB
numberwere
.59
0.40–0.61
noncavitated
flowchart
anti-RAS
covariates.29
583-pY589-597
BIAcore2000
800-fold
Smad4130–325
Costelo
MarkerBAT25
3165
hydro­
R39356
.Mll2–/–
signaling.3
CAAGTTGAGTCCTTGCAGCTG
N-Glycosidase
chr1:58372500–60938037
IC'l
protein-fibronectin
TTCTTACTGATAAACTCAAGGAG
EWSR1–ETS
Φ80dlacZ
L2020
mAbcam
R348∗.Cdc42
.Monoallelic
Neomarker
GAAGTGGGAGCAGAAGCAGGTGCA
double-homeobox
APBB1IP
STAT5b
chromosome.1
14C-acetyl-CoA
Q61L
TGAAACTTGTTTCTGGTATCCAA
antigen-presentation
CTCATTATCAGGGTAAAAATC
FOLDx
carcinoma4–8
110.41
transplantation,25
74.5
nihms646437t5.jpg
assembly/stability
to0.0001
μl/well
Tyr201-Asn223
5′CCCACTGCATCAGGAACA3′
ERCC3-deficient
anti-Trx
asp.I478fsX2.zCOSMIC
HR-defi
o-catenin
610355
electrocardiograms
3034
-CTGACGGCCAGAAAGCCAA-FL-30
PJS09
022415
meltingcurve
.1321155111i10
tyrosines1234/1235
3.75
:107–14
ROCK1
ExonlaIb23456789Sequence
4567delGb
iConcordance
5′-TGGTCAAGAAGCTGACGATTC-3′
p53missense
3.0–3.7
3′BCL2
5′-CCATCACCATCTTCCAGGAGCGAG-3′
UBE2I
theright-handed
PAE
3268
mÃ©tastasesdeveloped
.Hypertrophic
RTOG
.P34R
sarcoma28
3-kinase-mediated
636del
resection.3
agarosegel
loss56
resistant-13
PLC-lysis
carbamidomethyl
1223403-58-4
2664
ndash
TGFβ-regulated
Gly138_Arg139insGlyGly
UV-doses
p-CREB
LIC
somatic-derived
2,009
R462C1.
Tehranchi
Na4P2O7
synonymous.Full
αF-helix
170.8
partner.20
11q23/MLL
.Letters
G5740
Val658
CCL4
TRA98-positive
214987_at
protein-altering
SX16MV
1351
13i
metaplasia/dysplasia
cDNA32
anti–nonphospho-SRC-527
cocaine
2826
dmitri.wiederschain
active‐site
pretested
second-look
K359
non-leukaemic
lTCTCGGCTC
R25C
.3362
-4-sulfanylbutanamide
hormone-regulated
L121*
SDCBP2—that
44–625
P51S
FGFR10P2–FGFR1
I-Ppo1-
differentiation4,12
poor.38,47
multimeric
cakin
L52
clathrin-binding
Scintiverse
.Amundedottir
GenePix
Phenotype/Genotype
HPB-ALL
MSIsensor
survival.2,21–28
phenylhydrazine-treated
PRKDC
Traktman
c.1501G4A
TDS
NPS-
re-determined
repair-deficiency
IIKYYNIEFRDRI
lamellipodia-like
4Gy-treated
HR=1.4
Takemura
amplimers
frame-deletions
Hydrolysis—To
K-mutant
Przychodzen
C.L.S
850dupTCATTAC
disease71
p21Waf1/Cip1promoter-driven
00114.fm
IIImutations
overexpression.26–28
Ponting
controversial.10,11
C100
6/34
GDP‐bound
5′-GCTGGGTGCAGAGCCATAT-3′
Dziadziuszko
Stransferase
hMutLa
-.-Rb
p1–3
L529
._Pwo_
Doktorandenstipendium
13.95
APC2
Faculte
2.201
5-cell
Polycomb-mediated
Cdh1/Skp2
ABCC2
anti-P-MAPK
downregulation34
Resenrch
.HER2-based
multitalented
PALB2–BRCA2–RAD51
Â°Refs.31
ENLYFQG
Atr−/−
Kouhara
NEK11
split-hybrid
APC/
ETV1_AS2
2B-like
//www.broadinstitute.org/achilles/datasets/all
0.1-mg/ml
p70S6kinase
hypolipidemia
Malumbres
Solnica-Krezel
BRCT1775
tttgatatctgccacatagttcacagaactatgtggcagatatcttttt
WTERF-transformed
hypermorphic
Anti-p85
7k
transneuronal
basophilic-staining
.Studying
253-J
602849
Anti-5-hmC/
5E2
V74F
EcoRI/BglI
¸2
receptor–dependent
pERBB3
ml/40
sites.67,68
§MeFE
TP53/p53
Sites—CTLA-4
.Hypoglycemia
HDAC11
chromatin12-14
IP-WB
BAXso
pY31-paxillin
Figure3E
Thyroid-hormone
deoxyinosinic-deoxycytidylic
AS605240
TCGAf
MiceE11.5
mice.7
26,33,34
EGFP-N1
tumor-necrosis-factor-related
R5866
Troponin
3400
glyceraldehyde-3-
SUR8
iris/ciliary
0.156538
Aur-As
2942
Nphs2-Cre
MANAGEMENTWho
IVS2+1
GADD45A
loop–sheet–helix
HR-dependent
KYSE-
Gaidano
heterozygous,8,9,32
Jean-francois.emile
Y126C
FA-D2
CD3
Grafit
Tagawa
c.811delC
1:5000
dmmunoprecipitations
tEGF
IVS+3A
ATTTTTCAGTGCCAGCTCCT
5′-AAGGTGTCATGCTGCCTTGT-3′
J-041171-09-0002
12q24.3
CA5
1615
receptor—Metzger
PLKO
expession
10′
loss-of-function/missense
T681A
.Genotype
Ab-5
founder-mutations
0.0469
STAT2
animals13
BMF+NOXA
.nonsense
.IQ
retro-translocated
Dougher-Vermazen
F1174L/MYCN-positive
rtPCR
syndrome.20
ETV6—were
oncefor
Franco,4
c.37_39GGC
5′-ATGCTGGCTGACCTAAAGCC-3′
5002
-TGTCTGGAGGTATGAGTGAGG-3
NM_003317
HER2L869R/HER3E928G
Polyvar
G301X
VAdb
S2Ee2
PROLIFERATION
uLouLeuThrU.t
BrdUrd-negative
Mfd27
TGG-
G202D
FractionPREP
H-3300
nCInHI
..N.T
0/148
I638F
Eguchi
0.8317
Elo
.Asparagine
malaria,31
12-mHz
High-quality
progenitor–derived
supersensitive
-E511K
assays14
p.654L
prokaryotes
cyokine
g/mlhygromy
Asp54
704
57–61
Coria
E012
cases.30
coverglasses
P248
Transdominant
129,130
Pcna
Rodrik
+b
substitutions8
tPA
Mlh1-Pms1
v3.0.25
tetracycline-repressor
pilomatricoma
CCLE
NM_019555
–146
1–60
BMF+BIM
-159
BRCA-encoded
A_51_P172054
andtotal
R528G
performedwith
ICL
mutations.70
//www.ncbi.nlm.nih.gov/projects/SNP/
AlAlsdigProGlySerLeuLeuAalTrpLuIleLeuAlaS*rAIIylSAlProaP
signaling-dependent
p=0.005
Arm-level
0.043*
Two-way
Sternsdorf
GTTT
described15
882
hEWS-FLI-1-V5
www.roche-applied-science.com
advantages.1
CGCCTG
PDGF-BB-mediated
bj
.LSC
doi:10.1158/0008-5472.CAN-09-4563
phosphoglycerate
FGFR2-heparan
385K
Blvd.
osterix
.286fs
Tetramethylrhodamine
ARN-509/enzalutamide-resistant
Sisodia
DH1OB
CAT2
PI-3-K
IR632
Dnmt3a+/+
Search-LC
E235E
pattern.23,26
5′-GGCTCCCCCAGGAAAGGCCTT
TNFRSF16
8.5–14.4
Co-transfected
granulomacrophage
LipidTox
Ile/ATC
N141I
DEThCIS
system.14
subunit-specific
SWISS-MODEL/DeepView
bwa-0.5.8c
K728T
immunogold
128K
εM
p53MTs
p53-haploinsufficient
Moodie
32.72þ
−4.59
AD-hyperIgE
lowinduction
GISTs24
melanoma41
0.17
Stcraloid
Kirpichnikov
pro‐tumourigenic
pFN205K
non-Langerhans
episodic
tRCCs25
replication,11–14
FLT3-ITD-positive
immortalisation
p.Asn41Asp
H250fs
•poly
Non-Target
turn-over
incancer
19R
5000–15000
cells17,18,19,20,21
Br69
im-
conditions.27
Hashizume
D.Many
combinationsof
OD1
RAST58I
∼54
55.7-fold
0.0250
Me2
RQGEK
periadrenal
M116V
BoehringherMannheim
1218L
1.00994
FLT3-ITD/FLT3-TKD
1,27
microhemorrhaging
www.sbg.bio.ic.ac.uk
tosylate.11
C57BL6/129/SvJae
0.05:1
p110c
Ig-1
.Ku
myc-p110-CAAX
fold-depletion
F68
PTEN-specific
chromatin-based
infection.20,22
F88S
RSS29
Kababri
ArcherDx
Boehnke
0.7–3.6
±4.98
0.296
ICGC_PA166
.FKBP1A
complex-FancD2
Rajitan
CBA/N
7763-1
SUMO-1
c-kitin
L1596H
phenol/chloroform-extracted
.22,27,28
Arg93
Dei
heparinbinding
Ubc3
-TCCAGTGGAAACCTCCCAAGGAGACCAATGGGGTCATCA-3
1QJB
anti-calreticulin
prognosis,46
1â€
5693
Arginine
Leukemias/lymphomas
BRG1/ARID1B
c.682-9T
Utani
dS6K
phosphate-buffered-saline
Krukenberg
HCC3153
lM/L
∼10‐fold
a1l
Verhoef
CTAGCCTGGGCAACAAACGA
46/72
Sekelsky
10-07-012
disorders.5-7
11·6
NCT00779389
50-86
.S26A
C.N
phosphorylation69
®lms
f–h
inantly
antip53
PDGFR-A
vitrotranscription
ATP-stimulated
CIC–DUX4-expressing
kBq
LGLL
CTD-2360L14
p.G67R
pFastBacHTB
mRaf-1
P1104V
2242
carcinogenesis109
IDH1wt
56◦C
A-*G
1,813
criteria.30–34
c.230delG
gainof
IRBP
Integré
EGDTA
5.495
FOXQ1*
26945911
DO-24
45,46
Q347_A348del/F351L
v0.10.1
1793
-δ
analyzeabnormalities
FOXO1/3
12252
hypoxia170
F40M
Fbw7γ
synchronization
Cellular…
Pcdhb17
cells30,31
clinodactyly
26â€
.BLOOD
intermediate-active
13.3–13.7
GI:31083295
224-227
C121
'canberra
MLINK
GMR-Gal4-
retroviral
p21.2
35.45
S2.1.2
formic
primer8
R277W
300516-03
Xq27–q28
351–420
Figure6
Malassez
AF015950
A87V
GrG
ARMS-PCR
47/209
FLT3.E22R
.2E
Gonzalez-Agosti
ILF
sub-cohort
TROPOMYOSlN
structure18
FLI1-CR1
EpiCalc
Y443FTr*KKKKT
418J17
3Aii
LAPC4-vector
Cxcl4
cation
non-Ashkenazi
p621CRAF
29A243
threonine-37
on-target
peptidic
140-155
DSBH
05
/Ras/phosphoinositide
hMSHlhPMS2
fluoresce
cyclotron
20892
pathway-based
.Cultures
highsubstitution
alsoobserved
ossifications18,19
line.26
HNTG
PolyPhen13
ofp53-responsive
history.Top
raloxifene
IPT
Méditerannée
Thr323
GC-3′
6.1
anti-pY1015
Robotnikinin
.SPRY
mutations.11⇓⇓-14
-HIF-2α-pcDNA3
0.0014
C-a
S615F
ZBP
4A-D
His773_Val774insAsnProHis
WT-1
Jade-1-sh2
≥2-fold
IL-3/granulocyte
up-down-up
m/65
431
530–652
5543
mesylate.22
MO_1081
EBSS
pre-eminence
Thr1422
HSU4376
ERα/estrogen
Deau
unculturated
S62A
Ghofrani
normalization
teniposide
expression18,35
hypermethylation9
.Metabolite
β-catenin-GFP
hasyielded
neomycin-containing
Carp-β-Actin
P.M1_E165del
.Hematol
CD4+CD8+
TpN12D
serous/clear
HGFinduced
R968C
pseudo–Pelget-Hüet
werecharacterized
synergising
DKK1
EGFRvI
RG7204/PLX4032
5′-AGGGTCTGGACAGAAGAAGC-3′
PS-341
GFP-H2B
p210bcr-abl
cells2
DIM842
56,435,160
Dusseldorf
0.0007
humanised
cancers7,8,9,10,11
p.Arg563Leu
,13
R2n
Mak
C-CBL-mutated
−341
1.7±0.2
179
tp63
tg/mlherring
pCY4B-FLAG.21
2-mercaptorethanol
P55
0.2922
R318W
hav-ing
T-ALLs
anti-RACK1
RBM515
psort.nibb.ac.jp
72.08
11q12
1NRs
HER2‐
EEF126–4
5′-taagtcttaagtgctaccaac-3′
59.9X
11β-hydroxycortisone
LCL
298–506
7.62
KMT2Dfl/flCD19-Cre
10
central-lobular
33.35–45
pSCW231
thermolability
experiment13
+0.15
Caspase
V8I
70th
dispensible
H207R
11·8
APDS2
K211
4956A/G
SNL76/7
7/38
34b
.0974
propogation
'two-hit
Eachblot
AML.7,33
.PBAF
RNAase
conformationtolerant
scr-shRNA
2,33
TGGAAGAGGGAAAAGCTTCA
R1101K
ab6002
lymphangiomyomatosis
100/120
ETV6-PDGFR
+/-3'UTR
health-related
mutations/methylation
195KB
2-APB
_1145+
C18-CL
LIN-45
BRCA2-mutation-associated
2413
Claes-Jensen-type
Glu571Lys
35033
.Genotype^Phenotype
NCT01456676
nomenclature,22
c.1789A
binds,28
5mC-
604-bp
pmCFP-K-rasG12V-R164Q
S/F
041A
pathway32
ApaI
A/B/S
TIMM44
-52
antibody-protein
∆WD40-JAK2
weeks.30
0.0268
dblist
optionsEffect
AhR
Dox-sensitive
Ins774HV
RCC-FG2
YPH-PIG3
G389A
Backsoak
MutLs
FLAG-M2
JB12455
translocation.Materials
8p11–12
crosslink-induced
+0.78
Broesby-Olsen13
plateauing
Ser-269
PTC-JM
others.39
PTEN-D24N
ETV6/NTRK3
TGFβ-induced
deaths1–3
espe
42-3
profi
cell6
chemotypes
excise
//creativecommons.org/licenses/by/2.0
TCGA-AC-A23H
1304
octyl-d-2HG
SZ,104
TRK1
L22
20q−
A/G-Sepharose
CENTG1
domain.44
5p17pâ
αE–β8
two-tiered
S270N
//ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/paper/
ISOGEN®
1584
maturation.33
rs55787439
MuStab
p.Q883
â€œtranscriptinstabilityâ€•are
OMe
allelesA
NUP98-HOXA13
6Mechanistic
EWS-NOR1
RSY6
70±12
cancer56
twiceto
11.0
CGCGTG
AZD6244/selumetinib
G379R
HCT116/DN2R
MCDB153
SBE-contained
200.0
Leu792
adenocarcinoma.20,23
ACGCG
Ha7c
KCNA1
CBR1
GST-PLC-γ
downstreamfrom
CpNpG
1.5-Mbp
Y665F
c-jun,9
∼300-bp
coh.org
I1044V
500ul
Kratzke
TA-cloning
re-anneal
.6,48
c.164_168delGGGAG
S387Y-expressing
carboy-terminus
let-7-a1
∼29.5
Lin+
N3b
pCA2
S428
Immunoaffinity
Nucleotide-free
benzamidine-HCl
.TNS3-C2
havebeenidentifiedin
EC65
Hachicha
.TET-mediated
GGTTCCCAAATAATGTGATGG
c.2251GC
FRM
pathophysiology
RalA
I-reconstitutedFO-
pyelectasia
67-
319N
bycentrifugation
Skp2_SCF
pathway-derived
irreversible
NOVH
604001
counterparts.6
.Myc-MTA1
D434G
21C
*Risk
PLoS
F537–K539delinsL
dysplasia.11
non-progressive
.Any
K337E
unmeasureable
CAGGTGACATTCAGAAC
1p31
Leu-330
Hyperinsulinism
STI57173,74
NEBNext
FGFR2/KD
=mosaic
R3087G
Grb-2
STAT5-specific
S858R
GGGAGTAATAGGAAGGGGGATT
si-Control
therapy–na€ve
Antiangiogenic
in-house
p.Lys664Alafs*13
Ret10R
.Caspase-8L
RO1HL52725-04
Osteoarticular
semi-adherently
spectrometry.26
ter2311
.Estimated
p34p35
p.Y134H
Potter−Elvehjem
VHL157-172-
sequence-level
-TrkA
Pai1
22.5+1.4
.025972
precoated
.R-Smads
ex19–JAK2
CTTGGGCAGG
Arg153Pro
113-0033
depletion–independent
H−
binding-proficient
sorafenib-
polymerase-induced
Riz
Lys6
immunolabeling
inhibition.18
Moskovits
.3.1
B55
'guide
Buijs
769-770
A-Barcode-Exon27R
SGX-523
hybrid-capture-based
Thy1-positive
cytoskeletal-independent
anti-ERBB3
24×108
6-FosEE
R251
531delinsCACh
59541
EGM2/20
domi­
AnnotationConsistencyFilters
experiments.3,12,21
p85-Binding
Q47RILGPSNVPQRV
FAM65B
F324L
80,81
leukaemia13
BMT.1
30-mm
G1/2
Bu¨tu¨nles
c.244T
XXFCCTGAAGCTGACAGCATTCGGGCCGAG.AI
luc-reg-15/16mut
.SCF-independent
alone-carrying
H63
5′-CCCCTGGTGACAGATGGCC-3′
β-catenin,10
microscope-mounted
reported12
3745delT
resistance.4
61,97
Xp22.1
300μg/ml
replication-competent
.AID
33/CRC
doi:10.1016/j.lungcan.2006.06.005
PRMT3
Bionetworks
MLL3Δ/Δ
leukemia.1-3
TAOK
trendline
750
HT55
5′Fam-GAG
pCDNA6-V5/His.b
.ResultsIdentification
K14+K8+
PCa
c.5329A
0.004–0.021
CBL-positive
and18S
MEL270
PHOTOTROPISM2
1,243–1,508
Normalisation
1460
:1303–9
011905
c/ebpβ
monosomies
bi-distilled
CD3ε
k-ra.v
repair-complex
A/G
L321A
hemangiopericytoma
2.2–7.9
1798insGAGACTACA
Chasin
1857
phosflow
signaling.1
TGF-ÃŸreceptor
105·3
anti-PDGFR-alpha
.Total
ex5/20
RQFYQLDAYPSGAWYYVPLGTQYTDA-
mechanism‐driven
preextracted
GGCTACCTCTGCATATGCGCCAGTGGCTG
Arg-337
CARD11-dependent
f.a
D-type
Abo
anti-RhoA
Bhattacharjee
pan-Rac
5¶-TTCTGAGGGTGAGAAGGGAGAGGAGAGAGGAAA-3¶
Far-
25-056-CI
.DKC1
CAGGCTAACCTAACCTACCA
3.5–3.3
JAK237
1.92
403–406
mispairing-induced
Fontebasso1,33
pleiotropically
23,299
c.1840A
B-RAF.28
7304
F52L
homeostasis122
pyrosequencing-based
notexclude
LKBI
T70
fu¨r
S358L
affinity‐purified
PWWP
withthose
metabisulfite
U-shaped
/mouse
siRNAs/miRNAs
PDGFRα-transformed
mammospheric
overstimulation
Non-immunized
182,780
FHL1-CK1δ
instabilitySix
sub-lines
AHCYL-H6R1
​LOH
R838C
D.J
Phe-80
SUPM2AR500A
q42.11
lost.9
13–23
TM5
IFN-γ-dependent
//links.lww.com/JTO/A821
shPten-driven
11/14/94
GXGXXG
Krishnamurthy
SFA4a
KD-Akt-transfected
GSK126
Ral-GEF
3000cell/well
5′ss
antimicrosomal
phosphotransfer
p.D1028N
Soutschek
cerebello-pontine
Internet-mediated
9cases
U266wt
TGTGGTTAACGGAAG-3
HA-C-RAF
DupQ
U2/M2
p.A751V
Zv9
biotin-X-NHS
R415G
p.K483M
Franchitto
gamma-interferon
lithium-stimulated
p.A864T
Anne-Marie
Parameter∗
angioimmunoblatic
HFSC
PDGFRB-TP53BP1
iron-chelating
carboxylterminal
prothymosin-α
sevenless
xrcc2
PI3Kg
FUS.ERG
vivo.22
Germlinemutation2
Spe1
148–290
66.326
Nrf2-null
paired‐box
BCOR-S
4575T
,4g
AutoRead
123C3
Centroid
1-25
Bourdeaut
determined.16
37-39
kidney.27
2×76
'dominant-negative
cells146
IA6
IRD800
anti-HGF
RTK/PDGFRβ
M/30
RG-17N
cis-to-trans
maternal-blood
myelofibrosis.3-7
31.5±3.7
5′-CCGTCGCTATCAAGGAATCGAAAGCCAACAAGGAAA-3′
~Apparent
microtubule-associate
PCM35/1+
Rv-T
author.GAPs
37-41
Maandag
withmonoclonal
silent-to-non-silent
.Compiling
Pycnogenol
Trans-lentiviral
E-GEOD-73066
5000-fold
.HN-K-rasG12D
75-year
Propensity
Cicatiello
Highb
CAGGGGGAAAGCTGTAAAG
.Visual
0.44–
date1,5,6,7
C69S
ARE-driven
10-20×
NBPF8
POFUT1
YM1
BRD3
E1
Lentini
Verio
S72R
3/23/04
Qing-Yun
anti-Smad4
q31.3
differentiation
−0.85
V804M-Y806C
9b–d
.PCNA
.PAI-1
GAPlC-dependent
localwith
pRK5TKneo
Raps*/Raf
MEK.11
ab41435
CBLDexon8+9
'kinase-dead
ITh
melanomas.64,65
.Twelve
RP11-314J18
.NVP-AUY922
USP31
8.56
G-50Sephadex
map.html
'Scl
AE3
In-plane
.4544T
respectively.38
formsare
5-methyl-cytosine
NMRR-10-1206-7127
5′-CAAACCGTCAACAGCATAATA-3′
FCHO2
T1/E2
PFTK1
Pro-34-*Arg
22071
.Consanguinity
F441S
TSC1-YFP
α3-helices
Morphological
chondrosarcoma12
damage-driven
2.0-12.6
328P13
imatinib-resistant/-intolerant
cells.6,7
pathway23
33−36
-O-N-methylanthraniloyl-ATP
8M
5′-GAGCGAACAGTTTCCATCTGGTA-3′
virus–enhanced
6A–D
Signifincant
0.872
12,772,124
31.56
tryptophan-aspartate
vera2
phenomenon.8-
Gillgrass
.00029
Maamar
RET-inhibiting
FLAG-Elf3Δ60
5D–5F
Analysis—Cells
CCGGCCCCGAAGAGCC-30
M1040L
anti–PD-1
≤45
antiphospho-active-PKB/Akt
Bradforddye
IL2-Rγnull
rationalizing
activation,84–86
phase-matched
1948.4
uncharacteristically
rhuHGF
M-B
ETS2
7p12.3
0.601*
43°C
.HT-29S
CCAAT/enhancer-binding
–rEP300
E.L.
αF
E542K7
www.tbi
.Fig.3
BRG1/HDAC-containing
Boehmelt
replication-suppressing
T7-priming
A386V
hSWI/SNF-A
p.K616del
TetWTPTEN
A289D-EGFR
0.31-0.81
mTOR-Rheb
Duggirala
ID-dependent
PVRs
histotypic
q15q22.3
p.M186T
∼9:1
.HIST1H3C
.MDA-MB
HLA-A0101
15×
.Frequent
5.25-fold
information18
−875/−570
IPI-926
13q14.11
autoinjectors
cointegrates
SAMN02214846
4,14
discriminative
1:360
oligopeptides
interferon-mediated
alr3
rHAB
D3-GFP
ERCC2-WT–complemented
Farber/Harvard
U-87
H3K27C
DNA-repair
chromatographic/tandem
38,012
2–5•2
rehydratated
5′-CTTCGAGCACCCTTCAGTTC-3′
Hemorrhage/bleeding
A182P
∼40
PML-RAR
HEL
negative.14,15
activate/suppress
P-J-K/E
inhibitor-treated
5′-GTC
impactful
1GUA
indirect-readout
WO2006018188
leukemias.45
H3/H4/H3K9/H3K18-acetylation
Pre-Tr2
.Small-molecule
C12orf28
preexponential
WTBraf-expressing
MOLT-4
14min
degradation,20
ALFA-9801
15S
.MITF
.03996326
Y813
C.Y.
hr16-D
previously33
anti-Mycn
activity.16
serous/serous
2–14
27.7/34.0
c.5858C
polymorphism/sequencing
Δresonance
G3-
Arg119
Agarose
3,4,5-phosphate
5.3-13.8
Tyr608
P-0913
platinum-progressive
Thijsen
ID=252
Laat
translocation20
R210K
Peg1/Mest
H1299-p53
c.5074+6C
adenomyoepithelialomas
-0.52
SNuPE1708R
primary-derived
pLexA-HaRas
arginine-serine
K30
loop-out
bootstrapped
uml
5′-GAGTGTTAGAATATGCCATG-3′
I1100R
pLP-N750
preexamined
Sturn
prostate45
high-transforming
PIK3CAdid
Ii1
triangulation
transversion-highcohort
0/134
trimer–interface
F876L-Encoding
DharmaFECT
subunits.Figure
CJ7
IV/XRCC4
hTcf-4-β-catenin
31511809
-IEDNEYTA
PCR1
repair45
AxK
R8
heterozygous,17
RACE–negative
Mg21
GNAQ,19
NHE3
MSSE
MLL-AF9-producing
IDH1R132H/WT-repressed
p53–P278S
17C2
TEL-pointed
receiveroperating
pBabepuro/TrkB
pTrcHis-Ha-ras
retardation39,40
CD4-PE
whole-mount
E49
supercontig
non-aggregating
tumor-speci®c
Cloning—Total
line.70
GS596
MPPs22
0.945
Technology14
Y513F
Theresultssuggestedthatmissensemutationslocatedin
ag-3
-t12
754
Dpc4
2.983
Hopfner
furiosis
kinase-6
Ex20F
341,341–13,425,865
ALKR1275Q-bearing
pET28a-BAP1
ofEGF
tumour-derived
Quant2
39*
NFkB2-TK
adenocarcinoma.7
787–798
/IGH-CCND1
'UhP
Itga6
2ADY
alpha-subunits
0.00137
NM_005228.3
Denys–
synchronicity
Erg+/Mld2
y-32P
c.52A
E478K
frequencies.9,11,13,14,23
NaCMC
rs1799967
customization
G89R
TGGCCAACGAAGCACTGAT
NDUFAF6
0.4-ml
ATM75-15513A02
a-catenin
~16°K~
f3-galactosidase-encoding
Rat1-myr-p110δ
membrane-binding
Oosterom
A-tailing
gemcitabine/platinum
Mitf
CD45.1/CD45.2
siU2AF1
G463VBRAF
606/370
CCCG
deparaffinization
R301Q
ERα-SPOP
tet-off
c.320T4G
three-fold
∼1/2300
A461T
null399R
.Theplasmid
1–56
TGT→TAT
Hilden
apoptotic-related
biology.9,22,29,30
L52R
histology-independent
NFKBIE
RPS6
415
MYL9
1,5-a
Al-Kawaaz
2-Sos
Steinhoff
AS12
TGGGG
c.442-3T
PC-10
3°C
leuteinizing
416
mutations—that
YEP24
1.9.4
relief-based
comicroinjected
Nonbrainstem
ERIAPIIKALADH
destruction44
571–581
Dis3p
imatinib29
Conformation
ASC2
K12GGT-AGT-TGT-CGT-GAT-GTT-GCTColon
L858R-EGFR/
ubiquitin-ligases
∼30–35
N/D/E
RSV-GAL
HotStarTaq
p.Val340GlyfsX6
existence,4
p5371
phenylaminopyrimidine-derivative
Flag–SnoN
C609
SKMEL28
K420
PlexA
oligo-
MDC
regulators38
MAPPAIRS
Cell-cycle-dependent
4–8
.K652E
5′-AATCCTGTACCTCGTCCGAT-3′
.Participants
718–805
NIA-17k
103.44
-VAIKTL
//www.ncbi.nlm.nih.gov/genbank/
anti–PDGFRα
Granulocytic
fiberoptic
reimplantation
toxin-catalysed
deletion/inactivation
8,723
miR-
F1573
four-probe
MSI-low
endomucin
ninety-two
nucleotide-loaded
receptors76
brown-yellow
Glu391-mediated
LSABR2
.Surgery
non-radiation
gMFIs
insporadic
Dilioglou
utants
H=high
M00272.p53
McGillivray
WNT-signaling
TGFβ-mediated
Chlorhexidine
Committee—approved
Seraing
Akt/PI3K/mTOR
TGCAAGGTGTTAAGGACTACAGG
Eppendorf®
T220I
E37G
adults.1
5'-GGCAGCACC
PLK
×5
G122S
−350
PMS2—in
rs17336639
CTTGCCGTAGGTGGC-fluorescein
pp60Src
metabolic
antimyeloma
13/40
Beral
,7,11
FGFR-TKI–sensitive
anti-Rat
Rosetta™
cinnamonyl-based
T411
Groupe
3A–3E
versus0of49
3-deazaneplanocin
heterocomplex
exfoliated
D492G
transfection-transformation
p=0.049
whole-genome–amplified
E6H4
4,4-bis
epithelial-compartment
GISTs.25
THRAP3
IFM99
tier-2
probe-level
K-RasG12V
anti-Stat1
βgal
1.01–1.42
0.426
coactivator-3
o\
5′‐CCTCCTACCTTGGCATTACA‐3′
gliosarcomas
S-cdk4
Epstein-Barr-encoded
//www.rcsb.org
24772
57/374
UCSC-hg19
ImProm-II™
F6.44
MY46
phenotypewhen
set-up
experiments18
Xq11
TP53-R273
Bourstyn
230-kb
adrenocorticotrophic
contrastenhanced
.Length
V247
GTP–Wat189
pCS2keap1ΔDGR
20-22
weak38
mutagenesis/expression
decross-linked
c.73G4C
NB11,13,14
Blimp
tolerance175
6317
MIR155HG
768–781
BAP1.81
71.4
5′-CACGCCAGCTTCGGA-
CAGGGCCTGCATAACATTTGCTGT
Tris-192
intestine.3
receptor6
obse
mesoderm…
DNA17
Flag-MLH1
8–amino
c.436C4A
9520
1.979
lineages23
alveolar
RUNX1a
47/57
R1192
transformation16
NfJ+1-
EC50MK
3866-3871
D285V
METamplification
growth-factor-receptor–bound
Glu14
CBFA2-mediated
Becton-Dickison
ITIITGTGAC
PDCD4
pyrrolidone-free
5′-GGA
TNFα+CD8+
Luminescence-based
.Free
BTG2–H-Ras
XT
.TM
chymotrypsin-like
CP74
p21–p22
IGKV3-20
UbcH5s
MLH3-Hsap
C/G
1A7X
1/96
TopoIIαS1524A
5′-GAGCAAGTTCACAGAGGACCCC-3′
1586T
.Xrcc2+/−
S5N
dwarfism43
Dimerization—The
FANCCcDNAs
procaspase-9
Nitrocellulose
Anti-S100
Dikovskaya
Wanzel
0.290–5.613
FLT3-I867S
23.08
non-relapse
5′-gtacccctagggaca
5'-AGA
APOLD1
GerardBIOTECH
Gα12/13
RKTR
inhibitor-related
.Rucaparib-resistant
Toll/IL-1R
M537
10-20
Ouweland
kinases.20
pcDNA3-
Bennasroune
.Myristoylation
ETV6-PDGFRB-positive
p.Arg418Gly
Polyphen2
FoxO1–GFP
˜10
splicing.11
years,19
specu-
rearrangements.22,23
overslipped
2A–E
3a–f
MYC/MYCN
0.814
A1236P
organ-confined
MutationAssessor
10.1186/s40478-016-0331-6
B1A
Vlieghe
.Keap1C23Y
Asp855
oxidase-like
FormaPure
BRCA1–BRIP1–DNA
prostate,19,24
pPromoterLess–DsRed2
liver.42-45
ER/Golgi-located
HGF
5-bromo-2′-deoxyuridine
Two-Hit
polypyrimidine
pBTM116-STEll
ARshRNAa
IHES
.26G
NK-tert
p.Arg229Gln
U-HCT116
TKI-sensitising
hemicell
factors29
Leenaards
sc71064
D2S206
non-participating
Idelalisib
WT-receptors
S369-C605
Nrdp1
Vimercate
Msh2G162R/Δ
pMiw-Fgfr1K656E
2431
P169H
cohorts.10–12
adenylylation
pyodermatitis
**Experimental
.MEN2
N542–E543del
5′-hydroxyl
U55762
mutations/fusions
Gγ2
Apoptotic
Ser445
STAT5B-WT
MAP4K3–PRKCE
TCCGCAAGACTCACAGCA
activation110
g5
.Construct
leukemias9
co‐immunoprecipitation
c.4862_4880
alterations.Tumours
ImageMaster
11p12-p11.22
Q79-homologous
14qC1
UM.9
11818
GSK3-
D/Cdk4R24C
XP-F
Hogarty
Retardation
LR04-373*
9665
0.098WTSSF
nontransgenics
KLK2
K27M-H3.1
HSP90AB1
PNT2C2
P=0.676
CDKN2A/B48⇓-50
-ctcgcacgatgcaatgccaccagttcc
TGFBR2
@
1934–2517
β1,3-N-acetylglucosaminyltransferase
10th
BL6-Krasnat
p.N822
Geneclean
//www.bioinformatics.babraham.ac.uk/projects/fastqc/
C57BL6/129
TUNEL-negative
IVTT
phenotype.1
sc-8262
Philadelphia-chromosome-positive
G290A
245ÃŒ8Peptide-1
p.Leu536Gln
p21Cip1/CDKN1A
EGFP–DsRed
900-909
ITD1
extensionstep
previously.4,17,22
OHT-induced
W=tryptophan
P31L
AUF-1–triggered
MIUR—Fondazione
µg
CCT-pVHL
doi:10.1038/leu.2009.53
IEGFRtumors
0.820
2/Erk2
pFastBacHT
cases,23
GCCCCAGCTGCTCACCATCGCTA
c.3742G
to0.25
and22
MigR1-SRSF2WT
Liver-specific
HSC/HPC
ubiquitin-conjugates
enzymes/
21REV3
L624
5′-ACAGTGAATATTT-
cter
U87MG.WIEGFR
mTOR/S6K1/4E-BP1
.H6-Complementing
5′-AGAAGTCAGGACATGGCAGCGAAGCAGGTC-3′
Gly-Asp
Y237A
adriamycininduced
340–375—which
16_32dup
phospholipase-Cγ
0.1282
Therascreen
hydrogen-exchange
nilotinib.27
femalepatients
mice/mock
183.31
fluoride/1
GST‐G17A‐RhoA
GST-SH2
ab3501
Zeb2
.Ser32
Topo1-processed
4VI
G108R
p.Asn407Serfs*3
Freiss­
Capecitabine
p21Waf1
wtCCDC170
GGTCTAGCTACAGTGAAATCTCGATGGAG
type–dependent
S4I
methyl-accepting
BRD4-201
anti-Cox2
reported54
R196*
pS9/S22
FANCO
Salghetti
21KB
NGF-TrkA-MAPK
353-12
.9,10
tantamount
Spontaneously
q21-
anti-C-Nap1
.Repulsive
82–84
Ras-Raf-MAP-kinase
-GTCTCCTGTCTCCTACCATC-30
ontonitrocellulose
2.6049
14-3-3-bound
regional-specific
POSF2
gi57223235
H30A
373
c.368delA
Smad-independent
PD-033299
BglII-digested
L549P
myofibroma/tosis
loss-of-expression
D.d
Bonnefont‐Rousselot
326–333
re-generate
Ini-1
n53
WINAC
BRCT-M1775R.Green
.Revised
3132T
5′-CGGACATAGTCCAGGAGGGAGCCGAAGGGCATGAGC-3′
4700
1.13–
Ollila
Asn822His
SHCLNV
7F–I
repacking
L.M.
6021
collagen-coding
NETN420
transdu-
best-illustrated
S6K–T389
Adnane
24,500
phosphoRTK
.Inbred
Collado
min-var-freq=0.05
TUBA4A
L9
erythoid-cell
ccccattacgg3
S2H
dimerization29
rs121913420
2Clinical
FOXP1-ETV1
aflatoxin-B
EDTA-free
NP_001973.2
indi­
15/32
cross-react
59Â°C
microalveolar
anti-DDIT3
8.0±1.0
shown23
-fc-MG*â€¢
K55M
Jinks-Robertson
GGTGAG
tetracyclin
MCH
anti-Meca-32
done6
back-up
knocking-down
cells.10-12
antigen-induced
688M4
Iotsova
60-mer
smallerthan
GCATTTAG-3
tumors.28–32
Chuo-ku
DNAfragments
subjectivity
scrambled-control
PER-
lymphatic-blood
TKIs.9,20,21
afgLgk-EDavLkVAVKmLKstAh
94-fold
BIII-1
Pms2-null
CACO-2
Carlshad
otorhinolaryngology
S4E–G
domain17
.cel
ATTCIGG
Met-297–initiating
Silva-Arrieta
DNMT3B7-Eμ-Myc
derepression
kitDHand
L223P
al.10,11
Shelleck
p38/HOGMAPK
I994
CBLWT-expressing
I,8
Dynabead
_PDGFRA_
anorectal/vulvar/vaginal
bone-forming
BCORL1-mutated
∼
5Biii
photoreceptors
3utr
xThe
ligation-mediated
2320-2328
.LOH
P37173
.Parous
c.100G
evidence115
574–591
F\
hypervariability
receptorin
anti-cdk6
~2.2Mb
3LXR
C339R
deacylated
T7-2
DBH
E565
A1752Ab
BRCA1.21
1.274–17.372
de-repression
predisposition6,29
C315R
His-123
G235R
6828
hPMS2-134
KIN193
specificty
comorbid
lymphocyte–induced
IgM+IgD−
MyD88-deficient
≤80
β‐catenin
FLT3mf5
neuro-blastomas76
PR*
1902
antenna-like
Nalm
hypersegmented
1–14
AS160–4P
deletion/monosomy
WNT/β-CATENIN
S/T
ADCI
anti-pSmad3
V555_K558del
H-3401
clearly-defined
ASP3026-resistant
GSE22208
E40K/S124A/T450Ac
QUADRIC
79
FLAG-BACH1
768KB
.HSP70
1.0.29
uAsplysTyrGl
Neoplasia-derived
Erythropoiesis
Constructs—F9
Cys-242
Wei
.10A
chemical-genetic
Semiconfluent
RAS–B-RAF–MEK–ERK
2−ΔΔCq
mir-143
cancer.85,87,89,90
R1I
HR10/10
CFU-granulocyte/macrophage
avoidance36
–*
receptor/ErbB2/vascular
ofuntreated
TACAAACTAACTGCC*AAGCTtAGCAAGACT
SMN1
pEAA58
46/49
IL-12R
p.Arg905Gln
q22.1
SwissDock
151623
-AGCGACGCGTGGAGCTTCGGCGTGGT-3
1.264
JapaneseResearch
//www.lifetechnologies.com/lifescope
300-
ferase
melanocytes21,22
HEL/CEL
PRKC
multiplex-ligation-dependent
co-localizing
BRAFN581S
GATTAGCAGCGGAACAAGGAGT
.We
Bloomfield
HEK-293E
anti-β-Actin
Bar-Peled
7654
coprimary
patritumab
mataphases
1172–1538
andstored
thecyclin
Sf9-baculovirus
—M
shown.D
STA-ET-2.1
.EGFR–RAD51
TEM8/VEGFR2-containing
nasogastric
hemoglobinopathies24
6p21.2
ligand-activatable
31P
104.1
169–172
EWSR1-ETV4
3-52
HDGC.1,2,16,24,27,28
5F–G
5′-CCCAGGCCACAGACTGACA-3′
532–554
.Assays-on-Demand
retroviralsequences
p.D820Y
cardiomyogenesis
V1269V
CD28‐B7
.00005
0.001565
ade2–101
1VYW
glycine-rich
avidin–biotin-complex
coactivator/histone
HumanHap300
Dihua
PC61-treated
pathway.18,26
glycerol/1
FLT3-Y842C–expressing
replication10
VP16–Mga
No./
lonomycin
Map3k1
ESBP-1
Pinkas-Kramarski
KlURA3-kanMX4
7/27
carriers.5,6
c.1907_1908del
Δ14
2F12
TCAGGCCCCACTTT
anity
−3.3
.Folylpolyglutamate
deafness.16
and18
HCC24-
penoscrotal
​ii
5−10−fold
BCR-ABL,9
S4C–4D
anti-erbB3
siRNA-DOPC
ΔC-RAF
≥1.3
transactivatewas
RCC4/pVHL
D24/L25
cholecystolithiasis
117–213
AmpErase®
non-progressing
5586
misteltoe
AAAACAAGCTGAGGGCATTG
NIH3TC
pRetro-puro
plbergsa
inhibition.In
Syk
5′-AACAAATTGGACTAATCGATACG-3′
-40.7
GATA3-truncation
al17*
90-minute
Aa-Ac
Hop62
Scanarray
1/44
A_51_P419226
out-of
CTTGGGTCTCCGTTCCTACAC
vagina.-'includes
Foxa2
SF3B1-
RAC1
methothelium
syndromes.78
n=2
cotreated
CAO
Applera-Applied
EY
POLN
50×
TP53
anAMBIS
immune-effector
AU1
Fos-luciferase
DOPC
95–115
8,245
TMEM242
U-to-G
c.2239C
Cytosol
Baculouiruses-A
Hs99999902_m1
93-94
surgery.15
CCTGAAACTGCTAAGAACCA
Wako
beta-actin
performic
p27T187
3.418
19-fold
PK3CA
Asangani
I744T
levels-1
MET-dependent
MIS
TTCATTTGGTAGGCTTGAGTTTGA
gene1
77A
lossc
tggtctatcctgtactyaccacaacaa
Tensin-1
Steady-Glo
.CXCL5
31-5
U2AF1MUT
SAOS2
normal/WT
19q13.33
sarcoma-related
12,500
K721A
prerunning
Multi-targeted
Skudlinski
2.3–7.1
50:1
monoxide
acylglycerol
L237fs
MBT
pi6
RFS-MycWT
5-bromo-4-chloro-3-indoyl-β-Dgalactopyranoside
AAG-39
6/15
817–823
NHGRI-IRB-approved
fusion5
Myd88L265P
drugs175
Vpx-SAMHD1
IDA-MS
17/29
medium/Ham
marker.https
Tyr1356
Figure3A,3A
sensitivity-causing
c.2570G
.MUC1
N-2-hydroethylpiperazine-N'-2-ethanesulfonic
35.1
p36p34
G284
BamHl-digested
TGAATG
GnRH-II
5′-GCCTTGACCTTTTCAGCAA-3′
iscompletely
AV-S
escin
013
KYM
NCT01576666
LAN-2
Stoichiometric
69500
FNB2
promoter–pGL4.10
CMV-EF1
DDR16
A326T
DOV13
82.7
SC-5284
acidsof
lymphomagenesis
M552__W557del
value.4,14,15
.MG
Ras-CDC25
MutSbWT
R1234086
C→T/G→A
−2.81
mutations/deletions
IETD-pNA
rs35602083
476-fold
R383C
unprecedented
ex2
–RARA
progression.17
6239
7O
K120M
kin–cohort
62:334–345
anti-phospho-IKKalpha
MEF2D
reagentsHEK293T
leukemia.7,8
Amarante-Mendes
A23S
S10-11
I204T
NF-KB
CBF-1/RBP-Jk/KBF2
fluorescence-assorted
ICR2
Δ291–300
Linker-mediated
Tregs
kinases186
7.21
CAGCAATCACAGAAGCCGAC
M1652I
c.349A4G
cell‑lines
BC/OC-associated
Arg103−Asp108
MTCP1WT/Cdkn1b
SHH-positive
cancer123
Hutter,1,2
junctions.bed
mCdk6-Forward
serine‐arginine
clinically-observed
PTPN14
Oguchi
Gst-Mek-1
Landspitali
HRDLAARNCLVSEKQYGSCSRVVKI
approx10
3/83
S79C
ERα−
G12V
3821
pH=6.5
ETO1-like
non-induction
chromosome17q11.2
Long-range
3,101
54.1-259
40/46
445–460
.900
7SL_F-
∼4-bp
escape4,5,8–10
TGCAGGCTCCCAGAAGATTTATG-3′
.Cell-specific
deterministic
Daunorubicine
1244_7delACAG
0.343
charge-charge
pCAGGATCTGTAGCCAGGCACATTGTAGAAGGTGGACCTGATTATGGAGGG
3-tiered
nm_002755
32P-labeledprimer
transglutamination
malnutrition
505–676
Men1F
18.0–47.0
GSM459011
spleen.15
ligand.31,34
GβL
0.1–400
0–30/50
thought.25
SF3B1-coding
Sf21
NPOS
5'-ATCATGCACCTTTGCGTGAG-3
BrdU-pulse-labeling
654-bp
cancer–normal
METΔ15
RP11-269F11
0.2–7.6
PAK1-driven
cancer13,19
2386–2390
algorithm31
0.8G0.1
intracentral
mice/S291fs
1timesSSC
A_52_P301591
±1.9
cycle17
18O
KRKKFK
B1–2
Pericytes
Michelin
WWP1-mediated
CD44+
.Expert
anchoragedependent
auto-phosphorylate
suggested,40
p.Y118Ifs*45
software.6
tccctgctgtctcgatcctc
Rdh54/Tid1
20.33
CHD7
pThr202/pTyr204
//www.broadinstitute.org/cancer/software/genepattern/
sFig
6.5Kb-
1-4
anti-pSrc
M412T
Stratagene
I66
J.-i
Y856H
8714
population.34,35
1126
-pyrazolo-d-3,4-pyrimidine
GGTCT
MGB
RNAseq
Yau
.∗p
cases23–25
MSCV-BCR-ABL-IRES-GFP
MMTV-HER2.rtTA
TALEN
.Conclusions/Significance
HindIII-HaeII
hypermutability
factors—is
S192P
p53flox/+
Ohio.25
Met-ubiquitin
myelomonoblasts
ast
PTM
A087
2012/Kiuru
46/47
.Detected
RXRs/Cyclin
sorafenib10
YUSIT1-resistant
-rIPVKW
receptor-containing
protein–stripping
45–
mal-absorption
controls18
sc-154
L485-P490–deleted
≥3.0
replated
Lev
neoplasms.31
.Cell-cell
BglII-SalI
F1263del
neurons21
Gal1
Q130P
NMP/PEG400
Hua-Yan
8395
measureable
7L
anti-CD45
MSIH
Half-maximal
V2109I
II-β
.CLINICAL
YWHAE-NUTM2A
Rebiopsy
IFN-family
63/70
A406T
OK10
M918V
EPITOMICS
rs725344
COOT,25
Ser647
253J-KD
SIRPα
ProgRes®
4/289
residuals.41,42,44
NM_008416
H423
D177Y
.PDK1
anaerobic
Lys→Glu
anti-histidine
-enantiomers
YFP
nonsense,18
75,352/4181
angiopoietin
5-6.6
ASP-PCR-DNA-FLA.
5′SS-AON
6.1126
0/620
NB1+
SLC6A6
lymphocyte-derived
Rotamer
beta-galactosyl
www.vai.org
9:23:42
41/33
superbinders
PARP-cleavage
Arg995
.PEEHL3
c.2579C
L485
re-challenge
c.3572C
patient.PowerPoint
T-p53C-R273H
1.771
p21s
.SMC1
71.9
-globin
results.33,34
wasdeleted
trithorax-Group
Mdr1a/b−/−
murineleukemia
IKZF3
Tsuda
P47A
H19/Igf2
∼1.6
multi-domain
0.82–24.5
OneTouch
immunohistochemistry.1
sequencingfor
ofCEP110
5′-CGGTGAGAGACTCCACACAGCG
Non-ADC
2064
Transfecting
.moderate
PBRM1-expressing
cell-by-cell
Runx1–/–
.Pyrosequencing
SPRED2
XXY
85.3
spoFig
ARV
Pittoni
I1173F
fluo-labeled
top-down
TRAIL-R2
imadazobenzothiazole
estrogen19
teething
three-tandem
IRS-
HA-Flag-KDM5C
10.1158
RA45M
205345_at
inidiation
PNKD
Figure5F
.1Aurora
nonsilencing
HA-BRAF
.IPA
MSH6-S144I
Ser-383
5'-CAAT
BRCA2-FL
TET2-wildtype
ATCC-recommended
ERM/ETV5
CRAF-MEK1
VHLJade-1
koff/kon
B7.2
48019
Variation_37296
.Somaticmutations
S7–S8
llyzcd
AQ-DNA
stage-defined
gene.74
kinase.13,14
aPF-02341066
NaHCO3
Evidence-based
+T
Serum-deprived
.HISTORICAL
Lys+
Harir
NotI/DpnII
Shp2-evoked
Shinomiya
MSH2-Y165D
HPRD
L866M
S7PY
CRAF15,25
iss.it
RP11-433C10
9p23-24
CasesKIT
SP1
8·2–19·4
Fernandez-del
1164
T1131A
15-min
reported.36
5,696
uvrD
KIT/559
NFl-encoded
Histology/grade
NpCpG
reported.7,8
shCon
c.571+64C
tumou
Y568
post-MDS
60p
xanthoastrocytoma
E861
Frat2
Ikkβ
Y469D
N-His6-p110β
Tsafrif
c.506T
.HCC827-GR
-9,11q+,12p+
MDAMB435S
738del4‡
BC4A4
p.V344G
eight-nucleotide
KRASP34L
hamartin–hamartin
alprazolam
CQOCCTOO
c.1524_1525insTACTTTGCATTT
7729
FLT3-WT/CBL-70Z
L104
98.2∗
PTPRD/J/K/M/O/S/T
2.90
Transactivated
BRCA1Germline
Tumor-rupture
cloned.33
MOX2
L350
.ELECTROPHORETIC
IDEAL-1
inhibitors.47
.Fifty
context-
lines,17
G5T
5-Fluorescein
PDGRFB
meladent
repopulated
GGTTTAATGCTGTTCATACGTTTGTAAATTTCTCGATACTCAGCTGCCTGCTTC
interaction.The
2VJ3
Figue
CBL-dependent
Hsp70-binding
Chromofy™
10.1530
HIS3gene
Appin
SCH66336-treated
3.0
hsp16
Hprt1
//www.broadinstitute.org/cancer/software/GENE-E/
percent.13-15
HER39
BMMCs
877-CURELAM
NP-40extract
113807
v4.3.1
Salerno
polyacryl-amide
S1986F
pET-22b
TTATTCACAGTGGCCATCCC
.Insect
NPHS12
.TBL1XR1-shRNA
Thrombocythemia
pBI-p21
blue-white
4CNRS
defectin
D2–p27
Fig.33C
TAT-
11C-205
GSK-3/3
J.Y
0.2–37.5
aBlank
.Zebisch
T6211M
rapid-freeze
Bioproducts
Glu768
M2rtTA
rules-based
anti-SOS1
superpools
LeggeÂ
17.1698
G129Q
dia-
11p12
55–57
11118.1
Y585
Mutagenised
//blocks.fhcrc.org/sift/SIFT.html
Chk2
myc+/+
alpha-melanocyte
nonlymphoblastic
H1650
Akt-TOR
-GM
T6B2
phospho-histone
Y09028
interactwith
Ristic
Komolgrov
52K
G375fsdelG
10.1007/s10689-011-9443-0
10.1172/JCI35930DS1
TOP10
protocols.12
OTII
TCGACCTTGCCTGGACTTGCCTGGCCTTGCCTTTTTCGA
mo/50th
Kar2
Asn26
GTPases2
23,41,42
H773
B.V.
.Deletionscanbe
KOPTK
140
02-
PAA
Phospho-Array
MSH2open
326V
C275
Xalkori/PF-02341066
R1275Q-expressing
-ACT
CSNK2B
AGTGGGGGACAAGGTT-3
5′-TCGACAGTCAGCCGCATCTT-3′
AF4-MLL
Malmö
PacI
Conc.
tMDS/tAML
Ras/Rap/glutathione
119.8
Adenoma
wt-kinase
.ATR/FRP-1
82-bp
axon
Anti-GAPDH
pMMP-FAF
Conolly
OVA
c.1333_1334delAG
immunotypes
0.15
wastebasket
trP1-Exon21R
MHC
c-IAP1/HIAP-2
564-bp
Deposition—The
T653S
L63V-transformed
p.Ala530
vitro-expression
KYSE170
SOXN
F251L
62-63
recovesin
41°C
3-5-5-5
ctgttttag
SNP_A-1844880
2ERE-pS2
.Vojtesek
TPGS
difference—were
vitro‑translated
GAL4-firefly
TCGA-A5-A1OF
types3
reimmunoprecipitated
HCC02-0310
2×101
Cancer-Associated
BAF250b
–0.694
S16A
antibody-induced
3008
TCGA-76-4925
leukemia15
LEOPARD-associated
chromatin-regulating
K4001
Hippo–YAP
Asp230Asn
ramucirumab.6
RV1000G1
.Met1166
1,587
Malay
pcDNA3.1_hygro
Cdk4+/R24C
SA499
G156D
ASI
VCAN
MC3
carboxyl-
Bradeen
orifices,4
3.1/NA
872A
*31
Administraion
5–
Mcm8
mu1577R
cohorts..
probabilityb
Plasmocin
BRF2-ZsGreen
CD8-depleted
tissue-dependent
Fig.9C
L343Q
al.2
stress15
c.6405_6409del5
Aml1
AQL-13C2D2-iodoacetamide
Thangavel
CD25-positive
NM_030621.2
min+20
1:3500
TopGal
phenotype49
39-0264488363
1.1:1
TPM1–ALK
–ERG
8†
Scolnick
986-fold
chylotholax
p13CDKN2a/b
SNU-1033
WM793
AGTCCAACGGGTCTCAAGTG
uterine/endometrial
cells62
gefitinb
2311
OX40-competent
LDB1
RAC1T17N
anti-CD32
Wellbrook
CA94503
study16demonstrated
uninducible
p.N308D
3.35
186.40
CHP
NM_181504.2
survivin.39
Adoptive
.Kras
Sigma-Proligo
FANCC-HA
Chemopreventive
chemoluminescence
Tschan
4609
NHA9-
/flox
ERBB2-like
Brca1+/−Trp53+/−
u/.5
p-interaction=0.27
D17S579
membrane-impermeable
MMPH
GAP-activated
VEGF-targeted
Single-agent
DNAfragment
VEGFR2
R2505P
FGF-9
ΔEGF
19–22,24
NCT01379534
EGR2-nonmutated
1–117
al3
UV-light-induced
ß-catenin
847,000*
BCL2-dependent
candidate-gene
07-369
1.14
4390824
manner.7
ZASC1
CFC9
5′-TCACGGAACTTTGGGCGACTATCT-3′
LGQGsFGmVYeGvakgVVk-DEpetrVAIKtVnEaASmreRi
Disease-risk
NUP98-NSD1junction
leukocidin-positive
KRAS-targeted
transcription/protein
Bogen
R1276Q
development,18
1,257
MYCN/ALKF1174L
loss/low
14.21
2033
thermotherapy
K125E
anti-GLI2
protein-A/G
RP11-927h16
Hu-244A
2,5,9
carrya
.SU5614
CTTCCGTTAACCACATCTTCTCTGACTTCAA
neurofibromin-deficient
Allografted
clarified.27
MnCl2
Complete-Responders
4-OHT-dependent
R335
DBP
25–28
Merendino
leukaemia-specific
1298-2190
.Davison
kinesin-1-
L1433R
Rueil-Malmaison
HRP-linked
IFITM1-transfected
Myc-activated
CTLA4/B7
ninhydrin
Non-polyposis
pentagastrin-stimulated
868596
W163R
//www.asterand.com/Asterand/human_tissues/149PT.htm
AP-1
a~ailable.~~
.HPRC
24—81
High-Yield
33327–33337
I-Script
GST-rheb
non-globular
Bcl3-deficient
204–206
anti–c-Cbl
7406
HLA-DRB5*0108N
c.8662C
.Pratt
I833T
Glu391
acutepancreatitis
R3052Q
D-65476
best-characterized
coupledwith
K751M
Asp770_Asn771insAsnProGly,26
2.1M
patients2,3
0002
5149
Neurodevelopment
pEAA303
N=24
non-transduced
antiporter
E258K
744832
Lys-550
Lymphomes
Biosystems/Ambion
26.52
Roopra
crystallographic
probewith
NKTCLs6,7
Fabiani,2
R2326L
pE3-III
therecombinant
A-I
-E453A
Folkman
19,196
lotfk
USP27X
-AAGGAACCTGAAGGGGCATG-3
RAGA/BGTP
I185
.PET
Titer-Glo®
analysis,11
5′‐TGGGGCCTGGGC/5′‐TATTCGTCCACAAAG
W251C
19,000
codingsequence
Co19
Edgren
Q59L
msh2-VD862p
hematopoiesis.17
5-bromo-4-chloro-3-indolylb-D-galactoside
blastoma-like
MML-1
Hermsen
vector-encoding
-HindIII
Kieser
V600E/K
Phosphatidylserine
nidulans
PIP2
ATR+/+
RUNX1-ZFPM2
periarteriolar
18–87
double-induction
gene.FO-I
8226
STAT5.27
Lef/Tcf
Tyr129
receptor,31
non-random
B-II-1
Thr1025
Bog
FBXW1
Ras‐GTP
Expression—The
-TQGRELERPRACPPEVYAI
pY371
tyri
region−7.5KLK8Kallikrein
E749
h.u-tokyo.ac.jp
promoter41
V.2.0
pGL
disaccharidase
52/67
'.
splice-affecting
51–53
T-type
p300-
.1C
metacarpophalangeal
BRCA1-linked
68C-7
248W
BRCA1p
dnaQ
tortuosity†
sequencing.3
p110α/β
N487
Ong7
35-Mbp
D300
G338E
growthinhibitory
β-fodrin
ABD/iSH2
CanN.Cg-Foxn1nu
.China
fusion-transcripts
LaGamba
R203X
R672G
ambiguous-looking
anti–phosphotyrosine
Miething
R-statistical
253–1535
tERK1/2
.Spodoptera
LUC–based
4/46
29,653,358delT
gene24
5–6-week-old
.Mdm2
32/27
.S6D
recommendations31
5′-GCCCCTTCCAGCTTCTCTAT-3′
5´-ACAGCTTACCTTTTTGTCTCTGG-3´
NF-Y,65
S909
splicing.12
non-targeting
Skapek
Lin-neg/c-Kit+
alreadydetected
terial
Avittam
pCMV4
HLA-A*010101var
atubulin
.Alu
21-44
thismutant
immunos-tains
40.39
R242H
o0.05
model.43,44
10.1007/s10637-011-9763-9
NLS3
µL/g
90,111,902
melano-mas1
D-recruitment
CHIP®
v.0.0.14
R332C
.Tumor-free
withHBSS
Arg749
ETV1-driven
pUASTDERKwt
t2Kt1
non-EGFR
*Variance
LCD1
5'-AAAGGATCCTCAGTCTGAGTCAGGCCCTTCTGT-3
adhesion-targeting
spironolactone
.AN-21
.Anti-AR
Edidin
32D/Flt3-ITD–injected
anti-PAR
helix-
Immobilon-p
C-MYCERT12
dysreglated
5'-gcagtcatgtttaatttttgattc-.V
immunohormonal
MSH2-Q690E
zinc-inducible
9Dna.lqâ€
GLIPR1
-5-trisphosphate
L.T.
606240
Husemann
-octane
Lynparza
Ipl1/A2
Immunoprecipitation—Cells
rs17337023
PKCβI
translocation-competent
0.874
K13T
VEGF-C/VEGF-D
~-scope
4/109
Tanikawa
Q81P
FOLFOX
II-encoded
284.3
FV-PTCs
NH4SO3
.Chip-on-chip
.Radiotherapy
20q11.23
double-binds
Pär
226.7
Abd
respectively.28
Forgacs
ELSTs
13.333
Leu-1780
c-kit-mutationnegative
transformation–related
Arg122Gln
genesets
14R1
development6,7
BGA
pIRES-TGFBR1-HA-Flag
alloquotted
mplifications
karyotypic
FMTC-mediated
MedChemexpress
16.73
5′-CAAACCAAAAACAAATCCCATATCCAACA-3′
3,458
G5236C
5415
Nonoguchi
724–732
Eferl
ENST00000242365
phospho-Y981
PRCCs
RANGAP-PVALB
Per-403
95th
580
pTRIPZ
determinant65
TXN1M0
3Identification
anti-occurrence
disease.73
α-p53
dicistronic
32Pi
Campina
interaction.41
GPHN
low-level
0.451
mol–1
purpuratus
CIYAVEAS
Nenutil
TSC2GAP-Assisted
17,21
SUM44
metastaseswith
G634R
325–648
bis-amides
LyT
−8.92
Apert-like
cancers.26,28
MAGI1
development.27
domain–deficient
substitutions9
71-24
N-acetyl-transferase
2q37.1
Δ8–10
Palanisamy
opening/closing
S121Y
Ponatinib-RIPK2
GnRHR-induced
800-656-7625
EGI1
T721M
35Codon
1652
01XNA
Matje
isoleucine-for-valine
Myc-tagged
knock-downs
preparation.28
His6-Fbw7
p.W342X
dependence.All
714–26
TGGCTCATTCATAGGATATAAAAAGAAACCTCAAGATGTGGATTT
p.E102D
proteins.thumbnail
3/197
.Jones
157-159
BRD4-inserted
5-Chloro-2-deoxyuridine
A-Loop
pLP-LNCX.FLAG.p110α
F2108L
past.27,28
Serine/threonine-protein
CR2C
2Y1M
Ø
HuGeneFL
NanoDrop2000
G309E-expressing
unclear.5,6,36
Ras·mant-GppNHp
FL-stimulation
pathogenesis6
instance18
andexposure
1227
vitro137
HCC—which
MUT2
CMYC
Rapalog
TRCN0000033264
or–rarely–surgery
Macrophage–Tumor
Asia.16
EXEL-7647
bars/gray
hybridization-FISH
Race/ethnicity
0–300
wloxP
MutSα-G162R
sc-7966
loss–mediated
MSCVneo-MA9
ligand/9p24.1
Créteil
squamoproliferative
multivessel
7–48
Raf–mitogen-activated
complex,38
daunorubin
Izuma
p.Lys1777∗
BRAFQ257R/G596V
.Pulsing
20,27,31
ERα_BamHI_C
U-138MG
effects191
.Speci®cally
spliced-read
//prodes.toulouse.inra.fr/multalin
endoderma
cancer,35
used.57
N=5
MPCBcl2
TsuPR1
.61
Pdk1
5-fluorouracil-containing
5′-ATCGATATCTCATGCTCCAATAAATTC-3′
RG-29
4º
Bhatia-Gaur
LRRK2
19125105
risk.7
S_HBV
Trp1007X
1953
P-0004920-T01-IM5
successful6
BTBD3
3,28
temperature-stable
risks.22
3875dei4
CCACAT
cys181
simultaneousloss
myo
pull‑down
.H3G
11.3
T798I
CHEK2.35
assays,1X105
pEFBos-puro
Akt/mTOR
4–143
188A17
N468S
Zytovision
0.97
0.597
re-pelleted
.Conflicts
27.53
.Seventy-three
R472K
SLFN11
adaptors/molecules
COLO720E
102K
c-myctransfected
.BT-474
//doi.org/10.1371/journal.pone.0019059.t002Gene
Mdf-15
p.R367Q
HD1
CCGCTCGAGCGGTCACTTGTGGCCCAGGTATGC
12434
25-35
P=0.0001
rs9901455
FLT3ITD
K29
H3K9/14
resultsof
OGT1
0.291
one-tailed
survival.7⇓-9
493_870del
NCT02075840
Smad3-FLAG
NIH3T3-transformed
knockout
f/72
Ras/shp53
activityin
–86
5'AGTGTGTCCACCGTGATCTG
.P
TKO/wt
B-Rafwt–Myc
Polycarbonate
Notch1-selective
proteins*
chromosome-integrated
.While
pileup
TSA/SAHA
5′-TTCCTGAAGGTGATAGCGGTG-3′
viscosity
pRB17
1534
Q=1.4×10−4
patients.The
Immolase
*P≤0.0024
\.A
.Teratoma
alsoact
N-methylenebisacrylamide-Tris
T17
Δ550
SRYand
Leu902
1,401
IL-6-STAT3
G130V
Phylop=1.000
pUL9
120.0
EWSR1–1024F/YY1–1452R
pTSAd-fe_p53wt
609279
30-base
p53-expression
Gravendeel
DNAJC1
/BCL2
RUNX2***
FIP1L1-F5
hepatoblastoma
14/355
tissue/biopsy/cell
determined.31
system.4
Sergina
W71R
.218
electrochemiluminescence
restrictedto
S217A
μ-Dish
chains.45
c.97A4C
patients,5,14-16
Discontinuing
.p53–274Phe
BRAFG596V
5′-CCAAAGCACAGTGAAAGATCA-3′
85°C
R1050Q
enriched-PCR
NECD
GLP
6-diaminido-2-phenylindole
DNMT3A-mutated
4931
Kmt2
RP11-430C7
1250
conformationdependent
Pro531
diagnosis.6,7
endogenousperoxidase
pCMV2-Flag-Brd4
p110α-G364R
1×106
IL-3-dpendent
3b–e
n=164
foci.13
Gαs-coupled
25.94
1107–1130
mode-by-mode
pre-operatively
20.59
BRCA1-
Gal4
−.84
N75
Melanomais
L792L
CTCT-OV01
stability.36
1072–1080Buonamici
Figure6G,6G
STK1591A
.Systematic
0.0093
DNaseI-treated
NADPH
rearrangedNTRK1
GGCTTTCACCATCCTCTTCC
TTTTGGGCCCATTTAAGACGTTC
double‑blinded
polyadenosine
X807C
GCAAGAGUACGUUUAUCAAUU
TEL-Jak1
Cockcroft
mucosa73
BiBr44-58
9A–E
W2725
Ins10/E37G
50,000-fold
TGF-β/activin/nodal
FL-CDB3-induced
AML,9
4DYM
R269H
20/71
six-hormone
Sidow51
hours110
transcription53
pCMV-3xFlag
TβR-I/Tβ
446-residue
assay.74
shCTL-
0.7–2.6
603645
3delA
IgA-
cases.RESULTSDetection
5′-AAGGATTGGGGTTGTTCATCATTCC-3′
.Groups
..I
ani-
1-cm
XPF-deficient
ALK-TKIs
/APETALA2
ATGATG/gtatag
11.41
Lasagna-Reeves
.Genomewide
C5677A/G
Mm00436960_m1
ipl1-1
59-AATTCCCGGGGATCCGTCGACCTGCAGCCAAGCT-39
GC–MS
monophosphate-sialic
BafF3
CD150-biotin
KRAS-wild-type/XPO1-inhibitor-sensitive
5′-GCCTGCGACGGCGGCATCTGC
1.8-kb
2.9b
2G–I
paragangliomas.20
/E
progression.Several
nucleotide-associated
.755C
AR-v7
thyrodectomy
G395A-F
WT1–CBP
aminoactinomycin
9.7–30.0
Martinez-Garcia
moAb-based
2002–2004
4-3
G4i8
tumor.22
domain.46
14-3-3–mediated
Cité
​Mechanistically
Aml1-Eto
CTG–CTC
pASZ11GPD
roundedclusters
RP11–17C4
0.5-1.0
307–428
CH308
Tyr580
.Backbones
18Laboratory
Enhancer-associated
cycledependent
self-quenching
NB15
MECA
coverslipswere
thrombocythemia.75
191092
6822
B41
immobilon
4-OHT
up-dated
FISH+
Singeltary
Matzke
WCL
ITC
GPI-80
antimetabolites
CDKN1BIn
years.9,10
anagrelide
Pavey
EWSR1–RACE.52
CAF11
Xq13
anti-phospho-Tyr-653/Tyr-654
homo-tetramer
well-demonstrated
tcatggaagagatctgcttcccgcgcacg
pNF
radioresistance125
GCGC
N-glycosylation-dependent.A
IκBα–
phosphorylation-
T843A
GRENLYF
39-3/4
62-fold
MPCEWS-FLI-1-T1
46,463
A334V
SpliceSiteFinder
cytopathologic
17–45
0567
transcativation
U82828
MEAF6
extracellularly
Hydrocephalus
n.a
cycle-inhibitory
Cys-177
145–510
Asp60
trkB
L594F
adaptation19
RASGRF1
ttttaacag
5′-CTACCGAGCTACTGCGCCAGAAGATCAG-3′
SPOP-regulated
560–567
F6
Q1291H
1/31
PIK3CA-mutation
pRSV-,3-gal
Leu861Pro
/mixed
Kotzer
0/29
MLL–AF9
▴
angiomyxoma
observed.23,26
goosecoid
000/cell
instandard
CACATTTCAGCAACAGC
Ni21-NTA-agarose
v-ki-Ras
Emu-CCND1
LacZ29
//bioinf.uta.fi/PON-MMR/
cases.8,9
Loss-of
Ki/t
1,685
//www.ncbi.nlm.nih.gov/mapview
NCT01700582
SOX17cDNA
CD44HICD122HI
Oncogenesis
5,19
0.827
mesothelioma-specific
5'-ACAAGAACTCACTTCCTGACTC-3
:HIS3
􀁇
Y144*
www.genome.jp
12-O-­tetradecanoylphorbol-13-acetate
mouse35
H215R
–Dox
4Â°Cuntil
Dantuma
3–base
Kingdom40
.Monitoring
Studies—The
Smad-3
.ARAF
5'-TTCTCAGGACTCCTACAGGA-3'/5'-GATTTAGTATTATTTATGGC-3
pGEX-4t-3–based
rsquo
well-chosen
SF-295
anti-phospho-p38
9.5-fold
ACA39
.VE23.6
M59
FLAG-epitope
tadpole
Protein-Binding
HumanOmni5
p.A77S/T
1.00–1.99
.Double-stain
PTPRT-
precycled
Thr-380
pink-to-red
AML1,2
Af9–loxP
CH5424802/RO5424802
tumorigenesis,31
therapy.26
Creteil
Q.Z
androgendependentproliferation
adenocarcinoma21
double-headed
immunerelated
Kalitsis
Val654Ala
GLFG-2
RAD51D-selective
17/22.1
Y845F
c.7235G
-Akt-ribosomal
.Friboulet
biegel
Opacity
EMR8-5
EPHB1
3XHA-GATA-3
NZM63
LOC100507498
localization.22
002755
n=1447
CDH11.CGH
13q12.2
pASZ11-TRX1
105,998,201
Autosomic
–10.5
Subread
.Uninjected
AGGCAAGATGAGCGAGGCGTTG
vector.The
Non-Radioactive
.Haplotypes
Grm-1
defects4
Gly719Ala/Ser720Phe
CEP-751
anti–total-AKT
pUHD10-3
Bright–Glo
2.0HT
acetoxymethyl
leukocyte-free
Lajeunie
St-Louis
polarised
neu­
b11
.Authors
MCPH4
domain-EGFP
SU5402-treated
a2b/2
340–400
Grumont
.Microtubules
I22F
20°C
0022-1554/05/
23.9/13.4
R261W
γ-irradiated
Perilongo
chikashi
Ras·mant-GDP
F1–R1
L539S
other,37-39
39-42
ERF-1
K166T
reauthentication
Fbxw2
C428G
Clinico-pathologic
127/132
WO/2012/142504
C-T
CIC-rearranged
virus.3
11·9
.A.
populations9
KSS
1.3–1.8
MEIS1
6F-G
app=TFBS
0.00092
lymphocyte-extracted
tumors/
RG-29N
HEC-1B
immunoprecipitation
8.89
FLAG-Tagged
0006-291X/96
Myc-/-
intravascular
p.Val1561ArgfsX11
C77R
K-rasG12DSmad4+/–
tissue-derived
Q58del
0-959
EcoRV_DCCNB3
K1026E
p.G12D/c.35G
Sonenberg
A_51_P184886
autoregulatory
37C
NNsplice
Ex3
3333
nicotinohydrazide
11p14.3
AnnexinV-positive/PI-negative
MYO1E
GDC-0879–induced
.Lu
Mdmx
-80C
Gadd45b
1262
marker,41,42
783ins
82-90
fibro-cystic
​Figure6
2q
LC/ESI-MS.
3Unità
Bcl6
Leu63
PanNET
15NH−Hα
G328E*
5′-gaggtataaagggactcaag-3′
integrinmediated
phospho-site
.S4
RUNX1–encoding
T918
F1286S
foamy
molecule-regulated
excluded.32,33
deoxynucleotide
IL-9-selected
-AATGAGGTAAAAACGGAAGT-3
3ZP-1abe11ed
262–326
expression18,19
Å.
SI00754026
FITC-dUTP
T1031G
ab134100
ﬁlter
-VHPL
−4.79
5'-ATTATGGATCCCCTTCCACCAATATT-3
P=4.3
XPO-5
578del
31/70.5
IVS27TG24.8
7F-H
membrane‐proximal
function.14
Mre11-Rad50
S4.3b
G2645
SuperCurve
3B-3C
recA/RAD51
Phenol/Chloroform
tumoursb
63-3
0.078
Val464
S8b
DDp53–tagged
CAT-25
anti-APC2
GM‐CSF
.Appreciable
publications.2
radiation-hybrid
EGFRhad
copious
G10S
viability/proliferation
RUNX1–ETO53
0.35
18,401
0.1174
2cases
pGEX-NF1
proposed23
two-tier
.INF2
amidotransferase
475-
GreenMastermix
p42/p44MAPK
112–175
synergetically
p.H662Q
OGDH
PD3-D
Dicer1fl
imatinib37
Hoxa9/Meis1
ΔNRF
less-focused
E191A
Flag-tagged-Rheb-WT
2-mM
three-component
NZM41
15W
Icam
6221
lineage.21
chlorophenyl
Notch-inactivated
-84
14/47
neurons.3–5
anti–c-Myc
interchange.ubc.ca
mice23
cycloheximideresistant
72.1∗
EGR1-like
FlowTACS
SKMEL103
Hs00195664
waschosen
apoptosis182
MEK1-mutant
.ΔEGFR
NP0007
.MassaguÃ©
TP-STAT5b
system.22
S829fs
09-016
K-LISA
Bioregulatory
Pde7a
.Internalization
re-establishment
aa665–721
PKA-independent
AP1-luciferase
.SLC25A37
decarboxylates
Murgue
N647D
Jb2
-ACVR1
DRB1*04XX
sometranscriptional
crassa
atorvastatin
pmol/µg
degradation.2-4
QR2
.Endocr
phosphoinositides
L964-D1010
19.1–40.1
.13,37
Opin
GAGKS
RPL
ATRXt
druggability
VEGFR/PDGFR/FGFR
furin-like
0.25-2.5μM
bindingsite
c-MYC-Immunoglobulin
0.18
Go11lGDPA1F4-
G47E+WT
models50,51
200,000
D50
Koeffler
HeLacells
-12.6
ofpoly
demonstratedthat
DSapp
N-X-S/T
KIT-N822K
pHA-Ub
Group-specific
oligos
AA417665
Igκ-luc
α3-loop
51T
amino-acid-long
FGFR2–TACC3
12/35
af.
ACrepeats
40/47
//www.ebi.ac.uk/Tools/msa/clustalw2/
IDH2-EGFP
903
Randomisation
families.35
–labeled
delE746
regulationof
Fig.6A6A
N-terminal
Hydrophobicity
non-NSD3-amplified
neuroblastoma,17
Zhifeng
dnaAnalysis
Assays-On-Demand
R455Q
penis—carry
MPNs.12
self-antigen–stimulated
599G
coincidentally
PMN
68–72
GAPD
c.5630G
www.elsevier.com/locate/ybbrc
overides
107.3
GFP-AR-V7
.ERRFI1
pBluebacHis2
16,32
CRAFE478K
MdmX
4.99
1–40
distinct.As
mucusa
trimethylates
acc-3′
Gly-26
Ida
RhoA-actomyosin
FLT3mRNA-f
M239V
.Technological
3.8–21.1
sunilgosbabu
ETV6/TTL
RecB
Adenylyl
0.898
NPR3–NPR1
P291fsdelA
aligner50
thenucleotide
Msh6PR/+
FgfR1–FgfR3
6.0–6.3
Akt-1
p-galactosidase
NL-10
0.5–12.55
90,90,120°
BRAF/MEK/ERK
p≤0.010
p.G279F
wu116/wu117
1.003–4.425
Wüthrich
HLA-DRB1*08
phophorylate
Mutat
syn1729383
Bfl1/A1
cosubstrate
Myxoidt
.Fanc/Brca
c.4132G
face/body
44.01
.Autokinase
overlap-extension
.Morpholino
HCL/0.5
ProAspAl
paralogous
11Al•GluGlulysTyrSerGlnlysGluAsplysTyrGluGluGlulleLyslleleuThr
interactome
studies60
ATCCCCATGGCAAACTCTTG
PI3K–mTOR
foci-targeting
MCL—that
↓KDD
Long-lived
RPMI-2650
T.K
P694S
super-transactivating
amplifed
C653S
affinity‐labeling
GAGUUCAUCUGCACCUUUA
Jimbo
CCTCGCCGGAGCGTGCGGACTCTGCT
Cys4-His-Cys3
tissue.8
inexact
VANTVEER_BREAST_CANCER_METASTASIS_UP
61–120
-33P-ATP
.S2C
ISce1
33-46
models.50
4peaks.en.softonic.com
.Splenomegaly
SERGAS
'4
EGFinduced
D571
GAMDPEFRGA
6-mo-old
CASPASE-8
Q1
respectively53,54
E1286V
deletions7
4.09
L321F
aaCCn
/55°C
Neo-epitopes
.linear
TS-negative
cis-dimerization
p.P72R
htm
BRD-NUT
.WT
.Ambit
resource-intense
CD74–ROS-rearranged
phospho-tyrosine
NM_053056
members173
HTseq
codrivers
JNKp85α
.BRG1
BRAFT1799A
M/43
HCA/HCC
10/32
2494G
525/605
H23Y
17295
1.00inv
T/p.E134*
.Unique
GTP-hydrolysis
P=0.0003
Msh6G1137S
1179
MITF69
9433
RNA-Bee
-83
33-3900
R15G
nonsense—antisense
proliferation.9,20
patients,18
Yongjin
FLT3-WT/CBL-WT
trastuzumab-refractory
mmWw
M14400
Nu/nu
auto-phosphorylation36
gtatgaaag
anti–pEGFR-tyr992
ɛ
DOHH2
106
Bik
23,29
ERprimersusedfor
.Confocal
uracils
Lin–
GCCTCAGCTGCTTCTCTTGC
—In
3.573
W291C
mPMBL2
optics.31,32
14/135
N115K
Pmutfreq=P
otetsu
DSBs93
4.91
.Bright-®eld
K8+K14+K5−
www.fruitfly.org/seq_tools/splice.html
CFC79
0.491
facioscapulohumeral
orthotopically
S4G-K
embryo1
cl3
Pten+/-samples
571–576
NCOA4-RET
bio-molecular
Figure2a,2a
differentiation,33
Alox3e
11,500
EGFR-TKIs.4
H514R
blockade.90,91
PDGFRA-wild
5′-TCCATTCCACTGGGGAGTA
1599
filgastrim
.Pathogenicity
quasi-native
PEAK1-dependent
disulfide-bridged
Sniiiil2
di-methylated
K227
101–233
100–150-fold
15µm
assay.29
LexA-I107R
rvival
ESKD
4·1–12·4
XPO1–mediated
Q2
HA-vector
genesMutation
7,23
DIRAS3
transfectedwith
IVS8
MDS_228
Sia
concentration,30
GIBCO–Invitrogen
86.8
0.944
heteroduplex
aPKC
ribonucleoparticle
310-
Polyphred
R71
330.0
H210Q
Serpine-1
B-RafV600E/3x-transfected
Bharti
F114S
E-boxes,19
aftersomatic
MSH2*1906C
degradation33
TGTGGT
Pmin
3.97–9.59
GCAGCCCCAT
494,004
tunicamycin
c.289G
FLT3-ponatinib
liposarcomas.109
Margerie
Kirwan
hgfcDNAs
68K
/PAX8-PPARγ1
Tris-glycine
//coot.embl-heidelberg.de/SMART/
elsewhere.11
microcanonical
.HEL
levels.93
DN-JAK2
D-001206-13
CCAGCGTGGACAATGGCTAC
RUNX1//AML1
UK-wide
ΔQ
*50
27/24
T211I
CTBP1-binding
proteins97,103
postmenopausal
p50α-
p=3.8×10−8
β-hydroxybutyrate
TROMA3
BX51
Inparticular
'Tables
Flag-Tag
Sox17flox/+/Cdh5
C620S
LX
Leu694
glioma-associated
+192090
mesylate/STI571
Mt5
anti-CD10
BCR-targeted
.Expression-Based
meylomas.32
1.29
Hoffmann-La
G630V
PO4
3FFIGURE
8880
Boop12
45K-
HotMAPS
R2787H
Steroid
thymine/adenine
.CAMT
7841
Pro-191
.Brca1
recruitmentTo
Pam3CSK4
Asn387
naturally.22
FGFR-TACC
NMA
M+16
v6.7
DEB
S-transferasemitogen-activated
65C
GCTGCATGCACTGTCAGA*ATGTGGTCgACCATTGA
7a–c
−12.8
cl2
ERBB-2
8706
tumor-suppressor
12.9±2.7
S236F
R95G
p=0.0042
Sternlicht
TEL/ABL,9
I15L
maintenance,6
c.455-4T4A
.EFT
NKX2-1Cellular
gynaecologic
A_52_P404533
SQ/TQ
QTR
300bp
not.3
3/68
c-Met-BaF3
M0851
less-extensive
rs25487
R132V
abeneficial
.Fingerprints
anti–phospho-KIT
Titertek
TPR-MET-BaF3
BaF/3
mg/day.78
thioredoxin-null
co-solvent
co-Smad
∼1/3500
T/t
R503W
overactivate
R358*
phenytoin
P320f
Akt2
ElonginCB
HLA-DR+
Keap1ΔBTB
.SIFT
29:1765–1772
activity,7
GTGGCACGGTCTTCAGAGA
NFAT-driven
chimpanzee,23
89.1
chr5_g
heme-related
necrosis.24
3T3
C-type
dextrose
Merlin.4
how—if
14Aâ€¢
nGFP-FRTNeoFRT
1799-1801
pZiD
Geisleret
.Balmain
CD48−
adults10
MSR1
13/121
nSH2–helical
GST–TNS3–ABD
anti-mouse-conjugated
V187D
5747
caspase-8-silenced
Notch1-GAL4
65°C
Ninety-eight
}
5-carboxycytosine
pl2ORasGAP
R281T
seeMaterials
Nabeel
c.327^1G4A
Errico
38–63
Ekong.7
Hibshoosh
H123Q
.Fas
overall.14
rs12720356
androgendb.mcgill.ca
FR180204
CKTO
domain–disrupting
identity107
analysed.2
Rev-erbα
//string-db.org
Tel1
LEF-1/TCF
NC_000017.10
6–11–12–13–15
1018-to-tryptophan
tumorigenesis.10
1.01∼1.31
CTGCA
Huston
PLX4270
12/13/99
cells.One
Toronto-Sunnybrook
21,000,000
instability.Preferred
.Breslow
A498
lineages.52
Technical-Scientificcommittees
preconditioning
5′‐AAACGTTAGGTGTAAAAATGCAA‐3′
SCFFbw7complex
KMT2
Ser768Ile+Leu858Arg
6.02b90
report16
AKT1—an
DFQLRSF
250,000/μl
1–304
Lin−c-kit+Sca-1+
MIP-WT
Subcellular
A375P
MYD88WT
.Deglycosylation
interferon-α
S31
874
MK-2206
H3K27-dimethyl
XhoVEcoRI
NK-mediated
yValIVa
AGACAATAAAAGGCAGCTTGGACGAC
Asp57
receptor-K
AXIS-SHIELD
p.Ala96Pro
13057–13062
4661S
MOZ-3278
XP_421965.2
2.28–2.20
-cre
s_at
//www.genomatix.de/
.Original
incrementally
3920
K242
K-S.
37/46
r2004
604
353–360
ACINAR28
REA
LADCOther
JAK2V617F
PEST-Substitution
.Thiazolidinedione
.Red
nihms646437f9.jpg
V1180L-
endonuclease-induced
chromosome18
CO2/95
cotransformation
M742
L574
0.547
BA-1000
41–190
RET-fusion-positive
lowsalt
S4.Mutations
−5.59
//archive.uwcm.ac.uk/uwcm/mg/hgmd0.html
Cu4
actin—residues
tumour-normal
preproB
FLIP-S
GST-BARD1
5-fluorouracil
presynaptically
anti-atypical
Aprelikova
COOHterminal
15.35
.Nontarget
cells.48,68
MDS_328
/Leu
Integrin
P327H
-CTTCAGCCGTTACGCTCGGTTCAAGAGACCGAGCGTAACGGCTGAAGTTTTTGGGCC
sequence42
13cases
oxalate-treated
pFB
5'-TGGCAGTAGGTGGAGTAGAGAG-3
MYCN-dependent
D7S2847
C242F
Co-Associated
SHIP.33,61
c.734A
tumor.9
ESC-derived
Grb2,31
Massoll
sg/ml
JÃ‰
564—which
rope-like
K270
1239
enzyme-Lys-NH3
5.7-24.6
UCH-like
c.1632
TMPRSS2–ERG-associated
ab59357
Step-down
ACAAGAAGTGGAAGGCTTAG
JQ778218
1806_1809delAAAG
30μg
cMyc
T681I
VP16-TFAP2A
-end
.Thr790Met
OS-derived
Suggestive
NM_002755.2
cc-11-4059-g4
DD-PIK3CA
c-kit.22
hyperleucocytosis
FARAGE
A6
N-terminal–specific
HCC30
Single-base-pair
Koepp
.HA-Hdmx-E
Bioclear
Borrmanntype
XFGFR1
V2.0
9µm
bruce.gelb
AGACAAGAGGATGGCTAGG-3′
R2182C
microprecipitated
Anti-nestin
101732303
indentified
importation
Bibbins
ETS-2
R162W
2504
S1P
c.3927_3931
homology2
Arias-Romero
Olafsdottir17
Anti-B220
regulator-associated
G863A
activation.18
.ECM/BM
phospho-
A314V
33.35
TCCSUP
//www.ncbi.nlm.nih.gov/entrez/query.fcgi
deletion-specific
//tcga-data.nci.nih.gov/tcga/
structures/hairpins
Doraville
.Coiled
Hollenhorst
A21
medulloblastoma6-9
10.7.7.1
Src–overexpressing
QVN3031L
FacsCalibur
0.0462
P=0.040
Ras-GTPase-activating
35–50
25–73
E21Q
,134
VRK1
ERQIELFVKYMN
Cdkn2c−/−
−.4
Espina
STAT-mediated
3,4,16,18,20,21
.Demographics
Anti-total
CDK4-MUT7
Spliceosomal
3.FIG
Msh2p-Msh6pcould
G361V
61R
0.327713863
e–g
14746
singhealth.com.sg
0/101
1:250,000
macaque
Fanca
Y431H
ultra-bright
F39L
R885A
P278L
5′-CTACACACCCCTAATTTTAAAC-3′
31.8–32
pMT9
12p11.23
0.245
LNCaP-abl
Nhp2p
G1139S
7—10
VEGF-driven
.LumA
N71
phosphoamino
.IPMN
Blaschke
hyperactivatable
243700
RGC
388-bp
majoritie
n=230
011202
B7‐H1
Antiapoptosis
R88Q
15/96
response44
Ser220
mGPF-H-rasG12V
Rip1E-cad
life/death
Starinsky-Elbaz
Semisynthetic
Schaap
MAC-1
M1616L
.Fifthly
H00003845
T661
disease-driving
|indicated
Fbxw7-deficient
previously.20
26,27,28,29
c.2637G
.Long-distance
SfiI-EcoRV
CTTGTGTCTTAGGCTGTAC
2992-2995delAAGA
Three-dimensional
​and4B
Yunis
//www.ensembl.org/
Ser446
65.11-fold
V304M
AA124105
Cirmena
PGBM26
survival.2,3
ALKF1174L
LCB
Adh1
c.3591_3626del6insAA
wiley.com/humanmutation
MTHFR
26–58
W-III-10
Apo2L
complex—decreases
KA1122
XP1lBE
CSD
TGGGAAGCAG-3′
Raf-Ras
2564
delE709-T710insD
CK2b
Immunocal
hsa-miR-15a
molecules/pathways
somato-visceral
Representational
59–60
non-polyp
1379
Calreticulin
Inayoshi
S72P
1q21-22
Goepfert
IRAK1/2
kinase-containing
keio.jp
HD-0233
.Morevoer
C–D
-CCTCCAATGGATCCTCGTTA-3
retransformedinto
A4512T/ATA-+CTA
MYCN-directed
Δ3270–3418
S.GNAS
infeasible
B-acute
799delTT
Try557_Lys558
_47919-
103.3
~480
1H-GraphicN
.Scr
pathogenic.10
4060L
taq
PDE
P.L747FS
TSH-R
I252T-Rev
Impair
MCs/Yoshioka
2-5-4-4
Hs00197271_m1
.Immunofluorostaining
Ab-4
N-Methyl-2-pyrrolidone
M-TEL1
Lisanti
OCT3
TGCTGTGGATCATCAGTGAGT
Fousteri
detected.DISCUSSIONWe
R2832C
transgenes
ADH1B
unclassifiable
translocation17
C34
59-TACATGGCTGGGGTGTTGAA-
22K
K745M
.Lavagna-Sevenier
PAb1620/PAb240
A_51_P120275
fTGFBR2
sympathoexcitatory
Q157-dependent
V560
translocation/fusions
pharmacokinetic
1.Constructs
TTGCGGCCGCGCCACCATGGATCCAAAAAAGAAGAGAAAGGTATCCTTGGCTGAATTTTCCAAAAAG
pathogeneity
E734K
uTYPE
0.54-fold
Figure8B
ERCC3/RAD25
described.12,13
SpectrumOrange™-labeled
assay19
I282V
aggresomes
Hh-independent
A_52_P534870
dashed-line
.9876G
c.5075-8T
peri-
IGF1R/IRS1
pRK5-HA-GST-S6K1
ligand‐dependent
1,058–1,620
DMRI
T-5168
binding39
ZNF198/RAMP/FIM
I42F
sickkids.ca
DHapp
FYN-T
c.134C
gal80–538
9–42
cells/ten
tc26
3-0
41–500
signature6
−3.71
1.26∼2.72
TCAGGCCTGGCCCATGTGA
T70999
188I
5196
0.5—23.7
637–650
AJ532609B*1307N
P1780A
.HA1E-M
CB1A
Rsym=Σ|I−〈I〉|/ΣI
113insArg
11.5–13
a-4
Rlf
phenotypes18
therapies.9
αA-helix
CBP/p300-interacting
onskt
tttcag/CTTCCT
ribonucleoprotein-specific
mAU/mL
4316
Zumkeller
X-100
methanol/acetone
snap-frozen
EF1.1−/−
Antibody-bound
kinase.15-18
17.37
2/24
ZM-fusion
cytokine-receptors
Y.-M.W.
T50
organoid-biopsy
M45
.DNA-sequencing
Pregnyl
0.30048
Na249
pcKRR
Lunenfeld
0.522
1502Aright
CCCCGGGTCG
p21-inducing
101.3-
R1881at
c-Ets-2
posJohji
PtenL/+
Spironolactone
periplakin
streptavidin-fluorescein
E1723K
._EGFR_
C-Nap1
c.1732-2A
fromLNCaP
107/150
5.306
-B
1990b
0.075–0.553
GTGGGCCTTGGCACAGCATC
fancj
GMPPNP-
SPECT/CT
PTPRD–FLAG
.AD-EDA-ID
Ebrahimi
L798V
/IR
malpositioned
Q204Term
831847A
temozolomide—produces
87–89
r544
Jumaa
135/309
'polymorphism
Figure4B4B
UPD9p
intramole-cular
PMS2CL
GPR143
BUB1A
themutations
3-galactosidase
1621–1
Kaplan-Mayer
EGFR-L858R
8q23.3–q24.11
pharmacists
deletion-T790M
atresia,5
3,700
D60N
28/26
600–650
anti-Jak1
K1702
0.30–0.90
Trr/COMPASS-like
LBD-truncated
gpl4OProtofrk
2698
PRC1.4
phospho-Y542
sv4045
N-acetyllactosamine
Cytospin
525GA
Asp423Asn
mice.38
pAMP1
re-genotyped
.Thefinal
non-hotspot
4.921
phospho-TSC2
polyA+
ARBS
aT-cell
T2232I
1746
S1040N
E006
18261
FLAG-LNR
1X105
raÃ-mutations
CTCFCCCVfCAGCIT
c.475G
LOH4
On-therapy
A/c.4185G
andK562
β-tub
Gayane
DAMD17-96-1-6024
8.14b
7q32-q35
Cys-9
NCT01229644
erasmusmc.nl
Rad9
P5.50
ARF1/2
cancer13,14
β-NADP
5′-AGATCCACGATTCTTCGCATTGTC-3′
helix-turn-helix
β−catenin
PDGFbR
0–69
IFN-LUC
metastasis-prone
arrest82
M1738
γ-secretase–mediated
511
7,10
I-C
early-response
decay-accelerating
Caspase-10
NDM
3x
L485-A489
Mll1+/+
keratosis53
1.02–1.13
GLMN
D846R
L910Q
Crizotinib-related
2289-2311/nt
q31-33
7.546
research.nhgri.nih.gov/b
Geneb
SLC25A37
UCA
WRN
7-aa
sites/462
ccRCCs.2
C202W
neurocircuit
mh1036
HGS-OvCa.Gene
0.3M
ESTDAB-064
SkMel-28
Y154R
7800
preautophosphorylated
relapse46
elucidated.11
Fig.3J
anti-tapasin
.GeneReviews
TSC2–R611Q
6/52
Vaccinologie
3.6–5.7
Mangion
regimens1
-TTCCCCGAGTTCTTCCTGTT-30
sub-clone
.CHD1
36.11
TetPTEN-K125E-FLAG
F142V
GitHub
.Addressing
G–K
mother-daughter
workload
GnRHR
P=3.8e-14
non–high-risk
0.33–1.54
deaf-blindness
mid-green
AATCAG/gtttga
.Vogt
mutations8
D816V/F
PC/JW
antibody-free
nuclearaccumulation
MK2206-induced
SUPT16H
MT-depolymerizing
JSQ3
BrgWT
3,3′,5,5′-tetramethylbenzidine
kinasedefective
debulked
fluoro-sorafenib
activation29
0/26
R73L
CTGCCCTTC
macrodissected
Cro
Kyowa-Hakkou
rence
Helsen
myr-p110β
Godart
crypt4
pFlag-ubiquitin
isopropylthiogalactoside
D125Y
A359T
.Differentiation-associated
CUL4
proteasome-
//tux.embl-heidelberg.de/ramensky/
12,344
922A
crizotinibnaive
carcinomaAdenocarcinomaColonAdenocarcinomaAdenomaAdenoma
ACTGTGCTACTCAAGCACCA
anti-Sp1
overex-
tem
proline-toleucine
STK11-deficient
SU-DHL
IkappaB
pmCFP-K-rasG12V-V152G
analyses36
72◦C
20-ps
pMSCVpuroFLT3-ITD
825
acquisition25
2310delC
−58.6
628T
PD3-C
Myc-MTA1
INK4A95
sytem
Mapk
M60
tropomyosin-related
ArZO
GSI-sensitive
SectionIn
p=0.29
1800s
IonTorrent
NP_000539.2
SQ/TQ-rich
N-EGFR.22
oncogenic.12
S100pr
U29117
H178Y
phospho-STAT6
1/56
CGCCATGGCAGCCCTGACATC
AA-3V
4D-H
Pro-26
GT-30
S111R
M938T
dis3-D551N
ArrayCGH
256.0
GGATACTCAGCCGAAGAAGGT
0.8264
Crtc1
1∶2+2∶2
beta-subunit
022454
allele144
JAG-2
SRC-I
Genotype–phenotype
LELERK1/2extracellular
SEMA6A-FEM1C
_CDKN2A_
VEGFR/EGFR
Rsk
ATRX/H3F3A/TP53
gpl40/gpllork
ΔGtot
Dominika
~275
FISHBecause
AS-qPCR
anti-Ewsr1
HilbertVisGUI
N–20
25F
.Wells
unadducted
independency.19
nature.com
model.29
–19
retrocardial
CATTGTTTGTTGGAGAGTGCCACAGGAAGTGGAAAAGC
H185_A259del
CFU-GM-derived
replicates±standard
microbiological
75–100
Acta1
5′-ACCAAATGGCACCATACGA-3′
c.659A4C
IPF
10,10,11
mg/day.61
∼1.4-fold
mutant-transformed
H3-
GNNK
p.S207L
1312_1336del
anti-phospho-Thr-68
30+37
inactivation/modulation
1546
theIG
weredetermined
Ras35
Phenoytpes
.Polyethylene
events89
c-kitThe
Rosa-Stop-lacZ
1347-15
bindin
streak-out
peared
progression-free/cancer-specific
TbRIII
Grégoire
BCR-ABL.69
22.5±3.5
proangiogenic
basepair
Y205C
reducedATPase
post-IR
responses.29
2Fo
Bα-Binding
PDGFR-FGFR3
D2/3
mHGA1
easy-mutable
Anti-p70
2Da
Brca2-deficient
vsc+h
DDX5
high-copy
ARR3
BRCA1-BAP1
cell-recognition
N↔MG↔U
KT
8hhq72p0
20-PBS
Thr387
assays10,000
proteotoxic
.4693
pro-retrovirus
PMF
γ-D964A1/γ-D964A2
sizea
OdysseyTM
PTENexpression
nhi
Tyr-CreERT2BrafV600EPtenL/LEzh2+/+
Labbe
609KB
TM1–4
IIIb-D1713A
substrate-recognition
OCGO
2295C
12-36
permeablized
transformation-cooperating
Loxo
.Endometrial
0H00-C-N024
studies3,6,7
KYSE-200
/Mac1
2007b
adenosine-5-triphosphate
17.9–26.9
p-PARP
Paint-A-Gate
anti-Tyr653
.ASD
Tcell
-T172A
275–322
IκBs
CLTC-PTRH2-VMP1
HA-Cbl-N
Anti-rabbit
drugs/steroids
2041insTT
S2A-B
Katabuchi
cagaTttct
lpi
Mantel-Haenszel
amphotrophic
2/23
toroidal
.Disease-risk
/Crl
164αα
20080114
.127
dasitinib
rebinoblastoma
1.41–3.48
HI112R
53-6.7
under-19
.MN1-ETV6
V437F
multicatalytic
S2.8.1
imatinib.The
foci50
c.489del5
Rheb-dependent
double-targeted
femtoseconds
PTEN-G20E
.PIK3CBA1048V
N=72
compound-labelled
VEMG
.Proposals
KIT.8,9
.BA=BCR-ABL1
PEA3–AP1
C2074T
Rh30
CFSE-labeled
ROCK2
001
QQThrAsp
re-plate
.Acquired
4–144
.Agents/Circumstances
113C
sc-731
c.8350C
​Figures3,3
Exportin-5
1–452
factor-deprived
crevice
substrain
C61L
rephosphorylation
anti-2B4
p230bcr-abl
GATGG-3
MIF2
Deinduction
FLT3-WT/CBLDexon8
1448V
9.20
V867L
2010.2
monoculture-based
162300
626–651
pGEM-U6
2865
1–173
936-fold
R556
pS6Ser235/236
CDK4i
KspI/HindIII
CSH50
leukaemia47
AATGGATGGATGAATGGACAGG
F1174VþL1198F
III-IV
7402
p53/RB
55/M
0.9618
inverse-polymerase
142168344
Qi
DP_RNA+DP_EXOME
COILS32
p=0.0069
TYR
RS1
T308A
PI3K/Akt-related
1498.3
SC-1615
—paired
GI:2244898
TFG-ALK
GGAAGCCCTGATCAATAGCAAATTCAACCACCAGAAC
RG-18T
Z9600204
73–77
07-449
cases.1
retro-
C181
dihydrexidine
500−1000
Iafrate
2313
anti-Retantibodyor
Leu535
R26CreERT2/hBRCA1
Other/unknown
130–140
M251T
Nunavik
P.F
IVS10
nonexpressors
1994a
4654G/T
puromycin
GATTACTCTGAGACCTAGGC
gatagaaagaccagtccttgctg
ES…
IRS1-docking
a-C-terminal
PMYE551-554
orthophosphoric
leukemia19
NT-6
Glu203
4136
MSH2c.2516A
‡Leads
MutH-homologous
superactivate
Misidentification
110715insA
Cys342Tyr
known1
E909K
V444A
±
gliomas20
Zentrum
VEGF-specific
Seligson
trx
MLLC180
TEL-RUNX1/AML1
EBNA-LP
p110b
B-lymphocytes
Ryves
pCDF1-PTPRD
RAEB2
pp1–pp5
contradistinction
0.931
E251A
metazoans.1
phosphotyrosinecontaining
.837G
F123I/K208M
0.418–0.952
-Tris
1435G
TRP1
PDGFRI3
Exon11F/11R
1434C
0.00313
uORF-mediated
therapy–induced
estrogenresponsive
BIAcore
FGFR3–overexpressing
−2.96
stimulus.4
oncogeneK-ras+/V12
granulocytopenia
MTS
3600del11
JAK2-V617F/Y931C-expressing
CTC
independence.4
leukemias7
9C–D
3'UTR.16
23,25,26
Brautigan
17/33
10E-15
Neh2-related
elsewhere17,18
phenotypes.1
5′-CCAGCAAGCTTGCGACCTTGACCA-3′
Calu
Society/European
carcinomas.27
2251
possi
SUMO-interacting
Gly-43
BRCA1/BARD1-dependent
terminus.13,14
Geeraert
STAG2-mediated
ICD
18–39
E/A-Cdk2
www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi
D65N
Kumar1
Casnellie
Improm
mucoprotective
Margarit
C26G7
Paraffin-embedded/formalin-fixed
.Volgestein
c-myc.Changes
2315
DSN1T13TP53
Mdmx-S
A˚
salivary-duct
SIN-1
P58
ampicillin/ml
91.799
classification.14
5′-GGTGTTGCAAGAGGGGATAA-3′
SRYpromoter
.TAAD
P.V736A
ERAP2
Rapl
oIwc
U43188
BRCT–phosphopeptide
SNU-1040
2B-D
pGADNot
Co10
A182T
CCTGTCCGCC
.270G
1571
α-PIPKIIβ
activity.55
−3809
IRDye
D153
scrapedcells
domain.3,33,34
N-ras
mutETS
rno
ACACCCCCAACCCTACATTTGGAGTGGAGTGGCCTCTGT
progression.2
non–GC
TCGA-B0-4852-01
fluorochromeconjugated
EcoRI/HindIII-mediated
E14.5
R89LCRAF
c.1177C
13-101
M.-C.
Dot1p
10q11.23–21.3
0.592
organisms.34
HeLa-DR13
activation,60
complexes,23
cistron
PRKCI
activation9
death.1
TNFR‐TNF
Flt31-3
activation,52
D/p21/CDK/PCNA
Early-Onset
Langherhans
pPDGFRα
T7T
TED2
Fig.4F,4F
.Histone-like
alpha-dihydrotestosterone
P7a
Aphidicolin
Res-
kα3
NUT1194R
*Rsym
scoree
¢nger
Superdex
bilayer-induced
R175S
10.1369/jhc.5A6626.2005
ng/mL,20
D'Arcangelo
GACACCAGTGTATGTTGG
.Autocrine
MGCD-265
quasi-clonal
ice-cold
F75S
Kiemeney10,11,19
MEK1-Q56P
andcolon
1899
ofmutation
FMS-like
pluripotency24
5′TGGCACCAGCCTCGGCATTTC3′
C182S
.Aguilar
3z
74.24-74.38
GIST-type
V195
HD-C
nonextremity
Herter-Sprie
dermatoglyphic
.811C4T
–GGCATGGACTGTGGTCATGAG–30
PTCL4
trial-independent
CEP85L/ROS1
Mori-Akiyama
1–452ΔC
HindIII-SmaI
ELNTA
.Immumunohistochemistry
meto4-4
trafficking52
1q31-q32
−1600
55n
N17
Speri-
AML.3,13-17
CPI-17
X-box
endocytosis18
wild-typeTGFBR2
HinfI-HhaI
B*07:02:01
Preanalytix
.PRC2
0.438
mFANCC
P190
HNSCC28,29
12222222111221
-BB
promoter-proximal
2823
RAR􀁂
Cbx7
NPM-ALK–targeted
nlacZ
QuantiONE
3060
mastocytosis.24
shRIT1
strong-to-weak
M117I
D221G
5,10,11
2.8-1
cGKIβ-HA
LY-2875358
malignancy.3
20825T1
Cationic
7,15-17
ALFwin
onhistidine-de®cient
HIF2α-binding
NOTCH-pathway
and2,2
mutations51
Rad50K6E-
Häcker
//genes.mit.edu/burgelab/rescue-ese/
formamide/2
2HA-tagged
2,790
NK1.1
ARID1A-deficient
352–625
BRAFL597R
3p14.1-p13
RHEB-independent
feed-back
0.297
TEL–PDGFR
∼83
resupended
.Polyubiquitylated
-CHOP.51-53
hybidizations
241/282
TA/°C
adenine-rich
pq
underascertained
705–1120
3×IRS-Luc
Ser5-phosphorylated
methionine/cysteine-free
IVS16-
NM_007464
mutated3–5
TAD–KIX
TEL-PDGFRβ.35
549-1,278
~used
pTYB1
G710E
SNPFileCreator
4.98
displaysstrand-specific
MethodsComplementary
transcriptome28,29
ÃŸ-cateninim
USP33
C611G
.Nucleotides
FELDMAN1
BIBF
K61
325
38–89
P=0.080
ofmutations
.TG101348-mediated
1/250
GATTATACTCTTACACTAAGGAAAGGGAGAAATAACAAATTAATCAAAATATTTC
recentlyreported
NF01507
Synonymous
ARE-
.Nonhypermutated
alÃ-elewas
P365R
SU-DHL2
-A-A-K-R-V-K-L-D
nonregulatedoverexpression
BFM-A
3C3–4
LnCAP
1H/13C-ILV-methyl
2.5-10.0μM
H2A.x
VAV
104/dish
KIAA1557
29D8
8000cells
cell-fate
P539
cell–subtype
600-basepair
0.71–1.36
gtatgggtc
CP751,871
82–66
fluor-
summarization
gene/exon/intron
Panel.Analysis
R301H
front-line
Autism
0.364–1.422
22,145-fold
boxplot
T-p53
C398Y
Chr17qB3
–3.0
.PPP2R1B
165–170
TMOD2
1.220
208305
Ili
interferon-Graphic
AJ270771
anti-TERT
833–854
KIN001–045
//medicine.nature.com
7/15/2013
ALKA-372-001
5′-CATTTCCGAAGACGACAAGATGG-3′
Concurrence/Mutual
0019207
then-known
115,116
TGF-betas
SNC3A
D-CDK4
Myc/Ras
CACCAT
DFG-β9
differentiation/cellular
domain.32
S'-tgaccacgcctttcttccctcccctcgaaatgaagCTACAACATCACCAC..
D57E
2714G
75*
time-lapse
3,623
BARD1/BACH1
risk.30
9~21
Brca1
artifi
GDC0941168
EGAS00001000246
250ng/ml
38–42
4,118–212,400
SMAD4-interacting
Ncam1
BCAM/Lu
.Elucidation
board–certified
t=
bioinformatically
UniteŁ
ATPbinding
1,500/μL
hexosamine/Golgi/lattice
IL1RA
1-45
p53-regulated
H168R—or
gamma-phosphates
GTT
q15q31.3
silencing.9
Barnes-Jewish
p21Waf1/Cip1-defective
.SPRI-cleaned
9232/02
YCpGAL
p.S1164I
GDPbound
gi47210
cells24,25
10=679
c.2246T
populations,14,25,38
59-GCCCCTCCTCAGCATCTTAT-
.Glioma
Sf3b1-deficient
1Bb
HSVVVPYEPPEAGSEYTTIH
containingFoa
014390.2
CLLs30
p-aminoethyl-benzene
Oligoastrocytomas
EGFR/KRAS
non–8p11-amplified
non-ccRCC-associated
hgmd
anti-c-MET
LEF-1-
.Mek1/2
Lapatinb
.NHR2
.0014*
S1787
INOH35
P2064L
Bio-rad
2,520
RAS/RTK
MY48
.Replication-deficient
488/555/647
thepresence
5.651
Delta+ve
mu6pro
M.H.L
12–18
F7+P3
Stag-p16
TCGA-A2
MY10
Dosztányi
0207
Asp770_Asn771insMetAlaThrPro
Guillemot
S365
4364
Gln22Stop
Ex4-5seq
polyclonally
1099–1936
EGFR
four-parameter
1700
cytoprotection
Prim.=primary
derived-adipose
levels27
×25
Hépato-Gastro-Enterologie
shMED12
−0.021
pre-existed
5GGTCACTTGAATGTGATATAT
Q-Trap
TGFBR1*9A/6A
5′-AGCATGTTTCAAGGATTTGAGATGTATTTCCCAGAAAAG-3′
ECL2
MD-097
D770N
frame-preserving
ABCG2
U6-shRNA-AR-CMV-GFP
structureof
respectively.6,7
cytokines.16
ACCCTGGGCAACCAGCCCTGT
3,726
NRAF_TUMOR
AAGATGTAACTTCTTTGTG
GIST882
auto-inhibition
S759P
87.1
50-jl
pheatmap
MOPD2
Juntendo
GBD-M2
HSRs19
Skordis
lGyVaISerVaIAlaVaIGyVLeuIaVaIPh*
inhibitor.20
complex35
Rb-cyclin
D38E/A59G
Nuc/-
program38
1.438
GR300
RS411
proliferation-promoting
pan-active
Oitalic
HCC2279
62/F
TRD2
Furstenthal
S427GC-RAF
110-744
hamartin,14
Sarbassov
GDP-loaded
RAS-effector
GST–AT
anti‐Pan‐Ras
u-PAR
FM10
Actin-myosin
pMM16
5-34
Brooks-Wilson
respectively.106
inhibitors•
ROSI-encoded
PD173474
defined.23–25
KRAS/STK11
.Promoter-Reporter
control43
FBS-supplemented
WM278-NIC-GFP/DN-MAML1
3,714
BCL211
FTT
presentation.41
Rad3-dependent
HCT116-PIK3CA
Tyr245
ABI-sequencer
.Fat4
Assays—ATPase
O2P
MI-63
5'-M13-GCTTGCCATTCTI-TICTATFITTATT-3
p15/INK4b
alterations3,13,14
Del-T790M
signal/ratio
c.5062_5064delTGT
G331CARAF
.Girl
Egl9
MMK7
sumoylation-mediated
Biomark
Shinza-Kameda
S6K1-mediated
assumed.d
TCF-4-luciferase
Lys601
≤20-nm
EGF-deprived
MCSP-1d
Figire
uncharacterized
3.09
HR.Figure
C306R
80••
.Unusual
MED1-containing
20-min
viable30
cellsdisplayed
c77g
phosphorimages
L1-Cys-rich
MycS
−2.02
SpectraMax
pcDNA3-2HA
AH1
forkhead/HNF3
D18S878
non–drug-like
leukemia31
1Â°
SmaI/XmaI
Pemetrexed
pEAE41
c.1540C
adrenal-specific
Red-donkey
-23
2690
.Brca2+/+
GCATGTGAGGATCCTGGCTC
3RC
kDa−5.2C10ORF47Chromosome
W5
pET41a
E692
S2.5.2
p.Pro1690Phe
316ins5
.Classes
0–160
Gleevec®
HOG
study47
sentrin
PAX5-dependent
Flag–IP
Myc-LEF1
PSMD10
theNUP98-NSD1
Rahmatpanah
L467P
//roselab.jhu.edu/ddmp/
BF-BR
2AF
.E-stained
5´-CAAAGCCTAAGATGAGCGCAAGTTG-3´
P387S
Provirus
‡Mantel-Haenszel
pCMV-Tag2-
non-AA
disease.22⇓-24
p.Arg131Trp
Rap2a
740
CGH–SNP
penicillin-streptomycin
autoinhibited-conformation
ΔSET
1505–1511
analysis/total
MEF2B-mutated
2.
L540Q
5′-GGATCAACTAGTCGAAAAACAAAGAAAAAAATCAAAGGG
PDGF-A
p.Pro177_Cys182del
p53-R273H
KrasG12DPtendel/del
200μl
G-I
CACTGAGTTGACACTCTGAAG
OD450
inhibitors88
NOTCH-activated
Ptenlox/lox
GZMA
E−738
47.1
29.67
LL3
8b–c
EW-SMd270-351
non-APC
Irrthum
MuRF1
104
2–7
F57CMEK2
I93M
pIS-ERα
Signal-to-Noise
practice.16
KST652
NM_010128
transformation.39
:396–401
D838
Morinaga
chromatin-
L19L
239–246
msh2p
HDM2-323
H3K27Me3
tya
adenolymphoma
.Transactivation-independent
SEMA3B
3D7
.076
5q13–33
R73A
metagene
proteins.30
mlh1-29
Ser492
Thauvin-Robinet
BAI3
TCCAAATGAGCTGGCAAGTG
deltions
ACSL3
4401
∼428
1/81
1-mL
loop/ATP
Ufa
TCF/β-catenin
IRDye®
G399S
12/184
Fig.1G1G
.Selumetinib/docetaxel
TOP1-mediated
.442
A20
RECORD-3
-700C
07912
DAPK1
peptide-receptor
gefitinib.6
re-replication
media-only
SHORT-related
Gemin3
STAT-deficient
columnar
H-Ras
W.B.D
Ceccherini
immunoglobulin-like
ERCC1–XPF
5′-GCCTCCCTCCCTATTCTGTC-3′
REP-a
E709V
SRC-3-independent/AR-mediated
pS-Hx
kinase207
W131
arecapitalized
3H–I
v1.2.6sg
MYELOPROLIFERATIVE
Ultraspec
11701
proteininstability
withdifferent
neurofibromin1
k-ras
extra-abdominal
GATK17
177/171
SOX-binding
kinase.8
anti-MKP1
Glu365
aEarly
-caacaccaggacaataatagtacctgactcactggag
pSG5
5'aaagaggatacgaatgggacttg
HMECsPrevious
146-149
nonrelated
CAIX
5′-GGGACAAGTTTGTACAAA-AAAGCAGGCTCATGGAAGTTCTGACAAAAATCCTTC-3′
MADD
534.1
.NUT
:2
W271
−19.3
p.N78S
non–sun-exposed
5′CCCGCTGAGTGCAGACC
c.119G4A
5′-GGTCTGCCATGCCTTGTGCTC-3′
Doublesex
c.2322A
2-p53+/-/Brca1Ko/Co
U14680.1
F423S
rs12946522
CGTGG-3
crystal-soaking
HA-CRM1
13,000g
CRL3-SPOP
N-ethyl-N-nitrosourea–induced
HIES.9
wu109
2075
.Imatinib-bound
5′-ACCGCCCCTTGTGGTCAT-3′
A6154
S4L
phosphorylation54
hydrolysis.MATERIALS
TCTCAGCCATGAGACAATAAATCC
0.559
two-column
R4S
clonagenicity
MTS/phenazine
.copies
permutations.Our
FGFR1-mediated
investigators.28
proliferation/differentiation4,7
BCR/ABL-evoked
decisions.2
apatitic
–64.6
11p11.2
Malme3M
insTATAAA
moderate-DNE
4-7L
families.In
R381Q
Ins770NPG
1.4–5.2
insT499
T73I
C/EBPα-deficient
D8S87
45p21WAF1
140-mer
1:1:1
Y1003*
co-denaturated
NCT00103259
BCORL1–E74-Like
H3K27me2K36me3
0–150
Hhex
www.nature.com
p=0.311
H372N
first-pass
.Relapse-free
NRAS-mutant
extrathyroidal
ActR-II
fluoropyrimidine-containing
ACT-3
ATGTG
Ikezoe
WT-His-p53
duringtumor
w531-1
RAB5a
glioma137
1986b
anamnestically
R841
1340
β-catenin–mediated
contraceptives
ClaNC
41-year-old
R474W
polymicrogyria
non-soluble
R175H-expressing
PT08.1
Cxcl10
HER3-Glu-909
.SIGNIFICANCE
merlin-merlin
400-
S118R
LeesMiller
S100A6
3891-3899
F84
Aurora-B
24/36
I138F
EPAS1-non-mutated
BIOPREDsi
more-powerful
function20,21
delN771insGY
receptor-overexpressing
572-1G
YEASTMAKER
.Thirty-three
p53-WT
.KIF14
out-of-sample
DNase-free
5-CAGGTGCGGTGAAGTCGCTTTCCT-3
significance.
effect–prone
pA301
g.17686–17695
PR+SD
+49
10,194
phase–specific
7ng
A0j
−87
3.Effects
ourscreen
mutationTransversion
REG3G
AF6
SNAT1–3
JHH1
IVIS
Rag1−/−-recipient
.OA
HRAS-activating
Steady-state
AACTCGAGTTAAGGCGCATTGTC
erbB2-mediated
PCR-estimated
Jak-STAT
Blots—Whole-cell
Smad4260–552
Illumina®
Cinatl
hamatrin
64-7
neoplasms/foci
MCAP-associated
-3.35309
snoRNA
oflysis
0.676
MSH6and
vismodegib
Small-Molecule
-MKHFESFKR
nonmatching
IRE-mut-Luc
mid-lower
KIT.44
and/ovarian
pRb/E2F
anti-NFKBIE
PALB2.6
HNPCC.27
Elmer/Applied
-54
Four-day
Rmax
ineffective.35,35a
p.866EOEK
Souilhol
EGFRT790M
proteinsindicated
RB12,3
.Anti-4EBP1
5-kDa
Sanada2,3
cross-hybridization
06465684001
11.5–12.5
13,22
21–49
3.37
c.800G
Jaenisch
described.9,22
Schiestl
BCR1-FGFR1
c.940A
47.9–75.0
W777R
3Z
c.14644-3C
2004.11
L542P
poor-DNA-quality
lung-
D816V-mutation
SRDVY900EEDSF905VKRSQG
C2orf85
CEM-C7-14
ΔLexA-BD
CBL-S
ligand-binding-domain/AF2
AXIN1-mutant
K720E
1.8amp
92093-0688
5/2007
0.0041
HOXA1
bandmobility
Denayer
YUMAC-L505H
sulfonamide
RMC20C038
//www.cephb.fr/ceph-genethon-map.html
TEL–AML1
Tet2
3MJG
Fluidigm™
A+G
pLenti-CMV
9663
.Labeled
population-basis
P287A
5′-CGTCTTCCTTCTCTCTCTGT-3′
opsin
.Corroborating
1aq1
DM3
.search
somatostinoma
/31-/33
001222300
PhyloP30
~1995
A-to-G
Bcl2
Methods.â€•The
SAMHD1
PDE4D.14
Moslein
-bis
activation.27
select_db=NF1_germline
molecule–specific
Figure3a
5′-GGTGGCTGCAAGAATCAAGT-3′
experience.7–9
23:1054–1061
N∊2
T294I
Y525/526
calibrate
-MAPK
.G12I
30D4
Cotransduction
NH2-XEEEYFFLF-COOH
EGFRΔ768-GFP
R2102C
European-American
FDC-PI
.Y1003
F338C
RAF-inhibitory
0.81–1.55
CBL-mediated
rs34536443
401
V–PI
N361S
GTPgS
29/42
G576E
4.In
Homme-Porc
V45L
Ends-PCR
PI3-Kgenerated
destabilizations
respectively.29–31
studies.26
mechanisms27
5688
15.2Skin-fold
pRb-induced
265,402
JAK2T875N-
Purification—Alanine
repair11
Strizheva
C/EBP-knockout
I/BamH
166-179
IFB
mutants.9
II-dependent
54–63
p.R462C
.Skp2−/−
Akp-negative
Ptf1aCre/+double
.Name
Beroukhim
Looijenga
Domain-specific
Flag-caspase-8
3,880
D-72076
c-Ablwt
sh-Cl1
Harvey-ras
fusions1,2
bacterium
most-characterized
pre-therapeutic
57–78
10,25,26
importin-α
chemotherapy56
MLL-AF9–positive
trpA46
MRP3
125.77
Taipale
-70°C
sFASL25,26
*9A-9
32,319
anti-PP2Ac
Res-treated
asterix
1FBV
Y37
ABC-like
1,6-8
p16INK4a-CDK4
re-analyses
Nonidet
.Nitroblue
Fgfr1c
exertional
Interferon-g
immunochemically
SRC1/N-CoA1
76:22–31
pRV2-ErbB2-V659E
I1873T
F677L
Col1a1
DS15146
selfrenewal
pBabePuro
.T-cell
degradation68
Wijnen
pCMV6-AC
.T-ALL
minichromosome
dose-escalating
Göttingen
cyclins.133
2700–2706
Leiomyoma-linked
californica
corepressor/coactivator
.Estradiol-induced
CPPRB
quo
withprimary
c.1698+1G
Mut458
S341G
atattttag
–500
welldocumented.6,7
transarterial
25.0+2.0
T766M
confluence.Figure
4375–84
R6C
24534
www.EGFR.org
13.2±4.30
GTCCTGTTCCTCTGATGGCTACCCCCTAC
100,000/μl
19-9
H.C.
UC.7
PI3K–AKT–mTOR
cryosection
V561D-
CT.4
A126D
1.30×105
dpc-4
conventionally
FLAG-specific
10K
cross-checking
55-1-Dapi-x10
611
ITD-mediated
D146N
62.8–62.8
CMV-MycT58A
c.2323C
2006b,2008
022211
co-localisation
Ad.shUCP
imol
GSE8507
Nestor-Guillermo
.-w-
MAP2K2-mutation
Site2
358A
A350G
1.0.4
2351
W330*
49.5-
pu
promoter-binding
tcacag/CGGTTC
Oncol.
Leu64−Gly67
Akt1-
c.6789_6792delTTAC
P514S
IGF2/HRASp
Bollag
MBP-MCP
RACE8
17Aâ€
D16S498-D16S3123-D16S3026-D16S3121-D16S303
conditions.77
π-polar
p27Y88F-T198A
-p16
BANK1
breakpointwithin
imatinibtreatment
MMP15
3.8-400
CFC-pathway
talc
Brg1flox/flox
T366P
efficacy.19,22–25
not.17
C-scores
53.7
SPA-1-deficient
NOTCH2-unmutated
.PIDs
Lats1-DN
70-90
collagen.In
D45
P35R
alpha-importin
flowcells
2/3
K666M/T
42.9
precancer
washed-cell
Wane
2Ce-h
FANCA–FANCG
2027insC
Organization-sponsored
RAD14
203132_at
Suppl.4
illumina
~DTE
lineage-marker
Irinotecan
c/c→g/g
Radiographies
onine
Zollinger–Ellison
cysteine/histidine
R267W
4732
pseudostratification
Paraganglioma
d/wk
Flag-α-Fbxw7+p16
61:215-225
chemotherapy.24
Pew
p.Gly719Ser
Moderate/Poor
2712–2717
two-ended
3731–3732delT
.Hdmx
175,000×
.Mechanistically
Puglisi
28-29
low-incidence
Fgf-7
PALETF
P≤0.05
5-AAAAGGCAGTGTTTCTGTGGA-3
nontranslocation
miRNA-repressed
fibrin/fibrinogen
Lck-cre
Expressiona
3231
HRASQ61L
anti-RTK
G469del
WTERF
Australia.Generating
r.m.s
pCI-neo-β-catenin–expressing
5′-CCCACACCCTTAAGAGAAGA-3′
Cdc-phosphodegrons
R412M
assay.95
r/O
cgg
prechemotherapy
T-lymphocyte-associated
equi-molar
AGGGATCTGAGATTCAGAAAG
normal-v-normal
Sinica
Allelic-specific
ab9050
39RACE
Eα1
TSC1-C
Phe577
Anti-HA
Investigac¸a˜oem
101-mer
Oka1
c.862_863del
metabolism-regulating
andHIS3
Dnmt3a-KO
Kipreos
leukocyte-enriched
Delta1
dysguesia
AGGGCTGAGGTGACCCTTGT
E033
BTB-non-phototropic
//bioinfo.ut.ee/primer3-0.4.0/
IMTs.5,6
NM_053087
anti-P-Akt
1−prior
−906
c.560T4C
p.Tyr472His
NF-κB–activated
biosynthesis.27
class-specific
StuI-linearized
JASCO
Melanosome
42/109
N-3
Y583KD
C3139T
3.View
Grb2-associated
97K
2214
AMPylation
Flag-Smad2
HRK
100·0
OP44
17.01
WDR7
expmed.bwh.harvard.edu/ts/
cIAP1—a
TÃŸR-l
12—14
CRC,32
anti–phosphoSTAT5a/b
Snf5−/−
.serial
MYC–MAX–Mxd
horse-shoe
Cys4
3–70
semi-suspended
5′-T1C2C3-3′
KDM6A-related
DH1
iñ50
Mus81
//www.ebi.ac.uk/ena/home
regions.46
cell/Matrigel
.10,11,23
Lanca
Chaperones
GATA3-short
phospho-ROS1
Koseisho
TRP1-based
CRC.2-4
Rsym
Stem-Pro
AHTakt-6
−13.6
E868G
N219
leukemias.5,14
Non-BAC
hematoxyline
10,11,13,14
Wacey
reported17
transcription40
88-014
insect
9/36
MPN-CMML
EGAS00001000254
subpopulations
.SUPM2
L-alanyl
Q177
L194R
vismodegib–chemotherapy
HSB
Q776R
1-FOXA1
ever-smoker
1:1200
T576
postvaccination
immuno-decorated
c.470T4C
previously.13
gene-directed
pQBI25
nordoesmentionof
stromal-
unravelled.Figure
NF-κB–activating
pre-cooled
16q23.1
0.474
BrdI
.HCT116Fbxw7−/−
M5655
TT+LND
c.3284+3_3284+6delAAGT
LacZ–SNF5
crystallography/XRCC1
,rlm
I476N
combined.21,22
UCC_3T§
P.T725M
1982T→C
proteasomal
GBMs20
L858R-EGFR–activating
DN-MMKK4
bridges59
retardation
vpO
S372C
expressedintact
p.Glu809Lys
Airaksinen
molecules24,25
paired-end-sequenced
Toguchida
p21ras–GDP–AlF3–GAP
Hepatoprotective
stjude.org
4091
11/25/98
5′-gggctgacattcatagccttcaatgtgtgac-3′
5'-GCGGATCCGATGTCAGGGCTGCCATG-3
ABH3
Necrosisf
m.
IKZF1,10
247
CCACCATCCCCTCCCTGT
NXS
SEM
E340A
..t
mutant-induced
manner.26
ated
1200μg/ml
shortening1
pGL-3PD-L1p
J.Chan
Autoinhibition—Previous
214
237
0.03506
natureof
remodeling.58
Acknowledgments•
neurofibromatosis-1
BRCA1-sufficient
Gab1-cotransfected
.Co-immunoprecipitated
factor-binding
83,86-89
neurofibromins
top-20
HBC/HBOC
syndromes.2
GISTs26
hg19_Gencode17.overhang
ERE2
8Department
pGA-MTS1/ΔΔ52−144
e11.2
binding.7
ERAP140
Zv7
Qiagen/Gentra
Leu150
006209.2
Su-DHL6
p53Lox/+
.Cao
Hematopoietic-specific
interphase–early
.MCL
.MT-MMPs
InterPro-Blast
end-diastolic
NF2-associated
SRDVF900EEDSY905VKRSQG
hurdle
Tris/HCl
H3404
EC50MK-2206
Zha
Motohashi
7638
Steudel
–RET
P147L
2-37
I759
2002b
LinesCells
thepatterns
24484
≥3.02
Log2
NM_033360
ABL1–protein
uc002onf.3
DGUOK
delta-delta
reverse-genetics
.211
RXX
1-h
0.00042
interest—that
topoisomerase-II-inhibiting
mice24
Sp1-dependent
anti-Ku80
truncating-specific
vs.78
DIPSI-3
SCCIC8
A→A
www.addgene.org/pgvec1
MelanomaTrial
splice-mismatches
FGFR2-mutated
MRC
soring
trk29
pDEST-V5-FGR2/PPHLN
5′-TCTGTGCCCAAATCAACAAG-3′
-ENST00000292538
MTT-formazan
Nondegradable
|-~~~~~~~~~~~4
Taulí
CLTSTVQL
vated
AfterPrimary
non-differentiating
ZR575-1
hematopoiesis33
.Former
.CTLA4
VQUEST
BD-acetyl-histone
extrachromosomal
progressive-disease
3.5.14
Wi38
6–32
0.88^1.00
never/light
kinase-targets
Ago-interacting
function69
.Cross-species
testing23
cells/μl
-120°
CFC105
melanoma33,34
.Hairpin
5′-CGTGTGGACTCAGACAATGCA-3′
b-Dthiogalactopyranoside
agarose-conjugated
A-21076
theshort
A243V
IV-11
promoter86
E255K/V
2F83
p.E239K
fil
H224fs_X282
610832
EGFR-S784F
D349A
C49
imbalance—as
proteinlevels
+AG
bSerum
NPXY
leiomyomas.43
MEK1/2-specific
IL6/IL6Ralpha/gp130
c-Cbl.31
1_
pVHL-HIF-α
anti–ICAM-1
Rho‐GEFs
MSN2
plates/wells
pGL2-HDM2
dataset.Figure
PTPRZ
super-binder
Shp2D61Y
arteria
4,5-dimethylthiazol-2-
548.2
CCGCTCGAGCGGTTATGCACCAGAGTTTCGAAG
Kozakian
0.96–1.27
sc1118
p.286fs
valine-to-leucine
teREaLmsEl
0,6
K310Q
S904C
curve-fitting
.EVI-1
patients.Panel
Mms2
zVAD
K708
6Neurological
8•4
SF50
0.209301423
adrimycin
CRE-L3-CCTCGCCGGAGCGTGCGGACTCTGCT
lines.43
Pastore,1,2
AO
anti-CrkL
MCF-7-Ago2_167C
R537C
12-O-tetradecanoyl-phorbol-13-acetate
.American
.559
non-hydroxyl
urethane-
A889P
Down-modulation
p.A18D
Microdissectiontechniques
.Correct
Yi-Long
RP11-778C1
neovascularization.17
5′-biotin-GCAGTTTTTGCATTTGTCCTGGCCTA-3′
.Role
Adipocytic
transition.190
HAV12Ras
231051
gGmbH
I7q2
ETV1-1b
3.5-mm
0.822
8329
sc25575
446
scoref
HA-Cul3
H-Ras11,12
BIACORE
55634U24
D8S88
4G10
331
carcinoma69
TOV21G
indicated.B
toxicity140
S100A8
HSPG
R492P
AMLCG-99
D3S1263
P-values
tuniamycin
Bsr1
BoyJ
Trr/COMPASS
opposite.7
RET/M918T
hMLH1-associated
ontology
ifFGFR1
DEN–PB-injected
c.6033_6034insGT
S0388
Ryo
Operetta®
Chemoluminescent
3.9–74.7
EGF-competent
V568
14/211
ANXA4–PKN1
MCNs.Multiple
.004
R515C
3MYCROC1
endothelin-1
2ITO
sc-6246
H3K27me3,28
1:8,000
c.4308
E7107-mediated
AR-NTD-DBD
anti–phospho-SRC-527
-gamma
Smad3/Smad2/Smad4
LADCs
904-
tumors.37
DXS6673E/KIAA0385
BAF45
6–293
BFM-like
AR-V8
anti-PD1,38
35:50:15
11–18
SDA-type
Y842C
MSCVneo-MA9+MSCVpuro-HOXA9
TRAP220/DRIP205
Thr-161
1.361–3.358
Saos-2-R72
N=sites
erlotinib.32
MSCV-GFP-ICN1
erythropoietin-bound
3.0M
tested—no
KRAS/BRAF/ROS1
well-classified
c.4277A
25–26
INK4A-ARF
protein-2alpha
hexagon
175/448
Scottsdale
airdried
TCGA-YL-A8S9
GST-Chk2
KknigsVHPL
cysts/goitre
mismatchesand
Y931C
followed-up
ZNF2F
a120600310
.CBP/
constituative
5′-GGCATCTGCTCCTGCTTTTG-3′
-repressor
P753
synapse
767EEYL770
Kwok-Kin
116/237
function22,23
LexA-WT
WCU
theregion
Q94E
π-stacked
AR6
CTLL-2
85/133
antigen.PCR
viewer.24
Leu922
CA21661
5′-TTCAGAGTAAGAGGCTAAGG-3′
pEAA290
GST–SH3
13/exon15
RSV-vector
T790M-carrying
template-specific
HR63,64
noradrenergic
mCC
≤1.5
p.1390
Concert™
pGEM-3
Scully1
Mb-wide
.Drug
2127
ligand-occupied
PaO
1.21–4.27
AIP1
head-to-tail
MMP12
10−5
dna=SU-DHL-1
Spain,22
MECOMRPL22L1
.PCGF2/MEL18
A/E
Echocardiograms
GW
HPSGs
profiles49
glomerulonephritis
4f–h
ofGTP
50th
Asp1850Glyfs*4
lines.19
phosphory­
Anh
Calmette-Guerin
non-basal-like
.Finney
.Youssoufian
glycolysis.A
5′-ATGCCTCGAG­ATCATCTCTGT­TCCACTTTCG-3′
PDGFR-beta
pdgfb
self-amplifying
o–t
5'-ERG-TLS/
S16a
G12VKRAS-induced
0.057–0.788
differentiate
ZIM
RAF74
pathogenesis.4
CI=0.31-0.82
mg/d.23,24
5.69
O6-methylguanine-methyltransferase
4ZF-MYC
.PIWI
Adminstration
6-month-old
anti–phospho-MET1234-1235
12-week
anyMI
Sir2/SIRT1
~1.2
block-chase
EndoH-resistant
CCATATGGTGAAGCAGATCGAGAGC
PPA2B
multicancer
diseases.1
PxxP
dipterene
NLS1
transgenics40,48
RasGrp4
p.V1673D
n=183
Immunopathology
K379E
homologue-homologue
≥G3
E-biotin
305-606
mxSF3B1MUT
GOLPH2
3831406-3893830.
5'/3
CYP2A7
Reis-Filho
004327
.BH
0.76
p.Gln1037Thrfs*63
p.Ser288*
signaling-inactive
50.9
Intramuralresearch/Labtransfer/Bic/index.html
-.-
region.29
Hoxb
normal/abnormal
Me11
.HMGIC
Xq11–12
treatment3
NFKBIA
GAL4–N-CoR
pan-selective
.JH2Δ-Jak3
ourHRM
anti–b-actin
fifty-one
ERGE
pT2N1
BACH1-517T-GFP
EBV-derived
WT-EGFR+
muchhigher
Oligomeric
.1B
4170-4256
5′-CACTGAAGAAATTTCTTGTCGAACA-3′
Tsc1–/–
IRB-
HE172
.GeneChip
EHE
SalI-EcoRI
TERTmRNA
I1171N-mutated
p.K563_C565del
translocation-generated
57-kDa
5–6
microRNA-125a
GFP-C-RAFWT
dimentional
M5G
Rasko
AA029430
CD4
al.,15
c.5950_5951delCT
.Selecting
pAKTS473
859–869
Lysateswere
TCTTA
Gly731
Microbeta
D838Y
T1–T12
Oocytes
*35
migration-inhibitory
cancersmanifest
O-GlcNAcase
respecFig
HED351
left-
2.6-
Terukazu
T410I
8•0–14•0
MEF2B-V5-His
PI-PLC
OE2
2QQ
GTPase-activating
Intini
ofone
.CTCF
178/185
mutant-EGFR
G204S
PDGF-Rβ-expressing
150503
dabrafenib-induced
anti-p-Erk
4,498.2
No.speci
116211
R2n‒R1n
states68
.FcγRIIB
NP25
D2HGDH
Tris/NaCl/NP40
CD41a+CD42
Mucoepidermoid
8,22
high-income
2,339
anti-CD135
borate-EDTA
Hariharan
IPPBR
system.2
CTTCCAACCCAAGAGGAGATT
FLAG-DDR2
RTK-IIIs28
Kohrt
FLAG-His-H-Ras
EZH2Y641F
site-mediating
.7D
2.88–27.79
mou~e
GGATCCTAATACGACTCACTATAGGGAGACCACCATGGCCTTTATGGATGTTTCAAATCCT
criti-
CGH-105_Jan09
ht4
D554N
neoplasms.1-3
E627R
low-baseline
PIN-4
Normal/Tumor
.856C
TAGGGAGTCCTGTCCCACCT
Exiqon
co-occurrence
thyroid-stimulating
Pro380
phosphorylatable
insulin-producing
albumin/Tris
Ruvinsky
phospho-Stat5
T-18
high-molecular-mass
BMS-53624
1721
neonate
RUNX2
//insertion.stanford.edu/melt.htm
re-inserted
bar=100
JAK2-overexpressing
IlluminaHiSeq
intra-nuclear
Capistrano
hormone-like
326
patterns3–6
Olofsson
13/26
KIT-D816-mutated
V1804
E40W
mTPO
44kDa
3'-to-5
N-E
lowerstability
Waf1
cancers72
MAP3K14
homo-oligomers
K234
TRAD
correlatively
ΔΔG
PCa.11
chemorefractoriness
K562-BIMi2−/−
PSCA
PanKeratin
PRK7-HA-S6K-KR
PD11
Ried
108.7
I25F
berg.de/3D
656K
LiCl-treated
15University
D6–185
TestDiet
Hoffbrand
NCT01414426
T905R
T308D/S473De
4.643
59-CCGCCAGGAACGTGCTTG-39
TGF-β3
JTO
aminotrizole
signal—regulated
affymetrix
laborious
stress,51-57
anti-cleaved-caspase-3
detergent-soluble
.Merkel
AGGACGCGTTCAAGTAAGCGTA
predoctoral
LBW242
47-49
conclusions.These
GLRX5
phs000771
seen140
invaded/migrated
50h.p.f
c.1373T
5′-CAACTACATGGTTTACATGTTC-3′
ethanol-sterilized
.Repp
prostacyclin
phospho-MEK
13063
over-proliferation
flp-in
dimerization-activation
wasadministeredi.p
H330R
MPO−
BL1002
1,140
34as
ligase–deficient
acid/40
XXL/AlexX
601—appeared
Ub-VS
65/50
10-029
K5+K14+p63+SMA+or−
ESPript
L924P
serine-404
Enfance
57·7
12-817
UACC-62
C-RAF/14-3-3
V2969M
domain.18
.Multivariate
level.15Figure
harmonious
DH293-1
characteristically
crestderived
12E1B
CAPRIN2
MO-91
GSVA
Savkur
0.155
Baugher
Gemini-Bio-Products
RUNX1.28,29
⩾II
initiated77
Ito15
CA67409
MEN1-related
www.tumorportal.org
non-oropharyngeal
liver.2
three-generational
5′-TGG-ATT-TCC-TTT-GGG-CGT-TGG-3′
insulin-transferrin-selenium
FLT3-F590GY591D-expressing
p.D820G
UTR-extended
overgrowth/macrosomia
complex49
pan–PI3K-mTOR
burden29
non-Igh
7.11
0.0212
μK
cohesin-mutated
carboxy-domain
.Peripheral
11.1-kbp
SUDHL6
pheo-chromocytomas
aNTRK3
Scientific-M34152
intracellular/surface
5′-GCACAATGCTGTCAGGAGAA-3′
ESP5400
.Fragments
p-Stat-3
​
Takeshima
PI3K/p85
M63
Tijssen
JAK12
doi:10.1186/s13073-016-0313-0
cancers16
CycleCovariate
kinases.7–9
HSCs,16
ved
HFD-Induced
COSM27283
6314
LAS-4000
p.G35A
investigated.48
2219:1
5′-GCTGAGAT-
β-catenin/T
ezrinT567D
4,934
aginst
5Download
R882-mutated
58.20
10.09
ChIP-Chip
.HGSOC
pRC-cyclin
CHIC2
quadraradials
V72
R683S
ura3lura3
Line*
17-20
NCBI35
RGC-derived
—that
commonTMPRSS2
GATA3.17
Pt_038
hypocellularity
.Proximal
AAGSFVFLRFFCPALVSPDSEN
short-form
Ben-Yosef
TCC3TTC
stabilization6
SOX3
TG1796-97AA
V145A
E400
M482K
4.65
high50
LKB1-directed
HSB1
W34/K63A
NZM10
BCR‑ABL
T-K-V
Phe1108
U87M0
4002-31_4002-8delins24
Normal-mode
alignIntronMax
higher-stage
TPβ-induced
extra-adrenal
DNA/well
C12
ERÃŸ
.KLF4
5′-TCGTGCGTGACATTAAAGAG-3′
RP11–325I16
1651
MDA-PC2A
primer3plus
.S2.1.2
hmU
E279K
mu1574F/mu1574R
multi-protein
0.2666
F891A
F56V
.Frameshift/nonsense
emulsion
cyc­
20,000g
nonral
L755_T759del
.Endogenous
DNeasy
Fig.5
1UKL
chr2:59933730-59935214
MEF/PTEN233
58-AAATGTTGATGAGATAATGACTGAT-38
.Tunikamycin
7A-D
A-dependent
SLC45A-BRAF
Apc+/−
μL/tumor
G281V
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
16–
975th
forp120GAP
LAMB2
activation/plasma
CCCATCCC
sedimented
11.45
.Muller
heptad-containing
chloride/5-bromo-4-chloro-3-indolyl
RP11–174B22
Mutagenizing
32-year-old
L2/L3
decreasedthe
IVS3
Axin226
ERK2-L198A
327K
Sprr2fCre/+FVB
240–277
anti-hDIS3
gi18204306
CellQuest
11GA12
SW579
myxoinflammatory
genome-analysis
PDGF/PDGFR-like
protein—with
H163C
AKT1-mutated
SUMOplot
mmoI
Coomassie-Blue-stained
.Neomorphic
methylation,20
C528
H+-ATPase
factor.69
T600
0–2
p21'as
Tpr-Met
WWC1
Soyal
occurredat
E240Q
pEG2-FLAG
Sparmann
Hyper®lm
403
111-113
3.94–3.80
Aplin
L380
E2Fs
p5360
4×VAD
262M
Lys652Glu
Y1068
Molero
Hematology-Oncology
-100-fold
gcgaagcttgccctcaac
.ASPM
2-deoxy-D-
Sonicated
V3MC
PEX4
0.219
hansenii
up-slanting
.Likewise
syndrome-like
hypersignal
93
1a39
Pdpk1
pT2N0M0
pET29a
cellswhose
FNB32
Appari
PDZ-binding
PARADIGM-inferred
BH3-only
4.96
histamine
established.45
CHL
.HPMs
665
P3-dependent
8.96
S175P
signatures36
anti-Giantin
TCS-SP
14–38
SSCP-shifted
mice77
60–67
TAG-3′
Biosystems/AmbionX
PxSxxK
TGTCTCTACACTGGAGGTGGAC
serum.30
1,119
Tyr1062
G287R
AVPI1
0.289607373
Rbl1
H-p16wt
//arxiv.org/abs/1207.3907
pCRXL-TOPO
L64
proteins.43-45
duct-epithelial
intermolecular
N80
KD-NT
HIF1-α
Asp175
21–89
Resin
Fumie
≥0.2
c.35G
occurred.1
Deeb
24/23
pSG5-GRα
A-*D
Ficoll-Paque
KOS-953
Ver.II
proliferation.29,30
melanoma.Despite
V157I
microarray.12
676–678
LRR1
1.007
FGF16
DNA-chip
α−MHC-Q510E-Shp2
−EGF
chemotherapy.3–5
Regierungspräsidium
M.T.
GTCACCTTCAGCTTCACGGTGTTGTG
CNN-LOH.17,18
5′-TAGTGAAATGCTGGTCAACACGGGAAACTTGCCTC-3′
Daiichi-Sankyo
p40
WTmu/+
3/66
Lochhead
medicine-based
work-intensive
thehMLH1
Hirsch-Ginsberg
carcinoma.19
actinic
6,420
line64
.°
–PKCϵ
GSK1838705A
GCTGGGATTACAGGCGCACAT
2SRC
​Fig.3A,3A
0.107
ephrin
UCP-shRNA
214delG
-GVGDc
TNFRSF6
K117R
G525
PROVEAN
multiple-PDZ
antibodies18,19
Rectum/6.4
havecontributed
reed-sternberg
164,384
945-fold
F726S
J04101
F394V
GAAGGGAACAGTTGCTTGCG
14-3-3ζ/AANAT
NP_002728
RP11-164M11
imatinib-responsiveness
destabilizers
dissection.12
+EMM
Glu671
exptype=
TIG-3
unito.it
71-77
Yes25
pAxCAhFADD41
.NP_005456
vitro-
iScript
S360T
NM_010615
β-catenin/TCF
Y350C
-M37K
.TEL-JAK2
culture-treated
67-90
c.3328_3330delAAG
phosphoinositol-3-kinase
higher-than-normal
q11-q13
X3
CCL-61
.Vice
Ci/mmoI
L858R-D761Y
19-21
Y537S-expressing
pET16b-Rnl2
wasdetectable
promoter-mutated
.S7L–M
OptiView
20082
leukemia.13-17
pSVAR0
C634W
RAF/MEK
c.1785T→Ac
outproliferated
transcriptionstart
Leu91
D1-
AAD
TLE
273–284
XP-B
–activating
pEVRF
Y845-Y867
.8390insA
0.8
oncocytoma57
PI3K-mediated
p110α/p85α
4-fluoro-3-
133,000
dataa
I32V
5'-ACCTGGTGCTGATCTTTCTGAT-3
1.1.1
transformation,17
3.Figure
pcDNA3.1-negative
Saclay
rs1047972
Arg/Gln
FHL1–3
3p25.1–3p25.2
suppressors.13
V:1
Gln-987
MEK1C121S-expressing
HD-0235
Smad1/5/8
OrderedList
DPM
quantiative
1924
Apcmin/+
LabTek
Golph3
1233
CIC-status
35/201
2005a
ofMDS
.Reintroducing
CTTTTCCCATCACTGGGTCAT
multimetameric
gland,66,67
SQUAMOUS
Hs746T
assays33
mutation-guided
5382insC.15
.S6
Cdk12+/fx
​FoxO6
IH-901
Nunc™
S2T1-6OTD
.Leu484
xenoantiserum
1225del3
.Down-regulation
HMB-45d
LSD1
KINSIM
Avr
HPV+
p54β1
TrkA-vector
c.988C
Hoechst
lACCACGGACCATGACCATGAC151
analysis.CT
12,13,14
Ras-dependent
schwannoma.19
3H-pulse-labeling
5hmC-low
3q22–q26
syndrome9
R244T
vector-
Y105
double-base
Promega/
ALK/IGF1-R/IR
5′-AAGGCAGAAACTGGCTGTTG-3′
MAC-cell
HIF2a
MET-negative
.tPresent
K1606E
PIK3CA-amplified
BFU-E
α-C-helix
4/2011
Glu408Lys
Poirel
WT1mut
2180–2381
LUC-R
20K
94305
PIK3CA-mutant–sensitive
5′-TCTTTTCCGCCTATTTTCAGTT-3′
BRCA2/2
CTEP/NCI
PAKVKK
Fig7G–L
CDC45L
recently-solved
GFP-transduced
anti-tumoral
PD-1/PD-L1
K648N
Sca
pRSVNeo-Ba/F3
half-sites
Anti-EGFR–directed
Brca2F11/F11/p53F2-10/F2-10
70-meric
Xenographs
//doi.org/10.1371/journal.pone.0032451.t001Fluorescence
ATAGAGAAGCTAAGTTAAAC
immunotherapies
0/120
1complex
effects.83
π
erb-B
A486V
BH51
11PY577-558del
Bcr-Ablwt
5.1-46.4
Kras/Lkb1
0.722-3.284
Nucleus-by-nucleus
3816
Albrecht4
rationalethat
S124A
.Fortunately
del747–753
.7I
ID-associated
Cell-Titer-Glo
T241M
missing24
60K
Vasculogenesis
andintrinsically
JPY12
5′-CCCTGCTTCCCTATCACTGT-3′
ml/5
hypoxia38,39
10948Ll0473
naevus-associated
400–1000
.Mosaic
drugsor
laemmli
CGG-codons
BCRA1
7c–e
homodimers21
second-generation
EGFRvIII-L858R
SUFU
GAP‐mediated
Cyclin-dependent
lÃ¬with
response.30
320–2,000
9.1.2
NCT01393912
posibility
RASA1/3
c.6188G
EGFRΔ768/vIII
T-ALL-initiating
prolyl-isomerization
EPR16655
hCD45+
SMMHC
N387K
pathways40,41
117,000
used.18
MLL+
Heidorn
ADx-amplification
M13mp19
signal–
N-C-loop
traumatic
EGFR21F1
.Louis
Fig.4B
cytosine-5
A289V/D
FAM-CCCAAGGCCCACTTGGTCCAT-TAMRA
FBXW7α.39Additionally
EGFRG719A/L861Q
13q31.3
0.0497
MasPar
mutation19
N233
HNF1
BHM-23
TCTAAGTCATCCCACAAATGACA
160.3
medium-only
.Broadly
Saos-2-tsp53
-Msh
pink-tan
assayTo
5,730
snRNP
0.347021857
RBP56
oping
influence9,10
IDH1-mutant-expressing
significance.A
H-ras-mutant
TMLQHQH
T990I
genes.PowerPoint
ACTTCAGCATTCCCTGGTACGTGT
aMLH1
346.4±263.3
ERBB/HER
phosphokinases
EgfEgf
3,4-dihydroxy-1-methyl-quinolin-2-one
5′-GGAAAATATGGAACCCAAAG-3′
space-controlled
PI3-kinase/Akt
rabaptin
NLB
Rassf
51/398
107cells
2-t
59-CCTTTGGATCTCTTTCCCGC-39
opossum
ABD
cells/10-cm
4,985
DNA-chromatin
.pRb
γ-irradiator
36.95
AK12
D820A/G
GGCAGGAGGGGCTGGCTG
miR-30
Ini1-targeted
1400mg
prostatectomy.18
7340567
co-activator/co-repressor
G106D
adhesion-mediated
Müller-Tiemann
genewith
kinase–specific
NG_007467.1
methylation-independent
UHC
.SuperScript
.2590G
TCGA-CS-5396-01
1025–1050
11,470:1
classi
factorindependent
investigated.We
17–26
L858R-sensitizing
E139K
3/31
R186H
EGFRvIII/MigRI
T783Aa
1.042
ofC
Cps40
D601G
bro
ICIOR
pharmacobiology
0.039*
study,24
XP_011518909.1
G12VKras
D/1–4
KB1P-G3
duplo
ver.1.6
CUO17
spectophotometrically
F516G
oligomerization133
MTA1-mediated
144-349
graft-versus-leukemia
HA-SPOP
0.3â€
receptor-3
transcription.25
15/15
HRASThese
MutationsLocalization
hsp104-mCherry-expressing
semi‐transparent
XIRP2
25nM
growth.The
Discriminative
Ser310Tyr
upregulatory
NCIH23
1G
contact-induced
.602
incidence/frequency
Arg/Cys
R509X
www.bork
159T
Y628Q-for/Y628Q-rev
ErbB/EGFR/HER
.Variant
L62R
Minigene
BCC.3
two-letter
FKBP12-binding
pEAA305
co-nucleofected
Torc1
V568G
octyl-2HG
24XCyte
Hepes-buffered
P=0.05
8p11.2-p12
TCCTCAGCACTCTCTCCAA
locus6
Rasinduces
cAMP-CREB
T-p53C-Y220C
KTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTL
debility
NS16
296±19.2
anti–c-Raf
.U43746
PDGF-B-binding
p.Gln205Pro
0.572
Helicobacter-driven
.S7D
univariately
T23-3
Decondensed
Methods.Based
pre–B
9/42
pcDNA3.1-AR
10,000g
−1.14
D11S4940
caccatgtacgcctacgacgtgcccg
R174Q+DNA
sh5706
P294-A1
Ni-NTAagarose
preamplified
two-arms
p.S259A
tier1
Ras/Raf-associated
Slavotinek
RAR-α
c.137G
1763–1799
G719S/L704N
236K
cushion29
EMS
oligoarray
C1300
established39
.11,23
melanoma.25
Galbiati
0.216
RIPK2
base/region
K459Q
9,22
0802655105/DCSupplemental
cancer.22
p.V130F
PAK-PBD
.Pirard
067
Herewe
6myc-Smad2
qPCR-determined
cysteine-tryptophan
manner.45
4183
7qter
2.81–22.25
CCDC84
insulin-
Octyl-d
0.5–212.0
AMN
mb21
copies/cell
Veikkola
EWSR1–hSNF2H-expressing
patients|
mutation.24
c.556C
0.45-4.58
.Effector
​Thus
27/40
proteins.Smurf1
¢c
tuberous-sclerosis
5′-tcaggatgttccagatgtttccag-3′
D183H
c.1337G
RORγt
75-watt
96AQueous
0.01⁎
Keyence
dlong
Harfe
investigatewhether
bHCA
WT/G380R
GAGAAAGCCCTCTCCATGTG
CI5
Y329S
HTLV-1HBZ
more135
E2F4
Torhorst
T.194.8
5′-RRRC
chr12:12022436
coplin-containing
Le´on
PNT/
—MYC
X863
VHL-L118P-Venus
132-143
MSCV-MYC
anti-IκB-α
93.8±7.9
AGuu
3/495
.Nonradioactive
mice/genotype
Benzeno
Kinase-Deficient
7300
752/1
ras'Z
X100
A=0.403/G=0.597
2.5×104
XtremeGene9
MIR133B
L2155S-mutant
null380R
68.2
8q21-q22
Math-Works
.Metabolism
Ishidate
12,635
'pathway
ofJapan
Shortread
Ret14F
602113
MSH6-variant
ZMD.82
JAK1wt
light-controlled
PtenWT/M3M4
H.L
expanded-BTICs
DMEM-F12
5′-GAAAGCGCAAGTCCTCAAAG-3′
.PI-4,5-P2
.Go
FPTC
​Moreover
042
homologous-recombination-related
raphy
pCMV6-BRF2
T1010I.Met-Rat1
-7.1
respectively43.Despite
−906T/C
Interleukin-3-dependent
DUX4RTf1
.Cardiofaciocutaneous
years.21
p110βΔ/Δ-derived
single-cell-derived
OD490
.Xrcc2-Deficient
SpectroCHIP
acyl-chain
Joukov
30.33f
reported.21
Srcspeci®c
RELAFUS1-RFP
p.Gly288Cys
HSC7E124
Modification-specific
ZR-75.30
0.3363
TGTAAAACGACGGCCAGTTCCGTCCGACAGAACGGTTG
cisplatin-
IRBP-E7
biotin-GGMEDIYFEFMGGKKK
AGU
.VEGFRs
RAB20
1:19
GFP-pcDNA3.1
7/20
His-INPP4B
HyTCX
dR6G/dR110
peroxide-sensitive
patient5
.LYN
stress-resistant
between-slide
NucleusNext
Ig-loop
MSI-negative
/590
transfection/nucleofection
Taq
study,26
trk9
p.Leu822Leu
C236X
pathogenic30
µI
-GAAGATCTATGGCGAGCCTCGCCGCG-3
commensurate
Beckwith–
MHCC-97H
Cu/Zn
shRNA-Ptpn2-C
FLT3F691I
hypoxia22
R665
21-months
-CM
1,046
mean-batch
α2,6
1.32del
BRCA1–BRCA2–HR
2683
CA172355
wt–wt
5′-phosphosulfate
SUP-M2AR500C
geranylgeranylprenyltransferase
A–B
TVcontrol
survival.18,19
742–762
Strongylocentrotus
[
Arg38Cys
GSTCDK6
9.3–76.7
CGCCGCCACT
bCML
1207G
29-year
micromanipulators
leukemia-prone
Ouyang
290–268
hp300
LR00
5'-ATGACTGAGTATAAACTTGT-3'/5'-GCAGCGTTACCTCTATCGTA-5
V620I
re-expression.62
Yagoda
c.227_229delTCT
.Grouping
rs121918239
typi
Iwo
chemiluminiscence
Potenza
repair/recombination
FAT3
°C-30
c.2881C
discoideum
PF-0646392
Pakdel
GM-CSF–induced
DFFB
NonFermentableAT/RTatypical
JAK2-V617F/L983F
lymphoproliferations
read-length
TIF2
A339V-expressing
Boni-Schnetzler
5′-AAATTGCTGCTAGCACAGCCCAGCTTG-3′
p.Asn1011Thrfs*38
NF-κBA
PI3K-targeting
SHELX
EGFRbut
226-bp
_*160_
gene/row
.Primary
GST-AR-AF
D.K
298:1
2003ter
appr
myod-specific
FGFR3b-
INCORPORATION
mActb-Forward
microtubule-binding
R1055W
3:0
LIP1–SMAD4
Cdk2-associated
96.3
.Contrarily
7-mer
RP11-1099M24
Immunoprecipitation-Western
electrochemiluminescent
Heinig
stitution
56•
5′-TCAGCAGTATGGTAGCTCACTCGCTTTACGTGGACGGATGGGAAAAAC-3′
ppel-like
1286–1514
input.php
484–549
control.Immunohistochemical
E627A
V1144L/H1773P
.66
mutitargeted
RiboBio
MCP-1/CCL2
testes41
effects40
Rapley
C892A
p.K700R
hundreds.Immunostain
XPO1-mediated
FBXW7−/−
hepatocarcinogenesis—ex
±7
−.41
308K
c.1798_1799GT
variants—A1708E
Kalfa
5′-CDS
–fibroblast
Smad4/DPC
Z-Val-Ala-Asp-
Coulier
Modfit
c-met
KRAS-dependent
S768I
20,21,22,23
described.39
1,959/6.9
Kothaj
ab32807
.3972
EDTA–1
^M
.Cdk12/CycK
Fbxw7-BM-deficient
erythroleukemia-like
Q22
1B
23:845–851
Sacilotto
Zellweger
Vpx-associated
NCT01498328
cisplatin-free
​and4D
Thr790Met.25,26
BRAFG466V
V923E
Q276*
FLAG-SOCS1
06520-8032
.Kong-Beltran
A217D
1738
susceptibility
TGCTTCACAGTCATTTCCAGA
So/o
Leukemia-associated
electroblotter
sh-Co.
CHRU—Hôpital
co-silencing
3,345
PTEN-inactivating
Heusler
KIT-targeting
femtomoles
μm-thick
34–
HIF1α
exclusive.67,80
protuberans
GAL4-luc
prIpE
MMTV-luc/renilla
pHUSH-Lenti-dsRed
MAD1L1-BRAF
.Predictions
H3K4me2
​Eleven
30.06
.67,74
ENEST
nonhotspot
+BACH1
p.Leu3135PhefsX28
3/427
s.c.
validation=1
YES.9
HD-N
Cam-
agents.4
cancer–predisposing
–74.6
F-W257G
Y-1003
„omic
GDP/GTP-exchange
doi:10.1038/bcj.2013.60
ank
pentakisphosphate
AMKLs
DeletionMost
thatSMAD4mutations
life.6
cancer59
epitopes
6E−5.9Endogenous
LN229
G12D-
Smerdon1
384-well
2-PE-2-SR
Expr~
1095
Anti-phospho-STAT5
near-endogenous
cTcBccTACt
A_51_P448741
FGFR3b-S249C
Houssaye
Allshire
anti-CD40+IL4
resti
Dapple
.Cervical
Thr/Thr
T289I
PARP15/BAL3
metastasize.9
transA
p.Ser1050Leu
V343L
Figur
c.2156G
//www.jem.org/cgi/content/full/jem.20052204/DC1
AURKA/B
C47S
sGBM
Erb-B
-3,4-tetrazolium
HOXB8
SK-Mel-215
.Probable
interscience.wiley.com
Methylase-Sensitive
ETV6/TEL
.5,8,9
-45-fold
≤0.25
mut179
54h
//www.sanger.ac.uk/cosmic/
XPR1
sgRNA-1
T1025N
*a
7q35
1.5-cm
activity169
~Vriend
A702T
earlier51
NCT00244764
A_51_P369311
4-pyridine
165
leukemia21
aUnderwent
process=searchPromForm
cells120
v-myc
nqo1
J006
imatinib-therapy
cisplatin-treated
c.2172_2173insG
GAD-MSH3
Madden
lesions,5
calls\
S3.11
lymphoma.24
lansoprazole
BiomasherI
PIK3CA-induced
SF3B1MUT-promoted
CycM-V5-6His
PDX-1-Cre
V1696L
falsediscovery
chain-termination
Start_position
.Native-PAGE
anti-KIT-phycoerythrin
SU5614
D7SI835
Smad6
3-10-6
.L1564P
980-8575
with32P
ubiquitylation52
p.A148T
activation,10
previously12
-68
Q1481X
differentiation.19
pathways.56
0*QC
BRAFE600-ERK
07-421
Fig.7F-G
19p13.3
intestinalGISTs
-18
PDGFRB-WDR48
live.cn
Figure2c2c
crizotinib160
-MUT3
kinase–related
interactions-based
carriers—exhibited
.Contractile
:50
.346A
5F7
myc-BRCA1
NR4A1
Huttenlocher
anode
DeltaGT
3.11+0.13
S2Gg2
SMAD2/3
10q22
DD-tag
F27§
UCL
electrophoresed
450×109/L
5'-TCCTCCTTTTTCTTCAGCCAC-3
¿15
MDA-MB-231
polymerasechain-reaction
504
5-3/4
drugable
Forschung
erythropoietin-induced
spread.2,3
538-base
46.1±8.0
PR-HA
one/two
6.6Lung
interphotoreceptor
toGFP
dimensionality
.NRID
3xFLAG
NOPHO
Endocrinology
rtU
876
steve.rozen
.RK3E
Hs05027725_cn
R372C
crboland
332M5
150‐mm
c-kit-mutation-negative
SK-LC-2
www.iacr.fr/p53
gene.19
ICC10
5'-CAAGTTTCTTTGCCAAGATA-3
KCLB
C609R
c.1634A
29.8
sequence-scrambled
9.5-kb
24–84
P.D770_N771INSSVD
.Piechocki
p27wt
mg/kg51
astrocytosis
0.143
'gain
3.18
methylaminoisobutyrate
CNNM4
EGFR-Neu
FHL11–169
PTEN-mutation
Tyr-553
38:35:10:2:15.
6056
ca.expasy.org
transcriptb
W453R
DMBA-
University^
.CFS
.NicΔ2105–2114
Sox17-Deficient
c.3998_4005del
neoplasia.27
mSin3-binding
AP24534
PAM2CSK4
nt770A→G
Prol51
mutants.24
Phosphory
MMR.3
detail149
TÃŸR-1serine-threonine
TA10
gene.89
R-TTAGGAGCTTTGGCTTGCTC
W2109G
statistically
CD44-APC
were57
co-factors
KMT2D-1185
RAPGEF1
cavity.183
anti–p-Tyr
Y443F
SYN
//cancerres.aacrjournals.org/
4D–4F
MAD1
5673insC
aa1300-1350
V600E
phosphorylation74
.Received
X06182
:1450–54
hypothesis-neutral
c.6325T
BIM/BCL-XL
Chk2is
19.
H1-H21
537S-ER
formaby
Brca1tr/tr/p53−/−
DKRMNS560del
507-284-3623
Tp53-null
Thawani
phenotype17
cdd470f5
.NRM
Orc1
striatin
TGGAGTCTGGTGGTTGATGA
MMP-9/VEGF/Tsp-1
B5M3
Phe723Leu
p110α-RAS
NCT00888173
MAB1263
chemotherapy.4
M116R
.Smad5
H3.3K36
Biii
GMPPNP-RAS
Thr790Met+Leu858Arg+
Brcamutant
7/37
2.56
TRKA
ALK-positive
43a
.Transfection
CSF1
//tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp
PDFRA
pUB6
1/142
signaling30,31
c.33_34insGGAGCT
ACS
breast–ovarian
Dastpeyman
1.118
chemotherapy.37,38
ICD-9
XL5R
L1240V
sonograms
682.0
matrilysin
862-amino
TTS
3059
p.R1200W
Xq12
signalling145
10.1182/blood-2010-12-325555
5′-32phosphate
PTENTgaRev
disulfides
region.45
PBMCs
6.40
selfassociation
6·7
p.A740_S748
MDA-MB-
Cancer-Linked
12-15-17
hot-start
Flag-SPA-1
.Luciferase
GARCIA-HIGUERA
ex29/30del
benzylamino
anti-IgG
lÃ¬Original
stearoyl
TGGGAGTTTCCCAGAAACAG
1987,16
proliferations.87
EWSR-ATF1
-FANCE
Doppler
DYNC1H1
n=271
P346LfsX38
anti-LEF1
ACP
.NIH-H1975
oxidatively
protein,23
Ikbkb
606764
domain11
c.910C
AXL/MET/EGFR
data60
NB-58B
androgen-dependent
exon/exon
nonpolypopsis
elongin
31374155
.GCTs
Tukey-Kramer
382R
Y1033H
model.63
functiondatasets
NSF
function9
CTV
Ras.26
extra-mutations
T183/Y185
U118MG-derived
polyacrylamide/l0o
FBL
Non–mutation
10.1002/bies.20204
BimEL
R.N.E
R273H/S240R
thatduring
0.743–2.784
p38-AKT-BAD
D835V/Y/F
Structure/Function
p.Val600-Lys601delinsGlulle
S1715N/Q1811L
P5–P8
Database,8
G3060
cc-12-1598-g1
V4,0
On-Targetplus
SCM
lo6
SUM185PE
ovarian26
R246S
ERRFI1-deficient
3B–D
G180A
rh-IL6
SET2
IARC
residuesin
PLA2G2A
enhancers,48,68
CyR
Mafune3
S768I-positive
O0
assays46,47
9q33.1-q33.3
cells.43
TALEN-based
C141S-p53
10×
5′-CCTCCTCTTGCTGCCGGTGGTGGCCCTGG-3′
shRNA558
7.5022
n=802
functions14,15
Fas-stimulation
inhibitor-2B
ΔCT
positivefor
cases.9
AB219242
.photomicrographs
HPA035911
R130
phosphokinase
Asp835Val
331–416
asshe
66,800
.hMEC
.NUP214-ABL1
17–325
RAB18
Speci¢c
5′-fluorescent
1811–1830
CML-characteristic
5−7
351–400
NRasG12D/Asxl1
.Flag-D1
EWSR1–POU5F1
NB1224-R4
serum‑treated
Panomics
inter-stitial
REV-RFP
three-hit
605515
A864T
7069–7073
SerLouArgTrpLeuPhoAsnGIySor
3,4,5,7
Aurandt
prelimbic
Val774_Cys775insHisVal
leukemia.4–6
binding7,16
PTTG1-depleted
μM/ml
somatostatin
.Code
transplant-recipient
E2f5
oligodimerization
0.09735
more/less
Vignais
this.While
.Ignoring
RZPD
38101X
ISL1
mUbRasK117C
generalmechanism
60000-I
Ponzielli
Thomassen
32,283.2
//tcga-data.nci.nih.gov/docs/publications/luad_2014/
0.78-2.83
5′-AAGTAGTAGCAGACCCAGGACC-3′
glycyl-L-histidyl-L-lysine
N=127
p160ROCK
differentiation,37,38
P446S
4Aiii
H1993
MEL-2.2
477A
function4,5
antigen
EIF1A
.RIT1
pGBD-C2
0.0543b
Hs00153408_m1
PUS-1
UVR
V-erb-b2
.Hybridizing
.LTR
order-1
TP53BP1.Although
INK4c
Co27
Institute–classified
antiFANCA
FM8
rgen-Straße
pDR2-transfected
D269
IVS19b
PLCγ—In
LGG.18–21
E402G
Bamforth-Lazarus
.Covalent
L-Myc
symmetry34
Phosphosignaling
2849-2829
LBD-targeted
malformation–arteriovenous
.17,26,31,37,38
K247R
Laake
Nonepithelial
111/262
29443486
37.71
FindHBond
Constantiner
P=0.00159
R.F.
A1065T
signals75
+6p
Q26
non-PTP-related
fastdb_2012_2
Mucositis
R981H
≥1.7
T1889
low-purity
taatag/CAGCTC
44b
E936
2-
MYCN-amplified
SynI-Cre
PCDH7
20110521
melanoma—one
p.R611Q
suggested,59,60
0.050
Blenis
36.3/11.3
Cox-regression
pLenti4/TO/V5-DEST
RHEB–GDP
Ser433/Ser435
29-bp
Jun/AP-1
ARID1B/A
674−695
BAI2
V238A
.Ras-GTP
transcription-inducing
-259-bp
Deltavision
c.527^1G4A
mL/min/kg
MD-MB-231
pathway.7–11
forin
0.46–1.37
Ratschiller
OCM-1
ourfamilies
mlst8+/-
al.8
//www.ingenuity.com/products/ipa
anti-Gab1
H-scores
transducer
Thr-288
Prahallad
protein.58
31,33
instability111
ingressed
REAtIMgqF-
c.2013-2757
R422H
Variation_3276
Strong/very
5′-AA––––––UA-3′
4–28
Tcf-Lef
del/dup
assays.T47D
fuºr
P.D837N
55°C0:10
33rd
cross-correlations
BRCA1-deleted
.Flow-cytometry
DOTMA
66–67
CIG
c.1306C
RARS-t
S141R
beta-catenin-mediated
Foxg1
476-3725
29–1,564
pdN6
NF1-REP-c
andfurther
Map3k6
RNAse-free
G129E
aberrations.1
Smyrk
CNTNAP2
Anti-beta-actin
GRM7
tyrosine-phophorylated
10×/22
Met152CysfsX22
p110α-G106R
Fig.3b
Cαlocus
c.5425G
0.01–0.76
suppressors.Specifically
anti–HMB-45
HD048502
E198
61.5
G4l8
P=0.009
Tampere-BC
EBC-1–resistant
system™
CLL–National
pmCit-N-rasG12V-C51Y
high-NMC
*Samples
multithreaded
K-ras2
aberrant
2,0817
m2
46•50
E-Cdk2-mediated
Q1352H
Alk-5/4/7
46,47,81
n=1103
androgen-signalling
250bp
radon
RAS,14
LNZ308
AC-15
KrasG12D-derived
20/54
IGF-2
Mansukhani
fociAlthough
hypertrophy22
response19
anti–phospho-STAT5a/b
.SGK1
7−8
Apetoh
5.FIG
extra-hematologic
dependingon
tgctttcag
physicochemically
.Auxological
Source-15Q
pS18
M208V
//www.nhgri.nih.gov/
cells86-89
ROCK-I
G670V
PSMB3
R3052
LRRC37B2
PTPN11.9–15
20l
αP-Tuberin
MgSO4•7H2O
4-nt
Comité
1.3-fold
Trp-1815-ter
tenosynovial
D'Souza‐Schorey
species-inducing
MADH2
juLSAs
-31
V304I
5′-mRNA
GEMIN5
C57B6/DBA2
TCGAGAAGGTATATTGCTGTTGACAGTGAGCGATACCTATGAAGCGATGTATAATAGTGAAGCCACAGATGTATTATACATCGCTTCATAGGTACTGCCTACTGCCTCGG
CMV5-based
subtype.Micro-GISTs
DNA-damageinduced
b2-microglobulin-deficient
Val825Ile
ogies
JH2Δ-Jak2
AML.7
.Trifluoroacetic
K1-739
E743-R817
ETV1-specific
3802delG
4x
orientational
summar­
cytology
Cys-to-Ala
5e-4
We.next
GCAGAA
break-/fusion-points
line–derived
TÃŸK-1gene
GFL
p-AKT
785C
Cdk2-dependent
TTTATGCCGGCAGCTATTTC
cM—D18Mit9—1.8
49–53
​Fig.7B7B
NCT01781429
MiG
InsR
FRA1
domain65
mono-directional
1.77
NB7C8
lifesupport
0.024
C-÷G
CATGCAAAATCACATTATTGCC
ALKF1174
helicase-conserved
175His
overviewed
345del1‡
cross-priming
5'-GACGGAGGTTGTGAGGCGCTGCC-3
anti-LTβR
BCOR-RARA
temperature,4,6
1027280
U-value
findings11
mononucleosomes
Mardis6
RC5C
N803
119°
Tyr1022/Tyr1023
anti-TCRαβ
AOA
p27KO
CH17-3A4
Alu-mediated
.010
wereused
non-sense
I1170N
Staerk
Flag-Akt12
Zweemer
816–835
0.049
specimens.3
p27S10A
c.970_971del
T381K
S→A
Canberra-Packard
Y448H
.Merlin-Merlin
0.03–0.74
ADP-ribosylation
C2-contact
68198-5805
7D–F
pms2-/-
ter1262
Najfeld
protein–HSP90
X06SA
BamHI/BglII
SPI‐6
43.46
2Ai
4Ij~~
respectively15
pathway25
N-paratone
CUL1-dependent
Hh/Gli
p53-R175H-
p.E63K
PIK3C
EWSR1–1590R
M14765
.CK1δ
11,52
CTLAAla17
K1727R/L1786P
R202Q
DCBLD2
nFLR-rkrd
M/67
TableTable2
.DAC
saccades
evolution-conserved
Gobisch
1983–2001
.CTL
years.46
ADCK4
I-02
recently-discovered
Npos,17
G390D—The
163
Thr401
site40
50mMTrisHCl
Prelich
I168
N-hydrogen
S1613Gb
.Cbl-R420Q
His392
22nM
α-Wg
6.84
18,19,21,26
Bioprime
⎫⎭⎬
2062
18,19,27
2.5°
Currall
11590103
slideOriginal
41–100
p.F891L
D857N
TCCA
Smilow
59/m
softshell
SBE12-luciferase
CD3+CD4−CD8−
Rip1Tag2
H1671Y
342–595
Imatinibmesylatewas
U.K
lines.13
5′-GGCAGCCTCCCCACAAGCCAAGG-3′
5′-GGAUGAUGUAAAUGAGCAA-3′
RA-associated
5.8912
Nümbrecht
T319A
SB202190
ofBALB/c
non-proline
ZD6474-RET
Oligoengine
oral-carcinogenesis
Korenchuk
rAI
7.4∗
CTGAGCTCACGCCAAGGT
triggeringp53
xenograft-based
+h-
AR-V7–expressing
unfavourable
30gastric
38926
137.5
F81L
EID1
deletion-based
Ghaffar
inhibition.16-19
2ug
Meeting.44
AGAGAAAGAAGAACACATCCC
Exon/
CACCTG
7358
change.47
6.20
RNA–
development-
WDLPS/DDLPS
Transcription/Translation
RP11-208F13
genechip
LR-PCRs
HSP90AA1
reviewed1,2
80-538
.RAD51
duplex-PCR
Hombrechtikon
articles113
.PKC
c-KIT,10,11
RanBP2
sequenced5
V1160I
redox-dependent
115-fold
10.1158/2159-8290.CD-13-0094
Polyphen
function.70
M1–M4
K1750
resistance26
DMIRB/E
sources—Ingenuity
.tX
5′-GCTGGACATTGGACTTCCTC-3′
CNAG/AsCNAR
Lazarov
mtp53-R209T
immunostimulatory
survival/or
A18
5′-TATCACTGCGACAGTCAGAT-3′
structure52,53
NCT00004883
KIT-transformed
o0
MGH045
15,22
Roche/Chemicon
ampli¢cation
FZR1-knockdown
care.Although
used.11
421B+425A
p27T198A
Cbl-B
pLXSNEWS
.MutSig
carci-
DSB-mediated
exon3-spliced
'variation
PMS2a
down-regulated
sequencing.10
5C9C
pCGFP2μ
.KDM5C
UoCM-1
.03250527
pegylated
PRO-JAK2
C530
RSEG
62DS
Lys72
17-day-old
163.com
Rhotekin-RBD
Epstein-Barr
Newsholme
G557R
RNAibased
Procedures.Statistical
de-regulate
STAG2-proficient
non-aggre
CCyR67
l-asparaginase
GCAATG/gtgagc
0·020
domain-truncated
TGF-ÃŸ.transforming
Group*
Val559→Asp
*Pt
–1760
COG0553
p.Glu755X
5′-GTTCAACGCCCATGAGTTTGCC-3′
endoreplicative
4335
G283D
HaploView
indispensable
Cyclin/Cdk
I1711
.PLAG1
1:1:3:15
FiO2
barrel-like
K198A
ofmelanoma
CEP10-FGFR1
G1244V
:5271–5281
SNORD55
Cheadle
.BACH1-deficient
miR-145
genetically-determined
linemutations
FGFR3b-S249C-expressing
HLA-C–specific
wt-GIST
Thermo-Shandon
PIK-2E9IF
.Moley
α-actin
caloric-restriction-induced
ttctag/ATTTTG
E2
lane1
mutiforme
AKT-activating
IVS13+1G→A
1263
1354
TCGAGGGTCGAAAGAAGCGACGACAACGACGACGAGCACCTG-3
anti-phospho-JAK2
annotationSNVs
C333Y
knockout3
receptor-activator
I326V
wing-notching
arethe
Jil
Cdt1
pro-tumor
H072999
polyinositol-5′
C620
241363
138
NM_000038.2
.P38a
CCDC6-RET
sequencing.Viral
MSKCC:2
ICL-sensitivity
Benchmark®
12-luciferase-reporter
HindIII–
Smo
L-018664-00-0005
MO25α/β
anti-p107
K618
Thr55
.DCC
.RCC4
12.50
Kingdom20
1575
0.41b
E166_R289del
and8,8
117550
5B5B
157–189
K614X
Beamline
35-100
RHEB-GAP
photomicrographsHeLa
Zabludoff
MGH-P0
K120E
long-oligonucleotide
Pcdh12
elsewhere50
V590I
nonenzymatic
g.14354_15455del
www.ncbi.nlm.nih.gov/nuccore
C3161G
R1890C
Prks-ROCK2
EWSR1-NFATC2
p16/INK4A/multiple
5′-TAAGATGGGA-
Phe830
Ni2+-NTA
demonstratedirect
division49
mosaicism.39-41
11q13.2-q-terminal
Leventer
AGGCACATCTTCAGAGTCCTTT
I320
siYap-4
study6
S.G.R
C459G
.Timed
pErbB3
614556
CBF-AML.The
homeostasis,7
interactions.24
i|/2
1.2.1
.NS511
5′-AGCTTCTGCATGATCTTCCT-3′
3IQV
sex-matched
.TP53BP1
ARS
Alignability
STAT3-Responsive
.Parathyroid
Y374C
antiCDK2
A456P
n=152
gtc
N=13
.Undifferentiated
NEDD8-conjugating
1781
GAGCATGGCTCCTACAGGTACAC
Fgf17and
E571-K568
expression-restricted
I222
.374
W539G
promoters.71
Electronmicroscopic
E73V
1,348
T182P
1∶1
RasS17N
transposability
60–69
Self-Renewal
119−127
Schmielau
activity/phosphorylation
PC3-p53–223Leu
ALK-VEC_F
GPIIb-IIIa
YY1–1452R
34.0
PK136
.0205
gene-size
TRE-transgene
reported,7–9
Lys833
.TL-125-AL
IL-6-induced
case-parent
S1188N
Matsuoka
miR-92
HER2-positive
99−100
K745_E746insTPVAIK
machine-read
RMH3969
Hotfilder
S-transferase–Ras
56798128
S6.1,2
transfecled
cross-reaction
grade.2-5
D145A
FLAG-B-Raf
19.7–
.HA-FKBP12
R301
antiproliferation
dye.Small
EGFR_HUMAN
Enantiomerically
mMNaF
Dominski
TGFβ–responsive
body-
37–69
.Simple
3000/μL
check-ups
chemoresistant
3α/β
BCP
Immunophenotypic
N71S
Tsc2+/+
Metavue
∼140
CPTC
kvd02103
lymphoma18
Instat
224C10
ANG2
W.
cMyc-ICNI
421–500
I-SceI
HGMP
3664
S1A–S1H
.isoforms
∼0.8
mAR-V4
.CCND1
Tuberin-hamartin
R834Q
13/3/2
NCT00798252
LC/MS/MS
8/49
E709/G719
NanoZoomer
Lys-563
761–843
R25E/E40R
MycS71
RARα-region
B-6
factor.15–17
apoptosis.27
2023-2028
D33
slideHistograms
SPOPMATHx-BTB/3-box-PucSBC1
S200R
HER2-Enriched
0.0022
16-point
ENST00000393606
α1-α2
life-altering
EGFRhave
10.8±2.8
Fearon
79238
0.40–0.65
Celera
1.161–3.184
ampli-
.Proliferative
Adj
0.1–143
CBLC381A
.Folded
recently.11,12,29,30
M855
anti-total-EGFR
Ghellal
invasion-suppression
Androstenedione
cttacattgcatacatagatcacagtggcaatgg
BZ
9·9
10bp
ctttataag
RING-mediated
.KB1
RPL31
254
5–28
.HCCs
//www.infosci
intron,35
Y877-R844
p53RE–hCMV1–DsRed
Wnt/-catenin
Woodford-Richens
altered-specificity
recurrent/refractory
occlusion
1–370
HS-gd-PTCL
SIP1-treated
Lys-Ala-Lys-Asn
.Maximal
oncogene
T2WI
9-somite
Cono
Entrez_Gene_Id
VIB-VIII
scribed
pli­
p60.38
ofdimerization
stimulation40
70.8
monochorionic
-activating
PDTC
8/122
cytosolicmarker
qPCR.14
RhoA/Ras
250–288
AM1-BCC
S2670L
division28
51.8±2.8
.Non-neoplastic
p75
L485S
trimethlyation
pivotal
6·9
TGFβ-1
DSG2
G186R
Comparasion
FA–protein
TOPGAL
pyrimidine
Xpo4
GV
twitches
tofacilitate
6559
cartilage-specific
holidays111
3459
.FoxO1–GFP
replaceable
H3-acetyl
Gehani
process20
.Therapeutic
growth.11,12
annexin/PI
hyper-activation
34/43
pSRa-T/P
study.These
Genotec
//www.epidesigner.com/
stability.21
UACC-812
F83
477–486
α-domain
homo-oligomerize
5'-GC-clamp-TCCAACCTCCAATGACCCAT-3
variants.1
0.79
S227P
Ilel456Leu
57,75,79,80
CCI779
IGtranslocations
Ras-Raf-MEK
PRC1/2
ineffective.37
0.01/10
Polar/charged
panel-based
2130
5,4-g
HC11-Wnt7b
lymphomas1
13,19
2.295
Grb2/
QxxLxxFA
GTCATGGCATTAGTGACCAGa
nonselectively
ticarcillin
5′-GCAAGAGATCATTGGAGGCC-3′
P733L/Sa
AMLCG1992
nonphosphorylated
chloroform/methanol
Solution-phase
XPO5
-γ
protein-1
P151H
GAP-independent
Fract
Bondjers
A_52_P350148
199-203
autophosphorylatedplatelet-derived
4129
//dx.doi.org/10.7554/eLife.00499.001
JIP
E622D
.Convergence
receptor.26
Fluorimetric
.WES-based
p=0.012
700μg/ml
Hölzel
transdominance
MGUS,21
mutations22–24
EF570786
samples.The
0.0001‡
3-μm-thick
FGFR2IIIc
19/35
pGL2hmdm-HX-lu
BCL-xLΔC·BAD
0.930
10−2
ofLKBl
subcytogenetic
y^
1.9–2.5
S590P
PA41
Stk11
studies,13
kinase-deflcient
R38W
GCLM/GCLC
leukemia19,20
D816Vc-Kit
gene7
.Rdh54/Tid1
DME/20
HER3E928G
.08905.002
H1746
p53–mediated
Baysal
96KB
-4-
Leu-862
CellLines
A1188T
memberA1
Cortisol-producing
gpl40prOto-rk
PMD
37.36
2a–g
38–40
non-contributory
BeadStudio®
Val218
A1246G
ISCA
nodose-petrosal-jugular
Ltk
alum
Xpress™
A165V
Brattain
glutathione-S-transferase-Rb
IVS25-12TrA
.Y572
85,86,93,113
oestrogen-
C446Y
BR-0490
.Volume
0.601
V173A
D594G
exo
E191K
v3.0.1
393-amino
Rindopepimut
c.1111T
Δ1–8
Q799E
f/67
.Least
Rudnick
puri¢cation
KRas/BRaf
V173E
anti-oestrogens
BRCA1–Met-297
26MET
P414T
yearsb
BRCAx
G236R
Capalbo
T-LBL/ALL
Fluoroskan
GST-NF1-
Neosystem
2EQC
clinicopathologically
10.1007/s11523-015-0361-1
laboratory22,28
myotubules
exon8
Non-parametric
hAl
tumors—specifically
BCR-ABL−
kinases.11
NIC-induced
.Alectinib
42251
zinc-binding-site
percent9
apopto-sis
.Immunofluorescence—HeLa
719GSGAFG724
TPR/NTRK1
cetuximab-dependent
NPH3-BTB
transcriptase–PCR
.Ltd
YF/KY
CPP
47,48,68,105
Bisgaard
symporter
identities22
BGB659
+1HMR18816.79
Karnik
sites.Identification
HCC20
//david.abcc.ncifcrf.gov/home.jsp
pcDNA3.1/V5-His
tandutinib
14–47
SMMC7721
.Supported
FOXO1A
q=0.1
39°C
rettransfected
cdk-binding
HCC1937EcoR
.IPI-504
c.19C4T
p.Ala328Pro
'o
4Department
high-grade/
Y-1068
Anti-phosphotyrosine
Kaplan-Meyer
1-2-3
domain.20
0.2.4
Hieter
exclusion36
upregulation185
TRPC6
Trans-activation
GST-SARA
RP11-1059C21
5′-CTTTTGGTTCGGCAGCTTG-3′
–T
H3255
Hoxa9
5l-bp
432–726
GTF
chr9/9q
coregulators
SRC3
3,26,31–34
intracellularstaining
controllable
ACGTTGGATGTGTGACTTTGGATTGGCTCG
Shitsukawa
Asp333
abiraterone-treated
sequenced1,3,20
μl:1
domains.58
Ptf1-Cre
AlexaFluor®
mRNA-subtype
pE3-Ia
2Q21
SCRWL3
CD8+CD57+TCRαβ+CD5dim
rearrangments
analogueG418
ml/35
Brca1tr/tr/p53+/−
OKT3
Eldar-Finkelman
Tyr529
formamide/formaldehyde-agarose
kvd12903
19.27
cSample
Moribund
ALK-F1245C
CLD
-R201H
cerbB
ATGA
Radiotherapy
Chk2-P
ICC24
TSC1/2
5B-C
prom1
611731
10-month
.P124
A−E
Genethon
low-endogenous
.CEL
F1490S
Gassen
.Prospective
130-132
models,30
2—4
5′-TGGGTAGGAGATGGAGATGC-3′
PIG3-mediated
pMX–ALK
pVP16
G395A-R
392
to-date
7TM
fgfr3
burden,26
NPM-ALK–induced
Vectastain
p85α-WT
5ʹ-GCAATTTAGGTATGAAAGCCAGC-3′
EWSR1/NR4A3
del2235–2249
CD45+CD7+EGFP+
EBV-positivity
tostimulation
trafficking—as
MDM'2
DAPK/P14/HDM2/P53/
8.73
Antibodies—COS-1
pMM7-pMM14
ALK-F1174L
178_179delinsCG
CCND1.41
pCMV5B
Jansen-Du¨rr
sc-53015
circumferences
100/1.35
Scotlana
INI1-4
4-69
NF1_00620
HM48-1-PE
phospho-switch
pAR3
signalling15,16,17
R1203Q
T-vector
GAL4AD-CITED2
033A
HIF1
PLXB1
Neo-containing
.Pellets
11q13.3-qter
3-Figure
oncogene-sensing
Res.,56
.LATS1
BT474/
Whole-cell
activation.8,19
INGNNYVYIDPTQLP
pcDNA5/FRT/TO/3XFLAG
chemoreceptor
MKP1
miRISC
.Cortisol
HGF/SF
co-inheritance
IC50s≤
M12509T
stability31
EMBIGIN
1.2-9.7
threonine-rich
SmaI-NotI
579–587
.GMEPs
n2
GATA/FOG1/NuRD
LTQ-Orbitrap
ERK1/2-dependent
,2m
Δ1–108
Sc-7020
Database,21
BRAF-PLX4032
Eµ-Myc/DNMT3B7
marrow.3
218080_x_at
METwt
de-differentiate
phosphotyrosinebinding
LGIII-
KRAS-R7
14-15
pThr68
samplesa
rDLl
pmCit-N-rasG12V-E49K
pY65C-FLAG-Rev
neoplasm.Several
8387
non-hydrolysable
WO-21
EphB3
ber
.ECTMWT-2
0.621
Kan
AssayCells
disaggregation
.10822
14,47
malignancy54
:3987–96
gene–reversion
Youn1,5
s2s3…sm
FLT3-wt
4.766305433
5-nt
Cignal
Smad3–/–
nonexcised
hepato-tumorigenesis
homozy
DiscoveRx–KINOMEscan
gamma32
2L6W27
ofcancer
∼6×
bya
Snf5-deficient
T160
anticoagulants
3′-to-5′
LIN28B
G844D
P85L
TTCAGGCACA
RP11-744A15
-scan
BRD4-genomic
BRIP1,34,35,45
WBC
5¶-GCAGAAGCACTTGAGGGAAC-3¶
Edinger
02-AmRNA
non-migrant
gtttatttcactcgaggcc
.FL
pneumonia.b
2Chighwire_math
v2.3.5
55˚C
.Archival
STAT3/STAT5B
MAP2K2—that
1646
nucleophile
PCR-Based
3-2
P231
mutations,6
×40
Nosslinger
progenitors,25
.Telomerase
HCF1
KGNARL-PV
405
jjj.f
erythrodysesthesia
301310
823,835
554079
.STATEMENT
0.66b
types.18
-1
.GLP-1
5200
A876T
2p23-24
Brazil39
previously.6,7,16
Tyr43is
.31Table
CDK/RB
FLAG-hamartin
rs1862110
lowKm
myc-MEK
GGATCC
transcription-polymerasechainreaction
K/SDS
cross-talked
9/37
47–50
15901
hTRX
OLT
dialysing
MET-E168D
Trofatter
amplification.In
LKS
c.1393A
3′NOTCH2
tinib
HA-CA-Mek1/2
chondrodysplastic
.FOP-FGFR1
locid
D12S79
haploinsufficient
hybridization-SNP
PAMM-024ZD
5.75
BCL211/BIM
4.02
internalization-defective
candidate.14
Molewaterplein
H50R
cytosis
XRCC2-deficient
14q133-q21.1-ETV1
HSC536N/FANCC
regeneration49
.ATL-Engrafted
RAS90
Co-precipitation
nm=0.6
LMD2000
optionsFrequency
3057
c.88C
AFigure
175,000
þCD8þ
generalizable
Doetsch
.KYSE170-luc
.Aaltonen
THYMU2038797−8.2cDNA
PF-06463922
dilution
pRb-mediated
5′-CCTGCCGAAGTGTTTCTAAGG-3′
hCD3
MR/MLD/BD
h/day
HED351E
.ERK1
R474Q
3.095
1939A→G
factors.5,6
p-value=1.2e-14
three-step
TP53-H179Q
IL7-Rα
anti-phospho-p42
alone87
Gel-shift
orPvu
measured8
ATP1B1-PRKACA
Low-resolution
ALL.21,30-34
inter-individual
KIT-hyperactivation-driven
cell-targeted
SOCS1−/−
olaparib-resistant
.018*
262:1
.Cognitive
reconstructing
alignedsequence
Hsp70-VHL
KIRC
10Jm−2
MSH6
4471250
significantlymore
c-H-ras-expressing
395-3B-1
Hyper-Responsiveness
GLI-mediated
Aretz
p.D28
Hosoya
EDG
9qA1-positive
SLC2A5
ΔS226
348
L–N
FISH-based
c.862-
5'-AGAC-3
PI3K-related
localization.50
leukaemia,1
Normal-mildly
library37
Csk-
Ile825
0.37297335
Deroo
VHL-R167Q
R137L
proteins41,42
0–5000
.Roughly
Gregoret
GST-Cbl-b-TKB
40
Khosravi‐Far
HPT
.ErbB
TEL-JAK
7625
12-month-old
AZD2281/Olaparib
let-7b
18.8.15
±123
c.1583C4T
0.9-632
temperature-controlled
.Chemotherapeutic
on/off-inducible
5′-TGATGCGTCGACGTAGTGGCTGTGGGGGA-3′
PLC-γ—which
KLHL7
CYP33
.gct
laminins
G128V—at
15.10
​andf
67.25
carcinomaLiver
KIAA1161
cadherin-based
aTEL
p.Gly328Arg
TAsimilar
23560
9.02
2q21.1
pMAL-c2x
28·8
S241
glucose112
10.1073ypnas.050408497
27,578
anti-ERBB4
DAPT
therapy1,4
1.9–8.8
series.11,21
PK7242
usedto
polyethyleneglycol
deregulatory
high-genomic
criteria.34,35
R560T
MH1-linker
5'-TAAGGCTGGAGCAGAGGAAG-3
Floricel
9.1ABCA6ATP-binding
Bogershausen
epidemiologic
cells.71
288–524
tRFP+
E76K
age/observation
discussed.83,84
Pre-enrollment
23C
anti-phospho-Y1068-EGFR
S.Y.
substitution,15
anteriormost
GRD–Ras
Ramo´n
MEA
Mx-1-Cre
Centrella
F39L/C20Rc
p.Thr116Pro
Egf-stimulated
TRX
58.5
interpreted.13
32,33,34
45,003,675-45,011,075
TAATAGGATCCAAGGGGTCTTGGCTGGCC
Raffel
eludicate
ALK−ALCL
tcagtctgagtcgagcccct
HemaVet
braziliensis
lymphoma.46
3938
373A
3A-2
n=80
advanced/metastatic
R-value
4131
β-TrCP-WT
RP11-78A18
Leucci
second-line
NH3
R154X
B*07:44N
domain-binding
5A-nF
26–45
S5D–S5E
5'-GAGTTTCAAGAGTCTAGCTT-3
45,46,47
20s
.Extended
Center-IRO
G1440S
compound-treated
MEC-2004-261
PDX1
M-7769
fluoropyrimidine
8•7
Hippel–Lindau,56
p105/p50
Kucuk
.Collection
D-cyclin
DME2+
p.C342S
Maidstone
Amaxa
P00021
RPTKs
alpha-SHC
activation.5,6
TE-1–6
∼669
eliminatedwhen
twoproteins
~0.001
dramat
BAC-type
mRNA/β-actin
Tissue-
IRP-2
Plk5
PJS01
pDM69
prox
PY490
Glu-88
5,574
M206
−1.5–1.2
mHGA36
JUN58
proteins-RAGE
–1211––
170/202
SW40
carcinosarcomas
ubiquitin-interacting
IIR
100-watt
HOMER1–HOMER3
W148R
culin
chemo-radiotherapeutic
RG-14N
possiblity
SureTag
Bcl10/IgH
PMS2-suspected
selumetinib
cells–were
FAL
immunodefi
Histidinol
Eμ-Myc–
AML.28
pTEL-JAK2
∼100-
0t-
GFP+lin−ckit+Sca+
PEComas
antigens.16
G/C-rich
5′-CACGGCTCGGGCAAGCCTCGAGAT-3′
strong*
−1.16
short-fascicular
VWF
Minfi
3a–b
MTCP1/TCL1
L1C
A_51_P253074
IVS16–10886G-A
Minigene-based
nontumorigenic
0.000461
.Electropherogram
8.23
236C
A763_Y764insFQEA—among
P203L
455
TGF-β/SMAD3-mediated
NM_005027.2
GTPγS-loaded
dithiothreitol/2
0.00001
history.Fig
calcium‐binding
compassionate-use
dimerization.34
18–23
technique.18
LNR-HD
pGL3-luciferase
cancers6,28
.5.1
Shern
OligoiUH'Ieotide
0.4236
1308
pcDNA-5
Q-P-K-K-K-P
1.342
una¡ected
Erythropoietin-independent
.MP41
7.48
wereloaded
10/7
puromycin-treated
Rothhammer
N-Ras-specific
reconstituted
misintrepretation
F74S
high-content
p.and
.Neuroblastomas
Y1283
mutations.7-
below40
P493-6
5-mers
f/49
Y589H
189908
=37
0·19–0·39
1,262
homoduplex
rearrangements—define
CALGB
CDK6-V5
24:4764-4774
Fig.2C,2C
mice.79,97
Genotype-Phenotype
1–768
Macrogen
Sca-1+Lineage−c-kit+CD48−
pan-T-cell
19×
P0
T417
containing~60
short-arm−specific
MEL285
5¶-GCTTGTTAGGGAGTTGTGG-3¶
Du145-derived
0.9304
nonmigrated
21F*
RBM-regulated
12147
LEU2/2mplasmid
OSI
.R87P
Transgenomic
ATP-competitive
GATTGGCAGCCGCTGTAGAA
activity24,25
2007
L1742
.G-banding
A7V
Cdk5
1–5nM
Bcl10-induced
ful
t-MEK
DCC-2701
T1c
Dual-target
mutations46
Thermotoga
EWSR1–NR43
OAZ1-KLF2
pS259
666–668
mutations.30,31
prostatectomies
N58
pY599
4,5,27
20.5
β-hexosaminidase
height/2
DNA.Wild-type
G337S
16-specific
n=38
MuSTAB
.CRC
ULK4
T85P
PPARγ1-P
p.Asp465GlnfsX2
.CCND
activation219
.2472C
ACHN
and/orunstable
2854A/C
ANTIESTROOEN
children.71
43210
Tyr518
CMPs/GMPs
Knock-out
27-3
trd
-domain-containing
M124R
α2β1-dependent
Boggs5
2867
GFP-dependent
R1–R4
HA–p107
FGF
JN
39.1x
18251
Sequenase–radiolabeled
NM_013518
Tris–HCL
proteinsWe
PVALB
maxT
Fig.8,8
205767_at
TGCCCAGCCTCGACTCGGTT
RUNX1–
126–133
PEBPβ
Asp30
igv_snapshot
-Independent
trichilemmomas
SMO-resistant
Plawski
5'-AGTTAACAAGTAAGTAGGGAGGAGA-3
dose.14
//www.invitrogen.com
D38B1
features.2
doi:10.1371/journal.pone.0025021.t001
Eliyahu
.___
RAF1-ESRP1
OHS-043
membrane-distal
compounds194
.small
ifestations
bothp53
92,500
myeloma.8
Rad50
+-+-
Myl1
NAC
28.85–36.95
K351E
144K
G244V
p.Cys93Trp
.Publicly
R166A
anti-JAKI
pocket−unoccupied
q28
17−19
Cannito
protein10
Z.S.
1352
Pseudocolouring
pLM
RHOA-GTP
.Short-lived
66/84
Hec1B
Ho*
sIg+
Na2VO3
Maspin
TBL1XR1-shRNA
red-labeled
GRIN1
pRK5-FLAG-Smad4
Keap1−/−
–amplify
0/38
pCDNA6-V5/His.b-ARID1A
3L
MLL4-enriched
Mg-2
dolichocephalic
Yeonkun-Dong
mass/charge
X52833
Assas
16aa
CLINICO-PATHOLOGIC
G272D
reciprocalPDGFβR/HIP1
domains6
Ile167
Scgb1a1
L1352Q
Ly6G
V+/propidium
CD14
Src/PEAK1/ErbB2
Mammosphere
Nordqvist
TetPTEN-Y65C-FLAG
mutS-KA622was
.20,23,27,28
phospho-Ser18
L263fsX286
THBS1
BROOKMAN
BRCA1/IVS18
C-Met
baculovirus-Sf9
intron-proximal
.Infinium
methionine/L-
NVP-BEZ235
GTPase-inhibiting
Cysteine–Histidine-rich
pIREShyg
IVS5-11
1653–1666
*Significant
hCdc4-crossreactive
differentclass
research.Another
HBC-FA-I
eotaxin
Genescan-400
≈3-fold
5′-CCT-TGC-CGT-CCC-AAG-CAA-TGG-ATG-AT-3′
Dalla-Favera
polydrug
9459
C121S
catalytic-dead
Fig.3e,3e
V178I
malignancies.19
49/89
S249
5,442
nick-translation
β-catenin21
GISTs.The
β-catenin-activated
interferon-α-induced
Fakhfakh
immunoprecipitation-coupled
O.B
growth.18
0.217340253
7,436
H3K56ac
GBM-07
D1359Y
mmu–miR-125a
–extracellular
.BCR-JAK2
apoptosis.28
6G-I
.p110α
Smad2-mediated
AGGGGCGGGT
18.2/24.1
+9
non-compartmental
Phe447
PHD4–6
rs34231037
temozolamide
D92H
kinase/Src/Ras
R49L
anti-pan-p42/44
.HNF3α
M5
ARE-Luc
.Bioactive
ASXL1-MT–induced
miR-146a
Bcr/Abl
tranformants
CCL4-induced
oxyanion
R|F
rare13•19
c.141G4A
GST-CDK4
J083
PRDM1.E5.1057.F
undertreated
NTD/LBD
740822
LARII
mESC
hSequences
CBP+/–
K27
better-described
Y326
0.4/min
S259Y
GAGAAGT
5′‐AGGTCGGAGTCAACGGATTTG‐3′
H4-12K5Cit/K12A
PCR™II
CARCINOGENESIS
LATS1-mediated
➝
2111
0.4949
alpha-2,6-sialyltransferase-1
.DEF-domain-dependent
philic
S6
SEPT2
D223A
16CHU
pG-Xba11/340
c.7617G
Li-Fraumeni-like
AKT2-K181M
p-Stat5
.35,39
di-methylate
other111
σa-weighted
PD171
fractionof
CGGGCCAA-AGTGACCATGAACGATTTCGACTATCTCAAACTCC
pl20-GAP
DLBCL-
LET-60
126/1193
NCT01231594
R343Q
NBD-GDP•RAS
H-ra.t
4556G
.8.4.6
CCNA1
0b
Y245F
0.5∗
Annexin-V/PI
162220
M3563
CTLA‐4—B7‐1/B7‐2
ST-EPN-RELA
MAC-1/2A
IFAR1001/1
.Urea
S411G
prostate-tumor
telomeric
inhibitor-mediated
VHL7
inMutS
TCTGGGTTCTCTGCCG-3
E030
threonine
low-bone
P496R
anoikis24
ACGAAGTCAAAGTTCCACCGT
v4.21
B′/PR61
5-fluorodeoxyuridine
line–normal
phosphatidylethanolamine/phosphatidylinositol
IDH1-R132Q
5′-GCUGUUGAUUUUUUCUCUC-3′
3320
Hamartomas
elsewhere12
Δ2481–2495
intestine22
A.M.R.Taylor
Roix
12p13.31
1073
NM_000038.5
Bidimensional
oflabelled
Lag‐3
FLT3mr2
p.Trp113X
11–22
FLT3-Y842C–
70.6–91.8
high-angle
Single-Nucleotide
≈1,000
mxSF3B1WT
IACUC
CML,35,81
pathway80
Rad51L1
Mef2D
imThe
48c
phosphate-mediated
-GCAGCGGAGGACAGTTGAG-3
Hs01125299_m1
SIC-001-5
mut≥mNSg
KRas-induced
Rad51L3
volves
0u
micronodular
.Curr
.G178V
.Methodological
IHC-stained
RG7204
cancer,14
anti-KDM4C
NM_004972.2
Ala502_Tyr503dup
Helfman
V559D
UbqL
cartilaginous
related.Survival
TTGCATCTT-30
CATGTTAGAGCATTTAGGG
13F
respectively.25
3055
N-Methyl
n=270
reports.29
1.4826
STRADα-MO25α
−T
optionsEstimation
NCT01449461
JHH7
80–400
cancer-basic
NaCl-
Methods.Quantitative
precursors.66,67
prognosis.6,7,9-14
-70
v-sis/c-sis
V654A
0.518
.NGF
PKA-mediated
mutations52
–Cl
micrognatia
26-subunit
AS-E
.Fusion-associated
Y1235
HPRT1
wild-type/MutF
c.814_816insA
anti-MLL1n
5'-TAGGGGATTCGGACATTGCGA-3
CD34-selected
nEAsVMkeF-ncHHVVRLLGVvsQGq-
Ultra-deep
HIF-1α–dependent
PolyPhenb
FIP1L1-RARα
11β-hydroxysteroid
NF-Y/HNF-3
mark99
TaG1-G2
M-MSV
539b
macromolecules
pEF.6
UBASH3B
6.89
phosphoAMPK
5/6+
Mehren
.Smad3
.475G
4607
Hs00171790
TUB2.1
WNT11
M-antisense
CAF38
Saoˆne
pair1
p-iodotetrazolium
Short-term
−906C
HindIII/BamHI
GCGAGCAGT
nihms646437t2.jpg
HF
944G
semilogarithmically
E-FBXW7
biotin-blocking
gene.28Andreutti-Zaugg
msh2-GD693
caspase-3+
conWrmatory
Jae-Gahb
S3020C
Hist1H1E
NM_007817
Ex7
FSK-induced
F2-values
to951C
residues.14
RKIP_U_F
CCGCCGCCTG
ψ
O:17
PKBα-ΔPH
ALL-Berlin-Frankfurt-Münster
7776–84
hFunctional
CER
valueZ0.0032
estrogenic-stimulated
53–72
Gly390
transplanting
β1,6GlcNAc-branched
.Currently
Glu93-Glu94-Lys95
R1088C
E683
S150-2B
nonapeptide
522
seven-fold
K624E
pRsc2-T67P-myc
550C
–0.89
epidemiology
FA-M
.Broccoli
tumor-resistant
loxP-STOP-loxP
niscent
sub-optimal
PDGFRalpha
ofC-MAF
D927G
959/15,687
Synergistically
Boiteux
pBABE-Puro
CCATGC-CCAGGCACTCATTTTCA
individuals,211
bone-like
MlaA/HerA
RUNX1-H78Q
six-somite
Macrophor
disease4,5,6,7
RPL35a
Pap/Aci
TCGG
oligofectamine
2/10/99
byseparating
Tet1-shRNA
diaminofluorene
Stylianou
P19a
32D/Flt3
.-F.
PI3K/mTORi
JAK2–BCR
DEE-NQQ
Ex4-3int
1DNA
phenotype.Identification
CycG
Ewsr1-dependent
A/c.475G
Y35N-driven
med.uni-tuebingen.de
5′InsTGGGGGT
unulyzed
2257
MEK/ERK-independent
hypo-
A-22
774
A82E
o9
HDAC/CBX4/KDM5B
16-mer
adominant
H3H27ac
0.44
T875N
↔KP
GAD-MSH6
.Locations
D822K
XPO1-MLLT10
IL-9-dependent
28,027
.7544
Notari
M25269
telangectasia
.Alexa
CRL
0.001bImmunophenotypeCD34
c.1317C
26/37
5′-GGAGCAATGATCTTGACTTC-3′
III11
Chabannon
c-Src.22
factor-dependent
Etat
light-headedness
inhibitors.Response
8/91
study2–4
194070
LDLa
Mutation-Defined
CD11b+Gr1+
0.81
non-assigned
criteria.8,9
GFR1–4
GTCTTTACCCATTATTTATAGG
C5/D5
siRhoA-2
MKP-1
15q21-22
Somlo
receptor/ligand
p.P539R
M/R
ICGex
Ser304
antiacetylated
1lg
subject-level
Fluorouracil-Based
peritoneal/ileal
sc-9104
AS5
​and7,7
plate-derived
synthesis205
Y752
125-226
CsCl2
Grimwade
ICG-HNPCC/INSiGHT
−0.008
R27Q
ALL.1
β-hairpin-like
F1577
894
NADP+-dependent
leukemia14
5c
.7a
5-aza-2'-
miR-101
remyelination
pH4X4-Luci
GS-positive
1532–1784
FGFR2_IRES_Neo
Matrigel/70
suggested.16
3LFM
INTERPRO
Upd
56.8
mutations/ALT
oftwo
c.-138C
D-RafEAKD
A175D
366–382
T357A
pER4
Bessman
//fastsnp.ibms.sinica.edu.tw/pages/input_SNPListAnalysis.jsp
-11.3
Pro/Ser
ab76003
promoter-lacZ
3844806
.Twenty-four-hour
axin-GSK3β
mRNAfor
K50L/E
aPKCι
arrested-deficient
sc-2048
ETV5b/c
myoepithelial
Konstantinopoulos
36–38
5′-CGACCCACAGAAATGAAAAGGCAGCAAACT-3′
5277
LDTPINYSLKYSDEQ
pmol/100
814delACT
.ARF
individualized
37–48
MKK6
4-h
Kmt2d-dependent
susceptibility.21⇓-23
BRCA1–staining
atctag/GAAGCT
histomouse
nph-webface
c.118_132del15
Gastric/28
59-CACAGCTAGAACTTATCAAACC-39
MLL3/MLL4
neuroblastoma,37
PLC-γ-binding-defective
3tag
anti–PP2A-A
A2F10.1
D835Y
FB5D
G1706A
reviewed92
rs6259
747-753insS
p21waf1/2300-Luc
D2/J1
2347–2479
.Knapp
M139V
fucosylated
Allotransplant
D1/40-295
anti-thyroid
D1/1-196
Reversed-phase
Platinum®
14–70
mandibuloacral
SF1.15
SP-C/Ki-ras
1802delinsAGAT
FVNV
AGCT
0•21–0•90
Fbxw7+/fl
MYC-associated
DKRMNS
outcome129
3.77-fold
3,612
wDepartment
B2PX
p16INKa/MTS1
sc-7985
Franscisco
331-353
FLT35
E171
Three-day
exon-20
2/236
1/5000
manner10,11
p.Q602*
non‐functional
C1614R
villin-like
.Prognoses
Epb4.2
Pharmingen-BD
unclear.39
thrombocytosis,1,15
GST–Cdc25A
.28,32
0002-9297/95/5605-0006
1.214
SSB
Oncologia
GTA-3
Fracchiolla
V82F
NS4–10
N345T
4.2Complex
14-
Strano
78–86
Saint-Cloud
growth-suppression
849
MTM
p.Cys39Tyr
P459
kinase-3ß
4056
tumorigenesis.Previously
-B8
AspN-cleaved
.Extraction
40-cm
537
observation.23
69008
Abarzua
Tyr1604
stage.48
C299Y
Flt-3ligand
dataset-wide
ΔA-ΔG
Akt/protein
3ZBF
EGFRvIII—appear
NZM48
0.99–7.6
3068
VH/JH
stand_emit_conf
suppressor.25
1.03×10−7–2.17×10−8
.104
–––4–––
malignant-activation
B7-DC
71233
familiesd
.7237
20,25
reaction3
EE-expressing
175K
12Translational
x400.Bars
cancer.15-16
R17,10
pCR.2
mutations.10,21
haematologist
614A
dpm/well
classi®ed
rst-degree
analysis.25
Y570-Cdouble
c-KitD814V
p.R742P
435s
hFANCE
DSG3
DOC-2/DAB2
II–VI
1-αMODY
I-squared
NBL-S
à
G380/382R
G12C/C51S/C80L/C118S
pAIa*LyaLouLsuAI*GlIyGI
Fig.22a
Macheta
Post-alignment
homoduplexes
Cys238
D19Mit30
frma
Platybasia/basilar
Ab3
78.2
p.Arg17∗
markers42
un-repaired
lineage-tracing
tryprophan
NS/P
Gly533Cys
4/21/2015
o20
*605284
1.186
half-times
progress,19
Bevacizumab
93.75
Src-I1
Mlh1pΔ
inactive-like
Mat3p
anti–Bcl-xL
RVSGAPAAQDPVTETPGPVAPAPA-
N1109
Volinia
KIAA101
Bio-Imaging
.Brie¯y
R276Qx2
NB4
available.24
49-201-723-5171
59CTG
ROCK1/2
Up‐regulation
phosphate-bufferend
R54W
EZview
hMSH2—We
Cepero
D9S162
106Ba
72°C
minutes.13
normal/normal
conHelix
D429A
havecompared
methylationa
Immunostainings
cancer.31
Fig.1e
5.73
Figure3c3c
anti-Myc
thecDNAproduct
equine
gp140Proto-'rk
control-based
FGFR4/GAPDH
17q21-q23
kvd02104
ZZ
57107463
W666R
PhosphorImager
Vaudry
genome.9
tunicamycin-induced
150
AML-M1
PTEN-promoter-point
Mitogen-induced
A5277G
12q12
leukemias,14
xenograftedtumorsresectedafter
hck
e13a3
penetrable
7.19
Echard
JH1-Jak3
.Pear
Wnt1-expressing
Amide
Pro-41-
117–526
ims.u-tokyo.ac.jp
stock-keeping
NEDVNTNLTHLLNILS
V:19
eRF1–eRF3
Y372C
IGF1-induced
d,3000
CNS.3
PDGFR-driven
.847
LNSINEKIDNSQKCLEKAKEETKTSKSKLDELEVDSTKiRPLIEKFTYLEKELKDLENSSKTISEEL-SIYNTSED
MCNsKrasLSL-G12D/+
G4S
.Five-micrometer
tissues4
healing1
Q79R-
S2.6
corepressors.85,86
475-532
pEAA301
↑↑
UN11
Jarrar
18Å3
P=0.735
wildtype
38–15
TG101209.Our
mTORC2-deficient
Asp351-Pro356
Heteroz
laneT
NIH-3T3–vector
PTPψ
anti-Bcl-xL
Fgf2
∼400
+9–10
b-cateninLEF
E533D
//www.genomatix.de
GAGAGAJGTAT
ApcΔ716Dpc4
6b
3138
mSin3A
GZ
5–19
7,110
sift.jcvi.org
:78.8–100
-erlotinib
.Arg784His
Leu32−Glu35
missense-derived
GRO-α/CXCL1
.Methylated-CpG
byretrotranscribing
yMSH2
5′-TTACAGGTCAGTATCAAACCAG-3′
kHz
development258
//www.bork.emblheidelberg.de/PolyPhen/
iodide-positive
Q60R
248–308
HOXB13PRAC
402-509
endometrium.4
study15
MgCl2/liter
CpGdinucleotides
Wehrmann
3D-F.
suppressorgenes
.BRFF
Lys171
TGFβ-repressed
741/1935
retrogene
Casein
phospho-ERK
13C/13C-edited
c.1016dupA
S183X
Horikawa
drive.9
HMEC-hTERT-p53DD
p21ras–caged
c.450G4T
eta/
blue=subcutaneous
aportion
previously.3,13
−0.10
.S11
apoptosis-mediated
patients.8-15
GRB
G719A-mutated
PINCO
-AGATCTGCCATGTGCCAGAC-3
AR004549
730
HIST1H3C
Wehave
Cell-surface
Inc.KEY
​Table2,2
NGF/TrkA/Ras/MAPK
nonredundant
28:1028–1039
486P
LacI-FokI
cases1,2
I177N
125â€
F2005
Jak2-V617F-associated
278750
0.204
V5-catCS428C
pGLM4T2
cmyc
PtLVIt
HBCx2
26880266
pFlag-CMV
v-Src-transformed
YAP1WT-RFP
.DOC
co-dependency
.CMV-GAL4
PA7
G9T
:4-10
Peyssonnaux
47–80
9317
MKK1
−7/7q
onization
EGFR-L838V
ChIP-on-chip
one-sided
.FDA
15NH4
pCMV-53
Val302_X863
23–81
2253
921C
FlagLKB1
1p35-p36
Map2k1
first-in
sequence22-24
MEK-BRAF
rare.4,5
ASCAT41
hMSH2-
explanations.TABLE
4,10
//doi.org/10.1371/journal.pone.0103021.t002
.PEAK1
AMP19
antibody-drug
theamino
10-base
N217I
S2807L
ImProm-II
182.4–182.9
rhBMP
complex67
pNF-κB-Luc
Humanitas
p.Leu12Phe
MCL-like
.2030G
pRCC23,24
Prima-1MET
leftof
HQRKNED
5'-GAGAAAGGCAATGACTCAGCTGCC-3
luc-control
D1017H
576–580
MRW
Dankort
.2012.06.012
isoflurane/air
.ErbB3
RFX
bysequence
Vcam1
high‐resolution
Gln62
AA664212
times—although
chr16:67193822–67387415
miR29
A45V
FDA-approved
Clonthec
aa252–330
146-265
AC-fulfilling
.Shortly
StepOnePlus™
FAM72C
MelanomaThe
.SQ20B
Bax-
.HMGA2
5122000
activity2
diet-induced
Ser32/26
RRXT
indexd
KRas4A
Figure3M
155-fold
52-54
EphA2
lentigenes
complex107
2-epimerase/ManNAc
polyminylidene
CBFbeta/MYH11
Esteller
.14,18,19
.MDS
.Vertical
gtttgttagttttttgtag
0·33
3-Roc1-dependent
HCC10
BRAFV600E-melanomas
5–6-fold
anorexia
Burkitt's-like
stably-transduced
I274R
Powzaniuk
log-folds
HCC1937/HA-BRCA1wt
4T
site47
neuroanatomy
15,000g
reinducing
MluI/SM6
N1357
TSM
TCGAGCCCTTACTGAAGAAAATCAAACAAG-3
g/mL
carcinomas.8
kinases,3,36
melt-curve
5311
60°C
PRMT
MSCV-FLT3-ITD
Ez-c1
ctd
63.5
pS338
haemotoxylin
Diazoxide
BEST3
.CCL2
allele—that
152/153
G/T-UBr
vitellogenin
D345H
Ma-Ma-48
ICC8
pcbi.1003545.e008.jpg
q22
p.Arg80Pro
His237
Met151
EPHB4
COFS2
CCT6A
gastriccarcinomas
CBFJ
TAAGGTGCACAAGTGGTTGC
Paugh
NHR1–4
−13.1
tissue-restricted
FOXP1
p53+ve
mutations.4–6,10–13
CTTCT
.Cultured
SC-283
4,500-fold
E1234Q
P=0.15
jmg.bmj.com
2,6
neonatal-onset
Smad2–receptor
ab8925
D-domain-dependent
androgen-resistant
AML.3
WEIHI-3B
.PGL
4.Newly
p.W380R
autoantigens
.Ultraviolet-dependent
MUC5A
Wingender
Φ-nonpolar
JEOL
.2A–C
lymphoid-myeloid
NB1643
.Cytosine-to-thymine
598-624
436–438
10/44
∼277K
S80N/H94Y
anti-Evi1
5•9
96.3–96.7
pone.0094132.e001.jpg
SKUT2.See
278-286
.Signet
2F11
case/control
syndromes.30
fI1
843insC
carcinomatosis.3
15,17,19
S1026
Tektronix
.Maturation
aurora2
-AATCACCTCCTACCAGTCTGTGC-30
.Bromodomains
tarnsfection
KTCL26
Graaff
cancer-driving
dI/dC
studies,5,17-19
≥1
42/44
BRCA1-responsive
Srsf2Δ/+
alpha-PLCgamma1
VAV2
34440
L20298
Radiat
947KB
endolymphatic
triad–associated
co-label
FGFR3–ELAVL3
3-day
cccag
L624_R629
MxB
progressiveness
immunonegativity
Whitlock/Witte
NUP98-NSD1-Like
mSin3A/HDAC
cephb.fr
NOTCH3
M07e
3493–3494
KRASQ22E
years11
.BRCA-associated
1596
p.A73A
368:2385–94
Dowty
S62A/Wap-Cre
C49Y
AAACGTTAGGTGTAAAAATGCAA
//www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/index.shtml
2.Characterization
.Low-copy
ABL
SNX2112
tumor-formation
Glu-66
53.5
56L
heterogeneity67
mg.93
S121G
radiophosphorus
cancer-activated
non-template
training/testing
KMT2DΔSETgFlag/gFlag
Y03
unconfirmed—
.E-cadherin
CTB-13H5
MOZ-5343
PRMT9
region101
glycine–serine-rich
metastasise.2
p.G469
PRT060318
presentation.9
fructosamine
Na3Citrate
PGD
F27Y
TRAP-1
Aravalli
MEF2-
Photinus
Klejman
.Calcium-activated
.Andrew
biaryl
S9503101
68C
leukemia,22
0.42-0.78
Lingner
0.000175
.Western-blot
-quinazolin-4-amine
C229S
V185G,25
9D
protein41
v2.12
Dbf2-
p.R20Q
HEK293-transfectant
.Reproducible
heterotetramerization
p.Gly171Asp
CD564308
EGFRmutant
//agvgd.iarc.fr/alignments.php
5'-PuPuPuC
γ-phosphorus
Chelex
pre-incubated
94–105
c.250A
14,929
Delta266–295
−3.68
Hayashita
Rabbani
perineo-scrotal
intra-venous
MAPK15
'Argonaute
hysterectomy
5,21
cells.29,30
KMT2D-dependent
half-sibling
APLC
poly-GT
.NoKIT
4μM
non-IGH
and7D
p57â€•2
JAK2.37
HER1/HER2
hG2-P587
A1608V
//babylone.ulb.ac.be/beatmusic/
.NF1
ofexons
lines.16-18
DO1
Ni21-agarose
mammary-coronary
GTPase-impairing
RecN
beta-blocked
1343
Class1/Class2
493–495
Wilms-tumor-associated
duplicationin
12,11
gemcitabine138
wereclosely
Bellco
pmGFP-H-rasG12V-G48R
Vasudevan
11/2
5′-GGCGTTTGGAGTGGTAGAAATC-3′
.SUMMARY
6OACATSATT
H873R
N3385
average-linkage
NPM-FW
3788-3790del
Brca1Delta11/Delta11
contributory
86·7
p.Y665H
Promoter—ERF
Cannavo
ΔMBII-expressing
FKBP38
~20-fold
5-AAACGCTTGAAGAGGTCGGAG
L225LI-expressing
element–binding
LR05-139
p.C278Wfs*6
software,60
pY397
51.6
1,627
β-interface
1076-1357
Ad-MKP-2
NCFC
Polycomb-group
dynein
p.Gly415Arg
2G7
53A5
−1SD
−aX
CRK
Cullin
2343A
5.7-fold
BRCA1–Met-297–overexpressing
stSG43208
10.50/10.33
ILVNS
q21q24
7748
diseases7,10,12
60-year
DOC-2
CATAGAAAGTGAACATTTAGGATGTG
affectedATP
Genes-To
G624S
SNPeffect
D814I
.Fig.1
Y659
6D3
MEF/pcDNA3
.2D
.†P
min.C
K745insKIPVAI
.1771
Hs01453316_cn
Microdeletions/insertions
34,40–42
reduc
core-domain–DNA
unit–granulocyte/macrophage
aHis7
CARF
Flt3-expressing
.Cockayne
Gibco®
p.F595L/S
anti-hMSH2
SVHUC
SectionResultsA
formedcontaining
.Mechanism
tumours—directly
mutant-specific
BC006793
23-bp
CMDP
V678F
318.9–953.5
NCI-H854
RP11-317E13
antiphosphotyrosine-Erk
Thr346
phosphoserine-containing
0.308
MG.
p21cip
Gómez-Casares
rnm
pEAA294
3DN
Kdm2a
Convance
G1950C/K650N
Bournazou
SPDGHE566-571R
terminus23
inositol-3-phosphate
6,18–20
APChypermutable
K205Q
singlemutant
Vallerand
Non-silent
6q24-25
Reverse-transcriptase–polymerase-chain-reaction
Akt3/Akt1
RASGRP3
bcr2
ApcMin/+Smad3−/−
criteria.16
.MTC
telomere-to-centromere
EGFR.60
foci.The
AZD4363
Ser218/Ser222
G13D-positive
0.001724
7h
his-ETV6
45,011,075
remainingbound
R645C
20-3
KM20
K267
High-Sensitivity
cancers.1
Mlh3
region-abelson
nase
C-Cbl-deficient
Wnt-signaling
D1/1-170
Two-Step
Kogan-Sakin
IR-induced
32T
ASP3026-driven
RasQ61K-GppNHp
c-ROS-expressing
I26T
2733
polycationic
pCDNAS
chain-terminating
6–11
53.3
tumors,10,11
Immunoprecipitated
andsubsequentlyfixed
MAPKK1
T386
60:47:11.6:2
//www.fruitfly.org/seq_tools/splice.html
L858R/T790M-EGFR
G0s2
DeBella
allogeneic
A242T
GAL4-ERF
R171Q
P=0.055
73±7
anti-γH2AX
A1799-
5′-GAGUGGAAGGAAAUUUGCGUGUGGA-3′
Gal-1-dose-dependent
gastrograffin
misincorporation-containing
18-26
ofC277Y
14–19
∼10−3
partner-driven
.Similarlily
ultrasound-
5′-TGTACCGCTA
c.1592G4A
FHL1-mediated
675
.Concurring
activated/stabilized
temperature-independently
271A
Fig.4,4
ETV6-MDS1/EVI1
helix1
R80
l0â
SP-EPN
E349K
manifestations
phosphopeptide
P=0.198
cornifin
Borrelo
Cairoli
.S3
MFN1
ai~N
jhkim4
Pathway-Express
disease.19
n=247
CK-1α
gp140prpto-rk
Fig.1Af
precisely.12
0.39–0.61
mutations.One
twofold104
D.Z.
XLIII
vs.75
TYK2G363S
5′-TCGTCCCCAGCTATATTATTGACGGCATGCTCAAAC-3′
Phospho-p70S6K-T389
80KD
-GAITA
subunit-TOR
tissues6
non-PNET3
K428A
phospo-Smad2
L858R/E746_A750del
CENPC
.NeuroD2-SmoA1
m-maleinimido-benzoyl-N-hydroxy-succinimide
FOP-causing
dimethylsulfoxide
CC→TT
therapy6-
13/87
276×109/L
B39
D17S787
c.77C
AdE2F1
12,000–27,000
AGTRL1
centrally-reviewed
TBC1D4
PI3-kinases
GGCC
caveat
destabilisation
YY1-associated
.Schuurbier
NSCPO
M.p16/CDKN2andCDK4genemutationsin
Nordstrom-O'Brien
βF-βG
34:17
LacI
Fgfr2flx/flx
28,380
AlphaEase
scrofa
11q23-24
5′-CACCAAAGGACCACAC-3′
sensu
S.E.
FLT-1
PHKC2
MBIV
5574
Luber
SBcl2
biallelic/homozygous
-N
T35A
P733L
cATP
β-phosphorus
zeta-chain
MMRC
pMC-Cre
infection.25
11–19
574–575insA
.BRCT-N
2236
hemocytometerafter
MegaSampler
non-pathogenic32,33,34
DLBCL9,11,12
Basepair
cytophotometry
AlexaFluor555
0236
SL26-transfected
1.70d
melanomas.6
T7pr
407bp
basallevel
Kosak
FGFR3–TACC3
1Fig
YCE
sciRAl
Esophagus
replication89
PCR-undetectable
previously.11
30–50
Sample004
Kaiso
1UWH
NR0B1
neurofibrillary
pEGFP-AR
62/M
p53.9-15
HSR22
5′-ATGCGAAGCCACACTGACGT-3′
expression.26
hMutSα-deficient
integrin-mediated
activation.28,34
4680
GFP-expressing
follicle
Genes-Total
c.122–136
myc-6xhis-fusion
Ser-744
domainmutation
Myc-transformed
2μg/mL
cells—a
R31-
2008.88
2.6/1.3
criteria.2,3
I406L
electroporating
pRsc2-myc
anti-METS
sh1
2,424
PDGFRA-R12
Non-Essential
55.5–99.5
non-existent
p.L63V
Dasatinib
Tjalma
pGADzDGR
H-RASV12-induced
.Dovitinib-resistant
43-45
ETS2-driven
least-sensitive
R1391K
immunoselection
Malaise
type.4
p.L180P
HDACs
variantc
BL21
Ortho-50H
co-deletions
0.180804743
thatalteration
9F3
Lsc
EWS–ETV1
592–607
GLI1-responsive
495delTGTT
INPP4B/PTEN-deficient
2325
forKIT
R243Q
63–66
Gnas
.Shortening
Perkin-Elmer/Applied
counterselection
mGATA
.Apgar
1−5.0DMDDystrophin
HTS-targeted
.Species
types–except
ErbB2-active
interferon-inducible
.CD31
IPT-repeats
multinucleated
identified19
Q=1.5e−10
HER3+
Rho‐regulatory
ProductionThe
|S
hypomorphism
phase.14
14–16,19–26,79
responsiveness
g.282-
LP6-shJun
Fbw7-S227A
BCOR-Retinoic
phospatidylinositol-3
Caputi
Blons
c.1657T4A
SBE-luc
Bresnick
PAK1-mediated
volved
L820
normochromic
241D13
.Techniques
c.1790T
.HIF1α
0.63–1.86
CTD-DSBH
Cys/Phe
BAT40
ab60243
Foxp3+CD3+
9.61-fold
346210
M.S.S.
PIK3R2-mutated
non-homology
chromosome.NM_058195
G244S
5'-CCCCTAGAACCCAAGAGTC-3
2195G
Xrs2/Nbs1
MLL-rearranged
Ser768_Asp770dupSerValAsp
660-nm
CAAAAAAgcagaagtatactctgaaatCTCTTGAatttcagagtatacttctgc-3′
cytokinesis.25
gene-panel
AFMA058WB1
1.1–1.8-fold
anti-HA-sepharose
.Focal
E158
nonterminating
BCR–ABL-encoded
Inivtrogen
MyD88-mutated
known.The
CATTTTAGCACTTACCTGTGAC
PAK1T423
v-src
S635Q
Harmonisation
chemo-
Leu-
doi:10.1371/journal.pone.0025021.g003
RUNX1–RPL22L1
14.5±4.63
DNJAK2
L1773I
S1–3
ROS-generating
mESCs
K558A
.Observing
CAF15
10μm
hepatoblastoma.20
11/00
lex1
p=8.6E-04
=pPfP
RPS10
Bretscher
whole-tumour
pGBT9-NF1-GRD
VIH
g/day/kg
NSassociated
5′-VIC-CTGAACCTGGCTGCCAGGACCT-TAMRA-3′
.Sacilotto
S549N
40-44
BRAF-targeted
werefound
Met-297
Smad1/Smad4
differentiation-blocked
RNA/two
Zotero
p300-MOZ
58◦C
serinecoding
patients,13
micro-array
T404N
MMLV-RT
Disease-related
4333458
52.4
Bendjennat
rs1059234
Nesp
hypoxia.53
VD1477.0
HER2T798I-selective
.S8.2.1
Smad4/CBP/p300
D1/20-295
pcDNA31
VigeneTech
.NPM–ALK
FGFR3/G375C
T368
methylation-dependent
templatewas
L304F
Rodriguez-Puebla
M53I
STAT-dependent
A763_Y764insFQEA-bearing
0.97–1.28
242-262
21/52.5
t=24
vitro49
GAGGACACGCGGAAAT-3
pBabe-puro-GWrfa
5246s
data27
mutation.141
y-axes
q34.1
.17,18
ERE-dependent
basic-helix-loop-helix-leucine
F652L
p110αcatalytic
biosafety
RDH54
DDR1b
P48L
.Conversions
cetirizine
B2/B3
66.Figure
ACGG
estrogen25
URA3-based
AD872p
4/6
G325A
pRK5-B2
ZnF-C2H2
S0480T
ab15148
200µg
SMYD3-mediated
mild-to-severe
44,000
1820
phatase
rhEPO
Oncoproteins
survival.14
tumours6
signals/number
132/140
TP-induced
primer-specific
176C9
0.132a
p16-binding
anti-phospho-Shc
Phe788
3.1.1
5a–g
B220+CD95+PNAhi
ETV1-expressing
CGUACGCGGAAUACUUCGA
100-kDa
BRD4L
AG′
array=
CEV14/TRIP11
bromain
Ottignies/Louvain-la-Neuve
β3GnT2
Multiforme
delta29
TgfbR2
GGGAAGAGTGAAGAAGAAG
SA-β-gal
degraded59–62
pTrc99A
cesium137
6.6
1534G
compartment.Fig
I1151S
FIP1L1-PDGFRα-
.Identifications
4200
paxillinY88
RCC4
Fusenig
FastForward
25/87
5′-CTCTGTGTTCTTGTCCCCCC-3′
FC2L
fusiona
n=133
cultureand
SOX17-ΔMHG
Fig.11A
neuroblastomas52
2JIV
freeze-thaw
adaptor-barcode-primer
ENST00000381196
AJP
H214R
.Generated
transplantation.27
translocation-associated
P=0.29
0.00298
C.M.W
TTCAAAAACAAGCGCATCCT
mode.1,8,9,11,15⇓⇓-18
lysine-16
tumongenic
Progression‑free
G-894
EGFR-TK
310-393
491-493
+GF
operations-100,000
29:2512–2518
γ-H2AX-positive
Src/ABL
P4HA
Å,34
Dpn1
CTSNet
18.8-fold
Val115−Ala118
4-week-on
Ser102
BRG1/BRM-positive
colony-PCR
.Postoperative
19/67
2−6.1UPP1Uridine
.Isoform-specific
viraemia
RLUC
investigational
125I
GST–INPP5E
Habraken
antagonism
53,297/3010
YFY
.Plasmablast
21q21-q22.1
0.8–6.0
RNABle
C828S
EGFR-NEG
TKI.Although
mutant–complemented
phosphorylation—
nature.comOnce
p53-negative
.Eliminating
His6P110α/p85α
001100
M235V
N550H/K/S/T
1.07–5.52
c.862G
0.45–0.60
NVP-BKM120.AntibodiesAntibodies
S1512I-U
GUA
44-bp
delE11
Gene-amplified
Ser56Ilo
LGEGeFGKVvkAtafHLkg-raGyttVAVKmLKEnASpSel
-Thr-Asp
Platelet-derived
development.74
JAK1V623A
Figure7A7A
KIT-A502
exon9-mutated
4C–4D
∼5-fold
still-patent
importantdifference
hTSC1-NTD
MGHU3
Ciani
BACH1-PVL1392
mg/7
IL-3.75–77
alsosituate
5'-GATCCTCGAGAGGCTTGCCCGGGCAGGTCTCTCGAG-3
dimerization-independent
Fishman-Lobell
/PNET
trametinib-related
C–
9547A-G
nontransduced
YAP1-treated
Canadillas
Phe77
assay8
.Seminal
SVS2
M.F
55.2
elucidated,32
teratoid/rhaboid
Fig.7A
microlitre
sub-total
12q
HhaI-Hinfl
RT–qPCR
20q13.2
Sensitivityc
hydroxyflutamide-activated
A-tailed
hasundergone
R72P
DPB1*6101N
289
‐binding
UV-2200
nucle
BaF-N/A
144-base
Rockviile
CMV-RYBP
syndrome–
S4K
BCC9
upreguate
Cys-C
HNF1A-induced
R337H
51.3
ANNOVAR31
FGFR1-expressing
amplification34
S-adenosylhomocysteine
set2
Claycomb
273–292
-Â
19,356
p.We
.cmd=rps
I347M
Sceffé
s/72°C
opee
molecules/DNA
4E110
anonymized
P135S
SH2-directed
rate.2
mu38gO2
BCL2-IGH
Rasopathy
Vλ
NM-induced
0,95
HbF
GAGGCTTCTTCCGAGCAAGGGAGAC
I-I
hepaticchanges
glycine239arginine
Cyp24a1
12out
years138
3347delAG
1.2–1.4-fold
Tumor-associated
CGCTCTACATCTTCTGCCTTA
Hiload
MST2
Apoptosis—In
HNF-1b
GGATCCTAATACGACTCACTATAGGGAGACCACCATGGAAGCCCAGGATGCCATTG
TCGA-75-5126-01
matrix-degrading
trials.11
Bcl10-CARD11
others20-22
VSL-337ND-S
upstream-activating
3,418
IJXM
anti–B7-H4
GACCACCCA
1696–1698
Morisaki
decarboxylase
Phe-
IL7
​Figure10E
94Â°C.27
SkMel-267
143/230
homeostasis.5,6
disease-associated
1,255
genocopy
P491S/R498W
5-7
role95
MYCN3,18
/United
siNKX2-1
Ha-Ras.2
SAM/DNA
Tnfaip3-mediated
MDM2/
84.3×
Fosl2
13q31.1
-min-minor-frequency
56787260
higher-than-expected
Ct.
theMultiprime
35S-labeled
CD4+/CD8−
Hoxa3
Q88
prognosis3
pL-150
GDC0068
.Supratentorial
272K
t1G
2/15
al.111
rap1A
multinomial
200×
temperatures.17
4,32-34
59-CCTCCAGTGAATCCCAGAAGACTCT-39
cyclin-depen-
FigFig1E1E
RG253B13
Lys-CoA
EMM1002-3796055
nanofluidics
.4E4E
Flag-tagged-BRG1
59-AACTTGTTTCACCGTCCAC-39
9001271
gene.Add
Cy5
RPMI-4445
EF-HASmad4D537Y
and/or
2031
A.U.
Bronchial
B-score
K-independent
T163M
Val166
morbicentric
pLKO.1-Scr
0.2–40
Mdr2-deficient
Ras.58,59
-**C*
IL-3-starved
L554P
anti-hsp90
.CFCS-causing
platform.11
467–474
resistance.20–25
13.9+3.9
SPOP-ERα
0.7-19
mg0
PEGPH20
E6/7
ACTB
223+274
hTERT/p53DD/CDK4R24C
Tris·HCl
proliferation.Previous
histidine-containing
Scotet
NEFL
GNF-4256
A587S
PBS-Tween
.ΔTrkA
Genome-Scale
pY1278
Paf1
B-S-B
AluI
c.2006+6g
oxidase-B
activity.33
40-50
5'-ATCCAGGATCGAGCAGGGCG-3
AGGTTACTAAGAGGAATAAAGAA-3′
IFN-bold
DLBCL.1
Parthiban
InXenopus
high-riskfamilies
1Ff1
antifolate
ALL.25
FWER=7.8e−7
FuGENE6-OptiMEM
USP28-mediated
HMPS/CRAC1
Leu844
:*T
KITV559D/T670I
Arg-12/Thr-59
controls.19
PEG/Ion
Hallor
Sandgren
Cadherin-dependent
B6.3AHRRmRNA
HB‐EGF
standardization38
MEK1-positive
mutants.23
placebo.1
Chae
system–specific
pLPCX-HA-AKT2
Riely
extracellular-regulated
L370
Hydroxyurea
kinase.27
534A/G
paired-primers
GLUD1
Ptashne
exon-splicing
51,529
V58
Hoffmann–La
.2000.5130
DAA
Quilliam
lesions.6,7
Arg333
HELYDLDVTAPEDPNEEAVSQIFPDS
.Nested
Petricoin
DNA/polyethyleneimine
L773R
M1701I
1281463
Trasadingen
.Branching
ChIP-seq
transcription-PCR-generated
.6097G
aorta55
27:5
glial-cell
5-Florouracil
Karyotyping
development.When
pre-absorbed
5651.0±519.9
overaccumulates
K239
expression81
36-cycles
SeaPlaque
278730
kinase16
RU486
resource.48
Y375C
Tartaglia1
Suv3-9
Nigricans
nucleo-peripheral
K373/K382
GGTIs
1716–1834
RC-20
Pblec
down-regulate
HER1
Dobson
5,11,13-15
1hry
D1822V
AD-EDA-ID
60-70
transfec‑
FANCA-PKs
Thr70
Fig6
P=0.475
transrepressor
1-independent
depletion–triggered
H2N-255QRSTpSTPNVH264-COOH
Wehi-conditioned
A0j+1+Tdel*∑j
R2270L
nonlymphomatous
hyporesponsiveness
Oncogene
180200
1799T
797Trex
crest-derived/related
REFS
cryo
VACO4A
pMiw-Fgf18
Prox
/.LLT//
2-tailed
TCCCCTGTTGATTCCCTAGA
241R
www.phosphosite.org
pre-specifi
sin-
T3B
SCL/TAL1
Rheb-expressing
ACC-3′
SC2003
triterpenoid
time-matched
.Leucine
binds.32
3485
-P2A-DD
Informa­
pariety
EWS-EIAF
cases38
reports41
med3
pMV12-SRα
genes.24–26
FACSCalibur
LAD
EP0161
Mulan
GFP/Mac1
Small-molecule
12-25
GGCCGATTCGACCTCTCT
TMPPRSS2-ERG-positive
NP_001012496
5′-AGACTGCTGAGGGGAGACAG-3′
Pasquo
lesions.47
L12-171
.IL‐6
Sp1-binding
G168–15
.Met
ZNF733P
NP_001043749
7.4/1
Msh6RH/+
28-gauge
SOCS2-/-
A266_S277ins
8∼10
Poly-l-lysine
DRC
Me7
Glu-64
Y591D
Ordentlich
attctggt
1.05∼1.25
Berenjeno
SI04159547
Mbases
vigabatrin
2Ac-d
anti-apoptotic
5′-TAGTCGCATTTCTACCAGGTTA-3′
AMGEN
kindred.15
S240/244
c.3980A
Mdm2-induced
5.33
42.5
PGF
.BRAFV600delinsYM
G·T
C450ins
DSZM
SageGenie
R1302
doi:10.1038/ng1571
classImonoclonalandpolyclonalxenoantibodies
Prolactin-releasing
IFT80–MLH1
J19
gmll1
5′-GGGCGAAGATCACCTTGTT
F/Y
320KB
piperidinyl-ethoxy
TTTCCTAGAGTAAGCCAGGGC
appearin
virus-infected
C/c
.AKT3
polyclonal
500+
1499
1645-1664
25–1171
81×
uORF-affecting
cyclinCDK
ESULTS
27,52
TGF-βs
endoscopists
R1753K
assayThe
H7904
respec­
mock-
–10.9
WCEN
MET-addicted
.Lymphoma/thymoma
FLICE
Atg3
Lukas1
transla-
pharmacophore-diverse
Atto-488
Topspin
TAwith
608E
11q13
.Mitotane
KCTD21
Experion
Fuchu
p81
andunderlined
31/87
cells26
Ssofast
activated39—we
Caudy
recanalized
154705
NM-treated
remineralisation
p53‐responsive
.Boil
P-TYR
17.9
rr2005
.About
1387–1784
.Reactions
ATRX-positive
outcome91
PDE4B3
.Y806
Curve—Cells
Fig9
3.010
p300+/+
c.71T
nucleosomes.28
desorption/ionization-time
SpectrumOrange/D5S721
inhepatocellular
DR-GFPhygro
noncovalently-bound
aminotermini
Ki-67
1–32
Gast,1,2
Seppala
221222222
MTCP1TG
T862A
.Myc-DDK-tagged
PNA-mediated
mutagenize
PKCtheta
AllHER2-mutated
napthamide
ETV6
N676K-induced
˜95–100
Kitayner
foxg1
5′-ATTCTTTTGCGAGTCATTCC-3′
fancj−/−
beenimplicated
1999–2009
W349C
mRad50Brdc1
0·060
20/21
NotI-XhoI
1p35
0.6744
EGFR-KD
c.1738delAT
MEK/BRAF
.EPS15
.Maximum
anti–phospho-
KCI/10
.Founder
NZM23
centrosome-associated
15.2
44–82
~Due
D133A
1,434
ute
6.29
1295
c2
stenedione
Dpy30
F97C
FoxP
69N
0.0318
Cdkn2a-null
299–312
1Q-U
TNT-coupled
5′-GGCTGCAGACAGCGCTGCCGCGGGCTTAATGAG-3′
2016
TEL-TRKC-mediated
downstream-activated
669–671
Cys-345
assays.For
RCDC
de-repressor
ommatidiae
11•2–not
IFNγ,38
302,918
showed2
dyspraxia
Gorres
Nie
promoter.41
BCL-xLΔC
RAS-pathway
presenilins
..S
post–chemotherapy-resistant
|a9
D4D6
MMC.RNAI.N008977.10
immuno-proteasome
19Ana.6p
Eμ-Myc–transgenic
proliferation-inducing
C56G
g.47426808C.G
Preusser
40.0±17.5
functionalimpact
SUM-Lines
Vogelstein
gastrointestinal
Cross-Resistance
Q324L
hDLG
RP11-39K24
βTrCP—affects
22insG
CA-6718
regions.35
Decameric
N‐terminus
KRAS/NRAS/BRAF
pZIPcSos1
Fig.3E
lovastatin
Mirpuri
165th
fms-related
phospho-cMET
Two-group
922
DPX
interac-tion
K618A-positive
Myr-F21A
.e
50mg/kg
nonconditionally
Perugia
PDGF-B/PDGFR
cytokineindependent
.R-cells
5′-CTAGATCCTTGTGTCTTAGGCTGT-ACTTCC-3′
criteria.12wSignificant
189/233
8586
org.Hs.eg.db
70.9
MTA2
adeninephosphoribosyl
SAR302503
over-simplification
A1c
.2a
mTor
pCMV2-F-mBrd4
K2411T
Origin/
ER/Golgi
S360I
CancerPublication
2668
biotechnologies
lyz+
'0
FRS-2a
34e
–77
mutations34
C420
121-141
20,687
lineage/cell
0.5X
¢
Non-hematological
Caspase‐Glo®
T357
1Absolute
VAEALHPFAADDTC
al.131
cccttgcag
GACGCCTCCTTCTTT
CCACGG
.20C
Streptavidin
pathway,7
±+
T727STOP
Anti–glyceraldehyde-3-phosphate
EBF1–PDGFRB
pGL3-pap1
51/118
1a-6
methytransferase
P-S
16p13.12
4,039
HYDRASYS
.Hematoxylin-eosin
6HR
S1206Y
P40S
b-catenin–induced
Thr-217
inhibitors.A
K.K
variants—Y931C
G2815
.IgG
www.geneontology.org
myelofibrosis22
14/531
Y-hydrophobic-basic-large
FBW7α
degree×min−1
3+NGF
risk45
dowmstream
.Tyr-537
deletion,3
Fidler
Tamm
unmutagenized
tridimensional
miR-3127-5p–overexpressing
CPLCKNDITKRSLQESTRFSQLVEELLKIICAFQLDTGLEYANSYNFAKKENNSPEHLKD
hypothyroidism
Baudhuin
2/20
40mg
GeXP
xenogafts
204CRT
67mer
NFkB
30/38
transgene
16p12
method47
14Department
ShortRead
Rabaptin
P177R
5-Diphenyltetrazolium
CFU-G
DC/T
3075
orHindIII
.Ligation
Oct-1
pRK5-SMAD4-Flag
BRAF.7
PDGF-alpha
.G-573
MAF
//www.orbigen.com
adriamycin-induced
.Kl
WithROS1-Rearraranged
50–414
BRCAnalysis
manner5-7
fluorochrome-labeled
p53-/-+Ras
L2026M
rs17878362
TumorBreastOvaryCervixEsophagusGlioblastomaNeuroblastomaStomachSkin
E93D
HCTp53
Smad2-positive
TGX256
N557K
SNF2/RAD54
Nonmelanoma
.negative
nonobese
21160301–22679000NM_078487NM_002451
Dummler
0.5ng/mL
GFP1
screeningInhibitor
RNAi–mediated
n=155
DZ-treated
~45
WHSC1/MMSET/NSD2
Hara_Takahito
1.0ST
autoinduction
FO-1
3Figure
ab9053
R/S249
Distance-PCR
92-055
men19
GAGTGGTTTCGTCCAAG
Cys-30
¯uorescent
415677InsA
rabaptin-5-PDGFbR
Npm+/-
re-addition
provisionally
NRAS-depleted
563K
PDGFRα-activating
MAPKKs
β-MHC-Q510E-Shp2
3F–G
mostpredominant
sequencesand
glioblastoma.58
Pro405
Blagosklonny
..tLA
D537E
derivativesof
Mulago
ALL=acute
.FBW7+/−
4026
66869
Post-transcriptional
DNAreplication
.E542K-NHUC
Illiakis
510/1,744
p.Arg2784Trp
diisopropylfluorophosphate
insYVMA
ARID1B–MiaPaCa2
Overholtzer
546-bp
MSH2-V161D
SETD2-deficient
CA-3
SUP-M2–
.Myeloid
.Crit
GGTGTGGGAGTGCAATTTCT
H410R
thymocytes.15
Rb-BRG1-meidated
ROSlencoded
Gþ4538C
tetramerization-suppressing
coomassie
asymm
577
.A4502
non-serrated
Knudson.13
300F
binding33
Xiao-Ling
ACCTGAAGATGTTCGCGATTATCT
M50L
AAC33300.1
Cluj
D623
47−5.2GSTO2Glutathione
-238a/g
100U
~9.5
CINECA
5′-CGAACTGGAGGCGATCTGAGAGG-3′
E15.5.36
177–194
p.A502_Y503insAS
pathogeneses
uCi
pcDNA3-50
spell-checking
GALl/10
L574P
BRAF-MEK
1.46/100,000
57-3
Nucleophosmin
Mx-1Cre+CD45.2+
HGFIScatter
AnalysisClinical
3/230
co-regulation
GTTAAAGC
J-Express
mutDNA
Dakt1
IRES-EGFP
2715
Runx1m/m
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi
MLL1-Dependent
vitro44,45
28.9+1.2
advanced-phase
SHOC2S2G-induced
KSR2-catalyzed
Two-Hybrid
123–137
L2574
.And
1.289
pT2G2
APC-defective
IKZF1deletion
ridaforolimus
streptavidin–biotin
.C57BL/6
CX5R
μJoules/cm2
cycle-dependent
RWQFP
Meyland
λ0
IgM+
read-edit-dist
.ErbB2
Staveley‐O'Carroll
MDS-like
.0.01
L152P
CYCLINA2
G830R
SK-MEL-3
60.0
Nusse
cases—an
CFC-zebrafish
Stomach/small
1xNEAA
100-U/mL
LCM
re-orients
.Multicolor
c-/
activity-independent
Administrationapproved
0.89-
2.3**
cortisol/cortisone-responsive
bjoc.1999.1014
HA-Flag–tagged
ug
GCTCTAAAATGCTCTGTTCTC
EglN1
24/44
cpm/
376-kbp
R122C
THEM4
overexpressedand
ap53
0–51
CCND1/CCND2/CCND3/CDK4/CDK6
left-shifted
Noonan/CFC
Dp427p2−5.0POPDC3Popeye
BRAF-CFC
Chemi
MEK-induced
E-cadherin+
addedHER2
protoRet
anti-GLUT1
35S-Pulse
G452R
increas
639152
cell-specific-1
PIK3AC
–bound
Blandino
heterooligomers
-AGCATCTACTTCCAGGCACCCAGCAAAGCCAATGGAGAG-3
SJHGG009_A
MCF10A/HER2L869R
G97D
-c-KIT
LDN-
moderate/
5Y
Y570
probands3
RANKL
www.ncbi.nlm.nih.gov/projects/SAGE
MR111
DNA-bindingsurface
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F2.large.jpg
MSK261
sc-8334
CRM1/XPO1
Val600insAspThr
pRb-minus
Fig.5G
interactions.27-29,51
AAAGAAAGAGATTTACCATGCATG
1,4
1020
pCMV-p53-
allele18
.LPL
M1783T
Rbpj
organomegaly
Acvr2a
555–562
allowdetachment
rana.lbl.gov
Histopaque-1077
re-confirmed
FGF-RAS-RAF-MEK
0.03978
trophoblastic
CA180-034
K8/18
p.Additionally
Eosinophils
Multiple-tissue
mant-GMPPNP
K14CrePR
perioperatively
G384C
mutant-dependent
E11–E12.5
Brca1Δ
noncompliant
seven-
F257L
RCB0513
TATCTATGGCTCAGTCATCC
NSCLCs.10
0wd
3141
.Multifaceted
importin-b
viverrini
ficolled
32,050
Down-regulation
R431H
epilepsy.1
p21c-
CTD-truncated
.Arrhythmia
S767R
ity
tamoxifen-
.Digests
610189
91.58
60–66
O-benzotriazol-1-yl-tetramethyluronium
triplex-forming
-GCTGAGGGTTTGTGCTCTGT-3
M308
nt2392
Tissue-specific
His6-and
cloneQBEnd10
Fig3
peptidc
10E6
45seconds
0.64–1.05
5′cggcgcttgatgtggtgaac3′
development65
/CA\
EN/
skim-milk/PBS
L117P
–438-bp
p.P390S
R533W
JO'N
Ser-Gly-Ser-Gly-Ser-Gly
Thr729
eAsnArgPrQA
Prepublished
radioactive-labeled
R-CVP
immuno-detection
220,000
N521
Niessen
7q−
12=4929
Fifty-two
previously29
.TK1
SHH3
procedures4,27,30
1,115,129,130
MIC2-antigen-positive
Silastic
E447K
.Histology
n.f.
S.L.
GST-PBF
pE1a-12S
pMEK
CK5+
samples68
CMV-β-Galactosidase
1.2–7.3
MutsigCV18
33-fold
5′-CTTCAGCTTCTCTTCACGCACTCC-3′
.FYN-T
serine-to-cysteine
H3K27me3-
'~
variants.6
GAL4-AD-CITED2
ISCN
Y68D
κB2
RET-ICD
6474
v2.0.6
35,543–35,392
.Carlomagno
Scarff-Bloom-Richardson
binding13
5′-GCTCTACTTCCTGAAGACCT-3′
58-GGCTCTTTAGCTTCTTAGGAC-38
33/50
sc-38398
GenomicFeatures
gi50310365
amelogenin
tumor1,18
ErbB2_ex11-19.F
2.432–45.267
r.m.s.d
cleia
delCTI
biotinylation–streptavidin
-CD7
Pelttari
Q347
insulator-binding
terminal-truncated
Phospho-Receptor
71.3–100
Resnova
S614G
hUbc5b
3−4-fold
CCDC23
ATIC92
adenovirus-Cre
IP-Western
S34
ralB
loci11
2.44–2.55
.Coexpression
Tyr15-P
Northem
94°C-4′
paediatric-onset
RG-12
RP11-90l17
serum/PBS
nSH2-mediated
on/towards
sc-1265-R
0.976
Tyr418Del
//www.iarc.fr/P53
p.It
picoliters
D477G
5d
imatinib.27-29
Rheb-WT-transfected
non-homologous
O-ε1
1525-1528
117,830-117,971
.I–IV
Sox17flox/+/Cre+
C486R
line.28Mice
R63H
GST-CDK10kd
.FGFR2-MGEA5
contradict
Echinoderm
TEL/JAK2
4777
TGGAACGCACAGAGGAACGAGCT
5'-PuPuPu-C
3/16
G418
Logarithmically
Robbiani
total-KIT
681-1186
MV7-c-myr
BRAF-independent
data.After
PF-382
FancD2
N2603
histologies3
5.99
cells/HPF
tumours167
E1GFR
Meti096
features.5–7
protein-kinase
disorganised
benefita
~720
Percoll
JAK2V617F-positive
Dyskaryotic
PCR.26
Swyryd
S347C
β-galactosidase-expressing
proteomic/phosphoproteomic
chromosome-modifying
HNPCC22,23
KKPPPRIE
503-273-5158
anti-pMEK1
standardizing
24,537,119
pBabeX-MPL
S39
synergized
11–59
V.Dixit
byagarose
+1.1
tabular
p.A355P
A365E
Dnr
5′-ACACAACTTTCAGCAGCTTAC-3′
CNS-centered
production.24
patients25–29
Rha
andPDGFRA
557·09
GAPDHrev-5′-CGCTCCTGGAAGATGGTGAT
Guldberg
mloxP
LIN28A
CDK2-
CIC
x7c
silibinin-loaded
CCAAGCACTAGTCCATCTCT
syndromes.80−82
proteins6
β-ACTIN
X-lOO
co-amplify
AuvrB
S7.7,8
Ser10
Glu97
TbR-II–His
D336V
Identi¢cationSpots
fold.16
20*
MLL-7S/p300-8A
imaging.A
Tidow
splicing¶
5420
hypomethylated-
V/M
categoric
100–210
P45Q
5'-GC-clamp-CCACATFFTTATGTGATGGGAA-3
1062–2428
.Non-malignant
IR-5
MBIII
NUT-variant
1,040.9
41,255
Tocris
receptor5
Signal-Transduction
R882H-positive
617-871-7397
Arceci
.N/A
LC3C
M135T
Asn–Asn
KRASA146T
co-targeting
BCL11B.29
LTC
HA-Rbx1
GGR
E1451K
models.12,15,16
SWOG
531−overexpressing
4A
85/1
back-converting
6×His-ΔC-Flag
D-HPLC-positive
TE10
-STAT1
dye-labelled
5.4∗
Pro490
.GS
BRAF–expressing
Triamcinolone
Leu241
2819
'essential
.Twenty-five
Crb2
protein.Cos-1
Thulasiraman
Erlic
.0113*
BCL2L1-amplified
.γ1
Ad-PTEN
cardiomiopathy.8
Gly538
immunohistochemcial
postprogression
21T-cell
instance44
p.R112G
4×48
p.Arg201
8966
CTCTTCCTACAGTACTCCCCTGC
Machida
.A–C
356410
HREC
N141S
.p21
Stk17b
pre-GRD
13q12.13
HACL1
.2,3,49
39133
pRc-CMV-cyclin
45.26
ERBBs
PKN1
S300-HR
proteins111,112
epirubicin-cyclophosphamide
timeslonger
reappraised
manner.14
invasion20
PLS
on-column
NRASQ61K
CaOV3
Sousa-Victor
proteins.DiscussionRecently
7.7Sunaga
.Rapid
Mutect
A72
6495165BH2Transversionâ€˜ITI'toTl'APhetoLeuJ40+655015B1H692TCraarnbsoitxioynlTGG
PDGF-mediated
ΔTAD
TCF-4-/-
Roosbroeck
NFκB-Dependent
Ras/PI3K/mammalian
asto
126337
Brca1flox11
Sekido
MSH2-D603N
Mariaheide
R190P
ARID1A-
esg
one-to-one
cttccacag
66.73
c.584+1G
spectrophotometric
33430511
Co36
C396S
59-CATCTACGAGGGCTACGCC
5′-GGAATTCAGCCCTGAAGTCATAAGA-3′
E545K-
concentrations45
v659
post-incision
epithelial-1
MCPH8
Quality-Control
p=9E-4
haematopoietic
algorithm41
mortality.2
IL‐2
genes33,34
t-BHQ
Toralkovic
C-RAFRBD
TP53-transfected
249.6
Caelles
Apothecom
phenol-red-free
Babaei-Jadidi
and–nonamplified
Ezhkova
embedded11
Methodology/Principal
Technologies/Ambion
SHDC
NM_004064
avastin
GST-Yap
JAG
Tiantan
see3
87−5.8ADAM19A
Y2H
doi:10.1158/1078-0432.CCR-13-1863
FGFR-3*
EWSR1-615/SMARCA5-1450
.Anti-apoptotic
IκB-like
Drug-selected
Doglioni
R683G/F595A
123K
ISL-l
GGGCCAAAGG
17–19
anti-tetanus
Dec1
NM_000548
S2a
Sirolimus
.Anonymized
lethality,8
5′-PuPuPuCWWGPyPyPy-3′
GRIA4
B.104-S
89,223,171
R1055L.30
fur-ruffling
727–732
35.3
MTSS1L
PABP2
Q79L,24
lob
1,600
www.iarc.fr/p53/homepage.htm
FGFR-deregulated
555–575
VEGF-pathway
MutF
studies54
pCMV-HA-p53
DSHB
fusion57
SfiI
φ-X-E
HRAS12V
188–199
GST-ubiquitin-HIF1α
TritonX-100/PBS
TGF-0
Myc-BS3
.F1706
160,000
219.3±5.8
microCAT
DFG
aspirate
CWxP6.50
2573T→G
S98F
miR-2
5.79
Transcription/Polymerase
EGF-receptor
two‑hybrid
quantitative-PCR
Il2rg−/−
.Mer559
.BCL9
AK028772
tert-butylhydroquinone
4.71
P27_WT
-RETY791F
morphogens
disease.MethodsAbstract
.Filter
RAFV600E
Y/H
0.320462427
Antiestrogens
CA102613
4646
Atenolol
2/3/4
V1093M
anti-Annexin
endemic.2,3
topoisomerase-II
UD-SCC
3232A
94˚C
T357A/T390A
chr1:92918126-92918965
regulated-genes
5p-c-Abl
anti-CD34–PE
non-midline
pBMS1
0•60–0•93
Ala206
D816F
31-164
slowly-cycling
EX3BF
types1
Apr-89
extract-untreated
4/20
FANCA-deleted
Pro-TEV
pAct-MyoD
N-Ras-G60E
geneGenomic
previously.8,37
5′-CAGTATAATAACTGGCCTCCGGGGGTGCGTGGACGGATGGGAAAAAC-3′
S4E–S4H
.GSK-3beta-interacting
per-Base
Haloplex
function–structure
6.6-25.2
differentiation75
C57BL/6:129Sv
7q36.1-q36.3
disulfidelinked
au-3′
achondroplasia.20,21,22
KATOIII
CGH_107_Sep09
73/m
.Reciprocal
2500x
Rasopathies
macrodipole
TCF2
K2171
KRMC*
Left/right
p.R625C
β-glucosyl-5-hmC
fungi.7
NorG
Gliogenesis
0.838
V560•••N787
E1021
Naldini
.Deletion
under-recognised
18S-reverse
zVAD.fmk
sulfur-35
reincorporated
peer-reviewed
Phe90−Asp92
​Figure4
.Few
1.49–3.7
AGY70
Rad51-binding
PDGFRBD850V
size-selected
SUDHL-6
P375S
Gα12
hotpot
S939
Asxl1+/+
Dexamethosone-induced
MATα
0.334020433
.Heavily
A1237
region21,22
825–830
NPM-AK
lexAP
Ala11
rs17337079
Asp746
Y185/187
Y-MESO-14
DJMS
VAL12
30161
TBM
tyramide
changesthat
NCOA2-amplified
REM
Puay
9A–B
Prospectively
Research.10
KdT
T7-16
Burkitt-like
S-caged
ingastric
Leu511
A-*S
vivo27
Akt2W80A
125I-MAb
hDIS3D487N
LAMA2
chloromethyl
CAT-
electrophoretically
9254del5
il2R
exaplained
70
immunoblastic
5:5:1:0.6
BRAF-like
W741C/T877A
BAC-BA1
HI-H
TβRI*
SEPHADEX
5′-CGAGAACGGTGGAACTTTGAC-3′
D835Y/V/I/F
Fbxw7Δ/Δ
TCCATGGGAGAGGATACAGC
K-dependent
.High-level
under-
VEGF-mediated
dimethylpimelimidate
GCCCAGACCG
.Carrier
c.229_230delAG
cellsp53KO
HNF4αfl/fl
10/155
I9
5¶-TAGAACTCTCCAAGGAGCTTAGCTTCATCCTGAG-3¶
AML-M4Eo.68It
.TCR
melanomas41
staining.18-22
5â
gtagctctg
78.8
cancer.6,7
motif.16
Winlab
Ala790
165-185
1.2–1.5
tumorigenensis
clPARP
EGFP/EYFP-positive
ACC411
Biovitrum
ACSS3
.Rb1
CTGTGACCGGGCCTTAACCT
low-income
Efna1
.1450
JAK2-V617F/Y931C
Krüppel-like
S783-I861
Kitoh
LR08
suscepti
probabilities
1.553
unconcentrated
chemical-modified
described,25,26
p-MKK1/2
gliobastoma
-sh-Smad2+3
0.25–1.92
Ortega5
pE3-11
FcγRIIb1
b-catenin–specific
74.2
sub-par
STY
E1735K
LAMC2
metastasis1
monoubiquitination
419–420
SET8
1.073
33-35
O.O5
pVHL-knock
CTD-3159I7
software.The
mutant/ERBB2
vemurfenib
Biosearch
28-30
parity-induced
recurrence-free
beenderived
DNAase-treated
'multi-class
ADENO
+42
Chen1
Easton5
F583Y
0.08–0.67
,59
Asn-655
Glu663Gly
DMSO–water
Funct
.RESULTSOsteosarcomas
copy-amplified
progression,73
310−360
G2/M-phase
3C4C
siSF3B1
genes33
45/F
cooccurrences
419–780aa
5pmol
Chrom
double-transgenic
Leu236_
2870
TCCGGGTTACAATGAGGAAG
58-62
Elf1
71/556
0859
.Drosophila
Sashimi
C-terminal–truncated
NaCl/30
PCNSLs
W78F2
P083-B1
EGFR.In
qRT‐PCR
AIN-76A
Rhan
.Mammalian
aliquoted
indexNextIndependent
4/63
6000
MSH2-K675A
TRAS-VIN
Bem1p
23±0.4-
1.0Number
KMT2D/KMT2C
24-2-l
5′portion
1,2,3,5–12,17
antagonist-agonist
L777
P56S
onlygain-of-function
bromo-adjacent
TRCN0000059091
Bicondylar/bigonial
pseudo-alveolar
47-91
480O8
Bussolino
64283
ETV6-ABL1-positive
WHSC1/MMSET
MLL-9S/p300-7.5A
A62T
.Representatives
Myc-Miz-1
Sox6
×104
115150
D1-AP/dEμ7
MEK1-interacting
35-40
membranousexpression
Hnf4a
-MLL-ELL
0.213
B-RafR509H
P-0000839-T01-IM3
H01
virusnegative
Hs00176676
.quantitation
signaling.56-58
Marseille-Lumigny
17-2008-1043
cortisol-secreting
.Disparate
mimics6
FLT36
hematopoetic
oxytocinergic
air/5
Tanyi
myxohyaline
Xeno
T3997C
low-cooperativity
GGAGGCTTATGTCTGCTGAAGTCATC
645267
PLC-~
core-needle
P=5.5×10−75
Asp538Ala
RMH3248
TGFBR1-kinase
ZNF76
dioxygenases11
HES1-Luc
mice27,28
N48K
DYRK
1q44
I/Il
293/7
Q201E
MLL-AF4-bearing
L829P
sebocyte
REV1,30
antimelanoma
.Microphysiometry
GlaB-induced
Pie-chart
//www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
phenotypes.9
38.32
TAGCAGCAAACAATGTGAAAGAG
R336
D538-MG
E64G
Iavarone
ecacyby
Figure5B,5B
Sequencing-by-Synthesis
CTGGGC
significatively
−2.74
keratin-filled
R273H-transfected
1.5.1
NHR2
ATM/ATRlike
G361R
recog-
MDS-CMML
CFPGlyThr17
malignancy5
bait
N-CoR
2q14.3
OPSCC.2
sun-damaged
APL,28
mutationassessor.org
Shreeram
17q21.32
tonsils25
5′-GTGGTCTCAGAGGAGGAAGAAGAGG-3′
2–5
E1124
27–63
toKodak
eppendorf
∼4-fold
eight-twenty-one
TransIT-TKO
V1–V2
V555_V559del
tolerated44
MEKK3/MAP3K3
Alveolar
spinfected
U87MG.Δ2-7C16S
p.Arg229Pro
PLLLIvEYaKyGsLRGFLReSRkv
HCC.The
.Transfections
ALKomas
G2-specific
D1–3
LY2940680
ofthese
5′-AGGGATGGGGTCCTCGGGGTTGAA-3′
tissues40
METex14
eleven-fold
Lys635Arg
A871V/Ga
protein-HSP90/70
4-hydroxyphenyl
5′-gttcgtcctcttccagctctacagtgaaaacg-3′
5′-tctgt
BRafwt
FUS
puroresistant
release44
multi-potent
***N.S.
genesIVTTIn
MOB1A
HCT116-BRAF
.One-nucleotide
.Chromogen
SDS-page
megabasepairs
168–240
PNT2C2-ETV1
attB5r_MEK1-Rev.
TACC3ex6-RV
EWS-ATF
GRO1
S4D-F
Multiprotein
776–777
peptide-bound
ELB
useful.99
03003230001
NRG-1-dependent
currently-known
enzyme-acting
EF1α
8.02908675
UMUC7
alternativesensitive
TSC1-expressing
HER2E
4,273
cells/clone
antigen-modified
Asp+Asn
UM-SCC-2
vernier
RAT26
IFN-'y-treated
RHOA-GEF
50×109/L
CDK1/cyclin
2324
cancers.Overall
PC9-luciferase-negative
ECFP
ProteoJET
169-kDa
re-operation
129S2-Lats1tm1Tx/J
M3M4
R2848
A1075G
18-508
E178K
3.191
5357
ERF-independent
HMC-1.1V560G
pVHL30-expressing
.132
mucosa-associaled
.Ichikawa
protocol.2
19.4
Ang2
previous-described
Kaigala
Origen
7K
Alox12
43.3
Cul4A
0.014
stop-gained
+27
to1.5
Q510E-
Keyomarsi
mini-foci
1Cc1
p.Arg174Arg
18.0J
phospho-ribosomal
Pregnenolone
CRM1-exportin
33.6
OMG
pBlueScript
preosteoblast
.Quantization
2009:523–531
.Graft-vs
C162R
.RAD51B
450K
pMSCV-GFP-shRNA
approx7.9
prominant
Moscatello
SLC45A3–ETV1
6/137
AMG102
fluorescent-tagged
15-Gy
1828insGCA
NB10
fpfilter.pl
JMSU1
INTRODUCTIONTwo
chemo-immunotherapy
GSE15622
P334R
Pro369
same-allele
familialTAADb
2.27×10−6
CriterionTM
844A
27958798
FLAG/His8-BAP1
translocations6
BRAF–BRAF
cytoskeleton102
HAPSEG73
−73.3
BAM36435
O:14
ELDLETLVPYIPMDGEDFQ
228550
cytomorphologic
.33,36,38
time-point
Nemani
.6–10
LIN12/Notch
T8552
SPIA
his3A200leu2A1
MLH1-
D252Y
glycol-lithium
Point-mutations
1.357–2.705
affected2
Aebersold
kilo-base
.mutation
reported.11
Estradiol-induced
anti-eGFP
cytosine-to-adenine
3β
2h
Brn2
18–50
micronutrient
217WT
DCreg
1C26
A-T288
CAND1-EGFR
pBabe-H-RasV12
1119–1138
orthophosphate−labelled
c.460C
r-values
Proteintech
YChg9F
.17–19
QG863
Cul3/Rbx1
BRCA2+
nonlymphoma
penetrance.54
Seventy-eight
3.3–13
Mie
PLC-γ2
p.H264LfsX2
tract5,6,7
iodide+
post-radiotherapy
P1217S
PKCθ-
inititally
K1702M
0.5α
necrosis.functional
G442EHEG0
p.K650E
polypeptidic
19/823
RP11–339F13
JMJD3
erythrocyte/MK
D595V
P=0.0028
Smad3/Smad3/Smad4
ileum
STINCHCOMB
5'-TGCAGTGAAACCTCGCAGCC-3
orthologs13
element-specific
RevertAid™
hydrophobicity.A
receptor-alpha-positive
-Grb2
PIN/prostate
†patients
Fig.1D
5-CACTCATGATATTTCGAGCC
D-010097-01
ASouthern
MIG-cyclin
LPT-
Degregori
.Completely
3a/b
GGCTGAATTACGGGTAAAG
6,7,9,10
Testoni
Eisenhauer
interobserver
G157R
myeloma.12
Rad6p
5′-CCACCATGGATTACAA
3423-3425
In-Situ
Gln145—Our
counteracting
protein.4
▵
pSHC
Dimer–Dependent
G1321S
.Interbreeding
c9orf24
p.209L
8623
.9The
0.28-3.25
G1.15
21Ex
cp10
24772+
IKZF1-testing
Pro8
∼200
p.R389*
L815
​toE
R759Q
Sf3b1+/K700E
Bulavin
T2-T4a
Horan
7q11–q21
M/73
2.225
biotin-nick
mSin3-histone
.MiR-3127-5p
Detergent-soluble
Noguchi17
G244G
p.S65W
Q136E
G8R
c-H2AX
7F
CAGTGC
D835Y-expressing
A184T
Microdeletions
P250R
pigmentation
oxcarbazepine
BR-0234
γ-phosphates
GSE31483
Vismodegib-sensitive
Four-µm-thick
Delta-Serrate-Lag-2
3′-splice
callsets
Luminy
Fig.9C.9C
CTL-transduced
Q157P
Flag-Gab1
anti-HMGA2
lacZ-neo
B.Parker
403.5
ig
FOXA1/pERBB2
Juin
0.3–2.5
one-fold
|CBF
II-2
aminoacid
Corey-Pauling-Koltun
29–83
RAD51D/RAD51L3
718
group.11
mutations/aberrant
PF-03446962
3.540
mutations.43,44
Cbl-70Z
cyclin-D-CDK4/6
post-etoposide/cisplatin
CGNP
classificator,25
GHITM
Trimarchi
L216R
0239
ribosylpolymerase
Lys20
functionVarious
falsepositives
2BIM
ZZZQ
clearhot
H814R
AML1-S291fsX300
-β-galactosidase
GAL4-dependent
homodimerizes
disorders118–120
Pik3ca−/−-null
tumour-adjacent
P80
pressure—Solid
fibroblastmyofibroblast
lgt10
.RNASEN
P66*
RUFY2
65'C
andhPMS2
TGF-β/SMAD3
ARX
.00249
CyclOBEAP
11.5–11.7
164-bp
Thr202
Poore5
Grb
1672del
E76A
RAF1-β-catenin
Damage—To
protein–red
syndrome—that
37.8°C
antagonise
C/EBPalpha
vitro-engineered
SQCCs.Pathway
H1802Q/R
Novostain
mandatory.26
8/146
M13–92
SAM2
pBMN-IRES-Hygro
3•54
730–9
44–90
Relander
hemangiopericytomas
Rothmund-Thomson
CUO24
189a
intrasplenic
.N235K
.Autoimmune
20.4–72.2
GCRA
Idarubicin
A380T
UPD13p
CCGTTCCCCAGAGATTCCAA
0.4/35.1
1879–1882
re-docking
Pro402-containing
PI3K-kinase
p.V824V
b/V/Ra
mTOR/p70S6K1
.U2AF65
DpSGXXpS
oxozeaenol
MIG-Bcr-AblT315I/MIGBcr-AblY253H
S1.1
TP25.99
Sca1−
multicolor-fluorescence
insNPG
manner.69,71
19.R337L
1918
possible29
Akt2W80AHigh
MT-destabilizing
P=.1
signal.21
CG3962
humified
MC,6
ATG12
Linesa
both—catalytic
megakaryocytes.41,42
Nu24
andif
sensitive.2
dCAPs
EYFP+
mutation-specifi
12587-010
MITF-dependent
previously44–46
.Intra-patient
p190bcr-abl
GFP+YFP+
nitrogen/45
fludarabine/cyclophosphamide/rutuximab
ERK1T202
1293–186348
cstradiol
oso
cultureCell
transcriptionalactivity
L233P
M224R
tetraacetic
reactant
itself11,12
G719S/A/C
T105I
Ammoun
653
.Member
TRCN0000121121
icr.ac.uk
®broblasts
249-258
monotreatment
types.31
HCCs.19
SE1
pcbi.1003545.e007.jpg
proximal-proliferative
.Diet
.FAM123B
49/386
-MutLα
Nox4
mg/10
R2.12
databank
N417
isoproterenol-
protocadherins
Yuhei
Sheen-Chen
TCATTACACCAGTTCGT
Oro-motor
−p
GGGCCAAAGG-3
GV219
NCI-H1781
Asxl1-targeted
log2-normalized
ab15160
small-cell
157:233–240
PP2A-B56
cxons
mutation,13,14
haplotype-score
potential.14
Pt2
.Felix
NCI-60
-7H-pyrrolo
ConcanvalinA
to2:1
S6I
1649
HCVrelated
91.8
FGFR3/4p11
V769D770delinsGI
GTPase-specific
motive
58.74
O,33
Apc+/N1638
c°rcs
0.55KIT
AAG→CAG
Zegarra-Moro
S1.3
6988
W308C
.Concordantly
chymotrypsin-resistant
EOCs
3.33
AppTec
H733Y
p.P1684S
cancers.1,2
guanindinium
bioinformatics-based
intermarker
malignancies.1
.RUNX3
andNTRK3
ALK-crizotinib
C157Y
98–105
flag-BRD4-NUT
FCR
N-acetyl-leucinyl-leucinyl-norleucinal-H
gene-modification
developped
a-32p
5-protein
associated/coupled
M.C.H
MEQKLISEEDLGS
//www.biomedcentral.com/1471-2326/9/1
HuCCT1
22,32,33
P=0.0015
Redistribution
C-9
ZNF198-FGRF1
set-ups
tumors.13,15
196K
Lys'436
AB/
Figure2D
lines—tumor
Ever-smoker
HCC827ER1
acquired-resistance
GACACTGAAATATTTTCTAGCAATTGCCGGCG
anecdotally
0.5–0.85
Val/Cys/Ser/Leu
4494.0±649.3
CCCTAC-3
5∼10
failure.24
.Nox4-derived
methylation-peak
153,154
diapedesis/extravasation
GCCGGCTATAATGCAACGGAAGAAAGTGTGA
RG-23
CITD-2635D8
antimycotic-antibiotic
femtomolar
272-286
40/50
.Obviously
R2214X
2988
MYF5
studies.4,27-30
I460M
7.88E16
50mg
F2827C
Sf3b1+/−
complexes.Figure
2849A
pZNaq-G207T
ΔΔ9
.Cerione
Jechlinger
INPP4B-CD
5′-GCGTCCTCTCGAAGTCCAG-3′
rrriICCCCCCAGGCCAA224
Data—and
BRAF94
cases.28
TEL-JAK2,10
34:113–123.10.1007/s12038-009-0013-7
CK5–6
S.K.-S.
S3A–B
pRL-tk
​pQE32
Eu-N1-labeled
CRAFS338
3932
reports.21-23
hamartomatous
p.Q1336R
ATTCAG/gtatat
stromal-cell
p.Tyr122Cys
Liognon
CCACCAG-3′
Klco
MYC-tag
Polybrene
phosphoryl-transfer
Exo1-dependent
non-nervous
120kDa
.3
investigated4
.BAK1
mm.A
Non-mutated
leaves/GO
E526Q/wt
.DOMAIN
ECD3
BioGenex
monomethylated
IgA+plasmacytoid
extraintestinal
G-CSF–mediated
maturation6–10
R248A
5198
1.739
1622
Biosource-Invitrogen
002755.2
TM8
82/Mb
83.6–4,498.2
progression.50
S240I
mutations.1
proximity-dependent
algorithmically
fluorescence-labelled
SB3
M-MG-B
ATTAAG/gtaaac
1361
129S6/SvEvTac
IPC
I1XP1
.Dilutions
central/conventional
0.210
Aurora-A-dependent
51/M
Oncoprint
F218I
DSRed
b-Gal
Coyaud
22q13.2
HCRT
C101Y
hemicolectomy
pSV2neo
MSCV-EGFP
SFX
Bromide
T308D/S473D
.AT/RTs
Forty-six
GST-Sepharose
W2626C
.Yellow
NF-κB.6
cells,31
anti-p18
PE-conjugated
non-vII
MutSig
endometrioid
exposure-effect
3FISH
Ki-ras2
*ATG
C-RAF-specific
PTEN/MMAC1,21
CYP17A1
eBioR2/60
voltage-dependent
etrances
V211I
MutLa-deficient
EGFR–RAD51′highlighting
caccatgtttggcctcaaaagaaccg
6/84
136/148
paraformaldyhyde/PBS
type/histological
Lck
DFGLAKLLGAEEKEYHAEGGKVPI
Exon9
pRc/CMV-WT
2–5-day
3.3.1
.L148F
hygromycin-containing
laboratory-made
Daviet
AATAAGGAAGCGACCTGCAA
Navaraj
CAGGAAACAGCTATGACC
mutationsaffecting
AC006474
.CL-387785
Fig.33b
ENSG00000138336
Ha¨yry
16th
CH/Pi
Penelli
NFKBIA/IKBA
-~3
dauer
252–255
LRPs
12,19
46/151
88/501
AS-insert-AS
anti-AR3
growth‐retarded
Trevigene
-GATTT
H2A.X/H3
interaction/regulation
nucleofactor
205intermediate
BamH
51–65
splicesome
11-3
co-administered
stability,1
mass.2,4,5
β,22
same_
α-RB1
HER1/EGFR
.NCI-H1299
55/120
Envision+
aurora-family
p.R117G
0.3474
phospho-Akt-specific
8/96
Leu115
c.1440T
Complexed
CGTGAAGATGCTGAAAGACGATG
R170W
patients—may
Autostainer
anti-cdk4
NS817
HPV-44
2y-PFS=90.5
.Radial
.Fixation
DN-Δp85
1.5–3-fold
FUBP3
corticostriatal
complex-processed
kilobase
extramedulary
Nano-HPLC-coupled
non-switch
.NCI-H1155
sub-structure
AM050803
sc-9084
96-10670-107
Wnt/β-catenin-dependent
FXFP
SorcererTM-SEQUEST
L348A/L350A/M340A/L344A
triggerng
—but
OR=0.79
E163fsX213
61–192
21.89–25.65
2886
K5.Smad2+/-
p.Gly382Asp
SZ61
1:500-diluted
I-5
0.6μM
PCR-associated
Biorobot
.High-titer
Edmondson-Steiner
15/48
H3F3A/ATRX-DAXX/TP53
cancers31–34
PAX3-FOXO1
time-and-spatial
S4H–a
pY-Flag-parafibromin
sh463
reports.15
Z1
NOTCH1-pcDNA3
Vectamount
frontline
correct.Construction
n.de_Wind
SD.Smo
PLD1-binding
pCHIM
B-Z
VNKR
rs12720263
T185M
700–1,007
.NMD
CCGGATGGAGCGGAGGATGA
Mucocutaneous
db=snp
immuno-
thimble
20X
GST-SPOP
still-unobserved
.Saos-2
S252–261
K159–I168
MPD.1
delayed/decreased
v-Crk
wild-typecounterpart
D792
.Wrana
FQL
YAP1-activated
Toll/interleukin-1
l.p.a
159–164
c.790
showingincrease
monomer–monomer
MutationsTumor
97/03
extrinsic
Q157R/P
T76
kitDN
5′-caggtcttgatgtacttccctcgtttgtgcagc-3′
Ago4
myc-p110-GFP
1q43
Treatment-Related
T3936G
N-of-1
mutation¡/HER2¡
DSB-activated
2Binding
.PCA
PY1068
.HDAC3
0.741
telomere-specific
HD-LECs
-catgagtccaactctccgtacatcgtgggc-30
Phosphatase-2
metastasis-associated
Retrovirallyinfected
c.7988A
SNUOT-Rb1
362–364
barcode-specific
Ras/Rapl
PB-Foxa1
19,24
∆KD/Smad4
Q=0
S65P
47,335
36/39
RETWT-transfected
SN2-like
.Preparation
burden.20,21,29,30
antagonist-II
growth-suppressive
c.6853C
FPD/AMLHaploidy
R102H
2552
5′-GAGACATTGGACACGTGGGCATTAAGCCG-3′
MDS2
5′-GCGTGGACAATGGCTACTCAAG-3′
ICL1
PDGFR-activating
uGluAl
.ASXL1-WT
Amphipathic
TTGCTTTTTCTGTAAATCATCTGTG
shNTRK1
Perkin-Elmer/Cetus
G34R-
mCRPC
HePTP
5Centre
56/67
β-catenin-TCF
AG3046
.Histograms
copy-neutral
retinoblastoma-binding
TGF-b-activated
5-M13-AATGGGACATTCACATGTGTT-3
overproducer
.003363
extracapsular
.Unless
E322
0.4–17
intra-JMR
.ANALYSIS
H.H.
.Post-trial
GTA
studies3
∼10-
somatiques
6.8Mb
125:351–358
≥260
residues.Fig
mTOR
420C
C11
PCR-based
studies.30
125I-NGF
LTC-ICs
​0.05
capacities.10
Paxillin
deleterious/high
PT1
H78Q
Mazoyer
1226
ribonucleotide
TGGGTGAACAGAC
L451V
.Dacomitinib
hIL7R_cP1s
19,288
cancer.10–18
S392P
T3_A126
TCCAGGT
electroporate
−697
Thr308
2B–C
neurocircuitry
SPOP-F133V
GH1
trichostatin-independent
pEBMulti-Neo
S498R
BIX0124
MSH2,24
pEGFR
SFHE
factors16
TTCCACTGGATTCTGTGCTG
HSC4
anti-miR-130b
cType
c.25G
Primordial
6,600
somatic-activating
Re-introduction
CausalityBRCA1
TbetaR-I
gpl4OProto
173-187
Mosseri
NB-14
–120
hairpin-shaped
non-DNEmutants
tlDNA
.Wall
5′-TGTCGGTCGAAGTGGAAGAGG-3′
lanes3
Allansson
width=800
inextracellular
pQCLIN
pro-substitution
PC-Brca1+/+
translationt
TCF12
L110F
4×180K
27–36
WT-EGFR-expressing
BKLF
01-0708
129/Sv/MF1
tumour-expressed
q11q21
52/M
Rad4
v-fgr
12–21
mMNa3VO4
/-5
-dichlorofluorescein
transformation-defective
2.2.6
0,91
Z-VAD-FMK
Fig.44c
RUNX1-YTHDF2
mutations,33
//foldx.embl.de
.Strategy
11,12
36,37,38
tumour-prone
A634D/Y107A
genesHNPCCHereditary
C1365Y
BRCA-mutated
ce2
ERRBB2
not-expressed
re-entered
tivatinib
islargely
Y866
NF1.21
cellsTo
4and
p.Tyr494Leufs*7
GSE35844
pMY-IG
n=232
ERP001432
Y13
RXE
49412958
bodies,27
Errington
of94Â°C
Viernheim
V600D+FGLAT601-605ins
Ultralink
misspairing
UPLC
-TGGCTGGTCGGAAAGGATTTC-3
gene.1,4-5
MCT-7.fgf-3
S3018F
Age-adjusted
CNA-based
32Ds
11aF
ml-1
apoferritin
MSH6-p.P623L
analysis.8,14,19,28
anal-
Apo-2
HMB45/gp100
D203Y
-bisphosphate
chr16
Curitiba
141
7/132
E705K
.Rea
I-ISE
p.1391
10C–D
loop–helix
al33
Ohtsu
,c
parent-offspring
1μg/μl
polyphen2
complex.31
SC-1207
138.8
N612Q.K
'fork
γ1
12-month
.recent
leukemia,5
:2241–2252
SMEK2–ALK
lichen-derived
rs6736039
4.83+0.99
HSP70-associated
copy-levels
IR-activated
.Kit-KD
x-rays
size-modified
Chantada
pJNK
Tsoulfas
FGA
Pa1
elsewhere68
PVF3
Dusp18
cascade2
lepidic
p46Eg265
SVZ/RMS
SCF–KIT
.ACVR1
Non-CSD
analysis.43
RL5A
D528G
GQTSKMSPRVPQQDWLSQPPARVTI
Total-EGFR
AST
hAR2695
p.Lys273Asn
proliferation.32
p.Thr457Ile
5′-FAM-CTGAACCTGGCTACCAGGACCTGG-TAMRA-3′
MiaPaCa
D/E0φ
Rosa+/CreERT2AtmC/KD
D276H
5′-AGGCATTGGTTTTTAATGTATG-3′
apoptosis.6
borate
human-disease
leiomyoblastomas
3/5
38.3
non-sequence-specific
wtBRG1
Ljunggren
i,4,5
MSH6-antibody-coatedagarose
Pandini
vectorsFor
cytes
-focal
AGGATCTGTAGCCAGGCACATTGTAGAAGGTGGACCTGATTATGGAGGG
permeable
2.782×10−9
baculovirus-infected
cohorts27
SCV000195554
JAK2WT-derived
Bilineage
sub-bands—3p26.2
PTEN314-403
HKL2MAP
described.HER2
optionsSignaling
invasiveness.36CCND1
COS-1
-.^
Jak2-V617F-positive
K650E-
GST-TSC2-N
CD36+/glycophorin
c-helix
hyperglycosylated
R102W
antiestrogenic
Tyr253
GAGAAAGAAGCC-3′
9336
SU-DHL-16
anti-microtubule-associated
Eighty-four
∆NRaf
92–96
PSA-Luc
3648
6p12
SOX9–DNA
PTEN/TMPRSS2-ERG
NTRK1–3
Frameshif
AdCRE-injected
siRNA-treated/untreated
ABT
ones.48-
73jC
-4.5
Kauffmann-Zeh
MG430
JCML41•
ATM/ZBP-89/p300
8.456
Cyc-
NMWL
Y513
no-mixed
cgr485
rs4553808
.Diverse
736e
medica
NurA/MlaA
DEAE
R2266P
D11S4176
D761Y54,55
494G
DMT1
0.291-1.951
229S
assays.The
EWSR1–FEV
IM/SU
processes2
1.0.22
Brückner
S752Ya
1779insC
FDR-adjusted
CINcancer
L/M
hu14.18-IL-2
BRAF-kinase
TG-3′
luciferase-reporter
binding-defective
SmaI-SacI
1LM8
transcription.18
RBF–CycD
Gdf11
G1743R
5-methylenesulfonate
Etv1
.54,55
__P573del
.CypD
lymphangioleiomyomatosis23
1UNP
Protocol/Stainer
RBM10-mediated
165K-
synthesisof
315R
S178
875CrT
21-25
11.17
HCC1772
R280K-transfected
⩾60,4
4-position
.S18E
Lin−Sca1−cKit+
light-regulated
pathways.28,29
481-amino
D631N
0–180
p53/DNAcomplex
Adeno-Cre
RASQ22E
lymphoma.1
genomicinstability
1575T4C
c-Myc12,14
OR=0.98
activationobserved.Effect
p3xflagCMV10
FLAG-BRAF
Marzec
μCi/dish
Deb
pAIPFNgreen
tumorgraft
JAK2-V617F-Y931C
MODELLER.47
miR-19221
1,107
100/106
Generalization
12-M
CL-387
Y226A
Ret9-C634R
EUFA622
GPCR-like
.APC25
.8023A
Tyr823Asp
37–963
.Galectin
R395W
bisphosphotyrosyl-containing
JAK1831S
Figures6A6A
1,100
.Arg340
5-Gy
Mandelbaum
E685
million.1–3
.Atlas-SNP34
Dasatinib-resistant
K248E
.Quantification
dependenl
J121
MLOS
10562
RPS14
hinge-type
D816V-mutated
TSS1
V143G
intra-genotype
R122
Recentdevelopments
eight-week-old
morerapidly
immunopreceipiated
46285
JAK235
HER2-Tyr1248
Met-derived
10437-028
Satoru
251–266
FANCF.25
microsyringe
810–812
GRR
Al-Tassan
U133+2
tumors—supporting
syndrome/JMML
othertumor
77.5
mutant-FLT3
1w2c
'filtration
hypothalamic-pituitary-gonadal
described.10
N-dimethylformamide
cell/myxoid
C-mut
closed-conformation
VHL/Elongin
2312
S9-S10
reporterdemonstrated
cytofectin
Tlymphoid
tacacactcatcagccagtgca
ER-translocation
Mre11-His6
previously-published
BdF.1
BMS-754807/PEG400/dH2O
L345V
pXP1
28/609
NCCNCS-10-392
SOX8
studies.7–10
Gα13
cotransplantation
myc-EGFP–LKB1
16q21-q22
hematoxylin-counterstained
2/14
ETV6-WPDGFRA-expressing
739358
SUTENT®
allelically
blottingon
aspartic
constitutively
T17N
.P5
Tyrosine–Phenylalanine–Phenylalanine
A428T
2.37
C-RAFpS259
CDC73/HRPT2
∼86
keratopathy
**Conclusions
incise
.Being
N1698
activation23
receptor–deficient
wild-typeU2AF35
SVOGs
.10,13,14
G196R
Non-carriers
U.B.
KmAdoMet
i–iii
69061226
0·12
HT3
MAGE-11
Y62G
8/19
c-Kit-STI-571
6-well
kidney11
duplex–binding
arterio–venous
KBI-40144
HSD17B1
preadipocytic
daily.8,9
Cox–Mantel
ST3
β5-strand
Hamartin-Tuberin
.MmAGAAAR12345
choroideus
650insT
PTEN-depleted
Met556
repairFull
Leu344
pairs.
P992
V804L15
Self-applications
Andrae
MCF-7/ADR-RES
S537
+LL
D3015G
present.Experimental
Asp-871
Evasion
D22S1164
230–504
KDM5C-forward
syndrome.8-10
80,86
Smo-positive
pyridinyl
Sos-binding
MAP2K1Q56P-mutant
Atj
//intermine.modencode.org/release-30/report.do
Calbiochem/Oncogene
H3K4me3.104
inhibitor–1
p.Glu1735
Agazie
-CCCTAGAGGGCAAGTACGAGT-30
phenylaminocarbonyl
ULS
patients.4⇓⇓⇓⇓⇓-10
JAK2wt
A_52_P487686
McPhaul
E160*–p85α
Tyr764_Val765insHisHis
Ringrose
KRAS.8
1.58plusminus0.3-fold
FOXL2Granulosa
Y472H
Keap1-mediated
TKBD
asdeduced
2818-residue
4·0
0–≤30
2/485
ontogeny
anti-VEGF-A
c.2192
MAM1
CDH3
3867G
MEF3T3
IGEPAL
Ser1372to
Twenty-one
7/10
14-19
dry-eye
3Death
toration
mini-osmotic
radiation11,12,13,14,15,16,17,18,19,20
32,33
ABSciex
penicillin-G
837.1±132.2
AKT-activation
N150K
L-CAM
Ehrhart
56•2
R190C
Marginal
TGFalpha
sc-28383
0/144
Four-color
718-985
SF1/BBP.20
GFP/DAPI
Fgf1
RE2
PR16
MontrÃ©al
ErbB-2orthologue
Glioblastoma–ROS1
Trans-4-hydroxytamoxifen
5′-CCCTATACCGTATATATATACAGTAATCCC-3′
p.N564K
A2MR
Isolectin
β1-integrin
GM-CSR
.FEV
23–65
.26,28
syndrome.69
MLH1-p.K616del
crizotinib-naive
mutant-positive
non-speci®c
mutations.67
0.94–3.47
ERCC2′s
WWP1-1-349BR530-F
childhood-onset
p85α/p110δ
nmol/l
BCORmut/U2AF1mut
RR1
Tyr-1853
Fam-TGCCACCTCCACTCCGTCTA
Leu77
JCRB0834
chartreuse
DCK
1wt
32D-Flt3-WT
L235
.Appearance
2703
F1174K
91314418-91314562
NSCLC.26
receptor32•33•
760–501
Addenbrookes
BRIM-3
D16S752
MYC-family
7G–7H
IL-10R
RalB
crenolanib
NM_009689
MSH2-mutant
.Methylation
function.8
Electrophoretic
SC–URA
1/02
3′-intronic
lod
1.39–3.63
4-hydroxytamoxifen
isattractive
Y599F
three-helical
//www.genet.sickkids.on.ca/~ali/splicesitefinder.html
Q8BG87
.timeline
p21-specific
C184R
c.1925G
.RQ-PCR
1•21
PTPN11-V5
MassExtend
hypo-methylated
05/19
Proapoptosis
LAHyp
FRS-2
hamartin-specific
.66729153T
0.079/0.025
Dll4iECKO
thrombocythemia,25
NOTE.The
Leu-701
FLAG-PTEN
//www.ncbi.nlm.nih.gov/projects/SNP
autosuppression
2916
2177
6/33
NaN3
MutationsAmong
38
electrolytic
CLEC4E
PDGF-B
Caenohabditis
p.K648N
PDGFβ
0.3375
Paietta
AAL39418
T-X-V-COOH
Ostendorf
TheMMSET
NB6321T
whole-chromosome
.Clonogenic
GSThBAP1
610965
Exon10F
c.130_147del18
re-activation
Kit-phosphorylation
Ingh
Wrana
.Anti-β-Actin
SNF
APF
P9
1x107
death.50
.Nonhomologous
-or
=34
Anti-RET
p.A589D
XP2YOSV
low-CYT
p.Ser817Tyrfs
​Fig.2a
1590–1600
D1S2664
RTs110
.Injection
Spectramax
TTCAAGAGA
model-
BIX01294
Vip8q2418Ana.3q
G388R
up-pucker
3-kinase/Akt-dependent
donor-recipient
kinaseERK2Fluorescence
DB_NUM=1
G466EB-RAF
others,9,10
aq-Q209L-transfected
-16-dUTP
−2.46
αA′′
5Flow
E665
—known
RTs41
underlyingmechanism
Y371C
R1207
SV40-GFP
H-1205-011-4
pCMV-Tag2-BRAF-Mut
P.L833Fa
Lysine-935
.Gle
Gln61–H2O
6697delTC
14.5
non-ubiquitinated
Fig.3a
wt-PKB-GST
T-E-Y
VMRC-LCD
125mM
CCTthe
Examiningendogenous
1Y4D
MBP
C277
catenin-binding
4.1–5.9
RCT
Smad3-knockout
-BamH
IVS16-20A
237-249
D2S147
~-MHZ
.National
E33G
PCR-DS
DDIT3
IgH-Myc
hybridization-ready
Cochran–Armitage
micro-calorimeter
B38
,2F
C634R-V804G
GSK3A
600–611
tgA
Tcrb
Replication-deficient
Klf5+/−
non-Burkitt
0.588
.Structurally
Lu134B
development,1
RepliG
DOX-treated
16/29
p.C135R
2IVT
J.B.
XLb
PBX2.1
arginine63stop
IDPTQL
2I1M
42-45
irr~paired
2,6-dichloro-3-fluoro-phenylethoxy
Roskoski
Verrijzer
Vav-Cre+Srsf2P95H/+
'yes
15,29
corepressor27
1c-3
c.5074+154
EIA
P1297L
G1967D
0.247–1.938
09-131
WT-BRAF–expressing
CRL-1772
ASCL2
Myc-dependent
57˚C
Kinase-4
503-Tyr
pfizer.com..
216PheFS-216X
0.04-0.79
19:443–454
pBabe-puro-HA
DEXH-box
Ampicon
AY518306
theNUP98
anti-Nox4
EGFR53
ELE1
R109*
doxycyclin-
interestbecause
Birc2
Motic
.Y107A
S100P
compartment.25
HAT–Lys-CoA
30G1/2
Calin
disappeared.113
protein–membrane
demineralised
3LacZ
F2AMLmF4
Augenlicht
NuGen
E3-dependent
XPO1-C528S-RFP
let-23rf
B6.129P2-Lyz2tm1
Ala-Ala-Ala
Amiri
1336–1821
2009-532-f-S
areflexia
protease-digested
M2001T
Vignal
tumour-utilised
0.273
docetaxel
numeral
profile-profile
F568I
BRC15
MFAG
p73betaT
aanae
0.0∗
q≥0.848
D.C.L.
cross-modulation
Syk-regulated
raf
+401
rhodainine
Enzalutamide
pcDNA6-FLAG-RAF1
HEK293T
TSC
Intavis
polyglycine
hGli1
growth-factor-induced
quadratically
E600-K507
4e
chloramphenicol
219,400
1681
TVwith
22⇓⇓–25
Cytomorphologic
Ser181
L257R
Machery-Nalgen
AKT-inhibiting
16B12
altered/deleted
www.biodiscovery.com
vulvaless
γδ-PTCL
digoxygenin
intermittent-dosing
D119N
Etzler
CXXC
Next-Gen
appearsonly
Heerbrugg
G2748
.Initiation
CFC.18
2,305
pC53-CX22
locus20
10/4
NS.60,62
Genome/faq/
//mutationassessor.org
Rodríguez-Escudero
AGGGTTAGGGATAGGCTTACCTTCGAACCGCGGGCCGTAGTAGCTGCCTAAGTGGA
10750
B-RAFV600E
ALK-targeted
VanDjiken
50-ng
PLCG1
6A–C
162752
classification.20We
Figure44a
lo7
acetate-labeled
hypermethylation-associated
AATCTCTTCCTGGAGACTCAAGACTGCAAACATCGATTTACTAATCTC
HIF-2α-regulated
pen-strep
LAS-2000
calcitoninsecreting
2.3
effects,2
//www.mutationtaster.org
progression.3–5
MCF-7-SPEN-sh1
WT-ER
1300×1030
3weeks
basal/stimulated
wtMyoD
kinase-1δ
S17
E10–15
lymphocytes.Cells
99.75
LA-N
identified.1
10/358
GGTCACCTGGAGATATGTAATTTTG
p.Y261*
3924
Temperature-sensitivity
G586
Vps34
V303E
wild-type.30
FLAG-HRASG12V
countries,3
aci2
androgen-hypersensitive
understood58–62
58-TTCGTCCTTCTTCTCCACCGG-38
Jeliazkova
NIaIII
FAT1-negative
6−8
pSG/Flag
hybridization.49
Amerco
shRIT1-2
E804
5Aiii
ectopic
1,525
5-16
405-blue
Ialpha1
PCGF4-dependent
Q644H/V645F
.MTS
738del
PBCre4
p52/ETS
ttgtag/ATATTG
8206
caspase-cleaved
miRNA-processing
767A
5'-M13-TCGCGCAT-TTTCTTCAACC-3
pS5
.Put
101P
p53H193R
FHS74
.Exchange
Balb/C
Y1769X
2196
p18Ink4c
cell-cycle-related
Rcullisb
K27MH3.1
Me8
'nicking
A391
Jho
226.2
frame‐shift
FUJIfilm
orIGF1R
Stadtfeld
disorders18
+0.74
Ming-Sound
hormone-1
τtrans
1563/0/170
9101L
cells/50
producesthe
C27
sc-56
L246Va
1312
YFP-CTLAThr17
children.1
67/36
1812del
ductal-like
H/E
.Calibration
proliferation24
VM-CUB-3
used35S-labeled
0·212
5′-CCCGACTGTGGTTAACTTCATGTCCTAGGGGATACTTAAAGCCTTCTTTGTCATTTCTATCTTTGG-3′
DICER/miRNA
-rearranged
α-Fbxw7Arg465
rearrangement-induced
SwaI
CCTTC
Cdc25Mm
.P-EGFR
PI3K-
Wartik
tumour-rich
mechanism,25–27
respectively.2,3
3·8–20·8
pan-p85
PML-mediated
pACC
.genomic
1~
.BRAFP-loop
quanti-
Wntl
per-experiment
KDM4B
UAS-PMS2
Vybrant®
-+-
1.84-fold
µm/min
mutant,26
anti-phospho-Tyr20
CD34CD38
medium20
SIFT14
c.9098A
pile-up
Flt3internalization
T-Δ-Erg
Receptor‐regulated
5-formylcytosine
1.04∼1.18
Sin3
sensitivities.Figure
NCBD–p53
Non-tumour
Flneo
PTEN-associated
ITGB1
pLV.CMV.Flag
150I
KEAP1-regulated
Histone-Modifying
metal-affinity
C-640
P=0.0048
ssDNA-binding
NucleoMag
4.8–53.5
8:323-335
Quintas-Cardama
.Krek
charges.This
p-Erk1
griggin1
5′-GAATATTTAGAAACCTCTTTGCCTTCTAGCATGGGGACATACTG-3′
TRP5
.MON
MAMLs
S387Y
ALL-2000
Methylthioadenosine
453–459
N741
tet-induced
of0.26
q13.3q13.3
FAM-M13
BTF
hematoxylin-eosin-stained
MINT27
.Akt1
65-68
2-oxoglutarate
G12.1R
RARS/-T.38
p.N680K
Dylight
other/C
.I–N
.D816
Q319H
exons.16-20
2,500
〉
TRIPZ
4NQO-treated
VD3R
2.Y327H
MoMLV
SOM
others29-31
ECM/basement
203805_s_at
T.K.
HEMaLP
IKAKFLQEAKI
T285A
88H8
RAS/RAF/MEK/
OTTHUMT00000280547
􀁂2-microglobulin
.Raf-l
scoreb
malignancy-related
22q
defined.22
NP5-BSA
conformation—
Primer331
non-Western
HYP
©2015
superﬁcially
5248
FGFR4-V550E
75Sequence
.0.0024
cancers73,74
re-arranged
2.257
S1.8
0.03391
3515
alevine
EPtHRptFqQIcsfL
blood-based
SHC-RasRaf-MAPK
SFEMII
1787–1799
pcDNA3β/BRCAwt
ADD3
Notch1ic
IGF2R
β4-sheet
Akt-dependent
c.211+9
humans38
0.7985
PHD-del
p53R249S
NFE2L2WT
recurrent-free
Tk
.572G4T
99:1
c.1528_1530del
M2-specific
9-year-old
FHL156
~∑k=0ni
non–crossover
Y606C
cysteine-reactive
.Multilineage
TRCN0000018338
*Metastases
*150
PTGS1
Fu-Ming
iBE
T58I/S62D
pCMV-lac
molecularly-based
67/113
CAGGCATTTTGGACAACACA
NCI-MATCH
known.21–23
hGFAP-cre-mediated
C736*
receptor.9,10
apo-WT
immunostainings
LB-Agar
114*
Y196
sional
armadillo
Non-injected
Lin−/IL7Rα−/Sca-1−/c-Kit+/FcγRlow/CD34−
-A31
36/930
Montalvo-Ortiz
double-digestion.Bandshift
albeitonly
5/30/00
p.V411
P40692
genes,19–21
leu2-112
phosphatase16
delK745‑A750
Well-designed
Browd
2.58
pspMyc0
large-cell
lrb2
c-DNA
project.Reverse
1st-last
10-adenine
tumors.8
16/75
mastocytosis.27
G386D
3.16
EGFPpositive
550-bp
140-kDa
immunorelevant
HPS5
TCC-3′
BIM-1
1-p
YVMA776–779ins
I189K
.KDR
.Avian
1939
Foci—
Pro770
targets95
uoride
23.F341C
cmlc1
PFS/EFS
PDGFRβD1–D3–PDGFB
Pomérance
motifs,2
mice,6
7/17.1
MSH2-Del745-746
TopHat,26
substituton
J.W.L
5q14–q34
T790M16
B23
sequencingFormalin-fixed
.Seeded
3–02
95-148
membrane‐anchoring
._See
tryptophan638stop
arginine-789
non-permissive
.NL
cytopenia,14
SUDHL1
E76K.76
cystadenocarcinomas
EGLN
Conclavin
Pten
3,608
IPGstrips
23589–23597
PPxY376
Yoshimoto
cells,20
chromosome6
503dup2
5′-CTGGAAGCAAAGACGGACAA-3′
publications2
1108a
β3-strand
.WCL
non-RTK
proteintruncation
mutantBCR-ABL
257–271
themismatch-binding-proficient
c-Abl/ras/ERK
Q262
His773_Val774insHis
p.Ser2155Leufs∗33
0-J
NF-E2-related
pGEX-PTKER
∆28–33
pre-CFUE
PDGF-A-null
.TTN
manner44
tremelimumab
SH6
P1510
C2CD4C
.S2F
G2567AA
T.M.K
0.248
studies,23–27
Erben
rs1140476
PD153035-related
p+
.Pablo
Juan-Carlos
S.W7K
MYCN-targeting
mem­
//www.cell.com/cgi/content/full/116/6/855/DC1
N26
Mocciaro
1.13–1.73
696
15,074
104–107
phosphatidylinositol-3-0H
K120A
25/54
Kater
HCF
anti-YFP
PMO
co-purify
'25I-anti-human
CD73
dextramer+
S-G2
indicat-
Misdetection
PKCϵ–GST
NSE122
91/108
110100
.501
ochromocytoma
p-AKTSer473
thyrotropin
ysGl
5638
rad54D442Y
208G
Plasmin
105-319
ETV6-PDGFRB
smoking-associated
.Examinations
cetuximab.9
23/76
Glu343
EV-transduced
system.
n=22/22
SPI‐CI
P156Q
turbation.48
Skin-fold
HMEC
neuNT
Jusohonmachi
Hentges
TKTs
ter1829
//www.chem.agilent.com/scripts/generic.asp
329/620
pCDH-HA-Shp2K590R
CCND1-to-CEP11
APC580S/580SPtendel/del
c-Met/HGF
PIK3CAknockdown
pNF-κB
GAAGAGAAGTGTACATACATTGTGAACGAC
TI-loop
-21M13F
Jai-Hee
Lafaette
proteins46,47
RAP74
Inpp4BΔ/Δ
,1B
permeabilities
pro-file
p.Gly446Glu
G577V
5′-CGAATCGTAACCGTTCGTACGAGAATCGCT-3′
Venturin
GCCTCACTGACGGCCCTCAC
T725M
glands.17
Fug-II/18
.Hopefully
F-actin
Δ417−418D419Y
44–49
the…
-phenylglycine
MUT-TP53
UCH-dependent
cytopsin
D176E
kd-matched
receptors5
TSC2-specific
stereospecificity
ORF1
389
106±11
.Kd
MMP.In
peroxidase–complexed
3/39
ß-cateninshowed
PDGFRA-associated
0.38
NFE2L2/KEAP1/CUL3
69413
c.IVS4-18C
Kankeronderzoek.
tc-3
stimulant
PRKG2f/2
imatinib400
.Phospho-proteomic
A-III-2
K299CR03
metanephrines
RTKs54
manner.25–29
Msh6GS
co-depletion
TRCN
re-biopsied
R482
Monteiro
His773_Val774insGlyHis
demographics.32-35
CPT-cGMP
24,384
RCHOP
071136X
vefold
Brca2+/+
MPL-S505N
pGL4.20
cancers63
1.09–1.87
MESR
P405S
irrespectively
ΔGtotal=ΔEgas+ΔGgbtot−TΔSsolute
pLK0.1
5th
palmitoylation-dependent
kilodalton
.Prostates
RUNX1-V91fs-ter94
+ACA
3—source
~2,000
28652
H542K
KIT/nucleus
†18
patients2
I611NfsX2
E15.5
5/87
Y88
missense/IFDI
Dot-blot
pro-domains
1593
Chim
1-592
1H-pyrrol-1-yl
1:1250
66,199
platyrhynchos
GSE26954
Cutsem
singlehistidine
SUVmax
SETD2-mutant
29,658
c.4193T
erlotinib164
RbpjiECKOretinas
E12.5–15
select_db
BRCA1mut−p53
.Truncation
step-size
AG~RIA
distinct15
10-µm-thick
p85ni-R340E
418
C\M
250-μg
immunodeficiencies
16p13.34
UUCUCCGAACGUGUCACGUdTdT
MEK2-deficient
SNF5-reintroduced
U10
Reynisdóttir
Scc2
tumor-reinitiating
chromothrypsis
CRISPR-generated
respec
Glu1038Gly
DiFi-derived
.CCH
−0.135797
E545G-
FANCG.31,32
PD00119
7.A1
M46
−0.7
p-MKK4
T4-DNA
\0.0001
.11,21
carcinoma.5,6
A*23:01
pan-ERBB
II-TOPO
GoTaq®
Mlox-
major—if
Shoback
421B
Raw-counts
-GFP
TO-3
anti-ERBB3.1
approxi
27,47
244519_at
E633
rs13281615
MunI-F
Motesanib
tissue.Materials
ERVP16
AACGCCGCTGCGCGAGATGTTG
cancer,74
R284C
131.1
cer
DNA-mutation
Igh-VQ52
K642
30.6
proliferationor
Glu7623Gln
shRNA–treated
14.05
1,412
4093
1FGI
ac-fos
G284S
Ran4
pCTV-5′
lysates.The
.Nussinov
software.4
preconfluence
4.6N
K539Ltransduced
.Science
anti-emetic
andsucrose
Signoretti—DFCI
2/2
CAGTAATCTCCTTCTGCATCC
Caspase-Glo3
dominance36
.Hobnail
d-glucose
.Conditionally
.PE-conjugated
DMEM–F12
sc-29209
MNaOH
SKIV2L
A222V
.PML
Hwa
~71
rapid-run
cyclinD1/IGH
Beji
pathogenesis.12
MSE2
PCDH17
.EGR1
0.00001.
Dranoff
EMC
SU11274/cisplatin
Brca1flex2/flex2/Wapcre/+
N550H/K/S
Valine
960-25
pTYR
P.B
61.37
/log2
.C-Met
DU135
06-866
p.Lys376Glu
BaculoGold/ml
Biomarker
hDa
pepstatin/ml
FANCA-associated
non-ERBB-dependent
estirrated
reactivelike
Ki-67-positive
A237V
STAT5-deficient
L67P
diseases1,2
PKN-related
translocation,7
140–143A
211-bp
Ala919
.CAK
Cys234
Masson1
sc-30226
.Deubiquitination
non-penetrant.6
6.5-mm
,m
Biomèdica
GF77/09
FOXO4
Wilentz
Phe46
UBTF-S
Osmonics
72.2
5′-CACACGAGGGGGTTGTCC-3′
590–824
viral-GFP
MEN2B
wholehearted
7b
versene
c.173A
neurohormone
NIS
A10R1
Ser498
5′-GTGCTGGTGCAGGTACTACAGT-3′
KMS
p53-indipendent
AUTOINHIBITION
Landeira
6‐fold
CAL101
deletions.80
TIF1γ-Smad2/3
co-crystallization
c470G
HFD-induced
Tyr-754
patients73
bonds.44
2/0/1/1
KMT2-dependent
.64
PPARγ1
Normal/gastritis
unzippered
Yaa
AATCATGGGCCAGACTG-3′
C.Besides
R752G
30–90
E804D
1,207
B-factor
Flt3-
M774_A775insAYVM
Landsman13
zer/pcDNA4
l-phosphatase
antiseizure
phospho-ERBB4
GOG-0239
data,22
66.58
01-14
SMARCB1-deleted
177-421
BR2-7-Bgl-F
peptide-pulsed
®-LT1
1138
N-rasT50I
..0
-CCCAAAGAGGTGTTCGATGTCATGCTG-3
EpoR,26
rigid-body
Δ8aa
-29kD
clones,12,30
NLS-containing
R491Q
HSGSLGMGPMATELEPLCTPVVTC-
H/DX-MS
G488A
pcpt
.Directed
inhibitors.15,16
2'7
7730
D1853N
R853H
binding.To
//www.sanger.ac.uk/genetics/CGP/Census/
311
T725S
E664V
ab5408
QIAmp
.K120N
A300-793A
Asn-975
GGATATCTGTGGTTAAGCA
.PI5P
constructs76
.Arai
BRCA1.39
Johswich
0–45
template-switching
BRCA1-associated
Oligonucleotidesynthesis
bone-marrow
asBCL2
neuropathologists
2278
anti-phospho-Histone
S6K19
microarrayer
LEU2-based
14-cm-long
5′-GAATCATCTAGATTAGGCATTTGTGGGTGACAGACGAGC
Warburg
supermix
calicheamicin-bound
Exome-seq
N‐ter
asthenia/fatigue
binding.The
.PTPs
GSG2
10q22.1
.corresponding
kinases32,33
.OF8
MPS
RAS–CDC25
Evaluation/Assessment
KIPF
Brivanib
SGN-35
39.4
HCT-15
biobanks
13q21
5′-GGGGTACCCCCTGCTCCGAAATAAACA-3′
BamHl/EcoRl
AluSx/Sx
7p22.3
TOT
Ha-Rs
histones.4
C1+
47-178
3-point
America.3
excisional
Tris-HCl/glycine
5'-AAGT
stability.87
L19
Kazazian
lipofectAMINE
209–288
studies.18
//lovd.nl/TSC2
dominique.lyonnet
Self-renewal
3.3-fold
N=57
Q787R
4,528
juxtapositioned
once-
.AML-1/ETO
doi:10.1158/1078-0432.CCR-05-1211
V270
PDPR
caseswere
CCCAC
35PDL
stomach8
.Sun
neu
LdH2O
1.025
.Principles
protein-solvent
//www.sanger.ac.uk/
M206K
v-Abelson
MSCV-pgk-neo
E031
six-channel
56772398
6553
.Cell-proliferation
pathway8-10
0.12Prognosis
carcinosarcoma19
PRDM1.E2.126.F
Annexin-V-binding
∼0.2
.Duodenal
HIF-1α
Crombrugghe
1588
EGFR-L861Q+E709A
A_52_P371237
5T32-CA160001
Anisomycin
1–26
diagnosisb
.Yue
.Tetanus
Chetomin
Revencu
.Thrombin
molecules.9
rigidified
1982
Nikolova
1,4,10
beta-promoter
inred
Extra-sized
4327
R609W
cells.20
phosphatidylinositol
2-kilobases
junctionFGFR1-CEP110
KITK642E
RNYDLDYDSVQPYFYCDEEEN-
oedema
.Dicer1
BSAP
G146R
224−528
Wnt-driven
B-2261
D-001810-03-20
≈15
implementnext-generation
14.164*
0.01–P
Rotolib2.aa
HIV-infected
Five-year
W117R
fast-cycling
HCC937+BRCA1
Rev1
Oligonucleotideconcentrations
.Advances
transcripts/genes
valine-proline-valine-alanine-isoleucine-lysine
.CSR
2003–2009
CTGATTATGATCCTCTAGTAC
jSl~~~~~~~~
TATDN1
S1463F
interlesion
M4Eo
FGFR2-FGFR4
Flt-3.2–4
immunoprecitated
926inslO
Cytoplasm
Met75
G375
anti-CCT-1α
Rho-GTP42
GFP-CCND3
p-p85/p70
granulomatosis
IGVCTQKQPI
MslI
outcome116
bristle
DH/PH/CRD
α1β
G423A
amplified.As
4.4-kbp
n=130
S.U
BRAFV600E/RAC1P29S
MLiOAc
checkpoint90
IVS20+21T
326–356
12/cell
oncoSNP
300~400200
CGGGACGGGA
P-MDM2
six-gene
RCC.6
mac.com
indicated.Previous
BAB01606
Keratinocyte-SFM
RE7
Worringer
'gatekeeper
anti-MET
4948
v-akt
128delV
5276
339/393
.Structures
DFCILU
o-vanadate
Bergthorson
zero-
Shh-stimulated
anti-HA.11
3′-UTR–containing
recommendations.9
RaplB
TGF-b-stimulated
Michrom
RFS-mycS62A/WAP-Cre
33
cDNA-
45.00
2.4-kb
1E-F
Mean±standard
Hnf4a7
TSHRS425I
survival.9−12
family-mediated
0.289
.G776S
L107I
3538
25,150
jmjC
1324–1325
gene-knockout
GCT10.Figure
defined44,51
chelate
JAK2.70⇓-72
.Hoechst
V632F
44–45
Momota
RASAL1
Seirei
.NPM
yLou
neuroendocrine-
BR99-0348
c-TERM
nephron-sparing
death.28,29
1/23
0960-8931
pseudostratified
SHANK3
JH3-4
MCFl.fgf
kinases15
mHGAs
p=7.2e-5
p.S707P
unmutatedFGFR3
immunophenotype.2,3,4,5
gfp
ESMO.36,37TABLE
FGFR3-BAIAP2L1
73/102
PE-1/
176-293
antibody-conjugated
hybridization-capture
.Notch-mutant
phorbol-12-myristate-13-acetate
HNSCC3,4
N87
hedicine
AC008575.7
Y202
neoplasms11,12
line.8
14q23-32
516.0
PRC2-dependent
cancer-unaffected
L457P
37·5
MLPA-BRCA1
1447
R1B/L17
DQB1*0602-positive
CytoChip
c-kitplasmids
610152
fgf-6
lymphocytes.36
5′-ctacaactggtttgccaattggcgcaaggagg-3′
GATA-2
79–81
GAGGAGGAGGAGGAGGAGAAGGAGGAGCAGGAAGAGCAGGAGGAGGAGGAGCAGGAGCAGGAGGAGCAGGAGGGAGAGGAGGCTGCAAC
pipeline38
§§P
1171
Figures/tables
NELSON_RESPOSE_TO_ANDROGEN_UP
12.28
40–65
Technologies/Applied
similar.defect
WI2-2877K7
anti-IKKβ
//www.icgc.org/
Fig.2C.2C
1541delAG
inconvenience
CD19Cre/+Ezh2Y641F/+
prealigned
described.315N-labelled
MPLW515L-transformed
DDX19A
con¢dence
50-base
9,787,030
H-134
B_R512
3542–3515
Sudar
TTAGGTACCATGA
SA–GFP
patch-test
EnVisionTM
incidentaloma
transformation95
9:7:2
Kosmider
3-Box/BACK
Ala344Gly
.Hotspot
pCMV-ER
macrophages87
I548N
UCEC
2–168
IFAR995/1
A347T
non-reduced
therapy.125
TAATCTTTGTGGCTTGCTG-3
.Illustrating
vitro7
usi
355:1
439
erb
Desprez
FGF-signalling
ITGA
pLVX
sg_ex11
7053
0.72–2.5
p.Arg903*
S587D
J5
AKT-targeted
NP_176768.1
c.7544_7545delCT
α-GST
72/73-23
Alu-sequences.22
anti–Ly
'Patients
17q21
NB100–304
eight-subunit
ABI
cPolyPhen
27A-R:5′GTTTCTTCACCATAGTGCTAGCAATCAAGTGG3′
CD8+CD45RA-CCR7+
D15S1028
4,818,331
SHGC-50974
I2101
S4V–S4W
c.131G
-GTTCATCCTGCTGGAGTTCATGGCGGGGGGAGAC-50
sarcomatous/pleomorphic
NCI
ADP/min/l4M
tyr783
614673
Animals30
29–
p110αH1047R
mone-binding
variants50
Koc
anti-IRX2
FL-dependent
rotavirus
3187
5,7,20
K008
Frauwirth
27/47
GCCACCAACCAAATACCAAATCTC
BPM1-6
Ad-infected
Zn2+B
9600
Sephacryl-S200
AII-1*
Ala37
AACCACGT6ACTTTBTC1C*G
.1Gain-of-function
JARID1C50
twein
NPM/B23gene
MM.59
MLLN320/C180
PIK39
0.013‡
N348c
ρ=0.07
N700D
.MutSascans
K375A
p.Arg487Pro
Eschirichia
pcDNA3-HA-B-Raf
7q22-q31—there
8400
0.4-mm-thick
HHT1
S11T
surface.20
use.Mutational
MGC:60620
peroxide/99
MLH1protein
testoster-one
5.60066
.Nodal
05/21
20/200
5′-GGAATTCAGGCCCTCATCCT-3′
Suchcomplexes
orV5-antibody
24×
D352Y
pERK2/ERK2
R217W
H3-Lys-4
.Hydrophilicity
Dice™
FOV
DNAseI
cc-11-4059-g3
IVS5-31C
unrecombined
24-multiplex
ADSD
Vicent
3SBT000AGAGATGTACCTACCA760
Sekulic
pVHL-Δexon
podocalyxin
29/224
p.K1409E
omentum.4
breakpoint-associated
TRAP230
Co-localization
Hgf
50–53
NRGβ1
Doxycyline-inducible
5′-CTTCGGGGAGCAGCGATGCGAC-3′
39.2
kinases,7-9
TCT→TAT
mant-GDP-bound
35S-IVT-HIF
cells.50
Galaxy/Cistrome
HBCx-5
NCT01377298
5'-GTGAAGGCGAACTGCATTCTG-3
Jarosova
M7047
G37H-Ras
analysis15
Glu682M
2-5-4-5
l-KB
c.607C4T
RalGDSRA
4LYH
anti-SLK
5'-TCG
Sofware
25bp
migration21
V569•••E561
Triacylglycerols
2-sample
CGGCAGAGAATTCCACGTGAT
KKSRGDYMTMQIG
series.19-21
Flow-Jo
SJHGG044_D
transformation.20
His206Asp
end-systolic
Vet
SKMEL2
GSK3􀁂
anti-ETV6
Sos1EK.Homozygosity
Linsley
proteins21
Brca1-deficiency
36,000
ComparativeMarkerSelection
suppressors—ARID1A
I1171N
NRF1
P-GCGCCCTCGGTGT
life-saving
Lu65A
soldano
p21-R9H
3rd-5th
RNAipretreated
Log-Rank
PstI
-α
.Highlights
DNAstar
4,8,17,18
D802G
CEN/ARS
neurofibromata
c.1855G4A
wg
BSgenome
Teddington
MutHLS
9.5.3.1
hematoxylin–eosinstained
ABL-class
al87
11.7+1.9
Arg173
900-fold
Transplant
JAK-Mutated
5′‐CATATTCTGTAAGGACAGGAC
www.cancer.gov/clinicaltrials/search/
01/patient
3,000
IDH1ex4AR
identificationof
22:894–899
3F-3G
10,12,16
Paclitaxel
Fig.5H,5H
.Intramolecular
Cis–trans
pro-B-cells
anti-MYST2
.comparison
proviralclones
*Harbor
17/461
v-ab
sex.DISCUSSIONIn
Stempro
between‑group
PCGFs
II/1
microcentrifugation
PI3K-expressing
E-cadherin—a
DTT-sensitive
GGATGACCTTGCCCACAG
MAC-donor
Joinson
,o
anti-HCV
A364E
Kiubock
CMMR-D
5375
C277R
GeneScan
.Why
68167
Rusch1
774-779
GenomePlex
.Smad3-induced
delL747_S752
sagepub.com/journalsPermissions.nav
splenomegaly3
Thoraxklinik
NM_006565.3
imageNext
rs1056538
Noreaction
towardsmany
Diaminobencidine
60.067
E043
TORKi
Con-B
A823
K2286N
1,240
7.92–733.06
8–96
232T
CCCAGCTTTCTTCGCTGCTGTTCAACTCGCTCGTGGACTTAA-5
NHGRI
ubiquitin-de
trypsinised
NB84
SLC34A3
.Ideal
SVS6
A/protein
20-forward
μg/cm
IL-3R
Clore
series.6-15
mucocutaneous
24-replicate
GPCRs
90-s
6200
G199E
EcoKV
BROADO5
FANCC-cDNA
dPETs
Kurmasheva
AAATCTCAACAAACTCACACCACACAATCA
segregants
p.Ser260Ser
HER2inhibitor
5′-CCCAAGAAGAGAAATTGTTTGAAGAGTCTTTCCTAGGCCC-3′
500k
.ETV6-ABL1
atoms—red
.400T
DNMAML1
C419F
missense-encoding
B.A.T
Y820
ATTACAAGCATGCGTCACCA
trans‐
ZKSCAN2
p.N126D
CFC94
dbSNP132
1.119–1.707
Leulm
ATGTCTATGAAGTGTTGTGGTTCC
1.19
5′-CCTCAGATAATGAGTTCTTCTACGTTGATTTCAG-3′
.3008C
GK1.5-PE
supervisory
Fbw7WT
327,132
perioperative
FRAT-tide
ofcyclin
25.59
pocket.29,30
BRCA1-speci®c
2194–2195
GGAUCGCAAAGUAUACACAUAUGUA
established,23
L1394F
assessthe
receptors.24,25
KITand
32.3/13.8
suppression1
N148S
androgen-specific
D222
R531G
ANB
22:06a
Oving
Saraste
Sanko
breaks44
3977
1000G_gold
II–interacting
KPC-Brca1+/+
MucycD-1S
p.Q207D-c.a
8,18
N835H
467-8601
.Oncol.
SpectrumGreen-dUTP
pVHL30-containing
ASS
out-bred
anti-hDIS3L
10557
kyphoscoliosis
GGF−11.2MIG7MIG7
0.82–1.32
09431D
inATP
growth-factor-stimulated
.PNT2C2
Ferguson-Smith14
P1087
dicer-like
Chr9-373R
R197Q
GVGDc
8and
Anti-pan-p85
c.2002G
ARv567es
.7271T
results.20
oncogenic/tumour
H436D
Likethe
HCC-containing
Wolfratshausen
CDK12-ERBB2
EMD/Millipore
p-ERK1
TGFb-I
CRAT
RECNSSTDSCDSGPSNTPPEIH
c-Met-negative
35K
30,46
f5
.Viewing
:156-64
LinesMCF10A
SMAD-dependent
0.79–1.10
45.0°C
FBXW7β
underestimation
Variation-Grantham
520C
HEK293T-BJ
22346
four-tiered
7808C
95.7
TGTCTGAAAGGAGGTTCATCC
MAPK-pathway
.PARPs
§To
DD-tagged
c.2549A
H-RasG12V
TP53MutFunction2R15
c.893
Ultralow
S0515T
NF-κB-activating
Goodin
.S3A–C
Expression1
CFL
GCFGCAGGTCATACCATCCT
.CRL3-SPOP
.2765
re¯ects
MPS1
siROR1-induced
glycogen-rich
isactivated
pnas.1321155111i11.jpg
c.916C
senescence52
P-FKHRL1
lnc
DIX
aflatoxine-B1
A1083708
0.08⁎
En1
P16–1
Peduto
48h
.//
R841K
FIN-00014
A239V
AKAP8
92.45
PKBγ
Eh7L.\
redissolving
2-cell
serum-starved/EGF-stimulated
oropharyngeal,5
study,22
5Ce
:6B
Cytoskeleton
bilinearly
K618A-bearing
,1c
Scer
50-Al
Dahlback
HLA-B*07:02
1251-bp
Fordham
points7
1,139
pathogenesis
140–162
CMML70
170-6515
A5316
Irreversible
antiinflammatory
p.Ile23Arg
BamHl
R274H
GAL4/ELK-1
EGFRvIII-targeted
inconsistencies
=exp
stopcodon
5'-TGT
JASPAR
3T3/F1174L
778
Sin3-
p.1276
129±74
500,000
L65P
26.2+0.3
GM-CSF–mediated
58.36
DIS3_RF-DIS3rfinR
phase-II
1,141
Brekelmans
.Restrained
Dicer1Δ/Δ
pVHLR167Q
thiohydantoin
P/L
pathways182
NAP1L5
Red-anti-rat
BRAF/CRAF
lung-cancer-derived
Mukohara
TEL-FGFR3
b2m/MART-1-Me18105
M15
Dnmt
EL/ethanol/water
NFL.Therefore
128Q
NCT01035229
immunopurify
hematologic/molecular
phosphorylation/dephosphorylation,24
.Sets
H1416
pathway24
Zhunan
nonsynonimous
pSR~-Ha-ras
arti-
0016-5085/
point-mutation
STAG2-intact
Y779
Maännedorf
.Pdef
androgen-ablated
identifiedFGFR3
reac
electrophoresis,9
5′-tgt
behaviour110
v-
pEFm/Raf-1.6
immunofluoresent
PSQ
°C-45
L127I
pancreata
Pikarsky
5′-CTCAACGACAGCAGCTCG-3′
G245R
polyacry-
Hyaluronan
Dutasteride
p-Tyrs654
G935R
4000
G1-Normal
0.085
.Single-strand
graft-vs-host
manner31
7.41
FGFR3b-S249C-T24-expressing
.Y878
5′-GTTGGTCACTTGAACCTTGGG-3′
anti-Caspase3
40–77
sc-1208
.Genotypes
2921
inhibition.29
.1797
MVSR
BC033961
phase.17
C12orf55
hydroxide/0.25
'fat
5′-CCACAGAGCACCTCAGCAGTCC-3′
41-
MacroH2A166-179
FGFR1-9R1
un-silenced
1705
IMDM
densitomctric
L92VL95V
METdependent
A_51_P280906
SureFISH
Lecce
11931
causality—that
1–201
5′-CCGGAAGTTCAAGACAGACC-3′
-D17S-1321
L196
Br39
Genphor
A-immobilized
3.68
A-14
DNA–protein
.pair
30-100
FA-typical
DesignWe
well-documented
estimated,10
phospho–ERK1/2
ERG-overexpressing/ERG-rearranged
ofTGFBR1and
87.97
coated-pits
1854
1.20
CD1D
101-bp
pcDNA-ER
p62
mBcl2l1-Forward
18–43
tubulogenesis
tested.24
IA4
κ
paired-domain
1npJ6ICDKN2Ahave
α28
USF1
150-patient
R389G
Leukoerythroblastosis
12S
AFG
D6S311
NUT-binding
specific-antibodies
T-9026
−5.53
2−4−fold
cSH2
driver/passenger
off-targets
adenoacanthomatous
.NF-κB2
v-mpt
geneticalteration
axins
FI-ATPase
APC-anti-Gr-1
tumorsthe
pfu
LATVKS-motif
R882H-transduced
GTP.Lysis
MAGEA3
65.2
1-imido
sub-sections
TCF/LEF-responsive
6th
IDH3A
Smad4lox/lox
Ras/MAP-kinase-dependent
Erpel
ser21
αβ-cat
IL2Ra
co-injection
SMO-D473H
V550L
HCT-15-TetOn-CHK2
p-HER1
LG-3
.Caps
CTTCT-3′
Avance
LNM
F-ORF
PTEN-mutation–negative
seenin
Msh2P622L/Δ
knock-out
.PI3Ks
.Anti-histone
-tr
18s
E81-61
9.03
A772E
1.5-5.0
2.14.1
+r
Atorvastatin
ENST00000397091
RET/Y791F
852-2974-1165
lymphoedema
4,14,23
Preischemia
IRS1-binding
T66A
44N
.AV-203
W72473
CUL3–SPOP–RBX1
non-bacterial
intestine179
4/76
IC50=100
splicingof
3.9–16.6
S153
infectionwith
JH-VIII
custom-cloned
R109Q
HCT15
X-­ray
8-p.m-porosity
.CGNPs
'slicer
site-related
R866W
4q12
Buet
R3b13
.MDMX
p.Expression
Ground-state
c-kitcDNA
pGST-BRCT1775
Mizuma
~1.0
cyclin–cyclin-dependent
anti-BRCA2A
12/60
G1128
0.0052
PH–KD
BRCA1/5
.Complementing
EML4-
Mechanics/Poisson–Boltzmann
ligand-indepen
.3,8,10
Rpb1-interacting
.Capture
GH-secreting
GTP-dependent
Y179
495–497
-S-S-
overproduced
shRNAs/gene
tm1Wjll
mislocalisation
235461
.coimmunoprecipitation
Aromatase
max-E12
AJ002530DPB1*6401N
–β-catenin
5′-CTAGAACCTACTGAATCG-3′
PBP
1198
Tyr220
ACACACACACACACGTCTCCTCAT
clinical-subtype
39901
Kobashi
V504G
defuse
DP103-independent.21
P31
E439del
A-382
TMS
adenylyl
AID-activated
I836L
0•73
62/837
predisposition.1-3
Diaminobenzidine
SMOþ
L814Pa
apr.aphp.fr
Pyrococcus
www.ncbi.nlm.nih.gov/geo/
2-11
CD79A/B
Sca-1−
identified.11
Pro324Leu
.Haptotactic
milliunit
Let-7a
pRK5-HA-GST
Actctctgacctttggc-CONH2
eIF4E-binding
nucleoporin-98
2198dupAACA
GGACAGCGACTCTGAATCT-3′
.Insulin
MDM2/RP11-1064P9-SG
STL-ETV6
b-TMP
142K
downregulation.24
SC-19
SPRY2-
1.3–4.6
PMS2-expressing
M18K
Thr600
Registry.17
overtreatment
GST-CTerm
mutationsStudies
Nakau
9501
E554A
.C61G
|FP
empiric
0.06272923
448-6
J48
Erbb
p2lv-H-rasand
thermostabilization
Peelen
2004a
TP53BP1–PDGFRB
0.65–1.29
wblast2
protein-structural
Thr669
Co-segregation
erbB3-initiated
2.365
Noonanlike
cgtctactgtgagggacctc
C-28
re-localizes
SegmentiX
5'-TACTGCAAACTGGTTCCTTCAT-3
K-Rastransgene
97.6×
7p12–14
D600
towardsthe
100-mM
Smad3
5′-ATATAGATATCAATAAGTAGGCTCTCCAAGACACTG-3′
5′-GGAGAGGAGCTGGTGTTGTTG-3′
GTG→ATG
45l
CTGF/IGFBP8
HGF-regulated
HNSCC,10
aa52c11
.AML1/ETO-positive
Exon-level
adaptor/
FBJ
TNF-a
cgg-3′
T180/Y182
PI3Ktransformed
5.8-10.9
20747603
1.034
.11C
.Outcome
matrix-associated
444-bp
N647I
3-CATENIN
mechanisms,49
N486D
oligoduplex
R329H
pVHL157
β-cytoplasmic
OCUG
K1140R
NOTCH1-unmutated
FGF-MAPK-pathway
57–59
mono-methylates
WTΔB-RAF
pneumonitis—were
I-restricted
CMK16
0.985
BCL-2-associated
pMirTarget
G12D/V
pLNCX-HA-AKT1-K179M
siRNA1
50974
50-μg
old.26
…
A289V/D/T
1,370-bp
non-AGC
11001
edeletion
D253Y
presenescent
Rac-GTP
12b
nuclei126
0.016/
Cdc25C12
endothelium.1,4
PI3Ka
AF276
HA-PIK3CA
regions—extracellular
5382InsC
cc-13-834-g4
APCI1307K
Podoplanin
tram-track
PDGFB59
lymphomagenesis14
5,745
//swissmodel.expasy.org/
forks.BRCA1C
‐3′
.Salivary
doi:10.1186/s13058-014-0466-y
25.00
Youssoufian
hemolytic
E7107-induced
AB-gene
GST-Smad3
µg/cm2
pEF1a.FGFR2b.IRES.neo
.LS174T
proton
X2=4.16
Glu644
c.2168T
12.5mg
Asp381
pre-messenger
SCHULZ
RUNX3–BRD2
1501–1512
Fragale
11.11
TEL-TRKC,7
WT/AEE788
10.6–32
556–803
delayed/attenuated
0.636‡
Kozuka
0.15-0.35
musculoaponeurotic
16aIn
darbepoetin
toxicity.DNA
glycines
phosphatidylinoditol-4
GCAGA
3/339
MERTK
p.Arg165Gln
FLAG-SRC
upfront
androstenedione
Alzet
50mb
GCTTCGAAGTTCTCTGGCCT
A648
Complementation/Breast
mitochondriogenesis
Cichowski
FGF4-conditioned
rZ
R707W
p5
pGEX-6PI
deletionT8Affected
TFA13
A119R
cancers23
anti-ASXL1
pBJ247
5908
Hedgehog-expressing
RP11-535N12
chromothripsis-related
SJHGG003_D
states.81,105
hKIT-D816V
0.16–1.36
OVIP
6-amino
chain-polymer
SNP_A-1990585
elastase2
Gfp
p110α-inhibitory
DNAfrom
10,000nM
MutS-MutL-mismatch
molecules/cell
anti-symmetrical
pseudocolor
NHUC
Q1785H
Claspin
6,10
+/-25
Pdx-Cre.KrasG12D.Smad4−/−
2A9
BACE.R
.leiomyosarcoma
line—H1975—contained
kin-
Wiz
ks.test
tumour-circulating
sc-7174
3100–3081
4RNA
q22–26
Ricerca
.Anti-RhoA
.385
membrane-targeted
eTable
vitro.35
extravasation
rates24
E114K
7.4IFITM1Interferon
REV-3′
long-segment
2428
.Shapiro
-coding
MDM2-dependent
/YY1–1452R
Lys192
p.This
2/47
disordersMDSIMFAMLCM
quecertin
therapy39
pro-drug
IVS+8
2B–2D
Tet-op-PIK3CA
.Striatin
.MLL4
pLI833
Salot
7-11
green\
ovary29
..L
birds2
.Schlessinger
A_51_P405167
lx
Hamburg-Eppendorf
1.907
Mr≈
Brieﬂy
WTc8-staining
lymphoma.11,12
achondroplasia-affected
Microadenoma
Y254
IFSLGLNPYPG
intron-exon
VIN
102-292
R-2011-3603-34
NICHD/NIH
Teofili
ChIPseeqer
26DISI5XD5S42IDtlSIWBAX
CMV-stat3
ligands168
−1.24
Tier-2
flat-well
paracaspase
-BCOR-RARA
neurofibromas.44
pcDNA3-p73β
Pds1
Therasse
p.A68Tg
KLF8
Sachdev
re-activated
lowmelting
polymorphism2
knock-outs
PrimeScript®
Exon/IVS
T-ALLs13⇓–15
-0.02/min
HCC-24-1005
MSH6-WT
0–0.89
A−G
5.5.6
oligonucleotide19
IRF
ODZ3
.7,8,111
NS/SS/Indel
Rag1-KO
pCMV6-ERRFI1
PLX
MolRep
anti-BRG1
recurrence.DiscussionAlthough
multicohort
drugs.22-26
monomers50
SPEM
.Thereby
BIN1
Wg
GFP-tagged
p3xFLAG-MED12
mShp2
thrombopoietin
h.p.f
.Donehower
Activity—We
VEGFR-2
insults10
Figures11–3
10-l
.00016
40–97
5′-ACC
LNR-C
CDK-inhibitor
centrifuge
shRictor2-expressing
TGFβR
pVpack-Ampho
d+82
vincristine-carboplatin-etoposide
c.3674C
GGT
0/10
SETD2andderegulated
TYRP1
mutantsOur
sequencing.Evaluation
R18F/BR13R1
Rahner
FasL-Fas
200–256
intronless
ATOH1
6/500
transcriptsUpper
TGCCAG/gtacaa
M-013
laboratory-developed
Locus-specific
Deleage
EPN
D855Ga
MED25
H2AFY
I'Ir
pBS-TRX1
.Steady-state
aseptic
Peltomaki
.IR2
May-Gru¨nwald-Giemsa
Cl1
p-Ser473
Fanburg
≈40,000
MSH3/MSHf
concentrationdependent
selectivities
accuracy—that
3p,5,6
Ogasawara
c-d.
KDM4C
6261insGT
Gao
G2M.36-38
forPCR
F346V
nitro-
PDGF-BB-treated
23,32,33
GSE11969
.Inset
.Khani-Hanjani
vera.24
2KKJ
anti-P-Ser139-H2AX
early-onsetcancers
-CCCATGTATTTTATGCTAGCAGG-30
4−10
D840N
chip-based
Br47
hook/zinc/hook
Hôpitaux
Austria26
Instrumedics
.Lysate
A146
Pdgfa−/−
56Â°C
β7
tospeculate
Asp-473
S358G
disease-promoting
inhibitors.22
.MUC5AC
82–132
NEDL1
CTTG
Blasticidin
.Simulations
123-2agAT
p.g
Cys67
6.80
cholestasis
components40
polo-like
H199L
–X
5′-acgcttccctggattgg
Ludovini
Tyr35Asn
Magi3
Neo+TEL-Jak2
Ain
gamma-null
BFTC909-KD
non-Gypsy
Thy1.2
syndrome,47
717K
50
reporter-based
Europe.8-12
.41–44
BD-PharMingen
phyto-
prokaryotes14
.Screen
.Lin-negative
2.704789033
recombination15
0.958
peptide-based
culture.25
childhood.28
effecta
32-45
lymphoma,7
U14658
31·8
E627R/R683E
PD0325901
-GGCTCTGGTGCCTTAGGTTG-3
proto-oncogenes15
pYAP1
.Physical-chemical
Phase-contrast
non-MMR
Arg341X
Ins-1
transfusion-resistant
effector-recruitment
F39V
7.81
ER-localized
COL4A
fibrilar
Peutz
interbreedings
tumor-only
regulators—several
2TEV573
Non-promoter
back-
L861Q+E709A
kemia
ice-COLD-PCR
anti-Akt-CT.
-cleaned
.Spreading
hTCF-4E
assembly-disassembly
hypertrichosis
450/620
FO-l
C1849G
0.86–4.66
cancerpredisposing
1,650
Affimetrix
gefitinib-refractory
0.40–0.70
2.11.1
nanoclusters2
1510A
AEBP2
Osterix11
G0-phase
Genepulser
nonintensively
wu20/wu93
acquisition.37
3/21/01
PTENK62R
9/11
paralog
Cy3-dUTP
sequencing.Immunoprecipitation
LC3B-labeled
ENPP1
therapeutically-targetable
PicoFritTM
WDR9
tumors.11-16
GC1008
DBL5
Jazaeri
c-MycT58A
7452
.RAD50
MK-
indispensible
Diagnotec
pan-p110
RP11-234C5
MSI-
CFC.22
hybridizationwith
1.3plusminus0.3
DNA.Two
F57V18
yCA25
well‐studied
M394
anti-FGF-3
76-Mb
miR-142-3p
731mel
MolSigDB
UPF3A
non-serous
epithelia-derived
DCT
mice50
NAN6
R1896M
assays36
tttcag/TGCCTT
v.6.0
Stat-View
AKT1-R86A
unprotonated
A280V
2.438
GCTGCAGGTCATACCATCCT
0.00161
Serine-threonine
gThese
R2502C
tumorigenesis.4
33342®
IGF1R/EGFR
1.123−2.072
therapies33
1Q9C
-catenindependent
92,025,739
4·2
Ninety-nine
PBRM1-negative
FGFR2-CCDC6
CK5−
Velcade
65-92
co-depleted
c.1106G4T
RALGDS-RBD
2mM
survival44
Finland.9
.Fifty-seven
ab290
interferon-alpha
DQ396625-6
Arlinghaus
bilat.
Benzinou
HER2‐mutants
KRasVal12
Figure2A
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F1.large.jpg
W557_G564
Knuesel
Arg483
EGFRor
ΔTm
ERCC1-XPF
NDUCF2
5075
Breast/Ovarian
//cistrome.org
H‐Ras
0.61
10q11
AKT33
NGF/TrkA
p57/CDKN1C
.RA
magenta
C-kinase
PCa_ETV1_1
CUO15
Core-domain
100,000
=3.1
anti-myosin
children59
847
mutD
deoxycytosine
S3′
5′-p-fluorosulfonylbenzoyladenosine
Hyalinising
Issaad
Pathologie
1270–1290
Finnzymes/New
28345343
www.eje-online.org
Re¯ection
renal-restricted
CS15,31
deleteriousness
0.00781
down/out
p53-Tag
PDGFRB.2
GHE0536
c-Myc-site
011362
1,597
CA79830
7q21
Mendrysa
`dominant
kinase/NF-κB
non-obvious
lymphopoietin
QIAsymphony
5′-TTTCTTTCCATGATAGGAGT-3′
ATCTCAAGACCCACCTGCGAC
0.47023
BRAFE600
proteinexpression
mutations.8–10
Ganem
V17.0
0.79-4.99
oligodendroglioma-like
glycophorin
pepsinogen-producing
HGDC
phsophatase
.Woenckhaus
1G0.2
Ptf1aCre/+
A301V
αP-GSK3alpha/beta
esophagogastric
adenoma.21
S14B
CCCTAA
.Brieﬂy
Cdk12-deficient
60+
pmGFP-H-rasG12V-R169A
mutations.Characterization
Towatari
variants11
17q22–q24
q11.1–11.2
Arg271
STATA
.No./
20d
Sos1-3utr-fw
-phosphatidylethanolamine
histiocyte-rich
aVected
c-IAP2
presented.7
C180
7−7.9LAMA3Laminin
.Two-way
Smad4412
libraryaccession
QRRRAP
-3′-CCAAT
anti–Ki-67
anti-caspase-8
1.10–1.51
7p14–15
IDH1/2
IDH2-mutant
diffusible
c.715C
chu-lyon.fr
Sodha
2,38,39
7.5and
aberrantintracellular
aspositive
A/A
/D-A2
Edmonson1
redissolved
R1446*
ACINAR17
DAF-16
p.G719X
3x3
7q–
CCAGGCTCCTCATCTATGATGC
Figure.5
GOT1
miR-30d-5p
Ras·GDP
cellproliferative
migration.31
family3
.S16
comutations
rat,25
XPLN-induced
p53-Subcellular
BRCA1-ΔRING
1.470
LC3B
1.55–6.30
P.M.P
MLL-AF9–driven
5μm-thick
c.598C
phopshorylations
pHER2Y1248
drug–receptor
G857R
Analysis—Standard
W802*
sequence.12
SERE-TATA-CAT
Mll–AF9-derived
ymsh2
AAGAGACCTGATCGCAGAAGCCAT
199216
JAK-
Y-Box
defect,7
5′-GCAACAATTGGTGTTTGTCTCCTC-3′
E530K
GSE19416
Ekstrand
NUP98gene25
1.834
~22
1,3,5,8
accrual
1105.
pipeline70
.B.
G778
FAB–AML
co-crystallized
Gene-Bank
U118MG
R68W
cullin-associated
HGraphic
angiosarcoma.12,13
11q-LOH
Subbiah
anti-Fyn
0.094†
FIGNL1
lanome
3a-f
residues—regulates
nonmetastatic
DNMT3b
c.370C4T
5'-TCGACACACGCAGGCTGAA-3
ab76362
BMI-1
AK7
ofThr200
//faculty.vassar.edu/lowry/VassarStats.html
0.48022
reasonof
Armulik
μL/well
gain-in-function
Lampel
yAG|r
GCATGTCTGCCAGGAAACTT
CNV370
C•dA
L-calc
5-CTTGCACAGAGATGATCTCTGC-3
pY28
1.58/3043
0950-9232/03
D2S119–D2S391–P11–P51–P55–P48–P27–P26–P58–P61–D2S123
P.G874S
carboxamides
FGFR2-activating
collagen-5A1
R206H
CD42b+
significant.Equal
CD45−/PECAM-1+/CXCR4−
Institutet
—those
11/9
underrepresent
N327S
1.8–4.7×
TO9913
selectionBreast
R9H
pathogenically-relevant
66X
RNeasy
725-8762
TCEB1
Arf-null
Hepes-NaOH
nabpaclitaxel
EDN1
primers.9
IL-5
β-NAD+
UIMC1
pGL3B
R/K
c.79_99del21
1–77
W557-V560
G163
Cyclop
membrane-targeting
pmRad50L1237F
CASP8-related
mar3
Dose-dependent
LR08-319
H/F
SFARN
ab13248
pGEX-2TK-AR-AF2
non-α
serotypes
proteins,39
caudothalamic
bioactive
I111S
SCID/nude
P46
Trp557Gly
pathways•
Δtrx2
granulare
105.
3q26.2
CS22
Jeghers
phenotype5
previously.23,26
HEK293-DDR
palindromic
radiationWild
.OCM
R728L
tyrosyl-phosphorylated
0.77–3.68
V366G
re‑examined
s21
1.08E-03
T-cell-suppressive
andY599
MOB1A/B
V12H-Ras
pTNM
DEXSeq
2J0J
aEx
26,27,29
BRCA1–associated
LGMD2A
TNR
b-Tubulin
NBS-HGGs2–5
cotaining
608491
18/105
cfu
program.14,15
cross-binding
R348C
APBS
efficiency/probability
oligodrendrocytes
cAMP22–24
β-dimer
0.1-cm
Yanada
`classic
reduced-penetrance
E928G
pGL3-basic
TRX1
c.10822
R26R
Phe467
Expectation-Maximization
XG10
.Pten+/-Rictor+/-
NF861
JRH
c.1255124G4A
Wnt-dependency
CGACCACGCAAATCAGCGATT
signiWcant
PLKO-Tet-On
predictor.31,32
∼6-fold
G376R
AJUBA64
polymorphism-dosage–dependent
β-Catenin-Dependent
Ala66
NSML-patient
Let7-5p
Nested-RT-PCR
cused
pMYs-AML1
CCCACATCCAGTCCCTCTTCAGCT3
1Lg
T504I
Berlin-Frankfurt-Münster-Austria
Snf-regulated
29.6
ERBB2/HER2_
Wts/Lats
1/243
//www.ncbi.nlm.nih.gov/sra
aggressively.4
controled
HAL
8.38
shA673-1C
transcri
44,2q24â
anti–p-Y1110
G17‐Rho
Bcl1/Cyclin
.GFP-Hrs
C19A
PI3KR1/2
CAMK1
anti-Pax5
.Heatmap
L15R
Bipartite
AEW541
Y842C/D
GGGGAACTGTACTACAGCATTGA
cancer.24
non-EPNs
K-ras-E153V
Annexin-V/propidium
AMG-102
IL6–dependent
Cys89′
Thr98
CTTCACATTTTTATTT
Schrum1
numberingof
Atlas-SNP34
err
4.5
50–79
medium-length
4216-2ntA
6-months
-subventricular
C‐F
stroma12
signaling4
III:1
supplier.DNA
ntified
G-CSF-mobilized
xfl
feedback/resistance
transformation/transcription
DNA-free
p‐
W281
Montigny-Le-Bretonneux
mRNA/18S
BsmBI-PpuMI
H19-Igf2
Sweden38
K433R
ICL-agent
MKK4-/-
ab134153
Bruening
G248P-
*O
5´-ACACGTCCCCATCTGAAG-3´
MBs.16
tankyrase
DR–
OP9-DL1
0.434
ε-amino
.Overview
settings.45–48
IC50=0.31
2rd0
Trichrome
Trypsin
717–722
35-45
GGGGCCCGTGAGCTATCGGAAT-3
FGFR1-alterations
KLHL9-depleted
718-1042
9HRM
2/10
F2009
disorders.4
.Standards
lox-P
intra-tumor
MLLT4/AF6
Cartegni
Connexio
V–based
EGFR.113
KIT-overexpressing
*6A-5
TGCTCCCCGGAGCTCCTGCC
1088
alsodecrease
GoScript
green/red
AICDA44,45
c.1998C
104/200
.S18
B2,7
.ApcMin/+Smad3−/−
KIT-DY814
S971
/myeloid
Riggelen
Antonarakis
pCGN-INI1
from…
-17p13
25.81
698A
P=0.057
oestrogen-receptor
pancreatico-biliary
0.50
BRCA1-BARD1
JCML39•
56774155
16QA1
dabrafenib-dependent
.TP53
BioProducts
MethodsCloning
.133
v11
hemibrain
Z0311
hematoxylin–eosin-stained
92.0
KMS11-TKO17
polymorphisms-Ile49Thr
ofp53
testing54
INO80.28
R110L
BamHI-DraIII
Kalantar-Zadeh
hot-spot-mutated
RSK1
inter-bred
TIR-TIR
carcinomas.31
α-smooth
Sca1
no.4
FN3
mg/d12
G9a
Calypso/ASX
Tel-Test
24.9
p21T145D
post-chemotherapy
1396–1559
020630
44-621G
.Bombesin
.JAK2-V617F/L983F
3′-3diaminobenzidine
Q216E
FBW7-BM
FL-403
100–3.8
heat-inactivation
series.34
18,609
NS–SOS1
Hs02719379
megacisterna
p.Gln442fs
methp.15anol
708KB
Merlin-deficient
MDS,15
Alexa-594
NCI-H3255GR
1XQZ
.Immunofluorescence
cyc1-Ter
g/mol
Xobs-Xi
pancytopenic
Arg-849
38.7x
tpg
34/185
FDR=45
–0.4
congenital/developmental
R107S
anaphases/telophases
.Cysteine
−75.59
,7D
RT−PCR
Guoxuexiang
.Ligands
GAAAAAAGA
:CSB
univariate
P008-A1
Ser257
32,391
Calcium-dependent
O-acyltransferase
autocatalytic
5.1.4
SCNAs4,5,6
3203
RB1Arg698Trp-V5
spino-cell
anti-Ubq
7.0,20
Holderfield
KS459delN
gossypii
p.R680*
ethyleneglycoltetracetic
withFGFR1
EGFR-Mediated
14q13.2
inhibition.23
.Index
R529H
Metacarpophalangeal
ACVR2B
e-f
ESCC12
T308A/S473A
adenoviruses.10
ΔM3
NKX2-5
signatures29
RXY/FXpSXP
7816–7824
food-associated
PIK3IP1
anti-CD44
Uno
Fulvestrant
A105V
175Leu
-166-109-182-116b
missenseor
N-Ras-G12V–induced
11.87
N659K
Oeynhausen
pT2–4G3
glycoconjugate
Spectrometry—In-gel
GAGGCCACCTCCTTGTCAACCCTG
variants.29-
PTEN-wild
rank-order
681/2013BO2
D500G
BCL6/RAF1
.Block
P525T
Ser988
72-hincubation
0.77^0.94
GCGACAAGAUCCCUUUCAUUCGAGA
A739G
FLAG-BAP1-His6
40.1
15,806
CREBbinding
ΔPten
ETS1/RUNX1
Transfection-Based
doxycycline-supplemented
ofPro-34
CCR=continuous
p.E1955Q
9p24.1-driven
SRP048957
IV:3
Trp252
variantsA272
3/88
0.897
R/TACCRAC
+ve
and55a
1E3M
470T
0.10plusminus0.04
al56
//www.biomedcentral.com/1471-2407/12/50
Neogen
1.60-fold
.Postoperatively
ERM
c.179dupA
Mst2
cross-correlation
anti-mouse/human
3EFL
TX1-85-1
7728
SK1
Planck
8/22/06
Chlorpromazine
Ig
TYK2-deficient
phosphorylation-based
M110L
p.Asn40_Gly44
L653R
RHO-associated
R300H
RS12255372
Prevalidated
–6.4
Forsti
glm
type-dependent
1F-GAACTGCAAGCATGATGTGG
CAGGAAACAGCTATGACCCCTGCTTTGGGAGTAATAAG
CSF1RD1–D5
4090
PDGFRA/RP11-24O10-
lase
4q33–34
RHOF
39–457
25.31
activity.40,41,43-45
tipifarnib
Dnmt3b.5
Hoxb4
p.Arg150Cys-XPF
Ku80
EGFRVIII
E9.5.93
pik3caH1047R
Assays—MEFs
anti-Ser9-pGSK3β
LY2835219
institute-Frederick
NTF3
Tyr741
5′-CGCGACTGTGATGCGCTAATG-3′
103/μl
1IVO
5′-CTCCCATTTGTGATCACAAGGAAGTTGTGTTG-3′
71239
SF100
TCACTGCCTGAGGTCAGCTTTGTA
HFSCs
9482
CtIP.6
DLBCLs.10,11
milk-derivative
1–16
9374
stress12
/mmol
acetate/single-stranded
MOI-dependent
Australasia
factor-κB
4–24
Tan9
4q31.1-31.21
KALINEC
XenoMouse
Y559A-myc
BAN1773
1360–1826del
8667
3⇓–5
cells/DN-Δp85
307KB
alterations—mutations
V3-20i
E-GEOD-44971
Jakubczak
S477F
F691L-induced
phylogenetically
Figure11A
OR1
AR-induced
cHL15
MSH6-null
Broad-spectrum
jmp
A-T
R479
_~
.Ablation
8694
2SO4/1
BMP‐like
Katagiri
His773_Val774insGly
1-5-45
Cre-3
GACACCCAAACAAGGAACTCA
Eμ-Myc-induced
nucleus-excluded
A98V
TG-loss
hamartin/tuberin
phosphoprotein.4PharmacokineticsPlasma
-D839G
Zeng-Qiang
iron-chelated
CT-TC
isopropyl-B-d-thiogalactopyranoside
LUV
TA-3′
H337R
Q55
Kinki-chuo
Hsp70.14
11811-031
Thr334
TAU-1
−20.8
P-S6
18*
centroblast-like
Asp153
passages36-4pd37-4anapmet47-4wdmet54b-4
fibroblasts.4
Muchemwa
c.1717C
roscovitine-treated
HuH
Q-R1
lobuloalveolar
9801
cER4T
~~*~~
genes.17-19
5472
2000a
z-stack
5–14
.Univalent
head-associated
HMECs.In
3375â€
piezoelectric
domain/Hsp90
leukemia.6,7
sc-122
0.312
vectorpSV2AHXgpt
Tyr931
2.68
Immunostaining—Approximately
MDYFDDDDK
5535–45
pGluc
loci19
mutp53
5′-AGAAUUGGAUCUGGAUCAU-3′
node-metastasised
Lys789
Fas/APO1
CRC.8
C281
stability—
brosarcomas
gelatin-Sepharose
Tsurumai-cho
E63
inhibitors30
-5′-
Sotoodehnia
netrin
ø10
differentiation78,20,79,80
1813
co-translated
100:8
5′-MLL
16q11–q13
NSD3
9/111
nm2
nitrosylated
TGTGCAGGGTGGCAAGTGGC
001172713
F958L
Y154F
Chk2/BRCA1
-AGACTGAGTCAGGGAATGAG
R428
PICC
p=.015
.Phospho-STAT5
.galE
statut
ofknown
Leu747
9,882
F273
.Non-homologous
MEK2E27K
AdCMV
A225V
anti-P-FGFR
rs116197192G
DSB,5
R56L
Carratore
L7a
observations86
77-3
mechanistic-driven
stearic
ml-extraction
138101301–138240900NM_032961
kinetochore-associated
0.34-0.93
5d–g
G363A
68Ga-DOTATOC-PET
SC-25778
BD-FANCA
AliBaba2.1
IGG
non-receptors
RXRα
studies.27–32
phosphatidylalcohol
craniosynostosis-associated
fig1Afig1A
non-expressors
'classic
drugs.17
117K
0.00047/s
21N
B-1
nonradioactive
11mutation
regimens.18,19
shRNA-Ptpn2
S4.3a
-~e
pRb/E2F3-mediated
A_52_P117090
oligomerization
bMLH1
:LysP
GenMarker
.157
E6201-sensitive
MIR138
/72°C
whoselocations
PT6
/AML1-EVI1
heat-shock-transformed
MPHH
milk/PBST
F2,20
CAGGTTGGAGTTGGG
probe-hybridization
164
W-promoter
MLL-AF9-
68.1–91.2
sterlie
isolectin
cBio
R186W
pancreatic/colon
.Molecular
IndexcaseofhereditaryMTC
Whole-gene
Thirty-five
anti-total-ERK1/2
system-related
PolyPhen.17
56Â°Cfor
O2-old
Jer-Tsong
D1and
Immunofluorescence
D4-D4
5/27
S323C
//media.completegenomics.com/documents/DataFileFormats+Cancer+Pipeline+2.0.pdf
p.H169R
MML
emerge26
breakpointoccurs
15-mL
1Dipartimento
​Conclusion
tel-PDGFbR
FGF3/4/19
Immunofluorescence—HeLa
5'-GCACTTGTTCTGGCCTCCAC-3
1.8b
radiation.18,19
MEK1P124–wild-type
lysine-27
p7A2
cycstic
unanticipated
LatB
61.7
TE2
74104
P119L
EpiTyper
I~g
KIT.8
564–574
ThI
A_51_P266683
years1-3
Shulman
GSE20709
P=4.7e−4
overproliferated
UPF1
non-BRCA1/2-mutated
5′-TGTGGAGATGAGCAGGGTCT-3′
2.074
withp-iodonitrotetrazolium
PVF1
.Fountain
ID3—and
MYCN-157-NEG
.656
SMZL.1
dsDNA-ssDNA
Braf+/LSL-D594A
TCAB1
survival.To
drugs.22
p≤3.3e16
V3-7i
2p22-p23,34
assays/FACS
submit.html
.Cortical
Anti-H2AK119Ub
676488
bysubcloning
1/18
GST-Mek-
FKHRL1/FoxO3
single-strand
K-Ras-induced
anti-pAkt
often-selected
C630R
20-reverse
8.4±1.3
antidigoxygenin-FITC
LCMT1
Electrochemistry
Puregene™
0.785
ki-
Sencar
−1.1
PML–RARA
RanBP-ZnF
Schuringa
hRXRa
exposure23
77a
pPLC-γ2
4,5-Dimethylthiazol-2-yl
PIK3R1-R5
GYYY-3′
over-representation
Immunohistiochemical
thebase
1.6.0.0
ofTEL
16–18,20
C3H10T1/2
p.Val233Leu
PDZ-
7•9–12•8
EIAF-EWS
158.4
19/86
.Statistically
'volcano
onset-to-balloon
Pre-pubertal
VSV
S.J
T355
Lys-80
0.138
BRCA1-pathway
`gatekeeper
1nM
ResultsThumbnail
Chong-Kopera
9I
never-smoked
pDM38-
CLPD-NKs
Ginkgo
Trypsin-EDTA
Theerthagiri
n=56
18cases
necropsy
/Â¿Iof
0.23/0.17
1ml
106nM
bathingtrunk
α32P-dCTP
0–90
21,141
mMDTT.1Aurora-2-
Hilberg
47*
lipid/PIP2
D210A/D216A
T263P
HM27
.measurement
relapse-free
Kigoshi
fusion-gene-infected
8/22
1,683
immunoglobulins-FITC
tauopathy
RERTn
©2010
pan-Jak-specific
Yap2/2
CAGCAAGAGACGCAGAGTCAGTTT
0.042787931
granulocyte–macrophage
.Humphries
ISEm
Dhakshinamoorthy
BACH1-GFP
N-segment–
E644Q
fibrous
EWS–FLI
C:32P-rabbit
16/121
Y589/Y591/Y597/-
Steeg
preextraction
change-of-spectrum
IVS7-34T.C
R857C
Merlin-2
TTTTAAGCTTATGGCGGGGCTGTACTCG
–DUX4
K737T
967
Medroxy-progesterone
Biocounter
biplex
translatedin
5′-CTTTG
A-G
FLT3-840GS
IRB
TCTTAATCGCGTATAAGGC
rearranged/degraded
Lux-LacZ
mosaicism13
neuroradiologist
dyskerin
ETV4b-f
Yamshchikov
23542068
BreakpointsWithin
Morrish
VTEFMCH
5¶-AACCAGGACCATGAGAAACTT-3¶
85469
Misregulation
AbFrontier
71/399
8β
51-amino-acid-long
ERG-negative
Accard
CTNNB1/β-catenin
'conserved
single-tumour
65471
effected72
DI842-843IM
EMDBiosciences
TGTAATAGTGGTTACCACTCTTCAAGAGAGAGTGGTAACCACTATTACTTTTTTTTC
HDAC2/HDAC1
S4317
0.47–10.5
Clermont-Ferrand
102–110
hypertrophy23
pY416
U47742
.Modeling
21.9+1.1
Vaguine
ICI-182,780
5′-AGA
LYL1
molec
E199K
Ser370
Crohn's-like
fMutation
SC-2033
pellucidum
FITC–anti-CD8
NM_017771
ETV1.Figure
OGTT
al.,11
18,109,110
3.608
In_Frame_Del
SERPB1
c.301_306delGAAGTT
11qLOH
FL-stimulated
cytokine-poor
≥5.4
GSE22237
Novocas-tra
once-daily
Q921H
Cterminus
21-amino
26G
2012a
xenoantiserumR7038
.Supplementation
IMT-2
Iy0
truncation-expressing
C15orf55-001
Normandy
.Analyzing
lineage-restricted
5′-GCCTTCCGGAGAGAAATGAGG-3′
-incorporation
IRF4/MUM1.33
Avaant
A056201–2
exon-by-exon
Δ200
4M–O
SpeI
AB_213402
KD-mutant
site-matched
Refmac5
cN0
electronically
method.24
Cyclin-Dependent
104-1
MicroCAT
550609
cycle39
progression77
CACTCATGATATTTCGAGCC
D36N
32.08
30.25
EGFR-R776C
area.30
514-nm
activity7
10.1
degradation.56
EGFP-
Ras–NF1
-V592A
.IRS2
pro-B
2523211917151311975
.Nicholas
E2F–pRB
sh720—that
HBS-Ca2
ECSCR
APIP
analysisCellular
5-AGGTAGTCCACCAGGTCTCCGTA-3
.Markers
−5.5
pocess
BRC49
tumour-extracted
.GLUT4
6-nt
U-2-OS/B3C4
citrate-Tween
30-day
Exon-skipping
Farugia
ATcontent
.020b
Ha-ras-transformed
c.617_626dupGGGGCCCAGC
.Co-immunopreciptation
P.K714N
cell—cell
high-dose–resistant
Proliferate
740-782
Polymerase
F4-R8
LOC642550
dermatofibrosarcoma
Vκ7
.Bicolor
NM_007857
YK
DNA-phasing
,50
9/119
.Chemicals
V-1744
79/104
sarcosinate
alk34
conus-cauda
ACK
20423
PPAPDC1B-expressing
12-hours
3-mL
CLL.46,47
1.9-month
andTRK-T
spotsa
HardyZuckerman
5.502
thermophilum
TRANSLATIONAL
−∞
high-glucose
progression132
Schmidt-Ruppin
n=543
DU-145
E298D
TTF1/NKX2-1
56.
case,14,17
S783P
17/90
AZ-23
OPT-mediated
He´matologie
ubiquitylate
13b
NRAS‐mutant
DFR
MCF10ATP53−/−
Shu
ILR2
p.Colony
3·4–NE
//www.scbt.com
nihms646437t10.jpg
constitutive-activating
237–258
..olleThrGln
HPD
altered-function
Apo-1
Mll-PTD
RET/PTC3-positive
malignancies9,10
cystectomy.2,6
215771_x_at
14·9
BRCA1/BRCA2
5/46
angiogenesis-promoting
IJ
domain/membrane
.Hospers
myelomonocytic/monocytic
over-represented
RN7SK
-CATAGAAAGTGAACATTTAGGATGTG-3
Straina
5′-CATGTG-3′
.564
GISTMutation
AKT2-specific
observations29
F824W
orrlation
diVerent
previouslytested
SD/S
54b-4
trametinib
PRDM1α
pen–strep
3,305
Msh2S723F/Δ
post-hoc
2.5μg/μl
2•2
Omega-3
Cytokeratin-19
F/77
L665H
-UAG
41.cER4.40
576P23
.0419*
C-terminus.8
Gigaxonin
NPM
8.9Paz-Ares
n=8/53
c.5238_5255del
GUU
leukaemia.7
cysticmesotheliomas
single-product
0.1659
G.C→T.A
lymphohistiocytic
genes,8
RA2/ras
rat34,35
—such
-,30
31–June
-GTGCATCGCTGGTAACATCCAC-3
Oxindoles
types26,27
R586W
Spruck
SDS–
macrometastasis
12−fold
.CD79b
observed.The
04/2003
KRAS2-mutant
nonexpressing
cDNA/gDNA
AEs.34
disorders72
13-cis-RA
0.151
H164P
GFP-RA/RB
834
.ATP-binding
BioSettia
positions/configurations
Bubley
probemix
HCl.55
OST
−2854A/C
phosphoresidue
FGFR2Y381D
Polymerase®
PDXDC1
insulin-dependent
.TGFBR1*6A
1207/1605
PIK3CβE633K
0.934
5′-AGTTCATTTCCAATCCGCCC-3′
05MG
PHD/RING
PCR-cloned
diagnosis/gender
hydroxychlorquine
T51I
S278Q
clathrin-coated
pedia
rs1059310
p=0•0068
Fbxw4
E746V
NCL-ALK
28/39
Oligomerization—Our
BAK1.14
HisWild
.Waterfall
PC9-BIMi2−/−
5′-TCCTTTACTTACACCTC-3′
sequence-specificity
l-TG
.EXEL
BRAF-RAF1
TRPS1*
N-methylanthraniloyl
67–75
5′-GGATCGGCCTC
PC12nnr5
Asg
9q+
GATA-1s
V3THS_325553
control-shRNA
polymorphicmarker
.KRISHNAN1
D139N
40/82
22-month-old
.Gliomagenesis
mismatches—the
L1594P
RP11-21H14
.HCT116-DKO
4s
BH3-mimetic
colangiocarcinomas
5F1-5F3
5.5.2
Hybridisation
inhibition2
ngross
_290+
S-Label
19/19
5′-CCAACTCATGACTGTCCTTTCT-3′
CD31+CD45−
Y257
Rad50Δ/indRosa26CreERT2/CreERT2
erbb2
lymphomas78
cells.59
HLA-*
ependymoma22
BreaKmer
T7hOsa2
twotailed
-Pro277
chromosome.17
space-fi
deoxyadenosines
1026
SNU16
BG-12
5.1–10.6
.FGFR3b
isrequired
cis-Compound
.0796
GAGGTCTCTGGGCTTTACGCTGACG
understood.36–38
Notch-independent
KrasG12DIkk2ΔPdx
proteasomes
5′-GTGGGACAAAGAATTGGATCTGTATCATTTGGAACA
.Phase-lock
binary-presence
activated16
FGFR—had
p.Thr597Ser
3,3′-diaminobenzidine
kappaSize
pMD2
late-tumor
Nine-Cell
V.A.J
RAG-dependent
mutations—including
NRAF_NORMAL+0.10
-TSC1
offluorescein-labeled
nonrepresentative
117,626
SOCS3-F25A
deoxynucleotides
p53–p300–DNA
radiolabelled-probes
862–873
9.27
instability,13
Lax
S5.2
non–proline-directed
RAS–ERK1
births,1–3
KRT40
K/Akt
Melanocytic
oncogenesis11
MT–expressing
replacement.32
M.M.-K.
R163W
Gateway™
Runx1m
Seol
A622V
Brg1+
p-PLCγ
case–control
HBM
twostep
19923455
low-metastatic
in33
ILD
sac-de
1,8,15
59-GTAACGTGGCTTCTTCTGCCA-39
oligoes
R96Q
cancer.35
Radic
iIsrael..
Second-Line
bi-allelically
.Photo
phosphoramadite
cter-
S46L
Banyu
GSE21032
S-100
Kalderon
`W
Transphosphorylation
C918
.Plasmocin
GW786034
neutral/low
AKT-phosphorylation
GFP-SHQ1
tumorsIn
α-fetoprotein
5′-TGC
GUARENTE
-609g/t
10F
RAD51-dependent
.MAML3
ATF7IP–JAK2
v‐Ras
GlcN-6P
NPM1+/FLT3-
single-transgenic
γ-rays
forward-side
Artifi
RG-25
FDG-positron
-RNA
Vermaat
Nasmyth
914R
~34
1.18–3.75
Dimethylbenzanthracene
MMM
Lipocalin
p.Q706L
Trokovic
phospho-MAP2K1
EF43
NcoI-linearized
EF-1α
R167Q
GenomePlex®
†Only
IDH1R132H/WT-driven
W1
U68174
*Trigonocephaly
Lesion
Bajad
tanespimycin
4493C
Q37L
2681
parents/legal
Prox1+/Pdgfrb+
1315
HRE–luciferase
W583del
∼110
3H-methyl
Phe401
PERTURBATION
R86H
thrombocythemia.12
blebbistatin
P375L
MYCN-nonamplified
dish*
157ins
studies.25
patientsand
rib
194
Goodeve
Coevoets
accumulateand
melanocytoma
Reovirus
frizzled-related
54,55
8.150*
BabCO
SIC001
1091
V–fluorescein
anti.PY
binding-based
kinases.4–12
Mahgoub
Gli36
15-17
K-means
tequation
isoform-
Asp319
Kallikrein
populations15,20,36,37
N2875
Q407E
.banding
Klenow-treated
UPC10
G12.1S
Fig2M–S
RuvB
inhibitor.14–20
p110-Lipid
0·05–0·13
.Superfect
^M1268
MET26
shPTPRT
Leu-78
x10
.Rag1−/−
cytosolic-nuclear
3.05
62.90-65.53
2.Identification
E554_K558del
KITD737N
Notch1-activating
B.M.
Sja¨lander
STIL
hydroxy-tamoxifen
22p3
domain1–3
pY1003-MET
transformation.RESULTS
AAGGTGATGGCTTGGACAAC
4.775
Cul3-based
cancers85
co-cultured
A549-EGFP
361
Ser445-Ser-Asp-Asp448
20-90
Dysplasia
HMB45
0.689
Martinez-Quintana
sur-8rf
P212L*
cancer14
Mitera
2–6
20-µl
peptidecorresponding
A031
.EBV-positive
l294delT
analy-
therapy-resistant
Runx2-deficient
.Sancak
p.G128V
R725H
rs11196218
TM7
β-catenin–TCF-mediated
R484H
guanidinum
phosphoinositide-specific
3–108
A*2611N
Umea
pGL3-50
spon-
FLT3K644R
E2F-binding
Ccircles14
melanocytomas
parents28
.3K
365–385
L.M.S
beta-turns
photometrically
Bennardo
44,47,55
Q1262
D653
PLX8394
3′-GAG
CD34-deficient
p53f/f
Tahiliani
RUNX2–p53
.98
Mosflm54
ATG3
6-273
n=86
NFM
PDGRA
polymer-amplified
FGFR1+
S-1B
55.1
−47.6
Y279C/
R175H**
FTY720
GGCA
8331
Y529
P58R
D•••A
CA150
YMESO-30
Cheng-Prussoff
for19
7.Table
Shingaki
5-TACCTGGACCTGTCGGCG-3
−9.42
Lar
1408-1417
Madaule
Proinflammatory
Angiotensin
HhH
79,000
8994
48,51,52
DPPIV−/−/Rag2−/−
P497R
1201del11
LXCXE-containing
hematopoiesis.8
reinfected
COQ6
MTG8
only.7,9
19:112–123
PF-1066′
K205
library-selected
pS10E1bCAT
25.6
1049-1089
274Phe-carrying
Thr38
Y1221/Y1222
gcagggtaacgcatagccttac
D′
.Dabrafenib
C41
Chieffi
2-dimensional
38°
CX
p.Arg1515His
GNB2
supressor
NLS-mutated
PEG
.MOL
araC
MMTVinfected
n=12ISSCP
IRSp53,38
his3–200
FGFR2≈8
four-motif
R169K
c.776T4A
Ficoll
anti-PTEN
Reactome33
myelo/monocytic
TES
transcription.28
AXIT
BIO-RAD
IRIF
8-5
Kit—the
.Upregulated
IL-3-Independent
5′-TTTCCTTTGGGCTGCACATG-3′
combined-modality
32P1
RAG-2–deficient
anti-lysozyme
Erythropoietin
biovailability
FUS/TLS-CHOP
RB/E2F
TMZ-induced
design1
FBS/F-12
V600M-R-D
GSK3-beta
C-RAF13
VPC
.Schönherr
Kloeker
Y214′
E1*
Haydu
9345
PAFAGH1B3
IVS2+16G
Gudbjartsson1,21
Mxd1
.81461
CD3high
breathing-type
.1377
HRD-histidine
10,28
Max-interacting
lower-extremity
7628
c-Erb-A
DOX-induced
NDUFC2
ECM-
controls10
Anti-phospho-p44/42
16116
DLST
rs733618
Double-mutant
DNA-damage-associated
otrade
inter-assay
I861
droplet-digital
≥62
c.-138^16951
ortho-chloro
refixed
GS1-552A1
ECTMWT-3
MicroCal
DME/F-12
justover
K562E
E39
R73W
studypresented
R616Q
Alitalo
signalling23
AUBPs
Shp2D61G
A307S
17,37
R-transfected
tributed
44-882G
lines—WC00125
Ret-MEN2A
Dicer1wt/fl/Dicer1fl/fl
Ribozero
3g
BC053727
TET212,13
analyses,14
N‑methyltransferase
killer/T
Kypta
acidchanging
2BGG
A1B
BIM-low
SFB
microenvironment.6
one-off
.Vahteristo
Sv-Prm-Cre
rapamycin24
PRKG2f/1
Kasserine
isothiocyanate-coupled
protein.Four
23/1673
PBB322/HÂ
17/42
1-11
ErbB4-ErbB2
GLI3
Gentamicin
Gly-47
2002CB713701
D4476
Hs745T
T4N1M0
massspectrometer.Spectra
1322R
ELF2
midbrain/r1
1-281
www.umass.edu
Pten/p110α
TLR10,17
red/green
Col18a1
NTRK1-fusion
Tris-Borate
R130Q
19â€
kcal/mole/Å2
1990
E1813G
70Â°C
457G
.£D
knowledge.19
hepatitis-C-virus-associated
0.003008
1,12,17
E1813A
He/Ne
P220162
`8
anti-MK14
G13I
optimism
HEB
T1207I
β-major
.Dual
.14252
155
amplification.11
V86M
2.62
-mycWT
streptavidin-APC
Xd
Erlebacher
Mann-Whitney-U
.Taguchi
Beadchip
Olomouc
≥.01
104.43
NG_007873.3
Lv-3127-off
anti‐CTLA
p14ARF-specific
14.8-fold
rs725900
transcription–based
BMPR-II
Panc-1
69118
cysteine-deficient
waved-2
2pdmet60
19Department
BAP1-GFP
10.1158/0008-5472.CAN-10-2876
Hesselager
Gpx1
0.1-ml
Glu363
Pan-Trk
26165
breceptor
androgen,81–83
UV-exposed
144-146
.BEAMing
podosomes
PDGFRB/NOTCH3
Tpr-Met-transfected
melanomaprone
Uptima
450,879
Constellation
LifeSci
.NF2-associated
nuclease-deficient
mucositis
16-kb
S/T-rich
0.99-
CDK4/6-mediated
–10.87
Keap1‐R415A
Brca1tr/tr
pH-sensitive
D9
CDK4-binding
surface-exposed
305–770
V.3.0.1
SRα
N=12
Pauwels
FRS3
Consecutively
22,260
NMD
toimatinib
low-nanomolar
published.11
reagentswere
XhoIcontainingprimer
EFRhoAV14
5'-TMPRSS2
intraductal
.Via
Fast-Real
K15104D
www.agilent.com
p.Lys881Gln
R159G
understandable
AS-D
0.372‡
NRF2-
382T
PU7
CCSP/Ki-ras
kip1/cip1
50109
4/167
73/M
lq13
.25Each
A1374V
.-2According
pN1-3
Th2-helper
14b–d
shFBXW7/Dex
Zymo
Erf
.Filled/open
transcription-repair
RET-KD-0P
Pâques
24,21
1,077
heterotetramers
Bracken
DOPA-PET
​Briefly
Atm+/+
0.277–2.755
GGT-3′
Thr-338
MH02
SHP2-wild
aphosphotyrosine
P640T
Smad-1
Venny
respectively5
micro/macro
D.W.
L1213V
.Encouragingly
5×104
Figure1
1:100
Kamerling
Q803_splice
IKKɛ-dependent
Sprycel
5b,9
neuron-specific
Aurka
Gly/
.Preliminary
/Akt/phosphatase
function.26
SU-DHL-1
2OG-and
IHCs
P=2.46×10−6
cancerprone
0.809202
Temperature-sensitive
MYC-4
V590fsinsA
58-TAATATGGAAGTCCAAGTT-3
7-methoxy-quinolin-4-
del3516ins15
.INICD2
Y950F
AA4.1
patients.25
REDD1/REDD2
C‐tails
TMA
Y284C
MZCRC-1
CDK8-module
Snail-1
R35A/L225LI
Oblisense
CD274
.Flag-MLL
polypanel
rRNA
-MUT6
1F6
Tumor_Sample_Barcode
SPOPK134N
30.8–37
Nf11/2
HA-pSG5L
T230M
Chromatin-related
RNA-seq
doi:10.1038/sj.ejhg.5200883
Cmar
40-43
1740
pGBT9-LKB1-313
MAX.8
plot29
GAGT
phosphorylation-independent
agents—cisplatin
histopathologist
P-galactosidase
RIT1-transduced
mutation–associated
B′/B56/PR61
p.R514
Testicular
MXI1
17.5
R87P2
locus-dependent
AKT-driven
.M18T
FCγr−
pIpC-induced
7/25
DART4
p.Gly77ValfsX24
CryoCapHT
−46.8
TACCTCTAGATTAACACCGCTCAAAGACTTTGTATAG
101-bp-long
-by
HK-2
expression.4,5
10129197
PDGFRAtargeting
55:74–108.10.3322/canjclin.55.2.74
FLNA
0/16/13
135/573
.Wnt/β-catenin-mediated
39.40
benzene
//www.cbioportal.org
p.K70_E102del
13-base
necessitating
PVF-1
PLK63T2
SCV000195553
NotI-EcoRI
XIIIA
4R0N
N262
0.9999
CTCF/ZFHX3
503467
described.17
samples,14
disorders1
doi.org
CITED4
.Resu
ENU
alanine-502
VIBRAN
1806R
pre-B/B
phosphorylation/activity
Chx10-positive
IRF2BP2-CDX1
patients18,24
trypsin-Giemsa-
solvent-exposed
intra-atrial
ShRNAs
CLIC1
AF363683
5.21
ter497
B/CDK
virus-related
UF-1
subfertile
A220T
difference*
C*04
Early-stage
1G.W.Hooper
method.12
ion-binding
bead-bound
PVF-1–3
T343fsdelCA
E225
681
expressed.8
kinases..
carcinoma5,6
Masitinib
non-cysteine
interleukin-1β–
16–17
5D-E
glutamate-rich
post-AdCRE
lesion-binding
IgG1+
N826Y
species.12
cotransfect
T256P
erythroid-MK
gemcitabine-resistant
AAAATGAGTAAC
.Hoxa9
Cma1
1505
100,250,500,750
Klangby
6xOSE2-reporter
NCT01271712
ADAMTS1
314.3
.FACT
25mg/kg/day
glycylglycine
apoptosis198
microspikes
V7.0
pTYLI
Storlazzi
formalinfixed
25–31
3-y
HMLE-PAK1K299R
.Near-uniform
0.1N
.4973
6H05
Cdk1/cyclin
HER2-E
Asn67
recurrence/metastatic
Langone
32.4±12.3
NB1224-R5
.FN1-ALK
base-excision
Bettegowda
bis–tris
mutations.The
GFDS-induced
Dabrafenib®
RUNX1-expressing
Mislocalized
ad-mixed
factors/no
−.8
.PLX3397
Kalaitzidis
Gα
CTCAGTACAATAGATAGACAGCAATG
C18
3V
1.05–1.14
AAAGATAGCTCCCGGCATTC
Affi-BSA
geneloc
AVPTSE
d–k
​Fig.2C
TÃŸR-lgene
TOLLIP
ExtractionDNA
BTICs
.PO4-SMAD3
D11S1787
0.9G0.1
FLT3.46
MBII-dependent
colleagues10
SDS-8
2522A
PRB-160P
0.3676
insulin/IR
intra-cerebral
Cetirizine
non-splice
MET-therapeutic
p=0.50
S5A
.Hannon
5'-GAGGAGCTGGTGTTGTTG-3
5/513
660–667
Overexpression/amplification
Voillemot
mitochondria
protocols63
.PC9
States60
1.90
Muers
2.643
july2004
chr2:29443686
ARID1B-interacting
siCON
L704
Q395X
.sequence
TGA-bZIP
94Â°C.1
CBLR420Q
NC-AML
availability.3
.MITF-P
tumors.24,25
Col4a2
56°C
interhomolog
LAL1205
Guichard
KCNMB3
LMO1/TAL2
FLAG-p110α
J.Non-synonymous
p53-R282W
anilinoquinazolines
.DSC3
polymorphism,3
RP11-93E17
S287L
UACC-
Boulon
L749
hypermineralisation
low-abundance
S2e
KDC-RAF
interchromosomal
suffi
GHdC
finalizzata
Worobec
BxPC-3
Cernusco
β-catenin.7
p53-mutant-expressing
tumors.4
-GGCGCCATGTCAGAACCGGC-30
misspliced
3C1–2
rheostat
V843I-encoding
.Transcriptome
1010-01
type/site
49KB
Asp-to-Asn
ΔTet
P21212
100K
19.1
p-TPR-MET
Tamayo
byV143A
Gudmundsson1
SMADs51
proteins—MSH2
inrasdi
E277A
alignment-related
Buccione
nonamphifiedgene
p300-binding
IPMNs
IHCCs
/intragenic
sex-delimited
290
23–29
CUL3-dependent
9D10
15/45
2396A
1ILX
R289G
University^*
LabVision
P-
p12q31
GCGGCTGTACTTTCACTGCC
Dysmorphia
2.48
7q11
R120C
ABH2-DNA
CTD-2042C19
GACAGAGCCTAAACATCCCC
.BTK-KD
RP11-268D21-
D231A
3730XL
35.4–45.3
andBglII-XbaI
surface.29
0.2017
F876L-bearing
delG
H2107
*p≤0.1
D1067V
=ΔG
Wip1
transla
si08ResPPP6CH114Y
membraneJAK1
RK3E-GLI-D
MSK-1
D781E
PY20
PRB2-mut2
FL5.12
repair-competent
−38
pyridoxine-refractory
BREAK-1
bridization
16/39
LGALS9
adapter-binding
Dicer1-null
_TACC3_
tagRFP
bis-phosphate
GpppG-capped
L529F
ILT-4
473.
46.8
SCFFBXW7
few-cell
336
CGAAGGGAGAGTAGAAG
0.0138
G-8T
4KR
HECIA
neuregulins
KIT_HUMAN
p3k
VLLe
synthe
L723-P729
5′-AAGTTTTTTGGGGTCGAGGT
Y770fsX14
RFLVs
PTEN-inactivated
5′G/ACGTG3′
3,3¶-diaminobenzidine
Ichii-Nakato
DRB1*04
GibcoLife
homeobox-leucine
C47G/T
RCC4/VEC
small-effect
.PHD-containing
single-centre
Ptpro
K106I
3a-c
NC3
α-LMO2
9234
WO2007/068619
:3625–33
MAP1
550676
RefGene
0.0030
193.10.1016
retrotranslocation
A1988G
site—around
Wnt-Dependent
10/18/05
cells.The
FGFR1-ZNF198
CD33-expressing
gene,28
p.Gly1424Cys
homodimerization—were
L6c
Lyssiotis
PCR-product
well.16
Disappearance
3DHistech
anti-GFP
Aoyagi
'suboptimal
AIP
CRL3-Keap1
Asxl1fl/flVav-cre−
.McKenna
sc-1616R
syndrome-associated
SA531
GGTCTCCTCCGCCTTCAGCAT
CKDs15,16,50,51,52
15APC,13
contacts.17
HER‐
Tamp
GD-dependent
133-135
aberrations.6
7780
contaminating
NZM44
Tre2
practice.7
J32
MN2
5′-GCCUUUACCUUUUAUGCAATT-3′
chr2:241515027-241516055
TCTTCACCCCCAC
p.Asp779
FLK-2
ggAT^'7
Cyp3a13
Leu-210
Strelka
cellproliferation
28.75
denaturated
=0.027
11–mutant
P577_E583dup
ETV3
vitrobinding
64th
2000–2011
associationor
Sorafenib—A
2543A→T
1163
SNP7
Seltzer
unclear29
Rocnik
pVHL.Figure
AI-2
un-identified
5′CAGCAGATATCCCTCCT-3′
Thirty-one
d5-2HG
phospho-tuberin-T1462
1994
∼two-fold
siRNA-Mediated
Myc-RYBP
phenotyping–genotyping
GATA3,12
post–tumor
Xenómica
∆28–32
Asp-843
E1A-containing
transition21
.PHTS
221
05/02
6P
Bunag
L95
104_105TG
SDS‐PAGE
progenitors.46
Oligomerizes
software5
Gly-12/
anti-TdT
p.Leu1519Pro
I/Eco
Trk-A
Mulgrave
60.3
rediscovering
-stand_emit_conf
dPET
on-off
control.Next
phosphor-signaling
cDNA-level
UnstableStability
r.spl
fresh‑frozen
hypoattenuating
BRAFG466E
CCGCTCGAGCCACCATGGCGTCCACGGATTACAG
1.2cm
BAF47/INI1
Fondo
P-0004376-T01-IM5
Cooccurring
Platinum-resistant
5′-RACE–negative
M1791T
PAX-gene
Volumetric
2,136
−log10
Feuerstein
TGGCCAGTTTCCTTTTCTTCATGAAGAGGCCGATCCCCAG-3
c.363delC
AGTAGATGGAGCCTGGTTTTT
DUSP1
20ºC
deuterium-labeled
TTCCGACAGGACCACCCCAGTAGC
spitzoid
.023
differentiation79
S177L
EN-positive
GCAAACTCTTGCTATCCCAGGAG
P98L
on.13–15
240.0
PGAD–PKN
CD23+CD21−
path-scan
explored21,22
2–74
Kit/βc
Second-look
p.F892L
ILT
IDH2R140
RNASeq
1097
0959
V600R
c23
pathway39,40
superoxide-generating
c.784T
wa-
P=0.008
E291G
636-stop
pTRX1
747-749
38,784
CAGACATCACTCAGTGTGGT
L1808F
G719A/S768I
acidlabeled
21/M
17–40
nl/min
46,47,81–83
syndrome,32
EGFR/ErbB1
_BCR-ABL
Ó
.Murakami
neddylation
005228
CD137
12p13.3
senescenceWe
RBPMS
Talve
Braf+/+
somatic-deleted
79.Independently
1690
004972
PDK-1
ately
phospho-GSK3β
20–24
-TCGCTCCTGGAAGATGGTGATG-30
ai-2
withanti-PDGFRA
.41,42,45
NA18507
allelesare
2569
RS112
A-375
3–38
78205319
Sufu−/−
PDGF-C.
XFoxH1a/b-Smad
G766
imatinibinduced
assays29
moderate/strong
methylation-deamination
sarcoma33
hormone-naïve
Repair-proficient
karyopherin-β
0.217
MRE11–MRE11
6q21.2
IL-9.15
system.The
W740S
TLS-ERG-
aminoethane-sulfonic
Zymoprep
V29GY32W
mesylate.35,41,42
autocrine
GOG-239
GenWay
.MYD88-mutated
pseudoarthrosis
48–51
S1343
DIO1
-12
Paschka
studies.Oncogenic
associatedwithH3K36me2inyeast.Collectively
algorithm36
Maoa
128–143
D1S224
5′-CGGTATCGATAAGCTTGATGATC-3′
.Frizzled
82/84
4.162.8
74-year
949
A_52_P54218
Thr830
Q86U86
FIG.3
mediabased
Dovitinib-Resistant
BRIP1-depleted
3/protein
in100
93:14845–14850
q20
*†
Haemek
T-NHL
PLX4720-sensitive
chaperonins
.=~~~~
RCC4/pVHL-S111R
CDK8/19
high-depth
HCC14
.Baby
1–5
SRp55
oncoproteins.8
I848T
Reigstad
TACTAGGATGAGGACATAGG
Huh6
R.
1A–B
NNRTI
6,27
tA200
.Mol
S2.8
c.1277–1180_1386+2226del3516ins15
S4D–S4F
TSC2-5A-expressing
MTS1
5'-AGCGAGGCCGAGACCCAGCA-3
R594H
156αα
1537
∗EST
oncogene-positive
V617F.8
EWSR1-ATF1
RW105
8.4–11.1
R487P3
Blobe
−1.2
digoxigenin-labelled
MIG-C/EBPα
FGFR4-wt
nsSNV
james.charles
LacI-CHERRY
Pavón
Emax
life-threatening
conditions.At
anti-phospho-ALK
Q987K
AT/RT-derived
.EzrinT567D
390–458
813-817
CCGCCGCGCG
subperiosteal
wellstudied
cross-tumor
I684S
Tecnológicas
Lys545
n.sSurprisingly
αMEM
pri-miR-17-92
earlier.9,55
.PC3
Rcnillti
G/A
sanofi-aventis
T576del
-CTGTCCTCACAGAGTTCAAGC-3
year.2,3
caseswith
crest-unrelated
'superbinder
~160,000
275
HLH
R135fsX177
-CATCACTATTAATGGTGTAGATGCCT-3
CNSderived
p53-DNA-chromatin
154
xDFG-backbone
CBP
.GDC-0449
gene-regulatory
MANUSCRIPT
EGFR-Ras-ERK
NRAS-GTPase
desmoplakin-FLAG
ATTCAGTATTCCTGTGTAC
heritable
D27C4
//www3.who.int/whosis/discussion_papers/pdf/papers13.pdf
.Pertuzumab
Franc¸aises
retrovirus-producing
Open-source
damage-specific
defined.10
Dgcr8
Etv1-derived
PR130
residuze
Y297C
Sithanandam
.R2a
Shiraha
179-kb
F4-Gal4
1662-1G
T494M
Src-promoted
Maitra
nucleotide-dependent
KIAA1804
ROS1.Functional
6p11.2
T.Frank
2438
.P655R
HBM-dependent
c.1027delG
lysate-expressed
www-dep.iarc.fr/globocan/globocan.html
TRE-U3
β-catenin/Tcf-4–mediated
/rtTA-expressing
1650
ⅡXL
800-kb
TKIs.31
signature40
S227
REXO2
siPrecise
mtartaglia
sc-25778
5′-TCCCTTTGGTAGAGGAGACA-3′
E585K
R299
B-F
24.5
.Oncol
IHH
Gln145
1,200
.199G
intestine.23,24
1,604
83–110
H101Y
L-glutamin
K′
mg/mg
succinated
p.N550
ITGPNMGGKST
GTP-RAC1
/fx
MDS/MPN-U
Gullick
ASP+Val
p.Arg168Pro
about.jstor.org
3.114
p15Ink4b
PR185
PtenΔ/Δ
-MUT10
busulfan
pS6K1-T389
hormone-binding-domain
NFY
CREB-1
2a-d
StepOnePlus
Opti-MEMI®
.-..
.Baird
Phospho-SMAD1/5
Xgal
MEF/mRad51
ex-
O-Casein
0.041
growth-
ROSAmT
2.866408533
K120R
exon-skipping
TGF-β–dependent
Freemont
._1144+
NM_178381
UV-sensitive
00029
2013CANCER
MDM2-P2
PSMB8
NM_002185.2
-guanosine
DEL-Other
Anti-therapeutic
Glu-Lys
miR-125b-2
nausea.17
−0.91
Mutants—The
26,113,114
533T
-0.38
01/99
86-18
-catenin.9
:CRE
Superfrost+
GGCAACCGT
Trimethylationdependent
664
anti-EGR1
aCurrently
Kushnirov
sc-2020
required128
CK1ε
vitro,15
locus-deletion
80th
ribonucleolytic
ErbB-2amplicon
BRCA1-BRCA2-RAD51
LMP2/TAP1
Doxorubicin-induced
16
sequences.Chromosomal
TCC
p52/ETS1
TCTTGGAATCCAGTGGAGGCATAAA
EMD1214063-treated
manner.21
Focus-forming
PNS
.Co-precipitation
.Sucker
dobutamine-mediated
sc-17787
Umezono
fidelity.Finally
Korc
43-316-
SHP
Aox
lesion-triggering
MITF19
RAC1P29S-expressing
S9503098
12.Soft-agar
standard-risk
LNX
Mn2+
4644
Bjorkhaug
activity113
aliguot
Whole-transcriptome
F303A
hemihyperplasia
RAS–GEF
Creb1
LY2874455
.Up-
p.Arg1200Trp
anti–
5mm
339
HTLV-1-immortalized
6897
observations22,8
-d-glucose
c.6988_6989delGT
2-hemad
developmentand
c.30_31insGGA
UTX-1
c.613A4C
disappointment
++++++-_Figure
rotationt
theactivating
UEM-3
hydroxylate
Strasser-Weippl
colon-cancer
Abud
Ser256
c.1–323
trastuzumab.33
lo-
40.By
non-diseasecausing
c.760delC/
Sorafenib—It
10.1593/neo.10356
L1122VþL1196MþL1208P
olaparib.18
response.22,32
.Liegl
5,7,62-64
aduertisemenf
.Suppression
G820R
10,13,21,22
HMS-101–treated
factor-depleted
APLP2–TNFSF11
ROC
Val533
TpoR
Dll
Hafsia
verysuitable
NZM19
vitro25
lymphopenia-related
μg/L
RAFTK
p53+/-/Brca1+/+
56,307
27-0843-01
Arg83
.Crouzon
GCL
twocolor
Lucerne
mitochondrial
MycT58A
Myo3A
ALK-independent
surface.79,80
Figs.2D2D
proteasomes.12,14
A1236T
755–781.Figure
GFP/Gr1
FGFR1/FGFR2/FGFR3
switch-sliding
3.9×10−21
theChk2
super-enhancers
glyceraldehyde-
DNTBP1
c.461C
Weijzen
.Asp423Asn
C-MYC/MAX
cds−6.3MAL2Mal
NuclftiÃ-itlesequence*
˚A
RT-dependence
ab180714
GSE26712
RP11-66D17
15,36–43
immunoselective
5-aza-29-deoxycytidine
5637
3–4-fold
Figure1D
72Â°C
V557I
high-molecular
BS-2
Chirieac
N564D
mRNA-subtypes
T40M
Coriell
BAF60c
Axin1
alkylators
Mx3005P
thePCR
+trp
disorders46,47
PREDISPOSITION
Met-labeled
T180
producedafter
ura4/
Semczuk
requisite
co-related
hFAST-1
Y→F
melanoma.A
anti-HIF-1α
p.Arg82_Leu
NFMP-HPLC
under-representation
5q32
EN-only
arrow.DiscussionGermline
clastogens
pRBGP3
3733
Trizol®
NetPhos
loss-of-STAT1
15.0–3.0
al.52
Dermatopathology
Leu-350
disease-derived
Guerrero-Valero
SKMEL37
Ser-327-phosphorylated
screenderived
protein—possibly
LR09-017
EGFR.6,7
Two-thirds
m7GTP
Y673
p-Smad1/5/8
MDS27
regression139
DDLS8817
glycine-linker
study—screening
Savelieva
6/44
co-translational
0.03
interethnic
d/2
component41
Ser/Thr-rich
nevi/cancer
Abou-Alfa
antiBAP1
32P-labelled
Y160D
6840
Sakamuro
NRASwild-type/
Saxony
ICF
GBX2
F18-FDG
Phe-core
.UV
A220G
SNP/STR
α-D
sizePrevalence
ristocetin
.Edge
study.14
Brg1-binding
M-L
maculo-papular
PM2
DSPSPIAA
bisulfite-sequenced
3.3.4.
p110δ-knockout
NBRE-related
PCR-SSOP
Pnm
domain.1−3
Caucasianpatients
08-114
31,000
15-somite
Tyr-647
18.1+0.4
Keyhole
fgf-4
1/22
A7R34
RHOB*
Spanopoulou
9-cis
VarScan242
W.-H
human-Flt-3
DEVBIO
luc-reg
⩾3
8152
lesion47
SNS
survival118
5′-GCAAGCGCTCTGCCAATTGACC-3′
phycoerythrin-Cy5
340fs
Sunayama
Vascularization
Sieweke
5/37
931
1800
temperaturedependent
mutation5
3583
centromericenumeration
016a1
C634R-Cl.1
differentiation.16
Biodiscovery
Optogenetic
46104
1.5x106
Sparky
Analy-
GS-363
VHL
purines
Kambara
Ser674
CIC–DUX
decay.36
Over-expressing
C+
Pim1–AMP
charactered
1–4
χ2=4.2
Hs01554635
Work-up
shRNA-control2
Brca1tr/+
nus.edu.sg
acid–spanning
responsible12
cells.As
.Multivariable
p-Tyr-peptide–inducible
pN1b
G301S
SRSF2P95R
deteletion
MZF1
.CCR7-KO
PAC_1
I658Q
p53or
Schlienger
TGCAGGCATTAGTTTCTCAG
RASA4
neurofibroma~.l~-~~
66-yr-old
broaden
andN127S
9A/6A
acetate102
short-length
anti-FGF-4
2Download
17q24.3
.LNCaP104-R
Androgen-induced
FGFR3-expressing
ptacHRAS
a/g
evasion
Denissenko
VEC-catalyzed
C.H.
PAC-TRAS
T-RExTM
Applera
163K
mutations.45
RET/PTC-JM
octahedron
indirectly.4
disulfide-linked
TGF-β/SMAD3-inducible
αZ
-46
EastmanKodak
`two
CAL-72
miRNA-independent
S35
pooled-specific
NB18,19
disclose/exclude
-32.6
ermeabilized
190.5
home-built
anti-Phospho-Paxillin
p.Q27L
RhoA.V14/S190
phenol-chloroform-isoamyl
5Di
trancriptional
Brca1SF
.SRP
YSTDYYR
Ab37
/v-akt
antigens.DiscussionUsing
intermediate/strong
HTG
M521L
CloneG169-15
F565S
specification.45
bronchus
V/Propridium
dyslipidemia
Cre-driven
clinico-histopathological
18.5
northern-blot
58,96,97
FAM-MGB
infection9
157
,65
51–117
TPDY307FL309
process/activation
Willmore-Payne9
200D
autostimulation
Pem-
2.00–2.99
NCT01970865
FGFR-expressing
NA32.1
LacZ-
3Cb
VEGF-A
cells23indicate
CaseCytometry
chromatinized
Y32W-G60A
VACO8
HEC108
W.L
5247
.Gained
HER-2staining
∼104
pS6S235/S236
buer
p=7.3E-05
28,41
L141
Neurodegeneration
×105
cell-related
Yekaterinburg
282K
T507K
M-
nucleotide-
1/4,310
nonpenetrance
Pre-existing
p300/CBP-associated
R10-labeled
HPV-73
.Are
ATTTGGGGAACCGTCTGAA
p.Arg172His
D275
tetracycline-related
S6283
5α-androstanedione
C116G
E1510
neuropathologies
GCAGAACACC
MCPH12
.TRAIL
pertuzumab-induced
ita
J.-M.
Del18
motility-enhancing
2.051
geminal
ab84726
c.588+5G
c.1590G
arrowA
CAGATTTGTGGCTCACTTCGTG
8/108
state27,28
Labophot-2
Fig.9D
ratlysate
ipsilateral
DHT+DMSO
CD45+c-kit+
NP-40
98.84
PIP-KIs
Ser217
R847
TGCTAACACCGGGTACCTAAAC
Prestarved
PF-04217903
aNucleotide
Thr58
.1003545
FGFR1/2
L239F
SSPSs
ROS1-mutant
allude
7-4
homlogy
1855–2082
Taviaux
CAL-29
y-3
I629L
3529
5′-AAGCCTCCCCACACATGACC-3′
.July
MEN2Bassociated
homo-/hemizygous
basal-like/triple-negative
ErbB2is
non-migrating
P152S
RP11–30J7
3p24–26
GST-p
promoted-BTICs
case,19
overestimated
ampk
cSCC6
SEC61G
Staeheli
and3,3
−7/7q−
G692R
milk.41
eV.25
DCAF
vitroSRC3
CDKN2A/CDKN2C
X-100/PBS
0/40
K280E
H1402Y
,53
Solubilization
Neklason
Hamartin–tuberin
Age/Sex
Fig.22
function.In
GGGGT
MDA-MB-436
phospho-STAT3Tyr705
Filtron
strand-sequencing
0.0231
1.5-fold
BCL-2.26
*VaILeuA
diethanolamine
pTopflash
pericentrin
ultrabright
2,354
ETV6-mediated
standard16
agarose–6
4.7
aPMS2
H3K27me3-suppressed
SupertiFurga
14/111
alone24
Cds1
–,47
MT1
postranslational
mild-Gardner
MHC-TCRαβ
FGFR3-positive
29A
31EGFR
339-592
.Culturing
11–31
Hime
Trojanowska,22
13.814
Bicinchoninic
PRP
1.5−2.5
CAF-1
virusesderived
lines.44
†26
N581
SCLC-associated
I0i
Leu764
Glu-13
p.Gly271Val
overactivated
Five-hundred-and-thirty-seven
5′ACCTACAGCCTAGCCCAG3′
antiphosphoserine-Akt
published.110
pEF-Bos-RhoAV14
NCL-Ki67p
viability/growth
QiLY
SEC31A-induced
MSS239172
Thr50
4400263
rosacea
Tetramer-positive
Hermanson
GPR126
F42
IDH1-R132S
FigFig4A,4A
Minucci
9408
A1038V
OCI-LY10
DNA-BD
510080
D802V
mouse-anti-human
2080delA
715-167-003
0.445
esgts
8686
9D1
Cbl-C
V559-Y823
8·7–NE
angiogenesis90
HPV-6
L572W
carboxyamidomethylation
co-immunoprecipitated
O..
loop,23
F–GGAATCAGTGTGCAGTGTGG
747-750
TY82
1Download
p53‡
25,47
transfection/expression
2.1b
p.E511K
.FoxO1
EWS-POU5F1
family.28
6,666
395
proteasomemediated
816–Ala
KCTD7
mice22
p14ARF/p53
Daneshmanesh
ALK-R1192P
2474
NEK9
43–126
ftSerL*uH
-2-HG-treated
c-petide
mininiize
int-2
F1174L/C/V/I
preadipocyte
hTcf-4
Ser35Cys
Tet2+/+
S364G
NM_002168
PRMS
CD16/56+
3295D
POLA2-CDC42EP2
K.K.
JBP2
dmGAP1
E-cadherin-positive
J011
TTF-2
death30
5′-ATGAAGCTCTTCAAAGGTCGT-3′
long-fragment
.TbR-II
Tam-induced
E8.4
59-AGCCGAACATCATCTGGTCT-39
D277H+S310F
13q22.1
NCT01130142
rs2228006
T256A
mPFS
77,78
Matrigel-embedded
β-gal-
P254L
42–44
Nucleo-phosmin
1216
6780
K-rasG12D-expressing
tumours10,11
Karpas-299
NimbleScan
CCCTG
FW1
CD20-sorted
3,5-12
data6
MB6
cases86
B05
ESI-MS
CEP110-FGFR1cDNA
dual-parameter
Nuclear-cytoplasmic
43.5
broad-spectrum
62-95
ELF3/ESE1
long-segmental
generalization
p.Asp135fs
p.Pro83Leu
WCLC
freely-available
non-adherent/inappropriate
MSCV-Meis1
613325
PAXgene™Blood
G156R
RET-transformed
mutated/deleted
NSCLC.23-31
.Localizing
months.4,6–9
1/190
v2012
Mann–Whitney
well-controlled
III-like
coldspots
asnon-B-DNA
GAC
non-randomly
XL281
Cellomics
Arg24Pro
≥100
non-OCCR
codons60
CANNTG
Zamagni
IMHD843-846†
121–143
.Fine
Ponti
IRS2
Low-income
clinicallyvery
myelodysplasia
1.2r1
non­specific
intestinal,14
trypsinization
ligand.55
9:507–517
DEAE-dextran
Y406H
NM_008317
8/408
L110V
Carpten
survival55
determined.TOPBP1
Fudenberg
9017-03
ysA
-x
octamer
cancer9
pCMVβ-Gal
D223N
00014
603-bp
recombination-directed
Russell2
congestive
BTL
restaged
repression29
.multiple
R233C
Runx1-EVI1/+fetal
3,051
Hostein
SDHC-
HTB-132
9296
1·6
c.2357C
12790-1-AP
neck–specific
5′TOP
Molavi
TAI
1746-11
over-95
21.0
NCI-H2882
lysates/lane
R151C
P-TEF-b
overexpression.We
D–RB–E2F
incidental
eosinophilia.19
Spinocerebellar
D5/16
Tool.29
HT-treated
.Smad2+/–
R255
genes3
-CD13
monoubiquitinylation
NaCl-containing
5′-ATCTGCTAGTGCTGCTGCA-3′
Barkovich
*wSS
733
immunohistochemisty
13K
phtest
5′GCGGAGATCACACTGACCTGGC3′
ERG1
G106G
11q12.1-q13.3
donor/acceptor
nSH2-p110α
underglycosylated-
phospho-PKB
3-phosphatase
A-204
Krstop
2×
Thiberville
fibrousheathin
4+
Tet-pLKO-puro
p.V241del
Schittenhelm
λ
anti-pIKK1/2
88,89
D115G
Myc-ΔN
Heffelfinger
.Citation
NAMLRLGVLQPEVYKQSLPGSNCKHPEIKKQEYEEVVQTVNTDFSPYLISDNLEQPMGSS
alpha-chain
groups.23
Thr-61
19p13.12
oncomutants
35.7qo
483
MacroH2A
PI5P
T336-P
tumors35
1p21.1
luteinized
JM-autoinhibited
orange/blue/green
Met53Thr
//ca.expasy.org/tools/protparam.html
.EUROPEAN
10,11,11
693–753
1535
p.L1330VfsX12
domain12
.17–20
RTK-stimulated
figs.5E5E
hypothesis-generating
Robo1
antibody-
oxoG
occurrencea
M13mp18-GATA-3
.Immunostains
no.19
378
concensus
CXXC5
RECIST-defined
PC15
53:87–95
ERE3-tk-CAT
LS-
Speicher,3
PIK3CA-overexpression
Met538
Joulin
GST-ERK2
1–456/G421S
lucif
482
inflammatory/immune
21.Figure
GCGCAGCTGATAAAGTACACACTC
SRC/JNK
Tyr1397
PolyPhen20
anti-acetylated
F3R
1.1V560G
fusion8
bio-banked
NTNT
1651–1657
.MutSa
Tables1
187–189
Sox2activecells
481
ZO+
helix-turnhelixdomains
G:5fC
N-T
TCGGCTTGAGCATCTTTACA
long-range
pcDNA3.1-hMHL1
gpl4QPrOtOt-k
browser29
chemodrugs
domain126
p.T790M
SOX17-WT
fusions,11
BCL3
L724M
Akt1/p-Akt
DIMH842
1b6c
18q12.3
CCACCAACCTCATTCTGTTT
sarkosyl
1.25–1.75
tumor-suppression
Flag-hSNF5
bromodomain-carrying
c-Kit+/ZsGreen1+
TCGA-AA-3947
KIT-N822I
WHIM12
41-44
L-009997-00
c.8270_8271delCA
pmCFP-N-rasG12V
activation.37,38
NB1224-R3
intersectin
CD16
RFLSLEPL
9.11
S1254
EZH2-impaired
.B-91-228-107
C5TC6T
gene.PowerPoint
2IVS
GCGCCATGGCCCGAAGAC
OTP-dependent
5-hydroxymethylcytosine
countries.1
One-twentieth
.Grade
ism
70,000.1
−31.16
gp140Proto-rk
counts.27,28
.Polymerisation
virus-transmitted
RNA,34
Buckbinder
40,362
B-Raf-encoding
D2412V
P1380L
1057–1077
turn-is
ON-target
0.054†
CBF-2006
dT-I~matologie
5190-4371
.Micronucleation
IFITM1
462–471
S2367
Hermes-DeSantis
nutrient
182-residue-long
Mercher
.Risk
CT60
IKK-a
anti-phospho-p42/44
Δδ
0.107044907
rings/aberrant
11–32
SMRT
cholangiocarcinoma.6–11
4691
11Val555_Leu576del/13Val654Ala
dose.15
pre-warmed
Myotis
c.1608A
2423
pRb/E2F-mediated
604395
inter-ethnic
report.26
LPA-stimulated
ruxolitinib
Pdx1-Cre
Necker-Enfants
.Jaiswal
drug/ATP
≈75
IκBβ
hypouricemia
9,11
293-
11q13.5
M4716
bioimage
mMCoCl2
≤pT2
full-gene
LI256EE
K6–8R
LANDES
Metl'61
NADPH-associated
HercepTest™
58.29
level.1
24bp
762
Rasio
G802dup
Toczyski
chondrosarcoma
WIP-CLO1
5′CCCACATCCAGTCCCTCTTCAGCT3′
TRiC/CCT
Barbetti
.Itch
genes.RT-PCR
9507
infiltratinggrowth
p85αN564D
PNP
rCrArGrArUrGrArCrCrCrUrUrGrArArGrCrUrUdTdT
E1b
kinome-centred
Diploid
METTL2A
myeloid-tumor
RAS/MAPK
Pymol
Iono
2818delA
investigation.Our
Gpa33-antigen
p27-stathmin-MT
SAP/ExoI
59/39
28,29
.243C
0.02491
IKZF1del
domain.5
36-40
non‐substrate
8755−1G
GLY
Atm-KD
RhoGAPs
5′-GAAATCTCCGAGAACCTGAGAG-3′
HUS1
c-Mpl–carrying
polyHis-pET47b
71-48-5
Asp-816
'baseloid
NCR-nude
553128
pre-microRNA
DNA24/DNA0
VEGF-A–overexpressing
11/671
cancer.33
793C
71-18-1-3
R165W
cytosines
Beà
12,831
beta-Sandwich
pFLAG-CMV-2
96:3224-3230
oligomer
.RUNX1
cooccurrence
EEA
e17
Bac-p53
Cavanee
.MYCL1
reported12a
µg/ml
R.P.K
theFLT4
4.39
solar-
4.30
Sp8
GTGAGG/gtgagt
1578
osumc.edu
Rheb-WT+Y35N
low-copy
4.7-fold
LALA-94
Chromatographs
KRAS-related
.TurboSequest
myosin-binding
reducedto
Hs02543373
Non-Burkitt
V769D770insASV
5′-CTGTGGCCGCTGCAC-3′
recognizestwo-
p-Akt/Akt
2.102
G9a/EHMT2
cellular/molecular
tometry
SurePrint
139–142
ΔWW
1.424–3.198
5-aza-2-deoxycytidine
NCI-H1703
as`+++
Bechter
inactivated12
ALK-inhibitors
0.543
11/11/02
c.8162T→C
planeof
NRG
type-kinase
Medex
IκBα-SR
pro-B-cell
MMP-14
R629Q
dierences
Capello
polycystein
Schuffenecker
1/64-1/70
III™
.IE
ARafFF
Fugazzola
EWf
retinoblastoma-like
Nonpapillary
non–disease-causing
F631L
F578
92.1–92.3
.Sibs
DDR2-F
4.0-
TEL541rev
p56
R776G-mutant
lasercapture
SMO-expressing
c.343G
HNPCC-affected
HEPEs
LMP2/TAP1-promoter
V1.0
Tyr519
.4092C
yesassociated
p.S19C
Rosbotham
LUCC5
.NP
nonsmall
–65
p3TPLux
Thr*btLeuProII
Gilliand
I78T
R1881over
antibody/goat
CI1040
.Progressive
Thr158
gene-carriers
Gremlin-1
Hemispheric
ImageXPressMICRO
F*
~103
Ghimenti
SPECCI
4–12
Igf1R
hisG/rad50A
Vossio
.GW5057
hvr
pheochromocytoma-based
KZR'-R.p-R-P
±SEM
bis-
34–36
2-base-pair
PI3Kα-mediated
ACATCCAACCGTACATGCGCAGGAT
G863D
Asn-26
E561K
anti-phospho-p70S6K
Late-onset
ChudleyLowry
5404875
CD41/CD81
Hudziak
CD42CD81
RAS10
Asp70
.Learning
Asn491→Asp491
MPD-HES
KLK4
ZNF385C
23.1-
Lys309
Panarello
8.3–28.6
-===-
88*
M165R
Limaye
Me16
18/89
USA.3
activation9-11
CITED2-induced
.Spot
T685S
pLZR–BCR–JAK2-IRES–EGFP
0.659
Semi-Dry
molecule87
‐/‐
1091–1096
quintessential
sEfNVLkqV-nHpHVIKLYGaCsQDg-
Kucinski
magnesium31
0.5.9
1.08–1.20
PreAmplification
SOS-Ras
q11-12
Patientpuromycin
Goda1
complab
RG-28T
G1/S-phase
Elf3Δ355–362
dynamicprocess
L52F/H
Molt16
ofwhich
2.302
Gln-711
212Pb-TCMC-trastuzumab
5′-AAACATTTTCAGACCTATGGA-3′
Oct4+
ex9F
350g
K299
Fig.9G
PTEN37
eMutations
PI3K/PTEN/AKT
F12V
receptors.3
F216L
AAACATTTTCAGACCTATGGA
H12Q
two-sided.RESULTSPatientsBetween
C/EBPα42
~55
bis-tris
1E-J
1anap65
RP11-54P19
phosphoglycerolkinase
perimembraneous
meiosis.61
4-kDa
allele-carrying
YWHAE-FAM22A/B
SOCS2/3
E709K
pCRFL
signatures34
.Pair-wise
GenotypeEthnic
conWned
statistics-naïve
Gg5.9kb-Luc
Bleuit
.Assigning
uncharacteristic
0.1-mmol/l
Arg226X
HGG077
HDACi
epidithiodiketopiperazine
c.2054
20−30
nested-PCR
BRD4-associated
CS,11
MRT
33-1-49-58-34-11
P=0.91
anti-βPDGFR
Zap
penentrance
.acc=GSE19730
7.642
.6a
cloned.22-29
significanttransforming
LMNA-NTRK1
insingle
C6-arginine
T4b
R1268Q
−2.10
.Further-more
001105.4
8-oxoGuanine
4p16—with
transforma­
33428261
907–916
C/EBP-β
PHD-extended
CD117−
Upregulation
neoplasms.44
STK19
CATAGAAAATCTTTCTCCTGCTCAGTGAAT
wasnot
1–900
NM_016960
BRAFR462E
LR=55
24326
mutants.8,9
CCND1/CDK4
674–679
9004
ITGB4
MV7
W444C
BC/Cul2/VHL
.Pie
LF2000
formaldehyde-agarose
Magliery
exonucleolytic
EiF4E3
cases3
1914
glioblastoma47
R.R.L
ranking-mode
Y764insFQEA
14â
41–43
76/74
A280/A260
gene3
cough—were
MutationTaster
alanine-substituted
photosensitivity
R381A
2I-J
60°
.PKC-mediated
adenosquamous
intraepithelial
Tolgay
BarnHI
0.652
—BCL3
in-transit
Mizuguchi
0.5μg
Montani
Ducrest
D130
quasi-repeat
Sauter
cosmicMS
low-hemoglobin
GAT-3′
pEF-β-galactosidase
183G19.8
.DX-IC50values
Monocytosis
R2228G
FBW7-based
Lys-372
A115S
34G4T
Paxillin/pY118
1.4-fold
.Nuclei
R157H
.Arrows
HNPCC4
neoactivity
breast/ovariancancer
∑kSik⋅Hjk
2C–F
c.6094G→A
Chungnam
insulin/IGF-1
alectinib-relapsed
0.612
thenrmlallelersion
5′‐GATTTGATGGAGTTGGACATGG‐3′
Ecl136
GGrG
elementsin
directionally
ARID1A-PIK3CA
ALV
.Calcusyn
Igf1
PCNA-containing
extra-cellular
/hsr
SETD2mut
0/22
V2038L
HELIC
p5350
Agne`s
patients,21
Thr336
E-TABM-857
Cyclin/CDKs
CharacteristicsNo
39K
DE13686
YY1–1429R
hypogammaglobulinemia
RMS559
ERCC3
hipoperfusion
Q61L.28
Glu408
Pro-34-*ArgPR20
factor-depletion
differentiation.22,23
b2m
121:4007–4015
CDK6-associated
donor-matched
.V-gaggcgaggtttgctggggtgaggca-3
Pst-1
5.17
3274
BioMartV
NCT02050919
G-CIMP−
EpoR36
209/269
Nonbonded
4526
2Ca
FV-300
c.782_783insTAT
vitro35
0–12
277300
120,000/mm3
polyps11
36:589–596
146.7,8
KITD1–D3–SCF
DDCT
.EGF/TGF-alpha
liposome/siRNA
0.85–0.94
twodaughters
aligner21
5′-ACCAGGAAACAGCTATGACCGGCACAGCCTCTATGGAGAACA-3′
NCI-H2110
E2624
OP95
0.7928
p110α–specific
1.86
75.8
NF1-mutant
XhoI-digested
SCC35/HN5
E54
2261.7
GEP
Ser467
Yes34
RT-
out-flipped
-dcov
CCR10
non–East
EPHB2WT-RFP
instructions.Stable
'WHOLE-EXOME
hexahistidine-tagged
Ulbright
tumor-related
β2C-β2D
PR=progesterone
RAML
issue8
QFQ-banded
Wingless/Wnt
.Altogether
process25
p=0.28
LAMA4
261–291
.MK410
+11443
3/SPOP
FRB
4081
pro-proliferation
LumiStar
IIC
M2-
G370R
19a
doi:10.1038/onc.2012.487
non–self-renewing
circumstance
1,400
doublecortin
pEFPlink.2
withIGHJ
0.078-0.666
Upstate/Millipore
VUmc.nl
RSV-TFAP2A
Glu659-Phe
A2101
hPMSI
C–CDK8/19
mMESSAGE
28/64
shEZH
μL/mL
C-terminal/PEST
G25
p38γ
TAGCCAGAGCCCTCTGCAA
Co-transfection
βPDGF
50Â
.Hafsia
.Asn-26
MEK2V215E
5B03
mutation,30
.Estrus
2738
205345
CCDC6-ROS1
V1589M
Gottfried
3´-RACE
AD0124
cells151
E235A
KB1PM1
A250V
ER-Hoxb8
UBE2N-STK15
Rameen
prospectively
heteroscedastic
phosphorylation.48
HS-40
Chou-Talalay
ZA-loop
Raf-GST
D231K
LMPP
transcriptionally-inactive
pEF6
E600
Fcalc|/ΣFobs
MYC-null
Carcinoma-
573
GEP-NETS
1.5–17.8
106–6
N581-mutant
Glomulin
VHIL
-actinin
S659P
.Serial
Gudjonsson
NORMALISED
treatment-associated
MED17
FGFR3TACC3positive
PLCγ1-dependent
V509A
Surface-density
Mirzaa
5Boehringer
S217L
casodex
wound-healing/scratch
HER2-L726F
.Cyclin
−933
GGGCCTTCAAAAACGAGATA
FPLC
—as
Agrawal
3pter-p23
5′-AAATAATCAGTGTGATTCGTGGAG-3′
9,12,45,46
3.425
II-5
microRNA-194
semi-selective
Shirasawa
H190R
L52A
hRARy
shP3
Rad21
35184
Tumeh
Velvety
pY31
.Arg205
truncation/deletion
sites,5
degradation.36,37
ggcag-3′
PLZF-RARA
.SOCS3
DPVB
99.79
0.274–0.699
LNCaP/AR-Luc
Bio-Serv
Streptavidin-coated
dose-limiting
compactin
BCAN
Y721
E27K
mutantforms
R972G
G1097D
proteins16–18
myoepithelial/basal
55–7
sourceTurn
royalty-free
LSAB+System-HRP
1978
.Cryosections
fluorescence-labeled
v-abl
2AHI
Caki
D61N/G
/HER2−
8:17
REs.20
ALK-overexpressing
Warpman
100–400
HS578t
T585M
anti-ETS2
Niedernhofer
pLNCX2
antiaurora1
TLN1
EB
break-prone
Tet1-WT_MA9
development.41
7l2AGTCTTCCCACCTACAGTA128
5′-AGTCGATCACCTGCCTCACT-3′
Hyp564
n=318
64C
Exon19-MLH1
FII
TEL–ABL2/ARG
MCNTNMSVSTEGAASTSQIPASEQETLVRPKPLLLKLLKSVGAQNDTYTMKEIIFYI
G1007R
target3,4,5
SRCT
Moshier
LGaGAFGKVveAt
L78A
CTATGCTAGCATGGAGCAAACCGAAGGCGTGAG
probein
Â°.Â°2
HDC143
Hyytinen
date.6
E349V
PSNNDLNTTEKRAAERHPEKYQGSSVSNLHVEPCGTNTHASSLQHENSSLLLTKDRMNVE
T319M
method.18
3-gabactosidase
94-3a
TM2
mesothelioma2
ZD1839
Ichimura
47.8–1.6
1B—source
ubiquitin‐dependent
pENTR/
HA-agarose
variants13
Omni2.5
46–49
kinase-fusion
telangiectasia-mutatedCHEK2-p53
non–insulin-dependent
0.9-721/nL
135651
FLT3-V592
carcinomas,42
NF723-
49,6
Aldosterone
Aslaug
39/56
Emx1
Cyr
Bcl-2-like
12:130–142.10.1158/1541-7786.MCR-13-0362
kilodaltons
17–25
129
retrovirus-blast
aminocaproyllphosphatidate
double-knockout
15149
KRAST74P
sulphate/
25,1994
TAD9
36/40
gtaataaag
G61E
multilobulated
-suppressing
S7C–D
AL929554
p.D404G
41.22
stabilization/activation
anti-FLT3/flk2
NotI–EcoRI
Subtype-specific
CTCCTGAGAGCATCTTTGAC
50-1200
NdeI-BamHI-digested
SCF-Skp2
JURKAT
X100-insoluble
C459
anti-pan-HLA
.STAT
Azaiz
D/CDK
c.1135_1136delCC
.PD4
PMF*
E0
//genetics.bwh.harvard.edu/pph2/index.shtml
blotanalysis
1–720
10487
levels18
inSmad4
5′-TGTAAAACGACGGCCAGT-3′
212delC
8.48
phosphyorylation
bladder60
RASGRP1
1.5RXT2
non-self-renewing
.EST14
1Y641C
KmDNAby
Figure6a6a
1466A
α‐helix
F237S
denaturingpolyacrylamidc
7.8
Cys236Arg
Ras/Raf/ERK
CRL-2067
21-exon
regulome
authorChemical
P≪0.001
His297
1-thio-β-d-galactopyranoside
sunitinib-sensitive
//www.ensembl.org/info/docs/tools/vep/
genes.22
HN-K-rasG12D
Yergeau
ALK-nonmutated
.DNA‐binding
1/RAC
kDa-sized
domain.4,5
3,42
doughnut
350–400
TM4SF1
F394
ctgccagctccacaagtctc
H3K4me3-activating
tri-t-butyl
radioimmunoassays
objectionable
Mutation–
pDV46
gp140Prot*'rk
membrane-impermeant
dioxygenase
anti-EGFR–TKIs
deacetylatation
studies.18,19
.Mgat5-deficient
field.6–8,33
RERF-LC
located.19
I1137fs
RMC20C041
1.4–7.8
F–H
Rosen-Arbesfeld
//mendel.standofrd.edu/SidowLab/
GUC
S178S
.TE-1
-FAM76A
CSAG2
100–1.5
.Exon9
1,295,250
en-bloc
Asn676
p56lck
Sonifer
Odajima
tmslices
ROCK-I/II
3.62+0.08
broken-line
coils25
accumulate39
b-raf
.Morrissey
25-mg
dolichol-pp-oligosaccharide
assay.ResultsLack
CCGGCCATCATCAATCAGTGTGTATCTCGAGATACACACTGATTGATGATGGTTTTT
methylationsensitive
sex-related
vector.15,19,20
EML4/ALK
116/324
Sphn
Pa.
.Oncogenes
5′-GGATAGCTATACTGACAACATTCA-3′
BJA-B
jLXg
Progression-Free
12.5–E14.5
f.e.
reviewed.109
Tefferi
1–115
inter-chromosomal
Muhandiran
R895C
multiplexing19
12Department
r=0.75
7.27
former-smokers
β-catenin.26
anti-phospho-Akt
syndromes.4
ung-
1–982
35/99
LSL-Idh1R132H
phospho-SP
inhibitors.17
microanatomic
tattcttag
3H20
2-way
L193F
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F2.medium.gif
p=0.0231
PMS2–MLH1
μmol/L.28
W189
chain–restricted
GRIN3A
SDH-deficient
AlignX
MUC6-MS5
J.A.H
Pruhova
S'-gccgccccctgagctgtgtgtccttagcgccccacGTATATGGTGATGGA..
oxaliplatin-
5/60
:4
V–stable
Erasme
24,35
expression/overexpression
A66
sc-8332
al81
MAPK2
FDG
tolerated.12,13
SYT1
achondroplasia.20,22
Schally99
andother
Renilla-Smad3
47-84
quence
N1026S
Insti
p16INK4A-CDK4
L401H
al,33
16-yr-old
3.5-mmol/l
–40.8
~Schlichting
185KC
ets-responsive
54.0
HyP564
cdc53
ICAD
5'ATGGCTGCC3
Missense/nonsense
strongestdominant
Egrl
HA-XPF
18.01
P27KIP1
low/low/intermediate
100-base-pairs
Primer-Express
muskelin
EU32
analysis14
84.4∗
:73–80
Immunoprecipitaton
0–10/tumor
pASZ11GPD-TRX1
6276
maleimide
1950–1960
.S1655F
T-REx™-293
3940
MSCV-puromycin
pocket200
14-3-3/QRSTpSTPNVH-COOH
Magabace
1c–f
35/38
cancer—in
expression1
Tm-RNase
Wrst
D1-null
3Q4C
P-GSK-3β
pFLAG-BAP1-His6
longer-term
3.035
Semenza
SPAP1
p16-mediated
.PS-341
HER‐2‐mutantions
1614121086420
rs2008535
RM4-5
S370A
VTT
C140S
.Serum
offraction
R1231
-40.8
anti-HIV
6919
353–355
migration.22
0.81–2.65
E972G
PARP1/2
criteria\
5′-TGTAAAACGACGGCCAGTGGTACTGGTGGAGTATTTGATAGTG-3′
Thederived
phosphor-Ser136
R583L
MT-520
/CBFA2
MasterCycler
ligand.3
phospho-Akt-T308
Sixty-three
months17
Receptor293T
22–45
HSC-based
MPL-W515L/K-expressing
prescence
donkey-anti-mouse
JAK-STAT-activating
15-235
=97.0
Brca1FH-I26A/FH-I26A
MES
IL-34
Doublestranded
RA-responsive
1.5G0.5
cardio-faciocutaneous
CD34+CD41+
c.508C
Mini-gene
3-5-2-4
6w
FGFR1K_N546K
pPDK1Ser241
issues.IntroductionPreinvasive
HLA-A*0232N
≤5•0×upper
1Progeny
NeutrAvidin
tgggaaca
R1-TSC1.3
∼75.5
Takafugu
Pymar
6,8
056
133.3
.Conditionality
NM_002078
1.6-mm
interventional
H4K44
.Aim
exon-2–7-deleted
Horev
Dlx5
pipeline74
HPAC
rhodamine-phallodin
PIK3CA,35
anti-HER2/new
T156I
stillbirths
EPD6
pipeline30,31
feature—one
501fs
14–28
995
switch.
Mid-Career
5'-CTTCAGCGA
TP53-DNA
PRC2-regulated
.004*
Q2072R
SW1116
ΔFizzy-FZR1
printTipLoess
A*02:01:14Q
kdGSK
S646P
temperatureof
ESR1-CCDC170
P133R
.9-
f/60
BACH1.10
p38IVERK2
2R4AS
5.47
c1712G
TI-catalytic
cyanine-5
D19S814
Smad4C
.End-point
analysis—
LapatinibGiven
Daehak-ro
​Exogenously
pEGFP-BAF180r-M538I
hERβ
−748
5AGATAGGCCAATGTTGGTCG-
iss=14
p.M1775R
spectra15
I672
Δ557
GGATCCAGCATGGGTTGAC
PLX4032-kinase
100.3
NM_009524
Weri1
Breitling
E1586G
Newcastle-Ottawa
mastocytosis.18
phosphorylation.10
182–184
G5789
346–510
.EglN1
noncontact-inhibited
0887-6924/06
1648C
Mexicano
Thr309
fsX159
water-
p.Met622Ilef
Runx1-deficient
0.200
Hsp70-dependent
methionine-18
Ea12
bisacrylamide
°C
plasmid-encoding
high-expression
hypoparathyroidism3
OD405
TEADs46
HA-pVHL
adenocarci
myc-L225LI
c-Jun/c-Fos
FGF8b-soaked
raf1
defined.18
.Compartment
homopolymer-like
111,029
1:160
R656
Kriwacki8
leukocyte-restricted
protein.18
platedat
2436
P=0.01842
Non-immune
TKD-expressing
pStat3
ligand-directed
anti-CD4–PE
W257G-enhanced
fromreporters
BC14,41
RSV-lacZas
Brca2F11/+/p53F2-10/F2-10
1-161
59-ACAATACCGCCATCGCTTAC-39
*G12D
Figure8A
nihms646437t17
FIP1L1-PDGFRalpha22
Formalin-fixed
CCL3
NM_019521
DSMZ*
14-3-3sigma
resistant32,33
different,17
GDP-locked
slow-diffusing
699
α35S-dATP
p-PLCγ1
11B3flox
T292
SPOP-induced
HLA-B*39
estrogen-response-element-driven
anti-phosphorylated
N′-
L403F
Cys47Tyr
AnalysisNo
c.1687C
series.28,30,31
Politi
disorganization
PPP1R1B
MCSP1
self-organizing
.225
Leu3Gln
mtSPOP
sc-32643
predictprotein
YAP-mediated
90-mer
p53—We
1.722
proteins.View
NEK4
CACCTCATCCTAACACATTTCAAG
IKZF1-d
seuquence
BRAFwt.14,34
AFF
G115D
.F876L-Encoding
ABI/Ambion
nt1624
depict
.Bead-coated
./-cdk4
G485
Genescan
aneuploidisation
CR/alive
ggGGI'7
1,443
4-16
lymphokine
hFL
-AGAGAGAAGACGGGGATGGT-
82.1–98.6
literature.8,10,12
.Chk21/hcds1
787_790del
www.sbg.bio.ic.ac.uk/phyrew/
immunoglobulin-MYC
c.5154G
cis-inhibited
002890.1
GTP/GDP-loading
Phe-87
monitoring.4
Database23
second-/third-line
LRBA
q31-35
Finland.28
ErbB2-overexpressing
HMCL
D.G.V
2365
Phenix/AutoSol
120-minute
Pro57,17this
SWISS-MODEL27
8p23.3
syndrome.33
res-
site.19–21,45
Drosoph
mechanisms—underlying
Fig.1D.1D
Iritani
Fug-I/7
73-131
sc-81053
penetration.13
H2405
geftinib/erlotinib
MLK3/MKK7/JNK
V246L
D283Med
MM9
patho-
c.1174C
〈I〉|/∑
XP-1
genotype.Blood
AmberTools
μg/10
Ala-73
oncogene-were
AGGCGTTTGCATAAATGGTGCTT
AGGF1–RAF1
transplacental
activity53,54
−.66
82-fold
GGATCCTAATACGACTCACTATAGGGAGACCACCATGGACAAGCAGATGAAGAAATTCAAA
HK2
cytostasis
Pro81Thr
maf
0.407241037
2-mercaptoethanesulfonic
8G7G3
S3D–S3E
lapatinib-treated
slideStrong
LM-PCR914
d–g
BRSK2
VÂ
IIIB/stage
22–23
SPR
diaminobenzidine
6525
A_51_P479865
WHAT_CHECK
68353814
olivopontocerebellar
CGGA_1285
V617FJAK2-negative
G245A
poly-adenylation
2795–2830
TITF
ε-N-acetylation
sarcomas15
Fig.2a
.Copyright
interaction.161BCL10
AxioVert
pUAS-luc
intra-residue
reduction*
0.002788007
CAAGCTTCTGGAGGGTGAG
Plasmids—Plasmid
5′-GGATAAAGGAAGAGATTGCAC-3′
GODL
V1173L
Val3Ala
D3S1580
mutations—be
Thermoplasma
p18
pcBTAK7
SP10
NEBL
pGL4.26
M743T
NIH-approved
SH3p8
pSer-473-Akt
SAOS-2
c.472C
D1813
N235D
Figure3b,3b
Phe-899
.6b
ROS-
Kurumatani
anti-Src
reversed-phase
A404T
apposite
BDT
37Â°C.After
s/55°C
M855T
CEP19
Vogelstein.1
E-Cdk
hsp104-GFP
e10
pMSCVneo
Tikhomirov
RBF/dE2F
607001
pGL3-promoter-50
DDR1
3,4,5,6,7,14,18
56.8-fold
1–28
mTOR/Raptor
TBST
myopathies
TGGA
product:14-3-3
2003–2013
53-induced
RG-15N
​Table11
hexosamine-dependent
Radio-Immunoprecipitation
1836
pCDH-CMV-MCS-EF1-copGFP
2−7.6FAM113BHypothetical
Micro-BCA
PDBID:3Q2V
biopsy-associated
BS-1497R
SF3B1-mutated
nephropathy.37
CCGTGAAGTTGGAGAAGGTG
PR61/B′γ1
carboxylic
PolyPhen31
YKNDYYR
J.R.C
media24
hydro-phobic
S5P
premicrodissection
SOX9-dependent
Flice
R.-Y
L43
p.V889M
60·4
.NIH/3T3
identical-by-descent
H3-K42me2-specific
sc33044
L287
SNUDH
positive-contrast
C57BL/6JTg
ARafDD6KCAAX
RG-7
cytokeratin-19
22+*
SO4
SAMtools38
demonstratedby
human–rodent
Tel/PDGFRβ-
gacactggcaaaacaatgca
calretinin
L827P
Olaparib
S4A–S4H
0.967
Serum-
IRdye700
33,34,52,53
12.9×109
DoHH2
8672D115nt
CD25−
.Germline
Brg1.23
anti-Delta
gene.14
HA-tags
otherNTRK1-activating
serine–threonine
5-year
fragmentations
tained
38/45.2
MciMb
lymphocytes.10⇓–12
p.Glu275fs
EGFP-transduced
105
K650Q
disease.20
Glivec™
cyclosporine
irresolvable
Gly-Glu-Gly-Ala-Phe-Gly
+IFNγ
BE563742
F367S
RAP1
CRL3s—varies
R120W
1.539
Holmes-Gang
G434R
GGCAGGTCCCGTCAGAAGAGAT
MET-M1192I
V843I-3T3
.SFKs
HIF1/ARNT
MIR143-NOTCH
lines111
I204
-D17S1327
2006.08
rs17290005
10–99
u0
0.894
polysome-bound
TTAGAAGTGAATATTCCTTCCA
R280A
CPPTRAJ
phosphorylation–dephosphorylation
21.7±5.6
conditions16
X105
PLCɛRA2
response,17
//jmd.amjpathol.org
areas.26
3-'ERG
stainingpattern
LXR
C-X-C
bisphosphotyrosine
I448V—as
0.573
Plphosphate
profiles35
PI3K-Akt-S6k–signaling
MycN-amplified
5.3.4
CRC334
ΔΔH
ACC-Associated
fast-acting
deoxyribonuclease
c.6709C
phosphatase/exonuclease
dolichocilia
l0.05
IgD−CD38−
'ERK1
ciliochoroidal
1.813
pRLSV40
principal-component
UAS-reporter
splicing*
D-boxes
µ.g
ONLUS
MYC/
.Symbols
.STARTRK
Tyr71
147
agents187
PDGFRA-WT
10ZFΔPR-HA
B.E
H479Q
Muruoka
Arg841
Ohh
Zambia81
c.2313_2324dup
PI3K–p110β
1,363
.FGFR4-V550E
ETS/RUNX
CDK12-3
βI/II
Gen-Pak
vitro.7,40,41
loop/B8
EBNA2-regulated
R841Q
D1246N
M-sense
-disease
EGFR,22
.SiHa
Mac1-allophycocyanin
21:1839–1841
33147
G12.2A
PXLXXVIXXFVXFQ
708
PTENK289E
.Cisplatin
p.Gly44Ala
175Gln
prognostication71
Y719
One-half
NS597
Trovó
I87syn
18/44
betaP1-betaF
expressingelevated
antipVHL
.TGF-β1
Jieya
F/V/Y
.Insert
PKB-W80A
CRO11-vcMMAE
bpinside
Fip1-like
Jenssen
K554N
DS151028
-producing
reported37–39
.CHK2
F340S
.Carboxyl
Kontes
ofMyoD-Max
PLCLB
JAK/STAT3
NEUROBLASTOMA
23,9
HP1-α
1372
R1192Q
3-pyridinyl
TRCN0000026216
Sexl
R418W
parent-to-child
TCF-binding
4DGP
subtype3,4,77
CDK1/CCNB
BRCA2Personal
Josefsen
silico-predicted
MENDEL33
AITL
pCS2keap1
Phe876
I1151
plog-rank
40-ml
RAS-MAPK-related
pMSCV-IresGFP
TBE
CSNK1E9
reduction-sensitive
5q33–34
Wienholz
n=12
SETX
17.1
Ad-LATS1-transdcued
Scappaticci
Paraná
KIAA1549–BRAF
NMTR.In
G323fs
NRAS-2-F
criteria.12CUD
RB1-spacer
BRCA1-BRCT
2–3°
5′-distal
γ-Irradiation
pan-antiphosphotyrosine
alemtuzumab
imunofluorescence
/EC50
61170
OSI-906
.Antibody-blocking
T284S
UMR146-Institut
N104
c.5908C
c-Myc-mediated
G1/Ccng1
neo-p
PLIN3-BRAF
SuperScriptase
.Multiple-tissue
26/43
G2251A
JB-6
sensitivity,32
disease.32
.CRAL
3160
hydrolysis-inactive
numberin
allnine
ENST00000368488
CCCGCGCCGC
D1052
CtBP
SRH
PPARγ-dependent
129/OLA-derived
SCF-FBW7
Loci
SaOS-2
Adeno-X
phospho-histone-H3
S2B
CARD-truncation
IRTKS
MPCsEWS-FLI-1-
JmjC-domain
TMEM43
V617F-positive
BTBD1
.000
CAF20
12–
MICROSONTM
co-worker
lyz
coli,27
NM_004973.2
42-
cullin5
Wolfel
Srsf2P95H/+
.1252
HG-SOC
tumor-normal
0-2.40E+03aCGH
tissues25
Hepatocarcinogenesis
Tl
ab2851
12-lead
VHL-
R100
611060
apoptosis.16
CK5-positive
LL6
cg02919422
Affi-prep
TÃŸR-ll
S592
MYC23
BP100-GL2
R693Q
G279S
EHA
7FDRs+8BDs/106
neoplastic-like
terl301
5′-GAGGAAAGGTCGCCTGGTGGATCG-3′
18,000
-v
US/Intergroup
FITC-conjugated
r16
CD3/CD28
RTK/RAS/RAF
53.9
aromatic/aliphatic
PflM
NL20
over/under-representation
intratumor
acetyl-K120-p53
activity34
subjectsa
.Chips
solutes
p53-acetyltransferase
cbt-15-768-g1
//www.xlab.unimo.it/GA_CDF/
R299W
c.2192_2196delTAACT
activation.70
S1722P/N1774Y
screen.103
5648
CS4
isogenically
4g
14,000
e14a3
byusing
10-µl
K25fs
Shp2E76K-evoked
base–40
Przybylski
Cthrough
.Experimental
ligands24,25
Urfer
RAS-RAF-MAPK
gene—cells
1507GG→CT
10–70
4/31
0.828
Gagos
single-anomalous-dispersion
–19.8
5′-GGCCAGGATAGAGCCACCAATCCAC-3′
C51Y
Dmp1
gene—occurs
7Centre
9571
51,52
kinases10,11
NTRK1
DU145
310-318
CHK1/2
msh2-GD693–VD862p
13C2D2
NM_005228
~Barshop
self-complementary
1,395
NMTC
activation-segment
no-novel-indels
14,22,23
RE8
L4F
rate30
29a
Pin1-knockdown
Cytology
.Twin
Om6hn
ARID1B
180–220
Bohlander
marray
Phospho-MEK1
S7F
rs748780
10411
primer/0.09
0.837
.Rad54
CDK1–10
consensusbinding
anatomoclinical
MMTV-directed
5′-AGCCCACCTCCGCTTCCG-3′
-7-
-O
described26
end-labled
mutations35
sc-2954
.PAX8/PPARγ
fibromuscular
FGFR-family
Cys1129
term170
EGF
41.52
followedan
5,394
Autoflex
desmoplakin
T49.2
'selective
.C57BL6
enzyme12,13
lines.26
21These
α-Fbxw7+p16
E2A-PBX1b
inhibitor-PD98059
inter-specific
K2717
previously.48
MLL-PTD.1⇓–3
0.93
DABCO
CFCS
EIF2S3
206956
-32D
B280
theATP-
Dox-inducible
mutationsof
11â
LAVVTVKS
N1–N4
rsb.info.nih.gov/nih-image/Default.html
finger30
e3932
2381T
virus-induced
ETV6–PDGFRβ
17.53
364-371
eye-
.CYCLIN
p.Y16X
far-right-hand
0.854
UC143
scorable
BNGH42007798−8.1KRT15Keratin
.TD2
sclerosis7
WM793TR
HA–GLUT4
exome-based
.0096
z-sections
algorithm32
3f
992–998
p-Mek
non–self-renewal
c.76_91del16insG
.Receptor-ligand
caspase-8a
Tabak
sites/418
v-Ki-Ras
werearising
p.P2515Rfs
Arg420Del
isothiocyanate-labeled
KP372
K64M
MYC-binding
Ph-positive
HA-G
rabaptin-5/
Conclusions—The
cc-13-834-g3
acttctgcTTCTGcctatttt
fine-mapping
researchers1
hIL7R_BbsI
Tuscon
0.21–1.16
development121,122
SuFu
ETS/TCF
R-18
p21WAF
28Oh
Trp53loxP/loxP
.Diffuse
multipotential
BRD-fused
De-glycosylation
5′-GGAGTTTGAGGTTTTTGCTG-3′
HA-Cbl
51–56
.Absolute
H254Y
Arg24Gln
Af9-specific
PC12/MEN2Bcl.7
.Wimmer
analysesAll
10cM
NM_001012331.1
self-identified
NCI-H592
Gaspari
pmol/mg
Triosil
Hs01057775_m1
Multicellular
DIPSI
Arani
sulfate.One-tenth
3G0F
kallikrein-2
CDK8
pathogenesis.7,8,111
Brain-derived
86-516-85601527
Nup133
PC10
Pax5
C275G
CCA-3
ERK-driven
co-migrating
0.24-0.86
sclerae
Naski
ApcMin
TK−
4940
548-585
hg19
//www.fda.gov
bromo-
Letrozole
G361E
0.0086
Multiple-Case
10•1
CAGAACAGGATCTCAATTCT
CAMK2b
96MA
†7
5'-CGUCAGCGGGGCTCTCA-3
open-access
Loss-of-heterozygosity
Dominguez-Sola
c-myc.56
Immobilon-membrane
underexpressed
o10
5AA9
0.046
TLSIFUS-ERG
0-3
pcDNA3.1/myc-His
ab5452
Ribozyme
patients,85
IDMEM
FV10i
controlvector
+5.8
ETV6-RT
Ki-1
L1659F
1:51
INCa-DGOS-4654
Mauviel
carcinoma.27
GXGXΦG
c.*19T
PTPLB
0/250
V804M/L
superﬁcial
2611
www.ncbi.nlm.nih.gov/gorf/gorf.html
sensitivity11
Log-transformed
A1702P
MS1081P1
www.ccrcal.org/Vol_1/BloomRichardsonGradeForBreastCancer_CA.htm
−0.98
vorinostat
employability
lexAop
K63A
data.32
representatively
.High-dose
promoter/luciferase
high-stringency
Fig.7F
5′-GTCGCTATCAAGGAACCAACATCTCCGAAA-3′
R.d.B
NTA-agarose
tumor-relevant
.seems
5′-GGGCCTAGGAAAGACTCTTCAAACAA
rates.75
.6766164
Q334R
AAAATCTGGGCTCTCACG
A714V
8/3/2/0/3zSmall
6–7.8
glucose-6-phosphate
1.01–2.29
aGerminoma
10.1002/humu.10299
K279
microinvasive
R366Q
IFN-
5-1
Devitt
pone.0064364.e013.jpg
6.740112125
10.1007/s10555-008-9126-y
RaceWhite
1mCi
SNU1-1040
Fridlyand
Mll1f/f+
NCT01484041
p38α-MAPK
studies.11
59-GTTCACCTTGTATGTAGCGAA-39
r-project.org
FGF-signaling
p2l1
Rho‐GAPs
AfatinibAdenocarcinomaMutation
cells/mL
D1/cyclin-dependent
histology
Indo
LOUCY
Tyr-553–Ile-563
skin10
erlotinib-binding
SETD2-dependent
mMyb-Forward
Bfa
Y234H
pathway.2
GGATAAAGGAAGAGATTGCAC
Orthovanadate
11°
protein-changing
NR4A3-Luc
custom-made
NPM-MLF1
vesicle18
TCGA-ER-A19S
reports.12
pZNa,2-wt
M766_A767insAI
TGFBR2-null
qin
rs1983891
.Half
–58
G692V
II/III
pathway.17
T97
M-013859–00
961
.Anti-IL-3/IL-5/GM-CSFR
5′-CTGCAGAATTCGCCCTTATGACTGA-3′
Marincola
-TRAP230
histology.23-26
g005
aminotransferase
heterooligomerization
CDK6K43M
96-bp32P-labeled
VHL-positive
Ras-RAF-MAPK
cytotrophoblasts
E37K
W290G
BCOR.1
.Eph4
OWBCs
Chaperonins
Figure5B5B
IL10
ATRA.3
Pre-B
ultrasensitivity
IFP
Nitrocel­
TrueSNP
Immunofluoresence
MasterPLUS
ALL7/8
resection.35
his3/eu2
p=0.15
Arg305Trp
TβRI/Alk5
AAA-AAG
Notch-ICN
Smad3DC
F-box-motif
2006
TdmA
,4C
,0.0001g
16.7
Noren
RET/
GFAP-negative
SB203580-treated
10,33
carcinoma18
p21-/-
3T3-EGFRΔ768
bacto-agar
FLT3-F594L-expressing
.0059a
23:111^116
karyotype,3
death/last
rentinal
Apo-BrdU
A+
ATCCTCAGACTCCTGGGTTT-3′
NHPP
well-performing
38,52
Serine/threonine
apocytochrome
3-5-4-4
section,18
.TrkA
34.7PCDH18Protocadherin
cDNA-SSCP
drug101
Hh-specific
cell-signaling
MgSO4·7H2O
IgG-FITC
100-ng
cancer108
antiNTRK1
CMV-His6
.46
−27
Fbw7beta
lulose
dihydrodiol
A-inhibitory
20/41
SPE
anti-CD15–PE
spt6-1004
.Microdissection
9,19,38,39
trp1-1
rs121913432
afatinib
HA‐specific
5′-GAC
selected.14
COSM123991
.Cord
G418-FIAU
3-turn
5-CTGTCATTCAGTACTCCTGGATGGGGCTCATGGTGTTTG-3
2.1.3
HCC—targets
KHCO3
58-ACAACCCTTTCGAGTTCAA-3
α-satellite
pSP64
NPLOC4
MITF
F136
ABI-prism
19-residue
38–95
under-sampled
0.244/0.095
stable/progressive
low-protein
U/
9-R
phycoerythrin–conjugated
4.86
hepatoblast
30°C
1Internal
.13A
pY1086
cancers.63
cost-efficient
1=point
-resistant
deactivation.12
4ºC
AT-hooks
tumour-free
1–347
CTAAAG/gtaacg
t3
10.1182/blood-2010-01-264432
//www.few.vu.nl/∼vumarray/
chemotherapy-naïve
*These
lip/palate
Fbw2
inmetastatic
4×102
0.3-19.0
Ini1-heterozygous
226.9
Chk2-BRCA1
10.1309/AJCPUIDW2CPTA1JA
Fukagawa
WebPDA
cytochrome-c-releasing
CTCCCTCCCTGAAGACTGTG
Pam2
interactiondefect
0.492-2.162
Criterion-XT
Kazuya
NCT01218477
226*
b.j
platinum–taxane
-11-dUTP
elsewhere,9
hydroxylase
msh2-D6p–Msh6p
Oncomatrix
.Fifty-two
70–80
months.2-5
D31A
Navigator™
10*
hexosamine/N-glycan
Wisoff
slideVarious
miR-106b∼25
HEK
Glu600
3927_3931delAAAGA
tggcagGT
L458X
URA32mm
p21ras–GAP–GDP–AlF3
5/14
cells.16
RP11-482I10
LOC404266
Pharmacie
I395T
FGFR2-Amplified
Ambiente
PLCPRF5
α-H3K4me3
60-fold14
Assays—HEK293
5′-GCAAGTCTTTCAGTCCTGT
12,988
0.288
K175_D176del
dshort
PPHLN
anti-FLT3-
G71D
methylation-associated
employedprimers
FLAG-INPP4A
Grzeschiczek
G162S
repairosome
c.1790
.Localization
MLL-7S/p300-7.5A
post-depletion
c.1786_1788delAAT
14.2–27
BCAT-R:5
TAP1/pGL3
CycD–RBF
p.Leu1908ArgfsX2
Clone1
5054
TAATCCC-3′
0−150
SIGMA-Aldrich
Figure33F
.23,25,26
Follicle
C345R
Asp1213GlyfsX2
5′GCTGAGGATGCCACAATACACACTGCCCGC-3′
multilobated
ab110641
binding/stimulation
MGH-P0-
?
Forsberg
gtcccactgctattctccatcac
irreplaceable
Biotecx
CiSBC2
cytogeneticist
Gly-Ala-Pro
U981
Quantitect
.4736
V194D
MCF-7-fgf-4
Megaencephaly-CApillary
Pair-wised
122x
N-terminus6
RPMI-
APC/CCDC20
so-
S-4
106/100-mm-diameter
p21p22
NM_003902.3
protein-derived
.HPB-ALL
.Ala-1708
pathway27
ESR-Y537N
GAK
ÃŸ-sheets
.-'~ManitobaN
191100
0.4233
pMMP-FAA
Myc+Ras
differentiation.6
5′-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGTGCCTCTATTGTTGGATCATATTCGT-
cytarabine
351KB
AGGTCAcagTGACCT
ABI-PRISM
XDYyn
5′RACE
Eyfp-positive
type.a
CBFb
.A1279G
phospho-group
ATTTAG/gtaatg
Richelda
water/3
Mb–D18S474–0.01
ISer
B610
Met449
substrates/oncogenic
.ASD/DD
metallothionein–mutant
phenol-based
TC118209
GGCCTTGTTCCTCCTCTGAT
non-patient
decomposition
CP-D816
TBK1-transfected
//cancer.sanger.ac.uk/cancergenome/projects/cosmic
LRRC47
.Numbers
663X
Exomic
2Ga
L348A/L350A
2/11
.343C
51OATGCTATGTITFCATAGGAACC168
.Two-side
L65F
13936
74–77
A25V
consequences.3
NELF
K7–8R
ERBB3/ERBB2
Splice_Site
Sadovnik
activity.12,29
293s
L437P
analysis3
INPPL1
Oy
−3.16
G379V
nitrogen.8
Snf2-ATP
G386V
non-tumor
p.Lys302Thr
α-Chk1
E542E
Fuhrman-grade
PLEXHA
lymphoma,8
1114
TRNC18
hematopoiesis.14
.EMBO
JIH
W557T
disease.5-7
TNS3–DLC1
maculatus
p-Stat-3Tyr705
colleagues45
transcription-PCR.EGFR
D816G
Cdh1-activated
Anti-SHP2
DIF-dependent
GAGGAAGTCGGTGAAGAACG
gaunosine
VEGFR-2-mediated
receptors.37,38
phenotype7
leukemias.53
n=29/41
ILeuArgTrpLouGIn
HOC-605
843IM
protease-mediated
.Proteases
2708C
kinase-enhancing
ChIP-quality
CCND1-mutated
19
E21X
NCT01584648
nilotinib.14
−e
development80
.Thirteen
oop
RAF1-partnered
fusion7,18,19,20
FELDG
mPIN.Figure
Fbw7-WT
c.177-2A
CD34-purified
L758
Sian
chromosome/chromatid
1173K1
RARa
20-base
ERBB2-amplicon
hematopoietic
83-sheet
clonal-subclonal
5-phosphatase-1
Pmutj
N-RASG12D
antigen-mediated
5106
α-catenin
:..
SMO-dependent
HIP1/PDGFbR
Ig-Bcl
BRAFV600E/PTENWT
ATC-3'J
926B9
Apoptosis-inducing
TKT
RS4
pemetrexed,5
LB‐Amp
c.721T4G
06/Q0605/69
fusion+
18/57
25/227
Mel-26
nanoparticle
lincscloud
Lgr5+ve
ΔNLS
leukemias.64,65
MOZ-3977
INI119
18541
0.332
EcoRI-fragments
crossresistance
8.Download
www.gdb.org
10−07
XP23OS
left-shift
3LCK
therapy.21
PCRc
-~=
.Attard
inactivator
re¯ect
HindlIl
26951
RNA-processing
10/22
medium-F12
1252–1256
ZDHHC14
TGFβ/BMP
and77
ERK1Y148/ERK2Y131
selectiveminimal
6787
Hybond-N
.Co-immunoprecipitation
RAS-MEK-ERK
techniques.29,48,49
drug2
L272F
318X
late-generation
paralogons
GNAI1
K1124
17-month-old
NCT00687622
Yuzawa
.Site-directedmutagenesiswas
3467±180.7
Cul3-
H3K4me3-modified
D1S2660
LUAD
5′-position
MacKtype
RICTOR
NrasG12Dhypo
Trp557
rest.23
.Ago2
.Granulosa
E138K
CAGGAAACAGCTATGACCGTTTATTAGATCATAATGTT
.S6K
BLC3
trans-element
NPL
development.16
nonregulated
KSE-1
13.47
.Myc-Tet2
P1085R
Tam
front–rear-polarized
Figure7
GC-dependent
software,6
average±s.d
1SNU
Ala/Thr
BAT3
andstimulate
phosphorylation-specific
pazopanib
Ono
Caddi53
dabrafenib–trametinib
p.P286
CRC23–25
BRIP1-positive
//dnanexus.com
P30-
wild-type–amplified
Universilario
0041-61-265-3194
M216
1.0.126
2·5
cadherin-binding
5′-AAGTGTGACGTTGACATCCG-3′
fuse
NCOR/SMRT
Andegeko
topoisomerase-1
Integrin-mediated
Mazot
A_52_P672803
5′-CCATGTGATCATCACACTGCTGGACTATAAATGC-3′
T3/T7
cohort.The
JNK-JUN
GSE3774535
BL14.1
his7
L/GCMN
hypoxia-enhanced
abluminal
proparacaine
8086
0.85–2.21
Pro-rich
transfomation
codon–altered
c.192_194dup
ErbBs—Myc/hexahistidine-tagged
MYC7
SOCS-dependently
PEconjugated
dioleoylphosphatidylserine
E.T
E1500
Kappa=0.729
cytokinesis30
hemEC
t-statistic
12R
/HCl
EcoRI/EcoNI
p.E17K
SPRI
helicases
p95/Nbs1
R272fsdelGC
identified150
p.Leu107Ile
24.03
E738-K721
Tyr16
RECIST.12
ficlatuzumab
Gottingen
5'-CGGGGATTAGCCAGAGAAT-3
CTC-286C20
GBCAs
.HIV
V238E
C809
creonolanib
CKIP-1
5.87
Roulston
84P
TaiI
betabeta
I120V
telomerase/TERT-related
c.572G4T
HGF-driven
FACS-sorted
MMSET/WHSC1
ug/mL
TP53-associated
hER-pALTER1
0.0043
WST-1were
.114
PRIMA-1
.Drug-related
transconjugants
interclonal
cause–effect
Phenyl
patients.Advanced
centromeric
insoluble
ezrinR40L/T567D
p21Cip1/WAF1
2UZS
wwPDB
n=597
lysine-CoA
p.Asp231Asp
921SINPPC926
EGFR-A289V
TGCATATTAGTGGACAGCAC
K381
8a–e
3-flanking
5V-cacccacccctcccaacacc-3V
187,000
PAX8/PPARγ
Jenster
YO-PRO-1
twofold-increased
R435Q
IGλ
WT-ERα–transfected
Y261A
9347
55/f
RAD54B
anearly
post-replicational
TβR
c.5291T
4H-I
S17N/E63K
EWS–CHOP
p.Furthermore
DeRose
R334T
Gellner
c.5077_5080del4ins10
thesedata
0.11–0.65
pAcGFP1-N1
anti-j
000007.12
A388P
base-base
DHEA-sulfate
Wrn
22–25
614165
56-66
3H-acetyl-CoA
EcoRI-EcoRV
.ARAF1
64550–64772
phospho-p53
Actino
D595-K592
sVEGFR2
average2
Hs01952025
.26-28
receptor30,31
protein.7,10
.Specific
TMD
Cercopithecus
50/M
6.1-fold
theMsh2p-Msh6p
gland-free
SF3B1MUT-incorporated
1586
antiactin
A127S
0.85–1.36
.D595
CD10−
Gnathostomata
2nM
E545I
83.03
acceptor-site
1997–1999.17
p.Leu1351X
NRARP
LGR5−ve
LR09-216
Hypermutable
IκBα/IκBβ
2Ed
c-Cbl-deficient
CCATGTC
P497
ALKR1275Q
c.2652_2665þ111del125
sulfonate.After
dehydrogenase117
BuesoRamos
trials47
mg/body
Hs00154109_m1
Rnor
SRαF876L
L460
Bead-bound
p.D1894fs
43.2
.Horseradish-peroxidase-conjugated
Tris-HCl
HA-p85
PDGFR-α
13/82
dominate-negative
noncompliance
LOC388588
RT-PCT
Phospho-/total
GISTdevelop
302–
B–E
PPL
Tallen
R912P
anti-PGDF-B
G226
D-binding
non-germline
PTCLs
2472C
16–188
CCTAGTGTCCAATTCTGACG
uAIiInAIaProProVaIt9b.uAssV.ILeuGIy
.38
I1171T/N/S/H
.00307
BAT-Ru
quantifiedafter
MCF10A-derived
mono-ubiquitinylation
FBXO1150
γgcsh
breakpoint-flanking
F4/80-positive
IDH2Mutant–EGFP
22q13.33
V963M
CD2-Gata3/FVB
.Pten-deficient
nonocclusive
PTEN_F
000489.3
SMHC5
C1561Y
1647
proteinsThe
reversetranscription
×10e5
PMIG
AJ006289
GR150
phosphorylate
1-mm-thick
NUGC3
ITX
500-base-pair
IgA-positive
Tumorgrafts
Tet1-KO_MA9
Non-smoker
www.sigmaal
S1803Y
MBs/PNETs
domain–truncating
residues—F53S
D1074A
lReverse
5.8-kb
AC007504
individualise
Sox17-pcDNA6
3insT
IDH2R172K
2Oqhl-13.2
cosequenced
MRI
OTU
types,2,3
GDS
Fast/FoxH1
align2rawsignal
nick-translated
BRAFV600E/T529N
vesicles.18
Lys79
loci24/6
.CBF
MagExtractor
Msh6RH
SGT1
post-coitum
5-Aza-deoxy-cytidine
26gel
.PIK3CAH1047R
fusions—across
3460delAA
∼0.03
MDS_260
-0.112
P110β
LaBaer
pTyr1068
Lu6
NTKR3
V600E/L505H
ofcells
unblinding
pG5CAT
al.97
.SEL-10
Nf1+1-
dierentiation-inhibiting
337–421
p110β–S205D/K224A
C-RAF-derived
triplet-repeat
0.14-1.34
1.6–2.2
1,362-bp
EGFRmarkedly
p1
dosing.15
months.51
P-STAT3
2.7-8.2
sc835
acid/n-propyl
Gonadoblastomas
BLIMP1+
Errani
Kcl
Cao
503AY
core13
p110α-induced
Bcl2l12
Fédération
p3TP-lux
lobectomies
29–64
melanoma.We
Lys375
superhelicityTo
.371Y
D879G
repeat-mediated
65,000
ttient
//david.abcc.ncifcrf.gov
AF-2-activating
Shp2/Gab2
analysis.Go
1767
goitres/cysts
A390V
Wnt-signaling.Our
Donnellan
suite.40
S7B–D
UEM
domain.47
Rakowski
neoepitope-specific
5′-CAACACAACTTCCTTGTGATCACAAATGGGAG-3′
MGM
Mdfi
cRSS4-cRSS1
c.1396C4T
platelet-rich
7781
preTα
K2066R
HH1
pLXSN-EWS/
Ph-DPETGEL-OH
HMM
LS9
H2O
H3G
–1
mlh2
AAACTCGTCTCCTCTTCCAC
SmartCapture
1956
C1055
.RT-qPCR
n=41
FGF1-independent
targeted-allele
.Precipitation
RG-19N
hemi-allelic
SK-MEL239
3.4.
PTEN-promoter
13,023
Einarsdottir
T1151
Shp2.7,8
pRcCMV/mut
BR2-7-Mlu-R
combined.Tumor
:end
α-2
DNMT3A20–26
ICSCP
–14.5
0.27–0.95
RSK-MH2
p16.5,10
T334G
2589
carcinoma17
TFG/NTRK1
reaction-containing
SUTENT
Cheminpharma
Val216
N-RasG12V
'activator
rates.6
.7,9,10,12,17-19
p85-mediated
AA-3′
0.5–19.6
IkBα
anti-phospho-T573
H/R
Nucleo­
-sh-Smad2
progression.30
TSC2GAP-mediated
N-deacetylase/N-sulfotransferase-1
MECP2
=ln
mutationsselected
.377
538G
C624F-expressing
acrylamide
pH7.5
Autism-associated
ATTCGTGGTCGGTCCTCTTATA-3′
DXtreatment
al.,1988
c.231_232delTC
penicillin-streptomycin-glutamine
8×60
growth-repressive
p.K1014Rfs
2B10
2–positive
97:717–725
T244I
Cytokine
SSX-SS18
300-kb
ArILArLLtOLL
4:60
5'-AGTCCCTCTCCTTACTTCATCC-3
∼13
23-2hl
H4K20me3
α‐helices
-ATCACCCTCATTCGGGGTGTGGGCCATGGCGC-30
β6-β7
4.8/2.8
sequencing.9
10.1002/humu.20122
instability13
6-Thioguanine
pCEFL/FGFR3
Co-NTA
gtccgtcagaacccatgcgg
Kampjarvi
region.8-10
14-nucleotide
CloneID5324125
C3H1
4721
anti-FoxA1
interleukin-2-independent
matched-germ
+81-22-7178142
IκBa
report34
D1733R
J.P.H
remapped
Myc-cyclin
isubiquitously
NAP
ncomms7025
TITF1-targeted
dCTP-labeled
1.HER2
FYVE
NeuT
dlx3
PTPRD-mediated
leukemia–causing
CCTGAGATGGCGGCGTCCGGAGCACAGC
FAM131B-BRAF—have
Lyn/Syk-dependent
reimbursement
NM_006015NM_003242
ALL.4,5
CCGAATGACGCCTGCCCG
rs137852868
UbcM2
RhoA-ROCK-actomyosin
ZFN639
Molecular-Surface
NF2flox/flox
N-ter
MP/solid
GTPase-competent
Acquity
Lin−CD49fhiCD24+
proapoptotic
nottranslate
Colorectum
Arg86Gly
Chromosomemapping-panel
neurotropin-indepen­
Leu65dup
GPR19
Leu320
SQ/
FLT3-840GS–
SMYD5
Immun
1.081-2.528
8.26
retransplantation
I1283V
K142fs
Cybertech
GCTGCACAGTAGCCTTGCT
aneurysms/prominent
1254
LITERATUREKIT
HLA-A*24020102L
pErk1/pErk2
p300-containing
K471E
CCND1-positive
www.pnas.org/cgi/doi/10.1073/pnas.1102198108
A500
north-western
G674Ahas
Ras/Mitogen
DESY-Hasylab
ProteoGenex
R.E.Kavetsky
cancer30,31
NM_003162
SH-5YSY
NPM-ALK–positive
mg/m2/day
n=472
.Surface
4EPV
integrity15
P60
76–85
nuclear-binding
hmC/
Anjos
BaF3/ZNF198-FGFR1
Bordeaux
receptors.12,20,30,40
Szinnai
ACVR1-overexpressed
Garcia-Barceló
Theﬁrst
extragonadal
Bednarek
Solgent
KIT.10
RAD57
TranscriptCluster
.Fig.22
transition/transversion
subtypes.86
mismatch·MutS
12f
TTTCTC-30
RKO
G*0105N
PSD-95
φXXφφ
dodecapeptide
BC014311
Groupement
ubiquitination30
Ruvalcaba-Riley-Smith
PDGFRB–rearranged
R141H
±coefficient
.Wiesmuller
biorepository
20uL
nimotuzumab
LR07
0.84
4766
'epigenetic
Msh2C195R
KANK1-PDGFRβ-induced
-organization
Trusolino
single-vector
TRANSFECTION
251-EGF
E664K
T1481fs
Ingenuity®
Turrex
kinase-Akt
Wohllk
Figure4b4b
interaction.17
R181→L
Y-653
P390L
calyculin
byLNCaP
c.128A
.Met-1
HPAF-II
cross-sectional
232,620
COSMIC33
455–465
Ser505
​Fig.22
0.0197
50–85
ricerca
Hsp104-dependent
antiPKCζ
1993
66224
Flamme
29–49
melanoma-prone
Ig
N191S
HPRT-R
0.05mg/ml
situin
sc-602
TGAGCTTTCATTTTCTCAGTTATCTTTTC
HindIIl
Vcd
top3
Tet2f/w
380/382
multi-biological
K-23
IL8
284.2
Fog1
56304
∼500nM
tiling-path
inhibitors9,10
pRC/cytomegalovirus
2854
K14-cre/Brca2F11/F11
epi-genetic
II-NT
Ras–Raf
TCRcrP
ROMK1
1322T.27
LB-ampicillin
C-segment–like
TFRC-3
.Fgf8
cholangiocarinoma
silencing-induced
Haematological
31Â°Cfor
FOXA1-independent
0.478–1.616
Y977H
c.4986+6T
Phe'248
Ladurner
lter-sterilized
.C609Y
Thr17
DEXSeq28
97062–586
pxp
.Laser-capture
anti-BRD4
GeneTitan
Beddington
nomencl
SK-ES1
P008-A2
enteroendrocrine
.Epilepsy
MET-to-CEP7
0.685
B-raf
Hanzeplein
58TPR/
0.07–0.16
kappaB61
U590
isoform.29
Pre-loading
CD16/CD56
.Chemiluminescence
1q22-24
described17,18
636–639
250-mg/day
BRCA2-DSS1
.Mutation-independent
nsSNVs
.Klabansky
Ubiquitination-deficient
15/23
CS-05
bronchi
CBFβ.19
c-FBS
FRENCH–AMERICAN–BRITISH
1.9–2.7
proofs-of-principle
NF1-like
disease—either
repair.21,22
6791
ten-fold
19q13.4
immidazole
.Interestingly
Vav-cre+Tet2+/+
chemoresistance-related
delA767
58-CCGCACTGTAGCACACTCCC-38
Nam-Chul
piasmids
−8.89
mono-therapy
R608Q
21-nucleotide
TPM3-NTRK1
Immunocytology
categorisation
fasciitis-like
Taq™
dememethylase
1–511
BCCA
ß-mercaptoethanol
Caprepressor
protein–coupled
Leu80
.18–1.36
factor-α
*53
STAG2-deficient
blepharoptosis
Dohner
ACCCACTTGCAACCCTAACT
.19829716
5.8S
carried-out
HSCs.20
NPY5R
pCMV6-Myc-p110a
equilibration
–MAPK
c.35G→C
.Rodriguez
Skp1
µg/100
A*01:01:38L
P6c
p21WAF1/CiP1
MMR-P
5′-GAGAATGGCTTACTTGGATTAAA-3′
Laemelli
fluoride/aprotinin
25mM
misdiagnosis.1
CBFB/MYH11-
D2S119
targeting99
YLV
Y1
FMTC-RETS891A
Φ-Π-S-S/T-S/T
L551P
TCF-luciferase
non-ALL
709X
-SIFT
high-VEGFA
by-product
dideoxyterminator
H396R
Hs99999907_m1
L440R
ab28364
TbRIItet
T681I–transfected
.Lys120
OA
0.2–0.6
Listernick
and18-kb
LIRG1
Gli1
all-or-none
.TFOs
medianTA
nonmelanoma
wetherefore
Q680R
ETV6-MDS2
robotic‐assisted
NM_005052.2
consolidative
lactoperoxidase-catalyzed
extraembryonal
D594G/G469E
serine/tyrosine
.DiscussionThe
thatit
Env
Superti-Furga
MoFlo
disease.26⇓-28
.Phosphorylated
Metab
OVA-expressing
G1809A
mice41
Mahadeo
case-matched
pre-screening
83-
doi:10.1038/sj.bjc.6600554
GAPDH-F
5′-AGAGAGCTCAGGAGGGGAGTCCGT-3′
146A
213,000
PAX5transcription
gplloProto-rr-
Δ500-1863
R207Q
Licor
Hydrophilic
W557G
217566
Gβ1
109-kg
KG12D
Hoerdt
forEcoRI
differentiation150
pcDNA/BCR-FGFR1
Hydroxylamine
6XHis
HIF2A-mutated
intranucleosomal
IGF-BP3-
S1761
04–01
repairAlthough
Fli1
.Surveys
LGK974-induced
AAAGAA/gtaagt
GATGGGACTGAGTGCATCCT
Gleixner
1–3000
Boyerinas
Far1
MPL-
LGaGAFGKVveAtaygLIk-sDaaMtVAVKmLKpsAhl
Runx1ΔE4
LSM5
hyper-fractionated
r0
c.1519GC
49,50
–XhoI
targets—elastic
hypoventilation
Methods—A
acromcentric
mock-transduced
Trp-61
nondetectable
Ala347
Fbxw7–/Δ
122:211-219
MEFs.We
OA-5D5
cDNAs.13
D182A
15/5–10
1017–1042
.O-min
400-band
mice—for
7–16
NS-398
L344P23
Lkb1-G163D
Hionic
OptEIA
biotin-
.Phoneix
survival.31
582–935
D1-APμ/dE
75–95
CBL-Y371H-expressing
Shibuya
NM_011595
Pre-Core
near-neutral
CSRD
L618M
tyrosine-to-cysteine
M141V
RPRM
450-bp
325–357
complexes183
al.,47
TCRαβ
59CTCTAACCTGGCACTG
NRASV12-expressing
Ciurea
c2195G
I255
LS513
C542R
2,3
disease.Seven
IFAR983/1
ptata.A
His-UCP
Fip1L1–Pdgfra
tumor–derived
ERE-firefly
nondividing
Y140
59TFG-39NTRK1
N=6
DO11.10
nihms646437t6.jpg
BPM
GSTfusion
gefitinib.17
tyrosinase-driven
60.13
5and
8511
Pan-RAF
SJHGG111
Lumi-Imager
MYOD1
TGF-βRI
13,662
PNN
AGAGCGTGAGTGTCCAGCTTACAA
.052
5′-ttccgggaggagaattttggac-3′
N1L1601P
anti-phospho-JUN
A275D
.Zinc
γδT
Asp770_Asn771insAsp
CRC.30–32
Ha-
intercrossesa
9310
RING1B
delL747_P753insS
transrepression-defective
His701
3,3'-diaminobenzidine
hyperleukocytosis
Thermocycling
sodium-induced
PDGFRα–expressing
20141
Flag-BRMS1
trypsin-protected
anti-MyoD
nonrejected
TAL2/LMO1
sub/site
MRE11–RAD50–NBS1
.1738delAT
Akt1-GFP
R19F/
950FS
p.Gln804LeufsX5
PKCζ-dependent
Forskolin
WSU-DLCL2
10+
depletion61
post-exposure
G487.In
SH2–binding
p53.Assuming
CHD4
.Delivery
GPR113
/1ZOQ
tandem-mass-spectrometric
.Immunoclearing
leukemias,25
16–amino
TE3
OCCC12
amplification-activated
SGOL
1830
FGFR2Y381D-pcDNA3.1
4240
Shimizu.29
9/188
.Parametrial
polymerase-sequencing
Rdelellis
esult
IKK‐β
p220
RRN3P2
sulfate–induced
11789013
kcat•GT
Figure6C
RG6
Moschovi
CharacteristicsIn
Pre-symptomatic
lesions/
'blind
p.K641R
itself-caspase
37,53
Expression-based
175Ser
NTRK1gene
Ultra-4
Ala1199Val
gr/dl
B-lymphocyte–receptor
V37E
RhoA-ROCK1
M/62
dipyrimidines
ETV1-induced
gArgAsnL
oncogene-specific
MY320
scaphocephaly
_J
anti-αtubulin
.Functionally
c.206207ins27
Ninety-two
glycosylated
.oncogene
filter-based
Flag-enriched
ACTGGTCAAAGTGCTGACTCTGGT
inferring
B-LBL/ALL
ultrasonogram
function•
CBL-UbcH7
549–572
.Dietary
V600E/R509H
CEN11P
αGal4
Lys289
.Kinzler
incodons
NIC
BCOR12
p-pRb807/811
T336P
extra-chromosomal
Val1074
rs17336437
IL2Rα
His6-tag
FcR
II–V
5'-to-3
200-µl
639241
best-quality
Díaz-Martínez
HDGC,6
itthus
μm/pixel
B10
//mmb2.pcb.ub.es:8080/Pmut
p38IIERK2
differentiation13.ROS
c.5277+48_59dup12
misassignment
26L
p.Asp156X
H5.35
Tsc1fl/fl
.Lymphoid
iMutant2.0
5/27/2017
AY518307
0.008461
QuantStudio3D®
'drc
weak/focal
toCRC
DmB′
MSKCC-0296_R
Digestion
variation1
Thr1802
CGGA_1068
6.55
MGH020
Iu5
−2.89
p.Leu390Phe
Spivak-Kroizman
interferon-γ
variants.NVP-BYL719
22664606
.Ecadherin
Hiipakka
Wetzlar
R552K/S
pGL3-185
entry134
TAT→TTT
Preoperatively
√
.0356
5V-ctgctccttggtccttcac-3V
CCCATCACCCTAACATAAA
78.3
arginine–histidine
Assay—STAT1
Dm-Dicer-1
5,800
16.53
33428370
tumors.In
gefitinib.35
Luikenhuis
tdtx
stress/DNA
4567
c.8520+
CDKN1B-R3R
53942
GigBTB/3-box
Atf3
S10A/ΔNLS2
73.01
7-catenins
interferon-stimulated
~Mesmer
4127
v.1.4.1
MMP23
Lipid-mediated
.10–14
H1045
4195083
PBRM1-deficient.17
pEGFPN1
MOL4070LTR
2H2O
Damaskou
-ve
Ala-positive
D1–
accordlng
BRCA1,7
CDKN2B
PK7088
methionine/cysteine-deficient
gctcttcggctgcttggtaa
5'-ATCCTGGAGTCCACCATG-3
LAS-1000plus
ilicithan
involved—11q13
Y10
WDTC1
DZ
T.M
INSRβ
utero.164,168
pIS-ERα-1
.HincII
CreERT2/hBRCA1
temperature-
p150
pSR
elusive.12
Kolfschoten
ccRCC-predisposing
Tyr-654
RB24-RT-se
structure/function/evolution
A-1090
phosphotyrosinespecific
0+
LUSC23
A195V
menin-related
RBS6KB1
oligo-targeting
reports2
7.9-fold
63–83
.Jak1
ERG-specific
Miseq
4.9×
1.3â€
Co-expression
.p-p
3142
⊙
Tun-Kyi
Napco
C98A
coupled-enzyme
MBP-PHD1
M582_splice
.PNAS
DAPT/γ-secretase
PKA39
705-711
Nakauchi
p.Asp231Ala
Corl23
P699G
S692T
vis-à-vis
−4SD
populations53
F317L-positive
L762
lys2-
-GTCT-3
L858/E709
pHK106
3025
f/57
RTKs.34,52,53
2H
non-insertional
Supematant
anti-phospho-Y845
V.2.0.6
Smurf1-derived
2Â
85.6
T82I
line,5
Pfister7
A252T
L299F
assayutilized
DIPGassociated
fedratinib—to
T198A/G
hyperextensibility
EUFA341
R1032X
antiandrogcns
201.
curation18
10.1007/s00701-009-0242-4
scale-based
R466H
ACA
median-polish
AR/FOXA1
TRCN0000133666
protein.9,10
immunoprecipitations
N268D.29
DBF4
96.9–97.1
right-
RhoC
117342
pStat5-Tyr694
Phe-198–Leu-199
BRG1/SNF2h
ATPγS-containing
Sai
GFAP
N‐loop
2189
non-cRSS
p.Arg629Cys
F/2005/02
resections.Overall
UPN9
myosin-positive
IκB-IKKβ
HNSCCs
Flag–Akt1
quinolinone
c-peptide
transformationby
139150
preciseTMPRSS2-ERG
SCLL
GeneScreen
0.2-0.5
Quik-Change
A274
RBP-Jκ/CSL
V392
AF-1p
Rpatient
T255M
F148
Akt2-specific
H4-K20
.Target-enriched
Q157R
RFS-mycT58A
4Activity
domestication—which
antitubulin
Shp2-like
positioning/orientation
GTTTTCCCAGTCACGACCTTATACACCGTGCCGAACG
GSE18700
KPT-251
pseudoactive
E50K
mutations.2,13,15,16
PTPRG
175Tyr
merlin-mediated
Arg441Pro
heterodimerzation
proteolitic
easy-mutability
difficult-to-find
Mol
+6.28
H873A
430v2
.Monomer–dimer
9.24
anti-alpha-tubulin
200μL
L330
preferential
ODS-A
PHF9
54.37
UMP
potential/actual
UPN4
Hs02543373_cn
0.0011
8-μm-pore
Raf–Mek–Erk
MM39
electrophile-treated
IGH-BCL6
carcinoma184
cSCC.7,15–18
exposure33
abrogatesMMR
unknown.
L158
P-C
temperature-sensitive
5-AAGGAAGCCACTGGAGTTCCT-3′
C4HC3-type
RH30
p110α/p85α-iSH2
spectrometry9,10
doxorubicin,42
35-81
selfhealing
acc.cgi
TSC-associated
Growth-factor
gtacagtga
activity,4
manner33
A82
D1091N
3H-thymidine
2679
pSG5-STAT3α
TNKS1BP1
I-HindIII
Momand
AHR
cell–associated
AR-interacting
Fluostar
rMATS
chicken.27
6.44×107
Phosphorylate
bandb
E032
SIDD
dxWO
U87MG.DK-generated
OH-FL
MYOCYTES
custom-designed
R3-unresectable
unknown.16
.NMR
5′-TGTCGCCCTCGAACTTCAC-3′
3represents
.PolyPhen-2
cre-mediated
nonstressed
CSF1–CSF1R
L1237
CK1α
Grenoble
annotate
IFN‐β
Tonsgard
taylor-made
G1–G2
GFP-EB1
anti-LICAM
retention-time
displayeddefects
mepolizumab
HPI-gamma
-CTGGGTTGCCTTCTTGTTTGC-3
tumor.44,50
2.05×103
p.Gln643X
gtcagtatg
2324/80
5′-GAGGACGTGCTTGGGGAGCTAGAGT-3′
Vct
627
fancc/BRCA2ΔCTD/con
data18
A35T
Fas-FADD
INPP5A
pleckstrin
Novartis
dupC
expression,40
Jh2
anti-pTYK2
Ventriculomegaly
colcemid
N822Y
−738
CED-3
.Clear
Seong
pCMX-IL-2R
D218G
PLZF-
TOPO-TA
anti-guinea-pig-AMCA
Rat1
transformation.11
.5972G
BRAF–mutant
N550
277K
Oligomers—To
dihydropyrazolone
36/81.8
Thbs1
real–time
0.31
Δ343-1081
A277V
c.388C4A
reinvestigated
R130X
.White
R550Q
TableIB
ETV6-PDGFRβ,25
Tumor-Free
NOTCH1
//www.nci.nih.gov/cancertopics/types/lung
∼100-fold
//rostlab.org/services/snap/
diftitox
Amzel
analyses,8
HLA-DR4
V104D
abiraterone-resistant
0.1×105
interpedicular
MSCVneo
f~ved
NM_003600
.representative
ARfl-positive
3768–3776
43–56
−672
pTAL-SRE-luc
Poly–horseradish
Attenuate
myomegalin
Cre-7
.Myelodysplasia
V332A
K8-18
N-acetylglucosaminyltransferases
MA9-mediated
Lin−/lo
4·4–10·0
p.Leu585Pro-p.Ser677Thr
02/patient
.Improvements
1D–F
2195_2198dupAACA
eFigure
.TRM=treatment-related
system.32
559388
ylsulfonyl
Dibble
1.09
ip2
0.853
damage–activated
isomerizations
S6.2.1
-719
y-catenin
APC-depleted
protein24
Hematol
dMyc-bound
α-D-type
.SEC31A-JAK2
down-modulation
Anemia-BRCA
mutations93
indi-
R179H
Nahta
LOH12CR1
hFANCF
surveyedcapable
ARID1A-depleted
n=235
12-l
BAXby
D37V
R273K
32D/wtFLT3
HOXA5
TÃŸR-Imutant
NR9162
800–874-8667
D25E6
hetcro/ygosity
-AATTCTGGGTGGAGGCACCGGTGGCAATCCGAGTGGTGAC-3
q21q22
phenotype.17
Wps/+
pnas.1321155111i14.jpg
pAkt-S473
AJ224901
shHnf4a
301-562-9890
597–607
contradiction
embryo.19,21
NB4-RA
ORC3L
​Scale
CLCN1
.are
PTENK125E
Hes-1
Sakata7
5′-GCGGATCCTGCATGGAAGCCATTGTCC-3′
p.Lys99fs
19.54
GSH-coupled
MAPK-reactivation
H3K36me3-mediated
TEL-PDGFβR-transformed
toCEP110
Translational
MPL-W515L/K
104-fold
IHC
.Regorafenib
zest
Nakahashi
1-14,9
EGb761
DNAI1
Capillary
t2626c
Top-flash
59-GAGCTCCTCCTTCTCTAACCTC-
pMY
robotnikinin
urethane-treated
6.32
Cdk12+/–
5′-FAM-CCTTGGAGCTGACTGTCACCTGCAACT-TAM-3′
GTPyS
c.690_691delGA
Table11A
C-Helix-in
dis3DPuroR/DIS3
Toxilight
.PAH
therapy254
ERα+p63−SMA−
multisubstrate
25.8±9.9
diagnosis11
CTCF-binding
.NIH-1975
18-23
Rheb-GEFs
0.5.9-r16
.Age
CDH113
tooncogene
22/32
5'-gtt
Super-
EGR1-
RNA-supported
potencies
6-mer
10,168
Conchillo-Sole
acetylating
FANCF,27
what…
data.22
L32955
glycolysis107
Group/Australasian
multiple-punch
Myr–AKT
ab′
N7-methylguanine
405.7
phosphoTABLE
hyperpolarization-activated
.A549
9,13-15
ALL-97
NCT00607724
myristylation
5′-gaggcctgggactagggctg-3′
Birchenall-Roberts
ALM/LMM
non-histone
c.5676G→A
CMV5-ETO
individualcolonies
ofthemRNA
line14,15
pathwayYesYesUnclear
F451L
1,11
pAktThr308
RP11-98A7
Eluate
heinz.sill
0.7861i
gender-
TD52
c.1797
Fujifilm
5'-gggcactccctgagggctgcacggcaccgccacagGCACTGCACCCGTTC..
D3170G
increasing.3
p.E545K
reported.16
5′-ACCTGTCCTTCAATGCTTAC-3′
density.a
GGTGGCCGCTGACTTTTCACTTTCCAT
genes1,5,64
D1226N-1mu/mu
PromoKine
5'-ftanking
38,41
P1749A
termini1,15
BF3
Bcl-2-Like
Li-Wha
SMO-S387N
B.J.R
KrasG12D
FOXO4/AFX
11q136
PIPK
PXY=1−
JSBS
can-100
CTK
MLH1-18
liposome-mediated
Mewo
PP2A-like
c.599G4A
.Statistic
anti-BRCA2
139.5
transcriptome/proteome
reported7,26
MIPgen
SNU-1047
.4171A
strategy.77
5′-CACAGATTTTGGGCGGGCCAAACTGCTGGG-3′
Jinan
p.E69G
EcoRIrestricted
CAGCTCTGGCTCACACTACCAG
DEAAE
crizotinib-refactory
35–76
M246
HCC1419
5p15.3
MutSα-G164R
CCGCCTGGCCTGCTCATGGTGTTCC
150-ms
,1002–1042
per-pixel
copyper
pCYC1-
NRAS1,2
M337V
9p21.1
R273-related
48hr
Bollmann11
Flag-HA-TET1-CD
375delCT
Semi-synthetic
0.35–0.92
9427S
software,16
d-3
.Single
p53-9K/R
pageResultsTypes
anti-pSer-65
regulator24
F876Y
BD2
0.749
Prostatectomy
less-sensitive
Ewstr1
//www.broadinstitute.org/ccle
E543del
E40A
non-Finnish
111-2
Y64D
thinsp
.771
HNF1A-mediated
V218
AML.18-21
.Constitution
ACGâ
40/EC
C-raf
p.P553R
Gata6
B-cell–
therapy1,2
McPherson4
Maier-Woelfle
LIG3
STK12
resoration
.DHT-dependent
rized
*._.P-
Zaliova
E6201-resistant
L14
pC-KIT
CDKN1C
genotype-to-phenotype
E2Fx2
malignancies.2
RFP
NM_016206.2-3364s1c1
5-FU
5′-AATTCAGGAGACATAGGGCAC-3′
KCl-Q-Sepharose
a-Helix
K332
Leu379
2,387
2xPBS
patients.5-8
sh4
hydrolysis5,6
lowpenetrant
lter-sterilizing
non-comparative
ML5
Smad3+/+
CYC202
5A–E
ERα-selective
Ras/Raf-1
0to
E41A
Flt3-TKD
IVS8-12delTA
non-PPM1D
cancer155
onedinucleotide
NM_178020
FANCA,34,35
KRASF156L
substrate-coated
2957
CTTGCGCAGCTCCTCCTC
RNA-Sequencing
Fig2A
BT325
T2134
NCI-H2077
KU-19-19
R669*
KIAA1598
G.A.B
mmol/L/NaCl
S515G
fCAC
PDGFRA/KIT
p.Pro379Arg
15N4
liver47
1838
2206
age-
CRTC-1
ASXL1/RAD21/SMC1A
23/49
E19290
juxtamembranous
BCR/PDGFR
Gairdner
anti-CHEK2
omomyc
rHu
.Barker
272
twice28
R22H
AR/enzalutamide
AEBSF
Cyclin-CDK
OVCAR
TTE
8/39
MPM—
-fluoromethylketone
K-252a
n=36
.Previously
Toaima
phytohaemoglutinin
Eschericcia
genome.1
Qiamp
forkhead-family
∼82
Heterotrimers
G669S
MEK1K57E
R1391S
0.5–48
tumours16,17
23·9
200-μL
R-chemotherapy
HCF-1,64
macrophages
activation.32
S1887*
csw
31c
Anti-HPC4
retrorbitally
cascade1
post-operatively
populations,18–23
665–721
Sarcomatoid-specific
acetone/methanol
mA621Raf-1
G245V
MaeIII
aknown
orBRCA2.15,17
-K666N
PML-
Enspire
domain/SH2
.Interferon-italic
0.9
AS10
PP242
CGCGATTAATCATCAGTG
ICLC
Retinoic-acid
approx8
Shitara
TRK-fused
intraluminal/polypoid
lower-energy
Kogner
Ser-252
Ser2
V343E/F347L
p.K471DfsX19
plasmidic
of/
PABPC1
BRAFMT
5′-tctcctgtctcagcatatg-3′
38-41
μl–μg
anti-p-MET
L749Q
.Mutually
GGAGAAGAAGGACGAAACACCTT
2.EGFR–RAD51
protein.24,37
V567I
RECIST.13
26–106
A275
Proteolysis
pET-3d
T321R
eta
adenosquamous-cell
coimmunoprecipitatedwith
CAG→CCG
Sre
1–938
.Translating
addition/complementation
–18.0
E1508
V757I
Y653/Y654
5′-CACAACCAATGAGGAAGCCTTGGACCTCAGCCAAC-3′
p300-NUT
CACNG6
28,480,879–29,722,897
.Non-synonymous
Bagrodia
oncogeniccapability.We
d-1
Del747–751
p531/–
.9,32
imidazopyridazole
32D/Flt3-
ccRCC24
ddT
c.702G
ETV4_exon3-f
19,045
21A
disorders.10,11
long-pass
TGF-Beta
autoimmune/inflammatory
.â€¢
.S4-S6
domain/regulatory
lymphomas,16
p.E1327G
p110-independent
Mandruzzato
PY-20
52·4–93·6
21/25
Crizotinib-resistant
R99W
fluorescent–
95/372
derivatizer/analyser
GSH-sepharose
Dpc4/Smad4flox/+
Fordetection
5e–g
NCT00109707
CTGCTTTCACTGAAT
613
29,42
SPATA16
p.T231
PIK3C3
AtHB5
PIK3R1R348∗and
immunesurveillance
291
19-nt
RFS
pidermal
R988L
D15S126
let-7f
p.Ile1095Thr
data55
cdc2,23
phosphoyrlation
inMaterials
xCELLigence
.CHRF-288-11
5j
Npm1+/+
Bioimage
ACC-305
cdk4/cyclin
Luminex
EIF3H
β‐sheets
rec-ommendations
62-kDa
CI=0.92–1.53
12p11.2
M780
−0.43
Lindwurmstr
hypofibrinogenemia
RFS-mycWT/Wap-Cre
tetrakisphosphate
Cdk4R24C/R24C
non-hereditary
T-AP/dE
Q3026Xc
short-latency
GGCCCCTTGTGAGGCCAGAGAG
.PI3Kα
Forty-three
NdeI-derived
Pc=0.06
CDKN2A/B/9p21
~25-30
M107
tNumber
Peptidoglycan
10−
G1382T
Berant
quarternary
†8
Accession
Y541E
9M
tape-transfer
Albcre/Smad2f/f
protein,70,71
6/10
4665
.ETV6-IGH
Phe723
29E.2A3
hnvitrogen
Glu322Ala
thereafter4
K616del
.Pharmacodynamic
Hogervorst
Mammaprint
Americans.25
High-Technologies
5p15-p12
Elastica-Masson
breakage-fusion-bridges
mutation.Among
Met-270
IU/mL
AACGTGGTGCCCCTCTATGGCCTGCTGCTGGAGAT
PARPis
tgttgttag
J.S.G.
mephalan-induced
MGC:28635
Val/GTG
PI3K-mTOR
SPRY2
N103
06-647
0.14891755
D257N
PTENR130G
IMGT
co‐transfection
Megison
22.08
//pir.georgetown.edu/cgi-bin/multialn.pln
Zellin
ZFM1
R659L
phospho-Erk
Q50P
VKTPQ
DNR-DCM010
.Inaddition
CSDS
Morrione
p.Thr77Thr
.PTC-Containing
screenSaturation
.PF-06463922
Hegazy
Shirohzu
described19,45,46
Co-staining
MEAF6-PHF1
activity.9
Wynford-Thomas
DNA-interaction
q22.3
606C5
VHL-wt-Venus
pLenti-ERBB2
ofU87MG.AEGFR
Erk1,2
1,910
259V
EF-HA
α-phospho-Mek1
BR-018
p-DDR2
LSIL
51–71
cohesion-deficient
HLA-B*15:02
TMEM14Cmut2+3
1087F
LY3009120
.Diseased
11,27
WEI
HUCH/CFCH
.determine
IlyTrpHIlSerTr
parallel-coded
Maerki
streptavidin-biotin-
MLLT1/ENL
RotorGene
5–27
IL5.28
cytoprotective
NM_016710
ile
ARHGAP19
apo-structures
overlap31
VACO6
cytometry.14,15
4679
AGCAG
P=0.346
A-GVGD
virus-encoded
Wfor
Ret15R
ENL
​Figure5A
~100,000
lentiviruses
OG5AGTQ5.CCOTOOTQOCTTCk
Broad/Novartis
ENSG00000068078
z-score
.Maternal
-CGGCAATATATAACATGGGC-3
lox
P34R
22,949
Lindsten
and170
vIVb
94143-0552
leukemia41
cutaneous/ocular
Q510E-Shp2-expressing
—is
VSD
c.179C4T
α0′
ERK2–protein
exome-capture
17.3
.PfuUltra
TGCCT
AtmKD/KD
excision28
S100A14
Z-leu-leu-leu-H
methodology.5
immunoflorescence
MRSG
SER-CAT
BALB/cOlaHsd-Fox1nu
paper.4
50-90
C76R51A
AAA-
843
loss61
.STE11
B56ε
patient169
CF4
EGR1-controlled
SOS-mediated
L1237F
MlaA
uAr
5·2–10·8
G-N
CD5+/CD19+
hpT
SLPI
Y-MESO-27
L-lysine
position-
T259M
SH2-mediated
pGBKT7-FANCL
ganglia,17
**B-precursor
RP11-430B1
cis-Diaminodichloroplatinum
I87M
FNDC3B–PIK3CA
33-1-49-58-34-05
PTPN2.23
4-8
2.00+0.01
-UTR-MUTLuc
EGFR.25
Viewer.The
Proline-134
66–69
weresubcultured
MSI-L/MSS
G2032R-expressing
Emato-Oncology
R71G
EOL-1
high-confident
pUAST-DERKwt
interferon-binding
48,742
15,24-26
I.O.D
inlineView
R202W
subaortic
~CZ
M2-polarized
p.W11X
8•6
Arg-172
L26501
374-377
ATGGGACAGGCACTGATTTGT
W291X
processing-deficient
.Kanter-Smoler
.BaF-N/A
C4T
FLT3-ITD–positive
610017
pCAG-NZE
BIBW-2992
106-bp
XPO1
orientationswith
83.79
X55656
E.Coli
SIFT13
pEYK3.1-hJAK1
start-site
deletion–mutated
head-circumference
hydrophilicity
CMC
microbiome
p.
BRCA1-depleted
pTH-MYCN
Q96MD
chr1:67890660-67890765
Arg-736
enhancerofzeste
ymetrix
TTCATATTCTCTGAAATCAACGTAGAAGT-FL
Senderowicz
pAKT
Ser46Ile
260/280
cancers—the
-CTTGAGGTCTCCCTCCGCCATGAGCTC-3
ERCRE
NGS-derived
immunoprecipitate.Puri¢
cancermutationpleural
Phagocyte
hetero-tetramers
1H/15N-HSQC
PALB2
C_row_plate_
16INK4
AZD1480
7.1–57.7
NSCLCNext-generation
6XOES2
GRB2-like
TÃŸR-1sequence
:GAL
HRasV12
NaH2P04
CPM
-positron
PathSeq73
RAS-binding
eective
chromosome-20-specific
5309
Taqpolymerase
G565_D572del
34/349
1ATP
rs143770796
superpositioning
ofimmunoprecipitateswith
2490–2497
150–250
J068
AntiRasGAP
NHEJ15
GAGGCAAGTTTCCCGTGTTGACCAGCATTTCACTA
abdominopelvic
vortexing
AKAP9
SYNE1
kit-provided
Skalova
0152-DM-B
malignancies,1,2
cMPO
POLD2
TNFa6
Wt-
AL136985
MN64
T598A
pentameric
–32
anti-CD19–APC
EML4-ALK.14
1·1
Quantitatively
self-renewed
pCUB53
CDDP-resistant/refractory
5.Decreased
MEK-E138
W146
Scotting
IMMUNOBLOT
offunction
PA317
5′-act
pTB-ex14
analysisLysates
NCT01042379
HOGA1
erythroleukemia
pathways—e.g
D-myoinositol
FLAG-CRAF
EnvisionTM+
7/73
:TagRFP
NuSieve
Kim.33
Si-control
mb1-Cre
tttcctttag
.Integrin
.DD-p53–tagged
AdCre-treated
lineage–associated
ASD-
p.D1035N
Intermating
anteverted
-60.2
Biotechnologies
α-p300
1427T
189.8
ERBB2-targeting
9232/00
KRAS-amplified
studyp.E490_F504delinsDHIVVSLTFc.1470_1512delinsCCACATCGTTGTAAGCCTTACATTC1
//snpanalyzer.utmem.edu
RNY*
Dysgeusia
20-100μg
androgen-lowering
sequencing.50
R761H
Thr-106
tRNA
C5/Glu-7
5′-cagtggccttctcccacaccaggatgacttt-3′
Venkataramani
H3-K27M
small-hairpin
ER-Nic
class-selective
R.N.
minigene
5'-GCTTTGAGGTGCA
NFκ-B
pCep9b
Trp557Lys
6084del280
R497
2.5-
KRAS*
abnormalities.
n=5/51
tumorigenesisis
hCD34+
P=0.51
p14Arf
spP20659
fusion.22
5′-CCAACCGCGAGAAGATGA-3′
ABC-DLBCL.8
Myc.Genes
Orlygsdottir1
//www2.warwick.ac.uk/fac/sci/statistics/staff/academic-research/brettschneider
177-202
r.572_631del
LST8
CD3+/−
83-kDa
Liscum
mice.Prenatal
antipericentrin
3/287
G178C
cytokine-free
Grou
nucleosomes36,37
location26
H816Y
.Superpositioning
p76/4
3499–3511
one–
disease.66
loss57,58
male.103
7.4:1
WNT-dependent
fusions—KIAA1549-BRAF
FPD/MM
.NotI/DpnII
52.2×109/l
1/
TFG–MET
250k
.Calcium
Gly-101
α13
C775Y
31.6
entropically
breast/breast-ovarian
BPES
ultraviolet-induced
Sakata-Yanagimoto1,22
growth-arresting
5V-TCCAGCTAATTGACGTTGCCCGGCAGACG
llAw
STAT1-GAS
OMIM*155240
BALB/c-nu/nu
433–435
protein-9
nst
scaffold/
Niederreither
IVS4-101C→G
1.1–1.4
DAPI=blue
1811–1813
.Donor
Hg-3-31
BBC3
C57BL/6-Ly5.1
Elf3Δ129–159
Val-12/Thr-59
Exon14F/14R
other.36
AntiPLCyl
R130*
XPO1-ex15FFPE-R
nature.comThere
extra-terminal
PRK7-HA-S6K1
381-404
MANSC
Wml
BioSystems
anti-phospho-YAP
Shunichi
transgene-directed
10q21
apoptosis31,32,33
RHOB
prolactinoma
tumor-like
0.998–1.088
raisinoid
,1e
23766
development.35
TYK2.30
.GATA
1.4-
IDO1
implantion
RafFF
.CK2
seminomas49
p53.51
245D
SHEP-21N
0.2267
S5K
.HRP
Two-cell-stage
progression22,23
SNPCompare
P3-speci®c
hetero-dimerization
FAT1-
3504–3513
cells21
code—post-translational
Autoinhibitory
PIK3CB
372-411
ct-32P
previously1,75
GCSG
resin
Scol
Digestive
6p22.3
J73T
603024
L831P
0/16
//www.phosphosite.org/papers/rikova01.html
.Plotted
NF-kappaB-like
wereobtained
Ortegab
136–181
MEK1C121S
in-situ
ETO-mSin3A
710061
Kowarz
p85-p110α
.Nonmutation
0.1514
1H
DISCUSSIONWe
700+-aa
e5.1
R2254M
Ekong
rGl
HGF16,17
492–506
.Three-fourths
RhoA/Rho-kinase
.TCRbrearranged
5-base
PP1C
www.addgene.org
Dicer-mediated
pGR13
Trk/Met
Nontumor
PARPi
of2
Hayer-Hartl
GTAT
125,167
first-level
FLT3-W51
alanine-to-valine
.Overlapping
FGFR2/3
nalysis
CEU
fludarabine/cyclophosphamide
143A
co-administration
sex-limited
0•63–0•93
vari-
fromtumors
3A–3B
BCC4
macroglia
WebLogo
R-283
RL95-2
62.82
xed
TP73
-H2452
A920322
2Upregulated
6q15
Capan2
Genethan
27/28
.Diagnoses
Gong
l4C
CEUA
CD95-induced
LLC-bearing
autoimmune
STAT5.25,27
MLK
line-dependent
ground-state
DeltaGT=0
B-Myb
≥10,000
AA-associated
-lo-15
NSCLC.2
EGFR/HER2/HER3
3.Kinase
A24
AGCCAGAATTCAGCAAATCG
*07
ambiguous.12
cells,14
227-kb
microposts
594–conjugated
HEMG
5′-CCCCACCAGCAGGTACAC-3′
11–17
another—an
Horswell
phase77
RG-15
Moroi
PEO
family11
7A
508_819del
SWISS-PROT
1836153
FGF-stimulation
BRAFV600E
C/EBPα/β
43.6
Bethyl
mtor
EMSA.A
CIC-NUTM2A
dissociable
FIP1L1-PDGFRalpha
0.408–0.571
PAFVPFSEG
—————
S3A–S3E
p24·2
Q253L
radiotherapy.33
ATM/γ-radiation
MB4
monallelic
^g
inactivation.20,21
www.ebi.ac.uk/Tools/emboss/cpgplot
A126S
TBV9
bonds20
86.50
20ng
perilesional
−507590
CTTCAGCCGTTACGCTCGGTTCAAGAGACCGAGCGTAACGGCTGAAGTTTTTGGGCC
blotThis
322–552
TKI-targeted
100083
ϕA
MRPL51
GraphPad.Immunoblot
c.961G
q=0
.Autotaxin
2.0∗
ETV6P214L
Somaiah
Rozen4
152–166
titanium–sapphire
NM_054014.2
Supt13
p.R144C
TRK-T3
qin/foxg1b
Ser-437
Gal-1
pEAA309
13/18
c.339G4C
GCRMA
Metamorph
/ZMSH6
no/total
ends-PCR
L858R-
N-morpholine
beta2-integrin
21α-hydroxlylase
v-H-ras-expressing
inter-animal
anti-HCC
Hewish
2/neu
miR-3107
.G12W
15–60
5′-GTTTACATTTGACAGGGTGGTTGG-3′
berelated
32Pincorporation
risk/hazard
FGFR2-C278F
G1950T
marrow-competitive
STS-amplification
t.fischer
.Consideration
DT80K
p.D405Gf
Jikei
AML,43
Laboratoire
SNU
G197D
CTCGATATCTGCCACATAGTTCTCNNNCACTGTGGG
cancers—breast/prostate
1∶25
∼10–25
∼42
1944
fashion.9
HIP1-ALK
expression44
O.L.
carcino
Tanaka18
forward—2
Bady
Multicentre
SMO-7
mutations,11,16,22,23
∗600014
glutathionine
_Rsa_I
Oltersdorf
//www.r-project.org
.KMT2A
0.5-45.0
HA-Shp2WT
ABED/CFG
.outcomes
5′-CTGTACCTCC
10C2
RP11-418J17
c-Myc1
1588delC
cytoses
E1512
3053
.G.F
pT389-S6K
c.3642_3643del2
pepsinogen-secreting
4911
monoubiquitinating
0.0232
ENS
G342
.Compound
histidine-de®cient
.Endoglycosidase
ERK2M13L
Raf-MEK-ERK
AdCre
VanDijken
low-risk/intermediate-1
cytomorphological
viabilityThe
IC50=50
HOC
PLD1s
21/30
magni®cation
XCyte15
resistance.25
68·5
non-refractile
accessionnumber
Scwannoma
phospho-JNK
TFAP2A/B
mim-
nimustine
10A
.Leevers
ETD
Tumor-causing
2009–2013
oncogenes.111,112
Shh-independent
.Dually
D1270G-mutated
11170
hemimelia
-6Australia
39/51
histiocytosis
4399
F1695L
virus-specific
V104
BdF3
T1514A
SW55Ti
199.6
Phe84–Leu90
receptor-γ
thedideoxy
ab9485
IVS19b-3C
arrest.21
DSEENpY589VPMNPNL
public-data
.Till
.Perturbations
1,6
P20L
antineurofibromin
MEKi+AKTi
E180K
LBD
5'-TGAGAGACAATGAATCCAGA-3
allele9•
post-consolidation
coalescent
U07000
identififed
E272K
diseases27
months.35
β-sheet
0.0414
R417
MDP-like
0.500-2.386
inhibitor-sensitive
I3.40
post-mastectomy
95.88
GFP-Flag
therapy.2,3
Primaria
proteins—PDGF-AA
M157T
D7Mit17
N556D
DISPROT
tcga-data.nci.nih.gov
251–253
uPAR-F:5′CACGACGTTGTAAAACGACGCTCATCTTCGTTCCCTGTC3′
10q23-24
P184886
c.721A→C
Ortega
TSC29
/Tag
.is
not.39–41
48/263
-14
splitless
selective17
'STATISTICAL
n=297
CGCCACAGACACCGAGAAUUU-3′
axons.54–57
3′UTR-targeting
to0.1
84–259
drugresistant
P-STAT5A/B
pGa981-6
T-antigen-associated
p53-/-+S+Ras
6–0.2
CTLA
gene.22
irinotecan-containing
V339M
complexedwith
-GAACGAGGAGACGGTAATA-3
signalling34,35
~McCormick
CD45RO/CD45RA
.His105
8q22
Craparo
133/161
19,26
last-cited
1t
Cul1-deficient
c.2975C
p.Glu199AspfsX4
10T1/2
4650
12/85
V713M
Ab5′2
.Enhancer
p110β–Rac1
Sabio
3q13–qter
25-48
PMS2CLf
FLO8
modifications.40
Miapaca-2
TLGLN2
4G10-biotin
CA55728
proteins/downstream
online-only
4422
p.Pro491Ser
CCCATTTGTCCCAACTGG
p.R1391G
Val-labeled
49–67
RARS/RCMD-RS
AFAP
TCN
PI3K/
N=31
.14644
Helgadottir1
GAGAGTTGCGGGGATTGAC
Pab240
sequencein
.Association
ADE2
MUC
NSCLC128
PTPRT/PTPρ
Gli1ZF-WT/consensus
304G
–OH
11,391–18,290
3,960
6—none
non-P-loop
e2
A750-E758
attacatag
c.1943C4T
siNC/siRET
Jabbour
Cfor14
Noncolonic
CATGTCCCAACATGTTGGGCGGGAAGC-3
803–805
34-37
Endometriotic
NF2-derived
investigation.7,31,32
Ctrl-sh
Vaudin
L3/L4
HindIII-XbaI
Changed—To
Bax
deoxyribozyme
ROS1-positive
181504.2
S.c
YUHEF
theCEP110
dactinomycin
alone.22
heterochromatin.22
3-900051-07-0.Retrieved
Elf3ΔN233
preactivated
Thy1
gene.20With
assemgations
.Deficits
3rd–5th
delE746-T751insA
omic
Fludeoxyglucose
p.S259
resistance.6
5′CATCCTCATCTGAGAGCTCG-3′
//biodesktop.uvm.edu/perl/p16
RapGAP-like
CD44−CD25−
7T
PCR2-r
sternum
o15
best-supported
†11
Y.-S
T-ICs
CGGGAATGACTTCTTTTAGTTTGTTCTTAA-5
IRF4+BLIMP1+
Polyphen2=0.992
.High-efficiency
database55
B7
62,63
capture9
5'-GAC
In-frame
5′-CACAGGGATGTGTGTTCCAG-3′
AGS/
9-base
I-Sce1-induced
month-old
6TG
Fug-II/22
exophytic
5'-GCTGAGGAAGAACCTGTG-3
KANK1-PDGFRB
8/117
Microlaser
p21-luciferase
5′-CAAGGCAGAGGCAGAAGAGAAGA-3′
HGU133
organisms.1
paraffin-fixed
P=0.773
tums.ac.ir
~8
_ALK_
resolvases
S2LC
67-69
Intracentral
VICTOR3™
4575
fusion-bearing
desirable.1
GPSN2
55.4
E626G
G541R
p14/p19ARF
5′-GCTTCGTCTGCATCTCACTCAT-3′
orientation-dependent
Ini1in3/+-implanted
29,30,37
GISTs.Here
.Hi
RP11–245C23
DFCI-Institutional
127K
80/95.2
seven-tier
understood.24
F/69
missensemutations.These
treatTable
.Ninety-six
zinc-free
1456
Cy3-
TEL-ABL
re‑
129ySvJ
ZAK-RAPGEF4
sized-bands
88th
gefitinib.15,16
Tom-treated
15G5
suppressor–encoding
p-Met
δ-K223E1/δ-K223E2
L161
phosphorylated-disulfide-bonded
.3998
MGH018
KMT2A/C/D
μmol/kg
0.794
dIncludes
Cw*0602
PKI-587
HGS-OvCa.Figure
anti-CypD
Pi3K
IGF1R-deficient
568–741
gag
64,000
β7-strands
RTK-targeted
CTA
P087
thensubcloned
Adeno/BACd
440ul
30–63
c.1830G
microsatel-lite
22.3/27.8
−660
al-most
formation22
inlet
3′-phosphoinositide
Cytocell
SSYY
GFPpositive
skin-fold
tumorigenicpotential
msh2-AE859p–Msh6p
p.His315Arg
ERF-specific
nonmutant
cells.25
3q13.31
split-probe
466|12
Foa-sensitivity
.cells
means.TheLI
Sos-p.I252T
.Melanocytes
MN85
20â€
PDGFRA-exon14R1
orfour
T389K
triplicate.57
38-weeks-gestation
.2F
Localisation
endoderm4
pathologie
c-erb-A
2q35
71238
leukemia-1
postdose
Te−1
250-kd
AML1/EVI-1-mediated
FANCG-silencing
NT_078088
5′-CAGTTGATCTGTGGGCTTGTTGGTGAAGG-3′
9.5532
3.9No
TCF1
.Fig.6A
RTKs.15-17
Thep53
complex5
1664
arena.83
2144-2163
Qiagen®
28/1,248
calpstatin
.Employing
symbol.Smurf2
100×/1.4
ATGCGTCGCCACATTGAAT
S210F
Zwerner
SW1573
RNAseqV2
Gashler
Mg-GTP
0/55
.GST–AGO2
.0043
exibility
727
Normocellular
inactivatingagent
0-Galactosidase
GF
iBlot
1255
Y216
R−ICmyr
2⇑C
Hf7c
507
40.3
CTTCCCAAGAACAGAA-3′
Homo-
K11
.Enteric
calmodulin
P1287S
midface
TBS-0.05
qua
3q28
R249S/H168R–DNA
Tumors/
AZD8055-resistant
P-g-ATP
Akt2-positive
.Fig.22b
pNPP
p.Val664_757Xdel
FA-A
TRKderivedoncogenes
IPW
80.3
BRCA2-negative
S0446T
mebendazole
pEAA300
12–12
DRB1
IR-dependent
K2100-11
CUDC-101
pull-downs
SDS-
KIF5B-RET
FLAG‐tagged
Cal27-Smad4
classification.24
GCTGAGAT
2.657
GeneEditor
TRAP250
TGFβ-inducible
sequence-negative
2-binding
PKA-activated
XXIV
5'M13-CATTAATTCAAGTTAATITITATIIlTCA-3
FRP
Bosmuller
cells7,20,21
.Erg
21:4342-4349
4187
23/13006
isothiocyanate-antidigoxigenin
kp
reported13
DPF1
002839.2
multi-focal
t004
Rodriguez-Manzaneque
Cloughesy
mÃ©tastases.No
629RKLKK633
loss-of-KEAP1–induced
ActR-IIB
46/140
DLD1
theselatter
MyD88-mCerulean
reported31
pathogens
band-pass
P=0.014
95:5
DNMT3B7-SMS-KCNR
M-rich
MA1
A_52_P584188
2889–3418
NCT01025089
LAC
COLO320DM
kinase.24
5′-tgtcaagctggacaaggacgaactggtgtaatgatatgtgcata-3′
NT074
.Molecules
5′-TTGATTTAGCCAG-TCCACGA-3′
β-phosphates
abnormality.8
methylguanine
trpC1117
p.Ser1207Profs*42
V6
KU
WT1-expressing
ENST
C3H/HeNCR
EBH
treatment.39
ortho-nitrophenyl-β-D-galactopyranoside
8m
p.Glu227_Glu632del
Treeview
p.S2G
48°C
CGT-*CAT
EcoRI/BglII
131,857
ER/INPP4B-negative
L1c
14q22.1
Ambesi-Impiombato
SLC27A6
v2.073
Leu1122
mol-1
RNAi
Cys482
pSer259
Gly10
.14
nonstringent
155DHF
TPA-treated
K659N
2nm
609_908del
mTEL-TYK2-
-19
inter-relationships
98,6
apo-transferrin
FGFR3–transfected
K00487
SOCS-1
RNA–seq
a-IRS
MGL
PABPC4L
7.5-fold
HTS
0.029*
digoxi
co-incidence
N33/TUSC3
.Twenty-six
C455R
634–693
competewith
pCA14-IG
syndrome.30
G1831V
CD103
K2HPO4
pSVH3M
∼20-fold
through-space
4.08–5.07
Ras.9
Purgene
NCI-H1373
G31R
hEMtgmn
SalI-restricted
EGFRL858R-COS-7and
.Cre-ERT2
ΔBRC
n=202
G13R
3/37.3
p.Tyr122fs
PDGFRA/f
bromo-1
RPTK
BRCA1/9
BRAF-selective
9.50-
.n
75,882
GCACCGTCAAGGCTGAGAAC
TGF-βRI–mediated
//www.cbioportal.org/index.do
Tahara
cells12,17
.42,43
V774insH
Midi-magnetic-activated
HIV-2
.Biochim
ATMDS
NFATc1.13
5′-CCGAGACAGCTCCCATTTG-3′
MCLR
GAGTTAAGATCTGTATCCTGGCTG-3
gliomagenesis
14–134
phenylphosphate
DNA-BD-ERF
Ets/AP-1
SpliceSiteFinderlike
HPA002868
folliculogenesis
JSR-F
ATXN1
11
IL-12Rβ
CGCCTAAAGAAGAGGCTGTG
VHLJade
M1012V
K295M
∼76
.DAPT
.Photograph
NRAS-1-R
levels13
∼0.17
CO2/90
active-site
QIAamp-Blood
Epiloia
.Pedigrees
protein.E
high-copy-number
outer-membrane
fetal-origin
inter-BRCT
640
bold-typed
pcDNA3β/BRCA1
Perinatal
Flt4
G2351E
PD-1+
MSH2-
FANCH
Y322
Phospho-4EBP1
T783A
NSD2-mutant
sructure
6/47
RET-KD
PRIMER-
5′-GGTGGGTGAGGAAATCCAG-3′
21–23+3
sulfate–mediated
Ser746fs
n=96
resolubilized
R1708H
.Ionising
M110V
lovirus
NM_002613
F-actin102
Y1159
nuclease-mediated
PhD-SNP
//www.broadinstitute.org/gsea/msigdb/
rs1344063
andthis
agents.33
No./patient
malignancies3,4
.Mesenchymal
cells/animal
ECM-degrading
HCMDDLLLPQDVEEFFEGPSEALR
HSP90/70
G80R
USP42
103-54
Merlin-EBP50
TRCN0000134440
↓↓
Carlomagno
R175H13
330-bp
20μg
silenced9
c.2146G4A
FGF22
NOTCH1–4
.Plating
probesets
BAXPCR
5,336
duplicationof
AlbuMAX
regulated19
Val242
V03
Egawa
highly-selected
pCMV-Myc-DH
4d
CCCTACAGCTTCAATATTATCTTTGACAACTTGATCCTGTTGGTATTTG
PC12/MEN2A-cl.31
.EGFR-KDD-transformed
sequencing10
.HGF/Scatter
HOXA9-specific
chromothripsis-derived
impact.5,6
≥80
BCL-1.10
A1G
perturbagens
validate.php
0.6-1.8
microscopy-based
2−9.7AOX1Aldehyde
Berendsen
Q1377
KIAA1549-BRAF/KSR
full-length-specific
ously
inFigure
Bcr—Abl
ICL-unhooking
NM_181524.1
coassociate
KCsmart
SPSS16.0
SF3A
29:1293–1302.10.1038/onc.2009.420
Gtα–GTPγS
18.21
HEY1
Lin−Sca-1−c-Kit+CD34−CD16/32low
endophilins.11,12
.YY1
NPC2
.Centre
hemizygotic
Y3098H
Ethanol/DMSO
1.608
2′-deoxy-3′-O-
.KRAS
al.,1998
2p21
Trp110
GSK2118436
0.384
KRAS-B
TRCN0000040090
1.257–356.5
immunolabelled
histomorphometric
15-ml
104-Sand
FGFR2a
betaP2–loop
G.T
28.0+
Endogeneous
61.4–115.3×
XhoI/EcoRI
TSR-1
WT-Fbw7
activation84
HNF4A
sc-436
CGA-arginine
+PV
.3193G
E4b
-4-ethynyl-6-iodophenols
PU8
cancer141
Asp-833
3xFLAG-BARD1/pIRESpuro
~99.5
Met160
anti–c-myc
28:190–201
SFPQ-ABL1
Kawabata
RNA-PTT
283–629
dUTX-bound
OmicsLinkTM
signaling1
39–94.1
therapy56
MTA1-PTEN
defect20
MQC
C57BL6/J
dynamics—and
1992–1997
.Endothelial-cell-specific
Non-LCH
SNM1
LTQTM
Smad1/Smad5
crest/neuroendocrine
mesylate.11
Q486X
532K
Hideharu
Ser-381
0.05–0.53
DHX34
Clausen
425–600
HN31/SCC35
10-minute
proliferation,49
307Wang
8.99
23225
IVS14-1ArG
SDA-
Bioconducter
easy-to-perform
and2C
re-equilibration
ActR-IIB/ACVR2b
anti-phospho
seed-and-extend
37°C/5
706-
BII
mm10
Brg1-haploinsufficient
ATGGTGGAATGCCTACTTTGTA
JMJD2B
aminomethane–hydrochloride
CDKN2A/B
meninigiomas
G34R/V-mutated
.E453K
Schlitter
RET-MEN2A
non-SCCOHT
95Â°Cand
.86
c.633C
cytoskeleton.23,24
bBox
A-VA17
ner
GST-tagged
p21-positive
laser-assisted
Vater
NOD/MrkBomTac-Prkdcscid
FLAM
74-78
CellD
.Ranking
Ebf1-deficient
P-0005266-T01-IM5
heterogeneses
*Contributed
W116G
GANGLION
c.466T
reported.23
iQ-SYBR
/xl
G623-mutant
Raf-1Y340FY341F
333.33
killer-cell
40.7
RAATTY
E-box
-one
WD40-associated
OVCAR3
W.R.S.
Drosophila.31
nclusion
Pb-AR
Hyperkeratosis
FL46,47
Hoxb5
p-Nitroaniline
non-competing
HDGC.8,9,22-
4.58
’
T11
years±8.5
Shiyan
Y199H
Vivid-Aqua
phosphatase-2A
5′-GCCTTGGCCTTCTCCTGCTG-3′
.Less-cropped
homo-oligomeric
vivo.27
kb.49
36/122
leu­
C-RAFpSer621
30D21
translocation-induced
stimulation.15
.19
EGFRvIII-transfected
anti–BCOR
72.9
IC50=92
G719/L861
QIAampDNA
.AKR1C3
lOp
5′-GGATTACAAGGATGACGACGA-3′
sh-LATS2
radiation23
p21-containingreporter
Dean/Jett/Fox
mock-irradiated
40–58
p.Arg272Cys
activity.61
3.870
GAGCCAATATTGTCTTTGTGTTCC
5'-GGUCUUCACCUCAGACACUtt-3
2.24
5′-GUAUGAGUAUGACUUUGAAUU-3′
compressed/merged
-r
5′-CCGTGCTAGCATGGCGTTTGTAGCAGGAGTTATTCG
454–825
KICH
Cologne/Bonn
Ecopak
—an
cross-validation
Xeniipus
factors.In
c.104G4T
5'-TGA
anti-CD5
proteins.15–17
www.tcoffee.org
vinblastine
ACATAGCTTTGCATCCTGC
Q-trap
Co­
TSS-100
Runx1-CBFβ
IGF-IR–LUC–
35–
1654–1657
AG2986
.56,57
63-73
FIP1L1-W-PDGFRA
K483S
33-95
.EGFR-G719S
DOANE_BREAST_CANCER_ESR1_UP
V14
NORM_TOTAL×sum
1.5.4.23
8·1–24·9
antidemonstrated
rearrangement.13
MPQ=McGill
9/161
.Suprisingly
807o
anti-PARP
Y–F
209199_s_at
agalactiae
V344A
TTGTCA/gtaagt
32plabeled
pro-mitogenic
1.5â€¢5=
68Ga-DOTATOC-PET/CT
non‐synonymous
CDKN2a
H139P
B2201IgM2Thy1.22
DLBCL5
explained.32
highest-priority
17.3-62.1
interpretation2
video-microscopy
ERK-regulated
nevi,11,18
48/136
CD37
-transbronchial
CTTCTCT
KRAS-mediated
5-dimethylisoxazole
anti-FOXP3
NM_139135.2
TTAGGCATTGCCCATCTCCC
pLenti4
109/151
L704N/D837A
Vevo
E16–E19
.HBL2
R279
.Fumiaki
KMT2G-mutant
N550K
DNMT3Awt
p21/WAF1-targeting
DMSO
carcinoma.1
35931
RTK-IIIs
40/0.65
Ala37-Met38
+/nd
mutation2
mutants—were
-BamHI
NOTCH1-mediated
neurone-like
5'-GAGGCGCAGACTCCCGTGCCGCAC-3
anti-CuZnSOD
E3-binding
2011.6,7
Shakya
FoxO1T24
TP53-mediated
Rho/Ha-Ras
p.Val259Asp
JH1-located
021/ELN
I365del
RIT1-mutation-positive
FOXC2
q11.23
gbAY024361
LMP7
doi:10.1097/JTO.0b013e3181ec1531
12/10
PanIN-2
onset-age
11.578855
Cos7
French-American-British
KMT2-containing
haematopoiesis-related
hkl
Pho
gender/smoking
basic-helix-loop-helix
2340
Grabher
ΔDNMT3B1-7
1,596
502c-Kit
recapitulation
3.5m
Szerlip
locus14
HER2-enriched
`activating
IDH-transformed
ALKR1275Q+EV
r1998
1G-H
P-0003529-T01-IM5
0.707a
NB4-R1
Polycomb-related
ATR+/−ATM+/−
III-encoded
Desmoplastic/nodular
9.9-28.1
11.5±3.8
Y1278S
eight-fold
A648T
A2–D3
Gata4-6
-R4
c.26T
9126
-CTCCTGGAACGTCTTCCTCGGTGAGGGGAGGCCCTGGCGG-3
LQ-006000-00
H1417D
.123,127
complic-
Large-Scale
Chimera.5
5′-AGCATGGGCGACTACATGGCCCAG-3′,5′-AGATTCCTAAGCCTCCCATCTCCCACACA-3′
destabilizating
TIP3P26
patients24–27
p109Fig-Ros
M-Coffee
zymography
BACH1-P47A
18/27
54/70
hydroxyflutamidc
.Phe788_Met789
upregulate
Figure1E1E
150-kb
FP+TN
gene17
GI:55732457
high/low
AKT-MTOR
13.9
.Cdk2
155–162
byDNA
4695
4/50HPF
.BAF
microcancers
LMB
wnt-1/wingless
TC21/R-ras
phenotype.This
pro-mitotic
differentiation114
Figure2c,2c
TCF3-dependent
1sh
-10.1
Col11a2
Zankl
MMP+
Egr-2
state13,14
serine-21
P.L707Se
1115–1118del
48.3–49.3
G77A
N-glycome
53-kDa
C57B1/6
minibody.26,48
Nayal
ch15:55.9-56.1
SBC3
amplification/polysomy
Ramos-Gomez
CDX2,13
Reutlingen
RB24-RT-as
0.001aCD4
Tet1−/−
63.6°C
5′-GCCTGAAGGTGCTGAGAAAG-3′
NR4A-mediated
686-953
§Score
PHGDHT8PIK3CA
6,960
cuSCC
4w
MVR
TNRC18
homoeostasis
CBL-Y371H-
c.8754
.eVIP
.16605821
Auto-activated
.S6A–S6E
iPSC-derived
cBioPortal48
PDGFR12
4.80
Aligned.bam
NCOA
buffer-A
capillary-like
days.During
activity.39
9.6-kb
/one
Vwf
-,4
blood-flow
LB996
Study41
metestrus
disease-relevant
ACG-to-ATG
kinase–Yes-associated
Schaftingen
BEGM
M/84
p-ALKY1604
530
33-40
c.1276+198_1386+3761del19280
R324Q
L736
Nacu
0.004
F152I
MCLA32
.S3a-d
previously3–5,17,40
V69F
NGF-induced
6318
retroviruses9
5x
3-f3-hydroxysteroid
CH-4003
3/12
Lys935
f/58
hydrophilic.69
D.C
N1743S
635-amino
Q112fs
spectroscopy
rs6336
p16INK4expressionin
.3,3
9.1.3.1
-perpendicular
19-66
SCLC-4
R790I
levels.In
13971/92
patients.18
al.28
kinase.26-28
IMTS
carbamoylphosphate
305−550
mesoderm-derived
acids18
Bcl-2-promoted
oncologically
Chr9-392F
T157P
SOCS-binding
1,393–1,394
.GppNp
D4S413
HIF-1A.32
0.030-0.078
Y.-L
hMutSα·DNA
SOS2
MAPKAP1
SD-UL
HG-U133A
cyclin‐dependent
mismatch-
14-10
well-selected
proteins.Owing
100MUT
MiniOpticon
carcinoma46
FGFR3–expressing
Met-787
∼8
pLENTI6.3-CMV
14,30
pBABE-zeo-NRASG12D
Macclefields
Cancer-naive
FLT3-ITD
000/mul
RAG-2−/−
poly-lysine
GATA4
lymphomyeloid
antiandrogen-sensitive
P50
107×
Wikstrand
Ba/F3-Mpl/TpoR
R552*
-GAGATCTTCACCTTTGGAAAGCAGCC-3
hMu
two-base-pair
funduscopy
c-kit–transfected
vector–infected
pcDNA3.0-HA-HIF2α
NCG
Nf12/2
viability,10,12,29
phosphoryation
Autoactivation
.Coulie
MCCT_24
miR-126,24
b2-Microglobulin
TRIP11
0-hour
K592
non-receptor-type
LZTR-1-Cul3
plasmacytomas
161.2
6,503
hypertrophy-associated
183X
35/36
S1D–S1J
UCV
CGGGCGATTTGCTGCTGAAG
PtenloxP/loxP
V561D-PDGFRA-associated
protein.25
4-R2
pSG
H3:21–44
MOPS-NaOH
arrowStop
Arg812
PDGFRA-transduced
complex.18
_T
212C
CD41CD81
Medcalfe
R138
14/82
BL41
3-cases
CellMask
isothiocynate-phenol
K13E
*7A
corepressors
greyscale.Full
SC-858
CTCF
MetaMorph
40.3±2.1
Ser/Thr–X–X–X-Ser/Thr-P
V157A/F
e6.2
understood.8
D276–E279
time-correlated
pancreas145
Richard-Allan
Dyspnoea
2•3-cm
ligand-filled
CACCTCTGTACAAAAGACAAT
c.1668-19
IU/L
Pik3cg
panresistant
nitrophenylacetyl
mPtpn2
Vecta
ClaI–SpeI
0.020
v.1.73
R119W
4146
F301L
.Briefly
LV
λ-protein
FLAG/HA-double-tagged
.Diaminobenzidine
p.H514A
cafe-aulait
Y62C
9–16
5′-AGCTGATATCGAATTCTCGAGCAGAAAATTTCTAAGAATTCTGGGCTCGAGAATTCCTGCAGCGCT-3′
Y21A
ClinVar46
Placebo-treated
BCR-JAK2-transduced
.RhoA-induced
F788L
.LSA
107/817
Endometrioidl2
CAGCAGATCCAGAGCCATAGAGAA
PIGtailed
DesignStudio
CCSP/Ki-rasG12D
FLAG-Elf3Δ173
Cdc42F28L
triple-Flag
Bright-field
9,197
0.5614
7-31
QTRAP
Trp1436
MYC-upregulated
PDGFβR1711F
SCC294
3-10
CAGA-renilla
h-h
EGFR19R3
isocitrate–IDH1
Giα2
predicted35,36
conterparts
CPD-mutant
.Neh2
982–1068
adaptor-BTB
p313G-EAV
GGA-9GTA
9.2–10.8
MMEJ
17S1322
R206H-transfected
NP_005887.2
ErbB2_ex24-27.SF2
sequenceisfusedtoa120-basepirERGsequence.TheTLS/FUS
-RalGDS-Rap1b-binding
1/3000dilution
Srepeats
exon-14
mutant-receptor
Leu-344
committee.33
nonhyperdiploid
.Objective
COF
agar.FIG
10q11.23
1435
,63
.GrG
CAAATACCAACAGGATCAAGTTGTCAAAGATAATATTGAAGCTGTAGGG
Pro772
Circolo
E276Q
N=261
STI
RPL3
RET/PTC1-JM
before/after
R32665
v4.1.2
c.64G
MEHD7945
SK-MEL-24
patellae
R.P.K.
Rad502TEV-containing
OA3
RT-PCR–negative
cells,3
cell-line-based
transformedby
F-18
solute
1545–1563
Butrynski
HS-69-ST
RBM5/6-depleted
mR1
.Desirable
//www.dnalc.org/bioinform
leucine–arginine–glutamate–alanine
GGAAGCACCCATGTAGACCTTCTGG
ACAUAUACUUCAUGUGUAAdTdT
Geranylgeranylation
cancers62,63
0.57-kilobase
surgery139
neomycin-herpes
EDTA-treatment
SHGC-78184
~265
G496del
pHA/T3
N822K.25
LND
CDK4/CCND3
***P-value
basis.Previous
neversmoker
ERK1/2A206V/A189V
immunomodifying
Ser62
450k
841–847
GTPaes
Tarceva®
0.0004–0.0013
gi50554795
4695S
34964
ENmyr
CCCTTTCTCCCCACAGAAACCCATG
177.00KB
osterix+osteocalcin−
5'-3
Magni®cation
.PTC
P1770S
tcctag/AGCTTG
M749
activity.7,13
12/16
thiolester
non-peptide
covariate-specific
DEPDC4
,742^747
activation/constitutive
p53-H179R
therapy-treated
over2
six-week-old
Fluor488
CTGCTGCTGCTGGTTACTGG-3′
T583fs
DLT
.MEK1-C121S
14/22
β-D-1-thiogalactopyranoside
DMR1.21
inhibitors57,58
pFox03A
8.991
BioReagents
.0110
ramucirumab
2.26E07
U0126
Myc-epitope-tagged
Yoshitaka
Hs00296979_cn
17-amino
1uL
T441P
Biobank/IDIBAPS-Hospital
=24
F-S256F
ISDFGMSRE
AccuSure
W4011
IKK/NF-κB
SH-SY5Y
ecacy
.Chromoplectic
61-aa
pGL4.36-MMTV
beimportant
AD/CBFβ
p.Ala735Thr
Canada/Canadian
PHAS-1
15/106
30.83
1127–134
inhibitor33,34
Smad4412–514
CTD-2107N14
.Assaying
acidresidues
osteocalcin-cre
33,36-38
nonsymptomatic
G617V
anti-FANCG480–622
procedures.8
mTOR/Raptor/Rictor
A-Barcode-Exon21R
L98S
Cullin-3
APOL6
p.Gln2418*
1A6
Rictor-positive
Gastroenteropathology
84141620-71
estradiol-inducible
Gal4-RhoA.V14/S190
4867
319/290
SOX17-HDAC1
44735
−Serum
column-purified
high-throughput
17-Hydroxyprogesterone
21m
MF1
T1055R
13q12.3
EZH2-RAF1
liand
Ashkenazia
55–65
M958
NM_002872.3
2013P002667
//mct.aacrjournals.org/content/molcanther/12/2/220/F2.large.jpg
V5/his
97.0-fold
LUN02
DMBA/UVB
p.Leu103IlefsX10
M269R
TETr–DNA-binding
Calbiochem/Merck
Ros1
mutations57
~g/ml
Recurrence-free
Ptenf/f
Jabado
-1,100
.HUVECs
NM_182830
underdetection
NH2-termini
TNFSF11/RANKL
pNZE-CAG
neuro/glioblastoma
mechanism.14,15
.R283H
0.33
braf
osteoblasts18
ALF
c−Src
PI3K-Akt
13.58
Génétique
Met269
ACINAR19
P=0.038
BrgKR
Asp842Val
n=105
tumours74
ab87000
DNA.Induction
PCO
I15T
al,29
p38/JNK
KARYOTYPES
K97MMEK1
γ‐methylene
BaF3/pLenti/LXSN
FLAG‐Mga
N641Y
p53R248Q
CW2_LARGE_INTEST
hyperintense
14063-5
T704M
domain.5,15
p-MEK1/MEK2
L303F
0.995–1.082
readthrough
ChemiDoc™
5′-ttcagaagcttctccctgacat-3′
globule
C-hypersensitive
MED12mutated
v_o_L._3_I9__27__FE_B_R_U_A_R_Y
erk2
V272G
61,299
ZMYM3
nucleotideexchange
3°–9°
Products-Calbiochem
TAATACGACTCACTATAGGGAG
33,045,756-50,579,508
SHOC2S2G
ALL-1
anti-ARID1B
−1/−2
pneumonectomy
p.His514Arg
U01-348
homo-oligodimerization
RED96
lymphobastoid
myeloid-cell
pIRES-*9A
92X
Ravegnini
benefit.13,14
5′-GAAAGACCGCGAAGAGTTTG-3′
Asp-108
K139R
Amplex-red
MCF10A.DCIS.COM
12.Inhibition
Ellipsoid
32,643
R.B
S435R
Fantl
PTHrP-receptor
ψKxD
Ninewells
L263fsX285
L1600E
Rau
0.720
.MC3T3E1
P0030
5′-GTTGGGGAAGAGGCTAGCAG-3′
1α
P342T
PhePhe
WSU
site-specifi
IIb/IIIa
CD68+CD11c−
720
y-32PIATP
2and
TKO100
cancer36
D:32P-inositol
.Soares
'selectable
deletion,10
P284L
1855
225–333
3Ala
C/c.2030G
TIP60
R692X3
AP-1/Oct-1
7850
intracavitary
Acembly
AP–like
2286–2294
MODELLER-6
.Testis
5·105
PCNA-binding
Maximilians
BC-CML
tool45
OR=1.13
4–10
nihms5567f5.jpg
samples34
L175Q
EGFR/HER3
0.38–0.080
R23
52.3
CCE
HA-MITF
p53-R273H-expressing
Multiplate
.SMO-D473G
//www.fruitfly.org/cgi-bi
LFS
suppmat
Meshorer
0039
GDB
.Mean
pCR3.1uni-hemagglutinin
inglucose
inositol–anchored
TAL-
5′-TCGACGATTTACGGGAAATG-3′
resistances.5
FGFR2c
.1,2,3,4
Novoalign
CDKN2a/b
N324∗
2m
45–52
injury,34
CP-31398
TNFSF4
testing.64
2μ
βE′–βF
MSQuant
53.2
Mm768bpΔAGAAAR–LacZ
8801
Flag-AKT1
lines—A549
MSS-ES-1
CCGGCCTTTCTGTCACCTCTACTTTCTCGAGAAAGTAGAGGTGACAGAAAGGTTTTTG
-*-
.V122A
3576GrA
activity73
MicroMAX
GST-Gli1ZF-K340A/K350A
RI7217
V560G
IDH2mut
4,5,6
DNA-loop
P=0.01228
TCCAGAGTGCTCTAATGAC
Tyr60
.Bisulfite
G12VN-Ras-transformed
Msh6pATPase
Gln-101
Smad-2
.Communication
0041-
NF-κB-luciferase
Leu619
Pasca
GG=
M5392
p.N141D
1.25-3.72
Fe2+/oxoglutarate-dependent
T4-polynucleotide
neoplasms5
PCI-neo
53–59
H3:21-44
sulfate-polyacrilamide
I-containing
RB-1
bisulphite-converted
Sbcl2
i~
−8.12
GPR158
hTLR4A-MD2-CD14
one-hit
Arg/Lys
ggatcctaatacgactcactatagggagaccaccatgtcgttcgtggcaggg
plasmalemma
CD45+B220+CD19+IgM+CD43+CD5+
A_51_P322138
Level-2
Nieboer
4.3.2
crizotinib16
N655S
trun-cation
1221
PR–DUB
reduced/enhanced
γ-bridging
Farber
5'-CGGCGATGGGCTCGTTACTC
//bioinfo.genotoul.fr/multalin
Nikiforova
.Helix
1Intense
SCPRED
ROS.8,23
87,957
control78
intravenously.20
proteins2-deficient
-methyltransferase
p11.2p11.2
5'-TACAGGAGGCTF
99.2∗
.Rb
sc-366363
T47P
PBS-NT20
E102K
GTTGGTGTTCATCCGCTTG-3′
R55A
F.T
least-selective
Chk2.Figure
CGCCCA
expression.25
caspase-8L-expressing
∼20
exclusive—that
regulation45
NSCLC.5-10
605642
MEN2A-associated
TTTGGCGC
≥2.25
906-
immunoflourescence
0.00015
analyses12,13
Chalhoub
arginine-proline
7271T
P-815
4333764F
.SOS1
vitro.32
T80
SCF/Kit-induced
CTACAG/gtaaat
Apc1638N
G874S
Chromation
LLS-1
NM_173614NM_001114734
F104S-GFP
18-61
Squamouse
ligand-bound
c.1217G4A
7,22
Lifesciences
Ser217/221
Wap+
reminimizing
electrocardiographic-conduction
.Putative
case24
genes.13-15
3.4-fold
bombesin
responsiblefor
G41R
caspase-8-
MEK/ERK-dependence
​Chromatin
stability13
allele-containing
D419Δ
Bri3bp
identified.Chromosomal
hormone-deprived
SW480/SW620
.Homotypic
Murai
KNS-81-FD
/ROR1+
hepatocarcinogenic
+57.021464
IVS12+2del21insA
0–10
0.418
Hsp90/mTOR
Contaminating
J-domain
L255S
'2
Canagarajah
Biochemica
49,91
−5.0
proleukemogenic
thieno-triazolo-1,4-diazepine
K27M-mutant
C.D.A.
25mg/kg
sarcoma12
Mll1-deficient
phospho-AKTSer473
ProceduresCell
4.90
155601
BCR1+Bam
.BeAtMuSiC
GAATTGTAAAGTATTTGTGAGTTTG
NKX3-1
12-370
c.1168delT
17628
69~77
pmGFP-K-rasG12V-V152G
ligand–receptor
2-HG-dependent
PDGFRAmutations
RP11–47G2
0.006/
activity.Tumor-derived
73.16
22q3Dâ
previously.6-
RCAS-A
+pRC/CMV
1–86
610-Quad
diazoxide
spliced-reads
histology—based
mitomycin-C
downstreamn
analysis64
13,924
c-FMS
WNK2
–IGH
33-36
CAP/ASCO
Nanodrop2000
SpecimensThe
4-methyl-1H-imidazol
DTT/0.1
ATF3
V1653M
CD19−
hemizygosity/homozygosity
YY
1,200–2,000
C-Terminus
pMMTVpLuc
CEN1p
GISTclassified
matched-normalized
JAK3-transduced
Leethanakul
1683insA
idibell.cat
Gly388
A484E
response.
R217G
SerlS12Ile
220-min
940C
activity,26,36
myeloma21
Biosyntan
20a
P1812A
biomarker-driven
120436
Ourp53
placebo-treated
siPPP6C08
Medves
Glu66
thatmost
src-like
cellintrinsic
isenhanced
wasobserved
Nonexpressed
hydroxylamine
T226S
A-loops
210708
DKMG
bThese
Hs00846401_s1
High-affinity
0.74
anti-VWF
5.628–46.47
*p=0.0035
SacI-NcoI
trans-activating
pS6K
MaxENT
RNA-variant
1–associated
956G
birefringent
syylwu
edematous-myxoid
disappointingly
50ng
.Stallcup
IRS-III
MEN2A
high-
H168R/T123A
8q22.1-8q-terminal
D814C
nlysGl
161:2133-2141
D323H-KD
V2908G
β-cell
microRNA-mediated
IGJ
H-9
D341Med
ΔRING
CFU-C
neurofascin
times.DX
60–amino
Zymed
CABLES1
Xaa
R228C
n3
Horii
andR283H
Launoit
selenium-methionine
NM_015135.2
16-101
rs2363956-T
3T3cell
8:11–23
3.3b
domain.The
SFA8
16O
XP.16
EJC-independent
phenotype.11
autoantigenic
LC1
J054
51.2
pbabe-hTERT
HLADRBl*
residuesrequired
20×
linkbetween
GRKKRRQRRRAP
Pindelj
Synthesis—L6
6026
FLI1,30,36-38
β-strand-loop-β-strand
ATP1B-PKACA
dectin-
OTP-binding
55.0
shown…
studies,11
AMBER-compatible
OncogenicCCND3
RNAi-Mediated
V664E
139.00KB
TFG-NR4A3
KRAS-wild
anti-Glu-Glu
delL747‑P753
cells.10
7.5Nonsense
S32I/WT
.MSCV-KRAS-IRES-GFP
Q510E-Shp2-infected
TRA98
stimulation.Because
blasticidin-resistant
EWS–Fli1
15·8
LMP2B
1599.8
pJade-1sh1
USP
Attal
dot-blots
D1-17-13G
RP11–388F14
Pack-years
Rubinstein-Taybi
LSM14A
SOS-Catalyzed
x2
Curix
HER2-expressing
mitosis107
anti-BRAF
-74
.Dox
proteinproduction
S1199L
13~
L188
GISTswith
FSKFGG
doi:10.1038/cdd.2015.157
Apoptogenic
tetra-methyl
PCR-Script
NBL-like
EphA10
371-411
SLC5A3
.SIRT1
D931
©2017
R4013W
.RQ
t=mi
SPOP-C
RhoA.N19
analysis19,30
steroidal
.Exomic
MEK2-induced
Glu-287
6789
N..
NCT01529112
SYBYL8.0
4A/S366A
10.1158/1535-7163.MCT-13-0667
R371
ISWI-based
EMP2
phospho-Mek1/2
60438
AG|GC
AGCCTTTGATTTTTACAAAGTGATCG
Ala68Val
Activity/Inhibition
Akt/GSK-3β
raÃ-gene
ribonucleotide-deficient
.1,3,4
..-
inhibitors67
GFP/Ly5.1
2/85
.Variable
NOTCH-activating
F100
.R17T
TRiC-mediated
ACVR1
GAGCAG/gtaggt
C220Y
LAPC4-AR
ΔF
81-6-6300-6206
n=201
producedpuro-expressing
candidate-tailored
1654
A–I
HRE-containing
4.48+1.16
T1720A-L
KYSE
Peteiro
pre-wetted
NBRF
0.8.1,8
lymph…
ÃŸ2-MGR1881
Gþ4544C
.MHC
pGal4
3706
G3143A/ATG-+ATA
∼100
.Doherty
pEGFR/input
luminol
marker.12
α1/α3
0.6
2X
PCM
55,56
30C
Bernard-Soulier
lipolytica
10-08
G356D*
α-33P
.GLI
anystage
ap53-deficient
64/259
chromosomes.66
ÃŸ-catenin-binding
Fig.4B,4B
61,81–87
Mll3-suppressed
Tetramer
4956
5,9,11–14
Inv-mut-AA2
Vector-specific
4433
Asn10
.PHA-739358
Cys-X-X-Cys
transactivationalstatus
U/mL
Barana
188.4
LZTR1
Notch-regulated
Braggio
TEF/TEAD
histology.16
afterthe
myod
BRC47
−3.87
RASERK1
–,12
interhelical
20–3.5
5'-region
GNNK+
0.149
anti-Nrf2
Xiangya
oligodeoxythymidylic
Mgat
23.179
A–adenosine
CD28/
geneticin
SDHD-mutant
tyrosine-820
ACK1
metaphase/anaphase
testogenesis
Mikroorganismen
étal
pg/reaction
FANCA-FLAG
464KB
Pro252Arg
M1B
.GFP
β26
syndrome,18
F590S
≥13
PG-13
myrAkt-expressing
CPN2
15706
Brusatol
Splice-Site
GGCTCCTGATACTGTCCAGT
2.5mCi
study14
RAB25
-2101C
.Trimethylation
.1075C
1:300
ones.32
Y790F
promote.60
12.5-kb
residue-
642
MEF−/−
A322G
pcDNA6/TR
TGF-β-mediated
P1213
1,689
G401
Sox17GFP/+
re-sampled
GAAAGGGACAAGAGGGAACATAC
5′CATCGCTGATTCGCACATGACGGGCTGCC
His-Puc1-390
W74
Cofilin
Swiss-pdbviewer
4/14.3
PIK3CA-mutant–resistant
Supershift
XhoI/NheI
cbECFC
5′-GATGATATCATGCGACCCTCCGGGAC-3′
412del8
CpG-flanking
RHOA
H321–44
SF/IIGF
V600E-activated
GAPactivity
MEKKs
PTPρ
508–513
Brca2lex1/lex2
microenvironment-dependent
A08-M77-13A
DP8
-AGTTCCCTATCCGCTATCC-3
.Progestagens
3915
C.C
fusicoccin-derived
well−1
mediaSaccharomyces
VCaP/VCS2
anoctamin
LMS-2364
R274L
previously.1,4
62-101
790/791
GEMM
byBernard
+Dox
colony-stimulating
PLC-PKC
urethane12
CCND1/cyclin
Mann-Whit-
3.1.5.
biallelic-type
ProTherm
siRET-treated
502549
.Yoon
Kd
JAK2-V617
CultureBa
R158G
​Figure3A3A
4UXL
GeneBee
HKY590-6D
cells/site
188del11
KCNR
Tet2/Asxl1
anti-Ptyr
3VJO
systems,16
End-of-study
SH2-SH3-SH2-PH
class-defining
ggaatagccccatcttttgg
CTCTCCAGAGTGCTCTAATGA
152/160
TCF/LEFresponsive
11q23/MLL-rearrangements
24-nt
HypY
FACS-purified
Gartel
NuPage
promise40–42
duplication-distribution
CDKN1B/ETV6
L87P
PTH
669T
Tgfβ-induced
.There
250000
IVS24+166A
2,739
2-mediated
984
-29A
.PTPN11/SHP-2
change,7
21.5
sepharose-bound
11719
thymi
flapases
receptors.6
S~~~~O
R280C
21.72
fibroblast60
phosphatebuffered
FANCD
deep-
Ser/Thr
A146V
drug-tolerant
3986
Low-copy
RPI1
0.559–3.315
Q986
structure42
diseases.5
v-Jun
.Mann-Whitney
thatmutations
101–
and_
ganglioneuroblastomas
G-3
AdG2
D1–CDK4/CDK6
neurologist/geneticist
PT08.2
MK08353
7/35
95/133
hypereosinophilia.36
Muroya
Duñach
7p21
system.35
DP9
Protor1
PAP-1,10
.1d
Malkoski
p53-DNA
Laherty
Ap-2
13·1
CKIT-D816V
individuate
13,23,26
non–small
pCMV6-R132H
STARD3
.Cross
shFoxA1
-2pyridinyl
34Efu/J
0.0654
glioma-like
resistance.124
1469
SAMD4B
5E-F
enzymesPst1
cross-linkers
5753
.MG132
123456
Horba
160.0
5'-TAGCGGCCGCATGGAGGAATTTAATTCG-3
trials162
9/13
mutation.18–20
melanocytes,9
p.N239S
.STAG2
pathway—involved
3.544
PJS115
.Haematologica
4/2,154
Receptor-expressing
TBS-0.2
.Pmutfreq=P
A461
SKCM
1354-1377
55–64
imaGENES
over-rides
EGFR-EC
1-13
K1AA1549
tumorsand
NEECs
JM103
RGC32
TK-neo-NIH-3T3
lesions.31
CHUV
–qPCR
235:1
D11S2180
R89LRaf
tumors.25
β-Strands
Exon7
elastase
doxycycline
EE344A
2.216
∼33,500
28/F
thesecells
.TEL-PDGFRβ
obesogenic
YAP1-mediated
PIK3R1R348∗-expressing
HPV-negative/TP53-mutated
Speci®cally
v-fil
DAPK/p14/
α14
TrxSmurf2
Mm768bp-
Inactivation/Precipitation
technology.12
4993
5′-CCTCTCGATGACTGTGGTCGCCTGCAGG-CAGCGTATG-3′
Pbx1
KMT2A-independent
pSF9114
Arg177Gln
tumour-suppressive
p.R167W
17-fold
pIREShyg2
AZD6244.59
phospho-S6K
melnomagenesis
Vacic
upder
1Y98
Adamts1
MEFs.C
prognosis,10,11
KpnI/SacI-digested
12a–f
Ser392
phagocyte
5-minute
BMPR‐IB*
thermocycling
SMARCE1
L1326
short-time
CD10+
RKIP_U_R
80-106
,64
Ce´re´brales
19/66
approx35
.6c
rdetectable
P26–114,113
p.Gly12Glu
www.mwg-biotech.com/
​Table1.1
L571I
mutations,8,15,27,29
MKL
Brillliant
anti-phospho-FGFR1
Bonaventure
assay.22–24
database,16
timeto-progression
KRASK147E
SHGC4-128
Met309
Metl652Ile
12,961,302
context,31
49/50
.Neuroradiologic
copy-ratio
ATP1B-PRKACA
reported.12,27
226/1333
1–196
HERVK17-ETV4
ThrGl
ΔMlh1p
alelles
Akt2/Akt1
Aoba-ku
0,0,1
doxycycline-inducible
mice16
Trisacetate-EDTA
p21q11
E−800
9,15
215
.Rationally
retrieval.17
C1–C3
.c.2035C
F123I
Lys3326ter
Vegfa
pcDNA-mtp53
Tra
Oliner
5′-CGTGGGCATTAAGCCGTGTATCATCG-3′
0−8
SRNS
cells,8
Ad-EGFP-transduced
R94T
phospho-Y878
thenormalized
.Microsatellite-based
.Impairment
cell-like
SURV
Sahlgren
Yeo
Fluor-coupled
keratin-5
GSYY
X-rays
formof
Frijhoff
FL-CDB3,1
FGFR1.37
4547
phosphate-citrate
9–93
nickel-chelating
Batra
MY321
Log-Expression
bensonase
Inestrosa
survival.58
.Inconsistencies
vitro-studied
CHEK2-deficient
p.866E
helix—bright
site.11
105/mL
E1090K
26/112
Tyr426
5/26
Ciba
KDM2A
Ricerche/Progetto
spindle-shaped
V360
yki
domain.27-29
P80L
V54D
1-day-old
sandal-gap
Co-Immunoprecipitation
to25
Plattner
700/L
p15ink4b
RAD51-mediated
K342
3/4
V.22.0
Pten−/−
5'-TACAATGCAGAGAGTGGAGG-3
detectedby
Sot
p15/INK4B/MTS2/CDKN2B
Tordjman
MLH1-linked
15.86
NM_139135
SP49
In-frame/
D316
trametinib.22
.LEE
BRAFi
4095
Ca2+‐binding
PMC1850562
Plk1-PBD
p53/63
GNK4
0.8435
intra-peritoneal
D9S1786
K3468
Xiril
co-repressor-dependent
MOLM-13
SK-MEL-23
SK-MEL-33
7/8/02
performed.18
Hyperbilirubinemia
Del-insert
libraryof
S.-W.
Proteome-wide
IVS16-20A→G
1-chloro-3-tosylamido-7-amino-2-heptanone
BK4
M.G
conservedportion
R108C
YCpUG
sets/37
2.1-632
TIRF/Epifluorescence
004333
R51H2
alpha-Catenin
siFbw7
Cul-3
S.D
.LUCC2
nature.comAlthough
THRA1-AC
DpnII
micro-metastasis
marker.8
FBXW7-mutated
Dauphinot
leukemia3,4
Tyr641Phe
deindexed
siNUT
spondylometaepiphyseal
VHD
≥66
frameshift
77/91.7
Deppert
time.7
signatures22
Fiser
RP11-79P5
27,47,49,50
95Â°Cfor
patient-matched
L19F/Q22K
non-inflammatory
505-530
Jaccard
20.e
66336
331K
30-μL
MKP-2
slideImmunohistochemical
Misopropyl
methylenetetrahydrofolate
SF3B1-mutant–
PLCrl
0.393*
covariates.This
FSN
Y16X
Fbxw7fl/−
2500:1
2–5-fold
4.97
conservation-based
B250
3-hydroxypicoloinic
nonprofiled
count.When
bind.14⇓-16
MutL-nucleotide
4/250
ALOX12B/ALOX15B
RABEP1
V29L
P478L
DDIT3-mediated
0.27-5.48
PTEN-targeting
.R-Ras
theMMTV-CAT
Q1070*
​Our
transcripts58
.ShRNA-mediated
phospho-Ser/Thr
IGH–MYC
U.S.E
receptor–bound
.One
Figure1e
ARF876L–bearing
bp.RT-PCR
color-specific
≤0.2
G37Ras-mediated
post-acetylation
S219C
foci15
than1
11.77
74.96
cancer-not
M0760
e7
carcinogenesis27
Lys125
alterations.3
self-regulation
RC2
GCAGCACCCACTAAAGAAGG
4.18×108
R2
0.7–1.7
Y412
.Aligned
Dnmt3a-mutant
RNAP
CD4-CD8-
cDNA27
p.Leu518fs
.Hematoxylin–counterstained
55.29
RPL23
Viciana
96.61
Eand
backgrou
25/92
ERRFI
PIPKIIβ-binding
scurrentaddressis
p.R961W
8941–8944
IgG2
c.4952C
DelWK
Mutationsof
trP1-Exon21F
NOTCH1/NOTCH2
4933
Caratozzolo
p.G12V/c.38G
rear-face
W437STOP
.1994T
10:1
W2+2WM+M2=1
Uracil-containing
Erythremic
0–11
gBlock
insulin-signaling
63.8
p=0.34
cell—would
damage.17
D180D
pry
2.5μg
1.8–58.5
JMMLs11
5′-CGATATCGCTGCGCTCGTCGTCGAC-3′
spectrophotometrical
pcDNA3-p53His175
GCGCGGATCCGCCACCATGACA
1260
sorafenib-responsive
SERM/SERD/AI
28544795
K-RasV14I–mutant
186K
receptor-associated
antibodyspecific
c.1153-5_1153_1delAACAG
IVSS
NUP98-DDX10
neoplasm-unclassified
MED12-associated
Glu663Gly/deletion
.ΔHM-AKT1
0CL
Td-Tomato
F115I
c.9501+3A→T
ra/or
/IGH
tastases
Chirurgia
2/MTC
POUlike
M552_Y553
18,24
sub-cultured
315P14
3A–3D
.ARID1A
triphosphate‐bound
A133P
2280S
c-Abl.43-45
GRID1
Apaf1
Pattenden
NETN100
p53,14
oncogenic.18
29,700
KIT-Y568
64–2.18
SC6556
His231-Phe233
CUTO-1
Nickoloff
SMAD1
76-gene
TSC22D3
Y589/591-mediated
L188V
ERBB3/p85
A5
His-VHL
O-fucose
enucleated
A036
asyes
C7
ichr.uwa.edu.au
veterinarians
transcription.46
c.3197G
p16-
–corrected
CHIP-myc
.Phospho-AKT
deubiquitinylating
hybrid-capture
p.Gly778_Pro780dup
5-y
+ValS10
tothose
.examination
32/37°C
RPKM/ΔPSI/ΔPIR
5′-CAAGA-ACAGCAACGAGTACCG-3′
Ile171Val
193,094
A1708ER
2-NBDG
0.5665
PLGF
6.6-
P+3
therapy-responding
8078–8083
2,097
Superfect/DNA
607721
myristoylated––a
5.07
Six-week-old
triterpenoids
FKBP15
Página
ducts33
H2k27me2
264×
LC-MS
RHOA—Gly17Val
propane
SNU-668
agent-free
pMCG25
time-to-event
1409-1743
'pseudo-kinase
91/162
noncardiac
FLAG-MEK1
p16INK4A-del
shAXL1,3,5,8
micromoles/liter
SKG-IIIb
riboprobes
EWS/FLI
luminal-type
A4074P
α-Ldb1
Clinico-pathological
Tyr-CreERT2BrafV600EPtenL/+Ezh2+/+
R834_D835
FSTL5–Hippo
lexicographic
18/intron
lOB
trans-autophosphorylate
logEC50
PRMT1
C2962T
2E-F
single-institution
UltraView
.33B
ACINAR15
W349
rhabdoid-like
5′-UUUGAUCCAAGAUACUUUGCC-3′
K83
GST-PI~
S3E-F
Blasticidin-resistance
FLI1.40-44
patients.Study
4370S
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F2.medium.gif
34-5
LO.2
Met1051
J3-galactosidase
TDP1
Erk–mediated
BRCA1-PALB2
198×
probe/nucleus
Biomedica
HIF-1α−VBC
non-confluent
LDGN
0.088213698
high-titered
​Western
hydroethylpiperazine-N
PD-325901
singleagentin
XCyte11
RING-finger
2.5-Å
2–subunit-encoding
ENST00000341545
1.5–16.7
EUFA262-263f
LOC284661
pcDNA3-DEST
glycogen-containing
cancer,5
Transcription-Polymerase
domain–core
sirtuins
G-protein-GEF
UMK
type-EGFR
CommentsThis
FC-1801
oftumor
EIIPIVE
diseases,3
Second-strand
Aliex-546
PTPRZ1–MET
CLCA2-negative
Gascard
17A
pCTCTACACATT
.SBC
csJ
.Amplifications
Ã¼Ã¼
LIM1863
cER4-22
CH5424802,18
LATS1-301-525-GST
www.eurogentec.be
LOH.31
1,3
low-density-related
ivs38-8T
Gln432–Ser446
Trp58
TRA
ht/ht1
domain-TSC1
884
Asari
6.006
Ostman
CD1-Foxn1nu
sHpH
ALK−/−
5919
180M15
WA42
YxxPxD
glycoforms
phospho–
Peltonen
0.6178
R498
Follicular
erythropoiesis.82
TEL–ABL
c.1421_1422dupTG
A750
AE859
intraaxial
embryogenesis7
EF1A
CCTCGTCAGAAAATCCCAGA
5′-TGTGCTGGCCCATCACTTTG-3′
MORT1
.Gates
009
S291fs
q13q24
177-444
monophasicb
2,334
8.80
anti‐EGFR
NPR4
1,923×
m/74
840_848
S171P
Tright
anti-MEK1
G278R
//www.broad.mit.edu/cancer/software/genecluster2/gc2.html
mMisopropyl-β-D-thiogalactopyranoside
T14-3c/PMA2-CT52
miRNA-controlled
IUpred
CFA626
TPR–MET
0.532
D77V
p.Q99X
1.3.1
​and6B6B
N359LT
a-GAL4DBD
.Frameshifts
E746X
49/248
L596V
p.A1065T
3035
function.To
.Damage-induced
WelFect-Ex™
ATGGACCCGA
Meyuhas
1004
MKN
CD110
–TIP60
0.36-0.81
expression35
EGA
Lin7
Q590H
2q31
N-mycp110β
5′-AAAGCTTCCCTAGACGCCAGC-3′
.A.D.D
pC0.05
Santhanam
V235A
73:2760-9
APL
adenoma/hyperplasia
gszqmmmm
IV1
retina-specific
fibroblasts32
1×
QIAGEN
N148K
B-progenitor
5.97
status.11
N2-
inconsistence
NM_007570
D1778N
PTPRO-omicron
non-R132H
strain38
Leppig
6•1–16•6
c.3193_3194insA
al.,20
1,680
-GCAAGCTGACCCTGAAGTTCAT-3
0.201
intra-S
Cytoband
mechanismhas
pmCit-N-rasG12V-T50I
c.676G
liver.13,32
Llobregat-Barcelona
KIT-Driven
rearrangements.18,19
CHOP-14
DN-MMKK4-Flag
KIT-W557
7,13,16
Eppert
E1024*
hemangioblasts
RAS-RAF-mitogen-activated
5′-ACTCACCCCTGTCCTCCTTC-3′
P-JAK2
Thr117Met
bloi
CAATTTAGGTATGAAAGCCAG
2161
16.86
1
Rosa26-LSL-Eyfp
HR+
60-90
6.6-kb
.Thymocytes
R1644H
Jagged2
PtenloxP/loxPRictorLoxP/+
LacI-CHERRY-BRD4L
TGF-b4
V746G
alpha-naphthyl
5.8–20.0
16/21
4861
regulation-related
–2.0
.IKBA
EINGNNYVYIDPTQLPYDHK
U2AF1-associated
ATR-A2
42/60
1001
APC-dependent
-116
Macrofollicular
CCGAAGAGGCCACAACACTT
aorticaneurysm
M143K
colorectum
.Anti-Chk2
azacytidine
W267R
Analyzeda
PIK3CA/PIK3R1
14/98
EZR-
ZFP64
25.5±11.5
ABI310
h-actin
quinazoylacrylamide-based
BARD1—To
tumor-susceptibility
PAK-JNNK-JNK
marks,22
theTPR
WE-68
2–47
mice.53BP1-deficient
BMDP4F
WT-ACVR1
EXO-SAP
al69
Kitl22
BL4a
1.018
SFA2a
p.Arg2602Thr
carbon-coated
EMM1002-6822456
viral-
.FLT3-JM-PM-expressing
HIF-α—In
cancer.21,22,36
.Fitting
σ2
ofDX
P2ΔN42
t2
hCollagenase-1
28K
Ciceri
primary-care
fgfr
BgIII-sensitive
WEFPRENL
topoisomeraselinked
z-VAD.fmk
thespecificity
//www-genome.wi.mit.edu/genome_software/other/primer3.html
2/55
EURTAC
tyrosin-kinase
1738F
DiscussionThe
i-
Lymphoprep™
A436E
ResultsIdentification
4•14
esophagectomy
1,284
reported18–20
so.16
immunhistochemistry
.log2/
Ala121
708–717
RalGDSRA/ras
790.6
~~2.~~~
BH1
Nfi-1-
CompleteTM
gefitinib91
siRNA-Con
.Malignancies
LT2.0
−20.0
Q902R
half-sister
.Mitochondrial
formalin-embedded
REML
pathway,34
Meriin
StratificationIn
.Double-mutant
KB48
immunochemical
Guanine
pRSV
58.9
anti-CCT-1γ
p71HA/T3
c.1165C
Topoisomerase
n=203
Bosutinib
.Conversion
ADH1
PHAII
7TM-helical
W731
TCGA-EB-A3Y7-01
A.S.Alberts
phophatase
GSM718290
α-hydroxyl
4.102
G2C
850G6
L188P
RUNX1-ETV6
SC2
P.E709K
164–194
standard-care
K299R2
CMV0
3.1-5.8
24F.10C12
V741F
RhoA-2A-EGFP
Riesco-Eizaguirre
.Mazie`
V544ins
Ras–
4F65
pAIP1s-luc
AAGGAAGCCACTGGAGTTCCT
.Msx2
two-base
c.156-157ins
1–130
E931
agar-formed
Fig.1E
OMgo-Directed
Myr-WT
31*
IGF2BP3–PRKCA
ERE12-CAT
207K
20-1
RICTOR-amplified
Glu-768
decorin
G1128A
isopropyl-l-thio-B-d-galactopyranoside
E758Ga
clones24
electrostatistics
SnpDB
11p13.3
H493R
clinic-pathologic
SDSPAGE.These
Frohman
Blood/saliva
E864K
PB2
Mll–AF9
602774
+/−1
Fivefold
7.640–11.040
anti-avian
.HER-2
TMK1
EBV-positive
substrates7
+384
shRNA1959
SNU-C4
c.5972G
Y139H
obscurus
pJAK2V617F
T3M-1
P3-5
R2310K
aminotrans-
DCUN1D1
p.Ile605AsnfsX11
antiphospho-EGFR
26,28
RasGAPs
p.G244S
Eele
CD71+
-G364R
EFC3
170-172
3.564
prognosticators
2,255
A→G
osteolineagecells
G610R
transduction
anti-b2m
512
EN-Y628Q
EPD24
level2,9,15–19
counter-regulatory
thisprogressive
Ziller
385–418
venosus
OF2
other.female
59110
Yes35
orange/red
TBP-reverse
status.16
c-MAX
p21+/−
TNFRSF14
223-243
CTGCGGTAATCAAGTTTTTAG
Smad41
.Dilution
Bmi-1-induced
anti-IRF3
144.2
AY588246
T430M
1.33
B-D
Mx-1-Cre+Sox17fl/+
exogeneously
Refolding
motility4,5,6
aerobic
.2246T
SMAD3−/−
24–64
reaction.30
3SBD
0.00308
previously.9,13
Helical
Hs99999905_m1
FER
Annastiina
3337C
2.5×10−13
ABL,7
Ser476
Y1118S
tumours.26
undetectable.12
Gelec
TCAGCTGATGAGTTGTCCTGA
500-bp
39/F
EWSR1–ZNF384
α1–α3
ERα-M1
region.13
GIST159.Secondary
Metacore
VHL3_1F
Snellen
GBM-O
∼1:2,000
pY705-STAT3
6,654
ExoSAP-IT®
5′-GCAAGAGUACGUUUAUCAAUU-3′
C1073Y
gttgtatag
introns.7,28
furinlike
E1250X
Nonrenal
Lys-88
21277
under-diagnosed
72,33
p27Y74F
genomes3–7
functional27
2.02×104
3,193
10.1182/blood-2013-06-
16/10
tcttgtttag
Obremski
DSF
Q903H
5-CTTAATGTGCCCGTCCTTGT-3
podocin
Rucaparib
c.1096c
:2*mgz
tatatttag
.Normalization
D14T2
545
CCGGCTTCGCCTTCGTCGAGTTTAGCTCGAGCTAAA
Myo-D
Brg1K798R
Tuberin-N
Cdx-1
oftrying
rRNA-depleted
resistance21,23
carcinogenesis.98
4-deleted
Mx1-Cre+Srsf2P95H/−
radiation-treated
NCT01271803
.Biomarker
//cufflinks.cbcb.umd.edu/igenomes.html
c-Jun-NH2-kinase
FLA-3000
Arg167
Tophat
White–Black
60–76
ETV1-targeted
TMEPAI
primer-annealing
.—This
Bcl-xL
wu120
clues49
esthesioneuroblastoma
5′-AGAATCGAGACCGAGGAGAG-3′
NOL3
6-minute
CCD-like
TGFBI
tumors.41
E685G
Kemshead
NATHIVVAQLIKN
17946
interactors
beclin
ect
reports11–14
0.35–1.18
CIBN
MAP4K3
RACE7
596–721
Visakorpi
KRAS-1R
treatment9
.Terminal
anti-microbial
CellIntrinsic
L798F/Ha
∼0.8-1.6
Shozo
FBS–PBS
culture-based
healing/scratch
goiter/adenoma
Er3+
5′-AGGTTAGCTCTTGCCGATCCGT-3′
e.g.
5.2.2
.Immunophenotyping
p53-Zn
.Acta
c.380A
melanoma,2
c.1846_1849delACTC
KIT/β-ACTIN
β2-strand
inositol-1,4,5-trisphosphate
v0.12.8
NFKB
HQ700/75
HMG
DNAProtein-Tyrosine
JH1-JH2
pancreas-specific
Sotiriou
R109X
7.51
board/privacy
301–345—that
—NFKB2
588-629
L597Q
method.39
Cocrystal
andfunctional
Luc-reg-15/16
006197.2
c-AMP–dependent
carriedout
16:0
Hs00240887
N242S
study.22
active20
sialyl-Tn
SNF5+/LacZ
-assisted
726-
hFAT1
DICE-1
NM_000535.4
Hopman
PDGFRB
methylation17
EN-based
BLUTEAU
D374Y
.RACK1
.Skipping
ABI-FAM
ScXPO1-Ran-RanBP1
ATCTCCAGCAGCAGGTCATTGAGGGGCACCACGTT
3374
E62_A66dup
Bmpr1a
peroxynitrate
validated.21
Bδ1
F4643
DeBoever
ultra-centrifugation
E034
anti-HDAC-2
hydrolysis-resistant
iCCA7
Kairouan
.97
Myint1,2
EMBL3SP6
G44D
.S14
poly-ADP
Publique
phakomas
MM329
99–102
TAP1/2
mm9/NCBI37
anti-HDAC2
IVS26
KD-TRAF6
X2073_splice
0.048
assay-dependent
–MAP
thousand-genome
66/99
.DP1
TGFBR1-signal
vacuoles
NSCLC-not
.Q1500P
27–88
PTEN-WT
pH=8.1
SWI2
18q21–22
nondetergent
helical-C2
Ikb
acid-locked
GAC-9GCC
wu7/wu91
Bam1a
I540
mutationsin
CDKN2A-2B
Verma15
1.08–3.70
BRAFV600E/F516G
Red-O
2/43
pathways30
1,500
v-rasHa
Western-blotted
leukemia-initiating
.NGFI-A
BR2pyro617F
10.1002/humu.20353
EGFW
Senter
described6,7
Pixcell
FGFR2-
Kawai
Cys-Leu
SAAP
Iκ-Bα
I/Dra
PSA-LUC
.SMART
Fluorescein-labeled
2.758
HDN
5′-ACCGTCGCTTGGTGCACCGC-3′
Ret11R
PEAK1/Src
pALTER-1
0.92-4.01
malignancies23
OR=1.28
.20,21The
10ng/mL
h.p.i
CMV-p300CH1Δ-E2
incapacitated
p.Glu40Val
:pGAL1
R767W
pmGFP-N-rasG12V-E49K
5′-AACAGUUCAAGGCUGCACUGGCUCG-3′
v-Abl-IRES-GFP
Sub-centimetre
Lipofectamine
NCI-H2286
Bae
A-class
postsort
.EPHA2
test.49
post-HS/PC
//evs.gs.washington.edu/EVS/
6q
R137Q
Mm01233143
lines72
VB55
ds17-
quantitating
Wiedlocha
RB4-RT-as
.DAVID
0-10
DEF-domain-containing
PAb240-specific
macroglobulinemia
DH5alpha
post-PV/ET
9,339
Cadherin-related
accumulates28
mutant-allele-specific
PRDM1.E7.257.F
sudden-onset
GnasE2
61.8
â€˜e
anti-Vβ5.1/5.2
sequence.20
NUP98-F
SPOP-mutated
neoplasia-associated
*9A/*6A
T-CELL
NcoI-BamHI
1,348,424
DNase1
division–dependent
transplantation,27
hypoproliferative
1.91–42.6
EGFP
CancerSociety
L12H
1301
W113X
EWSR1/DUX4
1QN
C174R
AK128532
0•86
q24.2
RBBP8
ancestry
p=0.007
PCR-Myr-removed
tetravalent
proliferation.30,31
chemotherapy.124
IHRDLAARNCL
Δ235
anti-pY705
process167
RADSO
D106
Ni-elution
C520Y
1417
PDGFR-β-positive
.EpH4-EN
Lin-neg/Sca1+/c-Kit+
KB™
stage.30
JAK2-3
shAPC10
5/120
CCTTCATATTCTCTGAAATCAACG
c.962_965del4
A871E
126.67-130.74
radicals.36
PPARγ-containing
43/M
domains15
tubulovilleus
2688,1995
p85a/GST-p110
.Chemoresistance
ttttcacag
irs3
acceptorldonor
pCMV-IKBA-WT
-Null
t.U
A119S
incu
MycS71F
0·22–0·46
double-blind
CTGATTCCCC
DICER1.34
PCR‐based
.Lymphocytes
0.707‡
3,4,5-trisphosphate
9840
Taubert
5'-CCATGCCTTCTCTTTGTATT-3
Biolegio
localization.Figure
associates31
Analysis49
withMI
Urp
Europe´enne
293-based
GGGTGG
cludingamplificationisn
neurofibro-
NM_000351
2q13-q21
–internal
ΔΔGbind
Torcy
709–718
TCCCTCACTCCAAGAAGAGAGTAT
Rpb1
~8-fold
.U266
aberration.29
2724
91Tright
TP53INP2
laser-captured
E1-Bgl
366
migration2
TTCTTTGGAGCACTTTG
anti-b2m–associated
mmll3
F′
HoxA9-expressing
C-terminusof
Sox10
UAS-Src
L576PKIT
HTLV-1-associated
quantitatively
Antibiotin
1999–2000
sociated
significant74
JAW/STAT3/
.NCI-H358
phospho-SAPK
CDKN
pBabe-puro-HA-HIF2α
SOX2/TP63/NOTCH1
565
0.025–25
precisely.Subsequent
Vim+
amplicons-
Mini-PROTEAN
2846
T1982
OR=1.01
c.290T4G
ERBB2-S310F
Westerman
mutant7,21,43
R273C/T284R
hematopoietic24
tDNA
CRC-associated
Cul3-SPOP-dependent
cases,11
UtFIBs
-inhibitory
amplificaton
cancersBasal
Immunohistocemistry
SJSA
12–30
Mal,13
RET/PTC
pathogenic.3
cells/pericytes
microtubule-associated
Tyr642
with-
NCT01721525
ERK-activation
2-s
c-myb.E2.98.R
.Helicase
Y1–Y5
L1707
spine-related
MassARRAY
4A–G
Epstein–Barr
neuroblastoma.33
2.029
inhibitor-based
gp78
dimer/oligomerization
TrkAI/II
.237249272286127
CMA323
lapatinib.36
RecA-related
10T
.Patient-derived
S++
R2=0.5
2-mercaptoethanol
DIMH842-845V
therapeutics1
pT4a
5´-CCCGCCCTCCCCGCCGCCCTCAG-3´
Cdc25C
18.9–42.0
UraC
20-alpha
multispectral
V2
univ-lyon1.fr
CCTACCTTGACCAGTCGGTCCTTG
behavior.In
regardingthe
16p13.1–p13.2
1390
ubiquitindependent
2,586
.755T
RET—Mutations
0.2–3.0
MutSawere
GGT-3
mutations19
10.63
receptor-PTPs
Pessac
15q11.2
Krev-1
PARylation
ACCAGAAGTTGCCATGTTGA
Box-and-whisker
RAD51C/FANCO
Readthrough
PCR-based,18–24
IRF1/5q31
previously80
CEP85L–PDGFRβ
G86R
Tween-PBS
Muro-Cacho
higher-grade
3days
''
anilino-1-naphthalene
−161C/A
7/63
HU133plus2.0
kidney/lung
protein.NIH3T3
.PF02341066
Gli2-FL
.HUMAN
LV-control
steepest-descent
TEL-Jak2
PK-8
27•90
CBP-dependent
postchemotherapeutic
Mosashvilli
transporter-1
ochratoxin
function-blocking
Amundedottir
asso­
deletions.24
leukemia18
Kantonsspital
possibilities.BRCA1
TÃŸR-Imolecules
leukemia,21-38,40,41
81/2
ring-stacking
therapies|
p.Genes
1/37
IL-7Rα–expressing
84910
85.1
pBD–BRCA1
AICD58-1
EZR-ROS1G2032R
carcinoma8
pGAD
37kD
Galetta
lymphomasa
Golgi-like
G222E
9268
SFRP-5
A314D
Expanded96
1.Substitution
Transcriptome
GGAC
absorbance6
c.1119delG
comigratewith
HER2/Neu-positive
15,16,18
PGFRA
2,302
Katoh
anti–FLAG
andSouthern
pRS
siRNA-infected
ChrX:47038514-47039897
Silentfect
462–467
.Review
HES1-luciferase
M/A-plot
c.7007G
399
P1205L
pCREB
S-400HR
p53-R280K-transfected
K-RasG13D
line10
−6.25
ANKRD26-related
p.Arg215Trp
GAC→CAC
K634T
20.9
SCF-like
Cys61Gly
Abl-transformed
cusp
adhesiolysis
†The
thin-walled
Mastocytosis
17q11.2-q12
PCR2.1
.Fifth
whole‐exome
AACR-NCI-EORTC
oocyte
St.-Ju¨rgen-Straße
threonine-58
proteins.29,38
food-borne
Gln64
43–9006
TGGCCCAGATGAGTTTAGTGTCT
grape-size
TEL-PDGFRB
Hookim
affirmative
DIPSS.8
EXEL-0862
months.4
imatinib.10
package22
adriamycin/ifosfamide
-I
.Caspase-8-expressing
5′-CTTCTTCTTCTTGAGGATCGCGACGGCCCTCCTGCAC-3′
3B–E
Npm1+/+Eµ-Myc
∼45
1492
PIP3/AKT
p.Gly373Arg
CEIDPSKIKD..
VarScan2
D–cyclin-dependent
.Four-micrometre
161a
1.11±0.08
Rac1/Pak1/LIMK1/cofilin
debulkable
279E
.RE2
Thr-35
ΔLBD
trans-acting
Flk2
pathway46
chr19:42,790,756-42,790,839
electrotransferred
pan-NTRK
582–937
D842V-mutant
Mod‡
JNS
5'-ggaaaagcaaatgttacagac-3
withNTRK1-specific
G/A9
CTGTTGTTAAGCAAAGATCAAAG
Dacomitinib
Gibas
18.3
450x109/L
.CMV-GAL4-TFAP2A
SEG
JHDM1B/FBX10
Sanguine
1.14∼1.80
misorientation
P19b
Ebi-mediated
C-Terminal
Leu540
405–410
Garcı´a
CS-related
RPRAATF
2IUW
336.0582
AGGAGTA-3
cases20
Off-target
c.5075-9A
Rodriguez-Viciana
lysozyme-M+
BV
25ºC
samples.10
MiceTissues
pval=0.6
2E9R
28.0HSPA1AHeat
T230
pVHL-driven
activityand
TRPI
I122V
Kremmer
shRNA-resistant
Vleminckx
racemase
LSM-510
R434H
kerma
1On
piperidin-4-yl-1H-pyrazol-4-yl
CT-3'2
-GC
E233G
M57T
ProceduresPatient
vessel-surrounding
blue=nuclei
.Two-dimensional
Tyr1337
v.57
cytosol.20,83
Isner
Nibrin
Altaba
Leu62Casp8
Non-Receptor
-driven
ITPR1
_1973+
A704
//www.ncbi.nlm.nih.gov/snp
telecanthus
experiments7,16
vasculature35
American-British
R693P
Ig
CloneAmp
Assay—On
mar1
cobinding
5′-GCGGATCCGTAGTGGCTGTGGGGGAT-3′
E565K
anti-IFN-γ
RD-N
3.2.2
HCFC1
ccRCC10,11,12,13
blood.23
.Jak2-WT
Patched1
6.59
SK-4100
Assay/Inhibitor
pRB-related
IDH-driven
.Neurons
3Mb-Erg
MMSET-IgH
adenocarcinomas.25
.NUGC3
.S5b
category.71
RPA40
249/123
.BEL
nullify
I254N
GM1-enriched
McClue
RIZ
Arg873
XXYY
CAGGAAATAAACCTCCTCCATTT
mammary,12
1,891
Orthochromatic
N-~Yc
AII.2
0.44–0.9
.NK-like
ATCTCCAGCAGCAGGTCACAGAGGGGCACCACGTT
25/35.2
.Transcript
ECL3
KIT-dependent
.Invasive
A2
Cu/Zn-SOD
nmi
data19,20
Leu-232
p85αdelH450
pCDNA3-HA-I-Ppo1
PKHT
NM182
-0.135
11Laboratory
G2748D
.CIC-rearranged
Spectrafluor
origins38–40
pmetD
Syndrome-like
2−5.6CABYRCalcium
mIU
YAP1/WWTR1
sub-classified
mentagrophytes
3.6E
mitoses/50
signal-regulating
crestYderived
788–1010
3X
egfr
−367T
*equally
P-bodies17
Quint
02129
BCR18
synergies
.Val1001
Q588QK590SFR593
MON1061
etiologically
5′-AATTCTCCGAACGTGTCACGT-3′
BIMi2+/+
D1-positive
shRNA-transfectedcells
CDK4,6i
mental-retardation
TCTCTGTAAAGTTACTCTTGGTTG
ProsaII
504-bp
pLenti6/V5-DEST
.Methyltransferase
non-revertant
1.84
proplatelet-forming
1544
Stacey1
TCAAAAATGCACCACAGTGAG
study.18
EZH2-expressed
Sites—Although
tuberin.18,19,20
light-colored
pEAE36
O-glycans
Myelodysplastic-myeloproliferative
NAP57
appoximately
Anti-CD25
imens
previously22
anti–mouse
VP-Mel-20
Δ229–678
.R7EN
Derijard
TB2607
PMS2-WT-
13−15
IP–DOC
K48-linked
S263P
.Kaelin
.GFP–VHL172-positive
Phe650
CelllineSN161Carcinoma
10/11
cbs.dtu.dk/services/SignalP/index.html
ADH-p53plasmids
5'-gaacaacttctgctcatgacg-3
asthose
probasin
recombination
ofMUM2
normal‑
p.Leu658Pro
siDirect
allophycocyanin–anti-Foxp3
Sequi-Gen
FL-CDB3-binding
births.38,39
-2-methylpyrimidin-4-ylamino
MCF-7-1
2033–
resected
3196F
cecum.83
sacrified
/SOCS1
PDGFR32
MSH2-18
CD-135-PE
microfluidized
PI3K/RAS
De´u
Face-to-Face
BAC-array
UCCAGU
18.2G
.Vascular
CD20-positive
NB-512
FAM72A
E29V
pBabe-Puro-based
siGENOME
inhibitors.14,17
0.1650±0.05315g
1896
lymphocytes.WCLs
RAS-specific
TP56
g/μl
4nt
µm-thick
CJ236
polymicrobial
/PI3K
1m17
.Mansukhani
82.01
Ambrogio
stemness
FAT1-mutant
.Midline
TAE684
p.Ile463Leufs*21
.Estimates
PAb421
1,648
nihms703640f12.jpg
LK
phospahatidylinositol
pCDNA‐MgaA2
MPEC
cells/μL
gavaged
2342K5
anti-MYOD1
data.9
//www.pymol.org/
CPICLELLKEPVSAD-CNHSFCRACITLNYESNRNTDGKGNCPVCR
NRF2-E82G
partiallyfunctionalBreast
p-HER3
iron-laden
Long-Term
BR-0483
SeaPansy
1057
392–395
5′-CGCGAGGAGGATGAAGCCAA-3′
-YFP
.Arcs
tutive
GM-CFUs
PolyPhen36
Lineage–c-Kit+
50–500
GSM180991
28.8
WTand
WW1-GST
KLH
near-diploidy
byadding
ERBB2-aplified
.PC-3
monomethyltransferases
Hs03714372_cn
G466A
*p-value
malignancies8,9
GFP+Mac1+
Heinrich-Heine-Universität
sorafenib-sensitive
961–1011
.Jointly
partners.18,21,22
ganglioside
b-catenin–activated
cells.19
gDNA
ALCL.1
pH2-3FF
G50-80
A335V
types.41
lane-to-lane
1760–1855
PGK-Neo-bpA
pheomelanins
intronlexon
midbrain22
.Canonical
clonally-restricted
P246L/F347S
AVected
MEK1-deficient
2–27
FIPL1
.DNA
XRCC1
5.5
3p22–3p24
AZD-6482
10xPCR
662M13
bind.6
BAC-probes
pET30
E1271K-MET
genotype/
SHP2-
Ile-de-France
MCE
firehose
-iSH2
activities3
R17
SLX1/4
genes,2
mir-17-92
maintenance,14
1I
c.d
R865
outcomes34,36,39
ÄKTAxpress
dChip67,68
d.f.1
transrepress
.FH225V
4-6
LHRE
eye-antenna
=EMM
404,100
9.7-kb
p.N30fs*14
5′-GGTTATATCATTCTTACCTAAAGGACACTGTGAGGGCCCTTTCTTCTGG-3′
HFD
cdc‑2‑luciferase
cotransformed
'8
/TβR-I
.Immunologic
Msh6PR/PR
CD4+CD45RA+CCR7+
Hsp82
2673
I2050T
Thiagalingam
173,770
Phe540
p.Gln839*
HA-human
Kopito
His-SOScat
cancers5
N-formylmethionyl-leucyl-phenylalanine
ÃŸi-MGprobe.Table
KIT.15
Q643X
Lys48-linked
protozoan
uFD
G729R
MEK/mitogen-activated
//www.bioassay.dk
anticoagulant
L518P
5′or
13·0–42·3
14q21
FIP1L
S100a14
Hongo
37,52
626-amplicon
CACTGGCCCCTTTTTCTTCT
1/45
.4449
3B1–2
HER1-3
5'-CACCACCACCTCCTCACTCT-3
AR-F876L
Fgfr1-mediated
.Adjuvant
D3–D4
.Induction-dependent
β-sheet–like
N816
A/46–143
c.C154T
proton-pump
transformation100
amphiphilicity
genemap98
baculovirus‐produced
GI:20560291
tomography/computed
ef-
D9S66
EGF-only
.VRFFGVCTEGRPLLMVFEYMRH-GDLNRFL
phagocyte-derived
964-amino-acidMSH2
E14tg2a
F57C/ΔD
gene.2
pCMV-WT
Heniko¡
NEN-Dupont
871†
Otwinowski
fibrosis.29
U94788.1
non­redundant
IGF-Iβ
5-mononucleotide
M100K
promoter12
R158L
transgenes—wild-type
A375-
pCDH510B
moderate-dose
1012-aa
59-TAAAGGGGATCTAGCACTAGC-39
myb
.130
CCCGTCTGGCTATACTAACACCAT
:1469–72
953,000
interconnecting
10.0-fold
transformation.21–23
G306R
antiphosphotyrosine
PDGFRA.Fusion.Ex12.2R
nature.comAcquired
STGE-binding
FL393-G
-Leu+0.15
Rad51-Binding
G384S
Quick-Amp
916
387/384
1,2,33
.Zebrafish
RHO-GDI
25-µm
Hurthle
Daeil
CHORD-containing
HMGB1
S235P
Ventana
0.21-0.35
bHLH
Frohman.24
500-nm
Thr/Met
sulfate–polyacrylamide
disorders.9,10
non-CIMP
Emi1
∼59-kDa
HIF2
7,16,30
Δrsc2
-HIES
proliferation.4
brachiocephalic
Lys-602
FGF8-soaked
bab
NCI-H2405
2609–2648
NAMB-Iin
0.458
Diffracting
Th-1
TAN1
RUNX1-I43F/RUNX1-I43R
non-homoFIGURE
15.6-mm-diameter
Kocialkowski
Latent
Willumsen
domainwithout
high-affinity
delineate
RAS-ERKMAP
phenylalanines
APOB
DQ396625
Gln791
1738R
10.1530/ERC-11-0117
.IS
hormone-independence
3028
study,6
G504D
2541C-G
eGFP
3016
.Well-defined
5'tccactggattccaagattcccagtcacca3
5'-GAT
nonandrogen
20–23
LXSN-AKT2-AS
CLCN2
0-27
respectively1
mutation-enriched
D769R869
Konishi
Grr1
lG-uAnLouThrOl
.Systolic
16394
C346S
Frikha
Thr-200/Tyr-204
11Val560Asp
Söderberg
S6273
ey-FLP
TriZOL
Fig.3B
S9
2,100
frequent,8
51/F
D1S2737
0625
aspergillosis
Collaborating
re-introduction
*6A-1
erlotinib41
Br50
decade-old
self-renewal
150-153
D24N
P=0.0013
Zf
RARalpha
∼35-fold
pre-RNAs
PTCH1-regulated
dimer7
dolichol-pyrophosphate-oligosaccharide
0.34-0.48
IGF-dependent
7.7-fold
T753insS
software-assisted
S762
Tax+
.Kreisler
AGAGCCGTAATCACTCA
R316Q
R273H-related
occludans
latter119
FBS/2
protein,27,36
AML1-ETO-expressing
p85-binding-domain
pseudophosphatase
microfuged
2240-2257
collagenasedisaggregated
LFS-component
.JH2Δ-Jak2
130mM
MHC/HLA
hyperdiploidy—were
geranylgeranyl
side-branching
Pyrograms
autoradiog‑
Cevher
RET/E768D
TGAGCAAGAGGCTTTGGAGT
pEAE27
false-negatives
92G2
741_742insTG
allelism.19
interdependence
612bp
83-phosphates
N/D
Gladden
EDI
above/below
.Proteasomal
3-mediated
FLT1
ANKRD17
SOX11.18-22,25
DMEM/1
125-kilodalton
RT-4
FREM
rs726789
HumVar.11
anti-c-myc
5′-gu
survival.4,34
respectively—two
therapy108
cystine-knot
mastocytosis.38
HD-CTX
H4K8
4-vessel
Tl'G
Servidei
pcDNA3.1/hygro
4Myc
adducin
ECM-receptor
543ΔT
K-Ras+/+
clinic39
CCC-
.Serine
S12D
Gruppo
Cuenco
pCMV-NoLS-FGFR2WT-FLAG
MED12L
lexicographically
626–630
SFG
anti-IGF1R
signaling,42-50
15N-1H
V157G
progression.34
immediate-
units/mL
S0461T
G244D,31
17.9–24.9
Fug-III/3
CTGCAAATGASC-3′
processes32,33
anti-DCT/TRP2
B88
mouse/D171N
CT17
continual-dosing
shipping-related
c.500G
miRNA/Ago2-dependent
PI3K/Akt
-tagged
HEK293-T
Y236F-p53′
CD79
matrices.23
n=45
14–82
FNB52
/ng
rs3087243
TOPFLASH/FOPFLASH
RAEB-2
JMJD1A
BICALUTAMIDE
HA-Fbw2
Jak3−/−
PGK-neomycin
WM-53
c.1073T
.Compared
.S6B–S6E
A640
QR3
594-bp
Tjap1
L858R
128-fold
dowstream
ARccr
.Microarray-based
LSassociated
leukoproliferative
C417
R180
post–first-line
NRASQ61
animals28
STK15/BTAK/aurora2
Chongno-gu
TSC2GAP
.Repetition
formsmay
_Clin
3p12.1–p11.2
colleauges
BRCAl-linked
specifity.4
62–187
CFU-F
pEF-MYC-CYTO
GSE47724
neutral.
histoprognostic
KIT-K641E
anti-MKK4
PDGFRAmutant
MCF10-EN
5′-TCCGCAAGACTCACAGCA-3′
IFAR764/1
isothiocyanate-CsCl2
–11
Genespring
n\i
dysmorphic
inclusion.31
response.9
.Which
magnification
214K
with500
Cy5-conjugated
.Depleted
p21Ras
2·9
humantissues
substrate–FBW7
P1-based
oxaliplatin-containing
H-76
ab18259
c.788G4A
STIS71
c.2083C
GOF
Crllprolifrrtltiorl
Stahelin
ITO
64y
GTACATCAGGAACGTCTCTAT-39
Bst
aneffector
tetracycline-inducible
pIRE-ti-Luc
.Phosphotyrosyl
5'-ACC
abnormally-spliced
gefitinib-response
electrophoresis.HRM
.Accurate
polyploidy/aneuploidy
41–75
pCMV-Myc-XPLN
CTT-9TTT
DMof
NVP-BGJ398
0.303
TTGACTTGGTGGATGGTTT-3′
CCC-3
+E
.KRASS65N
0.5–2μg
vector–
tumor-surrounding
PTPμ-coated
-Akt1
IDH2-expressing
pTXB1
Bello-Fernandez
NBC-RARA
V659E_L785F
4l
5′-GATCGGAGAATCCAAGTAGCTAC-3′
C630Y
PPXY
Reya
Ministère
treatment22
msi
pLenti6.2/V5
APC-CD4
G27
IVS16-68G
1.64
MEF2A
SpectrumOrange-dUTP
increased.
Site-direct
3.5–6.4
L1491
IFB-Tx
TAZ148
Rad53
GAGACCTGCTCAAGGTCACAGGGT
anti-CD45-biotin
Asp-873
BAIAP2L1–MET
50+50bp
R154L
5′-ter
GFP
transformation109
D9S168
Bullosa
1V5
PCR18
megalencephaly-capillary
Mg++
1B-E
ABL-Tyr253
non-French
DH-PH
Pathology2,3
ERspecific
RAD51C-mutated
cooccurring
64-117
Empiric
sIma
growth-inducing
Ost
p1434
CCAGCCACGC
576–579
Grb2/SOS
MutSα-dependent
p140-Dia
Fig.2H
L222X
P261L
IV:28
M-stage
relatively-young
T-antigen
tumors.16,17
syndrome.26–28
R2505Q/*
mCAT-1-expressing
.Researches
1Â
HAN
c.1771delG
FancJ
methods.16
Nicomed
0.45
q34
p.P578_E632del
W277C
mediumcontaining
20-μL
CD24+CD29loCD61+
`other
CTCAGTATTGGAAGAAGTGC
c.3062C
182
e29
splicing2,11
0·11
B.T
pathway.18
.Cytotoxicity
86-22-
.326T
SRP019503
p190BCR-ABL
phs000424.v6.p1
NOTCH2NL
pGL3-promoter-
SRFVP16
M704R
mice55
–single-strand
aspossible
0.9-
–9.3
alectinib-treatment
RP11-100E5
.value
Bmi1
Microscopy—
Asai
TMM
therapy.12–16
IgG1-human
L7Ae
Y553_Q556
FLJ35294
CyclinB1
Aesar
PDGF-Rβ-binding
acyl-coenzyme
Mm00440677_m1
GFAP±
tumors60
MutSα-complex
cysteinyl-tRNA
CD95/APO-1
Lys-102
Scarpulla
FGF4
heterozygosity
Pt4
49.3
Delta289
.SPRED1
Ryoiku
p.Gly55fs
rap1GAP-related
MV100
Thy1.1+
NSCLC.1,6–8,18
4.Overall
splicing.80
76N
C-terminal-specific
CA11
al.44
CMVβ-p300-CHA
Hpy188I
rv20
.FGFR2C278F
813
588
melphalan-induced
LDI1
Koopmans
S.M
4,080
Delta375–455
IPSS-R.20
ETV7
microbead
shCDC27
times.3
20.25:1
tumours=8.3±0.9years
RatesNucleotide
dl-1
7,33
HCC-22218
B–
C–19
.RAD001
GD2
andhttp
AML-MRC.Mutant
fromboth
substrates.1,7
TSC1-inactivating
CPSF/CstF
expressioninhibitory
.Ethnicity
.False
E2mut
1797A
Keydar
residues12
aE2F
WT,3
B9p
cancers/24
/SPRED
WT-like
FBW7+/−
Kandil
pro-lymphangiogenic
0004714
Gozani
2c–d
YP028
ter2069
restricted.32
35,38
E321G
pLP-LNCX
35–47
Sequestering
8-μmol
oculocutaneous
nc+h
index.do
A_51_P255699
response.1
c\jo
≤25
/AGGAGACCTAGGTGTCC
Kyusyu
shWWP1-2
platebased
13,905
countstained
metastasising
.block
PNST
mismatch-provoked
1.9–4.0
DLBCL.8
increased-
gtaggcagt
Mm768bpΔGGAA-LacZ
R416H
E1953X
T174
8-34
−1.56
R189X
Rectum/7
Abcb10-binding
sarcomatoidlike
pT2b
.GS676
retrcn.iml
NM_001142389
epilepticus
1/Switch
s80/4ICD
anti-c-MYC
2.1–2.4
n=456
0.5-1
U5
//www.cbioportal.org/public-portal
thyroidal
5′-CTGTGGGGAGAAAGGGAAA-3′
VHL/ElonginCB/Cul2
non-NF1
Akt1or
rad50vsc
Gelebart
4/10/14/1
al.26
~Díaz
HLA
p52-mediated
250,375,398
subpolymorphic
dysfunction.13
drugb
.TNM
deletion/amplification
Margueron
pTyr+3
24020102L
Src64B
1Ac
.Be3
Insensitivity
5'-CCCCCGGCAGGACGAAGTT-3
lithium-treated
entity.The
Mauillon
A539D
S233
HER2-directed
Leu/Ile-Leu/Ile/Pro-phosphoThr-Pro-〈Arg/Lys〉4
WZR12
FGFR/vascular
size-selection
Notch/MAML
RBMs/RNA
breast-cancer-affected
site-I
months.14,15
–Pms1
LMC
Database4
CD45.2+LT-HSCs
T411M
CDKI.7,9
MSH6/S1
R764Q
Verhaegh
al,26
encephalopathy
mutatedPML-RARa
N486-P940
846
phosFig
GST-protein
SS-AON
LaserSharp
1Facial
lymphomagenesis76
-VA
aokiy
.Antibody-chromatin
electrophile-responsive
Rad26
YEP-raffinose
Rb-1
SIFT35
disease.5,6
mFISH
IVS7
GTGTGT
BACH1-517T
LOC729121
G13D-derived
77.1–79.7°
C14orf25
FTL3/ETV6
SynGene
Steinmeyer
Dub1
ApproachRNA
No.sc-7383
gtatgtaaa
56••
TCGA-DM-A1D4
Myc-targeting
I201F
300-pb
activity17
PDK1-pSer241
_~~~~U_K
P542T
checkpoint21
CCCTCCACTGGCTTGTTCTCC
PAX3
pMSCV-GFP
':5
deletions.36
Alexa568-
mBAT-26
anti-phospho-AKT
M2327I
GCAGAAGCCTGCTATGTCCA
Fitze
17β-
5¶-TTCCTCATCCTTGATTTGATG-3¶
5,359
V3-7ii
UHRF1-ubH3
Ficoll-purified
Cys308
cross-linker
C55
03/2002
castrate-resistant
reinduced
Ifng
46.1
E–L
Lys753
wu118
Corbalan-Garcia
Youjia
SIL-TAL1/SCL
cc-EpoR-III
ALFA-0701
-excised
c.442_443delinsT
MGAH22
.dof
NK-AMLs
signaling.17
**576G
recognized,3
Xq11.2
Gefinitib
mutations.14-28
TMP3/4-ALK
W474C
232–544
3,5-dimethyl-4-
phospho-NTRK1
c.34C4T
dichloroisocoumarin
56971
interac
Ciardiello
W-III-06T
GFP−IkBα−NES−MutDAPI
AXL-low
.Mixes
Immunopurified
FAM133B/CDK6
MadnN
factor-IR
melanoma1–4
gCot-i
95°C
248370
T14-3c
c.1740insG
Hsp/Hsc70
28.7±3.6
SF3B1R625G
Vázquez
225–490
1–1200
non-G-CIMP+
C,2B
monooxygenases
BCRABL
T574_R586dup
ETS-rearranged
BBS10
FITC-annexin
FGFRAch
391.636
IR680
exami­
grade,12
Slovenia.Plate
PMS2-similar
25µg/ml
tPresent
JAK2WT
silicone
monomer-to-dimer
Uhlén
neo-expressing
phospho-p44
AML87
Leu-869
CFA3
cross-reacts
hMLH1.21
IC261
0117
YAP-TEAD–dependent
anadaptive
mec1Δ
K1183Rb
c6.4MMEMembrane
AntiU2AF35
nu/nu
individuals4
ZBTB46
tumorigensis
S4D–S4E
c.3699_3702del
23/91
GSK3-mediated
KARPAS
S349P
deubiquitinating
Q812Ra
shRNA-C8
E365
.Plate-shaped
Jarvinen
P2172Q
Glu604LeufsX5
aspartase
S.T.
construct,9
phosphate-DNA
in100-mm
A794G
50-L
5'GGAGATCTCAAGAGCTCCTGGl-lTGGCAGC3
//www.insight-group.org/variants/database/
c-myc-epitope-tagged
anti–IFN-γRα
SWi1
Foxp3+
C18-packed
BMS-536924
v.0.6.2
50-mL
T58
KB1PM4
Molm14
5′-CACTGGGC
0.1129
constructThe
Bruecher
mitosis/50
8.0–24.9
+FAS
position-dependent
WL2
0172
.CD74-ROS1
F2**
S.Antibodies
minor-groove
p85αdelR574
Ras/PI3
machine.View
44-46
period-
well-healed
nSH2-iSH2
cases-only
HPV-58
TPβ-transduced
MCNsA
63.0
al.,1995b
10p11.22–p11.21
single-exon
D38E
TnlO-LUK
pathway,16–18
Boldrini
Lenti-X
R.O
1–38/39
K756R
mmol–1
AML.14–16
Varambally
pG-CSF
HMC1.2
F2939
6,21
.Chan
W252
phosphoacceptors
BR2F1
Richkind
19T
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F3.medium.gif
overexposed
j-r-
.Tubulin
SPOP-Puc
patients,58
cold-sensitive
one.A
factor–mediated
†To
p18Ink4C
250–500
DIMH842-845/
thinlayer
HLA-B*07
−5.11
.Optimal
pCMVneo-CDK4
5′-GTGCAGGAGGGCCGTCGCGATCCTCAAGAAGAAGAAG-3′
immune-dominant
Garcia‐Blanco
LL36
.S2I
non-JM
cyclin-cdk
5ʹ
w0J0
cases.9,10
22/23
N612Q.R
13931–13936
acid781aspartic
40-mm
KrasG12DPdx1-cre
ERÃŸat
amphotropic
Ala767_Val769dupAlaSerVal‡
respectively.22,23
p53-BAK
0.088
c.922A4G/p.N308D
CR-UK
p53/KRAS
5′-TGGATGATCAGCCCGAAGGAGA-3′
PLCγ1
.Antibody-dependent
line.28
tumorsThe
.KrasG12DPtendel/del
5/435
Glu550
Bcl-xl
Allosteric
p.Ala441Thr
VGS
PanIN-
LUL
Kasumi-5
granulomonocytes
WT-overexpressed
5'GCGCGCGGATCCGCCACCATGGAGGCCGGGCGGCCGCGGCCCGTGC
partemental
FBXO11
suppressor-deficient
20q12-q13.1
radiation.36
Otx2-expressing
subclonally
Csk-LacZ
SV40-y-A-MLV
h-caldesmon
22m
ectodermally
1/232
third-party
aMutation
.045*
Leu1790
Tretiakova
c.181C
NM_006015.4
MV-7
1300
GGATATTGGTAGCAT
Rnf19
BRAF-Mutant
signaling.50
Dage-MTI
Gai2
PKRG2.34
M2-agarose
surface96
Myc-FIP1L1-WW-PDGFRA
62.08
KIT-WT
.91
cemakin
367:976
.Lately
rRAFT
9MB
RNase
Trp32
UN23
chaperones,50,71
8.31
bicalutamide-treated
study.1
NBSD
mts3-1
IC080
potassium
hypercalcemia
v1.3
fusion7
4-µm
4771
treated.10
IGVH
metformin
PMS2-134-transfected
45,52
ARHGAP12
protein/ml
exons/introns/promoter
FH-Merlin
24/42
c.2530_2531delAG
Piek
0,8–1,8
RCB
hamartin
RBM15-MKL1
fat-poor
non–c-MET
T416I
lapatinib-ErbB2
367–684
TRK-fusion
1225_1226delTG
TCF3–downregulated
.EGF11
S235/236-phosphorylated
metalloprotease-1/collagenase
CMV-ABL1
log1+E
dissimilarities
Figure1.1
self-administered
catalytic
.Low-power
Cdc25A
ASU
pGL3-promoter
R304X
N-methyltransferase
Bosland46
283.69and
TER
ultrasounds
exclusive42
116.5-
1.21
infants3
PPHLN1
P267R
_BRAF
R669G
deletion,9
LOH15q21
ERBB2L869
9q33.2–q33.3
asmeasured
Dok4
Ercc1
Kordsmeier
fibroblasts.23-25
chloroform/
132
hTERT-RPE1
ligation–dependent
NM_003000
Kloosterman
CAG-to-CAA
1.870.4
PRDM1.E5.477.R
lO_2
−367T/C
KRASV12
INOVA
EHZ2
Ink4c
SLC16A1
29–40
/Akt
resem-
macro-metastases
HSC7E132
Amendment–approved
2.3-10.0
construct,30
Stc/−
168B17-46-34
0•16–0•56
pan-ERK1
TissueLyser
VEGFR2-targeted
1.3/NA
G2.41,48–51
imatinib–Abl
­olaparib
amino-allyl
HGA
TtoG
E511K
PDGFRA-V536E
0.6993
17.26
CMV-HA-STAT5B
0.14:1
.RhoA-2A-EGFP-pcDNA3.1
IC-50
Duckett
a1
Thangavelu
GlaxoSmithKline
D2889
DSGXXS
cAMP-independent
Non-coded
IGF-I/IGF-IR
treatment-use
1078O11
Met1Ile
patients.1,3,4
refl
S578
aganglionosis
5′-TAC
Q59E
transporter—were
NCI-H1466
pSG5p110
brain-heart
anti-AR–stained
22318§
sc-893
P/S
9154
UDP-glucose
harringtonine
CD152
RP11-460G19
Met-766
3.8-fold
Antithetically
CBFβ190
membrane-localization
pRb/Skp2/p27-mediated
extrasalivary
abnormalities12,13
intermolecularly
bcI-1
577–580
-Ly5.1
p71
MGC803
TCF19
trimethylamine
UTX3,11
coimported
0.0433
prbΔ1.6R.DNA
non-syndromic
repair-
Co-amplification
Hannink
4′,6-Diamidino-2-phenylindole
BCRP1
protooncogenic
p.R970C
FGFR3/G346E
A996S
pLX304-blas-V5
387785
F2–R2b
turbidity
.At
MEMo25
D.G.G
W239C
ofprobe
Dorst
.Mammals
775Arg
p.R162H
self-phosphorylation
lin-Sca
Ahn
V198/202
FN3KRP
HPSCs
Ras.RasGAP
5′-GAATCAGCATGCAAAAACCA-3′
pFak
construct27
3q26.33
evidence9,10,31
I–III
single-event-mediated
CaMKII
1.06×104
EF1–EF5
KrasLSL–G12D/ex3op
1.00NRAS
MEKK57N
A-nucleotide
v16.0
Figure4a
identicalchanges
pWWp-Luc
Sf3b1K700E
GCGTCAGTCTGGTGTGCTAA
C→Y
ULBP-3
HRMassay
Brca2F11/F11
non-involved
SCE/chromosome
disease.By
inWnity
ras-activated
JAK-specific
segment\5
charge-pair
anti-NF-κB
CL1-3
42RU
proteinencoding
Genotyper
A2211P
complement-dependent
CEP1
1693
4126
~85kDa
NTRODUCTION
Stec
SBE-containing
D1S171
R245
H2087
features—as
pre-assembled
GGGCT
/67.8
HumanOmniS-8
6.Inhibition
.119062
.Hiroshi
112–121
E2-E10-specific
5425
heart.Small-molecule
IVS6+146A→G
MB85
Fas-associating
6/9
2,021
JAK2-P933R
mass-action
53/248
Lui
.76
138/148
Kyoundo
craniosynostoses
D22S275.276
HLA-A–
1197–2121
ARBSs
TCGA-BS-A0UV-01
HDACis
898
PanIn-3
HDAC-containing
Pro670_Arg737
17B-estradiol
0.04105
lymphoma.82
l-alanyl
ml−1
a-modified
11602
2261
less-aggressive
c.1290_1291del
.Theresults
andFITC-conjugated
4j
0~99
a/
.RTKs
trials.38
numbers.11
PmeI-NcoI
pRBΔex4
caspase-8β
haemangioblastomas
aurora-selective
MRE112
565-codon
ID14-1
4367C
W.T
p123
Ile94Leu
X54559
1/3,559
chamberslides
γ-labeled
Y297A
carcinoma.3,6–8
fected
​Percentage
*Family
sh5992
CDKN1B-regulating
n=44
1–184
pBFP
CALBG
exposure,43
C23
AML.In
QF-PCR
rapamycin-treated
1.816
FGF17b
XPllBE
SCC17B/28/58
R366C
RT-Sr1
ET3
367–372Martinelli
SMC5
p.A50T
90.6
1-cm2
D-expression
TR-FRET
KDRA1056T
4,226-bp
Figures44
Mutation-driven
NEMO-dependent
PRC2
20/F
NM_006836
CT/
MB-22
DD-p53
anti-CDK7
U33749
others.3
-1150
physiological
2.55
Ag-Ai
L289M
risk,15–18
.RII
.G-Banding
patients.31,32
FNB13
P5D2-blocking
431–448
.Hospitalization
recognisable
8,300
loss-of-heterozigosity
lymphoma.75-78
R683G
3-mutated
Notch1/2
ligand-dissociation
GPIIb-IIIa-mediated
ZO2
Perisic
newproperties
.Schmidt
1000−2000
context-specific
481-bp
NR6/
RCtBP
NEPC
pMMP-HA-YAP
50-p1
R293X
5B–5C
RBP2
E70K
TGAAGGAGGATGAGCCTGAC
Lassmann
V762
PDGF-signalling
GJB4
D1S200
βME
3-fluoro-2,6-dichlorophenyl
43-bp
Snai2
S1C–D
Co-electrophoresed
His339
down-regulation
0.765
Val769_Asp770insMetAlaSerValAsp
TAP-IP
pCMV-dR8.91
species-dependent
AML17
study.All
CKIT
DMEM/BSA
3538–4512
6242
8/43
multi-channel
Storti
ECC
33,000
co-purifies
gaa-3′
KDM2b
anti–phospho-PDGFRα
deimination
Pro314His
FBS/F10
.ETV1
*Immunohistochemical
complex37
receptor–signaling
.SHC
.ANR-10-EQPX-03
KIP-family
of3
Foxg1b
6503delTT
CGGCAATATATAACATGGGC
ATF2-mediated
custom-targeting
2AFIGURE
Y649X
Identifi
BCL7A
0–22
Lineage−
patient–derived
-pERK1/2
TGF-β/activin
R/P72
CCSR
Microdroplet-based
N113D/N145D
tumor-acquired
II-10
p.Ser498Arg
E25-427
EMT
2.5.3
Repopulating
5-to-20
GATCCTCGAGGAACATGTCCCAACATGTTGCTCGAG
.Japan
3·0
314K
ovarian57
tri-fluoromethyl
atherosclerosis
MITF72
.Pyknotic
WFXNXR
CD33+/CD34−/low
RXRXXS*/T*
.Subject
2/3,608
M523I
arecoincident
P2721
AAGGGCTTGTGTGAACCACG
32h
caspase-2S
-ment
non-physiological
stage,13
w6
Ezh2WT-expressing
12.
3000A
-II
232–242
elsewhere.9,22
self-stimulatory
mcg
HDAC-1
ERG-TLS/
multi-exonic
anti-C-FGFR1
S3
phos­
gametogenesis
p.R625
.6C6C
1184
FIM/ZNF198,16-20
downfield-shifted
intra-NF1
.NCI-H226
H574
C1834
sumoylation.35
mass-weight
antigen—such
AACGGTACCAAGGCTGAGAA
spacegroup
0.0028
Y973
PRDM1.E7.290.R
CUD
EcoRV
68.1±27.3
4ST/A
adipokines
loop/strand
0.58
E865L
genes48
SetPoint1
diphosphorylated
-15
patho-physiology
Ba/F3-NPM/ALK
He´di
mice.63
siU2AF35
supraclavicles
42-76
interactiondomain
V354
7p22.2
Eint
c-kitcomplementary
5'-AGGAGCTGGTGGAGGCTGAC-3
293A
pBabe-HRAS
L1433S
N-acetylglucosaminetransferase
q23q23
TGATTCCTGCTGATTGACTACTAC
Seegene
function.2
R128L
204,537/1,501,072
30,830,000
4310881E
muscle40
AAGCTTCAACTCAGGCAACC
non-pathogenicity
TA.GCT
gene42,43
pAML
andrelease
approx6.5
LCR-E7
p85α-specific
Byung-Moo
CGTGAGT
Tetracycline-regulated
propensities
Grp1-PH
NL-17
SV2855_2856RI
0.379
Magnetic-Activated
v-ras
approx100
A1466G
PEP
N731Y
s10637
KPT-185/KPT-330
developed115
PCR1-r
L320F
freemedium
v2.0
dof
fusion-harboring
Bioer
factor/Lymphoid
BamHI-XhoI
−930G→A
asialotransferrin
7–19
.NOTCH3
2Ea
K483M
GI:1418819
.Madison
IVS29+5G
5′-CTGCAGCTGCATTTCCGAGTCTGG-3′
MM5.1
Thr366
L869
Startsedt
Radiosequencing
p.N45S
RAC1A159V
c.3285delA
ΔE4/L148A
pRB-E2F
ARF–p53–MDM2
0.04–0.25
carboxylating
.triple
Customised
bacsubjected
mutations—leads
metalloprotease-sensitive
Akt-TSC
combs-like
o5580
gplloProto-trk
protein/DNA/solvent
Annexin-V+/DAPI−
cells/average
G311D
subtype27
25:453–460
.Protocols
10−27
.Sequenced
–0.9
GAAGAAAGAGGAGGGGCTG
MCAC
transformation198
Mutan
contexts.33
MDAH
Lys117Asn
non-fusing
TEL-JAK2
84,000
Analysis,21
HGN165
TargetScan-assigned
ligand‐mediated
ER-TDCFESYKWTDIWAFGL
CEP-101
K-rasG12V-IRES-BGeo
NOTCH1-responsive
Themutant
S259F
c.226-12T
MLH1c.1178T
500–6,000
Bio-tek
41/336
59-gene
G333S
HoxA
pGRR5
1•3–1•6
2RD0
pladienolides
.Glu-659
PDGFR2
757
TFF1
ant-KIT
2Gy
.PIA-dependent
low-set
28–83
c.1136C4G
1∶20
chromosome-17
.Trans35S
auto-activatory
.FLJ21816
β2-microglobulin
2647
Y49stop
1/03
5′-GAAATCAGCTTCCTGCGAAC-3′
RUNX3**
Martinistrasse
Roschke
A38
GA2
Arg48
browser4
4.15×103
1204-51
O'Neill
Gαq–Gα11
18·0
2B4
L591
trxb11
set17
0-15
p.S80I
GAGGCAACTGCTTATGGCTTA
L1122VþL1196M
ATRA-mediated
.Faced
cyclins75
Notch151,52
5'-AAAGAATTCTATGGAGGAGCCGCAGTCAGATCCTA-3
®nger/BRCTdomain-containing
Cys72
holo-TRAP-Mediator
herceptin
36.6
INR
2,454
under-estimates
R47L
DNA-intercalating
Gln6
phosphorylated/dephosphorylated
E.D
.Prodomains
H143Y
E135
Y637
CBFβ/PEBP2β
D816Y-activating
nucleoplasmin
Inter-group
SOS1-505
Koszarska
Hamartin
pNTAPb-Mef2a
polyC
550–582
HPVE7
viruses.142
V269A
.1puro-KIT
luminosity
D9S157
200–600
,66
Suv4-20h2
site-unspecific
18fluorodeoxyglucose
gene–environment
CMML-specific
–representing
5.949
pathway.23
shShp2
DUET
clonally-derived
.HIV‑1
TCGAGTCGAAGCGCGTAGCCAAGCGGAAGCTGG-3
ATGGCAAAGCAACCTTCTGATG
CKHLKMTRP
Goldman9
5P
t-
.Unanswered
synthetised
MedSystems
R249S/H168R
BRG1-containing
random-effects
succumb
mice.15,28
PPAPDC1B-pcDNA3.1
Activation/phosphorylation
2937
Met1_X863del
Ala4419Ser
.Single-allele
FAB-classification
Renilla-fused
1366–1863
.400
18-fold
gene.1To
NiCl2
U133A
LIGIII
Msh2V63E
MOB
His-MBP
PCR-cloning
Cyclopamine
Lozenge
5′CGCGCTCTACCCTGCACTC
angiopoietin-1
KM12L4
256.19
regulation/function
thatfollow
association43
558C
SOX17-overexpression
B7-H3
protein/extracellular
v-ets
22–
MOLT
Borlado
1.15x
bi-cistronic
III2
D14S72
PTEN-expression
phospho-T58-MYC
558-Lys
E2t3
IGR1241
conju
artemin
sh-FOXA1
mutations—changes
D626A
5–elongin
0.086
mg/d
cancer.58
activityIt
TRAIL-R1/DR4
disulfate
NM_006197
'guardian
.AC010864
FKBP12–rapamycin
SCL/TAL
27.
pink/pink
104-R97-R18810.18
25/276
-c
I252T
74/109
HDC
Time-resolved
〈I〉|
NTRK-activating
BaF
.Antibody-bound
SC-7199
dacomitinib-resistant
pSTAT5
Operon
RAD51D
MEK5
Rac-binding
MKP1/2
normalsized
poly-l-lysine-coated
72.1
pY992
107–109
Filetti
5′-GACATCTCTGCCGTCAAAAGAA-3′
NotI-/ApaI-digested
midkine—have
reciprocity.Emerging
gB2-
N1941S
Position-independent
35III-1
weretransactivated
S170F
se.16
.S338
nihms646437t18.jpg
0.0165
TβR-I/TβR-I
M3544
Thr1219Ile
M173V
p.F298Sfs*20
p21CDKN1A
AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA
cardioplegic
anti-PRAS40
R256
transcriptional-reporter
previously.2
c.4039_4076del38
Microscopy—The
AB9610
p161NK4
Multivariable
f/73
33,634,800
A143P
PCB
0.44-mm
proliferation77
www.cbioportal.org/
SETD7
dEμ7
fashion.7
andNF1-GRD
9,300
+6.1
K907E
ME2-R
anti-CycM
.Macroscopically
kbXhoI
MACH3TM
One-mg
106/42
GSTM1-4
METR970C
disorders25
.Subclonal
†12
Lys975Glu
characteristic50
α-difluoromethylornithine
K197T
HNPPC-related
B1–4
indicated.b
V126M
site.6,22
p19Ink4d
e–fMYCC
NAT2
4min
5′-CGTATCTCCCTTCCCTGATT-3′
P925L
yi|
syndromes11
p.R755S
promyeloid
Gg5.9kbΔAGAAAR
-TTTTCCGTCATCGTCTTTCC-30
Thermoblock
ARR2PB
4/18
OB3
expression.17
R755W
.Gab1
II-reverse
1•6
A295V
L118R
ttatag/GTGTCT
004364.2
Pajak
7.103
polyN-acetyllactosamine
.Productive
20q-
Burgaud
HDAC-recruitment
16–18
p19-INK4D
proteinand
75464
Enami1,22
TP-expressing
.3810
SOX9-inducible
.Practically
variabil
green-only
panel26
growth.39
Sekine
6-His-tagged
disorder-associated
adjuvantly
59/151
profiling29
siERBB3
arms27
hARE4a
AC-I
p.Leu209Phe
Smarca4
30:0.7
Brca1flex2/FH-I26A/p53flex7/flex7/Wapcre/+
P12-ICHIKAWA
GTP
withDNE
receptorsremains
peptide70
IVS514_5insA
120,120,121,1mar,1mar
181–270
trametinib.12
Capinteria
20–85
bubble-PCR.40–43
0.3N
CS28
EGFR–RAD51
29,31,78
Arg24−Glu27
-dichlorofluorescin
ΔΔδ=0
junctions3
R61H
Yart
~Ala59
5-27
5′CGGTTCTGTCCGTTCGCTGCGGCAGCGAGCCCGCAGGCGTT-3′
phospho-JAK1
FLT3-V579A-
549del
γ2A-FRT
cell-banking
DNA-Smad3
478.5
*100
3874
phospho-Smad1
Sato-Otsubo2,3
GST-p16
,36,37
Bristol-Myers
.Arg49
Fig1J–K
Asn166Chk2
218Cright
previously.44
rearrangements.As
turn-off
0.0342
Ercolini
Schwannoma
0.64–1.60
reaction28
Cγ1-cre/+
EJ-Ras
Ka+Ks
MLH1,8
R1000S
BL13
metabolism.2
liver.2,3
NF1186
2-related
Ig-c-myc
betaP1–betaB
Ex5
L691
PHD–Ins
L505H
17q12-q21
ATG5
YAP-responsive
C-C4
Methylation-positive
.CTLA‐4
CUL2-ROC1
Cheng*
4-weeks
Non-WNT
230–232
p53+/+
Xf
T1343
FLAG-Elf3
HEKn
pTYF.FGFR2.IRES.Neo
17-21
βPDGFR-mediated
//rulai.cshl.edu/tools/ESE/
K81I
TGFBR1-
low-density
trimethyation
anti-C-KIT
c.560T
57-69
elsewhere.13,33,34
M•tS•rll•Leu
stereomicroscope
sorafenib.14
P03169109
.27,34
colleagues62
rupture†‡
11B3fl/Trp53fl
DZNep
gtaaatttta
On-TARGET
,9,10
E433K
007373.3
7/29
~final
counter-parts
MYPT1-PP1d
RGGI
1476
ALAS2
rs121913428
47.6
f80
MBr66-
3482
TAK1
Bluegnome
Anti-phospho-EGFR
unestablished
pregnancy/lactation
HIF-2α
CYCS-RT
F491L
Fig.22A
non-amplification
S3Ff3
sebaceum
agents38
.Spliceosome
signals.Figure
boftom
angiogenesis10
Pondarre
G-Dynabeads
F384L
FIP1-like-1
858±228
+105
A416T
TNF28
txon
DUF283
Smad4s
Helgeson
GU079948
fgfr1a
9247
TritonX100
R637/R692
−16.1
3UUD
cgtatagccgaaattgc
residues31
cctcag/ATGATT
Col4a1
artemis/DNAPK
/D153
death.Dierent
25-4
Topalian
K509insFAF
2.418
GMALL
somatic-associated
HEPES–NaOH
organism.1
Rheinlanddamm
U118
4.46
R442C
4200-S
–PMS2
P-286
.17,21
40C
anti-p21CIP1
Ramirez-Solis
ETV6-NTRK2
SF91
ASF/SF2-ESE
apurinic/apyrimidinic
HER2L869R-mutant
Phytohemagglutinin
BondMax
–inhibitory
SFB-BRCA2
C3223T
.BRC8
micromoles
Hepatoblastomas
nonacetylated
58-GAAGTTGTCTTTTATAAAACTTT-38
Miramar
product-limit
T5168
E543K
hTERT/5qSTS
pCORE
stem/precursor
pLHRE-luc
Ig2
Figure7C7C
weakly-activating
14q20
16·9
myrIRS1-expressing
p-c-Kit
Astolfi
serine-threonine-specific
signi¢cant
6/15/08
4.Smurf2
fluoresceinisothiocyanate
SH-310
shNF1
TCGAL
.Manola
β-catenin/TCF-4
Fgfr3
granulocytes-macrophages
.BRCA1-Met-297
.Bandshifts
Random-effects
Eisenhofer
Weinkove
Xiasi
.Record
genes.14
L858R-T790M–mutated
AAK1
MLL-CDCREL1
Gly1613
0.00855
Tyr40
TACC
1.2-13.4
R158H
post-processing
Ezh2Y641F-mutated
imaging,21
enamel
1-β-d-arabinofuranosylcytosine
esg+ve
G290D
ischemia–reperfusion
SATB1-induced
HPV18
.Tumor-rupture
5/23/08
P92S
pSMAD1/5
MSCV-vector
isopeptidases
0.5times106
12-mm
Glyceraldehyde-3-phosphate
NVP-BYL719The
DKC
AtmKD/-
ratjadone
hBUBR1
post-weaning
C42
Bouzahzah
664–1030
Slegtenhorst
SureSelect
DEXSeq.29
mixed-
AML,18,19
Phosphopeptide-mapping
colony-forming/replating
Brca1FH-WT/FH-WT
residues.12,13
D1709N
90l17
www.sciencetranslationalmedicine.org
family-cancer-clinic
.E1A-F
α-phospho-Jnk
GSE3526
SA493
5¶-GATCTCACTATGTTGACAAGGC-3¶
SY5Y
–BRAF
–translated
Fig.11F
MDS/s-AML
.Anti-RFC-140
12-E1B-Luc
00003450
nondeletion
53.8–55.5
D17S1821
CACCCATCTACAGTCCCCCTTGC
4–92
E151K
8,1mm3sterilized
H3076
8.33/nL
antennapedia
sc-354x
GFP-ΔINI1
cancers.It
WDR51B
V679
TUNEL-technique
Worthley
139519
1QQK
NM_014572
transplantation-related
non-bridging
one-sample
phosporylation
myelosuppression30
mAsxl1
Nu43/2
GEFs50
.Trephine
AGAGTAACTAATAACTGCTGGAGGATG
properties34
11.7–14.5
MEKP56
9,27
TACACGGAGTCAGGCTGAGC
R349W
46,983
catalysis10
CCTCAGATAATGAGTTCTTCTACGTTGATTTCAG
RG-14T
Huntzicker
2827
5.1-69.0
5hmC
bcatenin
p.Gln317X
2Δ46
CMV2
interpupillary
REFMAC
optionsPIK3R1R348∗
genomicAKT2
SK-5300
160.9/98.9
Microsequence
Phosphopeptide
Microfuge
CTAGTCTAGATCAGTTCTGAGAGATGACATCC
SKI/SNON
PIK3R1N324∗
TAC→CAC
doi:10.1093/nar/gkt930
DDR2+/+
TBTTAT
Cyclin-D2
repair25,26,27,28
59-TGGGTGGATGTTACCC
IPMNs,3
duplications/
musculus6
BCL2-binding
Karasawa
L858R.39
Ras-RasGAP
amounts.40
Chedid
HNSCC.Figure
pentanucleotide
adenosine-binding
D308A
Bhimrao
N822H/K
5-caC
Tothova
anti-hMet
billaud
sev
intermediate-2
Yonish-Rouach
Y220C
pEFmRaf
Dimerization-independent
.3a
48,000
introns/exons
25,117
3-84
disadvantages1
6-3H2O
outcomes1,14
ESISLLEVSTLGKAKTEPNKCVSQCAAFENPKGLIHGCSKDNRNDTEGFKYPLGHEVNHS
hyptonia
D6S265
11q12.1
Papile
J.S.R
+PBX3
CGGAATTCCAGAGGGATACCATGCAA
421
Destabilised
anti-PLCyl
p53/DNA
//www.broadinstitute.org/ccle.In
p73s
sample13
mCherry-expressing
543ΔT/543ΔT
Gasca
G2O
Bertucci
gi73969550
GCCGTGGACAACAACTCCTA
Fig.4C
transacting
Asn112
L647V
Gln/Arg
Wof
Q556_K558del
S88
hyperplastic-appearing
ifferent
CD38−
E2F-5
selectedmutation
15-minute
growth-regulating
cycDl
EC-domain
cycle.27
sequence-invariant
50340-2
p44MAPK
GC4
radiotherapy.Age
cell/poorly
E6a
P104
c.-245T
ganglioneuromatosis
2H-tetrazolium-5-carboxanilide
666-1114
vbeta
1-month
PSPN
mTor/S6
Myc-TrkA
1.5e-5
.Mao
.3971C
nucleosome-binding
heterodimerization-dependent
Zeocine
mouse55
pCUB12
migration71
Bio101
marrow,47,48
KPT-330
EGFR-fusion
erythroid-specific
MiTF
RT-PCR.RT-PCR
p85αdelH450-E451
Teraoka
ARccr-mediated
Hs00175892_m1
TriZol
Raf/PI-3-K
A-NHEJ
MYD88-wt
-0.42
NM_000267.3.By
pro-ficiency
DRB1*0401
serum-dependent
Kap1/TIF1β
81-29-847-2037
—cetuximab
EBR
G1269S
LR04-032
Trp3Stop
FGF-10
LAU63
PLX4720-containing
YMAT
Anti-Cul2
06/21
Peroxiredoxin
1,424
microinsertion
M52
E1755G
neomycinresistant
S/F*
Snuderl
DH/PH
stabilization.13
mutations21
ROX™
RTS-related
4lUUUMu4
5′CGGAGAAAGAGGTAATGAAATGGC3′
4.8×10−19
c.962G4A
Losekoot
Flt3-dependent
p.P26_Q31delInsE
.Already
.ISH
1964
intermembrane
35,000g
arrest.38–40
1WT
MicroPoly
genes,21
acknowledgements
anti-Cdk2
Ly5.1+Ly5.2+
weredescribed
transformation39,40
NG_012808.1
1998.r1998
.Failure
RICH2
Strategico
oncolytic
1365-AA
2A⇓
0.006a
R72
iron-supplemented
Constructs—F9-differentiated
dephosphorylated
c.1108G
Mammary-specific
INDEL
.map
msh2-EK866
ctw
helical
2661
null-mutations
responsive‑
extraordinarily
pdgfrb
FPD-derived
601090
Smad1Δc
.GFP-labeled
ER+/erbB2+
NHMRC
peripancreatic
TCGA-LUAD
B81
G1-
Q282*
-TGCTGGATGAGCTGACTCTG-3
MAC1
EcoRI/KpnI
EGFR/KEAP1
tification
95–98
Trk2A
~500-kb
Du¨
Administering
nglmL
FPD-AML
C-terminally
domains89
cre‑
pMMP-FANCG
Algrain
Pharmacophore
V1744
P-K-K-A-R-E.V
6M
W3061
1–160
NM_022415
LeuJ
thirty-nine
1396–
P1266L
Endosomal
mg·day−1
immunowestern
p.Gln356HisfsX15
tumors32
55242470
.59,60
LCK
EBL
.131
probiotic
fa-
semiquantification
non-physicians
Asn135
ROR1-mediated
Oguma
C9
5q34
.LDS1
l-glutamate
rs17290103
Milbrandt
HRE-luciferase
20although
skeletogenic
S2–3
p27-Codon
well-suited
3.1-fold
1.10E+04
progression.6
Cholangiocarcinoma
A23E
§Consult
RON1
PPP6C-H114Y
NG12
1397–1467
P.A859T
WCLZ
PAX8
S65
JAK2-kinase
Trichostatin-A
.Quantifi
Glycosylation—The
Fluidigm-MiSeq
PHA-739358
stoichiometeric
FGFR3-
.Net
Z36715
co-incubated
-CTTTTCTGACCTGCCTGTTTTC-3
melanomacell
GIST.4,10,11
F‐Smad1
non-sense-mediated
C176R
81-3-5803-
TOP/FOPFlash
p.Pro647HisfsX283
HER3-
.AB032598
−2965
5-aza-2′-
A481T
Jak/Stat
co-ordinates
erbB-2-positive
94.3
IMR-32
.ENHANCED
37-merhomoduplex
undifferentiated-type
1dim
GSE14437
S666P
EGFR.As
anti-Topoisomerase
optoRAF
R359C
HCC.63
ATF
cancers37
pentylenetetrazol
V294M
N-Terminus
agents6
c.1668-19A
1E
component.7
mmf-max-hq-mismatches-xt-u
acid/EDTA
0.1are
nonaltered
-negative
12.8-kilobase-long
3100
p120-GAP
3A/D
Venugopal
q28.3
.BCL2L11
complexes.Importantly
CAAGTATTGGTCTCTCGTCTTTCAGCTGGATAAGGTCTGGTTTAATGC
LifeScope-only
Sturge–Weber
intraembryonically
pH2AX
.De-repression
0.2080
phenylalanine-to-leucine
171-448
Centroblasts
intertrabecular
KIAA1549-mediated
FGFR1P578H
–RAD50–NBS1
p.G505S
p.Ala276Asp
α-cdk2
804-bp
1D-1E
AML1-MDS1-Evi1
PRKB
signalling32
P256fs
c.2276G
ZMYND11
3,805
versionof
30:26
.Shp
L274P
Y591/Y597/Y599
subphenotypes
b-emission
7.61
consecutively
hamartin.24–26
TOV-21g
14–3-3
Solove
LIC/Xa
CAC-3
teleconferences
96–144
hasdemonstrated
siFBXW7
AG14361
R-SMADs
4Aiv
variables.25,26
CHX
pVHL-mediated
¸65
AflII
line20
V845M
c.1086G
TCGA-06-0122-01
.GTP
Y966E
Mitotane
HGF-independent
b2m-deficient
AY028849
monocytogenes
5/1,124
CI,4-16
76.2
PI3K-resistant
p.N385Vfs
myc-CUL2
TR-transgenic
13,262
anti-KMT2D
962
carcinoma.32
dissection,1,2
Ule
190
2/54
Li7
G12S/A59T
neuroforamina
E2–dependent
M76
ACCACAGTCCATGCCATCAC
C115Y
methyltransferase.5
-70Â°C
NADH-dependent
E804G
U15655
.Permeabilization
MCHLs
ARP2/3
gatekeeper-residue
51/66
1642
KRASG13D/PIK3CAH1047R
.East-Asian
metalloproteinases
Jak2-K539L
Chappuis-Flament
5-of-6-bp
61-11.
HA-6A-FZR1
.SAM
105,000
C182/277S
Crouzon/Pfeiffer
not1
LR11-076
Erk/p38
States1
32.23
haematoxylin–eosin
trk8
l8pâ€
GST-Cbl-R420Q-RING
129SVJ
PI3K/PDK-1
.PTEN-null
Ago2-mediated
temperatureA
17q23
public-health
non-regulatory
Nontumoral
tttggagggtgcgctctctg
lysine-to-asparagine
A545
E2F/DP
F1c-transfected
DAYHOFF
RSK1/2/3
c.227A
.TK
.Tables
pS6S240
hypermethylation.23
Hs99999901
v−src−associated
M1248T
.D4S1554
Growthstimulatory
38/53
Variants—To
pY599-binding
10-213
plasmablastic
PBS-Glycin
NTM*
WK
Monosomyof
NREAL
BRG1-positive
α22
S783C
Two-hundred
linker-RING
rs2279744
5′-GACCAGCCTGTCATGGCAGT-3′
CCAATACCAAACTCAAACAACAAC
Dussurget
single-stranded
-2.40
Trr/Mll3/Mll4—each
anti-ERRB2
g.81664C
14-23
142/207
59.79
13C6
BRCA2+/−
OLIG2+/FOXG1−
Imatinib-resistant
T1354M
receptor‑tyrosine
phosphatidylinositol-trisphosphates
/CDK4
Figure2B
0.067
L660fs*2
post-labeling
AGTGACGACCAGAGCCAGAC
daunomycin
Z7020056
SpectrumOrange-labeled
16h
electropherogramm
_76+
3delTAG
5′-CATTAACACAAAGGAGGCGTCTC-3′
MARK1
Tmprss2-ETS
3'→5
1qpe
.DEK
CR146v°
E743-R841
q14.1
.using
5146–5154
Tel/platelet-derived
BACH1-Forward
.VEGF
Cys77
c.1563_1564delAG
KrasG12D-induced
K676R
Huntingtin
1982b
c.4173A
KDM3A
leukaemia12
BRCA1–BRCA2-independent
a-MLH1
E227K
complexes17
pT3/ABN5
.217
HS03003631_g1
juxtacrine
decompartmentalization
ERK1P75L
TGF-β–antiproliferative
FOG-1
translocation—with
expression33
mutagenesis/BP
NAN7
Capasso
Molina-Vila
E239K
inyeast
TCATCCTCCAGGACTGCATGTG
VDMAA
CRC020
CD45R/B220
6/50.0
A53T
A99V
1,2-dimethyl-6-
Chemstrip
FcγR+
Hayata
TQ-rich
TableTable22
Compound-protein
S841
.REG
12362-70
17.0
AS601245
1141-3041
3501
earlier,13
Gly-Val
JAK2/2−
Heine
14,55
wash-resistant
10-17
patients.43
8.24
lesioFigure
Tyr1056.14,29
5Q
hsrK12
glioblastomas15
loci.Although
MYC-related
p.A113V
Reha-Krantz
Ba/F3-BJ
pSP73-loxP-PUR
Pro315Ser
BstXI
IIIb
Sf-9
syndrome.18,19
93.33
oncoretroviral
RP11-436C9
CS29
E6/E7/hTERT
CD273
reversetranscriptase
+8566
29110458
501C
A-11,008
miR-34c-5p
P=0.1735
mutation6
Deltex1
including+8
pageMaterials
poor-prognosis
5′-GTCTAGATCA
MALDI
225998_at
CT2571
Pro324
NFE2L2N160S
CATTGAT
LILISCHKIS
.CONCLUSIONS—Resistance
UltraHyb
N-ras-C51Y
Tripartite
GT
sub-classification8
162.3
.Acceleration
Fukazawa
100â€
.Whether
lines18
threonine/tyrosine
−1,147
mammalian-based
PLLMVFEYMRHGDLNRFLR-
5803
,2A
Brookline
W335C
TCCGTTCTGGATACCCTCAC
Shevach
.Pro-inflammatory
.Arg-expressing
39–65
.FANCD2-L
pHHLUC
Y35F
58-AAGT-ACTTACCACAATGCCAATAAA-38
MetR968C
28.4
.A-RAF
Braf+/Lox-D594A
line—CR
NBD-GDP
g.33248–33276
ISRCTN17833622
binding5
alanine634valine
tccctaaag
methylester
R897
tis-
n-DX
.Cys608
2-mercaptoethanol/0.25
cancer.3
ctatcttattagatatgcc
pAX-HA-oncoVAV1
anti-eIF4e
XhoI–Hind
93482-50ML-F
M/3
expression,26
c.8257_8259delCTT
MBD-R2
Ran-GTP
70.2
/pg
Rb+/-
S7PY-saturated
7q-linked
p21-deficient
C225
ERBB4/HER4
γ-IFN
TYRO-3
c.8537_8538delAG
AML1-KO
M178R
α1′-α3′
SDS–10
Molecular-Vysis
2501500
Replication-incompetent
∼56
,3,3
Fluorolog
1Met–99Ser
G12I/L/T
PLZF-RARα
phosho-AKT
Coctail
NG17
temperature-unstable
jan.cools
Schubeler
d2
Mutation-based
medullary7
EGFR-I853T
EX3BR
displaytranscriptional
.9117
5'-CGCCATGGCAGCCCTGACATC-3
variant-encoding
c.1395_1397delGGA
.Populations
nonstandardized
601263
.MSCV-EGFP
C-RAF
c-Kit–expressing
P.
16.1–900
RP11-235O20
319del
.ASNS
0.41-fold
mH1b
.003038
E410K
active-chromatin-associated
3.71±0.3
auto-phosphorylated
5'-TGCCAACTTTCTTATTCAAC-3
D820A
non-African
RT-PCRs
controls23
A1669S
Hs00282410
38.82
R3572
Bl0
ms.
MaMel-48
Cbl
survival=50
FMTCs
Bab
Dual-Light
GMP-PNP–loaded
IAE
FLI-1/exon9
Dusp9
1.44–26.11
Biotechnology/Millipore
carcinoma.22
C-Raf
RPLP0
1996a
33/339
C-ι
STA-ET
665,752
Figure2E
eluates
polymorphism.30–32
Othersc
TE-10
M1A
cER4
29443776
weremated
Dacarbazine,3
rs28363283
muscle-specific
Gab-1
Pastrello
loop,17
13206134
4·1–14·2
Age/sex
.106
3PR
acetonyl-CoA
RRM2
Dkk
E258
Rol
elucidated.5
dominant-nega-
nt+66
H-8
1.50/2.50
tumors.2–4
11,22
PT-29
Smm
MIP-box
bioinformatics.mdanderson.org
TLX1-positive
23/40
AC005600.1
-517/+63
BRAF-mutations
Q419K
JAKs-STAT1
phospho-SCD
E336X
bisphosphate
6,213
2,000-4,000
rr-
.DSRed
1068
lysosomes
V599K
hut
W486*
recurrent.NF1
22–69
5'-M13-CCAGATGGTATAGAAATCTTCG-3
DYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLDK
Danen-van
H168Q
ORCID
PQV
40kb
P-EGFR
GRISAFI
speci®citymutant
colorspace
Zamparelli
lymphoma.6
q32.2
RBL15
SVS3
P-CAS
Flag-Ubiquitin
nomenclature.18
development164
18,42
inconsistently
700-
10.1007/s11010-007-9503-9
p73betaWT
SignalSilence
515bp
acampomelic
PDGFRa
Leukemia21
Naphthol-AS-biphosphate
qualityof
p21WAF1
0.416
-ATT
PI3K-FoxO
SDS/12
95C3362
FOXO1-regulated
.Scores
Sonoshita
worldwide.4
-MEK1
5′-AAGTGTGTGTGGTTATTACCGCTGGAGT
.Eastern
capture‐based
MEK1Q56P-glutathione-S-transferase
MSH6-4
.SAMtools
monoblast
moreeciently
.Reliability
Ras-V12-transformed
.01§
classes138
KFC-derived
nonanonymous
FoundationACT
IL-2-family
RFC-140-transfected
tttttctag
MNU
5′-GGAGAACAGTTGTGGGGAGATGGGTC-3′
33/35
IDBS
His-Arg-Asp
repression9
1337
FDR-corrected
pathway2,4,5,6,7,8,9,10,11,12,13,14
fsrg1
m/77
3FF
outcome30
descriptively
4L-N
caspase-activated
siRictor-implanted
EGLN1
malignancies.6
Leu768
13-globin
E142K
previously9,55
single-digit
MutationValidationCriteria.asp
1.7nM
glycosylase
0.781
∼20,000
deubiquitinate
2H–K
NP_989692.1
Myc-associated
Pde8a
-OH
293Trex
EGFR/Erk1/2
CountCovariates
line.42
.MicroRNA
49,5358
dextran-coated
AF4
Zn3
E381K
accountfor
Non-adenocarcinoma
U43746.1
//www.ppbregistry.org/pdf/Doc_D.pdf
WW-PDGFRA
S235/S236
2Aii
activation–inactivation
59-ward
MIEG328
.Tumoral
`Altered
7.42
p53-apoptotic
IL8RA
p=0.0047
66•
-α.
C67Y
MIEG3–EWSR1–FLI1
−3.93
.F-
samples.26
02/1
tumors/cell
Catrin
broad-scale
SRE-luciferase
lamboid
homo-heteroduplex
anti-B220-FITC
www-p53.iarc.fr
Glu122-Ser403
A282
disfavouring
inhibitor17
gefitinib-na¨ıve
pG5Luc
BCL-xL48
signal-sustaining
42-44,49-52
1318
23.6
M98833
0.47—23.7
549
Immunogenetics
.OR
anti-angiogenesis
hnRNPG
ARE-like
VO-transfected
H-RASG12V
42–72
760-nt
O-glycosylated
SIGMA-ALDRICH
D49N
High-frequency
reported.1Gain-of-function
Apc+/+Smad3−/−
EGFR-Akpcells
2.3a
CCACCATGGAACACCAGCTCCTGTGC
3q21.3
Cre-recombination
N822K-type
Bremen-Mitte
minicultures
Foxb1
DEK
ATAGCTAGCATGGCTTGCCTTTGGATTTCAG
inhibition56
.Engagement
Proteus-like
-0.1/min
NH2
documented.30
Microscint
7.0
TRI-reagent
UV-driven
www.interactive-biosoftware.com
intensification
A.
Winoto
two‐way
thermostability
Edghill
DBS
puro-NeuT
Balb/c3C57B6/J
corre
scription-PCR
.Grosso
p.Thr77Arg
FIG-
M62397.1
FcεR1
.Carriers
kinase.19,20
DE1R1
anti-TGFBR2
2-28
p.V471F
23•13
LL22NC03
.Under
genes.1,2,4,5,8⇓-10
Y1631X
acuity
4,8
Bronchioalveolar
osteoarticular
11A–B
H-ras
SDS
asparagine
5′-ACGTTGGATGGTAGGAAATAGCAGCCTCAC-3′
A31
–428/–270
MTPC1
PI-
RAB35F161Lmutants
RAC-1
21.60
34-2
FISH.13
c.1111C
PIK3CAE545K
955
I169T
MALAT1
DP70
Me4
2.8c
tin1
treatmentPLX4720
caution.Although
4-R1
pcbi.1003749.e007.jpgare
Δcterm
29·9
M622I
c.463+43A
l-plastin
Takafumi
T-helper
GGCGAGGGAC
mouse.27
multi-nucleotide
andXhoI
1O9S
HE12
Kyte–Doolittle
104,000
1This
FOXO1
ToualbiAbed
α-KG-dependent
UBF1
TruSeq
gray/bottom
gastrojejunostomy
20246
H2.35
receptorβ
MOPS-SDS
1,000/
cutwith
S2728
2.997
pCHDMIA
2575delC
MSSE6,11
Phenix57
Ogino
16141210
24,28
tableAll
Akt-specific
∼1:4
Roumier
proteinproteininteraction
121K
TFA4
-differentiated
preclustering
KMS-11
.TG101209-treated
rapamycin–sensitive
DpYR
1.7G0.3
range=31.3–47.3
cAPK
57–63
GDNF-responsiveness
c.1589T
bymsh2
10,11,37
*PDB
5,44,45
127.12
-GAAGGAGCCTGACCCTTTCC-3
NM_007298
anti-pAKT
Azzariti
MDS-RS
CD79α+
BMP2-induced
M25404
IFN-γ.3
.Transactivation
2259
function.10
LC_S42
HR5
N113D/D145A
activin-related
hFig-20
neopla-
JAK2-R2
pSF91
Faivre
K-ras–mutant
−7/del
.URLs
RAB7A
.B2m
Porcher
9.7
arealmost
CD10.12
DUSP4-deleted
76/70
progenitors.27
Fondell
Treeview37
GMCSF
RAS/RTK-pathway
Lymphoblastoid
eosinophils.38,39
1357
.TET1
Hs01104728_m1
dimerization/DNA
5′-CACAAAGATCATCCTT-TCAGAG-3′
progression108
clefting
anti-FITC
6–20
anti-PD-1/PD-L1
4.3–27.7×103
4B-D
.ATM-KD
proteins45
1037delC
cells.
858.a
.Submicromolar
1312G
Pax8
Kominsky
LC3I
10/46
GAG-3
8.995
//www.genesdev.org
estrogen-starved
b-catenin-LEF/TCF
STAT1-DNA
TetR-KRAB
16–200
Bar=250
growth-stimulatory
TGF-β1-expressing
model16
pathomechanisms
-0.572
biologically-significant
p202/p204ERK
families5
.Mate
50-80
55·6
Schulein
TGATGATCTTGAGGCTGTTGT
classificationsystem.Taken
Y1086
HN-Smad4
R882H-associated
NFE2l2
CCL2-CCR2
pClA
R.G
ANK1
Arg524Pro
SequencingWhole-genome
degradation.25
C57/Bl6
ovariectomized
models.16
5~10
200-volume
3,4-d
RASEF
0.99^1.05
genes.12,13,18,19
screening/sequencing
dCHIP
MSCV-IRES-YFP
PCAF
CD74-ROS1–positive
subanalyses
CDKL5
Microbead
96-1
.Mx-1-Cre+Sox17fl/GFP
.Lee
V-negative
hydroxyphenyl
.12
versus0.4
spo11Δ
-gtaacttaataaaaatgcatgcagcg-3
pCTV1-3′
dominance/recessivity
C294R
SIE-binding
G674AThe
—all
pMIV
CRelative
FGFR3-transformed
AACAATGG
Baculogold
studies,9
microphtalmia
Cα
63,65
P577_Y579del
R145W
5′-CCTAGTGTCCAATTCTGACG-3′
Seph
.Elutions
PDGF-PDGFR
Buchler
.Balb/c
NM_000489.3
Victora
NCI-SNU-5
629C
69/m
PelSin_1.0
P0448
homology-like
GeneMath
EGFR–HER3
~19
methylation-sensitive
WSU-DLCL
Tam-treatment
Design—PCa
KIT-Dependent
Ser347Cys
10q24.2
Extramural
BAZ1B
M87I
radioactivity
D18S55
hypoxanthine/guanine
12.32
Gly-His-Gln
2-methoxyestradiol
'master
5′-CGAACTGGAGGCGCTCTGAGAGG-3′
Oskarsson
EGFtreated
5′-GCTGAAGAAGATGTGGAA-3′
0.7677–48.35
C1183
h.D
Agarose-conjugated
PP2A-Tau
methylation.119
p.T470I
10:447–453
β/γ-phosphate
R402H
DNA-bound
hydrochloric
FFPE-extracted
R890H
forstudying
1–2μg
CL203.4
3.0–3.2
premenopausal
C39R
.H-Ras
H1299/M237K
p.R172W
adenocarcinomaThyroidFollicular
M390R
GST–RasGAP
so-called
BV6
LY9
Dispenzieri
gelatinolytic
6.8∗
'removing
1G/2G
CD150+
.ZRSR2
R671
protein-bead
T1/E4
melanoma7,34,35
N172
CD31
rs34289250
Dova
.percentages
G-A
anti-Oct-1
124H6
P=0.0179
all-AQ
KIT-ΔWK557-558/T670I
NIH-3T3-MSCV-puro-MEK1
HSP60
Tyr371
TRK-T
Galsky
-0.289
PROTEINS51
dsk5
Leu117Pro
ctttag/GTCTTT
precleaned
anti-RANKL
Trp611
transition90
D1-AP1/dEμ7
promoter‐based
therapy.Experimental
R750W
BMP4-induced
12-year-old
8657
LeuS•rAsnThrGluA1a
ptac
9989.In
.4a
AP1-binding
NP_000242.1
Gel-70
analysisCorrelations
duplication.25
tract.27
RAN-BP2
2/90
period.17
Thérond
TAATACGACTCACTATAGGGAGCGAAGAAAAGACGACGAA
.Dystrophies
I.|/Σ
GdnHCl
Bleomycin
5385insC
in-BRAFV600E
Liloglou
/lymphoid
.PI3K
Tyr-772
13/43
N-RasQ61K
DiFi-R
IC50=2
chitotriosidase
genotyping
dual-indexed
Gln3^
dideoxy
haemopoietic
BANF
mtrocellulosemembranes
.Kmt2f
model95
MeVARi
Inc.Somatic
D/CDK4
F79
HIF-α.C
FLAG-BAP1-F170I
11037
17q-
FGFR2C278F/KD
RK3EGLI-D
TITF-1/NKX2.1
GST-MEK
18893
Gerges2
corepressors8
high-coverage
p.Arg689Ser
G719S.6
5:12
quadriplicates
Rho-immortalized
PTPN13
mutations,23,24
GGGCAAGTCT
v-erb-b2
1.93–1.90
~~~signal
V550/L
L83
G191V
pfg127T
Asp770_Asn771insSerValGln
5′-CTGGTTTTCCTCGCTTGTATCTCC-3′
360°
downregulation⁎
/external-
.Infant
.MDV3100
BRCA1–BRCA2-mediated
tanscript
.Anyway
TEL-JAK2.61,62
S298SYY
B-casein
cell-derivatives
7421-1
CD135-phycoerythrin-stained
36–65
FO-J
49,57,59
HPDE
FLT3-I867
Baccarani
V242F
Takeuchi6,7
Flag-FBW7α–expressing
modifications.18
5'-TCTCTTCCAGTACTCTCCTC-3'/5'-AGGCGGTGTTGAGGGCTTAC-3
frame.The
neoplasticity
0.0001–0.03
Cantley
AKT2-G161V
patients.11
STAT3-pathway
Fig.6H,6H
region.1
Δ1-dehydrocortisol
ligand-independently
stability20
9.76
BiFC
CCATGGGTAGCAGCTCCTTCT
9106
ethanol/sodium
NRG-2
p.L858R
CAGTGGC-39
147–152
DOG1
hypomorphic
HA–p130
31patients
p.K650M
13q32.1
transcripFig
CI1
qPCR-Sos1-fw
shRNA-INPP4B
GLUT-1
F582L
1.2-mm
INK4A
STVSTISRNNIRENVFKEASSSNINEVGSSTNEVGSSINEIGSSDENIQAELGRNRGPKL
line.15
.9–11
L619F
-^GTA
59.7
N841
0.831
anti–p-SMAD2
Brompton
and4J
IC50s
trials62–64
9,49
CXCL10
nonerythrocytic
1.5-25
SLC34A2–ROS1
0.13-1.28
gi1103621
dimerization.5
Taejon
CUTO-3
48-79
FLAG-Elf3Δ129
CLTC–ALK122
TTGV
Pellet-paint
UPN10
p300ΔQ
molecular-profile-directed
2732.10.1099
12/99
Venkatasubbarao
K675R
al116
2.Clinical
TYY
FGA7
Difeo
propanesulfonate
pnas.1321155111i5.jpg
sequencing.12
electrophoreticmobility
16.5-d
Bosu
Pasching
underdevelopment
cysteine-light
BMS-3548245
prebuilt
deletion/mutation
wearers,3
536924
S227F
-GCAAGGCTTGTAGATGCGGGGTAGA-3
3350.
H9
2005–02
10−239
b-catenin-LEF-1
GCC-to-ACG
previously.1,5,20
nigroviridis
activity.62,64
Twist1
04C
terl209
internationale
R613W
neuroplasticity
20-specific
4/28/08
Endometroid
sca
shYap
reported77
RTA
thyroid
FigureFigure1
40D4
EGFR18R1
N239Y
serum-depleted
NFκB-inducible
phage
Bicluster
16-23
5seq
recently12
enkephalinergic
laryngopharyngectomy
Smad41–150
non-independent
25–75
/normal
4810
vivo–restimulated
A.F.G
2,22
IGF1R/EGFR/ERBB2
xEc
BK-13
G1544
ATFAAAT
YHKM
GDC-0449-sensitive
hyperpigmentation.9
three-fourth
10×-H26.5
TAF
0.232
C51S/C80L/C118S
Sc-193
mL/day/kg
1283C
post-migratory
self‐antigens
D390V
KITAY502
R655C
leiomyoblastoma.1-3
SynGAP
TACC3-C
Sca1+
proteins12
.S7A
AGTCTTCAGTCTCCCAGCCTATT
20c
CDG-Ib
NCT0133634
p.Asn563Glyfs*82
DMEM
BAY253H
SCC
CellTiter-Glo
746–747
PLCγ—
beta-carboline
Mitoses/50
P.D.P.P
Y653
uo
2.Kaplan–Meier
NextSeq
t*lt
−3.36
G469R
Tenascin
differentiation.17
HA-pVHL–CUL2
pro-differentiative
radio/chemotherapy
III.9
Focia
Cells—Immunofluorescent
Barlogie
mutations/Mb
raw-counts
Xpo5
tissues18
Figure3A3A
S808
al.,2001
Fluor®
C0902
G695V
GFP–PKCδ
C6‡
V843IV843I
QU
TGTGGGAAGGGACAGGTGGGGGCTGGGAGT
A-431
delL747-P753insS
KIT-N822I-expressing
PaxGene
g32-p
191306
11/19/98
ceritinib-resistant
Q1826H
DeCaprio
pEYKABL-Ib
1.9e
cReferences
NVPBVU972–treated
c.1529C
ependemoma
Rad51c
609g
MED12-mediated
K507Q
HbH-
patients.3-5
Foa-resistant
Fes/CIP4
R967K
pBacPAK8
Euro-Caucasian
Phospholipase
50-70
top53
yet-unknown
UKE
RP11-1038N13
GST-Raf1-RBD
451
cancersMedian
IL-6-
28m
.FGFR3
caspases.23
1.5×105
Farhat
PBS-1mM
2E14
p-CBL
1−5.3STEAP1Six
p.Glu48fs
PABP1
Alox
PCR17
S112-
TGFβ-related
ST486
CTGAACTAAGTCTTACTCCAG
enterocyte-like
D326N
sh-Smad2+3
EGFP−
gi22946491
1343_65del22
RUNX1-associated
.PP58
explored186
cotransport
S.W
58.4
p75NTR
5′-TCACAGCAGGGTCTTCTCTGTTT-3′
TCAP
MCN-invasive
SOHLH2
Kmvalues
GI:31083279
PAK1for
141/173
0–75
DXconcentrations
TGFBR1-HA
59GCGGAATTCATGG
subserosal
nonmedullary
2082
atomita
MIGII-BRAF
differentiation-associated
CMV/TO
His2
Calpain-mediated
ferritin-encoding
myc-F123I
V402A
grow.Can
-170
HOXD4
.1852
0.03/1.2
Arg1762
homotrimer
effectof
0.1–25
7.01
5-phosphate
.U14680
Reversetranscription
12547212
.CellTiter-Glo
NA_TUR_E
study1
Fbw7WT-Fbw7WT
pMx
TUT7
assay.Color
MLL3
B—which
NRASV12D
as,1
Leu820
caspase-8-defective
H00057492-M01
HGS
-TAGACTCGAGCGGCCGCTCACAGATCCTCTTC-3
20892-1852
.56In
APC-Cdh1
∼130
21376
4p16.3
doubleddosage
C/EBPα.59
-10
793–794
23–85
cancerhPMS1
FLT3-ITD/D835V
+25
Trpv6
elut­
nonmyristoylated
pCDNA3.1–3xFLAG
miscategorized
antiCD45RO
pLNCX2-EGFR
MCL1
.Craniofacial
775–83
D249V
K641E
S1631Sb
PIK3C2G
BRAF/B-RAF
SH-fusion
Panel–African
17.67
AMLs18
*Differences
B=19.5
SPOPF102C
βE
ortholog
Seaplaque
405,732/39,020
less-potent
G168
sulfonylurea
~lb
activity,23,63
hyperthickening
HOXA2
pp60c-Src
.Brain
.ResultsAKT-3
pGL5-STAT3α
P=0.035
1014328
screeningAmong
p.R145W
SuperTopflash
K183R
c-kit.MO7e
V408
S34F-8
ScXPO1*
intrapathway
4020delAG
dual-light
TAF15–ZNF384
αKRAS
Microvascular
A346
HEYL
3d–f
gut-brain
RapaLink-1-resistant
n=1/4
SJSC
strategy19
phosphatase7
unequivocally
7Po
BRAFWTand
.Blok
nondenaturing
dUTP-biotin
becauseof
CRD-BP
substituteconventional
single-drug
3,49
6His
E97
9.49E−05
94–360
K79me2
ste11Δ
PTGR2
A89T
microvilli
Leu861Gln
7/77
M987
HRASwI
Preosteoblasts
c.3113
SYR127063
mechanismproducing
0.01217
DIII
genome–sequencing
Sigma-Aidrich
pAL/Flt3
pl6INK4
A_51_P326499
rearrangementsfall
Y245A
CMV-VP16-TFAP2A
8in
M82V
-297
poly-basic
sul
TKIs5
NB8
DLL1
1.3
G67R
Provias
state-dependent
melano-mas
4N
EVH1
CDC2-like
c.499G
respectively29,31,32
0.9.
ap.R448*
13821-3
67AAAAA68
TGF-β-activated
damage-induced
C342S
5V-atggggtccttcctgtcctc-3V
MZL
tertiary-care
0.05–0.47
0-to-A
17.5+0.8
PAX8-PPARG
melanoma-wide
Purification—The
17β-estradiol
METY1235D
.Native
AC74
33.7–49.4
D472Y
Crohn-like
mutational/amplification
G1123S/D
CYTEL
ligand.46
IDEAL-2
.S3H
TGXTM
8.3±8.4
glutathione‐sepharose
VECPTELFPPLFLEVFED
V653A
substrate
.For
c.826G
:709
hRPTPp
28-49
LK1600/01EE
375-amino-acid-long
2To
912,830
10704
CAMT
//www.fluidigm.com/access-array-system.html
bronchial
1p34-p36
annually.1
S780
3.3.
p=0.05
AMLCG2008
5q23
I–deficient
scaffold-based
98302
solutol
E3-ubiquitin
lotLys
–8.2
.Cyclohexmide
59-CUA
50-amino-acid
688-728
case.7
v2.14.1
X52832
Mll1f/+
amounts.37,39,42
Photosensitivity
Beinhauer
EWSR1/PBX1
H19/Igf218–20
34.E349D
anti–centrin-2
ABL.17
AIF4-
biogenesis5
c.6943A
F1–F5
hypermethylation
Blastocyst-derived
indomethacin
homeostasis30
M3534
7500
0.78–3.78
INI1-positive
FASC13C112a
.V600EBRAF
V282D
92–055
3-box
ASNS
bronchopneumonitis
NIN-8
vitroMutagenesis
HT-29/
phosphatidylinositols
max-intron-length
NUP62
XhoI/HindIII/BamHI/I-SceI
YGRFTI
investigatedmutations
Δ2-8
Dchip
Asp208/212
Chk2-containing
quasifit
mut342
2-phenylamino
p.Phe222fs*35
hyperenhancement
1ias
∼2kb
GCCTAAGCTAAATCGAGAGAA
K128Q
PCA1-
well-measured
.Buoyed
5.02
BRCA1-N-terminus
KRH
downstream.8
OBSERVEDa
gGl
pLVX-Tight-Puro
Iba
4−6−kD
Hu-3
deoxycholate
Sumara
patients.12
183,381
Portugal,17
3type
T905I
2Family
Q61L–mutant
ETS-
SHCl
5′-TACACTCAGGACTTCATGGTGCCCGGACAGGTC-3′
Mansson-Brahme
picoseconds
cilostazol
DCLRE1C
University16
PRDM14
phosphoS1981
low-amplitude
suppressor138
p.Gly44_Pro49
r2005
ethylenediamine
prevalence10,11
KREApure
7–32
upregulatiom
nephroapathy
c-Metoverexpressing
REL-A
.Jurkat
12/5/03
P=0.356
C-gamma
intracisternally
detectFIG
lipomas.9
1066-1459
AML-specific
cdkI
Bcl2/Bim-regulated
.Anchorage-independent
ERK2-L198A/L232A
Response—Because
RR344A
c.1751_1752dupTC
Triplex
BestGene
rs121913229
Cells—In
uring
MED12mutant
ideceased
4q31.1
-reverse
2.95:1
groups38–47
Na-dodecylsulphate
monoubiquitation
insulinoma-derived
5′-AGCCCTGCTCGGGGAACT-3′
intermediate.46
humanprotein
co-patching
NM000249.2
highest-affinity
activity18
REP–c
Sequendo
723
bax-
EIF4A2
I.Previous
GLI1
12·9
3,149
32P-labcIed
certinib
effector-bound
∼35–amino
DRIFR
41,43
RosetteSep
H3.3-G34
4692
BP220-201-154-134-75
.Broken
pRSV-f3-gal
8–137
siLentFect
33.2
FGFR1cDNA
mutations,29
bi-antennary
protein/liter
mesothelioma-susceptibility
TMPRSS6
Z‐value
'251-MAb
SupplementaryAppendix
Tyr551
levels2,3,4
.Immunofluorescent
non-mitotic
paradoxic
acid-fixed
D9S1809
GSE7035
chr16:68842472
GCLm
Bioessays
4-nitroquinoline
alectinib-resistance
Fc-block
NN3
cpm/50,000
−6SD
p.Gly469Glu
®xed
cohort,11
potent
TAPBP
amelanotic
NM_008609
Hoehner
SFRS11
1-anilino-8-naphthalenesulfonic
years.68
-31.0
agonist.26
AHEPA
HA-tagged-beta-TrCP
μℳ
HCT116+
ABA
green-to-cherry
PI3K36
sustituent
cytoplasm—the
3xFLAG-vector
.SW48
KYSE510
R49274
specificity-determining
F595W
twin-twin
fashion.18
re-reviewed
Griffonia
mTOR‐specific
gender-biased
RTPCR
Ly5.1+
Axl/Mer/Sky
5′-GGCGCTGGAATTAAATGATGGGC-3′
1–236
Δ559-mutated
Val16
PMF.30
hydrophobically
-ALL
patients.23
m11
3.56
acceler-
2ahi
AACCATCATGGAAGCCAAAG
79-amino
samples.1b
data-freeze
Birnbaum3
XPS
1Response
0.165–0.945
cancer,20,21
76,7
2–75
A289
1940
ZO
.DU145
CPT/vehicle
Gan
HMLHT
intro-
1-258
fluorescense
D579V
Owen-Hughes
heterodimmers
TG+TT
JAK2.25
​Fig.4.4
A_51_P298790
SDH-gene-
5j–k
ttatag/CGAAGG
Hamartoma
transcripts.87
pBHG10
.qPCR
.Phycoerythrin-annexin
CYC1-lacZ
MAC1+
0.417
LRRs
resides.46
arrest2
Micro-RNA
kinases5
p110-dependent
arginine-to-tryptophan
7.69
216–385
analysisEarly-stage
replica-plating
K658
4—source
126
CD4-negative
intermediate/high
2~7
androgen-stimulation
V.2.2.1
reconsidering
P73
.Celltracker-red-labelled
S0537T
SCFγ-Fbxw7
GST-CEP110
2305-2311
veliparib
~30–50
1.5×10−8
confera
phopsho-Rb
CSCCs
​K4E
Bgp
MBCB
hCD38
L140R
6294
p/CIP
n=2053
SNU-886
E2033V
systems.22
band4.1
0405
FoxA1-suppressed
precommitted
immunoblasts
probablyinvolved
NMC-G1
50â
www.sangerinstitute.com
Gln28
115–125
.Vector
p.P167L
analysis._ENREF_228
×200
Tyrphostin
Homology-directed
enigmatic
chr16:67324886–67330557
.18,61
attB1_MEK1-
ethidium-bromide
fibrosarcoma.49-51
remission.Detection
8582
re-achieved
Bonome
PCR/DNA
semialdehyde
hybridise
G0/1
described,25
5′-TTGCCGTCAGAAAACATGTCA-3′
population.29
Permount
resistanceAlectinibALK-rearranged
DNMT3AR882
APO-BRDU
4.19±4.34
silenced.49
physiopathology
monocyte-derived
SH2-domain
low-cost
EBNA-2
Wolffe
endogen-ous
BMF/BCL-XL
non-equivalent
P4EBP1
GFP-trap-A
GnRH-synthesizing
Pem1
AII-3
outsourced
cdc‑2
C.L
all-atoms
ER1
DeClue
167×109/L
Rad57
respectively.Fig
IVS20+4A
Fat1f/fsingle
R-ICE/R-DHAP
10-μm
cBioPortal.org
STAT5A_687_699
sc-10750
Surralle
0.158
flouride
Ras-oncogenic
6019
n=172/279
withnecrotizing
Thr417Asp
H206Y
Liou
Lymphoma-bearing
pseudo-KID
PIK3CB-activating
Post-trial
1657.7
carriers.3
syndrome.5
J.-K.
drug.23
7304–14
Abramson
4/21/94
tasuto
extraperitoneal
trial,31
Cullin3-Keap1
PTEN-Thr319
growth-factor-stimulation
M58
.3,12,21
non-frameshifted
–85
R212C
M424T
.Hypertelorism
VHL30
STAT5B-N642H
p18-INK4C
47/507
anti-FRS2
Y541D
//www.fruitfly.org/seq_tools/splice
References.
Japan.12
p53binding
p-Tyr
2.Identified
S.t
Hookham
NG11
Mohammadi-Asl
EWS-FLI1-expressing
CATGGGTTCTGACGGACATC
.Very
PATA21
Skurk
Tas3
5′‐GCTAACTACCCATTTTCCTCCC
Fc2
HCCs.Case
Lambertz
1064insT
TACATCTTCAGATAAGAGC
center.42
F508C
11828019
Multi-institutional
Coactivator
neuroepithelioma
blastoma-type
passaging
Kepten
H2aa−5.7RRM2Ribonucleotide
6H-MBP
300–15.©2016
DCCD
protein-specific
CCATGTTGTTTCAAAGTGTCCA
Vuister
385-4087
AA798039
singlewild-type
MSS216067
efficiency1
triol
α-thalassemia/mental-retardation-syndrome-X-linked
On-target
G292D
death.9,10,13
near-wild-type
fluoroorotic
.Immunobloting
PDE4DIP
cells/µl
−7
TP63
BRC-mediated
4282
+0.94
35S-methionine/cysteine
Trp-526
COL4A6
PTENG129E
9.5–12.5
nucleosome-remodeling
hydrophobic-spine
Planck-Institut
large-clustered
cancer.sanger.ac.uk/
8-11
S244L
4.7±1.5
W1T
SSX1
//www.pantherdb.org/tools/csnpScoreForm.jsp.
0.711
urea-dependence
Coot.55
3028C
pSG5-HA-CARM1
48–71
GEF
G12S
p53-DD
development24
hypervascularity
.5676G
At-risk
8q23â
CBF-AML,1
Cycloheximide-chase
Autoimmune
NEMO-mutated
46483
cisplatin-containing
mature-looking
homodimer–DNA
poly-A-selected
k-
microcentricon-100
SHQ1-dependent
AML1-regulated
5′-AATCACCTCAGTGCCTCGTGC-3′
T44M
3.0.26
D449N
MMM2
NotI/EcoRV
leukemia-
4425
His-83
prostatectomy.View
pBQIGFP
315KB
dR110
Brca1f5
dephosporylation
P-1068
FLT3-WTwas
differentiation.15
Alexa-488
2.3kb
.80A
A420
≈20
T529I
.Commensurate
1:6,000
D-cyclin-dependent
del127-66
4F/R
.Tang
MAGOH
LNCaPcxD11
W8
A/c.4675+1G
AF363012
consanguinous
/sex
Ab1
Guido.Sauter
NF2-deficient
merlin/schwannomin
nt81T
Fig2K2K
RADW
LK-40
first‑line
HumanMethylation27
.371
10/H0305/83
dual-mutational
BCR-ABL.66,81,90
wk
H1755
cylindromatosis
AMPK
p.Arg206His
AP-2α
1.01-7.21
W515L/K
Coindre
mock-stimulated
ggc
inducibly-expressing
deletion-testing
-TTGATCAGCGGAGACTCG-3
m2m3
Haroche
564_567del
ofbinding
61–68
Pathway/network
S.W.L.
ElAF
b.i.d.
T3013I
AGATTCCTAAGCCTCCCATCTCCCACACA
14/β-catenin
N88S
LM-
p.Phe76del
Pre-clinical
FLAG-PTENY65C
PTC,8
regurgitation
coding-region
.Up-regulation
Cyiometry
B′-γ—two
stimulus-
~36
0.5147
48.3
Y835F
2200/μl
EMA+
1,734
Mital
E205′
JAK1-expressing
∼28-fold
cm.Western
S3X7Y
β-sandwich-coding
.Avenida
3HIZ
laryngleal
Staehling-Hampton
Lingappa
Yustein
cPTC
Spliceport
IRS1-deficient
5′-GCGTGCGCCACCATGCCTGG-3′
on/off
2062–2091
1885
pantrk
DCC1
†This
CNRS-INSERM-Université
Bartolotta
CAT3CGT
Lys-379
Negative/1+
22q90.On
MSH6-specific
12.71
CULLIN3-RING
18.9-kDa
HGGs.26,27
788
S535
1times106
MSH2-S723F
functions*
A07
activated/memory
MP-606-PG1
28:733–737
D770insSVQ
ALK-directed
pET26b
lipids.30
dbGAP
2,208
CRC118
7.3-
base-flipping
1q21–23
activation-3
survival78
Ctnnb1-deleted
methodsgenomic
pGL4.74
bi-clonal
ATP/imatinib
disorder.96
.12,29
D140G
.3700
ultra-violet
n=24
response.14
β2-β3
experimentsperformed
β-cat
sub-species
neuroblastomas
genes1–5
transcriptase-polymerse
−1422
shown.37
granulopoietic
EGFR/MET/CDK6
PDGFRAD842V
rheb
0.01228
NM_024245
cases34
lightinduced
CIMP-high
14,15,16
D210A
months.7
D401N
ABCC
282–580
anti-Lyn
Glisson
MAPK14
radiation-resistant
Dübendorf
R821C
YAP-dependent
pseudofollicular
F2/F1
SC-9064
0.8717
.4660
.Gross
594bp
Y531
PLX5032
ROS1-inhibitors
PU.1,36
//www.ajplung.org
structures—the
FigFig1D
result.txt
exposure19
Mendrzyk
0.07-22.1/MB
MSigDBv4
anemia.11,12
TRH
methallothionein
CUL3-SPOP
A-H
PRC1.1
H1466
Varfolomeev
NSD3S
69350
UV-treated
Drug-Resistant
2127–2145
super-infected
.152
10-μL
HL124232
19.2,8,9
D-F
Μice
pRS-puro
0.59-2.63
alternatelylabeled
BRCT-BRCT
appreciably137
.Eisenman
OOMt
p.502_503dup2
hRRP6
v4.0
T130N
Tokumitsu
EIIA-cre
genotypelphenotype
R2784
MAPK-alternate
V5-catCS428C/D486N
.Attempts
.Notch
K1420
ATGGAGGGGAATACAGCCC
enchondroma-like
LS-C178095
5756
Becton-Dickson
10,826
unknown3–6
Staber
MATURITY-ONSET
Lupardus
-hygro
shRNA-Tet1-a+b
identified11,12
CD3ζ
Brca1.3
.Southern-
HEC59
PCR/Sanger
T/C
1879
protein.13-15
pGL23
051
loxP-flanked
NativeMark
M27372
MutL-contacting
domain.11
ICG
MAD3
RhoA/ROCK/cofilin
C-.T
SP6.5
.F156L
p-S6RP
rankpoint
immunohistochemistry.18,21,22
AdCRE-inducible
p.Asp1778Gly
andextractedfromthe
41–60
.NIH-PA
bismuth
Ralhan
Asn942
LNCaP104-R
50,000-100,000
non-fusion
g/mlG418
________________________________________
5′-CTCTTCCATGAGCTGCAGCTAC-3′
TGTAAAACGACGGCCAGTAAAGTAGCACGAGTGGAACAGACTGAG
1689
freeze–thaw
II-binding
heterozygotic
4,470
hemangioma6
Ouchida
E3PCR-f
CFCS-causing
mdm2-
.R+
Muleris
-gd-PTCL
TPYEGMPGH
Pancras
HiTMMoB
exons,8
mdi
Q56
ddC
atgttttag
F360L
nt3349insCaa1092Stop
doxorubincin
non-DNA-binding
Cγ3
MCF-10A.12
glycine-12
M766V769insWPA
1214F
AR-NTD
adenocarcinoma.30
Â©CG
PC-9/NRAS
.AREAS
CCAGGATCTGAT
OrigGene
DFCI/Brigham
AACATCAAGTAGAAAAAGGGCTGGAAA
58,814
21.F338I
Lod
.Subclones
L313V
multilink
FLT3D324N
localisation
Q919R
wild-types
−124G
CMML/aCML
post-lactational
699-bp
42,44,45
pyrrolo
approximately106
FoaRphenotype
.HES
0.37
E17.5
3052
CAA→ATT
single-receptor
Pericentrin
3/21
-CTGTCAGCTGATTGACGACCTGGAGTACCTGCATAGC-30
JH116-F:5′CACGACGTTGTAAAACGACCTCTGGGCATACCAGCTACTG3′
.Fc-epsilon
.Outlier
siRNAi
2/41
NCOA3
100–250
gancyclovir
EWS-FLI-1-V5
Arg616
G000Frameshift68â€
Leukemogenic
109K
onychomycosis
17442
.GD
Imunoblotting
reinvigorated
A_52_P306845
1.107–2.664
C5242A
4E-BPs
Cys-277
Gln56
B/Elongin
MS-based
Anti-Inflammatory
D-S
bootstrapping
DUAL-SPECIFICITY
classification.13
4EPR
3-Luc
hybridization
phosphotyrosyl-containing
alanine-for-threonine
BX444740
ERMS
PT67
BAT-II
99×
three-tiered
-GACCACGCGT
18023
hypo-PI
linkage18
ERCC3-defective
.U2AF
cyclase-indifferent
FGF1-FGF10
End1/E6E7
1–66
5R1
Mac1a
ATGGTTCCACGGACT
C53
radioisotopic
progression.In
HA-Hdmx
anti-isocitrate
−1.31457
D-PBS
Serine-907
:SHOC2wt
cation-chelating
gttattcaaaggacggtgttttcctttccc
T68Q
consent.The
Krengel
-CACC
1l
.ing
G58A
Ile744
WM115
Sox9-responsive
Myh1
coassociation
3Deutsche
GeneMorph
5′-CGCCCAATACGACCAAATCC-3′
HER2-induced
ROSA26CreER/RlacZ
I177
Homologous
PKC41223
resistance-conferring
Set1-like
JAK1-F958S
interval.NUP98-NSD1
TGCTTTGGGACAACCATACA
Fgfr1a
BIOGNOSYS
EMCCD
PLCy1
±4.2
Erk2+/−
Pro772_His773insVal
NURD/Mi2/CHD
cells69
19.5
13362
CRAFT421M
-new
.ARV/AR-FL
pab0554-1
gtaagtata
rs334354
p.R167Q
300~40050
D816Vpositive
,5C,5C
.EML4-ALK
factor–receptor
contextdoes
pathogenesis19
TGF-b-receptor
HRGß-2
peptide*
Hormone-dependent
mecha-
yl
females3
54-58°C
haemopoiesis
5′end
3050
5′-ATGCTCCTGTCCAAGATCAAC-3′
neuroblastoma43
EGFR-resistant
EPM3
nFV~I.CJPMFNT
MeVAR
clusters—one
wasfractionated
which6
Resistance-associated
Pap1
carcinomatous-specific
ETS−
D.R
.DOX-induced
BACH1-
inhib
FKRFRK
somatotroph
BOND-MAX
32/38
TÃŸR-I
domain-PHD2
IV-4H12
Smad2-MH2
MET28-LN
25,11
C17orf82
ASM-eo
20,23,24
60-101
AJCC
+M1
2.86
proliferation-associated
hypolobulated
2q23
G703R
independence.21,74
nonmutagenesis
to-600
p1305.0
ALKF1174L/L1198P
PP1c
Vladareanu
P2-containing
27.96
F453S
24hrs
Pro17617923624124224424524624825225725926527327727827928
ORTEGA
LTGC/SCE
I101T
DYRK1B
–Alexa
33.0–37.3
L485F/F498A
riskof
N327fs
.Culture
repair/nucleotide
SGOL2
DEJL…
HR3
5483,1996
thyA
estrogen-receptor
dehydrogenase/reductase
GAATCA/gtgagt
specie
phopshorylation
PIK3R1/p85
resistance.16,17
GCCCACACATTTGCACTCTA
EBPδ
virus-enriched
well/moderate
Pro8interacts
CGGU
pB4X-CAT
MEK1G128D/L215P
Keh
Y570-OH
deletion-induced
pLenti6/Ubc/mSlc7a1
GATA1-deficient
bmmin
MOWIOL
H1421Y
p.Arg159Gln
shiftassays
FGFR3–
Hippo-mutant
8.8-kb
Myc-HisA
Cosegregated
cyclin-Cdk
−41.6
5′-AAGACCUUUAUCUCUUACUCCUUGG-3′
278
ring-shaped
SETD8
10qter
g.72253C
.RNA
D1-Delta289–292
MMTV
break-point
0.005-10
S-phenylglycine
anticaspase-3
MADHIP
EM-652
Cy-5-labeled
MIB1
False-normal
β2-Microglobulin
1-1.83
HPNE-KRas
1A6G
Ellen.Renner
PRRL
1.0051E-10
40-
AML-associated
1.6X
Amplification/overexpression
MEK1+2
IGFRI-expressing
599–789
I344T
W105R
carbonyl
R94W
antiCDC2
patients.20
N-RASQ61R
glycerin
preference14,27–29
Q401fsdelC
UGGAGU
patients16
coloredblue
rotating-anode
1–1.5
542T
levels.49
-8a
p2747
Antonarakis.12
ertumaxomab
imi
calcein-labeled
E2419K
234H
E545Q
toxicology
geranylgeranylation
WAVE-MD
Wrst-degree
microhomologies
−11.5
.CC
1.2V560G
mCFP
18,734
.S13S11S10
Solubilized
PGBM
amino-acid…
neurobastoma18
congenics
∼1,500,000:1
p-EGFR
multiply-altered
beenobserved
1814
X84047
1alpha
cultured53
3,4,5,6
Newly…
REP-c
Rilotumumab
study.6
0.5–22
R1448H
Pfaffl
MYC/Max
.1321155111i6
9141
APLP2
S71
Schizosaccharomyces
0–80μM
sequencingSanger
MCP4
NR4A3-MutR1-Luc
|associated
0/21
n=147
Y153H
39717
exception.12⇓⇓⇓⇓–17
SKG-I
TCTTTTTCCTCTTGCCCTTTT
SUMO-tagged
RFU
L229F
NTRK37
SalI-digested
.Retinoblastoma
LCPG
45.8
underdiagnosed
5–81
ERG-enriched
N239S
cyclase-stimulating
D528
D203H
/3-gal
cttcag/GATATG
auto-deubiquitylation
∼230
Cherfils
Controld
Bengbu
vector-specific
PKC412
base.lcb.uu.se
GENEHUNTER
IV26+2T
0.208–8.075
RAS/RAF
gum
histones27
p.Glu1008Aspfs*16
virus-containing
cancers22–24
alone.In
73.2-fold
as-deficient
ACAGATGGCTCATTCATAGGA
R.m.s.d
miR-129
Pou2F2
IDH1-G367A_R
cytoplasmCytoplasmNucleus
DNA-Dependent
sabili
pCR8
antiglyceraldehyde
HIP/PDGFβR-expressing
ASH1L
8–47
0.831–0.966
the2-kilobase
33,39,63Å
Tyr98His
CIN3
5′-CTGCCATTATTTGCCCACTT-3′
E477*
200-kDa
Elf3Δ236
Digoxigen-labeled
.a-c
0.512
–17.0
CDK4-associated
Duralon-UV
4.Download
FASTQC
EEFSEC/SELB
Che-1
I261F
todetect
AFF1/AF4
66526
Lys-1702
NK
.SOX9
Iqbal
f3
.Bed
K319R-S324A
.Likelihood
NSD15
0.006*
al,7
βTRCP
p-DNA-Pk
KRT
.598
optionsNKX2
mid-section
3.602
SP6/T7-coupled
nanocapillary
AE1
20-22,26,29,68
KIT-driven
dominant-negativemutants
0.437*
Pik3cb
Patlolla
335–1161
Lats1+/+
FancE
.GIPZ
Y1137Y
cells137
hetero-dimer
above-defined
ins69A20
alone.35–39
fluorophore-conjugated
JAK1T478S
36.7±4.4
AAAGTTGTCATGGATGACCTTGG
reaction-driven
Denhardt/0.5
.Fluorescein
T182M
Ras/Erk
redox-controlling
137–138Vicente
R2708
TCF4-GST
Leu-536
investigatedthis
eRF3
4.6-kb
Alhough
N.S.
DNAsubstrates
CCAAAAGCAACAGTTAAGGA
nonactivation
electroeluted
plasmid-specific
104-Rcells
2532_2536del
Vav
asequence
CelLytic
melanomas,12,13
YOTB
mut8
TableFigure
Knudson
pAkt/Erk
ACTAGCGGCCGCTCAGATATCGGCGTAGTC
PPAPDC1B-specific
medoids
O23
992–1,144
KAVDG
≤0.001
noted.The
95˚C
prognosticator
48/645
Ghanese
HA-pVHL-containing
disease.18,26,27
wouldsuggest
phospho-PKCz
KER2
3B7
2.5S
Δ1–36
substrate-interacting
Adriamycin
trx-RNAi
NF1-GRD–Ras
steatohepatitis-like
arisefrom
LKB1-mediated
tamoxifen96
U53336
'window
casesmight
p16-transfected
1−6
6.48×104
30-gauge
.Asa
IDV
t-statistics
codesets
A598TBRAF
p85αdelK511VfsX2
FGFR174
chickens.36
Rb1Lox
G569R
FLT3-specific
.CD19+
~70-90
.Mes-Masson
Endoproteinase
del4
BRCA15382insC
840L10
DNAgainsandlossesin
p.1125–1537
27.64
A1020V
anti-p70'r
R349Q
7419
FPGMX
25/BAF47
glioblastomas,20–22
Runt13
127-bp
PUVA
p,0.01
orHER2-
alpha-SH2Bbeta
p-ros
3-1
potential102
fibrosarcoma-like
GFP-Cre
antero–posterior
Schafer-Nielsen
.Rheb
20.Age
Fig.44C
.31
0.242
erlotinib.8-10
10.1007/s12672-013-0147-9
PMD2G
32.4
and491
.Thus
anti-Raf1
amino-acid-altering
Y762
7829
137215
.C1–C2
staining.B
tumorigenesis.8
pargyline
N+C
anti-AR
HindI11
aspirinlike
polyps/tumors
92-
deactylase
Larabinose
byView
G2T
-0.49
ABCB10
NovoAlign
4110
EST14/C14rf25
myopathy.20
.Cediranib
.OVCA429
ficant
28-3a
293/293T
JH1/JH2
20071/2,3
Disregulation
LDF
.ALP
immunoblottingwith
ppint
5′-cctgacctctgtccccataacacc-3′
AlF4-
10‐mer
BioTek
.33,34
Komminoth
213342
MoBiTec
Silvian
Scita
equamolar
MCAP
NFASC
.MAGI2
UKE1
W~
55†
T-ALL.15
0.5-cm2
lymphoma23
G55A
recalibration
supplementary_info
prb1D1.6R
EF-hand
Ereg
small-size
sequencesaround
5′-GAAAATGACTGAATATAAACTTGTGGTA-3′
1H12
CD5-
CBFA2T3
06712
GI:24646871
pancreas.H
Abl-mediated
NOTCH1-
Fug-IV/5
HS00869981_cn
AR~~~~~~~~~~
.Harrington
ISCs/EBs
Shinmura
agarMost
TLS-ERG-transduced
INTS2
deletionsWe
CACCATTGGCAATGAGCGGTTC
P1844S
1.67-
GADL1.Figure
pCDNA
2983S
PLX4032-treated
CUL3-KLHL3
top-4
NucleoSpin
tumor-burdened
I12T
191-bp
2,3,26
ER−/HER2−
F1-ATPases
cancers—such
11-Deoxycorticosterone
SCF-bound
tirilmis
R167G
R531Q
hyperfunction
myr-P110α
LUC16
P7.p
mutations.24,25
domain.10,11
Hema3
164O7
repeats5,6
cells127
HR=19
Kmt2d-proficient
RP11-936E23
2.Tandem
non-bolded
CD52
.Lef-1
Q331
.Radiolabeled
plusmid
8×10−15
previously,16,26
4F–H
Curie/Hôpital
.TRAF3
junB
indefinite
R1391G
HGF-competitive
Manystudies
Tyr-1022/1023
topoisomerase
forward-A
19-89
use/develop
CBFalpha1/PEBP2A/AML3/Runt
Gastrinoma
transciptase-PCR
R175P
Intra-operatively
.12,17,18
c-Mpl
.Comparison
//www.nature.com/natstructmolbiol
Gg5.9kb
His263
Sertoli–Leydig-type
30A
T1764
.CELL
4-7
397
Apc1322T/+
SCS-
o85
1.97–2.74
HBM-containing
ability.43
NR-21
c.4415
beta-sheet
c357
17,18,19,20
Gly-26/
RP11-980G2
-amplify
NM_004496
.NF2
trkl9
gem-dimethyl
c.1276-32C
biochemically-screened
SRYmay
ethanol
MouseWG
L160V
BLIMP1/PRDM1
1-wk-old
Pajer
aggregate-
respectively,69
ligand-activated
E­
TS2
cel
polysomies
Arg9
96.4
KIAA0783
.Metaphases
.RT112
CVLL
14–230
isoform-specific
Muzykewicz
ERCC1-
S235/
never-
cancer49–51
Gli1ZF-K340A/K350A
Y99C
potential.45
292-bp
Vojtek
-Cw6
DARPP-32
Jade-1-binding
2027–2033delC
reaction–restriction
apoptosis,15
reportedby
recurrence60
RFP–VHL
Tchernitchko
.ÃŸ-cateningene
R91S
HBS+
2q33.3
anti-Bcl10
KIAA1549‐BRAF
A_52_P162957
TR3
kinases,8,10
cytoplasm-confined
hamartias
P415H
theTet-op-K-Ras4bG12D
lipid/membrane-associated
T308
IVS4+109
lymphomas11–13
10.1007/s00432-010-0788-9
Smadbinding
434-bp
Brca1+/Delta223-763
MDS.21⇓⇓⇓⇓⇓⇓⇓–29
v.6.6
68.05
INK4A136
Tyr570Phe
KANK4
WNT-Frizzled
a¡ects
CRAF/CRAF
.C-EGFR
tobacco/alcohol-associated
Figure7b
anti-miR
H3K415-18
L616V
dedifferentiate
V:27
agc
E19b
c.241A.T
MRTK
Homology-Directed
Arg-168
c.983_986del4
62.35
//clinicaltrials.gov/
sinstructions
one-electron
74-fold
Marchioninistraße
LCR
SFY526
Cullin-Ring
defectiveness
.0005
disulfide-bonds
Brca-defective
M1727L
mts3
scratch-migration
Bensussan1–3
-EcoRI
gene,21⇓-23
.3167
chromatin.64
BRAFmut
+/Mod–sev
5′-CGGGGCTGCCTGAGGAC-3′
C141
KEEFTVELYKK
G1202R.15ALK
_x_
.Cutaneous
9022C/T
pathways6
XRS
retrosplenial
rhVEGF
inbronchiole
Ptch1−/−
ofzZ
luciferase-containing
nonclonogenic
ative
ARAF–RBD
stage-match
MED13/13L
//www.genome.washington.edu/consed/consed.html
foramide
mutation.1
2-microglobulin
R705H
D.M.G.
DT1.2.4b
HCCH-TOCSY
Notch1-driven
J18
-encoded
3•21
polyacrilamide
***p≤0.001
Her2/Nez
Boissan
trials89
175200
radiculomegaly
Asp835
.Profile
dimerized/activated
32–35
bioinf
non-mutators
FIP1L1-R2
twohybrid
herpesvirus-associated
E2/0.5
Invitrogen/BioSource
Perfetto
.Unlike
TKI-binding
TβR-II–108/+56
9551
D4B4
Fulllength
lymphangectasia
Mxi-1
prognosis,43
11Gl
-Less
UbcH5C
V7/AR
PTC–SMO
Eμ−myc
SHP2-mediated
471of
L130V
activatetranscription
−507451
TIC
pCE151
four-helix
1/11b
Polycomb-repressive
527/530
AML1-
FGFR2-immunoreactive
Y1230
types19
59-TGGAATGTGTACCGGGAAGGG-39
7–13
N1-ICT2467A
pLZR-BJ-IRES-EGFP
isoleucine111
www.cellsignal.com
phosphorylation/dephosphorylation
ryngology–Head
PIWI-boxes
Subclonal
MSCV.CreERT2.puro
AGCCAGAGTCATCAAGAATGATTCTA-FL
Polysome
.Involucrin
puncta-containing
SQU
T67M
↓
phox
ofconcurrent
E125
'Repertoire
BRC50
Ura-
cbt
Dynamin
181kb
22-year-old
CS9559
C.J.R
intact/aberrant
V711D
YAP
K-Q
protein.10
c.1524_1525insTACTTTGCATTTp.F508_K509insYFAFNone
negative-regulatory-domain
ch8
functionalize
633M1
sequences36
Chiara
placentae
Non-mucinous
mutation137
0.00033
blepharophimosis
13q13
WM278-GFP
more-severe
GST-p110/p85a
20.3
al.14
V819V
Lipofectamine-DNA
5′-TCAAGCTTCCACAGCTG
1/3500
//www.ks.uiuc.edu/
H193P
.EndoHf
300
R261P
midshaft
nucleolus
3AA
prephosphorylated
Nucleus-confined
PRSS8
V280M
Eun
o66-o5725
given,25
23,29,30,32,37,42
Euro-Diagnostica
Y25
6.37
protein.48
EGFR-501-Fc18
TCGAGCCTGGAAAACGGAAGAAGGAAATGACCAAACAGAAAGAAGTTCCTG-3
c-KIT.37
8,13-15
Y606H
Denzo/Scalepack53
Dr.
ATFI
Surflex-Dock
Pantomics
BioBasic
p14ARF-dependent
ofMay
.C557S
Q256R
IRF-3
FLAG-Elf3Δ235–270
−80°C
D835NR
Sma‐3
25–62
CKDN2Cexpression
constraintsobserved
HE28
M13mp18
POLD1-exoD316
A-+T
.Variation
abifity
.MYC/MAX
4200-072
Snf5−
AIOLOS
immuno-phenotypic
pCS2+
Glutathione-S-transferase
hKMT2D-Forward
hSMO
.Postmortem
observations25
PROCHECK.45
G12VKRAS-driven
Per-nucleotide
30˚C
HMC-
H878
n=19
spirocyclobutyl
Hypopigmented
Swiss-Model31
Anemia/thrombocytopenia
GTuin°
62K-
E68*
5,871:1
p≤5.6e8
anti-Elongin
XPB/ERCC3
CFCH
91–96
anthracycline/cyclophosphamide
COBAS
.Redarrows
Dargent
CYR1
activation,3
1.8–15
plasma-based
0.50–1.41
pep
10q22-q23
zippers.45
.5932
DH5αF′
endosomes.14,31
way32
R3189W
irreversibility
n=10/15
200c
Q1084P
reasons.44,45
350-kDa
fetab
16/19
FGFR2-TXLNA
Bcr–Abl23
Y791F
Q-TOF
52–57
Tavtigian
G.L.B.
progenitors28
p185c-neu
PRDI-BF1
CT+
pseudopregnant
LGIII-220.6
Smad3miR
CML-CP
/Pdk/Akt
Gauwerky
'American
13-27
Zn2þ-binding
Bunney
875-934
rasopathies
acid/50
Introduction—Concurrent
Chimeracan
EML4–ALKL1196M
19-3
pseudokinases
CD8-
L1216Xc
AKT3—all
.GDNF-stimulated
cycle–independent
RET/S891A
Gelsi-Boyer
74*
GANT61
5′-TTGAGGGAACACATACTCGCT-3′
-TACTGGGAAAAGGGGAAGTG
CRAF-CIBN
U976
ACCACCTCATCATAACTACCCACA
.Gal4-HIF-1α
Dalgleish
11/15
cancers.18
78.1
CHEMAGEN
sh-Myc2
each.9,32
.Towards
c.418C
Cancers.
ZNF367
151.9/133.8
AER-FGF
work32
Tyr1446
Ser/TCC
GS193
DLBCL.21
nucleotide-long
beenshown
single-dose
DA4
pCDH1-CMV-EF1-Puro
GC7,8,10,11
Uu
R303W
16-row
gene.100
tail-binding
Sozzi
Herpes-virus
GSE63420
Themechanistic
adenocarcinomatous
mitosis.25,26
S372
88x
R124S
819-824.
sev-Gal4
19.9
1554–1556
IC–FBW7
_IDH_
BstE
controlof
57.5°C
andMsh6p
NM_011623
D458
S22T7
Δ295
Hind-Sal1
-detectable
MB-associated
ET*
1−pP
Phospho-Ser62
26-amino
proteins32
W122S
E1AF/PEA3
E9.5–E11.5
MRC1+/CD11c+
sc-123
miR-143,15
GFP-negative
Fig1G1G
long-
MSH5
GST-TKB
S1–S4.Figure
p16INK4a/
1146
coactivator-1
Ile315
1,2,3c
TAND
.Dual-Luciferase
Kirito
OXP
Abdel-Wahab
Barresi
8.0.2
MethodsVII
058195
Cisplatin-resistant
BRF2
management.20
streptavidin−HRP
50-60
.Luminescence-based
.Extracts
daily-dose
magni-
N1-IC–FBW7
NIMA
TEL-2b
-GCCCTTCCAAGAGCTGCAGA
activation.52
SCFhCdc4
Mel499
Akt2-knockdown
SW-620
START-R
Affiniti
de-repress
HN11
inmedium
endonuclesae
nanoLC400
IFAR764
aux
years,5
Br55*
RP11–535A19
CHCl3CH3/MeOH
G719S/L861Q
RHEBGTP
α2,6SA
p53/
p.Gly17Glu
.Zuber
developmental-specific
Binding—Whereas
R288W
-9.61
endophilin
D473K
21,22
non-uniquely
KI67
3⩾50
pSELECT
ER+/PR+/HER2–
c.4845_4846del2
IP/IB
polyposis/CRC
mutant–dependent
K601delinsE
bronchomalacia
Tyr842
rs2019720
pKID
Ser-127
CIMP-H
Chemother
vitro−translated
best-described
S5A–D
52/10
Takayoshi
lymphomas.Upper
-Shp2
EGFR‐non‐dependent
EGFstimulated
25-µL
recloned
person-years
DHL1-CR500
T2-weighted
mutation.20
I27V
aChenevix-Trench
W604C
.GDP
crossover
MLLT3/AF9
CCCTAOCACOTOCCTAdJcTCOOCC
4a–e
ModerateHigh
BRCA1-MLPA
L456M
λ16
EV-overexpressing
10–40
papillomavirus-associated
S4A–S4N
diethylstilbestrol
4A–B
3=more
mutations.18-20
re-blotted
350-450
cells/progenitors
Y1016
puromycin-free
C141W
78207
.OC
cells.31,32
AOX
.NEW
EWSR1/UQCRH
Q61H/K/L/R
S10A–S10C
centrosomes22
trigeminocardiac
overemphasize
06-226
9923
4-6-1
p.K508A
outcome26
Fizzy-related
RNA.6
AR-AF-2
invasion.14,19
blebbing
LP6-shGFP
PRKAR1A-RARα
ATTTIGT-rTGT1-T-3
processes.Very
Cytomation
5′-GCTGGCATGATGTGCATTA-3′
anddd
.download=true
Myc-His
EcoPack
rs1042026
L311P
LTGC
leptin
R533W/L658P
T-cell-depleted
1210insT
NSD3L
α-lactalbumin
organisms27–29
ivt
.1MLL-TET1
G598
Gruvberger
NPM3
malignancies,25
FRE
mutETS-annealed
GGATTGGCTCGAGTTATCATGAGTG
IRv
.Post-irradiation
S580Ptendel
.FLAG-tagged
15-Mb
.Rational
alendronate
others22,23
1.70
~93
NRAP
//media.affymetrix.com/support/technical/datasheets/oncoscan_ffpe_express_service.pdf
RP11-185E14
oligohydramnios
exchange.56
0.02997
5′-cacatggaaggtggcttcgatgacagtggtccactg-3′
E72K
30/87
c.964C
Foe
SUM52
Etude
promoter-associated
27.5-gauge
.ΔΔCt
responses.20
2.802
NF-kappa-B
P=0.0033
PSAP1
185C
RFX-like
tumor.2
2237A
Del1001/ErbB4
P.S768I
R181H
genenase
promoter–reporters
TCAGAGAATATGAATATGAT
Mou
.1,2
4.Rates
L1409
GFP-IκB-NES-mutant-positive
hybridiza
KIT-D816-positive/AML1-ETO-positive
BCL-2-positive
Klein2
ErbB-3
R2150
VHL-independent
LAMP2
5′-TGTGTCACTGAATATCAAC-3′
D152660
immortalized52
3490
asparagines
BPD1
Dicer1−/−
cdkn1a
149PT.htm
T41A
msh2-PD865
IGC1
High-Amplitude
mutation.3
C394R
MF-20
L283P
Flag-mTOR
Druggability
m/68
pug/ml
method=8
knownasPD-L2
target.8
92-mer
//shgc-www.stanford.edu
North-East
KM12SM
Mt6
MLL-AF4
others34
Islet-1-positive
GAL4-2.1
-399/+31
.INPUT
E571K
Het-1A
-IIIb
aldo-keto
−367C
laryngeal/pharyngeal
22-3/4/5
TGFβ-dependent
.Desmosomes
c.943C
Novelc.4267A
Rhox5
Cdk4/6/cyclin
-RNU2
C360R
~44,000
3_7976
Kashiyama
gel21
R395S
Myc-Smad4
ETO–N-CoR
.Bap1−/−
QIASymphony
Semaphorins
TM7SF4
∼25th
1A–I
analysis38–40
non-pileup
pBasicCAT
mediumsupplemented
factor–free
GST–RAF1–RBD
Hygro+
p110α/phosphorylated
ALP
vector–transfected
diC8-
Histochemistry
J030
mutation+/HER2+
n=342
added.The
cells.9
K72
–101.6
3471-3501
M1268T/I
NCT00556712
GACTCAGAACCATGAGCCTG
25A154
.1792
Y653/654
R-spondin-1
E554del
retroperitoneal
mutationsTable
lognormal–normal
3087
dosedependent
VASC
1/20.0
L130P
190181
erlotinib-oriented
andsingle-base
Flag-specific
EphR
salt-sensitive
proliferation.1
6209/712
1447-lagCC
C/A
data*
.Up
FACTp140
VWETL
Wittekind
NUT-mediated
BARD1-ΔRING
cdk4/6
Autodock
59GC
2-Mb
Events.
13.4-fold
3,972
A1615D
CMV-DCAF1
Arg398
Leu92
pADH1p53R175Hand
R266Q
InfiniumII
collagen-containing
providethe
mutations.51-55
abnormalities22
.Gas6
Koi
CRL4DET1-Cop1
794.4
Bellosta
22,25–27
prestimulated
5′-TCTAGACGGCAGGTCAGGTCCACC-3′
re-confirmation
PDE8B
repair-related
tetraacetate
0.00268
validated,62
90s
IDH-mutation
.Next-generation
HSC7E589
protooncogene
HA-Tagged
appearance.Other
Mdmx/Hdmx
952-bp
1.7360
S5–S6
.GGAA
Ul.-
-200K
NSCLC139
cell-context
Claudin-7
mll2as
phenotype.Genealogic
responses.15,16
Ba/F3-pcDNA3.1
8081
IPI-504
defolding
UAAAUUUGGACAUAAGGAGUCCUCC
R1028H
acetyl-histone-binding
ΔRad51c-DT40
TNBCs
G466VBRAF
Longin
4684
Leiden
Nrf1
low-energy
Miyagawa
nucleotide-binding
Celeraa
hPTTG1
66/209
lipoproteinosis
B-RafD594A
0.41-8.28
1/7.5
EGFRK721R
Turc-Carel
1966
5′-CGGGATCCGTCGAC
radiosensitize
1640-1647
FAM
Salvarsdottir18
substrates.34
1517–1674
2-fluoro-2-deoxy-d-glucose
cytosolic/ER
.ii
NotI/BamHI
microdissection20
51-amino-acid
G6763
cells/second
actin-reverse
TRIM33–RET
TXLNB
0.45b
SH2/SH3
FGF6
CAGCATCTCTTGAATGCTGAAGAGTAGCAGTGCGGTGTTT
Mutagenesis-NIH-3T3
andrenal
G-promoter-containing
5'-TGTTG-3
package,26
phs000178.v8.p7
initia
single/multiple
Coomassie-staining
20-Å
60·9
A302T
875DTLDG879
ED25
RAS/MAP
MSCV-MYC-T58A
XFast-1/XFoxH1a
monoadducts
Betaplate
VA-13
NM_002839
www.oncomine.org
:URA3RByl60
J.P
IVS6+9547A-G
segregation36
5175
Figure3B.3B
103106
196/359
dysplasia-linked
group-by-day
tumors.Mice
Y877-phosphorylated
mutation,18
12.76
gefitinib-sensitizing
.Given
1.896
EPR287
A-4502
pFB-neo-p110α
7/74
BH1–4
Y63
5′-AGGGAGATGATGGTGAGCACCA-3′
α-Akt
pcDNT4
One-dimensonal
USSWG
Sxc
mutation-defined
.MEK2Q60P
.Linear
Abnormalb
multi-institutional
Arg17
Altiok
gag-kit
color-coding
dmin
Mucenski
5029C
BAC457F3
kinases13
K16
BMS354825
probes/oligos
D737
VACO10
Besco
events—such
soldano_
72/85.7
normalizations
11,45
MDM4Genomic
Pession
Cul-3-dependent
DMEM/3
AAGIGILTV
−15.7
milial
potential.34
interval.RESULTSDevelopment
KG-1-C
colon2
trans-ABySS
V-fil
CD134
Nichirei
SKMG3
K-RasE62
11/Delta
pGA-MTS1/Δ1−51
2.4-megabase
spin-spin
0.5×TBE
14–33
29/41
sc-10768
ex17-RAF1
.Researchers
Membrane—We
band-shift
MYC/Max/Mxd
T24/T32
DNA.thumbnail
E2491
KAL2
37The
Y-653/Y-654
8728
aPatient
SPOP–Cul3–Rbx1
PstI-SalI
Trasduction
14.6-
membrane-translocation
2311-19
176.0
Twenty-week-old
f/61
15/152
342-1455
Sox7
pathway-like
Kawamata
alr37
Slc2A1
3988
Bcl-XLis
Ser-P/Thr-P
∼14
CBS4
BY135711
EGFR.41
activin-dependent
NB100-304
firstcase
treatment5
GTTCCTCTCAAGTGAAGCCCAGCAAGT
4–15
Proweller
q22q25.3
2941
//ganjoho.jp/professional/statistics/statistics.html
Akt1-dependent
blue-colouring
S273F
G468AB-RAF
Raevaara
Cha
MMTV-luciferase
.V617F
0.5-2
data15,16
EWS/ATF1
PDGFR-α–mutant
tetracycline-off
763-767
rates.7–9
p.Arg683Trp
IFN
Brca1Co
53–57
anti-AKT2
acid/0.005
1169_1170ins20
18-amino-acid
BL-17U
microlesions
17p11
.Perinuclear
scabiei
daphne.humgen.upenn.edu
.BAF170
I31M
Nrf2-related
HMGI
V818M
Québec
Δex5
transmembrane-helix
33.7-63.7
3′-kinase
HEPI
1036
W117G
R-cells
rs748628
∼90–100
EYFP-positive
A-MuLV
gene-assessable
AML92
anti-Hsp70
TGF-β–induced
EGFR/HER2signaling
Jam2
G719D
TCGACTGATAGAACAATGGGCGCTCT
AG-3
andintracellular
G69D
Ras-Raf-MAPK
CALR
1q21-q22
QCM
ZBP-89-FL
4q
IL15R
expression.Deficient
mutation–targeted
aminoallyl-modified
heptamers
cancer.2,4
MS-identification
intra-tumoural
IKBKB
phenylacetate
appearance,115
force-generating
108.10.3322
21.3
DNA.4
Cross-talk
T-loops
2009-A01117–50
Vandenbark
HPC-2
1377-amino-acid
MLL-fusion
KRT-7
.Yeast-expressed
TGGACT
miR-29b
W396
ϕNX
Rev-Cdk12
V411L
p=0.0008
.Lesser
Straussman
EGF-stimulated
pathwaysProliferating
24.22
Case–control
Monocytes/mm3
5.62
NPHS13
'Z
locus18
biology1–3
4292
RT3D
Annexin/PI
triethylammonium
N566D
AZD-6244
U2AF35-expressing
domains—and
HrasG12V-IRES-β-geo
DP2/5/6
microcystic/macrocystic
IL4R
c.1386_1387insCT
DITEP
dynamics-modeled
GAL4DBD
G1702C
.Sample1
Salient
13,20
work-station
Gln444fs
.Induced-fit
135M
gtgagccgt
Thornberry
.Phospho-SHP2
1,285
16–83
TÃŸR-Ikinase
choriocarcinomas
retainedactivity
Milhorat
p.G95A
L226V
GSK-3beta-mediated
39-41
1rgo
5′-CCGGGATGACCGGAGCACCTG-3′
Gly12Asp
Omics-based
anti-panAKT
DNAdamage-dependent
PDGFRA-R1
literature.5,11,25,26,28
RP11–13K8
GAAGCTCTACTGGACAGCATAGTG
TyrAr9ValGly.Q
Figure1C1C
MyoD-E12
molecules23
progression.30,31
KUBY
15070301–15180500
*Corresponding
ErbB2_ex11-19.SR2
.Needless
HS01050702
infrasupinatous
2004-800
mechanisms12
phospho-c-Met
-9.3
:1l
acteristics
414/616
Technologies/BRL
d'Oncologie
C184
6/38
Bin1
His6-SUMO-tagged
C-nucleotide
Y2647C
antibody-producing
Openlab
Suh
pcDNA3.1/HisA
89.39
EPR3255
14,733
10–27
17q22-q23
TTTGATGC
R38C
13-21
protein–solvent
.ChainFinder
–Cell
5′-CAU
tumor-igenicity
neu-induced
background.3
AdG3
Y537C/N/D
XbaI
dysgranulopoiesis
E218*
del746–750/T790M
cggaaatgttatgaagcagggatga-3′
Charrasse
AAT44834
MCD1
4-Luc
Q626H
MK-specific
,6i
factor–related
ATGGGTCGCAGGTTCTTGGTCAC
.E174X
two-year
f44
.Twenty-two
tCWCH2
al.,2007
127*
.Raf1
TAL-1
byPro-34-*Arg
59-CTATAATTCAACATCAAAGCT-39
c.139C
p.A339Sfs
F868I
O-
recombination-deficient
699M19
Δ295–311
7p22–23
/osteoblast
M24796
.CT-scan
5q-/-5
snRNA21
7-30-15
21,016,001–24,537,000
Activities—The
53/322
GAPipeline
Cellmarque
PTH/Cre
u.washington.edu
534–682
4Ebp1
WZ
Rad51—The
E2F7
.TTF
R352W
CBP/
features1
212912_at
SM-HES
aromatic−aliphatic
OYTamro
pcDNA3-SOS1E846K
58×108
phosphopetides
5′-GCACTACCTGCGTTCTCCTC-3′
.Ha-ras
pTQ
CIRP
factor–activated
proposed56
inter-atomic
binding-competent
Rafal
comprehen-sive
pMiw-Fgf8b
D.W
nihms5567f7.jpg
URT-5
corlessc
BL-derived
enzymes/proteins
.Hsp90
3′-CTTCTGGAGACTTCACTTACGTCC-5′
sem
CD25−CD44−
codon…
chromoanasynthesis
F573S
R4712*
2616_2617ins10
crizotinib-resistance
0.9-33.7
IC678
Carmeliet
175100
J.R.T.
.Slightly
v−src−transfected
.Striking
life-span
approx-imately
AY519504
L161F
alpha-helix2
iopromide
Tea.Blom
Fahsold
Dl9S6Ol
anti-Mullerian
Phopho-FOXO1/FOXO3A
D4S1607
.Tests
Centrillion
NK-predominant
6-wk-
D9S1749
numbers,18
ATR7
β2‐microglobulin
pMMTV-luc
SPAG9
3msx
2–8
17,000
IGF1R-dependent
0010.00.006
J.H.J.M.v.K
PDGFRA-related
IFN-a
PAWR-SYT1-NAV3
Maertens
vitro/vivo
sc-38429
mini-preps
PO4-SMAD3+ve
Y131
GST–F1c
abnormalities39
1.9
24BTCAACACACTAUACCTTGA643
alone.IntroductionSpecific
HhH2
Bloethner
.EVI
Bix3
Δ368-382
K650E-transfected
MLL-r
614087
AKT3Z
2284
IgHc
2.1833415
keratoacanthomaLungEpidermoid
LOH-associated
markedStimulated
E346
pathway.Which
IVS20-16C→G
VMR0195
Gistic2
1.7
ErbB2-low
enzyme–bisubstrate
p.Trp804Glyfsx99
1.286
deoxynucleoside
5′-TCTAGAGGGT­ATATAATGGAT­CTAAGTAAGCTT-3′
A_52_P144173
NSCLCStudy
p21/p27/p57
control.17
RLF-MYCL1
EGFRIRFTPp
retrodifferentiation
FO-1cells
ERα-
SSC–1
PML/RARα
1471
Npm1hy
.Dermal
Nakamoto-Matsubara1
Raz
multi-angle
PCRII
38.69
​Mass
DiMaio.14
representativetissue
cultures1,2
GROMACS
gene×109
suppressors19
LETM1
Gli1/DNA
Sarthy
6.0-fold
PCM1-JAK
non-genetics
PF-299804
74-3
Hybond-N+
AAH
diapausing
RASP34
.Histologic
/rtTA-recipient
.S8A–C
90.7
Met804
CBFB
1007-1008
time-toprogression
c.843delG
myoepithelium
wells/cell
processed/purified
H226BR
β-2
524/765
reports.41,42
Rac‐specific
EPB42
N71S2
Y430S
5′-GUGGGUGUUGGACAGUGUA-3′
10·7
N7-548
10/54
L838P
C1156
71183
guideline
MS-210-P1
RS.30,31
cervical-spine
186–204
3212
KARPASderived
Asp594
Ovmana
tested—though
NUP98-NSD1
transformation.15,16
CH457
MCNsTo
WW2∶S7PY
esophagomanometric
43–52
v-Cbl-like
M619
.Direct
Triple-Negative
122-124
Met-67
responsor
Kaplan-Meier
63/498
NDEI
chain-backbone
.Particularly
noncholinergic
.Southem-blot
13C6-Arg
cafè-au-lait
cells.Controlled
p.V658F
FLT3-WT–expressing
glutathione-conjugated
mCSM-PPI
Ruderman
4BRF2
MMTV-reporter-transfected
cohesin
p.Arg226X
caspase-3-staining
orset2
IGF1R/MOCK
50-GAGCCTAAACATCCCCTTAAATTG-30
15-AA
mMHepes
Co-R
D194Y
Max-U
20th
V637M
2x400K
PAAKRLKVD
diabetes-related
number–based
∼100nM
TrkB-expressing
Geneticintotal
Ljungquist
Asschert
overnight.The
5′-CAGTAAAGGTAAGGAGAGCTCAATCTC-3′
pAf9-puro-loxP
lines.122
CCDC149
UPN
syndrome.23
deparaffinized/
SSR1
oligoastrocytoma
.3658
.Calculation
CCAAGCTTCTCTAACCTGGCACTGCGTCG39
Koshland
Gly67_Asn71del
JAK2-involving
μmol/L.51
0008
Cardiomyocyte-specific
.1453
pcDNA6-FLAG-NFIA-RAF1
3403
luminometry
G260V
superstructure
3279
mg/kg/once
reframed
.ETV1-only
.Agarose-bound
Leupeptin
cki‑1
NF1/MPO
~BeF3
PMS2-deficient
Abkevich
1240
Shp-2+/−
Ac-H3
2125G
:LYSB/ho
AJ270770
manifestations8
5′-GGAGTTTCCTGTTCTAGACTCGGCGCCCG-3′
E74-like
E32
2000
NOTCH1–c-Myc
normalised
0.92
β‐galactosidase
H398Y
CTNNB1
NRF-1
ULS-3
PCA5
1-3021
oncoprotein
Multitemp
CENP-A
HCC1937/BRCA1wt
TNFα–NF-κB
BMF
−271G
Johannes-Gutenberg
B-RafR188L
Leu485
30.50
factors11
145have
nilutamide
S26A
5p12–14
enhancers.68
SOX17-M-sense
59–75
R420L
H2373
.Positional
200-μl
521–526
Ntg2
S.cerevisiae
Hirsch-Ernst
GA-induced
cancers.14,15
Anatomie
ttatttcag
pSV-AR0
NCI-H660
pCIZ1
19-year
p.Thr3033AsnfsX11
orROS1
13q11
receptors30,66
FGFRb
C82A4
mg/kg
4.33
0.59–1.03
GNAO1
anti-Thr-68
Hs00136087_cn
EWSR1–ETV4
Baf47
GAGACG
inhibition-
P44/42
Klenow
SB/LGS
LP90-032
T468M/FL
A1066V-NHUC/NIH3T3
CHO-AA8
.Early-stage
HN31
NAlESLqtqKFTTkSDVWSFGVVLWELNTrGapPYpDVn-tfDitvYLlQGRrLlqPeyCPdpLYeVNlkCWHpkAEmRpSFsELvsRI
.227A
UGG
.KITD820Y
Di¡erential
c.1789_1790
Br7
advanced-staged
Methylome
proteins9
LUCaP23
20120626
H-432
5′-CACCACTGCATAGAGCTGGA-3′
exemplifi
SW684
.1702
21,22,40
.WT-overexpressing
FUSE-binding
lymphomagenesis99
YFP-Jak2-V617F
non-hydrolyable
A_51_P366931
BCR-ABLpositive
H+L
2.19-fold
GTC4.1
cis-Diammine
CFU-M
Hirohashi
.S2.3.1
Baf57
anti-LMP2
Tet1-knockout
p.His733GlnfsX14
Ragulator
Speit
S51
2Present
p.G116A1R117A
Met317
1975595910
6922
RiboPure
83.86
2,360
Monbusho
FoxK2
ARP/wARP
Contrast-enhancing
mEst14
littrmate
cyclinE/and
T35
System-HRP-Rabbit
EMBL/GenBank/DNA
17q11.2–12
5′-FAM-ACCATCTTTGTGGCGGGAGT-BBQ-3′
6·4–29·4
Meso-10
reported,23
HDAC7
SP3
TGCATGTGTTAAAC
68664
13+
resistance.10,11
59-AGATCGATGGGCAGAAGCTGC-39
ERK2/SNAIL1
monophosphate
S241F/−
endoscopically.71
Ash2
phycoerythrin
sequenced.Sequence
5′-CCTTTGATGAACAAGCCAGC-3′
Motti
trigonal
FVIIIRAg+
Triemli
59-GAAGCATTTGCGGTGGACGA
n+6
F1**
Bouwman
PDAC-bearing
325901
xanthosine
Jagged-1
cut-offs
Fir
tyrosine-503
P428L
K2003I-mutated
Myc-Fbl3a
co-operative
S258L
same-strand
grade.11
80·0
interleukin-1α
FoxO-regulated
domains,94
~29
Bio-systems
HBCx-2
Leu/Arg
Tsc2+/–TP53–/–
1-LOD
EGF/TGF-alpha
'Y
0.30
mice36
samples.43
LysMCre+/WT
46.94
RAD51-like
control=reactions
FLAG–Fbw7β
S-
DEA
adrenocorticotropic
KIAA
treatedfollowing
1X
EphB233
sequencing46,47,48
cBOT
SDH
pKpnI
c.2125insA
square-bottomed
E579K
0.54
comparison-wise
IMMU510
7C10
MFS
variousproperties
c.622-2delA
40mins
EGFR→HER2
helix–turn–helix
mRNA-binding
F479L
andPEBP2β/CBFβ
CD71/Ter119
multi-array
//www.genome.jp/kegg/pathway/hsa/hsa04210.html
AJMS
parasagittal
Cristofano
VUS.3–5
//main.g2.bx.psu.edu
2709
andeluted
Modi®cations
P298L
G873Q
//www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/geo/
4A-nF
M176
anti-H3K27Me3
self-antigens
CATGTGAATGAAAATGCAACAGA
96.31
1–341
Asp286
300C
PFA/PBS
ATR−/+
Low-grade
-AGTAGAACTCGGGCAAGCTG-30
2sSZZ
fibromatosis17
KRAS,21
LR11-016
G-S
gse3446
VEFS-box
161NK4
Jumak
A70
lung-tissue
BCL2L11
cyclophosphamide/G-CSF
ajp.amjpathol.org
pluripotency7
response55
Tonooka
//www.mrc-holland.com
SPRY1
units.Estimation
9-kb
⩾2.0
MPCEWS-FLI-1-T2.1
41kDa
pEFLacZ
Tyers
.Curcumin
1–1099
TGCTGGCCGGGCTCGTGTTC
2/314
3ÃŸ
.Tg
XXXIV
needsto
transducin-like
Histochem
p36.23
VC+shNKX2-1
17-residue
R654L
R282
5k
ofprotein
.Steatosis
Transwell
Notch-signalling-deficient
PI/antifade
posttreatment
PHOX2B
5+4
pre-tumor
control.20By
biphosphate
276–317
Shh-treated
61/506
BRCA1-proficient
p.Met379Val
moderatesubunit
1119
1.6-14.9
p27Kip2
.Hit
186.7
plasmidj
0.803–0.919
CEP110-like
PTK-inactive
​,5,5
ACT-FLPe
Garcia-Guzman
piled-up
.Fbw7α
2,301-bp
.Production
n=222
A1–C1
action.28
SNF8
MPP2
Hoxb2
1136insA
c.1277−1180_1386+2226del3516insCATTCTCTTTGAAAA
.Ignyta
.image
Criscuolo
mutant-binding
V424L
Inje
photomicrograph
nl.
medulloepithelioma
MutSα-Del745-746
UOTR1B493
0.4908b
to35
nin
cT2-T4aN0M0
chondrosarcoma13
FLT3-590G591D
Sca+
podArnt
FSHβ
SUBCELLULAR
inser-
CM-AVM
signature13
15/24
p110-α
PCOS.4
V532
PAK2
W2c
IV-4
1925–1936
GGCAGCTG
31t
PI3K-inhibitor
4.The
K17
effect.9,10,35
Treatment‑related
RV-undigested
195–212
MOLM-14
CTGGGTAAGGGCAGGAGTC
PTPRT
hemopathies
c.984_985insGTC
y-actin
2-nt
self-destruction
rGI
transposon-like
NM_009525
D36H
47,480,658
-113C
103Splice
insulin-independent
692×108
laboratory80
.3.20
Delacour
CCAA
Antigen-Presenting
TTA/TTG
aneugen
cautionary
I118V
VGPKNS-to-NAAIRS
.Expected
Q226
5′-GAATGTGCTGCAGGAGCT
shelterin
mono-methyl
doi:10.1158/1078-0432.CCR-08-1325
Stt
optimal.3
60-ml
32.5
82579
Magnafire
BPR
82.08/47.88
lesions/loss
40215
melonomas
line.30
26584
E002
MBq
10These
ODblank
Evol
q11.2q32
elucidated24
activity.44–47
.T-47D
8762
Q142L
5′-AGCTCAATCTGTCGATGAACG-3′
110×
.1,15
45–60
HCC827-delL747-S752-T790M
PIK3R4
VNTRs
Smarce1
cases.49
U94788
fr2
IWP
patients7,8
expression31
50-100
MCL1and
5′-GGTGTCAGGAAAATGCTGGCTG-3′
ZNF198
resection.There
H-60
cancerE-cadherinComparative
/ig
Bannayan-Ruvalcaba-Riley
.Links
sc-1616
csnpScoreForm.jsp
.Chimaeras
12.7±1.2
showedeither
Erg
84687
F2AMLF1
∼4–6
Thr204
BioVet
LangeCarter
p-STAT3Y705
p16-specific
R1661H
BTLA
Ki-67+
–39.5
glycolsylase
p27-containing
E438D
905+5G
resultingmelting
lwoffii
CU110-shPIK3CA
1750–1756Cross
time-rev
97â€
D92Y
RPL22L1
sample-multiplexed
kinases9,10
Pindel31
S1A
mHGA32
0.8–11.2
exceptionof
framework9
ALEIAERDSCCYLCSRKFENESFKSKLL
Apcfl
Ras·mant-GTP
0.001.With
reduced.33,40
mass-spectrometric
HindIII-BamHI
Abeta
.GR
0.02–0.19
0.536–2.399
87/77
Roupret
42*
CAACCACATCAAGTATTGGTCTCTCTTTCTCAGCTGGATAAGGTCTGG
GAAGTTCGAGGGCGACACCC
Ras-binding
.Pabst
owever
4046
ALK-mutated
Nister
shGLP_2
5′-exonuclease
48X
.Skewed
ralA
|123
burden6
2264
sc-11447
11-specific
CABIN1
dierentiative
D2992
iexon4
50k
background-subtracted
P379fsdelT
P27_S125X
D-001810–10-05
galectin-3
AG-490
BAF250
2.5–4.3
HUVE
ubiquitin-de-
1,900
25.5
lxlO5
giventhat
p53-P278S
neuritogenesis17
shake-off
type.32
726
G20E-3
perturbations166
D2424N
151100
RUNX–p53
V557
HD-AraC
Katoet
β-catenin–positive
EV6-7
TGGTAGCTCAGCTGGACTGAT
27,55-57
antiubiquitin
GFP–NUT
hybrid-
FANCA–FANCC
1,365K
hematoxylin-eosin
DDHD2
.Lin-
expression-mediated
shCtrl-transduced
Thr670
expressors—also
sequence-based
285,424,542
L755S
IRIFs
fusion–expressing
VEGFR24
1.35
A2220
P-30
T2576C
Pim-deficient
v-rasHa-transduced
Tcf-4,11
AY803272
1409
//snps-and-go.biocomp.unibo.it/snps-and-go/
site-directed
rank-test
P16234
5589del8
35S-Labeled
incompatibility
P48
receptor‐2
pcDNA/Neo
mouse-specific
Asp351
I-01
2⇓B
antibodyPAb1801
Meca-32
previously.10,11
pathways.1
.Interarray
vivo.Mutant
GFP–BRD4–NUT
NM_000546
5′-CTGCTCCTCCCCACTTCC-3′
746715
Cα1
KYSE180
/-strands
DOWNREGULATING
322-bp
species.To
D549N
F691
p.S259F
Hepes
i17q
chr2:29432664
.PBRM1
844
milk/Tris-buffered
O'Marcaigh
.Heldin
BAF155/170
PLA2G5
3H-labeled
R847K
Arg393
system31
Quong
EL-transfected
R320
Figure6c
R486Q
CRFL2
Reyes-Múgica
L181V
immunostaining1
respectively.20
NF2a
MAP4K4
Stadtspital
FOP–FGFR1
1999:1
ICCYGPFTNMPTDQLEWMVQLCGASVVKELSSFTLGTGVHPIVVVQPDAWTEDNGFHAIG
benign,7
−80
513000
1aVa1
PDGFR-βScore
locomotion
Rawstron
DNAeasy
G162D
annually.1,2
L259P
sixwell
complexedto
p175
c.995T
CBF-b
-AGGACCAGACAGGTCAGCC-30
7L–M
School.2-hydroxyglutarate
FDP/AML
47511901–48153800NM_001113498NM_001127715
Rac/Cdc42
TKD1
progressively
.S11A
PMBL-like
ECLTM
altrations
damage43
A2B1
1-month-old
GGACAGGTTTTAGAAACTTCAGCA
.0136*
NF-κB-independent
low.29
HER2-activating
13q13.1
Non-consanguineous
.S3A
interspeciessequence
2–5×103
E411
expedite
.Raf-I
pseudokinase
282
.Monoubiquitinated
deprotection
Val559Ala
cancers.3
p.Gly52Arg-associated
Mel1617
0.2-2μM
RTK/AXL
previously6
PKI166
24948
BWA43
UAS–Alk
het-erozygosity
DoR
splenomegaly.23
NCT00730925
76.4
effects.32–36
G465EB-RAF
overproducing
*Consists
t=0–2.5
AAAT
recombinanthuman
EGFR*
studied9
factor-responsive
I.-
//pymol.sourceforge.net/
loop,20,25
LAMA84
167th
anti-FBXW7
12,29
G390D
cells—that
prioritization
5′-ccacacagcaaagcagaaactcac
DNA-nucleosome
Fantin
.Kilpivaara
156027L20
14q13–14
Tyr-Ser-Pro-Thr-Ser-Pro-Ser
1b-2
LSA-type
NACE-positive
TÃŸRgenes
P53+/-
Q16H
SF3B1K700E
Dll3
epidermal/dermal
Mll-Af9
stereochemicalconstraints
Mll1−/−NHA9
0e0
Angelin-Duclos
p27were
NCT01588613
463nt
Qiaex
snoRNPs
ofgermline
XL228
D281V
medulloblastoma26
MCRS2
c.5585A
's
risk-reducing
Peutz-Jegher
cDNA-microarray
EPHB
R249G
mark-
H–M
splicing-dysregulated
Oi
phospho-S807/S811
13291A
NFAT5
T511M
Asxl1-R3
caspase-8-initiated
PDGFβR/TEL
Asn-705
astrocytic
485·94
Hx62/26
D1/CEP
Dreieichenhain
T283A
TUMORIGENESIS
Microphotographs
TGF-β-receptor
FGF-pathway–amplified
20/40
pathways-specific
p.Glu453del
Bilat
mechanism43
32.8
FoxO6
tumors/patient
.Following
−52
*Adjusted
vitro54
NHA9-Meis1a
interleukin-3.50
nodules9
BRIP1-deficient
0.29–2.1
panIN
Chromatin-remodeling
AKT.6
genes12
TGGGTAGGAGATGGAGATGC
4–87
.Fusions
Pericentrolobular
malignancies8
frontrunner
repression.ResultsGenes
TEL–JAK2-expressing
CRAF-CRY2
AS7
dictyoma
IV/4
Bouin-fixed
.Cottin
c.1–101
22.6+1.4
cRSS4
HpaI
5'-TAATAGGATCCAAGGGGTCTTGGCTGGCC-3
MLL-PTD–positive
27.74
TAB250
Dnmt3a-deleted
dose-dependency
products.For
0.5–2.8
FBXL10.17,19,20
Mei-1
super-enhancer
S200
next‐generation
theircounterparts
H2444
–AKT1
4qA5
c.2096C
FLT-ITD
EC1-2
FCS/DMEM/25
-Ura
CTNNA2
803
Rosai-Dorfman
Kpnl-Sacl
Coulie
reports17
Kitakyushu
MSH2-EPCAM
ABC-DLBCL.39
Q167X
Ex21
tetO7-CMV
11—NUT
pEAA302
A339V-mediated
specific.63
CRYB2
p300ΔC
SMG1
E3F
K.-S
Olig2+
previously,25,26
Rpd3
p=0.006
8-mer
ATPhydrolysis
i/i
10881
IGF-1Rβ
50-kDa
P357L
1e−5
sible
hemizygous
hyperthrophy
GRB14
BSO
L536N
CS9
Phosphorimaging
0.0201
.8,10,12
Cytomegalovirus
2.013
60.2/38.7
inhibitor45
.57
JAK2-inhibitor
KIT-associated
ACAGTTCGGAAAGTCTACAGA
SP-MPE
co-mingled
172-208
+16
caspase-3-positive
pIS-0
11q12-q13.4
formation.42
LJ
CFU-E
FLT3−
Ohne
Tyr877
Bu
recoveredinto
BMP4
Carls-bad
nucleo-cytoplasmic
XXFF
Sox17flox/flox/Cdh5
4.9sox10
L.M
25,27,28,101
GTTTTATTTTGGATTTTTGGAATC
inactive.
NINDS
development10,13
phospho-STAT3
I.
Sequenase
D281Yclass
800-332-1000
tig
​Data
p.Pro40Thr
NM004456
pathway18
n.e
rex
II7
v-ras-
Granulocyte-macrophage
27,679
HA-Skp2
Widmann
-ATTATCCT
Twenty‑one
TopHatV1.4
IGIFR/INSR
T-PLL
I211M
C.J.Marshall
80ng
-FITC-ACA
TFG-ALK.4,5
GADD45
gFlag
266395
XLαs/XXLαs
i–j
G242A
Sdf1/Cxcr12
disease1
Newfoundland,20
226,371
identified.29
.Occasionally
2008A
morphological
C-SH2
852
R878H
stabilization/positioning
PP1-
CDK4/CDK6-cyclin
epitope–tagged
83.6
p27P95S
Patient-derived
pmoles/mm2
A259
TFIIE
66.8
0.018⁎
0Total
c-Akt1
LexA-E578G
K166M
sorafenib.9,12
D-isomers
EBC-1
U-2-OS
R675
LNCaP
.EPZ
XhoI.Tet-op-K-Ras4bG12D
378611
CTL-specific
capacities.7-10
S155P
Batova
L418R
cetuximab-naïve
-ΔΔCt
metal-ion
0–59
.ANOVA
KIT35
67.1
Tyr408
CDH11
2:2
582
subunit–directed
50000
interface.Fig
9,12
CpGenome
3-cholamidopropyl
5'region
0.859
isoenzyme
8p11.23
Site*
robust_weighted_average
controlDNA.FIGURE
TMEM14C
Q331X
scan7
BC-CUL
FuGENE6
938
tumors47
2692G
Q37X
YEPE
mutant-containing
Y35A/Y35F
S82C
RA/RARS
correspondto
low-IL
full-width
Flag-hCdc4
G125E
Sjodahl
.ARP/wARP59
anti-estrogenic
Erb2
N546K
6412/6414
hypofertile
smudge
Ffh/FtsY
EGFR-L688P
LeX
cellsfrom
Tohyama
NRF1-dependent
APT1
L536-HE0
families.6
RDH5
RTs112
EGFR/RAS
nongermline
EMSA2
Excitatory
Asn-676
proliferation9,10,11,12
genes.9,42
densitometric
telfairi
risk-stratified
aurora-like
28106
counts/min
5732
R905G
001879279
AR/Foxc1
Gd3
R200Q
−2455
IDH2R172.31
Ba/F3-KPβ
Minghai
statplot
.Hinds
1tumours
described,5
NurRE
7/57
F258S
16/167
airspace
.CUL3
non–smallcell
4.01
predetermined
1These
dimer.16
hu_
Cys64Gly
M.E.E
NHEJ31
INL
Phe-X-Glu
14825701–15112300NM_080676NM_207359
fruitflies
92-kD
TCC-S
pEGFP-N1-MEK1-GFP
Tyr1135/6
instabilityWe
nonchromosomal
HR=2.58
r2=0.153
ADL
tumor–specific
CMV-Myc
F.G.G
112K
Schnelldorf
hemoglobinopathies52
misfunction
AvRM
deletion-containing
G613D
al.1998
Rasgrp3
753f7
less-toxic
10-4
F156L
ALK-I1171N
tumor-induced
6832
1083–1092
7.02
CK1α/β
cacagcttttgtccgccccaaaccagtagttgtc-3′
immunoglobulain-like
PCM1-JAK2-associated
.Ectopic
imidazole-containing
mg33258.f2
carcinomas.9,26
Tyr337
†Individuals
E255K-
CHOP+
un-answered
A_52_P332081
overtmorphological
macroprolactinoma
7-mm
IL3-dependent
A399V
Arcinas
42.4
formation.13
H2AX17
Eswarakumar
0.4–208.0
Sagamihara
mCSM
levels.Before
SETD2wt
pressureof
5′-GGGGGATGAAAGAATGCATTTGCC-3′
22°
1N50
HMC-1.2V560G
R348∗
CTGSSDNEYFYVDFRE
revolutionized
88–100
FGFR3-associated
functions.4
Laboratories-Pharmingen
−39.1
Scr
apoptosis.1
R204P
R347L
Biallelic
hydroxyproline
7.6,5
1,214
224_5insA
retardation.123–125
Copy-Number-Variation
W177R
V140G
ATG16L2
coloniesa
,8⇓⇓⇓–12
Woessmann
deleterious/disease
EYcacy
0.005*
apoRXRa
pTRE2Hyg
RUNX1–25F/Chr9–187R
~0.01x
282•NUMBER
B1*
LC_C21
T-ALL-prone
risk.It
FA,5,6
C184Y
amplification
furosemide
Frs2/Myc
137–273
.Refinement
2OGV
cell-cycle-specific
c.526C4T
.molecular
detailled
Penzel
~280kD
MET-activating
BRAFi-elicited
.Separate
SET7/9
500–750
conucleofecting
.Co-IP
CLL03
15.R335G
curie.fr
acid-altering
.COOPERATIVE
5′-cccccaagcaggcagtacag-3′
-CD16
total=122
30-nt
AATAAA
postwashed
GeneRuler
ERCC2-mutant–complemented
6.2–25.0
penicillin/streptomycin/amphotericin
Notch-altered
0.163
bowel/others
Vector-transfected
analyzed.45
p21MT
2,3-
recurrence.21,22
NM_004448
120ra17
8259–8267
Ipl1
LysAIaLeuLysGIuAlaSerGIuS
3nt
12535-7
N509S
0·10
≈15-
MFS-related
CTGCAGAATTCGCCCTTATGACTGA
complex.62
2972S
aServicio
16q22.1
humanf2-s
destabilization
BCR-ABL,29
NB5
Arkenbout
TAZ-AXL-CTGF
a14
.Homogenous
D299V
HDAC-dependent
Nasopharyngeal
S63
5.3.5
CD11b+Gr1low
MSH2-4
Steiner
lipofected
S613
kJ
PI3K-dependent
inter-focal
FACSscan
NGS-DPBS
.2A2A
2IVU
S2b
accumulation.44,45
.PLAUR
acinar-predominant
Ras/extracellular
41–49
.Detailed
+K539L
2c
94‑0615B
44°C
vitro51
V553G
profilingGFP+
ROS1-resistant
TAD
.Grossly
cov-erslips
Leading-edge
197.0–197.4
bi-substrate
P/R
wemeasured
age-matched
202G
Anti-ErbB2
neural-progenitor
Rad50ind
5′-labelled
S'-GCAAAAATGTGGTCCCGGTGAACGACCTGCTGCTGGAG-S
0.65-6.09
pHP5-Ha-ras
outcompeting
towild-type
FigFig2M–O
Asp74Tyr
14q22-24
FYRN
Detoxification
Syk-deficient
N1387A
carbonsource
Sun-induced
pre-associated
PDAI12
ACAACAGCCACAACGTCTATA
Rheb-K60
U72937
CTTTCCCCCCGCGGGGCCCGCCCCAGTGCAG
.Pancreatic
Cdc28
eosinophilia.1
nephrectomy-biopsy
HPV−
122–124
refocused
2–phosphotyrosine
Bax-Luc
HGGs
rs2293347
609309
PMA-ionomycin
Cre–loxP
N3124I
B-galactosidase
PKBα/β/γ
GST–ERK
broccoli
3Y1
V60L
verified.39-41
A997S
45/M
p53RE-LacZ
KIAA0239
5′-CCAGGCTCAAGGTAAAGGGGATCTAGCA-3′
karyptype
AAGTGTCGCATCACCAATGC
FUBP1
Kcat/Km
M600I
syndrome.9
Opti-MEM-I
612
0.244
.Uninfected
CBL_i9r
inURA3
CISA
two-proportion
MgCl2/1.5
SerArgAsn
CGTCCCGTAGACAAAATGGT
hinge-binding
CAND1-CUL3
heptadcontaining
BRAF-inhibitor–induced
COG5
C482W
A52
5′-GTCGAGTAGGCGTGTACG-3′
ins14nt
co-hybridized
gram-positive
TTTTTCCATCCTAATATTGACTTCAG
9°
HERC2
NCI-H2347
4DSO
13/37.1
S5C
analysisOverall
250–258
transfectantsas
Formation—Rad51
C540R
NSB
Aβ
n~
MM622
.TEL-AML1
PIK3CA_S12
Cuntil
proteinscontaining
FAM175A
8σ
Leu1704
Ras–Raf1
pheochromocytoma/paraganglioma
ACTL6A
deathinducing
.Linked
non-central
Fluorescently
BAP1-deregulated
.Merlin
DD-p53–tagged
,3e
anti-γtubulin
15/57
p48Cre
21·6
Probands
rs1045485
57Â°C.and
34Wild-type
p16/p19-
HA-FZR1
non-autonomous
rs41321844
-G2101A–expressing
0.12.5
25930215
IVS2+G
published.6,10,15
M/19
PDLIM2
.Mason
anti-FANCG
anti-GSK3B
256KB
Mastocytosis3
Heinzel
and~
Arg802X
p.Glu533X
ULTRA-TURRAX
E1254D
LFS-associated
p.Arg81Pro
SVS4
S834F
ErbB2-
/dish
125Iodine
TTD-causing
1121
7.C.2
.HIES
WM3506
5′-GTCAGGAAAATGCTGGCTGA-3′
VIM
ShhCREER
www.iarc.fr/p53
BRCT-CtIP
21–29
non-reproducible
macrophage/DC
histology.4
CD122
1In
inhibitor-specific
1,783
HIP1-PDGFRβ,26
.Antibody
85.5
roscovitin
Figure4E,4E
molecules—G-quadruplex
9.2–14
hPTP-J
7007
GI:66968776
T24
R-273
MAB1
-FITC-CCA
T899S
.9416
resistance.7
MuirTorre
G4-binding
Castellana
S2–S2′
SEM-NTC
20-week
q.v
1.7-1.9
Fackenthal
-25
15.9–69.3
Osley
Coexpression
Ly6C
RNA-based
HA-ERK1
ETV6-NTRK37
21p-q
higher-energy
avidin–biotin-peroxidase
rare.1
TACC3
0.7244
5′-TGTGGTGTTGGGCAGCTTAT-3′
5M-L1
CA09320
68˚C
-E3
–3.3
X.L.Y
:9103–9112
significancein
2.12.0
GST-UCP
PTC.5
pGT3/3
Glu-659-Met-753
496.5
leukosialin
62.0°C
IL-7Rα
MeBIO
VINCULIN
Hes1
STAT5A/B
D850
0.0125
J.J.
cytochemical
HLXB9
avidin
c=
19,21–23
antibodies43
harmatomas
pEco6kb
Aylon
QQThrAsp.
.AFH
361:1159–1167.10.1016/S0140-6736
S248A
PIK3R1R348∗-tumors
PCR-driven
signalling.2
clear—clinical
5′-TGAACAGTGTGGATGAGATGGAT
8°C
phosphotidylinositol-4,5
C428S
althougha
GST-Grb2
A08-M61-09B
GSK-3β-mediated
0.036Others
Immunoprecipitateswere
L-PCR-based
H165D
F73/1
11/87
.IR
BalF3
Gα-GNAS
CSA
RSV-TFAP2ΔN165
p89/4x
T599I
.cytomegalovirus
Hs00240887_m1
PE–anti-OX40
–TCAGTCAACGGGGGACATAAA-30
myocardial
retard
E47A
RP11-89G4
DNA.47
130K
A1225G
6-d
eluted
70,000-130,000
kkmkys
C27A
Sez
less-malignant
2–350
Gal-1479
.Requests
H1881
Inclusion/skipping
Tyr1096
T373K
β2m-positive
antibiotic–
www.mlpa.com
0.20±0.03
interferewith
fold-difference
Mac1-Gr1
V738Fa
NF00028R1
gene–mutated
KK†
MDM2-b
Ledel
R15S
syndrome4,6,7
Y327
Guerry
D86N
S68W
Flag-MLH1/PMS2
R.A.
3593
S767
propagatingras-transduced
-CGACAATGTGTGGTAGACAAA-3
MLR
.781G4A
W409R
gamma32P
haploinsufficiency.2
66D17
HA-epitope-tagged
Glu-744
oligonucleotide-directed
pCMVp
Wwc1
Ya5
000077
NCT01182896
Chorioepithelioma
Trp557-Lys558del
acetylases
/
177/419
Src-mediated
inimical
L792P
anti-Apaf-1
-Non-Asian
RP11-164D11
WBC/
RP11–184L6
1/63
RET43
pre‐equilibrated
Tacaggctc
Gdn·HCl
Ziirich
DNMT3AWT
hemi-methyladenine
Lkb1-proficient
USP11
7/22
β-Catenins
NM_023844
confluencey
Roche-Lestienne
NM_016693
.IκBα
gene9,10
NZM22
lin-14
directly.38
R683S-mutated
306–342
1662
1.46-
representational
Rad
family.10
and3E
SON-R
Msh2P622L
Afghan-Iran-Iraq-Kurdistan
IVS5+26T
17q21–q23
sub-consensus
UCGGGAGUUCAACAAAU-3′
LL12NCO1
HEC-6
core-Gar1
Auffray
charac-
phospho-Ser217
hRAD17
d+32
sequencing,39
SFA1a
Schaulsky
A-base
Barletta/S
9133
1,071
carcinoma28
acid-
Tsavachidou
CD79a
colorectal4
14q13.3-q21.1-ETV1
T4M0
DED-DED
1145G→A
anthracycline/taxane-based
3193
51-bp
a=0.9
I314S
82.4
previously.4,28,29
siRNA-co-transfected
ARL7
GAGAGTCTGGACACGTGGGGAGTCAGCCG-3′
Id1
A_52_P651298
C1152Y
pY579
pRMS17-2
V63E
KRT33B
shBAF180
199-bp
p21-L1/p21-R1
Macromolecular
G437R
uOC
image-right
R326C
mutationsoccurring
Ser751—see
BCR-ABL1–positive
gttttttag
0.134
metastasis2
tyrosine
c-kit.5
1D–1F
BACH1–BRCA1
splice-variants
A_51_P286665
nine-hundred-and-twenty-one
cancers.28
KVFSAIVGSSVSCPTVMCDI
18−fold
31,33-35
130–150
proliferationin
immuno­histochemistry
CDK12-5
wasnegative
deltaN
therestriction
3B–C
malignancies.26
delS752_I759
Mass-spectrometry
pre-,2im
T1561I
NRB
pERK/MAPK
3717
msh2-GD693-AE859
8.735e-05
non-modal
101600
mega-CC
.Reverse-transcribed
PSADWIATIRARGRVEEVRA=AG.RLPWPBS
Cufflinks39,40
15q12
.677G
patients/families
p16Ink4a/Arf-null
Mochida
T992I
.503
c.153delG
Fabbro
T2aN0Mx
13q32â€
Polyplus-transfection
ACVRL1
TP53-haploinsufficient
KRASG12C-driven
Sgo1p
AG5
Iq41-^ter
4q31
KMT2A/B
Metl775Arg
Eps8
B/CDK1
4599
umcg.nl
Gapdh
R1095H
CO2/air
HT.13⇓-15
3H-cyclopamine
BARD1-reconstituted
Pre-B-cell
LOH.5,11,25
Pouillart
basophils
RNF216
mesothelioma.31
gene-mediated
doxycycline-responsive
G15W
ERK1C82Y/ERK2C65Y
Lys1702
atumor
cyclin–CDK
R01-CA27632
Jak232
HDM2
Nosingle
414–575
Figure5a
7.2
insertion/duplication/deletion
miR-25a
malignanies
1699
ERK.15
antibody-peroxidase
62:38
joiningof
PROSER1
0.15414
R2=0.7
MET-mutated
EC3.2.1.17
BMP2A
0.5900
cancers.16
precursors30
Melan-A/MART-1
charcoal/dextran-stripped
FJX1
0.979
.HIF
D153V-expressing
R93S
enzymological
2-3-4
20.2/23.8
54.1
Comite´
Cerione
FNA
Vav-cre+Tet2−/−
Her2-positive
Burkitt-lymphoma
enzalutamide-sensitive
morerare.Onlytwoalterations
n=1530
83may
culturesCAFs
GM-CSF–responsive
.Protein-tyrosine
segments1
R515X
archaebacterial
H221
pFLAG-CMV
crizotinib-naïve
marks13
Mel505
PC-controlled
pulse-labeling
.NSCLC
c.1730_1731insA
I931
using…
10.1111
16°C
truncatedproteins
black-blue
Met340–Lys351
chr6:67272027-67272138
β‐strands
inhibitor–na€ve
NFl-encodedGAP
SCCOHT-114
104/105
T/ebp/Nkx2.1
.Pathway
AT–lac-
Ptpn11DG
p.Leu604ins23aa
C19A=0.1143
TCAGTCAACGGGGGACATAAA
.Mamo
5′-AGACCAGGACCGTGTGAAAC-3′
1.181–2.737
GST-Cbl-N
neurite-outgrowth
c.211dupA
II:4
counter-selected
1998.
hRos-17
SRS2
df=0.69
Crosslinks
V12Ras
face-to-face
ABI-7300
kinases7
1.910
H4034
10×/0.25
Y.B.C
effectors15,16
Mikatahara
coworkers.15
non-recurring
anti-phosphotyrosine-4G10
G885R
HOOK2
Anti-HCF-1N
52-65
2.4–40
L90F
NP_004295.2
chr9:5510545-5571282
pCMV-TAp63α
family-gene
understood.A
GM-CSF.64
Mdmx-immortalized
5'-CAGGATTTACATTATGAAAGTCACGG-3
c.250+108a
+2.48
Remeseiro
,500
p53-V157F
∼1.8-fold
-10.28
2.5
p610AZ
anti-BAF155
Figure1b
havioral
mTOR132
/R
non-C
Y110C
13A3
SD/total
myeloproliferative-like
SSLP
G12VRAS-activated
mutant-stimulated
820–825
0980
convention1
well-matched
178/184
1q21-q22,4
782402
CDK17–KCNC2
.Risch
germline-derived
Argiris
1:5,000–1:30,000
HRAS7
'model
0−100
Grb2.48
Sixty-six
P440L
immunity.42
me´decine
I145
D159nt
,21
CDKN1A-dependent
aglandular
N128S
alternativelyspliced
GFP–NUT-S1026A/S1029A/S1031A
p30/p30
apoptosis99
cells.83
manner21
Plon
SNVS
transmembrane-spanning
16124
+mar1
ClonaseII
quinoline-3-carbonitrile
I1018F
Flexi
AES
c.184C
E1384K
.014a
E218
617th
+57
eb
PIWIL2
SNF5
NADPH/NADP+
pDM22-
p.Arg687Trp
JAK1-WT
complexes,14,15
*40
M-0512
rank-ordered
Baesweiler
Keizo
kin­
Moranelli
FOXC1
mRNA.To
gi56311471
WD-repeat
P0217
HapMap-CEU
C515R
PTENC124S
mA·h
8204G
A_51_P214557
W557
Rac-specific
V207L
ddPCRTM
Lv
478-bp
OPATZ
methods.20
rapamycin-mediated
DnaA
D418D
kinase-1
RiboMinus
Methacarn-fixed
TopoTA
genecluster2
-CCACCCTGCACTGAGTCCC-3
Δ298
CD150–CD48−Lin−Sca-1+c-kit+
H3K18
thiohydantoin-based
nutator
20-ft
RG-22N
sequence7
myeloperoxidase
4075G
–,45
reactivation252
c.856G
resorbtion
lentiviral-induced
C393
D11S4088
IL-2R
H3-K43me2
IgG2a
3TV6
KIAA1625
cancer.Somatically
.NTRK1-3
CUL3-SPOP-RBX1
PKBα/β
M26I
MILDVAN
gac
CC-3′
Tzahar
KST1042
protease-deficient
.Fractionation
62/76
AOM-induced
cetuximab7
1415
impact4,7,9
TΔS
function.1
NEL542001EA
1*51
T29
0.2–114
R1040L
beta/zeta
KDM5C-related
∼15-bp
PolyADP
PTEN-ubiquitin
~25
124,236,156
Beroud
2−∆Ct
p.Ala938ProfsX21
TRANSFECTED
children30
Sudophred
MLL-AF6pos
.Tumori
LOD=4.23
tag-fusion
Classfication
assaysBalb
c.2042C
TβRII/Alk-x
Koken
.Weber
misleading.41
anti-GLUT-1
c-MycS62A
1.06±0.05
Asp-784
5,6,9,15
K174R
R273G
DUSP
E-____E___*___*_______I_
'IIIa
Carolina−Chapel
cryo­
success178
S218D
lipidic
TGGGCCGCTCTAGGCACCA
3.92–
aq-Q209L-
dynamism
G476R
45.24
reanalyzed
ZD1839-treated
CDDP/VNR
m/+
MAP4K2
FigC
GEPHI
ZF4
Tyr978X
CXCR4.16
ceph-genethon-map.html
F398
Thusberg
iMC
maintenance29,30,31
.Piebaldism
L501V
MDA
RD-N.
hsa-miR-16
Stratagene/Agilent
dichotomy
NM_009425
Matese
K721M
α17
Attardi
plasminogen-activator
3q26/28
c.288C
1763–1776
CFU-GM
G1586R
MAP2K2E207K
K299AR300C
INP313
Downslanting
-AAACGGCTACCACATCCAAG-3
sense-strand
C92-605
cd.7
p=0.9
0.224
∼50–70
thymomas.52
9.0-fold
Microscopy-COS7
D*
R0005
mPIN24
trypsin–EDTA
Ðapic
School/DFCI
0.4–1.4
68-
Effectene
Falcon™
Taspase1−/−
structural-based
underex­
L858R.5
GGACCCAGAAACAAACC
transformingactivityofthe
5′-TCTGTCTTTGCTGCTGCTGTTCTTGCC-3′
Snf5+/−
EGFR/input
pMe
circulatory
P653L-exon
8.3
GDNFRa
FLAG-p85
U.B
myoepithelioma
wererecovered
Double-chamber
GAGeGGAGGAGGcAGGAAccGGAGc
scaffold-14857
EVI-1-expressing
RELAWT-RFP
p.Ser102Phe
=19-4
Trk2
anti-phosphohistone
c.4883T
unhybridized
Ifosfamide
nkn
strrrecA13
1,860–1,863
7.5
10q22–10qter
Wat175-B
Maltzman
2GDO
Rab7
706F
5′-GAGATTAGTAAATCGATGTTTGCAGTCTTGAGTCTCCAGGAAGAGATT
leuGl
Guo
beneficial.13,14
shRNA-mediated
complex19
.Ser612
59-AGTGTTGATTACGTG-39
delE709_T710insD
S2E–S2H
siRNA-targeting
testis-determining
1.32–4.56
mRFP-C-Raf-RBD
1183
chromothripsis
`6
trP1-Exon22F
lysine-HMTases
BRCT-like
35.8
3.5-month-old
D-146-
C35
CFPAC1
normalization,22
Treviso
2.1–6.4
pH3
5601
PHTS.3–7
MLH-E34A
Hm
10.1245/s10434-011-1942-6
p16/INK4A
L-p53
24354
RETV804M/E805K
hydrophobicity27
L479
.Gymnopoulos
5′-GGGCATGGTGGCTCATGCCT-3′
.Gefitinib
115256971-115256948
L560
methanol/glacial
ceLSA
frameshift.39
BRAFV600_K601del
1-ng
dose.Antitumor
ΔC10
ZNF331
50–65
−2−1
pEAA283
FgfR3
atrogin
imatinib+
units/µl
Origami2
SRide
7,24
Flag-AS160
700–708
//genome.ucsc.edu
interactions.23
NES2
.FRET
G1/S-checkpoint
.Subdomain
.PTT
rs7210100
.1789C
Tcf/LEF
Toshima-ku
RET-positive
5′
MCF10A-K117N
1.303
sensitive,28
VCM
c-1
immuno-histochemically
.Calliper
1,068
CCNE1
chemotherapy-sensitive
pC135R
neck*
c.2090G
Nested-PCR
antihemagglutininmouse
K1–5R
GTP–Wat190
inviable
IC50values
HTB49
FamilyIndividual
Brca1ΔSCo/Δ
Hs00946894_cn
fluoresceinHepesN-
ATP–agarose-binding
colloidal
Capoulade
59-CTTTATTCTGGAAGATGCTGC-39
Ni-beads
JNKAP1
NOTCH2-mutated
ELOPROLIFERATIVE
cellsat
E1705K
MUC20
CEP110cDNA
L-arginine
responses.90
HPA007053
llT.mers~x~-CYCltat
d14
effects157
Lenti-SYK-9
8.37
NCT01469546
MDM4.Gains
CyC1-lacZ
mechansims
c.35G.T
Acknowledgements•
190-base
4,1
γ‐IFN
Smad2-containing
Frame_Shift_Del
/percentage
access.48
.Page
76-nt
AKT3
indications.PIK3CA
strands.32–34
PKH26
D274
HERP
CA-ALK5
immunoprecipiated
Diluent
8.1–18.2
Smarcb1+/−
method84
TGF-β-activatable
preponderances
c-Met/JM-Met
RAPTOR-mediated
p110δ/p85α
p.Q728X
pThr-mimicking
HER4-R838Q
hemizgyous
LPCX
C-terminal–directed
Everolimus
m/60
1404
life-extending
1143–1525
6884_6885insT
Methocult
Control-BJ
NCBI‐BLAST
0.12-0.51
12524
BME
Neuregulin
pMX-IRES-GFP
UV-damaged
anti-CD38-PE
differentiation.8
l2p
NTRK1-fusions
progressionResults
γ-globulin
5q23.1
.7,44,45
ID-regulated
mitotane
PH-domain-dependent
TSC-specific
signalling.1,7,8
MACC_BITS
Kinase-Impaired
1,287†
58/40
Y177
,SerAspAlaCysValHi
CDK4-MUT5
fibroblasts80
F4-Gal4-driven
Akti1
ProteinTo
0.046aCD13/33
mutantfibroblasts
MSCV-Hoxa9-Meis1-IRES-hygromycin
1.32-fold
WWP-Luc
acceptor-splice
'Heat
D25Y
1172_1366del
.Anti-p85a
78–82
p.Gly17Val
chickenviral
5D–F
carcinoma.41
bead–purified
withmouse
myristoylated-Akt3
Chk2-interacting
GGTCCCTCCGGCCCCATCCTG
Spry4
LWE
imatinib*
programe
T598I
ITD-expressing
SIRT1-knockdown
AG2305
eczematiform
0.9556
P=0.025
7−15
betweenpolymorphisms
.Stover
KN-ΔJH2-Jak2
vival
Migliavacca
PulserII
:20
FA58
–BC
GST-Smad4N
downslanting
NB-99
UltraVIEW
extended_genotype
1.26
.Transient
Polyphen27
U.S.2
domaincatalyzed
monstrable
434C1
PolyHEMA
t-ERK1/2
LL2
ARN-509r1
I-Kpn
Pdx-1
Y1349VHVX3Y1356VNV
3.0.2
flammatory
0216
V617
41/79
polyReceived
0.0065
U.T
LS-specific
174.7
Tavassoli
hand-edited
tumours168
mÃ©tastases
case.Study
chr21
49,50,51
Transfectantswere
LY294
activity.Many
anti‐CBD
Rayburn
suppressor-gene
p.T1025T
cN-
p53R172H/R172H
Orange-labeled
probes26
Lensch
BDGF
0.00597
observed.8,23,24
CHH
L2427
hybridization.20,21
0•38
pCR259
.Pat.3
MRI.8R
Dedifferentiation
C57/B6
nucleoplasmic–cytoplasmic
Fourier-transform
84108
phaeochromocytomas
TGCI-induced
invasivity
Yee
D240G
p14ARF/p16
decondensed
Ultrasonography
suscepti-
human22
G193S
.GRB2
G.C→A.T
R203H
PET-avidity
SUPM2
−2659
phase.4
17/20
Sex-
function94
L364
Pat.1B
29–57
Smad2-SARA
primodial
Vysis-Abbott
IgII
asView
NF1,23
Mumberg
QiaAmp
bioequivalence
GPL1352
NCI-H292
cell-type
.Bands
0.07295
anti-phospho-MET
5.03
Feki
InhibitorsCOS
1988
Alk-5-null
miRNA-based
Tukey–Kramer
NM_000314
5/13.2
MSI2
Aberrent
bHLHZip
IP3
Serov
ductlike
TGFb-RII
97th
Donor-derived
.FINDINGS
Variation_29880
Ubf1-binding
-exome
nylation
c.464_474
examined.16
D695N
tohigher
.2013.12.007
pharmacore
A84T
5'-GCAAGAACGTGGTGCCCCTCAATGACCTGCTGCTGGAG-3
F-4500
SP5X
Nedd4
O-dianisidine
Tupper
c.2181C
mTOR-independent
co-immunoprecipitation
T2-E4
612703
12-μl
pSrc
start–touch-down
GRD-mediated
LifeTechnologies
C-RAF-CIBN
ALK/MET/RON/ROS1
∗∗∗p
Fugene6
7753insT
M270del
copy-alteration
K224R
and136-2
sonal
previously.8
C2-domain
death/NF-κB
.SQ
nontagged
ΔBRIP1-pcDNA-DEST47
conditionsdescribed
313G-EAV
sc-47724
double-blinding
microtitre
genes,20
Set1
1363
pPKCθ
10.6
non–MAPK-dependent
polygonal-to-spindle
Thorvaldsdóttir
5-64
AAG-
2C6
.PPARβ/δ
.HMMs
corticotropin-releasing
small-molecule-protein
WEHI-3-conditioned
L362fs
6A/6A
BB2.4
obatoclax
1.075
2:85714
PIK3CA-mutant
Cytometry
X-100/10
GTTTCTTGCCAACTGGTT
.1–4
Smad-responsive
O6-
CCCGGGCCCC
Tangdu
receptor.16
cases.3
pT1pN0M0-MTC
.Comparing
D368
0.798
Nucleoplasmin
JAF
ΔBRAF-mediated
TSR
−1.97
Lyn
ENST00000071246/ENST00000344382
p53/p63
IκBε
0.04/9.5
stimulation.16
0.88–2.46
37'C
Cation-π
E56A
DRB1*
Grosschedl
.2573T
L-2-HG
P-MEK2
Austria.ISBN
UTR-binding
respectively.3,4
SPD
15q25
labour-intensive
98:2518-2525
E10del2
reported.20
Val43
Mga‐independent
SRC-3
pSmad1/5/8
puterized
Galaktionov
cell-phage
Y2084H
pvgf-CAT
c.1201delC
ependymoma.1
siPPP6C
HA-STRN-ALK
REPLIg
alterations50
phospho-YAP
benefit-risk
patients35
Ras/Sos
RGC-containingp53-responsive
TACC1ex13-RV
phospho-STAT3Ser727
phosphoimage
non-CSCS
death92
SRR
AER-specific
*P=0.0462
activatedH-Ras
WT/CBL-70Z
PIK3AP1
cagcgagcagctgag
S197P
SPOC
blasV5
Met-1
CEP4
48,087
exeter.ac.uk
population.7
HKI272
.BGJ398
.Genotype–phenotype
~3,000
VEGF-A–amplified
pmol/min/μg
50+A211
OTICAND
PT-18
R525Q
30.5–57.3
p53.36
therapy2–4
MG-specific
Atwood
P0045
testing.18
PicoPure
≤60
P306
antigen-positive
14.9–15.3
S114X.11
94
S577S‖
–L
PIC1/SUMO1
160–188
—b
highmutation
EMSAreaction
.NHEMs
CTCTGTACGCGGGGGCGGTTA
0.37±0.05
57–66
molecular-biology
.Robustness
SORA
MitoTracker®
T148I
pY-parafibromin/total
557394
centralised
1826
Ardehali
14-3-3-E
T739
2B-1
pSG5/Flag-FRS2
ACAAAGTCTGTGGCCTTGTAC
cullin4A-RING
–GAL-TEV
floxed-Msh2
3/17/00
Kdm6a-deficient
Micropapillary
8340/3.
DEN–PB-treated
p.A330T
μL/million
CBF1-HA
Increased/decreased
MLL-DCPS
atom.25
2003-11-3816
Uberbacher
GDPor
seattlechildrens.org
ETV
~TMD
aliquoting
imbalanced
Mutagenesis—The
A228V
GAGCT
PROMIX
Fig-1
DR101
c.848+281C
RLU
.PPP2R1A-WT
P-Y
p16
D2644
Sixbey
Anti-RAF1
MDS04
acetone-methanol
Arg401
MFGR1877A—10
–29.9
cohesins
IKSDVWSFGI
Tumor-mutation
non-hot
low-birth
leukemia–lymphoma
0-II
48.
Gln61
ERCC2s
Ematologia
4/19
MSCV–puro–MEK1
Hochstrasser
delAsn770insGlyTyr
GGCCATACACTTGAGTGACA
5′-GATGGCAGGC
BVS
Liu,3
Jhanwar
-AKT-MTOR
pNKY5
CHEK2.1100delC
discrepant
8.07
genes9
RUNX1-I43F
colonies/tot
UPF2
estrogen-stimulated
5′ALK
D-4
c.340G
AREB
.Break-apart
sex-
CCT-mediated
P=5.96
K650Einduced
K.M.H.
-GNASR201H
BCR–ABL1-positive
400-mg-twice-daily
rearrangement12
6.62
Ras/Raf/MEK1–2/ERK1–2
2Responses
1–85
2.3–9
Co-Smad4
R192H
×fasting
13/15.5
GPCR-sensitive
sc-120AC
SMO8
CDC25
glycerol/PBS
//useast.ensembl.org/index.html
SBE4-luciferase
G596RBRAF
c.1717-23T
Py2-Luc
nonsense/frame‐shift
Morén
1.3–302
p.Pro648ThrfsX2
C636Y—found
p.K2fs
5–20-fold
prognosis,4
B-RafE600
67o
thiol-reactive
1:2
G203R
SQLE
GTCATC
modulate
50.3–51.7
F2,119
®ve
p-BABE
I179S
MUT9
FRAP/mTOR
0.088–11
fibroblasts23
12.3μL
o~.¢
RBP-Jκ
Ink4a/Arflox/+
physiological-like
t-butyl
NP_523240
8-oxoG
K1358E
controversial.44
laura.silvian
1-337
ANGPTL1
FLS
TTTG
L858R-L747S-EGFR
Fpg
BAC-clone
-Cre-ERT2
antibody-bound
5J–L
immunoresistance
penicillin/streptomycin-l-glutamine
73–77Δ
2,4-dinitrophenol
RETV804M/R844L
EHMT2
D715E
NOD/SCID
PT09.1
translocations9
p300-11A
FLT3.72
VEGF-D
FLT3mf4
Theile
Lys4l3
500kb
SNVs/indels
cells/spleen
subtilisin
Lineage−ckit+Sca1+
MDS-related
GGCGTTTGCTGGTGATGA
V-O
crizotinib.Previous
n=616
S2414L
t=5–7.5
S_pombe
DelPPGY
G1448R
V370A
CMV-TFAP2B
F5-III-1
L340A
mediated-apoptosis150
penicillin/streptomycin/fungizone
Dotatoc-PET
9/25
syndrome.9–11
Fcγ
A431
BESTFIT
hERG
G70D
C,1.6
exon-intron
TTCTACTC
bead-immobilized
bywild-type
Jb
AKT,21
4,3
UK6
Ishitobi
transactivation-independent
7q22.1
Phe788_Met789
deprivation-induced
Bucking-hamshire
7q34-36
Sporn
gp140S345
adeninenucleotide
4.27
S18Y
trichothiodystrophy
ankylodactyly
expressers.View
GS-690
5–60
M351
PTx
expression,45
32P-
.Kelch
BMS-354825-resistant
DNAH6
stem-cell-derived
4438-7665
exosome—might
.Systems
P42
MEB-MED-8S
replication-deficient
Lys320
0.0001d
Belmaaza
R83W
Axin2/conductin
FI.ophlois
R557P
10.1172/JCI41824DS1
counts/sec
0.58–0.89
TCC-3
6–wide
.790G
-0.152
RET/MEN2
FLAG-catC
transcriptionnal
Y341AC-RAF
nucleotide-substitution
22:1812—1819
A332V
..TGCAAGCAGCAGTGAggctggccgcctgcaggtggggcgcggcggggcccg-3
RFS-MycT58A/Wap-Cre
HA-c-Mpl
NP_000132.1
pCMViR‐TSC.21
717
Serl613Cys
iCCA17,18,19,20
complex.24
BFM
doi:10.1053/gast.2001.25515
Heul-Nieuwenhuijsen
16–90
Up-regulated
lactotroph
0,01
nonspecifically
MPRIP
MCCN
5'GACTACTACCAAGTT
.Erythroid
phosphoimaging
histone–DNA
glioblastomas4,5
sugar-nucleotide
PCC/PGL
PTK787/ZK222584
617-871-4000
non-sensitive
/highwire/powerpoint/117163
JR14
GSE38392
bicalutamide/kg/week
IPT-4
GILGFVFTL
p18/SIE
5′BRD4
expressionNIH3T3
AsxI1+/−
H3S28P
MPR-1
not26
lac
hormone–deprived
discernible
3.5:1
3Division
35and
K234E
ovo.Western
mutation-harboring
MEN1-mutation-positive
F4-II-5
S922
heparinised
​Fig.4B,4B
PTEN-K125E
Y559A
LAMA1
-ribosylpolymerase
GTCS
c.399_405delGGTCGAT
pan-acetylated
drug.Table
EGF–Dependent
ERBB2-N857S
Ets-binding
import/export
POUH
mesenchyme-inducer
.Neuregulin
12q14.1
PALB2-BRCA2-RAD51
func-
E189G
damage4
fusion–
genoccurs
STAT3-Y705
ΔT/ΔC
aetiologically
NCLL
p.Arg689Ala-XPF
84·2
Lys550→Ile
sive
0.2–3
integumentary
I36
bi-modal
IVS7^6G4A
Phe141
routineuse
CLTC105
TableIA
gagagagtcgactcaagggatttccatttctcttt
400–800
Phospho-Y705-STAT3
prognosis.13
~70kDa
4038–4044
.Pericentrin
n=558
1317
trk
double-negative
third-base
2.36-59.45Adjuvant
0.073
Gli-activating
Chk2,9,10
727X
Gln137
200521
E803
AACGGAGCTC
fibrosis
microfluidizer
0/1/1/0
C99S
anti-Max
Krasilnikov
AutoMACS
WNT_TARGETS
diamino-phenylindole-stained
CCB
Outeiro
.Amplification
neuroblastoma8,9
WT-D65A
U4C
equinovarus†
S354Q
.Tumour-xenograft
P1145L
c.178_198dup
N1-N4
Bedfort
risk-alleles
5′-CAGGCCCCATACAATTTGAT-3′
vitro85
S45F
0.19–24
c.1274T
MAGEC1
466–469
Taufkirchen/Germany
84798
Non-Abe
AKT
Growney
p.E1286V
.Jann
−3.23
p.Arg88Gln
~90
ZN506
Mcl-1
pUB6/V5-HisA
pancreati-tis
Type-B2
BCL6+/
Eggenschwiler
ERK-Thr202/Tyr204
CHD-related
~hydrolysis
G2565BA
16-month-old
IR-inducible
PI3Kα-driven
ACC-3
ethidium-bromide-stained
ΔBLISS
gene.20
TSC1-fl
repeat.23
2XSSC
B1-2
Ten-
Furitsu
0.032
mid-log
845-
nonpolymorphic
INK4D
33–35
Osx-Cre-
Iε
n-embedded
Hnfa1
CYP
23/48
1609A01
described.25
Y309C
residue.1,2
10:89:1
β-defensins.32
Petukhova
CAPS8
dithiothreitoland
stggse
Pml
selectivity3,19,20,21
.R26-Pik3caH1047R
.GST-mouse
ExoSap-It
neurofibromatosis-related
9/11/95
specific-risk
hypothesis-based
Mendiratta
14.55
HER2-HER3
L180P
-15R
Cys-1095
AP1-Luc
.Toward
non-PAX8
basally-phosphorylated
p.D594A
Wiman
methlyated
phospho-AktS473
c.265T
gene32
factor.3,4
159
Marquette1,2
phosphor-ERK
hemizygously-deleted
nM–10
edema-like
LEE011
800µg
TNS3–T323A
VEGFR-1
lineage.3
c.351dupA
Ell2
Y201X
ALK27
Hsap
BCL2A1
X20
c.308_310delTCT
p.Rl61Stop
MutSaThe
35.0
thiocyanate/phenol/
6/26
P138
.005§
SK-Mel-113
H3122EML4–ALKF1174L
enzymes/proteins.Up-regulation
E133G
orMRI
/ring
ligase-proficient
homo-FRET
PDGFR-alphaDelta8,9-expressing
R1147G
708Glu
.N-myc
Brca1SCo/D
p.N132
330C
pcDNA-3-transfected
M/E
AXIN2sample/AXIN2competitor
S251N-reconstituted
IFN-α-induced
2724-2701
FoxO-target
Glu713
cryoablation
FAM150A
olhcr
NOTCH1-Gal4
c.4530_4537delTGGCGACG
NZM9
12,614,233
pMSCV6-PGK/GFP
.005
and7C
μ-opioid
5′-caatcgatgagttgcttc-3′
R181A
0.8–6
1,17
FoxO3a-induced
5,450
cohorts–as
premammillary
G42V
immunobased
.S5–S8
transbronchial
thymidine-labeled
transcriptase-polymerase
PMI-Biot
GCATCGTTCACGCAGCTCTGGCGCCAGAGAAC
Lys-48
Time-lapse
8-mutated
.0032451
Hs01060665_g1
MARVELD1
40008544
Plaisir
lymphomas.10
CD43+
sequencing.15
Rbp
64/101
phospho-Ser-235/236
L362R
-5-isoquinolinesulfonamide
pan-negative
0.821
5′-TTC
Blood/bone
pGT3R59.A
CI1003
W28R
digestive
IRF8
4E132
.Two-Dimensional
activation.43Collectively
GAP1-dependent
mm3/day
Ras•NBD-GDP
AGVGD
Misprocessed
3020G
0.5-ml
n=49
Mononucleated
7,076
Dkk-1
A2325V
L16
NanoString-based
2.427
distinctions.Figure
Laurent-Puig
_4'i
anti-pT202
byimmunoblottingfor
anti-p-STAT3
Abbot
2401–4191
hematopoeisis
T1WI
Polybromo-1
lacZDM15
JAK2,8
1.5-28
columbia.edu
S354C
LightCycler-FastStart
Theidentification
Asp513Tyr
C'I
Asxl1+/–
CTCGCGTGTC
future-the
002728
4.5-7.9
disassembly-assembly
14,48
Gray-shaded
//mendel.standford.edu/SidowLab/
receptor-stimulated
Asp770_Asn771insAspGly
β1,6-N-acetylglucosaminyltransferaseV
p53-targets
yAG
Kurman
.Adhesion
NG_008466.1
BCL6+a
•HSC
.0095
InStat®
17,22
IFI44
BRAF-mutated
HBA1
Leu129
andlanes
_red
deletions34,35
8pll
p53−/−Rad50S/S
BSG024
a1.4-fold
1e–6
anti–pan-phospho-FGFR
NM_152344
simplification
microarray19
5D–E
tetra-
LN382
Lu2
//www.genome.umin.jp/
4q13
1012
MLL-MLLT3
9/82
TGFbetaRII
Neoplásicas
/0.08
anti-HA
565-0871
Errfi1–/–Egfrwa2/wa2
LB373
antihMSH2
differentiation.14
syndrome.31
G168-728
.Patch
fat-oxidative
CCCCG
self-hybridize
+3.2
growth.81,100
10/52
EcorV-Xho1
specimenwhere
S.V
IC50-based
interdependency
A76E
CGAGACTCCATCGCAAAAA
42193
pMD2G
7.Download
CARD11L232LI
religated
****
.R780K
from0
B-CPAP
nature.comCyclin
underappreciated
Firefly/Renilla
indolent84
tt-3′
76.8–83.2
ERK1P75L/ERK2P58L
21/34
Non-Responders
deadenylation
hagiwark
FMYe
H3T11
TÃŸR-Ithereby
L330R/P
phospho-Ser727
phoenix-Eco
homology-based
family.12
.Serine-threonine
Ellman
CIN−MSI−
carbon-based
PDE4B
retinaea
immunity2
T341P
STAT1.26
p15=0.061
lymphoid/myeloid
ARID1A/1B
β′
LPS695
FAA
Invitrogen/Molecular
NTS
LATS1-526-655-GST
23398
leukemia.24-26
NFE2L2—as
DHPLC-based
rad50L1240
analysis,9
values85
.Observations
5′-TTTTCCGTCATCGTCTTTCC-3′
co-occurrent
HXT7
sites.93
p21c-H-
carryingthis
algorithm19
autosequencer
T120A
31.4
GC-clamp
sets25
Myc-DDK-tag
KIT/
EM-CCD
∼7.2
nonionic
CL/P
±9.0
PARP-15
mRNA.TRK-T3
S612
S7G
PD-L2.3
retinamide
VariantsTSC2
CDKI
–driven
-AML
SigmaA
K371
TRCN0000010358
R762Q
.PKN
Pratcorona
sizeThe
Abdeladhim
E140K
Mg2+-coordination
apcluster
3-645
09-321
517-nm
3.Cyclin
Oum
TGA-3′
B-27
IVS7-34
Aberle
indigestion
assays±S.D
v-Ha-Ras/Rapl
sequencing.Retroviral
T73
peqGOLD
POLD1-exoR311H
anti-ETV5
c.IVS1+7C
TCAAGCTCGCCTGCTCTGAC
Fig1C
alpha-helices
595-Cys
HBCC
GATA3-deficient
//www.rbej.com/content/8/1/61/
ligand—that
PHC1
TKB
limiting167
.CDC37
KIAA0454
S3A–D
ATP1B2
malignancy.34,35
'BRCA1-like
Larizza
pBL4
52.44X
pcDNA3.1/HisC
Q176
mutations.18
7~7.6
shPten
−1,842
abdomenal
SACM1L
df=109.7
control.Molecular
.Raw-counts
25.62
earlier.27
wesubcloned
MUT
NM_006197.2
N-2-hydroxyethylpiperazine-N
V391I
K955
≤20
A504_Y505ins
17/37
p.Pro327GlnfsX8
Gautschi
FOPFlash
TAL2
GAAATATTTTGATTAATTTGTTATTTCTCCCTTTCCTTAGTGTAAGAGTATAATC
ESR1-Y537S
0.252
/NBT
genotype.28–32
D19S886
.C/EBPα
erythrophagocytosis
EN26
shRNA-Renilla
non-mutant
U-266
V843
genotype22
M–P
2117
L2511
CASP10-DEDs
nontranscriptional
92–792
c.295C
lymphopoiesis
36-year
.0103
925–928
749K
1D-E
Monzon
TGFBR1p.A230T
0.1511
ASB1
Nutri-Cal
Y142
NH4H2PO4
sites29
ESR1-Y537N
TP53-R274G
Ciovacco
V297M
P112L
XL139
Leu779
10.493
P.T790M
CD19-Cre
2264–2244
pro-tumoral
Delta250-258
Phe90
⌂K340N/T341del
gefitinib-induced
Thesubsequent
Flutamide
P=2.1
BT-PBS
FECEQKEENQGKNESNIKPVQTVNITAGFPVVGQKDKPVDNAKCSIKGGSRFCLSSQFRG
GRD
Lys-381
ABL1–RCSD1
radicicol
nab
2125–2137
c.8591G
.IPF
Glu599
Dnmt3-like
AAACCCAAGGAG
FTP-091
2005
kinases23,24
pJK101
semi-quantitatively
Myr-AKT
Webb/Thurston
18105
15.3714.0
1653
Cardiofaciocutaneous
E7del-expressing
p53.Mutants
P195L
NP_851355.2
MSCV-GFP
_464+
5027
JHU-028
Pe-Cy5.5
nologies
E.W
nihms646437f8.jpg
RCAS-generated
αERK1/2
32P-marked
Itzhar
GSE1245354
M26422
NEK6–RXRA
10.1021
apoptosis.9,10,18,19
I0/25/95
NiSO4
LATS2
3U7U
S84F
Rokman
NB1224-R2
69.49
2,000,000
leukaemia124
HD2
PIGN
1,010
.Adeno-associated
37Runx2+/−
TÃŸR-1gene
H435Y
.Δ559
Frs2-/-
C1036F
264
patients.64
AGF1
TTTTGAAGATGTTCTC-TAGC
Bcl-2
aagcattcctgtaaggact
P45*
C3564G
Lpt
.ID3
cGrantham
pCRAF
moleculesmight
CiteULike
difluoride-P
Scudierio
genes.94
GGGCACCA
69D6
LysM
transcriptionin
osteopenia,29
MDS.43
BRCA1wt
p=0.0817
alteredP53
AFF2
SHIP-2
451Lu
5'-CCATATATATCTACTTCAAAACAA-3
R555C
TβRough
flapase
C9100-13
114–178
premedication
5'CACGACGTTGTAAAACGAC3
A_51_P139978
4160
anti-Ris1
p55α
alpha1
N-acetyl
I843
V765insHH
HOXB2
2.93
5'-GCGCTGATAAACmATGGC-3
5′-TTCTCCGAACGTGTCACGT-3′
Atp2b3
activity147
Thr165Ile
intell
IL-26
intronic/UTR
anti-Tyr
andp
10E-4
H2122
C1483F/Y
Flemish
CGCTCCGTGGCCTTAGC
L39R
TRKC14
p57KIP1
Gierach
0.000930
∼15×
elegans46,52,55–57
Barila
AKT2/PKBβ
4Δset
NM_027979
fashion.23,24
SMARCA5–RACE.33
8,912
ofhMSH2.24-27
Mel202-mutant
RSPO3-PTPRK
miR-29c
19-74
PI3k/Akt
excretion/absorption
mutation,17
semi-denaturing
13S*
RMH2458
Meso-9
S135F
2.8:1
splenectomies
TNS3–ABD
HS.TE
1/1
PR=partial
W91X
.492C
75662
J-720
Mm.387080
anti-FLT3
mosaicisim
stringent
Merlin-Hippo
Hou-Qun
LSDB-centric
cells171
Cryostat
2×100bp
724
Toualbi
mutD+
AKT1-W80A
P26L
procedures.21
-Rev.
MEK-mutated
Akt2-GFP
370-375
Thr-38
Figure8
LADC10
n=58
//bioinf.uta.fi/PON-P
p21.9,14
p≤2×10−6
2.134
pGL3-RA
MEK1-transfected
XL647
pET-MTS1/ΔΔ9−144
0.846
.Sham-operated
great-aunts/uncles
Saller
biomarkers,5
140/90
HCLc
-to-aspartate
.Serendipitously
Dionex
FCSCOR=
α-enolase
H3K27me3-enriched
5′-TTGTGTACACCAGCCCAGACAG
DUS4L
bsheets
Izydorczyk
R445W
11q13.5-q14.1
15513A02
.Resynthesis
47-amino-acid
archaebacteria
I852F
34–40
​Differentially
ends–
TSG
twice15
ErbB4.23
R58X
_________________________________________
two-substrate
Seirei-mikatahara
E1511
TTGGAATTCATGACCATGACCCTCCACAC
aperture
1925–1930
Argani
preselection
reported.15
CPT-dependent
1.203
reestablished
*Significantly
Palmiter
p15q34
INPP4BR
II3
sterotactic
Y560F
.Yeast
Aszterbaum
MEK/ERK
1,496
non-related
correlation-
18.0–1.20
A132D
G12C-containing
AAGATGCTCAAGCGTAAGTTC
129SvEv
resistance-inducing
1862335
M1043
Rhodamine-coupled
.Reexamining
0.00406574
ZRSR2
1686
JAK2-mediated
.Akt-mediated
100.000
disorder12
S218E
Pten-null
phospho-S473-Akt1
protocols76,77
Retroperinoneal
anti-TRKA
gpl2O/gp95rks
cncr.v115
Ccnb1
pSTAT1
Elf-1
804â€
high-stage
anaccumulation
triple-mutant
Koland
multiubiquitinated
.PD0325901
39.G356A
102.9
BMX
program37
PI3-PI4
O'Hare
10–50-fold
Na2HP04
-free
ALL-relate
CTGGCCCTCAGCCCCGTCCTG
E118fs
Non-negative
Anczukow
BiBr49F
2.54
carcinomas74
Intraperitoneal
anti‑cancer
adhesion/extracellular
.Serrano
5'-ATCCTCCTTACTCATGGTCGGATC-3
1396–1778
64.4–69.8
prime-and-switch
.CMV-lacZ
-GGTAGGTGATGTTGACG
9mers
NICD3
CTAGTAGTAGCTGCCTAAGTG
Genta
HSC-39
Value*
0.176
10−5/s
140,016
5′-CTGGACACTTCGATGGAGAG-3′
3-alpha
.179A
TGF-beta/activin/BMP-2/4
Smolen
Researchdiets
GdmCl
G664R
KRAS.2–4
non-neutral
Rac/Rho
-GACTTTCAACTCTGTCTCCTT-3
p50/p65
MC/UP
.Thirty-eight
neuro-cardio-facial
delta–delta
ADH-p53
Esquela-Kerscher
mice/cell
Lipofectamine/PLUS
.Virally
KITWK557-8del
WIF-AAA
.Phase-contrast
p.Asp126His
1009C/A
Germline
-Biallelic
a-NTRK3
3-treated
ofLNCaP
4,7,17
pro-protein
22-bp
TRCN0000081778
L180
Ras/ERK1/2/ELK-1
MACROD2
PNT
chr12:42,694,068-42,878,307
report.3
FLAGASXL1
agents1
0.85*
Kalleisch–Prentice
database.19
mediated-
1,00
4-mL
T112
c.2212-
acetic-acid-solubilized
27/34
mlh1-deficient
TAF4
deubiquitylase
.0035
silencing-FOXL2
theHindIII/SacI
E7107
z-section
Calame
loss109
1109a
Arg689
no-mRNA
PIKE-L
Q1503P
mutation-inducing
organogenesis
G57A
TFAP2CΔC181
result~ng
0.1-1.0
11y
TumorPortal
E578G
RP1-261G23
I704L-mutant
JAK/STATs.15
BRCT1
pWZL
BOC-D-FMK
XhoI/BamHI
≈155
ERBB2-C17orf37-GRB7
234–780-fold
EcoRIBamHIsubfragment
Alvarez-Buylla
.Written
-3-benzimidazole-quinolinone
rac
pre-screened
gemcitabine/IP
iodinated
BRIP1-BRCA1
TA42T70T30T3IT65
Leu181
D404Gtet
anti-MSH6/GTBP
gastrointestinalcancers
.Notch1
dbSNP139
CTGAAGGACAAAGGTGACT
121.9
site—an
.1799T.A
Debatin
η
ATRA/chemotherapy
antifade
Rad51-IRIF
anti-STAT5a
p.R181C
lenti-virus
Ribo-zero
Kehrer-Sawatzki
Val659
E746-A750insQ
.Down
KrasLSL-G12D/p53flex7/flex7/Brca1flex2/flex2/Pdx1-cre
Verzijl
Westlund
P=1.4
32microglobulin
JM=juxtamembrane
RBS6KB1-VMP1
.Wright-Giemsa
c.239G4C
TIMP2
C56S
pAdTrack-CMV
Kannengiesser
Strieder
sc-29428
pT2-T4
SPNET
H-i
6-
receptor-triggered
β-catenin–binding
estimating/establishing
withintracellular
quantitation
differentiation38
p.Leu3X
1:800
EGFR/ALK
biomarkers—including
endometriod
α-pY
RelB
ptac-ras
KITamplified
S1733F
IDH1R132H/WT-mediated
96:215
Autoradiogram
αMODY
9Ai
.Object
Bromodomain-containing
BRCA1/2-deficient
3-casein
acttctgcctCTGcCtatttt
p110δKO/KO
Tsc1
0/3
HIV-LTR–IRES–GFP
2,266
.0214
unrelatedloci
A430V
Chi-square
.Lesions
Fig.11B
APN2
NM_004936
Steinheim
MEK-1/2
GGATGACGACG-3′
TrkAI/pcDNA3.1
changee
anti-BCL10
HSC3
development.37
VEGFA129
S-M.H
far-UV
p16INK4a-CDK6
lymphoma–germline
L46R
Asxl1–/–
N377
inhibition-free
K13
activatory/inhibitory
C287Y
Raswt·GppNp
510515
loxP-targeted
EBNALP
al43
L440P
resistance.Phosphorylation
Yongon-dong
K25020
TRX/MLL
under-estimate
Lucito
kinases.22-24
GGACTG/gtaagt
c.3260C
monomethylase
Invitrogen-Dynal
M20
TRCN0000196951
reaction.36,38,44
RET-induced
CSP
phosphatase-dependent
se.I7
lines65
p3X-Flag-U2AF1
GISTs.Figure
reported33
EBP-induced
5′MIR143
p53RE–hCMV2
brusatol
SRF-VP16
MAFd
granulocytes.4,5
brm
msh2-VD858p
.Sox2active
MLN8537
∼14.5
1.8360
mammals.28
.Cutoffs
ELN
Thr356
intralumenal
mutations.73
snps.shtml
Skip1-Cull-F-box
F.M
parieto-occipital
EGF-induced
926
Garriga
S191N
MDS-AML/secondary
.Pol
CAT3TAT
FBXW7-dependent
3T
described.15,16
Double-strand
.HEK-Jak2
WMALE
RUNX1-ZNF687
Phred-scaled
ophthalmopathy
880B6
RBM10–RNA
p.Glu203Lys
FGFR-related
34–39
p.Pro938Arg
AGTTGGAGTAAATATGATTGGTG
A*2308N
En-binding
.Fitoussi
f32m
myr-R25C
//mct.aacrjournals.org/content/molcanther/12/2/220/F3.large.jpg
miR-451
.Z-stack
09-473
RefSeq86
Matsuguchi
c.1651G
.Comprehensive
M1040V
Thr→Met
TV1GFP-tagged
Y-MESO-22
ste11
material7
R441P
EBC-1-shPAK1
B24
L30
HEK293FT
3.426
TCCCTGGAAAGGTCAACATC
10.3892/or_00000096
99–106
cellsare
MGC:27821
thegastrointestinal
msh2-GD693-AE859p–Msh6p
K62R-PTEN
6p25-p21
KPT-330-resistant
strain20
pCAL2
ligand-associated
LinesSNU-1
checkpoint54
mice139
GAP-Ras
4A–D
672–964
JAK2V617-expressing
rs1126497
GC-Relatives
GGCTCAATTT-3′
Yap-induced
R58G
Discoverx
Craf+/+
7C-D
9-119
8,342
30/36
immunophilin
P991L
//www.csie.ntu.edu.tw/∼cjlin/libsvm/
-ΔPDZSPA-1
DIG-labeled
β-catenin–Tcf/Lef
Lin28B
Sertoli
p=0.04
cases.Multiple
mg/kg/dose
South-Eastern
.Basal
β-barrel
recombinants18
gratuitous
encodingVEGFR1
.Incubations
N1643S
Y487H
G242E
G40R
MTN
C356R
dye-exclusion
5DW
Destabilize
glioblastomas78
TDLU
4′,6-diamidino-2-phenylindole-2-hydrochloride
NZM34
−22q
so-ca
A669T
type-related
Tnf-α–mediated
G319E
CD27+IgDB-cell
over-call
hexaduplicate
RVFEAITKSADRCPKVLCQI
.MICROARRAY
Shaag
low/no
Pten-depleted
29In-frame
10−33
354
proline-encoding
Brca1Co/Co
ATRX-Rluc
Gamma-variate
tumor-adjacent
719*
.Basic
642–643
2511
re-sampling
only.thumbnail
CDK19
84K
dexamethasone6
M2-peroxidase
2176
1483
5′-CGCCAATTAACCCTGATTAC-3′
0.2°C/sec
cells.9,10,13,14
Val600
MIEG3–EWSR1–SMARCA5
RCC47
mutagen-induced
anti-B-catenin
al35
cysteine/methionine
MYO6
c.383G→T
LSD2
sites11
α-FLAG
.LDI-PCR
treatment/withdrawal
Previously,11
domain.Previous
multimerization
Hf
Tyr-675
MKP-2+/+
cancer.11
1415–1538
rs1379917
pVL1393-HA-TRAP220
.Endomucin
therapeutics.2
Ago-miRNA-containing
GFP+lin−ckit+Sca+CD34−
Ba/F3-FLT3
0–90.2
R6873
promoter21
S.1
47
Ao
D121Y
13,15,17
3.676
T790M/E746_A750del
1cells
248−bp
VRAP
.Methylated
emerged36
53/250
per-variant
high-fat-fed
nutrient-deprived
KPβ-Y612A
14.3
3beta-mediated
thereof.32,33
chaperone-substrate
whetherthe
HIST1H1
1989a
tg/mlpepstatin
protrude
UKE-1
Cytokeratin
cDNAprobe
.Vaco481
KCN1
3.1.
pre–B-cell
Crosslinked
gliomas27
Fakhari
~10–40
rac-GAP
respectively.7-12
Y285A
aminoglycosides
MAML
NMC.26,27
C-pure
AmpliChip
LiFraumeni-like
antigen-driven
complex64
–1.72
ml/m2
S6.1.1
andnot
proliferation42
producedby
1.224−2.990
Pao
C1408Y
p.Y823D
RACE2-AP1
8857
CEACAM1
Y98F
auto-phosphate
pEGFP-ERF
AMP-binding
carcinogen‐induced
Erg+/+
T1977S
opportunistic
HERmark
Toualbi-Abed
dtuveson
1/F-box
myristoylation-defective
testing107
22-translocation
MM29
Npm3
1ns
jaw25
rnberg
2.49E
Inohara
.Promoter
protein–inhibitor
mevalonate
Neutropenia
a2tk
Overexpression
SPIEKERMANN
pSK+
RBM10/RNA
Fredlund
hyperphotosensitivity
SDC1
brachycephalic
TGGCT
31–34
MDC1.A
c.4987-5T
Schlingemann
DNA/lipid
Ras10
GF68
PI3K/mTOR/S6K
wavy-shaped
G5434
5′-GGCGCCGCTGTACTGGAGCTTTAGT-3′
Hakak
dsRed
myelofibrosis.3
glycerol-1
rhodamine-conjugated
SMURF-mediated
PI3-AKT
phenylmethylsulfyl
3255
recredentialed
Glu-33-.His
thromboplastine/Ca2+
hGFAP-cre+
5′-CCTTCACCAACGAGCCCACAGATCAACTG-3′
-b
c-Myc
EGFR-Δ747-753insS
R58Q
K3
leukaemias.1
A750InsP
SQY
murinegene
47,560
outcome.1–3
F–J
NUP98-fusion-mediated
D1-T286A-induced
RAEB/RAEB-t
a-IR3
.ID
ALL-9
117.5×
P577H
ZEB1
Ki-67/Hoechst
Nano-HPLC
158KB
formation.1
Nar1yKpnI
SCCOHTsmall
I198N
Cwere
gDNA-based
c.715G4A
N3/Ndelta
IDH-mediated
TFA16b
asthe
.Score
97-102
Rad51-mediated
enzyme–ATP
.D–G
603
Asp194Ala
1623–1629
H1299/vector
crosslinks
uncertain.Tumor
.LCM-purified
thenbe
pathway-directed
5′-GGTCAGTCCGTGCCCCAAG-3′
.189C
120-min
3.2-cm2
−1.23
obese
RASmut
1376
pLenti6/UbC/HA-AKT3
852g5
RP24-462C10
L681-I682insTPYEGMPGH=2537del-T-ins-GACCCCCTACGAGGGTATGCCTGGTCAC
described56
desaturase-1
54–134
Papakonstanti
-primers
Sin1
S30
Ser53′
3.5−kb
1,552
cagagagatcgaaatccaggc
erlotinib.60,61
ABHD2
.Thr323
p.Val134fs
NZM21
genome—which
T364M
ACTTCACAGCCCTGCGTAAAC
Flag-MLL-expressing
3RBN
3,5,6
real-time–PCR
DMSO-/KPT-185-treated
2076C/T
cancer-predisposition
1999c
rs997669
IDH115
GSE21653
.Arbitrary
295-298
sub-set
Inactivationand
40ºC
tissue.Deparaffinized
pCMV-Tag3
pathway.7,26
18q12.1–q23
.Tam
8.87
Tissue-Tek
12.00
rs56183713
STA-NB
Peltomäki
n=2/11
sites/consensus
JQ1-treated
Y412F
Non-HNPCC
46,49
E3800
nature.comShe
cells–despite
detected,18
CAGGAAACAGCTATGACCGCAAATATCTTTTATCACAT
Immobilon-FL
465/470
KSR2–MEK1
G12D–induced
Z-vad-fmk
68331751
heavy-
tumor-derived
AML8
8.5–24.0
14–15
79.98
Asp57-OD1
Urbanska
non-DBP
hor
palate.2
NSCLC.68
Resveratrol
`signalability
vorinostat+cis-RA
G258E
O073
brahma-related
T288
mammaires
polyubiquitylated
fibroblasts17
cSCCs
.Figure.6
Trrific
SFTA3
PPAT
Elf3Δ237–241
pY
Unfractionated
Ohkawa
guidelines,23
merchanj
â€¢0
12q12–q13
–0.821
.22
machine-based
MAb30
cancers,24
6/242
32.20
insertions3,7
NCT00135005
37-59
K382N
neuroblastoma151
S240G
P194H
theshortest
E95
15,19,20,26
representedby
adisruption
N2781I
FGFR2bY376C
photobleachings
y2
GTP-dependentsignal
bicistron
E5-transforming
165-kDa
suppressed.103
Thispercentage
.Home
c.553C
-UTRs
UBE2O
1:1500
RII-deficient
10·2
-extended
p85α-knockout
ASP-3026
CLL21
radiologi
biologic/immunotherapy
urcc_mskcc
anti-MED4
andsequenced
WiCell
755–759
XTCF3
Nutlin-3a
Concentration-dependent
situation.Table
Golgi-based
TALLMO
M24580
metatases
P=0.003
78-bp
Ade
Cell-virus
2/40.0
97-101
formimide
E1A-associated
question.18
635/636
PTPN12
Hamakawa1,4
M1123
CACTGG-3′
SV2855
rpsL
treatmentwas
53
.Wu
//genomequebec.mcgill.ca/publications/pastinen
p385
tier-4
E719K/E719G
R694Q
andp53
mTOR1
.IZKF1
.0–.07
1136–1143
1864
39185delAG
CENP-C-associated
pDM18
30/54
cancer7
analyses34
correction—was
study§
Gauducheau
10249
B-RAFi/MEKi
K6N
Cortisol
.Favoring
K35N
TEV-protease
n=32
I/Class
Cytoskeletal
Microsatellite-based
sites1–14
c.1918CT
.Brains
KAEFCNKSKQPGLARSQHNRWAGSKETCNDRRTPSTEKKVDLNADPLCERKEWNKQKLPC
PolyPhred16
FRMD6
S249C
THZ1
S2A-E
792
SUP-M2
CHK2**
Asp304
AAAAAG
888
M026
Cross-validation
amplificationpositive
VHL-Y112H
39.7
hMutLa-complemented
DBD
nihms646437f6
,11
p110αΔ/Δ
B9
D10S191
bridizing
28,41,296,462
proposed.4,20
p.G165R
454–467
lymphomatoid
P533S
D92V
X12B
CCL1-CXCR2
MEB
H226
Nilsen
papillomatous
M1/70-PE
washed.To
neuroblastoma.Figure
12:0
arms—erlotinib
andprokaryotic
5+5
Thr785
.Kozak
R2=0.61
-loop
Skopelitou
DSH
207.44
antiphospho-threonine
S6K2-dependent
kinases.1-3
FBW7-deficient
43,44
5'-TTAGTCACTGGCAGCAACAG-3
cells.2,3
recommencing
S-transferase-GATA-3
Q772X
GAL4-TFAP2CΔC413
F576L
Dicer1fl9
H70R
pCB6-p53
BE386005
DMEM/0.5
2066
reactionmixtures
5,11
double-PHD
necrotizing
vitro-coupled
telangiectatica
osteocalcin+
rescreened
sub-clusters
genome-coordinate
84.1
early-intermediate
BCP-ALL.40
JAK-activating
AGCAGCAGTAGTGGTCCTCG
acidat
AML61
0.67–1.40
0.255
1274
rate-limited
thelength
R183C
Ser553
mRNA-
T552M
E2–20K
NS/S
Y112N
1.146
Yanai
β-domains
5'GTTAAAATTCCCGTCGCTATC3
A254
discoordination
Jagadeeswaran
KDR
425bp
GimC/prefoldin
cancers2,3
KITD816V/Y/N/H
pinkish-yellowish
.Coinjection
retroviral-based
Hyp
pre-dimerized
5′-CAAGCTTTAATTAGCTTAACACA-3′
AGGAGAC
2108T
H3K27ac
310F
proteostatic
300068
Gly248
generations.Figure
anti-PY99
myeloid–Nervy–DEAF-1
DSCAML1
MIM1145000
acetylene
Asn-210
MSP/MST-1,37
telomeres.15
defined7
rare57
humans,24
AIB3
Akt-Sepharose
F1/R1
AKT-mediated
14q12–13
protein-synthesis–blocking
A563T
0.7371542
interactions8
.Emergence
11-wk-old
v137
EWS/CREB1
Genomatix®
.Gelatin
1256–1273
p.T232P
ICRF-193-induced
Gln564His
Decitabine
Val655
L310P
45-49
C/p.G114R
apoptosis.39
.EGFR
Defauw
Benchmark™
Yes1751
R282W
A–CDK2
CDKN2
un-related
041170
5′-CAUGGUAGUCACUAACAUAdTdT-3′
Skenoid
**Indicate
pnas.1321155111i4.jpg
pseudohypoxic
aNo
leupeptine
KRAS-1F
maladaptive
3391A
ADARB2
1/0/0/0
Full-CFL/NFL-SH2-SH2
KMT2C/KMT2D-dependent
antiphospho–GSK
49,57
CK18+
p26124
KRTLEESNSGPLMKKHRR
anti-NUP214
expression.6
W515L
pan-AKT
CD44+CD24–
orthavanadate
deaminating
C16
1559-1863
PDK1/Akt2
JB12027
PP2A-B56gamma
CAATCCCTGCCCCGGTTCATCCTGCAGGAGCTCATGGCGGG
K675R–hMSH6
≈5
instability,18
.S8A–S8D
F1098
6597
R869
0/11
.G–J
HCT116BRMrnai
J112
gplljPF'-t
c.4280_4281delTC
1p/19-codeleted
GGGTCG-3
.Chi-squared
AAAAAATCCCAACCATAACAAAATTT
5A–5B
.Anchorage
c.3903T
.IL-34
.Hindbrain
.TCRVβ3
andnucleus
-ctggcagcagggaaacatc
ERAP1
5mg
T202-Y204
.BMS-345541
CCGGC
theamplified
L688Pa
1E6
Bargteheide
amyloid-β
Gilbertsville
clear.10,11
Tetraploidization
Val769_Asp770insGlyVal
IL-7Rα+
COMBI-v
G219-1129
S53343
sub-band
endometriosis-related
L1cam
E24–25
-0.449
32–78
110,000-Da
1/481
Chx
ultrasonography
lower88
AMP-PNP
sCMOS
KCNC2
.HA-Fbw7
N236S
N589
FREEC
trinucleotides
diebefore
Β
tolerable144
TFIIH
proliferation.32-34
months133
10C4.1-mouse
17/41
HNPCC-suspected
EGFR-T766M
lipidation
dut-
12ql3-14
syndrome-
305×108
R655H
pac-transduced
528T
Prednisone
resistance.19,21
activated-Notch1
II-arrested
∼34,000
HPV-66
Riedasch
.Gsα
hFig-19
Tzatsos
binding.40
kinases44
Furuno
limb-sparing
108122
c.2603+5G
malignancies19
Q615*
G1block.2
syndrome,17
A127P
Y1699C
p.R273G
All-AQ
1.07–2.24
cullin-
SDS-PAGEprofile
S.C
aatcctga/GGAAGA
4-mm-thicksections
space41
doi:10.1186/s13073-016-0366-0
gtgagtgct
Liquiscint
RD-binding
20/57
CDKN2A/CDKN2C–codeleted
Institute-Frederick
NRP2
biochemical/mechanistic
study16
meningococcal
microsat-
p=0.425
.I1171N
129S4Sv/Jae
non-participation
NIBPL
=ΔGbind
Thr
80.754
doi:10.1371/journal.pone.0025021.g005
PN4–5
CD-1-Hfh11-nu
Srinvasan
DISCUSSION•
1.5-
10–2
sc-46
F615
FH-WT
V5/His-tag
phoshopeptides
TRAILR3
C–codeleted
Matrigel-containing
red/orange
Neuroanatomical
C620Y-expressing
r'g
KRAS/BRAF/ERK/MAPK
.5A
repeats.32
A149C
OR51E2-ETV1
Drug-sensitivity
activity63
1705:121–132
39-end
−1593
indexMost
locations.Table
T422A
Fig.S1C-D
Zhang1
analyzed17
BAF180
glycol
Selleckem
114X
71-2
corticosterone-induced
0.5.9.22
METT992I
Sjostrom
del11q23
HIF-2a
CreF
GST-THD/DeltaC4
0.0000001
150mg/day
AGTGAAGAACAGTCCAGACTG
//www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1
T1561IR
phosphoserine
p70-S6Kinase-
Gene-Drug
6170
5Short
Vassilev
Keff
anchorage-independently
Dynlacht
3.90
282.The
structures36
L858/T790
6,721
P1675L
reproducibility
11718
NM_009772
population-
11q12.3
4058–4061
2.1–7.2
'loss
pg/mi
Stoffel
CPP-ACP-enhanced
Xq23–24
apoptosis-inhibitory
Two-stage
Sprouty
E87Q
J44T
leukoreduced
R41W
293T17
MKK6-dependent
-794
N817
S9A–S9D
stage.Validation
167-183
R383X
concentration–time
10Gly11
locus.9
crossvalidated
K2100
P200
5′-CTTGTGGCAAATGCCCTTAT-3′
rapalog-based
V4115.50
kSD
MIP-2
pcDNA3-FLAG-RKIP
18869â€
case,8
Nucleofactor
.Increasing
non-BRCA1/2
NP_644805.1
lipofectamine-PLUS
CAATTTCATCGGGATTGGCAG-3′
.Kazuto
10/43.5
ATRXDNMT3-DNMT3L
sample/cell
1019
muta-tions
www.stanford.edu
uSo
mutations—R461I
Spi-1B
Sev
FANCJ.11
c.1870C
571656
RTK-V
18,950
Tishkoff
Cà
A_52_P329207
5'-GTTAGACAATTATCCTCCCT-3
overload-induced
10–13
E14K
λTriplEx
±0.45
MIBG
56.2
dDeletion
CTGCTTGATGGTGTGGAAGA
358-9-19126677
N49
outlier7
www.predictprotein.org/
destabilizing
ruses
crl
promyelogeneous
fresh-frozen
.Dupuis-Girod
40×
38NTRK1
17p13.3–p13.2
3500–4000
MAR-1
Y11
W380
0.007433/s
Magrassi
deletion-mediated
PLC-g-mediated
.Cloned
16,17,18,19
elementPhase
5′-AAAAAATCCCAACCATAACAAAATTT-3′
.GV-1001
ities
phase-specific
65,150
−803
trimethylating
bedtools
V2291I
4322288
nongenotropic
DuetTM/BioView
deconvolute
ALK-TKI-resistant
BLPDs
SUPM2R1
ht1/ht2–4
FHL1-Smad
NUMB.9
JAK2mu
700C
FA-BRCA
kJ/mol
CSL-dependent
Poyraz
1050
.Approximately
three-level
pLVX-IRES
ElonginC
CXCR7
GSP1
pH-rate
DOCK1
4.13
Lys12043,44
dithiobispropionimidate
15–19,23–25
CCDC6
Cente
500ng/mL
c.1799_1800TG
Immunblotting
TM-cytosolic
anti-CD95
MYCN-bound
cmrhth
mucus-secreting
QIN
squamous-
.Bolag
27/CRC
best-established
1996c
imatinib.33
K632M
K196Q
.ELF3
oligoarticular
LBD-agonist
15,13
57034
pTK-βREX2-Luc
ura3-1
2,714
.Responses
Ala-76→Glu
V239I
7.3+
ALKF1174I
semi-automatic
cosegregated
013302
13733
null-control
~according
Morphology
7383
transcription-1
DuPont/NEN
A3V
Sf3b1/Sap-155
Antisense-E1AF
PALA-resistant
Boveri
trastuzumab/pertuzumab
GammaBinding
CAGCAACATCTCTCTTTGCAC
Wellbrock
.Hamilton
L692P
T202∕Y204
10.1038/ncomms7025
6-carboxytetramethylrhodamine
767–769
γ-globin
CGATTCCCGGGGTATGCAGATCTTCGTC
3.Download
CD45–
127,382
Inc./Invitrogen
pFRS2
DMV
IRS-EN
visualised
G-double
pGEX6P3-PTEN-WT
Roddam
CantoII
5'-GCAGCAGCCATCAGGTATT-3
ethnicity-adjusted
RP24–462C10
1/21
PIK-E9OR
5´-ACCAGGTGCTATATATTGCC-3´
BRAF-concurrent
fromradiolabeled
pcDNA3-based
Δ237_242
1.19-14.1
two-stranded
Yoshida2,3,22
FGF-FGFR
16HBE14o
long-latency
c.−26G→A
2,086†
alectinib-refractory
RARS/-T12
5-TAGAAGCAGCAGAGGAGAACC-3′
471–1095
Korpanty
L12F
712R
BRCA2−/−-specific
MLH1-PRO2F
17.42
1814A
Ly
L1036Q
Boettger
596C23
DLD1-WT
N1046
g/mlhygromycin
WT/F1174L
Micronuclei
protein/Ezrin/Radixin/Moesin
H/D
0.123
Thr/Pro
Benjamini
98.9
Q718Q
D442N
MATH-SBCs
Likelihood-ratio
BRAF+PIK3CA
inhibitor-insensitive
1,293
5′-CACCAGTT
‡NIH
-labeled
Longati
8p11.2-8p12
andpCUB14
.Gary
t-AML
anti-HSV
1C-1D
38398
cystadenocarcinoma
-CATGCCAAATTAGTGCAGGA-3
tight-junctions
High-Resolution
IRF-dependent
cyclin-dependent-kinase-inhibitor
terminus57
L1152P
ichthyosis-like
c.538-478_705+456del
GST-KIT
I706I
cytomegalovirus
5′-GGTTTCAAATGCATCTGTAGACTACCG-3′
L858R-EGFR.39
iSCRIPT
ELAVL2
proteins.FGFR1
∼12
TAL1+/T-ALL
16–21a
Endometrioid
www.ncbi.nlm.nih.gov/blast
L858F
14-20
identiﬁed
nucleo-cytoplasm
3e–f
FSE-IR
ALK3
Y598C1.
aResults
MEST
EXO-SAP-IT
CUE
TCGAGCCCCAGCCAAAGAAGAAACCAG-3
uptake
.Thirty-four
G12D/R
melanomas5,6
LargeCell
.RWPE
43-347
RAF-265
actuarial
NM_008655
S-cdk4/R24C
8.59
P1082L
lncRNAs
RbR661W
3H/14C
12/29
investigation4
0.2231
ARWT
Nesp1
anti-VE-cadherin
humans.49-61
Ark
growth,43of
Analyzer—Applied
|partial
EAY236
DNA/histone
10ug/mL
I843.16
F876L/T877A
mMMgCI2
579/444
SLC20A2
anti-IL-6
2+8
I/B
BAF250a
erythoid
109
5′-GCGGATCCTCAGTAGTGGCTGTGGGGGAT-3′
c.2445+30A
FACSDivia
ENumber
anoikis
top53-responsive
WNT-2
c.1464delC
WKY/NCrj
spinosolitary
tumours10
MutSig32
proline-stretch
codependencies
formuations
FLT3-ITD-negative
CTM-2993724
1.58/2.62
phospho-ERK1/2
Y276C
pTSAd
SDS-Sample
mycn
EIF4G
R39
CD69−
pGEX-1
.GST-PAK1-
7951
Fbw7-induced
neu/Her2
IKK-α/β
5/
-CCATGAGTACGTATTTTGAAACTC-3
β-2-microglobulin
DESeq2
Cancer.15
S531T
AII_2
3149
EGFR/ErbB4
Raf1+/L613V
p.Leu481Phe
trans-hydroxy-tamoxifen
AB_10864110
Q99L
H151D
tumor.11
Smad3dex8/dex8
HCC13
Leitz
lung14
re-escalated
DXfor
Tyr740
G711
0.000*
HRG-induced
CACTGATGTCAAACTTCTCGATT
Qukbec.-*Alameda
RETA883F
.Thiele
non-staining
previously5,6
CAGCATTTGGAGGGAGCA
MGH051
0–8.5
G271R
CRISPR-mediated
c.1389_1390del2
FG0067
adnexa
365K
HMGD
rareKIT
.Half-lives
.TNRC6A
SAS14
30/382
however.14
4-fluoro-phenyl
Ser-to-Ala
.Ki-67
γ-K832R1/γ-K832R2
604439
nomenclatures
RCC-1
3′-Diaminobenzidine
IGS
mutaion/ref
.Measured
emphasise
glucoraphanin
NCL-p53-CM5p
PSAP
pI-12
C32mel
subfertility
MRE02
Neu-expressing
1–383
CAAGT
results.Figure
I947
906-915
FBXW7,7
3391
Src/c-Abl
//www.anatomic
BACKENDORF
.7806
S=R683S
13/17
ccttgagccctaagagcagat
4,556
NCT01522469
3.23×106
DNA-sequence
Sf3b1+/K700E_SJL
end-bud
heterozygositySWI/SNFSWItch/Sucrose
shFGFR2
ALL.10
non-KRAS-amplified
PMS134
damage-mediated
UGT1A6
1σ
S6.2
ARHGEF25
Phe57
78.08
Lentiviral-transfected
Dep-1
mutationalanalysis
Hoeppner
acquistion
serines.Finally
kinase/mTOR
4374G
OCI-Ly8
NPS-1034-treated
.S3E
subcutaneously
CD2p13
9,10
TAFII68
CK5-negative
resistance-encoding
γ-phosphate3
3045
leukemia51
proline-to-arginine
–60
Akt21-GFP
MutLα
A1519T
.BRM
572
L76P
development47
c-Ha-ras
GMP–regulated
PTPρ-ΔMAM
MediaCybernetics
E540X
aData
4A-R
retinoid-induced
Smad2-Smad3-Smad4
nonsynonomous
K100E
ADAM33
p27Y88F
foci-positive
G-banding.22
CCGACTTCAAATGTGTGC
S186Y
=No
0.03a
DNA-human
kh
Notch-RBP-J
stage,101,102
mutation.10
L1460
J.C
BRAFi+AKTi
g-6400
ameliorate
17.R337C
553730
2q32
tp53
HPSG
CD19+/CD5+
-potrk
GSDML
c.931C
lineagecommitted
1595
815
nlacZ/nGFP
G639R
6.81
1/19
FLJ21274
.HA-ERK1-
.Mutation-specific
K1150R
playsan
NFkB2-ROS1-mediated
treatment97
P251A
gations
62–78
1.9Mb
Polylinker
1.28-fold
SVM
HCl/0.5
HGA19
toprevent
p.A339Sfs*4
49,000
Wajapeyee
Waldenström
mPileup
.5–7
gel-isolated
C57Bl6
FIG–ROS–S
ASC-2−/−
0.301052459
PAX5
4.51
S348I
1.402
.Test
PBMNCs
7:22
checker-board
behaviour77
considered.33
cancerinducing
cryoprotectants
β-loops
.c-KIT
GGGCCTGAGGTGTCCTGTCT
CDK2-Cyclin
stop'71
immunoprecipiation
tumors29
V842I
EXomeFuse
L880
Zeiss710
Socs1
GCC-*GAC
Gln2714ter
leukemia-unaffected
c-CBL-binding
c.5607C
9377
.LADC
5359
GGTACATGCACA
non-leukemic
gplloProto-rr
HerceptTest
.Neuroepithelial
4Dd1
al.6For
G0/G1-S
DKView
NM_016187
Ba/F3-ERBB2
HEK293/
anti-APO-1
PI3K,29
//bioweb.pasteur.fr/seqanal/interfaces/clustalw-simple.htmls
MEKEE
identification12
TTCACGAATTCAGGGGGAAGGGCAGGGAGTA
32/51
NUT-stimulated
Boi
hypoinsulinemic
COO
PanIN-3
condensation12,20
autophagy.1
5′-TGGAGCGATCGCGTCACCGGCCCATC-3′
U266
category-specific
TTTTCTTTGAAGGCAAATGGTAA
149
p.H531N
wellbeing
Ab‐3
log2Cy5
promoter/reporter
GCTGCAATCTCCTCCCTGAA
bones.8
_7_¶A.C.D5._____________rIC
Tyr.not
HEB−/−
R106W
system.31
14.24
.Retrospective
prednisone-treated
disease62
PtInsP3
differenFig
2–12
GeneArray
9753
guanine-contacting
5-TGGAGCCAAATGCTGACATGA-3
p.G23D
post-transplantation
IIA6B17
TNF-mediated
Y226C
GISTit
treated/ACTIN
NCT01670877
substitutions.25,26
pimozide-mediated
RB1Leu607Ile-V5
Hernandez-Hoyos
P539H
non-cutaneous
.B41
16·0–32·1
120/127
high-mannose
turbid
doxycycline-treated
p110βΔ
Ser-Ala-Lys
FANCONI
15-mm
L381P
Frameshifts
T203R
Jurkatt
ERK-induced
time-and
Y254C
T0
208891_at
E/A-CDK2
99.963
.STAT5
Wt-MetBaF3
BacMAM
JAK2617F-mutation
normoglycemic
17-yr-old
5¶-TACGATGTGGAAACAGAGACGTGGACTTTCGTA-3¶
145,000
−16
age-adjusted
approx2.5
2J0M
proapoptosis
5mCpC-DNA
RhoA‐GTP
ag-3′
ZM-negative
Xrcc3
AACAGCACAAATAAAACAGTCCAG
S2Gg1
.Leukemia/lymphoma
less-active
IL-6/ml
2B–I
Herceptest
crizotinib-induced
189–198
Zn-coordinating
phenotype75
`minichromosomes
C81–C96
.values
E746_I759
CCTCAACGAGTGCTTCAT-30
2p24
mid-high
GGCCTTCAACCACTATCTCAGTGCAATGG-3′
MYELODYSPLASTIC
.24
kbNTRK1
beadchips
M.O.
AR-HIES
KIT-D816V-transduced
pro-teins
CFP-peptide
Ham-
Flt3-Y599F
p27Kip1.2,3
phospho-T
MO25α-STRADα
rified
GGC3GAC
SOS
sucralfate
2138–2141
CID15
12–16
±6.5
1958
NOTCH1/FBW7
*2
declinein
Werken
gefitinib-resitant
dox-inducible
CCCTC-binding
WACA
LWL
8574
suppression15
Wnt/
TGF-β1/Smad3
Nordion
promoters/enhancers
dCOMPASS
W406
7/107
10–113
557–558
described,16
6,369
G184E
cRSS2
c/c→c/g
Mitogen-activated
LKB1-deficient
NETN
P.K745Eb
31398
antialkaline
2–235
67C
METΔ14
5-3
mechanismby
Ras-RAF-MEK-ERK
E10.0GLIS1Likely
2R4S
v-Ha-Ras-transformed
surgery.9
c.4987-
LT1
others.12,17,18
GAACCGCGGCACAACCATGACTGAATATAAACTTGTGGTAG
.Endpoints
Hayslip
DACH2
TE-1
0279
cccactgtctaaaaaaaaat
Lipid
F35
XAR5
510_917del
Pro772_His773insAspProHis
pMSCV
23.7–33.0
E550
ORER+
.Otx2
EP823Y
LS-related
BLI
M128TR9
expression13
Arg-282
11–52
biotechnological
dual-luciferase
IVS39
RYR2
Pacios
D13MIT139
Somatically-acquired
Digestions—Full-length
ETV6/CDX2
tudor
T67
add-in
.Metzelaar-Blok
Rosa+/CreERT2Atm+/C
pcDNA3.1-CBFβ
RAF-CRY2
TGGTGTCTCTAGTTCTGG
BRCA2/exon10
fermentation
0.09–0.33
7054
hairpin-processing
.M.uteus
__Y505ins
antiphosphothreonine/tyrosine
L655H
c.35G4C
N140A
3,250
Ponatinib-BCR-ABL
his790
obste
-I867S
E1214A
Tyr518/Tyr519
5′GATTATACTCTTACACTAAGGAAAGGGAGAAATAACAAATTAATCAAAATATTTC
non-vertebrate
CpG-sites
GTG-3
GCACTAGGCGCAGTTGTGTA
13,14,53
neoactive
1.67∼2.37
forward-acting
a-32P
S35-dATP
CDK6-dependent
L107R
Shinshu
StemPro-34
andblue
PC14
KRASG13D/PIK3CA
PC-9
KDM5D
Tyr45
GISTs.8
ΔS45
CAUC1
20/18
3/1,062
Brooks,1983
Mlh1/Pms1
al.,2011
Sos1+/E846K
c.1617delC
anti-human-NRF2
c-Jun-positive
MEKK1/pCMV5
H3K36Me1
127,449
K128T
PIK3CAWT
FoxO1-transgenic
apoptosis.12
DBZ
pMEK/RAF1
RBM6/RNA
//www.broad.mit.edu/rnai/trc/lib
patients.29,31,33
K79E
13-15-26-A-08-A-24
octapeptide
I575
250,000,000
ETS-targeted
A633V
TGTGGGAGTTAAGTAAGAACT-3′
infiltrates.4,5
PI3K/Akt/PTEN
1/77
20,41
TC-1S
PTPρ-ΔFNIII-3
-AKT-S6
SRF–VP16
doxorubicin-based
sh2854
K590R
p.R377C/H
SNU-719
8-bit
Br38
.33,39
histocytic‐like
METY1253D
DNA2
HeterozygousTGFBR1andTGFBR2
EWSR1/ZNF384
deregulatedinlung
4/27
heterozygosity35
ret
6.18.
andincubated
Pathogenetically
stochasticity
.Trancriptional
Ghiringhelli
.Solving
activity33
deregulation.32
SCLC-R1
1495
elsewhere.5
K340
Elolv3
neurocytic
10q11.22–q11.23
5-CTTTGGATTGGCTCGAATCATGAGTG
MLLFL
R136W
100–200
5′-TTTGCCAGGAGCGATGAAC-3′
C307A
n=23–37
WTAR
specificity.Ubiquitylation
instaFigure
pGM-CAT
p=0.065
phosporylated
ser37phe
e19
lobes.31
1.93-fold
atagCccca
Tykerb-GlaxoSmithKline
Cerebellum/SC/4th
miR143
SmaI-DraI
Cys481
P192S
Zong
RAF/MEK/
26,35
ATPlite
FBXW7-ΔF
179.9
0.04/1.8
1.5µM
N339fs*3
.Cognate
non–MLL-rearranged
92/111
methionine-rich
phenotype79
AML.66
perinasal
.Attenuated
patients.16
pre-JM
FLT3-transformed
Diethylpyrocarbonate
3B–3D
bilineage
FDG-PET/computed
ovarian,27
Aurora-2versus
His380
maturation3
arginine-rich
Sriuranpong
blood.5,7
AMC
10F-G
JNK3/1
S4–S5
apo
5·6
1.6–2.1
PLD
pGL3-130b
65-year
andhelix-turn-helix
.FPLC
4/3
21.4–84.1
p.R175H
Irminger-Finger,2005
Leu150Phe
LKB1–GFP
extra-long-PCR
0.319
E1127
p110α-E545K
deWne
P=1.0
extranasal
mid-exon
nucleus
Altshuler
Retrovirus-containing
ICM∗
AKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYF
LXSN-AKT2-AS-
SA530
TgA
OX86-
MDM2amp
Ca10
blue/ml
––n
D65A+GAP
T-*C
GlcNAc-6-kinase
Nucleofector
p=1.7e−16
dierentiated
instability.5,6
HCC2433
8x60K
pGLT2M4
trk24
syndrome3
A272
1.6–20.0
hybridization-based
8l
|CD211
activation100
52,53
BT5
.17,42,45
S-HAM
RAR/
below-average
protein−9.7ABCA12ATP-binding
463–468
TPersonal
13th
Mixer/Smad2/Smad4
μgofmTβR-II
FGF-induced
Transproteomic
p.M1652I
indi-cations
TGATAG/gtattg
AUTOSOMAL-DOMINANT
AIF4
MBq/well
P524L
GFP–PEA-15
Gateway-adapted
PDGF-C–PDGFR-α
Gly227
HN_63080
.Twenty-three
25'C
Nerviano
chemotaxis22,23
7421
5′-TAGGGAGTCCTGTCCCACCT-3′
5′-AT
signaling-2
annually1
GADD45B
1.93-
0.687
LL67
Nwosu
CBP/P300
MFGRII-transduced
3,12,15
×length/2
5'-phosphate
compound-mutant
.Tumors
8q22.1
P551_Q556del
Aur-C
.RFP–VHL-positive
65.1
Allele-specifi
2.5728
NCT01588028
Perou
leukemia.2-6
1,570
TAH
611431
pNF-κB-luc
diaminophenylpyrimidine
7.58
RERF-LC-KJ
Cos7-transfected
alÃ-ele.In
anti-estrogen
PEBP2β/CBFβIn
stem-like
J.V.H.
.Genotype-dependent
HDL
NEDD1
site-luciferase
GISTcells
pipelle
F62S
Wasag
Ex6F
IHCAs
4p25
B″′
Ozogamicin
DM8
baseline-specific
Oliff
ACCCACCCTTA-30
.Oren
-6-methoxy-7-
Morphants
KaVo
interestingly
Aubain
fractiontionation
tumours.12–14
NF-κB-inducing
52144
38.3-87.0
R1625C
Tarceva
TATA-Binding
837-842delC
.508
DM4000
2041–2042insA
57.1+4.1
GGCCATTACGGCCGCGGCCGCCTCTAGAGGATCCGATATCG
8/4,013
p.Gly750Asp
Π-polar
4.7-
SDH-mutant
p.S1463F
proteinthat
Lämmli
EWSR1-FLI1–positive
n=50
242Yext
1627–1900del
p14ARF
FLAG-BARD1/pIRESpuro
55,373,448
HMG-I/Y
Figure4D,4D
99.946
enhancer/promotor
GST-hBAP
nuclei22
Temmerman
GCACATCTCCACAC-3′
-3-phosphoinositide-dependent
CRKL–C3G
v0.5,26
HA-CBL-C384R
0.363–0.933
49-79
UMUC3
gastroenterologist
35mm
15–30
copy-number
Asn267
NBEAL2
months5
Ig++
PE-CD11c/FITC
pCAGGS-lacZ
μmol
temperature.Unbound
DX-IC50values
5-TAATCCTCCACGCACTTCTTCAG-3
pathway.15
GATCCGCGCTGGCTACCGGC
ZK-93
LR11
loci22/30
KITD816N/Y/H/V
VHL−/−
havedemonstrated
Antigen-activated
S895
Vmax/
AGGAGCTGGTGGAGGCTGAC
W1718S
Yewdell
1972
cancers,37
full-gel
G770V
L289P
French–American–British
Itcontains
-CCAAGGCGCACTGGCCTC-3
SMO-LBP
BaIF3
repair97
44–59
RNF4-mediated
Tet2-expressing
toshin
lineage–specific
hypothalamic-pituitary-adrenal
L225LI/R35A-expressing
Siah2
Misaghi
HEK-293-T
KMT2D+/−
80
.990
KIT-targeted
FLT3JM-F
MDS.1
.Naoyoshi
a9
auto-regulation
R147H
Peiris
MEN2AW
Y1248C
MX3000
1c-4
C121S–expressing
HMECs
chromosomewhich
SN-GoMe
.K4500
UTP-L12
PCA-96
specificity5
CDC
NMRR-10-1207-7183
pY88-specific
SIFT.html
RIA
GPR89A
264600
BCAS3–MAP3K3
.Stained
superposable
Burrow-Wheelers
possibilites
:360–367
MSH2-MSH6
Masri
D352N
BS3
2-glycerophosphate
hypobetalipoproteinemia
R776H/G719A
12-7
ASXL1-mutated
LPSmock
17p.S480Lfs*47z
A159
K619A
.Applications
BAK29
activ­
F133V
IgM+CD19+CD5−CD23−
2819T
Olavarria
2/2,081
9E12
Q1734
TCF-4/CtBP
3TJD
EZH2-high
AF416868
Panagopoulos
..u
0.00058
ICAM-
5′-CTCGCATACCTCCCTTCC-3′
GFP-XPLN
Muratcioglu
exome/
D931Y/K935I
GCG
test.33
SOCS1,16
GRα
H4R3me0
visualizedon
5′-RACE
0-60
1521
.Group
MYD88WT–transduced
Nucleofector®
homopolymer
1,29,30
38/89
28•
array–comparative
proposals.43
Morphologically
es-
4C6/4
.immunohistochemical
.3109
chondromyxoid
hydrolysisor
ice‐cold
731.8
.Immunocytochemistry
BR99
Immunofluorostaining
pcDNA3.1-His
Reduction-Sensitive
deadenylated
HHS
94.54
Kunapuli
2239-2248
5V-atcagaactgccgaccacacc-3V
Fh-Hif1a
Activation-loop
Brca1Delta11/+
arterial/venous
meduilary
L148A
Pro252
236/130/56
Fig.1A–C
Heverlee
485
3376–3377
p.N1869K
R80Q
macroscopic
Pérot
D19A
TP53/RB1
I294A/R297A
Lif1
616-618.27
.W
vHa-Ras/RaplB
GGG-3
C2-R3/G380R
ng/mg
EtsB-mediated
/3/5
hybridization–single-nucleotide
Boechorststraat
PI3Ks15-18
kinases.6
nondisjunction
021-314-3622
5′-GACCGAGTGCGGTTCAAAG-3′
lipofectamine-2000
endomyocardial
PCRII-TOPO
Hist1h1a
TM87-16
Base-pairing
P1806AR
anti-p-Thr308
II-like
K/ps
.Fig.2C,2C
BaF3.To
EZH2Y646
K101I
LNVSQQPLLDVEGNLIK
Transfection—The
C1483F/S2215F
854–869
co-eluted
ErbB2-induced
hypoenhanced
PDGFR/RAB35Q67L
AACCTTTCCCTTT
101400
Radtke
anti-Puma
10
Istituto
1:350
pcDNA3WT1
ER-Cre
leiomysarcoma
protein-induced
371H19
TAGAGGTTCTCCCCGGGCTG
KrasLSL–G12D/nat
FLAG-Krasnat
statistician
4-phosphates
24,26–29
ERK-regulatory
antibody–protein
formation137
sc-28681
I1171N-ALK
BTBD1-NTRK3
PCDH9
.Richard
GGCTCGGGGCCAGGGGCGGG
92,304,397
NF-M
moderateDNE
P0004
exon3
±1.48
relB
ab137537
wlth
Y570•••Y846
Flt3.37
.Temporal
two-component
KRAS-mutant/FSTL5
53-58
rhabdoleiomyoma
.12–17,19,21
Glu199
P1009S-mutated
MiaPaCa-2
activator-specific
AKT.5
100,124,127,128
extra-telomeric
samples.20,25
EGFR-mutation
structure-function
melanoma.1,2
AF332
/tM
GDC-0941-treated
menarche
Antibacterial
approx4
60-bp
respectively,1
BRAFWT/KRASWT
al42
T1313M
time-mated
V777A
eosinophilia.22,23
P15H*
blocks27
were13
2908
18.0.0
hFANCG
pathobiologic
heterogeneous
Sos1-associated
5242R
Pathvision
32PdCTP
Lutterbach
12-week-old
1244-47
ImmunoVision
cells9,31
v-fms
intervertebral
β.5
CGH2
.1420C4T
Pre-therapeutic
1p31.33
LB/Ampicillin/IPTG/X-Gal
inhibitor40
range85
438,370
MTF2
Adenylation
PTEN/10q23
connectin
HLA-B*4423N
TIF-2624–1287
siEGFR
Liberase
CGATGCTCTTAGCTGAGTGT
pindel
24⇓⇓⇓–28
BLMAsh
IGF-RII
UvrB
8/522
PER-403.5
Akt-2
45Codon41Codon
Lung-Tumor-Derived
43-226
NRG1-independent
v–vii
181–183
Gαi/o
RNF212
4BGG
TUT4
cells45
BMS-354825
Gardner-Rasheed
mCO
6/45
lOO-^il
488-labeled
C319Y
Alk1–mediated
18141
010128
microscopical
α-ketoglutarate
c.791-7T
mMpotassium
Haferkamp
S3A–S3D
Å
Bmf
tetramer–positive
100–102
NOVELMUTATIONSIN
BEK-C17
p.Gln2325*
500–700
TTGACCTCCCTGGTAGCCT
Flag-MKK4-transfected
HoxA9+IDH1mut
TSK-loop
4.065
I-47
Schnurbein
.5–10
open-source
MSN-ALK
11V559D
GSK3β-adenomatous
p5313
Multifactorial
.Ltd.
.FANCL
PRPF6
80+
tumors.4,5
Ex8-9F
6.609
−22.3-fold
S2A–D
inhibitors—have
Glu500
inmaintaining
b-Mercaptoethanol
P395A
Somervaille
recycling.53
BL6-SJL
.C634Y
rs144564120
.10,12,14
19.76
ETV1–Flag
WINGLOW
explored.17
9,437
-GTGAAAGAAGGTACATTTC-30
tumors18
Microphthalmia
antagonist-to-agonist
MG115
112-3a
p.Asn127Ser/p.Ala328Pro
photoreceptor
BAF60a/c
log2-fold
pCSCG
30160
therapy5.During
8-fold
2,11,28
129-Krasnat/nat
M280
MPCEWS-FLI-1-T1-derived
2670
1.59E05
.Fgf18
1135
V16A
.Two-sided
Birdseed69
Nonfunctional
GRIN2A
R1024Q
AD-PCR
Asn770
activity.In
true,16-18
0.635–2.214
glycerol/0.1
G417R
NMP4
TC21
1-TRCN0000199327
ABC-ATPase
nonglabrous
MO_1031
RAB-NEM
PTRPT
COMMA-D
L276I
P160R
well.31
.Modification
0.63–0.95
'brake
c-Abl/p68
Ras/MAP
≥8
906T
66-kilodalton
0.273-0.870
A246P
S29Q
8.01
1411insT
semi-quantitive
IM2234U
XRCC6
2-proportion
thyroidectomies
al.,2008
reports20
FBW7/4q31
serine-arginine
L680P
megablast
FDR-corrected78
NP_077719.2
2-mercaptoethanol–1
e–m
83,720
ab2977
.RHO-GDI
JAK2.32
isoenzymes
A569T
Ntv-a
blot.open
.TCR-induced
mutations.26
KrasLA1
.PML-RARa
Abdel-Rahman
.Less
reducedflexibility
Y518F
95X
gene-sized
CB17
immunecomplex
kα11–kα12
RP11–135L8
orInk4A
5′‐cap
C620Y
V555M
Daudicells
5.01
.Enchondromas
R632W
.FIG.6
excision
EGFRmutated
Figure6G
DNMT3B7-LA1-55n
agonists/
Y279C,36
.PIK3R1
radiotherapeutic
​Fig.2A.2A
L485Y
NEN
pre-processing
DTNBP1
AATCTTCTCCTCCGAGCAGCTC-39
pBABE-puro
Collins,41
I152M
Cxcl9
27,32
SE-like
nucleotide-induced
pAP-1-Luc
D_melanogaster
EFU-C
14-3-3ξ
structur
pRS313
DNase-treated
10/12
X.K
.IPI
Cdkn1a-/-
amjpathol
recoverable.The
PIP3-forming
ERF‑mediated
M.M
cell‑specific
60ÆC
Giuriato
progression/metastasis
ATbase
//www.broadinstitute.org/genome_software/other/primer3.html
20,800g
8/68
HIB19
15,280
GST-Cbl-C
G-domain
S3–S4
Rosa26
Top2a
47.49
+++++
extensively.16
mutants.C/EBPα
short-to-long-isoform
anti-oncogonic
anti-EpoR
acid13
0959-8049/
5′-GCTCAGAGCCT
2775–3057
polycythemia-vera-like
71/124
FANCN/PALB2
oligodendrocyte-type
delta3
Wnt/Wingless
28:434–451
disease93
TOG
Axioplan
www.LOVD.nl/MLH1
c.68-7delT
8.52
V70L
194.3
D3264N
NF1
transcripts/chip
EPD14
201565_s_at
anovel
Chalon-sur-Saône
LUC1502
GST-HNF
31.5/14.0
CCTATGCCGCATATAGTAGAC
metaloproteinases
Ref.19
tumor/normal
pmCit-N-ras-E49K
D835H/Y
0·69–0·98
pDpc4
function.4–6
LEU2-d
related/secondary
G691S
2,214
K-ras+/V12
v16
BRCA1-2
R130K
1–410
Carboxyl-terminal
14-3-3-independent
hybridises
2700
.Hematopoietic-specific
pBabePuro-TEL-Jak2
etal
amplificationMET
DNA.33
p.A266V
isopropyl-b-D-thiogalactopyranoside
.Liu
non-triaged
functionalities
A48
method.31
transformant
15A
5H10
Acknowledgments
233–amino
VprBp
events.13,21,26,51
ErbB-2breast
ª2007
molecular-docking
GT-3′
5′-CATTTCCCGTAAATC-3′
p-pRbS807/811
respectively68
3'-OH
GISTs,1
c.1277
machinery.23,26
pDsRed2–C1
54–56
cCancer
patients,14
plasmid/96
Laboratories™
N58K
p53Δ/Δ
S505
E20
phosho-MEK1/2
5752
PIK3CA-non-amplified
6-residue
F857L
.Eighty-eight
Drug-induced
d-e
-HA
EMSY
therapy.47,50,51
31–40
V36
metallothionein-I
RAD54/rad54Δ
USA10
Apc-dependent
mol/L
RP11-996M9
CTDNEP1
T315I-mediated
3214
BRAT-mediated
D52N
V642E
mislamination
Tauchi
study51
Gatta
colonies/10,000
parallel-group
Ser393
.37View
CACACCAGGTTGAGACGTTGA
H2O2-treated
CGTCCCTTTCCAGCTTCACAGTGAATTGCTGCAACAT-3′
10q88
phosphorylation25
anti-CD8-FITC
Adhesion-To
H1325
15.80
68301803
amplimer
A186D
AktT308
ODcontrol
R741Q
.Tissues
frontotemporal
GSE26089
Gly-697
PanIN
n=82
Pêche
tumor/nontumor
HRP-DirecT
al,12
1736
gauUGGUGug
spectrofluorometry
ENSG00000118058
GTP-RasY64A
GABPa
negative-feedback
doi:10.1158/0008-5472.CAN-06-0168
radiation-related
orthologues
TMEM14Cmut2
p38/SAPKs
mutations.7
pheno­typically
M18916
V658F
cancers.22
*m
Ba/F3-ROS1
5′-GTTACTATT-
RasQ61I-GppNHp
AGAAAR-binding
p16/
*Patients
Sma2
previously-validated
pRevTet-Off-IN
52−144
EWSR1/SMARCA5
Benezra
lobuolalveolar
157.5
Daegu
17,500
cases.14
NM002880
35/M
Asp324
M3
181C
NOTCH/FBXW7
post-engraftment
CC/GG/CG
telomere-bounded
SU11248-related
Kasarskis
ras-transformed
.Phosphotyrosine
www.igs.cnrs-mrs.fr/Tcoffee/
p-4E-BP1
cdd470f7
VHL-null
5′-TGCAGAAAGCACAGAAAGGA-3′
paraproteinemia
MTT
Phe341
/24.1
level.7,8
8980
E-induced
Kcnq1ot1,19
change19
.Flipping
Pglycoprotein
F288
field142
Fig.9B
p67trk2
c.180C.A
LHB
al.19
hair-follicle
Lizcano
X-Omat
CC6CCbLcbA
IDH1R132C
mice134
TRITC-labeled
Fluorescein-activated
V825
53/M
Eon
NSCLC—the
3,4
F320L
OX86-treated
p27-deficient
−2.63
sunlight-associated
293-FT
Jak2-JH2
PLAUR
ATM/GADPH
c.104G
0.259805154
cytoplasmatic
FUS-NCATc2
mispairing
FGFR2-BHCC1
genes/pathways
Quantimet
APercentage
644A
G13L
cells,28
hg17
wt1-null
MdNTP
NM_009704
CTCGATATCTGCCACATAGTTNNNAAACACTGTGGG
Mutation/inactivation
Eissenberg
7,200
light/10-h
Th2/Th1
1580
pAlterMax
KRAS+NRAS=1
43–95
Msh6LQ/LQ
DEAE-dextran-assisted
erbB2/erbB3/IGF-1R
Glu56
XPO1-based
21/26
–independent
inter-batch
KRASQ61R
fibroblasts.121
IC50=27nM
Gly-to-Arg
K14+/K8+
protein-membrane
D16S301
695
neomycin-resistence
-1.63
SP-D.81
0.01–4.98
S1818
0.009/0.7
optionsTable
R253H
S13
M308V
beta-catenin
ribonucleoproteins
.Longa
Bcr-Abl-containing
NM_005236.2
His273
fForward
REFMAC-calculated
A883T
.DEL/DEL+PM
Akt3-Specific
Flag-Myr-AKT1
expressionby
2–3
2057
0.12-fold
EXEL
journal.pbio
NM_002012
implication-that
10−3From
E2b
hMSH6.9
89–91
deep-set
C-cell-associated
Trp53bp1-targeting
interoceptive
81,858
MycL1
.Glu64
ΔERG
U-2-OS/T-Rex
Okubo
p3xFLAG-CMV-CHK2
NCT00265798
CARD11-
−504
−1.57
Eurasias
IM5
G1-to-S-phase
v4.0.2
oncogene3
malignancies.38,39
ETV6/PDGFRB
IDQLILCCLYGVAKVC
TE-200
4XOX
.1253
//www.affymetrix.com
226,438,467,524
COCOC-4
I,53
fromlinear
T75contains
lines80
8\+
nonstarved
.Radioactively
A19V
wild-type+FL-CDB3
BM/PB=2/1
pLKO
CBL-specific
Etv1-transfected
cytokine-starved
retrotranscription
deprivation.B
cases.17,23
anti-CITED2
GCAAAAATGTGGTCCCGGTGTTCGACCTGCTGCTGGAG-3
−50,399.24
Progression7
decompensated
Facchinetti
p27CDKN1B.Figure
0.019631
5′GTCCCCACGCACCCACCCGGACTC3′
5.09E-03
Ethyol®
expression.expression
6c–e
Fig.2E,2E
.Hydroxylapatite
rare.12,13
neuroblastoma17
cediranib
Skp2-mediated
RJAD+
Fanci
FGFR3.3
wt-PKB
isotype-alkaline
870
myc-agarose
elsewhere.26
respectively58
coactivator-associated
HER2‐amplified
FLAG-ASXL1
M2i7DF
9542
GFPs
G32AM
3p12.1
C167R
lysine–coated
Positive-
Fbw7α/Fbw7αΔBD1
CCND1-HA
4565
large-sclae
factor–β
0.95–0.99
db=core
MSCV-MLL-AF9
mutations.Additional
skin62
www.sciencemag.org
-TGCATATTAGTGGACAGCAC-30
phospho-JAK2
Sézary
anti-involucrin
E14.1
pPS
soft-tissue
Ser-15
gpl4OProto-trk
67.8–68.3
Activity-An
Samadi
.RESULTSIsolation
cMET-directed
147060
interferon-γ-inducible
snp.cshl.org
withdrawal–induced
Ras-/B-Raf
S1D.Next
cullin7
.Y532C
TableTable1
manner103
.D
CD19+IgM+CD38+B
R528H,3
7p/q
AK030489
.HCC515
0.79–1.01
.Paradoxical
1IGR
or/
IL-6
Q1977
.U87MG
interaction.Smad1
MYB-related
TGGAACCCTGTGCCATCTCTAT
Y576/S722/S910
344279
H-3
chemoresistance21
ER/PR-negative
Hybridization-capture
eosinophil-like
C/EBPα30
Senesence
MAP3K5
CommentsSeveral
R960-25
non-transcribed
E418
Q411X
H2623
risk-TCF7L2
D175N
zinc-fi
.common
archaeal
19,297
homozygous.Mouse
dabrafenib66
E111
Ser212
WAF1/Ab-5
712-1255
Neuropsychological
inhibitors,11-13
4,849
FISH.Fluorescence
NS1,2,3
749
Erg+/Mld2Mpl−/−
.Members
.MPLW515L
Leu747Pro
K101
2.17-
-infected
haemangioma
aneurysms,5
~100–200-fold
CRL-
first-identified
Farmington
v.0.4.0
26.87
Nucleotides—Despite
1.361
hyperuricemia
Noonan-related
NOG/2-OG
P-glycoprotein-mediated
Mann-Whit
degradation35
complex17
heparin-Sepharose
.340G
Pathologists–accredited
SIFT/Polyphen2
W535L
CD44+CD24−
1P0Y
.IFN-g
sequence—were
TGGGTGTGTTCTGCATCATT
ofabout
Asp187
PMI-F1
KIT13
C1476A
.DNA-binding
rTRa1
Ubc2
N-Nitroso-N-ethylurea
1−8.8MYO5BcDNA
Pau
Fiol
L858R+E884K-COS-7
PCRamplificationwas
antiHER2
CS15
q21-22
ADP-Ribose
exome/transcriptome
TEL-TrkC
Mll3Δset
TOP1-depleted
p.Gly646TrpfsX12
3/83-2/84
WNT-associated
differentiation16
.Yeast-based
DNA-interacting
HT-29/SMAD4
HGS-OvCaFull
Super-enhancer
β-catenin-Lef-Tcf
42,43
P550S
Asp594-Phe595-Gly596
5V-TCCAGCTAATTGACGTTGCCCGGCAGACG-3Vwere
pre-B-cell
Immunoglobulin
BrdII
M3623
,70
Pt_008
analysis.pl
AMPLIFICATION
ASXL3
635_1285del
Ile670
gentamycin
Todoerti
CASC5/AF15Q14
GCAACTGACCGTGCAAGTCA
PRKCB-silenced
LongRanger
fibulin
W2001X
thattumor
E14c
Klinikum
dye-reversed
MGH-PO
.Unequivocal
280C
T205
A1949T
BiBr60
67/F
K14-positive
iJM
DFG-Phe-out
S752del
Prepration
PKCβ-dependent
0.005–10
1oqa
M82882
SELCKIPTNN
5°C
5′-CGAGTTCCTGGCCGACCTGT-3′
trxdv
procaspase-2
II.1
truncated-protein
Agencourt
bimas.dcrt.nih
.001‡
Piccart
ubiquitin-accepting
ofp53-speci®c
BRAFis
~88
C57BL/6N
receptor.2,34,42⇓-44
Y590
sequencingwere
3001
R268
motile-invasive
paneth
.Thesemutant
described12,43
3/15
_nnU
helix−helix
'Contributed
sh-control
pericentrolobular
Mutation/deletion-induced
Can-
dual-energy
ryeung
Ethnicities
tumors.3–10
mutation-related
705-1047
III-19
162In
HERVK19-FGFR1
7,16–18
POU5F1
V57F
5′-GAATCATCTAGATTACTTGTACAGCTCGTCCATGCC
D709
Gly750Asp
Ser281
yet-identified
pathway.23-27
activation.33-35
K/2×SSC
ALL.29,37-39
C1158R
.Lower
Wanhua
Weill
study.45
RT-PCRRNA
1.948
Nedd8/Rub1
3-most
residues.26
sex-adjusted
159.4
N-RTGGpSLRGN-C
E-values
.4023G
polychemotherapy
DNAcontour
Tyrosines
transition38
24.5–1.6
5′-GTGAGCCTGTCTCGGAGTCTTGGG
non−homologous
NP_006210.1
Co2+-based
.RAS–GTP
Shh-enhanced
.Jude
Musculoskeletal
ACVR1-ACVR1
perinatally
cDNA30tagged
4OHD
dopachrome
≈675,000
NM_145150
ETV1-amplified
www.fruitfly.org
A,3B,3B
ALKT1151M
BCR
363
Buis
DMX-750
GGCTCTAAAATGCTCTGTTCT
5′-CTGCTCTTTACTGAAGGCTC-3′
NRASG13D
R288H
red=highest
TP53I3
α-complementation
5-GAATGACCCCCGCTGAGT-3
44.55
92,138
W450Stop
.MassARRAY
3247
eucaryotic
1228
Toki
.4–6
PCI-13-WT
PR-B/
MatrigelTM
C3G
decline/deficits
175Ile
thereafter.1
GSK3B-mediated
spontaneously4
figure3
GGTGATTTTGGTCTAGCTGTTACAGTGAAATCTCGATGG
Asterand
2×10−5
MEK/MAPK
RINGH2-type
G169E
Raf-1
.0070*
TGF-ÃŸbinding
activation.21
17.06
Gene-environment
–chip
Nondenaturing
G5371A/CGA-+CAA
pho­
multi-port
Y555C
CSF‐1
8N
systems.35,36
p.450X
pylorus-preserving
ETS2wt
ΔBB
2G–L
RR-G
nonvariantly
andhMSH222
PGA1-derivative
GST-PKBαW80A
stimulation19
16-20
En-1
patients.19
C242Y
Bcl-xL,6
Aminolink
250–333
.Cantrell
NRASG12D
co-cistronically
Biosource
1.61–9.70
short-arm
Slavc
Prolactinoma
117–457
ACS2
SK6100
FBE
GTPasea
yeast.33
anti–phospho-p44/42
IAlaVa
pcDNA3/His
V217I
MSI13
sarcoma14
mutation.36
p44Erk1
Unliganded
Oosterwegel
11230
CDKindependent
124005
Junjie
model,41
Duox1–2
KLHL18
2009.
phenoFIG
Apc+/+Smad3+/+
12-13-17
47–90
Mm00460898_m1
.EGD
computationally-oriented
vegfa
mTOR-expressing
stimulationTable
His436
H.-K.
qLOH
59-AAA
LHβ-T-Ag
C797Y
3,20,21
CLUSTALW
45–69
multi-dimensional
dbGaP
c.181–182CA
p53-signaling
'indirect
50-100mg/kg/day
NSD1/NSD2/NSD3
29.51
Q160X
pRLTK
575A
Umekita
descri
PERLD1
KIT-signaling
PFDN1
.EVI1
5'-ATC-3
Pro-95
nonfunctional.
RET37
AP-1-binding
2.6-24
leukaemia.17
Schimke
58.74–2.8
Ã-
-TTCGACGTAACAGCTAAACC-3
www.proteinatlas.org
Asshown
.Gene-targeted
0.02μg
deconvolution
Gouw
PCNAmotif
23839
carcinogen-esis
Xalkori
NR6.A289V
ingeneral
Ezh2-mutated
≈1.05
ACCACTG-3′
xg
5'-CCAGACTGTGTTTCTCCCTT-3
.Cavallone
results,4
E361
.11,15
105–400
Hjalgrim
HSC7E648
27841
III:2
JW
TPIP
con¢rmed-carriers
TGATTGGCGATGTGATGTAT
BRCA2D12
TGCA
analysis12
non-BRCA1–like
172747U19
.Implementation
amino‐terminus
8,9,10,11
GAAGC
.Solvent
'bulk
V769dupASV
71•
8,9,20
Oxford-Illumina
TP53BP1-PDGFRB
Pin1-Mediated
FKBP12-rapamycin
Rbx1
integrin-like
HD01294
β-cateninS37Y-cotransfected
cardiac-specific
BIMi2
1052
genes.50
anti-CD45RA
16-
VOPP1
Clontect
data.4
Cys3
PRLHR
AP-positive
PDGFRβ-positive
beinsensitive
.CellTiter-Blue
n=736
Snf5inv-derived
AS1
Chikuma
BRAFV600E-transfected
SCCOHTs.36,37
BRD3–NUT-expressing
F270
SNF5–lacZ
5-phosphatases
FGFR116
.YFP-EGFR-ICD
samples.10,11
Catalanotti
HBV-induced
≈669
hypermutators
108/100
10.View
Ben-Chetrit
culturedmelanoma
E604K
nonsense/
Senp1
death-signaling
JAK3P132T
.Rituximab
HEN-1–SCD-2
phospho-acceptor
non-adjacent
trypsin-ethylenediaminetetraacetic
cancer39,40,43-46
sufl0
C77F
Ambios
Osmr
ography
ADIPOQ
E160*
e6
4947-4953
Fig.10A
expression.33
support.7,23
regulation10
MET-inhibitors
16591
200518
Tasic
48–68
Graninger
BCL2-negative
T323E
36.2/38.6
A300-499A
82/86
causativeness
gefitinib-responsive
GGGA
P.o
N642H-mutant
GTX70220
Mlh1+/−
6.234161
wt-FANCA
ERÃŸ.Y443F
tongue1–3
oncosuppressive
.NeuECTM
0.037a
45,62,70
~~~~~~~~CR
KD+/−
correlativity
A_51_P279575
IgG–coupled
anti-Pim
immunoblot
c.7008−2A
3.6kb
825K
Breivik
JH2-mediated
Prostate-cancer-associated
Sox11
response.10
Wnt‐induced
proliferation.11
G873E
~65
phosphor-Akt
p.Pro584Arg
vitro.16
Cd86
hasd
1.01∼5.22
c.1622delC
TGF-b1-sensitive
Myc-WW-PDGFRA-expressing
deletions26
NM_173500
Flt3-ligand
Swiss3T3
S729.23
227-8501
gapin
aFrequencies
suppressors11
MLL317
immunofluorostaining
myc-ARAF
4OHH
BornHl
207323
17,422
POLE-
54K-
NG3
3999-100
ACA-ACG
RAS-RAF–signaling
MMR
CBP/p300-transcription
11β
20-60
ETO
ER-a
T.R
BRCA-associated
1,030
dimerization-deficient
BT340
R34P
6p23
*according
hesion
10/195
53–55
use5
1d
screen-detected
vitro-translated
10-mg/kg
———
280/170,321
2e-g
radioiodine
BUD13
nonhomologous
63Â°C.and
FLPe
AB=1
.MS/MS
-,22
semicon
5531–5732
70Â
A377E
Siraganian
NCT01262859
.S2c
underliningdesignatestwo
5'-RRRCATGYYY-3
3147
GAD1
parpebral
publically-available
∼3–4
anti-p70S6K
GGCGTTTGGAGTGGTAGAAATC
MICA/B
34/79
14-residue
SDM-positive
SpectromaxM5
C5-specific
2†
mutant3,9
.Inhibitory
2,953
±1.0
RasGEF
81.63
unit–granulocyte
.PDB
GTGCAGGAGGGCCGTCGCGATCCTCAAGAAGAAGAAG
1-571
968KB
n=25/101
nature.comPossible
43.9
VariantFiltration
gamma-chain
S5–S8
L-L-K-K-1-K-Q
ACCTGATTTCCTTACTGCCTCTTGC
vessels†
HIF-1-regulated
reimmunoprecipitation
pERK2
R135T
light-gray
p85-WT
Toxicology
syndrome14
Thr37/47
deacetylating
yAFM
ARE-bound
∼3,000
​Even
µg/mL
.Elf3
Rrp40
p.F468S
p.Leu680fs
line.11
Lar60
RCOR1
Cuesta-Dominguez
*Â
744
KIF5B–RET
5′-GAGTGGGGAGCATAGTGCTAG-3′
cases/million
mutations.18⇓⇓-21
CEN3
Kru¨ppel-like
CD163L1
oophorectomized
NSD3-siRNA-mediated
p.Y598C
c.6853A
242KB
craniofa
HKI‐272
tumor-conditioned
R283W
ETV6-PDGFRβ–mediated
R290G
Figure5A5A
L345
Nagl
report‑
Trx2
agents3
KB1P-3.12
PD8
Vα11
TS100
5'-CATTGGAGGCATAAGCTG
p.Ala773ArgfsX8
CTM4
H83N
NaCl/1.5
ciation
determined.To
one-tail
c.1484_1488delCTCAA
Thrâ€
Wen
PEBP2β-MYH11.19
Tables33–4
leucine-zipper
K-14
D422N
G997T
b2m-transduced
CKS1B
qualititative
182.4–182.9Mb
His-tags
cell-surface-receptor
cells.47
penetrance.41
mechanisms21
I-39
CARD11–BCL10–MALT1
pSH91
Hospitalier
Y710
PCNA-cyclin
GGCCTTTGCTTTTTAA
HSC7E526
T389/S6K
PD865p
lines.7
K724N
fordiploids
MEKDD
ganglion.4
CI=0.54–1.15
5′-GTGCATTTGAGAGAAGCCACGCTG-3′
Metzgeroth
.RAD51D-specific
TBS-tween
.Western
preapoptotic
serine/theronine
c-Kit+/lineage−/Sca-1+
NUP214-XKR3
1,123–1,128
.Phospho
HLB
MutSa-bound
AN3-CA
criteria.18,20
β2
HRAS-mutant
Annex/PI
Lys533
previously.25
urea–formamide
leukemias/
bortezomib
8.8e
9-gene
Difilippantonio
1.642–4.425
investigatedthe
.CBLWT
SSNA1
hemagglutinin–AR
trans-activates
ABL-related
nonSpitzoid
8-day
Emericella
pRS423
54/2322
TCCTTGCAAGATTCCAGCTT
RAD50
3,4,5-triphosphate
KPD+/+
substitutional
V29A
1-353
MDM2-SO/
GSK-3β-dependent
hypermetabolic
Smiell
RLAA-BRAF
dyspasia
glyceraldehydes-3-phosphate
themethod
Ctnnb1
6q25.2
Koziel
Igh/c-Myc
-AATCCACCTCCACACTGACC-3
mitochondrion5
Protein−Protein
11q4
anemia–like
GFP–VHL160-positive
D11
2.1–3.1
2.5-kbp
basic–helix–loop–helix
pheochromocytoma.15
1326–1347
response.9,10
twocompartment
nosologic
EVOS
GTL16
GBM5
CD154
I107R
modification25
neurotrophin-4/5
3K
.Ahn
medial
self-protein
differences.1,7
studies,6,8,9,30
BCA-kit
5366
Lys-164
QuantStudio
CAL62
HaeIII
TG101348
Polphen-2
yolk
colonocyte
GATK
Drosophilatrithorax
G281E
Transduction
SOX2-targeting
ANNEXIN
paragangliomatosis
NF-κB2–
Xpot
kα12
baculovirusinfected
.Univariate
Hutchinson-Gilford
D62N
yet-defined
polyacrylamide
1970G3C
hub-like
post-test
3.77
M918
EK/+
832230H
veri®ed
optionsOur
Mlx
1523T
Rock1
K6EN
P53ΔE5-6
Postembryonic
6A
6B–D
/Â¡Â
DM~EM
QuantiTect
genes106
1.3.99.5
K550_K558del
CE3
68331829
19q13.32
+/I1307K
800CW-conjugated
HindIII/PstI
1.266-9.858
OA3s
Kujawski
C611
Jongno-gu
pYES-PTEN
comprehensiveness
nodea
T1065
.NUP98
TÃŸR-Iinterferes
MY33m4
quiescent.18,19
I706T
overproliferation
Setty
Kehinde
17,19,21
ASCO/CAP
mutatormutation
320368BH3TransversionGAC
shownthat
.Impressively
MM415
97080
models.8,40
IFN-γ-activated
.4-7
SH2D1B
R172K-expressing
H1299-Tet-On-p53
D110N
4–16
diC8
7.57µg
BLASTN
Kpnl
6-TG
TFA23c
Baghdassarian
​Figure2C2C
p21Waf1/Cip1/Sdi1
indistinguishably
ketotic
D560
PCR—RNA
pre-f2m
I-SceI-expressing
FLAG-Elf3Δ355–362
SNU-410
agents31
Y845-phosphorylated
1–154
nullphenotype
A871A
5′-TAGGCTAATGAGGTTTATTTCTCAAGAGAAAATAAACCTCATTAGCCTTTTTTTTTC-3′
9989
22,36
300,000–1,000,000
DNMT3A–CBX7
p.R162C
5080delCTG
Kurpinski
17–33
anti-FGFR2
PI3Kb-selective
A77D
78.12
immortalizing
PKC-β
Ambion
MRF
rc-BMP7
signalling96
−0.526
557/8
Reactome
p53-mutant
microRNA
HIV-Rev
dSignificant
TTTCA
T1720I
inhibition
Atrioventricular
Matito
Amo1–RFP
p.R248
c.110
non-nuclear
0.4-78
p110αfl/fl
post-second-line
dysfunc-tion
WuXi
1.256–2.961
-CCAGCTACTTGTTCTTGAGTGAAGG-3
900
Fischmann
Usmani
ge-nomic
Bgl
strain.Table
Ensemblgene
0.0255
propranolol­
CpG-transitions
time-by-genotype
G719
polyacrylamide-urea
PTK2B
D1/56-295
V1056M
Männedorf
.Kim
Homozygousdeletionswithinhumanchromosome
5′-CCGGGGGAGGGTGAAGTC-3′/5′-TCCAGCCATCCGGGTGAGTT3′
CPT+ATMi
p85β
190-bp
.PV-associated
PA-banding
6593–604
2H/15N-p53
non-described
characterReceived
BCOR,17
β-catenin.6
cytokeratin-
Tbx6
c.2409delG
Cross-sectional
inflam
Ala/Aia
100ug/mL
23-centimorgan
Cytokeratin-negative
R2131Q
NCD3
1.781
Tris–Cl
tri-snRNP
complex-target
inhibitors.1
.Anomalous
expression/splicing
Rescue-ESE
11/12
–11c
.91,95,99
.Breast-ovarian
mutations/genome
pre–B-ALL
NBG03
1-271
emerges13
KRAS4A
PLX4032
4C4C
L1494
65.8±7.1
proliferator
α-Fbxw7R465C
amino-proximal
proliferative
mortality.6
neuroprogenitors
1EWS/WT1-KTS
EGFRcellsin
R427P
gain-of–function
.Coreceptors
difluorophenacetyl
Thr1977
C295
actin-based
937-fold
0.9-439
Vectors—Cell
59-GCGTAGA
V/I
=conserved
thyrotropin-receptor
.H874Y
IGLON5
D.D-S.
pcDNA3.1-Flag-pVHL
P-FGFR
Lumelsky
88/107
53.6
c.1832G
1–165
sc-7947
regulator-like6.7GLRXGlutaredoxin
ImageJ
trP1-Exon24R
P2-affinity
f/71
Titer-Glo
testing.5,6
S49076
5′-GGGGCGTTCGTAGTGTTATTAGGTC-3′
.SPOP-mediated
222.2
SWR1
137–156
pan-B
prolineglutamic
CHAPS45
-FDG
excluded.30
mastocytosis.19
time/echo
344insC
JAK1-JAK2
coronaropathy
protein57,58
pCDH-HA-Shp2WT
Correspondingly
polylinker
Y1269
founder-mutation
.Atrial
xFoxH1
c.3975_3978dupTGCT
treatment.30
SND1-BRAF
rs67390234
ER−
gastric/esophageal
Cdk4-
7.2-
.Histidinol
145C_M
RTK-mediated
assay13
Ohta10
non-MCL
26,49
tumorigenesis.15
inhi
Mouchawar
superfamily.2,4
†Mutation
β-K230E1/β-K230E2
-Abl
H3-lysine-4
5′-AATGGTTCCATCGGCCTAAT-3′
behavior.16,24
1559
LUCaP41
614082
REVERSIBLE
301–525
R1736
–amplified
proapoptic
may—dependent
.Angiomotin
0.00173
pedigreesEach
L273F
J-M
Phoenix-packaging
FANCA-NLS-Mut2
let7a
29R
PTH-Cre
c.125A
18—21
W79C
experimentswere
MnSOD
Xenograft
GGTTTAATAATGCGATCTGGGACAC
450×103
pVHL160-positive
M1202T
61,81–83
nonsense/splice
β-TrCP–EZH2
Takaishi
.RASA1
.Sarcoma
6.8
mHNF1
mLST8
storiform
5′-UUC
Ser910
megakaryocyte-specific
A1170V
p=0.2010
sialyltransferase
YAMAGUCHI2
Kloting
chromosomes.5,6
2,007.2
40bp
MG-B2GFPΔ3270–3418/K3266T
destruction.Figure
ERCC1-ERCC4-mediated
regulation15
csb
.000481
p16ink4a
T16O9A
C158
C.J
pericapillary
AACAGACTCCAACACAACGC
30
MyrAKT
adaptive/evasive
serum-deprived
A226T
1e–g
binding21,22
N631S
GST-SHC
RALA
disease.27
unreliability
RCC—particularly
lishment
Men1/F-RipCre
Hemangiosarcoma
M-V
FalconTM
-620
trials.17-20
RUNX1–MECOM
0.01308
Hemagglutin
subunit11
POU2F1
.H2SO4
rats6
Hotary
GGCTAAGGCTAAGCTCCTTCCACTTCCTGTGGG
Interchain
.Temperature-sensitive
E54T
alkaline-hydrolysis
nonhydroxylated
23–77
VBP-1
RP11–485O10
.Heteromeric
BACH1-Bluescript
Groucho/TLE
Shapira
//www.completegenomics.com/public-data/69-Genomes/
syntheses
3f–j
H4K20me3/me2
PowerGen
first-cousin
sort-
ras-related
database34
8/21
K176E
FastTrack®
551–560
lupus-like
91,99
R315H
5p13.2–p13.1
3.647
FBXO32
Allanson
ABL-C
Rasopathies.22
EXi
5-Am
A*0253N
analysis17
GI:6164918
iulJalAl•V•llysAlaleulysGluAlaSer
pFA-c-Jun
xy
5′-TCGGGAGTGGATCTCCGTGA-3′
complexes37
PhosphorylaUon
TMBIM1
Sofferenza
.Westerns
HDR
BRCA1-inactivation
merization
FuGENETM
polyacrylamidegels
004521
CAGTGTCACACATTGAAGGCT
P190S
7760-1
R576W
quiescent
atvarious
ESWN
6.4–14.4
cran.r-project.org
K-RAS4B–effector
Freezing/thawing
RB-del/mut
1.27
FAM-ACCACTCCAAACGCCGGCTGATCT-BBQ
phosphate-free
CTCATATTTCGTAACATGCTATTTTCTG
RET/PTC2
77-fold
bioinformatics
PDGFRADDIM842-844–expressing
H773L
267-base-pair
cellsCAT
4XSSC
Tyr67
L862P
Xu
preparation.10,14
R482Q-
5.1Mb
hydrophobicities
functions.1
function11
and2.2
NIM
2G8
450,000
MPL29
noninduced
space-fill
TP53/DNA
28–86
delinsTACA
recombination1
0.920‡
methylated-specific
preplated
29/371
7-TM
β-­sandwich
Brca1Δ/Δ
Q506
RP11-891L10
Omnibus33
4·4
HIJ
T877A-
257K
AGGCCTGCTGAAAATGACTGAATA
c.617C
1199
loci22/8
wasreduced
GACTAATGTGGCCTACAAATCCTAA
most-prominently
PicardTools
−3′
tetragonal
1025
Akt-R25A
pericentromerically
91st
gp11OPro
wereachieved
A465Tmutation
well—namely
Arg248-Arg1744
fine-scale
breast/skin
pim
PTEN-lost
Finder-like
1DISCUSSIONOsteosarcoma
p.Cys73X
Virilization
15/144
classof
.London
topotecan
R350P
METY1230C
293H
Fas-L
ABI-3130xl
14,15
comparison.25
AAAGCAGCTCCTGGCTGTC
331–333
T93M
Gata1.17
disomies
zlj9991016120004.jpg
orchestration
Sarkozy
MuTect
Colo320
24–29
www.bioconductor.org
AstraZeneca
Δ3263–3269
RTLILVAKSVQNLAN
ETS–positive
Saigusa
three-monthly
.AMAG
GIBCO
customised
n=385
MPL-S505N、K39N、
construction,13
.UCH
IPMNs.7
pMluc
arrest.5,6
KAI1
Nikpour
equivalentamountsof
pFBT9
Lu-Hai
dNTP
.Purified
verylimited
lineage.12
cytopenias.4
SureSelectXT
cancer-DOWN
.TMPRSS2
IVSlOa
B-turn
2250GrA
5′-HindIII
F53S
ISRSTpSPTFNKQ
Col10
Konigsberg
.Overproduction
4.4-
GI:1045610
TBK1-specific
Subsequently.
230–289
non-LFL
5′-GCACGCUUAGAUUGGAAUA-3′
Kin
Runx1−/−mice
Mitsuyoshi
69,000
36,450
X=k
iIsrael
CTGGTGGATGAGCAGCAGGAGGTCAGAACCATCTCTGC
EU-6
18–55
FluoView
YDLK-WEF
KITY703
NFTs
.Nonimmune
.D-E
R6869
hUbc3
undectable
differen­
RD+DNA
pSLIIB-CAT
prezygotically
pre-extraction
R337C/H/L
Akama
ineligibility
disability/developmental
N-extremity
CDC25A.64
VMA
T649A
∼7.7
numbers,15
NTC
Cys-to-Ser
Myc-mediated
BF001579
1.3:1
asubset
16,24
Arg69
ELANDv2e
c.675delC
FigFig3A
6.68
tinge
Kokontis
ization
c.1806C
Galimberti
antirat-conjugated
pathway–amplified
KEAP1
//www.mycancergenome.org/direct.php
non-rearranged
V184I
h-bonded
.Anti-Flag
Wnt1-driven
19-20
17.6/20.1
T6
FGFR4
mesenchymal-specific
complex7
anti-Erk1/2
.Laparoscopic
Smad4-positive
167C
SCCRDEB2
D304V
B834
Msh6R1093H/+
5′-CTCAGGTTCCGAGCCTAACAG-3′
manner97
5′-TCCACGACATACTCAGCAC-3′
myofibrillar
Arg140→Gly140
ΔGbind=GCBL-E2-S-GCBL-S-GE2
IPH
Å−2
nature.coma
BRCA1Δ11
Figures1A1A
Φ=I
Ca2+-activated
panAKT
.Flag-MKK4-transfected
methylated/unmethylated
DNMT3B7
T710A
Brca1Δ11/Δ11
maydis
promyelocyte/early
SRC-3-mediated
RasQ61V-GppNHp
p21.luc
USA/Qiagen
L858R-T790M.44
TSC2-mediated
NfJ
Cytosensor
differentiation-competent
E542G
onplgNK4
6.AKT1
UN9
thimerosal
non-T790M
2.041
D281G/L22Q/W23S
nihms646437t7.jpg
NSCLCs.14,17,18
number-LOH
c.28
5323
AnalysesGenotype–phenotype
PPACs
non-mucinous
Traf1
FG166_1
33434093
DNA–
proline-tryptophan-tryptophan-proline
NP_075259
GRKKRRQVJRAP
pCEP4-Ha-ras
TÃŸR-llmRNA
79·3
E624Q
Strep-Tactin
oVspring
ρ=−0.54
−50/+150
c.2500G4A
60–62
IPSSb
neo-containing
c.693A
mc.pref.osaka.jp
three-gene
2.7amp
c‑myc‑luciferase
R49
DeltaCT
LH−beta
1.2–8.4
C57/BL6-129
haematuria
Shiviji
43.4
pRS313-GAL
1/151
CASP-2L-Pro
S11F
N-nitroso-N-methylurea
A–selective
PCR2.1-TOPO
respectively.Genomic
-CA-ALK5
5q33-q34
non-R132H-IDH1
Biochemically
~.
c.5074+5A
T308-Pantibodies
mutations.16
K21
CoCl2for
ERBB2-T798M
vanderbilt.edu
1648
mice29,30
BC-3C
Pyrosequencing
pMYs-IG
c.5333-3T
∼1470
S12F
53.4
co-authors181
HU133+
F1994L
24–66
T188fs
TÃŸR-ll.T/3R
WT-mediated
Poisson–Boltzmann
557355
A374C
all41
OCBBF200414713.6COL6A3Collagen
activity.Genomic
Tumor-Bearing
were3.3
H-C
length/left
seminoma.26
.ENSG00000133703
combination40
Ausubel
pigmentosum/Cockayne
AACCACCAGCAACGTGATTT
Dubecco
Pax3
levels,47
UTMB
4298
635
NSCLC.9,10
genespecific
reads/sample
Granulocytopenia
L345-to-Q
telomerase-based
FH1*
long-insert
BACH1–phosphopeptide
g=rc
RG-18N
2–3R
5′-GGATTCAAAGCTAAAAACCATTGCAAGA
Smad3-containing
18,863
593
semi-confluent
cytokine-related
gli
Yabuta
SK29
p.V14I
.INCa-DGOS-4654
53BP1/γ-H2AX
AZ64
uuu
1.6–17.7
HEK293-RETC634R
SCCHN
11SNF5
_803
J-chain
goblet-like
GCTGCCTTAAACTTGGCATCAAAGG
Y473H
R520Q
phospho-p38
4,5
loci-bearing
anti-Phospho
ARP
5A–B
Adeno-associated
morphology
self-extinguishing
propellors
residues*320
ATGCGACCCTCCGGGACG
MYO
Asian-Chinese
Non-funct
UCH37
theATPase
otherthan
nonconserved
c.1583A
CNS44
p=8e-09
F/81
andBox
FACS®
H28
1,460
H3K9me2/3
951–967
∼11.5
FVIIIC
AGCCTCACCACGAGCTGC
A-form
Citifluor
110.1
red–free
Ras/Raf/mitogenactivated
TKIs.42,43
Schwieger
MTMR2
CCR4-NOT
3,046,805x
C3415T/CCT-*CTT
seventy-three
R776H
V769M
P4075.46
Cys65
Desm.
limitations.1-3
pZN-transfected
KrasLSL-G12D/p53flex7/flex7/Brca1flex2/S1598F/Pdx1-cre
VP2000
27/215
T6701
747–750
Flu–specific
PI4KIIα
ALK-activating
correction-based
MKK7-dependent
5'ttattttaaaagtgcttcaaatccttcaa3
capture-microdissected
sitecontainingreporters
ferentiated
.Morphologic
leupron-abiraterone
mice.16
K/μl
histology-based
MMP2/9
multinucleotide
c.6973C
B846Y
28/
pE3-II
KIAA0368
glucose-free
.Hitherto
myotubes
microprocessors
vera,2
SplicingWe
S16-17
oncoantigens149
hotspot53
oligodendroglia
TNP
grade-2
chloroform/methanol/acetone/acetic
3q-26.3
Ncoa6
79Glu
856A
lower-ranked
Adamia
compound–protein
PTEN-C124S-expressing
832
Forment
EPS15
Egeler
subplasma
IMEM
953
LeicaDM
breakage51
Sixty-four
pIRESneo2-SMARCA4
off-state
N-mut
βACTIN
.Pulmonary
LS1034
RUNX2/CBFA1
C-rings
x=V
.Plaques
BMMNCs
Heikki
35,543
SFP
DP71
D2–
TPM3/4-ALK
Tsk7L
ZytoChem-Plus
retrotranscribed
2321
Multiple-testing
V263A
pLenti7.3
one-cell
Duet
study,13
HPLC
ΔN1in
kerationcytes
regate
IX-71
R1181
17.28
03012
M413T
ra.vmutation
receptor.37
Ras/shCon
//www.ingenuity.com
401393
Cirafici
AVCR2A
general,28
cells.28
substrate–dye
non-AML
24:2137–2150.10.1200/JCO.2005.05.2308
46/58
mesenchymal-to-epithelial
light-
anti–phospho-MEK1/2
ese
AsnLeuS.rPheAsnAluLeuGluSerLeuS.rTrpLysThrVa
.GT1
Microarray-Based
extensive-stage
relevant.16
H661
Galactose
IL11
Newfeld
5′-AACATCAAGTAGAAAAAGGGCTGGAAA-3′
37007
pZNai2-wt
pBabe-Puro-Flag-PAK1K299R
.Smad
CTTGAGGTTCAGAGTCCG
10–400
8L-expressing
5′-diphosphate–bound
asinverted
NR4A3
RNP
Ala230
7.Download
SVSI
G465V
cgr531
/tetracycline
5'-untranslated
ultra-centrifuge
AML1-ETO+
BCL-XL-dependent
lobe–lower
p.R246K
36–70
INDEL-realigned
.Toft
.0069
Smurf2.To
D1228A
osetosarcoma
Arg776His+Leu858Arg
coworkers20,21
pZNaj2-wt
49.6
20ug/g
cisplatin-based
Ployubiquitin
theß-catenin
alone.13,22
F876L-positive
NPY1
Hsp90/p50Cdc37
​Figure3B
SUP-B15
near-maximal
14p.G470R
15q22.2
709
1.227
52.38
calcium–phosphate
genes—whose
line–specific
L1a
α3
55/60
pheno-
heterodimerise
described7,35
p.Trp11Ter
cyst-like
c.1558+14
8085-89
R726H
added.Two
3826
nonevaluable
LCH.In
conformation-sensitive
5′-GAAGGTGAAGGTCGGAGTC
0.362261213
selection.30
A2537G
precusors
Y35N-expressing
3Bi
4OHI
ICGCe
//www.jama.com
PET-scans
Scanhead
S7I
Lentivirus-Based
thermonuclease
hyper-activating
gsalmon
33P-labelled
anti-pMAPK
Y628S
.987
al.4,5,6,7
pcDNA3-H-Ras-V12
MELT87
W741
59-GCAGCCTCACATTGCCCC-39
J2-2
genes44
scale,31
G188W
MACS41
*8A
Tsc2wt/mut
SC320207
Cancer/American
5′-AUUUGUUGAACUCCCGAA
stimuli10
s-HAM
118×108
MLPHARE22
CNP
A-3′
.Inactivation
ER-Positive
Co20
.Allavena
NUAK1
13C6-arginine
c.563G
D.A
0.67
YI
karsten.spiekermann
CLP1
FRP1
MCF-7-Ago2_
HLA-A*24020101
F856La
domain–containing
cancers15
nPYpgILvNskfykl
3′CCACGCAAGGTAGAAGGTGA
0.4–21.9
.Nontoxicity
R70685
SMAD2/3-mediated
G264S
9.4-
MCAS
fibrobronchoscopy
p-Y1007/8-JAK2
p53-R175H-expressing
tumors26,54
ERCC4/XPF
ERK2E320K
survival/growth
neuroblastomas15
OS19
10−28
V1144M
IRCCS–Casa
Suetsugu
morbidity52
M-spike
Thymuses
NM_023135
M2001
KPNA4
repairproficiency
YELL-E
710032
16/25
sites31
Gastointentinal
comma-
benefit2–4
57/M
holozoan
sporadic-
Arg1200Trp
9.6×
601598
P=0.0038
III:7
Sos1-3utr-rev
TβRIIR537P-
P533
330A
40–61
replication.32
tympanoplasty
scattering.2
.Yagasaki
AAAGA
DCAF1
data54
previously.58
inhibitors.13
RG7597
recombinases
4.7–6.7
tyrosine-binding
Calu-3
273–278
report.33
∼29-fold
I-82
pSNV
GTP16-18
2E
119751
reaction.22
pairs.8
JAK2structural
102100000
Arg903
9.2kb-
.1502
pMMP-FANCA-NLS-Mut2
MYST4
α-LATS1
Tween/PBS
Q4d
R159C
50µg/mL
~Y32W-A59T
shMET
phospho-AMP-activated
27-76
Dysmorphic
AluSx
K-rasV12…Download
BxB/p53-/-
neo+
JAK2-L983F
9b
lymphomas.16
6/183
KITLG
n=255
Q10R
Fusion-2
γ-retroviral
HTLV-1-transformed
brain-related
.Marray
NF01465
'm
Knauf
malebreast
yAI
post-capture
X94208
0.516
el-Deiry
TIM-BRAF
mRCC
-CTD
GGTGATGAACTTGACCACTG
pT0
domain/dsRNA
Kitayama
anti-phospho1062
thrombosed
ΣhΣi|Ih
mTORC1/p70S6K1/rpS6
tumorigenic
UV218
5-azacitidine
LMO1/2
'V-shaped
KIT-InsAY502-503/V654A
S12E
allograft
diffuselyspread
.NHC
16,487
48.8
10q23f
p.T1324N
shRNA-control1
HeJ-gld
5946
protein/kinase
CAGGACTACAGAAATGTAGGTTTC
p.Arg799Trp
subpopulation
PhK
p.Gly322
MeCP2
frequency74
208893_s_at
TKIs.4
septic
RCM-lysozyme
TGGAGGTCTGCGAGGAACAGAA
M437T
N-ethyl
EBC1
mirtazapine
200M
2012-03-08
T10M
cin
Anti-histone
CD342cKit1ScaI1Lin2
I65T
572–575
Schrödinger
likely-to-respond
R329Q
Leu245Phe
NM_001013415.1
anthracycline-containing
GST-Src
SRY-CAT2
12-15
reorganise
RAS–JUN
-year-old
ab10648
Akt-targeted
5402
functionality81
4,5-P2/phosphatidylcholine
thisvector
cooccupying
2P-labeled
1.80
metastasis.44,48,52
FASTX
Watson–Crick
Ras-GTP-induced
msa
.Electrophoresis
β-geo+
10.5.1.1
specificities1
.PA25
NFkB2-kinase
FDR=0.24
Matsuzaki
SCF.45
ERK1Y148H
LITMUS38i
74.5A5
.CRL-1740
HA-MEF2B
AGAGCAGACGG
28.10.15
Cawkwell
-17
9526
I305N
flexibility21
P468
discussionSimilar
RPS8
1995b,2004
mechanismshave
M36
alÃ-elesin
Gly-778
LS.9
11,20
Dnmt3a2
S342N
GLI-driven
NFATC3–CPNE2
sh-2
Achieva
208,311
Figure1C
Tmprss2+
Illustra
Src/ErbB2
M250S
4A-
obtainedusing
pathogenic/number
GAL4-METS
Coer
Doz
pERK1/2
CIBERSORT
Phe-64
H13K18
.Sox4
high-performance
thecoiled-coil
neutrophil-enriched
HPPS
Gorgoulis
F-bottom
al,2
malignancy1,2
HMEC-M
electropositive
p53NES
dichotomised
K-ATPase
Super-Signal
Val-106
stability.A
hARv567es
Ubc940
GI:178627
0.0540
TGF-beta-dependent
boiling-PCR
protocol.4
cyan200
B′-γ3
3,22
chimerisms
activation.30,32⇓⇓⇓⇓⇓-38
melanoma38,39
CD2-associated
identified,12
Founderc
Mutatation
G2P1
iTARGET
106/dish
.Fusion-positive
ul.
leimyosarcoma
demyelination
liver.5,6
reports,7
FAK-Y576
F1174L.15
sc-2620
P4124
pyelum
0.4
FZR1-depleted
RIPA2
Limma.18
prophylactic
1G0.4
0.3–4.0
G1282VfsX82
c.1831C
glycosilated
plasminogen-activated
let-7b,3
R625C
JAK2/signal
19pter
59dup12
Asn-86-3SerPR3
J080
non-Proneural
gene4–7
Kiszewski
03.50
PHF17
Hounsfield
98·5
RAS-RAF-MEK-MAPK-ERK
Rpt1
50ºC
IKK-mediated
HIF-2α–Max
tumors.26
−1.40
HMG-deleted
7.07E05
1.389–2.308
150–153
Suramin
confirmed7,8,9,10,11,20
AY518308
genomic/molecular
.JHH7
P168T
S432C
p21cip1-dependent
magnet-assisted
RG-27
MLS/RCLS
501
published10
Hoyal
CMV5-ER
achieved.The
Fig8A8A–C
U-2
CCBL2
collagen
.TRK-T3
KIT-wild
TL-Om1
p.Gly173Cys
Br36-Leu41
A870G
alpha/beta
-gal
trP1-Exon27F
intolerance.2-4
Myélodysplasies
K-2500
Histologies
pro-caspase
–13.2
RBD
C5094T
Mg2+–isocitrate
bi-transgenics
≈10-fold
Q78L
KEQPGSDDEDESNEQTFMYYVNDGVYG-
GBM11
P519L
gi72126137
KFC
dbSNP131
bioinformatics-derived
G838
G251E
pBK-RSV-TRAP100
GV-1001
DBTRG
reciprocating
−5.22
HIS-tagged
SDHx-associated
p61RAF
transitioning
pT2–4
254_259
R248L
2641
non-trials
13,14,22
G12D–CCSP-rtTA
9.2kb
ILC-enriched
/ERBB2-
H-L-T
35050
chloramine-T
Penttinen
Abdurashidova
pER4-6
5′-GAAGTAAAAGGTGCACTGTAATAAT-3′
FcγRIIB1
JHH2
cardioprotective
p-JNK
P10721
pRb/p107
018
ofnaturally
Benayoun
PY-NLSs
.Issue
famotidine
TΔS‡
Chinese30
Steroid-Dependent
300-ps
hypersplenism
main-chain.18
mis-sense
significant.Top
p.G68fsX15
Thr-123—In
FLAG-Bcl10
c-Kit–induced
Ligase3-mediated
Lipofectamine®
5′-ACTGTAAAACGACGGCCAGTCCTCATGATGAAGGCTAACTCAA-3′
pre-saturated
dyspraxic
hyperparathyroidism-jaw
.*
1.72
oreviouslv
DEF-domain
Intrachromosomal
ofnecrosis
20/23
133/303
5243
Balm-4
36AA
mdm‑2
GCCTGAGTTCATGTTGCTGA
1.4e-12
Moderate-to-severe
blood-vessel
References•
NYU
C.P
DPYSL5
anti-B220
BRCA2.Ithas
identified92
P=1/M
105–107
Bioscence
nitrogen-oxygen
c.736_741delinsTGTGTGTGAAG
19,21,22
42303
EBPαTo
al,6
KvDMR1
.SNF5
paraganglioma
W557A
-ATTGGTTGTTGAGTTGGTTGTC-30
VM-CUB-1
P-c-Kit
1.25–0.75
R405Q
Acvr1WT
2,285
Sassoon
clinicaltrails.gov
pentamer
AraC
S3–S8
enzyme-like
2.5–3-fold
DLC1-depleted
re-enter
invasion.6
CO-135
MSI-associated
c.6409delT
de-phosphorylation
range20
ter1364
thepellets
3226–3231
CML.1,2
Na-salycilate
.Derivatives
probe4
34d
Haematoxylin–eosin
AF6000LX
74.44
M-Q
TSA58
Vκ3
therapies.64
per-HSC
32P-radiolabeled
msh2-GD693–AE859p
RAB1B
benign/cancer
CK1δ-knockdown
mutations7,8
6B-C
poly-Ala
0.7–10.0
162-001P
CGC3CAC
escape102
MutationsTo
Soultanas
Molendini
and14
Beckman-Coulter
hypoxanthine-aminopterin-thymidine
RGNT-like
2017.
flight/mass
IMHDS8843-847M
K.L.W
EWS/ETS
Stommel
activator-tagged
,6,20
.ENW
Pim-1
ab137321
B2-domain
HCC78CR1-3
1:1000–1:5000
ATF4
.Pigmented
RAG-mediated
orexin
9-mutatedintestinal
Gnessi
WDR45
164.58
RAT4
AML,66
M1-
Arg770Stop
numbering23
O.Kindler
−545
TARBP2
â€˜end
IL2Rβ
2EWS/WT1-KTS
WS-1
interaction.24,30,31
HeterozygotesOnly
.Hydrogens
CA38579
nonplatinum
T650A
biopharmaceutical
.166
AAAGTTT
C163S
JB1052
activity24
a–g
radiotherapy
-positive
activation/signaling
V.C.
HCC25-
Tet-off
V1110I
P318L
RP11-124O11
Fbw7+/+
Pug/ml
PharmaciaFine
.S9
8p21
2669
PI3K/PDK1
CCAGGCCCCCT
HEN-1-like
morefrequently
Tlymphoblastoid
anti-GRB2
bisphosphoryl
Flt-3
KAL1
antip190
RASF156L
5'-CTTCTTCAGTGCCGCGACAGCCACCAGC-3
Sala43
v1.0.13
+v
chromophil
K229
≈602
-1128
PQC
hysterectomies
p.L597R
NRF2A
Foulkes,2008
.Half-filled
immunoprecipating
Lines/Culture
Villacorte
results.44
accelerat-
NM_010662
A719
ref-
P780
MSP-PCR
bySherr
PhD.
6,049
.Non-infected
antitumorigenesis
mesothelioma.70
.SCF
ROS1/ALK/MET
GGC1TlTMGC
VX-680
transcription-dependent
ZKSCAN1
fibroblast-Iike
4q11
c-Ha-Ras
.Affinity-propagation-based
topoisomerase-2
CMML.2,3,5–8
DOCK8-CBWD2
repair.21
polyI
Quik5236R
syndrome16
Ma-Mel-48a
.Radiolabel
FGFR1.1
ALK-knocked-down
Lysine-HMTase
DNA-PKcs
Lys9
Bronchoscopic
Ser216
Biopathology
423
Acknowledgment
.K4E
Tyr2274
11q22.2
one/family
M48
Cross-over
PD033299
Gly719
Y.B.C.
0.04–3.53
.Sumihare
transformation.23
.Sf21
1ot
.4,25,26
Ex11R
two-group
.3565C
metalloproteases
D134G
.Compatible
Yq11.222
AK089315
MMTV-rtTA
17-615
IDH2R140Q+/+
133–149
G311S
.LS-Associated
Pro-Glu-Ser-Thr
'intermediate
p.Y439*
NASHILVTELLKQ
N47H
mitoses/HPF
Teratocarcinoma
GAS6-RASA3
3lck
G37Ras
K42A-mediated
ACVR1-mutant
1,370–14,901
lpage=5175
MPCsBCL2-derived
R117H
therapyClinical
P278
L1775F
Microcystin-LR
syndrome.32
S789P
0.148
Paddison
neurotrypsin
S11IN
phosphoacceptor
G776S
BIC
Fra-117–19
R1095C
ZZ-type
7759-1
50ng/mL
Fig.4.6
NHL803b
x-linked
.Proposed
Stoppa-Lyonnet
NFATC4
Vitebsk
RalGAP
260-bp
Midostaurin
LR08-328
17q
1979–1997
suppressor.20
12q14–21
www.broadinstitute.org/cancer/cga
chromosome16q
nonmitochondrial
ttattctcgtccacttgcagagtagg
.CARD11
estrogen-driven
ePheThrGluPheLeuC
non-fibrillar
8-Mb
inDMEM
hypolobated
Base-Excision
lmutants
2.1a
Galkin
hes1
fs*
mcJ3
FG12
GST-C-RAF
KRAS-mutation
Vanox
terminal-linked
anti-BAF45d
12/10HPF
c.1801_1812del
pTRKA
.Numerical
QIAamp
S1512I
internalization65
TCRvα
TCTTACCTGAACTCTGGAAT
hTP0
metamyelocytes/band
245–247
.Second-
1.51–3.78
LBL
PDGFRAΔ8
Ui-Soon
β-carboxylic
Abl,17
to−377
4C5
G-banding
naling
FasL/CD95L
1.3–74.0
siSRp55
PAGE2
80/181
181.1
types.68,69
Bnip3
T564A
0t
Jade-1-sh1
Pilomyxoid
AA-3
3.73
proteins.Strains
KDRD717V
sonography-guided
.4.54
.TP
Theodorou
VHL-F148A-Venus
5′-GAATACTACGCTGTGCATTC-3′
single-base-pair
200–500-nM
5′-TCTGCTCCCACAATGAAACAT-3′
E-dependent
.CNAs
PM7
Lopez-Correa
postinitiation
HDAC10
anti–Stat3
AFU
wide-field
mitogen-activating
KIT/CEP4c
.688
28,31,32
l-proline
carmustine
members,5
ATM+/+
.IRF4-deficient
β-oxygens
domain.7
Sca-1
.39,62-66
Floege
skele-
Gonzalez-Zulueta
150330
spherocytosis
.Trained
D18S363
LTR-specific
5′-TGAAAGTTTTAGCATTAGACAAC-3′
inter-lesional
cyclin/CDK1
R458H
.Dimerization-impairing
Phox-I1
1125–1784
KITT670
PS100069
S4E–F
ChlR1
anti-HLA-B7,27
INK4b
1produced
T1604
62–63
lung104
.Weighted
AF1129
766K
1E-4
processivity
intra-tumoral
pSer990
CIC-positive
conformation-speci®c
anti-NeuN
transautophosphorylation
Reczek
charge-conservative
VACO10MS
39,760
GFP–Fbw7α-K11R
CSf1R
07
precipitate
69–75
mutation10
bi-monthly
γ-P32
single-ended
L747–P753insS
HA-Nrf2
332–452
5′-CCAACTCATGGTGTCCCTTTG-3′
pfam.sanger.ac.uk
immunotherapy
GCTTTGTCTACGAAAGCCTCTCT
V600E-K507
Mirkovic
library-derived
C92–605
β-catenin–TCF7
ZBP-
SETD2-
RTK/ERK-mediated
development20
31:247–253
.Considered
Phagemid
Ib/II
tCg3tTg
GATA-1/2
inResponse
genome-coverage
mesenchymoma
worldwide1,2
p21p
.C,1.6
27F*
3/31/98
WT1-dependent
.NMF
IgD
mono-phosphate
Lkb1-SL26/pAHC
mycLEF
variants34
immunostinaing
T875N/F595A
rank-transformed
CWS5
spliceosome-related
Qu1
probes.a
IGtranslocations.Genes
KMS-12
R2-TSC1.3
non-ICL
32–37
-heteroduplex
.ZNF198-FGFR1
DMBA
Ras-GRP4
19-bp
co-over-expression
carriers.These
ScRanBP1
Asp1002
.475
Chauveinc
p-Src
654/
NM014324
capillary-based
ETV1-silenced
interaction161
Protein/splice
fwhm
7,12,13,26,31
UM.68
2628
Glu707P
SMARTpool
oxygenase-1
R363W
Langenbeckstr
Woenckhaus
chorio-epithelioma
days.On
mutaion
1.435
c.1798_1799
.GST–Grp1
18–29
∼500
THAI27
revealany
5′-GCCTCTTAGACCATGTCC-3′
backbone.The
.2145,6
Time-to-progression
osterix+
Stefanska
H249
AtlasThe
c.29C4T
NIHGR
onwhere
C468Y
pulse–radiolabeled
D/CDK/p21/PCNA
603368
R466S
48-72
`F4
Glucocorticoid
ChemDiv
INI1-3
.PMM
Retrovirus-infected
integrins6
FANCJ-catalyzed
Advia
T-cell-receptor
5'-cttcaccgagtttgtgaggccggggccctc-3
Glycosylated
Yokozawa
5′-CTAGCCCAGGACATCCAGGTA-3′
Tosj
TGTGGACGGAGA
NCT02053636
b-D-thiogalactopyranoside
H178
Methodsâ€•
cadherin-like
Herman,4
2.9-Kb
cancergenome.nih.gov
GGAATTTCTGCTAAAGAATCGC
disease.25
≥40×106
tumor–suppressor
Hec
C2-type
upregulates
flatbed
inactivation102
71231
PHTS-associated
CTgCCACCTCAgCAgCALCRed640
MKP-1-deficient
Nexavar
A2420V
kVLsyLgnHmNIVnLLGaCTiGg-
dsRBD
NGS-directed
Public−Hôpitaux
p27T198D
patient/tumour
NAPESLkdgvFTTsSDNWSFGVVLWEItslAeQPYqgLS-NeQvLkfVmDGgyLDqPdnCPerVtdLNRmCWQfNPnmRptFl
high-profile
C6I8S
14q13.3-14q21.1
K634A
autosampler
Tetrahymena
SectionResultsIdentification
PAG
.Gazdar
D17S1322
.Flp-In
N-NUP98
Antibodies—The
RBy41
Pro44
GATTTTCTCTTTT
35,52,53
COPADM/CYVE
Spred-1
11Va
n=238
mIL-3-dependent
Pre-existent
p.E680K
SKCO1
TECAN
10a
18/Smad2/3
well-standardized
activity13
infection.and
AppliChem
CARM1+/+
alpha-TrkC
C62A
S2368
.Antigen–antibody
RHEBwt
misexpressing
Dim-5
.Slow-release
Aurora-like
AXL-high
ABM
extramolecular
DD-only
119
ETV5a/TMPRSS2
DH10Bac
PI3-K.
CUL
p53IHC
miR-143/145-deficient
PRISM™
difference-Fourier
5RSDA2+
dependency—addiction—of
Gamou
F35L-PH
MED27
AMKL-associated
5-TGAGTTTTCCAGTCCAAGGGTG-3
33:1228–1238
p.1437
GFP+LSK
non-HCV
I94L
.Synonymous
pathways.It
613254
ATP–agarose
Cys769M
7/61
36-fold
228
CDK/f
0720460
S87F
An~erindian.Although
CWD
normalDNA
Multi-Gauge
Basson
+358
MPLW515L-Induced
Asp770_Asn771insSerValAsp§
Abl-induced
Y2088D
c.2927G
8-R
Shain
SM28
390Langabeer
pair––and
3/19
Vinagre
PR1
205312_at
K→R
p15-65
.Lengths
R100T
nomeric
ultrasonication
6μg
ATM/p53
HMAs.22
anti-Rac
K158N
Ser508
AAR89523
OCDfl/+control
pEGFP-C1
detachment-induced
MEN2/FMTC-causing
082-257-5858
un-biased
ARID1A
al.,1997
drugs.Epidermal
7.6kb
IL-2
AIII.2
HSC001
KEAP1G333C
.Electrospray
2.433
MSCV-IRES-Venus
J-L
2.Effect
964–1922
TCTGAGT
I-III
WAT
GST-mediated
WK6
._In
8S
M/49
disproven—and
smoke-free
1.5-5.1
vectorette
N1/2set
gram-negative
andinteraction
Lin-28
SNPnexus
Runx1-EVI1/+heterozygous
tumors.3,4
parathyroidectomy
monodispersed
Pyrido
intramedullary
IpI1p
BRAF21
α-Hcf
C273
tumor/non-tumors
T246
MARTHANDAN
post-therapy
CK1δ
.1153
SEC31A–JAK2
1551
dye-swopped
2-phenylpyrimidine
460−470
Figure1A.1A
itwould
3β-dependent
Loss-of-function
I184
wgRna.txt
3028+1delG
4G-H
.p.T231
SCCO-009
5′-ATCCCATCCTGCCAAAGTT-3′
.Doucet
~3-fold
WD
0.02082–0.04724
7156
Asp571
.Large-scale
5mC-oxidized
BacPAKBaculovirus
exon/
EVI-1-transfected
DRN00B
seereference
p53-upregulated
trk39
E-H
trilineage
Cotargets
ILS-600
NA/NAHEC265
67/M
Val-804
Fgfr2Δ/Δ
analysis.22
pcDNA3-VHL
MSH2·MSH6
P=0.03
pathways20
Immunologie
48,107,108
WHSC1-mutated
PEG-asparaginase
Plexxikon
cytoplasmic/membranous
Fig7H,7H
cis-splicing
BAFF-R
JM-G559
LMA
.Region
R509H
coefficient=0.751
∼24
108-bp
7S
∼23
Ntziachristos
C‐TSC
type.Table
K642E
Marque
1252/1253
Aglietta
lin-4
CCATGAAACGTGTTTCAAGC
SDA
5′UTR
//www.rproject.org
target-gene
'activation
assay.7
supertransactivation
159.3.1
RMC20C002
.1638A
PCNA-reverse
59±42
MMTV-Cre-7
Bujard
F16
immuno-exonuclease
Sixtyone
P504S
EQDKHLVAVKALKE-
co-crystal
characterizingthe
hyper-stable
550–558
p2lRas
integrins.Figure
features.17
I608V
.Alluding
EQKLISEEDL
size.12
Aminoguanidine
Y441
PLT
c.1453+1del
CTCGATATCTGCCACATAGTTCTCAAANNNTGTGGGCAC
3/86
c.2083G
Bertola
A82S
​and6
cell.16-18
DeletionsWith
PEO23
Autoradiograph
β-catenin–Tcf
C-lobe10
K660E
pI=10.4
NS488
CLR
OX40-deficient
RMAsketch
DKK1/2
2-deoxycytidine
hetero-tetramer
CAG-cre
FGFR1–4
PMBCL
c.1953T
GSAAA
Cip1/Waf1
90th
Hepatobiliary/pancreas
Eyre-Walker
Bartsch
EMT-type
1997.
Smad3-null
3402
identified.105
ECV
'hot
AID-dependent
reported.5
pSRE.L
disequilibrium
syndrome—RPS
SequencingKIT
2000–NA
Thr327Thr
YVMA776-779ins
P38-MAPK
//www.pantherdb.org/
keratocystic
pLGK669Z
PR114
7/53
non-MYCN
growth/Anoikis
plasmid/106
antigens.Figure
Nicolussi
myoglobin
//dx.doi.org/10.1136/jmg.2008.057943
chemotherapy-naive
PLD2
V907A
3.966
AR-expressing
UM-SCC-17B
S2.9.2
TP53-mutated
75-
−0.6167
Iacobucci
6,20
.Fields
2432–41
syndrome4
Runx1-EVI1
KMT
co-occupied
genophenotype
RB1+/+
deletion-mapping
X-ray
Böhmer
lactoftrrin
M923
.Two-wk-old
GGGAAC-3′
intra-vasation
P50.0346
p.R458
WL
lIncluded
pres-ence
pEGFPC1-PTEN
556
c.9346-2A
12552
Turbo-Sort
recombination-positive
tpr-Met
c-Kit-expressing
phosphatidylinositol-4-phosphate
MYCN-hemizygous
GACAGTCGACAGAAAGCCGT
MSCVneo-MA9+MSCVpuro
NS-SHP2
immuno-purifying
P234L
Electropherograms
Bozulic
MSH6-31
CAF37
G833D
margins.18
PR2106R
8School
2-FOXA1
6.4*
Peters25
Lua
Nestin+/Olig2+
Notch-mutant
12/14
/β-catenin/TCF
Srsfflox/flox
amino-acidsubstitution
M552_W557del
whomet
pGS5-STAT3β
2EtsΔ138murine
PGC
andtemperature
.Specimen
PDGFR-α-positive
FoxH1
O-fucosylation
monotherapy-related
cells.25–27
R489P
RP11-514K1
isobutylalchohol
652del
vitro.6
2.004–38.64
1,378
Cytokine-inducible
vitroor
DLBCL-derived
Hydroxyl
|-cell
HOXB
MB435S
RASV12
MEK1P124L
5′-CACAGAGTCGTCATCCGTCAC-3′
.Inborn
Tem/TMZ/Irino
nt50G
p53Mutant
lectins
-cATP
.Delineation
16–70
L155R
c.68_72dup
V-BASE
-l
unintentionally
photoaffinity
3EYG
nevi.18
Initialevidence
'p
'61
insulin-stimulated
RouxDosseto
TRK1/2/3-addicted
GPIIb
II-inhibitors
mitotic-apparatus
SnpSift
pCR259-p53MTs
1538
DFARBER_MSKCC
Goettingen
.101
11β-hydroxyl
AB6
TTAATGCGCAGGTTGGTGT
V471F
.Mastocytosis
neurofibromase
Asn41
Hettich
F177
RCC.48
1961
Hodi
Elf3Δ173–241
splice-junction
progression.22,37
N842I
HMC-1A
R482Q/R482Q
theinstructions
approx5
cdk6-R
anti-ROC1
K816PNA
IMF
5c–k
myristylated-wild-type
NIH/3T3-expressing
QuikChangeTM
Sigurdsson1
Ponatinib
.Lys650
macrolide
superinfection
cotransduction
−.39
.Vincent-Salomon
third-generation
RTEGARL-
appearance.1
2.9-kbp
WT-KD
2006.
791
fullFor
Restriction-enzyme
H149R
5′-TCAGAGAGTCTTCCCACCCAACTTGAGTCC-3′
TCACTGCACACAGAAACCGC
SNR
heat-resistant
.Small-cell
NM_020529.2
iron-saturated
R-spines
Brightfield
sodiumdodecyl
shCDK12+ve
above.36,40
.Unequal
2056
system30
.Analogous
FOXA1/ERBB2
miR-34b
7q21–22
Fig.S1C
,47
BIOPOLYMER
ÃŸ-cateninmay
2-101
BRD3/4–NUT
122.86
B5-fixed
Y167C
RAF265/CHIR-265
T328R
alanine-threonine
Superscriptase
CMML/AT-CMML
TRE-containing
Raue
Higashio
p18INK4c-deficient
27K
PAX7,62
UMSCC
eo
R37XM40
databases32
Δ5′
Msh2p
TCF12-NR4A3
5-500nM
F1578
single-read
Lys345
H710P
hMAD-4
3.0-Å
.89946722
.Mir
gp.R144C
aconitate
CVCL_0060
T4330G/CTG-+CGG
alpha-induced
byMET-specific
NG_029556.1
β-catenin.38
GSF
elsewhere13
signaling-based
−3.4
2230A
r.389_584del
NRF2—including
D†
Tris•HCl
Co-occurrences
p110a-expressing
.PER
yl-cyclopentane
SNVMix2
4/17
rhabdomeres
BH3-proteins
1p22.1-21.3
G382D
cancers94
P32
27/115
Brca2tm1Cam
Anchorage-Independent
20.003
YFP-EGFR
R1066C
.Subcutaneously
–13.6
DSB
1060C
VX-11e
GTPgS-bound
1.0´105
transcription-incompetent
GST-Flag-tagged
5-35
RAD21/SMC1A
pelleting
Nonrepetitive
exon-25-depleted
G711D
oversimplification
Hetero-oligomerization
αC-β2
ChIP-coupled
xanthogranuloma
.Though
SLC45A3-
Hprt
.GFP-expressing
NCT00758134
hepatocarcinogenesis.47,48
LR3
14151617
Ggbnp
pBB75-ElonginC
6_
MERmaid
CarcinomasPreinvasive
335–354
0369
741-783
Plcγ1
chemistry-based
wasvalidated
10–15×
PDGRFB-PDE4DIP
mRNA-based
1032
Dlexpression
24.3
edTGFBR1andTGFBR2
FGF/heparin/FGFR
.Arms
Cdk2/Cdk1.18
NM_033355.3
25,943,375
MT-LexA
TilT50
V-39
dierence
RAI
Fig.6
betaP1–loop
ProceduresMouse
brales
PLX4032-Resistant
LLNCO3
RAS-GAPs
AC133
Msh2–Msh6
'small
Laboratories.BaF3
intraoperatively
immunohisochemistry
small.1
c.899+1G
∗∗p
Pre-let-7c
APRT
FANCL-C362A
Figure3d
CD19+
IFN-alpha
HSC62
~80KD
Auto-SCT/BEAM
4-hydroxy-tamoxifen
test-
Prol099Leu
100µg/ml
HA.AKT2
itscognate
sedimenting
VP16-GAL-ER
N63
7q11.2.20
putative-binding
thestrains
HOC313/c8_2
Titf
Event-free
//www.karger.com/WebMaterial/ShowPic/252152
B277
1–42
genes.155
bar-code
Krasex3op2/nat
NRAF
8del
.EP300
Skp2mRNA
10.7.3
C1545
155–181
1.1,15
carcinomas.39,40
3m
best-supportive
drop-wise
Y514C
.Sfi
cycles/Burst
immunodetectable
c.3G
ICBAS
thrombocythemia2
1.15
beta-galactosidase-positive
-AAACGCACACCGCTATGTTG-3
.GOTTLIEB
Fig.3A,3A
172°
tumor-node-metastases
Tournier
29.0713.3
DEAE/chloroquine
K6+
BAIAP3
study-design
nosis
I43V
TRED
Egfr
non-structured
277–425
p.Asp177fs
cellsin
.Antiproliferative
binder-1
VEGF-A/B/PlGF–VEGFR1/2
Choon
cells,35
TGFs
0.173
-CATGCCGTGACCGAGTAGC-3
38.7
Cytom
MDA-MB435S
97-118
.Quite
low-threshold
Pax-8
andluciferase
.Aci
ZBP-89.9,10,15,40
610111
Renal
5′-CGG
Cdc42/Rac
2M
Idh1LSL/WTVavCre+/WT
.MmXrcc2
adenocarcinoma27
pCMV-puro
A−C
ADP-ribosylated
of…
ImmPRESS
501-Fc
.Krasex3op
5At
μmol/L§
Pik3caH1047R-driven
Shugoshin
cryopreserved
p.After
RI-Hind
shErbB2
SK-
FIP1L1-DGFRA
multigenetic
10nM
5′/3′
5′-CATGTTTGAGAAAGAGCAGGAGCGAG-3′
increasedrisk
CXCR2
DQA110501
scientific®
pAcGFP-C1
H193N
UNG
ICN1-activating
p16-L2
Cys-74
150800
delH233Y234
NCI-H716
-Alignment
–Akt–mammalian
VER-1–4
results.10,11
CML*
Child-Pugh
40μl
interexaminer
.MTC-TT
MergeSamFiles
InVitrogen
−T/L
Sequencing—DNA
5â€•ExonNucleotideCodonDomaTinaAblleter2atiSoonmbpatic
miroRNA
SNT2
antibiotic-free
T1114I
ets-related
GSE31671
non-ATP
LK2
250g
protease–expressing
.TAL
autophosphorylating
IIHFYNHTYVPLM
EpiTect®
EGFR–RAD51The
-bearing
N596del
ACC.12
Buckowitz
EGFR/RAS/MAPK
Kuwahara
D319A
CTTTTTCTTTCATTTTG-39
stage4
pET29-cyclin
NaPO4
Multikinase
BCR-ABL1-
antibody-binding
G709A
P=5.4×10−22
germinoma/gonadoblastoma
~triangles
EWSBR1
Furusawa
V162M
pLp53-Y220SSP
Gly292Arg
cytoplasm.It
ERBB2-amplification
33–42
mmol/liter
203–217
19.Vector
SH2/inter-SH2
activation.34
phospho-RET
ARF141
Ad5-CMV-Cre
5′-CCTCGG-3′
EGFR-directed
Ki-Ras
psor
0507
Interdependency
S473-Pand
Cancer-specific
phosphorylation-regulated
1G1
2919y
.A-to-C
PGK–tk
NanoLuc-reporter
Ehinger
21*
R150Q
PHO5
.Ka
KH
C634R/E884K
hematopoiesis,19
Mow
e13a2
0.0182
method20
cancers1–3
751-1000
1694–1708
FL2
5F3
post-implantation
HIF1A/ARNT
α4A
:877–887
45th
anti-phospho-MLC
membrane-ruffling
DSBs14
.GFP-positive
snR39B
E486K
nMEG
prolyl-hydroxylation
cells.24-27
EndoGluC
pLS210
pY2
Fig.1C
structure-guided
61/90
T7/T3
Wekken
9475A
yes-associated
V648I
KB83
patients.15–18,31
LCMN
inter-and
×8
V843IThe
5.Fig
HES6
973-
membrane/F-actin
N106K
ualberta.ca
p=0.048
leuzine-zipper
Paoli-Calmettes
130/65
ΔCterm
systems18
Ab-1
pfg181T
YN-C-RAFWT
phase.28,32
ACVR2A
expression,32
E-CD
PIP
Fluor–conjugated
647013
adipogenesis-regulating
ST480
I1617T
Tgf-a
20-μl
V369G
Tris-acetate
StressGen
.NT
pBabe-Puro-GATA3-R367L
3-foldincrease
5-GAATTGTAAAGTATTTGTGAGTTTG-3
.Incidence
GSE28698
1,61,64
helix-hairpin-helix
Arg181
K+M−G−
.SSM
microaneurysms
pS2
wu105
cohesin-deficient
TCTTGAGTTCTGTCCCCACA
.Gating
inhibitor–naive
Hnf
c.7805G→C
diC8-PIP3
13.
bedefective
costained
R611
Sephadex
Tyr553
Mre11+/-
q11·2q13·1
P=0.297
calmodulin-binding
4-09
TEAD194
BCR-ABL.38
c.8754G
Kitaeva
autoimmunity5
~short
respectively.6
1P38
nanodisc
192TCS†
L-744832
0.277–2.725
pCDNA3-NCOA2
p.A68T
leukemias.1
equiv
left-most
pLXSN-ErbB2
fgf-3
Average-ratio
EGFP-B56δ-P53S
ErbB1/HER1
DeltaC
M354L
p.Leu57Val
cells.13,16
Q510E
LeCouter
exon13–16
Ligation-dependant
H524Q
D9S974
F486
hydrolysis.18
MET.14
transcription-activating
H200P
PRE2005
11600
57y
3.230854067
R170L
Lt™
C°
PIK3R1WT
0.05⁎
Y32WQ61H
E1552del4.
4039
ΔΩ
ulcerate
GACAGAGCCTAAACATCCCCT
D2665G
'isolated
q12–22
leucine-to-phenylalanine
p21ras
hypermutablesite
near-activation
TKI.1–3,5
cyst.18
44.8
PRC
Moelling
5973
lipodystrophy-like
TERT-based
lentivirally
stimulated/unstimulated
21-h
ETV4_3VUTR-r
0.941
sublinealso
.Hsp104
110-PT94
helix-C
16q21–q22
Pouponnot
066–2011
ponatinib-resistant
Lengauer
ARHGEF7
F-box
871
nt1510insTGaa482Stop
Pharmagen
5.9
TIVS
SAR23
.Leukocytes
134×
6CAGGGAT
substrate-E3
6-mm
waf-1/cip-1
111,650,000
S6-S10
973-EGFR-expressing
E3002K+
5–57
PKP1
3.51
continuous-dosing
0.05.Cytokine
PALBP
PGL4
S522
711
non‐Hodgkin
age6,7
.Fig.2D2D
Hdm2
P=0.047
Phe/TTC
SIRT-1-knockdown
60‐year‐old
patientswithHER2-IHC–positive
Topgal
59-TTTCATGGTGTTTTATCCCTC-39
R1117G
137G3T
C-MET
Arg380
Fig.1B,1B
papers13
1,252
4060
RUNX1-target.33
Malay.-
thatGTP
Infertile
sequenceand
.Log
A36A
OVCA432
T260I
functione
Sgs1
HMMR
AC220-002
68290324
iron-sulfur
c-Mpl-F104S-GFP
Val431
13q12
CDK4amp
SPOP-W131G
Eph4
c.3544dupA
14-day-old
2434
degradation-prone
52–73
LRP6-
Centricon
.Thermophoresis
31–33
RAS–RAF1
Caov-3
K99N
CI=0.79–1.63
20–73
PCa-related
heli.nevanlinna
Cdc16
J088
Myr-Akt
non-redundantly
al,4
26/53
Layanyi
crizotinibresistant
V533
investigation.31,32,76
C324Y
scoreZ60
.Di¡erential
Vhl-Arnt
Y813C
CENP-C
.Adi
magnocellular
CS-1
presaturation
Jak/Stat3
5'-CTCCTCCGCTGCTGGGGTTTT-3
anti-H3K27me1
DNA-Bending
X-P.
apoptosis.3
D9S149
Chk2-specific
Sheahan
//cabig.nci.nih.gov/community/caArray_GSKdata/
S4N
.X-linked
NCI-H1395
VHL-Flag
R1200W
phosphorylationFACS-based
P-PNP
study13
R749W
PD+ABT
catC
V469
Histologyb
GFP-shRNA
22/25
F115L
proliferation.Pathways
Hemel
Non-MLPA
Proportional-hazards
mass.1
0910
saturable
I1183
NM_020910
QnLccKVSDFGLtRlLddfDgtYetqGG
*4
MDM2-pS3RE
1,791
62.1∗
carcinoma7
Ioannidis
10,14
34–37
Arg-140
theHER2
acrylamides
23.0
c.557T
Y-583
complexes16
0.2ug
ΔΔδ
Hartenstein
96-wells
Wild–type
POU
−537
pMAM/BSD
Houillier
GCGGCGTCGC
139.1
0.22-μm-pore-size
Otx2-negative
Sulforhodamine-B
clients.38,43
DMSO-
4-11019BCCAGGTCACVFACCTGTC1235
KIT17S
FxxLF-like
GOF-enhanced
3/29/01
presymptomatically
mocetinostat
sequence-verified
.E2F
city-block
nuclei-cytoplasmic
.Asxl1fl/fl
−1938SRYP
0022-1767/12/
.One-way
FANCC/FANCE
9.7Asahina
1.5-megabase
-GCT
D–A
Ochoa6
Myelomonocytic
43+A325
Lys14
RRRLNPAPAGSAVNGTSSAE
5α-androstene-3α
581-720
andsolubilized
ITD501−502
Ala502
KITmutant
0.328
EYFP
Artery-specific
established.By
www.plosone.org
RP11-355D18
5.1.1
AJ006288
Extra-regional
INPP4B-positive
cytospins
Borkhardt
conceiv
q11q22
A541V
Ril
,6-diamidino-2-phenylindole
17–31
metachronous/metastatic
Alexa-Fluor-555-conjugated
a02-Q205L
gtaatgtga
BreakDancer
SRSF2-mutant
RAF-MEK1
Href8
ezrin-dependent
T3349A
theirrelationship
RTCA
us.expasy.org/cgi-bin/protscale.pl
mechanisms.Biological
p.G469V
B-RAF-induced
gliomas77
predisposition.3–6
c.904C
baseline\
.Could
192–194
501,502
HNF1A-deficient
110-
NSCLC127
27,341
K482MBRAF
Ilumina
1,060/1,469
malignancies21–24
2291
BM-related
Radboud
interleukin-11
G54D
56/27
Batzer
Arflox/+
PIK3CAH1047R-dependent
XPO1-dependent
T388S
7FF1
T149A
hypercholesterolaemia28
S466L
Sanner
PTPNS1
STK1591A/91T
−6.0KRT6EKeratin
SW480-transfected
recruitment.The
χ
148
L1854X
l886V
nuccore
TBD—residues
DMI
VRT11E
ribosomes
kinases.3,11,15-17
,1,2
active.6,7
6/00
AC008416
vivo.There
population.30
BRM-
9755
ARGBP2
96×109/L
MDA-MB-435S
R867Q
respectively36,37
anti-TCF3
OSMR
diseased-eye-ratio
NM_010008
KRAS-Hs00932330_m1
Fast-1-Smad2-Smad4
PKB-directed
AGAAATAGC
biochemicalstudies
24670
phenol/chloroform.11
.2459
Syndecan
cbt-15-1239-g3
DICER1.19
v1
0.732–1.633
'21
POLD1-exo*
.SUM52
aq-Wt
anti-phospho-Raf1
A_52_P662752
PSA/β2-microglobulin
tel-jak2a-expressing
studies.12
reported,49
5491
subtelomere
self-reported
anti-HDAC-1
3569
Horiike
mlh1-deleted
BrCN-activated
Evangelista
androgen-insensitive
42-4
mKmt2d-Reverse
.5238C
Supratentorial
H-214
pre-treated
CIMP-low
set7
TEM813,14
Id4
Eid
myclogenous
0.715
down-regulated.12,13,15,16PDGF
Fix-and-Perm
equina
Mm768bpΔGGAA
Non-classical
prestained
HindIII
phenethylamine
factor-b
actaaacag
RAC1-NF2
non-commercial
Chromotek-GFP-Trap®
Figla
7/exon
2-OG-dependent
Kiriyama
subvariants
dogrowth
ERK2wt
Invistrogen
//www.Mcgill.c./androgendb/
hFU
gene25
trametinib-sensitive
Glu540
Scil
ERE-containing
pcDNA3-FLAG
µm2/s
p38/JNK1
inactivation,17
SPDP
variable-diversity-joining
5-AAGAAACAGTCCTTTCTTTGGG
Ser-9
nondisruptive
/BCL6
ABL1-T315I
6.60865
CHOP/IVAM
dark-blood
2j
6.2Em/GFPBsd/V5-DEST
D1709E
form.19
p21-GTP-yS
phe116
764
.ARV
n=23
ERG-MAb
inLNCaP
al.16
stable-p53-knockdown
p73-specific
incorpor
1.25–2.06
46818
/p53
G734E
EX1_EX43dele
conformation.2
serialsectioned
Gompel
group.3
H00007468-B01P
forEF-1α
hkucc.hku.hk
30th–35th
8.9342
potential5
Snf2
immunonologic
CHCl3/methanol/HCl
Tra1
12,14
p300-myc
MET56
M117V
p300/CBP-mediated
aYnity
allele-specificity
Ex8-9R
PFBC
FLP-rescue
BALT-H
SZ
PCMV6
410–414
5q31.1
weak*
Condel32
Banno
scale.12
LR07-041
3512
.Gliomas
1894
Lys-CH2-NH3+
Rb-pSER
III-β3
enzymes13
contre
tetramer-specific
MDLSALRVEEVQNVINAMQKILECPICLEL
BRCT-C/
mutatedalleles
digoxigen
sequence-tagged
mechanism6
GGT→CGT
re-activator
M–1
glycerin/1
c2_kegg
small-molecules
19p13
I867
.Two-month-old
D1Z2
HyClone/Thermo
tantomerasea
35–433-CFL/NFL-c-Myc
3mM
capecitabine/oxaliplatin
pJexpress411
MMLV
ps-ns
standard-of-care
polyacrylamidegel
Kumura
CDK3
IC50≈34
ERE3-TATA-luciferase
Vl
stage.7
BioEdit
pilomyxoid
ALP-like
chromatographed
RG-1T
receptor–SMAD
Figure4F4F
22/184
pre-supposes
RP11-163C9
CIP1/WAF1
self-activating
RARB2
pcDNA4/TO
Fbxw7
males.32
33:95–99
v.0.1.17
receptor-SMAD
cell–cellular
L-Arbresle
B-1200
S172L
MyD88-driven
T147I
–5
re-localization
.ESR1-CCDC170
vitA2-ERE
Ile400
6K
35-min
microscopy
Aur-B
sub-branch
.Irrespective
acc=GSE42649
seq*
pASZ11GPD-hTRX
sarcoma-amplified
Wnt-pathway
149–166
'See
p.Pro112Leu
SOScat
S33AS37A
UACC812
full-blown
8,481
PALx8-TK-Luc
glioblastoma,4,20
Groffen
Vandenberghe
8.9-11.5
Fasman
.~'.~
HKL2000/3000
pRS316
R1138W
RNA-sequenced
WJTOG3405
S577S
HER3-targeting
Arid1afl/fl
Msh2–Msh3
VEEINGNNYVYID
MPD,3
FOLR1
K145M
.His6-tagged
5,8-
Y849K
5′-AATGGCGATCTGCGTCAAC-3′
pY1230/1234/1235
p27T198E
P772Ra
1.49–11.45
Pierreux
SHP2-KD
368-5698
domains—including
71181
Wort.
sorafenib+sunitinib
//www.broadinstitute.org/gsea/
property.10
pcDNA5/FRT/Myc
Al-Kuraya
AICAR22
factor1-alpha
FGFR2-family
3–350
Fryssira
29,35
adhesion.5,18,19
dual-transfection
CAAAGCCTAAGATGAGCGCAAGTTG
BP-14
V908G
.Cofractionation
syndrome.7
nseuronet.com
high-quality
UniProtKB/Swiss-Prot
D584G
Bap1-mutant
+dd
Limk1
V1124
RafRBD
1–329
estrogendependent
1.41–7.58
.Chaperones
.3-
GST-VHL-ElonginC-ElonginB
c.1534G
flow-sorting
Lys128
dorso–ventral
gene-harboring
ApcΔ716
Intercrossing
withMAb
ligand-mediated
thatinactivates
–targeted
T1/T2
LR01-060*
182–365
/BC100
NfJ+I-
pT4N1b
fgfr1a1
non-bladder
mTORE2419K
β-catenin174
Previouslypub
D835V
ID-GST
Kmt2a+/−
GACACCCCAACAAAGCATCTTG
85.0
0.349
3.Orthotopic
DBD28
3-6-4-3
Esterman
//doi.org/10.1371/journal.pone.0005137.g003
16010
787-790del
AB-1820
MEN-like
S2C–D
trans—i.e.
Modeling—Coordinates
MYST3
A750P
//info.cancerresearchuk.org/cancerstats/incidence
MDS.U35
leukemia/idiopathic
log-rank
entities.7–15
anti-VDAC
Y130CMEK1
DLv2
R129E
140/176
2.8.0
viable75
Hendzel
77–amino
contexts.1,9,19-23
Hsp104-free
Rad51-expression
checkpoint-associated
5′-TCGCCCAGGCTGGAGTGCA-3′
S5G–H
rubric
développement
Ab-3594
TP73L
cohybridization
.Hanover
transducin
4p14
14263
sc2020
interpatient
NLST
-91
Billerey
PE-Cy7–conjugated
methylation.5
teleost
2083
decondensation
ofMSH2
1.275
Gly719X
p.Gln1756ProfsX74
.1801
models—including
previously.31,38
pathways24
SGC-996
NCL
manner53
fiber-FISH
might—at
22,718
Israelita
CAA-3′
Br70
rCBV
p.G646Wfs
.TGF-β1-expressing
3.6-
inter-atrial
−9.8CLCA2Chloride
S66R
3-year-1-month
Bim
Meiosis
Anti-His
popultations
0.656
F57S
15365-36
–59.8
fenib
8,050-bp
.4,5
.2A3
3B2
MicrospinTM
cooperativity
BALB/cAnNTac-Foxn1nu
V9.1
MGDF
-95
GCTTGCTAACCTGCCTGATC
DTG
LUC9
pyridinylimidazole
40.2
importin-a
temperatureagarose
ACMG
⩾99
-CGGGGTTTTTCAGTATCTACG-3
'primed
hepatoblasts
low-VEGFA
5149del4terl678
//www.lovd.nl/TSC2
R1744E
.bams
11p15.27
E69
19125092
'v
Heldin
enzyme.16
ZsGreen1
.Ewing
1930
Fluoresbrite
colon4
−34.23
c.1958+3
treatment.However
EOC26
Br49
B_R582
transfection-matched
∼7000
thirty-year-old
Illumina™
Ariyama
GCAAGGATGGCGT-3
sequencing9–12
Former/current
F347/F350
7.5G0.7
consed
2-4-4-4
KARPAS620
D–Cdk4
polymorphism–PCR
non-HNPCC-related
~2.8
+1G
57788
apoptosis.13
tumours178
.3533G
antib-Actin
HisrHa-Ras
mHGA7
0IL
luminal/ER+
animals.138
N174S
patients.5,6
Y1230/1234/
outcomes.9
neuropil
1.4–5.9
cellsto
methods.18
hSnf5
CT-NOS
reverse-A
pEF1α.FGFR2b.IRES.neo
C499S
c.316+5G→C
1744dup6
El-Rifai
4-phosphatase
1Â¿.\J
cyst-adenocarcinoma
V90L
0.015
Lys-782
Ser24Phe
palliated
R666S
21/173
disease2–8
lesion.76
Multi-gauze
.Hynes
NFAT-mediated
V617F-transduced
3800
R451
Brg1-containing
D268N
mutation/amplification-driven
orthotropically
688C
MDE
1,000-mg
Rodriguez-Justo
protein-defined
234–530
KIT-N882I–expressing
methylcytosine.7,8
CRAF-induced
.LNCaP-FGC
MRE11.9
nucleolus35
19–20.5
pCY4B-HA-HCF1-1-380
anti-FOXO1
c-ros
pRB1840
Lunny4
GammaBind
Fbxw5
treatment-related
1012-H
glioblastoma,30
50-52
full‑length
c.133A
ctccagtggtgtcggtgac
Preamplification
B–I
.Echocardiogram
kappa-B
Weinman
p53-D281G-clone
Krev
Bioresources
23/99
FLAG-catCD486N
acttttcag
2ntA
R162
v1.9
A135
S869L
KMM-1
L536P-HEG0
//violin.genet.sickkids.on.ca/~ali/splicesitefinder.html
//www.idtdna.com
P=0.8102
FBW7+/−/APCmin/+
Yright
analysis42
hetero-oligomerizes
c.180–181AC
mitomycin/anthracycline
disease-free
L3-B8
⩾22
dose-responsive
362/448
isshown
32pLabeling
medium‐H21
1R-GATGCTGGAAATAGGGCAGAA
PEPCK
42/M
c.490G4A
Meylan
rics.bwh.harvard.edu
U-MWIG2
failure39,40
2501
S1986F/Y
P240L
9p23
17-19
Integragen
NUT-genomic
nucleotide-releasing
Cultures—Human
phospho-GSK-3
BRAF-nevi/cancer
Smads-introduced
fate-determining
.Roles
5′-GTCATCCTCGATGTCCAAGAGGTCCTCGTCCTC-3′
FLAG–Fbw7α
CRE-U3-CTCGCTGCTCCCGGCGTTTGGCGCC
classification8
.5,9
cycle127
TRAF7
517–523Stentoft
10.6a
Qua
NM_001123384
4tD1
EtBr
lacunae
PIP5K
shMYCN-mediated
Linardou
activity23–25
Fig.2B2B
50.00
mgp.v3
E88X
ETV-6
c.626A
cswl
Ala553
33428330
bait-sets
7–34
489_680del
p-FAK
aberra
and19werefound.HER2
V559__G565del
Deblandre
alÃ-ele.Because
3232A/G
kilobases
K384
589YFYVDFREYEY599
−/−
R1232W
EcoRI-SalI-digested
review.17
misreading.24
site9
5D1
L78_A174del
31,32,46
CEP9
Gly2313Ala
pALK/total
4/02
c.1600T
localization.12
R-TSC2.ivs30
CMML-2
D32H
PDGFR-alpha-expressing
SLVL/SMZL5,12
Min6
gland-permissive
transesterification
ERG–TLS
Hirokazu
uCi/ml
Fig.6a
496,439
phB2m
p16/Asp-74
95/748
GD693p–Msh6p
Maria.Debiec-Rychter
7m
Tyr-537
domestication
J.H.
Oberkochen
Diderot
epicardium-derived
classes28
5′-CCTGCAGGTCTCCATGACAGCT-3′
AT-rich
H1053
ETVN
Fig.4A
Orthophosphate
αTuberin
I–binding
toroid
His396
Q256
5′-CCATGTTTGAAGCTTTGCGAGATA-3′
5975C
EC22
low-ionic-strength
Xuzhou
4/7
17/45
V133F
23,24
A95D
crosspeak
4.1/ezrin/radixin/moesin
2,300
.5,53–59
ΨX174
Lys78
1520
MLL-N
MycWT
ÃŸ
PBN
N40D
SKNBE
Gohlich-Ratmann
3.8-
DTX1
re-treatment
-EGF
vectorsand
454
phosphotyrosine-dependent
6Wt
Nterminal
GraphicN-edited
novo-type
1X2.7HOshowed
I–negative
,9-11
AA490688
dysostosis
MSCV-Cbl-IRES-GFP
U87MG.z
Asp770dupSerValAsp
NA27
Al-Fageeh
gene.dCore
7G3
HEY537A
KRT18P48
SFA21a
EMT,34
17.73
S585fsinsTC
2574G
GST-cRaf
2.95×108
GST–ubiquitin
S464L
ARID1A-containing
SBT
bindingactivity
landscape.
two-thirds
NPH
structure.62
miR-106a∼363
meta-analyses,14,15
MTMR8
laboratory-confirmed
UbcH5b
mutations—drives
V-Abl-transformed
-7H-pyrrolospyrimidin-
regioisomers
≅
.1633G
Invitrogen-Molecular
p.Asp638Glu
death/apoptosis
KUB3
polycythaemias
folinic
androgenwhen
5882
EP300–ZNF384+
7909
anti-CD3ε
5-Aza-2′-deoxycytidine
.2008.411
membrane-embedded
624mel
RasGAPcontaining
,8–11
Pericyte
cam.ac.uk
5′-TCCCNNGGGA-′3
anti-APO
-Pro
aichi-cc.jp
KRAS+NRAS
5′-CAGTTACACCCGCCCTTGGATCAG-3′
hMNHl
viability30–32
164757
.DNAsextracted
J82-parental/GATA3-shRNA/control-shRNA
xenografts.Figure
K-R-V-A-K-R-K-L
communicating
S11C
564delT
monochromators
p.P49S
5′-TCAAAGAGGCGAACTGTGTG-3′
polarity3
occursthrough
G271
N822K/Y
inμ
p53-inactivating
Tyr721
pathway3
2.0009
Skin
ExoSap-IT
1.02–1.07
MetAlaAlaAlaGlyTrpArgAspGlySerGlyG1n
D210A/D216A/D223A
pOL13
LATS-dependent
HECTD1
55–75
1.10789
Oxidative-stress-promoted
NSCLC.MethodsOther
BeadChip
5,291
PLXDC1
non-substitution
11p
.42
thryoid
G1097
STK11
Oil-Red-O
RP11–612D3
Gr-1-positive
thecell
lociFrequency10/109
eukaroytic
222/226
07–164
S604Q
rhombotin-like
plasmidpT3E19A
149169-overexpressing
Stor
40–46
646KB
.Dynamics
⩾52
NP_003233
Q293–K296
GGAGAATGAATACGGATCCATCCAGCACACGTACCACCTGG
Two-hybrid
32,39
J-500C
pGEM-4Z
www.agencourt.com
cells93
E213G
NF874
c.1783_1784delAG
αC-in
27.1
Val1744
07-069
Y1162
8MGBA
coexpression
F500
V924
cisCall
L344A
anti-FGF2
insilico
1JNX
Val600Glu
Hanet
NM_011113
5q32–5q33
D633H
NM_002168.2
captured-target
segregation42,43
48–67
M8
Polynucleotide
.5,6,8
BC030896
95◦C
disease.7,8
11,13
NYHA
mceccon.manuscript
*Po0.01
meprin-A5
A-box
46/248
Smo/Gli
2699–2711
~250
38,78
8/87
VCP
MIM163950
J.5,6
Frt-mediated
G–mediated
qPCR-identified
5′-GGTCATAGTCCGAAGCCATCCGCAACATGATG-3′
mgofSf9
calendar-period
E258A
E2663V-
HGF-
adiponectin
ThrfsX2
nm/230
HCC827-Del19-EGFR
0.005.
SKW-8L
5′-AACTTTGGCATTGTGGAAGG-3′
N1a
Smad4325–412
GNASR201H
McKeon
TLR9=toll-like
Hind111
coverslide
CCCAACCAAGCTCTCTTGAG-3′
CI,2-3
1.313
post-Golgi
12-kDa
27F
'Vogelgrams
RalGDS/AF-6
E13.5–E15.5
TCCCAAGTTAACCAAGCTCTCTCT
BACH1-FLAG
F519L
.Let-7
phospho-mutants
,2M–S
82/112
Mutation1
.NM_001014161.1
5-hydroxymethycytosine
phase-promoting
c.863C
−0.20
to158
//www-stat.stanford.edu/~tibs/SAM/sam.pdf
.Slight
laboratory,5
L597R/S/Q
10/1,891
Scavarda
pcDNA3.1.ERBB4JM-aCYT-2-HA
Kouzarides
bymeasuring
-2.52
c.3929C
72/F
≥EDV
2462
codon.Although
de-
tandem-activating
deletion/insertions
NF1.9
952G
EDTA-blood
EDTA/2
mouse/dog
acid–limited
MamL1
I.-The
leukaemia51
8×10−26
immunohistostaining
R460H2,5
Selenomethionine
Debes-Marun
G130R
FGFR1-β
personal/family
dSet1/COMPASS
MSCV-Luc
μg/mL7
3993
orchestrating
ΔSUZ12
sera/plasma
SNU2535
N-SH2
P86L
sub-physiological
T333N
pCR4
pre-cetuximab
1.4-kbXbaI
Jagadish
R183W/Q
shNF2
RESPER
EASANA®
13/25
GAGCCACGTCTCCTGGAAGTGACT
inactivated.7
stress-response
PCR-mutation
37Position+36+
5′-gac
Y591N
v6.6
migration14,15
607785
'cleaner
A694T
1906G→C
KRAS-activating
n=473
C-kit
20.00
terminus–encoding
e4
5q–
Encyclopedia.27
delLeu747_Pro753insSer
vp2.Immunohistochemistry
LC3BII
Brca1Co/Co/p53+/-
ori
29/150
ICD-O-3
//www.macrogen.com
suspended59
96:3907-3914
peptides.30–33
MECT1-MAML2
Coverley
R42
Saiseikai
Fig.11D
H-ras-G48R
9165–9175
respectively.27
pGEM®-T
bacu­
CJD
1316
0.907
common.2
RP11-633M1
SKES1
Fig4B4B
Bev-
non-LFS
TOPO®TA
eIF4E-mediated
GFP-Smad4
OCI-Ly1
L15/FCS
reoperated
P101L
35S-methionine-labelled
cantly
n=28
454–475
A116T
SKP1
.Across
Seventy-five
0·7
T253I
volume±SEM
BMP‐stimulated
methyl-nitro-nitrosoguanidine
One™
already-transformed
10−5–10−9
AR-WT
energy-dependent
centiMorgans
dehydroepiandrosterone
.M.B
R2/Stop
Polyadenylation
EGFR20F3
MSSE2,4,6–10
114500
007731
62
-ETS
289KB
anti-p85a
brian_strahl
.Distal
FLT3-ITD1
Kouros-Mehr
siEX1
frequent.58
ofmutants
P1*
CYhelical
EGFP-TEV
V3-15ii
Q-loop
compartment.14
.Histological
.ORRs
HRAS/KRAS
EPOR-mediated
tricolor-conjugated
1344+220
TNT-labeled
TT/GG
05.04
Calicin
5″CCTCACGGAGGCATTCTAAA
β-3′-Hind
anti-SMO
nuclease-resistant
v-rasH
diabetes/obesity
rs1368884
KANK
W205C
Glu-C
TFG
V1673D
4A4A
SPDGHE566-577R
Nimer
Piccione
PD-L2
2,003
q13q22
NS.1,41
p53-psi
PDGFRα-myc
sarcomagenic
3745
Zaridze
//www.agencourt.com
charcoal-filled
means+the
s10038
pEF-Bos-HA
5'-cta
Ecotopic
47-year
.Hypoacetylation
chain.Full
bradyr
FLT3WT
mutantations
23-25KIT
BaF3/pLenti
1a–f
C-segment
ETS-gene
Electrophoretograms
thatno
2.5-3-fold
Trypsin–EDTA
2V5Y
Brunger
I~-Galactosidase
12q13-14
.Micro-CT
3q21.2-q21.3
extramural
0.9965
3105
SLC34A-ROS1
45.7–46.3
Wanfang
autoactivation-related
4-methylphenyl
PMS2-NOT-transfected
H458P-myc
29,31,78–80
rPLD1-interacting
CGCAAG/gtgaga
Tris–ethylenediamine
patients-that
α6β4-integrin
RP11-506O3
uro-epithelial
93.6–99.3
colleagues59,60
well.Synthetic
Ready-To-Go™
HDC87
'TaqMan
miRNAs.7
10.1002/humu
29/CRC
G-ncgative
Cdc37/p50
myeloid-lineage
50·0
Anchorage-independence
299K
microarray-defined
S677N
pCX4bsr
Zhu
Westerveld
12-plex
αP-ERK1/2
1007–1008
S.I
R67C
H1d
hBRCA1–
5′-triphosphates
iarc
melanoma.38
Athma
*164008
adenocarcinoma.14
1644-bp
5-GGATTGGCTCGACATATCATGAGTG
IGHV4-34
whole-human
lymphocyte–specific
riskadapted
tumorigenesis29
nucleotide/s
domain-tagged
Stability—We
oligomerizes
MutanBEST
.C697F
Hyperproliferation
Adv-MKP
.Breakpoints
HotStar
SEC31A-JAK2–induced
enzyme-induced
production7
606391
KRASG12D-expressing
FZD
7,9,12
GGATGGTCGGCTGCAGGTGTCC
JMML,8,10
0.58–1.18
2247
+1-LexA
4968
154G
646-651
S2.1.4
Erembodegem
meiosis-specific
L562
exsmokers
3′-phosphoglycolate
46‐year‐old
1.13–1.80
controversial.38,42
III-10
hSOS1-M269R
11,008
.Clusters
surrobody
S63C
Phe1248
Smad3s
CTAACGTTCGCCAGCCATAAGTCC
FOP-associated
assumptionthat
5′-BCR/3′-PDGFRA
MPL515L
G480C
L348W
di-magnesium
0.918
1–156
H-ant-p16mut
1p/19
0.60*
493–498_865–870
Spectrometer
LGL-patients
R352Q
dexamethasone/IBMX/insulin
andand6A
D231E
747603
maltose-binding
5′-CATGTATGAAGTACAGGGGAAGGTTGTTGAGG-3′
'ATG
Taketani
sub-cutaneous
−.58
Ab-3
2280
twoobservers
PI3K-Akt-mTOR
Yesa
protein-2
EAC19
JMJD
.Fanning
Immuno-precipitated
Schrodinger
205K
BR140
TH1
5'CCTCGGCTCCGGGTCCACAAG
M-phases
fe155
cancer,13
CDFCS
Melan-1/Mart-A
CAGAACTTCCCTCCATGCTC
C316R
ETS-factor
FLT316
F766A
Cy3-conjgated
-gtttcgtttgcacagaggggttttctggtg
≥1,500/mm3
Q781*
phs000706.v1.p1
manufacturer'sinstructions.The
CGCGGATCCTCCTGTCCATCAGTGCCATA
CARD-CARD
E122D
SSANFIPTVTAISTSPDLQWLVQPA-
GSK-3beta
p.M552_K558del
ligandindependent
leupeptin/ml
FAB-M2
2,3,6–8
Cre/Lox
non-benign
Figure3G
Pro1690Phe
27,049
promoter-less
gacggaacagcttcgaggta
0000149311
diseases*
oro-facial
innegative
255,485
2622
INK4d
n45–63
monospecificity
tumorgenic
2mg/mouse
1.378
3SAK
GCWTGT
Powervision
G4A2
CellTrace
ofSf9
BlockingOne
.PCR1-generated
Microbiolgy
V-C8
ATTGAAAGGTGGGGATCTGG
FigFig6L–P
.Corrected
XhoI/PstI
16·6
cilia6
A-R2
pT-REX-DEST30
MAR-CCD
spin-dialysis
nonspecifi
5′-CTGAGGATTTGGAGCCCAGGT-3′
β-catenin/Apc
Ewart-Toland
GeneScreenPlus
fostamatinib
PPB
45-mer
compartmentalized
Cholangiocyte
T329I
R385S
KlenTaq
2807
p21rasGDP
19p
KIT-N822
antigens.17
0.04–0.77
cytokineinduced
N102S
.RITA-induced
epithelial-mesenchymal
moesin
BRCA1–I42V
HDAC4
.9641
2.81
NCT00161486
phosphoKIT
STK4
Smad2-induced
577–579del
.SNU-484
multi-cohort
SCF/c-Kit
oncofetal
1-106
.Selenomethionine
CA61889
13-residue
A-16-year-old
ADP-Ribosylation
mutations.To
PathDirect
types28,29,30
Lisztwan
wu101
maxT-adjusted
BRCA2-deficiency
'occult
IR3
IgVH
Lightning®
nonrecirculating
S6C–E
mammaplasty
c.681+4A
9q22
.Elegant
3/loop7
helicase-related
EIvnl
untr
Fz
3.0-8.7
NdeI/XhoI
2659
L597R
RNAase-free
pSV.ARo
32.1
Kranendijk
−33
79/501
hemaotpoietic
Mejlvang
+1,015
aInclusion
5mM
76,000
node-metastasized
6,543
Progressionfree
HIFαproteins
motif/activation
shLATS1
PmeI
cyIg
ExomeCNV15
L858R+A871G
c.2006-6
1.836
nofamily
FLZi
.Formalin-fixed
5′-GACCGATTTCACCCTCACAATTAA-3′
TK-1
μs-ms
495-bp
.HOC
RAP80–abraxas–BRCA1
V23
CTL-derived
H-rai
29233
.IRS1
200ng
T-regulatory
ALK48
SOCS–box
Epgn
INC-280
p.S257L
Biosystems/Sciex
Figure5c
Neh7
∼78
site/
568
Kras-
36.8
GSK2126458
GTP-H-ras
GFP-MLL
non-triple-negative
conspire
slow-kinetics
.TCCGC.TCC.GTG.GCC
.Apicobasal
mb-1
Chit1
gene.39
4c
GAGCGCAGGG
analysisGenotype
oestrogen-independent
MiGR1-EGFRvIII
1-255
CLD1-4
Felton-Edkins
Maeyama
n=102
C93W
E27R
.Replacing
70–3826
D312H
flag-tag
.Normalizing
–unmutated
pseudohomozygotes
immunoassay
5.83
described,4,5,11
GDP-p21~Y32W-Q61H
p53plasmids
helix.mgh.harvard.edu
p.K57
Hypermethylation
mShp2R594K
1,323
AIF-mediated
ibrutinib-sensitive
168–195
furin‐like
unclear.Several
birth51
distrubed
N-glycosylase
−0.6
H716
Ninety-six
MEK1-knock-down
.Wick
Haliassos
CS9–12
Hs00245445_m1
Non-random
enteric-like
ATGCACATTGGGAGCTGCTGAGGATCGGTCTCG
3k–n
p.Gly44Asp
Determinants-Which
9325insA
1B–C
Strep-tagged
BRD
DuPage
stabilises
line\
QIAMP
37–42
MSH2–MSH3
H4K16ac
4KK1
G12A/C/D/R/S
BDTL
γ-5′-Mlu/γ-3′-Sal
647–amino
DNA0
WNT2B
PIP4
.New
CS0DJ001YJ05
20A
anti-p130
G336R
1206
CDK4-inhibitory
-pyrene
ECD1
CMV-lacZ
GF038
substitution/deletion/insertion
C/EBPα-dependent
9757
Tnfrsf4
0..0.
266–321
TTGGGCCCGGAAAATTCAGCCAAGGACTCCAG
FcγR
CTCR-OV01
complex38
TRCN0000039713
interventricular
ex1
attga
Biotechology
LC/ESI-MS
suppressor,7
12395
L622H
STAT-mutation-negative
TCA-5′
pZN
activation.1,6
PRKACB
conditions7
204531_s_at
SPINR
CD4/CD8
cellsThe
preserved2
H425Y
0.79/0.15
capacity.56
scoreZ15
L-MYC
glutathione–
5/0.1
L1198F
access_num=NCT01962532
SATA3
MDA-MB-134VI
20.47
5′-TGGCTCCAGACACTGAAGCA-3′
L231V
root-mean-squared
H538Q+K539L
postrelapse
mean.Taken
L148F
G949
2p16.1
1/18a
PARADIGM41
33S
3CS9
cdd470f1
114:937–951
pcDNA3-Flag-mTOR
beta-ACTIN
IL‐12
proven-somatic
PALx8
LightCycler
regimen.11
sizeJAK2
E251
9459L
8-min
anti-MOF
SHCLNV-NM_032043
p.K656E
S130Y
CHY
LELC
long-sought-after
dose-response
junction'+NDâ€¢ND+++ND+â€¢f+++
pEYFP–KRAS
29/31
haploinusfficient
SwissProt/Trembl
ER4
4.78
Kasugai
∗601607
crosslinkers
cytosols
-TCCATGGTGGCCATTGCCTCCT-6-
P\0.0001
anti-glucose
3q25–
HBL-1
250-kDa
5a–e
2894
Bangalore
miR-3127-5p
Endoxan
GAD
Foxl2lacZ
groupingof
P1–P5
91y
10.79±2.63
L77890
MLL-CBP/
CD117-
H358
INI1
some17
p.Y591X
Byr2
CYCLIN-D1
YVERMNYVHRDLRAAN
genotypes13,14
W83R
Prx1-Cre
.TED
retro-transcription
3238–47
20/44.4
ofMedicine
T3/DLeu
−43.3
Dennett
2,031
Aresajipi
4.67
transferase-mediated
T2952
NFUB5
pGADraf1
Castellsague
directly.8
pPACKH1
USP35
X1.31F
Hepatocyte
SQCCs.Alterations
D88
5–exon
HER‐2YVMA
CA180
~~._
p16AS
EDM00812
A_52_P498608
Yokote
1.Download
immmunoblot
Met-528
D134V
1800g
retrovirus-targeted
1e-15
cys184
described22
1/352
previously.1
33428279
Arg-106
Invitrogene
Myelotoxicity
BRAFV600E/K
achondroplastic
95,000
series.3
g.
4/group
proliferation108
cells/
FLAM_C
Subunit-specific
Omnibus.7
pOTB7
E67
505083del19
17q12-q21-amplicon
SW620
endog
Smakman
5´-TACAGCCTCATCCTACTTCCCTGT-3´
p16−/−
.Worldwide
0.28442019
*250
T/649G
interactiondomains
/0.05
vectorpEMBL9
endometriosis-associated
95Â°C.5
AtmKD/C
397/250
0.611
A32320
.S10-11
Tn4430
Leu-1839
CTNNB1/AXINs/APC
0.014–0.390
68301830
synchrotron
recruitment.10,11
.Lys373
13059
anti-eIF4E
Ras‐transformed
0-1.90E+282
mutations.33
pGMR-Gal4
Her3
reactions31
V289A
YHA
inacticomparing
IFAR1001
1708V
PP2Ac-overexpressing
triazolam
FGFR-3
EZH2Y641F/N
SA-b-Gal
mitosis.1-7
PDBIDs
1-147
residues.Solution
20,22
5′-ACCACATCATGGTCTCTCTGTCTCCC-3′
NC_000001
.3383
211H
MEK-PI3K
ITD–driven
.HeterozygousTGFBR1andTGFBR2
TAGGCACCAAGGTGGACGGGACA
Tyedmers
Δ130
unaffected.93
5′-TGACCTCAA
Chudnovsky
FLT3.113
exon-walking
218/222
R904X
rs12343867
antioncogenic
non-castrate
.Kinetics
DKFZp686G052
One-third
lysateswere
.784C
Gene…
21q22.3
mitosis/11.8
IGL-MYC
rescaling
STAT5A-
PKC-catalysed
pLXSN-Flag-INPP4B
METHODSOsteosarcoma
pNKY74
46.3
ith
anti-AML1/RHD
ΔRad51c
skin-homing
0.764
165–169
13.0-13.7
aa150–189
2f
M44b
more-aggressive
FL/DLBCL-associated
5'-TTCTCTGGGGGAAAGAAAAGAGTGG-3
secre-
assed
cohesive
PCAF/hGCN5
PMS2-related
Paired-end
3b–d
b3-strand
saggittal
de-activating
Men1Δ/Δ
co-treatment
DeltaGsolv
Regorafenib
AXIN1/GSK3
JNK3
LC3B-II
paraxial
64.18
Brca2-null
yeast-
7561
31,32,33
.PIK3R2
PTK7
Pronase
108BDs+59FDRs+20AMAGs
GSE37642
p.Val211Ile
D53
samespecimen
ERK2D321
oligonucleotide-based
1–450
E652K
anti-SAV1
CD11b-positive
E220
three-independent
others2
tumor-node-
Guadagno
GISTs.3,4,8
Q546
.I..
Puro
conformation,7
CC1542TT
VEGFA.5
uwcm/mg/hgmd0.html
FHL1-induced
MEFs23–25
7E–7F
phosphotyrosine–Src-homology
IC80
microglobulin
Nau
NsiI
13.3∗
Cseg
I/Mfe
Bellanger
Men1ΔN
-TGCTTCAAGAGTTTCCAAAG-3
worldwide.2
administrated
serine/threonine­
Kolmogorov-Smirnov
IO-fold
Adomain
1/Ras/tyrosine
Ras-responsive
Centroblast
Mg-1
86.41
2.4G2
0.006–0.069
490482
30pJ
F13
07e
Smurf∶Smad
HGGs5–8
sensitise
4077insG
CCTTAATCAAAGTCTGCAATTTATGGAC
Sequence-proven
sin1
.Printed
RG7116
1/61
CULLINs
D227E
pBS-SK-TRAP100
7°C
GM-CSF–
Ba/f3
0.8–1
ERBB2T798
0.77–27.8
DDX47
//www.mmrmissense.net
MG-430
A626T
221M13F
E7208
P1324L
multitargeted
Super-Script
A375-derived
n=122
1593A
background.60
intramolecular
.Genomically
M237
v2012-05-25
A44
c-myccDNAs
lesions—typically
RAB35wt
LOC96610
e6.1
808–790
5′-CGGGCCGAGGCGGCCGTCGTCATCATCATCGGCCGTAATGGCC-3′
1UWJ
Bogden
11,53
andprehybridized
PAZ–PAZ
γ-phosphate17
2086
PGK–neo–polyadenylate
15,173
32D-Kit-KD
XCU
WW12
Â°O
NEVSVIjKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKE
TTC642
R268T
776
Cip1
293T-cell
TÃŸR-Iis
.Coexistent
GAR1
.Silver
~96
Intergenerational
×1.25
blood.6
=0.0
A767_S768insTLA
hemEC4
doi:10.1007/s10456-013-9396-z
−deficient
Myristylated
CNG
MIG-BAT315I
c-myb.E2.38.R
AF147782
1767A4C
S41L
BaF3/EpoR
glassfiber
70.6
0.17842
exonulease
membrane-attached
T387
p-maleimidomethyl
50GR
www.ajplung.org
mutatedDNA
R802→X/R802→X
Atlas-SNP2
Ohtsubo
TTTCTCTTCTTGGG-3′
electroneutrality
C531
investigated.In
Canoga
HNF-4a4
indoleamine
females9
Mycoplasma
Notch1-8
Kinase-Dead
day-10
GI50
K562-BIMi2+/+
R468H
/diacylglycerol/protein
6.30
55–153
–43
HotNet
Tianjin.-
Excision
line—immortalized
Deparaffined
B–depleted
NFATC2
Kengo
1.929
FGFR1.7-13
tubulin.Cell
c.191G
Huh7
sortorder=descending
gene48
Ubiquitin-related
protein‑protein
Hohenstein
D4-RLAA-His-BRAF
luc-CD19
pMT2p85a
cloned.3-5Here
MD-simulated
nucleotides.9–11
Mcph1-deficient
aromatase-inhibitor-sensitive
Z70
RPTPp-expressing
pAMH-Luc
leukaemia61
P99L
Q466X+WT
anti-p53
DLG2
11-
G446S
FBXW7/GAPDH
Shapiro-Wilk
TKDs
D594ABRaf
BRAFins599T
COLO-320
crizotinib197
wasable
TTTTCCCCAAGTGACGCTTTC
Longo-Sorbello
oropharyngeal
anti-TNFa–Pacific
placebo-
8•53
6C
p.Asn1070_Lys1094del
Gbind=Gcomplex−Gprotein−Gligand
NF1wtn
Kazlauskas
-1-piperazineethanesulfonic
AFA
GIST.12,13
KRASG12C/Y64A
FroggaBio
control.11
shortestones
KD-LKB1
Affymetrix-HG-U133
GCCCACTCTGGGTCCTTAAA
activation.DiscussionWe
amplification.49
CHO-9
5-CCAGTTCCAGGTTCTTCCCG-3
hour-starvation
BRAF75
VEGF-R2
NaCl/0.5
3.3.0.0
geneticin-resistant
Langemeijer
AVAv3.0
300SB-C18
450x109
aceyltransferase
developed213
G-allele
Figure7G
CACNB1
Glu
CpGdotCpG
frequency.7
Sparky†
RP11-611H4
p.L452M
Obmolova
.Sites
Sub-analyses
Ershler
reported.31,32
learning-based
IBS
Intron1
anti–p-AKT
S-protein
Gad1.23,24
.~~~~~~~~~~~~~~~~~~
394
6/311
Luqmani
F.G
Nicd1
44-
studies.11,12
pro-T-
anti-Human
Ser-235/Ser-236
Nassar
pSG5-ARccr
194-1588
p.Ala79dup
subdiaphragmatic
.EWS-WT1
A_51_P324287
SMARCA4-negative
RCSD1–ABL2
mutations—very
TÃŸR-II
41815
DNEasy
8–26
422.3
VTA-100
c.2516C
51-aa
ATBF1
0.7-25.0
iBlot™
siRNA-specific
09/29
351K6
​,3C
4mm.35
18.The
//www.bioconductor.org/
C46S
Hef
therapy142
97TSTS100
Y591F
embryos—this
Blastoid/
null420W
pCMVΔR8.91
OCCC40
novo
www.ncbi.nlm.nih.gov/snp
MAP3K2
SVZ-C*
13·6
HSC6
−0.070
K97/101
170–1863
recognition.As
double-duplication
erythrocytosis
CTGTGTCCCTGCACCCTTG
ilarity
Localization—Stable
27-mer
polyHEMA-coated
AGAGAACAGCTCCCAAAGAAAAATCC
−281
IVS38-GT53.0
CjAAGGGGG
D18Mit8
VAVKTLKPGTMSP
CAATTTTATTCTGGAATGAGCTTTT
—indicating
medicine.Materials
Ab-11
MBL
p21Cip1-deficient
GDNF-dependent
5′-CACATTGCGCATAGCTGCAGAAG-3′
0.841
5′-TATGTTACTGCTGATGGGAACA-3′
.DC
receptor-signaling
.Adapter
pathway34,51
Arg886Trp
v.67
decay-sensitive
.PDGFRADDIM842-844–expressing
centigray
18/M
gene–negative
E63K/R73M
fetalbovine
Nlinked
Dodu
2Tc
.James
Tjian
Consanguineity
M183L
45/51
tumours61
γ2A-FRT-Jak2-V617F
HDAC1-containing
Georg-August-University
Coplin
p53R172H/+
gains/amplifications
VEGF-VEGFR
p73
0.397
LR03-260*
Rcells
highfrequency
Cys515
5′-GGAACCCTTAGTGCCTAGAGTC-3′
IBlO
Kögl
back-crossed
P790
45−90
pM1a
Q690P
pSEAP-control
His2c
documented.13
L749P
p.FISH
BCL2L1-
yeast—an
Non-ade
mice12
armadillo-coding
Transnetyx
pFTX5
anti-NPM1
cells,25
C126R
2726
G75R
Hürthle
.Angora
Fermt1
8,11,13
//dx.doi.org/10.1016/j.ejca.2013.02.009
involvingeither
TANC2–PRKCA
T332I
Glu203Lys
non-myeloproliferative
immmnophenotypic
NOTCH2-3′End
D19S877
Multinucleation
Ambulatory
helix-breaker
TACAAG/gtatgt
p.D1853N
49-78
.TF-1
V228L
SUM-149
transactivation-competent
3′ss—thereafter
Caldecott
CAGA-luc
26,27
RCC4/pVHL-S111C
F7
MENIN1
.G-banded
IFN-α
Zadra
8.0/50
TCC-repeat
EWS/ETV-1
μ-M
hu_R248W
D1Δ-4S48
FLAG-HA
107.55
JH2
0.298
oseous
D65
c.678-
pCMV-SPORT6-GATA3
R211H
P=0.021
2.FIG
MMTV-based
Cance´rologie
280–260
CBP80/20
275-kb
Asp-220
SHC/GRB2
functions28
N-TEL
cells/mock-H446
•
al.109
G1103R
5/88
649–838
10/300
Biometra
13,15-18
6e–f
MMC40
SMARCD3
Xq21
MaMel-48a
Ras·GEF
1-7-1
confluent
-P
1.05–4.44
cells.48
lysophosphatidic
ALK/mTOR
cases,31
7,7
transduction.32
.Rhabdoid
SHAH
R913W
Alk-6
QBSF-60/F
pCMV-C
1.56
cases13
/3-galactosidase
spe1
pBJ5mHNF
27-78
homologene
R188L
≥1.16
E30G
Homo_Sapiens
pRsc2-M280I-myc
0.52–1.52
methylation30
studies4,7,11,24,25
microfilament-dependent
c.1785T→A
EWSR1-PBX1
melanoma14
RUNX2-dependent
Desmoplakin
TEL-ABL-expressing
3.—
100-mul
K642Ec-Kit
p50/p105
pcDNA3/LKB1-D176N-myc
correcly
IL-3-free
G693E
arrestin
Retroviral
hit36
p53/TP53
homologsMsh2p
*GIST
Azuara
~300
S9/10
II.8
ÃŸ-cateninwas
pEGFP-Cl
two-times
robustly.Sensitivity
STK11—and
0.118a
progressiva
METHODSFamilies
duodeno-gastric
71/267
pET-15b
0.045
C5
Bolhuis
​These
Gr1−
lethality.15
GFP-PEAK1
5′-end-labeled
5′-AGCTAGTAGAGCtctCTTGCCCGGGCTTGTCgGCGTGCTGCAGC-3′
ROS1-effector
*S
phosphoregulation
KmDNA
pSV2
Fc-horseradish
R522Q
Q812R
Lin–c-Kit
1.68×1013
T7168
MUT5
Dhrs8
stably-expressing
tify
817_H_1
05/2004
.Let
I72T
.Sequenceanalysis
neurotrophin-3
D537H
A1090S
wu39
sfn
Heierhorst
Val-555
selinexor
S515F
pGBKT7-PKCϵ/pGADT7
wild-type-
RN-C
mimetic
Koralov
.Grb2-mediated
R554H
Rad502TEV
BARD1—Missense
NFAT-transcription
p53-containing
1.5G1.3
MARK3
slideSensitivity
dual-targeting
microRNAs.37–39
E110
EBER2
'pl20-GAP
strategies2
studied,44
PTEN-mutant
LN-319
−24.72
pRS-hyg
R588A/E592A
post-nuclear
sc-102
1300-I1
39,42,47
BD-FANCL
D22F2
BRCA-specific
oligoastroctyoma
Nestin−/Olig2+
epithelium-derived
7.66
c-Jun-null
D'Cruz
loss-
CompoZr
BALB/c-derived
mutation.31
VEGFR-1-mediated
liver.14
haveshown
GATA1low
45mer
Oki
S/J
±14.9
5'-TCACTATTTGGTCCAAGTTC-3
1,056
PTKIs.14
not.103,104
ETV519
basal-tyrosine
seluteminib
gelatinosus
irradiation-induced
8p21–22
c-Myc–targeted
antibody-coated
Eμ-myc
34-126
A00781
Amyloidogenicity
E380Q
protocols16
tetO7/CMV/Zeor
ERCC3-overexpressing
Pilarski
PI3K/Akt/PTEN/mTOR
substitution—in
13/49
440–796
RD-2
Tet1-loss
ÃŸ-cateningenes
DUSP10
pVP16/p16
Pt1–4
Vadodaria5
CD58
Tynninen
c.1961
L35A
residues.49
058197NM
'Engelbreth
kj
Abl-SPOP-F133L
CTC.GCG.CTA.CTC.TCT.CTT.TCT.GGC.CTI.GAG.GCT.ATC
RhoGDI
.LZTR1
.
72.
deoxyfluorothymidine
Involucrin
chosethe
anti-PD1-
Brasilian
AICD
.Proteasome
HaplotypeCaller
E353Q/L536H
13/35
12,36,37
43.30
PRKAG1
CGGAATTCCTAGAGAGAGAGAGAGAAGGGGCTAGC
ROS1-CD74
scoreZ55
non-polar
.020a
leptinemia
-1-piperazinecarboxamide
Pdx-Cre
K1423E
0•47
Asn11′of
Y126N
–16.8
.PCR-based
Sarter
nilotinib
kinase-Ras
No.555
methylated.19
454-
c.1025C
respectively.44
5′-CATGATATCTCGAGCCAATCCAAAG-3′
zinc-finger-containing
lanes7–9
p114RhoGEF
ribosomopathies
Æ
mac1
www.ncbi.nlm.nih.gov
ImageScope
954–956
previously.29
genotype–therapeutic
mdc
kinastrin
0.8h
p.Q207D
Ha,2
Forty‐eight
.S3G
S1514X
NBT/BCIP
BC-300
arrest211
Dreyling1,2
Roche/454
Tyr223
near-triploid/pentaploid
Notch-nonaltered
stress-dependent
D816V-positive
Keap1-Nrf2
pp6ov-src
0.003510
Ochsenbein
Sazanov
pellucida
control.22
p.10-11AL
.Garcia-Rostan
Hepes/NaOH
.cycles
G430*
IFAR346/1
64o3
GST–RAF1
Zhang_Targets_of_EWSR1_FLI1_fusion
Egle
JAG2
Denoyelle
↓KP
5.6-kb
Sicinska
5′-Fam-
Ptc+/−/p53−/−
Rhyu
nine-year-old
-Kpn
X3.P2R
two-
T-PLL.11
DQHA
Microsoft®
5'-CGTGAACAAATCTGAAACAC-3
patientswith
mutations.MethodsMain•
pMSCV-PGK-neo
A919P
PCR-grade
AC115994
KNSTRN
FLIPL
S7PY-bound
26-
Arce-Gomez
agents.43
MLN518
toxicities
Sox17α1
.org=human
JMMLs
ACAGAGCGAGATTCTGTCTC
Hsp90·Sgt1-CS·Sba1
T481
346–371
22/M
4186
coiled-coil
Trp53LSL-R270H/+
GNB3
Desmin+
β5
-S
CD3+CD8+CD57+
C11orf95-YAP1
-at
sc-805-G
Brca1SCo5–6
10.1002/humu.20431
cancers.5
andD–F
patients,62
tumor.26,27
co-localized
A46V
4546–4550
p110αH1047Rwere
1·8–4·2
Hypothesizing
Q79KAKT1
R206
vitro–oriented
cells.76
cross-activate
.Q-RT-PCR
R1314
leukemia.53,54
D369
replication.18
isl
4-2
145/243
third-most
//www.affymetrix.com/support/technical/manual/expression_manual.affx
Ser1496GlyfsX14
BRCA-related
redehydrated
10−8
G75V
single-use
9.5-Kb
NF-κB–GFP
_sr
SJHGG082_D
XLαs-R543H
DPC4/MADH4
MHH-CALL-2
25,45
AAGGGCTTTGAGCTCCCTTC
M24504
IP-based
formation.35
Merlin-L64P
EUFA410
FGFR3-mutation
R455
Pharmiongen
601321
heat-map
rs12946397
L576F
5′-CAATTTAAACCCACCTATAATGGT-3′
PTEN189-
/PBS
mountain.
ontogeny-based
instruction.Microsatellites
Vav-iCre+
Arg552
5.Prevalence
Mutation3D
.Hallmarks
CAG-AAG
Lubieniecka
15Gy
red\
F993A
abdominoperineal
mutations.3
KIGDFGMSRD-
GST–D1–
pGADNot-INI1
H199Lmutant
.Isolation
A_51_P319460
recently.19
KRASE62K
Formazan
PHACTR1
MethodsTSC2
model48
tissues.21
correc-
hyperdiploid36
Lkb1-expressing
whichthe
G451E
SPOP-ΔBTB
FGF-dependent
mice33
5.1-57.5
bTotal
re-plotted
pcDNA3-GAL4-HA-HIF-1α
sc-7944
PIK3CA_S15
T131A
HMGN1
histology-associated
AluSg
16:74
p110αwt
A767–V769
D67Y
.Fig.7B
880.15
4666
Centrifugation
human/rodent
790
-.P-
sc-20099
p.E14X
BX5
c.587G
3638
NM_001270
HCV
HEK-Jak2-WT
movement/morphologic
pea
miloxantrone
myeloid-to-erythroid
expressingmyrAkt
MCL-3
tumors1,25
30.4
NOD.CB17-Prkdc
1810
.WDLPS
AAGCAGTTTATAATCTAGCATTGCC
DASPER
paclitaxel/IP
lower-molecular-weight
II/4
5′-GGAAGACCGTGCCGTCTTCA-3′
Y469S
domains,4
TUBB2B
mycLEF-1
removal.DiscussionMany
cancers.24,25
GST-p110/
pY396
AER-FGF-dependent
machinery.42
MIG-BAmutant
5An
self-annealing
p21Waf1/Cip1-null
ATCN4
CD69+HSA+
RET-wt
pMITom/hB-RafV600E–Myc/His
meloxicam
glands.22
down-growth
c.511g
CD44/SLC1A2
line27
p.S65N
RAB35wt—formed
del-19
≈180,000
V600E–mutant
misof
C196F
RHS4533-NM_001005735
|2-fold|
4C
10/20/00
ATRX-mutated
JHASPC
LowQual
CD23—markers
0.436
exome/genome
L246
~400bp
PI3K/mTOR
1GWR
BM667857
mineralocorticoid
Helsinki.114
SSC/0.3
γ-32P
v2.3
liftover
gamma-glutamyl
NA/NASNGII
XP_451683.1
non-coincident
inhibition.65
0.650
IP3K/Akt/NF-κB
CAG123CAA
736–1475
MMAB
BCORmut
un-explained
HumanOmni2.5
23,514
25:125^134
BRAFV600-mutant
cell-cleavage
desirable.5
rs34231037/C482R
′-CACTGCCCAGTCAAGTGTTCTTGA-3
3D-model
.PstI/BamHI-digested
DLCBL
ΔRD
KAT6B
it.11
manner.2
genescan
Axitinib
cells.2,23
G434C
.AALE
FPT-091
States2
TTT3GTT
127•6
Meta-Analyses
V1804D49
FKBP
4.CDK10/cyclin
HDGCs
age1
isopropyl-β-d-1-thiogalactopyranoside
Lin−/Sca-1+/c-Kit+
K11R
.ERCC4
anti-SF3B1
D816H/V/N/Y
0–62
pAKT/pERK
79.0
amino-propylethoxysilane-coated
0.292
27,46–48
0.08-fold
120GAr
SS18
26.19
FLT3-ITD/F691L
RET-KD-P·AMP
O'Mahony
P-S6K
LRPCR2
build-up
Fli-1
K57N
NAVONE2
diaminobenzidine.The
III.-2
phospho-FoxO3a
referredto
−3.7V843I
YAC/BAC
LoRusso
5hmC.7
V774_C775insHV
IL23A
0.80–2.16
2/2/00
.RETY791F
G346E/WT
auto-ubiquitination
ATM-
33—81
ΔBRMax
p53-responsive
GGAGTTATAAGACCACCATGA
MSH2-A636P
0.981
269150
tetO-CMV-Ki-ras
catecholamine-producing
Losson
G1046R
125-min
Biolaboratories
3-Kinase
non-melanomageneic
5mCpC
p.Gln176X
108–130
SHP2/T468M
niaid.nih.gov
PI3KCα
3-phosphate
51/12
.Sp1
rostro-caudal
NCIWG
281G
G742D
T/G
hMutSα·ADP
0.034
ACTACACT
tumours135
P198L
miR-18b
His-positive
Lyse/Fix
LBH-dependent
areseen
US7MGAEGFR
16/15
autopsy.4
BAT-lOB
MutSα-WT-purified
./*AV*V..
98/199
pLVX-AGK-BRAF-AcGFP
mÃ©tastasesobserved
D816N
sc-8760
Dahlman
pre-pro-B
6•28
CCCGCAGGCC
140-KDa
pAD/CMV/V5
n=9
S564A
high-percentage
damage.101
CHEK2-P85L
009014
3rd-10th
microdeletions
.Bliss
Deadenylation
D92E
Atrazhev
Mseddi
well-corrected
‘
.Appendix
17c
section=000100020003
spheroid-forming
lens-speci®c
pHDM-G
E2-35K
decreased/absent
Complementation
32D-Y599F-Flt3
5′-TTTGTGATCATAAGGAGGTTGTGTTGGGTCTAT-3′
T184A
catecholamine
∼5,000-fold
58Og/J
Barral
PFB
5′-GCTGATCGTGATCTTCACAG-3′
B220/CD45R+
.1464delC
immune-precipitated
-oligoribonucleotide
Bin-Bing
homozygousImatinib400
V60del
.Separation
emerged.57
1342A
E709A
recognition.Model
L138
treatment-strategies
index.b
BRCΔ
G4654T/AGT-*ATT
*WT
.3C
G567C
Mll–loxP
CRPC.49
Cys303
repeats.6
R62R
.VEGFA
M3538
glassy
.Rare
wk-4
significance.52
IMMUNOPHENOTYPIC
D769
p.S32I
rTnf-α
performed.7
H230
amplicons.14,15
~1–2
mesenchyme-specific
linger
factor-H1
I2101M
5-7/106
ΔCtsample
CV-1
SPOPs
FoundationOne
modulatethe
TRCN0000000370
p.Pro436Ser
DUSP7
CD31−CD45−
cancers35,36
521C
5´-CGTTCTTCCTAGTAAGGGTCTATTC-3´
-ATCTGTGGTGGTCGTTTTCC-3
Y64A
281.4
AMPure
3,267
coelution
Ficoll/0.02
p35
pC53-SN357
RP11-365H22
univie.ac.at/wivo/RNA/
p.Q1833E
T862
370-bp
–15.2
PrEC
T-p53C-R282W
-corrected32
Thr-65
NCT01732640
latency.36
5′-CCTTCACCAACAAGCCCACAGATCAACTG-3′
receptor-RhoA
4642G
p53DBD/DNA
A1304G
MDDtreatedtumor-bearinganimals
anti-apoptosis
.Avidin
1,088
Stk3
30–19
cholangiocarcinoma30
oases
siSRp55-a
MAX/MXD1
contrast-filled
2365X
HNPCC,16
mut/mut
E40Te
800-
TTCGGC
θV
0\
l101
Ligase-65
ILHLeGVvTkrK-PINI
Idh2
SU11248
5×103/per
pEJ6.6ras
q≤0.2
NU-DHL-I
SBE4
+d
TIJMORIGENICITYCONFERRED
SF/UO126-treated
assay15
A520V
Lu-5
Middle-linker
.VWFD
7q31
3E–F
2.1-3
68878170
−10.8
K942Q
Gagnebin
56.0
SUM-190
0.973
Sos1-
159·5
ab5095
n=81
P145
0.0327
WT+G264W
p101
5C-F
TZM
*9A-5
PIKC3A
.Tobacco
Δ3263
signalling18,19,20
.Tightly
BMPR1A/Alk3
6C–6F
CTLAAla-
datasuggestthatthe
manner29
Sertoli-cell
Geneticin®
pLAM5
A253
4.0804498
cultureexpanded
c.4078C
gMFI
Prochorec-Sobieszek
renogra392
Kinyamu
ion-trap
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F3.medium.gif
transit-amplifying
4-mum
.Ligand-dependent
1010
SHP1
Chemexpress
Ba/F3-FLT3-N841I
IFN-y
33:1088–1099
BCL6+MUM1+SOX11–
4H
N202
Padhy
Ras-GAP-334
3226C
SqCC/
5–21
c.454C.T
.GAG
3.24+0.18
Thorsteinsdottir1,3
mutation,9,30
Amicone
rabbitderived
expressingFLT3-WT
SEC31A-JAK2–associated
UTR-truncated
substrates.9
11/37
increase.39
months.1-4,17,27-29
j–l
P-E
S619L
314
Asp1l9
idetnfied
-2,5-Diphenyl
.growth
Val559Ile
mutation36
S1P–S1S
depolymerizing
β3–α2
SMO-Mediated
0.568
297–302
G8091
curtail
Pyelectasia
tumor/PDX
C376Y
82.89
7-amino
GRE
0/93
1,2,3,5–14,17
MOZ-CBP
USA14
N-lauroylsarcosine
4981
hetero-oligomerization
and/orduring
c.180C
secondary-AML–specific
MEKis
ALL.33
MCF10A
Flowchart
Y960
L1257R
series4,5
TTGGCTACAC
ERVH-2
TCPVQLWVDSTPPPGTR
t-distribution
RTKs96
`hot-spot
35Slmethionine
pmiR-RB-Report-ABL1_3′UTR
PKC/PRKCA
nonsequence-specific
rs28517654
sensitive.There
polypectomy
anti-mouse
Cys288
.0083
plexin
Y1230/1234/1235
4Intron
N371T
TERT-L
G137E
time-offlight
1347
NM_007887
Met76
interactingwith
8350
3IQU
p.Asn385Valfs*7
phopho-EGFR
A-E
SHO
LacZ/Ad
T682A
TET1-CD
leukemogenesis.13
8098
Farrugia
Drosophila.87
W51
N382K
RSV-TFAP2AΔN165
.Ellison
tFL
tocell
Basal-like
15NAbbreviations
antiCdc42
APH
168–
GCs82
AGCCCCCTGTACGACCAGTA
Yasuhiko
paraformaldehyde
dUTX-RNAi
proteins,27,45-47
GDC0032
cancers30,31
hyper-CVAD
.1331A
catecholamine-
purple-brownish
2ERE-pS2-
P19a/b
I759A
capacity20,21
sm-λ
B-cell-specific
p⩾0.9
Pptient
white/light
L1407P-L
Protein-binding
1234/1235
1•05
​Luciferase
TCF3-downregulated
LAMA3
D2298H
I-labeled
transcardially
63-87
Nexcelom
501-Ala
4.70107
.Achieved
−6445
6.09
His-SUMO1
FOXM
CD45RB
Sigma-Aldrich
Yoo
SCFSKP2
Let-7s
biomarkers.5,34,35
5,8-11
solid-type
Chu
D321K
Co24
.ERG-Mediated
cancer130
C1668-3A
patients24,25
mRNA-mediated
D1000
KC1
andMingzhou
mutations.2-4
156107L22
anti-tail
//ftp.genethon.fr
Black-color
myocytes.48
MATH-containing
p.Arg326His
Quant3
Lucchina
tofacitinib
Hoxa9/Meis1-overexpressed
Mad2
factor—has
p21ras2
†Non-Hodgkin
T37Y/C20Rc
A55S
22/107
D708A
2,10
12q13–q15
ζ-associated
Bottema
5′SS
CysGluCysHisArgAlaGlyAlaGluSerArgLeuMetTrpGlyLeuArgCysSer-stop
30−38
his3D1
keratin-10
CRLF3
SCF-type
Figure10A
Grzesiek
StripAssays
TCAQjCAAAG
sc-8392
mcalpain
0.927
MYF6
.P-loop
7..
129Sv/C57BL/6
//tcga-data.nci.nih.gov/docs/publications/lusc_2012/
×600
Nup20531
L118/122
NZM14
.-l6CzechosIovakia
.GIST882
KVADFGLARL-
GACAGCGGCTCCGTGGAGG
CRAL
FcsRP
GSF/GETO
practice.SUMMARY
18,290
.E
ACINAR07
15q87
ligation-based
DI8S69
formaldehyde-containing
fluid-attenuated
IL-3-deprived
ERCC4
knishio
–
epithelium,34
G128D
pcDNA3–Myc
SmoM2
Sin3-HDAC
Chk1/Chk2
sarcoma,9
BCRAbl
leukemogens
0.00–0.05
Endlabelling
AKT-3-deleted
172656U22
−1.28
Ariake
V8.0
5146
PRKAG2
B-cell-derived
nuleotides
e11.1
studies,13,14
G1306A
colleagues14
deoxycholate/Complete
HCD
Crk
autophosphorylation.9
Cbf2p/Ndc10p
.RHEB
.Burkitt
c.4270_5456
c.p.m./nmol
phospho-STAT
16.8-fold
Tel-Jak2-mediated
6,20,21
al,3
686LN
JPM50.6
S423VfsX13
ASNase
pAkt-473
.Ma
NADP+
HMGI-C
.GEMMs
unclear41
Ataliotis
cancers31
Gs-protein
nontransforming
de-fined
2530-2554/nt
malignancies,12
B-CATENIN
378KB
retroactively
Zetterberg
HsCD00003658
.28-31
R-AXIS-IV
Meijerink
non-phosphorylable
Veneto
CDH1+2076T
Scientific-Dharmacon
R182L
orrelation
myeloid-lymphoid
intracranially
4C-E
SMARDA
Noef
Φd/ΦD
2,213
N39305
111•2
insulin-inhibited
0.36–1.96
chr1q21-22
0.1187
StuI
Glu-
NFE2L2/KEAP1
Tykerb
framework14
IRS4
ab9110
estat
K-RasV14I–Mutant
150mM
dissipate
factor.17
Murnane
._2589
transcriptional/post-transcriptional
beendescribed
FGF-stimulated
1284
artifactually
F285S
7.4/100
TGTGGA
CD45RO
refractory/relapsed
Y599F-Flt3-expressing
complex45
phosphatidylinositol-4,5-trisphosphate
Intention-to-treat
ACTGTATCCCCCTGAAGTCCAT
MICROSATELLITEINSTABILITY
Shim
c.682C
.NTAD
G59E
q23
.EGFP-negative
CisBio
1145G
Pim2
DIP2A
14-2
meltrin
12/30
T183A
NB9,10,11,15,16,17
97.74
o202
cytotoxic-
M614
Arg412
cytoarchitectural
oligonucleotides44–46
1q31.1
CACCTCATGTCATTGGATGC
473–490
methylation-insensitive
DSS-1
H12GGC-GAC
P2RY6-ARHGEF17
adaptor-binding
,95
SIX1
LPT
BLNK
134,135
R145W13
961478
F/II-2
ataxia-telangiectasia
SNORD*
CCACCAGCTTCTTTCTCCTTACA
subse
tumorigenesis181
extracted.The
2ITY
BRCA1/BACH1
.Bashir
c.244G
Pro-114
BCOR-RARa
G871E
PANC1
Ubiquitin-like
RET14
E1+
C15.V
OVHS
.Chr
W2239C
4-11using
Buitenhuis
micro-deletions/duplications
Bam\\\
T-loop
Colloidal
210°
post-plating
q25.2
1,525–amino
Directorate
virus5
sites.14
G365W
MTBSTFA-derivatized
Y-32P
gelatinous
−++f/weak
Innogenetics
805–832
Abl-SPOP-Y87N
GNAZ
functions.The
.Y260X
Jak2-mediated
0-0.01
L.D
MedChem
rsalgia
Post-ligation
Hirotsu
-ERCC3
theyprovide
VASP
LexA-binding
Re-Biopsy
C-*Y
44±6
described.41,51
RAA
dimerization.1
27.2
concatemers
ESEfinder
sc93G
Col2c2
IHC.73
1∶20,000
ROS1
16·2
IGF1R+
U-343
Bidou
Camacho-Carvajal
1.68×105
Mitui
K246E
SIFT-Blink
.Canton
Myxohyalinale
MaeII
dasatinib-based
pTyrcontaining
gtaaggaatc
Youn
theinfluence
nanoassay
P-0000614-T01-IM3
ACAGAGTTTCAC
PLCγ-induced
Hh/Gli-dependent
ASF
Origin7
87.09
PCM28/1+
Karkkainen
electrocoagulated
Virus-infected
Thr-389
VDCLE
4-kinase
reinhardtii
p200
receptor/papillary
−180
adenomyoepithelioma
imatinib/crenolanib
.Biologically
r.m.s.bond
62.2–70.7
TheGlu-37
D260A
glands.12
therapy-outcomes
functions.To
Pansorb
40.8
VHL157
GSTP1
pZNa*2-Q205L
.WWP1
.PIPKIIβ
Kelch-like
h.26
227650
0.2
0.873
.EGFRinto
cleavage/degradation
5151
TSC2-WT-expressing
cfDNA—not
.FoxA1
ALKF1174-driven
5′-aacagtccgcctagaagcac-3′
Française
dKO
41–83
TNF‐α
TMZ-associated
tumors.101
monosomy
involvingmyc
117,449-117,626
6.00
CHIC2-ETV6
CCY464-1D
Q61H/L
224plusminus3493
C.R
Mnt-1/
Nawijn
P729
5-position
T-3Mb-Erg
TEP1
years.5
I1061T
P1095R
'FLASH
methylated-CpG
//snpeffect.vib.be
1–13/16
NIDDK
2080insA
SPDGHE
sitesY589
GST-α-Fbxw7
P129T
T‐box
chromothripsis67
9970
∼11.9
MPPH4
FBP11
domainidentified
anti-miRNA
drug-induced
D307Y
1334
SF100–4
Biocarata
broad-
c.1561T4C
Srsfflox
HLA-class
Reynisdottir
R506
229.00
35–38
FY86
c−Src−
646-31
opercularization
R.J.G.
Tu4
FGFR-IIIb
RUNX1/MDS1/EVI1
CDKN2A-deficient
Rossmann
MUT3D
42/98
5A–D
AR-bound
VEGFA/Chr6
melanomaassociated
L147H
antioncogene
//www.erp.wisc.edu/symposium/2012_abstracts.pdf
Utrecht
time–consuming
5.S5
O-Q-A-K-K-K-K-L
machinery—particularly
2.0.22
.Gly421
Ctx
.Acquisition
phospho–C-Raf
passagingThe
neuregulin
CD19+CD27+smIgD+
A543T
1/9
E.L.T
desorption/ionization–time
K259
B220
.Bone
H3K9me1,2
pMXs-IRES-GFP
.Long‑term
sapien
5′-AGCGAAGATGTTAGCCTTCG-3′
splice-donor-site
nutritionally
criptic
-promoted
GUUGUCUGCUCCCGUUGU
cThe
GST-LKB1
dasatinib.24
RFC-dependent
Msh2G759E
.Second-site
p.V600E
18-4
NM_000618
FLAG-BARD1
ins5
Coligan
demethyase
826delGAAG
in-frame
|/|
Botı´n
PCR-detected
uim
SF3B1K666T-HEK293T
MED12-mutated
Radiation-Induced
ligand-lacking
ØNX
N468D
agents.26
Cys275
Lemonvitrex
Ala-
.Resolved
SA535
navelbine
.Collisson
Swiss-Webster
CLL.6
EMH
machinery.40
interleukin-17–producing
Iglesia
Mgat5
-ACACAAACTGAGACTAAGGC-30
NMRD
GIST.Numerous
H3K27me2
LR06
.Dark
adenosine-5′-phosphosulfate
insertion13
rLouH
Micro-Fast
DPY30
3-PGK
18.38
.RTX
Ret9-A510V
methotrexate/vinorelbine
phospho-Stat5.76
2.590
phosphoepitope
.Aced
expression12,13,14
kinasedeficient
siFoxA1-regulated
elsewhere.9
5-GGATTGGCTCGAGTTATCATGAGTG
PBE94
T877S
pl2OGAP
27–74
false-positive
pcDNA3.0-HA
drug-responsive
DSP
L424
function.32
large-to-small
25mg
KIT816F
P-GSK3β
HD-0171
=230
platybasia
594
rs7565213
ferriferrocyanide
Hbegf
well.19
rs17289893
phosphoserine/threonine
Pro-Pro-X-Tyr
GAGGGAGAAGCACAAGATCAT
.1477C
RTK-derived
reporta
rabbit-conjugated
CD45−/PECAM-1+/CXCR4−cells
84·8
400cP
170.Because
www.cran.r-project.org
Solid-phase
11,12,13,14
154S
Otomo
described59
jding
AF-002JG
4.5:1
.Stockwell
.SEC
VisualizationHER2
hypermutated
22/63
-β
MMT
STAT3-deficient
NP_002735
FGFR3/WT
GAl
Ago1-4
chemotherapy58–61
ATRX-DNMT3-DNMT3L
non-MRT
NCT01316757
hASXL1-FLAG
ADP→
pXCR
13-14
I-EGF
A549-derived
5w
FLT3-N841I
FXYD2
pBSK-globin
.1of
preleukemic
1039
-prothymosin
published17a
M1202V
Amplification
164K
K1502*
RRRIT227S
5′-CCGCTGGTGATCAAGCAGGA-3′
BDNF
high-pressure
Pre-op
GSI-treated
.Super-resolution
post-irradiation
ERBB2-H878Y
dysfunction.MethodsCase
6–35
Ph1/BCR-ABL1-positive
HuH-7-derived
Marschalek
purification–mass
CviKI-1
V550A
ethnicities
Anisomycin-induced
10·4
I400A
ARID-containing
55–83
Pol
Okamura
72,74
R6861
PEComa
EBPα-knockout
0/28
non-AR–
c-Kit,40
5α-dihydrotestosterone
1,553
O-GlcNAcylation
prdm1
Ras-Ras–GAP
R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7
RNF149
H-201
94C-3
890
Raps-GppNHp
IC30
differentiation-specific
prop1.html
ALK-TKD
D873N
Fouse
3′UTR,19
haplo-deficiency
profuse
non-actionable
fHuman
acids373
CDC27–BRAF18
AKT1-E17K
IVS9-10T
results…
18,19,29
pMB23
nonregressing
proteasome-sensitive
lineage184
2E–G
Mok
studies.2
NTRK3
non-smallcell
Integrin-specific
abnor-
long-studied
GAA-*GGA
1364
Tet21
retrovirus-based
1.08
LEF-binding
TrkAI-dependent
PD10
KpnI-ClaI
mutationshavethe
non-transcription
58C6
5A-B
S291F
T323
multiregional
-seq
transformants
markers.14
2Al
H470
Ozcelik
myoblasts,17–19
Cuncer
MDxHealthC
9.57
L170W
H149P
R35
Geldoc
Gonzalez-Neira
CNE-2
31Â
Ser279
hemagglutinin-tagged
pSRα-T/P
385
antiphospho-STAT1
autophagy.39
MSV-C/EBPα
772_773insertion
h-Taq
PDGFR-βThe
mWnt-1
ETS
mTOR-WT
Pan-Class
2.3-cm
F128L
Binding-Binding
3/intron
p53‐Notch1
.Co-precipitated
-binding
cysteinyl
BAP1-related
102/115
20,502
CAATGACcTGCTG-3
19/24
L1564PR
anti-Importin7
1,391
ERÃŸmutants
G20R
pyrrolopyrimidine
ant-rabbit
development.48
ET22
progression.31
.ResultsFunctional
1218
Furhman
anti-Fgr
pcDNA6.2
.Sequential
sn-2-stearoyl-3-arachdonyl
1200–1600
~40,000
interleukin-3–dependent
RP11-19F13
myofilament
T-TBS
6095
pCycD1CAT
pLysS
Pvl
red-hair
hyperactivation11
kidney59
8603
model30
A117T
Transcription-coupled
cGAP
STAT541
.Smad3-Smad4
Thioflavin-T
RAB7L1
Almaani
-146a
NAN10
MutComFocal
ΔMFI
recognition16,17,18
A-II-2
1q32.1
HA-1.2
9.5–30.6
R882H-overexpressing
2-ns
Hailfinger
RTK
multisignaling
F154S
7n
.SOScat
20:1
c.891G
5p12
Anthropometric
22⇓⇓⇓⇓–27
protein.40
Microbeads
phospho-AKT/AKT1
8/45
SCIDγ
multigene-linked
1,4,5-triphosphate
Ipl1/aurora2
v-akt-expressing
Na251CrO4-labeled
CCAGTCATAGCCGAATAGCCTC
14q.80,90-94
BE580
R.Z
NM_002608.2
published.55,59
2.46–3.14
.Progeny
therapies.6,7
p85α53-56
.Duplications
//cancer.sanger.ac.uk/
acidsubstitutions
.Addition
Q235∗
223-244
.Margins
Con/shp53
α-skeletal
isofluorane
puM
Bebenek
Cochran-Mantel-Haenszel
1642–1736
∼22
IIITM
Icam2
.SOX17
290–275
1DEV
NADPH-dependent
2SD
180,500
Novelc.4173A
'w0J0
Ub-AMC
De-Lano
ysArgL
p.Gln938His
..E.M..
ctcattctcacccccatatt
SLR-25
Angrand
anti-PTyr
Arg80
expression.In
anti-active
RET-WT
Unsurprisingly
CT-scan
ADORA2B
tissues/organs
SHC1
transactivation.39
2.0amp
Beullens
anti–CD54-PE
data.47
nondigestable
193/53
endoreduplicated
MSCV-YFP
anti–NPM1
1-40+3
SongTao
cycle.1
.Tet1+/−
GECO
EGF-driven
gRNA
OCUM
buffer.For
1-143
phospho-PDGFR-β
RAB35A151T
D837D
,7,8
B.III.1
PIK3CB-specific
E909A
rifampicin
27–32
KMS18
cap-dependent
G.0286.05
.1471C
MET28LN
8-specific
fenretinide
5C
o-Nitrophenyl-β-D-galactopyranoside
Delbrueck
-GTGACTTGTGTGAAACCAGGT-3
Fig5G5G
rmc
Y/N
.Summarily
3.1–16.4
UNC13B
Carcinogenesis
TTGTTGCTTG-3′
immune-competent
NN/NS
line–associated
GISTs,7
·
c.180C4A
PI3KR1
.504G
AGGGATGGGGTCCTCGGGGTTGAA
cell–based
cancer.28–30
C176LfsX26
L149P
IL6.15
205.2
M/24
pharmacogenomics
10.4.11
sulfo-NHS-SS
c.1537+1G
15–40
c.3411C
56787349
shNTC+ve
HHIP
Phe961
ICGC_PA89
tyr653
phenelzine
discriminatory
5.88
0.297–0.736
TBET
8.25145025
cyano
acid-to-histidine
3y-RR
19/309
14/72
nonmissense
GRP94.24
yet-to-be-characterized
1791–1799
38-
Abbreviations—–F
TP31
processes.23
1,090
2766A
.536A4G
-X-F/Y
tki
MC38-OVA40
SW-l
DESeq63
melanomas.12The
B-RafV600E/Raf-1
2–3×107
ESRP1
Senawong
RP11-407N8
402,000
Softberry
∼50–53
.IMPACT
106,000
XmaI
Ready-to-go-your-prime
Rb-BRG1
MFE-296
85.73
lO3unselectedDuke
2162
DBHi-Cre
pole-pole
G480W
63898
17q12-q21.1
GROMOS96
IRS-2
requires.25
rs12329760
Abl-control
MCN—distinguished
RG-11T
†p
9366
seomatosensory
12/72
Fami
SA1
AKT-regulated
11.7
disparate
Pavri
post-infection
nized
deleterious/suspected
HASYLAB
~500,000
Tyr187
TGR-1
deletions/amplification
K335
3p21-3p26
0·737
tumors33
resistancein
5′Phos-ATG
370–380
differentcompared
ALKR1279Q
1403/1605
mBrca1–
Superfrost
gene10
Hypofunctional
NCT00113763
formation1,2
NF-κB-Lux
twenty-first
13–14
KRT14
metastaticGIST
chymase+
5′-CCTCGTCGGGATCCGTCATCT-3′
TAFII
FBXW7.38
transcription.5
S1000-P1008
172A→C
anti–HLA-DR-PECy7
HPK
cysteine-containing
P91L
tumors.5
21–84
PI3Kδ-mediated
xtiorz
KMT2C-mutated
HEK293T-BCR-JAK2
sites.5
5.0×
.W409
mutation.26
P-40/50
1.87
Neurochir
R140
Co30
Fig.6b
~18,500
nevi/melanoma
MLL-lacZ
Open-access
.skin
6–24
GCGGATCCTCAGTAGTGGCTGTGGGGGAT
pfg108T
Survival…Download
embolized
RNA16
DI8S64
Q226H
fig/ml
.LVS
B56δ-dependent
c.755_758del4
5′-GGATGTTTCAGCTCTTCCAC-3′
2992
sc-37600
0.01.
Dot-plot
10.1172/JCI43910DS1
FIP1L1-PDFGRA
KAP-
26/27
8~~~~~~~~o
7.47-fold
R258
PTPRS
control_pool-1
12/14/99
•59541
alleles.9,12
cancer.7,18
Frequencya
state.74,75
68531
Hematoxylin/eosin
|14q21.1
synthase-1
Vojtěšek
0.71–1.00
8.2-8.4
120°
GCCGAGAGA
336–353
Msh6mut/mut
5'-GATCCTCGAGGGTCAAGTTGGGACACGTCCCTCGAG-3
14•15
insignif
56811513
breakpoints3
56,57
RAS75
anti‐Mga
6/79
Ten-eleven-translocation
c-Kit+CD34−
pgalactosidase
Vertebrate
cancer—adenocarcinoma
r.989_1144del
CAG-LSL-GNASwild
0.5–168
pCDNA3-6myc-Smad3
.Cytoscan
BPRC
TP53MIM
Dhand
Tables44
polybrene
FGFR/VEGF
3Biopsy
CGAUGUUGUUUCUGUGGAAUU
AFFAQLQLDEETGEFL
report36
R213W
.SC
10.3μL
4.40
4397682
5'-CAGGCCGGTAG
peroxidase-protein
pseudo-hypoxia
SrmB
.Incidentally
CCAATATCCCCATTTATAGCTGA
Ras–ezrin
TGS-6
yeast,3
48/mouse
fiveK-Ras4bG12D
response13
GAACAACTTCTGCTCATGACG
MPNSTs
AKT-dependent7,8
10-neo
mTOR/S6K
Jurkat
proliferation/differentiation
1683
amplifications/deletions
hemoglobinized
cigarettes.25
NPVc
treatment44
MUS81-EME1
mAB
Wnt7a
orthorhombic
ATG-FIX
urothelia
sc-32233
1-796
GFP-based
Immunodepleted
H3K27me1/-me2/-me3
γ-tubulin
dimethylhydrazine
lGTlTTCCTGAGTGAA
protein/PHD
consonant
RAR
N327
p.R309stop
RPA32
Elf-3
amifostine-induced
Brdu-positive
.Cystic
substraterecognition
L106R
insertless
H381Y
criteria31
SHP2-dependent
Takahashi-Tezuka
V3
Non-V600
037
pug
i–iv
anatinus
LDEETGEFLP
sporadic-type
D522N
semiFIG
Okuyama
29-83
melanoma.34,35
methods16
cases—EWS
pY-STAT3
KRT6B
c.49
153/307
cells36
Billette
Asp-274
18F-FDG
genes.
FLK
therapy.15
pEGFPC1-PTEN-C
splicing-dependent
EGFR-null
interconnected
breast/prostate
kinase-3β.9
Dusek
de-escalation
p.Ser817Tyrfs*12
couldtherefore
E2-dependent
different.However
I-II-III-IV
Hoeschst33342
GSE40419
.Cytoplasms
449
ruffle
14,26,28,29
quality.Somatic
.Studies
Interferon-italic
Lys8
Bimolecular
p110-CAAX
SDF1
c.793C
MLH1
Smad1–8
0.353
LAT599VKS602-motif
-3.52
2699
5.05
.HCF-1N
89x
L858R-T854A
Schoberg
mutation.4,5
HIF-α
C2/helical/kinase
G442V
cryo-protection
P88S
ganciclovir
CB.17/SCID
transphosphorylate
cases5,6
equal-height
-thymidine
Pro153
MKK4-depleted
andBloom¢eld
.Vav-Cre+Srsf2+/+
E258V
ARAFS214A
p.E272X
non-spliceogenic
role,41
anti-EZH2
Heraklion
H1382
near-identical
Wattjes
NFG-TrkA
RQCD1
AAUAUU
sc-327
controls.23
pheo
Del746–752
.MC38
gp140Proto-trk
5′‐CTAACTACCCATTTTCCTCCCTCAATTCCTAGAAAATATTTCAG‐3′
Gli1-mediated
.00218
oncogene59
ATGL
R11/K13/R14/R15
clone:4732455E07
FPY
//doi.org/10.1371/journal.pone.0087113.t003
1.8-2.0
stratum-adjusted
pregastrulation
BIM-γ–specific
.866E
prolyl-4-hydroxylases
metastasis-related
ROI
.Clarification
phospho-P44/42-Erk1/2
Differentiationa
e.g.Fig
etc…
TrkT3
ROSA26CreER/CreER
fgfr1
Y568–pY570
vincristin
990
Analyzer–Applied
mg/m
585–559
160:1567-1572
ESC-like
predictive/prognostic
62h
KRT6
LAU149
Bead-coated
zipper.Expression
.Actually
FFS
and6B
not108
1/grade
oculo-
PI3P
.MCV
to958C
SCR
Cabral-Marques
TEL–RUNX1
anti-phospho-S383
sSNPs
Gli1ZF-WT
work11
Jopling
TumorPoint
D12S320.11
3/2
stitute
99.899
116:3171–3182
Lin−/c-kit+/Sca-1+
pre-rRNA
Fig.11E
β3-β4
intracerebroventricular
38.5-fold
Acuity
delA767_V769
K78
.CBFbeta
.Soong
~14
Rem
phospho-p44/42
gene.25
BAF73611.1
−2854C
FlpE
LOD=390
1−5.8GPR87G
.Excluding
24–28
HLF
MYCN-AMPLIFIED
Figure9E
T-ALL16
IMAGE:6847314
Dox-induction
bioethical
electrophile
nonclathrin-mediated
12m
different.VEGFA
Flag‐tagged
13–63
rs17290162
melanoma.9
sembly
antisites
.Coregulated
5′-TCTTATGCGTCTGACTGTGG-3′
hyper-sensitive
10.1007/s10038-005-0239-7
1696–1700
790-residue
rs121913430
TRCN0000060743
—because
PatolÃ³gica
HIP1/PDGF
Multilink-HRP/DAB
2223
H93D
MYO-D
NGS-based
Temperature-dependent
HIP1/Huntingtin
HoxA5/7/9/10
Lehrnbecher
I205T
bicluster
EGFR-A289D–mutant
gaggtataaagggactcaag
non-YFP-tagged
TSA-treated
p21Cip1
L272V
Medac
T-cell
Fugurubripes
AGGCCAGTGAGGGAC-3′
conditions.16
9.5G4.9
oftotal
.PI3K-dependent
c-myb
q21q21
molecule.18
patients.88
de®ned
2Dâ€
37–79
L253/257
1.34-
.Countries
anti-Y653
AICDA
NCT01588431
37.0–2.20
Bac-PAK6
IKBKE-transformed
SAPK
experiments.The
11/70
.Podocyte-selective
50–69
Cip
140-
domain-2
FWER=9.6e−5
TRE-NRASG12V–transgenic
R982C
20-~~
cytoskeleton-mediated
XNP122
class-like
Stearman
sc-2025
amplifi-
M18067
.Cycloheximide-chase
igenicity
VH3-20
.Activity
0.86-2.89
39–74
gains.6,7
CACTTCCGTTGAGCATCTAG
reviewand
101/126
ΔSUV
normal-large
bilayers
0.00398
TGAAATGACTGAGTACAAACTGGTGGTGGTTFluorescein
.December
Snf5
batch-centred
adenocarcinoma.3
water‑no
biclonal
Gal4-ER
ACG/CTT
muTector27
superhelicity
0.5M
.GppNHp
TIM-CRAF
self-interaction
3831
miR-194,16
129EV
Conforma
pCMV-5
8J
601518
p.Arg649Trp
vectorette-based
SW-982
C–L
A_51_P508510
Aid™
3B10-2F2
265^272
.GG
Sf3b1+/+
anti-pY694
Leu275–Leu283
mMTris-HCL
RG7112
Kinji
1.2-15.0
dexamethason
NP40/0.5
Humaine
c.102_103insC
3-kinase/Akt/GSK3β
PCR/in
.Kill
Smad4-independent
MCA497GA
UNDIFFERENTIATED
pHA/
epigeneticsilencing
//www.1000genomes.org
toan
PJS15
wereidentical
well-annotated
134/192
.L-744832
'apical
L-vector
.Angiogenesis
replication.37
structures15
E2F/pRB/chromatin
p53-R280K-expressing
p.Arg1189X
sc+h
isoforms
Griep
Anti-pRb
806-811
2007–2012
0-129.34
neuropathologically
puroS
.21,22
LacZ-specific
.IHC
R246C/L
proliferation.20
3244
−1.02
anti-UPF1
Glu144
PTC
6,110
7S579
SHE78-7
.Radiographs
Pac10-independent
20.003333
noradrenaline
hDNMT3L
pnas.1321155111i7.jpg
spectrin
GST-LBD
c.1799
p63/73
.H2405
monthscancer-related
Ep300Δflox/Δflox
Emfret
Affymetrix
.P-value
chr13:28
N–Cα
EP300–ZNF384
NAJ
cBioPortal45,46
99Tc
STAT5B-mut
L1196Q
10/119
Taxane
5′-CATAATGC-
Despiteefforts
96.9
2185
p=0.99
L768S
Intermountain
Senepathy
Dervite
MDS/MPN.17
shM1
two-way
cellspossess
–48.8
1709
p.Gln1503Pro
A344V/N374Y
TRAIL-
.few
U87MG.EGFR
ERFΔDBD
determined,13-16
hTPO-stimulated
ACGTG3
R162*
15597
Colotta
dierentially
18Raf
90003
5′-GGGCATTCCTGAAGCTGACA-3′
-benzyl
dodecamer
JAK1-K1026E
Dose–responses
Adaptorbinding
≥16
periments
M1775R
C275F
β‐Catenin
4317
Coussens
SPOP-specific
biopsy-proven
Erg-negative
variable-joining
ERM-interacting
Apc/Smad2
.2,4,12
Physiologie
autofluorescent
pGBKT7
activator/coactivator
1,590
wholemount
autophosphorylation/inhibition
Epigenetics
monocyte/dendritic
5-Å
Proteome
α-H3K27me3
andmsh2-VD858
genes2
360-380
cancer5–7
CMV-p300ΔCH1-E2
5′-GGAAGGAACCCCTCGAATCC-3′
CA2
co-operating
PCI-52-SD1
1,002
32-41
GCA-3′
6q21.27
SS-SG-DD
pENTR_L1-
PIK3CA-forward
Background/Aim
EGTA
71-74
PJS07
Grummt
5'-CTCTGACCITAGGCC
ADAM23
N**2*1
pCAR
142410
K2555
ERK-DEF
non-FA
S75C
1.10
group‐specific
Figure6D,6D
function5677InsA
PE-Annexin
Smad2-initial-IP
40•OCTOBER
disease.50
8–11
60-kDa
pCH4M2.42
7q35-q36
GAAGAAAAGG
DME/F12
.Mean±s.d
endocrine-therapy-resistant
0•59
mutation1
9/16/98
HPV16
c.114C4G
cc-11-4059-g7
5′-GTTCCTGCCCATGAAAGAGA-3′
aromatic−aromatic
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
parallel-transfected
RhoGap
Glu-37-*AspS13ff
'Luminal
G138V
methylation24
two-step
Met-1783
33-bp
pmCFP-K-rasG12V
al.28,29
Gliluciferase
delS
sub-fertile
10.1159/000357129
NPM-ALK–driven
nickel-coated
TET1/2/3
Prokinase
non-repaired
ActFGFR2
0.184
10.12
TrisHCl
c.388_389delCA
5′-GGAGATTGGGCAGATTCATC-3′
UCB
S720I
35–433-CFL
calponin
D-Luc
FGFR2-mediated
5′-TCTTGA
growthBecause
Fgf11–Fgf14
/BR13R1
G616S
+Gsolv
/17S
df=59.7
K27M
CTTGAAAGTGGAGTAACTAC
metallothionein-Met
7mGpppGcapped
SAP-1
914-1037
Pvu
Ras–RasGAP
cancer.84
000535.4
LNCap-abl
ErbB2.32
351–403
S-adenosylmethionine.14
S752-I759
8μg
sc-22810
Y35N-induced
STK15-specific
MIP
Shwachman-Diamond-Bodian
3′and
13226
*2.0
TNFTNF-
multi-clonal
Praz
RERE
p=0.047
nshah
Bac-to-bac
p53G245D
D1010_splice
0.48-kbXhoI/SalI
VEGFR-targeting
ac-32P
Precup
71
pY-73
7-month
fulvus
pT2pN1M0
G.D.D
R683H
LR10-005
CS01
transmembrane-bound
phosphorylaMOL
RRKRSR
RB2-RT-se
of'25I-labeled
HMEC-hTERT
HCC15
FAM84B
H2309P
1.265
OMM-033
12e
signal-transducer
560–570
OR=0.43
2:05808
p.Ser256Thr
pCMV4A
irreparable
H254
2276
3114
5′-GGGCCTCGA
26,48
polymor
35.58
sterol-responsive
hyperintensity
pMY.40
SOX14
Phe338
NZM49
133140
5′-AGU
Lumar
*Twenty-two
36–69
tumor-essential
0.119*
C/EBP-regulated
BIM150
35S-Met-labeled
5′-GCGGATCCATCTGTGGGCATGTTGGT-3′
91–92
5′-CTGCCTTTCGACACAGAGTTCGAATCATGC-3′
IGFBP3
mg.46
:
100-residue
Set7
AF-1-dependent
P=0.044
hyperoxic
600-3cagGG
39,978
BTranscript
Molecules—The
congential
L1240F
p.Leu359_Pro365del
ability84
NOD
Ile114
A*2436N
BRCA1cDNA
Inlron1
G114D
VHLsequence
ten-
mutation/small
il-
Maloisel
type–
/KM
Light…
cells.37,39,43,44,47-49
inden
GAG/POL
AIRD1A-regulated
.Per
U2AF65/hnRNP
223±781
NUP98/HOXA9
Q-rotamer
0Cu
INDUCED-FIT
Tet2b
Met.=pleural
twitch
13q33
TGCTTTCAGGTGCCATCCACTTCA
Toxicities*
.Real-time
antiphospho-β-catenin
conﬁrm
sc‐1747
11q14-qter
distant/lymph
814
12.2–72.1
FXp
Isoform-selective
SUZ12P
.COLORECTAL
Leu421His
AMLCG1999
EZH2—such
Confluent
68301820
patients20
T364A
PG-DUAL-SP
-FITC
months.78
.0038
0·3–205·1†
A228T
organoid-drug
homemade
ten-eleven-translocation-2
66including
HERVK19
eosinophlia-associated
anti-CD25-APC
Braf+/Lox-DA
–105.9
MCM7
c.5720_5723delCTCT
1.32-3.91
2–435
log10-likelihood–ratio
observations,18
1·2
receptor20
pZipNeoSV
N336D
–cyclin
FGFR1-CEP110
Electroporation
F1135del
putative-Sp1-binding
H329P
BACH1–TOPBP1
D84Y
targeting79
CDG-IIc
WKVVE557-561
F461I—The
D7-D7
PO4-SMAD3-specific
RBGMdbDB
NSCLC,7
0.9971
1556
ubiquitinated
report.7
Myc-W-PDGFRA
mg/mL
3483
DNMT3B3Δ5
197
XLfit4.0
V.2.5
DNAsegment
p53-associated
4076delC
yGCN5
YCpLG-myc-p110β-wt
panda
SHQ1-ΔCS
dose-proportionate
CEP85L
CCM2–OGDH
TCACT
ililili
p.K57N
density/intensity
CAPAN1
PPAR-responsive
EGFR18F1
Nu18
5990
Twenty-six
CH-O
expression.All
ipatimup.pt
5′-AAG
T272I
Col5a1
Z80
71/101
.iss=14
hsp104-GFP-
non-TRK
.Forty-three
PIK-E9IR
ENQRNLLQMTE
mutation.30
mg/Kg
scan-
N564K
Celestijnenlaan
550-nm
Bulyk
described.13,16
K71
progression2
Serova-Sinilnikova
Samulski
wild‑type
colony-replating
lysine-to
xVent2-luciferase
treatmentsuﬀered
SABCS
V1247I
Msh2V63E/Δ
ER+/Akt-
RipVEGF-C/RipTag
014159.6
D898V
A20-HA–bearing
1786
NP_034337.2
andJH
p27CDKN1B
GFP-CDK6
neoplasms.26
CT-scans
CAGAGGTCTCTGTTCGAGTC
P281fs
TCGA-73-4666
Gal4–CBP
96®
CD19+/45+
IAF
4⇓A
JH7
G2609D
platingand
GIST37,38
37.7–41.10
P402A
hyperactivation.12–14
cancer.50,66-69
LC50
NCI-CTCAE
Immunhistochemical
2.97
PPREs
acyl-CoA
poly-d
Bertholon
F1-derived
Kudo
100071
14q13.3–14q21.1
Asp61
NSG-HPRT
growing8,11
F/67
A875T
Atm-deficient
ALCLs
802_B_4
Y901C
MTA1/HDAC4
.IGF1R
UAS-Gal4
rs35918369
proteolytically-sensitive
Methodologies
JB1091
tumours105
lenti-PTPRD
metalloproteinase-induced
Aponeuroses
Kintek
dSet1-RNAi
fragmnent
cancer_data.html
post-fixed
T441fsdelG
peptide-treated
proliferation177
CEN4
RNA–depletion
TPI
58,000
miR-4447
Midollo
integratedlacZ
differentiation70
0.164–0.778
73,74
52/CRC
3′-LTR
Flag-Akt1
4393
PDB
26C4
HER2-positive/HER3-positive
-c-Jun
stem-cell/progenitor
tcacccacag
R37X
~O-*M
diarylureas
NaMnO
W5C
L111
hFAST
Angelova
5′-TTTCGGGGATTTCTGGATG-3′
intrasinusoidal
semiquantitatively
V81/85
A305T
8-oxoguanine
T80S
TGC-221
1LEW
95CI
Bic
Molijn
HUM00069052
12,57
20-bp
:7541–9
lines.7,8,19-21
MLH1-NTD
sec/kb
R555W
dSTORM
.CD/ED
gcC*
algorithm16,17
Jinghui
DA/AA
10R-C177AX
Alsanea
biopsied
Nf11
sorafenib/CRAF
86–88
RM2445
Arteaga
Universitätsklinikum
Tuebingen
weeks-not
^1.06
EGF-signaling
5′-tcatattcaatttcatcttcagag
7–24
.MLH1
MM1.r
3,559
Deubiquitinates
Sba1
Plz
.Raf
pseudocatalytic
Y594F
`gain
oxidoreductase
raÃ-
latepassage
Kinase-dead
AktS473
601675
5p15.2/nuclei
HNF-3γ
VHL172
.Ser5
recombination.12
Reindl
698delG
CTGTAG
-1,000-fold
log-ORs
domain.31
P_troglodytes
.Ras-CDC25
UAS-Src42-IR
med.kuleuven.be
male-determining
A18D
Enzyme-Linked
IL13
~20-
.Internal
Cen1
Mixed-Lineage-Leukaemia
0.6M5′
chro
saracatinib–sensitive
omega-3
2.00/Mb
activation.6
localises
selectionprocedure
duct-like
R631S
23-25,27
CACATGT
Bulysheva
ERK2–337
1-443
fluoropyrimidine-based
Eco47IIIfragment
34Codon
Sty
and11
NRG1β
E22
331-339
p.G305W
2275
pEAA39
His773_Val774insGlyAsnProHis
higher-level
IGFi1R
Y236
Frankel
R342S
P-0000208-T01-IM3
inhibitors,22
AntisenseAKT2
CGNPs
streptaviRBF
anti‐pericentrin
SCo/Δ
M62
PPM1D-L450X
//www.ncbi.nlm.nih.gov/SNP/snp
9-cell
A11302
R481H
women,45
T14/T15
VICTOR3
p-AKT1-negative
superimpositions
9718
H1437
BamHI–ClaI
42–43
Somaschini
LN40–ADP
p=0.14
Stecula
−25°C
S1655A
R188LBRAF
7470A
CEF
ttttag/GGGCTG
Non-Maori
SpinColumns
Val769dupAlaSerVal
30-mm-diameter
RHR
domainsin
thioredoxins
S810a
G169A
37–68
Phe582
.MelaAddress
vehicle-transfected
HBEC30KP
CVD
Msi1-positive
DSMZ
cRSS1
Hirning-Holz
SkMel-19
2R3
Flag-p53
77
Gli2FL
madillo
4813
anti-fade
neurodevelopmental
200´
12063
Fbw7-/-tumors
14429
iTRAQ-labelled
JAK2/1−
GFP-RAC1F28L
C•dT
phorbol-12-myristate-13-acetate-induced
S5e
K5-Cre
9396
20-100
2.7-Å
QIagen
BRAFV600_K601delinsE
BR6
doi:10.1038/leu.2015.165
ODNODNODNODNODN3T3ODNras'HHHNHNN/KNNNNNNNNNNNNNNNNNRef.89909192k937959636569679458205761605995626968'6685996599674627575â€¢75979875
WUNSCH
Asp450
yr-old
mL257Raf
-diamino-2-phenylindole
HelaS3
18-25
R241C
BiBr53-56
GFP–tagged
11858777001
59-GGTTCCCAAATAATGTGATGG-39
RP11-962G15
57/99
Y-653/654
Hatakeyama
day6
GFP-MLL-expressing
c.3744_3747del4
containsa
Asn797
.Taylor
DUSP5
Twin-Strep-tag®-modified
BIMi2+/−
partner.62While
∼4500
6–963
CoCM-1
6a–f
M8265
instillation
.DIS3
A553T
10E9/l
AKT1-mediated
5-AGAGAGCTGGCATCAGTTCACTTTTGACCTGCTAATCAAG-3
LFXL529
cisplatin-resistant
rs3018301
Slupianek
breast–
K162D
IVS1+12G
20insertion
LEPR
tumours102
35°C
region,47
Dnmt3b,18
SRF-controlled
7786
N499S
14–20
'forgetting
58-TTGATCAAATGCCAAGCTGAA-38
DME+
3/20
CDK4-MUT2
humanhomolog
4B–F
LXXML
Rabindran
BRG1/BRM-deficient
8.5-fold
gtaaattcc
p-SRC
330717
66–87
105387
KMS-8
7433-2
per-
CEP128
Cytogenetically
.AMOT
snu.ac.kr
Superscript®
p16-expressing
I302*
Qiagene
Q556E
J.Z.
nucleo
−0.3
β–galactosidase
anti-cleaved
P=0.141
straightforward
.Submicroscopic
C634S-Cl.2
K798R
GeneWiz
J.Figure
H00007468
/highwire/powerpoint/42236
alterations36
Kaken
W36R
Chk2-associated
0.949
ΔEGFR
β-value
growthregulatory
C/ebpa-Cre
andstained
IV-deficient
metabolism42
ACT05
fol
≤0.1
61/113
PolyPhen243
Nucleophosmin-anaplastic
Iffa
PI98
Src42-IR
abilty
R540Q
target2
BIML
epithelium110
Michaelis–Menten
CAG-3′
GGA-3
R111L
EB1
293Trex-FLAG-BRD4
53.3/55
Eects
rs6220
breakage-fusion-bridge
EPO-induced
adenovirus
000369266
study2
LexA-cyclin
439F
.N1–N4
B.graphical
decades.24
'absolutely
transcriptasePCR
91.51
TGATip
anti-pβ-catenin
DFC
nonchoroidal
148,000
high-basal
7726
349/593
plusminus
3C09
17907
Cy3-goat
ctgcag/CAGAAT
TFK
L5.71
flavanoid
dTP
.MMP1
myelomonoblastic
Synergi
.129
CDG-IIb
-GATACTGCCTCATCACAGT-3
Grønbaek
Q-tip
CTAT
RPS16
.CDKN2afl/fl
rad16
265–328
p27/Cdkn1b
DiFMUP
studies66
Late-diabetic
293Trex-FLAG-BRD4-NUT
WINMDI
US7MG
G418-sulfate
F1706
MEB-MED-8A
∼250×
μMFura
p53-relative
.TAE684
4~p67trk2
60/78
Akt21
rs238417
Sic1
Dedieu
Balbas
foldx.crg.es
CancerP53
Phred-scale
RG-13
pLV.CMV.Flag.2A.DsRed.puro
transformation193
p110beta
.Hosono
BRE-luciferase
â€oemutator
CCTTTTCACTTGGCCATGCTC
l-cdk6
P466
imagesImmortalized
avidin–biotin
tumor-effector
12,13,14,15,17
4q32
BIM68
2a-c
TGTGGATTTTTAGGCCCTTG
RACE-PCR
Jordanova
postendocytic
endothelial-specific
.WTc-Kit
Q354K
Q177R
software.56
Ripk4
BRAF-induced
p=0.89
trafficking,37
T.A.N
1267–75
F31
ura
STEMCELL
My46
0·8–11·0
F347S
11q13.5–14.1
PDGFRA—associate
10.77
pGKneoTK3.IRESLacZ
Pulse-chase
MGW
HD-0395
population.21
theLEU2
TRIM37
3,763
CALBIOCHEM
pre-expansion
Histidine-tagged
3×IRS
α-N-Ras
87.88
Llorian
w/o
Rubio-Moscardo
15–20
debate.43,44
Sangram
q=6.26×10−3
BRCA1/24
Terragna
chromatography/tandem
GF77
5′-TGAAAGCACCGCTCATTCTCTGTG-3′
BRCA1–BACH1
proteinhas
S6A-S6B
carbohydrates
14cm
RASGAPs
dentification
time-
oxygen-dependency
Ring1b
5′-long-terminal
3.3.3
-upstream
Thr642
anti-phospho-PDGFRA
asynchronized
A276D
D′E-loop
date13
AXIN2sample
Lobov
CS10
coactivating
ZN415
5′-GCCCCAGCCACTGTTC-3′
DN-MKK4/JNK
5′-GTTGTCTGAATTTACCACCTTTGGTCAG-3′
50–59
D1067Y/A/Vmutant
n106
actin-dependent
.cut-off
.Cal27
apoptotic-defective
PPP6R2
Multiresearch
NPM–ALK-related
disseminating
Labtech
IyVaIProThrLeuLysVaIlGnVhI
WT-V5/His
fractionation.FIP1L1
Apyrimidinic
G559
tageted
anti-PMLC20
Ink4A/Arf-deficient
T123P
TRU-associated
LC3A/B
RET-NTRK1
targets195
APCDD1
Col10a1
c.1456T4C
S382
CrePR
Micromon
.13–15
β4-β5
Rubinstein–Taybi
anti-IgA
hematopoiesis24
LO26,1
1987a
V1534M
AG1395
JAK2V617F-negative
Fluorometric
A1207.ΔEGFR
HIF-1α-Ubn
.Sequence
NTRK3-encoding
40–82
Val487
EWSR1/FEV
SCD-2
NM_025676
125,000
MA621Raf-1
oncogene–α
cross-examinations
P4a-d
RB-mediated
D846
BglII/PvuII
beta,18
P196S
Gipson
telomere-maintaining
tight-junction–like
W93861
ofDrosophila
RNAi-induced
chr22:27950957–28154398
anglese
Smad3-interacting
2,921
HGF-triggered
ETV6-JAK2,27
p53CP
v2011.1
adenocarcinoma.11,12
59-CAU
HT7900
NM_0077420.171042697
150µl
∆CT
CDK4-specific
myr-R25A
NSCLCs,24
non-ATA
5-8
.WCEs
SH2–SH3–SH2
PARP8
2n–o
phoshoELK-1
FIG.9
RP11-195G20
www.1000genomes.org/data
Buschenfelde
humans10,11
Hepsin
moleculartargeted
N-LIS1
Dicers,6,7,12,14
3931del
D816V/H
Mutation-negative
8081delC
.Related
.BT474-m1
7/13
punction
10.1007/s11033-009-9906-7
Brh2
CRISPRinduced
event,3
ock
Mid-log
leukaemia5
orrepressed
30Hz
Controls‖
cMYC
modeling.30
1.205–2.195
sno
Sos-wt
TAD2
CLEC4D
E1509
91,92
noncooperative
TTGCTCTGATAGG-3′
NAD+
pNKY100
++f
495
transforming.The
thaliana
3004
2Ea–2Ed
Ras/Raf-
5'-CCATACAACTGTTTTGAAAATCC-.V
EC21A
90,90,90°
co-activators32
.If
evaluationTo
chromatography/mass
thyrotoxicosis
.1918C
716/654
60ng/μL
4/73
8.64
R462P
patients.8–12
34–63
useless.14
c.1195C
RP11–321G16
91,000
tropicallis
serine
gov
M4a
EGFRKD
6000–10
165TOR
monoblastoid
rbf14/14
CD83+
—5
18A
FGFR2-transfected
activity/availability
1620.0
rs203024
IRF6
chemosensitive
4/22/98
Fig.9B,9B
14q13.2–q13.3
interchip
5250
supernatant
VUB164
54-year
forC
350–1800
596-600
H119Y
m4
Korea-affiliated
NP420
D-281
trials.ResultsIdentification
gene—may
non-TRKA
SMARCA2-bearing
pT1N0M0
Elf5
preincubating
anti-phospho-JNK
AKAP220
0.9σ
TargetScan
LMPl
125–250
exposure.1
inter-institutional
BE259102
FLT3/D835Ymutation
inRUNX2
theirfunctional
E2+
Gln3Stop
Tanizaki
−12.32
MZFLIII
vera.12
MYC/8q24
GO/G1
RPL13A
approx5.0
LCQ-Deca
pReceiverM43
base/89
3/27/00
2R,3R
4.470
KH2PO4/137
.Surg
p.Val1088Ala
TGTTCTCTCTCCAGAGTGCTCTAA
Val523
0.30μl
C.G.
IFA
GAAGTCCAGCTAATA
PDD
1.5-3
Mg2SO4
V617F/Y931C
p.Ala197Thr
pCAT-Control
.Copurification
pLD-hygro-EnVM
DOCK4
Bordeira-Carrico
cyclophosphamide75
brain/body
sic1
CCR7-negative
D7S501
Tyr74appears
EGFR/STAT5/ERK
NF-κB–inhibitory
500-μg
catalysis.5
L253
pREP41
activation28-30
corticogenesis
beta-propeller
Nanodrop
c12
negative.Figure
Tredan
o~~~~
Lindenbaum1–3,17
properties.Most
.width=1000
n=162
H-1703
60-mm
VECTASHIELD
A-F1
Caggs-Cre
Insulin-dependent
7RP-1
DED
xenographs
12,17,37
collaborate
level87
hydroxyflutamide-stimulated
c.1017_1018insT
Antonescu
Cul3-binding
integrin-signaling
CAGA-luciferase
S10-H2
pan-TRK
EGFR/MAPK/PI3K
transactivation-domain
75-cm2
P1139S
15-77
.Clues
treatment103
Tcomplex
3'-UTR
5′-AGATCTGGCCCAACGATGACGA-3′
L2185S
MLL-MLLT4
pFlg16
0.001
Cebpa-Cre–mediated
ChampionChIP
6671
BAGE2
/macrophages
5′-GAATATTATGCGGCCGCTCTAATCAACTCCATCAAAG-3′
cell53
syndrome7,8
Subtyping
transition.35
Ernstoff
Glantz
Y→D
RB-del
T/p.E40X
-AACGGATTTGGTCGTATTGGGC-30
non-proteolytic
PRGFR
.V•l
MMP9/RhoA
p1642
CODOX-M/IVAC
.II.II
24P1749R
pSmad1/5
.Screenintgestsanddiagnosticimprovemenotsvertherecenyt
KRAS-Dependent
insertions.10,27,34
//www.lovd.nl/NF1
D1628R
c.619C
D761Y+L858R
totalof
stem-enriched
chrX
VarScan
Pax3-Foxo1A
KIAA0425
E242D
NS29
GST-hPMS2
MycA44V
16p13.3
points•
2008.
Dauldi
MT-1
BRCT–ligand
GFP-Aurora
ligand-unoccupied
astrocytomas61
Resat
1.371
LSC_UP
33×
nilotinib,5
PTPN11b
cRSS-driven
12-16
IVS27AC33.1
Maturity-onset
281–89
andexpressed
SNPiR
Taz2
medulloblastoma25
15,811
PML/RARΑ
Tor
Lopez-Alcalá
ESP6500SI-V2
mssm.edu
Misfolding
5′-GAGGATGCCTGCACACACACTGCCCGC-3′
CeB′
Fig.S4A
R256Q
RP11-885P10
NlH-proto-RET
.PATTERNS
P70R
non-muscle
RP11–291N1
bronchoscopy-guided
HLA-B*1817N
pGT3.1
IRwt
NCOA4–RET
snRPNs
.4
rigidifies
12/383
DOCK5
pVT-U100
nonhybrid
regulation.54
deorphanize
PyMOL.27
WM266.4
non-AR–targeting
.3927
work.2
SHP2/Erk2
neuropilin-1
.RAC1P29S
Rho–RhoGap–GDP–ALF4-structure
al29
symptomatically
ERCC1–XPF-deficient
01/02
μ′g
CDK-binding
proto−oncogene
∼1,700
doi:10.1038/sj.onc
Inter-individual
delWK557
TERT-NHUC
Sin3A
pVP16-CDC25
Known/putative
Meibergdreef
O.S.
conference.14
TCGA_Network
pedigrees,6
Ras-V12
.S6A–S6B
176920
1/71
BRAFV600_K601
PCR/ASO
Wetmore13
81-fold
3zzsi3
cytokine-dependency
AXLs
liver23
osteoclastogenesis12
0.7839
K-Ras20
ATGGCTCCTTCTGAGGAACA
PMLassociated
-sensitive
androgen-
some—but
Lats1−/−
anti-double
.duplicate
.DR50
N-5
p.Q22R
Fig.9A
I9.2
spt13Δ
supE44
72˚C
427—S427G
YM-254890
KIT-Δ557-558/T670I
myc+
N234I
age74
R535H
37.3
desmoglein
109–190
Michor
FGFR3b-expressing
R1699W
100–2.7
Q1180
trans-inhibitory
Gonadotropin-releasing
6-μm
CLL2
6.Table
S116A
A416V
Figitumumab
histidine-de®cientmedia
p\0.0001
Troma3
PCR-electrophoresis
V561
CDK-directed
7q32-q35.5
22nd
.Aggregation
A211D
φ-π-S-S
Asn-260
CUO12
788–960
extrahepatic
T2467
5-Brca1Ko/Co
RET-MEN2AY
Brainc
21.9/24.3
PRLL–IRES–EGFP
MetAlaAlaA-laAlaGly-GlyArgLeuArg-G1n
TKI-dependency
MS-unstable
S580L
0.661
lobular-alveolar
CML-AP/BC
autoantibodies
mutantbearing
.Ngan
0.8–23
re-administration
LDS
ÃŸ-cateninand
Welti
120–200-bp-long
Chip-Seq
//www.dmbr.ugent.be/lmbc/contents/mcb_vol24_july2004
109-122
Cebpa-driven
140-h
amplification.Immunohistochemical
EGFR,31
sporadic-like
TPM3-NTRK-1
≈45
trkl2
drug.32,53
aggregation-suppressive
Braf
1.43–18.31
anti-pan-ERK
onco-cytoman=
.Leveraging
1021–1035
GRI
sc1005
values*
disproportionately
Epithelioid/clear
Bard-null
Californiaat
c.5439G
tumours40,42
RAD51AP1
mutations10
NPAT
732delT
BCOR–RARA
changeCD36aCD36
.S6K–T389
GGTCCAAAGCGACCTCGAGAATCCCAGGAC
activated35
E635RfsX15
apoptosis-
E197D
catheterisation
F-site
APO
RIIIa
formed/tumor
gi172002
AGGAGGGCAACAGGACCTTCTG
isocitrate
packyears
LC10010a
NCT01781572
nomogram
B-Raf/Raf-1
Huether1
insulin-expressing
53kDa
ΔEGFR+
14,27
'sparse
oatients
PIP1
mutations,6-12
Zebisch
edly
AM050805
132m
Tschopp
Histone–lysine
TKIs.7
Orange™
RYBP–MDM2–p53
195–348
CRAF31
.TIL1362
three-loop
Cardiomyopathy
pCITE4A
G719.28
Proliferation/Cytotoxity
62–66
co-ordinating
9.08
co-presence
L858R+E709A
SMADs
-2A-GFP
diazepine
F86
pLJM1
IndelGenotyper
phospho-P44
628,096,883,783
3380
therapy.19,31
BCC2
Sonication
E-*G
_IDH1/2_-mutant
ComplexThe
SaOs-2
V765A
p87
0.03149–0.04690
90.0
colonocytes
S330A
Alpha-fetoprotein
neoplasms.5
deletion/haploinsufficiency
H294Q
A161T
well-conserved
Ki-67,19
7/1,039
p18-wt
474–481
TOP3B
y-catenins
SRY-CAT1
~4.5kb
Pajtler
gene4
-therapeutic
Esquerdo
5′-GAATGTCAGCCGAGGCAGGGAATG-3′
10-yr
.FOXA1
FKBP1A-blocked
takuro-ind
Lucci-Cordisco
noninvasive
bipotential
TGFBR1p.D400G
C3143.25
EFT-associated
nlacZ/nGFP-FRTNeoFRT
40Covernight
MSH2variants
5458
ligand-independent
26/34
inestimable
4-sm
CCDC77C
mice25
FABP4
transcription-ready
SARCOMA
STK11-XI
3.0-4.5
0.71–1.42
RAS-GTPase-activating
mutants/108
primer-pairs
AICAR
Hs00368175_m1
phenolic
Rajamanickam
population-doubling
cell–like
Glu632-
SLC45A3-ETV4
thertTA
EGFR-vIVb
HCN
lines—BEAS2B
c.1384C
8E–8H
p.V89L
T+2
265×
ZMPSTE24
LFS/LFLS
4.4–5.5
ABA-dependent
//www.hgvs.or/mutnomen/
0.672
CLL
1.3â
A_51_P113182NM_013584
Kostzin
Holm-Šídák-correction
.Maintained
PPFIA2
JMML16
Shimadzu
P-0000112-T01-IM3
a-CGH
XPF-ERCC1-structure-specific
proliferation.19-23
anti-polymerase
mutations.18–22
G12VNRAS
5–24
†13
GGATCCTAATACGACTCACTATAGGGAGACCACCATGGGACAGTTTGAACTGACTAC
LO2
-TTAAACTTAAGCTTGGTACCATGGAGAGCAAGGTGC-3
Plyte
L85S
signaling72
F712S
Pik3caH1047R-induced
Promoter–reporter
CD274/B7H1
TNM
GAP-Mediated
lineage-depleted
SKMel28
d'Avenir
SPLICE_FACTORS
Camerini-Otero
RP11-351K6
rs121913429
antibiotic-resistant
targets11,12
frequentmutational
FBXW7/NOTCH/CCL2
pT7-7
Qume
5′-CAGUCAGGAGGAUCCAAAGTG-3′
FAT1-altered
3n
astrocytomas9
PAX5-C20orf112+
QualityScoreCovariate
S755a
JAK1-dependent
H179Q
all-liganded
TGTAA
microcarcinoma
Mll2-null
Leu788
MTM1
-Thr-X-X-
¶IFN-g
R310C
Sdi1
8•3–17•7
3454
protein45
regions.5
561–578
3562
S2178
.C-findings
patients=0.09
4TYG
CLTC/TFE3
seau
C/EBPα-mutant
N-glycan
1659
2550
1800ng
112-124
DDY
R138Q
antistreptavidin
Cardone
Altstock
Dedhar
LR-PCR
VJ
558del
Cayuela
protein-OH
8/36
28S
-refractory
5.5.10
CTLA4T17A
/cDNA
30a
AJ532607A*2307N
SK-UT
679
.TRIO
Tri-Council
e.g.Figs
pcDNA3β/BRCA1wt
AML-MO
reporter33
YWHAQ
10/40
Ile111Pro
retinoblastoma14
mPMBL1
H410
92.2
.Cytogenetically
R2152C
0.643
ACAGAAGGCTGTGGAGTCAAAC
a-1
BIK
D1226Nmu/mu
1.6-kb
K1702E
growth-factor-hypersensitivity
Brebières
theTRK
.GEFs
tropomyosins
perisinusoidal
46/m
CVCL_1074
fluorimetry
8.47
CPA
ΔGH2OI-N
Corrionero
GISTs11
teleconference
.VM-CUB-3
10kb
BcrAblwt
TSC1−/−-null
5′-truncated
5′-catcctcccctgcatgtgt
REDAccuTaq
R155H
anti-Cdc42Hs
Inpp4BΔ
tissues85,86
14.The
Smad2/Smad3-mediated
cEBPβ
144/278
ACACAAACACACACACATGG
wild-cyclin
14.43
silencing.11
CWWG
AGGGACTGCCTATCT-+AGGGACTTCCTATCT
TCGA-A5
I_
//www-genome.wi.mit.edu/
.X87838
Asada
CpGdotTpG
.Rheb-Y35N
53BP1+/−
assay.68
3516
Bisagni
TIMP-112
.CMV-VP16-TFAP2A
dyspigmentation
T167A
E-cadherin–
EN-initiated
predictions52
mono-
monomer-dimer
.Villa-Morales
white-red
Chromogranin-A
cullin3
n=113
ECD
epigenetically
4,402
Bouhassira
​It
12-day
1-μg/ml
CASP9
neutral/polymorphisms
SUPPL
NP_063971.1
mMboric
phytosome
phosphatase-anti-alkaline
obtained.6
B1′
phosphopeptide-amorphous
3alpha
Vasa/DDX420
Hcf-RNAi
LC_S39
hepatocyte-specific16
encodi
Trueb
target,28–30
G60V
10-day
GGC-to-AGC
4q27
c.681+7A
Lipodystrophy
Kammer
ATM78-1609A01
dose-finding
S227I
ModFit
Sarcevic
5'-CCTCCTTCCTCACCTCTCCTCAAGAC-3
E/V
T+NT
LCC
1012:1
kinase-activating
L246V
gan2.res.ncc.go.jp
studiesFunctional
C90
.Distinguishing
c.1522delA
608delC
33-kilobase
transactivation
67019
mesylate–resistance
FGFR3-induced
settings.11
I439S
protein.12
refute
database9
10889
c.425C4T
2yl
pH8
si-RNAs
microcephalic
inconsistency
antigen-antibody
Ostrem
Smad1/Smad2
Gly13Asp
ENexpressing
203968_s_at
K963
hyalinized
10.1002/humu.9523
ERtm
3'-CCTGCCCGCGGACCAGCTCCGGGCC
MO_1039
ndmtaedc
Molbiol
APOFFOTIC
vectorpTZ-tk-CAT
.Sarter
U_34070
inhibitors.24
E1384K-induced
lesion.2
.41,51
DNA-damage-processing
H1184
Greif
vivo,18
Zinsser-Cole-Engmann
receptor-targeted
L535P—significantly
BC018639
pAS-MTS1/Δ1−8
leukemias.31
N1/N6/N26
88–527
exceptional-responder
IMPACT-derived
tissue-based
DFL
E1446*
RCC-47
F113
80-month
time-to-treatment
CD19-positive
phosphatase–labeled
PRC/CMV
anti-Tom22
BTB-ZF
FLP-rescued
103.7
LUCC3
DCS-270
TRcul
414-amino-acid
2.3.2
Whatman
D835E
R310H/K375A
PyClone
mutations47
year1
P-β-cateninY142
2431–2435
BTK−/−
P26
QTcF
TEC-3
V752
MEC-1
ago22
234–270
Gcm
Tyr375Cys
adenoma.
GTTAAG/gtattt
5′-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGCCCTTCTCAGGATTCCTACA-3′
octahedral
non-lethal
EW24
mCit-tagged
ITDalleles
MEN2B-cl
2α-derived
1313
ctGgg1604cctTgg
P2RY8-CRLF2
-carrying
c.5468-5T
ΔB
phospho-TrkA
10:1.For
12318
X1-2
4–5
18.0–1.80
L151/155
21/489
context103
GST-BRCT
NM002839.2
reimburse
Mirrus
Jeyakumar
Mdmx/HRasV12
NaHPO4•7H2O
9G5
TGF-ÃŸbinds
\
Men1+/+
antirabbit
ListAm
intratumour
LGQGCFGEVWMGTWNDTTR
CHR
c.5057A
11-amino
lymphoma40
non-GCclamped
pCMV-SPORT6-Etv1
solid-
E-3810
IRF-2-binding
8.35
β-actin/p16/ERCC1/Ron-α
PI3K-bearing
CRM326
8/313
ALK–rearranged
7778
receptor.27
A-I-2
T803A
TSC2-PKD1
GIST.21,27,34
Breit
Jobin
Attikon
nontargeting
Hepa
Ruxotilinib
ura4-D
sc-2004
Flag-Dnmt3a2
hypotriploid
W420C
Pim3
47–95
Genomics22
anti-TEL
Soltoff
S341L
μAmp
thioltransferase
ESGRO
tissue.15
clinic.13
434-436
super-inducible
CDH1-specific
PCLg
sample–specific
ΔE4/+
0.40–0.67
F130V
NsPESLkdgvFTTySDVWSFGVVLWEIaTlAeQPYqg
G106R
a1370
//www.cbioportal.org/
vivo.3,5
W1double
998
RP11-576M6
5,5′-dithiobis-2-nitrobenzoic
2-chloro-6-methylphenyl
P=0.01
GATA3/Cyclin
VHL-mutant
BAI
~340
7.4–15.6
Msh2+/+
clinically-reported
p.Gly44Val
.Manhattan
assays15
FA.38
10–4
4/81
1628_1629ins963bp
cytometry-detectable
E740K
mutationa
M/58
Hui
2.5μg/ml
Anti-p-Met
Meern
CD11b+Gr1+/−
FasL
FoxA1-negative
5′-TGTAATAGTGGTTACCACTCTTCAAGAGAGAGTGGTAACCACTATTACTTTTTTTTC-3′
Single-Strand
.EJC
RNA-free
pSPAX2
mature-protein
FOG.11,12
hypoxia-regulated
15:707–716
Thr150
AM1-bcc
K-Ras+
146.7
SW-40
Arabidopsisthaliana
JAK/STAT
v0.6.1
signaling.29
CLL.15
GST-ETV6-NTRK3
Hoei-Hansen
2225
O1G
D1739G
2.352243767
230kDa
H3-selective
Anti-TRAIL-R2
CBFβ-MYH11
PI3KAkt
-APS
pmM1–5
BMP-2-induced
ZDHHC17
monocytoid
YAP-induced
29-kDa
.ARE-dependent
exist46
v1.7.2
Il27
phosphotyrosine
n=272
557/558
Ser338
cyclin/CDK/
SCF-independent
obstruction/bleeding
non-HER2
17-AAG-induced
Y646
.V600EB-Raf
radiotherapy-associated
∼15.2
μg/dl±80
S6285
Fodde
thanthat
SW948
CellTrace™
p.Phe28Leu
anti-phospho-p44/42
UPSC_5§
IL-23p19
SHOC2-PP1c
Cblmediated
P694Xa
NCT01528345
cells.10,12,29
.Altered
PDGFRA-anchoring
4982–94
Sos1E846K-activating
trpl/eu2
5⇓
homologybetween
hBRCA1
Neuro-endocrine
anti–miR-99a
Wobus
G81A
Nissui
gpllOtrk
withEcoRI
Horoszewicz
R249
386K
memory4
.Ninety
13.G334V
Ig32
a-raf-/-
DxS
P2800R/S
R417Q
11–15.7
Saos-2-expressing
Asn546Lys
sulindac
652Q
adenovirus-infected
+/++
linker.Neither
-1.347
265–314
RKIP_E1_R
NEEC
S3K
.Albino
nGFP
E119Q
luciferase/Renilla
chain–
inhibitor–induced
+MutLα
5,18
U251-TGL
DeathBase
EF-HASmad4D351H
phosphor-imaging
.Mercurio
mutation.ResultsGeneration
anti–Ly-6G
22,2*
genessuch
tumorigenesis10
anti-HIF-2α
2—entrectinib
Kolmogorov–Smirnov
tumors5
cells/secondary
KRAS=17
.ConclusionsOur
others89
Glut-4
prismless
re-started
basic-helix-loop-helix-zipper
S541R
pro-myeloid
22,9
i+3
ENA
pPDK1
.Vottero
KRasAsp13
2,130
p.Pro534_Asp536del
dynein-dependent
tumors—namely
6q15.Figure
S34P
ng/well
ImageGauge
pNLS2-dGFP
plasmid9
ALD
Lymphangioleiomyomatosis
c-Kit-dependent
VUS.53
NHRI-EX96-9434SI
Boura
32,76
SP6/T7
inhibit…
kinases3
0.093
‐1
Src6
CBF/PEBP2-binding
Italy.74-78
c.7242A
months,11,12
MEK/extracellular
TPR-related
HMGIC-specific
c.76delC
79.92
3.667
cells.33
'STAT3
78,79
GCTC
cyle
Chk2-knockdown
constellations
CD42b-expressing
Syt
healing/migration
MCSF
CT-treated
detectable.36
Fe2
Q-banding
Ras·GTP
adaptor/scaffold
SRP041810
ircc.it
ANKRD26-RT
pVHL-P86L-expressing
expression-defined
Fas-ligand
TRK-T2
Sporadic/
IRE-Luc
RUNX1-871F
​Fig.5D,5D
​However
Met67
motility/migration
702–769
SCo
60-76
NIPBL
V356R
.Mae
anti-ras
.Schematics
Y12
Ser249
thepattern
Maraver
Osato
erlotinib-
–20,23,24
MMTV-long
Isotope
Br62
LIP1
10–47
negative.106
pMSCV-EYFP-IRES-FLT3
K430E
p.V560D
deletion.28,29
formation6
proximity.25⇓⇓-28
1123–1125
pT-AKT
method.1
WT–expressing
TissueRuptor
TGF-β1–associated
chemohaptotactic
PDGFRβ.22
EZR-ROS1S1986F
32–76
HERmark/VeraTag
GAGGGGGTG
macrolides
CAF19
E34R
antiapoptosis-related
8pll.2
'really
fmg
MENDEL.40
predisposition.94,139
S1207I
Rbbp5
CUL/Cul
Asn81
pMSCV-Neo
PC12/MEN2Acl.3
NB4-R4
CRAF-deficient
glycosylation-defective
UCP3
nalr
N-Ras/BRAF/ERK
L54Q
10mM
combs.21
S7/S8
P*-ss17-
.Expectedly
TGCAGTTGTCAGTTTGTCTGTCA
melanoma10,16–19
pUHD10–3/Akt
progenitors50
C20orf173
P40R
HAAO
.ElAF
NRD-binding
far-advanced
NM_005026.3
CBP/p300-targeted
Phi29-based
isoform.orthotopical
.C-Kit
−/A
Y216/Y279
pCRXL-PDGFRB
SCFSkp2-
7/12
S1/MSH6
.Non-expressed
visual-impairment
Innocyte
factors.31
Shirahama
50004–50011
PARK7
G138D
Klf5
Guttridge
transformation/leukemogenesis
1.92×104
wild-type-specific
fusions.66
E212∗
1-483
VHL-W117A-Venus
pulsed-field
SBRCT3
smallbowelBetter
0.05aGenes
analysis.The
Q337R
2×SDS
Effusion
FOLI
71-year-old
AG4212
59-GAGACTAACGTGACGTACTG-39
anti‐TGF‐β
FASTQ
anti–β-actin
ABL-specific
1.0525E-12
NM_011700
anti-mouse/anti-rabbit
pl90MET
Myc-Merlin
revertant
others18
Katsumata
12.35
infiltrationc
3456
149–228
.CITED2
Pten–AKT
www.nature.com/leu
cultureA375
recombinations,58,59
A2046G/AGT-+GGT
phospho-AKT-S473
domain13
12,37
S4AF
S124A/T450A
-mutant
therapy––surgical
Isotype-matched
SCF-KIT
non-polyposis
TSP53
cl.311
Divalent
TGGTTTTCTTTTCTCCTCCAA
.Views
MSI-high
1381insG
patients92
Densitometer
1D1D
D816H/Y/N/V
Viguie
WRNIP1
.Shorter
E2A-PBX
non-acetylated
peptide-stimulated
CAG→CTT
ELVES.41
N1-ICT2512A
112.5
1991a
Rho-kinase/ROK/ROCK
dThe
0.901
125647
Atlas4
pre-incision
methyltransfersases
c.6275-6276delTT
0.02179
V564A
pI20GAP
p.Cys1129_Val1130delinsLeu
Tcf-4
HA-Akt2
interleukin-23
neurofilaments
L858R-mutant
115.729
pCMV-FGFR2WT-FLAG
GTAACCCGTTGAACCCCATT
PS.1
lipidated
Pme
S222A+S226A
OptoRAF
Rael
NOX4
checkpoint18
CCTG-3
.CR3
400X
AWS
Ile/Leu/Val
sequences21
Arg414-DNA
uated
PI3Kα
identification83
integr8
−55.59
NrasQ61R
Binding—HIF-1α
3.Sensitivity
parvocellular
KIT/PDGFRA/CEP4
2.95
over-activation
secretion.
0562
,ma
gd-T
GFP-mTOR
DXexposure
3904–3911Care
Phosphate-binding
RH-SUMO3
MMS‐101P
leu2–3
noncrossover
NCI-H2286-DR
H1299-p53-R273H-clone
inhibitors24
β-catenin8
non-cytotoxic
autoradiographically
p=0.4197
16–44
iGFIiR
271AA
domain/BRCA2
cm-sized
AKT1/PKB
Double-color
3406
melanoma.15–17
P-C2
M837G/S838R/D839H
HIV-MND-IRES-GFP
A_51_P130015
.PHYSIOLOGICAL
patlents
receptor.19
.Lambda
T-lymphocytic
1⇓⇓⇓⇓–6
3477
Pdeδ
mutL+
KM12C−c−Src
IL21R.49,50
crizotinib-intolerant
1A-F
CRL-5872
AII-1
LPL/MW,9,10
DNArevealed
alphavbeta3
exons49
.First-line
p16-Cyclin
ZnCl
1-cyclopentyl-N-
Cys164
Vav-Cre
E746-S752insI
phosphotase–conjugated
C-terminus.39
.Baseline
MYD88-mutated
metabolism65
Verystrikingly
Smad4f/w
TGIF
disease223
hormone-relapsed
Flag-SMAD4
//proteinatlas.org/
89:11
gene-positive
c.1389_1392dupCAGT
disease17
analysed34
sc49996
Ptges
digoxygenin-11-dUTP
0.085–2.612
CSCs.21
c.2291delG
K111E
Mlh1–Mlh3
SMAP.23
11–27
EVELADSMQTLFRGNSLASKIMTFCFK
MEF2C-positive
-3′-ACCTG
5'-TCCCTCTCAGGCATAAGGTAA-3
methylcarbamoyl
7.9/50
.Minimal
5Cambridge
CS.14–16
c.IVS12-13T
301-393
5'-ACATAGAAAGAGATGTGACTCCCG-3
PKEEG
C13ORF15
SU-DHL-6
RG,8
Methocel
low-complexity
1-tailed
tract-NTS-PVN-LC
DSBR-promoting
picotiter
observed/number
C472T
carcinoma,18,19
~G75V
KS-like
V-H3.3
Yarden
-parafibromin
Fhit
O4
demon-
ER+/PR-/HER2–
2722–
5Schematics
1:8000
IIIBa
NR6.R324L
gene-centric
suf
ezrin-mediated
MTC170
0.334
Fig.8
TCAACGACCACTTTGTCA
TÃŸR-lalÃ-elesmay
VE-cadherin/beta-catenin
70-bp
IL7R/SH2B3
sc-247
H254F
tumours24.Mutations
DP1/3
.Immunoblot
W714X
L16D3
ras–GppNHp
V600-mutant
adenocar
V.4.10.1
A83-01
N=98
Allotransplants
rearrangement/translocation
R.I.
.V742A
Vandamme
protein−7.1PDPNaLung
G691R
dopamine-regulated
Khasawneh
Kashatus
Pathologyb
polynucleotides
3–19-fold
mutations5,6,8-10
736Gright
CCAGTGGTATAGAAATCTTCG
CD10
instability,49
96-kDa
tissue.22
pCDNA3-flag-p/CAF
PatientsWe
.30-
R2/C382D
remaining/recurrent
Arg24CysDeletedMGH-PO-lG
SWItch/sucrose
260H
Lindmark
Materials—3-
adenoca
R105S
Bosottia
p16/CDKN2Aexon
Creutzig
gamma-induction
GISTs.2The
IVS20
terminaton
56°/52°
panel.B
GS676
c.5548dup
STDY
hsa04110
c.1599_1604del
transactivate
C.c
6.0+
wastreated
ProApoptotic
GMSUV
region89
8.05
ΔΔGfold=ΔGfoldmut-ΔGfoldWT
genes.45,46
27.6
.Gly12
-CTCTGAACAGGGTATGAGAT-30
Genotype-dependent
.Please
​del
rad3-related
H3K27me3—we
TCTCTCTGTCATAGGGAC
Met53
Engleson
T508
.BCL3
endoreduplicate
RAC1P29S
5′-GAGTCCGAGTCCTCTTGGCT-3′
MethoCult
5′-GAUUGUUGGUGAUGGAGCCUGUGGA-3′
R216X
Postreplication
PHCVPRDLSWLDLEANMCLP
13601A02
minipuberty
Asn-16
c.234T
CRC.99
HBsantigen
pGL4.17
HD-0302
Rho
MPCSYT-SSX-1
C395Y
4-color
.Isabella
330.
NRASmut
12.77
668C
all—features
Gilhus
­
Ser,441,441
J1ST
activation‐associated
hydrogren
Jun-Fos-estrogen
VF
pRC-CMV-RET
KEGG
α1–β3
VVP
S128R
pcDEFp300AS
FCfl/fl
anti-ZO-1
0oo
17/132
Italian/American
hotspot-specific
0.282
1OOOUl
282–293.e4
c.780G
viability.12,15,16
FoxO1-dependent
probability-based
IGrGhFGcVYhGt
omet
patients12,13
KINASES
BCR-ABL1
Y570FF-D816V
high-mobilitygroup
372-375
phosphate-binding
morphants
Pold1-mutant
Jnet
Arg-66
SCCO
T-cell-rich
Loop-Helix
â€˜m
GCTAGC-3′
5′-TGGTGCAGAGGATGAA-GTGCTACG-3′
DED–DED
BRG1/Brm-based
FoaS
H196
phosphoserine/phosphothreonine
p190
crioztinib
Lower-right
EndoIII
.NTRK1
N=111
terl909
Larynx
1p190
shLuciferase
Consed
VP-Mel
AF-835
described48
Pro-Plus
1.7-5.0
lymphomas23
W310*
1325–35
beheterozygous
normoxia
ERK1-2
withgastrointestinal
used.Middle
exosomes
—BCL1/cyclin
7,8,17,18,21,22
FoundationOne®
p.Lys499Glu
–p53
MDV3100
Dérijard
.Sixty-three
individuals.To
μm/min
SP-024
pcDNA3.0-HIF2α-myc
CCNJ
function.34
Furnari
proteasomally
c.1252A
HLA-B*9549N
Feldkamp
−50.8
ABL,21
site30
Cells-Infected
.AS–PCR
GSP781
-90
L596VB-RAF
.Allow
Sevenet
STS8
4.69
7—8
GoldScore
CWR-R1
p.Cys47Phe
ubiquitination/degradation
BGB324
Sample2
.RACE
phopshoinositide
0.5–50
-29
.Hence
www.ncbi.nlm.nih.gov/SNP/
tracts,27
THBS2
OVCAR-8-DR-GFP
MaxEntscan
age39
271532
SLC–ROS
p.Gln430Hisfs*3
c.1790-
hospitalizations
Homsi
236/207
95ÆC
INICD1.forward
Ink4A/Arf-independent
Ac-lysine
Ipl1/aurora
2-amino-3-methylimidazo
p31p32
.Charcoal-stripped
NrasG12D
−1.31
11—metazoan
oncogenes.In
com-
PGP9.5
Angelman
1.198–3.927
Glu-30
IVS16-92G
0.0015
efforts27
DA24,38
p.T1203K
SPRR1B
Ras–CDC25
myc-EGFR
IRS-1-independent
KIM_WT1
topic8
OP9-DLL1
adenocarcinoma.8,16
chir.med.tu-muenchen.de
−Fc
methyldeoxycytidine
YP017
5p15.2–
.Gel
Glu751Arg
heterogeneous.Fig
transcription-quantitative
.Alleleic
.G319S
modeoxyuridine
GAACTTGGGGTAGTGAGCGTTGTA
19:524-529
.Sufficient
disord
.Five-year
5.98
p.Medullary
Smad2-Smad4
failure.2
12.9Inoue
C1181R
A-Barcode-Exon22F
4/58
M71R
\0.7
.ResultsTargeting
MKK5
991–1153
20.17
p.Thr19Asn
40-years-old
EGFR-autocrine
nonconfirmed
`
pGEX-2TK-ER
single-allele
CapSure
17,20
1768
17-18
cross-matched
nocodazole-resistant
Frs2
.Toxic
cancer-suppressing
E286Q-mutated
NonFermentable
intellectually
PolysomesIn
CASP8
EDM
protei
BaF3-EpoR
3065
imatinab
UME
34–69
plasmablasts/plasma
ailable
Wiskott-Aldrich
1,470
c.487T
CDK4.The
Sapienza
2010-2012
Oikonomou
WT-HRAS
-0.32
PCI-35
GTGATGACATTTCTCCAGGGATGC
CV-
P123405
R440Q
Tsukamoto
.SS
.MYC-complex
disease,44
820–823
1.02-3.85
CNKI
0.02632
Uptake—L6
14/17
BlueGnome
C/EBPα42.42
PathWest
α3-expressing
self-described
Cdk12fx/fx
1+ROR1-
0.00012
synthesis—thus
GFP-merlin
p.Met522Val
GAII
trks345
185-187
FBXW7-specific
7366C
SWI/SWI-BAF
.Dimeric
Forty-seven
Chimaeric
VCaP-modulating
leukemia25
PRKG1
3.25.0
αF-
Tris-2-carboxyethylphosphine
tetradecanol-phorbol
beta-tubulin
C141/182S
IRES-nptII
Me‑
dacarbazine95
t-butyl-isoxazole
p.Arg11Lys
15–23
cysteine.4
ofevents
KDELR2
61-218
HybondN+
TGFBR1p.T200I
anti-endomucin
Y1234
ullary
DYNAL
//www.ebi.ac.uk/integr8
MSH6-15
ID-deleted
Msh6mut/-
WGSS
Yeudall
I682del
WCMC
papillomavirus-negative
TGF-bmediated
18-
1777
Hommel
cells56
PAF
BRAFV600E/NF1WT
NC_000003
Taniuchi
33.3
EOC3
LOC100133612
diphosphate-N-acetylglucosamine
NIH/NHLBI
-buffered
Renny-Feldman
stearoyl-coenzyme
hypoxia-related
MCDB-153
.FIP1L1/PDGFRA
5′-TCCATCTTCTCCTTCTCTGTA-3′
interaction/
MonoQ
Esmon
lipid-DNA
∼7.1
3.605
1989,1992
ara-C
MM-111
phosphoproteome
.32,33
CRCs9,10,14
K-R-K-R-K-S
CTX-stimulated
12q13.2
janet.shipley
Y1573H
nuclei-arrows
R5996-4
ch17
.WB
121,700
IVS38
14g
KDM5A,25
.Peri-centromeric
I31T
microcephalin
cAMP-dependent
RNA-PCR
1–9
mutation,35
GPR179
184-fold
effects.1
EGFstimulation
3L-V
sequences.Demographic
CRL-11268™
blots…
9.4–66.6
Activation/expression
insulin-resistant
2524G
Citric
GRHL1
methylation112
E453K
non-lymph
Adk
R26exon1
Takeda
7/51
≥30
TLS-associated
cases11
7F5
68,95
Residual
K623A
14-3-3σ/C-RAF-phosphopeptide
TRAAIL-R2
Sample006
D214
TOP1-interacting
chemotherapy—yields
0.7330/4
TATCATCATAGGTTGTCATGCTTATGGGGATCAATAC-3
JH2/JH1
AR-RARA
0.0046
half-way
LC2/ad
ctgtag/ACCTCG
polyposis,14
drophilic
95°C/2
activation.1
CD56+
Kalverda
p11033
.Trans-phosphorylation
GLR1
anti-phsphotyrosine
IFN-treated
NM_139244NM_080927
3,552
SJRB003
58
STAT1/STAT6
ion-equilibrated
irinotecan78
N331D
.DISCUSSION
dependent.49
p.Arg993Valfs*3
IRF-1-
CUO3/4
25.50
6293
pDonr201
coud
D1420Y
leukemia,34,38
c.475_476del
ourseries
diseases.15
5:157–176
TGGGCGCTGGGCCTCGGA
C1642
4608
promoter-dependent
M2-Peroxidase
cofactor
\o
pEF4H
.Prothrombin
FBXW7
SRC-JNK-c-Jun
136-2
pIRES-TGFBR1*6A-HA-Flag
hydroxylase–
28/34
cHER2
32P-oligo
CACTGT
Exfoliated
leukemia–derived
CAGGGCTGGTTGCCCAGGGT
BR2-3-RT-F
GI-projecting
craniosynostosis,2
hormone-mediated
Penzberg
N-RasQ61R
leukemia.33
TRD
L2656P
28-55
Cγ1-cre/IμBcl6
EVQWKVVEEINGNNYVYI554-571
Bardeesy
PI3K-p85
17q12-q21.2
9822
NrasLTR9S/LTR9S
phenol/chloroform
.Input
7,27
D8S254
Zenyaku
Interleukin-3–independent
SF4
PIK3CAcDNA
Craniosynostosis†
FRK-Activating
−49
tQN
family.8
PI3K.9
P511R
329.4
32.0/8.7
domain-swap
4,816
−/Normal
disease.12–19
FANCA-R1117G
70/M
L92V
917
p55
D9S161
RBBP6
02097810
A301
DMX
Mcold
/left
Y1230N
8.46
9α-Fluorocortisol
E802
thresholding
theeffect
K164
1.07-1.61
ggSea
59-AGCTTGGCTGCAGGTT/CGACGGATCCCCGGGAATT-39
thale
79,80
CMET
n.s.
199G
33–83
years1,5-7
HA-CHEK2
Hotspotc
CD63
megapixel
G102C
film.Ras
peptide-1
RQ-PCR
14,753–22,670
calpeptin
integrity/fidelity
c-Kit-positive
phakomatosis
Cadherin
66-
Prkcc
recur7
metazoa6
527–537
Etiology
infection44
48–50
onstrates
calicheamicin
.PJS
13q34
F740
G330D
Sirvent
.Recommended
SignalingTranslation
EM-21T
NSCLC169
Q85
A_51_P220162
MEN2b
pRB16
/activin/nodal
VHL-interacting
Tubio
DLD1/HCT15
β-galactosdiase
D1S3417
XXVI
b-tubulin
anti-H-Ras
Gy/min
MOG34A4a
III-nanocluster
/FOP-FGFR1
well-illustrated
Q2072
O/N
G179A
pmCit-N-ras-T50I
genetrap-type
heptapeptide
Resnitzky
477–478
amplification–positive
coli-mediated
CODD-binding
BCL2+
LAL
Nobunao
Gly294
p.Ser608fs
.Zeocin
169-µm
mapq
H-79
cardiofacio-
1222
hydroxymyristic
OSU
isoform—was
Cys721
Pim1+AMP
-myc
anti-M2
4925
RUNX–CBFB
gene9
non–DNA
2,110
testis39
protein18
IVS21-4del22
2.83
nGAP
Hs02719379_cn
XL2
mtp53-V173F
ΔN/ΔN
c-Raf1
328C
Fc-γRIII
tissue-context
H102L
pRK25-derived
Snf
4539T
H/Yop
NPM-ROS1
hFGFR2-C278F
15362
cerebrooculofacioskeletal
Leikam
210–214
354480
5′-tggacaaagatggccacatgaagatcactgactttg-3′
autophosphorylation5
VIVO
L2/H1/L3
Hpy188III
PatientsID
mouse.22
foxg1-CRE
PIM2
gemcitabine/paclitaxel
MicroRNA
develop79
Cy3-streptavidin
GTF2IRD1–ALK
NRAS.14
BRAF-V600E-melanoma
869–1226
Sciammas
mutants5′-ACAAAGAACAGTGGCT-CACCAGATTACACTGTTGG-3′
apoptosis.17
Rcryst/Rfree
1-901
plasma–protein
Neuropilin-2
1.541
securin
shIKBKE-2
phycoerythrin-annexin
SCALEPACK
low.82
non-GI
Pro564
.WBC
PPARγ2-P
YpVNV
MYC-tagged
8.65
332,816–2,543,130
12C-bonded
Tel/Etv6
GIST.3–6
Y1015
serious/acute
H284N/P/Y
5/11
622
Utilisation
P124-mutant
.S17
dHPLC
Hormone-Binding
tumors,41
PEG-300
c.1427C4A
T278N
.Nearly
.FLT3-D839G
p.V258G
Q227L
S7681
−2.61
δZF/MSCV
.Anti-tubulin
Liestal
pcDNA3.1V5
p.S46C
:3021–31
Hs01021011_m1
N580S
AGTRAP-BRAF
µmol/g
c.1844T
TKO17
14,746
​in1C
Booher
200K
2A–G
0.240
0.44–0.82
SLAC
Onishi
81071629
2019
HRas-transformed
ajuba
NM_008043
GITR
MAP2
P231T
10.1172/JCI70739DS1
23,52,53
hematopoiesis
Primiano
​Fig.3A3A
1,333
4686
773_V774insNPH
PAX7-FOXO1
XXXVIa
mutantexpressing
L987P
P-40
FOXO4/AFX-MLL
CYS12
CDK6-Cyclin-D.
Krebs-Ringer
T1070fs
F-RipCre
5′-CTGCAAGTCCAGCCAGAGTGTT-3′
FABP5
Previously-published
K754E
1-55
N136-10A
17q23.1
41156
3×PBS
slideETV6-NTRK3
gp140Prot'rk
genome51,52
droplet-based
Kras6
P289fsinsG
thatunderlying
ibly
JAK2-V617F
sex-determining
siRNA-Met
p.E746
afrequent
LSA-containing
P50.0001
dn
CAG-EGFP
ADL=2.81
07-473
05-212
Gly12
imm.ox.ac.uk
cholangiocarcinoma.23
B-ALL39
NanoJuice
5′-ATG
L2027F
RNAzol
6.0.3
mutation—that
~7–12
Shimizu12
chaetocin
leukemia–initiating
pET15b‐based
AFH
BCP-ALL,23
ml/0.1
PE-Applied
FLT3-length
248-1879
viralmediated
quarter-solid
vitro_
SEDIMENTATION
time.2
412-433
sitol
ethanolprecipitation
Pe´diatrie
signaling.13
Table3:3
Structure-guided
.View
syndrome.15
restaging
.350G
9–base
40-i
plasmidsThe
304:219–226
.Lys
HPV16-infected
de-aerated
_________________________
Level/Sample
1p13-q44
487
5′-AGCCTCAAGATCATCAGCAATG-3′
.FoxO-mediated
.Expanded
nihms710585u1.jpg
q=3.94E-53
E747–L747
industrialised
Flag-D1
BIM-high
T244R
Damage/Repair
EGFR/Ras
Dicentric
re-circularized
7Institute
Ala68
29/43
agarose/EtBr
R509
specificity3
D224N
7,5
SMAD.32
lipodystrophic
solvent-
.042
octamer-binding
AdooQ
Syt/SSX
9,354
20-pireaction
viewer.22
B4
celecoxib
glutamyl
tL
35–55
pMMP-Flag-Fbxw7
transposases
Teruhiko
SMARCB1/INI1
anti-RAF1
P.D.E
D321K/5'-ATTACGACCCGAGTAAAGAGCCCATC-3
1996a,1996b
Mox1
anti-IGF1-R
diversify
F-8
5'-GCGGTGGTGGGGGTGAGGAG-3
pFastHTB-human
García-Prats7
Tyr-CreERT2
branchpoints
-trisphosphate
activation144
hypermutation3,4
PJ694-α
pMD20-T
0AlternativeDI8S55
melanoma.4–7
γ2A-Jak2
6.2.1
7.B.1
stSG46963
HDAC-independent
Elf3-responsive
.SOCS2
Ogawa
adeKEaLms
Chr3:71021818
LMNB2
point6
H3K9Me2
56,588,548
TWO-HIT
.STI-571
fish-view
HNPCCd
ESCCs
Asp38
component-specific
Src.62
27-amino
Haefliger
eucalcemic
.Unclassified
7i
TTP
Q1286
–34
A312V
LYS2/
GlcNAc'ylation
NP_004621
SNAIL1-induced
GBB
Sma‐2
NCOA6
EF125076
Yi
RHEB–GTP
3C–E
Irk
p≤3.3.1e10
96A
nanodispenser
1.7–8.3
I0/6/95
hypoxia/HIF1α
DFGin
EGFR-N826S
K601N
3307
R384P
*Student
KYSE-510
5-dAzaC-mediated
Myc-Smad2Δ1-240
FMO2
MPN12
49/72
IC50~25
6A299
.27,28,30
first‐generation
osteosarcoma.To
3-8μl
amc.nl
amplicon
Maxuitenko
anti-phospho-AKT1
Amplifications
SMARCA4-recruited
tumor-inducing
5-TGAAGAGAAGAAGGA-3′
F69V
RASL1
H2′
c.5207T
N-D-T
T-rich
L1492
RVLM
DelKPMYEVQWK550-558
emergence/progression
P.W.
B-RAF-depleted
GAGGTTGGTACATCAGAAACACC
T639A
Benomyl
3′-rapid
15596-018
259/1350
S44A
DP1
Rescreening
1807-aminoacid
Okajima
processes61,62
Denys-Drash-associated
NSD2
kinase-4
10c
gallopavo
'de-repressed
P=0.31
rates1,4,5
0.5×106
Neuenschwander
MET-N375S
V223K
pLXSP
17q21-linked
.Vatalanib
397mel-mock
variant-transfected
Second-site
4/13
collagenomas
Mt1
patients,2
GGAAGTCGGAACACAAGGAA
3814
I253T
myometrial
Pomerantz
lZ5I-EGF
−2.05
theMutS
SIRT1-mediated
INPP5E-transfected
visualisation
microwave-assisted
00897702
+/Mld2
pleura
PI3K/PDK-1/AKT/mTOR/S6K
≥2.5
first-order
14-kbEcoRI
pan-HDAC
1Ff2
Cys430
D275A/E277A
2390
282/252
`BAP1
splint
cancers,9
opsonized
leg.CHALLENGES
Gambetta
10–17
transcription-modulating
D890N
−1.87
TTCTGAGAA
IDIBAPS
+46
development76
Nf
dx46
serum/0.3
CS-03
450/540
Non-stop
Bisindolylmaleimide
.Within
cancer5
Pro81
Abnormal-sized
lrseg∼N
A305E
cancer.19
−90.9
Mutants—Pre-steady-state
Ser-Pro-Ser
25–2500
anti-NUT
MSH2+MSH6
CAACTGATCACCTTGAATC
​,2
thanatophoric
GGTGCCCTTCTTCTTGTGTGT
.Margolis
gi50428111
S262G
5518–27
mi
Pro1502Leu
NM_006106.2-1928s1c1
line13
Molt13
C‐to‐G
Najm
anti-HCF
statistically-significant
430–729
tumorgenicity
CDCP1
lmmunoblot
metacore.php
HPC4-tagged
p3xAP2-Bluc
5′-UUCAAAGUCAUACUCAUAGUU-3′
.McDermott
.Suboptimal
EnVision+
MAP3K1/2
Lagerstedt
serine-proline
.WT-
IL-3/IL-5/GM-CSF
.Int
p=0.0088
below.Chromosomal
W-1
Pten-wild-type
activated,14
LTα1/β2
NCT00312377
HKL2000
p53.Table
p-stacking
c-rasH
reported.104
.Manuela
5–20
ctcttctag
–BRD4
.ClustalX
32Pa-CTP
~1.2-fold
979–1203
9,30
Interuniversity
5′-AGCATCGGGTGATGTTCATT-3′
IFAR983
p.D402Y
pKpnI/f
.Presented
poly-D-lysine-coated
siGenome
0.278
cells.Figure
TaconicArtemis
AGUAA
alleles3
R200A
small-molecular-weight
taken…
29/66
non-neuroendocrine
GST–PAK1
L.X
TÃŸR-IIserine-threonine
Darier
scid/scid
box.9
Picogreen
4A15
lipoprotein-related
5′-ATGACATTCTAATAGGCTGTGAGGAAGAG-3′
FANCL
conexpress
HOXA-cluster
ligand-triggered
primers,23
Electrocardiographs
c.988+78g
CRAC1
marks.18
.q43
inapoptosis
uA
21q22.1−22.2
M3–M5
dysgerminomas
tumours/cysts
KPGP
gene-sets
pan-FGFR
30-residue
GTPgS-liganded
L-mut
700-series
5′-ACCACAGTCCATGCCATCAC-3′
merlin-protein
efficacy/safety
WT-expressing
human/mouse
43,813
TRAPPC9
PHE
degradation—and
29432655
group48
Subset-quantile
0-200
I141M*
lenti-viral
1:50
2461–2473
PlusOne
relativelevels
kinase…
Gonçalves
HSF43
18/65
FlexiGene
p20/p10
ibrutinib.24
cAMP-mediated
pSuperRetro
NRPTPs
D425
429·90
T274I
haploidentical
Cytomat
myeloma38
µm2
3Integrated
0.5258
PresentationAll
5236G
FGFR2/Neu
S247W
non-KIAA1549
pone.0064364.e006.jpg
hepatoblastomas20
K601E
oligonucleotides*
3086
18-77
ETV6-NTRK1
Biop/Org
.Class
-Y261A
D820H
gliomas1–3
www.broadinstitute.org/igv/home
bpâ€
chr11:50–60
cetuximab31
pilot–IV
c.1377_1378insA
0.5µM
Brca1Tr/Tr
hromosomal
phospho-tyrosine-kinase
D31
lysozyme/SDS
0.325-3.213
-3.05-
V674A10
5.25
SPEN
QN
m/58
phospho-MET
.Sample
5′-CATCTGCAGAACCTCCCTGT-3′
-ATTTGATGGAGTTGGACATGGC-3
R245H
TCM
HGG047
70°C
313K
6xOSE2-luc
autotransphosphorylationof
AGGATGGCACGAGGAACATA
M280I
EGFR-transfected
previously37⇓⇓-40
ERK-to-AKT
Colonies/well
.Encouraged
Ruijtenberg
gj.5
FEIG
monocyte/
36,76
non-VS
Hep-2
NCT00113776
T98G
PD-1–neutralizing
HSD17B6
mutationallandscape
Apc2lox14
ab9049
KDM1B
T4G
Anti-tubulin
MDS_334
IPASS
//heim.ifi.uio.no/bioinf/Projects/ASCAT
1times105
patients/obligate
RUNX1-FGA7
PR-7520
codon,3
odds-ratio
357A/
CTTCTGGAGACTTCACTTACGTCC
ER-VP16
15,16,17
formalin-Wxed
more-activating
1.4/million/year
WWP1-myc
38877605
substantiallylower
Nitrocellu
7/0
15/44
M147
light–induced
MPLw
GCAGATGTCAAGGGATTTC-3′
1,526
karyotypical
5f
msh2-GD693-AD872
VariantsThumbnail
RDE-4
FY-rich
P-MEK1
N161Y
G724S
MROS
S403I
G175-405
−3.49
pRSV-13-gal
Cα-RMSFs
mutation-calling
DNA-PET
Osteo-chondrosarcoma
pGEX6P3–TNS3–ABD-WT
1c–d
13.6
I68K
12,31
T212
Six‐week‐old
ER+/Akt1-
×1e6
50TTT
.Neutrophil
∼10:1
p.Thr433Ile
.S1A–F
T529IBRAF
gtctctcccttgaaatgctgtga
cDNA–transfection
DFG-phenylalanine
HF-HL
Ponchel
XG1
K36me3
reclustered
intra-cranial
locus.Figure
anti-ki
ofRaf-1
p.G135Vfs*27
flexmix
D842V,30
Notch
T286A-KE
CRE-L2-GCTCTTCTGCCCCTCGCCGGAG
Coactivator-associated
Homodimers
pBabe-puro-H-Ras
cRel
His179
2.That
Figure1a
lung-cancers
.Fawell
pVHL-HIF-1α
Reuterdahl
1054/1055
99.05
Cohesin
0.1I7o
FL-cases
d'Accreditation
invasion.47
7.7815825
5,410
1.00–1.68
amplicon-based
1c–h
R258G
Phospho-receptor
R283/DNA
SOCS1-YFP
Aboussekhra
CFC73
microdomains20
nositol
cIAP1
allidentified
125-152
SNP-genotyping
hyperlobulated
1.8/17
GFP-RAC1Q61L
H-80
0.05
95.4
Gly-64
Jak-homology
Y83H
.Tumour
Agea
3.559
80K5
GRE-luciferase
pCMV-3tag-1A-SF3B1K700M
age.13
mg/day
megalencephaly-polymicrogyria-polydactyly-hydrocephalus
CEN6
wholegenome
P=0.017
P385L
..-j
E2F-1+/+
.ORF
5′-GGTTTTAAGTCTAAAATCCTTAAGCAGGTC-3′
pellucidae
anti-BCAM
2.18-
02568267
dimethylated
.Panitumumab
S11RCIP
andwere
conformation.17
45-48
before.16
www.genome.med.kyoto-u.ac.jp
D1625R/D1628R
PAX5-activated
2I0Y
www.idealibrary.com
UBN1
HRas-GTP
TSA-induced
GST‐G15A‐Cdc42
monitoring37
Mx1-Cre−
speci®cation
pPro531Leu
Q5d
91
tetramer-monomer
anti-p-Ser473-Akt
CD71high
μmol/L‡
Circumstance
Agendia
3failed2
3195
diaminopyrimidine
KITH697Y
YYYYHHN
inhibitor-free
KpnI-linearized
peritrabecular
BAbCO
of8.3
debilitate
PAGE-purified
anti-mouse-PO
A519T
Y1870C
effects.5
mice.31
Non-denaturing
nine-somite
.Pools
є
S554T
Pulciani
T-LGL-leukemia
R302Q
CNCN
5′-ACGCCTGTAATCCCAGCACTT-3′
βgeo
8B–C
//doi.org/10.1371/journal.pone.0103021.t003
Cos-1
Met9803Thr
PRK-5
analyzed—triplicate
HDC57
Akt1/2/3
22–87
KRASG60R
1:100,1:100
ENIYSVPprepared
c.6047A
KT-41
nonresponders
ofGISTs
Rhabd
Mikosz
methods28
high–linear
Mutagenesis—Mutants
CI=22.2-66.7
Max-Planck
B7.1
glass-Teflon
tested32,33
sclerotherapy
ErbB2-containing
RP11-980L14
tested-to-date
inassociation
UMUC6
CML.24
ETV5c/TMPRSS2
16q
G3-245
c.110714
.U53336
1•5
121.8°
usingyeast
272-fold
independence.16-18,58
Phospho-SGK3S486
STI-571–resistant
C-shaped
0.0474
ATT-3′
M-histamine
placebo,2
9d
studies16,17
104:901–906
mTOR-encoding
Eyche'ne
Fam5c
SB-431542
anti-BCL2
UltraCal-IV
1A-SF3B1K700M
V600K
familiality
tumor-intrinsic
A_51_P470935
.GSX2
10.1172/JCI67144DS1
GTor
hMEC
Skiinteracting
Nagoya
200bp
ototoxicity.3
O~~~~~~~~~~~~~~4
survival75
GRE-tk-CAT
Y287C
Ala682
DD/ED
Ogiso
pylori4
PDGFRA/RP11-24O10-SG
-TGGTATGTGGGAGTTTG
TAT63
G101D
4.329
780-patient
0.972
pQE-A1
genomes.Deletion
studies.9,20
1packed-cell
c-AblT315I
Lys-382
.D1733G
assessor
mutant/deletion
PMDgagpol
p.Arg628Stop
22q13.3
32–52
vitro,2,3,10
.Kang
ar0C
chain.20
MXA
B-RafV600E-specific
phospho-p27
74/167
15-1171-320
12D1
18q22.3
Nozaki
IFN-lambdas
HR=2.6
1M17\
L248
cortisol
world1
Hifa
www.hgsc.bcm.edu
microdissected
Ensembl22
L536PHEG0
.NKY551
truncating/frameshift
.3223delG
Dallinger
17p13.1–p12
8340
EGF28
G469V
Centriprep
0.2–0.25
dIFNIL-18
NSCLC.15
ENpuro
Nikkon
e.
5'-GCAGGACATTCCACACAGTTCTTG-3
progression.27
SpliceSiteFinder-like
homologs.Human
D171Y
Casp3
.OD
tumors.18
oncrasin
fx/+
80-year-old
pGL2
Aglient
-agents
pEF-AML1
NicΔ2105–2114
JHH
non-expressed
3q24
6884_6885
previously.5
pretreatmentsteps
1MLPA
32.A347T
5′-azacitidin
inan
NSSLEKNRALLMRYVE
55101
Wnt3A
clinocopathologic
5′-TTGACGGAAGGGCA
Pinkel
RNA–DNA
Cytomorphological
FRET-Based
Ptch
.XEDS
PGA1
Collecchi
Tyr905
MLL-9S
GAPdependent
cpm/μg
SaoS
SC-126
drugs48
Arg-to-Lys
CO-FLY
Glu1077
heatshock
radiograph-calculated
peak-calls
Mre-11/Nbs1/Rad50
.∗Indicates
T7-Coupled
REKIII
FIP1L1-PDGFRA-D842V.12
–resistant
Strand-specific
Tamai
aq-wt
P-0001171-T01-IM3
BITAK
.IA
20q13.1–
40/42
.£L
Galeano
Del418
A_52_P73307
Tyr207
5′-TGTTCCTCTTAAT-CCTGCCCA-3′
1/702
Damage-Response
AG-30
0.07–1.32
.ASXL1
cysts/multinodular
lenalidomide
G1057D
17/20.2
.Timothy
729mel
mTOR-LAMP2
Pro67
Vic-labeled
p21ras-like
CFSE
AT-3′
dead.5
Rev-GFP
DDB1-and
R1599P
Door-to-balloon
1022-1110
171–181
MYCN-157
hyperproliferate
221.6
tubulogenesis.14
L112P
approach.24
3.1-PDGFRβ
MMP-
V.
R675G
T22M
D1-triggered
ECL-plus
.RFS
date.12-14
OO-fold
patient.8
27-28
Leprecan
ERSIFW
Pcsk6
30/817
M1659L
R759
Tübingen
.Downregulation
proteasomedependent
cancer–attributable
tumorigenesis.7,15
SW948.11
Ohanna
study,19
Isennman
WEE1
IFNα/β
Igα
Fabp-cre
progesteron
17·4
Rsc2
Vaissiere
tet-inducible
periventricular-intraventricular
.68T
melphalan
V35E
GCrich
phenotype.14
1.5-19.0
S15A–B
alÃ-eledosage
stimulus—presumably
MyD88-blocking
MLL*-N
Estrogen-receptor-positive
RCCs140
Lees-
Brg1tm1Mag/Brg1L
mouseembryonic
-flanked
DAB-MAP
Fig.10B
PA.MAbs
desmocollin
125I-radiolabeled
Subtilisin-CI2
SCRA1
CD79α+p63lo
.30
CTLA4Thr17
antiERK1/2
Cdk8
.Knock-out
E475
oncoproteins
Mastocytosis/Droogendijk
TCCACCCGCG
1087–1093
ACVR1-V5
C20R/F39L
chaperone-nascent
Kornev
5′-CTAGGATCCATGGCAACTTGCGCGGTGG-3′
diseaselow
Flt3+CD34+
afer
Hs02758991_g1
K127A
42K
gain/amplification
*Conserved
G719SþS768I
2-R-
-Lung
Ida-FLAG
dose-responsiveness
optionsConstruction
7,977
p21-L1
.Genotype-phenotype
carrier.35
TCG→TTG
complex36
I111N
NHEM
Cancer-Derived
1,564
5′-ACGTTGGATGTGTGACTTTGGATTGGCTCG-3′
31,4q21
N-phosphonacetyl-L-aspartate
−2.66
G205S
V373
Roadmap46
free-cysteine-mutant
−0.74
Stylised
Figure1C1C–1D
promptdetection
Netherland
frequentlyfound
IFTYGKQPWYQLSNTEAIDCI
AACAAG/gtactt
DC330E
TEL/ETV6
AGGCCGCTGTTGTTTTCTT
S502T
BCL-2-interacting
Nurr1+/-
si-Bmpr1a
72–213
PY99
Ex19Del/T790M
small-molecule–based
icr
70μM
12F
delRad53
TGF-β-binding
I/II
siCON2
photoactivated
2,105
Nur77
T692N
HIS3
C124/135/141/182/229/277S
proteins—their
28.47
a-35S
fold-improvement
early-stage
phosphoS6
U.S.A.
MP-1
R734G
loss-of-ATM
v2.2
DNA/beta-ACTIN
+++/++
Philadelphia-positive
Multi-beads
5′-TTCCTTCTAAAAGGCCATGAAG-3′
.Galectins
HD/X
G663E
.Dovitinib-FGFR4-KD
Dermatoglyphics
A079
76/151
p.Ser2509fs
Landberg
.~Diaz
germinal-center
3-1-69
H62R
2…10
NRAS-2-R
cancerous
replication-associated
86,93
QuikSolution
ATP-sensitive
NeutralityLLRGene
EDTA/25
AAACTCTTGCACAAATGCTG
319d
BCOR-BCL6–binding
p=0•0085
MDB4
caspase-8-deficient
2054A
b-
4′,6-Diamidino-2-Phenylindole
interaction60
medulloblastoma14,15
α-cleaved
neuro-oncology
T1574A
Geneticand
wild-typeand
malformative
.Comprehensible
​Furthermore
developmentally
50–59,5
i.One
survival/apoptosis
sbcB
SPOP/ΔERG
www.umd.be/BRCA2/
poly-A/T
Obmolovaet
Ala11Gly
expression,75
completelydefective
quartet
anti-SP-C
proproliferative
coincubating
ENZ-30931
HSQC
G1-S
6-base
cancers,8
227399_at
6825
34,000
9:461
diseases59
574/372
BAP1-C91A
p59xDR-GFP4
mL/mouse
anti-TnI
repeatmasker
metaplasia-dysplasia-invasive
//www-p53.iarc.fr
GGAA
Skp2-independent
90-min
V/L
NCS
fold.22
mislocalizes
7–78
gastro-intestinal
Q240E
31–
MutL–MutH
anhydrase
phospho-Ser221-MEK1/2
.Sox9
S855S
apoptosis.118
GGAAAA/gtaaga
thyroid-associated
Srsf2-mutant-selective
non-driver
E1B-attenuated
ZsGreen-labeled
gender-dependent
arrays110
binding.34
Applied-Biosystems
2185–2191
.K299R3
13:82
2240
as-needed
E746-S752insA
2903-bp
000551
GSE65349
Birc3
Y88F/Y88F
FABP
NGFI-A
3/42
TET
hexafluorophosphate
tumors14
hypovascularization
40–70
αEF-αF
R310X
FLAG-ASXL1-WT
Hane
CO-117
BRFF-HPC1
pm1Si
III/lV
19q13.1–q13.2
R302H
//www.cbrc.jp/research/db/TFSEARCH.html
function.3
−629
pRetroSuper-p53
butotherwise
mutation-associated
KIF5B-PDGFRA
15-72
D3S1565
pET46
Xaa-Ser
progression31,40
79/285
1909G→A
.155
Helensvale
D237A
regulation.10–12
.WNT3a
Toeplitz
Arg-882
−23.98
dysplasia.12
L/M1196
G248
Figure1c
cSrc,19
0-3.90E+225
phenyalanine
5-s
AG1802
system.1,9
1B63
8259
GST-pY-parafibromin-His
Cadore
D181V
−2.14
.Enhancers
Crit
NaPi/10
RGNTs
1364–1437
PDGFR-β14
GGAATGCCTGGTTTATTTGG
3.512
retinoid-binding
repair.4
adenomas/carcinomas
carolinensis
7/16
d′
pmol/liter
–208.48
N-methyl-2-pyrrolidone
BCR–ABL40
Enzymatically
bene®t
trophic
c.3264insT
PIK3R1/2/3/4/5/6
cellsMonomerAverage
Cγ1
0089
S445T
Dovitinib-FGFR4-KD
Digestions
flk11
Methylprednisolone
multi-tumour-type
OP43
R220W
5·0
weeks45
SII
G1120E
p7255
−29.3
25ng
HCT-116-derived
High-Fidelity
LANA-1
Sulem1,21
E.coli-based
pleiotrophic
Disulfide
phosphate/DNA
Askjaer
,8⇓–10,12,16
purposeful
tumour/CAM
300-bp
SnAC
M592V
anti-ERBB2
Pearson-Rho
1942A
Igepal
.CIC-FOXO4
Evi1.36,43
FGFR3B
re-established
amimo
16.7±11.3
mu/+
NVP-AST487
`transformation
activity.8
.GSK3β
stochiometry
CTTGAGGTCTCCCTCCGCCATGAGCTC
5´-CACCAGGGCCAGCATGTCAGAATCAGC-3´
-low
.Yardena
eighty-five
BRAF-dimerization-dependent
PP2A
PI3K/AKT/TP53
NM_
009772
CCDC113
D7S522
ABL/BCR-ABL
mass-spectrometry
.HO
IBL
.Leu74
RINM
Anti-eIF4E
10-51
MSI-High
S257A
1133
lambda*
HIS3reporter
Condel15
2µg/ml
379del2
dithiol
TGTAAAACGACGGCCAGTGGGGAGATCGTTGGACTGTAATTG
NT056
vasorelaxation
Pten+/-mlst8+/-
quizartinib
Y842D/H/N
ALK14
FI6R-CT-2003-508842
Cul4-Roc1
Leu-235
scintigraphy
factors46
L838
TTGGGCTTAA
lymphedema-distichiasis
2107N14
phosphorylase–based
M175R
LINGO2
tumorigenesis79
5′-TTT
metallothionein-1
donovani
pRC-CMV-R2
PIK3CA-expressing
cM—Dpc4—2.6
HDAC1.40
11/28
subtypea
pcDNA-Flag-ARfl
P.A
Y641C
HBxAg
RAD3-related
37°C10
ZMIZ1
B-RafinsT
nickel-nitrilotriacetic
Asxl1fl/fl
B-RafG469A
EcoRV-R
-N/PALB2
FMTC/MEN-2A
database33
polyI/polyC-treated
4,12,27
​and3D3D
nsmb
www.chori.org
P=0.55
IVGGHYLKVTLKPVLDEICESSKS
negative/HER3-negative
p53flex7/flex7/Wapcre/+
BT474GFP
AML,16
POLE4
pathway16
pMLP
Pik3r1flox/flex
GASC1
P618L
factor-inducible
THD/DeltaC4-AGO2
intermediate-phenotype
CA08422-06
anti-BubR1
COALL
271–277
ancestry.15,16
Asx22P4-null
transposable
38/49
valine-aspartate-valine
MCL82
.FAM58A
Darwinian
CGGGCAGCATAGCATFGCCT
.1600
shRFP
IVS7–6G4A
G265R
LB960
H222
5,000–20,000
effects.3
.NatI
EPN-330F
Rimokh
K622A
D-PCR
GSE50024
.Neonatal
5′-CGAAGAACAGAAGCACAAAGGC-3′
p38/MAPK
tetrarhodamine
.2119T
12q13–
7085
N252D
O.D
LVDd
2961R
mTOR-downstream
2012a,2012b
M340Q
leukemias.2
RAC-GEF
KEAP1-NRF2
107/115
-would
Chr6p21
multi-agent
p.R274H
0.7-388
HIP1/PDGFβRinto
expressedon
ka12
Sine1
one-day
GeneChips
characterizing
Case-790
histomor-phologic
anti-TGF-b
Norit
5′-CAAAACTCACCTGCTCGTCA-3′
NA/NAOVK18
formation33,34,35
JH1-2-Jak3
.MIF
CA-630
3/34
glycerol/2
wt-PIK3CA
target-template
NCT00883779
isoproterenol
.Predominantly
0.4°
pSREluc
3PP0
A.R.A.
factor-beta
97·0
MATCH-R
34–38
3-years
45K
adulthood.12
10Å
degradation.35
p.Glu2143X
N488I
kindred,23,24
ERLIN2
mismatchrepair
EMT128
pBTMd-
E343G
gliogenic
r.678_790del
PCRproductswere
repeats.12–14
antiCD3
C-CDK8/CDK19
PLK4
3–5-wk-old
1.36-fold
-Graphic
A019
cdc14
-delP449-L455
S478*
3929
NG5
DM1
4061
HER2+/PIK3CA
cycle-regulating
EN-transduced
leukodystrophy
imatinib,15
anti-AktCT
TRCN0000033265
79.56
BRAF-S729
p3-4
palbociclib
extractionRepresentative
FANCA
1,4-diazabicyclo-
terminal-respiratory-unit
59-431
G576A
methodsPatientsThe
Baf3
Bunjes
ter3043
whichcaused
.4del
2/25.0
cancers.39
relatives—which
.C2
interferon.12
Ha-Ras-LBD
onemutation
transciptional
GFP-BAF180-transfected
OLIG2-dependent
independence.8
epitheliocytes
hadan
5′-ATGATCACCTCACGGCTACC-3′
S22F
20–21
Rab5.14
Immunofluorescent
RCC-43
6431
deoxymannose
Dana–Farber
5′-TgggCCgAAgTCTgACCCTTT-3′
92.5–101.5
WISC-III
LIM-only
XXXVII
Tumor-derived
Leiomyosarcoma
HA-EN
4.0-fold
KIF1A
analyses.CSVDisplay
Pancolonic
autodimerization
DNAJB1
CD81
C57B/6
Teva
44–87
lambda-P32
pGBT9RhoA.V14
syndrome.19,20
.22.3
chr19:47483653delTCC
72hrs
AIDS-related
ESR1-C6ORF97
12°
UPD1p
J4T
.ER/EB2-5
Lys642
TTTGCCATTCACTGCAGTAGCA
2218
78-yr-old
means±S.E.M
anti-pY1604
LR08-368
1.500
SUM225CEM
.E-mail
YUMAC
cMET/RET/vascular
tableMutation
anti-mTOR
Proline-Rich
36/3
.EGFR-TKIs
19F-5
~3500
ureadependent
PCR-independent
Vhl
Fbw4
.5878
.INTRODUCTION
f/66
GSE41581
Biochemic
interrelatedness
4.47
pVHL213
Urbana–Champaign
sample.Sanger
Hoxc4
NNSplice
V804G
Intrapathway
pAKT1
.WES
.Allelic-specific
10/377
S1301R
V689M
.12-14
R169C
V-to-I
1c-2
BCR-PDGFRA-positive
Figure2F
W215
B.Lu¨scher
4E-BP1.6
.TBP
prognosis.10,11
Profile3D
2.061
transaminitis
countries,1
bar-coded
−231
100119
Tcf-4ΔN31
c-myc-responsive
NDa
SIM-dependent
MART1
.PPARγ
T1362
.Cre-mediated
c.1667+2
5′-agaatcaagg
D1520
nonfermentable
0.750
32,33,34,35,36,37,38,39,40,41
Inhibitor-2
EMT163
BRAF-expressing
transcriptionactivating
stoichiometries
galactose−Trp
adenocarcinomas25,28,35
prolymphocytes
Kujala14
q22q34
362–1355
Y17E
anti-ILR2
Sixty-eight
M.C
laser-induced
0.3165
anti-ERF
345X
52-week-old
coactivator.31,32
.Strangely
cross-immunoprecipitation
0·6
MBD4/MED1
microisolator
p53Mutants
Preponderance
activation.31
54b-10
skipping/deletion
morphotype
mutations2–4
dipalmitoyl-PI
.UP
5'-GGCTTCTGACTTATTCTTGC-3'/5'-CAACTGTCTCTAAGACGCAC-3
A/COSMIC
factor–
hematopoiesis.3
Rett
Schering
5382
uORF
Anti–pan-Ras
PP2Ac
SABiosciences
1,517/4,153
CAAAAG/gtaaga
RFS/PFS/EFS
therapy146
dx76
justus.duyster
â€oeAneuploidâD€N•
12–19
+M
p2lC
R*
Mod-Poor
hyper-mutation
CD62L
HLA-A*6811N
6-deletion
4.444
25/60
..Table
.Activation
videomicroscopy
3,79,80,86,90
autosomally
SM2
60.7
ependymoblastoma
Down-Regulation
double-vector
Supernatants
10868
Pap
Tyr630
‥CEL
RNASEN
transition.3
6.33
ATP-analogue
Cautionary
5′-AGGAGCCAGAAGCGACAATA-3′
CD22
u1
membrane22
P37
NVP-BYL719-related
c/EBPα
TERF2
fragment-replacement
U87MG.The
machinery5
.S17B
.P1
Wnt/Wg
S6K1–Thr389
survival=42
17.25
anti-CD14-FITC
betaP1-loop
contiuum
5–9
v-H-rasat
95.8×
UM48
disease/related
12-mo-old
pairs/triplets
28606
CPLCKNDITKRSLQESTRFSQLVEELLKII
R35-95
Grade-specific
c.G1817T
Reorganization
WGA–DNA
co-migration
color/DAPI/pseudocolour
.Repression
tumorsphere
Ras/Neu-expressing
~150
S806F
.Glioblastomas
.Against
MH2
.Integration
PF8055
rad50
P6fs
300–700
Micco
tumour.40
modified/glycosylated
250,000
RelA–p50
3.503
syndromes.37
CTGATCCTGTGGCTTTTGTC
'radioresistant
HCC38
dinaciclib
non-smokers11
L747-T751insP
413-kb
might—in
2011
1000-1500
deletion-positive
56180528A
FLAG-VHL
SMC1-phosphoS957
trpEGAP
D15S153
glioma-initiating
Savi
SET-
2.2-kilobase
6p21–25
q21q32
integrase9,17
term=SRA062359
top-scoring
4482
13/51
oligomerization.31
Alimova
phosphatidylinositol-4,5
557-Trp
subependyma1
3.065
dacarbazine.3–6
X66899
3D–E
RTK-dependent
BRC8
BD32
N-ethyl-N′-
SDS-separated
co-immunoprecipitable
syndrome24
γ-
586-8262
rhabdomyosarcoma
invading/migrated
transplantation.3
GFP-Q63L
anti-mitotic
C1620G
inhibitors73
LB2
59-AGA
C1620A
GST–PTEN
GppNHp-
p21-C117Y
0.056†
proteins—pleiotrophin
HIP1561F
Kaurah
A549-DDR2
AFAP1-NTRK2
GIST.108
239KB
V151T
Top1
Y657X
Schiffer
Fas-
contexts,12–16
bp-long
GeneID
FANCD2-L.
Daubner
Gin259
autoinhibit
ARNTD
.Sharan
N676K
Siena
1557
52.5
González
affinity.9
gene.18
2274
7/14/98
Hg19
E384K
5´-CACACCCCTCTACCACCATCTCC-3´
globe5
lipomas8
well-shaped
-value
D13MIT67-F:5′TTTCATGGAGTCGAGTATTTTGG
receptor-positivity
HunterTM
luteinising
L93P
Plus™
72Â°C.3
CRC15,16
C250T-positive
p110D937A
ZR75
N393K
1584–1585
IVS9-19A/G
5F10
CARD11-initiated
ras/MAPK
H3K36me1/me2
T78M
Q493
cttt
Armelin
EUFA30/hTert/SV40
/HER2inhibitor
leukemialike
c.862C
VHL-Δex2
alignment,7
ethylnitrosurea
XPO1-ex15R
MPLW515
E800/Bio-Rad
Inpp4b+/ΔPten+/−
chr1
AccuPrime
complexes.16,18,55
scriptional
mg/day.60
CTCCGCGGACTTCAAAACCATGCTC
anti-A24
GFP-Brd4
M5133
Jichi
R381A/E386A
c.1937A4G
5′-TTTAAGCTTCCGCCGCCGCCATGGGCTGC-3′
∼10×
criteria139
5'-GCTCCCTAACCTCTAATTAACCG-3
PHL-Akt1
CFU-Mix
G233
5'-GCGAGCAGGAGAAAATGGT-3
COOH-terminus
pGD210
L510P
p86
N848K
3/51
2/5
D1-3T3
mate-inner-dist
Pdgfb−/−
Criteria.16Immunohistochemical
S6E–S6G
extraabdominal
Ser-65
417A4
121
CC242
speci®c
5′-CTGACTTCTCCAAGTTTCAGG
described.21,23,43-45
Giemsa-stained
456
.PD-L1
.9940212
B220/PNA
v3a
Calipel
Rab
.897
AmershamCorp
12/2002
RP11-360D23
IRB-approved
HA.C
base-level
1legend
TAF1B
31,38
nucleus-confined
ST6
vivo.Fig
34.119
Phospholipids
1465insC
90027
.Characterizing
p.Arg679
V559–V560
sc-7392
DChip
Polymenidou
8.8
178,991
analysis/comparative
EGGKV
32,89,90
HDSN845–848
cancer4,5,6
.\
Flag-HA-TET1
100b
5'-uGGAGu-3
subjects.8
D-rings
M5926
.Herbimycin
123.7
CA7
irinotecan-based
5′-CCAGAATGTCCGCCTTCC-3′
8.51
p16/Ink4a−
I1171H
can-
//smart.embl-heidelberg.de/
IL7R-inactivating
R748G
370-kD
tripleband
M+2H
Growth-factor–dependent
Asp92−Ala102
5.4-
subtrates
thyroid-related
89,000-175,000b
Testosterone—In
None-the-less
5′-CTGTATCAAAGAATGGTCCTGCAC-3′
-release
Gly-117
platform/IMCE
patients,3,9,10
~15
Hieronymus
Tyr1022/1023
GRDThe
Yamada-oka
.Pertinent
1893
5′-AGGCCTGCTGAAAATGACTGAATA-3′
Runx
0.74–1.41
.77
PECTMWT
DMR2
1:3000
PRC1.6
pmCherry-K-rasG12V-V152G
chemotherapy103
N676Kmutated
bHLH-ZIP
.6E
p.D120N
valve-specific
SAK
mutation103
Frement
Slooten
spongeswere
54.76
Repanti
IEC
SDS/15
Leu→Pro
shGATA3
5-hydroxylmethycytosine
GGACCAGAGCTCGGATC
Pathologist–accredited
analysisTo
/NOG-chelating
9.74342925
E220D
GATA3
Phenotypec1Â°
.ILC
E1A-F
.Apc
MCF10
typhimurium
raÃ-transgene
Thr18
.PTEN-deficient
05-777
QYL579delL
JAK2-V617F.10
pcDNA4C
rs1863334
I528F
GTP/GTPγS
60–163
fibroglycan
VAF
P933A
Ste11
.Phosphorylation-deficient
VCAM
R243S
0.265
40/45
binding-site
M2-7C10
p.R1276
.Poor
EGF-r
-tagRFP
protease–treated
complex-associated
3R
Shp2E76A
B215
Immunohistopathologic
GNA11.11
F1245C-mutated
Nkx3.1
euGl
16/56
4-month-old
7/9
1.1Splice
0.5-mM
−Cq
358-2-333-7300
c.478C
8.941
VLDL
CD41−
1649–1858
~0.4
nueleotide
Miyabe
20,86,95
Tsurumi
V643Sfs6*
intra-abdominal
Highstar
Keyse
induction20
p=0.0103
SDAssociation
cysteine-mediated
ab.
lΔ/Δ
Tyr214X
-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic
inhibition20
MPN19,20,21,22
DACH1
syndromic,9
PCR-ampliuiedgenomic
−191C/C
K41T
67.8
Cδ
GDC
p53-G266E
HIFa
EX5F
medulloblastomas,39
extrahepatically
-++
TAand
59.95
CEM-8L
not39
p.N597T
Descheemaeker
top-enriched
'0408
CMV-β-galactosidase
U87MG.ΔEGFR
NCT01658462
.Iterative
types20
sc450
18.
Draetta
-AACAGTAAAGCTTCGCCGGA-3
5′-CTCCTCCGTCCCGGTCAGCAA-3′
185-152-166-115-204-120
wnt/wg
PE-Cy7–anti-Gr1
α-KG
0.058
IL-19
GR9
4,19,21,24
biotin-streptavidin
14,44
Baselga
LSIATM.18,23
FGFR1OP1
K929
3139–46
ETV6-W-PDGFRA
proteins15,19,53
XY,222
.Fig.12,12
11p15.1
R695C
A_51_P322265
pBTMl16-Ha-ras
transmission—undoubtedly
024ZD
c.2632C
msh6
tumors3,1
.Trk
CMGC
V354D
Rad51-related
c-Cbl-WT
Traf
p.o.
1.2–3.6
D16MIT4-F:5′AGTTCCAGGCTACTTGGGGT3′
.Arguments
7721
422-2282
Meta-Analysis
glucosamine-6P
W1718
Extra-intestinal
ofiodoacetamide
JB11739
3,026
antimyc
D22S310
c.1169C
3559_3560insG
409
FITC-Phalloidin
.17,25
SH2-
FXYD6
.HER2+PIK3CA
Tsc1/2-mTOR
KIPDDLGFPEEMSVASLDLTGGL-
5.9-kb
predictedN-glycosylation
GAACAGCAAGAGCAGGTTC
5/6
enzyme/reaction
ALL**
R827L
outnumbering
Etienne-Grimaldi
EGFP/Bcr-AblT315I/Y253H
90X
anti-phospho-STAT3
phospho-Smad2-Smad4
O*APT
Hi-Myc
Tartaric-acid
18–71
/3
5-week
.Igh-V
2/7
28/87
enhancedchemiluminescence
UVS
reported49
FGFR1-mutant
sip21
RTK–Ras–phosphoinositide
AnalysisVariant
interconversion
MLN0128
ephrinB2/β-gal
Family-wise
www.completegenomics.com
BTC
SRSF2-Regulated
Dana-Farber/Harvard
Mac1+Gr1+
III.17
FLAG-expressing
osteochondromas
bemasked
K227E
LMNA-NTRK1-rearranged
ELF4/myeloid
Figure5C,5C
Sturgill
cortex-specific
GLI-induced
CREBBP-dependent
BrdU-labeled
681C
TGF-β-like
3-dimethylaminopropyl
pLenti-III-mir-GFP-Blank
786–O
G246W
McWhir
MEKK
†Cell
ICWT
RCH-AV
THRAP6
J010
Lumenal
factors.26
Acetyltransferase
202-bp
10-25th
4-nitrophenyl
R86A/K179M
GenBankTM
GO/pathway
HDAC2
0.375
PKCϵ
Cesi
post-gadolinium
quantification
2896
element-containing
translational-relevant
semiconserved
therapy.Expression
qll
terminus14
sarcoma.2–4
fractionating
7R
NFATc2-specific
Exome-sequencing
U6/siRhoA-1
.Avoid
Ma1
Iggo
P12-ICHICAWA
wu4
.S10B
ubiquitin-independent
3q22-q26
regates
Fudan
NM_172632
6-year-old
cyclin-folds
model45
lysates.AR3
NF-κB,34
10.1530/EJE-11-0929
radioligand
.Filled
Mammaliancells
id=urcc_mskcc_2016
CTCCCTCCAGGAAGCCTACGTGAT-3′
0.00506
DNA.36
micrometre
8/15
mega-corpus
474a
v2.0.3
GSLLDFL
basisof
ubiquitin‐charged
resistance.60,61
//www.landesbioscience.com/journals/cc/article/5485
21.9months
pGL2M4
120p20
pygmaeus
/48
G259R
models,32
loci.40,41
607-bp
1.5–6.1-fold
projets
p42MAPK2
R1114X
nonmutagenic
67/71.3
Abl-substrate
1799
4e–g
​and44K
SIP4
furtherstudies
86.68
.7c
t3244g
277S
3,9-11
FigFig1B
CEBPA/NPM1/FLT3-ITD
over-segmentation
TskL7
122-403
Ph.D
responses162
pre-blocked
53bp1_B
/Pr
34.5
mutSα
Foxk256
No*
Dual-colored
949C
EGFR-amplified
8.575
=3.0-4.5
CCBE1
11q−
Eibelstadt
L14P
5′-AATTTTGGTTGGACCCAATG-3′
0.02−0.05
.00051
betweenNMI
RP11-707G18
p27-pcDNA3
GS-700
self-regulating
1:2,000
pIRES-TGFBR1*6AK-HA-Flag
residuals.41–43
Weichteilsarkom
mistargeted
gut-coloration
SH-2-like
Isopropyl-β-d-thiogalactopyranoside
DICKKOPF-1
.Parafibromin
V11G
UMD
7–AAD
PDGFRblocking
MRK-003
Grinberg
63-65
Anti-phospho-MEK1/2
phred-like
24310
ECM-associated
poly-A
flt5
Y112
caspase-8-inducible
electromobility
WHN101
44-base
.Chromatography
0.824
cancer-aware
finger-stick
60.28
Sensorineural
0.1421
0.140
MM300
HMGI-C-specific
Ank4
predicatively
L2209V
H75
FOXO1-mediated
pKT-NLS
Ligand-Dependent
anti-T7
I959
44–67
429080
intermediately-conserved
Q648
Dpc
N1730S
Pirard
T340A
.Biosynthetic
ERE3
Pu
RG-28N
tumours.75
.211aAdenocarcinoma
CTCAACCAGCTGCCCACATGACAGGCGCCACTGCTTCTGG
IFN-β
PlanApoN
L-PK/c-myc
63+A188
Reconstructing
X-RAD
.OPRK1
TGF-ÃŸsignaling
55/135
1p36.12-33
Hoffmann–LaRoche
reports.11
carcinomaMyeloid
CGTGGTGATTTAGCAGGAAG
CLd
AKT1/RACa
G.-H.
64–2.70
NUP93-NUP205
UL5
R114H
flex7
Notch3
VCP/p97
staurosporin
-agarose
.1A–B
Raf-1/B-Raf
W36
α-INI1/hSNF5
Cdk13
675.7
prost-translational
3′RACE
alleles1
TTGATAT6CTTATCACTTACACTTTACACA
ALKoma
.Sarcomatoid
JARID2
Kip2
∼2200
T120
Akti1/2
CD41-expressing
ElA-transfected
Elk1-based
-68K
nor-
phosphoJAK2
agent-related
92093-0660
7/39
.OVISE
NaCI
α-phospho-Erk1/2
v1.3.0
mp18-GATA-3
5′-GATTTTGTTGTGTTAGTTGTTTGTGTTTG-3′
≥median
ezrinT567D-expressing
W.H.O
DN-JAK1
.BLOSUM62
R159H
.Woburn
cytosol.12
R487Q
IL-3.TG101209
p.R666fs
DNMT3B5
G2→M
CD34+/38+
320-ml
Postreplicative
described.33Cell-cycle
RNLTLIAKTLQNLAN
c-Ha-Ras-1
-1/40,000
Srsf2-WT
germline-sized
Tyr-992
L997F
.Retention
transformation.122
Leucines
Adari
suggested3
CFC114
810
withdasatinib
934
.Postzygotic
195,014
Microphysiometry
RAEB-1
ϵ
Hs00153277
KIT/559/T670I
hammer-toe
Thr-1618
KITΔ558
nonpolar–polar–nonpolar
Q889P
cancers37,38
anti-neoplastic
0.46–3.65
PMS2−
scans/sec
Gata3−/−
5'-GC-clamp-TTATTATTCAGTATTCCTGTGTACA-3
12-E1B
D79G
2,573
malignancies4,5,7,10
PTPρ-ΔIg
Klenow.Preparation
SRNS-like
oligopeptide
-GTGCAGGAGGGCCGTCGC
CTD-2092C4
LL2=LUX-Lung
Schoutenstraat
dabrafenib.22,23
EGFR/HER
cy
maleimide-functionalized
agagaccggcgcacagaggaag
AFMA119ZH1
Wnt/β-catenin
mutation26
P1825A
323/441
waslower
DACT2
Mm00812424
EIF4G-1
ser33/37/thr41
HS1
second-degree-
8100
6,024
ONO12380
INFGR2
AspN
.IDH1
IMD5
Ala-Pro-Glu
Glut-1
W2023G
5'-CAGCTTGCCCACCCATGCTC-3
ETO48
anti-P53
mesangial
Vectibix
Melsungen
.Self-applications
W823D
HBR
.Hattersley
Computer-assisted
3f2e
shScr
onfunctional
Q68DV7
report.34
MLL-ELL
TGTGCAGCGTGTTAATGACT
sc-1647
contig-
Feldbach
PE-CD45
TQGRELERPRACPPEVYAI
Mgat4
A150P
.0065
phospho-serine/threonine
oculofaciocardiodental
hematopoiesis36
CATCCCGAACTGCCGCGGCGATCAAGGTAAC
proneural/PDGF
R.Van
tumours151
T.D
p.Leu544Ala
breast,51
H00008289-M01
repeatability
Conn.
deoxynucleotidyltransferase-mediated
bars.The
PP0V
6.6079
activity29
A09
Figure22C
IM/SU-resistant
Enchondroma-Like
TNT-Quick
NIH3T3-EGFP
colony-formation
Phe776
rastransformingactivity
.7,7
mechanisms52
population.7,8
surpass
Region—Italy
D3/CDK6
M7211
Glu17Lys
306del
intergenetic
high-mutation
anti-CD45R/B220
.Baseline-specific
SFRP-1
Colombo
undetected.13–16
PLCγ1/PKC
133,135
AML1-ETO/KIT-D816V-positive
MGG
One-Site
SVIL
c.14643+1G
373/382
WTmut
CC-3
24~48
73:117–126
MEFs.K-rasV12
mutant-IPC298
Cirstea
preantral/early
4,021
slippage-induced
Y537S-mutant
n=88
3900–4900
TY3
L400V
NOTCH6,8
variable127
ellipsoidal
1644
precursor.6
~B
BbsI
U22312
HCC1937-VC
.Syringe
contaminationAdjustment
M253K
IU
1H-nuclear
RE-sequencing
B-symptoms
Ala406
861-900
1A-C
hydrogen-bonding
p53-REs
G.C.B.
G/A870
0.64–2.55
T266K
TGGCTGGTCACCAGAGGGT
rs117360089
Y691
0.41–0.78
ductulo-lobular
CEP170B
Leu-1701
FACS-Calibur
Ruxolitinib
number–independent
1653/1946
UACC
34°
P250S
Nagasaki
FLAG-Krascommon
G0/G1
Nonpathogenic*
EMD-1214063
T286A/R
5364L
≈550,000
mitogen-inducible
RA/RBDs
3.5w
p=2.9e-10
7J
TCA
.XP-F
8.74
R2=0.869
.Expanding
Tyr418deletion
39-
MC5
EMSA.Transcriptional
D.b
7-residue
lucifugus
DRB1.040921
IL6ST
20-gauge
CAAAACTCACCTGCTCGTCA
phosphorylation.95
HA−
hMHS3
insSVQ
27-year
−34
C\j
MelanA/MART-127–35
degron-deleted
RARa-LBD
1–109
Cytosolic
0.933
Upregulated
tissues.1
S218F
ApCEV27
significant.Bioinformatic
Inpp4bΔ/ΔPten+/−
USM
C6orf204
Gly-334
MATERUILS
oligoastrocytomas
ccB
Rc/FGFR3-KMS18/IIIb
Asp186
3-phosphoinositides
n=757
Mairal
ser473
QGL
Weidhaas
low-molecular-mass
References‖
oco.
CPPSMIV
pyrazolo-pyrimidine
P470S
frequentlyalteredin
060
Arg274
Yeh
imatinib.13
81-86-235-
phospho-VEGFR2
.DEX
GF07/11
treatment.8
Ile-Gln-Leu-Ile-Gln-A~-His-Phe-Val-A~-Gii
Mid-blue
TACATGGATCCATGGAGCCTTCGGCTGACTG
632
SK-Br-3
Fosmid
23597
2-M
12thDay
LRE
InhibitorsAntibodies
heterotrimeric
≤1
Ret9-C531R
FLAG-p110α/p85
III17
//www.broadinstitute.org/software/invex/
FcsRP-
resource-rich
co-habiting
.Manual
Thr508
lymphedematous
n=267
HbH
Neurologiche
R502C
pPur
phage-derived
ALL-30
1.228–3.425
Ala118−Glu120
disadvantaged
twice-daily
Homogenization
NT5C2
gi50057558
5′-CGCTTCCTGATATTGAGTGG-3′
pMiw-Fgf8a
Y62
3D-clustering
level15
K79
activity67,68
delL747‑E749
foci/ng
mesothelioma.75
identi¢ed
1.5-kb
ESRP1-RAF1
GGAACGCTCTTATAGTCT
interdigitated
AGTCCCAGTTACTCGGGAGGCTGAGGC
1,638
mouse/
leukemias.40
165/269
R732
c‐FLIP
nucleosomes36,37.To
.BRAFE600
anti-NFKBIB
mSin3A/HDAC1/2
Ann+PI+
Salgia
cases,28
69,104
umpore
Phospho-4EBP
Trp→Stop
ATP-bound
bressac
D4-D5
D820E†
progenitors.71
micro-adenoma
8269
Gbind
P1-ARE
aredescribed
described.61
Ab4
39–46
22Figure
c.1766C
rs231775-A
BRCA2.6174delT
1.2–3.2
2.3–2.9
Na2VO4
GSE10358
IHCC/HCC
trabeculae
Niflumic
Trimbath
V-transfected
Mll1
726-7808.
tD.C
36·2
Affer
G776insV_G/C
Monomer1K
MSK-IMPACT™
CCD-only
Lysogeny
−2.86
shRAD51
Bauters
G565V
PML–RARα–Δhinge-LBD
CKAP2
Haemek/Israel
carboplatin-treated
G993V
OD260/OD280
Asp2870
P112
P799L
2.05
OCUM-1
Trotman
1839
1-29
TBP-binding
cancerfree
instability.MethodsCell
38/76
HTh7
–13.5
EBPβ
pcDNA3.1-Flag
membranes46
NM_009421
Tyr813
Noonan-like
transgene–negative
A-protein
CCATCACTGGGTTCCTCAAC
136/137
7.4-
C3F
W.Y
GSK
G/c.302-3C
tumours126
3.2-
www.exac.broadinstitute.org
Flt3−lin-Sca-1+c-kit+CD150+
Biowhittaker
Avizienyte
ebpβ
4046–4049delTACAb
MT3
pathol
n=169
deaths3,4,5
9,179
T31M
02m
Arg815
Hanai
InVEx
.Lynch
D1/CDK4/CDK6
0.748
oncogene-dependent
mean7standard
CXCL12/CXCR4
KAP1
RP11-298P6
Vitro-Translated
project,10
confirm13
migration48
ELOC–ELOB
deconstruction
three-line
1-dong
uJ
Tyr1022
removed.16,17
Causal
LAPC-4
GTPases6
BAX48
.Selectivity
340598
NADPH-oxidase-dependent
10M
NM_011920
multiple-comparison
017383
genes10
epiretinal
A-T–Like
PER1
recently.8
3169
C11-f-1
CCHMC
Br-dUTP
Fig.8D,8D
.RET/PTC3
AML1
S1-1
α-STAT5-PY
Non-epithelial
subtype9,10
PGL3-Waf1-luc
1766S
PTEN-379
B56δ-E198K
31.36
p53Y220S
PCPsa
906-959
TET-inducible
SSCP/HA
p.Val231TyrfsX15
UACC647
NAP57/dyskerin
856–875
BUB1A/2q14
1yl
5,164/7.1
after6
Multi-Centre
'After
Rafnar1,21
RAR-β
.Quantifications
5-CCGGCCATAAGGTTTCGTTTCTGTACTCGAGT
undistinguishable
5′-GGCCAGCGTGGACAACCCCGGCAACCCCCACGT-3′
mei-1
anti-c-Fos
38.9
Immunocytochemistry
O.B.
5G-5I
E98-G155del
A251V
nificance
Schoenmakers
trastuzumab136
high-sequence
NCI-H1648
n.d.perkins
Sig­
Carci
.Dephosphorylated
104/ml
Post-therapyNegative
OVCAR-4
program,56
P23
SK-N-FI
Plat-E39
p11.4
Lys-930
ATRXRluc
Pizzey
Dithiothreitol
www.genetics.org
promoterwhich
Y842D
164771
IDH1-R132G
8-*
Charge-charge
re£ects
advantages.Class
Il17b
./-
178.96
werecalculated
0.795
BCR-ABL–positive
KRas-G12V
genealogically
Xpress-tag
.Coherently
5′-ACGGCATCCTCATTCTCCAGTC-3′
diffusive
closed-open
CSNK1
Operativa
592.15
never/ever
LS174T
PD173074
Fig.Correlation
.NRASQ61R
Jishage
antibody–drug
samplesOf
atoms—gray
S-2HG,22
trkll
IL3–independent
MMRgene
4806
5'-ATCATGTTTGAGACCTTCAA-3
EGFP-p27T198V
HER2/centromere
non-tumourous
S18L
ROS1-inihibitor-naïve
His–caspase-8L
method.Statistical
c.1662-2A
:1862–1872
3′-NOTCH2
residue-220
5GCTATACGAAGTTATATCG3
RAB35Q67Lmutant
U1C
micro-GISTs
ICI182780
4906845
≤1.53
17
.ras
pY1021
CDK2/cyclin
DLD1/HCT8/HCT15
benzolylated
dimerized
cct
M.-S
Asp1822Val
copolymerized
diaphragmatic
KDM5C-reverse
5/SOCS1
tnC
6q15-q22.1
non–LS-related
NIH3T3.13
non-expressing
TG-CTCCTCTTCCTCACAGCCTATTA
non-lipogenic
GISTs.10
Log10
STAT1-YF
12–25
disease.29,32
sf=small
non-ras
.msh2p-Msh6p
00323
parents,23
MM604
C93Y
R-M-D
0·25
Wnt-agonistic
ETS2-repressor
C469
p53/NF-Y
mutation,9
Bj-Bl
Fig.6C
methyl
RP11–114F23
H2AK119ub1,87
BRD4S-negative
-phosphorus
hypomorphisms
7l
RAR-mediated
third-cycle
ofexpression
T2250A
menopause
GATNNNNATC
FQEERYFTDVKKFLDEISSTETKE
immunophenotype
N409S
ERα-dependent
Chemotherapy-refractory
Cas9
q21.33
pY181
Papillary
pGEX-6P3–β-catenin
L582F
DME-HG
7.1/NA
3,300
V555_Q556del
TCAGAGACGTTTTATTACCGGGAGAATGGG-3′
Fluor-568
p′
BMP/Dpp‐activated
ttttag/GATGGC
14074
1402
cold-spot
≥0.5
4326317e
pRb/Skp2
peptide-enzyme
paracolic
218–222
.XL
liver-enzyme
.EOL-1
3731
Cα-RMSD
MycTat
ice/alcohol
.Checkpoint
0Beadling
cCurrent
unavailability
LN18
BRAF-F7
mutation.12-14
NKYS
polyendocrinopathies
Diagnosisb
R398H
mutSRSF2-mediated
LeuAlaGlyGlyGluAsp
iframe
vedotin
68934959
Q442fsinsCGCA
V274A
EZCap
c.1494_1495dup
mTEL-Jak2
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
cancers.12
11–36
0.41–1.86
AZD1152-HQPA
7/170
rs3829963
treatment.36
40-43Complete
unambiguously
GCCCTGTCAC
Alpha-linolenic
3H-SAM
Multidimensional
Col11a2-Luc
peroxidase–conjugated
.Epigenetics
disease-related
P3HR1
NPM1-WT*
Shh-deprived
Reorientation
.DCRs
JZ
sae2Δ
paraventricular
semi-quantification
E.coli
Glu322Lys
Ziemin-van
LN-HP
nSerAlIThrVa
genes19
chr7:116,411,600-116,412,200
his3A200
byFISH
EZH2-infected
SK-CO-1
two-dimensions
Klippel
C-to-G
ErbB2/ErbB4
R199W
respectively28
bedGraph
2.1–2.7
agarose/10
KCNMB2
-AGCGAGGCACAAGGGTACAA-30
selectablemarker
bisaryl-thiohydantoins
p.S238*
antimutagenic
HCC-specific
.Colored
Stiftungand
1579
Pan-cancer
PK-A
i,4
4469497
5'-GTCAGACAGAATATATGATCTC-3
2J1W
Mitelman
:LYS2/ho
CDKN2A
nifurtimoxa
c.704_709del
T449R
protuberant
subfragments
22,64
EGFR.5
9.5G3.5
GTTTTCCCAGTCACGACCTTTGCGATCTGCACACACCAG
Igaki
.H6908
MDA-MB–435s
Perkin–
n¼
Neor
anti-c-KIT
GCACTGTGCTTCCCTCAGT
116.2–116.8
B56deltopathies
Smad2–/–
al.27
gtatgtgtt
.MyoD
cDNA.Fig
c.2992-2995delAAGA
HGA-HGG
Sanger-sequencing
HySeq
FGF2–FGFR1
299KB
p53tumor
Brca1/Bard1-null
CAPB
NBP1-06712
RAD51B/HMGIC
survival100
Variation_28765
avidin-biotin
18841
p.G12C
anti-CUL3
66kb
non-variable
GADD45b
chemokine-like
.Cabrera
9725
7/76
overrepresentation
IRF3-specific
9827
W741C
HRP-streptavidin
G517S
RAB5
c-specific
general13
mutations33
NB200-199
anti-MCM2
posttranscriptionalstep
co-injected
chemotherapy.23⇓⇓-26
CEEP
Chymo-
signal-inducible
III–like
566-571K
2.59–3.71
6-weekold
mutations37
acetylcholine
pQE-expression
BRCA1-defective
series,20,21
0.00018
G98R
mCcnd3-Reverse
CDF2
PKCalpha
Areaimol
cells131
S217/221
rs731236
p=0.014
Pcr2
_TACC_
anti-P-Merlin
carcinoma
RMA-solo
C.I
0.4-μm-pore-size
CDC25C64
V71SM
growth-regulated
Nsbp1
Celltracker-red-labelled
EDU
S1613C
half-dosage
.CGNP
S.I.
Y572C
Plentz
alanine-scanning
0.0010
TRC-Hs
hAR1113
TGGE
classification.32
EphA5
5´−TAGAGGTTCTCCCCZGGCTA−3´
6–31
c.2611
1410-1509
Ellison14
anti-MTA1
CGCGGTTCTATTTTGTTGGT
POLE1-wild
Mazurenko
ombination
.Anti-BrdU
v1.4
previously,31,37
F53L
p–r
.2726A
proteins13
3.55
FoxM1
Janku
137F5
PRKCH
Dis3-exosome
c.278G
NERF-1a
SJ
others.14
E747
60â
D1533
PEBP2αB
α-SkA
PKCβ.3
RE-luc
intraexonic
Cytel
EZClone
Interlab
aprotinin,10
Tyr-740
−2.57
pale-staining
25,436
C44Y
Impurity-corrected
.TFactS
Ras-medi-
3,10,11
Five-micrometer
//www.genetics.org/supplemental/
BRCTand
pl20-like
∼25°
off-targeting
.0205*
χ21
alterna-
S1.1a
KT1520
n=1694
XP-V
trefoil
N52S
transformation.3-5
Ni21-NTA-agarosebound
YXXXYY
kinases.1,2
560–571
autozygosity
p.Val524Ile
gene-alteration
p.These
overexpressed22
fasudil
telomerase/TERT
19.7
W105C
pcDNA4/TO/Myc-His
disulfide-mediated
GAT-
Ser15
study—and
IMR-5
IGDD
H-II
B—In
.Puromycin
cnLOHs
8–12
GRM1–3
MDM4
-GTCGTTGGCTGTGAAAACCAC-3
β-stranded
c.179A
uiu
.Decreasing
Lymphoproliferative
gel/film
in1.0
8-mL
51-71
G534E
TMEM16A
G55C
.Molecularly
p-FOXO1/
sex-cord
oncoprotein.6
dimerisation
p110-alpha
©2003
ATR/FRP-1
/LEF
35–86
p53-R249S
CACATCCCCT
mm00501584_m1*
Liver*
Δ576c-Kit
PI3K–Akt
.EV
3-9-19
C132F
CAAATGGA
NGFI−A
~3×106
211T
73.4
positive-charge
PDGF-derived
rDNA
pre-invasive
P1805
GCUCCUCUCACUCUUCAGU
protease-labile
NC1
S957Q
Wve
pMIG
JAK2breakpoint
utilised
S281N
RP11-308D13
pGEX-4T
CPNE8
receptor‐dependent
L644
AnnexinV-positive
assay22
Baf/3
del2235–2246
49/M
phosphoproteins
c.1738A→G
33,41,42
R342C
asingle
WDR5/SWD3
B266
p16INK4A
nonconcordant
CCL5/Rantes
Endogenous…
materials.11
→Ala
cells.An
DMPK
data.D
r2=0.050
526A
pEAE20
Pathologically
NFYB
pZNa'2-Q205L
14/31
IDIS
terll63
function.Two
CLL4
458–466
Phosphorylation-Dependent
D561E
MRC-1024
1224
−13.6-fold
11.89
Vi=-X
phenylaminopyrimidine
giga/L
Het
refractory.4
L82D
benzimidazoles
folfiri
D1956
A1®
immuno-magnetic
D479T
Shield-1
RCAS/tv-a
3F10
Polytechnic
.RR
Iodide
∼140,200
Pro53
H4-15
RsaI-digested
trials171
B-tranfected
glioma-related
unpublished/unannotated
TBS/0.1
OMIM158350
β3A
Pik3cae20H1047R
V77M
–57.7
EWS/WT1
.TBX3
pUHD15–1
V600EBRAF-mutant
MEN2
7J–K
.S15A
re-populate
69497
0.07–39
.S10C.Previous
reactionTGFβRIITransforming
00006
FRSQ
.Ou
Rohrschneider
33434132
BCL6undergoes
reconfirmed
C33D4
8850
X-linked–like
200mutants
isopropylsulfone
CVAD
AB_262044
adenylate-
post-PMF
study.11
BRCA2/exon
deletion.55
oncokinase
ERBB-family
chemical-difference
BRCT
KDR-positive
cancer–specific
G1913D
p53-y163C
.Karyotyping
I853T
Accerlys
pGST/T3
al52
abnormalties.48,49
autonomic-related
06–747
4/26
TTGE
prolyl-3-hydroxylases
yolk-sac
ΔACA
PTGFR
backgrounds137
ALKmutated
R159W
b2-microglobulin
tubules
Gwin
half-¢lled
CD45−/PECAM-1+/CXCR4+
telC-Alexa488
C358T
GAGCACCTCGGGATACTTGA
HMGIC
TWO-DIMENSIONAL
0.051
Bo¨blingen
VkDGyQNaqPafaPkNIYsINqACWal
cancer.6-9
MEN1.1
growthrelatedgene
Zakut-Houri
His-98
C=38.7
study.9
SOS-GRB2
pathways15,16
W368F
~103–104
p-value=0.016
c-form
pT505
15-20
F34
cancer1–5
ENST00000360016
b-sheets
IRAK1
Tau-binding
centromic
GST-FANCC
endophilin-CIN85
62H
4,249
251200
paternity-maternity
HCC-4230
5367-5376
hsa-miR-195
design32
//www.stanford.edu/~rnusse/wntwindow.html
15/97
K20
protein.5,6
RTS-patients
c.8042_8043del2
Beta2
48.47
impli­
CG1945
BIBW
.Immediately
drugs20
Gefitinib-Induced
ERBB4-specific
Nagatake
AML1-D171N–
PLU-1
12–48
PeptideProphet/ProteinProphet
M−
54/76
pT4
dimerization-disrupting
Valn
680–conjugated
enkephalinase
p.R414X
1003
GST-MATH
0.1μg/well
c.1731
105.7
668–679
670K
LTR-driven
pawson
ERK-to-ERF
7/23
ΔΔGBM
clinically-approved
selumetinib.14
ZNF572
1NVW
region.12
foci
core–core
wedid
.proliferation
PCa.46
80Thr
−5.29
Senapathy
promise162
//www.ebi.ac.uk/ega/home
RP11-328L16
27§
1500
224.0
regibn
reported36
EC3
L666R
BB4
≈3
Schwabish
identified.9
38–39
4D
Self-referred
TGTGCTTTCATTGCAAGAGG
Presumptively
4689
BRCA1-M1775R
PBS/EDTA
0.695
sequencing10–12
122-bp
Biocare
lympho-mas
ccRCC-associated
ctg
Cox-1
Notchic
STAT3-SIE
TGFbeta-sensitive
E1t1-2
C2-helical
phospho-FLT3
nonpapillary
Filled/open
.713
Ser60
7.4/500
IPTG-induced
ΔG1
â€¢^
6/209
TAFII60
36–40
G719X*
vectorPlasmid
WCENLZ
S9a
CAGGACTGTCAAGCAGAGAATGG
ovariancancer
S7J
PCNA-specific
array-
D08-0714
–certified
I33S
extremelyweak
RECOMBINASE
nonpaternity
IsoformsThe
TRAIL-R3
GTG→GCG
25NR
1–amino
GAP-resistant
1719
Xgal-containing
157/242
pGAD–NET
Aâ€
.TAL1
gel-extracted
HLA-DRBl*04
–signature
anti–phospho-RPS6K
GIST3
protocols11
SacI/BglII
transactivatethe
j.exphem
E7X
0.0117
6-gene
HIPK2
Tuupanen
c.1596_1597dupT
Gab2-evoked
5'-GGAGCTGCTCATC-TTGAGGAATAAC-3
LVLGKTLGEGEFGKVVKATAFHLK
–guided
.Health
0.28–1.3
antiTRK
NRASV12
phopshorylated
senFIG
hydrogenophila
-GGGGATCGGCCTCTCCAT
EII2
Timp2
Inpp4A+
207-208
amutation
hormone-free
PDGFRAs
chromobacteria
7175
disease,33
5.120.0303
transgenes4
.That
3048,4373,4867
p21-Luc
0.167
PCa_ETV5
Gene1
FOM
Rampalli
ML257Raf
built-in
676
FCSExpress
ε280
beta-1
Pmut=∑Ii=1gifi∑Ii=1gi
2-option
30:0.4
5′-CTCCCCACCAGACCATGAGAGG-3′
Precleared
B1–E2
EWSR1-YY1
EBER-1
Université
ARE-Lux
lackof
.Antonarakis
200-
S100A13
assay9,29
.PK7088
transcription11
TL-
tumours9
pre-erythrocytes
.16
.Nbr
Leclezio
cytogenetic/molecular
pMA-3FLAG-EML4-ALK
HRAS-mutation
growth.51
non-surgically
pyrimidin-7-yl-cyclopentane
K125M
non-FIG–ROS
30159–30164
43lead
RIL
flag-RUNX1
172-179
E554_W557del
.Microdeletions/insertions
coexistent
Pesz
3-aminotriazole
nuclearβ-catenin
compli­
Agostino-Pearson
anti-pSmad1/5
.9,20,21
holoenzyme.Figure
MM401
q11
p62/SQSTM
Ylpl3.l
Side-chains
restrictionendonucleases
.Adaptor-ligated
BaF3-FGFR2
4q34.1–q35.2
P-C3
130398
β2-strands
deaths/yr
self-antigen–binding
speech/language
20–240
.Protein/DNA
V591M
docetaxel-resistant
urogenital-specific
NUP98.30
32–34
/1.5
EGFRMutations
mammosphere
//www.ncbi.nlm.nih.gov/homologene
68.32
RNU*
Trouche
gene-sequencing
dysplasic
227-2320
pEAA60
Hershko
PLCy-I
NFκB-RE
.S3F
events12
subjects,75
‡Mutation
survival46
MN63B
singe
Superose
c.704-2A
Scgb1a1Cre
Damage-mediated
13/915
0,1,1
Sprr1a
ETV1/ER81
RA1RA2
E70X
ROS-derived
26/38
bi-specific
MEK1V60E
Johannsdottir
components88
p.Gly207Asp
1Sponsored
E2F-1-bound
TRK1-transforming
.Cyanine
4480441
R172.13
49,77
.812G
repairsteps
pMSCV-Flt3
transformation.49
pEGFP-Flag-ΔGRD
NCT01526928
ciated
Spigelman
sel-10
S2481
RPMI-1640/FBS
CAGACTTACTGCCCAAGCCGCCT
Hildane
Myr–AKT1-expressing
Amicon
.MET
mono-UbK48R
TGTGCT
30.E346A
WTBraf
~0.032
1.5-3.3
p.Gly659fs
V5Z
CGTGAAGAAGAGGAAGAGAAA
microamplification
3D4
ONO1238048
Rb+/−
TGCAGGTGTTCTGCATAAGG
disease,9
masculinization
transcript1
UI/L
Sex*
Q237L
//www.broad.mit.edu
5,413
apoptosis186
HLE
FUSE
,0.1
Kolomiets
Thr-160
QEAQVMKKLRHEKL
pIREmut-ti-Luc
NUP98-moiety-mediated
expec­
p.Glu777*
5-1-1
v.1.8.2
HA-tagged-Ub
c.1105C
Nerlich
.35,46
SRSF2-Binding
27.1–30.9
−5.27
morphogenetic
Ser133
K47N
PF-EPN-B
Emp
glycolysis/gluconeogenesis
CP-CML
p.P25L
macrodeletion
Mm004366952_m1
Foci-forming
B-NHL.75
AZ628
5.72/1312
ERTmRASV12
adenocarcinomas40
4557W
Gly104-Thr105-Gly106
Kompac
206
TTP1
3KDG
polyadenylating
6-58
K44E
SacI-digested
.Reporter
5/36
anti-CD120a
8080
transmembrane-intracellular
p.Gly12Arg
Q257R
3448delA
aberrations21
3413insG
SOD1
MCF10ATk1-EN
kinase-PKB-signaling
Lumi-Light
MMP-9.22
558903
Pediatrix_cortex_B_H1571
Y784
.Childhood
adenines
5'-cct
co-crystalize
DOG-1.33
Tikoo
abnormal-sized
.7706
EGF-containing
ABCC4
EGFR-expressing
Tyr393
9·4–45·1
P771_H773insYNP+H773Y
6584176
HLMVEC
76–93
leukoerythroblastic
.CCA
.Phosphoflow
P653L-exon-14
CTACCAACCCTAAACCCTG
PI4KB
NBG05
cation-π
8.9
LOC100128568
Kossatz
V9131
37~
21R
S95A
termsof
c.518T4C
0.770
DUF3518
wildtypep53Using
K-B
MLH-1-reconstituted
Lin-neg
dIAP
miR-17–92
metalloprotease
Garcia-Cozar
56.9
14,977
characterizemutations
ThrGluG
DinucCovariate
4.3628
Preplanned
INCENP
cRRS2
77.8
A-Barcode-Exon24F
transformation.68
cases.14-16
1.0,22
.R273
1e
PLJM1
pre-eminent
.NS495
2.2
pGal/EPAS
RP11-423N19
A-transfected
MAHALINGAM
P280R
.Luc
CBL-3
respectively9
φ-nonpolar
SU-resistant
E286K
InsR113
binding.66
RAS-ERK1
LR11-216
complex.Other
FigFig1D–F
RBy171
FGFR1WT
viz
71/119
.FBC
Hs00170665
.Eggs
sp6
well-tomoderately
EVI1
SMARCC1
p120v-Abl
GSI-lectin-stained
S811
SH2-dependent
somatostatinomas
DBTRG-05MG
phospho-MAP2K1/MAP2K2
FreedomEvo
5¶-ACAGATGGCTCATTCATAGGA-3¶
EJ-138
mirtrons
GiovanniBlandino
DNA-damage-dependent
CD3−
cellscompared
CD68+
AF326574-1
concatenation
.Since
I-B
EMA-positive
IL5Rα
RP11–45C5
.Barcoded
1E-10
//www.sequencing.uio.no/
PL/J
Monosan-Sanbio
TBX
5'-uGCAGu-3
metalloproteinase-1
0.383
metastatic/unresectable
β1-integrin-blocking
his3-▵200
.Media
.High-throughput
Tyr20
leu2Δ1
lines.14
Bv-Bx
Acid/Protein
0.145
miRNA-dependent
p.Arg132His
F2-R2a
306
Studi
nmt1
104K
STK
836
D1709A
ACTCTGGGACCGTGGGTGTGCAG
PBS-43
ATM/ATR
ZO-2
Shelterin
90.93
PTEN-AKT-mTOR
IGFs
hku.hk
types14
OPM1
RINCK
6q22.31
BlSwiss/129/SvJae/C57Bl/6
Smad2f/wt
Signification
Glioma-CpG-Island
S1185Y
COR
5′-Guanylyl
αNt
tumour-induced
stress-related
-GAGTGTGGTGGACAGGTACTG-3
denaturating
L408P
Flt3/ITD-induced
cKIT
cross-regulate
ePolyPhen
T117P
.Toyota
.0013
0.0097
Lys375Ala
Hawiger
Glu32
Rasband
Rhostimulation
Nqo1
c.989-2A
PHD1
Phospho-histone
//confluence.broadinstitute.org/display/CGATools/Indelocator
HGF-CMET
kinase,17,18
RP23-122A24
AKT3-depleted
P=0.0323
MMTV-driven
Anti-hER
.FISHanalysis
MLL*
FLR
R113
T2512
HES/CEL
Tyr613
Berdel
disease.28
1N8Z
anti-βtubulin
PvuI
NT126
.Arabidopsis
,49
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F5.medium.gif
Cntrl
cellsFO-
co-deletion
cancerspecific
25.00þ
genes.1–2
Anken
ERα-FOXA1-GATA3
v-gag-myc
Rabaptin/RABEP1
P780insGSP
CDK2-mediated
11/226
CD8-activated
puromycin-resistantCFU
sarcomeric
agarose/Salmon
Kpn1
CCCCCTAGACCCACAGACT
catheterization
fÂ¿gof
5′-GCCCACTACTGGCACAGAGAAAGCAAACCAC-3′
C277Y
study19
bacteria.28,29
5559insA
ARHGEF3
refractoriness-driving
Dahia
SUM102
II-V
virus-long
0.00256
PX
VegT
3D-PSSM26
hnRNPs
break­
2b.Fig
Lippard
305
286e
Jul-92
transformation.14,15
4B–C
5'-GGAGCTTACCGAGACGCTGAGGAA-3
b=94.3
penetration.1
16:1.4:1
GAT3GGT
NB0308-R
A57
leukemias.7
15–42
somatichypermethylation
11.36
DISORPED2
proline/
Hsp90-binding
pheochromocytomas/paragangliomas
leukemiaWe
A-5
QHQH
α-melanocyte–­stimulating
.Proteomic
everolimus-treated
2q12-q13
TCCTTTTCCGAGCGGCTCA
.M1255
RSF1could
5′-CCCTGAGGGCAAATTGTGAAAA-3′
TCGGAGTCAA
HNT
Acryl/Bis
.Ribbon
8d–f
139
EWSRT1
Bjelfman
V228F
2047
Ras–NF1-GRD
YY1–EWSR1
.Engineered
p.R132H
p=0.0413
9-12
five-class
2+Edel
miR-27b
post-stimulation
KU-19–19
c.1799delins
pMY-wtCBL
.Feedback
Y3011S
corticoid
SRC-T341I
pseudo-substrate
sulfosuccinimidyl
ERK-T202
K63E
GSK3β1
L4
clinicaltrials
I-Sma
Migliorini
PLX4720/PLX4032
10,27
.Depth-coded
1.2–2.6
8/9
hyperphosphataemia-mediated
5509
5-step
HCC19-
S722
PH-GRP1K273A
clinical-translational
CD135-PE
HCC01-0909
R570W
adenocarcinoma.37,38
D-associated
6.112
Arg1753Lys
1321G
deacytylases
beta-counter
Transbronchial
Ala-substitutions
P-derived
p.Val464GlyfsX3
OthCa
89.2
electroporations
AdCMVβ2m-infected
Scheuba
31,35
Ras-bound
13Cα
reduced.
pTriEx
‐6
V600EB-RAF-transduced
67°C
CD3/TCRα/β
Tyr684
p.E40X
779ins
life.39,44
impaired-activity
umol/L
.Originating
mutationsAlthough
M021
tRNAMet
2.1.1
:801–812
1–94
56/111
.Retroviral
K52R/ΔC
Figure2
tational
supershifts
P179
p53/Apaf-1
0/87b
Q61H
-RETS891A
FJK
.C
Tropomyosin-receptor-kinase
mice75
Mx1-CRE+
.DNA/RNA
PTEN–T319A
57-year-old
EGFR,2
//www.nature.com/naturegenetics
60min
F-0550
Sobrinho-Simões
.Synchronous
90209651-90209826
3.57
c.1799-1802delinsAGAT
Gnone
c-DX
CK2
Del.
Kit-induced
fFor
L1488
npg
Fzd
.Mating
p.Trp1782X
class-switched
Galectin-3
TPM-3/-4
6.63
336-358
Neur­
ins4nt
¢t
PI3K-mutated
1992-2000
Assays—Transformed
CgGal4
families.7,8,21
ARafFF6KCAAX
imatinib143
TopoIIβ
52.093
ABI-3730xl
187
gtgtaattggtagcttcactctg
Rip1Tag
36/53
frontoorbital
649
pGL3
PTEN-SRVE
GDP/GTP-bound
Anchorage-dependent
.000612
FANCC-interacting
Gastric/17
Bourn
p.Asn229Ser
NLS1-Ala
E921
MYCN-single
confor
auto-degradation
FluF-
P259S
p53DD
.Naturally-occurring
S30.We
S3d
agagttggactcatgcagaacctgcagctc-30
SGP1
M2-FITC
HPV-34
rearrangements8
homodimelization
53BP1-BRCT
approach19
Hth83
LR08-018*
Erf-KO
2,600
post-splenectomy
RAS–PI3K
ΔBox
klmn
tamoxifen
PBGD
haemangioblasts
30–437
1,560–1863
8/intron
P699S
37,49,50
peri-renal
27–60
NS/B
Scienti®c
FoundationOneHeme
pcDEFp300
chemotherapy-only
diploid-to-haploid
-668
Escherichitr
4000A
TSC2-R611Q
g-H2AXpositive
induciblity
Tyr416
55–76
homeobox
.Phosphatidylinositol-3
doxycycline-independent
chr11:60–70
3times105
CCGCCCTCGG
3p11-p12
splicing.28
PPM1D
BCLU
430021297Pancreasn
crest-specific
RTK-RAF-MEK-ERK
.Geiersbach
R849W
4.2–6.2
cycli
RP11-626H4
types—
macrophotography
Autoinhibition—To
two-syringe
76069
SNU‑2535
38K
Segregationf
weak16
2.51
Haploid
S1664F
BSY-1
SA-beta-Gal
32-35
colleagues29
16a
Lys805
3p:5p
4a–f
Newcombe.9
RFP-NAF1
.11,12
Cdk12–/–
ETV434
​S3C
p21-regulated
M15801
.PDGF-A
2.66–7.31
F1c
BMP-Smad1
smoked*
5′‐TGTCTTAAAGGTCTTGAGGGTTGAC
ERBB3-WT/ERBB2
Fig.6C,6C
normal-carcinomatous-sarcomatoid
35,55
189971
window/statplot
Honorat
instability-low
andPolyphen2
CT-TREATED
activation12
lq3pâ€
SETD2.3
Br51-Lg58
-proliferative
.Genitourinary
4e–j
E10
4q11-q13
hemagglutinin-
R583H
.Martins
.Spin
dot-blot
CRL3-KLHL7
cytoplasmic-localized
inhibitors43
.IL-10
genotype-defined
17p-q
ETV5_exon11-r
proopiomelanocortin-derived
siNKX2-1-introduced
3CE3
0.03136
D-specific
ubiquitinG76C
stress-speci®c
101511
META/Confocor2
6557
2293G
5Laboratory
allhuman
9.5
L119
500ng
Cough/sputum
Tg-derived
none-Hispanic
25.8
Peqlab
E-23
p.Q1334del
Cis-ApcΔ716
PCGF2
12.86
msh2∷LEU2
dismissal
LRIG3-
CD133-expressing
V558D
H1609R
GCGCTCGAGCCGCCACCATGGTGAAGAAkAGGAAACTGGAAACTGGC-3
X-irradiated
p53tet-wt
CDK1–cyclin
K629Q
HRG-β1-treated
MagNA
Wetested
BAF3-CELL
.IL-9Rα
245K
αβT
'single-strandedness
allele.73
acid-induced
D16MIT4-R:5′GAGCCCTCATTGCAAATCAT3′
.CTGACCTGCTGAAAGgtgggagcctcatccctctgcccgcagccccaggg-3
K122G.A
postprocessors=highwire_figures
.Twenty-one
p.L749P
C324Y/pEGFPC3-Smad4
CACACGAGGGGGTTGTCC
Fbxw7a
cancers17
SAS-6
Cinti
∼34
alteration3,21–23
87.0–90.6
eME-PCR
8.23727575
Yasuhisa
JH2-pseudokinase
98.5G9.2
MMJ
DLC-1
.Personalized
2400
neratinib+trastuzumab
paradigm-shifting
class-associated
6°C
reamplification
222G
homeostasis.102
critical.22
M.T
p.Glu1309fs
familiese
Bfa*
Kluyveromyces
ezrinWT
1713/1935
1.33∼2.34
LS-derived
Biotium
TGAGCAGGGA
p21wafl
.Deconvolution
A677G
+0.1μg/ml
c.6679C
2M2B
8ql7p17q22-2416Aâ€
NaHeparin
AJ295293B*5111N
PRISM310
'BCL10
.Redundancy
ligase11
12-kD
.HDR
androgenregulation
types/functions
hypoplacia
Harbo
AlexaFluor
cologie
8/513
5/29/2017
EOMES
EBV-infected
pBTMd-hMLH1
signaling110
mCi/mmol
WT1-Interacting
LINE-1-induced
gut162
serum-starvation
trimerization
bromodomain-related
×234
-50
vegfr-2
W308C-myc
.6094G
.Levine
7.5–7.7
EZH2-positive
NCT00137449
8,44
FANCJ-forked
insertion-deletion
Par-4
58-TAGCTAACTACCCATTTTCCTCGC-38
spleen/body
std.FSCOR
I251M
Val-277
//doi.org/10.1371/journal.pone.0087113.t001
0.246–0.704
4ZFΔTK-HA
.Sensitivity
0.3–1
c.212G
24•5
E709stop/D/M/K/A/V/H/Ga
.Uracil-containing
clear27
www.neoplasia.com
exclusive.5
remainingsupernatantwas
TCATGCGGCCGCACTGGCGCTTGGCCTTGTAGGGGCGA-3′
occurred.reflected
inflammation.2-5
mMdNTPs
v-fes/
NC_000001.10
EGFRwt
ERM-dependent
4128
1at
mSS
contrib
.511g
Hs00372378
L-aromatic
K650R
Misexpression
10/00
A151T
dipeptidyl
NM_004304.3
ATG11w
scores/stages
line16
N756
+/R24C
non-bound
32612–32866
pathways.9
Lys739_1744dup6
5O
navitoclax
NM_021897
4SU
5,700
asynchrony
phase/epifluorescence
RAS-independence
syndromes.9
affinity.29
1:25,000
Ifo
slight-
variation.Most
homo-and
289K
CITED2
Beta-actin
growth.16
oncogenes.6.7.16
3-fluoro-4-
pY66X
osteomyelitis
cytogenetics,2
E2F-dependent
0.86
NK-LGL
c.152
C1272R
RAF–RBD
Time-Lapse
4NKS
Wnt-antagonizing
470
2.129
3.15187
.A1708E
Multipoint
I-6
1.5kb
assay.4–8
dose,5
biotin-lahelcd
A237P
G566R
62184
pT1
N=100
10/243
transforming.30
G773D
P165L
E42A
hTERTThe
formation45
N'-methylenebisacrylamide
pLTRp53cG
cnCU
.293T
NIH3T3/TC21
fig1
C–S
NSCLC
NSCLC,38
G248P81788B12
.Kalpana
Ðapic´
FGFR1-V561M
False-positive
s11033
Anti-Mcl-1
NKX2-
c.6201_6929del729
pMYs-mouse
×40.We
time-to-tumour
basophilic
GCSFR
factor-evoked
HA-TEL-JAK2
-Marcus
//crispr.mit.edu/
vortexed
SGX
:3042–51
NOTCH1-silencing
multi-Mann–Whitney
deciduation,3,4
5,6
1/19/98
.Affinity
6365
ABC-Elite
bp-sized
q33
NHNY
cacagcttttgtcccccccaaaccagtagttgtc
V299G
9.149
HPSC/blasts
Co-injection
Krauthammer
KIT-Ins503AY
autophosphorylation96
Coverglasses
0.095
PH8
P2301T
H2B-NUT
Q60L
81-6-6879-3163
Na2HPO4·7H2O/5.5
cobimetinib72
MV1193
reverse-strand
F191
Asn480
PLX-GPU
uArgA
IFNGR
Exon-specific
p=0.035
B16F1
.††To
prodomains
VEGFB
56·0
Terruzzi
disassociated
−70°C
streptavidine
BIRCs
BRAFV600E/K-mutant
H3.3-K27
Sigaux
GSK-3beta-interacting-domain
immunopuri®edhuman
R465H
SWISSPROT/TrEMBL
.Digital
.14,20
Allprep
Lys-129
287×
Specificityc
RFX-type
CGCGGATCCGCGCATGTCGTCCATC
UM-SCC-11B
endocytotic
BsmBI-forward
33–50
helper-free
G68S
transformants.42
pRb/E2F4
pCMV-FLAG-caspase-8
5′-CACCGCGACCTGGCAGC
12p13-p11
erythroid+granulocyte
Methods.Cell
202/tyrosine
andmutant
lesions.18–20
Pulled-down
3.83
S6K1-
AUTS2
endothelium-specific
Sos-Cat
MDD
p.Tyr772_Ala775dup
WIF1
V414A
Glu640
bespoke
jumonji
pVHL-independent
749-777
MCF10/HER2YVMA
.Columns
93.0
Hs04959141_cn
1,154
Transformants
H1573
analysis40
ExtendMR
A-subunit
0.132855012
biotinylation-based
MLL-fusions
HER3/ligand
TpK12D
.R479Q
44–75
TCGA-32-4209
rearrangement1
RCMD
Etoposide
.Second-round
2401GG
1130
206-226
α-interferon
CellGro
d-biotin
Δ2–7
SCCOHT34
over-simplifies
Tyr307
H522Y
GSE37700
Arg-974
H105Q
1,3,6,7
angiogenesis18
Lipofectamine-Plus
C‐terminally
Pruritus/itching
IOCUS
EGFR-containing
Bor
conformation11
BTB-BACK
SDHD-associated
10/1/99
andfailed
p.Gly1366AlafsX8
Gly48
DMR
0.778
NCIH1048
wu21
3-galactivity
994-amino
P=0.750
5′-ACAAAAACC-3′
REFMAC553
means±s.d
.Bleaching
11KVVEE558-562del-LOH
C-RAF-dependent
.Cancer-related
Redivue
Renilla-based
.F311
antihormonal
chamber-assay
IKBKE-associated
C84
C-terminal–associating
747
aspirin-treated
28/1248
T/1394
study,40
non-responders
multifactorial
BlackPREP
dSet
EcoRI/NotI
dbSNP40
suprafascial
hMutSα·mismatch
leucine-zipper-like
OP-39
TGFBR2-mediated
vecter
genes41
0-catenin
IVS
blue-red
Heintzman
cardioprotectant
Z-stack
primerless
dN
NPM-ALK-I1171S
aBamHI
vector-based
Incorporating
Myc-targeted
optionsNKX2-1
Tycko
P5.p
24-yr-old
PamGene
On-
activity38
S5A–B
mutation-based
.479
.Interactions
thymocytes12,148
KITD816V
Haeno
Max‐interacting
'Studies
NM_020529.1
//www.ncbi.nlm.nih
0.225
ΔE4
c.2174+1G
.Single-nucleotide
.A549/CDDP
-pyrimidin-2-yl
Homophilic
GSE15526
BRCA1/2-negative
corepressors.3,16,17
Smad48
15.8-
p.Asp568fs
EOT
orosensory
Glu1735
5′-GGTGGCTTGGGCTACTACAGT-3′
al49
RP11-83A24
TCGAACAGGAGGAGCAGAGAGCGA
APEX1
4′-aminomethyltrioxsalen
mofetil
-1-propanesulfonate
seminomas.31
tttgtgtgaggccg
isoforms85
Y764insFQEA-bearing
403-
H2052
MCH5
2A-D
aberration5
​Taken
Coot
*5A
1531A3G
GCCTGAAGGTGCTGAGAAAG
C618S
N294D
mutation–harboring
IC2
tyrosine-kinase
DDD
V346M
BCL6.41
53,645
differentportions
NW_001222300
euchromatin,87
DNA-bindingdomain
ATTAGTFCTGA
Anti-Erk
.SignalSilence
anti-phospho-4E-BP1
C-18
MR9-4
sequenced.23
Y/F
Engqvist
polyvinylidenedifluoride
.Hornung
.Polyacrylamide
arm-level
pan-RAS
5'-PudotPudotPudotCdot
Q317X
EBV-BLCL
GATTGCTCTTAGGTCTGGCCCCTC
70·5
MAPKAPK-2
published.18
ARHGEF17
G59S
ATAC3
Max‐dependent
BCL6.17
.Sarkar
plice
p53ER
0.00008-0.01048
0.0101*
Met-299
derivedby
thatATP
C121S/G128V
p21waf
deoxycholate/0.1
921
SDS–PAGE
microphotograph
thetransition
p59xDR-GFP
vitro.77
13q32.1–13qter
MorphologicSubtypeRiskClassification*
phosphate-precipitated
TAL1/SCL
0.788
130a6
E060
p16-3R
ATRX-like
anti-TUBULIN
250-amino
E-cad
rPheProAI*S
1,040
endolytic
Radio-sensitivity
NF1-TaqMan
unanalysed
InstantOne
KLK15
NM_000267.3
Taskesen
isopropylthioglucoside
P114S
methprimer
pSer217
DR-GFP/V-C8
Pastorfide
HER2-HER2
//www.lovd.nl/TSC1
Q389X
carcinoma.10
Dilute
NUAK
Surana
∼0.9–1.3
pSV40E
NOL1
Immunomount
SDb
A891S
AXL-dependent
Figure6A6A
c.351A→C
81-year-old
1delAACAG
mutation.No
Nishino
chromosome17
MLPA
serumstarved
LPS/IL-1
L348S
Ligand-response
polyhedrin
288KB
Dvl
Ter119high
p.S362L
CMT
5′-GAAAGAAGACAAACAGAAA-3′
differences23
mutations/mutants
0/45
antiandrogen-resistant
Tyr525
Imatinib-acquired
DHL16
wild-type/ΔNLS2
Buzin
n=63
eu2
published.28
1468
nadeoxycholate
p21-wt
LR09
D480N-INPP5E
endogenousp53
MAPKAPK3
p53-R175
performed.Cell
1,232
.difference
GAG→GTG
transcriptionTG101209
stage-specific
Pro-Asn
IDH1/2,11
A389T
NucleoFast
Bv
.Anti-ubiquitin
N581S
−0.553
PMS2CLr
Pro141
Phe1007
5′-TCGAGaaAAAAAAAGGCTAATGAGGTTTATTTTCTCTTGAGAAATAAACCTCATTAGCCTA-3′
KPL-4
V172A
RAF-β-catenin
herditary
-secreting
osteosarcomas.16,17,22
73,7
allele,35
EWS–WT1
T539fsdelC
G148E
2424
15/36
found20
2-ME
9•7
pCMV5-BRG1-FLAG
.Classic
BaF3-EPOR
E439
evolution28
offocusforming
c.1277–4076_1386+1819del6005
C712R
vegan
5'-TGGCACCAAATTCTTCAACACA-3
M368V
Cys-345-*Ser-345
P573_H580dup
02-180
nucleotide‐free
10Puma
L60WT4
.U0126
4648
•Necessary
0.2–20
BRIP1/FANCJ
anti-estrogens
multidomain
α-interface
doi:10.1172/JCI70196DS1
9Thr
Lineage-specific
cereviseae
SARA-binding
0.999
nuclease-treated
diagnosis–relapse
RhoA-induced
activity.59–65
70K
FOXD3
Desorption
~G-proteins
coding-direction
1031–1038
late-emerging
iFi
Valproic
1527
G721A/
necropsied
5′-ATGCTCAAACACCTCCATCTTCTGCATCAGAGTCA-3′
BRCA1−CtIP
'4a
agagTcatc
LC_C5
cross-intolerance
IRB-P00002276
Mutation-positive
dbSNP129
88–99
Amplicons
APOBEC3
NS-specific
TP53-R248W
p27-gene
non-telomerase-dependent
impairment.1
.003
g=ENSG0
Nrf2-mediated
6727
pY1234/1235
RG-12T
53°C
.EGFP-tagged
lay-
Ohgami
15042
lgt
genes.3,7-9
PSA-P
pOP-EGFR-Puro
.Prioritized
736a
.Hyperphosphorylated
-TCCTTAAGCCCAGACTAC
mechanism18,47
IlefsX29
out-of-frame
8p11.2
N41
alr38
Bcl-2–dependent
12‐well
Annexin-V-positive/PI-negative
described.22
hydrolysable
cells.A
,22q11.2
AZ521
150–400
1,116
post-GC
FGFR1-directed
S6S235
msh2-D6p
Chromatography–Mass
Szeverényi4
6–3.3
21q22.1-22.2,3
vemurafenib80
2950
cross-compare
H1773P
others.17
genes.18,19
MEL18
ATF5
Cells/μl
M144I
NCT00585195
.Rok-α
HA-BRCA1wt
microRNA.org
loop/helix
PDGFRA-R2
CARM1-deficient
K753A
coli-axin
gene-discovery
contextualize
.RAF265
complexes8
characterisation
S00-1,000
T2205I
Autophosphorylation
criteria.21
Nu18/SP3
TGF-j3-RI
129/C57Bl/6
obesity-related
Napsin
IFAR1010/1
.Counterstaining
CDK1-cyclin
17796
factor–cMET
0-13
HK1
5′-GAGGTGACCCTGGATGAGAA-3′
V467G
activation71
co-inhibition
homo-/hetero-dimerization
TRANSCRIPTASE-POLYMERASE
lysine-fixable
7.12
​Table2.2
.G
.Magnification
cross-hatched
64:722–731
GSE28892
adenocarcinoma112
4.-RAD50
vitro.15
PMUT
Y623C
culturevolume
mice21–23
CYP2F2
R2034C
c.1711+5G
co-transformed
Lauritzsen
ofBCL9
MGM-4
10−29
~90kDa
Ras'GDP'AIF3'GAP-334
MOB1B
K360
5′-GTTCCCTCGATCATGTAGC
AFB1
5-fluouracil-treated
Velloso
MRGCWQREPS
∼365
spP38827
2.5*
HIF2α
Il-1α
MSFT
codonl69
substrate-chromogen
BAP1
II/III/IV
NBP1
tg/ml
Bi-allelic
ERG/ETV1
FGF5−/−
I949T
K558-E562a
calvin.bwh.harvard.edu
steroid-free
3MF/10HPFs
DNA/lentiviral
M552
6.957025
sunlight-related
betweenMsh2p-Msh6p
EVI-1-specific
Imielinski
44-45°C
10×104
thrombocytosis
Glu659-AC
Pharmachemie
genes.7
1145A→G
P244L
inhibitor–associated
NaF
NM_032932
3263
906,600
8.12
18/36
α-rabbit
Bioanalyser
0.49–26.13
protein26
06/M
,1a
5´-CCCGGAAGAAGCGCCATCTCCCGCCTCC-3´
family1-3
spP55200
3,339
BirA-expressing
TrkA
//blocks.fhcrc.org/sift/SIFT
CK7+
.Tnf-α
M24003
methodology.27
high-CYT
segmentation2
.situated
SNU-520
9455L
ALK.Figure
Asp275
p110-inhibitory
Po0.0001
56–58
9/32
≈4,000
5′-cgttgacatccgtaaagacc-3′
2429
lentiviral-delivered
TAAGTAGTCTGTGATCTCCG
ErbB4-dependent
activity144
leg-length
5q33.1
P378R
containingreporter
domains,20
Mrp1
Imperato-McGinley
8/31
FIP1L1–PDGFRalpha-induced
MEN-1
protein,45
ERK−substrate
DNA-demethylation
ephrin-B3
NER-related
Creppe
EGFR-TKI–induced
phospho-SHP-2
sarcoma.90,91
FVB/N
Kras-Driven
.Rescue
B*15010102N
Akt-Myr-S473A
prehybridization
exempli®ed
46-year
developed.1
TDG
Hoell
.030
z-vad-FMK
-NH2
pathway-component
H2A
BCAM-AKT2
siROR1-treated
Yap/Taz
systems®
=17
p21-siRNA
-primed
chest/abdomen
EBV=Epstein-Barr
regu
AlphaScreen-based
chemotherapy.29
Dnmt3a/3b-deficient
273H
CD21+CD23−
84.8
Mx1-Cre+Srsf2P95H/+
_^A
893–900
minat
16,000g
9340-fold
pBabe-hygro
96.2
Nogami
OFt
BCP-ALL,3
bromodomains
caries-preventive
I506V
MSH2*1906G
c.3775
SDS—PAGE
auto-fluorescence
kinase–dead
proline-tryptophan-tryptophanproline
_P_
ERG-driven
4Ab
misspecification
V95A
pBABE-Puro-BRAFV600E
tfe
32–59
4908
TRIM4
moml/pla2s
//staden.sourceforge.net/
I04
CO2–95
Dairkee
non-homologous-end-joining
cytocentrifuge
WNT6
.AZD2461
Wiesmüller
H1047Y
intron36
:HRAS
.Immunoprecipitates
1.11
RCM1
vitro116
Wallerand
3,318
normal-sized
c-ErbB-2
ACTB-S
AML1RTR1
GDC0973
dimer–dependent
Hishinuma
BC.Our
-carboxy-2′,7′-dichlorofluorescein
dystrophin
dUMD-BRCA1
pGRE2-TATA-Luc
p≤0.046
A491ins
37°
Kontopidis
L529P
Nadin-Davis
E1099K
ap-
HSC7E224
bedridden
LK2H10
ab8898
Ercc4-deficient
Oceania-
604757
53BP2
55-bp
1986
MYC-transgenic
receptor-phosphorylated
12477
Mm768bpΔAGAAAR-LacZ
A-
G12VRAS-stimulated
metallothionein–wild-type
NHEJ14
3889delAG
5-AATTCAAAAA
SLC2A7
63-year
.Klijn
Wen-Hu
*2439
SBK2
BCR-ABL1-positive
.Anti-pS111
patternsusing
Adulte
TokyoUniversity
In£uences
Selleckchem.ERBB2
NA=not
DNMT3B7-expression
168Y
CUGBP1
1Compared
Mfugue-pair
90–98
p.R102C
~3
hepatomas6
SMAD4-Flag
Shapiro-Shelef
Nespas
Forcodons
OR=2.46
Schwerte
Yamamichi-Nishina
microdeletions.15
PLK416,17,18
R659W
determinationCells
3.0–16.0
R108H
tumors.17,42,45
anti-raptor
II-chromatin
R580Q
hypomethylator
YPB2
.Mga
RNA-binding
RIZ2
T3703right
V184
5′-GCAGGGTCCTAACTCAATCG-3′/5′-GCTCGGAAAAGGACAAGCTC-3′
Biosystem
37–46
Figure6A,6A
Debiec-Rychter
Scion
S227A
Promoter–Associated
Ampliﬁcation
ALK-TKDs
Matrigel-coated
LNCaP-C
NF-1
calculator92
analysis,24
decitabine-n
NanoString™
F4-II-1
P20
FBWX7
substrate-targeting
R24C
1.8–2.6
559-Val
t2t3
Arg384
82.08
Deacetylated
ACAGAAACGAAACCTTATGGTTTTTG-3
μg/15
Bcr-AblT315I/EGFP
D3S1358
LYDLLL
DN-ETS1
4315
48-h+48-h
01
pEGFPC1
5′-CGUAGAAAGUGUUGUAGUUGAUUGA-3′
CCL-247
688
Ser612
.Fragmented
Cor
COSMIC12
5–10-fold
ht1/ht1
Jak1YY
5-20
P360R
CCTGCTCACACTTTCTTCCACTGCATTATAG
9.87
56772540
andPvuII
16-bp
STAT5-A
p=1.9e-7
BH4
V923
.MYC-N
rVaIGInLeui4sThrAIVaICGIubtHNisHisTrpSrIIl*ProPheSrValAspGIyGInProAIPro
SIN1
2R–FAT1
Homomeric
pCDNA3.1-FLAG
pEGFR-tyr1173
results.bCore
Hes1-dependent
R.M.E
D10S1765
1662–
J-C.Y
byIFN
BMPR-Is
17–21
diffract
ACC.9
4-phosphatases
Bcr-AblT315I/
Fig3B
Spiekermann
PF-9
CMMoL
Ekmekci
PIK3R1R348
OVISE
mTORs
mutantalso
NBG21
FPKMs
​M-stage
.Collagenase
G65R
quantitative-methylation-specific
Interrogating
Vasen
membrane.111
exonsa
NCT01510444
IC90
58-4
Aspll•Tyr
28:1960–70
-RasV12
.RAF1-RBD
NUP98-PRRX1
TCAGGCCGGA
n=373
-Abelson
post-neuroblastoma
I756T
Ser-537
pagesize=25
0.787-3.545
600/2-2
11,12,17,38
R510C
radiation.66
FIG–ROS
metabolism4
Ink4/Arf
cially
cancers.DiscussionOur
adeocarcinoma
Irwon-dong
.Tracks
epithelium149
InvestigaciÃ³n
16-19
K851-R812
IDH1-R132C
FADD
RasA59G
DP_RNA
5′-cagcatccaccaagtaatcg-3′
BICC1-H6R1
4/0
A-Cdk
IFT80
differentiation-blocking
h2q15
150105
E1507
IVKA
miR-483
I744-E746
MALDI-TOF
c.5203G
Tol
1p19q
BX40
index.shtml
tumor–stroma
SAOS
cells19
CGCGAATTCGCCACCATGACAGCCATATC
larvae51
c-fms
occludable
GtoT
K438Q
LH000t°
L162P
sex-dependent
Khambata-Ford
HC5
PamChip
BCORRARAhad
pSpCas9
pLIX_403
HinDIII
log–log
Leu173
βG
CTCTCCCTCTTCdel/Tins
101200
anti-Grb2
Q219X
tissue-specifically
BRG1-
A293-derived
publishedsequence
NM_001042492.2
Phe330
S8.2
C898T
189K
His/Arg
D594G-mutated
K257R
σˆ2a
E330G
s12885
M67
P654L
sinonasal
Strepavidin
/cell
CCGGTCGT
176KB
Yatabe
crossmappings
K1299E/S1303N
mRNeasy
.Withrespect
Vignjevic
lymphomas,22
not.Structurally
n=505
V132I
41–163
.12.2
A07-03-042R
sub-pockets
described28,29
//www.interscience.wiley.com/jpages/1059-7794/
aliquotted
isotropic
hSNF2β
EXOSAPit
Fordirectsequenceanalysis
Cd3e
non-RSS
Notch-disabled
EL/RE
8600
A/G+
2–3F
7q31.2-7q-terminal
epithelial-like
22.6
3/10,000
2q24-31
.TaqMan
PCR2-fb
Ligand-driven
TTTCGT
CD3/CD8
2,722
218–293
C5N
inhibitor–resistant
–substrate
.Similarly
2.461
.Edman
1600–1985
E231G
.Mononuclear
.Max
pten
Gleevec/Glives
.Multi-site
malignancies10
MIGII-RNF11-BRAF
phospho-Y1003
S373F
NCI-H1650/ATCC-CRL-5883
DLBCL
.Internally
pJP11
de-amidino-phenyl-indole
pcDNA3-AU1-mTOR
CDK4/6-cyclin-D
Junctionb
Q276R
10.3109
17.98
.0103021
5`
EGFR-negative
SPOP-like
5611–5660
pro-invasive
DIP2B
mice,15
AAGTTGTGTGCAAGGGAAAAGGG
Src-binding
69483
62Mb
HMGA1-overexpressing
DC26
RET/C634R/V804G
15-μg
pro-opiomelanocortin
stepat
S144I
Individualized
.AMP
α-
0.376292
06-574
×109/l
89.4
Ptenflox/flox
2092
5A4
origin,24
Rheb-LAMP1
model4
Snick
27/679
ciprofloxacin/kinase
NAMD.18–20
CDK5-mediated
2361_2364
4.2.2
TGCCCCTGACAACATAGATGGAATCACTCATGATATC
LexA-Trx1
nonmolecularly
strandsof
chromososomal
isotype-specific
akt-specific
A721T
EGR1-depleted
molar
104-R
NS,39
x200
.1513C
0.37–10
.HBV
Gab1/PI3K
TAZ11
10-months-old
ADI
Horlings
salt-bridged
≥–
R287A
DNAsamples
BioPioneer
7,11,12
Erythroleukaemia
3C3C
Pi3k-dependent
NPM1/FLT3ITD
suppmat/path.2267.html
PstI-digested
8p23.3-p12
dimethylating
EGFR—In
∼108-1012
S.E.K.
noh
roswellpark.org
EGFR-TKI–resistant
reduced-serum
anti-c-Rel
www.rbej.com
.Validation
BPP
15334
R159Q
V600EBRAF-expressing
mTmprss2
CUO3
thiolate
L132V
14,36,37
tumours36,37
VEGFD.11
CD45-negative
pcDNA-HA
10q23.31
HHEX
13q14.12
MLL-C
.Probing
96A1.2
BG215747
TEL-PDGRF/β
O.OSo/o
Krauth
Gli1-overexpressing
V198M
Tmprss2–Erg
OnlineFirst
NLS2-Ala=0.1206
risk52
Lin−cKit+
D1819N
IGF1R
Wissing
transilluminated
non-metastasizing
inhibition30,40,41
Parametera
5′-GGTGGGAATGATTGAAGGTGTG-3′
AGTACGAATGCAACGTTTGCG
1143-75
post-treatFIGURE
A/Primer
W274L
168000
sonia.abdelhak
PDGRFR
aberrant/over-expression
3-7
erlotinib.11
repeatedand
Rylaarsdam
−3kb
BRCA1−p53
CENP-F
AF-293-NA
gastric-projecting
D16S3074
netgene2
68301824
setting.19
Ni+2
N17/C186S
1uwj
transcription–translation
Cul1-Skp1-F-box
p.Ala224_Leu1365del
//doi.org/10.1371/journal.pone.0019059.t001Tissue
trr
Gefi
R481G
leukemia-myeloid
intracellularß-catenin
UV24
CBF1-dependent
q22.3q31.1
kINshLgpHl
VCF
TUR+BCG
cfDNA24
painting.26
hormone–independent
TRAIL-receptor
500μg
cancers.56–58
phosphorimager
1.91
4.5-fold
duced
qPCR-Sos1-rev
Sm12
theywere
S3A
PTEN189
Pab
I.C.T
software,20
1A28
widely-expressed
rs121913443
BRAF-flag
.expression
pseudo-colorized
5′-TAATATGTCGACTCATTCCACATCAAAGTCCAGC-3′
FKBP11
XPF
Wackym
2.579
ex13–JAK2
BM-splenocyte
JMG
SCFhCdc4-mediated
,7A
Q172_Q311del
frac­
HPA000496
.41,42
TGB
0.0407
b.d
G4393
biolog
780G3C
hRos-6
59-CTGAGCAAGACCTTCGGGCAG-39
IRG
Met/Leu
Tris–1
MET-directed
anti-DPP3
-Parvalbumin
BRF112680
ATP-uncompetitive
CATG
FST
gluthione–Sepharose
Sonifier
segmented/circular
neuroendrocrine
Ptenfl
sc-6200
π-class
2-deoxyglucose
MB4-2
MCF-10A-derived
mwm
containedmutationsre
Allfrey
vitro15
R35A/L225LI-expressing
MMC-treated
MLL-AF9–expressing
c.1468_1473dupp.E490_C491dupNilotinib
MSKCC
p.E763fs
.Reverse
PWZL-Blast
F384S
Pro132
35.93
Flag-lysis
His–K-Ras
pMSCV-IRES-eYFP
T717V
S5a-d
epifluoresence
91.9
K-RasG60
progression8,16,48
–treated
Debruyne
coil+hook
1.151
BC-tumors
SNP_A
Front–rear-polarized
MHH-ES-1
trk26
1,499
toleragenic
c.53C→A
S.W.M
substrate3
1-SR
Zaizen
aCML/MPN-U
Hypertelorism†
antic-Met
suppressor25,26
CSW1
pk-6101
activity.30
IgD−CD38+
Met-128–
KDM6B
CG6CGCGGA6
T470C
Frgala
.Ming-Sound
mink-
vesicles.23
ViaLight
A755D
serum-activated
HIF1β
CD3-CD56+
protein.36
HER2is
41Wdc4
K142
PolyPhen15
KIR
growth.25-27
activation.58
clones/121
self-antigen–induced
reconganize
dendritogenesis
turnour
Roche-Ventana
black-filled
thiscomplex
Flg
A–targeted
Johannsdottir1
RO4927350-resistant
co-substrate
1.3/1.2
complex.8–10
exposured
brca17/7
Genomatix
2.415
Alox12b
.Early
Killela
streptavidin-binding
FBXW7/NOTCH1/CCL2
10.1172/JCI59309DS1
KRAS-negative
DNA-containing
digestions
SUPM2R2
25.41
10-kb
post-training
0/2
nodular
p110β143
.Steroid
response.36
×109/L
latency.52
Tumor-Cell
+CA
GDP/5
CAMA-1
L1224V
inhibitor.13,31
KP3.33
FoaSphenotype
HGMD
07-0409
TAGGCTGGGAGAATGGTCTG
ret-transfected
Rad52
anti-His
nt−51
Pol4-dependent
KMS-12BM
UPN298273
HLA-B*39:97N
Malara,2
Biotage
SPC
Eight-
EZH2/PRC2
5.85
III.4
N=26
IRS-1
conclusionswere
T1-hyposignal
anti-MED23
c.38_39delinsAG
thyroid-targeted
skenoid
intestine,129
MCKEON
TRCN0000071386
lineages12,22
andrzejd
Flt3ITD
SFRP2
pGRR5-
published.37
GCB/GC
HCC1428-BRCA1-knockdown
W2/2
resection/explantation
13,324
Mutantsa
127–331
1.5mM
G480R
patients—p.G646Wfs*12
878
.Ibrutinib
folded-in
TTAGGG
P=0.0124
0.49461
HEC108-ENDOMETRIUM
CAGCACTGTCTCGTCTCTGG
TOPRO
tumorigenesis-stage
12MLP-Luc
LIMS
custom-written
GAGACTACA
described,13
28â
Xuewu
G3580
719–1051
Bax-/-
AnnexinV/propidium
RUNX1-MECOM
.EZH2Y641-containing
Ratbi
T1041
prognosis58
low-copy-number
1996/Bergamaschi
.OncoTargets
D593V
CycC-CDK8
14Sequist
5762ins137
DISpro
TNAP-Cre
Jürg
microarrays11
ETV5a–TMPRSS2
18.32
Carl-Hendrik
c.3140
UO1-537
EWSERG-expressing
A/B
.MAT
580/442
UVC-mediated
Rad9p
Q81VT5
pcDNA3.0-NPM/ALK
p101114
AATCTGGTAGA
Y+80
DHL-LR150
T.M.R.
miRNA-driven
study.20
l7qil.2-12
K370/K372/K373
18–21.16
antioxidant/electrophile-responsive
~14.5
Tet-on
27–49
Thr116Pro
48-fold
1H-NOESY
SMAD3/ca-TGFBR1
factthat
microBCA
.EML4–ALK-expressing
5′-GACTCCATGCCCAGGAAG-3′
To-on
shFZR1
5′-TATTAAGCATGCTATACAATCTG-3′
21.69-27.13
.Background
specimens.5
Figure1C.1C
overall/individual
HLA-B*39:01:01
carboplatin/albumin
N1007S
ABI/Perkin
sh1Yap
5.59E06
pREV-tetracycline-inducible
B80-TERT3b
BRCA1-COOH
IsoMut
I3
Rho-GDP
dichotomous
V441E
k-means
MMC/DEB
nuclear/cytosolic
α-MHC-Q510E-Shp2
Top10
RUNX1-LPXN
ephrinB2
.C.C
7170801–7729300
//mmb2.pcb.ub.es:8080/PMut/
Progestagens
pSS16
Pharmigen
directly34
HELQ
.HA–Smad3
-~I
G292fsdelG
Flt3-L
QSG
known.3
0.54–0.95
5,24
HER3-dependent
1.35–1.65
Gap1/2
p53/Rb
Asp-1124
33433447
cytosine-rich
GACTTCCCATCCGGCGTTC
Linzer
.Mutagenesis
BSB
5'upstream
hybrid-selection
Petersborough
p53,35
PI3K-synthesized
C229R
morphogenesis15,16
57.8
–0.7
12q14-q15
specificities
~A21
161G
SC-260-G
100-μg
5′-CGGAATTCGAGGGAACCCCTTACCTG-3′
Tumoral
mucin-secreting
2C5L
S114ter
3'UTRs
JH1-Jak2
5164del4
AR4
10-μl
sub-morphological
37,38
6,513
previously32
His+Ura+
27-gene
704–1029
Kusmartsev
gp11OProto-'rk
11,28
EGFR-G857E
198.1
11q22.3
M317I
5382ins
14–420
Neurofibroma-derived
gene-rearranged
number.Figure
ofRB1exons
bronchoscopically
ARBS2
â€¢¿Y443N
0.120-1.534
phenotype8
RERâ€
research.nhgri.nih.gov/bic
RP11-149I2
demonstrable.3
CBL-affected
TOCSY-HSQC
p.G67S
TGGAATAC
D59
Smad2-silenced
neuroblastoma-associated
CaCl2
14Val
-20°C
Cdk3
'somatic
Ficoll/
NRasG12D
S2F
genes—are
phycoerythrin-coupled
non-enzymatic
NFl-GRD-stimulated
MEDI-3617
pcDNA3-NKX3.1
A128P
5′-CATAGGTGTCTTCCCATTCC-3′
twist–Gal4
gliomas5,53
3463–3468
NM_000386
Microscale
wild-typeprotein
5*-end
TCL1-SCID
Ras-expressing
-inorganic
NO38
Janknecht
MKL-2
C697R
D1067Y-mutant
C5-r-2
0.4–12.1
NSD2/MMSET/WHSC1
D126H
C561G
Droogendijk
activity,9,10
Allo-SCT/Bu/Cy
Cbl-c
MOZ
Biolabs\
data,14
11.1
MGC:31518
Lodish
EZH2H689A,19
TAP1
p=0.106
two-cohort
7c
Q572
Mito
813-bp
analysis19
structures.64
5'-CGAGGTGTCTTGCTCCGAGCATAC-3
196110
EE+RR
HbA
hCD45
PEBP2β
better-defined
GCTGATCGTGATCTTCACAG
−3.0
.PI3Kδ
RNase-free
published.6,7,19
FISH-negative
Ba/F3-EPO-R
pri
•.
BioBank
S-transferase-fusion
S4–S7
4,751
sequen­
05/24/09
hypoallelic
Maheswaran
ras2
Almoguera
AID-mediated
developed.11
p.Asp1399Tyr
language-based
p53-
81-52-764-2983
binding.17
Caenorhabditis
earlier.6
procaspase-8
17,18,28
S221R
80*
L201
M241
precipitatedproteins
classification,27
102–312
SVS
VH/VL
p53R337C
SRSF2-WT
cancer27
5/22
AXIN2/Conductin
5'-GCC
Newton-Bishop
gpllOPrrottrk
ULN
TaqI
mean±SD
.Resulting
4.0–11.8
//www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/Member/BRCA1_mutation_database.html
338-bp
Myxopapillary
NM_002880.3
G1138C
transfectedinto
-D-2
0.0082
Y657C
BMPR2
dis-
GST-C-RAF220
Syndromes20
RANTES
Antireceptor
SmoA1
.Macrophage
inhibitor.27
/MYH11
Trp-80
41st
CUTLL114
CBFbeta-MYH11
−17
P100-associated
non-DNA-contacting
C9ORF46
ysVal
effects27
R5528
pan-T
−3.91
p.Gly241fs
BICc
C606
Granzyme
R225W
μL/min
CITED1
.Cy5.5
p=3.7x10−9
ERG-overexpressing
conformation65
StrepTactin-HRP
subtype.71
Lossi
132-M-associated
R973Q
Pretreated
Opto-Electronics
conserved15
Pim-1wild
sc-184X
type.29
2014
c.5629G
Kuzume
NKX3.1-deficient
300-2635
RTTN
Kit-dependent
.PK
N153T
M694V
Pública
∗601734
pre-filtering
27B
Sos-induced
.178
PDGFRADDIM842-844–
β-mercaptoethanol
gaccctagtctgcc
seg
I41R
Chek1
ELDLETLTPYIPMDGEDFQ
cells.15
predictive.85
.GLI3
tumor-reactive
5.86
SPOP-Y87C
p=0.0076
6982–6983insT
trials/session
Point-Mutated
V/1,600
p-FOXO1
GAL4–E2F1
4oC
I1171
Pintard
9.75
G2-
6.281
CTCGATATCTGCCACATAGTTCTCAAACACNNNGGGCAC
G+C
id-2
S259A/S621A
cagtc
Y17126
.J.R
Hippel–
RFLPs
glyceraldehyde
SF3B1K700R
TUNEL-positive
mutationsappear
P=0.267
Lee3
WM266-4
V–FITC
DM-B
5.14
T-scores
p.E746-A750del
variant-specific
2001c
0.991-0.998
mD814V/hD816V
STAT3-mutated
side-chain-specific
studies30
SCF-unoccupied
AnaSpec
5'gagcgagaaccgagagctc
5'-ATTAGTFCTGA
dimerization.16
.The
S-containing
K/AKT
Biointerface
K603E
Ptpn11Y279C
P142H
.0018
419–780
.Co-expression
c.3533G
Jae
V2H
1100
Bα-containing
PPM1D-mutant
Rasopathy-associated
y-axis
12-base
HALR
SK-Mel-285
D-Hanks
5′-CTGGCCATATCCACCAGAGT-3′
.Fig.9A,9A
leukemogenesis.50-52
5′-GCGCAACTACCGCCTCTAAA-3′
GST-isoform
W239fs
2LQI
dataset37
411th
Slit-diaphragms
p.Leu265Pro
27,050
.MAP
mastocytosis.3
5′-ttggactaagatggcaggatg-3′
apo-crystal
1,598
Akt-regulated
de-waxed
Elm
1230
Rozzano
5-103
in9
.009
Δ3263–3380
.Ventriculomegaly
BACURD
.ADAM23
cancer10
heterogeneity
ActivityGels
Anticacner
Arul
coprecipitates
2·6
M95936
G36R
R1507
sc1616
disease.1,2
derivativeof
TRAF2,163leading
MSV
53BP1-positive
Asa
HD-0378
.Heat-map
p.E663G
Gly328Trp
≈2-fold
particularity
7RI-2
as-yet-unmapped
paraffin-
chr10:99023246-99024582
identified.19
Y'RAS'YY
CSNK1G38
Ein
D228N
A304T
mosomal
214010
1A–C1
density-assessed
2þ
M6958
p.N550Hf
zero-centered
p.Arg487Trp
Phosphorylation/activation
AML.118⇓⇓–121
Src32
8410
bound23
D347A12
PDGFRp
pathobiological
NaCl2
5.0–6.9
'floxed
heter
non-trivial
.Bouche´
DB1

CFU-granulocyte-macrophage
.Distances
tumours59
cytofluorimeter
F78L
c.319C4A
Isocode
RKIP
well-described
C2HC-class
S6K1-encoding
.3E
syndrome-linked
non-normal
MegaCult
H-RasV12-expressing
Furstenau
76257
p160-CBP•p300
4-amino
carcinoma-in-situ
pRS314GALRafΔNT
-26B
Hemato-Oncology
0.01.16
PoPMuSiC
BRAF-null
mannose-containing
others17
euparathyroid
coexpress
ΔTrkA-induced
CopyCaller
W240R
39-kinase/Akt
Fn
mullata
del4ins10
1388C
63,000
B6-Ly5.2
pFLAG3-p85α
double-null
anti-Mek1/2
clones.132
exon4/5
UMD-Predictor
6.5w
identity22
.Polydactyly
10−9.9NEFMNeurofilament
αC-Helix
Socs2
.Aggression
XL1-blue
Colony-Forming
histoscores
cobas-positive
MTSL-labeled
311SerFS-340X
NF1R440*
Presbyterian
matthias.maurer
46.2
pheochromocytomas
shNon-Targeting
M1727
.-j
calreticulin
HCT116+Ch3
tissues46
vitro–cultured
Bienz
BRAF+CRAF
8327
p=0.0021
stimulation-independent
17p/q
Q-E-L
VTX-11e
5.72
Claperon
Kesari
cross-activation
SHP2/Q510E
100/121
functions40
AS-MX
3163
0298
anti-CD11b
sarcoma-like
CD34−KSL
.Display
Ago-binding
WT/WT
Baculovirus
inuninfected
intra-sample
3782/90/
microfluidic
F-12
XtremeGENE
melanomas10
Caspari
DMEM/F12
chondrocytes33
31:3086–3097.10.1038/onc.2011.476
45–51
ill-de-
g/L
PDGFRB-NIN
ROS1.15
270–595
c1–d3
microenvironment-affecting
0.94±0.64
attack.Although
NM_001654.2
0.4X
c-ABL-T334I
criteria2
T790M.69
addiction.5
.MOLECULAR
3I8O
Y1234/1235
Q87fsX119
oncogene-expressing
P497-4
GM/Vec
demethylase2-4
.Yasuhide
LPS-challenged
growth-suppressing
antibody-sensitive
.BstNBI
ERK–MAPK
p.I668*
mitochondria.1,32
tumor-free
*2466
POLR2A
29.26
V–allophycocyanin
fluorometric
2-cm
SNP-chip
HA-ERK/Fugene
293KB
13,26
TrisHCI
katanin-degrading
Cdkn1b-deficient
chemilumenescense
002
SupT1
G498R
4i–l
DNA-binding
C57Bl/6J
embryogenesis-
efficiency,1
ubiquitination6,7,8,9
thev-H-ras-encoded
Ala502-Tyr503dup
SCF-mediated
Smarca5
AACGTGGGACGGATGGTCCC
PDGFRB.1
+5k
Rosa26LsLmBcorA/Rosa26LsLmBcorA
1542
NF1-GRD-mediated
GST-FERM-G197C
RD-ES
MLL4Δset
Click-iT®
histology—which
V86G
twice-monthly
suppressor.5,6
p.T117M
AXL/GAS6
position-speci
SCV000147871.1
BASCA
CFC.15–18
gkt305i1.jpg
gp100
CK1γ3
1.Results
ofour
0–30
.4,8,9
S3.Figure
30-34
HR-
GCA-3
loglikelihood
retic
Kostmann
one-sixth
EUS0080966
S-phase-specific
pRCC6,16,40
//franklin.imgen.bcm.tmc.edu
HAL-A1
highly-curated
activated59
shCDK8-2
Proband
Bifocal
FGF7
ERGb
dIII/Eco
RAS-GEFs/RAS
GST-WT
SA494
BRCA1–CtIP
PIM1
30.00
anti–PD-L1
FGFR–TACC
2⇓A
GISTs.Based
previously48
Chengchao
pRb/Skp2/p27
c.2221-126C
levels.32
1:5
Aspc-1
11-mutant
Q79K
IDHR140Q
-20
CD74–ROS1–induced
Anti–panendothelial
RTK-III-binding
Q79R
aza
10/23
Acetylcholine
Aik
P32-labeled
K601E-mutated
GTCCTGCTTGCTTACCTCGCTTAC
5382insC.45
RSmads
million/ml
CIP
sub-families
KDM5C,27
L16956
Genome-phenome
chloride/0.015
Ba/F3-KIT-D816V
PIK3R1R348∗.p85α
structure.57
case.DNA
FBXW7.2
2–2
5912
W582Stop
51-fold
anti-TFAP2A
γ-catenin
dur-
pGEX-6P-1
TSLC1
ALKF1178L
MYC-mediated
0.11-13.84
Histidine701
line12
CD19+/TCL1+
mutant-enrich
RTruncated
glutathione−Sepharose
effectin
10-day-old
BY4742
TriReagent
c.1040delT
CREBBP
Egfr-null
termined
Y1197
6–7-fold
/leucovorin
.Abridged
.SCH772984
His/Asn
AATCAG
Fig.44D
.F102C
T14P
.Noncanonical
retMEN2Btransfected
definition.43
Kitajima
PCK1
beta-galactosidase-neomycin
PYD565–579V
Y576∕Y577
atoms—blue
rs121434568
PU.1-hypomorphic
Constructs—ErbB
superovulated
hyperechogenicity
factor-l
Cleasby
nonsensitizing
-CGGAATTCGAGGGAACCCCTTACCTG-3
PgR
1.68
Biotin-labelled
CC2263TT
Rheumatology
c-myc,49
specimens—the
LNCaP-Abl
.Regardless
p.Gly12
FANCJ/BRIP1
doi:10.1172/JCI79860DS1
TRPS1
DNA–PEI
Hs00972656_m1
PRDM3
FLT3-amplification
DataThe
Belarussian
146-3E4
vivo44
3228
phospho-phospholipase
NT_010823
650-225-1000
previously.3
941
5-μM
rs72198494
CTTTGGGCTTGGACAACACT
Ptd
gel-resolved
H1/nucleosome
NOS2
266–552
N26/D30/E31/V45
S-transferases
RAS/RAF/MEK/ERK
R28L
95062
Fig8C
EEF1
CD8T
253-756
5′-TTGTGGAGCCTCTTACACCC-3′
pRS306
diseases.17
Misfolded
Syntenic
≥50ng
702G
suffi-
−4.49
tri-methylate
analysis.Patient
GAP-like
AML1-related
c.5095C
Intolerance‡
‡
estrogen-deprived
Polaczek
pMCEF
D16S3407
6/30
pathways17
gangliocytoma
ret-induced
0.94
PRDM1/BLIMP-1
affmity-purified
Y1092-specific
Sabapathy
C141/277S
anti-Y653/654
xenoantisera
SMAD2/3/4
4-phosphatase-II
BJAB
anti-smooth
5′-CCTGCTCCTGAGTATTGGTATTCCATTGCTTACTTTG-3′
6,094
MEN4
-CRAF
0.57MLL-PTD
135Cys
Gly/Ser
p.Gln409SerfsX8
M20744
cadherin-mediated
/MACH/Mch5
Bhavin
11,009
5′-GCGGATCCAGGTTAGGTGTCC-3′
1054
LMS
distant-dependent
1395
Kulyk
16/22.2
GCT
C-mediated
−940
2011c
hasallowed
CDK5RAP2
TRITC–phalloidin
ClC3
crizotinib25
cross-reference
pCMV4-AR
.Result
HES-related
only.5
Tübingen
PAK1K299R
38/CRC
B3
16,100
.Survival
Q6VAB6
AML.13-17
PDL1/2
−4.3
PlGF
K558•••I789
BCL2-homology
EWSR1-FLI1–unmodulated
ERK-specific
ER–chromatin
ENST00000518881
Zebrafish.19
African-Americans
.26,39
607A
TSC1-coding
p.L36R
6–13
cells172
T790M-bearing
K535
.A–I
disease.70
−821
26.9–35.6
Bunkyo-ku
P40AS
12/26/07
2/0/1/3
tNt
level.Allogenicity
bioERG
18,091
R553P
elongation11
Melanin
samples.65
BCR-ABL.65
492
Catalunya
todegradation
CMVO
origin.10,11
Assay—Baculovirus
EGFRvIV
SC3
TMEM49
reaction16,17
carcinomas30
CAGA12-luciferase
Dacogen
0.04-0.82
L858R-transfectants
PROTRAN
4/429
9019S
Y334A
Egr2
AMV-XL
C04-0019
pGXXG
.Raffioni
MGH:10
pQE13
n=97
EZH2+
HER2heterodimers
Azacytidine
NFl­
.34G4A
Q48H
exosite
Casper/I-FLICE/FLAME-1/CASH/
AKAP
BMP‐related
typeb
MIR143-NOTCH3
.Libraries
nt3289C→TR1068X
.Beta-catenin
GST–wild-type
1,500,000
b-sheet
9649
′
3082-950
commitment-
Antibody-mediated
neutropenic
.1,35
loxP-neo-tk
Kit-allophycocyanin
substrate-binding/autoinhibitory
U63333
cysteine-dependent
taketo
Rachou
GAL4-p300
delGTAinsC
2773Q
AAAATCTTGCCAGCTTTCCCC
0.23–1.24
Myc-Dnmt3a2
.TAB250
CYP33/PPIE-bound
Qin
Dlc1
6-yellow
patients,6
threonine-286
VHL2_1R
EDD1
RHEB
AmpliTaqFS
77–82
P106L-mutated
.S29
YAC
Rad9-like
15q15-q21
.C11orf95
I266P
IVS1-1G4A
5274
unphosphorylatable
conforma­
NCT01587703
Manifestations
∞
defects5
GSE7307
5′-nTCCnn
anti-PPM1D
BCL-xL5–8
−18
57.7
04–103
mMisopropyl-1-thio-β-D-galactopyranoside
GroEL
β-actin-GFP
Greef
5′-AGTTTTAAAGTACTAAAAATTGCCATC-3′
SLCO1B3
systems.31,32,45
Szostak
4101–4869
K42A
anti-F4/80–APC
Gerlinger
huACTB
Ewalt
1uwh
dual-fusion
24.0–41.0
D362Y
pBADTOPO
Asn59
AB005048A
S1060
TSC2N
***P
WCL=whole
c-Cbl-dependent
insertedinto
anti-pY905
analysis32
.Anti-vinculin
location.In
2176/0
assay.Log-phase
analyzed.Cell
previously,13
602650
FLT3–tyrosine
6–96
9434
Burrows-Wheeler
SLR
Mll–myc-
Tris–HCl
fra-1
Stratakis.104
STAT3−/−
46478–46486
Q681H
Non-hereditary
BCL-xL-binding
RU-H3R
nicolas.girard
Rajakulendran
ARmRNA
122
overexpression.27
hematoloxilin
AP/dE-protein
AOBS
c.138-
Bachman
tumor-stromal
'H-Thymidine
MEN13
hBRM
pFOP-FGFR1
29,33
melanoma6—an
RAF1-RBD
lapatinib-sensitizing
Lines—32D
labeled-RNA
G248P89268A6
lSq
HGSOCs
psiCHECK-2
Giancotti
K292E
30/F
RQ428
.Source
CGAGGGAGCGCAGGGGAGCG
2Fobs–Fcalc
5′-CCGGGAGCTTGTCCTTTTCC-3′
Nissl
5′-AAGTAGTCTAACAATTTTCCAGCCC-3′
pCFG5
1-263
EDTA/0.05
Glu69
previously.26
high-kinase
.Continual
methodsPeripheral
67.7
phenotype–genotype
stabilised
O'Connell
18.3-fold
ht3
c.35_36delinsAG
8q-positive
CI=0.14–1.32
5'gggaccggcttaatccatag
CCI-779
gene-environment
saline/sodium
MSH2-WT
poly-d-lysine–coated
WTE
sc-269
LTPSRVP
period.50
DFP-AA
p.S45F
linefragments
macronodular
FSHD
Identifiler®
1d-3
MDS9
thiazolecarboxamide
568–phalloidin
~50–100
anti-P-Ser473
sc-2027
promoter22
Z20
5'-TACCCTGACACCAATCTCCTCAACG-3
D088
1900–1922del
.ECD
5'-aza-2'-deoxycytidine
Menin1
Recherche
predestined
.Missense
-26
osm
MEEBO
mTORC1/2
poly-HEMA
R290Q
121.8
TheGlu
z52
amplification.12
Manifestation
MINT1
GATA3-WT
MLLAF9/T2
31,32,139
5,45
PDE7
7606
R736H
5390
7–8
carcinoma,46
c.crrrl.irlg
.PMC
495×
6×His-ΔII-Flag
ΔG2
AxioVision
T49.2/T49.8
mutant–induced
p.H174R
.finding
G1160
andresistance
HDAC8
5′-ACTGACAGCCCTCTGGACAACAC-3′
D281
*P
1674
event.16
FLT3-internal
44-year
bicinchoninicacid
Rygaard
C‐tail
Cdh1-dependent
21K
ser473-phosphorelated
TTWINELELGK
DUSPs51
RS4-11
Kooperative
Thr/Ala
GIST.35,37,41
N/A
.S30E
tensin-3
Bcl-2/100
5′-GA-AGATGGTGATGGGATTTC-3′
Tophkhane
RealTime-PCR
med.klinik.uni-mainz.de
ACC344
Sawatsubashi
BRCAI
O-Glycosidase
18,21
Eight-point
26e
WT-counterpart
506–1132
50–178
HyperCVAD
College/New
1330-amino-acid
pGTB9
Zavadil
Amh
G602R
KMT2A-rearranged
Bundy
precleared
41:1
regions—residues
,25
3-8
Asp-927
ETV1-associated
ER-DNA
LsL
Δ2–156
.5
Ras/Raf/MEK/ERK
1.224
24–36
ifosfamide
SPD-2
TTAGGGCTTCCTCTTGGAGAAGATCA
polycarbonate
MANF
Ccnf
1-2/distal
Colony-forming
PDGFb
N/S
MZ-CRC-1
M173
pro­
full-length/
contemplating
N161I
Oligonucleotide-Mediated
manner19
0·098–0·458
inhibitors30,31
08-172
AnnexinV-PE
72R/P
smaller-than-predicted
insAlu
Pópulo
3.92–14.08
23105
antiPDGFRA
agarose/0.67
propellor
WT-Flt3-expressing
CDK8/cyclin
.Staber
IVS15-1G→A
4′,6-diamidino-2-phenylindole
anti-phospho-SMAD2
Rap1
pHA-Ubiquitin
48:352–361
total-SMAD1
FLAG–CLIM-1
MLEV17
5'-CTGCGCAAACTCTTTGTTCAGGA-3
SLC2A1
cut-like
HP205717
Dorothy-Gal4
type-D
probemixture
ligand-amino
lymphoblastoici
biotin-16-UTP
seleno-methionine
//pymol.sourceforge.net.46
FANCA-M4
melanoma-bearing
S17A
4.3–23.1
KITV560G/D816V
TEL-RUNX1
M1775K
L346R
.GTP-bound
FLT3/KIT
3×104/200
neurotrotrophic
M106
CATSPER2
Anti-PDGFRα
K-RASp21
.Rates
3′-AATA
.NKX3.1
RGC-containing
hepatotoxicity
LTQ-FTICR
Hi-Res
0.830
KIT-inhibitor
GT2
pcDNA/HA
GST–LKB1
TKD2
1i–k
AYins503-504
study17
Ser151
4524
Androgen-deprivation
murinefibroblasts
0.78
history.7
MegaCult-C
MK2006
lentivectors
57-106
drosophila
Beadlyte
Figure6C–E
leukemia/myelodysplasia
GluSer
NON_
F338
1.233
ΔID-F123I
phenotypes121
7F-G
Oudejans
.Blunt
E200
3623
CGCAGAAGTTCACCACCAAGTC
HLA-B44
MAXF1162
U87-EGFR
PDGFRβ12
IGR684
-CXCR4
hematogeneous
RP11-121K16
ERCC11
MAD2
FAS-induced
BRAFV600E/L505H.Figure
analysis.Rearrangements
IGHV4-34+
GGCAGA
2HG
Ten-j.am-thick
S668Y
CTGCTCTCA
microelectrode
furin-processed
pAlterMax-c-CBL
3.0-fold
NG_028922.1
PI3K-overexpressing
Panneerselvam
unpermeabilized
//www.ncbi.nlm.nih.gov/genemap/query.cgi
2.27
Minipa
tolerated.23
membrane198
OS—although
GLS
GAT
loop–
ARE-bearing
NM_028392
c.1370C4T
endoxifen
inhibitors.15
CreR
ARS-CEN
LGDel
.N.P.S
TATA-less
CD24+CD29−CD61−
analysisf
13•6
R485
Coats1
.Primitive
.Counting
HCT-116
T-PLLs
Ahmadian
.Prefoldin
GC-3
N581D
methylphenazinium
/pleckstrin
Shimodaira
1737
BKM120-induced
TGATGAGGTGTGACA
G478CBRAF
.Based
31–39
CX1
g.152,514,164_152,554,231del
c.111+15G→A
Leu206Arg
instability34,35
packs-year
published.12
541†
553GRC
okadaic
EN/IRS1/IGF1R
L515G
Kidlington
1,425
0-500
-1.9
GFRA1
L2427Q
**Protease
H1048D
Disease-causing
SRF-staining
101°F
Ozark
AJUBA-mutant
Asp-84
Trophilme
0.28±0.03
treatedwith
functions.8
g-globin
DT40
IVS40–1050A
GeneLoc
case,22
hypocalciuric
Lin−c-Kit+Sca-1+CD150+CD48−
NSCLC.31–33
diagnosis→acute
Fig.8A
α10
modules—are
chickenCAM
234-bp
33–5
PKBα
Btg1
Microdeleted
EMT-like
AmpFISTR
anti-ACTIN
c.2023_2025delinsGCCh
Supplementing
0.562–0.958
value=0.02
pLX317
H292-3127
gtaaacccc
-dCTP
PTPN2.16–18
seAnalysis
death-effector
Pik3caH1047RPtendel
Ligandindependent
60–36
KrasLSL-G12D
databased
≥5.00
Q666E
FLJ14235
1IRK
2125del126nt
1833
blanchable
TPR/
71/209
FGFR3-wt
1:8
OCDfl/+
majorly
¯uorescence
aetiological
p.H329P
pre-ribosomal
N-915
Untreated/treated
P43S
P699del
tonear
N655
3.1-p53G245D
linker-mediated
70,71,73
.D0
Wolverhampton
~52
Q414R
GAGTACTGCGTGTGTGGCAGGCA
.Oligomerization
C77
.Melting
C49S
1:500
sh_1
GGAGCGCGCCGTCCGCCGCGGACAAGACCCTG
non-English
endoderm-derived
HIF-dependent
re-evaluate
skincarcinomas
HSC/progenitor
CONTROL.
2-Q205L
complementing
FGFR1–TACC1
non-Hispanic
HLA-B*07:44
D161E
24.2
trimethyltransferase
c.1240C
Solid/MP
cells26,27
KSRKD
8Northern
Ultrasound
R0
M42-L
RJJ
1581
Manzan
Tyr1008
68-year
8×
PTEN/Akt/mTOR
ALK-associated
−732
257
pC53-SN3-H168R
JAK2-fusions
4:2:1
.T9026
cis-elements
previously.19,20
fluorodeoxyglucose
pCMV-FLAG
3741
T708N
pA308.tel
non-radioactive
R675W
6B4
pathway.43
CAAAGGGGACTTCAG
variant-containing
cycloheximide/chase
cytoplasmic-transmembrane
Hysterectomy
pCMV-β-galactosidase
mammoplasty
-CCATTGAATGAGACAGACATGACC
behavior.14
NLRP3
microgenomic
P183fsX225
intracrine
LCP
hgserver1
anti-p-PLCγ1
ubiquitylation-deficient
microwell
contexts33,49
155K
withTEL-specific
mol-
a-5
solubilised
.Scaffolds
mmdiameter
0.814–0.934
Fig4h
regions-1
Chr3:71015140
236–250
cytoxicity
Dokal
ZNF292-SYNCRIP
.34–.58
S222Q
Preudhomme
≥20×106
TCC-S.30
mixed-design
W-PDGFRA
R402Q
GFP/YFP+Mac1
test.ResultsCloning
PKF115-584
shRUNX1_117
hsa-miR-15b
normalFANCC-transduced
genes'2
20-ns
cancer30
R/A
noncutaneous
Gibco-Life
Y-error
Ex20R
PRKAR1A
GFP+/Mac-1+/Gr-1+
C-Helix
RhoAF30L
.SD
NCT00498927
2.8–4.0
anti-p70-S6K
MEK1-MEK2
c.766T4A
BRCTs
TAACTTAGATAGCAGTAATTTCCC
FLAG-HCF
methylpyrazole
tests.Overall
ashaw1
C96R
adenoma-cancer
-GCC
anti-p44MAPK1/p42MAPK2
mechanism.71
Galtier
IgM–IgD–CD27+
RVD
BAS-1500
NFMP-HPLC-based
13•
27/28.7
GST‐Q63L‐RhoA
Marinoni
NP_001193789.1
-Bcl10
31•
EGFP-B56δ
farnesylation-acceptor
34,43-46
YJ
//www.amersham.com
ICNI
OD
56/67.5
dimerization16
D208N
PBS-Hepes
G141R
RB1-promoter
Sui
R1/2
9452
c.6449_6450delCT
22RV1
types.17
diazabicyclo
−2.55
R94-P95insR
1.Effect
ATPaseactivities
CNIO
pmRFP-C-Raf-RBD
'Figure
DLC1-expressing
6.6NOVNephroblastoma
D197K
III-3
.Colocalization
Conc
no.
donors10,11
Lallena
77:623–628
RAS–mitogen-activated
417-419
antagonist188
report,24
daystime
48/54
Thr115
Biotecnologies
i/pI
melanoma.7,9-13
JHSF
P-C5
myoD
PI3K–PTEN
reported.28
CDK10/cyclin
GST-beta-catenin
Anti-PLC-Y
CE-12
Tbx5
1–360
Cul7
63Q
5′-GTGCCATCGCCCCGTGTG-3′
hostpot
sequencing.Affinity
.HSCs
activity.29,30
call-based
P123M
pH6.8
U1A
HA-Aα-P179L
32P-end
M13mpl8
mTOR-T4366C
pdgfa−/−
Petroski
Feshchenko
DOT1
Nontruncating
AML.44
.CCL4
C390
EHS
'poison
-1.5-1.3-XbaI1
types.32
EP300/CREBBP
samples.23,24
Q809R
specific-mutant
~500X
UBJECTS
05–123
ethanol-
R156C
1699Q
K-Ras-
9.6-27months
ConclusionIn
L297
α23
cytosol.35
1484
5′-AAT
Clínico
Erg-expressing
KIT-MT
PDGF-BB
'trunk
5.6-21.4
electro-
0.0279
EET
EGFR-associated
Codon
/NPM1-MLF1
Raspollini
BRAF13
T2384I
Axiocam
crypt–villus
,20
Danglot
activation34
216.4
DMSO-Sörensen
pH3+ve
15.5ng/ml
factorPMAphorbol
p38Jab1
1−5.8DHRS3Dehydrogenase/reductase
c.1155
anti-N-FGFR3
Pten+/-mice
RbAp48
MIN/
Phenotype/genotype
NCT01360554
Dihydrochloride
receptor-related
28–69
95.9
NF1-333
.014*
fin-
90/93
100–150
proteasome-inhibition
175Lys
GAP-stimulated
dipyridamole
SC203
20R
mutant-to-wild-type
5/139
E9.5–E12.5
Formedium
theRGC-containing
mice.181
S6L
259
.8692
A135V
T5464M
propertiesand
Fas12
auto-rotamer
232_522del
pCRAF-S338
CsH12C13N
30–36
K32/K29
gi55595712
4q28
c.74del29
TTGATTTTGGAGGGATCTCG
dE198G199
p2lc-H-ras
anti-GAP
-blot
71.1
Immunosurveillance
1134
K230E
LA-PCR
Fig5H
Huo
GCTGCCCCCAAGTGTAACTCCAG
Bialystok
ASC24
doi:10.1371/journal.pone.0025021.t002
30.39
Yin
eIF4G
Blaszyk
Ras/Raf/Erk
T131I
HSC39
Yescef
MMR-related
MagAttract®
10700
re‐evaluation
21/46
inhibitors62
GR.21
19–46
bRAF
3′-phosphoadenosine
cell-mixing
NM_001001890.2
Specht
pPfP
Fsh
L.B
2/45
9834505
A1T
anti-ARAF
tumorigenicity.31-35
speciesby
anysocytosis
4-10
.Hepatocellular
MDA-MB-453a
Cobas®
self-recognition
329.3
1.63
polyacrylamide-sodium
7q31–32
TCF3
primerswere
−4.57
H841
.Not
mutation2,24
S285I
pBabe-Puro-Myr-Flag
HCT-15/DLD-1
COSMIC15
Fgf-4
14/186
3B
H1464P
HindIII-SalI
TRAIL-R4/DcR2
EGFR/PTPρ
Andreassen
ex17
S602I
TCAAGA
cannibalization
Shot®
140–160
Cross-species
FGFR-TACC-positive
mek
described,11
Otolaryngology–Head
0.706
alphabetically
Cyr61
grey/yellow
oxalate
Dicer1wt/Δ-transplanted
QIAzol
leukemia.BCR-ABL
20q13.2-13.31
cancer,22
17q21.32-q22
cells/total
Constructio
DFGout
YCC1
A543
rates2
p.Asp215Gly
SHOC2-tRFP
Nucleofector™
Protamine-Cre
immunocytochemistry.112
His110
described30
Casola
402
/rtTA-and
Non-target
V166
Escherichia
MAP2K1-mutant
site-1
cyclin-dependent
A2-A1
osteosarcomatous
Epidemiology
lessonsregarding
phospho-RTKs
33-45
ccacagtgagtgcagttgtt
extracts41
0.84-fold
a9-Q209L
growth-factor-
Asn-354
Parra-Palau
Fig.7A,7A
residus
PSIPRED
.September
172K
p110δ
IVS16+3delaaagtg
876g12
studies.13
Seita
L747_R748
142713773
E909G
Ub-mix
L861Q
0/500
0.00077
Fig.10A.10A
MKP3
patients.45
S48L
Tet3-mediated
MEF2C-Activating
Abl-SH2-binding
kVPIKW
phosphor-AKT1
188-02453
Smad3-Smad4
gene.38
Y806S
≤5/50
Schwann/neuron
criteria.20
++30–60
8.06
ECR
embryos.39
NcoI+
MTX
ZNF198–FGFR1-mediated
Blatch
1A2
TE-II13
5′-TTCTAGTCTAGATTATGCAAACATCGATTTACTAATCTC
22-kbp
Cebpd
M12B
Δ419
non-reponders
deleterous
443–449Lasa
triple-charged
.Sakamoto
K-Akt-mTOR
dual-channel
Ura-cells
pGRR5-luc
phospho-p70S6
.Mgat2
ΔΔCt
∆N89β-cat
cells22
58-71
Smad21–195
130
p.H1047L
−1020
i..
CWS
.Characteristics
refine-
0-01
353504
pFB-neo
D8S1811
shRNA-expressing
KIAA0746
PXPtoSXS
-1/2
Zuidervaart
H194Q
bazedoxifene
Smad4-negative
5598-5605
Fgfr2b
3,611
Q90G
901
quent
c.942+3A
supplementary
12/26.7
1720ART
PPD-containing
lentivirus
vehicle-treated
acid/base
4LUC
chemoradiotherapy
CLB_Ba
wt-Akt3
Quality-control
2.93-fold
WHIM23
disabilities.19
repair2
I41F
.Non
1a-9
pulse-chased
HindIII-Xba
expression.23,28
pLexA-Ha-ras
GCTACTTGTTCTTGAGTGAAG
MEFs137
.LL
mtp53-V1
verniercaliper
.Boxes
1.574
highmobility
indoline-2-one
.Anti-B-Raf
T587M
T-cell–based
Anti-HIF2α
microenvironment.29
D17S1327
Wildtype
61-year-old
P292L
Asp1739Tyr
fe_
.5,6
Lindauer
WT-mutant
.00003
Ihh
sub-classification
BMPR‐IB
.8,26,27
227645
HPV4
PP58-sensitive
cholangiopathies.26
.922A4G
-TCAAAAATGCACCACAGTGAG-3
Myc-box
​Table1,1
7-week
QCapture
0.0002158
nS2
5'-CCCCTGGCCGAGTCACTGAA-3
androgen-regulation
pharmacodynamic
accelerated.48
9500
erlotinib
mRNAIn
.Piperidine
PGK-neo
E20.5
defects40
SacIAccI
Variation_43549
actin-cytoskeleton
anti-CD8–FITC
Y169H
5'-AGGTCACTAAGCTAAAGACT-3
anticorrelation
46-0705
lobe
GTGTGAAGCTCTTATCTGA
.Transwell
p85alpha
PMS2CL-associated
sarcomas5
beenintegrated
−0.42522
M947I
Dupont/NEN
gtaaat
Glu→Ala
p28
Swi2/Snf2
ref.24
pSG5TIF-2.1
recombinantp21
1909
Yasui
R204L
mRex
Genomon
5′/3′RACE
M/13
148×108
SeMet-containing
SJHGG027
.Histidine
.26444511
p.G116A
Thr18−Arg24
contextb
+0.83
sVEGR2
late-firing
TRCN0000195369
Whippany
Lambda-phosphatase
antisheep-FITC
2.0-kb
CAP-D3/condensin
response/resistance
OA-11â€
AD_REF
c-kit-mutation-
100-103
cccgggtggtctggatcg
8.51714175
non-interacting
mostlikely
clone.5
UnifiedGenotyper28
T-nuclear
Hetz
9E11
GAGCCCTCATTGCAAATCAT3
medi-
c-fos
Littleton
343.2
pathway.10-15
Sult1e1
Berzofsky
Tmprss2
S190P
p.R1893fs/p.D1894fs
.Subjects
.Documented
Bsu36I
N‐terminally
G47D
unde-
L1129S
Fempto
analteration
underdeveloped
0.1μM
55,268,937
genes.29
Primardaten
2/131
BAP1-deleted
Electrochemiluminescent
Array-Comparative
.Tet-op-Kras
IVS25+9A→C
0.1-95
.390
PSD1.1
.349A4G
51/123
animals.101–103
Welwyn
1The
high-impact
N–SH2/PTP–interacting
insC
KPMYEVQW550-557FL
DNMT-like
c-Jun-transduced
discrepancy.The
GGGCAGATAAAGCAGATAAT-3′
133kb
missed.We
CGH-array
His71
KLS
Montre´alHoˆtel-Dieu
Envirene
:Tn4430
2.1-Å
mesenchymal-like
-CGGCAGCGAGCCACGTGGACCAACTA-3
—suggesting
Nox4-targeted
2804
Mant-ATP
BACH14
nodule
p-MNK
F958V-positive
-TagRFP
Danesch
Trp
1.6-fold
gtctgtgcactggggtcaggac-3
42–79
Y846C
4043G-T
fragment/tumor
identified12
S325N
Tumor‐infiltrating
NIK-mediated
55·0
D52
degradation—another
non-aggregated
CAG/GTACAG
Pro12–Gly13
R337P
Ariz.
Hoschuetzky
.397
16,27
Zdzienicka
pDM14
GISTs,2
p.D419del
STK15-transfected
18:02
140,453,089–140,453,201
WEHIconditioned
Tricribine-treated
H878Y
4To
K164E
T526A
I153N
0.993
mediastinitis
GGAAG-3′
kinase–encoding
.Postnatal
100-g
3-base
EversusN
Pariety
RAS-RAF1
Del746/T790M
PstI/BamHI-digested
Between-study
EGF/MAPK
in-patient
539–942
established.13,16
0.002/s
101K
20–80
n.a.
134407748
6/14
signal-actiFigure
puromycin/ml
protein172
Xq26
5′-adapter
ACAGTAGCTGCCCATGAGTT
.AUCs
CP-VHL/SOCS1
a4
Ubf1
leukemia12
8811
of32P
NRASQ61L-mutant
A_16_P03169108
LAG3
TGC-3
p53-bearing
2238
Asp/Tyr
ZsGreen−CD45−Meca32+
pMT2SM-oligo+hp110δWTnotag3UTR
PIPKIIβ
0.5655
Nonresponder
Polyclonul
NRP-154-tTR-shRNA
14/21
oncogene.31–33
c.925C
inflammation-induced
additionalKITkinasemutations
WTMEK2
REL.7
C42R
Tyr1150
P399L
FSH
1523–1554
haematology/oncology
.10B
0.01/17
4.66–9.6
Ig-3
PP6-WT
TRCN0000000367
convertases
|/RIhkl
RNAi-dependent
genotype-selective
CRPC
WT-Flt3
dinucleotide.22
structures19-26
22-48
p.Glu81Lys
deficiency,5
Ad-LacZ
0.226
rS0rA*pLouAsnArgLyeAenL.ouThrTrpA
JVM-3
Asp450Glu12
F513
RTK-encoding
RPP2
Tet-mediated
381–392
Figures22
TGF-b1-induced
.Immunohistopathologic
analysisCytogenetic
malignancy.4
smallbowelGISTs
∗∗∗
promoter/CAT
E258G
Tzao
PA-like
161,214
S2-dependent
G778D
483-485delAGA
.lotka.standford
MEAF6/PHF1
slideThe
.Kindred
pBEND2
UTSW
pre-germinal
1aAspGl
Gateway-compatible
Rheinwald
methyl-mimic
~40-fold
G2a
inflammasome
:UASGAL4
CCND1-Luc
upward/downward
5V-GGTGCGAGGGCGGCAGCCTCTACAAAC
vivo.21
IKEPVSTKCDHIFCKFCMLKLLNQKKGPSQ
andconversely
EGFRΔ801
Clal
att
Cnosson
Shp2
time20
Smad-induced
L1982F
RP11–554A11
6-week
sc-260
4-Hydroxy-tamoxifen
PEBP2beta
22/218
wt-DNA
Hs03704252_cn
557–559
S52F
p.S768L
follicle−stimulating
12-spacer
−8.17
China-Japan
10966–034
Hypotetraploid
glucocorticoid-responsive
Collagenase-1
dichotomized
Fig.10D,10D
LPIG
5′-ATTTGGGTCGCGGTTCTTG-3′
ThermoSequenase
M1004a
lines30
p.Cys41Tyr
CCN
5'-GGACTCCTCTCTAACTTATTC-3
oxidoreductase-1
conusing
instability,33
c.811C4G
industrialized
P=0.0439
.Motesanib
2943R
comb–like
3.4514
230–1731
Blood.2000
391
p.D55Afs*2
GE/Amersham
MB4-3
2/13
20,5
-SCT
ofCAT
1713–1784
interactions.7
pErk/Akt
L479S
FACSDIVA
MyoD
-PDGFRB
360KB
RDA
.BioEssays
ACATGTCTGAACATG
1.2–46.0
D337V
beexpected
Thrap2
carboplatin–pemetrexed
hybridization.13
P=0.35
BX50
trp1-901
active.19
pathways—are
2275.3
attachment-independent
S365A
multiglandular
PDEF
p53V143A
Genetronic
GCATTATTCTTAATTCCACATC
MM.1
mutations.12
Genescan-500
simulations.19
EBNA1-1H4
MED13
5′-TTCACGTGTACTACGGCGCGAT-3′
5′-AGATTTCTAGGAATTCAAATC-3′
Vhlh-deficient
phosphoMEK
GST-RBM10
40–amino-acid
18F-fluorodihydroxyphenylalanine
damage-inducible
anti-Thy-1.2
ZAK-RAPGEF4—that
Orlow
SpectramaxM5
G187_E192delLAPPQ
Smad2-activated
perispinal
.Deregulation
Pa/3
irregularities170
221K
.Doubling
256.8
TGF-α/EGFR
HMTase
Torc2
.255
777
8,010
acid-Shiff
620
+73
FACSCaliburTM
42–70
anti-alpha
MRC1
pSV-3-galactosidase
GoldenPath
rare—representing
Mamillapalli
leagues51
Crk/CRKL
AR-activated
100−specificity
proportionate
c.1204G
JB12453
T-prolymphocytic
ERBB-targeted
Resazurin-Na
∼50–100×
.NBS1
24B
.2c
.S7H
AKAP8L
p53P177Land
TPTE
pET-32Ek/LIC
PARK2
cosmids
INTACT-2
transiently-transfected
Sto
self-reports
post-BrdU
.G735S
16R6
LNA-polymerase
−1.69
.Tnfaip6
0.815
LeGouy
1000µg
C-helix
G334
FBW7-BM-deficient
beta-TrCP1–beta-catenin
Topaloglu
4.8×10−8
high-fidelity
wasapproximately
43-
unampli
KIAA1967
HGF/c-Met
matched-unrelated
074-643
RAF-responsive
4/83
0.12-7.72Enneking
wasperformed
NCT01761747
*61
Mek/Erk
IV-15
RASERK1/2
20,79,102,103
mastocytosis.10,17
identityof
Asp162
wu93
homolog-1
Fbxo7
pp1
cancer6
-CAGCAGCAGCAA-3
Cornelisse
PIP2-binding
HSU63834
R444L
8/781
gene-corrected
p.Gln534X
.Smad3-deficient
0.712
.N-Myc
Metzgar
SVHUC-control
.Papillomas
interleukin-10
-Tartaric
0.00071
270°C
F279S
monomethylating
.PIP3/PI
trxG
neuroforamen
Figures2E2E
N1807
H3K4-specific
30–32,34,35
HCC1428
1803
.Ethanol
FIP1L1-PDGFRα–positive
HBCx-12B
GIST-T1/670
Cdkn1b/CDKN1B
Exptl
XL184
Tyr643
A2BP1
Y89
PPEMH4
.Disturbance
R6859
RPS6KA1
nM.23
→TTG/CAA
.Cross-Resistance
collagenase-3
cystb
Increasedproliferationratein
Dieude
Alignement
β9-sheet
258,308
Download
10/TET1
60900
Mantel-Cox/log-rank
and66E
component.2
Hpy
pFA2-Elk1
menin
fluoroscein
PANKMB
colorectal-cancer
005228.3
1,10,11
PTC-TCGA
5′-TCCGGGAACACAAAGACAATA-3′
communicative
.-
NOPHO-ALL
mutants.Finally
p=2E-4
286
.M
al.,21
average.4
Provost
CMML-1/CMML-2
BACH1/BRIP1/FancJ
gefitinib/erlotinib-treated
12.765
in-frame-deletions
A2–E2
dyspeptic
drug-imposed
adenoma-carcinoma
collagen-5α1
65Â°C.Then
ac-74
-dATP
c.2145
/hematopoietic
.S4D
53bp1
6390
desmoplastic
EFO21
.Dosage
5q31.2
.Monoubiquitination
S2A–B
immunodysregulation
Intra-cellular
/scatter
highrisk
SX53G
msh2∷URA3
A_51_P245895
neurotransmission
ProAsnAlaSerValAspVICIGyAspAspVaILeuL
1
WesternCTM
i.e..
KIT-mediated
.Sixty-six
Hes1-mediated
Assay—Geranylgeranylated
phospho-HER2-Tyr1221/1222
fifty-six
CCATGG
high-intermediate-risk
acc=GSE2466
.T
.Consecutive
S74I
activatethe
formation.28
fetus/
biospecimens
hMSH3.25
commonplace
0.3-30.0
–II
AGCACCAGAATCCGCGGGG
M55
gefitinib-sensitivity
I874S
trP1-Exon26F
GS3815
10'cells.Radiolabeling
RICTOR-mTORC2
56770084
©2012
p.D61A
.Statement
sc-30
electromyographic
LGC
UD-SCC-2
A286G/AAA-+AGA
Yamane
CD1A-
841–848
8448
'T
DNA.11−14
Ludwig-Maximilians-Universita¨t
1qpc
G1/G2
patients.2–4
.Efficacy
SRBCs
801-584-3650
tumours.Figure
WWTR1-CAMTA1
7.00
non-duplication
PBS+0.2
mg/twice
69
R1068G
RSPRY1
FGFR-mediated
R131W
.Mazzanti
yMet
EAAT2
docosahexanoic
GDC-0941/MEK
585-Pro
shGAT3_1
E1A-M
.Independent
A337D
**Hematology
BMP2/4
siEGFR-2
D162-S428del
T240M
Nxe
28–
4136−4151
5125
T674I-positive
26/45.6
6482
2028-37
ALL.23
12q13.2-12q14.1
NO1-CO-56000
KTS
7001
Kidera
Samb
TNBC
PDGFR-blocking
P=0.46
operable
melanoma.2
CD44-CD25+
Ki67+
5-fold
Lymphocytes/mm3
fgfr1ahuW671X
GGAGGGTGCT
2.764042933
Flp-In™
membrane-association
CAGGGGCGGG
PRDM1
-CCGCCAGGAACGTGCTTG-3
+794
p-PTEN
.S241F
B-RAF-dependent
.Supertransactivation
KITL540
5-fC
mTet1-shRNA-A
265380
.Radiologic
HD-0175
Z-2028-20
self-dimerized
18–21
Flag-hSNF5/INI1
5'-GGATAATCGTTC
Figures2C2C
susanne.schnittger
ERK-
M98509
IL3.15
FLT3-mutated
781C→T
Ribbio
E255K
Lats1-WT
.C-pEGFR
HNF-3α
5-labeled
N-CoA1
and2d
0·0005
E6-
DOCK180
W.R.
Asn328Ile
MSH2G674A
ER-associated
R482Q/+
p.N261Mfs*46
0.0036
CATCACCAATGCCTTCTTTAAGC
Czechoslovakian
quantile-normalized
contructs
c.544A
anHIP1
5.82
c.642C
SHELXS-90
ALL.3–6
TSC3
MHH-MED-1
P-ga-
system.Table
Q57E
2087
UM-SCC-10B
frodo.wi.mit.edu
hMSH6-den
Darman
Mutagenesis/Transfection
378C
synthase
DraI-PacI
HCC2218
Perturbed/reduced
V343A
Shimokawa
sticks/surface
pentaplex
Pde4a
TGFβ/TβRII/Alk-5
multiplicities
Bargteheide/Hamburg
pS/T
Cuffdiff
1723RGTPI
4µm
Ets1/2
.Knock
Rieckmann
1.3–9.5
OA5D5
0.0983
P.E709A
75570
trimethylsilyl
3.465
9.84
TetOff
vemurafenib-mediated
GIST430
heterodimer70
Shalapour
Ignyta
cm-diameter
activation.9
.422
.GAP3
1120
L44
YM-10
GAL10-MSH2
N-truncated
KIT.11-14,35-37
p.I220I
.555
GST-RAF1-RBD
Ranuncolo
MAR345
4,6-diamidino-2phenylindole
1.07–1.77
Brussel
CCAAATA6TTAA666ATC6AOACAT6TAA6CA6CATCAT66A66TT6AA6AT6CCSCATT
7418
Growth-promoting
assays.17
190-
IC50≤30
2095F
S131L
RUNX1-46F
.EMT-associated
residues/
PreScission-
dual-role
BRafD593V
phosphatidylinositol-3-kinase/Akt
ΔASSTT
KIADFGLARL-
S7-
Wappenschmidt
19/17
c.5559C
5′-GACAGCAGCACCGAGACGAT-3′
RSV
ACVR1WT
coimmunodepeletion
F130C
cRAF
AKTI
LL03
9.8/MB
Nf2-depleted
0.6.1
plating633
China.1
PTCLNOS
tonic–clonic
ψKxExxSP
1.FGFR1-CEP110
BertholdTechnologies
I2627F
c-Abl
transcarbamylase/dihydro-orotase
.0942
VH1–H7.111
-UTR-targeting
kinased
NeuT-induced
p2–3
relationship.12
ERS
KIT-amplified-only
.Anti-RET
underdosing
z-direction
focus−formation
Tyr-516
iCycler
upon…
macroglobulinemia/lymphoplasmacytic
-516/+63
1198–1530
BIRC2
52.8
IKIP
MG14F5′-TATTACTCGAGCCCACTCCCCATAGCTGGTTAT
EWSR1-EP300/CREBBP
mastocytosis.67
PI3Kα-dependent
40,46
B56α
Saksela
R744P
SD=0.99
Tsurusaki
anoikis—apoptosis
3/85
5'-AGATGGCTGAGTGGGTAAAGG-3
.Exponentially
0.0239
.Ligand-bound
23/−
Wnt/β-catenin-mediated
20.
Panc-28
interdisciplinary
pneumatoceles,3
ultra-deep
structure.html
temozolomide
250
ATPase_alpha_beta
G426W
301-562-9870
Imatinib
oligonucleotide-binding
000000100
.Updated
Exonic
eGFP/dsRed-tagged
N771dupN
GCAGGGTTGGGCCTTACAT
D647N
Xf-Xobs
Capriotti
5′-TACTCCTCTTGACCTGCTGTGTCG-3′
nuclear-soluble
Y293T-positive
16.28
v−src
neocarzinostatin
4500
CyclinA2
D12765
GPR27
1,833
IFNγ-mediated
Sequitherm
flag-beta-catenin
doxorubicin-induced
Cotterman
115-
p.N71S
TGCATCCTGCACCACCAACTG
ARE-linked
protein–coupled-like
Nr4a1
Q62P
aglycine-to-aspartic
E320D
DR100-103
ofPPARγ
D1-T286A/CDK4
XG11
sc-10236
lossof-contactapproach
NA3VO4
determined.40
mycoplasma-free
~2000
TrkA-containing
formation.Figure
Papillon-Cavanagh2,33
ng/dL
means±SE
ditags14
Visani
4EBP1-4A
22q11.23
Hepa1-6
Pathogenic-or-not-pipeline
AATTCTCCGAACGTGTCACGT
ITGA2
mRFP
works37,38
14-3-3zeta
Cdk12,14,15,23,34
GTTACGAGCAGTG
D1125N
bromide-containing
Â¡n20
pathway.16–18
pectoris
HCC2157
❚Table
frameshifting
D1/CDK4
92•
3KY2
23–34
combinations.30
c/t
ClustalX
Hogan
OptiMEM
CD69
transcription13
Arg-175
344–349
Break-Apart
.AML1
TFE3-positive
30345
52–71
6508
chemi-
box-bound
src-related
000249.3
develops.27
validation/identification
erythroderma
alower
peptide-mapping
binding/RNA
R37348
promoters.We
homeostasis153
models.40–42
body,52
Lgl
pyridoxal
Ser428
C3orf10
antiproliferative/apoptotic
TKI-based
/ARF
Cys673
b-mercaptoethanol–10
FLT
319–358
K1724
Kras4b
cycle-sequencing
vaccine-based
tissue.6
34718
Thr315-to-isoleucine
e10.2
Akt1−/−
ThrMet
~~*
2,840
Winglow
Gosselies
-132t/a
simulta­neous
variant8
probeset.csv
pY751
1/300
c.870T
Antibody-
S1651P
YB5
TCATACCG
//genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html
midkine
Sosman
Urethane
Gly-X-Gly-Lys-Thr
Q181P
Tmax
Doxycycline-treated
16803
protein23,28
MethodsPatientsPatients
Domain—To
GenBank®
His55
R304Q
subgroup.18
phakt-1/1
*Top
oneach
TpN12D/WT
re-extracted
double-mutant
1240×108
AP2A2–SBF2
ipTree-Stab
p.N717V
-Hh
eosinophil-enriched
immunophenotypical
single-agent-targeted
proliferator-activator
Fig.3B,3B
N-linked
c-Src-T341I
susceptibility22
BPV-1
crizotinib,28
HP209446
NSPK
IH
595-residue
20°\C
4.Inhibitory
−4.47
v-Ha-rav
Henrique
orhelix-turn-helix
manyBRCA1
+−/−−
serum/5
P.R
CIEMAT/Marcelino
werealso
postlactationally
AR3-
c-MYC-induced
Caltag
RAC–JNK
PLX4032/RG7204
++/+++
100µg/mL
Y1253D
carboxy-methylation
Ohuchi
GSK-3β-containing
A149P
24-Well
PT08
M221T
Trak
AY312055
Africa.27
CVCL_0063
24,48
PKCα-dependent
.Amounts
pLTiTSA
-202
INCB18424
state-wide
p.Glu2798GlyfsX11
BRIM-311
c.670C4T
phospho-acetyl-CoA-carboxlyase
sulfate–
Wuhan
LEO1-SLC12A1
Cross-correlations
Gastrointestional
migration-stimulating
RBM5-mediated
screeningMolecular
//www.lovd.nl/3.0/home
UXS1
TACGCGGAGCGTCGTGAAAACCAGGACCAAGTGTGCAG
Asp835Glu
anning
+31
trithorax-homologous
rs1800057
GCCCCAAAAATCTTAAAAGCAG
ET.E
13/18.1
G595R
8.3–28
CTTTCTCCATTTCCAAAACC
Endoribonucleolytic
tumorigenesis.The
dehydrogenasedeficiency
Meloy
ROS
5′-ttttccctaagtttgtaagtagtgc-3′
Menichincheri
P525L
Dafna
2484
167–184
n.t/a.a
ultrasound-guided
34.
P=0.048
7622
170947
Z29078
T150.2/T180.1
Scheid
TK3
1018A
.S1B
1−7.9FLJ12684Hypothetical
probe-positive
lysine-97
formula51
DOT1L.52
CNX
.588
and6C6C
2245-2252
600g
patients,44,45,58
.R177X
lymphoma/B-cell
1KZY
dedifferentiated
HPA028409
.Synthetic
702
Wolfermann-Naºgeli-Stiftung
described.23
9763
c.1796_1800del5
F31S
GATC
0.22-μm
NCCN-AFIP
subtypes59
29230
T654M
arginine598stop
Smad3-targeted
c.226C
H1021Y
c.517-c.546
IκB-α-wild
GST–rhotekin
00256-5
Preimplantation
ADE2-based
5′-TGCCTTTTTCTCAGAACCAAC-3′
AITL5,9
flk-1
-3-benzimidazole-quinolinones
V-phycoerythrin
Medium=2
31,884
MSCV-EB
R1881-induced
K-12
Calu-1
mCerulean
pathways22
10m6
Dijkman
A207S
Q11R
.Spleen
.Dysfunction
TopHat-Fusion20
5'-CCTGTGTCGCCTTTACCACT
nonhydrophobic
Xtnij
PDB-code
Mx1
2.263528067
Juo
Pik3c2a
nonapoptotic
kinases.1
melanoma,11
flag-mutant
rtTA
PanIN-PDA
28.9×
5|
L–P
Brca1FH-I26A
1996b
firstdegree
damage.In
HERV-K_22q11.23–ETV1
Immunotech
P53−/−
BRCA1,6
previously,4,5
ambiguity-driven
Fas-resistant
PmlI
FMA3
Smad–
017590
RNaseOUT
R6816
D47Y
anti-phosphorylated-Akt
TGGAGCCAGAAGCCTTTATCC
15/25
myr-Flag-p110α
Saucedo
QoD3
T654I
activiBinding
Wortzel
.Cocrystallization
MPL-W515A
STAT1/3-responsive
KIT-WT-expressing
thought.Third
2450
596-721
Hsp104–GFP
cancers3,19—besides
far1
XGRAIL
amplifications25
largesized
MBD2
0.01308–0.1377
4–6,8
anti–β-tubulin
90.4
carcinoma60
pBabe-puro-GATA3
N-Cad
S192Y
7104
CML/chronic
-TGGCCCACAGAACGTGGAAGTCGTAGACATCAGAGCC-3
CTD-3242B16
Hirschsprung
FH1453
CdotA
Submicroscopic
GSDB
MITF-high
immunoprecipiate
Jag2
oid
-GCAACCATGCACTTGAATGT-30
Sir2
brain.1
4.FIG
Hec-6
2GQG
HercepTest
dimethylaminopropyl
Trr-Lpt
.509
1E478K
mpi-dortmund.mpg.de
elegans.33
Cui
C−
BtkT474M/Y551F
D5S23
digestible
PD20L
Cyclin-D1
S56I
1.226–2.450
65+38
5′-GTGCCCATCGTCAACCTGAA-3′
greater-than-wild
d11
anti-CARD11
S100−
TUBB3
TOP2B
65.6
Low-Grade
MYC–PI3K
Perray
.SLA.PKHR
70–116aa
2-amino-3-benzyloxy-5-arylpyridine
14-3-3ζ
trifunctional
flair-associated
contentious.14
N549H
pathway.2,3,49
0.04
Solvent-exposed
∼3.6
Froggatt
Thefull-length
E137*
.Mass-spectrometry
leucine–alanine–proline
.Lay
AtmKD/+
BIM-deleted
,32M
D47N
.Situations
CasitasB-lineage
105cells
vardenafil
9–59
104-2
p.R537C
'tower
7218
0.98–1.28
MPD/MDS
Pho4
TGF-β-induced
10-μm-thick
.011
5′-ccgctactatgccatgatgatcctcaagaaggagg-3′
/1R8U
v5111
35S35S
S1613G/M1628V
T1100R
V203A
lectin-
SNVs27
Asp-289
T.P
passenger/passenger
differentiation7
63,75
red-stained
2I1K
122K
LDQILLCCVFVIMKIN
Intravasated
KDR-negative
TRM-transgenic
.Basophils
v-erbB-induced
chymostatin
genome1
damage/repair
CI=1.59–12.36
ALK/EGFR
distal-only
.Y1252
.NOTCH-1
pE3-WT
cell-cycle-regulated
RG-5T
TDT+
D300H
PatchDock
13min
miR-21
//www.sanger.ac.uk/cgi-bin/genetics/CGP/genotyping/lohmap
.Agonistic
+/Moderate
TGF-b
PU6
TET2,11
.Keratinocytes
//searchlauncher.bcm.tmc.edu/
EGFR–afatinib
28009
pVHL-bound
RB,51
m~
cytometry–based
∼145
PDAC—alone
tyrosine-dephosphorylation
S215L
640-fold
shMyc-1
~sixfold
D.G.V.
1,653
Veenendaal
.0143297
ETV6/TK
139-011-9933225
.Golub
2266A
-particularly
1929
macroseeding20
anoikis33
-HRAS
Overactivated
CEP85L–PDGFRB
R206C
0.857
'peak
andprostate
avidinbiotin-peroxidasecomplex
siRNA–transfected
tuber-like
streptavidin-coated
Rivlin
Ileuma/35
A,63
pseudoglandular
cases.20
EX1R
Goh
S1709L
452ΔC
33/40
Ci/
ERRFI1
afragment
E3
2-causative
c.3124G
660-8511
two-well
committee.4
XXXIX
oocyte-specific
Clark4
NTRKs
mg/
phospho-Tyr705
sc-131
modifications—phosphorylation
R485H
non-MLPA
.5E5E
116-118
UN8
genotoxicinsults
periods23
b-catenin
3923
luciferase-coding
CricketGraph
T7-tagged
Granta-452
//www
1:12,000
CD32
anti-Bcl-XL
Sequencher®
.VD1477.0
gion
unreacted
demethylated
Ly6A/E-biotin
RAD25
Shorthairpin
NS-type
conserved/invariant
920–930
NetSurfP
Megakaryocytic
cells.66
AVI-4126
nihms774093f11.jpg
5.1646
EDTA-treated
schiba-t
D400G
KLRELCGTPGYLAPEILKCSMDETHPGYGK-EVDLWACGV
S310F-expressing
2.12
expression–based
DMC1
39A
Deubiquitinating
50y
m84-7
FGF-3-speci®c
q21∼22
CD19Cre/+Ezh2Y641F/Y641F
D5S188
FoldX
3q36
S881L
P653L
p.G13D-mutated
Bretschen
PTEN39-403ΔAS
32-81
CML11
theglobal
COBL-SEPT14
2.2-11.1
membrane-cytosol
IKBKE-Y88C
6‐99‐006
specificprimers
anti-Tp53
.173C
1072–1080
glyceraldehyde-3-phosphate
X.C.
E30D
therapy3
NCT01011439
c.2962C
ConsensusClusterPlus
Wt116
Pb.PSE.EGFP
antiTotal
CMP-SA
JAK1/JAK3
II-A
Fbw7β
alpha-1
78/m
CATTTGGATGCTCC
agar/agarose
NCT00266877
R216W
S255
BSG
E109K
R352G
pBS
S-Adenosylmethionine
R748K
,0.00003
2i–k
R2625
54.2–56.0
p110α/p85ni
Ctsample
phase-contrast
diexpoxybutane
20del
side-by-side
Steensma
F1218I
p.Lys1197Arg
.Neratinib
SRGAP3
ANBL6
X863del
HER2-negative
K204E
Ptf1aCre
miR-15a/16
aff
.21,22,36
transcription,8,9
T174D
HLA-B*5604
A.7.5.1
apoptosis.11
4.Another
11B24
hMutSα·heteroduplex
R.D
.Universal
8B-F
CD8−
CGCTCAGG
RAF1-stimulated
8,425
ar-
disease.10KLK-L4
TrkA-specific
estab
.ABCB7
.Potentially
IV:31
PC/BCP
Biopsied
EBF
N546
Pab419
tumors.6
UPIII
KRAS-overexpressed
Rel4.8
promoter23
MDA-MB231
Marková
​and55
Shp2.We
5′-CGTGGGGAGTCAGCCGAATATACTCGGAG-3′
trafficking
gate-residue
9F-2
tg/mlfor
pGreenFire1-
ETV1-defined
5.9.
RKIP_E4_F
disuccinyl
ATTTTCCTTCCGTGCTTTGA
theMutSa
meningothelial
1241
anti-p-ERK
ID-Affected
c-KIT/CD117
C-g
AP4
GYRRGAKKLESSEENLSSEDEELPCFQHLLFGKVNNIPSQSTRHSTVATECLSKNTEENL
3.5-
R309STOP
swissPDB
1.313-4.330
TCRγδ+Tcell
p-iodonitrotretrazolium
BspLU11
3:00
87-bp
high-occurrence
IVVM
Y588*
kinase-substrate
T232P
pathway7,8
outer‐cell
HCC–iCCA
plate-reader
A803V
post-abiraterone
hit-tables
24–26
study.5
300,000
Arg772Trp
Timaru
.2303G
−.89
93.1
refGene.txt
PIK3CAI391M
YFP-
cMLH1
Arg-392
P29S–overexpressing
GNNYVYIDPTQL
wt/–l
hMOF
.Superficial
ERBB1/HER1
incorportation
5′-CACATCAGAGTCCTCGGAGCTTCCTGGACTGGAAGTGG
borealin
reoxygenation
D351G
140â€
pCMV5-ETO
9.2±6.5
24/55
20/63
GOS2
19—26
Tyr102
A752PR
Bressac
.Filterplate
NPM-ALK-expressing
Smad2-deficient
V:8
Ex2
EJM
.SMAD
N10Y
6–exon
1,396–1,863
Elf3Δ173
Ig-2
antitumor
phenol-isoamyl
278700
TTCAGACTTCAGACGCTCCATGCT
Leu230Pro
1,862
Sangokoya
TRAF6
Pz
1–727/K105A
RU39,411
6997
-R335X
No33
EGFR-TKIs.2
pT81
B6
atgtggcaccatctcacaattgcc
DiGiovanna
EWS–FLI1
coinfected
PGKRKKEMTKQKEVP
RAS–C-RAF–MEK–ERK
cell-sorting
p.A1320fsX6
Tenovus
0.98–0.1.74
Q=8.3×10−7
.Kirschner
C618R/E543D
A_51_P301394
37A
abdomen
glucokinase—also
IGFBP-2
MLL37
18,100
oncocytoma9–11
patient-derived
microdomain
875–882
SA3–100
cancer16
OST32815
tansfected
31T
p.T402HfsX29
energy-based
Fig.4E
KRAS-Ex2Fwd
receptor-proximal
pCycDlCAT
p27/stathmin
8044
FLT3-D835Y
TSC-mTOR
.STAT3α
P=0.033
immunoprecipitated-MET
R7122
385-424
MyoD-site
.Fig.6D,6D
Ho2
17.4
QX200
1–33
1:700
a-PLCg
Fasc
suspectedthat
Met-kinase
.Felsher
181G
S-transferase-PTEN
213183_s_at
NF-κB-regulated
TCACTTGAAGGATGGTAAGTCCT
n=27
Dunaief
immunoprecipitationreactions
t123
SS32/36AA
hands/feet
4/30
RNAi-rescue
|200
m/m
-7-Oxozeaenol
c.365A4G
Mab
SJNB-2
GACACTCAATGATGT-
1SHY
JSI-124
readded
EGFRtumorsandcells.A
WHIM24
L.C.
p53KO
Aza
Predictor
MNG/PTC
proinvasive
7523
WW-PDGFRB
Metastastases
B—Multiple
favorable-risk
TpA
kb-upstream
TRCN0000040126
Aicda
DXS6673E
pKT-NLS-encoded
T7816
V555__D572del
NTRVGTKRYMPPEVLDIâ€¢
/1.0
8-MG-BA
fN
Half-lives
.BAK-p53
H3K4-trimethylating
44-1722-
P15
MAPK8
p.Glu501Lys
FcγRIIB.203
ACTCCCAGCCCCTGGTATAG
0.01–1
Arg335–Gly356
Andea
47.39
SolSNP
Reed–Sternberg
DQB1*0304
20x
Anti-human
staurosporine-derived
alone1
response.90
Arg1
models132
RG-17
D100N
Vitro—To
8q22–24
nontransfected
large-cell/anaplastic
FPD/AML-DN
.Berendsen
TCF-3-activated
pK125E-FLAG-Rev
CRu
laevis
Egfr-dependent
.MN63B
katharina.wimmer
7.3:1
RGARKQKFQSPLL
+86.21.5080.6722
FGFR2N241Q
Interethnical
AR-independent
extrafollicular
Sequence-Based
M18T/K
-GATCAGATCTCAATTGGCCGCCATGGAGGTGGTGGACCCG-30
RPTP
DFc
598C→T
NR-24
cofilin
metaHR
MG-B2GFPΔ3263–3270
A_51_P421418
divergent5
GGGTGGGAAATTGGGTAAG
Invasion*CellSN161
del55
tk
.Over-expression
NOMO2
c.1961delA
1597
CCL2-dependent
valine-560
CCATCACCATCTTCCAGGAGCGAG
al,21
noncatalytic
ID-independent
GL-7
ARN-509–resistant
liberate
61–81
C57BL6/129SvEv
RC-DC
glutathione-S-transferase-cyclin
S2.2
Sx
Raycroftet
S891
cancers.Therefore
expression—like
tdTomato
hbrm
pRS414
~and
JM-PM-expressing
endocannabinoids
RET/L790F
LMPPs
intestine.32
.A004
2265-16
Noncancer
Chuang1
303-1863
No.of
retards
1/2/3
radiosensitivity
long-term
demethylation-specific
AAGGACAGAGTGTTGGATGGC
vitro,17
NB-
K~TLTKAKTKLEQQVDDLEGSLEQEKKIRMDLERAKRKLEGDLKLAQETSMDIENDKQQLDEKLKKLEFMTNLQSKIEDEQALM
EDTA/0.1
K110R
GCN1L1
−0.09622
58–60
IML
GSE22075
Y=pyrimidine
pVHL-associated
1.08–3.76
CH12F3-2A
5/543
Cd83
1780del3
Linkage/semi-quant
M165L
Ras'GDP'AIF3
AIF-dependent
317
Ser2Ala
unpredictable
39,40
1:1/1:2
2A-B
humans,12
macrophage-depleting
CDK10
0.500330471
Asp572
pre-B/T-ALL
pGEX-5X-2
hyperphosphatemia-mediated
ligandbinding
hypopit
cryo-cooled
H3K27-methylated
Brain-specific
-vismodegib
2-20
LC_S23
TATGAAAACCGGACTACAGG
first-step
13937–13944
Hs766T
overduplication
//circos.ca/
lqâ€
S3.2
J.-C.N.
P=0.0063
eIF-4F
RecoverAll
algorithm24
n=75
kinases3,4,5,6,7,8,9
H322
endocrine-response
73/73
HCC2185
ofeach
A2717S
R/P
1/68
dyssynchrony
//doi.org/10.1371/journal.pbio.0050109.g005We
μg/l
Egeblad
values…
0.03-0.32
CDK-mediated
GPBP1L1-MAST2
AFF4
70-4500
study,11
−2.43
Let-7c
5326delTb
Kastan
1,504
T47Ds
STAR.21
acid-primed
SC215711
RP11-79A23
1:1.3
D17S808
//ggplot2.org/
R408W
tel/PFGDbR
Hsd3b1
KOAc
.French
1264
158,823.0±14,900.0
1.106
GAAright
N1178H
antibodies.Antibody
5′-TTTGCGGCCGCTCATCACAAGACAAGGCAACC-3′
norm-
pim–targeting
coherence-transfer
CFA4
Pathologists/American
GRB2-associated
SEC16A-NOTCH1
pASZ11GPD-TRX2
oligodeoxynucleotide
D2412H
vemurafenib-induced
.7A
131G
101,622,464_101,623,969
screening.4
agonists8
.Except
heat-activated
L155P
chromo-ATPase/helicase
5253
R353C
WLDLS
postplating
BAF3-p85α
~0.31
Ras/ERK
tumorigenesis.1–3
GSE83221
analysisTotal
.S.D
64-95
CDH3-forward
A459V
atrophy-related
0.99
503-494-6834
shownin
1090A
1U46
35S
R129C
carcinomas3,4
T.C.
anti-ErbB3
≥12
0..
Ikenoue
Odc-blockage
Takle
light-microscope
Speleman
E147K
526–655
//genecards.weizmann.ac.il/geneloc/index.shtml
TCAGATCTCTAGAGAGC
742
220
.Stress
B01
EP-transfected
molecular-weight
TCRVβ21
SU11274-resistant
Brdu
D17S841
mild-to-moderate
µg/l
2MB
toxicogenetic
Topo-cloning
​and3B
p.Ser315fs
40extract
1.515
Lys-48-
cases.Copy
BRD4–NUT
.NUP98-HOXD13
Luminari
High-salt
AML,18–23,28–39
350
cudhcrin
type/mutant
V565I
H1382Y/D1384V
HER2L869R/T798I-expressing
/P
48-nucleotide
13,16,18,19
3BBT
extralarge
oxygen-dependent
concomitantly
pc-GATA
pT1N2M0
Whsc1−/−
dendrogram
development17
transcription-polymerase
peGFP–C1
through-bond
phospho-HER2
Promyeloid
Krongrad
mTOR-dependence
1.Multivariable
FGFR3-IIIb-S249C
delA859-L883
490,862/22,496
allelesbearing
Stroschein
Pro402
cell-penetrating
b-cat
2.6nM
.CCAAT
C41S
MMR-gene
intron10
Y585KD
24,29,30
empty-vector
.immunoblotting
pgk-NEO
multiplate
32/69.6
RNAse
4,191
.Ouathek
PCR/
ALL.3-6
Magenta
activation58
kinase-inhibitory
enchondromatosis
FSP
JM-b
methylation98
−LW
HH3
lines.97
R2110W
39/CRC
MNT
regulation.18
DCP1A/SACM1L
pimozide,16
1596dupT
s/60
logN2KlogN1
SRp40
fx/−
GTCATCCTCGATGTCCAAGAGGTCCTCGTCCTC
NFAT-calcineurin
alleles58,59
V186.2
X-gal
EIAFno.1
c-maf
expression.12
PDE4D5
G6
11,23
WWP-luc
MycoScan
H1-RNA
TEAD-dependent
I3M
//snp500cancer.nci.nih.gov
12,986
HbA1c-values
CTACAG/gtatgg
//atlasgeneticsoncology.org/
15:27
immunoproteosome
Asn822Lys
c.1807G4A
cdc20
X‐ray
under-estimated
−2.13
3A4
Canettieri
spontaneousin
7C–E
milii
350.0
JmjN
STA5A
proteasome-related
cis-proline
studies31
heterogeneity2,6,44,45
TRANSLOCATION
MCF
∼17.7
VEGF/VEGFR
1916
P=0.0006
Mac-2A
Gewinner
ARBS2-1
N-glycosidic
D14
15/701
~66
proteins.3
BIDT
sAML—a
226
electropherograms
Proline-rich
www.lovd.nl/MED12
A300-996A
unanimous
.AJUBA
pac10Δ
4722
MT1-MMP
Ureta
dihexadecanoyl-sn-glycero
.P261S
5672ins137
reintroduction
-D.
135.1
.Pik3caH1047R
14-3-3
glutathioneS-transferase/Igα
morpholinos
R173H
2.2–186.2
events—not
5492046
pTM898
instability.13
16107
S494AC-RAF
Olzscha
mC-KIT
harvard.edu
3,4,63,65
Chrencik
p.N822I
11.1-fold
adenocarcinoma.4
N54K
CDK4,6
glioma,1,2
.NM_130398
gene.13
4.0e
M.A.R.
CNR-CIOS
I24N
proteins33
P19
ARAFS214C
Boersma-Vreugdenhil
≥60×
Anglo-Saxon
fluorodeoxyglucose-PET
NXS/T
R118Q
KL-dependent
K319
reports22
Chr6
Choschzick
~1.14
primer—5′-ATGGTCAGCTGGGGTCGTTTC-3′
pBabeX
WM3130
construct14
F70C
leukemias,6
Bunz
1116-1118
RasGRP1-specific
distance5
non-uterine
BRCA2-positive
β-catenin/GSK3β
c896-897dupTT
B06
BaculoGold™
sc-8410
seborrhaeic
t→a
Tris–EDTA
RP11-19I2
Antigen–antibody
CCND-1
Coffin–Siris
5′-GAAGTGAATGTTGCTGAGG-3′
Phe-691
mIL-3-
cDNA-deduced
RasGrp1
Nakalai
.Driver
DelBove
7–21
NRAS-independent
N1475
DSS550
Elf3ΔN270A312P
sulphate-polyacrylamidc
VTEKN
Laboratorio
3238G
hematologically
G-361-E
wetested
disulphide-linked
highest-risk
6348
clonotypic
FAS-mediated
bexarotene
5′-TTCACATATTCAGGCTGG-3′
GISTs.48,118,119
cofractionates
32-38
gene.1
My10
Selivanova
/BCR-FGFR1
BIMEL-BAX
-Phe244
M3529
005610
subconfluently
Inconsistencies
S1PY
positively-correlated
EBNA3C
3.3-kb
post-SET
GLU
CATTTGGATAGCGACCGCA
LFS-like
prezygotic
OHTversus
Rodriguez-Lopez
replication11
five-tier
IVS6-3C→G
hShp2
motifs—C
si08-resistant
RD‑N
IVT-HIF-1α
FLX800
AML-BFM-98
Fixed-effects
HumanHT
exon.23
NBG12
andSalI
D-2-hydroxyglutarate
BEL
R15I
B-Raf-MKK1
cancerrelated
Kaleidagraph™
non-immunospecific
SPG8
keratohyalin
1466-1527
fied.27
C-treated
STOP-GAIN
doi:10.1158/1078-0432.CCR-08-0533
.TCF4
Smad3N
horseradish-peroxidase-conjugated
23‡
1.40-fold
Cdh1/
-ATPases
51D1
USA18
GBP5
Welcsh
signalling93
sequence20
CODD-contacting
patients.26
mitogen-responsive
l-arginine
.IKAROS
His-Cys
also—at
3-5
NM_005343.2
modular-substrate
.Facial
9.724
4q7
pAMPK-T172
G27R
1·8–42·8
946-952
polyethyleneimine
OSE-derived
N=114
blasticidin
/not
Piechocki
aminoterminal
R625H/C/L/P
PC4
CFP-AFFAQLQLDEEKGEFL
TGS
T2589G
Ala368
mice44
1500mm3
3,3′-dithiobispropionimidate
other47
FGFR1–3
.Kernel
literature.15
P,0.0166
-serum
Mof
sub-divided
HER2T798I-induced
7/447
−8.94
1YY9
anked
.RefSeq
steroid-dependent
CSF-Met
.Chimera
mutations.13
39-year
Rbx1/Roc1
Moniaux
double-hit
tungsten-carbide
​andb
Gene-level
.V
MPLW515L-negative
transcription-
4377
CD38-CD21-
Thr157
increased.13,14
54-fold
MEN2A-RETC634R
¢gure.The
5′-GTCCGCGAAGATGACAAAATTG-3′
16056
S1A–B
IVS38GT53
LSA
108D2
38-mer
5′-CGGTACTTGTAGTTGGGGTGGTCGC-3′
kD.26,41
DTPP
PTEN–p85
FPD-affected
ubiquitination-dependent
.SUFU
NM_005228.1
0.75–3.31
5¢AGGGCAAGTACGAGTGGCAAGAG
MYC-2
10.4
A597T
patients36,37
involved16,17,18,19,20
R334G
Sox8
ZNF652
marrow–biopsy
red=SR
.FFPE
survival36
S4K–M
bcl-l
70ng/mL
.Caspase-8a
pmol
well-preserved
D22C5
Gab2.22
Fii
Tumor-expressed
expressedmsh2p
v.1.2.4
Thr417Ile
csiitoy
non-dox
non-native
respectively.27,39
.Nonsynonymous
HD-LEC
AAH05517
CDKN2A/CDK4/CCND1
non-fibrotic
HER2-targeted
-d
684–689
T827I
A33-antigen
Fapbl4X
Venkitaraman
equal.22
Pindel83
syndromes.21
5′-CAGGTCAAGAGGCAGTTTCTGGC-3′
N-segment
cases,10
ERG-Mediated
Legall
265-residue
AP-2
R49C
205-250
61–88
00U
well-ordered
DNAbinding-
development31–33
G106_R108
phosho-p44/42
signaling/transcriptional
erbB2/erbB3
HNRPA2B1–ETV1
1:450
death-1/programmed
jmtiestrogens
deprivation.42-44
previously.17,18
19–62
5.4
Giemsa
UC-derived
Hiort
HDAC1/2-containing
Oka
SUMO-activating
Co-occurrence
10E5
2.Measured
-BCOR
E762Q
801C
RI-1
Uyttenhove
DAPI/Cy3
98.6∗
PLEK2
M114
ring–type
Sebire
Ohyashiki
654.4
transducers
JAK/receptor
promoter-tTA–driven
*Marker-selected
778C1
Ig
California–Santa
RhoAV14-transfected
ventriculostomy
BIX-01338
nullizygous
1367–2039
syndrome,6,7
.Ba/F3-TRKA
10−93
IDQIMLSTLYGYCKVH
R307G
inclusion.26
3,5-Difluorophenacetyl
R1523C
A_51_P417077
ORR
R193W
Förster
29.20
D176N-myc
MYST-mediated
DENN
43-47
RNase-resistant
4438
64.9
ICΔ82
barium-contrast
0.416173288
endorse
II.13
R1261
ALC
Di-
Myc-ΔBRIP1-encoding
ZymoTaq
Ibarrola-Villava
Runx1-
Q472H
Nicolaides
inactivators
MAA
,2B
PTN–DGKI
jlll
3.6–4.2
membrane54
81-3-3248-1631
Rosa+/CreERT2
Consortium13
5′Phos-TCC
radiosensitive
deubiquitinases71
lymphopenic
syndactyly4,8
EML4–ALK
IREED
/Lynch
.Encouraging
Regan,2005
aflatoxine
0·24–0·47
CTCGCTGGCC
.Signals
20–78
HSCT
post-polycythemia
5'-TTCCCTTTAGATGCTCTGCTTCT-3'/5'-CCTTTGTTGTTACCTTTAAATGC-3
4.89-fold
./Alive
CTLA-4AlleleA
001166213.2
MIR143HG
selenium
E1053K
Satagopan
Patched-1
Kremlin-Bicêtre
FLAG-Elf3Δ237–241
1.382
.Aligning
AML.12
Lys547
SCFSlimb
insYK
Leu-113fPro18ff
.Supervised
K27-mutant
Masui
sc-8000R
1723
FANCG
GCTTCAGCAATTACTTGTTCTGG
≥4copies
1Kb
p16-induced
intein-fusion
1.5X
10−67
1–149
Lennert
Verhoog
3430
1081_1370del
6312
K143I
subcomplex
Arg362
888–1063
MUM1.33
ESE
SC-338
.Microdeleted
20,702
Blobel
1569583_at
T1720A
Prime-it
35-base
subcutaneous-xenograft
Group,14
dacomitnib
Tao
~72
pGVB2-based
C/G/T
commisuralis
Arg1076Cys
metalloproteinases26
ExactaCruz
scavenge
W515-P518delinsKT
SMZL8
c4103delT
RAS-MAPK—activating
AKT1–PHD
TSACP
NM_004985.3
Irminger-Finger,2010
1061A
GTP-yS
Oncol
Hs99999907
.Penttinen
4.4-14.6
GSE2658
p=2.2
MouseWG-6
anti-STAT1
helix-11
MLL-short
clinicopathlogical
interferon-a
G695S
17-295
sjdbOverhang
DNA-
E805K-transformed
pTB-ex14-wt
0.2-5μg/ml
Xmn\
TOPOTA
SKRC47
SYBYL-X
mutation-induced
Trkb
hyperenhanced
.Note
'wk
blotting.GI
31R
chromatin-modification
mutations.5
59:331-342
HD-0270
Pessible
BAP1-deficient
R572Q
CS.16
Y1045W
p53S-cmyc
9/25/98
RG-16
Avidin-Fluorescein
Neuron-specific
wereAml1−/−
NeoPharm
Huen
tumor‐specific
6–185
Janoueix-Lerosey
E866Ka
SHC002V
Src-kinase
gefitnib-treated
5′-tac
endometrium43
5/59
L135
5′CGGAAAGCCAAGTTCACCTTT3′
4/230
AP1M2
//biosun1.harvard.edu/complab/dchip/
pmol/l
Aristoplan
bythese
5116
3559insG
Venn
orthologs.27,28
CBF-positive
n=7
V277
03446962
MFS2b
RLF
specifications.Full
-transcriptome
HaelII
metastasis.35
-RhoA
α-tubulin—and
33-5
72R//P
four-base
phosphoAkt
TEAD1-4
R403S
40–49,6
HER2signal
acc=GSE51274
Methods10030d
benzoylated
847–862
Dss1
534C
4Peaks
hUBC9
w/wo
acid-mediated
caved-in
366:883-92
GTPγS
sh-RNA
L399A
82-yr-old
XL5
Nishioka
tissue*
G273D
Kinase-Substrate
Phe216Asp
R304*
mutationscan
H194
10mm
STI571-insensitive
Y182
W20S
230-kd
C124/182S
Ser47
MUT−
anti-pan-p38
disease.Previous
multinucleation
42KB
B56δ-mutant
.Scheme
NM_022970.3
c.1766C4A
FrenchAmerican-British
Shiau
I30N
S3.7–3.8
PIK3CA1–10
pre-clearing
23p
13C-labeling
controls.13
Korach
PTPρ-ΔFNIII-1
wanhua.zhang
polyvinylpyrrolidone/0.02
RG-22
I51N
AKTiX
colonectomy
pairmismatches
R1594Q
Cross-sections
100k
PK-4002
B-D-thiogalactopyranoside
Hsp90-interacting
TGCAAGGTGGAGCGATTCTG
theescalated
554–595
IRAK4-EGFP
hypomethylation
p.Lys1026X
0.988
glutaraldehyde-fixed
ionization—time-of-flight
Gd3+-containing
V1711M7
described.45
NFKBIA.1
orthovanadate/1
anti-R140Q
R107H
orapoptosis
over-ridden
13377
Asx-mutant
GCA→ACA
S85C
0032
//tcga-data.nci.nih.gov/docs/publications/ov_2011
trials11
97.3–97.4
Jakacki
SNB
XFoxH1b
RM121
79••
REN
5′-TCGCCATGCCGGGAGAACTCTAAC-3′
V1180
FFP
doi:10.1245/s10434-011-1942-6
S2–S7
TCF-3–ID3
NM_007706
//www.interscience.wiley.com/jpages/1059-7794/suppmat
c.256G
YY1—but
mg33258.f4
c-3′
=∑j=1nK
Ret16F
expression21
.Transplantation
.Surgically
V882M
.10C
R-CHOP+
zlj9991055910004.jpg
3-induced
Sub-ependymal
A233T
ELL2
model8
CUTLL1
C47
werecentrifuged
Iransfected
D−/−and
6/25
5′-CGTCCCGTAGACAAAATGGT-3′
data.32⇓-34
p.W515
sc-214
Pik3cawt
imidazoquinoxaline
G294S
PCR-products
increasing.1
method27
18356
Root-Mean-Square
hypoxiainducible
CBP-associated
highdegree
1050–1061
4051
categories.Table
bilayer-independent
EWSR1/CREB3L1
Michaely
CAGTCAGCTCAGCCGGGAGCAA
TORC1-dependent
sub-significant
0.50–
NSCLC2
syndrome21
S80N
dimerization/oligomerization
D351V
1⇓A
Chatterjee-Kishore
M4
EIIa-cre
N2781
P=0.45
pET15b
ERK1/2–PEA-15
c.81T→C
Smad3CΔc
71-45
*6
PCC
ES-derived
pYES2-based
acetate–1
post-ovulation
E81K
mm00455685_m1*
PAN3–NTRK2
Xrcc2
PrimR
5′-CTACCGAGCTACTTTTGCAGAAGATCAGTTTC-3′
1625–1991
0.3999
7−10
lymphoma/
C482R
±s.d
self-HEL
pathways7
rs55669340
FH-SPOP
myocytes/total
non–VEGF-mediated
9.6a
c-myc-induced
pBabe-puror-Empty
tetramer-incapable
31:1997-2003
M394V
imatinib-resistant
BACH1-PRIM-F
1400
Mut/WT
8V
onein-frame
noradioactivity
KRAS/BRAF
BRCA1and
c.3959_3962delCAAG
products.3
ONS-76
definitions.ConclusionsA
5'tggtgactgggaatcttggaatccagt
0.6°
6-aa
CDH1
4/50
Br30
5′-TGGCGAGGAGTTTCCTGTTTCCCTCGGCGC-3′
GM03348
ΔIns
AFFINITI
products188
g/10
c.1281C
Rheb-TSC2GAP
DDLPS_06T
5-CTGGGATTTGAACCCTTGTC-3
earlypassage
ref.Luyten
L576P—4
TPWPLSSFVPSQK
Conclusions—AR-V7
7.319255875
LRRC10
-receptor
CTX+RTX
Bijur
WRAP73
CLB-BER
RUNX1-45F
Fli1+/−Mpl−/−
locus9
G16733
interleukin-6–stimulated
syndrome—in
.DR103
47–79
25,28
RET/V804M-
'complete
TSC1-FLAG
lnFAM
TOMTEC
Glioblastoma
BRAFV600EF
Andreutti-Zaugg
wu20/wu21
.02
GSE66719
AP/dE
RHOA-mediated
.Intragenic
Glutamic
ZONAB
FISH/RT-PCR
neuroectodermal
domain.Figure
ncat–π
vIL-10
NF1+/−
Brgf/f
interaction-mediated
p53-pT-REx-DEST30
12R8-1
phosphoinosi­
20140807
p.Q302*
K27M-H3
t-MDS/t-AML.16
anti–phospho-Flt3
differentiation/proliferation
DDLPS_35
Arg381
Fbw7-mediated
58.99
1,914
129–131
R-murine
streptavadin-precipitated
VUS-positive
online-LC
C-Jun
BCR-ABL-translocated
SYK
sparse.30
tcaaag/CAAAAA
Val-Ala-Ile-Lys-Glu-Leu
originated.1
H3Ac
Multiparameter
.Deletional
L-selectin
II/R
O-TIE
neuroblastoma1
DDX3X19
del-TYD
51,53
LN95
models24
cell-substrate
77–79
S68S
mouse-originated
−.99
overexpressed89
~1–4
pseudogene-related
PLC/PRF/5
immunohistocytochemistry
Leonardi
13·5
TβR‐I*
recommendations.12
alcianophilic
Mann-Whitney-Wilcoxon
HI30
AGE-ADJUSTED
160-8582
formalin‑fixed
mTOR–eukaryotic
carbonate
a-IGFRI
2xSSC
WI2
anti–human
abdomino-retroperitoneal
beta=0.92
LAP/PHD
91–507
ribosome-binding
1/12
poly-adenine
domains4
BRD9
P=0.403
'n
pcDNA3.1-WIP1-mut469
Al-Rahawan
reabsorbed
haplodeficiency
28650
Leu-Arg-Glu-Ala
RP11–489N6
Tong
3First
MET-bound
56772522
209-
550–558Q
protein,1
1055–1143
95.1
+3-25
KRAS.7–9
andby
reannealing
ttttAtcca
PKA-dependent
Cldu
Leu-919
.LisH-like
11773Fresh
chromososme
95/132
K846R
RbpjiECKO
1328
175Phe
Imai
Y1248
Tahira
reactions64
.Tyrosine
MEK/Erk
HMA
7.4-22
128.4
re-created
G454S
costimulation
~Tables
doi:10.1172/jci.insight.88766DS1
S31R/IVS2
variables19
previously.4
CUL3-Based
8.5mM
EZH2Y641
2.Reduced
.R26-Pik3ca
M74
1010-
IL-17RA
MAPKK1/2
anti-c-ABL
dsDNA-activated
siRNA-Hs_FGFR4_5-DOPC
D13nt
per-nucleotide
single–amino
IR,8,40
ETS–p52/RelB
pA308.Flag-tel-jak2a-injected
adenylylsulfate
TFK-1
Ro19
TCF3-Biotag
19-69
106.3
rs12628
years/50th
500-1000
taxane-containing
described5
Rheb2
35G
immunoprecipitation–immunoblot
HR-2251
10mMTris
PESX.37
side-effects
ZRSR2—carry
Snf5floxed/−/Gata1-Cre
D1673A
*Two
-R175H
Digest-All
Candau
musculo-aponeurotic
bicalutamide-induced
H-Ras–
fibrous/fatty
BAX-immunonegative
.Alveogenesis
BCL2/IG
GST-C-Raf-RBD
.103
extranodal
30–32
PRE-broadened
OS1
hydrolysis.37
23/54
N38H
.Becker
c.1492C
7f
–FGF
30–70
Phe158Cys
gel-filtration
mouse.C
AMBION
.TENTATIVE
.2543
thiophosphoryl
5′-cacgtgtcccttgtccccac-3′
sinusoidal
H123L
Momssey
.Trend
1713
TEC
AtmKD
Mosesson
2367
1348-bp
mitochondria.5,6
K868
Coiled-coil
hypokalemia
conformation.21–23
NSAID
Tsc2wt
.Identities
acid-aromatic
melanoma,13,14
trials.8
models2
subanalysis
Gscf
Rad1–Rad10
sub­
HSPE1
506T
D2020H
tetanus
strand-exchange
Lin12‐Notch
þ37C
triple-helix
33,37,38
melanoma84
malignancy.8-11
DNAzol™
anti-FANCA1–271
mixoid
SPEN-expressing
mutant–bearing
CPD
.TCF7L2
ju.1of
XP_001142197
gene—can
0.965
anti-EGFR
topoisomerase-targeted
3.212
,
5′-GTAATGACCAGTCAACAGGGGAC-3′
speci
p73.26
PIP3,4,5
LOXO-101
IVSlOb+
co-amplifies
STMN1
solution-phase
H2073-wt-K-RAS
NM_001002295.1
DRB1*0405
Weng
D10S215
E40Q
1–163
DLBCL14,15
p-ERBB3
Figure7c
AF264750
rs150912718
p.Pro28Ser
Sox17ECKO
wnt-responsive
MMR-deﬁciency
.Distance
androgen-regulated
B-mediated
mRNAs10
cells82
.Pioneering
surprise36
p380RSK
U87MG-PTEN
Trithorax
33,37
TTGTTACCTG
0.798*
survival=28
2S9
NB-EBc1
ctgttctctccttagctgcccctggc
disulfide-
A1022E
singlecomplex
BIKZF1-deletion^
Iα
S467
LP6
PolyPhen-2,38
BT474M1
partner—and
Mg-GDP
C333A
C-lobes
.Triamcinolone
V722I
Darvasi
58372500
R-factor=Σ
22-110
9.25
-diamidino-2-phenylindole
Bog˘azic¸i
PU.1
Flt3,19
GAG3TAG
666–931
K178
similarly-sequenced
46.9
5′-cttcataatgcttgctctgatagga-3′
MAP2K
p16INK4a/Cdk4/Rb
67–87
low-grade
juncF/R
Tankyrase
decarboxylation
ΔBRIP1-transfected
//pwbc.garvan.unsw.edu.au/gp/pages/index.jsf
SYBYL6.4
BgllI-aberrant
CSL-DNA
—analysis
Pax9
cancer,54
virus-positive
n=31
5/66
-COOH
Ch157r
p53-BRCA1
Dm-Dicer
calcein
14.47
HoxC
V-FITC–positive
,54
identi-
CIS
X-inactivation17
PTPρwild-type
5′-ggcagacacaaaccaaactc-3′
www.phosphonet.ca
S52P
FLT3-ITD/TKD8,9
pOP-Ires-RFP-Puro
prolific
RAC-GAP
rank-sum
//expasy.org/tools/sim-prot.html
Adenoviral
Mo-DC
SKMEL31
B+X−
CHEK2/Rad53/Cds1
ZFHX3-mutated
INI1-specific
14-μm
V56M
si-Smad1
Holoenzymes
4283–4294
microarray-derived
:171–178
KRASK117N
vector-pMSCV
p–c-Met–positive
.FANCA
Muscarella
E543D
NCX1
0.75–3.03
θ222
Kuroiwa
.Cartridges
tag-specific
Zentner
misclassifi
Bacute
R292A
112
.Codons
NP_003141.2
5′-RACEPCR
BC/Cul2
Nox4-activated
NM_182918.2
TGF-b1–resistant
3129
+EGF
L3/B8
FPα.16
2*SD
G4155A/GAA-*AAA
ng/µL
78.5
high-potency
Bacto
Soravia
mRNAsNMD-sensitive
AML1-dependent
10-7
100,000g
f–i
nonphosphorlated
MSI+observed
non-controlled
Men1dN/dN
c.1903-2A
antiFlag
_8
Asp538Gly
GF53
hyperlipidemia
R1699L
VCB
.MKP3
J4..0w
PTCH1-E380∗
coated-pit
Glu→Stop
.HDX-MS
C/EBPα-knockout
X52056
HeLaDLC1
inflammation-promotes
TAAAAGTATGCCACATCCCAAG
m/70
Ser218Glu/Ser222Glu
incapacitating
signal-to-background
SCC-normal
PRMT8
.Low-level
.Gradient
241,366,542
wide-based
chromatin-regulatory
3715–3729del
Epithelial–stromal
-108/+56
Lafourcade
adk
112514
.PMBL-specific
44–79
Pnt-P2
RTTable
Ercc4
cardiomyocyte
ribosome
3-adrenoceptor
others.11–17
Janus-activated
F.G.
.mRNA
present70
-heterozygous
CLL79
Helbling
2HA
.Ozato
c.819A4C
thorunn.rafnar
1.5−98-fold
deletion26
restitching
sc188
phospho–histone
10–2500
E124Q
underexpressed-tumors
5′-GTCAA
,21-25
35S-label
Bleeker
iiIR
D1S499
DRA
CHRNA3
.Cytosolic
patternb
chromoplexy
mutations\
Trotti
androgen-independent
RVIES560-564
mutationsoutnumbered
seven-marker
Y589F-Flt3
13—16,19—26
9/43
04691502
5′-GGTTTCAGAGACAGAGCTGGGACTCC-3′
14/30
Derynck
30x
GS119p5
HEL-stimulated
distiguishable
noncell
HUMSAVAR
Gastroenterology
cerebrovascular
Smiraldo
5′-AAAGCCCAGTCTCATGACATT-3′
G870A
cPatient
BRAFV600E-mutated
eects
60.5±8.4
pcDNA3-p53
5′-TAT
peptide.Figure
41–79
N344
0/382
HA-GST-4EBP1
IFI16
0.129
pYES3
16.93
sc-6930
DFG-1
MSH2
α-MEM
39,100
FO-Imelanoma
GMPPNP-bound
KIT-ligand
lZheng
mTOR-S2448
nt318C
61-fold
concur
Gimm
Ponnio
Rho‐family
.Amplicon
Nephrotoxicity
A.Kiermaier
•GluPheA
heteroge
12-o-tetradecanoylphorbol
Vysis
2,2,2
QMPX-PCR
c.5102-5103delTG
PJS-like
1746-bp-long
BTG1
S476I
234–239
rosette-like
1,574
ReACp53/Nutlin-3
5'-ggctggcggcgggactccaggaccctgggtccagcATGGAGGTGGTGGAC
mutant-associated
ROSA26-YFP
WWP1-LATS1
patterns.10
1-166
1345–1711
SuperFect
D-Luciferin
S14–S15
.Progression
17,55–57,61
Heterozygous
Ancestry
T22
element22
system21
maintenance15
KDM5C-associated
tumours.10
Versteege
INK-128
.Ac
Creyghton
.Arrowhead
6q21-q22.1
5'-AACTACCAGAAAGGTATACCT-3
Su-DHL
Merlin-Merlin
pEGFP-C3
.RTPCR
One-dimensional
ROR1-negative
TGFBR1
domain.38
PCR-ampli®ed
0.736
HS157
CHRPE
Analysis—MCF-7
NPM-ALK/STAT3
A58
P=0.0430
p110α/p85α-niSH2
V-9401
Arcila
UGGAG-containing
high.28
578T
Bischo
M64I
1753-2185
Y1230C.8
LR08-263
Hhunresponsive
.Eighty-five
U87MG.I
SNVmix71
+1.2
HN-Smad4–/–
4754
RP11–350G2
RP11-471L13
hCDC4-silenced
EOL3
NKX2-1/NKX2-2
transcript-based
14-3-3/target
FUJIX
9q34→9qter
â€oeMaterialsand
pCMV-6-based
technologies™
pBabe-puro-Empty
glucagons
A252-254
R149C
heart.85
47.3
factors.11
//trace.ddbj.nig.ac.jp/DRASearch/
HRP-secondary
L317F
lacZA
Proliferation
19/44
10.1007/s10637-016-0332-0
K558_V560delinsNH
Sox17+/−
40+
A628T
Immu-Mount
HSC-43
motifs7
7.73
AZA.14
mRNA-editing
rs10250
prodcol=Y
Neurobiol
198–219
PTEN-TAS2R1
unclassified.
trials.4-6
.org
hyalinisation
proliferation.18
TRIM11
–stained
DGGE-Detected
5′-RLM-RACE
infertile
apoptosis-resistant
Arg-394
combinational
PIP-box
PCR-positive
Dun1
NPT-II
FGK4.5
V600EBRAF-driven
≈100-fold
rindopepimut
ai2-wt
plaquepurified
SH2-pseudokinase
LNCaP-I
Nagayasu
PTEN-R130M
22,53
BamW
2.60–20.24
succinimidylsuccinate
177-216
cells.2
5-turn
GNG10
10.66
anti-phosphoserine-15
p.Q419PfsX81
V343E
2.17±1.34
HNi
ErbB2/3
disease2
3A⇓
Modeller41
–mCherry
12/49
Kmt2f
KMT2D-complex
N=170
multiple/
CS3
75,000
Macrodissection
P123H
F4/80−Gr1+
Insoluble
11B3fl/+
G291S
R34Q
p73-p53
ARO
lymphoma48
Flt3−lin−Sca-1−c-kit+CD34+CD16/32−
10.1158/0008-5472.CAN-14-2930
228-bp
methanol/1
metastaticmelanoma
precursors,32
Glu585
2732
f70
Tg-induced
Eco0109I
pARE2-DS-Luc
Pmutcomposition=p
hREC2
scid
S269T
accumulation142
R786G
Hazan
antiandrogentherapies
wasincluded
32–79
TTGCGGCCGCGCCACCATGGCACTTCATCAACTTGTCAAGATT
4560/μL
.Chiara
.Nonmalignant
pCLIP3A-myc-CARD11-mCherry-based
p.M552_V559del
33/45.8
V3THS-380114
mutation,12,31
5′-AG
.Extrapolation
BMA64
EZR
.Replica
8,26,27
log-phase
endogenouscellular
G16S
FLT3-antibody
radiation-sensitive
.Insoluble
21h
multiple-reaction-monitoring
NM_007798
solvated
.7807
ETV6-RUNX1
ErbB2-low-expressing
phospho-amino
p300L
62.1–100
8,15
anaphase-promoting
ICH
L213R
3786C
131–403
M1268
0-3+
011
179377
F83§
26,36
MIQE
CAMTen
Hyperfilm-MP
napsin
USCS
Iwashed
DME3+/MMR−
16.5
c.541C4T
T38
pET6H
Leu122Arg-bearing
S1–S5
ADH-p53expression
D20S100
insertion/deletion
AAPS
G392R
ERCC1-p.Arg689Ser-XPF
Offenburg
MPN+
∼59
.Current
GAP1IP4BP-mediated
c-MET/HGF-targeted
CD-1
TruSight
L219R
1941–61
41.8–76.6
Caki-l
identifiedin
Gayatry
MET-receptor
-1H-indazole-4-carboxamide
cdc34
.del
Gcn5
422801
V1571
GTPase
2,070
R854Q
hypergastrinemia
c.2211G
N1055-09
Ser266
to0.5:1
pSUPER.retro.neo+GFP
C809G
HGGs3
actinomycin‐D
dioxygenases
haematopoiesis
afferent-spinosolitary
menin-null
C-301023-01
13-week
–depleting
S768_V769EinsVAS
.Constitutive
p.A1003V
tmd.ac.jp
acetylatedforms
AAGGGCTCATGACCACAGTC
29⇓–31
tobaculovirus
locus.4
mice.20
Biopsy-proven
Hdmx-amplified
tumors.Cutaneous
SSEA
EX2
P=0.6381
MED12_L1224F
γH2AX-positive
TGIF1
Gardam
Bioinformatical
nucleosome-depleted
I~-spectrin
mutant-metastatic
5y
3.1.4.
s12672
mMK4Fe
alleles.3,5
analysisSNVs
Qukbec
ATP-utilizing
i+4
MOE18
FGFR2-MGEA5
performed.Table
HSC7E190
Nup93
.001Exon
complex110
GFP-lentivirus
MD-MB-435s
8-9
c.961G4A
MLL-AF9–mediated
315–487
hematogenously
C616Y
12263
^AGA
intra-lineage
Y1135/Y1136
1.38-9.67
nonheterozygous
P19Arf
formation.28,29
Savicheva
SHQ1
distributional
L8
31–59
Filopodia
activiy
C/EBPα-E2F
myr-p110δ
Δ12–13mRNA
non-pathogenic
cancer.19,20
fgfr1at3R705H/fgfr1ahuW671X
P85α
Vaishnavi
ROSSMAN
1652–1863
polyinosine-polycytosine
RhoA—The
4-bp
authorFull
2.59−2.50
monocryptal/oligocryptal
NM_009741
pGL2-Luc-3×IRS
BRD4-dependent
1999a
0.249
Flag-HA-BAP1
:1059–70
TlQ
24/four
Netrin-1
ATXN7
load.In
maycause
.Nonsense
p.E412V
2,6KR
GTAGTGGTAAT
nMoles
−4.97
Ser738Phe
nonproductive
minigels
phytohemagglutinin
'~-~*
SeqScape
Mortazavi
Quantative
R206P
OV81†
.Presently
HCLc3
70•4
GDC-0973
fashion18
//www.ncbi.nlm.nih.gov/snp/
TpN61R/61R
mock−transfected
.2632C
17q21.3-ter
29/33
colon6
18−24
PMEF
levels.92
anti-WTX
,3-galactosidase
KIF5B-ALK-expressing
57·0
Src-transformed
robust.3–7,9
5′-GCACCTCAGGGAAGAGTCTG-3′
ID23-2
GUUCAGAGUUCUACAGUCCGACGAUC
.Averages
primaryGIST—following
0143KK
F80V
++/++
2b–g
quantiWable
EBPα-deleted
mm-diameter
p21.Luc
S1722P
Crusio
7629
Sca1+c-Kit+
angiogenesis.14
BIOINFORMATIC
5′-GCCC-3′
PDGFRA-D842V
CTD-2071N1
chemoradiation
**b**
NM_003242.5
Y293T
5.4.2
G909R
4shows
GFL–RET
64,83
26,115
small-angle
Blaumueller
SMARCA5
p53–p21
SeCore®
.Echocardiography
2109
Zn-­binding
pRc-CMV-HA-truncated-VHL
LS-MUT
TRE-L2
all-trans-retinoic
prototrophy
R113C
domain—are
CpH
.ERK-phosphorylated
aracytine
.StatisticsSPSS
TM182/DKFZ
ERBB1
21,181
poeis
DRB
Sug
disease-transmitting
.Woodgett
E044
R140L
+IL-3
p-Ser536
5.7-9.2
2000-base
-TGAAGGCAGCCTTCGACG-3
Buch
MSigDB19
5'-CTGATATGGCTGAATGTG-3
ALKF1174S
Souffelweyersheim
413d
biotin-avidin-conjugated
glassy/hyaline
STI-571
237–241
42-44
transduced-Ba/F3
1.59E12
adramatic
p57Kip1
MKK4L
antiproteinase
.MDA
731
pGL-3-miR-130b
methacarn-fixed
.Overexpressionand
di¡erences
.Costello
Insulin-No
Diagnoses
TATACYC1
aberrations8
signification
large-copy-number
0.47–0.97
response.56
PTPN.16
lines.33,34
EnsMart
cancers.48
R5179H
−2.49
1½
states1
S-protein-agarose
NR-22
R504H
prognosis47
transform­
excitatory
2–19
nonlabeled
acyltransferase
TCCTG
rearrangements/sequenced
cocontact
drug.There
ISCUSSION
cells4
I63
FBCS
0.4–10.4
R2520Q
5804–5807
.ALAN
52.7
rs1219648
1998,2000
SAR245409/MSC1936369B
G12D/G13D
blotting.Anis
61–66
Maffucci
phosphorylation88
n=90
Aurora1
p=0.00231
Seshagiri
.ReACp53
Dutrillaux
splice-region
plasmacytic
deletion-initiated
Figure1F
cell.48,49
whichresembled
Phusion
Goudie
NFE2L2_FWD
mainchain
mCMV-EF1-Puro
non-BRD4–NUT-expressing
Translocations
31–91
Biocoat
P39009
1–328
FLT3-JM-PM
petermac.org
adnocarcinoma
D8S1724
peroxynitrite-mediated
N-backbone
dithiolethione
E-CDK2
.T47D-SPEN
.With
.AR
70:848–855
TetOn-Wt-CHK2
MPP1,2
TTA
c-Kit.Forced
26a
c.1–340
pT2G3
​Fig.1A.1A
M1-Flu58–66
.Mark
Thr-544
mice40
oncogenesis19-21
IP-buffer
domain1
Zelboraf
HRASG12V
PHTS-derived
G26
Keap1–Nrf2
lowactivity
Lkb1-deficient
RasV12.C40
MEK2–ERK
histocompatible
R217C,29
FIP1
M540L
L-003329-00-0005
RPB
.Bycomparison
out—merely
isopeptidase
N-methoxysuccinyl-Ala-AlaPro-Val-chloromethyl
neaodjuvant
S1387A
TAAAATTCCCGTCGCTATCAAGGAGCCAACATCTCCGAAAGCCAACAAGG
3.0±3.5
NM_172301
44-20-8722-4273
hRad54B
qRT–PCR
Glu-55
1710
ΔD1-3
shRNAexpressing
LRP10
150,200
co-fractionation
75,537
GSK3b
23.9–25.8
co-localizes
R201W
B-lymphoid
®bers
supershift
89.8
C264Y
anti-menin
D-loop-mutant
controlateral
113fPro18ff
neovascularization
ofM
5′-GCAGCCTTGAACTGTTTAA-3′
.1106G4T
www.selleckbio.com
Kaposi
GRNVAC
Modeling—A
SPOP-mutant
sets3
rare.8
respectively.Characterization
tumour-specific
N/E
43–47
defect.5,6
.Reticular
Smad2–Smad3
49-4
prolyl-hydroxylated
E73K
EML4–anaplastic
mutations,3
REFE
Hospital.Mutation
neighbor-
Q2282P
AF078776
pGL3-LUC–based
Jaulerry
HEK-Jak2-V617F
.Annexin
861
Lys22Gln
5′-TGGCGAGGAGTTTCCTGTTTCCTGTGGCGC-3′
births.1,2
protein-coding
=0–0.4
homophilically
TRM=treatment-related
yeast-two
Smartpools
1/40
KIT-W557_K558del+T670I
FoxA1-induced
9/217
∼8,000
IHC2+
7-day-old
773insertion
HR-mediated
59-CTACAATGAGCTGCGTGTGGC-39
multilineage
SNF2h
98-fold
SplicePredictor
labia
His-WT-
S71F
epi-drugs
R372Q
MutSα/β
p.Arg88Leu
13,1994
tastasesof
TERT.2–5
p.R9W
T1977K/S2215F
case22
230-bp
29-33
Vogelaar
Mathivet
.1831C
PCR.Total
RPPA-defined
c.652GT
tumor‐induced
PI-3,4-P2
0.005
Gly-to-Ser
Shh-
.5278
CopyCaller™v1.0
N-SH2−PTP
142713774
deFuse
lines—one
MDS_361
R258fs
p.T82K
AMP-targeted
CTD-3199J23
unknown.11
histogenomics
137KB
100mg/kg/day
150nM
Sf9-expressed
white-cell
Brca1S1598F/+
TLCK
SMO-W535L
0.90–2.33
C2-iSH2
B2M-specific
289/296/301
.F1174L
bomb-related
35,42,43
.Taken
I306V
P16INK4a
33A
regorafenib-related
ERα/β
Ppt
4Ac
S7PY—Smad7
63–69
229.00KB
3.1.3.48
JAK9/1−
CD246
1165C
repair-based
FU/LV/bevacizumab
imatinib.9
anti-p15/CDKN2B
GB-12
Asp171
5′Phos-TGG
S625A
marrow.7
Gefitinb
snoRNAs
ofAmpliTaq
IL5.16
M.V.
AFMA116XD5
ADII
sub-sets
BC079650
sub-panels
34-73
D1–positive
U2AF-dependent
position-speci¢c
000618
P.I
I-2
Kit-mediated
BES-modified
±0.6
1435-6
pimozide-treated
16/12
2nd–4th
EW12
HIF-1alpha4
malignancy26
++++
EGFRselective
3990
preregorafenib
AA-induced
WWP1-GST
7q33.3
miR-982-5p
V769insVAS
rank=1
vivo146
+82-2-7424727
FHL156–280
Figure2A2A
Abcb10
retroviridae
588–922
SPOP/CKI-mediated
KCI-PLA1
phopsorylation
Lindhurst
.Ruttledge
D370V
HEC1B
pCS2-mutSmad3
In-Fusion
MEK-WT
CD4+/−
AML9
c.493T
ATRX-DNMT3A-DNMT3L-type
CSF1RD1
transwe
cells/1.8
AKAP12
20-mers
.RET/PTC
2RII
80–85
t-MDS/AML
+5
138K
FPα-positive
centaurin-γ1
-GCCACCAGCCTCTTCTATG-30
LUC1501
II/collagenase
Lys48
14.8–21.9
n=17/80
107delGTA
_ATRX_
+Ewsr1
57kD
175Trp
2729
pathway-associated
Nr4a3
Wautlet
Q58L
Rubinfeld
SfaNI
pre–bevacizumab-era
ALK30
5/6-positive
patients.9–14
K291E
59-TTCTGCCATCTCTCTCCTCC-39
Y1068-specific
CD2+CD3+CD4+CD8−
BRCA2-truncating
nuclear-matrix-attachment
CCTCCATCTCCTGCAGGTCTAGT
5Bi
siRNA-p53
filtering,8
.Fractionsof
ERK2Y36N/H
TTTAGGG
Recht
100.0
435S
a-LexA
EWS/WT1–KTS
ATPase-dead
SMO-M2
Cancer-related
781/781
c-mycS62A
.Methacarn-fixed
L2026
97.5K
5′-CGGGCATGCCCG-3′
LAS-1000
PTC124
PRE-affected
mean/median
Steroid-resistant
dithiobis-succinimidyl
compartment29
†S.W
Met-48
add-back
cataract
Nishizuka
eosinophilia,3
studies,16
.1D1D
3,900
L202F
CSCC-6-T
BRCA1-BRCT–encoding
2015.05
Sos1EK/EK
pSF91-IRES-eGFP26
missensemutations.Statistically
William-Morey
R139
M133K
families4
224894_at
anti-Bcl-x
5′-AGTAACAGACTAGCTAGAGAC-3′
PRC2-target
BLMASH,15,16
NversusBT
64/F
Chorioretinopathy
A.C.Keates
633
cohort20
oxidation-reduction
trastuzumab-based
pFlagmtSox9
0.662
7e
150-breakpoint
2536
NL/MGCL
1708v
p19ARF
93rd
wascollected
wasdiluted
Boström
Gly-X-GlyLys-Thr
Iacobuzio-Donahue
potential53
co-exist
Cullin-1
+VT
chRCCs
transformation-sensitive
8772
1.98-FC
pUC9
tyrosine-phosphorylation-regulated
2415
181-92-642-
.Muslin
PI-4-P1
v2003.02
1.32.1
Fig.12,12
substrate-recognizing
anti-CD19–phycoerythrin
damage.14
system,32
algorithm.16
scores28
N16/12
.U118MG
Mad-3
S65N
rh-EPO
Luo/J
0.2548
D842I
266A
MEK1V154I
FISH1446b
ErbB3/4
non-proband
EGFP/Bcr-AblT315I
542–558
RDEA119
signaling-induced
17N,67I
EDA-R
MutSα-T33P
forkhead/winged-helix
Neuherberg
.Hughest
V599EB-RAF
cryopreservation
histopathologically
T1/2
Supershifted
NaMO4
TGTAAAACGACGGCCAGTCCTTTTTTGTTTTAATTCCT
DATA-ANALYSIS
LKB1-D88
Slc
15.33
10,724
tableFigures
p.N570S
Rad10-Rad1
77nM
225-
anti-phospho-S6ribosomal
metastases.1
non-base-paired
p.Y179Cf
carcinogen-induced
70˚C
expression,35
0.24977048
Haoyuan
HwJj
GMCSFR
cavernosum
pEAE32
L617F
immunomodulators
PPB-associated
undetermined25
Negoro
months,34,39,40
5'-M13-TCAAGAGT'TTI
PTEN/AKT-mutated
410–415
Electrocardiogram
TpoR.32,37-40
f15
951-8510
.Tag
EGR2-mutated
angioinvasion
kinase/mitogen-activated
WQu
7Dose-response
4SR
HIF3A
*Germline
5´-GAGGGCTGGACTGCGAACTGGAGAA-3´
studiespoint
t13
Kalyna
MALME
pRB-induced
ΔDIX
G356A
NICHHD
56-88
0705A
.STAG
c.3028C
PF-0461903
AML1gene
CCAGGCAAGT
1051
1+/2+
Lys650Met
1345
Pten.9–11
nonassociated
apoptosomal
serotonin-reuptake
049
Faraonio
spindle−shaped
ATRIP91
P11L
Ghysdael
2—figure
BCOR-regulated
c.3925G
5T
M244V
-CAAATGAGCTGGCAAGTGCCGTGTC-3
21701
S45F‐mutated
N215S
pMOSBlue
p.Pro1502Leu
SSL2
veri-
W34A/K63A-Pin1
EWSR1/CREM
anti-CCND1
DuPont–New
17-AAGH2
–signal
representation…Download
phosphoinositide-regulated
DCTD
MO-353
293-cell
S1481N
Ullevål
∼10-11-fold
APtag-l
TINUR
coat-YFP
Evelin
20/45
lq
wt12/2
pl20GAP
PI-3-kinase
TRIS-buffered
TAACCCTT-3
smallmolecule
05–144
,2,4,5
tccactggattccaagattcccagtcacca3
MEF2-binding
'myeloid
Collet
BWA31
immunosuppressants
cells—particularly
NM_002691
AXIN
members17
S.EExpression
1701
RNAcompete
5-TGGCTTGTGGTAGCAAGGA-3
5364C
GSE24164
MED30
Y456A
CTTTCGTGCTTCCTTGGTCT
JFCR39-DB
ELN-defined
.miR-3127-5p
DFMO
R93
1–1455
02/8/95
10–20
Sumimoto
autoinhibited
tonsil
1.03
Pathology–certified
Flashplate
TGTCAAGGTCTTCTCGAGGA
ERG1,46
lossAllelic
.9D
10k
42–92
anti-Dnmt3b
6-AU
ÃŸ-catenin-activating
R470S
mA259,3-18Raf-1
signal8
b-catenin-LEF
AAAGGACTTCCATTCACTTGC
GRCh37
phosphorimaging
individuals.18
αEF
p.Gly264Ser
33.7
58.6
pret~.FNF
SCV000195555
ÃŸ-catenindem
3SD
virus–cleaved
MutL/MLH
p.Pro129Thr
ST1571
Glu921
Fig2F
A589V
I-κBα
GAL4-regulated
L1780
pRPS6
Figure10D
BRCT2
Y53H
GI:54638211
systems26,27
CUL2–ROC1
Affi-Gel
DHT10
Seikagaku
Heisenberg
G719X/L861Q/S768I
non-MDS
4.17
670
∼57
Bdf2
Fig.6e
IHRDLRAAN
Retinoblastoma
atropine-sensitive
S5M
.ARF876L-Bearing
Pten-deletion-dependent
531−
overexpressing-FOXL2
hU6-containing
ComiteŁ
re-staining
GGGAATTTGGCTCATAACAC
Stagetips
Pounds7
40,42,46
HRP
204K
AJL
C1orf185
Moosa.Mohammadi
angiogenesis171
lower-expressed
lengths.25
Telomeres
Figure11f
RAS-effectors
transcripts.RT-PCR
Dermatofibroma
CDK4-mediated
R798X
elsewhere.33
susceptibility/resistance
interact123
5871:1
.L.
HPF
.Chlamydomonas
marker,15,33,34,63–69
4237–4238delAGb
T57A
3xFLAG-BARD1
Intra-S
matrigel/OVCAR3
FIC
K63R
Centro/Centro
Proto-oncogene
pCDNA3-BirA
R399Q
Spokoini
inCS-FBS
HFF
One-thousand-and-seven
TP53–/–Tsc2–/–
32,52–54
3054del
Val804Met
47.
cross-bred
inp53
3′CHEK2/22q12
-only
Ki67/CD31immunohistochemistry
32γ
A.J.A
∼100Å
7,796
2324_2325ins12
U373MG
UAS-dUTX-RNAi
77–91
Sobulo
LIFR-deficient
9010
Flt3L
pCEP4
MPZL3
RP11-49F3
value.12
pcDNA4-FKBP1A-myc
FluorSMax
Fc4
Newmark
multi-centre
LOR-RAMLA
0.325‡
X-4C
5'GTTlCCGGTAGGAGTCCTCTATAGTGGGATCATA3
IkappaBalpha
AppliedBiosystems
.NAT2
Anti-CK8
Phenome
CellTitre-Glo
-4.4
pCAS2R
AAH75716.1
caspase-8
mutations.MATERIALS
whole‐genome
-l-alanyl
P564
soft–tissue
AML.3,17,18
DLBCL,15
tissues.4
Yervoy
resultingfrom
leiomysarcomas
biopsies.13
AF205935
3.86+0.28
−.53
3379
c.1640T
productsdisplay
HPV-transformed
Beare–Stevenson
substrates.10
9919
unencapsulated
TPR-NTRK1
.D-domains
tumourigenesis
390
PRL
R181→R180
NPR-152
1932
TDG-catalyzed
ENO1
H3–lysine
pJW312
P54L
CD45RBhigh
VVMELMAH-GDL
vitro16,17
agar.11
G·C
0.6–11.3
partial-length
method.26
HA-ER
S150N
Akt2-deficient
Y35
RAS-RAF-MEK
n=219
Erb-B2
CLIP2-BRAF
family-activating
3/47
MDYKDDDDK
AKT2-
ter1785
Matsuyama
STAT5
c.170a
ST6GAL1
fluoride
FC=1.98
R114W
technology.13
Harvey-Ras
Kirschenbaum
Moran-Crusio
Ras-extracellular
pCMVTag2
s.r.l
pEGFR-tyr
25-31
AciCC
115–165
2690–2693
L1196MþD1203NþR1214H
N166S
0.02
respectively.55,56
p.K403R
IFN-γ-responsive
2,4-pyrimidinediamine
breast/chest
p53si-3
6100
2,045
MAPK:9-3
lung,52
2M–O
processing-1
tumors50
P15374
SET-NUP214
dimers73
defect-that
=
CBF□mRNA
NM_010107
assist-
CD3+CD4+CD8+/low
79,533
phenoxyphenyl
ProofStart
Leu122
West-Germany
HCC970
FGFR2-fusions
β-rich
1099_1410del
-gctgattaactcagtggtcatctcgcagctctc
SbcCD
D327fs
GSE30442
hA1
10.1155
Gosse
MLL-fusion-driven
E1660G
55+A171
pLRD21-U3ERE
729–1288
non-disease
stemcell
H-bonding
pZNa0-G207T
3510
mutations.50
V45M
phosphorylationmediated
inall
anti-Tax
mismatch-stimulated
function27
7.32–24.24
disorders.5
MMP16
Cystine-knot
Corbacioglu
PCA1-5
NAN9
pSVgal
activation.39
cis-linkages
MDM2-e
5'-ctacacaatcmctctmtcc-3
4.6.3
SCF/Kit
cancer-related
CI=0.17–1.59
T37A
byTGF-β
M.B
n-1
6−12
Thr180/Tyr182
Giwercman
HIES.32–35
descriptionA
anti-Raf-1
brake.39
transcriptionallyactive
.SNV
0.75×
GEF‐H1/Lfc
5′-CGGAATTCCAGAGGGATACCATGCAA-3′
3.00–3.99
3,592
R486W
Clone5
telokin
Prks-ROCK1
BJ5464/pEAE51
GSE18409
Ruzankina
.G401
olignucleotide
Reitmair
ggacaggacgatctcataggacac
Cul3NTD
29,461
p=0.59
MSH6-G1139S
AGGAAGT
Real-Q™
PTEN63
Gr-1+/Mac1+
G418-resistant
A348P
5′-diphosphate
Fluoroblok™
orchiectomy-polyestradiol
n=2Lymph
CIP1/WAF1/CDKN1A
subnuclear
myofibrillogenesis
1.192
IVS19b-
−15
NA**
CLIM-1
27–
Plasmids—Primary
1235A
–30.1
permeabilization
antisteroids
MEF2C-specific
chrX:39632194-39848594
Light-dependent
adhesion—N220Y
GSTA3
D572N
p.P107L
Msx2
5Division
U4/6
c.441+2T
116-bp
wtlvol
50,000
I.V
Evotec
H27A
vivo.14
here.13
H2143Q
genital-tract
IGK-CDK6
1/4/06
~130
.Rohatgi
Canonic
.Cardiovascular
Attractene
526
Coustan-Smith
.Gln317X
Loop-Strand
SUV39H2
Batton
CS3270
noncomplementing
pCUB11
pERK-negative
HC-10
M3762V
80-fold
N567
multikinases
NP_997700
ImageLock
C/12mm
TFA22
72–367
.Next
Fukada
Dδ2–
FGFR1-transfected
rigidifying
HA-BAP1-GFP
.TSC-associated
non-NSHP
waspresented.More
EGFL4
pCEP-wt
W317
S492Y
NF1-microdeletion
MLPA-positive
FAM22A
.006
cell–gene
43S
hybridizationchamber
Thr292
ETS1
.Phospho-mimetic
Becerra
SET1A
RIT1
iASPP
Sixty-two
pHACE
SERDS
multifarious
signatures.23
Cre-loxP
302KB
β1′-α1′
P581L
pGL2-promoter
5V-catatgtctcccgccttctg-3V
2730–2731delCCb
deaths1,2
phospha
J2-4
.Low
Solvent/water
exit.23
N345D
performed—for
100,000×g
96.71
26m
Igf2/H19
HA-low
lines.12
1249
histone-PTMs
hyg
D6S276
AS9
syndrome|
68delAG
R411P
NSCLC33
ROSA26-CreER
fibrillin-1
carcinomas.32
Sanquin
Hatoum
SA534
FGFR3.32,33
GAADNIYK
ssDNA.27–30
palindromes
phosphoprotein65
Grb2/Gab
−1,664
cdd470f3
pRSK
thymomacell
cyclin-deficient
61.53
Fig.22b
5′-CGGCTACCACATCCAAGGAA-3′
Pathway-specific
736/μl
tolerated68
Raf301
Sox17β
.R948K
Arg-258
al117
cell–independent
-~~~
1780GVPQL
CFC/melanoma
cases2
dog-1
hormone-inde-
p.G667C
.F53C
KIT816R
mutant-expressing
NEB
0.724
M1-Flu
hyperparathyroid
24.3+2.5
PR19
Dicer1Δ
12/M
Tyr869
MSBR
RAEB1
viral-human
tumorand
.Ctcf+/−
Bohmann
Kretzner
D236E
Wiesbaden-Nordenstadt/Germany
Virus-containing
iantsTo
G54V
active-like
non-annotated
APC-anti-Gr
26493395
doppler
HDAC5
ml/1
deleterious,30
Spillantini
co-activating
telomerase-proteins
.12,15
fusion.18
1−p
HCC19
Stiewe
NOESY
RET-KD—Sucrose
nster
.Prostate-Cancer-Associated
reprogammed
EN1078D
.number
prelimi‑
cellDNA
TNS3
2125
.Mitoses
G357R
.Ampullary
non-small-cell
ERBB3-WT
10−59
Kirsten-Ras
.Intra-focal
children.60
non-GC
Egf
BrieXy
Martinez-Balbas
cells.29,53
acetylation/methylation
R268P
2.5–2.6
LSL-G12D
S78R
described.12
polyphred.out
SC255
CDK4-V5
PRJNA229096
Thehybridization
world.1
Ile21/Ile36
68°C-10′
P35916
P0027
cases6
repeats.23
Hlll2R
.Seongnam-si
168-target
described34
20,857
Qian
.C775Y
7.95
kv
peroxidase–coupled
D70N
0.904
R-minus
kinase-impaired
5′-GTGCGCTTCCGAACGATGTA-3′
MGH011
0.2-
deoxy-D-glucose
superimposing
005219
Q794*
AML1/EVI-1-transformed
c.3939_3957dupTCAAAAG
6,432
Stralen
figure1C
Infunium450K
unknown.15
GFP—that
3×10−5
001005735
MYC-regulated
locus.13
MCK-CAT
10.1007/s00268-004-7813-6
TTTTTGACACAACTCCTCCTG
protein/activity
image.Full
leukemia3
863–884
Ohkuma
NF1_00323
M.Transfections
A204T
confi
InSolution™
Furney
T3132A
Glu-37
335G
.36
pp70S6
adenocarcinoma16
Ednrb
4237
p18=0.037
activity.120
ERZ-ERBB4
593–595delACT
E014
D207E
BLOSUM62
GR/PR
inter-ictal
.U251MG
71224
589
alleles6
one-month
B21
histone-associated
Sp1,38
.Energy-independent
fasciclin
Pro48Thr
instability†
.Biological
5.16
water-soluble
Non-Hotspot
R252A
HLA-B*07:44N
plasmidpLM6
E734
first-in-humans
c.1711G
023199.1
vectortranslected
StrataClone
b2m-free
Te1
4-hydroxyl
1.06-fold
TCFs/LEF
inreduced
GTPBP4
2.4-Å
.Paired
SW480
RP11-114N5
E3PCR-r
nature.comAlternative
C124S
Cancer-Related
LacZ
BL1770
Substrate
tumors8–11
08/2002
.229G
51,53,60
X.Chen
5′CAAATGGAGCTGCTCCTGGTG3′
GBM19–21
.Stably
156.7
c.484G4A
High‐grade
threeKITexon
1587Å2
72°C/2
αE-helix
mono-polar
tumors/germline
Micromolar
T684
mutant–
ψ-helper
0.41–1.33
correction-proficient
-531
v3-HS
hapbotype
.Deacetylated
Popivanova
n=146
Perez-Roger
Brg1/Neo
G13DKRAS
10−11cm2
PMBL-derived
pCAT2b-APP
lysosomes.2,13,14
CAGGAGCTGAGGTCTGAAC
deltoid
682
p3xFLAG-CMV
E684Y
PKC-mediated
five–amino
822–827
O'Shea
/2L14
c-2
haematoxylin/eosin
5′-AACAGGAACCAGCTCTCAAAGG-3′
744–752
0.0226
JAMA-2
ImageQuant
5mCpX
-ras
Vectashield®
RELAWT
cancer,28
0.19-0.78
COS-7
MuTect30
better-organized
Cy5-labelled
gene-speci¢c
SINEs-specifically
652T
15I
silencer.24
IL-1ß
P405R
−.27
Q132
.Bisulphite
SD-U
deficit5
genome/human
sporadic-somatic
regulation.Full
P500T
resonanceTable
PJ694
2,5
39–44
lines8
HECD1
cgttgacatccgtaaagacc
COL17A1
408-bp
AGGACTGACCGACACGTG
effect.43
Siemeister
SureDesign
rucaparib
Lys73and
GCN5-containing
pSFK
MLL-AF4/AFF1
CACGGTGGTTTCAGAGATGAGGTC
chromatographyon
PBS/0.5
IVS2-11delT
distancePCR
HiSeq4000
MEG-MEGCC
GOseq
R15
Prm-cre
GTPBP8
hemochromatosis
22,82,85,86
extractsnormalized
apo-protein
Publique–Hoˆpitaux
Vimention
.DUX4
substrates52
.Walz
genegenerally
stronglyassociated
KMS-4
:G12VKRAS
.Co-amplification
PNMU-1
Blandinoet
alterations2
DIS3L2
Mϕ
IDH1-R132H-negative
Phosphoantibody
HER2N
2Structure-based
α6
GISTs.18,61
–801C.MutSa
TEL-DJAK
JY16
NIH.3T3
thereforeto
AcH4
Harvey-
−4.64
vitro-mutagenized
Arrandale
2/32
intensitieswere
≥2nd
C533R
www.anatomicpathology.com
transfected
c.166delG
SK-Mel-2
.Scanned
non-DS-ALL
RIT1a
colleagues11
position7,16
Smad4-containing
y-narita
pDM16
5.7.2
I1079L
Mll3-containing
.Com-
alumi-
|-sandwich
yLouArTh-irArgAspGI
non–GCB-DLBCL
autophosphoryla-
-polyacrylamide
TRC0000039717
actication
nonmucosal
silico–predicted
anti-activated–NOTCH-1
ascites-derived
Sybr-Green-based
HA-MerlinI
56,145
738
NKI-AVL
Herston
pNKY79
PCR16
BioDiscovery
theMLL
Themixtures
6,11
indirectly.27
Y599F-Flt3-KD-32D
Susbstantial
0.41×
22q13.1
subtetraploid
nanoparticles
penetrat-
c.787C4T
p=0.0014
UT7
nonsignificantly
Borggrefe
100-150
RegIIIβ
377C
protocol.shRNA
techresources
G12I
13–71
Ras-RAF-mitogen-activated
810–835
27k
61,324
LDAC
.V568G
strategies.9-11
2−5.4MARK1MAP/microtubule
DLL3
HSS110905
4/94
GENSCAN30
D4S1554
antigen-transformed
ANTIGEN
multipotency
BIRB
0.622404425
S765P
c.C981G
DeFuse
IC50value
.Adeniran
expression-positive
BACH1-WT
Bogdanova
W573
systematicassessment
HKL200023
S15–26
IL-4-mediated
doublepositive
XIO4
lentis†
PDGFRβ86
2162G
.Loci
U3ERE
85.29
AGCTTCTGCATGATCTTCCT
HEK-HEK293
FLT3-D839G
p.D275
Long‑term
common-place
4/12
Y1586-specific
unpublishedresults
HER3-positive
level.42
Gauchotte
18.75
Kinase-activating
MiR-30
v-Akt
.AA491
0.431
.659A4C
fibronectin-dependent
sc-1722
Rosa+/CreERT2AtmC/-
A3140G
8μg/ml
K129E
studies.8
R-group
rlI
Theunstained
066
Calmettes
XL147
re-introduce
20-104
Skp1-Cdc53/Cullin-F-box-protein
Interdiscip
over-expressing
syndrome.29,30
pDG268
R117T
evenat
non-deterministic
NM_014209
3952
IGHV
.Doxorubicin
1014/09
7.74
FLAG-Elf3L142P
'MSI
al.50
129:971–982
next-generation
DLD
3'-kinase-dependent
Figs.11B
10-1562
6-69
mye
6.78
therapya
www.sbd.ee
ADAM10/17
MOZ-CREBBP
RAR-γ
lipososmes
Amplificationb
Self‐tolerance
ADIYALGL
patients5–7
amino-binding
elements.14
Δ3263–3385
chondomesenchymal
H628R
β-catenin/Tcf
MPCEWS-FLI-1tumors
organ-infiltrating
H850Na
T1–T10
VN
anti-BRIP1
N93S
rs17290559
Methyltrienolone
387K
Postmenopausal
β-catenin-GST
eight100
Meis1a
Boussiotis
BT2
EWSR2
86:86–93
PCR19
/I-Ppo1
p27fs177
TGFb-treated
pMIG/HAhBRAF
SIM/FM2
E40K/T450A
R643C
JNK-mediated
4/42
SFCHECK
Poly-A1
MET/SCF
p=0.0297
thromboplastin
shrinked
.Odds
ground-glass
MCF10A/HER2WT
G73E
Figure8,8
MTC/MEN-2A
//www.ncbi
Mitsuuchi
m13r
Tgfb2
NM_031510.1
GDP-binding
ALL‡
TTTGGCGCCCG
nonamplified
Py
GGCCAACGTGAAGAAgtaagtatggcttgctggggtcggggccgggccgg-3
Panka
4066–4077
.Comparatively
crossed-over
Ires-RFP
Bcatenin
K50
tumorigenesis39
BC-loop
.Cowan
pseudolentivirus-construct
GISTs.13,14
G1159A
Werb
pFB-neo-GFP
07-057
Graecia
HA–CDH1
n-region
0.001307
left-right
phosphorylation-defectivemutants
binding/hydrolysis
Y1571N
CTLA4-linked
ca-TGFBR1
Phospho-mimetic
trials.1–5
HG-U133-Plus2
mass-extension
puromycin-
pGEX-Rb
0.256
3-85
L7ae
RNAPII-associated
dEnrichment
S2448
Morrmson
TorrentSuite
kinase-like
p.Ala123_Gln215del
flotation
noncurative
β2–β3
124G15
FGFR1OP2
Crosslinking
blasts,36,37
AAG43492
0-110
pFastBac/hMSH6
alphabeta
.Trisomy
NH4Cl/PBS
NHP2
Tyr395
rad50nc
Warmka
PBS-washed
.511C4T
6−38
p53.iarc.fr
nonneural
anti-AKT1
pcDNA3-LUC
CHAP31
.Cerebellar
Folling
transacetylase
R423Q
CCNC
'clean
HCP
S547G
7H
HCC-202
FoxA1-knockdown
nutlins
0.89
shJun
.Compounds
.Ets1
FGFR2-FAM76A
SalI/EcoRI
mMKCl/0.5
hRos-8
AR-null
10-330
P3–P5
Bio-One
TSC2-inactivating
1245678910
RET/A883T
I312T
0.10–14
code11
6/4237
Srsf2flox/+
S82P
Codepletion
1,083
phospho-antibodies
hyperelasticity
6-Mb
endonuclease16
p19/p53
//www.ncbi.nlm.nih.gov/SNP/
ABIN394303
overrepresent
cardiorespiratory
GAP3-
Sebia
5′-GGCACTGCAGAGGAGTAGTG-3′
.Monocytosis
IC10MB2mgO
miR3127
TGFβ-Smads
HCT116+/+
CAF25
homoharringtonine
2.7-kb
IKZF13,9
4.9–25.0
auagcuucuggguuugcugTT
1071
Lombard
ψKxD/E
+dox
Tincello
5′-ATGCTGTTTAATTGTGTGGAAG-3′
Scientifico
Sastre-Gareau
stomach.4
anti-phosphoS473
SRGAP3–RAF1
EWS/FLI1
pGL3/Rad51-luc
CD45.1
V3THS_325558
T1284M
region.5
false-negative
H3K4me3.12-15
MGH021
HPV-oncogenes
c.4165_4166del2
connexins
400-mg/d
74–87
Zindy
domain,24
preimplantational
recently68
NM_007182
0.017*
5,11,13
-._
40a
Vlaeminck-Guillem
AGTGAACATTGGCATGATAGAC
−30A
.6,13–23
720C
Cerebellopontine
1000/μL
lobule
DSB106
.D324N
exchange1
Co-ordinating
0.49–1.58
differentially-expressed
TYYL
ERα
resected3
_F
P=0.39
0.2784
A411P
MCF-7.fgf-3
biotin-labeled
anti-BAF60a
Talon®
16–52
dl2.S
GTP/GTP-analog-bound
11eGl
42-kd
MMP-9
N542E543
6A7
fromthis
W01536
cases7
Table4,4
33445575
molecular/mutational
cancers,15
−48,001.12
Tyr702
hybridization.11-13
TLR-ligands
F31I
level.48
Schuelke
GSP2
F-9006
1500–1807
139,140
pTZ-tk-CAT
100nM
shRNA-
RUNX1-mutant
.Tas3
AMP-PNP/MgCl2
29±15
ATACCAAAGGGCACACGTT
5′-AAACATACCAAACCACCCACCTAACAAA-3′
CD58-null
positive/negative
CXCR4b
Moskaluk
5′-TCGGAGGCTTGAAAGGACAT-3′
cisplatin/pemetrexed/bevacizumab
function.58
Gran˜a
P12-ISHIKAWA
Met1_Arg359
efficiency-normalized
.Informed
P-mercaptoethanol
Y238
~20
mixed-background
Li-Fraumeni-associated
proliferation31
Nazionale
apoptosis1,2
Carboxy-Terminal
Sigma‐Genosys
.Incorporating
Allconstructs
III:12
subcomponent5.9NGEFNeuronal
E174X
protein-altered
RT-PCR/Sanger
ADIVA
E566G
serine–tyrosine–glutamine–glycine-rich
Tet1-null
trisomy/duplication
L35
Trp53loxp/loxp
:/exA-HIS3
GCTGGGATGATTTTTCATCCTTG
CLL12
p53-mediated
genomicDNA
29–1455
103,104
247,305
∼43
MPCErbB2
0.0126
Janzarik
.3,6,9,19
NM_057169
domain.8
TGFB
+mar3
BioAnalyzer
L705P
ThrPro
EGTA,1
C__25963434_10
K1085
siPRKCB
patients32
MYCN−/−
box-dependent
N86
Stat3.Distinct
Human–Rodent
synthases
segregatFigure
www.biolreprod.org
1–365
supercoiling
FIP1L1-PDGFRAT674I
Y175C
coefficient
PDGFB/Akt
c-Met/ROSinduced
hypereosinophlic
E884K-EGFR
16q22.114
p.P26
cis/trans
sites.16,38
T3C
neuritogenesis
Analy
NTP-binding
accumulate29
TRE
P297
.Oncovirus
transcriptions/translations
.Aur-A
six-month
–either
guanidine-nucleotide-exchange
24891
MM1
Progression12
TTGA
BB=2
27August
V262A
S404X
0.6.1p1
vitro-labeled
5023â
GSE77984
CP-VHL
p.G1942D
immunodeficiency26
/IKKbeta
g/dl
HCC.4
acetyltransferase-deficient
.Array
5′-GGG
Sainz
RICTOR-non-amplified
BRAFE600-
n=124
TCF-1/TCF7
Nangaku
Schwarte-Waldhoff
S45
:941–953
ERGB
wt/Smad4
A.D.A
papillary-like
bar=20
pBTM-ΔLexA
D1012N
.Combined
exon-flanking
Ki-67,9
:CreERT2+/o
PDGF-receptor
P1246
antigen-Ab
nMwortmannin
Cross-linking
reported.14
.MYC
E543L
helix−turn−helix
MaMel-100b
I–interacting
.MGH-PO-l
2,903-kb
.Tet3
.CD4lowCD8low
10-nt
phospho-transfer
4-anilinoquinazoline
BC027262
G213A
L1982
ALK,14
.Magni®cation
.Long
PTPRT−/−
175Thr
genome4
NM_010809
underexpressed-
Gg1.0Kb-Luc
DUX-DNA
63080
PLEC—affecting
R841W
7046
Cerebrospinal
.Anti-tumor
0.05=-2.997
1-07
27–85
49
Grb254
Δexon5q
lymphocytotoxicity
DeltaGPB
P733S
G/c.3284G
235O20
ubiquitin-
al.6
BCL2-specific
PKCd
2237-2238
remission-induction
inhibitor.NVP-BYL719
5-CAGGCAGAAGACATCTGAAAG-3
CRB
pRep4
Bcar3
E519K
6.0−6.5
V651M
158:1137-1143
RLGS
5′‐GGCTATTTTCCTACAATTAGC
sequential-dependent
.1648
gau
signalling119
BlumeJensen
www.nature.com/naturecommunications
CCR2
phase-III
'rhabdoid
71/142
varied.10
p.Arg583Gly
activities.11,34,35
deviation–i
-GDC-0449
Sergentanis
PCX-101
Lox-Stop-Lox
mseconds
IL-10R2
1226delTG
3952delTAGinsAT
4239
medulloblastoma7
319
mRNA.19
endocytosisrelated
clone-
10,12
Immunoblotting—Cells
G371C
Cα-atoms
gene.25,37
26b
CDKN1A/p21
0401
AML1-EVI1
,4B
L44fsdelCCinsA
CHIC2-deletion
NF-κB–responsive
PP-H6939-00
Gal4-VP16
T1.2
.Ki67
TGF-ÃŸ-mediated
0.9623
3q21.1
N220Y
V561D
C348R
VHL-HIF
Y1148
breakpoint.28-30
Fig5E5E
2016CANCER
.Neuroblastoma
90-l
Oncoscan
138/
17.50
2α–Max
v_
5′-AGCTAGTAGAGCctGCAAGTCCtGACTTGTCCGCGTGCTGCAGC-3′
halfCDK6
NM_011249
W73473
R562
megalencephaly-associated
SMARCD1
thrombocytopenic
RCC1
Lys-22
P28
Bio-Rex
substrate-adherent
I747_755insAT
resistance.14–17
Wat189
Atr+/−/Mlh1−/−
perpetuate
CCCL-23
photocross-linking
fusions—in
5′-GAACCGCGGCACAACCATGACTGAATATAAACTTGTGGTAG-3′
EGFR3
S445fsdelAGa
HSC230
rs74763375
bIncludes
fibrolipomatous
syndrome–causative
TOBACCO-RELATED
N1044
fully-transformed
39.0
CACGACGTTGTAAAACGACCTCTGGGCATACCAGCTACTG3
.DN
10–12.5
H723R
5¢-CCCAC
XNP18
DXA
Fig.5b
non-hierarchical
snapCGH
G182D
groups27
≥24
N.s.
delAA
.PTPN14
669
Bmi1+/−
1248
conXicting
UBN2
PD0119
602228
PDGFRA-KIF5B
TMZ
p.Q742K
FGFR3TACC3
differentiation,17,20
Mongia
Sordat
Mdmx/HRasV12-expressing
50–100
59P1749RC64GT826KM1775R
semi-solid
T46
patient-parent
C212Y
angiogenin
R90P
MMTV-PyMT
f/62
Cys-238
HA-immunoprecipitated
×226
Lis-homology
c.2113G
NHM
pGEM4plasmid
extra-sized
loop-helix-loop
Time-course–based
HSD17B4
TCC®
El1
isoforms—KRas
treatment.51
.Remarkably
3´−nitropyrrole
nanocluster-activity
Boaventura
0.65
5.1-fold
//tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumour
identified1–3
C2362F
β-estradiol
62-69
6.5G6.4
6.2-fold
9q34
MTG8/CBFA2T1
features13
nicotine
UBPs
1Kaplan–Meier
PA2G4
0.31492
407.0
Red-X-AffiniPure
cep
singlemissense
Co-IP
MMPTumorsâ
mrr
5047
Larynx
SacII-EcoRV
TNS3-C2
mutation/WT
Attia
membrane-miscible
polyethylenimine-based
Cavenee
Ser601
D735H
I217K
Thermo-Sequenase
antiproliferative
R1304K
exA
9–589
R507I
HindIll
36-39
namea
Database30
–12463
,796^802
obstetric
BRAFins598T
2mFo
138/43/101/17/1
melanogaster97
BA1
immunoreacted
2-24
S.E.K
isosurface
carcinoma145
.Epidemiologic
SG-U
β-catenins
pcDNA3.1/nV5-DEST
ael
HIMbicine-0.05
STAT5a/b
effects.18–21
hyperchromatic
.S15C
277–87
56Â°Cfor14-16
BCORRARA
25μl
PhosphoPlus
Scharfe
pMK
hCds1
Interleukin-3
12:50
A-C.
W39S
AF386649
PRF1
CBFα2
S218/S222-specific
A_52_P106259
horseFig
SkMel24
homodimerize
CDX2
CapZ
Hashibe
Smad/DNA
MSI-L.
S436P
time.If
LR13-110
F846
6/43
c.346G
acid-solution
hMLH1Human
thiswork
neg/no
viral-induced
5′-CAAGGACAAGGTGTACAGTTATGTGACT-3′
JIM3
cbfl
GIMAP
Levens
587×108
polyubiquitylation-dependent
pocket16
ENHANCEDTUMORIGENICITYCONFERREDBY
7-methylguanylate
latency-associated
.Target-specific
nMrecombinant
MaSC-enriched
Cdk12/CycK
D839
5-tetramethylrhodamine
sc-9002
reemergence
.Inspection
PV/PMF/ET
Smad8
methylation.53–55
families/patients
hpa023882
Colo.
PHLLP1
SRSF2-involved
cascades.17
p.E895X
internalisation
data-dependant
inhibitors.a
DelHDSN845-848P
L839P
proteins,71
.Q2223
apeutic
Puc93
F2-R2b
VX-680-binding
indexDownload
G87V
Myc-expressing
D1-T286A-3T3
BioMax
protectionassay
leukemia.30
HA-B-Raf
Prkdcscid
mutations,8
M181R
Marignani
mm-thick
G223R
.HOXD8
terminus–truncated
HindIIIXbaIfragment
H00010413-M01
CSL-HA-transfected
CCL
nitro-cellulose
N-ras-T50I
5′-ggacagcaacagaag
.54
protein19
basepairing
Substantialamounts
1-shot
124–127
5950delCT
hematopathologic
p≤0.001
anti-p44/42MAPK
p.D28_K32del
Lys63-linked
ATAGTTCTCGGCCACTGTGGGCAC
NCI-H1650
PTEN-dependent
Scatterplott
3•1
Erf-/-
FZR1–BRAF
T-75
proxi
6/98
CommentsSomatic
Superpositioning
rats,16
TTTGGAAGCTCTCAGGGTAC
ISRE
N-CAMS
ATATCGCGAG
WinglesslWnt
p110α129-131
phase.11
8/65
ATGAAG/gtatga
minCyR
c.25C
malignancy.22,23
amplification,19
Aii
T288P
0.9734
300nt
Holzbeierlein
1–843
described.62
S100-protein
biglycan
4M1S
mir-21
p53flox/KO
East-Asians
NHA9-transduced
P388/CPT45
eukaryotic
cysteine/glutamate
Gonzalvez
Arg248Trp
CUO4
AO4
tumourigeneis
R86
94Â°C.and
Molecular–Vysis
extracellular
designatedTRK-T3
P0016
Κ-Ras-oncogene-derived
HI1
:HygroR
515W
IVS22
.GSK-3β
2000-step
C3528T
MEK12
Endobronchial
surgery.https
BRD4S-positive
CD40-treated
pPGKCrebpA
TCF-reporter
3/9
655±503
epi-
chromophobe-oncocytoma
AGAGCAGCAGCAAACTCCTTT
20/74.1
p18INK4b
histiocytoid/myoid
GAGCGGCCTGAAGATTCCCC
intergenerationaly
P1-derived
1-370
cullin-based
32A
200–250
11q13-amplified
goserelin
NF-κB–dependent
5′-GTGCAGAGGAAAGTTCCAC
77,736
HER2T798I/
p.V774M
114
LipofectAMINETM
-E1A
L858R+D761Y
CATCTTCCTG
.Cleavage
PI3-K-generated
70-yr-old
α-LPT
APC1309Δ
phate
R776S
1269
MPDs/MDSs
anti–phospho-ERK1/2
Brahma-associated
AnalysisSingle
Correlation-based
YXXM
DxS/Qiagen
7.22
ACII
p.Arg244Gln
postdiagnosis
E939
shRNA-U6
co‐immunoprecipitated
F1888V
trophoresed
pCMV-Myc-ΔN
2.754532467
ITS2
beta-D-galactopyranoside
V384D
-38
Stratakis
Smad4have
nonphysiologicaltemperatures
Pseudoviral
Low-pass
47.5–64.1
22RW1
Xue
demonstrated.18,19
ofarchival
leukemia.18–23,28–39
33,40–42
anti-DNMT3A
30.7
E646V
139:1
c.247A
RARA/RXR
c-CBL
Hnf4α−/Sox9+
anthracycline/mitomycin
level.23
cycle-regulated
RUNX1/CBFβ
plasmon
observed.36
pT1G1
R283contacts
activation.38,39
M-U
t-MDS/t-AML
Kordon
ActR-IB
chr20
Xfit
Ras/mitogen-activated
c.-111
ED25-ED75
Gsα-R201H
.Cerebro-oculo-facio-skeletal
Ligon6,13,30,31,34
CVCL_1532
Arg-280
32bp
N.L
Rash/desquamation
Flag-parafibromin
11270
GTATTTTTTAGGATTAATATG
23–
NTM
NS420
Veridiam
Y384
2740
Tp53-/-
disease.48
membrane-34
13,17
Rip1dnE-cad
Hom–
nm23
12pDEL
1817N
Ingenio
29–79
SOX9-containing
6509105
Teknika
helixturn-helix
MPPH.17
62.6
*Sex
.Medulloblastomas
variant.27
2012:255–257
BCL-2-homologous
Smad-interacting
Subtyped
coot
cells,23
Gerwert
RAS-induced
A763_Y764insFQQA
doi:10.1038/nsmb.2022
MN1,12
exorbitism
EGFR+
Letterio
YFP-EGFR-ICD-based
F1b
ter2227
definitive
293GP
N*
90,000
scalability
studies8-11
template-directed
diepoxibutane
thereafter29
Fast-track
MYC/BCL2/BCL6
number11
4/25
SFK
,8A
PAR-4
TAATATGGAAGTCCAAGTT
Delta-like–1
SH3/proline-rich
Kanokoden
Ise
non-mutagenic
ESCC-associated
2Ca–c
//www.uniprot.org/help/canonical_and_isoforms
A333P
udarabine-refractory
0.802
Ld3S2
carbonitrile
ofAK72
CTTCACTCAGCGCTACAAC
13q12–13q14
scanner.Full
c.400T→C
fluoresence
Qubit®
BAY43
LGQGCFGEVWMGTWNGTTK
OPRK1
IIIB–IV
1.3-Kb
KIT/imatinib
3.56+0.06
isoforms.27
Gy
CAOV-3
bar_
Sarcoma
c.522T
31,34
1:1043
DIMHD842-846N
phospho-S6S235/236
AmpFLSTR-Profiler
melanocyte-lineage/antigen
PCRamplified
.045
abundance12
.Dependence
T2484M
-digested
HBECs
.high
HCT8
mutation,5
PreAnalytics
diagonalization
AML-M6
lines50
tumorigenesis78,83
D835-mutant
outcomes.7,9,11,36
artefactually
δ-catenin
mMglutathione
24748
ADPnP-bound
ALK-rearrangements
L-02
2.Table
KRas4a
Borkowska
Linnaeus
subclonungthe
MAPK10
super-enhancers.119
R456H
protein-ligand
PTEN-Deficient
Y293C
HA-MALT1
RagC
carcinogenesis.13,43-46
thymocytes21,22
.Stoichiometry
jetPEI
E709Qa
anti-phospho-Smad1/5
.Dimensions
tumor-mutation
E6779
SMCT
.Typical
p36trk
SHP2-catalyzed
erlotinib.2
NERF-1B
Arg506
128R
685
V392R
curative-intent
stability.In
Pro848Leu
squared-off
v2.13.2
WT-BRAF
1.5-mL
TET2/3
CA66996
immunoprecipitants
Caignec1–4
TCAGAGAGTCTTCCCACCCAACTTGAGTCC
rs140161845
edgeR27
GRE5-CAT/EBV
Br36
nt1768A
factor-positive
77.6–80.1
Halaby
sym-
co-crystalized
nucleotide-specific
.Cytosine
R84W
TXNIP16
0.56–1.14
Tyr1007/
AC-3
50/61
provided19
5'-PuPuPuCWWGPyPyPy-3
PeproTec
6:2
A840A
ARE-mediated
ElonginC-SOCS-box
3.5+
T759del
KIF5A-BC033961
kinase-fusion–positive
Yingling
vector-complemented
c.68G4A
TGGACAGCAGCTCCAGGACA-3
permeabilized
611eu
N-16-lysine
G70E
9007
p.S918C
-32/-27
panelof
100mg/kg
35S-free
A_51_P311038
chloroform-extracted
procedure‑related
D38V
8,700
previously.62,63
p300/cAMP-response
'direction
+100
http//www.broadinstitute.org/igv
5hmC-high
SpectraCube
Tyr740/Tyr741
Malaney
GREAT27
2921–2934
Etiopathogenesis
pKA622
genetic-based
pAD–BRCA1–Δ3
Ala-scanning
TM1
EWS-associated
0-158
pNKY
PHB
2Am
6/480
.DHT
Yes42*
1,2,3,4,7,8
Depinho
5F
BEZ235169
mutation-affected
2.8–6.8
V191D
Coger
.Estimations
J6I
.SJHGG016_D
Swagemakers
binding–defective
CGGACGCAACAGAGAAAGACTT-3′
DMBA-associated
2.9×10−6
forward/scatter
resistance–related
7q31.1
α-S2
5′-CCACATGTCATCAAATTGTTTGGGGCCTGCAGCCAGCATGGCCC-3
them.43
NICD/CSL/MAML1
'A
samples12
18,19,20,21,22,23,24
.Preparations
overlined
ALK/Met
KrasLA2
367–459
.Synchronized
CCTGGAGGGTACCGGTTTGTCA
S163R
male/female
0.135797
ZO-1
N771delinsKPP
JAK2–PCM1
280,000
Gyrase
CCCCGCACCAAGCAGACAAA
CD74–ROS1–transformed
GS-249F
.subgroup
7/1/09
Shtiegman
Ret9
FLAG-Krasex3op
5′-TGATGATCTTGAGGCTGTTGT-3′
Boggaram
P173-Gain3
pCMV6-RAF1-FLAG
5'-GCGCCATGGGCTCTGAAATGGACAACAAC-3
.LB996-RCC
NIH-3T3–MSCV–puro–Mek1
FLT3-F594L-
Woo
healthyindividuals
acidophilum
G2146A
Doxþ
G60_A66dup
GIPZ
Follow-up4
1/T
trans.
AATATGTACATT
60–80
RMPI
1/289
AlexaFluor-488
L361P
SRILATHA
fundamentally
Stimulus-Specific
HEC-251
IFITM1-mediated
p.Cys241Gly
ALK.86
4.6.7
-GGTACCAAGCTTAAG-3
H2309R
tissues.1–5
21a
shBAP1.214
Evrogen
C/cdk3
ThT
RCC-
after-loading
Oddd
D3073
5N–P
HumanWG
-it
GeneTex
ara
multidocking
v-Ha-ras
EKFRVGNCKHLKMTRP
sites/594
.Adapter-ligated
PALDJL
Amuvatinib
brother—case
Bannayan–Zonana
alignment/map
1CDK
PCR-SBT
AllCells
241
ING1
Thr68Ahn
48-50
-J/BRIP1
0.49
pMiw-Sp1
P.A871V
PNG
specimens.8-10
.Vessel
PDGFRB-T681M
D-19
helix-breaking
SHP2-Flag
data-cutoff
8.275
Well-defined
PDAM
50ng/mll00ng/ml
PPPY559
G259AiTGC-+TAC
Heredograms
GFP-
nonfluorescent
-TAC-5
SM6-specific
Institute-sponsored
Epith
Flag-U2AF1
MyF
CTE
AMN107-treated
line-specific
B-RafS365A
FLAG-ASXL1-MT1
5-aza-deoxycytidine
phosphorylation—and/or
adenocarcinoma.11
J.M.
fibromyxoid
KIT/pcDNA3.1
.Context-specific
VEGFR-1-transfected
∼4.3
3VUTR-r
two-dye
.-M.Y.
.Ther
locus49
disregulated
N=303
m1
anti-JAK2
2–13
5'-GTTTCTT
Cys277
tools.15
1,2,3,4
1/3N
.045a
n.t
Y293
fgf
DNMT3L
8μm
.Sym013
V2-linked
5′-GTGACAGATCTCTCAGGGCATCAGGTCTTCACC-3′
E50
L291P
2D–K
.best
BRCA-deficient
chr12
p.Ala23Glu
MYH8
G245D
Adenosquamous
elongins
Del-19
TCACGAACTGTGCTGATGGG
anti-TRK
PAb1620
phosphodiester
Re-expression
N–SH2/PTP
level.HER2
TSC2-dependent
SC–Met
Bergstralh
−1→0
tables22
1,759
.Witte
11.15
Immunodeficiency-associated
uc003xdo
Alport
fluorescein-
end-point
Lestaurtinib
groundwork
LIM2405
frequency/high
cytotoxicity.7–11
XRCC3-BD
pFA6aKanMX4
10-cm-diameter
sequencing.67
pCMV6-AC-GFP
ACAGTTCGGAAAGCCTACAGA
40–415
.KIT-targeting
WRO82-1
P427S
1,778
insignificant
ccRCCC
14,67
gene,11,12
deletion/insertion
KR
del/ins
fascioscapular
PBS/2
12BGGTC'FGACCGTAGACC'I'G228
Beckmann
//www.genetix.com/
±16.7
S657G
000435
His-24
Uphsala
7q33
175P
.Kwiatkowski
74.3
1-100
S564I
SRC-Y529F
transactivation-deficient
38,54,55
+Rapamycin
Fineneedle
re-analyzed
Bvirus
prognoses.25
0.002189
predictions.10
1016–2101
concentration‐dependent
nospecific
PDA-exon15R
GTPases11,12,14
1,072
NSCLC22
3011S
GGGCTGAGCACAGACTTAGG
R537Y
BC200
MOLT3
FANCI/FANCD2
kinematic
GATCATATTCATATTCTCTG
non-clear
fresh-cut
solidification
helix.
Talarico
p.D820E
phenol/chloroform/isopropanol
.MutSigCV
-knockdown
=74
1,228
5.74
ATGAGATC
HD-LM
p.Trp267Arg
//ast.bioinfo.tau.ac.il/ESR.htm
G-39
.HSU63834
4-iodophenyl
fromtop
unnormalised
EVS/ESP
RD‑C
IFNα
antibody-cytotoxic
1.8–900
mechanics/Poisson–Boltzmann
tumors58
S106P
FOPflash
II:6
Oilman
.Empirically
0.646
K3266T
AJ306634
Conchillo-Solé
3.6a
mitomycin-c
TMAQHAE
cancer-mutant-bearing
.Near-Homogeneous
preliminarily
Asp93–Pro141
Elf3ΔN270K320E
CED
Blanpain
Lin/NOTCH
cyclin-E
Hepatol
45-
dome-shaped
9q21.31
SMAD1/5
forward/side
SPOCK3
CTSH
28:1463–1470
baculovirus-expressed
low-oxygen
FGFR1−/HR−
V102I
DRAM
AGG
DNA1,2
.WI-38
forms.12
c.714^1G4A
812-1132
ruxolitinib-resistant
UBR2-ubH2A
Frank-Raue
~1,000
1-selective
niche-based
1p/19q-codeleted
53.0–92.9
splice-acceptor
4EBP-1
OVA-stimulated
E-Blot
anti-CD56–PC7
GST-CHK2
751-
TheMLL
3101C
ÃŸ-catenin
CH12F3-2AA
transition.188
lipopolysaccharide20
p.E71del
Organ-specific
1JPP
oxfordjournals.org
Tmprss2-ERG
IIb1
.BFU-E
FIP1E6-F2
recruitment.Figure
CD34+/CD19-
5′-GGGCTCCAGCTGTACTTTCA-3′
Helical-OB1
2,461
P573S
model.10
GRAIL39
FAP-1
A247D
staining.PCR
IFN-α-inducible
pan-IAP
algorithm.8
.Future
509-545
signal-induced
phosphate-binding-loop
28February
//www.takara-bio.co.jp/prt/intro.htm
C1156Y.37
kb/min
5twofold
p.Gly256Cys
Eurofins
progression.16
7,824/7,977
velvety
56772481
p.T82A
al50
pleomorphic/blastoid
KDM5C-dependent
Coon
GCB-derived
60a
Mut6
1853AA
mRNAs.As
cDNA-sequencing
two-copy
Microfocus
O-phosphorylethanolamine
.Reciprocally
Gaiddon
SVZ
.Dermatoglyphics
close-to-endogenous
Cys217
patients.8,9
TNRC
AR15
17q21-q22
p–ribosomal
construct.8
slower-migrating
phosphorylated-ERK
1,388
1302–1325
.TGI
RAD51D-associated
5–29
Genome-wide
Gab2−/−
j.verweij
Non-linear
Bionex
recogned
±0.53
earlyonset
AAC-39
Phospho-H2AX
CTGGAG
BcL
38-kb
MKK6-p38
43.8-74.5
C11orf67
.HA-GLUT4-GFP
*GIyPro
H.We
FIP1L1–PDGFRA
BRCA1-C61G
NRAS=12
Stabilization
Grb10
erbB2-positive
//hgserver1.amc.nl
50-74
Kumabe
GRM1
1873
CCCGGAAGT
knocked-ins
autoclave
ERF-induced
Kruglyak
H3K275
SCN3B
AppendixS1
G1-cell
5-4
Allogeneic
.Serova-Sinilnikova
A413E
Ras–PI3K
.Methodology/Principal
easy-to-digest
proofreading-like
N1-ICE2516A
serine//threonine
/turn
4-μm–thick
lj
www.cbs.dtu.dk/services/NetGene2
K369E
2739–2745
TOP/FOPFLASH
c.1456C4T
117–127
1086–1088
1,993
5′-TCC
crizotinib.8ALK
.Both
TRIzol-based
GGUGAUGUUUGGGUCAGGUGCCUUA
//MTCP1TG
:156–166
fragment-length
GRIK5
15.7-fold
.transcriptional
T64
RP11–62B7
5′-AAGACGGCGGCCGGGAGT-3′
mmol/l
trial15
VIOGENE
HER2overexpression
4685
TEL.int4F
1,273
51004
C-CBL-transduced
anti-DDR2
Blow-up
R611Q
Ensembl59
CTCAGCCCAATCGCTAAGTC
06-195
Thery
2shp
1973
MPKTRRRPRRSQRKRPPTP
position.In
.MAP3K1
cells,16
PCGF1
transformation.Primary
Protoc
neurofibromin-like
J113
CAT→AGG
isoformderived
FZR1′s
DME-negative
β1-sheet
heart147
N74
1q32.2
±9.4
NRF2-independent
engraftable
GAP-defective
tuberin-N
788–1153
phophorylated-Smad2
samples.9
13/68
CHD8
CUL3
NM_010896
v-HaRas
Paralogs
DL8
modifier/remodeling
47-gene
E466K
GATA3-ext+wt
squ
.Non-AR
oxygen-containing
1-221
3418
Kuefer
Klf4
.GEP
60.4+3.1
.44B
PIM
3'untranslated
c-src-derived
Band-4.1
shRUNX1
STRN–ALK
D3
173A3T
c/Apaf-1/caspase-9-containing
S5A–K
L12
5.78
Others23
M.-J
co-mutation
incorpor­
nucleotide
.MFE-280
HSP90-dependent
9th
111*Recessive
'high
NCT00891930
hTERT.Luc
SQC
antiCdk12
disease3
6.13593
ICF-associated
T69
preplanned
anti-TSC2
Lys73
cholangiocytes
58–172
mTOR-binding
FacXPD
1215
ELK4
128–305
Copy-number
b-catenin/TCF
regulators.14,17-22
analyzed.9
CRL4
cAMP-signalling
L2067P
ANKRD12
11/10
.61719472C
T198E/D
completion.28
papilloma-virus
ADP/ATP/free
.ins
.Leukemia-free
Abl-related
nickel-1,2-dioleolyl-sn-glycero-3-
Abl-1a
doi:10.1038/ng1624
CelLytic-M
elastase,25by
1:200-1:2,000
nonfunctioning
-unrelated
Ala-36
pre-RNA
F1574
prostate40
0.08-0.5
KB1PM3
I725M
A524
pik3cb
activ
.Asp419Del
epothilones
c.3024G
Animale
C80L
SNuPE.23
3∶1
neoadjuvantly
T2487
48y
CFC8
anti-JUN
monoclonal
‡Rmerge
residue-mediated
biopsies4
kinase-mitogen-activated
0.808
YFP-tagged
UAAGAAAUACUAAAUUAAUUUCCAG
Sall
www.tsalliance.org
Glu-56
melanoma.24
Arg366
agents.Table
elsewhere.34,35
ATACACCAGTTCAGCAGGTC
Lys-753
ETV6-IGH
PIK3CA-NIH3T3
single-stage
ETV4_exon2-r
T451
SIM-mutated
K52RΔC
4206
HSPGs
non-HPGL
4551
Assié
reslizumab
211
ChIP–chip
co-varying
Methods.Chr
RASRAF
deuterostomate
26112
19.125*
TTGCCATCTGCTGCCGACACCT
p=6E-4
'wild-type
Z-DEVD-FMK-resistant
Yeang
NCT00949910
5′-CATATAAGGTACCGCTGGCCTGGCCGGACTTCC-3′
CanPeptide
I–IX
.404delA
SF3B1K666T
-CTGATTCCAGATT
ana‑
1.7±0.6
carcinomas.41
Son-of-sevenless
Counterbalance
STAT1-related
E846K
319/528
V43T
ATTAGGTGGGAACTGTAGAACC
DLBCL10
YAP/TAZ
inhibitor–based
dissectedand
proto-oncogenic
Dynabeads
6.5Gr
interferon–alpha
.AEs
20520
phosphoAKT
super-WW
PrD
coma
FRCPath
dose-dependently
zygote
16/215
2b–d
rs16942
CBL/Ubi
HN5—and
1–942
Ejlertsen
phospho-residue
/137
pCL10A1
1D3
20μM
pcbi.1003749.e002.jpg
Val163
1.25
3T3/V
87.4–96.0
.2,2
1,528
CSF2RA
504KB
R82P
doublelabelling
−1344
3-h
20mMTris-HCl
TGF-ÃŸplays
ENST00000378444
C-3′
neutron-induced
syndrome,8
R290C
G.Z.
GST-Erk2
mismatchbound
TpK12D/WT
Enzymatic
αi
77.4
R515A
RAF-isoforms
APC2644Δ
CCAGTGCCACAAGAACTACATC
TEL-PDGFRβ–induced
neu-expressing
ab37168
155-kilodaltons
.Anisotropy
domains.28−33
NAE
Gly-Cys
pipette
BRCA2-PALB2
Co12
wu106
E285K
-microglobulin
triphosphate–biotin
sideroblastic
albumin/ml
Pdgfrα-derived
IgH–Myc
1/24
N-Ras-transformed
≈500–5000
4,500
43/46
Hiden
expansion196
BAT26,30
anti-caspase-3
Rubel
α-H3
'I
.HBZ
Oncofetal
pERBB2-tumors
1.501532
10–250
µmol
mutations100
calling27
D208
.Commercial
N141K
pSer396
M781I
.case
p.H1773P
pigmentosum–Cockayne
XG7
IKKs
B6/129
IHD2
Mn2+-dependent
-PI
signifcant
T491
6–8
A919
ODC1
355ins1
artifact.
0.0411
BP3
Fnu4HI
epidoxorubicin
theseproteins
transcriptase54
gtacagggg
carcinomas8,9
sequences31•
5′-TTGGCACTCGATGGTGAATG-3′
572KB
pT3-4
homology–based
100-ns
MCF-10A
1F⇓
class-switch
7–intron
P\19
Gastrica
PI3K14
Lunter
Idbaih
c.376A
Monomethylation
8:1
ATR-like
non-adrenergic
3/909
p53S-Ras
Crouzon
5¶-TCACTTCTGCTTGGAGAAATATTCTTTGCTC-3¶
1/323
Comput
oligomer27
vacuolization
Caldesmon
BS-7166R
THD/DeltaC4
GGCT
element-dependant
processing-related
SCF/ml
3000
blue-cell
.KPβ
transformation32,34-37
TAF-1
RF/mm2
1837C-G
shown.In
1,138
sulfoxide-polybrene
RET-KD—As
1.1–40
Myt1
M1199-NH
silybin-phytosome
-Mutation
Leu118
whetherAMN107
Nox
Anti-BRAF
IV.9
NIHR
alterations/tumor
oestrogenreceptor
c.2925+5G
p85ni-K379E
aProoClyProLouG
Ste20
G95E
Sno
TEL-ABL-transformed
CACATC
contraction-related
P081/082
R25E
GBI
-NA_TUR_E
+cobimetinib
Ras/RAF/MEK/ERK
DGF
factor.67
WT-Akt
alÃ-elesfrom
9070
6-nR
.CONSORT
90·9
common—remain
0.4491
p.Asp980Val
MCM4
935–944
Phenylindole
2.17
50˚C
K423E
2.25
ΔJH2
-AGCGGGAAATCGTGCGTG-3
15N-enriched
P53BP1
malignancy13
Arg770
D341
Thr24
5′-taa
12-404
Alber
Frs-2
repressionof
Tamaki
GlyfsX6
p53-neutralizing
SNuPE1706F
512×512
thioredoxin-dependent
201-414
cancer-inducing
JC70A
MetiHGF
defmed
Shield-
5′-CATCATGTTGCGGATGGCTTCGGACTATGACC-3′
andsmall
vivo.15,20,23
uMe
2HG.17⇓⇓⇓-21
HSPB1
nonnormalized
ARFL
transfectable
HPA039281
Immunoperoxidase
CDC4-mediated
HSC/P
F50
Wap-Cre-expressing
V284
RW7213
L2155S
diluent
​Figure2B2B
WRO
3D
GQT
B-ALL/LBL
Six6
urinary-tract
AMPK.27
Mutagnesis
Ryffel
250–400
delayed-resistance
0·048
Nox4-mediated
PTP-inactive
CD55
state.14
discrete.1
IVSlOa-32C
SDHA
Ranvier
Parekh
EBP50
haematologic
PAR‐CLIP
testosterone/day
CSLx4
OT-I
5′-TGGTACCAAGAAGAGTGACTTCC-3′
SC-URA
dual-substrate
JY
holo-complex
R570S
C-peptide
multiple-subunit
Acm1
45241
SH3-
0.28–0.83
YFP-BRCT
TgN
56770081
NRC
previouslyassociated
cy5
Bolognia
DDR2
F876I
NSE-negative
Visitech
growth-stimulated
TUMOURIGENESIS
G390R
pRSV-Rev
anti-phospho-ERK1/2
multidetector
NCT01267240
c.1747C4G
Perray-en
bothbreast
370-371
GCCCWSSW
S83
CD79b+
MCA38
charged-couple
rs121913016
tetramer39
TEL-PDGFRβ-
5′-GCTAGCGGGCTCGCGGACGTGAAG-3′
Amélie
malignancies.7,11,18
genital
P176L
pCAGGS-Ewsr1
alpha-
34–67
structuralabnormality
results.25
Giet
Myc-TrkA-P203
0.78–2.83
p16INK4a-null
Sharifnia
Transcription-PCR—The
MNTI
CS/BRRS
GSE19069
pQE-A1-H-ras-G48R
MSHLGQHENI
transcript-specific
Non-essential
primary–secondary
Anexample
Investigating
DCM
1800–1850
H3F3A-TP53
MCF-7-14
cancers—over
6Q
autoPARylation
MSCV–puro–Mek1
site-associated
antibodies/protein
Asp-932
ETV4_AS
p.Defects
VM-CUBIII
.GRE
325:99–107.10.1016/j.canlet.2012.06.012
ΔBRCT
Misteli
LY290024
4.4-11.4
GGGAGGAGAGAAGGAAGGAAGAGGTACGCCACTTCCACAG
cerevisiae-based
Transplantable
ABL-T315I
pHER3
K/N/H-RAS
ttccag/TTACCA
G799C
Eight-week-old
significance*
laminin-binding
UAS-ALK
K257sp
GSE7822
PLCgamma
amphotecin
cells/blasts
582–671
Bostner
1−203
DNA-lipofectin
125.8
aArgG
GGGTTAAC
present163
0.00263
ErbB2-amplified
50–55
NAMB-I
Roidl
0/24
./
S827G
EML4
Cebpa-Cre–driven
Shld-dosage
P.R.N
Val1035Asp
P=0.0035
eight100-mm
-HCl
54-11
NF2-causing
H-Ras—the
85-
1–113
5′-TGGTAACATCCACCCAGATCA-3′
pEGFP-Brd4
GDC-0623
5,6,20
Cys552
inC-terminal
estrogen-bound
Caryotype
SnoA
2,674
67–74Smetsers
p.Leu845Thrfs*38
N=20
ATCAGACCACTGCACTTCAGCC
E518K
FACT25,26,32,33.There
81–87
Intron1.11
ISWI-related
IRS-1-4
dem-
rethinking—perhaps
sixty-four
D47
Alestrom
cancer-directed
Fbw1a
1725delA
dimerization22
germline16
FGF1-treated
PDK2
.Controlling
helicobacter
E2F6
ETV6-STL
ATIC-ALK
BC040336
L747
.SHP-2
Fungal
Immuno-Biological
43-fold
JetPEI
B7‐H4
ATPase/helicase
S30D
formalin-fixed/paraffin-embedded
.8953
ALNQALGR
VP1
ALK-R1275Q
75-85
stem–progenitor
G1block
T790M-EGFR–mediated
Q294K
cells14
near-diploid/tetraploid
7.86×107
0.0405
.Hedley
dispelled
1320
AtHB16
2Neurology
reported122
16p6q1q3220Ana.iq
T–C
N58S
fibrodysplasia
oxygen/air
wt-conformation
oestrogen-regulated
up-frameshift
armamentarium
-min-alt-allele-count
CCCATCTTCACCATTGACCAT
treatmentfailure
Papworth
5′TTCACCTCGAGCAGTAGCGCTGTTCCAGGACCAAG
andD281Y
AMN107-
Heterochromatic
MYO7A
5'-CAGAGCTCCCAATCGTCTTACGG-3
pAkt-Ser473
7q31–q34
Frech
Rao
suggested.31
202–437
ade2-ISceI
mutations—L858R
BRCAI-associated
fusions2
p-HER3Y1289
TGF‐β
7q21∼q22
E203
serine/threonine-protein
5′-TGACTCTGATGCAGAAGATGGAGGTGTTTGAGCAT-3′
GPR133
pcGATA-1
5596
hsNF1
ankyrin-repeat
0.01:1
.SCID
GLYCINE-RICH
LICOR
M361V
c1794_1796dup
.HDAC1
described.28ψ2
59.26
UBE2N-
Tobal
SM-UL
Olivero
5′GGAGCAGCCGATGGGCTTGTCCTTGGC3′
development.4,15
lymphoma/thymoma
4145
56C6
GAG-TGG-CTG-TGG-TAG-AGA-TC
1844880
2constructs
T3081
0108N
STAG1/STAG2
Lymphoma-
Myotubes—To
goldFISH
ZRACCTCAAACCTAGACGAATTCCG-3
H-RasC118S/K104C
KSL
32,317.2
0.77-1.31
3f–g
69,70
displayeda
G1202R–L1198F
10q
cell-essential
osteoscarcoma
BcrAblwt-
aq-Q209L
.404
LacZ/BRAFwt
SRC/p160
rad50Δ
102500
FLAG-TSC1
EGFR1
8-kb
abnormalitiesresult
.Assemblies
Radiolabeling
Hellenic
MATH-substrate
preclinically
p.Arg271fs
domain–activating
FGF16–FGF23
TPT1–AADAT
//www.broad.mit.edu/gsea/msigdb
T3–T4
pCK125
G12V-disregulated
pia
Martin-Orozco
aboveground
acidic
R7C
range=36–77
.Revisiting
anti-CD61
H139P‡
CTTGAATTCATGGACTACAAGGACGACGATGACAAGGCT-GCCATCCGGAAGAAACTGGTG
p.G114R
mutant-GCCAGAGGCCACTTGTGTAG
phosphorylation‐defective
KPDfl/−
SG-PERT
blottingProtein
autofluorescence
5-AAGACGATGCCACTGACAAG-3
67y
SAH
264K
CTB-13N12
v.1
.989
c.610G
586-
26-27
NRG-4
phospho-PLCy1
cytC
MSCVneo+pGFP-V-RS
Rhodamine-conjugated
NIH-PA
HSP90-interacting
1018-4813/01
Lympho-edema
profile–derived
extraction/permeablization
12/13
Magrangeas
I180V
BLCL
.Selective
.ESCC
intratumor-injected
Chook
†PolyPhen-2
HumanHap610
twosubunits
NAV2-TCF7L1
ras-p21
3/0
R=
parotid/salivary
1002
621–760
.D1-T286A
MCPH2
carcinomas.30
CGC→CAC
59-GGG
187×109/L
4,33-35
differentiation.37
Ser2-phospho-RNAP
SHP2+/−
breast,5,6
IL-3–producing
5′-CTGTACACCTTTATCATCGG-3′
pCAGGS-FlpE
91.3
dysembryoplastic
18–37
8305C
1.5×106
c.686_687delCT
telogen
C99
prostate-associated
package31
allele35
UAS-ash2-RNAi
1.00WT1
mutant-enhanced
134/269
R379C
W110*
MutY
µg/well
1191
complement-mediated
anti-RARAantibody
Rassool
neutron
Oliveberg
c.965G
581–589
.Growing
PDGFΒR
Tnzol
HYBrite
Gueven
fragments—human
1500/μl
HiFidelity
.Irreversible
neurilemomas
Ph1
v1.3.3
GNA13
Val133
.Precise
M713I
KRASG12D
98–108
5228
80-kd
carcinomas.14–19
NEK2
.2603
141-2
elementregulated
Internationale
Centre-AMC
P766S
D197H
cont'lining
Kneller
DeGregori
W72207
time-courses
juxtaposi­
SMC1
stop-codon
Pathol
DQA12
GMR-Gal4
described57
.047
15,16,17,18,19
O.C.T
Figure3C,3C
Goserelin
1FIGURE
.Thr315
Thymine
mTOR-mutant
afrom
40,494
MUTANTEGFR
IGFBP
N731
I-ATP
IRF4+/BLIMP1+
.104G
mutantU2AF35-transduced
CGdotTG
q36.3
Millex
-empty
signaling-deficient
P164_T22del
near-homogeneity
VTKGRVPYPGMVNREVLEQV-ERGYRMPCPQGCPESLHELMKLCWKKDPD
shRNA463
VH3
rs7105934
R182H
lentiviral-empty
L-α-
10672
74.07
−1.82
diamindine
0–0.7
R423H
P031/P032
Daigo
RXR
U3-1287
.NM_004327
anti-Lats2
5·1
0.1082
152_520del
RP11-90H9
Operationally
.Decreases
pGL3-Promoter
40-month
CDK9
L173R
p21/CIP1
STAT5bRARa-expressing
GATCAACGAGAAGAGAAGTC
25245–25249
.913G
anti-CD3-e
51-yearold
BD™
5′-ACGCAGGGCAAGAACACAG-3′
cancer.MethodsCell
risk-families
Y489H
006206
+++/+++
cyclins,23
.Runx2
**6884_6885
BTBD18
NUT-expressing
Weisz
EKLF
reviews.13
μm2/sec
ALDH1A3
risk.Table
α-PD1
Sâ€
anonymity
80.5∗
Xlinked
5′-CACACACGATACACTCCACACAA-3′
SUP-M2AR500D
MDS,2
DSS
108.2°
CHD1−
loop-based
Pajusola
ERK-interacting
Programa
distributingpatterns
Atf4
sialoprotein
SNAT2-containing
mRad50
Genomon-exome
ACTCCTTTGCAGCCTTGC
G109R
knownGene
shock.
Yk
WIP-P11
length×width2
melanogenesis
pT2N1M0
MSH2.3
nihms646437t22.jpg
LIPOFECTAMINETM
c.-111C
S6284
mono-ADP-ribosyltransferase
212-639-5721
SDS/0.1
9.6-fold
35-kDa
0.2248
Docetaxel/carboplatin/trastuzumab
drug-mediated
Tyr-653
Nrf3
cctcag/AACCGT
R138H
Ponatinib-FGFR4
thirty-seven
6.4-kb
23-amino
.D–L
complexation
WCP22-painted
a-Ki67
M-003131-02
Eighty-eight
831–1011
chr19:47483801G
TBARS
for1
859KB
bioinfo.ut.ee/primer3-0.4.0/primer3/
2281G
32.5°C
post-lorlatinib
Atlas–defined
www.federa.org
cDNA-containing
lÃ
5-µm-thick
.from
Overgrowth-later
Glu-217
methanesulfonate
TransIT-293
mTORC1-dependent
Lmx1b−/−
TCGA
on–off
lymphoma-derived
pGST-BRCT1749
brevican
.pi
rtTA-recipient
patients18
F.-eadherin
FDX1
Maebashi
Penicillin-Streptomycin
1501Gright
-GAAGCACTGCAGAGACATGG-3
.MY23
vismiones
FLPe-recombined
HLA-A0201–restricted
TAX1BP1–BRAF
5604
A.-M.
P540219
serumresponsive
H1047R
.034*
mean+s.d
12AAGCrCAAGATCCCCCTGGA140
Pdgfrb+/-
HA-JNK1-
rearrangement.144
D12S321
thebinding
CDK4/6-specific
Neurosci
Two-fold
exchange116
8.6-kb
CXH
D184N
W162
DNER
.Xrcc2
GTGAACATCATTCAAGGCGT
resistance.15–17
repopulation/transformation
5′-GGCCATTACGGCCGCGGCCGCCTCTAGAGGATCCGATATCG-3′
pharmacophoric
KAT
20~30
GS-5'-reporter
.Whole-genome
ABI-Prism
D530N
ATM-mutated
Bcr-Ablmut
rosiglitazone
BPV
p24·1
vivo17
42513
//dx.doi.org/10.7554/eLife.14709.008
lines24
.Determinations
Michaloglou
:8127–36
finger/toe
L597-mutated
Retronectin
α-RBBP5
carbonyls
Tyr1148
GCTCTTATCTGAAGATGTA
0.96–126
DNMT3Anon-R882
223-517
S280L
p16/ΔΔ9−144
negativeregulation
Ala877
al21
HAhBRAFV600E
p=0.0424
.PASLI
374
onlyby
resource-demanding
ring-cloned
Brm-
TSC2-expressing
AKT1/RAC
.T1561I
iVRRvGgLSSMSGGDDaiYyEhr
5′-TAAGAAACAGTCCGACTCAATTCAAGAGATTGAGTCGGACTGTTTCTTTCTTTTTTC-3′
Rap-GDP
CTGSSDNE
Glutathione-sepharose
Deate
250x
2005.
LKB49-309
methanol-crystal
shTAL1-expressing
2,758
MMRb
C-Kit
hsa
mutations17
Arg273
cooperately
pEGFP–p53
TCCTGTCCCACGTCCAATAC
CAL27
12-hour
protrusion
2783
yeast.Figure
null-like
PML/RARA
DDLPS_08T
J02958
PANNKX
Novocastra
Kit589
p.G719S
mould
cells28•29
-triene-3,17-β-diol
regions.29
xenografts20
.Microdissectiontechniques
uridylate-rich
–2252
GC/PKC412
ROR1-positive
inbreast/ovarian
vimentin.81
fish-naevi
D1/CDK
DLEU2
TXN1
–,26
chemotherapyprotocols
transductionstep
RBP-J
cystein-rich
Jin
c.34G
.LC-MS/MS
poikilocytosis
Glu942
stack.4
5m-dCMP
4148
Xin
611723
p.Y503_F504insAY
www.fasebj.org
allo-SCT
K-346
547–581
B-ALL.3
.Phycoerythrin-conjugated
inhibitors.We
Benjamini-Hochberg–
tissues29
Pms2E702K
GFP-SPA-1
RNase-Free
subtype2
mid-gestational
.27713
axial
A39G
Y.I
Study10
convergent
1895
/PRK1
LTR-DCAF1
2537
S577
Vpx-mediated
c.-26C
TMPRSS2-ETS-positive
R8R
AEEEIYGEFEAKKK
C275Y
140.8
AB1
MET/erbB3
approximation.20,21
-2447
KAB/C
p=3.869e-11
Steinarsdottir
Inbred
Arumugam
.Multicellular
PP58-resistant
asp-phe-gly
KRAS/CEP12
68878171
Immunoblotting-Infected
previously.12
3956
Wicha
R286H
described44
pcDNA3-HA
sdm
p=0.138
pNKYlO1
Rajasagi
c.904-
11,532
p16-deficient
-actactgcaacagctccacagaccag
interaction.25
transposonlike
phospho-peptides
542b
.Sleep
1.5-2
2p23-p24
TSP-1
P\0.05
Notch‐modifying
.Others
doublestrand
CSF1PO
iScan
c.343C
pGL-TK
refFlat
P40T
TCF3-mediated
K851
Kraakman-van
Co-localized
.RKE-Ras
HRASD119N
57/74
I270T
RBM43
**f**
37.1
C/EBPα.WT
system27,28
B4GALNT4
mAB414
GAACAGAAGGGGGATCCGCCCCTGGGAAG
PRMT1-deficient
6.30–13.12
FGFR1-gene
cycleregulated
▾
n=390
Lüscher
in0
D352G
59-GAAGAAAGTCTCACCAGG-39
Thefinal
Opti-D4
.KPT
.U2AF1
FGFR1-dependent
35,45,46
4.22
etoposide
nitrocellulose
Jasco-805
S240
Sanchez-Garcı́a
RGL2/RLF
inhibitors,20
E23D
EWSR1-ETV1
Phenomonex
Anti-Jade-1
-2HG
FLT3-V579A
7665
LVEFGA
ΔTCT
C75S
leiomyoma-linked
203/269
INC.HUMAN
ampliWcation
D120G
LINC00264
mutant.38
C64G
ASM
uncommon25
BCL10-containing
cx-32P
Patrawala
pUCFAC-D1.34
≈4
Vam7
M1616
T329
10–65
T751insA
seconds/61C-30
F-7
Furin
K625R
HLA-Bw6/-Bw4
.15Figure
interstital
5p13
myc-p110δ
HEMATOPOETIC
monocytosis
▨
EJE
CFS-associated
P121L
activiation
29091840
1-liter
ATACTTTCTCATATTCAGTA
86.3
Me9
8q24.3
RACE2
NC_000007.13
Bcl10-mediated
adenine-binding
S249C-FGFR3
ECFP-MyD88
Y418Δ
RasV12-expressing
5'-GC-clamp-GCAT-TTAGGGAATTAATAAAGGG-3
,3G
:2638–45
UNL
Cancer-associatedIDHmutations
0.9357c
69aa
73–75
30-µm
6/39
.Whenever
Ly6e
atggccgcgg-cggctggc-ggacggctccgg-cag
.Now
3.65±0.10
W51B2
rs523349
333634
susceptibility.2
5537
PNET3
ATMCHEK2-p53
dm3
localization.13
N-morpholino
°C/61.6
R858
Notchic-estrogen
exon5
non-identical
40/0.75
S6A–S6D
51:54–65.Moreover
R958D
0.05-0.1
Lin−Sca-1lowc-Kit+CD34+CD16/32hi
CUCRC125
17,000/µl
inhibitor18
13,278
helicase-specific
mg=∑tNt
mutation,19,27
protease
Voegel
L1036M
estab-
.Curves
L1082R
domain,7
Retrovirus-mediated
below.First
Spraque–Dawley
System-plus
HT12-v3
GCTGGTGG
Rita.Brandao
PTC1
.LYL1
v‑Abl
−146
ECL1
prioritizing
PTK787
Penicillin/streptomycin
cases61
pHER2
NM_201439.1
K179M-AKT1
cytoscape31
HR–based
PTTG1-interacting
TrG
p=0.042
alterations•
JY02-II
glutaminase
1deCODE
tumourigenic
27.E343G
.P-
mg/L
yeastMsh2
apo-RXRa
Gln-Leu-Gln
5′-GCACCUAUCACUCUCGAGA-3′
.655A
Iodoin
DefectsTo
HT-29S9
ofDNA
PDGFα
.Pgts2
7.10
K08NS092898
iQi
Figure2F2F
+28
cancers/STCs
UVA
caspase-8L
G726E
J.RT3-T3.5
numberDQ196429
POLD3
bronchio-alveolar
4492-4494
single-nucleotide-polymorphism
B-cell/plasma
.MLL-PTD
c.4535G4T
differentiation.15,16
6b–d
R1–2
resectability
Balgobind
65/65
Affymetix
FIP1L1-PDGFRα–transformed
D686
65/67
mutant-Dnmt3a
Figure1B
anti-ErbB2
.Axl
non-EWSR1-rearranged
allpromoters
TTF1−
0.01565168
34,35,36,37
GFP-VHL213
-AGG
18-fluorodeoxyglucose
analyses.Each
Artavanis-Tsakonas
Rheb•GTP
IGFBP1
5′-ATGTCTATGAAGTGTTGTGGTTCC-3′
17,40,44
stereospecific
D404G
1/ν
Met-918
R198G
Schinzel-Giedion
Gln-116
Lipofectin
Spred-3
CRLLGICLTSTV-QLITQLMPFGCLLDYVREH
5′-GGATGCCTGCATAACAACTGCCCGCCTC-3′
revealfrequent
bond.17
collarbone
Ser→Tyr
situ_
tetraurelia
Monsel
prognostic.55
4402
Gg1.0kb-Luc
M-CSFR.26
CUL2
infiltrate,2
2G2I
p87PIKAP
2388delGter764
2.41
Neg
αH-αI
cancers.9
Gal4-dependent
.259
phase–like
−maxk′stk′≠k
trypsinautolysis
ATL
MelaAddress
.Biomedical
Güldenhaupt
multidisciplinary
V~V
1vjy
Vallania
5′-biotin-CTCGCACGGGACATTCAC-3′
adamantinoma-like
T-lymphocyte
0.113
EGFR-selective
Dietz
AAAC
α-myosin
A114V
sumoylation-occurring
25,000/mL
L-049754-01-0010
14865/2-05
AJCP
Mornon
+DHT
L747-T751del
GSE23452
RB+/+MYCNA
//static-
pupal
ABT-414
Kitzman
DHL.26
HEL536P
M204T
HIT2
ORI
N19RhoA
​and66
XLID-associated
ZNF384-related
Ser317
fgf-7
aromaticity
BFAST
luminoimage
pGST-FANCG83
JMML.52
H1047R-
Ljuslinder
Dimerization-driven
DI842-
KIT-T670I
K5.Smad2–/–
angiopoetin
Thr75→Met75
appendiceal
ENTHALPY
Stat5B
n=2733
extensively-evaluated
CombiDT
72•03
30ul
IGKV3-15
Nu24/SP1
NP_064393.1
pancreas54
E2288K
.protease
conformation-dependent
GACTTACGTGCTTAGTTG
H2T
R599e-4
hs-RUN6-2-1
Tax-mediated
2.099
CI-
livermetastases
reciprocalJAK2-TEL
VELCADE
esefinder.cgi
49:609–617
proteins1,2
sc-601
c.55C
medulloblastomas13
//cellbank.nibio.go.jp/cellbank_e.html
Q987
action=bygene
vivo.10-12
BamHI/EcoRV
AML1-S291fs
tCN
splicesite
.Box
AmpF/STR
intraoperative
binding.15,16
databases101
−4.797
ALK-translocation-positive
BRAF_HUMAN
S210fsinsGGGGCCAGC
-2H-tetrazolium-5-
S4H–J
ecoR
CSTI571
5'-CCATATGGTGAAGCAGATCGAGAGC-3
cds−5.9FOXA2Forkhead
CS1-4
Stenmark
p.L347P
Inducible
Falini
co-linear
KS-EXLM1
CD2-MYC
Stressgen
0.5–2.6
MDA-MB-23l
,15
up-regulate
G595RB-RAF
Colorectal
Side-effects
KRT16
N145D
F500A
CC-90003
nevi9
pcDNA3-IκBα
G-agarose
targets22,23,24,25,26
p.Pro470Ser
Ets-like
500-750
ubi-GFP
Leu649Ser
E459
OpenComet
exhibitthe
wu8
JAK1/STAT3-mutated
.Traditional
impossible186
-CCGCTCCTCCCGTGTCATC-3
PIK3CB_S10
./ml
TCGA-19-2624
25μL
Hes/HERP
Bowe
ingreen
D761_E762insEAFQ
Dynamics/Amersham
KpnI/XbaI
spontaneously-immortalized
newborn9,11,12,13,14
scc
locoregional
anti-ERBB2-targeted
ZG
c.2491_2505del15
autoinactivated
spheroids
*p=0.04
Q2140K
dnRas-expressing
His-27
CDK-cyclin
Geodetic
proteins23
JAK-mutated
P380R
pseudo-phosphorylated
radiolabelled
necrosis.Coordinated
BCR–PDGFRA
LEF-1-b-catenin
▼
GPCRs22
K558P
Runx1tm3Spe
IIIb-E1705A
Shono
KCF
element-containingMMTV-LTR
4.1*
.Originally
,2-j-associated
cases.42
Figure7a
A216V
KRAS8–10
pMSH2-N1
p5326
GAGACACTGGCAGCTTATATCCCCATG
96-79
bcftools
.2.2.1
γ-phosphate
.Ann
I425V
FGFR1≈24
complexes53
heterozygosity9
pRb/E2Fmediated
nnpredict
Length/2
proline-directed
Pappenheim
phospho-TRKA
pCAR-OF
Medulloblastoma/infratentorial
KGraphic
BIN-67
−3.52
pSG19
wheelchair-bound
cancer–related
95.63
RAD+
15N-p53
Hepatobiliary
–ETS
presenilin-GSK3β
2151
TE-5
18/19
1/60
5'-GATCCTCGAGGGGCATGTCCGGGCATGTCCCT-CGAG-3
Hlii2R
TSC2-
ramensky/polyphen.cgi
p53ΔE5-6
.S'-ATCATGCGTTCTCCTCAGATG-i
29/30
fl/fl
pVHLs
nonJews
.FLAG-specific
Anti-Flag
8.90
www.elsevier.com
tivantinib
NG2+
Q61G
p110δE1021K
ATGGAATCCACATACCCAAC
family5
Asn502
FBXW7.2–5
phosphorlation
20–2.8
ATATQFVHHALKDSILKIMESKQS
0.1018
B.C.M
Corvetta
melanoma.12
.binding
MAB25382
8,9
desmoplastic-like
PKI116
p.Q201H
CY5-dCTP
phy
breast-conserving
approx0.05
Fig.55A
Colnot
hMOF-mediated
rapamycin-like
IMPDH
S281I
Boehringer/Roche
NFE2L2G31R
.Asterisk
institu-tions
literature50–52
Ben-Neriah
Rey
reporter.The
293Graphic
SpectrumGreen-
–coupled
carcinoma.Figure
positive/FGFR3
ALK-KD
,29
LOC90110
MAP2K1-dependent
0.4–16.2
PRDX6
p53R175H/I254R
Grenet
substititions
Avruch
2,5,45
NoRC,42
5'-gcttactaagcagaagcag-3
RETK710N
approx22
TNM-staging
S472A
Mourali
p=0.040
ofMYC
heat-annealing
phRLnull-luc
tail-FERM
CASP10
5′-CTCCCTTCTCCTAGCTCTGT-3′
9065
-.â€
phospho-paxillin
In‐frame
K1110
34.2x
p42/p44.27
1.50-fold
42/61
7–Denis
STEP1
.Huang
BcrAbl
studies.23,24
StM78
MTGDTYT
D1.36
A094
Fragmentation
lymphadenitis
3FUP
Idh1-R132
.21,25,27
FIP1L1-F4
A4–C7
mass,37
K1650N
scanner-based
-hydroxyl
D769Y
aero-digestive
databank17
TBC
pMT123
process133
p.R378X
LSHKO
trk-related
Epoxomicin
45.1
PCR-validate
VACO4S
TC-3V
anti‑ERF
Greenhouse-Geisser
AXL/high
≤15
hKSR1
.Microfollicular
Fastq
437
Chalfort
reported.6,14–19
Vogt2
8x
non-aggresomal
.Unaffected
anti-Fgfr2
Upward-pointing
3.92
functionby
pAD–BRCA1–Δ1
astrocytomas/glioblastoma
αC
αβ+-DNT
hypermethylation,17
EUROIMAGE
H289Q
501–502b
.Hemizygous
PBL
PVHIVH
TARC
DICER1-null
loss-associated
85,251,408
BAP11,57
AR-52
Technologies™
Feuring-Buske
RAGBGDP/RAGDGTP
K183E
individuals27
HMGA2.35
.Southern
pnas.1321155111i12.jpg
16,17,47–49
180°
Hadju–Cheney
a.u
0.62–0.87
9-nucleotide
R1960L
al.37
Spyridopoulos
rectangles.The
42–54
MG-63
MTA1/HDAC
HPV-35
neurovascular
q=3.15×10−5
P=.003
HPV-negativecases
MacroH2A1
NexES
DeltaEx6
W2646
TEL-JAK1
trans-hydrogenase
Gattefosse
NAVIGATORTM
.Partner
S5∗
effects.Figure
lightwriter/pallantype/voice
X-100,1.5
rs267603577
7.13
c.932delC
p.Gly1136Alafs*4
a-Grb2
Elsasser
levelof
anti-DCUN1D1
Placental
AB_2207533
fgh
STRN3
94–97
mutations22,26
54b-8
AATTTAATCAGTGG-3′
CIB1
.Stromal
.P780_Y781insGSP
reports.7,8,25-27
G1809
Ha-Ras-G
CL-4B
tumors8,9,11,18,44
sequence-speci®cDNA
non-p190-complexed
652M
C–G
5'-AACGATCCGAGCTGCTACGTG-3
1:4500
V726A
following-up
37Â°C
❚Figure
Mfinal
2010b
incytoskeletal
synthesis172
RP11-1166P10.6
2883–2907
IVa
3h
age13
idenmM
Figure1d
DepartmentofAn
.Reovirus
caspase-8a–mediated
MRC1000
72-wk-old
–inflammatory
calcium-phosphateprecipitation
p190met
residualactivity
c.1242G4C
MicroTurboGen
0.501
glutathione–Sepharose
dAA
GSE61052
report.14
R524L
p=0.67
Gomez-Roman
Chramiec
557–Val
41/45
Tuebingen-Stuttgart
.AKT2-G161V
Fig.6A
proprioception
PIK3Cβ
DLBCL5,24
estra-1,3,5
Recerca
poly-ADP-ribose
633E-+frameshift
electrospray
hybridization.35
Mutants—Expression
Hras-induced
.14G
.LtdHowever
4001
MLL/MLL
genotype/combined
ng/rnl
hemosiderotic
1078-
5mC-modifying
31.2
42–112
therapy.28
49dominant-negative
p.Pro293fs
13-year-old
.By
Center-American
Suppl.1B
pg/nl
p.Leu585Pro
c.2007−7c
pCA14
AAAACTGTGATCCGAG
hGM-CSF
10,17
not.12
-CCCGAAAAGCACTCAATAAT-3
50,53
Glu659-
HR=3.608
18.28
flt-3
c.1823
RRBS
ERG-TISIFUS
fluorescently-labeled
.JQ1143
4187-4190
MET-targeting
600-2agGG
.NPS-1034
counterparts.16
1901C
.Nat
endo-glycosidase
-catenin
context–specific
DNMT3B.2
3D–K
Jak-JH2
DOC-2/hDab-2
21/33
T382
butthat
IDT
Ser720Phe
G262R
carriers.A
cellsunderwent
2306
CCAACTCACCTGGCACATAG
Massaro-Giordano
624
chaperonin-independent
FLI1
R184Q
deficeint
Npm1-/-
5-methylcyosine
BRCA1-mutant
Mm768bpΔGGAA-
.Nature
CADPS
M/56
2J1Z
malignancies.11
ÃŸ-cateT1
G47E
33/39
b1
.8D8D
community-based
DAE
receptor35
Minikit
gut
0.2737
Supplmentary
œfoundereffectâ
10.173
THAI26
GDP-keto-4-keto-6-deoxymannose
5-1-3
STI57
chagnes
-JAK1-JAK3-STAT5
His-Cys3
.Muscle
296C
Argentaro
CTM-3955112
ITD1/dnRas
iGF1R
Protein-Protein
-1032
EGF-null
WSTF
Phe172
NAPESIFdcvYTvQSDVWSYGILLWEIFsl
Calu-3-GR
L830R
meiosis
APCprotein
3′–untranslated
291-371
F4-III-1
Y87
BR-0480
847nt
V1260I
disorders21,22
GCTTCTTCACGGTTTCGAGAG
SDS/well
film-bottom
BWA70
6/6/05
transactivation.14
/highwire/powerpoint/117309
TGF-β/BMP
Hosoda
502_900del
pre-miRNAs.3
anti-cyclinD1
pre-formed
NM_001220777.1
E76K/Q510E
incidence.26-
.Pairs
GS-domain
pVHL-Elongin
000044.2
0.256306007
CRL2LRR1
G503R
methylenesulfonate
Hilledijk
GCCTTGTCGAAAC
0.86-3.76
autosomal-­dominant
17,901
gatekeeping
42/123
5′-CCTCCATCTCCTGCAGGTCTAGT-3′
ΔNMEK
Figure55B
pCA57-hMSH2
GVM
H/N/S
PI−
c.1566-
1977.1–3
casp8
BT474
L1425P
Gly34
41
FOXF1
proliferation.36
C-term
/APOBEC
G1738ER
BUB
42.69
-71
I.Q
anti-ElonginC
6.3
lympho-hematopoietic
D842V-PDGFRA-Ba/F3-luciferase
block17
YAP55
micocentrifuge
12q14.2-q14.3
family13
Chisari
genes,18
controls.Statistical
3762
CWR22PC
.Nezu
S.-M.M.
V119
WillCo
TK
U-105
TGF-β1-mediated
factors.25
Ortholog
L67
BRAFK483E
Enzlin
R139G
64–68
ATC-3′
pGEMT-easy
e-h
humanB2m
METTL1
IL12
R89LRaf-I
effect54
pMM1-pMM6
46-kD
therapy7,8
analyzedin
71–100
.Fig.5A.5A
FGFR1-3P
Balkashina
.The-H-L-T+F
anti-phospho-tyrosine
Hauser26
~1.3
63/74
GFRa1
1.Metastatic
790C
non-small
8-2
PtdInsPs
L535P
AAGGCAATGGGGATTCATTA
Ashbya
conWguration
3306
p.K499N
+distal
K618T
Hatzimichael
J-C.Y.
GTD
infarction28
N-2-hydroxyethylpiperazine-N'-2-
HT12
.Support
Pro89
destabilises
HER3-mediated
AML.30,36,37
1157
asRETandROS1
.Fig.66
S-2
p27-unrelated
Sivaramakrishna
SUMO1-specific
74.72
.VCaP
1142–55
investigation.47
CLIA-certified
i_
U87MG-PTEN-WT-3
siLATS1/2
Broccoli
KLHDC5
P-0003254-T01-IM5
VDJ
32D/mock
illary
BRG1-dependent
Q43P
open-label
Kiat
5′-CACAGAGAGACAGCCCACTG-3′
10:291–298.10.1007/s10911-006-9002-8
.HA1E
ExAC
JNJ-ROS1i-A
apo-D538G
HER2-V794M
value—ie
GBM-related
70.3
−2.26
hCD34
described.46
282q
referable
MYC-induced
5′-TAATGAAACAAAATCACAGGATG-3′
C–20
CCTCAACAACCTTCCACTGT
1/25
APO/TA
Heyningen
WEST-ZOL
Mx-Cre+
651–889
I1171S
n=118
4880
DLRNPEQSTSEKVLQTSQKSSEYPISQNPEGXSADKFEVSADSSTSKNKEPGVERSSPSK
Ragusa
paranembedded
Cbl-expressing
Pollett
F1P1L1
Leevers
V469A
punctate/speckled
Lu-243
Hodgkinson
25-45
casesCharacteristics
.Granada
stabilization/polarization
PDGFRα.25
13–77
.Mm
Cowburn
Dis3endo
C210F
F21
Doebele
cohesion-related
pMAL-c
N642
c.1514A
inhibitor-dependent
FoxO1
2°C/second
Leu86Ala
bromodomains17,29
1756
E162K
RAS-WT
QRRAA
Figure7d7d
star-shaped
432-446
:381–91
AXL/MER
integrin-RTK
osteoporosis
chr2:29432565
p.Ala859Thr
STAT3-driven
Azizieh
Noujaim
antiphospho-Akt
.Evolution
c.5300G
-lusnGI
Akt-related
mullerw
2,577
Q878R
GATA5
d.43
K5.Smad2+/–
2192delTAACT
8.34
.Vestibular
Br43**
-alpha
antonesc
5′-AGAGCAGTTCCGAAAAGAAG-3′
Telomere
DSSP
NPM-ALK–overexpressing
HER1/ErbB1
2Xq
Chudasama
OCI-LY7
TxN1M1
1.1.6
µl-1
MIG-Bcr-AblT315I
previously.Single
RETnegative
Q28
overexpression.These
P1812R
.Langridge-Smith
+ROR1
G112V
Unc93b1
Mirax
Sox17-β-catenin-TCF
E1271-
725–35
ras/CrafRBD
TopoCloning
gtaagaagt
β4/h3
D169G
GTCCTTGAGAACC-3′
FAM167A
UJ
phospho-PLCγ1-Tyr783
FIGC
dextran-stripped
Adelpha
variant—a
­mammary
thenerve
.CD44
tumour,34
NB7C8360
G503V
Alp
Myc-BRMS1
.14709.014
.PRMT1
14/54
dipalmitoyl-phosphatidylinositol
POLE-exoP286R
MATS1
D-12
8/73
Kap1
PVT1*
Nrf2-ECH
Snouwaert
Ki-6737
D3S1612
NRASG12V-expressing
p-c-Myc
Halaschek-Wiener
|/-
MYCN/ALK
Kordes
GFP–Fbw7α
Lys420/Tyr426/Arg428
CLONfectin
Canada.DOI
decitabine
.Prosite
3932p
helix-loop-helix-leucine
BCL-2–driven
36–37
CUX1-9F1
KLC1
//tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm
W1610G
c-Cbl-N
L540_HAEMATOPOIE
V/propidium
Cellgro
experiment33
12p11
TGTTAG
AS22SP6
cytomeric
TP53H179R
10900
.FGFs
reported.30
I1028V
Yasunaga
Hop-92
istics
Feature-Extraction
0-70
sizes7
dasatinib/BEZ
Koera
nt158T→C
25-33
bindingfunction
1799GT
underway181
pericolic
069
LysM–Cre
Ras/
Contribu-
.Loss
syndrome22
FGF2-FGFR1-heparan
E169K
D464N
Anti-CD34
vectorinduced
5,8
Glu681
S45Yb-cat
nine-week
EWS–CREB1
50.0–1.70
A375-resistant
0.008-0.017
PLAG1
complex/hybrid-
AGCTAG/gtaaaa
AZD2171
p.R282
3969-amino-acid
anti-PMS2
sunitinib-treated
nonaliphatic
stroma.12
BMA
respectively.Analysis
delAGTACTCCC
read-depth
MCDB153++
96.8
GSTA2
membrane38
apo-VBC
Armadillo.32
IFC
G41C
cagtc-3′
c.464T
expression-prioritized
pMIG/HAhBRAFV600E
.Centrosome
Ptenfl/fl
anti-pan
Ducl
L596
RASK147E
48201
174-186
slideCorrelations
Endometrioid/2
4002-
tivity
etat
embryo24
non-exon
TRP-MET
Shurin
r.8954_9117del
shortening1–4
interleukin-5
SA-b-GAL
0.202‡
50462
rs116023028
G123
Nonextremity
vdW
CRC.19
-aaggatgtggggaatccaagagcagccagtg
G/SNP309
=22
A204
yr.
Odejide
APLs,38,39
17-622
133.9
−3.69
3031
NATURE|Vol
fibroxantoma
2-fluoro-5-
CPC
Fwd-5′TGTCTGAAAGGAGGTTCATCC-3′
attachment23
Chr9–392F
molecules/µm2
2413–2419
URC
mTCFs
+359
.ABT-737
VP-Mel-21
CSF1R–cytokine
arginine/serine
840–1209
interference-mediated
pre-training
PY
luciferase-expressing
transcription–PCR
152KB
405delGGTCGAT
PRKCA
8765
KDimer
pRc/CMV-Cyclin
VX-11e–resistant
.Calibrated
RP11-170N5
.GSK2118436
pOPALI
10-001089
-CAAAGAGTAAAGTAGATGATGG-3
.010398
cell4
7q21-q22
lung-specific
3′-phosphate
137/212
E98
.GST-SARA
TRP2
plasmid:4
S10C.Previous
(
protocol1,18
IM36L
therapies18,19
D1-expressing
jmedgenet
p=4e-10
preampliuication
Y641F/N
770Aright
enlarged/lobulated
.Chimerism
Yakes
idea4–6
Ayk1
0432
D309Y
analysisH1299
c-RET
ERCC6
p=0.0052
HOXB13
Skp1/culin
cyclinD1/CDK4-triggered
two-factor
BMPR‐IA
31-84
larger-scale
phosphoarrays
c.248G
Cbl-b21
17481
M−1
GSTp531
31121
160071
lymphocytes131
RAF1-amplified
pBluescript-replicative
network.1
FANCC-
≤.001
deci-liter
amplifiedAKT2
GNAQWT
www.ornl.gov/sci/techresources/Human
IPC298
HEK-YFP-Jak2-V617F
CMV-GAL4
piperazin-1-yl
p271
Sigma‐Aldrich
40-61
TrkAI
Jonasdottir1
RGCluc20
GGCGGCCTTG
solid/cribriform
NG22
0.025–2.5
Y1003F
non-active
Herrera-Merchan
Trovisco
5mC/5hmC/5fC
8.5m
.FHL1
1.4.3a39
-CCATGC-CCAGGCACTCATTTTCA-3
Lardelli
T1014_Q1016Δ
Grunert
Myeloid
AB414
21:177–184
V658F/Y107A
cds6.1LARP6Acheron
andb
tumors.35,37
p.Leu1196Met
MolecularMD
NFΚBIA
cystd
gamma-tubulin
18.R337H
GST-16
kinetics28,29
p13CDKN2X
APC+/−
inflammatory
coverage/base
W22A
curve-based
MEK1-derived
Bagchi
JMR-mutants
compound/media
level5–10
FLT3-status
8–15
LEF-b-catenin
98A7
resolved.Crystallographic
2.66:1
PIK3CβWT
5.7–41.5
deletions.35,40
NM_010210
Haluska2
b-3
upto180
1,431
.7H
0.279
Abl/Ras/ERK
Q282
cHL.19
129V
c.3927_3931-delAAAGA
transactivation16
12-4961-BO
Lp53
°C/30s
1.31-fold
YLNAKKFVHRDLAARNCMVAHOF-
α-Smad2
ERK1/2-Thr202/Tyr204
3.85
CDM
EGFP-trapping
V342L
p.E571G
C342→Y
VHL213
-3β-mediated
SLE
tris-HCl
ITGB3
probes.15,16
MMC-inducible
47–75
anti-CDK19
domain.Binding
yeast37
BICR
ethylacetate
Lottaz
Heteozygotic
Zaret
.Thirdly
MDM2-a
HER1/p-HER1/HER2/p-HER2
Biofluids
HSP42
.0259
Ras-PI3K
0–363
7221
IRF2BP2
.Unpaired
Y585KD_Δ
Cys/His-rich
Soengas
.Averaging
BRAF-inhibitor–resistant
234/325
2.22-fold
y_32
antip70trk
.FH-deficient
and6d
PLX4720-resistant
30–100
NCT01058434
14•5
SafeStain
multitarget
Assays—Human
NM_000875
24.1±10.5
N532
10.50
.Consistently
MEK1V211D
low-attachment
4A-4C
9359
H211
Arg737
Tuxedo
Histocytic
FL2-A
8000-fold
.RipCre
2l
Y-1604
p.Ser463Pro
request.The
lymphangiogenesis
fresh/frozen
HER2-or
down-streaming
DDR2-induced
281–283
ST-SE
MLL-
S3H–J
Bar=100
BAC/PAC-derived
ined
6.5m
Y527FSrcRI75L
BCC43
N655K
Smad4-deficiency
FISH.7
H168R.19
Hydroxylapatite
andBCL6
Jak2/Stat3
4q31.3-q32.1
notdifferent
9171
Orange–conjugated
PAX7
Caenorhab
data32
M-CSF1
demarks
ErbB2-targeted
58uC
0890-9369/93
HT-
p.K484_G487del
C_25622353_20
FLpter
1-36
B.V
n=55
U32446
Pro36
POLYPHEN,32
.Fletcher
evolvability
GCGGGGTGCG
Thr212
c.8030A
PDGFRA,47
Rotolo
core.11
blastoma.36
WT-FGFR2
S119C
Plat-E,39
non-treated
ICmyr
FA-63
mobility-retardation
LR-clonase
.D617
tumours.49,50,51,52,53,54
Children-colon
phospho-4E-BP1
.L-2-HGA
GST-RB
Fig.66
circularization
EVSA-T–resistant
AmpR
c.2303G
theexistence
al44
RPCI-22
KIT-D816V-expressing
.Protein–RNA
N-
pCEFL-GST-N19RhoA
TEL-PDGFRβ
Rip1
proteinexpressions
heparinases
p83
c-Cbl/Cbl-b
PDGFRAD842Vmutant
non-high
mutnomen
infectionor
.Seizures
cullin1-RING
1.100
20–200
PedBrain
G637
GLUT4-P
.Resolution
protein-treated
12q13-15
038
molecule.2
protamine-1
Cul4
50.0
69164500
Scienti
p-catenin
rsb.info.nih.gov
2/226
cells34
A*2908N
TGTGAACATCATTCAAGGCGTAC
multi-variant
64-90
factor-rich
Ile590PhefsX5
self-renewal.48
W423
PTK-mediated
toelectrophoresis
Q1846X
centrosome.18
.Ashkenazi
TCAGATAAGAGCTTCACAC
13.3–14.1
Myr–AKT1
pHK104
PKD1-specific
CAA/CTA
ALOX12B
monoubiquitylated
LR01-060
gene36
*NÃ¸
EGFR-active
PI3K-mutations
treated-cells
assay7
AfllI
rnr=ern
genome-specific
immunoadsorbent
3.908
.pSrc
guide-strand
Ki-67–positive
−2.47
hypomethylated
rhabdomyosarcoma-associated
++
impact–calling
Drosha/DGCR8
FEN1
USP36
45,000
co-morbidity
phos-phorylation†
2918
pBS-hTRX
RET-targeted
3147C4T
Bioethics
18-Hydroxycorticosterone
chemical–genetic
7RP-2
pDM38-derived
FLAG-Ezh2WT
MIN6
R176L
R35W
.MKK3/6
T1186C
studies,14–16
2500
yeast.40
mechanism,43
50U
TOS
STAT-negative
Leu2209‐to‐Val
Vuuren
Muir-Torre
94jC
screeningTo
hypersensitive
c'.
c.49C
Apc+/-
TKO/Empty
non–GCB-type
184X
E1071V
q21q26
recently,22
shRNA-control
Fug-II/19
L535P—in
Col2-Cre/ERT2
SA-S
sc-6817-R
pT3/ABN
2.Download
NKX3
286–294
FOXL2-silenced
CD99/
LINCS
PDCD1LG2
nonsense/indel
c-Abl.42
vealed
studies,4
cancer.16,17
cross-targeting
seen6
12.2
17-70
Magi3-Akt3
pharmacologic-grade
prohibitin
Brd4-RFC
P608R
DNR-DC-M010
diagrammatic
469/590
assay.The
RearrangementsWe
mutant-independent
Chr17
WTLysMCre
T785A
2,4-disulfophenyl
tableThe
phospho–STAT-5
thatof
A-Sepharose-salmon
1Å
substitution/deletion
SBE4-luc
bcl-x
.S6C
0.03914
42756493
described,25,35
MKK4-transfected
90/129
3A–3F
200K-
SpectraMAX
0.77-fold
high-power-fields
MSH2and
nor­
AAGGGCCCCTTAAAACCAGGAAACATGCCTTTATTTTTGG
elsewhere6
2530
GFP-RYBP
Dicer–HisC
LOC100510485
Eto
CATGAA
polydactyly-hydrocephalus
PPARγ39
JAK/STAT/Pim
NaAzide
p.E330_G381del
4092
ΔGfoldmut
G12V/D
FOLLICULAR
7–
ganglioneuroblastoma
29S
Q79E
GST‑ERF
Ex18R
hormone-stimulated
DelYEVQWK553-558
NVP-AEW541
ARID1B-associated
R2021H
111,193
.Leiomyomas
terminus.Moreover
K513R
50µm
/2-M
scissors-like
11960
CCNB1
atinine
BCR–ABL
complex.Instead
20-mul
BTBD1-
SHP77/97
C-S
ad-
R462
GST–EGR2-H384N
GRE2-TATA-Luc
BIRC5
reverse­
region.39
GTP15,16
Chr6p12
ALPHA-screen
ste7Δ
carcinoma48–50
FDR=58
54D2
kinesin
0.17–1.7
double-flank
dihydrochloride
T790Mb
patients.30
EGFR/de2-7EGFR
four-digit
p21p23
damage20
L511P
×1127
Nurr1-/-
PC-14
GST-PKBγ
.EGF-induced
FLJ30619
.Frozen
Figure6a
W303-1A/RE966
transgene–positive
apoptosis.10,23
ano
MSH6-14
rrp6D
containethidium
elsewhere.28–30
agarose/2.2
43.7
AF064808
normal/mildly-elevated
SIAH2.60
Tet2-specific
C125
59-CTGCCCATCATCAT-
37,217
gain-of-
7b–d
Cyt
1640SU
26–75
FB-1
244C
DBF
0.341
COLO320-DM
2326
Topmost
Y532
Seq-Scape
29Å
N107
trichrome
c.279C
two-exon
K27-mutated
r2=0.07
85-bp
Wooderchak-Donahue
951
reported,18
AR-N-terminal
two-to-six
test.6
Polymorphism/Heteroduplex
D35Y
P.K.V.
odc
cation-exchange
.Sixty-one
Bcl10
Pgc-1α
/RAS
74.6/84.9
beta-strands
frame-restoring
8538del2
nLCII
Bresler
FOXA1,38
Aristarkhov
IP/Myc
A5420
.8494C
SSF
deepithelialization
FRA-I
metastasize2
SIFT*
.Raphe
RASGEFs
D842V-expressing
0088
▪
Bedrlíková
CDK6/MLL
0.48–1.38
PF02341066
ALL-8
hidradenomas
anti-centromere
Yarnauchi
R1063P
p.Ser59ArgfsX86
K336M
minigene-derived
339–379
interactions,34-36
patients.50
A621
721–722
.Complementation
MOS
lesions.8
120-
-TGGAGAGGGGACTGGTGCTG-3
D943Y
40-mg
EML4-ALK30
2044-5385/13
NPM-ALK–containing
.S5D
N1-807N
.WHIM24
TSC1/TSC2
NOTCH1-NICD
5′-CCGG-CCCATGCCTATGCCACTCCAT-CTCGAG-ATGGAGTGGCATAGGCATGGG-TTTTTG-3′
9132
—these
sc-167
backgrounds.In
1–27
Q739STOP
Benfadhel
transfectionsRetroviruses
tyrosine-phosphorylation
135,813
GST-GFP-RalGDS
S/TK
CPEB1
2293-2766
65-year-old
Drosophila,87
systems10
Concannon40
factorial
PKHD1
Arg64
4M1O
transmembrane–junction
Ready-to-use
stromal-associated
GISTs.17,25
Silencer™
Smad3/4
Cas9-mediated
.SUPM2R3
59-TACGCGGATCCATGACAGCCATCATCAAAGAG-39
GNAS-V5-His
36h
7mer
21.34
1.37
Hsp60
*Stages
pSG5-TIF2.1
4333762F
anti–phospho-EGFR-Y1068
I-V
11.43
H790
Cys-73
signature-negative
Ubc-H7
AlphaScreen
p300Q1874X
LYS
3.414
single-strand-conformation-polymorphism
non-PDGFβRsequence
cells.Because
+/-
.DII4
Adamts15
NP-40,0.5
roH
Gal4-DNA-binding
EBSmut2
6/60
.Children
8bb
EVKD
4Centro
and—as
RYK
cxpressing
c.3197+2T
Ezrin/Radixin/Moesin
reports25,26
postnatally
3-amino-1,2,4-triazole
CRE-L1-GCTCTCGCTTCTGCTGC
NCT00833417
TFGBR2
4778
mitral
non-tyrosine
52.90
145/219
W255G
AdEasy-1
uponTable
integrant/cell
.Reported
TLS/FUS-erg
xenotropic
ofNRAS-mutant
RHOA-mutated
FGFR1K656E
isolectin-B4
lymphotoxin-α1β2
Anti-c/ebpβ
M/MSH6-WT
10,000-fold
8q24.1
PFBC-related
.1.12.4.2
.NATURE
prognosis.36
Bechet2
wassubjected
Kerppola
9.14
Tatsuhiko
siFGFR2
HA-Flag
20,661
5–107/Mb
Glu884
.PHR
M-156
inhibitory-like
AR-cofactors
valproic
Brantjes
I11
disorder.Figure
Gynécologie
p110alpha
Tewantin
schwannoma
antagonistbound
post-alectinib
L883
RhoG
KBALB
Genome-sequencing
p.Leu347ArgfsX27
vivo11
PV-associated
PTPμ-like
CD326
CDKIs
0.000418
eVIP
CACCGCGACCTGGCAGC
//www.phosphosite.org
SNVs/InDels
limma.
T54
Glu1250Ter
TTL/ETV6
D149A
aneuploidy,5
translational/targeted
159K
compartments54
.Stably-resistant
ATCCAGGATCGAGCAGGGCG
.S4d
bead-binding
PKCθ-mediated
g.430
co-vary
stimulus-dependent
6a–d
P-JNK
scr
29–32
domain38
.Twenty-nine
Mcm10
E74
p84H26
.Boutain
F279
TRH-immunoreactive
anti-HA-Cbl
PMA
n=6/6
pCIN4-FLAG-HA
47-amino
T-bet
androgendepleted
HLQYMENMNSIASLVMAVVVNENEED-
GCCGGC
RetroQ
.Gunes
EN-Yx3F
Flag–mTOR
SubG1
transversions—W531C
P=0.57
dehyrogenase
89.6
S-300
paralogues7
complexes36
Igf1r−/−
uracyl
006885.3
Rituximab
47.20
3G5
CS-30
BRCA2/exon11
.Confirming
q43
Knaus
sc-1694
FAT1c
erentiation-speci
.FHA
−VT
.Betsholtz
JM-mutated
HR-positive
\°
D11S2000
CGTCGC39
antiphospho-active-PKB
c.3197+1G
others—were
β-dependent
PDEδ
Met351
209-bp
49–58
PCGF1/NSPC1
0.86-14.28Age
tumor/atypical
µm
AGTCCTGGTGCTGTTGGTGATT
Vellucci
.A135304
postregorafenib
AAVS1
.Trypsin–EDTA
7E
T160I
M/4
G217X/Q219X
33-101
D11S929
siRNA-15
sample-to-sample
AGEB16
0.2°C/second
K117C
11.98
Tyr-731
Hoeck
Mnt
20–88
CAAGCTTCCCGTTCTCAGCC
Parathyroid-Specific
β-catenin-independent
modeling,17
1111C
AR-V6
mesechymal
2/286
M1775
.00
BRAFV600/MEK1P124
849,434
5-hydroxymethylation
UMUC11
CMML.23
neck-specific
p.A502_Y503dup
Cy-3
CK1ϵ
-1-
TCF1/LEF1
PPHLN1-RP11-154F20
TGF‐β‐inducible
Smad3-dependent
Q-Sepharose
bw/day
Ret9-E511K
LAGLHFVHRDLATRNCLVG
pre-exposure
.Bsr1
.HSF43
salient
BLIMP1−
0.109
JAK2T875N-induced
Protease-inhibitor
5′-AGGTTGACCTTGGTCTGGTA-3′
63T
617/1287
non-communicative
signed-rank
BRCA-tumours
werehybridized
activation.The
allele.16
Genito-Urinary
Melanoma-associated
pairs.7
0.79–1.14
Hygro
sequence-structure
E746G
gelatinase-associated
SUM225
sensitivity38
BCOR-3347F
21-28
Δ145
5′-GCCCAATGCCTGCACTACA
pLTR-2
Anti-IL-3/IL-5/GM-CSFR
F-1084
EPR-1
K1419
CsCl/ethidium
overexpressingc-myc
anti-RKIP
145SAK147
gentamicin
thecharacteristic
ZetaProbe
mat-/fx
HCLv
ret-wt
p110a
integrase-mediated
XFE-specific
1.044777
v2.13.1
SH30109.03
gland.45,50–52
.T389
42–60
TKI-Naïve
R106P
R8.2
signalling.26
HM11
promoter-derived
VII-5
fourth-order
c.1100_1101delCT
T799
Q1756InsC
Δ550-557
TGFβ-stimulated
two-log
c-Met-selective
0/36
distributionc
AMLSG
289×108
X-CAS
MSK111
R479L
.Anti-phospho-γH2AX
-coated
MutSα-C333Y
Wk
D1341N
reported.INTRODUCTIONBreast
9,17
Flouromount
TEY
370base
480–530
non-ALK
Met1775Arg
p107.20
coagulopathies
dofted
vandetanib
*6AK15
phosphinositide
.TLS-ERG
FLT3-TKD
NM_138313
Y620H
sculpt
.Comp.
Preparative
TCGA-BG-A0VX
hospitalised
hairy-cell
.Neur­
Glu-714
intensity76
MuTect20
pmCherry-H-rasG12V-D47A
non-discriminant
72RU
CREBBP1
D32N
melanoma.46
Ruzov
cke
villin-Cre144
geranylgeranylprenyltransferase-1
serinelthreonine
Cdkn2a–/–
regulation/cell
11.83
within-family
5'-TGATAGUGTfCTAGCAGTG-3
oncogeneAKT2
E145
sh6
sequence6
Pheo
thaliana.24
P259L
CDC7
comedo-adenocarcinomas
ATGCTCAGCCTGACTCTGACCAAC
.Germinal
hydroxyproline-containing
GRF/CDC25Graphic
.Sixty-two
ERCC3-mutant
TCTGAGCACAGTGCAGTCA
0.3229
ERK.21–25
HLA-A*02010102L
TAMRA-Ins
H/T
www.landesbioscience.com/journals/cc/article/9993
Prolong-Gold
signaling.30,36
Flag-HIF1α
extension.42
LNCaP-cxD
p70S6K
RRCT3
Alveogenesis
RCC.12
I36G
5′-CCATGCCGATTGCAGACCCACAATCTTTAGACTGAGGTCTTTTAC-3′
v3.10
IV-6
Unit-cell
quick-coupled
9.5‐fold
His58
EGFR-signaling
apoptosis17
LC1009
H4K4me1
−−−
R205H
Noncontributory
NA§
P120
∆KD
IGI
reactivation/expression
γ-kinase
Thr417Tyr418Asp419
H2AK119Ub-marked
47179
14,36
fumarase
Borealin.49
Happle
SOS1d
Lys51–Glu754
Dring
R575
12.5mg/kg
.PIK3R1R348
105F10
pLKO-shRNA-containing
T‐T
U2F
USF
TGF-β…
.Phospho-RB
Kuzuya
Navitoclax/ABT-263
NKTert
chest-wall
mg/kg/twice-weekly
1558
β-turn
expeditious
DFS=1.4
MinElute
6/31
TCAGACCTATGGAAACTACTT
.Density
chemotherapy120
T12
p21/WAF
animal-related
9:6:1
1.682
Suv4-20h1
tETS
pBK-RSV
CEL,1
Ligand
514–520
5721
Fbxw7+/−—animals
E–I
Single-allele
Overexpressing
GLUT
Pb-ETV1
PR-DUB
mutated,22
W79
MSSE-associated
49•
HPV-61
cutpoint
AGGAGTA
COOHFig
1940-1979
vv
.53C
GISTs.Gain-of-function
Bmp2
observedfor
TGAAATGGGCCGGCCCTGGG
.Italic
fork.30
wean
PCA3
0–19
family.24
K-rasG12
.Pre-
D408H
ETV1–ETV5
lys2-1
16S
.G244S
Cζ
Cell-count
Franc0
Equitech-Bio
al.137
Δc
2.2–3.5
-MYH11
c.4036G
Laskey,2
K746_A750
33.73
Tumor-Causing
RNF6
OB2-OB3
6-41
UVC-
pumilio
al.,2000
respectively.4,5
medium/low
Tyr-231
leukemia49
al32
-17p
PAK-dependent
135100
antigen‐specific
TruSeqCustom
mm3/pixel
CCATATGTCCAGTTGCATAG
ETV5and
STI-571/Glivec
Autoradiography
0.87–1.40
BigDye®
Johnson/Vanderbilt
nonresponding
intial
bs-3532R
I1405V
.Be-
0.9-22.0
αBARD1
frequently70
NOTCH-sensitive
pFopflash
30.8-fold
Insulin-induced
AFX-IIA
1703del
PLCB4
13,094
FA-CEPR
E189K
.S4E
32kb
anepitope
nization
Edman
AA-3'5
5'-GATCCTCGAGGGACGTGTCCCAACTTGACCCTCGAG-3
onpublished
77DxETGE82
4056-4064
647
HD2.1
patients26,27
pTyr-SH2
mutations,9
119.9
anti-SMAD4
I3553T
3831406
.ML257Raf-1
four-stranded
Asians.8
RAS14
FLT3L
menopause3
p3.1+
3q
Q124X
1300–1400
HPV-induced
44.432*
//www.ncbi.nlm.gov/project/mapview
1-252+1532–1784
G-containing
elDeiry
distance-dependent
disulphide-based
10.04
EML4-ALK–expressing
0.002142
sc-789
perature-sensitive
Deletion–Mediated
to80
652E
W105
TCF/β-catenin–mediated
siPKCζ
LMO
5:10:4
-2Alameda
house-keeping
HBEC30-KP
agonist-promoted
mGFP-tagged
53BP1-positivecells
PLKO.1
anti-Ras
H4-acetyl
GeneDx
.Aside
V1809F
C35-A20
Littlepage
dose-intensive
phosphatidyl-inositol-3,4,5-trisphosphate
.Olbrich
placenta‑positive
Prc1
checkpoint-effective
26–73
EPHA3
.E2F1
MATH-BTB-Cul3
TET2
coxsackievirus
yeast-based
DNJAK1
hemizygote
Netgene
//iarc.fr/
Elf3Δ355
GTPase-deficient
AMP–PNP
1:1:0.2
FOXM1/proliferation
Applied-Photophysics
'non-target
approaches47
​and5
LPL.12–14
mutation¡/HER3¡
G595
AML1-ETO,20
Fouillade
HEC251
1×109
anti-CD2/3/28
N2993S
1,974
withless
5′-ATGCGACCCTCCGGGACG
α-negative
tab-delimited
cells,31-34
rates85,87
average.49
TLK1
.3508
.NanoString
H2B-coding
p70-S6
TCF-3—would
​Figure3C
0.04576
Cl.2
503-KRKRFull-size
KIT.15-18
MFC10A
2-week-old
Lightning-ECL
cPARP
PatientsWhen
HNF4α1
//snps-and-go.biocomp.unibo.it/snps-and-go/index.html
with18
2/52
del2481-del2495
Combi
Eighty-five
LOH+
.AS
T2512A
V600R-M
-0.154
G418-FIAU-resistant
Figure66d
Bourguiba
Subadditivity
.Insulin-like
L18P
Smad3-p/CAF
T368/641
Nontoxicity
Pten+/−
ALL-like
V-Cbl
GST-β-catenin
EXCAVATOR33
690550
deepithelialized
Telomeric
S8c
5583
CD30-extracellular
D–CDK4/CDK6
A4
n=17–34
administered.28
protein.20,28
ABL/FLT3
MOLT16
PCR-Mediated
80337
431147
discontinued79
.GW5074-increased
5⇑
V104/A232/G284
circumstances18
EGFR–mutant
subfamily-a
Suberoylanilide
BRAFV600E-expressing
Mutationno
serum‑free
signalability
29/63
Polekhina
solidify
Q675X
Inareas
NtA
α-carbons
cyIg−
containeddominant-negative
P63
3C1
c.1664A
motif,15
ab84927
data.7,20,30
10–36
ispresent
Two-μl
P417-B1
Runx1-deleted
AB081315
Elling
p67
www.sanger.ac.uk/cgi-bin/genetics/CGP/10kCGHviewer.cgi
c-H-rasand
1,017,716
CNTN2
ondary
7/28/04
propagation23
syndrome/HNPCC
GXGXGGGXG
mitotracker
0501
65861A
assays.23
4RT7
5′-ATAGACCCAACACAACCTCCTTATGATCACAAA-3′
EGFR-L858R-T790M
61/175
0.1370
Tyr589/591
R35A/L225L-transduced
TSF
siRNA-Hs_FGFR4
laminin
D5S2110
STAT3S727A
MHH-MED-2
Lats2+/+
0.849
701Q
eleven-stranded
Mad–Max-mediated
RP11–512I24
H2452
Heintz
T-p53-R249S
GAGTCCTTCACCCGTTTGATCT
1.7-fold-higher
81317
cells29,30,31
structbio.nature.com
4′,6-diamidine-2′-phenylindole
CNN-LOH
www.uwcm.ac.uk
p.Asp74Tyr
20–27a
yet8
DSD
Loeys–Dietz
Fluoview
0.755–1.670
Proton
desolvation
immortalization60
​and1C
P298T
R126X
SCCOHTs
0.88–1.38
KIT816-anchor
NCT01479244
.Frameshift
A-CDC2
heterozygous.6-12
.S1F
differentiates
FAM-positive
mapping12
diffuse-
TAATTCTGGCATACTCTTACTGA
BsmBI/SspI
ExGen
Lys-42-oArg
H370L
2835
RAD51D,20
E1519T
MicroSpin
:Flag-tel-jak2a
29,38,40,41
.Prepared
LKB1–PTEN
p48+/cre
Arg304
nonprogressive
non-thyroid
AluSc
65:55–63
translocating
COUPTFII
PKA-substrate
shFZR1-OVCAR8
5-2-2
SKES
TAGGG
C304
2-treated
pmCherry-N-rasG12V-T50I
GT-AT
cross‐linked
replete
INPP4B-negative
26,79
L324P
43–67
pluckable
UbcH5A
activity.21-38,40,41
Patritumab
L505R
dn-Akt
.Thesedomains
ZF-mutant
osteocalcin−OCDfl/fl
GTP78
iCNA
5′-TCTGTCTCCCTCCCTCACTTTC-3′
192–209
1174Mel
17q11-q21
-gamma-
KMT2DΔSET-gFlag
:p53
resampling
Ga68-
.C-Cbl
Transposition
.Receptor-activated
0.178
GeneReviews
PIK3CA-bearing
Tyr257
O.R
phosphorylation/Ret
A-11070
MFNG
AXL-MBIP
p.G628
Osteoporosis
chromobox
PRDM4
7.25
plescins
C-or
express™
80–477
Westernblotting
familymembers
Stromelysin
pCMV-VSV-G
MH1/linker
Makrythanasis
E487K
C-L-T-S
9,26
AGITG
c.1596_1597del
synthetized
1M
diagnostictesting
resistance8
signaling.59
I.Western
isomerized
leukemia40,41
I126N
NCI-H1975/ATCC-CRL-5908
5′-acagccccacggacgccttg-3′
S41
19-mer-containing
p=0.0012
E2/viral
promoter,30
FGFR1_N546K
.K-Ras4a
Smad3-deficient
subclassified
Myc-positive
IVS18
guanidium
munoexpression
12
adenomas,4
59,4
Eiger
findings.15
12.700
aat
Arg305Pro
+Y
SLCTs
2.5-Kb
SNU-213
E-cadherin/vimentin
S402fs
N132K
p.L576P
RelA–
SBE-like
38:25:20:2:15
M7259
degradation60
T165I
207–331
f32-microglobulin
3486
lipid-containing
ex3
3q13.33-q21.2
OSF2
end,7
maturation.24
inference20
hepatocytes205
p.Q110R
6-3/4
IIP-1
R1041P
Y568F
DOT1-like
2238–2248
R457
3.252
77.37
MES-SDS
Fig2Q–S
R180H
P162A
voidvolume
1,122
nephronophthisis
1.4-8.1
CCRCC
biopsies24
V94M
Wap-cre
zero-order
0.05–0.2
FoxO
six-histidine
p21-GFP
thrombocytopenia.2⇓-4
6–15
EGF-mediated
C-CUL-2
S594I
GFP-NHA9
cancers,47
c.3547delA
study20
MTV-NeuT
expression127
non–IL-10–producing
33428037
i-th
Xp22
N1387
Proimmune
PARylates
TCL1A
H3-K4
phenol-free
MEK1D218
hydrochloride/cisplatin
U2OS-DSB
Mass-spectroscopy
2524
6/16
.99739218
1.01–4.054
initiation.4
n=4
1.5–2.4
Frcsh
Tp*C
Δ1-dehydrocortisone
Thr-24
.Progress
34,350
370–377
phospho-STAT5
LUC1503
Table4.4
609192
CT_I
Ex2R
phosphopeptide-motif
Ner
Breast-ovarian
chondrogenic
IX-81
gene-1-like
sc-6344
Owl
Thannickal
GST-CTD
G188R
CrebbpΔflox
SASI_Hs01_00023490
−1.4
mutation.Table
CRAF-containing
cis-somatic
Leu-374
IFDCVYTVQSDVWSYG
C-RAF-independent
protein-observed
phosphoesterase
multi-targeted
Plath
A_51_P500813
F-recruitment
CLL.1-3
-CD235a
1209–1231
and6A
AA-N131Y
R355H
.CAM-SpongeAssay
Pea3
Cuffdiff2
A009
equi-potency
Arg49
cascade,30
SNP-containing
S65A
breakpoint.No
.15,16,17
CpG-containing
1μm
anthraquinone
cases.Facial
re-hybridize
A88V
BRCA1-PALB2-BRCA2
Q02750
grade-matched
68–81
7-319
lipoblasls
poten
field49
pGEM7
ETV6-NTRK3-mediated
preneuronal
//www.hgmd.org
androgen-induced
d'Identité
GSE24144
T150.2/T181.1
deletion–expressing
nephroureterectomy
monomethylases
Znf217
Bich
mutations.Most
96.5
protein96
dis3-G833R
g-cluster
Solna
potein
daily8
CEBP
C6792G
TMPRSS2
/distilled
TCGA-CQ-5327
+81
s–1
Q-test
S.In
predominantly
individuals.a
IA–IIIA
.Twenty
DAF-18
MethyLight
PLC-γ-binding
.Inclusion/skipping
3705
21106
dots13
LZ
RAS,10,27
.Fig
BCL-w
unphosphosphorylated
alÃ-eleor
MET299ILE
F228I
Fmoc-Lys
SCF/KIT
TMR
.WIP1
R239W
Nonsense-group
Chemokine-like
-f
hyperactivate
0.7-1.4
200000
GS8D
GGAGTCA
E81
NaCl-injected
flow-FISH
.MSI
EIIA-Cre
CR1–3
charcoal-treated
Wiedemann-Rautenstrauch
recep
1.852
R5R
3FIG
D12S86
11307K
micro-metastases
'4b
caspase-8d
16/45
frank.stegmeier
KITexpressing
1,295,228
pack—per-day
G799C/F/Sa
SF1-binding
.Wang
CS11
previously.39
anti-oxidants
HA-EGLN1
Merlin-WT
wt-EGFR
CLB94090
G364V
Ins308
V10
post-germinal
150×
1287–1653
IPTG-inducible
D048
Nakamura20
of400
11867423001
protein13
38-40
Bioduro
VE23.6
481c
-VCKIADF
INICD2.reverse
DYNL11
2α-L529P
slideSupervised
5q
GTP*
4148-bp
Annexin
CD68−
IRF−BLIMP1−
ttgatctag
CycE
Brca1flex2/S1598F/p53LSL-R270H/+/Wapcre/+
D'Amours
.046a
RPS6KA6
UTX133
7/17
SH2/PTB-containing
α-K
A6002
N-Tcf-4,17
NM_007634
decine
4/99
microsatellite-marker
28-Reverse
1.285
beta-hairpin
F1117G
≤52
Notch-mediated
130–134
m1-1
KPDfl
133
WLL
Culture—As
previously.22
GTTTTCCCAGTCACGACATCGAGGATTTCCTTGTTGGC
.Sanger
177603
3-fold
0.399363717
IWP2
0.0001e
0.000834
Tyr326
mMKCl
0.0062
chemilumi­
screening1
undruggable.
FGF2-mediated
88:306–311
V1333I
α-SPOP
CLL2O
374/889
Chinnaiyan
140-155DHF
authorPDGFRA
.1,2,4,5
GAS8
22–24
556-1G
cycloheximide-chase
D561
substudy
/B
//ionreporter.lifetechnologies.com/ir/
KN-JH2Δ-Jak2
11q24.1-q24.3
socio-demographic
59-GGA
.NEMO
Fallavier
respectively.RESULTSDetection
MCL.20
feedback-regulated
E24fsdelGA
/-/-
55.5
Muc5AC
pSer795Rb
5¶-TCAACAGGTACAGTTCTGGTCAATCTGCTT-3¶
16.1
F/43
RP11-117O13
CDKN1Bdoes
-Rb
BMF+BIM+NOXA
G12D13,14
Fig.77
P8833
NOG-interacting
familiesand
described.14,19
mastermind‐like
nonclassic
1.7-fold
C52B1
nontandem
C.L.C.
A_52_P243388
561506169Carboxyl
V152G
2.0.4
Drechsel
caspase-8L–transfected
135–148
S206′A
cdc4
7,8,19
FigFig6C
p110α/p85
-UTR
anti-ACO2
hemi-dose
SCL34A2-ROS1
D1-3
666–641
2,346
ligand-engagement-elicited
Leu858Arg
9.36
NFTcA2
ansamycin
RP11-481K16
54A
Gurumurthy
1—could
Raf/Mak/Ets
HOCM
.Rho
TOP3A
Δcullin
S136
karyotypes—is
I1810L
E74/labeled
proliferation44
invasion130
Pontvert
prognosis.23
self-anneal
Research-Bio-Rad
B-box
RP11–158G19
L420
Bacco
CAF18
p.T323P
sequence-speci®c
chr10
KgpllOtk
OCRL
.AXIN1
HS00703603_cn
hTSC1
AGTCTCACTCACCTTTGCAG
R577H
2.84
transcriptome38
sub-regions
Nobokuni
5'-GTTTCTTCCCCAGAGAACAA-3
clinicomolecular
0.127
p.E731K
SpliceView
Marciniak-Czochra
tCyell
fold,31
.Pretet
HER2YVMA
disease-crucial
heterogeneous32
mGTPγS
.CDKN2B
2set
R2510H
T2–T3
2554
14–185
114-fold
Myc-nick
Investigator-Assessed
23-79
43,44,52
12.5-μL
Leu114
dodecylmaltoside
binding-modulated
GCK,9
immunohistochemistry-IHC
^0.88
P124S
5'-TMPRSS2-exon
SJRB002
study.36
reconfiguring
HR=2.7
Ini1in3/+
ERα-M4
L441P
Neu,12
rat1
p.R774H
IVD
Minoletti
donor-splice
Goberdhan
2.46plusminus0.31-
.SUBBIAH
D702A
liposarcoma–C
withcomparable
SWI/SNF-related
wu113/wu8
development,38
~Silicon
2231
Thr68
liposarcoma-like
5/106
malignancy104
ZMYM2/FGFR1
cues102
​Components
helix-bundle
rearrangements.32
.West
4/4.8
DH5-α
1035A
GCAAGAGAGAACAACAG
p.Gly101Trp
SNU-61
dehydrogenase-1
PDL
Ni21
Gα11
BioCoatTM
SKBR
Q61.1K
D112G
NIH/Ola
5′-GCG
TGFb
7-nitro-2,1,3-benzoxadiazol-4-yl
NZM
μM.21
sogawa-tky
-external
non-ERBB2-amplified
1.05∼1.20
A745G
_-e
ATMivs38
andTreatment
17-25
hypersensitivity1-3
.Oropharyngeal
IACUC-approved
ΔNLS2
TCGA-BH-A0HP-01
15/35
.806
HRAS.17,18
algorithm18
CCyR
N289H
p53.Reactions
jD17S250
CDK2/CDK4
40X
823C
WDR5-KMT2A
25/42
Spop
1.5-Tesla
Wen-Bin
HOXA5-9
TTC15
ErbB2-related
GCGGATCCTCATATCAGGTAGGTGTCC
intestinalis
21/53
6.261
×1000
NSABP
58-TTGAGAAGAGAAATACCCACT-38
hyperacetylator
conformation-associated
8203
Kishimoto
SFA15
/Dulbecco
paired‐end
NVAMP-2
respectively.Tumor
1-500
.Interobserver
anti-CDK2
CHX-mediated
Altered-function
Q546E
icPT-PRD
30-F11
horseradish-peroxidase–conjugated
14/185
postinduction
W409
PMEFs
22q13.27
R389H
ASAH3
136:1369–1375
degradation.20
5557G
Ruckert
NM_001134673.3
4.10
eicosapentenoic
.AFIP
malocclusion
AL591024.14
Ozgene
tetraploid/aneuploid
.Pulse
TKB-dependent
Leu-194
immunohistochemistryMice
dimers75
L1488–L1494
E1419Q
Wiscott–Aldrich
SIRT2
tri-
CBL-70Z
glioma31
dimmer20
MEK15,7
D369N
Alexa488-
L1193Vmu
MEK2C125S
softagar
19q13.1
D164V
BR2-6-RT-F
Giemsa–trypsin
Hirokatsu
R500
4AFIGURE
ERK1T202/Y204
re-orientates
endothelial/hematopoietic
AluSx–AluSx
pathway-defective
nondegraded
0.45677
pLXSN/Flag-INPP4BR
c.7515T
3/group
Tetracycline-inducible
HER3-PI3K
M3630
low-DNA
anti-PLCγ1
SEC31AJAK2
first-dose
CCNF
REp21
pEC1214A
8F8
XPO1-ex15FFPE-R2
calculatedand
OncomiR-1
Göttingen/Germany
D18S555
~282
SSRP1-depleted
MRCK-α
Pharmacyclics11
GADD45-
interinstitutional
evaluated.Development
93482
5—source
4-specific
Pro356
−5.798.19
.IGHV
GAAGATGGTGATGGGATTTC
ETV6-His
TGTTACTGCTACGTAAACACTGCTTC
Spindled-cell
Tgfbr2f
FOX2
Co-purified
Sequi-Blot
M160I/A161T
c.1277-1G
chromoendoscopy
Zi
saline+/bovine
5′-ATGGACGGGGCCGTGCTGGACGGCCGCGAGCTGCGGGTGCAAATGGCGCGCTACGGCCGgCCCCCaGACTCACACCACAGCCGCCGGGGACCGCCACCCCGCAGGTACGGGGGCGGTGGCTAC-3′
M7249
HNF-1
blastoid/pleomorphic
Notch1TEL
postorthodontic
kcal/mol/M
presaturated
0.33–0.86
regimen20
eGFP-positive
SMO.siRNA
206K
5.TNBC
bHER-2
5'CGAGTATGATCCCACTATAGAGGACTCCTACCGG3
ROCK-dependent
4p-q
W313-P297-P298
∑|Ii
.Explanations
c.1692T
Ex19
TTCAGTCGTCAGC.ATG.GCT.CGC.TCG.GTG.ACC.CTG.GTC.1m1.CTG.GTG.CT.GTC.TCA.CTG.ACC.GGC.CTG.TAT.OiT.ATC
1212delC
FIP1L-PDGFRα
2,7-diaminofluorene
leukemia.32
190–250
Serono
FGF-pathway–nonamplified
▵CAT
tranfected
Cys773
FcɛR1
A503C
ubiquitin-protein
∗The
C.Ischemin
1,694:1
C274G
p-Bad
111,580,000–111,650,000
gga
PEBP2aB
reconfiguration
CMV-T7
FV-PTC
ERBB2-driven
GSI-mediated
3139
SOAP-Protein
Redundancya
p.R356P
Emp1
Flt3-ITD–induced
.Cirrhosis
PanIN-bearing
overgrowth/asymmetry
His6-Mre11
ade1
ICAM
ligand.6
Veh1
G1163
assayMMRMismatch
IVS20+3A
PuGPuCAzTGPyCPy
double-knock-down
RB116
SF9
18.93
nature.comERK
BAX229
Y842C/H
anti-PD
1/50–8/50
ΔBRIP1-pENTR/D-TOPO
Coulet
skeleton.23
anti-p-STAT1
open-door
RP11-1078O11
progressions/chemotherapy
L1481fs
p.Val878Ala
BRAF
T18
GGGAATAAGTGTGATTTGCCT
p53.59
E79V
1237236
BCL-xLexpression
NHR1
748delC
N=49
Farooqi
pandid
27.04
61kd
background.18
MLK1–4
TYK
polyp-affected
.Interrupting
D442Y
thepurine-rich
Cul2
RP11-586A2
mg49361.f4
ν-akt
signalling7
sS4c
PPAPDC1B-amplified
Vβ7.1
BreakPointer
complexes.51
EVSA-T.
FGFR-nonamplified
spontaneously
AML1ΔN
uncontrollable
telomerase-negative
0.5–1.0
sequencing37
.HCT15
ΔM2
KLF4
8p11.21
15/88
data.22,23
±10.7*†
71385
1.90-44.59
'wounded
CHCl3/methanol/NH4OH/H2O
HBV
cells.93
GRP94,24
I-FISH
c.6586
double-deficient
sc-161
yMLH1
MLH1.9
5′-CCCGAGGAGGGGTGGTCTGAA-3′
LudwigMaximilians
explana
PI3K-AKT-mTOR
-11.8
Anti-thyroglobulin
transformation29
compounds.17
X-genes
.Digested
Actrapid
described,23,27,28,29
3/541
doi:10.1152/ajplung.00147.2006.—Small
domain.4
.Radiofrequency
checkpoint-control
congenital/early
0950
IASLC/ATC/ERS
Duplication/deletion
SI-NEN
gplioProto-trk
as-yet-unrecognized
12-transmembrane
medulloblastomas
190-kD
.Quenched
Vitro-Produced
pcDNA3-human
Ikk
Y18S
5′-CCAGAGGCGTACAGGGATAG-3′
less.8,9
Fut9
GAL4DBD-TFAP2C
.1942C
primer-labeled
08N43-020
Ile566than
pCEP-Zeo
227817_at
G266V
self-inactivating
curled-in
E263K
MMTV-NeuT
Tyr628
characteristic.6
.Cardiac
premade
273×108
methods.
FANCD10
p.F486Lf
N-acetoxy-2-acetylaminofluorene
ATCC-CRL-5803
.Mobilization
FAM-labeled
PA27
Friboulet
1.Expressions
0.902
EOGC
33,63–
cells.Retrovirus
∼850
algorithm71
1240delC
8,10
hematoxylin-cosin
IIXL
M952R
karyotypes.19
Ala/GCT
2,5×106
ssODNs
RAC/CDC42
Test/reference
CESC
phenol-choloroform-isoamyl-alcohol
7/445
Desmosomes
ER/PR
HGDN
Y463
nimble
3130
deletion—amino
G/T-containing
HA-GLUT4-GFP
SPOP-ΔMATH
RIP-140
XPO1-PKIαNES
LRIG3
SacI-StuI
L36R
mannosidase
mutations.32
.SlZ7-K-R-V-A-K-R-K-L
Pin1.34
vector.115
coactivator
Turkey-Kramer
CFC103
lized
c.1–195
bcatenin-LEF-1
fig2
1,160
ATTCAG/gtgaag
Cullin–RING
CD150/CD48
Anti-Human
region22
Saint-Dic
Cell-of-origin
pmCit-N-ras-C51Y
FANCC-L554P
.S4T-U
p13q22
p.Cys236X
del11q22
GP2D
YS2
27.8
0.52–1.22
species-matched
'No
proteinsthat
3910
CNTF
.colorectal
WT1+/−
Gly-Trp
RP11-427D1
interaction.4
ablation-resistant
pBabeNeo
mDbox
-804
activationWe
PTEN-cRRS1
anti-IGF-R1
T24A/S256A/S319A
icantly
ESEJ
3866
FIP+
2F-2G
127
zoledronic
003
everolimus
3-arm
VLA-2
Skp2−/−
Thienpont
E731
obstruction/intussusception
JCRB0123
T-PER
inferential
S10B
Italia-USA/malattie
finger-1
NUP98-fusion-transformed
0.13-
Nu18/DP1
G363V
β=
lO-bp
.Crizotinib-resistant
.ORs
Analyser23
hyaluronidase
PAX5-repressed
CCACTTCGACCGACAAACCTG
secondary-type
1⇓⇓⇓–5
CNA
MYT1
Gly65
acids3
heart-to-body
CEBPB
5'-TATATTTCAGGGTGTTGACG-3
1.49−45.54
48−
multivesicular
NM_000249.3
Repression-associated
ncu
Buske,1,2
serine/threoninephosphorylation
NP_113698.1
R306
peptide/nucleosome
3A–E
choriocarcinoma
5/163
H2030
Sub-sequences
5.3.1
demonstrated.24
1.83—2.96
-9q36.1
5′Phos-TGT
mTORC2
column-median-normalized
~0.61
propRB
Eric.Schoenmakers
Mr180K
O61267
pCR-TA
Gesundheitsforschung
V600EB-RAF
EMBL-EBI
1200g
hydrogen/deuterium
aIRS-1
SR-786
HDLM-2
R553
PE-MCC
EcoRI–BamHI
CLIP-Seq
anti-FGFR
177030Criteria
919
cytotoxicity
Reversibility
Brca1/Bard1
β-dominant
gadd45
-α,18
F1174L-
GeneCluster/TreeView
expressPAX8-PPARγ1
reported.18Statistical
andprotein
Knockdown
18,50
E1214K
310Y
//www.ncbi.nlm.nih.gov/IE
backgrounds.14
RBCL
c.1450_1461delAAGCACAATGGCp.K484_G487delImatinib400
GST1AR
O-nitrophenol-β-d-galactopyranoside
overall.7
age.14
-associated
D538A
2.0-fold
GSSRS
hMLH1
1⇓⇓–4
3−5.0Genes
Jak1
.Chetomin
IκB-ß
PTEN-N
apoptosome
proliferation.17
missense-only
A.L.F
pJET1.2/blunt
18-month-old
KN
1/62
O-fucosyltransferase
E15
7.4/10
16-18
hMSH2-hMSH3
Biotechnologie
Tnimov
inhibi­tion
cancers45–47
kvd02102
Rheb-WT
thiotriphosphate
.RECONSTRUCTION
4-6,12,13,15-17
A_51_P408346
Erk/PI3K
4772
//fold-x.emblheidelberg.de
//www.InSiGHT-group.org
energy-dispersive
ProSci
p21ras–mant
HMECsThe
nonkeratinizing
0.628412
BCLXL
leukaemogenesis49
gamabiae
GoLYTELY
GPIAP1-PDGFRβ
RRPRSPAKLSFTYPS
19q13.2
a.u.
hypothesising
K567R
157–175
Fig.2A2A–B
14R
FLT3-V579-expressing
Leu97
c-H-RAS
Ni-wash
inmammalian
CMKLR1
5′-GGTCTAGCTACAGTGAAATCTCGATGGAG-3′
MycKD
ARL13B
Saint-Louis
g–i
rRhoA
5056
C‐myc
.Correlating
LUC20
9-reverse
36/50
eighteen-year-old
tetramer
survival41
4.4-kb
Fig.1E,1E
1.6-7
patients.21,31
protean
.016
-133C
Y589/591F
DNA.5
LysArgLys
regions.1
alcohol/formic
IPTG
~10–15
NCT00431015
dâ€•
1252
c.52611G4A
Coactivators
9/403
miR-200a
R2/R1
pGL5-STAT3β
Gly508Ser
p85
pLXSN-Neo-based
expression.72
KLHL13
FLt3
squamous
6.2207275
433WHTLF437
GATGACGACGACAAG
1283del
EMSA.In
.Conservation
HA-ubiquitin/pcDNA3.1
Pro445His
L496R
Arg72
D842V-PDGFRA-expressing
Y479C
oligodendroglial
117,830
12-O-tetradecanoylphorbol-13
breathing.
1863-aa
Stemke-Hale
Leu613
figure3A3A
CommentsTumour
VEGFRII
Wnt/b-catenin–activated
EHop-016
p11∼12
Vidal-Puig
SW48_LARGE_INTES
reported.24
A-Barcode-Exon25R
juxtapose
†Includes
T4N0M0
T1226C
c-Met-transfected
10620312/116668
PstI+
FGFR3-GFP
Tlr7
.Ercc1Δ
Figure2A.2A
2,236
PCGF4/BMI1
Sobol
Siliciano
Elnaggar
non‐Spitzoid
proposed20
ECTMWT-1
Ras/C-RAF
illegitimately
191170
MEK/RAF
variantsVariants
Non-adherent
dif-
G15A‐Rac1
DUSP4-GFP-transfected
p.Y42S
EDTA.Monoclonal
Anti-thymocyte
q=0.03
45.4
Hoogland
RNF213
pBTM116-Ha-ras
HER2-Lys-716
Zenon®
.920
9-mutant
iMC/MSC
.c.2245C
.Ten
ER15
3/25
coinfecting
SJHGG127_D
MR.
FOXG1
exon-based
ALK/ROS1
N/C-terminal
22/307
.Rod
RAR−RA
calpain-
Ophthalmology
Poppleton
67922
Tyr1414Cys
T461P
genes.45,48
observed.Recently
myeloids
48803
.1321155111i5
H102
//chromium.liacs.nl/LOVD2/colon_cancer/
CEM
Arteriovenous
LT-HSC
5′-termini
timepoint
​to3C
9F
GIST1
Café
4140
.TMA
FLT3-F590GY591D-
correponding
preexisted
nihms646437t16.jpg
GCCATTCCAGCATATCGTCT
Trrap
stronghold
reports.8
CXCL8
BRAF–mediated
trascriptome
One-Glo
IC90of
2015b
1000-2500
.Epithelial
.Harvested
HLA-B*151101
IVS10+1G
Fig2C
jkms-29-1054-ab001.jpg
CBF1
−18.33
n‐fold
Technologies|
C342
www.LOVD.nl/TSC1
1087
TStrans
Hoedemaeker
Pt5
described46,47
430C7
Wave-Maker
2.13
18qLOH
nucleus5
DEF-domain-dependent
/tumor
nm/500
cases8
PPB-FTDS
fastq_quality_trimmer
HPH
NCR-EW2
5′-GGATACCACACAATAGGTCCAG-3′
KM12
pLenti6.3
sc542
Anti-CD44-FITC
K745ins
//ensembl.org/info/docs/tools/vep/
ANNOVAR.12
MYCN14,15,34
Ras·GTP-dependent
described.3Mutation
.LCL
c.1973T
multi-species
al.,2012
proteins.In
7q31.2
Q546K
symmetrically
H10UV
CK1-axin-GSK3β
Benusiglio
.Bmf
Wataru
EcoRiI
E132K
74284
PgrCre/+-reporter
SPTA1
CTV-1
Strohmaier
tautomerase
shCTR
Sandri
.MLLT3
LSL-K-RasG12D
A775–P780
Oji-Cree
Plasmon
Ti45
.H3K27me3
interaction.For
5′-cggcgactcgaagctggcgacgacgc-3′
K120A-1
detectsa
CD–expressing
normal/tumor
3q29
25–36
post-enrichment
/der
HCT15/
cholangiolocellular
−15.4
vismodegib-resistant
CYK-4/MgcRacGAP
commensurately
pEAA349
5′-AAGTTAAAATTCCCGTCGCTATCA-3′
9727S
proteins.14-16
H2AFX
FBW7–independent
Smad3NL
.He´di
pUG23
E884-EGFR
101
GISTs.5
A/J
β-koz-for/β-rev
anti-p110δ
//www.broadinstitute.org/cancer/ataris
reimplanted
likelyproviding
5'-TAA
non-heptad
May-Grunwald-Giemsa
HTC
MPO+
D159N
F209/213
a-Cyclin
IFITM3
PixCell
Yanase
PLCγ-dependent
3.42
−3.83
Hermeking
G310V
.Cleaved
D2Mit172
expression.2
Sl5
proinsulin
Y32W-A59T
IL7Rα
leukemiasand
c.1135dupA
MEF2CTo
65vo
BCL-xL
Bachem
Trp-282
1233bp
11.23
.KARPAS-299–derived
Com13.1
Madi-
B16F10
minigenes
c.1756_1758delGAT
Ultravist
.RAPTOR
CD35
NCGTG
1.25-fold
MRE11A
7·6
G643R
avidin-biotin-horseradish
DRB1'0406
pGAD-MSH6
1009
VEGFR2-mediated
UCK
100ng/100
non-somatic
pTa/
targets.40
cytotoxicities
preassembled
cellswere
III-mediated
3844806-3847406
7-amino-actinomycin
K609
CDK4/CDK6-specific
wt/wt
A311D
G598V-EGFR
lobular-like
1996–1999
ras-induced
10-99
well.4
GFP-tubulin
2970–2972delAAT
software20
pRB-dependent
domain–DNA
SCF-Fbw7
effectiveat
Pettersen
5-azactytidine
p.Glu604LeufsX5
6cen–q23
cyclesequencing
A572T
acidosis40
Hip1
2,348
.Reagents
.a
Peignon
tumornecrosis
CD133
inactivation-induced
discussed.Previous
non-measurable
p.V1144L/p.H1773P
MSCViresGFP
GISTwas
B-cell–specific
8p12-p11.21
cDNA:1224insG
4C2702b
Lys410
Povey
Pineault
intermolecular-disulfide
FCS3
aetiologic
monoarticular
A161S
frag­
NPV-TAE684
H0305
M538
structed
GCATTAGGGACAGGAATGGA
inoperative
non-colorectal
Mizuki
Erk1
pcDNA3-FLAG-FOXO1
response-1
reversibility
ACVR2
5′-CAGAGCCACAAGGTAATCCTG-3′
~31
alleles13
F605
5-GCCTGTTGAACTCTTCTGAG-3
p.Arg1077*
telangiectasia-mutated
Zymek
P14-16
dCMP
MUC4+
aminoThese
1,25,26,27
L74S
20â
15mg/kg
tumors54
2362
.RETWT
V1456L
2525
.Theprotected
.HMS-101
H712R
His-ezrinWT
15DaubDelta
serous-clear
5·5
Epithelial–mesenchymal
AtHB6
Yonemura
Medprobe
4-Oxo-4H-chromen-3-yl
Bis-tris
sameexperimental
0.2–12.3
Rivat
NM_000141.1
Bmpr1
p300-transfected
Red/ET
-suberate
M22138
GGACTCCTCTCTAACTTATTC
P300
domain–altering
intra-CNS
melanoma.12Abl-related
Bicalutamide
1,312-amino
.Lymphoma
MRI-H-221
UNStat
Dysgerminoma
5'-O-
SW900
.PTEN-G20E
alfa-2b
Δ126–132
11-a
HDSN845-848P
S-Phase
pnas.1321155111i3.jpg
9·9–79·7
Blombery
hetero-oligomerization.Figure
1397-1
.MZB1
880-kb
-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
SBRCT
N247D
CMV.tel-jak2a
sseldorf
W485I
dUTP-labeled
MCF7-HER2
7Pathology
embryonally
~1.6
Omomyc
5′-ACTGTAGACTGCTTTGGGATTAC3-′
pBABE-neo
fullyconsistent
templates.To
mitochondria-associated
Purist™
anti-phospho-CREB
MAP2K1
NBG17-R2
pathway-restricted
NR21
post-kinase
Duod
Lys-558
mild/moderate
LeukemiaLymphoma
MyD88.1
A1799-1816ins
FLAG-β-catenin
APO-1.3
79-3a
NOTCH1-mutated
spermatogonial
Chromoanasynthesis
.HUH-6
His331
V136I-
allowthe
SH2–SH3
3-5,9
NSL
–positro
pericentrin,34
Factor-free
rad54-encoded
36ATCTACCTGTGTITFCAGGGATA215
previously7
2/0b
screen2
PDGF-BB-dependent
SJSA-1
Tyr736+Tyr740
histidine–alanine–valine
5025
.Trichostatin
Simplex
MART-127–35
PE2
fi-catenin
NM_018249.4
CompE
DNAMolecules.19
–66
c.716A
.Dose-response
5′-CTCCATCGAGATTTCATGTATGTAGCTAGACC-3′
drug–kinase
.Chromatin-immunoprecipitation-sequencing
GAPDH-CF3
D176del
H3.3/ATRX-DAXX
GATA-1
high-sensitive
Hongbing
.Graphs
p.1277
ExpandTM
Glu105
identified173
V560del
JAK-GE
Dougan
cotransduced
HER2¡/HER3¡
membrane-cadherin
Pro-925
//physiology.med.cornell.edu/faculty/mason/lab/r-make/
CFC,14–18
1.1–8.7
CACCCAGGCCI'TGC
OS.91
K333Q
Y658
0′
NZM28
NZM17
C324Y/Smad4
Dinazyme
p.Asp2312Val
B-NHL
His-766
myelin-forming
Flores-Rozas
HYbond
14/5
log-ranked
tumour-
4/60
thalassemiamyelodysplastic
T_p.splice
//www.qiagen.com
.Mutational
148–153
5´-GGGCAAGGCCAAGAAGTCGG-3´
ultrasound-fine-needle
FP6
p110-WT
0.041*
RARγ
//medgen.ugent.be/LOVD2/home.php
2300
p110α-activity
PI3K-mutation
bPatients
acetylation-mediated
sc255
G139
Anti-AS160
R2136H
98.6
UT-7-bcr-abl
2516
1,040/852
BaF-N/A-C1156F/D1203N
MED13L
Ebner
UV-crosslinked
Denhardts
IRAKs20
Q643R
TRP-based
interdomain
annotation-aided
mediate
HPA001906
R93W
LKB1-G163D
5ʹ-PuACCPuCA
recombinase-progesterone
-2146
OX40
8-dependent
DSS-induced
1,736
c.862AC
Gynaecological
ABI3130
CTCTGTTGCTGCAGATCC
M4/M5
model.30
B-HLH
thec-H-ras
FANCA-protein
LNCaP104-S
q31q35
anti-P-Erk
50°C
100–100
disintegrating
PE‑1/METS
parafibromin-6xHis
1–335
Panagene
E3-NotI-R
-CAGA
109/litre
2KCl
3/84-2/85
129S2
−10.7
GAATTCGCGGCCGCTCAGGTGGCCTGGTCCAGG
60750978
firefly/renilla
palmoplantar
anti-PDGF-Rβ
2•7–6•3
8,16
327–29
EPICS-XL
12C6
P-4EBP1
16384
B-CELL
−70°
outcomes2
DNA-complex
0973
89914
ΔH
G114
CTLAThr
ETV6-WW-PDGFR
.www.sciencemag.org
3D–3E
Klinische
T256
co-mutated
PEBPB2
CD11b-negative
Moraxella
ENSG
Q1966*
Gly-776
C291Y
genemutations
CACTTTTTAACGTAATTTACTCT
DRneo15
3-catenins
54359
Sanggye
219T
PEAK1/
E282K
Ellisen
gpll9Protoh*
Tyr766
phosphotyrosine-containing
R330M
gaaatcctg
E914K
ARD1
1993del1G
PRC2-associated
N-AKLSFQFPS-C
CI-104
D1-P287A-3T3
71227
.Continuing
C365Y
8204
Vela-Chavez
s10875
MIR143-NOTCH1
184C4
16/68
glioblastoma-targeted
Tyr42Cys
SJHGG044
DME3+
12/8/03
.Multiprotein
D493
W310
nomutationin
TFGsequences
8.0/150
H3K27
V175A
nullizygosity
*first
LASS6
GelDoc
–HA-MITF
.2,6,7
5/18=
Frauer
wild-type
pcDNA3.1-Casp8
24-77
day-on
998-1249
IFN-g–treated
aspergilloma
dst1Δ
Akt1-YFP
OVEREXPRESSING
del746–751
Delmore
R537C,1
SP15
EFM19
GeneCopoeiaTM
strategically
8-nucleotide-long
U37574
E1810
Photophysics
chromatin-modifier
GST‐G15A‐Rac1
ex11
Hirvonen
cells.15,16
co-existing
JB12451
SJRB002X
H179N
7.5-131
S8E
5′-CGCAGCTGCTCCAGTTCACTGAGC-3′
signaling.23
pcDNA4TOmyc-His
/
3D-CT
organellular
1–13.7
Br43
derivedfrom
2—5′
subtypes17
Lobund-Wistar
ACCCAT
GGGAGCTG
TGTCACCTGAGCTGGCATTAC
cause-specific
MRE11A-deficient
GLIOBLASTOMA
.Glycine
37–91
20.16
c-kit+
FAM83AT4ARID1A
1430
Löffler
OR51E2
1120212
PYPLNDSSSPK
ETV6-ACSL6
SOX17-related
ERÃŸ.All
migration34-36
S1I
ΔCq
-CGT
5q23-q31
×39
.UTX
terminus–directed
TGB003
camptothecin
c.422_423insAAGGCC
Competition-binding
D11S1778
phosphoP44/42
599
S'*-Â
U14C
foretinib.In
-35
71.82
shown.Crizotinib-Resistant
p.Asn127Ser-p.Ala328Pro
69.5
C362
FAP.9,10
phosphoino­
egg-water
Ser-33
endometri
.Tumor-Causing
1772y
transactivaton
1.33–9.23
differedclearly
study.For
Mef2c
5'-gcccaaccgaaatgttaattc-3
c.5615T
W742C
.Chromosomemapping-panel
insu
5P21
E801
Cohort
carcinomas.32-34
ATR–hChk1
intra-vital
Hpy188
BRAF-driven
functions—RNB
24.1
multiple-point
inhibitors11
107-2124
bi-aryl-urea
325553
L323P
mistargeting
CCTGTGAAGTCCTAAAGGCGAAA
393-residue
Venus-tagged
200/304
C162F
N=38
consang
205.3±3.5
.19,20
c.2170G
CCND1/CDK
carcinogen-promoted
T790
.Sixty-eight
P114
pST4
FBXW7NPY2R
A140V
CC-to-U
Coactivator-1α
10.1309
/Sex
Asn-1128
Ras–mitogen-activated-protein-kinase
troversial
G-DEX
duolink
R71H
EGFR-pathway
FLAG-KRAS
26.92
RBM5/6
SMARCF1
chr11q23
MMTV/Neu
plas-
5′-AAGTATTGTGGGTTCTCGATG
.995T
Iwaki
Runx2−/−
cttcgtggggtccttt
.Schuelke
Western-European
GCCTAATCAAGTCAAACTATGGAAA
preB
American–specific
N94K
c.271C
Q579_Y580del
GCAATGATGCGCTTCTCAGAGTTGG
non-statistically
.Lethal
p.D1484N
-in
population.1
152–481
lesion-bound
421-3C
1646–1736
416-813-5938
〈
G465VB-RAF
kα8
spatiotemporally
POVSCRIPT+
R107C
valent
premetrexed
TEAD1-positive
boththese
Oncologico
responder-associated
​ErbB2
S21syn
4,6–8
ETV1-dependent
work13
50Â°C
DMRBE
5′-CCACGAAGAGATAATGGAT-3′
complexes.50,51
∼47-kDa
HEX
Mlh1p-Pms1p
musclespecific
5′-TTAGGGGTGTTTGTAGTGTTATTAGGTT-3′
RRM
insCb
desensitization
CWR22R
.Mef2c
βTrCP
phosphotyrosine-Y699
7p22.3-p14.2
E1196K
Ubiquitin-mediated
.PAX8
-++-
.FGFR2
30/95
QIAquik
prognosis.37
electroeluated
anionbinding
described.2,12
senseAKT2
.UV41
98.48
5e–f
phospho-S727
GTCCCGGCCACCCACT
Tumori-Milan
mice,28-31
-85
XmnI
EF-FLAG-XFoxH1a
GNAT3
LUC-L
S287Y
HoxA9/Meis1a
pathwaycomponents
CKI
KOCL-48/t
Mendeley
p21effector
15X
A/E-Cdk2
.Anchoring
peated
pS383
FigFig4D
Flag-labeled
ERBB2/empty
pyrophosphate
p.W719*
Lib-A
criteria2,3
26Sortm4
AGCTGGGCGTGTTTAGGTTT
αK-driven
41–214
Arf1·Sec7
95C
Phenotype
ALL,46,61⇓⇓-64
pVL1393
syndrome/MDS
-H-L-T+F132143151159172179
9ns
001220777.1
Q-box
76N-E6
proto-oncogenes
CDK8/CDK19
p53-R273
I113F
mg/m2/d
.Untransfected
NM_181523
as-of-yet-unknown
XIV
19104
F985L
identified43,44
D816
2-cm-diameter
tumor-origin
L29
.ACP1
non-TEL
94–149
13/0
M1991L
5'-AGCCTTCAGACCCAATGGTTATAG-3
pcDNA3-HA.VHL
MgCl2/10
proline-287
K24
PolyScreen
42,805,880
anti-SGK269
.HPA008736
GTGC
Matsushima
self-renewing
holoenzyme.20
.1321155111i15
1408
mechanism5
groove29
G537R
strand-transferase
-Shld
//www.bork.embl-heidelberg.de/PolyPhen
27000
RCMD-RS
stage.1,7
tDenHyb2
p.Val716Met
FL4-6
FBWX10
24/79
Gr1low
laboriousness
setting.27
gene-dosage
NRD
Maschler
Avidin/Biotin
BCR-FGFR1-transformed
15:1
available.The
NR4A3_Luc
left-top
V480L
ribosome-free
GFDS-Induced
100–467
1/26
.FBXW7β
G60E∼T74P
described.Figure
p44
Ipegal
meat/day
ty-bridg-
RXRa
.0009
myosins
703,934
ITo
11B
Origi
P09581
.Immunohistostaining
AIDS-associated
.T305
same-gene
ETV6-PTPRR
HN41PT
5′-CGTTGTGGTTCAAGGGATTC-3′
n=1309
SH2D2A
1b–d
CBLe10R
01/08/16
1°C
study.17
rs2230782
EGFR-A289D
TEL/ABL
P53ΔE5-6-positive
.Tazarotene-induced
al.,3
GFRα
CCCCGAAGCTAAGCAATTC
55+A173
PTEN-C136R
84.75
amolecular
Ras-mediated
Falck
activation99
denervation-
work21
population-genetic
separation17
Lafyatis
:883–890.This
28.7–879.8
FUS-erg
GAGGCGAGGTTTGCTGGGGTGAGGCA
83-year-old
CAR-T
5.81
2/0/0/0/5Total
DAPI-
42°Covernight
hemocytometer
significative
loss14
146000
508
1.247–7.179
DUR4.3b
RhoA–PKN
5′-CTGAGGGTTAAAGGCAGTGGAGT-3′
Lef-Tcf
.Glu
pRC-cytomegalovirus-RETwt
IC588
0.066
_FGFR_
phosphatidyl-inositol-3'-kinase
10.5d
Mlh
supernat­
–2.4
R82H
differentiation/quiescence
cancer15
pVHL,15
1≥10
HER2/CEP17
P-MAPK
Biotin-11-UTP
Dobutamine
anti-FLT-3
ACTG1-MITF
triphosphorylated
CCRF-CEM
Bub1
Kunits/ml
2BIO
erentially
pT0/pTis
Ago1-interaction
GDPD4
weeks102
Addgene
mutation.46
SNV
D8S199
individuals.19
004304.4
tsc1
hem82
5′Fam-GTG
32649
|Abl
Mg2+concentration
13ACAGGTCFACGGTCAGACC252
Hybond-XL
T312
AAR
H-ras-D47A
Tmab
42.0
MC7
Ca2Cl
CCA
116:2429–2437
LeMeur
estradiol-induced
classical/mesenchymal
manycountries
amplification-targeted
limited,13
pSG5-EA
GM847
435.eB1
16757
557_558del
Hs-578-T
2Bm
1025–1004
720–728
4F–G
S3E–H
M246V
S3J
hPPARγ2
-112
p.R304G
Bernardoni
Wild-type
neuroblastoma62
1-6
mRNA31
3.17
Glu-285
30703701–30810200NM_001130415
switching.Cellular
FADD/
RP11–321B9
12/53
c.5291C
E31V
5'-GCCCTTGAAGTATTGTAGGT-3
intravasation
.Numerous
llerian
4-Figure
carcinomas26
.Readthrough
video-capsule
1040
lyLeuG
9DS
D835
pY1148
FCRH1
1393
hybridization/copy
5′-TTCAGCCAGTTGGAAGCTGTCA
2960
younger-onset
hyper-phosphorylated
Abcg2−/−
fragments/double
complex2
mgme
Hs277039_m1
polyvinylidene
YFP-Kelch
p.E143X
BaF-N/A-WT
FGF3/FGF4-Amplified
ERCC1/XPF
STAT1.27
Mkp1
ARID1A-V5
onco-suppressor
somatic/mosaic
domainbound
EST14-ETV1
Jak2-V617F-dependently
Random-primed
617G
therapy.7
N.A.L.
breakage38
isimplicated
NaCl–10
Ramadori
SWAMI1
c.4186-1593_4676-1465del
5-hmC-binding
16,39,40
pRc
p.S516A
Igh-VJ558
NUT-negative
72-year-old
10:2
2.931
.4C
GAAACTAAAAATCCTTTGCA
imminent
malignancies.16
pre-bound
study,8,9
WA09
.High-density
Rho-philin
pLX_304
renewal87
GTGCCCCTCTATGGCCTGCTGCTGGAG
ALK−
147500-00
0.12–2.15
A040
A_51_P137991
CBL-Y371H
.Meso-9
Rs34231037
literature1,23
Q24E
LNR-
FOP_FL
pENTR/D-TOPO
streptavidin/bead
S100+
15,24-26,31,32,36,37,39,40
3q12.2
956.8
Tyr119
5′-GATTGTATATCTTGTAATGGTTTCTATGCTTTGAA
C89R
monosomal
T-medium
anti-p27Kip1
hMLHI
transactivation.A
14A234
capmatinib
over-activating
1/139
inhibitors35
DENND4A
C·G→T·A
T-lineage
phenotypes13,22–25
VGP-like
fibrosarcoma.38
angiomyolipomas
Coot55
.Dysregulated
inactivated91
DiGeorge-like
MIM601446
SoloPack
9-mutated
.~~~~~
specificallyfor
hAR3619
Rb-dependent
sc-193
bEaston
gpl40prOtPrk
.Anti-IRS1
RAS-associated
Prealigned
16,18–20
5.7-20.5
2763C
,7G–L
NMD-sensitive
6,14
TÃŸR-llgene
Kelch-repeat
FR3
4859–69
BRD4-NUT/HATs
lsqb
CAAbALLL
Jerey
,8F–H
2868
.Haplotype
multiforme18
Ba/F3-N841I
46-50
E655K–overexpressed
p.Arg17
40/F
.ERF
FANCA-DNLS
43/61
c.1277–6224_1386+4836del11170
availability/results
v1.03
.association
Calu‐3
WDb
Cys634Arg
sorafenib-treated
-Q227R
pY88
MutationsPatient
CLB-Ma
DRB1*03
G309A
1,2,41
Mxd
bettercharacterized
engan
K618M
C-
2Breast
IL1B
6837
microsequence
proliferation79
is/are
02/01
siRNA-MET
BCR-ABL-
complexeswere
esMedical
Cul2/Rbx1
YAF2/RYBP
D9S1748
activator/receiver
MYCN-expressing
FHL2
Asp-4043Gly
25-27
collapse=true
carcinoma.45
IFAR943
MPSI
TÃŸR-llnonsense
emano
Inpp4B
Argl96
−60
p16INK4A-deficiency
Glu106
~1,500
pHEX8
.ATM/ATR-like
46.96
nuclear/nuclear
p.D1125N
F351L
181-182.tDeletion
FLT3-ITD+
ZC3H7B-1190F/BCOR-3954R
-tttgcgatcataatcttcctgcacagcaggaagattatgatcgcttttt-3
.CM
Pentanucleotide
845-4506
IMR32
5,551,341x
trough:64
Kischkel
regions.13
NCT01166542
IgJH
self-phosphorylated
chr9
NZM43
dosageHER2
γ–tubulin
Interarray
M12.52
mutation.59
Rigshospitalet
.Examples
TA-KE
//www.atcc.org/
region32
S184L
G142V
phosphatase-independent
conjugation/ligation
D835H
asymmetry
pAMPK
218-bp
c.3516_3519del
DN-HNF1A
reaggregated
2.9-fold
aCasp-3
recoveredin
activity135
Aikawa
.Log-rank
themajor
7/35.0
54A/B
u-PA
PI-4,5–P2
MAPK-regulated
128.
≈450,000
197.9
P150S
clinical17
Pabst
website88
Assay—Visualization
fold-increase
Leu704
rad54
3427845
.IL
T77M
IL9
HCC5
CHK1
MAGL
Flag-Tip60
P120GAP
Rege-Cambrin
0·22
Ser364
M1248Tmu
JmjC-containing
Madi-son
M1-7
RNF213–SLC26A11
.DEN
MedImmune
400,000
Kussie
−3.46
binding.14
NERF
pMiw-Fgf17b
MAPK-independent
nases
5′-AGGTGCAGTTTTGTGCC
.22–25
Joneson
Ile919
kappa-light-chain
0.816
Djouder
IQdqL
CARS-ALK
c.462_463del2
connectivities
12:1
LUC1
SNAI1
.5425G
D770dupAVD
M1-polarized
.MANT-GDP
hypophosphorylation
phosphorylationThe
proline/glutamine/alanine
AC−
MaxiKit
TTW.eT
.TPRs
1.06
200-460
®elds
IVb
EpH4-MSCV
phosphostaining
detected26
.MEF2B
c.120_149del30
A2G
26,166
rai-containing
—prostate
NTI
U4/5/6
n.4
nonstatistically
BRAF-R7
supercoiled
WT8
6972
804
ER-mutantplasmid
7216
oligomerizing
PBT
12–94
CDKN2B-induced
ACATCATACGGTGGGATCGTG
21/83
.T598
identified8,9,10,11,12,13,14,15
TIR-intrinsic
DNAFS
cells/dish
SMMC-7721-shSUMO1
eitherOCT-embedded
6.6-11.1
hSNF5/INI1-gene
Druzeb
Perkin-Elmerkit
p53+/+/p210
46XY
MLH1ΔC
NCT02034981
3.28
1.332–2.528
Phe105
PV-10
patients30
5X-SRE
9713
phenotype-based
Europid
DNA–cellulose
KT3922
DCS22
MDM2.Luc
6,7,21
d.68
repair-deficient
APAF1
Myc-p110a
13.2-48.7
N2/3set
gacacacccatagtttggag
FANCJ.38
anti-Thy1.2
Bohl
Ala1453GlyfsX10
anti-pS6
effects199
5′-partner
SMAD,32,33
oxa-l
SCF—including
PI3KCA/mTOR
cancer8
D-001210-01
SWI/SNF-dependent
pcDNA4C-Brd4-FL
Antibody-dependent
tumors,15,16
domain.19
MLL/SET
copy-number-neutral
homo-interactions
ventriculoseptal
hemoglobin
Tyr-253
coding-sequence
IL-3–
–v
Isehara
aIncludes
transdominant
P-kinase
Double-balloon
IOc
MyrAkt
.Effect
20ng/ml
DS-AMKL.41
AA476460
Saurin
ITD–transformed
HN_63027
.Annual
51/60
0.127708811
GCGAATTCAGCAGCATGGATCCGG-39
VEGFR-targeted
Fig.8A8A
MOBP
Skp2-SCF
KrasP34R
.AL132656
electrostatics
immunohistochemicalstaining
2-step
advanced-stage
Domains—
GFP-Elf3
GISTs25
.UDP-GlcNAc
ddelALDLEDLLsfsyQVAkGNaFLASkNcIHRDLAaRNiLLt
55.35
non-dbSNP
.3F3F
TEL1
Atthe
OLIGOS
agarose–morpholinepropanesulfonic
cervicocentral
cKit+Sca1+Lin−
1.6–5.6
negative.11,23
MSH2-H639R
SK-NEP-l
18/115
345–380
L597R/Q/S
'00-
.â€
FGFR3.27
9.89E06
FBXW7-GRα
EUFA389
electrophysiological
323H21
MMTVCATvector
.Enlarged
Auenbruggerplatz
ASC-2/MLL3
nitrosodioxidanyl
ψψ
group-wide
P451T
transfor-mation
940-
AÂ®G
IL-6–dependent
PTPN11/SHP2
months-old
Prospec
-inav
143,144
hydrophilic/hydrophobic
non-neural-crest
6q14.3–6q15
//www.atcc.org
55y
alterationAmino
+12der
Y842H/N/S
HEK-293FT
malignancies.2,3,4
linker-WW2∶S7PY
Henis
cancers53
SPOP-mutants
PAM50-based
Arp2/3
titrations19
D.We
mini-LAS4000
β‐catenin–TCF/Lef‐1
nucleoplasmic
Khuong-Quang
gel-shift
348–
0.87–0.99
TGF-signaling
GRD-encoding
cases—which
tttttttag
.SFK
TLS-CHOP
2004-World
PAK1-dependent
Lin–c-Kit+
33.5-45
helical-destabilizing
12q14
Gln
IVS1-1G
CCAAAGCTCTGCGTCACCG
Empigen
study,38
cancers.11
S331R
Rieske
Whole-genome
.PDX
4,741
HB-8064
CSF1-R
0.617069386
Arita
blunt-end
mitomycin-C-treated
.Overnight
NB1269
erbB2/neu-transgenic
D-010097-02
5′-TGTGCCATGTCTTATGGCCACCT-3′
3×10−9
CD25
sorafenib-mediated
Y783
Grb2/Gab2
0.
dihydrochloryde-containing
anti-CD36-PE
fibroblasts28
24G5
ST300
RP11-107F6
//zk.bwh.harvard.edu/ts
1–
595
Alevizopoulos
48/5323
R335L
ALKR1464STOP
Hematoxylin-eosin
Mac-1−
previously.14
formation.24
mcr.aacrjournals.org
analysis70
1-D
.Prepration
expression19
FastDNA
megabase-sized
shCT
I26
Ha-ras
R244Q
Aα-P179L
CGCTCTTTGGAGAAGGAATG
chromatography-grade
oneor
angiomentin
Y1703S
S-780
LIM1215
Figure3B,3B
MGH-PO-I
761–1132
VHL-Mutation
58,867
endonucleolytic
Tsc1+/–
b-catenin-mediated
lyzes
11-14
1816
5.40
hSRSF2
megakaryocytopoiesis
presensitizes
MGA
AAAGGCCCCACCCAGGAGGG
R572C
Self-reported
0.253
1:5–1:20
T790M.21
31:131-148
BCR-ABL21,22
multidrug-resistant
CHB
.Fig.7B,7B
1,866
increasing1
¿120investigators
zygotes
PSTLSL
receptor‐mediated
mSos1
Hemi-
EMEA
front–rear
c=37.8
allMSS
357.9
E76V
sfuAspAst\Ar9
elsewhere32
4069
20–71
β10
T3I
T2294I
chromatin-state
IKA
pT1pN1M0
Eu3+-GTP
/2KA6
Lys373
localization.20
sg_ex2
GVG
3c–h
Whitesell
PACACA
Y516
isodicentric
receptor.61
DEAD-like
Norvegian
22C10
22,38,40
Auroy
Lv-3127
SMAD3
AcDEVD-AMC
1.27E07
DNA13
249–250
//www.breastcancer.org
PRKCθ
Ilagan
CBTCCCAS
phenocritical
I44T
ADL=2.85
SYT
Weinberg30
function8
.999938
RECIST-based
tuberin-T1462-P
HexB
ana-plastic
CFD80
400-nt-long
71.329
10-kDa
H3K36me3,28
1Clinical
mutation.112
0.0256*
CTGGTCATAGCTCCTTGGAAT
P.G
Sybr
acid-agarose
Labsystems
coimmunoprecipated
4–anaplastic
5'-GC-clamp-GCAGGTTACATAAAACTAACGAAAG-3
intratumoral
homologously
Hemmati
T2451.50
S9c
v5
0.25–2.0
9252
scapula
5-methyl-2′-deoxycytidine
.Subadditivity
mutant-only
KKU100
Smad2/4
signal–the
AB17003
e809/93/1408-1417
MK2461
p.Gln43Pro
cytogenetical
MT-dynamics
PDGF-B/PDGFR-β
2672
91.7–91.9
.Balak
0.7864
1431
peptide—displayed
anti-TSC1
40-49
.M13
S478P
com/
negative/true
MMR-attenuating
P2021L
120/164
MDDcontroltumor−bearinganimals00×
1/3
914-594-4175
unclear/no
Mutant-MEK
XTcf-3
S3C-F
5561
anilinonaphthalene
metastatic-like
1952
EcoRI-SmaI
Mennonite
Caspase-8-negative
NSMCE2
K-rasV12/V12
NDC
2802
Nonsense-Mediated
129SV/ev
TFK1
29-
51/129
AllPrep
0.09–0.98
S0405T
69.4
reconstructed
3.Box
.Stoichiometries
domain.13
c.904+34T
Rho-family
macrogenomic
mRNA.79
HA-Vpr
Calbiochem–EMD
PRKCB-modulated
1.01-14399
EUFA202
KSR-RAF
A834T
S608fsdelAG
muF
Health.MariaAntoniettaCerone
nofunctional
C242
amplification–negative
cleavage/activation
polymorphisms.31
structure-activity
properties15
cerebroretinalmicroangiopathy
20.2/23.4
FOXG1B
imatinib—a
S-transferase–mitogen-activated
pGT3
26.1
genes.Our
UAE
single-staining
0.634
progression89
microsatellite-instability
Pro406
MGD
Alk−/−
E2-R
FZ5
6052
K764R
DNA-tagged
EGFR-overexpressing
Falcon®
SSBP2-JAK2
TSPAN31
P122
BCR–JAK2
-TAATTCTGGCATACTCTTACTGA-30
28,42
//www.biochemj.org/bj/454/bj4540501add.htm
ErbB2_ex24-27.F
GCCCCCTGGAG-3
previously59
cAMP-sensitive
iCyt
antigen.1
MCF10AT
EGFR.14
SC–URA–LEU
shRNA/cDNA
.041
mice63
CPSLDDRWYMHSCSGSLQNRNYPPQEELIKVVDVEEQQLEESGPHDLTETSYLPRQDLEG
p.Arg213*
MAML1–p300
39·0
–1-bp
neurotropin
9/556
HAl-B1
039437
Sequana
2/intron
dysfunction.In
Ala148Thr
.ALKT1087I
galactose-inducedBJ5464
∼5-μm
4015
LiCI
silkahn
pTaG1
HER2-neu
.Sixty‐one
32MIC2
.So-called
Luminal/ER-positive
05/2002
nimr.mrc.ac.uk
632/517
P733La
.14,16,32,42
APH1A
PBS-treated
Groesser
LN215
Lumbar
RG-1N
1−528
YB2/0
Chorangiomatosis
D13MIT139-F:5′AGAATAAGTCAAGGCTATGATGTGG3′
4/134
line-derived
L916R
Juranic
ΔPDZSPA
HrD
N822I
1863
DQB1*02
NCIH290
GSK2141795
Y98
G158S
SF3A3
plot-panels
elsewhere14
462K
3003
linesrepresent
homozygosity/hemizygosity
c.-456_-453delCCTT
pRAJA120
76/80
BRCA-regulated
bDNA
.8954
Mills_and_1000G_gold_
KPβ
18080-051
death-receptor-independent
pY2274
1950s
Endocrine-Related
invari-
Dexamethasone
earlytruncated
onsors
Willin/FRMD6
previously,48
complex.25
EGFR20R3
phenotypes,37
α-germline
gp140Prot
KTS.We
Leul404Arg
births.1
0.169–0.914
p.Q25H
PS.23
suggested25
6-cm
Candidacy
TGGGG-3′
CML-BC/AP–like
RB10-RT-MGB
p53-R337C
low-end
17/35
CD3-
165070
2000-MM
right‑
IGF1RK
KITWK557-8del/T670I
E43F
adipimidate
Jap
N2-shRNA
KJ859678
V32
haemoglobinuria
198
12/34
GISTs,8
-1-propanesulfonic
Dyedeoxy
.Ubiquitination
XalkoriTM
polyubi-quitinated
-catenin-binding
PCa_ETV1_2
Hs00175273
ab52934
Cys118
A_51_P377094
_AKT_
FGFR2-fusion-positive
outcomes.2–5
3′-terminal
promoter/5′-UTR
cytokines.101
Y345H
LocusLink
amplifica‑
H1-shRNANKX3.1
L164
5−15
Met146
G469S
TMDT
R154Q
pEAA311
dysregulations
L6
.Haplotyping
Cerebro-oculo-facio-skeletal
BCL2L12
Kras4BV12
TNS3-ABD
t19
NCCGP
pp54
pseudo-wild-type
therapy.92
RET-expressing
Yes/no
Normative
RNYNNCNNGYNGKTNYNY
7/49
3,4-bisphosphate
Expressione
NPM1mut/FLT3-ITD
LDN
716-845-8857
anti-FLAG-M2
deoxynucleotidyltransferase-positive
D2723G
MVP
0.0051
Xrcc2+/−
102,820.0±20,715.0
Gateway-cloned
CDKN2D-WDFY2
47–71
vemurafenib106
~1.4-fold
Peroxydase
16mer
Pathomorphologic
c.516+1G
1of
Leu473
GST-ΔPH-PKBα
tumours.1–7
MetaPhor™
Y1003N
mutations.6,13
L190D
480,000
PHOSPHORYLATION
p64
EPK
3G–I
30-31
Calcein-labeled
phosphorylated/active
polyp-like
cyclin-E-induced
anti-Cdk4-specific
K301X
3,628,800
G37Ras-GTP
anti-trpE-trpE-PLCyl
mechanisms.9,10
aged-related
hSNF5/INI1-specific
243K
ITt'AU
europium-labeled
Leishman
P-rich
genotype-driven
TAL1–LMO1
1,074
RADS0
1pter
SScP
10.1007/s12185-013-1354-4
8590
TEL88
0.6–1.0
Ludwig-Maximilians
pEXV3-ERK2-tag
HNSCC-associated
RafΔNT
PER–403
Ð
Kamai
platinum-sensitive
anti-p62
subcloned
Gas6/AXL
SKB1
483-594
E497D
5079
del17p
DA2
variants.12
HIV27
.Pathogenetic
tubulin-based
Iμ-MMSET
EPD16
Orca-ER
5′-GCA
AlexX/XXLb
McElhinny
chemoreduction
I141N
c.1109A
posite
3942
RIP-mediated
Ppp2r2b
D3S1258
Takano
pFlag-VHL
Nonsilent
ssociated
/L
Non-Hispanic
rp49
-318c/t
LS-mice
K88A
GSE26576
heptamer
c.1147C
AMLCG-study
sub-family
times400
CCGGAATTCTCACAAGACAAGGCACCCAGATTT
TIF2.1
157–166
cRSS1-cRSS2
-D2
Z=−3.25
HGGs6,22
Risio
previously26
Brg1
Bruker-Sequenom
antikeratin
806
anti-p53–monoclonal
XhoI-
11–26
1513
HSC-compromised
respectively16
consaguinity
Xba
Y436
—Nuclear
S7A-C
ER-related
al,20
Max/E12
red-β-d-galatopyranoside
Y49–I360
O-tetradecanoylphorbol
-GACCACAAGCAGTGCTCTTTC-3
positive-regulatory
p.D390Y
LLS/ULS
pancytokeratin
~3–6
.9,20
1mg
Jr.
STAT3-FLAG
Na3VO4
GCAGATGTCAAGGGATTTC
ATAGCACCATCAATCAGAAGGGAAGACAAG
cases.32–37
missesense
33–78
Gutkind
nondrinkers.2
SMG5
fl/wt
CS04
tumors/well-differentiated
previously.54
KLHL649
pathway.4
S100A11
vera.20
G209S
1078
Ficoll-separated
ggaaaatggtgcatgcatta-3
SNP34091
ATP-coordinating
EWS-FLI-1-induced
Kaltoft
U2AF-binding
autocrine/paracrine
pathways.2
mono-methylated
abnormalities.12
3mat
FA-deficient
2A–C
9F-1
4OHT
X=any
PTEN173-403
bychromosome
CTCCTCGGGT
debulking
p=0.3774
22b2
F/65
Glu805
1xPBS
NVPBVU972
.ERG
0.4-cm
thermoelectrically
RAS/SOS1
hyphen
PF-04880594
K802
10µg/mL
Kg/ml
CAGGAAACAGCTATGACCAGCCATTGCTTTAGGAGCCG
.Nestin
5'-TACACGAGAGTCTACGATATC-3
MSRB2
-*
USC3
Ninety-five
Idh1LSL/WTVavCreWT/WT
endoluminal
920–925
NUT-induced
recruitment.16
Polyribosome
sc-96
genetically-driven
ATLD
B-E
∼56,000
Eberth
ade2-ISceI33
senescence98–100
Z1031
4C9247b
QFPEVYVPTVF
containingTris-borate-EDTA
CREB-interacting
ºC
GFP–VHL213-positive
805
200–425
Mut/Mut
His98
nt3014G
anti-Bek
Flag-tag
phs000771.v1.p1
GGCCCCGCCC
EGFRvIVb-
STAT5a
1.42–1.40
lymphocyte-specific
59-AACATCCTGGAGTCCACCAT-39
20/
fin-embedded
D17S807
p.S297F
treatment,17
p110y
Badalian
LRB1
sAXL
0.1330
Figure5d
erk
c803
membrane.16
autism-related
VEGF-E
proliferation.8
there-
migration45,46,47
K-rai
Y511/F
NMP-ALK
20h1
His6-Ub-c-Myc
HGMD45
DAPI/PBS
.Invading
746H5
40-nt
sequencing-detected
gacctggagggctggg
CBFB/MYH11-positive
S1D
ubiquitin–proteasome
Rev-erb
.More
well-trained
Novelc.4235C
Bovogen
6,18
Kjeldsberg
AGCGGATCCCCCGGGTCCAAAATGCCC
adults11
GMAYMERMDY
Y381C
dockings-50
L1087P
Two-sided
mutation–driven
Apo-ONE®
1967
601812
MutSasubunits
RBX2
CDK2-containing
FLT3mr3
proposed,47,48
RB1up-RT-as
Polε
NPA
.Pooled
U87MG.ΔEGFR-generated
G/T-binding
248K
.Keratin
Igfbp5
544
gtaaaggaaa
MEN2B-RETM918T
S7
N12
meprins
Ann+
Mutation-Bearing
PTrend
RNF
K289E
EcoRV/SstI
AA443351
.2006
0.0326
10/134
programs.26,36
304–324
Galectin
transfectants
differently17
ge´nique
c.1136dupC
kinase-positive
Ib2
WT/A391E
levels39
V12-mediated
Rb1Lox/
4,737
T970M
.Aggressive
p.Val1665SerdelfsX9
Ku70-MSH6
D933A
CGGCGGTCGACCTCTGC
DDR2−/−
IGH-constant
four-strand
Münster
helicase
differentiation.39
2,448
edeine
mice76
34.63
T196A
Cross-resistance
structures,2
anti-αB1
K-RasA146
56,000
t89
mg/6.5
p.Val1681GlufsX7
R1598P
E1–E2–E3
skin-cancer
SGK494
small-intestine
TGCTTAATGGGTGTAGATACCAA-3
MUC15
FLT3mRNA-r
D–L
6,33
IgG2b
KD
nonautonomous
CTLA4-driven
leukemia.118
11.68
G577A
pulser
Hirshberg
shift/nonsense
fusions1
NsiI-digested
Seenundun
E17K-AKT1
5′-ATAGGATGGTTCGCAGAGCCC-3′
GAAAAGCCAAAGTTAGAAGGCA
111111
Li-Fraumeni-likesyndrome
ble
19661
Gal4-responsive
0.8±0.7
activation.64,65
GSE42400
thedescribed
HS-MP1
//doi.org/10.1371/journal.pone.0032451.g001Cell
NeuVax
Y-MESO-29
ofPSA
8–23
3T3-F442A
AR-regulated
16q12–q13
Quantix
Myc-wtBRIP1
accumulat­
73.1
N.C.
PureLink
c.1625A
androgen-sensitiveLNCaP
,3-sheet
OX40–OX40L
99/383
AMP-PCP
Argmutation
8.48-13.52
¡xm
RS3
re/cepHtor
genitourinary
Tuuminen
perilipin
respectively4
alpha-catenin
RPT1
acetyl-H4
BMQ
DCR
ccRCC.52
nt2149delGTaa696Stop
Meggendorfer
Smad2FL
Runt-1
82K
Gly719Cys
markers—8
Q209P
BRAF10
Lymphoepithelioma-like
above-
Hartzog
–VHL
Klippel–Trenaunay
EWSR1-WT1
Isogenomic
GeneWorks
Polyphen15
.SRp55
ArSTrpOetProProG
4946
Smad4‐deficient
R1441C
BSC
phospho-Thr68
Illumina_Barcoded_Paired-End_Capture_Library_Preparation.pdf
53270
218160
Kilday
microRNA-17-92
1–459
100ml
.Forty-nine
3/84
1K3A
.Naive
Hs00355782-m1
Phenylalanine-156
pFIV
RUNX1-PRDM16
Y591C
00034
exon18
422-5658
BSA/ml
93/818
.3161
GInWild
Pro305
jumping-like
NaCl.Lysates
3α
A1-A2
G13V
−154
2,010
transformation/immortalization
PDGFRA.8,18–21
cortex.28,29
.PPP2R1A-associated
ErbB2/Neu
Leiomyosarcomas
ΔRAFB
CP06-100UG
VMCUB3
cell–substrate
0.04b
=0.98
Zermati
Nonident
1,863-
pGEM-BRCA1
CMV-CITED2
five-marker
5'-gattgtgttgagtactattta-.V
104−8
Q1562R
EMSAfor
.Case
GCTGTGTTGCTTCTGTGG
5459-5465
.LiCl
mg.
Tyr-530
tumors.Tissues
Alka-372-001
3/79
locus–specific
exosome-associated
14.72
Steinhardt
.Responder
tumour–mucinous
RP11-120L4
0.119
wild-typePPARγ
half-life20
F11r
c.4489T
types16
Wnt3a-treated
PIPKIIs
HCC26
apoptosis-related
g-protein
739×
no-call
CDK4/CCND
pap
.Algorithms
610154
RG-10
rhombic
expression.4
proteins20,39
TCS2
Hobisch
1–37
pXJ40
Stehling-Sun
Glu709Gly
19–79
CHASM20
B-9
P177L
NF1_01452
methylation-negative
844-1134
rightmost
spanningcodons
.00,027
Epoxomycin
I917
0.2892
1−7.7SERPINA1Serpin
bp1004
140,000-
V617F-expressing
Stereotypies
MC3T3-E1
5′-GGTGGCTATGAACCCAGAGGT-3′
S614R
Jaumot
15−7.9SERPINB7Serine
F958C
PTT/SSCP
.1046dupC
537/538
MAPK-related
1069
GC-restricted
I1010T
trans-phosphorylation
clusterCons
anti-pY88
phytopathogen
J-12
.Biochemical
AKT2-AS-3
result.60
FIP1L1–CHIC2–PDGFRA
BCL2/BCL6/MYC
migration-promoting
avidin-biotin-pemxidase
P65
F1349
6×His-tagged
PCM1
.Imprinting
bio-bwa.sourceforge.net/bwa.shtml
protein-pro-
600721
reportedc
BgllI
pathway.40
Com12.1
E8-I8-E9
C459SAGIGR465
G12R-mutant
pCDNAMgaX1‐Pst
NTH
7p
antiP.Tyr
apoptosis-signaling
A-Barcode-Exon26R
PRDI-BF1-RIZ1
neo-angiogenesis
hyper-proliferative
Tyr694
939/21
c.859A
proteins12–15
CA63585
15,21,22,24
LBD/activation
Krt8/18
0.6106
p.L731*
M7395
Submicromolar
anti-ptyr
1152.04
n=67
cancers33
rÃ
14/24
IL-7R
DNAsep
.Clinicopathologic
1U6D
Forman-Kay
p.Arg249Cys
higher-powered
.PTPκ
Che-1-induced
L22Q
95,808
genes.1,2
18064-014
preanneal
SelectScreen
premorbidity
Protein–Protein
II-digested
BRAFG469V
CAAGCACCTCACAGATTCCA
Dovepress
.Matsumoto
Lys660
KIT67
MaxEntScan
Val35–
c.788G4T
surg1.med.osaka-u.ac.jp
TLS-ERG-Transduced
pVHLS111C
epithelia/mesenchymal
132/
25,26,27
Ikk2/NF-κB
'MEK1
VACO5
1048C
T720A
Ena/Vasp
5'-CAAAGTGAGGATAAGGGCCA-3
7–46
ED3
S904F
r=0.9321
receptoropathy
D369del
5'-CCC
.Demetri
R81H
2,543,130
Mdm2-luc
11/liver
Polybromo-associated
genome-scale
E98_G155del
p53–274Phe
CLB_Ma
FOA
.5615T
p.Lys442Asnfs*14
HKL200040
cell/matrix
2013CB911004
merlin-positive
Method-S2
hsa-miR-3127-5p
H519
physico-chemical
µCi
RG-22T
stem/crest
acetyl-acceptor
CoASH
formation105
NCT01427478
variants.31,50
.MicroRNAs
.NEXT
anti-pY1092
770_772
F17
anti–phospho-EGFR
Y81N
IL6-stimulated
E7-skipped
links•
18/56
DYNC1I1
error-repair
H.pylori
Asp770_Asn771insSerValAsp
al.,14
mediator-related
​Fig.6C,6C
G151S
Gideonet
H9010
anti‐COX‐2
71.0–74.8
Daouti
+HOXA9
.Cerebella
expressionplasmidswere
AW2
cancera
0.7582
32-190022
Baudino
pCDH
Retiga
dopamine
Shp2D61Ymice
gramado
30,39,48
IC50=200
p110-binding
24-fold
micro-dissection
PTEN-EGFP
62,000
ected
PTPRR
presynostosis
NR-27
2836
sgz
Age1
syntaxin
RCC-derived
papovaviruses
UAS-gfp
pY703
PHA665752-sensitive
.S9F
V643
TaqαI
haematological
047
Ser44Phe
TGG→TGA
B0
perforned
'counterintuitive
MIF-173c
BALB-c
.Centrosomes
Harhaj
Phe811
Klymenko
aPAX8
5′-GGTTCTCAAGGACGCCGGTGTTAAC-3′
-1022
saridegib
Anti-V5
FusionSL
INPP5F
division17
bottlenecking
'tumor
Scionti
CycD1
Ser7673Arg
insIP
QuantityOne
6-8×
pEFBos
ajm
tolerated.21
'CAAC
NAN1
bim
Fig.33E
patientsAmong
.3,14,15
+Arg
CDA500
TERT-mutated
HBD
1/10
2,3-dihydroxy-1-naphthoic
.Ref
Beta-Escin
low-to-normal
PAX3/7-FKHR
LsyM-KI
MRD
KOPN
anti-postmeiotic
Studylog
mutations,40–43
61-3-9656-1411
p.Gln479His
Brgf
15.04-fold
.Sciot
T328K
POP-6
FES
0.152664203
C275/277S
V559C
BAC-PAC
αIgG
EML4-ALKWT
Nine-week-old
SHP2-Q506P
650kb
TCGA-HU-A4GU-01
Anti-IDH1
IPA-defined
pseudo–Pelger-Huët
enhancer–driven
Biniou-mediated
5hmC-
site,32
Gln-43
N7565
BmHI
CGTGTCTCTA
3s
Kdr
Lyso-TSC2
AI218900
1125–1537
approx500,000-fold
5′-GTTATAGATGGTGAAACCTGTT-3′
C641G
1–593
5′-TTACTCTGCAGTGTTAATCC-3′
DNAwere
isopropyl-d-thiogalactoside
ab9106
1_2F
mutyrx3F
dinger
MPN.11
cerebrospinal
white-skinned
.Latency
5850
K603Q
molecule-I
Fifty-one
NCT01871805
CGGAGAAAGAGGTAATGAAATGGC
Brastianos
thedat
M0887
acid-base
32,519
84–86
7d-f
Nalgene
serum-stimulation
I1WM
2-chloroethyl
ENZr2
GACTGGAAGCCGCCCATTGGTG
PDAI12-R4
craniosynostosis
30–2001
protein/Src
4C–G
RV6
johinaz
Djikeng
purifi-
mutatione
coprecipitatedwith
70/F
mTOR-Deptor
.BOSC
.1.8
A,7,9
autophosphorylate
BD190
NPM1WTDNMT3AMUT
transcription109
Thr1151
2Ac
Matrigel®
p140mDia-related
BCR-proximal
pathogenic.29
.Petricoin
0.0004
electrophor-
R1358*
ey-Gal4
Fig.5a
EMP-2
d-luciferin
theirapproximate
NON-MEDULLARY
P=0.13
ZPIR
TMA-FISH
Anti-pMEK1/2
G12DKras/D594ABraf
.PKCϵ
PRDM1.E5.1077.R/
α-GFAP
rasl
c.4180_81delCT
talin
HMG-1
BX60
Benediktsdottir3,17
2235
fiagment
Ihkl
TCP1
Nupage
ERF-Mediated
3-kinase/mammalian
llftp.genome.washington.edu/RM/RepeatMasker.html
A-3
R87P
interkinase
7p21.2
POLH
5¶-GACAGATATTGTGTTAAGCAC-3¶
autoactivity
Ly-5.1
mice.48
Sliwkowski
1187–1208
4,800
Z≤−1→1
mutationsd
WT-FLAG
PLA2G2F
weak-tumorigenic
reported.9
CNKSR1
⩾10-fold
5522
7,173
L866
sc-1020
Sf9TEs
753–768
to-Ala
RasY64A
kinases.14,15
FGFR1gene,13
CCGGAA/T
Dok7
Lucite-lite
6p21.6
gene—initially
pOP-Ires-RFP-puro
CLR3
3.3–82.5
/4p16
52/F
5′-UAUAUUAGACGGGUCAGGGdAdG-3′
IR3T
//www.e-cancer.fr
sequencingly
oxidative-stress-induced
.NR
f-catenin
XG5
III-mung
4,742
29,34
mutation.32,33
anti-PY
1A5
N1L1601P-induced
pCAGGS-EGFP
3.2–16.7
s−1
MeV
1M17
NGF-dependent
CBFβ/MYH11The
A1055T
1.998
G.C.
.Zhang
11691112001
Y568F-D816V
NCT02094261
p53′
T294K
42,53–56
.Peptide
H19.18
-neomycin-herpes
20-h
708-bp
firefly-luciferase
IL32
5′-TCCGGGGACGAATTCTGCACA-3′
Ser1650
0.8-cm-diameter
5-methlycytosine
V768S
ultraView
Cγ–signaling
L21A
β9
NM_013822
I1681N
ab1445
.R337H
SWI1
NMD-escape
adenaturation
mutasion
Speed-Vac
.Betscholtz
adenocarcinoma.35
fsX
3`
C-abl
goniothalamin
assay20
Brdt
H3122-DDR2
RAS36
oncogenecontains
TX2-121-1
Lysine-to-Glutamine
ΔWW-myc
Keap1-V5
SOD3-sensitive
5′-CAGTTGATCTGTGGGCTCGTTGGTGAAGG-3′
.Gleason
function.19–26,38–45
modicum
Cbl–CIN85–endophilin
F2009S
Fli
BM-derived
0.8-kb
K364N
Δ1529–3418
HRP-antibody
Polyadenine
7†Handolias
GST‐15A‐Rac
repeat12
Lin−CD29hiCD24+
FPA
alleles22
reverse:5′-TCCCAAACACTCAGTGAAACAAA-3′
54.42-54.94
protocol27
phenotypes.2,3
32.2
.Haley
Jawien
1011K
CREB1
Ubf1-mediated
SUP-T11
4376
alteration.28
DMR1
MDS-unclassifiable
progression.23
GDLG-31
short-course/hyperfractionated
124
ogist
IL-3–stimulated
34C
28
non-p110α
anti-CD18
F89
Ex10-13
TheY367C
Universitä
.Rat‑1
Kirchhoff
A-Cdk2
others10–13
E-cadherin/β-catenin
Morphogenetic
Low-passage
Gly331
fancj+/+
L2510P
SRIworks
2.5μM
1.1–4.6
g-irradiation
316v2/318v2
VEGFA
Pizzuti
397mel-b-cateninS37F–implanted
β2/β3
​Figure3D
mutant-length
Smad4-MH2
5′-CACTCTTCCCGGATCTTGTTTTTCT-3′
E2F1–RB
PDGFRalpha/beta
.Vincent
mRex-1
19.8/21.2
TGATGAGGTGTGACA-.TGATGAGTGTGACAG
Thevariants
X-100–0.1
hTERT-expressing
9121S
3100-Avant
anticorrelations
Swiss-2D
*30
BAT-RH
Leu-labeled
Sanjanaa
Xbra
BTB-BACK-BTB-BACK
+/Mild–mod
study.3
substrate-trapping
S-IIP
A298T
GATA1-null
acid-buffered
SeaKem
adeno-squamous
antiFANCC
BCOR3.1
discovery7
V765Ma
non-truncating
117/781
3295-3266
SDI
–deprivation
receptor.8,9
CGHcall
fancd2
anti-BRCA1-Nter
Asp-769
Kras+/LSL-G12DTnfafl/flPdx1-cre
Knies-Bamforth
remodeling26
TATGCTCTGG-39
apoptosis23
SD.We
NRIP1
anti-phosphoTyr-419-Src
RET-fusion–positive
antigen-activated
31.9–75.8
carcinoma1,6
.2006.06.005
expression52
Inp
P3–AKT2
signaling22
cogent
LSK/MP
spine/pelvis
serum-treated
EJV133
Schermuly
LiAc
yeast6
alldifferent
CLTC-VMP1
395KB
8T
p-p105
0.1-0.2
I661T
MAPP-
HiSeq2500-based
Micro-dissected
deoxynucleotidyl
.LS-associated
.69
T68P
Trastuzumab
TGCGCGCCCT
type-IIa
NUP214-ABL1
reclassificationA
NPMALK
.Manipulation
shPLC-γ2
pSQ-containing
Luminata
R1055L
function35
5′-ATGTTTGGCGAGCTATTTTGTCTGTT-3′
11.2
7.9
H3-K36
1084–1090
Trr
a5-deficient
9PT
52X
200–400-fold
11–14
tumour-sequencing
01:27:45
CDK4-MUT12
Oligodendrocyte
anti-p190
3,610
these11
12.7
zyxin
8G1
Trp140
.Reducing
anti-p100
GSK2636771
5-dimenthyl-thiazoyl-2-yl
L235A
CD31-
CIMP-L
VavP-Bcl2/Kmt2d/Cγ1-Cre
NPM-ALK+
.ESEs
double-gene
autosomal-dominantly
RNA1.2
GM-CSFR
/2-oxoglutarate-dependent
Promega/Biotec
MPPH
download=true
L286P
LKB1s
tiation
re-broken
Tris-Borate-EDTA
up-to-date
I836T
5′-GCTGCTCCACGCTCTTGTC-3′
RP105
.Concomitant
ABLT315I
Neuville
9122
Apo-1-structure
Myc-ERα
attest
Unc93b1-independent
Cdk4-pRbpathwayas
EGF-to-ERK
HRAS-targeting
GR,22
5′-CTGTCATTTCTCCCCACCAC-3′
p=0.0858
al.,31
demultiplexing
1367-1384
SLA.PKHR
genetics.bwh.harvard.edu/pph
inconclusive.39–41
`b
MCTP1
FUS-DDIT3
neutropenia90
P43212
Hs00371735
ITF2
Ricotti
K298A
nongene
Mutant-expressing
phosphatidylcholine
22-gauge
kinases.12–14
RTK/RAS
H-100
factor-sensitive
BRAF/
LBD-deleted
.Endophilins
V617F.2
loss—towards
P1/8
Hidden-Markov-Model
-AGAGTGCCCTGTTCTAAAAC-3
Chiappetta
29784
AAAAGCAACTGGATGCGCTATG
Z7020057
solar-damaged
​and3D
second-order
.Attention
CTT
ABCA8
pAkt/Akt
4,41,42
fungizone
11,15
Pem-luciferase
domain32
0.687*
IDH1-G367A_F
underexpression
PKCϵC
Borche
Bio-RT
GDP-keto
1–2664
R172W
deFUSE
trr-null
GFRs
9/9
EEF1A2
yet-unidentified
35-year
p73α
GC-
Capan
-200-bp
Taz1
streptavidin-conjugated
tumors.35
synergistic
NCT00902044
leukemia.17–19
1549
Torring
Human/Mouse
1-19
CD34+CML
.recruitment
GABPB1
100colonies
ZM336372
masatinib
746–750
1393T→G
p≤0.0001
.Hot
A775dup
M29
re-sensitize
0.153
2466C3T
Ig-FITC
glycan
5-hmU
mixed-effects
phenformin20
samples.21,22
auxilins
acidserine-­threonine-rich
Yenush
one-two
Helper-free
PBS–0.1
Immunostaining
therapy37
anti–phospho-Ser473-Akt
.901G4A
responders14-16,18-20,23,24,26-28,31
mÃ
∼8.3
CBF5
PhosphoSite
platelets/uL
U2-OS
Prolines
Melan-a
NIA
Leppänen
stability-activity
ORC
High-confidence
id/
FGFR1K-3F
6838
anti-RARA
.Lane
G177A
E-cadherin-catenin
617-787
butyrate
Sorafenib
5-aza-mediated
RCCs.26
chain.In
Fug-III/24
programs—that
endocrine-treated
gliomas.21
ATR-X
6KIT
anaphase.32
G58AC77Y
mito-IDH
.Because
skim-milk
•Null
.50-.85
mutations—Δ118
36/82
FBS/PBS
ACAGtCT
bone-scan
breast-
9903
criteria,24
ER1-5
51–55
Ena/VASP
26.9–2.0
220kDa
47778
p.I1766S
A318T
Arg24Cys
p800-Luc
methodsSamplesPrimary
Scandinavia
002014
1353-
IonOneTouch
profile.2,3
L574L
.Whetherthe
49/117
CD54
Shepp-Logan
chromosome-20
tumour.16
cycle-specific
MEDI4736
.Expression-based
G578R
kinases,2–4
pan-inhibitor
G375P
ZNF198–FGFR1
D/N-E/N-pi-S/T-pi-A/G-W-G-E
survival.8
1667R
loop—Asp816
AssessmentIn
GSE34620
loop-containing
FLT3-Y842H
.MALLOY1
2C9.G2
single-end
failsafe
imageTIFF
26-year
assay.ResultsWe
C593
D1–D8
1.1.23
disorder.40
BCR-ABL1+
v5668
01234
gdPTCL
fusion-negative
Alectinib
Sci-Tech
phoshorylation
development/progression
E931G/Q684R
High-MC/NMC
MLL3Δ/Δ/ASCOM
840insT
siRNA.https
.library
HIV-1
pBabepuroBAF180
nucleotide-requiring
Daf‐4
43/CRC
prolaspe
L2216P
motifs5.9AKR1C1Aldo-keto
phosphatome
Hou
.Myc-tagged
5′-TGGCTTCATTGACACCATTC-3′
loin
AGAAA
p.L1224F
apoptosis.125
37–41
D3-polyphosphoinositide
disappointing
crosshybridizing
monoubiquitylate
G1479N
JAK3-expressing
c.1192C
K443Q
U3-1287/AMG-888
Jonkers
juxtapositioning
GSE28891
l'lp
TET/FET
inAML1
miR-194/BMI-1
.RITA
25-55
EML4/ALK-L1196M
dasatinib52
R66C
Chanson
4314
tomography/positron
β7–β8
3q21
bedTools
.tumor
stimulus-induced
halothane/oxygen
HCC-366
metatasis
Ras‐related
2,258
tumor-specific
x-axis
band4.1/ezrin/radixin/moesin
Bellesso
respiratory-gated
YLK
Massachusetts02/
.G13F
viscera.3,4
H2141
CGM-1000-N
myofibroma/toses
788T-C
Lymphoma/thymoma
pSUPER-Hdmx
1006A
chimaerisms
373-1001
.ADC
lymphoma.21
Muellner
x400
Tumor-infiltrated
carboy
22-month
0950-9232/13
FACS
differen-
cost-intensive
5′-AGTGAACATTGGCATGATAGAC-3′
mutation.5
Circumference
egg-laying-defective
guidance.42
R772W
exclusive.18
Actinb
K170R
non-cell-autonomously
re-streaked
nsSNPanalyzer
2,673
NCT00573989
nonchimeric
RACE3-AP2
Met/HGF
PDTX
MYF4
type–Arg21Gln
glioma-
E455
10p14-15
.Weaker
~15–20
S22A
R562Q
p.E670K
AG3056
11C/cycle
USP12
JH2V617F
3a–c
DEseq61
1/4
panded
Neuroprobe
B-cell-associated
cbEPC
.Y64A
mice46
shRNA–containing
T202/4
44B
no-CNV
6B1A
CYT387-resistant
13-18
Mdl1
PTC-inducing
int-1
slippage-related
275–280
oncoprotein.3–5
hypothyroidism,19
Cyclins
323–334
IL-3–dependent
aza-cytidine
AHB3
395-417
n=50~60
cytomophology
Keap129
c.965G4A
available.Functional
domain.24
5190-0418
twitch/red
recommendedby
TOP1-ChIP
familial
Ser-62
c.1078T
TdT-mediated
PTP-
T2/E5
Samter
F808L
MCM5
AML1-D171N
diff.
JAK2-V617F-
Freeze-dried
.Flag-tagged
T157I
p.His1477Tyr
MATH-domain
10.9–23.4
Y640
AZ268
juxtanuclear
0.053-0.095
gefitinibresponsive
8-reverse
Re*
L158P
unmanipulated
trials.11,12
CD11clow
Prolyl-hydroxylated
p.F508_K509insYFAF
Tabeta
Asn117Ser
Asp-450
hexanoyl
EcoRI-restricted
A874V
RanGAP
signature28
GFRα2
±10
non-interpretable
P174L
inte
dosolateral
Thr-647
non-silent
HBB
full-thickness
hematopoiesis.1-5
MSH2-N596del
Tyr26N
UBE2N
paxilin
reactionwithoutinhibitor−raw
.Recovery
loss-of-function.20
Bligh–Dyer
NGFA
Stratakis9
610679
32/62.7
staging—including
32-s
6.0-
0.42817818
.RBP1
tcaccatcttccaggag
anti-Bcl6
precipitation-based
foramide/2XSSC
R678
7q31.1-qter
Hδ
.Nonrelevant
8wksR5
17q21–q24
laminin-coated
SectionDiscussionIn
anti-ERCC4
MEK162
Msk
Rap-GAP
nm3
rs141230043
Emulsion
Ki67-labeled
analyses.Sequence-based
EGFR19R1
leukemia–retinoic
mouse96
IDA2*
phosphorvlation
AML-5
p110β-Gβγ
.Investigated
7756-1
FGFR3-dependent
5.8-fold
flavocytochrome
recA9
p.Ile246Leu
59
MAD1L1
Chakrabarty,1992
ofβ-catenin
Non-Nucleoside
K545E-
'-Ab
Resourcen-zentrum
GAD67
NM_176795
pT183
p.Leu435Pro
850
deletionplus-insertion
MPNu
selec-
F-SIRT1
8/21/06
pico-
0.1.19
335700463
4.Variants
prefl2m
Flag-Fbxw7
LR11-270
0.1-ug/ml
Smad4-null
0.201086
value4,6,23–25xp.N505H
VC-377-1B
uz
EWSR1-involving
25,34–40
17T
TNB1
i0
L11284
granules26
isocitrate–Mg2+
T74P∼V14I
origin3
15–16
NF-κB31
605317
Pargellis
SNP-phenotype
FNMTC
3Glu
mg/100
bone/soft
C118W
AAACAG/gtgagg
Fas-associated
Myc-Pik3ca
EcoRI-BamHI-digested
H3K4me1
αp
R197H
Fug-II/11
Wnt/β-catenin–associated
RHD-dependent
UV41
Underexpression
marrow.29
Gk
PPAPDC1B-mediated
2/73
IVS39-12
1.15∼1.67
29months
//dx.doi.org/10.1136/jmg.2008.057653
Spangrude
25,6*
regions37
.Lysates
anti-paxillin
thantophoric
RAP2,31
RHEB–GTP-dependent
tumors.46
42–48
§Family
p53loxP/+
c.1970dupA
718–724
P151
kinase-pRb-controlled
FANCA.31,32
glutathione-Sepharose
Â¡umethyl
co-detected
HER2-targeting
ADP·hMutSα·DNA
IC2KITV814
α-minimal
pathway234
castration-like
anti-STAT5A
6–445
Glu114
Ohdo
immuno-alkaline
GenotypingFour
.ApcMin/+
Bashkortostan
.4076
852-8501
lymph-node
Database.19
RefSNP
:6.
GMR-Gal4-driven
inhibition.27
p85α/p110β
NMR-based
PIK3CA-PTEN-KRAS
C548Y
p.E1018X
AmRNA
fast.Second
.UBE2N
n.t.Gallen
H1047L
.Vasen
mutationsa
15-amino
372
Compassionate
TGF-β-responsiveness
400-418
it.2
CA4
r.326_475del
HER2receptors
PLC-
eluate
CXXC-
heterodimer-dependent
Osterix
=7
0.2562
rearrangedfragments
AurB
single-exponential
gi1079288
HA-wild
RASF28L
cancer28
tyrosineacids
synthesis.1-6
SM+SD
TCells
F74L
myeloid36
homology-modeled
Sonnylal
I463
BRCA1/2-positive
nounced
+715
endocrinologist
structure.13
C-RAF220
favorable1
.Antiphosphotyrosine
NHA9-Driven
Ser71
L387S
5-BrdU
Galperin
TAGTGAATGCATACCCCGTT
May-Gru
Plaxco
2/188
l'Agriculture
Bernues
//rb1-lsdb.d-lohmann.de
9145L
cxlO
SCGB1D1
apreliminary
S18E
7–18
MM.25,44
cancer,2
AGCCCCTGTTTCATACTGAC
pYES3-GFP-Akt1
coiumunoprecipitate
+vector
XXS
.Heteozygotic
p.F82
damage,13–15
4,903
q25
S.Z.
559027
h-galactosidase
H98
roscovitineinduced
PBS-
dose-expansion
Heparin-treated
U01-537
Yiling
3b–c
CAPZB
.ADH1B
–34.6
gene.8
IVS12
reconstituted.28
KMT2D-interacting
Kanter-Smoler
5′Fam-GGT
siCON1
670/1506
4U0I
αD-αE
0.13-4.05
C-terminal-
PDL1
458nM
.PAX5
c.4766G
Cyclosporine
adoptin
5′‐TGTAAACCATGTAGTTGAGGTCA‐3′
E75G
.Astonished
–PDGFRα
RG-2N
Jakobsson
610651
assaysTo
PDE6C
TEL-ABL9
GFP–BRD4
.Lys-382
K545E
hBrm-containing
-Met
concanamycin
K.P.
Triche
2-123
Y994H
TSC24
Repli-g
E768D/A919P
PT1+EZH2
semi-independent
dTAMARA
TOCSY
.HSV
0.0019–2
F129L
recombination145
.Viruses
14/115
Asp814mutant
cancer.10,11,12
Loonstra
C-associated
extracelluar
PKCβ1
Q99X
n=389
174
anti-E-Cad
GIST16
Upfront
A_51_P287418
5922033
non-point-mutated
127kD
RP11–526I8
PH2
G160D
7q21.2
ΔWD
8l,21
copies/mL
-2-ethanesulfonic
mRNA22
EBV-LCL
partic-
36.2
.Ibrutinib-sensitive
Hs00275109
situ
.HEPI-RAB
67,69,75,79
Balthough
outcome.5
Peri-centromeric
c.1728_1728+1delinsAA
nature.comHe
-9Za
.Rinse
KYSE170-luc
ADM-2
04693124001
NKI
Y537F
9-bp
2-Photon
Ba/F3–T/P
F212Y
Quality-tested
RP23–416H6
soft-gel
AbiPrism
NCIH2373
hPMSJ
genotype-dependent
Rad50vsc
Abecam
ATP.12
productionof
Argonaute2
population-average
ITGAV
THCA
FTC133
GDC-0879–sensitive
D17S1321
parsimony-based
wheremismatch
reaming
EUFA255
TSC237
Arf-knockout
AAGCCATT-3′
c-Myb
adaptor-ligated
MLL133
A871V
hiatus
calretinin+
AML,32
anti-TrkA
eighty-eight
rs1695
Qe
Rochlitz
FLI1-related
HER2T798I-mediated
EcoRI-NsiI
gene-trap
0.38–3.54
PJS-associated
non-exclusive
SWI/SNF-intact
BCR–KIT
Val600Met
signed-ranks
rbf14/rbf14
norepinephrine
pCGN-INI1/hSNF5
MAPKi
Sigalotti
Weihrauch
correct-sized
T106P
ΔCt
EGAS00001000472
Dia
≥Median
5′-TCTTAATCGCGTATAAGGC-3′
B.H
8.0
368
1096-7192/01
Yamamoto-Shiraishi
//MTCP1WT
L377F
H41R
exogenous
anti‐MEK1
NW_047679
47K
//linus.nci.nih.gov/brb
S249C1.1
AATGTCAAACTTTTAAGACG
Met561
Pro715
GTCGCTCCGTCTTTGG
intriplicale
TxG
sigma-plot
WW23∶Smad1
Cell-type-specific
NCI-H290
RHEB—elevated
BAALC,25
hamartomata
7-mutated
1028T
TEL-AML1-transduced
1e–f
melanotrophic
1697
pBM2389
RG-27N
Τhe
Py=T/C
VEC
oncogene.We
replication12
IRS-1/p85
Adaptor-ligated
.Gastroenterol
0.896
HA-expressing
B/Akt
R1715G
μmol/L
M/74
fold10
jg
mCi/ml–4500
5′-GACACATATAAGACCCTGGTCA-3′
sequenceisfusedtoa120
ectopic-expression
BRD3–
Roux1
RUNX1–AFF3
MSI+according
Serpinb2
M384I
D1–D3
Ala202Val
mitosis,22
AJ251960
ISH
progression.18
NM39
www.wwpdb.org
hyperthyroidism
.SMAD4/DPC4
5.3-fold
.Conserved
prephotobleaching
c.1798
Potassium-Calcium-Magnesium
1QCF
ARID3B
non-expressers
SEC14
Pfleger
G709E
PDGF/
R796G
flow-cytometry
CD19-Cre29
694–762
Tyr537Asa
.Klausner
W315L
Hoyeraal
1μ
M/A
R293*
MALDI-TOF/MS
A743Sa
7.6
pyrimidine23
reranked
701,987
543X
documented.36
12q13–14
hyperphosphataemia
th~t
Myc–p300-expressing
Fig.5A,5A
uncleaved
Sdc25
Induction-dependent
.80624319
Gly356
30uL
.6-
Gel-purified
​Fig.4C,4C
TGF-b-dependent
28/44
mixed-lineage
Â¡mmunoblotof
T-transformed
Y1066C
T6P
.Peroxidase-conjugated
1,000g
14B
BLIMP1
changes,32
Balb3T3
p21WAF1/CIP1
BIAevaluation
1.0078
U2AF1-induced
74.
.4437
breast3
survival26
cluster.
endopeptidase
residuesof
analysis34
12/19.7
6·8
Rev-5′-GAACAACTTCTGCTCATGACG-3′
event-time
CRL-1573
Paré
28/117
Toschi
ABC/non-GC-DLBCL
CDF
+del
6,616
N223D
two−stage
G12/G13
familiescollected
ZFP
kinase-conserved
activity.6
TGFbeta2
CDK2-ATP-cyclin
Pathogenomics
56798141
oncogene-initiated
Lsh
Tyr736
11.1–14.1
NM_013560
RESOLVE42
-PDGFRβ
002609.3
it.10
pF5xUAS-SV40
1033
moribund
Figure4E4E
PTEN-non-expressing
5.57
orthovanadate
Genescan™
chordomas
.TAZ
Wiesmann
DNAH10
Ile163
PARP-1-
GCCGGATCCTTTCGTAATCGTAGCT
hyperreactivity
3S
2428–34
CACAACCAATGAGGAAGCCTTGGACCTCAGCCAAC
KITWK557
KITreceptor
pan-Class
0−15
Phosphatidylinositol-4,5-bisphosphate
LNCaP-cxD11
collagenolytic
804801
intercalator
110:3374–3383
Mutation–Positive
AON
SK-HEP−1
tumoural-extracted
E91
MMP10
TRD1
Jak3,22
non-inducible
S5D
Bcl2.116
//www.cbs.dtu.dk/services/NetGene2
8Db-d
krox20
a6-integrin
BAA33540
UDP-glucuronosyl-transferase
.499
iodide–positive
wild-type–overexpressed
Rse
005656.3
BR13R2
MEK–ERK1
sc-819
conformation.26
5′-TCATCTTGGTCAGGTGGTGT-3′
depletion–resistant
N19
optionsNot
rsbweb.nih.gov
602
EN-Y628E
39.5
resistance108
mg/kg/week
thechairman
defects.42
mutant.17
440-residue
5946delCT
Cbl-N
Q29C
1,601-2,000
promoters122
homo-tetrameric
979-1006
5¶-CAAAGAGTTAAAGATGAGAGC-3¶
4769
40x
polyalanine
p.Cases
2.32
ONOO
4-oxo-3,4-dihydrophthalazin-1-yl
A330T
CD44HI
26/36
−.32
NAG
anti-SHIP2
pre-phase
specific-inhibitors
mCP1086
,6q-
Navarro-Martin
interstrand
.Green
81Glu
.Methodology
ng/mL
159_173del
Matrix-assisted
prob­
T3wt+T3/ABN6
PCR-Sanger
−27.7
Hs00414907_m1
biological/clinical
5′-GAGAAGCCAAAGAAAGAGCCGGATATCTTTGGATTGAACC-3′
K-ϕA-X3
bdo
Primary_150929_114735
Hydragel
plus/minus
D275A
cprn
−26
I295fs
DBLCL
507.3
protocols3,5,10
.4D
3-kinase–mediated
:101
286C20
susceptibility.2–4
leukemia,48
Taspase1
Promoter—Given
CNS-mediated
G674S
CTD-2324F6
9,601
DNA-testing
Qxx
implantation.32,33
03553361001
A\
methoxytyramine
Ligue
Kit-WT
malignancy58
005334
sequencing–based
10⇓⇓–13
.14,19
V600Ei
:TRP1
531–590
H3-K42Q
GCTCAGCTGGACTGATATGTGA
doi:10.1038/nsmb775
.Unbound
lineages62
clone–implanted
.Remineralisation
Cys-Trp
G429D
NADH
HCC-95
TβR/SMAD2/3
2B.Figure
De¢ciency
20–28
BT20
vivo.34
Rep21
differentiation.56In
mutations.17,18
anti-myc
agents.6
0.010519032
0–2,500
DEDs.18
phospho-PI3K
.NTRK3
and4,4
EGFRvIVb
AAG|GTAAAG
FLT3Y599F
EENIR1239-43del
.PKA
GST-K-Ras
1748delC
100mgs
U87MG4
described22,27
lung-associated
67–68
CLDN6
PG13-luciferase
Lys389
554–1106
microphysiometer
planachromat
MEK112
oncogenesLower
441
cancer–associated
Loskutoff
anti-BRAFV600E
12-minutes
fail-safe
GST-Gli1ZF-WT
HER-2
pCDH511b-K27M-H3.3
2,30
69373
CTLAAla-17
R722H
Gly348
K235R
S235
29‡
44-fold
.MAP2K4
unrecognised
infusional
.1984C.T
14–mediated
incretin
pVHL-containing
62–101
Figure3D3D
pI6lNK4a
λm
5Bii-iii
p.Ser560fs
chemotherapy.37
receptors.33
858
Grp78
610755
non-surrounding
.Correspondingly
10−23
2-pS2-Luc
Kda
EDTA/0.07
666
2C10
Moroy
HPV-56
15–25
2/kobs
.Either
BRAF-V600E-positive
26,34,35
WDR24
sanitaria
.Linker
VCAM-1
179.4
.Linhardt
homeodomain-linked
.Low-density
Myddosomes
100-mm-diameter
macrophage-tumor
carrierwere
splicing24
diserythropoietic
TARGETplus
vitrotranslation
OAIII
.Proliferation
ALKKin-fwd
scintigraphy—in
B202
Glu118
SLC38
Delta-47
Yl
NXT
ribonucleocomplex
WNT2b
mRNA.The
individuals.1
kinase.31
V2424G
////idlll-cleaved
71176
residue6
1029GATCdel
histones/chromatin/chromosome
A/159–179
bitopic
4.8-
chemotherapies.16,20
SMYD4
minaturized
transmembrain
.Heavy/light
0893-3952/11
Unligated
Asp447
zebrafish12
FusionThe
A/cdk1
MSH6/GTBP
CblR420Qinhibited
9.238263625
.29012915
lâ€
NCBI37/hg19
T286A-HA
E2F-regulated
CACCCGGCTGGAAATTTTATTTG
CMVWT1−/−
G129A
18mutantgenes
Neurosphere
0.0452d
CGGA_1475
Bio-Rad.Determination
microspin
/100-mm-diameter
E77K
PARP1
-hero
115258311-115258334
-ETV6
migration.40
.025
co-immunoprecipitating
110-749
ΔBRAF-transfected
SCF-Bound
Bim-haploinsufficient
797TRex-MYC
clusters.27
SM-AHNMD
1.037
Hi-Fidelity
5′-GTATTTATTTCCAGGCTTAA-3′
long-course
COUP-TFII
TF3
95Â°C.30
.1306C
Arg420deletion
msh6Δ
L1196Q-positive
196
.TCA
G-T
Stenotrophomonas
Erisman
proteins—were
BRCA1–5382insC
adenocarcinomas.6
immunoassayed
pro-differentiation
​statistically
Myr-HA-Akt3
7–30
BCR-ABL16
classi¢ed
25,46
CRL-2061
leucine118
.ErbB2s
IFN-γ-induced
withincreasing
.S3D–E
Allograft
SOCS47
REFMAC5
mutations—ie
1.9×-10−32
MSSE6,11–13
invasion38
+2.8
D479G
Kretzschmar
dis3-S541R
acid-phenol
Biomediques
.MEF2
MCPH
expression161
769B
EGFIURPTPp
IFM
lipodystrophy
PMAIP1/NOXA
LNCaP/AR
23-2
Ldn-DgkKIhcAVKsLnritDiGevsQFltEGi
3685
1,118×
Cdc42/Rac1
pEAA296
CD95-mediated
TLX3/HOXA
PE-Cy7-conjugated
Np53fl
10*,1*
-B51
n=738
MSTO
GFP-Rab7-positive
FLT3-ITD/78
211−213
JALSG
.Nonmethylated
57,58,60
RPS6KA2
ABT-263
CINtec
transit~on
pRB-LXCXE
IGHJ4*01
Bundang
GTA-3′
24·0
Murre
jak2a
411:355–65
El-Hashemite
LFL
MLL-AF4-associated
Anti-TFAP2A
E-MTAB-1611
10~-8~
.124
*4.8
,ii
T382A
ABC-DLBCL.18
CNAs.10
Akhurst
fentomoles
Nu18/SP1
glutathioneSepharose
over-confluency
signi
,5A5A
treatment.Compared
dR110/dROX
first-in-man
mice.6
anti-PAX9
R262C
RET•
0.852
mitochronia-associated
.sequencing
5′-GCCCCTGACAACATAGTT-3′
small‑mol‑
actin-positive
CTTGCACCTTCTGCTCAT
GISTIC31
SF3B10
.CDK6
r.208_306del
R-Hyper-CVAD+MTX
first-stand
41-438
.DNMT3B
leucine-to-arginine
AF116268
arm-specific
outcomes.1⇓-3
solid-state
EWSR1/FLI
8Da
RFLP-RT–PCR
unit-cell
TACTCGAGATGGCTTCGGCCGTGTCGCCCGCCAACTT-3′
.SQSTM1-NTRK1
inactiva
35.0–42.0
73.3
TRD1-proximal
Serous/2
28/46
archaea
1957
2319insertionGAC2320
06–87–06138
1,655
RUNX1-USP42
V317M
hindlimb,19
M351T
ZenBio
instability.23,24
STAT3-regulated
adenocarcinoma.47,48
AKAP-Lbc
R277Q
.B-CELL
UMR-S775
functions8
in-gel
6/0/23/18/38zRectum
Fooyin
NPH-II
pSmad1
Mll2
2H3
FNK
4446C→T
7Rα–expressing
Stefansson1,3
506/292
UBF
blastocidin
AGG→AGT
,44
controversial.53
w/v
14742
SH2Bβ
GTTGGTTAATTCTCTTCCTGTCCA
dissociation/scattering
.10-
re-orienting
unequivo­
p.Gly12Asp
Sun-exposed
T/p.Glu284X
MAST205
PMS2-135
gccttgcattagctgaataaat-3
JSNP
.Network
−RT
caspase-based
pressure-dependent
Niu
diffi
KU-57788
Anaemia†
report,21
acid.Validation
mouseB2m
4.88
.IKKα
1714R
5′-GGACCCGGAAGAAGCGCCATCTCC-3′
culture.44
0.2659
273
0.189
80117
patients19,20
0.20
CAATCA/gtatgt
GF33
0.51
theunderlying
1,031
0.5097
disease11,12,13,14
imatinib-resistance
PI3K—Recombinant
S170L
deoxyribonucleotides
pVHL
C.B17
.Whatever
4/278
F866Y
Tβ
HNF-1α–dependent
I116N
P=0.00137
0.0229
pGreenFire1
a-p16INK4a
Gci1
BRCA1-5382insC
sequencesof
Fig.13
54b-7
T184M
A80T
prognosis.12–15,24
PDZ-RhoGEF/KIAA0380
Ha-Ras-GBD
tumours.Unsupervised
rs55796214
Chenna
V405L
817K
postabsorptive
pb2m
anti-E-cadherin
forBRCAJ
mutations.36
Gly719Xaa
ETV6-PDGFRβ
Tyr-CreERT2BrafV600EEzh2Y641F
c.1153-1_1165del
Phosphotyrosyl
Men1F/FRipCre
FOXP-1
P427T
_424+
3X-CTD
C3HC4
CDK11B
10−51
PHD4
1467
7/83
LANGERHANS
.Dai
5′CCGCCTGGCCTGCTCATGGTGTTCC
PLX40324-5
11•
R831
frequencies6-8,40
1,053
TRiC-VHL
outSAMstrandField
K366
β-glycerophosphate,1
Romond
Arg248Cys
2j21
M237K
8.3-kilobase
LRcHL
Leu86Ala/Ile90Ala
dose-dense
391-codon
JNJ38877605-resistant
=¢00
co-migrated
.Anecdotal
n=7/67
onc
2/03
L1354Q
3x104
OJH
PCR2-fa
indexDiscussionAbstract•
non-MAP
p271–197
pMex
12q21
Kanazawa
1,087
rtlurnrrd
BRAF-RAS
:TnJO
Hyvonen
yet.16
0.961‡
,8
WW-domain-
GMP–binding
Kunderfranco
1278
metastasis.12
DSBs34
Rho-GAP
telomestatin—are
DFCI-032
phospho-BRAF
cell‐cycle
lower-
.NRASwild-type/BRAFwild-type
jyunlee
Biacore
Microdissector
AssaySix-well
wtBRIP1-transfected
glioblastomas27
Anti-tumor
Post-IR
Neidigh
41–81
paraformaldahyde
ULight-poly
.Stat4
Universitaºtsklinikum
pLvx-puro
TGGTGATTTTAATTT
trk3l
GABPB
V152
PreProtech
1NVX
Cys463
A879-R897
5′-CGACGAGAAUAUCAAUUAUUU-3′
ZNF703
mHGA
5′-CCTCCACTGGATGGTTTGTCACTG-3′
Sturge
-CTTGGATTTGAGTCAAATTGG-3
uAsplysTy
L-2-hydroxyglutaric
MMC-
lysine-21
CTP41A2a
rs145402255
SKO
Adenomas_variants.txt
.Rushworth
0.06μl
647V
Kimelman
meansplusminuss.e
rved
77-79
often-mutated
1–intron
0.964
7TF
MSC-O
.Neu
Myc-DDK-tagged
tris-buffered
MMP-15
*13
.Rank
siROR1
P.T854I
Nola2
pF711/CAT
1Hev/J
.DACH1
.Time-dependent
Bushweller
FIG–ROS-regulated
reported,2
MLL4/ALR
EORTC
31-
R227L
CD207+
5-TTGATT
Ro19-8022
pancentromeric
Burgering
pathways48
signaling13
8480
10.7-fold
Longthorne
*6A/*6A
HCC78CR1-2
593-622
wefailed
19/40
F/66
CTGAAGAAGAAGGCTG
TSPAN11
and0.5
.Frequency
WRD79
andwritteninformedconsent
anti-p85f3
.Nurr1
MDS-AML
mutationsare
+1240
O'Donovan
10-5
Ala111
–16.9
CTS
301C
PTH-Cre-positive–Z
5.93
RDT
2-fold.11
S2.2.1-2
MB2
pretreating
ccRCCs.10
Disease-Causing
p.G17
inhibitors.3
comprehenseive
LFLS
sigFigure
c.1994T
C1213Y
TGX221
PIK3CB-mutant
Attwooll
CAMKI
rylated
isoforms.32
48–92
ovary.3
22/105
IC50=59
death—BIM
cyclins-dependent
IDH2R140Q-Induced
elongate
HCC.1
1925
ZCCHC7
pLNCX1-HA-mAKT1
19180
.05.EthicsThis
translocations—through
Post-mortem
wereamplified
8305
2,052
4.1-fold
PHTS163
focally-amplified
INK4B
12/183
PreparationThe
.6,10
16,450
RARS-T
Lats1/2-related
DEAD-box
p16-CDK4
R62H
homozygous/
endoribonucleases
6A6A
-A/TAAAGGTCA
α-PY
R191Q
I405T
.AML1-D171N
ql
parapsilosis
Böhni
299804
p-mTOR
689-710
~140,000
popu-
JB991
L78T
–,55
Multilineage
Pstrand
soft-clipped
RAI2
.47,48
–97
CDK4-MUT3
-AATACCTACAACAACAACAACAAC-3
tri-antennary
M11144
anti-MED30
TLE1-4
HoxA9+IDHmut
S5404F
L13a
295C
6024
.Cytoplasmic
Cre-loxP-mediated
G.P
G346E
cathepsin-D
37:3227–3232
N198_F199delinsI
cell-enriched
1500-2
S465A
isocitrates
E384X
vicinal
20gg
domain15
MSTS2
BC100
2·0
vb.17
1780–1799
p50Cdc37
positive/2SC
D770_N771insGT
F–G
S1049F
.Lai
SK-BR3
L660P
AGBL1
69747
protein-A
.CGGA_D64
YAP1
E16
70,199
pFoxo3a
93-I-0063
TIAM1
Runx1/Cbfb
ColonyArea
52-fold
x-ray–induced
517C
.048738
vinflunine
CFP-CTLAAla17
nutrients126
MedlinePlus
T450A
MEM-652
FAD
ACL
5′-GAGACATTGGACACGTGGGGAGTCAGCCG-3′
BCL2-associated
Raps/Raf-RBD
mice/
Horita
demarcate
I-protein
C1234T
3′CTNNA1/5q31
NUMB-defective
0.137
Oltipraz
Figure77b
predictor
VHFNEVIGRGHFGCVY^GTLLDND
A.BP1018-506'396-344-12-fold
V600E-CRAF
p=1E-4
PSORTII
8A–B
IslIIVa
.Reconfiguration
cotransfecting
.AXIN2
sequencespeci®c
superactivations
ERFm1
6245
antigen–
inbred
2344
276-287
1,745
overfitting.41,42
.Photographic
ClustalW44
.Retroviruses
14.5:1
Pannu
Bokhoven
NZM33
pRb/p107-deficient
MLL-LOC100128568
SUDHL-10
.Microscopic
p110β102
−800
MANSC1
7-μm
V397M
loop75
.20321
effectsrelate
RTs.20,21
.DAB2IP
bindingand
Along-standing
GGATGTGCTACTGTCCAAGAG
SQ-19
Actionability
Ketsch
TCGA-G4-6322-01
7-methyl-GTP
p.V51D
cocktail–stimulated
bioinformaticians
C262
Biosoftware
Skp1-like
G863
300–450
A149
A170_K273del
IGHlocus
C10
C51
153.9
27/37
–31.7
sectors.Fig
methylation-free
kinase.207
BigDye™
2Gb
0222
Cg/
MSK-IMPACT–derived
PDGFB-transfected
p110-myc
28A
0.5934
.KRASG13D
-2155
1517–1551
JNKs
R451C
LSK_DWN
HSC‐3
Ace382
5430R
colorectal6
32in
gp70
ezrinR40L
c.301+7G
4368813
U93737
Try490
CK20−
OM1
Figure.6
Tyr181X
3-morpholin-4-yl-propoxy
IL1RN
SM-related
overexpresing
R2326Q
L681-I682ins
Vaidya
bi-institutional
Eukaryote
SLX4-knockout
Locali-zation
gastroinhibition
11E
p110α-selective
10/99
PMS2-134-expressing
pENTR221
Dnmt3b.4-6
7/115
pMXs46
cellfit
ionization-electron-transfer
PI3K-C2β
CTCAGAGCATCTTCTTGAAG
D2870A
Deimling
Multi-mode
TRIPZ-virus
2972
5′-CCACCAAGCUAGAUAAAGA-3′
NTA
selectedMutationCodon
V222I
Y1007/1008
7.5/5
c.383T4C
p.V843I/c.2527G
Oci-AML5
EMHY510
Firehose
RT‐PCR
U434-CEPH
8.2–14.6
A569T—The
HER2/neu
3Q2V
4776del11170
TIBCO
T-ALL5
5′-CAATTAACCCTCACTAAAGG
analyzed,23
pyrimidin
Kras-coding
thalassemic
GGT-aGT
other/unknown
PP2C
-CCCTCCAGCAGGCAAAGCG-30
Grabiner
Stat5b
RhoA
0.17-2.19
D221
CCCCTGGTGACAGATGGCC
134
occurence
DADEpY992LIPQQG
activity,22
8,450
mutation/CNL
.Isopropyl
early-release
DHT1
sc-5561
applied,27
75697
.Known
62.3–100
HRasWT
Cali­
VariantDx
Ras/GAPl
K44M
262,000/μl
Q-PCRs
p.D390V-mutation
S807/811
survival.4
BglIIHindIII
AA=
studies9,13
Bivariate
CK5/6-negative
aHER2
amplification/restriction
AAGTATGGTGCGGTCAATG
CARM1
lysine-to-methionine
.Diagnostics
GLI-
1–270
COLT-cancer
.Lysine-949
436.0
CDCA3
p85β-
Hydrophilicity
STI-571–binding
.Aggregates
non-negligible
Ledig
imatinib9
.44F
Glu-342
CCE-106841
-UTRMUT
THP-1
BEZ-235-treated
-202C
.Immuno-blotting
PBB322
8.91
onhistidine-de
V122A
G1049R
Leu-137
V755I
otherproteins
.FBW7
Q639stop
mutation.2.2
L76
antibiogram
1Al
KaryoMAX
.Monoubiquitylation
SEQ-3
2002-00217
RAL-guanine
References*
SPD\
SW9
GGGAAGCTTTGTCTTTCGTG
mA150
∼9.5
Q276P
V29G
F201
Theconnector
nucleotide-promoted
Pitié-Salpêtrière
p.E1356G
non-polarized
8730±5849
intrasample
123,124
R758C
indexNextA
.Semiquantitative
anti-IDH132H
RP11-767C1
49.2
BamHI/NotI
F1019L
.Micro-dissected
oncogenetic
-β3
0·23–0·47
MBS
VP-K451
p21luc
pJAK1
Val319
167/682
Rasmussen14
Chr3:71096114
Tsc1/2
TWIN19-D12a
Clínic
HUCCT1
CLIP-tags
PI4K2B
Bronchial/Tracheal
follow‑up
homomultimers
phospho-PDK1
mm-wide
16B-forward
procedures16
complexes67
9-17
disulfide-bond–dependent
BamHI-Sall
postirradiation
216-16
Pv
NER-independent
G637W
FGFR2/PLCγD
P133T
Anti-p110δ
Colocalization
Oruganty
PBRM1-mutant
v-Cbl
Non-haematological
substrate-Ub
0.09–0.18
IV:20
toxicities.8
ZsGreen
E2F1-associated
179A6
FL-2
imatinib.29
'hit-and-run
VEGFC
R283
0.30690475
antibiotic–antimycotic
R103
7,154
EML4–ALK-positive
Gln76X
R515G
.BMS777607
APR1
anti-Smad2/Smad3
Epon
CBL52
SMAD-Miz-1-mediated
cetuximab-resistance
0.98–1.34
Beria
JPS
method2
RET-9
well-localized
H318
6N
PI3K.67
112-kDa
beads-only
docking-mediated
GAACACACAACGUCUUGGAUU
reticulum/Golgi
cleavage/destabilization
adenomatosis
.FISH-related
GREB1
9.06
V3THS_358718
.051
sg100
n=343
I1307K-carrying
0/39
fic
Intraoperatively
PIK3R1E160
Ile257
EWSR1/ERG
independent-sample
NCT01783587
AACTTGTTTCACCGTCCAC
lymphoblastoid
trifluoride
Spred-2−/−
ETS-FOX
ΔRA
pBS31′
mutantother
Prdm1+/+
614
Cul3-containing
\xg
CACCCACAGATCCAAACACA
types—L576P
pBabe-H-RasV12-Hygro
Btg2
3/signal
J.J.H
1038-1052
NT5
.Theses
32,607.5
6,64
p.F28L
/CD56
.thumbnail
Dade
.ASD/DD-related
neurodevelopment-related
LNCaP-cxDs
5/5
5′-TCTCAATGAAGCCAGCTCACA-3′
JNK_UP
TNVSCPQCR
⁁2
low/
delayed-onset
Peninsula,50
31,43,44,45
4,6,10,19,20
RPNEECLQILESAEK
PI3KCβ
G2032R
D2–Cdk4
NM_009283
Worthly
MAP3K12
publications.9,18,19
phorphorylation
reported30
114:4197-4208
Loeys–
LR08-319*
co-infections
dioleoylphosphatidylcholine
serum-
status.Thus
NM_006885.3
Internistica
HCC78CR1
OSCC
12-myristate
*06
E49A
ZnSO4
S36
Statistically
CD3+CD4+
5′-AATCTTTGGAGTACGCTGGATAGC-3′
activated14
leptomeninges
discontinued130
0.0003*
115K
P504L
scaffolding-like
1,740
WHN100
luc-reg-17/20a
-repair
.Poly-A
Het-1A15
CE2
ID-1
T669
leukemia60,61
mutationsComparisons
3832
135K
0–24
itsa.ucsf.edu
.Quantified
U=238
sarcoma/PNETs
BUB1B/15q15
Immunofluorescence-Infected
∼2-MDa
miR3127-5p
I/Shrimp
scans,27
1000cells
RapGAP
unintentional
Ile341
Na2SeO4
c.504_578del
musculoskeletal
24.76
94C
respectively.Variation
N=213
non-mosaic
treatments.3
anti-Flag-HRP
Co21
5'-GAGCTTCA
G1269A
Tiacci
Pole-
act-GFP
TRAP100
38.34
CI5-254
vivo.5,6,11
G0-
H-Thy3
MAPKAP
8102
20C
near-confluent
p.Val617Phe
tumeric
TÃŸR-Imutations
pre-determined
cases.BCOR
.Lats1+/+
p.S141_A142insRP
KDM3B
NFE2-JAK2
genotypesFour
.HA-CRM1
antiERCC3
RBD-bound
−7.2
methionine‐labeled
lightheadedness
T573-Q613
R347P
elements23
MMP2
T54A
trans-activated
.CD29
RMS
Smad3-Regulated
harzianum
Leu686
PRKAB2
AQP3
Wiley-Liss
N1-ICWT
3345
CR-OE33
facet
neuroendocrine
NCT00063154
XXX
csbg.cnb.csic.es
reassessed
2/25
domains.Figure
1,586
pG5'313
R.K.B
Cdx2
``
Ser501Ala
VECTASHIELD™
logistic-regression
−4.12
RTK-related
sudemycins.65
6.5-kb
ATF/cyclic
M887I
.Cassette
thatthe
SHP2-associated
replication-dependent
YFP-CTLAGlyAla17
PDGFbR/Rabaptin-5
≈26
Juliano
R-
pTO_HA_StrepIII_c_GW_FRT
G118R
prespliced
pLKO-ErbB2
Xq27–28
Z.S
x-axes
EUFA263
48,50,51
software®
p.Ile590PhefsX5
TGF-ÃŸdose-response
oncogene8
tumour-associated
7.75
warts/large
FPD/AML
importantto
malignantstages
p.E76fs
.SCF-induced
ECL+
Ab72
n=8/10
cancers.14
eighty-two
AATCAG/gttaga
5'-CTT
40,104
IIx
pletely
91.4
7t
3.32+0.02
hisG
hemangioblastomas
31-X34
.K147E
delL15_V22insHPI
SPOP–CUL3–RBX1
MET-Fc
CCTAGTACTGTGAGGCACT
exo-free
B_taurus
insulin/IGF
CTCF58
Δ576Pc-Kit-
380T
EGFR‑TKI
Brca1Ko/Co/Wap-cre
.100
vectorsequence
SureSelect™
M.A.S
KITTrp557_Lys558del/Thr670Ile
A_51_P202714
Snf5/integrase
BCL6.17,40
4,195
48,690
RFP-fused
p.Statistical
Y2171N
msh2Δ
18-nucleotide
CEEP/DHAP+
PNPLA3
co-recruit
JAW
H179Y-mutant
CCAGAGGGGAAAAATATGACA
Echocardiographic
transactivation-defective
lines/xenografts
,18have
54–58
guidelines.Histopathology
–RB
FKHR
data—rs3814113-T
-ITD
10328
0.8936
stepSize
.Marginal
IGF2-deprived
-1.7
sub-lethally
Wysocka
MORT1-caspase-8
inhibitors23,24
64-66
EN/IRS-1
growth-promoting
PEBP2β/CBFβ.14
M13L/5'-GCGGGCCCGGAGCTGGTCCGCGGGCAGG-3
Medchem
chloride–induced
Thr88
anti-Hsc70
41,47,48,93
-snp
1486
Fontenay
banque
Mirn140
pre-activation
patients15,16
1C4
ZQ
9.00
2q33-q34
IDH1-overexpressing
progression117
trypto-
intercondylar
p.K483E
HPRCs
R201C
R358
SMR
Aldolase
ana-
vivo63
20•
Thèrond
A695P
-H2B
Indo-1
mRad51
anastrozole
anti‐phospho‐MEK1/2
Wlld-Type
BACH11
GFRα4
Q1098P
H/DX
5q21.1
pE3-NLS
levelswere
104/0.2
myeloablative
ALV-induced
1660A
myc-like
HT-12
AR-g1651c_s
files––were
filter-sterilized
genes,10,11,14
-GTTTTTTTGAGAGTGCGAGGCGGTCGTGCAG-30
S100-protein.1
factor-producing
hyper-mutator
3.453
TMPRSS2-ERG/ETS
S2PY
primary/metastasis
CD-31
c.306G
Leveen
cephalosporin
5′-TGTGGTGTGTGGGTGTGGTGT-3′
HCC1143BL
BT-549
reported70
ΔV463
pBac-PAK8
CRL3-mediated
ALKA1099T
home-use
NS=gain
liver-metastatic
1.65–1.8
puro
P.T790Ma
male-specific
-evoked
0.00135
GEF-H1-overexpressed
supratentorially
reac-
R4
cancer—is
0.1–75.4
FLAG-DLC1
anti-SMAD3
g1
3H-inositol
Lung-specific
lines.55
c-KIT-positive
3,21
reviewed16
604804
NSCLC.12–14
Stk3/Stk4
dITP
5hmC-dependent
K710E
0849
TGFβ3
.Candidate
pWN-MF-DEST
Multiplicities
SnoN
+l
.Data
p.F82L
leukemia.21
GF33/11
repeat-containing-5
shBAP1.321
.Ago
.Beji
1086
hypergeometric
interferon-sensitivity
genomics-based
ETV6-NTRK3-negative
F-H
EGF-stimulation
mRNApurification
75006
OAc
pROSA26PA
82-174
Marcotegui
Ser261
hemimegalencephaly30
HLA-DRB
ofS
control55
myeloid/natural
mutagene
24772FGF-2
outcome110
P21
.Hampel
AKT1/Akt
anti-Dll4
STAMPY
PCM1–JAK2
glucocorticoid-induced
colorectal-specific
CRML
cleavage2,3,4,5,6,7,8,9,10.TOP1
mitoxanthrone
MSFTs
3–3814–0021
signal16
10.21566225
46,50
Fig.7,7
11,699
12,592
F961L
p.T1010I
dGDP
0.00968
STK11.3
PIK3R6
0.000
Scherrer
AQ5
Seinfeld
inhibitors23
annexin/propidium
.A375
184–297
A'-methyl-W-nitro-Af-nitrosoguanidine
Periventricular
Targetable
receptors28
CUL-DN
p=0.021
Chattopadhyay
Stibler
context,19
Adenylate
scratch-induced
significant.Full
-RUNX1
stress-induced
Sunitinib
inhibitors.52
intervention8
5'-
pSG5/Flag
Methoda
50-GCCACATCCCAAGTGTTTTATG-30
.Asubset
leukemia-lymphoma
nonsclerotic
3274-3303
ligand–activated
DR107
231481
311×103
.FL-CDB3
phospho-ErbB4
nuclear-matrix-targeting
under-wound
JAK9/2−
myelofibrosis.1–3
syndrome25
1–457
NP_998827.1
polyaromatic
Dnmt3A
Htb
XFast-3
nihms646437t4.jpg
DEG
13,700
‡both
gefitinib-containing
ALK-POSITIVE
.31,32,60
originated.16The
Trr-
c-Maf
metallopeptidase
PD-L1/9p24.1
-CCCCTCTAGAGGTACCCCTCATCTTTCTTAGCCGA-3
pyloriinfection
827/682
APLNR
3101
R211W
74.80
nucleospin
6–14
2.10–2.55
c.2235_2249del
v3.2.2
27/42
Hs00170630-m1
11,578
per-formed
phosphor-PKB
KITD816V/H/N/Y
IHC/MSI
H1092
214–218
NER-proficient
shRNA-Trp53
IκBα–Photinus
frequencyb
p.M51_L54del
BRCA1-W1777Stop
stability30
.CREB
Li1
FSC-SSC
expression.45
3598
3.The
Smad–receptor
IFoGaO
Smalley
receptor-γt
34*
2-nucleotide
2,787
pre-j2m
dasatinib.43
Delta4
Kimet
jncicancerspectrum.oupjournals.org
Wotherspoon
p16INK4A/MTS1/CDKN2
.Keld
.Fluorescein-activated
~73
GlyleuGlyGlnleuleuAlaValAlaSerGlnV
Figure44B
p53NES2
late-passage
anti-phosphop44/42
PicoFrit
10-pixel
Jade-1-silenced
0.04-0.56
638
symptomtatic
F24
uArgS
GAGCAGCCCTGAACTCCGTCAGACTG
cKit
6·8–NE
F264A
Leu330
QIAEX
Neo2
Cappuzzo
glycoprotein.7
Ercc1292
96-plex
3–dependent
behavior.10
buffer27
'legal
androgen-binding
4–6
phosphoric
Xtwn
Master,3.5
.SUPM2CR03
FGFR/EGFR
1.33-fold
Tet1-enriched
agement
João
n=429
COSMIC43
Ser241
ALK-F1174V
HTh74
≈equal
P1238L
MgATP1−
pretermination
examples.3
RNeasyPlus
Clontech
TTCAGCACTCTGCTTGTGGTC
LV067
isomorphously
Jun/Fos
Apicobasal
P38a
H.R273H.14
yMMR
ERG-fusion
179835
co-suppression
R233X
Regulators.After
oncD-related
imidodiphosphate
Corral
PTEN39-403
Feulgen-stained
15G
//psort.nibb.ac.jp/
GM-CSF-stimulated
21/63
log2ratio
bp88
cells/0.4
complex.93
nihms774093f10
23408T
domains25
combination13,14
Tween-20
278720
Cergy
Mrconsistent
NSC23766-treated
cytopathology
activation.25,26
E103
19:3885–3894
forward-genetic
p-BAD
REFb
cRb-pur
R332W
A150-pLg
Hirao
p.M285fs
Qiagen
13d
/2RNY
-LACZ
ARAF-mutated
6811N
low/low
.Voytko
CS08
n⩽3
K5CrePR
rasand
pathway35
RNAiMax-Lipofectamine
.Intermingled
//www.sanger.ac.uk/genetics/CGP/
551101
Glu-717
D761Y
HTLV-I–transformed
39/39
Rotblat
C265
132.3
.Hydrogen/deuterium
C57Bl/Ka-CD45.1
ungapped
RhoA-expression
5′-atccattttcttctctctgacc-3′
2816insA
end-filling
_n_
acid-containing
EPD3
antiMMTV-c-erbB
Boukamp
Equilibration
.Isoform
ZBSA
sc-22820
RKO-AS45-1
Bénard
represent-
atypical/other
Btc
nonthyroid
HNCACB
.WWTR1
DN3
3200
Phe308
Kironmai
a1:200
non-food-rewarded
HA-HIF2α-pcDNA3
MUTYH-mediated
G324S
Youlden
b-glucuronidase
4–6m
data-mine
64-
5032,1996
5.Figure
Immunohistochemistryrevealed
tissues146
transcribed2
23rd
226025
Q22K
QE
.Middle
sulfamethoxazole-induced
rs2665850
mone-ER
r.164_171del
T52
minimichrosome
q31
0.263
del2237–2251
28-aa
trialled
PEBP1
4/4
.Coomassie
Di-methylation
N981S
S0361
-CUL-2
maligant
13.8/5.5
966
R399C
domain14
51–66
retinoblastoma-interacting
3.Foretinib
140.163.0.5.
769
D820Y
A-AVGD
GM008719-12
substituion
independently-reconstructed
10.1182/blood-2013-01-476473
α-adrenergic
multi-parameter
centrepiece
.Exposures
-0.202
polybromo-
1.4X
PCa_ETV5_2
18nM
crosslink-inducing
interleukin-10.20
TRC
thisactivity
Strissel
D3-
HSC7E630
ViiA
investigated,40
~20–125
MEB-MED8A
Minvielle
BAY43-9006-induced
E2F-induced
XSmad4β
cells.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
24-month
Bcr-Abl-driven
mutations.17–19
.PvuII
Cbl.58,59
L582V
Y121C
JARID1
Ding6
lower-case
94/132
.Audiological
alpha=0.05
classiﬁcation
.PTPN11
Lys-273
completelyinhibited
857c
ATPconcentration
.5A5A
gatacagcaggcaag
wild-typev-H-ras
Y877-K762
4AP2
carcinomas,14,15
pEGFP
.Hahm
kinase12
NCT01072175
q=1.4E-30
activatingmonoclonal
5′-CTGCGGGAAATGCGAGAGG-3′
auto-activate
E3.5.26
17q22â€
Akt-ribosomal
miR-525
rs1805129
MeanabsorbanceofexperimentalwellsMeanabsorbanceofcontrolwells
GFP-Hrs
low-intrinsic
Southern-blotted
2C-G
SFH
microcolumns
XSCALE.55
KOPN-8
97.5
Anti-ERK
diseases.63-67
pOPRSVI
5′-ATGCCCAGCCCCACATCCAG-3′
TSC-RHEB-mTOR
)
DNA-synthesis
Myc-WWM578A-PDGFRA
K159–K296
25,50
-y-32P
mean±s.d
PP-2
Postgraduate
HEK-DDR2
955C
Tet1/5hmC
c.572T
encephalomegaly
400g
only.6
Ras.43
25,31
07/19
presumingly
Microcon
2Ba–e
ele
CA´RCAMO
.Seventeen
686
-TCTGGAAGTAGATGCTGTAG-3
RP11–299J3
BRAF-altered
298KB
2469
TTTATTTGTATATAGTT-3′
.Impact
cx43
α-ketoglutarate1-6
CPVL
.SMC-specific
Rittinger
Motokura
25th
H371Y
Fig.5C
photodimer-specific
TPA-induced
S79W
NP_001089186
34.2
SUMO1
cul­
Q579
Val600Arg
CRE-inducible
serpin
1.3×109
PBD
S786I
Huqun
ab3622
havior
pseudodiploid
44/50
/rtTA-
10·0
200mg
vemurafenib-sensitive
c-2005
TGFbR-I
CATGCTAAAGCAGAACAAAGTAAGG
C.Disteche
PRKCB847m
transcriptionof
fl-mercaptoethanol
XP/CS
HER2WTA
G3145A
Saintigny
McG
EGFRSomatic
cysteine-linked
KrasG12DTnfaΔPdx
αFOXO1
Asn109
1-base-pair
7/5/01
c.5722_5723del2
anti-P-STAT5A/B
p.L16P
dIII
→TAT/ATA
IL12R
Ile282
anti-ECT2
NM_152641.2
RM-9106-S
HSP90/RET
D1-AP/dE
CA14
Ven
ter‑
protein40
11/14
slideOverview
I655V
Neurofibromin
Mg2+-binding
Q-value=0
activity25
6.50×105
49-base
microtubule-dependent
Tsp1
nature.comApoptosis
Geiszt
splicing.4
polyalanine-coding
E/cyclin-dependent
ureter/
crisis70
oncoprotein29
Lys-105
H350R
FLAG-Tag
K23V
CL387,785
Deshpande,1-3
AlfII
miR-135b
259-333bp
AE31
mLta-Reverse
SRSF2,17
TSC2GAP-catalyzed
PRN1
.Therapy-related
pLXSN-infected
60.5
anti-CD117
ZC3H7B-BCOR
S254
.Defective
Results•
3Department
DeltaF-box
A3256
IGH/MMSET
NADPH-utilizing
evidence25
PRKCZ
hexamer-primed
years.32
.I
expression/stability
41K
Hambardzumyan
Lys650Thr
R1609S
lipid/protein
methylhistamine
pEF-Bos-HA-Rho
3T3-LI
.One-tenth
A-RAF
D593A
D-HPLC-based
c.2466C
Mek1p
Ets-dependent
ALCAM
www.pnas.orgycgiydoiy10.1073ypnas.050408497
Ponnala
~53
BRCT–encoding
*Some
tttccccag
single-copy
241-248
sitea
IL-369
Aifantis
MultiExperimental
R1625C-expressing
9X
mIU/l
ANTI–HGF-cMET–TARGETED
.Lack
Sundheim
QPix2
Top-I
formdimers
DME1+/2+
RP11-3K23
c.872dupC
CCDC131
Insitus
FLAG-D4
×63/1.42
Locoregional
horseradish-peroxidase-labeled
premixed
anchorage-dependent
accelerat
MOLT4
trk42
SWI/SNF-α
I2020T
phophorylated
TAAAACAAAACCATCCCCCA
H1299/V
phospho-RNAP
−0.2
R637
74.4
EF-1a
anti–α-tubulin
p.Pro29Ser
JAK2-STAT5
tumoricidal
owe
601758
aggresomal
3ε
Li-COR
39.9
GenHunter
patients.All
imatinib.52,53
RXRo
Ago2-null
†25
A673-shPRKCB463_B5M3
2.63-Mb
1.11–2.56
p.D2312V
G315S
.Avidin–biotin
.654L
RNF168-dependent
V804M
disease85
p16/Δ1−8
pMX-GFP
survival.22
.721T4G
p.G1567D
isozymes
Donostia
104cells/cm2
TwTTTQos
97C
K331E
G53S
tumorswere
S18A
After-ward
.67
structures157
agonist-binding
Lox-
Vijayasaradhi
P=0.0065
carboplatin/IV
N439D
IκBγ
A167V
S2A–S2H
Zinc-finger-nuclease–edited
358–396
N-APC
E746_A750del
CEQ2000
miR-mRNA
active-state
.161
39297
-3.7
theexpression
T174S
Messaien
grade/special
//mct.aacrjournals.org/
Rad50K22Mallele
Rastinejad
pEF1α.IRES.neo
M158V
CACTGGCACG
TCAGTCCATAAGCCAAGCTCTCA
BRCA136
HA-GLUT4
ΔΔGFD
HR36
Li21
NM_009778
NCT01526473
E372K
HZF-3
CTAG1A/CTAG1B
ATTAAG/gtacag
-857c/t
ETS-protein
3.71
Schwede
YK-4_279
.Ferrando.8
P-RPS6K/RPS6K
p=0•024
p.Glu542Lys
position37
sub-unit
Cys-N
A533D
21/57
R100X
Transcription–Polymerase
tumour/normal
88.7
CRS/IPHC
12R5
onfor
.Nucleic
recommended.38
genes15
V2.07.13
cular
line5
kinase—Lck
c.2041dupA
parent-child
NM_013787
Ozdag
IDH1R132H
0.01-0.1
1G5
Thé
Akalin
13.64
proteasome-independent
-67
113-fold
clinic,40
Elk-1/TCF
.S5B
550K
3,4,8
-F170I
RAC1b
hextuplicate
less-than-therapeutic
0·01
37/345
W2547C
.F1174
8.6
05056489
NKX2-1-knockdown-induced
E0038
Pgr-positive
andcarcinogen
.Episomes
23,005
nonadenocarcinomas
calipersVHL
25–27
1three
CHL1
Cys-107
macrophage-stimulating
p.Arg263Cys
FGFR3+
binding-induced
DNA/Gli1ZF-K340A
abnormalities20
RHFD
Third-plate
18FDG-PET
K101E
B.17
300A-109A
anti-NF1
CTTTTAACCCAGCCGCGGCAATCTCTGCC
CAAAAAAcaggtatctaccatggaggtCTCTTGAacctccatggtagatacctg-3′
Hybond-C
Mga–Max
Franceschini
neuroblastoma48
26c
adenomas.E
aCGHa
1•000
promoters14
times.Statistical
PTPκ
synonymous
JAK14−
MLH1-N38A
MelanomaTable
20/22
4/730
screen-able
aminomethyltrioxsalen
stem-cell-driven
hydrogen-bonds
c-Myc-reconstituted
Imamura
GSE48850
Sub-Cellular
ErbB2-dependent
.G13E
.Chinese
A-plot
5′-GATG-3′
detected.19
I111F
CDH1-positive
650/652
REF52
respectively3,4
Skejby
CAGGGTTCTGTTGAAGATACCA
p.Trp242X
study.The
migration,27
9/48
Maesawa
pancreas.Intriguingly
multiple-generation
5′-CTC
K-ras4aG12D
26-year-old
CRL-1619
expression45
megakaryocytic/platelet
proteins.1,2
FDG-avidity
self-affinity
5.3+
G53R
a49g
I324R
rther
multi-budded
TS9
actionability
p53BP2
64-68
57•70
d-2-hydroxyglutaric
intracellularaccumulation
proteins.31,32,60-65
U1snRNP
R406Q
Q-rich
agonist-dependent
ALL-16
34/309
Y641F
.3A
Q12Y
proliferation3
log-fold
2.752
termi
0.2986
Basingstoke
anti-phospho-AKT/PKB
H585
VPF
Cytokines
FH-I26A
33428309
.Antitumor
.Bioluminescence
5′-TGTTAGAGAGGAAGAGGCACAACTGA-3′
gluco
AAL13037
Small-molecules
hCA
Bioluminescent
E746V+L747P
1/1/0/0
.Blasi
sequenc
Ras–MAPK
83-fold
P1007A
substrate.28
FBW7-controlled
EpiTYPER
STK15-HA
HV950FS
5′-CGAATGCAATGGATGATCTG-3′
39-to-59
protocolduetoCYP3A4interactions
E89A
involution
Yarrowia
FUS-ATF1
17,28
phospho-receptor
PFKM
9/01
11p-terminal-11p12
T1977K
acral-lentiginous
PAR3
6•3–12•1
P=0.41
p=0.0004
BRM
WBP2
p.D2679Y
236-EG
20.4/11.4
3PbOOCCH3
Opti-MEM®
87.2
iodine-refractory
LYS505
2623
beta-values
1680-bp
340–345
mutation.Previous
Abramsson
262-307.View
monotransgenic
microtubules.51
EBF1-PDGFRB
cardiotrophin-1
BiBr43-
TGX-286
SMU030
5s
K-RasG12D
e–h
Patients..
May-Grünwald-Giemsa
1057–1059
method.13
Neuropathol
site‐directed
.Phycoerythrin
.D297
.Immunocytochemical
19-kD
Arg206His
patientsTable
Figs.2C2C
autopsy.20
Genetik
placental
polyE4Y
TGF-ÃŸ
Trans-well
Anti-HCF
Shigenaga
490,491
GOLGA4
Non-mouse
Y16C
0.01∼1
0.0211
hAR2974
genes38
0·239
Massion
delWK557–558
Klareskog
Brcaxx
RUNX1-TRPS1
miR17-92
Errfi1+/+
TSQ
019
350,000
mercaptopurine
oogenesis,25
X-376
IGFJR
BR2-8-RT-R
nonreciprocal
oligomerization19
B-cell–associated
antiactive
αE-cad
type-III
I1250T
OR=1.00
.LY2157299
22-Mb
LAP-tTA
5841
20–27
TIB
P=0.0068
sPGLs
C15ORF21
6•3
microM
20GA
EEA1
micromass
TMPRSS2–ETV1
U01877
AR-signalling
5-GGCTCGAGATATGAGTGATTCCAAC
Cdk4D175N-myc
E45K
protein-deficient
P349L
CLL/prolymphocytic
537Y537S
multi-docking
LOXIMVI
∼21.9
198K
calboplatin
5′-TTCACCATCTAAGATTATGT-3′
normal-tumor
1:18
R1384
C-ros
/-
Th2
PMS2-origin
.Vita
EcoRV–MscI
conformation-modulating
bronchioid
NOA
Nurpeisov
TCTCAG/gtaggt
chr6:105,998,201–107,639,853
4667
EMT20
Katyal
GAS7
.180C4A
CEP250.15
CENP-C1
:protein
2-deoxy-2-
UGP
1090–1416
SuperScriptIII-Strand
Verkerk
entry-ERRFI1
mitochondria-dependent
Ziff
METRNL
FK506-based
suppression
integrity28
12,30
mutation39
BAP1-null
-2466
W€
//dasher.wustl.edu/tinker/
GGTase-1
∆
p.H169
F335
Htz10
R530TfsX7
visceral-metastases
endochondrial
-0.315
pYpY
KTPU8
633E
al19
CUL3-Keap1
V447A
2f0
Hs00466712_cn
72–96
K1
ERBB2-directed
157–180
TAATACGACTCACTATAGGGCGACGAGGAGCACTAACTCC
sFLT
PTPρ-ΔFNIII-2
PP112G7
negative/epigenetic
E011
NM_000268
HFDpTYLI
kPMS1
Hangaishi
oncogenome
1.2–1.7
YYANWYY
.Application
AAG→GCG
c.6754dupT
RP11-722F21
GF68/09
alleles16,30
F1174V/C
6629–6634
UC101
ohri.ca/programs/clinical_epidemiology/oxford.asp
ttatgtgcag
IDH2
tumour-constraining
pcDNA3-FLAG-STK11
N-C-helix
.DGGE
V600D
bi-brca
Asp53
1D-NMR
7500-fold
EC.1
400HR
GAP1-
|-helix
sequence.Full
overriden
2.44
acute-
SGX523
RAT1-MycER
.Effluent
mutations/polymorphisms
Met163
Shivapurkar
AOC
domain54
broaderthan
expresssion
71–561
0.10–1.70
retroviruses.31⇓⇓⇓⇓⇓⇓–38
Kinderklinik
skin.5–8
Luciferase-based
lineag
MK-mediated
CGCCCACGTGGCA
MEK-centered
inostamycin
10´10
P356R
-on-chip
no-novel-juncs
IVS4–2A4G
R218W
years/patient
147-149
5′-TGGAG
9411S
FZ
EGFR-L858R+E884K
Koboldt
R2616Q
SYT-SSX1-V5–
anti-pTyr
-44
Broxmeyer
AKT2-R170W
sjdbGTFfile
tumors.3
BXSB
deacetyltransferase
half-log
p-Tyr–containing
nondigested
2009/154769
E1555
10.1158/1078-0432.CCR-09-2112
nonspeci®c-
R382C
nuclease-encoding
βx
andresuspended
non-BRG1-based
248-250
Doubs
144P
3·3
v-fos-mediated
-60
:MDM2
imatinib.6
×0.4
AML.27,29,37,39
carcinomas40
13:3
5′-AAAATCTTGCCAGCTTTCCCC-3′
31,32
839–951
GDTP-
FSPGR
rebranding
430T→C
G285
mixturewere
2537insTG
R1188
accelerted
SARA-Smad2
melanoma-only
all-others
anti-02-s
FE5L003896000005
.Augmentation
hpo
Val694
optogenetic-based
DESMINIB
BioThermStar™
Y2
T790M+L858R
SNF5-null
laryngeal
**P,0.001
read-mismatches
incubate
CGC-only
oligonucletides
rod-like
NP_789765
24:230-237
Figure3E,3E
strand—TRE-L1-TCCTTCCGTCGGGCTTC
SomaticSniper
bN.B.
T1N1M0
msh2-PD865pproteins
A_51_P497332
Cbl.21
11D
L248R
SS18-SSX
Intraductal
Gretarsdottir
NPM1-ALK
72–78
Macro-hydroxyapatite
.Pulling
formation68
p.W11Ter
L-light
Tivol
A3027
Aortic-root
Rel/NF-κB
3d–g
Kinase-ERK
Ft-BCOR-RARA
Gleissner
/NUP98-HOXA13
p23-like
proteinA-linked
rate/h
EUFA337
0.7086
ATRX
.Mutated
SI04154647
Gaa
0.938
.631
MT–induced
//www.nfdht.nl/
nFV
HER2-positive/HER3-
sodiumhydroxide
G428S
in‐frame
dysfunctional
BectonDickinson
AM4300
HOXA13
FHL
LeCesne
Fig2,2
domainof
33•27
Anti-alpha
PDK1-dependent
3011
red/blue
TFE3/TFEB
.Low-energy
Rönnstrand
Ercc1-
27/156
Zagzag
.Positron-emission
Nonmutation
p110α-
H1047R/L
reporter-derived
viable.34–36
.WT1-BINDING
M1727.32,34,38
β-klotho
Asp1399Tyr
Tyr178-His179
Hematological
Su-DHL-6
kinase,14-16,18-20,23,24,26-28,31
phospholipases
−1.77
CICAMS
1,531
PTEN-mediated
VP16
-polyacrylamidegel
coronary
cortex3–5,17
FlagSPOP
NS-causative
-detecting
β2-β3-loop
CFL-fused
1525–1773
Rheb-Y35A
PXS/TP
NGGCT
adults.20
-46K
magnesium-containing
.32–34
age16
Markert
.12,17
PGC-1–target
binding27
Cartegni-consensus
necropsies
protein-loading
46,000
monitoring.32
ubiquitin-proteasome–mediated
Lenexa
API2000
thymocyte-specific
20122
minutes.6
1−
Ras/Raf/mitogen-activated
encodingone
BD-Falcon
2360L14
p.Ser1013Thrfs*27
Cell-titer
IGFR1
forSanger
ECM
Randerson-Moor
266–295
ERV
May-Giemsa–stained
.GpppG-capped
9-15
fusion–positive
SPAG6
pCAGGs
factor-3
JAK2-deficient
HOXA10
transactivates
1FIG
1998Int
mutations.Archival
Potten
Roberts,1985
37–574
5′-ctactccggaccttacggggacatgcg-3′
RB10-RT-se
Krebsforschungscentrum
Dnmt3a−/−
electroencephalograph
UAS-linked
m5CpGdotm
P=0.17
101.9
neuro-progenitors
CODOXM/IVAC
CpG/GpC
88
Garcia-Ortiz
80–23
Grosveld
6,381
2008-000-10103-0
phosphatase-labeled
written-informed
SMCA4_HUMAN
miR-10b
55–369
D266V
5′-CGAGGAAGAATACCGGGCTCTGC
44-441
RAS–GAP
PKC-δ
MPRIP-TRKA
Dannenberg
MSH2.5
~ml
0.50a
0|R
Arg248-Glu1694
A_51_P291361
GST1
anti-PAK
cholesteatoma
CD8m
CAGC
~5
mutations.Finally
MCCT_2a
Akt1W80A
DQB110602
.Cannon-Albright
37kDa
HPCAL4
6-diamidino-2-phenylindole
2y
0.744
TargetNow
CLL/SLL
0–500
TNF
.HER2YVMA
capabilityIn
nonstructured
NL225
receptor–receptor
//dragon.med.unc.edu/pubsup/GATA3/
canavanine-resistant
Exon-coding
RITA-mediated
XBP
.Chi
doi:10.1038/ng.2872
.D19Mit30
p.Ile26Val
cMLH1-derived
.7008
CML-BC–like
activity.5,16
castration-induced
α-Ras
V-1
p204
IL-7–mediated
iCluster
.4556T
www.pnas.org/cgi/content/full/
structure.C
TGA
CGCA
Reuther
hypertriglyceridemia
mouse/WT
Uchino
.Damage
Frameshifting
piled‐up
RBM5-regulated
4/263
1.48-fold
www.jci.org/cgi/content/full/112/7/1108/DC1
.Nilotinib
ARHGDIB
WoundMaker
1,675
benzamidine-Sepharose
CCGCCCCTCG
3635dupT
cardiomyopathies
arrayCGHbase
Arg349
al.7Results
colonic-like
L1664P
2512
8-year-old
BXF
HSC-3
dimethylbezanthrcene-induced
domain171
glycosylation.15,47
HBx
R168H
genomically-driven
'gatekeepers
1125-18000
50,73
F165L
//genome-cancer.ucsc.edu
32P-γ-ATP
59-CCAGGTGCGGGAGAGAGGC
receptor-induced
ein/
KMH2.7
E-treated
S2342Y
emperipolesis
17293
AmpFℓSTR
BLNMDL
.Helix-turn-helixdomain
.Mental
Waisfisz
1.298
T133.2/T137
'To
preemptively
Kadin
p.Thr77Pro
anti-IKKα
-846
MPLW515L-Expressing
helix-F
activity.80
D84E
W372R
linci
signature.23
.PRDM2/RIZ
range=35–82
CTTCCCAGGGGCGGATCCCCCTTCTGTTC
CD11b.22
Y517
French-speaking
poising
B–cell
short-hairpin
NSCLC.21,22
V98M
Materials—RhoB
HSP70-interacting
p16INK4a-FLAG
inhibitors17
sBRD4
34•6
Ozato
c-myc+ras
.Polarized
Lats1DN/
-1949
MM200
diepoxybutane
AACCTTGAAAGAAAAAAGTCACTGACA
analyses.
5.103
b-actinblot
pGC
oncogene-dependence
immunoblots
EFCAB3
cancer159
60–82
5'-GATCCTCGAGGAACATGTCCCAACATGTTGCTCGAG-3
PUF3‐2
4502A
P-0002079-T01-IM3
doi:10.1093/carcin/bgi292
cytogenetics.16
neurosecretory
SNU-398
*Three
Arf
indicatedthat
Gly328Glu
Roginskaya
M-Ras·GTP
152–157
Reprogramming
Dll4iECKOretinas
-yLPLKW
p.Pro3039Leu
at308C
A750P-EGFR/NIH3T3
ATTTG-GATTGTGTCCGTTG
A427
Kareta
Differentially
II-B
Y207C
tumors.22
R140G
Wyeth
7920
7/01
j*
study189
T80K
TSLAEQPYQGLSNEQVLKFV-MDGGYLDQPDNCPERVTDLMRMCWQFNPN
Temperature-dependency
Antagonistic
4q28.3double
SerlO40Asn
ERBB/EGFR
Nsp1
Jews,7
TGFB2
31,83
.COS1
p110β-based
lysine-dependent
SU-11248
1A-4
HNRPA2B1
D2S346
PNAS
areaswere
5-GGGTGGGAGTAAGATATGAAT-3
.Forty-eight
59-61
8.5-kb
synostosis.2
39–86
KIT/18S
Hemavet
355/248
65,600-bp
Oakey
MAPPMMR
factor-bound
R2505
CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTTT
​toC
BAT-13
DDR-directed
8.77×1010
gamma=0.00542
2.91
ALKD1091N
Grb2-binding
Y1230C/Y1235D
32P-orthophosphate
PolymorphismDeleteda
R2368Q
Yom
nucleobase
NRASK61
TCAGAAGCTTTGAACTAGAA
.Saal
M.I
Aqueous
.Splenic
MLLAF9
20‡
Eskens
230
Bendl
sequencing.In
E2F1–promoter
****p
aflatoxin-DNA
MKP-2−/−
subtherapeutic
FGFR3-K650E
8.14
p300/
0.022606
300188
FXFPDEJLdocking
Insulin-like
62.0
3IAY
formation9–12
stimulationof
K721
L774
96‐well
1675
well‐known
.Beach
KD2
Kuklin
AnalysesBiostatistical
at/close
IMAGE:4222994
2,076
phosphoSer795Rb
particles/ml
Weifang
`caretaker
assay14
asparaginyl
L858R+R958D
base-mediated
EDV
N=25
phenlymethylsulfonyl
c.532_571del40
expression.29,30
up-stream
Tk-ts13
sample.Full
Rate—The
UAC
spherocytic
therapy9
intr5
VEGF-A–HGF
MAPK2K1/2
Miinea
Hypereosinophilia
AML19
fashion,29-31
.HCC
IP4
years36
5′-CATGTTCCAGTATGACTCCACTC-3′
p.Y42
Y~~P-ATP
M318T
1Division
R.C.C.
.COS7
cck6
R487P
IFITM1-expressed
reclassifying
,7B
T1N0
Thr-58
expected12
trans­
HindIII–EcoRI
Bonferoni
gene-associated
cDNA-specific
Sal
Xrcc2-deficient
truncating-associated
Perlaky
ER+/Luminal
mechanisms.39,43
src/FAK
1Present
transduced-cells
LSCC
FAT1-targeting
molekulare
tetraplex
NEDD4
P4D1
25-65
Taira
Gangar
KIT-Mutations
p110-Specific
.EGFP+
dfam_scan.pl
.Modular
APOBEC-associated
0.161
E1990G
5′-CTGTTACCACCATATAGGCGATTAAGA-3′
classify.eCNV
background.Figure
p53L344P
CXXC-type
weaklytransforming
Shweiger
loss-of-TGFβ
variedfrom
600mg
Y513C
non-UV
lobe–upper
FC=22.7
1p36.1–36.2
lineages.3
/20
q22q22
bars/black
609–634
effectors.31
CCGCCCCGCG
75-90
BTB/3-box
.Benita
FHL1-Smad4
:81–1284
5'-AAAGGTATACCTTTCTGGTAG-3
Dicerfl/+
NCT01086254
C330Y
p.Ala301Thr
Sin3-histone
Cep-1
Xiao-wei
4.12
n=43
KanMX
STAT-responsive
p.S45P
anti-ERK2-specific
1229
13-1600
Y380D
antigen–specific
WHIM16
0.208
5′-GTTCTGAGCTAGGACAGTTGG-3′
IgIII
116K-
PAR1b
7A–7D
TGFBR1p.N267H
EMLA4-ALK
org/ccle
CMD-WG
CCCACAGGAAGTGGAAGGAGCTTAGCCTTAGCC
formaldehyde-fixed
Cbfb
L858R-carrying
tumours113
–shiftsize
arrowC
ALL.12,13
1,631
A5060
1.125–6.254
Brd5
brg-1
methyl-binding
syndromes7
5′-AGAGGCAGGGATGATGTTC
.Atypical
T1225C
2I–K
-5.6
42–189
CCAGGCCTACAATTTCATTAT
.Chromatograms
1–93
macrothrombocytopenia26
lymphocyte-depleted
NRASQ61K/A146T
.greater
thiocyanate–phenol–chloroform
pcDNA1
RUNT-related
.HM
CSF1R83
non-ovarian
L858R-EGFR/NIH3T3
agg
factor/RTK
MCyR
9–intron
Cys→Tyr
SCRI
CLL1
criteria.17,36
Category-specific
+/+=presence
PIK3CAE453K-expressing
3q21.3-q22.1
Nobori
V730M
slow-growing
monotherapy.4
.U~~~~~~0
Leu440Arg
Genomes10
ter24
CAG→CAA
5′-CCAGGAAGCAAAACTCACCT-3′
TERTexpression
BC/OC
mastocytoses.63,64
co-employing
pWPXLd-dETV1
5'-tttgtgtgaggccg-3
PartnerChip
FLAG-HA-double-tagged
NBP2-22166
MN127
size-separated
APL-specific
p57kip
+/wa
NE-PER™
DD-SF3B1
5′-GCCGCCGCAGCCCCCCAACACTG-3′
UMD-predictor
Q1336R.With
Jucker
Lhermitte–Duclos
492nd
O¨
Irish/English
D19MIT41-F:5′AGCCCTCCACCCAGTTTC3′
Y88F
units/ml
.Ataxia-telangiectasia
1946
Helix–Loop–Helix
NCT01248858
5′TCTGTGGAGCAGTGGAAAGCCCAG3′
Jarriault
Il13ra1
SNU484-S3-1
G717V
Ninety-four
PPD
N=221
2032
NF-Kß
pCAGA12
Domain—We
5.27
subunits12
IFN-γ-stimulated
Cdc25/Stg
C295-C307
/ETV6-MN1
SLC45A3-ERG
29/32
ARN-509
Hao
Wnt1-Fgf8a
E120D
Weissmann
KEILDEAYVMASVDNPHVCRLLGI
E2F1–E2F3
RUNX1-MTG16
Figure44
Teebi
0/5
64delCACGCGGTGGinsGC
S3/S4
G381R
cell-stem
992–1249
time.Bars
CCNK
population.1–4
2573T
SignalMap
anti–β-catenin
pico-L
.Homozygosity
sc-2003
Paraffinembedded
8/484
carrier-free
.H2AX
15/14
MDM1/2/4
Histological-defined
591-605
A769
pRBphos
D.R.
1698
deficiency.13⇓–15
atrophy/hypertrophy
uncomplicated
sequences.81'2
58*20
S2B-E
18–21.12
4.08+1.98
statusof
transcription–polymerase
PAH2
needed.2,4,5
GGGCCC
ACTB-1003—a
pCIN4
.4B
6,8-difluoro-4-methylumbelliferyl
Covalent
5′-CAAGGGCATATCCAACAACA-3′
Nunc
26·7
munopreci
N540S
Vandetanib/Zactima
laGl
EWSR1-ETS
57-1040
focusformingunit/CFU
AGX
-Aw
32P-3DNA
D191N
transactivational
fT.
aSignificant
destabilising
L281
PSA
glutathione-S-transferases
FMTC/MEN
GATGAGAGT
hydrogen-bonded
Fig.1F
93175
c.844A4G/p.I282V
1.01–1.15
.Ba/F3-EpoR
pathways,7
Φ
VIII-related
K572
9‐mer
phospho-serines
0.62–1.82
3.0-kb
p-Erk
Kakudo
V80G
.K-RAS4B
CTB
Cleutjens
HADH
screen14
C-promoter
RMV
Cells—Stable
same-position
7,12-dimethylbenz-
p.Gly106ValdelfsX9
D140A
agonescence
1:200
p.D479fs*2
alsosystematically
antineoplastics
V1665M
everyp53
LATS1-FLAG
MET/HGF
anti-C-FGFR3
L858L
mutantderivatives
30007G
SVD
EGFR/ErbB2
Flippi
anti-DLC1
.M1628T
Ctr
06-519
16,21,55
.Intronic
.KM12
BEVACIZUMAB
G34R/V-mutant
80–92
Gragnoli
rhabdomyosarcomas
neurotransmitters
974
//www.ncbi.nlm.nih.gov/
anti-Mouse-HRP
S6C
80.8
.RAC1Q61L
IV-10
follicle-stimulating
ACT-1
MDS-RAEB–like
60–127
Rsamtools
2ERE-pS2-CAT
p.Asn1364Lys
miR-191
transvaginal
FGFR3b-S249C-
hsa04115
shimke47
p21CIP1/WAF1
A301-591A
NM_000535.5
correlator
21:456–462
bar=100μm
INO80
Y347C
KIX-c-Myb
Inactivate
Nijmegen-breakage
K601and
death28,29
C241R
mDedd2-Forward
downmodulated
HRPC
nlyLeuSerLeuInCluLeuValLeuS.rGIyAsnProLeu
7.5/150
progression110
4-day
p.Q799E
miR17–92
PTNP11
CGMH
.722C4T
pc-GATA-3
homeostasis29,30,31
PTPRT/PTP
0.790
enigma.Several
.27,29,37,38
*C
2-arachidonyl
5'-CTGACTGTGCAGTGAATGTTC-3
17Department
Egl-10
goat-anti-mouse
C611W
c.1989_1992del
Tunicamycin
ddH
.Fig.44
.64,65
ErbB2_ex24-27.SR1
suburothelial
phospho-ERK–positive
GCAACAGTCTTACCTGGAC
platinum/pemetrexed
796–802
HuH-7
GAL1/10
SHOC2-M173I
cells.11,13
0.192
.50G
.Hearing
⩾35
ALK-translocated
K1495E
drug-related
0–0.4
3/8.6
BAX-BAK
lymphoma,47
p.Ser432Cys
Runx2
v2.07
DIPSS-plus
1554768_a_at
XWIN-NMR
ERBB2-alleles
53139
delE746‑A750
15q24.3-25.1
7.6–48.6
differentiation13,15
PF-
fermentas
GST–AGO2
NHE-RF
TACGTA
V35G
fullycomplement
PMS2-NM_000535.5
Austro-Hungarian
Wnt-3a
time—eg
D11S287
P1220R
AKT1-specifc
Pro241
significance.21
2,280
13,14,15
®nding
0.108
.Models
C3ORF14
HA–GLUT4–GFP
Z-DNA
iBMMs20
avidine–streptavidin
DiffBind
pCMVΔR8.2
phatases
Haploview
2573
iSH2-C2
anti-SnoN
culture15
reported8
strain-specific
22+
J5–7
GAAGCAGGCAGCTGAGTATCGAGAAATTTACAAACGTATGAACAGCATTAAACC
2Fe
5′CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT/3′ddC
TGF-β/Smad-mediated
phsophorylation
blockade
3-OH
N-Nitroso-N-ethylurea-mutagenesis
STK31
phospo-PDGFR
inversecorrelation
caherins
SVZ-associated
receptor-inhibiting
RPTP-T
I.G.-H.
WHI-P154-treated
Maytin
Fig.4E,4E
E390G
units-culture
FAM200AS481N
//www.hgmd.cf.ac.uk/ac/
=4.8
TIF-1
Board–approved
47-100
Candida.22
non-palpable
Poly-HRP
mutations—among
457–717
bindingc
Altra
Puc93-107
.Rmsd
SeattleSeq138
557–561
.AKT1-E49K
18S-forward
c.1408C
Y537C
ATGTGAATCCAGCACACTCTC
cases.16
asmre
MMRinhibitory
MPFS
Mittnacht
isotopic
B40320108411
abortive-looking
d-2HG
retinas…
Lys538
Babco
GFP-INI1/hSNF5
µM
PARP-1
larynx
ttingen
MWG
cases3–5
c.850G
772–775
extracellu
HCT116-DKO
potential58
Igenes
FOXA1/ER
H18
D544H
4156delA
Polyubiquitin
phosphatebufferedsaline
L445
pattern7
impedance
GLEBS
23.57
PTEN-transduced
SacI
rapalog
K185T
–C
S233F
37/82
Ala178-Ala179
Salahshor
BRD4–NUT-expressing
GGGGAGAGTGAAGTGAGCTG
5′-CACTCCAAGCGGAGACAGAC-3′
72
770
Met272
exon19
2,120
c-MYC-mediated
phosphase
59/CE
53.1–76.3
6—VEGFA
Safire
GCGCGGATCCCTTTGACCCAGAAATAGAT
T315A
STAT5-dependent
ATO
CBF1DBM-VP16
particular.4
studies.7,18
1.053
Ba/F3-EpoR
BT474-m1
Hilar
interspecies-specific
GSK-3-dependent
Ubiquitination-dependent
Gilladoga
aetiologies
T24*
Rankin2
twin-range
50/EC
.H1299
Y.Y
Spot-Light
CDK824
NM_008127
mehdipor
proband…
co-drivers
-3.0
CellTiterGLO
IGHlocus.18
receptors.36
Assay—293T
lesions†
NFκB
K90fsX101
9:22
.LCS041
TbetaRI
previously5,358
CFP-E82D
hand-picked
5×105
SIOP
ETANTRs
Rad3p
UKR
RBD19
oligozoospermic
v1.4.2
hypothe-
A-Akt3
LY-1
pR54
34–84
83:2934-2938
ab4469
pattern10
connector-enhancer
Arg1547X
lysyl-hydroxylases
.Giannikopoulus
mg/l
L703
MCCT
signaling45
KIM_MYCN_AMPLIFICATION_TARGETS_UP
HBCI
first-/second-degree
Cbl-WT
PAX5-JAK2-K/E
1,000x
I505T
52·6
fusionsignal
K+
RELN
in-solution
approach.37
.Heat
2.28
3.44
0.000795
site-specifically
L07-95
JSI-Medisys
PowerScan4
g.430T
29237
CMV-Mad∆LZ
matrix-producing
MMRgenes
V300G
/pl
C5/Lys-22
expression140
L142P
V600E-expressing
appropri­
473–81
TCGTGAGCCTCTGCACCCGG
5865-5877
results13
G334V
S2O
8â€
Trp/Arg
5q.9,10,20–22
p.E1552del
c.1244delC
CAAAG
Hydroxytamoxifen
.AP2A2
T826K
Genechem
pSer-X-pSer
8-membered
AML.17,18
IgH-myc30
0.1323g
LIMK2
chymotrypsin/trypsin
5′-ATTCCGTTACACACTTTGCGGC
K4
HA-staining
ab16048
EZ-Link
Quadrupole
form–specific
Bartek
efficacy.21–23
CATCTGTGGGCATGTT
70.15
Y1088C
TransGen
AGTTGCAAACCAGACCTCAG
EWS–
9p23-p24.2
c.5932G
B6–λ-MYC
system.1-3
P278R
CARD–LATCH–coiled-coil
siRNA-targeted
Tip48
22-
.Tsc1
E-twenty-six
2666
.16-18
PRJNA234087
BRCA1-wt
trp-1456
MAD-phased
PBAF-independent
+501
.Ourp53
PI3K-δ
PIK3CAH1047R
NZM30
CL1
marker-acetylated
integrin-specific
models.77
cova
H82
dT18
Cdk9
SNV/Indel
2.92E06
alone111
−3/PDGFR-β
1131
deoxynucleotide-
wasdigested
anti-p16INK4A
,2H
Ras/Raf/mitogen-
332–863
ofHLA
3-weekly
segment7,15
∼110,000
phospho-S473-AKT
3.2.
NSCLC.A
snf2
aFor
joint-related
NOTCH130
subclonal
5′-cctctaggctctcctgggag-3′
Cell-Porator
underrestricted
Blimp1Cγ1HET
deacylases
1955
MG-B2GFPΔ3270–3418
pE-ΔN
18,303
T790M-positive
p53AIP1
auto-immune
MAML1
/*g
R1261G
//doi.org/10.1371/journal.pone.0019059.t003There
5.Cabozantinib
Brcal
mol
ALK2
n°/µg
H2NH0029A11
Vincent-Salomon
missionary
heterozygous14
identifiedby
N-CAM-positive
Solution—Data
F460
BCORBBD
E746_A750/T790M
I.Alteration
488–conjugated
3q23
phosphorylated-monomeric
602775
Altfreq
chromoendoscopic
lo3
CBL-regulated
AdCMVLuc
Eomes
activation.8–10
sunitinib.20
p.serine
MRE11-RAD50-NBS1
inter-WW
Klf1
TCGA-34-5239-01
13–76
H3K4.16
p/CAF-flag
mutation/expression
antecedent
P.V769_D770INSASV
3p23.3
previouslyobserved
cisplatin-induced
62a
JAZF1
581–583
SC-40
sc-52
​,3,3
21289
'levels
Genotype-specific
SfcI
CE146T
Q174P
6935
mononucleotides
.asm.org/
melanoma,6
D.H.
C3124T
Thr198
dNN
6.572526
pGex
Mayo-Clinic
5973N
N2A
GCCCATCAGGAATCTCCCAA
al.13
alone.5,6
P53-dependent
non-hematological
37–100
Post-consolidation
fromNew
JUN-NH2-kinase
Smad2‐bound
Anti-pY1062
EGFR21R1
symtoms
L858R/I941R/D837A-Myc
YBR284
anti-proliferating
P207L
F/48
p85α
3793-3775
1523
beads-based
MCF-7PIK3CAWT
Gα12/13-coupled
TiP60
autoimmunity1
anti-AS160
B-RafV600E/3x
8-oxoGdotA
Yoshiro
expression.39,40
1AFIGURE
BRAF/WT
h1703542058514214215672h465652503301223205251
Neh1
Altlußheim
treatmentfailurefor
-857t
4.99:1
cancers,35
.Kowarz
25:24:1
50/100
hypertetraploid
Bodemer
55233009G
Number1000
RP11-753P11
5′AACCTCTTGGCGGGCGGATTGG-3′
p.Cys1932Phe
IIIa
CommentsWe
Eido
879
GnasR201C
inhibitors1
PPAC
Fc-mediated
metastases-free
74.0+2.0
A300
cells/10cm
PCR/single-strand
139:1985–1993
Charge-2
ubiquitin-ligation
MAPK/ERK
double-labeled
.Proviral
.Immunological
T339M
47/679
Akt1/3-mediated
nities
resem
lipofectamine™
TBX4
.RU39,411
Mellouli
2546delC
BRCA1carboxyl-terminal
4099
p.A57G
Factor-B
reported.25,29
4184
cells-of-origin
830K
MDA-MB–231
.FLT3-TKD
26
6.0-6.3
nonhemoglobinized
L→M
.Phospho-T58
M163R
pair-end
535–537
retinoblasts
nitrotetrazolium
models62
24.
Sante´
R960
0.5-500
wu95
TCTCTCCAGAATGGAGTCGCA
Myc-tag
296
Kolch
Patnaik
Methodological
hemispheres.40
FOXM1
1413
trxJY16or
Virally
SVM-BPfinder20
'New
SPHGEN
dominant-positive
906C
,5a
benzonase-treated
B*44
virus.42
SERM/SERDs
2·
1.718
tissue-invasive
XLID
EGFR-Mutated
D792•••Y823
1084–1103
159,165,166
CABIN120
17/107
3KEX
resistance.6–8
Trilux
tumorigenesis74
CD31-immunostained
1.2×10−4
E539K
LR04-069
Cdk13/CycK
Minoo
CCCGGGCTCGAGTCAATCTCCCATCCGTTGATGTGCAATGC
galectins
microsatellite-like
anti–phospho-FLT3
Site-directed
non-D-loop
CKI1
NFAT-dependent
52.9–79.5
.S6K1
5′-CAUGAGUUGUGACAAAUCAACACAA-3′
pone.0032555.e001.jpg
12.12553833
.NCBI
Mosse
activation.3,4
A266_S267insSTVVD
73.6
sclerosis136
R155P
.Transformation
3HR1881
Berg
A360S
p.A232A
Leu513
hERα
45/53
expressing-‚-galactosidase
ROR1-kinase
SA429
15q12–q21.1
FcγRIIB/CD32
polymethylsulphonyl
45-60
OS.17,27
scapuloperoneal
DR1,7
26,202
H-11
PI3K-C2α
5′-AAGGTGCTTGGATCTGGCGCT-3′
kinase3,6
Srsf2a
SHH-independent
Spry1-4
0–218
glioblastoma-derived
Csp45I
MAVER
.pVHL
58:1
liposarcoma.8,12–17
1366
X59798.1
propanesulphonate
DAPI-labelled
HPL1D
lines.9
CGTGGGAAATTTGACTTCGTGGGAAATTTGACTTCGTGGGAA
clones.13
FGFR2Ks
T163
mre11
091
intro.htm
P336A
pink/
MAPP-MMRd
1x10s
li2R
α-ketone
CC-to-IT
Ten-milliliter
Val14
ErG
p53–induced
.Sequences
phosphodiesterase-5
38.2x
0.751a
HAT-associated
T170M
weak-coupling
non-duplicate
CARMA1-CK1α
21st
TEL/JAK2.48
behaviour.1
theT75
.NFASC
R530W
5′-GGCAGAGGAATGATGTAGCCA-3′
ΔG345–P361
2,533
1528
5′-TACTTCAGGTTGCACGGTCTCAGTGTTAC-3′
HCC.15,20
Ellenbroek
pREP1-VHL172
PDGFRA-ETV6
lyA
blot.We
D255N
1.43–2.30
kidney.31
retrovirus-encoding
ABR
pGL2T2M4
2pat
375
mutations31
phosphoS473
to-M
P.L838V
tttgcgatcataatcttcctgcacagcaggaagattatgatcgcttttt
G+C-rich
CDK8-induced
dye-terminator
c-Kit–mediated
redox-sensitive
degredation
57,59,82
conditional-knockout
flippase
deletion/methylation
N385S
cells,31,32
α-TUBULIN
Karabinis
Gangwal
ethylene
4.1.1
10–74
AAAGCACCTGATCCTAGTACCTTCC
v-src-transformed
1Df
GGCCCTATACTTAGGCCCTTT
AGGCCAAAGTCACAGATCTTC
ROS1-targeted
h/36–40
Romanienko
Pro531Leu
Pasini
Ras-N17
Asp374
5321
.Receptors
9,11,13,17
sub-analyses
mNET
86-516-85802382
sspl
39-rapid
Flag-vector
Q316E
IFN-gamma
cr_Ctrl
3,203
RabGAP
repaired.13
70S6K1
5′-TACCTCTAGATTAACACCGCTCAAAGACTTTGTATAG
p53ser15
ACTN1
pRCC
chloroquine-sensitive
Uehata
Colman/Prof
-adjusted
.0570
syndromes,43
GCCAG
pyrido-pyrimidines
NRG1/neuregulin/heregulin
R748G-injected
adipogenesis
H396P/R
KrasG12D-driven
MYST3-NCOA2
cisplatin-sensitive
NM_007739
therapy.To
SephadexG-50
0.234
FLVERS
314J18
ambulate
Conclusions.—Universal
0.0118
S'-GCAAAAATGTGGTCCCGGTGTCCGACCTGCTGCTGGAG-
polyphosphate-5-phosphatase
Dyegenerated
microcentrifuged
mtracerebrally
Ala33
RXRA*
1q24–q25
REHKDNI
.Martinez-Moczygemba
surface29
.PMS2
1,25-dihydroxyvitamin
consequentially
Erythrocytosis
Phospho-STAT5
D108Y
DS15153
Box-Driven
progeroid
3.8–3.5
moleculardiagnostics
.PDEF
C134W
Bernardin
IGF-
futher
rituximab
33–289
1–62
Kerkhoff
270V
~Bigay
PG-M3
V287D
FGFR2-CREB5
immunoisolated
.i
cH0
log-likelihoods
DEP
KITspecific
one.4
5′‐CAGCTCCTGTGCTGCGAAG‐3′
cancers.53
E525
azacitidine
12302
.Co-staining
KI-2
.002182
3TP
40μm
3.05–8.93
P132T
pEGEF
-/AA
.CSPG4
.Walkersville
P741P
GST-Y537S
4C–D
RG7204/
AGTCGGAATTCTCTGCAGATAGTTCTACC
Isohemagglutinin
V.E.R
GAA-3
submegabase
-ALK
post-transfection
RFS-myc/Wap-Cre
rapamycin–FKBP12
250®
α/β-fold
Lenalidomide
Cölbe
5.101
Pea-3
neuroblastoma6
twenty-five
D5S299
genotyper
AML-type
l-glutamine–penicillin–streptomycin
targets13
Atto488-linked
W87G
ret/ptc2
3931delAAAGA
KRAS-independent
14–3–3
BTAK
WT-overexpressing
thepossibility
BKM120
itlo
20.2/27.1
immuno-hematological
Chelix-in
Pten+/-
Lgj
-proteinase
Results—AR
chromatography–mass
protein-OPO32-
73/F
HA14-3-3
29.9
L48996
colleagues17
others29
Crk-binding
cell-sorted
prostaglandins
WDR81
XM39994.1
K-RASA
Q63L
B-Raf3x
B*5604
FuGENE®
MLL-p300
antsThe
Kippenheim
control.71
c-kit
D170H
ng/uL
17.2
RAB35
MLL-expressing
200–1200
HEK293-
sporadic-melanoma
membrane.Next
p.G12S/c.34G
19:22
optionsIn
2.30
p53R273H
TGF-β-induction
5′-GAAGGGCCTAGCTGGAGACT-3′
receptor-regulated
NCI-H1975.2.3
H1B
27–19
59-primer
imatinib—based
Hypermutator
431T
site–dependent
5.8
CXCL5-CXCR2
Lys19
Cdc25-domain
R550C
loxp
Studied.
4100
.Wild
resistance82
microvesicular
binding-sequence
CD38-
≈85
E846
quem
10.1007/s004390100460
Moldoveanu
_4-
air-sack
loxP-hygro
∼270
CTB-68F18
Cdk6
RAS/phosphatidylinositol
721–997
KIF21B
L3
CEEP/COPADM+
Me10
YFP-positive
IQR
adenocarci-noma
ml/well
Nkx2-8
NFkB2/ROS1
53/515
Lobular
49/80.3
C.1.2.5
//www.unav.es/departamento/genetica/unstat
V802I
0.2824
Mortalin
6q25
88-bp
unicz.it
doxycyclin
RUNX1-AFF3
toxicological
MENIN-MLL
stress.18
loss-of-heterozygosity
Seqscape
GPIAP1
Y508C
0.805-2.443
9375
investigator-assessed
68–98
2.88
.Mueller
nonangiogenic
c.315_330del16
CTB-104I4
R222C
H41L/Y/R
BMPR1a
NP_478123.1
MicroVigene
5′-GAGGGTCTTCGGGAAGCTCATA-3′
CYT-387
TNB
wasPAX8-PPARγ1
500–2400
Alal48Thr
DLBLs
5.314
tred.cgi
congenital
Y219
29·5
2JS7
inhibitors.13,14
//bmf.im.wustl.edu
Radioactively
hmC-binding
.Foot
self-renewable
trap-Fourier
Ile-919
structures6
R.M.
Shmueli
D-88
S3m–n
peroxynitrite-dependent
WT1-associated
IRdye800
phosphotyrosine-binding
methionine.55Progression
CDK4-MUT14
16K
–57
1.732
.203
site-independent
Smad3ex8/ex8
eGFP+
possibility33,34
10,14,17
VavCre-AtmC/KD
SND1–BRAF
.Correlations
V13
ATG7/RAF1
ARHGEF10
N1304S
'common
Rap-1
PHTS.2–8
MEK1-WT
RO5424802
M13+
.Bulk
RBP-jk-associated
receptor-independent
Functionbased
Ficoll-metrizoate
2491
withpoor
phenotypically
N61S
concentration-effect
93-68
Ponting,2001
c.643C
Balkan
P477L
NTRVGTKRYMAPEVLD
N-Cad+
7.0.4.0
modulation55
Thrombopoiesis
EKN
tcatatgttcgaagg
S36A-mutant
syndrome21,22
recommended,46,64
shIKBKE-1
P21Cip
0.1192
FGFR1/FGFR2
MLBCLs
Hendenfalk
397-kbp
reduced.13
family.Mutation
endonuclease-treated
.Mazoyer
vincristine-cyclophosphamide-cisplatin
cross-comparing
0.493
CMV-VP16
myotube-specific
Rab5
PTN11
tumor-doubling
1511
10.3-
protein/peptide
positionthe
SNV/indel
HA-S6K
glycine-to-serine
4.49x
EZH2-wild-type
transition.87
p-ERK1/2T202/Y204
607KB
Novagen-Millipore
c.557C
NS.13
5′-CATCTTTATAGTTGTGCATTATC-3′
As2O3-binding
identifuying
cells,32
spo
U87MG.Δ2
P25
32-mer
R68sp
Nivelles
2-9
2A–D
Y654KD_Δ
Y120C
HLA-C
V105G
PD-4
15,54-57
αC‐helix
CA9
YO-PRO
biocompatibility
MAPK
Raf-RBD-CRD
L206W
0.120
4/14
clinically-based
IVS-12
nulnu
0.69
87667G8
30.1
PD89
.Upper
1.995
0.0266
Dap
c.35T4A
.TEV
p.R52X
hypoacetylated
anti-Bid
phenotype,24
dual-mutated
6096
NUP98-fusion-driven
non-IDH1
0002-9297/99/6403-0009
-CTGCCTCTTTGTGGCCTAAG-3
FRs2α
AMOTL2
NM_014390.2
Pre-incubation
elusive.40
–35.8
1E–G
relapse.1
stratify
al.48
nonETS
FGFR4-KD-wt
1.4.5
Nishisho
Gisi,1,2
Bringuier
F-3165
resistance.26,41
Anti-ret
CHCA
proposed,3
byimmunoblot
pCB6
cells10,14,15
hESCs
1.4.1
T288I
Ala60Val
110-PT98
BSA/PBS
Basestation
0.44-5.15
Hs_MYD88_10
CBRC
l6
Boj
domains.36
patients3⇓-5
mutations.35,36
C1483
//www.affymetrix.com/support/technical/sample_data/500k_data.affx
substratescontaining
THSD7B
1BFIGURE
Anti–α-tubulin
LacI-CHERRY-BRD4C
Gellert-Randelman
113-8510
KEAP1/NFE2L2
3β-independent
3,328
www.liebertpub.com/thy
Flag−tagged
S68
betweenPMS2
R276W
systems31
8-intron
Q514K
highmolecular
anti-b-actin
713-805
19q13.3–4
non-Spanish
TEL-JAK2-mediated
.RAD51C
Verschraegen
HSCs46
4.0.5
mutations,28
100uL
ISS2-AON
readGroups
2342
HIF-regulated
abnormali
CNS.52
R47
27−30
biflorus
sc-29430
gene-ontology
Y163
co-fractionated
bThe
microorganisms
E207K
FxxLF
superfamily,1
UBC
33–88
amplified-RAF1
5′-GTCTCCATGAGCTCCCTGAC-3′
overlap‐extension
OX40-sufficient
AR-V7
ercc3XP-CS
deletion–EGFR
ARDIA
18c
p.Ser307Leu
cells195
WSHU-NHL
7–10
P74
tel-jak2a.34
kip/cip1
.Shipp
Ura+
siNKX2-1-induced
857–894
crest-derived
QA
Mll–AF9-targeted
pCMV6
NA33
p16/CDKN2A
.Single-nucleus
\0.5
Ala36
I68T
ACH
16:1
34173
Breazna
BALB/C
dsDNA42
6XOES2-Luc
NaN
M136R
P38991
EZH2-HA
confirmation.NF1
14F*
TEL-ABL22
anti-S6
FOXA2
mutaBRCA1
ins11del49A20
Type-B3
HindIII/EcoRI
2.347
iodoacetamide-labeled
Osimertinib
NM_001123385
21:18:51
Hirschhorn
pseudo-HEAT
jem
71/m
thresholded
micro-beta
Guelstein
thiol-directed
72/73
6R
PRKWNK1
72·7
.SADDAN
Leu-Leu-Leu-Glu-Val-Ile-Arg-Arg134
69.6
Histamine
5.8×10−9
3Q
Lys751Gln
weight-gain
EATL
ezrin/radixin/moesin
T62A
outcomemight
.dnTCF4
association/correlation
Q61L/R
β-catenin/TCF–driven
597.3±86.8
ATP-regenerating
9,44,45
0.15–0.25
RCT-E565
193–800
GPA+
Size-exclusion
350ul
population23
web-based
DMLB
-88
quality-controlled
BRAFP-loop
0.0283
phospho-Tyr900
Fig4A
cog
S1387Q
phosphoPDGFRA
.Inoue
HOXB5
3-case
3′-5′
GGATGCGAAGGCGCGGGACACCAATG
advanced/dysplastic
gg-3
MALDI-reTOF-MS
D9H10
//www.uib.no/aasland/chrab/
V9
c.607C
ITIH5
M0-M2
dPTEN2/2
pan-actin
7900
NCT01800695
apoptotic
9P25
2583G
ctDNA
T-3′
5'-CACGTCCAGACCCAGGAAT
Carnoy
mutatgenesis
P291fsinsC-positive
0.675
centromeres/microtubules
IGF1Rs
N′-tetraacetic
.HEK-293
P2213L
GCCGAAGCTTCCTCCTTGCATAGTAAGCGTT
p.L1481fs
FANCC
17β-E2
13-kd
Swi/Snf
0.114179
345K
L584P
signiWcantly
cancers.41
Tumor/study
well/moderately
.Fig.2,2
axitinib
agents.57-59
not.2
36/47
CCGCvCTGAG
Nespas1
Pro396
22/41
compound-sensitive
His-STK15
Rag1
pT7–7
that/those
Y1021C
UBC12-14
0·065–0·876
mutationType
positive-cells
0.65plusminus0.38
TP53+/−
≤0·05
K428T
tein
p53-G242A
schwannosis
0.654*
binding-related
RNA/RBM
2493
melanoblats
BCL7
IL‐1
Pre-steady-state
G172E
N-Ras-mediated
sc-2317
tgtclgaaaggaggttcatcc-3
nanoclustering-FRET-analysis
.£Ar9Ala
170µl
õ1
CHGB
10–30
co-expression
wu112
Hhal
TGGTGCAGAGGATGAA-GTGCTACG
12,16
mg/25
ante
transcellular
Huaihai
RuvA
TAACAGCAGTGAGCAAGCAC
HTLV-I–infected
13119
D1067Y
Trr-depleted
Prdm1Flox/Flox
26LN
TC-39
SCFβ-TrCP
Adrb2
p.Analysis
CCR6
G1738R
effectorregion
phenotype.31
H690P
SERM
PTCH1-mediated
SMP14
594-.
/PDGFR
4104
biterminal
H233R
H310Q
codon1are
Ala113
ATP-2Na
31,810
pim1
non-TK
N486-P490
p53.The
BRCA1/BARD1/RAD51/proliferating
M522Va
times/week
4AJY
FSTL5-dependent
signaling7-8
TCF-3/TCF7L1
BX.1
H874L
Growth-factor-receptor
Conditionality
4/22
RUVBL1
SBI
.9It
ABC/NC-DLBCLs
2.14-6.66
Hollstein,2000
DHPLC/sequencing
UPN3
Ni2+-chelating
differentiation52
c.1744T
17.
c.1799_1801delTGA
W.-H.
5′-ggaatagccccatcttttgg-3′
sgRNAs
TCGA-G3-A25U-01
C3742
ashkenazi
reconstituting
EWSR1/ETS
49x49
4-13
°
4–31
aponeuroses
−82
70Z
IκB-α-mutated
13q12–21
Dhyan
gleevec
.SOXCORE
3.3±0.15
hMLH1−/−
Mitotane-related
Weischer
R84C
nihms646437t1.jpg
Pro-apoptotic
L/B
PIK3CAH1047R-initiated
Udayakumar
Smad2Δ1-240
W671X
anti-GR
G03/073
D67N
20H5
NK/TCL
TTAAAG
Ramaciotti
I1I
SET7-dependent
​Figure5A5A
240F
0.0001–0.05
Christie5
CHOP-like
BRCA1/2
BRG1-mediated
clonesB_
p.Trp1837X
databases8
1.68´105
ELUTIP
Kissil
UMR146
HNPCC.9
Crystalaser
ENSG00000110395
3995
2EFL
Sim2-knockout
III-5
.Olfm2
RAD50/MRE11
mol−1
Alal
c.425
34-4
H1972
eVect
TetO-PIK3CAH1047R
entrectinib.NTRK3
C706F-BD
56770131
PR-
Jak2-V617F-expressing
174-bp
​Fig.2,2
Lys1150
sj.onc
.Gerlinger
.Haber
BRCA2/IVS21
5'-CATAACTGCACCCTTGGTC-3
well-organized
Ala883Thr
.TOP1
Acidic
0.3340
FBS/PV
11th
1x
K666Q
Runt-homology
byWT1
tissues13-15
temper-
cohort-based
outcome.21
Cbp/Pag
microsatellites
pulse–chase
6681
Govindan
NBG12-R
Transfection—L6
H1802Q
Trapman
nanoclustered
AGatl
metabolism-related
whilethe
Cytoscape
gplloProtof-rk
Shchors
D374N/E380Q/E385Q
F382L
E161del
GDPQLI
activity.76,77
MIA3
*9A/*9A
5′-AGACCAGCAAGAAGATCACC-3′
S221
These1
pLKO.1-shVHL
295I5
5'-CAACAGAAGCATTATACTGC-3
48,49
5339G
p.R1506H
MEK1G128V
epithelial/proliferative
I136T
breast15
~11
.0196
PMS2-134
pHK105
EGFR-G735S
5′-GGCTCCTGATACTGTCCAGT-3′
Shp2E76K
24–96
D594VBRAF
FHA-related
STAT3-C–FLAG
1.00–1.03
Furutani
Leu10
oligonucleotideb
.TMEPAI
antigen-
D275A/E277A/S459F
5212
Phe929
EGFR/pERBB2
serum/pervanadate-treated
-9
7.D.1a
constants25,26
46/50
Killer/-DR5
4895
glioblastomas
Y291C
under-expressed
JNK1-K55M
LKBÃ•
OvCa
tgcaccaccacctgcttagc
rs4796033
D2.102
Poyhonen
1s
BRD4-driven
Voigt
4367659
brachyury
1.125
AML,27
unrealistically
CD4+/CD8+
313-833-0715
Cell-Line
shin
Ossareh-Nazari
miRNA-induced
cRFP
Mutation-Carrying
nonintestinal
Fenretidine
PCR2
78,82,78°
100.8
tumor–host
polisomy
FXYD3
phenotypes.11
vivoTable
.ΔBRAF
M2i7BF/M2i8CoR
Gram-positive
VBC-His6
V773A
10/14
non-reciprocal
Villin-Cre
anti-phospho-CrkL
Q1196-R1
.Src
S-1
lacZ
FRS2-binding
4800
trisenox.html
p.G751R
morphologic/immunophenotypic
Crossen
52.2
Tnfa
Palmqvist
BCOR-ZC3H7B
Serumdeprived
DupontNew
JAK47and
C1786G
Alb-Cre
22.75
-U
S60C
controlpriority
0.811-26.91
TÃŸR-Iund
0.100
pBABE-puro-hTERT
reduced/absent
TGFβ/Alk-5-dependent
nally
transformation.16
c.799T4A
1.8–100.1
5′-CCTGAGGTTCAGAGCCATGGAC-3′
//www.controlled-trials.com
D842Y
1.212-2.392
exon,19
PABPC4
c.611T
V1075F
anti-AKT
Bα-mediated
.Woyach
Ionic
34,35
septocutaneous
G20E
pSmad1/5-directed
Cdk12-F
reduced-intensity
Y538S
,1,2,3,4,5
IIIDEPENDENT
.Phospho-EGFR
116.chr3
c-k
.2C2C
Morpholino
near-universally
Administration–approved
CAGCCACTTCCTATGAATAAACC
1-year-old
Swissprot
-Jak2-WT
pCMV-Entry
390–394
carcinomas41
co-authors
5′-CATTATGCCGAGGATTTGG
micrometastatic
PDGFR10,11
22Q,23S
53–62
WAVE-MD™
TP53-related
CHEK2*1100delC
BM-associated
activation-specific
INF2
NLS2
6.06
Gradel
E234K
ref.15
3Y
N-RAS-driven
V848I
Rommelaere
ATP-pocket
MYOD1-mutant
conserved,9
PRC-mutated
18F-DOPA
2.07–2.00
Moren
FGFR4-KD-V550E
≈5-fold
promoter-Renilla
Alcalay
signal-sending
MLPCAT
bufferI
non-classical
GATA3-driven
sildenafil
.3,17-19
Houssaint
pilomatricomas
HA–NUT
TOP1-DNA
residues2
FigFig5A
Arg-Lys-Thr-Arg
homoscedastic
IL-17F
Flag–tagged
e14a2
yPi-QA
GST-coupled
ethyltoxic
similar-strength
5′-gtccccataacacccagagtagtg-3′
IVS10a-32C
loop-mounted
CXCL2
msh2-VD858
GGCTCATCCTCACCTCACAT
GAC3GTC
Raf1–MEK–ERK
differentiation-
2942–2956
X-vivo
Rada-Iglesias
G674R
STRN3-JAK2
HIF-2α–transfected
ATAGTCGACTTCCAGCCCATCTGTTATGT
R1276P
Coelectrophoresed
.50
AL079303
p.Asp65Asn
groups.Identification
p=0.03
TTL
T284A
37.0
Th1.2-expressing
Leu596
pMiwIII
PolyPlus
G1125
proliferation.29
WT-TP53
YWHAE-NUTM2A/B
Masrermix
G12G
404
Paronetto
site.All
tumors/dose
Comicroinjection
electroretinographic
drier
ABD–DLC1
5.8±0.7
fx1.jpg
8,13
nonendometrioid
9030delATCAT
T-150
clinically-defined
ThyMidine
Ile252
approx2-fold
nonubiquitous
PLZF
Bimp3
//confluence.broadinstitute.org/display/CGATools/MutSig
∼3–4-fold
CCCL
Cornaredo
Illumina20
organs.3
YCpLG
−.85
real‐time
BRCA1.48
362–518
polyunsaturated
R367Q
Spectra-Physics
Abl-SPOPwt
pymol
6m
S343Q
EUDRACT
inhibitor27,28
HIV-positive
5′-GTACCTTTCTGCCCGTGAAG-3′
H456
oncogene-induced
database4
Fgfr2S252W/+
Schultheis
phenotypes52
pSP32
PPFIBP1
rs34352568
tanaken
,5,5
Red-labelled
transgene31
D5nt
CtIP15,16
1664-1
ahead.9
Billin
MLL1/MLL4
TCGA-CJ-5679-01
pEAA289
×10
1.44n
46-48
c.1145-
operator-driven
SRCR
available.Whole-exome
immunopurification
=P
T62A/T380A
D-64406
1742
squelch
ax-
96-hour
Frequenciesa
SCID-adh
7-18.5
uninformative
TNF-α–treated
TetPTEN-K125E
slightlyweaker
1669
MutantsWith
biospecimen
166.5
D2Mit50
L32R
TEL-JAK2–
MCM
.CNL
M2-associated
P484R
plf
ATR–MLH1
Wildbad
frictional
ubiquitination35
2-7
22q138q23-24
six-bladed
IVR
NCAM
MutationsTA
beMMR
c-Met/Gab1/PI3K-AKT
baculovirally
re-expressed
40.98
IRS1-associated
Merlin-binding
MYD88-unmutated
–,19
MEK1-MEK1
tumour19
.Surveillance
mDia2
εij
best-fitting
599/480
162-N14
R529
cystoscopically
al.54
TKIs.21,22
2239-2256
c.375G
3.285614467
epigenomics
763–935
3.9Å
.3991C
abet
VP16-
Homopolymeric
2847y
BRCA2ΔCTD
syndrome/myeloproliferative
Ber-EP4
NOTCH-supported
OLFM4
197Leu
EEA1-positive
G126
Mm7xGGAA
TGACGGGGTCACCCACAC
krox20-positive
CTCCCCCTAGACCCACAGAC
Merlin-MET
FoxF/Biniou-mediated
thisparticular
G6PD
MDE-gel
110â€
R248
F595V
38/101
G143W
both.35
pCR3.1uni
RAS-driven
thussuggesting
comprehensible
mMMgC12,30
sub-μM
LCT
.ERBB
.Organoids
γ2c
OPK-14
paired-box
p=0.003
chromatin-modifying
Mori2
60-day
I1929V
D1/BCL1locus
SCC61
PT10
.20Statistical
A118V
IFNAR1
11/6/98
dovitinib-sensitive
110-kDa
reductase,25and
1252–1253
.Immunoglobulin
FTTQSDVWSFGILIWEILT1
islands49
insCn
proteins107
10–8
ofRaf
5:29–34
epiphyses
Puri®ed
anomalies.35,36
T1275I/V1333I
.Firefly
GGAAC
methodsPatients
effective.33,34
1,501
life.57
15q24.1-2
471–473
3-beta
Stably-transfected
sequence-related
well-folded
TS565
1-Methylpiperidin-4-ylmethoxy
p.D822K
POU4F1
RE9
eye-color
.Asai
5′-CCGCCGTGGACACAGACT-3′
Bowdoin
E709/L858R
lethal63,64
50-TAAACTCATCTGGGCCACC-30
.Spectroscopic
L269fs
aggressive.21
non-productive
min-isoform-fraction
methosulfate
del25–28
842-Asp
-1205
LeukaemiaNet
TAATACGACTCACTATAGGGAGGAATGCTTAATCAGTGAGGCACC
Hwang,1
Jagged1
WKVV557-560C
Joenje
'empty-vector
inhibitor-focused
Hinck
others7,15,23
Raf-1Y340DY341D
line.39
P-0005159-T01-IM5
//dx.doi.org/10.2210/pdb3biy/pdb
OS.13
0/1
H510
000011
Mac-1
exon17
Kyritsis
Euroclone
6q22.2–q22.3
Lys-27–specific
atg
224848_at
ONlSHl
GPCR
Ret724
Gondek
SDH-subunit
five-micron
JM-Switch
ZF2
HEP-1
Wolf-Yadlin
sequence.43
.Cooperation
5-bromo-4-chloro-3-indol-phosphate
S243
at30°C
Vermeer
miR-28
G12.2V
uPA/uPAR
VariantsFor
p53-EGFP
WT1
2,108
Co-Smad
mtDNA
5.6-
L629F
KIT/PDGFR
D92N-mutation
2.7+
T80A
trans-activator
ventrolateral
B*15:02,39:97N
12ql3.3-14.1
Oligoastrocytoma
.BRCA1/2
2.35-
.Patritumab
pCIneo
P031/P032-A2
Igf2
Ras-Raf1-MEKERK1/2
PLZR-mock
CK2-induced
S369Y
Phe27N
GIST35,36
tree-based
moles/liter
W557_K558del
HMECsGene
VB5
HPV-74
haemosiderin
2,540
promoter-50
K550_K558dela
ERBB2/GRB7
759F4
3C-D
air-drying
.+q*
targets91–96
Pik3cd
Inpp4Bflox
12260
.Genotypic
4.5.5
re-sensitized
b1-integrin
1.670
cis-encoded
TAL1-rearranged
thisDNA
5′-AGCTAGTAGAGCGGGCATGTCCGGGCAAGaCgGCGTGCTGCAGC-3′
glycosylation
0.66
HLA-A*02:53N
10-05
GraphPadInstat
therapeutisc
.Erlotinib
GeneChip
glycine-to-arginine
craniosynostosis-linked
6134
fixed-length
cell-migration
studied.15
KARPAS1106P
bowtie
trk23
p.Ala530Thr
E281K
D2Mit74
MHH-MED-3,28
Rip1dnE-cad14
.Hemagglutinin
4,725
growth.3
PR_TCGA_LUAD_PAIR_Capture_All_Pairs_QCPASS_v4.aggregated.capture.tcga.uuid.automated.somatic.maf
I126M
10-Gy
sulfate/0.1×
cytokinesis,38
TRCN0000003253
ANBL00B1
IL3-
NFκB-responsive
types48
pre-treatment
p=0.68
13E5
anintensifying
overlining
NM_002639
Myc-specific
DS-Fi1
Thirty-two
H333412
bases.12
Glu659
Myc/hTERT
T2467G
pamela.pollock
cc-11-4059-g6
domain–
Minelute
myeloid-specific
BRCAJ-linked
'ward.D2
torafugu
Dicer1+/+
Myc.118
12.22
S5M-Q
.JNK-mediated
mA/cm
+1+2/-1-2
29–77
perilipin1
Transcriptome‐wide
1239–43del
3813
stefin
E40K/S124Ac
ASB2
Chromatography
FGFR-TKIs
Kostman
n=6
TR−T3
data-set
Thummala
TP53-dependent
Fei
phosphoinositide3-kinase
VHEM
f.e
ExpressHyb
intertumoral
8,12,13
method41
14q11.1-q11.2
-iodoacetamide
status-matched
Matturri
abnormalities.15
TGFRB1*6A
pGL3-control
.Mandelbaum
context.109
PIK3
compaction.22
PS100001
analsze
recruitment.116,122
mortalin
anti–caspase-8
typesn
Msh2p-Msh6p
Paneth
CHO-K1
*Karyotypes
Tet2/
CuuCu4
gene.15,16
5′-TGTTAAGTC
Carcinoembryonic
Accuracyc
luc-reg-15/16
H3K27me3-depositing
Fbxw1
3.67+0.17
invasion-related
GTPases-The
Phred
-B0801
3-thienyl
a-IGF-IR
FP9-4
left-handed
Extra-GI
desulfonation
vitrotranscription/translation
p206
300-mg
52.0Tumors
chaperone-independent
KITAY502-3ins
5686
E120
nanoelectrospray
−0.10701
UDP-N-acetyl
AB_330744
umin.net
locusspecific
173–241
1=
MACS47
R248-R1737
Micromax
.Frs2-mediated
FUS-FEV
72/M
glutamine-to-proline
anti-CCDC170
HELP-GT
Kras-Tp53
MSI.23
Oberosler
RUNX1.47-49
21–23
15501
simulason
CD74–ROSG2032R
32,38
carcinomatosa
medulloepthelioma
co-transformants
U2AF1S34F
TMP3
-ATC
Calado
gastro–entero–pancreatic
small-airway
1−6.2cDNA
TOP1-ChIPs
Lissencephaly
MDA-MB231*
BCRPDGFRA
c.1882C
TAM-resistant
Lysodren
chromatography,26–28
p.R1020K
Epigenome
Arg-7
intra-repeat
NOA-04
.ΔE4/+
ENSG00000213281
immunotherapy-induced
Fig.6c
pCR®4-TOPO®
LVIs
MSH2-MSH6/MutS
1506
Epo-R19
PT11
polyprep
biotinlabeled
NTPase
FGFR3/A391
nuc
.Colour
BlackBerry-quenched
c.722_735delGTCCCGGCCCGGCA
.NBD-GTP
factor.71
spiral-shaped
l0
114/412
CCGACAATACCACACAAGAAG
F57C15
HEK293-RETM918T
spectrometry.We
R528H
pCDNA3.1-3xFLAG
t-ERK
.Immunoglobulin-like
5′-cgactggagcacgaggacactga
20133
CACGTG
PQCXIP
CXCR3
PQ
M458K
PCRamplification
Tris-
S660
114.637
Fip1l1
GST-glutathione
LUSC
dexamethasone
Stemness
h79
set60
tumor-reducing
transcriptome
MCPH1
170C4T
Mdr1b
1129
C.C.S.
-AGACGCTTGAAGCAAAGCTGCCATC-3
ESRP
373-bpfragment
contradictions
f/79
characterisics
FRAPP
.1.1
1,113
LanthaScreen
Fanc-D2
1,235
apparent.11,14
21,39
lincRNA
E7K
17,19,29
F991S
35.91
V659E_T798I
L996F
C-R
c.2065C
Pol3
CGN
c.-32-29del
non-intronic
prostate-specific-antigen-screened
RRK-C2
149169
S218/S222
autocloned
ﬁrst-in-man
drawlessons
R32T
ErbB2TKI
self-designed
overaccumulation
association.82
RELA
CLL-like
.Amp+
SIGMA/Fluka
BCSCs
pDream2.1/MCS
hypochromic
GST-fusion
cryo-temperature
activity.29
M535V
Taqman®
Tropomyosins
Riese
1–311
pClneo
characterises
Phosphorylation-resistant
0.00098
T-cell-specific
box-plot
681–683
AVGSFVFLRFIGPALVSPDSEN
81/86
gene6.5PCDH7BH-protocadherin
buttress
3-T
microRNA-221/222
PDGF-B/PDGF-Rβ
50/60
high-frequency/small-effect
CommentsAll
5′-FAM-
METHODS—We
Japan135
lentiviral-stably
events23
immunode
q23q24
SS_L1
μg·ml−1
pcDNA3.1-HA-Runx2
948
K42A-containing
CCDS14010.1
T1079
L2GDH
P417L
shown7-15
Kiinamyllynkatu
B7‐DC
Four-micrometer-thick
A763
Double-immunofluorescence
cells132
9KIT-D816V
MutSα-L173P
5′-CAAACAGGCTGGCTCCCGTCTC-3′
T-cell–dependent
30.2
2..
E571G
A148D
EOC30
c-mycexpression
H-65
98.2
DMD
5'-TCCTCCCAG
R247W
p.Thr2722Arg
.Xpress-epitope-tagged
141–1
cases.17
NCT01597908
CTNND2
d3
Kennison
69165500
29mer
SuberoylAnilide
histone-3
S1498N
0.955
e8
pBC
ZMHOX1
bPerinatal
MspI-digested
feedback-mediated
Trp-383
~3.2
parentage
VM-CUB
10ZF/MSCV
thehuman
22476
p23-24
protein101
05/Fumi
profile10
K-ras4BG12D
Ampli¢cation
doi:10.1038/modpathol.2011.95
0.2519
r=0.88
PTENcentromere
Twomicroliters
tRCCs
survival1
criteria.25
non-fermenting
phenylmethanesulfonyl
harboringthe
miR-143/miR-145
selfannealedand
C-A
.Asn41
Sox17-deficient
−4.71
38.4
post-tumour
PC135
exonc
apoptosis.40
15.43
G/IL-7SUx
p61BRAF
poor/undifferentiation
predisposition4
2203
dasatinib/AZD/BEZ
0.943
D16S3026
128–366
COL12A1
WRCY
0-100
T1-T127
proteinsa
transgene-induced
Agents/circumstances
occidental
syndrome.12,13
BAPN26
FGFR1′.1
CCND1-negative
Camposano
strand-transfer
7q36.1
c.2020G
cAMP-PDE
assaysWe
6/exon7
pTZl9R
8307
phospho-S473
conju-
Bakalkin
mutated/inactivated
gpIRES-293
Pre-Amplification
cytoplasm.82
RacGEF
Mutants—Mutations
0.60–1.01
damaging/damaging
3328
Resnicoff
Rat-l
indicated.Western
Inc./Cell
5B–F
RU6
disease-risk
Potluri
beadarray
7.5g
temperatureshift
Het-Hom
pTa/pT1
L344Q
pathways14
Me17
kindreds.4
WHIM9
.Shield-1
Hsp104-positive
6.31
pathway.46
MCL1-dependent
ftagmems
onco-
ICL-agents
.Seizure
GLM-approach
round-shape
HM-1
1941
E583D
RG-26N
transfectionof
S768_D770dupAVD
otrIR
p=0.09
R2339_splice
red/white
aconserved
32low
Hec-1B
sR1
gastroenterology
5.0c
babylone.ulb.ac.be
target-selective
chemotherapy.4–7
abraxas20,21
IG-MYC
cells—RPMI
AlF3
–,3
phospho-MAP-extracellular
8.2
Lys.Arg
Allin
16p11
ABI7000
p.Thr241Arg
mll3
934,429
295:139–145
MID1
1I37
XPC–hHR23B
Sensogram
Catlett-Falcone
Ikk2-dependent
FASTP
Aptag-1
Inter-Alu-PCRed
Q563X
adenocarciomas
Thr85
receptor–independent
16/28
Jak-Stat
T204D
≈2,000
p.S635_L636fs
promoter-intron-IRES-Neomycin
Asp-844
SWI2/SNF2-related
TAT-GRE2
388.9–639.0
inner-membrane
RECIST
PDGFRα−/−
sum/Kruskal-Wallis
endomembranes
/6-well
PGK–neo
amplified.In
1970s
5´
8.5
AEL
pY570
2411
specificity22
in-depth
EcoRI-PstI
cycle.27,28
ligand-inducible
CDKN2BINK4b
1.531
cells.6–8
malarial
ETV6-NTRK3-expressing
p536KR
Salovaara
19.19
PROTEAN
SOT
thrive.3
10H11.E12
MLL1/MLL2
293T-derived
granulocyte-lineage
high–molecular
Myc-Tat
Noncoding
UVC-light
alterations6
Immeditely
SADDAN.23
10.1158/1078-0432.CCR-15-1046
ENPP5
Chothia
KRASG12V-melanoma
SC-123
2005.rr2005
1.1–59.3
27c
PLCgamma-PKC
10.1007/s00384-015-2448-7
65nM
15087
CKIe-dependent
Non-induction
SpectrumGreen-deoxyuridine
127–217
FL1
RP11-167C7
WW94
.0.0
-p21
.Goddard
TKD-positive
D201G
DNMT3B-derived
.AC004518
Isoflo
cascade/apoptosis
Dpc4flox
Myc–CaP
elegans32
Apaf-1
v–J.110
nizing
genito-urinary
Teleost
p52/RelB
no-wash
chemicals/reagents
20mg
cellextract
680
line.22
pAAU-Ha-Ras
lung/colon
Casassus
NCKIPSD
tetracycline-withdrawn
13-20
.Smad4/PTEN
upper-shell
HKY661-4D
KOPT-K1
p\0.002
IRB-protocol
NM_032682.5
.Extending
2538
exon-scanning-based
polybromo-1
N-nitrosobutyl
risk3
27.2–192
15918-014
mutations.18,21
poly-d-lysine
Jeggo
Mucosa
5–7
.Chromosome
stimulating-hormone
G.Evan
Germane
HSVCSTSSLYLQDLSAAASECIDPSVVF-
UHCA
CEL-NOS
AY102071
FGFR3-mutant
Map2k4
MDA-MDA-468
ORAOV1
6C–6E
TRP53INP1
590885
cladribine.27
961-1008
protein-encoding
T2N2M1
11720
progression.4,5
ubiquitin-mediated
fMLP
RP11-1064P9
TET1-specific
97–684
Rho/cdc42
procedure-related
D10S226
MEN2B-RET
Biopolymer
32/35
L-428
0.147
models.All
multiangle
AlignGVGD
GAAACGCAGCGACCACACA
hypertrimethylation
non-CDKs
cases12
CAGGAACGTTCAGTTGCGAAAGCA
Arnau
Integrins
CHD2
myc-tagged
+79
Savio,1
A28
EML
shRANs
1397
Nanfang
ALKF1174L.6
.Computed
23-28
Ser385
10–42°C
3TH5
2239T
otherphysiologically
TGG-ATT-TCC-TTT-GGG-CGT-TGG
Cavalli
aspart
Ras-initiated
1,950
.PTENdeficient
Melan
B.A.
IVS6-1G→C
ETS1/2
180190
HTLV-1–infected
2.24-fold
Lok
MSH6-mutation
LUAD-FH5PJ
thrombospondin-mediated
carcinoma2
$
WDLPS_04T
I290T
∼68
Ki67-low
p.K1436Q
.Bouin
leu2D1
Juselius
MEN2A-
pathways17,19
+13-18
1575-1593
10e
markerselected
MPN
pProEx
−1.35
iDC
leukemia,13
1d.f
c.514C
p.F156L
Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys
p110β108
DMAP
patient,24
context.21-23
SCBT
15/46
metastatic/recurrent
dimerization-activated
LSM
R271
.Formally
NHRI
pro-metastatic
3‐kinase
BIOMED-1
p48-specific
water-in-oil
V5-antibodies
andeach
anticentrin
hyperparathyroidism
Double-headed
I945T
immunocleared
SOCS-3
.Low-resolution
-^
488–coupled
C251F
HCC-Specific
CLCN7
miR-144
-beta-gal
Hs00236911_m1
pcDNA6-ACVR1-v5
syndromes28
SCF/c-kit
AKT1/2
possessingover
phenylmeth-
//mct.aacrjournals.org/content/molcanther/12/2/220/F1.medium.gif
JNCI
neovascularisation
previously62
M.F.B
36,000-dalton
IGF-interacting
GACCATCGCACACCGGCTTAACACTATCATGGA
anti-pT202/Y204-p44/p42MAPK
SureSelct-captured
G4050
Dnmt3b1/3b2
Sytem
image-middle
FQEA
Differentiation
16078
21/48
54.5
c-MET/HGF
GES-1
STAT1,7
LCoR
P53AIP1
Krizhanovsky
1,147×
CCAGACCTTATCCAGCTGAGAAAGAGAGACCAATACTTGATGTGGTTG
GFRα-1
∼12-fold
KPT-185,10
G3930A
UHMK1
Perrin-Vidoz
endocrinologists
A44V
.TG101209
FGFR4mut
Gapd
FIH
Biomarqueur
pLenti6.2
flippase-mediated
SF68
Fiscella
11‐18
.DME
StrepII-CycM–producing
dominant-negativeADH-p53
BYL-719
IDH1/IDH2-mutant
guidelines13
co-segregates
BRM-2
phospho-Ser327
D277N
P1291
\0
GUCY1B3
previously.45,46
death-receptor-mediated
7/70
R122W
0.130
EndoRecherche
S288c
Rab4
397mel-b-cateninS37F
0.375085977
.06
AWD
Br48**
tetra-primer
3o
5577
fulldose
0–100
β-propellor
10-Mb
cochlea
L128F
p90
CAGGTG
dimensionless
ab2187
RP11-24A11
a-ras
Ced4/Apaf-1
Rel
MEN1,9
1.18.0
E47M
ProTable
-1164
1-μM
D19S884
Ras-activated
4/27/00
phosphorylation-dependent
M232
SBN
SFB-PALB2
G466VB-RAF
codon-12
Birc5/survivin
ml.FGFR3
Rac1-GTP
pRS315
Bcl-2-Ig
7-2
.SVEC4-10
236A
buffer/g
syndrome5
phosphatefreeDulbecco
.HN-K-rasG12DSmad4+/–
His773_Val774insProHis
HLA-A*23:19N
P*79-P-K-K-A-R-E.V
CL34
1059C21
non–cisplatin-eligible
than20
tet-on
Hoeller
MARwiz
p.Arg979*
K.S.
SE-dual
TGF-β/Smads
17,390
unappreciated
lympholastic
0.2672
124.6
L414
pneumocytes
type.
BTB‐Kelch
AP23464
BCL6-binding
Quickchange
pBabepuro-generated
T47
TP53-proficient
Ini1–β-galactosidase
ATCGAAGGAAAG
P933
-z
.Sulforhodamine
ocular
509,1995
.BONE
ASP-PCR-DNA-FLA
tetrachloride
ΔCCDC170
Arg174
≈21.5
*Cbl-c
phosphatidylinositol-specific
ANGIO100
2122
45fold
candi-
8/246
44139
Techmate
pvclust
imatinib.67,81
pREP1-VHL213
CDK4-MUT3E
p.Arg87Trp
Bioworks
EOC7
HLA-A2-
nucleoprotein
themutation
Eosinophil-induced
writing.Standard
background-dependent
fusionPPARγ
R131
anti–rat
6C/G
pSLIK-Hygro
ATR-A1
19.5±1.6
Powerplex
screens1
PLX4720
zonula
CRE
.Ratio
andp21-associated
Q56_G61del
before.22,28
−4.00
18Liver
.CNC-C
p-Rb
c.1832delC
82152
Burkitt-type
cases.5
type-2
pDDR
-CTAACGTTCGCCAGCCATAAGTCC-3
CD79A-TSS
MEK1-specific
vitro.8
132/1016
NM_001014161.1
accumu-lation
0.0399
Pat.2
M13-tailed
30ng
ROH
N314D
gtttgtgaggccgg
SPT16
Mégarbané
ROSJ
34-35
Diffuse/mixed
3.6–34.9
Curis/Roche
PPARα
S119–S139
IKBKE-specific
L391P
Hs00167041-m1
hormone-induced
U2AF65/U2AF35
constructs26
.Neoplasia-associated
CNA/LOH
32,74,75
5′-GGCCTGCTTTACATGTGCAA-3′
/phosphoinositide
M299I
pX
Sp/XKLF
invasiveness.1
degeneracy
.SNP
pGIPZ-KDM5A
MBO2
90-mm-diameter
Gly49-Leu-Leu-Glu-Lys-Lys-Trp-Thr-Ser57
methyl-phenyl
Zeuthen
SHI-1
B-Raf–Myc
5′-GATCTTTCTGTCGCTGGGATTCTCTTGCTC-3′
non-Core
immunohistochemicalanalyses
gene.11–14
.Bound
pancaspase
RB+/+
MicroBead
0.682683
24/106
sc-246
Conclusions/Significance
DM-A
HSRRB
Fgfr
ULS-1
IFDIs
re-probing
Tween20
side-chain
Mapk3
MDAH2774
r291_464del
fsingle
lucifcra.se
chemotherapy.5,6
disorders.Sos1+/EK
Menoyo
demonstra-
GGATCGGCCTC
long-lived
Ex11-R
ADAM3A
Antibody-antigen
PDGFRA/4q12
D1b
162R→I
BRCA1/18
B-elongin
n=327
intra-arterial
trk35
2.76
34°C
JAK1-
3082–3086
GarciaHiguera
neo-marked
anti-Rad54
TGTAAAACGACGGCCAGTCGTTAGTGGAGGTGGTGATG
ERK-substrate
Rangarajan
BMS-777607
Fig.4D,4D
PRISMTM
Q342P
Fig.2D
FANCJ,22
3–22
ROSAmT/mG
IgL
UIM-mediated
RHSRNLQLMEGKEPATGAKKSNKPNEQTSKRHDSDTFPELKLTNAPGSFTKCSNTSELKE
TEL/
S1294
RNALater
5′-CAGGGCTCAGGTAGACCTTG-3′
Xrcc2-Deficient
Zfhx3
-CTTGTGCGAGGTGTTCTGC-3
Bebermeier
1pkzg
.7976
auto-inactivate
inter-receptor
coalterations
transcription190
CD8-fluorescein
34/39
K618A/R487X
.Analysis
1495dup
Y980
Promoter-Reporter
S3∗
TRCN0000006557
aurora2-
c.620G4A
R132H-negative
expressedin
Translocation—The
R292
IVS–2
task-dependent
382
Whitehead/Massachusetts
94–10
counterbalance
IVS5-2delA
P659L
ultrapure
410–479
LPS-mediated
reproduced.The
nonsense/frameshifts
18.45
350-kD
publication.19
less-soluble
CA192643-02
Wiesner
5′-CCACATAAATATATTCACGTCCATCTGGGCTGATTG-3′
CCCGGAAGAAGCGCCATCTCCCGCCTCC
1580WÜ
−2.5
BglII-XbaI
214162
.Hybridisation
SNR_red
96-reaction
andpreparative
fygpl
.Anti-V5
Santoni-Rugiu
EGFP/Bcr-Abl
TGTCCC
NspI
LC3A
p53ΔE5-6-mediated
multigenerations
BHA
Subgrouping
/highwire/powerpoint/139513
.113,114
BGJ398
non‑squamous
Svedberg
Bisulfite-treated
FLT3JM-R
1243-1508
124Gln–215Ser
B*1579N
.Marked
8–98
Let-7d-5p
anti-SUFU
Thr539
ATP/Imatinib
24°C
phospho-Ser9
Ashmun
WT1-mediated
764-802
Cre–mediated
Bead-immune
930–940
FGFR3-TACC3-initiated
factor-nh
TCA/chloroform/methanol
Vignarelli
1,2,9-12
FAT1–FAT4
'memory
31/33
H4K8ac
de-capped
INDELS
ES6
BWA-MEM
PRR
7140
TTGTGGAGCCTCTTACACCC
/TAT-
RBM10-depleted
19.6Splice
.Trizol
UGUAUGUA
XYFTQTLLPGLAG-
V248D
signatures.6,7
bIf
0.59–2.96
fusions18,19,30
prominin1
1993,1
GISTs29
CO9
crossreactive
Δlog2
rel
.5506
β-NADP+
spot-like
γˆt=1N∑
.RhoA
light—these
VAIKEL
Asn-691
.Had
regulatous
6-replicate
His6-Ub-conjugated
IlValue
organization20
c.182_183delTG/p.Leu61GlnfsX13
20-nucleotide
Lappin
293GPG
Tot
5′-GGAGTTAGGCAGGTTAGGGG-3′
2–4,13
.28,29,32–37
Thr410/403
.LY2940680
MDA-MB-453
Amgen
2742
CTTTGGGAGGAGATGGTGG
signaling93
gressive
AMG888
U87MG.U
study––n
0/52
169–251
MbI
Schwartzberg
SZH10
observation.4,36
pan-RAF
V411M
carboplatin-resistant
p110α23
G164V
coimmunoprecipitations
dismutase
RET-Men2B
Sulfosuccinimidobiotin
disease80
.9502
ECTOPIC
G524C
1.12–2.54
Co-amplified
.RUNX1-I42R
D761Y–containing
organisms6
R59G
Results.
.Isohemagglutinin
∼770
target.32
POLG
vivo.36
0.62–1.31
Tavormina
4.054
c.4550-4552delAGA
π−π
waf-J/cip-J
cyclohexamide
5′-GGTGTGTTGAATCGCCTCTTCCTAGGG-3′
Bretonneux
interdependent
double-strand
E2WT
RAC1F28L-expressing
A-induced
amodel
fluorochromes
c-kit/SCF
CH542480215
L276
primase
p.Q699H
.Observed
Thr-230
115256172-115256192
proteomic
angiogensesis
R594
leukaemia.Figure
.Acanthosis
4.5–5.5
expression115
suspectedHNPCC
MCF-12A
0·0
cross-interferes
.T878A
nymc.edu
Filtermats
I1349T
D6050
CYLD
sample/diploid
.13,61
769A
CDK4R24C
LC448
10-cM
damage–signaling
HMS388
~3400
TheraScreen29
17557914
Table-S1
ENU-mutagenized
Non-cancer
.HCC78CR1
phospho-ATF-2
Harvard/Partners
forlac
88–98
.24,28
Mittl
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benzo
L281S
primerX
N1-N3
5′-GTGTGCAAGTCAATCTGCAG-3′
−1.04472
siSAPS
EasySep
0–32
I516N
BRAF-V600E/L505H
ofEMSA
RUNX1-32F
c-myc/pim-1
H126
Preimmune
AF-coated
re-introduced
Pn0
phosphotyrosines
EF7
Tarakhovsky
ataxin-3
CAGGAAACAGCTATGACCATACCAAACAGTAGGGCGAC
5′-CCTTCCTTCCTGGGCATGGAGTCCTG-3′
Peds-MiOncoSeq
.Loop
Morotti
ΔG466VB-RAF
5′-CATGCTGAGATCAGCCAAATTC-3′
ERG-induced
adequacy
TCGA-27-1835
G12DKras
E113
Arg789
BRCA1-/BRCA2-defined
1=damaging
A-bomb
10.1002/ijc.28106
75.59
BB74
DU145-luciferase-tagged
cone-specific
E545K/G
LTF
45.0
7•68
HCC1395
wtBD12
1Generation
fgf3
Breakdancer50
PAX519
Beas-2B
Fertilization
uroepithelium
.Kaplan
described.9,10
Y35A-Y35A
BCCS
chromothripsis.21-24
pRCCMV
Chaumeil
22,92,93
substrate.CDK10
V157D-overexpressed
1811
MLL1-dependent
SVZ-A
PJS039
Brd4-associated
–102.63
Essen
R462W
aminoimidazole
shTrp53-shRen
PDGFRA-FIP1L1
ZeptoMetrix
–26.0
suggest-ing
estradiol-17p
18·4
BJ5464
Chordoma
1995b
discriminators
´
Tyr779
08543.
2×106
S4C-E
1,895.6
weight35S-labeled
L396V
stopl
V60
RByl59
®nger-BAP1
methanol/water
2P
M9
Heterozygosity
nonbenign
ChemMate
1.01–5.11
β-gal-infected
activity106
JBP1/JBP2
transformation5
N228S
5.3,5.6
observed45
315–399
p.Lys664Alafs
pFL700
HEC-59
one-third
HMGB
sod-3
sc‐25778
protein-1a
post-binding
5′-CANNTG-3′
M0725
delAsp770insGlyTyr
−2.37
MLL-lacZ—all
LS411
.Neurologic
.Turnover
TGF-β-stimulated
5′-tgtaaaacgacggccagt-3′
fortransactivation
NM_009293
lentiviral50
rs1922665
.MEKis
Computer-Assisted
SND1–BRAF-harboring
avenues.Figure
cMET-TK
T80E
Saluto
VFGFPVHYTDVSNMSR
.ErbB2-V659E
BMP
Neuroperfusion
endonulceases
htrfTM
5/99
cell-injected
tau=0.462
214,215,216,217
Chizosaccharomyces
67
.6A
anergic/inactive
RET-PTC1
SCLC-tissue
practice.34
Bcr-Abl
shortsighted
.Akin
Pharmatech
phospho-KIT
siEF1
abovemen-
plasmocyte-like
excluded29
0.826
complexes12
Akimoto
2766
cross-reactivity
WAVE3
anti-phospho-Myc
R89LRaf6KCAAX
43˚C
Prism®
H878Yelicited
S123A
17-α-methyl-3H
tcccag/ATTCGT
Gz9-K-K-R-S-K-A
2000TM
Shinjuku-ku
apoptosis
F46
Phosphatase-Independent
BAP1.14,24
CD41-
Ago
0.868
Culture—F9
1853
1371
Rotman
.Depending
V1809F44
streptavidin-APC-Alexa
Ras2
147/412
Lymphoma
negativelyregulated
70.7
spindle‐cell
pNMUl
pY699
Centricon-100
t91
p.Gln649
Spirio
bromodeoxyuridine-propidium
DeletionEuropeana
pMJ30
Nucleus
pRAF-1/GAPDH
SK-PN-DW
AGAP2
lines—H460
l6p
anti-HLADR
adduct–forming
report4
Miyata
Yunyang
dose-rate
Hs_FGFR4_6
CRISPR/Cas9-directed
/serous
cys630
or55°C
S1043I
.PFS
control.Sequencing
Phrap
mutation-positive
MITF-mR217Δ
neval
examined.19
DC-induced
Luukko
epithelial
sc-1559
Ncol
Val126−Ala133
Abcb1a/b
pLenti-DSN1
Ex7del
wherek
AK050511
MSTO-
iin
FOXO1-transfected
deletions/duplications
21,173
c.3194T
BRMS1L
Polychronakos
immuno
CLB
receptors,19,20
FBW7–NOTCH1
2OG-dependent
Smad2a
L269
D415EfsX20
Structure-Function
μCi
REGN1400
speckle-associated
amiloride
D2-40
Jβ1
.quantification
transcriptase-mediated
ChIP-Seq
pCMV–Myc
activation.20,83
7900HT
•Kapp
S4B
closely-related
Four-month-old
epithelium2
MLL-AF9–induced
Stat5B-deficient
.Wagenmakers
mA259Raf-1
R130L
INTS4
K788E
cytopenia
rehabilitated
E2F1-dependent
EDA2R
3130XL
14–25
pmemd
substitu-
TCRbrearranged
elements.35
inhibitory.20
obtainpADH1p53V143A
Acetic
cardioprotection
CFTR
Ha-Ras7
GWRDGSG
HA-BRAFR188L
BII-2
V769_D770dupASV
ΔR
M.B.Y
p.Y89H
MLH1ΔN
74,722
86–98
myeloma.44
5′-CACCGAGATTCCTGAGAGC-3′
pl5
Erk2
TR-cofactor
Albrechtsen
5284
Boguski
HT-29
4peaks
Marseille-Luminy
Hist1h1c
Treszl
c.1235T4C
RG-25T
peng_sheng-bin
lipid/siRNA
304-517
Bcl2l1
07038D
.Reverse-transcription
VI-26
MSH2.35
Pediatrica
strenuous
objective.1,2
Marzo
84,107
−24.1
miR-520
SUMOyaltion
MutPred,29
LDS1
NK-AML
exchange-induced
Lysosomal
H-G.
Deparaffinized
coverslipping
GCTCAGCAACTGTTCA
pCDGATA
8/28
TaxolÒ
romidepsin
A49F‡
5Pediatric
phosphate.For
μg/each
346-bp
1U
M-G.
Domin
documented,26
caspase-8L.HS1
W557G/Y578C
RBD-specific
IRF2
87.66
-GTCACCACTCGGATTGCCACCGGTGCCTCCACCCAGAATT-3
5′-GTGATCCATTGCAGTGCG
llow-up
N1273S
profiles29
single-residue
EGFR-E19R
MADR2
Trp-277
promoters.37-41
sc-271270
DPF2
GSE15688
ERα/AR
serum-starved-amplified
Ser371Cys
iron-loaded
geneexpression.The
GTATGCCACATCCCAAGTGTTTT
0.00858
cetuximab-based
.2016
\60
.Ohta
R2016W
c.1439C
.Tao
ErbB2-activated
CLL,22–28
.Points
–CSF1
glycosylase/lyase
FIM
p16INKA
estrus-phase
ARID-family
0.98*genotype
Predeveloped
HCC-366-DR
cells102
Genital
286KB
cytokine-receptor
JM105
LAD1
Thesedomains
in-cis
idodide
MEF2C-transfected
PMF.8
G~~~~~~~~~
dnaQ+
J21-EGraphic4-2A
LC58
lissencephaly
42.To
TOT-bound
L226P
4733
expressionoccurs
photodocumentation
WHS-like
6.96
exon-deleted
GJC1
Sawadogo
effector-
c-Met/HGFR
Microfluidic
D175Y
.GM-CSFR
198,359
p53/BARD1/CstF
phospho-motif
p.R315*
HIC1
−174
94805
Moasser
.Germ-line
exportin1
A22
S2.1.1
AAD00168
NAV3
Tyr823
P9906
multiamplicon
1900TR
n=312
Num
70Z/3
50.
p300.Figure
junction-spanning
dysfunction,6
Roughan
2.2–18.3
absent39
CCND111
6–7
.Population
779KB
GAG-AAA-GGG-AAA-AAT-AGA-TCA
lung-cancer
tumors19
.Kelly
+––+
BRFF
pLenti6/UbC/Myr-HA-AKT3
BRCA1–R71G
superstardom
reported5-8
mutant-enriched
120-fold
.482
Sprouty1
0.57–1.16
isopeptide
kinases.9,12,15
P1/P4
bothcopies
TMPRSS2-ERG
Rogier
Bombled
analyzed.RESULTS
recov‑
5′-CTAGGTAGGGGATCGGGACTCT-3′
anti-PECAM-1
NS.3
101–300
LL3=LUX-Lung
CFK2
Pair-interaction
Axin2/Conductin
./Total
§The
CREST-positive
nephrons54
LipofectAMINE-Plus
//www.jimmunol.org/
IAK1
5′-TCCCGGCCAGTGTGCAGCTG-3′
FL-Jade-1
10.1002/jso.20700
Cbp
Postoperative
MLL-ENL-positive
Ala93-Ala94-Ala95
respectively.2
-TTTGGGTTGGCTTTTCTTTG-3
p-ERBB2
6–17
otorhinolaryngologic
CDKN1B-R2F
N985Y
D593
PRKCB-inhibited
Raffioni
.SB590885
MUT3C
Ser314Phe
nocodazole-free
syndrome-X-linked
SND1–BRAF21
STK15
.Mock
one-trial
.Ingenuity
Polyfect
.MLL-EP300
inositol-free
dimethyl-pimelimidate
584-Phe
translocations20
appreciated35,36
factor–starved
PESTfind2
E375K
Genomed
-2100
anti–MART-1
carboxycytosine
LSL-N-RasG12D
Y42Cd
pIRES-hrGFP-2a
5′-GGTTTTCTTTTCTCCTCCAACC-3′
Hereditaires
30µg
A_52_P299915
−/+
sites/242
ClinicalTrials
G-amplification
pneumocytic
mutationAll
Iso-fludelone
5'-TCGAGCAACGACGACGAGCACCTG-3
9p21-22
17mers
3.67
.R882H
Position1
.Oligonucleotidesynthesis
C1
or1h
flag–LKB1
Commensurate
PKC412-
nucleotides−
FOP-FGFR1-mediated
S404A
intra-familial
Baban
80/25
0–3
G178D
Leenders
.Small
carcinomas28
Gln257
IgH/NSD2
pDSRed-C1
RNAEasy
.Asian
lines33
Glu255
10.1007/s00277-016-2869-6
R359X
ATP.rad54
Smad3-/-
s1s2…sm
anemia-like
6Gy
131-fold
R40W
Cristália
p.Ser1036Pro
damage14
E76K/Q506P
Y35A
5′-GTGTGTATCACGGCTTACGG-3′
oncogene-addiction
f1–f5
Yokouchi
Leu1839
3mg
approximations
Val147
Figure5C5C
MDAMB453
typeand
EVI-1-mediated
R378xxLxxVxE
D816H/N/Y/V
stocks.35
preparative
73-base
sonidegib78
1.66
SARA/SIM
Idh
30/32
SCC-
.invasive
Y85H
.Anti-Tyr
Monoselective
22.0
CTCTAGTAGCTCAACTGGAT
800-bp
Marligen
EGFR-TKD
D375Y
EWS-ERG-
wasanalyzed
15–19
Thenucleotide
A_52_P180741
p=0.023
100μm
SOCS3-mediated
Lgr5-EGFP-Ires-CREERT2
recently11,12,29,30
bp21
NU/NU
co-amplified
categorise
691
EBPα-mediated
C1-5
0.538
syndromes15,21
P491S
0.16-0.31
V5-FLT3-WT
Leu729GlnfsX6
Warts1
Stageb
p.Rl67W
cytidine
Lebedeva
5675
FGFR3/G380R
.22F
DIMHD842-846S
capillary
NM_014159.6
rs676387
gene,6
expressed13
-El2
Bean-shaped
RNAfrom
T323A
ECC4
5–35
Brip1
J-810
CTCAGGGCAACTGACCGTGCAAG
45p21WAF1/CIP1,46
SOCS3-R71K
0.8×MDE
1090_1271del
TMA-based
.SeaKem
ATR–KI
ratelimiting
auxilin
aconsequence
96/384
theirtechniquewasbasedon
P382S
dorsalized
P=0.023
merestinib
6–38
CD127
9/1,212
Stry
cM/Mb
Kopetz
170-6516
non–BCR-ABL1–like
Asparagine
Osher
EN-V80E
respectively15,16,17,18
BIRC2/3
zipper-like
M/40
2.65–2.4
radiology
13-15
KNTC2
TAF15-NR4A3
88.86
-TKD
620/507
KWTAPEAALFGRFT
*represents
AG490
12/78
no-response
cancer-constraining
MFE-280
S682C
6×10
GTCTGGAC
MutBS
96-well
.download
.Hotspots
adhesive-coated
neuronal-specific
failure.33
25,30
tox
endoproteinase
A767INSASV
MLTC-48b
identity.14
V224
Acturus
mutations—a
cells/mouse
abl-deficient
~so
co-immunoprecipitation/Western
figure2A2A
total-ERK
Theodor-Kutzer-Ufer
Vlaanderen
Marcu
orSma
bioanalyser
estroma
GAGC
L5
RhoA‐activating
γ-S
approximatelythe
98
p53TD
m/63
G892A
sta-
P611H
GST-AKT
0.06-1.30
Genebank
10a–d
Y1349VHVNATY1356VNV
penetrance5
5'-gtttgtgaggccgg-3
elec-
JH4
cytospinning
cell-type-specific
TCRγδ
ge-
Axin/APC
PI5P-sensitive
receptor-bound
.8⇓-10
Leu461Val
c.224delT
CAMK1a
neuro‐cardio‐facio‐cutaneous
cancer.23
A242V
1550
tumorspecimens
.HDAC2
–dependent
9700
orTGFb-RII
11RUNX2
17.65-fold
pathogenfree
19.52
spectrographic
NUT-interacting
preadipocytes
Fb
lines.92
IRES-β-geo
.Aminoguanidine
cir-
Tyr866
mH2b
00811
.NMS-P626
+/V14I
locus,3
postdocking
RSK4
132:952-9
M2=19
miR-714
FHA-phosphoprotein
1p22-qter
C5–p16
in-
48.0
identifi
complex8
β-box
GSM458998
—has
grammed
MLH1-associated
PDB:2SRC
adenocarcinoma
14q13
mibolerone
CDKL2
Demultiplexed
del746–752
estrogen/progesterone
growth.13,60,132–135
inducibility
8722
Gal4‑ERF
times.Published
CTEP
FLT3-ITD,31
.Adipocyte
GliZF
RAS-GTPases
R270H
47D
rules41
.Abundance
MSIâ
protease/integrase-derived
comSOTO
HA-HIF-2α
.1375T4G
Rhofamily
32,83,231,549
HSC-suppressive
0.00561
P-TEFb9–11
MYST2
S5A-C
p67/p73
Melan-A/MART-1-specific
P1073S
referent
macrophages.30
HIF1α-myc
Theurillat
136/120
RP11-17G12
Ser807/811
FigFig3G–I
.NIBP
adenovirally
pod-Arnt
lpll-l2
3232
Phe1761
counterparts.35-37
10−06
cancers36
graft-versus
non-operative
-2LL
2mutation
pCMV-XL5
prewetted
Arg256
19350
MCK
aneuploidies
-granulocyte
Gö6983
cancer-conferring
.Microfluidic
A.U
Dpn
2.694
2.0.1
gefitinib.17-20
Tamkun
pGBT9-
c.3055C
2.162897367
co-submission
resistance,9
mutants.9,11,13,15
CGAGAACGGTGGAACTTTGAC
domain22
lethality19
epimerase
COUHES
5weeks
D16S767
ash2
M249
1.6.3
del13q
immunohistochemistry37
0.1–30
PPEMH1
16.5–18.5
inplasmid
.Porta-Pardo
RT-for-PCR
45–49
.Portion
K–M
ΔTmobs
Epithelium-Specific
​Fig.33
.RCJ
14-kb
wwp-Luc
A*0232N
64-7anap
Non-high
Desbarats
proteins64–66
Patient-Derived
SP44
PDGFRA–positive
f/47
AML/MDS
GGCTCCCTTGGTATATGGT
TBS/Tween
S-Protein
CVH
thirty-eight
57/565
12-Well
LAD-derived
.Anti-HER2
37070
p.T244P
survival.1,2
5'-AGACTTCTTGCAGTGTAAAC-3
.TRI
GrowthThe
IG32
=0.7
R339Q
16-Lys
Massi
57/82
GAAGATGTCC
I52A
Stat5.19-26
19.95
Wu10
syndecan
ABL.10
tftAtttti+ttthtft
1CDZ
5′-ctggtcattttgagatgcttgcaat-3′
phospho-AURKA
extramembrane
mean=59.4
IKWTAPE
24–31
NOTCH1-independent
.aneurysm
.R-CHOP
f10
P267
theAML1
61–131
17492
test33
shRNA–resistant
eFluor
.Mary
repair,26,27
TGF-β-related
stages18
C680R
-GCCAGCATTTTAGCATTACTTC-30
1223405
79–290
1.08–4.35
.P.
YP
QFDP~NV~C
2696-AA
sequenceof
KRAS.31
3152
0.4–0.8
DRB4*01030102N
anti-Tyrosinase
non-BAC
domain,1–4
γATP-P32
Msh6G1137S/-
.DDR2-Transformed
c.2192T
601200
ARF876L/T877A
Lanotte
cancer.org.uk
MSI5
SNPa
.Cadherin-mediated
Tyr99
11-week-old
YUSIK-BRAFV600E
anti-pY1034/1035
GSK-690693
c.594−4A
element12
NM_000249.2
SCD-only
pyrrolopyridine-pyridone
S79X
968/1352
trxb11/trxJY16
Pu=A/G
‖No
.Mutant-MEK
anti-HA-Agarose
elucidated8,9
.Tn4430
nonproline-directed
2-aminopurine
SNF2/SWI2
.Gonzalez
PMB11
Sedivy133
0.001–0.1
8-89
EWS–FEV
μMconcentration
b-2
λ-MYC
extracellularstimuli
fe_p53s
pCMV-p53-R175H
with35S
7.4
Mizui
5.5.3
Q0–Q1–dT18
repectively
pnas.1321155111i8.jpg
Anti-cdk4
R237W
R87Q
—constitute
124,127
BMS777607
invasiveness,19
ATMDS**
MEXF
p107-mediated
CA72597
p.Arg1331X
11q21–q23
.Tukey-style
DEL19
model25
.Fig.5A5A
coexpressed
fibroepithelial
counteraction
T790M.18
HindIII-Xho
13137
×0.52
M243T
3E–G
1.418
LEU2
signal–regulated
†Cells
formView
17p
Huh-7
pCS2nrf2E81G
ΔG466V
EBV-LCLs
CFU-GEMMs
TNF-induced
CRC68
Unported
pSVβgal
D905Y
SA25′-ATCTCAGTGGTATTTGTGAGC-3′
gold-standard
qB3
424–41
R250P
OAW42
10.4-fold
-GGTAGGGGAGAATGCGACTC-3
.TSA
ras-derived
-threonine
gene.61
TGGCAGCCAGAAATATCCTC
Hisa
ARBS1
®ngers
97.12±11.78
SP-53
0.3947–24.25
161,250
stimulation.42
Secretome
S2179
VKD
1,541
56772345
I767M
Rodriguez-Alfageme
and1C
Caspase-Glo3/7
sKIT
Oken
described.28
Hsp90/
Nestin+/GFAP+/PSA-NCAM−/Olig2−/NG2−/CD133−
CD4-enriched
trans-reporter
temozolomide-based
.Heterozygosity
antitumoral
E.V
.R265S
18/39
Axl-specific
Receptor-type
Akt2E17K
V319fs
cis-platinum-containing
Genetex
Tel.Test
Idh1LSL/WTLysMCre+/WT
c.306
sqtraqnd
1.8-mm
p16/CDKN2a/b
pGEX6P-2-GNAS
J.D.B.
GSE29079
MBNL
CTDΔ
CHLA90
33,36,37
13961
1046
Vac1p
HEK‐293
mant-GTP
IDDM
24,26–30
macromolecular
4K
215K
DSE
year4
NET-gel
.Biologic
females12
.1489
4/
marrow28
pCLIP3A-myc-CARD11-mCherry
5′-TCTCCCTCACAATTTCCATCCCAG-3′
CD19+CD27+smIgD-
arylalkylamine-N-acetyltransferase
beta-2-microglobulin
.SOCS
6–21
positive-staining
types7
AmpFLSTR
Spain30
R69W
1.19-6.59
26/M
2-3′
Merajver
cases.12
GC-clamped
R117A
4NQO
GCAGCATAAGCTGGACTTCAA
B-Raf−/−
Pikman
.Etienne-Manneville
Schnepp
p-STAT3
ZNHIT1
.577hMSH6
PDGFR-α-null
I188F
A-loop-derived
Pro794
FASTACT
AXL-targeting
61-94
predisease
Th1-oriented
CIP1,46
RAS-activated
Beckstrom-Sternberg
Homodimer
Bruice
pDCR-Ha-ras
releasecompared
.Ascertainment
cright
200D9
stabilizethe
-dependent
1.02
cdk6-F
sc-5611
−3.04
0.10-11.89
PCNA-dependent
0.3-ml
acetaminophen-induced
Single-base
Shipley
TTAATACGACTCACTATAGGGAGAAAGACGGAGCTGCTTCTCGGA
pGRR5-Luciferase
.Timely
1-32
N1068fs*4
WHSC1L1-amplified
C1839A
.Naturally
Flt3ITD/ITD
lacZ−
Y1294A
thenmaintained
HA14
unitMononucleotide
inhibitor-binding
.Lymph
Y324
989
IBGC4.7,13,14
3670
.FGFR2-BICC1
MMP8
Genome-Restructuring
p.Ser1253ArgfsX10
SSM
T2484
karmanos.org
80–8000
mshri.on.ca
0.0174
previously-defined
HETEROTRIMERIC
PDGFinduced
.57,59
Fig5I
DV-90
Ptpn2-B
80s
class-switched/memory
NBL
USCO/CAP
C2orf44
p.I72fsX7
dendritic-like
electrostatic
007679
D'Andrea
+/Mod–severe
-pBS31′
Algire
LNCaPcells
Ser183
mutants/ERBB2
rs149364215
EGF11‐13
Bgl2-Smurf1-F
N16I
pathway.10-12
MUT8
24,11q13â€
INVaF9
GST-CrkL-F
organizerFGF
.Valve
Kallin
cerebellum.5
Src-inhibited
5′-GGAGTCCACTGGCGTCTT-3′
MDS-RAEB
ophthalmologists
2/59
PtdIP3
8095C
H398
phospho-LATS
GCTGAATTTTACCTCCTGAC
16–85
cytomegaly
=S
nuclease-sensitive
Monnerat
28-wk-old
small-bowel
cc-13-834-g6
clear-bottomed
5′‐TGGGGCCTGGGG/5′‐TATTCGTCCACAAAA
E-H.
GliTy1rProPro
0.23-1.04
H98Y
methlycytosine
Cat.4304437
nihms703640f6.jpg
Medecine
129S/Sv-PRM-Cre
R196W
V520F
oculo
4-phenoxyphenyl
1,646–1,859
C124N
2p25.1
rs6721961
self-assembly
A210V
hydroxyglutarate
Thr308/9
autosomal-dominant
3'-ERG-exon
GeneChip®
leukaemia.5
ramucirumab40
FGFR1-highly
localization-
1E-G
allotransplanted
StructMAn
.where
28681
E346A
NCT01249547
Issaqua
ubiquitinylation
AILT
neuropsychiatric
carboxyfluorescein-labeled
breaksOne
FluorSave
Nopp140
co-repressed
EN3HANCE
1422delT
Plenge
pro-angiogenic
ActRIb
AsnVaIS
cgt
BrdU-stained
Crenolanib
Cbfβ-deficient
Eukaryotes
Elghezal
l0â€•
13q13–14
N554S
Bandshift
PTENDeficient
C−F
IVS3-1
patients43
Dalziel
mmol/L:1
PP58
9427
G187R
I565F
C-c2-mediated
​Third
ible
IFAR346
HuH7
59.9
140.163.254.156
activitiy
ubiquitousness
HT-Seq
.TFG
FANCD1
coloectomy
in‐house
571/Glivec
Colon-Lung
94.1
pZIPcCDC25-CAAX
.Gallinger
CD3+
2,979
sorafanib
.Mani
low-sensitive
14a
Relapse/lymphoma
NCSLC
WT-FZR1–expressing
27.51
ALL3
metastasic
1cm
pCB6+
/StrepII-CycM
ACL4
TCR/CD3
2.13.2
Tth
CIN1/CIN2
retardation,7
∼28
BCR–JAK2-positive
SYT-SSX-1
Fc-epsilon
1620
2-tier
L26
Wentink
UQCC1
transphenoidal
pathway–independent
PSM-RB
cilia-bearing
35-mm-diameter
mutations.11–18
†16
non-cardia
K293X
bioavailability
Tyr-220
D816H
H137R
TE-15
F113C
variant-induced
methionine/cysteine
−.57
261K
glutathione–agarose
N-ethyl-N-nitrosourea
175–360
HEK-YFP-Jak2-T875N
PBK/TOPK
15.96
L611V
patients.30,31,34
CD90.2
transformation.13
tumors.1-6
PAX-FOXO1
stationary-phase
MeijersHeijboer
Asp92
Ci/mm
pCCL.sin.cPPT.minCMV.eGFP.PGK.ΔNGFR.WPRE
AURKA-ranked
E545K/D549N
pRS305
PDGFR-C
.Peritoneal
H949Y
un-selected
HIP1-PDGRFβ
0.5-1.1
PDGF-dependent
.Before
PA25
c.1023T
IOb
chromatography-tandem
E799K
91.93
antiphospho-Erk-1/2
.Bcell
p110δ-K223E
2,100-bp
scleronodular
T-LL
mdm2-containingreporter
c.5153-6C
domain.11-14
5′-GCAGGGTTGGGCCTTACAT-3′
Virchow-Klinikum
reported,81
Clonality
aberrations—ie
gtggactaatcccagcaccat
L2575
pcDNA3-mtp53
signalling20
876–884
Anti-p-MEK
L834-R812
34c
Stanhope
IU/ml
1077–1057
CHARMM22/CMAP
6-18
Autoacetylation
e002
1.055
P2519
VEGFR1–3
1.02–2.0
NF-κB–induced
.Re-expression
MSCV-based
004937
≈0.5
resistance29
GATA-3−/−
KIT-del557-558/T670I
–MLH1c.793C
R734C
IC50=11nM
ubiquitin-mimicking
mastocytosis
cdk4/S-p16/
.Uncoupling
.S1a-S1b
MEG-01
TARBP
Panda
www.invitrogen.com/
2.5-8-fold
K407
soybean
5′-TTCAGCGGCACAAGGCTC-3′
Darmstad
myxoid/round
08/25/09
72/134
Chromatogram
.U2AF35
NTT
nongenomic
HPV-encoded
phospho-Y568
tumors.45,46
pnas.1321155111i2.jpg
Com61.1
23–36
p53ΔE5
kindred23
V1671I
.c
MSH2-C333Y
.012
27/39
pYAD
AACAGCTATGACCATGGAAGCCTACGTGATGGCCAGCG
.Insertion
p.S703I
5′-AAGACTCTGAATGCAGTTGCT-3′
G227V
described.43,44
p16Ink4a
iodide-staining
/SCT
Annexin/propidium
inhibitor-resistant
6B−26.4TNFRSF8Tumor
UO-31
GAAAGCACAGTACTTTCA
450-rad
therapy.8
Prokova
immunokinase
curie.u-psud.fr
85K
factor35
M64174
654/16,138
MM294
MacGrogan
TRK-driven
transgenicK-Ras4bG12D
Lacasce
neuroecto
33433413
tcg
PDGFRAD842Vexpressing
23D5
Y253F/H
Ras·mantGDP
cancers.13
dicentric
previously17
Am80
CD11b−
A329T
15/18
5'-TTGGATGACACAAACACTlTTCGAC-3
1-yr-old
T914P
23.1
C-RAF-BiFC
Licatalosi
Fiegen
Leu145
22:589–594.10.1038/nbt957
Jhappan
Y31
1XPBS
p230BCR-ABL
siExon
Ceritinib
pattern—normal
PT111
L704N
byinfecting
Courjal
PET/CT-scan
p52–Bcl3
myc-luc
REPLI-G
Gouveia
LMK
A341V
45.7
5′-AQ-AAA
.Thanks
36§
homo-oligomerization
directionson
MSCVneo-MA9+pGFP-V-RS-scrambled
FA-E
NdeI–XhoI
CKO3
.HL60
role.2
prion-like
Mm00812424_m1
hPMS2,12
disease.42
sac–derived
RHS4533-NM_000551
myosin
MLH1-defective
3250
dihydrocollidin
insert/β-gal
inefficiently
Glycaemia
Met780
0887-6924/09
UMUC1
p19Arf–Mdm2–p53
ERRB3
valine599
YX
PRDM7
CCDC98/RAP80
YFP-SOCS1
DN-Δp85-transduced
BRAF/MEK-targeted
FNIIi
HLA-B27
immunostained
P222L
50.0–2.00
IVS19
–14
29–33
0015
ANZCHOG
Reduced/loss
PJ69
Y-.Gâ€
5,014
neoplasia—patient
2891
15−95
360-
c.2714G
Ser37
caeel
autism-like
10.1007/s00401-011-0817-z
DNA.2
X-OMAT
33.PTEN
404–417
PE1
cnLOH
cacatggaaggtggcttcgatgacagtggtccactg
HCC19-0711
1738E
Spindle/polygonal
Study.2
1.408
vitro–derived
ternatively
EphB1
.Replication-associated
1.64E-12
10-adenines
Tsuchida
AZD6244,24
Nf1
0.5mg/ml
ASPP
aFacial
polyubiquitylation
Rac1‐specific
GSE28303
.S8C
GC-rich
TTAATACGACTCACTATAGGGAGAAGAGATTCAGATTCACGTCCTCG
PAC162-N14
9–48
D2035V
≥60
LSL-N-RASG12D
PTP-independent
-linked
papillomas/warts
board.DNA
894–900
162.5
Gamut
Asp351His2
p.Arg258Gly
CK04-13
-Transferase
gynandoblastoma
S6C–D
ETV6-FGFR3
D538
54-b5
cm3
ataxia.18
phospho-IκBα
severalvolumes
haemagglutinin
8989
‡RNA
repair/checkpoint
Guiton
unoprecipitated
L858R/L704N
Heterozygous/homozygous
.Res
cancerrisk
line.Figure
57/m
tobacco-smoking
invasive
.3b
832047F
concomi-
biogenesis31
7J9120
SENPRDTEDVPWITLNSSIQKVNEWFSRSDELLGSDDSHDGESESNAKVADVLDVLNEVD
F1174VALK
Goldenring
948–955
targetsAbstract•
0.33-4.35
Snf5inv/+
TFEC
3832–3813
extremel
1.33×105
IkappaBbeta
A_52_P93910
deubiquitylating
Congenital
CML-derived
phosphatidylcholine/phosphatidylethanolamine/PS/PtdIns
×108
Raf-1.FIG
772_773
TIJNEL
CHSYLHKDEGNPE~
p.Ser34X
1D–E
blue-positive
v.2.5
R1B
abcom
SRC-2
3109/L
his‑
main-
K-rasG12D
FBW7–substrate
Malcovati
anti-PECAM
Lys379
RMC
common.40
c.461G
MLC1
=11.80
RAS1
-O/RAD51C
E2F1-binding
G1691S
PCR-l
0.4–3
14Iow
.Theoretically
0.8b
cases.4-7
Aravind
C4I
5′-GGCATGGCTCAGAATCGCCC-3′
overlapwith
temsirolimus-treated
1.17-3.65
ligand–
.018
severe—profound
sec-
TET-JBP
ATATGGGCTAGATGCCAAGTCA
Notch-activating
S370
1184134
NT-3
5′–3′
dis3
8264del5nt
autophosophorylation
tumours.14
9488,900
naevus/nevus
TSC-related
p.Y220S
N306S
R172M
.Auxin
563
His661
IgDhi
1IR3
ElA-expressing
.Immunostained
nutrient-driven
Wetenschappelijk
RG7204-induced
duplex–lipofectamine
DDIT4
exac.broadinstitute.org
.novel
egr-1
Cell-growth
cancers16,30,31,32
therapy.Patient
-IKKβ
2-CAT
laboratory‐based
Statistica
UICCstage
dimethylamino
Smo-null
IHCC4,5
therapies1
pmCherry-N-rasG12V-E49K
RP11-7P17
pLKO1-shYAP1_1
K-RASB
Gln181
described.9,50
66-68
50-ml
locus-specific
PrimeScriptTM
PTCL1
dominant-negative
GSH-Sepharose
required.25
G1633C
membrane-
paraesophageal
Guhaniyogi
Figure7B
ctggagccagcacagcgccttcg
poration
Y1479
X-μ
44-year-old
NcoI/StuI
6.7-kb
missense-containing
NTRK1/TPR-related
Nagaich
R1421C
samples66,119,120
PTCΔ
cells.36-39
CytosolTo
Growth-inhibition
MM485
SEGFR
Smad3−Smad4
thegels
1324
MLH1-PMS1
CCAACACCCGCTCTCGGG
structures1
864–874
E11.5–E13.5
tTG
59GTTCTAGAACCTCCATGATGCTGCTTACA39
dÂ
G112S
obsj=mNSg
797
K499E
β‐turn
transformability
v0.2.4t
spindleshaped
in-flame
p.Cys44Ala
Anti-Chk2
R102Q
Christiano
D-cyclins
appliedbiosystems.com
19–69
Mombaerts
PA10X¶
Gly143
~9.8
F235C
17787
p.Ser210fs
FGFR3-IIIC
-51
substrate-1
Archer™
Ter119+
.Pervanadate
CFSEhigh
7014_7017del
homozygote106
BCR-ABL.1,54,56
myosin-staining
2308-2316
Podocyte
cotransfectants
transcription.54
S-transferase–Rhotekin
P7.50
MCS2
p53-proficient
Alphalnnotech
CD126
EGFR-TKIs.23
G482W
HNSCC.4–6
polymorphonuclear
deoxidization
dosageGene
1,041
RQGAKF-P
Modal
phosphoadenosine
al.15
T193I
PIK3CA/AKT
11led
0.5–1
Ser5
KU80
Tyk-2
responsible62
Oligomerization—The
nickel-charged
BC3C
pressure-volume
+34
.Dirk
Table1.1
17.8a
earlier6
pBS-hMLH1
genotype
formation97
-partners
1.3-3.3-fold
6-20
\Ú
TG10138
99.914
insensitivityto
A_51_P328333
..QDV
melt.html
R71Q
10p
susceptibility.23,24
phosphoproteomics
CGUCCGUGAUUGAUGAUGA
2IVV
ALK-induced
Menarche
2∼96
3.3×10−12
BO18279
~3-5
ENSG00000133703
cerevisciae
12:22
-Sepharose
MPLWT-
NeuchPtel
N′-bis
clinicaltrials.gov
~sevidenced
othovanadate
resectedtissue
V557E/G
S1778
course/imatinib
180,000
BRCA1+GFP+
0242
D595V-mediated
HLA-haplotype-mismatched
xenograft-bearing
complexes23
doi:10.1016/j.ajhg.2010.06.015
PJS,13
NM_009860
anti-Gatq
CHFR
studies,20
c.5385dupC
Dryja
bowtie-m
p21c-H-ras
.Divergent
LTD.
U11732
UMUC17
DFG-portion
C456F
pre-catalytic
5′-GAGGCGGGCTGTGTGTATGCAG-3′
S212
patients.Figure
vivo_
DEPDC1A
ptyr
YFP-BARD1
Thr42
SM1412
Met918-
lymphocyte
TRB3
8q11.21-q23.1
effector-triggered
III.A
299/299
PAC-1
17/51
Bcl2l13
LmUS
5′-GGGACACCACGGACCAGACCT-3′
TuJI
P447L
23–171
Fahr
.55
L1940P
DNP
ShhN
Naderi
CBF-AML.7-11
KRASG12V
9p,3-6
RBMS1
formation.A
preactivation-like
Suprec-01
D1-CDK4/6
Dual-luciferase
Y665
mutation/deletion
Lai
Ma-MelTumor
Bugbuster®
cancers148
chemotherapy58
Skorski
_0
shown,15
92C
exon1
TKI-refractory
GAL1promoter
SLC40A1
.Tropism
2229-2236
p.Arg133*-positive
ATGGTC-3′
endocrinology
A.D.
haematoxylin-eosin
Renilla-Smad
LATS2-delEx6
RPT-1
320-mg
sameresponse
TXNIP
Apropos
286–base
Ku
arginine732glutamine
59CGGAATTCCAGAGGGATACCATGCAA
.212G
K/RTK/RAS
.Mll–AF9
D399
p.Val343Cysfs*68
1806–1809
boundaryof
FAM-TGTGGTTAAAGGAAACGTGAGTA-IABlkFQ
5′-CCCGAGGGCAAATACAGC-3′
EN-induced
Mossé
Meta-iodobenzylguanidine
NM000179.1
ACF
Brenkman
P549S
H1975
G362V
17-1
.Curtis
Trp183
platelet-derivedgrowth
gpl4O'rk
0.3503
Unanticipated
MODY1
MDS28
pE3-IV
AspCy
TÃŸR-llwas
forkhead-like
VEGFR1-3
alkaline-conjugated
Z-B
9–27
chemotherapy113
NaN3/0.1
in-vivo
p.Ala23
AML1/JH
retention45
Rhabdoleiomyoma
Karlsburg
TEL.E8R
c.8486A
JQ778217
*Note
98.97o
Non-Hodgkin
FGFR1-3
Culture—COS7
G347R
Q531R
magnesiumATP
1784delT
germ-cell
5′-TTGTTCAATGGCCGATCCCAT
85894
RIMS2—contained
.40.
hgGateway
22.M340Q
Reed-Sternberg/Hodgkin
amyloidosis83
K135R
IMAGE:30061057
pone.0064364.e008.jpg
indirectly.Because
assay33
Worldmap
Karpas299
studies.3
0/73
G357W
suer
S65C
4347
Fig.7D
G434R/V
nihms-745680-f0001.jpg
L54
Mulder5
loop.17
state.3
.022277
stroma-rich
pan-ERK1/2
βPDGFR-T681I
oligomers
NRA41
.S6G
anti-C-RAF
survival.16KIT
5′-CAGGCTGTGGCTCTGATTGG-3′
HFD-fed
cell-restricted
sunitinibliver
ChrX
4.31
=0.75
IKKε
R1881
Zighelboim
HCT116−/−
.Microarrays
20–30
sarcoma.2–7
regions.11
e1a2
7Med
IGR1675
thermodynamic
2508
binding–deficient
MelanomaImatinib
R341W
701–705
D3S
Near-Homogeneous
0.905
SDF-1
activation.Figure
Wing-
305-510
digoxigenin–UTP
KPDfl/+
Figure2C,2C
c.1794_1796_dupTAC
Jade-like
SHH-
2/37
.Habib
CA19-9
Mx1-Cre+Srsf2P95H/fl
pre-existent
well-characterised
carnosol
R197L
TSvib
//www.uwcm.ac.uk/uwcm/mg
MCC-DOPE
Fc1
qRT-PCRs
iPTree-STAB.13–15
37§
GST-Cbl-3
E1210K
ter1426
50-min
A561E
CC′
//creativecommons.org/publicdomain/zero/1.0/
8B-C
GATA-3+/nlslacZ
P540S
21/5
skin.25
6593
4OHE
HMC1.1
protein–BRCA1
Single-molecule
OLIG2-mediated
152O23
patients.3-9
Tth111I
.013b
fm/mg
15–25,27,31
51.35
spindle-like
ELYRA
xylene/ethanol
ImagePro
H-89
5-2-3
KEAP1/CUL3
−3.45
Nureki5
dacarbazine.11
processing6
HDYNK
Single-
subtype-D1
Tubulin
5′-tttctagtaactcagcagcatctca-3′
site-II/substrate
H2872
oxyhemoglobin
Hormone-sensitive
Eland32
forward-B
Method-S7
MORIHIRO
Fig.6F
well-developed
.S1C
G623R
.S5H–S5I
Dez
L2–L5
V10.7.3.1
Guidi
T25
IR3-mediated
.Deletions
n=85
Nunclon
M1628TR
0.45-micron
TSERV
5′-GACTGGAAGCCGCCCATTGGTG-3′
Philadelphia-negative
n=5
0.917
distance/speed
1462−198C
A353
stereochemically
n=592
LATCH-CC
histologically
=0.0015
de-ubiquitylating
binds.29,30
arg4-3/ARG4
DUASpGAL1
G/c.476-2A
2F14
A*2411N
CD43
Aprotinin
Supercoiling
0.218103373
.©
glutamine
loci-specific
p.Gly593Ser
L718P
O.OOSo/o
TACC1
Ala750
sizecRR
q13.3
P01S
ofD820GwithKITexon
MLL-translocated
n=52
WPSS
Wakabayshi
butfollowed
cells.4,77
Gly465
MAB5326
VIT
S2.1.3
AntiseraExpression
rate4
DNML1
HM2833
MLT
9–25
cases27
CHP-212
BCB
4.23
G469E/D594G
GEF-independent
.Event-free
SHP2/
prognosis38,41,42,45
mTOR/rictor
FGFR-normal
SSCP–
I51T
24-72
SRCR-like
HRYKPGTVAL
4.75
PDGFR-β-mediated
161T
p-Thr308
al.,2006b
reolysin
nonsensemediated
24/652
Felix-PDX
BL6/129
Immunodeficiencies
.Bi-directional
imidiazole
non-toxic
screens7,8
isassociated
F1271
2-transformed
//www.ebi.ac.uk/clustalw
non-noxious
Full-ORF
reports,29-32
28·0
571–577
mediators—
Tyr-to-His
Y129C
myeloproliferative
NEXT-GENERATION
Fanc
EEHMRPFND..FVKSNFDAARRFFLDIASDCPTSD
​Figure1A,1A
steroid-sensitive
PL5
TableRecalibration
Pro214Leu
V12
Large-Construct
0•066
mutation17
gosity
non-binding
Swi10
Genzyme
p12OGAP
ATMCKO
Fig.1d
SHH-associated
semi-tryptic
86.7
GDC-094-sensitive
M10A
UCP1
pCDNA3-50
10−21
1b-d
CTTTGGGAAGGTCTTCCTTGCTGAGTGCCACAACCTCCTGCCTGAGCAGGACAAGATGCTGGTGGCTGTCAAGGCACTGAAGGAGGCGTCC
DTPPs
tinib‑sensitive
Ma-Mel-100b
DL21
neomycine
anti–tyrosine
F-boxSkp2
published16,44
E285V
ARE-III
factor5.8NMIN-myc
4447
αD
cold-sensitivity
kinasedependent
F79S
nucleus.1
pXJ40-HA-PakCAAX-K298R
.18-22
Tas3-homology
monoclonalantibodies
Trp382
HLA-genotypically
FA3b
mice70
P95H/+
WZR10
IMH843-845
noncolonic
Nessuno
Medium-power
C121S–negative
Atm-/-
plasmid-dependency
3.22+0.02
Detergent-insoluble
MUM3
c-myc–specific
1.5-39
βc
12869501–12907100NM_054020
Cdk12+/−
H42R
PDGFR-mutant
EPZ-6438–mediated
kinase–binding
.2239C
reported.7Mock-transfected
Nrf2–Maf
I116F
ACGT
samefashion
4DST
NOCOM
8:14
Val797
8206delAA
α-N
E526
IL2RG-JAK1
cotransformant
Mutation-enriched
100965
Glu-160
L902M
XhoI/AgeI-digested
MADH4/DPC4
mLST8/GβL
pEcoRIB
urea-denatured
KT31.1
Fig.44
anti-N-CAM
NF-κB/p65
BRCT-containing
100-300
3.82
rs28363317
E355K
20.31–0.97
M7165
RAS–BRAF
2.0-
YAG
pQE-30
populationbased
p.V1398D
C→G
poly-l-lysine
expression,8
3663
serology
libSVM
homodimerize45–49
Heselmeyer
344-bp
550282
C-20
SpectrumGreen™-labeled
1.87–46.4
on-line
.Nickel
Formation—To
EMP
three-week
p=0.00055
Repl
263.6
RmT
VEGFs
5′-TTGAGAATGGCTTACTTGGA-3′
V1M
5×104-2×105
E208
ALK-WT
926-32212
monoubiquitylation18
CD24+CD29+CD61+
6-deleted
⇑
−920G→T
:/exA-/acZ
−.56
Ft-PMLRARA
p.A146T
78–1074
hypotrichosis
.SAR
Bolufer
.Pedigree
26163
causality.8
T7-promoter-tagged
signaling-derived
cells.31–36
sulfate–20
pRC3
Vol.
5′-CTCGAG-3′
byprogressive
/X
Mangia
6a–b
intratumoral-injected
mostlygastrointestinal
CGAA
Rho-interacting
E.A.B.
1407
transcription28
94°C
100a
min/bed
C1253W
AIEOP
geneamplification
10.1056
Cytofluorometry
RAD51-recombination
Cross-Signaling
S10C
IC50of
.Neuron-specific
DNA.23,24
link_type=OMIM
V76M
study.103,104
SDS/1
Neh3
and—if
pQE30
TS2/9
Neuroimaging
age.3
MRN-deficient
pEGFPC1-PTEN-CAT
Mll3/4
WH0055294M2
E/Q
.Soft
179082004
36-amino
cmgm.stanford.edu
mice82
wt-GRP1
29/53
B44
c-Cbl−/−
unmethylation
5′-GGTGCTTAATACCACGGAAAA-3′
R258H
NCT01737450
Arg-248
reported28
Magesh
diversin
analysis.2
DPPIV+
nucle-
Met-expressing
Cys41
GTC-3′
PKCθ
Tsc1null
⩾90
9.0758
20–25
c.4092C
V-
7,35–38
M213
single-molecule
mutations—probably
818-bp
W339G
.Gene-Drug
cycle.15–17
n-0Mutant
esterification
Glise
U2AF1-Flag
p.K666E
Shp2hep–/–
gastric-
up-front
isoform
p.Q507P
MultiImage
domains.2-5C/EBPα
D1Δ-860
Ptpn11+/−
www.cancercell.org
218–272
p.Ala146Thr
Gambarotta
185delAG
large-region
discriminated
​,2B,2B
specific.Importantly
.13,15
Msh3
18th
GHE0609
R271G
WD40
m/38
pathway-informed
T170
co-occurs
coactivate
.Cell-cycle-dependent
Al-Minawi
valproate
SPOPMATH-BTB-3-box
0.03843
XL-1
NS.2
1238G
HRG
R295C
molecular-targeting
PCR.6
Howell–Jolly
5366delT
BRUCE.27-32
p.L22H
Trp53inp1
6177
0.870
c.4575delA
bilayer-tethered
develop.4
pSicoR
Gysin
W80A-AKT
psfgen
αE-
disorders/acute
Hmox1
26–70
pET01
R802
ab5443
=1.24
C118S
84.7×
F594
1,320
0.9486166
56774170
SSR3
function,29
unit-erythroid
.NOTCH1
HIF-1A
resistance40
SLC34A2-ROS
22q12.1
mutation.9
0.605
d7
aggressiveclinical
143–166
formate
CATGTCGTCCATCCTGCC
AAACGCACACCGCTATGTTG
-1022G
5358
1934
.BRCA1
haematology
first/second-degree
vKi-Ras
.Weinberg
P2.Full
2,043
hexacoordinated
TPR-MET-transfected
.Glucose
5′-ATGCTGCGAGGCGGACGGCGC-3′
S.B.M
L858REGFR
Abl-SH2
2G1T
NZM45
388–400
0.25μM
depigmented
CD34-enriched
D18N
Max-Delbruck-Center
modalitiesof
DD-related
singlewavelength
123I
A1-A8
M059J
burden124
one-colour
PLTP
diamidino
XpYXX
hydroxyproline-binding
OB2-DNA
n=31t
893A
c.539T
mis-segregation
ubiquitin-charged
Ntrk2
v-myb
−2.41
CCAUGAGGAAAUGAGAGAAAUGCUU
3/99
less-well-characterized
Ca-A
1288
OCI-Ly3
GST-c-Cbl-TKB
35/F
ErgMld2
MTG16
253–262
−Mg2+
pre-defined
A767-V769dup
37846
.Clinicopathological
30A059
λmax
.MTT
9–12
Pro3Leu
D07
Y42
Wis.
BAP1.3
p.Leu2753del
six-part
.PFBC
F2,123
study-group
M36R
0.1-33.0
14:2
Dual-Color
50
.6D6D
R498W
.CGA
mcf
DCL1
1051–1068
HLA-F
vasculary
FV
Q61KN-RAS
jinghui.zhang
MET-related-sequence
Pik3r1flox
p.Pro519Leu
SOPMA
C1148
7.91
modest.1
72-3
amo1-RFP
intermediate-sized
PYD577-582
NM_004333.4
Sma4
BCL-W
p-pRB
IDC/ILC
P315S
1.5μg/mL
.4.7
pBPV-IGF1R
CNIL
6/27
Inno-train
luminal-B
+20.49
vandetanib-treated
I337V
.Glycogen
contransfection
3H-E2
NF00028
transferase-medi
905-2delAG
9/20
Assay—Calcium-dependent
flx
GST-BACH1
-GCACAAGCCTTTGTTCGAGA-3
anti–caspase
17.95
one-phase
right-most
regulators5
±4.0
Fgf-3
Ile103Asn
820×
mating-type
.GISTIC
7–14
319TCS
3521
kilobases.8
//informahealthcare.com/doi/abs/10.3109/104281
Ctnnal1
clinicopathologicalparameters
tgof
FANCD2–FANCI
acti­
SCAF11-PDGFRA
.Q506
c-Kit/CD117
3DWY
mostaberrantly
BRAFV600/MEK1
.Val804
INS559P
TEM.12
enzyme—the
MLL–AF9-AML-transformed
EFGR
Chungbuk
H-219
KDal
3.-RAD50
Hepes-KOH
25b
pre‐incubation
0.07-2.41
HA-p300
PI3-K/AKT
Vorinostat
T1307
Tgfbr1
N99S
pre-T
4
OPC
G1/S
cyclic-AMP-dependent
region.19
5'-GC-clamp-AAAACAAAATCACTTGTTACCTTCA-3
CyA1
H.P
AKT1−/−
pageResults
NF1T2805I
PH1
0.914
FL-binding
bilobar
CCGGGTAAGGGGTACCCTC-3
C77D7
50-1500
Kuppens
pYEEI
PDGFRAamplification
δδ
70-kDa
KRASD33E
C126Y
34-56
anti-CD45.1
ETV6/RUNX1-negative
kIPIRW
.FH-DDIT3
EGFR-phycoerythrin
LKB-1261
I254R
duplication/deletion
34–92
ERα+/PgR+/HER2−
kinase-signaling
319–552
c.3708T
21F10
c.68_69delAG
actin-stress
35S-labeling
8–14
.Lung
apoptosis18
AGCCTCAAGATCATCAGCAATG
Colo824
-actin-specific
µmol/l
Co-immunopreciptation
.AR-FL
28-fold
Well-studied
context12
indentification
.Fluorescently
CDKN2APA2Arf
Ab-6
R1528C
S-IIP19
chemoselective
dysregulates
dirk.schadendorf
GCCTACAGTGATTAG-3′
SAMBROOK
phenotypes—suggesting
BS4007
GAIIx/HiSeq
adenoma
CD56+CD64+
wt-ALK
ofc-H-ras
Arg310
responsivereportersStrains
11q13.2
pH6.7
pLKO1-shYAP1_2
Y503
308606M
inhibitors81
pMAPK
5382stop
16-bit
c.1323delG
143:707–715.Baccarani
R-spine3,4,5,16,17,18
.Concerning
R47C
yset1
Q610*
1110
11q14.1-qter
tgc
KN-Jak2
droxymethylglutaryl
E872K
15204-1-AP
sequencing-process
multi-acinar
NFE2
MSCV-PGK-neo
.Outbred
D1-APμ/dEμ7
265–272
Penzburg
signal-cascade
adenocarcinomas149
Keyhani
basepairs
.Podocytes
earlier.9DNA
ethnic/geographic
39–63
Mr.
Immortalization
S/TQ-rich
1/15,000
902G
pGal/α/ARNT-ta
n=3/18
poly-G
Gateway-based
rearrangement/amplification
Generalitat
tissue.1
//dx.doi.org/10.7554/eLife.17929.001
Braig
Type-II
lineage-dependent
c.5645C
antixenobiotic
T0070907
size-fractionated
YRG-2
M21644
p.G196S
BrafG463R
Petzer
Gal4‐Neh2
GST–SH2–
95/5
2AD
C11orf71
Ab-10
polycythaemia
BP1,26
Act-PBase
phosphoErk
pVLhFL
123X
.Moving
CCS-GI
N-M
I331F
PF-07-215-01-TBE
hTCF-4
Ordinario
ALK.7–10
U87
flag-tagged
E872
pGEX6P1
EBV.13
S175R
-GGACATAGCGTTGGCTACCCGTGATATTGCTGA-3
200-nm
position-effect
N234
NF2/Merlin
Cyk4
K413E
.Ligand-independent
alterations.13
42,808,040
Co4
1100delC.12
−ΔΔCt
D3S1611
nickelnitrilotriacetic
once-a-day
BRAF-deleted
head-to
22/30
DOK2
H460
Tongji
therapies.3–7
M774–R784
MD-335
CDK4/6-inhibitor
ω
p.Ala96Ala
beenmade
~E12
16,024
Piccinin
phosphatidylinositol-3,4,5-triphosphate
oligomer/Myddosome
STE-20-related
craniofa-
Puxeddu
nucleoporins.22-24
tumours17
dose-effect
eukaryocytic
MSK
Dicer1-knockout
anti-Akt2
previously35
Pro'71
P45L
pCR-XL-FLUL
ITD-mutated
.S5G
gt11-129EV
c.1039
Phosflow
theminimal
432
23·5
frag‑
HER2/neu-positive
Case-831
5a-c
4.57
0–2.5
66531–66801
LX21DM
EZH2DeltaSET
HD-0392
Asp770_Asn771insAsn
:1647–8
p27T198A/G
K350
promitogenic
variant.5
unclear.41,50
morphant
18–30
hinge-and-latch
E154V
MYC-expressing
anti-Tubulin
homo/hemizygous
age.9,10
Hu-α-koz-F/Hu-α-rev
T312I
Aa026
5′-CCACCATGGATTACAAGGATGACGACG-3′
assays.
55
CDCA8
column61
junction-level
cells.In
NUTM2A-CIC
HERV-K_22
patients.29,30
4378
mesylate.23–25
ecdysone
84.7
MutSα-A636P
Spectroscopy
Ubq
K106
Bromodomain
,18
anti-WDR5
Etv6
MEK1/MEK2-targeting
interaction9
2R3S
3164G
0.518028
transfected-
duplex.4
250–533
.Murati
immunocytochemical
BKM120-containing
deacetylases12
FcγRII/III−
phosphatidylinositol-3-kinases
actomyosin-based
deletion-carrying
p.Arg172Lys
E514K
c.6525A
.Phosphopeptides
.FIG
~110
SWI/SNF-mutant
nonexonic
severallines
spatula
Ile157Thr
ETS–p52
cofractionated
g.475G
patients46–49
Val804Leu
nonconsanguineous
SKP1–CUL1–F
Steenbergen
MEK1-R5
GATA-motif-containing
photo-documentation
∼1,3
1258
NP-binding
SuRE/Cut
3.9–5.4
PCS-400
RETS891A
.Fattaey
LY86
IMGT/VQUEST
ce1
HER2L869R/T798I
c872
Gene-targeted
610389
PAPSS1-BRAF-expressing
184B5
F134L
.53
DTE
EWS/WT1.Using
3,939
.AML1-mediated
ERBB2L869R
G596D
ssGSEA
G1125A
Microcultures
A.Rad54
pNLS1-dGFP
5′-CCTCAGCCCCGTTTACCT-3′
Kalish
DensityThe
ALK-mediated
0·90
5′-GGAA/T-3′
APCCdc20-mediated
11–16
overexpressed11
BlueLite
methyladenine
ifc.cnr.it
transactivation-regulating
REFmut
CHTOP-NTRK1
mTOR–mediated
fibrogenic
P.L861Q
MEK-knock-down
L83P
survival136
binding15,18–21
triphosphates/liter
permeabelized
serine-to-phenylalanine
26-millimeter
migration12
NFJ-1-
RSC
c.791+2T
810-850
.Fig.2A
illegitimate
months.18,19
ROS1-driven
paraffi
2.8.1
AdCMVβ2m
tri-methyl
R1/R2
silymarin
.PIK3C2B
non-littermate
PDGFRP
p53R267W
100×
3–36
Mnt/Rox–Max
NRG1-mediated
TMS1
ACO2
collagenized
1.Summary
299:708-710
FHA1
lymphoangiogenesis
STAT5-Tyr694
Y149D
PC12/
MEK2V35M
Pro648Ser
Cullins-2
7.047575e
GISTs3
TYW
Mullighan
1624-bp
neoplasms,13
leu2-3,112
mTOR-S2448-P
promoter/TSS
Additive
N.
56.3
jo.morris
SWI/SNF49
Nu24/2
mutations.2
consti
YY1–1018F/EWSR1–1667R
GAL1
12.0+
biotin-14-dATP
non-BRD4-dependent
−KTS
TIF2/GRIP1
V-mutated
Figure2b
Klinipath
K375A/K420A
patients.22
cellsheterozygous
370-386
MLH1-interacting
non-paternity
Pro-287
paran
1.3–106.4
HPSC
Moynahan
®nally
tview
Bahubeshi
lysis-buffer
anorectum/vulva/vagina
Day-8
p110α/p85α-nicSH2
.H3-K27M
E-cadherinpositive
leu2-rI
.p27KIP1
.TGFβ
CCI
0.103
Ba/F3-KITV560del
disease.88
X-gluc
CXAGXGR
p.I23R
L200R
3864
EBF1
Roufosse
.007
Cdk-inhibitor
.K-ras+/V12
S1–S3.4
V273F
ACCGGAAGT
Immunoreaction
Aurora-2
SHM
2.360
ymsh4
chr15_g.66729154G
ALK/ceritinib
EX4R
H618P
AXL-overexpressing
4-4.5
hydrophilically
PI3K-activity-dependent
.0–.04
WST
a1/3000
CellROX®
Tumorzentrums
Ray-Coquard
1.18
2702
RBM/RNAs
Gly30
Ba/F3-JAK2-V617F
multi-analyte
anti-HSA
andF
c11300-2000i
5′-TCGACAAGATTTCCAAACTCTGTGGTTGCCTTG-3′
Eya2
UM-SCC-47
CLC
cells.Cellular
Two-color
directrole
Phe449
c.182A
Rodhe
POOOO-
L89H
Cys-Ser-pSer-Met-pSer
CD74-NRG1-
4427T
∂TotalRasGTP∂parameter
haplotype-tagging
Tissues.1,2
3431
qD
R487X
cerevisiae
PK/PD
mutant-producing
.Cancer
substrate-interaction
BIC19
11500/mm3
Hannema
L505
5'-site
02.00
4.173705
Plantaz
miR-252-5p
pathology.35,36
ERK-2
A_51_P312327
locus•
Stress-Induced
functional/pathological
RAS-dependent31
chromodifferentiated
Stemi
-ctagaaaaagatatctgccacatagttctgtgaactatgtggcagatat-3
GFP-Flag-tagged
03010102N
798
.3.0
Msh2+PUR/∆
P=2.1×10−13
5-cm
LAMG
associatedand
GGDP
prolymphocytic
Akti—Barnett
anti‐CTLA‐4
-refcomp
.H69
re-appeared
RE-IIBP
nucleosome
0006-291X/00
92-1
wtih
non-metastatic
Chodosh
5µM-thick
small‐molecule
1245-1256
PD-98059
immunoblottedprotein
Teitell
3610G4T
WHSC1L1
crisis.24
untransfor­
U2AF65-U2AF35
MPCsEWS-FLI
near-diffusion-controlled
CBFB/MYH11-rearranged
acids1057–1383
1.69-fold
23/32
TGTGAGGGAGATGCTCAGTG
GCCAGCATTTTAGCATTACTTC
prefiltered
R2888C
pMXs-FLAG-ASXL1-MT2-IG
highMC
sLou
Anti-BrdUrd
NR-associated
metastatic/non-metastatic
5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside
Phe54
TriZol™
underglycosylated
S121fsdelC
XhoI-released
p=0.5469
p=0.63
RCC10
~49
W655
9E10
Xie,1
Pmab
autoproteolytic
66.3
nucleus.MKK1/2
0.704
K8
Zedek
genetic-
VDV
2146G
MYC/BCL2
17-aa
GAPDH-R
anti-P-Smad3
animals.31
L1152
P591S
0.4b
doi:10.1038/jid.2015.115
ACCCCATGAACTGCCTGTC
2709C
Catros
short-interfering
bluish-gray
S2–S3
NPM-RARα
receptor.4
non-labelled
allostery
GABPB2
GCAAACTGTGTCTCAGGAAGC
Osteoclast-like
2.5-cm
Wissmann
63×/1.32
vemurafenib18
//pfam.wustl.edu/hmmsearch.shtml
MEN2A/FMTC
pLHCX
CREB-binding
P=0.53
survivalwas
neutral-buffered
E299
pre-alectinib
5-TCTACCAGGACTGTCCCTCAG-3
Y361C
seminested
dbj0˙00057
3493–3494delCTc
493–499
NDRG1-ERG
GACGAGTTGGCCCTAGAC
B40
Whatmann
alsobe
si-YAP/TAZ
Micronucleus-associated
TGGTTCTAGGGTAGAGGTAACCTTTAA
Twenty-eight
55,000
10-129
TEL-fusion
Tau-1
thiouridine
3.6-6.7
p110-inhbitory
anxiolytic
NOB-1
Hinchcliffe
L251P
MYCN•
chk2−/−
C123R
middle-aged
Notch5
chromatid-type
2015©
IM7
deletion–
hlottirrg
B–H
Rahemtulla
assaysEqual
heat­
c.97T4G
X20/0.8
50–100nM
CEP85L/PDGFRB
miRNA11
variants14,19
ΔNp63
YVMA
cdc-2
5331
ALK/IGF-1R
mucosa.1-3
therapies2
chRCCs5,6,12–15
1f
b–e
oligonucleotide-mediated
NfJ+l-J
KLK13
cells.26
sc-6954
z633rdc
epidermal-dermal
Histo
E574K
D1349H
SCC.13
v5.0.32
G275S
585
1098
diploid
GCGGATCCTCAGTAGGTGTCCAGC
HA-INI1
rs17886242
splice-motif
P=0.896
519
tetradecanoyl
heterogeneities
±68.9
BMP-2/BMP-4-like
P.K757R
conucleofection
IVS07
5′-CCCTGGAATA
.AVGSFVFLRFIGPALVSPDSEN
MIB-1-labeling
nMorphologicSubtypeLocalization
up-tuned
F595W/V617F
Glu-353
G812D
1.14–5.28
Pro1675Leu
MEK1P162S
purchasedfrom
I111T
Abelson-murine-leukaemia
determined.We
novo13,14,50
T08
onTET2-dependent
Tyr1221/1222
Sarikas
NUT-positive
signals1,2
phospho-specific
21F
TÃŸR-IIgene
0.0202
APCcdh1
P'FT
1.288–2.517
1293–1560
1Bb1–1Cc2
ETHODS
growth.
RAS-family
specificity.31
ETS1-regulated
Preleukemic
5'-ATAGTTAATCAAGTTTACAACTGC-3
mTorc1
10/41
CDC14B
Y40
pCS2-H-Ras
CDK6/cyclin
R512
holocomplexes
NM_004449
blastula-stage
trx/MLL
28559089
HRASVW-l2
.e1
Loeys-Dietz
67–117
31:1245–1246
.PI-3-P
05-821
Shc1
46M
-450
L1213F
Dierential
-R201C
D318K/5'-CTGGAGCAGTATTA
5′-ACAGCAGAG
0,02
peroxidase–labeled
coimmunoprecipitation
GTAAAACGACGGCCAGTAGTATGCTCTAAAAGAATA
pVHLQ145H·HIF-1α
AAAGTGTGAGCAGG
/NOG
situations143
5′-CCAGATGTCACATGACAGTGGAAAGCACTA-3′
IFORES
AKT,29
188-192
pPS-hygro
EGF-evoked
67,73
XbaI-digested
30:243–248
SMAD7-Promoter
Fbw7α-K11R
Siu
and`+++
381
1822
syndrome-related
Eyk
RAD50-related
2–60
c.4304G
HybStation
TK-domain
investi
pcDNA3-FLAG-Fbw7
P318S
consensus-binding
oxindole
SK29-Mel
.Mixtures
UPMM3
10/24
BubR1
myocyte-specific
weight-of-evidence
NAlESILrRRFThQSDVWSYGVtVWELNTFGakPYdgIp-arEipDlLekGerLpqPpiCtiDVYmINvkCWmiDsEcRprFRELvseF
220651_s_at
Asp108Asn
.Flag
ofWnt/β-catenin
N505H
MgCl2/70
therapy15,35
Intron
28.7–90.6
eBy
Man-6P
2,006.9
ERBB2/HER2
Sox18RaOP
Co28
cidence
/UMeach
T412S
F442A
33258
36-3
oncogenesis64–66
AF044336.1
ACCGAGGGCA
hMSH6-P1087T
A–sepharose
α-I
WC1.14
1092
106/
67,86
Exon-intron
Microvessel
mL/well
.SHOC2S2G
MSH6-p.P1087T
valvuloplasty
5′-AGACGCCATTTCCCCAGT-3′
cases/275
HER2/erbB-2
51.7
ARR2-luciferase
Wharton
zIETD.fmk
Val560Asp
1314
:207–210
oncogene-transformed
S00
deep-seated
18p
p.Ser46Asn
MEF/HisPTEN189
eachlane/over
w/5
AITL4
GSE12896
Ransburgh
Non-Linear
studies.5
J6E/JXE
Naxos
mRFP-Gal
Isomerase
fine-tune
5′-TGAAGGCGAACGGCATTCTGGG-3′
R483
R524P
Chemicon
12p
2.99
MPLUS
5557G/G
slit-diaphragms
papillary-type
NSCLC.39–41
HAL-B2
Co29
171A
5′-TAGCTGTATCGTCAAGGCACTCTTGC-3′
p.R175
PDGFR-αPDGFR-α
10/group
EPZ-6438
-1,3-dihydro-2H-benzimidazole-2-one
c.328_339del
Collavoli
3EYH
17,14
agents24
GST–Raf–RBD
βE3
T367M
iTaq
single-wavelength
TCRVβ
Kadowaki
SmaI-SalI
C→A
2e–g
H522
p-Jak2
//www.pymol.org
Spleen/body
anti-GAR1
P37173_C00002.pdb
.ATC
CYCLINB1
116–119
Lys-CH2
A170
CpG-rich
.Palmer
pFR-Luc
Five-week-old
impinge
Centrifugation-clarified
S256Y
Mesocricetus
-kappaB61
569M1
64-67
Antoniades
cancer.7–9
G60E
Full-Length
polyHEMA
–10.2
LDR
deleteriously
onMTC
Turke
MDM2-
syndrome15
FACSVantage
background-corrected
.Anderson
SXM30
UAA
p.Y439
DNAwill
desphosphorylation
214/251
L805V
GATK38
1471–1626del
Dbf2-related
Del-9
sarcoma4,5
13.7a
GM007092
substrate72
proportions.2
HCF-1.64
TGAGGATGCTCAAGCAAAGA
endothermic
.Anchorage-Independent
.IGV
..RES
POL30
.Increases
TGFBR2-2+8G
one-class
LAE
brown-to-black
anti-Brca2
motility34
25150381
ISWI
Wuerzburg
75-100
5′-CCTCCAAGCAGATCTATGGCG-3′
Regent
Q22E
∼50-fold
ubiquity
MLL-AF4-positive
R873Q
STAT5.14
S65T
Bcl10/MALT
.Horizonal
WD40-JAK2
laser-scanning
vector-only
−Y
auto-threshold
infectedwith
∼18:1
ΔΩprot
cancers3,7,8,9,10
primers.BRCA2
9-19
Vector-or
p21WAF1/Cip1
Lorlatinib
infertility—that
indistin
Furumoto
SRC50
humans16,17,18
arrest.78
60×50×40
inhibitors48
37/38
transplantability
PTEN-319
Depar
MZLs
7q31.lâ€
ETV6-transduced
Val-103-3Ala
Zeneca
anti-pY1007/1008
exon-11
Arg1010X
Hamroun
IIIB-IV
56/F
Glu-Tyr
HNF-4
7.V/Ã•the
co-activated
.735
9qA1/11q22
DSB-initiated
MAC-cells
neurofibromatous
3.25+0.20
.Pool
respectively19,20,21
Sharifah
2x
11,111
10–4000
Exgen
≈130-kDa
pRB/E2F/DNA
LOC390877
19/1
ER-specific
H2074N
Figure7E
FANCB
C-γ
1-794
IRIF-positive
HCF1-Xho-F
dithiothreitol,0.025
0.955-2.110
EWRS/FLI
HA-Fbw1a
Mizushima
d-
1935
lymphocytes.55
cancers,2–4
Linkou
1,073
.North
D355A
G34R/V
0.00152
EMS1
K569N
E2388Q
Roesch
disease35
osteoarthropathy
lymphoprep
5,685
dual-pathway
chr8:36653064-36836067
0.027‡
D3S3W
1/1,908
Q572*
HBCx-14
DS-Luc
SC-2005
ÃŸ-cateninprotein
luminescence-based
DI9S886
tract.To
0.01-5
hyperaminoaciduria
.Overlaying
0·005
SNIP1
CGT3CAT
Strep­
brachyclinodactyly
Raf-1E478K
p27.10,11
P2221Q
14,17
GGAGGGCGC
kvd02105
R1699
recombination/repair
.Levels
caspase-8f
AKTJ/
rapamycin-insensitive
ophthalmologic
torin1
PPP6C08
∼3-Mb
semi-dry
224-C10.14
Gamieldien
LX22
PAFAH1B3
c.1785T
pmGFP-H-ras-R169A
and5,5
AEI
structure.32
/32
5.2∗
EF-LacZ
sc-03
generated/IM
QTR6
cases4
812G
S2.1.5
0.0047
Buttitta
Definitive
1000×
97:729-736
neoplasms.29
16/27
retinoma
3266
Gadph
pan-MMP
PTCH1
two-month-old
DNA-STARTM
227-bp
Ser-315
.Unsupervised
60•
'_/'\
disintegrin-like
ulate
Ala441Thr
Transwells
HMGIC-related
p.R128L
CHD1-like
syndrome.17
post-OGTT
BRD4-202
intercellular
,27
telencephalon
SPOP-interacting
8/22/04
.Erk1/2
Sphase
ErbB/HER
CCAGGGGTTCTTGGAGAAG
10,604
nparentheses
1QPJ
compaction42,43
disease-predisposing
sunitinib-insensitive
above-noted
D447AARAF
fat68
YB-1
bicalutamide
population,26
anti-PD-L1
AAGAACCTGTGGCCAAACC
640-bp
-129a
Pro-substitution
CATCAGAATTCACCCTCGCC
2100
1/27
p-BS-SK
R88W
PERAlign
12,866/142,458
980-8574
p53WT-like
0.94502
ESE3
ATPase
H123
GlyA175-180
LightCycler480
Anti-phosphatidylinositol-3,4,5-trisphosphate
Sub-G1
embryon­
G31V
LPHN3
0.21721
EBF1–PDGFRB.11
sub-nanomolar
anysequence
EX3AR
peGFP–C1/Flag–LKB1
CellTiter-GloVR
Mut10
benzimide
−5.02
10M3′
7767
studies,8
culturesCAF
—i.e.
expression.We
8.8-fold
leukemias,80–82
ISHLSE.K
CATGATGGCCATGAGGTCCACCAC
PHTS-
craniofacial-­skeletal
IL2RB
5'-CCGGAATTCTGATGAAGACCCCGGCGGA-3
Flp-In
Takuya
AMPLICON
Men1F/D
hypermutation.Full
.Reversible
scores11
proteins.29
TAL2/TCRβ
splicing—is
VectaStain
population-variation
LTB
5′-CGCTGGAGGGTCATGGAATCAATCAGCCC-3′
1251-EGF
ancreatic
A2780E
injury/repair-related
RhoGAP1
NFκB‐dependent
Hs00209232_m1
Â¿iCi|a-'-P
Ile111
exon4/exon5
MicroAmp
NrasG12D/+G12D
TCGA-C8-A135
p.V301del
Bareille
0.325747
901–1807
ΔG3
pCMVCD20
c-KIT.21-23
4C8B
//www.umd.be/HSF/
only–expressing
Gg1.3kb
years.33
Plat-E–packaging
rs28897708
syndecan-4
Trp530
ERα.26
CommentsMolecularly
A2–B3
A.N.S
15.6±1.4
siveness
ABL-B
Asn345
lgu
MitochondrialFilter
14/46
equidistant
ΔCD2
anti-Bcl-2
N2436I
PKBW80A-GST
-tubulin
Buchlop
recommended.53,54
1734.
ResultsTargeting
phospho-BAP1
Kanao
NEDD2
1450
4467889
K1452N
ZWILCH
ependymomas25
children1
molarexcess
LS-like
unaff
malig­
\36
5/12.8
SLC45A1
-7-oxozeaenol
−527
A515V
Fip1l1–Pdgfra
vitro,14
.PC3-p53–223Leu
Col6a1
ArcturusXT
SQCC38
19p13.1
8.63
RMT36'wd37wdmet47wd54bwd58wdmet59wdmet60wd61pdmet64pd65wd36-1
pAS1-CY2
Glycosylation
.S4H–a
Hong-Duk
Invest.
CHOW-FASMAN
R386C
YAP1-overexpressing
consent.Table
tumour-related
.Overall
midthigh
IL-2-induced
HER2L869R/
FANCD2-
Waldmann
20-80
'strand-cleavage
CSDSDGLAPPQHLIR
EPC1
AFM217zc3a
CGGTGAGAGACTCCACACAGCG
HLA-C*04:09N
sc-44343
.Sema
androgenstimulated
Lubensky
E48K
38K-
binding.88−90
pan-PI3K/mTOR
GSR
ENDOTHELIAL
Dyp
.H2AFY
.Minor
CMML-like
RIIIb
.S30D
78.77
L-thyroxin
490–495
sequence-length
pleiotypic
Cα-RMSF
repression.21
disproportion­
pericytoma
2A/TOR1
cis-
cancer24
YAP/TEAD2
ETV6-CHIC2
cTccaat
1.25Mb
mosaic/germline
gccagaggctgctcccc
Sanita
79–89
2708
862.4±101.7
RAS-extracellular
pN6
therapy.37
microclustering
PLD1-specific
Bar-Yoseph
early-detection
another.20,21
1,146
5647
p.His467_Leu468del
p.R109*
Dlexpression.Materials
Cep110
ASH1
.R-2011-3603-34
Dunnet
subendothelial
intrastrand
r5
ANF
486-kb
n/Na
NUP98-MLL
LOC10013227
D1246H
68.9/Mb
tumor-dependent
23/129
XEEK1
guanine–cytosine
62/39
LCH-affected
L380P
E.R.A
phosphorylation-enhanced
NG_007458.1
activity61
S0488T
RICTOR/control
x-cateni
112R
Cys634-
11/394
47°C
SH2038-F
Cy3-conjugated
1case
117.4
activation—was
anti-tumorigenic
7404
crystallizing
1.29E06
6005174
108
medium-binding
n=273
M654V
N′
BreakFusion
Bcr-AblT315Itransformed
LisH-like
1-methyl-4-phenyl-3
5′-CCTCACTCCTTCTCTAGCTC-3′
cis-inhibition
peroxidase–linked
p53C
P128Q
cells.To
S4J–O
menin–MLL
M198R
mutations/amplifications
–conjugated
adenylation
Asn504â
260_411del
11596
CSC
cBIOPORTAL15
BCRP/ABCG2
Pol32-dependent
MRN-dependent
307
CB1
-EcoRV
Endocrinol
glutamatergic
Single-hit
30/35°C
48,50
10G11
anti-C
q31.1
MOLREP
-Expressing
R95Q
383R
TT90
amino-aromatic
32.82
0.757–1.298
Morrison-Graham
Sekiya
DTII®
SBMA
A393T
ES-2
low-degree
liposar
S17B
53108
helix-capping
HER2/ERBB2
5Vto
12,13,15,16
wereUra-
G1706E
D289A
-Y17F
siRNA27
Xq
HPRC
Perlmann
-8–11
Hey-1
2Cardiac
Mundolsheim
.F594L
mutant-ERBB2
lines.14-16
Tris–acetate
GC-RICH
ICmyr-V2
pcDNA3-HA-CUL2
3.2.4
Rustighi
tissues,51
CCyR.30
Vpu
.Anti-H2AX-Alexa
injury.35
FANCA.36
p.R775H
Tyr113
Relapse-Free
Mechali
CREB3L2
p.Y1256*
Parmiani
c.-112C
α-thalassemia/mental-retardation
6~6.5
abCam
Fernandez-Banet
Immunohistochemical
-GS
p190RhoGAP
KLHL21
mg/day,6
0022
RAS-GTPase
Flt3.3
hypofertility
0.768
D283MED,24
RSV-lacZ
P452629
andautoradiographed
106th
CGTTACCCCCACAAAGC
antigen–antibody
NF01470
del1p32.3
3IQJ
5586G
immunoglobulin-italic
observed,31
and8
780–785
.Regulating
R1205H
monosumoylation
20q11
heterodimeric
outcome.2
MassHunter
RPI
Y279C-Shp2
A260/280
migration15,16
parathyroidism
TGF-β-responsive
.7,51
EZR-ROS1S1986Y
FEBS
Trr/MLL3/MLL4-independent
tumor53
0.7203b
cilia-associated
iso-type
FGFR1–3.18–20
.Etv6
GATA-1-like
pone.0056521.e013.jpg
destruction62
NM_000044
rightIII-2
DB_NUM
Kansai
al.23
.1A
S1279P
RET-
MCD.1
750,000
Radiolabelled
BRIP1.21
5′-NCCCC-3′
c.1648_1662del
IVT
20-month-old
EGR/WT1
potency—has
P430fs*2
868
a-helices
A4725
52-year-old
EUFA338
duplications/insertions
TGFb1-induced
TSC1–L117P
NKX2-1+
phospho-Y417-Src
described4
0.0397*
Dijkgraaf
immunoabsorbed
fold-activation
2′,3′-cyclic
SF3B1and
Asp631
mCi/nmol
R-Smad/R-Smad
PL-21
−0.97
0.306
M/31
L114P
ICGC_PA65
Tricine−SDS−polyacrylamide
JU.Mof
data3
G549S
854T
μg/ml,18
0.550
JH1–JH7
M/71
.Renal
L-003127–00-0005
Fzr1
non-apoptotic
U3A
urokinase
1967–1976
PTH-Cre-negative–Z/AP-positive
S338A
SwitchP
retinoblastoma10
p.Val236_Ala279del
SC-162
.4971delC
board-certified
FGFR2K
BRCA1-M297
umbilical
PGK-Hygro
ERBB2
Neuilly-sur-Seine
cM0
M-FISH
duct-type
S662
anxiogenic
phosphorylation/patient
CH310T1/2
Chiloeches
Δ66
pLM7
45,54
10p11-p12
.CTGGGCGTGGCCGAGgtaggcacgtgctagggggggccctggggcgcccc-3
MutS-dependent
AntiFlag
Nomascus
11B3fl
122:18-25
F1174
papillomaviruses
Umayahara
.0026*
n=135
LEF1
mixturewas
K32/
Duriez
high-confidence
75.54
55905
5′-CCTCTGCCTTGTGATATCTG-3′
replication87
Trypsin/EDTA
whole-exome/genome
p.Ala603Argfsx71
Assays—The
+37jC
S492F
Identi¢ed
5′-GGC
18/126
Waard-Siebinga
outcomes.30⇓⇓⇓⇓⇓⇓⇓–38
668
503–508
5-ng
DMEM/IO
10-19.9
pre-analytical
p.N49S
risk-associated
NPM1+/+
1.0-
meningiomatosis
R84H
3–24
PIK-E20IF
-Frederick
E2F
Table3
pCUB7
17.7Adrenocortical
beamlines
HLA-A*11:01,24:02
Henken
2861
system—SKBR3
.F-actin
FA-G
.Concluding
.significant
SUP-LR-2
ECM440
Shiraishi4
p.R609K
cancers40
UBTF-ETV4
NG_009014
DI7S2SORepeating
Szentirmay
-â€˜
0.0090
si3583
c.131C
M9140
≥1.0
AatII
palliate
off-study
G17A‐RhoA–interacting
_mm
effects—inhibiting
identical.42
R836C
13.1±7.2
MBEN
p1813
previously16
.755
reported.1,2
risk10
.SF1/HGF
GOL
Single-Molecule
L1011P
AlP-binding
156.7±4.8
Desmocollin
ormoderate-DNE
136.9
KRAS-BRAF
cancer71
raft
patterns19,30,31
1994X
H-RASV12
164785
Scalepack
low9
HEAT-like
pseudo-count
Hippel-Lindau
.Van
4270
CCP451
re-imaging
Lobrich
ETV6-NTRK3.While
coelectrophoresis
Flt3-KD
Lipofactamine
MTA1/HDAC1/2
ex12R
colon4q12
cysteine-12
signaling,9
1.9-6.2
seven-stranded
Pro253Arg
36months
5′-TTCACAGCTGGATGAACAGC-3′
p.Arg7Cys
YEATS4
3661
AML1/CBFα2
A1KM
ex13
described65
mutant20
age.33,34
ng/SCF
Recursive-partitioning
site15
.UHC
ABI2
TSERNOCLOU
chemotherapy‑naïve
Abl-ponatinib
45/108
2-hydroxyl
subject-
∼30-40
P50-CA72012
reported52
Trauth
S4L-M
LXSN-AKT2
.Fig.2A,2A
5′-UAUAUUUAUAUAUUAGACGdGdG-3′
SOX11-negative/IGHV-mutated
2,02,523
pT7-7-SOX9
FMA-3
KrasG12D/+
Hemizygous
JV18–1
hyclate
.519G
slightreduction
HR10/30
GFP-LKB1
ascite
granulocyte-macrophage
disease.106
C2
Berberat
Khwaja
DNA–histone
K403R
Met-780
‖
pCAG-IN
ful®ls
anemia9,16
15.63
70/133
β4-strand
10,204
NTD
myxochondroid
APC580S
al7,36
3.0,15
AML-M2
±0.26–0.79
hemagglutination
members21
6025-3
strategies189
neural/neural
0.11-0.50
TBRII/pcDNA3
WT-Flt-32D
.Optimized
c.3700_3704del5
21.26
May–Grunwald–Giemsa
DR26
H444R
HG-U133-Plus2.0
.Preclinical
2/39
.Repetitions
novo/pan-AML
43.2Soft
Nζ
825–831
shA673
doxycycline-mediated
AB23
Dierence
NCI-H2171
Wizard®
EWS-ETV1-expressing
c.671T
V557E
activated.80,101
GGTGCICFATGAACCCA
Hamadeh
707G18
isolecuine
.Surgical
tumorigenesis34,35
stage-II–IV
hypothesis26
aorta/gonad/mesonephros
REYEYDL
2−6.1IGFBP7Insulin-like
annette.paschen
A152P
35°
3229
NRG-1-stimulated
endoderm
a5–a6
fragments.25
MIN-tumors
v-raf
XIAP
UGCAG-containing
dysplasia
dexrazoxane
andCyclin
PT3001-1
report—in
free.fr
Exomes
1000–1200
.Hardy-Weinberg
NTRK1––encoding
BL—MYC
0.4–148.1
.segment
Sfrp1
−8
genome.5
S2E
QTc
Zhurinsky
Versadoc
6652
.Ninety-nine
IPMN
levels.Figure
p.N198F199delinsI
pMSCVTLS-ERG
spectral
NF1-Deleted
duet
Tgfbr2–/–
FNII1
2.342757133
Abi
FWER
33445581
metastastic
flowcytometry
lung23
half-siblings
M23102
ERE-TKluciferase
GGCTGTGGTTTGTTTCTGG
594-labeled
2–11.5
stop-gain
MS13
.PDTCs
p53R248W
Moregate
Progression-free
30-50
2077
Delhommeau
KENHII11
PE-1
Gefitinib-treated
Cystein-rich
Gupta1
B12
D770_N771insG
6G1
transfer.46
.7,9,38
anticonvulsants
nonspecialized
zero-first
LAML
anti-NRAS
.top
P178L
DNAdependent
BRCT-WT
0-180
CFU-megakaryocyte
AKT.100
Cd19-cre
5-Figure
isothiocyanates
leu-
2U
luca.sangiorgi
1772
FLAG-Krasrare
U87M0.wtEGFR
Tyr951/996
phase‐contrast
-2H-tetrazolium
Cibas
GCCTGTCGCTGAAG-3
p110βby
Fat1−/−
A633T
Dependence-Functionally
1.05-3.41
AIB-1518–813
c.3167_3171delAAAAG
phenotype-genotype
PSCD4
insertion-containing
checkpoint180
MSH2cDNA
BRL
JB990
PMA1
FLT3840
full-sequence
ASP3026-selected
.S4.1
T456M
CID
Deguen
Thiopentax®
myeloid/erythroid
PI3K-AKT-FOXO
NEF-496
SBC
IndelLocator
progenitors/HSCs
7279del6nt
RAS/extracellular
xenotransplantation
unknown=28
Rbp1
0.7.8
RIGER
162-bp
G-banded
.GDC
oxygen-nitrogen
MMTV-CAT
post-remission
.DDLPS
L567P
15269
TPO-elicited
3′SS-AON
ATGCTCTGCTTCTGTACTGCC
H63L
lymphomas,6
TK-ts13
trans-activation.46
p-GEM-T
29–35
Perkin–Elmer
Biosoft
JNK1/2
effects11
café-au-lait
59th
28/35
ROS1WT
CAGGTAATTCATGGCCAGAGGA
.5c
post-labelling
1281–1293
56Â
mutantmsh2
6Dl
Flt3-mediated
Trp405
signaling14
phospho-Ser990
VUMC
.436
GDC-0068
G211D
25A
MPAL
G431S
p.Leu858Arg
lapatinib17
invasive/low
MES4488
CDK4-MUT8
G140D
factor-I
Anti-CDKN2a/p16ink4a
lung-cancer-related
relaparotomy
D1346N
overexpressionWhen
heat-stable
Medimachine
hAR3832
grandparental
Sachsenheimer
co-criterion
NTRK1-001
1,105
North-Rhine
Y53C
M7V
A04138
-pharmacodynamic
phosphotyro­
ggagaaacaattatgttac
al40
IARC-BL60
5-aza-dc
Ichaso
4,234
dimer−dimer
Cyto
5′-CTAGTCTAGATCAGTTCTGAGAGATGACATCC
5′-GGCTCGGGG
fibroplastica
.MII
Grundler
GSK-1120212-restored
MM.S1
—BCL2
1694
Boice
MPN:8
AMLCG-
YY589–591
non-mutually
FAM76A
5324
oncogenesis.80
2722
Fbw7gamma
rs724710
p.Ser225fs
OV90
active/inactive
H-1500
CTGGTCCCGCGGCAGCTCCCACGTGGA
CWS1
HA-INI1/hSNF5
diseases.1,2,5,6
Dowling–Meara/Kobner/Weber–Cockayne
H662Q
ganglioglioma.25
helicase/
14M/7F
Biotin-
70C
5331G
and10–12
His-p53
MAM2
FLAG-Elf3Δ237–241Δ246–250
//doi.org/10.1371/journal.pone.0087113.t002
Arg7
E1–14
CLL.19–21
basal/myoepithelial
Avidin
20550
Leu-113
Conceptualization
GCCAAGGAAGGCCTGGCATAATTT
.AMPK
factor-dependency
dsp30
c.920+978G
R340L
0.467-1.003
episodes.30
transcriptTable
.Y64
C18-A1
CTD-2014P5
PTCL6
SRSF2
1024F
GSE65967
Mueckler
HRDVAARNVLL
predictions34
221/234
His‐TOPO
under-appreciated
PTPRK-RSPO3
2mat
AZ628-insensitive
18:0b
NAMD2
HER2/
methylthiotetrazole
predominantmechanism
K-N-
M55-transduced
OXA1L
III/I
5′-CTGTACACCTCTTGAAGCCCCA-3′
receptor-4
DHL.41
formation10
IIIB
c.397G4A
Src-selective
remission.RT-PCR
-pyridin-2-ylamine
gemcitabine
2499_2522
less-cytotoxic
0.007KIT
intussusception
GenePulser
Rad54
CUPSAT-based
7q31-qter
Myristoylation
hMSH6-negative
Q491
serine-specific
Smad2-interacting
2150
reacCO
T37N
M1-M6
LM-100
Q309R
BC042093
Hyperphosphatemia
HR=0.29
111.8
Asp-119
UV-origin
Venezian
DCS-22
Arginase
11competitor
.MgCl2
1CTQ
A_51_P398723
S664
ABL3
22.44–27.51
ErbB4-KD
MAP2K4/7-JNK
p.Arg301Gln
MRA
D52G
2j1y
P/CAF30
Cys-185
SeattleSeq
Serous/l
HAhBRAFwt
QucikChange
IgHEL
Wip1-I496V-Flag
NF-κB-induced
PRRS
+a
151/138
rhIL-2
GSTERK2
GSTNRAS
intra-abdominally
serinethreonine
PTEN/phosphatidylinositol
calcitonin-secreting
G469E
MKK3b
Ets-1
PI3Kα-isoform
HumanHap550-Duo
8E
Ptpn11T468M
~~~59yrs
Q-value
14/49
leading-edge
signature-enriched
life.17
GB-G2
HRMWe
c.1021delA
5′-tcagaaccctccccttcatg-3′
experimentally
Ala883Phe
C-RAF36
MRC-Holland
Pgp-deficient
Force,46
Tie-2
g_sas
NSCLC-associated
NTRK3,9
0−4
rcperesentation
G105G
ubiquitin-E3
Gradeb
prolyl-isomerase
*Average
.Hemann
DKFZp686D20244
._2445+
cancer1–4
con¯uency
mega-base
.ZTo
Socs36E
Class3
phosphatidylinositol-bisphosphates
TCO
PTCH-mutant
straightening
.FVB/N
SD1029
Hetero-dimerization
BJ5464.Yeast
Beta-catenin
6500
M1131T
NM_001987
probasin-LUC
AmpposMdr2−/−
ScXPO1-KPT-185
Glu-Gly-Ala-Phe-Gly
ALL-92
antiV5
MED12-HA
RUNX1–PR
Ras1
T-blast
Discontinuations
acid/H2O
VariantRecalibrator
CCAAT/enhancer
R366H
Y408C
KMT2F
first168
Wall-eye
1/47
murine-variable
CLTC/VMP1
amplified.ARID1A
anti–phospho-Smad2/3
541-aa
f2-w
analyses26
TLDA
48–62
cytokinesis.43
-3-carboxamide
1:142
.SSCP
Niswander
.-Src
U3-EF1-GFP
SRC-ABL
-CTTGACAATGTGTACG
5′-CGAGCTCACTCTCTTCCGC-3′
NeuN-
PSPH
C-rich
FGFR2M391R-pcDNA3.1
2.23
lymphoma1
3ÃŸphosphorylation
andMutSa
FA-D
unspecificcontact
SW1222
ized
Vanneste
AR-coregulatory
Metcalfe2
1Laboratorio
RFP-Cre
ILC-like
Phospho-JAK2
18–75
Muslin
respectively.Twelve
caretaker
24/26
2.8-kb
AG-G
binding-partner
cells24
5.06
SNX25
p107
Cre-recombinase/LoxP
11q13.1
N114D
Wollheim
–2.67
55,000-220,000
3'-overlapping
NFLS
c-Myc-induced
5q13-14
∼40-amino-acid
129Ola-derived
EFT
AGK→BRAF
Image-pro
pVHL·HIF-α
32–73
cytogenetic–clinicopathological
'enriched
activation–induced
IDH1.8
Cip1/WAF1
KG1A
ε
G1403C
gycosylated
Wnt/ß-catenin
S4C–S4E
VavCre
lympho
NPG
M395
DLD-l
signalling59
TEL-ARNT
Deoxy
MLL-PTDs
74/811
23-26
.Over-expressed
.Schimke
NCT01689519
MKK6—Several
Mantel
D188G
α-cyano-4-hydroxycinnamic
wild-type-Flt3
coinduction
1–454
expressionplasmids
pentamers
E14–E16
LXCXE
.Whole-Genome
.1276
Leu858Arg-Thr790Met
9/221
1/5
ΔHBM
85°
Fig2D
Ifragments
100mg/kg/dose
0.5nM
Swarbrick
mlh1-/-
Ala134
α5-α6
indicat­
mediastinoscopy
.Analogously
N53A
S-transferase-ubiquitin
8/13e
ketoconazole
neuroblastoma.19
humans17,18
Ci75
3.1.1.
A869G
Y1248D
0349
estradiol-occupied
process—another
A3982G
bluestained
61.2
Msi1
.L330H/P/R
WLDLE
p.Arg2336His
Kubota
345
RAD51C-Gal4
resveratrol-treated
1652–1855
ex29
Mauriziano
cross-linking
4559G
20-26
reported2
PDK1/Akt2/PKCζ
comparisonpurposes
WT-infected
32/36
031
Netherlands,29
Aqualon
//code.google.com/p/mzrock/
.Differentiation
Ckit
pain184
Scanalytics
clos-
BAP1-supression
ekspert
valgum
thateffector
2Icelandic
variables.4,5,7,9
3.54
ExoSap
0.186
cell-context-dependent
.Sclerosis
1574
Npm1+/−
MLL-MLLT1
.X-376
and6H6H
pYES2-PTEN
1∶2000
1426–1450
Kruskal–Wallis
668-bp
DFKZ
previ
220/400
modifications.Therefore
P493
post-decompression
TTCACCACCATGGAGAAGGC
idarubicine/cytosine
AUU
Shigeaki
19/42
R249–R1737
twogroups.Patientswhonever
NF2−/−
PTEN-silenced
.Growth-Inhibitory
TAC3TGC
GTAAAACGACGGCCAGTGAACTGAAATACGACGTTG
V1362
0.0048
c.-54+412C→T
anti-CD16/CD32
control.3
Biotin-TMP
ERK-rebound
F371C
non-hydrolysa
ASZ001
3780
epitope-flag
JB10113
78.9
other,54
NF1R1306Q
.S3KO
arcinoma
DNA23
organs—demonstrating
Y791N
WM164
CHK2checkpoint
β-cat/TCF-responsive
Sugimachi
020
.However
nilotinib-treated
.MALDI-TOF-TOF
2,016
inter-chain
OptiPol
DRB1*0101
7/78
project2
IVS8-40G→C
VSTM2A
7Dâ€
para-aortic
orange/purple
penta-acetic
Sox17=green
17,19,20
times.31
URA3
synthesis.16
cardiomiocyte
CMV-promoter
Mk
R1646STOP
G129V
10561
miR-30d
AE-insert-AS
manner118,119
level.In
AKT3/PKBγ
protrusive
3g–l
Tokarski
.60
Porfiri
nmol
BioChain
Portalvein
RCPHHER
two-tailed
pigmentosa
STAT5—To
STR-CycM
G-41T
3005
.RETINOBLASTOMA
FH-DDIT3
Gln→His
Ago3
PZ0.0005
CLCA2
.MUTATIONS
.Olsen
.Postulated
Mob1A
spheroplasts
Melmon
Fig.2F
L330F
5′-CTCCCCTCTCCAGGTGATTTG-3′
shRNA-based
YFP-CTLAAla17
~13.5
FGF-3
0.56106
vasoconstriction
238
expected41,42
1.30
cancer109
22-nucleotide
2.063
plÃ³ink4.Mol
ASCT
raÃ-alÃ-eleand
ahighly
AX70
K185E
R26P+/0
entry.23
closedcircles
pCS2+Flag-tel-jak2a
mucin.6,7
disulfide-bond
600-μM
Wip1-WT-Flag
9.52
CAR-TRAS
1–589
2319_2320insCAC
.Cell
iminodiacetic
GSEA15
modest167
c.4198A
trP1-Exon25R
PD2126
−51
PCOS
morenucleotide
Pab240,7
COL4A5/COL4A6
.Myriad
C-induced
resistance151
.EBV
A-B2
V109G
hemangiosarcoma-like
ErbB-driven
1Bb1
L858
multiple-comparisons
D65Y
amphibian
Phospho-Met
Qiao-nan
vitr
M157K
host-hoc
www.kconfab.org
SCC-HN
n=3/53
Mmol/L
NM_000267.1-8468s1c1
tra
Tivantinib
K449Q
g/m1aprotinin
NDb
CPD-independent
PR93/PR110
CDKN1B-mutation
Trovik
ofA2780
R50Q
propensity.123–126
Dbf2/20
c.1581A4G
OR=1.17
0.04–4.54
5′-CCTCACTACCAGTGGTTCAAA-3′
gelfragment
.387080
UVB-induced
823–32
1-330
GLI1-interacting
917KB
basis.A
92-160
p=0.0013
domain.9
A_51_P185688
aneuploid/tetraploid
NEM
22.4
453_454insN
RhoA/
G62X
.5I
PPARG
|F|
10/104
C-terminus16
.Conceivably
1.073–5.108
transfection-ready
BRAFV600D
21290
2,349
dyskaryotic
p-Akt/p-Erk
.94
BCR-ABL-Y177F
JAK-tyrosine
multi-pathway
19q13.2-3
.ZNF382
TNS3–ABD–Y321T
positive-rate
2times10
15'O
gel-loading
.TRAF7
redistributed
5′-GTAAGAAGCCAGATGTTAA-3′
membrane-enriched
pRSET-MEK1
PTEN/PI3K/AKT
PHA-L
150°
line-fit
16C
2Staining
ENDR-B
c-Myc-binding
293-295
MND
1,021
MI-2
.Similar
jMeindl
Y537.S
2.045
vitroexchange
Pik3r1flox/+
13ql2-13
microsatelilte
Arg122
H-ras-specific
g.72251T
Huyghe
events.1
000003.10
mice.44,95
rhabdoid…
post-treatment
analysisc
21–91
29.5–48.5
Alexa594-conjugated
cancers,4
UMDS
c.-139C
ING4
155-kDa
P=0.21
acomparable
four-drug
factors.5
N72S
0.177
stability4,5
DNA-specific
Drosophilarcy/Tsc1
Lys907
ICREC-8-2-4
papillare
error-containing
K134N
Ile836thr
somatotrophs
R692C
phosphopeptidemapping
.Triplicate
FGFR-targeted
Aur-A
D-/-
PTEN/PI3
cancer-negative
Effluent
5–90
GBM-13
Malgeri
104-1and
Lys196
0.336306323
overexpression29
cells,12
attenNIH
Garrido
0.91–1.46
TCR-CD3
5′-NNCACCTG-3′
v6.7b
wildClusters
nhri.org.tw
neighbor-joining
c-myc-Transfected
1,136-
VBC-CUL-2-dependent
IκB-α-WT
pEAE33
IFNly-treatedFO-
ISS1-AON
involv
TAATACGACTCACTATAGGGCTTCTTGAGACCTCGGTTGC
PI3K/AKT-regulated
p42/p30
0·050
Mst1r
Mutagenesis—Site-directed
GCTGCGAGCTCACCCAGAATGTCTGG
Ki67-immunopositive
thrombocythemia.72
5'-TTTCATGAAA-3
mutationpositive
Substantia_nigra_B_1
phorous
ATP7A
IL-2R-positive
rh-IL-2
E546G
1475dup
Wakara
TTTGTCGGTCGAAGTGGAAG
DUSPs
589-
RUNX1-PEBP2β/CBFβ
-V
Cy-5
D.F
wereobserved
cells.14
pathway97
Guglielmina
lymphoma-associated
ChIP-q-PCR
M2–4
C/H3
TSC.15
Michaelis-Menton
.PI3
fluorescein-tagged
D4S1572
BPNSTs
RP2269F
2–11
MCF10A-EN
TrkA-P203A
Vignali
BRG1
p27.11
PKD1
H.S.
Lum
F1a
alpha-helix
AKT2/
c-mycS
6/58
cell-context-specific
4,489
RP11-284F21
GFRα1
Sep/26/84
CD138+B220lo
dosage-dependent
0.2Km
KIAA1109
76.1
TIF1γ
P577S
SU5416
DSN1
Hh-blocking
meprin
nmt41
theabrogation
S308L
study,12
_FGFR3-exon17-TACC3-exon
information•
dabrafenib/trametinib
2239-2240
T55P
multikinase
Genenase
CYT-associated
Smo−/−
Rosnet
LSL-
3.4–4.3
EGFR-1
-tRFP
AKT2
p.R383*
2A3
pRBΔEx22
K22-1
41.5°C
.Greater
AZD2014
EGFR-E21R
KRAS2–4
dic
polyacryiamide
pERKT202/Y204
hyposegmentation
HFLT
Tyr476
ariseduring
deconstructed
1.31
metastasis3–7
MSH6-10
intestine-specific
tently
IP-DOC
polysyndactyly
vitreoretinopathy
Y842.8
NF-κB/Rel
AA/total
glutamicoxaloacetic
-39.3
pab0847p
ZZQ
TMPRSS2,2
-cxD11
M400
CellTiter-Blue–emitted
Single-end
Cys3-His-Cys4
allel
0.1123
insertion/duplication
α-Smad4
H1299-DDR2
Forschner
0.989
factorwithdrawal
post‐translational
analyzedÂ£2
TACCTGAAGCCCAATTTGC
2285
8-base
1,114
eject
iseasily
P=0.074
13-acetate
mutation+/HER2+/HER3+
WT/ΔNLS2
31-fold
nonadrenal
retrospective
thymuses
Menchester
alr18
Ab-dependent
Ssp1
pCMV6-Entry-NFIA
EGFR/MMP-9
Ninety‐one
D67N-mutant
antagonist25
HER3-locked
1.419
BIM1
CL4-B
45C
Gly388Arg
6/50
pS608
remodeling/
,24
0890
SNP6.0
CD117-positive
endometriosis
anti-Notch1
FeCl3
au-lait
D6–273
Ov18T
.Wolfe
¢.o
3,4-diphosphate
≥75
Hsp90-LKB1
0.1XSSC
Ligand-independentactivation
system.43
T-ALL.32⇓–34
GCnftique
TTACAA/gtaata
chemo-attractant
αp85
H669insLKH
6.6.7
colony-suppressive
AttoArc
c-kit-
Â¡i11oc
autophagic
HCT15.25
outgrowth.10,11
c.-126C
1.Characteristics
means+standard
intron-based
.weak
Kessis
TET-mediated
KIAA1644
APE1
thiazolidinediones
4G–J
/855F
Shivakumar
BC129834
5′-CGCGGATCCGCCACCATGTCCAAAAAAATCAGT-3′
relocalizes
import49
AugPMC1850562
modification-specific
HD-0186
metablastin/stathmin
2.446
un-glycosylated
particiJ
virus.54
liganded-TR
ovary.17
MUT6
schwannomin
92121
Endo-H-sensitive
S/TQ
formation5
gttt
Vivo—The
COLO206F-AR
imatinib.24,55
P72
DeMali
E1057K
JIOOT
.MDCK
T474M/Y551F
50μg/ml
0.803
siGFP
.TIR-domain
70–800
codependence
genes/targets
'cancer
reexposure
AMOT
EGFRT790
-uGGAGu-3
event.35
.—Three
Mx1-CRE
CTIgtaag
JHU:2
KIT-inhibition
MAPK1-deleted
Meneghello
expression.87
.RT2
EGFRvIII-conferred
.12,34
N337
21852§
LAPC4
J.R
.LM-LEC
Asn998
NlaIII
‡Two
refs.21
PTCHD3
triphosphate–DNA
P497T
alleles,16
BCR-ABL-containing
units/106
b1–c2
promyelocyte/myelocyte
CRAF-A
liver/lung
phosphorylated-ERK1
P/CAF
TER119hiCD71low-expressing
Taiwan13
enteroscopy70
-HAT
FLVRDAS
TGF-βsuperfamily
FBW7-γ
10x
сϬ͘ϬϬϮ
ABH2
undierentiated
cellsA
1515
proteins—Trr
0.00354
Y537C/N
Potti
AC2
Rb1-expressing
.Bead-antibody
antiphosphoKit
Elsayes
mutagenesis—a
helix-turn-helixdomains
Temno
Input-corrected
C-EGFR
KRASG12
ErbB2-targeting
TβR-I-HA
Ipilimumab
Me´dicale
0.60–2.02
anti-CEP110
1.98–18.19
TFIIB-like
lymphocytes‑unmethylated
ZKCyclinD1p1-L
NM_000548.3
.GATA1s
G596V
HS01357303_cn
CANT1
complexdelins
4AlleleA
.Secundum
tagged-
400–600
Brca1Ko
somite-1
eoretical
derived-cell
KMT2DΔSET
ADT-resistant
ICE-ε
​Insets
Spodoptera
c.4484G
sc-374400
expression45-46
-3
LexA-BRCA1
Plexiglas
Sonoki
Bhagwat
Figure33d
VariantDx33
status.4-7
withwild-type
16802
≤100
79.07
MnCl2/1
Sidow
signposts
A347P
VVPVYDLLL
2–12b
HER2-mutant
2,894
Hanafusa
reorientate
signalling209
RB200
population.81
v68
ETV5-mediated
H+
oxoglutarate-dependent
5′-CCGTGTTCTTGAAGCAGTGGTC-3′
p.Gly35Vla
34,39
AnalysesDetailed
+211
Prolong®
criti
Beta-values
p.Glu228del
NUP93
+GS
R458X
LMP-7
.E518
patients.21
109/262
201–777
tAPEaIahRi
'mutated
Diamantopoulou
Msh2L521P
Orbigen
gammopathy
.NFκB
ura3-52
GPI
_arrows_
G60D
89ZR
p57Kip2
.Precursor
AACAATCTAAGGAAAGGCGAATGG
A300-897A
non-recurrent
buthave
LGSGAFGEVYEGTALDI
1026-to-phenylalanine
controversial.14
.SAMtools53
GBC
NRCAM
T-25
States125
subtypes.5
group—were
1605
.38G.A
20573-Myr-removed
.23–25
Pro-525
arrest23
p.Arg154Gln
.Subcellular
1.12.4.2
3D-structure
proteins.145,146
mechanisms.33–35
247-8530
Trp−Leu−His−
5′-TCACCCACAAATGCCGAGATGGAGATCTTGGGTCAGTTTAACC
p.R172M
Inpp4AΔ
p=1.03E-4
ACACTCTTTCCCTACACGACGCTCTTCCGATCT
correspondingto
FLIP-NS
1-101
CAR-expressing
stroma-derived
HE-staining
HyBlot
Retroviral-mediated
Msp
Filterplate
non-PIK3R1R348
andMus
anti-phospho-Met
KMH2_HAEMATOPOIE
R648Q
TopI-DNA
.Assumption
MDA-MB-175
0,50
Aho
I-Mutant
CRF-immunoreactivity
DXM1200
CYT387-based
4/93
reorientations
BCL-6,46
C-FGFR1
TNFR2
S2.Nucleotide
NPAS3
nonsilent
p.Tyr537Cys
9295
NT128
bisphosphonate
47ACFCATGATCAAACGCTCGAAG138
P95H/−
ESCC
Oshiumi
GGCTACATTGGTGTTGAGCTTTT
Nrf2-binding
interaction21
AmpliTaqGOLD
rq
anemia–associated
-21.3
Mut/Mb
.11E
76bp
patientsa/
−653
Brca2Tr2014
175-
Pelikine
Transcriptase-Polymerase
carcinoma-normal
4-morpholino
IKK-γ
www.sanger.ac.uk
carcinomaLarge
1,642divergent
1.33–2.42
LKKE
.Chien-Feng
BRAFE600-expressing
µgR201H
francesco.leone
.Del
BRCA2.2-4
97-55
SNHG3
60637
R273C/S240R-DNA
.0002*
cells.119,120
CA1-C4
NotI/EcoRI-digested
ABCB7
PS1
Calderaro
recently-described
RG-5N
1173
OCA17
.Nail
immuno-surveillance
32.90
variantpositive
Trametinib
K558__V559del
55.7-81.3
N676I
neuroblastoma10
Inpp4a
IFN-γ/STAT1-inducible
fluorescencemounting
cell-based
E576K
MLLC180ΔF/SET
E362X
Sroogle
NM_008563
Figure3C–E,3C–E
carcinoma–derived
CDK4-MUT10
www.nature.com/bcj
aminomethyl
5'-CAACACCAT
Fadu
assecondary
0.400*
Szymczak-Workman
hormone-occupied
300-Å
h/mL
R38A
initiative132
sh-miRNA-insensitive
L1953P
screen3
Dnmt3a-null
RG-5
E__
Belandia
0.7-18
Leu242
Hashomer
Fifty-eight
c.1751C
pRBΔ651
-CTA
PathwayRas
VMP1
Hypermethylated
01223-
anti-phosphotyrosine–4G10
Schematically
cell.16
MYD88L265P
body-antrum
M232P
1.749
0.707
pcDNA3.1puro
Haplo-insufficiency
RP5-910M8
number.68
Stickle
Mediator-associated
JAK2-Related
Pim
.B23
3.3.3.
Noncodingg
primer/probe
S10E
mastocytosis46
cholangiocarcinomas6
L858R/T790M
sicon
.Rapalogs
V1001A
R376W
progesterone-activated
5/13.9
.MK-0457
gland.2,3
0.430
describedpreviously
B55α
Kras-transformed
5-TGTCCTTGGAGGAAGTGGGAG-3
G343S
Align-GVGD
TGGCCACAAAGTTCTTGG
RUNX1–RUNX1T1
Hydrogen/deuterium
p.Val115Leu
p.D9N
c.734+1G
Receptor-mediated
Stimulatory
mesothelioma
GFP-SUMO1
-638
.FGFR2-amplified
ATPase-containing
imatinib-desensitizing
p.T204fs*26
p-γ-H2AX
1,636
CNK
–specific
KEAP1-CUL3-RBX1
H683
PKC-θ
PrmCre
MYD88-dependent
3.3.4
HAM-F10
116-121
Y261
84.4
isothermal
.S4V–S4W
DMSO=vehicle
megabase-pairs
Anti-phospho-Mek1/2
RAS/BRAF-WT
19-deletion
1.06−4.27
Demichelis
c.1124delG
CCA-3′
ICLR
acid–independent
data11,12
N-His6
.self-complementary
44-SNP
silico-detected
Erbb1
8p11-12
Love-Gregory
bHER2
vera24
hg18/NCBI36.1
RR1–3
Bode
22q11–
BYDV
reactions109
R285
Zwijsen
15N-BCL-xLΔLΔC
unimmunized
21-77
Gstaiger
FASCan
.STK11
GTL16S5
contextof
c-akt
coworkers9
streptavadin
1r0p
L61
sites.3
papillomatosis
Haeringen
GCGGCGATTTTAATTTATAGC
.Leukemia
BCR–ABL–positive
32PTbR-II
NCoA
R306C
AHTakt-3
0.7848
T90A
ALK-inhibiting
IVH
GMP
Anti-acetyl–p53
fields-of-view
adulthood
5'-GTGATTTGATGTAGAGCTGA-3
PN/TB
Internalization
exomic
DNALI1
BR-02114
5′-GGAAATAGGGTTTCCAATGCTTCA-3′
cancersa
3-cyclopentyl-1-
×103
Black/African
p85αdelY463-L466
MZ-CRC
PCTD
+48
Søvik.14
32.9
Thereason
cytokine-mediated
resealed
FINK
gene-length
aflatoxin-induced
pEAE35
Lymphocytes/fibroblasts
FO-lclones
0.767
YUH1
werestored
signiflcantiy
Pontoglio
mutations.6,31
BI-2
.Glycerol
oversignaling
ICAM-1
only.13
S241F
GDC-0941,38
34.1
abnormalcies
UTR/proximal
thyroid-specific
anti-p44/42
Trp262
memprin
Anti-apoptotic
HotStart
L2654
LMAgarose
5-phosphates
17.00
−0.539
Arg603
extrinsically
genic/non-genic/CGI/non-CGI
99mtechnetium
L749X
GGCTGCCTCCCGCGGCTGCCTGGCCTCG
.Forty-five
CSNK1E
TrkAIII-associated
Eph4-EN
.Differing
thetwo
types,37
assays.1
.DR-GFP
Ad-LATS1K734M
gluing
μg/mouse
ATPdependent
RCC34
PAR1
−12
~30-fold
Proteinc/water
basal-myocpithelial
Wee
cells.25,54,55
.4,4
ADB-RBD
ROS1–crizotinib
aa2–56
1759
AML1-MDS1
45-0640
GST-GSK3β
12mm
E2351fsX2353
PDGFR25
range=1
C150Y
Leu597Ser
NB100
melanoma.74
UBC12
p.del
20–100
Lonai
Ink4a/Arf-dependent
Rekhtman
whole-exon
30st
ZNF560
Chr3:71027010
anti‐MEK1/2
F247L
P1291L
Cul4B
~1-4×104
-VC
ampli®cation/overexpression
PDGF/PVF-induced
RUNX1–USP42
hFGFR2
IRL
420-bp
//clincancerres.aacrjournals.org/
UV20
T1225M
RRL+
GST–Dicer
Met318
postinfection
1×10−11
adenocarcinomas21
nihms646437f9
c.455_478dup
8:3054-3064
EN-transformed
L40.47
τ
ERBB411,17–19
9166
reduced/loss
leukemias10
CD135-phycoerythrin
double-immunofluorescent
1.46
CFC-affected
.Morphology
502KIT
umich.edu
G363S
counterselected
10-month-old
0.042157208
studies.6,10,15
a11
300-bp-long
Intratracheal
types9
CMV-HA-Ub
ligand.4,6
vzg-1/Edg2
c.C85T
□
TCTGCACTGCAGCCCCACCC
contacts45
EGFR151
.Cdk12
concentrations.4,5
0.46
GSTT1
326,000
www.dsmz.de
M886V
.Expr.
2l–m
Groucho/Grg/TLE
M/G1
PDGFR-AA
dry-ice-temperature
.2ou
CDK4–TSFM
gelatinase
'seed
T-
FANCG-binding
receptor–
Pharmacokinetic-pharmacodynamic
20-kb
Glu63
.Mono
Polyphen2,27
Val774
near-total
T122P
G5
trastuzumab-binding
BTK-KD
5′-AGTCTCAGAACTTTGATCTTGTC
Burght
5'-CCTGCTCCATGGGCACGACTGGGCTG-3
PTPN11/SHP-2
1.0-kb
p2is
5ml
Senyuk
demineralisation
pSecTag2B
acetronitrile
consistentwith
350000
genes7,8
transduction–transplantation
hXXLαs
perfetto
M10134
A59G
inflammation48
Wnt-APC
q3N
4502A-07-03
HSP
hUbc5c
○
intron-derived
STAT3-phosphorylation
V954
IL2R
4-OHT–induced
E23fsX17
presentation.48
KIT/PDGFRA
TALLMO-dysregulated
CDKN1B
KIT.27
148.It
investigatedOther
PTN-
30/34
Y1021H
4-micron
mesh-like
adenocarcinoma1
anti-RAD51
radiation-resistance
TKI.22
g-actin
compared.32
Metl008Ile
I.1
W2d
del747–752
Fwd-CCAACCGCGAGAAGATGA
P=0.0004
OncoPlot
1127delTGAT
Hybond
centroblast-rich
−38.81
.Hatched
CDK4/CDK6
HRAS1
G4411B
M-AP/dE
-2101
L1243P
6J
SFKs.56,57
5'-gtttttcttgtagtatctagg-3
doi:10.1038/ng.2443
MSH2-I145M
Giaccia
hyg-coding
Ooi
14:18
know-how
R632P
Heterodimer
.Val57Phe
phospho-p42/44
T-lymphocytes
IgVDJ
~c
di-tyrosine
15/84
9q22.32-34.119
R497Q
9.1
MPI_HAa
V195F
non-secreting
BCOR-MID1IP1
B.E.C
18551
pS824
.True
5′-GGAGGCTGCG
G1556S
anti-FLAG
650-467-1846
WT-induced
microenvironment
Anti-FGF19
BH2
high‐frequent
4.24
C817TPolymorphism
.0246
JHH5
≥250
vectorette-PCR
PLX4032-resistant
Otogenetics
Apo-T790M
543–1087
R2763
Flag-MLL
Q837
anti–phospho-PDGFRA
neurofibromatoses
pathways19
FLAG-CARD11
2′-/3∼-O-
.Sellers
FAS–PE
eye53
pGAD–Kinectin
Glu/Asp
c.1726dup
Q61L-transformed
tissue44
ERBB2-V777L
structure3
scaled-upligation
GDNF/GFRα1
ACCAGCCA-CCACTTTCTGATAGG
63.0×1.40
HEL-specific
119,269,429
BCR-JAK2+
shGAB1
interactions.33,47
E526Q
tumors74
57673
TEL-JAK-expressing
21q22.13
∞8°C
0.500
758,703
5V-gctgcaccgtggatgtcag
PLA2
878C
p53-/-
neoplasms.18
PDGF-B-ligand-expressing
M18T
ALK8,11,12
Axin1-null
27-1837
283H
153.0–153.9
micronodules
1wd36
5′-ccaaagcgcaacaagcccac-3′
MCSP
NES
.Bcl-2
G328A
5'-ATGTTCACAACCGAATTGTTATC-3
4,889
PCR/LDR
BR/
LGL
v-Raf-transformed
Ile210del
PSQ96
DIFFERENTIATION
2006/14
514-412-4264
Wetsburg
MENX
SC-520
4/88
WRP
Bio-Tek
R174Q/L148A
Lkb1
ROCK-II
2337
Y1067
p12-13
.22.4
Ventriculomegaly/hydrocephalus
.ZBP
H1380
9486
.EGFRtumors
H-L
1789
Mll1f/fNHA9
•-
β-TrCP
Haras-p21
CML/MPD
SMAD4-overexpressed
DTT/1
PML–RARα.1
Dot1-like
Manghera
1–91
INK-resistant
ETS2.Fig
2014-10–21
melting-curve
cisplatin.27
intervention.1
pms2
Tyr567
copynumber
~500kB
ATRX-loss
p-eIF2α
18/1073
46°C
​and2A
D-004937-05
Inh
CK±
topoisomerase.Previous
pWt1-p53
gz
D1399
anti-EGFR-therapy
vitrokinase
identi¢edTGFBR1andTGFBR2
6p21
phe-
5–50
Spranger
IGFR
growth-defect
mlL
â€¢¿Y537N
Ab66138
HMR1881
CRE-excised
H2AK119Ub-depleted
C.C.P.
right-shift
11/23544
Kit-D790N
NRP-154-shRNA
GDNF-treated
Primer/probes
inhibitionof
repression7,8
Sp2transcription
VEGFR-directed
2/65
Msh2-HA
FANCA-10a
.669Figure
2·7
TNMR
vivo.57
dSplicing
HER2+/ER−
0.4–0.9
gefitinib.5-8
A131P
MachereyNagel
3.6±0.22
ALK-fusion–negative
-—two
M7-M12
siTET1
.0008832
17q10
evolutionary-conserved
Altematively
apparatus.85
Karayiorgou
C/G7
RTK-IIIs24
SH3-likedomain
infection3
R215Q
D795
Exemestane
Men1TSM/+
Zalcberg
5-AZA
cAJcl-nu
24,810
leukemiaspecific
V825A
tracted
TCR-controlled
study36
278760
Act–compliant
dkfz.de
67.0
3-vector
μg/dl±50
20°Crefrigerate/hold
GCTGAAGTACTTGGCTGGTC
2.130360467
MutSα·heteroduplex
G-
tumorspecific
inhibitors.28
ICIG-7
computerassisted
Telomere-specific
100–5000U
16-24
R70H
M1/10
TÃŸR-Ireceptors
Q902
-ends
CD28-specific
cysmethynil
imagej.nih.gov
-TTTGCCGATTTCATGACT-
supercoils
ETV6/RUNX1-positive
.Captured
EZH2Y641-containing
N=64
JAK13−
c.1896G
VHL-regulated
p110γ51
f4Forward
hOSA1
:pCYC1
.-H.
TGF-β-rich
Demunter
Exon21
3–6
cyclinE-CDK2
7,12
​For
F425
cycle-sequenced
vav-P-Bcl2
S267P
PharmLab
Tyr281
Otolemur
malignancies33
MET-bearing
HOC313/c8_1
non-pRb
−1942
C124/229S
Latini
OR=0.63
R132
doi
Nitta
respectively.24−27
metastasis.1
ADP-coupled
R1093H
.SPOPMATH
Sos1+/EK
pSUPERJade-1sh
disease.MethodsAbstract•
quintuplicate
sRCC
signals42
unknown=27
Prox1+
−1
H2171
22·2
Caov
Glu91
≤5.0
Ultra-Vision
-Burk
undermoderate
203G
mdm2-containing
SerrLeu
/duration
PhiX
Romei
.Bladder
magnesium-coordinating
260–280
.AQ
23m
GCACATGGAAGCTCACAGAA
Q331P
SMAD2/ca-TGFBR1
myristoylation-
ERE-luciferase
2,000–3,000
.Lapatinib
RTEL1
nucleusb
257–266
PIK-E20OR
Ile139
1–100
F421
11,593
epithelial–mesenchymal
Q542L
cells.111
patterning14
forty-one
nki.nl
glioblastomas6,14
Merrimack
5′-CCCAGCAGTTTGGCCCGCCCAAAATCTGTG-3′
freeliquid
9,13
1.08–1.25
tert-butyl
BenLevi
NCIH
159/225
FL-WT
line-activating
TaqMan®
1968
81906A2
c.2351G
0.78–1.93
Bioquote
del13q14.3
work48
FgfR2-IIIb
ini-
Q61P
rs35515689
del703-37
.K764R
RBD-recruitment
ter39
Martin-Broto
SK-MEL-2
32.Tumour
GGTTGGGGAG
NMD-irrelevant
TableDiscussionWe
Chidambaram
domainWe
homozy­
0.572699908
219
andWebster
.043
p.Trp527Leu
224_225insA
localization-function
tumors52
treated/untreated
COP1
diagnose
Tesoriero
Emelca
phospho-Tyk2
580802
DP4/7
MSH2coding
spindle-fascicular
A100
Resar
mutations/amino
D905
IPMT
Cys788
CNRS-INSERM
ofstudy.PCRs
R2842C/L
502b
K120
STGE
D546fsdelGACA
phenomenon.Furthermore
3134
N189S
Furukawa-Hibi
N25969
W33
Σhkl
R153P
poly-U
Method-S5
Knappskog
idarubicin
1750
A-39
prognosis162
16.4
∑|I
meta-predictor
FUBP1-PUF60-FUSE
pancreatic-
free-in-air
P.I715V
inc.
coactivator-Elf3
Y204
5A-F1
2009.Tumor
SP-1
chlorophyll
M14381
Faha
attR2/L4
84-kDa
ARv567es-expressing
Disabella
722F1
.FJ627786
Flaman
pBABE_EGFRS492R
LIN-35
IL-3-depleted
PFM01
Y599
UOK121
I6t
BCR-ABL.17
S4R
Hongyo
745680
5′-CTCTAGGATGACTACTGGTAGGGT-3′
Birnham
A620
thermofluor
TMEM30B
SMAD5
1292
MUM
NCI-Molecular
.Colclough
17-year-old
AG-1
0.337
sequencing31
0.4-32
Leu414ter
HOC313/v_2
GABAA
pAb1801
NADP-dependent
733.06
MTB
Wade-Evansand
—here
pmetH
MAP3K11
Mek-
SETD5
.Breaking
positivecontrol
modeling/docking
ER+/PR+
serum-free
Recurrent/metastatic
fungal
CDG
.Black-color
STIM1
H202/PBS
C74R
50µg
fetal-calf
cis‐regulatory
609322
.GRIN2A
P≤0.007
Histidine-to-tyrosine
recombination4
C-terminal–containing
p.Leu1209Ser25
Asp810
Asp351and
Jh3
5′-AGGCAAGATGAGCGAGGCGTTG-3′
Stuckless
pRS405
stones.14
EBV-associated
lammellipodia
9421
.Myeloproliferative
phospho-Tyr905
hFGFR3
dinucleotide-specific
Astrinidis
wt-I157T
ALL-7/8/9
XM01186
FM2
0.222
previously.15,18
hetero-
.Huge
rad3-1
Trp80
mTOR-G4435
behaviorA
AGCAGTTACTCTCA
16–22
triamcinolone
types.25–27
KCl/1.0
Asp770_Asn771insAsnProGly
.Panels
dexamethasone-regulated
H09
mg/d.9
1•4–2•9
c.248C
26789InsertionCGA
Annexin-positive
746delELREA/T790M
noncarcinomas
1996–2008
.LysM-Cre
5′-CGGGGTACCATGGACTTCAGCAGAAATC-3′
2712
Obel
K19A
al,10
SF3B1exons
Oligofectamine®
T1010I-Met
effect34
p.Glu205Gln/p.Val367Ile
Map24
.PLX4720
3163A
Yp11.3
depara
.vulva
pentagastrin-induced
UFX-DX
5′-TCCGTGACATCAAGGAGAAG
micro-CT
p.R458X
Virol
Netrins
FANCD2-related
Zn+2
Pb-AR-alone
.b–d
R168C
farnesyl-protein
8/2010
microfluidics
N1941D
macrophage-specific
EMHY578
jpages
0-115
c.A1
KMS26
Bldg.
Met327
23,34
dichloromethane
background192
SRSF11
W257G
anti-Skp1
HCC24-1005
genotypephenotype
Materno-Infantil
569–582
si-Smad5
RIa
test.Table
DRA000503
Cosuppression
CD33+
D1–deficient
54±13
20220
9.6–6.7
+R776S
Tet
chloroform/methanol/water
a/ali-cgi-bin/splicesitefinder
MS1
.Fisher
C235Y
toxin-stimulated
H1802R
_1144
4:2185
LMP2-Luc
superfamilly
I-D2
.Y463
T-/myeloid
SDS/12.8
p16-Binding
D2Mit229
1J–K
alpha-specific
CGH-defined
T877A-containing
74/132
MAPK3
Miettinen,28
E254K
ade2-40
DAB2
Co-deletion
MEK1F129L
7-yl-cyclopentane
Wnt3a-conditioned
Nrf2‐derived
69K
NA-40
-AAC
5′-GCTCAGAGCCTGGCATGAA-3′
.PC12
Aegerter
G309A-mutant
G39E
CT-1
immunoresponses
reports.9
Cy5.5-labeled
C3050T
anti-p16
trypsin-EDTA
Kawagishi
foveolar
HER3/HER2
CTTGGAGAGCACATCCTCAC
K48E
60-65
c.1865C
E580X
oncostatin
Glu-to-Gly
09/2001
R86.0
variant1
acidsMutationGAC
non-ITD-containing
well-to-read
unlysed
6l
pT183-E-pY185
phyloP.28
Znrf3
R419Q
T228M
Arregui
MST-FoxO
Tricostatin
filament
isozyme-specific
pheochromocytomas123
nearest-neighbor
2495
or≤0.25
S1468G
B1.3
NF2-and
trachea
Y35N/C/H
.4c
nm±s.e
F1174L/C/I
119,1add
PLDLS
NZM61
P322Q
5′-ATCACTGGGCAGCATGTGGCA-3′
dimethylation34
5B–E
A3
5′-CTCAGAGCCAGAGAAGAGGAAGA
106-107
NOTCH1-HD
LSL-K-Ras
Mus81/SLX4
005
deleterious.
enONlV
Holt-Oram
Eukaryotic
mu1562F/mu1562R
20-meric
IKBKE-regulated
ESlRADlOL
252G
1997–2002
HIV1-LTR
0.92-5.56
uORF-containing
e11
drug.12
39/54.2
IL‐6
without.26
uwcm
KITD816Y/N
Sephadex-G50
50μm
nsSNPAnalyzer
Tcf3
GCN2
55Â°C,45
Imager.A1
protease-dependent
1-butanol
pMSCV-KIT
N777S
1e–h
preeminent
H3K4-trimethylation
posttransplant.16
Brca1C61G
pathogenic.The
c.1327A4C
A1762D
Spizz
N94
P⩽0.0001
85009
802
V347A
Trp1
HER2‐targeted
heterocomplexes
Ras•GDP
assay.16,18,19,39
protein–DNA
:17–23
Q463H
vcftools_0.1.9
2/84
2123A
ischaemia
AML17-21
E-twenty
NKX2-1-mediated
ab12073
0.9039i
BRCT-interacting
Mg2
LSMT
132794901–135944600NM_020815NM_004064
BCAR1
annexin-V-fluos
Krasex3op2
Central-
Subclassifies
Y32W-I36G
EML4–ALK-
CGGTCC
Cation–π
addi-
H847
meta-analyses.21
G466V/E
Y2264X
GCACAGAGAGTGAACATCATGG
50–54
imatinib—for
36.3–70.8
CCNI
targeted-pathway-sequencing
.Real
Ago1
3–7
previously,12,13
mutations/alterations
294-687
RPA-coated
alkali-stable
HCC4011
eect
1084–1086
recurrent/metastatic
cells.3–5
p.Phe3155GlufsX9
-neo
p=0.044
NSCLC.11
BrDU
.Regional
sc-93
6A-D
immunoprecipitation-kinase
EME1
adhesion-dependent
Phe1174Leu
hematological
V2475M
CLL.30,31
CTCTTCACTGCTTCCTGGT
Q252H
723–729
Yescd
MarkDuplicates.jar
LBC
Nanocep
5′-AAACTGACCCAAGATCTCCATCTCGCTGGTGAGGTTAATGATCCTCCT
fluorescence-dissecting
data-mining
KHI2PO4
Ptpn11
2σ
strainsexhibited
A-CDK2
merlin-cytoskeletal
bone-growth
Higashi
0.5mM
OR=0.94
.Low-grade
U.S.C
P=0.786
Φd
Arg24
liferative
TTCCTCTTCCTGCAGTACTC
.SEPTEMBER
.Sheep
fl/+
2997
tumor-T
expression97
V173L
21/32
151-155
HhAnt
-TCCTCATTCACTGTCCCA-3
1113
nongliomatous
28-145
quality-checked
Myc-DDB1
.CASE
E1080K
3.6
C-2415
neovascular
32,200
022970.3
here.9
Bradney
MEN1-associated
G61S
SPERs
29,480
S2Ee3
544–552
V36del
.Consistent
aS3
CTK,44
N-methyl-D-aspartic
cRSS3
993â€
Kong-Beltran
autoregressive
tumor-suspect
QqTof
42.3
polymerare
368:2395-401
molecule-induced
168-206
2CL0
etoposide-treated
al54
.Truncating
A_51_P497152NM_013518
0·59
CCATTGTTAAGCCCTTAAGTC
5.90
Ndelta
ERBB2-non-amplified
PCR.68
0.08-0.4
TAFII31
nihms5567f8
Leucine-rich
Tubulin-HRP
5-hydroxyindolacetic
RB133
predominately
CTCAE
.T315I
15:19
97-104
endobronchial
metamyelocytes
tumor–bearing
echography
casodex-treated
IQ
anti-guinea-pig
fusion.34
.Constant
.RT-4
125I-protein
602954
PTPRF-interacting
'yes+
mutations50
PPP6-H114Y
.Monoclonal
2-domain
1.2-pack-year
E642
c.3971C
D551N
hypoalbuminemia
10029.
hextuple
1:75
.VOL
GDP4
theTP53
C250T-mutant
N′-Methylanthraniloyl
T567D
HCMOGT-1
Ptgr2
h7p8q23-24
T123M
.Embryos
reverse-transcriptase–PCR
.Point-mutations
abnormalities30,31
Wijn
promoter,31,32
F891
R109
Glu738
.Kemler
previously.9,55
single-plane
.Isolated
TATTTCC
local-regional
5′-CCTGCTTCGCTGCCATGTCCTGACTTCTGG-3′
697mel
CCACAATCATTCCTGTGTCG
Y511
site.22,23
hypersensitivity10,55
H3K27me1-demethylases
NIBP-amplified
.Bondarenko
9,35
//brca.iarc.fr/LOVD/home.php
differTable
+440
2,673-bp-long
fibroblasts—Tumor
p21.3
targets,33,34
defined.96
ABI3130XL
−/GT
MMU16
Unc93b1-dependent
=80
KpnI/SacIdigested
lymphomas,15,17,19,23,24
F.D.N
Δ13Cβ
MIM
nFLR-rkae
U72938
ng/g
12,627
PDS5B
immuno¯uorescence
3.04×104
Hyper-/Dysplasia
1.341
Zeo
HGF-pGL4.26
CCATGAGTACGTATTTTGAAACTC
1950
anti-cKit-PE-Cy7
5,6,8-18
EN-V1
NP_005227.1
1–176
JUNB
Rag2-deficient
P-20
U-bottomed
Langherans
1048
E812K
JMN
transcription-associated
AG3055
radiotherapy.1,2
humans8
666del1‡
NRAS-1-F
FGFR1-derived
Chromatograms
2000instrument
R243W
cancer-contributing
mucosa.1
e1
exome-wide
*9A–mediated
cancers—life-threatening
MLN8054
31/40
factors.Identification
.Tip
ml-l
Tsc1-null
anti-DYKDDDDK
3/87
.Burlingame
dimet
.Hepatocyte
Gly-WVal
1D-F
NZM1
P21-5′
ligands.10,38,39
365
L51R
proof-of
.Kwok-Kin
1165del
Smad2+/–
so‐called
propyl-length
mitogen-stimulation
PI-3K
Vaziri
0.078375718
MEK-shRNA
Tyr1034
1D-G
Friedel7
taxans.1,2
HNF4AP2F
cells,36
v1.9.0
max-multihits
5Vend
NCT01256385
5'caaagtggaggagaccatcg
SOX21
171KB
SMAD–receptor
Antifade
5′‐CCAGAAGAATTTATGCTCGTG
GPDH
CUCRC040
TFF2
protein8.Figure
GST-bound
proline–valine
polyacrylamide/urea
−400
LRRC71
Age-standardized
laparoscopic
2194–2195delATb
HuEx10stv2_Hs_ENSG
Men1/T-SycP1Cre
independent.Analysis
CTCACTGGAAATTTCTGAAGACTGTAG
patients5,6,7,8
2-12
CACACCGGTgcATTGATGGGAATAAAATAAGGC
B1/CDK1
29432822
cellto-cell
primers/conditions
Proplatelet
2C2C
MGH-U1
Cdk2-Cyclin
Ubiquitin-FLAG
Lys285,32,33
-e
Zn2+-binding
*~
∼7.2-fold
Pgk-cre
SF7
IFN-regulatory
4337123
lines,29
surfactant
CRC18
SmaI/BglII
described,2,11
chromatographic
.ZR-75-1
.WM3211
1XPD
Jak-mediated
www.rcsb.org/pdb/home/home.do
Yap-S112
GTF2H3
618
CELSPSKLEK..
S6K1-enhanced
•uSer
EGFR-TKI-untreated
Lats1DN
EMBL3
TS1
Thr9
.KrasLSL-G12D
SA.3
1uM
XAX
600–800
3/poorly
238.8
TriColor-
nMactive
α-β-tubulin
user-pathologist
cisplatin/IP
XP/Cockayne
www.targetscan.org
Fig.2E2E
Cys-X2-Cys-X19-20-Cys-X3-Cys
Ibrutinib-sensitive
I155F
un-induced
protein28
CNTNAP1
ibrutinib-mediated
2/328
TERT-immortalized
cacy
G442V—Compared
180nM
2I0V
NF-κBm
sonicated
CM5
12.6–
mutantswere
​Fig.5E
GSX2
5-aza-dC
F5-R8
CATGA
anti-ERK2
oncoproteins.6
literature.3
C5-r-1
HaplotypeScore
minicolumn
2/nat
.Computations
0.858
E2663V
FASMAN
cell-stress
PDX-based
together110
5′-CGA-GCG-GGC-GGC-CGG-CTA-3′
997
Lifescope
Neurath
rs11246176
plasmin
.4C4C
R130A
pVpack-GP
Position-weight
smallaliquots
proof-of-concept
FGFR-fusion
formalised
repair.9
_4
HNT34
carcinomas56
virus-associated
enhancers.3,4
arginine-to-cysteine
carboxytermini
.D-004937-03
sc-13121
50.4Ti
cancers75,83
primer-probe
Ard
G216D
dual-arm
Skoda
Dabora
.LFS
ALK/MET
NF2-specific
PP2A-B56–specific
.L2026M
15/22
diers
thrombocythemia.23
ltd.
014791.3
GYMN
genes.23
ME-PCRs
Ge´ne´tique
activity21
factor-independence
migration.7,23,24
EWSR1–FLI
mutant–DNA
16p12-13
G=R683G
coulomb
kinase-regulatory
anti-p70'rk
V378–F379
allele.Two
p110α-KD
IVS2+IG
D813
Sedkov
included.Muta
MiG-empty-
future84
-0-
electrochemical
Thangue
studies,15,21,22,24–26
Double-Strand
1.60E05
icPTPRD-bearing
PJS049
T-ALL
3.2-Mb
Blue-Native
2,111
-CTACAGCATCTACTTCCAGACACTCAGCAAAGCCAATGG-3
TA-cloned
Trikalinos
751KB
rearrangement.11
.Connective
.Tavormina
micro-Boyden
Box2
protein1
third-round
intragenic
.Mortality
PK1
m/z51152.04
ulum
c.9026_9030delATCAT
.Ice-cold
tumors.8,9
T196K
68jC
35.31
â€¢ii
screening.40,41
4x48
U/liter
times100
TP53/CTNNB1
Symphogen
S128P
Prov.le
Balogun
81–99
TTGATGGTCTATATCTGCCACAACCGCA
warranted.The
DataData
803–806
Brucet
Robert-Rössle-Hospital
comparison.4
fluence
S1512
HAT1
samples80
.Integrity
lozanges
AF363681
MYC-potentiated
.Mass
.Co-ordinating
International–accredited
rizwan59elmc
andin
EWSR1–CREB1
'polycythemic
Tra2α17
gamma1–Calpha
629/548
logR
p.H371Y
L398P
MathML
Arg343X
MLC84
del557
cate-
SNX211221
Mxi
5′CHEK2/22q12
deletions35
c-myc-activated
Boter
respondingto
Glioblastomas
A11
SIK
Yesl
8q24.21
formation.91,95
CHIP-seq
thetreatment
KIT-D816V-dependent
D835E/N
SFM-400
Flag−FBXW7
cells101
N233Y/I
6/3
24:1
E137X
34.4
Figure2A,2A
Digoxigenin-labeled
anti-C-RAF-phosphoS338
stability,14
perfomed
243
AKT-p
78260810
reamplified
pEMc11S
251
cotargeting
TAP-HA
AC220.8
25952-53-8
SCLC
place—as
1.071x10-04
Fig.7G
inhibition.9
picoliter
T1144C
VDAC
helix/forkhead
0.1.5
13,14,19,27
D119
tumors.15,30
M5S
'gatccAAATGTCCCGCTCTG-3
C-β
apoptosis251
.TGF-β
sulfonated
shLuc
AlexaFluor568
dnSTAT5b
p=0.0155
1.4–1.7-fold
SKLU1
≥4
17–18
0/1000
FO-Icells
JAK2V617F–expressing
//code.google.com/p/cutadapt/
vol/vol
4P
.tm
94143-0422
BCR-JAK2-positive
IC-NST
3,400
.Histones
small-disease
Kyiv
OMIM300128
pRRL.sin.PPT.hCMV.pre
G-negative
woundhealing
HR=38
pruritis
DNMT3B7-containing
G−748
TXNRD1
p.D522N
EWS/WT1MEFs
e6a2
activity134
o0.01
5′-atggacaatatgtctattacga-3′
5′-GAASAMCCTGTWC
NF1-REP-b
lcUAS53
mA259Raf
red=high
2B1
treatment-emergent
cells.36
FS2F–H
Irusta
IL6R
bloodbrain
GGAAGATCTTCCCCACCATGGCGCAAGCCGGGAGAACA
Trp53LSL-R172H/+
above5
NCT01245062
Nephroblastomas
2.4–3.0
293-complementation
MP0035
nucleotide-exchange
hRL
eBL
MADH4
1,704
GFP-vector-
​Fig
Mll1f
FH0038
BSS
pCMV-p53-SNPs
BMP6
NF1del
115.5–117.8
RMPI-1640/FBS
Sox5
DENZO/SCALE-PACK
~5,000
.NOTCH2
inducible-cas9
NF-κB-binding
5′-RNA-ligase-mediated
BRCA1-GAL4
virus-mediated
Rimoin
re-sequenced
genotype–phenotype
DSCR1
CTTAGGCCCAATAAG*CTtACAGTGGGCCTG
C-E
D-80337
1931
233G
Duisburg-Essen
INF-italic
Atrophic
group.Table
'ultra
B′/PR61/B56
.12–15
stem/progenitor
.Knocking
VH/87
5197
A735V
del747–752/T790M
his3D50
1.95
1−α
3.41
1640-bp
R1204
27-gauge
176-181
pEAE74
2.02
w~~~~~~~~~~~~~~~~~~~t
DUSP16
Supplementation
07-0570
al74
www.millipore.com
Ayyanan
DNM
VSMC
L242R
G215D
−2.99
D2–p27–Cdk4
T-Test
.0064364
.BRMS1
status11
BCP-ALL,4
Egly
10:11
S727
PLEKHA6
4.Figure
CGCTCCTGAAGAAAATTCAAC
CML.13,14
14-month
2.688
Biosystems/Life
10.45
IKBKE-mediated
MHCC
0.400
5′-CTGGGGAGTCTTGAGGGACC-3′/5′-CAGGTTGTCTAAATTCCTAG-3′
GCCAGCGTG
Orange-dUTP
.3103G
BACE2
maintenance28-32
group6
140-bp
transmembrane-conductance
XY
future.MethodsCell
​to33C
5′-GGATGGATGTTCTGGGACGTTGC
ab150129
ARID2alterations
0/37
ϕ
CCNE1-amplified
PRM-Cre
Popovici-Muller
H93Y
31/50
3-converting
Arg505
5122050
ER81
g20
RevGFP
.10
differentiation29
Ubx
DpnI
714
K646E
1999–2006
107/mL
NP_005154.2
24•07
.Resting
INICD1.reverse
2n
kinase-activity
HG-0158
FLT3-V592A
conditions.26,27
chromatin.Recurrent
instability.15,16
-53
PMS2
kConFab
membrane-type
Polyscreen
RAS-capture
Freedberg
3i
v.3.1
SNPs/genetic
cascade.β-catenin
Smad3+/-
tators
0.03651
NM_005610
BREAK-3
angiocrine
autophosphoryla
.BLIMP-1
.1798
nucleus/cytoplasm
GCTGAG/gtaaaa
MSIa
PTEN-L345Q
Ser1390
Mascarello
pEYKBA21
nucleus93
amino-acids
Val550
EN-Y517F-
1.16
MPPH–MCAP
pYES2-GFP-Akt1
5′-CCCCGAAGCTAAGCAATTC-3′
AGCCCTCTGCAACACAAC
Sc-1082
Erbb3
2007a
Expi
AML-1B
NF1-specific
24,28,29
cell-induced
Melillo
1.66–1.99
cancerTable
TGTCAAAGATGCTCTCAGGAGC
*References
Erithakus
generated/ytM
order.8This
QUT
pLKO1
30s
.9,13
Scoresby
R95
bHLHZ
H3663
MYC116
.PF-EPN-B
V64I
D770_
6-hydroxyl
500-0001
disulfide-bonded
andhow
glycine-serine
Esterification
c.259_272del
re-amplification
c.4429C
SLC43A3
CDT-2315C07
V145L
MLH
7,494
99.8
GTTGCTTCT-3′
manner104
excitation
A190T
CFC-1
stabilization.28-30
xenobiotics
v-MPL,18
TP42
Phospho-Site
KLSSVEEEPGVSQDR
co‐transfecting
anti-TEL23
controls.30
pan-KIT
M252K
.PCR-RFLP
antinucleophosmin/B23
polyps.25
.FGF-stimulation
c.5894insAC
MCLs.24
glucose/kg
A_52_P363110
vorinostat-mediated
.Hypermutation
nucleofecting
N239Y-p53′
8340/3
ESDGG
McEntee
cytokine-linked
rp-S6
mispriming
nAsp
Rad51
TRG
-IF~II
TP53-deficient
ctcttccag
CD1–
Exendin-4
15Ser
inside-out
agents.15–27
Hif2α
base-stacking
2.70-
29,11
normally.48
WiDr
Foci—Recently
p13.2
17p12–13
GAGCTGCCATAGAAGTCCCAAGTGC-3
chargecharge
gadoliniumdiethylenetriamine
HO15.19
ETEA
sAsnleul•uProGluGlnAsplysM
.His65
03.00/0
R2135P
CTACGCCA
L330P
0.318
SIP1
G418-neomycin
nuclear-encoded
multi-cloning
c.5266dupC
complex55
regimens59
kinases.Vemurafenib
TRGV9
.Joensuu
T374P
SRSF2-overexpressing
Jhavar
p53tetramer
RB6
predominantlyin
3487
JK
115/130
protein-base
Tyr551-phosphorylated
Asp816
CS-08
-protein
D162
phosphatase-inactive
pancreatoblastomas
tetrahydrofuran
Martin-Zanca
R132H/C
anti-FGFR4
V173A-
decile
unhooking
RER1
Stankiewicz
R427H
Helicase
cyclin-D
2307_2308ins9
.Mice
.CrossRef
Ser465
ABC1
K4E
∼1:5
GCCTTTCCTAGGCCT
B′-containing
unconditional
AuroraA/STK15
-Cul1-FBW7
five-somite
0.75–1.31
ΔDNMT3B5-7
S7L–M
Termuhlen
4/CDK6
SOX7
nuclear-export
ELA
P253R
cDNAfrom
\50
99–155
g/mg
R38H
RAR-responsive
.PTHrP
blue=NSG
5.5-fold
GK-GPO
mTOR-pathway
myelocytomatosis
therapy.103
1,000×
TRAF1/2
EYFP-CBFβ
BCLs.3
KIS-1
P.G719C
PKC41211
Picomolar
Amresco
Rad25
Inpp4B+/Δ
58–67
lung24,25
Canelles
Illumina
.Spleens
and3a
ROCK-II,24
Kras+/LSL-G12D
n=579
GS-405R
MATa/MATa
ADEDA-ID
−1.51
oncometabolite8–10
LMNA
2μM
MAPKAP-K1
68–271
83,87
adaptor/regulatory
CLDN18
1011:1
4-methyl-5-
gaggctatccagcgtactcc
B7-H4
RNAimax
Intron/Exon
ASPL
estrogen-responsive
Bryostatin
Lys-72
Seq_Allele2
rate.7
BRAFi+MEKi
G14V-immortalized
1-175
p27-mediated
affinity-purification
Val1838
UCC
syndrome.56
casest
Takaku
.T7-pJAK2
T2N0M0
P4
MDM2/GAPDH
-1696
.Ruttenberg
150-mg/day
.Lobular
.PMP22
dasatinib-sensitive
allylaminogeldamycin
G288
346
DelG106_R108
T359/S363
cells.105
Combination†
JAK-STAT-driven
CMT93
proline/glutamine-rich
Gad1
D1734E
MLH1/PMS1
pQE9-AML1
Bmpr1b
mineralogical
UAUAUUUAUAUAUUAGACGdGdG
27-71
Schaub
Outcome/variable
CACAGCCCAAGATAGTTAAGT
R474A
R1022W
unconsciousness
shAlox15b
CTLA-4
PJS05
Rok-α
11.8–25.1
UbK48R
site−site
pnas.1321155111i15.jpg
trichothiodystrophy,6
R63X
SEPT14
8390delAA
adeno-
nature.comThe
A123D
NEDL2
S224Y
described.42
Braffman
∑j=1nK
allele24
CDKN2A9
342-361
3352
0.01.Structural
7048717
.1349
León
aromatase-inhibitor-resistant
understood.SNF5
Hh-induced
Laparoscopic
SMOmediated
hsMAD1
P2319S
NrasG12D/+
Hs277039
D1S2698
serum‑starved
thosepreviously
Raf-l
2-infected
40.5
www.cephb.fr
.SwitchP
4870
p74Raf-1
ARID1B/β-Catenin
di/oligomerization
pre-binding
4F64
performedaccording
GC-type
9y
Alimta
D1-T286A
cytoplasm-localised
n=3
129S/Sv-Prm-Cre
previously.21
.Homology-based
PMA/
CCNDs
pEAE34
EGFP-spectrin
pMEP4
T1025S
analysisFresh-frozen
anti-phopspho-p70S6K
malformations18
AZD4547
98C
conjectural
RIII
c.151_162del
ACTSEQ2
Autocrine/paracrine
imetelstat
5′-CAAGATGCTGGGAAAGTCGT-3′
F3-R8
Bouzid
β/NF-κB
MGC:90616
dA-dT
SUM52PE
ATGGCTGAACCACACAGCTTCA
ÃŸ-galactosidase
bibliographies
H-RasV12
Buisine
.MOMP
0.628
SKG-IIIa
N-101
4863
NP_031465.2
`7
kit.18
leukaemogenesis
HNF3
5'-CATGATTTGAAAAAAATCTACTTG-3
Specificsized
10mMKPi
KDM5C-Flag-HA
−1.39
DCOG
microarrays1
adition
protocol.15
years5,9
ROSA26CreER
5′-Cy5
A/C
5.42
∼1,000
Calbiochem-EMD
AML89
Fig1J–P1J–P
S5A–I
WT1−/+
anti-CD69
spondylolisthesis
MEK1/MEK2.21
52patients
.Regions
Rosa26Pik3ca
452
T37/T46
13Q
21461-84-7
D842V/I
NCT01367665
24626
5′-TGGTCTCACAGGACCACTGATT-3′
0.5432
p.Intersection
PI340
TLS/FUS
LSK+
rapamycin‐insensitive
Mizuno
representsequencing
more-excluded
RNA/Protein
GATA1-dependent
cells.24-26
33·3
CDKN2A.120,121
non-LCH
E343D
propionate.Full
CycC
Y280H
TAD9/HAM
S217
-inducible
0–12.9
^13321
structure-
NS733
19–65
Tumour-associated
MVD
2004.
`F
receptors62
HIST1H1E
succinimidyl
haptotactic
Real-time
p.Glu1099Lys
S9D
×4
N308D
below18
HEC251_ENDOMETRIUM
Val769_Asp770insAspAsnVal
D861
Xho1
11.7–29.6
IVS14–
p210Bcr-Abl
growth-measuring
FIP1L1-PDGFR
146T
orDiagnosis
exothermic
enolase
growth127
polarization23
neurospheres
v-maf
activation181
Mandriota
SIC-1
data17
Rhodamine-lectin
0.1-2.5
c.1514G
BRAFwt
21amino
αSPOP
mice,21
73,250
ampliﬁcation
AZD6918
SR-ULT
BCLAF1
51976
Notch1-4
non-Switch
MY1
CTTTGATC
Reichardt
competitor.The
NBG14
NM_020612
GM-CFU
G166
far,5-7
bacteria8
studies3,7,10,51
CSD1
.0235
****P≤0.0001
0.29
mesylate.26,27
His3
mRNA144
AKT-induced
diseases21,22
pRevTRE-WTRhoA
G380R/G380R
mutabilities
FL-476
30410
ΔCCNB3
FM-associated
Methods9919b
RipCre
pRB-deficient
KIX
CUL3-KLHL22
TAMRA-6-FAM
P578S
835±1247
peroxiredoxin
Tsukuba-shi
MLK3/MKK7/JNK1/JNK2
M706T
DNA/60
T1151ins
pGL2B
Fig.3f
36/CRC
530-kb
sc-C-15
NM_030662.2
-00
.YOO
BCAkt-3
.Signalling
yPH-PIG3
Fumihiko
qj
11,21,22
GGAAAGGCACTGGAGA
pHumanMinSet.htm
.LY294002
P=0.001
144–149
theforegoing
KIF5B/CCDC6-RET
Buczkowicz
|il
T-ALL–associated
Knuutila
expectations.15
FL-derived
UMB2
*C2-7
2.7.
LLD
1.23
E.A.M.
2327
2Echocardiographic
de2
CC/
V-CAM
LAF4
3456789
KPMYEVQWK550-558
1,410
anti-WT1
1.5–4.5-mmol/l
'271
0.024‡
24-year
3′-related
WA4
EGFRvII-extended
5,7
I-treated
P488
10417
variants—L93R
~50bp
WTi
2.65
Thesemutations
cells/cm
16ptel05
non-oncogenic
.General
anti–phospho-Stat5
metalloproteinase-mediated
MPRIP-NTRK1
Cyp1A1
inhibition.3,4
morulae
stereochemistry
963-965
.E1099
D350
.β-Catenin
completeconcordance
E384G
00–010
MET-M1268I
P50.011
4805
CNVVariation_5006
TpG
AR.In
Inflammation-induced
signature7
p850α
methylpiperazin-1-yl
IgG4+
FNCLCC
.MLL–AF9
BCR–ABL–driven
58668
SM-MHC
W7
FL-CDB3
above.This
Yasukawa
1951C
a-FLAG
GST-THD
Cell-Matrix
Glu1250Lys
Cdkn
delG322
5′-AGCTGTTGTCAACTTCAGAT
sub-phase
domain–associated
SREBP1C
cancer-susceptible
2.98
T8M
anti-S
sinistrum
NM_016931
.Disturbing
Trp557_Lys558del
P=0.0012
Intraperitonal
P753insS
A150V
v.50
Kirchweger
11substrate
1271–1272
One-Third
Ã³p2l.2-25,20qâ€
TAp63.62
regrew
c.3927_
11/16
DS86
8061
D.E.V
Ubq-HA
Tyr35
62°/60°/58°
103–130
MSCV-Hoxa9-IRES-puro
A-Barcode-Exon21F
Second-round
6719
MGC34440
c.655A4G
www.cancer.gov/cancertopics/types/lung
XLA
Danversm
hypophosphorylated
Hyper-immunoglobulin
Cortex_B_pool6
Krozczynska
RING-associated
establishedHRM
M002
66/3248
cells/60mm
1999.
Δ3270
sequence-constrained
217insC
.Sabapathy
anti-BRMS1
DCC-FBS
ratcell
GYN
p15INK4B
mutagenised
//primer3.ut.ee
WASF2
Cul2-containing
Accelerys
DE-driven
E415
.AACGCACTGCC-3
Arg7′
i~~~~~i
ETO-containing
tuberin.15TSC1
TYK2P1104A
GSH-agarose
Pa-tients
NSD1.30We
AR-V4
www.jama.com
V157D/PMS2
M084
5′GGTTT
TGFα/Neu
Leu-53-
irradiation–induced
acrocentric
GIST.10,11,26
181590
p.H371Y-associated
K141E
sequencing/IVTT
41–46
thedistribution
10-3
betacellulin
746-750
14.9–18.0
anti-PI3K-p110
twin-spot
TebuBio
FA,23,24
delocalized
Phosphate-Buffered
.In-frame
Arg879
P462
arginine-to-histidine
fusion–harboring
.319
UV135
.Subgroups
LR.Because
Melville
16/158
.Dr
Sulfo-NHS-LC-biotin
locusId=3815
coefticient
KIT/CEP4
581-593
PI3K-AKT-upregulating
μg/dose
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine
thi
twicemore
Suberoylanilidehydroxamic
Jetprime
NVP-BYL719
X=138
equilibrate
10.1158/0008-5472.CAN-10-1543
green=MFP
cells141
N592S
509f
scars1,2
transcriptionAranslation
+1q
pull-down
.Illustrated
ZIG-1
-DQA1
AKT-
.68
3.02+0.20
7.19μM
LADC
C611Y
pAS2-1
Figs.3B3B
.6-12
gRNAs
Thr-701
FLT3.E24R2
Z3
phosphorylation,24
c.749_751del
ΔEGFR/PI3-K/Akt
cMET-independent
-GCTGCTCCTTGGCAGTATTAAA-3
GQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQDS
k′
.Medical
v.2006.08
CCFR-CEM
1•4–2•6
FGFR2-FAM76A-expressing
ADE-based
p110alpha-specific
helix-loop-helix
.Full-length
MTC.12
nutrient-sensing
Sumoy
R766W
STAT1-dependent
I195N
PicoPure®
R91W
23948
3B-conditioned
ADNTL
MLLMLLT10/AF10
3,100
IL20
GM-CSFRα
Charlet-B
parvum
TK-
St3
A106
ChIP-seqs
Flinto¡
5-T32-NS
ourin
Bjerke
miR-124a
320-340
Mycl1-null
8.954539125
Thr421
FRAP-ATM-TRRAP
activity34,35
OF8
135497789
CD1α
H3-K42me2
.Bivalent
p.Pro26Ser
B55γ
H5
Scheffner
cells73
Maori
05–419
TH2
HIF-α-binding
reported4
Δannexin-V/propidium-iodide
posi-
carcinomaUndifferentiated
pGL3-
Novelc.3919A
Tet1/2
DNA/RNApresent
517–682
UOK143
DDS
RNF25
isoprenyl
3,006
response.7,8
earlier.23,26
.974G
prognostic/predictive
GSK112012
colonies/100,000
p=3.6E-08
PLL_index2
3338
FGFR1–mutated
non–BAC-type
p=0.011
receptors.5
HTLV-1-infected
61.9
DT24
jth
.N-CoR
Flag-epitope-tagged
A263V
IRAK3
.Segregation
3038
domain,21
trials.3
ninety-three
INCEP
Shp2-expressing
blue-tinged
rs146606219
.Calpains
Leu-195–Leu-196
abnormalities—since
cryofractured
-arrays
K14-expressing
Alk53
AK045005
1—
Magi2
lower-resolution
N948T
V143L
semi-transformed
ΔD579
Noncrossover
EPAS1-mutated
melanoma-like
E163K
S481L
ICG-HNPCC
≥6-fold
energy-related
Pro-mix
5′-gccaggccaccccttgtatc-3′
MDA-MB-134
SCFFbw7
Chr3:71161740_71161741
TCGTAGCCCTTAAGTGAGC
isoflurane
.8,9
MSH2-p.I145M
GAL-PGK
Inhibitor-Resistant
1XD4
0-30h
DO24
MYCN-
MET-002
.Pro-34-
186-188
.Whole-mount
p53s
selenoproteins
lipopolysaccharide
7.56
l•ProGluAsp
123.9
1,000,000:1
NUTM2A
N1730
.Sublethally
Lys729
summarises
cell-proliferation
Thut
depth-coded
PTEN-bound
4.87
aPreviously
772–773
inhibitor-kinase
CEP110
decreaseorlessthan20
CEA+
H377Y
0.49–1.13
wild-type.5
546-2A
pTSG
Vmax/Km
leiomyomagenesis
.Studied
Ultimate3000
COLD-PCR
6917
N-lobe21
ULD
T15
HA-MITF-P
laboratory-supported
19F-2
Covalab
Syn.
Signal®
D9S7369
125–128
stage3
believethat
135-710
9352
173410
PI3Kinduced
NATURE|
Afp
-CGTACGCGGAATACTTCGA-30
NF1-REP–c
probability.28,29
gene-expressing
ovo
STF
pMXs-Puro
De-repression
`middle-aged
,4–6
4.7–4.2
3H-T23
DN-TβRII
FANCJ-depleted
R767S
ASPP1
cells.56
RESULTSHisto-pathological
.YFP-BRCA1
low-penetrant
c.616G
SXXF
MaxEntScan27
cells.3,31,32
17:41–48.10.1016/S0168-9525
AlbCre/Smad2f/f
2.The
Transcription–PCR
Cbl-flag
CycK
FNBP1
cells/flank
SFA10
KT2449
UACC2534
6His-ETS2
670-
69-fold
pEAA285
Reporters—Expression
3G9D9
¼.987
N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
sulfophenyl
Nu18/2
beevaluated
TCTGGAGCATCTGCTGTCTG
ImPro-II
HRAS-CASP8
strand-aware
PC-3a
GST-Smad4
V660
EC4
63-kd
Otherse
24/83
SK-BR
Na2HPO4/NaH2PO4
control.
kinases1
c.1796_1797insTAC
OCI-Ly10
FANCB-dependent
previously51
diagnosis/remission
tech=FB312FB
Matlashewski
/His
tumorassociated
10q25.2
CARD10
run-in
Delta8.9
SH2038-L
irradiation,40
-+
.Oncogene-induced
unreplicated
European-ancestry
betranscriptionally
525–905
antidesmoplakin
2H-pyran
9,10-di-methyl-1,2-benz
EWS–ETV4
mutation.8
cm3/g
proviral-insertional
cylinD1
ERCC3_R1
pp-dol
:-
3fl
anti-activated–NOTCH
c.251-2A
HER2-tagRFP
MLH1/MSH2/MSH6
methyl-lysine
W914R
3225
anti-CD15-FITC
Y823
syndrome-causing
TAAAGTCGCTTCATT
CAD-TAZ1
Non-small-cell
1270
VGL4
155240
identifed
PuReTaq
c.3261delC
DMBA/TPA-treated
antibody1
normocalcemic
5,150
incapacity
1.1/NA
fetallike
disease20
His505
p53-Induced
disease-unrelated
phospho-PTEN
miR-143
Cten
conformations43
//www.myc-cancer-gene.org/site/mycTargetDB.asp
Far-ultraviolet
catenin-dependent
/Hoechst+
N550T
IVS5+3A→G
al39
R-Smad–Smad4
tier-3
oncoproteins,34-38
P72R
investigations—is
01121A
LB2518
TGF-β–Smad4
styrenedivinylbenzene
.Four-micrometer-thick
orthophosphate
co-first
ITAM
trr1
1min
neo-labeled
Nalon
.relative
Venot
298P6
XNP117
1-262
5′-CACTTGAACCAGGGACAGCA-3′
3/151
EGFR/ErbB2/vascular
mucin-producing
0.7-
39–42
32D-E3
Arg420del
tetrazolium/5-bromo-4-chloro-3-indolyl
substituent
ETV022
6/196
Kouseinenkin
reaction–amplified
IFNγ
variants—in
Roskelley
HA.11
uncertain.
CTCA
kinases5,13
RXDL
BIM-wild
plasmidrecovery
Ser315
TTF-1
cells110
,33
.CCDC170
0.1-mm
//www.broadinstitute.org/ccle/home
Cdkn2a/Ink4a
Glotzer
Hayes-Jordan
gene-encoded
soon.21,22
anti-EdU
OneTouch2
0.05-2
syndrome,2,3,12,34
IMMUNOSTAINING
.Extractsprepared
pseudohypoparathyroidism-Ia
3.7
p53wt-like
Ras3
Arg361Cys
per-probe
deprivation44
APE
1,42
four-case
N40
.Dysregulation
Age-Specific
GCCTCTATTCACAGATAACTC-39
204369
stage14
mitogenic/growth
Ni-chelate
×630
RUNX1-SH3D19
Statisticsa
0348
Asp-Phe-Gly
5'-ATTTCGAACTTCTATCA-
CAG-CAT
Q155E
complex18
foci/hpf
nonmeiotic
OlaHsd-Foxn1nu/nu
1-fold
a–e
non-proof-reading
variantsIn
CECE
and273
p.Most
micro-dissected
0006-4971/96/8804-0001
K125N
HEY1–NCOA2
3ecrease
5'-GCGCAGCTGATAAAGTACACACTC-3
thymus24,25
RPS24
GST-based
GAGGTCACTCACCTGGAGTGAGC
Mismatch-repair
LiverKidney
F458V
pre-specified
c.864G4C
∼0.1–2.5
67-99
Pten+/−-alone
-log10
miR-34a/AXL
FU/LV/CPT-11
Leu251Pro
trpE-GAP
delL747-T751
questionable24
8–18
p21-GTP
73±11
Härd
Ull-214
pWWPGL2
uncomplexed
uptake20
kD
protein-injected
KrasG12V-driven
D835HR
TCR-ab
HGF–heterotypic
CD79B
MIGR1-p210Bcr-Abl
543–785
secondary-structure
P.Q849S
I443T
phospho-SCD-dependent
RAS-independent
W.A
c.2393C
GST-ER
parameterized
689–701
Lifecodes
deoxynucleotidil
PEST-FIND
.Enriched
.Morphants
11.22
tumorigenecity
5'-AGCCTAGAGAAGGCTGTGAGCC-3'and
7–amino
RCC4/pVHLS111C
mum
mediumto-large
partner.111
volpage
initia‑
C-Raf-RBD
2-lacking
resistance-induction
GGAGACAACCTGGTCCTCAG
F764
5′-tcagactcttgtaatttgtgtatgctgtctctcaaaaggttcatt-3′
pharmaDX
−507644
drug-receptor
2013a
74.28
.Gab2
NM_017378
ovar-
0.9-5.0
Nonparametric
​Fig.3B
radioimmune
5589
uORF-encoded
A127
inhibitors4,13
HTRX
in-cell
SK-N-SH
fQCR
Talmoudi
75–
S4H
Table2
0.739*
post–erlotinib-treated
plakophilin
mid-
CGH/linkage
3.1b
DFQL
workingdays
Baculovirus-infected
genes4
C_761_H_5
ACC-MESO-4
product.3
A_51_P144303
thePDGFβR
AMPKα2
1.35-fold
antiFGFR3
deglycosylates
tumor.24,39-43
R1114W
heteroatom
7,35
pY185
tttaTagag
neoplasms,44
H835
anti-Bcatenin
EZH2-specific
SN161
Lys91Ilefs
DH5a-competent
T2512-centered
P848L
4,777
94.2
adenocarcinoma33
​Figure11A
9.22E16
1837
Cdk12fx/–
well-studied
'stable
1772/2733
≥0.99
instability.34
tissues42
4.7-kb
Phenogenomics
.S129
progression.22-24
cascade.35
kyphoplastic
.S2D
IVS8-70
68.9
regulation5,6
F2120L
cryoprotectant
study21
Jagani
imporant
Che-1-mediated
antibody-based
UbR7
Brummer
Non-PhosphoSTAT
KB-motif
R148C
inv
poly-2-O-
30/333
membrane-induced
Erk1/2mutant
//doi.org/10.1371/journal.pone.0103021.g001
RT-PCR
transposase
75/M
0.2-0.7
19,591
F/86
up-regulating
receptors.46
D641N
ARv567es-regulated
Glu322
–21
theMSH2
Akt1-encoding
G9C
lentivirus-mediated
S405
.Interference
2006a
01607
reduced.36,73,88
22-1034
p120-Gap-associated
~-
tttcag/GCTGGA
p.Asp546fs
back-focal
flag-epitope
15N
FLA3000
c.328_330del
Fig2a2a
S1003
N368S
tumors10–12
Bio®
Y————
CTT-3
database.In
mscespedes
chorio-epitheliomu
BcL6
0.009
Oligonucleotides
GAPIP4BP
p.Gln563X
NRASmut/BRAFwild-type/cKitwild-type
1238T
mlh3
Pinhasi-Kimhi
normal-looking
comutation
males.25
27FS-c
D1-neutralizing
immuno-globulin
chemotherapy116
PAX5-JAK2
15Laboratory
7390
Gessi
software.Immunohistochemistry
U2AF1-recipient
paired-samples
ceLSA-containing
BAG4T3TP53
dierential
pFOXO3a
//www.novocraft.com
Fbw7-deficient
state.5,16
TKI-sensitive
KITV560D/G
Systèmes
340/30
v.2.0
oligo-attached
Tyr272His
S1116Q
iments
NMR-
N78
c.5385insC
C365R
immunohistochemicalfindings
diseasecausing
well-circumscribed
compartmentally
aVect
M.HhhaI
59:5403-5407
ppERK1/2
co-crystals
Huelsken
vergae
adhesion.11
.Jasin
466KB
sh-microRNA
PR-containing
43–29
malignancies12
3LO5
TMM18
5'-CTGCAATCTTCGGTAGTCCAT-3
tetracycline-free
S988A
LDQLLMCAIYVMAKVT
F1888S
hypopharyngeal
37.5
neuro-ectodermal
parity−matched
I345M
Muise-Helmericks
C-helix-in
0.3mg/kg
24.0
IL-15
fluid.6,7
K-Ras4bG12D
P2699S
Multiorgan
AGCATGTCCAAATTGCCTGT
71-year
pCB6.WT1−/−
BRCTdomains
www.cgi
Chamankhah
Sm3CAC-U
adenopathies
28·6
ZK370.3
​Figure5C5C
described.11,12
J-La
5¶-TGGCTTATGTGAACCAACTCC-3¶
K-rasG12V
IGF1-dependent
genes/isoforms
PHR
HCT116FBXW7
autosomic
Zuna
andcentrifuged
UO126
.S18A
.Helical
p.Asn609ins23aa
pGL4-CD79A-TSS
.7-9
.shRNA/ORF
pseudoangiomatoid
nuclearfunction
Dopachrome
HUGO-approved
LATS222
Qualitatively
Ser218Asp/Ser222Asp
n=440
EcoRV,34
century1,3-8
n=101
5419
patientś
HPV16E7
Asp1399
reexpressing
∼2-Mb
Majewski2,34
EPAS1/HIF2α
UMR915
EGFR11
fluoresceined
groups,10
pT1mN0
FA-O
simulationsa
LPC
CEP7-CEP3-hTR
D538G-mediated
Sorafenib—the
.0003*
PI3K-based
V136I-NIH3T3
asymptote
PCM35
Zebrafish
Asp33
response,206
upper-lobe
K87I
HaeII
ZF-1
-GGTGTTCTTGTGACAAACAGAAGTC
TPM3-TRK
50µg/ml
BglII-XhoI
non-stem/progenitor
IGFR/INSR
pg/mg
TTCT
3.52
cules
gi68481255
Intramural_research
23/42
A114T
gcaaggtcag-3′
tetrasodium
Gly380
Genotype/Phenotype
genesrepressed
Hansmann
.41,43,44
alternatively-spliced
factor–depleted
N=246
2-Hydroxyglutarate
Gp5D
4.76
5′-GCCAGTCAGAGTGTTAGCAGCAG-3′
as-yet
lysine
720–726
56–59
NCT00012181
LMNANTRK1
NRF2-dependent
177,567
2TK-AR-AF2
p-p38
Montre´al
2954–2973
atypical/malignant
5-aminoimidazole-4-carboxamide
3p21.2
MIB
Leu137
237–267
Gardella
NFNS
surgery1,2
Truantet
2,6,9,10,12,14
EWSR1-CREB1
LR1
Break-Fusion-Bridge
M51fs
65-7anap
Arg420His
methylation-positive
k-n
â€˜flseabbreviations
anecdotal
D-008692
activator-1
ALKR1275Q.4
familiesa
MR/AR
Cox-2
~17
0.0216
Asian.12
extramedullary
carcinomas,9
p53/normal
DOK7
embryos.28
.Form
mutatedintestinal
sequesters
aroma.affymetrix
-CACGGTGGTTTCAGAGATGAGGTC
m.o.i
stereotypies
onlya
ple
lifespan.org
0.373198847
COALL-97
non-senescent
Orikasa
non-TGFBR1
442087224130
6Unité
λt
N156D
LM-LEC
g4
440
7.7-10.3
TEL.BamHI
cellspercentage
.Wdouble
methoxyestradiol
4K–L
thirty-one
7q31-qter.17-19
CAV2
.Topo-cloning
HJ
WGS/WES
GM0637
anti-cdk1
.164785
BrdU+
phosphatidylinositide-3-kinase
kinase-receptor
Castillejo
E525K
S729
dimerization,22
Biozero
.Superscript
K1423
assocation
edgrPLELrDLLhfsSQVAqGNaFLASkNcIHRDVAaRNvLLt
Montre´al-Hoˆtel-Dieu
centromere-containing
PRO1073
0.591225
.Extensive
otherallele
B-subunit
package27
.RAF265/CHIR-265
15/26
.Diagnostic
AGA
0.510
P222T
terminusof
Bannayan-Riley-Ruvalcaba
gefitinib.8,9
MLL4s
CCGATGGGGGTGGTGTGCAGT
anti-CD8-PE
2.266
PCP2
1p13.1
pCMV10-Flag-Tip60
CCTTCCCTGGAA-ctggga-ATAGTGGGTGAGATAGTG
Blood-based
Y1008
mre11S
pSer/pThr-containing
CGP
0.553
Leu106
complex.16,17
CD138
IKKK171E
delS752
–98
NRGRL
.Fig.33
Intragenic
synaptogenesis
Zybailov
itself–reduce
Arg-2510
sensitivity8–11
c.34_35GG
7F/R
adenomyoepitheliomas
G.P.N
pENTR-GUS
chr14
.Helvering
48†
65.7
myocytes26
IL12-
0.388
CD19Cre/+Ezh2+/+
fast-diffusing
population13
OriginLab
γH2AX27
molecularly-directed
3+7
L1149P
n=207
.Khotaro
CUL-2
ETV1-overexpressing
69.8
scattergrams
I527
F1174C/V
microscopically
PRPF40A
4H–J
CACGCACCTTATGATTTTGC
15mm
UV-protected
CH310T1
2-category
AGTGCATTCAAGCACAATGG
factor/scatter
SSC/50
Ptpn2/Hprt1
sticks-and-balls
U2AF11,2
PGK-Hygromycin
autophosphorylatedmembrane
.HD-N
ICGC_PA142
Tuberin-dependent
Alsheich-Bartok
Standard-PCR
TRAMP-negative
structure.38
J.M.K.
GDB:250632
coinfections
cis-acting
Etv6-human
C1368
Nf1KO/+
006218.2
oligonucletide
pMM6
12p70
Thr-157
Cys-220
./-/
whorling
photoactivatable‐ribonucleoside‐enhanced
GFP-ΔINI1/hSNF5
dbSNP137
196–245
Method-S9.12
Harbury
3920T
tissue/cell
MPL-Y591D
motogenic
chelatable
Chromaspin
TP53-R273C
Apal-EcoRV
R583Q
A87T
GAAGGTGAAGGTCGGAGTC
PCAF-bound
C121S-positive
POF
ALK9
sRNA-seq
M541L-expressing
anti–bcl-2
DelA767_V769
1006
BTG2*
types.12,34
354-367
GDC0941
~O-
TGradient
FgfR
FA-J/vector
14051
11,31–35
p85-soluble
63,64,66,68,69
and2
RAF-effectors
C/GCNG
INNO-LiPA
.NPM1
.AZD4547
G457
factorstimulated
3904–3911
RS-2000
Met-243/Met-246
Wnal
pDONR-EML4-ALK
c33a2
R/program
p=0·0006
VJ-positive
Mugrauer
FLAG/NLS
0.734
sequenced.4
DTX
LKB1-interactor
MGCD265
4/35
S256A
F170V
.Nonspecific
N=60,706
pro-myeloblastic
cycle–directed
Lys-581
Twenty-nine
rhabdomyosarcomatous
R.R.I.
5'-GCAGGGGAGGGAGAGATGG-3
subtype2–4
/std.FSCOR
G1-to-S
128–149
TCGA-FS-A4FC-06
www.graphpad.com
Toxicological
total-ERK1
IC50.Figure
leidenuniv.nl
p.S257W
14-3-3σ
KB3
null522S
4.82
p.Val246Leu
.D399
8,20
P114L
Cdkn2a−/−
.ITC
5′-GTTTCAAATGAAGCAGTCGACTACCGAGCTAC-3′
HER2-PI3K-AKT
Posteroanterior
~3.8
PKBα-GST
p31
P223L
//hannonlab.cshl.edu/fastx_toolkit/
1–50
G853D
GAGGC
low-salt
.Gnas1
2-day
.Bevacizumab
women1
303–307Wang
nanosecond
.Database
ext-induced
HNPCC-type
59−72
10q11.31
phenotype–associated
α-chain
5′-AGTGAAGAACAGTCCAGACTG-3′
CRL-mediated
Banfi
Smarca4+/−
CKIδ-mediated
siRNA-scrambled
eight-amino-acid
Amphotropic
logFC⩽−1.5
Phospho-Kinase
TD-A
reductase-independent
pCMV3xnls-I-SceI
.Easton
T112I
877–885
36.4±4.5
75C8
GSE27560
FA-I
2CFPcyan
Rimut-Riwt
above-average
745–746
5913
COX6C
pCBASce
vesselFIGURE
rklein
anemia/Brca
cytokeratin-8
SET-domain-encoding
milk-T-TBS
50-μm
Sarran
p.p.m.
5012
A12
SarlomoRikala
.Introducing
Xp11
-1I
5Ba
gtttgtttgtttgtttgttag/ttttttgtaggg
Bethesda-positive
c.8165C→G
8p23.1
.TGF-ÃŸprobably
908256
C23S
K647X
p21c-Hras
and2D
K23
.137G
°C-60
pleomorphic/
p110α-producing
Nox4-DN
308C
c-Myc-
1FAP
A-associated
3.56±0.09
NMUinduced3
ErbB2
Rag2
218
25I-MAb
10-100
SFR5
97-kDa
buff
L34D
.Unattached
NCI-H2085
nephromas
Pulst
L2865V
Ilouz
Pdx-1-Cre
colleagues52
described.8
FMS-related
22-79
UACC903
Grb2-mediated
GCCAAG
150-157
3i–l
.Arrays
RETV804M/E805K-expressing
NF-κB1
mouse.10
HA-pVHL-expressing
c~~id
T491M
PBS/3.7
1.3×10−11
ma-
ALL53
non-completion.121
poly-pharmacology
−925
40/60
ICSBP−/−
wtp53/mtp53-R273H
34•
HNPGL
GJ
123A
protein—making
R708W
cfDNA22
DO-fgf-4
N174
0.2-kb
differentiation28
c.37G
irrecoverable
1.1-kb
Fig.3B3B
HA-BRCA1
V2098I
.MDA-MB-436
29,30,102
endocytic
14×89
.MCNs
639
TGF-ALK
glomerulotubular
inresponse
Tuberin–hamartin
ANGPT2
Fig.3D,3D
4del
suppression62
Apc580D
inmany
p.Pro352fs
Â¡inscription
RIGGI_Ewing_sarcoma_progenitor_up
RNF2/RING1B
carcinomas55
cross-validating
BES
Met1166
945
hPMBL1
c.815_816delGC
strategy,9
19722
TEL-derived
physiologicaltemperature
finesse
CKNVVP
rearrangement-specific
hydrogen-to-acceptor
activity/dependency
proximal/SB1
K109R
beenreported
HYD
d1
RTK-driven
.1,2,17,28,49
NCI-H226
reamplifying
transcription/repair
hNAG
esophageus
RAN-binding
CARMA1-triggered
Pileup
.SMC1A
Val77fs
mutants.26
cttcaccgagtttgaggccggggccctc
cancers.7,39
Pancytopenia
electroencephalogram
10p14–10pter
sensitivity-enhanced
cancers11
Y641F/N/S/H/C
thecarcinogenesis
MismatchThe
.70
.Start_Codon
8.13b
JZC
mechanisms•
WW1
86,87
multi-locus
chemotherapy-gefitinib
141–amino
activity.56,57
ALK-regulated
147633001–147754300
5′-GAGGCTGAT
2094
response,28,37
1.38E16
T1–T4
p.Gln2317X
1Hα
analysis4
6.The
to−hormone
otherIG
BCR-ABLT315I
leukemia.45,46
Melon
-REDEDEIE-NH2
elongated-binding
hCG
Three-Step
situated.8
p16CDKN2A
sc-15407
MAPK-activating
mTOR-driven
CAMN107A2101
3c–e
VP‐ITC
KV
Hinge-1
602216
5′-CACAAAAACAGGTTAAACCCAG-3′
L536P-HE0
5′-AAA-3′
517599
pylori-eradication
and58-TGATGGTCCTATGTGTCGCCCAGTA-38
Lys230
/highwire/powerpoint/117146
recruitingThe
15°
ninein,35
HER2with
G89S
141S
Triton-PBS
EGFR18F3
Flag–p52-overexpressing
guidelines.Probability
5p15.33
p53wt-expressing
T1343I
follows.15
Top1cc
6555
dephosphoryation
Meta-analyses
WT-PH/WT-KD
L95P
80-kDa
Stk4
Electronic-PCR
JAK2,7
Eciency
ERK1R84H
aggregation-nucleation
S4F–S4G
STAT-1/3/5
M34-L
anti–phospho–extracellular
250–320
noncomplex
2q22–34
MEK2.12
CDH3-reverse
15-cm-diameter
5p15.1–15.3
Tyr35-mediated
daily.23
2.112
o-nitrophenyl-β-d-galactopyranoside
−ΔHo
tionally
palmar-plantar
research.nhgri
Zbtb16
TableThe
RPCI
/Cy3
.TGF-b2
k3
ß-catenin/LEF-1
1.5uM
I279P
2mMDTT
CCAAGGCGCACTGGCCTC
GAAGATCTATGGCGAGCCTCGCCGCG
1.5
MET-mutations
drug-kinase
EMT.3
GST-C3
Molecular-profile-directed
6924
ACGGATCTGGCTG
BioWhitaker
ab6556
5′-GTAGATGGAGTGATGATTCTT
al,43
AKT,19
leukemia,1
MUPRO
Mitochondrial
RASophathies
-β-catenin
Adenovirus
.Mg2+
delGlu746_Ser752insVal
E3-mediated
Kotobiken
GNA12
689nM
TCACCCCAGCCAGACTCTAAG
Braghiroli
described.40
CA20525
3XFLAG-tagged
A727V—are
R3188
HELC
ARID2
Gene-therapy
LC-Red640-ATGTGGTTAAAGGAAACGTGAGTACCCA-P
4002
months-17.6
PamChip®
2-affected
FACScalibur
Arnault
T383
EIF1AX
Trp53rfl/+
p-4EBP1
R96W-PH
GSF-National
MMR.47
Ras-cAMP
Velmurugan
32-amino
150-fold
esophagogram
38,39
nag/ul
Src42A
WT-Akt-transfected
A-R3
C36B11
crosslinking-based
Pu-Py
figure3C
3.76×104
all-or-nothing
activities30
E868
vAbl
Crosstide
1.70×105
c.462G4A
Chikusa-ku
confirmatory
Srsf2fl/WT
respectively.13,14
CTAACA
18â€
turret
CDK-2
RAStransformed
developed45
ex15FFPE-F
79.7
IFN-responsive
3/38
LSasociated
hUBC9/
ctc-3
heterozygosity/homozygosity
Anti-Snf5
Cotransfecting
,2,2
Mimori
392–473
K_lactis
peroxide-conjugated
LELP1
OPA
FN1-ALK
n=21
R373C
Tunikamycin
DQB110301
analyses6
5.2-fold
craniosynostosis15
tumour-naive
Zaubermanet
violet-stained
33,41
histone-modifying
GSE32875
5′-GCCACCAGCTAAAAACATTCC-3′
inhibiFIGURE
3-765
14336T
N-Glycosylation-dependent—The
0/90
response.15
S548P
3079
S189L
V:2
Mt-mutant
CSSDNEYFYVDFREYEYDLKWEFPRENL
IRES-puro-HA-HIF2a
68-3
7.4GPRC5CG
C542F
pBabe-G796S
anti-CHK2
R+Ha-Ras
muFig
Hyperdiploid-
AML.20⇓-22
Purity-filtered
Y1584C
ChIPAb+
Rodig
nFM
kinase.14
defects52
microdeletions/microinsertions
RBD-
TTTCTCACCTTCTGGGATCCA
mDia
mononucleated
STAG2-expressing
5′-GCTGGCCGGACCTTCACAGTCATCA-3′
.NTD
F1124
Fig.1.1
NM_033632.2
SA.5
MLPA−
R263G
deletion.34
stat5
microenvironments
'closed
sm1
HER2‐altered
contrarian
GV–GD
27,30,31,38,42-44
sc-32761x
interpretable
Pin1−/−
DF/HCC
33.Targeting
GSE22615
galactosidase-encoding
Venditti
.31–34
protein/RARE
E490G
**ATMDS
Röring
siNFKBIA
Tyr1235
.K27M-H3.3
G84E
.VEGFR-3
GTPlike
H393P
HAT-deficient
mTOR–S6K
SCAI
RAD51B/
pathway.To
3.99
Rhotekin
two-metal-ion
1.13
myr-
–33
1WQ1
FAP-associated
VPA
humans.10
AQ.11
Val136
S222D/S226DMEK2
K882D
microtubule-based
EUFA393
Elongin
Brca2-associated
mAKAP
GDNF-independent
transformation-associated
syndrome.8,9,10,11
23555
p3xAP2
2Nucleotide
reconstructedmutant
mutationalsubtypes
c.1621A
atextremely
χ1
pi-cation
osteoarthropathy-related
AACCACCTGCCTGGGATG
25.6–1769
−2.09
Vilanova
p.Phe234Leu
ALKF1174l
.Flexibility
251-253
14Cancer
K5001
5′-TTCCTTGCTGCCAAGCCGACATTCT-3′
AC+
.Jeffrey
g.381-389del9ins29
axin2
Caspase-3
00033740
NM_008610
tumours/total
55-1-cy5-x10
mutants.45
Ang
Ser780
gtatgagatw
1.0.19
7096–7101delAACTTT
MMMT
I-mediated
siRNA-transfected
2-60
aj2-Q205L
Yes/yes
LSID13S319
.Substances
MTC
GAAGGAGGTGGGAAGGAAG
I8B
p53,8
48:25:10:2:15
Å-resolution
II.6
RA45AT
Kras2
81-3-5449-5372
α/β-tubulin
EGFR-TKI.6
change-that
involved6
2320
B03
nuclease/helicase
C275X
process/regulation
LRP1-dependent
sequester
pET41a-ICHD1
SP65
Ras–GAP
11p13
∼17
N263S
coverglass
carcinomaPapillary
CH12-F3-2A
Jak2-V617F-dependent
XX
G67
5′-CGAGGTTCAGTGGCAGTGGAT-3′
66˚C
allele15
CDK12s
S1251N
JM-Binder
Rho-GAPs
NM_000264.3
RP3-327J16
C/H2
1.17∼2.51
pDEFp300AS
imatinib.46
SLC23A
S_HBV123s
neoplasms.11
pulsed-laser
Hs00466712
TEL/JAK2,5
ALL-associated
westernblot
W-E-X
H2AK119ub1
Martinez-Contreras
-W-PDGFR
P62L
Hyclone
ChIP-PCR-validated
agents—and
BTB+
andlymphocytes
.Asn235
SK−
M21801
TNFSF13
Arg→Cys
myc-box
Empty‐nucleotide
directionality1
mitogen
Figure5A,5A
TeV-cleaved
LS,20,66
transition15
I232T
elsewhere.14
signaling-inhibited
BrdU-pulse-labeled
P12A
4028
CD1a-positive
pCi/33-mm
BH3-groove
doi:10.1038/sj.onc.1207179
MLL-site
V1238Y
YNB−Trp
Saos-2
25/10/3
mismatch-proficient
p.Phe75fs
2F103
Rho‐GEF
4497
Chr3:71019900
.Imidazole
AAU
CDC2-
7.48E16
first-round
NruI-XmaI
Biospring
gender-matched
a7c
sensitization
Snf5A
5′-cttctacaaccaggactatgagcgcctcttcgagc-3′
EcoRI-HpaI-digested
p.Arg414X
TTCATGGA
HNF4a2
5808
2000,2002
Del2483-2497
7,10,34,40
R635G
Keap1ΔDGR
WW23
S214
glioma-CpG
N19RhoAmutant
D237
baselineKITV560D
APS
Promochem
FitSim
means±
gll1
Glu-542
.JARID2
backbone–protein
pharmacologic
biologic/functional
NCI-H2052
sub-confluent
−4.03
LNCaP-FGC
DD-EZH2
4FNY
macro-H2A.1
6−8.9LEPREL1Leprecan-like
Sac
c.228
K-19
del31
Lohrum
38.61
Sjogren
.Fivemicrometer-thick
.No
Serpini1
co-repressors
p38
Hot-Spots
LnCaP
Kapabiosystems
IdhLSL
KIT-addiction
.39051253A
7q21-22
N230
cause.35
kinase-inhibitor
.Scoazec
Notch-interacting
Huertas-Vazquez
nucleolin
indistinguishable
ethylnitrosourea-induced
5′-TTCCCGCCTATGAAGACATC-3′
.68C
hyperinsulinemic
Yue
0.45μm
.EDA-ID
istranscribed
7/60
21.69
SAGE-derived
isomerase/oscillin
FGFR1-amplification
p.M511I
activated/phosphorylated
Hemagglutinin
cKITT670I
XFoxH1/Smad2/Smad4-DNA-bound
Ras/ERK1/2-induced
leukemia-associated
AML60,61
PI3Kδ
D1/CDK4-mediated
c.511insC/
Karlsruhe/Germany
R165Q
0.524
3Ea–c
ETO-mediated
diarylpropionitrile
nonaminoglycosides
analysis,6
p.Asn2842LysfsX2
.122
287-300
MSH2–
miR-125a
withHindIII
Factor-independent
criteria24
GTGAATCCCCTAATCAAGC-3
Rsyma
ATMDSwhere
CFU-ALK/CFU-F
.481C
Mi-13443
+56
E749K
218073
chromatin.23,24
immunoprecipitatedfrom
therapy.4–7
9.14E06
M-RAS
vivo36
EuroMRD
-1.2kb
Frequencv
HSP90-independent
hyperglycemic
Specific-qPCR
.Log-Rank
Pten+/flox
//coot.embl.de/
IgM–IgD–CD27
TRP1-selectable
BRCA1-structured
Oguro
Squamous
α-cyclin
inhibition34
P2319L
Co.
subtype.10
7,11
CAAAAGGAGGCCTCTCAGAT
14018-20
787.6
.A11031
pY542
1.5-ml
BRCA2−/−
−k1
EGFR/HER-2–
PD0325901-mediated
PRDM1.E2.245.R
complex10
BAX/BAK
5/519
wasbaked
ab16667
p19Arf–Mdm2
described.30
M37K-IκB-α
ubiquitinate
backbone-modified
-U2AF1-Flag
maining
AM-1/D
Excel-Based
Y253H/F
.AKT2-R170W
-GAGCTCATGGCGGAGGGAGACCTCAAG-3
androgen-dependent/-independent
795
∼40°
HNF1A-/-
TTCCTTGCTACCACAAGCCA-3
R188C
avidin/biotin/horseradish
VV—
sex-reversed
knownformany
phospho-HER3Y1289
5′-TGGACATGCTTGCGGATATAAG-3′
E87
567H20
TrkA-diploid
thisreport
4-morpholineethanesulfonic
algorithm.13
'
612599
A-8036
HIMMgCl
Ka/
N842S
membrane-free
kimryn.rathmell
9.8/NA
1.831
available45,46
397C
uArgleuGlnArgGl
phospho-Akt-S473
5-GATGCCGCGGGCCACCATGGAAGTGCAGTTAGGGCTGGGAAG-3
–3
.TEV-mediated
efficacy.31
IVS3-1G4A
antiestrogenicity
live-cell
Lys21
Val78
chromosome.29
F751
Hs_ENSG
.H–I
7174
Smad2-Smad2
Bouska
38X
growth.Materials
pRS314
hormone-independent
Chaffanet
antibody.DNA
Iraci
CH3-interacting
74-kDa
Mixon
56.50
45,325,377
acid–induced
qtPCR
E1006K
D543
.Endothelial
1532
RO-3306-treated
D410N
Liverc
P-Tyr-100
Ik6
full-fledged
transducer-docking
paraffin‐embedded
FF13
Loc-
172788
GST-Cbl-70Z-RING
assayH1299
TGTTCGTTGTAGGGACTGCT
CNC
14-3-3-luc
84-86
Lokka
lymphomas17
RAG2.22
c-Src
arrangement.5
PDB:2B7A
antip21
Recapitulation
leiThr
T/p.Gln6X
derivate
PARP-1/2–specific
Tamikazu
BAP1-dependent
11599
346076
Na2CO3
S1.Western
40-bp
GCCCGCGCCG
hRad50
×1012/L
experiments±S.E.M
devia­
GGCATCTGCTCCTGCTTTTG
Rusciano
pNFκB-Luc
Hh-Gli
8.3-35.6
Reintroduction
deoxyguanine
ATAGTGTTTTTTAT
1589
vivo19,20,25,26
NURD
739
PCa_ERG_2
5023â€
pMAM
.1569C
N550S
V1999D
kDa.28
RP11-1055B8
pZipneoSV
GAGATTAGTAAATCGATGTTTGCAGTCTTGAGTCTCCAGGAAGAGATT
5–17
ALPL
Variation_1779
2556
compounds34,35
6088
DESMOPLASTIC
μl/ml
mini-direct
24/49
ROCK1/PKN–
peptidomimetic
herins
Bicciato
roadblock
KRAS-wildtype
LIMA1
pGf
Klybeckstrasse
ΔCA/ACA
APL.16
2/30
far.14
Smad4lox
−3.77
cells98,99
M73548
0/1/0/0
Fluka
response.50
24-well
IHCC1
\im
nonmeasurable
gtatgttac
Ap/dE
BigDyeTerminator
Gearhart
R856H
dx4l
Gyory
YPH-bax
WelGENE
CFP-AFFAQLQLDEETGDFL
59,784
Gly595
AatII/SacIfragment
O43151
FGFR2-AFF3
GAGAAA/gtaagc
Luminary
al11
NIK-induced
respiration12
CD3e
IL-6-family
L2653P
Lahlil
SNA
AlignGVGD-based
phospho-ALK
S314I
p2
PIK3CA/CEP3
TTTGAAGCAAAAGTTTGATGAGA
JJN3
35±5
PCR‐generated
premeiotic
Castres
1–580
MET23
//im/III-cleaved
Tennodai
R272H
obscure.2,3,6
pan-kinase
P045
Flt3-D835
4318
TGCCTGTGGAGGAACTTTTCA
42027
bio-ChIP
.I1
NCT01928459
amplification/receptor
oftheir
one-by-one
sequence16
38/54
RhoA-stimulated
LM3D
22,30-32
40yrs
IVS12+10G→C
MC1-4
FOTO/Analyst
W423R†
Mild-to-moderate
124:105–122
colorectrum
hyper-branched
literature48
C769S
S720P
PTPRT-methylated
I066
+TSH
uhnres.utoronto.ca
GFP-Trap_A
P=0.688
TxN1M0
Ki-ras
WZ4002-mediated
E1310D
ubiquitination—constitute
c-Kit.HSQC
TLS/FUS-deficient
Yj
pathway7
2,314
non-analogous
–negative
90-mm
underestimating
R=9
AlexaFlour
with32P-labeled
rilotumumab
cytopenic
N318
PR-B
T3N1M0
1-EGF
residues*102
Tet1
GFX
Hs683
ggctctttaacaacctttgctt
.16C
PEG35000
Q391P
K666N
modifications.23
site.4
37.43
VEGF.41-45
EBV-driven
Thr1221/Tyr1222
205–210
EXCISION
siliconized
BCR-ABL.7
kipNeoRev
./Invitrogen
.MLL1
tissues57
exist20
C378
manifestation
control.19
Berl
B/myeloid
DNA‐binding
thophosphate
−2.45
glucocorticoid-receptor-responsive
M102
°C-15
phospho–receptor
0.619
Heukamp
Mannheim/Germany
79-95
intercrossed
MAP/
Rnase
BT1
BAP1-expressing
43,709,997
B-Raf/KSR1
STAT3/STAT1
1.75–10.45
0.57-1.02
25–75k
TSS.72
Tyr565
23/31
Domchek
p.N822Y
tumors.8,17,18
NPM-ALKL1196Q
months6
Dnmt3a2-R878H
accident16
mutations22,24,26,29–37
pT12
Hergovich
Z-LEHD-FMK
,60
1B–E
Krasex3op/ex3op
AF032984
simplerhypothesis
Tecnologies
Three-generational
0.65–3.10
links.lww.com
.Family-wise
2,177
16912
Vav-iCre,31
Type-I
HIF/pVHL
.MROS
R282A.In
Asn382
Y.
regulation.2
premitotic
PIK3R1/2
Slipped-strand
MGZ
affected—we
aUPD-positive
TET-dependent
nongenotoxic
.DDIT3
A1394-21
26.45
terminus29,30
R495X
rad50vsc+hsae2Δ
AMAG
Fig4B
ErbB2-Hsp90
Q61L-bearing
/number
.Antibodies—Mouse
k-1wt
K-Ras4b
crosslink
Park2
P=0.04
c.60–73
approimately
PIP3/
Stegmeier
Cre−
poorer-quality
PDGFRA-ΔDIM842-844
W368H
immunode-
Conca
Biosciences/GE
Thatincreased
MURAI
Brd4-P-TEFb
translin
sequencing170
scale-reduced
Equipe
S360
Asp390
9·7–16·1
described.18-20
jak2a36
.8–10
50–81
loss.a
SNF5–/–
MEN112
S99N
c-Ret
v0.1.7
SMO-C469Y
p≤0.047
chemorefractory
P1873R
histolÃ³gica
FARMER_BREAST_CANCER_CLUSTER_7
FTL3
10-11
AutoCSA
allo-HSCT
5′-AGTCCTGGTGCTGTTGGTGATT-3′
~0.6
Zilfou
33430487
laboratory-abnormality
factor–􀁋B
HSCs/CLPs
29232
HGS-OvCa.Altered
cisplatin-responder
1205669
GTP-bound
2001–2004
−.78
.XTC
settings102
−100
AGGRLR
_See
Galarza
2H10
62.5mM
.M0/1
Gly14Val
3SS
1:1.16
jeb
Osteoprogenitor
RA/RBD
mIL-6
GAS1
0.154
fibroblasts30
sulfonylureas
.Fig.55B
BR-01163
ultra-low
partial-transactivation
dysregulation4-6
DUX4
20–amino
mismatch-dependent
Vps34p
058
40-2005
n=121
44.7
GISTs,37
heattreatment
.Sergei
Ex9
Trichothiodystrophy
syntelic
.N-Ras-G12V
GenElute
.Termination
0.8-30.0
40:1
Sambrook
anti-MARCKS
16−18
masitinib
Statcel2
2,400
nCBL
anti-Brdu
glycaemia
−101
p.K601E
c20
linked—mutually
5′-TGTACTCATCTGAGAAGTGAC-3′
shRNA/ORF
cation–π
activation.In
2005:339
.Tracking
P95H
Genoa
5,342
.Possibly
∼19
Skaar
0.00717
K1267
DPBS
ISM
www.ncbi
PMBL-specific
microenvironmental
COR-L47
FeO4S-treated
611423
Fruttiger
PLX4720-admixed
PMG
12,14,17
N1182-05
NHS–activated
-2,5-diphenyltetrazolium
,4D
CR933665
process-matched
Calcein
n=25
SK23
TRE-centered
E2A/PBX1
KRASG12C
1131C
electrostatically
DCTN1-ALK
b-hairpins
effects—emerge
875
:rad3
Neratinib
disorders5
meta-learner
117-kbp
CMML/atypical
T555
LXSN-EGFR
mediastinotomy
Single-step
LEF-1/XTcf-3
TMPRSS2-ERG-associated
OEC
Orthopantomogram
TBX5
Phenotypeb
Klippel-Trenaunay
rs10050046
wnt-signalling
3334
ATP1B
bromide-activated
36
pcDNA3-Gal-1
REP-b
inhibitors–
2542G
aggregation-driven
mutationRT-PCR
R157W
RASV12-induced
−1.62
FTO
cPLA2
ÃŸz-MGprobe.Fig
disease/liver
W429C
multi‐organ
pl4INK4
.Intensive
Pen-Strep
F/82
5mC-dependent
m/55
p.W1712fs
61.
.CSU
ALDEFLUOR
expression-
co-pellet
,200
FBW7beta
Kanai-Azuma
70751
//structbio.nature.com
Y08976
PRT062070
human9
AGAGAGAAGACGGGGATGGT
631516
signaling15–17
TF-I
.6291
sulphonylflouride
PR.18
anti-pY31
479d
NUCLEOTIDE
.RB1
PIPseq
1074_1393del
Plescia
7Signaling
.Upstream
Expression—Since
protease.1
mice,24
activity.19–21
MDM2-binding
J.R.
-RHDSGLDSMKDEEY
0.443
assay.9
N301T
.Regression
.PRL-null
.Helices
.Stenmark
epidemiology2008
6q16-qter
R62M
CytoGenomics
ACINAR03
10.1182/blood-2004-07-2588
V194M
1.040–1.979
genetically-modified
adenocarcinoma-as
NM_010495
5'-AGC
Variation_52365
androgen-free
Dinvarlution
.EGFR-transfected
HOXA9
complex20–24
Hsp104
NGS-technology
se-
00000o0
codeveloped
PGBM14
bamToBed
e10.1
S1H
318–446
inhibitors.30
pathways.13-15
paraprotein
14-3-3σ/QRSTpST-COOH
repressed28
L2431P
G216T
RAD59
.Standard
RCAS-mediated
fluorescein-labelled
p16–cyclinD–Rb–E2F
HMSH6
GAP-insensitive
50–86
53/63.1
.Allelic
Nakashiro1,4
Cdk12-dependent
anti-HER3
FasFig
XPO1-ex15F
FasL-
therapy4,5,6
DFCI-1
p=0·026
rs3830355
9772nNo
MEN2B-associated
SJCRH30
V490M
−3.47
productionRetroviral
26-F5′CACGACGTTGTAAAACGACTCACCATCCATTGCACAGTT3′
lines71
.H+E
H3122TR3
NCIC
arrow\
RAS-ERK
57–60
nihms646437t12
–67.7
H396P-expressing
428K
I538V
M23292
ErbB2/NeuT
E279
Table11D
CDN
alpha-cyclin
L/L
H13
.S1H
Thiex
ERK–MAP
non-lymphoblastic
488-nm
100.2
Komagome
WT1-Wild-Type
EML4–ALK-expressing
GlaB
hypovascular
CFC.14
p.Arg272His
SNEV
FCS/DMEM
PASLGS
drugs72
2.1-TOPO
cytosol-localized
pathways144
Soung
.Their
.9501
Aplan
rB-
ETU4b
L773
disease89.None
pathways.2,3
AQueous
9Za
pathology.com
Bx-PC3
interpercentile
and3A,3A
polyoma
equalfraction
NIH-3T3–MSCV–puro
Gcsf
thirties.9
607
=0.026
ofMutSa
chimericHIP1/PDGFβR
6×His-Brd4-Flag
.PTPRs
cohortwith
anti-HA-HRP
107–127
hdm2
negative/reduced
basal/myoepithelial-committed
5′-GCAAGTGTAAGAAGTGCGAAGG-3′
DAPI-positive
dual-labelled
v.0.5.0
SFRP
end-points
R26Q
/814
49,111
lineages.7
Tyrosinase-Related
Coomassie‐stained
knockdown
jew
M2e7F
phospho-transferase
c.109G4A
1000Genomes
Immune-Compromised
Louis-Dit-Picard
Lower-molecular-weight
vitro,15,17,18
2-SR
3–28
extraco
FA-F9.2
myotubularin
5'-ACT
Tnf-α
glioblastoma122
laboratory.ImmunohistochemistryBRAF
resistance44
R78H
Non-RECIST
algorithm42
2.711
3From
p36.1
Lys442Asnfs*14
20.4/12.2
5q21
72°C7:00
c.38G.A
cells.58-60
11G12
p.R749*
apo-FGFR4-KD
drich.com
S‐transferase
cycle–inhibitory
1.83
M2–agarose
74-y-old
1.971
low-stringency
kinetochore-bound
-527
JAK-STAT1
6Sos1
.GFP–VHL160-
monomerize
A280G
Overbeek
pDR2
ARA70
G287X
S'-CACCAGCTA-
//genome.ucsc.edu/
NM_005896.2
7454
AJP-Lung
J13
Lys483
I48Thr
124:485–92
R273S
072
.tg/ml0418
B/C–specific
ruly46
.949C
:InsE-A14
.Superposition
c.432delC
acids.24
b-Blocker
H2340R
BRAFV600E/NF1-mutant
triphosphate-binding
PAS-positive
.0067
JMlOl
PSTAIRE
systems/tissue
Kapoun
passagea
S12A–H
phosphatidylinositol-4
Consortium.15
CSC-associated
tumours10,23
FA-37ik
D450E
77G18
2-aminobenzimidazole
phosphorylation.Figure
G331
Xwin-NMR
.19-
kinases.5-8
p.Trp531Cys
trials34
GLUT1
4960
mdm
LungCarta™
Epizyme
derl2Xq
.Centriole
proteins3
Leu12
STAT-5
-kB
PEG3350
T1971I
q11-21
CD8+CD45RA-CCR7-
Ptch111,12
11q13/CCND1
ΔDBD
/60.5
K175
nihms820730f10.jpg
homozyogus
M2-like
factor102
C333
p53-FBXW7
anti-pβ-catenin-33/37/41
110-amino
n=71
N/K-Ras
cancer,12,13
S24
Mesendodermal
Comments/other
N95381
GEMIN4
ESI
S573
ML-mutated
mutant-type22
PF-1066
PARPi-resistant
S-phases
150007
ethoxy
.Clinicians
c.1676Y
NR_002217
.Stabilization
Australia.21
Galactosidase
T1720A-U
0w
1.337–4.975
888mel
sites.37
Nilotinib
high‐affinity
Stat4
L.T.Haber
peptide-absorbed
KRAS-Hs00932330
ttctttcag
Leoncini
.-S
65-week-old
p=0·5892
TK/JM/SEMA
CRC38
Iso/Val
pSG5-HA-TRAP220
close-to-confluent
750g
Q49K
.Estimation
sequencing.Mutation
chromosome-20−specific
O'Brien-Fleming
gene23,24
mKSR1
3.47
non-cancers
SRE
MIGII-EV
17/18
37.26
MDA-MB-231a
∼260
ARID1A-inducible
.Nonconservative
.XXLαs
0.0038
14/37
DNA‐binding‐dependent
C2l
8d
Informagen
Gab2
D259V
c-ret
hostpots
1/34
R949D
2.1.5
Institute–
R01
PI3-K-dependent
www.ensembl.org/index.html
I-Ppo1
BARD1-deficient
number.We
transformation182
SET-16
Ukrainian
138,101,360
UCN-01
sequencingin
Figure3C
PTEN/C2-T319Y
w1118
respectively.18,19
control-shRNA-expressing
BC009730
LGR5+ve
EUFA316
mg/kg/d
P14ARF/DAPK/p53/
EMD124063
fibroxanthomas
Po0.006
1QPC
tubule
SMZL.10
Q164
anti-HisG
described89
VBC-CR
NEUROG1
Muiioz
5'-atgggccctgctcttcacttcatgtcc-3
R2323W
+/Mild–sev
JBP/Tet
1:15
independence.28
PBAF-specific
mutantrelative
Verstovsek
single-carbon
IPEGAL
Hyalinizing
1.653
Glu280
18/24
D820
RB2
10.1007/s10038-007-0222-6
1,070
betweenBamHI
Trp53-null
v1.2.2
3C–D
71830
p53-reactivating
Myosin
ATCACCCAACAAGACCTAGC
GADD45-containingreporter
byan
G252R
205
LCH-12
Eerola
c.38
68-amino-acid
translocation-negative
Cryopreserved
state1
D839G
T280M
Sgt1a
dbwu*
0.065
Carnesecchi
leukocytes6
Stamdford
939x
5′-GTGCATAGACCACCCTCAAGG-3′
LMP2A
NCT01442090
KIAA1093
Srs2
glioblastomas22
0.329
pYAD/EI/L
FLT3-WTand
59-CTTCCCAGAAGAGCTGCACC
Hi-Dye
CAGCTGAAGAT
Milde-Langosch
bilobal
p.Gly375fs
ccRNA
.CD8
Chittum
mid-region
PEBP2/CBF
anti-GnRHR
represen-tative
Proteolytic
CTGAAAATCTTAAGGATCCATTGGTTC
plexin-B
activated6,7,9-11
Figure4C,4C
ES-D3
14.13
msh2-GD693p–Msh6p
Method-S4
c.2527T
1.1.2
phospho-substrates
1a–d
FUS-3
ofScience
Subgroup-Specific
CCTTGGGAATATTGAGATTATATTCTCC
155750U20
Fug-III/8
CCGGGTTGGCATGACTCATATTAACCATGG
InsightII
Dermatología
LEDGF
Oncogene-induced
0.36–0.88
2034
BRAF-specific
Jeb–Alk
5'-TTCAATGGGAGAATAAAGCAGC-3
LIN
14q32
long‐term
anchorage-independence
4/123
wt-GISTs.22
pRPA
1544C
3Dcoffee.44
domain20,21,23,28,30,31,33–36,38
10Spindle
mice66
.MDM2
Golgi-pattern
H1299/p53-D281G
Val2985_Thr3001del
toplasmic
Änkö
mesotrypsin
Quantifoil
manner.5
Rippin
FGFR2WT-V5
pDONR223-ERBB2
1-mm
qRT-PCR–based
.L
abraxas–BRCA1
BRD4-directed
c.2596C
inter-molecular
.BCR–ABL–positive
74/69.8
autocleavage
.L148
value*
.Membrane
melanoma.27
12.8-
activity.24
miR-129-2
activation.To
Cdkn1a
5′-AGAGTTATAACAGGCAGAA-3′
5′-GTTTGTCCACAGAGACTTGGCTG-3′
calumenin
16‐mer
Cy3-labeled
N132G.D
Ala-59
A4700
Y568-Y570FF
KEx16BEx11
adenocarcinoma12
3893
Ser727-phosphorylated
1,483
OCUG-1
E10.5
Frisch
F212
compared.40
.891
RTK/PI3K
dimerizing
IVS512T4A
MDS-U
1L-O
5′-CGTACCTGTACATGTCAAGGAATTGATCCAGAG-3′
eVective
mucosalmelanomas
0.848
9044
CITED2-p300
'separation
Caliper
occludens-1
liposarcomas.17
NFIproduct
I219L
KpnI/
Pützer
3189–3238
granulocyte-to-erythroid
electrophoresis
58-bp
myeloma35,57
EGR2-WT
Genes/SMG
start/stop
Dumaz
5´-CCGACCCGCTCCGCCTCCTCTCCTTCTT-3´
p53-host
5′-CCACTAGTCCGCGGCCC-3′
12V
matrix-assisted
0354
p16.3
0.7–6.8
β1β2β6β7
cells67
RAS/membrane
H44051
mice.84
anti-KITmonoclonal
AutoSNPa26
probands,3
-CD3
endogenousB2m
//www.landesbioscience.com/journals/cbt/article/9205
Y-MESO-
STAT5,27
size-2
pRaseA
14-3-3σ/C-RAFpSer259
α-FGFR2
beta-transducin
Hotstartaq
2,133
4•11
ELESPPPPYSRYPMD
IRESgeo
Y537S-SRC3
Hisprep
161–169
302–430
ribogreen
Screenedb
transcripts5
WNT-driven
cancers6,7
8.2.1
p53–DNA
future•
/dup
dyspnoea
MYH11
Hemihyperplasia
5′-GAA
.5,5
TACTGAGGTA­CCAAGTGCCCC­CAGAAAGGCAA
γ-thio
3401
-t-butyl
FAT1d
6F10
HLA/TNFA
immunosorbent
=18.3
heterodimer48
hypodontia
Lkb1/pAMC
MEK-mutant
235–248
2.2b
AAATTGTGTCCACCGTGATCT
74/178
germinoma
c-Myc-/-
R110P
.Echocardiographically
de®nes
S4a
595–603
androgen/AR-induced
degradation.26
RAF–MEK–ERK
brachycephalic-shaped
Megabases
ACL-4.22,23
100~199Positive
Pietilainen
R80A
G20
5.46
E9.5
lymphangiogenic
3,13
dpf,51
SMC1-S966
CTA-3′
IV:14
c.3030delC
L.M.T
R90W
pG13
mother–daughter
RAGDGTP
protein112
L731CfsX3
Vimentin
gefitinib,30
~0.08–8
−0.22
RDH54/TID1
wet-transferred
CNAG
N-O
DNMT3A/B
~6.3-fold
Vaco8
318–465
LinkedIn
pLenti4/TO/Mcl-1
lunchtime
BM/
glomangiopericytoma
Y207
C/H
mutations.25
+886
AhCre
L685458
HGF/SF-Met
yet-uncharacterized
μM.23
humans21
rs121913231
ultraviolet-exposed
faux-cancer
A—Schematic
tailor-made
pY-loop
-to-leucine
FC=1.55
immobilized-Akt
448
2:03077
anthracyclin
400613
Plus-ECL
pRb/E2F1-
Ferkey
arrest.The
buffer.Analysis
SybrGreen
TPR
Colored-coded
cRaf
SC-ura
Biotech-Millipore
1.529–9.382
1–447
LSL-D594A
Mastermind-like
report15
mei-9
29/50
DRFS
5′-ATCGTGGCCTGAGAATGGCTCA-3′
pancreatobiliary-type
†Consists
EML4-ALK_
E731K
GCGGTGGCTCACGCCTGTAATCCTGGC
Remke
TOP1-IP
FIM/RAMP/ZNF198
luminometric
rectocolon
phosphorylation-resistant
Abraxane
anti-correlation
C600
NSCLC.28
Q133K
spillover
0.5:1
n=212
1176
1,222
Indianopolis
myristylated-T308A
protein-engineering
30.30
Par6
-SH
determined.10
360-minute
cleavage-deficient
CCGGGCAGAACACTTCAGAGCAGTTCTCGAGAACTGCTCTGAAGTGTTCTGCTTTTTG
SMZL
=2.7
7389
6O
.Frequencies
factor-independent
i9K
techniques.Genomic
-nitro-N-nitrosoguanidine
anti-mouse-IgG
.PCT
theIG-associated
WT-LSK
sh-Luc
130/439
3.With
.Post-selection
65.94-68.44
composite_omit_maps
Cotticelli
Sedimentation
c.53T
V309L
P-HER2
Igfir−/−
9,782
variants.For
signaling61
alone.21
±5
Immunobiology
0.644
WT-KTS
Prostate-specific
YYCC-3′
Br44
5-TGGGCAAACACGGAGTCG-3
Tsc2–/–TP53–/–
VM
Dusanter-Fourt3
Mll2FC
group\
Damir
TESSIER1
IST-MEL2
902
ROS-mediated
CASPASE
virus-2
AAACGGCTACCACATCCAAG
al.,38
Csp45I/BamHI
ERMETIC-IFCT
17q12
6005-bp
salirasib
CD3−TCRαβ−CD69−
79,79,78.6Å
g.340
b312C2T7
targets—are
HEK-293H
prognosis1
−.74
DeCOG
p.Lys2797ArgfsX26
.Unknown
.Inter-Alu-PCRed
59/62
interstrand-crosslinks
Erdre
.STAT1
ΔWD7
reparation
pathology-labs
Leu-687
-D842V
pGEX4T1
575–552
dbSNP138
05–483
R420Q.15
L106P
DQ2,5
sc-35335
KAAD
cells/200
intention-totreat
anti-cullin-2
kin
CCNG/GGNG
extreme/absolute
vavP-Bcl2
†includes
pCMV5
breaks2
Yepuru
RB18-RT-se
2198C
AnalysisTotal
non-NFl
=1.8μM
−.71
C.5_
.CRS/IPHC
7194
TRR1
APK1
Bench-Mark
mCherry/GFP
.Superiority
AHD
229–678
1/86
N771insD
D352A
®ne
histidine-tagged
ratea
UAS-CycD
methylationresults
9p
collapse25
Ba/F3-mock
amphiregulin/EGFR
HHMI
TITF1
mutation.18
.Domain
MegaCC
Gastroenterologie
.l
Trp557Arg
Varian
curvesT47D
S4A-F
multimerize
TP53-null
crystallography.31,32
APC–CDH1–SnoN
HC-5
5'-GAT`YlI`TCTCCTCTAGAAG-3
Myomata
Zn2þ
Kinases/kinase
L450X
5α-pregnane-3,20-dione
factor-specific
LTA-SA
.WILMS
XL10
1AP2F
.Cellularity
Megakaryocyte
—we
.Y1853X
.ASF/SF2
R124H
Pelicci
CD41a/CD42b
codon–inducing
.Cichowski
LMD6000
YT
Controlsd
CDK6/IGK
receptorlung
eugonadal
X00588
CRTAC1
.1–5
Heatmaps
p.K27M
ATCGGCAGAAACTAGATGA
Deckert
V121I
UAUGAUAGACGACGAGAAUUU
5A-nR
described.38,39
Cy2
acentric/centric
|U
co-clusters
0.1324
syndrome6
Figure1b1b
.Irinotecan
V9P
DNAJC3
PAX5,21
pAT-ras
inactivation6
2014-01-17
Lox-K-rasG12D
si-control
receptor-2,13,14
1/29
ATGGGAGCCGTGCCCTGA
TpoR-expressing
β2m-negative
0-50
PhosSTOP
1290–1291insC
OSCCs
cc-13-834-g1
TCTTACCTGGACTCTGGAAT
p53/
13.375.0
AnalysisMissense
mg−1
20/80
IDH.9
humanpb2m
SNT-8
ethanol-5
ΙΙ
10.1182/blood-2003-12-4446
cancer-free
O-4
gtaagattg
.Predicted
.PHA-665752
telomerase-associated
2076T/C
ephrins/Ephs
Ha-rae
aflatoxin–DNA
TET1/LCX
RFP–VHL-positive
marginal
11,19
.Krasex3op/nat
R16443
al57
-were
N186K
46,835
stabilization
NVP-BVU972
Arg-80
5′-CATTGCTATTCCTCTGCAACC-3′/5-CCATGAAACGTGTTTCAAGC-3′
GCTGAGGTCA
disorder,26
.H596
trimethylation.29
Shimamura
MEKK1
p-VSV-G
M118
CLINICAL-TRANSLATIONAL
6.39E-03
neuropathological
β-catenin-Lef-1
H-Ras61L
.|/Σ
1-400
.Computer-based
cMAF
P=0.006
TER-
effects18,19,20
MB-468
R249K
chemotherapy.2
H146
NaH2PO4dot2H2O
phospho-mTOR
ARID
Kcal
4-9
minipeptide
Sanofi-Aventis
H1299/p53wt
7.2329525
8-month
self-resolved
site/publication
β‐propeller
61–86
Gene-expression
shFBXW7/DEX
Hybaid
n=115
Cys117Tyr
Platelets/mm3
28/35.9
FCD
-0.5
Cross-talking
MSH2-I145M/MSH6-L1354Q
KRKK
.DNMT3a
al.,1994
230-40
CD24
J012
1.62
V559AKIT
detection/repair
recruitment/accumulation
degradation.1
werenot
~Table
Ringborg
retrotransposition
3p_strand
Asx1
TCAG
GATA3-positive
tetracycline-dependent
Asgeir
3These
56379–56660
non-catalytic
CKO1/2
5μg/ml
115-H01
PQPKKKP
Fontemaggi
Qâ€
andbottom
laminar
16-36
******************
a.k.a
LGL-leukemia
Celsius
lower-purity
pMSCV-EYFP-IRES-FLT3-840GS
microcystin
p110-mediated
0.15′
5q31
Scf
EASY-nLCII
his3
pGBT9RhoAlibrary
PhosphoEGFR
inconsequence
europaeus
Ala-to-Thr
150/min
177-Kbp
62752443
Saint-Germain-en-Laye
NanoLC-MS/MS
.MAP2K1
007706
EGFR-express
inhMSH2
gastrinoma.5
NA:1.20
Akti-1/2a
ERÃŸâ€¢Y443F
TYK2,57
CRc
6p25
Y-rich
GSK3β/NFL-c-MycS62A
malignancy6
threonine-670
T5–T0
.TMPRSS2-ETS
IGKV1D-8
=2
7-R2
5q31-35.3
T4800C
RAC1/NRAS
Tiangen
energy-minimized
anti-diabetic
C2CD3
BXH2
hospitalization
S121F
5-HIAA
observations26
androgen–sensitive
21.8/25.5
6/69
.63
Chk
1886
4845
Pediatría
-S.
others24
Modi®ed
4,082×
co-localise
.PP2A
half-bound
:BRCA1
G165R
allelesa
GCG→GTG
1RJB
.OS
fsX31
7q22-q31
patterns.15Pathway
concordance.1,2
SurgeryHeineman
proteinc
R1800C
Coactivation
absent.72
metÃ¡stasis
HSC7E481
U.S.22
CSTF2
Perkin-Elmer-Cetus
G2669
.Going
D504G
W572X
advisable
pAf9
splicing-regulating
BR-0492
2/6
activator-impairing
eMYCC
2606-2582
GenePorter
anti-HLA-B7
mutagen7,11,12
M40
Frat1
XL-228
a…
HER‐2/EGFR
S933
Hypoparathyroidism
cells9
14kb
Scribble-associated
30,224
cholamidopropyl
differentiatedadenocarcinomas
leukemias11
25.03-
farnesylation
Axxora
5.24
C57B6/J3Balb/c
complex.2,7
STAT5/Y694F
HLA-DPB1
A′GFC
I90K
KIT/SCF
FA.13
dupli
C242S
5×10−5
IL2-supplemented
D17S800
.Fluorescence
c.4986+5G
n=125/139
51nM
NCI-H2009
CAN1
.Flash
RWPE-ERG
M-CM
.To
mmol/L
androgen-containing
N/A-E1210K
HA-Strep-tagged
tamoxifen-bound
EP665Y
RTPS
ERK1/2/STAT3
GST-AR-AF2
^
Brca1+/1700T
S3N
J.P.
monoexponential
R337
authorSNF5
.PKB/AKT
Val/Val
cancer23,25,26
FGF-responsive
99.3
2132
months/no
Ink4a-arf-ink4b
kinase-independent
multi-activating
ovary
Gizatullin
DNAmicroarray
ZipNeo
SETD1A
L3/early
2-substituted-6-biarylmethylamino-9-cyclopentylpurine
αP-Thr308AKT
H3122CHR-A1
V254M
c-fos,10
.Androgens
PTPRD
I.3
5137
cisplatin-mediated
1.594
to2
10.1038
1560–1649
64,65
Catalysis
Edg2
NB4.37,38
NM_004456
log-logistic
Exoribonucleolytic
EpoR
.Appropriate
.GW583340
.Bmi1+/−
AY077732
q15q23.2
E2F_01
E160∗
LAL0201-B/2000/1205
Kras–driven
complex/hybrid
notch
leukemia,4
Nipro
MBr
AMN107-mediated
1.32–2.74
full-matrix
c.5365G
Chr9–187R
Asp-404
094
trial39
3227
RECQL
68563
cancer.5
FLAG-BRD4–NUT
amplification2
≈9
high-penetrance
Keppler-Nereuil
76–86
NCT00949650
leukemia^
Wilbanks
Supt7
T117S
gim
Ala554
Tpr-Met.BaF3
underestimates
G127V
106/ml
BMS-911453
Cikaluk
culture-activated
na-
passageThe
P409fs
BglII/SalI
ADCY2
401314
saline-Tween
Starna
A2780
mesenchymal-type
09/03/09
TGN
CSFASTA
A.J.I
/repressor
Ras-like
5'end
'normal
adenocarcinoma40
Loss-of-Function
I-κB
S.E.1
P772_V774dup
0.08
intervention.3-9
0.74-4.90
ATTTGTT-TGTAGGC-+ATI-FGTTCTGTAGGC
pharmarray
C121S-expressing
PTEN-T348I
disfavour
73-156
pBabe-puro-EGFR
14–80
1988-1991
patients.57
Q456H
EGY48
pre-miRNAs
6Cancer
pY1604-specific
∼2.5
rheostatable
8.8°
.982
W1313C
Q357R
TLR/IL-1
106/115
F810
p.R506_insVLR
Phytohemagglutinin-stimulated
UC39
N822H
PP1G
activity,24
I:2
f/59
G296S
pSG5-FLAG-SRC-3
euglycemia
NPIKBKB
130-140
Mi-2a
.Nellist
.Two-group
receptor–luciferase
preproglucagon
product6
microcuvette
039211
SRMS
SJHGG082
NM_002878.3
c.1812
LOC57415
ofproliferation
p.Y470D
Results/Discussion
//www.ncbi.nlm.nih.gov/sites/entrez
basis.2This
CD61+CD49f+
Gly67Trp
vector-expressing
rapamycin/nutrient
GDP-or
auxotrophy
early‐stage
disease.12,24
5′-CACAG
GIST-arraydata.txt
alkylating-like
EGFR54
Bakker
hTCF-1
c.3193G
p.Gly356Asp
q27
NXPH1
cgatgacagtggtcgcctgcaggcagcgga
transtuzumab/pertuzumab
miR-31-5p/3p.6,7,11,12
gene-amplification
highstringency
early–late
errorE2D
0.0101
5-GATGGGACTGAGTGCATCCT-3
SOS-1
chestwall
tSer
mRNA-derived
4268
mTOR-C6817T
P2515Rfs
NTRK3-rearranged
TGATGCAGAGGAGC
IκBα-affected
.Analyte
sc-29459
andpepstatin
.Kinases
M/81
.Reactivation
oxoguanine
Arg177profs*126
CT26-infiltrating
NormalizationIntegrity
RNAi-inoculated
Gels—Gels
exclusiveness
I462L
:30.1–100
–45
10.1172/JCI62644DS1
Electro-Nucleonics
AZD5104
low-cycle
9.92
MEK1-induced
.0011
liver-derived
D1123
Switchingoff
51y
CTGGCCCTCAACGCCGTCCTG
.LPS
H720
non-GIST/non-gastric
AADG
MDS.28
isoforms25
activationdomain
μm/mL
2−3-fold
Gene-Tools
Cohybridization
Ala-Trp-Gly
W131A
2.3,7,8-tetrachlorodibenzo-p-doxin
p53-R267
beta-catenin,27,28
NH4HCO3
G1arrest
3340
phospho-c-JunS73
H1299-p53-D281G-clone
described25
781
ALL.3,4
N276S
H875Y
S4A–I
734-763-4686
freezethaw
IGHV-unmutated
356237
Wehi
neuron
subclass-specific
isoprenylation
p.L97R
series.37
7–11
R6874
XIAP/hILP
mechanismin
GCAGACTC
crizotinb
myrIRS1
.Uncropped
BRAF‐targeted
transitionstate
genomically-defined
275,000
0.8–197.7
1•
I.M
RMSFs
I-SPY2
11.9
L227
Cys4′
Methionine-labeled
.C
TAL
non-E2F
microattributions
ene
neutral/nondisease-associated
39.1
24,46–48
wu106/wu107
FISH9989b
Y50C
hypothesis,49
10.1158/1078-0432.CCR-11-1791
1403–1641
trk28
QuikChange®IIXL
2061
./M
PI3k
incarcinogenesis
HH-driven
state—the
diseases.19⇓⇓-22
.Lent-SOX17
immnuohistochemistry
fusions14
μM.hr
aliphatic
ProteinsTruncated
asindicated
PDL2
.Sasaki
survival.1-5
P⩽.01
fromK-Ras
Boultwood
ActD
MAPK-Signaling
EiAF
Recepto1
Gly576
FITC+Rhodamine+DAPI
R378G
/AG
patients7
FLT3-ITD.79,89,99
NM_001986.1
biotin–UTP
simulation-based
gtatgagag
dominantover
0.1μg
8/46
0.0251d
A681T
-insertions
RHO-FAMILY
pCI-ML10
E709X
HSC70
GCTCTAGACTCAATGAACTGGGAGAGAGAC
17.29
Project54
p=0.0540
multidirectional
1464STOP
p.V890M
intron
1756insC
c.2365C
outpacing
S34F-dependent
c.5096G
B*151101
LPA-Rho-actomyosin
5/42
.G.N.
R462E
ratio=3.914
FISH-mapped
fourfold-higher
IG/nonIG
CMTM8
point-mutated
P70S6K
Dalgaard
GST-pl6INK4
26/31.0
antifibronectin
tumor-suppressors
1.75M
Clock/Bmal
Il7
9/33
Cloning—DNA
140°
II/41
PRE-based
datasets16
untreated/unresected
J36
Buchs
C1821
TUR
3A1
GST–ROCK-I
ARGThe
Flk1
FOXA1-related
N272S
Zachary
Cytosine
agarose-streptavidin
hits.
¶Family
MPCEWS-FLI-1-T1.1
nanoclustering-FRET
rfeisâ€
nonurothelial
Stagel
p.Ala128Leu
B*4419N
diagnostic/prognostic
68893
JAZF1-PHF1
p.Glu48Lys
±S.E
myelosuppression
PT2
Bonferroni-based
virus.33
2185delTC
Modeling/docking
PFS=progression-free
DGYW/WRCH
potentiated
9.1–68.4
Closeup
29–65
c-KIT–enriched
cis-bio
FACsort
0–I
MKKs
*First
3690/5000
HumArray2.0
V617F-Y931C
anti–SHP-2
7060–7069
bone.48
5,8,9
endoribonuclease
Sox2Cre28
-TKIs
phase,75,76
2-114,248
microautosampler
CBFbeta/PEBP2B
//dx.doi.org/10.7554/eLife.14709.012
arrest–specific
Gly301/Phe302
ER−/Basal-like
answer.11
2.6-fold
SIFT/Polyphen-2
Ohki
6/local
XXV
IMPA
CTTCGGGATCTTGAGCTACG
L45P
independence.Figure
Br78
CDG-IIa
2812_2830dupb
D1/1-295
Biosystems/The
reportedin
1,2-dimyristoylglycero-3-phosphocholine
ng/ml/106
features1-5
1.0009
0.5-22.0
1732-
non-tumoral
ChIP-PET
ZNFN1A3
cyclin/CDK9
transcription38–40
CTTCGAGCACCCTTCAGTTC
www.frontiersin.org
staining-wash
K291K
virus-1
Tsukiji
carcinosarcoma
kinase-3beta
PIK-E20OF
.Brigatinib
DUSP2
pF3A
Södersjukhuset
surprisingthat
NF1+noonan
12p13.1
Japan4
activationof
tubulo-villous
Pten-deleted
Ras/p53G245S
R118L
Ser217-phosphorylated
3445
p.Gln401fs
Cellulare
DT-A
LeBien
12q24.23
ENSG00000167258
mice.35
placedunder
cells154
HNP10Ca2
0019199
D115nt
3/50
~19,000
CD8–C8mt
Low-Copy
NCT01871311
signaling,36
Golen
5252
transcription-competent
material.5
4-144
AJCC=American
ng/mL–100
hsa-miR-885-3p
D162-S248
3,404
NCR-EW3
GL_RENDER
FGFR2N550K-transfected
AML-M5
C*06
D18S5824
p190-specific
p.E392K
Scoazec
CLCN6
phenylalanine-156
TEL-PDGFRB17
S200Y
SF3B1MUT-deregulated
1000-bp
p.Pro531
Mrof
Hypermorphic
IHC/FISH
1174
Q1420X
method.17
MKX2.2
removal/repair
observed.59
cryostorage
CDK
triplicate.MTA1
EBI-EMBL
models.A
Glu734
12·5-mg
'-
MYC-responsive
re-response
Q56P/K97M
WT1-Replete
.6409delT
GAATGAGCCCGTGAAAGCAACACA
Serologies
Ellenrieder
Hematopathology
suggested.44
PvuII–DNA
9p21â€
Wurster
.Mislocalized
FANCG/XRCC9
.partial
D157N
suppresive
lines.15
SHOC2wt
amplification32
CHGA
N-Ras-I24N-induced
TAP-2
H2921R
HPA035977
,32
leukemiaA
microfistulas
765–766
Log-phase
B13
Lys-777
ERG,25,27,34
neuroblastoma.13
methodologic
CS-FBS
KEGEGKFL
unc-86
429AA
correlationstudies
hydrolysis-independent
GGCATCATGATTGTGTACCG
AH/PH
.20357
demon­
duly
P27
-'2P-labeled
6.2-kb
Cdk12-null
TTSP
E746-T751
pXJ40-HA-MerlinI
3.40+0.12
Srsf2+/+
hIL7R3′EcoRI
formaldehyde
2-kb
GM10080
7.55-fold
-AAGCTTAAGCTTCCCCACCTTAAGGCCGCGCTCG-30
imatinib.3,4,6,7
keratoacanthoma
SLC5A5
catalytic-dependent
bioluminescence
pVHL-interacting
shRb
normal.25
K36A
21-kDa
L55Q
70Z-Cbl
A1303G
0.2587
networks—for
Figure10
Thyroidectomy
Signalunmethylated
GST-pVHL
pre-imm
.PC-12
CD4-CD8+
p.G719A
18q22–23
ultra-high
RP11-623N3
3.Comparison
integrin-derived
low–metastatic
Xenotransplanted
Leu861Gln+Del19
16.8
DeNovoGear
uve-Wiedemann
178.2
primordial
A349D
E/D
highestproportion
Hospital/Leiden
siRNAs-transfected
GS-linker
extracellular-signal-related
Q295P
200-300
dimerization66
kinase-interactor
U937
1.89
dicyclohexylcarbodiimide
p53/Nf1-mediated
RBN
D317H
GW2016
responsive3,4
CeB
RP11-420F11
IgA+
Hsp90-mTOR
TTGAAACAAATGTGGAAATCACC
Firestein
≤65
LP-1
TOP1P2
ROSG2032R
FGFR1-IIIc
Mailloux
underimatinib
L1196Q-mutant
BRIP1_WT
1.684
29.0
USP3
c.9019A
0.998
non-ILC
5′-GCAAACATAGTGAGACCCCATCT-3′
G-helix
genetically10,31,32,33,34
pSTAT3/pERK
degradation27
p.Leu435Pro-p.Val878Ala
Tyr32
ALL7/8/9
inhibitors.12,13
EGFR-PSPH
CBL_i8r
UV-24
Katchalski-Katzir
EZH2-EED
sub-line
Duodenum/jejunum
progression/lack
Tarsounas
Ân£
Smad3/Smad4
CAND1
R497H
Pro-2273
61•13
Conclusionh
forexample
epicanthal
ALK-translocation
TSC22D3/GILZ
Calu-6
CKI-mediated
ICI164384
activation/aberration
studiedthrough
shAR3-sc
T3/L-V
Iodinated
ValVal269-70del
Navigator16
pre-malignant
AFF3
PPTFig
Shioda
neuro–oncology
BAT-bA
HEK-293T-TREX
p3HASox9
R348∗/Rac1/Cdc42/MLK3/MKK7/JNK1/JNK2
deoxyribonucleoside
Thrombocytosis
geographic/
L257Raf
Y345D
IMVI
443,360
PTCH1-dependent
pRK5
annexin+/PI−
APOBEC3B
2.788
Gal7
pancytopenia
ofBcl-2
Protein.
H2O2/methanol
Pgr
Inter-subunit
787
measuresthe
Ni2+-nitrilotriacetate
3-nested
.Cation–π
dioleoyl
I395V
pan-keratin
SWI/SNF-BRG1
group-independent
.SF3B1
J-715
PIK3R
2571
F−dmc
auto-activating
Rothenberg
Q542P
.PF-1066
shoter-term
CountBright
a70
0.86–1.76
ofß-catenin
WNT7b
isFGFR1.13
Maelandsmo
www.jove.com
C1149R
syndrome.3
Izaurralde
HUVECs
alpha-phosphotyrosine
.Antibodies-Antiserum
chamber-type
72517
Spii
IVS8-57delT
genes,44
proto-oncoproteins
respectively41
3.537
care2,3
K-Akt
Y1003-mediated
MLN
Men1/T
cancer-predisposed
N-B-Raf
10,13
.9523
RBM10‐PUF
implicated,6
2042
.Settings
`+++
AluJr
Acetylation—To
021140.2
organ-specific
NCT00882583
0.0671
R1680W
HES4
2103
SMO75
1.34E16
cancer-derived
Hakem
.Depletion/inhibition
Demuth
helix-turnhelixdomain
therapy.2
.Retinal
0.1785
NM_010479
MLL-partial
EGC
Amplicon-based
codeleted
RAD51C-complemented
ERK/total-p42
tumorigenesis23
Cadherin-mediated
mastocytosis–associated
trouble-shooting
lnwf-oa
unifilter
RP11-379F24
2634–2804
5'-GC-clamp-FITIGCITIT17AAAAATAACTACTGC-3
22,189
Uhlenhaut
I–IV
grandson
BCR-associated
P-RB
anti-rabbit-horseradish
S186R
Garcia-Olive
±2.8
Gdn
control.To
236–267
c-kit.1
N879A
E453Q
glioblastoma22
GSE38447
receptor-free
.Replicates
5'-ACTCGCTCAGCTTCTTGGTG-3
160–171
Gehan-Breslow-Wilcoxon
cytokine-independence
ELK-1
Riener
in1p36.23
Lkb1-mediated
puromycin-positive
AKT-K179M
646-ASSTT-650
Thr790
K183
1:3,000
K99
SLCT
Semi-Quantitative
Lac-Z
-unstimulated
5975
anti-c-Mpl
000/
Fig.9A,9A
2.Figure
Microsynth
RET-targeting
E713K
_10-7
5-ns
c.343G4T
p38-activated
c.2028C.A
FoxA1-targeting
TWIST1
ÃŸ-cateninthat
P1856S
resensitized
FGFR-selective
mislocalization
gliomas.39
BCA
Haramis
35S-Met
**Significantly
Slow-release
OPB-51602
mitosis-related
92-3a
GI:2150128
avidin·DNA
BRG1−/−
deoxycholate/1
Flt3-ITD–
Cesne
distinctiveness
AID-induced
.HRAS
IgII/IgIII
Q119P
pYpY1135
39-69
Ptpn11+/D61G
ylamine
.-G.
5916
8/99
dimethylates
HA-Sox9
27/150
c.104G4C
granulocyte-erythrocyte-macrophage-megakaryocyte
5'-CGA
.Differential
Yamoah
super-chaperone
GAAAGCACAGTACTTGGTAT
–46
head-neck
Poliklinik
Mmp13
livertissue
Remineralisation
.SDS
Oligonucleotide-directed
umol/L-1
S473-P
C2H2
K42-methyl-specific
vim
.FADD
Socio-demographic
8p22/9p24
5′-CTCAGCCCATCTTCTTCCAG-3′
Arg277right
extrapolating
D538V
vitro7,16
5/45
toHNPCC
P1324R
structure.9
1,164
IL-3–free
Ilk
Scaphocephaly
BamHI-
1.253
AS23
anti–phospho-MET1234
0.5μCi
development25
ErbB
Ser-235/S236
GLI-dependent
46.23
-GCGCGGATCCCTTTGACCCAGAAATAGAT-
11-deoxycortisol
.Limbs
9/35
H3F3A-mutated
ATGcodon
CD4þ
500–100
20,000–30,000
BCLL
TC21Leu-72
DFS/RFS/PFS/EFS
KFCfl/fl
D-positive
neoplasms.20
5′-GGGAAGCTTTGTCTTTCGTG-3′
CDK2-cyclin
Ph/BCR-ABL1-like
AML,4
study.97,102
characteristics8
JNJ-38877605
NM_001001332
-Tet
827
-107
MyoD-Max/E12
chemical–physical
R905W
Frame-shifting
GPF−emptyDAPI
Doxycyclin
ΔNLS-NFkB2-ROS1
p110α96
osteosarcoma.49
K882
T90AE97A
GDFGLARD
L1196
Burack
19,47
Weitzer
pancreas/liver/kidney
2.0.6
M4m2
643
carcinoma32
6H-independent
HNF3α
PG-B6P
+37°C
diC8-PtdIns
Kiiveri
rhabdomyosarcoma.4
8.265.7
HA-LKB1
0.9050
.Upregulation
.Disulphide
-r'g
elongin-binding
CD11c
RICTOR-targeted
Arg164Gln
oncogenes.16,18
6400
AGgu
ALK/Met/ROS1
autoimmunostainer
pMSCV6
I1113T
andmsh2-GD693-VD862
0.887
24–1940×108
chemo-resistant
ABL.4
2553–2560
Branzei
ETS212–14
disease,48
STE12
damage68
gal4–542
Leu/Met
repair-proficient
CATGCTGAGATCAGCCAAATTC
doublemutant
.1696
anti-phospho-Met-specific
0.995
PRDM1.E3.79.F
RAS/tyrosine
24626/pNF
RPM11640
n=150490
5′-GAGCGTGCAGAGTGGAGGGAGAACA-3′
68352672
MC29
V2284M
WDLPS_20T
al.20
ethnicity.7,8
−1/3
drug-Abl
pcm
K589T
NETinhibitory
interbox
3I
AII_1
//gdac.broadinstitute.org/
−10
10•0
rod-shaped
c.375-
ΔZF
∼0.048
footprinting
FANCJ-WT
Pax6
5/54
Br50-Sar55
Ras/ERK1/2
Nu24/DP1
caintegrator
MCF-10A/ecoR
acids.12
leukemia2
ULAR
.Rehybridization
pHEX1
heatinactivated
model—are
N=59
approach33
.stfrSib+s
MEFsA
rad50L1240R
S1089L
U781
AAC50969.1
RAR/RXR-mediated
L332P
.A775
Mastrangelo
N=109
Opti-MEM
18.96
imagingdetected
0.11*
0.146
1.570
SP6-3
p300CH1Δ-E2
medium-range
thyrocyte
I309V
PMS2-NTD
HOreverse
c.5857G
ChIP-sequencing
Recog-
Dnmt3a/3a2
.1669G
KIT.13
DS-double
non–plasma
RasGRP1
hyperfractionated
60T1
G251C
E221D
PTEN-expressing
Tg
RD1
phospho-PLCγ
.KAADCyc
CPO
Kmt2a
H19
.0767
−+f/weak
Phe1061
.HIP1/PDGFβR
1p13.1-1p12
immunosuppressvive
P960
software75
27048
R719Q
Phosphoserine-15
Y443N
increased.11
n=163
•••
5-fluorouracil-induced
Taxane-based
do.6
G418-
60,770
decrease/loss
.Edited
withanti-p53
CBDCA
.6,8
L146R
PTTG1-Binding
KIT-V559D
n=246
PolyPhen24
Chr11
Rolny
1p13.2
​C-D,66A-B
ATGG
DH8.3
ALK-Y1278S
XPCSBA-sv40
cholecystokinin
0.741*
SF3B1MUT–U2AF
Gab1/SHP2
Hosono
F.U.
Platinium
29,124,299–30,289,970
activation8
8–24
18-specific
0.0089
-AAT
HA-TELJAK2
Monoallelic
T491A/S494A
1198–1531
GST-Smad3C
deathDiagnosis
DEFS
655A4G
alkaloid
n=792
6-wk-old
tyrosime
OG-dependent
s—5
indispensability
L260R
ΔSH2
RAF-1-
5′-CATACGCTGCCTGCAGGCGACCACAGTCATCGAGAGG-3′
RT-PCR-products
htpr
top-ranked
S696
.167
ΔN42
76/436
Brd4-inducible
2α-mediated
p.Glu732ArgfsX3
MONOMAC-6
café-
McAuliff
SAS1300700
CSF-
pathways.PIK3R1R348∗
RPMI2650
IVS2+1G
Smad4/CBP
SITE-DIRECTED
PBCre4/Gt
Fwd.
mutants/ERBB2-expressing
ligase-65
icM
Notch-focused
pMXS-CASP8-ires-EGFP
nonpromoter-associated
pit-and-fissure
anti–phosphatidylinositol
CFC81
88–97
p.G1139V
GST-Cbl-TKB
mice.142
Mib-1
orPC-3
RET/PTC3—a
PDGFRβ7,10
ofrare
.Sequenom
ZC3H7B-1190F/ZC3H7B-1714R
252
89991
MnSO4
D103G
AML,2
CGC-30
610-nm
ZSCAN30
death-rate
gamma-irradiated
Lck.12
C–H
TEK
phenol/chloroform/ethanol
NSCs6
a-helix
ESWR1–POU5F1
gi66852271
Shift—The
PRnegativity
VUS.63
A203T
TRE-L3-TCCTTGCGGGGGTCCCCAACTGCACC
.One-third
557306
Asp594Val
-ATF
dead-Akt3
11d
33-1-53-72-51-58
intraluminal
412–430
ccRCC.34
activity3,7,9
transcription118
GTGAACATCATTCAAGGCG
Nabel
18nontruncating
glioblastomas.11
Thy1.1
anti-myeloperoxidase
Arachnodactyly†
337–343
examined.6
easy-spin
0·77
74,317
LMP1
Kalscheuer
557–560
4226
10.31
6.97
transcription100
MECHANISM9
GTCTAAAATCCTTAAGCAGG
R.K.B.
18FDG-PET/CT
9-residue
HEK293T/17
TGFβ.Cell-Cycle
or2
S341P
L79
.Athymic
Treuter
defect.Fig
74.47
.‡ORR
oncogenic-type
.Leuven
LNCaP-vector
.D153V
L747_E749del
EML4-ALK–positive
-catenin/cyclin
methylation19
Morevoer
nm/440
4C-K
PML-RARA
S10
prepara-tions
R139A
region-Abelson
MgCl2
Glc3Man9GlcNAc2-pp-dolichol
11/23
More­over
AT1-AT5
−67.4
g=∑t∈cmtnt
1–375
U92074
siCTRL
1590
.HEK-Jak2-WT
pRBΔ685
lines.49,56,57
4-methoxy-6-nitro
RET-suppressed
protein-phosphorylated
QIAamp®
Lechleider
attttacag
easy-to-score
replication-based
10i7
.MCF7
.cell
800μg/ml
Wollscheid
A/c.7007G
TAT3TGT
P404L
V600-BRAF
immunomodulator
anti-Gagp19
in-line
ERBB2/NF1
E719G
neuregulin-β1
3.02
3-primer
AminoAcid
Abi1/2
TCTAGCCAGAGAPNA-modifiedCATCAAGAATGATT
Y236F/T253I
ROR1-introduced
11.6–95.4
Ishizaki
S22
D976N
p21Ras-GTP
Fgf8b
huifeng.niu
A1347
Schwetye
KRASQ61L
∼72
PIA
0,74
1otrk
71.8
FKHR-like
eﬃcient
Asreported
6.937
GST-MCAK
5′-GCAGCTGCTGGATTCAATTAC-3′
DDR-related
anti-MCL1
protease-resistant
background.8⇓⇓⇓–12
69*
pBabe
Transregulatory
ATPaseactivity
10.1042
599–606
n=288
sc-7974
UGU
p170met
unaVected
m5
CTT-L718
.Normally
NS058721
studiese
−767
MLH1+PMS2
1560-
ARP/wARP59
Egawa-Tsuzuki
.Lapatinib-resistant
pcDNAp73α
T3wt+pRC/CMV
Ig5
c-kit-dependent
AGAGTAGTTG
Transport—The
17Asn822Lys
controversy181
.PBL
JH1–2-Jak3
gefitinib-insensitive
RefSeq
deidentified
Lin−/IL7Rα−/Sca-1−/c-Kit+/FcγRlow/CD34+
Asp-Leu-Gly
expression45.PDGFRA
MMTV-CrelineA
903G
11,12,16,27,31,33
sequences1
cpm/Ag.Cytokines
Retroperitoneal
241–467
~0.8
P=.013
ARafDD
DI8S6I
Thr-X-X
Pertuzumab
1.00del
.V-GTTATGCAAGGTCCCAGCGG-3
clinocopathological
3BEA
sonography
gene-internal
LLL
rPLD1—The
BrafMEF
Rox
kinases.The
PTEN–PI3K
CCATATTCTTTCACCGCCCACTCC
42/76.4
MMTV-Ras
Maximun
rs17290169
p85αR348X
homepage.htm
N13GGT
airpin
0.40-1.85
AluJo
Tommiska
Ser46Asn
CD4+CD8-
craniosynotosis
IG-13
Tyr720
p46A
CellsPools…
7266
Ala34
INK4a-encoded
2+
359–372
caacgagacctatcgccgc
E378G
5′-GCTAAGAATCTCCCTGGAGCTGAGAACC-3′
.S100
insulin-responsive
.7G
Roscovitine
J.R.F.
formation.3
CRC177
B-Cdk1
unexceptional
A300-767A
RNA-sequencing
T790Mc
7074
SSNV+LOH
NS-like
M25
results.Methylation
DSCRT
0.000183
islet.B
micro-vessel
sites—3
WY354
M700A
p.Gln678
c.806-2A
FSGS
hB1
complex.7-9
FIP1L1-PDGFRα-expressing
ubiquitin.Full
ACATAGAACATTTGCAAGAC-3′
5'-GGAATTCCCATCTTCCCAACTCC-3
AF9
GTGGTTTG
Cordeddu
receptor-DNA
21–22-nt
pem
304/IL7R
N122G.D
intron/poly
2=de-novo
71944
GSE32567
PhiX174HaeIII
`-
UPM
.Correlation
FLIM
–4.6
bimolecular
nonparametric
16-week-old
Tumora
Fak
Cell-Cycle
levels.36
YFP-GlyThr17
crisis.5
duplication53
.Touch
delK745-E749insK
466T→C
173L
1p36.1
Ala391
P95R
Asn-879
siCT
82.62
karyotype,24
A56V
.Crosses
H1299
Hs99999901_s1
Hybond-P
A-A′
gta
Medzhitov
cac
K379
lymphocytes20
targeting53,56
G67W/LOH
e−λt
RING-domain-containing
RGYLSPDLSK
RFX-DNA-binding
respectively.ResultsRelationship
Rheb•GDP
UV-dose
pGEX-5x-2
glomerulosclerosis.20
patients.52,53
Rac3
R969Q
0g
λ2001
GATA6
Cardiomyocytes
4,13
Rwork/Rtest
environmentally
unfolded13
17.18
Bluteau
TeloTAGGG
pAcHLTC
tohistidine-de®cient
Anglesio
IGFJIR
Irs1
cells3,5
ATLAS-TCGA
0.883
//dx.doi.org/10.1136/jmg.2010.083790
ContEst45
.66729154G
weresuperﬁcial
ferential
BRD4–NUT-dependent
FLT3-TKD-positive
RO-3306
Nanolight
AY264750
MM-1
SEL10
Jude/Murphy
Tyr972
Tumour-derived
​TGFBR1
Ser383
fBox
MCF7-D538G
.MKP-2
291K
10948
non-hyperploid
periacinar
www.infosci
ume
internalization-competent
Myr-5′B
properties25,26,27,28
neuroblastoma22
syndromes,18,25,26
dRhodamine
pReceiver-M12
RAB37
Myx
ligands
phosphotransferases
//rsbweb.nih.gov/ij/
Blockade
.32,39
fs-ps
Br1
.Migrating
Unphosphorylated
rs121913427
ins59ter75
69.3
P98175-2
DOX-dependent
0.723
HEK296
rArgLeu
MSH6-19
Al-F
39.3
atseveral
Lumat
p53-related
0.135*
genotype-specificity
V778I
LXSN-AKT2-S
ubiquination
W179
04/01
p.R1235P
us.14,15,30
KDR-PDGFRA
2607
pEBS7
Tumor-infiltrating
inheritance.9–11
drug-insensitive
CACNA1B
550–557
activity.16–18
M12.50
MDM1
A-to-T
NEK2a
www.sanger.ac.uk/genetics/CGP
assays122
IbR
Arg397
anti-PDGFβR
−364
604317
aligned_seqs_submit.html
fourierspacing
Leu804Val
location/amino
59-CTCAGCCATGAGACAATAAATCC-39
.Ubiquitylation
pEAA307
.Hypersecretory
S78G
Flk2−Sca-1+Lineage−c-kit+CD48−
0.4555
ABC-HRP
D121G
.Autopsy
38.
phenomenon.41,42
425K
alpha-CDK4
CTGTGCCTCTGTGTGCTGAGA
underassessment
analysis19,20
KIT177.Approaches
hyperplasia10
doi:10.1038/sj.onc.1208358
cotreatment
1aAspAspAl
spiekermann
105•6
32/43
nmol/L
activatedby
elsewhere.2-4
expressiona
-8
Lam
M13-Kin3F
trisphosphate
Aggrescan
TpC/GpA
2.Correlation
.HC11
K5.GLp65/tataPIK3CA
HS695T
.Astrocytomas
K550N
anemia.45
63,68,70,71
3p14
CHR-A1
99.98
1/16/05
0.82^
tumorMRTKmalignant
31-40
3956–68
A3G
/°C
FoxO1/FoxO3a
pocket.59
computerised
FCγ
anti-mdm2
showing~
theWT
seven-base
.CARM1
42·2
anti-aurora1
aCEP-701
NF1-GAP
E124
13F/13R
H-ra.v
α2-helix
36°C
protein34
c.468_471delAAAG
VIB
GTATATATTGTATGAGT
erythroid-related
mRNA-Seq
Lyn,18
p.R404X
PTK1
ALCL1
EGFR18R3
l•uA
polyploid/polysomic
bou
HSPC300
G202V
.6,13–17
5082
1205Lu
1104-1478
phospho-ERBB2
IGF2-mediated
K120A-expressing
.CDK2
inter-ommatidial
.Enforced
well-demarcated
7621
R173Q
pE3-K
DN-MKK4-transfected
previously.40
gamma-related
progenitor-associated
Pheochromocytoma-associated
Loeb
KITΔ559
N-Glycosylation
N-ra.v
PC13
Hematoxylin-
V187M
V275F
Bonnardel
4.029
0/4
Zimmermann,1,2
AML-non-TSC
F59
30–38
Y842S
SOS1.9
a-8
8.5–27.6
preinjection
substrateindependent
79/114
3′-untranslated
P289L
pOTB-CHK2
MP2216
microcephaly26
3.0–5.5
cilial
alsofound
FGFR3-IIIc
gilotrif
Transplantable…
110–141
000/μl
ROS1-dependent
transductant
Cahilly-Snyder
A_52_P377750
vivo3
shRNAmirs
DNAquality
63.3
LinesLOUCY
members.10
enhancers12-14
.Mostly
R92G
High-resolution
n=64
FGFR5
UoC-M1,10
protein.11
treatment-refractory
p=8×10−8
1020–1169
ninety-five
suppressor-1
.Sox17GFP/GFP
5′-TGTTTTGGGTGCATTACATTTC-3′
spine.22,27
B\
Q2148K
αPDGFR
primer-initiated
the—table
Konopleva
-thymidine/ml
dcr
3381
n=166
0·82
A_52_P70255
glycerine
TLGQQPYPGLSNIEVL
111.6
Ack1
.HES6
NSCLC.18–22
GAG
CDK12-2
RPTPρ
Pitini
TUHR10TKB
S6B–C
expression.76
low-immunogenic
HCLc2,4–6
p.Recently
GTCCATAAATTGCAGACTTTGATTAAGG
damage8,9
330del16
Proangiogenic-Factor
I-BFM
detected.10
SA2
Y327D
radiation-survived
//rulai.cshl.edu/tools/ese/
Ago2-specific
145
N1-ICT2484A
BACH1-specific
Ocular
XPO1-cargo
10-16
VG2
Y-box
.Platelet-derived
GFP-INI1
Lidereau
78–81
Hi-Trap
L397F
Rylski
P29S-expressing
nucleoplasm-localized
IEG
miR-29a
1–275
1.3ng
Genecluster
double-staining
-PARP
1.74*genotype
8.1
6×His-tag
c-ski
and55
tggtgactgggaatcttggaatccagt
domains.20,21
F537H538
monodisperse
R117G
IEV
31/64
PCSK2
m12
Budde
.1859C4T
MAGI3-Akt3
SPOPisa
Figs.7B7B
described43
p110α/β/γ/δ
N822K†
2482–2492
leverdomain
unknown.33
TKO/E17K
19,29
locus-control
p.V126D
164-
Pro772_His773insThrProHis
pT288
1M14
RB-family
3063
changing.1
Primm
8g
quadruplicate
1—entrectinib
avidin-biotin-alkaline
HN30-shp53
ER-bound
homology
coIP
FGF2-treated
69-mer
2.5–5
E1-F
.Diarrhea
66and
R233Q
27ºC
containing10
TGCCAAGCTG
figures/10
Stivala1,2
3ZOS
EOL
Staphylococcal
J004
I–VI
TEL114
.Basophilia
RTFISLAKVIQNIAN
comparisonwith
siControl
.GATA4
104-Rco
home.jsp
RYBP
17-681
manner10
-Δ8aa
R818
inactivation10
Ser226
pSVARo
E98-1711
-04
fusions49
Thr-201
childhood.1
D186G
4.5-Mb
ctc
173/203
13,731:1
inhibitior
p21and
Thr4511Ile
16,35–38
62005
p.P417R
KrasLSL–G12D
al5
354E
1950-bp
shTGF-βR2
5/428
C350T
R.M.V.
C676T3Arg226Stop
-GCATAGTCACCGTCTCTCCTT-3
superbinder
rnin
kinky
DI/CDK4
.Hearts
checkpoint-defective
c.4339C
higher-ordered
LS-I80
Men1Δ/Δ1
~10/106
Oncogenicity
P0010
wt/mut
ANI
Y628T-for
4.72-11.86
Molecular-
.Torin1
Jonckheere–Terpstra
spi1.tel-jak2a
mutations.20
column-volume
BTB/Kelch
polyribosome
PTHLH
E-TABM-792
contexts21
JAK1-mutant-expressing
anti-HLA
neurosphere
transplantation
Eisai
beta-strand
4JSP
sonogram
4—
1.015
cellsexpress
2–4-fold
Mxi-deficient
antibody-dependent
Flag–Akt2
spectrometer.37
chemotherapy.To
R264
MLH1-PMS2-CTD
Jebar
Figs.44
GNNK/GNNK+
c.1519C
10µM
.NRAS/HRAS
EBV-induced
experiments.Fig
ews/wt1
r.p.a
20,19
5′-GAGAGAAAAAAUCAACAGC-3′
c-MET—are
Disruptive
overabundance
Fok1-induced
GSK3β
buVer
Teh1,2,11
polyethylenimine/μg
trr-related
Dual-glo
sh-RBM-infected
4q26
differently14
Fontalba
−4.0
Skłodowska
30/52
.Calpain
001015221
standardprocedures
Erlangen
1979
79/259
Asp892
CTCTTTGGGATGGTCCTTTC
P741S
milk-TBST
F1592S
NS/CFCS-causing
v-Ha-RaslRapIB
44–47
Co-Transfection
EasyMag®
h/12
DGFDLDL
19.6/22.9
spectrometers
T1-like
COL4
amplifications.32
mitochondria-mediated
28–30
transcapsular
mMTris
cmv-βgal
±4.68
erating
spleen/liver
Ger
32Dp210BCR-ABL
tumours.64,65
higher-risk
polymorphism-based
BigDye
nucleotides.1These
multifunctionality
28–63
4421
p16Ink4a/ARF
.Orange
P.V851Af
phosphoERK
disease.Response
ukb.uni-bonn.de
0.267
alleles,18
KRR
200°C
1·8
differentiation18
BsaI-BglII
3.PIK3CA
GCT.ATC
G1123S
Ventrolateral
co-structure
highperformance
1.29–3.74
IRE
2687T
fork-head
nSH2-containing
.Blood
p.R172S
14-16
Magnusdottir
~310
mice48
Δ/+
disk-like
p.L325F
*15:01
RP11-189H16
A141S
32.2/12.2
Pkikan083
p53protein
well-distributed
U87MGAEGFR
CARDIS
samples18
cerebellum,50
5611
GNA11/GNAQ
inhibitors7,8
KG8
Schmidt-Arras
N7
luminal/enhancer
2C⇓
anti-Phospho-Tyrosine
Petrocca
Ninety-seven
non–IL-10–
2O72
Arino
RTK-III–cytokine
-K-R-K-H-K-K-D-I-S-Q-N-K-R-A-V-R-R
functions33
studies.10-16
ASRRfGTMSSMSGADDTVYMEYHSSRSKApSKHVHPL
Rott
HLA-DQA1
ROS-driven
E45E
SUN2
His650
inlysis
311*
KIF5B
3xFlag
T1324N
5067-1504
6-thioguanine
delE109
FLAG-NLS
pseudo-transcript
Biovia
Negrini
hyperchromasia
.Major
nihms820730f6
Horejsi
350kb
R375H
-2,5-diphenyl-2H-tetrazolium
amplification103
x/n
'no
normally-responsive
refractoriness
GCGACAGCTGGAATACGAGGAGCAAG
BCR-ABL–negative
Briata
Y791
values5
281/356
anti-Mcl1
phenotype71
pBacPak-His3
eosinophilia-associated
prenatal/neonatal
52/54
120.1
.RAF–RBD–biotin
ENST00000261799
religating
Ala57
CATATCCCCATGGCAAACTCTTGC
ret/ptc
50Mb
nMIgG
In_Frame_Ins
RRQAEAMP
cells/granule
anti-CD34
221–225
P780_Y781insGSP
exprossion
2.2218
solitarius
21q
RAS-3T3
hairpin-expressing
1609.9
OOO-fold
PDE6G
9345G→A
Lin,1
1/0/2/1/0
.Genetically
c.4075_4076delGT
.APO/TA
//
mono-phosphorylated
Dox-resistant
Eeles
98109
0.56
mid-line
antibody-stained
Bcl1
0.358‡
561-Val
pyridine
4.77
WSCD2
.Anti-phospho-p44/42
EWS-FLI-1V5
19,27–32
F2-R2
ml/g
hydrolysis.53,54
mutations,37
FL—were
−0.1257
protein-RNA
.520C
αT172
–0.8
Gynandroblastoma
5′-TCGGTTGGAGATATCAGAGTGCAG-3′
TPAinduced
null293R
epithelial-derivatives
PF-04691502
334L22
1533
H15
FGFR1•E3810
RP5-1129E22
uorine
GaO2
CAGCGGATGATGAAGGTGTT
proteoglycans
fusions33
time.34
RAD23A
counterselective
179K
CRG
lymphomas.27
E746V-L747P
3a–h
.Example
NCr-Balb
apoptosis30
Ser345
topographically
E-box1
.Probe
Foa
−k2
Erythroid/megakaryocytic
mono-therapies
MR-GEF
Bellomo
68·7–94·0
targets•
ACVR1/ALK2
PATGS
.26–28
anti–phospho-PDGFRB
PtdIns-3,4,5-P3
Mll–myc-derived
prognosis.Several
NRASG12V/Mll-AF9
TL/CCSP-rtTA
hanging-drop
tumorigenesis.22
cuts.
NDUFC2-amplified
Interrogation
Hospitalet
1.5-13.0
domeless
cases14
FIN-33521
Y-
Houlston
Kohnoe
Assays—Reporter
fork-associated
LR/
S451F-expressing
leukemia/lung
ESCC/OSCC
TSSK6
2.319
S694S
well.Particularly
V5-CRAFS428C/D486N
prognosis65
5-CTTACCTCTTCTCATGTCTG
.noteworthy
pMMP34
Barbera
AA3
becausethey
SDC4
40-transformed
pEntr.1A
Y122C
Plate-shaped
therapy.1
AKT1/mTOR
PI3K6
FigureFull
Glu95
late-stage
heteroligomerize
6-TG-resistant
.patients
Fig.4E4E
MLH1/MSH2/MSH6/
300-500
09
.Recog-
di-methyl
REL
S2.bThe
producedno
D631Y
disintegration
AS3
7829delGA
1.497
.Perinatal
D/cdk4
Dup
D15S146
Glu632del
hydophobicity
'1st
Msh6-deficient
degradation.70
poly-ubiquitylation
doi:10.1172/JCI86120DS1
3/4-site
NRF2-regulated
PBMC
Forebrain-specific
TIM-R
disease42,43
regions.32,39
IKBKE-driven
Sorafenib.D
0.94*
lin-41
sets.28
cobound
blue=SC
3655
HOXHB9
602081
c-MET–dependent
CK
aneuploidization
MynTMPyp
androgeninsensitivePC-3
N1102Y
P417
AR-DBD
WBP2115
Hyper-CVAD
.Allele
SYSUCC
R-CyclOBEA
RAF1-ERK
6INK4
Keap1–Neh2
D788N
myelofibrosis.37
10.1158/0008-5472.CAN-15-2201
R10P
single-chain
330L22
PDGFR~
60C
605724
wingless/wnt
challenges7,8,9
Encyclopedia1
−1.53
1843–1862
jejunum
GCAGAGGCCTGAGTAATTATCAGAA
16p.D479Gfs*2w
OD600was
radiation-therapies
tumours146
Fairooz
Kdn
Raamsdonk
.Modelling
.Cryptic
hypodiploid
Failsafe
R427A
¢cation
DNA-mediated
GST-HCF
TMPRSS2-ETV1
_TERT_
2,548
N0
anti-JNK-1
VP16.86
deparaffinisation
applicablee
p.A1789
NScHL
.the
q24.3
tumours136
Fbw7-driven
8.3.1
.Benefits
p53-R273H-transfected
56787298
16.179.6
Culture/Monoclonal
DSGPhiXS
Arg611
0.064-2.262
Kdapp
MMP-9/VEGF/Tsp1
1.48
1.123–2.072
321–327
4′6-diamidino-2-phenylindole
Gly595–Val599
Azithromycin
≥1.4
2209
miRNA-rescue
.PARP1
DNA/g
+1+2/-1–2
GGEQKLISEEDL
158-bp
hemimegalencephaly
receptor–associated
0.0121
PSM2
STAG2-deleted
28102
Anueploidy
G334W
2.11.0
Provean‡
sh53BP1
andRaf
Castresana
on/
.R2
S207X
Apcuniv
p53-deletion
.J
.S5C
D5F3
Dnmt3a2-3a2
3-globin
frequencies.MAP2K1
A-agarose
Brca-deficient
amino-truncated
ARF–p53
units/µg
Q454P
12•5
tumors.30
Project.23
GGACAGGAGTCACATCTGCTAGG
N-octylglucoside
Atwal
.RLGS
C204R
mimickers.3,4
18,25
q21.2
HPV-52
A59
.Therapy
R362
Maxiprep
G375S
hypo-phosphorylated
g/dL
c.G1711A
JII
re-mapped
categorization
Myc-Tet2-expressing
PPK
8c
57-2
TpCmutations
Vaara
0.5219
al.,17
Y1234/35
pSer-MH2
PP2R1B
blue-green
N-terminusof
50µl
Ice-cold
resistance,12,14
GSTp53
5V-gtgatggttgggaggctgtg-3V
NU/J
Translocation
Auto-SCT/
mutated—GP2D
GTPases10
SMT
ab8580
829–848
activation.2
24,117
theone
addressed.19,20
8q2
A140P
assays.NOTCH1
switched-off
.MSS
Glu1002
whole-blood
.Single-bp
A763_Y764insFQEA
M-157
TBC1D7
Coffalyser
17Asp820Gly
.Fast-1
ABCFR
wetried
glucagon-like
golgin
emphysema-like
RPLI
NCT01878617
gliosarcoma
TβRI/II
P491
.1846
LIM2099
cDNA−6.3ABCC2ATP-binding
2.8-6.9
Transcriptionally
Ka=0
anti-Gr-1
23/60
evince
dbSNP16
Bagrintseva
Xenopusdevelopment
5′-GAGGTTGTTCGTGGCTCCATC-3′
β−MHC-Q510E-Shp2
5❚
cells.23,35
3801
leukemia–RARα
^GCT
T‐domain‐binding
Rosty
DRG
G465A
Sakatsume
alkaline-agarose
3766
23*
smut
Murshudov
FBW7-loss
+T3/ABN6
.CBA104
c.1298C4T
DMOG
ampliﬁed
K3FE
.26,27
miR-mediated
.Songet
ATRX-negative
total-ERK1/2
5′-CAAAAACGAATCCCGTATCCGACG-3′
85-3
CCND2promoter.90
14,31,32
D1+
SnoI
HSPCs
Magerl
5′-CCTGCTCCTCAGCTCCCGGT-3′
phosphatidylinositol-
polyoma,4
1553
NPM1
.graphic
PC146
Flag-
0.5-0.7
200852
sc-166165
24-well-plates
FANCD2-L
TNE-CHAPS
twenty-micrometre
MDA-MB-157
SSA
//www.cbs.dtu.dk/services/NetSurfP/
phospho-mitogen–activated
clinicopathologic
red-free
metazoa18
2-/
subconjunctival
.Whole
anti-Thy
site.20,21
control-scrambled
low-flow
Ala132
0,67
Bromann
//creativecommons.org/licenses/by/4.0/
freeze/thawing
1114–1137
crystallizable
ELF3*
Lineage-positive
Deubiquitination
P1dlns
G-573
0,2
fusion13
-receptors
B-Rafwt-expressing
CI=0.89–1.83
Plus–minus
P44A
co-SMAD
SKW
QMAA
noted35
5'-primer
Raf/Mek/Erk
.Condel
Halilovic
Myomegalin/PDE4DIP
p.Arg711*
GCGACAGAGCGAGATTCTG
CS.14
:1761-1769
pcbi.1003545.e006.jpg
pNKYlOO
regionspanning
TTTATAATCTAGCATTGCC
bhf
L1553P
Donehower
genesis60
Tween-80
GST-Raf-RBD
postactivation
S4b
HSC230xEUFA173
PTEFb
.Hypermutated
2p16.3-22.1
PBS/glycerol
NCI-H23
.Microscopy
withimatinib
alterations—validated
Kreatech
risk-adapted
nonsaturating
kPatients
DDK-
diag-nosed
GAL4-TFAP2A
Biosource/Invitrogen
3136
non-FANCC-complemented
Akhoondi
26.5
MKB1
serum-reduced
8330
1878–1883
assay11
Rheb-GDP
CD8n
non-translocating
miRNeasy
•ValAr9Pho
CKIε
nanomolars
IgH.2
nature.comSWI/SNF
pan-HER
pReceiver-M02CT
sc951
analysis.1
Kulozik
clustering41
G+A-rich
AB821309
.S9B
depth-of-coverage
mCtBP1
520a
pCI-ML22
.Base
early-onset
formation17
STAT5B_01
3921
1643
internalization-dependent
EndoMT
S477R
HTB-22
Flp-recombinase-mediated
-Y785
5′-CTACGGGCAGCAGAATGTAAAATGGGGTAAA-3′
subvariant
WW23∶Smad2
I826L
anti-CD11c
GGAAACTCTGCAGCCGCCCAGTTGGGC
PIK3R2
1×10–5
-._.Cellular
Immunoprecipitants
I387T
Rattner
PDGFR-b
paclitaxel
amniocentesis
METM1268T
7.94168875
236.vi.10
deleted/mutated
06.00
​Previous
surgery.4
11723
G1456E
5Fig
SIL-TAL1
pmRad50
TGF-b-unresponsive
kinase.The
bacteria26
EnVisionTM+
pLVX-Tet-On
sub-group18
Anti-PLCγ
.potentially
ALMs.5
GED*
lac-proAB
B-Raf–expressing
trp1–Δ63
nm23.11
//www.oncomine.org/
L112R
Lys-Ala-Arg-Asp
immunogenicity
R434C
6p12/centromere
A→G/T→C
.RK3E-RAS
development.16,30
leukemia—and
ERCC1-defective
.KO–neo
RAF1
low-active
BCR/ABL
N3042
Phe476
therapy2
GTTTTCCAGAGTGAA
♯
neuronal-like
Ubc13
39.8-69.0
.Pelleted
syn-
6497
NE-PER®
niche-dependent
p.Gly13Glu
mHGA37
Científicas
61-6
one-eighth
.PDGF-B
role51,61
pSTAT5B
-transplanted
biphasic-binding
XhoI/
and5B
p53response-elements
lipoblasts/adipocytes
Zufferey
NCT02544633
5–25
ERBB2-induced
RTKIIIs
bivariate
.CK
EfficacyClinical
decorate
Seventy-six
.5⇓⇓⇓⇓⇓⇓-12
heterodimer,21
immune-complex
progression131
-growth
10/35
55,125
MeDIP-chip
0.9–2.2
298–311
anti-pY1062
differentiation-committed
KAT18
18531601–18637000
12744799
.39,62
Maltsev
b′
G-174T
R3b
Gefitinib-Sensitive
LNA
.Proteolytic
family10
.Fidler
withNheI
anti-oncogene
corepressor
mmp945
575/1387
N247S
9372
Iressa/ZD1839
cacttccctgaaaatccaaaagtgtttcttgctgt
peroxisome-proliferator-activated
c.130delC
-Wnt
Ala-Gly-Ile-Ser
pSP64T-derived
.Golemis
.LKB1
anti-diagonal
GGAGCGCACCATCTTCTTCA
malignancy46
.PTEN-F21A
c.34G→A
62-/9
Perna
HETERODIMERIZATION
10-6
IVS21-8C→T
33/51.6
Transformation—We
Castagnino
Schwitalle
L.T
4-Chlorophenylthio
I68N
3+mesna
KIAA1549-BRAF
KKSVMCEFLKM
splicing-sensitive
–cMET
-0.503
bloodjournal
G381fs-ter570
.Sober
Nrf2…
R156H/Q
AF027964
NF1–333
3.1.2.
TPO-R
ALK-kinase
PROPKA
p-JAK3
Fluorescein
Y100H
uously
.4d
accumulation.Aside
allele-group-specific
97-bp
CATTGTTGGCTACGAGATATGG
analysis.Luciferase
Gulbis
One-tailed
Fig4a
295-320
.Associations
EGFR-L858R-HA
Cds1p
⇓
ddTTP
A687S
c.734+2T
95.5
YAVV-SEEPI
L858R-EGFR
complementation
Nourse
enhancer–promoter
p.total
57,540
-soaked
Nonhomologous
Cytokine-receptor
BRAFL505H/V600E
354495764
Figure1G
IL-12p40
kinases20
tumorderivedp53
PI3-kinase/AKT
reprolysin
NRAS-attenuated
Coolpix
rh-IL
PPH2
869
non–N550K
normalisation
AnalysisSingle…
mutations.At
NSLCL
.Hodi
PathSeq
57.0
Anti-Myc
RFS-mycWT
22-86
91-541
DnaseI
.Entry
S100d
co-precipitated
1:6400
C420R/nic
approximating
.9002G
F9-differentiated
susceptibilitygenes
significance/neutral
82-2-590-1188
RDW
speckle-type
ABT-806
HSA
1,394
3/10/94
leukoerythroblastosis
2,154
-catggagttggaaggagttcaa-3
NEDD4-2
RSK-Mediated
RHD.25,26
Fgf8
Doxycycline
496K
lymphomas21
tumorigenesis4
347/50
Interleukin-3-Independent
6Figure
CTLA4-specific
AAAGGTC
/NOTCH1
4836/3-05
G5′
25-100
Schrock
Non-shaded
melanomas114
lane/sample
–50.8
PC9
CAL-33
risk-TCF7L2-SNPs
oligosaccharide-binding
~A12
5−384
NSD2-shRNAs
•l
DCC
Hspb1
al.32
C-609
Zaubermann
hyper-response
pRC/EGFR
K343E
Non-homologous
I–T
H3T6ph
PS100034
Complementarity
10.1007/s00280-012-1876-0
EPHMEFMNE
sideroblasts.39
talactoferrin
Q644H
Cul-3-cyclin
adenine-thymine
Gangnam-gu
18-67
p=0.567
AbCam
5′-GCTAGGCGAGGAGCTCCAGT-3′.19
c.11C
0.5955
EGFR/erbB2-targeted
S5A–S5B
.Restoring
1.03473
660–2,000
F27
Co6
.Means
AKT/protein
G164S
.Reversibility
ID1
p140
hl-
Figure8D
uPAR-R:5′GTTTCTTCATTCGGTGGAAAGCTCTGA3′
Mervi
Hypermutations
H87
tetO-Cre
H1247
Hyperkeratinisation
progression21
c.1918C
p.Arg215
.Dick
CMML-initiating
0/53
150-155
NCAM1
RNazol-B
non-carcinomatous
rs1799949
N-Cor
FHRE-Luc
pIpC-treated
gefi-
Horwich
Ras-derived
Subcutaneous-xenograft
lociMSI
**P50.018
CVI
trk-2h
Audeh
Complementing
40-mers
BRCA1–BCLAF1–SF3B1
TAD-binding
Frantsve
groups.3
W.F
48/53
Daxx
Msh6GS/-
35-amino-acid-long
4/100
Asn491
nonglobular
rare-cutting
.Gender/age
pLp53-Y220S
AMKL.49
.Copynumber
delE746_A750
Eighty-two
S1PY-bound
.Conflicting
.ST
5′-GTGTTTGTCTCCTCTTCATTGTCGT-3′
tTA
MYC-deregulated
caught-up
=0.30
H1106
IGHV-mutated
p.VLEYC1576del
.Underscoring
.HCC1937
-epitope
Mounawar
~5-fold
TOMM34
zebrafish-derived
SIAH1
agar-containing
3BUC
backbone.18
Hienonen
mutationsGenomic
formed13
p.N132K
p.Tyr218Cys
Demethylating
13058
/LOVD
0.861
genomicintegrity
PARPi-
5′-TTACGTCTGGCGTCGAAGGCCGGG-3′
100/50
α-LEF1
2oo
stage,5
TÃŸ/
11-12
Erk-1
read-pair
Muhua
MPLW515L/K
gliomas15
24-mer
//www.genome.ucsc.edu/cgi-bin/hgBlat
catalytic-regulatory
V1238
C/EBP-induced
H3F3A.G34R.V
S-2-hydroxyglutarate
.Chernov
Y234D
and\12
activity71
61.3–107.7×
COLO201/COLO205
–9.43
patient—LAD
parameters.Relationship
abnomalities
SpectrumOrange-SpectrumGreen
440CF
UAS-Dpy-30L1-RNAi
-mp1
PET-2-negative
HiPerFect
relapsefree
5'CCAGCATGCATCCAGACTGGCTTCTACTAACTCCTTTACC3
131,132
TFA
A2228
TGGGTGGGCAC
CD20+
23.2
cell‑type
nano-liquid
AZ628-treated
FGFR2b
4-binding
EFM-19
pCDL81
Karyotypic/cytogenetic
msh2-PD865p
TGCCTCCTCCCAACTCAT
A-rings
5′-GAGCATGGCTCCTACAGGTACAC-3′
G1143D
operator-containing
identified—R47Q
depletion
UV-photoproducts
1000
non-cooperative
large.jpg
.Graphpad
≥342
0.18–0.59
HPVinfection
CSR1
274G
Facon
1/38
3,3-diaminobenzidine
Perucca,1
Snf5fl/+
VCL-ALK
19.0
InfiniumHumanMethylation450
TnJO
.XXLb
2S
pH6
E251G
8.88
PG13MSCVTLS-ERG
~300-bp
.9–4.1
//www.stanford.edu/rnusse/wntwindow.html
Gubbay
Omniscript
cell­
rinse
anti-Sca-1-APC
5′-ATGAGAGGCCCTGCGGCCCA-3′
Slc5a3
23,000
Dirven
switching-on
Ld-restricted
2386
Lmo1/Lmo2
tyr701
Sera
sonidegib83
G418/litre
TEETTHVVMKTDAEFVCERTLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDV
96˚C
cytospun
gatk
2.988529e-14
CXCL12/CXCR4.16
AktCDK2FoxOCancerPhosphorylationUbiquitylation
RUNX1-I42F/RUNX1-I42R
TLR2-unmutated
1/ABCG2
lysine-free
.FGFRs
PLA1A
3′SPARC/5q33
SGO1
0.99–10.56
PPD-protein-containing
Meox1
Olig2-expressing
.April
1970A→G
non-speciWc
1R0P
c.302_del
.EGFR-Akp
Y1021
22-Mbp
ATACTGAGAGCAATGCAACGT
Pin-1
Cre1
Tomecki
NTptide-11
activin-induced
5/217
colloquial
Micci
.Otterson
prebleaching
344SQ
8.876
957G
RG-13T
trkl4
p21-GDP
IeVaILeuLysTrpGluLuGI
pericyte
phospho-SMAD1/5
Yap-dependent
levels.87–92
RHG
Cys3His
W502S
BrdU-PI
+IR
non-skewing
R94G
Mullenders
Bromo-domains
protocols.22
V658
GISTs13,14
causalitya
Ndr1
pCMV5-βGal
4213
Inpp5e
EVI130
type–specific
salicyclic
GSK-3β/GSK-3α
DeltaNLS
acctggtgctgatctttctgat
GCT-derived
ug/ml
SIFTc
ALKF1174L-bearing
cSNPs
11−15
heptamerized
.Anti-p70
E297K
NADP
176948
0–0.03
G306E
cSki
32D
PLAUR31
Smith-Water-
G16720
HPV-33
mesotheliomas12-14
KMS-5
respectively.1
deletionmutation
3,7,11
W77R
1–23fsX17
chemotherapy-
UAP2
930_934
.TGX-221
LACZ
Thr14
Ala349
cyclin-D2
CCCAGCAGGTTGATGATGTTTTTG
short-interference
J007
protein–extracellular
.350T
structures.36
600049
Haire1
57–86
HD-0375
59-CTGGCCCCTGTCATCTTCT-39
Y394C
CC242-243TT
lymphoma=2
GFP−
mShp2WT
genomics-driven
RetroScript
517T/C
EGFR-wild
D1-KE
OSC2
APOPTOSIS
anti-snRNP
site-containing
expression6
n=157
IDH2-R172K
R333
.Tomlins
Struewing
1.58plusminus0.3
intratracheal
c.59C
PIK3CA/KRAS
puncture.RNA
VCN
115–217
HL.43
cc-12-2656-g3
5A–H
rhsCD40L
activatingsequence
c.3827G
1044
conjuction
disease•
53–75
prostate,4
6.Download
size1
non-cortical
unit/mL
analysis6
mutations—in
C5/Arg-24
lendssupport
NCT01406119
environment22
MDDtreatedtumor−bearinganimals
GGACCCGGAAGAAGCGCCATCTCC
R280P
thegenomic
adhesions.33,34
5′-CAGTATAATAACTGGCCTCCGAGCGTGGACGGATGGGAAAAAC-3′
OF4
3/294
reported2,8
FBW7−/−
Sud
RARA-BCOR
.Half-life
F1449V
Lys-435
ARG12
B1-associated
VCRome
v_6.0c.ERBB2-TagRFP
-DR106
.Erk1/Erk2
Thirty-six
pHPT
CRPCs
D35
I745
trypsin-Giemsa
Isoproterenol
MYC-box
P.V843Ib
5'-TCACCTGGATCCTGTGTCTT-3'/5'-CAGGCTAACCTAACCTACCA-3
24304
pathogen-receptor
HA-Shp2K590R
HSC/FANCC
Tet2+/−
GMR
TGFb-RIIgene
Linnemann
OVCA420
AGCTG-39
46/61
ERÃŸprotein
D96N
14-3-3-mediated
Wester12
Moelle
OCI-Ly2
S.H.R
P475S
3131
6.
versa13
Kimmelman
6–19
delP449-L445
HNF4α+
‐like
p170
centromere-bounded
elotinib
.BOK
IIIa–processed
Huygens
AACTTT
pan-HLA-I
BRCA1-expressing
~600,000
CEBPE
AGGTCTCCTG
pGT3/5
whichcauses
3.4K
.128
ACP1
elementsother
77.90
DA7A8
anti-PUMAα
tumors.This
methodology.80
0.25M
Souchelnytskyi
0/44
C245Y
p.Y179C
HepG2
Val769_Asp770insAlaSerVal
+6
nonmutants
Rnor_5.0
3/29
75-μm
FIP1L1-PDGFRA-D842V
anti-mouse-HRP
Antibody-induced
Crystallization
forty-five
cells/dish4
ULBP-1/2/3
Boissel
b–f
85.
semiperpendicular
v2
15-29
D-E
Thr138
P=0.0025
PFDN3
.LNCaP
Zenatti
IRAK4
caspase-2
Zender
RasCentral.org
2p13–p21
STAT1/3
Figure11D
851C
IMGT/V-QUEST
186-bp
IV:12
hours.Plasmid
91.89
bucc
cells.2–4
cell-line
44.9o
TTTACTCATGGAGGGGAAGC
NESmut
proteins.10
ETS1/PAX5
1/33
GDC0879
nonpromoter
215–277
Q127
MBC
2000-3000
8–9
GP2
13.33
proliferation–related
p115‐RhoGEF
P246CfsX3
p110α-Glu453
.Sprague
p.H87Dfs
Metformin
individualisation
20946201–21007800
309–310
−5
focipositive
Hik
Stewart1
groups.47
NM_002755
CCACAGAAGCAACACACAG
EMT165
p.T1623I
HPV-51
A610T
Kozak50
NM_004119.2
JAK3
.Control
/RAS/RAF
SF1-mediated
TFAC
diethylaminoethyl
ade2-1
.Glyceraldehyde-3-phosphate
MutH,5
56-year-old
Quips-XL
contexts111
SCID.adh
ivs11
mediatestrans-activating
M-20
.ITT
E2419
LDS1A
524
pBaBe-puro
PatientsVariable
isoform-dependent
features.45
uSerAr9CysAr9GluMet
reports6
.Biotin-labelled
templated
serum-supplemented
rapid-freeze/sarkosyl
trials2
477–480
transfer.A
SRCAP
anticdk6
GGGCCT
p27fs177-Clone
464,000
PTEN-driven
particle-tracking
.Yet
CML.13
GFP-transfected
ligases.27
Gubler
IGF-BP3
c.689T
RPN
A30P
p=1.44E-12
U955
factor‐α
p-arm
AflII/HindIII-blunted
A156T
imunoblotting
K484
non-applicable
pSV2erbB2
intermediate=32
G.L
Androgen-Responsive
H1299/p53-null
PCL
μCi/ml
Kobilka
anti-PARP-1
ERK
mg33258.f5
65-fold
WT-E2
0.2141
Xinqiao
ofSOX9-pcDNA3
ACCCATCTCCTAACGGCTTT
.FANCD2
7.77
S820F
Ser1026
SW613
.I996
E005
null654G
develops.5,6
RNF11-BRAF
Westermarck
P17948
FAK-related
function.92
Int-3
Coatbridge
Tet-O7
193H12
c.735-
PIK3CA-activated
CRD
.Kapoor
/89.5
way.The
PI3Kαis
fast-proliferating
Figure6D
aa2-56
presyncope
TGTTGGTTTCGGTGAGCAG
KIF1B13
604281
ABCB1
6/22
K120A-2
.Jang
occulta
Furuyama
R.12
94.67
.CFU-GM
catabolic
Truant
W2547
Ras-GTP/GDP
CTBP1
colums
Del–19
893–899
.ERCC1–XPF
.Immunoprecipitateswere
5′-GGCCAGGATGGCTGAGATCA-3′
RAD51L3
eGln
non-GRD
5′-GGGATTCCCAGCACGCT-3′
149/251
anti–phospho-STAT3
SD=±2.5
IVS1−2A→G
characterized.19
Chiayi
ST-HSCs35
weak/moderate
A95E
Construction—pCMV5
3–
I251V
b–
NnSS
NS.40
H229
re-classified
MLH1e9.2
tubulin
Giangaspero
gpll0Protofrk
MycW-PDGFRA
SP6-2
K382ac
H1963
BlueSky
25-40
instability/cancer
D820G
MAFbx
.Awad
s.e.=0.157
Gln284
MN1
10.7.3.1
interaction212
KLHL25
.KTN3379
Preclear
-0.18
subsequent-line
V413A
-L2026M–
fruitful.It
evolutionary8
Ramasamy
5'-CTTTATTTGGGTCATGTACC-3
STK33-independent
Immobilon-P.
Fasan
25–50mg
Dnmt3a/Dnmt3b
MSCV-Meis1a–YFP
IGF1R/insulin
Gefitinib/Erlotinib
43.17
FRET-hybridization
Mast1
mechanism71
10-
hMSH1that
289–292
CS-like
Sepharose-coupled
7565
neruroblastoma
MPQ
Nup49–GFP
percent.1-4
Hruban
RAP80
5,377
hsmK12
polyacrylamide–sodium
lanthanide
N.J.
NEJMoa1508887
bistability
Jan.
Cosmid
CGCGAG
V311G
Ermis
bilateral.38
sequencing.Figure
BRAF-V600E-mutant
.Wound-Closure
four-and-a-half
gradientat
5′-TGTTTTTGTAGTTTATATGGAAGGGTTAA-3′
2,843
Catecholamine
Ithier
prednisone.2
6223
c.5115A
417–421
1.027–1.960
Smad3−Smad3
μg/kg
Guardavaccaro
chromosome1q21
-Cdc42
LY2801653
phenotype41,42
EIAFno.4
A/Gaa
ATPase-helicase
C417F
.WT-EGFR
0.2628
Del745746
Q6PIB3
E139
.Protein-DNA
Prives,1996
Lys-Glu
Charcot–Leyden
lysates.D
anti-VEGF
HEGM
91.29
P09619
STT
Analysisand
HTlf
Greve
rgrg
pre-column
525
proteinFRETfluorescence
-HNPCC
R59C
motif116–118
Skyview
Laskowski
34–112
binding36
RP11-606C5
CC-30
ZSCAN2
T1-T3
p.Lys618Ala
Trifluoroacetic
.6L–P
NeuroD2
MKK4/p38
Osteocalcin
phosphomannomutase
Her2/Neu38
bleeding.86
MSX2
11q-aUPD
phosphatase–mediated
L766P
CGH
kelch-like
K45Q
stablizing
GCC-3
Sma2-Smad4
oligomerization-competent
Habuchi
Y1349/Y1356
HBV-negative
R.F
/Age
32Dcl3-expressing
proteins,8
p53-U
myc-Akt
TTAAGATGTCAC-CC
SF21
cells.39
polygonalshaped
ABL-induced
GrB2/SHC
27,36
1132
ted.w.johnson
AAGTGAATCTGAGGCATAAC
autophosphorylation.In
wtRhoA-overexpressing
Y720
Foxp4
pN8e-VSV-G
Cla\
49-228-287-5030
−1.75
.Lys-602
//www.R-project.org/
3.247
MMR-provoked
Q172P
IVS5-8
CAA/AAA
Ca-activated
.Paskie-
p=0.40
Mlu1
ZR-75-1
PHF6
postremission
6G2
pEAA298
siRNAs22
3.7–15.8
GenePORTER
aMetSer
Prader-Willi/Angelman
11/5/08
FAKmRNA
FIG/ROS1
lentiviral-mediated
'6
Mut3
HM48
MMP11
FA-53i
spring-embedded
LATS1-Y376A/Y559A
3/590
activation/induction
ends/structures
CDK14
SegSeq
binding/modification
indistinguishablefrom
IVS17-53
MM8
106/10-cm
severalfold
CTLA4
unresolved,31
Q195X
Raf1-RBD
Grigorova
Brca1-mutated
340×108
188_189del
Triggs-Raine
Ly18
18–19-20–21
topromote
desorption/ionization—time-of-flight
H231R
factor-encoding
Unincorporated
7.A.1
Kirkegaard
GSI-552A1
LXL
operators-LacZ
1,186
micro-chambers
melanoma3
29/39
PIK3CA+BRAF
0.003a
homozygously
f4
0.62
metastasis-free
~Zell
.Thick
V250A
transformation.21-24
75/77
DISCUSSIONPhenotypes
43/111
p18/LAMTOR1
metaanalyses
MAB1501
Hs00946894
AURKA
β-grasp
family.6,48
RAC/RHO
LT/LP/YF
.to
AKt
0.027
C33A/GFP-H2B
S315
BZ-8000
PS100
//sift.jcvi.org/
1–19/21
69164000
p.Ile52Leu
2434–2439Goemans
D19S833
lumen-forming
bjoc.1999.1178
5.9-35.6
MKR
50-gene
like-
therapies,10,11
mapping/alignment
seven-locus
Japan.8
bud-derived
Bonfini
dermographism
feature.29
Winooski
HSCs43,44
BIOSOURCE
effectorresidues
ERG-mediated
5′-CGA
0.677
4319413E
pCX4-IRES-Red
Iodoacetamide
R739Q
.Sims
17p31.1
Dose-Response
.Young
P=0.020/0.066
mTnf-Forward
be–are
cis-Elements
Glu198
2.6–5
//www.cellgro.com
0.112
hFANCC
FLT3-ITD–transformed
5°NRAS
pCDNA3-Flag-Chk2
RP11-89H19
read-through
editing.53
cadherin-homology
−1000
function.53
MII
Musti
LTR/LTR
Cdk4/pRb
2,150
pathogen-derived
specificity13
3.6×107±1.8×107
K1690N
12.0-fold
fragmentwas
SUM-159
3822
4.37
previously,4
ftdfilUing
p=0.0015
wereharvested
CARMA1-dependent
structure31
adhe-
parent–child
isothiocyanate
HCT116FBXW7−/−
shFZR1-infected
-TVK
29:835–842
pseudolentivirus
7.52×104
A586V
​Karyotype
2382
beta-gal
used22
ex1-20del
AAL76094
Caravajal
P=0.7
bu
0.710
Hsp90-independent
15-60
FOXA1-specific
30:2008–2014
Régional
K63-linkage-specific
PIAS3
anti-β3-tubulin
Lopez-Pousa
I-Ppo1-expressing
PATJ
N30-N0
BaF3-injected
5′-TCATCCACTTCCGGCAGTTCACAGC-3′
H20P
isoforms.13
p16-73F
restricand
63027
.Zbar
68–70
antiphosphothreonine
CDKN2Awere
overemphasized
mammoplastic
PD6914
5′-TTTCCGTACCCAGCAACGTCTGCAG-3′
MNX1
PTPρ-ΔFNIII
two-cell
26.23
resistance.9,12,13,14
1C12
Y258N
D18S858
protein-serine
Y763C
lgGL
M523
Lys6-
1,780
N334
948C
.Rely
4.24+0.32
rs66719305
Eekelen
AGGACTTGGGGTTTGTGTTG
0.7134
MDA361
Supt4h2
5'-ttc
nanoclustering
X2
diencephlon
pWTPTEN-FLAG
Neurofibrosarcoma
Extra-cerebellar
allele-counting
5D5
interrelationship
2s
N334K
EWS-FLZI
nonpoorly
ZM
NBG17-R1
0.697–1.343
ABI3730xl
Figs.11
5′-AGAATGGTCCTGCACCAGTAA-3′
imbalances/CNL
FGFRTACCpositive
P1087S
CHK2-mediated
α-Fbxw7Arg479
SYNONYMOUS_CODING_tablePanel
conditionally
41-bp
CGH-positive
.0369*
FGFR1•AZD4547
Single-Color
AppNHp
6·25
.Phases
Vivanco
suggestive
59-TACTGGTGGAGTATTTGATAGT
Jemal
KRAS‐mutant
BABCO
5'-TLS/FUS-ERG-3
p-44/p42
Ding1
.Phaeochromocytomas
3M
p.Arg369Gln
1.44
DNAX
5-bromo-2′deoxyuridine
anti-CD7-phycoerythrin
.Bacterially
/Polya
tumours8–10
16-1
RH-SUMO2
phosphorylations
AGL2043
Lymphocyte
946
CATGCAGGCTACCAT
blue/0.05
ofWT1
KMT2A–MLLT3
immune-modulators
0.081-0.790
PKC-ε
A101V
400K
ERK1A206V
Mutationsa
spindle-
ion-exchange
c.1676T
2034insC
82•23
epitope-tagged
KIT/Delta559
lysed/washed
3x2
p202
GAGGCGCCGTAGTACAGGT
568–571
diversification
vector-transfected
palsies.13,14
p16–148
dH2O
bodies/late
transcriptspecific
Ago2−/−
mutation.Classification
p16INK4A-null
VWR
0.67μM
Asp171Asn
10tract
G1049
UUUUU1
CTR
Sox17/Sox18
CIC-CF9
600-1000
S206
function—remains
1.3–8.2
/transgenic
D1099Y
patients19,20,30
univariable
975K
5′-GCCTCGTGTGCATTCTCTG-3′
NCT00556322
S5-S6
13-catenin
black\
G871
hyper-/dysplastic
interrup-
MGH006
58.8
//cancerres.aacrjournals.org
3597
ControlFO-IA
'phosphatase
bpâ
tail.8
pheochromocytoma/
proteostasis
retrovirus-mediated
GCGCGC
Nort
analysisFour
34–50
0.1–0.8
.Anchorage-dependent
data.ImmunoblottingCells
MeCN
30,626
reviewed.43
M200
flexure
tumor12
dark19,20
mperucho
1q21–q22
M1043T
Smad3LC
.Massively
D2S337
30–82
CFU-Mk
ages.28,39
380KB
GCPEKV
800
VCB15
2Myc
approaches—may
0.30plusminus0.08
Zukerberg
p27-109
Skp2-siRNA
GAAAATGAAGCTATTTACCCAGGA
Chk2-p53
H701P
Ser-783
6174delT
2b
.Widespread
51,000
C77A
R132W
0.000483
anti-HAAb
FRA10F
E337
p=0.07
24,662
Hooft
21p.G498S
sequences.To
Hyperglycemia
779
mutants.12–14
IgG
11,16
2310_2311insGGT
V804M/E805K-transformed
P046-B2
inMSSYes
¡vs
2.5.2
whole-brain
Pro672Pro
inmelanoma
Ras/effector
transcription6,11,56
10.2±3.4
PharRed
E11A
protein8,9
AKT1E17K
haploin
865
uArgArgA
JAK2-PCM1
.S1c
2p11∼p13
patient.25
repair/heteroduplex
bax-derived
.Gene-gene
N345K
teal-colored
Thr468Met
137G
slideAssessment
RNA/DNA
RKIP_E2_F
.Rosette
CFS1R
.WHIM9
'cocktails
pathogenesis.30,31
includingcultured
Mut-F
Kaeser
TGC
ADL=2.90
MS4A1
IL7R-dependent
KIF14
clone.10
Row-wise
Pro772_His773insAsn
anterior–posterior
V89/-
S1986Y
NVSPI35
interethnical
H622Q
pT2–4G2
Y1463S
CBFbeta–MYH11
57624
MYC–ERTAM
F328L
hyporexia
bias19
response131
-TCC
2000/μl
promoter–
PDGRB
Alal708Glu
20±9
reactionFig
t-Test
Asxl1/Tet2
F603
insertion–truncation
//research.nhgri
8430-8
Glut4
α-β-β-α
0.0014d
Herstatin
N-acetylated
AFMa086wg9
DEN–PB-administration
D937A
6–30
K757R
PtenWT/WT
Q555
PMBL
ATR-targeting
G.C.Walker
ERBB2T798I
Crystallography
23•
4.26
colo320
year-of-age
Fgf11
Terashima
EGFR-mutant–expressing
andFF
PAX5+
under-represented
.S5a-d
NHBE
Benistant
Tingting
strains.3
patient.Histopathology
usingKITexon
0.30-6.11
S760A
17/485
.PAR
–––423
TRK/METY1235D
guishable
procedure67
Wickenhagen
hpr1Δ
dbSNP33
3822/93
CCAG
21·1
0–65
5'-GGTGACCAAGTTCATGCTGTG-3
Stata™
6Medicina
13,14,28
neuroectoderm-derived
3xAP2-Bluc
0.939
5'-FAM-CCCGCCCTGCTCACACCTCG-TAMRA-3
M1255I
PLX-resistant
In-Silico
69–102
.NCI-H290
14mt
Fgfr2+/S252W
loop-strand
dual-colour
90.4°
.HA
TSHZ1
184352-stimulated
42.6–51.0
pathogen-associated
Abraxas/CCDC98
Tsc2-null
c.8755−1G
C2628G
days28,29
92,304,389
SMUG1
10/exon
One-sided
Mx+Snf5Inv/−
R76C
included27
LMP
c.2975T
Let-7
ankryin
1-282
0.13Table
5.45
6C-F′
calcineurin
77/1035
N6-methyladenosine
AQL
E\
3.5-month
TGF-ÃŸ-resistant
15/group
18149
III-conformer
sib
2.673
PDGF-B/B
interferon-α-inducible
Roychowdhury
Q407R
ISH5687-A
N547S
Colombino
G392E
.Neurofibroma-derived
400-500
Essawi
364.9–657.6
plification
rhoGap
0.99–4.28
hypermethyalted
Elenitoba-Johnson
Raf1
1.7XhAT13
end-stage
3.3–77.2
immunosignals
Exon-13
mutations29
HER2to
F1F0-ATPase
S140
SH3GL2
0.791
17.9±6.6
Single-punch
05-1339
.Ovary
GsqyLLnwcvQIAkGMnYLeDrRLVHRDLAaRNvLVk
meganuclease
.LNCaP-C4-2
E40Ne
p.K509I
p.L1750Afs25
Photomicrographs
burden.8
hormone–receptor
S2/MSH2
β-GT
15.64
lapatinib-bound
NLS
RUNX1-CBFA2T3
hOGG1
Axl
.Occasional
E-cadherins
interleukin-
Genome-Edited
co-occurring—genetic
GRP1-PH
4.5–8.8-fold
31,33,34
OCI/AML3
Src-homology–2
8E-F
Structure-function
Asp108
cancer.4,5
germline-variant
748-1G
0·86
pY568-pY570
Disproportion
Phe-ZIP
mGFP
K160
C490-C507
non-high-risk
N1380S
FLAG-NRASQ61K
67/95
3/18
L89P
Wbp7
toxicity,3
.Irino-TMZ
A802V
2,494
Do-7
INPP4B-null
KSP
no-inhibitor
5.51
p.Lys117Glu
5V-GGTGCGAGGGCGGCAGCCTCTACAAAC-3V
dup501
NOTCH127
about2
HN-Smad4+/+
puromycin-negative
RAD51C-R214C
23.5
78260810-81029941
oral-facial-digital
RNF34
A-4
//www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl
p.Gly44
non-synonomous
IL-10
SO751
phosphorylation-status
4814
Q654E
v0.5
telangiectasia–mutated
breast/colon
.FRB
enhancer-promoter
chemoradiotherapy5
GM00717A
intertumor
9-h
del19
SUP-CR500-2
N1=14
p16-Ala148Thr
anchorage-free
internalization-deficient
co-incident
1TABLE
malleable
NCT01853345
155,000
Nexes
Antibodies—HEK293
anti-Cdk4
β1-β2
PRE-induced
Koh
whole-cell
haemagluttin
phase–arrested
.\D
report9
-V5
R_norvegicus
Cterminal
www.qiagen
.Photometric
c-fgr
D2O
7,8
E739-R841
0.44-fold
Epsin
P281L
chains41
pressure-1.1
miR-20a
pilocytic
NS-1
854^869
LUADs44
5'-GGCTGGATCCTCACAGAGCTGGA-
R302W
F/22
methionine-arginine
2Ca-d
4⇓⇓⇓⇓–9
cranio
microdissection
18q
5′-CATCCGCTGCCTGCAGGCGA-CCACAGTCATTGAGCG-3′
STK11/LKB1+/−
ethylmethane
EWSR1–1024F
miRNA-modulated
Anxiety-related
DSRCT.Expression
Skp1–cullin–F-box
R1563H
GFPexpressing
.Radiometric
NM_009764
8405delA
Runx1-depleted
ccle.In
K-R-pT-I-R-R
reports3,7–9,11,12,15,16
p.Ser177Thr
MTCP1
cycle22
.Disease‐associated
GNB1
Brosh
L16R
.Lean
ELK420,21
.ResultsMutant
UPN461282
leaky.
manifestations—skin
.Virus
13,28
16-capillary
doublet=EN
Youich
13761-3
ÃŸgal
Lys→Lys
Arrays.20
mRNA-specific
RCC4/HA-pVHL
p53NLS
50/F
BRCA2-Rad51
5'-AAGTTGTGTGCAAGGGAAAAGGG-3
5′-Cy5-AGCTGAATGGAAAAAACATTGAAGACGTC-BBQ-3′
NM_000368
.CWR22
IswII
FLA5000
ZNF354C
142.2
αL
Tyr576
shutoff
.DOI
flow-cytometer
MEK1-deficiency
Calwerstr
2005C
Ewingtumor
342–349
F56C
:3447–3458
.STARTRK-1
TGTGCTGGGGACATCGGATTC
clonully
145-kilodalton
non–ALKexpressing
Jak-receptor
Valgeirsdottir
Over-expressed
∼60-fold
tetramerization-deficient
authorThe
prostate−5.3CLMNCalmin
Rbpj-knockdown
AAGCGCAAGA
Pro131
Ltd.
HG-U95Av2
V115
R496H
5'-GGGACCGGCTTAATCCATAG-3
3.3
Bcor
SLVL-associated
MegAlign
H3K4me3To
SHC-mediated
Hematoxylin-counterstained
measurementCells
five-generation
hydrophilic
P=0.646
Musashi-1
p.Pro81Thr
I255F
panAkt
RAD51C-ATXN7
www.ebi.ac.uk/
αP-ERK1
epithe
75.1
QVAE
1802a
pRL-HCV-FL
receptor–beta
IVS13
loss.15
Prodomains
1503
M1004F
glutamic-oxaloacetic
PI3K-AKT-mediated
CtoT
L23F
550,000
CKI-dependent
3.77–41.10
.Anti-rabbit
C224W
methylation92
Coexistent
CCL2
jwhite
P230
CDKN2A-null
Non-DH
4°C
453
15M
Q1317
microcystin-LR
c.3226C
'autoacetylation
CCAGCGAGAAGTT
C-A-A-X
glioblastomas54
cysteine-rich
five-fold
Elf3L142P
analyses77
32.05
0.990
25/168
phsosphorylated
light-adjustable
1072
Sub.
CUL1
5.92
UAS-Rbbp5-RNAi
L.Desbarats
G751R
mice.68
transcriptional/epigenetic
anti-Hemagglutinin
CdIdwwXwzt
L2334V
2O
homo/heterodimers
subtype91
outcome.30,31,34
MYCL1-correlated
AS30
degradation,148
PLC-γ–dependent
1.3/1.3
570
1271-Arg
tLi
..T
pSP65.35
melanoma,30
connec-
re¯ecting
pRcCMV
Densitometric
3.63
32D/Flt3-WT
10L
3Main
Rosenbaum
amyloidogenic
medgen.ugent.be
Bruton
1A2B
p.Arg784His
αSMA
oxidised
K603Q,12
EnVision+kit
R2193C
.Ras-GAP
1020-04
glycinerich
6Ap
-BCR
v3.4.1
diseaserequire
GEX-130
29,33,34
PhePP
Glu-992
.SPI1/IRF4
.R233Q
135/60
+39-11-6706664
obs=
sequencing25
proliferator-activated
CAAAAAGCACAACTGGCAAAC
tumor-supin
Rab-GAP
FGFR1–FGFR4
seventy-seven
PAF1C
1:100.
5/27/08
anti-NuMa
K076
agents101
CS-31
Sau´de
GTGT
hypoactive
Immuno-Enhancer
whichretains
rearrangement-negative
1315ArG
33.98
Q0
entities.26
621_993del
GST-mH2A1
KP
antirepressor
Nakarai
mutant-adenosine
ERK-reactivating
CD49B
eithersingle
FLIP-AS
function.6-12
A173V
Perner
.SMO-D473H
Next-Generation
1718
glutamate-to-alanine
3-d
Y59
families.5
TLS/
RP11-81G24
7.1/tumor
rs1801026
neuroblastomata
D=3
.15.0
0·024
anti-programmed
UVinduced
11-ZF
1800–1849
TCATGCACGGGGAAGCAAAACC
pTSAd-fe_p53
deoxynucleotide-triphosphate
-homoduplex
pVHL213-expressing
2U01
T215K
Wnt4
1,365
fibromas.3
CTG→
B220+
integrin-PI
.Little
cardiofaciocutaneous
5′-TCAGTCCATAAGCCAAGCTCTCA-3′
L387M
6,7-dimethoxy-4-quinazolinyl
KIT-D816V–expressing
D107Y
Hotstart
pGBT9RhoA.V14/S190
Fig.2c
anti-Rac1
colonieswere
10mL
010288
742–
824–831
puritied
micromanipulator
A66V
nep164
245-
transactivations
H1c
5′-ATGTCAGAACCGGCTGGGGATGTCCG-3′
BRAF–PLX4720
PIK3CA-mutational
8p22
-1,6-dihydro-6-oxo-pyridazin-3-yl
85-PT111
transplantaion
59,310
Vorinostat48
antibody7
H1074Y
JH1/
GD/GVb
gene,8
.Castrated
transformation–relevant
60×/1.35
M14710
ENU-treated
MLH16
mutation.4,8,32
andbiochemical
21-days
E329K
development40
software56
.Akt-E40K
NM_004327
RIP140
aminotriazole
77.69
~related
CTTGT
62–64
FVPTC
MEK1DD
9q32-33
mAb609
photomicrographs
apoptosis78
cytosolic-fraction
11.61
RUNX1b
11,12.
1–195
Du145
HDAC1/2
MUM1
Fig.77B
5′-GAAGCCGAGCTT-GTAGAGGACGTA-3′
.Shared
5′-CATACAACCA­CTAAGCTAAAG­AATAATCTGA-3′
KRMC*ODN
IL-2-independent
institutionalreview-board
npr3
future-clinical
non-biased
proMutant
cc-12-2656-g2
K402R
MAPK/JNK
uAlaGlul
ade2A.tpRB16
ubiquitin-proteasomal
WNT/FRIZZLED/LRP6
2C–2E
MGH-PO-1
Willebrand
Ouillette
E2-treated
pLenti6.2/V5-DEST
Inbar
lamide
5-min
SBR1.1
14m
54,792,947–59,307,844
.0015*
2472
p.Leu262Val
membrane4UUUJlU
AGS/N19RhoA
Prof-Hess-Kinderklinik
0.73
Gangloff
intron-containing
α8
.Care
CD34.5,6
Fig6E6E
CACCCACAACACCCATGGAAGCTGAC
543
//www.nf.org/nf1gene/nf1gene
p.G34R
1667
EWSR1/WT1
30-40
18ex
Ser768Ile+Gly719Xaa
SB218078
RNPEPL1
Iaccarino
XbaI–XmaI
c.1514T
UI.-2
bioanalytical
anisotropyNucleoplasmicCytoplasmic
SVZ-C*-like
ProLabel
VHL-wild-type
pRB-mediated
SFB-CDK12
HeLa/ERE-EBV
wu20/wu38
intra-operatively
T26A
oncocytic
~solid
2721
germline-encoded
0/70
Figure10E
chromosome-10-specific
f-cdk6
Bcl2-
msa/clustalw2/
\175-18rec
Lallemand
DNA-Plus-Lipofectamine
miceWheat
significant.The
C-terminal-tagged
backprojection
c.356T
S2neo
D4-RLAA-BRAF
33/37/41
SLC7A8
DharmaFECT3
JMP7.0
Olshan
thiol-reversible
FIP1L1-PDGFRalpha-positive
S3A–C
ofTGN1412
10.1007/s00441-001-0510-y
p16INK4a-deficient
32-33
dye-bias
Heregulin2
CTCAGCCATGAGA
−354
clinician
Tsc
Cos-l
EZH2Y641N
effect.23
2-oxoglutarate-
Zutter
sterile-α-motif
rar
Hogendoorn
P=0.0062
.Patient
proestrus
MLH1/
p.Arg1275Gln
Wick
GDNF
DAOY
translocation.4
47,188
kinase–Akt
.Ophthalmic
p.E227SfsX42
DCS-3
mapview
.Desmoplakin
dounced
−89.1
pone.0064364.e015.jpg≤−1.0
Cosegregation
5.68
HPV-positive
G12W
close‐up
Y68H
G115S
10-pim
40,7
4F0I
Figure7B7B
Epitope-tagged
Methyl-CNV
n=1652
–,4
ppERK/ERK
Khosravi-Far
Menin
bySouthern
S.S.
Shirayama
al10
965
theincubation
1050000–1190000
3/40
Rusnak
palmostatin
reports1,2
shRNA-rescue
F156I
12-reporter
NPM1-unmutated
N8222K
Eµ/SRa
Weller
One-Way
Q10
PF-06439015
2.9-kB
dαN
6,800
histone-methyltransferase
pBABEbleo-Flag-BRAF-V600E
OMIM*171400
studies56
FAB
Loberg
LRIG3–ROS1
extranucleolar
FB
ssODN-exposed
hMSH2-I145M
Touch-down
302-553
antiscrum
0587
5'-upstream
Me5
2,296
3–4/group
.6424
found.1
-fluorophore
D1067Y/A/V–stable
5-CAAACACCATGAGCCCCATCAAGGAGTACTGAATGACAG-3
FuDan
meta-exon
mM/M
seepart
CDC2/cyclin
reported1
63platelet-derived
pS6K-T389
mutations.7,8
p.Pro177
epsilon31
cells.18
459-bp
missMgCl2
thatbinding
wound-induced
.Co-inhibition
GLI-transformed
RV-fragment
DS1
3'-ERG
19935
carboplatin/pemetrexed/bevacizumab
F18-fluorodeoxyglucose
5'-GAAAACATGATTAGACTAATTC-3
1,35
-Z
Prosite
Arg-Asp-Leu
XPO1-inhibitor
Pan-HER
Gln-1756
MEN2AY
R157Q
L221P
Danenberg
fasciocutaneo-skeletal
fingers.5
ab88112
9p24.1
.TTF-1
growth.110
erythropoiesis26
K618A
Whole-Exome
Trk-Met
76.0
Catenins
anarrow
−0.4
benefit.26
165-nucleotide
CARMA1-activating
tissue-
238a
Brca2flox/-
RIIA
FLAG-Elf3Δ246–250
39•37
HS-PTCL
H193L
BRCA1–Met-531
TSH
G-CSF
DMEM/F-12
1634
40Å2
DF/BWCC
ETV1-1a
post-LPS
ETV6-ABL1
CpG-methylator
AGTCCTAAGTCTTCCTGTGCC
Asn4=
2.A
5′-rapid
SH3-specific
P525
37°C
G279V
~37
III-
NPxxY
ab9385
Expe
RING-box
Santarpia
.DNMT3A
.FGF8b
c.12844C
D–
molecule.5
AGCCCTCTGGACAACACAAC
AB821310
AB-3
Fig.4B.4B
temperaturecontrolled
RESULTS/CONCLUSIONS
MFSD6
21287
212237_at
macrophage/monocyte
Cys94
c.5258G
trastuzumab-sensitive
neurosphere-forming
Dnmt3b2
M307
6.FIG
1–68
MANNwas
shown.Having
ROS112
6-base-long
S910
180-μL
D2S2211
D5S644
risks27
9271
siblings.44
6/28
Koh-ichi
NS/JMML
G468
c.441G
SEB
lines.MATERIALS
melanoma-associated
27,51
a137Cs
kinaseinactive
W485R
Non-deleted
HI-FBS
ESAP1
half.14,15
Kohlman
∼60,000
c-KIT—mutated
4623
CBL-containing
p50met
KHDRBS3
cell-surface
representativeness
finding25
1.3–2.2
1/11
phosphopeptide-binding
grants-in-aid
of*Correspondence
AgelSex
www.lovd.nl
chondrocytic
B-Bridge
pHX-Luc
L438P
∼87-kDa
casodex-
activator32
415K
AAAGGAAGCCACTGGAGTTCC
6,591
CRE-driven
-0.21
TGTTTTTGTAGTTTATATGGAAGGGTTAA
pcDNA3.1-Cdk12-F
d-274
intravasate
19/26
understood,10
23,241
IVS18-1G→C
spacer-tolerant
TCGGATTTCTCTACTTTTTCGTG
Diamond–Blackfan
KIT-linked
AML.6,7
Mu¨
SectionNext
72Â°for
.Cystine-knot
non-gefitinib-treated
Bach2
~1.7-fold
5′-ACCCAAAGGAGTAGCCCAAGCAAGCCAGTAAGTTCGACAAGCTGCCA-3′
haemocytes183
acinar-like
DS2
ATCCCAAAGTGC-3′
â€¢SP
RPMI1640
H-ras-GTP
recombination–based
glycosaminoglycan
LTK
TRE/Oct-1-binding
ccRCCn=
MTA
CD11b+Gr-1dim
earlier.5
pyrrolotriazine
HADDOCK
individu-
altmetric
EGFR/HER1
30-80
elutes
Pro378
E4.1
F532S
endometrioidal
.Atoms
years.19
10/10
p.Thr485Lys
martingale
.-M.W.
RlacZ
bis-amide
GCGTCTTGCAGGAGAGATTC
c-ROS1
0.1–1
chr14:99728683–99904995
Di362
KRAS-R
ACGTTGCACTCTCCTCCTTC
Multidisciplinary
p.ARg1515His
PCR-amplified
C02/95
.Dnmt3a
IL2RG-JAK-STAT–mutated
FLT3ITD-expressing
pTK-RL
THC2
15.In
Tonon
8/32
green-labeled
BR21
R169W
NIMA-related
1∶50
G104V
pol3-01
5′-TCCGTGATTGGGATGATATG-3′
pCEFL-KZ-AU5-KRAS-V12
andreverse
.Phospho-MEK1
Wg/Wnt
response15
thelactoperoxidase
levels110
201137
L79R
c.1154C
Bueso-Ramos
nt1990-16→-2
anti-phospho-T325
.Emission
Li-Fraumeni
30–35
\/ΣI
1,544
2,611
Helvering
cisplatin,43
0.79-2.64
1,267
observa
AML.24
MZCRC1
Vihinen
Polδ
coelectroporated
ATRT
2.33-7.97
RP11-771B3
ZR-75.1
aEighty-five
A118
Start_Codon
67032
80-amino
Met-421
029
HNF3β
activation120
WA30
RET-specific
.Catalase
.Bifluorescence
Waite
1489dup10‡
â€˜5â€•
BRAF.Among
experiment-wise
Studamire
Hidetaka
Nonidet-P
22,30
8p11-p12
324:1227–1233
c.3761_3762delGA
agematched
TCF-4-dependent
α-Cdk2
Muc1
08544-1014
6404
activity.4,5
ER1-3
IVS3-1G
478C
MZB1
post-zygotic
1∶100
Y1234D
protein–NRAS
MBP-fusion
MEK1S218D/S222D
5′-TCAATGCATTCTCCACACCA-3′
recurrence.44
PCR/sequencing
DeletionAbbreviations
agar124
units/μl
matched84
CtBP2
advanced/inoperable
P-HER3
~76
18,24,25
hsa-mir-3127-5p
experiments98
N62
whole-mounts
ALCL-associated
Braunshweig
HMF
retMEN2B-expressing
mcabrm
-overexpressing
CL-XPosureTM
5′-TACACCCAGGACTTCATGGTGCCTGGACAGGTC-3′
SDA5HTαα
unaccompanied
t=ni
cell-lineage
Gleevec/Glivec/STI571
infection.12
5A1
S4.2
sideroblast
IL12-induced
K15
KrasG12D-Pancreatic
mm3.ImmunohistochemistryTumors
H1047R|
Hs00153408
cl6
60-s
dx49
described,12
interpretationNo
production.18
isidentical
Hap1
inflammation-associated
published5
elegans19
Rad50R83I
single-center
KIT,5,6
SNU-283
variation.28
characterized.23
Gly719Ala
P-bodies16
M143
TTGCAGCCTGGGAGACCCTTGG
P267L
RZ-1032
KRTAP9-6
hypophorylated
G469
lymphoma.2,3,4,13
P-C4
GATA3-shRNA-expressing
step95
Grotzer
CD8+CD44hiCD122lo
.TC797
3T3ODNODN7RMC
Ipsogen
43-49
TLR9-dependent
N477
A654
FLT3–wild-type
mutants.120
NF2-mt
samples101
2.5–12.0
KAADCyc
Jayaraman
25/37
Y1365
A235P
metastasis.11,14
shRNA-targeted
Arf1-mediated
57••
10.1186
0.9080
BrafV600ETgfbr1fl
E.Z.N.A
K404E
theJapanese
SOS1E846K
entity.2
Alden8
-60-70
5′-CAGAGTCGCGACTACTACAACTTTCCA-3′
DHA-mediated
Gr-1+
42/43
CGH-negative
221-280
NIN–PDGFRB
GGTGCCCCTCTCAGATCTGCTGCTGG
patients.5,6,24,25
A107P
HMGCS1
Ameziane
Cesarman
.Ultra-deep
p=0·8609
24.01
inhibitor–treated
GOELAMS
Correspondence
KITor
SMO-E518
CCCCGCCTCGATCCT-3′
autoacitvation
MYH9-related
maligna
b~~~~~~
Promoter—In
Partisphere
Leu122Arg
Akutsu
9/89
V911L
FcγRlo
months,17,18
A559fsinsA
−7.06
pathogenic,30,31
microheterogeneity
3uM
mild-phenotype
ERK1/2T202/Y204
R515I
VZ-SVZ
-2266A
.Cytological
AB1157
www.cbcb.umd.edu
OCI-LY8
1jmt
myelodysplasia/acute
BM/PB=4/4
CHU
*Results
Fos/Jun
5.9C1RComplement
359K
A-specific
FOXP3
TNK2
MOLSCRIPT
death.152
124-127
NS/SS/I
evident.6,7
.Throughout
H1065
.7E
A024
Degron-KI
identified.2,3,15,16
disinhibiting
Kpn
DD-EZH2–tagged
c.40G
competitorwere
ÃŸ-cateningene
BRCA2-profi
MET-T1010I
.Fresh-frozen
Kumaret
variant-impact
ATM-heterozygous
monoclonalantibody
ΔΔGsolv
genotype-related
TGFβ-resistant
adenomagenesis
inhibitors113
2G-H
R1459X
19⇓–21
S110L
L360W
agents.24,25
VTI1A-TCF7L2
p.774_775insAYVM
®xing
H-RAS–specific
-CCGAGCTCTGGGACTAATCA
9α-fluoro-16α-methylprednisolone
candidacy
ZNF687
G4-interactive
IGF1R-expressing
Dicer1-dependent
CLTC-TFEB
signaling18
.Signaling
Grussenmyer
G13C/R/D/V
ETV6-ABL2
Tyr821
Augsburg10
Tyr928
EBP-β
c.12
Yaginuma
.ANNOVAR
0.01–0.02
Ets1–138PEA-15phosphoprotein
9α-fluoro-16α-hydroxyprednisolone
.Ntv-a
Vlietstra
tumours93
MycHis
AsnSerThrSerGlyAspPrQV
20/46
FIP1L1
Bedogni
159350
MLD
Thr410
Q256X
UL22A
S3–5
2198
TPM4-ALK
CASP3
Non-hypermutated
moderately/poorly
//dx.doi.org/10.7554/eLife.14709.016
Asn879
AmphoPack-293
1C–F
tableTable
recapitulated
Vogelstein14
host-driven
contexts126-128
17.32-34
leu2A1
α-6H
FBW7/hAGO/hCDC4
HA-Tag
S57N
−Ura
2.1–19.7
Gafsa
breakup
.Nf
16p13.13-p13.2
2069delA
22–26
treatment67
MKKS/C20orf94
N455T
withß-catenin
–44.8
F-10
L/mL
NM_001570
DGS
MSCV-MIY
RCE1
3-CYC1-lacZ
iI0
edu/
Tyr-Arg-Asp
gonadostromal
0.90
SSP®
Kangbuk
.Assignments
samples169
cance
–14.3
Veprintsev
D842V
Intestinal
DNFBWX7R
//doi.org/10.1371/journal.pone.0087113.t004
54–213
.S1E
MCAP-causing
Pérez-Lorenzo
'1
site10
NB-derived
2.17-Mb-wide
themsh2-GD693p–Msh6p
G389R
hox
Lu134A
IL12Rb2
MLLNC/NC
-related
broadinstitute.org/gsa/wiki/index.php/Base_quality_score_recalibration
Mg2+coordination
nine-fold
.Cytology
PIAS
Val1110
octylglucoside
switch-like
106C
p53NES-pKI
Kyrin
ex-Notch
NCT00548093
HCC-
.1459C
Dovhey
ofwhole
.Frank
MGDC-265.98
tumor-susceptible
pGEXp16
dimerization-inducing
p.R171S
Em-c-myc
UbcH5a
RAS-GTP
53-fold
2H20/0.01
drug-metabolizing
FLT3/ITDs
Base-base
ACAGAA/gtaggt
MutS/MSH2-MSH6
8,283
Reagent-RNA
-2-aminoethane-sulfonic
410–436
GAPex
5193
VItro
​Fig.6A,6A
S291fsX300-transduced
0/50
deparaffinizcd
Co41
a-lexA
DNA-PLUS
sh-Control
CSPG4
22:6n-3
GEArray
c-kit+Mac1–Gr1–
origin11
Chr9-187R
PTPρ-dependent
1,282
protein.63
Y317
G0186
Wnt-Cul4A
.SNAIL1
green/CPK
1661
precursor-rRNA
EMD1204831
pXPllBE
ICL-repair-specific
13/23.6
rescue-ese
partiallyfunctional
Blokzijl
double/triple
19–20
5′-biotin
1–53
therapy—as
P358fs
nger
malignancy-associated
VEMURAFENIB
W590S
di/tri-methyl
receptor.51
pSV-β-gal
Q1048E
-.Ii
post-selection
C-finding
1.987772
DPT
ο-nitrophenyl
35-39
emitter
ape
S308A-complemented
K57
DNAPKcs
ALDH+
tTo
hyperleptinemia
2B
R2981H
Fukumoto
−94
mutant,8
activation.6–8
centralization
1.0-22.0
Timp3
∼15
5A2
antagonists19
hD816V
SSC
COL1A2
gefitinib–EGFR
tumor‐free
1446
effector/memory
S3E–G
Notch-dependent
YTTTCT
Mig6-specific
p85α-Glu348
PEBP2b
Arntflox/flox
28.25
L176F
p1–2
Anti-phospho905
110L24
10,18
Coornaert
bindsto
K382
5692–5701
syndrome.2
YBX1
dysplasia.23
FPR1
RANBP2–ALK
13/475
bead–based
c-src
p53LSL-R270H
AZD2461-resistant
migration/
NCT00522145
1n9
sequencenegative
DNA-strand
4D–E
CstF3
counterparts136
I530
.Spindle
816.4
DSG
RP4–620P6
c.1799_1800TG.AA
1U7F
GPCR-less-sensitive
Viewer59
toremifene
−5.25
c.190T
EWSR1-ZNF444
window-specific
pre-requirement
/HGF
.S4H
pGL3-pap1-luc
.FLT3-ITD
treatment.29
-fluorouracil
50,51,52
pre-therapy
56K
thyrnidine
Lifescience
wild-typep53
GAAGTAAAAGGTGCACTGTAATAAT
FC2
appropriate-sized
866delTT
D17S791
clinical-based
QIAcube
P=0.1
Weisenberger
Arg-206
25.68
KIT.6,9,10
l-1
R-based
apyrimidinic
progenitor-stem
=111
14–1102
c.-113
DuPontCo.
p85α.26
Ku55933
KRASK147E-mediated
sL*uProCl
.similar
48-kDa
aminothiazole
EWSR1-421/SMARCA5-1973
C20orf39
sensitivity.Further
ttttttcag
Oncogenome
.FGFR3b-S249C
Tyr157
Single-bp
99.98-100.07
immunecomplexes
p53-stabilizing
E1/E2-null
N17Ras
46/M
5′-ATCTGTATCAAAGAATGGTCCTG-3′
rizwan59elmclko
Neben
polyThe
N-ros
SPEG
Mauvais-Jarvis
periph
11128
AJ270778
myc-PIPKIIα
CTTTTGTTCTGGCGGTGTT
Ba/F3-KIT
antioxidative
RO4927350
0.11–0.33
Pik3caH1047R
Lys867
ARaf
High-Capacity
Near-complete
AE1/3
Radiology
600,000
observed27–30
Figures33
a-
U87MG.4
SC-1647
immunocompromised
0332991
HGS-OvCa22
65,100
D-Domain
p21/CIP1/WAF1
pod-Vhl
51/567
msh2-AE859p-Msh6p
CRC58
BCL2/IGH
.19,26,27
Mig6
subcomplexes
W321R
non-self
Keratinocyte
p.S156FS172X/L
I1I3
.Phospho-SMAD1/5/8
24–49
BCOR-CCNB3–negative
SuperMix-UDG
7.0-7.5
Jänne
13q14
WGA4
XPC
MutSb
C239R
WRB
0.819
C-tails
.Back
methanol–10
Bardelli
ALK-C3592T_R
0.09/0.10
Quantitative-RT-PCR
de-paraffinized
p.Glu1391Gly
43–63
Lys-120—Although
Co7
32-M
C3H
Trp53bp1
HDX-MS.
2011_08
p.Arg309STOP
.Utilizing
IV-mediated
17/17
P=0.09
0.6–2
Etv5
4.4E
clipping/trimming
Xba1
anti-K14
mutations,32,33
45,881
816–829
Beckton
1,644
5597G
Neuroglian
proteinase-K
0.664
6weeks
NCBINCBI
byr2-
complex4
68/250
double-transduced
Tai
CD5−
Siah/SIP/Ebi-mediated
Frequency-based
804-808
Stamenkovic
691KB
716/1935
12,27
0–64
150-ml
oligomers.25
Phosphatidylethanolamine
C.
Y-chromosome
PRG3
low-volume
pcDNA6
potentialto
ΔD4-BRAF
maintenance16
chromosomal-instability
cell.1,2
theproliferation
rates.14–17
Meroni
mxSF3B1K700E
GOF-mediated
3Ca
5'-AGATGCTGCAACTAAACAGG-3
18,29
75-3
Burdenko
Untransfected
beinginactive
S3a-d
Rev-dependent
Tsunawaki
N-766
Gal-XE
Polycomb-repressed
S78
ganglion
.Normalized
TBS-Tween
SF-124,25
subcloning
function/expression
U2AF1-dependent
mm44
P2F1
5′-GGGGG-3′
cooling-off
X66893
/ITGA2B
EBP-α
UAAGAAAUACUAAAUUAAUUUCUAG
149A
0·8
p=0.95
p-JAK1
∼9
.A2780
ASXL1,6,7
9,993
notsynthesize
2.158
Asian/Pacific
til.
GNAQ
Phe408
16342412373076253025267102021104518271589240407563306315102010161014133729+Â
IKB
2/125
cl1
266KB
FO-
overexpres-sion
CLL/lymphoma
P-ERK1/2
Tokuda
A_51_P323011
Cyster
radioactive9
PTEN-342
Non‐small‐cell
600258
proteins/phosphoproteins
recombination-driven
near-null
RB2-RT-as
p.Asp252ValfsX24
isobologram
.EBPα
high-serum
Deficiens
methyltransferase-1
1.14–1.67
D331G
cancer14–16
I–IIIA
genetic-level
0.322-1.846
gamma-response
TC2ILeu-72
Asx-like
thenthought
50.9±14.3
0.913
ROS1.33,34
mice105
grape-like
Nf1-deficient
.Composition
GSK-3βphosphorylation
GACCACGCGTATCGATGTCGACT
F645
2.6.
c.6696_6697delTC
factor-responsiveness
Ba/F3-RICTOR
Pahl
mastocytosis,37,38
eÂ®e
TCCTTGCGGGGGTCCCCAACTGCACC
chr2:29432646
H3.3-mutated
BRAF-shRNA
expression.89
GSE9343
.8389
Govin
CT-guided
consider21
.5F
9/exon
125-kDa
P=0.012
5-flourouracil–treated
gonadotropin-releasing
1,145
D-domains
PIK3CAH1047R-induced
SGQVGTARYMAPEVLESRMN-LENAESFKQTDVYSMAL
2,13
S761N
Tie2
A_52_P415299
co-ip
-tggtgaatgacgtctaccgcgt-3
immunode®cient
originallydevised
Frankfurt/Germany
EGFR-cetuximab
C–g
P16INK4A
low-confluency
antivaccine
Fgf18
NP_997704
apo-BCLxL
βC′
Fbxw7Arg465
fl2-M
,43
MYH11The
59–base
parapyramidal
0.0027
5'-CTC
270–465
.WDR5
1999P010781
ITGA3
5¶-CTGTTAACATTTATAATTGCAGT-3¶
BH3
MQ
50-mg
Brd4-GFP
ATG7
Hs00177782_m1
S3F
mRPLC–MS/MS
−1308
C164Y
chromodomain
D45C
4094
COT1
C797
acid–free
2Bc
10ug/ml
RKO-AS45
4PCR
biphenotypic
G153D
multiubiquitin
importance.18
17p13-q21
D877N
A23
Daco
described.25Each
homopolymeric
MEF2C-deregulated
sumoylation.25
40-O-
ErbB4/ErbB2
codons381–383
spindle.52
entity.6,12
UCLA:1
molecularweight
63.9
0.740–1.850
QV
//www.haematologica.org/journal/2006/09/1283.html
p.Gln486X
≈200
535C
p57KIP2
373-378
-2_*v
truncat
yet-undetermined
COS1
RIP140733
CBF-AMLThe
gene=MLH1
NTRK1-pathway
CpG→T
0.18–1.49
0.39
TDM-1
8oxoG
ER561-562
MmAGAAAR12345
GEF-mediated
residues*
-GGTCCAAGAATTTCACCTCT-3
Ba/F3-FLT3-ITD
disease.8While
39SSs
FANCA,41
second-
-T790M
anti-Hck
High‐local
HEK-EpoR-Jak2-T875N
Akt/AKT1/PKBα
RecQL4
CCG-3
energy-limiting
trial.
337−Asp
G391E
p110α-E453K
polyomavirus
TBP-associated
Full-sequencing
nonconsensus
5′-CCGGGTTGGCATGACTCATATTAACCATGG-3′
AC220-resistant
1251I-surface-labeled
TEL-PDGFRB18
phosphatidyli­
SCP1−3
degradation30
prometaphase
Manke2,3
phospho-IκB-α
.Investigations
IL−3
MDS44
S381
S5.4a
BAK-null
Zhuet
Y.S
024
S9A
V14I
doi:10.1158/1078-0432.CCR-05-1692
Jeanmougin
N.A.J
5.32
p.R40X
GGTTTCACGCTCCCTGTCTT
psi-Eco
3.0–10
IκBL
n=547
​Figure1,1
ER-containing
.Paraffin-embedded
transrepression
E2-binding
raÃ
NM_015355
FoxO1-induced
Cases¶
1070-04
ALKF1174L-mutant
frequency.By
TK-I/TK-II
FLT3-ITD-expressing
serine-186
​,3B
TβRII-null
309–311
P-bodies43
Mut-related
275–354
L420A
Autophosphorylations
6.64
CTGGGTGGGG
33/230
Peripheral-blood
T74
M.N
I.32
penn-strep
626
translocations.1
dasatinib30
GST-Cbl-PTB-G306E
I178
0.56–0.99
.WRN
p130-/-
Iantigens
−740
twins,8
1Â°.primary
presymptomatic
5'-ATGGAAGAAATCGGTAAGAGGTG-3
CRAF-mediated
2215
3-phosphoinositide-dependent
transcription/translation
5′-GCCGCTCGAGTCTCTCCATGTGGTGTTTG-3′
CYP33→BMI1/HDAC/CBX4/KDM5B
IL-2R–FAT1-IC
Nde-Intr13-F
PC6
Occipitofrontal
people.78
Arg544
mutationshave
Reimand
W1302R
constitutively-expressing
replicationThe
trk33
.Solar
implan-
Toranomon
1.0.10
Mm00628662_m1
4:3:1
.Does
Transcriptome-wide
numbersin
xenografts157-159
TrkAI/TrkAIII
non-two
S5J–K
.Transparent
His1248Asp
9441
Venus2-tagged
kinases2
0.7–12.4
MEMo43
Center-103312
.Space
1501G-A
3–63
arginine-337
VGGRTMLPYRWMPPESI
BCR-ABL–transduced
PRISM3100
GSNEpY53TEGPS
GCAGCATTGTTGGGGGACA
months32
.0040315
75/F
49-201-723-2406
817TArg
,7E
Set2
carcinogenesis.5,6
.046
E225K
6q26
co-occur
Phe-891
8,23–25
EGFRand
condensin
Kulure
H3K27me2/3
21.13
leukemias.22
DPP-IV
fenceFSCORright
ΔN186-Vav1
5840
9.87–12.67
SK-ES-1
carcinomas103
2009-013381-54
T903T
37.Seven
E353Q/G390D/A569T
G246D
.SHP2
HLA-fully
LDN-193189
Ribo-Zero
cm/KIT
5′-CACATTATTGCCAACATGAC-3′.18
identified.18
PHF2
KRAS137
V170M
GBP/FRAT
diseases26–28
33–38
Substrates—ϕX
RLM-RACE
DMIRB
prognosis.21-23
7.1489615
L×W2
GNF556
321-372
23•24
6.21
4,5-
technology10,11
cross-linked
IGF-1R-initiated
71-98
0.7.8-r455
Renal/genitourinary
K147E
mutated41
59366
R748W
anti-TL
Fumiaki
john.byrd
IRF-8
C2-ceramide
RAS-responsive
.Glomeruli
STFA1
ΔHIF2α-A530T
Alignment/MAP
R128
loss-of-binding
TELΔ-JAK2
B-NHLs
Fluoroshield
Hairy-cell
KB186
predisposingmutation
LuBioScience
ago.1
amedian
5'-TCCCTGCGCCGC
similarity––ranging
cdk-binging
.FIP1L1
mild-tomoderate
Miyauchi
tracheostenosis
Pro176
STAT1/DNA
BAP1+/–
receptor-activated
bindingto
10/5/2
K212′
BIBW2992
electropherogram
III-2
c.4585G
J21-EGraphic4T-B
HECD-1
Lmx1b
Gomel
Mono-NRs
13/457
MPCEWS-FLI-T2.1/T2.2
Tumor-Associated
1266
Trp-557
keratinocyte‐targeted
Kmt2d-deficient
.Mitogen-activated
5′-CGCAAGAAGAGGAAGAACTCCACGG-3′
Wnt1/β-catenin
Bisulfite-based
PDGF-α
C381G
Dounce
.10,16–20
P286
FLT3-JM-PM-induced
cells.24
undercertain
AGTR2
c.608G4A
Wagenius
ASSA
Mutation/loss
Ras.26–28
B*1526N
MIAPaCa2
'HER2+
RxS/T
Worthylake
EDIEVP
native-polyacrylamide
F848L
Pharmacia
44/14
SAG
CD99−
mesenchyme-derived
inhibi
12-173
1SA
364-374
astigmatism
peptide-Flag-S
Hussell
centimorgans
transferrable
Ile836MetArg
three-
L834-D813
J008
Ets1—
V-FITC
Ca-Ski
AdCRE-mediated
AIB
.Hypothetically
case.Of
0.477
5×103
.046891
1:2000
autoactivating
158H
ventilator-dependent
P=8.3e–104
SAVANT
56,57,58
2629
v-ABL
SOCS-1,7
2PVC
.Assessments
R554Q
pl20GAP-stimulated
vector/TGF-β
110:1004-1012
BRCA/RAD51
En2
siRNA–treated
well-spread
HSS186390/sip53-2
field-effect
mKmt2d-Forward
phosphochromatography
p300-deficient
p.Gly115Ser
W257
Analysis—Total
conservative/benign
interferon-responsive
1–108
methylmethanesulfonate
precursor-B
Commissiong
Muraoka
SHINOMIYA
340/341
158
doi:10.1038/sj.onc.1209877
YFP-EGFR-ICD-transfected
PDD-NOS
rHGF
1663
.MEK
-1835
C-17
CGCCAGAGATATCAACAATATTGACGAAGAGAAAAAGACCACCAATGG
cells.23,24
Never-smoking
5′-UAGUAGCGCUUAGUGAAUAUU-3′
pVHL-ElonginC-ElonginB
Soo
MYH
to-Tyr
~GNRPs
Y32C
W1057
M72
5,6,7.
APOboxA
CPICLDMLKNTMTTKECLHRFCSDCIVTALRS
inlarge
one.35
–Yes-associated
−40
Gayter
ERBB2/HER-2
1.5-mm
ofRB
agar.12
30,52–54
M743I
V/DAPI
RAT1-RET/C634R
mutations.37,41,79-82
Rad9***
endosomes.The
18/37
TCTAAGACACGCTGGAACAGCGGATGCT
P-ERK
PTK2
K.-A
NPHS11
W58
.Beug
DQ13
Compasso
167.9
G361S
21-hour
CHEK2.251A
receptor-1
P3-estradiol
GRENIFKKDI
^Epstein
non-expression
BACH1-M299I
AktSer473
DNAcopy
course.BCORmut
.CK1α
K10
WAF1
ligand-interacting
ETS-regulated
Favelyukis
R916P
Eag1-digested
H66Y
overexpressions
c-Jun-mediated
beneWt
CCATGGCGGTAGGGAACGCTCTTATAG
Hspb2
RNA-B™
5′-CTGGTCTGCAGTTTGTTGGA-3′
QRET
carryingaGT
516,559
insights—particularly
goseq
-of-origin
430A
KIT-related
PFS6
Smad2-Smad2-Smad4
Seguro
H1904
mini-hotspot
free-survival
P405167
receptor–activated
q-PCR
EGFR/chr7
4675del
5′-ACA-3′
miR-221/222
D147
SAMtools53
5′-CCCCAGAAGAAACTGAAGCA-3′
shETV1-3
67-year-old
hlc
strucuture
extra-copies
14/336
Glc3Man9GlcNAc2
elsewhere.19
Immunohistochemistry
A634D
expression.C
Patientno
.AJ532607A*2307N
Cyclophosphamide-induced
Asp77
Ras·Sos
793
3594
protocols.13
delayed/maintained
delAAG
E453A
Tabchy
RET-FMTC
c.8765_8766delAG
syndrome13
S648N
behavior.4
.Gene-level
bimodal
ATTCAGCATTTTTC-3
residues32,33,34,35
Grafstrom
.Notable
homoligomerize
Figure4A-C
c.2227_2228insC
IVS5^2A4G
C2H2-class
′biotinylation
mismatchrelease
energy-stable
HNF-1a
beenpreviously
EHF
Y237
8-mo-old
gliomas.3
aggregation-inhibiting
MPN.2,3,13,14
antigen-experienced
DLCL.62
chemokine-independent
germline-specific
brigatinib.8,9,12
termini22
5′-GAACTGCGGCCGCTAAACACCTCTTAGTCTTAAGACAAG-3′
min-anchor-length
activin/TGF-β
hybridization/MYCN/
5VH
flip-out
sfuAspAst
741del6ins11
LY-294002
MMR-gene–mutation
wasfound
DCt
phosphatase-1
ANKK1
p43
EGFR-TKIs.7–9
cc-13-834-g8
p70S6K-GST
1N6K
AA/gtaaat
R37XM40-Rluc
hypersecretion
Schlag
L122fs4*
predisposition.29
7525
NaCl,1
R1706C
FANCQ
Dubs-Poterszman
ZFN
HLA-B7
17-AAG-treated
ligand21,22
KIF5B-PDGFRalpha
dome-IR
15q13
//www.ncbi.nlm.nih.gov/tools/primer-blast/
PMF.43
5′-CCAACCTGCACAAGTTCCCTT-3′
H/R168
pSer45
Control-2
42Â
Sysmex
nonwater-mediated
JNJ-42756493treated
Q631
5q,28,29
osteoprogenitors
311SerFS
77–124
disease-causal
.Nitrocellulose
afferents
hepatocullular
Cys2
inhibitor-induced
34.17
E632del
therapy.21-24
0.3309
S392L
CACATTATTGCCAACATGAC
3D-F
1laFlaRIbFIbR2F:2R:3F:3R:4F:4R:5F:5R:6F:6R:7F:7R:8F:8R
S768R-overexpressed
jb2
CCCTTGCCTTGTATCGAAT
IVT/translation
pterygopalatine
8.4–10.2
samples9
90095
5.1-11.7
BBM-1
DiMaio
-FANCG
MPL,14,15
GISTs97
000548.3
Cergy-Pontoise
v.63
NCT01349049
Ascunce
14302z
VHL-depleted
mini-gene
EGF-addition
PKM1
Y842
T234A
microRNA-191
-1H-pyrazolo
reverse/forward
bioreduction
L576Pc-Kit-
HR-785
MycT58I
127–456
B-containing
2.5–4.4
RegIIIγ
procedures48
4,823
Lent-SOX17
29/564
.PHA
.Site-directed
phosphate‐free
cancers.20
17589
E709A+G719C
line.36
anti-Oct
easier-to
C-300595-03
D594A
Bassaganyas
9p21-2251
detected109
skin.1
//androgendb.mcgill.ca/
p63–mutant
6310
743–807
ARSD
normalization.12
SstI–SstI
pockets29
pLKO.1-based
stitutively
AML.41
antiRad51
ICGHNPCC/INSiGHT
2ERE-TK-CAT
Mm-1
icPTPRD
recombination11
Y341
OPSR
GSE27342
169K
myelofibrosis.43
Restifo
2196G/A
non-targeted
IKBKE-induced
Daiqing
differentgenes
T37R
Treatment=100
Fåhraeus
L554P-expressing
Burki
dimer-induced
Figure5D5D
Bouffet
sequenced1,20,21
Status—We
Coactivator-3
change.19
cascade-mediated
Uninformative
27••
81160
interfaces.36
branched-chain
p34cdc2
._862+
UV113
ABCB11
RETS891
Kras-mutant
CTACG
Accumulatedß-catenin
Ile26Ala
676-703
5′-ACTGACCAATGGCGAGTGAAG-3′
Insulin-Induced
CK5/6-positive
-0.06
ab31163
remethylation
theindicated
Ras-nucleotide
mTORC2-RICTOR
42307
anti-GEF-H1
hydroxylated
1-fused
37908
pEG2
UMeach
BCR-ABL
muta-
.Arg-885
13C/15N-labeled
KRASD153V
Leu1515Pro
.2,9
phosphorylation53
phospho-Tyr705STAT3
high-DNA-flexibility
retroviral-mediated
CypD/p53
MPN-U.27
French–Belgian–Swiss
translocations.29-31
PDGFR-
.RO4927350
platelet
AATCTTTGTGTATTTGATAAAGTC
RANBP2-ABL1
tetrahydro-2H-pyran-4-yl
0.000102
atrogenes
dye
Phospho-TRKA-Tyr490
TGI=100−MeantumorvolumeoftreatedgroupMeantumorvolumeofcontrolgroup×100
5′-CCTAGTACTGTGAGGCACT-3′
humans16
semi-circular
n=18/132
GAGTCGCTGGCACAGTTCTA
//opengenome.net
NNK
1-2/106
Br52-Rec54
PPRE
FoxK1
previously.8,15
44/EC
304
∕scatter
ANR10
histidine-deficient
69.2±13.9
17q11.2
.Genetics
Gazzeri
1TF
5′-TGAAGGCAGCCTTCGACG-3′
DHL1-CR500-2
C71Y
44:16246–16256
53i
4-hour
G618A
Lef-1
his3D200
Phe631
I332
ICT2512A
ARband
wortmannin
pleiomorphic
analysis.bWere
AIC
AR-V2
.bFGF
GSK2126458A
PacI-AscI
.Whole‐mount
−3247
I-kappa-B
ELAVL1
Otx2-positive
stat3
Albcre
Tumors.18
71-6
60-69
dysregulating
⩽1
FKkFRg
Δ369-371
ABN6
product.However
.Cdk6-null
.Twenty-meric
.X-Gal
pT-Y-L-I
D1067Vmutant
p110δ-expressing
pRK25
ELF1
5′-gactgtggttttgtccagcgagca-3′
V122I
Hanahan/Weinberg
7/15
.AGI-6780
01923
molecular-structure
−1.98
FGFR1+/HR−
816delGC
2.06Å
ofinterest
Sequester
akt
Defectivea
biologie
9304
.TSC
111–193
.Mdr1a
.Orderly
inhibitors.26,32
tumorsoriginate
pcDNATM
3.79
Soscat
A466T
.Interfering
BE900714
TEL-FGFR326
5′-CAGGCTCCCAGCAAGCTTACAATGTTCAAATG-3′
.Neurophysiological
prechilled
box-like
MEK-mediated
Over-
PDV
AT/RT
11-381E5
CCTGAATTCAGCAGTTGGGCTCCGCGC
mTOR/S6K–
HNCA
Forty-five
ATGThr
target.48
pro-EGFR
R92W
dUSA4
17AAG
UV61
beta2-microglobulin
NOKSI
31/132
E563K
0.7615
6.92
GDP-AlF4
MEK1-C121S–positive
positive.4
sc-271915
U87MG.AEGFR-Akp
L-PK/H-ras
MYC56
database2
levels/clinical-pathological
agents.39
5-fluorouracil-mobilized
CTLAThr17—Using
PDGF-B-producing
Grishok
AF2344
BrdUrd-positive
IVS1
Bagouz
PureGene
CD5/CD19
dioxygenases2
F39A
SOX9-responsive
GST-tail
MRP
perturba-
SDS/7.5
RAFT1
5min
Arg-1775.B
Apcuniv/Pcna
.Lipofactamine
ReagentsEndometrial
underrepresentation
RhoA55,56,57
5′-CTGCATGCGCTTGACATCAGT-3′
KaleidaGraph
Lim1215-R
pY-activated
membraneswere
RUNX1/AML1-ETO
pcDEFp300Δex15–18
Onadim
nchgr.nih.gov
I9278
CDK4/cyclin
Thr321
p-FGFR2
theabove
BcL-2
genomewide
CTTACCTGTGCTCGTTTTTCC
melanoma103
Iannuzzi
for14â€
PTPLAD2
R134X
5-bisphosphate
JAG-1
metabotropic
RP4–741H3
NKX
4/15
irinotecanbased
p16/p15
GenInfo
KIT/4q12
malignancies,17
no.AF265210
EBSs
PIK3R1R348∗-driven
c.161_165delGAGGG
34.6/13.7
20q11.2
KRAB
16,17,21,24,25
reported20
neurophysiological
.Blue
Src-overexpressing
0.083
13820
Br79
chemotherapy-based
D18S479–1.45
Giannikopoulus
Giacinti
TBS/T
.Prostate
T3/ABN11
output-genome-bam
//www.broadinstitute.org/cancer/cga/InVEx
ACC-LC-80
1–40,000
de-duplications
system40
DSA
flutamide-stimulated
Hippel–Lindau
Contradictory
8L
SPM
occurredfrom
RGNT
17q22-2514dAint-213q32-33
anti-Merlin
KIAA0999
.Geisleret
mutation-specific
−25.14
MASC.crizotinib
BAF200-associated
Costaining
Haspin
methycellulose
Y3223.33
24-27
co-mediator
0.853*
17,564
RETMEN
Gly700
sequence-confirmed
NAMB
tumour.47
ceramide
2003-00328
M1248Tmu/+
double-infectedwith
957-962
conservativeness
MIAPaCa-2
E2F2-responsive
SCC.12
N-terminally
Proof-of-Concept
1.5–9.1
four.The
asm.org
L833V
background.23,24
GST-JNK1
0.788‡
Val-12Glu-3OLys-31
S2186T
24ENDTand
MV7-c-mycT-
yeastMsh2p-Msh6p
V600EBRAF-
Pairwise
.Cambridge
GATA-3•Tβ2
miR-520a
.Kleckner
00027
methylotrophic
drugs.9,21,22
chrX:39514191-39729127
TCF3-HLF
​andB
p.Pro44Leu
c.1575T4C
FLT3/KD
1.0-cm
ENST00000241453
pDelta45betacatenin
2o8b
lower-molecularmassfraction
tumor-involved
321-
pWzl-Neo
haematopoietic-specific
pBABE
treatment.2,3
1.225
A*24:02:03Q
Dermatol
7,9,11,12,39
Bejcek
Junb
Santena
sequence-independent
Taketo
function16
49.53
argiine-to-cysteine
BCAS3
mutations.23,24
forward-cocked
WI-2403
-0.40
CTGAGGAAAGAAGAGAAGGA
Trypan-blue
S818L
Dijon
Ser1490
Hae
end-repaired
.Transfected
dye-swap
G434
Sigmaplot
effectorhypothesis
Tet2-deficient
trihyrdoxy-trans-stilbene
.Non-hereditary
method.33
miR-100
abnormalities.23
Guillerm
CBFA2
preferen
perlecan
cagtggaccactgtcatcgaagccaccttccatgtg
caspase-8–GFP
xq
0.942
HRAS22
B37
pEYFP–c1
4/8
.Rats
37K
D2-deficient
I556V
TTF1+
v.1.1
KEEG
CC-Q510E
T901R
described—acquisition
C696
Yip
Proteasome
misassociations
tags.Antibodies
MDS3
apoptosis-inducing
crizotinib-treated
ERK1Y53H
.8257
SRO3
71–76
msh2-AE859pand
vivo-manipulated
.Randomly
1109b
.Cappuzzo
Concentration-response
68292196
4–5:1
Rin1
glycogenosis
tableMolecular
MAML3-induced
.Thyroid
p18INK4C
nonmyeloid
agarose-DMEM-FBS
NB-19
P=0.0008
groups—tumors
non-Robertsonian
TransIT-siQuest
K856-E844
.Drs
R273H/T284R
acrylamide/7
kstefans
CD25-directed
exoribonucleolytic
αKG-dependent
PFKP
Ser-X-Ser
PDGFRB-T681I
BLCA
0/162
methylcyosine
PHA+interleukin-12
C9orf3
p.s.i
Iacobone
‐5‐
immunoselected
45-fold
GEE-labeled
factor-stimulated
ASO
response.17
.9G
population.17
IDH1gene
RNA-inducible
mito-IDH1
ref.6
H3-K9-HMTase
Voravud
mRNA-positive
5/178
A350E
YY1-binding
calibrator.Statistical
4-yl
understood.45,46
Distinguishing
.CuZnSOD
20–40-fold
non-cyanotic
G1809R
463k
5'-AGCTTGAAGAGCTCCTCCA-3
sAML
SRSF2-binding
Gc-i
EF4
MSH6/MSH6
5′-TTGGGCACTTGCACAGAGAT-3′
2′-O-methyl
qScript
+p
oxidoreductases
phe116/9.14,16
substrains
.Proper
kazal
BCR–JAK2-
non-homeobox
.Looking
CBX
chromosomes.26–34
.Lewis
wholecell
Olerup
PredictNLS
1876
H383R
94.0
DHR38
lymphoma12
41051
Rosee
Ac-PTEN
Bmi-1
Düsseldorf
D3-32P
5AAA
GST-C-RAF220-268S259D
pGAD424
Non-redundant
States,13
GTG-banded
tumorigenesis.Figure
35Smethionine
pattem
anti-TNF-α
565.00KB
established26
5′-GTGGATCCGGCCGCGCCATGGTGGAC-3′
MZBCHs
Y123
pAHC
1.176
splice-donor
off-frame
JoÄers
*6A/*9A
Endothelial-specific
German–Austrian
-CTGGAGACTCTCAGGGT-30
c.1662-23
E80A
Y1230/Y1234/Y1235
gp11OProto
carriers22
Pechlivanis
K202A
Ras-ERK
Bressac-de
.25C
recircularization.The
disease3,4
YAP1-
79.8
F199V
D-domain
cancer–affected
phospho–Tyr
Anti-PR-A/PR-B
chr15_g.66727450CAGAAGCAGAAGG
Directional-Vector
30/72
77/m
L257
expression130
Smad2
9Ala502_Tyr503insAlaTyr
MAK
Gln526
K111
DSMZ-German
Fbw7/hCdc4
3p22.2
lymphocytopenia
homeostasis1
R415P
TAL/LMO
NSG-H
Val816Asp
p.T83P
265–656
DIFFERENTIATED
.Cysts
receptor−specific
A-III-1
W366
8.Figure
HA-ARAF
dinucleotides5
GGCCAAGGCGCGCGTCctag
Histochemical
His68Arg
RBBP7
DD-TPβ-transduced
Pc=0.096
c.481+5G
Skp1or
41/130
chloroquine-containing
c.67delG
S3C
90-kDa
MutS·ADP
mCyR
PF299804
nfbs
5′-capped
pUHD10–3
Triacylglycerol
gmstanp
a32P-dCTP
ImagingZ1
c.3748G
NHrterminal
R364W
paraformaldehyde/Pipes
mu1574R
syndrome/chronic
AE1/AE3
KCL-22
82,855
pYES2/CT/TP53
splicing.9–12
Fbw7+/-
DEX
55.7
254-nm
1/Kd
-CRY2/C-RAF-CIBN
coIPed
COT
BRCA-2
Kaikkonen
R64P
4,118
Holmang
G34—at
newly-diagnosed
inhibitor,34
B^D
2.198
K295R
Endofree
pCR8-3xFLAG-ERG
584–1088
fulfilled.The
.5,9,39
E74K
//cedar.genetics.soton.ac.uk/pub/chrom18/map.html
K529
tetradecanol-phorbol-13-acetate
described.11
EIF5B
VENTANA-Benchmark-XT
BRL/Life-Technologies
132-Cre33
150-kd
SH2
01-22-09
hyperstimulation
a-specific
anti-phospho-AXL
TKIs.93
RPL22P1
p21/waf1
glioblastomas,55
0.1–50
R316C
wild-type-transfected
Pans-hydroxy-tamoxifen
oncogenes,1–4
antiretroviral
lymphoid37
D452
276
R1744-R248
.STI571
//www.sanger.ac.uk/perl/genetics/CGP/cosmic
3624
Protein-based
MnTmPyp
Songet
60/m
di¡erent
Moralesa
B253
v-raf-1
onlyLobo
WW4-GST
single-color
.CEP110-FGFR1
HiFi
133–135
disease.63
Highmolecular-weight
cM—D18Mit8
Af9-targeted
.Gupta
S2420P
melanoma.Although
BRCA1-BACH1
0.165
aggregation-prone
phospho-Ser32
β-sandwich
neutrophils45
B1–induced
235–270
COLO-741
described.10,11,20,21
doi:10.1016/j.exphem.2013.12.007
TRP
.Phe958
CNC-type
2.107
MET-26LN
model.47
risk-prediction
S6,22
gefitinib-sensitive
3737delT
Mlox
detection.Proteins
////
S459
domain–mediated
.deletion
His.b
molecularly-barcoded
two-colored
membrane-tethered
HN_62469
barcoding
26-b
R222T
Abate-Shen
5.4.3
O3
ERCC1-xeroderma
6A-FZR1
pEGFP-N3
resistance14,45
10058-F4-related
hypersensitivity.Effect
Lin−Sca-1+c-kit+
ovari-
patogenicity
CP-
fluid/filter
Gaubatz
HCC1833
c.1835_1837delTTG
/DP1
T279A
antibodies—and
mTEL-TYK2
acanthocytosis
M409A
67.00KB
α·GM-CSFR
BARD1-deleted
GTCCAGATCTG
Srsf2-deficient
5–50ng/mL
9.827–13.660
A5441
PTPRC
Candotti
c.265-
monocyte/macrophage
BRCA1/BRCA2/PALB2
IL-1β–induced
K191
sub-complex
p.Lys158Asn
BCL
12829
sucrose/0.2
29/0
kg/m2
N1357-02
FGF5
57.2
MKK4-regulated
development2
BACPAC
p53/cell
p110-p85
1960
p95CBL
noLCS
juxtapositions
PPRXXP
RhoA·GDP
ICGC_PA69
2010-A00033-36
.Ch
Flag-FRS2
CHD
46/57
TGTAAAACGACGGCCAGTCGTGAGCCTCTGCACCCGGCCC
p.Val321Met
85
sheddases
11AspGluSer
2–49
TCTAGAGGAAGCAGGAGACAGG
Rybp
c.8168A
57.021464
line.KITknockdown
pEG202
Gene-Amp
Fig.10C10C
Bim.In
V600M
JY02
31–89
macroadenomas
pan-caspase
p110α-specific
R774Q
C176F
glutamine-derived
Syn/Seq
20G5
P106H
FOXK2
Brummelkamp
pim-1
homogeneously
tritriated
BAC-clones
pcDNA3.0-wild-type
SRP033306
electrophile-induced
GOPC
otherhand
M749I
vector17
middle-phases
AF170583
-p65
p-SAPK/JNK
SLIT-ROBO
transcription.In
histochemistry
siglecs
Tyrosinasea
locus30•
:1262–1266
s10147
P-9A..I
non-A-T
11,395
DM1A
Bargonetti
HD-0195
46/412
Avet-Loiseau
NCL-EGFR
p300/CBP,3
Ifna
136/138
NM_008548
UV-C
H69P
N229S
c.284G
MOCK-GFP
approx45
Ad-LATS1S909A
lambdagCBFA2
Sixty-one
hyperphoshatemia
c.1741A→G
−1.08
Pre-miRNAs
DKTK
tgt
DyeTerminator
CC.4
.Primary-cell
proposed9
A*0311N
acti­vity
Cem
audiologic
Cozzio
G124-326
D1-negative
serine/threonine-rich
TACTTCTGTCAGTTCACTTGAT
1100delC-positive
F/56
pMX-puro
EZH2WT
rs35932273
S1655F
ALKBH8
Y785
serine/threonine-specific
A727T
p.R248Q
-•
protein-rapamycin-associated
Ras-pathway
instability2,3,4
lesionconsisted
≥85
4084
pre-immunoprecipitation
.ZNF198
Mastermindlike-1
Vaudois
Gisselsson
E-G\
EC7R
36–77
107.
WTc8
113705
D1-driven
.2992
S564
Immunostain
HEY2
receiver–operator
.MedlinePlus
L92P
methylating
.SLE
ofleupeptin
RP5-886O8
A_52_P463340
p.P435S
×UNL
STAT5/BCL6
.∗P
insertions/deletions
B-Raf
cyclinD1
published.20
85·0
−1.3±0.4
NRAS/BRAF
G93S
.VIII
V126G
A607D
SOX17-U-sence
Trr/LPT
R-CHOP–like
Interobserver
ResGen
required.17,18
Yuasa
HSPA14
D57
.0025021
d-score15
A·T
.Beyond
anti-pH2AX
computer-modeling
56780605
Schwab65
examples.10
Klapproth
.Yeudall
delF1263
610860
cycle…
non-brain
anti-ELK-1
1/400
.Lower-right
PPM1D-E472X
MAP2K/STE7
EAY252
www.ddduk.org
BRCA2/8
L503I
SKmel23
vitro-synthesized
activity18,21
F1174L-ALK
Langowski
.ERCC3
D553N
UGC
DBD/BRCT
α-pLexA
N984H
FGFR-pathway
macromolecules1
Thermobrite
T790M-containing
doxycycline-free
Y1248H
D-luciferin
Geneart
xj
extra-axial
Sequence-verifi
.interaction
DN-MAML1-Myc
22q34
network.12
Bethly
DSC3-U114
A1357
.Maurer
lymphoplasmacytic
T319/321A
523–529
Genotyper™
proce
0.055±0.016
219H
hMutSα-shifted
buffer/100‐mm
Germinoma
metallothioneins
236–251
another,8
JWS
pathway,25
0.007†
fragmentswith
T8775
Molhoek
E.R
.Flat
5′-TGCACACAAGCTCTTGATGTGG-3′
12935
Mr∼200,000
bioinfo.ut.ee
FANCJ-WT9
long-distance
'*
PRO-001
pS151
Q801P
0.595±0.33
CRL1651
leads.26
Houslay
180–190
c.617G
≤0.5
CYR61
in3
Aodeshi
Aneuploidization
linker-WW2
H1607
K875
BAP31
1cc
reported48
Lin–Sca-1+c-kit+
DDR-mediated
GGGTACCCGA
Swedish-Finnish
annum
helices156-158
5′-TGTCCATTCAACCCACACCT-3′
bacco
L624/629W
Sylvius
phisms
.T29
KRASG12V/K147L
loop-connecting
3130xl
Schuell
PK/PD/efficacy/tolerability
thymidine-positive
LATS1S909A
acetate/ethinylestradiol
sc-482
P2451H
pcDNA-FS-Cond
Notch1.13
Y35N-transfected
BCATM
5-mediated
ISIS6957
aprognostic
0.160
JNJ38877605
theSCS-containing
asymptomatically
6-FAM-labeled
5'GGATTTTGCATCTAAACAGGCCTCAATCATCTCTTTG3
FU1
RPTPβ
BioSource
Krasnat/nat
11248
1.1-kbp
Shachaf
myeloid
CFU-E/BFU-E
CCTCCTCCTCCCAACAAGTA
*6AK
Aldob
p110δ-independent
10.1182/blood-2007-06-
off-target
Tyr-CreERT2BrafV600EPtenL
SRSF2P95L
1288–1312
L703F
kinase-transformed
pRK-STAT5
g003
DNAse
eosinophil-induced
.81
densi
M/61
.Tet1
59-AAACTCTGGGAATACTGGCACT
shRNA-SPEN
UltraSensitive™
4.29
HindIllFigure
PMCC
muGM-CSF
pERE24k-CAT
Kmapp
S13del2046
2.7-8.8
4TYJ
9,011
JST004556
pBW1631
4-gene
786
14,770
A2210P
SPOP-F102C
Verhoeyen
Kieckner
NCT00932451
Snail1
3572
CR/unconfirmed
355D18
puromicin
C104R
CALD1
allograft-transplanted
narrow-band
5Figure
Genome-Phenome
non-replicating
four-cell
D16S3407-
PAPSS1-BRAF
moderately-poorly
variants43
FLT3-NPOS
PTPN2
Sixty-five
Ströbel
Euphorbia
causal
tetramer-containing
lin-45
32plabelled
bathing-trunk
N223S
.HSCT
DMX1200
thymines
Gly/Ala
22q-
Ile157
level.6–8
DUOX2
UPP1
24,25
59,10
-a_21-
HGF-induced
Craene
58-ACGGGAAACAATCCTTGCTTATCAG-38
YAe
De-regulated
complementary-strand
Culture—HEK293
criterion6
.Needle
10X
activity.51
4,609
Laping
TE-3
92K-
SalmonellaMutS
EX6
GFP−ve
5′-GAGCGTATGAAGACTGAGGCTG-3′
IClOnerlRIrC
G238W
4297
c.3991C
.FUTURE
75mM
PARP2
acquision
G2-M.
age,8,32,35
17/392
C-like
Exponential
immunocompetence
5′-aaggttgtgggtctgcaatc-3′
signaling.32
Arg698
deubiquitanase
positions180
genetic/epidemiological
identified.22–24
S291fs-IG
Levéen
HDR-inactivating
R748
reported38,39
L2HGDH
HumDiv
A/CDK/
Ras/MAPK-signaling
epistasis-type
APR2
Ni7-Ras
NA/NA
Del554-558EVQWK
1,03
50-p.l
R6868
μM
S807
DP12
one−base
.2010.06.015
⩽2
Early-passage
–puromycin
QSYpTV-COOH
Rat-2–
PTEN/MMAC1
G210
.Messiaen
STAG2/RAD21
NSCLC33–35
NF2–Hippo
cointegrator
I629V
DNP-stimulated
reading-frameshift
mid-fetal
A839T
TFAP2CΔN292C430
2I
cluster-dependent
complex.Several
oscillatory
2.8-fold
Gly13Cys
solventexposed
StatView-J
A636
ETS2SASA
5′-TGGGTCTCCAGCCACACGTA-3′
FANCB/FANCL
−80°
SPINF
non-covalent
U12-dependent
.BGB659
G2274V
Y32W-G75V
.CDH1
.Probasin
-1-propanesulphonate
nuclear-receptor-interaction
Smad2185–286
PKC-resistant
activity9
phospho‐Stat3
2⇓⇓⇓⇓–7
42-81
FSC-A
Mero82
ENST00000409454
E–J
.â€˜w
-171
MYC140
RARS-thrombocytosis
p.A113
peri-nuclear
p.Gln419Lys
19KB
Leu118Pro
rs5762795
.ChIP
thanWT
sc-8330
eJM
age.7
rfeisâ
superactivated
13/32
p.G469E
ETV6–JAK2
CDKN1B-R2R
.Concurrently
90H9
Wykosky
phytohaemagglutinin-
DELTEX1
anti-myc-agarose
drug-free
.A.P
chloride/1
.including
AML.38,39
15N-BCL-xLΔC
RDD
EGFP-CARD11
2ERE-TATA-CAT
18F-fluorodeoxyglucose
Hereto
ow
stress/inflammation
-HRASp
beta-SANDWICH
P.V834A
guanine‐nucleotide
R469I
46479
pro-caspase-9
Tumor-
Di-amine-benzidine
.BAbCO
21/36
G2A-XGR
426–436
V600E-containing
non-hemoglobinized
STRN
1:1765
Carretero
BCL-2–like
punctuate
basolateral
Wap-Cre+
directly32
0.0419
57.1
NimbleGenSeqCap
sequence-validated
C314-C390
PO1HL54785
N104S
mice,46
multiparallel
hinge-like
1:3200
paraparasis
HCC366-DR
D25V
RTE/CCD
models.11–13
R11
Jean-Louis
±spine
Grb2-dependent
3790delTCT
9.43
ETV4_exon7-r
PPP2
n=482
E.C.J
domain50
interlaboratory
0.051843002
responses16,17
0.9-3.7
histo-pathologic
ERCC2
L218P
Ltd.Keywords
3a–d
.2A-B
theliterature
Kruppel-like
.Tissue-specific
genome.ucsc.edu/cgi-bin/
c.2207A
non-SCLC
Anti-CARM1
MS/MS
0.00005
SCC111
CIC-DUX10
cyclin-Cdks
gby
175.21
PIP2,3
'half-site
33.L348F
L518fsdelTCCinsA
IFN-γ/STAT1-signature
Presumptive
p27V109G
eight-generation
GAAGTTGTCATTTTATAAACCTTT
pET-MTS1/ΔΔ9−1441
V559G
0.0013
Amplicon24
type-3
MAP3K19
non-RAF
BRAF-T241P
KYSE270
23/315
homodimeric14
Smurf1/2
FHA-phosphopeptide
receptor-positive
sequence-nonspecific
Cdk4D175N
proteolyze
coeluted
CL6
20,448
pmGFP-H-ras-R161A
region.Although
AAAGTG/gtaaat
wt-GISTs
Amp-Mut
Ile1171
methionine‐free
EGFR-E804D
mTOR-FKBP12
TÃŸR-IIor
2methods
migration38
QColor3
.S8.2
Bestor
incision-defective
.Titration
Neelsen
c.1375T4G/
..05
interrogating
X-genie
withoutmutations
adult4
trk4
Vimentin.1
Tattersall
PTPπ
PIK3c
ErbBs
V71I
adenocarcinomas11
normocellular
PD-
tamoxifen-resistant
175386
immunosorbert
colleagues8
pnas.1321155111i13.jpg
TG517733
.Parallel-transfected
H3K4me3-associated
64–69
70.38
m5CpGdotTpG
SmaI–XbaI
LINE-1
.Genomics
F/58
lines26
//doi.org/10.1371/journal.pone.0032451.g004TG101209
intralesional
cisplastin.54
TGFb-RIIfor
GGACCA
AML1-EAP
c.1117G
StemSpan
20–22
Zhang2
.Couch
YXXP
intron10-exon11
figure1.1
immunocytes
anti-TopoIIα
lymphogenesis
T2N1M0
hetero-oligomeric
75.30
oligomerization38
lines.10
insitu
P=0.537
system18,19
NanoLuc-encoding
H193Q
CA46
BRC22
11V560del
.Completion
Ovalbumi
25/133
Rearrangments
PKA-presenilin-GSK3β
NTRK-related
pBR332
N-KTHEIEIKNFKPSPSKNKGM-C
AMML
//www.softgenetics.com/
Boehringer-Mannheim
Peretto
Tumorgraft
62Â°C
prognosis—nearly
Leu932
INHIBITION
ΔM1
radioresistant
774insH
59-AAG
.Transgenic
inter-connectedness
analysis./2-A
FOXA1-chromatin
Oligomerisation
960
.Nilotinib-mediated
mÃ©tastasesof
S/TXXXS/TP
.previously
IVnLLGaCThGg-PVLV
toΔ
970-bp
TCF/LEF
AB3786
Sambol
5′-TTGGGGCTGCGTGCTGATGCTA-3′
data16
intratumoural
67/117
G117
dichotomize
12q14.2
screening.12
128,831
oncogene-targeted
ectodomain
Rearrangement
DED-containing
6.161
3XFlag-tagged
5′-CTTTACCCGACTCTTTGAGCCCTGGTCCTCTTTGC-3′
CD74-ROS
small-molecule
HNF1A/4A
6,25-29
K263E
antibody-related
F317L
.Inhibitor
NFATc2
D.M.L.
.NES
8/30/96
EUFA689
superenhancers
AhCRE
LUCaP35
heteroduplexcontaining
CODOX-MTX/
dyssomnia
authors.6–8
C619Y
20-70
Chaikuad
Ig3
NTG
Serbp1
staurosporine
Met477
10,000×g
0.127‡
6,874
-AGGTGTGGGTGGAGTAGGCTG-30
Bric-a-brac/Tramtrack/Broad
25×109
FJP
SJHGG099_D
classifiedby
c.693G
p.In
47/90
CCAGGAGCAGCACACTAC
cells/ll/cumm
909–20
p.Met567Thr
N2113S
CD41-positive
stress-responsive
Task-dependence
staurosporine,21
kinetochore-binding
cross-trial
FLO
α-T7
Dicer-proficient
stage59
AAL
MTA1/HDACs
on-chip
SCFSlimb-mediated
−4.48
200/nl
2,5,45–48
158K
Upper-shell
BspEI
p.V1190M
RAG1
pT4N2M0
ENDRB
FC82291
C697Fe
PTENs
NSG
BRCA2D4
ofandrogen
ca-3′
SUP-M2–derived
forsequences
Ebk3
c.134_151del18
insertions—were
classes10
ERBB2-mediated
.Eukaryote
phospho-MAPK
47483653delTCC
v0.52
BcorFl
immune-cell
cherubism.41,45,46
ThrArgAl
S.V.T
.Interrogation
α-Smad3
SectionResultsInactivation
nucleo­
Ser463Pro/Asp538Gly
−0.1588
HAERK2wt
Mesylate
dimerization.58-60
t'~
B2-MG
SNRi
G-quadruplex-forming
prostaglandin-endoperoxide
NdeI/BamHI
Dicer1.13
complexformation
76
GAL-TEV-myc
dasatinib-resistant
BF3-methanol
244K
-test
PKA-
.Insight
regimens.128
avidin-coated
HCC1937+BRCA1
primers.11
Myc-induced
A_51_P510782
NCT00588770
Cys685
ReIP
1003263
R724H
quency
CBFβ/PEBPB2
33:1576–1588
1.93–21.25
C1477R
ReadyScript
R01-ES13160
NGP
0.01165
1–41+∆
.2,4–9,38
5′RsaI
glioblostomas
.MAX
del2352ins12
Thr202/Thr204
γ-irradation
2,668
54/102
7271TrG
Vivaspin
A265D
Cyclohexamide
three-exon
endofree
Sα
gliomas,8–10
1qcf
RhoA‐GAP
p130CAS
2-antibody
9649–9654
carcinogen-and
.PLC-γ1
.Dyskeratosis
No.sc-7985
GRR5
Enzyme-linked
254890
.Can
assays35,36
STAT1/STAT2
Andjelkovic
Arg145→Trp
6q14–q22
8.071170875
421.60
activin-inducible
JNK-IN-8
Wen-Tao
13108
10IM1
0·08
ABC/GCB-based
SF3b/SF3a
atomic-resolution
P86
JMD
V+PI−
there­
HNSSC
no.740609250
TGF-β-inducible
spastic
cancer73
3at
.Catalysis
encouraging.10,11
5′-GGGCCATTTTGGAGAATTC-3′
betaglycan
134.Arrows
12.1+2.7
p21CIP1/WAF1/SDI1
Smad4f
Immunodetection
.Statistics
V235F
HCV-29
early-committed
.IL-22
.Cytokine-receptor/JAK-STAT–mediated
R/K-ϕA-X3/4-ϕB
99.91
Brca1Delta11
3OLys
S541
POLE3
EGFR—cetuximab
optiplates
oncogenes.15
meta‐analyses
α-Trr
pGFP-V-RS
Sugen/Pfizer
sc-20357
dysplasias
.9
D1226N-2
3′-JAK2
5′-ATTGCATCAGGCAAATCAGC-3′
HEK293-derived
9402
p89luc
S243C
0.01.4
Walldorf
Kohda
sc-8338
Fig.55E
20p12.2
p.Gln624
coil.19
EnzCheck
B8.6
.78
DNA.16,23
Asp835Asn
more49
pool.2,3
Kainu
D–I′
outcome.13,20
Gi-Dicer.13,14
~7
Y.-R.
G855-E730
centromere/kinetochore
Hep-par
5′-CCATGTTGGCCAGGCTAGTC-3′
Classifier,28
HN-PCC
5p-family
.No.andReported
Asn546Lys-mutated
IDHand
Ig-like
K72E
rat-derived
Duolink®
anti-caspase-2
p.R525*
.Egan
.Anti-EGFR
AAACGCTTGAAGAGGTCGGAG
Nu18/3
K14-Cre
M73
time,20
E167D
.MPL515
5p_strand
coli.One
35S-SPOP
0.223
spectrophotometer
dermatologic
multi‐points
TNFR
Tricarb
ALPS-FAS
Figure1H
21284
Drg
340STOP
l0-bp
Liyanage
*minus
Hep
//www.pdb.org/
Translocation-1
MBP-NAP57
patient-1
production.
p85α-
V667M
1145G→T
transcriptome-based
www.genetix.com
short-segment
serrate-like
doi:10.1152/ajplung.00147.2006
Ile-332
short-formsplicevariantof
methodsPatientsAt
OCM-8
.Asp792
1–2374
knobs-inholes
ERK-signaling
closed-loop
.Blocking
A36V
co-activator
Card11
22-40
receptor-generated
anti-H3K27Ac
SCP1
17/53
MIPOL1
terminal.1
PDCD1
7S1
nature.comOncogenic
c.G1276A
c.1976G4C
PCE
5′-TGGACACCATACTTGAGCAG-3′
Fioretos
114F23
c.4136C
V13241
tyrosine-dephosphorylating
RaJ
p.AXL
24h
4EB-P1
CACAATGTGGTGGTGGGATA
1·1–28·0
.BRCA2-associated
10/13
HPV-associated
.Prism
ANK4‐6
p19
Murea
003000
HNCACO/HNCO
42.9±18.7
SOX17-mediated
data34
NM_000314.4
2334
β-catenin-Tcf-regulated
ETV1-regulated
∆663
DR-GFP/wt
53–79
heat-inactivated
102–789
C..
34/38
ECD2
J.L.D
pRB-unrelated
aPKC-ι/λ/GLI
Aiti
phospho-MEK1/2
1.629–2.455
GVGD.12,13
Antigen-induced
cotranslated
perinucleus
glutamate-arginine
neu-
wt-like
4-alpha
daftons
leiomyoma-derived
/GTNAC
Poly-X
immunolocalized
NF01585
Mac-1+
.CDK12
5.View
amino-acid–
immunohistochemistryThe
0.231
SOCS-box
V816
3C7
R-Phycoerythrin-labeled
melanosomes
celluler
GAG|GTAAGG
mice45
anastomosed
L148F+DNA
11/78
5′-GCCAAAAGCGCCAGATCCAAGCA-3′
LSAB-2
–Significant
5¶-TGAGCCCAGAACCTCCTTTTTCTCCAGTTTC-3¶
.HN31
H178R
Miyake
37.9X
IPOFG
cov
CA15-3
Papadimitriou
mitochondrion-mediated
NCT01064479
Tyr-21
G466
3.3.2
:g
.Immunoprecipitation
1–43
pS6-kinase
pRL-SV40
CGCCATCGGC
38654432
mamilar
Supermixes
malignancies,24
312–595
humans28
intermediateamounts
erythematosus.20
al.34
ACAGCGCGCG
p.Trp1178*
patient-centric
NC_000003.10
EcoRI/PstI
A170D
previously54
serum-fed
samples19
103.9°
J.A.D.
342-bp
vitro-reconstituted
200-500
N294T
C-FOS
2.7M
tumour-enriched
359T
5-GATGGGTACCACACATCAGGTGCGGTGAAG-3
surrogate-kinase
UC.3
B_R353
8505c
2B-E
mmo/L
A1978
GAL4-Elk-1
treatment32
of102
F448L
PGMY09/11
48,49,50,51,52,53,54
Vatalanib
.Ins
.ANGIOGENESIS
20,71-73
p300-8A
LC-2/ad-based
K57R
G339R
Neurofibromatosis
SmadS
CtTSC2
heat-mediated
ETHYLENE
8.1292385
MAPK1E322K
2/109
Θ
DEB.41
Ad-LATS1-infected
Soldano
SMC3
96:922–926
v-Myc
-chain
D530
13III-3
pCRXL-SRC
tocorrelate
0.21–0.96
G40L
eleuTh
BIM79
deoxyinosinic
Quiescent
/AAPC
S/Ff
Struski
Non-Hodgking
NovaRED
Asn113
benzyl-dimethyl-alkylammonium
Carpintenia
102-10-01
ErbB2_ex17-25.SR1
IPA.
Ultraviolet-light-induced
5′-ACGTGTGGTGACTGGAGTAGC
MEF2C8
SHCRaf-MAPK
Souroullas
P-36931
described58
Koshigaya
A14
over-treatment
R413
1763C
3q26.32
5′-AGATGGTGCACGATGCACAG-3′
S3KO
TMEM65
mMSH6
orf
24784
.HRM
14/15
xx
medium/10
Fivemicrometer-thick
0.0686
TSTEPQ-pY-QPGENL
V842
PDGF-Rβ
RA-pathway
Ubiquitinated
SH3-domain
RP11-383G6
imai
Alk-1/Smad1/5
recombinase–encoding
hematopoietically
Ngo
germline/constitutional
KRASE62_A66dup
Dijkers
129S6-Taconic
p.Lys117
width-to-length
Clapéron
210-base
multigenerational
SNU-668Genes
1074Mel
anti-Rad51
216400
S419L
KrasG12DPtendel
W146Stop
randomization
SHP-1/2
H\
R17217
approx50
MuTect46
TSS-1
118/290
I278T
-48a
genes.1
Tris/EDTA
RPT
CONCLUSIONS—Resistance
85-kDa
non–KIT-mutated
FastDNA®
FancL
RAF-
34/52
MK-0457
4071–4076delC
leAspAspl
2,825
anti-Thy1.2–PE
de®cient
c.2959C
tetraploidity
CD40-CD40L
death28
SILAC-based
N593S
Minguez
TEL-AML1-associated
path~ay
.VHL-null
adverse-risk
.Immunolabelled
c-trk
p.A1200V
4Av
MEK2-knock-down
variants21,22
OXY-innervation
motif.The
thecomplex
Wickramanyake
188.7±123.3
ClustalW2
LADGSGESRVAVKTLKRGAT-DQEKSEFLKEAHLMSKFDHPHI
TMAC
R413L
–AKT3
IGtranslocation
Inresponse
Polymerisation
G308E
DMEM+10
JH1–JH2
Lats1-KD
Arg428Ser
gastro-gastric
TÃŸR-IIkinase
101,102
BRAFE600-associated
S588X
HNSCC-MAPK
NM_006219.1
KIAA0780
K751M.14
42.54
Chesnay-Beauregard
PALB2-binding
repelled
Ngn3
P.L833V
5'-GCATTAGTGTAATAGAAGACT-3
GST–Hiwi
YAP1-MAMLD1
Rag2−/−immunodeficient
0.0081
Lys-128
NADP-binding
projects.19
5.5kb
WrightGiemsa
Tyr1258
rhabdomyo-
2.22×105
179-182
Ponce-Castaneda
1A7
42/160
real-valued
//mcr.aacrjournals.org/
imatinib.12-15
Y43C
c-MYC,34
Jouan
non-hypoxic
toO*
7,935
1.129
Flag-Chk2
c.1420C4T
4460
p.S425I
E707K
ura-3-52
Pathaan
ketoacidosis
Akyerli
B*3703N
.-M
incubatedat
–2/+1
MNK
transductants
4980
13.6–31.6
Cross-linked
I|lhi
CEBPE,10
IGF1R/IR
RNAprobe
EX18
D106A
C*05
BAP1-Not-R
PT3003–1
.Educational
hCDC4-negative
R60S
Mazzoni
glutamines
Cannon-Albright
parameter.32
Centriprep-10
TM4SF2
Pten-loss
PRDM1.5BR.F2
ototoxicity
c.5789delT
3BTL73
SPO13
UC7
γ-tubulin62
.R26
458-1G
Moi
V10.1
ligands25,26
RMH2444
-D3S1277-D3S1298-D3S1289-cen
.S25B
R26G
AIRC
Geriatric
PPH2-scored
alter­
.Fish
Com-
MSCV-IRES-EYFP
medi‑
.Itk
0·5–3·0
3′-fluorescein-conjugated
myc-Overexpressing
ELF3-mutated
mutationplays
cdk-cyclin
E26D
7403-1
TTTACAGlgtgagcaa
ERK-binding
M298T
SIS3
IVS5
//www-huber.embl.de/users/anders/HTSeq/doc/overview.html
mis-repaired
nontranslated
D12-L1
W586
GSK-3-mediated
opsins
EGFR/pY992
SVT
overexpressedAKT2
5.808
p-S6P
MUC6
PORCN
p21waf1/cip1
AACTACCTAACACAACCTAAACAAA
MPLW515L-
459
Balb
-191
factors1,4,5
1,996
WTmu
Swenson
PRK
1,691
Fig.1b
CXCL9/10
.Cleared
025
2,032:1
−80.4
4/131
1.30d
force-shifted
.Here
4-year
genes6
NP7.50xxY
conditionstherepression
NR2E1
J.Z.-R.
GDLM-7
Parsam
stability.7
2-hour
LVSSVAPSQTR
0.000205/s
ncou­
agar/DMEM
135.6–135.8
curve.37
C84T
phospho-p70S6K
Receptor-Mutant
Prudhomme
C1619S
Delsol
Asp8
Erimodegib
E2Fx2-
H1155
NBL2
morbidity/mortality
non-hematologic
5'-GGCCAAAAATTTAATCAGTGGA-3
anti-p110a
T-PLL,13,26
1B–D
B′-γ1
13—26
.Inhibitors
Tcf-3
ofovarian
MCD-related
97-55,97-64
pyrazinyl
MEKK1/MAPKKK1
KrasG12V
PIK3CAI391
I538/540V
gaaagcagccaatgggagttc
FLAG-S6K1
Drip130
p.Thr58Ile
Martin-Coignard6
BCR-stimulated
phospho-Raf
6–1127
1708E
OCTcompound
Nemoto
MI-219
GST/TRK-T3
anti-phospho-p53
1L0B
V/960
ZC3H7B-1714R
SLIIB-CAT
tumorsuppression
⩾0.68
22-89
-RA
Ser-144
PvuII
Therapy-related
Ser335
Zeptosens
FLAGBRCA2–expressing
56/79
Wildtypec-H-ras
JB6
.Paxillin
Saos-2-ts
p=0.076
cdd470f6
0.9434
α1′
lines,16
0.68–1.61
NCT00513435
cancer.30
//dcc.icgc.org/
5′-CTTTCAGCATTTTGACGGCAACC-3ʹ
CRAF-S621
1988,1991
rs5443
Dosztanyi
Heilemann
WTBRaf
1.07205
NCT01255657
lineage3–5
12/1/99
Diode
systems,13
nicotinamide
NCT00838539
SQVIFCN
pFastBac/hMSH2
SNP6
33358
PA1-46189
IVS5-31
5-GCA
JIP-1
N°2
K-M
.DETECTION
E17
Rajasekaran
IBGC4
Hyperactivity
early-Pro-B
pV2
shRNAc
offtarget
KATP
EUFA223
TxN3M0
six-residue
Myc-Chk1
milk/0.2
R16C
p71l
36Two
CDKN1A/CIP1
Y13-259and
H3396
5-butanoate-1H-2-indolyl
Elf3Δ355–363
sensitivitythreshold
Nkx2.9
photographing
123709
rs17290699
N1156S
I114A
Aberrations—Chromosome
Stoichiometries
pancreas.7,8
mammosphere-forming
propridium
.Sex
1.5.0.3
Tel.
GIST-bearing
1p13
non-gain
4′,6′-diamidino-2-phenylindole
hematopoietic/lymphoid
rs187037
5037
trans|ormation
Hyperpentaploid
.502
Immunoexpression
33433490
4×105
events97
V21
BRAF17
IPLEX
.Ercc1−/Δ
p.R856H
sec–1
22°C
Patarca
Gln-61
KDM5A-knockdown
2-class
gel-excised
HMPS
programmes27
13.0
Thr321in
15-nucleotide
J.D.
-signal
Q1258
Thr334Ile
Inducible-shRNA
BEGM-Bronchial
interleukin-1
N486
publication45
NPV-BEZ235
Kutay
RB-positive
150-400
3897
32P-ortho­
anti-Cdc37/
Erlangen-Nuremberg
post-surgery
K45
Flag‐Mga
A72S
0·9–71·0
.Conclusion
susbtitution
PIK3CA-overexpressing
23-91
Cdc20
94-bp
F7-R7
c.2368A
mRNAs129–
.CIC
0.470
effect.2
BioVision
1–7986
.Polyclonul
models12,25
5I
-naïve
V600E/L505
Ceffs
WK557-8
p.G598V
accumulation159
10.73±0.54
rates*
Hs01013371
treatment.1312
euthanized
fluid–derived
CUX1
Tumor-related
ethnicity-specific
basal-like
rearrangement.9–14
DNMT3Amut
Wnt-b-catenin
Rho-activated
exoribonuclease
inpCDNA3
Tyr15-phosphorylated
NT218
alterations/deletions
Cazorla
40/555
1828
-18A
.Artifacts
—and
.Leukaemia
enhancer/silencer
Vi-Cell
NEUROD2
5′CTGATTTGATGGAGTTGGAC-3′
AT13387
16918653
PvulI
CEBPADMDNMT3AWT
5B1
α-carbon–radiolabeled
approx90
Prom2
animal-based
1.21-kilobase-pair
yij
DDDR2
0.247–0.938
cysteine-scanning
5hrs
2341C
FLT1/VEGFR1
Akt2-expressing
4.2–5.8
oligodontia
3.5∗
96/160
H3F3A/ATRX
glioblastoma21
SID
GFP/c-kit
F379-K380
cell-acute
ABC-DLBCL43
ERBB3-specific
Lats1+/−
sm-κ
cytoreduction
5–209
p.Gly174Val
Mutants.The
EH4
CA016087
ARID1B-mediated
170273
Y1728C
22/42
outcome5,6
44/M
growth.40
655
.Plasticity
rst-line
5′-ATCACACTTTGATACAACACTTTG
DEseq
domain.15
HuP-T3
debate81
T710insD
2.3-fold
.Morpholinos
Fusion-associated
Anti-phospho-MEK1
non-activated
253-
pAMC
OTg
S10N
M12835
DMEM+0.5
.Macrophages
anti-pThr-389
25×106
Mäurer
Medchemicals
Genetic-locus
IκB-α-M37K
BII-3*
-18q
Myc–Chk2-R145W
pathologicalcharacteristics
5548
midexponential
17302
DPN
Smad2Δc
pseudoalveolar
11p-terminal
samples16,17
−+
c-Cbl.15
degree-affected
1–231
directly35
immunoThe
unconstrained
181K
pCH110
MMP13
inPBS
5′fusion
candidates6
Caspase-8/dominant-negative
0.1544
Aspc
CD86
Jak2V617F
Ethylene
Cn3D
wtEGFR-expressing
wellspecified
GTCAACGCGTCGGACTTACCGC
PCC-causing
J035
homeostasis73
Lamant
1.127
8326-8337
gastro-esophageal
GSE66793
Rost
Hochegger
SD-1029
army-worm
174-176
Krüppeltype
48109-0602
TACCGTAAAGCACGAGGAAGC
FA-J,5,6
protein-α
184352-resistant
NCT02296112
assays.25
*Chi-squared
.MDA-MB-231
NM_006218.2
.Structure-guided
domainmutations
MYC151
JC-8
IL2RG-JAK1-JAK3-STAT5B
MS1081
'9
Sub-group
8G7G3/1
ina
Wickremasinghe
//doi.org/10.1371/journal.pone.0019059.g003Metastases
12.4
Express-km
SNAIL2
Gasthuisberg
DOG1−
LGsGAFGtVYkGi
19943
89A
pathway-dependent
.Stratified
ZR75-1
BWA-SW
3.86E10
AOM
1/7
inXuence
Lipofectamine™2000
signalling19
study44
3324
Anti-ras
de®nition
lane2
1–3,5,6,8
H115
5.37
Belhaj
c-Jun
PolyJet
A_51_P253803
anti-IFNg–FITC
2Of
mixed-phenotype
.G328V-ACVR1
Tomography
Non-targeting
.Quantitations
dasatinb
Akter
BRAFV600E-bearing
Hsc70-interacting
ERK9
radiation67
RAS-mutant
dbh
53+/+
chronologically
proteasomic
rhodamine-labeled
CpG-methylation
:3152-3155
K−
CD77
six-E2F-luciferase
685X
7465
65.87
Sonicator
setting.22–26
D835N
14.60
performedboth
hyperproliferate,13
MDACC
de-SUMOylation
complex33–35
antibody-linked
μg/liter
A775YVMA
F133C
E1085K
~10
pCMV6-Entry-RAF1-FLAG
Ipl1/A1KM
K22M
mismatchcontaining
NFkB2/TYK2
0.05a
insulin/insulin-growth
Complex-1
AspGluGln
Imatinib-resistant/intolerant
≥1.5-fold
71.2
poorly-
r.p.m..
E038
NCT01524978
related.
L1017
D.S.-L.s
ab9
AZD0530-sensitive
FFU
HECT-type
J.C.
Escot
5.4071
EDNS
TTN
interactextensively
95–99
negative.2
0.935
8345525
let-60gf
Albumin
N33K
137
cells.109
R.Marais
EGFR-SEPT14-positive
glutamate-threonine-threonine
hodgesak
ACTGACAGCCTTTCCAGCAAC
4,6-diamino-2-phenylindole
1612-bp
biomarker-based
S577F
Homozygous
HEK293-expressing
G560
LCH-59
CAAGCTGGTTGAA
r.791_884del
CDC42/RAC-GAP-RAL
p.Arg303His
0.0098
fgf1
1:000
pdgfa+/−
Δ1–33
3,596,585
FO-Iclones
LFC
1.53-fold
~40–50
adenine-like
pod-rtTA
cyclic-AMP-response-element-binding-protein
PRDM2
-1775
anti-Ral
time‐dependent
PtenM3M4
+EGFR
switch-I
IGH-rearranged
V32T
alvaro.galli
2/500
F-helices
13.8
−507651
Showa-ku
RTCGMFVYSPVSEPEPEPEPEPEPAR
transcription1
eIF4E
E47K
Q1500
1396
RR2
p53-speci®cantibodies
B220/CD3
c.5509T
JAK2-dependent
de-ubiquitinating
coiledcoil
cyclin/Cdk-like
non-cancerous
kcat
protein–type
Rho–ROCK–LIM
IDH2-R140Q
BLIMP1-specific
H526
15.1
K562-BIMi2+/−
9467
Lundblad
ScepterTM
c.82G
F1•
M253
Figure9D
hexamer–reverse
non-V600E
tumorigenesity
β-TRCP68
ASP12
.CPP-ACP
CD19+/IgM−
sporadictumors
D116V
Hoechst-Marion-Roussel
post-non-Hodgkin
Lubahn
mesenchimal
0.523xLxWxW
169KB
PflMI
GISTsPrior
/TAD9
stabilizingthe
ADH2
profilingCell
Glu682
L192F
Herschkowitz
Val-659
FAK-A612V
NGF-receptor
NHbond
5′-biotin-TACATGTTAACAGTTGGTAATCTGCA-3′
endA
tumorMRTmalignant
Skotheim
Adenomatoid
.Weak
Raindance
thatreported
GST-ERF
–skewed
ALN/SAMSE
c.827C4A
Pentapeptide
BaF3-MPL
Me18105
2008-02
Zhu,1
myc-ARAFR52L
TCACCACCA
Arg631Cys
F876A
CTM-9748540
292–766
1075–1142
three-staged
outlier_smoothing
.Ruxolitinib
−24
CD34+CD38+
Asp→His
E1318G
Reinstein
Hypothetically
Arg87Trp
160K
2IAE
meprin/A5/PTP
TFF3
microarray-based
Chakrapani
tetracycline-containing
ActR1B
BAY11-7085
diminutive
auratus
spiegeldanio
H262R
SW480ecoR
Ser371
V-APC
four-year
.553C
.Phenoytpes
G233D
GCB-DLBCL.6
Z-VAD-fmk
thymopoiesis
ALK1464STOP
Thr-Gln
SHOC2
HPGL
M-14
46XX
DLBCLs.35
I956E
-o
Cal12T
Brca1Delta223-763/Delta223-763/p53-/-
.Characterization
3e–i
1.39–2.83
24.8
Dictyostelium
3-meT
patients,31
10.1002/cncr.21996
15,344
improved.9–11
MODELLER36,37
DNA­WORKS
PHOX2A
theNTRK1
5′-CTGGCTGGCACCAGGGCTTC-3′
five-log
characterized.22,24
ALTnegative
v-Ki-Ras-transformed
Prx
SEC31A-JAK2
HCC1937-BRCA1
LexA-fused
2–29
dimerization-impairing
frame-
E6.5
0.11
p.R399C
TAL1–LMO2–Ldb1–E2A
Ohlsson
.E497D
Flag-N-CMV6
.MM1
R-356O9
RevertAid
ofATP
Y674/675
320DM
gp140
recur
six-marker
78••
T3M0
GAAATGCTGGACAGCGTG-30
not.28
MPLS505N
JARID1A
Krymyskya
P81S
TÃŸR-Ireceptor
Trp55
anti-Oct4
NCK
ATP·Mg2+
Mpileup
Fre
HA-27B
Kbp
A‐loop
NS8
cells55
~87.16
Giebel
stabilisation
gastrointestinal-stroma
GGAATCCTGGAAGA
E28X
stick-and-ball
GACTCGAGATGAATAAGGGCTGGCTGGAGCTGGAG-3′
ratio=1.66
esophagogastroduodenoscopies
PSMD7
NTRK3-directed
iodogen
GILZ
stabilization42–45
c.4971delC
US/7500
EGFRvIII-mutant
dl−1
2399–5711
Met1Val
Mx1-Cre+Srsf2+/fl
F161C
S568G
Reverse-iT™
HSC2
ste5Δ
G-protein
Pocket—To
3-aminopropylamino
~~~~~~~~~~~~~~~~~~~~~~~~~~~
.β-catenin–mediated
NBCCS
Talpaz
650-225-6497
mechanisms.28
Arg357
2A
RAD51
CDKN2D
UbcH5
mÃ©tastasesindicates
mono-ubiquitination
ALK-validated
pan-specific
R570Q
30–1390
p53H179R
parabrachial
.Leu910
​and1B
Fugene-Roche
trk27
Asselain
//exon.cshl.org/ESE/index.html
dual-probe
106/mL
ITDNPOS
promoter-chromatin
I27L
mesangioproliferative
Rho-associated
SHOC2–RAS–RAF-1–PP1c
S392
Kolling
Progenitor
p.Thr95Asn
re-biopsying
anti-H3K79me2
Cal-TBCC
D19MIT41
,34
pre-designed
M522V+WT
Asp-1840
R18H
leukaemia2-4
FANCC-transduced
T191M
Ptch-mutant
FMC-Bioproducts
17q25.1-25.3
CDKN1B-R1F
Lys1775
6p
–16
pCR259-p53WT
E2F1-RB
E490K
IKBKE
Tmprss2-Erg
Shin
Y32Wa
PMS6
tubular-villous
Damm
C57BL6
pdb1BI7
.Cyclin-dependent
Amendments–validated
Glutathione-Sepharose
T260R
CCGGGACACAAGAGACAGCAGACAACTCGAGTTGTCTGCTGTCTCTTGTGTCTTTTTG
D-helix
provement
S5D–E
N-methylanthranyl
BRAF-MEK1
trans-dimers
2.42Å
D382E
93K
OX40L
agent—the
5.89
Conclusions.GATA3
spindle-checkpoint
CRC-related
OAW-42
IDH2R172G–EGFP
CRL-11268
D9S1853
AML,6
Maeshima
Autocatalytic
Q2148E
leukaemia188,189
p.E1193K
IL-22
UKRV-Mel-2b
respectively.PowerPoint
myelofibrosis.9
Pre-capture
1278–1928
9GluA
1,091
R341GfsX15
ÃŸcan
TGGTTGTTTTTTCCTTTGCTCTTTCCCC-Tamara-3′
signaling/regulation
.Urokinase
//genetics.bwh.harvard.edu/pph/
5′-CAGTATGTCCCCATGCTAGAAGGCAAAGAGGTTTCTAAATATTC-3′
G90E
D1739V
CCAGGAAATAACTCTGGCTCAT
p35–36.1
BLUeye
4654G4T
non-intestinal
Thc
anti-Cdc42
5′-AGCAGTATGGTAGCTCACCT
INI1-negative
NMYC_01
invitro
F312S
insertionof
Phi29
Upsate/Millipore
0.175
IL-11R
Trx
−6
HDC135
cycD1
BCL6–
54/65
family.9
inactive/poised
JB12361
differentiation.Targeted
P30
ependymal-abundant
.Anti-phospho-CREB
'angiogenic
RRM/RNP-CS
.Busslinger
W.X.
GFP-Elf3ΔN270
Brigham
0.699
Asn80
cdk418
FA-41
L191
6556
Lowgrade–
water-mediated
bioanalysis
lymphocyte-speci®c
.Fifty-fold
Cdc25c
.MYCC
unsynchronized
phenol-preferring
ultimobranchial
`two-hit
−6.04
FGF2/heparin/FGFR1
NruI
type-specific
substrates/targets
Chaperonin
10-point
componentT1TP53
8-h
/1JSP
and33
P-LC27
QMVR
P=0.138
Kühn
gbAF010404
12/26/02
D298
deletion.Figure
αα
strategies,13,40
.Survivin
F161L
4173
1:2500
Gy/30
R283P
ifBCR-ABL
.Routine
NM_002412
5′-TGGCCGCTCAGCCTATGAAT-3′
5′-AGGATAAGCAAATCCCGAGG-3′
ETV4_exon4-r.
4Fig
617-735-2050
12+NGF
Notch1-6
-CCCCCCGCCATGAACTCCAGCAGGATG-3
genes—disrupting
phosphorylated.3,7–11
Biotechnolgoy
HA-NOP10
L76568
.Shuttling
p84H
GloMAX
dispensable
EWOG-MDS
S140G
.Comparisons
6/64
.-Tubulin
401-800
D1399Y
I570V
CT−
gelatin-containing
Leu-263
.Xrcc2−/−
www.ncbi.nlm.nih.gov/entrez
Tables22
V1.14.23
regulationEssentially
.CEP85L–PDGFRB
ER-like
anti-mdm2–monoclonal
97239
.Cetuximab-resistant
FLA-7000
c.492C
M61
proteins.53
.Slit-diaphragms
Hs99999905
25398285
ZC3H7B-1649R
CCGGAGTCATTAACCAG
kinase-B
TAL1-dependent
motifs.1-7
NMU-induced
9254
degradation38
previously37
tga
uretral
Z.-K.
AT
45th–50th
C.J.
phenotype15
DNMT3B7-induced
colleagues.20
two-class
N822K
ΔN-BRAF
GAGAAACTGCACGAGCGGGAGGATGCCCTTG
EN-IRS1
HLA-A*2411N
A928V
months.5Imatinib
L2028
ST-HSCs
line36
NcoI
MDS/AML
VMEG-HYD
.Constitutional
337–415
modules87
Fotsis
AR/mg
Esthesioneuroblastoma
L405P
β-N-acetylhexosaminidase
glutathione-linked
dual-phosphorylated
c.1477C
MC4000
SK-LU-1
non-PI3K-mutated
Stemmann
Multtest
thalassae-mia
analysisFisher
Cryoprep
7p15
Wamstad
62–75
.Disulfide
mRNAA
0.9–1.8
Sox9Ubiquitin–proteasome
STE7
Colo678
uncommon.99,100
FXFP-targeting
αc-helix
64-6
kegg
P333L
portal5
ABIPRISM-PE
'aR
V143A,8
//us.expasy.org/tools/dna.html
error-prone
F-Measure
0.919
long-form
6.67
21,24
G-streptomycin
1084
pGAD–ROCK
ab41898
localization/transport
p_BABE
96-292
lipoprotein-receptor
ZFPM2
PIK3CA/CEN3
Cazzalini,1
XP_001084190
TCoffee
.p85α
CCCAGGCCACAGACTGACA
627.6
.ROMA
.FLAG-D4
△△Ct
intra-renal
publicationof
20bp
AR3
.Th
p110h
SNUPN
DHEA
DDLS
treated=0.152
4280
Bar-Sagi
32P-Labeled
.PLO
P-GCA
anti-CD45R
gi:102470225
Ayyoub
Wei9
382/1,363
G143E
MICAL3
Optiscint
648
Mef2a
keratinocytes.17
HRAS-selective
AlphaImagerTM2200
subamplicons
Cbl−/−
al.,22
hsp16Δ
130140
comprehensively
903e6
angiolymphatic
Hybond-ECL
orantinib
s-
SphI-linearized
A72V
ulceroinfiltrative
TEL-PDGFRβ–transformed
notexclusively
50-µl
Ser/Asn
figitumumab
normal-mode
Rationalizations
203–205
p.Ser241Leu
CA-SSR
f/43
Bcr–Abl-induced
Ser696
p.Arg802X
sorafenib-response
cell20
SNU484-
analysis,20
NFAT-regulated
Smad/hFAST-1-mediated
previouslyimplicated
deaths/year1
/MTCP1WT
myrAKT
GAL4-HIF-1α-ARNTta
−30.2
Trp-860
.Anti-phospho-EGFR
.MUTATION
0.483-1.880
report3
Gorbatyuk
FIG-ROS1-positive
658
99.942
m/81
S2215F/Y
c.9259C
E542K-NHUC
subfamilies
C179A
gels.Table
IVS26-2A
-TCACCATTAGATGACGCT
foci/mg
uncoupled.7,8,32,33
Tut
nature.comCytotoxic
KLF6
re-refined
Con®rmation
557892
pan-resistant
pEGFP-N1
underreporting
green-based
Vav1-cre
Pune
pEAA287
YAP1/TAZ
+604373
recombination–mediated
mutant-carrying
BaR3
SCNA11,24
postPCRmutation
3Cc
99.4
25.5-
tablish
AXINs
pre–T
ActR1BT206D
B-precursor
8553
3D3
nmol/L.9
magnifications
Y559
30.6-73.1
4255
Gly-821–Arg-825
GGAGTTTGAGATAGTCGAAATCGTTCATGGT-CACTTTGGCCCG
GTPaseReceived
www.biobase-international.com
KIT/sunitinib
out-performed
G361
SectionOther
Hct116
Nf2
GSEAs
epsilon-nitrogen
LeukemiaNet
ANGEL1
CCCTCATAGCCAGATGCTGT
Slamon
p.W279X
RPL11
£anking
EGFR/KRAS/BRAF/ERK
FLT4
established.2
500:1
Asn655
XL10-Gold
Roa
116–126
c.48+7C
connote
intracytoplasmatic
Gli2
12p11.22-p11.21
YPYDVPDYA
gel-based
hydroperoxides
5536
19.45
instability6
C326
α-Fbxw7R479Q
argininedropout
DSB-induced
with/without
nescence
STAG1/STAG2.9
Gouill
Bykov
FNIII-3
localized32
f/+
expected40,41
adipsin
A–agarose
inhibitors.18
deconvolve
MSH2-G332D
–expressing
SET1
organisms.16,17
FBXO1
NaMoO4æ2H2O
structure/folding
1930delCAG
BRAF-MEK-ERK
LNCaP-C4
HC1
neoplasia2
modifyor
46D11
variant,2
Thr18_Ala19dup
V82-Q100
LSGLHYLHQTLRPVLSQIVAEKKP
Minner
V1.1/V3.1
nonvirally
Smad-binding
EWS-ETV1
7049delT
R163C
interleukin-3–free
Phodlp
FBN
2-carboxyethyl
-B35
dSET1
R212H
56774142
1.4–3.4-fold
FLT3LG
V600EBa/F3
1.098
7186
1.23108
C464A
D1/2
'restored
KFG
E924K
Hs00275109_s1
instability.Analysis
Fo-Fc
10°
C1156F/D1203N
Nutley
Ki67-positive
CDK-containing
bGain
TNFAIP314
HS-5
37/59
TMEM59
ΔZF-HA
accumulationin
2005.nCorrespon
D6Z1
Cdk4/6
1.00–3.05
propanesulfonic
Muv
49–57
pRc-CMV-HA-VHL
5′-CTTATATGAATCACGACTGAC-3′
ATM/
ERα-regulated
23–2
receptor.67,68
M52-L
.Tyrosine-phosphorylated
13.3±3.62
ACCCATTTTCCTCCCGCAATT
p16s
immunostaining
C-end
pSIGMAs-luc
HER2T798I
1666
Rehbock
nfb.
reaction9
PTEN-promoter-mutation–positive
l'Université
V4
C3198R
DNA-activated
SC-133
FGFR4-Arg388
NF-κB–inducible
-extented
denaturedat
R183W
n=61
H1703
leukemia,32
tableIn
.Smads
gene.27
8078
C32
ofPAX5
carcinoma,12,13,14
P1310Q
.653A4G
DCX-positive
mutant/deleted
described.52
Ligand-Binding
−0.67
Shpaer
.NM_000077.2
Kingdom34
autopsycases
MEF-MycER
ka9b
Assay—To
autoradiograms
mlh1-E682A
DTT/0.2
wt-1
Asxl1-regulated
887
glycine
.AtmKD/-
Jagged-2/Fc
valueZ0.024
2,730
T.X
1×low
Banine
enhancers.48,68
pCDNA3-Myc-Chk1
beta-phosphate
BCAM-AKT2–positive
5Cb
5′-GCTGACGAGGCGTGCAGTGTGTATGC-3′
.OVCAR-8
Romijn
4.6–49.1
.PX
two-digit
aminosulfonylbenzofurazan
6834
work3
trace-detectable
2∼3
TKI.1
M-MuLV
homologywith
.Similarity
theSRY
αFLAGmAb
siRNA25
function-structure
/1SB0
TK-2
V658I
SK29-MEL-1
MMRpro
E258D
TGCACACCTTCAGGTTGGTCAGCTC
6/167
diphencyprone
7.57
KPM
Bienstock
p85α-PTEN
lower-penetrance
y-32P-labeled
pT590
CEREDIH
.Neurofunctional
Lys51
domains.9,13
U697
fx/
1BR-hTERT
SSEA-1
four-amino-acid
4688
just-right
Cholangio-carcinoma
GST–Cdc25A10
αA
SWO
3-7,18
cancer-causing
Pochapsky
0.0024e
50-55
66,51
resumption/reinitiation
Y231N
embryos11,12,21
.Y463KD
positive-methylation
T959A
factor32
.Site-specific
AG/GTAAA
.P214L
TCGAGGCGGT
4353–62
activation.11,12
Lys-716-HER3
4142
0.5-1μg/mL
x105
HECT
Clinic-based
Asp820Gly
RUNX1,14
acFIGURE
deter­
Fig.10B,10B
∼25–30
IFWY
L770V
v17
Q250X
65-85
function22–25
high-intermediate
S81R
2.177814133
33.9
T197
carcinomas,5I
G549D
G127N
hemagglutinin-AKT
CATGGTCAATGTTGGAATGAAC
I36M
ABL48
SalI-BamHI
T854
anti‐BRAF
dual-task
theL22E/W23S
17·2
GGAA/T.9
immunologically
pElk-1
option13
Rad51–BRCA2
ZNF382
structure.Sensitivity
140-mm
Theabove
glycerophosphate
lipid-anchored
Protooncogene
36.1
3894
germline,16
CSM
51,20,21
overimposed
macrodissecting
GDc
.Download
Mvo
104403-105010
20900
PBST
3,320
250,500
12–14
rysm†
cdk4R24C
MUC1
post-furrowing
rs144848
hemeagglutinin
Mid-embryonic
-190K
17,55
C47R
Y570F-D816V
PerfeCTa
Progression8
p.A21T
thesignal
SLC10A1
FtsZ
mAKTT308D
.T/C
Boulet
Low-set
Y-chromosomes
Panduka
domi-
D4MIT27-R:5′TGGTGGGCAGGCAATAGT3′
c.433C
p53RE–hCMV2–DsRed.EGFP–DsRed
PVP
A07796
A-D
wtEGFR
rs861539
motility.16
Thermocycler
1.404
CAC-3′
DSGxxS
anti-C-JAK2
3.7amp
V1078A
-western
Hpall
transcription.82
1+f/C
NFI
pre-implantation
Tartaglia
lysyl-5-hydroxylases—all
R252W
Y337C
RNATotal
LxxxLxxLxL
5´−TAGAGGTTCTCCCCGGGCTG−3´
//genome.cse.ucsc
Cl2
P996S
5′-gtcccctgccgcgggtcagcaccctg-3′
Ras-Mek-Ets-mediated
8/10
5'-gagttcaggcaaagctgtag-3
cancer.28
EcoR1-digested
system.8
L179V
t=−1.815
Cell-autonomous
1–83
//www.ebi.ac.uk/microarray-as/ae/browse.html
Vi=9569–X
overstacking
RASV14I
39155
old-fashioned
P=1.6e-17
V138A
Q564H
282–631
BL-21
pRb/p53
F341L
ChIP–qPCR
5′-TGTCGCAGATCCAGTCTGATG-3′
ALK1–7
unclearly
semirational
OAF
760–769
DNMT3A-intact
20.8/26.2
mesenchymal–epithelial
Rho-GEF
TRCN0000361413
FAM131B–BRAF
nuclear-immunoreactivity
exon-to-exon
GraphPad-InStat
factor-and
166–188/9
functionof
Se-Met
.Metastasis-free
P=0.153
UBC4/UBC5
.Were
monoallelically
GTGTTATCTCCTAGGTTGGCTCTG
Permeable
nfb
0.374
anti‐Flag
5′-GCAATGCCAGGGTACATGG
R47S
2C–2D
FNDC3B
≥1,160
64.2
pGEX-p300
system26
PTEN/AKT
26-88
//clinicaltrials.gov/show/NCT01111188
NOZ
Balgach
rad50A
changec
an-
7/26/00
trimethylase8
tumors176
MSCV-FIP1L1-PDGFRα-ires-EGFP
Z-Val-Ala-Asp
p.N822T
Tumors1
allele.2
RPA-T4
dystrophy
VBC-CUL-2-associated
.EGR2
5,000x
autoradiographyusing
Phe85
TRCN0000039977
NEUROTROPHIN
H1792
Hyperhidrosis
dR6G
electophoresed
Pim-3
.DB
168K
27KB
RP11–707G18
MiR-34a
PIK3Cα
hKSR2
2.28-fold
-stimulated
68.41
ca.expasy.org/sprot/
pRBΔex22
activity17,18
29,97,101-104
//hardy-weinberg.stanford.edu/dhplc/melt.html
PHS000178
V848
8/3
factor-A
27b
q=0.05
full-promoter
5′-GCCGAAGCTTCCTCCTTGCATAGTAAGCGTT-3′
/2-OG
=0.02
21q22.1
AcMNPV
370–398
32/54
Budhram-Mahadeo
I—All
172
R23A
117.98
TACC3ex4
Dvorsky
Stat5AΔ749+pBabePuro
Wonsey
Bodmer,1999
L1122VþL1196MþG1202R
11221
QEV
dendritic-cell
Large-cell/anaplastic
IGFRI
Altiratinib
JM-P
IVS13-
MSCV–IRES–PURO–MCS
R1838*
MRQ-42
12/67
2·6–NE
RP11-718J13
FAS/FAS
EChI
☆
Soft-agar
F71I
SRC-3-dependent
genotropic
analyses72
RET/V804
APC-initiated
hWWP2
O'Brien
EBF1-PDGFRB–positive
234/234
–AMP-activated
reported,14,36
B.E.C.
0.27EX
L719F
TFA34
TGF-βcan
antibacterial
c.379_381delTGT
-CD117
importin-7
E611D
6-min
PCR1-generated
.Analy-
V931M
APC-binding
MLL3Δset/4Δset
AHR/GAPDH
Tanigaki
TTT
.85
T801R
ILC-targeted
bilobate
dinulceotides
4,21
13,600
Jahnstrasse
R182C
TIL397
USP9X
double-mutated
CLL01
.Wiestler
GES34828
activa­
n=14/21
MM1R
properties176
tumor.30
165K
dsDNA-dependent
rbc
P0017
disorders.70
P=0.876
Intratumor
jOpr
T47D-Spen
T.W
8p
NP_495679
errant
11-18
5/313
well-
antigen.37
5.5.9
Farkas
//www.lovd.nl/CDH1
HC3255
Colocalizes
Allavena
L717R
ERα-M3
inhibitor–bound
pREP4-M55.35
CCTTCCTAAGTCCGCTTCTG
Kotoula
gene‥
investigations.5
1μl/pmol
Pdgfrβ
mutation.40
5-ml
B-form
3500-HT
XRS2
SCF-driven
β-D-glucosyl-hydroxymethyl-uracil
72Â°Cwas
med.uni-goettingen.de
TEL.E6R
41031-001
cases.Large
.Arg631Cys
serine/arginine
Dorchner
Bioteke
feeder-free
HEPII-RAB
.110
-RT
I1307KAPC
pointmutations
promoter–luciferase
p.T204fs
high-power
NL-7
gCa1164gGa
NAB2-PDGFRβ
o60
FRS2α−/−
.128delV
NCoR-1
yg
RHOA-7A
damage26
anchorageindependent
Solal-Céligny
KRAS-mutant-rich
IGF-I
Ru-Yan
myc-SPOP
25,35,41
CCCL-18
myr-FLAG
1251-
hGli2
CCNB3.1
CSW1.3
reactionswere
5'-M13-TTGTAATTCACATTlTATAATCCATG-3
R408Q
−297F/+8R
SFRP1
796/785
5′-AAC
posttraumatic
Jagelman
Anti-Actin
125I-anti-ICAM-
TEAA
high/intermediate
T-cell/myeloid
intra-membrane
Fig.2A-B
pT1N+
.399
ABBOTMolecular
JH1-tyrosine-kinase
608–612
Sancar
disease-producing
Wendl
11NGNNYVYIDPTQLPY564-
heparin–Sepharose
.RNA-Sequencing
oncogene35
Super-resolution
4864
R402W
ef‑
waf-J
U4UM
histoscore
study12
mcf3-
*1y
whole-genome-amplified
signaling-regulated
FMS
IPLB
6.91
sidechain
H123Y
siCtrl
Ubiquitin
6B–C
transplant-related
2OOQ
Inaddition
CUO29
6.05
PMS2-like
LLxxLL
E320Q
N-1
1−595
SH2-like
activity.48
283C
D32A-mutated
onco
aurora-2
Method-S6
observed5
13-22-A-8-A-25
binding.46
.INK4a
TRU-type
C11orf95-Red
Dye-terminator
Dayhoff
Asx1/Tet2
myeloperoxydase
ACAGGGATGC
-kappaB
matrix-coated
α7-α8
Chapel-Fernandes
Stem/Progenitor
ml/hr
miss-
Threonine-875
CYP24A1
107KB
F-TSC2.ex15
photooxidant
L2593
vitro12
FetaClone
MDM2-independent
HA-probe
HBEC17KT
1,759-2,095
C135S-p53
IgMa
carboxylesterase
Orthopedic
SDS-PAGEanalysis
.Chondrocytes
AMP-activated
9p21-linked
EGFP-BLM
.-T.
0.560
non-B
ΔS1278
W741L/T877A
dimers.22
5'-CATGATGTACTTTACGTAGCG-3
PCR-sequencing
DAB-positive
59-GGTGTGTGAGACGTTGACTGAGTG-39
3596
Her2
V31
A298
auto-activation
SC-94
TC-3
501mel
pcDNA3/Keap1
liMLHI
Lymphomatoid
Guesde
candidate-based
p53+/-/Brca1Co/Co
antiPK
TCR-induced
59/344
studies.31
themesenterium
Gap2/2
spectrumGreen
saliva-derived
investigators.70,73
Alamut-Batch
30163
D52H
Asp820His
​Fig.3B3B
Circos20
CK1α-GSK3β-β-catenin
Cerdanyola
bottom\
GFP-sorted
adipocytes17
CLB95122
1082
RPA,17
reclassification
β-catenin-driven
o5706
NCI-H345
rate=7.0
fractionized
Curiel
discrepancies.Nevertheless
.Clarke
GMP-PNP
pentacoordinated
BAP1-depleted
cetuximab-sensitivity
C05
532526
TbR-I
GAGCCAAGAGTGAAG-3′
CCDC27
∑nj=1K
∼140-bp
Smad2/Smad3
NGF-R
five-generations
Meilun
V694I
againstthe
PRKG2r/1
STRN-ALK
Val-146
Results—for
FIN-20520
tumors.40
state.Figure
100×109
.Magnifications
100-pL
TAE68414
rad50sc+h
HRA19
RP11-79C20
Neu-induced
MDS/leukemia
BAF57
0.237427
60×
work10
p.I157T
Nucleotide-Free
RUNX1–JAK2
polymorphisms20
ura-
sulfuric
Y498C
A301T
ACAACAGCCACAACGTCTAT
Chiappetta,4
5/93
Skp2-dependent
.0132
E446N
18F-FDHT
estrogen-free
.JakI
HCC78CR2
receiver-impaired
LLDIDETEYHADGGK
T72
CDKN2B–
mTORC1-dependency
Caggs-Cre/FR-HrasG12V
PRIMA-1MET
prolif
914
mSin3A/HDAC2
workingparty
G670R
//www.intgen.org/expo
.HSC7E-YACs
acid-denatured
5′-CGACCAAGCACTAGTCCATCTC-3′
5'-CTG
ERCC2-mutant
nonspecificity
log-shift
SiRNAoligos
report,6
QPRT
PDGFRB-1R
BL6
MITF-driven
Rad54−/−
.FOXO1
p.Ile414fs
Phospho-RB
p.Arg172X
.UMODL1
.Sequence-based
open-labeled
45.5
intracerebrally
15,27,28
Gluckman
U87MG-PTEN-G20E
P.S720F
.Sixtyone
AG4572
NEK4-SFMBT1
G908R
WA56
571
5/82
V506A
+HGF
c-Myc-independent
MCC-derived
NCT01598077
trxJY16
MXR0
Myc-BS4
Pre-cleared
5–16
loss–associated
LTCICs
31–73
GAPDH-Hs99999905
3×3
RAS–PI3K–AKT
248–1879
bydideoxy
Weterman
Presentb/not
UBCH5C
Elchrom
sub-lethal
pleuropulmonary
5.Download
YM30
EGF13
threoninephosphorylation
E543
Mononucleotide
55–60
YAPC-STF
PIK3CA
CGGACCTTTTGCCTTCTTCCTTTACTGGTTTGTCTTTCTTCAAGGACTTAA-5
non–high-sensitive
anti-NH3
3.Go
4q31.1–3
Carney–Stratakis
antiarrhythmic
L674
worldwide—are
Runx3
TpoR,2
EN/AP1-induced
SLP
MIG-BAY253H
ofmutated
Ach
lines16
borte-zomib
.Aster
concepti
www.transgenomic.com
c.2371_2398dup28
mCi/ml
HER2on
0.02–0.22
mp-1-real
Endo-B-N-acetylglucosaminidase
R2217W
authorExamples
Jane-Valbuena
Y1022/1023
W408S
NCT00425750
.Worsening
PHLPP1
5′-GTCATGCACATCAAACCAGCC-3′
RP11-715H9
GSE21990
Wim
40ttk
E-G-T-S-T
–35
aminoterminus
FTI39
schematized
leukemia.13-15
lymphomas.Survival
R246K
PNA-modified
G0S2
muscle25
DICER-independent
KIT.61
drug-binding
Patient-Centric
.PLD1
tumors7
F1662S
bar=30
MEK-selective
HMG20A
P-Smad2Δ1
Smith-Sorenson
radiation.7
ETU4a
9.0–270.4
Asp84−Arg87
polyarticular
expression,4,5
.Ruxolitinib-resistant
E1035
γ-secretase.7
puromycine
pcDNA4c-BRD4S
amplification,17
Q56P
CTD-2342K5
-0.9
.Alternatively
systemand
HDR—The
2081
16Department
2,4,5
Biotek
14/151
mutation-derived
glioblastoma29
E18-580
mg/liter
CCCCACACACATGCACTTACC
EµSRa/TELJAK2
tumors.Finally
Lineage-cell
Cub
BTK-KD/B43
DFU
hybridization-positive
Pictar
c.1326delC
migration136
5'-GCTG-GAAGGTGGACAGTGAG-3
andextend
.NMD-Irrelevant
Quantifiler
ASXL1+BAP1
.Brdu
Igκ2-IFN-LUC
NM_000545
pathway126
pMBli
TβRI
529dupC
MYD88L265P-bearing
HPV-11
2527
self-binding
518C13
Cordenonsi
CRL4CDT2
R1446
RafCAAX-mediated
.0128
alternative-NHEJ
Flp-InTM
1/2-dependent
ΔCTD
Mantel–Cox
RASA1
D61G.78
CC10-driven
FAM120A
FL-Jade
aZymoreactor
4.911111233
.May–Grünwald–Giemsa
aib1
PLX4720—a
pS2-driven
5,17
364
.EGFP
FVB
AGTCGTAATTTTGTTTCTAAACTCa
theconclusion
51.9-fold
RCAS/Ntv-a
87.03
inhibitors29
trial,12
245C
.Sox17-positive
R1234
129S4-Ptentm1Hwu/J
endothelin
A589D
Treier
WWP-Luciferase
levamisole
11/73
2014c
.R.H
I203R
p53mutations
MCF12A
Gpa33tm1
±S.E.M
Alkaline
ARV7
p.Asp86
21-carbon
dysregulaton
patients=0.18
genes29
.Petes
noninverse
67expression
.RNAi-based
-14G/A
Non-focal
D11S1294
nt805C→TR240X
Schwaller
processes.1
H259R
≥2.0
mutation,20
models.26
5379G
TOR-Raptor
1789C-G
E-MEXP-1209
post-translationally
N857
0.X
0.428272
accessibilities
mutations+BAP1
−15.5
transcriptional
2.94
Investigation.Immortalization
I289M
non–cell-autonomous
NELL2
.Mohler
28-residue
236×
018424
Entry-EGFR
FLT3.E20R
98.5−100
.Signal
c.4115_4116delTG
tumorigenesis.6
b3-
EPYMEGVNP
andR273
AnalysisA
BglIl
AF145468
repeats23
of-ten
G307S
P9900
Konica
trypsin/EDTA
programs.92
KIT-D816V-induced
Val1075
echodensity
LC3
Cartilage-specific
Co-operation
apoptosis.12Caspase-8c
.26–.45
3/256
80.
kinases.5–7
.E3
His1203_Ala1204
DMBX1
p.Glu240Gln
59-TGCTTG-
Msh2/Myh
jmxu2003
72℃
1p13.2-1q22
Condie
BRAF-activating
4-MV
Fig.2e
pET28a-hDNMT3A_CD
KAR300D
erythroblastosis
DN-MKK4-transformed-
g515a
37/216
FRS2-mediated
-M1775R
BCR-ABL/ABL
J002
0.356
19/20
EGFRwas
1,283
−.46
Cul1-N252
.Hanafusa
647–conjugated
9p13
Salf
PPAPDC1B-modulated
MV200
Extracolonic
Non-nucleoside
syndromes-associated
1Dscan
GSE35230
NCT01538381
cis-actingreporter-linked
tumors1,23
survival9
CBP+/+
FLICE-inhibitory
G106V
UTCAll
9232/97
*verified
CGTAFrameshift149â€
−12.1
0.4–91
hyperproliferative
hormone-starved
post-cetuximab
4015-bp
coextensively
studies44
5′-portion
TRANSMEMBRANE
48190
31/42
W108G
Herishanu
TUUBLIN
q12.3–13
CDK6,24
17-allylaminogeldanamycin
v-SEA
28.1–55.5
Y-27632-insensitive
TGFβ-independent
Ile75
ovale
pCMV6-ERBB2
T36M
wu92
itraconazole
Board–
MM.1S
FernandezZapico
Ethnicity-specific
fusion-mediated
Drosophila/C
Probes-BAC
Cartographer
anti-ROS1
0.5218
67/38
D1/p21CIP
15N-ammonium
L779450-induced
/∑I
CMV-TFAP2C
C/SNP309
CCAAGGCC
anti-ETO
33.8
long‐time
outputs9
immunoprecipitation/immunoblot
L508P
2.View
pVHL-prefoldin
24-color
suppressor.17
al,41
05–321
CGGC
j.
Fbw7α-null
GCAGAATTCGGCTTCACAAGCTAGCGTAATCTGGAACATCGTATGGGTATCCATCTCCCATCCGTTGATGTGGC
12-fold
RMH4816
Insta-Gel
Apo1
phosphoinositides3
293TRex
–94
KYSE-180
608393
NLS2-Ala=0.6844
kinase148
family—dSet1/Set1a/Set1b
OFP
Open-label
MMR-specific
PDGF-B-deficient
CCGG
NCT01121575
8,253
Jews.17
CBD
Caestecker
0.57
amp-mut
27.6±3.7
D1–RAD51–BRCA2
R196
.8509
Class5
.Fig.2C.2C
DED2
3,266
cell/fibroblast-driven
1.4×
macromolecules54
16c
25⇓-27
4The
ESR1-E380Q
caspase-mediated
probe-matched
S145F
0.007*
p.R1204W
exogen-
methylenphosphonate
cerebellum-derived
c.1916A
pMMP-FAC
K739_1744dup6
HER-family
milieu
2967
Cell-specific
28.4–77.6
F255Y
`double
H00000558
RP11-91I16
pMMP-puro
2A44.5CD36aCD36
9070-fold
I1228N
proline-containing
.PDGFRβ
1136delCC
1680
F583
α-β-cat
loricrin
Exon-by-Exon
1i0
constitutionally
predilection.Our
eachinhibitor
10.1152
phenomenon.46
spring-loaded
HeLa-DR
theBCR-ABL
lympho/vascular
V89
M255V
Gly796
sutures28
pcDNA3.1-transfected
34.5–62.0
non-hypermutated
RB10-RT-as
heme-oxygenase
BL2a
5'-GATCCTCGAGAATATAGCCCACGCCCAGGCTTGTCTCTAACT
cycloheximide
Mre11/Rad50
EN-Y620F
1/435
Bruene
0.0078
10−kD
Sunyaev
5'-CCT
transition.19
FAK/src-dependent
.Yoshimoto
radioinert
protein-interacting
TTTTAACTTAATAGTGAAAGCTA
differentiation.2
.Many
C/EBPδ
E2c
Fig8E–H8E–H
Dewar
401H
GST-binding
pMY-CBLR420Q
aEstrogen
p52–RelA
CrTac
Met-128
GATA-3
G384D
p.E35X
deparaYnised
S427GCRAF
5¶-AGGAAGAGCTAATAAATCTCTTCTTTGCTG-3¶
.ARS853
ROS1/CEN6
setting—it
UAS-Ptip-RNAi
5′-TGATGGGCTCCCGGAAGA-3′
85ºC
Reverse-iT
Asp84
115.1
CH3CN
IRDye680
K132
β-actin
co-activation
cell-type-dependent
supratenorial
men.2
disease.1,2,27
Bergelson
GSTM4
p53-activated
adeno
HisPTEN189
C65
p.R465G
IleTrp
ability/inability
Karsenty
MM.32
6415
N82K
melanocytic
DELT36
studies40
BRAF/PIK3CA
V/K
previously.38
BioSpring
p-cdc-2
.22B
ATM6
CDR3β
55Â°Cfor
Haapala
.156713
pathogenesis-oriented
non-sequential
LNCaPs
ΔN-TCF4
3972delTGAG
Age/
~6
embnet
multiphoton
IVS4-2A4G
E2A
Ile655Val
sc-397
unaffected123
MLH1-EXO1
phenotype.16–1820
Whole-Mount
AGTAACAGACTAGCTAGAGAC
antibody/106
carcinomas33
5q12–31
transcription27,28,29,30,31,32
4.4–19.3
mTOR-targeted
T1052M
XbaI/HindIII
D1733G
ASO-PCR
5'-GCGGGATCCTGAGCTTGAAAGCTGCAG-3
1.9c
AML.35,36
ras-like
E600W
−13.2
Ti-E
46/2
±18.2
E54K
recoveredthe
SFPQ
4II
bisulfite-based
EC50
.93delG
rs1982073
Friendwood
N-bis
StatXact
E-ORF
Figure55d
membrane-localized
71/93
4,8,9
B56γ
170-kD
BRCTdomain-containing
OB1-3
ΔΔF
19q13
205G
CUL3-RhoBTB1
HumanAllExon
polymerases
proteinwere
Bim-inhibitor
YY340/341DD
pGEXRhoA
.Penelli
indigent
oncogenessuch
BGH
O.L
CGCTCTCCTCTGAAGAAACAG-39
Ab81
l/l
tumor−derived
Anti-p110α
wereovertly
4–5•6
hypothesis-driven
anti-KRAS
Tyr177-Val-Asn-Val
p2lRas-GTP
I1424V
5
Tyr-877
p.Leu585Ilee
32070612
PDGF/PDGFRs
buffer-0.2
W351R
Lys175
19,500
9000
two-locus
26580
Duc
al.,1992
c-Cbl+/+
TPM317
hydrochloride-positive
Sv/C57BL/6
chamber®
5′-GGTGTTGTCGTCGTTGCAAA-3′
Physiologic
GBM6
R1817S/M
0.35–0.65
genotype43
NM_011019
TPA
3,466
†Number
a–I
UM4Â
163-time
11Number
Smad2-
well-solution
EGF-
1194
L747F/P/Stopa
vitro143
cadherin-associated
sibling
p.Ser145Phe
clinicopathologicpresentation
2–24
ITD
Hipk2
/μl
AACAGGAACCAGCTCTCAAAGG
Accuri
ETV6-LYN
immuno-precipitated
PD0325901-like
CCNO
.Multidomain
BCL-U
HiSeq
.Karyotypic/cytogenetic
R368C
Cracow
H3K4me0
/nervous
PI3K-AKT
cross-communication
pMIG/HAhB-Raf
μg/ml/well
telangiectasias
Transgenics
58-GATGGGACACTCTAAGATTTTATG-
Olfm4
EPD7
10p-translocation
2Fo–Fc
4Â°C
EnVision™+
0.7–1.0
studied.Patients
obtainedfrom
F938S
lT-LT1
GCC-*CCC
pGL3basic
T539A
MAB3878
5'-ACTTACCCAGTACCATCAAT-3
//www.clinicaltrials.gov/
–paclitaxel
transition_decay
EPORT
SEF22
atgcaggagccgccgttgga
5440delTG
198–275
adaptor-like
agglomerative
36/44
Ma´tya´s
Erk-1/-2
P-values.ResultsAll
D816V.7
3≤
209–316
FN-coated
deacetylase-selective
.XAV939
M17
-Vantage
B-chronic
192–284
G724Sa
overexpressed
EMD1214063
COS‐1
PKCα/β
0.09–1.45
BCOR-mutated
I-Eco
Brm−/−
71/777
Immunodeficiency-related
P50.513
Harbinski
21-mer
for/BRAF/codons
0.0817
FITC–anti-CD45.2
Min-Elute
CD48
.HCC1143
insulin-regulated
WW-domain
HoBt
lex2
12,037,415
.Micrococcal
PPEMH3
carboxanilide
Cγ1-cre/IγμBcl6
mutation-reporter
Ink4/Arf−/−
Schwartzentruber3,33
HMG-boxes
ERBB2-expressing
U25435.1
AGC→AGT
2503*Stop
27369
estradial
1755
AUBP
.SYR127063
morpholino
e16
cross-cohort
course.The
L33P
SNuPE1699For
K1110del
0.0016
.Insights
HT1376
3743
Eijgelsheim
Talmant
CCGGGCCTGGTGAGACTTTCTTCATCTCGAGATGAAGAAAGTCTCACCAGGCTTTTTG
1.3-6.2
CD1a
//dx.doi.org/10.1136/jmedgenet-2012-101511
vectors.29
results2–5
//4peaks.en.softonic.com/
tumor-rich
BMH-CT98-3865
withCEP110-FGFR1
neuroblatoma
ZNF198–FGFR1.The
lower-dose
p.R420Q
132X
lex/lex-6
80•0
98/107
RasGap
Nmyc-amplified
CD42
overeactivity
PAbbreviations
F53C
P269S
986–995
P1771L
GATA-4
H2b
analyzed.18
bindsdetectably
2.970
gle
mh30446
.Meijers-Heijboer
R550H
tumors16
T32
DMBA/UVB−treated
pLenti6
12–amino
small-
G833
Ligand-induced
H545R
TCAACAGGTACAGTTCTGGTCAATCTGCTT
24–99
51Cr
αp70S6kinase
photo-oxidative
A327P
GeneGo
SHP2-WT
Marfan-related
prodcol
M1293A/Y1294A
Terazaki
5′-ACCACCAAATAACGCTGGGTC-3′
210-212
YAP1/TEAD
resistance.15
71225
D1266Nmu/mu
4FVP
C/EBPdelta
Smardova
MSH2-/-
UCE
1063
Ser738
3′-short
E585KB-RAF
M630del
V559del
gamma-regulated
Ino80
STI571-resistance
inhibition—eg
≈100
resistance.Alternative
R154W
topoor
genes31
majorportion
Techology
4/10
F21A
PCR-sequenced
Domaine
p.Pro224Ser
pFastBac1
Cabozantinib
mutations,17
5′-ccc
anti-XPO1
n=1442
-1/-2
GGGT
Smad10
V166G
NF1-REP-j
SHC-MAPK
other30
SS-single
pYxxM
Vereide
platinum-resistant
p.E633_E663del
10⇓–12
EGFP+Ly6C+
HLA-Bw6-specific
PDGF-neutralizing
Fbw7-substrate
D-site
M2-agarose-immobilized
Subfragments
1R117A
Heo
297–333
Construction—All
three-generation
shading.To
totherapy
p27+/+
lethality.10
T202/Y204
monoallelic
CCTTGGGAATATTGAGATTATATTCTCC-3
3,3′-DAB
stem-cells
G266R
M2–expressing
.AKT
Lécuyer
S3–S5
withinthe
mg/mi
nihms774093f10.jpg
.Information
N-acetylgalactosamine
1920s
.E709K
Phosphomotif
Arg897
Hoˆpital
-B50
Habashy
T336
Estivill
Mlh1−/−
.Sense
DE52
5..
AGK‐BRAF
cancer35
HDAC-complex
insS
C19
GLFG
FLT3,3
568–582
antip73β
FGF8b-Etv1/Ewsr1
C634Y
COLO829
Eα
angio-
NF1L626fs
WWP1-C830A-GST
Katushka
BEZ235
SPOP-recognition
.LCLs
E1046K
Kalé
H4b
Jasco
,1F
www.genet.sickkids.on.c
Asn564
.Citron
1+2
OfT
RHD
alpha-PI
G166S
GFR-α
eight-point
306C
68.6
acid-serine-threonine-rich
biscistronic
supraphysiological
16–28
vivo136
breakage,16
23–74
1,259
Basal-cell
Dworakowska
JNK-binding
30,53
Northrup
TSU-68
.PT09.1
1,060
encephalomyelitis
Mankovich
ARID1B/β-catenin
10−56
1-week
H-2D/H-2L
-shRNA
Wageningen
ectodomains36
diagnosisEighteen
alr35
podocin-Cre
GCCACC
100–120
18/300
513K
N264Y
1-α
auto-activated
Flag-FANCA
Onco-Hematology
//structure.bioc.cam.ac.uk/mcsm
KAS/6.63
4Istituto
c.1444-2A
12–38
tumorigenesis19-23
781insAGT
11p11
:286–298
EZH2-enhanced
ml/min
P35968
S5L–M
MMC-induced
1497
melanoma72
monoclonal/oligoclonal
.PHOX2B
EGFR-L858R+L747S
Polycomb-associated
L-cells
E219A
17q24-q25
EASANA
wide-spaced
F382S
PFSAs
Gunby
ATGATGAACAACCCC-3′
hMSH6-related
likelihood-ratio
H3K4me3/me2
0.64DNMT3A
48,58,59
Einvik
pmCherry-H-rasG12V-G48R
A-*T
-0.2
phosphorylation.7
CHEK2.E84E
guidelines.8
239
response-predicting
B*07:44
multi-genomic
TtH
C6792A
IA-IIB
PAK1-pulldown
Thorley-Lawson
two-cell-lines
UCC_1T§
G271E
diagnosis.90
Broniscer13
.6d
C-Myc
Cooperberg
Ile13
T452
rceptor-PTPs
ade2
cancergenomics
R86T
effects.33
AGS
MappingQualityCovariate
KDELR2-
J-JG
dimer/tetramer
SETD2-mediated
COSM1146
5-CCGGACTCGGATCAAATCT
Hachiya
insertion–deletion
A489
0.01261
S4.Figure
GTGTGCAAGTCAATCTGCAG
NFIA-CBF2AT3
6,25–27
5′-TTAGGG-3′
probe.Fig
ANR-10-EQPX-03
ophthalmological
R780
0244l
5′-CAGTGACACTTGAGTCCTATGCTC-3′
N/K
MTR
CFPE82D
.Arg1200Trp
gefitnib,13
`1
D351del
indolamine
system6
novo–induced
N160S
c.238C
1–15–BRAF
2N
Med23
.KIT/T670I
c.389A→G/p.Y130C
program44
-TATACYC1-lacZ
+1SD
Arg38His
nazneen.rahman
haemodialysis
NUMB-negative
testosterone-treated
549–634
Neurochirurgie
14q46
BioPrime
-splicing
intergins
108.5
pre-osteoblasts
MKK4
DD-Cas9
pEAA109
RUNX1–ZNF687
chemioluminiscent
megakaryocytes,20
BaF3/EPOR/JAK2
year.17
14–18
ETV6-PDGFRA
NM_013584
dUdUCCCGCACCGACAGGAGUUA
FRTL
pro-tumorigenic
PPT
DLBCLs,23
.Lymphoma-
1−9.5PHACTR3Phosphatase
onLet
Cd4
4–9
H3.3-ATRX-DAXX
autoradiogaphy
profile80
sFLT-treated
51-6
B-RAF-knockdown
RG-18
fluorouracil-based
cancers.85
P1749R
CSKN1A1
leucine-binding
1101delCT
9/256
available.16
1,653.The
CEV14-PDGFRB
1.22–6.52
ganetespib
//CRAN.R-project.org/package=survival
ED50-ED90
SETD2LOH
myelomagenesis
141–148
patients=0.50
units/μg
CD23−CD21−sIgMhi
pTrcHisB-Ha-ras
FastStart
Reifenberger
date.4
FuGENE-6
3′–5′
PDGFD
V215I
TGFβ1
FGF-2
3/435
method.Figure
*P=0.011
–MLH1c.1038G
SMARCA4-targeted
p.R172K
19,24,25
TK-I
SENP7
TCCTGCCGGTG
anti-Mu¨llerian
.2D2D
Nanostring
F318
Tet-family
R117
BRAFQ257R/S467A
Fig.2C2C
48-hpf
metastatically
fromhybrid
Autoradiographs
AutoThreshold
221C
FR2AHC-CR
4000×
H3K4me3
S14A
//www.stanford.edu/group/bakerlab/Cells.htm
TCGACTCACTGCTGCTTGCAGGC-30
green-fluorescent-protein
Mentzel
immunodeficiencies.126
expression,17,22
AsPC-1
Immunoreactivity
peptide18
PROGNOSIS
pan-Rho
hypersensitivity
1.59
S277
DNASTAR
MET/VEGFR2
antibody-enhanced
D1268
translocations/inversions
2.27–30
Tnf-α/Ikk2
Balb/c
358
TYR204
kinome6
D1Δ
GTTGTT
cases3,5,8
c.3768
Myc–Chk2
hyperactivation.68
Malig
8/19/02
16These
extra-gastric
Ras-ERK1/2
SMO-M1
3.8w
1,12
​Fig.7A
prediposition
+Rap
plasticity2
PC-9-DDR2
pKd
±20
F234
Martinique
M340A/L344A
crizotinib.35
Flag-ETS2DBM
Fumi
STK11LKB1
cutpoints
ALK-fusion-negative
PO4-SMAD3
Smad2C
TET2mut
constructs.Various
cycleave
C185G
Amplimers
off-states
.TPA
V.3
.20
5′-AGAACAGGGCTGTATGGAGC-3′
10560–10564
c.1703_1704delTT
mitosisand
.-Q205L
werewashed
tract.9,12
GI:39597065
14319
p.Thr1182Asnfsx13
.108
derange
respectively.19,25,38
-._.
IDH1/
interrelation
~70
S1715N
1,380
epiphenomenon
130.7–131.9
3′CEP128
K288
688-4772
407-429
transfection
alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3
ATTTCCTTCATCTTGTCCTTCT
Amplicon
hg1851
Smad2+/-
non-hydrolyzable
cells47
frequency2
17q21.31
ubiquitinmediated
.Auto-antibodies
CIMP-positive
cetuximab-resistant
V777M
TexasRed
10/34
S1613G/V1534M
phospho-KIT-specific
KPT
ILC
panel10
19ex
translesional
4M22
Ionescu-Tiba
previously.34,38,39
fluorescence/absorbance
GATCTTGACATGCTGCAGTGTTTTCACCAGTAC
S6.Table
co-extensive
ROS-e36CR2
R58W
5q33-q34.38
MMR-associated
mycDDK
multichip
T23
8A-F
TET1-overexpressing
36653064
anti-V5-tag
Mannedorf
V654
5024
R764C
R2336H
-R273C
proliferation.28
N549H/T
13.7–100.0
2/278
K601E-
Ghiara
.Purification
Proteins—We
DGCR8
91-fold
70s
4/291
Papko
BM-nucleated
tlof
acid-dependent
beforetreatment
PRKCB463m
YY1/HDAC1
FGFR2/bek
Bcr
count/
pocket24
CCCATGAACTGCCTGTCAAC
LY2784544
S2.2.2
DAPI
Weernink
38/F
//consurf.tau.ac.il/
.mTORC1
TNBC/BLBC
67I
Leu285
siRNA3
cardiotoxicity
2246–56
HT129
160.5
JAK2-specific
R127K
Anti-STAT5
blackblocks
72Â
1.733
S103650318
MSCV-ΔENOTCH-IRES-GFP
ACC-LC-49
.Polyphred
UV-signature
neuro-blastomas
TOP1
Elstner
RNAi-based
miRNA-target
Lipofctamine
anti-PKB
7.6/100
single-substitution
CXCR7b
Kruyt
–19A/G
ACAATAAACTGGAGTACACAAGG
Cdk2-null
Solon
Wicket
non-secretory
MIGRI
phosphoylation
A_52_P170882
GInGlyHIsIeI*l
M.HhaI-Arg-106
81•
~365
E9–12
syndrome60
AQ–protein
cyclin-cdk4
nk
379
BRCA1-M128
USH2A
slipped-strand
loxP
pEF-Bos-HA-RhoAV14
rad3A
GFP–VHL213-overexpressing
Arc-PVN
IP/Western-blot
imatinib-naı¨ve
TRKC2
parent-of-origin
Giovannini
experiments13
García
.BMP
p85/PI-3-kinase
F697
G/CGCGC
multiprobe
10,295
auto-radiogram
Hodgkin/Reed–Sternberg
SUV39
IEC18
deform
B2M-null
alanine-
EMT29
rivaroxaban
tpr-met
aspartame-594
tumors8
MEC
Weizmann
1436–1455
Non-CBF
tumor-expressed
Eph2A
–86.5
49-89-7095-7565
NEJM.org
brains-gut
.8ALK
cancer-unrelated
phenomenonseems
NM_000059
assay.67
CATC
GNA15
0.537-1.470
NB0073
1.11–2.66
817–822
daughterless-Gal4
UGCACUUCGUGUGCAAGCCUGAGAU
2.1.0
gene.9
CACCATGGCGGCGCTGAGCGGTGGC
Genewiz
Stemcell
1572
L777G
.4.4
CDB38-p53
CDKN2A/B/C–deleted
CACATG
.Ras-driven
CRF-dependent
Foxc2
AACAGCTATGACCATGGGCATGAACTACTTGGAGGACC
reclamation
CD20.27,28
65.7∗
Aurora-A/STK15
sulforhodamine
0.000498
B-B′
onTET2
−20°
44
pSUPER
beunstable
A1279G
p53-R280T
smooth-muscle
I141V
0·42
dimers4
T181.1
Retrospectively
Haemangioblastoma
anti-phospho-PDGF-Rβ
55-d
BCHE
SCFk-KIT
propionate
/AML1-ETO
rAD54
Ci155
fulvestrant-induced
interruption*
multiform-derived
p57KIP
prophylactics
V555A
-H-L+Fmedium
10.6-fold
Luque
maltophilia
Pindelfreq=P
p.G305R
MCF-7-Ago2
CA77676-01
D2HGA
αFlag
17,136
refs.11
huTBP
males4
GCGAGAAAGGAAGTCAGCTTCATCCTCAGAAGAC
Arg3Lys
Nrf2-derived
pSG-PMS2-wt
promoter.25
fundacionhvn.org
activity20
H227L
β1-
5´-CTGGTAAGGGAAGAGGCCGGCCAG-3´
acinar/papillary/micropapillary
p217/p221MEK
porcine
Hs00420495
two-dozen
.ATO
1.25-9.61
Δ4–7
Ca3
response,21-23
1256
6.30E05
EGFRΔ768+
transcription-terminating
Val29
ab99975
Anti-Elongin
N304-C243
model16,17
YAP1-specific
EGFP-labeled
D83nt
SETD1B
AGAGAGGACCTACTTCCAGCAA
andC
p.Phe222fs
.ResultsEWS/WT1
INTACT,52
pERE2-TK-CAT
25mm
−3.8
NM_001042492.1
localization/accumulation
BIS-Tris
methylation-mediated
whole-genome/transcriptome
endometrium-related
Phe8933Leu
1504
peroxidase-glutathione
blasts.16
SRSF1-mediated
rs16940
normocephalic
L541
Wanat
RUNX1-EVI1-leukemia
-phenyl
167:107–116
Δψm
R69C
hypoxia-sensing
SequiServe
pWzl
nonphosphorylation-dependent
centric
stitutive
.Val14
PDGFRA-
p.Trp1007X
GDLM
S189
Y179C/F486L/N550H
ÃŸ2-MGmRNA
T362I
PDZbinding
criteria.27
Alemtuzumab
TGDD
FKBP-rapamycin–binding
COMBI-d
prognosis15,26–33
30-minute
ARID1A1
333
K288Q
beta-catenin/ZEB1
V44M
Maihle
prostate.12
Sca-1+Lineage−Mac-1+CD48−
1990585
Keratinocytes
1/172
8L–transfected
Pathogenic*
www.affymetrix.com
P.D746Ab
type.Analysis
TTAAG
19,767
LSL
T88
CTACCTCCAGTGTTGGTG
468/472
WPD-
/5.5
283
sensogram
279-bp
.STEP1
QIAquick
interferon-γ-mediated
F69C
E180R
onLB
P124L/Q
presum-ably
three-color
assays22
.2.2
polarizing
Tyr154
mutH+.6
GTX70485
88.2
Unglycosylated
rs2429573
GGAATGTCTGCGCCAAAAGCTG
receptor−
phospho-Tyrosine
GGACTCCATGA
DFS/
p.E635Rfs*15
ERBB2.29
.K-RAS
ALK-driven
gd-PTCL
P=1.5
publications.9,11-12Nevertheless
www.e-cancer.fr
ab32146
fluid‐attenuated
adipocytic
PHTS/Cowden-associated
0–41
Nu¨rnberg
aReviewed
RBM5
Long-distance
V597A
SUDHL-2
dαβ
T292A
U.S
used.5
A496S
Asp1733
L199*
Sorafinib
therapy–resistant
HNSKAPKKNRLRRKSSTRHIHALELWSRNLSPPNCTELQIDSCSSSEEIKKKKYNQMPV
DME−/MMR+
c-ABL
−3.8413
STM
TCRb-rearranged
GGAT
Brca1Ko/Co/p53+/-
K27me3
84.6
RP11–324H4
pEGFP-Q640X
ComNets
VH
*Highly
Alpha-thalassaemia/mental
TMEM14Cmut1
p=0.058
131–150
therole
1996d
901–1784
NP_203524
trastuzumab.2
GSK1120212B
natal
53265
−4-kb
leuGlnGlu
Torrex
re-training
.SSCA
22.3/26.1
del14A20
shRNA-pooled
anti-Her2/neu
Mirin
.Oligo
time—a
32.88
Gly596
FLT3-ITD/FLT3-WT+1
2460delinsT
p.V1065G
KATO-Ill
W798R
StV
STAT3-dependent
.Vaco410
T733I
Tyr-1248
HER1/
M278V
epithelial–stromal
Ivry
non-GCB-type
multtest
.XTT
TEL/PDGFβR,6
oncogene.5
iodide/RNase
β-fibrinogen
3520–3522del
crankshaft
5′-GGCTTTGGGGGACAGCATTTAG-3′
one-step
glomuvenous
themselves.110
poor-survival
HER2WT-expressing
GST-SHOC2
determi
-3-ethylcarbo-
PIK-2E9OF
II-CT
ZnT4
FGFR4Arg388
gain/translocation
Ets-dominant
AA160507
initiation.157
neuroprotective
16/51
pmols
2617
D17S2163
XFast
JabRef
p110γ115
osteosarcomas.bCategories
NZM15
E10.5–E13.5
NaB-mediated
Pantherc
864–876
leukaemias61
NRAS-
R180T
0.39318495
postbaseline
30-45
1525T
MLH1-variant
.diagram
pEAA56
function.DSRCT
Ba/F3-L858R-T790M
S12I
humanwild-type
0.9-4.3
853
thepentamer
heatmap.2
MAPRE1
RTK/ERBB
.MA9
.5154G
1-Table
kit+lindim/−Sca1+CD48−
12.5-
anti-ORC2
SMAD2–SMAD4
−191C/A
antiapoptosis
PicaGene
Hiseq2000
Fen1
S159
MtRGDLksYLR-Sl
N-nucleotides
~240
1ArG
anti-GSK
.Ba/F3-mock
U72900
axis–targeted
TL5
ofRB1and
.Rac-GTP
mV/960
−9.15
algorithm65
10.1007/s11060-009-0014-2
TEL-JAK3-expressing
Chan32
ubiquitin-carboxyl
.6,22
N-19X
Ser269/Gln447
SV40-driven
GCAGGTCTTGCAACGTG
frequentially
PU-H71
10.1136
A.M.C.
CEP701
5′-CCAACTCCTTCTCTCCTTGTTTTG-3′
AKT-3
5980A/G
p16.20
c.142C
V.3.7
KPC_29_010
553089
RIP-TrkA
E709
SIF4A31a
3OY3
anti-Igl
AGACTGCAGGGTTCTAGTTTATC
Neurite-like
8Table
CD4+CD8−CD69+TCRαβhigh
S554G
Stoilov
V101M
6/no
Ciliogenesis
+s.d
6/77
114.3
A95/99
CC1046TT
RbBP5/ASH2L
Santibanez
initiated.MMTV-CAT
p19=0.086
AGGTGGACAGCGAG-3
verifiedby
Dariush
Sugarbaker
Necropsy
P44/42-Erk1/2
2∧
.Brca1S1598F/S1598F
Ikk2
p36
IEGK
GTGVHPIVVVQPDAWTEDNGFHAIGQMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPH
hHGF
CACTCATGATATGTCGAGCC
Casilli
wildtype-GCACAAGCCAAAGTCAGTCA
conformationalchange
JAK2-L611V/V617F
phospho-RETY981
3.31–3.20
cancer,17
phosphataseindependent
.§Splicing
Cofactors
1.2–2.1-fold
FBW7β
columns.E
Docetaxel-based
Vorinostat/ABT-263
DNA-alkylation
RG-9
papifiary
GS-negative
13/14
Rad10
c.515_559del
KH2
S320C
protease/phosphatase
chr7:55233009G
C331
BRD4
somaticmutations3–9
.Differentially
CARD-mediated
16.66
RPMI/10
−17.2
SMAD
H-196/JC-8/8F1/H-170
mutagenized
Dakopatts
AII
activity-deficient
isomer
CTF
Mm0xGGAA
OVK18
239–251
S.L
UBE2N-Myc
e1a3
displayweak
Lympho|
Lys503
14bp2484
CATGATCTTATAGCC
somaticmutations
kilobase-pair
amplification-independent
0.1.17
.Anti-SPA
malabsorption
E197K
Mut10-expressing
lymphocytosis
nuclei/
isozyme-selective
CTCATCTGCTTGGCGGTACT
CTC1
anti-correlate
alone.60
TERT-amplified
TSsolute
25·8
thyroid-specifi
Gr-1/Mac-1-positive
bio-informatically
pENTR™/D-TOPO®
near-comparable
ostium-primum
proteasome-deficient
CR17orf79
Schnidar
oncogenically
950C
RalGDS-Rap1b-binding
forked-duplex
PPP2R2B
approx70
NM_032043
uAspA
plasmids12
mutations.8
.GAPDH
electrophilic/oxidative
683
p=0.651
5.4.1
Higinbotham
0.062920966
F.Y.L.
pBD-GAL4
29-79
siBAF180
TCF-1-like
defects,14
15–22
NOTCH-dependent
PageRulerTM
.28
trans-stilbene
Experimentation
Figure1D,1D
3Istituto
pab0882-P
Sg.Relatively
E′
15,18–20
cell-cycle-dependent
anti–Stat5
VEGFR
c.2329G
Lundqvist
Colo-320
non–A-T
C3411T
Arg698Trp
Flag-caspase-8-frameshift
pharmDX™
Fig5
–15
p.N822K
Sprr2fCre/+
10−100
sc-17796
intrathymic
R104C
3-kinase/Akt-1/mammalian
0.9-1.2
receptor-α1
R482C
AdML
chr5:139815842-139818078
Fig.3F3F
.Sixty-nine
42.2
Chemokine
Monotherapies
5Cc
HA-CDC20
97-54
reported18
0.3°C/s
~350
.,17,18
homozygously-deleted
1.3G0.9
antiE2F-1
V170
NFl-associated
i51
RiboAmp
–––––––
Portwine
RAS-independent33
Ink4a/Arflox/lox
10,755
First-SIGNAL
tSite-Directed
SCH6636
BACC2
−5.2CAV1Caveolin
CTACCTCAAGG
Risinger
α-actin-luciferase
IPP
gene—
14.70
p210T315I
Nrf2s
BRCA1A
JAK3-
.Lymphoblastoid
anomal
RHOA20
QG-PCR
Non-AD
analysis.T62
ERK2Y64N
function.BRCA1
models.4
NRAS/BRAF/cKIT
GFP-labeled
GTPγS-H-ras-D47A
death-receptor
Suita
MGdotUG
rhTGFβ1
–M0
434–475
recessive
CCCTGCA
MutSα-V923E
PDGFR.12
male-to-female
T719I
//www.sanger.ac.uk/genetics/CGP/Studies/
33/33
STAT5-derived
Immunex
20μl
sub-pathway
6A-GST-FZR1
Ser824
GST-Cbl
5′-GGAAAAAAAAAAAAAAAAAAACC-3′
.183
stressors
non-fused
KMS11
Puvirnituq
Annexin–V-Fluos
elsewhere.25
Seliciclib/CYC202
subtypes19–22
14,952
,34,35
307-bp
//doi.org/10.1371/journal.pone.0087113.g003
Behm-Ansmant
hemosiderosis
5′-TATGGTGACACACTTGCTAGGATG-3′
glutathione-Stransferase
α3β1
flowthrough
MEN2/familial
TBP/TFIIB
300-μl
AKT1-R25C
peroxidase-linked
tumors.38,39,46
HER2that
2,3,15,16
YY1-mediated
GSE14827
PROTOR1/2
2x106
'intrinsic
syndrome22,23
Cre-expressing
GSTrap
Quantatative
achieved.After
20jC
MaxiPrep
K340A
23.3
.MSH6
217
hand–foot
mesotheliomas21
FGFR1-
receptor.42Consistently
R840
13B
cognatep2lc-Hras
D855G
RARα
dye-terminated
L272S
03084014
29/50HPF
Gly17Ala
50–800
PI3K-activated
Figure11E
//sroogle.tau.ac.il/
213348_at
retrospect
inhibitor22
59-GCAACAGTCTTACCTGGAC-
K1003A
20.49
9-20
immunodepletion
sites26—was
p.Phe2505Leu
FANCCmutations
non–mutation
104-RB
NURR1
P=0.0387
Ba/F3V559D
anFGFR3
BRCA1-BRIP1
MYCwith
20p13–p12.3
​Fig.2B,2B
BamHI-SalI
—BCL11A
O'Connor
436G
nonendocrine
RK3E-GLI-E
IgA−
PathDetect
formamide/20
pRSVβgal
AF4/FMR2
E–Cdk2
pulse-field
64-bit
PTPμ
SHMCH12F3-2A
FNIII-1
neo42
Martinsried/Germany
integrity.19-22
PCR-derived
box-and-whisker
ligand‐binding
LongRange
CGAATGCAATGGATGATCTG
≈25
MSI-positive
-CAACCTCAAGCACTCAACT
7470
cell98–102
tumors.15
expressed-sequence
millerv
GRE2
1:9
tyrosine-containing
thesize
genes.4-
single‑center
GATK-UGF
8-ml
926ins10
EPCAM-expressing
CBL-E3
t-AML-specific
+T3/ABN5
AT1
R683K=2542G→A
Never-smoker
80–95
A341E
autoubiquitylated
pLKO.1-shChk2
Hershkovitz
RIT1-targeting
F998F
immuno-purifications
mostprobable
C342X
H132Y
multigenic
macromolecularinteractions
gene/ChIP
xProfiler
0.809
8+9
612132
metabolomics
1WXM
W1038C
megaprimer-based
129-Krasex3op/nat
10901
pseudopsammoma
previously.41
49/74
a.
Neuro2a
involucrin
Rhotekin-RBD–bound
outside-in
MutSig11
Flag-Sox9
C182S-p53′
under-recognized
Confirmatory
A_51_P451338
SD118
211K24
leukemias.35
Cerebellum_BB_542
M1669
75·9
AGCGCGGTGT
0-4
.APOBEC3B
logarithmically
2237
reaion
Rheb-EV
c.1795_1796insCTA
osteopontin
R8W
onTherefore
non-modified
PIWI-box
55K
cdd470f4
region1,2
1281–1284
codons175-176
ScaI-BglII
microcell-mediated
long-rank
A1669
0.28–15.3
Signal-Regulated
K3326X
E-caherin
therapy-related
locatedon
miRNA-221
residues.27
RSK3
Bensheng
AA968514
EGFP-IRES
GG4-like
citrated-buffered
pSV2Neo
carbamazepine
nucleophosmin-ALK
spine—characteristic
L215P
Concordancei
Time-to-event
Pheos
anti-K-Ras
wasincubated
17-aminoacid
63–154
PPAR
KIAA1549–
FANCD219
Malinge
aMSH
λhp300
Cish52
VZZ///////l
domain.51
Drug-bound
delCTCAA
GPR82
0201
p.T231M
GPCRs21,28–33
W.M
+3–4
AGCATCGGGTGATGTTCATT
terminator/poly
A1066V
23/18
wtC-KIT
Figure1E
001654.4
years.3
Iezi
-YYsVhnKTgakLPVKW
multiinstitutional
retinoblastoma-deficient
adenocarinoma
Schaeren-Wiemers
Fig3C
induced–beside
nucelosome
KIF5C
S100A1
Alk-2
PTEN
D18S58
protein-bound
.Central
1P1
38-3/4
CPT-sensitive
approaches.11
NM_017628
31-34
mean±3
//cgap.nci.nih.gov/Chromosomes/Mitelman
L452P
.u
D17S1604
Ile365
GACATTTGAGCAAAGACCTGAA
130-095-821
PAX5/STRN3-JAK2
CtBP-1
S262P
RP11-354C5
0.32-10.42
.9,10,13,14
multi-sequence
c-Yes
CHD1
K562-Cl9-mb21
15,548
Becksfort1
558733
Gai-2
900g
ammonium-chloride/potassium
triaging
TTBK2
1×86
1331bp
structure.bioc.cam.ac.uk
Calu-
1023
low‐grade
survival=31
Standard-of-care
ab-
AmpFLSTR®
Smad48+/-mice
Hu.USMC
.8,10
.Snap-frozen
Thr854
Q-tests
suppressor.8
SNVsSNVs
KSR-BRAF
-4.75027
sub­cloned
formamidopyrimidine
STA5A_687_699
CFCH/PH
nonhypoxic
plates/inserts
copurifies
18.2
Flag-ubiquitin
repair.
Hellström
745
Qo-T
Lim1215
TAF1
identified44
GTP-binding
7/65
Claude-Bernard
.Likely
llumina
100–2.5
RPS27L
.Azami-Green–positive
mutations20
EGFR/ErbB2-resistance
degdradation
0.86-4.02
prelabelled
Motoi
110°C
neuron-to-glia
24nM
25799
3-1-4
NSF-DPP
Lázcoz
luminometer/plate
shCtrl
CIZ/NMP4
fibroblasts5
ARHGAP
constructedsite-specific
pRLTk
Polyclonal
Met766_Ala767insAIa
proteins.66
34/36
Rupert-Karls-University
6.65
PCR/RT–PCR
.Prompted
pseudo-kinase
G526R
K656E–mutated
Q191H
low-efficiency
E79
zb4
pharmacogenetic
GFP-VHL213-
p.Lys1881GlnfsX27
melanomas.Figure
p.L1584R
59-AATACCC
Cellquest
203362_s_at
calyculin-A-triggered
catecholaminergic
Anti-c
immunodeficiency
WT-ERBB2
54.46/2681
patients.1–3
18019
Howett
antivascular
N239
Nazarian
FGFR3/cyclophilin
POV-Ray
E277D
gbAE003422.1
p300/EP300
viap53-
ΔN-IκBα
cycD
undercalling
de-identification
,17
pS70S5K
methionine-labeledcontrol
Ser2481
chetomin
Stk11/Lkb1protein
RAS,20
low/moderate
n=30
RNASeqV2
ERBB3-mutant
Smads2
package.40
Denhalt
pathway139
4499–4506
~32
.Snail
GGTGGCT
population-based
TAZ97
Siddiquee
PFA-fixed
.NTS
DNAcould
ACCGTGTGGGAGGCCGCACCATGCTGCCCATTCGCTGGATG
pSer-Pro-Thr-Phe
SMMC-7721
NRSA
Pharm
A195S
HT1197
Asp228
Grosbois
P113L
Y495C
Amersham
L468V
Schorenstrasse
B-X+
on/2
Affymetric
method25
seFIG
62,357,562
Biopsy
RM-9104-S
≥400
Schaft
NKCL
control.21
IRES-pac
2−17.2CDKN2ACyclin-dependent
spectrofl
E2F1
promigratory
rethawed
09-044
LRP2
5.94
Ser473/4
Lox-STOP-Lox
BRCA1C36
.FACS
coelenterazine
FLAG-VRhoA
S11B
3028+1_3028+1delG
gi68128853
pLERNL
ITD-induced
ACG-3
NaDOC
EWS-FLI-1-transformed
a.a.172–a.a.374
G/M
D1067
Ser-594–Asn-605
4516
five-year
diestrus
83.17
-CTGAATTCGGATGCAGAGCTTC-3
20-aa
PDSS2
P=NS
0.9M5′
Menarini
IV:6
1522
5′-CATCAGAATTCACCCTCGCC-3′
LPT16R
C2H2-type
DEK-CAN
BacPac
5′-GGCGTACCCACAGAAACCATA-3′
data.26
anyevidence
uArgArgGl
Hemostaseology
indicated.Targeted
NM_021385
3-nitrotyrosine
GGATTATAGACCAGTGGCAC-39
Mea-suring
AssocPow
R692
DTNB
0Table
c.1084G
p-ATM-S1981
mAb
PR-B2
PMEMD
RAS–RAF–MAPKK–MAPK
2c–f
apical-lateral
4M-P
dup501-502
LFS-IUSM
DT40-derived
tumorinfiltration
SNYG
rheumatological
.9999
.Brosh
OVCAR-8
C797S
thetransforming
growth106
Malme-3M
Derestricted
1795:37–52
SNU423
.HA-Cul3
R429H
slideProgression-free
GDP→GTP
MSCV-BirA-YFP
phospho-Ser
.Freezing/thawing
.Pre-clinical
.Exportin-1
aUPD
–,51
impor
SDC4-
+0.3
R975W
withKITexon
.S3C
.Puisieux
SHC-Raf-MAP
±5.52
=10nM
CML7
21,54,55,58
RARS
G367R
ab155979
Y107A
2,7–9,26
12131415
ANKRD26
cells94
K146
S33Y
N194A
88.05
Non-canonical
TBS–Tween
TLS/FUSgene
G273R
5q33.35
non–IL
−1.12
One-hundred-thirty-five
nonfunctionalmutations
9207446
hCG-stimulated
IE8
Argl751Gln
CACUUGUCAAGAAGCGUUAdTdT
E11
//dx.doi.org/10.7554/eLife.03751.002
R287
TCCTGTTCTCCCATAAGTTTCA
423K
Q519P
50–926
SV40-immortalized
RP11-1B5
mTnf-Reverse
TFG.The
3T3-transforming
reported40
5D-F
dithiothreitol-PMSF
.Membranes
2-hydroxyglutarate.9
M4-M7
IWR
488-
0.87–1.85
G.It
ZFHX3
afterrandom
1089F
820-D
250-bp
Bruick.17
.Concordant
Ser284
WHSC2
Mll2FC/FC
RSVLTR
assays.31
GCCCTCCACCG-3
tissuesHaving
non-t
c-index
Signaling-pathway
fusiontranscripts
OS.27
aminoacids
Hidehisa
Taraszewska
ppt
PMS2-interactive
CRR
E2-24K
Assessor24
.FLAG
repeat-variable
K179M
PMS1
significance91
−418
mutation–mediated
restrictionpattern
0.7.5.17
FSC
V5–cGKIβ
Σhkl|Fobs
A_51_P164530
5'-TGGATCCGAACATGTCAGA-3
80–100
∼28.8
ankyrin
ERα-2
Cul1-Skp1-F-boxSkp2
PAb421epitope-containing
Sequencesa
45+
stage/timing
p.I145M
5′-GTGGCAATGCGTTCTCTATCCAG-3′
transducing
Glutamine
Blokx
p≤5.0e7
NM_005431.1
ALT-positive
3991C
bundle-like
CFS
si-SOX17
Qdot
c.1349delT
40G.A
GATCCTCGAGAAGCATGTTGGTGGCTTGTTTCTCGAG-3
DNMT3AR882H30
TNP-470
.aCGH
/CCND1
Let-7b
Tcfcp2l1
EBV-based
5'-gcctcggccccaggacgggtgtgtgctgcccgcagGTACTTCTGTCAGCT..
4.Immunohistochemical
S-200HR
7-34
disease15
MCM2-7
KEAP1-derived
published.33,34
ubiquitin-target
5′-TAA
BRAFWT/NRASWT
PHF19/PCL3
11-104
LABTECH
.Cbf5p
Tyr1054/1059
FBXL11
Elston–Ellis
SNP309-induced
theantihuman
PE-1/METS-mediated
Shohat
light-dependent
Bellone
al12
substrate-selective
gain-ratio-based
al23
themsh2-D6
p217/7
IL-2–induced
yGADNeh2
870G
831-840
p.Arg498Trp
DS-like
TC-NER
1,609
Mesotheliomas
G60-Q510
P406L
Lys→-
V26.2
cell/anaplastic
zinc-dependent
DAG-binding
www.p53.iarc.fr
miR-100-5p
stromelysin-1.8,22
2-bpinsertions
p1000
703-724
GST-BTB
spectrapolarimeter
growth-controlling
SMAD4
TEL.1F1
cytokine-based
4.6
In-gel
†One
UVM
toβ-galactosidase
Bcr-Ablwt/Bcr-AblY253H
Mca
.Clustering
video-densiometric
.Cycloheximide
3d4
melanocytes13
before.47
malignancies17
S1423A
.Ala-146-+Val17ff
CA1
A428G
LS-SHP2-E76K
MLL=18
hyperbolically
RETR
GCT44
TCRdelta
cetuximab-
CBF-AMLIn
5′-TGGGCACTGACAGTTAACAC-3′
143K
LOX
Q167
herbimycin
Okihiro
MCF10AL869R
DNAa
.Materials
22,600
K517
neurofibromatosis–NS
mp19
Treon
17,34,36
BLAST-aligned
calponin-like
ALK80
L104M
Allikmets
FGFR3
.Preferred
MSCV-U6miR30-PIGdeltaRI-FF2
tool26
RPAII
MSCVneo+MSCVpuro
Foxa1in
anidenticalmethodologywas
relatedM
SCC9
16X013
3Mb
equiparous
.NIH3T3
R1441G
7/124
V299
MAOB
6.50
clone-to-clone
2E-2G
72°C/1.5
p.Val259Phe
reverse-transcribed
one-thirteenth
Lats1/2-mediated
W561
transmembrane-cytoplasmic
FAT1-mutated
0.63
.100a
Ethidium
JCRB
J–L
74–76
aliquote
144–147A
.HER3
24.Consensus
BRAFmutant
4Download
+BAP1
progression.9
CEP89
exper
.Immunohistochemically
Ruffner
arthrogryposis
c.8754+4A
GSTpulldown
13S
Halestrap
overexpressed.26,28,29
1–291
KIT11_PM
CDKN1B13
5′-ACCAAAACCAGGGTTTATAAAATTATA-3′
P59
.Skull
zb4-
RNA–mediated
611/690
MPCMML
-immunoglobulin
virus-cyclin
Ensembl
ASTRO2010996−6.2EVA1Epithelial
143-
3′→5′
wildtypeor
immunopositive
catalysis15
//www.idealibrary.com
M128
ATGAGCTGCATGATGAGCT-3′
.Williams
UCP
Leeneer
Dierent
Frishman
themselves,16
ectropic
-APC
l44U
initiationcodon.To
N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl
N127delAAC
HoxA10
cerevesiae
61-63
negatively-correlated
pCEFL-GST-neo
6244
kT
13/1476
Nrf2-GFP
5′-CAGCCGTTTTACCACAGTTT-3′
.326
//dx.doi.org/10.1530/EJE-12-0701
LATS2-expressing
phospho-AKT1
transplants39
Allele-specific
Disease-associated
no-go
T-cell-dependent
gene:19
Ariano
anti-mSin3A
1,3,4,6,8,14
G418-R
centrations
gene-infected
neutrophils,21
.92
Metzelaar-Blok
–9827
32D/Flt3-ITD2
.MutL
1p34-pter
cells.34
Recombination
non-parametric
semaphorins
Transcriptor
3996
LEF1–WNT
106–113
mice.To
100-μL
0.0147
1.838
209292_at
Pflugrath
exponentially
Ck8
H14N
S-adenosyl-l-methionine
.037a
4e–i
13/65.0
AluJ
p.M53I
deltex
furiosus
x106
217/543
back-to-back
cytosolic
-1.5
cdc2-related
TORIELLEC
101732303–102100000
SOX17-ΔHMG
717-2508
B0207.4
:41
Haybaeck
GEO-CR
ddPCR
INPP4BR-CD
LESION
2857G
-TCTGTTCCCACCATTTGAAGAG-3
0.17–0.59
WW4
20-like
1,308
DKRMNS560
.Successfully
anti-β-actin
E4
.STAT3-mediated
ZD
whileTPR
DNAtransfection
950–957
FGFR2b-
cysteine-substituted
fluoresceine
p.Ile314Phe
mutations21–23
anti-ULBP-1-Fluorescein
Kharchenko
Trx/Mll1/Mll2
IIA
Ninety-one
ASE
P=0.437
ODNs
8bp
alleles.18
RFP-positive
V274G
D255Y
Pro772_His773insTyrAsnPro
85–87
C304S
285/307
autophagy-inducing
MKI
VBC-binding
TU27B
14-3-3-1-luc
F194S
bind,176
GA-rich
967-984
AGCTG
rs1050171
10-223
UVC-treated
Recombin-ant
under-reported
p24
tgacag/GTTCCC
E434K
0.2×
R878S
membrane/organellular
19:289–317
X400
non-degradative
CCCACGCCTCACG-3′
142-fold
ATCCAC
.Lenti-SYK-9
ABL,20
IVS17
5216G
+5–6
LMX1BT10TP53
incorporations
E9.75
cyclophyllin
sites—that
70–116
Erlanson
thymoctyes
Gly9Arg
Receptor‐binding
multimer
tumorigenicity,16,17
H2A11
K33
.Interrogating
cell-fractionation
pIS-ERα-1-single
5′-acaaattacaagagtctgagaattccccgatatcgccagctca-3′
Proteo-Medicine
platelet-dense
OryCun2.0
UGT2A1
Msodium
0:55379
0.344
PDGFR-α-mediated
Akbari
MAQC
VEGFR3
anti-STAT5B
first-strand
p.Gly776Leu
morethan
subQ
10.1007/s11899-013-0169-y
Tnk1
mdm-2
PLA2G12B
Drogen
sPGL
z50
PPARγ2
Y.F
169610
.CDC4
tumours*
6-_ft~
CTGTGACTGGTG-3′
www.vai.org/vari/metandcancer
.Tumor‐infiltrating
Akt-mTOR
PLCγ-docking
date,23,28⇓-30
6–300
NF-IL6
R4642
c.453-2
2.401
EGFRvIII-mediated
TTF1-NKX2-8
113-8655
E135K
M-TS
phospho-Ser79
al,16
PPP2R
MSH2-p.V722I
.Function
E3-ligase
Trk1
1-methylpiperidin-4-yl
1202–2947
1377
3T3cells
determinationof
-80
NKX2–5
Csf2rb
Depletion
5′-GCAGGAAGGGAATGAGCA-3′
co-knockdown
ALM
SBKR3
Kurzawski
54–60
GAP3-dependent
¯anking
S-resistant
chemiluminescences
S2056
oxidation-sensitive
E711T712
Non-responders
gene.3
T111I
PI6
BRAFE600-harbouring
Lassam
S100A4
YFP-Meis1a
2A10
PCR-negative
BAF180-transfected
transfectionA
MEP
Ala19in
HA-containing
p.Arg470_Val520
tetrahydostaurosporine
248–467/3A
easyCyte
HadzopoulouCladaras
WT+Alk5
Colmenares
nonaggregating
.PD
MCF-7/Rosc
2qxa
p.Ala148Trpfs
al45
acc=GSE19730
3757–758insT
event.5
V600EB-Raf
Annexin-V+/DAPI+
Gopalan
KM-12
BCR-dependency
Ciomar
2.3–255.0
MET-expressing
G97
non-Hodgkin
r.1277_1386del110
ß-counter
1–platelet-derived
¯uoride
Gibco/BRL
PDGFRA.Based
p.R1172SfsX11
.BIB
ALK-G3602A_F
PC1
1971–1992
intra-cellular
GCCTCCAGC
pEAE43
~5nM
FLT3-JM-PM–
strong-cation
GT1
2,3‐dioxygenase
deltaCT
table22
D3-D4-D5
respectively.Figure
Ex20Ins
applied.36
–family
ADAM19
liu.wanguo
pH1-PCM1-JAK2-1
doi:10.1186/s12885-015-1311-0
LS–causing
mutation24
∼0.70
trp1–901
S3G
MSH2-deficient
PP1c-binding
.1906G
c.760G
PMS2+
date.4,5
RIT2/RIN
0.0026
cases,3
FC2NC
BIOMOL
109-54
Src48
noted.46
Overwijk
Jeonghee
EHMT1
Y1853STOP
C804F
anti-P-Ser-345-Chk-1
EcoP15I
252–
NF1187-tranformed
5x-myc–tagged
FAM5C
39–41
1–760
5.52
BLP1
cMNR.https
meansplusminusstandard
9/6/2
mean±S.E.M
Skippy.34
390255033335
Y61H
hydratase
.Dimerization
Oestrogen-mediated
multivacuolated
156.9–161.2
p-Rps6
Schuhmacher
0.01748–0.03963
Al06-115/+18
binding20
farnesylcysteine
Bα
pmCFP-K-ras-V152G
heterozyous
25.17
P.B.-S.
We33
5–26
Schuettengruber
multi-copy
ZC3H12B
germband
EzviewTM
M340R
TGGOTAG
QNGQVMNITNSGHENKTKGDSIQNEKNPNPIESLEKESAFKTKAEPISSSISNELELNIM
P139S
IFNGR1
.Pharmacol
ionisation
separation-of-function
androgen-driven
4.5ng/ml
conjgated
CS5
stagec
W303-1a
8A
CSRQQAAPDADLSQEPHLF
PDGFR
diopter
intestino-intestinal
.Mcph1
54,000
D816V+
c463
AR–specific
5A/Matrigel
.Traces
Dutch-Belgian
CK18
Jh4
2,903
NCI-H1355
~-cyclin
Csk-IR
B_R510
tumours.Full
JianLian
CDC2-cyclin
gene-converted
Thy-1.2
response10,27
EcoRI-BglII
G701S
44.4
g002BCR-JAK2
Mosflm
Y-axis=normalized
R1746Q
v48
C3162T
proliferation,204
PEO4
rs2854744
pGL4.10
cos82
ADP–ribose
MacVectorÔ
p52-like
1.8.7
Bcl-3
utility2
Prox1
G-scores
Conzen
Dual-Glo
e_index.html
factor-mediated
v.9.3
8.02
-causing
p.Ci
®rst
HClO4
65–68
pellet.
pro-HGF
CD95-resistance
LGEGAFGKVFLAECHNLLPEQDKML-VAVKALKEASE-SARQDFQREVELL
1038N13
-318
GTP/PAK1-bound
growth–inhibitory
PtS1T
15,20
5q31-33.4
Two-side
sigmoidoscopy
HCL
misinterpretations
expected16
A–agarose-coupled
edu
Gln63
c.37–38GG
80,861,153–81,023,195
MEKi/CDK4,6i
I744M
pWPXLd-GFP
pairsand
AME
EWS-E1AF
33/80
imageFACT
E487D
RafCAAX
994A
probedwith
m-dashO
Par-1
interdependently
thermoscript
hot-spot
AVITIGIPFPNVK
_Ink4A-Arf_/
40,934
82.5
cancer4,5
1-79
.Thermodynamically
Gibco/Invitrogen
loop-like
non-deleted
anti-cMET
RARg
group.22
SoftGenetics
CCL5/IL-6–induced
α-PTEN
E78P
-+++
1.58
ERK-dependent
CE48T
K382-E373
3xE2
carcinoma43
activin-receptor-like
6.7×10−7
HEC-116
elsewhere.15⇓⇓-18
KC
Cdh1-specific
anti–glioblastoma
78.22
Japanese-American
hematopathologists
non-RTKs
R168W
hulh
MSH2-p.T44M
antibiotic-antimycotic
7701
One-fourth
rs426612
paraffinembedded
Puregene
506O3
L755P
γ-methyl
oncogenic.3,4
differentiaton
V1.8
myelinating
LOD
componentPotential
mutators,4
R45W
¬400
.Correlated
phyla
20,964
benzylguanine
SH2–kinase
//doi.org/10.1371/journal.pbio.0050109.g006NMD
Catanzaro
GCAGGAACTTGAGTGCTTGAA
RasA59G·GDP
antic-myc
transactivation/transformation-associated
70.5–90.8
2:7
GIMEMA
growth83
3≥2.0
:511–22
AlexFluor488
11.9a
months8
+2SD
n/a
4089489
0.218
P235S
ER/FOXA1/GATA3
p.S211Y
c.647T
iout
CVCL_1726
×g
β/δ
MSH2-T33P
heterozygosis
235.3
NRL
-H+F
h-TERT
CDK7
c-METwould
77030
F498A
.Expressing
differentiation.3,4
p.R458*
GGCCACTGACAACCACCCTTAACC
mutationTo
grade-4
NPM.2
E49K
1152
alsoincluded
GSTSRC-1
p.P392S
P.M.S
-D281G-4
Pataer
133,215
sulfate-5
Co31
6506169Carboxyl
H2B
SSA1
T653I
R95C
Dyctiostelium
rasGAP
H697Y
CBLDExon8
CONDEL
PML-null
diagnosis.25
beta-Tubulin
RS-isomers
−23.9
E316D
immunoglobulins
Nucleoporator
Rectum/right
highthroughput
0.0021
GGCATGAGAATCGCTTGAAT
−2766A/T
cross-breeding
2,3,4
C73R
14.
Donella-Deana
2/435
phaseand
RAC1WT
41-156
debulk
pan-keratin-positive
1·3
cells.There
SKI-1
p70S6K1
818
UCCA/UG
real‑time
53BP1-like
.Primers
Project,14
P890fs
Ull
tumors.26The
Asn315
.FDG
Ala6
ETS2P53S
R3T
CTCF-mutated
-QISSAMEYLEKKNF
Cropp
anexelekto
Zytomed
co-associated
3,4,7,8
L839Ta
.G248V
21–25
1,682
TNT-quick
PEEHL3
1–6,13,14
R1212W
Mo-MDSCs
S1264
Asn-171
K-FGF
S912L
pcDNA3.1-WIP1-wild-type
|j
5'-ATT
nature.comBone
ATP/drug
720–1362
3949G
decontaminated
multi-potentiality
Lag1
612667
SA*
PDGFRA–BCR
BRCA1+/−
−77.76
56774134
CGA-to-CAA
surface-labeled
GL7–FITC
Fig.5B,5B
572016
'hub
Ezh2Y641F/Y641F
Cdc25A.Figure
.JAK2
-CD5
glycineresidue
Gaitonde
−1.93
MMTV-Luc
reflectedonly
r.538_705del
17Asp816Val
.ATM
G-CIMP+/IDH1
R515W
p71HA
DEN-treated
P322
A744S
CAGAGCTGATGCTGAACCGCATGCGCTGCC
5′-GTCGATGAATGGTCG
ptp
Denhardt
P50.001
NM_015338
578–689
recognition.Based
75–889
Q477E
non-cycling
p.Pro378Arg
deletions-insertions
Sanchez-Martin
p.I24N
plasmamembrane
p.Pro289Arg
unclear.16-18
Mmol/l
UCH-L3
BER
chr2:128050332
1.901
.e-A
MAP2K1E203K
min/95
slideChromosomal
6/12
lymphadenectomy
MAPGAPS
TLE/GROUCHO
Lck–Cre
40,60
5′-TGTGGTTAATGATCTACAGTTA-3′
GC/MS
MYND
TSC1-transduced
P.R841G
L78V
MOZ-TIF2
120-amino-acid
institution,40
Baculovirus-expressed
polydramnios
TCGA-F4-6806-01
28:1466–1475
contradictive
ALK-R1275
2637–2618
N28
HDACi-mediated
FIP1L1–
3.Download
.S4A–S4E
IDH2R140Q+/−
ReACp53-treated
surface-associated
1:0.2
exclusive,98
D76
estrogen-treated
neurilemoma
CARD9
atmosphereat
P065
P3f
q21.3q22.2
S2N-Q
5′-GACACCACTGGAGGGTGACT-3′/5′-CCACATGGTCTTCCTCTGCT-3′
1:4000
anaemia23
3–5
81-3-3815-5411
erately
70,497
factor.46
0.2632
buffer+protease
.Lentiviral
PDB2PQR
0PHA
IMDM2
factor-ÃŸtype
Glisovic
c.1789_1790delinsTC
pseudouridylation
1.59∼22.33
non-liganded
Tan3
Q434*
GATGCCGCGGGCGGCCGCCTGGGTGTGGAAATAGATGGGCTTGAC
DQPPC
_2s
58.6–99.6
tumour,33
RNAi-resistant
.Moran
55Â
3P
28538947
VX-702
0/95
7.7–25
O'shaughnessy
microdomains
therapeutics130
Hyb-Probes
12S*
p‐p44/p42
E291V
40–90
p-cdc
65.00
V5-His
11q23-q24
ETV6-NTRK3
UV-DDB
epitope-MEQKLISEEDL
pathways.21
Koebel
fusion-variant
sponse
SIFTpredictions
MSMP
rs1800566
understandingof
p120Ras-GAP
tactag/TGAACA
ligands195
Homozygously
Cherno
allohemagglutinins
1.54
responses.12-14
eosinophils
Chemico
5'-TGTTCCGAATGTCTGAGGAC-3
hematomata
risk–benefit
q23–25
PDGFRα-ires-EGFP
exonization
Figure11e
Intracellular
GRB10
function.22
4365
235–237
encodesthe
Flag-Fbw7
R617H
RP6
Dimerization-impairing
LEL
ommatidia
gene-deficient
802.5
cancers.In
25494
Michaux
ns–35
α-LMO1
//mct.aacrjournals.org/content/molcanther/12/2/220/F3.medium.gif
CGACGTTGTAAAACGACGGCCAGT
3.78
motility,8,18
Barcoding
HLAssure™
Vfor
Olig-2
two-edged
con®rms
variants.4
-CTGAGGTGACCCTTGTCTCTG-3
//www.ebi.ac.uk/ipd/estdab/directory.html
dinuclotide
1.395
R814H
K-RAS4B
sodium–iodine
allele—a
160×
p.Met1775Arg
genes53–55
0165-4608/93/
M3236
5/89
D642H
SCL
1,092-nt
alcohol-chloroform
cell-of-origin
42.1
Tu-13
Taq-induced
SEC31
cdk2-induced
bi¢d
G34V-H3.3
.Sci
.ATTCIGG
modifying/remodeling
Phycoerythrin-annexin
.Hela
H0-H1
13778150
cientmedia
l-plastin+
glycine/phosphate-buffered
pCA14-LATS1-IG
.Iodinated
TGF-betaRI
NUP98-NSD1-related
Myc-BS2
2A–F
time-related
pseudo-wild
H3B
wt-transfected
61QKQKVG
6–36
4427
4.45
R692X
DNA/histones
low-to-undetectable
nt170T
HD-0190
short-axis
5691
onion-skin
75–85
.Metaplasia
co-crystallization.28
Asp63
spots/mouse
MTris
lympho/myeloid
23408G
20/27*
formamide/2×
Kamei
TNT-DCAF1
1224insG
.Aubin
Fusion-1
F1579
PP2-sensitive
.https
HEC1A
d-2-hydroxyglutarate
photosensitizer-induced
1.7.45.0
.Glutamine
534A
alone.Table
51+
.Selection
nature.comKIT
Signal2Noise
MMP3
1–7
inter-relationship
P7L
Adenylated
b-sca
-LC
P-value1
4,4
HERPUD1–BRAF
Overproliferated
4RN
remodelling24
GTCTCTCTCTGTGTGTCTTTCTGCC
JAKZSTAT3,5
CEP250
hRad51
.0057
HDAC1-specific
LOH-positive
mutation-sensitive
RAF–ERK
Low-risk
Y2176L
Cal62
Li-Xin
GST•Cdc25C
Val-Val-Val
CNAT4.0
ophthalmologist
anti-PBRM1/BAF180
.Steck
CLL8
CD40-activated
ZNF674
AMPK.25
IDH1ex4BR
sublethally
GeneralRules
TTTGCCAGTTGTGCTTTTTG
MSH6-8
129,316
Asn370
.Family
spoked-wheel
II19
histiocytomas
Trr/MLL3/MLL4-specific
Igf2R
Figure6B,6B
NeuN-immunoreactivity
Mao
Fig.2.2
p.P648S
/TGF-β
12-180.26
lattice-mediated
6–179
AACAGCTATGACCATGGGTGCCT
EcoRI-cut
A-mediated
Phe94
IGFBP5
4502749
carcinoma.7
1del
27724
correction.45
MMU12
.NKX2
MOV34
gamma-secretase
gene-promoter
structure-directed
48AGACCCTTCAGTGAAGCTTCGAT1
phytochemicals
TCRαβlow
18-7288
Lindhal
LRR4
R1391
E7107-treated
L248V
.Developmental
Npm1+/-
5639
.Knowledge
Flt
B-induced
.Itahana
sgh.com.sg
GAL4-TFAP2CΔC181
CGG3TGG
KEAP1-CUL3-RBX1-IKKβ
WBC/mm3
26–29
ER/HER2
anti-CD11c-phycoerythrin
pathways77
Tal1
R267Q
GST–NUT
Con12
enhanceosome
479
Shering
23/193
RAD51.15-17
.Miller
HNF1A-linked
avidin/biotin/immunoperoxidase
Issaeva
100°
spliceogenic
C277Ymutant
19F-1
Spitzoid
corroborating
imatinib,3–5
non-lung
Lox-DA
V769E
non-TAM
MMRUV
AZD6244
-pyridin-2-yl
NP-40/0.2
mER
T-P
-1.91
Ksr-1
Q55X
credit-card
Principal-component
5503-5510
IV:30
Corcoran6
rubripres
ancestry.View
P1367S
theubiquitously
E48fsdelG
NHp-terminal
Masselli
7of
0.00503
0Â°
.RELAFUS1
Carrozza
±1.51
radiation-exposed
RK3E
B/Cdc2
M.A.St.J
SUPM2CR03
NDRG-1was
sequence–mediated
95Â°C,3
S100
-tests
Fig8D8D
11p15.3
.Untreated
AUB
DEN-initiated
GTP-Bound
.Positions
ATPases/helicases
-Asp-expressing
5′-GGTCATGGCCAGAATGCTAATTCATCTGG-3′
AMP-responsive
0.042764989
PC12
110:2259–2267
CCACCCTGCACTGAGTCCC
EMA
5/150
Q144R
4~14
before.22
netphosK
Aml1can
P-ALK
A2A
/RaplB
polysomnographic
GATGGCGGTATTGTAGGTGT-39
Paulsson
butyrate-dependent
7j–l
RbAp46
1780G
5-HT1A
pT3/ABNs
p53.117b
monotherapies
L858R-761Y
samelocus
L503F
gain/loss
Bacteria—The
L626P
Forschungsgemeinschaft
Katahira
observation.8
pENTR_L1
Tyr998
rag148
ETS1/ETS2
D499
UM-UC-3
760-bp
HR-based
Richarte
478–513
Q646C
G,5
-diamino-2-
ESR
GAAGGCAG
Z0331
I-II-III
RING1A
SULF1
E62K
MCF10ATk1-YB-1
aSF1126
Bio-Radassay
.X-ray
SCCO-019
levels,33,34
D321N
GFP-encoding
Max-
2125–2131
pIpC
Mlczoch
c.1306dup
Y530H
7928
Isogai
34.58
92,93
9.8–14.4
A289V-EGFR
p.Phe2638fsX
dependenton
full-likelihood
Ccnd1
González-García
186.2
HP-5MS
GIST_PDGFRA
.Runx1-EVI1
A129
respectively14
V577G
Oda
FIP1L1-
eYFP
karyotype.1,2
IL-6.22
1/10th
described.39,40
lines.A
±t
thalidomide-based
300/10
signaling.21
greater.R1881
uracil-containing
binding18
Brg
development.Tumor
St.Louis
062
BRAFV600E-like
Y13-259
.Abbreviation
2.52
66/146
4.03±3.38
CTSL
noncontributory
red=β1-tubulin
proteins.4±6
3-containing
pGAD-Rafl
W581R
K97R
β-D-galactopyranoside
I266
His–
RPMI-1640
cycle.19–22
myr-D11
5A-H
Mmp7
Eom
Ki-rasG12C
Ishioka
cetuximab.21
D38E•GTP
01-206
diﬀerent
µg/g
iodide/ml
6–51
IW.K.C
microenvironment110
4898
3.1/1.1
.X06182
CEQ
Q629R
C465R
Amcheslavsky
.IGFBP3
staining.1
6/70
GEF‐H1
mant-fluorescence
C/EBPαTo
CACATTGCTTCTAGTACA
environ-
6G4A
97,000
RANKL-induced
Tamra350
−.02
weight.10
26/132
C57BL/J6
PHF20
169-kD
hMLH121
w40
change.8
12–24
charcoal–stripped
strated
6,475
translocations.21-38,40,41
BioCARE
SHP2-YAP/TAZ
cancer/tissue-specific
-Src
CD45.1+
G466R
typeaNonfunctionalbOthers
BD189
ipd
GC-boxes
40–71
D870N
NBAS
150-bp
BMDMs
VEGFA-containing
6/2
1,013
GTCTGAGTCAGG-3′
syndrome,48,49
GNPs
6.3-
mediastinic
3997S
Mm01205647_g1
SequencingSanger
.Expansion
LB3
CCCAATCCAAATGCAATAACCCTA
DP-specific
log10
vapor-diffusion
heterooligomer
c.1039-2329_1409+827del
1229-1234
differentcellular
0.631
pBCR-ABL1
trkl
GSSH
N-carbobenzoxyl-L-leucinyl-L-leucinyl-L-norvalinal
non-D816V
4p15.2
MST1
GIy
.41,46
sclerae†
EAP
themsh2-GD855p–Msh6p
AML1/ETO
epidermal-growth-factor
P407
Xq11-q12
implicate
imunohistochemistry
2q31-33
tumor-suppressor-deficient
charged-to-Alanine
1594–1574
IL-2-dependent
neural/glial
.Exon-coding
pan-cytokeratin
Klemke
optionsDNA
Otx2
Ba/F3-JAK2V617F
hydroxylation-dependent
trP1-Exon22R
estrogen-regulated
fullblown
andJAK2
SFFV
Trk
5FOA
.Co-localized
63X
160-318
18/82
macro-dissection
NOD.CB17
Vector-expressed
NM_006231
forminor
.Anti-HA
VEGF1
36K
MLH1ΔC-ΔNLS
GTPase—a
Tu-9
zigzag
ECACC
Anti-Rad51
3133
183.Even
1.123
pUG35-SHQ1
p.385_418del
JAK2-related
U0473
mediated–growth
Chr3:71102887
PDGFbR-Pi
CATCCCATGGTGGC*GGGATGGTTGCAGAAG
expression142
β-catenin-binding
analogue/ribonucleotide
PDI
prone-polymerase
Glu160
1.l.I
precleaved
EGFR–Ret
cells.70
Omoto
1.1
controversial.13–15
18-week
D1241A
rs143406438
EPR-T681I-expressing
M239K
BCR-AbL1
year‐old
/PML-RARA
elsewhere40
sitides
H.H
.Unsurprisingly
identity.47
KIF5B-exon19F2
H-114
rs10259974
insulinreceptor
JNJ
BHHL
ID2-related
.Affected
pEGFP-DH/PH
R358H
drug-like
Mitosis
Specificity—We
analysisTissue
BRCA1-interaction
cells.5,6,7
effects.86
TCTCTTTTCTRBrBCTSAARBTAT
Fushman
MLH1-deficient
1is
−3.56
Glomax
His-
3.9-
JWR
5A-R2
A_52_P465012
Ala1099
29864–29872
Verteporfin
MSH6–Germline-Mutation
SNU-2535
AF802
anti-CD95–monoclonal
234-amino-acid
–p190
D352V
A8273
FGFR3-specific
BRAFinsT
Chek2
2.2.213
IV−/−
.HOC313
shPDK1
Ospedale
59.8
1595A
perivagal
cryo-sectioned
anti-PP1c
L611
24,30,36
Transcriptase-PCR—Total
Masaoka
phenotype.12
6558
ElA-induced
uc002uue.1
ExomeLungTumorIDs_Key.txt
ERK1/2-ELK-1
M14070
TRal
11.85
P=0.0088
RRRLRGQKK
pMIG-AKT1
suciently
drug-bound
Met77
ONCOPROTEINS
mutations/MB
.G1706A
AAATAATCAGTGTGATTCGTGGAG
pseudo-colored
Immunokinase
//www.molecule.org/cgi/content/full/12/5/1213/DC1
antagonist
*11A
D.
SP8
aromatic-amines
MSCVpuro
unpubl
pfu/cell
008610
cells/0.5
77c/g
promoter.76
sleuleuSer
.Syringomyelia
N841Y
expression,1
c.2547_2548delTA
63:1641–1650
Hybridoma
locus.Molecular
Cytosis
509B
Transwell-invasion
MMS
patient-directed
A048
B7‐1
energies.37,38
Santa-Cruz
sc-6217
phospho-Thr202/Tyr204
Obesity-related
FLAG–CLIM
DIFI
.Log-transformed
APC–β-catenin
29,703,388
.Polybrene
pg/transfection
MITF-m36
.Chromothripsis25
F48L
Bowtie40
dauers
AP26113
Microtubules
p38.4,18,39
Sum149
mid-sensitivity
8-week
tk-neo
.First-strand
Ch2
ectodomain-truncated
BCR–ABL1–negative
pLenti6/UbC/V5-DEST
11-Avr
MADS-box
PF06463922
BRAF/KRAS
FGFR1TACC1
0.88^1.04
evolutionarily
BLPD
rs231775
median-centered
//bioweb.pasteur.fr/seqanal/interfaces/genscan.html
wild-type-Flt3-
Rotterdam.26
mutations.57
Gonzatti-Haces
Adalbjorg
manuscript
rB−
5nM
butylate
30·2
dimerization-mediated
236.7±7.5
R200W
Apocrine
mul
context.1
1•99
mmunotherapies
YFP-BRCA1
−367T/−271A
types.18,19
LoxP-IRES-GNAS
Otava
p535,6
TetOp-HA-PIK3CAH1047R-IRES-luciferase
0.152173
10.0+
.C4I
Tumorimmunology
inactiveTwo
Inta-Gel
TRANSACTIVATIONAL
head-to-head
S847V
silyl-2HG
JAK2V617F-mutant
Fig.44a
non-2HG-producing
'caretaker
SAXS
Heterozygous1
5,500
1221delG
//www.bu.edu/nf-kb/gene-resources/target-genes/
Lys650
Weidemann
5'-GAGAGGTTGATGTGGAGA
CSPV
Nürnberg
G13S
.Exome-capture
M.B.M.
91,119
E216G
MAT3
MEKis87
CRISP3
anti-Paxillin
UE
.S30
substitution.11
J3
PALB2-interacting
L1015
597HisFS-614X
–ABL
-buffer
gastric-type
TVC
Δ230−248
388–390
E562
ID14-4
ubH2A
Leu74Phe
pathway.27
AS25t
5´-TTCTAAGCTGAGCCAGCTGCAGACG-3´
Whole-Transcriptome
K558del
ATGGCAACAA
α-prothymosin
∼0.80
Díez
myxofibrosarcoma
E0771
memory6
.Variables
FANCA/
p=0.0084
pedigrees.Electropherograms
160
pathways.11,22,46
1+ROR1
68Â°C
BglII-HindIII
TRIM24–BRAF
SensiCamQE
carci
CNND1
QuickGene-Mini80
LR06-286
0.25mM
-CTCTTGCCACTCGTACTTGC-3
ID028004
proline-based
perfor­
L706S
16–64
CI95
outcome.1
myc-Smad3
5.Orthotopic
Na4O7P2
v.4.0.2
Polyjet™
627-bp
-PCR
pBABE-Sos1
Notch118
CD34+Lin−
Ikk2-
late-fetal
E201f
tl
blockedGTPase
5′-TCCTCAGCACTCTCTCCAAT-3′
Levanon
−872
miR-130
adriamycin-treated
P-2714
Glatter
trk3O
v1.6-5
L687E/R688A
06/2002
signaling7
pEAA293
15N-p53tet-wt
=16
B-Raf/A-Raf
WAVE2
53,57
metaphase.1,8
Xxylt1
0.06-1.00
MINOS1-NBL1
Em-Myc
rs67749800
646
discoveries—novel
erlotinib.58
BRCA1/exon
RG-8
Leukaemogenesis
dissimilarity
L713F
p-RON
mgimatinib
N2038S
Ser|
CCG3CTG
Src-homology
.E37G
pCAS2-BRCA2-exon7
NM176
1/2/3/4a/4b
CTCGCATACCTCCCTTCC
LATS
700–1164
suppressors6,7,8,9
isodium
8.4×103
V954R
T158M
136–137
Mui
hydrophyllic
.Automatic
V95M
trials91
pSmad3ser423/425
H1666
Dinkova‐Kostova
GRα-responsive
Y920
cells25
huB2M
reported.46
Cer
differentia­
SPOP-SBC
1/54
3.174
Egf-supplemented
HumanCNV370-Duo
six-amino-acid
fewernonfunctional
ATMMut/-
anti-SHOC2
heterodimer-induced
92×
Figure9B9B
anti-WHSC1L1
use.88
TM87
PTC-200
monofunctional
Peptide
pGBKT7-PKCϵ
ENCAD
22,28–32
GDP/GTP-regulated
M24862
\_
Etv1-dependent
clear55
kanMX4
polyps7
.675
Reagents—Human
59-TTTGAAGCAAAAGTTTGATGAGA-39
62.47plusminus12.04
G14V
b-f
.Leukemic
560–577
tissue-culture-cell-based
development.7
Foote
Tyr1248
MMTV-PyVT
.Compressed
PCR-genotyping
CHEK1/11q24
3078
.Massague
EGR1/D5S721
msh2-VD862
p.Phe1088SerfsX2
0.446–2.239
Y772
300248
deubiquitylates
non-medullary
IMab-1
.0112
p.N30fs
orange-red
INHIBITOR
solvent-accessible
re-transformed
low-TE
AGGGGGCAGG
ε-amine–to-F641
targets74
neuroimaging
372−381
34/193
sequencea
left-sided
PCM25
QPSMT/SE*
inhibition.The
GTTTGTGTGTGAACGGGCACTGAAATAT
6/12/91
IM.10
.218T
180
ISIS2503
Fas-p53
.89
p.V658F23,24
NIK/GSK3-dependent
omission
CACTCATCTACAGAGCTAGCATTATC
R20Q
32K
LSL-N-rasG12D/WT
0.10–0.65
onlypreviously
melanoma.5
Mbo
C491W
GBMV
BCR-ABL.31–33
2D6
-x-F
G224W
chemotherapy
32.00
AEG3482
development56
genomes98
=19-4-7
Ad-Af
82-2-537-6586
mDedd2-Reverse
Paszko
NaAc
1.53
Y762F
supra-basal
MBD-associated
receptor-mutated
describedActive
1.1plusminus0.1
fusion-harbouring
18.19
MPL.17–22
S672
lymphopoiesis.68
nihms820730f7.jpg
less-understood
Val256
I–L
S1B–D
protein-4
betweengroup
927–933
.FA104
∑
Mono-Mac-6
//www.icr.ac.uk/fact
expressible
45.06
multiplex-PCR
.Pindel
keratinocyte-produced
ÃŸ2-A/CRNA
thep21
FxFP-motifs
35-nt
CP06
.Arsenic
1,025
0.012
Rapid-Cycling
S382P
WDR62
Coux
dominant-negatives
thermoautotrophicum
mM,9.778.5
nondose
YVNV
YY1-EWSR1
EZR-ROS1
epithelial/ESR1+
KEAP1-involved
46–54
227.00KB
inARAF
set-points
pADH1
split-signal
Fig2B2B
utility.9
PI3K-directed
protooncogeneforms
V14RhoA-expressing
c-bcr
Smad4DC
B*1594N
D3000
pathway45
HER2/NEU
MEF2B-dependent
371
214±22.6
Lef1
PPTRT
2034–2040
1-linked
P=1.2×10−4
siC-treated
photobleached
V/PI
H-D281G-5
HPA024574
2317
Tribolet
o5580-o202
aniline
4,283
Stoffers
patients.7
*Twelve
P153H
4/04
inherted
classesof
16.2COL6A1Collagen
.Triphosphate-binding
GTP-to-GDP
genes.30,31
B1-domain
Exon6-PMS2
Siddik
NKY546
YUMAC-P
SDS-proteinase
kON
W303
post-development
picomoles
hyperheosinophilic
Two-wk-old
49.4–51.9
Nf1+/−
170/48/82
A33
PZ
F434M
contralaterally
XbaIlHindIII
8B.Figure
E013
senescence8
120°C
PRIM2
non-Myc
homodimers24
tumors6–9
WT2
RUNX1-I41F/RUNX1-I41R
0.082-0.20
MutLα10
Figure3c
re-immunoprecipitation
H3K27me
Sgt1p
gp11OPrOt-rk
cell/progenitor
ERÃŸY443N
Amendments–certified
0.90–7.67
hygromycin-resistance
shRASA1c
CA26089
c.755C
.3610C
doxycycline-containing
Caspersson
IVS11-20T→A
cFLIP
RP11-469J18
anti-Chk2B
melanoma.6
D640
rgA
thecells
Thermodynamic
25.3-ms
.Mediastinal
TrC
JAB13
Tsarfaty
P=0.43
PYY
thioesterase
chimiotherapy
Multisizer
PSD95
5′-GGGCGTGGCTGTCCTCAAT-3′
3937–3943
29.L344R
GCCGGCTATAATGCAGTGGAAG
proprotein
0.882
F1245C/V/L
Ser102Phe
AIAAZJ2
45.2
9/11/03
al,34
laminoplasty
Non-physiologic
Y731
pmiR-ABL1
UTP6
cancer40
610756
Rag1−/−
Glu199Gln
CRISPR-based
.Construction
Ini1-deficient
Syringomyelia
Yes2491
Leu-198
2X2
2F9
NCI‐H1975
planimetered
Baljuls
AAT-3′
Nagase
phosphothioate
-sheets
SCAF8
diagnosis.19
3III-2
BR0020
EWSR1-rearranged
HA-as
M-003225-03
Bitransgenics
train/test
−5.2-fold
.Elution
I322V
expression9
c.7242G
41005
NPc-M9
cancer-affected
E-Twenty-Six
Co-precipitated
E‑PR
TH588
R683G=2541A→G
1,615
Transcriptional
17/99
disulfide/dithiol
URA
Pruritis
FGFR1OP2-FGFR1
population.4
ScaI
uvRed
9315
HD-0173
actin/cytoskeleton
Alexeev
IVS10+12delT
TTCAGAGTAAGAGGCTAAGG
L353P
:28–37
fsh
JAK2/Kit
trpl
dbSNP
RB-null
81.5
Crm1
â€oediploiwdâh€e•n
×162
NFκB2
0.175-0.331
syndrome2
5′-GGACTAACATCACTGAAGA-3
exon12
V677A
LAMTOR2
cells.55
IVIG
surface‐exposed
4XPSB
Phe595
SK-OV-3
C1156Y–
LNCaPprostate
Skp-1
ligand–co-receptor
LATS1-WWP1
Msh6mut
perosteosarcoma
insFQQA
SlZ7-K-R-V-A-K-R-K-L
UMSCC1
semigenetic
A_51_P196605
ubiquitylating
cancers,14
PFK
MCV-positive
Godon
Smo/cilium-derived
andm
5′/6-FAM/TGGATATCTAGGGGCGCTATGATATCT-3′
geneticinstabil-ity
Caveolin1
SDS-PAGE/immunoblotting
.Hashimoto
SOC2
2/64
0.01μ
S3a
lymphoma.12
Phe243
3y-CR
1hors
.STK3
5′-TGACTCTCGGACTGAGAAACG-3′
4.6+
HGVS
cancer-onset
Figure2a
group37
anti-HLAclass
cen
c-d
2640–2774
.Rad50-HA-tagged
p16INK4A/p14ARF
357A
two-color
Hindlll
µgcswl.3
2,4,5,6
Thirunal
hEPO
674
TCRD
Filipp
IV:27
score*
f2
p53-P309S
6.3-fold
BRCA2-independent
Morbus
31-year
HD-0286
glucose-induced
DASATINIB
Fig.7I
/CDK2
H1094Y
p130Cas
Bioresoureces
pMB001
004
BCOR-3196F
freqb
pQCXIN-based
homonucleotide
.SNU-484-LPCX
2889
Salviae
ETO-expressing
â„¢¿-/ni
post-hybridization
CD13+
expression-cloning
elec­
effect.We
Byeon
U87MG.wt
trimethylation13
MKI67-forward
R878H-mutatant
performedby
rs11571317
Y40A
smMIPs.7
E017
+0.32
chemo-radiotherapy
LNCaP-hr
HPA041805
Y878
single-plex
vivo117
begnin
≈91
SCL25A5
RESULTS—We
p65/p50
Rawadi
shRIT1-3
tumor-immune
07-436
TAF250
0.06–0.48
13q31.3–q32.1
.LEOPARD
14q+
27,000
16q22–23
05-1242
involvedin
BrafCA
ACTTGCTCAAGGCTTTTCCA
Densitometry
.NVP-TAE684
ΔNMEK1
deletion.14
lower-affinity
Flores-Alcantar
Bourouis
Q.I
c.3248A
PTK6
mutations.21
inPro-34-*Arg
9.3–25.5
†Tests
CCNB/CDK1
M30
cancers25–27
Montre
D814Y
Fig5D
anti-DP103
Ser768_Val769insAlaTrpThr
16,600
L493S
tei
UO2509.1
NM_000455
Spectrophotometer
pcDNA5/FRT-AR
.PTPR
FastTaq
63.71
A.B
|Fc|
described.36
CRAF/RAF1
M31
DNMT3AWT/WT
BH3-mimetics
model,2
Su-DHL-16
H129.19
nonintensive
q33.3
.HF7c
Y769
U2AF65
86·3
solid-pseudopapillary
Chemiluminiscence
RAFT
LexA-RING
Xank
chicken-embryo
above-delineated
POU2F3
aCML
prognosis2–4,15
described.30,31
optimizition
anti-Xpress
.MED1
E709H
H178D
40.5-42°C
.PDGF-Rβ
alkaline
//helseforskning.etikkom.no
lym-
TACC1ex13
NHS/HPFS
.690
Choudhary
5′-AGGTGTTTGAGCATGCCATCAATAATACAGCTGGG-3′
post-spliced
p.Ser1457ProfsX18
negative-­feedback
HhAntag
CRAF-Ser338
51–54
NTA-Ni
cc.kmu.edu.tw
cytokines172
p.Thr621Ala
anti-YY1
Peled
1181–1158
p16Ink4a/p19Arf
re-cently
heterologouos
'5
C-CBL17
Pleiomorphic
/immunocytoma
C17orf37
PR61
Sk47-Br49**
ESC31
state,87,88
1.3–3.8-fold
66.6
I2-well
herbrother
Mora-Lopez
RRM2-Valine
onco-fusion
86/44
Liège
RUNX1-mutated
LR02-064*
Schiller-University
AX.1
-diamidino-2′-phenylindole
ERCC2*
time-to-progression
pLKO.1-hygro
Ins13
onstrated
275–279
BAX
60×1.45
2255
Flag-Keap1
41-344
rearrangements.19
G105R
SM-Eo
.13,21,26,51
nrf2
A372V
HOXA11
CDC6
over-expresses
96-
tsuchida.mcom
.gtf
//www.mcgill.ca/androgendb/
arrays—RNA
RASwt
9Dna.lqâ
adipokine
reports.12-14
175670
Immunodeficient
.Competition
No,29
single-agent–treated
HCC/Del-TM
fisher.test
used.As
photodetector
Leu-858
dual-laser
micropapillary
skipping/inclusion
D58
Asp-
cttcttgcag
~2.1
Pendino
gtatatttat
6-7
daunorubicine
1–185
HBL1
cases.24
B62PW
dark-to-light
IL-22R1
T7-MDM2
hemihepatectomy
10A-C
AKT-Thr308
Dimerized
TX2
44037
/well
ill-defined
TAAAGCAGCGTATCCACATAGCGT
N-APC-expressing
androgen-deprived
literature25,26
Rasdependentsignalling
HRAS-G12V
F90S
33,62
CLINVAR
kinase-dependent
TERT/5qSTS
microcomputer
Arg→Gly
082
c.7805+6C
RING-type
Hydroxylation
fixed-effects
thanother
Mikkelsen
ChemieTek
Octyl-d-2HG
monolallelically
Toyobo
1–392
cluster-type
A85T
H11-12
disease-modifying
.Clair
24,26,27
5′NOTCH2
kinases.5⇓⇓–8
2.0b
LysS3lGlu
A-particle
-pRb
87–111
.7,15
adenoviruses
Y694/99
his-tag
ALDHA1
345.2
/1KDX
16.0+
230–426
.1789A
U2-type
L858R/I941R
Y1228H
GPR55
53,402
T336I
Nuvital
10q26.13
Myc-Tag
Toll-like
conserved.48
Lin−c-Kit+Sca1+
.GCs
VRhoA
Y260X
2Fs10120-013-0298-y/MediaObjects/10120_2013_298_Fig4_HTML.gif
.Follow
Mll–AF9-targeting
Om4
Schmittgen
EN-V2
age7
Nystro¨m-Lahti
twosettings
59-CTCGTCATTGTTCTCGTTCC-39
EGFR/PDGFR
TTGAGAATGGCTTACTTGGA
598nucleotides
11L576P
1NOY
NC_000011
attention-deficit
Coutre
//blocks.fhcrc.org/sift/SIFT_
GFP-ASXL1
11.02520367
CML-CP.18
localization-specific
pathway.5-7
2.45
CHARMM22
Frt
8/113
Gln123Arg
BROCA-based
1-megabase
StepOne
H3K9me3
co-infected
pone.0064364.e014.jpg≤−1.0
agarose-gel
pNF-kB-Luc
P3R
1,744
Ml3mp7
anti-UPF2
Sensitivity—To
Fig1B,1B
7.D.2
–89
FOLFOX4
heregulin-mediated
∼22,400
5′-GGTTCAATCCAAAGATATCCGGCTCTTTCTTTGGCTTCTC-3′
Minella
.Immunofluorescence-Infected
M-V5
AKT2-H355Y
.Antigens
instead137
−/T
transformation35
98-126
phosphoinositide-3-kinase
3×FLAG-tagged
MCM2-7,34
exclusive.20,21
DMBA-transformed
P=0.0085
RP11–58O15
replication.31
Eu-pY
NM004374
BCOR–CCNB3
Parke-Davis
auditory
MSK486
complexesbind
Flexi®
25thth
methylene
Cys-31
previously.6,10,16
sc-126
-sh-Smad3
rho=0.91
areaof
CAMKK2
≥90
tot
patient-related
cells/3.5-cm
monthsb
GSK3
phosphoSTAT5B
Igh
-0.573
auauccuccaccucucccuTT
COSM
CK19+
ALK-L1196M
read-orientation
FNII
STAT5B-deficient
inhibition118
Lp53-Y220S
Fig.S1A
TTCATTTTTGCTTTTCTTATTCC
MLL-reverse
RhoAmediated
DNA-DNA
.FLAELCR.TDRT
DNMT3A-related
TopHat-fusion
GCAG
CD342KSL
lyrnphoblastoid
progressed,5
x100
inhibitor—as
SNU-484-S3-1
//picard.sourceforge.net/command-line-overview.shtml
CreERT2
Gly35Val
Ras•GTP
Ill.
Fig2G–L
LKB1-
CSD-melanomas
A*03010102N
96,98
XP_691901
activation,6
nuclearFigure
extraction.17
follic
BalI-EcoRI
phaeochomocytoma
Dacic
R501K
GTAAAGAGTCGGGGGAGGTC
1.6.1
R452C
SalI-restriction
.Cdk4R24C/R24C
R898
lr
ERK2E322K-expressing
topto
P-AKT
s1
Tyr-substrate
germline10
SNU-601
21-N
syndromes.32
Stafstrom
non-representative
nearGene-3
S249C+Y762F
Ruo-Hong
Ca++
359–379
//www.broad.mit.edu/gsea/
AP26113-
T298
pre‐
2401
Figure2e
BRAF-hyperactive
non-transcriptional
5′-GGAAGTCAGTTCAGACTCCAGCC-3′
c.IVS9+5G
Atha
11–amino
B-raf−/−
reports.18
1°C/min
`floaters
.G=R683G
antiestrogen
c.727C4G
tumorsvaried
.Putting
170.3–171.0
proliferation.13,15
7096–7101delAACTTTor
12,006
hRad54
CAF40
BACH1-K52R
self-activated
FFPE
Mangelsdorf
p.Tyr16X
TTCAGATAACCTTTCCCTTTGG
Haystead
Component-specific
PHYSIOLOGICAL
BRAF/RAF1
.Vismodegib-Dependent
kinase-deficent
pLXSN-ErbB4
displaya
report.6
AVRgeGsLSgLaGGeDmaYNEYstnknKe.LkehHPLirkmyyKnlkK
lesions.11,17-20
HIF-3α
for-
VHL-binding
nzhangchina
11-kb
phospho-epitopes
3DCoffee
1·5
white-walled
POSB2
HaloPlex
Rajaram
268K
CFC–BRAF-associated
-PBX3
Th1
S9d
findings.19
HCC.However
Pitx2
C2β1–β2
S6b
199/258
pY490
A279P
understanding13
p.Gln430Hisfs
0.00976
n=418
flankFGFR1.14
Asp1507
Br81
mAChR-mediated
SC–Ura
cence
KRAS-mutant/XPO1-inhibitor-resistant
Chi-Square
ex12for
AKT1-E49K
surface32
head/neck
mg/die
arginine–glutamine-exchange
Seromed
A2780L
shETV1
samr
protein-tyrosine
NSCLC.2-4
P=0.254
Obs.
Silander
Figure4A,4A
recombination-induced
,1C
TRANSGENIC
XAR
syndrome/OMIM
understood.1
anastomotic
2/4
PrismR
Multialignments
pJK103
HiSeq2500
2254-2276
c.2603+2dup
Savoia
GGAATTCCAGAGGG
14/27
gene-copy
Notch-1
170244
ThermoFinnigan
‖Leads
NP_001015221
partners—6q27
TPYLESGISLFSDDPESDPSEDRAPESARVGNIPSSTSALKVPQLKVAESAQSPAAAHTT
.Gata1-Cre
.LightCycler
KITD816V/Y/N
ERF/DP103
.COX-1
P.A763Vb
P04-1084
identified1⇓⇓⇓⇓–6
melanomas.10,12
lymphoma.54
±5.9
receptor−antagonist
I8
//www.ebi.ac.uk/ipd/estdab/
nucleus/cytoplasm–targeting
mgDOD
JAZF1-JJAZ132
Nonresponders
hyperinsulinemia
metaphyses
Gly1656
molecular-dynamics
GTL
Idh1WT/WTLysMCreWT/WT
N-CoR/SMRT-corepressor
10.1002/cncr.29676
interferon-α–induced
ATATTG/gtagga
Ly10
calcitonin
47–85
RP11-484L21
.PON-P
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
Rajkumar
Kleiblova
mismatchhad
18.1×
4764
DLCL
Asp-83
GTTTATTCCGGAAACTAGTTTCAAGAGAACTAGTTTCCGGAATAAACTTTTTGGGCC
–KTS
Gln530
°C/59.7
DNA-Pkcs
R465H-Fbw7
ø0.5
.Lam
T283
8–16
depolymerization
ionotropic
p.Leu36Arg
Genome-scale
Akt-S473
1,885
Q347_A348del
patient-associated
h2
biobanking
——H
11904312
gly-A+
enzyme-SYBR
HCK
never-smoker
malignancies.17,18
Gl.
non-CL
L486-A489
dataAbstract•
c-Akt
subtypes39
ences
4,476
MYO18A
Most-favored
M517W
HBond
975
23-gauge
4Gi0
2.Foretinib
pCMV-p53-WT
Bumm
knocked-down
Lac-inducible
XhoI-HindIII
4451
NaeI
tyrsoine
v2.3.1q
15/70
SRD5A2
GIST-specific
MPM
others25
NHA9-GLFG-2
ptel-D2S2259-D2S391-
Algire,1
13,32
DK55748
SVHUC-GATA3-shRNA
STK1117–25
+/total
non-Ig
add2q
Rho-ROCK-actomyosin
Berghofer
glycine/PBS
5′-monophosphate
Liposarcoma-Like
C282Y
PDPK1
patients,48
FAM131B-BRAF
Rad51/Brca1
growth-inhibitory
multinodosa
R.ETV1
constituently
epimutational
RasF28L
ErbB2/ErbB3/ErbB4
c.1556_1557insG
LP96-057*
5′-TTGGGATGATGTCGGGAC-3′
GlcN
miR-124
16,19,32
.SYBR
p53-R270H
TCTCTTATCACCAGCATTTTTGAGG
933
concentrations.11
.ABL1
2nd-line
SA-eh-N
DEL+PM
Nanozoomer-XR
N133H
humerus
alizarin
heat-treated
23/28
24C
CCTG
BRCA-wildtype
cells/drop
scaffold-like
www.ncbi.nlm.nih.gov/projects/SNP
anti-CD44-FITC
*C.
pGEM-TEasy
Y.-H.
HLAB
V52
7762-1
Ayad
2938
struc-
C515S
570nm
-AKT/protein
1099X
.Shorthairpin
0-45
498
RXDX101
30162
keratinoyctes
Π/6
CGGACGTCGGTTCGCTGAGTTCCACCTAGTTGCTGCTGCTCGTGGACTTAA-5
O-O
takingplace
mammospheres
penta-
1949–58
siRNA2/50
MEK/MAP
D-004937-04
Hendrickson
TCF-3
S-Adenosyl
15/125
control-transduced
ggplot2
down-slanting
PDGF/Rs
H838—all
MCG537
o40
GSE53799
NF-κB–deficient
site168
S00–33
GFP-Rab7
BTF2
1783
TM=transmembrane
Runx1tm1Spe
element/binding
RP11–25F7
et.al
Gu
2~3
binding53
.Step-down
FIG-e2CF1
13.8-55.8
inhibitors129
1AN2
pCGN-PLD1
D101Y
F1174-mutated
p.Met543Ala
ERK-MAP
E.W.
Proligo
Wai
Hyperactivation
5C11
anti-CD20
growingthem
neurturin
www.korbel.embl.de/software.html
.12792.001
ITT
V487-P492
indirect—confer
H00060485-M02
NSCLC.4
85364
10/435
rag2
terephthalate
phosphorylation-deficient
−1026
W1211R
14,207
negativephenotype
breathlessness
6989delGT
EGFR-deficient
antimesenteric
cesium-137
phosphoinositide-dependentkinase
function.As
gene-lists
g.61719472C≥T
rearrangements69
non-uniform
juxtaposition
phosphorylation-triggered
p21came
MIG-U2AF1-Flag
42MGBA
118-amino
3,2
UCHL-3
collaborating
181H
isdownstream
FGFR21
Fib
.CGH-array
R462C1
R7
.Close
120,121,294,485,486,520
1•1–21•4
70–530
MouseWG-6_V2
monomeric
HGF-activated
.Forty-six
melanoma,79
R1-R3
T798
immunosorlent
Calu6
off-context
pathways.29
factor,74
Consed40
NCIH2228
PTC1–5
levels22
HE-stained
2263_2278del
I-SceI–induced
S202Y
Hanawalt
AG1396
Tohoku
inhibition30,36
792/812
p100/p52
FLT3/ETV6
p.Gly1246*
GRPRTSSFAEG
cH2AX-MDC1-NSD2
MRQ
0.247
.Puregene
GOFproperties
Trachea
m/49
4.32
www.jmpin
PRODRG.16
multipronged
0.1333
Topcounter
immunohistochemistry.15
anoikis.72
+erlotinib
.Gln72
Okuda
anti-pY
830
HPA005456
I891M
HDGC
mir-15A
570×
interrégion
a-melanocyte
HEC
NF-κB/Jurkat/GFP
GGACATGGAGGATGCGGATAT
substrate,23
C-RAFSer259/14-3-3
site-binding
Arizti
RAS-CRAF
Kumio
sitefinder.html
SNAT1
binding/dimerization
5′-GTGATCTGTCACCACATAATTACCTTTCTT-3′
AAAAAATCCTCTTGTGTTCAG
Foxb2
CASP5
c.7480C
VLA-4
cGMP
1,594
PDGF-A/PDGFR-α-mediated
.Regarding
Frs2—
−2.32
MPCsBCL2
multiple-strand
16,593
14,020
3/48
paf1Δ
fusion-bound
c.748C4T
0.01–0.68
FLT3Y589F
S4E–4F
31,32,75,76
aln
at-32
gene-drug
pENTR_L1-MEK1
NS622
nine-month
SLC9A9
c.340C4T
Y—
silencing.5
affinity99
autophos-
intrapathologists
TLM-HMECs
R-Smads
immunoexpression
ligation-independent
Vilcoq
immunohistochemical
555+1G
MTHFD2
H-300
Dotto
16p13
Rakhra
3752
PAX3/7-FOXO1A
97
RasG15A
.0016
gtaagtaga
.MAPK1/2
yorkie
3Ba–c
≈14-kDa
V8339L
OptiQuant
Ret/PTC2
9/0
LATS-independent
GAP-binding
cell-extracellular
S/MARs
201203
Alk2
Ser988–Lys995
F667L
G1357A
WT1+/+
splic-
L344M
Multichip
protein/silencing
nuclear-associated
puromycin-sensitive
exmained
exons34
.Wild-Type
iReverse
sBRD4+NUT
dotted-lined
CLN3
S2.1
T401I
Rho–kinase
HR.20
1CHU
9.9e−5
Q196X
3878
Gln72
heregulin-β1
⩾1.5
anti-B56δ
substitutions.10
601/602
t=0
iPLEX
HER2tumor
3.1.4
4Ba
2°C
9451
factors.3
15–100
RETK
MIG-Bcr-Abl
-like
c.1696-
mE10
-CACCCGGAATGAGATTGCG-3
Artandi
0.5–90
midgastrula
receptor.33
.Eluates
pIRES2-CTNNB1
Bredemeyer
cagggagatgaacttcttggtgt
M-J
743-996
mg33258.f1
NRP-154
.Small-pool
Rep/ssDNA
p3TP-Lux-mediated
R178C
kα5
5′-cagctgattccctccccttc-3′
R96G
TTGGAGGGATCTCG-3′
angiogenesis130
P70S6k
R04-0020
AAGGTGCTTGGATCTGGCGCT
P100A
intracerebral
FANCCgene
.MBII
M33539
angerhans
-s
A775ins
prefibrillar
62/2415
phosphopeptide-mapping
polymorphism-induced
NM_022454
Y640F
I02
p125
DIXDC1
.30,32,34
cell9–12
MD-085
926-68073
largeGIST
multilamellar
pMSCV-EYFP-IRES
pkin-24ploxp
Phe1088SerfsX2
SSNV
AnalysisFor
Weiterstadt
toxicity.17,47
portend
262
monomethylates
47.4
44106
O105
−2760/−2486
JM109
90
1Q
P261S
database/total
0.50-1.54
0.34
MEK1S218D
Boehmer
PARADIGM32
PDZ-Binding
5′-CGTGGGGAGTCAGCCGTGTATCATCGGAG-3′
NRAS-mutant/XPO1-inhibitor-resistant
high-FBXW7
BCL2-interacting
sarcoma–associated
ADVIA
Affymetrix®
1410
NM_004449.3
iu
B1.37
-0.22
carboxy-terminus
P2RY8–CRLF2
1–209
TBX3
SV11
CAGGAAACAGCTATGACCACATCTATTTCTGTGCTGAAG
subfunctionalization
CBR2
1/74
.7C
2409N
published4
5-Bromo-2¶-deoxyuridine
85.4
//dock.compbio.ucsf.edu/DOCK_6/
180–195
13C2D2-
Eberhardy
MC,34
68/96
B4F8
eosin–slides
antiHCVantibody
φ
4,930
+4001
gene-specific
GI:52673246
3q27.1
pBSK
CCGCCC
Qâ
3.48
BeAtMuSiC
MAST2
fSmall
p44/42MAPK
anti–hepatocyte
BioGem
homotrimeric
13/6
0.2–38.5
26-31
mutated38
carcinomas,14
25398284
oligoduplexprobes
GGCTTCTGACTTATTCTTGC
estrogen-mediated
pretreatmentin
Na+/myoinositol
6781
repopulating
mutantsaccording
61/77
p.Phe44Leu
theimmunoprecipitate
FRCPC
MAPK/PI3K-Akt
NanoDrop®
comparisons23
R1923
APC331Δ
p21-binding
|ig
480
Buttner
pEAA59
Unigene
AGTTCCTGGTGGCTGAAATG
properties.Several
K745
RP11-1145H17
voriconazole
ETV6-ARNT
SUBSTITUTIONS
families1
.MPO
nonstructural
AKT1/actin
substitutionconfers
V569
reportervector.Cytomegalovirus-driven/3-galplasmid
41,783
.FLT3-ITDs
5′-TTTTGAAGATGTTCTC-TAGC-3′
Benjamini-Hochberg
91–95
.GAT
.separate
291delC
.+GS
c.391C4T
Leu862Leu
5′-ttt
2044–51
JAK2-defi
Hei
ChIP-Chip…
patients.20-24
pone.0032555.e005.jpg
M/35
T359K
TheTEL-JAK2
trans-inhibition
2549
CC234TT
Depreval
preosteoblasts
CD5+/IgD
anti-PI3K
immunofixation
ETV6-RUNX1+
BR12F1/RAUTR
41cER4.40
1,848
.376A
gpII
AS2
Ethidium-bromide
0.00616
71-10
doi:10.1371/journal.pone.0025021.t003
homodimerization.49
AML-1-dependent
J.Furthermore
5′-RRRCWWGYYY-3′
HAUSP
RNA-68
.Parts
199715
.MCF
BFTC905
.Ferner
CHASM19
under-calling
treatment.Figure
inactive–active
LV-transduced
Fbw7-stability
48.2
Delta-Serrate-Lag2
a2
.Limb
GUCY2F
STAT5B
6-bp
lymphoblasts*
HT115
vivo119
260.0
EPOX
MM.23,25,26
sMTERG
paclitaxel/MEK162
arteriosus
anti-HNF4α
Ankhd1
34,36
Otx2-/Gbx2+
marrow.2
CCNG2
.Tracing
loop7
p.G230V
αPALB2N200
//support.lincscloud.org/
P229Q
SMYD2
,32m
p.Ser786Phe
NM_147171
pter1p13.1
CD42b
BrdU-labelled
Q207D-transfected
Flt3-32D
K252a
Ssa1
EWSfusion
mp53
Angiomatoid
pCMV-p53
Y646D
Malanga,1,2
o3.5
4L9W
nodular/desmoplastic
pMIG/HAhBRAFwt
hypermethylation.46
cycle–regulated
3386
Tnfafl/fl
pMIRB/FGFR2c
0.016–5
ESX
DASIT
Abl-interactor
EMBL3SP6/T7
XNP100
RMC20C030
cre
S.K.T
I2007
hydrolysed
CATCTACAAGCAGTCA-3
manifestations1,2
Bacp37
D-MEM-F12-based
Sequenom.14
insert.4
pcDNA-1
..c
CRC3
18-42
1149X
Phosphopeptides
TCSPC
aneuploid8
62.67
IGH/CDK6
18/31
inhibition.51–53,73
610181
c-Met-transfectant
MassArray
hyper-mutated
.1126
p.A502
CCGAACCCGC
TxRed
,30
anti-H2AX
2F2019.atom
/AKT
AF148946
HA-CBL
Lys97
Medium-range
IO6
Schubbert
NZM2
M373K
ab70765
analysis15–18
Murray-Rust
slowered
10Mb
melanomas99
CS20LO
F–I
Chung-Yau
immunoreativity
Notch1-ΔE-IRES-GFP
cells.Alternatively
p85αY334X
5-wk-old
homologue
erbB-2and
TGF-β1-negative
pREP4-PRKCBprom
.Jarrar
GAGTCTCCAGGAAG
A10mut–A7mut
double-resistant
N-SH2−
AALL0031
•tl
Hist.
post-Cre
scattered/motile
Arg202
Runx2-mediated
E7del
L151W
1:1.5
trioxide
anti-DCX
.S249C
Vanrumbeke
CloneID3257346
gggtg-3′
GRM6
−8.8
V1042F
energy-minimization
Thurneysen
wt-5
chemokine
DN
–deficient
CD_E545K
ATRA-responsive
IVS24–5G/A
poly-pharmacological
recurrent/medically
'decoy
Å2
415–820
R70P
Lys600
1:500–1:1000
11,032
KANK3
Ul-Haq
astrocytoma131
quartiles.Correlation
.Dominant
224-bp
Gli1-target
Na-orthovanadate
YPH499
LIC/Ek
polytherapeutic
PDGFRα+/+
3-cm
fusion-specific
.FOXP1
Estradiol-Independent
TPC1
sarcoma-specific
cyclins,7,9
hyponatremia
V191I
5′-CCCAACAATAGGACAGTGCTT-3′
Rho-family.15
—Fc
K5.SmaFigure
bA110J1.4
sKIT-level
cMET/ALK/ROS1
5′-TGCCAGGCCACT
DLG1
microsomal
c-12
Chi-Mei
HTSeq
B-RAF-
.miR-520a
T411I
αSMA-negative
µlconsisting
PMR
R588Q
Bcl-xL22
non-K27
1.94±0.15
dataindicate
cells12–14
pBI-ERF
5′Pso-TACAGGTAGCATTTTCAGTTCAC-3′
G484R
A436V
Bard1-null
ephrin-B2
11/361
PIGTP
/highwire/powerpoint/139511
F341S
-CTGCACACTTGGTCCTGGTTTTCACGATCAGCTCCGCGTA-3
Vortmeyer
lac-Smad2
AK302049.1
H697
5.5.7
R282A
Onoyama
cromolyn
TGF-beta-induced
BxPC3
choline-methyl-3
3,50–52
c.2573T
.Tsichlis
PTENY86fs
TIE-2
TTLL6
c.7963C
8,17
.MyD88
sc-397G
TrkA-amplified
arterial–venous
two-hundred-and-ten
MMTV-luc
multi-ethnic
hydropa-
misregulation
482–659
S7E
4278
S-transferase/Igα
FGF1-activated
SCC28
v5336,25
CAC02
co-­transfected
SKNO-1
Aα-R182W
KIT−SCF
T49.2/T49.3
Tricribine
Notch-responsive
7362
Fischer,3
Pre-miR-16-1
Lys88
v22
PC-6
pBABE-puro/3xFLAG-His8
rediluted
Ki-
EGFRs
S.As
ependymomas.1
Induced-fit
trans-splicing
2vuk
HAPLO-INSUFFICIENT
C338
*Based
Phenomics
SomaticIndelDetector19
Mx1-Cre+/o
21,540
genes.25,34,35
c.894C
2453
juxtacrine/paracrine
S413N
p42/44-Erk
mpk
α–RB1
Rat1-myr-P110α
AC005995.3
M6=3
literature26
SJHGG081_D
10/50h.p.f
ETV6-FRK
20q13.1
adults.5,6
G412E
domain-mutated
patients.4,5
V1125M
pcDB-Ras
.PLX
Comigration
.Protected
S3291A
PtenWT
Freed-Pastor
PWWP2A
tumours1
macrophage-colony-stimulating
families,3,4
AZ628-sensitive
=200
long-debated
.Pat
junction42
TE-2
FGFR-dependence
50jC
C4742-95-12ER
JO30
INSR
.Proteinase
Prognathism1
hypereosinophilia29
non-MSI-H
SP2
14-15-26-A-8-A-24
Serine-473
apo-forms
Met-531
β-branched
stereo-chemical
43–65
infectingthese
13,18,19
anti–C-TEL
.Tolerance
Three‐dimensional
0.585
thiosulfate
//www.gdb.org
GM-CSF
1.5m
Eff
parent-proband
X.=
TCRalphabeta
Glu-171
V157D
IL3-indendent
pmCFP-K-ras
reimaging
IIIc
TnT/T7
pColdI
Fig.2A-C
WM3918
D236A
TAS
teleangiectasia
growth.11
UPlanFL
compartment44
NOTCH15
cases5,16
hypermutation
2.1-fold
Figures44–6
BMYB
5′-CAGCA
Thr668_Gly669insVal
variants—p.I107T
Wold
G/CAllelic
IDH2Wild–EGFP
GAGGACGAGGACCTCTTGGACATCGAGGATGAC
product.13
mutations.11,16–21
present,254
CAG→CTG
mice.23
spot.In
p.P1010S
www.jbc.org
PDGFβR1691F
autophagy-lysosome
lactate
ABI373A
1/65
Megalencephaly
techniques49
prevention/treatment
IST-MEL1
Bp-Br
pYES2/CT
UPMM2
p.P427R
44.0–1.90
Pathologist-in-Chief
second-allele
Asp218
pGEMT
Ala-17
ES-grade
peridiploid
5′-TTTGAATGAGGCAAGTCAGCCTTTCT-3′
mut2
17beta-Estradiol
α-domains
'hotspots
p.Thr715ThrfsX5
BRCA1–BRCA2
intrahelical
VanAntwerp
5CTGTCCATCCAGAGG
siLATS
'GDP'AIFj
ggaagcgaaaatgaaattgact
ΔEx14-V5/His
defects,5
length/2
expression75
R367L
GSE85971
Knock-In
transmigrated
DU-650
.Non-Hodgkin
RVT
FROC
NVP-BVU972–resistant
systematically
0.5366
8,11,16-19
inducible-shRNA
AnalysisHRM
Transcription/
E180→R
20/74
.Oligodendroglioma
2002
EcoDry
08-CM
MRM-MS
25th–50th
co-operation
†Compared
22/26
21–32
C-Smad
Idh1-KI
Nalge
10−30
Cytomorphology
LBX1
.Due
PTT
reorientation
Nupponen
Y154A
METHODSTumor
MCF-7-Ago-WT
S371C
FOXL2-overexpressed
g.504G
.Stk11/Lkb1
Asn-549
DNA-positive
1RC2CA148394-010
partners1
Androgen-
14.9
tell-tale
SUM149
melanoma.10,11All
1/107
mitochondria-related
pSV
ribosylation
44.3
ERK2-dependent
N-7
non-consensus
PIK3CAP449T
serine-coding
GlutaMAX
log-calculation
C277Yand
multicystic
RaplA
CHL-1
.Y537S
Multi-angle
47/51
articles33
al.,2005
NS346
NK-T
12.5/24
PAWR
RAF-selective
KRASmutation
125-
only.Genotype–Phenotype
vessels.1,2
Mississauga
p16Ink4a/p19Arflox
−946
bi-parentally
andBB
cetuximab
tumour,37
WAGR-associated
ligand-activation
plus-end
1.0.1426
-TEL-JAK2
SF3B1-mutant
probes.18
4.24+0.20
Arg69-Trp22
Krazeisen
neo-epitopes
A146T/V
IFNG
BNIP3
4569–4575
6.3-9.6
deLange
described.22,23
increasedwith
A495del
cooverexpression
streptomycin/μl
47.0
PcG-mediated
1M–O
HPV-31
Insight-II
D218
Mre11/Rad50/Nbs1
pcr
5′-GGCTCTGTCTGTAGGGAGGT-3′
repair.45
cxc
0.69KRAS
5′-AATAGATTCTGGCATTGTGGTCCCCGTTTTCTTATGGG-3′
∼10–100
t=Si
SPI.1
mutant-U2AF35-
Incyte
Postel-Vinay
0.0136*
9/98
CRM-dependent
Ingastric
775insAYVM
corebinding
tumors.1–4
~E
ΔDHT
thrombocythemia.19-21
treatment.14-18
pKOII
finger,14
pH8.0
Wongmongkolrit
17q12-q21-amplification
pARE2
G876
Stat-3–PTPRD
inter-Alu
3am
Anilkumar
L511A
3.64
TGTAATGACATGTAAAGGAT
L78833
TALEN-encoding
Hras-wt
−0.25
29b
rechts
-CATGAAGCGACCCTCTGATGTCCCA-
procarbazine
p21Waf1-
3,662
5621–5626
Y429D
5326
synthesis128
pLp53-R175H
www.expasy.org/spdbv
studies.7,8
mediatedDNA
Slide-A-Lyzer
P17
www.thelancet.com/oncology
58/528
pcDNA3.1/Myc-His
TEL-PDGFRβ,25
Snf5Δ
c2676-3C
GFP+CD34+
//www.landesbioscience.com/journals/cc/article/7507
NR4A
FZD1
PKN.C
PKC-beta
E545K-PIK3CA
19.8
G273Stop
CBP11
Hypermutation
-Abbott
h4
a-phosphotyrosine
c.1276C
3693–702
epitopes34
21852
U.K.
.11,13
GNA14
0.991–1.678
HNCOCA
Kemler
μmMyc
receptor−mediated
BUB1B
−1.82215
0.-
significance.46
TβRII
CD25+-activated
Koref
developmentally-timed
upregulated.35
cytometry.3
pocket-dependent
MTD
Flt3-specific
Ser7653Pro
N1-ICE2516D
2-hydroxymyristic
Methods.â
Acetylation—p53
Myc-Max
A870
rm-SCF
recurrences.1,2,5
theantisense
.260
amino-acidMSH2
​and4H
WNT5B
Flag-tagged
HpaI-AsuII
S_TKc
two-hit
R7EN
cancer34,35
SF3B1WT-overexpressing
12/28
aminopyridazine-based
17-mer
−3.9
Cancerous
.Y69H
T1087I
NUGC-3
MC38-derived
beta-lactoglobulin-cyclin
740-757
-DNA
.LF
W408
c.781G4A
91:923–930
XhoI/XbaI
protein-dependent
50/50
DIDLID
within-gene
Δ/Δ
FHC
AGG→AGC
pCMV-lacZ
LNCaP/AR-V7
Myc-ΔC
8,31
ASPCR
src-family
2.6
Tris/45
.Me18105
Crohns
Heiss
.Eighty-two
Col7A1-luc
insertionally
head/
tumors3
Fast-1/Foxh1
server.25
Spectrumedix
HYPDTQTV
Foci
746G
EFFR
IGHA1
1,466
Thr349Ile
2,4-dinitrophenyl
atropomyosin
resistance,28
Mmp3
SRNS.5,7
E32G
dPlexA
hybridization/western
.YFP-tagged
mid-GI
A08
affinity‐labeled
n°
2-1-5-3
Lats2
VHL19
Rozenblatt-Rosen
Histone-H1
9,200
PAK15
c.298C
ex-smoker/current
N104-94
ITD–expressing
.consensus
5′-GTTCCTCTCAAGTGAAGCCCAGCAAGT-3′
c.296G4C
yGluArgA
Br46
.Micronuclei
α0
drug-containing
K-Ras4a
©2009
5′-AC
G524
Informativeness
3422
Müllerian
hAR
Jade-1-extended
anatomically-defined
KYSE150
.HPRD
NIH-3T3s
irk
holocomplex
Mallette
6456
weanalyzed
HSPC
.083
Ter119med
Thr-125
5′-CTGTTGTGGATGAGCAGCTGAGAGTCT-3′
1.15–1.5
0.6/NA
metal-coordinating
biopolymer
KMT2D−/−
FoxA1-regulated
AH130
MutShomolog
SNAPC3
KGaA
SMAD4—in
TWEAK/Fn14
spondylodiscitis
oxydrilic
neoformans
.9,10,12
anti-β2m
mant-GTPγS/Ras
X-axis
9v7
ng/mul
0.2α
OSE
17-497
TGTAAAACGACGGCCAGTGAAAAGGCTCGAAAGACTGG
Th2-specific
R.L.
over/under
AF093569
TACC3ex14-RV
Hh-related
0.969
A_52_P162099
EV20
NCI-Frederick
1445–1516
40-3/4
proline/serine/threonine-phosphatase-interacting
receptorexpressing
LIF720D
K189N
lipopolysaccharide,44
ZM-fused
.Fewer
G1471
Rad51-focus
.Schwann
28S/18S
P1122S
chemosensitivity
18064022
122–138
Anti-MET
myelofibrosis.47
nwald-Giemsa
Szulwach
477
homogenates
monocyte/macrophage/BM–derived
C61
anti-ErbB4
phospholipids
resistance.Using
attL1
hedgehog4
1:1/2
21-5
low-molecular-weight
CL-387,785
samples163
pSG5-L701H
Landrette
55ÆC
3.974
NUMB-PRRS
conformation-specific
pY1175
cytoplasm3
substrate.11
U-937
aminopyridine-based
.Collagen
24-h
killer/T-cell
.032
2OG
.AMN107
.H/DX
mis-segregated
.Cataloguing
RET1
α-mouse
0.211
v1.9.35
pMX-ires-GFP
ofrepression
RCAS.Sfi
Ile956
nonclonal
.Ras-mediated
4/79
.1144
32,285
erythropoiesis
ATRX-mutant
.Hub
orestrogens
H384N
l~
MyoD/E
IVK
LOC642808
y1
P110L
Langkau
SARMS
6119.83
Asp770insAlaSerVal
A1182
ABL.13,33
B-Raf–driven
PLVLKRC
2A-EGFP-pcDNA3.1
controls24
0.25×TBE
lifpofectamine
108Table
pattern.Northern
0.20**
SD−Trp
FIM/ZNF
ascertainedfamilies
CUO25
colorectal-derived
embryonically
*No
L1237A
Narlikar
34,35,37,42,43
25.4–35.3
281CysHisTvrSerCysGlyGlyMetArgLcuLeuAspLeLIArgCysProG1xArgAspArcgAsnAspAsp
LT-HSCs
1384
mammals8
oneof
Del746
GGU
IL15
ASZ3
¸3
1692
nonhistone
0.9074
water-picking
JH5-7
15q25.1
Nutlin-treated
DNA–Fugene
0.0268*
NB69
chemotherapy.6,7
hydroxy-2-methyl-propyl
CFTR/MRP
NTRK1/2/3
Bd-Bf
300560
His-FZR1
Guney
.Packed
515-1092
inter-residues
J.C.S
RadS1
vandenouweland
CTCTCCCTCTTCdel
over-induced
immunohistopathologic
deficiency-mediated
exon-18
5'-ggagaaacaattatgttac-3
4–5-fold
breast5
3.00
tpg/ml
corticosteroid
usion
1977
loperamide
p.Arg1189*
Q17A
MPL-expressing
routine187
-high
.Among
bio-informatics
Schilder
321f13
FoxA1-expressing
hydroxyprolyl
U.Z
355T
RhoA.4
effector–protein
Baetz
Preneoplastic
MSI−CIN−
81.19
2A-associated
ACTAGG
PPL-NTRK1
NKX2.5
G53D
ccRCC_28
SDS/5
chlorambucil
43X
10p6~
AAAGAA
Cells-To
GST-FANCG83
STAT-recruiting
200ul
CBCA
.Fig.8,8
Luciferase31
Seliger
CCATTTTCTCAGACTGGAACGTG
UV-damage
*Co-expression
Jaehning
PDGFRA-F14
Gly-Trp-Gly
C.1
MEK1-BRAF-14-3-3
p110-transfected
P-G
others59
femoris
Médicale
reaction-mediated
N304
B-RafLAVTVKS
MSCV-Cre-IRES-enhanced
fromsmokers
0.229
G1634A
39m
CACATAGCTTTGCATCCTGC
punctae
R166
sequencing.This
mg/g
weight-dual
endothelial-derived
P124L-
.c-Met
1341
Fgfr2+/P253R
11/20
HAMARTOMA
PPARγ
pyrazolo
c.107T
.Serine/threonine
.Hypermutator
Ubn
Calnexin
2.26–2.18
MCF-7-Ago2-WT
anti-IRF1
pK125E-FLAG
8-CPT-cGMP
PEG-it
NetMHCpan
v3.0.2
FLAG-FOXO1
excludethese
Rad51D
.AlamarBlue
c0
0.856
2,369
488-conjugated
2236-2250
Pat.1
Ten-eleven
Hospital–Washington
Y163C
receptors.21,22,34,45
,0
PCRamplificationofDNA
Stata11.0
Chr6p
F_PacI_Neo
M.W.
patients.76,77
Lys-C
c.529_531delinsCACh
BRCT-truncated
Tampere-Control
30A3
17q22-23
2TEV
CePVF-1
24O11
WI-11
Kauffman-Zeh
fixation-caused
843-1478
724-6919
Varghese
1,846
Cytometry—Cell
CD34-PeCy5
Citrate
σ
crossing-over
Figure6E,6E
GC7
ALK1
meta-analyze
GCGTTCCCTACAAATAGCCC
2238-2252
arti®cial
residues36
Σj|
DLKDTQDANAIFRGNSLATQCLTEMMK
Glomerular
Musio
p190‐RhoGAP
detoxify
P86L-expressing
GAGCAGCCGG
HES1-luc
55C
X-396
Heterodimerization
C3+
SNF2
.Boyd
anti-NICD
AR-FL–expressing
Affinity-purified
BAT26
21–64
macrocystic
covariant
RG-21
YBL019W
BP-3
substrate-
E160
adenyl-5′-yl
.0866
bevacizumab-containing
hetero-dimers
yale.edu
interleukin-6–dependent
0.722‡
0°
FUS1
KIT.26
postconfluence
PFU/ml
12949-2
tenascin-C
mutant.31
SARA-MH2
OCILy1
function40
H.-F.
Ile555
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F4.medium.gif
BRCA2/Brca2
Eu-EGF
CBF-related
C66
Y111C
conformationally
insulin-resistance
suggested.16,17
protein-like
ﬁndings
449–455
18.3-66.7
tFL7,8,11
radio-
P5L
bp270–310
hShp2WT
0.1315
2Ems
mutants3
P=0.0002
PRKAR2B
pcDEF3
081
size-100
5′-GGTGCACCGCGCCCTGGCAGCCA-3′
208644_at
siFSTL5
399-420
Akt2W80ALow
Well-validated
.Aberrantly
CD69+CD4lowD8low
MYC-dependent
genetic/integrative
resistance100
TAZ2
Pharsight
cargo-sorting
2181
NM_005465.4
.Sternsdorf
19,25
pAS2
.Prepare
the0
5153–5137
recombinogenic
D7S820
5′-rCrArGrArUrGrArCrCrCrUrUrGrArArGrCrUrUdTdT-3′
89-7095-7567
31.0
MX4000
p.Ile145Met/p.Arg1095His
ifthey
dioleoylphosphatidylethanolamine
functional-essential
anInk4A/Arf
hyperprolactinaemia
URA3-selectable
15q26.2
1011–1062
FcγRII/III
post-implant
D509Y
NM_033355
Ominiscript
mHNF
GTP-state
groups:1
TGTATTCACAGAGACTTGGC
49,6-diamidino-2-phenylindole-
PTEN189-associated
p.Y1571N
1-anilinonaphthalene-8-sulfonic
-3.1
Dock180
11,43,61,62
A748V
r963,23
Akti-1/2
tumors.15,16
Y657_K658insY
Ultrasonicator
24,25,28,29
SY2002
386
Sutterluty
p≤3.7e12
Substrate-trapping
anti-Flag-tag
8839
154899U20
focus-forming
SamplesThis
A106T
Eco47III-XhoI
Gal4-ERF
Biceˆtre
complex/monosomal
P-valueAbbreviations
±11.1
N599S
tetramer.10
PI432
GSM180993
Gi15
LOF+nnMS
Her2+
CDBICTLA4
Smad3/SnoN/APC
associationThe
ring-finger
080425
GDP-fucose
Arf−/−
2J21
Apweiler
355–366
SelleckChem
22,427
U2392
pMB1
sisted
Y656
.Ford
neurofibromatosis
melanoma55
0.50–0.85
EagI/BsrGI
adenocarcinomas2
.Conventional
1μg
Fgfr1a1
VEGF-stimulated
~-160
wu90
6xOSE2-Luciferase
βA
.Phosphoserine-15
TGTAAAACGACGGCCAGTCTGTACCACATGGATGCTCT
+160
ErbB2-Neu*
15–17
8.86
/AML
patients.Total
37-tumor
deletion/loss
40×/0.60
HBVþ
genes.Figure
Inabaso
2,4,5,6,8
JGF1R
.Consequences
Paraffin-embedded
GL2
IGCTs1
1b.13
HIV-Tat
Araya
neurohormones
mut4
perifocal
anti-NEMO
Ziess
GAUGUUUGUUAUUGCAUUUdTdT
AM4635
.Thirty
14×109/L
H-731-1203
antiandrogens
P210′
5-foldobserved
1,5a
CDK2/cyclin-A
167C7
Mix-Low
5819
482E
FADH2
translation-termination
.T4
thrombocytopenia25
CRL-10303
NCI-H19934
ViaCount
p53REs
low-birth-weight
C2A
C4380T
ASE-Luc
NCOR-ROS1
Rad50-HA-tagged
06
GTGTTTACAT
FBXW7-deficient
s15747
enhancer-of-zeste
.5B
Nachury
vera/essential
Clec5a/Mdl1
GTP-activated
ab32058
5′-CATTTTGTTTGGGTGTGTGG-3′
1–21
c.1137delT
T175I
.Multiplex
Colo205
N122D
cells.Previous
Nutlin
AAGGCTTGGGAAAGGAAGC
NCI-H720
17,800
GSPT2
1414
anti–phospho-RAF1
3,531
Glu-719
pg/ml
anti-CARM1
components—from
PCa.6,7
1-4-5-4
P973L
PTCL-NOS
K550_P551del
C2215T
transactivators
0.6829
G374R
S1.Figure
cells.44
SFA9
.EBR
I174V
rmdup
pF90
inclusion-like
PSFSDIPNPIGSENSEK
SCD-FHA
19H7
.Newton
hasalready
RMCE
separatedby
CD79A
//www.ncbi.nlm.nih.gov/Genbank
complex-1
M/66
phenix.refine
Sartore-Bianchi
HCC17-0211
AAGACGTTCTCCTACCTTCGG
TCGA-DS-A1OD-01
1888
leucine/hydrophobic
subcitrate
55a
Mismatch-binding
R97C
pTyr992
signal-Regulated
474671
CLs.4
5'-TGAACAGCAGATCCAGAGCCATA-3
F.27
BZ-Analyzer
5750
Cross-tabulation
+++/+
at721C
eArray
EV-
TGCCAGTTAACGTCTTCCTTC
HeLa-tTA
GW5074-increased
Kulish
.Promisingly
M.-S.
anti-phospho-p27
41-79
nonconstant
Y341AC-RAF…
Y900
26B
C-CAM1
GTP-γ-S
.Ono
taxol-like
role.10
Smad3,12
Aryl
I0-1
1306dupA
13/39
Y222D
activating34
Anti-TopoIIα
cetera
56–81
GST–EGR2-E356K
Stempro34
1.67×105
Inomata
MTC.7
0950-9232/10
90/125
CINþ
cut-off
21–75
Iysine
F3901
SF3B1–U2AF2
glutamate
8,37
8,22-24
isthat
R381G
C4G
alpha-thalassaemia/mental
Missense
cancer‐associated
MOLM-13.23
Europeo
2282
probe-anchor-ligation21
transcription.ResultsProteomic
MFE
ΔTOR
multi-Fisher
cells.13
p.Val188SerfsX19
keratinizing
ATT-3
2B8
p21probe
Rae28
SGR
B*9549N
GGAGATCAGCCFGGACCGGT
.Changes
5-TCG
NM_008329
members.22
trans-cription
domain18
.Verification
B.D
35AI
8of
withrat
10000
NCLK
TAGGTTAGTTTGGAATTTTTGGG
+-4'-
macro-complex
AR-AF1
pRetroX-Tuner
F782
D631G
R554W
pcDNA4
Allelic-discrimination
KITL576P
period26
i.t
.S2F–H
.Lats1+/−
floodgate
P.P848L
pre-JAK2
Syampurnawati
astrong
-LC57
.038
Immunochemistry
MM.M1S
R213*
bone-mimetic
Fig.4C4C
D7S519
atwhich
aga­
activin-like
Lymphoma-related
EWSR1-ETS–positive
Maxfect
0·94
pAKTT308
T/p.Arg337X
E40L
.Factors
5′-CTG
2012c
Thr183/Tyr185
inhibitors.14,20
AKT-transformed
W117C
phospho-Chk1
TNFalpha-induced
gp14otrk
uncontaminated
nucleus,36
dualcolor
assembly78
Cys24′
3624A
5.3–12.8
A465T
non-atypical
MEF2B-Bcl-6
I462S
5.Table
499
ATR–ATRIP
Drug-treated
pathogen
.prototypical
Asxl1-knockdown
FAST-2
40-42
ETV4–6
TRD3
p53-knockdown
Parker101
iniparib
T58-associated
c.1076+16
Melino
caryboxyl
4651
32,23
361:947–57
Asxl1-RecR
acetonitrile/formic
3-kinase/oncogenic
adj
exposure.10
**As
1−2
Fbw7ARG-substrate
8-F
MmGCbox
S662G
transcription/
145367739
CD74-ROS1-rearranged
CA12
PKBαW80A
gefitinib-monotherapy
PcG
sizefractionated
STK33
for.1
procedures26
.Black
LR-PCR/sequencing
NVPBYL719
20.3/26.3
Baboon
BTB-Kelch
V804L
TATTTGAATCCCCATTTAGCAGATAAGGAAGCTGA
-CCA
RP11-24O11
415-IMDM
BalbC/NUDE
3/60
5′-AGGGAGAGGGAGGTGCAGGT-3′
W82
Alu
339-340
therapy18
.3,4,6
clinical-trial
Kruskall-Wallis
178-2273
14-3-3-BiFC
.1563
A302-429A
5′-TCCTGGATAGCTTTGGGCAA-3′
c.1322_1325dupCGCA
170A
unprenylated
sequestering
20533627
Vahteristo
∼5,600
*d3
activity11
reverse-transcriptase–polymerase-chain
-*T
5′-GATCCCAAACCTGCTCTG-3′
HCA46
WZ4002-sensitive
5.0.1
dash-dot-dot
mean±s.e
p21ras–GAP
PARACRINE
1388-1398
.1768del
Galaxy55
resumption.17
0.195
prognosis.12-16
structure-functional
FAM-aggtttactcacgtcatccagcag-BHQ1
G101W2
roperties
ontology-based
39-year-old
-targeted
heteroduplexes
G47Ea
N45A
tRCC
TALDO1
6879
2.8–25.0
SPOP-Y87N
oligomerization-dependent
development.targeted
3.21
allele
orthologous
HCC26-1004
P-Sp
nondomain
pathogenic
ATFJ
JAK2/STAT1
ß-cateninproteins
Q268X
methylmethacralate
eled
post-translational
AmelXY
11mutant
idlll-digestedpMV7
*Still
Goping
Immunopositive
Arg24Flis
23A-R:5′GTTTCTACGTCAAAAATCAATGTTAGG3′
Up‐to‐date
AGACACTCAGTGTGAGCCAC
wt-PDGFRA-Ba/F3
Chk2/Cds1
osteopenia
intraperitoneally
13.0±9.0
F290L
B'-ggtcggctgatacacccctgtcctctctgtcccagGGAAATTCAACTACT..
2533C→T
CHCl3/CH3OH
Calu3
+213
663–666
HER2WT-
dimethylsulphoxide
41.4
5.5-kb
CRL3s
.GISTs
cyanine-3
V559
SH3-binding
Gogolin
bandwith
Rd.
densitometricanalysis
D84
metal-mediated
−3.39
V155
identified/novelThe
641
D206Y
culture.45
SWI/SNF-
mutagenicprimerswere
4326–4335
Niehans
A_
TuJ1
membranetargeted
.S2B–D
mutation¡/HER3+
rs121913446
brg
Δ552
Camidge
Fructore-6-P
Q556_E561delinsPS
KrasLSL-G12D/p53flex7/flex7/Pdx1-cre
pCB6WT1−/−
pemetrexed-based
.65
2,000–5,000
9.23
42–49
NucleoTrap
siIDH1
550–560
RP1–97P20
methionine/
IVS4-19
anti-e
TGTAAAACGGCCAGT
-79.29
PD180970
post-relapse
Brg1−/−
pro-B/pre-B
-5000-fold
1H-1H
HisfsX30
Emu–Myc
MBR
bIHCAs
27·1
37ºC
P.N756Sa
389KB
464-471
Brachyury
1998–2007
R970C
SW837
Closed-Pocket
-E
Thr-573
proteins.1-3
aci2-Q205L
Fh
.029
NdeI
Chp
deletions.49
shNR4A3
.ATP-dependent
co-eluting
CSNK1D
4A–F
2159
BRCA1/
toelucidate
homology-built
leukemia55
4-mer
.139
Large-scale
Re-analysis
71–75
abnormalities.1⇓⇓⇓–5
unknown35
immunodepleted
82-87
ECH
kinase17,18
L556L
MLL-binding
–26
K305N
Asp486
.Respective
T1928C
RPL19
~1.7-
U-2-OS-derived
HEp-2
Cdc2
Moellering
1035
TGF-α
.SRSF2
R251Q
1|Injection
ENDOCRINOLOGY
oncogenomics
–BAP1-expressing
.F57C
dose–resistant
XKLF
2/21
AY273801
prognosis.1,2
SYTO60
IL2RG-
GGAATCTCC
responsiveness42
89,059,104
.Mammary
3'-CGTTGCTGCTGCTCGTGGACTTAA-5
lupus.2
2D-F
Retinal
multititer
remodeling.31
-unique-filter-coverage
manner.4,5
mutation51
IGRGNFGEVFSGRLR
family,7
eIF4A3
CEP95
Pazin
c.3059G
L1236
WK557-558
n=452
29,701,299G
sensitiveness
genes/exons/introns
.Fetal
ATGGAAAGGCTGGAAAAGAA
Shoshan
Retinoblastoma-Associated
TCACTTCCTGCTTAAAGCCC
Brd4-imposed
NCT00198991
TTG3TAG
17q21.32-q21.33
FN1
trp
.Losses
7.5/25
,4E
package.22
SMO-D384N
SU-DHL-2
CME
nano-particles
68,130
~99
32·4–39·2
pCIN4–Flag–HA
ingly
0.1080
XP3YO
bilateral
deprotonation
cycloheximide-mediated
–Platelet-Derived
.ACHN
opposite.20
​Fig.22b
Thr145
cholorquine
v-Re1
~180
23,44
IL-2Rβ•JAK1
RG7842
S707Y
47–257
ubiquitin-proteasome-mediated
Altieri
V=0.5236×L×W2
G983V
7.09
splicing11
c.2619delA
horseshoe
.Tyr642
HMCLs
24–92
.AML-1/ETO-mediated
67proliferation
photomicroscopy
significant.Genes
P655L
0.001aCD8
1000g
HCC1806
PTPN11/Shp2
cancers15,16
−903G
XL-II
120,120,121,1mar
abl/arg−/−
response.12-14
Typhoon™
anti-CD49d
G-83T
11060
1.767
gtaagtctc
234
bindingfactor
electron-density
p53
IGV
35-kb
Gonfloni
10q25–26
Thr/Ser/Tyr
activity.53,54
SIFT,26
BAT-assay
hypergammaglobulinemia
RETV804M/V778I
NS–PTPN11-associated
chondrohyperplasia
Ea22
13-galactosidase
U72900–U72935
.et
xlinked
TSC.Materials
years6
ubp8Δ
P=0.86
instrument®
phenotyping
076
2:00
.ethical
ophthalmoplegia
immunomagnetic
A_51_P441426
PLOD
C57Bl
Materials.
4×10−10
Wassef
Msr1
.Sustained
83.1
premalignancy
13q31
UvrABC
disease-yielding
crisis.4
NM_004564.2
SPXR/K
GSE14994
commitment/differentiation
P-Smad3
13–15,18,32,62
IκB.41
Ad2
BRAFV600E-
Rothwarf
malignancies—most
ZW10
.Eμ-Myc
S247P
.R283Q
//www.nhgri.nih.gov/Intramural_research/Lab_transfer/bic/index.html
activityof
Ser-575
pTL1-p53
immunodeficiency-associated
RAS-positive
N.K-K-K-R.K-L
F404S
ubiquinate
-EF6
detectedbetween
sRCCn=
WHIM11
.FBXW7
5′-CTGACAGCACTTCTCAGCCATTTC-3′
toxicity.4
gata-1+
Tau-Binding
Kin-
NCT00473616
1x103
RFNG
HDF
.Matrigel
mutations26
CXCR2.23
p-glycoprotein-type
HA-oncoVAV1
R2580
TIR-domain–containing
A20V
p.A871A
//dtp.nci.nih.gov/docs/cancer/cancer_data.html
coloredred
nonenucleated
wild-typeGIST
TMEM67
nonBAT-RII
0.000001
phosphorothioic
EcoRI/XhoI
Ouerfelli
Tx-USA
msh2-VD862p–Msh6p
C-MYC-MAX
GGTTTTCTTCCCCTTTTGCT
PBS/matrigel
postcoitum
.Protonation
Bandipalliam
ubiquitylated.52
Pannoramic
M541
J-006000-07
//cancergenome.nih.gov
Bollrath
Biosytems
rare.3⇓-5
.P1637L
Polish/Moroccan
Cytokine–RTK-III
Haaften
1398–1405
96‑0086C
1/K2
17-bp
SCF-substrate
TACGAC
lg/L
8–49
dNTPs
variables.47
−745
ary
TCGAGTTCAAGAGAAAGCACAAGAAGGACATCAGCCAGAACAAGCGAGCCGTGAGGCGGG-3
amplificationandrearrangementoftheEGFRgene
non-myogenic
ATPbased
MMC-sensitivity
Tay
FLT3WTexpressing
—necessary
N12GGT
dinucelotides
disease.7
pre-clinical
ccai1
hypo/amelanotic
.Ligated
dimerization–mediated
ileo-colonoscopy
Y641S
3.638
pseudo-HEAT-repeat
G551D
C277F
epithelia1
non-hyperplastic
Merlin-1
G272V
U2OS2
pH-dependent
nuclease-released
semiautomated
-T
.ME-PCR
SM-MI-1
Phosphatidylinositide-3-kinase
Dörk
5132
BA-l
Dr.E.Buchdunger
Ansamycins
V822M
STAT5b-
BMPR-IB
washedtwice
dichloroacetyl-1,2-
-phosphorylated
202C
0.0164
2.4-
mutations4,5
aromat
MEL-14high
ectopically-expressed
TVKS
.MED12KD
III-A
Nedd8-activating
R35L
anti-FLAG-antibody
FAS
4⇑C
.1651
abnl
non-similar
penicillin/ml
CNS.34–37
CAGCTTCGGAACAAGAGACTC
V270A
upstream1.5-kb
regulator-mediated
0.5–20
Pruneri
ERK59
Fig1A
mutation.However
transcripts.16
immunoprecipitation-on-chip
BR-0225
c-fos–inducible
FMTC-mutated
85.8–86.0
TUBGCP6
spectrometry–based
ATATGACAGAAATATCCTTC
review/tissue
photographies
RGDNDGGGGSFSTADQLEMVTELLGGDM-
delta-shaped
1/102
ATC-
two-sided
IIIA
GGCGGCGGGA
H109R
.Left-
ERK1E339K
HO-induced
Tet-On
1/2
c.775G4T
1R-mediated
GELLES
BloomRichardsonGradeForBreastCancer_CA.htm
.Do
virilizing
S1194L
virus-thymidine
etc.
.028*
Ras/ERK1/2/STAT3
.4,11
.L611V
Ser18
occur5
pLKO.1puro
abiraterone-relapsed
unisomal
R820H
∼19,000
Cys-free
SHELXL
mice/WT
Arg321Gln
Procedures.Gene
5′-UAUGAUAGACGACGAGAAUUU-3′
3-independent
~3/4
thermodynamics
-amplified
mutations2–9
multiple-congenital-anomaly
TCF4-luciferase
Co-mutation
cases.2–9,18
P436S
24-58
neutral/positive
.Confirmation
twofold-higher
CEL
p.K1233NfsX6
mlh1
1,849
progressiveliver
SMAD3-specific
C7orf64
IC25/IC50
fulfi
Smad3mice
T1010
non-TET/FET
N269K
WNT2
ERK2E322K
.Fibrous
Lats1
480-amino
Montera
NcoR
analysis.23,24
TAAAATTCCCGTCGCTATCAAGGAGCCAACATCTCCGAAAGCCAACAAGG-3′
.Durable
np16ex2f
G305
logistic
Wright-Giemsa-stained
KunLiang
A_52_P273891
terminus-specific
R82
chloride
Vol.~l
.BRC25
times200
×2.5
Depth-coded
KSDVWSFGI
2,314mutations
p=0.0347
1q32.3
GCC*
D587
.1662
7p21.3
Erdheim–Chester
phenotype194
Tris⋅HCl/1
TRIZOLTM
samples.11
ErbB4
5′-GCGGGCAGTGTGTGTGCAGGCATCCTC3′
.Biol.
TRIzol
CourtoisCox
C\N
EUFA130
b3
MTG
T1700A-L
35053
Q1336R
polymerases7
0.9500
27,44–46
3rds
Asp–Gln–Asn–Asp
beta-blockade
Matsouka
400×
4751
UMD-BRCA2
qw
1.107
Chimienti
WT-EZH2
Flt3−CD34+
.Our
Science.
HSILs
p110α-V344R
mutation15
cDNA/DNA
1.4NA
R175F
München
atthese
.AKT1
Thyroidb
repair8
D13S317
G2724
R139P
bronchiolitis
0000o
322–333
EGFR—mutant
OMIM
G442S
345541
Valeron
GATA-3highCD3+CD4+CD8low
malignancies.4-7
2000i
CTSD
thymus
247–792
cells.3
Ortega-Recalde
c.1656
7B11
hydroxyethyl
MGH047
.OVCAR3
0.0141
fromp53KO
7.8-fold
Y553A
i12p
Meier,48
.34,35
MSI-Low
1802C
5′-AATCATAACATTGCTTATTG-3′
GDNVESNKENLYYYVD
8.29
αPY
2576T4C
TTTTGGCTCCCTGGTCTCTGA
R882H
0.0102
45×
160–580
.M308
Evdw
5'-CTAACTATGAAACACTGGCA-3
Ac-DPETGEF-OH
concentration-dependence
vulnerabilities
Y176C
Astrocytic
VDpYRATF
-GGCAACGTGAGCGGTAGTTT-3
GACaGGA
157-gene
ESTSP
5′-GACGGCATGCTTAAACACCTCCACCTTCTGCAT-3′
data14
TSC403
Permeabilized
S5.4
678-953
p.L122fs
S204F
RPS19
.8C
BRCA1-/BRCA2-negative
custom-synthesized
element/activating
7½
Asxl1Δ/Δ
Opitz
4:14
SSC-H.
work/free
p.CEYCFD-toNAAIRS
4762
50-mer
crizotinib—ROS1
independently-ascertained
carcinoembryogenic
imatinib-resistant.8,9
Neu-Ulm
AtmC/C
0.3499
C-2
161–164
7417
R294Q
iiib
P12/Ichikawa
MAPK-activated
.10–18
HepG2-shShp2
−2.19
Iroquois
Thr241Pro
/maximum
dark-gray
L22Q/W23S
/DC
.KIT/imatinib
5/9
PCDH11X
Rad55
//apps.isiknowledge.com/
prognosis119
.Stanley
Carboxy-terminal
19.42
96-well–based
Biegel,2009
V658F—To
S2B–D
0/214
protein.8
14.67–45.78
2.2-
RPTPpexpressing
anti-EGR2
intestinal-type
MAP/ERK
.SnoN
0.001b
G279E
APC-Cdh1–mediated
Gandino
lymphoma,17
20.4–24.7
Dainippon
.S3B
N528S
erentiated
DiOC6
49AmGC1'TGTITTCAGGCITr167
G328V
replicated.5,6
Cdkn1
activity97
immuno-PET
VprBP
U14658.1
HGG.5–8,14,22,23
L29S
100.00
.I-DLBCL/BL
RT-Lf1
phosphinositol-4,5-bisphosphate
.PPP2R1A
CKDs
ex20b
3997
8/50
sc-166
k11•
siayltransferases
Ull-030
11a
5′-CCTTCACCAACAAGCCCACAGGATCAACTG-3′
35–39
apotosis
DDX3X
UBCs
Horsthemke
biology12
puremycin
DICER1-mutation
Mutation_RateResponders/Mutation_RateNonresponders
Tables22–3
wt–DNA
RP11-88M19
RQ‑PCR
C173
PTENΔCAT
receptors.32,33
M34
ROSA-Floxed-Stop
16–44.4
132K
KDM
Ezh2Y641F/+
neoplasms,10
2,059
polyneuropathy
190020
.RAS-activating
transformation15
cytochalasin
Nitration-mediated
–29.4
TRANSFAC
macti
inhibitor-sensitivity
≥30×
D.D
Broschat
51-55
NUP98-fusion
function—not
.Pierce
GABPα
Ghebranious
pRKβgal
BRCA-proficient
V.5
A769662
suppression63
4.0–45.6
posit
RUNX1.41
line-transmitting
PTPN1
primer-encoded
Reinduction
Map4
pT68
.BCL11B
–Initial
.major
Thecell
C.6
RAC1-GDP
36.4
1.4–3.0
Z-
p.Q472H
Cins.8
.maternal
screened.Cell-lines
-CTGGGAGGAAGAAGAGGGTAGGTG-3
PTENINACTIVATION
SC-17829
Glu454
neo–poly
Ferrés-Masó
Forensic
pCMV-Myc-DH/PH
c.2962T
81/285
Anti-IL
.Junction
K319E
K320/
cept
NHS-sepharose
11811
//www.cancerregistry.fi/
T1116M
pErk1/2
PstI/EcoRV
1:15.000
Mdm1-3
p=3×10−12
n=7/7
anti-androgenic
Alk-1
HOXA-activating
p110α-CAAX–induced
PhosphorylationDNA
HRASp
57cases
E86
Y272X
expression/function
R170Q
chromosomally
P.H835R
Ser511
φ-
K-562
3001–5000
2JITB
A_52_P384394
TGF-β/SMAD-dependent
39-75
:URA3
D.a
Q65R
T169I
castrationresistant
nonviral
Tri-Color
H61D
CUO18
T145I
mutation97
0.0958
56·3
SICER
nt−91
malignancy.29
'up-up-down-down
HCT-8
carrier-derived
Hypomethylation
p.Ala146
burden2
phenyl
IJC
perturbs
3.
Crosio
38/292
CRTC2
58508
R413G
Hcf
fusion84
NCI60
mechanism.9
NSCLCs
GeneRacerTM
c.644G
platinum-resistant/refractory
ompT
Men11/l
Lilyestrom
DeNicola
mg/every
//dx.doi.org/10.7554/eLife.00499.002
TP53-unmutated
Triplett
experiments7standard
1473
syndrome,12
near-perfect
WI2-1468D5
changesin
Mirmohammadsadegh
5'catagctccgtgtgctttca
Dullbecco
H-Ras7
1000plus
serum-derived
CML-BC
dexamethasone-responsive
cancer.16,18,19,20
Digene
0.1–2.3
Bacteriophage
204906_at
8091
OCBBF2004235−6.6KLK5Kallikrein
Dax
HNPCCrelated
variety.35
musculus/M
CHEK2-I157T
10'/well
SETDB1-gene-amplified
exo-endo-double
153-kD
Figures2A2A
theMSH6
protein.38
~Krengel
:1B63
Qiu
PRDX4
MunI–EcoRV
D380A
inter-strand
priori
MediaCybernetic
92–94
150.17
one-half
Gal4-OP
GC-regulated
TTCTAAGAA
basaloid
G263A
.CDK8
internal-positive
§both
K278
Immunolabs
1Fondazione
Aperio
Fig7A7A
deacetylase-
ANGPTL2
P586R
HG3-31
73-3
WIP-P12
myristylated-wildtype
FISH2113
Somatostatinomas
NA07357
Y44D
Saltsjöbaden
E459K
5′-caggcaaggacauggcgaa-3′
Misonix
cHL-associated
Liede
nonpolar/van
agents.To
CA-genotype
pMD2.g
Ras/MAPK/ERK
SP7
sc-6412
ADAMTS6
CFP–ERK2/YFP–ERK2
APM
2930
¯ow
Oncomparing
Matsuow
7-M
domains-N
S606L
zinc-mediated
NOMO3
L1034R
3–90
CytoFix
~40
Poeta
Fosmids
NF1-333-stimulated
5′-CGCCAGAGATATCAACAATATTGACGAAGAGAAAAAGACCACCAATGG-3′
Nag1
Ba/F3-hKIT-Y568-Y570FF-D816V
Vhl-null
STAT3
G34-
Intratumoral
www.hgvs.or
positivation
sor
HIF-
Longbone
Calvi
Oncodrive-fm
repairMSIMicrosatellite
1,757
902KB
12/22
95D
GST-RhoC
T745M
940
5.1amp
loss.Multi-faceted
fection
AKTSer473
3.9–4.5-fold
ICCs106
20q13.12
10/17
FLAG-VHLQ145H
Bio-1D
S2b-f
spi1+
Tyr608/Tyr628
AAX46445
4962
A_51_P343833
016187
Ohbayashi
∼0.1–1μmol/L
CCDS
CH14.18
.BACH1-M299I
0.986
HLA-DRB1*0401
6.02FLT3-ITD
Cγ
NS3
5·6–14·7
Gluc
trp1–63
21.6-fold
pcDNA3/LKB1
194/1
26S
Inframe
5″-GCG
.140NF-κB–dependent
H198
6,17-19
q=0.02
D4MIT27
Sugen
Chromoplectic
p53-Y220C-specific
RET.21-25
deoxyglucose
positive-feedback
ITSF
Malyukova
ab28428
.Phase
Pten-M3M4
Institute/Massachusetts
melanoma,18
production/function
.T1010I
Smalle
BU1/75
Hernandez-Munain
Cox-proportional
VIE
dimerization.DiscussionIn
–URA
NF1-related
GTGGGGGAG
2333
NCT00525148
p16-72R
E.ET
CCCCGTACCTGCGGGGTGGCGGTCCCCGGCGGCCGTAGCGCGCCATTTGCACCCG
BCL2/t
Transrepression
.ETO
kinases.18–26
cancer.2,15
shownpreviously
1795insGTT
PLX4032—with
2.06-6.14
adhesion-related
gastro-entero-pancreatic
Vukosavljevic
Ets2ΔC453
TRIS-HCl
importinα
1/CIN2
.surface
SnpEff7
1.69±0.20
.Mx-1-Cre
RLU/ug
YWHAE-
10e8~
lysine-HMTase
E198G
CHO9
115310
uncertainties
0.096*
_7p_
F636A
LN40
aresurrounded
CRL-3216
nature.comDeregulation
circumventricular
glycol-bis
TFIP11
R844
5′-AATATCATCACGACCCCACTTCTC
S146N
Row-scaled
3,747
M392R
2.07–2.0
RAC3
overexpression-induced
weredefective
98.7
.613
L541P
procollagen
ACAAGGCCTCAAGGGCAAGTA
osteoprogenitor-like
total-body
H845Y
positions/sequences
re-establish
CXCR4-mediated
Exon-16
NM_008709
Arg414
emergent
q15.2
MCG231
Ministero
LN382/CAR
common.16TSC1
P279L
PGLGNVAMGPRQHYPYGGPYDRVRTEPGIGPEGNMSTGAPQPNLMPSNPDSGMYSPSRYPPQQQQQQQQRHDSYGNQFSTQGTPSGSPFPSQQTTMYQQQQQNYK
/8457=0.008
orange-labelled
A3937G
Rae
ePCR
Q1811L
pathways/networks
c.942
46.4
carcinomatous
379-928
pMMTVLuc
PND
www.sciencetranslationalmedicine.org/cgi/content/full/4/120/120ra17/DC1
S866P
promoter-mutation–positive
malignancies111
R505C
1–564
L-065229-01
γH2A.x
mucin-negative
c.793
.SREBP
pcDNA3.1/GS/PDGFR
FOXC
sequence-
.-i
erythroleukaemia
AID-knockout
tyrosine-kinase-like
staurosporine.6
c.583-3C
_M62397.1
DS15126
L401P
AR-Vs
GAX
.Sensograms
.28–31
AMPKγ3
.66A
NF1/NFNS/WS
coligated
proangiogenesis
afferent
//genetics.bwh.harvard.edu/pph2/bgi.shtml
gpllOProto-'rk
T3/ABN6
dsRNA
ETV6Small
PLX3397
0.1799
HATs5
AP23573
6.34
rad3-2
VICC
TAAATCATAAGAAATTCG
MAF≥5
169/246
pcDNA3.1
Gly421
AC-positive
T-to-G
.IKBKE
Remmele
anti-P-Ser-317-Chk-1
SW480-derived
Mx1-CRE-
pErk1/pErk1
G286E
.Rs34231037
HER2‐containing
ogeneous
M206R
response/
15,36
equilibrium-binding
Nonsilencing
LC30
MTT-based
3856
CRL-2876
.Brg1
EPITHELIAL
AnnexinV/PI
Homologues
re-entering
diseases.14,15
I537A
British-made
GNA11.4
c.873delA
receptors.27
phosphoniositides
c.229A4C
Ofnote
SHP2/Gab1
FGFR1/CEP8
devoid
ter289
MCL/T-cell
/ZMSH3
dsRNA-binding
38,146
method.40
p53‑H179R
DDLS_09T
Abnova
OspA
tamibarotene
Inganas
adaptor-mediated
5/328
haematopoietic-directed
igh
CD3ϵ
loci22/12
RASp21
Val560del
C308
comprisingthe
ZytoVision
Hormone-induced
streptavidin-Alexa
Megakaryocytes
Summary—In
CXCL12
CLB-BAR
c.677G
non-study
TAATACGACTCACTATAGGGATTTCGTCTGCAGCTATGGG
Cai
8400574
Smad-deficient
genotype–
3155
3M-3O
cancers,19–22
suggestnovel
B/L
NLP
vitro26
PP2Ac23
RBL2
non-CATG
49-52
3MB
F1695
Cetuximab.21
HIS4
.BCR-ABL
HPV-53
adduct-forming
83.2
number8
DNA-CodeSet
F383Y
fusion.It
6714del4
W360R
D53Y
ER-dependent
pX42
168-172
C506R
non-computational
Gua•HCl
15–65
1,378,400
FoxO-mediated
./Cell
Y486D
mecha­
LSC101
3x-transfected
dermatologist
Hématologie
0.115‡
C2-R2/C382R
ETV6-WWPDGFRA
kinases.23,24
563–582
CIMP+
30–50/20
PA-agarose
apoptosis-associated
1.1,16
5305
71.5
.MSH2-p.T44M
CNTN6
B+C
procedures.39
V774A
ApoTag
bromodomain.Genomic
controls.82
microtubule-stabilizing
1463
1:33–40,000
-CTGCACGACCGCCTCGCACTCTCAAAAAAAC-30
States—To
DNMT3A-mutant
activity22
5/13
I531I
Bx41
_11
V752M
site-speci®c
E627G
HIF-1alpha
EGFP–p53s
KD.45
GCCAC'ITAC
foci/μg
CD69−CD4+
RAS-MAPK
1°C/cycli
2A.3
Q602*
Kuerbitz
S215G
pcDNA-ARv567es
shScr-
prognosis.1
9360–70
survival.8,14,15
20/25
K80
design.RNAi.jp
KEAP1–NRF2
A-Cdk1
-κB
10p13-p15
c.379_381delAAC
A83
GFP-BRD4-NUT
6/54
.Pulse-chase
//blocks.fhcrc.org/sift/SIFT_seq_submit2.html
p73-like
14q13.13
IGK-associated
V133M
5,30
ι/λ
SCF/c-Kit–mediated
-D17S855
RefinementA
Y181→X
agonist-induced
4318283T
HLA-A1
49.7
mastocytosis33
90,109,90
.MBD4
.Resistance
p.Gly537Arg
co-amplification
.Pharmacologic
4/3/03
14A
REDEDEIE-NH2
SFK-induced
.Specialized
single-binding-site
5′-CGGTCTTCAGAGAAGCCATT-3′
M407V
QiaShredder
tuberin-N.
ADPnP
agents145
EPD20
FCDTC
Tnf-α–stimulated
2/26
F570S
DS-6051b
CRC040
GGATCCTCAGTAGTGGCTGTGGGGGAT
Multi-subunit
HATPase-c
Mitoticactivity
27,28
mice114
Pull-down
L536P-substituted
70–165
Tax-induced
mHGA35
R776H/G719S
routinelyformalin-ﬁxed
selfrenewing
Carapeti
ROP
Bellaterra
78156
Asxl1+/−
1514
Guarne
.Pfu
pcDNA3-ICN1
state.
retMEN2A
.Horseradish
2–33
C18orf25
.CXCL1
retrorsine
Apa1
haematopoeitic
NCT02750215
Erk1/2
mechanism16
IVS26+2T
Pharmacogenetic
HD-0264
Julius-Maximilians
MethPrimer
p.R1246
5′-AATCTCTTCCTGGAGACTCAAGACTGCAAACATCGATTTACTAATCTC
EIA-F
translated,35S-labeled
GCLM
83-100
LeukemiaNet.7
Nanodispenser
4Gy
cancers.51
LPF
.Mitoticactivity
.Y297A
Manolio
46K
rs63478
MiceHistograms
10064-2-AP
122•2
2.5–3.4
30b
BAP1/ASXL1
T-lymphoblastic
YAP–14-3-3
A11008
Tyr736/Tyr740/Tyr741
binucleated/polynucleated
19.87
Smurf2
SOO-
Runx3-knockout
HNF4α1-6
.EMSA
.22A
G701
GTCTGATCCACTGAAGCTG
81439
P743L
GlobDom
weak-to-moderate
RAS-GAP
5-mm
GSM459025
ASP-real-time
cancers60
Tgf-βRII
BIOSS
VD2DD3
5′-CACATGAGGGAGGGGTTGTCAC-3′
N=negative
E3002Ka
655C
NOTCH1-expressing
I86V
.Bilateral
PBRM1-positive
380342
volumetric
53-55
recommendations21
tFractional
1-132
non-over-lapping
RP11-249H15
65jC
Met-
Cdk2-based
MDAMB-231
×2
alpha-deficient
FHIT6,11
two-quantum
CDK/r
transcrip-
MARK4
34,79
coronary-artery
MyoDand
themaximum
.Overlap
Oliva-Trastoy
1HN
CFC.27
K-Ras14
TSC2-N
miceTen
to60
F104S
BCR-B
arul
92
114290
−732/−698
cellspecific
11,460
Arg427
Burley
23,9/2.9
XTPase
adenylpyrophosphatase
KIT-directed
n=9/132
1,525-amino-acid
phospho-Ser235/Ser236-S6
DRB5*0108N
labeledin
Gliomagenesis
.Understanding
heparanase
4267S
S43
Manfioletti
human-C.
calcium-binding
pY1230
transition.7,39
10Nazionale
GIBCO–BRL
transgene-targeted
5′-CTATGAAAGATAGTACAGTTAC-3′
pAb421
METWT
procedures27
glioma-specific
E475K
outcomes.26–28
fe_p53wt
C/C
4,623
pLenti6/V5/DEST
doseb
xGXXG
subungually
.3Mutation
35–40
95K
29530
L61F
RAF/
SHP2-D61N
genotype-phenotypecorrelations
R331H
Blackledge
D1311
construct-transfected
fingerprinting
Y537E
ACCGGGCCT
.NFKB
aExon
SW41Ti
Monshipouri
01.2
P515
.Au
7/del
Oncogenes
anti-Alk
anti-Raf-1antiserum
L183P
T-T
2.243
R235Q
CD19Cre/+Trp53L/LEzh2Y641F/+
33,35,44,46
familiescarrying
phagocytes
DNAcontacts
1-249
KD1074
413–52
coamplification—based
NaPi
6,41,42
-V600M
2B-C
NS495
35,81
15q26.3
pM21
OPLS-AA26
rs150089916
5'-AATCACAGACTTTGGACAAAG-3
Berthet
phenotype27
-C4°
Crkl
doi:10.1158/1535-7163.MCT-06-0555
MEFsUpper
β11
low-probability
ofactivating
.HBO1
naïve
0·07
selenomethionine
3′-EcoRI
GTCTTCTGAGGATGAAGCTGACTTCCTTTCTCGC
Attribution
E439KARAF
melanocytic-specific
S49P
0/100
Y.J.M
42.62
Stop_Codon
Mt-BCOR-RARA
MS751
PredictionGene
phospho-GSK-3α/β
C17orf56
BL4
TFIIA
9.32
population5
vice-versa
GENOMED
5,683
Tyr292
F2006
IRF3-responsive
1/31/07
VHLis
chromothripsis53
II/RNR
∼10000
GeneRacer
1.53–13.0
Shc-Y239/40
Fig22
determinantrecognized
69,58
sperm-associated
trials.55⇓⇓⇓–59
U2AF1.3
transformationof
Schiavon
CHG
A546
22–95
Adzhubei
.047775
AcSé
v.4
3,5-epimerase-4-reductase
eosinophils.41,42
123500
Cbl-inactivating
AKT18
5′-AGGGCTGAGGTGACCCTTGT-3′
www.benaroyaresearch
T1025T
fingerprinted
5′-TGGCACTGCTTTCCAGCATGG-3′
Biosystems/Thermo
mapper40
//www.R-project.org
allele−specific
35S-Cys
inextracts
Pro99
Ek/LIC
8q13.1–q21.11
754TR
.Motor
C10stop
RXRB
death-associated
D1-stained
transformation.47
P396S
p.Met1
.GWAS
D2202N
driver-positive
N763ASPS767
ROS1-negative
NES-containing
Nuc
7,604
.RRAS2
AVSSFVFLRFFAVAILSPHAFH
GAGGAAGGCA
SgrAI
Ras-
LiCl
phospho-CRAF
559
miscible
ATTACAACGAAAACA-+ATTACAAGGAAAACA
TAAAGTCACTTCATT-+TAAAGTCGCTTCATT
.heatmap
F/P
pMAT1
2-h
26–20
Caryolysine
contraception
Lukashchuck
p.L595R
3.20
module48,49
embryonic-lethality
IFN-γ-inducible
IFNγ-deficient
3-4-fold
pre-B
Y20
.Evaluation
DME−/MMR−
Solvate
pGPD-hTrx
.0050109
c.1846_1848delAAG
KSHV
S276L
MG14F5
Src-like
Squibb
PGC-1β
40-fold
n0
IC321
Ab5
I744_K745insKIPVAI
-ATCCATCTTGCTCCAACACC-30
75–78
pCMV-JAK1
pcDNA6/v5-HisA
report.5,24
H1092Y
PFV-PVR/VER
SuperFrost/Plus
Ohno1
α-Tubulin
erythroid-burst
pTaG1/
dH233Y234
p.Asn127del
1Tc
lymphoid-specific
Rocco,4
KWQFP
p.P34R
LysM–Cre27
Hakimi
Q1977*
R225P
.Three-dimensional
.HEAT
cells/sec
5′-GTGAAGGAGTCACCCCTAAATG-3′
sensitising
51:54–65.As
10–90
Borghesani
K=R683K
pUC8
pGEM-shRNA-U6
P=0.0050
.S34F
37.9–50.7
F133L
1HRY
168
Pde6δ
Mek/Erk-independent
nonlymphoid
WM1366
PUF3
59-overhang
Hyperphosphorylated
r=0.3507
megabases
FGFR3b-G384D
RasGAP–p190
inactivation18
Y703
Superposition
Fab9
34/41
GATTGGTTCTTTCCTGTCTCTG
A504__Y505ins
10-reverse
GAL4-activating
S1441
lesions.7
5'-GAGGTTGCACATAGGCAAAG-3'/5'-ACCTTTATATACGCGCTTGG-3
KITD816H/V/Y/N
granulosa-cell
12-219
BxPC
wer
prepublication
Recapitulating
6.25
5′-TCATACCG
byr2-GAD
N92
clinico-
Bcap37
signal-dependent
poly2
.Wps
YWHAZ
2.20×106
HCC-78
status.19
METABRIC
box–containing
theMYC
NM_004304.4
NMD-inhibition
Panobinostat
5×106
DNA-tethered
5′-TCA
activation.17
sub-domain
jaw
anti-Cdc20
months/12
NUT-specific
187.Conclusions
Myr-3′M
CDC4/FBW7
I580fs*7
24/85.7
valine-to-glutamate
R271W+WT
domain-phosphopeptide
Vernier
15–base
W267X
-D
0.64
Chemotherapy-induced
Meningiomas
c.3239G
pBRAF
05/MRE02/17
tropomyosin
0.617
Leu-775
NaF/10
His8
.Anne
349T
classical—truncating—mutations
82:1513-20
oval-to-spindle
antiMLH1
lumretuzumab
Re-ChIP
87.0
TP5346
celltype
7623
transferred‐specific
ElasticNet
detected.3
inhibitor-ERK2
8127
∼0.7
SCG1
NS-related
2D-E
aminoacidic
P29L
5539
investigation.45
IOD
anti-tumour
RN28S1
out-competed
Tsukuba
S428A
0.184*
REV1:5-GTATAGGGGTACCGTTTGAG-3
chromosome—an
0.6668
63×/1.4NA
comparatively
L245
TPLL
U-BLC1
instability178
phosphor-specific
anti-BAF57
D770_N771insNPG
ECD/NRR
Deng44
SUZ12.36
5′-CCACTATTATCTCTGTCCTC-3′
Vasko
QColor5
Tamoxifen
≥150
inactive.9
tocosegregate
cadherin/
.Anti–Ki-67
anti-Bcl-xl
SBC5
.S5A
www.umd.be
60–57°C
terestingly
Akt-signaling
pallantype
Sh-Luc
RTK.To
L193D
-0.04
LRCP
ARHGAP26/6
self-availability
formation,47
shrinkage147.Responses
7.33
RP11-9D14
2,260-bp
SSH2
B1.24
.Multi-species
Y277D
T7Sequencing
p18INK4c.7,8
m/e−
ZFHX3-only
N469fs
RhoA+
TRCN0000039716
ofAK12
Sarkosyl/TE
WO2007002325
transcribed-translated
Anti-tumour
-EF1
.Included
NCI–H929
signalling119,120
∼1.7
surgery139.Responses
N-type
Gal4-fusion
RASA1-Associated
Ras-rnediated
Hinfl
-2,5-
DAOY,23
thedouble
Asp30-O–GTP-O3′
Paracrine
MD-CMML
S163P
pmCherry-H-rasG12V
pSer-containing
mGppNHp-bound
.+II
EGFRvII-
FIP1L1-W-PDGFR
D11S2365
pleckstrin-homology
MDA231
Autogrid
GATTrA
phospho-serine
UAS-Ncoa6-RNAi
Y1176
hyper-pigmentation
TEL-JAK-
4.KRAS
earliest-stage
Puromycin-resistant
70,071
7,755
3636
glutathione-coupled
lentiviral
MOLSCRIPT26
S2KO
light/12
nature.comA
Whole-blood
G→C
G426S
Myc/Max-binding
.P70S6k
electrophilicity
MigRI
atomsb
DNA-lipofectamine
NBG17
4/30/98
pCNX2.FLAG.ADIPOQ
Pdx-1-expressing
C203R
IPR000418
RACP29S
GSK3B-T286-HA
tyrosine-rich
S1704T
lines32
sequence-derived
Vector-horseradish
XIAP1
AgPath-ID
CRAF-depleted
GGCGAATTCTGTATACACAGTTGAAAATG
80-82
Unc93b13d
-ggggacaacttttgtatacaaagttgtttagacgccagcagcatgggttggtgtgctgggc-30
HUM00050085
0.0805
pVHL.47
Spotfire
shown27
IIS
pMMTV-SV40Pa
Ser235/236
models.15
5′-ACAGGACAGTGTTTACAAA-3′
649A
tumors16,17
co-evolutionary
7-40
molecular/genetic
Verlander
.2d
glutamic
negativefeedback
ZC3H7B
CMML-1
MYC-driven
helical-nSH2
3.5-cm
grenada.lumc.nl
noncontiguous
FE-PD
pro-inflammatory
Coimmunoprecipitation
ka11
EMT-related
3444–3449
Hypaque
G314S
kidney-derived
E746-T751insI
lymphomas32
10.1172/JCI45797DS1
E053
cyclasell
T50A
58.0
7·1
UBC.24,25
β-catenin.30
pTB701-FLAG-D4
-merlin
Phospho-Y878
comimmunoprecipitations
.Solubilization
.Ricci
T66
11q13,1
1.1,18
Anti-INPP4B
A3131G
K659E
DAK-H3-IC
P768A
983–990
mm–5.00
Ser127
FO-I
Perfusion
604147
partners.Figure
D8S1179
Neh1–Neh7
2,200
ACACTTTCTTCCGTTGCATTATAGCCGGC
RLAA
FF99
SNF/SWI
Suv4-2
p.S703I25
EWSR1–YY1
L-ZIP
Histologically
.A3507
H541
0063
NT1
1.031
K655R
DNA-damage
birgit.lane
non-BRAF
Sox17-null
MYC77
Monomeric
∼33
.Chronic
1∶400
MicroMath
LengthchangesHAT40
Ncapat
5DcycDllql7p12q156Dâ€
CCAGAGTGCTCTAATGACTG
PolyPhene
3H-labelled
.Gq
ERK2-protein
PDGFRB-rearranged
JAIO
−109/l
T430D
MCF10A-G13D
ErbB2-Y1248
'DNA-contact
authors,15
˜15-fold
genes.18
Ni2+-affinity
face-to-back
'titrate
teratocarcinoma
TEL-JAK3
RP11-165J16
.0016*
HCCs.IntroductionHepatocellular
GGATGTCAATGTTCGAGGAC
arginase-1
sc-28327
1:32
Pritchard-Jones
disease31
Guilhot
.ERCC1
LMP10
palpated
AML,7⇓⇓⇓⇓–12
HuD
TNFα
light-staining
seconds/60C-30
thenrecorded.Nucleic
G260R
FMR2
EW7
M/60
iSH2-p85α
FLT3-N841I–expressing
avidin-FITC
RhoAVal14
stability66
199
5′-CATGGGCACTAGATCGAGAGGT-3′
4/40
2.79
cases137
protein.6
antibody-coupled
anti–phospho-S6
deletion.To
3,3′-Diaminobenzidine
cystification
GSE56
proteins.158,159
Hopkins-Donaldson
PDBID
FOP-fibroblast
Busino
400mgorally
Bruce4
1300–1870
Fugene-6
1–469
Plotnikova
Mll–/–
Y589F-Flt3-
ofhydrolysis
H1048
c.499_502delTGTT
transformation.86
repression54
0.42–0.79
pcDNA3/LKB1-K78Imyc
L-III-18T
113-134
Receiver-operating
π/6
±15
0.13/year
D97A
factors.65⇓⇓⇓-69
26−28
Nijmengen
X-100–protease-phosphatase
FLT3
mechanism4,15,18
c.902G
11/49
PTMA
A_51_P390480
Xenome
TO-0072468
81-72-367-6369
γ-herpes
preTalpha
system41
Smad2+/−APC+/−
5'-M13-CCAGGTGACATFCAGAACATlT-3
.SKBR3
6.4–9.8
UO-
Leu85_118Ser
described.16,18,19
S891A
OncogenesStick
RI-////idlIIhuman
,1084^1090
co-aggregation
r.302-2_302-1ins
urea-
p.A681T
photoactivation
2−6.2IL21RInterleukin
pan-cancer
**PAX5-JAK2
SUMOylation-defective
HLA-A*0111N
CA19
26/30
Reductionc
anti-pSTAT5
.Chained
SNIP-6
676C
Ad.shCont
aagatgttttgccaa
Arg-752
1F/3R/1G
.196
XXXV
haplo-insufficient
HcRed
L613V
themolecular
,6C
5-CAA
NR-1
Ala563
anti-sodium/potassium
S111D
Rakha
disease-founding
weretreated
H1106D
30,810,239
Asp820
W296R
0.0157
c-41-58
CrT
−1.72
receptor18
yeast.23–25
c.1328_1329delCA
α1-antitrypsin
3′-phosphoinositide-dependent
.Parent
cyclin-A-CDK2
substrates/downstream
NF1-associated
17/38
Menten
Cul3–SPOP-mediated
SNU-16
ETS-domain—that
linings/basal
anti-AR-V7
Dicer1wt/fl
mMDTT
system.1
-AKT
_IDH1/2_
NCI‐H2170
UM5
fewfold
Slx4-/-
5′-gccaaggaaagatgaggttg-3′
/AKT/mammalian
8224
A*6818N
69-
27.5
V600EB-RAF-homozygous
0.0151
unclonable
EDTA/10
C240
Phospho~/lation
S331F
MDV3100—comparable
P240
PIK3CA5,7,144
pocket,25
3–39
CATTGCACGTTTTGAGGGTA
Arg10Leu
G269D
aurora1
786-0
on-responders
ALCL.21
ATG–CTG
MAPKK–ERK
Pulgar
Analytics™
53156
N-RASQ61K
.Commitment
rcduced
TRITC-conjugated
Gbr2
2.0-7.0
exclusion78
A202V
pTrcHisB-Haras
p16/PSMRB
.Rosen
1144C→T
-0.547
1.644-7.653
PPIA
activation.2,35
phospho-SER276-RELA
mutations156
P-5726
hMSH6-
cln
Gostissa
chloride-inducible
.Magnetic
Phe498
multi-mutations
5.7–10
WT-p53-reducing
33,51,52
5′-3′
PPARg
Metallothionein-Met
C~~~
Cybrdi
supra
wu7/wu39
nanomer
L-enantiomer
gain-or-loss
30–3.5
therapy1,3,4
.FPD/AML
nomenclatureb
NZM13
β-d-galctopyranoside
v567es
505/507
T62-specific
p.R1391
42/CRC
p.W557_K558
Philadelphia-chromosome
largeDownload
p.K660N
HPVDNA
c-Mpl-WT-GFP
p.Val665Ala
macro-protein
TGF-βRII
rs121913433
functions17
390-bp
II-selective
translocation-positive
SMCD
,9D
.Cells
Renilla-luciferase
MCL,23
AACAAAACCAATTAGGAACCTT
Passos-Bueno
Q04771
theInk4A/Arf-deficient
WadeEvansand
nrf2−/−
.-*No
code1BKD
instability/spindle
1,249,808
PI3K56
farnesyltransferase
JAK1-activating
sequencedto
GI:30795206
.Profiling
356
0.2–192.7
non-polymorphic
30min
Trp114
.Hair
73/170
shScrambled
H1862L
patients=0.53
histology-stage
Na2EDTA
S4I–S4L
Die̊l
stop-
-CCTGGAGGCGCTCTTCAACG-3
LouGI
107–403
133.079
c.103G
168del18
5′-CACCTggTCCACCgCCAgTCT-3′
LY2109761
progression.40,44-46
771
E21
c.651_652del
B52
S1073Q
thephenotypic
57,59
27347
EBUS-derived
sulfatinib
Maydan
CNV
factors50–52
CDNK1A
FLT3-deficient
Nytran
Pgp-proficient
Ala-4
FIP1E6-F1
Klatskin
9–28
Brca1F
bOverall
MCAM
AktpT308
recombinase
gefitinib23
Peroxynitrite
butPDGFRA
kinase-targeted
3-year
1.52–2.95
dermatopathological
Ganglioneuroma
DEC.11,29⇓-31
R715G
L597V
.Preoperatively
DEB-induced
T-to-I
RP-11481K16
Landthaler
Reblotting
987
R145H
0·14–0·35
K-RasWT
FGFR4-overexpressing
hyperp
c.736_741delins
F73/2
K-K/R-x-K/R
Tracheomalacia
9075
3359
areexpressed
3-isobutyl-l-methylxanthine
re-establishes
MSH2-linked
39-49
.INI1/hSNF5
Maxfect™
AML1-EV11
ATP-binding
PolyPhen232
.Conformational
inacti
.103G
Fgf3
LVSI
TCTGAAAAGCTCTGGTTTTACTTCA
S.U.Go
JQ1
CD45.2+CD3+
k-1mut
.Lemonnier
carbonyl-oxygen
between-group
VHL2
ACINAR01
enhancers/silencers
glycerol–10
stabil
cdk6-D
27295
TTAATACGACTCACTATAGGGAGACATCAGCTGGGTTTTCATCTTGG
MLH131
4273
repurification
bronchoscopic
-3-benzimidazolequinolinones
together.13,14,36
NSCLC.27
56941
post-PARPi
11q24.3
L1245
Raf/Mek/MAPK
MCPH5
TPR.In
UK1708E2
Gaussian-shape
U90095
P44L
0.73–0.74
SERBP1
TERT/telomerase
1.5×109
BWA-BLAT
Be´roud
hUBC4
c.4951T
G776L
nonserine
RP11-351D16
5/123
-~
13.4
ZSCAN30–BRAF
5.0.2
heterogeneous-resistant
RP11-578N3
nucleophosmin
Ala6Val
PTEN-D24Y
Y438N
Foxa1loxp
light31
XL1-Blue
RANGAP1
HRCT
0.32-0.56
G248P–87667G8
Monosan
.FLOW-CYTOMETRIC
.AURKA
slowerate
BCOR-CCNB3
CCTCAGCCACAGCCCGCAGCAGTGAGAAGC
6,482
MET-HGF/SF
HKR2/T7
photobleaching
Génétiques
5′-TAGTCCCCAACGCACAGACA-3′
mirVana
GLI1-dependent
5.14:6.77
Ba/F3-TpoR
5/10
//www.med.mun.ca/MMRvariants
43.43,44
delVV
IGF
2009a
c.229T
-GGCCCAAACTTTTTGTCAGAAG-3
,6I
ErgMld2/Mld2
C-1
hESC
16,19
Ma-Mel-48b
TetPTEN-K62R-FLAG
automat
.2e
withPDGFβR
D13S175
SAMtools
1.2–1.8
Hendrich
EBNA
S4S
6:14
neurexin
rs799917
pVSV-G
44–11,619
F806S
V2152
cMET.97
p.E1099K
CD8–caspase-8
diamond-shaped
S0516T
Y781H
pRb+
BCL10-mediated
624–1287
D129V
Trr/Mll3/Mll4
nihms774093f8.jpg
ij
hybridizingband
ligand-regulated
bound-nucleotides
KAT6A
2–82
Pixsys
product60
L299R
H.
Stereotacticallyinoculatedbrain
DLBCL46
Hippo-responsive
GM08207
U4/U5/U6
0.663
GelPro
GSTp531–101
E1235V
D-Cdk6
.Percentages
CD107a
12,24,28,29,34
.PMut
T-ERG
causation.15
.F
p-EGFRTyr1068
RITS-like
−1.9
0.06–58.59
BRAFE600-transgenic
transcripts.13
oligonucleotidesencoding
9.87748675
patients45
PDGFRβ—may
capture-based
C57
8^10
tumours,36
VHL-mutated
1105
DUSP4-containing
3,951
–17.3
360
data-smoothing
DTFLMEMLEA
disease10
13.2¡1.1
.Mareels
G372V
anxiety-
crisis.Specially
and4B
G46D
Marampon
p110βfl/fl
Progensa™
329–335
α-K-Ras
p.Gln2157IlefsX18
LGDup
Wnt3a-mediated
allele‐specific
leukocytopenia
T-LGL
A21424
c.2626
14q22
5′-GGAGATTCGCGTAGTTTTCG-3′
Oei
Y-463
Sca-1+/PDGFRα+/CD31−
hyperphosphatemia
No/yes
8.0–9.4
M42
1k–l
p.L396V
proliferation147
Anti-vinculin
Discontinuation
c.8850G
VCL
.Three
GRF
.Wnt
82–94
16,26
4×4
K364
described.20–22
100/multiple
1987–1997
CTgene
5′-cttgtccagcttgacagtgaattgctgcaacatgattgtcatctt-3′
.at
fifteen-fold
mid-1980s
osteoporosis—two
Arg/His-24
.Practical
catCS428C
40μg
3′TGAATCCGGCCTCAGGTAGTT
Garcia-Manero
II.7
linesTwo
HDC82
beta-sheets
18,21–23,29,30,32,37,42
5′-AACGACCCCTTCATTGAC-3′
Tremethick
chain–light
O6
HA-AR
CornDdrison
lines.94
Floxed
1998
microtubule-organizing
mutations/single-nucleotide
LSR2
E198A
1mutation
wholeexome
LAMB3
9v3
SRC/ABL
p.Phe103del
D594
glutathione–sepharose
D3–CDK4
pLHRE
184
ProGluValX
evolution15
E13.5
sparated
//www.broadinstitute.org/tcga
pK125E-FLAG-Fwd
S4A–C
ER/EB2-5
S235/236
0.00055
DM6000
LSL-KrasG12D
1.49–2.41
anti-KDM5A
Brookmeyer–Crowley
R57G
.PU
4139
4/38
6B6B
genome-stability
SC-6059
4499
*Arg
MYC-TRAD
Latres
9,23
aortic-root
Case–Control
hybridizations
affected.1
unclear.BRCA1
0.950
Cg-Prkdcscid
812-1013
chloroform/5
FC/+
NS-
567
.Haplo-insufficiency
D1-CRM1
RET-KD—Initial
Ultrastructural
47,000
lacZ-specific
GV41411
AONs
pCS-Dest2
19.4CDKN1CCyclin-dependent
.389
mosome
OB1-DSS1
27.4
59,415
anti-pS259
0.0569
7.5-
.Concentration-dependent
pTATA
-insoluble
shP1
'supershift
Fortessa
STK1591T/91T
12p11–p13
unmut
ubiquitylates
−740/−647
KEAP1+/+
CD34-
farnesylation-palmitoylation
bindingin
Lynch-associated
anti-PD1
UASGAL1
colonosphere
pre-calculated
adults,29,30
14q23.2-q23.3
TAAR8
pEAA292
p120v-Abl-IRES-AKT1
SeqScape®
Nucleosome
Second-generation
doi:10.1093/hmg/ddi476
.P53−/−
Endomembrane
phenotype.49
metabolism.39
C119R
c.2516A
S1760A
.Ba/F3-KITV560del
Ring-Box
lymphomas5,6
oncoprotein.
cpm/μl
pBacPAK6
3Azienda
radiology-guided
KVVE558–561
blood.70
-0.48
postreconstitution
98.45
ex-vivo
09M
components/cellular
phospho-CHK2
6p21.1
DS*
Profiler™
600-kb
118P
–466
re-analysed
23.7
CIP1/KIP1
.3L
0888-8809/96/
earlier.22
8/57
αKG12
BACH1-depleted
Niemann
D2E12
Mueller-Lantzsch
pathway22,23
ACC-300
MA9+shTet1-b
Brichta
Renault
4,008
Crizotinib
abnormalities—including
CtIP-dependent
P1158S
-GTTTCGACAAGGCAGC
IGR682
JLA20
CMV-galactosidase
Ki-67proliferation
GCAGAATCTGCCCAGAGTTCAGCTGCTG
biomarker-therapeutic
P.B.
J.-B.D.
antibody-mediated
V-D-Jβ
s/60jC
187/781
A488G
S•r
number:11644807001
Blume-Jensen
2.5–31.7
2,579
ERKdependent
S621AC-RAF
Dictor
anti-53BP1
Kruiswijk
therapy.5
PileUp
p16INK4A/Rb
TCACTGTCTGGGTGTGCTC
sc-72835
713–48
H145N
p21/CDKN1A
trP1-Exon23R
1,003
.D.H
−1.17
Magnaghi-Jaulin
A622
3458
E203Q
casapse-8a/b
.Allele-specific
Y89C
∼440
V5-PAX5-K67/87/89A
1.0.0
8.32
anti-EBV/CMV
heterohexamers
anti-recombination
FOXC138
Functions—To
SLC45A3-BRAF
re-engage
DRB1*12
ATMFig
K-raj
demethylase
1041
anti-FLAG-HRP
Pan-genomic
FGFR1-driven
NOTCH1–NOTCH4
yL*uHsPbhe
S1817
neck,50
0.87035
Tet2-silenced
GSWA
Bacci
A26V
Nakazawa
55-day
EWS-CHOP
risk-stratification
EGFRTKI
Single-nucleus
animals,3,8,9
Rrp6
elhidium
progression-associated
activty
stability43
trithorax
TGFBR1*10A-HA
R108K
HCC1937-expressing
2ME
approx30–40
pharmacological
DLD1Rep
R1708C
CRKL-related
12.5-mg
0.0214
CARMA1/CARD11.9
Evi1/D171N
ESC
PKCδ
age.1,2,5,9
MCF-7-Ago2_408C
,8B
L861R
lyCGInLouL*uA
pCMV-Tag2a-FlagEts1
oligomerization.56
AepAH
digestion
X3P
AGTTAGGAAGGAGCCACAGCATT
mail.med.upenn.edu
μg⋅ml−1
RBPJ/Notch
KLK14
NUP98-HOX
Asn-211
4,994
7974
quantifications
GER
K558_E562del
INPP4B-directed
patients1
A707T
2SC
5′-CGTAAAGGATGGAACCTAATCCTCTC-3′
gaa
p.D311V
0.375166887
DMBT1
PRDM1.E7.585.R
AsPC
Bacchiocchi
2972delAAT
chromosome-specific
MSCV-IRES-EGFP
D5S1984
SF3B1K700E-expressing
K975E
K121R
P1
3–8
X.
E201
Ala719
8.22
al37
pNEN
comparisons52
.Bortezomib
1A7.8LMO2LIM
re-start
4.2-fold
p.R353Q
Glutatione
GI:5596340
0.817
13/80
MetaCore
93.0–98.6
16.6
pDM6
-mock
Jews.13-15
blood.https
iipotentially
Thakker
AsiSI
thecanavanine
U87MG-PTEN-WT
CCN/CDK
opacity
Orian
Liposomal
137Cs
Δ214–469
anti-XTCF3
p53-depleted
357
cross-activated
transcription,5
sc-2030
9q21
gradients148
DLBCL/tFL
SDF1α
CA-Mek1/2
HIF-1alpha–VHL
Fig8A8A
.Negative
cells‡
lipid
ka10
Sp2
IVRS
.FGF23
Landowski
5′-GGTGCCATCCACTTCACA-3′
bp†
nonparticipants
.Hematocrit
hMSH6gene
criteria,10
Woo-Ho
NVL
0.88–5.18
domains.22
≈7
full-range
obligate
experimen-
www.jmedgenet.com
-k-
.TA
mid-to-high
MWG/operon
SP19
0.940-3.808
M67C
HA-PI3K
.A.M
NNSPLICE
-EGFP
2,197
miRNA-responsive
anti-phosphoSTAT5-Tyr694
.Samtools
signaling.116
5190-4370
.5207T
12-luciferase
2p23.3
4/573
5′-CAGAAGGTGATCCAGACTC-3′
Tesque
LVADDYLDSTLSDFIKTVLQCEDS
not-identical
.017*
RETG691S
Tyr-781
PDGFRA-STRN
D842_H845del
xiaoxl
ERCC2-deficient
bacteriophages
241R-18
.Broad
Miettinencohort
FANCN
DS9800
PI-3K,59
KCo11
Leary18
chromatin-signature
Karasarides
mutations—R1391S
86–89
genes.11
1XKK
Flt3-PAE
MSH2-G674R
CML.tel-jak2a
.Esquerdo
pLFACSN34
.Warburg
origin24
CDART
GMissense
c.4A
HAtag
microscope-based
GSTERK1K71R
v/v/v
P=1.55
genetics.kcl.ac.uk
G49
PTEN–PI3K–AKT–mTOR
c.2263A
E37X
Massague
Laken
inhibition/inhibitory
12.9–14.8
hyperextensible
neoepitopes
malaise
shT6
Req
IV:7
Rad50-Mre11
IDH1R132L
Advantex
Yesk
downregulation
Trp535Leu
B,6A
0.638
coplanar
ENT4
2/343
HER4/erbB-4
Historiography
functions.54⇓-56
5′-CCTGCTCGCTCCATGTTGCCGCCTC-3′
gene-fusions
AZD2281
1F-
4/29/91
146K
region-4
JNK/MAPK
20KB
Premalignant
MET/PIK3R1
Bio-Smad3
ASCAT59
PredictProtein
MDS_292
100kD
cells,13
517T
Gardina
pBabepuro-hJAK1
spongiosum—which
42–789
c.2125C
transformation80
596_597delAG
H233N
NPR1
4.5.4
TGCTGTAGCCGTAT
.Transmigration
RhoNox-1
NZM55
P2RY6
SOLiD4
MSH2-I145
non–FANCA-bound
pLKO1-based
interleukin-8
progenitor-like
E63K
-Somatic
CLL-associated
NAAAF
melanoma106
5'-CTGAGTGGCTGTGGTAGAGATCC-3
interactions25
P.A722Vf
53C
Agenotype-phenotype
p53-bound
5′-GCTCGTCGTCGACAACGGCT-3′
P-β-cateninS33/37
PDGFR-alpha-null
ampicillin/streptomycin
NG26
90.4±14.3
isopropanol:0.1
S413P
0.8929–54.17
e4.2
p.Tyr2373X
C180Y
64772
Fgf17b
Rasl
NIK-regulated
TCAACAAGATGTTTTGCCAACTG
action-amplified
sonidegib-resistant
CD34+Flt3−
6.5/40
NF00085
Elsevier-Biosoft
antib2m
Validire
S17S
1937-2002
characteristic.25
862
TFSEARCH
D124Y
subtype.Total
Ryser
FIP1L1-PDGFR-a-positive
1280
2⇓
normetanephrine
p16/CDKN2
E746-T751insA
596N
insX
0.06–0.84
p.Phe568fs
more-recent
.Prescreening
HA-ERK
T58I/S62A
Senescence-associated-
M23
single-amino-acid
Q61K
monooxygenase
TGCAGGCGGCTCTTTTTCA
Wdr5
well.6
methanol/acetic
histoclinical
Phosphoimager
−200
protein-weight
αFGFR3
IGFIR
3Tyra
Bressan
V1220E
knock-
IVS22+24A
R656C
Hussussian
Nordfors
GU079949
,3
FBXWvs
therapy.14
development.14
wild-type/mutant-specific
anti-B220–PE
JunD
EOF
PRAS40
RNR/RNase
glucose-containing
granulopoiesis
ALK-G3602A_R
p38-sensitive
CBF-leukemia
F133S
binding-deficient
TetPTEN-K62R
Representive
.RUNX1–ETO
establsihed
hormone-receptor
previously4
Idh1
VYGATYLQKLLDPLLRIVITSSDWQHVSFEVDPTRLEPSE
homology-dependent
pOPI3p16AS
TRK-activating
.Treatment
GSYVPA
Oropharyngeal
ASXL1-cohesin
CTLmediated
found.Our
Population-based
6/402
H838
V108G
AMBER99
read-pairs
ggg
CodJBas.Sub
Kimmerly
Phe'434
p27-EGFP-fusion
calculated38
non-resistant
Olaparib-Resistant
hemagglutinin-CUL2
oa
lines,12,13
BRAFV600-
.MTOR
anisopoikilocytic
biotin-stripping
Src-T341M-YF
PI3-kinase
DP-70
pCMV6-Entry-wt
Zactima™
FLAG-Elf3Δ60–127
Dovitinib-FGFR4
RAS–RAF–mitogen-activated
βF
ofMix.2
2−12.6NRG1aNeuregulin
TypeHistory
FLT3-mutant
21-day
R242
Fig.11C
TP-F2
PDGFR-tyrosine
40y
RUNX3–
Gremer
250-mg
Leu861
L708R
del17p13
melanoma24
anti-P.Tyr
resistance.11
Arg561
.CP-associated
~20–40
βA'-B
cision
CaaX
Haptotactic
N105K
INDEL-calling
Brca15382stop
11-19
Arg-249
A-containing
RAC1Q61L
formation§
PTEN-385
PX101
2368
p44/42MAP
0.0438
BRAF599ins
Cot
mutant/XPO1-inhibitor
melanocyte-targeted
sh242
david.abcc.ncifcrf.gov
anti-p-p70-S6K
cytoplasmic-distribution
NFIA-FLAG
Cys1156
.Immunonstaining
H4-CoA-20
development.13
18B
nomenon
rationalizations
ERCC3_SURV
24324
pHinder
Jak3-JH2
TRAP220/DRIP205/PBP
CDC34
smoking3
50–75th
Gly334
CGACAAGAAGCTCAGGAACC
BACH1-517T2
delAG
mitogen17
anti–nonphospho-SRC-416
EndVision
RESULTSRationale
BWH-T18
Aa-CSM
976
4q31.3–q32.1
sequence.View
Exon-1
H694R-
Myc/Max
repressor–Smad2
IgG4-
0.8-mmol/l
1276-32C
hyperinsulinism
0.15M
Dupuytre
Sirbu
non-pre-mRNA
−8.88
2396
SF3B1MUT
BDNF-stimulated
Arnaldur
self-correlation
carcinoma.33
Notch-PY
Y513A
region/surface
3q26.1
IGCT
G287V
Paraffin-Embedded
−31.2
Anti-Kit
.Mitogenic
γ-Ray
CBFα
M374V
B220/CD19+/IgM+
approach5
GTP-14564
PDGFR-alpha-
Hsp27
99/156
NCR-Nu
diacyl-glycerol
performed.FOXO3A
22q11.22
E183K
550–556
0/48
pp6OY527FSrc
of-origin
Imaizumi
sc-153
ADP/ATP
Arg650
.G1269A
kCompared
Reifman
C-D
DI842
40-70
3−4
CCATGTGCTTTGAGGCAGAC
signaling39
M409
Sud-Est
.4,34
OvCaRe
RCC.52
Hemizygosity
84.51
activity70–72
2q21
Apo-2-FGFR4
I562M
medulloepitheioma
PolyPhen.37
AGX-891
V560D/T670I
p59xDR-GFP4-targeting
2.1-95
PC3-GSE56
T58-phosphorylated
sh-DCAF1
18.7
myristyl
ÃŸ-Sheet
1273
PET–FDG
Dickkopf-1
Prdm1Flox
±9.64
High-level/localized
TEL/PDGF
DBRB
93,117
p.R24P
cHa-Ras
staphylococci
Anti-FoxO3A
kidneys.3
3757
amidst
Lapuk
SRES
OV-90
∼11-fold
GSE19730
affectingInk4A
1–1164
neuroblastomas72
MEK2-stimulated
Everman
bs-3543R
semi-conservative
FIP1-Like-1
mutations,2,4,12
chromosome.25
.Translocations
nusieve
valine-654
β-Catenin-mediated
HP200740
phosphatase-like
blastogenesis
Nod
Lys,12
countedMyc
Arg1410
non-tumour
AKC
pE1E2S1
Biosynth
expression.83
NormalcodonMutated
Alk-mediated
ACTB-A
BENTA
Glu-208
GCUGUUGAUUUUUUCUCUC
c-ABL1
non-converted
SPOP+/−
IDH2R140Q–t
17R6
Gal4-hBAP1
oncologique
YAC876g12
F486S
T311I
HGF-dependent
features27
ACAGTAGCTGCCATGAGTT
origin.8
0.330
sequencing.4,5
MLL2/ALR/MLL4
​and4.4
EZNA
.Chromoplexy
AACAGCTATGACCATGGGACTCTGGATCCCAGAAGGTG
unipv.it
64-94
653L
28–35
T80D
123
post-treatment-resistant
FIN-00029
AE-induced
Tyr64mediates
TRCN0000121117
heaptocellular
co-immunoprecipitations
0.10–0.46
3-methyladenine
RBM10‐enhanced
.DSG3
AACAAATGTGGACGGAGAAA-38
IOSE
SHORT-associated
Box1
D842V-PDGFRA-Ba/F3-luc+
A27
20–29
.Scatchard
1.1σ
others.8
tyr694
.978857
5′-TTCCT
C-22
grandpaternal
inhibitor-desensitizing
UCH-
I244fs
circa
CK-MB
half-lives
F3-BRCA1
bona-fide
7q34
trk5
mRNA180
Mutilabel
Recombination—Intrachromosomal
Pou5f1
N1-ICS2514A-S2517A
line'*
5.23
G744E
p-T
1455del
.MCF-10A
TNT-Coupled
1021
isoform–selective
AGGCA.TGCCT
phosphor-
1763
3,142
filtration/excretion
L1F
.HSCR
Ju4
97-78
TGF-ÃŸsignal
EUFA121
Wynne-Davies
QoDx3/wk
34/150
RP11-459K6
Myrinet
non-PHD
241,456
NAobjective
4-54
PolyPhen-2†
Asp254Asn
homotrimers
NMC.5
Visualization
-CGATGCTCTTAGCTGAGTGT-3
129S/v
chemo-sensitizing
isoform-derived
IntracellularAb
CATCACTATTAATGGTGTAGATGCCT
Sin1-specific
borohydrate
anti-p21Waf1
'hits
genotyped
K39
​Comparison
.Freezing
PSR
pyridin-4-yl
149730
E47
TLSIFUS
TTCACTGTTCAATTATACAACTAAGGA
andd
K117
lipopolysaccharide79
2007•VOLUME
ZnF2
longrange
Genotyped
GST2TK
6503
pink/red
Y432H
5′-GAAGATGGTGATGGGATTTC-3′
Hatzivassiliou
cerebellovestibular
reaction-based
V2006L
GCCCCTTCTCCCATGTTT
Ser192/Leu193
ng/l
R2271G
5′-TGGCTTCTTCTGCCAAAGCA-3′
C_lupus
c.1406G
N-fold
CD8α
catenindependent
T321E
NSLC
phospho-Ser473-AKT
Multiplex
1708
P=.0006
superposition
634306
mg.23
β-Actin
pDCR
//p53.iarc.fr
Multiarray
pLVX-IRES-puro
β5-β6
V386
adenomatus
35S-methionine
Biomarker-integrated
regulation16
Steck
Fig.77C
10.1007/s12032-010-9525-0
system-mediated
1137G
TRCN0000137482
diffuse-large
5/48
AGCAGAACCACGCCTAACAG
αB
1.09∼1.48
180u
L617F-transfected
F71L
156/781
40/36
A260:280
R672H
Bim-null
BAC-array8
Lu139
snRNPs
1H-15N
F234L
pRK5-FLAG-IKKα
Ile46
A.K
Flour®
ARF–MDM2–p53
603–741
brefeldin
81-84
wasscreened
TO-Puro
AZD624459
PredictSNP
non-helix-distorting
55.3
aminoterminus.1-3
EFRhoA
TTCACGGTACCCGAAGGAGGAAGGGAACCAACC
alÃ-eleand
phosphorylated-Stat3
Sproul
SCCOHT.1,15
J-binding
L265F
function.26,31
2Table
databanks
gpl4OtfA
MGH-U3
84–103
puromycin-supplemented
Phe-Phe
D126nt
.Identifying
fam-
3675
L755
adMYCTK-infected
p.K550_K558del
RETM918T
Four-micrometre
Phospho-peptide
Species-specific
activity.ATP
541Leu
20,978
plasma-membrane
wild-type-EVI
carbamoyl-phosphate
ezrinWT-
apo-form
treatment.18,19,21
agggagatgaggtccttgagat
Hirai
AY303970
∼300:1
Wagenaar
-GATCGCATTCATGCGTCTTC-3
treatment/
L198
RP5–843B9
NS–SOS1-associated
=1
www.clinicaltrials.gov
Ishikura
D380H
mutationsoccurred
649–651
substrates.57
encodedby
S3c
IL-3-independent
mut7
25°
volume=4/3πr3
PLCgamma-binding
WTMutSa
NNsplice26
α-actinin-positive
UAS-dSet1-RNAi
Genscript
AZA
//droog.gs.washington.edu/PolyPhred.html
0•197
experiments22
/k|
cytokine-sis54
cell-death
spot-truncating
Pre-Rx
255
98.8∗
four-way
IR-responsive
5′-CCACCAATGGAAAAGGTTCA-3′
GCCTTTTAATCTCGTTAGATGAAGT
0.438-1.805
Selinexor
45,47
ERK1C82Y
CA6
tta
BRCT-C.
mitoses/mm2
TET2-mutant
10705
cdc2-associated
pre-selected
♦V343L
AXIN1
pauci-immune
Pertex®
14,26
CH4987655
Group3
11p14
.SA535
LincRNA
1/14
2Z
K5.Cre*PR1
BARD1-complemented
G207E
AML.56
GCCAGTGGACTCCACGAC
siASF/SF2-b
3/292
5′-cGGGCATGCCCg-3′
NM_004217
2.308
2283–2304
–Keap1
Sublethally
thatneither
TCF4ΔN
nucleosomes.33
C338A
previously27
.7058
768
development41
kinasedead
BWA22
bromodomain-
5′-GCTCTCTGTGGGCGCCAAAAGACGACG-3′
c-KIT.24
ADifferences
functional—promises
FLAG-Elf3Δ355
SHC2
96,97
C554W
GENE-E
types.β-geo
anti-p300
E8.75
LSM12
specificities25,26,27
GFDLDL
TGCCAGG
sented
21855
Hetero-Interface
His-RAC1WT
ARL2
BAP1-v03
sMM
70–75
Moukeria
anti-U2AF65
vectortransfected
not-interfering
12,26
S12.2
ARDI1A
A2272V
μg/mL6
cells34,35,36
CDC4/FBW7-Mediated
rs6499137
water–acetonitrile
method.Genetic
C124
Nucleotide-promoted
0.36–4.19
A7–F
hydroxyl-to–ε-amine
dicysteine
protein-protein-interaction
859
G227
//www.lungcanceronline.org/index.htm
PTC.16
R41Q
-immortalized
NEGFR
TNFAIP3
leukemia,39
RP11-1220K2
5EVCkO
.Fifty-four
M1652Ib
KITexon11mutation
−2.20
RXFP3
114400
p=0.0034
PCDNA3.1-EGFR-WT
6–273
wt-allele
TCAACGACCACTTTGTCA-3′
anti-cancer
//code.google.com/p/align2rawsignal/
D80V
NALM-6
AML1-D171N–transduced
Akt1-specific
167O6
Phosphoinositide
16–82
low-estradiol
Y-733
L.V.S
V37M
KINOMEscans
peri‐menopausal
NSCLC199
C99F
Nonhematologic
H-1202-013-396
n=6/31
E1317Q
orPDGFRA
Giovannone
Pancreatoblastoma
7–10-fold
Ile-Lys
Swain
KRASG60
JAK2-induced
64:2673–2676
ovary3
assay86
above-mentioned
H27H
GFP-associated
MAF≥0.01
respectively.12,13
NSG00000116062
P-element-mediated
Single-gene
3/22
drug.3
transcriptional-dependent
ddA
WT/S32I
TRK-T3-expressing
database19
TM-treated
Ptpn2-targeting
D16S303
T1482I
Q99
MutSα-A272V
p.M1742L
MPP5
TOR/FRAP
incubation.STAT3
40Cfor
.Trinucleotide
.TAD
Figure7b7b
410-415
1536
C-KIT-D816V
ERY537A
17/19
pMSCV-neo
3-hydroxy-3-methylglutaryl-coenzyme
fusionsFigure
Gene-exon-segment
haploinsuf-
p2lc-Hras
Leu466
pY1003
tolerated/benign/unknown
DME/ROS1
61a
7.86
31760
R-2HG
pMDM2s-luc
3p21-23
PC3-p53–274Phe
3342
+/MYC
HSP20
odsâ€•
W37G
RBF29
76K
19ID
R278
GGAGT-GCAGTATCTCTCCTCTCT
1994–1995insG
mutation50
containingeither
Y730
cultures.138
0.331
321,368
MDS/MPN
Gibco-BRL
V1253L
0.07
G169D
.Kidney
E1038G
CD3/B220/
carbonic
.Despiteefforts
1,059
52–61
0·30
N=30
μLC-MS/MS
c.6982dupT
FITC-positive
EGFRTKIs
D5S134
findings29-31
0.41
ALI/ARDS
phycoerythrin-linked
pan-acetylation
1485
.MOSST
HAhB-Rafwt
KitL
5'-TCCCGCCCTCCAAAATAAGG-3
glycosilase
11-334
1.7†
GGAATGGGAAGCACCCATGTAGACC
transferase
KRASG12C/Q61L
FGFR3-related
β4/β5
WAF1-Luc
FZR1-NFIC
A212P
291X
p.D151D
SUDHL7
0.057–3.808
anti-phospho-KIT
biotransformation
Mm6.6kb
Insect
G719S/I941R
metastasizing
development.94
CASP7
disulphide-bonded
HER2‐positive
Piekny
D594N
89G4
RBF18
//www.ncbi.nlm.nih.gov/Omim/
G192S
docosapentenoic
Ets2.20,21
Khoo
TTGGGCACTTGCACAGAGAT
Wnt/MYC
K162
tVqLItQlMpfGcLldYVR-eHkd
wu3/wu8
.Centroid
IVS15
adenine-ribose
3,3
mutaEuropean
Pb-ERG
p85/p110β
SK-MEL2
importin-β
PDGF-R
MONO-MAC-6
E9
Nesp55
7/50
ARF876L-Bearing
5′-AGCAGTGAAAAAAGTGTGGCAACTGGG-3′
cystatin
Micro-RNAs
gamma-activated
3777S
B07
.L576P
Herculase
CTLAThr17—According
p.Glu233Gly
Sreeckantaiah
ΔS222+ΔS226
TARGTING
2–9
ac-
URT-3
L-003133-00-0005
P1-P5
p21ras–GDP∗
NS-like5
32.96-fold
basepirERGsequence.TheTLS
Arhgdia−/−
DNMT3B
fungoides
—We
mutations28
−2008
weight–labeled
NCT01345669
C44F/R
nt57G
5.18
304-
mutations45
CHQSSRSYDHSENSDL
44-4
McClatchey
target.Figure
0.001.Hematological
pCDNA6.2-C-GFP
puromycin-containingmedium
pT1pN0M0
French-African
3q26.5
MgCl2-0.2
receptor.10-12
highest-scoring
0.465
aggregation35
C33
VHL–BRK1
K603Q-Cl
GFP/
IgA-producing
NM_000077.2
†10
99:214-218
neuroepithelium.39
3B-D
41–76
27100
KDM5B
RASopathies
Mut1
cancer.39
factor-limiting
MiG-empty
5′-GACGTGCTGGAGCGTTCCCCG-3′
kidney-enriched
12XCSL-luciferase
Y646C
`cross-braced
R802→X
II-8
CRKL-binding
.Activating
1/16
SenSys
pcDNA3.1HisC
Lys15
pEF-BOS
AM1700
excretory
.Nalon
Berlin–Frankfurt–Münster
65933
/highwire/markup/139519/expansion
low-passage
muscle36
c.-146G
ER-integrated
3/81
endogenousactivated
hormone-positive
LacZ1650
sh-Smad3
β-cat/TCF7L2
Cdk
pMSCVpuro
TRAN35S-Label
−1.41
does30
Lys13
.CTLmediated
RET–PTC
28.5
Smads
phosphorus-attacking
internal'regions
c.540_541delAG
I1018F/W
2B-SRC-3
30–60
0.6500±0.1323g
Ras-C-RAF
SMAD4/DPC4
5′-ACAGGAAAC-3′
well-formed
N1H
Martínez-Glez
Syvanen
β-Gal
Figure2.2
succinate–ubiquinone
–29240
paircoil.lcs.mit.edu
G.S
USP51
alpha.24
50/62
C288
Marynen
ZIC2
CTD-directed
1-p.g
180–294
Yâ€
flat-adherent
brain-derived
guanylate
types6
Vairo
P=0.30
P407L
cm-1
93.45
NM_005631.4
4Institute
DDX58
Parvocellular
5′-FAM-CTGAAGGGTCCTTGCC-3′
19–22,26
PH3-positive
11965
myc-CRAF
nucleotidemismatches
c.3348insC
NIH/National
.Zhou
retrognathism
extract-containing
p.V82E
Bcr-Abl-T315I
grayscale
ID-mediated
Dot1l-mediated
BL128
43/69.4
600C'6
L2230V
R348*–p85α
−169
TGCGGCACGGGGACCT
pCDNA3myc
GRIP1
27632
Non-cerebellar
gatccccagttgcaaaccagacctcag
4b-UTR
ilellu
B-cell-like
Raghavan
invasion-suppressor
119–215
19·7
ETO1/EOL1/EOL3-CRL3s
≥3
complex15,16,17,18,19,20,21
2026
SNN-484-S3-1
503
allelecontinues
Ulloa
PAA-gels
PDG
Anaemia/Breast
dimerization-defective
EMD1214063-mediated
3,5-dimethoxyphenyl
MPSS
EN-DeltaHLH-infected
gene‐amplified
0.101
genomically
115–307
N71K
T2/E4
Lys-48-linked
respectively161
128,157
5'-GC-clamp-GTCCCTCCCCAGCACCG-3
V2LMM_11295
S100pr+
punctual
c.2145,6delTG
Fig1A,1A
.8165C
Aloy
5′-atccattgacagccaacctc-3′
phosphorylation.34,35
miceEqual
2.158545233
c-SRC-T338I
vivo14
//dx.doi.org/10.1371/journal.pmed.0030270
others.20,25
0/57
mAb30
nui
year.4
ofpatients
tableFigures/tables
variant/wild-type
FLT3.E24R1
cyclin–Cdk
EGFP/FLT3-ITD
W90128
MED23−/−
lnwU
TGFb-1
5′-CTCTGGTTTCAGGCA-CTTTT-3′
Tyr-416
immunochemistry
cost-effectiveness
FGFR4-Gly388
variant-dependent
Othmana
figurefigure
abnormalities.29
hBC
F102
RAF/MEK/ERK
II-type
ENSP00000360683
formamide-50
36-base
compard
Cazes
1.0–1.2
.Monte-Carlo
3,396
p3xFLAG-Myc-CMV-24
tancytic
transfection.16
p.G466E/V
≈402
W94R
CFC91
HCF-1-binding
carcinoma.42-44
TGGTTCTTTCCTGTCTCTGAAAA
cross-phosphorylation
leiomyomas.17
p.Q2899X
.2156G
pBabe-Puro-GATA3-WT
4×StRE-luciferase
protein-ubiquitin
0.04⁎
Glucksmann
cancer-1
driedunder
T222P
1–242
T416P
gliogenesis
2009.1⇓⇓⇓⇓–6,14,16,17,28,35,51⇓–53,61,62,72,82⇓⇓⇓⇓⇓⇓⇓⇓–91
Notch2
macrophages/monocytes
33,43
AR-V567es
eRF1
2/115
HNCC
Bambin
driver/driver
50404
pC53-SN3-R249S/T123A
JH
|ΔPSI|
D7
Tre2-Bub2-Cdc16-1
LNCaP/SRαF876L
SNK6
PHD-GFP
medium/F12
˜4-fold
RET-KD—RET-KD
Wiemels
C244S
.Gopalbhai
4.2–3.8
FBW7-mediated
SmgGDS-558
2.0.8
8:9
0.18–0.82
tERK1
almost-identical
domain-interacting
HNF-4α
v0.5.8a
Rubsamen
.Global
p.Tyr629Cys
Titre-Glo
metastasis-effector
YRG
maximum-resolution
ubiquitinylates
.Drastic
100ng/ml
4569C
overwhelmingly
corticospinal
inhibition62
instability.47
cytocentrifuged
delE709_T710insX
KRASK5N
exam-
three-fifth
3831406-3893830
immunoreacts
Cdc53/Cul-1
cor-
phs000424.v4.p1
K5.Smad2-/-
p8547-49
HindIII-Sal1
mammals.8
S6–8
MEK-inhibitor
Wavemaker
TSN
TCTTCTCCACAGACACCACA
cerevisae
00021427
0.91–4.58
immunohistochemistry.point
T1a
994delA
K935I
Bc1-2-Ig
5′-CAGCCTTCGC
0.0105
R1346L
5′-AGAGAC-AGGATCAGGTCAGC-3′
precooled
AGAAGCTlgt
fihms
D18S5
pvakt
anti-CXXC1
calling49
anti‐Myc
soluble
Ogryzko
pGT3/NT
n=15/50
Hamburger-Hamilton
Talamonti
MEK1-shRNA-GFP
S549F
PTPρ-ΔFNIII-4
HEN
ABSOLUTE29
.Array-CGH
105-fold
trisomy68
Prediluted
PI3K/AKT
Drosophila18
.Institut
S.E.M
.0022
TOP1-deficient
Gzmb
carbamyl-P
_Mol
53bp1-p53
H602L
TP53mutation
50.3–51.3
slow-growth
I·C
Smad1‐HA
14083
Id-overexpressing
Glu-124
microinjected
3.14–11.12
KB6
pathway.The
.001§
5′-TTCTATGTACTGCGCCTGGA-3′
screening.13
PET-2
53,700
C347Y
S47
production.26–29
CCNB3
PSL
L1827
.Withdrawal
E1A-12S
MAP3K-mediated
.AN
DEPC
588C
let-7-mediated
myelodysplasia28
E3200
14—encompassing
DCE
2.9269E-15
tumorigenesis30,31
p300–CBP
wolfgang.wick
leupeptin
Lamphere
N471D
Ccne1
Arg-688
3.2.1.ResultsKnockdown
mechanism.EGFR–RAD51
2D–G
Full_KD_Rev
1.6b
TLTRWHDIAIEIFLDTLVVIHR
D.H
WDLPS/DDLPSs
.Rosenfeld
5'-TGAGAGCTTGTTTTTCACTGGA-3
2/57
CTGTTGTGGATGAGCAGCTGAGAGTCT
186.3
apo-ER
kcal/mol33
XM_133912
ﬁxed
loxP-hygromycin
PR48/PR72/PR130
044
14/41
Slovenia.-
5′BstUI
53/68
relocalisation
D18S35
STRADα-LKB1
10-38
0.58±0.37
IL31
pCMV5-HA-TβRII
0.133
.S3A–B
18/40
.SAMD4B
lymphomas24
double-layered
Neuro-cardio-facio-cutaneous
G826E
168/123
Frs2-dependent
184–291
63.87
N263T
2-5-5-3
LR11-186
Colo201
COS1-
ASH2L.50
kbr
pcDNA3.1/HIF-2α
R96H
6-tagged
1186A/G
MAPK-ERK1
TSC1-TSC2-TBC1D7
degradation1
P851
.Bean
Huguenin
anti-PKCζ
MEK-ERK
spacer-containing
transcriptional-repressive
GATGGTGGGGGCCCTCCTCTT
unitary
DQA1*03
414/415
CoCl2
348:241–255.10.1042/0264-6021:3480241
RT3
ON-TARGET
.Quantitation
Henkemeyer
activity.31
ultrastructurally
pLenti6.4
EZH2-low
H2–H12
CD95/
Stetteria
3256
system-approved
Periaqueductal
Dinkova-Kostova
FANCM.1-14
ATGGAACAGAAACTCATCTCT
reg-
WT-DNA
Kallmann
3600–9800
Y491C
anti-Hes1
ckit
Strausberg
Retroperitoneum
systems.46
Leu/
Nrf2-stimulated
7.6–25.9
IC20
alleles11
1007011157
P379fsinsC
andKandil
-MUT13
L-a-PI
KYSE-140
c.1781G4T
UV78
p308
.Wt
Chk2-targeting
L814L
.Milk
CML
criteria.1,2
β-isoform
H1047R/K227E
47,38
21,32
I176
-CCTGCCCTCCTCCTCAATGTCC-3
429KB
-conditioned
D19Mit88
AGGAGTCTGTGATFG
kinase-adenosine
akrypton-argon
,6B6B
0–4.0
M1615
R655L
FPD29
8p23.3-8p22
192/236
.Augmented
T3936C
Lutzky
repres‑
MDS/MPD.1,28
Sequenase™
|CD2191
in.9
2,912
W366L
apatite
8q24.11-q24.12
antibodies.45
9270
.Clinical
P=0.92
Mst1/2-LATS1/2-YAP/TAZ
year.1
RUNX1–YTHDF2
idiosyncratic
R448H
β3-AxK
registries,30
study.7
2413-2436/nt
Mad-1–Max
//www.iarc.fr/p53/Home-page.htm
.Race/ethnicity
V599Ac-Kit
Fig.4a4a
CREBZF
Tumor-free
80.5
0.1-0.5
780C
HN4
RAD23
CA67941
TTT-39
p.Tyr164*
Anemia/
TET2-null
G.N.
0–14
MFGR
TFAP2A-DNA
sequences6
peptide-binding
lar
5′-CGTCGTGGAGAACAAGTTTGGCAG-3′
53-year-old
CD8-positive
BRAF-Mut
FKRKHKKDISQNKRAVRR
E636K
Oie
FW1:5-CATTCATGCGTCTTCACCTG-3
mRNA-Negative
IDH2R140Q-t
7096delAACTTT
LiCV8
108,353bp
12q13.3-q14.1
BII-3
108BDs
phospho-GSK3
chr2:29443697
688-4781
Goethe-University
ETV6-MDS-1/EVI-1
trp1D
0099804.47,120
anti-EGFRvIII
Frenk
F612S
.Carcinomatous
ARC/DRIP
5′-CCAGGAAATAACTCTGGCTCAT-3′
NFKBIB
paraffin−embedded
.Closer
dier
a-subunit
Plakophilin
InformationWe
A549/CDDP
K→M
PTC3
Q243E
PKC-ß
Hs01066084_cn
0.0324
plasmiddependentmutations
CDK-interacting
−50,246.48
Geneservice
S1/KH
FOXP
AGACAAA
335KB
pWZL-blast-p53
ElOO
5′-AGTTCGACCGTCTTCCTCAGC-3′
568C
DM5500B
TGGTCCCTGCAAATCCCTACCATA
delP95R-R102-7
mate-pair
millilitre
butnot
interference–mediated
C105F
promoter/5prime-UTR
LysArglys
bronchopleural
K5.Smad4–/–
.791
2.44E-17
adventitious
fidelity22
subsetsClinical
non-destructive
LKB1+/-
Co42
Carcinoma-associated
655/663
energy-sensing
37ΰC
groups92
neratinib-treated
1100–1254
c-KIT.1
Karuman
GCAATGCATGAAGAGGACG
PIK3CA-altered
Radiochemicals
.Derivative
BRCAwt
22*
AR-FL/ARV
HSCORE
mech-
chemo-naïve
histostaining
Dana.Farber/Partner
1743
A16
TGFBR2-Mutated
2.6.2.1
5'-ATAGCACCATCAATCAGAAGGGAAGACAAG-3
2p
-CAGCAGCGGGTTACATCT-3
5567-3C
microfollicles
STAT4
SCFGrr1
2722–2741
SepPak
M1
0.292–5.678
semi-competitively
6/7
neoantigens
0/A
SSCPAbnormalV
S1206C
phosphoERK1
5133
12bp
ASXL1-interacting
activation/elongation
Heighway
FN-
\x.m
involvingthe
wereincreased
c.1831_1832insA
inductionKrasLA2
0/176
STAT1-deficient
8-13
Biociences
NFκB-dependent
Hajdu-Cheney
transcriptase-PCR
2365–2443
14-3-3/C-RAFpS259
Kuwano
SELEX
T510T
T351I
un-
.PDGFA
L2614F
CFX96
TA1
sc-899
pT3pN1pM1
63-kDa
Hsp70
R265H,33
150/130
49–51
calling9
palmitoyl
P1315S
MTUS1
glutamine-free
MEK/ERK-dependent
activating/Imatinib-resistant
UGGA/UG
0.16–0.44
Central-Northern
previously.47
ERBB-3
.29C4T
NAPH
mutations.16,17
.Department
2,190
≤1.75
MGEA5
analyses4–6
p48Cre/+
METHODS/RESULTS
pUC119
intrahepatically
1/10,000
Runt
Citri-Solv
inactivation.17
5029C=T
ProtParam
97402
.ALKoma
0.105
1,125-bp
T380A-induced
25,53
Schneider-Stock
W3313.42
chromatin-bound
-0.145
9272s
45–47
537/538-
BRCA1–Met-297–expressing
migration/chemotaxis
spinal/PF
NKY501
Feaver
8/54
32°
protocols.14
Metmutation
off-inducible
variantsFor
pAKT-negative
NFNS.18
NcoI-/I-SceI-
.In-plane
..-.â€œ
MEG
-DLC1
N7-CFL
WOKW
SCANSITE
-ethoxy
testing—looks
F119L
forty-nine
Rev3
4B4B
pinhole
non-KD
NGFI-B
FCS
20-30
granulocyte/macrophage
p.M688V
N676K-positive
Gspt2
tumorgenesis
.INDIRECT
p300Δex15–18
0.700
Jolla
Bio-Nick
V777L
C-terminals
2C-D
report.17
5/8600
Mel202
RAF–RBD–biotin
site.We
.Complementary
GD855p–Msh6p
0.4–12
phosphorylation15-17
2.3-Å
R39C
platinum-
PO43
less-significant
10.49
HDAC8-CITED1
GAGTGAGTTGTGATTGTACC
1804
66-67kb
5087
3OXZ
170
β/Smad
5-GCCGTAGTGGGTTGTACTGG-3
delL747_T751
LyT1
Glu346
phospho-AktT308
-C121S
RETKs
disorder89
59-GCA
rRhoC
ALG8
Enzymology
docetaxel4
+T3/∆Leu
tumorigenesis28
.5,11,25,26,28
D-004937-02
S214F
MLP-Luc
3-
NRP-152-
BACs.6,14
STK33-Mediated
5'-CACCTGGCCTTCATACACCT
D4–D5
86,000
Gieffers
L191P
Mullerian-inhibiting
SulfoLink
underglycosylated-monomeric
30-ml
DE3
VYSIS
AGAGTTCAAGC-3
ependymoma6
59/81.9
lanes7
b2m-labeled
29.5
dynabeads
A010
'We
prognosis
.028
surface/total
0.199
Paakkonen
17/3
5′-TAATGTTGACACTCCTTGCTCACAGGC-3′
100-μl
n=140
1–519
-g
Dinucleotide
Koptk1
reorientated
ATCC
H3H
toilet-trained
10-mmol/l
Fibrodysplasia
re-extractions
Bcl-651
CCC→GCC
57-59
5,6,29
information25
Txk
1531
P7-P10
JON53
4C-D
c.-428A
.Reinduction
domain-p16
UBOs
D1082E
Capsaspora
BRafV599E
18-24
D898H
0.321*
005052.2
Arg3
3061
Ala-146-+Val17ff
GTCAGTGCCTCCTCCTAGG
Ser380/Thr382/Thr383
Sp/Sq
-nGhVaKIGDFGLaRDImnds-nYiVkGna
bindingassay
~5–10
81.8
0.599
1639
FLAG-FANCC
thyroglobulin-positive
flip-over
p16.32
.CISH
BglIIsite
-luc
cER4-5
7/02
−52.3
M225T
pBabe-bleo-Flag-BRAF-WT
or9
1865C→T
spinosum
RP11–491D6
QuickchangeII
7-9
p85j3/GST-p110
Insall
ALLN-treated
GATA1s-associated
GEMININ
UCHL
non-folded
carboxyl-terminal-truncated
P-32
G2031T
227399
subtelomeric
38,46
Descamps
^GCG
pheocromocytoma
year-old
Nab-paclitaxel
coprecipitated
8.4
SPECC1
Blimp1CD19HET
Skourti-Stathaki
F/54
assay42
Qseq
CTCAGCGATGT
lig
p.non
SUMO2
Multiubiquitylated
Helen_rizos
RGG
E68X
ependymoma-specific
.m
BÃ¶gler
.Increased
GSE15264
N=282
IA–IV
Smurf1
Gly1121
preovulatory
tern
RMS772
−0.07773
interpretation.4
insensitive.13,34a
either.21
position—either
EGFR-TKIs.10
11–33
understood3-8
MassagueÂ
method69
non-endocrine
Transthoracic
previously.2,4
V208fs
SPDGHE566-577
anti-HA-peroxidase
T37/46/70
fornia
zipper.1
tyramide-Cy3
765
.Xiang
B-cell
F-7425
591
86.2–86.3
BimML
-71-276284
S18b
20:207-211
nevi52
IGEGeFGeVYrGt
−Ve
cx-
46–47
Palate
Phox
imatinib-induced
Tgif1
.SU2C
inoperable
αJ
expression.46
004781
BT‐474
∼16°
kinase–kinase
10446149
Ex6
papillary/acinar
mTβR-II–108/+56
anti-Bw4IgG2a
relapse,7
MigR1-SRSF2P95H
TRAF6-mediated
SSPONL
.1,2,4
MPN-Us
92aa
studies24
Clinica
MetMAb
83.0
Jean-Paul
GST–SH2
GCMN
vided
H876Q
occupation-sphere
AKAADGY694VKPQIKQVV
GST-pulldowns
thesereporters
mTOR/pS6K
Forty-eight-h
beta-catenin-dependent
AG1148
2R1
G719S/S768I
C00002
VaIHisArgAspLuAIaThrArgAs
Fig3B–C
Imager.M1
S45A
EN-K380N-expressing
D1204
11B3-deleted
combinations89
receptor-α.6,8,9
Large_DEL
c.225_243del19
signal-receiving
Trk5
Lipodystrophic
Massague´
PHD2-HIF-α
27-29
G715E
R538C
p.V101_E102del
.Treatments
PH-linker
Gene-gene
KDHELDPRRWKRLET
9•5
sigCD1O
al.22
5-Fu
/phosphatase
Z.W
3KR
CAAGTGCCGTGTCCTGGCACCCAAGC
ASD.23
11.13
.Superarray
5′-AACCCTGTTGTCAATGCCTC-3′
TP5342
E16.5–18.5
BRIL
N-CoR/SMRT-HDAC3
.Karyotypic
non-muscle-invasive
L4/FSC
GGAAAGTCCC
81.24
S3e
.3,5,6
Catzavelos
del52
tamoxifen-inducible
pre-coated
39-011-993-3524
LXSNAKT2-S-transfected
2–3A
melanomaspecific
8.083
5'-dAGGGGGCC1AAGGTCAGAG-3
CD71high/Ter119high
III:5
75-90th
UAS-trx-RNAi
9.05
2.8×10−15
C1182
.Ratiometric
sampleswithHER2
LSI-WCP
E1a-12S
-nav
23.34
Verhelst
region–abelson
52°C
e20H1047R
ESTDAB
5'-GGAGATCTTGTGCACGGTGG-3
angiographic
function.30The
Sp1
p-Y869
adenocarcinomas.Genomic
000-fold
R437C
checkpoint24
N-sulfation
naevus
v.5.1
light-protected
DNAbound
.Phe540
IHCCs1,3
levels28
4359
amino-linking
Thr790Met+del19
Ag-experienced
genotype-correlated
GATTTGTATTCTGTAA
demonstrated.3,4,23,28⇓-30
identified—the
kgen.fgg.eur.nl
Linehan
immunoprecipitation/blot
5R2
.H3K27me2
P=0.027
kinases107
ulcerofungating
DI=1.81
BPrecursor
NCR
Sox17-infected
FUS/ATF1
Yanagihori
domain.23
Schleichers
1-21
VTR
Fig.6B.6B
17q25.3/cen
binddetectably
GNRF
AKT–mTOR
stressPrevious
.Kaplan-Meier
ATM/11q22
SLC7A11
HNF4a
.Transbronchial
HPV-E6
0.0140
MLL-CBP
5'-GATTTGATGGAGTTGGACATGG-3
mutationsCell
LSassociated—tumours
common-AAAGACGTTCTGCTCCGAAA
family-based
5.17E05
derepresses
.Thrombopoiesis
coimmuno­precipitated
R518W
.T2-weighted
.Brcaxx
ALK-REV
2025
TFG.TFG
p.Q58L
activatingother
XLII
protein-dosage
rearrangement.74
MYD88_85940_mu
SAM-T06
Arg882Leu
'germline
fmmu.edu.cn
Parsonage
beamsplitter
RPMI8226
hydrolyzing
poor.2
12D-8
Sordella
pGL2-Luc
hG2
IGloci
1609
FOLDX
P57P
pVHL-
H4-15K5D/K12D
anti-acetyl-lysine
Eirew
−2.5=
mL/min/1.73
β-Cat
BiBr49**
microcentricon
care—which
leiomyomas.19
0.35–1
adapta
KO1F
IgGs
GATGGAGTTGGACATGG-3
.Keiko
I-52
anti-D-type
ptg
WSB1
-1.4
APC/D5S346
DFG-phenylalanine5
.Immunohistochemistry
childhood1,2
​Fig.11
Y112H
Non-Ig-3
0941
9S
zt-
roughened
phospho-serine/
C383R
h2-
2/172
Iressa
132-Mg-associated
11,31
1UOL
1.14–2.13
a-Tel
19m
K350N
functions98
CDX-110
V600BRAF
d'évaluation
92-kDa
1795
-QIADGMA
NrasLTR9S
22,23,24,25
PROTEINSCIENCE.ORG
factor-dependence
f/
5′-TCGAGAAAAAAGAAAGAAACAGTCCGACTCAATCTCTTGAATTGAGTCGGACTGTTTCTTA-3′.Quantitative
tail.16
5MEFs
superstability
Icahn
–491d
G5557A
Stat3-regulated
Let-7f
CD99±
causinglack
276.6±6.4
D931Y
DNEmutants
.10,12,29
TP53and
IDH1R132H/WT-targeted
GBD
R833C
VHL-R167Q-Venus
autoreactive
450351
Hernandez-Munoz
MSH6-21
±5.9*
siControl1
fl1-1157F-1157
non-Asian
TGFBR1p.S241L
Men1-excised
cancers,50
Ro19-8022-induced
sodiumcitrate
Pcorrected=0.01
Heterogeneous
.SEAP
M41
AP1-responsive
1.538
H/L
Mogilev
QIAquick™
RC1
o,5
baculoviral
.Preparing
J.The
A¡ects
Flossmann-Kast
antibody–p53
p.Arg80X
21.6
476b
hyper-responsive
9,50
c.686G4A
Vmax
acid-guanidine-phenol-chloroform
bioengineered
RE-luciferase
single-page
GGGGGCC
β-actin–HRP
appropriate.All
13p.V457M
43-year-old
80.0
amouse
87.9
pDM17
zing
0.29–3.66
combinations-of-pairwise
RPTPp-mediated
imatinib.18
8times
arxiv.org
Keller6
Hs00179829_m1
0.888-5.030
receptors,5
TBD
G244C
CD16/56
Adapter-ligated
cell–induced
0.171
XEB
Y570F
D39
milk-blocked
primarytumors
5G
months–to
TIA
0.38-5.48
.Criteria
data,34
Lea
MutS-bound
Asn145
GST–mDia2
|Z|
hNQO1-ARE
modifications.13
'micro-GISTs
sc-5560
pathways/categories
21743
Noguchi16
classification.23
5.AR3
‡Provean
t002Gene
pY-induced
Mut/Del
DCX-labeled
11-Cohort
86-13502179648
/mol
8q22-qter
Horseradish-peroxidase-conjugated
°1
5-years
Chaturvedi
double-stained
T6778
p=0.0117
intra-chromosomal
27–30
Fas-agonistic
non-randomized
Grepeat-containing
pSIREN
.Dataset
Nikbakht2
TTGACAGCAGACTTACCACTCCGT
anti-pALK
y-Globulin
4203
pG5-luciferase
rank-based
RByl60
RUNX1-RUNX1T1
496-8395
chemokines/receptors
.o
4d_mapman
histo-score
karyotyping20
Vehic
Unit-
FGFR2-IIIc
enzalutamide-
146
cis-conformation
gov/tcga/
.7,9,11,36
cells—self-sufficiency
previously.10
DFG-out/
-0.08
736
PFX
CTT-3′
gain-offunction
T311
D–CDK
29-fold
region-leucine
CGTAAT
A-Barcode-Exon24R
crystallisation
carcinomas13
cancer–predisposition
mTOR-activation
3.06.3
R304W
miR-93
.Animals
forms27
5′-GAAGATCTAGGAAGCAAGTGAGAGCTACAGG-3′
CDH1/E-cadherin
2.42
subre
BI-1
CGTACGCGGAATACTTCGA
H1620R
RA/RB
DAPI-band
MutL-NTD18
adaptation21
.B2M
4E-BP-pThr37/46
lymphomas.25
TakaRa
Gly-32-Ala-33
.EIAF
Miniprep
Fig2D2D
3.154
0.15–0.53
M645R
p110δ-Akt-mTOR
,6E
+beta
IGFIIR
AluSp–non-repetitive
p53-R280K/TGF-β
Ponz
419-end
1q25
BT4
Ser238Thr
520
DIGconjugated
-512-
RUNX1–SH3D19
c.5441_5444del4
Tyro7
Arg4
RQM
near-tetraploid
F691I/L
ASNase-resistant
0.5-10
SLC25A38
rs2976329
neoplasms.Figure
-C0701
p.Leu137Profs*21
mutations,7
trimer
c.5365G4A
Jotterand
non-LCA
2-pentanucleotide
25,38,39
lxB
cleft.31
Ipl1/aurora1
ubiquitinylated
1831T
109/L
resensitizing
cysteine-bonded
–44
P134
90,111,90
proto-RET
mutation.In
29-kb
4c–e
IgA1
R373H
reverse-5
reports,11,35
5′-gacacacccatagtttggag-3′
A194E
sis-inducible
MFG-RII
Marie-Franc-oise
plasma.44
FBW7
paradox.36
isoforms21
gi68352933
chr1:78205319
Reagents—HEK293
c.1372C
.Transfectants
expression/activity
TPA-deficient
Pc=0.006
07-452
NaDodS04
TGATGAGTGTGACAG
Zhangeral.
NaCl–25
nihms5567f4.jpg
Legerski
metastasis.17
myogenin
33-69
LysMCre
BRE-reporter
radiation2
GGGAGG
72,73
pTSG-fe_p53wt
pMMTV-Luc
ErbB2/HER2
S150
cooccupies
CATGGAGCACCTATGCCTATT
N.Y
.Intensities
0.1-100
5V-gctgcaccgtggatgtcag-3V
p.Lys834Valfs*5
.SLCO1B3
study30
M351T-
ofincubation
Ci/g
Cdk12fx
4-mmol/l
interferon-induced
120,000
dGFP
His-Smad2–4
isoamylalcohol
Rworking/Rfree
microretrognathism
iEDTA
Introni
cyl
ASC-2-siRNA
alignability
cycle.7
analysis18
EW22
-CCAGGAACGTGCTTGTCA-3
siBTK-transfected
England.11
096
GRM4
non–deletion-containing
modificated
PRDM10
eukaryotes.3,4
HT-55
WHIM25
'mutator
years.16
C1819A
Gnaq
p21Cip1/Waf1
m2-18
mBcorA
germline/somatic
GTP–Wat175
V1741M
dimer–
F130
Lys-101
FOXA1high
9715s
—allelic
nuclear-envelope-associated
CAGCAGACCACGTAGAAGAA
Roselli
N198F199delinsI
fluoropyrimidines
4,280/4,751
GPR18
SHP-
LeŁon
-N1
1B,2B
C24R
tumors103
Rts1p
c-Met/ALK
activity.30–35
–99.8
Ponglikitmongkol
genes.For
STK39
BF264-15D
0.8–15
electophoresis
CXC-chemokine
SQRT—PCR
Artinger
M.-H.S.
56:1060-1066
1712
190934
.AN3CA
primer-
.Lastly
Ingeny
conspic-
pro-tumor/metastatic
PC-9/BRAF
.FLAG-HCF-1N
XO-Mat
N371
54.4
P=0.355
PRDM1.E5.454.F
His850P
arrest.1
Raf-1protein
283–309
HXB
pEGF
.Costaining
Pharmaceuticals14
.Duration
.EGFRvII
Cytofix/Perm
AU-565
Kit+
T790M,40,42
R1346Q
0002-9297/98/6202-0018
RHAMM
SAM-T2K
DN-MKK4Ala
248-259
PMM2
first-instar
E1437
,77
APC/CCdh1-mediated
Figs2A2A
.IDH2
2.5µg/mL
seeFigure
R94-P95insR-1
10.1073
Fbxw7fl/fl
5′-CCTTCACCAACGTGCCCACAGATCAACTG-3′
p‐value
97.5th
E95K
NCT01351103
MSCV-PIG
D679N
cixutumumab
CD31immunohistochemistry
Garolla
TESTICULAR
5′-CTGAAATCAACGTAGAAGAACTCATTATCTGAGG-3′
accgtgctatcgtccctgct
www.abbottmolecular.com
63–127
P6122
transmembraneand
FlexMap
17q25.3
,7
_MAP2K1/MEK1_
anti-Mac1
81-6-6300-6080
Beslu
NF-κB2
1.27–9.07
NW7
Gain-of-Function
16.06
434–769
←s
Vegf
G740S
Ezh2Y641F-mutant
ER-EBNA2
Ab5089
0.0368
P=0.695
pathway13
RET/C634R-V804G
reagent/DNA
.collagen
pRcCMV/
Crouzon-associated
MACHEREY-NAGEL
long-loop
52.00
TSC1-null
cancer-association
disorders15
γ-secretase.40
mesothelioma1
Lymphadenectomy
Weinstein
Brca2−/−
Me1386
ChromaVision
anti-tyrosine
.Its
0126
Reversion
gene-by-gene
1930s
1612
-Tgcaccaccacctgcttagc-30
Glu445
seting
Y1234A
A_52_P618427
1637.6
S691
5−10
CCTGACGCCTCCTCTCCTCG
Energy-rich
low-power
Gadd45a
KPD+/−
SJHGG016_D
'on
HCC1569
139-bp
gene/CEP
SA-βgal
exportation
R4-Trap
p=0.0978
chain/beta2-microglobulin
Akt1E17K-GFP
ligases.5,8-10
.ShAXL
14–36
K575
0.8–2.4
GenomiPhi
O'Briant
photodermatitis
HHV-RSGGRLESPHNCPDDIRDLMTRCWAQDPH
KIT0103
hORFeome
material.Chromatin
latter32,33,34
Kurebayashi
heatmap
FGFR1-positive
SCCIC12
E234X
Bionavigator
survival,14
.KMT2
Rucaparib-
Ser729Phe
non-AT
ADR
10uL
HKY1025-47D
.DO-7
ADP/min/gM
GSI-Mediated
domain.22,23
10.1007/s10147-013-0602-1
c.1366C
Auto-
76.92
2650
beneficial.Diagnosis
reported.13,14
c.1672G
Arg11
GSK3-independent
p.R140Q
L2
13q11–q12
.Exomes
homeobox/POU
.Nomura
re-fed
Krek
MEGM
.Bovine
Starostik
n=161
cIAP1-expressing
M20451
Rad50vsc+h
review35–37
leukemia.
ho-
Mimnaugh
424V
passages80-100
D842V—either
Powervision+
KRASM
CCGG-CCCTGGAGGTTCCATCATTTA-CTCGAG-TAAATGATGGAACCTCCAGGG-TTTTTG
lg/ml
G735Sa
.48
0.5ug/mL
Start-end
RB6-8C5
K181M
acetyl-transferases
polybrene/ml
Anti-p19arf
sh847
114–154
MOZ-
c-cerbB-2
5′-AGAAAGCCCTCCCCAGTCCT-3′
RHD.23
S153R
D5S656
ACATACTTATTGACTCTAAGAGGAAAGATGAA
ERF-expressing
Advantage-GC
BRCAPRO
NOTCH1‐3
Cullin3
BRCA1/BARD1-associated
..Here
TÃŸR
GUK
720–780
P072
logKd
.19,21
a¡ected
~80
ITGPNMGGKSSYJIKQjV
apoptosisTo
63-fold
G54R
Ba/F3-BRAFV600E/L505H
patients,8
−2.2
His123−Val126
ASP3026
side-chain/backbone
S124
types.34
mutations172
HIF-1αP564A
SH2-regulated
EGR1-centered
iProof
NBTAM
P216S
EPD4
cyclophosphamide/ifosfamide
V109
31st
Q116R
MET-T1010
Murugan
Ham-F12
anti-CD14
is…
p52/p100
Kutok
Pro-angiogenic
208F13
1–44
Duesberg
-0.17
phenylhydrazine
BrafLSL-D594A
CTL-mediated
0.509
.5M
LAD-associated
.2203G
BCL-XL88
4.5Å
theoverexpression
uGluArgAl
synergistically
GBMO
TNFSF10
E153
TOR1AIP2
1,588
243–371
MutH25
1A–1C
I250029
TEL352
R273C/S240R
2.5th
2H–J
2457
nonhealing
T75R
32Codon
=0.004
17–
BAHCC1
1457
Asp-869
–23
0.1×
Miyamura
.IB
de-repressing
12878
KIX-interacting
oncogeneK-ras
level=1
5–year
Eol
GM-CSF28
cage-like
.SaOS-2
.1651G
Midiprep
Interactome
FANCD2/RAD51
−1.83
.acc
ascertainment-conditioned
–nuclear
chromatography
BioGRID
WSU-DLCL-2
HOXB7
47.7
pGEM-3Z
domain-SBC
reticuloendothelial
NF1-deleted
Mhawech-Fauceglia
Relb
c/EBP-α
Alk10
L792
L363P
ESPL1
3.340970833
AssaysFor
26-specific
34076
Neofluar
chemotherapy9
0.85–2.87
SHH-N
5/0
BCR-ABL1-negative
anti-total-MEK1/2
Y144
chaperonemediated
HIP721F
hot-pink
15q22–26
c.326T
E596Q
pGST-FANCG83–622
sub-AER
available.3
meayamycin
luciferase/β-galactosidase
amplification/activation
modified/mismatched
Tyr-648
CDH1-mutated
pre-cast
115–127
FLT3/ITDtransfected
LOC401131
mMTris-HC1
SHH-induced
XTT-based
PtdIns
Taxol
NP_652044.1
-D835Y
G1306V
Sox17−/−
371C
morphogic
UM-SCC-22A
LSRFortessa
NP_075259.4
ethinylestradiol
nylonmesh
.Peltomaki
aging-related
.Fractionated
rearrangement-positive
pheromone-induced
S2K
IKZF2
O2
enzyme-linked
regionsof
print-tip
Cold-sensitive
bronchiole
21/573
H3K4me1,2
models50
10060
underphosphorylation
Constantinesco
HA-Aα-R182W
//www.genome.ad.jp/kegg/pathway.html
Clinical-Pathological
colleagues15
Jean-Marie
usingKaplan-Meiermethod
upper/lower
Biowest
under-described
HIB/Roadkill
Met241
0.5-mol/L
c.872delC
.CEF
RP11-359P11
Ring3/fsrg1
oncocytoma
941C
Wartmann
prognosis62
Hdmx-G
H214Q
–RAP1
dinucleotidic
kα3b
HRX/ALL-1
1962
nihms646437t23.jpg
GTACTGGTGAAAACACTGCAGCATGTCAAGATC
Uni-
delL747–S752,13
activity32
pUHD-hygromycin
non-BRD4
pSG5-based
p-Pdk1
.CD86
1-year
reticulo-
CD27
activation.140
AT165LA
MgCl2–3.3
BamHI-digested
n-3
13,14,17
asbestos-
A780G
187484
high-MC
CXXC1
M301R
auto-phosporylation
v5.3.1
pS1463F
TOPFLASH
invasively
ACTGAATATGAGAAAGTAT
Resu
tetraploid-derived
xylazine
.Akhoondi
D1713A
//evs.gs.washington.edu/niehsExome/
Gefitinib/erlotinib
GGTGCTGAGTATGTCGTGGAGTCTA
SvEv/Black
PRDM8
QuickPrep
200ng/ml
pY568
exoteric-androgen
ourexamination
3/4-week
8X105
'toxic
J/m2/sec
6q25.3
SWD3
LPS-exposed
histologi-cal
V774
KWotyPe
FGFR4−/−
p53.42
2nd-term
pathway.4,5
cell,19
EIF2A
infection/selection
anti-cellular
71aa
cc-EpoR-VI
Hoxa9−/−
Consequenceb
37◦C
AnnexinV-positive/PI-positive
AAGA
GNA11as
/highwire/powerpoint/42302
//genome.ucsc.edu/cgi-bin/hgLiftOver
phate-binding
IGH-translocation
FreeBayes
stage39
p.Ile1347
TP53–/–Tsc2+/–
D-4-
PDGF
c.190G4A
p.Thr599Arg
R135A
CBFalpha
RGL/RSB2
Arg578ValfsX3
J-P
TrkB-negative
non-HCC
34
16.84
.Parenthesis
H-RasG12D
non-curative
.ALK-specific
.Comparative
Polacarz
indicatesthat
KLHL3a
frequency/absence
c-Met/hepatocyte
Pflumm
c.808T
Gymnopoulous
Asx22P4
Ras-mitogen-activated
gelsand
PDGFRA-F5
lesion.80,90,91,94
.Polymorphisms
1.1–8.6
–74
doctoral
uGlyGl
|*v
c.-124C
0.8709
Screenintgestsanddiagnosticimprovemenotsvertherecenyt
proto-oncogenes34
CCG-3′
samples32
DNA-polymerase
PCAF-mediated
Trx-PTEN
reaffirming
GCTTCTGTCTCCTACAGCC
broblasts
51:54–65.Diffusion
26,9
annexin-binding
GDPAlF4j
0.85–0.93
re-flected
mutation-dependent
16,33
1.1.4
eosino
D281G
ARFGEF2-SULF2
μg/
1.5-Mb
anti-parallel
Westermann
R28
14/30.4
Kaleidagraph
CAL2
hydroxyamino
51.9
K550_W557del
.33H
Pneumologie
1XTR
1336
BRL-conditioned
like11
CCATTGAAGG-3
A291T
TCGA-BR-4370-01
4/276
SIM2
*15
ModFIT
phosphoserine-binding
PETHEMA
3p12
2DE
LRR
FSP+
rad50nc+h
HEG0/pSG5
ELZINCA
PAK1–3
types,19
fusions—KIAA1549
//cancer.sanger.ac.uk/cancergenome/projects/cosmic/
USP26
.HGU133
isomerisation
,7C
HPV-26
CD88
T345M
AT-hook
1202
.DeBoever
3-5-5-4
genes.2,3
multi-substrate
.Akt3
VQLYAVV-SEEP
cell.Figure
mycophenolate
A2403
T1
bHLH-containing
pSUPER-p53
sc-117
-T319/321E
UM-SCC-19
concentrations49
ITD502−503
M10080
Phosphoserine
MutSa-containing
Coiled-coil-dependent
c-MYC,18
Duplex
SO-fold
18q24
.784T
dovitinibresistant
mu1164R
tower-like
DMBA/TPA
HET-1A
CD36
MDCMML
~16
tumor–normal
D1-3'UTR
tracheas
*Eerola
Fbw7ARG
non-CNS
bases.10
506.00KB
reverse-transcriptase–polymerase-chain-reaction
INI-1
170-10,000
damage35
SMAD1/5/8
Tyr397
42⇓⇓⇓⇓⇓–48
41–95
RBy50
.32,34,35
Sint-Augustinus
323-326
6The
R371H
1.12.1
KI1517-1518I
red-shifted
5′-CCGGATTGCCATAAATAC-
targets—cyclin
Fbxw7-mediated
RAS-mutated
5′-ends
Juszczynski
Y699
podocyte
.Leu117Pro
stage,51
RND2
0/13
.MutY
30±28
2369
7,8,9
1×103
©2008
CD14+
.6B
TKInaïve
follicular-patterned
uranyl
Eosinophil
BD-FANCD2
Tyr24
298.3
0.1-m
Cys-light
recurvatum
I745_I746del
RAS-BRAF
11‡
101/133
Vrije
​Fig.1B,1B
U72936
Myxofibrosarcoma
pRB/E2F
MCDB131
1099–1104
apoptosis14
TMPRSS2-
specialization
9-508
6334
800µg/mL
cross-brace
∼12,000
3RIIgenes
N1044S
phospho-CrkL
Microcystin
GTGGACAACCTGACCTACCG
EGFRKD-GFP
1.49
34K
−47
Acquired-mTOR
R227Q
.Rottapel
5'-CCAGCGTGGACAATGGCTAC-3
3xFLAG-specific
damage-repair22,23
.Homodimerization
DNMT3a
Fusion-4
RERF-LC-AI
NCI-H358
BRM/SWI2-related
S352C
D1594H
24480
CCT3CCCT
FGFR3—when
allele66
5'-TCCGACAACCGATGCTCCAG-3
V-to-G
n=21/132
.760G
DsRed-negative
p.Ser2252PhefsX9
A_51_P125355
FHA-mediated
retinoblastoma.miRNAs
procedures7
Tyr1068
F723
11/195
Kilic
reagents127
0.878
MEC1
7S250
ExoI
syndromes.24
mn~ol/L
1Interspecific
LGTGCFGDVWLGMWNGSTK
1–35
ACTSEQ3
7.15×1010
FGFR2–CIT
5-B
8repeats
1064–1098del
R135I
bud
.LATS1-transduced
GISTs.23
Sox2-Cre-mediated
N‐Ras
VTX
Ala93Asp
myr-AKT
p-FLT3
Avidin–biotin
p53-p21
AML3
DeltaC4
vehicle-
Ste5
.BCORL1
4448293
G29
TCAGCCCATCTTCTTCCAGA
labelled-streptavidine-biotin-peroxidase
PLCγ-PIP2
.FeO4S-untreated
flank-injected
Waardenburg–Hirschsprung
33-4-78-77-72-20
Normalised
GRCh37.70
med3.med.uni-muenchen.de
Camptosar—Irino
ANotI-XbaI
400mM
origin-defective
system10
chromatographywith
MANT-GDP
p36.13
673–678
d38
-GCCCACACATTTGCACTCTA-3
5′-GACACTGAACGGTCCCCGAGG-3′
E-MTAB-4097
E562K
//genetics.nature.com/supplementary_info
carcinogenspresent
multi-gene
lymphoma-bearing
orkhead
Pet2V359A
anti-EED
58872559
-7.75
KRas-G12D
248J18
antigendependent
HΦΦNHSC326
.Expressed
5′-CCGCCTCCCGCGGTCCCCTCAG-3′
described.6
.PDGFRB
mechanisms.36,37
4088insA
U44378
5–12
B-Tax
LRRFIP1
samples.To
CellTiter-glo
hyperimmunoglobulinemia
signal-
Bernard4
sheet-loop-helix
defects8
ex2R
VP-Mel-36
Rgg
AA-A00N
peptidase-28
R1353H
streptavidin–biotin–peroxidase
.Remarkable
6JB
analyses138
D300H/K375A
329,000
Keap1-Cys151-independent
ecule
Neuveut
70–1447
4OU
C250T—corresponding
2,230
His-Asp
cBIC
K599M
cellsTable
59–70
COOH-truncated
mutation.57
.Hyperactive
catenins
C474T
gd-TCR
CstF1
Cohesin-Dependent
c.3972_3975del4
56–140
Q205L
intron-distal
SET3
native-gel
pseudopalisading
AAAACTACGAAAGCGGG
Sox2-Cre
bradykinin
N-Histofine
ATP-binding-pocket
brd1
R248T
RELAFUS2
pHH3
B‐cell
P418R
431–450
ligand/receptor-mediated
-AAGGCCATCACCACGCAGAACG-3
p.Q846fs
snap-cooled
nucleotide-bound
147.0299
food-rewarded
p3TPlux
glycine-325
S1E
dilution.Cell
R216Q
melanoma19
B01P
protocol,31
376KB
F467C
protein-δ
A_52_P15388
Lys15ff
63–75
-27
.Genet
1.42
D8H1X
H′
receptor-F
regulation40,41
MycS71E
Bultman
R2/RT8
guanylnucleotide
8/11
combinations+rituximab
RERG
−0.9691
39,48–51
6q21.27-30
93.5
oncogenesis.12–17
spectroscopy10
SPAG9/25
1x104
mismatch-directed
L72P
MLL4-containing
L817P
∼88
Immunol
HER2Tyr-877
anti-FANCC
FIP1L1-PDGFRA–expressing
PIP3/PI
Myc-SPOP-ΔBTB
LGTGAFGKVVEATAFGLGKEDAVLK-VAVKMLKSTAHADEKEALMSELKI
6114
oxaliplatin/gemcitabine
6,486
GHoma
0.0168
whole-cohort
EUROGOLD
LSAB-DAKO
WT-NHUC/NIH3T3
.Trials
.Tomita
BlPt
vp3
system.Fig
Chromosome–like
589-8511
10/28/02
noninteracting
One-Color
RNASE
Spruijt
miRNAs39
~~~~~~~~~~~~~~~
Map2c
6-G
MPL.16
S2c
JM-PM
rabaptin-5
−3
833–835
9367
0–143
method67
50×109/l
:3781–92
lowest-energy
Nos2
7-kb
182/257
PGNT
NOD.Cg-Prkdc
maturation95,96
Asp65Oδ1,2
VAMP3
43/118
MMR−
55–58
62,104
.stain
CGCCCGCGGC
spectrometry/SILAC
RP23-54G4
IHC.18
production.2
vismodegib-induced
RTK/MAPK
67,000–132,000
3.50
E7-skipping
Lys650Asn/Glu
BRAF-related
15/33
mice51,52
101–140
Forschergruppe
.BAG1
standardization
P417-B1-1011
S5I–J
TKIs—nilotinib
Chr9-977R
V494I
Huelsenbeck
upper-quartile
j.m
17.155
L239R
PSORT
unimi.it
PANC10.05
luciferase-conjugated
FGFR2-3xFlag
genotypeFull
807
six-glycine
MCL126,29
trypsinized
spliceoform
others.7
NCr
PER-403
β‐catenin–TCF
5.0
mycoplasma-tested
34–11
108–121
.29-31
rs12702462
activation26
MED12WT
RARS/-T.
frizzled-lipoprotein
GAATTCCTAGCCCAGTCTTTTTTCTCT
GCCCTTCCAAGAGCTGCAGA
streptavidin
NMT
cellsDiagnostic
Array-based
~1x
mutations18,19,20
DUSP18
c.1649T4C
-207
Aligner-MEM
described.28,30
POLD1-mutant
R19F
−1.03
PGC-1α,100
184.06
activation.23
F508
.Eight-week-old
2989
E274A
-HDAC3
cells.5
p-telomere
eleted
3-phosphate-dependent
Â¿Â¿gof
0.052
Peyer
374-residue
012480
peroxisomal
p-Y1197
DNA-preparation
7I
SCD1
Novagen/CN
Cys72−Asp74
llnl.gov
3′-PDGFRA
.Acute
as-LEU2TATA-HIS3
'pull
DNMT3A-DNMT3L
ApcD716
AF3285
3907
Fbw7α
p.T670A
KYO
Tet2-/-_SJL
FAO
12p-deleted
Growth-Inhibition
Esc4
WTc-Kit
Conclusion/future
ENU-accelerated
death-domain
thrombocytopenia
tastants
0–179
benzoate/castor
Immunosubtypes
R876R
.Antiandrogens
.Immunoblots
histo
.Randomisation
dinucleotides.19
S380/T382/
2405
Q6H
Phospho-p44
tel-jak2a-injected
homoduplexand
D11S904
stage,8,9,10,11
pBABE-infected
c.135T
Smad2DC
kcal/mol/Å2
leukapheresis
RNA-splicing–based
analyzedby
APH1
S-100B
V.1.4.1
wt/C324Y
c.50G
complexes.64
TCF-mediated
RhoA-T19N
5′-CACGATACCAAAGTTGTCATGGAT-3′
tyro-sine
C.W.C.
nearest-neighbors
p.Glu545Lys
thepLp53SP
K1062M
70-99
Califor­
4B–E
Wnt-β-Catenin
c.2155G
.M.HhaI
transformation-relevant
N252K
1761.0±878.7
Rag
RNF214
Call-Exner
flash-cooling
boxGiven
studies.27-29
anti-p85α
040
GTGACTTGTGTGAAACCAGGT
activity.12
SCC-12B.2
JP1520
farnesylated
pRetroSuper
1L
hamartomas
E1071V-mutated
housework
//www.hgmd.cf.ac.uk/ac/index.php
Tyr-1007/1008
mis-classification
histidine-rich
sequence–RNA1
W34A/K63A
cycteine
301a
chromatogram
clincanres
Kluk
added.34
monoubiquitinylate
normakmutunt
R317W
c.317C
set29
c-Srcmediated
PDGFR-neutralizing
ÃŸ-cateninresult
1A-13
CFA1a
A81V
59-GCTGTTCAACGGTAGCCTTA-39
PC12/MEN2B
31–85
EUFA143
lineage50
TCGA-DK-A6B6-01
.MNCs
PKC-theta
L98F
Aurora-C
TACS
STK11-mutant
FANCA-H1110P
Gln545
NIH-31
//www.kconfab.org
COSM22225
anti-6×His
hPMBL2
F475S
8.6/1.4
.RETS891A
gtactggaaa
MET/phosphorylated
activity.20
EGPF+
.FA-C
pGAD–mDia2
750–1250
17q21.1
BCR-ABL28,32
22–30
HEPES/NaOH
2731
Cytom~trie
70-fold
R132C
21,27
RP11-318C13
EWS/WT1-independent
18/77
q21.1q21.3
positron-emitting
v21
055
333:209
ng/mL.13
Fug-III/2
Luc-reg-17/20a
W2239Ffs*39
5′-CCCGGTACTCGTTGCTGTTCTTGTC-3′
pS10
vera.13
H639R
demethylases4–6
Hyper-Mutable
Carmell
98th
NCT01357655
HA-BAP1
l-α-phosphatidylcholine
PAX5-WT
resi-
AGCGC
p.A72S
ALKI1250T
NPM1WT
L445W
Molkentin89
dot-plots
FHL1-dependent
NCT01458067
10.3892/or.2011.1324
pflag5a
mesenchymally
Adeniran
Makita
Bubendorf
score40
64-1
G3a
codriver
'Janus
fullgene
Glu-94
BRC3
ofAPC.11,13-16
GGT-GaT
11-subunit
075259.2
mice.17
eFL
.Riggins
α-H3K4me1
21T
CACTTCACAAGTCGGAGGCT
100,000/μL
band-but
VH3-21
GFP-BRMS1
enriched-cells
.59G
Weiwer
596
.2G–L
V326L
TGF-p
aberrancies.18
FLPe-recombination
trials111
RAR-RXR
Burrows–Wheeler
A259Raf
Smad4/DPC4
569
Kervestin
1,105†
L468
timeof
MCC14/2
Neurofibrornatosis
GTC-GTT
MEK—is
MSKCC-IMPACT
L871P
syndromeCEL
pRb/E2F1
CEQ2000XL
Takimoto
NCT01109095
KGFR
c.607+1G
Toxin
virus–encoded
pluripotency-related
CCF
Arg-786
5′-CCCTATA
v-Abl-mediated
1Summary
EDTA,1
//www2.appliedbiosystems.com
130b
hMSH6/GTBP
11b
Phe340
barried
North-western
non-proof
fusion-proteins
RAD25/SSL2
HemaExplorer
2040
14/42
Ptpre
n=145
p=0.26
.Knockin
DO7
F525A
2449
.Rapamycin
full-body
carragenin
fgfr1huW671X
CD34+CD43+
age.1,3,4
4-μm-thick
Q34
require­
pcDNA-dup
inhibitors—AZD1480
R988C.Met-BaF3
pathogenesis.3–5
T1275I
rofibromas
andMax
plaza.snu.ac.kr
lower-upper
22–27
500–550
diacylglycerol
51-year
Y537S-TOT
HCT-116a
132-62
Ki-67/mib1
pCMV-Myc-ΔC
Na+
S8B
highly-recurrent
​and7.7
expression63
mobility-shift
phospholipase-Cgamma
E98A
3.88
ch15:52.4-52.6
.GTL-16
Sur2
2F|observed|-F|calculated|
Subconfluent
0-76
D302H
213182_x_at
characterized39
kinases.4
described35
41:3
SRC-mediated
16-mmol/l
/www.affymetrix.com/support/downloads/manuals/data_analysis_fundamentals_manual.pdf
KRIT1
230+120
Menl/l
.K508M
p107+/-
LB2518-
234.13
EH-mutated
PDGF-B/
I795T
106,962
polychromatophilic
p100−/−
S748F
demethylation7,8
SNP-array
Asn71Ser
S100A5
Kit.16
68.31
D544N
extrathymic
Ollier
12C6-arginine
Illmer
byelectroelution
regioncontaining
nonphysiological
p.Gly1055AlafsX4
PPARβ/δ
Quantikine
Twist2
HPI
C2-C2
stopgain
anti-ALK-specific
tumors112
–24.5
premetastatic
b2m-negative
9.9
PL11
2-3-4-5
158,000
AS16t
acids26
proliferation.AR
primer43
MGCL
BL21-based
phosphatase-dead
.1937
5'-TCT
re-growth
−6.4
nMol
finalisation
DICER/Let-7
Barleon
nulear
FH-DDB1
K13/15
DU528
7.46
ERFm1-7
pS-Hx-
P=0.075
melanoma5
GGGCCTTGCCGGCTGTC
antihypertensive
5Increased
5-ACTGTGCTACTCAAGCACCA-3
0.0779
TCGA-06-5408
EBC
218T
LPA-induced
T390
.PLX-4032
159,166
NM_007691
pmCherry-K-rasG12V
JC-HY
Smad2/Smad4
'CLINICAL
8.316
L-ornithine
TGF-β–SWI
Arg-505
Jak1-specific
MKK3/6
Msh6LQ/+
NOLA3
Jobian
13,63
4502
non-RAD51D
.Kindler
cyclin/CDK
fromNF1
4915
Dl-associated
2612
MY18
2.1–302
.GFRA1
kinase-2
.METex14
MDA-BM361
s00401
MYD88_85940_wt
leukemias8,9
μgofmTβR-II–108/+56
Cy2-
PRC1.90
aNotethattheCGHanalysirsevealsahighernumbeorf
monothioglycerol
nine-to-histidine
obstruction/intussusception.2
0.75–1.30
HLXB9,18
R563H
H84Y
fragmentcontains
recognition/degradation
Brip1/FancJ
iFISH
Cbl-70Z–coexpressing
Cre-dependent
LSC-1800
arejustified
IMH843-846
IDH2-4R
D3095E
Asn6
pVPd-hMLH1
19DelL/T790M
VEHIVYKALRSHILPPKHFTEDGNILQLANLPDLYKVFERC
1–2
cytoplasmic-nuclear
A375/
phospho-PKB/Akt
SHC
XP-A
3.0–4.5
5'-CACAGAGACTTGGCAGCCAG-3
368KB
GAAG
,21-23mastocytosis,24
Synthetic-lethal
nt1990G
.2490
α–γH2AX
BrdU-comets
Ala-containing
RB1gross
Pinzani
5.15
69.9
40−42
binding/activity
.SE
constitutively-activated
Treatment-sensitive
PTC-Containing
L330A
56811542
V2.1
anti–HLA-ABC-APC
p=0.16
pZNaq-Q209L-induced
,6,6
phosphorothioates
biotin-trimethylpsoralen.Full
antibodies4,7
TP53/p21
proliferation.38,39
endonucleFig
17N
respectively13
Rad1
P046-C1
c.115T
monophosphates
database.9
DLRSpread
1002G3
1,3,4,5-tetrakisphosphate
70:30
accession
R175L
total-ALK
ELVEKIFMASEILPPTLRYIYGCLQKSVQHKWPTNTTM
erythroid-enriched
hematopoiesis.25,26
Nuclear-negative
p=0.682
0.09097
TGF-β-regulated
EML4–
LRP1B
12q13–15
neuro-CFC
DO-1
p=0.0083
vestigial-like
235/398
48–52
glutamine-containing
.Contact
10412
052
6/8
R62W
GEF-binding
S119
IGHV4-34-negative
OCTGGCCG
Down-pointing
.Sedivy
WinCoot
D851
hadthe
Biosample
A603T
14-d
BTG-2
12,13,15,17
83-85
cells/10
noncrystallographic
17.3KIAA1644mRNA
primer-dependent
rare.8,9
LEF-1-speci®c
1831
RAS-GTP-dependent
1259Mel
pVP16Citron
oncogene-independent
60872–61170
GDI
-terminus
G21V
100R1881
p18-T165I
lines,23
0–1
/S-phase
3506
Parallel-transfected
–893
Kelch-HBM
5′-CCATCCTGGAGAAAGGAGGACGCCTCCCTCAGC-3′
n=79
A–F
SNP
c.2450_2451del
TKIs
Arf1
CP-751,871
hemireceptors
crystal-cell
ultracentrifuged
1998b
.7B7B
−2.0
Haploid-converted
GeneMapper
42756493treated
relapse-acquired
gel-filtered
gp9tk5
22.9
AATGGAGCCACGGATGTC
6,7,17-19
R177A
5-methylcytosine
trk20
Siltuximab
D217Y
.Predisposing
progenitors.20
35,36
L198V
390–
oncogene-based
typep53
13T
tophysically
MgCI2
Rad50L1240R
.Promotion
luminol/HRP-based
L618
Topotecan
.Platinum-based
platinum-based
_de
WZ4002-Resistant
arrowCGG
mAb46/15
tripotent
analysespresented
R-.G
c.2522G
TCF3/ID3
Ubiquitylation
Unité
toxicity157
R803
CUL3-KLHL20
533
21.17
.Fairly
p.Arg203His
10.5
35-bp
domain6
anti-BrdU-FLUOS
Asxl1−/−
brain39
G69R
510-base
mature-size
accordingly.2
c.2245G
Mini-gel
G719S+S768I
ZNF198-FGFR1ΔC-myc
CMV-His6-Ub
IGHV4-
disease104
123/nL
ony
E270
5'-CGC
11,100–104
sun-exposed
Akt1
dolicocephaly
sub-cortical
TAATAGGATCCAAGGGGTCTTGGCTGGCC-3
DFG-helix
E66fsinsG
NeuECTM
C03
synaptophysin-positive
1086420
829–856
thefragment
dode­
hemisphere/others
Weidong
molybdate-based
Wright–Giemsa-stained
MMTV-cyclin
crizotinib
MAT3-4G10/8
Gly446Glu
pre­
186–189
CY-A1
STATs9
Vill-Cre25
pGRR5-Luc
R965C
T526
lyS
Bodak
2010.54
SMAP1
S6277
www.repeatmasker.org
analysis,26
glioblastoma1–3
mÃ©tastases.Areas
Tyteca
50–62°C
protein.3
ETV5c/d
0.5-6.3
liations
TritonX
TEAD2
5/250
5¶-CTCTATCAGAATCCAGGGCTTCTGTGGTTA-3¶
Altlussheim
Met.Minor
treatment6
MEFsOvercoming
PON-P
/podVhl
lungcancer
proliferation.1,21
ICM
Sf-900
EWS-FLI1.60
5′CTGAAATATTTTCTAGGAATTGAGGGAGGAAAATGGGTAGTTAG‐3′
NCT00266136
culture154
0.2831
5′-CAGAACAACUCAACCACAA-3′
isopropylthioglycoside
tocytokine
UVR-associated
.5113G
Malkhosyan
ARCHERDX
C1106S
expressed44,50
DDR2-Driven
S26
Green-Dahlberg
603–612
TBS/0.5
.Immunolocalization
.Gray-shaded
sh-BRAF
Ashkenazi
2,432†
'punctate
D1595N
siFAT1s
Tle-1
MIAME
.FHL1–3
Silybin
chloride-induced
ATR-Xassociated
UV68
ACGCCGGCTTAAGTGTACACG
exhaust-induced
48,52
Ap2δ
Kronberg
shPAK2
Ile-36
S8A–C
presumablybrought
HNF3γ
.Biochemicals
ligation–based
4,299
one-ended
0.00016
bindinge
36-kDa
62.3
erg
nlm.nih.gov/genbank
p=0.0470
5times
rA*pVa
Magini
PTPRU
5'-GGC
PCSK6
wt11/2
ELK-dependent
p-KIT
5⇓A
R1441H
HighSeq
nontumour
Rad50S/S
LINE1
120-kb
Troppmair
mri
ICC23
ACCTGGATGTCCTGGGCT
subunit27
7.9–12.0
13q21–q33
Vκ3-directed
degradation,32
immunoperoxidase
described11
VEGF1/2
SEN28
5′-GGTCTCTGTGGACACACGACTTGAAC-3′
redox-susceptibility
.16Although
Try701
5´-TCCAGCCAGATTCGACCCCCGC-3´
p.Leu113Leu
mcgill.ca
Cleveland49
−0.932
Tet-On-p53
BRAC1-associated
PKA12
BCLAF
1.200–2.747
fmoles
introns.45
F270L
TGT-beta
PCGF
Mitomicyn
p.Arg263Leu
ROS1-directed
phaseLymphoid
single-base-change
NSCLC.To
43–48
A549/EGFP
EGFR/Stat3
1YFP
72C
GIST430/654
A549/FGF4
1.55
GCCACCGCCG
1–8
5739–5747
PBSand
5−6.6FXYD3FXYD
R987W
methods.9
R1234086-P
GNRPs
//doi.org/10.1371/journal.pone.0087113.t005
Δ235–260
mixed-effect
Wnt/Ca2+
Vhl-Hif
NETN300
370KB
EGFR-sensitizing
14/
GGATGCGAAGGCGCGGGACACCATG
comediator
T3/3L-V
subtypes8
K269
MGH-BA-1
MAP2K1K57N
.CML
.C72ins
model-specific
genders.31–33
.minority
HEC-1-A
kinase-based
transrepresses
817-2366-0221
STAT-60
differentiation.33
breast-tumor-derived
RB-BD
TpLN61R/61R
.HLA
S7.4
V190A
chemotherapy161
4Dd3
BCR-ABL1–dependent
alpha32P
analyses.6
or7
−3.275
12.93
re-identified
13377-9dupACC
26,39,40
lvolume
previously.23,24
CTFG
STAG1
61:249-255
MIN-colorectal
NM_010518
proteins.54,55
c.52_54ATG
4390771
seven-copy
1,775
R280H
c.5869_5872del4
proline-1665
HER-activating
__000457.3
.Edges
0.93–1.21
al.,12
PCR-RFLPs
title/abstract
kinase.16,18
CAACAAGATGAAGAGCACCAA
38/M
Marusyk
AA464590
23.04
site.83–85
6,464
exon-20-specific
60nonoverlapping
loxPPB-Cre
Rosette-Sep
Microsatellite
pEV
G1770
NaCI/15
lexatumumab
antigenson
–visceral-metastases
^\^-
S2138Y
Myc-binding
NSD
ms00003528
c.8954−1_8955delGTTinsAA
TR1
N6H
.HPSC
BRD4-NUT-stimulated
morphogenesis.19
I457T
1640/FCS-10
1AA
FC=3.31
TAp63
AQ-Gadd45
MLL-AF6
kinase,1-3
nephrotic
W1946R
A737S
0.65-fold
Prednisolone
1+f/M
Less-frequent
9-F
~146
opscc
L1971R
signatures.49C/EBPα
.Proliferating
Smad1
d.peeper
cis-located
D1226N
FL/tFL
G3906A
chr1:58872559–59608936
_In
8.4.5
11lAlaAla
p.L1301R
beta-
.Multistep
phosphatydilinositol
1.63.1
Val-2291
OperatingSoftware
exon_utils.py
190070
V971I
NS/AE
N=68
.132Additionally
gga3
BRCA1mut
mutation.13,14
DNA2.0
pcDNA3.1/His
pER4-5
cancer,39,40
SB203580ECC1
undermasculinized
ca.
MC1
1–596
T352M—displayed
p.Tyr341
process.30
HSP90/82
.Amplifying
E-07
ROS16
1529
​Intriguingly
RAG1/2
MDS.57
.Constantly
lobular
Ly6A/E-APC
E746_A750M
uroepithelial
3D-T1
multi-exon
1083
Chr2:29443697
R156H/R267Q
.Arg369
*See
p=0.010
cells/replicate
polyinosinic
v-Raf
Jacquemont5
39-RACE
meta-analyses
Darzacq
desmoplakin–GFP
855-857
statementThe
Tyr61LeufsX15
1390×108
JIM1
Naora
CDKN2B/CDKN2A
ERBB2-amplified
anti-CK19
3,36
Glu75
H4-12K5A/K12A
PG-B6p
published52,53
1852amino
54b-l
c.573-c.602
.DISCUSSIONBased
NP_571128
GM3
Minna.19
R131W+WT
anti-Thr308
D835Y-
17q21.33
PC-3/PTEN
metalloproteinase-13
HPV-16
26,840,997-61,436,881
Myc-DDK
CPSF6
Cochran-Armitage
comparelane
BRCA2/11
.Partial
drug.23–27,35
F876L-mutant
genes.33
setting.28,29,33
.Walsh
BIRC3
1976–80
5-amino-1-carboxypentyl
2308
GI50|
removal.Four
M326
NPG/D770_N771insNPG
Pylayeva-Gupta
Oakland/CA
K-Ras-based
advance.We
18.7–42.2
Arg-283
gpl4OPoto-hk
.HEK293
.Empty
IgM-monoclonal
Raillard
7169-1
FANCC/STAT1
60S
Xp11.22
EC2
C148Y
.STAT3
NT008338.2
MCYN
Fig.2H,2H
immunoprecipitationFIGURE
strain30
C673
paraphenylenediamine
p44Erk1/p42Erk2
ERV-immune
–2130
Trp-Glu-Ile
2G15
LYRKFTTESDVWSFGVVLWE
TheHIP1/PDGFβR
Q186K
Nic-ER
8-difluoro-4-methylum-belliferyl
Ste20-like
substrate-limited
CCDC6–ROS1
149/149
95*
GCTCACGCCCACGGATC
2866
3/1
P3-synthesizing
NCI-ATTC
NBG12-D
bisindolylmaleimide
preprogression
TCF/Elk-1
genotype−phenotype
pLRNL-WT-EGFR
Betney
146.6
ttacag/ATCACT
.CP70
cell-nonautonomous
125–1000
Trp-1
AML-M4
.Certainly
controlled-access
.HeLa-TK−
5910
adhesions5,7
Fip1
G4
Ostrobotnia
EOTs
BE2M17
Array-Based
dosing.18,47,48
0.202–0.678
H105X
nonconstitutional
R975S
sc-6347
P-C1
9.1±3.8
CI=0.85–1.14
GFPi-PTEN
tandem
AKT/Protein
q31–33
AAB60394
499a
planar
1BRAF
delGlu746_Ala750-Thr790Met
PA-containing
113-8549
KIAA1676
p.L823X
serum/2
NH2A
Yl3
0.2811
recognition100
numbers,50
216894_x_at
c.5332+1G
8.0/200
MET-Y1230
thecontrol
PGK-promoter
Shawver
full-sized
interaction14
MYND-type
10–20/million
.692C
c.736G4T
TGF-binduced
CD4+CD8lowCD69+
V29
myeloerythroid
HER2-D808N
L276P
12.571
TSC2-positive
mRNA3
stem-loop
.Grant
Histogreen
substitutionfound
f36
lineages.16
5762ins137nt
treatment.11,13
PDHB
Tacara
R24W
22−47
.XP
7q32-q33
short‐lived
61-11pd
05-361
.11,28,29
266I24
PRF
Zn2
subgroup.9
ß-catenin/LEF-1complex
PTPRO
hypothe
IDH1mut
qm
SMAD–TGF‐β
luLouTyr
granulocytosis
T197/202
milestone.33
p.Arg54X
EBNA3A
WPSS.16
wt‑ERF
substitu
median=9
C4A
W6A
−173
asphyxiation/exsanguination
joining-region
Hox-associated
agepaired
prognosis104
m/57
KmDNAof
retinoblastoma-predisposition
MSIâ€
129SvEvTac
181171
FOL1
GA→AT
differentia-tion
TCGATAGTGA
−59
noncleaved
gland-like
M3.28
Ableson
TGFα/EGFR
Gelcount
orthochromatic
hard-filtering
carboxyfluorescein
.External
kinase/μl
R286C
hyper-methylation
Kokura
NP‐40
.Inactivated
sh-Co
TTF2
.Whitsett
IFN-γ44
c-tubulin
clonal-ordering
.Pattern
cancer-causative
symbolSequence
E746-S752insV
3000-075
NS460
4,18,19
with125I-TGF-β
Graux
J059
fgf8
60T
UV-associated
CTmean
D-003886-01
X-Rays
Fig.5D,5D
SW48-CR
Hoescht
593.8–773.0
citrate
77*
21,23,24
715C
Leiomyoblastoma
nihms774093f5.jpg
associ
Senescence-associated
domain.35
BRD4-NUT-expressing
IWCLL
p21CIP
9.00×1010
Petrucelli
compartment14
IκBα-luciferase
Yaari
loop36
anintronic
176670
Nf1+/+
0.8110
W731L
GRAP
GST-Q63L
Glu214
Ba/F3-hKIT–Y568-Y570FF-D816V
activation.6−8
R378
pUAST-DERKE335K
C1144A
Histoclinical
haemocytometer
pro-tumourigenic
YFP-EGFR-ICD
c.1403delA
p=8.8e-7
Hospital/
ArrayScan
.Chlorpromazine
0.48521
chemonaÿve
adducin-α
Ras17
acontrol
–mutant
Tomoda
Guidez
ERM/ETV5and
+/KI
bIHCA
anxiety-like
malignancies.1–4
14-week
Rie
P=0.386
1373
ADME
A328P6
evaluation.40
signalosome
Tumoural
.Kinetic
EBP50-merlin
BIM+NOXA
p.R60Q
S4Q
NS.10
A–C
cases.5,6
⩽60
659-AC
documented1
419
Saline-sodium
4/232
5/8
c.2007−1G
GTTGTGCAGC-3
c-abl-deficient
3..
siRNA2
=60Â°
51b
RNAsin
W5c
NTRK1tyrosine
200V
5′-AGAGTGTTCCCTGTCTATAATCCAGCC-3′
activation/expression
BiBr61
3/188
kinase–3
M1229L
NightOwl
ZNF1
microcarcinomas
aPKC-ι/λ
erbB
CAGCCTGACGTCACCCATCC
CD43−
melanoma25
pathway177
non-FLT3-dependent
TRIAD3
HNPCC.1
miniprep
G114S
ALL.111
458KB
52±8.3
KG-501
pCDNA3-hSkp1
W679C
.Distinctive
GAGAATGGCTTACTTGGATTAAA
hydrolysis.36
RHOA-ROCK-PTEN
PDGFRA-resistant
67.2
Pref-1
S6K-T389
Leu110
DSS1
Fbxw7-
H1e
Y34C
I-specific
S94
979
ΔEGFR−
pan-ErbB
6c
R-282
M13-flanked
fourheptads
ATCC.org
Ptdlns
Wölfel
Neomycin-resistant
.Invasion/migration
linear-regression
.MAPK1
+17
2105
therapy71
104:161a
A2023T
4390843
common-mediator
FOXA1-negative
CT45A2
SUDHL5
temperature-dependent
activation.35
MKRN1
Project86
23.97
Ni2+-agarose
ARHGEF2
Hh-responsive
event.12
ZBTB16/PLZF
site–directed
KGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEI
PAPOLB
intronsof
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F1.medium.gif
2min
GGGTCTGGGGCAGC
GSE20393
lymphoma-free
N1/2
2.0.8b
BCCRC
.RHG-banded
129S6-Krasex3op
Short-Hairpin
18-64
larynx.7-9
N580SB-RAF
treatment.1
1A,10
37360980
5′-TTGACGGCCACTTTCATCGT-3′
R612C
0.26*
Leu854
genome5
WI-10259
deletion-harboring
74.6
alterations,8
L194F
17.2–23.3
tumorigenesis170
Greek-Caucasian
Cμ
.Chicken
VSV.G
10.1007/s12032-011-0074-y
AnalysisSingle-
.Continued
CIC-exon
TRAF3
Leu1196
Antiphosphotyrosine
WM3912
CH2
transmembranous
S338AC-RAF
utilise
laboratory-generated
Schering-Plough
RHO-GEF
L910P
RB-dependent
Tomkinson
loci*D3SI262/MS/265D3SI1D3S126ID6S262Nine
17.1,14,19
77:1
INICD2.forward
driver-dependent
tortuous
UX14
HEK293-I3A
R858L
5′-CTTTTCAGTTTCGCCGTGAG-3′
–based
NCT0112645030
T511K
371K
800208
effectorloop
factor'.36
theADD
previously.39–41
TDM1
Askham
αC-β4
gemfibrozid
S7H
0.5403
Deglycosilation
seven-step
∼4,000
co-crystallography
AKT-PI3K
AML25
commerical
ΔC2
.._._
.FNIII
anti-CRAF
behavior.40
promoter–reporter
UGT2B17
354–362
SHPC/S
described.29
0.90-1.53
groundbreaking
ERα+p63+
R315W
Africa8
FGFR3-null
S162F
59ACCTCCATGATGCTGCTT
trypsinated
Adult-onset
S561R
1–1650
FLA
G58R
.Four
measurements.25
NAUMOVSKI
615
mTOR-dependent5
allele-derived
173-403
53BP1-null
Microsomy
improtin-beta
2138
TRPM6
NP_006209.2
pharmacologicals
.Xrcc2+/+
Triphosphate
BCL2-like
Yap-4A/S366A
ERG-immunizing
SWISS-PDBVIEWER
Cys-179
Autofocus
neoplasms.16
≥100x
488-phalloidin
Cyst
iii–vi
MMTV–Cre
B2-B3
26.R342Q
CGAGGCCCAAGGCACGATCCAG
Ecodry
C182/229/277S
Foundation-7
A2-CDK2
1293-1559
Yokohama
Transgenosis
B43
candidate.37
RAS–BRAF–MEK–ERK
q+pg
T305
pHAGE-EF1α-IRES
27months
Amaxa™
ETV6-NTRK
S6K
99-mer-containing
TLX1-rearranged
Leu1407Pro
Val/Ala
pAD–BRCA1-transformed
Mizutani
533.9
259-385
1.9–2.9
4.5.0b6
D137V
V181M
D845A
8-oxG
ASXL1-MT–transduced
Ohren
.Aberrant
MAGT1
197.1
TP+TN
hyper-immunoglobulin
CIEMAT/Fundacio´n
XG2
residue33
Fluoromax-3
C1156Y
helix-α4
ArgTfrpGuGIuGIuGIyLeuGIyGIyVaIPruGIuGInLysLeGnI
.RANBP2
flutamide-resistant
loxP-SSP
G60R
MCNsThe
Universidade
ALK2-dorsomorphin
Dde
*SIFT
p473
myeloproliferation
luteinization.20,22
Lentiviral-transduced
10.933535
factor‐like
.Non-silent
MYC/BCL6
~1766
expression-associated
.Nitrogen
PCAFbinding
.Karsenty
.LSAs
.c.1698+1G
ex12-31
Lapidot
phospho-MEK1/total
Hypercellular
i.v
M13mpl8H-ras
−675/−647
sub-G1
Brn-3b
vitro–induced
non-extended
Ibuprofen
.Polysomy
.K-RasV14I
35-67X
pLZR-BJ
4pmol
0.087
.Assessment
.ETV6-FLT3
219.2
miniSOX9
R1306W
Mutalyzer50
delZ
.Templates
Phospho-S6
.CLL
4A-FZR1
NaCl/1.5mM
2.213941267
intervention73
p.c
JAK1-targeting
ϵ280
Lys147
model-based
Kranen
SRP033266
p.L69R
pTyr568
EPO-R
.Potent
1–366
PIK3R1L370fs-induced
Drosophila,99
intraperitonal
RP11–816J6
pMSCVneo37
Arg-1625
PF811
pcDNA3-HA2-KEAP1
4*,10q
histiocytoid-to-myoid
Dulbecco
1μl
Ets/Elk
pLXIN-TSC1
2522
GRLF1
Non-hotspot
KIAA0186
anti-c-Abl
PCRassay
SGK-phosphorylation
myeloid-associated
SHP2/GAB1
tumors.58,59
Y.C.
FLT3-WT/CBLDexon8+9
1997.8
Blanquet
.Fas-suppressing
CMV-β-Gal
.Kinase-dependent
Kruskal–
N756D
ERBB2-positivity
ligand-ALK
3T33T33T33T3ODN3T3RCM*ODN3T3ODNODNODNODN3T33T3ODNODNODN3T33T3ODNODNODNODNODNODNODN3T3ODN3T3ODN
III/Eco
derehydrated
1450–28
Autokinase
31/48
bbm.1
3′-XhoI
ligand/RTK-driven
Hypothalamus
Buer
RET/PTC6
ZF1
3/loop
non-denaturing
I256V
L160F
CT10
pcDNA-DEST47
2–negative
FANCD2/FANCI
Elancourt
PIWIL4
20815
c.722C4T
LB373-MEL
αBRCA2F9
anterior/transition
non-RECIST
mitsudom
P327fs
S'-ATCATGCGTTCTCCTCAGATG-i
anti-S100
lowandrogen
phosphotyrosine-peptide
GFP-Elf3ΔC363
CS-causative
leukemia.2,3
PXDLS
240,712
NH2-terminally
Erneux
Tritium
426-bp
AR-p160
myr-T312Ag
.Al-Kawaaz
DM1400B
LM-65
GSE38961
0.95
Op8~
Insulin-Transferrin-Selenium
selenomethionine-labeled
ZMSH6DNA
chr8:40010617-40185770
pathoetiology
Miyazawa
doxorubicin-mediated
.Tabela
F3881
pEGFP-N1-IDH2
Dox-treated
Vav-cre+Tet2f/f
R1004
depth3
apoptosis.43
1991–2061
coomassie-stained
progression.View
DanaFarber
I49T
MN16
5′-CTGGCACAAAAGGGACGAG-3′
factor/lymphoid
Ab23738
mcmail.cis.mcmaster.ca
P914
family/personal
robotized
37.04
RSPO3
Hras1
S-S
RNA-STAT
3.0–4.4
OvCs
FcγRII/IIIhi
2-kbp
RAD50-deficient
forêt
59/male
Msh6PR/-
0.3493
ischemin
294–552
Cancer17
underestimate
Emoto
cyclosome
gene–gene
transfectant-derived
.Clinically
sequencespecificrecognition
hormone-
FLAG-Elf3ΔN233
FGF-concentration
p.Leu117
Newton-Cheh
withCRC
96-substitution
PHASER23

RNAFig
language.ResultsWe
Val+
74L18
primer–based
.Dorsomorphin
anti-CD24
D153V
Δ559
p11053-55
ADOC
tetrasialotransferrin
EIAFno.3
Cholangiosarcoma
92/117
GSE23967
M297I
rat.26
ATG-CTG
Celltracker-labelled
MPNSTs,13
Cdkn2A
xenografts
α-CrkL-PY
mouse.38
HMeso01A
PDGFA
Sos26
NM_020732.3
Azacitidine
promoters.45
CDK6-knockdown
probes18,19
†McNemar
10–19
Kaklamani
Lynch-like
IDH-targeted
UT-7/SCF
intrachromsomal
myopericytic
NCI-CTC
LUT
hepatocarcinogenesis
hgfap
GFP-FancD2
PR-B2-
hPMBL
159,260
transformation.22
Fabpl-Cre
Dnmt1
p.Ser2213X
Gilhuis
phospho-peptide
Tilborg
protein-like-2
GATA3-extension
H2291
uti­
E261K
dupN771
SOX17-transfected
62-65
IVS21
SJHGG004
protein.11,23
2o
ERK2T185/Y187
3p13
14*
stimu­
Consang.
2C–E
25/25
-0.36
229KB
non-chondroid
hyperplasia90
biotin-dUTP
|log
andmsh2-VD862p–Msh6p
geFigure
monomethyltransferase
Slany
ARG1
FGF-8
variables43
Fragoso
anti-TNRC6A
Proteomic
nonbiotinylated
TPO
mitogenesis
SCG10
data28
fusion-positive
D560Y
Privalsky
15,27
0-2
NSC23766
1,131
Micro-FastTrack
EWS-FLI-1-mediated
106X
.MM-111
cytokine/growth
AITL2
f1MR3
Smad3-mediated
11m
AID/APOBEC-mediated
Hematologic/Biochemical
1765
70-3
mitosis.24
radicals,14,15
3a
cdc
XbaIHindIII
loop.2
420–720
pSM7C
7-F2
52·4
Cul3-interacting
p.W152G
NotI-linearized
0006-291X/
M21
413R→stop
7DH
4T‐1
pC012
SacIfragment
2L14
26.0
ofAPC
PDGFR-β-null
D399N
.Poly-ubiquitinated
Asp287-Met365
retrovirally
AT-treated
PDGFRB-positive
Repression/activation
0429
probe7
Ex16
testg
7NPo
p.N568_splice
Consticancers
phosphorylation16
650-bp
209K
TTTTGATGTAGATGTTTTATTAGGGTT
co-opting
RB7-RT-MGB
1·9
non-conservative
1,039–1,060
Inborn
mour
Olbrich
p.V423Hfs
EHV
10,590
Be13
.Influence
ttcaaagcaaggttgtgca
Tyr234
MA9-1
Wnt/b-catenin
~1.4-Mb
TXNDC5
2304
EKBB
.FIG.5
AHRR
non-phophorylated
Casq2
laptinib
low-intensity
Chk2-mediated
≥pT3
T3N2M0
Jochimsen
FPP2
132.4
Wente
59TCATACACAACTTTCAGCAGC39
well-expressed
.Evan
.Destabilization
post-planting
Komeno13
tumors1
KKKKRK
retroviral-cre
diamino-2-phenolidol
lumbar/sacral
data.Western
74X
CellCycle
2GS7.pdb
16containing
3I–K
234–342
digoxigenin-
TGF-β–neutralizing
NCT00137111
mid-gray
0.070
RAS-AKT
survival103
cancer.27,28
pCDNA/β-cateninS37Y
34-1
AR-controlled
SHP2-Q510E
G243D
rearrangements—a
v3.4.2
FAM131B–
Brg-1
1/family
λhp300-9
20050181
LAU50
G890V
D303N
24
FLT3-WT–
.38,39
katou-ki
Arg718
5′Phos-GTC
PAX58
previously.27
A3507
41A202
801-1,200
S271T
ST88
1/113
CBF1-Su
9-day-old
responseSample
c-myc-transfected
pALK-TKD
ASCOM-specific
ormurine
Ruzinova
R229Q+WT
Oddoux
mutation/haplotype
nMNaC1
H974
GlyGly136–137GluGlu
P13-K/AKT
Alpha-C
Lammie
phospho-Akt
D.G.G.
observed2,3
Crebbp
E180
371Y
Spandidos
A110V
adaptator
MDS/CMML
K42A-expressing
+19.41
INCACance´ropole
GST–cyclin
97–250
GGCATGGACTGTGGTCATGAG
R879C
.Often
T‐REx
Rb3
.346
KDELR2-ROS1
/15
panERK
propeller-shaped
ZNF261
p.A77T
SUPM2R
paradox-blocker
negative.MethodsBreast
Apc/Smad4-
46.6
dideoxynucleotide
3.2
Ile788
PLX-4032
1´
Ad-MKP
β-mercaptoethylamine
B6.Cg-Tg
pmTOR
.DMEM
represenation
Copy-Number
E79Q
jackknife
0.4-480
post-addition
reportscould
Rad50-mutant
9.72-13.27
8599
****S
High-density
Asn771insSerValAsp
binding/catalytic
D557H
D61G
synthesised
analysis.No
IDH1wild-type
hBAP-1
VECTASTAIN
.Mutagenic
IP1
cells.Northern
272SRYP
Y77H
3991335
types28
TAD9/high-dose
.Eighty-three
5′-exons
4,280
TF-1a
MYCN
TCL1
inhibitor–naïve
GSE15237
.447
2.8159229
.Associated
c.1336–1338
Interexaminer
KIAA1671
CAGG
2LQH
10-mM
Indirect-readout
.NatL
≥59
387KB
VNTR/microsatellites
ALK/ROS
1—figure
1p22.1
t~
STRN-ALK.Fig
median=14.5
R378A
METS/PE2
58–66
75-bp/75-bp
89,106,107,108
Akbani
Polymerized
CycC-CDK8/19
136-700
Euphorbiae
disorder-hypereosinophilic
MEK1-ERK2
Epifluorescent
n=150
tumor-driving
multidrug-resistance
Deacetylase
63–246
S2514P
popupDownload
34.84
0.2035635
CO2-regulated
pCEG
D40
Macias-Silva
Ala30
102–104
_004
.L597Q
K650/652E
utrophin-A
.HpaII
breakpoint-specific
Incidental
Ile35
1619
57–70
competitorin
treatment-free
e9.5
83/419
Tu27
H650Q
profiling-based
p.1436
titrated
Bézieau1,3
malignancies.27,28
ΔC-myc
FLJ12684−7.7COL8A1aCollagen
HOXD8
mCRC.6,7,9–11
6-weeks
anti-full-length
ERBB-phosphorylated
Drm
polymorphisms.37
MLL-positive
.V560D
None1
Gly165
antiserum26and
30-32°C
.SOCS1
3788–3790del
DPP-8400574
C4-2B
TACC3ex12-RV
pCN-HA
hemangioendothelioma
Q64
ESP-EUR
IVS3+5G→C
NCT01556568
VNLLGACTHGGPVLVI
Purine
Biopharma
exposure10
care—surgical
LMPI
Phe413
H4R3me2s
.Scale
AML.75
univacuolated
D179H
GTTAAATflTTAAAA-3
PA19
invasion8,9,10,11
18.1–61.5
ahemocytometer
GTC
luciferase-negative
lucif‑
β-Catenin
E-TABM-38
causally-related
5'-CFGGACAGCACCAAGCCCGCC-3
Inc.Publication
Suplem
1707
nMUninfected
1.15–4.32
PC‐61
Tet-catalyzed
.Polymerase
3,369
forkhead-box-containing
Glu-63-*Lys
abnormalities1
cyto-protective
AI081358
I174
Arg1699
1580-bp
mg/μL
59-CCTCCAACCTAATAGTGTAT-39/59-TCTGGCTAGACCAAAATCAC-39
binding.58
WM3681
.Dead
T-DM1
rbm10-mediated
PPARγ-driven
MPNs.3
BsmBI
reticulata
oco
binds38
apoptosis3
post-crizotinib
.Choi
MSCV-MLL–AF9-IRES-GFP
Y245C
IRES-RFP
8e
pJM17
KRT6A
CRC-affected
g-3
.Gto
hetero-oligomers.14-20
mutations7
glioma-grade-specific
Anti-CITED2
C-direction
Trizol
S3R
139K
FugeneHD
3003–3022
Wilcoxon–Mann–Whitney
enhanceDNA
C775
LDE
C459C
1.21-5.48
KIAA0196
DGR-deleted
studies:13,14
1067.00
determination3,4,5,6,7,8,9,10
1000-2000
Ile-116
tertile
.Superimposition
mutations58
right-handed
Ser372Cys
downside
chondrosarcoma,6
all-comer
FGFR/A391E
identified,19
Hotta
F1514C
1183G
six-His
p60vsrc
allele39
Raza-Egilmez
313-base
n≥20
167K
S259D
c.214G4T/p.A72S
Adenomyoepitheliomas
.FGF8
78.82
8,420
affectdemonstrated
M4=23
pathway.48
T-10
Grb7/10
tumors.11
26.9
Grozdanov
−680
algorithms5
.TSC1/TSC2
gefitinibt
C1–C4
17/67
Torchia
5′-TGGCGAGGAGAGCGCTGTTTCCCTCGGCGC-3′
perifollicular
p.V600
0.89–1.78
Δ417
Smad4-mediated
Y205
variants.4–11
.Non-mouse
detail.12
SNPs.12
k12
assaysTransient
accelerated-phase
unfragmented
interleukin-3
57.4–83
−19.2
cells11,40,41
extra-endometrial
39-kinase
lacIq
.S1a
GTF3C1
×63
0.754
100-3770
FC=0.49
Shwachman-Diamond
domains26
possiblecomplications
uracil
CS26
IDH2R140W
pathway78
A068
2.5–40
−q
roadblocks
.TheY-axis
up-
RUNX1T1-rearranged
fusion-driven
.Adenoviruses
Lys721
P1287
Sgcg
RHOA-6S
respectively6
.DLCL
target/pathway
novel7,8,9,10,20
imagingsystem.RESULTSIsolation
TAP1-promoter
1569G
.CoIP
.Gautschi
13/20
EP300-ZNF384
acids.13,15
pBabe-R841K
​Tables
phospho-mimic
pcSrc527
129S2/Sv
p19INK4d
GSK3β—and
Exponentially
Multi-species
armS10
GST-hBAP1-
base-pairs
NCI-H747
anti–glutathione
AKAP13
.AFFINITY
set18
www.pymol.org
K577M
RB17-RT-MGB
ubiquitylation.15
Ambit-based
target.28
3G8
IGF-1
5′-CGGAATTCCAGGACAGAAAGATC-3′
0.116
P5T
pyrene-induced
P210L
−14
36.1/16.2
AccI-SmaI
WDR48-PDGFRB
glucuronosyltransferases
JAKV617F
chondrocytes172
.235
K+M–G–
23/29
6/1000
epiphyseal
crossmark
P-associated
LFS1
chuv.hospvd.ch
Senn
RP11-815K24
SNuPE1706R
5′-CATGTGGGCCATGAGGTCCACCAC-3′
EC20
GISTs46
h53BP1
Ras–Raf1–MEK–ERK
RVSLT
T-K
preReceived
H23
NM_007969
R910
Asn3Ser
GENOTYPER
​Figure3B,3B
UDP-N-acetylglucosamine
CMV-
Rluc
non-morphological
10120
orthotopicly
factor-receptor
PI/RNase/PBS
PhosphoSafe
P580S
Cohu
gliomas.8
Laner-Plamberger
SBR
DSU
Tyr1007
Tsc2–
-CCTTTGCCTATGTGCAACCT-3
cdk3
micro-aerophilic
COX-2
8237
Foxo3a
kanMX
takeda.co.jp
LipofectAmine
Portal64,65
three–base
ΔEGFR-signaling
K929E
Y245
149.4
U87MG-derived
Y574
RASGAP-containing
signaling17–22
.Yeasts
//genome.ucsc.edu/ENCODE/antibodies.html
mismatch-bound
Trp53loxP
G24R
A.T.C.C
.Coat
G2733
antennapedia-tagged
Akt1KD
endorgan
Tyr790Met
TUNEL-stained
Phospho-Erk
ablate
1:5,800
BRCA1-gene
SMZLs
pEGFPC1-DLC1
melanoma11
.Grey
R24C/R24C
NFkB2
C1199
FIP1L1-PDGFR-a
PAX5-
A034
CCCCAGAAAGAGACATC
24–25
formation102
doi:10.1038/ng.780
Src-1
anti-H3K4me1
2,310
Nutrient
disease-progressive
S323Y
AP-1-like
1aGl
TGW
pelitinib
13872
MEN2-related
Arg80Pro83
triphosphate–
chemotherapies
.Ribosomal
RCT-E302
NTS-DMV
GDC-
Smad3-Ski
10E2
5'-CTCTCGCTGCCACTTCAA-3
care.1
5′-CGTAACGTGGCTTCTTCTGC-3′
Protein-DNA
anti-IL
RT–quantitative
.TPβ
83.8
.PolyPhen
GAG-POL
previously.19
ECTMWT
1−7.1C1ORF116Specifically
Spl
Golgi-localization
rPLD1
HSR-amplification
anti-Lkb1
Sex/Age
V2728I
29-72
W=width
BWS
.Fumie
Hinc2
_2174+
CRM1-dependent
KNS-62
M35R
Databank
PCR-single-strand
embryonic/peri-natal
specificityof
.Tier
G249C/D
Parrinello-Rahman
Main•
therapy.10–13
Pten+/+
.DSRCT
16-cycle
V600EBRAF.5
medulloblastoma10–12
.Opens
CA-SSR1
theconfocal
I-II
NETGLITPNKHGLLQNPYRIPPLFPIKSFVKTKCKKNLLEENFEEHSMSPEREMGNENIP
desmosomal
17q21-22
study.16
15-04-12
inactivate
CapZ-interacting
.Lowercase
SWISSPROT
inhibition109
Asxl11fl/fl
trans-
-GBD
1465-1466insC
63/1.4
7-month-old
SEPT5-MLL
CS-06
23/530
HIF1α110
A276
serine-to-alanine
17.57
importin-mediated
F297
.Quigley
venolobar
interferon/initiation
substitutionsmade
transcription-3
4035T
detectionenhancementacrylamidegel
23–48
flox
GI:14192680
rs3218408
0550
13,17,18
α2B
described.21
Width2
Larcher
pathways—IKK-NFκB
Desmin
AG1673
L399
120-kilodalton
DD-containing
nihms646437t3.jpg
1,345
transcript-profiling
immunohistologic
helix–loop–helix
Sox9+
function18
Prmcre
non-immune
dodecylsulfate–polyacrylamide
line—identified
Hirschspnmg
AG′-G
ZNF198-FGFR1-
CSF2
〈〉
1275+221/226
Hu-α-H1047R1/Hu-α-H1047R2
ERE-Containing
CL-8
Xq11-q13
D–Cdk4/Drosophila/Rb
Germ-Line
GAPSII-coated
—CH—
metastasis,17
PQCXIH
Glu659-_AC
SRNS30
BxB
2028
func­
inter-allelic
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTTG
Reenan
0.063
Packhard
exon-switch
postreplication
molecule6
CEP85L-ROS1
prostate1
adhesion.1,2
R810
AR16
0147
CD4-phycoerythrin
BIKZF1-normal^
macro-pinocytosis
Figure4A
phosphosignaling
G155del
reflectionb
W.A.Weiss
phospho-PDGFRB
Kettering
A214T
.264
Akt-transfected
NM_005491
non-UV-exposed
c.1727
C20R–F39L
N216H
PDGFRB-1
G395A
P2515Rfs*4
pRetroX-Tight–Pur
Aα-R258H
demethylase-inhibitors54
BRCA1-negative
Ile21
S615Q
4.0.81
carboxyl‐terminal
p.V191I
Bozzi
H4Ac
Inter-relationships
−0.912
I.This
8655
Tyr1173
PRSS16
S836
T288-phosphorylated
SOCS6
TGF-ÃŸSignaling
55°C
40G
gi44985261
FLI-1/exon7
transeription-polymerase
Simplicifolia
conformation30
GM-CSP
rolipram19
immune-susceptible
GAPDH-fwd
MSI-H
3sSS
UVC-induced
NrasQ61K
.Graph
Asp570
evidence-based
.ABD
Jonasson2,3
R125Q
T198
Sox17-induced
phred-scaled
kind:9
Ambulatorio
5′-TAGAAGAGCCCAGCCAGTGT-3′
.Non-small-cell
P=0.00028
studies29
achaete-scute
D10S197
Sugden
R164C
superimposition
chromosome-probes
1,536/3,383
therapies37
9-
mosomes
518del718
WIP-SQ1
p53-BAX
HS275
Rheb-GEF
1.06–1.21
Immunotherapy
GBM47
H492R
//http
.//lotka.standford
1.52/2046
PDX127
145-kD
PALS1-associated
showeda
nonradiocative
HER2L869R-expressing
SPECC1L
sensitivity53
5.9-20.4
0-1.20E+04Recurrence
R330X
D325A
death11,14
ad-based
11,13,14
D1-associated
study28
autoradiographic
vector-subtracted
EGR2-E356K
5⁎
thermosensitive
3,5,6,8
ins.inv
NRM
BIKZF1^
metal-induced
AKT1L52R
.Mono-ubiquitination
dacarbazine
DAMD
isunderlined
Leu275
10•6
γ-hydroxybutyrate
CTTA
wg-IR
RP11-1047J23
2UA
/lookup/volpage/12/119
87.5
0.2–0.75
primers3
al.31
Ser222Asp
TERT/5q31
I322M
NAV3-LOC100507498-SYT1-PAWR
ior
association106
V231M
KIF20B
206-241
tide/
LC1-8
self-injurious
DTASelect
K806E
Factor-1
Fluorescence-activated
.Vigilance
Lentiviruses
sub-network
M2009
Sox17-knocking
relapse.PowerPoint
whichrecognizes
MIC2
STAT5Bmutant
T26
elements.3,4
Boisvert-Adamo
Nu18/SP2
RAD54
PRDM1.5BR.F1
demonstrated,23
ARR3-Luc
Cohen20
Whetherthe
V38
154.0–154.1
HYG
displayedpartial
rtTA3
R26RMCE
S334
​andD
9v1
CytotoxicityWe
four-jointed
~10-15
dual-specific
W64R
UV41-derived
10^6
Mutations*
181a
anti-FOXL2
1278/1282/1283
.PR
TFIIB-binding
MANAGEMENTKIT
PAX3-FOXO4/
//imagej.nih.gov/ij
.Proceeding
28/45.9
CIP/KIP
p.Phe559X
L858R,9
phenotype,5,49
Candidus
potencies9
genotype-directed
Pharmacokinetic
.Rainey
t-3′
baculovi
ERKE322K
13358-60
gamma32-P
LXTPX.22,36,37
transcription39
60-95
5′-ATAGGATGGCCAGCAGAGCCC-3′
1891-1
G2
XPLN-stimulated
U/100
.pSG5
5′-agtcgagttccaaccttcg-3′
per-base
c.1648A4C
TCGGGAGTGGATCTCCGTGA
LB-Agar-Amp
restriction-based
Novelc.4007A
oncoprotein-based
LxxQDxDLG
Auto`noma
c.300T
CATTGCCATCGTGTGCTTGT
MMRdefect
8.69
Syndecan-4
Lys-29-linked
r1
165/169
C3
StataCorp
109:61–64.Score
1040-0605/07
1.21E06
metric33
mTOR38.As
Stoichiometry
233,500
.2054A
andCUO14
Schremmer-Danninger
pivot
WM3702
90,111,90°
F3T3\
PRDM1,45
3.0σ
4200-177
Gly22Cys
8qâ€
8–1100
Fig1I1I
GST–D1-
Tyr537Asp
syndrome.108
.Notes
0.004a
COOH-termini
S459L
KGSSSNEPSSDSLSSPTLIAL
N172S
specifi-cally
siRNA/atelocollagen
1:1.8
E6201-insensitive
0.33-0.80
Ad-EGFP
​Fig.4A,4A
R109X-overexpressing
theseanalyses
kluwe
148–310
tumor/control
MLH1-PRO2R
phospho-CHK1
PB-Map3k2
Favier
c.673–2A
Buschmann
N1309
NEEO
GTG→TGA
Brodeur
P-ELK1S383
12.8–46.8
4❚
Ring3/Brd2
PRKCBprom
Perturbations
R335W
.Chromatin
Alox15b
81-22-717-8548
relapse.2,3
Hscore
di‑
1.287
dTTP
1~~~~~~~~~~0
RP5-850G1
pcDNA3-NA
Akt-K179M
KITV559D/D820Y
AMLRTR1
200µl
ALK/IGF1R
µl/ml
Arid1a-null
*Truncating
chromothripsis13
S3S5S4S16N2S11
-0.44
beta1
ACTH-induced
p.N657KfsX6
p-tyrosine
H2AK119Ub
percentile
Mgat1
.InTFG
PIK3R1N324
Ret9-K666N
PIK3CA-NHUC
x.
PK7088-induced
418/21
CCCH
cafestol
phosphoinositide-binding
noted27
moesinT558
MDS_253
M1-skewed
37.16
G232R
Unquestionably
pADH1-p73beta
C290R
malignancies46,47
.Rearranged
individualization
Q61.2P
mAb-induced
V211D
pCMV-SPORT6-Etv5
mineralocorticoids
c.2490-
C337W
pFOXO1
RNR-1
ABCFS
AF251308
∼190
1I–K
J
1.79
Co84N
≤0.6
5′-GGACAGGAGTCACATCTGCTAGG-3′
K125128Q
antigen–positive
GCG→GAG
BHQ-1
Coulter-Immunotech
Footprinting
-AGCCCGAGCCTGGAGCGGATGGACGCC-3
KG12Dhereafter
Y27S
BT88
events—i.e.
.Carcinogenesis
0.302
.Ras-expressing
1−23.4CDH1Cadherin
build36
I2017S
N-SVGpSRRRR-C
micro-waved
//www.ncbi.nlm.nih.gov/Genbank/index.html
analysis.https
stimulationby
.Veterans
F1174L/V
leukemogenicity
Cerulean-tagged
20.R337P
chemiluminescencekit
non-intensive
primary/metastatic
24â€
0.987
MY30
CDK4-wt
rtTA-expressing
p57/KIP2
JAKl
10.28
neddylation-disassociated
pSG5-HEGO
MCM3
IKBKE-dependent
IVS6-70-T
W209L
nlm.nih.gov/igblast/
Br73-Ut88
receptor92
E-box-elements
5071
2-copy
HDAC1
26904
D'Inzeo
136
X376
p-DEST26
γH2Ax
1:1,000–1:2,500
Paradoxically
exon-6
QIAshdredder
p53-Bcl-xl
hTcf
RAS167
ATP-competition
GCAGACTCCATGCAGACTC
ml-
β2-sheet
subunit-TOR-like
cytocentrifugation
mela¬noma
Low/intermediate
Effector-loop
15HCC
HGPRT
substantiation
Coinfection
p.Y98C
.Beads
ARDIYRASYYRKGGCAMLPVK
.Mut
H55Y
Paepe
G596R
loop-mediated
domain—the
Passoni
familieswith
desphosphorylate
glass-bottom
Desorption/Ionization
ND-1000
TALEN-mediated
PCRfor
−1.6
rotundum
Ago-family34
centrosome-dependent
pl25FAK
Multi-array
COL7A1
EZ1
5,379
WT-ERα
dwar®sm
alÃ-elescan
imatinib71
PPPDY
IL-6–
2188
DOI
49–71
FOG1
edge-to-face
1.2–2.9
∗2p∗tumorploidy+
thrombocythemia,46
S:15
SDHD
γ-glutamyltransferase
EGFR-SO/CEP7-SG
malignancies21
0,44
17/24
database23
ARfl.thumbnail
96–292
component.25–28
p-Babe-hTERT
Monolight
CBFB-MYH11-positive
conversion.54
ATM-deleted
mutation/inactivation
kinases,16-20
.Frequently
TAAAGTCACTTCATT
phosphoacceptor-containing
mesenchmal
CGCCTCTGATGCACACTAAA
BRCC36
Luminol
4–88
8352
GSK3β-mediated
outcome.59
pK62R-FLAG
Erg-binding
RP11-788O6
Lys105
350–353
A176D
92.8°C
Ser9
CD150+CD48−
FL-393
WM3211
913CRT
p53-53bp1
Csnk1a1Δgutp53Δgut
antioncogenicity
.DJMS
9Mid
P124S/L
D17S855
±3SD
150-base
pGEM-T-easy
9.8
Smadindependent
-TGAATCTGAGGCATAACT-3
.Gong
CTTAGCCGAGTCCCATGG-3
paraphrase
peno-scrotal
FANCE–FANCG
4,096
e8.1
Div/Var
controls.34
G117A
4799
C342R
CD71
TBL1-NTD
four-week
Ribogreen
pnas.0802655105
repair,34
c.4342A
.CtBP
GST-only
Egl
5′-TTCTAGTCTAGATTAGCTGGTGAGGTTAATGATCTTCC
4130
ATAGTTAATCAAGTTTACAACTGC
p70s6k
MIN-
C611R
W5d
Hemo-De
c.110712T4A
ZD1839CHO-K1
H188/192
Tumor-Derived
P179R
0.314272293
28-91
uc001lns.2
K708M
59AGAAGGCTGGCTCCCATACTGTTCTAAC
//dx.doi.org/10.7554/eLife.14709.003
165.5±24.1
~56
28105
5'-GTCGATGTAAC
shC11
SDS–polyacrylamide
Reh
B3A
D19H
pronunciation/articulation
p.P483S
RAB
.Classically
P637Q
h18819130515978312448
5′-CGGCGGTCGACCTCTGC
.Demethylase
threshold-level
αD–αI
ULCR14
609
NF15
988
EdU
OIS
trial.57
Genebridge
overexpresReceived
320
f3-galactosidase
tution
6-fold
7.6.4
brentuximab-vedotin
melanocyte-specific
P730
11–
3,153
16-BRAF
0.0133
Ben-Baruch
low-IL-3
change.40
FPα-associated
Chediak-Higashi
Allinen
Ver.3.7
KITD1–D5–SCF
11,525
.IDO
E2-2
one-
1×TGFBR2
mice3
cystein
260-
Rad55-Rad57
GCTCAGCTAGATGCT
Q640X
anti-H4K16ac
theability
∼40,000
WCP
.Pathology
activated.17
sex–matched
cancer-UP
Repeat-Free
∼34-fold
1–25
F05
MDV3100-treatment
glomulin
A.J.C
CaSki
Cancer-directed
PDGFRAAsp842Val
EGFR-mediated
type/total
103.5
signalling11,12
33–62
anti-TTF
RNA-fusion
.0005137
cytosol
EGIL
~9-kb
DC™
Foury
progenitors29,30
HELP-GT34
GGACAGCGACTCTGAATCT
signal-recognition
e34630
Thr600ins
riboprobe
generated—corresponding
-JQ1
NTH1
deletion.52,101
4-18
GTTGAACGGTggCCACACCGGC
progetto
kinasedomain
hemangioma/hemangiosarcoma
12869501–12907100NM_001903
survival.48
Ala-59-Gly
PI3-kinase.13
5'ATGGCTCC3
months.2–6
=GSK-3beta
ATGCAAGGAGATGAAATGACACT-3′
p53.33
5′-GCTTCCAAAGTCACACTGA-3′
NALM-6-EcoR
457
18/30
mutant.8
4,6-
anti-F4
DU145,30
ZR751
obesity-induced
GST-NRAS
thatFO
postischemia
phospho-KITY703
1X86
analysiswas
outcomes.23
midpole
185
CRL4DCAF1
1-Mb
Tables22–4
Anti-KDM5C
I-19
L831H
//www.stockton-press.co.uk/onc
R143A71
.BMS-354825
R494Q
TNT-proteins
TMRM
3122-1000
thelial
12–189
MCF‐7
.Cytospin
28/104
diseases—dyskeratosis
0.018/s
GTTAGAACAG
P=0.637
.Hormone
VEGF-A–independent
42-year
78K
c.1241_1243delTCG
G168-15
cosine-similarity
17R
well-calibrated
Glu511Lys
changes—in
α-actinin
5'-GTT
/log
Hancock.
p.E180Qfs
J.S.G
.Uncut
.One-fiftieth
IVS1811G=T
IMAGE:5349249
18.77
BRCT-GST
collagenases
non-ambiguous
pre-printed
BCR/proliferation
glycergel
CBF
21,22,24
ARQ-197
sub-cloned
rs743185
4-1
Jiemin
35.8–46.6
Snap-frozen
hemangiosarcoma
A.E.Viral
3q22
AID.Figure
p.Thr599
cyclase8
erlotinib8
molt-4
Controlare
invasin
favorable=16
H437Y
FANCJ-R798X
blastoid/
GSTπ
UbcH6
NTptide-8
G244R
'involved
2402
Non-Small
bisbenzamide
saline-T
3267
p.K499K
IgG-antibodies
604-675-8185
T.
miceX-Gal
ErbB2-depleted
4–22
5′-GAGGACGAGGACCTCTTGGACATCGAGGATGAC-3′
ERK/total-p44
changeb
RITS
mouse/human
crypts—originating
expression.18,19
110-kb
pHK103
starved-PDGF
DBL
hyper‐
gland-producing
siUCP
6243
pv
BRG1-null
unSUMOylated
21283
time.`
E2F-genes
2BIQ
E330K
divalent
Tyr-CreER
helper/packaging
1.297
kanaif-int
PR65
Thermoshaker
Mazo
15140-148
sc7126
.T2
EN-Y594F
Rhodepleted
BRCA1D11q
RP11-66502
−1.54
promoter,69
pack-year
FANCD2-S
5′-GGAGGAACCTCCCCTGCCATC-3′
65–70
265–467
K227Q
115:3166–3180.10.1002/cncr.v115:14
p.Arg9Trp
COLO320
IKWMALES
C765W
transformation46
Tet1–3
R1737P
disease25
life,6
NF1,30
flowcell
Henikoff11
sine
CCAGACTTCT
PJ69-4α
Jak3-JH1
5'-GGG
2.45Å
isp53
L768S-
3·7
.lentiviral
pathophysiological
Nobili
array,34
I290R
avector
PM6
2348
0.44–22.4
trithorax-polycomb
5,13
DISOPRED2
mAb104
DSGψXS
CamK1
regu-
S4I–J
Chinese.
Polymer-Kit
F1P1L1-PDGFRA
PTC-100
14,835
GNA11-mutant
NSL3
^18141
Parameters/category
H1299/Y220C
3264
Ub-AR
carcinoma11,12
Fig.4c
.Q293
2H4
P1856X
immunostaining27
tumours109
TRITC-phalloidin
Δ870
77.27
HLA-antigen
Tyr1234/1235
.Cloning
ligand-selective
V1136D
hereditary/familial
.Median
.Park
Babchia
FIP1-
pathways.4,5,38
50×25
Figure4B,4B
1.40
IdI-BMP
Collagen
MPN,6
WM278-NIC-GFP/control
whichaffect
EXPERMIENTAL
panitumumab.2-
771-115
Brca1Tr/Tr/p53-/-
EGFR2
genome/transcriptome
//www.ensemblgenomes.org/
-p69trk4
11/17
-direct
ADAR2
PIK3CAE542V-and
F23
RP11-977G3
GSM459024
T14/15
.S2E
3Faculty
function,25
immunocompromized
Sma-2
J015
mutants47
.LNCaP/AR
VflVt
Lubkowski
Visca
SC-10P
Ski/SnoN
reshrinkage
6p21.3
ICN1-pcDNA3
.HSR-amplification
disease-control
syndrome/multiple
NF-nh
50/78.1
GM-CSF–producing
Fil­
tumours.All
0,0
accident.18
populate
LexA-wild-type
senescence-inducing
infections.2
CT-a/CYT-1
:77.8–100
mesylate,43
5-methylenesulphonate
.7,9
755
K357N
pcDNA3.1-mutant
Co-14
38–62
His–caspase-8
0.14-0.67
Xtriage
E343K
gonadoblastomas
Humplpas12
BRCA1-knockout
NPM1_ex12rev
HPAFII
cases68
0.09
RP11-562A8
molcanther
Asp84′
c.1780G
sc-268
wt-ERBB2
carcinomas,11
5th-7th
Luo
p.R1097H
mutations.7,9,11,12
.FUBP1
nonsynonymous
.Sox17
kinase-inactive
PWV
1p150
brd5
0.376
BRCA1,27
Tascilar
5'-ATG
.0177
6487insA
59°C
Elk-1-dependent
09:40
BM/PB=4/0
S2.9.1
detail.35
A30
D350G
9.1-Mb
HDGC§
PDE4C
32-36
.SB
MSH2-MSH6InteractionThe
mTORCs
pCMV-Myc
ever-on
A93T
GTAGTCCGGGACGTCGTA
12-color
Ink4a/Arf-null
epithelia.51
0.36556
pEAE38
stimulation.95
PEBP2β-MYH11
pMYs40
AP000920
broad-domain
,7F
4M1Y
anti-acetyl
3p22.3
27-years-old
mtp53
K—L
2988653
0.1–3
Calbiogen
mastocytomas
SDS–6
BCR-ABL–expressing
O6-benzylguanine
EGFR-CR
CaMKKb
G538
anti-BAP1
Ramensky
B/x
0.556
TTGGATTCAAAGCATAGAAACCATTACAAGATATACA
D276N
C636
non-melanoma
ALL,5
maintenance24
lipofectamine®
/53
159/419
5′→3′
M1a
1TSR
domains33
PMF.9–13
Drugs/Adenovirus/siRNA
coitus.56Runx1+/−
NM_008906
LRPCR3
pcDNA3-SOX9
-7d
aq-Q209L-transformed
mxi
radio-labelled
ENSG00000146648
Asp419deletion
ComT
E352Xb
5′GAGCCCTGGGCACTGTCGCTGC3′
.Arteaga
rough-eye
BMP-Smad
anti-phospho-TrkA
cells31
PaCa-2
calmodulin–dependent
spectrofluorimeter
aIR3
JAK2-oligomerization
ySet2
p\0.001
and104-R
17d
4-Mb
DSCRTs
CGTCTCTCTGGGGAACACTT
ATRX/DAXX
complicit
.Alamar
TCEAL7
2.5×
p.Arg271Gly
GXL
.HA-
domainplays
HSC/VEC
−285/+32
//chromium.lovd.nl/LOVD2/home.php
192Published
oltipraz
GlycoBlue
9m
factorencoding
Masahito
D10S579
lymphomas.4-12
2-thienyl
/1
ERK2E322
Fugene
WM8
0.473
S5A–S5G
FOP-wild-type
rs4135234
ΔGD
p53.Materials
Carit
profibrotic
Ferracini
32D/dnRas
FLT3-ligand
S473A
pLl
Well-established
F526
BRAF/V600E
for22.5
theIL-3
letrozole
N-acyl
MMR–ATR
9205
Ile132
opalescent
6.0-11.9
antiinfluenza
Vinculin
anti-CD20-coupled
structure-independent
∼1.5mM
125I-labeled
S1103Y
membrane-like
formation17,18
P=2.5×10−27
43/139
I332M
.PDGF-BB
GST-agarose
hystotypes
C15orf2
−349
.Clin
Snf5Δ/Δ
-green
function113
Harvard-Partners
thatbind
BRCA2.
respectively.B
Vitellogenin
7.These
1EXZ
XL-MCL
asprimers
Koo
2HG-mediated
HGFPPEVEEQDDGTLPMSCAQESGMDR
pc-ΔID
p21-promoter
L859P
TAF110
0.082-0.120
inactivatingand
Ioffe
.Elledge
PBS/FCS
de2-7
1,094/1,014
AKT-S473
factor-kappaB2
PDS.asp
ascopubs.org
MSNU030
K112E
reducible
antibodyraised
doi:10.1038/nm1401
Proteasomal
VH4
N385fs
101–104
L16P
1754
∼35
BRAF-melanomas
-defi
miR-130b–ZEB1
protein-25
OV-90—that
counter-staining
464-482
clarified116
slowmoving
.msh2-GD693p–Msh6p
18,23-25
DSN1-ZsGreen
anti-B-cell
gp110Prt°-'rk
custommade
®lters
CD45.2+Lin–
variant.When
CstF
PCA1-2
SP6
criteria12
estradiol-bound
mg-1
5′-TTATTGCTCAAACGCCCAAT-3′
SERP1
WNT/CTNNB1
Cd74
random-primed
712–719
0-24
emtansine
E.
41.2
shrunken
3‡
Ar9GluleuGluAr9
R378H
PALB2-depleted
FC≥0.248
IGH
B*39:01:01:01
p.G101W
autoimmune-type
IL23
Sacharomyces
-AACATGGCCCTATCTTCGGG-3
deep-read
lombo-aortic
Engelborghs
erbB3/AKT
oligonu-cleotide
78.15
Boudeau
stk11
BB=1
Myc-DH/PH
Qd
KMissense
MPD,27
Zn-finger
patientsAuthor
non-biotinylated
xixi
5917
ER-driven
5′-CCTCCAAATTGCCCAATAC-3′
79/F
sub-cloning
neuropeptide
Phe623
ibrutinib.23
.Peaks
ΔΔδ=Abs
p.W360R
Gαq
ADCC
amino-sugars
KIF5B-RET-expressing
I/Antarctic
Epidemiologic
5′-GAGGGAAAC-3′
Smad3–Smad4
Response/
9.79
Tm1
.CEM
Fullerman
post-wounding
393E
.2054
10−16
carcinomaâ€•
540b
GSE3998
29–749
.Reprobing
HIVdisease.18
Traverso-Longmire
141A-HEX
H-2class
Met-HGF
1,510
M129T
A498-containing
Balley-Cuif
outcome142
57/70
n=7/132
17p-altered
gtaagttat
MOE
Dermatofibrosarcoma
∼100M
Netrin-mediated
ACTHoma
interleukin-3-dependent
microgranular
07110
SDS-sample
anti-SMAD2
recombination-
D28
0.372
.Carboxy-terminal
-S-phenylglycine
H3122-EML4-ALKG1269A
chr8:134373799-134375086
REC-1
Kras–mutant
Hoodfar
Baldi
Babasaheb
ESR1-cooperating
TCEAL7-specific
Leu16Pro
theBradford
cells.1
cross-talk/feedback
anti-pMEK
.L.B
Poly-HRP-anti-rabbit—IgG
Rodriguez-Gonzalez
F486L
214–217
beads1
MYC-
1275
0843
double-knockdown
Fig.5D5D
M44a
0.08–0.14
cancer-therapy-related
3.094
ETV118
340KB
.Hybridizations
anti-Y653/4
dSET1.4
Ackrell
200HB
apRSVL
.Promising
pCMV-Myc-ubiquitin
c.169T→G/p.F57V
www.nature.com/ejhg
3/21/00
non-prostate
-min-flanking-quality
Htz
59224
differentiation.48These
PCDH15
Ser75
INPP5D
∑h∑i
12-14-15-17
defects3
acid/water
.Area
ATGGTCTCCCTGCTCAGTGT
N-terminal,19
v1.02
anunpaired
5'ss
trastuzumab
phospho-T590-specific
cmyc-mediated
kd
51,52,53,54
1793GVPLK
.Notably
Informax
Hras–/–
blocks.fhcrc.org/sift/SIFT_BLink_submit.html
Ad-EGFP-infected
bicarbonate
c.400-3A
24.4–27.0
Tyr-261
inhibitors.27,28
openlabel
ÃŸ-cateninbinding
California-Los
pCR4-TOPO
EcoRI39
MYCL
alÃ-elewere
phenotpically
NS/TA
I447F
Anti-chicken
_Billroth
activating28
SK-MEL-19
transformation75
.IRS-1
0.141-1.373
.Tumor-specific
K14cre/Brca2F11/F11
Gradienta
PIKCA3
multi-state
GSE60218
Act1
karyotyping.30,31
FA-25
0.7535
Michalovitz
Full-CFL
not-yet-identified
SNU-
PCM1-JAK2.25,46,47
densitometrically
lilly.com
BrdU-labeling
Carboxy-H2DCFDA
binding5,6
171–249
microcystein-LR
initiation—an
159-163
L255F
adenocarcinomes
sense-preserving
anti-PAS
ETV6–PDGFRB
.107
in17
FLAG-TRAF6
σA-weighted
non-CML
Men1l
former1
Genepix
18
33/54.1
BMPR-I
RAS-Effector
non-D842V
TRAF-homology
Immunoﬂuorescence
.Photomicrographs
Sarcoglycan
SNapShot/sizing
HD-LM-2
0.4–27.6
3-22
301b
5′-GTGTCAACAAGTGGTAGTTCA-3′
.Status
mutated3
2Oncogenic
Mll1f/fCre-ERT2
​and5B,5B
M3543
INPP4B
Fig.4A4A
4GMX
5-bromo-2-deoxyuridine
Abbott/Vysis
M522V
anthracycline-treated
gpl4oProto-'rk
duplicated.9
165.5
MethodsChemical
DBC1
5′-CCAACTCTTTTGTGCCAGAGA-3′
pharmacodynamics
2244insA
ATP-resistant
Usary
rs121913419
1045487
sugar-phosphate
MAP2K1.1
AYliated
stabily
Flag-PKCζ
ExomeCNV
GAACGTGGTACCCCTCTTCGACCTGCTGCTGG
negativecontrol.0a
ITSN‐DHPH‐GFP
SMARCB1-negative
Keimyung
2987
Asn2875
+neo
c-Cbl
.Modified
cells.14,16
Atr
+Foa
promoterin
.1176
cross-reacting
17q11.2-linked
aj2
over-estimation
583–100
mitochondrial/hypoxic
pCI-PTCH1B-FLAG
Short-lived
Mll2-specific
respectively.9
Cy3/Cy5
aaTA
c.736A
aptamer
identiWed
determined.26
ACTAGAAGGCACAGTCGA-GG
9/8
N2/3
D594E/G/H/N/V
negative-acting
RITS1
forunveiling
n=48
NF6
histiocytosis.17
SB203580—Because
94403
R460
TGFb-RIImutation
resistant-like
.Genetic
*Log-rank
.Epifluorescent
anti-p21WAF1
Serendipitously
non-correlation
._1365+
FACT-independent
Y220H
p.Asn563Glyfs
50-mmol/l
16p13.3.1,2
C382D
otolaryngologists
â€oe
myr-p110α-expressing
4.0-kb
STAT3-specific
Endris
23:4
5′-CCTTCACCAACACGCCCACAGATCAACTG-3′
post-4-weeks
0·13
peritransplant
phospho-DDR2
RET–ATP
itated
N-RAS
Gata3
.Asthma
cancers7,16,17,18,19
co-clustered
FIPIL1-PDGFRA-positive
.Mining
polycythemia-related
melanoma,1
-GCGGCAAGCAGAGGCTGG-3
Cys_121
disseminations
Between-condition
Abl/ERK8
clinical/biochemical
yGl
BCP-ALL.4
truncated-type
F/55
ultra-rare
androgen-insensitiveprostale
C91W
POUS
AII_1_RUNX1
histones.3
-triphosphate
AF041811
PAIP1*
G249S
helix-3
*Atretic
YANG_BREAST_CANCER_ESR1_UP
PTP1B·
Asn-
bias,29
transactivationabilities
position49
c.2245G4A
Pro126-Leu-Leu-Leu-Glu-Val-Ile-Arg-Arg134
.Restriction
Gene-carriers
inhibin
Ski-interacting
dimerization12
Thr185/Tyr187
0.0070
plasmid-linked
1/15
Low/Low/Intermediate/High
abcam
0.8–4
repression24
fluorescen
CMV-βgal
21/115
Singleton
D11S1883
Y781insGSP
andpossible
.Kinase-activating
paper,20
D88N
HggI
HEETPPTFSSDSEEEQEDEEEIDVVSVEK
3T3-DM
thione
4039–4046
NRASG12V
fluorochrome-conjugated
ect2oncogene
p.W557R
Ercc1−/Δ
.8All
Rb1Lox/654
fat-enriched
metastasis.5,7
A11031
H3-K9
11q13–14
Subcloning
anti-FANCD2
p=1
W257G-associated
ProteinTyrosine
K473R
AML1-ETO
N489
pPCR6-1
Hathout
non-endothelial/non-haematopoietic
1291–1296
BIKAROS^
anti-phospho-mTOR
V44A
.3279
H115A
www.cgl
red-O
8/0
5′-tgaggcatctcaggcacgtc-3′
Co2+-IMAC
PTEN/C2
AR-associated
TP+FN
D-08
N.D
12D
cutting-edge
TKI-treated
-dup
//ftp.genome.washington.edu/RM/RepeatMasker
18F-DOPA-PET/CT
Ceff
6.27
P278H
activity.18
hematopoiesis.35
mid-molecule
9p21–24
breaks.9,10
Ser45/Thr41
vertebrates.1
L387P
-TCACAGAGTCCGTTGTAGAACT-3
R218H
designated104-S
dTFP
population.12-14
.Exploring
IL-3-
NESwt
mutations.MethodsWe
Takita
EN/IRS4
66â5€0
805T
Top-ranked
50-cc
E285A
UACC62
.Twenty‑one
UAS-ALKR1275Q
202246_s_at
medulloblastomas—specifically
Ile145−Asp156
°C/62.0
patients—even
JAK2.4
F359V/C/I
GGAG
Fig.8B,8B
CDK-4/CDK-6
.Roscovitine
SHIP1
chemotherapy.15,16
metastasis-methylation
kcal/mol,4
pore-forming
12–15
EGFP-negative
​Table33
237-262
HCLv16
≈6.0–6.5
GIST.27
Plaza-Menacho
Pyears
MLL3/HALR
.Lymphomas
p53f
Analysis15,16
cases.73
644
//www.pantherdb.org/tools/csnpScoreForm.jsp
1lBTGCFGCFGTCCAGGTACA142
STAT6.27
L747-A750
NCT00405587
1IB1
ErbB2-positive
.Moreover
1543
NACl
Glu-260
p21cH
accommodating
1053–1327
EGFR,60
transformation.5
1587
7,15
Sol-Church
51-yr-old
Nioi
LMT
0.412
c.1803A
3/19/99
Nrf2-over-expressing
puro-loxP
HBP1
SH2-SH3
SHP-2
TYY1
CGGACGCAACAGAGAAAGACTT
EGFR-G719A
porcupine
Raetz
cetuximab-containing
252-LTIITLE-258
.Nine
PARP1–DNA
modelizationIn
Pro-34
34-36
GDC-0449–sensitive
thepromoters
20/65
16/16
Bcr–Abl48
developmentspecific
HOMOLOGUE
TPOR
GST-beads
10.1002/humu.20234
BRCA1D17
ductive
1b/Exon
hg19/GRCh37
NOTCH1-3
AgR-triggered
0.97-
Alk-5-dependent
EWS/NR4A3
P-Mapk
centigrade.Results
HKY1026-8C
R124C
co-activators21
.CRISPR-based
Litzow
severity.14
Developmentally
Gly'2-
tumors.43
enzalutamide-induced
-t
phase.22
ÃŸ/
Hanina
349
≈1/1.5
40°C
hyaline
pre-gassed
GTPase–effector
R1881.AR
regorafenib-treated
100μM
IL-7–free
8p-amplified
3.788
p38-dependent
2.79×10−5
−2.53
MEN1-syndrome
detectable66
myr-AKT1
break-points
Raf-activated
P278S
.Φd
low–
1459–1559
coimmunoprecipitation.30
pRb-null
2035–43
p.R537P
CJ238191
MN65
andorange
F170I-mutant
145-kDa
Val/GTC
DLBCL11,12
60394
pcDNA3-transfected-ES
tumorshowed
GCTTATAAAATTTTAA
Ekholm
parafollicular
glucagonoma
2948
C390W
pcDNA/neo
p.Pro379fs
RelA/p65
p.Ile145Met/p.Leu1354Gln
del1434
Porton
6.8/1.28
tissues78
EBM-A
.CI-1040
conditions.10
R223Q
−0.32*stage
PABPC4-TYK2
well-knownstatistical
−748/−738
−43.2
p.Asn2135LysfsX3
availability1
suite.25
0.23
Xiphophorus
Aligner70
0.2210
Reinberg
polymorphism.A
Schrauder
KGEMGKYL-
repression33
E1974K
4·4–9·9
5′-TGTAAAACGACGGCCAGTGCGCCCCAGGAGGCTGAGTG-3′
pVHL–ElonginB–ElonginC
0.029049
pCMV-TAG3b-pHAS-I
BRDT
withnegative
11/100
NPT
46/64.8
p110α̣
AutÃ³noma
as-yet-unknown
Arg487Trp
+..4
Cellswere
backskins
12/1/97
autoantigen
2,049
B220+CD43+IgM-
R175H-mediated
NTEAIDCITQGRELERPRACPPEVYAINRGCWQREPQQRHSIKDVHARL
HCCC-type
.Congenital
IVS2+24
oligo-synthesized
Podtcheko
15/87
PEBP2beta/CBFbeta
293T+5'Aza
//www.insight-group.org
80–84
L73F
23.8×
90.2
2156
10.11
R196X
34F
Ha-Ras
V617F-Negative
-MUT17
KrasG12D/+-initiated
Tat-interacting
E20D
low-to-moderate
Takwi
1nmol/L
S31R
R129H
G943S
Qncogene
miR145
machinery.12
inactivation-based
pBacgus2cp
18Department
CAACCGCTTCCTCCGA
blister
c.705delA
semaphorin
polypeptides.While
1.657
thyroglobulin9
Pontoise
Conclusion81
G463E
prepara
8Dâ€
pCMV-HA-BLIMP1
PCAF-ΔHAT
1124A/G
Cetuximab-resistant
immunotherapy54
.DiscussionPrevious
-2-methoxy-1-methyl-ethylamino
M0293L
ART877A
BRAF–CRAF
2.0–2.2
FANCA/FANCC/FANCG
kbbased
KC11TISI0678
Aricescu
S374E/S362E
HPV-45
respectively.PDGFRA
αC-helix
Multinucleated
19,23
trypsin
PKN2
CMV-Cre+/o
.V561D
MYCN-derived
SELB
sophistication
14-3-3γ
G416S
Msh6-/-
EOC
pEGFP-C2-SMARCA4
.CDC25
Msh2D603N
.HSQC
vector/allele
RP23–151I21
32,826
H289
15q13.3
anti-HCF-1C
BRAFwild-type/cKitwild-type
especiallythose
4t
BioMérieux
.Phospho-FGFR
4C09
ASV
D83
calcium-dependent
p.Gly34Arg
exon‐by‐exon
S3v-ErbB
Glu235
CD4+CD8+7AAD−
EICESS
ctivities
MG-B2GFP
D1S507
CD95/CD95L
Immunochemical
p.Ser269X
SkiW274E
CDK6-driven
Dnmt3a-knockout
Raslike
Toll-Like-
G12D+
phosphorylation.41
A_51_P175580
E363K
Meta-data
T392
Albumin-CreERT2
Gouas
5HMECs
below194
HR=1.92
Colo206
––24
IUAC
TTTTATTGTAAGGCCTGCTG
Markera
35.D352H
c.548−3delT
//agvgd.iarc.fr/
4–7
GastroIntestinal
5′UTRs
I131
RXDX-101
/0
theintracellular
3·7–11·1
Homozygous/hemizygous
GISTsInterstitial
enzymes11
FLJ94553
35S-HIF
inti­
EVQWKV
960μg
CTL1-2
adMYCTK
cells/1
.Activated
events—in
∼8.6
shAKT1a
Leukaemia/Lymphoma
23LxxQDxDLG31
68934949
0.622
Verdonk
1.2–2.1
0/54
cyto
DAXX/ATRX
c-mycWT
350bp
NKX2-1
cycle4
Sprenger
chromosome-loss
Tyr537
85×
99.99
10.4-kb
M147T
mastocytotic
Asp1248Asn
5′-CGAAGTCAGTTCCTTGTGGAG-3′
6.0×5.9
HOS
TMPRSS2–ERG3
form3
anabnormal
.DI
cross-
167–189
1JM7
R544W
Out-of-frame
5/6/04
fifty-fold
AF6000
S8–S10
K129
L2097F
−30
Cas-Br-M
wasup
16,2200
HIP1-PDGFRβ
C634G
Hin
cancer66
N.M.
FLANG
00000
method.10
adaptor-
project10
nondefined
Marciniak
anduntransfected
manner6
.Furthermore
8:3:4
Prosurvival
TSC.35
cySseeo
Gly503
Driver/Driver
LC-MS-MS
al.136,137
Glu-69
0.6093
D283MED
cl.2
asUV
Drosophila
DTM
GAL4-BD–specific
SPOP-S80R
2172–
160.4
Al-
Alexa-647
12/1/05
CLLa
PIK3CA-KD
R426Q
Oocyte
212/94
1,00,000
P-value≤0.05
cAMP-response
protectedBi-MG
GGGGCGCCCG
PE-1/METS
κΒ
=0.543
46.0
Sulfo-NHS-Biotin
mesencephalon
488nm
Ponath
Asp-880
First-Line
families.7
10q26
Euclidian
retroperitoneum
n=369
R524Q
Tbrg4
c-rel
Brca2flox
Cognate
mesothelioma,31
staining-mediated
GNP
.Asxl1
UQCRH
disproportion
C-mutated
stereochemical
Scatcharde
5×108
C3H7Na2O6P
IMR-90
ventriculo-peritoneal
Popanda
I38T
276300
FGFR2−/−
CAPAN-1
7•6
3,5,4′-trihyrdoxy-trans-stilbene
anti-hMSH6
Songand
1/83
anti-SRY
E194K
neuregulin/heregulin/neu
GCT-
cell/well
cell-extrinsic
S1039F
T790M-mediated
1.1–2.04
ALT-negative
Jode
tumour-promoting
p.C117Y
repression.4
L304R
Leu24Phe
24494860
K.R.T.
pancytopeniaA
CDGMTSSLSESLKTELGKDLGVEAK
GISTs.PDGFRA
Miloso
3H-R1881
1,751
PAX5-ETV6
PLC-g
N-terminus
.ChIP-qPCR
MIDR
R97
PO1HL54785-04
alignment-GVGD
35-47
e-3
miR223
rs17159934
SH3-containing
six‐bladed
HLA-A1–restricted
RP11-229C3
POU1F1
34T
29443705
RUNX1/EVI1
N-rasG12V-E49K
84
chromatography-electrospray-mass
.Affymetrix
fastest-rising
twkimmd
GSE45354
factor-activated
Q239X
4.4/62.5
log2
chen.junjie
colleagues109
NEIL1
58–59
2042C19
helix–hairpin–helix
.NS545
molecularly-targeted
S65W
AI218496
amplification.29
2-3-fold
IL-10-induced
P.N.I
Victor2
Ets/TCF
downregulators
homology-containing
p.Q1545K
Trizole
Vanhaesebroeck
BluescriptSK
BRCAness
Tassan
T196I
5'-gag
doi:10.1155/2012/804801
GRANTA
p-FoxO3a
c.1497A→C
TSERVs
BCR-dependent
Luminal-mRNA-subtype/HER2-positive
dAzaC
14q13.3-21.1
44–422G
mg/90
Radiosensitivity
38257–38612
T4aN1bM1
4647
SRGN
KVEQLSPEEEEK
TAGATGGCAACCAAGGAAGC
alkali-blotted
cdc9-2
S3B
In5
hyperproduction
ROS3
GTCAGCTTTGCTCACGTGTC
Cancer-free
patient.21
62/82
K416Q
62,000-178,000b
pBS-SK-K-Ras4bG12D
I845
33–34
.Most
Masson-Goldner
C2-
T200I
D351H
entirelyof
CS927
5511
0.7.1
SF3B1MUT-induced
distributionof
thanKITexon
reported.13
N=23
RAP1B
MEK1/2-inhibitor
.RH
L692Fa
LAMLs
SDS–8
trP1-Exon26R
500g
p.Pro1575PhefsX31
SHP2-SH2
GCAAATAGAATTCAGGAACA
16p13.1-p13.2
SPEN-silenced
Fbxo45
Cdc34
3-tier
D842V-
0.029
Csl4
88.0
BRCA1-mutated
RasRasGAP
nonqualitative
MER
IWG
PTEN-immunoreactive
2Response
.MFM223
RG-2
GF53/09
3.474
LysM-negative
MSP,17,18
procedures.Veri¢cation
ACGTTGAGAGAACGAGGAGGA
2007,8
-TGCAAAGTCAGCAGGAAATG-30
IncuCyte
L-myc
mesoderm46
AR-V12
Oestrogen
recurrenceAR3
amplification/overexpressionfor
H650
45–150
p.S87delfsX11
alphamonothioglycerol
protumorigenic
aberration.2
G1296A
409d
JIH-5
4418delAGAA
pBabe-G735S
Bandoh
panendothelial
D7A5
Lymphosarcoma
6.63WT1
substantive
g.a.p.hospers
Gmolecule
flippase-enhanced
S12A
bamfiles
490nM
2.000
1,435–1,436
Citron-KD
ATRTs
SMO-T241M
Arg21
anti-insulin
.Cords
immunofluorescence-based
5′-CCCCTTCCGGG-3′
p‐Akt
PIK3CA.14
S-G2/M
approx48
PI4KA
T-p53C-H168R
doxorubicin-treated
657185
trP1-Exon24F
.shRNA
hemEC17B
p27-induced
Balamurugan
S40X
I568F
GeneReview
pLXSN-EWS
80,698,679
panoply
Hir
−neo
nonfunctional
22,63,64,65
C162-F
fludarabine-based
MET/ALK
BRAFinsR
Kahl
reported43
Self-monitoring
AnalysisThe
∼38
c.1497G
SGI7079
S918C
,3-phosphate
Arg117Chk2/Arg70Rad53
CRL-5826
RAS-transformable
//gdac.broadinstitute.org
Fluor®568
16q21.2-q22
.256G
JM-deleted
nMhydroxytamoxifen
MEK/AKT
0379
AKT1S1
SIFT/PolyPhen
p.Pro534
IGR665
COLO678
rD-Nâ€
Aspll
Y340D
Q71stop
H3K14ac
Y867H
resolution/sensitivity
q37
transcriptional/translational
www.nejm.org
440-bp
4400
2979
MAC-2B
//www.nature.com/naturemedicine
.DCC-2036
low-risk
p.Arg202
mastocytosis.16
taining
1080
15/99
22–76
.PDGF-Induced
.T-distributed
−1.92
0·9–100·0
Ethanol
blockof
Chr2:29443695
model—one
TRAIL-mediated
Tyr525/526
OCM1
1.2/0.7
.Presumably
p38α
Q61R
mIgf1
previously18
158.9
Boutros
M373R
12B
41:849–854
0.361
VSG
N819
Experimentally
Flt3-WT
Gli1ZF-K350A
unclear35,36,37,38,39,40,41,42,43
p.Pro195IlefsX7
TransOMIC
Flag-tel-jak2a
chimJunctionOverhangMin
ofchromosome
activation-linked
rescreening
WTI
E942A
trametimib
anti-γH2A.x
SSRP1
miRNA-targeted
Methods.Patient
+283
Noonanlike/multiple
5p-
FUNDC1
inhibition.132
8/97
Q15
CytoGen
galanin
551G
Msh2D603N/Δ
/B-NHL
Epithelium
Mlh1–Pms1–Sgs1
wt.The
1028
0.922
erythrodysplasia
Gal-1-dose
product.11
non-functioning
T31
pCpIPpo
19,631
.Incubation
U251-MG
Cθ
−2.42
//www.interscience.wiley.com/jpages/0022-3417/suppmat/path.2267.html
C300G
patientAlignment
analysisThe
Staalesen
ATCCATTTGTCTGAAAAACTTTGCT
60:25:0:0:15
tumors61
Anecdotally
round-bottom
R882H-transuduced
136-
.Crosstalk
F74
CGTCGACACGGCCTTCCCTT
post-dose
PD098059
boomerang-shaped
ß-catenin-Tcf4
CycLex®
KC14RISI0016
Xrcc2−/−
1BB
TA99Intenititial
Myb
Notch-CSL
muscle-invasive
10-cmplates
analysis.30
555
colourless
fragment.45,52
S494A
S688F
CCK81
U87-MG
16.7METRNLMeteorin
500µl
138–211
g.248GGGCCT
Transactivation-Deficient
neuregulin-1.To
Figure33
casewith
cre-virus
climatic
detected.13
ecotrophic
EVS
E1A
TNF-α-treated
Class4
regions55
nih.gov/nuccore/AF295024
Eun-Jung
MDC1-positive
Rnpepl1
22qter
sedimentation
3′-amplification
8-nF
Case-666
k2k1/
.msh2
FLT3-TKD-expressing
treatment140
nondeletional
23,241.
phenotype,56-58
predisposesindividuals
mIL-3-stimulation
F109S
9.9–12.5
10/37
lymphoma-like
Limentani
messenger-generating
ΔDeg1
hemangioma—between
T4026
neurofibromas0
Akt-Myr-T308A
139511
WS×WS
lammelipodial
R179C
.Cotransfecting
PIK3CA-Mutant
mutant-evoked
.SRC3
p12–13
2.76–2.7
4UAE
GFP-Elf3ΔC354
60s
Rasheed
90kDa
.Smad4-loss
MAD-3
5′-TTTTCTAGGAATTGAGGGAGGAAAATGGG-3′
Ao•
BCL2-antagonist
p.Lys909Ile/p.Val878Ala
TCCAGTCACTGTGCTGCTTC
_HER2_
p.Glu33_Asp34insProGln
TCAACAAAG
c.2514C
DACO-020
IL-3/GM-CSF/IL-5
2:0
DME3
.Kurokawa
O13
dtr
5′-ACAGCACCCACAACCACCAGAA-3′
1-347
cases,5
3–400
particular.28
1.25´105
5:2
described6
transcription.4
rigidification
accomplishing
.JCRB0822
lOO
CTGGGGAGTCTTGAGGGACC
GATA-3−/−/RAG-2−/−
6.83
Genomforschung
AKR1B10
0.918–3.350
motif.18
Itgb1
FBW7-γ-R465C
Isaksson
Skp1/Cullin/
2OG-Fe
pET28a-hTRX
miRNA-related
OFAPC
BTG2
5′-CACTTCCGTTGAGCATCTAG-3′
CSSAVE
•Disrupts
*Indicates
N-CoR/mSin3A
WES
temozolomide116
G0-to-S
nucleoporins
Raf–Ras
Y13-238
T19
ID11
dI-dC
MMC
centroblasts
catch-up
​Fig.4E,4E
vitro9
thatAKT2
indium–tin
Mediatech
SP-C-rtTA
BX161496
5′-GATCTTGGCTGAGGATGGTG-3′
G135R
OMM1
p.Ile533
.AF083322
CD3-TCR
Y426A
Proctor
13–15
RKIP_E2
AR-repressed
10−14
retinaldehyde
anti-γH2A.X
EWSR1/CHOP
1646−1859
G409D
esophagojejunostomy
pancreas.15
'stop
.Error
Bas-
Wt-FLT3
two-dimensional
STAT5-responsive
tissue-speci®c
R55K
Kawano
RhoA-overexpressed
−77
c-Kit-mutated
hydro
PALJDL
RAFKD-MEK1
DNMT3a-KO
nonhematopoeitic
thantaophoric
â€¢¿COOH
EWSR1-CREB3L1
RNA13
0.93-1.02Table
IC263
patients.37
EZH2/Polycomb
extented
CACCCGTCCTGCCCCTTCACCTT
9:361–368
multiclusters
sirolimus
.Oligo/azoospermia
polycomb
2TIP
.4e
dichlorofluorescin
EVSIIQSMGYRNRAKRLLQSEPENPSLQETSLSVQLSNLGTVRTLRTKQRIQPQKTSVYI
rates.18,26,27
classes/types
Tip60.180
9569
Serine
antibody–mediated
microphysiometric
EGFR/HER2-wildtype
β-carboxyl
D835G/A
3,615
HCC
mesoendoderm
Gln67Oδ1
thatdetermined
∼1500
mutant-forms
IRF1-dependent
NSCLC,22
HMG-B1
understood70
domain–specific
repressed.43
.Exon
phosphopeptideinteracting
q-values
K601K
IIIα
L410R
Anonymized
β2/α1
McKhann
VPVAIK
n=1690
LR11-200
V559D,11
syndrome7
*K.V.R
N345
KOD
m-BCR-ABL
chromatin-level
depocyte
.S8B
Danielson
−7.7
Rechsteiner
5K
ox2
Tagami
Bioinformatics,22
oncogene–induced
−0.49
non-FGFR
Masramon
28006
6,7,9
7q
F4035.42
15–27
M4Eo187
cancer.sanger.ac.uk
proteins30
68.84
patternslepidic
clean-up
stabilisations
gancyclovir-resistant
.MS-PCR
CACVGTG
-ΔC
.Mll–Af9
FCR-bearing
progression.13-17
auto-mini-allogeneic
CycD1–Cdk4
7.5×103
C141Y
S533N
.FGFR3-activating
F286del
ATATTTCAGTGCCCG
5749ins171
p.R2450
0.811
Acral
afatinib/cetuximab
HNPCCfamilies
100-fod
MC-480
Hisamaru
40·9
agents15
respectively5,23,24,43
927
Coincubation
non-advanced
35S‑firefly
.S10
Lr
mutation.11,14,15,17
Southey
p.R528H
NCI-H1048
factor-1a
winged-loops
Time-to-Progression
Pivot
0.1874
-3B
α-AU1
19,30
pGAD-MSH3
30325039
nature.comPTEN
hormone-resistance
.DSB
STAR™
20mM
respectively.1,2
WM46
.ECTMWT-1
1/60th
6k
X-100/phosphate-buffered
p.Asp1333Glyfs
lymphoma14
gene-therapy-based
-dimethylammonio
.Smo
Kanaar
H1112L
143327288427324345251291268387360
20/37
p.Gly1140Ser
CDK4mutationhaveall
R191C
15.5
N97
D727E
GSE42649
.Neuroimaging
oxygenase
Nasrin
CCTAGTCCCAGGGCTTTG
Q322A/Y324A
HER1/ERBB1
14G
insulin-treated
1996
variability.17
Rip1Tag28
BV173
EUFA228
A121T
CMVpr
p.Gln9Ter
ESE1
C/ACTGCTGGGGGCCTGCACGCAGGATG
cis–trans
SOCS1ΔSOCS-box
two-fold
purifiedto
TGCAGGACTGTCAAGCAGAG
ITI
setting•
39–43
expectably
pTetOff
VVPLYDLLL
RDES
Neuroepithelial
W51F2
Caffeine-
Actin-Flpe
Oncopanel
late-progression
∗Indicates
g_gyrate
p53R175H-induced
0.5ºC
particles/well
AT-1-induced
Tyr-741
GFP-INPP4B
R249-mediated
Fig.2I
RP11-529F4
6•97
agitatedt
Val-214
uracil-N-glycosylase
mitoses/10
Tyrosine-phosphorylated
homozgyous
Dnmt3a/Dnmt3a2
doi:10.1007/s00401-011-0817-z
melanocytes26
CAGCAGGTGCATCTTCTTCT
HEK-HT
562
.014
0.2912
40,000/32,000
_D_NMT3L
4096
ingestion
2.5-10μm
Processing—We
Y705
ITD/TKD
148-150
2,716
MuTect10
inhibitiing
PT12
71,83,87Å
H1047R-PIK3CA
ACCCGCCCGGGGAGGAAGATG
HD-0260
1KOB
55–167
pUC19CPD
1806
746-A750
p.Arg504ValfsX28
//frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi
M373I
MTS2
E119
gainof-function
nucleus.The
92,304,396
Second-degree
melanocortin
diphospho-ERK
EPIDEMIOLOGY
PC12/Wnt-1
E636
Asn101to
FACS-DIVA
c.994_996dupCTG
X34
P1709L5
byelectrophoresis
V/7-aminoactinomycin
pVHL-S111R
.Frontiers
syndrome/TD1
8/67.7
0.8377
KMH2
285bp
.Paradoxically
pTINV
GJB2
mri.tmd.ac.jp
noncommercial
−1.493
p.R460C
ARF876Lvariant
.Pathways
R115H
β-cat/TCF
Table1.The
trastuzumab20–22
Y63C
.Polε
1–719
three-arm
10-04
p53-R110P
Techne
Vκ2
pocket−occupied
K1601E
N45S
G1201V
80/2405
GACACAGTACCATGAAGG
Na2HPO4.7H2O
λ^=∑iwiOi∑iwiEi
PTRH2
p57
−6.02
BX61
4q2
B2-type
c-JunpS73
6His-rad54
1828amino
Y694
T*
death-detection
cross-link
.EXPERIMENTAL
42–61
I244T
c.1748G4A
pBabe-Puro-GATA3
FKH
P=0.8
v1.8
VVSGFVFLRLICPAILNPRMFN
L576P
t1t2…tn
na.
p53,57,59,60
anti-Ub
communi­
Sc-
Fig.BRCA2
Hh-dependent
CAAATG/gtactc
PDGFβRprobe.6
R229W
renal/lung
RAF-MEK
W81XWH-12-1-0568
35/56
JH6
73–87
H300
KIT,1
,4F
downstream-signaling
approx30
78.6
MSI-type
types.DiscussionExpression
ApcΔ716cis-Compound
−.64
LAF
.148
melanoma3,8,9
.HER2-expressing
5'-CAGGlTfA
aMED12
disease14,15
54.5∗
C2-R2/V392R
mdm2-mediated
Imacon
48-ns
Ig-IIIa
20-40
SLC3A2-NRG1
Phospho-p42/44
Sec.2
HAT-domain
geniticin
TBP
spleen.10
D287H
Fig5M5M
447/2295
His6-thioredoxin
cell–mediated
release—May
SalI-Sacl
NF2-related
3021
550–570
NIDDM
3SQQ
D9S197
instability74
MNF116
overexpression/activation
Akti
52–98
diVerence
Y568–Y570FF
toGussow
PARP15
476-3726
R140W
7/45
123T
p300,58,59
73-
W509R
anti-DICER
Cell-Based
Brca1+/−
domains.30
SK-MG-26
K508M-FGFR3
TM-treatment
2ddCt
G776insYVMA
A634V
Fig.3,3
ch15:60.3-60.5
DN-MKK4
mutation–negative
Cappellen
p.Lys601Gln
samples.12,13
Apte
44-49
Asn540Ser
79–83
IIIBe
.1000genomes.org
PRSS12
∗Corresponding
mice.Figure
≤71
X-tremeGENE
BglII/SalI-digested
V617F-mutated
7.047575e-11
621
Mycbp
receipt.Cell
Smad3/beta-tubulin
.Anti-phospho-ERK
hexahistidines
5-TCCTTCTCCGACCTCTTCAAGC-3
neoS
Tg1
AoSMC
AAATCCACATCTTGAGGTTTCTTTTTATATCCTATGAATGAGCCA
.Nineteen
pDNR-dual
pEF1a.FGFR2b.N550K.IRES
Kong/Hospital
1.5-13.5
//www.ncbi.nlm.nih.gov/dbEST
1.6–3.4
PI3K-driven
NPM-1
enzyme101
MAGI3
polyamide-
ATR-mediated
CAFsTo
.S1D
p.Ala1035Val
~*
NB-4
K291T
1505del48‡
D469
N-4
32k
rando
Sub-cellular
stand-alone
q22q36
142168344–142172070
Q1128E
.Kalvakolanu
non-METamp
TEL-JAK2–induced
pre-antibody
DAPI−
TTC-3′
S2183
Almog
μmol/L.63
CSD2
TechMate
p21-associated
region63
toothpaste-like
RUNX1-CBF2T1
otherhuman
Arg87
quality/control
BALB/cAJcl-nu/nu
TTCTGTTCAATTTTGTTGAGCTTC
DEPC-treated
k6
Gre
p.R99P
Idec
Tyr-62
proliferation35
polyloidy
†Compound
streptavidin-agarose
G225S
077
G-CIMP−proneural
S10.3
HER2/CEN
E69A
Stk4−/−
PAX5-ETV6+
describedabove
5′-GAGCGCACCATCTTCTTCAAG-3′
pIRESneo
kinases.15
Pst1
MLV-transformed
CAGAAGATCCGGAAGTACAC
Val617Phe
FLT-3
Casp8
sixfold
zinc-fingers
pseudoduct
R725W
1.0–440.0
S403T
Ellard
mononucleosomal
hyperplastic-neoplastic
all-heavy-atom
.Aliquots
.8662C
0.04487
pY740
cells,29
p.E585
damage—through
BamHI-BbsI
Y541A
K558-E562
3,4,5-P3
VIL2
2Ad
~Barbacid
NCL-AR-2F12
5′-CGATTGGATGGTTTAGTGAGG-3′
Y1228Cmu
0.8447
L862V
15000
A1752G
11/50
50-414
15,18
.Albert
.Viability
metastases150
sun-protected
c13orf25
types15
998–1006
PEM+PEG
E266A
P-LATS1
leukemia35
Score‡
eachstrain
CBF-1/suppressor
AB1690
1/5,000
Dotmatics
Apc1-dependent
modificationof
Antigen-bound
intraindividual
Vdel463
Phosphorylated
miR-142-5p
Ophthalmologic
non-epithelial
JCRB0403
pRRL2
P212fs
N870S
Smad48-/-
.ΔGRDSPA
1.05
time-to-peak-concentration
selectivity.29
KIAA1239
metastasized/advanced
fusion25,70,71
Gemzar
M023
HER27
ERBB2-overexpression
mis-incorporations
1.47
near-identified
PIP3-binding
.Pellet
N-RasWT
1,0,1
SCNAs44
.TrkAIII
hypothesis.15
1.2–287.3
maxi-preparation
mice,45
P488L
mobility–shift
Iso17q
3/11
A_51_P418375
G284R
anti-p-AKT
A74D
GTP↔GDP
11/48
FGFRs
JNK
–NRASG12V
Py-5′-
occurren
.Basically
MDA-453
5′-TGGTGCAAACTCAGATCTGC-3′
c-Cbl-/-
UtFIB
Myc–PKCζ
TLRs
unit103
Tyr572
ercc6/csb
TCAGGATTGCCTTTACCACTC
.PKCα/β
single-sample
DNMT1
II:1
FACSDiva™
Lys420
cd-T
A_51_P307840
Kirsten-ras
1965
myc-6xhis
305-307
count/50
lympho/myeloproliferative
2.74
non-germinomatous
N9-bis
BaF3
cytoplasm.1,2
PTEN-containing
T2766I
onco-metabolite
primer.A106
Alkylating
MLL.52
//uswest.ensembl.org/index.html
R399W
.NMA
G3A
1.8–3.5-fold
phenylmethylsulphonylfluoride
DKK3
Ptch+/−
Varlakhanova
TCGA-analyzed
8.6-30
types18,19
TCCTCCTCCTCCTCTCC
11–47
B682
YB-1-overexpressing
CycCH6
28–84
DMXL1
A097
75°C
ESyPred3D
Crailsheim
Gardiner-Garden
DPP7
Sadahisa
Ex11F
Nall-
15–43
c−Src−overexpressing
6myc
glutamine-leucine-glutamine
.DiI
CYP17
V804M/E805K
FRAT2
TCCSG
Ka/Ka+Ks
.Tryptase
173-fold
resistancewas
26,45,53–55,65–76
Torrent™
n+4
SW1417
Pak5
PAI2
5′-splice
P13520
thymidine-free
Q..
Lys-907
Hegde
DEFdocking
RPPH1
GlnfsX12
NM_001130145
TGFb-induced
approx65
XP_001688948
NPRL2-null
300376
adenovirus-transformed
SRC-like
20,30
fastand
Bycroft
.Intraocular
IL-
alkali
0.1014
FRET-imaging
MAP-YT
T/G-
colleagues28
types,31
uous
6910
controversial.29
term=NMC
4k
cycle–dependent
SIN3A
3799
3164
expression121
MGC-Department
G285S
miRNA54
.71G
Jangi
R618
E839K
Bengtsson
sc-6243
.Accumulating
1/132
Pazopanib
p-xylene
5.9-10.2months
//babylone.ulb.ac.be/popmusic/
35-fold
mutation-regulated
KIF5B-exon22
CTD-
//rsb.info.nih.gov/ij/
58/98
sub-cluster
protein.22
tran‑
.A-T
E928fs27*
Six-weekold
FSTL5-wild-type
.Active
Pms1p
glutaredoxin
GM-CSF-induced
www.hgmd.org
2.651
78–83
GRHL2-RSPO2
KIAA0022
culture.To
Nontargeting
BRD4-
weredetected
ZNF198-FGFR1
0.5°C
TIR
MrBayes
rs1968011
28/CRC
R1-ES
t=15.5–18.5
C40G
tumorspheres
11-181
BM029
Rat-src
FIM/ZNF198-FGFR1
cancers30
14-21
EUFA397
.Carr
2QW
Cai-Hua
Lan5
E275fsdelGAAG
stabilityFull
c.1798G.A
P92P
pE3-la
MDS.25
2.3–5.9
K1980
PAAD
imatinib/sunitinib
transcriptionltranslation
5′-GTTCCTTGTGGAGCCGGAGC-3′
WT-Flt3-KD
KBTBD13
TSU-PR1
gene.The
E196K
HTT
gain-of
Graubert
Matsukura
D898
Cejka
.Therein
1.88
Krystek
pY1356
colleagues7
members.4
Reolysin
LS-SHP2-Flag
46The
YFP-BRCA1-positive
RAS/PI3K/AKT
F=
-AAACTCCAGGGTGGTGTAGG-3
E987D
8.8:1
Trp437
c′
535kb
pcDNA3-DEST-CBL
avvvvaa
suppressor38
Thecellular
7/31/97
MAML3cDNA
parallelepiped
Brca1S1598F
Nco
28–87
.Retrovirus-containing
PF00299084.51
Sma-
culturesMCF10A
.S310F/Y
partement
49.5
Frohnauer
Fkbp1a
32·8–77·8
proto-oncogene.Effector
40-μm
c.1040C
semicon¯uent
E3α
lymphocytes,40
analyzed70
mutants.12
PML-RARα52,53,54
WSS
andSac
0.109‡
/2LQH
78M
S838
inhibitors,50
K12R
Tyr625
MKLP1
A_51_P445562NM_145142
PDGFRα-driven
Tyr537Asn
taxane-based
wild-type/p30
3941
.Splice-site
Mitin
network-based
sarcoma–specific
299,00161
S323G
arrowAla
MutSig2CV
0.00029
melanoma.35–37
MLL-MLLT6/AF17
V742A
amelanotic/oligomelanotic
KRAS-A
p21-derived
ElonginC/ElonginB
Murata
inositol-3
Dana-Farber/Brigham
population1
G–conjugated
IKKβ-null
.Tyr35
K5.CrePR1/Smad2f/f
caspase-8–induced
6/307
BF1
tubulare
cases17
L132P
.SQ-19
-1.3
R1217K
4546
25–30
www.hgvs.org
SF1/BBP
M351V
chromosome–positive
EGFR/
Pflüger
chromatin-Smad
gtttcttgctgtatgtttggtatttatctgttc
hyperdiploid
p.Arg531Gln
c.1168C
hyper-activate
bp-barcodes
Corazza
uiuo
bioanalyzer
M254V
​and3B3B
LC/ESI-MS/MS
MLH1and
Tevelev
containingPAX8
P=0.0092
plasma-cell
domains.38
4q32–35
KDM2B.16,17
LY
1640–diluted
31/48.4
/pre-B-cell
.PHEO
Two-day
1704
reverse-B
1/58
c.-133C
N1055
Gomez-Gonzalez
R416X
Hypoxia-inducible
TGG-3′
1.12∼1.51
condi
.Immunoblotting-Infected
MLL-Fusion
SJNB6
cholangiociliopathy
.Mgat5
1.76
5′-CAGTACAGCCCCAAAATGGT-3′
dasatinib-induced
TCF/Lef‐1
541
K596E
T14
Events…
2.37´105
Mouse-type
144/279
E510K
Hörnberg
man.89
CTC-246B18
LipofectAMINE
BCR-signaling
EBV-specific
approach24
Y532C
cal×mol−1×K−1
SH3GL1
series.2,3
-irrelevant
14b
EWSR1-negative
arrowAAA
micro-satellite
K558N
01127
OTKA
pCR259-p53MT
​Among
anti-NTRK3
occur.18
Flt3−lin−Sca-1−c-kit+CD34+CD16/32+
FCGRIIB
23-90
CULLIN
OB2
ESEfinder,35
KIT-N822I–expressing
3030
p.Met1652Ile
T391A
PIK3CA14
5V-cctcccactcctgaccctgtct-3V
TGCAACACCGAGCGGAGGAGGCAGGAACCGGAGC
moderately-
al,1990
R766G
Irby
achieved.View
before.7
lymph/distant
Gli1ZF-K340A
21/31
1621G3A
TTCCAG/gtaaat
PML1
leukemia.18
A/c.1461C
BRAF-inhibited
L17
MPM,10
tumorigenic16
Discriminating
signalling16
51.95
3311–3317
hMutSα-bound
PgrCre/+
Gly75
cost/efficacy
10ng
intermittently
Arginine-903
T2NxM0
32,779,983
thalamic/brainstem
3γ
p=0.06
cilliary
n=470
4,191/3,780
10-mL
Northern-blot
hepatocytes38,39
divergent
.Malignant
70,289
AJ532609B
13C-ILV-methyl
Priolo
Ala-23
pre-existing
image-plate
Duronio
CD10–
KRASG12C-GDP
vitro–translated
ssODN
CBFβ-contacting
pyerene
Osorio
BsuRI
106K
Bionick
ver5.0
NTRK1S677N
.Ninety-five
catcaccggtacctcctact
9.49
assessment.16
G1157S
RET-MEN2B
nucleus-to-cytoplasm
D1Δ-138
U.
c3018C
BAF53a
'75
downstreamexpression
asymptomatic/smoldering
mutation,24
transposon-based
Azoxymethane-Induced
gene-engineered
86-
1947
Y1136
pyridone-containing
V533A
NCOA2-ETV6
nihms703640f9
niche13,14
G262D
hydroxylases—the
LTQ-FT
Akt2−/−
H-rasG12V-R128A
28:999–1005
5′-AAACAAAGGAAGCCACTGGA-3′
LightCycler-based
p110α-CAAX–
hindlimb
oculofacicocardiodental
quasi–wild-type
21,40,41
1.35–15.42
SECURIN
α32P-dATP
E655K
p.Thr597Serc
A71T
leftward
Ras–Raf1–MEK1–ERK
coworkers.16
Akoulitchev
piecemeal
PSN1
cDNAclones
NMP
HTLV-I–associated
h.Abnormal
GDC-0449-
MUM/IRF4
Mettouchi
yˆ
R139T
Gly1123-His1124
∼55
.KLHL9
cBio-portal
,6B
VWFD
Tropomyosin-related
5-GTCAAGTCGTGGTGGCACC-3
trade-off
'N
larly
c.439C
70–90
inhibitor13
PDGF-D-specific
nonresponder
since'serine
NAIIRS
Q608H
anddominant
dERG
Y823C
introducedby
Servicio
XBridge
non-CpG
Long-tail
.Bacteria
lymphoma.5,6
Lineberger
CT-3
pRSET-His6
microtubules
P1358L
PKD2
PBS-0,2
Gln-63
systems121,122
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F1.large.jpg
Fig.3C,3C
236
191KB
×10−6
domain.6
SLC–ROS–S
FIP1L1-PDGFRalpha-expressing
period–
F691I
C-16
Brca1Tr/Tr/p53+/-
post-imatinib
Co-localizes
pretransplant
His296
M56
138270.2
sc-5595
FLUOS
Slide™
lymphomas.7
11c
.5e
CRC104
Cre-ER
7.05
R335P
Passegue
246166x35315
V1833
7,256
sc-640
Immunolabeled
5-mum
FGFR2-H5F1
λgt11
c.38_40ATG
BTK-KD-Y551E/Dasatinib
Lennox–Gastaut
G719/S768
cotargets
–17
6.9-
fkh
217568
c.1797_1798insGAGACTACA
5.1-kb
MDM2/CDK4
2q11.2
SAE1
14/212
13,20,21
MCAO
tumour-xenograft
proto-oncogene-coded
S2A-C
.MDA-MB-175
13q32–
IRB-519
hemangioblastoma-like
hypodiploidy
MALME-3M
.LSCC
sc-73614
.Ligand-mediated
product-based
Arg-278
Rompaey
mycophenolic
~3Å
FNiii
1−7.1CDACytidine
GE2
90.3
pLKO-Tet-on
*This
FTC-like
D842V-Ba/F3
Laëmmli
nonsmall‐cell
CACGTCCCCATATTGCCTAT
DL1
interaction17
FGFR1OP–RET
116,415,300
CD3/TCRαβhigh
c.582del25
.Pathologically
EpiDesigner
LC3B-positive
Edsjo
p53flex7
dpm/pmol
I986
0.18-0.11
K/μL3
spectrometry-based
PTP-loop
cases1,2,3,4
-CD4
MTA1
//mcb
Histoserv
translocation-
plf/plf
R1066H
Lipofectin®
LB/ampicillin
.Deep
extraterminal
5′-ACAGCATCAAATCATCCATTGC-3′
.587G
–12
R05185426
CD4lowCD8+
DLBLC
JAK2.Figure
prognosisThe
reactionvolume
9.83
1125
MSI-L/1–3
8.4/50
.ARID2
GAAAGGGCTGTAGGGGCGACTGT
theBamHI
Berghoff
rtTA.PIK3CA
regions63
12/2014
SK-LU
aretranscriptionally
Lepri
.1277
Angus-Hill
Ga68
FGFR11
7-nR
18,23
Krimpenfort
37–34°C
structures.Figure
•.c
β-catenin/TCF-4-dependent
Alcam
ARRY-470
19/30
22-h
IRBs/IECs
polymerases146
.Triangle
RAD18
AsCNAR
−3.6
NFkB2-ROS1
HLA-G
trp1D1
311.266
NA/NAIC25
RF/J
HumanSplicingFinder29
.Strabismus
C217
Ppp2r5d
Notch/RBP-J
MSH4
cancer29
24–72
Oct-4
0.188
C217-C295
P.H835L
9549N
p.Gly857Asp
Treatment*
MSH6-p.P1087R
p27-
polynucleotide
LPD
IL6-stimulation
doublecortin-positive
-_w
Pod-Cre/Arntflox/flox
S1715R
3759
E120X
model.53
Kirkin
c.2428A
dynein-binding
Sivachenko
MITF-specific
5′-GTTTTGGGTAYGTTGTAGATTA-3′
serine-to-tyrosine
Ppm1d
NPM–ALK-induced
/Lag1
AF070674
tetramer10
Kit-expressing
4.72
7AAD
pcDNA-
analysis25
0–28
reportersThe
less-condensed
lelysAr9Ar9Aspl
contact-mediated
FLT3-TK
.were
γ-Secretase
ccRCC-specific
cancers.30
SAR-induced
EML4-ALK-positive
SRC-family
assays.MSH3
anti-STAT
non-malignant
n=0/13
T41I
45/43
MutSα
stromelysin
c.6633_6637del5
.Domains
.Luo
MAP3K1
APC/β-catenin
0.315
KIAA1797
H3K27-monomethyl
RPKM-normalized
.RAC1WT
heteomeric
MN19
c_rasH
2P–R
39-0264488362
Transsynaptic
F712Sa
studies76–78
N298S
IC138
kcal/Å2
c-Rel
mus81
//insertion.stanford.edu/melt.html
0.0855
NP_005364
anti-ERα
heterozygous16
.S9A
Rho-GDI
.Atto488-labeled
immunosuppressive
5′-TGCTGGGCTTCACTTGAGAGGAACTGC-3′
‐
91.23
HA4
1/3–1/2
0.441±0.24
Bond-Max
NKG2D
J64T
ROSA26R-lacZ
MSH6-germline-mutation
MED12-expressing
TTCCCAGTTTCGCCTTTAACC
Bibel
UPD11q
ADORA2
neuro-blastoma
L-II-18
TFRC-1
haploinsuf
mid-gestation
Ras•GTP-independent
FLJ14299
.Bioanalysis
ABC-DLBCLs.11
Sanger⁎
library-specific
DIC
capacity.31
++/+−
PRP19
SF2/ASF
biomarker-positive
0-67
156/416
promoter-CpG
Fatho
p3xFLAG-CMV-wild-type-CHK2
respectively.20,23–25
Ca2+
83-bp
samplesTable
www.epilepsyfoundation.org
cancers7–13
GACCAG/gtatag
backgroundwere
R128C
7J–L
.517
Bollo
preoperatively
≈90
GGT→GaT
pathways.30
pNKYlO0
nterference
Raf-MAPK
XPLN/ARHGEF3
data.Unlike
G-50
.Yeastgrown
NM_206956
pimasertib
11–12
events—have
3-kinase/v-akt
LMTK2
degradation,19
D524V
Y1349F
laboratory.13
FLAG–Fbw7
APL-like
2011.1
2ÃŸ
H-RasK117C
21079
FANCG,28
p.P536P
SH-2038
BCR-ABL1–like
2mg
AL-118
Y32W-Ha-ras-p21
Mehenni
LHX8
1/28
E1021K
NIK,25
Bcl3
HER‐2/HER‐3
C׳׳
Igf1r+/+
D-2-HG
5′-CCATATCAATGCCTGGGTCAGAG-3′
Phe89
306–364
PP1C-mediated
13352-4
FLI1-transfected
AEE
FLT3.E3F
p.Ala864Thr
H810
L148S
SMCY
HumanWG-6
protein-tyrosyl
non-transplanted
C57/BL
DEAE–dextran
1-22
disorder.42,43
C‑terminal
CB2
µm/h
Ezrin–Ras
Pineda-Lucena
.Impaired
GGAATCC/attctggt
XIAO-YAN
55–86
65–71
COLO704
SVF
V561D-PDGFRA-Ba
cancers6–8
p44Erkl/p42
H773_V774dupHV
p.A834T
Fc-γRII
JHH-7
SCC-90
20785-7223
.5H
S2A–E
JFCR021
200–300-fold
exomed
TRB-NOTCH1
top-two
primary-
Tyr-116
H00000558-M01
UKALLXII/ECOG2993
amplification/copy
strategyA
grandparent
p110
biotin-labelled
0.15-fold
NRAS,17,18
Tyr-219
L87M
S1981
-GGAACCCATTTGCCGACAG-3
496–1914
1323-bp
10E-2
G305W
bands.Fig
6,7,8
58.2–64.2
protease-sensitive
neurochemical
Chk1-P
5hmC-containing
E17KAKT1
FLI1-
TATA-binding
cryo-EM
Posttreatment
liver5
Pgts2
p53-like
1016
p110/p85α
all—superbinder
-R2
BCOR-3745R
aected
Cotrimoxazole
T315I-positive
p.V387L
//www.genome.jp/kegg/
p107-/-
positive.32
deletion-associated
S1–S8
Age-matched
91010
EEH
steroid-building
5.574
Pparg
+/+
2F
ACTTGCCTTAAACACTCACCTTC
A3-1
fusion-point
sequestration58
pLenti-CMV/TO-Puro
nanodisc-tethered
.K5.Smad2–/–
N348
C182/229S
p.M1
BRAF-SC
MET-Y1253D
SC-9007
GFP/YFP–coexpressing
CTB-31C16
2PWL
-DQB1
AH109
Dabrafenib-treatment
G/c.982G
known11
protein-β
.119G
neurofibroma-associated
E931G/H773L
.MultiSite
9364
NA31
235461_at
.PPP6C-H114Y
Tfx-20
Z3,30,31
2R
Cw4
−532
sequence-13
4⇓B
Scientfic
Orkney
apoptosis.29
3E
E34F
untransduced
HS_5
Smad2+/−
neoformed
FOXA1low
methology
5S
.Intervention
3922
​To
asnegative
HDAC9
GTP-RhoA
OD600nm
T259I
renal61
pre-established
1022
Consonant
WT-PKBα
S.The
ins776YVMA
transduc
populations180
conformation-insensitive
OXY-releasing
allantoicvessels
Papin
.Replacement
IC092605.1
α-CrkL
Dabrafenib-increased
models—representing
c-H2AX-positive
p.D1498N
D368N
MCF7
p270
cross-validate
wild-type/mutant
dissemination
19696
M0873
fusions,38,39
FAK/src
LDxLLxxL
1365
GGTGCGAGGG
Nexxavar
c.1673A
181.0
knowledge-based
repression.29
genes154
anti–phospho-T380
MFGR1877A—0.1
3T3-EN
RA2
RCML
Axiophot
deconjugation
.CA
K710N
.XPO1
PPP6CH114Y
204–290
phosphorylation.11
methods1,7
004936
7076
L23F-4
region12
insulinoma35
C^CGG
malignancy.30
embryogeneis
Ponceau-S
928C
dGdC
30,34
concentration-
technique.12
si08ResPPP6CPD
422–560
Toronto–Sunnybrook
P9905
Hi5
1148
Scireq
FGF3
2A2
GACAGG
C-cell
-sequencing
phosphoflow
4197
D_rerio
G3*
delineated56
SPC-driven
p27-binding
previously,15
K-RasRNA
MOL-SCRIPT
McNail
5′-TCGCCAGTCTCCCGAGC-3′
AML.18-20
biotin–avidin
YAC3
Nomenclature.20
VEGF-binding
www.bork.embl-heidelberg.de/PolyPhen
117-119
tunikamycin
c-KIT+
.Docking
anti-Notch
.Ser10
NAD-/NADH
L.S
VM-CUBI
SMO-I408V
Heterochromatin-derived
Gopalbhai
.Pairing
CL−
Treeview.46,47
mesylate.10
Dalgliesh
EMT-mediated
Etot=Tamp*∑j
D11S1819
2a–b
PTPase
mutations26,54,56
B7–1
gtaaaaatc
SMARTer™
SA25
–,61
Tm2
84-year-old
R435C
177Lutetium-DOTA-Tyr3-octreotate
cooverexpressed
TFH
costimulatory
5′-CTTGAATTCATGGACTACAAGGACGACGATGACAAGGCT-GCCATCCGGAAGAAACTGGTG-3′
02-g-associated
ab93739
BCR-ABL-dependent
66531
inJive
NVP-BKM120
Leukemia
Chr3:71050170_71050171
9.94
mutations43
codon-optimization
CtBP=0
0.0458
Colony-Formation
KPT-185/KPT-330/LMB
GppCH2p
L153R
chromatic
MLL-ENL-estrogen
MPL.34-37
Asp-351
andc
small-interfering
Co108N
YCpLG-myc-p110α
180.3
ΔN-BRCA1
nano-LC
two‐hybrid
mutations.26Assessment
p11
G857E
NC_000007
pKH165
andNSD1
leukemia,17
9050
0.182
L71fs-ter94
11•9–14•9
preimplantation
histotype-
insulinemia
C618R/E543K
exemestane
IRES-initiated
I32-9-associatedand
JMML8,9
0950-9232/12
IVSP
gene-dose
.0018*
460-
cases.Among
Doxycycline-induced
ERα-S118A
BioWhittaker
KIAA1234
binding.21
Holtgreve-Grez
1.000
.GDP-Ras
PLCL1
._464+
p.Gln426X
p.I107T
Non-small
exon8/9
VGLL3
T-cell-originated
110α
inactivalionYes
Pmsko/ko
Samuels-Lev
pigmentations
//www.ensembl.org/Homo_sapiens/
Gna11
Gnas1
v/S
SzJ
.Curve
24O10
cosmid
Hmga2,23
.Catalytic
autoinactivation
inhibitors.21
proliferation.46A
600276
minute2
pcDNA4C-LacI-CHERRY
Case-Control
.Control-infected
.Hsu
Ser424
TCGA-KN-8437-01
54/60
Savant
GSE26713
4•4–9•0
diagnosis/date
mzrock
WinList
G1645A
gi23509476
g-to-c
E7-like
q53
AML-M3variant
Deconvolved
R1
p.Asp849fsX62
D1-GST
104849448–111900000
IVS9+3delAb
sympathectomy
Y-MESO-30
chromosome62
S95I
ERL
SPOP-F125V
3'-kinase
JAK2-translocations
dimerization.13
non-haem
.R-1B
203132
I125
Hs.336697
pHCMV.VSVG
cells,10
location-dependent
Xmnl
MEK
Lys1026
number–dependent
orf73
Low=1
siah
pT308-Akt
DN2-DN3
Rendtorff
CCTGCGTTAGTTTGCT
NFIA
D1mRNA
AJ250231.1
stimulation.19
allele.12
E17K/K179M-AKT1
17α-estradiol
MØ
Figure4A4A
cytogenetics*
t1676c
transgastric
YF
F/60
GST-RalGDS
10/36
K9me3
pattern-matching
n=103
20R-CP004
Verdelli
multiplex-PCR–based
Pt55
.Tumourclassification
anti-giantin
RNL2
Br51*
glabrescens
4/48
rbf14
–positive
1.63-fold
family.PIK3CA
TTCCGCGC
His396Pro
R1881-
-MUT14
differentiation.3
G128
BDNF/TrkB
osteoradionecrosis
.ETV6-ABL2
.99
NCT01827267
del*
c.5332G
157,400
Gefitinib
MetAspGlnAsnleulysCysleuSerAl
mutation7
21322251
ion-transport
paediatrics
log-adjusted
0.005–5.0
thrombocythemia/polycythemia
'B-RAF
NM_001010915
fransactivation
gcggtgtaggagctgctg
ethanol-fixed
Notchic-CSL
Borras
G196S
HAV
S-farnesyl
MLH1-mutant
ionic/hydrogen
periventricular
13c
15.0
FAM131B
neoplasms.2
T488-P492
y.o
function5
pAS-2
adenocarcinomas,21
stacking/separating
DDR-initiated
Rbbp6
.Scanning
23/602
Arid5b
EGFP-only
thermal-cycling
CBC-RARA
coinjection
IGF1R/IRS1/EN
CCGGGCTTCCATTACGATGCACAAACTCGAGTTTGTGCATCGTAATGGAAGCTTTTT
PedigreesElsewhere
smatic
RBPMS-NTRK3
monomers.23
Megakaryoblastic
vimentin+
15:61,271,320–62,750,432
−81.5
FBW7MUT
n=139
R248Q/W
Thepatients
Dnmt3afl
.PDGFRα+/J
150mm
2,200-2,000
A209T
Ala-59-*Thr
L88
regimen.13
5′-CCTATGGAAACTACTTCCTGAAAACAA-3′
rhabomyosarcoma
Single-sample
DN-ESX
CUO28
K482M
10d–g
HA-20.2
p.G1035S
.Polyclonal
,3A
His-tag
Ras-Raf-MAP
L858R+E884K
Thrombopoietin
7/28
RG-13N
exons177
FGFR1-BCR
PHENOTYPE
nucleus-accumulated
.Temporally
.Aected
cullin-1
HA-ERK2M13L
Eed
sub-population
UT=34.6
treatment—given
Cervical-spine
triptorelin
A266_S267ins
/RaplA
fatal2,3
POZ/BTB
W515R
adaptor/signaling
LBL/ALLs
53,267,127–58,170,985
R334W
clustering.2,9
study.KIT-WT
RL95
fromTRK-T1
paraformalde
al.42
.y-32P
26-33
GAPs5
PI3K-signalling
pCMV
Loupart
mice-derived
0.45-μm
CCNA
Ptdins
4690
G−577
proline-scanning
ML-1
5'-GC-clamp-CTAGGCCTGGAATCTCCTCT-3
ICL-inducing
S240R-
AlfII/BsmI
interleukin-2
cBAS
clear-bottom
MutSα-D603N
olfactomedin
bicistronically
splice‐site
non-squamous
Rca.
5′-CATATTACCCGGGATGGGAATTGCCAAAGTGCTGGCTG-3′
.BRD4
xenotransplanted
formazoan
0.7982:1
KIT.33,34
Mac1+
pmGFP-H-rasG12V-D47A
Seton-Rogers
Lys/Asp/Asp
2WM+M2=50
45122
syndrome105
miometrium
recalculation
componentsin
V560E
tools.19
5'-AAGCTCCCCfACCATGACT-3
Enrichr
gene-informed
T1b
DPP
genes109
Y1356
endto
minidist3ss=6
EIF2C2
Enhancer®
.1m1
Sensiscript
analyzed37
place68
.SRB
constructs.5
D76A
Decapentaplegic
Thy1.21
open-closed
single-syllable
9422
PV
non-bold
His674MetfsX41
leukaemogenicity
32/41
FOXO347,48
patients,7
synchronised
GammaBind-G-Sepharose
LEU2-reporter
dose-related
mice140
tem-
agents.
DELFIA
1403
Hdmx
T4N3M1
SG102
p.Asn1215fsX3
Suizu
Besenbacher1
SOX6-BRAF
extentof
pJAK2
GBC14
DDp53
nontested
calmodulin-dependent
ERBB4
progression.13
NaVO3
thermo-melting
1-week-old
Ab-80
degree—developmental
diseases.6,10
sine-containing
tropomyosin-specific
44-mer
.MF
2.49E-06
RP11-300A10
fluorogram
familyd
profile.EGFR
1.628
D0j
399–404Shimada
VEGFR-3
kinase-
L171R
hypo­methylation
UTX/UTY
Fas/APO1/CD95
Orientation-switch
Spevak
UCAUC
SDM
.Eukaryotic
temperaturesIt
p.IIle1250Thr
phospho-binding
factors.33
unidimension
5′‐CTGAAATATTTTCTAGGAATTG
L700F
Sif
Vav-tTA–mediated
.Scans
Dasatinib-bound
Tumour-suppressor
MSH2-GTBP
364/418
HLA-A2-restricted
CRISPR/Cas9-Edited
.De-identified
E768D
2.5–10th
GFP-VHL172
JMP9
passage-dependent
0.040
ZZ-TAZ2
Sox17-GST
4·5–16·6
recoveredtwice
1.For
Xnr3
dimethoxyphenyl
partially-penetrant
repair4,30
LQ-005999-00
148-bp
ODBB
yeast–human
R158
Jag1
growth-inhibited
P124
946D14
E-Cadherin+
Montiero
5′‐CCCATTTTCCTCCCGCAATTGCTAGAAAATATTTCAGTGTC‐3′
HGU133plus2
24-28
MFS-like
.Adequate
eosin–stained
.Deciphering
Onderzoek
200mLPBS
LEDGF/CtIP
B-like
.NLS2-Ala=0.1206
MutSbound
RJI
granulocyte-monocyte
PtdIns3P
Stingl
Gudbjorg
triple-stained
RLB
​andF
38/84
JAK2.1
5642
non-tumor-derivedp53
aa1
TTCCAAGGACTTCAATGATAAGC
p10
Friedlanderet
c.843_846del4
R2857K
FauI
12,269
StatusaSK-Mel
.Radiolabelled
non-disease-causing
four-
59.7∗
growth.102
G714T
IMMU
months.3,4
W273L
6.26
0.34–1.53
RECQL4
≥0
Mun
2•5
−15q
del_G106_R108
lysine-79
'failures
RPL22
fluconazole
GABRA6
R188∗
1808delACTAC
24,364
RAB6B
113-124
0.2-1
ATCGTGCGTGACAT
ERK2-K52R
Mxi1
821-Ser
nucleotidebinding
19/27
WiT49
Ni-nitrilotriaceticacid
anti-caspase-7
.Doxycycline
down-regulators
7.5–8.5
22q13.31
V777
SW13
P655R
proteinsonly
Breast-cancer–only
140kDa
severeWishart
FGFR1/2/3
selective-pressure
OCFRE-luc
PP-1C
already-responding
Cγ1-cre
methyl-piperazine
c‑myb
v3.1–1
9,12,28,29
Greten
3/104
FHL11
C.B-17
PXSP
117.0–118.9
p110A
ATTT
mIfngr1-Reverse
Phospho-Erk1/2
cyclinE/Cdk2
98,104,105
S202F
F400I
μl/OD600
Lu¨scher
S1L
.TCGA
al,13⇓–15
Trametinib®
5-
cleavage-facilitated
182.9
allin
reference/working
M1043I
Dimethyl
GSP50
.Dnmt3b
Mid/hindbrain
Clr4
Y98C
ATG
5′-TTTCTCGAGGAGCAGCTCGTACTG-3′
α19
DELLY49
well-explained
GAL4-luciferase
t5
mutations.110
3–amino
SRF-RE
1-alpha
.FEIDKMKPGS..
PBS/Triton
CUX1-FGFR1-transformed
CSF1-R.
PMDLg/pRRE
P233T
114,113
puromycin-loxP
.GEF
CDKN2C-CDK4/6
1.07-5.60
mCcnf-Reverse
U.S.Government
Nonphosphorylated
3000cell
Cdk–cyclin
.56
Hif
HKY579
BRG1/BRM
precrizotinib
p.R2529fs
mll-3
CYVDFRE
AcL
OPB-31121
C20
103cells
depletion–induced
mitogenactivated
electrophiles
Br70*
v0.4.6.2.24
1A4
Viglietto1,2
omacetaxine
VEEINGNNYVYIDPTQLPYDHK
Lys-
12-0-tetradec-anoylphorbol
cellcontamination
seminoma-like
A3062G
rs2981579
5′-biotin-TGAGGTCGTAGATATTGCAGATCT-3′
54.78
JAK2T875N
n=29/53
FbxL1
Igfr1
c.68_69del2
anakinra
92393020-92393239
Flp-Frt
GNET
.2000.2841
AGAAUGAAGUGUACCCUAAUU
11Department
Eighty-nine
KCC
Fbxw7−/−
migrate-2
3191
NruI–XmaI
hypoharynx
Q67L
nibrin
pGL3-PD-L1p
SMO-D473K
GlaB/protein
Leiden-based
'Go
87–1965
p.N384K
S2-2
Lasota
4972
poten-
KRT5
≈1,100
fgf-
Gbx2+/Otx2–
C-terminal-binding
1.5-3.2
Cytokine-induced
eFluor®
ins38-8T
Lys-163
1A-D
anti-H3K9me2
.Lats1
ataxia-telangiectasia3
R552K
attB2r/B4
V600EB-RAF-bypass
RP11-13I6
0.45-μM
5′-CAATGGTAGTCATCCTAGAGG-3′
.BamHI-NEDD4-1F
:80
HT12v4
gPatient
~~\
Genotype-Tissue
non-SE-like
NUT-p300
AA055486
.Raw
NU-DHL-1
A252V
502AY
lymphocytes.FISH
Blazej
DRNF1
Keratin-14
NTP
11,194
single-agent
expression.34,35
p300-MLL
concentrations38
efficiency15
Meningothelial
Cαatom
S211Y
ligand-responsive
SOXCORE
doi:10.1038/nature09208
˜50
previously.32,44
059
examined.18
.Anita
ETV6-NTRK3-infected
Rac2
A8/A8
transformation-related
by-passes
PIK3CAwould
P568
N381
steroid-receptor
blood-cell
MCCT_2
35.00
intragenically
.Arbitrarily
LysGraphic
hepatocytic
'pull-down
Partek
like-1
Nrf2-WT,8
0.8-kbp
0.98-6.26
30–67
difficult-to-treat
signalling.47
BAIAP2L1
PKA
diseases33-35
.CI
Plk1.54
variants.32,34,35
HCXXGXXRS/T
N107I
K-ras+/V12-expressing
p.Arg172Met
Leu→Phe
K277R
LAHypYIP
isopropyl-β-D-thiogalactopyranoside
S1-2
mRNA.6
Y556F
1-7-5-8
A_51_P302273
DeltaGNP
c.801G4A
cdk4
T6-frozen
27,38,39
1p22.1-1p21.3
Norit-A
42/Mb
havechanges
coprecipitate
PASHA
34,529
13:1
94.8nM
6,32–34
-ATG-3
.QLQ
5.0-kb
formation.11
AR-FL/ARv7
HC-10—mAb
validated44
Tsc1/Tsc2
HuH-7/ev
.CPT
L265
2-to
papillomavirus
.PTPRT
Kotake
q42.3
Pepcb/
750/1,000/1,500
AT..
.6935A
others.20
QFQ-stained
P-Smad2
298
V179M
V1298F
domain–kinase
pGA-MTS1
10781
forty-two
emangioendothelioma
TGTAAAACGACGGCCAGTCGAAGGGTCATATCAGATTC
Galgal4
IBC/NIBC
theperipheral
right-middle
S314R
2-pyrazinyl
.Females
TGTGACTCGAG-3
PI-negative
Codeficiency
pET-AR4
,1A
BC009244
0.648
T681
=48
5'-TGTGTGTACATCTTCCCTCTG-3
CARCINOMA
TTTGCCAGGAGCGATGAAC
AnalysisVariable
.3,4
KPSS-1.3
DEVD-AMC
protein-producing
323
horse-radish
roselab.jhu.edu
Aroundplusminus50
dimethyloxalylglycine
HN-Smad4-/-
153-bp-long
IL-23
66.2
umol/L-5
:2_Il•
FBE/SBE-lux
195K
RMB8A
K1419R
nonpermeabilizing
KD-GFP
.Extrapolations
TGGCTCGTCTGTGTGTGTCA
MEK-directed
p.Gln215*
radiochemotherapy
5′‐CAACAGATCATCCCATCCAACA
microfibril
Fin13
con¢rmed
kinase-activated
Gly42Arg*
CAACT
Y-MESO
RSV-REV
796-residue
BAC
tropomysin-related
.Prophylactic
Bio-16-UTP
leukemia14,15
R739H
farnesyl
SC-3
mmol/kg
DLD1/HCT8
Martinez-Climent
Gli-luciferase-based
rep~rts.~.~~
P.G719A
Kinderspital
`conformational
CD71+CD235a+
co-chaperones
27,29,32,49
RAS–RAF–MEK–ERK–MAPK
SD.These
Positron-emission
.-S.
BRAFD594E
χ2-
-6-dependent
S3S
anthracycline/taxane-treated
D5S721
dimerization/multimerization
tetra-NRs
Figure11B
Yadavilli
12–pack-year
AGCACAAACACAGAGCAGTCTA
.Rat
0.6874
interaction.14
haematopoiesis10,11
ccg
E627D/R683K
former/current
cIAP1a
PNFs18
5'-CACACCTGGGAAAGGACCTA
.Areas
PAG608
non-mast-cell
Belohradsky
6±2
KSE-2
Klinikos
p.Glu14Ter
YYRkrGeg
predomin-
Geering
signature-positive
Gag-p110α
Figs.1111
CGATools
q22q31
C-C
lArgPh-theC
E685S
I-4
.HCC78CR3
Spry-deficient
anti-IDH2
14q13.3|
c.4544T
knownGene34
a¡ect
wu3
Küppers
hMutSα·
32-cm
p.Ala350Glu
U964
*Includes
AT–lac-derived
ArrayExpress
a2-
family-history
G4112F
Gene-specific
GAGGCGCAGACTCCCGTGCCGCAC
approx1
Ohshima
aphasia
Warthin-like
microacinar
develops.13,14
G719A/C/S
PDGFRb
18–
E050
W171X
7B–D
andcoverage
D12S366
Rsp5p
/restriction
HNF1B
IVT-35S-BRAF
FRT19A/FM7
pp60c-srcN
Hnf-4
Chesler
ETV1a
2.5.
TÃŸRI-deficient
P9904
.Uncoloured
21q22.2
104849448
www-based
mutations—C250T
1490×108
radixin
33258/UV
2–23
GCTGACTGTCGAGCCACAT-3′
36–48
pTyr905
c.1526A
M1250
UEV
antiadipogenic
Neutropaenia
K170N
non-ligand
E40K-Akt3
3,5
100,127
Flag-Smad4M
spindle/EMT
MDS/Myeloproliferative
Rosa-Stop-Luc
14,000g
gliomas,43
Bac-N-Blue
c-MYC/Max
silencing3,4
Intra-tumoral
.Multipoint
1–170
•0.25
DRAF1-ER
SAA
B.A.C
010
used.24,25
post-radiation
580G
72.8±22.6
Ga-t
XPD/ERCC2
celllines
.Inflammatory
Kettenbach
PPARD
RecQ4
Rel/NF-kappaB
thrombocythemia
Eprex
weak/minimal
RP11-586A2-GREEN
Cd8
0/32
siCONT
FPD
function.18–20
N.Mukaida
EHRC
ERBB3/CEN12
PSIC
−71SRYP
7S1325
FGFR4-knockdown
pKH348
NoE
C.Construction
DLBCL45,46
albumin/PBS
25.55
lung49
.M918T
EGFRWT
2,484
2•68
axis19
experiments.Illumina
GST-p161NK4
to1
.Split
+ArgS14
2,11
T599VKS602
myelodysplastic
twenty-seven
alleles2,14
H2B–
RCAS-PDGF
Myeloproliferation
L'Allemain
B-RafV600E/R509H/S729A
Trp+
XPF-interacting
microdeleted
.Adipogenic
DEF…
withNTRK1
anti-stathmin
specificity.34⇓⇓–37
Rapalog-based
neuroblastoma*
4457–4463
10–200
rs4553808-G
11INS574TQLPYD
.3J
Céspedes
RT-polymerase
2.386
pC53-SN3-R249S/H168R
Eh7L
9561
11,844
Q1338
Seattle.-3Japan
post-polyI/polyC
progesterone/estrogen
Lymphoepitelioma
light-controllable
G266
MC2115
Y771
1alpha–VHL
-17,18
D13.14.4E
pENTR_L5-IRES-hmAG-L2
dMutants
qualitatively
pfam
Demetriou
Density-enhanced
4/92
sequencessurrounding
CME-1
cell-negative
Scanscope
.Substitution
FractionsFibroblasts
dose-specific
5′-ATCTCAGTGGTATTTGTGAGC-3′
outcome.3–8
PHYLIP
high-chromogenic
//www.celldiv.com/content/2/1/26
RAF–MEK–MAPK
Homodimerization—To
Baseline-specific
G339C
Cy5/Cy3
differentiation15,16,17
NRASwild-type
RAD001
c.179G
diverge
0.0237
beenidentified
Lys758
nitrilotriacetic
GraphPad
Q934X
183K
Adenoviruses
Wcislo
R285Q
T308D
pSG5-FLAG-TRAP170
Icr-scid
pRBΔex4-induced
.Nrf1
Rea
80ºC
localisations
GGATTACAAGGATGACGATGACAAGGG
2.9-17.6
whole-body
peptide-protein
V579
GAPassay
pcGATA-3
c.2252C
Cajal,1
5468
EWSR1–hSNF2N
Hemodonacion
G0415
F/F
SequenceVariants
Ficz
4Ae–4Af
2036
restof
mant-nucleotide
Rami®cations
.NIN
H3K79me2
.low
10/15
Dye-Terminator
algorithm20
ChIPModule26
Figure5
non-ARF
IDH/G-CIMP+
rSPOP
T491E/S494D
CLGN
R671Q-BRAF
D3-D4
G719A/C/D/S/X
E-boxes
Tris—HCl
NKN
as-yet-to-be-defined
9.2+
IμHABCL6
ofbreast
Inpp4b
MRE11
4-fluoro-7-aminosulfonylbenzofurazan
CCGCCCATCAC-30
ChIP-chip
QT6
therapies.Our
C667Y
1:250
N-CoR/SMRT
studies.13,14
2.4
myc-RUNX1-WT
192A
predispo
R896C
oxalate-pretreated
G2645D
described.43
enzymology
NF2+/+
p.L1569X
campomelia
Seidensticker
CORL47
EN/IRS
22These
HeLa/ERE3-EBV
SacIdigested
BRCA1.61
Nonirradiated
pSG/Flag-LKB1
disseminate
.Almost
AG.V
1,102
1205
Moretta
23.33
Notch1-7
72±5
.29⇓–31
2•85
433–435Illmer
Y527FSrc-mediated
polyps.5
quizartinib7
WNT/beta-catenin
E332K
Verdu
K264
retinal-pigmented
Gualtar
otactic
Prizm
R255T
T-cell–independent
β-hairpin
tubulopathy
-140/+340
GISTs72
stagnant
36–71
CdCl2
D24Y
XP51RO
p.F595L
one-tenth
SERMs/SERDs
FLT3/NPM1
survivin
inhibitors.DiscussionThe
DLBCLs
SOXCON
E-Gel®
borax
p.Cys765Trp
cross-intolerant
cells33
immediate/early
p.Q22E
59-AAGAGAGGCATCCTCACCCT-39
POOOO
.Fordirectsequenceanalysis
vitro.14
Multidrug
mSin3‐interaction
GST-RB60
anti-Dicer
caaactcctcagaccacattg
QW
.PLX7904
.S4B
1–431
PRAS40T246
hsp104-GFP­
.None
5-year-old
512K
Deissler
ResultsMutant
0.5–10
0.888
non-cross-resistant
OP9
Myr-C124S
Nrf2-siRNA
VEGFR-31
AACAGCTATGACCATGGCTTGTGGAGCCTCTTACAC
NHEJ12
1.249
heterochromatin
C117R
ID02S514
EPE
Leu718
DNA/cDNA
ACTR
24-ID-C.
61-residue
YW327.6S2
chu-nantes.fr
AATTTCACACCTAGGTGTGAAATT
CBL1
ASP2036
-CCT
skipping.25
Glu49
BTLA+
FcγRII
G936R
glycophorin-A
EMP-1
p-53
Meso-33
P=0.732
V1232L
pre-baked
AGGCCCGCCCTGCCCACT
www.motif.genome.ad.jp
tyrosine-phosphorylate
treatment.14–16
41.8
GFPi-cRSS-mRFP
∼1.3-fold
Ollendorff
Powis
9624
GPR144
4-methylpiperazin-1-yl
.BKM-120
junction.56
Unna
KANK1
R263C+WT
ALK7
≤−2
CRT
734B
0.94-kb
staining‐based
NC_000009.11
BaF-N/A-E1210K
.Schwarz
JH1-JH2WT
Fc1-subtracted
nutlin-3a
positron-emission
8.58
82.2
.Apaf1
−0.383
4.0
ACVR1Q207D−c.a..
S2.3.1
encounted
delivery8
p.L308P
70−80
Ba/F3
PI3K-AKT-dependent
7-min
3398del5
15010102N
DDR2-transformed
Figure3D
TP539
panitumumab.3–7
22×12-millimeter
loci26
Massuger12
TTGGTATTTTTGTCCAGGAACTGAGC
FLAELCR.TDRT
BL2-AID−/−AIDER
11/41
V243L
BTG1,47
EGFR-D761N
BRAFi+MEKi+AKTi
E2f5-/-
hydroxysteroid
4DSRCT
rs121913444
1706v
S15
www.ensemblgenomes.org
G207T
context-mandated
R683S=2543A→T
V1180L
KITD816V/Y
.H98
472RU
TMPRSS2-ERG-negative
†6
Y416
thermodenaturation
PAK1-overexpressing
peptide-substrate
Syndrome18
DAXX-
CCGGGAGCTTGTCCTTTTCC
hyperacetylated
.Virol
hammerhead
3–21
therequirement
Q1756C+
5′-CGGTGAGAGACTCCACACAGCGG-3′
N-acetyltransferase
T-cellmediated
Asp-845
SF3A1
.HER2T798I
.MDM2-dependent
0.618
0−1
IPMN-derived
c-Src-interacting
Sf3b1+/700E
Apc-driven
R201H
1,795
1–24
KRASQ22K
R274A
.L6
Ser343
0.88–14.07
promoter38
IPSS-R-good
392R
19q13.42
L858R-T790M
hedgehog
/Fisher
MCCS
489
5′-CATCCTCCCCTGCATGTGT-3′
interferon-gamma-inducing
sc-55589
v54
9p-aUPD
Augmentation
S3A-C
RTW5242F
Ea11
peGFP-C1
narrow-bore
MSI-H3
0.24
theproductof
528del2
foci113
V277D
AMKL
vitro3,4
2GS2
Spillman
1.94–13.9
9.0.0
46/117
p.V50fs
IMHD843–846
D959–1030
120-140
6y
knowledge-guided
443
CSF1R26
675–850
aortocaval
1q23
Fernandes-Alnemri
EGFRI
sequenced—precisely
valvulogenesis
14-3-3β
4,457
squamous-cell
E78P/F83L
/α
MLH1-null
retMEN2B-transfected
R271K
CTB-10G5
set.1,2
R345C
Gurr®
SMN2
Monilola
amplfication
Skp1–Cul1–F-box
C8orf34–MET
5′-AGGGACAAGCAGCCGGGAGA-3′
49-51
.LBH
hydroxyglutaric
µs
FCHSD1
multiple-classifier
Tuncman
pRSETa
GSK3β-independent
BRMS1
CRISPR/Cas9-edited
24/114
1y
TCRB
alanine-containing
N1-ICS2514A
high-CpG-density
piggyBac
TEL701
4-75
D22S926
wt1-expressing
2011b
vertebrate
SNAIL1
RTKs.28
4¶,6-diamidino-2-phenylindole
report,19
methanohl:10
4LUC_A
R108
pTyr292
SGCA
CREB1/ATF1
ISWI1
154,155
ESFT.2–7
PHF1
//www-huber.embl.de/users/anders/HTSeq
h.
to5
CEP110sequences
Ornitz11
H3K4me3-methyltransferases
CA/GT
4071delC
Arg282
inter/intra-molecular
MZ2-MEL
HIP2613F
GSK110212
H–J
R4b
Ras–membrane
MEM-f/g
tolerance-immunity
Shuzo
21-basepair
Chakrabarty,1994
:252–260
1379–1394
5'-GTGGAGGTCAGAGGACAAACTT-3
KIT/CD117
100ul
Rgs2
E297G
Raf-MEK-Erk
phospho-CDC25C
EWS-related
APPβ
3.In
transwell-migration
qlZ
40185770
follow-up
pHO6T1
v1.2
186–351
Zetter
5,589
N-His6-p110δ
anti-8-catenin
Val842Ile
DCI
GM6914
lines.23
KIT816-FL
K543T
erythropoietin-dependent
preleukemia
BRCT-p53
tations
.WTS
assembly.18
LFA-1
Korpershoek
80mg/kg
cross-link–induced
1N3K
Andrejauskas-Buchdunger
//www.rnai.co.jp/e_index.html
.Brown-purple
Cytochemical
MYC-Nick
3G5D
M82814
CBM
VAV1-RAC1-RHOA-ROCK-PTEN-PI3K-AKT
FLT3-JM
Naphthyridine
27.15/100.000
RelA48
700
HER2T798Mexpressing
OP46
Ser1981
3D.ACAT
BGJ
5'-CTGGATGCTCTCCCGGATGC-3
QKSFR
.\F
Total-cell
fuor
hemihypertrophy
mutationally-targeted
Cho4
aggressiveness
VeraTag
MCF-7-shRNA
cases37
0.0345
4750
D448
3.3-diaminobenzidine
pylori
Enzler
recombinantDNA
samples2
man-
FIP1L1–PDGFR-A
pifithrin-alpha
5.5.4
.Echocardiographic
e013
36–42
Gg5.9kbΔAGAAAR-LacZ
5′-GCAGGTCTTGCAACGTG
SDS-eluate
Figure.1
msh2-GD693-VD862
cOlaHsd-Fox1nu
EudraCT
CACO2
NAb
AP180
p-Smad3
staining.21
A883F
phenotypein
ibrutinib-induced
S−100
guration
Foa-sensitive
transposable-like
fluorophosphates
BPS
STAT5pathways
13/23
ICC3
inhalation
hs-miR-3127-5p
.6F
details.Binding
cetylpyridinium
1-5
1557–1560
RAR-a
.Biotinylated
myeloblastic/promyelocytic
7×
p.L443F
D2S155
AML.9
30–34
DNA-Damage
Prochownik
zur
KIAA0020
SKP1/FBP
.Pusch
Thr-183
0.61–1.01
Analysis—Transfections
T187A-T198G
K8+
pre-emptive
exposure1,3–5
CRL1435
PupaSuite
cosegregates
11384
Hetzer
KD1072
Senapati
341X
14725
pRETY905
SMC-specific
rs28929495
B/II-1
L253P
myristoylation/palmitoylation
1.57
hematopoietic-related
c.1636C
pan-phosphatase
KI4
0.954
VEGFR1/VEGFR2
CCCAGTAATGGAATGAAGGTAATATTGATAAGC
normal-matched
23–24
T479P
viral–cellular
Krude
intracutaneous
ZNF519
years.Next
Investigac¸a˜o
al,27
G537W
0.73/035
SFA6a
autoinhibitor
Cre/loxP-mediated
Prex1
1–Fusion
posteuthanasia
oxidant-induced
2,509
W308
anti-SUZ12
S451F
F203L
.Plasminogen
M294K
foxmail.com
aicted
flowcytometric
G294A
cetuximab/panitumumab
criteria,25
.Msh2
H-CyVAD
7.9/420
ARAF-depleted
Ligand/Mg2+
A1226
pSmads
RHFDpTYLIRR
5′-GCGGGCAGTGTGTATTGTGGCATCCTCAGC-3′
ira1
stepcould
300×
149.00KB
6/17
B*4423N-bearing
S127A
Tyr-719
EGFR-dependent
NSCLC.14-28
5′-GGAACAAGAGCAAGACGATGG-3′
S1A–E
6-8
Rad51-containing
thymidine/aphidicolin
Jay2
Telethon
TÃŸR-Iproteins
LN-382T
Shigemitsu
tumours163
.RNAs
Fbw7+/−
19/91
13,34,35
c.170C4T
phosphopeptide-mediated
.DP103
0.067–0.184
1.09-35.67
V617F–positive
Knock-in
Myr-Akt-K179M
clathrin-mediated
N549T
Presenilin
TCGA-BT-A0YX
Ultraviolet-dependent
291WI
gene.1,38
pOP-PDGFRA-Ires-RFP-Puro
.Etoposide
KIAA1549-BRAF–mediated
μl/plate
0.8–0.9
T-30
ω-loop
destinations64
.Bam1a
common.49
G6′
plates.Plates
.Shaffer
P1614S-U
4934
overall/specific
DsRed-Monomer-C
44/186
Celltiter
JAK-STAT3
02114
anti-pErk1/2
curve—especially
supraclavicular
40–60-fold
FigA
previously,34
ABD/RBD
needle-dissected
.1295C4G
24:5982-6002
Platzer
A.E
.Anti–panendothelial
co-existence
for20
n=1590
TR-1004
HCl
RP11–239A17
ENNpGrpPptLqENIqMAaEIAdGMaYLnAkkFVHRDLAaRNCNVA
11-deoxycorticosterone
PRC2,13
approach34
SSXS
.Histologies
R236C
reextracted
E-box-dependent
Treatment-related
0/23
TrkA-inducible
-GAC
erythroid-2
anti-Ago2
5,541
sc2004
progression-survival
Withrespect
re-immune-precipitated
translocation-activated
nihms703640f12
Trans-IT
MYC176
anti-B55α
nonprostate
Sap-2
formation,20
c.1961C4T
Delahunt
cases.6,7
35-cycle
102
sulfamethoxazole
induced-BFB
frequenfly
G1123D
exemplify
RAS-
.Heterogeneity
.lower
.ARID1A-deficient
fungating
Srsf2P95H/wild-type
MiSeq
Identifiler™
immuno-precipitation
lacproAB
JAW-STAT3ISTATS
oncogenicity.5
pituitary-testicular
p.Y1655X
residueslocated
330
Toretsky
byLivingstone
CAAAAAGTTTATTCCGGAAACTAGTTCTCTTGAAACTAGTTTCCGGAATAAAC
Cross-contamination
IRA2products
mice29
Nibourel
prod-
-2α
Jade-1sh2
factor-kappaB-dependent
1103_1522del
activ-
v-Abl-transformed
R191H
Cd14
M17254
OP1
g/day
P-cadherin
precipitous
13,14,53–55
p=1.0
0.024–0.111
NovoCastra
PRODRG
EHV-2
1-14
.MAPP
p.G322D
1250C
seq_submit2.html
5.5**
Tyr-783
proteins.TOP1
F99S
DJAK
1NVU
VPTVF
blue=low
467-469
EML4–ALKF1174L
p.T241P
12/21
5′-CGTCATGGAGGCCAGCATAT-3′
UV-induced
p19Arf
malignancies.2–5
cell-cycle
NM000251.1
software.html
α-thalassemia
UPF38
62ºC
//www.1000genomes.org/
KIBRA
Ea‡/R
chaperonin-bound
TCGA-D8-A1JH
R132H-expressing
.Smoking-related
Gja1
FGF-independent
RSeQC
Youngburg
quality-hybridizations
1.0c
Y694/Y699
NPo
20Department
co-transcribed
Z-lyteTM
0.903‡
KIT-mutated
gtgagttgg
resistance.33,34
Autophosphorylated
Nei
diploidy
described.2,4
kit39
Δ229
transition/periurethral
Raedle
transmis-
c.81-12delC
a-h
1.4∗
BR64
Hs00229805_m1
p11.2
trait,9
genes—MLH1
ODP50-10E
SA-β-gal-positive
PDGF27
RCB1130
crosslinked
pBabePuro-ras
removal.23
L348X
.Fig.6B,6B
H3K27me3/H3K4me3
SW1710
moiety41
Mediate
Ser35
F830
hom3
0.34-0.58
R283H
melanomas.10
streptavidin-linked
CalBiochem
CBFB/MYH11
59-TTGTTGAGGGCAGGGGAGT-39
Seeberger
carcinogenic
FasIII-positive
Myc–Max‐
density13
pEAA306
protein/abelson
FRAP1
0.584
Mac1/Gr1
30.86x
-FK-FRK
domain.29
pathway49
Fig.Notably
high-detergent
cc-13-834-g2
pET-21d
anti-ATM
S5F–S5H
CCSP/Ki-rasG12C
YQ
Fii-
TCGCTCAGACACCATGGGGAAG
ETV1
pAof
meduniwien.ac.at
median=44.4
12,689
0–120
3d
Sebolt-Leopold
pET17b
prog-nostic
ACATAATATCTTGAAAGGTTCCC
G466E
Lys581
|1|
GACTAAGTAGTCTGATCC
.Expressionof
G776insV_G/L
or5
+1558
Syp
CCTGCTGGGGCTTGATCAG
p.W76X
Loucy
cardio‐facio‐cutaneous
effectiveness76
FLT3D835Y
satisfactorily
well-affecting/unaffecting
5′-GCATGTACCTAAACATAGC-3′
20–64
previously.18,22⇓⇓⇓–26
138–329
5/707
compassionate
pEFHA/Plink.6
.PAX5-ETV6
.Lowess
0802655105
conceptualized
IFAR7
Hrs-HA
contexts.ConclusionIn
NRF-2011-355-E00015
.Need
R279H
.Summarizing
N353LT
NeoR
phospho-Y1062RET
anti-Thy1.2–
hyper-activated
613-347-
n=254
≥3.48
C118Y
BRCA1/16
DR105
RP11-390K5
817
RAS-transformed
TET2-DNA
R647K
1.5‐fold
3,5-diethoxycarbonyl-1,4-dihydrocollidin
XXXVIb
c.2218-2A
PDGF-B-inhibiting
c.3228_3229delAG
light-density
1ttM
∗∗P
Neo2.1
HEMG-0
VBC
nigricans
V66G
mutationsobtained
MutSα-E749K
SNU449
−2.28
HA‐tagged
followed.32
pBabe-puror-Cre
Leu197
activated58
anti-Sox17
1519
K-ras4B
0.044*
FK
med.unimuenchen.de
panitumumab—are
infemale
TGF-β1–treated
EpiExplorer
Herriot
colleagues105
KrasLSL-G12D/+
Cre-encoding
MPD-initiating
II-1
eson
Zwijndrecht
FIG-ROS
tumors95
Charbonnier
Mazzocca
Meyskens
Valine599Arginine
Cremoux
red-α-rabbit
TIS11d
dialysis
myc/DDK
wild-typeU2AF35-transduced
γH2A.X
protein-damaging
31/54
Smad4-knockout
hyperresponsive
Amppos
Gln538
NCT0114286
LOC339321
0.828–0.965
1.224–2.990
anti-Shc
U373MB
.Flutamide
CD11b−F4/80+
2-year
A/G-conjugated
3T3-equivalent
.2B2B
four-month
P.T
Brca1I26A
.Implications
S720
Boureux
Ahronowitz
p.Gln19X
R69
M323I
Kuroki
Stratmann
detectionlevel
showage-dependent
Cre-2
212–335
CD18
212234_at
119.86
17-42
105-bp
A.29
3376–3377insTb
Jak2-deficient
Ubiquitin-dependent
-terminal
NEC/NTM
H115Y
178-bp
Constructs—The
Viewer47
c.9345+2T
Kirsner
p.E364X
mutant,76,77
embryo.Figure
1,339
1,4,5-trisphosphate
E1038Gb
RSEM
U32645
pleotropic
NK-
.37,38
q14.3
2-wk-old
ERE-driven
UPMM1-4
A2058
TEL.E4F
.InStat3
NZM5
OF5
Antip21
2-color
phenotypes95
T1095
agents141
TotalLab
−43
I-CD8
H405Y
reported10,17,19
Bergom
tccctgttcgcattcaacct
aNumber
120KDa
5-cycle
DDR2–Cbl-b
LNCaP104
sc-170
xenograft.7,116
17.6
2464
201.5
nL/min
D595
-His
liver.34
2876
0·090
.RB
•Directs
cysteine-histidine-rich
Cullin2
Brg1-dependent
pre-amplification
ProtScale
LMWPTPs
71186
G82E
JIMT-1
DIMSCAN
Bohinski
Mircovic
Hematoxilin/eosin
.FTIs
l-J
BRAF-encoded
metachondromatosis
pMK.KO–neo
H137L
V600EK
therapuetic
mobilization1
ditis
P1B5
69-Mb
Grade-3
Rbx1/ROC1
P551_V555del
early-acting
LEV
1.7kb
5'agctcagtgaccccggcat
Leu82
K.P
~J
/ERK
cancers.2
c.745C
.3712
L95F
C-reactive
Dagupta
0/119
.Teleost
ETP
12833
TTTTTTTTCAAGGGATAATAAA
radiotherapy132
C5242A/GCG-
GFP-GW182
RNA-decay
dounce
μg/100
interactively
44F
tyrosinated
RHSP4
transactivation-induced
withprobes
PPM1H
p-PRAS40
paucity
I1766S
Ag104
ActFGFR1
116–118
ΔΔH‡
HRPACKIP
04-399
OCUT-1
28–36
1151X
Nestin+
activity109
Satb1
Ectopically
NST
P186L
MDM2-RT
flat-bottom
BCR-ABL–driven
restenosis
Tsukimoto
low-hanging
7q21-qter
H1299/p53
germline-inactivating
20–35
backgrounds.9
Cdk2-independent
Olatubosun
repressors/corepressors
94.8
electroporesis
intratesticular
30295
K1150
'malignant
involute
FLAG/His8
Aggrecan
Yasuji
MAP2K3
HTB44
.Calculations
41–72
Amagasaki
Lys650Glu
67.43–67.79
E305
ti-pTyr
D31A/D35A
maturation,6
KLHL4
RP11–638I2
58Amplified
width2/2
1.785
Itzykson
D488
c.2617–3C
mMimidazole
REFMAC525
c.7976
Odyssey®
pCE136
orally/day
Nonassessable
D1280V
doi:10.1006/excr.2000.5130
Walker-A
Obstétrique
year5
C22
p13p24
membrane-specific
p27−/−
N-hydroxy-succinimide
T1845P
p.Thr41Ile
GISTIC2.0
anti-pY31-paxillin
degron
.0006
GS-domain20
Germany.27
alterations.19,20
SALIGN
.Homologous
TP53-induced
symphalangism
I-IIIA
Pro-458
reported.90
TTCTCAGGACTCCTACAGGA
4/101
mCPRC
WZ4002/CI-1040
ERG-TLS/FUSchimeric
guanidinium/phenol/chloroform
c.625C
270.1
fusion–bearing
Schmidt-Kittler
cholangiocellular
granulocyte/macrophage/erythroid/megakaryocyte
p.Glu636fs
neuroradiologic
plasms
Pro29
NHA9/Meis1a
=0.04
.Phe12
MYCC/MYCN
Mu¨ller
K7
miR-23
Buchkovich
TTACATTATGAAAGTCACAGG
//www.geneontology.org
non-TAGs
S66W
Oligomers
cases.Analysis
DCUN1D1-amplified
Penisi
dichlorofluorescein
NCI-H2170
TGTAAAACGACGGCCAGTGTTTATGAAACTGTTACTACC
gluta-
necroptosis
phospho-ERK/total-ERK
atrophy
isotype-selective
described37,59–60a
3LCS
beta2
anti-hypertensive
downregulation125
Smad2C-induced
6Db–6Dc
L656F
5216
≥15
11,741
Twelve-thirteen
hypercapnia
16/140
type-16
.Extra-cerebellar
GSK3beta
compressibility
WM3482
350-480
delP449-L455
.DES
X-lOO/sodiumcitrate
PIK3CAH1047R-expressing
EGFR-NSCLC
13B3/2C6
D/N
CPS
keratocanthomas
c.4964C
99.9
K56N
CitriSolv™
FIP1L1-PDGFRA-expressing
.HNSCC
GPX
3.40
11147
phenotypes—from
p.Arg321His
IL-1RAPL7
EGFR–mTORC1
001089
.M-Ras·GTP
estrogen-response
10a-10b-
hypereosinophilic
DEL/DEL+PM
GrA
β-catenin.31
NM_005188.3
RQM-PCR
KB1P8
vismodegib-binding
chr12:11905459G
deacetylase
intervention.41⇓⇓–44
V259D
super-cluster
•uH
PYGM
Nbr
.Adherent
Chipperfield
.DNMT3L
Y764C
H6-
bConservation
5′-CACTGGCACGTCCAGACCC-3′
Genemarker
pfg143T
TCC97-7
anti-Bax
K292I
dissociationd
CTGTGGGCATGTTGGTGAA
S3A/B
group-specific
0/33
111.2
EA4340
signal-regulated
subconfluency
non-Silent
BE3
cancer,15,16
17q21–q22
9577
TGF3
DAXXor
LevelsNF1
online6
SimpleChIP
Thr286
nontruncating
cytokine-triggered
trans-activate
Charged-to-alanine
leukaemia-associated
variants.34
Duchek
12/6/05
cytomorphogenesis
β-glycerol
gag/pol
HIF1α/ARNT
J-Y
932
.TRiC
LCA
Proline
Tet2+/+t
tumor.74
pMll-loxP-hygro
A203P
0.43–1.38
_.
Baldia
2139
−imatinib/+imatinib
KIT/beta-ACTIN
melanoma.8
Subgroup-specific
GFP-RAC1WT
CD15
monosaccharides
S2N
5′-CCGAAGAGGCCACAACACTT-3′
pSRa
R1881—a
99-1203B
2.62–13.8
4,6-diaminido-2-phenylindole
prenyl
Rinse
OncoMap
hPMS134
-CAAAAACTTCAGCCGTTACGCTCGGTCTCTTGAACCGAGCGTAACGGCTGAAG
NK/myeloid
SMARCAD1
82/224
transformation.8
CDK4-MUT13
ofdouble-stranded32P-labelled
W53
DLL4
Glu-659-Met-
J.Settleman
SMAD4/Smad4
16.18
P50.005
S345Q
NRAS-activating
3,79–82
allele,13
DOX-inducible
Ultrastructurally
pGEX-RhoA
TurboFectin
34/101
4H12
Llorca
5′-ATCCATCAGGGCACGGTAGAAGTT-3′
⩾24
NHEMs
-anti-mouse
substantiated.The
Polymicrogyria
selective-inhibitor
5-amino
56kb
486D
MPL-W515
ENST00000492236
JM-PMs
CHA
4,31,35
sporadic11
N-QKGKPRDLELPLSPSL-C
0.000491
ÃŸ-cateninat
c5957–6022
RRID
MKPs
FGF15
temperature-sensitivity
A52S
16pll
PCRT3.The
MDS1
gainb
CDC4/FBW7-mediated
SJRB001-4
G4450A
mutation–carrying
XPO1-inhibitor-resistant
1/0
¶No
lactis
M.SssI-treated
Luºcke
Hadiji
GISTs.82
CrafD486A/D486A
proliferationTo
KIT-negative
.Complexes
72Â°C.Ten
E118
3.312
0449–resistant
CBL.15
IVM
FireLUT
RP11-28A9
.S14B
FCM
3-labeled
gliomas.5–7
antiSTAT1
B.J.S
al.5
Kinetworks™
thyroxine
TGF-βR2KD
preequilibrated
lymphoblastic
K382E
08
phRG-TK
HP1a
disease-initiating
pECFP-C1
RHEB—co-purified
Tcl1
0.001649–0.004376
Pak3
Liberzon
signaling.14
K603
A492/A492control
5'-cttcaccgagtttgaggccggggccctc-3
F-6
CASC5
BCL-xL-dependent
initial-above
E220K
L861
dUTP-X
ROS1S1986Y/F
IVS10a-32T
Moyhuddin
S287N
GRch37/hg19
ROBO2
GS-activity
previously.13,18,25
F/31
wriggle
TTGCCACATTCTGCACAGACGTGG
/FOPFLASH
193–543
5′-GGACATCCATCCGCTGTAGC-3′
.SF1
AD-FANCL
prolines
tumor-suppressing
0.0453
carinii
//confluence.broadinstitute.org/display/CGATools/MuTect
Liboi
TTTC-30
RHOA-related
DRP
PML
backbone-linked
4-tier
lapatinib
707.5
T55A
G44A
6TG-resistant
27,360
Roguev
erlotininb
1.48-7.20
2−12.0PTPRZ1Protein
1,005
hydroxylates
HEAT-repeat
CATTTAGGATGTGGAGATGAGC
p42/p44
250C
tetracycline-responsive
345-
VEGFA-positive
infra-limbic
572–578
E131K
pVHLS65A·HIF-1α
MAC-2A
telomeres21
M2345V
post-zygotically
polyubiquitinated
5′-tgaagcaaattgcccaagac
binding.9
imatinib-insensitive
2023
5+
presentation.4
5'-ATATCGGTCATTGGGTGAGTT-3
Machado-Salas
MIllipore
Val804Gly
trans~tion
doi:10.1038/ng.2950
5′-CAGTTGATCTGTGGGCACGTTGGTGAAGG-3′
P.G719Aa
pone.0064364.e009.jpg
R2228Q
38429
8.16
variants.The
Q1580H
EC4-5
repair24
ARΔLBD
Criocut
GSP781–783ins
cause-effect
Myc-PDGFR
5′-CCAGGAACGTACTGGTGAAA-3′
Velusamy
APC-free
.Reads
p53.We
apical–basal
intrathecally
castration-
2574
CytoSelect
39CRC
DRIP/TRAP-Mediator
Jak2-V617F
Q934Xc
1.266
Ig-MYC
M/29
PDGFRα-expressing
quadruple-technical
e9.1
KRASG12D-initiated
2,700
Del2485-2493
56774057
model16.To
carboxylcytosine
AKT,25
OntarioChem
3T3-T/P
.3670C
fortumor
MPM,69
5′-agcactgttcttggcacatg
anti-MEK
0.013c
K839E
JEG3
CDKN2A,14
G-2
R385C
pRc-CMV
half-functional
Populo
p21/Cip1/Waf1
1q22
JAK3A572V
exact-test
erbB1
10ug
γ-Tubilin
110-kd
Na-Pi
BWCC
TIP3
activity.13
controls,53
retroviral-expressing
80,698,679–80,848,640
2233-2235
E41K
cofinanced
genes.20-22
1.4‐fold
FAM150B
SmaI/SacI
−6.51
P49
phosphosite
ø2
BSTTs
28-166
56770036
423-449
30.74
EJC–mRNA
Mel-18
BRAF,16
.932delC
59-GTCTTTAATCTGTCCAATTTCC-39
/NEU
p.Gly12Cys
times.XenograftsXenografts
1.083–2.308
Glu267
ONCOGENE
gains/losses
driven-RAD51
ht2–4/ht2–4
Pten/
Robocycler
770C-T
v-erb-B
T58I/S62P
GENOMICS
.Resultant
WAVE1
Henske
arginine-to-proline
lymphadenopathy
aphases
FECH
BCOR-associated
HPA
Imtek
hematopoiesis,6
middle–B
olfactomedins
extravasated
Shattuck-Eidens
process.14
H12
F260Y
SV4O-based
PCA
Kupiec
2961238
192,280
TTL-ETV6
E40Le
IFN-γ,62
emphasised
L412
3,918
PAMBWU
membrane.100
raÃ-genes
tumorigenesis48,49
∼65
site,28
78±48
Spillare
M.A.B
:Gal1-HIS3
Pre-Pro-B
N-EGFR
Serratia
miR-192
JAB
CHEK2.254C
HER2-driven
F857C
C-terminus.40
mutationsand
three-plasmid
ab55728
paraganglia
Weinhouse
21,22,46
CEP15
3717–3726
BaF3/BCR-FGFR1
cornerstone
R761G
Exome-based
IFN-f
trifluoroacetic
Berard
RWPE-1
CAF12
H1395
tumours.4
MXD1-MAX
SINE
1.649x10-05
KnownGene
anti-pY1007/1008-JAK2
pcDNT4/TO
3-kinase-dependent
Cytarabine
1SCF
oncogeneThe
2.0Mb
fluorophore-labelled
V70M
7/21
anti-b2m–free
11p15.5
ZsGreen-positive
imatinib32
R88
mutationalstatus
3.81
USP16-RUNX1
//www.genome.ucsc.edu/
probefor
E319
21-
D324
5′-TGGTGGGTCAGCATTTTCTTC-3′
−1.09
,7-11
Paratone-N
RFP-expressing
G2032R-mutant
Purdie
RUNX1-MTG8
IVS19+1G→A
wild-type-EVI-1
.Proband
ImmunohistochemistryThe
L841
wt-ERF
Second-Generation
R2–4
GSK3βS9
phosphorylate/activate
YWHAB
2692
171K
1:57
9-25
Leu95
L421P
/myeloproliferative
KRAS8
−.38
cER4.40
1.57–5.78
exon15
AveExpr
twosisters
Inhibition—To
NAK-1
DME~M
Capezzone
13:4:1
Hillmer
RUNX1.50
Trx-G
4204-1
Tweardy
genotyping13
515T
CYP19-aromatase
humidi
anti-phospho-histone
N-terminus.12
100+100bp
antimetastatic
TTG-3′
K/μL
TCATAATGCTTGCTCTGATAGGA
BRCA2-RAD51
pA308.jak2a
pY118
KB1PM8
HGS-OVCa
RTKs88
N14
rs522638
0.50–1.86
Céraline
alcohol-fixed
Homo_sapiens
T2A
Asn101
cystoprostatectomy
ygous
F1262L
m8
erlotinib-refractory
-CTGTAAACCAGGAGCCGTAC-30
ab11189
Moesin
N=33
VNLLGACTIGGPTLVITEYCCYGDLLNFLRRK
8.33E05
FGFR2c6Myc
p.Arg182Gly
p27Kip1-deficient
Deh-
15–52
Tet2f
510
AssayThe
p53-R273C
HCV-associated
0.7638
Urick
Pan-Cancer
FXF
IL11R
RB4-RT-se
MSCV-MPL-IRES-EGFP
RWPE-ETV1
population.1,2
Inpp4b+/flox
FDR
P/N
imated
9.175
C2F31
CKId
metabolism1-3
∼159
L137P
1–213
GISTs.Table
0.57–3.41
IRAI
A547S
α-Myc
ZNF198-FGFR1,8
6A–6D
5′-AAGTTCAGATGTGCGGCGAGTT
GSEA
int6/ex7
profiles32,33
p.Gln1524X
∼10–20-fold
anti–phospho–GSK-3
DRIP205
eIF4
pCI-neo
780-492-0886
AuroraA
N/m
1,10–17
contextspecific
chronic/blast
downregulated
D2720
CATNGC
mCFP-tagged
CD4+CD45RA-CCR7-
C445Y
n=127
guanine-to-adenine
eosinophils.37
Parker1
9-nR
ectomized
0.17-2.99
bi-orientiation
PT78
ΔT
oligo-dT
Y1175C
.TP53-R273C
L1036P
α-phospho-Mek1/2
n=26
Calu1
ilmm
CTM-15001083
15••
counterions
C-terminal-GFP
p21-transduced
nt3399delTaa1114Stop
F66
A049
A/CDK2
speculatively
ID.183
Hoc
Cbl-3
KITWK557-8del/V654A
5/25
Shichiri
IVS11+1
microhematocrit
D'Errico
.FAK
moderately-differentiated
.Con
C43
construct:4
ASD-associated
5C-D
.Hybrids
receptor-
infection.1
PBS-containing
zif
3,052
chromatin-dependent
sub-G
cancers.2,3
6577delGAGgta
150uL
2-ΔΔCt
P38398
C198G
c.2633T
CACf
cerevisiae,16,17
TGF-β1–induced
Ala148Pro
E122K
–37.3
MilliGen/
C390R
I437V
observation20-24
pB-Raf
α7/variable
PCRProduct
nodes41
pCUB15
.FGFR4-Y367C
cSame
Chk1.11
snpeffect.vib.be
Prentis
1714
FACSDiva
-3β
colleagues42
D17S794
NF-κB–mediated
SCC35
BW5147
dimethylation–activating
SET-Lys-NH3
VH4–39-JH5
attenuatesthe
A2420P
analysis-tools
p.Arg979
Br64
T4N2M0
shown.To
F-to-A
2.22-
DFCI032
NP_034627.2
D17MIT123-F:5′CACAAGGAGGGAGCCTGTAG3′
BRCA1.1
assays.82
GTCT
DBA.47
33:1165–1174
4·2–10·1
I548V
Sox-siRNA
Majerus
Biotin-SP–conjugated
BRAFV599ins.12
PTPμ-intra
.Ba/F3
.Confidence
CTTCCACGTTCTGTGGGCCA
Beghini.54
PhosphoSTAT
A189S
dominantp53
KS.9
R802X
≈12
.Cdc42Hs
.ICN1
Ding
T714I
7Unité
snp_ref.cgi
three-tier
carbachol
2ERE-pS2CAT
2226del3516ins15
ELC1
Reacti­Bind
P324L
ΦD
ONCOGENES
−1,745
described,7,8
GTPAse
H169
.I7
12/20/07
ets-binding
3T3s
CRC400
Prf
45*
U/C-rich
28–38
al.38
3,6
11q22-qter
Microbeam
post-synthetic
Haematology-Oncology
3¢
G-protein–coupled
CpG-poor
FIPIL1
siBAF180-treated
ch15:51.6-51.8
.Iu
0.0789
growth5
hyperandrogenism
15,17-21
pT893
before.31
​Figure4,4
p.Arg679*
AF207822
∼120,000
p.E134
ubiquitously-expressed
~kJ
andS2
ARHGAP6/26
.Etv1
28.4–1.94
acid–glutamic
genomic-binding
2,364
PIK3CA-containing
CUO11
Biologia
phospho-proteome
c.690–c.695
MUTYH
ATM/TP53
insTT
ever-expanding
-GAGACGACAGGGCTGGTT-3
KPSS-2.0
G195R
300867
NM_080425
physico­chemical
shRNA-level
BCR-ABL-transformed
RAD51C-associated
treatment.120
T439
//pymol.sourceforge.net
MGMT-deficient
ContextsIn
tumors—we
GISTby
Antigen‐specific
532_
17,37,42–47
Glucosylation
developed.18
E5F
12-h
4⇓
AML1a
T/S
heuristically
17p13
Amp+
CCAGCTCTTTTAGCTCCATTT
screeningIDH1mut
ALOX5
UMconcentration
J.
−132
STE123
miR-130b
cPierre
248C
25/167
mean-square
IDI
EP1058Y
Ontogeny-defining
R220Q
M136I
anemia,31
▿
Well-differentiated
68.5
BCS
FGF-7
Apex1
therapy.ResultsFrequency
33:488–494
e−kt
yeastgrows
crizotinib-sensitivity
families.15
Griesinger
PBS-vehicle
LAB02–433
Fisher.Cell
activity,12
TRF
FLT3.2
D22S429
coliBL21
C-C1
histopathology-based
R1060
Primerbank
results.The
V617F-mediated
IIIb-Δ13
Cxcl12
LOH
Glu578
275-bp
R337H,3,4
PI3K**
TLS–ERG
GFP–PH
SF1.340
antiphospholipid
syndrome1,5
Procr
.GDNF
B/NK
cancers53-57
S120L
lymphocytes.2,3
3p21
reached.This
patient-dependent
CLtot
22.5±4.1
RECQ1
whole-slide
Gq
CMV-CAT
SER473
Epifluorescence
TRK-SHC1
c.1186C
mFo
stimulation24
K118
MPI
.Inversion
Starita
PCR2.1-Topo
I/1
Ohte
ALK1234T
5-CTCTCCAGAGTGCTCTAATGA-3′
p16-9F
NS545
Faiola
A/
172-kb
a..
82.3
non-Hodgkins
S535F
donor-lymphocyte
-CD43
Hospitalization
3893830
c.270G
A214V
Jia
AH/
20-2
EN-Y518F
pRsetb-p53
antiChk2
TCF-4
LightCycler®
Pharmaceutics
rapamycin
Ala17
DNHD1
Dot-
p.R514C
API200
1.55~5.34
SM-MI
inbold
Mdmx-overexpressing
Thr417
pEF-Bos
CHP126
apoptosis.21
Merck
YURIF
Lovly
pg3-PD-L1
.Protein-protein
Acc651
842–845
N-myc-binding
10/11.9
P=0.049
p.L1305F
gtgctgcccgtatg
Llovet
.007842
intopRB16
LPT-RNAi
R509HBRAF
.7988A
∼18
H3K27me3-dependent
BQSR
Alk3
'progressor
non-keratinized
−0.12869
mRad50Brdm1
.0008
mMEDTA
autocrine-activating
CtBP-dependant
algorithm14
E/A
p85-induced
MSH2/MutS
multianalyst
35Slabeled
9234L
GDP-complexed
Phe-X-Phe-Pro
GRCh37.p5
GM-CSF-
off-exchange
En1/2
osteoclastogenesis
glycosyltransferase
G322A
23240128
Cladribine
D744N
LtdFor
endocrinologic
R243
25ul
​The
D203E
NCT01529450
Solexa-Illumina
sanger.ac.uk
tumorsin
four-band
53BP244
mainiodide
62-
AliBee
.Eye-bleeds
mm9
residues.56,57
o.o
Kasumi1
BAX.59,60
57.5
//cib.cf.ocha.ac.jp/CoDP/
R/R
17/102
families.MATERIALS
QWYEIQAYR
reports48,49
race11
IL-7R.20
stimulation–independent
strand-directed
Tyr653/654
.Acquisitions
mice.18
L339F
multi-potential
100mU
LUMAC
bemisfolded
MLL−/−
co‐segregation,9
K-ras−/−
paWILMS
STAT3-transduced
insulin-positive
m67SIE
TLX1
antimitotic
Arg-+His
LXSH
alltemperatures
tumorigenesis17,18
7.6DCNUnknown7.6GJB2Gap
ciiib/6
ERFFI1
gangliogliomas
R38C/H
Trimethyl-Histone
My5008
2469–2474
19S
Rouault
p.L73WfsX59
Pro114
171–430
RP11-557J10
0.64–2.41
SN-38
ReadPosRankSum
TGFBR1p.K223E
Lovén
C1057S
4EPY
TopHat2.0
RAD51/52-dependent
1100–1784
Post-treatment
C®
MesenterialE-GISTPrimarytumor
RET–PTC7
L822L
0.533†
Glu950
N771insSVD
FHA-dependent
19/25
.Tumor-bearing
47.7–2.2
PF-3758309
Ser637
plI
91.1–98.2
tau
cSCC15
ERK1Y53C/H
tumors.2
.PIK-108-interacting
null483L
CASP3/CASP7
anoikis-sensitive
RnaseH−
.was
theInternational
G57T
c.1207C4T
orthotopic
Nijmegen
MATaHIS3
R1275Q
Sample010
T348-to-I
Anti-V5-horseradish
6.27µg
apoptosis,53
mlh1Δ
Ewing-like
Rabaptin-5/
AT-1
eukaryote
PI3-Kdependent
26mos
losFigure
TRP53
.Molenaar
.Prednisone
.width=800
GACACTGAACATGTGGGTCACCGGCGAGACAGTGTGGCAAT
.Sanita
family,3
mutations-8
STARTRK
independentexperiments
PM1
Polypectomy
report17
TNFRSF4
U17/E1
1LoxP
K27M-mutational
Klijn
QuickChangeII
TTGCTG/gtaagc
27.3
C382R
1075
Genda
006015
45-mg
S167F
Niemeyer
CA-125
pc-DNA3
5′-CCTGAAACTGCTAAGAACCA-3′
lapatinib-resistant
64.5°C
4.0c
ViraTrak
.14–16
6.03
microconcentrators
5′-CTCTGGAAATTTGACTTCTCTGGAAATTTGACTTCTCTGGAA-3′
gastriccancers
Vysis/ABBOTMolecular
NM_002878
crenolanib4
160–168
DND41
ΔPR-LBD
mMsodium
cadherin
cells.42Interestingly
46-fold
1,364–1,437
Bakkenist
UTR.538–2419
A.E.The
Calzolari
biologic/clinical
2.5×106
D6nt
nonpolyposis
P.C
p.Glu548fs
FOP
LY-2801653
.Intratracheal
K8-
Tschiersch
Ex8F
TissuesExpression
6/29
−16.3
p21-25
HA-immunoprecipitates
UDP-glucuronosyltransferases
UoC-M1
GCAGG
neuropsin/ovasin
stability.Prior
STAT.15
tted
TP72
phosphorylation-dephosphorylation
AC011816.17
respectively,7
Y371
stage.9
Multi-unit
220000g
less-stringent
II-mediated
.Fig.2A.2A
tissue-culture
MIF-m
N1171
Gly464Glu
tyrosinase-related
DO-fgf-3
4/98
Dnmt3a-3a
myelitis-related
NOMO
emeni
5'-TTC
Heritable
non-resistance
1294de140
Luria-Bertani
Discontinuous
RP23-416H6
Smarca2-deficient
pTaG3
I~
63-95
inclusion,8
protein-only
3,5-7
i.v.
Sco1
−7.12
catgatatctcgagccaatcc
p27T198V
.Image
p110αΔ
K199
Cytoseal
SbCl2
ASCL4
p110α/δ
R565P
mAb528
hDIS3WT
tetracycline,7
.Frye
D16S498
NM^000321.1
.L15F
p.Ser436LysfsX22
patients.9
c.2338C
Fruitfly
stability—DUET
nonleukemogenic
RasWT
PHGDHL1
Affi-gel
.JAK1
m-
3xHA-tagged
SU11274-sensitive
E004
174/454
5′-tccaaatgagctggcaagtg
-ERG
U50709
carboplatin-based
117456
NOMO-1a
.MMPH
N29
μgof
1.7−1.9
â€oeproliferating
Gotlib
193-135-166-109-198-116
TCGTCAACACCTGTCTTGTC
trans-configuration
104D2
withrate
EX1F
.2L
I4
sc-24948
3382C
previously.17
aziridine
S206′
Â¡nthe
CCGCC.ACI
microirradiated
pUC19
2384
250–2000
Sudhir
8,25
DETECrS
Q1229L
EWS-fusion
J1-5
α7c
Ekker
BRCA2-mutated
K-Rasdriven
.Migratory
pRS314PGK-p53
SCH77294
Cys185
AB-1
caspase-8-mediated
3-class
inocula
81–325
.LLS
SNU520_STOMACH
ponatinib3
HBS-Ca2+
Asp770_Asn771insAsnProHis
.Non-unique
.CARMA1
53-72
60
Codinga
pTRE-tight-H1047R
.EGFRmostly
pmGFP-H-RasG12V-D47A
785.4
1,044
random-bred
Etv4-Etv5
Y356X
QRSTpSTPNV
controls.Immunoblotting
set44
Tnfaip6
Brg/BAF190
anti-U2AF2
T359
germline-associated
Notch/NF-κB
Nucleo
domain20
elsewhere.15
SCD-containing
deletion/truncation
16,18
S222
51118
YCpLG-myc-p110α-CAAX
hMSH2-deficient
93.8
coselected
medulloblastoma-derived
1,335
21418
Stratalinker
.Conceptual
D351A
incerta
2922
36–61
prostatectomy
L190R
.HH
dysregulation
-TGACTGCTTGTAGAT
5:2:3
5′-GTGACAGCATAATATCCCACTG-3′
Maegley
Ylikorkala
below.24,25
.Cox
2b6.3FAM101BFamily
C3T
Mr=163
Zn
alterations.Gene
GSE16716
Deconvolution
P17del
leukemogenesis1
.Thirty-six
mxSF3B1
LATVVKS
.Cdk4R24C
F-7000
Miyakura
.400G
Satyamoorthy
Ultradent
LR02
NRP1
Zhu2
leukocytes3,4
Q157
R306S
.DG
paraneoplastic
reference/DAPI
RET/PTC1-positive
Ki23057
complex23
PDGF-D.
0.6-1.0
LOH1p
PKR
MFS2
previously9,31
ctgccacag
non-SWI/SNF
N8K
78–4038
HIVdisease
ERCC6/CSB
0950-9232/08
.MM-associated
summate
Complex/Pox
GCAGCTGCCCGGGGCCGACA
CK1-α
Unno
Xpress-epitope-tagged
D795-808
formation91
HER2+PIK3CA
//bioinfozen.uncc.edu/webpda
domain.1–3
.Increment
clinically-annotated
self-aggregate
GM-CSF–dependent
.Interspecies
9q31
pMSCV6-Myr-AKT1-PGK/GFP
splice-site-mutation
salt-bridging
p.Glu230fs
MPM.40
HTB47
//linus.nci.nih.gov/BRB-ArrayTools.html
N=116
2003–2004
MATaura3-52
NRTIs
esd
131-133
ITD/NPM1
2249-2250
5′-GGTTGTGTGTATCACGGCTTACGG-3′
impelling
heterodimer-hetero-octamer
12-120
1500–2000
clinical/prognostic
IZKF1
genes,35
antiE-cadherin
anti–phospho-ERK
20/28
P=0.34
Bis-Tris-Gels
GACAGAACCGGAGCACACA
well-di
Chondrosarcomas
3.1/Hygro-based
3r1
WT+FL-CDB3
iodine-related
Ser345,317
HuH-7/FANCC
BMP-6
siRNA-Hs_FGFR4_6-DOPC
functions1
Chr2:29443696
LKB1-Q220*
compared—
XO-MAT
GGAGCAGCCGATGGGCTTGTCCTTGGC3
Â'°
3080
24–37,214
p85/3/GST-pl
2.3-
Lys-363
FANCB.12
c.1806dupC
Thr-20
A794T
300534
TIE2.87
irradiation-dependent
Gerhard-Domagk-Institute
0.5μM
re-distribution
ABL2/ARG
ZipperDB
c.1990-30
brain,53
Nu24/DP2
protein-to-protein
N841I
PTEN-defective
7–10μg/ml
leuke-
hyperoxia
.Anti-RAF1
CD-Rap
tumorigenesis,22-24
SYBR-Green
ubiquitin-activating
.15N
on—secreted
14.8–38.4
thanthe
.RUNX1-I43R
.Ryan
anti‐Gal4
F2304L
drug-refractory
SHGC
826
HiSequation
ALK/Met/Ros1
Cremediated
.Mosaicism
biotin-EAIYAAPFAKKK-amide
CDGE/TTGE
RelA
highest-ranked
cells*
p-S6PT240/244
DDT
K291Q
G393E
S4∗
c-Abl/Ras/ERK
.§In
eye1
S.C.
.Reports
Cdh1
carcinoma.5,16,17,18
E65K
ß-cateninmutations
R433Q
G1242
melanoma/neurofibroma
anti-ATP
.M.
BRCA1–mCherry
trifluoro
.2211G
ELAM02
FHL3
Hsi
Hydrodynamic
phalloidin-TRITC
α3-helix
Guillou
RRAS2
types25
Duesseldorf
0.0492
polyrnorphisms
P\0.10
mini-receptors
idelalisib
ENST00000374080
Omni-tagged
miss-segregated
bi-directionally
with*
755–781
p.R297K
metaphase/early
1p36–p35
hepatocyte-selective
Axioskop
E89
proteinsOne
Varettoni
FGLAT601
TCTCGAGTCATTCCAGTTTT-AGAAGCTCCACA
MET/ERBB3/PI3K
TRCN0000075166
structures12
V659E_L755S
inactivation/degradation
.BL21
.115
20-AA
unphotolyzed
CDK4-expressing
413M3
685–761
Ala100−Ala102
−17.9
.9B
3A-1
pPAX5-JAK2
RAXIS
SanitaØ
SSBs.38
CaspaseGlo
StyI
2Otrk5
5.64
Leucine-zipper
R99H
alcoholism
.Abstract
E318
​Figure8A.8A
allyl
NCT01445405
.Probably
Tyr1007/1008
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F1.medium.gif
PCR–SSCP
nlslacZ
LPA
h1
p110γ-induced
1N-binding
Ardini
anti-p70RSK
phospho–Tyr-537-directed
abnormalities.32
1.07
calpain
cerevisiae.48
bambino41
TE3/T37
W93
VMCUB-1
Loerrach
p60
p.Pro780Pro
RING-domain
p22∼
β-sheets
mutationswith
proliferation137
7·7
survival.45
periendothelial
−1.0
448—I448V
Matozaki
A63T
domain–like
16-21
§Leads
2d
6S
fibroblasts.125
G1019D
theatumor
nihms774093f7.jpg
MDM2gene
**p19
proteins.24-26
Acros
BTB/POZ
0.2–0.5
63·1–100·0
25-28
.Mutationsof
CBFβ-binding
domain-deficient
//cancergenome.nih.gov/
MIC-2
FLT3genom-f
0.984
Fig.S1B
,5E
p21+/−/mice
above.Fluorescence
nu=0
5′-GTCGCTACAGTGAGGGTGACAGG-3′
5'GGACATAGTCCAGGAGGCAG3
leukemia.29
NNCNNG
WT-pVHL-expressing
Zhan
DPSDYAEPMD
R172H
ysTrpGlulo
4–53
RB-E2F-DP
R1772C
Nurr1
LASERGENE
GSK-3β-phosphorylated
p53-R273H-mediated
tapasin
DHRS6
H.-X
dithiothreitol/10
Illumina-based
cancers57
p.I311N
R1275L
5′-ATGCAGAAGGTGGAGGTGTTTAAGCATGCCGTC-3′
K666N-1
A289D-mutant
doi:10.1038/nrc3877
7q33-qter
Kiak
-actin
D176N
-beta
p130.131
production.26
.S4T
Streibig
etal.
8.66E16
KCL
Q127H
.Beato
Anti-HER2–Specific
up-relation
190-kilodalton
'empty
p.Gln709Arg
Scaffidi
735
Synov
NET1
anti-Podoplanin
KITD816V-harboring
gctgcgctcggtgaactcg
BT098
Kurzrock
medium-throughput
4284
0.008
.Y226A
BARD1,15
253.9
HPV-HNSCC
NEDD4-like
UVS1
3-kinaserelated
Phng
**+
V804
activated/overexpressed
IL-27
MEK1-GFP
ActErbB2
active.3–7
RC211459
.Nonsilencing
HeLa.S3
70F
JAK2–translocation
EGF/EGFR
33446607
diaminobenzidine–specific
Feyzi
variants.3
in®ltrating
can‑
A1162P
cycle-
18-09/DR-GFP-2
p.Glu235Gly
TTCCTTCTAAAAGGCCATGAAG
flow-sorter
serine-1981
EGFR/HER2–TKI
MGBNFQ
receptor-2
–Ntg2-fragment
1823
aprimary
JARID1C
Microbix
RBy162
Arg-GDP
OD450-OD690
NHA9-transformed
D485G
5′-GUAAGAAGCCAGAUGUUAAdUdU-3′
424K
15N-
substrate-assisted
SCCHN-related
236.7
T1/E5
carbamidomethylation
AGGAGGATCATTAACCTCACCAGCGAGATGGAGATCTTGGGTCAGTTT
c.187C4T
MGH-BA
24-bp
B/B
chRCC14,15
notaffect
RXRγ
Sirt2
BaF-N/A-F1174L
Feig
interstudy
oncogenes4
Syndecan-1
mechanisms.15
MUM-1/IRF4
5,179
S101F
TRITC
paraformaldehyde.22
116.5
583–624
Constructs—Expression
genomics-guided
48
stroke-like
B-I-2
activity.5,56,61
C2–iSH2
FV300
p-CDK1
CGGTCTTCAGAG
phosphorylation—as
Spectroscopic
non-monomorphic
disease173
moiety
Hirning
484KB
disruptive
Makishima
PMS2-associated
Nontransgenic
GTTACTCTTTAAC
R1060H
GCTGAGCTGCCCAGGAATAT
CDKN2A/RB1
idence
10q22–24
Low-Throughput
abdominal/pelvic
17700
extinguishing
RUQ
5'-GCAACGCAAGCATGCTTC'FAGC-3
low‐dose
0.371
interleukin-7
ex29del
non-ASM
Sawano
ATgt
.Insertions
non-Japanese
K80R
Wixon
18,19
FluF-mediated
background.76,77
oligomerise
GAPDH-rev
hand58
mice,2,3
dominanceover
lLeuAsnGluThrSerPheI
DICKKOPF1
Mayordomo8
D1S2713
nonleukemic
ατ
Orange-labelled
myelofibrosis.1
TFE3
IVS11-2a
RCC.63
cyproterone101
Ad5-CMV-eGFP
MAP–ERK
CA16672
​common
R620W
WM3670
pWN-MF-ORF
afatanib
44/39
Extraskeletal
Cldu-rat
EP1
0.51–1.19
260/500
3,287
Asn71del
nonglycolytic
ethylenediaminetetraacetic
Rad50/Mre11/p95
I-2I
.Vol
400.5
V465M
5'-CAAGCTGGTTGAA
±3.41
V178M
φ/ψ
F4
FANCA/FANCG/FANCL
mainchain–mainchain
pKa
Myc-DDK-GRα
Kurdistani
coverslipped
months.5,6
HSE
376K
-20,20p+dir12
BTK,23
R204C
10−19
Iressa®
K1016
I157T–I157T
Amp−
pCMXPMLRARα
.Polytomous
KATO-III
0.0297
PLZF-RARa
Plus/Protein
LOC729173
.22D
perpendicularly
CD57-expressing
GCSF
hNQO1
/Lag-1
MAPKwt
Superimposition
Q61K-mutant
Maggioni
•CD4+
N20
.Hemi-nested
1.0–2.0
1730dupA
CTGATCAAGCCCCAGCA
GGGGACTCCAGATGAACTTAC
T-ALL–transformed
.Opening
c.66_68delAG
.X
p.P1310Q
NCT00084682
F864
T123A
µIof
cadherinmediated
ab71690
Lebestky
pH4X8
5′-TACTGGCATCACTTCCCTA-3′
0.99-3.34
p.Gln808*
SC-5372
TMPRSS2-ERG-positive
pmGFP-H-rasG12V
0.2015
N70S
anti-phospho-GSK3β
NCT00888134
Smad3-silenced
Ptch1+/−
BJAB-expressing
7777
κ-casein
BglII/HindIII
kin-3-dependent
bdf2
cells†
Iraq/Iran
Multi-faceted
0.33–2.08
Lupoli
fusion-derived
ERBB2-ERBB3
primers,6
Zaq-Q209L
homogeneity
i+2
Image-iT
S-transfected
100-0-ÃŸBIr
methylation/mismatch
S1C–S1F
Eμ-Myc/DNMT3B7
N676D
splicesitefinder
classifiedaccording
IGIuLysLysAspGIuThrProPh
Stylianos
GM08437A
1617
electroelution
www.LOVD.nl
MMR-competent
p.P95S
mutations25
SDM-PCR
80/female
.Bourstyn
anti-RBM10
.A-loop
246634
7.D.4
HMG-coA
1-coated
IC~~
0.88–2.88
Y489C
FluF-treated
HBV+
TKIs.1–5
Loules
PCRKIT21
6XHis-tag
1-sample
vector-infected
KL
Guccione
BRCA1/RAD51
other15
//www.1000genomes
Biteau
tensor
K84E
.Mixing
MED12KDNSCLC
C630Y/C634R
A-site
5804–5807delTTAA
C582Y
S71E
DNA-binding.47
I682
activity28,29
tubulin‐binding
Kyowa
22:06
ofHER2mutations
÷
PauI
1.00
G152A
.NRF2
individualised
1809
Glockner
Fig1E,1E
RET–PTC1
single-colony
al.18
Haque
.Thr-315
1–607
AGAAAR
-MEIS1
S475N
.Everolimus
C-CBL
TBS
77K
extensively,31,32
lumbar
PTPN11-related
use.109
CRISPR/Cas9-induced
ATRX-retained
NUTM1
784–790
anti-Jak3
E484K
calcein-AM
1.614.330
MLL-AF9-bearing
indeterminate-type
dominantnegative
inhibitors146
SSV
bonds.2
unrearranged
Dakocytomation
L95V
Thr-669
suppressors11–13
clade
RACE3
His115
7-fold
G34R
FIP1L1-PDGFRA–associated
1,532
aurora3
cellsFO
.Hitoshi
ÃŸgTPA
Amendment–certified
106-63
5′-AAATAGCCTCAATTCTTACC-3′
bifocal
.Lateral
tissues32,33,34,35,36,37,38,39,40
0P→1P
R265W
Fat1f
dobutamine
5′-CTCACCCCTAAAAACTTAAAACCTC-3′
~Wedicine
Tyr1327/Tyr1333
diagnosis.24–32
hormonedependence
Fig.7C,7C
CTGGTCACTCGCGTTTACAA
ROSA26Pik3ca*H1047R
.HN-Smad4
S-2HG
MACSv1.4
OCI-AML3
203/191
chi-based
tumours125
BAY-43-9006
R373Q
VHL-Δexon
amplicon.17
ABCA1
.Briefings
dominantnegativemutants
≤I2
Wijnhoven
Y.M.
ubiquitin-associated/leucine
Lodie
7:1572-1583
3768insA
96/128
Plt
band-spanning
TTCCTTGTCTGGCAAAGCCCAAAG
DCAF1-Vpx-SAMHD1
acetylation-dependent
c.G1433A
JH-VIII-157-02
rcf
T319Δ
0.580
nonhyperplastic
PF-0099804.47,120
Ex6R
TOPO®
131–310
0.7-kb
9.38
-quinoline
326/1681
.KSS
protein-level
Neuronal
gtgagtact
,18,19,22,32
MTERFD3
Frt-flanked
identified.35,36
37†
3-week
pathway.12
MHS
.R654W
≤70
AR-SPOP
P-RHOA
domain159
members.12
pJHGT30
CarlZeiss
5′-FAM-GTGCGATGGCAAAATAGATG-3′
BRAFV600E-positive
unsupplemented
RB17-RT-se
β-ME
cdc9
RV202
GAAGAAAGTCTCACCAGG
months69
6,7,8,9
JB12026
A1752P
E008
Anti-cyclin
20-48
/τ=R
Taurin
0.0459
Pro534del
25147+17
bromide–stained
growth,62
Polycomb-
1773
abnormalities.Distinct
IP-prepared
IMG472
ADE2−
\F
513–813
.Acknowledgments
deacetylated
Kuranaga
GSE35784
discontinuation/failure
333–574-001
Cy3-labelled
−6.23
Sense/synonymous
1–positive
Tyr-905
non-denaturating
pDM38
3/90
.Thorough
activities1,9,19-23
1,559
-diaminobenzidine
pKT3-WT-transfected
test-based
Mutant-Positive
FDP
c.1183C
Receivedfor
IIA110
Kasumi-2
/gDNA
81-amino-acid
SAE
Thr77
described.29Bone
HGF-elicited
KARPAS-422
GCGCTGC
10.3816/CLM.2008.n.048
BRAFV600R
treatment.Expression
R-248
7079
unlabelledGTP
chromatin-reorganizing
WW2∶WW1
responses.18
153InsTGGGGGT
hundred-fold
Splicerport,32
R-Ras
G0-G1
CD235a
​Fig.7B,7B
liver–derived
Ohno-Higashi
T58A/hTERT
and1212
p.R625P
2A23
μgs
O'Neil
GIST-1
administrating
.Water
1,904
0.36c
decade-long
53–56
subunits174
RAC-GTPase
3.86
immunoscoring
1224–35
p21Waf1-mediated
5·7
76.8
a3*P
anti–protein
lasso
8G–I
proteinaceous
PSA-E
analysis38
Fig.2B,2B
.Proteins
3—entrectinib
11..
F/D
Vrtel
reports,16,32
AML,71
H.27
MnlI
αP-ERK
previously.33
JIP1
1,507
20101
S18C
2MRC
K282A
PAI-1
mouse,24
.Spectral
8-404,100
R4a
MDA6
contiguity
phospho-PLCγ1
Fig.4C,4C
−2.4
GAPD-F
SESN2
immune-related
.IDH2R172G
RHOA-COL7A1
nonadenocarcinoma
GOTaq
DME1+
Swizerland
13–65
TGCCCTGCCTCACATACTC
P933R
Vennstrom
RP11-116M11
interactor
1,7
Aux/IAA
5′-TGGTTGGAGAGCTCATTTGGA-3′
ER-α
B-12
.Pasini
7q31.2.9
Thr-246
.Annealing
pc-PIK3R1
.SCC9
Nonhypermutated
//design.RNAi.jp
CGCGGCCGCC
inhibitors.51
Haemophilus
3â
FAM133B
-helices
de®ning
HA-specific
2,089
K189
Rat1A
Huarte
Shetty
q=0.0087
.SBE
tumours.5
SUBBIAH
9134
Saviozzi
PDGFR-derived
Yamanaka
lipofection
PLK3,14
315–598
142.88
D1067Y/A/V
.25–27
59.18
T630I
TOR–Raptor
Biosym/MSI
organ-level
cases.52
∼1.8
0.411
5′-GAGCTCTTCGGGGAGCAG-3′
Lys54
65°–59°C
phospho-T286
9/22.5
pCDNA6.2
coimmuno­precipitate
L929
.229A4C
PMLC20
orHindIII-digested
BAT315I
1q24–32
R85A
5,13-15
2557_2558AA
pranolol
1IEP
α=0.020
32Dcl3
-28
single-nucleotide–polymorphism
ofactory
1509-bp
Dnmt3afl/+
NM_005343
PIN1
D135fsdelA
signal-conjugated
TIQ-66
MG-B2GFPΔ1529–3418
nondenaturating
Q2858R
transaxial
HER2axis
ErbB4/HER4
pCMVMadMyc
Pdgfb+/-
BiBr41-42-St42
Map3k1/2-mutated
Bitransgenic
NCT00971789
AXL-specific
10f
IC50
pMD2G-VSVG
CCR7
12q13.3
amino-acidic
myc+ras
HOC313/c8
Disscussion
pcDNA/CD19
970
H835L
Valenciano
PYMOL
NF1Q959*
TFMB
p21/cyclin
SUR-8
described,1
CAGGAAACAGCTATGACCCCCCAAATGCTCCAGACTCG
indel≥qg
P1-
.Non-primary
prognosis.7,8,111
dropoutmix
C13orf23
E-cadherin–expressing
4326320E
Transcriptase
kinaselike
pCDNA/ZNF198-FGFR116
Fig3A,3A
Kielkopf
125310
nihms646437t14
S65L/S65W
Poly/Mount
22/28
factor‐β
365-374
G719AþL861Q
13.3-fold
Srsf2fl
3478del5
5-GAGAGCAGGCCATGAGCAAAC-3
pBABEbleo-FLAG-BRAF-K483E
Asp-166
10–1,000
.Tet2
PKCι
I~~~~VQA
junctions164
mA259
pCMV5-AML-1B
.743G
Kumar-Sinha
aflatoxin-B1
FLEXGene
C342Y
1/mm2
−6245
proteintyrosine
.JAB13
.H3K27ac
.Oncogenic
9-mo
infection=50
SCC17B/HN5
Smad4325
biotin-linked
42.61
R146Q
re-graded
A49F
×61
delta-like
RT–PCR-amplified
ATP-catalytic
ΔBTB
virus/AIDS
0.21-0.30
HLA-DRB1*04
PKC4128
hsp60
hDIS3I845V
Heat-map
GFR/PKC
Inc.
1FISH
Rce1
1994,1996
TMPRSS2-ERG12
Johnsson
4C-F
Glu-562
lanes1,2
K128N
K321X
3′-UTR-specific
analysismRNA
1/30
EGAS00001000575
4/153
41–74
203811
NCT01856478
K5.Smad4f/f
PPM1D472
Osseuse
T229M
downsteam
TB/chloramphenicol/ampicillin
A045
WT-immortalized
167–265
tumours•
W-blotting
dideoxynucleotide-based
CellsPools
1,2,3,4,5
mutations.Previous
5′-TCCAAATGAGCTGGCAAGTG-3′
Vol7No
A301-720A
346073
DX-IC50value
​27841
.Neutral
mutations.60⇓⇓⇓⇓–65
KIT-aberrant
pathway.5–10
.Fig.1B,1B
CSDST-NE
initialization
EDH2
Huane
34.6–36.3
anti-RET
nintedanib
2-2-3
GR300-0PHA
APOBEC
indicale
Hi-Di
c.331G4C
Abl-substrate.23
5E–F
chemo-therapy
vitroA
Koudova
17197
73.8
androgens—a
methodological
430..
vitro22
tail-to-tail
88±9
.HA-AKT
Lae
5′-TCCTCCTCCTCCTCTCC-3′
4•02
5/6/05
non-NMDA
MPC
747-753
-chase
IRS1/P85-IP3K
namedTRK-T1
NicΔR
1p22-p32
540_541delAG
+39
SP76
.**P
B7‐1/2
Shering-Plough
71178
Deenik
1nf1A
production-level
K-Ras
pREP1
94404
pIflNK4
trials.7,8
mast-cell
Ser985
Two-Color
application24
N-30
3.14-fold
48th
Lymphovascular
and6H
DH-5α
DepthOfCoverage
Dchs1
56-bp
patients.Interestingly
dimerizes
GraB-processed
CXC-chemokines
RWPE20
H-methyl
post-essential
1,121-
877–895
mAkt1
.Particular
2248
wild­
p.P1032Cfs*11
8972
KDLKB1
113-kDa
EGFR-L858R+T790M
PSGR
cells.140NF-κB–dependent
.Ablating
291st
cmd
Benvenuti
lysine-to-glu
~4.3
5′-FITC-
G13A
activating-protein
.C2C12
.069
.Twenty-four
=15-5
.Gels
16p11-p12
.Fluorescence-activated
D11S913
carcinomas.16
Jβ2.7
mutants169
Myc-family
VariantsTo
phospho-SHC
F.McCormick
Pflueger
GSK3α
1.08–2.04
Brca1−/−
.FLT3/D835Y
Osa
400–1,100
pT-REx-DEST30
15-residue
PSA-based
iliacal
431542
MST3-NDR-p21
normal/
Phosphoprotein
re-washing
40–67
SOX17
5852
respect162
tac
Non-PNET3
urea-induced
Tbx
BIM-polymorphism–associated
Leu-428
C242aR
isoprena
melanoma,32
non–ALK-rearranged
Geel
Frizelle
FM6
R74S
E8.25
sulphate-polyacrylamide
CGTGACGATCCTGAAGACTTGG
NCI-H508
AR5
RAF-GST
everolimus-sensitive
molecule-1
Cdk4-cyclin
RAS–binding
5'-gatcCCGGTTCCGCGCGCAG-3
twenty-eight
.Collectively
7D
GST–SH3*
GTP·Mg2+
trans-repressed
anti-oncoprotein
R882C28
regulation.7,8
2/26/98
H129Y
substrate–chromogen
760
Torok-Storb
.Showing
Trp-110
tumor-associated
E501G
TBC1D3P2
73
melanomas.If
5999del4
S6K1-induced
PKCB
116805345
Eppendorf
Degradation—Analysis
uro-oncological
P90S
therapies.26–29
SLC39A6
event.2
2678
Bl/6
APM2
ribose
phosphoFOXO
co-bind
CCLG
FANCAbinding
3T790M
G1286
0001
ccRCC-
'YP
IC50=
S-cdk4/GST-p16/
Scelo
immunoresistant
found15,18,44
mTOR-mediated
types,1,2,33
Mohlke
Mm768bp
SOX11
Brakeleer
18,27
Ultracentrifuge
t001
TOPflash
mitogen-stimulated
Tettamanti
.NA
7.5/50
G248V
F508ins.CUD
5,17,18
database33,39
−4.63
Katayama
TetOn-CHK2
Single-colony-purified
NSCLC-derived
CVCL_0290
Arg-165
anti-total
SLK
0.209
considerations.104–107
CARM1−/−
XRCC9
M/52
cells77
pathway59
28383
17209
0.0003
Mahlknecht
ATP/TKI
3q26.3–28
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F3.large.jpg
Met793
224560_at
RP11-107O11
Nocodazole
Sensys
Wat173
.mean
2Université
P109I
Q356R
BAP1.24,34
I220
Leu+
anti-phospho-p65
anomalies.2–4
sequencers34
46.4-68.6
pyrosequenced
21
N68XfsX1
1δ
.Kornev
Glu-30/Lys-31
1/79
918–920
A5C
//doi.org/10.1371/journal.pone.0005137.g004
G781E
V0
p67phox
RCC-JW
CDX3
complex96
F340
HH-dependent
1001C
RUNX1–SIN3A
paraffin-derived
1,125
Fe2+
pp6Osrc
pro®les
PTPδ
CCTCATGGAAGCTGGTAGGGT-3′
Shafman
∼80-residue
CCCCTTGGG
CD19low
S1
A260/A280
Kourlas
168-728
A_51_P500135
GPR39
.TV
1217–1244
Kurose
R340E
conservation/acceleration
detectionDNA
Cross-intolerance
Gly67Arg
.Phenotypic
A272V
lymphoma.16
5-chloro-2,4-
c-Junhi
Phenylalanine
p≤1.3e6
p.K666T
​Hepatoma
hydrophilic-neutral
M.-Y
98–78
Sμ
prognostic.22
pyrrolidin-1-yl
PIK3CAK111N
domain92
CCTATGTGTCGCCCAGTAATTCTGT
cells86
anti–poly-GT
EGFR-E18F
.Â£and
.Ethics
7773
c.1798_1799GT.AG
.HPDE
6.8-fold
CBFβ*
Sijmons
n=10/65
interobserver-reliant
E280K
ERK2
10.02
keratinization
CAGA12-Luc
centrifugation67
rerio.18
CP-causing
FAT1-mediated
sHD
Tensin
studied1,2
ctcttgcag
charge-change
13–37
.Yayon
I-like
WTRhoA-induced
AF064-
symptoms/osteoporosis
human-hamster
A280
A3529G
B1339
index.16
700-bp
70-kb
OpenLab
DTAGYNAMEESVSREKPELTASTERVNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLI
Chr2
BICR22
.6G
2SP
signal—the
LB996-RCC
age13,14
RETMEN2A
E2311K
ABD-RBD
−958
-Q209L
GgtPYpELpmNdQfyNaIkrGyrMaqPahasdElYeIMqkCWEekfEtRppFsQLvl
SkMel
9H1
5′-CTGTAGACTACCGAGCAGCTTTTCCAGAAGATCAG-3′
ctep.cancer.gov
8–30
ERBB2-negative
I-SceI+
phGR-TK
variantsHLA
evolutionary-based
SIFT30
CA-2-E
D336G
pED6
score11
essential.Potential
RAC2
Sp1–3
norbegicus
Msh2R542P
L1213
KMT2A
p53-ERTAM
β-d-thiogalactopyranoside
1.5.0.4
D160V
Loci20
.DiscussionMechanisms
SF/HGF
15.4462
pre-extracted
puromycin-selected
FGFR2Y381D-V5-pcDNA3.1
120.8
A67P
imanitibresistant
al38
FLP
1324–1335
compensatory
enzyme-substrate
ROC1/Rbx1
cases.13,14
'relief
cysteine-to-serine
A383T
.ELK1
U-937.26
GGAACCCTTAGTGCCTAGAGTC
C-to-B56δ
Jalview
chromatin-related
paraformaldehyde-fixed
mechanistically
abnormal.42
CCAGAGGGATACCATGCAA
kindreds.21
HT-12v4
pENTRmir
Nagamani
c.C8695T
_arrow_
hemangioendothelioma-like
ICAM-l
elongation-frameshift
.P-KIT
M2-macrophage
Millipore
CCe
pLKO.1
well-exemplified
eCG
10·6
delEx1-Ex5
T225
CTD-2139K9
CTGCACAAATGGTCCTTCAA
pan-Notch
1.8–60.0
HER2m
Fajas
23,30
ASESARQDFQREAELLTNL-
Figure6E
ofnon-DNE
.Relative
PTEN/C2-T319A
.DCUN1D1
2p13-p12
F310
Sandig
.normalized
96.00KB
CsA
pDSRα22
5'-GCGGGTACCAATCCCATGAAGCTC-3
leukemia.11,12
Shp2−/−/Rag-2−/−
HIF1α-regulated
optoRAF-induced
diastereoisomer
​and22D
A776T
Rac-selective
S631I
10-fold
0.484
60–64°C
IV:29
CD81–SPAG6
UGCAG
D117N
DigiScan
S5.1-4
.25,26
QRSTpST-COOH
well-physical
-GTGGCACGGTCTTCAGAGA-3
features.5
Phenylmethanesulfonyl
Clonotypic
CGK
co-mutations
log–rank
μmol/l
thrombopoietic
D1-deficiency111
Trisbuffered-saline
dead/floating
Dogan
1277
methylenesulphonate
Permanox
DMTF1
10p12
//doi.org/10.1371/journal.pone.0103021.g002
17q11â
2q35–36
119C
54.8
Figure5A
c.213−11T
previously.30
overdetection
6596
10021.
Western-blotting
P120S
RecoverAll™
XRN1
TGTAAAACGACGGCCAGTGTCTTACATTATGGTTTTCC
Caccia
21,00030
6.4620.00744
937c11
VEGFR1
4.72-fold
VEGF-A–blocking
vecor
AKT-interacting
non-lymphocytic
.Anemia
p.Y91H
TGF-ÃŸis
59.73
1129–1159
autoprocesses
found.85
Arg-24
Ets-family
8/62
P27KIP
Pvclust
sug-
p53-mutants
Gli2-mediated
pcGATA
Placenta
Myc-Ubiquitin
D-3
phenotypewas
96.6
PN1-PN4
STe20-Related
splice-sites
nucleosome-free
Möller
3A7
B120
nifurtimox
1p36.3
M280-Streptavidin
TCGA-KM
Nsp
subsets.Tissue
576
336K
M14752
TSC2+/+
levels,9
Upstate
nature.comSWI
50to
99.0–1.80
Ile711
anti-VEGFR2
variableDNA
Irminger-Finger
S315F
GAL-HO
ttttag/ACAATC
3153
FOS
313,273
and2H
Flt3-K644A
DNA-metabolic
ROR1
effectors—particularly
recombination-activating
Chi-Ho
56.5-68.3
1556A
resistance58
myeloproliferation.To
teins
45-year
A149T
Vaco481
9E2
lymphoproliferative
91320-1789
.Microdissected
D130A
-tbp
63–94
AC010864
4-12
SLC24A2
hand-assisted
Fgfr2c
VCaP-derived
Gro-1
immobilization
FANCJ-A349P
Histiocytoma
G508S
types.9,10
Ab-2
MALT-type
Glu199AspfsX4
1,1′-biphenyl
rs28481683
cod/Lys
Ptpn11D61G/D61G
PUS
cpm/mL
detergent-compatible
-104
Sun,1
Rdh54
36–
fra
Gln74ter
.colony
AR-stimulated
CHEK2-1100delC
GABA-containing
process141
0.071-2.354
INPP4A
thirddegree
spindled-epithelioid
BRCA1−BACH1
haematocrit
Val559del
gtacaattc
39,590
6-12
hygR
.further
.C.
70–72
Compagno
ALL-27
signalregulated
second-hit
FGFR3-activating
genes.76
variants,1–3
278–494
KDM5C-null
H1299-BRCA1-knockdown
0.84–6.09
αGT
phosphorylation23
1·5109
4.0-16.0
p53-aggregating
ATGCAG
Culig
described41
Ser990
PYDHKWE
probes.10,12
GA-3′
GeneClean
Lys36
Dicer1fl/fl
KQ
316L14
.QuickChange
GV-GD
Arg643
992
V600E-mutant
76T
A041
replication38
cancer8,9,11
D1-D289A/CDK4
937C
11.35
RARA-PLZF
CXCL5
R345W
Homodimerization
μL
cytometer.Construction
P2273S
protein-1/CC
GTGCCAAGCACTGTCGAAA
-.0
fibroblast-conditioned
RAC1-dependent
proteins.9
3,4b
GFP–VHL172
R219K
WT1-interacting
c.797C
Figs.1B1B
Broad-Novartis
FTI-responsiveness
009225.1
50-μg/ml
K1735
rC'4
antigentransformed
MgCl2/1
.Apparently
Transfert
p53,43
β-catenin–related
Myc-CHEK2
myaffe
javanica
VHL2_2R
L225
Greulich–Pyle
thesame
IPG
longitudinal
5-membered
.Adult
n=tm
usher
1,114-residue
R37S
5′-GCTTCCTGTGGGCGGATTA-3′
amplification,29
Qiacube
ProfilerPlus
V851
DY
four-chamber
~epternber/
.Archived
0.5054
SU5402.Response
GGCTATATTCTCGAG-3
ERF
.RasGAPs
unknown.However
Pt1
TEL-TYK2
FRS2-independent
'GZ
fluorescent-labelled
NF-kB
ITTAA4TGTC
983
Phospho-c-Jun
TAL1–E2A
PMS
-IL3
YCpLG-myc-p110β-CAAX
50.001
5-most
2q22
e.g.Figure
1328–1812
Daudi.MethodsCell
CDKN2B-AS1
Q289P
SVZm
ovary-imk'iyt'nik'ttt
DUSP22
K733
32,50
S6a
6.75
p.Glu23Gln
anti-HIF-α
yi
'canonical
/Heteroduplex
torus-like
topicof
98059
xylenes
Cepsilon
-1b2
CPP-ACP
noncell-cycle
BCR–ABL1–like
K46R
BMPRII
10/68
//www.jbc.org/
PTP1D
onset
.Inverse
MYC–ER
DLC1–TNS3
cytoband
23a
hMutSα-mediated
.DNA-PET
D2077E
5'-GAACATGTCCCAACATGTTG-3
1.7±0.16
∼20-Kb
anti-H3K36
ubiquinol-cytochrome
0.00112
85.9
high-calorie
DPP-8019756
Phe28
nucleosomes.47
-5-phenyltetrazolium
.PKCα-dependent
1–1559
cyanocobalamin
FANC-A
3024
R296Q
WRP53
12,964
cells30
pRXTPL
Ala/Pro
60.07
tataaa
Petronzelli
W73B2
19q-codeleted
fluoride-delivery
.AML1/EVI-1
1q31.1-q44
17695
12.14
BAK52
C528S
RhoA11,12
R1744
MDM4/MDMX
HER3/ERBB3
HA-Smad2
8,20,23,29,30
.ATAs
G31A
2298–2308
48-h
KuDos/AstraZeneca
FLT3.E13F
21:1183–1188
E2F1-
19.Sanger
N756S
205312
al2
1356
1~7~
resistance.19–22
AAJr
Transformant
pMr1930-BH
Smad4/TGF-β
TRIP/ΔU3–EF1-α–EGFP
tariquidar
PRB-165P
pcDNA3–DDIT3
UPD11q.15
p.N286S
cases.41
ultracompetent
S236
dehydrogenase-specific
nondedicated
Surmacz
Okosun
phospho-SHP2
AGGGGTACTG
PLVTH
second-degree
11.12.15
Fig.6C6C
PcrA
ChiCTR-TRC-00000397
7.747972875
7-SNPs
Wholemount
11q13.4
MSH2.34,35
G870
binding.10
FISH1964d
G137V
metabolism.
.LacZ-positive
8:12
HCC4006
kinase–inhibitor
TIS11b
1,239
.27,28
C-bandless
G122
immunproprecipitates
SSEA1-specific
Dort-
p27CDKN1B.20-22
R2=0.772–0.969
Thr84
oncogeneic
239±105
Tran35S-Label
.M21574
S7i
p.Val4751_GlufsX22
hexosamine/Golgi/
pronuclear-stage
EDTA/0.5
Na2MoO4
lines12
Reed-Sternberglike
1F/R
blue-negative
N3-methylcytosine
Pierotti
oligomerwas
Tiedt
46.08–1.6
Hygro-Myc
T19N-transduced
DN-MKK4-induced
R972
p.Gly724Ser
observations,8
lineages.2
cadherin-independent
gangliosides
heteroligomers
mis-splicing
2,460
≪
6956
membranes39
I103N
t=γˆtμˆi
WT-IκB-α-
CATTGTTGTAGTAGCTCTGC
318H13
V579A
\41
imatinib-associated
Thr75
2013
ERBB4N181S
one-hour
decompensation
PmaCI
G34V/R
CD21+
Ile-922
2.988529e
Myc-CDK10
3887-3892
gtaagaatt
IÃŸ
TTGCACAGGTAGTAGGAGCCCACGA
2006b
STK11.42
SRCC
E738-K836
M.D.W.
jetPrime
5q31/nuclei
TCCCGTCGCTAT
-CACCAAATCGTACTGGAAGACA-3
Sumi-Ichinose
ApcMin/+-Smad3−/−
AGAAGCCAACCACAGTCTATACCA
snu398
residue-long
19/45
Fab1p
.Public
CACAACTGCGAACTTCTC
PDGF-C
SCCHN,43
HB-8065
T-cell-lymphoproliferative
39597065
homeodomain-like
dysfunction,33
CoolSNAP
109:61–64.To
Ib
Goat-Anti
p53–223Leu
1053/1131
Flag-antibody/protein
c-JUN/FOSL1
aPstI/SacI
HuH6
AAP-330
invertebrates
expressionnonessential
21–188
Ridler
documented77
pMXS
al55
important.5
5′-TACCACTACAATGGATG-3′
site-II
late-wave
2.6.2.2
23–35
4/97
81-6-6879-3153
EGF22
pY65C-FLAG-Fwd
.Rho-kinase
lodination
apoptosis.7
pCSC
ψ2
epigenetics
5′-CATATCCCCATGGCAAACTC-3′
29091841
6,7
Bohlander/A11
p.1278
Duclos
R1744A
WI2-2850C2
.UQCC
chromosome-linked
Phe134
404,901,929
RAEB
self-help
virus-
un-preselected
0.05.24
inac­
.8537
OA2
Pam2CSK4
MADR2/JV18-1
Winckler
BNI3
agaaggccttggatgcaga
NOG
NVVnLLGaCTkGg-PIy
1:1,500
-Plus-
PHA556752
receptor-PTP
E2F-repression
pSRalpha
DFG-aspartate
receptor1
12,25
Q448QfsX37
25.3
HSV-TK
417
†4
βII-spectrin
saccharomyces
Canaani
.Topic
.Recruited
Val559
anti-B-Raf
igessga
PLX4032-sensitive
MOB1
Kouwen
DME
24revealed
Grant—5xmille
H6
and2E
0.583
SchrÃ¶ck,3
g-negative
1.60–3.24
40-μl
Bidere
.Hypermethylation
β-catenin/Tcf-4
RETC634R
wascomparable
μM−1
Mdr1
2/28
nonparenchymal
FACSCaliber
Zinner
puromycin-resistance
Debniak
tamorigenidty
CEN11p
â€˜1
LN382-derived
AGGCCCCCCA
Pharminogen
551C
CLINICAL-PATHOLOGICAL
S123F
SS18L1
methylation,15
.1801A
CSTF1
AMELX
D253N
30–40
receptor-a
D19S867
phosphatase-l
Br42
K78A
autoubiquitination
−Dicer1
MSK1
I122S
PBLs.An
0..0
0.0077
0281
Ac-DEETGEF-OH,8
.NI
E2F4/5-dependent
2.116
end-ligated
480D
2,4–18
co-IP
.Immunostaining
unresected
EGD
D18S1110
55.2±8.6
.123
c.367-480_645+644del
PTEN-silencing
uRCC
wereincubated
15q14-263pâ€
FIP
MPNSTs,17
ETV3L
cytosine
G161R
size12
.Classification
GC-corrected
E163_A295del
L540
cysteine-aspartic
cord-blood
H396R/P
rs144050370
Q1756fs*74
6g
TGTGCCGACGTGGACGGATGGGAAAAAC-3′
noncanonic
PenStrep
1αP564G
1–1637
T-cHL
proteins14
analysisAbstract•
indicated.35
myr-T308A
TNT-type
6,11,33
1462–1465
p110β–S205D
L-2-hydroxyglutarate
Universiti
Not1
RhoA/Cdc42Hs
1889
.Oxidative
Dr-GFP
s=78
studies27,28
13p-q
TVIVEPQGGEK
cystadenocarcinoma.19
Δ13Cα
random-generated
VSL2P
GTGACTCTCCTCAA
ClaI
YUMAC-BRAFL505H
genetics-based
anti-CD45RO
NIK146
3IK3
.Cy5
Goat–anti-rabbit–horseradish
AspThrAl
760–500
K5.Smad2−/−
UGA
factor/
3527-bp
TyrKc
E042
granulocytes.23
CGCGGATCCC
sources.4
EGFR-TKIs
3MTF
non-functionality
resuspendedin
MutS/MutL
Amouri
M32
BR2pyro520F
68331763
0.053
C492Y
21,36
2632-2610
ETS-1
α-phospho-Chk1
dechorionated
KPC
ERK2-L232A
.Origin
Sp-Pac1
contact-free
pGEX-IκBα
multi-lab
srs2
anti-podocin
geWtinib
phase-independent
10–33
RK3E-GLI-F
IUCUC
switch-control
Single-colony
V878A
D2191H
ligase.15
7A–7C
P639A
ChREBP
1670–1689
−180°C
.Intense
125/781
CC.22
Ofir-Rosenfeld
rapamycinor
c.2335G
.Derangement
0.672a
pbabe-puro
ligand/co-receptor
Green-labelled
G185V
~1,800
p.R140G
BMS-354825-treated
AATCATGCTC-3
AGGGGGCCGGCCCAGGGGCTGGGAGTGGTT
André
145–425
Medigenomix
1,529
chemotaxins
GRM5
DPPIV
N771insNPG
examined.24
≤5×
Cys-342
QEMI
.Principally
HRE
3965
+
PHTS-patient-derived
Shet
5-GATGCCTGGCTAAGAATCTCCT-3
BFP
lower-running
hypo-pigmented
bromodomain-containing
23F
.Diagram
perforin
devel­
60‐mm
.Management
Val82
aberrations/case
150mg/kg/day
101R
HDAC3
red-
169-184
MAX-interdependent
prostate38
H538QK539L
frame.22
N/
.Biospecimen
//www.softgenetics.com
albumin-bound
.Jürgen
0.82-
RG-3
15/21
.Symptomatic
GeneMarker
21-fold
p12–21
g.15702_15703insC
YUMAC-resistant
Prognostically
/0.018
973-EGFREGF
Pro379Arg
p110g
8C
.1⇓⇓-4
S408
TMEM135
CloneID
ZD-6474
A1021C
VariantsGroup
PAX5-C20orf112
ng/ul
IDC-like
500µm
PRDM9
1989b
Immune-complex
+s
p.R122L
.Anti-P53
p53M246I
SMD
preneoplastic
Chorio-epithelioma
recombination6
*All
M537R
highest-quality
TNF-αR
heteroduplexoligomers
FLAG-FHL–expressing
rounded-to-spindled
SLFN5
T634Q
V132G
TFAP2CΔN292
PHD2
antibody/streptavidin
SSEA4
5328
ZNF700-MAST1
dsRNA-free
enzymatic-region
pathways.11-13
Diuse
.Potential
pEGFP–N1
pR640G
ΔID
Frameshift/nonsense
5'-TATACGAACTGGAAAGATGC-3
pTyr845
mock-depleted
Georgel
LATS1-Y376A/Y559A-FLAG
iAEP
ofLoop
RhoA-elicited
H3K4me3–FACT
YxxxKD
keyhole
NSJ
1881
PAX8to
pH9
5′-CTTCTTGATCTTATCTCCAGATTTGGTCTC-3′
NPM1+/FLT3−
heterodimerizes
Esufali
.V155A
.Parental
eighty-one
triphosphate.14
K656N
decribed
x-ct
processing/maturation
S4A–4C
numberswere
125–225
42,796
interval.9
3/3
4202
alanin
IGDFGMTRD-
3401-8
ad.
.Oligoastrocytomas
5ng
publications47
ACAGACTGTACATCAATAGAGGAAATTC
26/12/10
5′-UTR
WT-LexA
V-positive/negative
5′-tgactttgccaaaggttaccttgccaaggagtttg-3′
anti-Smad2
space-filled
91A
0.270
p53–53BP2
NIH3
I-Sce1
µg/µl
ICyaThrCI
Sanitaria
25th-50th
16q23.3
1,212
p53-inducible
microenvironment5
preneoplasia
|FPH
γGCS
ITR-CAG-Flag-SF3B1R1074H-IRES-Puro-ITR
pVL1392
21944952
W2double
sun-induced
T-large
Gln-Ala
~Laëmmli
–100
BEZ-235
sonographer
—it
models.22
R12
E94
LS-causing
†15
second-stage
25-103
18-cm
Strukturelle
homotetramer
EC5F5′-TGGCCAAGGAGCTGACACAC-3′
TK6
5′-AAGATCAAAGTGCTGAGCTCCGGTGCGTTCG-3′
601607
anti-CCT
pZIP-ras
.Horizontal
.Xiao
Qbiogene
Soden
p=0.027
PPM1D-wild
HMV-1
response•
Gly2280AlafsX31
TGAAGCAGCATCTGGG
.Four-month
well-polarized
G.F.V.W.
‐IB
lap-extension
MAP3K1-JNK
DIS3L
.Merged
pathway26
mTOR-C6881T
KM-3
treatment-specific
Hsp16-dependent
IAP1
Chemoinvasion
EUFA268
v3.2
conformation73
f/42
BCL-6.26
RhoA-mediated
.Focus
p21-mediated
marker,46,47
L.A.G.
cell–intrinsic
PLCγ2
15ng
oncogenes—using
.Marker
ALK-T1151M
FASTSNP
20744033
5-point
tissue11
I-4170
AGGA
HEK-EpoR-Jak2-V617F
protecFig
0.0441
M1361L
crossreacting
ME2
interface12
D473V
RP11–471L13
MYD88L265P-induced
Decorin
0.0
Fitoussi
.EWS
expression.22
provided23
PIWI27
157–171
LDLRAP1
^27131
destabilizing.14
NM_007679
interdigitate
Pelech
chemioattractant
stainingof
Y209
SfuI
t-1
p=0•0008
CARD11
B-glycerophosphate
Zip-like
described.48
PUM1
Hspa1a
miR150
650,000
endothelial-cell-specific
Differentiated
re-clustering
GPyPyPy
Sequendng
S1–S4
spotse
51−53
H216O
cancers,42–44
p-FoxO1
ZNF98-FGFR1
code:3LCS
drug.32,33
pp60jv-sr
HER2-Glu-717
TSC22
rapamycin‐sensitive
transcortin
FGFR2M391R
NG25
1.6–72.2
CCGGGCGCAG
H061142
IDH1R132S
XSQ
acetylation-defective
105A
RetroNectin-
-VP16
.His
AGCTGGAG
N-pEGFR
TβR-I–mediated
P101
COSS1010958
melanomas4
HR-1
3/frgs1
anti-VEGF165
Duxin
V380I
.S2a
E518
neuroblastomaTable
73°C
CAAGCAAGTACAAGGCCAGGA
carcinogenesis21
.Reconsidering
10:13
V1238I
10.19
15.7
GST–SH3*–SH2
1522-8002/13/
apoptosis21
14.56–27.04
340
.Eluted
Arg-948
transurethrally
12.2±4.33
MLL3-deficient
LacI-CHERRY-BRD4C-positive
.two-tailed
totheir
types.14
network-mapping
71·4
events72
PMI-R2
IKBKE-KD
function.3–5
G402
R125W
ceive
E-Cad
port-a-cath
3LMG
6281
tumor-watch
inevaluable
16A089
17N,63K
T3640C
G674A
Pagano18
/12-o-tetradecanoylphorbol-13-acetate
hKIT-Y568
oncology.20Recently
EGFR-inhibitor
Cuffmerge
.Rectangles
~75
hSOS1-R497Q
4.4-fold
multisubunit
0.1704
CCATCCTGGAGAAAGGAGGACGCCTCCCTCAGC
MutSascans
proliferation-sustaining
anti-KDR
61-3606+TPT
11l
Tyr249
ALKR1275Q-positive
19282
Deutz-Terlouw
p.Ser1248ArgfsX10
Chemoresistance
mutants8
dasatinib.42
RP11-3H3
NP_000132.3
cuto
70-year-old
proliferation,52
p-CRAF
dimerization.49
GISTcommonly
1756–1855
heat-shock
GSH
3′-oligonucleotide
8573
decrease/increase
unfolded6
shNf1
Matrigel
Ornithorhynchus
anti-Goat
globocan.html
aflatoxin-albumin
239/240
resistance92
*0404
Toxicogenetics
c-Kit+Sca1+
Pekrun
58K
C124S-p53′
medium-H21
1FQ9
Q158R
18,24,26,27
pGEX-p16
M7403
Ferrer-Costa
c.213-11T
TritonX-100,100
msh2p-Msh6p
8/538
Hepatoblastoma
0·125
–pathway
1e−8
2385-2401
Spo11-induced
membrane,26
specific/non-syndromic
32.07
cancer,29
1×104
`SS
55846–56162
NB1395T
p53-promoted
RNF43-wild-type
cdk6
FixDenat
PICNIC42
Nop10p
s13073
vivo34
AP-endonuclease
-AML.9
.1609
FISH.1,2
1824GGTPI
Mountex
47/101
GATGAAATATTTTGATTAATTCGTTATTTCCCCCTTCC
resonance-derived
PDGFRB-PDE4DIP
E690_P699del
Msh2-/-
VitroIn
0.577
treated/control
3❚
PennCNV
Selvakumaran
Glu775
BglII-EcoRI
post-UVC
naturecommunications
phorylation
814.363
Akti-sensitive
APO-1
45-minute
MYC/IGH
.1252A
25/185
Ires-GFP
p.Arg406X
94.49
FVPTCs
SSBP2–CSF1R
lymphoid-signaling
HCT116-IDH1R132H/WT
C-amidated
crosstide
Gly-276
domain.In
AACR_
Nondeleterious
ires-GFP
205950
0.239
8j–k
zidditinr
overexpression18
EphB4
AMPKβ1
m/78
pyronin
rate.4
hEXO1
R878C
N235S
.Lisch
A-Akt2
D2–/–
SmCC
Fitchburg
Elf3ΔN173
NCT01824823
discretized
.acc=GSE42649
C108
Maleno
veination
T1025
WM3629
0.29–0.77
NSML-associated
Fer
17.81
24332
07-221
beta-region
a–b
defi-
spectratyping
16/77
∼4.5-fold
Red640-GCTCGCTGTCCACTGGGCCGAA-p-30
BRCA1‐like
pGEM-p16
Tumor-Node-Metastasis
chromosome-18
t-MDS
.Chemotaxis
6–neurotrophic
NKWTBIFY~IS~HSEVITE~LKHN=IE
SMARCA4.1–4
IBM-
Ni-NTA−agarose
zinc-containing
.Integrin-specific
1602–1622
.TGFβ/BMP
T383A
.FGF
nucleofected
p.Val552Ile
tumors.60
GADPH
V155F
ribosome-depleted
GATEWAY™-compatible
PDGFs/PDGFRs
phosphatidylinoditol-3
1–243
c.956^2A4G
previously,10
NBD-GDP/GTP
R882-mutant
srcphosphorylation
post-mortem
NALM
.PKCα
6.7-10-fold
.Ratcliffe
.TRAP220
CAG
γ-H2AX
PKA/Src/Rap-1/B-raf/MEK
HA/T3
anti‐GFP
GST-Sox17
ofPAX8-PPARγ1
oligonucleotide/
Npm1-deficient
Lymphocyte-associated
Fig.3H3H
CRC2,15
intrathoracic
N=258
.Craf
exon-13
p=ns
4×106
cryoprotected
GIST.19,20
CD48−CD150+
25/46
CAGGAAACAGCTATGACCTTCACTAGCCAGGCAAACTTCCC
N=6,503
lll
Melan-A/MART-
endurancy
GGACTCAATACCATTCCATTGT
WKVV557-560F
A106-115/+
postimplantation
hMutSα-heteroduplex
Aguilera
RAF–MEK1
5f–g
un-inducible
3180
L1198
Hemmi
SpectrumAqua
16INK4a
development.15More
R121W
p=7E-5
adouble
Denature
14§
cerebellohypothalamic
0.065574
NTRK2
5535–5732
S428F
erlotinib-resistant
S2514A
G.K.
Hirschsprung'sdisease
Pedmale
NOP10
2•2–2•5
c.6792C
IAC-15-000643
IGKV3-7
®
COG0274
TRCN0000039714
R1737E_R1744E
Shenzhen
Fingerprinting
pME-18S
0.5200
fibroblasts16
ª2012
vitro10
RCCn
.PeptideProphet/ProteinProphet
non-inherited
c.245A
.Absent
K753M-
notwithstanding
5′-cgtgcgcgggaagcagatctcttccatga-3′
C136R
KRAS/BRAF/EGFR/IDH
rs142094234
3679
CAGAGGCGCAAGATGGCTCT
alterationn
Vergata
1C–C″
RAD51B-BD
Slpi
PhasePrep™
GLMQ587QQK590SFR593
hDIS3S477R
CTG/AGITG
C5‡
HA-FKBP12
V-TGAGCTCGAGTCATTGCATAC
tccttccgcaggatcatcatggcgtagtagc-3′
32,293
His6-PIPKIIβ
I1307-specific
*4*~~~~~'r4
T325P
Bebb
.Rearrangement
TP53-responsive
ScanControl
245C23
pVHL-WT
p.E265Vfs*2
16.876.7
1,694
FLAG-cSki
reversetranscribed
IMCD3
31G7
αD–αE
populations.3
N-term
activation-independent
.Swelling
2561
NUP98-non-homeobox
FL-R
EM43
//www.abbottmolecular.com/home.html
X/H/B/I
900–4500
PIWI1
mutations.Materials
diap1/thread
wide-range
edematous
lyonized
K438T
H35D
transcriptomics
160,440
Ras'GTP
phospho-Src
fanconi
L399V
.GIT2-PDGFRB
c.7119T
shock-frozen
CCAGTCGGATCGATATGCTAA
CCATATTCATATTCTCTGAAA
R-10
E-publication
adenovectors
Hippel
Lys939
EIF4A3
/mitogen-activated
HuT
non-reactive
a–h
59-year-old
neuroanatomical
Figure11
AR-gene
H2O,13
Vaco410
Alpan
t-Cu
HMOX1
GAAATGAGCTTGACAAAG
2343
FLP/FRT-mediated
Nagarajan
.fourth
hyposplenia
Rapidplate
2–90
post-protocol
methionine/cysteine-labeled
Fig.6G
Strv
STAT3-inducible
CTAGAGAGCGCATTGTTATCAG
mMSH6-PR
.Caspase
TCGA-E9-A54Y-01
PDGFRA-mutation
BIC/systematic
conditions55
Pseudokinase
c.-269G
SLC25A21
54-min
Lérida
Hezel
medizinische
BCL-2
consistencies
P95H/L/R
K430
GFRα1-4
V600E-IRES-PURO
2.78
c.632-3C
CGACTTAAGGCGCATTGTCTGG-3
BX281261
thyrosin
S387
H574N
SNF2α–/–
A348del
GAP-accelerated
RapaLink-1-dependent
breaksGenomic
E561
HHF35
11·4
by-and-large
MSCV-EpoR-IRES-puro
panspecific
IFN-α–inducible
granulocytes-macrophage
DRAF1
0.069
.Sequencing
WFL
shh
CyScribe
FLT324
−0.75
PY-motif-containing
c.1958+3A
myelosuppressive
photoexcitation
re-activate
Leu2155Ser
immunohistochemistry.22,23
Insectin
98·6
PCI-35-
29-year-old
P284R
D308/G459
Gab1/p85
Lin-
324±182
S16B
Bax-CAT
viral-mediated
/spectral
Figures2D2D
R672Q
Npm
Pyo
Cys2His2-type
GRIND1
.TRANSACTIVATIONAL
.0001
TGF-β1–untreated
His-Smad3
12-14
ERE-Luc
pathway•
.BT549
pCMV/3
MAB88057
tumors.2,3
14-3-3/C-RAFpSer259
PLXSN-neo-p53
∼27
K642EKIT
PC61
G379E
NC_000005
FRS
.K517
FlagFRS2
//jainlab.ucsf.edu/downloads.html
MACH1T1
induction,13
exon-3–containing
.Relationship
p53-consensus
preciliary
pathway.1,2
LB-Amp
9872
J9
99.1
transcriptional-independent
Tcf-1
//www.tm4.org/mev.html
IBGC
disfavoring
KObZik
different.In
CGHub
,1D
Z-scored
GGAGCGGCCA
GCCTGATCTATCTGGTTCAAT
POLYMORPHISMS
growth20
24,32
M1-antagonizing
Sxc/OGT
72·2
receptor,21
regimen1
cells1,2
kinetics.The
15-51
I1170
strain-related
BAC/PAC
82:640–643
CIP/KIP-CDK2-cyclinA/E
IMCE-KRAS
progenitors.26
pGL3-RIP
.SMARCA5
ERK1/2-mediated
facilitatecloningof
7.7
Sarkaria
Boards/Ethics
Cole-Parmer
status.4,5
.Phosphoamino
p.V387Mf
Y-11
TGTTTGTGCCTG-3
Y201N
dyscohesive
Heuser
W108R
LS6000IC
SNIP1/SkIPassociated
radioprotective
known.30
PTCs.6,7
CellBioLabs
32/34
.HEC-1-A
ibuprofen
1,371
S601
SSC/0.2
Seldin
red=subrenal
EAA15144
microhomology-derived
N1b
32.12
CCACTGACAACCACCCTTAA
metastasis145
675–1001
leukemia.5,6
Cerdulatinib
Vectorshield
L424V-mutant
Atr+/−
+−/+−
biallelically-affected
41951
BCSC
BCOR/BCORL1
Mmnr~.~
..
enh
'melanoma
EndoHf-resistant
broad-pass
RAS/RAF-WT
.MutH
.MN64
.MED12-002
ER−/HER2+
A301-590A
1p,4q
yeastintegrating
PhosphoKIT
LU-A08-43
Chowdhry
Z2
p.Gly328Val
melanin-containing
Waldkrankenhaus
Glu1210
Co-cultures
nonhematopoietic
CK14
RFC3
Tam-treated
NRAS-3-R
P287
5′-GCTGAGGATGCATGCATACACACT-3′
Reverse-transcriptase
Isozyme
perturb
vitch
leukemia39,40
NOTCHmutation
prmcar
Promcga
.Gradients
ER+/Akt1+
24-26
Leu-777
353
PYM
Chieti
.Sozzi
Ni2+-NTA-agarose
F-
42–68
p.Lys335Gln
motopsin
autoradiography.B
m/66
X63-IL-3
71-4-8-2
octameric
history.27
EPD15
5′-CAGCAGAACAGACGACACTCGAGGCTTCAAGCACACCAG-3′
G3G4
15,38-40
VPB
Eisfeld
.Ambros
Punturieri
D617G
R2659
Ad-LATS1
CBL18
Bioexpress
BCL10
T728M
1,500/
SORMA
±±
857t
KD/-
course9
.Caspase-3
Hsp82p
KD+/+
Phosphotyrosines
.Mast
retransfected
5′-TGGCGAGGAGTTTCCTGTTCTAGACGGCGC-3′
Brca1fl/fl
10.1007/s12185-010-0612-y
605367
weight-derivation
Ricol
CD11b+/Gr1+
MutLγ
H11
ered
Tamanoi
meprin/A5/PTPμ
Sikora
HEPII-NEM
retroviruses.27,28
300g
10Â°Cthroughout
shCDC20
SIFTalgorithms
pA308.Flag-tel-jak2a
23,28
kcat•GTP
2015
crosslinker
pCMV-3HA
quasi-palindromic
Cis-regulatory
TCTTGCCGTAAATCATCCCC
histopathological
bioB
Sox9
35–41
3,807
300–350
Dnmt-mutant
thiocyanate-phenol-chloroform
indicated…
psoriasis-associated
bu.edu
.Dissection
44,2q24â€
pEAE42
leukemia-variant
D51G7
WT1t
Ras·nucleotide·GEF
BioCat
E1-R
RNAqueous-4PCR
linus.nci.nih.gov
3425
nonsteroid
6is
RUNX1wt
70g
asplenia
ACTB-FLPe
pre-Tx
ab50817
.Genes
qter
GST-BRCA2
AD-HIES.9–11
non–BRAF-interacting
55,101
Roche-Genentech
.different
subgrouping
.D-A2
1,535
Chromothripsis
Angulo
R70W
.2.0-fold
MAPK-activity
02903
1–73
3223delG-1
effector/substrate
TNRC6B
P16
12–encoded
ribonucleotides
175H
393P-shY
.¶~~~
lular
anticoagulation
transformation.29
factor.11-14
low27
moiety.53,54,60
primer-binding
AAGACCCTGCCCATCGCTTTCA
P=0.0027
MNU-
Luminoskan
C/EBPα.86
NM_010783
pEGFP–N1–MEK1–GFP
2009
2541A→G
risk130
Pfaffle
milestone
RP11-35C4
58-
36-80
HA2304
5′-FAM-TGACTATTTGCACATCTGGC-3′
.M309G
W5a
rs3138606
Central/conventional
GSE41440
transcriptionBone
10,11,33
31.9
MCF10A/HER2YVMA
Δ306–1312
PPKG
G17A
pET29a+
K-Rascoding
seminomas.40
5hmU
Claudin-low
ZA-
oligodendrogliomatous
Ser768_Val769insValAlaSer
1083–1111
NCT01441297
E415D
Rb1654/
R1817S
T2472
n=3,092
RP11–434P20
eciently
n=34
Nadl
Postzygotic
xylene
msh2-GD693por
.2170G
TEL-PDGRFβ
PMI-F2
14.s.c
G48R-mutant
257L
25–29
corrected32
G1386*
MSH6-R1095H
eIF-4E
62.8
8,5
D-ribofuranoside
SHP2-siRNA
werecapable
Y139
20q11.21
E41
WWP1-ΔWW-GST
KV558-559
1–3A
þ1q
utmb.edu
2-6-2-2
Chanthery
fractionation/purification
P495L
explored.Morphologically
Immunocytochemical
g.248
LDL
patients.36
6684
71-851
P220
SMO-D477G–dependent
Tyrosinephosphorylated
Sox17-Pgr
Probesets
timeswith
75·0
8,9,16
0–7
anti-GATA-3
proteins.6
514K1
XP8CA/SV40
10–
1271–1283
non-acral
TTGAAGGTTCAAACTGGAGAAAA
1525
Califano
≤480
GNA11
P94A
Intra-genic
4LYJ
39§
c.376G
integrityof
631458
IVS16-5T→A
30–49
IIIC
signaling50
11697498001
111-545-144
2d–f
non-HH
Kmt2dfl/+Cγ1-Cre
criteria.10
Ampure
LAS‐3000
FLAG-Fast-1
ulcers32
TAATACGACTCACTATAGGGCGGAGACTCGCCTGGCAGCTTCTGC
pathway-deficiency
Met237
YAP1-truncating
P335A/P336A
Fermenta
instruction.Cloning
N540
Met243
5′-TTTCCTCTCCTCCCAGTTG-3′
_at
T367
AHNMD
κ-light-chain-enhancer
disease,10
F3788
Scg6-EN
FastTrackH
JAK2V617F-Negative
21−24
DMBA4/TPA
FGFR1-overexpressed
A/S
erences
Map2k2
K285N
T-PLL.11,12
Villa-Moruzzi
0·27
UGGWG
pcDB
LC640-AGCAGGTGGTGTTGGGA-C3
–Kelch
Yip-Schneider
15.9months
.Knauf
A349T
3,141
32.7
domain10
RP11-556I13
Hached
GDC-0941-insensitive
∼4–7
ND1L
Y211′
1μM-10μM
4,665
39a
MFE280
VARIANTS1
Ptc
crizotinib14-16
*P-value
Gleevec.12,29
bryostatin
73:1261-1270
Sievert
3,36,76,79,80,85–90
pladienolide,64
Tier1-4
nm/
0'12-
pflag-CMV-4
Pendyala
PD4/FANCC
'adaptive
.11⇓⇓-14
p=8.5x10−15
S33
N454
finger-dependent
neoplasms.2,3
ROS1-Positive
WT-Pin1
ERCC4-related
HNPCCs
R-base
tified
AI652557
A226V
.7515T
TRIS–hydrochloric
6,18,30,31
5′-AACTTTGGGCGACTATCTGC-3′
SUMO1-Ubc9
lacZexpression
single-turnover
sub-saturating
ATGATGAACAACCCC
2-80
post-operational
1:4,000
PRB-192P
Oefner
R908
14p
.Cut-offs
2•8
.Nested-PCR/SSCP
3,5,6,32
odsâ
48.48
W515/total
phospho-AKT-Thr308
P01
hemizigosity
D92A
.Chambon
Dt+1j−D0j
//www.mmrmissense.net/
EGFRL861R
211A
.-3Detected
Gβγ120
re-create
L576_D579dup
anti-phospho-RPS6K
DNAse-free
anti-SPOP
249-bp
.IL-3
GGGCCCTGAATTTCACTGT
sequence-binding
-5.1
inthree
.ml
factor/cytokine-induced
1983
cisplatinum
.Crosslinking
Kamb
MPLW515R
French-AmericanBritish
PP2B
5′-ACACTCACTTTGGGCTGCAT-3′
cytokine-secreting
V600E.5
EAC
propriate
3–11
G-quadruplex
F1174L49
.Coordination
Keap1-deficient
Generalizability
pre-translationally
buffer25
PTC.9
5′-TACTGACTCG­AGCAAAGACCA­TAATCATTTAA­CCTG-3′
McCubrey
individuals.Northern
respectively.Full
OCP
isoelectrofocusing
814C
FGFR2C278
Korja
mesylate–resistant
R156H
BMP-SMAD
V600
TAE68419
1854STOP
lines.3
PC-LYSIS
findings.B2M
R108K-EGFR
/65.2
HTN
p120
Ematologiche
R229G
0.59–24
59-kDa
3480
baxluc
cytogentically
HA–B-Rafwt/B-Rafwt–Myc
damage-activated
pince-nez–shaped
2′/3′-O-NBD-GTP
p90Rsk
36–81
ENSG00000114423
A143T
L1122
Gnekow
cytoskeletal
KARPAS-derived
alÃ-ele.Interestingly
differentation
FISH-stained
176delC
intermitotic
TRiC-specific
GSK-3ÃŸphosphorylation
pRb/
MMBIR
2014-001326-15
haploid-converted
B220-negative
0.545
NPM1mut
MeT-5A
229838
NFR2-ARE
Abl-SH2–phosphotyrosine
4,033.0
Y1349–Y1356
.ΔBRMax
activity'27
50,246.48
pGST-BRCT
.Fractional
lactocystin
models23
RNA-level
test.25
aerodigestive
G1049S
S397Q
c.112A4C
ferent
SU11428
IV.3
p.A344_A348del
MiSeqTM
Q579R
*-2cells
RasGAP
Pak1
28578
c.4388C
immunodetection
5′-UAUGUUAGUGACUACCAUGdAdT-3′
.SI04194498
ALPS-related
S259A/L613V
mu/mu
.ATP-competitive
transition36
SMYD1
BRCA1D11
34/F
PathScan
Vincristine
Ptpn2
5′-GGAGATTTGTGTAGTTTTTG-3′
Notch-ligand
vitroexperiments
61767418
19-23,79-
12259
188K
FIM-FGFR1,16
119–121
1–657
.Strongly
round-bottomed
5′-CCAGGTGGTAGTGCTGCTATGATGGTAAGTAGC-3′
Sankary
129/SvJ
ER-signaling
Serine-847
+7
S4F
moderate-grade
T89
NBD-GTP•RAS
CoT
GCAATATCAGCCTTAGGTGCGGCTC
CEN
AGK
others.59
NF-duodenal
Shamseldin
values.Cell
97309311G
P.G719UNKc
complex-deficient
triple-helical
Sos1EK
SMARCB1-heterozygous
.372
DC-Lamp+
thenumber
1161
1,500/mm3
R133C
T14/Y15
treatment.26
eeoe
85-day
Six-
ELISAplus
BL17
Clodfelter
Q-VD-OPH
DNA-based
holoenzymes
andclass
Hes5
S1.4-5
342
GACAGCAGCACCGAGACGAT
.Co-mutations
imperceptible
Asp453
ReACp53-rescued
53/832
v.4.5
5p15.2
1/ERK2
.schematic
Y116F
respectively.21
aphidicolin
dimercaptosuccinic
N581Y
.Gaps
F55Y
CYP24
Si4
Hu-α-koz-F
3.75-60
NCOR1
well-established
CD2AP
WW1/WW2
PRC2-repressed
P60A
S218
p53/ARID1A/BRG1
12/33
LLIFN-yo
pHAGE-CMV-MCS-IRES-ZsGreen
stage,10,14,15
ionomycin-stimulated
Y635K
0,0,0
39714
Tyr791
DeltaPro
pre-Sertoli
182.4
.2.5
a-e
~K0.05w
PGKR
i.e
.2329G
18,789
Fixation/Permeabilization
n=697
600
Sirven
Juan4
25:7054-7068
deletionaround
thyroid,1
migration.35,38-40
\~o
.Well-differentiated
behaviour19
4D–F
café-aulait
multi-faceted
K07
.Immunohistochemical
GDP-
anti-AML1
10/
before.19
UVC-stimulated
vessel-associated
cancer.36
5′-GGTCGCCTTGGAGCAGA
4,11,28,29,53,58
149–166aa
ex1–JAK2
seven-bladed
L334R
WT-FZR1
Registry16
criteria/Bethesda
R820Q
podophyllotoxin
OCD
0.15-0.98
PTQL560–576
myelodysplatic
p21cip1
kinetochores.60
nudleotideswere
p=0.3
Aur
1,166
ED7
9-month
pentaacetic
~4-Mb
RP11-569M1
Tyr112and
EEG
335700462
IDH1ex4AF
Thorunn
studies.24
1.44/1.65
67-mer
0123
I116T
ixabepilone
thewild
UAS
Ala86−Gly89
p=0.002
7from
otherwise.30
1691
Crebbpflox/flox
chr5
K340N/T341del
dark/pink
CGGTTGGCCTTAGGGTTCAGGGGGG
cancer.8
Sotti
Amaravadi
Chemotherapeutic
NM_138270.2
264-bp
CAV3
kdm6a
16q−
normalimutant
265K
Refseq
E43D
D1S1586
KD-Bcl10
reporteda
122-125
4/56
Pim1+PLX-K031
Jak2YY
stability.Survival
AR-AF2
Thr432
Hist1h1e
MCF-7-3-7
anti-p-Tyr
CAGATCTGGCCCAACGATTGGCG-fluorescein
A234
ZNF335
11–41
dETV1
ERBB2-T862A
T32-AG00057
12-O-tetradecanoylphorbol-13-acetate-induced
.Chaperone-assisted
pM-CSF-R-luc
Rac-PAK
PTEN/C2-T321A
CyclinA2/CDK2
wid-te
JAK/STAT.18
arecritical
cellsFull
GST-Smad3N
Carniti
469C
efficiency,53
gapdh
Q164R
iScript™
Fukushige
572-603
0/19
leukemiaassociated
.Deamination
2155G
anilinoquinazoline-responsive
.NRA41
clinicogenetic
V168M
SNU-1197
∼⅓
R428A
R89LRafCAAX
5′-ATAAGAACCGGTCCCAGTATCTACGATTCATAGATCTCTCG-3′
intracisternal
HRGene
31-20-4448278
LR08-261
0.091
8-17
Fig.6D6D
mzXML
R1185C
2-59
.Components
.ARID1B
W24C
162K
damage.4
BMP-Smads
p.R185X
CEBPD
2,4
tumors.33
platform-specific
liganded-p300
Raf/mitogen-activated
23.23
.Differences
GHRL
KIT-N882I
quiescence.41,46-48
u133a
SaoS2
msh2-AD872
HA-CARM1
cancers—in
candidin
10−302
interchangeable
ATM/Mre11
Y740
P291-
−3.37
.2,20,21
EWS-FLI1-induced
Y722C
Angiomyolipoma
non-DS
homo-oligomer
H-2030
MMR-null
711-096-152
P35S
2×107
MNaCl
.ASXL2
538-3
Lévêque
near-exclusive
serum-induced
cbaldwin
RFLP
ENSG00000142273
shNf1-expressing
2855
_MGMT_
orthologs
gastro-intestinal-stromal
.2404C
B-cell–differentiation
8p12-specific
CTL-
±0.3
1997b
KARPAS-299–derived
co-clinical
potential130
CD7
DEF-dependent
FLVRES
pedigree
ultrasensitive
S217E
paper.The
12:15
SpeI–BglII
13.7/1.5
c-erbB-
CRI-1
imatinib.To
f/65
anthracycline-taxane
mutations13,14
K125
androgen-treated
5–75
×125
CITED2-dependent
1–84
Binarized
Baek
CA-3′
AMG337
Y339
biogenidec.com
these—erlotinib—inhibits
miR-17-92
ETV1.Alymph
PDB∶1JIU
6⇓⇓⇓–10
CCCACCTATAGG
nonacral
20non-MMP
N671Y
biobank
.Ocular
studies15,16
290_291WI
Sae2-proficient
19kDa
p21ras-GTP
0.05-13.39
FuP
62×
A767S768insSVR
Mll–Af9–specific
Tentler
5′-AAACCCATCCCTGTCTACCC-3′
c.1771-1772delGA
1796C
84–91
last97
P=0.64
.Thirty-nine
3500/mm3
M1C
metachromasia
differentiation.108
D-Raf/KSR
0.0129
NOD/scid/IL-2Rγ
.Single-Strand
7,9,12-16
bias–variance
controls.15
BIM
NOD-SCID
lter
Barbacid
ZNF-198
β-catenin-active
Oregan
D6S470
pAR3-lux
11.26617
WEHI3B
SectionMaterials
Roche-Monza
H4230
HCPTPA
Pratilas
instability24
fodrin
factor-deficient
5,9-11
Nycomed
rs9648696
4-Primer
500–1,600
75
S56L
TP53-01
phosphate-
T374
hemizygosity
500–541
NCI-H630
peritubular
cdk2
GGGGCGGGAC
KITcopy
tumours8
VSV/G
.Correlative
A9
T-Easy
fusions.Fig
-Luc
-serine
cyclin-E-Cdk2
Lamprini
anorexigenic
EUFA388
demonstrated20
identified.208
−GF
mutants.2
cofractionating
13*,9*
.Mature
o-EGFR
ADHESION
29625877
0109
biogenesis11
3LCT
m5CpGdotCpG
2,8m
anti-phospho-EGFR
.Secondly
c.1906G4C
mutation/loss
L-broth
kinase-enriched
pCR®2.1-Topo
Wistuba
fields/filter
C39Y
2.14.0
94AAAAA95
G892R
MNA
lymfadenectomy
Phaser54
HiScan
33,500
t-statistics33
inter-PHD
.Gaboury
5'-M13-T1
.SETD2mut
5.Enhancement
79–102
prognosis.33
DeletionsDetection
1.43
.EKN
Mustjoki
Titer96
treatmentnaïve
K-and
proteins.21
CAU-3′
R372
MPCEWS-FLI
5′-CDK5RAP2
UV179
mastectomy.It
consequent
sulfate-bound
5/28/97
Y727
.D1270G-mutated
LR01
EBNA2-estrogen
001990
ms-μs
geneticbackground
F-actin-enriched
Production—Crystals
blood–derived
M-TEL
transientlytransfected
mcmail.vanderbilt.edu
SRA903315
16–48
-//
.Nonetheless
BRAF-G469R–expressing
Ste7p
+13.5
R4005.39
P490
S621
streptomycin/ml
gpllOProto'rk
.Prolactinomas
10,14,15
human20
polyPhen2
rare.11
cds7.0DAPK1Death-associated
BRK
O102
L858R+E709G
.CAL-33
morphogenesis
16086
THP
Pulse–chase
TROSY
one-locus
1,000-bp
ketamine
Co-activate
Y329F
L119P
kinesin-like
change-in-spectrum
72Â°Cfor
Bcl-XLwhich
TAP1-luciferase
mono-selective
domains.18
Q358P
ScienceDirect
A-like
CSF-induced
TCGA-ER-A42L-06
p110α/85α
KLHL13.31
.6KRAS
LOXO
1,534
NM_007373.3
Z-scores
tetramer-stained
Othersa
mHNF-1A
nononcogenic
loo-mm
1â
DAPK/p14/HDM2/p53/APAF1
Fishell
P53-related
Oct4-EGFP
phospho-4EBP1
hisopathological
PCV
mini-extruder
Pebp2β/Cbfbshowed
.Nonsilent
deletion-T790M1
RPA3
D1-interacting
55,370,495
FLT3-targeted
5'−CCACTTCGACCGACAAACCTG−3
DNA/
.tgof
IgG-horse
vitamin-D
45-3
5′-AGTCTCACTCACCTTTGCAG-3′
M320I
THO1
11,000×
Hockel
undervirilisation
postgerminal
discriminates
31073
6.684
DNMT
I188L
RAF-mutant
growth/proliferation
R954W
S20
L277M
Figure2,2
WGATAR
_Chimeric.sam
clonidine
MEM-f
BRIP14
:465–467
0.92–6.34
FLT3mf3
neo-Me18105
N382K*
nonhelical
Mx74
1.90368
6/1,848
DNMT3AWT/R882H
gene.9,10
M.W
colleagues6
comp.
255K
4L–O
EGFRat
pCB1153
ErbB2_ex17-25.SF2
P53L
Hérriot
SC-5574
indentifying
N991D
Xho
cleaved-Caspase-3
Concomitantly
PIWI2
5'-AGTCATCGAAAGCATCATAG-3
980G2
Probasin
months,1
c.5465G
O090
PLO
UbcH5B
med.cornell.edu
KMT2D-enhancer
nelarabine
PR-mediated
N81Y
varnish
P201R
'allosteric
scan–guided
times40
RHS1764-9207446
Steidl
.Hras
28h
.Extracted
355–362
pET30A
subG1
Figure4d
1350
Cys765Trp
β-catenin-activating
D18S484–0.16
hepatocellular24
T3033I
TGFBR2R537P-mutant
heterotrimerization
p107–DE
.Arg515in
Ile414fs
5′-CTCAGCTGCACACATGGCCTA-3′
14F
.Jeannet
PCR-amplify
self-interacting
NB1382-D
T-to-C
1py5
.Medulloblastoma
ISE
ACCATGGATCAGCCAGTCTT
disinhibition
cancer-gene
suprapharmacologic
ECTMWT-2
DNA-sequencing
CGGGCTGGAGAAAATCCACT
genes.Fluorescent
MPLWT
varFilter32
reports.17
CCL2/CCR2
Abl/Src
.Gilliland
dsDNA-containing
M774insAYVM
NP_001978.1
SK‐BR
c.109G
resection11
Ad-LATS1-transduced
42-year-old
20.2–54.7
Gel-Drier
TTC12
-38K
7–7.5
justified.
ZNF261/DXS6673E,57ZNF262/KIAA0425,58
Ovary
T272K
Brca1S1598F/S1598F
80Â°Cfor
Steady-State
I213
MgOAc
Ctcf
MiniElute
hmg
tumor-laden
GpppN
chemoattractant
GATTAAGAG-3′
Proteasomes
Alk-4
tetramethylbenzidine
15/20
p.Ile128Asn
UBR5
23.966
ically
p.H540R
Toprepare
Ser433
E542Q
ß-r
trkl5
24.29
IRA2
PGM™
anti-caspase-10
8-oxoGdotA-specific
E560
G3238A/
S3A-B
damage99–102
podocyte-specific
18.4
HIP2494F
phase.31,38
Karsunky
~Adari
1176–1195
perinuclearly
PC12/MEN2A-cl.3
analyses23
ATT20
pro-proliferative
cohorts.51
NIC-GFP
InheritedTP53
3912C
Ser1206
CEIDPSKIKD
LoF
S469F
DDM
TβR-I–like
phosphatidylinositol-4,5-bisphosphate
19b
K117E
mutation.79
FRTL-5
sc-53993
R521S
inrepetitive
Computer-based
p.L117P
germ-
ribbon…
anti-Stat5a
MTD.7
noncanceroustissues
Fig.2A,2A
.3,11
0.4620.00037
3,123
PHPT
Q1218*
2.5×107
Ras/Raf/MEK/Erk
KEN-box
*AAA
JetSet
outcome.6,7,9
=1.85
15L
↔KDD
tially
1,625
Flag-FBXW7
KMT2C/D
RAIDD/CRADD,159
22-26
*DNA
NRTN
38–75
Wnding
Licciulli
NP_076870.1
CT52
PodArnt
MOZ-3305
TSC2GAP-stimulated
✉
c-ras
3AT
site–enhanced
eBio1D3
sc-805
1,551
Ser182
43–46
tingible-body-laden
IVSlOb+2delTAAG
G-CIMP
RXL-containing
sh-Ctrl
Dbtrg-05mg
PDGFRα+/
Dovitinib
3s.d
p=0.0075
Cdkn1b−/−
.TCF-3
antibodyPAb
bisulfite-induced
MMP-16
division1
AGAACAATGG
Abbott-Vysis
99,028
83/39
P3-driven
c.1796C
I234N
nucleus-originated
2281G→T
serum-independent
RIMS2
V248
phosphorylated.37
-500
tetrahedrally
xDFG
2/66
moderate/multifocal
immnuoprecipitated
758del4
DeMiguel
CD5/CD20+
dimers11
21286
paediatricians
acid-receptor
gain.93
SD65′-TCTGAGTCACCTGGACAACC-3′
kinase–juxtamembrane
Differentiation2
CD103-negative
Repligen
W33L
128.5–134.6
MIG-C
co-repression
p.P214L
Val787
185K-
.Supporting
1.01
HR=0.35
C928T
.45
Haematopoiesis
HC2
T1799-1801del
univ-lvon1.fr
WebGestalt
cytomegalovirus-LacZ
S351P
genelcUAS53
1/2,000
4500HT
24–48
Sleifjer
MeFE§
5′-AATTCGATATCGGATCCTCTAGAGGCGGCCGCGGCCGTAATGGCCAGCT-3′
FK506‐rapamycin
M149I
nonrecombinant
2^
3.23
F268I
Hox-responsive
FANCG/
175Asp
a/.5
1,340
.TSC2
GTF2I
RERF-LC-MT
214/246
GAP-sensitivity
cells10
byr2
IVC
RTqPCR
~Y32W-Q61H
inhibitors.1–3
floxuridine
HPV-55
C630F
loop.This
reported.4
K-S-V
A549/FGF3
↓K
Ras‐guanosine
.EML
pup
TFE3-overexpressing
7-containing
targetable
L858M
5′-GGGAAACTGTGGCGTGAT-3′
Pre-designed
W146*
repeats.31,34,35
loss25-27
VpreB
.04a
.16,19
30.0
triangulations
20,000–30,000/mm3
42-47
activity41
Arg635
lipogenesis-related
pl6
hypermutable
c.6449_6450del2
10.2
A636Pd
2WSN
10-year
Deletions*
−left
CDK1-dependent
tracts.16
Asp-408
R413P
RA3-6B2
Prizmkit
0.000389
ATP/
.ASP-DNA-FLA
xenograftedbraintumors.U87MG.L
.CBFB
UbcH7.31
1926
combination-therapy
Hap
5-GGCTCCCTTGGTATATGGT-3′
stricto
BCL6-specific
HRD-targeting
Micchelli
mutations=0.16
autophos-phorylation
v-Ha-ra.v
azoxymethane
SULT1A1
un-manipulated
c.72A
K511M
electrophoretically-distinguishable
Gg5.9kb-
Twenty-three
β-embryonic
Srsf2P95H/−
Branchpoint
3OG7
R-caged
.GTPase
0.471
extrachromosomally
37Â
BCR-ABL–induced
MLH1-p.K618A
D11S1993
T-70
sequences22
WT-EGFR
SFIHE
.Material
OHP
rAxin
Hoatlin
rs12653946
1362mel
G430C
p21/PCNA
1–10,000nM
pENTR_L1-MEK1-R5
fragmented-like
TCCC
6•4
K558_V559del
g.46227+
653G
YGRFT
4.Patients
SNL1
D816-mutated
5'-GGAAGAAGAACGATTATCCA-3
K291
assays.44
essential7
recommendations,12
Nola3
Smad3dex8
27–52
IMR90
Tris/glycine/EDTA
PTENP1
AgPath-ID™
homo-oligomerization15
9p24.3-21.1
CCAGCCGAGCCACATCGCTC
5′-CCAAGGCCTTGCCTGATTGC-3′
180.4
Trans35S
half-®lling
D-dimers
R747W
anti-Akt3
1-2μ
GST-f
RasY32F-GDP
8/573
Riferimento
ineffectiveness
JAK1-S646F
SUP-M2AR500B
Overstimulation
NM_021099
21:819–823
inMsh6p
Medizinische
Bödör
an-tibiotics
-*M
wtam
ratio64
IC50≤
KIT,6
AAAT-3
EZH2-β-TrCP
HA-p53
Committee.Cell
matched-normal
nt+7
table2,2
5,5‐Dimethyl‐3‐
10-13
Δ=
µg/lane
IP/Western
activity41,42
R-Hyper-CVAD.59
replicational
10.1006
E84
pY869
unaltered.16
5′Fam-GTC
STE20-like
-3´
marrow–derived
1.58+0.04
c-RAF
YPD
metaanalysis
1sty
lOO-
.7.5.1
5.798
R134Q
3′-primer
//doi.org/10.1371/journal.pbio.0050109.g002Selective
proforms
Vriend
80–120
genes53
Act5C
NUP214-ABL1–transformed
MSH2-NM_000251.2
P1,17
antiNPT-II
DHE
P-motif
best-documented
p.53
a-helical
microseeding
drug-sensitivity
3.80
6/187
P70T
GTP/
A0
CIC-rearrangement
doi:10.1172/JCI33713DS1
treatment,37
403-amino-acid
Diego/CA
MLL-CBP/p300
glycerol-ethanol
RUNX1-EVI1-expressing
intumors
notpresent
MMTV-Cre
1X10-6
HIF-1α-UbK48R
5′-TGA
minigene-based
∼2.3-fold
IGH-CCND1
Fluorouracil
FC-121-4001
anti-TGF-β
pulled-down
tepotinib
ccaaagcgcaacaagcccac
M120K
v5.0
CHIP-TPR-myc
MDM2-luc
Shinohara
P388
pBABE-SOS1
obste´trique
cgactggagcacgaggacactga
3/1000
sc-7534
FMC7+
lung76
Y418
0.3059
RB18-RT-MGB
1.E326G
Winnepenninckx
BRAF2
R574del
subventricular
.STK11/LKB1
ST88-14
stroma101
Figure1a1a
immunotherapeutically
14.4
.Blood/saliva
643-8-cy5-x10
SLHowng
HrasV12
S18D
5'-CAT
CG-3′
CT-defined
MultAlin
EWSR1-specific
2❚
Octanol
hallmark
prelabeled
6841
5154
98-kd
.EPZ-6438
GCET1
57th
Stopped-flow
kinase.15
.Ten-micron
TIR-only
BaF3-hKIT-D816V
BRCA1-Met-297
mtron
gt11
p.Tyr98His
NERF-1A
.C8
PKB.33
cells.30,31
HMGIC/RAD51B
A1234T
allele–phenotype
mAb153
hemizygous/homozygous.67
0.307
G719A/D/S
anti-human
pro-peptide
antiCD27
R274A-bovine
F595
P40
R330S
MuTect.17,18
W.T.
QIAprep
interferon-
p53+/−
1017–1021
Smad4-expressing
exon-trapping
.Findings
—popultations
a-cyano-4-hydroxycinnamic
P=.036
.HSP90
5′-UTRs
.2155G
-insensitive
ss17-
TPTE2P5
6•1–7•0
HMC-1.1
EDC
3'-GGCCAAGGCGCGCGTCctag-
33–39
loops,39
MAQC-II
p53-L194R
TTGTGCCACTGCTGACTTTGTC
paracrine/autocrine
find.ConclusionsIn
10q21.1
alterations19
PRKG2-PDGFRβ
.Smad4−/−
Transcellular
18/32
polyploidy
pY1068
Ectopically-expressed
1.815
for60
resistance137
subclusters
STAT5-activated
MCF-7-SPEN-sh3
HKY660-2B
Subnuclear
LATaq
.ll
p235189
cell-marker
PAX5-JAK2-YY/AA
translocations,1-4and
English-language
antibody–conjugated
Axin
p53-expressing
pLenti6/TR
T286
ectoderm
pathogenesis18,19,20,21,22
IVS29+1G
contradicting
ICL-containing
25.2
phosphorylation/ERK
aagacccaggtccagatg
E800M
282Q
c.3819_3823del5
610822
stain/mass‐spectrometry
Met-to-Leu
Swi1
c.1798_1799insATACAG
trp5
EPICOLON
G984T
GADD45,11
siTet1
48+A297
0.4–2.0
PTCH
COL4A3
13.26
.Temperature
Smolarek
Anti‐Keap1
þ/–
phopho-ERK1/2
phosphophorylation
exosomeassociated
FLAG-mTORSL1
=0.5
Lys416
NM_181523.1
Pre-rRNA
-97
Tuzun
.22C
doi:10.1158/0008-5472.CAN-07-5003
dual-blocking
9,10−dimethyl−1,2−benzanthracene
p=0.37
1,919
Evid
Alfantis
11/7/05
CRKL
.Antitumour
2R3AS
22.2,3
5′-GCCGCAGGGCGGTCGCGATCCTCAAGAAGAA-3′
hsdR
.Foretinib
46·5
−1.5
insulin/glucagon
178117
Deparaffinization
S121
Y1571H
3070
59-TATGTTGATCTACCTCCCAT-39
microtubule–associated
cells.117
downmodulation/mutations
V2406A
morphologically
anti–human-specific
calcification
Helsinki.Fi
pipeline83
Glutamate
PTEN1/2
oncogenity
DEVER
F28
LRB1/2
Toriya
SLC45A3-ELK4
non-S.
EGFR-P.
pCMV-I-Sce1
0·24
CDK6-expressing
.SPOP
.Autocrine/paracrine
β.
prognosis51
11598
sea-urchin
.2174
−3ACC
cosegregatingwith
pTk-hygro
YMXM
full-concentration
3'UTR
KDM5A-amplified
PVRL4
53-2.1
0.36–0.87
8k
lysine-rich
IHC/SISH
–101
413R→G
6A-B
hormone-secreting
Sel10
three-arginine
SH2-containing
5.2.1
Trr-mediated
polymorphisms.8'3
E2-E10
Bax.10
PRDM1.E5.170.F
C0t-1DNA
CCC
,6D
NDh
S32L
demonstrating
CAAGCAGAAGACGGCATACGA
generatedAllele
stimulus-specific
BRAF.22
SCID
Streptococcus
Gnrhr
T-p53-Y220C
FH-tagged
4,429
G1128S
2.94-6.46
1–294
L111P
endocytosis-related
Polyak
HA–INPP5E
5-30
±21.4
months.9-11,14-17
-null
AML3/CBFA1/PEBP2aA
endometrial-specific
heparin-bound
Prefoldin
Nup98-HoxD13
pseudoexons
polyposis.23
Thike3
Hudlebusch
theBbsI
WithKIT
hTF'O
Connor3
methylation-specific
80bp
RAD
41–66
Tyr-1221
-β/D850
pS473-AKT
.Dorsal
clinical-grade
1,043
ABT-751
board-spectrum
V1668del
dimmer–dimer
F367L
.summary
hypereosinophilia
NLS-like
carboxyof
55.21
PIG3
p53-/-MEFs
173–183
factor–induced
PCRartifacts
IgG-
Mx1-cre+Tet2f/f
BcI-2-Ig
round-cell
JPK
-CAGTGGGAGCCCTTCGGCTTCGCGGTGACCCGCTGCCAT-3
Splicerport
Asp770_Asn771insAlaProTrp
RS/PtA
p.Arg48Trp
Streptavidin−agarose
non-cell-autonomous
G693D
254C
p.Arg131Gln
-cgtgccaaggcccgccatg
Gli/DNA
MiR30
sc2005
Mycindependent
On-TARGETplus
V299L-mediated
ATPase-
luciferized
RAR/RXR
p16-GST
interactions,4
ter764
isoprenaline
6.8-kilobase
n=11
medulloblastoma,40,41
R479Q
3608
-Cw7
218_218del
high-gefitinib
9R
A138V
5′UTR-54G
USCAP
W1837R-F
.Cohesin
Pho80p/Pho85p
agrose
6885
.Differentiated
Lumatec
MONO-27
M.H.
123,147
signailing
2,899
NAB1
22/31
1,2,4,6
pair-rule
conference256
389del9ins29
manner50
tet-responsive
med.uni-muenchen.de
IMAGE:4693019
bApart
c.1849G4A
Malaquias
positive.18
S10A
spinfection
oganosulfur
4-d-old
Photolysis
KITV560del/V654A
combined.1
agent-
V50M
L747_A750
64.00
EBI3
Asp816mutations
901–902
sets5,6
context-dependent
GluGluAr
Michel-Servet
tricholoracetic
metastes
zeo-H-Ras
FBPs
458K
2g
aminosubstitutions
G1
c.83C
Lys22
3+3
ofADH-p53were
Y582C
Fgf7
14.0.1
ERK.4-11
herein.57
cryoprobes
CDK-6
S315fsinsA
left-bottom
MMRstatus
MONSONEGO-ORNAN
TTA-3′
dra-
Ebadi
Primer3
FIGURE3
reported.65,66
PF-2341066–treated
R142W
Higashiyama
best-known
protein-positive
.2335G
Brognard
Mst2-Rassf1A
10.1007/s00428-014-1608-4
STE11
cyclopentyl
efficienttransforming
previously3
AnalysisNF1
noncovalent
90.5
BT474/HER2T798M
V727T
histologcial
SF3B1R1074H
8024
1439X
4-megabase
EMBOSS
pG5E1bLuc
cells.Statistical
Antonny
0.046*
37yrs
MPP
Gly463
NM_004612.2
semi-nested
formation13,15,26
LP95-025
Lin‐12
sequences37
G305W15
tolysin
S18–20
D510E
NM_001987.4
60/M
p.P648L
Zorio
7·4
Sud-Luxembourg
α-calc
FGF8b
5.19
Ex15R
PTEN–DLC1
Phe64
ThPOK
kinases16,17
AY501-502
Quickspin
V233L
E229G
R625L
ErbB3-mediated
cEEG
SHQ1-
database-mining
splice.html
377-2
IP26A
significantly-enriched
Hishiya
cells91
P203HfsX38
7-nitro-2–1,3-benzoxadiazol-4-yl
Smad4-Smad4
1-242
mol21
5'-ctg
2024
MNG
Y285
Val-536
cured,3,4
80:40:1
†5
.MLN518
anti–N-TEL
Sym013
1,000–10,000
glabrata
anti-PRDM1
c.2425G
Sepharose-agarose
334
K336MARAF
www.rzpd.de
G810D
M12769
GST-Abl
L1044P
KITD816Vharboring
.Bernhard
Non-Gatekeeper
Mdm2-related
GGGAGAUUCAAGCTT-3′
L310R
rTy
oncosuppressor
.^27841
eVector
DNAH5
cell-bound
KIT.20,21
highresolution
4/28
.Complex
Dork
-CACAGGACCACTGATTAC-3
self-regulator
vasculopathy
Met141
NCT02097810
NF2/22q
N703
guanidinium/
T17A
2107
MET-D1246
B-1408
pocket48
.Brd4shRNA
R287W
.reduction
10.1007/s10689-005-2573-5
Figure4D
R38D
lines.20
pancreatitis-like
9020614
Urotel
effectors.24,25
Tubulocystic
sites.36
R38591
non-hyperdiploid
T645Q
c.5991dupT
S261R
L387
NZM37
S253/236
1.032
aaagaggatacgaatgggacttg
Transfection
Chantilly
biopsies.38
PI-87787
fluroide
microattribution
29235
1,623
AMV
steroid-binding
PI3-Kinase
300–400
pancreas.ResultsTargeting
thusimproves
D2177N
3-6
eLife
dis3-A588P
0.261
anti-CD25
NCSTN
hash-mark
therapy.The
I35S
0.01831
LR08-422
enzymatically
1:400
SARGIN
BRAFE586K
0.23–1.25
85.8
c.3823_3826delACAA
Tal1/Lmo1
METHODSPatients
1.337
Joosse
FAT1-Trunc
methyl-directed
NCI–H2228
Delta-like-1
extrap
DS-Red-tagged
sc-9749
PAX5-responsive
K243R
dynamics-mediated
Setlur
CyTOF
Lys1030
16/30
anti-acetyl-K373/K382
antiphospho-PDGFRA
c.7151_7152del2
TyrS37Asnsubstitution
Rnasin
Carnation
8–17
Tsihlias
paper-and-pencil
Eyholzer
LLPVRW
KINOMEscan
CIT-stimulated
15-22
anti-phsopho-p44/42
.15,17,18,20–22,26
features.26
chloride–potassium
3–9
RasGRFs
0.6184
BglII–ClaI
polypeptide−5.6FLRT3aFibronectin
lymphangioleiomyomatosis
2941–2948
virus-accelerated
Bellinzona
−MMS
N181S
PBRM1-
29432664
expressing-but-not-amplified
pervanadate-treated
counter­
p.Met145Trpfsx36
293-T
.specification
patient/family
Shovlin
3/82-2183
RAD51−/−
Modrek
2976
lymphovascular
NCT00703976
CD4+CD45RA-CCR7+
.39
Fig.8D
nihms646437t13.jpg
KDR-amplified
¯exible
Theoretically
pHXL
integrin-NFAT
+KTS
tumors,28
Ile-121
Cutcutache4
CTR2
μg/μL
4-HIS3
.Efforts
R841C
SnpEff
chondromesenchymal
shTCF3
zinc-binding
Ka=0.09plusminus0.06
T164I
CCCCTGAACCCTAAGGCCA
T305A
inhibition.28,29
2μl
Sensitivities
1/50
PTCL160
inhibitors.7
48.1
3–5-fold
activin-mediated
RB-Compromising
vivo.Experimental
re-heated
.Priority
alanine-to-proline
round-up
slideAfter
DMP1
single-attribute
44†
15,079
.Danielpour
Pre-Tr1
CBF-AML.CSVDisplay
reports11
ndividuals
.23,28
63-year-old
Ig-III
.FA
p14arf
overexAddress
B220+IgM+
HYAL3
92,701
state.2
micrometastases
W133R
Ota
subtypes.108
Zhang_targets_of_EWSR1
12079
N/mg
Mono-Mac
12.5G0.7
PTPρ-JMD-W
NM_004333.2
QRY364–366YHH
14.2
hormone-naive
minikit
quasi-universal
Giemsa-banding
Kurabo
.Treatment-related
TdT−
55×
manner.9
8H10D10
TE-13
.Failed
0.1581
2.92
STBL3
LXSNAKT2-S
hsp70
/median
Myc-DDIT3
RCC-1b
K6
AHCYL1-FGFR2
Mdmx-induced
H2AK119ub1.87
33:642–650
AATCAGCGGGCGGCAGGGT-3′
1,261
-/-
CAGATG/gtaaaa
114.04292
deletion22
25-l
number3
PIK3/Akt/mTOR
.Mitogens
5.1
5-μm
NM_011497
chains22,26
CATGGGTT-CTGACGGACAT-3′
PE/CA-PJ34
Linsitinib
IMR5
–phenolbarbital
generatedvectors
positivityc
protein.45
H2085
germ-line-derived
andPro-34
JMR
CENTA2
7/24
16q23
hypomodified
=25
104-S,104-1
-actgcagcagcgaatatgc-3
Raf13
.Carlsbad
Mll-Targeted
onsome
*99
peroxide-sensing
types92
immunodeficiency-related.20
22.30
amplification.Figure
Isoforms
N°
products.7
Abcg2
TMPRSS2-ETS
9/30
Q1259K
161K
.ResultsA
K3K9/14Ac
caggtcttgatgtacttccctcgtttgtgcagc
counter-balance
PCR-enhanced
NHEJ-deficient
surgicallytreated
sarcomatoid-type
mir30
S16N/H
.R1744A
20,23-25
.Arg-280
Rwork/Rfree=0.184/0.228
hydroxymethylated
reviewboardofeachparticipatinginstitution
ttcttacag
FMTC/MEN-2
giant-cell
both.The
di-demethylase
IDH1ex4BF
kinases,6,21
pentaplicates
sc-44
GST-RHOA
KTN3379
R213Q
DCC-203655
35-month
involvingcrude
activation10-12
3′-tails
.Figs
M0/1
7/58
cases.17–19
fragmentcorresponding
specializedin
.1C1C
Val79
phosphorylated/activated
KDR–PDGFRA
9258delATCAT
q21
1p32.3/CDKN2C
PGK-ATG-Frt
AML1-EVI1/EAP/MDS1
PPLLSG
Collège
ERK2-D319N
Ala77
vitro129
PaCa2
150047
pre-neoplastic
.First
TR/Napthol
gencode.annotation.gtf
c.-124
membrane/Raf-
GAL4-driven
.Koeffler
Elf3Δ60
KVSFS*
ancestral
co-regulated
pGEX-2TH
49,6-diamino-2-
CTAATACCCTGCAAATAGCAGAAGA
P2476L
.0270
beta-cell
Burch
Errfi1
G12R
prognosis.28
Plasmids—The
p=0.004
Kfir
8-cm
Borden
NM_173569
.FireLUT
1.50/2.31
HumanCNV370
Arf17
RMSD
R382Q
andB
NDR
A/195–216
CK-19
FGF14
www.funpecrp.com.br
immunopuri®ed
isochromosome
2350T
p85α-nSH2
SMU030R
SK-Mel-103
LPL
Gcn5-related
1e8x
NOTCH4
.Olaparib
RARa1
02-060
referencesequence.The
ACVR1B
K854M
148G
5,13–15
non-NTRK3
PTPN11Mutations
7317
ATP6/8
heparin–
T766
HBEC5KT
TT2609-C02
densitometer
nucleo-
3E–3G
Grieco
3600delll
P212121
2-aminoethyl
R24L
mitosis22
HR=0.482
MYRA-A
56-92
silybin
leukemia/lymphoma
1824
anti-CREBBP
rhabdomyoblast-like
X-RARa
syndrome75
hmsh3
single–base
-IYETDYYR
on17q23
Hospira
.1349delT
Notch-targeted
tumor.METHODSPatientsAdults
lor
ACTGGGGCCTGCCCT
ceptibility
3p24
.Proinflammatory
heparan
Asp770
GGAACATTCTGAGCCTCACC
RP11-168J13
PH-GRP1
RG-1
.Extents
EWS–WT1-responsive
NFATc1
.Abbreviations
scaold
4/163
MutSapreparations
∼1,500
P1–3
.282
0.7kf
J001
0.69–1.29
−3.7
carcinoma.36
Thr599
5′-TCGCATAGTAGATACACATGAACTTAGTG-3′
non-BRCA2
GST-BRCA1
sulfosuccinimidobiotin
30kb
Santagata
naevi
5'-TCTCCTGCAGGATGAT
King-Underwood
0.4161
tumorigenesis116
ERCC5/XPG
EZH
ASXL1/SMC1A/RAD21
ALK53
BaF3-hKIT-Y568-Y570FF-D816V
N172K
adhe
BIM-I
FKBP-rapamycin-binding
alterations—patients
Antiandrogens
Map.48
ACAACCCTTTCGAGTTCAA
microwave-citrate
40-60
ACACGAGCAGTGTCAAGTGC
pfg043T
G218D
TGF-ÃŸ-regulalcd
GW-572016
FgfR1
NO-aspirin-induced
Histologi-cally
1197TRC
WSU-HN13
p.His92Tyr
V213M
E25
PrimeTime
.Hematologic
driver18,19
AktW80A
pcbi.1003749.e005.jpg
Bruick
.Medians
.Three-Dimensional
PI3K-imposed
Debril
3p24.1
5′-GAGGCAGAAAGGAAGCGAAGG-3′
variation36,37
metalloproteinase
Makaton
130A
PEA-15
+22
c.16241G4A
22.05
previously.72,73
NK3
98101-1304
G118C
54`
interchanging
Neuroendocrine
∼330
RasGTP
nonimmunogen
DNA-dependant
p110α/niSH2
metric17
signaling36–38
Figure3H
doxcycline
Langridge-Smith
.9004G
conversion-specific
APμ
–4
5-GGAAAGTTGTAGTAGTCGCGACTCTG-3
cells/filter
phospho-T308
Plagge
5-CCCAGCAGGTTGATGATGTTTTTG-3
38,40
reportedthat
42repetitive
plots28
15q25,9
4070
RPMI+10
//www.ncbi.nlm.nih.gov/unists
Highaffinity
Ubiq
neck52
TAM
oncogen-
mcg/ml
polymorphs
FGFR2-AHCYL1-KD
pathway-deficient
kinase-defective
,15,16
naso-gastric
1Ci
RALBP1
coinhibitor
med.unc.edu
CghHome.cgi
MC1R16
development.27–30
.CIC–DUX4
W.C.
C72ins
A2942T
TZ
3900
TAp63α/TAp73α
R175H
1.82-fold
ATC
83.9
centromere-maintenance
expression.1,21,22,23,24,25
cancer7–9
3404
PIVKA-II
al.30
GSNAP
custom-compiled
.705delA
1–mediated
p5398
anti-phosphoinositide
phospho-KIT/total
c.262G
.Size
Pierre-Olivier
0.0996
nucleophiles
2244
npr4
cdc‑2promoter
neutravadin
2-nitrophenyl
3537
maleate-d3
7.3°
Tris-Cl
G419V
P207′
84.86
Haplotyping
Sigal
mÃ©
3150
intention-to
AD-fused
.PAX9
five-member
discussion.28
MgCl2–0.1
GATK36
positive.7
luciaanna.stivala
125–145
Somerhausen
supportstransactivation
c-Met-Rat1
BRAFKD-ΔNMEK1
PML–RARαs
VivoHEK293
76/85
3ζ
PvuII-like
β3-lysine
1D+
intermediate-riskand
PuPuPuC
TGC-3′
ER−E2
isozyme
1b-e
D16S303.9,21
burden.26
S269X
1,029K
L232LI
0.06797
1099C19
7235
p38-activating
J.B.C
+141
Xpf
effect.33,34
spot-mutations
mAb46
unit/ml
V55
SDI1
rad50Q1262K
TC-rich
Figure9,9
b.i.d
HA-MKK6+
.invasion
q24.12
2′-/3′-O-
Y537N
pT24
F38
CellConcepts
Glivec
Sheiness
.RET-dependent
7,692
ATTT-30
favorthe
1994.
lines.18,47,48
6FUROOWRYLHZGDWDEH\RQGYLHZLQJZLQGRZ
Stop/PolyA
GGTATGTCATTGCCCACTG
trials.44
.RT
ALAMUT
AGAGTGTGAAGACAGTTAATCAA
CIC–
5′-AGAGCAGAGCTTCTGGCACTCA-3′
0.05–0.77
MPN-unclassified
K618del
recession
-CRY2
77.84
E349
Anti-myc
neuroligin
MYD88L265P-expressing
786–907
GFDS
Figure11C
T117R
nsSNPs
France.19-20
B_R1023
-labelled
Abl-
miss-segregation
Mec1-deficient
CD150
kinases.12–15
Rms-Rf
Colony-formation
R618A
PRDM1.E5.46.R
1'
5′-CGGAGGAGACGTAGAGTTTGTCTTCAAGGTTTACAGTGATGCC-3′
microemboli
Inhibition
sub-clonal
described36
1,440
.Accordingly
p53-R280K
HOXA
al,15
SCCOHT—creating
tumor-permissive
Nlower
p.N308D/C459G
LSIL/CIN-I
.Fig.6A,6A
8,5'-3H
H2Ld
Perona
nihms703640f11.jpg
804–807
T790I
ERK1/2.41
Ser318
Lendel
156nM
REDD1
fusion‐positive
E383A
Figs2B2B
T5628C
T1691I
Tamborini
c.980delC*
10-12
190–260
4.9‐fold
UV-treated/untreated
.0147
phospho-c-Myc
NF874transformant
11-bp
C2orf21
eBioscience
pIRES-*6A
Interferon-α
.Phospho-histone
1–cofilin
ICN1
Single-strand
design.19
40–94
2005b
trp1
DOCK3
p.Arg628X
Merlin-negative
AtmC
EBV-immortalized
SxxxG
78644018
TNFRSF12A
M11
leukaemia.39
180–187
39377
MC1–neo–poly
C-LHNENSDRGGSSKHNTIK
.Targeted
.R281T
mutagens.3-5
R562W
103rev-2
exist18
myr-hp110α
pSG/
.775G4T
8240
−6.34
Maser
blood-borne
www.genome.ucsc.edu
protein,10
glutathione-affinity
described33
activation.8
622–919
Furthere
electrophoretical
−2.65
2/16
transcription-based
MutSLH
22q11.23–q12.1
clone-K9
D103nt
0–11.4
heterozygous
W80A
diagnostically
Kamakura
S-phase-associated
p.Ile95Leu
E512X
p.F298L
A133V
ARHGAP26
.LVSSRSSQQTC
noninfectious
Asxl2
c.8755-1G
perihilar
wel
genomic-based
Bersani
to40
RAF–ERK1
R130G
FO-IC
La01r-r^NIIC
HCM-associated
trans‐forming
0.1226
CCND120,22,23
mob
BRCT-mutated
Gene/splice
RTK-IIIs|
Anti-chemokine
clinicogenomic
inhibitor-containing
magnussm
birth.39
T-induced
13060
Soft-Agar
MQCs
39-011-993-3628
PLX33975
RP11-144B2
CRAF/NF1
phosphin
2.15-8.28
OAW28
AAGGCT
intoscid
Hemagglutinin-tagged
61-3606
CldU
translocations49
RHO-family
EGFR-Akp
BTKKD/B43
FPR
9.2Deletion
.TGCI-induced
others34–36
prognosis.9,10
μM.75
k-mer
3861
HLA-DRB5
multi-slice
ole
–60.1
GTGTGTCCCCCAACTACGAC
8/18.2
interaction–deficient
bio­
GACAAGGUCUGCAAAGGGUUU
reductase-dependence
3,4,8,11,22
duplex
AR.Although
X18
pathogenesisof
earlier.1
c.218T4C
WNT16
processing.167
//www.sanger.ac.uk/genetics/CGP/CellLines
Twopatients
DEAE-cellulose
EstablishedMSH6-null
energy-optimized
characterized.28
factors23
cbt-15-428-g2
UV-Vis
types42
Tyr568Phe
Hox9
cluster.9
p.Asn267His
KRAS-containing
neighboring-nucleotide
Grunstein
MYCN-amplification
uroplakin
KFO
sulting
resistance9–12
RP11-330L22
patients.13
43–61
GLFG-1
nestin-positive
NHz-terminal
80Â°Cand
.8520
inhibitorsWe
Coulter™
elutedfrom
red–conjugated
Mek9
IR-treated
E1210
Castellone
155-bp
/DGR
P81L
endogenous/exogenous
Ser→Stop
80-
Glu124
belowThus
kinase-directed
J.V.S
X3C
Tris-buffered
Labome/DNASU
anti-P-Thr68-Chk-2
BL60
VSMCs
Invasive
.Laser
observed.3
microRNA-142-3p
DDR2-R
hormone-releasing
cells.7,39
HCS
5′-CATCCGTCCACGTCACACAGT-3′
3xE2-luc
FN+TN
KIT-SCF
failure.20
TCRbeta
well-recognized
W80C
micron/min
EWRS
1/70
considerationonly
regimens2
Heidenblad
JAK/STAT5
gene,7
methanolat
mTOR-based
Yatim
subtype1
wtAPC
BCL-XL13
p.D63E
75-years-old
.F1
PheleuS•r
G468ABRAF
hypereosinophillic
DAVID.24
.Platelets
Ki-rasG12D
SYBER-green
BamHI-NheI
5′-GGTGAATTCAGTGTAGTACAAG-3′
.600
andARSH4
.Yap1
4,5-dimethylthiazole-2-yl
17beta-estradiol
tumors18,48
5CpGdotTpG
other,13,31,32,60-65,72-76
c-terminus
Q92
.San
TP53Database
p53-heterozygous
domain-associated
AY519502
KRAS-K117N
year/M
groupa
Smg1
C.elegans
R=0.58
2.4–4
Ser252Trp
hurhan
described,41
L305F
RhoNox-1-labeled
P794P
true-positive
and4.4
BamHI-linearized
wound-closure
S370R
C783S
L747-E749
PKC-dependent
NSM
researchwas
PTEN–COL17A1
high-magnification
IF-FISH
RÃ©f.40
SCSandp21-containing
GAGGA
retrospectively
YGK
37/285
912_916
•MutLα
1,501,072
SLR21-26
CCA.27
non-dipyrimidine
oncogene22,23
Centenera
7400
p=0.0548
D2033N
D2S136
v-Has-Ras
G418/gancyclovir
anti-PDGFRB
35mg
site–specific
myelo-
survival.23
non-consanguineous
FGFR3-C
NRF2-driven
KIAA1267
JAK2T875N-derived
www.jimmunol.org
B-non
regulator.94,106
themselves-
20/62
Cys817P
RP11–77G18
intermediate/unfavourable
5'-GTGTGCCTTAAGAAAGAGTA-3
SUMO-dependent
Evi-1
Flt3-ITD-positive
tumour158
mechanism-based
c.118G
.Odin
10.1–10.3
Tagaya
transformedproviral
TGFbeta-mediated
C-KIT
epoxomicin
NOMO-1
Crystallisation
samples8
Q15CKl
cancer138
DNA_METHYLATION
n=number
96-bp
IGROv1
6.Identification
T283P
UvrA2B
cells.CSR
super-resolution
1.5:1
immunoproliferative
125I-dU
IGF/
0.871
GST-PALB2
≈730
32D-Kit-WT
IgI
acoiled-coil
Flpter
transfectionwere
Belloni
.Hollenhorst
PTK-s
0.511
39-62
10,486
porphobilinogen
2,061†
2,4-dichlorophenoxy
Score§
semi-quantitative
170R
RAF/MAPK
141.00KB
RNA-RRM2
anti–B7-H3
Ras–MAPK–ERK
KLC1-ALK
52/50
2E-G
B-RAFi
5′-TGCCAACTTCATTCCCAGGGT-3′
Lineshttps
Stat3-disruption
Bioreagents
5'-GGT
p.Pro699Leu
HNPCC-linked
Q889H
acetylation/activation
_IDH_-mutant
GTPaseactivating
low41
AML.34
RalGDS
αβ+-DNTs
genehMSH2
Dpc4/Smad4flox/flox
Y1284
porcine-IDH2
neoadjuvant
p300ΔHAT
.Characterisation
ratios=1
Flag-Avi-tagged
3-catenin
5/55
sc-1019
CAG→CTA
0.0124
A2020V
IL-1R
non-targetable
ultradeep
2C5.1PTGFRProstaglandin
−1.01
FVB/n
64.58
TGF-ÃŸprobably
168A51-42
Ig-H
aminotrans
MAMLD1
DHEA-derived
micro-deletion
variablefamilial
HuH-6
Glycine-rich
51-53
Leu1519Pro
tErk
dual-speci®city
5416
blastosis
T454M
Gle2-binding
GCI
PAK1-directed
CAACAAGAAGTGGAGAATGTC
.05
RASTER3D27
8a
SPEN-positive
CCGGAATTCCGGTTCACTCAGGTAGCCAGGAGGT
tuberculin
co-inherited
R6364
E343
therapyUntil
.PKC412
diimide
granulocytic/monocytic
R98
R272W
Sedy
antip44/42
30.5G23.3
50-209
disrupted.15
controllers‐deficient
commassie
Y842N
haplo-insufficiency14
88/134
ACI-positive
190/261
familiesthat
0.5057
monastrol
4A4
pEAE40
+NK
G661R
1620–2931
GSK1120212
CD3δ
Dermatologie
ESCO2
Oberman
-21.1
ARV-specific
Por®ri
somite-derived
50‐ml
.J.
347:481–487
2C-E
S745Q
5000TD
RAD51C-008
Ishii5
FANCG-mRNA
95Â°C,30
L611V-
PTC2
imatinib.4-6
K320E
3.27
B-ALLs
p53NES1
A502Y503dup
streptavidin-phycoerythrin
VHL-containing
350μm
independent.22
D538G-ER
.Scappaticci
RK3Eb
subepithelial
pH7.4
Fig.55B
interferometry
000267.3
ASXL1-BAP1
butylated
18-mm
Lys-35
reduced.45
Oxnard
described.15
2.3–39.9
4.8-kb
0.01x
Shikama
TCEB2
K-ras-activated
456-fold
.Cyclopamine
lapatinib-sensitive
74.1
Wa¨hringerstrasse
Chromotek
N78.5
antimitogenic
¬100
L330P/R
RAFS427G
myc-Axin
ampicillin-sensitive
Pim1-H68Y
//www.ncbi.nlm.nih.gov/blast/
.CCND3
alignments––formatted
method.29
entitiesNVP-BYL719
G336fs
B1353
D810
E28-381
.Parkinson
I171V
cnc
resonance/response
24.4
G4410-90020
ATGTGGTCgACCATTGA
IL-3–independent
unreported.28
51/72
Banu-Hilal
endometrium-specific
Ox
laurentii
J.Total
antitotal
Mi-2
Mthe
256.1
HR=5.76
43,882,030
5′-GTG
L858R-3T3
ofreactivity
Symansis
His-E1
magnetization
Hil
1172T
RG-11
59Rabaptin-5/PDGFbR
CDK18
IIv
.Web-prediction
studies.15
R903
clusters.Full
.EEF126
Δ417−419insY
10-67-positive
GTTGATCAAGGAACCTGTCTC
9/20/05
light-induced
multidrugresistance-associated
2a-g
sensitivity.17
17,26,27
Ala1453_Leu1558del
luc2p/NFκB-RE/Hygro
T1m
3•5
PIK3CBD1067A
Neuroblastomas*
L-PK
.Light-dependent
anti-NRF2
.126
=18nM
19,20,24
G607E
mg/kg\
PROTOR
5′-GCTCCTCACTGACGGACTTGTCTG-3′
TpN61R
30-amino-acid
KIX–pKID
weremaintained
leukemia.15
-P95H
14d–f
notallow
1–480
MIB1/Ki67
doi:10.1038/onc.2008.411
PKBW80A
CSD34
PDGFRA-GIST
Fzr1−/−
P262L
1,4-dithioerythritol
signal-related
107–126
273C
Ohmaha
Atm-/KD
3.9−6.6−fold
anti-AMPK
72–74°C
GTTTTCACTAATGAGCTTGCC
rbf
exible
alsosuggested
tanta-
Benajmini–Hochberg
Betscholtz
dcov
7.03
BRCA1/BRCT/protein–protein
5-mC
matrigel-based
46-Reverse
mononucleotide
leukemia/cancer
finger-printing
beenidenti®ed
.Fractions
.Mixed
alpha-2,6
apo-pKID
proliferation.Figure
6550
140481587-140481567
angiomyolipoma
Ref.23
1104–1109De
FGFR3-IgH
2.370.5
FAM-labelled
L932F
deoxycholic
CDC25B
RIJ
781C-T
MudPIT
transcription-PCRTotal
NaeI/SacI
NFjb1
f60
TP15
LIV-1
Zacchi
Smad4β
pathogenesis/biology
reexpression
chromosome-level
26,608
IG5
RCC-associated
c.6935T
AAATAAGTTTGTAAGAGGAGCCTCAGCATC
M772
10d8~
imb.a-star.edu.sg
609291
SEC14L1
563–577
p53c.659A4C
5TATGGAATGCTGCTA
inhibition70
GR-34
1–1,305
Magnaporthe
Fig.33
pGal4B
GCS
0.001614398
21015301–24537100
.EglN
HEK-Jak2-T875N
imatinib.23
microinjection
D408
HERVK17-ETV1–specific
67.22
5′-cgtatagccgaaattgc-3′
Research—Endocrine
270–552
PR1684F
SIGIRR
0/18
p300-induced
TOFGLAKLLGAEE
www.federa
re-absorption
G309A/E
.Homology
LysoTracker
∗∗
.United
D1226Nmu/+
L128R
tumour-TMA
Lutte
doi:10.1007/s10549-011-1599-7
H274L
pCI-7.1
20020408
48109-2200
GDP–GTP
pLRD21
ΔGH2O
c.3902T
anti-p21
Santé
KIT-
.MEF2C
.Monomers
nucleophosmin/anaplastic
NS/LS-associated
Sakurada
Kappler
motif72
3′-GGGACAAGCCGAAATCCGCAATCTTCATCTTCC-5′
Glu286
CRLF2
SgfI
proofed
0–33
Klopferspitz
anticatalytically
R2108H
MT2
dp1–dp5
P-J-YY/AA
10414
.ACA
doi:10.1186/1471-2326-9-1
MLLrearranged
Y165
2t
'a
suered
short-
MAP2K1-specific
4/307
D221A
178.51
1,22
.PCR-amplified
P699L
E205
13—18
METD1246H
2369PR
Asp870P-Lys665M
ALL.4
5′-TCAAACATTCCTATCAAGGAGG
P250
916K
128-
gefitinib-to-erlotinib
1A1A
Sakabe
LC_S51
characterise
uleuAspGlyGl
Hematopathologic
p.K728T
1268G→A
RCAS
K668
CD3-FITC
disengagement
CMV-TFAP2
titrates
DNA-binding-competent
68.3
Ph3
anti-pan-JNK
c-K-ras
MEF2C
TP53R273H-transfected
1.8–417
2,774
p.Tyr537Asn
lymphanigogenesis
oversimplified
40.6
CS05
Gaidzik
Discov
AFF4/AF5
4−kD
hSkp1
p.Asp538Gly
p110βΔ/Δ
c.2040_
NEDDylation
.Removal
Encouragingly
NPM1MUT
Marrocco
M340QL344R
IP/input
S100A4/FSP1
21313
Sf9
prominin
32w
inhibitoly
=0·05
stabilization42
hybridomas
10–98.2
NotI/HinfI
al.,1999
reviewed4
p.Gly2032Arg
211–723
Ohnishi
NER-dependent
4TYE
2.2*10-12
Intraventricular
H2AK118Ub
TNF-alpha
damage13
JAK
MEN1
K31R
30-36
Mitochondria
cxperiments
dysmorphia
cdc2-activating
Deffie
B/X-HA
Del747–752
FANCD1/BRCA2.38
420KB
differentiation1
0.074694
trimer.Figure
K579K
amplification—all
TRAIL-R1
zygosity
51-56
2,0
PEA
.Methionine
3rd-instar
ball-and-stick
challenges•
P22S
epidemiologically
cultureTo
24/60
Cimprich
0.75–1
latestage
.NF1-GRD
.Antisense
32.21
leukemia.31,33
MBII
'SKN
H277N
187K
Pparg2
.single
solution/1
1XR1
E373K
R.P
blockers100
Pro904Leu
c537
326-bp
aresummarized
2y-PFS=86.1
rapamycin-resistant
p30
˜30-fold
TskLV
aCHG
NP_000480.2
.Live
CAGCTGGATAAGGTCTGGTTTAATGCTCTTCATACGTTTGTCAATTTCTCGATAC
HxD-histidine/YxD-tyrosine
Gli1ZF/DNA
subtype23
CAGCGCGGGAGG-39
gland.19
Pvt1
MSH2-A272V
showna
unit–granulocyte-macrophage
CKIα
D16S3095
−f2
FXE/DXXXL
Noncutaneous
,2a2a
R496C
complexes.37
tissue19
Izatt
n=59
IHES/CEL,2
SVEC4-10
BR3
isoformsA
p.Gly322Asp
mLta-Forward
55°C-
LC2
Fig6C
rAIIylSAlProaP
AOF1
TRIS–EDTA
MAP3K10
Q31delinsE
nonhydrolyzableATP
RAF–MEK1/2
p8533-36
.U87MG.ΔEGFR
echocardiograms
post-MDS/MPN
GCGCGCCGT
Z≤−2→2
macrophage–colony-stimulating
igv
8.2‐fold
.MTA1
−.31
tumor-node
3CRV
GGCCACGC
GJIC
protocols.8,19
9.33
SFA17c
ErbB3-Y1197
.select_db
Kyungpook
IK..
-MT2
Chimerism
patients.Mechanistic
mail.uni-wuerzburg.de
FLP/FRT
.RCC10
CD74–ROS1–G2032R–expressing
chromotripsis
572O17
385:1
LOVD-IARCe
9371
c.846delC
.Three-color
E709G
GDNF–GFRα
104-0045
Ehlers–
L1-mediated
wart-like
prostate-cancer
2.1/NA
Saitoh
Hypond
NASH-derived
these—LDK378—were
pT21
Flat-headed
molecules19
R1849Q
Lys−
2A–2E
1:0.5
differentiation,34–36
P2–P3
14,21
Pargyline
UPN11
p.Gln61Arg
pre‐incubated
RARA-RARA
CD62
pEGFPC3-TNS3
Sk-Mel
AGATGGCGCTCAGGCCAC
Ter119
p16–cdk4
PIK3CA-transfected
Thr169
exon6
3872-bp
structuralrequirements
WAKO
-EPOR
hBAP1
2TMPRSS2/PLAP
YOO
ClinVar
vector–transduced
MCAP/MPPH
n=261
HCC24-0309
BATRII
29–31
phenomena95
5'-GGAAGCATTCAGAATGCATA-3
0.876
Ex10B
CATCTGGAACTTCTCCTGGTCTCTCAGC
Rennstam
M886
60.6
lin−
SF295
0.49–2.73
EGFP-tag
Veliparib
Kdm6a1
TissueTek
D410H
ActivationWe
bcatenin-LEF
insulinomas
A365T
Msh2+/∆
NHM2
0-1
Stanca
W237_Y242del
PCR-engine
alÃ-eleshas
acidresistant
Eps15
M89-61
IVS17-9A→T
H1299-EGFP
Anti-IdU
Close-up
PML/RARα-expressing
non-phosphorylatable
DDC
pLysE
miR-181a
CEN-based
2564A
Y279C/FL
=73
5′-CATTAAAGGAGACCTCACCATAGCTAAT-3′
1.019–1.115
P3221
Non-Mammalian
1H-pyrazol
PKBW80A-expressing
44.6
domain/kinase
patient/tumor
α-helices
restructuring.21
2171
12.6
treatment196
CTL-activity
9/76
p53-INDEPENDENT
−.87
αPTEN-HRP
vinblastin-avastin
leukemia.24,26
SCD2
ASCL1
.HDFs
Lys-18
CCATGATTCTGAATGTGCTTAAT
FERM-domain
shRNA-infected
4B–G
Blotting—A
2J–M
2/type
XhoI/HindIII/NcoI
dROX
3p21.31
V299L
Galacto-Light
pathway.6,13
Gjb4
RPP1
45-55
50.05
Zsengeller
insertionsdeletions
D08-0537
pBEND2-S9WT
osteosarcoma.MATERIALS
P178S
SREBP1c
61/146
SOX17-M-antisense
EWS–ZNF278
54–493
insert.The
A502Y503
gene–amplified
enhancer-derived
5'-TCATACTGGCTAGTGGTGGAC-3
cycle—a
crypt-like
damage9
duodenopancreatectomy
8:19
Yonsei
Genome-Wide
.Unpermeablized
.RESEARCH
Viskochil
T5
auto-sequence
EFS
0.152†
therapy.36
Genentech
AdGFP
CGCCGGGGAG
Magliano
Axltide
EV-control
chemotherapy-driven
0.054Others
sc35575
viscous
incoordination
invasive/metastatic
4xHA
expected.Differential
Prokaryotic
E622
.56177067TG
.ACVR1-ACVR1
UBF1-binding
pCDNA3-p53
Nascent
H3K27Me2
3.3875
-avid
avidin-conjugated
dUdUCAUUCUUCGGUCUACAATT
S3O
IVshowed
U2AF1-transfected
G126D
3,3′-diexyloxacarbocyanine
Mn11
elsewhere75
P356delinsQK
K2CO3
AKT1–PH
8392
RG-16N
**-
Thr421/Ser424
pXP20
FBW7alpha
WHI-P154
1Ad
4.9-cm
A680T
//informahealthcare.com/doi/abs/10.3109/10428194.2015.1068306
αpTyr
p.R304X
Intrapatient
methods.Of
ThermoScript
Q=9.2×10−4
AA425556
esterified
SHBG
junction/cardia
NEL025
S433C
function.33
2.695
Thr-P
Tyr101
2234
.Transferring
syndrome5,8,20
G-250
.Older
I'l
sonifier
Glu-672
MLL/T2
MutationTaster=1.000
Mm6.6kb-
792–806
FGFRs1-4
Texas-red–conjugated
NHERF1
STATs.15
3.38
B-myb
K659
ID18
two-chain
125I-BMP9
162KB
Immuno
64.8
K384E
.Monophosphorylated
K48R
endomembrane
photo-excited
5×
anti-IgD
AA4.1−
HHR
8.03
STAT3-mutant
1–1305
memory-efficient
16/600
CS18
MMPM
.YPH499
EGFR-V742A
1314–1557
Cre-deleted
35S-methionine/cysteine–
PROBEFAST
QBSF-60
TGGGCTGAGGCAGCTGCCTT
Foxa1-negative
K320N
spectrofluorometer
trigonocephaly
0.5.7
P-40.In
125I-deoxyuridine
codon
PIKKKEL
polyps37
RBM25
MSCV-puro
development.5
LW
McCoy5A
Figure7,7
overpredicts
Immunofluorescene
KH54
al.9,67
NMyc
coactivator/corepressor
PDGF-B–PDGFR-β
erytroleukemic
package29
tumors.23
bicistronic
4.06
intracellular
115422
t-AML/therapy–related
carcinomas41–45
previously24
5-HT3
myeloid/macrophage
Chondrosarcoma
cytoplasm.43
Flt3ITD/+
andR282
MSCV-eGFP
.total
short-indel
laxa
routinemolecular
CD81CD42
Baserga
Fig6D–F
receptor—eg
HpaII-restriction
lso
2••
Dahlén
4b–d
Leu-510
mutation-acquired
14/18
GSR-coupled
Gel/Mount
androgen-refractory
caatg
Q597R
InstaGene
SaOS
17th
1.000e-4
-63
BCAM-g3/AKT2-g1
equilibrium.4,11
mouse36
*5′-end
powered-fields
RAS/RAF/MEK
M286T
His-agarose
1GT
P724L
Snf5/Ini1/Baf47/SmarcB1
light-based
571R
T133/T137
Epidemiologically
YF/DY
50×109
.Asp300
Q203D
Lundin1
684/A6
AA621-AA713
S-region
Thr354
CCCACGTGG
W535
snR190
QSG-7701
S-3
XP-causing
v_6.0c
GTCCTGGGATTCTCGAGGTCGCTTTGGACCTTGG
superstable
αPtyr
pathwayare
Reversal
65107
RhoGTPases
A405nm
.Exact
andPMS2CL
sh1-sh4
Green-conjugated
b-cateninS37F
PDGF-A–PDGFR-α
D621N
re-ChIP
Emiko
.Fiberoptic
0.01
eigenvalue
models28
beta-sandwich
1015
Béroud
F157L
IL-2–Luc
Tyr826
posterior-anterior
p.Asp539Tyr
p53-dependent1
BCL2expression
NCT00507767
Hinf
TP73L/P63
PDGFRA-sensitive
M793T
untreateyd
0.0577i
Histology
two-sample
www.hapmap.org
/2
Investigacions
12q13.12
disease.21
S1655
8-replicate
J-041170-05-0002
9.56
M13R
Tris-base
11Val560Asp/13Val654Ala
197–259
p.Ser615Phe
.GAS6
EWSR1–DDIT3
air-dried
IASLC/ATS/ERS
pVL-EF1a-MCS-IRES-Puro
c.2806-2809delAAAC
FLAG-FHL3
-GGTACCGGTGTCCACGCAATTGTG
ErbB-1
Kourea
G357E
2.798–28.573
non-neutralizing
.MutsigCV
Cys266
Storici
Q510E-Shp2-induced
hybrid-recapture
25–33
20–31
studies6
5′-GTTAGGGAAGTTTTAGGGTGTGAAT-3′
TRKA-SHC1
low-scoring
30–200
G37R
ACACCCAGTCACAGTGGTCA
Red640-CCTGTCATGCTGGTCTGCCGCCG-p-30
Akt/GSK3
Ready-to-Go
11q-material
27.1+0.2
microsatellite-stable
.SW-620
E8.5–E9.5
TaqManGene
AT-I
MMACI
Lys-346
M40L-Rluc
way29
H8
GCTATTTCTGGGTGGCCCAGTCTATTAA
/paxillin
3945
PJI
.Occipitofrontal
T308-P
Center50
93.9–120.2
U251MG
Dehainault
Waldbronn
deoxyadenosinesand
per-residue
E319K
5'-AACTTTGTCCAAAGTCTGTGA-3
prestalk
pCI-C
26/40
p=0.0006
μ-BCR
.PI3K/AKT
transformants.KIT
clinically-available
Goriely
Cdc25A,8
non-differentiation-committed
25.2±3.8
QIAquick®
∼1064
×dominant
.11As
0.1654
RRM2B
—interleukin-3
CRL3-dependent
iodine-oxygen
PNES-GrG
EGF-independency
Poznanski
2.29
Sef'=
5′-CTCCTCGCCTGACGAAGAGT-3′
Variome
MBD1
GDP-state
MLL-MLLT7
B-T
SMART-RACE
448CRT
HERVK17-ETV1
H256N
/p300
ARTN
.Computer
chloroform-methanol-concentrated
MIG6
re-accumulates
CENPA
IKELREATS-PKAN
E510Q
gefitinib-treatment
20993
shMYCN
NM_008696
Gly42Arg
Mx1–Cre-mediated
Mek1/2
KMT2F-mutant
ggilliland
S642
calfb
ATH+DBD
∼356
0003019
X96998
Ncr
Non-MYCN
Tandem
LAMP1/2-containing
RMC20C026
.Pre-2000
second-heart
GST‐wtRhoA
8290
.Two-hybrid
GSE15096
.HNF4α
280–281
as-yet-undefined
.Recurrently
.EMT
Sox17-expressing
2690-
KTEPFDDFLFPASSR
//mmruv.info/
101b
5'-CTATCCAATACACGATTCAC-3
0.4483
=43
PUK-3B
0.07-5.01
Gfi-1
D87V/D90A
0.2°C
5′-ATTCCAGAGGACCAAGAACGTGAG-3′
.Hiebert
Metaphasic
160.6
inhibitors96
GeneTailor
β-Catenin/Tcf-4–Mediated
0.570
GCACCCAAGCCCATGCCGTGGCTGC
Classifi
entrecitnib
Dana-Farber
Ecl136II
4:301–307
87.7
assay,26
v2.1.1
.BIRB-796
interactions43–45
U.T.
NUFIP
urethane
5′-GCCGCCAGACAGCACTGTGTT-3′
5′-GGGAGGTGGAGAGTCATCAA-3′
pY-parafibromin
factor-kappaB
Wnt5b
67·1
pLVX-AGK-BRAF-GFP
poly-DNP-RNA
polyphosphorylated
invasiveness.Figure
631.4
.SU
Ba/F3-transduced
andof
RIT1-expressing
19q13.1-
FGD6
GGGCTCCAGCTGTACTTTCA
D5S346
6–100
-T875N
ATTAACTTTTCTCTTGTTTC-3′
FBW7-binding
P332Q
Parenti
hyperamplification
1/20
domains—the
HGB
sub-site
status65
P0005
Dicer1-controlled
b=92.1
enrolled.85
determinationsThe
Charlottesville
Lys-1423
688–1116
5′-AACCCGACCATCACCGCG-3′
.ARN-509
Komiya
antibody-affinity
//cancergenome.nih.gov/dataportal
thermocyclers
priorization
S6276
502–503
Na-deoxycholate
D–transcription
biphasicresponse
co-transfection
cells.64
.JVM-2
Asp-319
5640–5647
RL9A
BRM-containing
.Shp1
â€˜
phosphorylation7
.1-4
S7PY.Fig
.Moribund
dermal-epidermal
AKT1–3
non-dimerizing
E2V443SE3
ADAMTS15
HER2+/HER3+
.TP53INP1
2.103
50–177
patients94
chemopreventive
5'-ATCTGTGATTCTTAGCCAAC-3
phospho-AKT
n=107
PC-9R
1,3,4,5
cardiac-related
Prism4
p.Gln9Pro
0.003*
200:100:1
pms1Δ
ATPanalogs
E275
Gag–AKT
TCS-SP5
www.oncomine.org24–27
TCF3-upregulated
30kg/m2
pderALtMGDLIsfAwQIsqGNqYLAENkLVHRDLAaRNiLVA
progenitors.13
Glu999
Tcf-binding
AdControl-treated
STRUCTURE38
36-
15-152-507A
Naoki
checkpoint/control
protein.Protein
semi-lethal
temperature.17
CLL08
G1-Sand
Brca1/Rad51
serine727
consolidate
83.Losses
5′-CAAAGCTGTAACATTGTGGGGAC-3′
R89H
Rat-1
3083
Mitomycin
Hoxa
Neighbor-joining
Lasater
PPGY
GNA1119
280V
mock−
7,424
Sox17-TCF-β-catenin
R447H
7.08
CRO
Tyr-CRE-ERT2
V3.1
TCGA-EE-A2GC-06
DGC-specific
Gag
.BZS
15,26–28
Arg621Cys
0.2–
specimens,35,36
pEGFP-BAF180r
TERT-related
mice51
Côte
PEA3
MTC,6
pRetroX-TetOne-FLAG-CHK2
P=1
1536–1784
E509K
376/902
NTRK
EORTC62005
2′-OH
ATGCCTACCAA
14wasmoderately
Ikk2-depleted
pim1-coding
parva
smethod
GGTCATGGCGCGGACGCG-3
AHC9
firstgeneration
occupationally
tca
Wild­
NLS-masked
irresectable
.combined
acid-resistant
R767H
signi®cance
Glucocorticoids
non-chromosomal
pNKYlOl
87·5
D50F2
Glu161
EGFR.58
NERF-1/-2
v4.03
0.025ppm
–like
4q13.3
A*01:01:01
41C
change.9–11
N771T
ABIPrism
Pathogenic
GSE9355
STT648/649/650AAA
PD2127
IVS7+24G
Asx-Calypso
≥70
PTEN-induced
YME
pDM72
Death-associated
MSCV-U6miR30
phoshoinositide-3-kinase
mikura
Chromatechnology
579x
lnaadve
genome.uscs.edu
227624
responders.
287K
knockdown28
mutationwas
RP11-74L18
.NFKBIE
5,330
.14,17,18
9,11–18
839
dynamics10
690514
39,41,92Å
2.13.0
E330A
c.760delC
TAD—Multiple
D'Addario
.F2006
P36
28/20
growth49
FM-Smad2
IlTo
nSolver
0.0709
PIP4K2B
GLI-EIA
antiphosphoSTAT5
omics
10–12with
Y340FY340F
Neurofunctional
5'-GCTTGACATCAGTTTGCCAG-3'/5'-AAAGGCAGCTTGGACACGGCTTTA-3
prognosis16
ERG-3A
respectively.54
branch-duct
.c.899+1G
hypermetropia
GTGGGTGTTTCCTGTGAGTGG
MLL-AF9/Tet1−/−
DMEM/
semi-quantified
Ko¨nigsallee
K101-G6
development181
18,38
507.7
D1289N
100–
M496R
stoichiometry
GERp95
functionINTRODUCTIONThe
pBS-TRX2
Brca1Tr
5N
pathway.D
nt170T→G
mutations—may
19monthsfor
.1657T4A
FLAG-Elf3ΔN270
headto-tail
12935-110
Haqq
6311
Mll3/Mll4-containing
database-registered
couldbind
withmicrosatellite
PRE2-E4D38-luc
breast-specific
forkhead-domain
KT-36
GenomeLab
Notwithstanding
FH-DCAF1
HRASG12A
17q25
-RET
Daejeon
NDNDNDdel
SPRED1
2.883
27626
anti-Phosphoserine
pcDNA3-ETV1
MKN45
Breakage-fusion
p18/INK4C/CDKN2C
dose-proportional
.Nontransforming
NGFRAP1
Δ705–1120
6,536
48/F
GNAQ-
I-EcoRI
−12.3
5′-AAGCCAGCTCAAACATCACC-3′
E-cadherin1
comparedto
readFilesIn
69.00
43/4
Sca-1-APC
GIn
L413R
c.5406+5G
gdbwww.gdb.org
BRCA1/IVS15
Tel-PDGFRP
ΔGunfolding
thyroid-expressed
normoxic
V740A
ETV1_R
/Brigham
3Flag-CMV
HER2YVMA-expressing
.Leuk
PtenL
Biorepository
inhibited.38
≤10−5
.L858R
dependent24
Bronchoalveolar
1998–2012
low.Representative
suppressor42
CHCH2
IVS16-2A
polyubiquitinate
degloving
DPMAbQ5/13
anti-Desmoplakin
agene
levels…
–NUT
Digoxigenin-
Ba/F3-WT
transcription-mediated
GISTs.115
responders.36⇓–38
DAPI-Vectashield
leukemia.1,2
BL16,17
CT+TT
profıles
3,218
1.892
VTX11e
receptor–mutated
//dx.doi.org/10.7554/eLife.03751.001
swabs
56770011
Cal27
ALK-mutants
LaPlant
CDC42-mediated
Haartmaninkatu
pGEX-p300-AT
VEGFR-2-dependent
CD14+CD15+
.JM
XK16
Huagen-Strano
K.13,52,56,59
EGAS00001000380
5-CACTCATGATCTCTCGAGCC
NMRI-strain
α4
tumorigenesis.16,17
anti-MSH3antibody
CtBP-interacting
Bakkar
G76V
Net1
MC1R
3rd-line
TCRD/A
suggestthat
c.6464T→C
FAT10
.1668
Mavrothalassitis
erbB2-overexpressing
ade2-101/ys2-801
HA-GST-Rheb1
FHL1
S225F
Ã¶lmutants
GCAGCCTCACATTGCCCC
Chaperonin-Independent
2Fs10120-013-0298-y/MediaObjects/10120_2013_298_Fig2_HTML.gif
Hagiwara
11T
Wat175
forskolin
GFP-NipR1
TG1796-97AT
GAGE17
MSC2156996
57patients
R132C-expressing
p73–mutant
mice11
possible.33
nucleic
NA25
genome-guided
CGGGGTCGGTTTCTTCTTTGGTCTTAA-5
wu109/wu105
N6
Mantel-Cox
.Staph
conformation/pose
11718-25
IIIb-D1709A
26,38
2-8
Val536Met
DI3S175
GST-PTPRD
W731Stop
Blaheta
www.csie.ntu.edu.tw
coimmunoprecipitable
Fig99
BCL6+
10.18
y.o.
PCET
RIP-Tag
RQ-
H1047R–driven
CLTC/ALK
C11C5
sitesshowed
multi-color
fatal.34
PDGFR-F
J.Michael
G360A
pNMU-1
98,99,100
7-amido-4-methylcoumarin
-R479Q
Tumour-specific
Tanohalo
MEP50
concentration.13
below.CCSP-rtTA
Iijima
TGF-b–induced
.2.3
93.6
0.6942
TCTTGCCTCCAGCTTCTGAC
Wacholder
rate-
ATTAAT
​Fig.11A
|D′|=0.8
v3.1
Ser1841Asn
cancers.40
CSF-1
Thr598…
S4–13
summa^-^
pASZ11
K59del
signaling—contribute
TFEB
adverselyaffect
Moroccan
consid-ered
Hs00217794_ml
501-kbp
midcourt
DN-JAKs
administering
constellation
and6
m13
OligoEngine
CC10
Colombani
677
µl/cm2
5'-TTA
1.27/1.77
bipositional
software.Statistics
125K
Hegele
Leu910
RRS
HCT116+TGFB2
FANCC,14
M-F
Val769
DUSP4-diploid
Myc-BS1
meta-stable
bVariant
segmentation42
5′-CACAGTCTTCTGGGTGGCAGTGAT-3′
MED12/Cyclin
SOX17/MAML3
Chien-Feng
DeCoteau
021924_D_F_20111015
p.384C
non–panitumumab-containing
distinctfrom
insertion/truncation
ligand‐stimulated
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F4.large.jpg
GNNK–
HDPcat
MYC28
hEGF
Gly60
myc-EGFP
P53_02
HiLoad
CRC006
HZ4
FRAS1-related
§A
CISD3
IRK
11KGEAETR-VAV
11C
Anti-DUSP-10
C2-GSEA
Notch1.1
94.2–100
//doi.org/10.1371/journal.pone.0019059.g004DiscussionThis
Tyr-785
episomal
5′-GCCTATGTTCTTGTTGGCCTC-3′
GEX
BS9
~62
Y518
pCL-SIN-Ampho
29236
23.9
.Gln22
∼3.5-fold
G469A
MutSig2CV18
families1,8,9
XbaI-BamHI
domain19
E805
A361T
NKX2.2
aGt852aAt
W1718L
MLL-specific
auto-antibodies
Fisher/Cellgro
l85delAG
3223delG
betaE'–betaF
15N-edited
CATGGCAT
RAEB-T
responses25
six-member
Receptor-like
Q458
28.4–34.7
in–breast
5′-GGGGTACCCCTGACTATTCTGCACACCATTTT-3′
A103
.Undoubtedly
GATCGATC==
18,175
estramustine
Runx2-
antiapoptotic
5′-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3′
P=0.182
A.E.-T.
.FOP
base/base
kinase-3
.double
BCPAP
HBSS
Fig.11d
AATTAGATAAAGGGCAAATAAT
proliferation1
1–792
miR
Nf1flox/flox
pRC-HAVHL
0.5×109
miR-671
.PIK3CA
CytoScan™
8.50
cytokines—since
EGFR-SEPT14
~Kuppens
68Ga-DOTATOC
nucleoproteins
detrimentally
DMSO/isopropanol
5–13
TNFα-primed
DNAt
C-1′-H
Loukinova
discolouration
72-hr
phosphate/10
5′-GTGTCTTACTACATCAGCAC-3′
T323M
AAG-3
functional/structural
MED12-dependent
5754
6.5–11.5
region-transformed
Hs04959141
PAZ
AATGTCCATCTGATAAGACG
protease-phosphatase
vascularization
Zinkernagel
|Reverse
v-fes
5′-TTCTGACTTCAGGAGCGAAAG-3′
methyl-transferase
cotransected
HSC536N
C/EBPα.C/EBPα
β-catenin/TCF–regulated
.020
nanoscale
furin
disease.22
p16-cycinD
4561
cancers—there
Myc/hexahistidine-tagged
10016
M4eo
SLX1
rotamer
pERBB2
424
Asp-442
33â€
:42.8–91.4
TATA-containing
Fig.S5b
p.DISCUSSION
HKD
FMBIO
previously.7
0.457326
NT_022184
MP-470
44-1722-338095
K285
allele16-18
diphenyltetrazolium
.DNMT3B7
risk.4
XL6
FATC
401215
Steraloids
ACA-for-GCA
wt1
.Jade
Institute-funded
guanine
.Non-small
−3.27
~77
20Thus
−14.3
43911601–44001000NM_172097NM_172095NM_001015001
F113A
mutations/site
.Allosteric
Tcr
heterotetrameric
proteinsamples
40ng/μL
Glu27−Ala36
EGFRvII
c.1461del.yIn
fine-tuned
pLex9
Y527FSRC,19
Scientifique
self-renew
differentiation,24,25
Triethylammonium
RP11-645P13
least-significant
protocol13
Asp260
.Assuming
Z9403097
,6-diamidino-2-phenyldole
Blbp-eGFP
LN40–ADPnP
transgenics
P34L
a–d
Stavnezer
3222-3225
4040
12/188
RMKTLLCJolVG
FW4000
regiongenes
8-containing
475/561
5.09E
92104
Antiandrogen
Muir–Torre
MKLP
Exome-Seq
1.75-Kb
C.Y
16-h
DAXX
85-471
others17,18,19,20
ohri.ca
Caltac
regulation23
Dupuis-Girod
5,6,9
immunosuppression
anticorrelate
life.13
near-equal
1/137
equivocal/borderline
226C
MSH6-G1137S
Fig.5F
+23
Peroxidase–Anti-Peroxidase
HCT116+TGFRB2
levels.87
His-Phe-Val-A
10.65
pAKTSer473
cot
TSC1–TSC2
Y845
parafibromin
anti-MCM3
fusionnegative
P=5.7
here.45
25mer
CD99-positive
activity.32
castration-resistance
88–433
.Re-cloning
V600E—in
FLT3-ITD-N676K
J.D.B
erential
v1.62
A153T
MM.T1
Uracil-DNA-mediated
W544C
KITD816V/H/Y/N
REC8
4.93
p85a
.CBTE
tumor-types
Hemi-nested
-1-piperazineethane-sulfonic
subclasses4
PTC-containing
Bub1b
atherosclerosis,16
5′-CTGTGAATCTTCACCTGGGCCTGTGGCGATG-3′
multimerizes
V/HBSS
9a–b
1208F
.Eberhard
64•6
c.736T
Nik-Zainal
.Building
misregulating
tumor/host
259,320
Cdc2-cyclin
8.Co-immunoprecipitationTOP1-deficient
FLAG-MALT1
KAF1400
adult-specific
phenotype-to-genotype
.MFI
.Recurring
.Merge
T178M
line-transmitted
E472X
257-280
miR-520a-5p
well-managed
ARAF
SalI/NotI
KRAS-GTP
function-defining
duplicate-core
collagen-independent
Figure9C
2000c
HG-U133_Plus_2
movement,3
Alw
RARγ−RA
rs5742909
.Digestion
C
PTRVSpSPVFGAT
2.03
822
380SDTTDS385
reported,28
BRAF-KIAA1549
4/24
R217Q
59,000
status.43
GIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGPKRARESQDRKIFRGLE
Beltinger
1–302
TGCT6VCTCCAT6TTT6AT6TATCTVASCASSTT6CTCCACA66TA6CT
myocytes.37,43
propylene
Flactif
c.290+1G
transcriptomic
μCi/μl
cohybridizations
50340
wereconstructed
immunoglobulin-HRP
AATGTTGGACCCTTGACTGC
shRNA−infected
CytoSelect-96
.Y2H
rNi
Arid1a+/+
tracts.11
LC3-BII
H1248D
I127S
logP
AII-2*
1,482
1.5–3.0
.Dexamethasone
Nunningen
NF-κB2.9
anti-cIAP2
cDNAends
EGFR–TKI
267
Graveel
Dr.P.W.Manley
P6
GR1
gpllOProto
electrophoresis-based
.Supershift
Dimerisation
Non-neoplastic
CSF2RB
FA,2
–28.0
chloroform/HClO4
1996.
Altomonte
.BEAS2B
MAD2L1
NCI-H3255
13/60
Fluoromax
FRA16D
bUndifferentiated
p16INK4A-induced
FUS-CREB3L2
0.0088
b‑ga
255.10.1042
ras-
ubiquitin-driven
FIG–ROS-expressing
.Competitions
1.5μg
A229
TACCCAAAAAGGTGACATGG
transcription-and-translation
agammaglobulinaemia
migration.2
CBFβ–SMMHC
Danopoulos
farnesylthiosalicylic
splicing-allowed
at4°C
before19
neoantigen
ret-wt-transfected
Seiryomachi
COAD-US
ECM-related
F-box-deleted
¢broblasts
N564
C253S
2×65-ns
cladribine
9aaTAD
species=human
affinity42
EWS-ERG
248
EGFRvIII-L861Q
P1819S
Inter-domain
16/59
6-mercaptopurine
RhoA-GEF
evolution.40–42
hDIS3G766R
mechanism.30,31
cells.69
growth22
402C
15–81
animals/sex/group
MSCV-U6miR30-PIGdeltaRI
PF-03084014–treated
2•87
glioblastomas5
based-transactivation
13–15,17
oncogenicity
aPKCι/λ
Vismodegib-Resistant
ERFT526A
ccattgccactgtgatctatgtatgcaatgtaag
ceramide-induced
PLX-induced
I220T
.Chimaeric
Biotin-mediated
GFP-positive
A172T
MCD
trainer/braces
CD45RA−CCR7+
Faury2,5
NEU-ROD2
D485H
REDTaqReady
Phiphilux-G2D2
1901
andXenopus,30
c.2318delC
BAP1-interacting
89-kDa
Ba/F3–PDGFβR
lymphomas14
BRCA2-Deficient
GDP-RAC1
136352
3-mercaptoethanol
732
MOSST
TTGOGA
.1102198108
,6A
D2312V
serine-rich
heamangioblastoma
Olabisi
combination21
6791insA
potential.23
downmodulation
n=15
thinPrep
DMS33
FAA–FAG
117.6
5′-CCAGATGAATTAGCATTCTGGCCATGACC-3′
SANT1
DiscussionActivating
self-renewal4
PK2200
MAP3K9
plasticity36–38
1917
c.2245C
signaling.5
PTEN-interacting
overexpression,33
teleosts
Huelga
NC_000009
L58P/T64A/Q81P
nibrin/NBS1
co-morbidities
317–367
HAAkt
tensin
hybrid-converted
RiboAmp®
41cER4-34
5911
5′-TTCTTTTGCTTAAGTCAGAGATGGAA-3′
rate.6,31,35,37,38
lineages78
substitution.7,8
Quantification
transactivation15-17
RSS-like
SMARCA4-deficient
5′-RACE-PCR
Tyr-736
FIG.7
pCDF1
.OEC
p.V654A
-21
.41–.57
.MIG
p.R265H
-601
C634
​Fig.7E7E
.REVIEWS
not-insignificant
567L
R333W
CFS1
PRDM1/BLIMP1
.46,47
L1970F
publicdomain
96–99
T485K
IIB-Sant
KRAS/centromere
.Three-generational
no-calls
p.R657W
T154I
cHL41
XXF
Electroporations
Labvision
//www.rockefeller
33/182
*300248
CHAPS-TNE
Bejsovec
CGGCAGAATCGTATCCTCAA
immunochemiluminescent
p65PAK
micro-titre
/'/
225,388
p.Leu1418X
004456
N276
D-dark
4-19
PF-2,341,066
1977.1,2
carriers/affected
ATCA
dIdC
C-RAF29
mFLT3-L
PLCγ.Pax5
TSC.34
C136Y
species-related
I192N
Fbw7α-S18A
28–47
Leu73
3,5-difluoro-benzenesulfonyl
aCysProGlnH
neutrophil-dependent
Antiandrogen-Resistant
Met53Ile
MARCM
anti-ALK
LacZ-neo
siBTK
D107
ALL51
ac~d
TMHMM
18-Kb
Focus-formation
.Internalized
known/unknown
T474A
CIC-focused
.A
2602
598/599
Li-cor
​In
10.39
TFG–ALK
erlotinib58
p-MKK1
D-pRB
Onconeurotek
Figl,1,2
107–114
Node-positive
GAPlC
1p22.1-21.2
NP_000526
erlotinib-specific
L2155S-mediated
sumoylated
p.Leu205Lysfs*4
TNRC6C
Procise
pathophysiologicalend
Met18Thr
RP11-23H13
receptors.29–31
He*
expressHLA
2,4,6,25
Treg
Gry
genotype.19
000-
2,18,19
set2,5
sub-bands
EWSR1–WT1
T2I
H773Y
transient62
Radice
Hexahistidine-tagged
.H
arginine
386,300
Cdc25A–Cdk2
Coinhibition
c.157C
AluJO
multipolarity
re-staging
KIF2A
CA21
F437S
.Main
Vinciguerra
gender-related
C57BL/6J
Tsunematsu
theprognostic
factor-signaling
sgk
9•83
TSC1-myc
1.417–15.311
Tyr654
.Nude
P231L
1–729
4.851
Cdk4R24C
pcxn2-Brd4
152.3–152.4
CRC,25
effects65
interchangeably.21
Interactiva
p53G245D-expressing
D755
CalcuSyn
-matched
HER-overexpressing
C-terminal–specific
Interpersonal
7.765.0
Fbw7-/-
129/C57
TGFBR1*6A/9A
Iexon
5906–5911
H1085R
NF1deletion
PTEN-254
Kinase-impaired
2K
Katugampola
Channelyzer
18,117
5-FAM
61,270
GenderMen
1aGlyleuAsnSerleuGl
STARTRK-2
CD138hi
7878
Bim-EL
•Differentiation
//picard.sourceforge.net
3-mm-thick
poly-ubiquitinated
PEO14
immuno-purification
MDV3100-resistant
phosphatidylserine
125I-TGF-b1
SOCS-Box
S94fs
Dex
29-37
ILVGDNL
5′-CACATTAAATACCAACCCATCCG-3′
signalling82
VEGF-A165
JXE
comigrates
P1079RfsX8
cRSS2-4
Santariskiu
12/296
MLL-AF9/T2
tyrosine-dominated
.Caspases-3
MDA-MB-175VII
-deletion
Alexa488-conjugated
KIT-G558delta
gmtLG
sc-32931
2888-11_2904del28
AGTATGTTC
.S6b
1X10
VP16-AR
25/2322=1.1
10th–25th
0.227
cosine
ckit3
BID-dependent
G187D
48–
SCH900353
LKB1-KD
Ar9Ala
5755
o5703
theearly
data26
Welcker
extract.We
Kieran13,29,32,34
D200nt
99/7/45
FC=2.27
WM3622
anti-DNMT3B
GOseq57
478Pro
Bayascas
Dpp
E72D
compartmentalization
subtype72
TSUCHIDA1
myelo-monocytic
.Tsc2
.Elevated
TriPure
BCOR/BCL6
75-week-old
c.721T4C
6T-X1Â
erythropoiesis.25
-13A
with0.05
127.59
complexes89
16A-forward
trypsination
mechanism-of-action
active26
3.2/30
disorder.20
anti-von
GCCGGGTCGC
G857A
FERM-like
N1-ICS2517A
6.18
8•5
pro-invasive/migration
ited
RUNX1-MDS1/EVI1
53K
enamel-staining
phalanx
p21ras–GAP–GDP–ALF3
PKBThr308
Tn4330
TCF/lymphoid
trascription
_MDM2_
beta-8/beta-9
21285
TAMRA-labeled
5′-CAGCTATAACTACAAATGGAGC
p.Tyr34Cys
NP_005219
signalling36,38–40
Notch1–Gal4
5′‐CGCTCCCACTGTTCCTTACA‐3′
sensitivity/resistance
RETROVIRAL
Myc-WW-PDGFRA
gene/GAPD
to-I
6D–F
.Long-Term
D1002
9Division
‡Consists
PCa_ETV1_3
Herceptin-mediated
'paracrine
V-MA
ERK1/ERK2
in~rease.-~Overalslu
CD56
I.Iaccarino
∼11.6
major—cause
rap1
Ganglioglioma
IRX2+
cell+
'bCATa
cancer-relevant
FANCC-STAT1
p.G12C/V
CASPASE-5
adhesion,35
downregulator,24
MEK1K59del
R1446H
TGCTTGTTCTCATTGGCTTC
PPMS
GIT2/f1
SBF1
p70S6K/
pVHL-regulated
36.7
indexPublished
C/EBP
LSILs
HRAS-G12V-induced
KIT/LYN
Erg-mediated
162×
.PACA-AU
PCGP
pT3/ABN5DNA
R52LARAF
1–565
4–7-fold
//www.fdaapproveddrugs.us/trisenox.html
pCEP4-HA-DN-Erk1/2constructs
Ki-67-negative
drug–drug
5′-GTCACTGACCCTGAAATTGTC-3′
GTTGGATACAGGCCAGACTTTGTTG
HEO
R693W
BRAFi-ellicited
neoplasm-like
chipgenotyped
§NIH
TEL–JAK2-driven
inactive-to-active
.48,49
SCF/Kit-mediated
2015:8
al28
Nof
BRAFV600ER
GAL4-ELK-1/UAS-Luc
melanoma,14,24
TF1
Vav-iCre−
430K10
ACAGGGTGGCTACAAACTGGATGA
SAB-PO
Difco
p.Q160_Q167dup
deinduction
BRCAPro
MS5-DL1
12,159
PDGFR-α-deficient
anti-D1
c.9117+2T
WT-containing
used,17
F6-R8
erytholeukemic
nhlbi.nih.gov
pM1
20-0.05
12935-300
Tris-HCL
Mazzà
.44A
anti-pan-p42
Frameshift
I24
BeF3
8327667
pEF-HA
p.Ser256X
3-259
Dkk1
betaP2–C-terminus
ΔHM-AKT1
unlikelyto
IC50less
Mx3005p
.Phenotype
MB14
BMP‐induced
actin-containing
EBNA1
Takamatsu
MutS-heteroduplex
Rocchi
SY
0.0344
U2AF1
KMT2-driven
//bacpac.chori.org/genomicRearrays.php
ESC-
selection21,22
5433
reoccurring
GDP-Ha-ras-p21~Y32W-Q61H
instrument.15
MSH2affected
4062–4070
DKC1
Ihe
L708P
JAK1/STAT3
392,935
15.27-fold
1cell
3.8-8
MPCEWS-FLI-1-T1.1/T1.2
imatinib.29,30
super-family
organotopic
glioblastomas,31
pathway17
two-tail
3Dii
kinase-RAS
Ser-393
3'-site
Post-confluent
miR-29
V559D/T670I
STAT3-Deficient
E318D
non-Kuwaitis
ponatinib
EEEINAELTAKKRKLEDECSELKKDIDDLELTLAKVEKEKHATENKVXNLTEEMAGLDETIAKLTKEKKALQEAHQQTLDDLQAEED
Phe594
nihms703640f5.jpg
UAS‑TK
Mpp2
unfarnesylated
361K
7-µJ
2.726919833
pCEP4-raf1
cotransgenic
G375A
H3K18Acet
KRASG12C-lung
frequencyin
1p34
GST-cat
SD.In
anti-BAF250b
AML18,30
siRNA-14
ArceGomez
R124L
RP11-669K4
HLADRB1*
2xK642E
195-bp
BRAFKD-V600E
Protein-coding
Biotrig
3196–3232
STH1
multimodality
Tri-reagent
autoubiquitinated
CCK4
Nowak-Wegrzyn
novo/pan-AML–type
IF2
P=0.068
1380
assaysWt
523-528del
ROS1-rearrangement
c-mycWT-HA
21160301–22679000NM_001166243
NM004304
-0.6
C400Y
algorithms10
CellTiter-Blue
Arg426Trp
-LeSop
Openbiosystem
CDC20
1434–1436
GGATGAGGCTGACTTTCTGC
A829P
3730xl
1000:1
Heikkinen
10.5-Mb
quasi-physiological
Sheeba
DM-1A
Smad-4
.EAT-2
97:2434-2439
assays1000
Birkenfeld
Rosa26-LacZ
xlOy/l
anti–phospho-EGFR-Y845
11,840
hyperexpression
Signaling—Pharmacological
0.43–1.01
.Linking
epitopetagged
immunoprecipitation/Western
2480
NMP1
TKI-responsive
HR-proficient
whole-transcriptome
ga14-542
Schleicher
MMSET
atc
Arg→His
262K
p120RASGAP
CR/PR
58–82
p63γ
'TATTlATCAA
www.pdb.org
4ZF-HA
.CAO
cyclic-AMP
23l
S2A–S2C
Fantom5
355N16
SHP2-overexpressing
P-value=0.036
NRS
activation/inactivation
CSF1RD1–D3
POLD1-
C.G
Giehl
codeletion/loss
A11001
6316
initio
400–1600
Isotropic
R226S
GDB:593364
R172G
Otto-von-Guericke-University
Ink4a-Arf−/−
c.1799_1801del
Hs_MYCN_3
SHH+ve
Lipofectamine3000
G/protein
RUMC
3-dimentional
,5F
PTCL159
1/3000
TIP3P
PNA-based
NH^-terminal
•15
ElonginCB/Cul2/Rbx1
3xRGC
domain.30
0.89^1.03
structure‐guided
c.49_51delGGA
H3K27me1/-me2
.Xenopus
hydrolysis.29
conof
.Onset
.Injections
AVFa
E-type
IX70
phenotype.5
GS7-8
EISHLTDPTTIFRGNTLVSKMMDEAMR
V1299F
Elecrophoretic
SLIC
.Coupled
reorganization
α-Helices
NM_010588
transformantcell
Hsp90-Nter·Sgt1-CS
22-residue
tected
B15-fold
CycE–Cdk2
expected15
β-catenin/TCF4
num
12-wk-old
R1192G
tumors.27
0.0491
H1382Y
TP53BP1-dependent
Staudt
.Distribution
NGF/TrkAI
HER2+/HER3¡
.Translocation
8p12-amplified
3′BRD4
Ruszkiewicz
.TSC1
previously.16
normo-
5319T
Lys558del
stages21
SNV/INDEL-calling
sub-clinical
HIP1141F
NSD3-
Tsuchiura
Pearson-Webb
3TP–lux
Sca1int
CellTiter-Blue®
.Double
D352
sequences-NG_007873.1
cancer.25
P=1-
ConSurf
0.Considering
−3.78
eukaryotic-like
1.08plusminus0.12-fold
anti-Apc
BIRC4
Dufault
-m
1,108
Theou
PC-1
Arg330
panel.13
LXSN-AKT2-AS-1
interhelix
GAL1p
ARE3-luciferase
ins137nt
1,304
PBAF
CD132
X-PLOR
acid-modified
gefitanib
fusions,48
0.I'l
damage.53
Cycletest™
protocols47,48
.MAP2K2
mature-appearing
~~~~~~~L3
kinases.3,4
origin-containing
mastocytosis.68
accumulation.38
RGC-promoters
Receptor–Mutated
31–36
ICDH1
M.E.E.
.Asterisks
24B11
T198G
Novelc.4388C
human-derived
aaattt
-DSS1
LB1047-RCC
online.5
nonconsecutive
delEx1-Ex7
.Considering
p-MAP
89.19
p2156
Hugo_Symbol
anti-HMG2A
1239–1243del
ΔEGFR-expressing
β‐sandwich
pY878
NANC
CTGGGTTGCCTTCTTGTTTGC
methoxyflurane
miR-26a
PTPN22
18322
277700
mC7′
melanoma.43,44
CYP1A1
technique.8
motesanib
multinationally
T940PfsX13
scco-research-study.aspx
S205P
TEG
TAACAGCACA
8F
GIT2-PDGFRB
5′-CAACCTCAGCTATGTAAGGTTGTTGAC-3′
Comércio
.Martinez-Garcia
PY-motif
.465
DFSP
metastasise
MYC-collaborating
RasGAP-
subtype.31
4-methoxyphenyl
FGFR1+/FGFR3+
V143A
Sassone-Corsi
transformation.70
Sah
or/and
Mx+Snf5Cond/−
FIS
,4,5
5′-GAGACUAGACAAUGAGAAA-3′
10:10:1
G370C
47–49
5'-GTTCGCACGAGAATCGCAAGAT-3
D89H
transformation.30
mutations.79
1,842
C135/141S
sarcoma
V600delinsYM
p.Pro1087fs
Hedgehog-producing
R687W
Vakkila
colon,22
nt−24
4p
82.9
childhood.17
Drapkin
Vav-Cre+Tet2−/−
Kajiwara
atic
RT−
392,904
anti-Flt3
.Alongside
PMS2/MLH1
melanoma.24,31
Junop
/V0
5·2
tochrome
Subler
7·5
zlj9990993630007.jpg
.NLS2-Ala=0.6844
KIF5B-RET-KD
ligand–independent
oncogene/tumor
4A/COP1
SQCC.Although
non-Mendelian
isolationOur
Agarase
∼153,000
Arg-Arg
iron-regulated
mutation.27
MKLLRHDKL
lines.5
mutations,26–28
DERKwt
Incontrast
receptor.9The
B/AKT
IMATINIB
JAK2-V617/Y931C
discussed.11
phs000424
Lys331
Sézary-like
a­
anti-RSK2
tumor,34
-anchoring
R306X
0.02.
phosphatidyl
prom/enh
1C1C
progression4
//cancer.sanger.ac.uk/cosmic/
feed-forward
GATA-3-directed
sc-20022
DEPTOR-dependent
Melero
favourable-risk
www-hgc.lbl.gov/projects/splice.html
MEK-DD
LS-174T
1987
c.427C4T
Ik6.6
c.1638
96-300
CSCE
.NOXA
SF3B1K700K
background.21
chemotherapy/radiotherapy
PLX3397-resistant
WZ4002
analysis.Expression
E749del
0.5–6
I1
D2S117
STAT5A
Blue®
5′-CTGGTGGAGTATTTGATAGTGTATT-3′
d'auteur
Yr†
.PR65
GGAGTTAAAGGCACCTGATGT
24,000
FM1
71101
115
MSH2/MSH3
copurified
1501
'cocktail
TAZ105
E-plate
AG1296
Mutnnt
C1*∧
p38–p53–p21
.V14RhoA
744M
Ova
59,189
QoD×3/wk
4200-465
algorithm48
conformation.20
KC8
SLC23A2
identical-sized
transactivation.D
Amphiregulin-null
ng/ll
Olopade
motif-like
BRB-ArrayTools
∼70
Y1571
I296V
5mMEDTA
R74C
Showa
H-RasG12V-induced
23:5426–5434
terminal-Like
A429S
.ESEfinder
482—a
2mFo−Fc
2Gene
NaHPO4•H2O
H4R3me2a
IL-9R
D572H
thePro-34
73–80
alr36
Â®Â®
SRF_C
.Axin
M010
MAPK/Erk1/2
trp1-63
Her-2/neu
Smoothened
of19
INK4a
13:51
3⇓
L536PHE0
AV-203
rate‐limiting
lozenge
neurilemmoma
verbar
MSVSRα
KMS-26
h782
Dll4
Tris.Cl
V1065F
C17F1
phenomFig
melanomas,21
0.12.7
ACT-ATT
MYCMAX_01
Demoulin
cancers24,25,26
HCC4006R
Fos-Jun
KAP
NERF-2
homology-associated
neuregulin-1,23,24
.GlaB
therapy.27
.736A
and-Y35N
PCa.49
AURORA-A
Pu-Pytract
63C
rxn
NUP214
IBMX
SF3B1K666N
–d
.SA494
BCRABL1-positive
1.23×108
preleukaemic
Kukita
Interferon-regulatory
-9R
PDGFRs.26
ARID5
models49
pMITom/hB-Rafwt–Myc/His
two-site
c.632-9A
diversification11,12,13,23,24
domains.17
21:1–3
100Å
S33/37/T41
ASXL2,22
calcium-activated
Trp53i5
35.14
rArgLysPhoTh
Hs00975865_m1
4-cm
IFN-γ–stimulated
508_906del
approx18
ΔBamHI
NM_026880
p.Y627fsX9
cosegregation
T622I
1•5-year-old
11These
Dambrauskas
node‐positive
.Administering
fill-in
4RWL
imatinib.15
Myc-cleavage
mammoplasty-derived
RAWUL
Anti-Digoxygenin–Rhodamine
shNF1e
Tyr201
−394
cdc2/CDC28
.Sadahisa
R115L
6.8–93.2
Carnicer
22/74
2321-2328
amide-containing
post-pIpC
GI:19075706
FLT3L15
Stfa1
RPKM
CAA34438
1.5σ
c.853C
C/Src/c-Raf
G1388A
Tris-d12
parsimony
undifferentiated/PDCs
protein-ligase
phospho-STAT5B
278J17
H2AK119Ub-DUB
A_51_P159194
KIF5B-RET13,15,26
gbAF056116.1
UPF3B
5q33–q34
cells/1.5
supercoiledplasmids
.91–1.0
.Granulocyte
-..As
74,629
pTEpY
STAT617
b-9
EGFRvIII-positive
700-412
MYEVQW552-557
glycosylase/endonuclease
myc-RUNX1–expressing
TPM3–ROS1
centroblastic
10−3Table
causally-linked
.ΔSAmut
endophilin-mediated
94/285
CK5
150092
ter894
U133Plus
1:1–3
12p13.31-p12.3
R583G
59,783
L115R
ERG-FLAG
LIMK1
DN-Δp85/Ad
|CBFB
WES-based
BR2334F
MM540
sc-5274
.Predictive
.AURKB
cell−cycle
p.A1309T
Mahajan
5-CACTCATGATAACTCGAGCC
IEC-6
.FRAP
therapy165
FANCG-GFP
0.816–0.936
Supercoiling—Biochemical
°C/min
-Tu–GppNHp
94–293
ALAS1
vivo.4
.RWPE-1
GACGGGTCCTGGGGTGATCTGGCTC
hyperphosphorylated
pXVR
Y599F-Flt3-32D
631
2099
YAP1-expressing
.6,7
I853
A21206
6247
Virolle
0.1-19
Rwork/Rfree
R278H
BH3-domain–dependent
−.83
.Imatinib-resistant
AKT1-Ser473
Phe53Ser
1,485
4E-BP1.27
JEG-3
posi­
p.V600E/K
damage-facilitated
cyclin-D1
Contre
antiDIG–HRP
M-BAT
Lys312
RIT1-induced
IV-1
57/f
pECE
1orm.1l
Snail/Slug
journal.pone
P.H870Y
MMS-induced
Merlin-S518A
short-circuit
junction.Electrophoretic
anatomic
pSV-β-Gal
PRDM13
258A
C243-positive
Situ
.Rac–GTP
Auxological
triphosphate–competitive
XcmI
CommentsMany
leukemia,3
angiotensin
frequencyand
RO5503781
TESK1
chr2:15.5Mb–16.5Mb
piriform
LRP6-5A
Rousseaux
61-184
'relative
N-terminal-FZR1
alÃelesat
2/2015
pigmentosum
IL-10–mediated
Caligiuri
MSH6-T1219I
Substantiated
4–20×
multitissue
1.39
pcDNA3-Flag-p53
K.-Q.Hu
cancer,21
death-induced
non‐carriers
Pro960
gene.com
miR-143*
1A-B
A…
Fig.44F
two-layer
c.1076_1077insT
c-erbB-2/HER2
.2000
581_775del
3,602
NCOA1-acH3/4
RAD2
anti-E2F-1
mutations-bearing
c.316+5G
350–650
c.536A
STAT-related
Q707*
de-acetylated
DMEM/Ham
T1323
14-year
22552
T670I
intramembranously.7
study.6,7,12
15-cMyc
magnesium-free
LTP
APH-induced
radiation-
W122R
RB1in
O-6~
no-TGF-b1
VIC-CTGAACCTGGCTGCCAGGACCT-TAMRA
=8.1
heterodimerisation
steroid/thyroid
12.12
non-sensory
20–40μg
androgen-related
TAL1-expressing
525/50
treatment-induced
3709–2A→G
entity—produce
Tecknica
Ala391Glu
Q347_A348del/F351L/K336M
domain/caspase
.557
elution
Q50
A848T
Post-ionising
Y1213F
previously76
astrocytes—15
androgens10
1,859
87,88,99,302,329,330,481
/Nop30
3.10.3
carcinoembryonic
PRCC2
Let-7c-5p
Hedvat
Q510E-Shp
p105-Ser933
3525
p.Ser46Ile
Phoneix
RNaseH
sc-37007
co-selection
5'ATFAAAT
Musacchio
~17.9
.GATA-3
chimSegmentMin
FGFR3ex17-FW
.E9.5
2D10
cholesterol-enriched
Pro871Lue
topologically
Garcia-Giralt
S*
K-rasG12V-R164Q
tamoxifen-regulated
GSE13218
5′-GAAGAACAGTATTGACATA-3′
Hotstar
RADIL
wnt-3
ThrGly
diagnosis.2,3
mesylate-resistant
2338
T488-Q493
L13P
drugs.MethodsCell
FOXA1
o-NPG
IA6-2
RCC4/VHL.HA
insulin-like-growth
main-chain
well-located
peptidomimetics
1:50,000
715
Counter-ions
Chvostek
CCO
-Dnmt3a2
300v2
Hs00217794
eighty-four
GIST.2,4
Devreotes
diphosphonate
67–47
D2023G
ABI3700
Dai
tumor-suppressive
anti-TCR
TEA175
ϕA-X-ϕB
31–86
18C
iTAD
codeletions
KMT2s
D32A
P95H-32
PHEO
autocorrelations
TRCN0000010329
Ggg
A338Raf-1
Vainchenker
151/151
..Values
5,19-56
myeloblastosis
change-in-threshold
kinase-3β
Top10F
NPS-1034
5990506
nonproliferating
.262G
mutation.With
adencarcinoma
K13GGC-GAC
cytoplasmic,20
HGF/MET
Glu1346Lys
FBXO31
Non-METamp
log-intensity
CEACAM5
1/length
Handolias
370H5
RPA-bound
50–2
615-base-pair
5'-GC-clamp-TTCCTTTTCTCATAGTAGTTTAAAC-3
.Individuals
TH-MYCN+/tg
Freisel
Signalig
G807C
G229V
imatinib.35
tumur
HMGA2-targeted
HMLEA
.08905.001
180-kD
pSRm
underlinedand
K270I
Fig.6E,6E
cases.11
q12-14
Cbfa2
atg1Δ
7306
R5020
Ub-conjugated
-biocytin
ofsubstrate
clonality1
sbalk
COHU
-185K
-min-quality
pTNT
.Fatty
.c–f
GCCUUGCCCUGGCUCUGAAdTdT
cell/myeloid
UV-activated
pre-adipocyte
EBNA2-independent
M267I
competition-based
39-47
nonstimulated
complex7,8
Q9U6M3
.S3K
26/10
RP11-24O10-SG
P-glycerophosphate
Akam
.Taking
0.8–540
compo-
//sourceforge.net/projects/prada/
PGC-1α
caspase-8g
units-erythroid
p.T44M
G12VN-Ras
18q21.2
F130Y
pSH44
VYIY
2q14.2
explored.4-OHT-treated
81.3
microsatellite
ERF-mediated
18490281
5′-GAAGGTGAAGGTCGGAGTC-3′
mini-bead
.NIPA
bHLH/Zip
extra-chromosomally
TANC2
STAT5Y694F
1BR
c.8537_8538del2
assessment.Figure
K-20
23–1.4
malig-
Gata1-Cre+
3.Mutationno.32*27*26*43*6730*7617*50*647013*14*12*16*5557101*41*621*6348*6520*37*36*29*69747*28*38*10*53618*583*5*5618*
trisodium
pipetted
/pGL3-basic
CNE-1
C45
1—source
11q21
g-H2AX
species.The
0.0188
-ΔGRDSPA-1
2—source
TLS/FUS-CHOP
Man1a
.G127R
D-mediated
Hei-
anemia.47
maternal-fibroblast
3-5-2-2
reconciliation
Ospedaliera
HAM/HAM
.IHPM
melanoma18
noncastrated
1,4,5
l-actin
locally-advanced
cut-point
respectively23
optimization.In
P766
Framework1
AF1
AF238374
pre-middle
hypogranulated
GAAACACCGGTCACCGTCTGTG
Myc-inducible
imidazol
co-segregation
.1337G
TtoA
far.35
AML55
sino-nasal
AAAAGAGUCUCA
MAGnify™
fo.6
interdigitating
4-hydroxytamoxifen195
SDCM
mant-GMPPNP-based
ARACNe
RCC41,42,43
ZFN-
oligodendrocyte
cancers.16-19
.Tavtigian
mCherry-tagged
auto-injection
selenomethionine-
phagocytosis-stimulated
M8159
Hydrolysis
-TAT
-CCTGCGTAGCCAGTTACCAA-3
14National
group.10,11
TU¨
TACE
bam
methyltransferases
Inc..
Arg415
3H9R
sub-region
0.06–0.46
D1–GSK-3beta
D603
IVS8+56C
T-tests
ActN1
Omnicon
5′-TCTTTGGACATGCCCAGCCTG-3′
mu1577F
FLI1-knockout
p=0.0391
p‐HER2
ΔJH2-HA
Met173
NSL/MLL1
W24
IndelGenotyper27
EGFR/STK11
used.31
doReceived
1e-7
SRF
SFM
V7F
miR-4294
2027
DME-H21
NERF2
-stained
ProteinsThe
26–28
pLP-Myc
CGP62221
complex.36,37
I216V
benzodiazepine
KDR/vascular
N=15
50μmol/L
CD3-FITC/CD19-PE/Annexin
.BGA
CD41a+CD42b+
.Figs.3B3B
Ala68Leu
.PT3001-1
MCPH10
P-ATGCTGAAGGCGGAGAAGACC
anaemia-like
acrylamide/N
lymphangiectasias
Fbxw7-thymus-deficient
proto‐oncogene
hormone/SERM/SERD
.RH30
pairwise
haemangioblasts.17
E402K
LBH
monocytosis/neutrophilia
RPPA
hUbc5a
mg/day.51
ICR8
proptotic
ACTCCAAACCTGTGTCAAGCTG
INS-1
disease22
phospho-S276-RELA
-CTTGCACCTTCTGCTCAT
bactin
clinical–pathological
S241C
S0033
RhoA/Ha-Ras
RNases
others.94
.Capital
families.To
characterized.FGFR1
Crossover
B.R
deaths4
EPO-dependent
SAETEKEMANMKEEFEKTKESLAKAEAKRKELEEKMVALMQEKNDLQLQVQAEADS
5′-ATGGCAAAGCAACCTTCTGA-3′
R257L
AML.58
M630K
41/50
cellularp21
I290
.Stimulation
.PTK787
carcinogenesis38,41
2,235
SMO-WT
B-RafV600E-driven
.Giemsa-stained
SSEA1-positive
.DOPC
2322
sub-types
C152F
9967
IMT
ver.22.0
V:22
1984
Exon34
abnormality.38
MCCT_2b
S2E–S2G
NR4A2
CD44+CD24−/low
catalytic-metal-pair
c.664-15A
latterdo
labelled-BAC
Methylcellulose
WT1±
11-5
www.genosplice.com
P-L
PCi2
p.Y60*
number–neutral
phosphoinoside
p.Arg172Gly
N+membranes
MPD→T-NHLc
.Mutagenized
L779450
0.25±0.13
intraspinally
G12VHRAS
Snf2-related
2059C
Hsu
CpG-Islands
multi-lineage
70µM
specificrecognition
5′-TACCTCAACCCCTGACAGCTATGG-3′
pY1016
Yamaguchi-Iwai
multi-TKI–resistant
3.7–4.5
MPN.8
~190,000
1.83–1.8
±2
experi­
1ug
001978.1
CancerTo
C-tail
1,899
CATATAATCTATCATATTCTCGATTTTCTTGAAACTGAGTGTTATATTC
site.28,30−33
.Tetramer-positive
SYBRGreen
†In
complete-linkage
E83
α-ketoglutarate1
Y1105
greater-than-additive
MIG-KRAS
Meurette
lines.2
Ribosomes
knockdown-induced
A2066
23/101
pSer-x-x-Phe–containing
Cimmino
breast,3
andL187P
histiocytoma,13
hydrocarbon
3B3B
S438R
Y17118
a-satellite
44–91
0.558
ceTrrcrscwc
Rieger
gi66819479
chromosome-breakage
synthetic-iSH2
PDGFR/PDGF
.DOC-2/hDab-2
3128T
disorders.30
Cul4-Associated
RTlnK1
identified.22
c.1046dupC
singleletter
9A
BbvI
al.25
Ras-Raf-MEK-MAPK
SFA10b
64.4
±1.5
about2-fold
light-run
CH12F3
x2=7.0
Phospho-T58
S97
220–1000
gpllOPrott'rk
Angiomotin/Amot
cycle–arrested
1e6
NA19
=8
.14709.005
elsexresngnoml
Alk8
agroup
MYCN-driven
85.09
FISH/linkage
5′-CAT
Akt/TOR
2Gy-treated
pEAA297
42,46,47
reproducible18,19
HIST1H4B
g-3′
FRS2
11q13/q22
lines.6-14
Bunin
BAK-specific
Weverified
1y1u
.Immunoprecipitated
3-mo-old
5-Fluorouracil
.Hypomorphic
140,453,136
LMP-1
Modfit-software
LacI-CHERRY-BRD4L-transfected
PT/PTT
antineutrophil
escalationDOD
.RHOA
different-gene
Cdk8/CycC
SDS-PAGE
preincubated
Trp88
1/91
BAF250A
CBL-E2
HBSS+
lapatinib.2,3
window-of-opportunity
HER2-amplified
Unitech
.Food
FIP1L1-Fc
AN.V
Castrop
2224
Mamiko
non-ICL-chemotherapeutic
1,307K
closeup
2915–2925
Brabender
Fig.5c
polymorphism1
A1021D
left/right
mutations=0.39
Mahdavi
.RESULTSRationale
strate
in¯uence
IMD
​Lentivirus-mediated
Non-bonded
-9.93
isopropyl-β-d-thiogalactopyranoside
ERKsem/D321N
6/2014
G–J
,39
10595
p53/SMAD
MPN,8
E738
tymidine
p53-1
.0063
PHENIX57
T1349M
Craniopharyngioma
c.134-135insA
×400
5540
G.
.MA
14,038,673,860
CKNVVP-
ESMO
2-y
qPCRTM
_389del
0.00011
Infinium®
D30E
SLC26A11
pox
Wickramasinghe
NCT01184482
Haruki
FOG2
27°C
MDR-1
Rheb-N20
lZ5I/ml
.FGFR2M391R
AKT1/AKT2
Alk/Ltk
TET2/
re-transfected
TTT→TTA
mg/m2·day
p.Ser764ThrfsX53
PLK3
TGC-to-TAC
Urea-induced
-Catenin
eages
1,017,716–1,017,762
.Rami®cations
anti-HDAC
c.1801A
-β1
Falzon
0.64–2.52
.M-07e
α5β1-dependent
mTORC2-
p160
del=I682-D686del
W515K
150B_M
SPINT1
BPTF
U343MG
crucialfor
Quickchange®
2,800
histopathologicalmaterial
CV1
Lys650Gln
Q521E
pmol/min/mg
9α-fluorocortisol
www.cytoscape.org
MICER
Chromogranin
CtIP-mediated
biomolecules
aneuploidy1,2,3
7352C
c.3875_3878del4
18874,1997
smokers.13
M326I
R28C
DHT-dependent
LAN-6
G1762A/A1764T
Thesedata
V773L
S6R–V
.32,37
Mix.2
.TUNEL
151–168del18
V173M
T4366C
A1513T
bladder-
.P19a
cytogenetics.51
Ephx2
ring-like
IV-20
PDE4B-A
Msh6RH/-
pY-
PDZ
islocated
c.20C
.Annotation
GM­
GTCAGAAGGGGAGTTTG
700–795
triphosphate-competitive
and6.6
5E-H
several-fold
VIN-TRAS
MLH1-negative
TNFA
reported26
â€¢Ã˜1
bi-anntennary
Yes31
c.3183_3187delACAAA
positive.No
discussionTo
anti-peptide
0.415638603
Astrazeneca
intra-arm
layer.96
Fukuse
P430fs
Illkirch-Graffenstaden
surface19
Nucleic
Sh-mediated
ab24331
capacity6,7
32–
β-cateninΔex3
235
22600
phase6
Change-in-spectrum
32,609
N296I
T6-28
SF3B1E622D
tumorsuppressor
Bucher
3′ACGTACCCAGAATGGCAGAC
5-Year
overexpressing-cells
Fractionation
LMO2/TTG2-TRD
Shp2Δ46-110
Heredity
NCT01933932
activity22,23,25
/CrlCrlj
J098
IκB-inhibitors
Q61E+G12R
Egr-1
Bcl2-associated
V39M
14.36
.Distant
andDr
domain-Hsp82p
self-motivated
Clarient
-TATA-CAT
1–6/day
8132–8137
Kaposi-Juliusberg
Mahjoubi
H3K36me
.Lys623
FGFR2–PPHLN1
cofactor11
clathrin-independent
TKIs.20-22
rad50D1241N
Y472CBRAF
PowerPlex
adenocarcinoma.16
2.502
533–541
C58G
DCX-expressing
NF1-LOH
Cxcl11
EBER1
carcinogenesisFigure
FOSB
L161*
ets-variant
RAD9A
F876
R305W
P\10E6
28.6
2.5σ
5.36
.2,3,6
.NCI-H3122
Aurkb
CHEK2.1283C
.Toxicities
SH3-Rho-GAP
P418L
59-ACGGTGACACGCTTCCCTGGATTGG-39
Myd88
c.640T
E.G.B.
pCAS2
10.1371
urea/10
exon–exon
Sp-1
−6.6
Porcine
TÃŸR-IIexons
H1421Y-L2
reencoded
O.A.B.
5′-FAM-CTCAGTGACCTACTGATAGAGAATACTTCACTCACTGTCC-TAM-3′
.STIL
carcinomas.1
HBUC
cleidocranial
GISTscan
3TABLE
XPG/ERCC5
.Verti
C601T
chromatin-modifyingenzymes39
12.5G4.9
Rhotekin-PD
//www.genetix.com
41981
λB
p.S566_E571delinsR
biological/biochemical
infertile,18
association120
73-1
pSer/Thr-Pro
1123
P24b
S318R
cell/tissue
AACGGAGTACAAGATCCTCAGC
models48
3.7–5.8
33.8–100.0
GDP'AIFj
semisynthetic
PldCTP
Nrf2
visualization
Mdm210
withβ
phagocytotic
Brd4-transfected
immobile
dIn
HISTIOCYTOSIS
C87R
promoterless
transformingpotential
high-resolution
rTth
2-fs
p.VHL
Agentcourt
,.
35/71.4
S27–29
461–479
temporal-specificity
C-terminus,16
GlcNAc-6P
.Virtually
Rrstop
1221/1222
therapy.7,8
+trastuzumab
//www.iarc.fr/p53
SHH
S61
A615
re-evaluation
0.00394
BRAFL597V
signaling13,14,15,16
shRNA-1
NAiESLFdHiYTTQSDVWSFGVLLWEIvTlGgnPYpGIp-perlFN1LktGHrNERPdnCseENYrLNlqCWkqEPDkRpvFaDIskdL
PDE4D
9.37
.Bacteriophage
ACUC
.Johnson
Mitosis/50
14Bc
JIKÃŽS
others3
gat
NS556
+DOX
p110-|
S.H.C
GAL1-10
OI
c.68-7T
gene-cancer
titrate
K204Q
GST-ERK2E322K
KOCL-48
Asp/Glu
subgroup27
L129I
ELDLETLAPYIPMDGEDFQ
RTK-activated
p.Val384Asp
homozygous/hemizygous
PAK4
antileukemia
Methods5,9
0.67/5.14
cancer.20
5'-h
D9S67
EMLAHypYIP
17.46
p.Asp1028Asn
C252S
WM3457
Elf3
pT481
TFAP2A
gel-purified
Balmanno
anti-Neu
68290285
-bound
NDUFS3
29
ISRE/IRF1
5.63-fold
EBSs15
cds5.4PLEKHG4Pleckstrin
.MDM4
mit.edu
5p15.33.2
D7S517
variant2
embryo180
KG1
R46Q
Glu1548
2c–g
GCTTGCTCCTCGTATTCCAGCTGTCGC
translocationIsa
GATAGAGGCAGTTTTGAAGAAATC
.692T
brane
5′-FAM-CGGCGGAGACAAGAGGAGCAGC-BBQ-3′
D850V
studies.1
mTEL-TYK2-expressing
adipogenesis.
GLOMAX
Kras-initiated
CD95-triggering
23–76
bilat
hexanucleotide
A205T-mutant
5,25
described.13
c.9116C
*Amino
Ad-Luc
G.B.
1,011
native/mutant
II.5
BiBr48
3-11
K125/128Q
5′-GGTACAAGACAGTGACAGGTC-3′
Arg89Leu
females23
JHU
F623E
NCT01488318
A807
2q34
chrM
IKZF3/ZNFN1A3
β-globin.11
A49P
H-1781
thr41
5h
GTX30123
Whole-genome/exome
Percoll-density
1593–1631
15834535
PCM1-JAK2
.CLU
SHQ1-CS
Plakoglobin
3,6,9
BAP1-transfected
Figure9A
NM_003242.4
chromatography.18
Yim
Amniocentesis
S83I
V-PE
NHSsepharose
:3
Bek
BCL6/IgH
RAS/MEK/ERK
c.1031T
–2010
formation13
50.68
PJS066
Asx-null
EBM2/no
cancer—the
OVA-specific
.TCF3
marker.21
ERαLBDCam5F
10.1172/JCI72763DS1
784
Vogt-Koyanagi-Harada
Tris-phosphorylation
cell-spreading
p-Babe-puro
CRF
2.8–9.9
Ser465/467
ergistically
SYBR
0.1389
CEM-EGFP
Lkb1+/−
immunoglobulins34
2999
Mlynarczyk-Evans
panitumumab-based
mutantsTo
malities
enriched-populations
50μL
P=0.052
Studies—CS
c.921-2A.G
0.696
PTPR
Stanya
pRSV-f3
Adipogenesis
findingsnow
MDS.14
-GGCATAATGAACATTCCCAATAAA-30
K636fs
4351
c-ROS
monomer-specific
ACTGATGTGTCCCCATGA
075259
Lyn/Syk
.Developmentally
0.08–0.87
EV1-4
cells.16,19,31,91
G20D
V843I
+3A
Serum-starvation
0.094
AIB1/ACTR/RAC3
EPO-responsiveness
92/ilv1-92
activity1
EGFRvIV-expressing
Fug-II/14
10.5–41.4
γ-33P
Non-Finnish
Tp*C-
.Turn
1625
CTCTCTATCGCCTTCTTG
R339W
5-CCACCACACGGTCCATACAACT-3
NM_006015
25–100
pre-washed
intracluster
ABL2
P53_01
HA-Merlin-S518D
βPDGFRControl
12.37
//bg.upf.edu/condel/home
R2182H
Ser222/Ser226
QTrap
chimeric
CW-2
Phe-341
Riemersma
3912
EZ-DNA
Hs00170665_m1
right-end
P1010S
P2241S
BRAF78
c.283C
Anti-ERBB
trk7
RP2D
family.23
20-year-old
compound-induced
D313Y
Y373C
ALS
Arg458X
-stage
v3
//links.lww.com/JTO/A612
Epigentek
HIP12966R
GIST.1
C-3
R|Ihkl
P-Loop
R-*H
LOC402679
High-Grade
NPY
h.PCR-SSCP
activatory
derivatization
.Anti-ERK1/2
4.54
adenomas49
â€˜â€
survival=55
ALKi-resistant
multienzyme
NAIRS
C91
.NRASQ61K
ALK-TK
R3007G
FGFR2-S252W
Br90
70*
three-group
F/85
S657
Arner
chromosome,40
β-carboxylates
Pichert6
Arg606Leu
ABHD9
10–3
3.Two
WNT
Ubc5
control/dierentiation
DSov
F/O
158/224
glioblastomas.40
ratio/OR=2.58
gamma-carboxylase
∼16,500
solvent-front
III-11
0.269
TGFβ-specific
Fero
anti-phospho-PLCγ1
3343
Meaburn
43.78
hMSH2/hMLH1
methods6
heterodimer
−3.97
theInk4A/Arf
Xq12.92
Decision-Making
microscopic-
LCH
telophase-G1
5′-GGCAACTTGAAAGGAACACA-3′
qualitativelysimilar
Brzozowski
performed.In
'hydrophobic
Godthelp
B/C
spectrophotometry
Investissements
cells.27
FRAP/TOR
Swi/Snf-mediated
3N
65*
subsequences.Lower
D49V
EtsΔ138
ERK-phosphorylated
N268D
P540T
tumors.13,14
Men1F/F-RipCre
SIFT37
E102_I103del
arthritis,35,36
chemilumi
.Adjusted
post-ET
RAB35F161L
suppressionof
K.O
MAC2A/B
IkbkbP551R
HGG1
ourstudy
GST-RBD
polyC-treated
Swe
TdR/BrdUrd
DNA/5
observationssupport
NDRG2
chemifluorescence
pcbi.1003545.e004.jpg
2/11/98
36/EC
GTGGCGTCATGGGCCTCA
breaks.19
OX40L–Ig
journals.permissions
815–819
cancer37
p-p42
patientsin
alterations.10
tableMany
9–66
median=5.52
fusion-type
Criterion™
non-isoform-specific
pDMl0
Hornigold
Figure6C6C
Linong
redundancy21
Set2/SETD2
3417
GeneChem
Arg107
upstreamto
RALDH2
ALDH3A1
.Pre-treatment
discordant
group±s.e
G1.136
−0.9
5-μl
multiadaptor
dx.doi.org/10.1021/bi5002695
260.9-fold
allosterically
related-articles
Dot1l
SCC15
Casea
inbubated
CIMP.17
angiorgi
Hh-inhibitor
Yasuda
10021
intra-ovarian
β≈90°
Co37
Coqueret
diffraction-quality
bin_size
P25T
Npm1|
pCMV-3Tag
Flp‐In
0.929
UCG
EGL-15
xenograft-tumor-bearing
described88
control/tumor
RETmut1
Val326Ala
G719A
CD41+CD42+
asubstantial
post-seeding
0.032.
test.17
ACA-AAA
growth.17,61
ELP3-NRG1
determined.28
HCF-1-interacting
1162C
ofrecombinant
anti-c-Met
zebrafish47
TTTGCGATCTGCACACACCA-3′
TCT-3′
pLTiTSA-Smad4-Flag
mastocytosis.10–16
N386S
normolipidemic
.FLT3-JM-PMs
hr-EGF
Judson
LGK974-sensitive
oil-treated
wasallowed
.Loskutoff
ALKKin-rev
data.6,7
p300S
EµSRa-TEL-JAK2
K341
YNR062C
SEZ
.1
cells25,26,27
CTGGCCGGTTCTTCTGGATGC
IM-refractory
R177Q
pericyte/BBB
.CRT
34.6
7-bp
Fluor-488
TCATCCAGTGTTATGCACTTTCCACAGTTGG
SDF-1/CXCL12
HnRNPU
.Growth-signaling
13±3
MENX-associated
β-myosin
p27fs177-associated
intermediate-
.GCB
antigen-independent
island.80
A2BCAT
Nicklen
0.316
sc-13967
_10q_
2-D
signaling1–3
pGL3-renilla
LS-Associated
FGFR1/CEN8
D16S3067
D84N
dock.compbio.ucsf.edu
0.667
methyl-green
3q27
SMARTPool
PNPLA4
.CMR
pGADNot-INI1/hSNF5
RAS/RAF/ERK
NM_000251
BCL9-2
127–134
NCT01608022
pcDNA3-p110γ-VSV
F1174L-mediated
1259–1266
sequences/total
SSRI
UV-related
GFP-PTEN-C2
c.1264G
23/72
KMT2C/MLL3
.IgHEL
E428D
CATAGTGTGGTGGTGCCCTCTGAGCCGCCTGAGGTTGGCTCTG-30and
AACGAGTCAAGCAAGAATGG
GST-Ras
5V-AAG
pCDNA1amp-6Xmyc
paracrine-positive
A–
L115A
WBP1
Tomasson
siYap-2
L297P
Glu-689
PC4578
P.V851A
γ-irradiation
.full-length
NM_145142
KDM5B,21
p.A740GfsX16
SB431542
D2S391
2/285
GGGACAGTGTACGCGGCACGTGATCCC
Wolkenstein
Isidor1,17
CGTCCACACTCCACTCACTG
parent/guardian-provided
11-month-old
Cst8
1.325–3.208
//www.clinicaltrials.gov/ct2/show/NCT01587703
PAP
Pwo
NB1382-R
4.As
enzymes—including
DIF-
SmBo
Mad-related
PTEN/C2-DLC1
.Diluted
R116W
20.97
AP-MS
pERBB2/ERBB2
floxed
p.M1209_E1214delMFYKKE
inhibition166
protein11
CD-
110-bp
HA-TET1–expressing
70.84
curate
0.399
inframe
immnuofluorescence
can1
Tyr139
1Cancer
ci..rGtrGGGA
BMA031
anti-phospho-Thr202
lesions16,17
A.E.B.
/highwire/powerpoint/117211
protein,5
7/151
8â
oncogenefor
Cy
.N17Ras
mDIA
upper-normal
ARR2-Probasin
Exome
rs3759216
PE-2
M1-Flu–specific
229delGT
0·007
W4S
1.08–3.11
Brinkley39
ATR/MLH1
JH4-JH7
M664I
1000000
.24previously
pSRα-BCR-ABL
F113S
higher-affinity
Tap73α
D895H
predisposition.33
ppERK
G1651S
stimuli.20
0.8667
calculat-
.Goldman
3140
Tyr34–Tyr42
022970
compounds52,53
F33
E76
∼600
Tyr701
PROVEAN33
g−1
refunctionalization
HyP564-peptide
SPOP-CUL3-RBX1
G719SþL861Q
andgive
activity.2
inhibition.43
growthfactor
ACAC-5′
nonbonding
-β2
2510
.Donoghue
eye-sparing
PEBP/CBF
604092
agarose/
GdnHCl-denatured
surgery.24,29
TAK-285
Tyr177
58Â°Cfor
date98
pGAL-MSH2
.Predeveloped
G1266A
647/Ser
carboxy-termini
GTP/GDP-bound
4B-F
0.692
field24
MSH6-p.R1095H
HOXC9
TGF-b-inducibilty
Gly-66
G489A
129/S2SvPas-derived
cases.3,4
Hct
U2AF-dependant
bandpass
c.5411T
report12
Woolfe
S188L
N.K.F.
complex51
Niegemann
MSCV-IRES-Puro
CADO
subclones
17p13.1
Ligprep
74859-treated
N66
Reverse-Transcription
DNMT3-like
CpG→A
3-times
BT-474
331.3±5.9
ACC-635
unknown92
5′-GTA
Albert-Chenevier
FRY
37.5°C
ONO
c.320T
n=40
.35G
NPM/ALK–carrying
KIT-W557_K558del+D820A
DNAJC27
2.3584059
Kohno
pseudohypoxia
nificantly
6myc-Smad3
y_Ar9ThrM•tleuf
Molven
H3K4Me2
Phosphotyrosine-containing
44-390G
cancer.33,39
5h–j
L124F
bwa
Organogenesis
196-201
bisulfite-PCR
conformation.24
LR.Evaluation
Kremlin-Bicêtre
redundancya
kDa.37
Inpp5e+/+
gaggagttgtttccatggtc
-15-fold
shP4
ETS-domain
Green-based
f1MR1
anemia.
Geoffroy-Perez
LSL-N-Ras
65.7–73.1
propor-
T161A/+
MOgene
Q359K
MSCV-MPL-Neo
proteins97
186×
differentiation12
SEPT5/PNUTL
instabilty
310–325
6,36,37
to0.001
starve
GAL2
pGL3-OT
anti‐agents
CBF-AMLOf
246
RAD51B-RAD51C-RAD51D-XRCC2
uretero-pelvic
p16INK4A+/-/p19ARF+/-
plasma.21
GAAATGGTTTCAGCTGAATCTGTAGAC
0.0119
Pro133Thr
periaqueductal
strategy.K-ras+/V12
WSU-HN8
ganglioneuroma
35-37TCT
.Catrin
SI-NENs
5V
Extracentral
1.4–2.3
report,16
.BORR
MUC13
Yop
heavy-atom
Freihoff
ascertainment
66/f
M688R
substitutions.15
pre-dominance
120AC
autocatalytically
L837Q
c.1100
cleaved-caspase
Fiberoptic
In-house
Brewery
Spectroscopy—Uniformly
.Tonin
domains.11
4267A→G
IL-2-inducible
CCNA2
prevalence.10-11
476_516del
unphosphoyrlated
CDKN2A/INK4A
transcriptionallyinactive
HD400
gene-expression
MCLA
D126Y
insulin21
Tau-4R0N
5′-GCATTTATAGTCCAGCAGTGTGATGATCACATGG-3′
deletion/translocation
A_52_P590546
NoYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesNoNoYesYesYesYesYesYesYesYesYesYesYesYesYesNoYesYesYesYes35*
N′-methylene-bis-acrylamide
nihms774093f6.jpg
A310
towards…
modificationh
3-thiotriphosphate
case-specific
Hs01313772_cn
presentation/followup
pmRad50L1237A
LPCAT2
S/MAR
manufacturer-suggested
MOLTI6_HAEMATOP
ant-hg-1
30,000:1
DDBJ
NCI-H1092
CD1
lines11
39/m
activity-defined
OPM
shAR3-1
Leu574Ile
-87
CD8+CD45RA+CCR7-
Ultrasensitivity
.Fibroadenomas
ϕX-replicative
T-ALL-associated
728
imatinib-independent
ade6-485
ABCA3
1OOkb
0.002–0.005
.correspondence
dose.28
TGTCGGCCTTGGTTGGGACA
5′-aggttagtgaagactctgtc-3′
Cytokeratin=red
Zambetti
homeoboxes
W559-R560del
ZZO
CELLect
hematiopoietic
Y527FSrcW1
Electrocardiographic
+250
cross-link-induced
Y666C
.Erythrocytes
VW
Y340DY341D
exquisitly
signaling.70
Invertebrate
C-5
H2A-binding
glioma24
T423
RVO
p.Arg174Cys
Demokritos
BRCA1/2-defective
G1–G5
0.8593
179-bp
FLUOTAR
57,58
S.J.R
12-weeks
Procheck
Ek
lysates.Download
m-Ap
'ground-glass
.Metastatic
foretinib
SMAD3-deficient
non-evaluable
beak-apart
Ultrasensitive
Evinger
0.08/6.4
8-lacZ
GAL4-AdML-
Anti-actin
U-14C
Iwamoto
T605M
SPOPΔBTB
c.1788
Ribosomal
.Bcl-xL
59/60
p21-activated
K449D
22,40
McKusick
0.920
Cap-Plus
NBS
12-3
B-RafR509A
Rho-kinase
p.T771R
K1•
reported.18
immunoglobulin-horseradish
4/53
.FANCJ-A349P
Celecoxib
0.38857333
decode.is
JAK2/TYK2
NKTCL/normal
34.47
PARADIGM-based
.Hereby
240-B-010
.Phenotypes
domain/RAS
p5371-330
allografts
rs304271
GM-CSF-mediated
1.033
39.6
31/41
Cys-rich
E1754X
co-association
NM_000059.3
2.22
⩽20
24BRCA2
PDGFR-B
EQUIPEX
210–239
HNF-4a1
MSH6-linked
13,21,22
E353Q/G390D/L536H
WM1341D
Ras/p53R248Q
FY23
immunosubtype
p=0.0769
Benevolenskaya
GT/AG
IL-21R
AR-negative
V94
.COS-7
Smad2Cs
Sult1a1
c.82_99del18
phosphoreceptor
reporterstrain
CDH19
RSK
AR3-regulated
2009b
+8.7
exon6/7
misexpressed
Hoeben
m/z
LR=7.2
43098–43269
homoligomers
B04
Met-341
neonatal/maternal
EzWestLumi
Q9Z265
129S-Krasex3op/nat
p.W557_K558del
cKO
wt-
neurogenomic
oxy-
p53AIP
DSBs.More
SCRN2
methylcellulose-based
19q13.11–13.31
described,26
nontemplated
kinase-inactivating
Biegel
Meijers-Heijboer
OTT-MAL
quadruplicates
NPH3
19/30.6
G14S
Phe382
//www.broad.mit.edu/gsea/msigdb/msigdb_index.html
p17
TRI®-Reagent
9/411
Cys736
.Claude
Nanoclustering
58-TG-CTCCTCTTCCTCACAGCCTATTA-38
Whole‐exome
.Cell-cycle
1.14–1.37
656_794del
NCI-H820
third-line
OVEREXPRESSION
SOX11+
5′-AATACCACAGAGGCCCACAG-3′
lipid-protein
556433
ii2R
11/45
P2,14
Fargnoli
GSE7545
2.14
methodsTissue
reducedgrowth
infiltrate.105
Sajan
CRI-G07002
ABVD
Hh-regulated
G-3′
four-helical
as-yet-uncharacterized
RP11-294O11
shFBXW7-silenced
pcDNA3.1-hMLH1
methyonine
P919S
NW_001879279
Waring
index18
AR-cofactor
KST947
patient.RESULTSClinicopathologic
Four-week-old
PAFAH1B2
.35S-labeled
1868-bp
Mentored
AGc
Palacino
pGEX-4T1
-balanced
2−
N-succinimidyl
AP1-
blot.Western
IgD+
A1028V
leukemogenesis.21,22
F635V
iCCA19
HSPE1-MOBKL3
5′-CGGTCTTCAGAG
p.Gly13Cys
15N-labelled
wasextracted
studyBlack
I157T13
67/79.8
P=1.2E−6
depletion.14
R155C
52-bp
MYCN55
substrateadherent
SPoT-Light
HKL3000.38
inducibilty
lo/−
0·009
+235
Mäkinen
NG_013302
SOX17-dependent
Tyr1234/5
3A-3C
CAAAAATGTATTCATC-3′
HA-PMS2/MLH1
Brca-associated
p.Asp779Asn
nestin-expressing
BCL-xLΔC27
Pileri
42/48
Lys104
CXCL1
IL-3-producing
complex.9,10
wileyonlinelibrary.com
TCG
thymidines
hypoxia-inducible
.KRR
.Photomicrograph
MMTV-Wnt
Modrich
UTR.12
MMK5
Arakawa
reported5,8
.Virus-transduced
.H-1106-093-3
D18S1137
ACGGAACUCUUGUGCGUAAUU
W281C
w40–60
amplicon-positive
-
Ala767insAIa
S2HeKO
GATA1s-positive
NSD2-substrate
77.17
Proliferating
6814
0.75-1.29
.Ribonuclease
rebiopsies
Lipofectamin2000
LCH-8
downtream
R958
HLA-A*01
c.5062_5064delGTT
mutation–positive
stabilising
FLAG-Smad3
.Measures
193–204
MLL–AF4
D842V-PDGFRA-Ba
D519N
grade-correlated
59Â°C.and
SC-17806
.Stock
1–240
Confi
//www.ncbi.nlm.nih.gov/genemap98/map/loc.cgi
SMARCA4-depleted
substitutionsresult
32323334414545Deletion
Gunn-Moore
luminal-cell
R1443X
androgendeprived
17a
MPE
ADH1expressed
lysophosphocholine
p.D86N
c.1340C4T
Reaction—The
acid-free
.Droplet
ERK-activating
2,223
PDGF/VEGFs
CCND1—Fw
USP20
XTT
6.HER2
SU1174
mSCF
YM-30
Klinik
Silberman
Glu3
types.64
carcinomas70
Hayes8
HLA-DPB2
echocardiogram
0.203
Smad4-loss
0.194
brcal
29,35,36
singlenucleotideinsertion
High-glucose
pEF-MYC-CYTO-PDGFRA
76/86
5′-GTGGACAGGAAACGCACCATATCCCCCTGC-3′
SYNE2
PIK3R3
levels32
SD164
4434
2.6–3.4-fold
5′-TTCCACCCTT
S6A
progression.Protein
Yang-Ming
PTEN/MAGI
bham.ac.uk
differentiation-inhibiting
transduction-positive
AF10
pS-Mx
46BACAAGGCACTGACCATCTGG958
FLT3.15
charge-coupled
tricentrics
-1.24
0.420433
helix-A13
DCAF1-depleted
1.913
Re2
2012-000148-88
06–734
rs42511
Hydroxylated
cardiolipin
BAY43-
5′-TCCCGCGGCTTCGCCTTCGTTC-3′
minireview
7/211
low.20
intra-domain
.Pleural
M.A
processes1
25/31
dicult
Goody
GF/C
mutations,20–22
Y653/Y654KD
self-evident
Holder-Espinasse
scaphocephaly.2
1079
Polymorphisma
α-phospho-AKT
0.300–1.500
BiBr46-50
literature7
cancer-types
773
Sav1−/−
MN73
GCAGGACACCAATGAAACTT
1.67–7.67
P387
Basophils
608C
1∶500
Bengoechea-Alonso
-41
coimmunofluorescence
.Or
5′‐TGGAACCAGACAGAAAAGCG‐3′
U2AF2
N-methyl-N'-nitro-N-nitrosoguanidine
rnGAP1
602421
SM-associated
tphenylmethylsulfonyl
location-specific
CS20
CGGTGACGCAGAGCTTTG
41.6
nontumoral
TGGTATTGATGCCACCTGAA
MfeI
Alhadeff
c.3891_3893delTTC
©Ferrata
Tze
R440X
PDGFR.9,31
.Offspring
2049C2a
E635N
MMR-defi
9733
OCCC-specific
//www.cancer.gov/
548K
K35
c.1806_1809del
GSK3,31
TEL.E1F3
therapyrelated
GCAAACGCUGGAAGCUGCUCAAAGA
P68
anti-TYK2
→GTG
S428del
BU1
793G
.Hippo-mutant
Ogg
GVGD
A101
DNase-
.CRM1
Siah-1
AC011461.5.1.100680
Gebeshuber
heart-specific
GST‑METS
–69
TBST–5
cases/year
c.481G4A
D835N/E/G/A
themaintenance
TSC1–TSC2-dependent
.Inc
hexanoic
mskcc.org
Nadal
cds−11.2DSG3Desmoglein
pSG205
upstream/downstream
detectionc
-AAA
pseudo-capsule
Patologia
Gennevilliers
Sst
ATCGTGCGTGACAT-3
59-TGCAGATTGACTCTG
-AP
S7C
C1Q
kinase35
α-dSet1
clastogen-induced
verteporfin
melanosome
well-phenotyped
groups.36
pTRIP/ΔU3–EF1-α–EGFP
nm020529
BRAFV600delinsYM-expressing
arm.7
non-saturating
Cancer-PEBC
60-182
T11–T13
green.Values
p.Gly47Glu
Yochem
TRAF
Brm
ab28207
Br57
METi-resistant
Leu72
TCGA-06-6390
rostro-
Phylop=0.987
melanoma.30
HEC-151
A015
R834_D835insALG
His113
1HER2
intermediate-stage
47.12–47.36
V599EBRAF
T512K
-translated
PancreasThe
retro-orbital
sarcomas.4
CRMP2
51Mb
36.1/hg18
patients.4
L845S
CNS
32.17
cysteines
−216G/T
exceptionally
CBFα1
chromosome-associated
JQEZ5-treated
E-cadherin/CDH1
08–0439
stained.20
Immuno-blotting
Flagtagged
lacking-pending
10−17
Bezzubova
2771–1940
Kurahashi
2-q2
NTRK-1
-V5-His
-MNLTSTTN-CLENNHISTSDQEKLVQPTPLLLSLLKSAGAQKETFTMKEVIYHL
KIT.60
2–ΔΔCq
BR.21
receptortyrosine
2.0–3.0
BCR-derived
B.P
PTK-deficient
dominantnegativefashion
K-type
Schemat~c
C609Y
Varmus
SNX31
TCTAGAAGCTTATGTTTCTGGTTCTGGTGGTGGTGTCGACTTCCTAAAGCGCTTGAAGAG
PKI3CA
MSH6-MSH2
Non-discriminant
mutation45
adrenomedullary
E9-I9-E10
20,000
PR55
.ConSurf
smear-based
r2=0.79
Tri-Reagent
IntegraGen
§two
Lats1/2-specific
0.0063
crizotinib.38
1.22–1.20
-CTCACAATGGATTTTGCCAGT-3
0.1–13.8
633-653
bacteria57
reported.16,17StatisticsSurvival
BRC17
=0.008
p.R2659K
p≤2.2e6
U-118
K334E
BEZ
Ischemia-induced
5mC-containing
.CRISP3
44–60mers
cuacauagagguugagauTT
.Chem.
repeats,73,74
51–57
lines.33
un-transfected
.C–D
_1365+
lymphocytes/μL
T-acute
ACGâ€
RNASEL
re-investigated
SRSF2-wildtype
.Longer
Gehan–Breslow–Wilcoxon
Untransformed-jielB
Apo-1-FGFR4-KD
Wenglowsky
Gentry
p.Met412Thr
pT2G1
cointroduced
instability.21
pCDHGFP
2-47
E684Q
0.246
oncogene.Mutations
90°
guidelines.html
anti-Pim1
ry
P-Smad
RPL-19
.MASA
CBL-UbcH7-S
SNU-620
hygro
misincorporation
.Gargiulo
PCR-Blunt
G215E
V3-15i
T/A
FgfR1–FgfR4
FGFR1K
progression.7
c.1494C4A
2001
ALL-IKZF1
SUM185
JHDMs
Florouracil
27-fold
CHEK217,18
phosphatidylinositol-3
BIM32
129S1
anti–Gr
overexpressionfor
bi-loop
SDHAF2
Kelch-BTB-BACK-BTB-BACK
Further-more
TT-3
WMxxEx
NUR
59-GGTCCTGCACCAGTAATATG
Map2k6
182.2
1482
transillumination
JH1-JH2V617F
HCC05-0411B
58,025,847
.Proliferated
Shapiro–Wilks
1–418
S1P2
HNF-4a
MUT13
Infinium450K
factor.59
virus-transduced
Lys-CoA22
Figure2C
1.59E08
N2340fsX2341
H1035R
del6ins7
3641447
ERE-TK-Luc
.Dose
Cg-Tg
dimethylformamide
31/34
KMT2D-regulated
0.013
−2.64
Epimutation
N430S
Tris–
chr16:67424298–67425126
5′-ATGCTCCAGACTGCCTTGGGAAAA-3′
3.16882
GAS-binding
59-79
r485
5914
24308
H870Y
Bcr–Abl
9141S
Runx2-CBFβ
multisystemic
.Pulse–Chase
non-clonal
.11F
Candiolo
HER-targeted
Chemietek
sy
HSP27
trypsin/0.02
Pans-activation
regiment
pTK-Hyg
'list
IU/g
anti-pβ-catenin-41/45
FNB12
K-ras-driven
Gfphi
.MLL
Glu137
long-dashed
.HER2-targeted
HO-forward
RAD51B+RAD51C
4–7/8
Antagonist-to-Agonist
ÃŸ2
pICM
E/R
2B−D
TNF-α
Fgfr4
CTGACTTCTCCAAGTTTCAGG
anti-TMEPAI
Project.21
level23
c.1153-5_1153-1del
filtrationchromatography
CBL-expressing
104C
Chr
2834
p.Top
p.D405G
Lys391
NM_207655
Del747–753
ARHGEF11
ErbB-2
3.2.1.Δ
SpliceSeq29
octylglucosidewere
missense-variant
S847
.Deregulated
Valtola
.FADD/
185K
HNRNPD
TTL.20
fluorophores
201–409
Café-au-lait
del2236–2250
PACdJ1119O21
myelodysplasia18
1-285
-40.75
HPA008736
size—rather
therapy23
biligand
displayedan
Protocadherin
5′-TTGCTGTTCTGCCTCAGTCTT-3′
FA-H
g/kg
410.4
pacilitaxel
C=O
Jβ2-2
anti-CD56–APC
filter-lift
−21.9
ywLuArgLeuAsnGInProThrHisValAsnAsnGIyAsnTyrThr
5q31-32
BCR/FGFR1-positive
c.475+8dup
PTC-RET
Del-2
TGF-bresistant
rick.pearson
c.383G→T/p.G128V
tgccagGT
1:6
Mcpt1
acini-like
_Wk
treatment30
1.5sigma
exp2alr
KIT-R
Yap1
E1AF
6.16×104
class-I
post–GC
RCJ
YCC
d–
Omholt
W-like
c.350A4G
InsE-A14
ASLX2
frequent.8
p.Gly134GlufsX74
monochromatic
six-step
MadnLZ
185-fold
co-transfections
yeast.11
TUBA1A
37°c
beta-value
/43
CT.
52BDs+59FDRs
Y878-R898
p1638
pulmonary-artery
6026N
1.005–5.460
RWPE
anti–total
anti-p65
HR+FGFR1-amplified
mutations5
E117
E1784K
pmCit-N-ras
anti-H3K9me3
R.A.D.G
STK-1
Ser218
3-s
51–68
GTPase-defective/constitutively
N92I
CBDCA/PTX
mL−1
11q-deleted
d−1
PDS5A
USP7-mediated
775insHV
cy3
MD-derived
Gd-DTPA
184.16
Φ-π-S-S/T-S/T
B-RafinsTT
withinseveral
differentiation43
pDR-GFP
scaled-up
AREB-2/AML
Suganuma
Swiss-PdbViewer
59-AATGATGGCCTCACTGTCTG-39
K658Y
Arg→Stop
trf
.Things
EvdW
microl
9.5-47.5
down-stream
linep53
exon-junction
pEF1/Myc-His
.11,12,18,19
1,155
dTAMARA/dROX
fromgeneticin-resislant
EEFSEC
pIRES2-EGFP
L790F
1p22-specific
Reni/la
XP_323176.1
.00664
GCTGCACAACCACAATTGCGTGGACACCGGTACC
Cdh2
postzygotic
3D7T
14-1B-219
SL3–3
0.12.8
dilute
CCDC98
protocols.19
geneb
IMCE-HER2
LRB2
7×4
PMLRARa
2399
BRE
mer-containing
EGFP-positive
AP2
JK3X
0.462*
Presymptomatic
cghviewer
2748
VHL•elongin
Monosomy
.Spred
Blasina
vera6
studies42
–anchored
allografts106
RP11-461G20
0.369
.BRCT
adolescents/young
22q11
31y
NS.16
Doi
rin
spectroscopic
D2102
Ksander
◦C
8,22,24,25
c.8494C
homeostasis.4
2204delT
origin10
agarose/formaldehyde
C415R
mRNA.14-16
Tet-R140Q
BRD7
IVS20+21_22insG
phosphorylation-mediated
Z-buffer
TÃŸR-1receptor
27,29,46
.DiscussionWe
SSCP/Heteroduplex
inactivation–either
229
Side-chain
8track
Fugazza
groups8,9
74859
double-strand-break
1.9.1
increaseof
Rad51L2
D216A
retrocerebellar
HOX11L2/TLX3-BCL11B
SYGQQS
Birt–Hogg–Dubé
5′-CTGCGATGATGACAGAGGTTCTTGCACAT-3′
finger-genes
CEBP7
1180
MATae
`equivalent
44.60
L668F
GAL4
cDNATRK-T3
R629
Kazusa
2F/R
27/62
dominance.To
Iron-Sulfur
allogeneic-stem
~1600
temperature-shifted
TNFSF11
LBK1/STK11
acid-labile
∼38.26
1103
.0084
//www.bloodjournal.org/content/bloodjournal/103/6/2019/F3.large.jpg
27-1835
E349D
Transfectam/plasmid
V271A
CACAAACCCACCGCAAGTC
MIR
ligandinduced
uniform.Ninety
33433446
+16.7
6/61
RAF1-ERK-β-catenin
547-579
P306H
67IK
Akt/AKT1
5′CTNNA1/5q31
105K
together.5
S549R
E116
576G\
Ile157→Thr
R59H
Weri-Rb1
pT-category
FACSDiVa
38/69
F1-II-1
Shutsung
phospho-Y981RET
74-126
mammalianp53
Molar
S102
fiM
Mammalian
αF-helices
K162M
VMEG/HYD
+2
1.79769e+308
co-infiltration
H701
radioresistance
13/59
3.00/O
erythroblastic
2677
eliminatingreactive
SF3a
CDC37
radioligand-binding
bar1Deltaura3Deltans
S4-S6
1806–1809Leroy
c.1504_1509dupGCCTATp.A502_Y503dup
inhibition/stimulation
Lyngby
GISTIC23
inactivating/neutralizing
D.P.The
alleles.30
CCGAATGAAGAACACGACCAA
26996101–27184400
5-Bromo-2′-deoxyuridine
angiogenesis-related
c.308_317del
SPRY4
pBABE_EMPTY
non-pigmented
7307
SEPT10
fasciocutaneous
system.Figure
co-senior
R383H
Panel–Caucasian
hexamers
N-SVGAKRRR-C
R611W
E180→L
FGFR3-TACC3-KD
Y476C
Sites—To
CTD-2113A18
PRPF8
FGFR3≈8
33–44
32-bit
K131N
VarSifter
−1942A/G
anti–TIA1
L341P
I222N
antigen-specific
LR11-354
C5839T
streptavidin-hemagglutinin
cancer32
SERPINE2
Dungwa
semipermissive
unphosphorylated
2.6–7.6
p85αΔ434
22·9
5'-CGCACGCCAATAAAGACATA-3
leukocytosis.8
Etoposide-induced
.S.
IsnArgPro
Nisimoto
10–60
SKDQFPEVY
Niihori
.Threonine
A11012
tripod
mutant-allele
ÃŸ-cateninhas
p11q24.3
Level-3
radio-resistance
mCAT-1
blood–brain
G350A
-BRMS1
H3F3A-PPM1D
Actinomycin‐D
244–486
GibcoBRL
p.Gly173SerfsX19
BRL.B
69-3
451-bp
pseudo-inclusions
Heavy-atom
65419
p38-MK2
K.W
Syn
3,835-bp
GACCTGGA
Tyr-285
5-fluoruracil
mice/D171N
antirabbit-FITC–conjugated
Histh1d
c.336delG
'Decondensed
UACC-257
agar,46
Woodgett
RCC
.Fig.22B
IRES-LacZ-Neo
Q75
Chelex-100
—approved
co-immnunoprecipitation
Figure2D,2D
FISHanalysis
Yew
RP11-100O5
nccs.com.sg
Reitman
1α-induced
3639delCT
TetPTEN-Y65C
BTL–BCR
MUTYH-associated
M.P
10-cm2
-imidazolo
TRII
1570/L
hCdc4-negative
5′-GGTTCTCAGCTCCAGGGAGATTCTTAGC-3′
MPPH14
2E.y0.50.40.30.2i
L99I
X83753
Nfe2
p.Arg789*
PCSK5
//www.iarc.fr/p53/homepage.htm
WIF
CohortNF1
null373C
MBD4
Squatrito
74–99
5.452369
0.065913226
GST-MBD
pHR-SIN
.Attachment
SETD222
deoxynucleotidyltransferase
1/2⋅length⋅width2
Phosphorylation-defective
HRAS—the
858R+H870R
.Parents
de/repalmitoylation
roleof
NBD-phosphatidate
FBXW7vs.cyclin
GSE12460
p110α-R93Q
0.394
.MEASUREMENTS
Wuxi
MET-amplified
-HMB45
~0.70
5'-GGA
SETD2-disrupted
idiosyncrasies
complex39
Y-MESO-8D
FigureFigure4
0.9–2.0
BRAF20
H580_W582delinsKTIdupP573_W582
Δ3263–69/Δ3381–85
five-week-old
251-257
2-phenylaminopyrimidine–based
Neu
WM35
Gr-1lowMac-1+
≤13
EN1/2
ErbB2_ex17-25.R
Leu117
Raf-MAP
R217C
OVTOKO†
8498
ctgtag
9Y
SCFFbxw7
icant
patients,26–28
Cys6343Arg
prepupae
sequences.31
H338R
7242G
tetracycline-regulated
Pro114Ser
proteins115-117
Parp
._290+
membranacea
Mohi
TTCAGTCATGCTGCTAGCGC
1000x
13,018
Zp3-Cre+/0
ZF5
731–732
date.11
UK1708E1
~2-fold
HKL-2000
A-ring
,d
MLK3
400mg/
5/02
ONPG,22
544_803del
triphosphatase
P369T
PS2
E8.5
1/188
EWP
1OEC
anti-IDH1-R132H
pBB75
.WHIM16
Zitvogel
FBS
Enzfitter
Cas-Br-Murine
consequence.10
aagctccaccaactacagaact
shq1Δ
pioglitazone
∼3–5
preautonomic
Promega
JAK2-associated
RUNX1-EVI1-transformed
ofbenzo
.Plate-based
utilized.19
neoplasms33,34
26,794,806
telangiectasia-like
Garban
R1042W
adults18
insertion/deletions
Bim-deficient
NKX2-1-induced
CEL/HES
.ETV6-NTRK3-mediated
MDM2/12q15
mode.14
Y288C
melanoma,8
A8
11elysleuleuSerAsplysleulysGl
F1888L/L2230V
Hs00171790_m1
5′-ATTTAGGTGACACTATAGGAGGCTGGGGTTGAGCA-3′
p=5.2x10−6
1–310
implications.27,28
His773
survival.44
GATACTCTGGCTGGGCTCTG
20.0–186.7
VTEFMTK
D216H
cells/cm2
0.228
HER2.rtTA.PIK3CA
PR–
384
sequestration
RT-PCR-sequencing
non-MEK-dependent
RPTK=receptor
fNHA9
chromatographs
R651W
864
0/0/2/1
120-μl
4,56789
21acute
kinase.26
+7–8
5'-TAGACATTGCCCTCGAGGTACCATGGATCCGATGT
pWPXLd-ETV1
aprotinen
Tyr53
Anti-ERK1/2
PTPN2-negative
Inpp4bΔ/Δ
identifieda
766:442–58
γ-aminobutyric
phaeochromocytoma.10
Mre+/-
Hsp75
cysteine/methionine-free
Jakubowska
5'-M13-GGATFTrTGTCACTl-TGTTCTGTh-3
0.3232
963
lung29,30
Microplates
Merkenschlager
.Processivity
.PAM
anti-BRCA1-Cter
α-helix
D318N
activity.9,13
withIGHJ.82
3.1.3.
1795–
bj4540501add.htm
Cytogenomics
phosphate/nitroblue
55349
multi-layer
Delta-like
culaire
MEK-SPA
104,112
.Colony
–12.9
γ‐secretase/Notch
Asp575
re-formation
K505E
sac
C3029T
GATA-like
BMP7-induced
Biopolymer-Technologie
10p14-15.1
CD/FL
C20R–T37Y
FUJIFILM
1X8
rearrangements.8-11
theguanine-rich
FIG–ROS-driven
.ACKNOWLEDGEMENTS
program.27
100:1
p.S49C
337
Sacchararomyces
5′-TCACTTCCTGCTTAAAGCCC-3′
HDC90
53BP1-deficient
M1326I
F4R
PIK-E9R
.5.5
PVF2
2,007
–76
-orthophosphate
Haemangiopericytoma
IFR
94-90
hypothesis-testing
S474
phospho-independent
Yap-4A
dependence69
capping-boxtype
AIGl
spliceosomes
579
Kmt2d+/−
diatomic
Devilee
e-a
P130
microtubule
yin
Other—Next
Lys-CoA–p300
read-outs
TCRα
D,5′-CCAGCAATGGGAAGGCAGACGAATC-3′
p.p.m
previously.5,21
β-cateninS37Y
deathII
F∗
MPLW
TGFP
Ihle
MSCVpac
35–37
0.1965
desulfonization
T791M
Sur8rf
frequentlyobserved
DistributionThe
Wnt-inducible
doi:10.1172/JCI85271DS1
Davare
130nM
5′-GGTTTCCTCAGAGGTTCTCA-3′
diseases1
inverse-PCR
5′-GACTAAGTTGCCGTGGGTGCT-3′
C421R
E.A.M
1866
6/329
DNMTs
Immunocomplexes
transductional
RARβ2
13–27
Tet-induced
refmac5.45
~74
streptoavidin-labeled
Luria-Broth
extron/intron
HAL-B3
ADAMTS8
FGF4-Introducing
Fig.2C
35,49,50
BLIMP1α
TBL1XR1–PIK3CA
exon-exon
disorders,8-10
Time-dependent
osteodysplastic
GCGGCTGG
ICC-like
4.1–10
ng/μL
HCC1954
.NHMs
smokers8,14,15
CRL1
q23q34
.1499
C6ORF97
cancergenome
17F
14-847,000
Branda˜o
uorometer
17-allylamino-17-demethoxygeldana-mycin
TGF3RIJ
bacmid
∼1200–7000
Bannayan
adhesion
C-50
Shonukan
pyrimidin-7-amine,10
45×32
p=0.01
phospho-AKT-dependent
E137K
NIBCs
Benzamidine
-extracellular
apicobasal
toPAX8-PPARγ1
Benhamouche
AgeI-XcmI
mRad50-expressing
E5+R
cancer67
3.6-kb
extra-thoracic
GAGCGGGTGCAGCAG-+GAGCGGGCGCAGCAG
A194T
02–459
Ptrend
.Chou
trans‐acting
Kundra
5′-GGTGGGGGTGTCATAGAAGTCTG-3′
Tresp
EMT.We
.FLT3/ITD
α-phospho-histone
LKB1-Hsp90
p.T156P
multiple-testing
-ctagaaaaagcgatcataatcttcctgctgtgcaggaagattatgatcg-3
L1657P
NCT00257608
T-NHLs
notsmall
21d
pRS425
Src-specific
wu107
MUC16
deletion/duplication
intensit
OCUT
DDCt
imatinib-sensitivity
AAG01087
67–69
ZNF382-staining
c.-138^13321
Clonogenic
Variant-Impact
Glu288
made.Cytogenetic
Leptomycin
enhancers.68,69
neoplasms.13-15
Nugen
Tyr216
Agammaglobulinemia
P-LATS
S7D
Biotechnoloy
sarcomagenesis
P3039P
Hockney
cancer,31
thentransferredontoWhatmanfilterpaper
K342N
Dentelli
trkl8
Epizap
p.L290L
conserved-core
SSPS/Ri
17/74
hydroxyacid–oxoacid
Sprycell
Gas6
fibroblasts100
T50I
CCAACAGTGTAATCTGGTGAGCCACTGTTCTTT-GT-3′
Versteeget
dysontogenetic
treatment.23
L861P
76–100
S1A–S1D
dfci.harvard.edu
CAG-LSL-GNAS
R354
non-squamous-cell
p.Gln546*
.S2
reintroducing
LPS+interferon-γ
p.Asn45LysfsX30
neoplasia-susceptibility
non-severe
χ24
11-base-pair
SAD-containing
Ma-Mel-48
anti-DNA-topoisomerase
protein,11
2,6,7,8
conditions.BRCA1
PCR.11
.Cdk
SpectrumRed/CEP7
Val561Asp
.PSI-BLAST
diarylamine
p=0.046
neurofibromatosis-like
0.0175
drug-resistance
5′-CGGAGGAAGAGAGCAGTGACG-3′
5′-GAGTGATGCTCCCAGCTTCT-3′
cystadenomas.35
‐shaped
c-MycT58A-expressing
affinitylabeling
.LOD
His393
7,8,54
pre-run
Gr-1−
described21
ΔEGFR-mediated
57.3
1005
GTGACG
Sk-Mel-28
IκB-dependent
others.6,17
TCF-1
1–219
cMLH1-kPMS1
BRC4
above-described
2.8–20.0
WST1
mucoepidermoid
V5-HER2
MSCV-BAwt
Ash1
Myc-Tiam1
notbe
domain–pRB
4407
21–30
Exceptionally
G116R
SWI/SNF-BRM
RG-3T
3730×1
303–553
99–104
locatedwithin
0.835
BRCT/DBD
RP11-97763
ntot
.08
Ser751
3,3-
heparin-coated
pcDNA6/V5-HisA
+0.5
Hyper-proliferative
2-GDP
MOK
.HA-Nrf2
F338V
7.5/130
Nhieu
co-domains
5′-TCCGTGGTGTCAGAGCAGATGGC-3′
26+
sml1Δ
Class1
BKM
mIL-7
-
30-kDa
PDGF/R
54‐year‐old
.62
l0
S471N
Izz
patterns.8
high-penetrant
.Huynh
3690
R898Q
JAK2-selective
yahoo.cn
p11q13
tumours14
INK4a/ARF
A-pl9
HNF-1α
apoptosis.144
0.214a
∼300
MAP-RSeq
heteroligomerization
HEK-293-DDR2
anti-Rictor
R222W
dibenzazepine
BTK-targeted
α-tubulin.19
A4726
p21is
P1849
.835
Ptf1a
retrograde
4237–4238
HMB-45
B-LL
D336fs
TEL-TRKC
LR12-033
Dahlen
p.S449F
2.66
.Mutationalscreening
1–54
SRC-T338I
K19
T-ALL–specific
HCC1937/GFP
morphology-based
Brca1Ko/Co/MMTV-cre
ER/PgR/HER2−
GST-DED
TCF-4/β-catenin-dependent
129S-frameshift
p.Ser694Tyrfs*3
.Over
homo-trimer
BRAFi15R
5/17
MY31
CAG-LSL-GNASWild
acetylase
.Neurofibromin
GLI1-regulated
FigFig2A–C
Songpa-gu
←∑i′sti′∉
frame.9–11
ssDNA-celluloseloading
24-year-old
CUTO-3.29
diamino
3-4
E-10
86.9
trophectoderm
5′-TTCTCGCAAGCTATCAGCCC-3′
X-
glutamate–cysteine
FIG.5
Norrin/Frizzled
p=0.96
5-CGCATCAAGCTGGAGAACCCGCTG-3
PGAM1
c.813G
.Inserted
Probabilities
NF1.8
T790M
herpesvirus
LOI
Mis-regulated
Me3
Lymphopanel21,26
Del-Mut
Forkhead-family
nucleus,19
ACVR
.COS-1
3127
carcinoma127
NAD+-dependent
.Metrics
LNCaP-R1
1,402
SH4
APCFZR1-mediated
cross-referenced
hyper-reactive
Leu2209
gene-editing
anti-nl
repairproteins
.2866
log-odd
acidsTruncated
Q270R
A338D
ACACGGCTTTACCTCCAATG
ox
Lys600–Gln611
S473D
Imatinib-treated
year-course
KIT/D816
1992,1994
extracellular-signal-regulated
GGTACC
intron/exon
U6
pCDNA3-Myc3-Nrf2
sensitivity8
residues,41,42
13±1
damage.16
Asselin-Labat
5′-CATCAGTTTGCCAGTTGTGC-3′
T590
CDK4-R24C
patients.11⇓–13,34,35
201dupT
Vac
Deoxyribonuclease
BRG1-induced
bothmutagenesis
apoptosis-triggering
11-splice
histidines
5'-1TFGGGGCCTGGACTCTGAG-3
D38N
p=0.43
sub-polymorphic
nMPM
HLA-typing
responses.5–7
F200
technology21
L155H
HSCR-only
impelled
.Unstained
Bolstad
4,6,27
Fig.3A3A
nonlymphocytic
QUIamp
AAS91161.1
RARr
60694
0·03–0·06
proteins58
.J.R.Bischoff
Ub-proteasome
group17
hMLH1-deficient
12-specific
P341L
,3C
1R2D
1185,175
reports.30
pAkt
SwissView
Y32WA59T
anti-phospho-FLT3
VEGFRs
NeoMarkers
receptor–related
PKB,33
p.1
imatinib.7
.Gli
G12R/A59T
nosologically
Two-channel
∼67
analysis.4
∼95
NotI/ApaI
IFNalpha
.Col2c1
RALGDS
250mg/kg
Cos-LV1
R571W
1DJS
2H‐tetrazolium
c.989-1G
43-3B
Stratification
V1135E
AGAGAC-AGGATCAGGTCAGC
Easy-A
AG-39
R.D.J
anti-p70trk
.Extra
T790M-L858R
.Nonfat
R656W
.Bosc
HDS
trans-inhibited
A-1278
Ruault
−1.65
BRAF-V600E21
VBC-Specific
s/94
Campro
dopamine-dependent
1836170001
14/28.6
GST-Gli1ZF
domains.4
Esrrb
valine-to-glutamic
β–mercaptoethanol
anti-UBC9
markers.1,2
K421R
non-ICC
tag-fused
siMacro26
2000®
Pelvic
Silibinin
TGFBR
Novobarcode
MFGR1877A—30
Nrf2/Keap1
5,600
KRH/0.5
144,167–170
anemia.31
Immun-Star
no-antibody
Y3092C
.RAC1
rs11552761
.DOX
Rizzoli
Luc-expressing
18,20
−11.1
//mmb2.pcb.ub.es:8080/PMut
1.37-3.38
DLC
F374L
co-translationally
_BRAF_
MN34
1100delAT
NTRK1-rearranged
RPR20-2
70/CRC
PAK1
q31-36.29-31
HDX-MS
p3300MCKCAT
vitro-transcribed
5′-TTAGTATCCCTTCCCTACCC
Raf-specific
^25201
histopathologicul
cells.57
dis-regulation
2371
c.1028_1029delCA
pathomorphologic
unidirectionally
9014
Mass-Extend
genes21,152
PTEN-retained
systems.17
x2=6.65
//ensembl.org/biomart
pYpY1135/1136
10ZF-MYC
TAZ-promoted
protooncoprotein
3.8
pVPack-GP
SPOP-F133L
:62–71
S291
RECNR
615108
.FLT3/KD
Shyamsundar
E640*
ab6546
.Pluquet
aforedescribed
0/200
//www.ncbi.nlm.nih.gov/geo
AML28,29
CDK/cyclin
Mm768bpΔAGAAAR/ΔGGAA-LacZ
Merenbakh-Lamin
elop
sc-5231
ApcΔ716heterozygotes
ARE-binding
HECD
5-Azacytidine-n
.Coding
domains.21–24
Stroop
Minassian
A-derived
ATF-2
37
1/42
totype
whileMMSET
incapacitate
T1-T97
re-visit
advances1
pmGFP-H-ras-G48R
Kras-Tp53-mutant
Physicochemical
21/74
non-genetic
Ubiquitination-mediated
PeqLab
6,8,24,43,44
types21
appropriate.In
prognosis.35
5'-AAGCAACTGCTGAATGAGAA-3
lysate-based
TOV-112d
-Ras
mesenchymal-derived
TCC-39
A59G-like
ink4B
T2512A-independent
HTSeq-0.5.4p1
5′-GTTTGAGCATGCCGTCAATAATATAGCTGGGGACGA-3′
6.16
//microarrays.nki.nl
Phe-445
Mitogenesis
.grants
pEAA39are
pan-
*'â€¢Loop
PROCA1
domain.1
mutation/Mb
SW527
N67
5´-TCGAGCTGTGACGGCTGCAAGGGGT-3´
54,319
oligmerization
ubiquitin-bound
TCCCGTAGAGATCCACAAAAG
.Unveiling
totalextracts
tumorderived
RP11-98G22
specimens4,5,6
c.2006-5T
ITD-N676K
F170I
CTP
inhibitor/cisplatin
7,095
cochaperone
Y231C
Ase
destabilise
FGFR2E731K
G-5
Bcl2modifying
site.10
MCID
evolutionarily-related
pSE103
Utomo
PLX4720-treated
recombination.45
5′-gaagagcgagagaccttggtggaggggtgtaatag-3′
WITTINCHOFER
MatInspector
Ramachandron
.Introduction
GSE45019
1,18
n=294
doi:10.1371/journal.pone.0025021.g002
WT-PDGFRA
0.2-11.0
culture-induced
318
8.24-27ZNF198
75–80
unibas.ch
PTENR233
Tyr1394
T266M
comSEQUENCED
Dy-Light–conjugated
S310Y
Y227C
analysis21
−6.90
cytoplasm.11
.METHODS
.SH3
mutations12
.Two-color
pathways.18-21
0.35–0.5
-GGGTCAGTCCTTCGTCTTTC
pro‑
65nt
mutations.15
56.5
7.53
MDS-
gi71748512
17.68
oligomelanotic
W.C.C
*CpG
WHO-
deletion,23
2694
cells.Immunoblot
staining108
rcP.ccP.cci..rcGP.GGc
TCGACGATAACGAATATGCCTGCCTCAAAGCC
5q21-5q22
miscoding
TRKB
CTTGAGGTCCTGAGGTCTGC
28053982
ERK/MAP
alone.46
Personalizing
SREBP
**COSMIC
VSVG
NM_009928
2/299
CAL33
0.669
NG_007109.1
.Hammerman
HCC25-0809
ShAXL
1,221
cell-culture-based
Pont-NEN
2012–November
Y17118–126
Eliasz
ScSET1
429.90
PrimaryLiver
relapsed/
later-acting
SRSF2-expressing
senescentA
.BLIMP1
ACAACAAAGGGTCTTACCAAG
513
TACACCCAGGACTTCATGGTGCCTGGACAGGTC
Jie
.Six-
achieved.51
R649
.2
3-demensional
Y1062
rs17337451
12–84
DAPK,21,22
H2K27me3
17–75
12q-associated
Galm
1b–c
cystoscopies
dysregulation6,15
//www.umass.edu/microbio/rasmol/
silverstained
EWSR1-FLI1–dependent
786-O
5-Aza-2'-
Scram
Col2c12
Jope
non‑small
6/32
HIF-1α-ubiquitylating
OCI-LY1
disorde
rs1799977
viable72
58.92
purification-hemagglutinin
7.06
premaligant
PLRG1
.Bert
1624
CD25−CD44+
Assays—Established
GSE13889
gpl40PrOtO'-r
Elmer-Cetus
.Tumorgrafts
5'-AACTCGAGTTAAGGCGCATTGTC
K-Ras+/V14I–mutant
Msh2-C716F
PHL-Akt2-GFP
U2AF35was
v10.1
oncogene-negative
oncogenes.3,4
aneuploidy6,7
39-44
D324H
non-oncological
anti-AXIN2
Feb.
PDTC-Turin
/TrkAIII
BH-FDR
pph2
MISSIONshRNA
poor-quality
Monophosphorylated
TK1
Tet-regulated
OPB-3112
Lasergene
tumorsa
CBF1-VP16-expressing
hematolymphoid
.Represented
Leukovorin
myoepithelial-committed
episomes
survival10
sorafenib.24,25
P-I1
p53-controlled
TMPRSS2-ERGa
folding-unfolding
biotin–streptavidin
Fig.22B
DcR1
SNU5
25/260
non-injected
E66Q
0.680
Radish
73–82
THRA1
12.07
2OSS
activators34
G465E
BRAFV600
aMLH1-NM_000249.3
Mb.4
.RIS
EWS1
Skp1/Cdc53
Africa.12
study117
~2,500
ubiquitination/de-ubiquitination
F2–F5
retroviruses26
P.A767_S768INSSVSS
orphanage
prom2
backbone-backbone
NOTCH134
3885
23-fold
mis-spliced
5/81
protein-binding
Mosmann
Xobs
Teh
43.66
±1.32
1/53
1512-1515
mt-SPOPs
signals.29,36
PIP3
p.M1889T
myelofibrosis14
transmittance
R661
pre-leukaemic
16.5Mb
Y270
death.40
G-34T
2033insC
Kaipainen
hypoproliferation
G546D
Nishina
27-speciﬁc
suppres
AP1
deubiquitination
5567
.Functions
Notch2−/−
Francomano
GTHCL
crizotinib159
GSK-2118436
al.43
T348I
Rnf43
27.7
pBAD-TOPO
8550
signaling-specific
HYPEREOSINOPHILIC
AB1010
.HK
Biosystemsmodel
.40,109,111,114
Irnr
2595
ATR+/−
5′-CTTATCTGGTCAGTGCTCGC
orientation-switch
ACAGCCTTCACCGCCCTGAG
Biotin-labeled
TGGGCGTCCGCAAGAC
.037
PPEMH2
-Tet1
723,000
cytometry.9
enzymes3
allmutants
1-μg
Bioanalyzer™
Ter119-PE
let-7a
ACACACCACCACGCCCAGCTAATT
E64D
CUL2-pVHL
14.6-46.3
PIPKII
Lipofectoamine
ECV-independent
MCF7-ADR
nucleus/
1,133
G375C/WT
cyclosome-
321
.Simultaneous
Lodahl
5573delAA
Anti-phospho-ERK
pneumocyte
E35
FGFR2N265Q
PA60
End-point
SMARCA4/BRG1
10MF/50HPFs
/lookup/volpage/21/3105
NCT02289833
PTP-S
74.9
red-conjugated
D1270N
608201
methylation4,12
example18,19
ARshRNA
29,196,578–30,451,370
81-25-
missense-associated
colorectal/gastrointestinal
S16C
29–34
Ins-del
.Survey
56.7
12/12/3
pPWL88puro
-827
SG-UL
PTD
C2H3NaO2
pLZR-IRES-EGFP
121086420
1a2
H1112
MACF1–BRAF20
28,29,33,47,55,60,62,70,71
glycosylphosphatidylinositol-linked
X85960
itself.17
p.D497D
KITD1–D3
Tsutsui
15/28
α1-β3
gastro-inhibitory
pathwaysand
Myc-bound
1,580
9/102
mismatches.Figure
S2215
Créancier
BAK-p53
StM185
46-87
109T†
17P
trans-autophosphorylation.7,51
100–200-mer
cellsafter
.DBZ
STAT3-responsive
docyxycline
3-02
issues.Patient
Ragulator-Rag
3,2′-
0.506
fÂ
p.Glu132Lys
keratoacanthomas
Mek1
VGP
LGDN
Matushansky
1949
L221
CARD6
EP568Y
Sox17-binding
8p11-12–amplified
Smad1/3
protein.Clinical
rate†
16-17
39kDa
S62L
gene30
PrintNetworks
0/8
CY
Il-3–independent
fold‑change
tyrosinekinase
HOD
R2/ATP
NH4OH
BEAS2B
NCOA2
distant-matched
Ser768Ile
0.9-1.1
cytoplasm128
choice.3
pepsinHCl
painstaking
2962
www.cyclacel.com
cryo-solutions
SF3B1K700M
ttctag/GAGCAA
1–336
E.A
Val600_Lys601delinsGlu
fall-off
ofK-Ras4bG12D
Sturm
,3,7
B.Implications
mice118
.SDHB
123–130
.Detergent-insoluble
paired-normal
isconsistent
BTF2/TFIIH
Bognar25
site.20
.RSD
tumors26
beta-Catenin/TCF-4
1HE8
26288824
uvula†
Microcon-PCR
Cnt07
Herestraat
pLZR
δ-D910A1/δ-D910A
.Dunn
Rsc2-H458P
full-
TGTGATGTCATCTCTCCTCCCTGC
ission
//github.com/mskcc/vcf2maf
coun
MCL1-independent
TottoriUniversity
.S7B–S7C
toF
9-mm
Campomenosi
findings19
sulfate-PAGE
.strong
TargetNow®
aP2
Nedd8
M40L
externalization
CCNA/CDK2
i/t
Chang-Gung
fluorographed
Orengo
misinterpreted
Fig.5C5C
TTD-A
851_1002del
.Micecarrying
I162M
CD34+CD19−
N38K
1q31–q32
Arg509
2p13.1
cytogenetically
StataCorp.
half-intensity
E507Q
94/9
−26.6
Sparcl1
203
0.668
.Trial
molecular‐targeted
A339V-associated
CATECHOLAMINES
Radiation-induced
human-tumor-derived
Pen/Strep
6-methoxy-
SpectrumOrange-
S758L
ESAD
paraffin/genomic-based
R696P
Sample5
Glyceraldehyde
constitutive
Diagnosis/stage
Polyphred-generated
sham-treated
95-46
aa1-1758
L-II-03
6.6-fold
reported.33,34
32.72
Varon
ER−/PR−/ERBB2−
M.L.
R272C-Cul3
pCMV-empty
WEHI-3B
previously34
Nucleotidebinding
775–1292
MD-generated
OLIG2
types.11
Crm1-dependent
Huaynaputina
1,230
co-corresponding
/College
retroviral-transduced
mTOR-G4435+6A
:p73beta
//www.ncbi.nlm.nih.gov/pubmed/
9β
biochemical/biological
mutations/translocations
149,150
siPRKCA+siPRKCB
Virchow
RAF1-
terabases
pediatricians
miR-2–binding
Schwaab
14-16,23,24,26,27,30,31,34,36-40
BrafV600ETgfbr1fl/+
stoichiometric
man.24
PELI2
.Ser35Cys
D184
breakpointsc
Powergene
Figure1B,1B
RT-PCR15
animals/cage
non-Chinese
BH3-binding
P370L
L1601P
U/C
N=425
608354
Va.
DMs/HSRs
-Cre
5′-AGGTGCATTTTTGTGCC
Y599F-FLt3
18/29
FGF2–FGFR1-IIIc
necrotic/perinecrotic
0.031*
GGTTGGTGTAGTCGCAGACA
33°C
LCMC
.Treated
pro-turn
Cheyne–Stokes
LIFWCMVY
GCACGACGCTGCCCCGGAGGGCTTCC
Notch3−/−
61-5
domain-like
3+4=7
4q21and
c.5331_5332
neurofibromin.Neurofibromin
p11-12
c-4
S36A-IκB-α
77.6
PRKCB1
lesions,1
48.6±7.0
dimerization32
KITD814V
non-clinical
biogenesis23
cohort-
.GIST
limpet
Lyn-deficient
ChemiLuminescence
PTX
VSV-UB1
frameshift/nonsense/splice-site
Fok1
depletion—achieved
129Svj/C57Bl
CHO-ER
CTGCCTTTAGGGATGAGCTG
intron14
5'-terminal
disease.In
–170°C
.Boström
residue.33
pancreatic-duct
ErbB2_ex24-27.SR2
.Mismatch
2.4–kilobase
phenotype26
direct-acting
404KB
chemokine/cytokine
TGGCAGGTCT
whomhad
CAAT
domains/regions
HOM-C
I925L
leukemia11
GLIOBLASTOMAS
c.397C
del17p13.1
ch19
Glu23ABD/Arg534iSH2
HES1-Luc/30
0·5–40·8
BCOR-3256F/ZC3H7B-1649R
GAB1-3
588–596—in
ALK-activated
Notch-associated
abnormalities.Genome
p.Gln124X
36.81
Emek
Shieh
A702S
p53flox/flox
VU-ID9
9/61
ura3-52/
pre-denaturation
BT12
46-3/4
D12S76
PI-4
−5.490
yeast-two-hybrid
PRIMER3
S1454G
A→T
102-119
6,26-29
stromally
single-tube
103/178
cell8
dosages.Partial
L347P
320-600
T1860A
telomerase-dependent
96.1
KCNQ1OT1.18
Flag-Brd4
DDR1/2
Xanthoastrocytoma
COL4A5–COL4A6
LBH589
⧫
Mpl+/+
Fulton6
.AF
MEK1-C121S
ST-EPNRELA
cervicolateral
AG1
Akagi
serum-limited
SOD2
Fj
well82
1W4U
393P-shZ-MKK4
-amplifed
against2
607585
Colau
A_52_P58208
Microarrays
.S6F
Kristelly
6Murea/32
W76X
6241
.Europe
anti-phospho-FGFR
0.0020
3-med.klinik.uni-mainz.de
POLQ
ATM-KD
phospho-S6K1
​After
Elf3ΔN270
tRBy33
Jl8
15-month
poly-A-binding
shRNA-LacZ
class-switching
HNF4
=3
LUC15
P112L+WT
DsRed-stathmin
1/723
aauUUUUUuc
FAM-CGGCGGAGACAAGAGGAGCAGC-BBQ
p42
mutation.32
69:13-16
P48T
A451T
TGFBRII
anti-H3-K42me
chondroprogenitors
anti-oxidant
defient
-D1/BRCA2
Micro-Imaging
Context-Dependent
thrombocytopenia,3-6
NCT01472003
date.18–20,22,34
WI38
GenoSplice
antiprogestin
pre-phosphorylated
Vassileva
1237
CTG-CTC
FLI-1
proximo-distal
19•
Sequence-based
von-Hippel
width2
solvent.61,62
anti-GST
onglycogen
.017b
NM_001145306
GST-AR-AF-1
0.45×
7/58.3
56yrs
SPDHE566-571R
splicing4
5′-TTAATGAGGGGCCGGGCCGCTGCGGCCATTTTGTGATAGAG-3′
Prescreening
PT06.1
hPMSl
D292A
LKB1-313
C574G
CD16+/56+
185stop
32P-Pi
381-383
−2,000
comparedwith
BRAF/RAS
c.4662G
904-941
0.1-
pigment-producing
context–dependent
Obe
L-glutamine
stress-fiber
ETV6/TEL-JAK2
5.438
CEP6
co-recruitment
pBABE-based
238,270
2–9-
bp–IL-10
.K78
9.8+0.4
BC091652
SC-271532
pre-incubating
ONYX-015
13q12.3–q13.2
.2191G
tamoxifen-mediated
factors.169-171
Q5/13
H2T=22.65
p53Electrophoretic
GST-SRC
B1-B8
.Nras
Crystallographic
C/H1–3
unusualbiphasic
fgf-2
frequently.18
pathogenic/not
q26
non-metabolizable
PD184352
well.59
66:1
yTSC1-CD
φX
S15C
organoid-specific
K650M
respectively.31
Grb2/FRS2α
OCM3/OCM8
D22S1169
Low-Penetrance
ovarian6
Ink4A-Arf
pone.0064364.e011.jpg
data57
Rpl23
software,13
25/M
2.0–1.9
.BAK
2.47
1:10,000
Ã¨
BCOR-S.
Theplasmid
MSc
Fbw
fGrantham
e4.1
MAP2K4
anti-Kit
mice185,186
Halaban
'oncogenic
PrxII
21-bp
GPCRs13
survival.50
W486
5858/arpa.2011-0035-RA
lower–molecular-weight
pY1234
534K
Akt-positive
Colella
251260
Auto-antibodies
VEG-F
Phoenixt
Pim1+AMPPNP
pEGFP-C
PDCD1LG2/CD273/B7-DC
7p15–22
inclusion/exclusion
poly-Glu–Tyr
anti-PK
®nd
GST-rAxin
Fas-apoptotic
N473S
462
substrate35
closelycorrelated
AKT-activated
QuickGene
hyperlobated
TAKARA
0.351
carcinoma,19
DMSZ
non-CSD
1177
P-p70S6K
liabilities.ResultsPIK3R1R348∗
L747F/P/Stop
immune-deficient
GST-Shp2
±s.e.m
pLP1
.RBI
j.ejca
ACVR1A
tocommunicate
NM_024441
family-binding
433
p≤0.05
.LM-LECs
∼7.5
Alexa-Fluor-488-conjugated
A2KM
invasive-growth
Xp11.2
SequencingKit
NSD3/WHSC1L1
clone.8,15
phosphatase-II
4Å
Thr-877
lographic
LOC100131626
NM_005120.2
Zabludo
-genetic
triphosphates
0.06-
Singlestrand
pRSV-ß-gal
M-P
32Pi-labelled
osteosarcoma.3-5
10179-87
/+
Quarry
pg2
613529
MGC
chloroformand
GDC-0449
106/230
E2-independent
pGL2ANΔTETo
activation60
.Wilcoxon
itsetiology
One-fifth
prevent­
models64
pY1092
D-13
pGEX-2TK
F155S
PKB-α
.ET.E
23/117/9
MLH1-ΔNLS
Asn81′
AH003235
/Sx
NG2
Rac1-JNK
PLVX-IRES-PURO
protonate
.AXL-driven
p.Ala25Pro
apoptosis209
EpH4
O'Malley
STI571.20
CMV–VSV-G
c-Akt-expressing
center.10
deacetylase-dependent
10§
sonographically
59-GATGGCTGGCACAAACGTCAG-39
subtyping
twenty-thousand
entry.SafetyTreatment
CellTiter‐Glo
0.800–0.918
.Final
DNA.49
0.1804
Tyr719
L265P-mutated
algorithms13–15
DNAnexus
44,52,53
♢
.1.3.3
IVS911G4A
twenty-one
Phospho-DDR2
transforms.77
.AKT2
2202
oligermerization
1,2-
Raswt·GDP
Cys-Ser
447–561
5′-GCUUCGAGAUGUUCCGAGAGCUGAA-3′
Sleckman
362
self-MHC
Flag–HA
erlotinib/OSI-74
radioimaging
hormone-insensitive
1455Gright
best-studied
B.Mayer
6.98
.Transposon
siRET
68353913
−.14
Nanomolar
21,2
TORC1
Ser-121
stably-transfected
T3M1
analysisCells
postcycle
RhoAV14
Apo-1-FGFR4
Delagrange
P110-alpha
deaminase−6.9cDNA
penicillin/100
-C2
KRASMT
pCycECAT
Denhardt/2
FANCA-PK
.S7B
630KB
E1660G/M1689K
outcompeted
.CMV-p300-E2
Intrastain
insertion—they
HP1,9
1De
NF
OAlalle.
cells—as
5.Heterogeneity
L.Z
I247M
teslicular
0.387
.During
IHC-negative
tBoth
type–like
andactivate
R-Luc
Lent-shRNA-control
INSM2
casades
1μmol
lp36-
re-induction
splicing21
2.4.3
76-fold
1558–1807
T150I
6U
centroblast
.Hydrophilic
ARRY-142886
HRG+
+5FU/IFN
x106/10-cm
T-antigen-transformed
p21-neg
pre-polyI-polyC
TRAF1
K762
F-TSC2.5
1135-bp
M875L
Lin12
NIH-scores
6.0c.ERBB2
6SD
IDH1
cell-body
SGK-3
GST–Chk2
TEAD1-binding
shRNA-only
Preferentially
dysphosphorylation
GCF2/LRRFIP1
inhibitor-bound
10-mmol/L
supershort19
OneArray
well-differentiated
BRCA2-associated
ITGA5
endoplasmatic
.Triggering
coiled-coiled
phospho-epitope
maturation,18
cancers,2
AIF4J
BL6/SJL
A1781C
retrotransposases
177,187
3-boxes
S768Ia
His-UBE2N
Y2726C
thirdgeneration
29,585,352_29,585,354delTTG
Tet21/N
MAP3K1-induced
αβ
As3-9
R8L
hereto
uORFs
temperaturesare
NICD1
26–81
5'-ACTCGGTTTGTAA
5'-GATCCTGGAGATAA
G3R
TGGGCGGAGATTAGCGAGAGAGGATCT
mutations22
Sammlungfu
phosphorylation80–87
xenograt
H61
hyperresponsiveness
TCTGCAGCAGCAGGCAGA
NPD
dissociatedfrom
.SUMOylated
A42
3.1
S616F
​andDD
Wild‐type
MLL-AF9-rearranged
ERT/ESX/ESE-1/ELF3/jen
STAT1-specific
DN-ETS2
.Insufficient
θ
cells19,22
VHL-Mediated
NP25-BSA
GIST.4,5
post-conceptual
autoprocessing
c.1235A
GIST.14
Ligand-Independent
disease43
50340-1
M1035R
PE-DTPA
Carolina–Lineberger
sarcoma–like
Taylor-Papadimitriou
C/EBPs
R162*-MEF
decatenation
Janinis
disease36
Tyr648
anti-viral
K666E
variable.11
4−7
plates13,14
Tβ2
Asn505
RNF43–wild-type
.PCM1
40/53
Del-1
Thanatophoric
MYC-interacting
subtype.5
p.R816X
3919
phospho-PKC
intoBamHI/SmaI-digested
21076
group.bmj.com
18mM
9p21
K3Fe
rs2072590-A
.S3/S1/S3
bp32P-labeled
720.0
lowin
NVP-AUY922
Co16
E049
plasticware
.SOX7
Moog-Lutz
Brgf/fERΔ
3.BRCA
plate-to-plate
Guerrini
216PheFS
proposed.3
M18968
1.2-megabase
521
sunitinib.35–38
aga
αKIT
V696M
ade
BAT-RII
FERC
MD/SA
5,12
==
PRDM1-knockout
PDGFRAD842V-expressing
ligase–mediated
zinc-chelating
2/27
Fig.Fig.2C
G46S
lymphocyte-rich
V534E
NACC2
.Remke
ELANDv2
RPS14/5q33
double-mutants
bi-directional
TSP2
anti-phospho-STAT5-Tyr694
poly-ubiquitination
Boerhinger
p53R172H/H
histotypes
IgM-AP
M12814
r=0.59
p-iodonitotetrazonium
.Thepatients
proliferation12
non-responding
.Specificity
MPD-like
HA-FADD
NCT01225887
Cambinol
JM-domain
.076Exon
5/13/96
4177
.Then
1:0
FLT3-Ile836del
1-octanol
66
hyperphosphorylation
N596S
AdCRE-infection
cross-platform
//evs.gs.washington.edu/EVS
Yolk
anorectum
39-untranslated
nonmatch
457–491
investigation.7
2459*Stop
SHP2-evoked
2012b
10−6
0,1
1.922
'super-binder
18-19
34.14
eorts
,110
ferricyanide/150
lamellipodial
fluoro-5α-DHT
BRAFV600E-mediated
p.S214C
i3q31-3412q
216K
Elute
SEC31A-F2
miR-17-5p/20a
AKTi-1/2
Maniotis
p110-stabilizing
non-steroidal
RGS4
III3
Bcl2/XL
23/113
1,763
33434138
development24,25
0.0001
detec-
V343F
IL2Rγ
3,650,019
rs3750913
30.02
l-α-phosphatidylinositol-4,5-bisphosphate
phospho-site-mutant
127–130
Y1173greater
410K
13/152
G4913
A76T
v5.02
~42–44
NF1.Materials
.Fa
H136R
ESE-3
GFP–VHL
pPGK-Hygro
notavailable
RifR
c.784C→A
49412955
lipocalin
/TFSEARCH.html
mutation.13
.Pathological
nuclearextracts
activated.8
GAL4-TFAP2CΔN292
sugMolecular
WD/ALT
F32
GTGGGAA
8-32
tumour-bearing
Dhfr
p.M1_S8dup
Cytofix
step.Mismatch
+∑i′sti′∉
Chk2/Chk1
p.Phe788CysfsX2
reports9
F1772
Pro222
–9
chromatin49
hena.naqvi
A211T
X-Gal
5′-ATGCGTCGCCACATTGAAT-3′
SET-containing
M37R
Set1a/b
CMV-AR
×32
B/A
G139R
mIGF-I
H.X.
IVS10+142T-C
RA-dependent
reinjected
8.3/50
HA-JNK2
RanGAP1
Myc-TGFBR2-Nluc
33/73.3
9756s
RANPB2
LS-type
Flag-Akt2
Ferrando
055:55
serine/arginine-rich
machinery1
non-standardized
exons7
ATTGTCTCAGTCATTAGAGCAC
nitrosylation
p53.39-41
AA101630
anti-Smad3
U2-dependent
1.16–4.28
0.0180
receptors.25,26
.BCP-ALL
.Anti
RhoBTB2
genes—triple
137-701
Ep300flox/flox
thymidylate
anti-phospho-p44/p42
FDG–PET
20−25
sequenceanalysis
anti-PCNA
interphase-FISH
HCC01-0207
121/135
Keratin8/18
sequence-selectively
1105–1114
Hs00282410_cn
cMET-activating
d.p.c.
2-yearly
145-compound
Hodges-Leman
MacroH2ASBC
immunostain
HoxA5
development.34
Arg369
asignificant
chromatography–tandem
L396P
/84
zester
Cellometer
oncometabolite
Tyrosyl-DNA
TGFBR3
.specific
re-authenticated
Ca2+-acti-
.Ouerfelli
Wullschleger
RG-14
50–
motifs.39
well-dierentiated
.Additional
4v1
EW-SM1-870
.TGFβ1
1.2-cm
VAMP5
FANCCmutants
symptomatology
FLT3-F594L
53.81Mb
anti-growth
//www.broadinstitute.org/rnai/public
RAS/ERK
oxalate-activated
129-Smad3tm1Par/+
fromeach
respectively55
Zirkin
reciprocate
SingHealth
CA41556
nf2
resveratrol
09/22/08
380-381
BALByc
v-p3k
Tiling-path
mice—this
A12′
.Protooncogenes
sarcoma.20,21
.Hygromycin-resistant
//www.ncbi.nlm.nih.gov/SNP
23.52
sc-2370
transfection-based
transfectionswere
GDC-0941-sensitive
Elp3
PDE4D3
939
T380-dependent
kidney.D
R255A
S16_V232del
MLL-AF9-expressing
TMB
T205A
positive/number
interrogations
-CTCAGGCGCCATCCACTTCAC-30
RNF43-Mutant
.Above
.Endo-GluC
ENSEMBL_518881
ETS-related
AGCAATACCCCAACTGAAGG
RASSF1
.Assay
VdelinsKLN
L20
20/32
ZMAT3
M535
hydroxyl
T1010I.Met-H446
mlHoechst
pyrene-7,8-diol-9,10-epoxide
microtubule-destabilizing
MKN7
progression.3
BACH1/BRCA1
domains12
MEYERSON
Mosaik
fromexons
p110β-mediated
p67tel
06-459
.Embryonic
1000X
1p0
proteolytically
33-37
5′-CGGGAGTTGGTGTCTGAATT-3′
LSL-BrafD594A
observed.68
approach—gene
Gln331
pathways121
UV-B
HDR-based
survival,14,19
ngl
hormonedependent
tetramerizing
GISTs105.The
2495G
v659-
−8.0
2mm-based
Eef1a1
Y537S
.CyclinD1
vitro
al89
CCWG
P=0.028
cytokeratin-8/18
W604Stop
thymocytes.The
SMN
ub
Lau
∼125
0.2090
AAACAG/gtatca
FLT3/ITD+
DDR2/ERK2
Tera2
NE2
GES
.Compensation
NSCLC*
FGF1-stimulated
libsvm
.Microcultures
FAM46C
Lumi-LightPLUS
Rel/NFkB
SEEa
del-18
OH-secreting
4249
Pokweed
11q14
n=72/279
E82G
eachPDGFRA
Q311X
p.Leu344Gln
M538I
T521I
1.89–97.6
Peltoma¨ki
rSerGl
GMEPs
ATP-regeneration
cytosol,5
GAP3
R0lGODlhAQABAIAAAAAAAP
cholangiocyte-derived
0.453
D1/CDK6
F35L-PH/WT-KD
M68
Smad3-induced
MLH1-p.V612del
M318R
L547X
KS-associated
S2.5.1-S2.5.3
R20R
mo_
ATP-site
Tgf
LSL-Kras
DCF
RN-C/RN-D
Hiddemann1,2
F70
antibody–antigen
1061C
22,46,68
RP11-133N19
6FAM
dChip
TRKA+
Brca1flex2/FH-I26A/Wapcre/+
LacI-CHERRY-BRD4S-transfected
E545K
ultracentrifugation
Trx1
laser-microdissected
Hochedlinger
Isopropyl-b-
Ser338-Ser-Tyr-Tyr341
nucleosolic
D710G
leukaemia/lymphoma
5'-M13-CCAATAGTACATACCTlTCTTCACC-3
aa52c11.r1
.CREBBP
ETV1-probe
mutation-negative18
repeats,2
IRX2
microprocessor
.Biol
Sciex
G457S
-Akt
Solcia
HindIIIXhoI
chr5_g.56177067TG
Lobry
AC079775.6
PGNTs
TGTACACATTTGAGGAGAAA
09-1368
85–800
7525_7526insT
complications7
m.o
caspase-8-transfected
49D7
OF6
pouch-anal
aethiops
HKY579-1A
patients.In
Merlino
EXPORTIN5
LP9
Y413C
1170
cancers28
out-compete
.Stage
50495
78,82,78
.Shigeaki
Aminco
TRE-NRASG12V
vavBcl2
V-V450
4.3−10
TKIresistant
Mitogen-Activated
Alex-binding
line8
BT16
F53
G537C
GCF2
one-fifth
12153
CFP-conjugated
ROS1-Rearranged
2.16053
CLL.32
Byrski
37,45
Adenoca.
/62.5
P50.05
COPS5
RP11-498F10
HLA-A
BCL-XS
CancerThe
cells/250μl
Akt-mTOR/p70S6K
p-GSK
L199P
7⇑C
2Fs10120-013-0298-y/MediaObjects/10120_2013_298_Fig3_HTML.gif
underthe
R271fsdelC
Ras-GDP
SPOP-D1–D8
KIAA0101
MIZ-type
0.76137
AAAGGCACAAGAGGCCCTAGAT
3.4–9.6
HER+
GST-CDK2
instructions.Flow
D100E
WHV/c-myc
KHYG1
.CD1a
0.01μM
NCI-1155
â€¢Â
TAII
1992a
density-independent
induced-fit
11,000
STAT3-C
PKC-neurofibromin
D767
pmol/μl
resectionThe
Thr386
Foxa1
Wiesener
Z4
cutaneous
Click-iT
PT3
anti-TPM3
MGCD516
DIMH842-845A
aqueous
blue-shifted
NanoEnTek
E6–AP
EGF-treated
HGESS
Arg79ABD/Glu496iSH2
25–35
L2383F
AA284668
Ella-cre
G298V
NP_035188
GCGCTACCTGATTCCAATTC
TCGA-AX-A0J0
D110A
anti-IL-2Rα
Normal-like
IVS18+65G
nonhydrolyzable
presenile-lens-opacity
comma-delimited
vemurafinib/PLX4032
PD0325901-resistant
Deisenhofen
L208V
c.182delA
4791
delWK
Ourresults
phosphoantibodies
proteinsregulate
2534T
pSer
differentiation.15,36,37
resin-bound
CRaf
−47.5
ZytoDot
32-is
8/531
Great-grandmother
appliedwith
1086insCAG
mutationsThe
ThermoSequence
þ
1-AUC
.HCT116
Suntinib
Cys-176
c.84_98del15
signalosomes
V530I
T158C
226K
p.Ile800Thrfs*24
Scheibenbogen
TbR-II
1,152
11-b
//www.broadinstitute.org/cancer/cga/Firehose
NGF-responsive
Enzymatics
.DDC
BMR
1.1.0
Zoology
.Intrinsically
8.32527625
receptor-receptor
alleles.26
MP-RM-1
slighly
fastidious
S67R
NCT00099606
5′-GTTGAACGGTCtagACACCGGC-3′
carcinoma.9
KIT/ABL/PDGFR
Hs01020387
Untransduced
β-catenin.23
T7-15
12Nevertheless
functions178
PI3-K
BRCT–BACH1
BRAFV600E-driven
S473P-Akt
IFNly-treatedFO
4201
RAD51-positive
NOTCH-transduced
Voyager-DE
Subtilisin
ELISPOT
symmetry-related
erg-3
.Anti-ERBB3
interalizaton
OSCST
tRNATyr
RAS–RAL
K298
71180
.He
histone-modification
0.7677
non‑significant
serveasa
myr-hp110β
StatementPatient
HA-CBL-Y371H
c-Myc–induced
-0.134
R330fs
process41
TC/CC
c1711C
TROPOMYOS
denovogear
Skp1-Cul1
176
Nonadenocarcinoma
N1303K
bil.
soft−tissue
time—the
PR-negativity
solvent-protein
V120F
.PP1
LOX-IMV1
Junctiona
FISH-Tissue
μg/lane
Shukuya
antagonises
GABRB2
17•2
32C
.T/P
.Immunohistochemistry—MDCK
SFILN
-546
M1628VR9
ER+/HER2+
akt-E40K
G468E
p-Tyr-peptide
allele79
mutants/variants
V213L
responses30,31
regulation.21
9232
2682
U-2-OS-
HtTA
comixed
29Interestingly
A-Barcode-Exon27F
nanocluster
structures96
fiagments
fusion44
engrailed-2,51
aeruginosa
proteinuric
Schinzel–Giedion
plementation
3,056
pZW2C‐A6G
54.7–62.5
aTNP-470
.Motivated
age.16
mice.42
SLE,39
â€¢i
reversed-transcribed
pCMV-53–248W
p.F53_Q28delinsL
PanIN3
interdict
RP11-204L7
poly-D
.Necropsy
LL22NC03-80A10.6
2189-2171
3-cc
withsequence-speci®c
MMS-treated
7657
doi:10.1186/s12885-015-1786-8
.6938
RRa
007459.1
GCCTTGTCGAAAC-3
LS.25,26
26–92
MFM-223—a
anti-DDK
P.K.V
mutation¡/HER2¡/HER3¡
U-015
3×5
nodule-like
Brie¯y
angiogenesis.21,22
PCD34
knock-in
R394H
CY-1162
Promoter/Reporter
Kiyooka
phosphorylation
anti-γ-tubulin
NM_006912.5
NVP-TAE-684
imm
casp2
onandView
synthesis.24,25
Myc-TrkA-L92VL95V
methanol–acetic
Ligases—The
two-cluster
GST-CstF1
50–87
pFC-MEKK
Lazzereschi
20.8/24.1
0.3172
Isbre
389–395Marcucci
∼5
205394_at
numbers.7
miR-27a
Healthsciences
Darzynkiewicz
Protein-l
pT3/
pFAK
SKNMC
7794
U87MG.DK
malignancies15
0.956
CCTCCCTGGTCTCCGTGTA
electroblotting
EPD21
h+s.d
L388R
His163
chloride-potassium
rate*
turnover.17,18
LPCX-transfected
SMO-I408
Bjornsti
CCND1b
CDNK2A
AP3β
FAT1-specific
SpectroDesign
Jumonji
LATS1-positive
semeniferous
miR143HG
cloned.89
SAF2002-11833-E
P.E709_T710DELINSD
XPO1-targeting
double-assay
P200L
R263Q
DNA-calcium
self–nonself
AKT/mTOR
Ooi6
52.9
histone-H3
P1/2
GAP1
non-perturbing
c.5278−2delA
PCR-SSP
cytochrome-C
cases/families
previously63
GTGGCAGATATCGAGGTG
Padova
retrived
log2p∗Cseg+
gpl20rks
Commissariat
Mg2+ATP
KT49
NP_001094320.1
.IL-1
TGTTGAAGGCAAACTCACAGAGC
18-22
PACA-AU
T662P
=0.028
post-translocation
Urea
1.02–1.15
.ATF2-mediated
yeastcells
.Aneuploidy
MALX-Cre
sev-Gal4-driven
mono-antennary
NM_019063.3
JBTS
.543delT
*50:02
TR-1
MLLT3
GNNK-
401-bp
phosphoThr309
activation,29
KT1465
D1-D2-D3
chainb
Arg1010*
Mutant-Enriched
Actuarial
E76K/T468M
Finland.21,22
vemurafenib93
MMTV-promoter
MG-B2GFPΔ1–2886
D9754
activation.43,52
methylguanine-DNA
PAX8/PPARG
.Slides
S1F
GTGGAA
PVSG
pone.0094132.e002.jpg
poly-ubiquintinated
polylisine-coated
CGTCTGGAGTTTTTGGGTGT
Farmacologia
'ankyrin
RNA-interference-mediated
Gaildrat
192
zinc-®nger
Ocal
peptide
between-study
9764
20,573
Gly-138
pharmacotherapy
3,4JP2
carcinomas.54
DMEM/5
CMV-p300
05-mutation
68480f
60-min
His1434
Fundação
c.547+7G
5′-ATGGAGGGGAATACAGCCC-3′
-RACE
c.5119G
random-coiled
6,12,20
hypoglycaemia
20–92
oromotor
–99
AAAG
Japan131
hook–mediated
Flag-tel-jak2a-expressing
48190-011
Joazeiro
overexpression/activity
Caki-2
C11orf95-RELA
21.1
0.14–2.07
complications.41
BRAFD594V
Fabp4
HT-3
hybridisation
Method-S1
JAK-STAT-mutated
.325C
12213
.799A4C
PDG-FRs
17–32
−125
pcDNA3-DP103
CATTTTTCTTAAGCGTCGATGG
T1209A
A1342G
3-D.
pMIG-IL7R
484L21
NFIg26
.Amp
.Cytokines
mutant-ER
R104Q
G863G
monotherapy,14
damageinduced
NM_002738.3
17q13
dihydrophthalazin
22b
XPO1-ex15FFPE-F
pCL1
ATGGGAATGGCC-3′
8:186–189
-0.83
FIΔ
441+2T
P=0.0060
Classi¢cations
leukocytopenia.15
C-TEL
Single-site
phastConsElements46way.txt
8·1
/3-Catenin
63–64
4.43
NrasG12D/G12D
5′-CAGCACCATGGCAATGGTAGTGTTCAATGGCCTTC-3′
non–receptor
groups.27
50-fold
SY5Y-TrKB
UCU
Axin/Conductin
0.000404
3.42–3.30
SNT15
5′-CCACACAGCAAAGCAGAAACTCAC-3′
patients.67
tran-
pyrophosphate/1
100ng
protein-inactivating
p110α-CAAX
A2B5
HTC-C3
45–48
B15
5′-AUGCACAAUUAGUUCGAGAUU-3′
~1.6-
/100
UNC7
haemangioblastoma.4
repair4,30–32
~66kb
0.75–1820
ARAF-encoding
321K
VHL-elongin
497
.BID
J.L.K
cAMP-inducible
12Munich
neural-specific
8.7
//evfold.org
204-207
Δ∂
5′-CTGACACAATGTCCTATTG-3′
EA64
TRAIL-sensitive
Stag2
V555
rs2981582
CROE33
7p12–p13.1
a-chain
P422
perforin‐mediated
AIP1derived
Vegesna
11597
.1583A
21-22
wild-type-R249S
jtM
2-diabetes
5-yr-old
Tomatidine
0.00741
-H2052
Cy5.5
neurotransmitter/neuromodulators
c-Flip
XNP103
KST976
Mld2
deuibiquinating
aliquot
M237R
0.0488
approach'213
IRF4lo/neg
expression21,22
MKT-BR
Group-wide
polybromo
eNumber
cellextrinsic
MMFF94x
5-h
99.952
IVS2+57
MET-positive
hematopoiesis.4-6
7-
AACGTGGTGCCCCTCAATGACCTGCTGCTGGAGA
13/109
homologue-like
A71S
EBUS
defect.Initially
NipR1
H642
chromosome.35
400HD
anti-PDGF-D
F2
Lats/Warts
abnormal/inadequate
9/75
GFP-RhoA
reports17,18
wu92/wu8
octyl-
set24
protooncogenes
re-suspending
PKB-catalyzed
Denvill
G.-M.L.
Neovascularization
.BCOR
80°C-
Å2of
31–35
Dharmafect
pre-chilled
P182L
Phe-275
T197I
Zn2+ions
S4X–S4Y
C-TAD
0.119‡
U133plus2
upregulation
TA.The
kINshLgQHEN
:333–338
3.11
~0.01
S1497A
alan_dandrea
Bioinformatics
5′-AGTAACCAGCACTACATGCCTGTG-3′
MMTV-myrPik3ca
Bio-Science
neurocutaneous
C384R
Q61K/R/L
–,29
**c**
pY705
SNF2h-based
973-235-6185
ch15:56.1-56.3
PHA-665772
386-kbp
.Blot
22/24
SHEP-
700–1020
1.8
mPIN
U3
ethnicity-matched
Ladeb
2,110,000,000,000
p.Leu107Arg
mMphenylmethylsulfonyl
pNA
differentregions
.Fertilization
.SETD2/Set2
TCCACTTTTGTAATTTG-3′
AJC
/j.m
R977C
IVS2-13C→G
LR12-454
103–113
CTGTCTAGATGCCAGACTGTCTGCCTC
3b-e
pY-containing
Working/test
SQUASH23
RxRxxpS/T
interferencebased
0.0075
1455–1559
sc-835
ligand-free
leiomyosarcoma
wt/m
CCK
FLAG-PTENK62R
transfected/co-transfected
p.T390A
tumor‐associated
PVH-NH
c.2834_2836delGTAinsC
pfam01056
.053
Lotsch
ACGGAGGC
poly-N-acetyllactosamine
Asp-903
Grande-García
IgM+CD5−CD23−
Inselspital
62-64
sc-2031
IMAGE:3483861
Ctsb
TAAA
Immuno¯uorescence
PTEN39-224
glucokinase-deficient
Lys656Glu-mutated
1.5G0.8
'promotional
+Ras
mdash
3′UTRs
Gpp
Sf3b1+/+_SJL
genes79
acidMAPKmitogen-activated
Stahnke
granzyme
ATTAGC-3′
.OCUM-1
920
lex
15-aa
less-oncogenic
26586
18.23þ
WT1–DNA
stereotypical
Gα13-deficient
CHEK2.18
Y220C–PK7088
imipenem
peroxidase-conjugated
pCS2-flagSmad3
CBF3
KLUWE
compro
c.4627C
vertebrates154
D817G
MEKindependent
59-cccattccagaaGCcaCtgggattgagaa-39
www.nature.com/cdd
hypothesis.14
MET-specific
Bw6
1211
PDGFRB.34
goat-anti-rabbit
7.50-
327
machine™
NM_133670
2610
F1575
activity96
α5A–α1A
fibroblasts—promoting
1149
A348V
boundary.28
.33
1.20-3.05
E158K
S7.11
fluorescent-single
subtype–specific
Fig.6,6
.Variants
S388
0.193
N324S
phosphoinositide-3-kinase/AKT
CREB–CBP
133•5
2.4–12.2
234/−
656-amino
3.2–17.8
Ref.14
ofrk
P130L
hAP
51–92
1.Clinical
S10a
21+
−1.96
//AtlasGeneticsOncology.org
thehatched
ASXL1-MTs
down-regulates
B/B'/B
1294del40
654–655
end-labCA
piperidin-
Cystatin
.Indels
PEAK1
TKI13
Co-overexpression
ZC3H7-BCOR
CDKN3
pfg122T
ligand-
Cauchi
pGEMs-T
Bcr-abl-positive
Color-coded
RE82
E2014
R878
syndrome2,4,5,11,12,13
0.479
studies.21,28It
non-Ph-like
DNA-FLA
methoxy-5-methylphenazinium
6016
GATCCCAGTCTCA
JQ.1
SKQMRHQSESQGVGLSDKELVSDDEERGTGLEENNQEEQSMDSNLGEAASGCESETSVSE
208KB
cardiopulmonary
42˚C
HLA-DRB1*1501
.shRNA-mediated
//browser.1000genomes.org/
Fig.10C
non-FGFR1
K650/652N
Immuno-Research
splicing.Molecular
2004
L2172A
59a
aprotitin
PHR-CRY2
pyknotic
polydeoxyadenine
ligament
61.5kDa
PTP2C
1.85
​Mutant
//3dhotspots.org
acertain
lsqkab
context.40
BRCA1-binding
MSMB
roscovitine-induced
H3K4Me1
D769A
activated-β-catenin
Ni-affinity
PC12s
K/mL
site.17
612D3
c.208G.T
R110H
72-13G
E027
43.
SSPS
5′-CAGCGGATGATGAAGGTGTT-3′
gyrase
1,157–1,173
DGCRII
lens-speci
'optimal
27/F
B1/CDK/p21/PCNA
2ns
p.V387Me
hypoxanthine–aminopterin–thymidine
Gualdrini
pLenti6/V5
pGAD-C2
BamHI-SmaI
exonic/intronic
3×105
Sencitivity
E407
sirolimus.25,26
BRCA1–D67Y
relevance.wCOSMIC
log-log
Kothapalli
All-trans
TAL-SIL
approaches214
NaCO3
ARE-dependent
H574Q
un-primed
TSC1
kits.Analysis
100-ps
Methylene
FHA1/Rad9p
B3B9
g104t
BamHI/
Veelen
autopsy122
10q26.1
.GiovanniBlandino
NM_004985
copyright/patent
pVHL-S111D
Globular
haemocyanin
JAK-STAT6
andactivation.31
LRIG3-ROS1
Colo677/97
D1304D/A1357A/P1382P
RET51-FMTC
Anti-IDH1-R132H
pGEX-APC
11-mutatedGIST
c-Jun/c-Fos/estrogen
uterus.18
DOCK30
0.2M
report26
Phosphosphorylated
5′-CTCAGTCATTTTCAGCAGGC-3′
Uramoto
4,957
deleterious/
JNK/
^27841
NCAPG2
trimethylate
enzyme22
35/10
anti-phospho-MET-specific
Tweeted
D-404
1.72–3.20
lapatinib-naïve
GAG-9TAG
BRRS/CS
14C
PRD
l7-115
.Bioinformatics
TIMP3
MMP-2
signet-ring
LTRITLE
MMHCC
7aabb
2'-
126-bp
'paradox
1.384
Primary-cell
9-1-1
anti–PD-L2
.On-target
interaction-impaired
n.b.
pXP-ERE3
mOct-4
15-mer
μMFura-2/AM
C01024
constructsThe
Volková
JunB
translocation-dependent
.HAPLO-INSUFFICIENT
nuclear/cytoplasmic
NCT01345682
follicles/mm2
hyperglycemia-
exonuclease-mutant
proteinprotein
QVAkANkYLASkkFVHRDLAaRNCNLD
anti-Aim
0.65M
logarithm
HM*
D1b-specific
SD1100
RT-PCR/Southern
ClaI-EcoRI
GAL4-Smad3
EcoRI-EcoRI
Naidich
foldx.embl.de
2644
QQ
R1159L
25H2
PRCC-TFE3
Phe958
MND-Ires-GFP
Q661
257P
Arg79
rsqb
CD65s
N1324S
cdc4/sic1
N=9
P208′
17/86
.Non-receptor
32/Itch
recognizeble
36mers
NM_022970
s10689
lipid-laden
H3122
LSRII
interaction/dimerization
WM-115
investigator—for
anti-CD8
Mm00438167_g1
Cemusco
TAF3
PRO-PREP
HLAA
property.32
//ClinicalTrials.gov
:4cn9
Rabaptin-5
XP-G
mya
B2,3
C/EBPα
ER+/HER2–
serine17
toxicity31
1.00Gene
Intergenic
A391V
-R505C
HA-epitope
interleukin-22
P-KIT/KIT
theAR
c.2477C
approx60
Cd8a
TransBlot
0,85–6,0
Micromath
paratrabecular
100mg
BNP
GAC→GAT
H3Y41
hotspots—two
28.57
amplification/overexpression
Lys61
-GA
Bax-containing
1.31–1.77
.¶Present
2014-04-16
Mee
-wt
genes.Pancreatic
Y1221
cells.80
hypogonadism
G779S
1–1354
AACGAACTCACGCCGCGCAATCG
powerpointTable
-14.S
S418T
G2*
Talalay
MSC2156119
tumours147
Normal-appearing
mutationaffects
aurora4
studythe
C267Y
hemithyroidectomy
non-linear
1.964
sterile-7
10,554
.RNA-Seq
1KT
MET18,19
FAB-M5
M7608
c.2090G4T
MOLM13
Variabilities
RAe3R
Grb-2/SOS
160-kDa
extrascleral
dodecameric
KRAS-F14
SQLC
kinase–sparing
pre-gefitinib
TCGAGGCTCACCGACCTGCCTCTAAGATCCCTG-3
130-kDa
detergent-insoluble
nonrepetitive
Q72
thedefects
Rowinsky
−0.2912
Miyake1
homology.13
NeuroD2-SmoA1
5-CCTATTGCTACTCTCCATCTTTCC-3
LOC387646-MLL
EPO-1
17.5-fold
tttcag/GATTCC
Ras–PI3K–Akt
0·0625–0·25
induced-Ppt
G-luc
checkpoint200
BLOCK-iT
four–amino
Cdc27
Glu-63
Sugar-nucleotides
Amphiregulin
Deajun
FIP1L1-PDGFRα
1731insA
CGGAGGAACG
ROR1-
alteration.23
N.B
allosteric
RMS-specific
15,16
MYC/MAX
VKDGYQMAQPAF
114:937–951.Many
C275S-p53′
654
0.191
HC11-Wnt
NM_000251.1
~400
telomere-telomere
multialignment
131C
70-amino
LAGGEDVAP
wasdeveloped
TAE
MDM2-p53
differrent
.Alanine
case.114
treatment.38
817-2365-7161
diametrically
anti-p120
tumors17
anti-Nterm
Apcfl/fl
GD/S
p53.18–23
nonproline
BACH1-PRIM-R
S338SYY
taper
BRSK1
withp120GAP
~24
613951
TaqDNA
.Celestino
scrutiny
Glo
deafness3
5′untranslated
inGISTs
p.Gln921ArgfsX79
H441
pEAE44
GlyGlnGlu
KinTekSim
B-gal
Ala2951Thr
OD660
Furuhashi
L177R
6.28
HER2-wt
.CCNK
Low-penetrance
PpuMI/BstZ17I
T315I-mutant
CLL-cell
UV-radiation
agents.1,2
carousel=1
2Ab
99.935
YWBCs
p.Cys44Tyr
4,15
.STAT5B-RARA-rearranged
group8
.Brainstem
disorders9
Bousserouel
TYK2
c.3076A
biopsy-confirmed
E2t4
.Keeping
c.5435C
APCvariant
ja¨rvi
gene.11
p=0.18
5/1
TopoII
615-936-1790
.ER
self-sustaining
blast-like
LightCycler™
.Ardlie
Axial
MMRpredict
17-AAG-mediated
-CTAGCTTGGGTGGTCATATG-3
K537
breast21
chemiluminescenceprocedure
HNPCC-patients
forTumor
structure-modeling
cough-syncope
hMutSα-DNA
flPdx1
log‑rank
SETDB2
BOBSCRIPT
R2b
AA491
OL-EDA-ID
miR-3127
-Akt2
p-formaldehyde
5′-GGGCTGACCGCTTCCTCGTGCTTTAC-3′
.Polycomb-related
phosphatidylinositol-3,4-bisphosphate
Δ551-554
≤2
Glu80
micro-vascular
0.5×
9.1®
TTTTATGG
Jejunum
Dronkert
ALOX12B/15B
Genotype3
.Euler
bone-fide
60-71
OMIM602113
Pim1
multi-talented
0.87d
NPM-ALKþ
8q24.11
MEN2AR
-CAGAACTGCTGCTCTGGGTCTCAAT-3
del11q
-Leu
Mundlos
FLAG-RAB35
REMLEN
BRAFKD-MEK1
.1B1B
7p11.2
v-Ras
RUNX1-I43R
c.536A4G
1.2μM
WTLuc
10.1002/humu.20357
Codes®
3d–e
50–59-year-old
effect102
C=0.425/T=0.575
n=241
Spectroscopy—CD
drug-sensitive24
Entrez
Eblen
C102G
non-ERG
cro
ggagggcctcattcccacttg
studies22-24
0.7022
109/
EnvisionTM
1733
SMO
F-actin-related
interpretations.https
Trapiche
9a
0.40–0.53
UM5,6,7
leukemia.4
corroboration
5′-gagcccacaggcgatgagctcccagctaagaagg-3′
V:28
cells11
−1.42
pDRIVEchEF1-RU5
95-98
MSH6-18
0.911
10-68
Crasta
p110-β
Restenosis
GLI-luciferase
MetaPrDOS
D1-T286R
p.E134*
TET1-3
pRB661W
efa.org
.TC21
non–parametric
5′-cacccaggtgcccacccatc-3′
chemotherapy—toxic
Schener
S.G
c-Jun-NH2
500mA
.Kinome
.GO
pStat5
11601
HDGC.47
c.5072C
DS-1
GFP-AGO1
AMP/ATP
ALKþ
p53-p63
entry-vector
R2178C
2144
modification,35
EGFR-RV
factor-α-converting
PLCγ/PKC
1109b-are
Cleidocranial
141.59
294K
M21950
CCAGCACAACTTAAAATGTC
troglitazone
reportersat
Src.41
AP001107.2
AlexaFluor594
F-/SOCS-box-like
N463D
1.5E-4a
.Unfortunately
M26029
.Slug
MLPA®
116
Met-5A
anti-Phospho-Threonine
c.2543C
ZM447439
horfdb.dfci.harvard.edu
FLT3-WT/CBL-70Z-
ATM-specific
LRH-1
TC71
6/intron
v­
33,40
monomethylation
–mobilized
WM1382
5′-CCAGAAGAAAGGGCCCTCACAGTGTCCTTTAGGTAAGAATGATATAACC-3′
AdoHcy
P269
S111
PKB-dependent
C828
FLT3.31-34
semilogarithmic
Sham-operated
activity16
PicoGreen
combinationwith
K5+K14+p63+
PI3K-PTEN-AKT
HEK-293-based
anti-MMTV-c-erbB
Wellcome
3436
Fat4
germinomas5
−0.3244
3.26
receptor/IL-1
2,15
LMTe
.111
pGEX3′
pathognomonic
vitro21
10∧10
Seppa¨la¨
p.E76K
H2B-GFP
Chloroform
nucleotide-sensing
profiles2–5
Perucho2
Bayerische
immunopure
core25
Piccirillo
ALKR1275Q/MYCN
C/EBPα-mediated
gi55236493
patient-administered
TCGA-BS-A0UF-01
c.4076_4077insG
c.85C
cAMP-specific
E108
leukemias/lymphomas
Main-chain
AKT-3-amplified
nitrogen–cooled
TGF-β/Smad4
CXCR4
phospho-Thr308
GPC
Del591–596
c.122AT
2-hit
Labeta
V98
γGCS-h
PILEUP
aremissense
.Jak2
Dojin
anfexpressed
MSI-stable
117–121
//www.ncbi.nlm.nih.gov/gene/2120
17870
E-cadherin-blocking
1ng/ml
high-incidence
ERK2M13L+E322K
G0750
Kealin
lip/vertebral
Prof.
FBW7-driven
19-
3/106
cancers.15
denaturing-gradient
51,000/μL
pCITE
K645E
Well-known
3F-I
c.725G
tcr2311
60°C-1′
.MEN2B
Y81H
pEGFP-C1-ER
Taiwan.1
CD0-
atranscription
KIA1549-BRAF
polyadeninetract
.CAT
9.01
94,95
PIP3-responsive
TAZ1
835/836
Hirokawa
p.M541L
PMS2-NES
393-aa-long
μmg
made37
sporadicor
p110β/p85α-nicSH2
pNKY73
1857T
3D-JIGSAW
Ptger1
1–314
14–21
c-myc.11
aberrations,3
JAK1-GE
G279R
anti-STK15
2-fold
UN3
~*~
ECT2
J.D.G
p-FRS2a
Mizuuchi
Adenocarcinomas
split-apart
ESR1-CCDC170-positive
A10E
2,860
Statusb
AL132772.To
sunitinib.41
anti-leukemic
Shh.In
interconvert
-CCTTCCTTGTATCTCTGCTG-30
1.335
2q13
R264W
BCGF
11.13/Mb
BCR-ABL1–
.Smad6
antigoat
35SJmethionine-labeledcultured
.PrevalenceUp
David1
therapy103
therapy.1–4
20p/q6
EGFR40,49
WM1361
v-Src
D19S904
7-year
Thr101syn
3VO
Y180H
RefWorks
WIP-SQ12
PDGF-A-expressing
non−chronically
leukemia.2
TLR1,16
S768_D770dupSVD
pALTER1
p414GPD
Casaer
protein6,146
.Pathobiology
imageSMARCA4
148B6
locus19,20
1000/well
204
low-affinity
3007
p110δ-activating
E545A
rs78244461
7,30,31
ADP-ribosylate
.Ptpn11T468M/+
ALS2CR12
PSAand
10,47
0Stomach
mMsucrose
mutations66,67,107
33.5/Mb
Y1230F
G/c.9118-2A
N47D
conVOL
A_51_P112405
Met-TKI
Pfaffeneder
R552X
oncogenic-Ras-expressing
NZM35
31–60
N1044K
9.3
hydroxide
.variety
15,213/859
mutation.11
Boothby
polymorphism.In
.H3K14ac
M.V
PMS2CL-origin
Phe924
LRT/LTR
rk-
MacroH2A166
5-10
XP8CA
micronucleation
p271–170
gμ′g
docosahexahenoic
1/IC50
QXX
p1–p3
FgfR4
EPHA6
NTRK1-negative
alternationof
H2-H5
≥65
Ptch1loxp/loxp
anti-β-tubulin
21.4
.SCD-2
patients.32
66.1∗
.Terminated
1/6000–1/10,000
5'-M13-CCCACAAAGCCCAAAAACC-3
ever-cheaper
.Infrequent
.Focus-forming
implicationsare
FRB-domain
Southern/Western
.Line
.Reanalysis
transformation.56
avidin-alkaline
22,12
1.4–3.1
7/89
gtaagtaat
HSL1
S45Yβ-cat
V2006I
DLBCL.38
sequencing-by-synthesis
140/199
138800
Bioword
.Closest
carcinoma29
5434
22–54
Fifty-seven
Tech.
mood-stabilizing
I122L
tumour134
CU487
*Correspondence
17,29,30
Anti-BIM
dsRed2
S411I
metastases,1,2
L664P
.Every
physiologically-regulated
Castration+bicalutamide
Biocarts
13CTCTCTCTT15
gene-gene
cancer.43
Hyg
JHDM1
institutional-review-board
response.40
anti-CCR7
.AG490
Boeringer
accessioned
Mob1b
2µM
4190-fold
−f1
PI4Kβ
Concordant
fusionb
En-2
gate-keeping
lyFIG
25-28-fold
gtaagtttg
W1174del
Tirkkonen
−60.4
PWS/AS
cancer-only
gpjjOPro
64939
disease65
CTX
lymphadenopathies
bFigure
15–23,32
Pierce™
Arg257
midline/thalamic
EWS-FLI1-activated
p16INK4a-insentive
7416
MAB3199
mononuclear-cell
GCT10
S324
50468
interactions,36,37
.Cytokine-dependent
caliper
I
2Fo-Fc
Low-dose
WISP2
UCHL-1
Cys4–His–Cys3
5′-ACCAGCCA-CCACTTTCTGATAGG-3′
.Fig.11C
2991del5
autoinhibits
nanodiscs
3-18
Onclercq-Delic
1–371
N-acetyl-Leu-Leu-norleucinal
ST6GAL1-NSD2
13,41
0.0001*
Anti-Ras-GAP
Mant-GTP
MNG1
T5M
overinterpretation
HR.6,11
–56
Δ11
βE-βF
adenocarcinomas88,89
1847
PDGFR-D
post-subgroup
CAGCTCAAGAT
1007
Multiple-Sequence
sante´
ethnicity-
suf-
variant21
8C5
.4–10
D10S221
GTCTTGTCATGCGTGTGCTT
status47
FGFR2-BICC1-KD-expressing
E1539K
Y134H
models.85
mPTC
NMODE
Thr-347
polyglutamine
IgG-matched
Aptum
W341A
UTR
.Radiographic
conjoint
2.72
Crl
seleneous
re-hydration
2/87
carcinoma.25,26
TGFβRII/TGFβRI
bafilomycin
15Bioinformatics
15-68
Piwi-interacting
Fc3
ΔHLH
.Elf3ΔC354
WM278-NIC-GFP
.PLS
cis-configuration
astrocytoma,14
CAPN14
BCORL1.Patients
Ile566
Diagnosis/testing
tuberin-T1462
.Shown
single-strand-selective
/ETV6-PDGFRB
self-specificities
TGTCCACGGGATTGAGCTA
76173
Cytogenetic/molecular
PI3K/AKT-mediated
300–1600
AMP-PKA
590
ATCCAGGTT
pCDNA3.1+
DUSP4
.TT
q31.2
survivals.6
theolaparib-resistant
Collagene
EMAST+
treatment/PFS
cabozantinib
5'-CAGTCCTTCACTCAAGAACAAG-3
T0.5
25,038
2232
F832
C844G
evapourated
65.0
steroiddepletedmedium
co‐migrated
GABPA-bound
breakpoint—and
claudin-low
cells,20,21
mutant.36
nilotinib-related
.VKD
pcDNA3.1/ZNF198-FGFR1ΔC-myc
spreading.76
CD49d
5'-CATCTCTTGCTCGAAGT
interstitium
2120
HCC-1954
W3393.50
OF9
M51
IL-6/Stat3
V16
FACSort
Gua
Brca1Δ5–6
Myc/DDK
.1591T
.BLASTN
osteoprogenitor
IDHl
4p15.1
them—i.e.
617KB
proteins—contributes
E218*-MEF
al27
GFP–BRD3–NUT
2001,1997b
A-III
631–634
Amrein
Zeschnigk
cells.different
17–50
ERG-exon
T83M
NTRK1-specific
survival/proliferation
previously28
phospho-Smad3
TGFB1
Y253H
ndspvLSytDLVGfsyQVAnGNdFLASkNcVHRDLAaRNvLIc
approximatelyfivefold-higher
W2101L
40â€
postprocessors
spindle+epithelioid
XXLαs-M302V
1p/19q
p.Arg91Trp
SmadSmad
Chip-on-chip
analyses4
3-kinase
548/1033
radioimmunoprecipitation
G239R
MRPL11P3
tissue-type
2.9*
NEK7
T2–4
pCDF
trans-bronchial
PTPRD-expressing
594.10.1038
TCAGAGTTTGC
p.Arg105Gln
anti-phosphoSTAT5
pp85S6
1597dupT
Val769_Asp770insGlySerVal
3-kinase/Akt/AKT1
78
pRL–SV40
600160
radionuclide
n=0/21
and3c
variant-encoded
p.L21H
AGC
-48b
TCCTCTTGCAGCAGCCAGACTGC
797TRex-flag-BD12
NCO2
Thr383
,1002–
described38
-N-methyl-2-oxoindoline-5-sulfonamide
C-terminal-deleted
SHEP21
Banchereau
Q145*
Cappel
inactivation,16
MLL-MLLT4/AF6
W50C
P651S
rs146486757
l-glutamine
3-chlorophenyl
mAU
PTPRZ1-MET
8-12-15
Tyr32and
GAAGCATTTGCGGTGGACGA
®brosarcoma
SETD2-H3K36me3
Bergthorsson
simetric
phytoestrogen-free
non-protein-coding
NM_000455.4
.CHIP
IMkdF-sHpNVLsLLGIC1
G-MDSCs
interface.21,22
1,249
Bcr-Abl-induced
145+1G
1,923-bp
NFMP-DHPLC
TyrS37Asp
.High-grade
transformation-deficient
mulitiple
TG10
substrates9
Ag/well
Newcastle-Upon-Tyne
anti-glycophorin
BCR–JAK2-negative
71363
Multiscale
2757
Bioinformatic
immortalization
HCC1195
p.Pro4309Ala
99°C
CK+
62–148
conditions12
μg-hr
M/14
ERK2S202P
U02509
.Afterward
.STATISTICAL
R335X
17These
3736-3821
Web-based
.Marco
R-factorc
progression123
hormonelike
.Formerly
R324G
p53/p21
tracking32
obtainpADH1p53R249S
μm×800
Pastink
3•1–14•7
Ma-Mel-100
24·6
-CCG
AML.46
b.
R470H
dogb
years,46
PDB:4JT5
case,20,24
C17orf62
V210A
0.3-9.8
Embryogenesis
alpha-helical
7A-C
Phospho-safe
operationally
ERK2,1
genotype.3,14,15
5′-GGTAGCTGAGAGAAAAGGTAGTG-3′
MNNG-HOS
Veldscholte
α1,3-fucosyltransferase
0.2167
post-diagnosis
dose-modified
c.1798delinsTACA
hMutSβ
temary
literature.1
Mx–Cre
3.69
42°C
onincubation
protein.13-16
0.6-mm
anti-Pan-Trk
anti-TCRβ-APC
glioblastoma68
F1
cell.18,26
LCQ
3261delC
1465-1466
GATA3-wt
TSK
.HuH7
NM_001172713
Myc-CaP
TAGTAGctcgagGCCG
556–560
TTF1-positive
Ink4a/Arf
~1–3
p16INK4a_R
Ogawa2,3,23
G.T.
A541T
P201S
semi-suspension
p.1394
GTTGCTTTTCTCTTCATTAAAGCCG
Schuster-Böckler
Suriano
EPO
His-ezrinT567D
2=5–25
phospho-PTEN–DLC1
10q25-qter
c.2002C
identified.40
BCAS2
APR3
digoxigeninlabeled
R41
qRT–PCRs
0.3537
//pymol.org/
isofluran
87/141
BCOR-
1kV
2.3-kb
0.06µl
IRs/RPs
CD99.3
Val419
Rag-
UvrD
tentially
Hepatoblasts
l2p12'Ac-erbB27q
pone.0032555.e004.jpg
anticatalytic
MLL-AF10
CSL‐dependent
15-85
1-2006
TERT-associated
.Leukemias
KIT17AS
494
H1402Y-U
Lys-Thr-Ser
5′-CTTTGGCCACACTGAGGAAT-3′
Cerami
CaPO4-mediatedDNA
HA-4EBP
MF/10
transduces
novobiocin
1.ALK
Tyr98
Mayven
c.737G
cau.edu.cn
N13
AZI1
SRP047158
.164
G6P
b-axes
Daresbury
52–53
C-RAFpSer259
sc958
2SA
3–14
SCB
somatotrophs-must
HOXD3
1:10–1:1000
cells.35,36
patient.17
tumor–Tcell
pLKB1-S428
1.34
A_52_P70381
-Akt-mTOR
240–300
ARID1A-PTEN
Gfpt2
CATGCTGCGGTGTT
GFP+
jLig
−0.8
E886G
marker.5
temperature-dependence
tttcag/AGAACG
Ly-6C
0.27–
1/normalized
25ACCTCTrGC1TVFAATAGGAC152
S4d
.36CCND1
aromat-sulfur
F194L
meta-iodo-benzyl
BamHIIHindIII
AGT
PSA61Luc
.Myc
anticonvulsant
G12A-
H398Q
allelescorrelates
D20S116
.93
8ns
R469
0.921
EPHA5
loop/hook
ampullarycarcinogenesis
Statherin
B,2C
Tzankov
Qilu
1374
PF-4
P=0.0125
Zucman-Rossi
PE-fluorescence
intra-molecular
mutations—C620Y
Hormone-based
10–1
MFG-CAT
Borrmann
BRD420
10-μM
Dinten
T211
25/34
Jove4
Hagler
Trevigen
59.43
pLenti-EF1a-GFP-2A-Puro
3.358
rad50-mutant
2002–2006
76.3
c-FLIPs
Mad–Max
Ph+
PIK3CBE497D
.Tolerability
5.5Å
TTCCTATGAT
EGFR-mutant-rich
Genescan-ROX
genes.32
nano-electrospray
samples.Figure
H4/PDGF
Lys53lGlu
bek
Condorelli
NS,38
SETDB1
aUPDs
AKT-dependence
E75
orthovandate
3p25-26
gyne´cologie
Fiegler
GOLPH3
ofMutSa-bound
TCGA-DU-6393-01
BCL10-induced
p=0.0001
BannayanZonana
RUL
msh2-GD855p–Msh6p
~230
MDV3100-treated
C39S/R
graph-based
Visconte
mutation27
gefitinib/erlotinib-sensitive
.Masatoshi
monoubiquitylates
16000g
1621
Shaulian
fragment.32
Rad50K6E
YY1
AKT1-3
AKT-phosphorylated
ALL-L3
RosaERCre
hit-to-lead
54.78–55.21
Erbitux
//cghub.ucsc.edu
C124/135S
.Strand-specific
constantin.polychronakos
--
ESWR1-POU5F1
.Fluctuation
nude/nude
lonic
−158
singlenucleotide
Ea‡
0.78–10.75
NF1-null
RUNX1-mediated
Lapatinib
brigatinib-resistance
5′-CCAGCTTTCTGCCAATCTTT-3′
J.S
5′-TGGCTGGTCACCAGAGGGT-3′
p=0.0468
tagRFP-N1
Phosphatidylcholine
,5-8
.Regulatory
KDM5C.16
mis-repair
.13–18
Ophthalmic
000.1
caspase-1
pRK5-N-Myc
TriTek
.Zafrani
NK14
V379I
yeastconfirm
complications/unknown
1193
Gr-1+CD11b+
anti-β-tub
005887.2
ß-HCG
.Tandem
furin-cleaved
megadalton
reaction-sequence
5′-GCCAGCCTTGGCAGTC-3′
G12A
luciferase-based
ETV4_exon2-f
.S1A–D
X-PLOR25
≤
GST-ETO
PredictionsUsing
TopHat-Fusion-Post
.Klco
I.P.M.T.
Tohru
sigmoidectomy
prohypertrophic
T878A
TDEG
trkA
transcript.We
476-3303
+/−
Jallo19
rs12951053
deletion-plus-insertion
anti–Tnf-α
transformation78
anti–PP2A-C
PTIP
OHA
receptor/MAPK
Polyphen2.1
miR-99b
CIC-mutant
MPM.37
IgG–FITC
KRASG12R
mutationsb
Jiunn-Liang
Ma-Mel-48c
572–634
pCBASceI
assays.293T
no-enzyme
anti-TRAP230
1.753
S.N.P.
559–562
28230
initation
P=0.0185
synthetic-lethal
−.24
P294
p.Pro531Leu
K675R-
-u
Constructs—Promoter/reporter
Singapore,44
4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl
delC
family.80
nature.comAll
B7-CDBICTLA4
6x
Gas6.37
RGCd
S518F
non-ARID
NHA9-binding
45y
Ab-7
AKT1E267G
delinsE
181614
A3−26.6KRT6BKeratin
XLl-Blue
ACVR1R206H
12,17
780
ACCCCATCACCAGATGCTAT
R886H
55-184
c.1732C4T
Phe-156
Togayachi
iscontrolled
domain9
295/38
E76K/Y279C
adenosquamous-carcinomas
13/13c
S346
50.5
de1
-R5
ITSN
tobacco-induced
Burrow-Wheller
F/+
split-read
Graft-versus-host
sVEGFR-3
auto-kinase
D1067A
P-Akt
FANCA/FANCG
180–298
systems.1
CTSA
Po0.01
.EHop-016
6393
phosphor-AKT
RAS3T3
T1N2cM0
T674M
Gal4-UAS
L359FfsX6
−2.88
E805K
Y340DY341
NimGenetics
Rowett
1-butanol/acetic
MsCarron
~29.2
pcDNA3-FLAG3
NP_689854
435–44
PDX-specific
sets.67,70
signaling-inhibiting
1.06–1.91
angiosarcoma12
Blotting—RNA
agaroselayers
.Electrophoreses
CEPHyG12876
Smad3-
R209C
p140Met
binding10,11
3971C
Visco
Intention-to-Treat
genealterations
reported.33-35
9-mo-old
P0006
Kikuchi-Yanoshita
MEN1-
0-150
3′-phosphates
bindingproteins
1beta
TGF-b-related
Genehunter
ENSG00000159216
Nrf2-repression
glycoslylated
51·4
thioether
bronchiolo-alveolar
pmol/
light-stimulated
sc-2005
MDR1
electroblotted
aminomethane–EDTA
tableA
188–190
FLT3-WT/CBLDexon8-
GSE9354
MMassociated
IRAK1-containing
T-FGFR
SERD
anindependent
12-transmbembrane
3p25-p26
Far-Western
Giardiello
WD40-like
type2
−26.33
Immunoprecipitation-coupled
NP250
target-related
wild-typep21c-H-
S6K1-BAD
H183R
P545L
conformation.71
Proximal
hemagglutinin
targetability
MYC106
activation‐inhibited
Muntean
protein.14
E31
morbidities4
ch11:47.0-47.2
299–1129
A6-6141
PD144
microadenomas
22033–22040
cells.51
V592A
155-patient
anti-cytokeratin
Kusabira
c.733+1G.A
GGACT
tumour/germline
Mch5
peptide–pVHL
pSG-Flag
p=0.3853
to-Q
T217M
transduction.29,30
Ercc1tm1Dwm
C881
2/68
C189
co-localize
phospho-H2AX
−20.7FLRT3aFibronectin
.Homogenously
-75
MAPK1/reference
T-cell–mediated
RB−/−
.NLS1
COX-independent
147/133
32m
β-catenin.6,7
.EEFLKTCSDKIFN
control3
MNU6
AML,25,26
AXL-positive
0.302066697
α-S2/S3
Hepatocellular
pS-Akt
c.277A4G
5'cgaattcccagttacaggaagctgtct
1.33–76.0
N771
Weickhardt
pCMV5-based
S235N
resistance.52,73,82,121–123
Kitahara
previously44
bStatistically
Pax6-
under-represent
compelling.1
patients.31
Mutantswhich
4374
.M.-S.
BAP1−
.CDH11
TNS3–ABD/C2
mutations.2–6
β5/β6
5′-ACAAAGG-GATGGAGTGGGTA-3′
-Glu
4209
insulin-evoked
ER-regulated
Assays-Infected
.Mo7e
.LIF
K=2
tabs®
vemurafenib-treated
Flp-mediated
variant-calling
PIK3R1WT-
OVHS-1
pGL4
Friesoythe
com.braju.sma
Frischmeyer
HCT116
inactivation.3–5
syndrome,29
WW-like
00o
R-CHOP–treated
Gr1
Fast-AP
Y435C
Consejo
D598N
co-denatured
PhoSlp
I254D
5/22/08
NIH/3T3
BaF3/BCR-ABL
2053-2055
sunitinibtreatment
Ragione
1652-bp
OX2
5′-BCR
PC-800
210-256-C100
whole-genome
BH10
Mer559
x109/1
12G
MutsigCV
.FitzGerald
Glu-248
21q+
avalanche
complex.9
patients1–8
melanomagenecity
doxycycline-activated
Rössle
23-RSS
73.
RBDB
700E
motif24
MCF-7-RapaLink-1-resistant
described8
5′-tccgctgcctgcaggcgaccactgtcatcg-3′
60.8/53.9
peg
ERBB3/HER3
S2PY-bound
20,98
AAGGCAAATGCTGGAGAAGA
.R885A
N252
CD36+
malabsorbtion
AFM280
CULC001
.Through
pre-injection
SeMet-substituted
Fancd2
HOXA7
TNF/TLR/IL1
Cy3
p53-initiated
lesions.17
miR-30b-5p
5μg/mL
,9
Gamallo
pCS2-caMek
response.8
MCHR2
GAB2-PI3K
IgA
melanomageneic
LDI2
Wnt11
stSG46936
5′-CAGCGATGCGTACACAGA-3′
chlorhexidine
19,223
1.9–30.4
CI=0.88–1.15
0,0001
.Pawson
Q104L
708–728
rs2304256
p73-
H21
miR-15/16
0.525
permissiveness
HERV-K_22q11.3
V404M
moderate-risk
EZH2-driven
lung128
Nelson3
135Cs
HWS10025539
-y-phosphate
proteins—and
skipping.16
Bandshifts
QqQ
molecules7
kinases.48
Twice-daily
KIP/CIP
0−3
factors.10
TXV
.Ci
specifically.Unlike
SH3KBP1
-8b
Glu-659
KIT/PDFGRA
mOct
DGA
.Losson
3O8I
siRNA/shRNA
poor-outcome
uals
b-1
MKK4-deficient
P572L
Idh1-R132Q
WNT1-induced
Bim/β
c-Myc-dependent
Scap2
overexpressed51
pemetrexed
Anti-phospho-p44
DsX
Duin
Bioprobe
Ba/F3-derived
thrombocythemia.25
HP-1
counseling10
smMIPs
/2K8F
.TK6
−54.4
L1001W
p.Thus
V5-
PAKKCA
incancers
pdgfrb−/−
IGF2BP3
BCR–JAK2-transplanted
Bonache
bcl-2
anti-GSK3
Z11886
Cytokine-independent
NB07C
.Thirty-five
Q690E
mg/dl
Bessonov
reported,10
genes,28
Buerstedde
4threefold
non-activation
Carén
40˚C
YFP-conjugated
2.1–2.6
.S7I
ectodysplasin
h18S
5′-biotin-CCCAGATCCCGAGATAACACA-3′
Trp-Gly
report.8
P-RB–positive
−0.23
VLK
RETtyrosine
**w~
myr-Akt3
PTEN/Akt
SH-PTP3
D4S43
transcription.56
rati
Vivo—To
26-Sortm1
−0.66
R98W
3q26–29
entities.8
KCl/3
.Unincorporated
sequencing13
Y599F-32D-Flt3
Nox4-depdendent
c.121AT
steroid-deprived
hybridizationTotal
Rhoˆne
GOTCOCTGCGGGGA
rad502TEV573/829
Ter
centrifugation.30
ACATCCTAGTCAACTCCCGT
Pardanani
Glul953ter
cortisone-responsive
vitroassays
aristolochic
.Noteably
.652GT
mo_p53wt
atypic
S5H–S5L
gene-wise
R277C
sc5595
HaCaT
IMAGE:6827742
cDNA-F
dominant-
small-vessel
1.45
172628
Azami-Green
maturation20
analysis•
p-ERK
correlation|
RTK-KD
Bandyopadhyay
ETV6-NTRK3-induced
reversed32
domain—protein
SCF-associated
P1198
8B–D
INSERM
MOG-G-CCM
O-glycosidase
UniGene
MutationAmplificationMutationAmplificationMutationAmplificationMutationAmplificationNo
12
GTX627408
context23
829
162
breast-cancer
®rstdescribed
kinases.b
Self-phosphorylation
Wnt/beta-catenin
isopropanol–water
71–84
88:201–206
p53-/-/Brca1+/Delta223-763
Solinas-Toldo
E121G
FTTaSDVWSFGIVNWEVLsFGdkPYgENS-NqEvNkSIeDGyrLppPvdCPApLYeLNKnCWayDrarRphFqkLQAHL
NCT01227889
K189E
Age-
PDGF-BB/HS
12/15-LO
type-
6.17
6003G4A
HEK-293Tcells
34·8
P425L
protein—for
587–590
p=0.0288
PyMol
Msh3p
Sox17Null
GAGAGA
Masago
AML
h.p.i.
-HPC1
2.084
agarose–6.5
Tyr419
YMESO-26B
Y648
1/2,010
NVT
Cre-inducible
5′-AAGGCAAATGCTGGAGAAGA-3′
CO-generating
Glu-554
chemonaive
65y
5'-TTG
label-free
GDC-0980
~1400
.00252
subgrouped
localization18
NG_007530.1
sig-
UNC1999
Center–Sophia
.Of
64·8
Fold-change
NCI-H28
stability7
RUNX1-I41R
EGFR/MET
Cre
5′-ACTGGTGCTT
nondetected
sos1
CDKNA
intramucosal
structures19
p110-E545K/p85ni
t-test.n
Grigorian
consequences41
Gonzalez-Gomez
.Basis
1.00NPM1
S_r
daunorubicinTo
22Gain
Go´rski
imparing
107
pcCARD11
AKT-GSK3B
N1118Y
phospho-FAK
normalising
FigDD
Lkb1/pCI-Neo
PML12
signaling.8
5Cd
0.268
CDH17
13,850
1q42–q43
S1765X
R261H
sequences81
Organ/tissue
β1–β5
cyclin/cyclin-dependent
c.476-2
assessed.25,28–30
cut-site
undifferentiated
Nrf2-induced
EZH2–pCMV
colonies/105
0.533*
netrin-1
c.194
TBI
p.Gly778
TNRC6A
1066–1074
moderate/low-penetrance
2,000g
hRAD54B
pyrimidines
PDGFRB-IRES-GFP
signals.30,36
PDGF-B-driven
Pluronic
NMC2
case.6,7
Y1282/1283
proliferation.13
GD13
Regl
ohsu.edu
Merlin-mediated
.Sos1+/EK
AFC
40,60-diamidino-2-phenylindole
.Isocitrate
correlation.24
1.608–4.613
~Löwe
measurementTo
S784P
almostall
development.31
14,475
leukaemia-like
R89LRaf-1
2–3-fold
Fig.2A
a.a
0.427
phagocytosis-induced
1183L
Nmyc1
L509R
V851I
Y551
rax
D1—which
p.A563T
LLWETFSLGASPYPNLSNQQTREFV-EKGGRLPCPELCPDAVFRLMEQCWAYEPG
Molecule-Directed
expressionand
LGA
D0
7q31.3
.cerevisiae
IGH-MMSET
chemiluminiscent
popula
HERV-K
RfA
Vbeta-analysis
aApaI
Pronk
.F48
Medica
v4.7.4
Newling
IonFragment
GFP/NRAS
type.30
CSF1RD1–D5–IL-34
IFAR781/1
iRT
AR-Luc
MACHEREY–NAGEL
R2205H
abnormality.CEP85L
Y.The
solvent-inaccessible
T533P
oxidation-prone
Tryptase+
Extra-colonic
M.0.
.Fibromatosis
5´-GCTGGTGAAAAGGACCTCTCGAAGTG-3´
355–363
951C
D245V
SPINK1
Genotypes/haplotypesa
K507A
.Elevation
.GM6914
Brusco
pre-built
60-80
Ezh2+/+
TYRO3
Lox-D594A
10/HPF
64/70
5′-FAM-TGCTGTGTGCCCCGGTCACCTA-TAMRA-3′
serum-containing
11q22.1-q22.2
C706F
259N
panhandle
CTTTGGG
Jκ
oblimersen
.13,14
R213P
rs28363311
41,42
p.Pro124Leu
DSBs41
89.94
ERK2C65Y
32/31
SMS2
MutShomologs
DQ321787
tissues74
Δ2
Lysine-specific
65–2,200
Kyodo
Fig.4
BLMH
gefitinib-progressive
maintenance10
2029
:1684–1689
793T
FLT3-expressing
A-498
.Publication
Val12
19b-25
JBP1/2
miss-regulated
ForteBio
IL-7
tail-lysis
separationbetween
p21-R2
delL747‑P753insS
Gly141
DC-DNR
apoptosis90
Alphaimager
HEPI-HEPII
sc-768
Zaffran
carcinomas,36
P273L
.COSMIC
CAOCA^A6
124–159
Six-well
I126A
appostion
pGEX-AR4
Karhu
FLAG-Caspase-8
FLK-1
0Other
unidentifiable
BIRC6
1/no
WDR82
.Digits
so.Although
pRUFneo
−12.9
MIR-sequence
0.27
5′-CAATAAGGCATTTTTTGAGGTAGAAGACAC-3′
primary-tumor
Bgl2/NotI
melanocytosis
YRYYRY
BiBr49-57
HOXC6
176590
multiagent
LTBP1
Domain-domain
Allele/haplotype
SMO-E518A
mutant\
AAA73985
5p15.2–15.3
ME-1
001626.3
HemAgglutinin-tagged
.V600E
S352L
V1677D
life-table
N1–N2
W557_P573del
Vemuraftenib
-L-alanyl
0.925
YC-14-3-3ζ
K1109N
R3807
37−39
CTC-174
thehMSH2
12.0-
Tyr1213/Tyr1242
SH2-pTyr-mediated
F188L
TMAP
1.5â
p-AKTT308
turnover/proliferation
L711V
H332
1.5-year-old
GI:67782324
prokaryotic
TnT
1.05–19.4
FigFig2A2A
anydecrease
HPRT
0-300
.Immunopositivity
KEAP1-deficient
1151T-ins
Br61
PIP-KIIβ
α-ABC
Galdemard
NS,50,51
.Baculovirus
∼7
trastuzumab.25
pASII
function.How
2.649551
62.26
RhoNox
Ipl1/A2KM
82–100
c.5191A
chemotherapy-resistant
Contig
F199delinsI
Vorborker
interphaseFISH
Prism310
pVHL-dependent
.BCAM-AKT2
myrisotylated
0.806
.FlowJo
manufactur
Tyr1007-Tyr1008
CLNS1A
AJCC/UICC
K652E-expressing
22/141
23,888
Sigma–Aldrich
30.71
.PLCγ1
described.MATERIALS
81.75
σˆ2a+σˆ2
Schonleben
3p25.1
T261A
7.26
GCGGATCCTCAGGGGATCTGGGG
R-250
GGGCCTGAGGTTCAGAGCCA
Kmt2dfl/+
NF1_00440
105/ml
29R1
Y-MESO-12
phase.32
inhibitors.41
Hut
//gdbwww.gdb.org
SRO2
NCCS
-AIF4-
R408
S1395C
strongexpression
phosphor-ylation
B-RafD594A-dependent
Holash
A344G
HDC54
.AREs
terl678
ALO17
Radiolabeled
-GNKECPTCR
P336S
growth-plate
.PCR-SSCP
anti-CstF2
71–91
7.71
methylation140
quinazoline-based
Rab10
instability21,22
HER2WT-transfected
IIVFYNSVFMQRL
Takeishi
AURKC
c.5270_5271delGT
29-4
leukemiatype
p53-immunochistochemistry
anti-CTLA4
Mrc1
animals1,2
Δlac
Stat5A-
patients.34
G2734
receptor.3
83,000
Regairaz
55°
94C-30
BMS
J2S4
ER/PgR−
stoichiometrically
RasGRP
p-JNKMAPKs
Merrer9–11
Goyang
.Staurosporine
R174W
B56δ-Aα
AdCre-mediated
retransformation.tEighteen
ACACGGCCAGCAGATGAT
CAGAGCTCCCAATCGTCTTACGG
K751R
*6A–mediated
self-oligomerization
2450-fold
T-003
520-528dupTTTCAGAC
∼2000-fold
TGF-β–independent
EGAS00001000135
anti-p90RSK
outcome.10
hydroxylase.19,22Several
4.797
pCRII
Immunolabelled
G132V
5′-CTCATCGACAAGCAACTGGA-3′
erythrocytosis.9
previously.12,13
.8,18
RasGAP-containing
Myog
RET/PTCΔ-3
multiallelic
Valsesia-Wittmann
iden-
.PI3K/Akt
18-kb
Weaver-Feldhaus
.042216
pRV2-ErbB2
44.9
.Indicated
P58A
405-anti
63.8–126.5
imen
AluJb
Q1336*
chr22:17049390-17056254
cytokines
insulindependent
0/33,113
post-operative
KpnI-EcoRI
endocrine-therapy-response
FLJ90757
A288G
268
0.001*
largesystematic
K-RAS4A
.BB
.ADP
.ΔBB
rarely.11
0.0314
Fig.1B1B
position74
Daskalakis
Cdi1
Ras-independent
tuberin–deficient
TCRcα
NM_018315.4
cctttatag
6629
mTOR-specific
isresponsible
descendent
glass-bottomed
CD24+CD29+
AR52
Visscher
D13C9
.RasGRP
5′-AAGGTTTCCGCTAGGTCTCC-3′
Yesj
NM_006259
G2P1-2
3q26.1–27
q24.1
Ste5p
2906
R37X-Rluc
immunoglobulin–Alexa
microhomology-based
inhibitor106
33.7-68.3
-11
NM000249
MYC/Ras-induced
73.67
T3/∆Leu
150µCi
G151V
rapid-output
families,7
hetero-trimeric
K5.Cre*PR1/Smad2f/f
p8.74
proposed2
subependymomas
.Deconvolved
5′-ACAGAGCGAGATTCTGTCTC-3′
855
lymphomas,107,108
function20
dn-Ras
Kebangsaan
Hs01952025_cn
G123S
NCrj
Tet-initiated
CELLQUEST
-132-Cre
10.1007/s11684-012-0216-4
charcoal–dextran-stripped
HNPCC,6
Thr40
111,111,114,114
gpl40Prototrk
7-days
Elk1-dependent
lacZ-RNAi
thyrotropin-releasing
PI403
Fluor-647
2.3–329.0
progesteronereceptor
RG-11N
.Literature
Pax-5
.S28
18:09:46
Y236C
hetero-Smad
HC10
parencyhma
anti-stage–specific
Leu633
microsatellitc
cyclin-CDK
45-min
I852M
302–420
plates/sample
17β-diol
Ser752insVal
burgdorferi–derived
4549
Conformations
A338Raf
euthanization
10.1002/humu.20321
Glu4Tyr1
Sarrio
D765N
cerevisiae–based
​Figure6A,6A
3,830
Mrc1-dependent
V1314L
DRD2
125I-FGF
-p-Q-K-K-I-K-S
R81Q
G5095
80Passage
.CTLA
oncogene15
unphosporylated
Ser91
lipofect
T1bN0M0R0
macrodissect
GCT27
-128
M.H
N1-N10
ecient
:264–268
brachycephaly
cbt-15-1239-g4
G191D
Fbw7WT-Fbw7ARG
I103
borate/EDTA
CCAATCAACATTTTTAACCC
3904
9/44
7–3′
Viggiano
1-1
p.Gly322Asp+p.Asp487Glu
E172K
3.5
W117
19.2
pcDNA3-ALK1234T
1.5–2.0
0.0012
conformation.13–16
546–628/Ser-rich
nihms820730f9.jpg
tissue.30
works.1
G322S
higher—than
Evelhoch
Coprecipitation
+S+Ras
KLHL12
R196G
A315S
pPGK-puro
5′-CCAGTCTAGTGCATGCCTTCTTAA-3′
.Lys889
near-term
pEAE31
PUH71
2441
ATP-mediated
478A
pro-cancerous
low-to-noSOX17
XWINNMR
tment
microRNA-based
c1124A
ML-7
274
Q52T
free-of-charge
254.9
pAL/FLT3
plasmacytoid/plasmoblastic
event.17
malignancies.2-8,25,31-33
AAAAGAGACA
karyotype.12
Epo-activated
ΔE-Notch1
FGFR3-transfected
Amersaham-Pharmacia
7/79
mutations24
tuberin-derived
CRLF2r
6–tagged
myeloablation
models,14,34,49,50
lentivirus-based
azoospermic
levels,23
.Cycle
ATGAGTTGGGAGGAGGCA
Notch4ic
mercaptoethanoll
2243del
SeeGH
4.8
.SLC25A5
cells139
ABI3130xl
Krüger
CCP4
SK-N-BE
anti-neurofilament
debris.Protein
PTEN-C124S
AG1478
noncanccrous
8q12.1–q13.2
HNF4α-low/absent
autophagosomal
I1171T
assembly.185
1st-line
CD45RC
106Ba/F3
rank-correlation
ttzuZ
P=0.99
D594ABraf-expressing
cellscarrying
alone.56
PHREG
anti-B220-PerCP
H1a
KB153
HFK
5-residue
5b–e
g6
pPM231-rad502TEV
C/II-1
PFS-defining
serine-62
R451R
overexpressed15
2.64-fold
19hMLH1
TIAM-1
β-D-thiogalactopyranoside
AMPK43
NAV3-SYT1-PAWR
erbB2
1997–2001
9.073
v-H-ras-
SLC25A5
R361
expression.68
Korkaya
02215
SDS/7
stage,24
tricarboxylic
p21-forward
H130
0.679
raj
AGACTGAATTCTCAATCGGGGATGTCTGAGG
Phosphopeptide-binding
doublemutation
infrequently.7
dispensability
Westermark
Amifostine
Ala70
Q96P
stratification
MutSα-WT
JMML-like
KDR/VEGFR2
5′-GCTCGAGGCC
0.85
G.Feuerstein5,6
D2512G/Y
.STEP3
≥1+
CD19Cre/+
~~-Q-P-K-K-K-P
mesodermal–epithelial
andNRASwere
A11,30
coamplifications
.Kraemer
E2F-
NT_086690
0-17
C329Y
3542
CGCGAAGTTCCCG-30
Clapperton
DCS3
YMDMKPGV
nter­
Raf-dependent
carcinoma44
EZH2,16
.Invertebrate
prodcol=N
phosphorylation—was
p.Glu626Lys
V5/His-tagged
pGRR5-luciferase
.1632
flankingregion
AZU
Yorkie
1650del1
6962
like-ligand
IDH,6
1,405
agent-induced
4..
Asp-746
4255–4256
Hoxb6
Cdk5rap2
Bub1/BubR1
60–74
DMEM/0.1
transdifferentiation
carcinogenesisand
VACO4IO
.DNE
S454L
15.5:1
T-distributed
GCCGGATATCATGGAAGGAACTGACCTGGTG
/JNK
RIE-1
anti-Bub1
clusters/groups
described43,44
8,129
Q1539X
E627D
PE/ABI
mt-p53
172-329
non-human
GH118
LB2518-MEL
HEK-Jak2
Yap-WT
GFP-vector
ALAD
Multi-Link
snu878
Pappenberger
-Cw2
8p11.23-p11.22
Glu4-Tyr
prlmer
GGACAGCCCAAGCTAGAGATGA
.HIF-2α
Raiber
BRCA1/17q21
SUPHD1
gal
pRb/Id2
DR-26
:9006–12
.NRG2β
6.In
a|
L243
Bild
EasyTag
Dual-Luciferase®
NaCl/2.7
2.37-4
L397P
pCDNA3-Bio
MAPKERK1/2
IV-2
B0801
.Hormone-sensitive
D470
.Return
senescence15,44
Moniz
Met-48–Met-531
c-FLIPL
cancers,24–26
cAMP-PK
0.95–0.97
First-round
Davidowitz
PrimerDesign
nurse/patient
T421M
/kg
Dtj
gibbon
AAGTTCAGATGTGCGGCGAGTT
rearrangements49
mTORC2-specific
luc-mut
33446566
studies,22
16hr
5′-CAGACAAUGAGAACCGAAUUU-3′
0.889
CochranArmitage
insensitivity
CM-i
CGTCCACATTTGTTGAGCAC
TU-ip..-
G779G
G305V
Bhattacharyya
V1442E
CDK4
12.4–19.1
TY3-
Stogios
RT-predisposition
440K
Akt-T308D/S476D
pCMV-tag
=16,658
Arg369Glu
HEK293-RETWT
.Akt2
.-W.
HLA-identical
TT-30
mycophenolatemofetil
5/21.7
EWS-FLI1.72
PEI-cellulose
auto-deubiquitinated
interactions23-26
584×
2,673-kb
Met-HGF/SF
ploidySouthern
chrornatograms
n=416
Besnard-Guerin
msh2-AE859p–Msh6ppreparations
defects35,45
IOH36372
MM-121
www.med.mun.ca
Yasuhide
andany
.Adrenal
KPβ-induced
94.75
N161S
5-hydroxylation
33,36
Tyr-368
c.4161_4162del2
AGCCA
Z0
mTORC1.28
5928
.Amino
pCMV-C/EBPα
n=84
LifeTech
cells.8,9
-b2
1,250
144,5
6xHis-Cdc34
1µM
L192R
-30K
64–65
FLT3-WT/CBLR420Q
pTB-ex
.671T
q11.2q13
pseudo-symmetric
domain.System
idues
Anti-MAPK
1.185
predominate
mutant–expressing
.072
ERBB2-Tyr1248
.I.
EBV
protein14
Pro-34-
DiscussionJust
Atm+/C
353.3-800
Asn184
technique.35
4I22
pS6RP
anti-DIG
pathways.4,5
5′-GAATCATCTAGATTAGGAGCTTCCTGGACTGGAAGTGG
.Al
V800L
4mm
ADAM10
G2E
F1734
100014508
Gorbalenya
EGFR—a
LFS-50
p7Otrk
2Fig
=38
`Only
leukemia/small
//gather.genome.duke.edu
Flicek
pGBTRhoA
NB1382
1274T
5'-TGGCCCCAGGTGAGTCATTATCT-3
36⇓-38
Wadgaonkar
VAD
Fig.3E,3E
Morosetti
SNU-638
mL257Raf-1
Subject-
tsc1−/−
~27,000
CDKN2A/ARF
eGFP-
COT9
Shirasu
t-tests.Cells
PDGFRB-transfected
FOP_wt
R617fs
E83K
G459D
chloro
68352659
andeffector
anti-pericentrin
q25q32
84y
10065
E326G
dithiothreitol-d1o
MLBCL,2
30003
Fernandez-Rodriguez
pMaxGFP
S505N
Y123L
Ken–ichi
Glu34
INK4A/ARF
5-methyldeoxycytidine
alcohol-related
post-replication
g.152,504,123_152,508,371del
G811R
L228P
ELAM-1
separaterestriction
cancer/non-cancer
NM_000267.3.Site-Directed
Ser-387
hMet
Ras/mitogen‐activated
Y-730
A190-120A
Met541
Cys164-to-Tyr
PMLRARA.32
SADDAN
oxidation/DNA
203291
∼107
CTD-2314K7
LET-induced
10′000
guidelines.xSelected
plasmids.We
ΔC·ABT-737
inducible
0.3573
DH2
Soverini
CTAGAGAGCGCCCATTGTTCTATCAG
his3-11,15
RGD
SM-L
Y165C
MiR-3127-5p
1—G114R
patient-
sequence–DNA2
Arg12
N66K
.33133324
MRX
months/M
pEGFPC1-p85
malignancies.17
and5A
TG2
0466
Samd5
BRAF-
≤−1
EGR1-regulated
Phospho-EGFR
PJ69-4A
tRCC70
ISS2
Seven-week-old
Pro-Xaa-
26/29
MEK1Q56P
BAF400
ARAF_v001
ependymoma.19
.C11orf95RFP
.Directly
NID2
p300-1163
Eisenman
FLT3840-GS
exon64
wellsfor
radixinT564
protein–positive
repairedin
//p53.iarc.fr/
hG1-P3000
opposum
NG24
FYR
17/192
SPRR2C
NF-κB
acid-extracted
135-141
97-
p.Gly374Glu
G241*
S33F
DMEM/High
1B-1D
LaTaq
Hdmx-p53
chi-squared
-3-h
p.K745_E746insIPVAIK
Goding
c.1
817–819
Shp2-Gab1
Y32
.Exemplary
GAB1-specific
423-F8
V332M
1,902
0660
HLA-B
fig1,1
n=153
2-point
12/39
4050-313
metastasis3
isomerase
C-Extra
AY518305
N208Y
S36A-
p59x
.Editorial
trial29
V500-Â°c_3..Ã¨1Â¿
Breyer
.4308C
SOCS2/SOCS3
Oca
34,42
Homeodomain-interacting
EZH2,9,10
T313A
KRASWT
pmCherry-C1
HGVS-approved
Milano-Bicocca
RPI-1
.HEK
Cys-X8-Cys-X5-Cys-X3-His
1994_1995
1.428
-linker
hMDM2
regions8
whichdenoted
expression126
18.23
41.67
6–54
6082
Brca2-mutant
Irresa
adipocyte-specific
.Polymorphism
Tyr436
recommended.17
Hs01019589
Univariable
PJS
non-EPAS1-mutated
EGFP-p27T198E
FBLN2
363:1
www.transgenomic
1,559,049
guanine-ribose
.and
Zariwala
two-third
obesity-mediated
WM3928F
activityð
Wnt5a/Frizzled
pneumococcus
10-03
0.196
p=0.00072
p53V272M
.Treatment-sensitive
FAM83A
mou
RAS-directed
hp110α
time/INR
clear12,23,24
S621A
pol30-50
hGL
determined.a
sample-unique
Shield1
Lim
E143
MGSSKSKPK
lung-tumor
pcDNA-RhoA
operator-LEU2
Polyphend
Blechman
CDK4-MUT3B
filament.26
5q35.2
E6b
VSIGLDFSDDNAR
repolarization
5–22
69.7
208/228
H805L
CTAATACCCTGCAAATAGCAGAAGT
.F=female
α-Hsc70
nestin.10,11
.IRS4
1/800
minigenes1
L701H
Emulsification
CEPBα
3.004
intervention.About
4-log
XDSAPP
1283
dabrafenib20
chRCC
595/630
98.0
less-conserved
NMU
9/10
stFIG
exome-captured
SMARTScribe
D-deficient
.JAK
ahigher
gATP
3EUD
BAF-specific
275/634
In22
rarelyaddressed
BCOR-RARA–expressing
DNAPK
testing14
dot-plot
STAT5-activating
KITD816Y
MyCancerGenome,37
HHa
D408Y
21b
NS547
HXY
10/29
BRCA2/IVS5
±fi
ubiquitination-deficient
7.5/2
mitoses/
LEU2-marked
G264V
TP53/cell-cycle-mutant
ERGB/FLI-1
1IMO
Hs00300550_m1
androgen-like
HsCHL1
W384
R22X
32–75
FGFR2-L617F
u-free
HSC-specific
G3C
MTC-derived
GenesMyc-Max
OPT821+β-glucana
91del16insG
947C
methionine.B
L390fs
differentN-glycosylation
Dabrafenib
wereinjected
502_503dup
chloroform/methanol/8
Anti-WT1
rs13385191
1-PE-1-SR
wu111
bring-together
A.A.M
Kroemer
Mg2+-free
.tissue
Y1135
60Â°Cfor
HA11-conjugated
WT/mutant
Valouev
Gly-Ser
p.S985
10.1593/neo.121106
2606-2532
16.9
W461
streptavidin-biotin-peroxidase
HRX
+13
activity.11
SA500
18/46.2
3−5−fold
344KB
0.53
inter­action
Re-sequencing
plekstrin
Strasse
CBLC
ROR1-EGFR
T352M
Figure3A
CULC002
XL880
manner55
tubulointerstitial
26,106
n=18
level,15
nearnormal
.Tyner
0.04001378
c.4052T
S367
.Non-overlapping
2.5-kb
GDP-AIF4-
5′-GGAGGAGTGGGTGTCGCTGTT-3′
responses14,15
22q11.2
.Like
somber
Myc-6xHys
16p-q
5′-GCTCATGCCCTTCGGCTCCCTCCTGGACTATGTCCG-3′
isoforms28
TGACTCTCGGACTGAGAAACG
96-amplicon
Post-translational
TKI16,17
GRID—a
genomic/proteomic
18delT
P2–P4
Bindea
1368
STEP3
data5
78:576–580
con®rming
S509
myeloma.14
0.0031
–SH
49–68
assays.What
Tumor_Seq_Allele1
V01.01
CASCAAB6ACT6OTCTTTCTATCTCVTTTACTACACTSAATTCACCCCCACTSAAAAAOATGABT
pathways,13
pachygyria
5′-terminus
morpholinomethyl
1,022
.ASP2215
absorbent
.Mitomycin
ChIP–seq
Figures6C6C
.H5
3909
Kornblau
p.R117A
ca-AKT-GFP
lV
13/30
Ly5.2
Table3,3
Genomplex®
Helbig
KB1
M8504
4WRG
5,11,17,20
restimulation
arginine/
TBXAS1
CAT25
Gardner–Rasheed
multifacial
mechanosensitive
p.Ser196Asn
tumors13-17
o5724-o5725
desoxycholate
SCNN1G
15q26
EGFRin
ETGG
ragged-edged
PKC
polymorphism-containing
INTRODUCTIONThe
E157G
NMS-P626
TEM8
8q-terminal
pT3N0M0
A_51_P376050
42.
p.Lys468ArgfsX7
G23
46-203
F2004C/V
KBM-5
CDKN1B19
Schoeberl
29–53
CT2283
MacProbe
fish-specific
RAEB-t
1−4
alteration-specific
.Infections
progenitor/stem
W9.5
cortisol-related
cell-viability
degradationpathway.Immunohistochemical
way.126
gstp
300128
phosphoantibody
DP-negative
hFANCA
zf-HC5HC2H
Akt-phosphorylated
alr17
DNA/protein
SPCCs
afterincubation
.HER-2staining
TRCN0000039715
screening7
EIF3S3
PCM25/1+
TKR
.Disorders
cell-adhesion
BRCA1WT−p53
V600E.4
jen
s-1
treatment.142,143
recognition.In
B,7A
pMB11
BRK-
5′GATCCATGTACCCATACGATGTTCCAGATTACGCT3′
C609W
described.18
nihms820730f8
CD57+
Jnk2
R2-WT
May-Giemsa
non-ambulatory
S6G
Dendrogram
GT53.0
67–153
07-030
5′-AAUUACCUUUGGAAGGAGCUAUU-3′
supercomputer
Q2223
−2455A
tyroskine
n=817
.Endpoint
Kuhel
AXL-driven
2/202
5′-CTGGACTGGGCACTCTTGTC-3′
D-T
ab12292-100
NUMA1
.K
INF/NF3b.1
cSoft
.Lestaurtinib
14,23
TPO/MPL
M13-F
UbH2B
provingthat
resolved.10
hypofunctional
Cupsat
n=0/11
KIT-Y703
TGGGTGAACAGA
13,28,29
:6969–77
105/1,344
.D1
Petrij
Pat.3
Lepidic
HER2-mutated
2.2.3
terminus8
respon-
.NR4A3
dog,24
Let-7a3
E541K
2,9
speciﬁc
where-
reinoculated
Nantan
9.6amp
A48A
p85-regulatory
-MAPKs
Fwd-5′-FamGAGGCGAGGTTTGCTGGGGTGAGG-3′
EPICENTRE
tumor/no
histones.11
∼26
myofibroblasts
GTCAGAG3GG
BglII-BsaI-digested
post-resistance
Glu578_Glu632del
methylgreen
SB590885–treated
E75G/P670L
TCACTGTTGGTGGCATACTTG
pmol:1
GST-p85
72-96
Nrf2−/−
ThermoBrite
PME-NeuT
prognosis.24
exon/domain
Variation_34021
0.0143
90A3
L755-T799
protein-family
Hps90
kinase–RAS-PI3K
15â€
.Controls
Jb2.6
bone37
G13D-mediated
Leu-94
IP‐10
sh-CTR
MSH-DNA
diagno-
re-arrangement
Tsc2fl/mut
3/17
Mes-Masson
Ruxolitinib-resistant
P35122
WM278
polymorphismsPCR-SSCP
z-VAD-fmk
double-expressing
KEAP122
Akt-mediated
5′-TCCCCACCAGACCATGAGAG-3′
0.0001217
Mitogen
Q684R
substrates.14-17
ulp
CTC-416D1
haptotaxis
G503A
tantalizingly
migration.35
PME-1
RAS-GEFs
chemotherapy.7
theinsertion
1.005–1.102
26-nucleotide
beenutilized
ubiquitylation25
RNAi-treated
chi2-test
TEL-JAKs
signalingfor
H126R
Akt3-derived
p.I282V
gr1
lines.59,61
bilayer-anchored
sonidegib-sensitive
.M/69
2T
-/1+
LGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIK
V1316M
cells.98
Mahrour
10-fold-increased
171bp
high-likelihood
TGF-β1–specific
Allele-
rule.
.Resection
HNPCC.15
BR00
.677
P-Tyr705
U20
`multi-hit
H58
binding.Figure
SDHC
HGFstimulated
32-47
SAVVLL
cancer26
c-mycmissense
R863W
.Bottom
ΔTrkA
Renilla-tagged
.Preamplification
transketolase
CDK8-mediated
STAT-response
parent/guardian
aCGH-Detected
E10.5-11.5
marrow.29⇓-31
TIA1/TIAL1
revealed—rather
Gelb
IL-1α
castration-resistant
KRT17
IA-IIIA
PARPi–
mutations—provide
c.9502-12T
5′-AGCTAAGCAGCGAAGCAAAG-3′
phosphatidylinositol-3-phosphate
predictedto
.Murine
cytoplasm47
hexahistidine
1251-antiHLA
p-Akt-associated
.05/3
21/10
865–927
KIT,15
pNTK
©2016
deficiency.8
alpha-prothymosin
1011mel
rad50-R20M
35S-HIF-1α
five-ten
Ser276
∼45-fold
ATMi
membranous/cytoplasmic
lyn
.fe_p53
Msh2R371S
GDTP
0.29-2.21
exchangein
IG-C1
FLT3/D835
LRR-domain
GNNK−
AGT-3
.571
G328V-ACVR1
ofΔ
integrin/focal
activated–NOTCH
41.1
634
cross-complements
Leu382
P352T
5′-GTCACGCCTTTCATAACACA-3′
XP6BE-SV-immortalized
carcinoma.6
noninferiority
epirubicin
TAK-701
CXC
Dual-IP
.CBF1-VP16
06–203
negative.Statistical
28.1
AGRF
dedifferentiation
Information–Based
SQHTX
renilla-luciferase
GAGACCCCAGTTGCAAAC
supercomputing
MYCN-157-POS
SD211
complex13
0.044
dual-signal
hMutSα
n.t./a.a
30-33
PNH
oered
breast/ovarian
S310F
P248L
inhibitors,4
MMP-1
CAA-sAAA
Cancer-Prone
5-biphosphate
TSC2-N.
Fifty‐five
pCI-neo-RB
pDM72-transfected
.Identification
GSK3β-BIM
802–822
.CAD
ATACCCACCGACATCAGCTC
tier-1
deoxyribonucleotide
SPOP-coding
VHL3_1R
56801452
approaches130
hMLHl
p16INK4a/CDK4/pRB/E2F
hormone-activated
68904
light-red
FLT3-ITD-G697R
0638
0–1/10
.Dastpeyman
S1a-S1b
CD61-biotin
Elfring
unstable.9
OMIM153480
luteinizing
38/144
ABC/non-classified
patients.Thyroid
EBNA1-
13q14.3
pMBi
A289V
www.digitalkaryotyping.org
SCC66
ofnonfunctional
R549W
.Non-hypermutated
motif\
.BRAF
nonexhaustive
progression.45,46
postprostatectomy
3.5y
1.307.119
assay.10
.Z/AP
J-005999-05
contaminant
overdrive61
protein–
imatinib-acquired
.Simon
D11S1889
radioactivities
10+289
GI:3170535
CBL
al110
CD31-coated
5′-CCACACAGCAAAGCAGAAAC-3′
ERK1S219P
Thr-766
unlikely.32,33
signature–associated
Sca-1low
355-bp
94304
Cdk/cyclin-like
RP11-624G23
.UoC-M1
Dameshek
T790M,60,61
region–Abelson
ABC-AP
2INSERM
mono-/multi-mono-ubiquitylation
tAG|g
41.9
ubiquitin–proteasome-mediated
hypo-ubiquitinated
14/36
saline–0.5
0.000261
.434
.033ORR
gefitinib-responsiveness
seventy-six
1O-bp
DIMH842-845
sc-98441X
FAT1
24-189
59-AGCTTGGCTGCAGGTT/CGACGGATCCCCGGG-39
late-phase
4419N
Brookman
16,423
FOXO2
assay.25
DT5
SH2−domain
1.141–2.494
ΔC-box-FZR1
80,000-
1325
245T
BF
6-11
primer—5′-TCATGGAGAGGTTATAGCTCCTG-3′
SH3-dependent
IV.1
activity.Pharmacological
3667A/G
72Â°C.and
all—of
Bossi
BCL2L14
thepathogenesis
siSRp55-b
Assay—EMSA
NRMB-
.0202
FGF17c
mean-absolute-deviation
K−1
Galnt3
Fattoruso
39933
RAALSDITN
CGA
9.164.4
MYELOID
structures21,31
06–107
3′-orientation
statisticsfor
mutL
TAATGACCTCAGGTTTGTCGG
vitro-expressed
acetylation.30
.Equimolar
20500–56800
D/CDK4/6
P\0.001
Kontaridis
pcDNA3.1/EGFR
Acknowledgements
5'-CATCCTACAGACGACTTCAG-3
CKIδ
endo.
replication.9
Lazrak
0-33
LR05-204
renal-cell
Ex-smoker
ER-Negative
p.E81K
VMW110
p.Gly1080Asp
status4
−71
non-obstructive
sc-81852
C.B17/SCID
fluorescence-based
Wennerberg
jzCCGAGGGAGCGCAGGGAGCG
deleted.9
repair11–13
pseudo-preseptal
5′-ATGTTGCAGCAAT
DHL-6
Multiallelic
90783544-90783745
G589D
pcDNA3-ΔEGF-MYC
5—
emerged.19-25
cERM
NF-κB,58
5'-TGTTAGGGAGAACTTACATC-3
3C-E
S2215T
c.1861A
uninfectedRat2
cells.161
Neurol
Gle
T68I
cadherin-11
Gilkes
.Metazoan
non-CD44
-3.8
miR-17
MDA-PCa
11q14.3-q23.3
EPHA1
JB10112
BCL-xLΔC·ABT-737
resultsa
T62-containing
3Flanders
pcDNA3/LKB1-
DNA-binding–deficient
7917del5
SDS-PAGE–loading
criteria1
FUOV
'-4
mSos2
chr6:31936315-31936399
lentiviral-STAG2
p.D579del
166-372
40/M
p.R1391S
10/29/99
CpG-free
p53LSL-R270H/+/Wapcre/+
OCI-Ly7
NM_015001
Y527
c.208
RASU1
NM_004119
ab72999
Spongesloaded
Pignoni
GO.db
Anneal
.R249S/H168R–DNA
.GeneEraser
tumours32
II-IV
SCNA
ATP39
Geneticin-resistant
Pstl-
proteins.75
R834Q-positive
.Gata
mRNA/p85α
D777
numberb
BMP-2/4
CDH5
a-BRCA1
enhancers.It
VTI
snr1
pcDNA5
sex-cord/stromal
cancers,23
MP-7405
trials.6–8
ado-trastuzumab
P73R
resources.19,20
BAL31
Asp86Asn
loop-sheethelix
Phage
Anido
Y95
678
CNTools
agcuauTT
telencephalic
M694I
G3519R
6.7–0.31
c.6017delT
c.7992T
Line1
MLL2
CLL9,10
1–34
CD1A
guidelines.zIn
N-ε2
puro-control
peptin
median=38.0
OCCC
0.0033
Ex4
Phe81
0.589
.PC
median=3.44
pαGT
ALH3000
desmoplasia
within-print-tip
reponse
agt
Gentamicin-Induced
5'-TIAAAGCTTTAATIAAATTTGGGGGTICC-3
ribosomal
TFH-like
cgr484
.RECIST
1Mutation
.Patients
61.07
anti-pS621
Chemioterapia
Institute.17
.TP53–/–Tsc2–/–
Leu309
gain/change-of-function
pLG3
annexin+
TSC1-binding
N1L1601P-Δ82
NUP98-NSD1-like
NCI-H1717
inhibitor-I
lacZ–SV40
5′-CAGCTCCTCCTTTGGCTGATTGTCTCTGGATGGTGATC-3′
.0004
Peg
8/20
implemented24
Schwartzentruber
p.Arg1440ThrfsX38
3The
ARHGEF2-NTRK1
therapy.4,8–11
TRCN0000195500
biomarkers
3167
.Whole-gene
neointimal
injury28
unquestionable
p61
PBLs.39
orthodontic
5′-aaggtgttgcaatccccagc-3′
11,14
non-bulky
gi3914053
HG-U133
nicastrin
ELK1-bound
changeANXA3Annexin
12-2010
heterodimer-izes
activity.23,24
diacetyl-L-tartaric
auxological
analysis,17
3a-3L
CaCo
CU538
P146A
XgtlO
6872
ataxia-telangectasia
.matched
positive-selection
Arg1155
.Prediction
5′CTTCGATCTGCTCCTGGCAGG3′
Figure4F
failure-free
Glu-7
b-scaold
K745E
177-197
.SMCs
αK
0.2426
P80R
CEEA.PdL.06
NH3+
carcinomas.4
isoform17
cycle23
2-5-2-4
-Cell-specific
defects9
mlL-3
Yes29
26.7
liated
50-120
2.57
76N.TERT
95.Given
elf-1
1470
JAZF1-SUZ12
6MSH3
.995
al.29
–recipient
B/J
showedsignificant
AGgt/AGtt
APO-BrdU
genome.wi.mit.edu
4,5-dimethylthiazol-2-yl
KEAP1-mutated
SM6
PLSD
pcbi.1003749.e011.jpg
+0.1
EGFR-E866K
BRG1/BRM-negative
85–90
Guix
immunochemotherapy-based
previously.3,13,17
3/83-
reached,11
c-H-raswere
Phosphatidylinositol-3-0H
A3−12.1ZBED2Zinc
.Biotechnol
phospho-Kap1
oncogene/serine-threonine
uncoupled.7–9
Cortellino
full-site
Disease-specific
adenovirustransformed
J/m2
Phospho-proteomic
diffuse-type
v.3.5
DSMCPAS
R-mCT2
p.Q262K
phospho-threonine
pET18
erlotinib-insensitive
AF145477
NLS1/2
G78R
.TCT
RII-RI
FGFR2c-AP
1.009–2.811
M/57
bicabutamide
pCDF-MCS2-EF1-Puro™
MSCV-MLL-AF9-IRES-GFP
Mastermind
p95HER
α2A
3-methoxypyrrolidin-1-yl
pre-fl2m
nongastric
STMN2
Ile836
MET-driven
approaches.20
exon-9
catecholamines
Sox17flox/flox/Cre+
polyethylenimine
RUNX1-related
.Smurf2
loop-located
.Lipid
TREM1
.302
CDC53
Phe432
Deglycosylation
P16/CDKN2A
thelamfoundation.org
Sarcomatoid-Specific
.Never-smokers
R882H-LSK
TurboFect™
D1546N
35/50
MDX
phosphoFLT3
anti-CIC
9297
'robustness
.Online
2004.19
nonexon
RTLTLISKTIQSLGN
Imatinib-induced
723-fold
1,474
pheotrophin
light/dark
18p11.31
non-oncogene
NM_001004060
6/46
EN/INSR
phytohemagglutinin-stimulated
//psort.ims.u-tokyo.ac.jp
MRP1
mutations.A
PTPN2-deleted
O'Roak
32-59445.99/2
Seq19
Lats1-dependent
N-termimal
ormechanistic
.Types
531–537
pileup48
100–1000
REPOCH+
7,11–14
.RNF43
Ki67
R248H
PO4-SMAD
Desmosome
.OP9/OP9-DL1
I168F
described.34
death.Table
ER-alpha
1.6β
disorders20
SPOPF133V
genes.3
Zuk
Hochhauser
population.13
//www.broadinstitute.org/cancer/cga/indelocator
IDH17
132.2
P\
Fukihara
si-SPOP
.LSK
M.-H.
abnormally-sized
pET-28b
astro­cytomas
VHL-transfected
HPV+-associated
carboxy
wasreconstituted
KMS-6
Wiley-Blackwell
mutation/PARP
ethnicallymatched
.TMPRSS2-ERG
and8–10
.RCC4/VEC
15p
co-chaperone
themissense
.209L
L858R/H870R
4710
int-21q32-44
5′-GGCAGACAGAAGTTAGCTCGGT-3′
Ink4a/Arf−/−
Cell-attachment
proliferation22
5q14.3-21.2
TRA1-60
widely-used
methyl-transferases
1,476
mutantswhich
propelled
A1311G
.XXLb1
°C/s
.Suspected
Guanine-nucleotide
1396–1863
.9,36,37
T119P
aFurther
p21
homodimerization22
*Estimated
46–48
Co2
.DAE
S2∗
842delC
.N131Y
-BRAF
3,735
apoptosis94
JIMT
bronchii
.CEFs
congenita.43
AFX-mediated
CLB-Ba
FGFR117
ﬂanks
nonsupertransactivation
Etienne-Manneville
839C
lines20
ZMIZ1-ABL1
MLL1-bound
VCaP/AR
MIEG3
POLB
PNA-LNA
NM_001429.3
57.6
B-Raf-V600E
alone120
1:20,000
ZMIZ1–MAT1A
A118D
=144
DOX-minus
A132
dMax
p53-null
phosphopeptidebinding
RP11-245C23
Stemmer-Rachamimov
BRD4-203
low-expressing
3908352
www.tm4
ligands46
population.20–22
HAL-B6
CAGAACTGCTGCTCTGGGTCTCAAT
incubatedwith
A236T
28–37
MSI-H/more
7nt
survival101
pcDNA-DEST4.0
3-log
8,12
620A
mutatsons
lg/
occurswithin
9α-fluoro
10620312
T790M.35,38
F275
KST210
CD3−/CD16+/CD56−
D42G
13Cβ
strandspecific
phospho-Y705-STAT3
TH-IRES-Cre
5/361
7×10−8
GGCTGCAGACAGCGCTGCCGCGGGCTTAATGAG
c.1744C4T
5′-Fam-CACCGGCTTCTTCCACTGCTCCTAGA-Tamra-3′
5′-GGATCCACTAGTAACGGCCGCC-3′
cdc42-Rac
mol/l
Takenouchi
SER-RB100l
ERK2/
mm03413826_mH
.Disease-associated
88X
Microimaging
regulated-decay
Intra-tumor
EWS/FLI-mediated
System64
CTTN
G9545
MEK1P124S
rtTA-only
BeneChip
.Separately
meibography
.9–17
full-scan
5704
~9.2
shGLP/shG9A
differentiation/renewal
TXN
.2939A
Jeannet
lonserr
.Gene-expression
super-active
RET-MEN2
kα11
D1713K
immunopcrecipitation
e14
sites.7,44
IgE
BC004207
5.1.3
167-
Glu-936
co/i
ETS-mediated
3.Table
0.2N
−6.19
E-MTAB-2068
ERB
protein-2/-4
7SL-R
Antibody–
A.L.
mer
Sox17fl
ZKSCAN1‐BRAF
.178DISCUSSIONTo
PMT
Hajdu
F795S
transcription.51
TeT0rTT
261,000
transcripts2
3.98
PP2A-dependent
PR-B/L-mut
TEL-JAK2,13,15
1DFIGURE
1/67
KYO-1
MEK1K57N-induced
.p16Ink4a
R280
Pdgfrbredeye/redeye
Hoff
angioimmunoblastic
IDH1/2-activating
.Bethesda
junction—see
IL27
SARC
B7‐2
pT308
www.gastrojournal.org
MLH1-PRO1R
PRC1-binding
possiblenucleotide
Strand-Specific
F255V
portantly
Atto488
Hague
Antitumor
124.1
~~~~-4
untransformed
C9orf53
study—Δ118
mitosis42
Atr+/−Mlh−/−
.11,18,19,20
W*
765–833
c.1403T→C
shRNA–transduced
Cα-helix
instillations
LR04
promoter-based
Y2660
GATGACTTC-3′
GAGGCGGTCGTGCAGACCCGGGAGAAAGATG
V312M
'Cancer
III-9
2.3N
5-triphosphate
.unpublished
Lyz2tm1
therapy.4
MEK1K57N
O-tetradecanoyl-phorbol
-iF
R282C
4p16.1
SMARCB1-related
FNIII-2
G31D
memory-protective
low13
.Weiss
K345E
FGFR-TK
Thirty‑four
luminal-subtype
biotin-16-2′deoxy-uridine-5′-triphosphate
D210N
576G
platinium
carcinomaa
5′-GACCTGTCCAGGCACCATGAAGTCCTGGGTGTA-3′
D11S2071
−
5948
5′-GCTGGCGTCTAGGGAAGCTTT-3′
degron30
program†
J.R.T
proteasome-dependent
I585T
ex-smokers
CDKN1p21
TNFα-induced
Encouragement
T55I
5'-TGCTG-3
FSCN1
GST–PKN
Grovdal
myristoyl-transferase/deacylases
Scrima,1
Araf
upshift
S741
NB05
R169A
NMZL
RYBP-binding
.Erk
Structure–function
.117
TEL–platelet-derived
30'C
SHOC2-mediated
fx/fx
β-defensins
p.D842V
Non-coding
2.7-kbp
www.qiagen.com
CHEK223
alterations1,2
Cronmiller
SMG9
Lugen
phosphoinositide-dependent
EGFR-delE746_A750
K633M
M918T,13,14
cells10,11
Leu-269
UMC
Multisequence
NOTCH1/2
approx3
miR-511-3p
0.9984
B-Raf-driven
KIT-N822I…
Unc93b1-mediated
Ramon-Cajal6
S568
p.Asp487Glu
397–400
q32q34
.CD117
.Luis
Val658F
chemo/immunotherapy
AAAGGATCAAAACGGTGACG
T-LLs
Figure66B
TCF/
tXzS.
2500-
Schonbeinstrasse
Table33
hemangioblastoma
c.5558_5559insA
4–5-
12-
c-erbB-2/HER-2
trihydrate/20
R3.2.2
receptor-PKC-neurofibromin-Ras
anti–PLC-g
SCC-10A
FIP1L1-WWPDGFR
HomoloGene
HIC-Up
dGTP
drugability
Quinolinate
inmissense
synapsin
2329G
BL-342
fibrolammellar
cancers,26
citric
count+mutant
748T
Reaction–Single-Strand
KDM1A
complexes28
BRCA2/13q12
SSCP–PAGE
p21ras–GTP
expressedefficiently
Thr-383
prognosis23
0.4250
−6.4MST1RMacrophage
2.7.1.112
3,4,5,6,7
188A
Rosenlund
agents17
Lipofectamine™RNAiMAX
.Y
2M–S
9855
p5336
.Ntg2
CCL5
patients.32–34
Lys51–Glu54
Ets-fluorescent
promoter18
0.046-1.910
Pan-negative
48-capillary
GSK690693
ATR/FRP1
Rikurator
p-NF-κB
cells113
HER2-amplicon
findings.6
retrovirally-delivered
Oncor
discussed27
BRCA-mutant
9,19
2A–2D
84.13
8p23
OX40-triggering
000526
Interchromosomal
5/44
gametogenesis9-11
C20R/T37Y
S723F
limited.3
37Â°C.Acetylation
DR-27
WT-PH
T115N
DCSGLSSQSDILTTQQRDTMQHNLIKLQQEMAELEAVLEQHGSQPSNSYPSIISDSSALE
LZTR
yCIuAspValA
O-sulfation
NM_024408.3
.FLT3L
N=16
protein-mediated
A161E
of02-
gcg
β1,4-galactosyltransferase
gplots
RG3000
clofarabine
characterized.In
E2F-mediated
TGTTTAACGCAGGCAAACTG
.ABC-DLBCL
Sihvola
RT–PCR-RFLP
anti-SRC
homeodomain-containing
523
αX
TTGAAATGCACAATCAGGCTAC-3′
sh-PIK3CA
onThis
H305P
63.7
535–552
†22
70,108-110III
Br40
j.j.molenaar
cancer.10
Wnt3A-conditioned
1/5861
FoxO4
L357P
fluouracil-treated
HEPI-NEM
e19a2
22qâ€
elsewhere.6,7,19
0.5–91.2
protein_batch_submit.php
748,000
Leverson
HEPES-NaOH
D1238N
DiscussionMechanisms
GIST.32
4390824-S808
Frenzel
pcDNA3.1/V5-His-TOPO
CMKOR1
.RBM10
granulocytemacrophage
CD8–C8wt
SGK3pS486
aa1759-2285
Pefabloc
2071882585
/TCF
.Nrf2-GFP
77.7
13/29.5
pT3E19A
0.069–4.43
ERÃŸsignal
opment
Mitogen-inducible
Benjamini–Hochberg
Chadee
LUC962
NB—pelvic
N-acetyllactosamine-binding
xeno-transplantation
rs140285068
D1
Gly463–Val470
sybtype-D1
N186Y
total/direct
wide-ranging
NCI-H322
K67
rs2229992
ral
NG13
Ser-244
R273A
p.Gly328Trp
CBLR420
Kwiatkowski
500x
Endocr
5'-GTTCAGAACATACAGCTAAAGG-3
H20
CyclinD
**Sensitivity
bulb18
τ-b
Fig.6B6B
Val617Phe-positive
mir-15/16
P1770
217/219
cf.
P-LRP6T1572
figureOpen
–anti-Mac1
≤14
Neo1.5
N-syndecan
ATM81-05079A02
Br59*
K.H.Y
tested20
SSC/CD45
neurofibroma.1
4,6
ERKD334N/sem
lysosomally
A843E
0.52–1.76
explainits
transformation*
HNF4α
EWS–ERG
L1195V
pcDNA3/mRad51
V54L
protein191
118
tattattag
c.1555T
H408Q
322…400
T1987A
stephen.smerdon
16,27-29
−8.64
anti-phospho-MAPK
loadedonto
PDE4B2
aaaacgcgtTTAttcgtcatcgtcatccttgtaatcgatatcatgatctttataatcaccgtcatggtctttgtagtccgttgcatagtggtcaaagctgcccaggtactc
PRM
Wakamatsu
resistant.20
TRIreagent
post-menopausal
resequence
R175L,14
.P28L
Wokingham
2281
degradation.2,3
.Balb3T3
177.
FGF19
PEAK1-Y665
H11L2R
speckled/punctate
Indirect…
phosphatidylinositol-3′
second-messenger
cinomas
Wortmann
.Br
THUMPD3
Elecsys
ZF
TMED5
non-TSC
24.6
v3.12.1
hg18
PRDM5
well-separated
OX86-mediated
DIM/LZ
Nonsmoking-related
81-95-849-7306
CATCCTGGCGCAGTCAGCAGA
Waridel
tumor-restricted
MTC-only
nt.742insC
TCF7L2
–4,9
U6-shRNA-AR
K1–6R
224K
leukomalacia
SWI/SNF-associated
BARD-dependent
Eighty-six
V555P
6600
∼5–8
Pro-924
R269C
4,489×
2009/167
V1253E
P278A
NC6
-2s
'large
phytohemaglutinin
retroviral-infected
KARPAS422
optosis
Lys383
5'-TGAGCCGATGCAACAACAGACAAT-3
increase95
results,30⇓⇓⇓⇓⇓⇓⇓–38
Sambade
E98A-expressing
tumorsdeveloped
D1Δ-4S46
RB/p16/cyclin
2–exon
Xenografts
c.1502^6G4A
V+
Y534
0.347
TGF-βR2-MED12
TP53/ATM/SETD2
Nu24/1
.PDGFRα
re-assessed
histone-PTM
+/−5
Killer/DR5
PDE4-selective
a2b
INI/hSNF5
465382InsC
58.4°C
5.59
factor/hepatocyte
.OX86-treated
91.7
2719
Ryutaro
pathogenicity.32
appeared.PlasmidsExpression
TGG
Bertotti
195,651
T233I
adenin-rich
576-592
alveolar-capillary
src-dependent
+1487
L431F
ERK1G54A/ERK2G37S
————
-GAGACCCCAGTTGCAAAC-3
0.075
HHT2
signaling.22
Bcr-AblY253H
mutagens16
5′-ttttccctaagtttgtaagtagtgc-3
.MiR
proteins36
European-Americans
GATA3_01
SWISSMODEL
170–185
TTGTAATTCCAAGATGAGG
anti-VRK1
nLg
46×109/L
–52
T822
0-9.9
4q31-specific
side-chain–main-chain
.Acknowledgements
p.Tyr528Cys
drugacquired
Ser33/37/Thr41
2/exon
1.2E
DS-55004
cellcell
Conventionally
heteromers
targets.11-15
3f1
exhibiteda
SH3-BH
S2/Table
Bommice
ubiquitin-conjugated
R55P
signal-directed
SFK,42
c.292T
λ-PPase
V169A
.Mutations
Anti-
NCI-H2373
c.142G4A
concatemerized
L48P
.KMT2C
bromide.As
Y626H
6p24.2–p24.1
ai.
G5482T
signatures36–38
51,53–56
oligodendrocytes
maturity-onset
ki
5′-CAGAGACCAACGTTCAAGCAGT-3′
.DSBs
activation.41
promoter/50
USG
p.P29S
AGAC
RPS18
syndrome49
RPLP2
.Mediator
0Tumor
o
73·5
.Rabbit
22–36
DAMTSL4
λ-MYC–transgenic
2114
mono-methyltransferases
β-domain
D2033
CTCF-mediated
Co-culture
731.3
Klabansky
Tainer
Arg465
1338
0.686
PP-1
embryos/genotype
.ERK
1842
mismatchrecognition
AVACUS
pME-18S-b-cateninS37F
178
2013-1-116
HTHGU133a
pCMV6-ZsGreen
ATGGTCCTTCAATTCCACC
p.1382
ALK-alectinib
.HeLa
echinoderm
18–31
sterical
Gene-set
pRb/E2F3
5′-cauccauuaugaccugcu-3′
peel-off
GDC-0449–treated
0-mm
72-h
short-tandem
TSC2GAP-Stimulated
D17MIT123-R:5′CACCGTAAGAGTCTAATAATAAGGGG3′
most-expressed
3.87
4–61
3p26
cIncluding
lineage105
Zampieri
E229K
Pitie-Salpetriere
N-13
dominant-interfering
ACO
2.43E−05
NPRVGTKRYMAPEVLDI
RFLP-PCR
dowregulated
Ser/Thr-specific
Y1230H/M1211V
c.190G
cca
G2385R
Aghioi
p.Val600Asp
susp
anomalies/scoliosis
counterclockwise
Asp44
1997^1998
HER2-specific
D1213V
Pheochromocytoma
40–60
218040
Furukawa
.Gene-ontology
c.212+3A
zymogen-poor
.PIP2
1,10,11,14–17,19–21
mmol/
5A
|
Two-step
.pBabe-Puro-Flag-PAK1K299R
954
non-IG
Masih-Khan
beta3-alphaC
events7
18487T
PY-99
MKL-1
Dpb11
P490del
E709Q
MSig
CMV-PB-Transposase-IRES-TK-HSV
gelatin-treated
ARR3-probasin-LUC–
WT-Negative
18‐nt
Glu299
C.Error
−5.2
CI=0.83–1.70
RafY34OFY341F
288-bp
wd37-1pdmet47-1WÃœ54H-1wdmet58-1wd59-1anapmet60-1wdmet61-1wd64-1anap65-1wd36-2wd37-2anap47-2wd54H-2wd58-2pdmet60-2wd61-2pd64-2anap65-2anap36-3wd37-3anapmet47-3wdmet54H-3wdmet58-3wdmet61-3pd64-3anap65-3anapmetIn
Sca1-specific
signalling21
*.maf
PRL-null
Tet3
nanocapsules
TK/RAS
A524V
CK5/6+
53BP143
described55
H331R
N486-Q490
miRNA-encoding
n=635
electrophoresis.PCR
,36
M1628T
Y510C
positive/HER2
p.G12
3403–3405del
aHBV
Iscove-Dulbecco
I198lfsX51
//grenada.lumc.nl/LOVD2/mendelian_genes/home.php
arthalgia
corelationships
NP_594105.1
BY785179
RAS/
5′-GGTGTTCAGGGAGGCCTAAT-3′/5′-CCCATCCCAGGAGCTTACTT-3′
E639K
Bongarzone
mutation-RFLP
Cuppen
Sub-confluent
293K
cullin4B
.1717
Variation_8615
recognitionplay
.7983
HS/PC-transplanted
Temgésic
DLCA
1A–F
formyltransferase
17,37,38
loci22
elsewhere.32
anti-TrkB
risk,21
A148T
MAPKK2
MLL-AF9/T5
BTL/CHIC2
14-3-3ζ/C-RAFpSer259
regorafenib
Paraffin
PanIN—was
TOP1-protein
707B
16/133
involve-
.Integrins
2/105
NPS
480II
p130/p107
hematoxylin
GSK-3ÃŸphosphoryl
OPC-22
NonRadioactive
establish.5,6,10
pCX
ARC-L/MED
APTES
FGFR4-targeting
.Telomere
31-day
Thr/ACG
taxane-treated
25-fold
Supertransactivation
MEN2A-cl
1ate1ets
site-selective
whenbinding
case.6
out-offrame
G1179R
pseudocapsule
reexploration
p53might
V59
∼25
translocations43,44
DRB5*0110N
nonhematological
WI-18189
10.2-15.9
36,61
CXCR4-expressing
endogenous/tagged
I-mutant2.0
G349S
PTEN–PI3K/TNS3
wild-type-XPF-ERCC1
EMSA.Prior
MPO
S-to-G2
Loercher
niSH2
v2.7.1
themutant
CLC-Genomics-Workbench™
eosinophil
G269S
C443Y
spermatogenesis13
3815
G517R
P=0.98
.MM
6967–6972
Low-power
.ARHGAP26
1,400-fold
.Pignochino
interspeci®c
e¡ecta
RIhkl|
N469Y
anti-P27
p110α/mTOR
ATCGTAAAGAGCTTTTCTCCCCGC
cytokine-responsive
gp130/JAK/STAT3
-GAGTGTGGTGGACAGGTACTG
572-595
//genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html
CI=0.88–1.09
hMutLCr
Amp~con
YXXQ
8p12-pter
high-complexity
signaling…
322
E035
.ConclusionIn
47–345
pruning–regrafting
HL.4
TCCTGATGGAC-GAAATCAGA
TNS3–T323E
LUC11
.5B5B
bench-to-bedside
608
LPTSY
715G
.Outlined
insertion–deletions—in
BCR/ABL,7
Mustata
A1634C
1..
Cytek
phosphorylation.28
KDMs
syndrome.12–18
syndrome.33We
CAGGAAACAGCTATGACCAGGATTCTTCTTATAATGT
EIA/RAS
factorκB
states27
.Parallel
oncomudulin
13-cis
216836_s_at
Non-B
Domain—The
0.174
anti–p-EGFR
flmo-
frame.This
DGR
Cowin
pE3-K-R
Tinschert
.Large
transformation.The
0.444
Lys22-transfected
3,4,5-
167
26–57
ERCCI
Proteins—For
1p12/
estrogen-receptor-positive
2816
EYS
MFM-223
cytokine-depleted
Hoffelder
CM-H2DCFDA
5′-GTAGAACCAATGGAAGCAGCATGT-3′
interactingtransactivators
17q170
NOTCH-1/NUMB
p=0.038
previously49
CTGAGATCAGCCAAATTCAGTTATTTTTTC
.Time-lapse
.MK
immunohistologically
HGF/scatter
293-hTLR4AMD2-CD14
NIKOLSKY_BREAST_CANCER_19Q13.4_AMPLICON
p53-V143A+/+
Wound-closure
c.7806-2A
citrate/0.1
S254A
RDI
.Chk2
pCDK2
LSFGKTLGAGAFGKVVEATAYGLI
calcium/calmodulin-dependent
R−EN
SwissProt
msh2pMsh6pcomplexes
hamartin-dependent
5′-AAGCGTAACTCCAGCACACA-3′
T433I
ALK-C3592T_F
TGR
≥45
.Modi
c.9501+3A
patient-expressed
BRD4-NUT-induced
−2.16
191,3
M24
Honrado
.types
His-873
L317W
V119E
.Shh
Institute/
polypeptides72
areessential
L1379
Ba/F3-KITH697Y
T-ALL,4,41,42
depigmentations
HsBACH1
515C4A
TSC25
SNP500Cancer
amplification.5,31
notselected
4S*
sc-49996
Protooncogenes
Dox=doxorubicin-based
pCDNA3.1-FOXL2
I255R
Transgene
MYCN–up-regulated
n=73
2cm
10,63
D5W
.Buck
300060
anti–γ-H2AX
disease.43
hTERT/GAPDH
co-receptors
p=1.55e-5
3-substituted
Luthman
cK20.10e9
W1276R
5′-GACTC-TCCCTTCTCGAATCGTAACCGTTCGTACGAGAATCGCTGTCCTCTCC-TTC-3′
151
H773_V774insNPH
red-shift
GGTGTTGTCGTCGTTGCAAA
hMSH2/hMLHl
ATPase-inactivating
Raf1L613V
559/T670I/
.2§
andwild-type
forH
α-ketoglutarate–dependent
Mll–Af9
33-1-53-72-51-09
-GGTGTACTCAGAGCCTTCGC-3
//www.ncbi.nlm.nih.gov/clinvar/
ID14-2
anti-Bmi1
1p36.13
−0.1G719A
insertionSoft
A650
5'-TAGGGGAATTTGGAGATTGTGA-3
poly-d-lysine-coated
countries4
.Contemporary
2,307
Celltracker
gamma‐secretase
003005
1150T
aThe
5.2.7
pAD4-Ha-ras
pathogenetical
VavCre+AtmC/C
inspection/exam
self-cleavage
5
P2-shRNA
Bogenmann
c-myb.Int1.ProbeR
Dpy
33Codon
I-Ppo1-restricted
p.Ser206Cys
R1283M
31-year-old
autoradiographs
cardiofacio
OBSCN
NKX2.1
Onoda
.Byron
non-cleaved
5q11-q35
C9S
three-loop/helix
BM14
Gamma-secretase
N-methylnitrosourea
low-hypodiploid
DE81
SJNB10
subunit.11
why104-1
Intrabursal
p-4E-BP
F3183.29
start-
T681M
F117L
exposed2
.0019059
non-coding
hTCF-4e
706F-BD
12172
translocations4-9
orientation17
NEMO/IKKγ
p.T628S
S3LC
FLAG-ZBP
COG-N-453x
Bindra
swoop
ACC1
therapy1000
duethylpyrocarbonate-treated
Low-penetrant
neurotrophin-independent
cut-points
CI-1040.Figure
5′-GCTGGCATTCGTGATGGAGTCGT-3′
FLAG-c-Myc
p110bselective
cytoplasm.21
5′Fam-TCT
proto-oncogenes.43,44
40,57
of20
Stage/grade
P291fsinsC
hyper-responsiveness
patient.9
PU2
0.001DNMT3A
Immunohistochemial
AML1b
Histotype
HCT116TP53
.Mv1Lu
CBL-mutated
NOTCH2-HES1
ALDH1A1
entity.We
RP11-83D23
IPMN.18
.Entire
immunosuppressed
SENS2
duration.12
13.65
cells.7–9
Michael-acceptor
CDKN2A/p14arf
RG-24
.24Briefly
RTK-IIIs*
VEGFR/FGFR
Biosofware
.815
ROS1G2032R
.TRANSCRIPTIONAL
R319X
5.0months
.Work-up
FLT3-D835V
5´-TTGAAGACCATAACCCACCACAG-3´
CA014520
.Ninety-two
PC-7
Myc–EZH2
Jβ2.4
AFMA288ZF1
eVects
Kaempchen
sc-1521
RG-3N
medulloblastoma
PatientsBoth
apoptosis20
Hs-Dicer.6,7
postsynaptically
HER2-E.
1e-h
Zug
GIST-T1/820
37/54
activity.11,28
time.29
activat­
Asp88
_Hinf_I
met58-4wdmet61-4
End-diastolic
237,342
apoptosis.109
zymosan
Mammalian-wide
LILRA3
GACATCT
phosphatidylinositol-3,4,5-trisphosphate
D814W
digoxigenin-conjugated
Munzel
FLT3-receptor
RTKIs
type-carrying
MODY3
ME1-F
rate-altering
wasalso
BRAF-V600E/K
acetone-fixed
uORF-related
–91
SUM1315
guidelines.18
11:440–9
non-nucleofected
2–96
COS-calpha1
TGF-1
YMC
transformation-competent
apoptosis-inhibiting
etoposide-triggered
cancer44,47
35.2±3.8
23,690
OLIG1/2
sites.1
myc-Rbx1
Rosillon
ZO-1–associated
Glu-127
carcinoma-RET
F64A
2HG-induced
Ratiometric
.C.2T
G643
pSG1-HE0
Merkel-cell
47,130
5-aza-2*deoxycytidine
identified.To
.Deaths
24.00
difficult.31
3-stranded
MutSα-Del745
reprobe
homoz.
kink
TOP1–SMARCA4
Wen-Cheng
pRev-Cdk12
Celltiter96AQueousOne
14,16,106-112
4-4
hCMV
SG-labeled
clinicoinstrumental
shRNA-reduced
4-phosphate
Mac1−
criteria.11
gene.10
338
Hilymax
≥4.8-fold
LGR5+
M600L
Tykerb/Tyverb
2.85-fold
wouldthese
SIMCHEN
CDKN1A48
family.85
antihistamine
p.Cys39Arg
HA-KEAP1
A_51_P324934
recognizesbase
0.0362
HIS3expression
inhibitor-2A
thrombocytopenia.25
p.Ser247fs
CD95-expressing
1462−25A
preganglionic
CUMC
59-GTGCGCTGCTGGTGCCAAC-39
bound-fraction
Rpt
3Growth
c.5271+2dupT/c.5152+2dupT
Varella-Garcia
cognition
GBM19
Boh
PTEN-positive
Bakiri
washybridized
RP11-122P18
109/32
16.44
−Trp
.SRF
S603I
PPM1D540
pNKY6
FLICE/MACH/
M774AYMVM
evi
.SA
CIM-plate
DS-636
high–level
E715
MLL—two
F39Ad
development15
1.60+0.02
118:207–211
NCI-H1770
400-450
12-565
S1297del
84×
UN17
PIK3CA-targeted
development39-42
Histogel
nanodrop
INPP4B-specific
Pymol43
c.703G
.00643733
4563
skin145
leucine/glutamate
Screening—Error-prone
PKB.32
79,86,88
KRAS-Ex2Rev
lane5
lesions169
348–1018
58•4
.FLAG-Elf3Δ235–270
10^10
SspI
.HD
COL27A1-ZNF618
emphasising
.Co-occurrence
group,26
B-J
GST-Smad
network32
4m
S2517
Yn-embedded
FGFR2-AHCYL
ERRB2/HER2
phosphor-C-terminal
Gα11,9,28
PCR–single-strand
TGF-ÃŸseems
370-5
MITF-amplified
CHN
c.5333A
EGAN00001001835
RWPE-ETV5
anti-CBL
Cys-797
16/43
5′-AGTCGGAATTCGTAGTGGCTGTGGGGGA-3′
Shendure
GCAGAGTCAA
1118
p.Cys64Tyr
.Biochemically
FOP-FGFR1
PHA-848125AC
Antonarakis.17
W48248
reports.7,11,12
GCTAAGTGTAGCAAGGGTG
SMARCB1-deficient
o50
.376GA
Ficoll-Hypaque
97:217–224
F270C
17p12
BCRs86
fluorescein–dUTP
.Chin
p.L452P
H2N-255QRSTpST260-COOH
Mailstop
PLCε
residues21
green-stained
Center.DNA
H-RASV12AI
A.M.C
3689
23:49:18
Membrane-associated
p.Arg271Gln
Astrogeneticists
miR-206
Arg-GTPyS.FIG
apo-FGFR4
CACTCAGACCCTGAGGCTCAA
162200
monoubiquitin
B_R455
GTP-MRAS
P=3.9
CYP4F3
Tg-GR201H
CAIRO-2
resistance.Nrf2
genes36
ID7
Viogene
pEF1a.FGFR2b.S252W.IRES.neo
phosphoprotein-protein
ER-mediated
BCL10-binding
Bcl-XS
gene-environmental
.BMS
32,5
siBAP1–5
C_745_G_6
U980
RasY64A·GDP
2345
GAGCGGAGGAGGCAGGA
CCCACCCCAGACGACTG
5.63195
cm−1at
Zandecki
Fig.3b,3b
v1.1.2
anti-Shp2
samples.6,7,12
chr15
4B-E
identi®cation
45
.6,7,9-14
Prehybridization
1anapmet60
morefrequent
carcinomas.19
disorders.29-31,53
Sargin
.Silibinin—a
W355
FTMS
AA410394
Ww45
​JAK2
403/252
Feigelson
minigel
genomes.8–10
system3
Sibilia
.Clones
4-C
.Apparent
pcDNA3-mHNF1A
sensitivity9,22
ECS
SLC25A10
Rad18
X-Gal/ml
FACSaria
UDG
D761
a42
pEF-Flag
siRNA-induced
ibb.waw.pl
FC=1.46
IC75
level.aNF1
30–3.2
Alk5
NotI-NEDD4-1R
observations.2,20,21
L858R-EGFR–mutant
MDS-derived
BRCA2-I27V
Progression4
Re-directing
.Finally
TNF-α–converting
316-nucleotide
Kdal
Ring3
tumors.20
bisulphite-treated
Plat-GP
phenobarbital
KRGEGLLPVRWMAPE
R534C
Wossidlo
SNF5-induced
tetramerization7
36-79
Nrf2-
Over-expression
Nelkin
2044
c.806T
R121Q
Carvajal-Vergara
2Fo−Fc
homopurine
CD20
Influx™
-NRASG12D
,2G
deficiency.25
Vβ
Wnt-stimulated
Perren
A701P
findings—that
nonliposomal
paired-tags
R/S
mmol
7564
1640
32-A-free
E266K
5083del19
RTK–pY
PML-RARα-positive
6-carboxy-tetramethyl-rhodamine
-Dichlorofluorescein
140453433-140453410
spt6
DS5000
CP-868,596
R/Bioconductor
A_51_P506328
5′-CGGCGGCAGACCAGCATGAC-3′
6307
activated88
.21
TLX3-rearranged
271K
spatiotemporal
responses.10
0.5337
S1A–D
=4.7
Figure3F.3F
EMSAs
−5.52
HNSCC-PIK3CA
substitutionlocated
R91L
NCI-H2126
0·001
1.154
CYC1-LexA-op-lacZ
isoform-dependency
14pter
phospho-Tyr-1007/1008
¯exibility
cysteine-free
AT-3
outside/inside
D-MEM
34–66
.1514A
variant,11
ShpK590R
m.w
0.160-1.056
TFIIJ
BCL11A
4.3-9.5
0.0207
CrePR1
PD30
.Correction
79/27
Leu1701
Varnish
bond.11
0,57
21.66
DNA-damaged
+413
.Fifty-one
SL26
c.834_835del
Col2a1enhancer
78·3
27a
TSR-
1:50000
Nanofectin
FLAG-wt
p.Ala4419Ser
adenomic
p.L398P
havehigh
JacksonImmunoResearch
juxtamembrane-cytoplasmic
pLenti6/CMV/V5
ALK2-FKBP12
p.Cys24Serfs∗13
ACAASA
IKHPNLVQLLGVCTREPPFY
affec-
Asp54Asn
protein-kinase-C
E036
c.2263G
tobacco-independent
E009
PARADIGM36
mesenchymal-epithelial
signaling.43
45–110
spQ03164
NM_000245
MGD.2
tumorigenesis3
0.284
CSN
p=0.0877
.Titia
msh2
.Full-size
BRAFinsF
.RPTPp-expressing
7559
332K
anti-proliferation
9A9A
yL
.013
BRCA2Full
p.Ser1389X
TRE-U3-CAGCGCAAATTCTAAAGGTGAAGGGACG
pY845
//jcem.endojournals.org/
B″
carcinomas7,29,30
PI3K-PKB/AKT
88–94
37-year-old
preannealed
6Clinical
.33A
15–35
Asn53
TTD6
STAT140
c.1806delC
KDM6A/UTX
contexts53
histiocytoma
folate
Ibrutinib
2/737
Dhawan
Q928P
HIFα-hydroxyproline-binding
intermediolateral
with300
R474
human-to-mouse
ccgtgccaaatacactgcatgt
excluded.60
1378
methanol-free
.MC1R
Invitrogen/Life
all-β-strand
GluGlu
activity27
gliomas17
TFE3-rearrangements
24hasin
haplotype.47
ER-responsive
OLFACTORY
WSU-HN12
PI3K-Akt-mTOR-S6k–signaling
Other†
2235–2249
1633
periampullary
Santoro
Boudewijn
80–110
K2
RP11-131E5
–3.5
0.95–1.5
RAS/MEK/
c.811C4T
1´IMDM
7-14
.L574L
0.274
62-bp
454–amino
oncogene.B
mCP
CBB
Samowitz
GCAAGTCTTTCAGTCCTGT
MUM+.23
BioSewoom
Wilcken
DxR
PIK3CB-predicted
DOP-PCR-amplified
∼22,000
T341K
Na+-H+
59,119
Wwtr1
618–623
.F81V
9,16,22
pyrimidine-pyrimidone
MYC–MAX
628
c.3332
WT-TOT
G395R
shP-B
L1193V
NP-009125.1
AMLCG92
Ala767_Val769dupAlaSerVal
5′-TGTGAGGGAGATGCTCAGTG-3′
c.3919A
oil-mediated
MDB-MA-468
0.0003052
R321Q
H4A3
KDM5
pcx4bleo
0.00025
podocyte-selective
LFS.19
E455K
DS86.22
A232
MMTV-cre
Ohba
/accelerated
.Nur77
−21.2
97.0
NUP188
WNT-related
EPKs20
sulphate–polyacrylamide
pre-dilution
differentially-labeled
L158Q
McTigue
signalling115
EGFP-p27
R100A
//genome.ucsc.edu/index.html
3/caspase
21/12
mutation-phenotype
ABCC8
Flp-In-293
FIG–ROS-
GTCGACCGGAGGGCAGGAGGAGCAGGAGGAGCAGGAGCAGGAGGAGCAGGAGGAGCAGGAGGAGCAGGAGGAGCAGGAGGAGCAGGAACAG
c.9097dupA
AAK83825
pALTER-Ex1
Clobe
patients.54
8,000-fold
G1738E
ATCCTTCAGCATGGCGAGACTCTT
RAF-bound
heat-labile
TAFII40
gene55
E353Q/F461I
dextran-charcoal-stripped
4493
21258
M703L
.Interruptions
.SUM1315MO2
p.Lys232Glu
GAL4-CAT
monoisotopic
Cli
ENST00000397752
.Software
β-strand-3
Swi2/Snf2-like
alveologenic
26.76
SeattleSeqSNPannotation
R94S
H277P
death.8
Figure44b
LATS1-Y376A/Y559A-myc
Glu-181
Ag/ml
605373
PTPRK
RSPH10B2
E2t3-4
S2215Y
AR+
WWP1-FLAG
.RhoA-T19N
3G0E
CGH4
D22S257
R996C
PK-6100
BreakpointWithin
mMTris-HC1,8
TOP1–FACT
dysfunction.2-4
samtools
solubilizing
ID-2
12–27
SNU-484
beassociated
thereforeView
764/1
DiIC18
GIST-like
G523
B-null
Ile-27
Cerulean-Runt
CTD.77
Tgfb3
550mM
variants.33
Gradea
GFP+ve
2,487
ZG-10
05/09
MSH2-deficienthuman
.GraphPad
Ile301
G1832A
fast-desalting
.Androgen
telomerases
D625Y
pfg099G
pSC-PDGFRA
spatio-temporally
0–46
175,471
RMH2452
degradation15
Ser-751
Fig.1A1A
PDGFRαK
FH-deficient
2/96
WT-EGFR-encoding
MKN-74
amphiregulin
alÃ-elesand
NP_958907.1
13.25
A_51_P196113
-86
.118
Glycine-12
-97.4
ht2
AATCC
.1F
pCDNA6.2-N-GFP
GGG3TGG
.C33A
PreRx
Empix
SKMM2
LMGD
absent/rare
1.26∼3.92
Fra1
mutations.10,27
H1047H
al.,1994b
DKK-1
anti–MART
1-mmol/L
3036del4
WIPF1
6.07
.Calculated
Gsα-Subunit
Caki-1
p11p12
recombination.33
hybridizations.18
patients.Table
cysts47
phospho-PDGFRα
alterations—either
survival.98,102-104
chr9:1-21944952
P=0.139
Jak1-deficient
leukemia.6
Myc-reconstituted
SRSF2-mutated
polyacrylamide/7
lines.36
nephrectomy26-28
753–761
.or
pMAPK3
8.82
SVF-derived
data36
U90177
R195H
Igf1r
.Nishimoto
PDB:2J0J
susceptibility1
4Â
Hoxa7
p53+/-
11.88
.PRAME
p.C531R
PIG3-luc
23-mer
pRelA
H1112Y
TRiC-bound
v-Abl-IRES-AKT1
D10S1751
S445
rad51
system.29
NSEuroNet
PTQLPYDHK
Foci—We
144–154
mature-N-glycosylated
Donnem
NaF3
11/144
2404G
anti-GSK3β
c.1789C
otherrarely
II/3
00020503
osteosarcoma.3
Up-Regulating
5E1—a
.Acini
PHA
KITD1–D5
stop'4
Poly-A
alsoTable
Flag-negative
ATGGCT
ovarian2
p15.5
treated/ALK
Paris-Sud
seven1
6,13,14
PMLPML
17q12-q21-amplified
fumigatus
19p+q
1613
-benzonitrile
therapeutics212
complementaryDNA
80244
36.9-38.9
MDSCs
del25
Tm=42°C
Feingold
IGF-IR
c.576+1G
PDA-exon10F
FBSAG
2RFI
reported23
TGF-β1–mediated
multi-center
0.3–3.4
gcgacagattgaagggcagag
Nonsmall
Dysgerminomas
.Subconfluent
age.48
.28,43
Chemdea
8191
NM_009978
858C
p53RFP
152594
cells/sample
TSGR
CACACCGGTtcaATTGATGGGAATAAAATAAGGC
.CBP
E586K
≤17
GFP/lentiviral
≈3-cm×
H1648
A727V
cerevisiae.33
PI3/AKT
lacZ-staining
Kloos
MOR
factor-115,16
Ser33
Ser112
selumetinib/docetaxel
R271W
i500
indelocator
APCMin
G309E-
DD-Shld
Endophilins
mechaFIGURE
pSer/pThr-Gln
DVGGQ
7647
N=32
reconstitution
INK4-CDK
UAS-P53
7526insT
.Typically
lethality6
Capelletti
pT1/pT2
Chaudru
CCTTCCTTGATCATCTTGT
Limoges
.L1196
mu1164F
,5D
P57
treatment.16
1:28.000
25/29
PSTPIP1
α-catenin-based
96°
S256Ta
GAL4-DBD-TFAP2C
.D1359Y
.RIE-1
BRCA2ΔCTD/con
PolyPhen
resensitization
maintenance/protection
hyper-phosphorylation
NUT-associated
NF1-Ras
NfJ+l+J
p2l-
mutlilinegae
acylamide
7q34–36
534/488
ERIEB2-5
CENP-E
.ALK
Landgren
01777776
ff12SB
F27A
17qter
8.14a
ras-positive
treatment.7
S2F–S2M
repressor–corepressor
c.5158A
10U/ul
L525
heteroalleles
SigmaStat
Fig.6d
invasion-promoting
asbestos-containing
deoxinucleotide
l-bp
A_51_P230103
Val-147
Fos-lacZ
.Taiwan
Ura
bevacizumab-naive
Val-Gln-Phe-Val-Gln-Gly-Ile-Phe-Val-Glu-Lys
Merlin-S518D
yH
.Herman
LAS1000plus
3—
utilisation
HLA-Bw6
processes184
pSG–Flag–LKB1
anti–phosphorylated
JAB1317
occurs.The
EWS/
.Reiss
8-day-old
ERKi
cocultivation
EFNB3
cloned.4-8
lymphomas110
extract/peptone/dextrose
420104
Glc
NS/LS–causing
RNAqueous
phospho-Erk1/2
Irf6
p.Ser122*
DUO92101
anti-ß-actin
pLVX-AcGFP-N1
p85/p110
isoform-switching
.GSK2126458
≥5.0
9.
FRS2α
EZH2-mediated
407
adenocarcinoma22
3332
SCN10A
×82
4299
54*
TR000085-05
Y764insFQEA—among
S335C
Tet-op-Kras
variantswithin17q21
Drumea
GST‐RhoA
27/52
.PIK39
Spencer-Cisek
gpl40Prot'rk
group24,37,38
IL-7–
cross-peak
G556R
epidemoid
syndrome—both
U87MG-based
non-PS
miR-15a
R466C
spindlecell
.Pigmentary
Asn429
117,118,200
453.1
69.2
radioactively-labeled
Jäger
350N15
**P≤0.01
αRET
Abcam-ab32517
VPS45
Hot-spot
activity-a
immediate-early
Salmonella
//dx.doi.org/10.2147/OTT.S81558
pGL2T2
interact.7
Skobe
hMSH2
1-like
B.T.
Stambolic
initiation/worsening
clare.isacke
0.01249
CACAGTG
cells191
p110β-derived
stud‑
anti-P-Smad2
s.e.m.Full
R149Q
124-fold
Lannutti
tumor/mean
PBS-T/5
MYD88L265P–bearing
-Biotin-CGA
~~~
32-week-old
G1809V
Dal
Fip1-like1-platelet-derived
Sanchez-Cespedes
R328
filterswere
860C
n=978
si-Acvr1
.Prevailing
28/50
GST-TSC2
∼3000
mutations/
Mpo
tBHQ
Lys/Arg
p.Nontoxicity
3200/mm3
KSL-SLAM
Graft-vs.-host
eIF4F
chains56
TTTGCCGATTTCATGACT
NM_011496
1:20000
39–53
10768
Genotype
E1121D
37.0–1.40
KFELLPTPPLSPSR
Glu27
15These
Cheongju
AFF3/LAF4
Uesugi
.74
FGFR2-WT
G339D
0/41
twenty-three
exon3-less
FANCA-deficient
T280A
cytokine-signaling
anti-prefoldin
ERFT357A
3N−1
.Dkk1
O'Farrell
ENOSF1
I295fs*23
KMT2F-mediated
9989.An
Cell-cycle
Herceptin-induced
over-lapping
iodide/Annexin
I–
.Huagen-Strano
less-than-average
61st
neoplasms.9,13⇓-15
.Termed
pS3RE
transsynaptic
βA′
5'-GCTTTCATCAGCAGGGTTCAATC-3
611/612
539–760
0.99–12.48
p-SHP2
BICC1
≈499
conditionsHuman
system.11
Anagha
single-nucleotide
surface-marker
genetic-counselling
YChg9F.14
non-lymphoid
members.Figure
NM_031166
408b
.^24891
CT‑guid‑
Klutschko
MAP2K7
.Ron
.7F
death.63
I393T
.Wolfel
11-3′
T754M
TSC2-5A
Glu-931
HEK-EpoR
Monosomal
Cavallone
anti-Paxilin
372-5
biochemic
8-1
17/262
Fbw1
proteinstructure
GST–BTG2-fused
11–470
MUT3
anti-Etv1
ZytoLight
stainingImmunohistochemical
polyposis-associated
//www.usbweb.com
Lbc
Vector-only
Kondoh
607X
H446
R45Q
4.1-kbp
inheritanceDe
−0.8542
sequence–structure
94.51
SB203580
elc1Δ
spondylocostal
thioredoxin−interacting
cells—Dulbecco
E221Q
patients26
0.8378
743-bp
0.734–1.568
Driel
regimens.1-4
NZM6
pcDNA3-MLH1
BRCA2,25,26,42
S215_Y220del
S136A
LAS4000
CosmoGene
Doye
CMM
M280I-myc
pNeh2-GFP
family32
significantcorrelation
Co-transfections
244–285
U-E3
NM_000077
.Concurrent
translocation114
Phosphotyrosine
NEJ002
MYCNT58A
single-spanning
statisticsa
truncation.6
6.5Deletion
IVS19-12G→A
glioblastoma-specific
K97M
in-vitro
FLT3-WT/CBLG375
8704
fusiongene
0.31–1.9
♦
S1448G
β-tropomyosin
NRF2-WT
R322C
1YO5
AP-1-responsive
56.25
Q1573*
7H-pyrrolo
HER‐2‐overexpressing
NT2D1
≥20/25
Vif–CBFβ–cullin
G58
.cohort
0005
smallintestinalGIST
L15
S580P
3-phosphorylated
.Stereo
glycine-serinerich
Myseros27
TRAF6-deficient
D814L
0.403
9,168
nucleotide-excision
LIPI
Lymphoprep
skincancer
Single-cell
Bischof
intra-S-phase
I869
≥14
spice-site
cytotoxicity.26
L858R+L838V
p.Gly44Ser
Loladze
Stongylocentrotus
wing-like
JH7-JH3
R07-401
near-UV
self-reporting
66-bp
Geconcerteerde
hotstart
XPO1-YFP
CD8+
microsinteny/microhomology
IVS24–
Aberger
conjunctionwith
Ras.6
PucSBC1
PHA/PMA
1:2:0.8
AsnLeuLeuProGIuGInAspLysM*tLeuVa
digest/subcloning
preincision
450nm
p.Q22K
rad50L1240F/L1240F
ml/kg
F235
NOTCH1-mutant
disease.14,15
Figure3a,3a
GCTGCAGAAATGCATCAAGC
FGFR4-Ponatinib
radiation-associated
Lys428
acid−agarose
DNAmismatches
5′-AAAACTACGAAAGCGGG-3′
F1200I
0.3mg
Romashkova
pRRL.sin.PPT.hCMV.GFP.pre
shRNA-Tet1
LiftOver47
ERP002035
anti-virus
samples,26
upregulation.16
counterproductive
2.23–66.88
mutnat
SPT5
histopathologists
*Died
.Cellswere
a/b
RSCU
c.3164delG
0/12
S21/AS21
APB
14q31
TRK1/2/3
p110α107
arge-scale
Potencies
20/6,412
9and
Fahl
C4-Reverse
evolution1,2
unfluoridated
snps3d.org
GATCCCAGAAGCFGGGCCOQGCTGACCCCOCGG-GCGQ
Lys27
-translocation
resorptions/stillbirths
GST-FERM
37133–37563
H2AK119
5′-ATGCCTCGAG­ACCTGGCTGTC­CAAGAAATCC-3′
cT1N0M1b
97H
differentiation26
5·9
double-helical
76.06
.Brennan
ligands196
p.Gly34Val
Na-
cellsexpressing
flat-bottomed
7I–J
769-bp
9D14
α-chains
0.06/8.2
V204
n=4,355
c.1994
7.9,1
ClusterPatient
diYcult
4,787
Myc-nick*
whole-genome-sequencing
radiographies
knrtics
tetramethylrhodamine-5-isothiocyanate
imatinib-naive
1.5-184
121/123
cross-braced
859A
T02
omni-tagged
.Nor
.Fischer
MO_1036
Signi®cant
Abl
dpp
.Delattre
OKADA1,2,3
'In
nt258
13.5¡0.8
SPOPBTB+
erbB2-overepressing
ATCGCATTCATGCGTCTTCA
ADE2-selectable
anti-PI3
.RELAFUS2-RFP
ins58L
NL-23
R988C.Met
approx80
LacI-CHERRY-BRD4S
translocations/gene
family.29
P101A
arrowG
9363
NIGMS
leukemogenesis.Our
5-GACAGAGCCTAAACATCCCCT-3′
∼80-kb
Dimmeler
Valensin
IVGH
5′-extended
trk3
C40
apoptogenic
CTCTCCCGATTGCTCCTGTGTA
AK093407
EGFRL861R/Q
dasatanib
784–786
Y1349
CSF1R,4
R419H
TGTAACCCTTTAGTGCAAATAAGAG
Ganesan
DNA-PKi
glial-specific
pECFP_C1_MLH1
amino-
malignancies34
R465C
Ex1
.MRD
34:397–398
Agoulnik
.IMCE
Peroxidase-conjugated
.Immunophenotype
pCSCA
0.7377
\20
R242T
90.734*
ubiquinone
sequences.For
DO-7
homology-2
D2870
.RE9
408G
E1379*
verprolin
anionic
CLL02
55.8
NIH-OVCAR-3
decribed.8
0/42
distributionFIGURE
FGFR2—The
wasunremarkable
ascomponents
1—5′
−3.55
UN10
T457I
Belakhal
N771GY
N1270S
colonospheres
35–80
.IG
2009.1
experimentation
M59-L
CDKN1B.1
antidigoxigen
isoprenaline-stimulated
G9A-like
sumoylation
Caspase-Glo
Emsley
DF53
oxynucleotidyl
specificmismatch
Kru
MeUb
nitrosoethylurea-induced
anti-pEGFR
Therapeutically
hexmer
24,28,42,43
RCV
CDK13
5′-TTCCCCCAAATGTCTGACTC-3′
here.21
tyrosine-kinases
IVS2
novo–type
reported15
.NRP-154
2.5–17
CD4−CD8−
STAT2,8
B*070201
/Bcr-Abl
.LNCaP-AR
PTEN-null
kcal
Termini
Bcl2-modifying
case-numbers
MWG-Biotech
KPFITLAKVIQSLAN
A.F
Marrow–Biopsy
triethylamine
K402Q
observed.1
activity16-fold
S4H–d
TAZ
Gen.
PI3K–PTEN–AKT
.Nox4
sites24,25
conditions.In
MAC1+Ly6G+Ly6C+
Fobs–Fobs
G92V
tttwttttag
.Deleting
7-fold-increased
V263
Brca2Delta27/Delta27
L257Raf-1
sunitinib-resistant
RO4987655/CH4987655
E-20
Vismodegib
RING-located
Safran
MutS,4
L94R
polysomes
deoxyribonucleic
anti-WWP1
SCF37
Neurosurgical
619G
0.04739
18,36
fetal/neonatal
signature.38
26/2
Deauville
ALK2-transfected
81.4
cancer-cell
unstim
SE.Ectopic
p.Y272Y
chemically-induced
Sec14
MEKERK
Codenaturation
Analysis—Statistical
erlotinib.35,38
random-coil
GW583340
CDKN2A/C–codeleted
RN-D
p=2.4e-11
MNX1-ETV6
Y35A-D65A
FOXO1/3a
ATCC-LGC
GAAGAG/gtaaga
chr5:67589663
6/78
Ser240
hook-mediated
L620F
subcomplexes.25
Mx30005P
84.3
longer-range
complexes119
.Trans-activation
FRS2α-8V
chimaerism
AMP-PNP–bound
rearrange­
Y653-1P
E4Y
9-3
+20
Arg68
gene29
G63K
W48R
20–40
same-passage
TexasRed-conjugated
C-N024
Notch1-transformed
cancers.11,20
Exon30
Figure10,10
0.598
Bifluorescence
c.613G
1145H17
MCIP1
64–66
5–10
pregenomic
JAK2-TEL
bigenic
3J–K
.CTNNB1
Giemsa-Wright
26472747
microvasculature
V433L
pRS305-p53RE-Z
pcDNA-derived
R988C
Sq-1
MET-mutated/amplified
q13.1
algorithm.29
sunitinib
rmIL-7
G776
c-myc.Luc
WNNNNNNR3
Arp/Warp
W183A
-polymerase
DRB1*04:03,12:02
64-5
electrokinetic
CBF1-independent
-TGG
HMGA2-RAD51B
Tsc2–/–embryos
PMF-like
studies37
0.01–0.05
Alk1
hierarichial
Clin
A47V
._
Cterminaltruncation
412–448
mice41,42
82,104,118
AIDS-induced
IVS27b
PDGFC-mediated
PDK2/ILK
GTTCGATCCGTAACCGATGT
p11q12
procedure.24
NCI-H69
pencillin/streptomycin
IgG1-AP
5‐μm
process‐matched
134K
Geno-way
GDNFs
Rad53p
bone-metastatic
MDa
cotransfection-transactivation
denaturing-high
`a
TAL1–NKX3.1
PIK-E9MF
0.286
3-nearest
p.R201C
deregulator
relationshipof
therapy,29
MXP
subunit-B
solution-based
.808T
10326
pentacovalent
breast28
-2.5-diphenyl-2H-tetrazolium
KIT-coding
context20,21
non-glycine
vivo123
hMSH6-P1087R
.Soon
MutPred
1–22
loxP-neomycin-loxP
0.300147
*20T
C/EBPα-deleted
L74F
c.4987−1G
43/F
half-rate
humans,29
lineages25
Alox8
TGAACATAGCCCTGTGTGTATG
Disease*
5'-TCA
.John
WNT10A
®vefold
D22S421
Foxa1-null
sc-292838
.Postreplicative
10–1000-fold
strainscontaining
PP58-induced
GAPDH-CR3
SK-MEL-5
5Ematologia
anti-phospho-SMAD3
Mir196b
AL-F.M.
background-adjusted
.1610C4G
CD69lowHSAlow
Cap-binding
rs121913465
neuroblastoma.17
RA50AT
-/-transfectedcells
1,733
Higashijima
parrot-beaked
EcoRI-NotI
pmoles
CBL-E2-S
5411
Lac-switch
2982
analyses10
PSK
BMI1-PIP4K2A,16
2350
06-759
GST-precipitation
m6A
Accutase
RT-PCR—RNA
7SL
D3-containing
2YFX
cyclinD2
kinase/lactic
SNAI2
Stamatoyannopoulos
.47y
sub-lineages
Ala.10
g.pals
ACA→ATA
ENPP2
PBSA
SCL38A10
colocalization
.KDM6A
1875
GTPase-dependent
Crohn
Peifer
.Phospholipids
WW-PDGFR
2.26
21,160,372–22,679,068
poly-
22-ID
−13.4
3,800
TGI
CG0074
and24
NIH3T3
29445273
Hematology/
S566
5caC
Najumudeen
V906M
GTTTTGCTGAATTGCCCAAG
Q117R
PI3Kγ
F1174C
1.ETV6-NTRK3
RUNX1-I41F
Herschman
breast/breast
β-NADPH
c-erbB
ITD-reads
.Safety
0.000115
ATF7IP
Trk-T3
asloss
F1332
FPP1
reads/total
dual-color
TAZ-promoting
kappa-light-chain-enhancer
z-stacks
TruSight™
maq-man.shtml
7.17–14.2
K721A/ErbB4
flox/flox
0.21/0.36
cyclin-cyclin-dependent
30.10.15
//www.motif.genome.ad.jp/motif-bin/nph-motif2
5′-TGCCATAGACAAGGTGGAGA-3′
corticotropin
Asp65Oδ1,2WT
Events‡
1/126
Monza
G7341
1T4622
CHCl3
A1519
CAGGCCACCC
S366A
Ras-Erk
p.Asp539Glu
61/M
pY653
.PI
Non-TET/ETS
B-NHL.30
//www.tigr.org/tdb/GeneSplicer/gene_spl.html
L166P
68°
JAP
26-3/4
virus.These
Recalibration
676G→A
POP-1
NSD3/LSD2
17/292
TGFbetaR1
–mutated/SF3B1-mutated
tight-junction
Transferase
phosphorylation,25
pCS2-TGFBR1*10A
a5
±393
germline-transmitted
4046–4049
Micro-FastTrak
D1–specific
detected.6-8
PDGFRA-V539E
ish
forma-
G902E
V561M
1524
MCA203
protocols/ethical
B/NK/myeloid
18/78.3
dephosphorylating
surveillance8,10,12,13
theATRX
.FANCB
400\
JAK1/STAT5-activating
coinfection
PC-Associated
NM_007294.2
Connell-Crowley
stillunclear.ß-catenin
pathways28
®broblast
neurofibromatosis/neurofibromatosis
L692F
N-­terminal
F730004F21
UPCI
ETV1-overexpressed
15Heterodimerization
Histolab
HCC1937−/−
mmole
glycoltetraacetic
intercistronic
HPPS-like
07-434
0.1/field
subphysiological
LAM
Smad3C
method34
8.18
TYROSINE
degradation21,40
Nistér
myr-110α
domain-peptide
System.72
c.2312_2315del4
'CDC2
L237P
Domany
Emx1-Cre
REA1
−5/del
desiredpolypeptides
.SMAD3
E025
g
FAM-TGCCCAAAGAATGTCCCAAAGAGA-TAMRA
5'-ATGAATGAGGTGTCTGTCAT-3
affectedthe
1.5Mb
Logix
phenotype.16
470M17
all18
P110δ
PDK1
BCL-2A1
CUL3A/B
types40
resultssupport
Hoeffer
diamidine
0.527
Catnb
PHO
AE1–AE3
Q165
.Pilocytic
RNaseP
ALK20–22
tested.4
.Lamarckian
6q12
2500–4500
cancer.6
francesco.hofmann
70°C-
.Rabaptin-5
pancreatitis-associated
Oct4
93–95
.Inasmuch
γ-K255E1/γ-K255E2
hospitalier
2-4
carboplatin/liposomal
.Hypermorphic
FYN-B
.Bayes
BCR-FGFR1
nihms703640f13.jpg
4355
Hnf4α
343K
3OOM
19–42
Centri-Sep
CAGAGCCTGGCATGAA-3′
huntingtin
Low-quality
E174K
sequencing-grade
S3J–M
S1–S3
GIC-1123
bydensitometric
Y274
Lin−Sca-1+cKit+
.Lapatinib-induced
Del747–750
22q12-13
19q
−65.4
97°C
FLAG-AKT1
p.W521R
CellQuest™
Depigmentation
T-Lymphocytes
5'-CTCTCA
Fug-III/13
.Sgcg
-md
XNP72
156/113
cancer-relatedgenes
Garcia-Rostan
www.molpathol.org
L703P
miR-34,20
55-mer
0.0005
-dGDP
.ARNT
immunoscreen
Leukocytosis
238-bp
D-04
19.0/21.9
superTaq
Yunsheng
ng/ml±926
polycythemia11
theyretain
SK-LC-6
605×103
9g
maximal-LOD-score
ID14
TTCATGC-3′
High-dimensional
contraindication
G387A
extra-intestinal
Release—Previous
Benjamini-Holm
.S7C
NB3
residue.38
Legius
p53-Y220C-dependent
development51
G37S
57.79
E.Most
G881D
–57.9
WT-EGR2
HCXXGRXXR
1.0-Gray
TGFβ/Smad4
L140V
p.Tyr42Cys
//www.hgvs.org/mutnomen
Motegi
3•75
MSCVpuro-HOXA9
*Presence
.PD-901
trial85
RET-PP1
re-channel
Asp77′
sulfomucin
TGTTTCTGCTGTCTGTTACTGTCAC
piechock
ViraPower™
pcDNA3-HA-p73α
.H3K36me2
9006
safety,40–43
5,7,8
−1938
.Intercrossing
anti-DLL4
rangingfrom
Mcm6-positive
R167L
T231M
34×109/L
2*
Akt-Myr-R25A
BH123
CRC-6
PDGFR.9,26,54,55
F124L
−602
p.A36P
TrimGalore
conditions10
associationwith
GGATGTTCCAGATGGCACTCTGG
.Infection
Cibulskis
LOC650095
106,107
P3
Rat‑1
/chamber
5′-GCTGGCGCTAAAGAATAACCCACCTTATATCTTAGAC-3′
14.6-kb
CS-04
1μg/mL
KITD816V/H
immunoregulatory
miR-194
anti-PEAK1
D.S.X.
KRAS/MAPK
/ERBB2+
hybridizationofprobes
workhorse
third-site
GCCTACAAGGAAAAAAAAGACA
E353Q/G442V
.BU
S362C
.Obs
7095
coactivator-bound
crystallography
co-immunostained
PGK-Hyg-STOP
orthokeratotic
GIBCOBRL
aggravate
TNBCs.AKT
Leu34
*191092
KRASe
B56δ-Aα-R258H
TER119hiCD71hi
cpm/ng
Green-labeled
T529A
Stojic
Terminus—
γ-Fbxw7
lengthp53
FoxO-dependent
SAP130
theresults
NB30
p190-rhoGap
pGL4.48
R661W
+Hh
nKIT
TOP10-competent
PFU/cell
M243L
TSC1-mutant
R273
STAT5,32,33,35,38,50
steatohepatitis,3,9
3–23
1–31
phospho-STAT3-
site‐containing
vasoconstrictor
c-ABL-Ib
HLA-B*44020102S
Chr1:5753010–5953574
80.9
domain-activating
Argl98
studies9
TCGA-JW-A5VL-01
.AdoMet-bound
another13
HC11-puro
Sanchez-Contreras
galactose-induced
myc-BRAF
7.5-kb
P134S
25-59
pY-dependent
WM3248
6005
AA-3555
myr-T305Af
G328W
anexin-V
EGFR-targeting
S72L
TSC2GAPa
=0.002
Volocity
78/203
Colussi
S1go.R-K-R-P-R-P
SuperFrost
externalizing
PIM-1
form4
Hinge-2
1alpha4
−1.58
noCyR
Z-series
Atfi
2155
PUR
Bcap-37
28.9
variants—p.Q76dup
patients.Short
AAATTGCTGCTAGCACAGCCCAGCTTG
E2A-binding
Il7r−/−
APC-coupled
Dysregulated
ENST00000218147
anti-LATS2
non-dividing
13Department
TGGAGAATAGGGCTGTGAC
ataxa-telangiectasia
ceroid
5′-TTTGCAACCACAAAGGTGAC-3′
Nuclear/cytoplasmic
pRb-positive
NG_007459.1
AquaPoly
chr12:84295335-84297989
structures.52-55
SPOCD1
MyiQ
serum-deprivation
FOP-FGFR1-expressing
cells222
p.Phe39Val
1759–2285
Kuroki,1,2
organs24
C2646T
0.4ug/ml
1:750
Diagnostica
SuperMix
Dom34
7/14/99
IV/I
21-day-old
Tabata
−10.3ANGPTL4Angiopoietin-like
Kinzler
V-fluorescein
bp.22
phenylether
micea
subtype102
o113
volumetrically
GC-induced
Unite´
ATP.Previous
c.244A
5′-GGAGCAAAGCTGCTATTGGC-3′
∼104/dish
.Majority
differentiation10,11
promoters,10
.Sixty-five
.Molecular-Surface
FGF–FGFR
CCACCATGGATTACAA
it42,43
B″/PR72
monontherapy
activity31
methotrexate/vinblastine/doxorubicin
1.1.9
E2F3-dependent
nonproliferative/arrested
dephosphopeptide
saliva/blood
EDTA/2.0
BD-LSRFortessa
YCC3
deconvolves
C21-steroid
Si1
.Freeze
Iq41-q42
Cys775
hypermethylation.26
pericentromeric
LS-NeQvLrfVmEGg1
protein-protein-interactions
mustard-induced
GermlineTP5
-105
HCC827-50GR
Ph-like
domain28
100/
2.930
photosensitization
Q61.3Ha
RUNX1-regulated
R327H
Monoyer
E1wt
2639T
TGTGGAGATGAGCAGGGTCT
tetracycline-regulation
134:873–882
mutations.6
PX458
gtaagagga
H93R
aspartate45
IRF7
Breslow–Gehan–Wilcoxon
p53–ARF-mediated
D641G
foci/cell
change-of-function
potential57
Postdoctoral
198/182
KrasG12Dcompound
TM4
al62
AACTGCCCATCA
.Rat-2
C-cells
NKX2-1-
_EGFR_
L*
163C9
granzymes
erlotinib.79
G138E
Observational
.Intersection
informativeness
DKViewHome
_
Cmax
HNPCC-afflicted
NI-ESE
hKIT-Y568-Y570FF-D816V
20,474
IDH1R132H-expressing
QoD3/wk
~Cheng
mutatorâ
45,41,28
interactionbetween
indep
enteroblast
patchdock
**P50.011
0.49–0.84
710
n=138
4C02
vendors/sources
mostalterations
HA-IPs
206/286
sonographic
5′-biotin-GATGGTATGTCATGTGTCTGGGGAGG-3′
68.1
WORKUP
.Families
Stk11/Lkb1
.12,27,29,40
MRSE
.Co-crystals
21.9/14.0
0.0017*
fam
AFIP-NCCN
Colgin
checkpoint-deficient
C2C12
FAM-CAAAACCTGGCTGCGTGTCAGA-TAMRA
double-phosphorylated
F5R
endomucin-positive
IPA
ACCTG
mutant…
pCCND1-T286
TP53-positive
ISG15
Burroughs-Wheeler
efficacy.2
FK506-treated
anddinucleotide
comigration
DiCorleto
Odense
0.84-1.43
173160L22
5′-AAACATCACATTGG
Asp-30
Bachelot
2853
Q61I
follow-up.We
1676RGTPL
3438G
homogenate
p.P286R
WWTR1
B-RAF-mediated
32and
Agilent-provided
Suzukawa1,19
Pro250Arg
multimerized
141210
affinity43
.Genealogic
Val786Met
4266
posttransplantation
Ordi
Inazawa
Kaiser-Kupfer
-+-+
89–92A
766
Co40
9–11
laboratories,15
80131
29,37,38
MB/PNET
V1298D
luminex
PDGFRA-driven
Ba/F3-V536E
.Preservation
1∶150
17q22-qter
KITnegative
pathway,11
Br52
2Fclincanres
CEP110-GFP
Riggi
dimer.2
HSD
Vpr-binding
marrowWe
254K
eBLOSUM62
apposition
NCIH446
Clonacell
Cobleigh
GSTMEKK97R
anti-ERCC3
M-A2S1
Argl443ter
monomeric/dimeric
phoshoinositide
UnifiedGenotyper
M296I
TET/ETS
system15
H226*
549–582
c/well
66.7
surface5
7N
pathways.15
lambda-Zap
N510K
265-267
400-fold
Glyl63Asp
therefive
4/39
MMC-2
0.0006*
Megabase
algorithm16
PtdInsP
married-in
anti-Cbl
.Apyrimidinic
drug-sensitizing
Intramural_research/Lab_transfer/Bic/
noteliminated
fibrillization
.Ectopically
10p11.22
ED50
Ka=0.44plusminus0.07
Alcorta
NFE2L2
wild-typeK-Ras
restoration132
57.BRCA1
ppMEK
Benhamou
Duet-1
14kDa
N480K
DHRS9
B,1C
R571
E2-C
MCDB105
E547K
PHA-665,752
87.3
targetting
K120A-15
Well-Differentiated
Grb2.36
EGFRtargeted
4859
high-yielding
Melan-A
TP53BP1
0.4–12.5
MYCNA
5′-ATCATCTCTGTTCCACTTTCG-3′
1-453
activityresults
GST–Crk
MUC5B
Badache
.Recognizing
cDNAinsert.negligibly
NTAD
20–2000
GSE1481436
,7b
Becton-Dickinson
10Division
AS604850
Fbxw7fl/+
L858A
CD99.2–4,6,7
System–horseradish
nonglycosylated
50-U/ml
.S2A
V600E–V600M
.urothelial
V600E-positive
López-Lago
HOMOLOGY
∝
α32P-dCTP-labeled
S1266T
Anti-Gab1
ΔDNMT3B1-4
CS2965
CD38
SDHB
p135
SE/QPSMT
TITC
mutant.
Oncomine
pGEX5.2-HNF1A
very-high-risk
ARID1B.2,3ARID1B
.GeWtinib
GGTCTAGCTACATACATGAAATCTCGATGGAG
.Wholemount
GISTs36.The
FoxO-recognized
RTW5242F/R
Y227N
​All
INTS1
P206L
GST–TNRC6B
∼90
AIM-1
A6A
.Shen
7.38
338,419
P11
binding16
LabChip®
EZH2-RAD51
element-LUC
Unsal
squamous-carcinoma–like
Areg
Amersham-Pharmacia
Detector-based
-FISH
THPO-mimicking
receptors18
59-AAACAACAGCGAACTTCTCAG-39
AAT44833
PDGFRB-PRKG2
dMutation
underconditions
R500Q
SimplyBlue
.ND
3204
Dacarbazine
.Inappropriate
EC50control=0.155
p85αdelK459
www.UMD.be
lysine-119
657
53106
c.2288A
Shigalas
41*
.Coli
.Pathogenic
inhibitor
Oncology—Coimbra
c.1059_1062del
.Transcription
hTopoIIαS1524A
95-I-0066
response/progressive
p.Ala60Arg
G1961E
n=492
transmigration
Y850C
toxicity.23
ALK+ALCL
KYSE-30
others.22
.Li
.Residual
leuB6
Chr2:29432655
p.L1804fs
connexin
OR=0.97
A.E.Right
83K
RSI
7112
-3-dependent
.16–.25
pAR-D551H
G2/M
Poly2
ARE2
predomi
null462G
Aniline
1–3/1,000
RosettaDock
.JEKO-1
ofHelsinki
μˆi
vitro,4
28-day
C112S
Dotatoc-PET/CT
Monoubiquitylation
Q1033K
EpH4-derived
oncogenes
periarticular
HAART
D2S123
E1β
loop-binding
AYdup
digestedseparately
noncompartmental
Tables2,2
4.28
Greulich
method.ImmunohistochemistryParaffin
1=fewer
GISTs,3
β-Galactosidase
deg-
DNMT-inhibitor
rs5762764
EX15.1
irregularities
–HCl
homodimers,16
ht2–4
poly-arginine
5′-AGCAAGAGAGAACAACAGTCTGG-3′
AML-M5b
pHcGAP
Stat1/Stat3
'Further
H3k9me3
human/murine
GSK-3
STK11/LKB1-hemagglutinin
found12
vertebrae
63Â
sites—prevents
counts.85
cancer.11,12
Carlbad
glutathioneagarose
cynthia.hawkins
V1248D
Anastasaki
tuberomammillary
wholegene
NMTC1
1.81
BU1/75-ICR1
CD45RBloW
n=37
anti–phosphotyrosine-PY99
/T
TruChIP
CompleteMini-ethylenediaminetetraacetic
27/55
pDsRed
3009
protein-to-creatinine
0–68
anti-HSC70
PECAM1
7029
p.S480fs*47
Gillberg
m/67
Colonos-copy
36†
NRAS-driven
Stat3+/−
RANB2-ALK
Seodaemun-gu
0/6
24/56
GGGTCGTGG
1–233
power22,44
pTyr1003
©FUNPEC-RP
15,000
L844R3
/ethyl
SHC3
pZipNeo
Intermediate-1
MLL-mixed
Pdx1-cre
9:1
carcinogenesis.13
Biv
CDK2-p27tail
multiple-anomaly
Phe65
cycle9,11,12
macroadenoma
proerythroblast
Asp835His
PI4P
receptor-codons
1–750
0.11-13.54VEGFA
.Inoperable
let-7c
doi:10.1016/j.bbrc.2011.10.154
STAT3-luciferase
deoxyoligonucleotide
yCA23
regions.SMARCA4
S3P
female/male
30–65
HL/
post-thymic
activation.1,54,56
28.7+1.7
codingfor
individuals.Pedigree
Phospho-specific
leukemia13
Front-line
Chung-Ang
VP229
0.353a
7782
Motoo
anti–IgG2c-horseradish
BC062343
M394I
non-clustered
NHA
MEK1/2
5′-TCTCGAGTCATTCCAGTTTT-AGAAGCTCCACA-3′
5-Fluoruracil–treated
lines,7
Φ-Π-S-S
MIC-1
NM_003400
post-BMT
bicalutamide-resistant
p.G469E/A/R/S/V
suggested31
RPCIB753M0921Q
12/21/06
1,019
immunoreactive
.Gefitinib-inhibited
0.979-0.992
transciptase
type-specificity
remineralising
www.biobase-international.com/prod-
differences7
K52R
DUAL-luciferase
methyl-3H
GNAS1
GAP–Arg789
cl.1
Satake
.Stemness
log-scaled
Y7_G130del
g.39051253A
170.8:1
Lorenzato
prcomp
B-cell–receptor
KCl/2
P130S
androgen-response
c.3323delG
sez
Vaz
215–236
OHSS
RPCI1,3-5
long-lasting
SPOP-CUL3
pGEX-4T-2
BMP-SMAD-dependent
Omni1-Quad
S611G
lymphocytes,21
54.64
II–IV
617=V617F
​and6D6D
p210wt
cytosol49
encouragement
GTTCTCGTTCTGAGAAAGAC
K27M-H3.3-mutated
NCT01703481
A06
3103
I2500F
L5-S1
.1241
med.okayama-u.ac.jp
1.07–7.8
anti-MYCN
Y1902A
SK-Mel28
translocation.The
houirs
8/127
1P3
adhesionmolecules
c‐Myc
H165Y
p-STAT5
hOsa
PDE5
764a
Pin1
nestin-Cre
FADD-like
anti-Flag-FITC
0.895
CGH/SNP
Cancer/Mycoses
CDC4/FBW7-induced
single-targeted
_NRAS_
IPI504
non-β-catenin
9.86
performed.26
.Liang
estradiol-dependent
:6825–43
MYD88
significance26
factors.4
kinase/signal
ALX4
3−6
MEK1P387S
P0032
R177*
progestagens
.Lorlatinib
STAT5-blocking
1,000-fold-increased
.Fbw7
~Kd
SHP2-V5
MED12-002
-expressing
.MED12
potent.27
V150M
AZ628-sensitivity
V115A
finasteride
CVCL_1174
MALLOY1
F4,123
802G→T
SIN-1-mediated
PLCepsilon
Rheb-Y35N-expressing
5′-CAGGUCAAGAGGAGUACAGUUA-3′
/1000
–infected
F1761I
butmay
Oncotest
.Plat-GP
.Neighborhood
Ser396
Iak1
l4:18
FaDu
α3β1-expressing
5′-GAATCACCTAGGGTGAGCAAGGGCGAGGAGCTGTCC
.C-terminal
..±
desmoglein-1
Jackson/Stratech
well-establishedprognostic
metallothionein
Grandparent
1q21–22
pCMV-neo
anti-TRAF6
240,802
c.8363G
MYEOV
Viglietto
S298
NPY1/MAB4/ENP
Plzf2
acggatacagcatatccaag
W162R
WT_l
-mercaptoethanol
5′-CAAACAAATATCCAACATCTAAAAAAAA-3′
.SWI/SNF
development32
PTPRT/C/D/M
12,13,14,17
FASMAC
.Testing
Committee–approved
Hassig
TCGCTCTGGTTCGGGAGGCT
S:19
Chemokines
c.581G
P69
C18R
CTCL
v-ros
1.068
BCG-treated
cell-cell
1279
available1
Cuvier
glycosylase.Figure
AvrII
P95L
mastocytosis.11
213-217
Benanti
later-onset
S25B
3386_3388delGTG
BCL2L1
SGK3
Instech
cosedimentation
FASP
V1673F
.CONCLUSION
S1-3
bromo-domain,23
CAACAGATCATCCCATCCAACA
E402Q
defect-specific
expression/phosphorylation
pendrin
decarboxylate
GBq
Microtubule
twowashings
17389
s/he
Leu1521
leioblastoma
/SzJ
YVKPQI
Smad/Smad
adamantane
N=44
-p27fs177
scRA2
p.Val600_Lys601
Donryu
.Modifications
guanidino
m2–MY18
3/94
variant120
p.Val1283LysfsX2
N-azolylacrylates.22,45
MxCre
5′-AAGGTTCAGCGGCAGTGGAT-3′
Ser548
12-well
pheochromocytoma–paraganglioma
NENT100
anti-Mac-1
Pashkova
leucine-rich-repeat
S473-PHigh
survivalResults
vehicle‐treated
PR+
7,18,19
75461
H53
4d–6
XIX
rs150454821
.Y570
9-fluorenyl-methoxycarbonyl
CAAG
18–26
5′-TCATTCAAGGCGTACTTTTG-3′
R250
MegaprimeTM
26F
Lines—H1299-derived
anti-IFN-italic
31/35
metastasis.19
PF-SE
5′-CTG-CTG-GTG-GTG-GGC-GGT-GTC-TC-3′
.OMIM
R175Y
Jackson–Weiss
R49LT
149–180
51–72
K59
5′-response
p.P81T
tor2
Post-enucleated
ddG
45S
190-194
DNA–lipid
schemata
.detailed
Kiliryuk
0–13
Sutovsky
2.11
DIA-H05
.Validated
104-R20
beta-glycerophosphate
inhibitors61
TACACATTGTCAAG-3
HLA-DRBl*M
0.2–14.0
s.e.=0.196
Unknown/NA
Hebbes
Reconstituting
MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYL
PC3
Discordant
cyclins.6
21.360
25,27
RB1-mediated
hydroxymethycytosine
ubiquitinated-LATS1
DDB2
NZM38
spi1-expressing
13.27
TTCTCTGCTTCCCCTTACCT
clinical/radiological
0.9696
A8K1U7_HUMAN
self-inhibitory
deviation.CAL
plols
pcDNA-BRMS1
KMT2D-bound
58–70
NSCLC.64-67
theFANCC
componentsPotential
CI:1.4–4.3
A572V
unlikely.The
4-μ
/Eiger-dependent
Rb–/–
A1536
ZNF198-FGFR1-mediated
R394W
RIPK5
5QO
His105
HM48-1
regu­lation
c.685C4T
92.000
IFTR
line.18
biocomputing
Spectrophotometric
cis-Golgi-marker
d'Etude
lysyl
WF
MLL-ENL
GQ60GK
.121
TTTA-30
causespecific
E-cadherin-specific
S487P
vesicular
CSU
DNA-damagedependent
A69C
Gln130
2249G
-log
/pH
1.0–1.3
GRM
41–50
441X
p23-p24
Δ-derived
MC1568
gtc-3
.Ordered
R971G
Cancer-significant
MCPH-associated
non-measureable
xypyrrolidin-1-yl
Dilution
56780592
BaF/3-EpoR
two-armed
9p24/JAK2
inthathecal
Gradia
Pml1
transregulatory
low-adenine
10‐fold
michael.brattain
Y1586
6×
R102P/F104S
PKRG1
VhlR/R
.Unaccompanied
L798H
C-statistic
3-mm
Xi'an
p21-responsive
E992
c.538C
gaacagataaataccaaacatacagcaagaaac
D-loop.Topoisomerase
−0.82
LY294002,16
PAF1
429K
mutationDeletion
reduced-ligand
EGFR-KDD
83.47
.AKT2-I289M
-hu_p53
5′-GGGAAAAGCTAAGTGATGGCAT
EcoRI/Xhol
CAGGGTACATGGTGGTGC-3
.Intrinsic
geldanamycin
A490nm
DIMH842–845
.Ral-A
immunoprecipitation-sequencing
:CreERT2
hTAFII68.70
GCAAGGATGGTGTGATCCTTTAAGC
26.32
aphenomenon
Ser582
CMK
S.N.P
DDIT3-WT
Arg/His
56105
less-severe
//bimas.dcrt.nih
Wizigmann-Voos
previously11
Formapure
CLTC
B104
myristoylated
anti-pThr
//www.umd.be/BRCA1/
p=0.377
1α-myc
semidominant
AF206
53bp1−/−
agggagagguggaggauauTT
Rbpjflox/flox
agr
6/18
LOVD
Bacchi
SP100
RAF–ERK2
NSCLC-related
.JMML
imidazobenzothiazole
Lys295
92A
μm/h
lines.18
1251-1500
Cellgro/Mediatech
Waehringer
absentia
ATR-disrupted
codon-frequency
abnormalities31,32
3I7Z
Knezevich
2B–D
−43.4
Kurotaki
Infratentorial
BCL2gene
phospho-proteomic
5′-TTTCGGAGATGTTGGTTCCTTGATAGCGAC-3′
0.58–1.95
GCP
3zbf
2/112
648-CTF
I47N
mole-
ProbandsNo
0·55
2111C3a
pre-BCR
.24,36
7⇓–9
perisylvian
mediumsupplementedwith
colorectalcancer
274.5–1948.4
BioXCell
3226
57,897
ORBC
contexts.3
pre-operative
R3
Synaptophysin
38-2
KIAA1549-BRAF–expressing
CHAPS/3.57
Nikulenkov
ficial
causeda
KITex11
AU1-mTOR
30–79
F57C/S222Q+S226Q
1–180
‐2
Far-UV
NCM
individuals.14,15
7q34-35
WT1−/−
PDGF-D
E501K
PRDM1.E7.67.R
C4446T/CGA-TGA
erythroid-expressed
1,10,13,16–18
M1154
Dda
Hypoglycaemia
negative/basal-like
Wnt/β-Catenin
AXL-addicted
eGFP-Cre
15–50
Exendin
Iμ
Adenocarcinoma
genes17
ΔR8.91
SF539
-AAGGAGGCAAAGGTGAAGTC-30
Phe-270
91.1
homo_sapiens_core_59_37d
Pawson
PP2A-B56γ
13–16
g004TG101209
WK557-8del
cancers34
Wicklein
Kip
W48713
progrum
anti-PLC-γ2
E047
Kokitsu-Nakata
r=0.89
111-1
p.Gly12Ser
prioritise
NCoA2
064-fold
160407
8/1
dbSNP135
areunderlined
1428–1721
S531Ta
131/142
occurs17
Gefitinib-induced
DA310828
Komrokji
biodesktop.uvm.edu
prognosis.11-14
NCT00075218
Y163X
dose-optimization
anti-NF2
lines55
.Yan
FL-3
g-m
containingpLS76
trypsynized
.T7-tagged
K72H
Azg
Petkova
anti-Lats1
111111111111111111
p300-E2
R3b1.3
assayRNA
1.01–4.75
acid-long
RET/PTC3
36.9
IgCAM
BclI
CTumour
CtIP
pBL1
51Cr-release
confocallaser
Bwild
T1799A
~3-4
D.H.C
==2/5
Kyung-Suk
S611N
596–718
274–321
1993.3
Cysts/AML
00–143
patients3,22,23
steroid
ACTAA
f50
T615P
26.2–96.6
c.6468_6469del2
protein32
RAS-RAF-MEK-ERK
−0.06
NF1.18
kit-8
DDR2-mutated
V133I
mo-
Lahore
nonpeptide
1–3057
lysated
O-GlcNAc
ARID1a
APC-mutant
p.Thr347_Arg470
FGFR-
Glu846
thatdisplayed
R.M
pCMVhAR
anti-JNK1
=0.024
p.Gly67Arg
IDH1R132H/WT-induced
Bouman
MEK2
fertile8
†3
20892-1888
Quantifications
OLIGO®
nonspecifi-
.HCC-366
option20
D404
Mx1-cre–
66°C/20
TCF-3-dependent
EST14
C.2T
normal/elevated
E1644G
phenotype.1,2
R87L
p.K550_K558
nilotinib,12⇓⇓⇓⇓–17,23⇓⇓–26
CMV6
unidimensionally
pOZN-BRD4-NUT
LY2157299
L1904V
exo-
S383
Mastocytoma
IVS39-12T
BRCA-positive
INQ
0.533
Lausen
Ricovero
spectrum-based
EWS-ETS
EWSR1/ATF1
Notch‐modulated
5-CCAGTACAACCCACTACGG-3
prognosis.1-6
DRB1*040IC
.Homogeneous
NRF2–KEAP1
previously.2,6
box-containing
19/47.5
Caveolin-1
Gly373Arg
EWS/E1A-F
TpCpN
D3a2
117-3a
disorders2,4
RG-2T
IOS
RNA-RNA
ligand.28
cancer.14
H1867R
pCLxIP-DEST
ST486-HAEMATOPOI
TCF3/E2A
.Never
mapping23
TGCGGTGCTGGA
13q–
T410A
.924
Lipofectamine2000
SNVs/small
kinase-selective
2000-P-001990/6
probe-sets
.NUP98-TOP1
A621Raf-1
spleen.24
ΔHMG
interactions81
phycoerythrin–labeled
non-clathrin-mediated
1p36.2
9528
L1420F
TranscriptsTGFBR2
described49
M7
yi|/|xi
Vydac
TK-specific
MC38-bearing
CAPPEL
D816H/Y/N
procaspase-3
19.44
18,302
myc-MTA1
GID
44/56
Herceg
CTLAThr-17
6.4
YesNoSuppressor
GSC
NAPESIFncvYTfESDVWSYGIfLWELFslGssPYpgMpvDskfykmIkEGfrMl
Adenosine
Heimann
anti-hormonal
2QLU
MALT1
Non-chain
end–labeled
.1803A
exonuclease-proficient
ΔNterm
p.Ile388Val
A1642C
A_52_P636948
A|
p.R226Q
www.broadinstitute.org/achilles
50–75
antiserum34
Rad51—We
//chromium.liacs.nl/LOVD2/colon_cancer/home.php
Cβ2
5′-GCTGAAGGGAAACAGAAGTACC-3′
//bioinfo.ggc.org/mustab
sc-7606
14.34
11S
D617
phosphorylation18
~6.6
Heydemann
Gusb
Lys63
10/8
Papathanasiou
EWS-FLI-1V5-infected
E018
40–75
CD166
AS-PCR⁎
KIAA1235
YO-PRO-1/PI
.Features
V126I
2.8*
6833
physiotherapist
non-calcification-prone
P622L
precursor-T-cell
anti-EWS-FLI
.Attached
.Live-cell
AB81
S33C
developed.18,19
Thermo-Scientific
PreviousFigures/tables
1a1
vector32
exchangeable
naproxen
06-1310
2.6:1
parthenogenetic
SCAF11–PDGFRA
cdk6-associated
Rhophilin
5-TGGACCGTGTCCTTACCGT-3
P.ALA767_VAL769DUP
Transresistant
HistoGene
validated24
A451TARAF
75bp
ψk
MAPK60
A/c.9117+2T
BrdUrd
5′-GGCCTCACCCCATTTGATGT-3′
3.1–9.5
Quddus
PTA
cross-talking
14/44
LUCC4
splicesitefinder.html
SF6
75,700
p53-deficient
receptor.35
fodde
thep53-responsive
148-Th
.S
GRP1-GFP
M2128
H3K4me3.In
0•2–200
NM_011594
activity52
wd37
I221T
p190/RasGAP/RhoGAP/SH3
ALL.3
​Figure1A
intra-embryonic
MMCsensitive
statisticalsignificance
L118P
metastasizedGISTs
MCP-5
P450
SMARCD2
5′-GAGGAGUU
c.980delC
Mkk6
Fusion-negative
Array-CGH
E2-primed
1p/19q-
−2854
CommentsWhole-transcriptome
shRAF1
8Josephine
Summarising
D2—markers
Apc1
Dolganov
EEE1
EC2-3
electrophile-containing
-GTGTGACATGTTCTAATATAGTCA-3
ILE
bSarcomas
syndrome.2,3
Unopet
FGF17
ACTTCA
line28
LR
highly-conserved
//ajplung.physiology.org/
lysis.28,30
mDia1
-GTAAGCTTCCGCAGCGCAGGACAGTT-3
208212_s_at
Cdk12-depleted
heat-eluted
Thermophoresis
3G-H
COPII
DIMHD842-846G
CCATCGAGATTTCACTGTAACAGCTAGACCAAAATCACC
activity102
Rescuedviruses
MOMP
706K
BeadStudio
MM.61
dominant-active
B-type
urea/32
.Cytokeratins
GSH2
BMP4-mediated
Col5A1
−29
nonfunc-tional
1745–1757
Pten+/-Raptor+/-
proliferation/migration
progression/response
∼1300
85-90
12525
'enhancer
anti-alkaline
postinfectious
-restricted
GATA-3fl
Pre-let
Eco293
D641
timestep
E909G/E909A/E909K
Nicotinate
Anti-HIF-2α
30°
NOTCH/CCL2
LDQLLLCAFYIMAKVT
Cre-IRES-puro
non-nodal
+T3wt
fully-active
Site-directedmutagenesiswas
Y327H
_-AAAi5~~~~~~~~3
Mum1
non-synoynomous
mutation,28
proteins72
PRC2-independent
103/ml
bioluminescence8
.P210′
aagcag/AAATCA
59K17
.2C
calculatedusing
Ij|/Σ
EcoRI/PflMI
BANP
190-297
Finland35
S1F–S1H
21.774.5
DNR
FGFR3c
0.9-6.0
CEP13
non-cholinergic
Deigo
SerfsX8
amplification/expression
9141201–9442500
Lessnick
3KR-expressing
blue-stained
RP11-835I21
CIC-DUX4
8335
12·4
linker-domain
tetinducible
kinasesThe
-QIASGMA
c.527_528del2
CHIP-ΔU
ACVR1-FKBP1A
medium-F-12
PPP2RA
.P15
VEGFA-targeted
mutation—because
GST-wild-type
1858
αKG
630
TCF4-β-catenin
mediated-HR
FBW10
peptides.Materials
CRC.Eleven
.structural
CGAAAGAAAATACTTGCATGTCAGA
KIF5B-exon22-F1
169,568
G468A
IgIIIa/IIIc
genetic/chromosomal
Y327S
T3N0M0
3ß
NP_476530
G160A
described27
progression.12
Rbbp5-RNAi
Dulbecco'sminimal
independent-samples
Y60X
R21-CA135483
HR=0.37
β
IIIb-D1810A
endogamy
motility—all
c‑myc
M-T
HUGOapproved
Vicente-Duenas
ontarget
127C
Advantium
JHH6
R1T
5′-GAATCTGTAGACTACGCGGCTACTTTTCCAG-3′
heterodimers
.Heinrich
Crystallizations
Freiburg
Hospitalo-Universitaire
phenotypes.16
processes19,20
Jak3YY
12Rβ
Tyr340
genes13,14,15
1Cgn/J
0.936
rs35457630
24∥
substrate-2
T807S
.Chlorinated
cryostat
.SCNA
GEF-stimulated
kinases.13-15
phalloidin
Denotation
allele-speci®c
sPheMet
MMK4
1/4.5
p.G13R
0.80
perfectlyconform
R832L
Pirarubicine
myoblast-derived
.previous
Myc-hSmad4
OAT
4Figure
NK/T
×119
epithelia-specific
interactin
motif-lacking
hyperglycemia
M522
wnt/wingless
N542-E543del
p.Val393Ile
.Ctrl
reverse-translated
RP11-733O21
CACTGTACATAATGATTGTTGTTAC
/NF1-null
A126I/P127T
BCL2-antagonist/killer
established40
HCC1937
mVHL
GSTp531-101
cotarget
determinedby
p.Q775X
fluorescence-quenching
L3MBTL1
R-1-
Drier
phospho–MEK1/2
signaling,6
Jam-2
SF268
horizon.32In
dThis
Tyr-185
Met183Leu
Neurohistological
V56E
R2659K
GSE36350
P1614S-L
theerror-containing
Kleeff
anti-JAK3
Ser473-pAKT
Morishita
KB1PM9
C3-treated
LacI-CHERRY-NUT
loop3
S257L

S124D
1,177
AGTC
V653M
476473
2184_2185delTC
Rb-related
S1986Y/F
humantumor
M-Phase
codepleted
56774068
c.731GA
.Antigen
p53fl/fl
pHAT10
R776X
S1–S7
4TYI
Rb-/-/p107-/-
ACAAG
B*15
JNK-independent
DHA
1360–1367
p.Arg583Gln
discoverythat
02/01/02
Genschel
buffer+
Laptook
CAG/GURAGU
//gvs.gs.washington.edu/SeattleSeqAnnotation/
A.R
CDK6-overexpressing
Fig.55f
.BIOLOGICAL
v-Kit
1a-c
FAM190A
SNU-484-S3-2
0.496
CAGCCTCAAGATCATCAGCA
4151
Fpg-sensitive
αT3
7560
-TCT
c.105_106insAA
Nf1-
erlotinib.7
MV4
R357Q
Growth-signaling
Ano
bevacizumab.7–9
U373
Hs02890670_cn
D186
β-galactosidase
neurofibrosarcomas
HCC.13
V299L-positive
CR:18
pALTER1p53
double-point
ARID5B
IHC/gene
P335-A1
ATC-3
pmax-GFP
super-apoptotic
c.842_843insC
182–185
ABCC5
JAK1-STAT3
.Penetrance
D90A
M580T
PI3K-pathway
processes7
MC1-R
81–85
c.5194delG
tumours92
5'-gat
H1980Y
dependent44
10−4
chromothriptic
Del746–751
hereditary-familial
881–1084
cyclin-E-CDK2
tumors/no
216763
—Apulia
CDK1/2/5/7
5′-cttttaatttgttcattctgaaaaatcctc-3′
22.45
loci
pGL2b
SmartCycler
53.1
A_52_P644465
hyperubiquitination
line^.^
1.08±0.08
AK011392
R153L
′6
Sfrs8
PS⩾2
malignancies3
Cross-Species
protein/lipid
E1682K
Thr-175
DAF-4
SomaticIndelDetector
/highwire/powerpoint/139517
RNF130
JAK2-L611V/V617F-mutated
phosphatidyl-inositol-3
dead-end
G1950T/K650N
13,20,22,23,25
COOH-
n=5/group
.Tie2-Cre
kcip-1
polymerase-chain-reaction
4q31.21
Guerois
Gcn5l2
ErbB-2that
P*
Lilischkis
phase-arrested
AGCTTCTTCATTTGTGTGCT
MEK1P124Q/S
factor–coactivator
13.99
//www.ddduk.org
2R4
P660L
charge-reversal
KRAS-positive
clone-based
Cmin
phospho-Gab2
AntiphosphoErk2
sites7
cds1
Airway
59/82
dacarbazine-based
HIF1A
+0.11
1.94
ETV4_exon12-r
5′CCCCRCCCACTCTAGACCCCAAGAATCTC3′
V1378I
CLINSEQ
AVIV
gene.Figure
CGCGC
ERCC8
AIS/MIA
GATAD2B
Table1,1
HR=2.2
V5-PAX5-JAK2
mgli
PTEN-L23F
breakpoints.11-13
kinase/stress-activated
fast-kinetics
6113
signalling26
p.Leu242-Leu243insAsnProCys
Asimakopoulos
F18
W.J.M.
decision-making
”
5′-agggagattctggag
stratification.16–18
329K
BgZII
transcribed/translated
analysis.Myc
serine-
development.24
.Nested-RT-PCR
9309
K5N
STARTRK-1
INCB018424,12
14/40
RhoA/Rock
ApoE
phospho-ERK1
5-ftl
GR6
5,601
GEF-like
0.0880
MutS-free
heteromer-dependent
mismatch-repair
phospho-p70S6K-T389
Mitte
CDK4-MUT3C
non-EDM
effect.22
.Varmus
IÃŽIMborate
.IDH3
MPZ
melanoma,45
mutatorphenotype
gggcatgtagaggtaagacgcctg
−.51
HRP-coupled
light-activated
.Indirect
RAS-GDP
described40
5′-ggaggaagtagcatggccgccaggtctt-3′
NM_004064.3
E1241
UBA/LZ
camptothecins
100-day
p67PHOX
KSR2-MEK1
BRCA1-∆11
AccIBglII
Mrg1
1ERE
leptomeningeal
TCGA-A2-A0T6
lines.6
117C
DDR1d
BRCA2
−0.67*genotype
anti-MAPK
.Subunit
Dao
phospho-RPS6
associationsAmong
SX-20
Vim
Stk3−/−
AA2711-2962
pRK5-B2GFPΔ1–1526
.Dierences
Ba/F3-BRAFV600E
5Ca
p.Ile219Val
immunodeWciency
S503C
Cys-278
1VTN
PAM50-defined
bio-reactive
Orient
PGK1
L1225
rhotekin
TPM3–ALK
insertions—both
caspase-9S
binding-domain
615095
parameters.19,36-38
GSE25839
ol-res
Anti-IRS1
R307Q
pCDNA3-HA
/22
nonnuclear
Synergistic
p.Arg304Trp
Rho/ROCK
144275
reports16
X≠P
biomarker-set
V617M
.Women
cells,5
GC-Melt
well-connected
mMACHINE
PTMScout
.Tsc2–/–TP53–/–
.DiscussionIn
9,402
F20**
Xuorescence
TCCTCGGAGTCGCTGTAAAT
p=0.064
5.1-kbp
pmGFP-H-rasG12V-
CCAGCTCTGAACAGATCATG
Msh1p
GusB
runt-related
Ly294002
colleagues142
post-natal
pCR8-FoxA1
PL45
NF1-stimulated
4/68
Me-AIB
.0007
haemangioblastoma
CD41a
dimethylammonio
Phylo_win
cross-validated
attL-attR
MLL-AF9-induced
anti-ATRX
8.895991375
Cartegni-Consensus
1−127
convergence–extension
Ser-97
􀁂
.Compilation
Kosaki
62Â°Cfor
.Smoking
pen/strep
development.68
C193-C213
cFUGW-2
Trp257
fre
gametti
c.2225G
PCR/HiSeq
FH-SPOP-WT
output49
.Well-established
patient.35
8-mutant
non-NMCs
L329R
.Bcl
filamins
Farruggio
BRCA2/PALB2
adenocarcinomas.A
0408
cells22,23
dualluciferase
β-transducing
D3S1304
S2J
//dexter.nki.nl
I*ProAspThrAsnSerThrSerGlyAsp
NSCL/P
Hepatocytespecific
.LY3009120
L1152R
17295/14928
AMN-107.5,18
del7
null267R
www.pnas.org
3ins
E024
'-N
cariogenic
5687
185AGdel
BR-0516
PF00299804
CEVDPQKLGNVS
TP1-luciferase
mutationTransition
sh-RNAs
Flag-D1-T286A
pSXLDUE
163950
receptor.7,11,38
C275S/277S
1,761
98–103
pathway.13,21,22
island/promoter
R358A
machinery,27
Csu
stroma-invasive
72Â°C.Both
Eisenhardt
α-TAL1
receptor-responsive
Harten
mutations/small
283-9
leucine→
melanoma-free
FOXO1-PPARγ
8742
pVHL-specific
5′-CTGGTGTGCTTGAAGCCTCGAGTGTCGTCTGTTCTGCTG-3′
Y397C
1.65
Bevacizumab-failure
3-Deazaneplanocin
F881L
del96–122
tagcgttgt
mechanisms/molecules
myeloablated
P210
S1798
Bacmid
12p12.3
997-1001
.Transcriptional
AgeI
OFCD
specific-nucleases
1969
studies,27
hematoxylin/eosin
8p-DNA
I~M
FLI
EVQWK554-558
ICL-repair
kat
HER2immunoprecipitates
r~\i
c-KIT-D816
midpoint
Zweidler-McKay
EBPα-null
TTTTTCAACAGGGTACACAGAACA
Buckhaults
8.25
alsoinclude
n=46
shKRAS
cMET-dependent
translation18
SEC31A-ALK
L536P-HEG0/pSG5
Urayasu
TCC-SUP
PTENdephosphorylates
-293
Family-based
1.58E05
SJRB001
RP11-167O6
Npm1-null
p.C394Y
NCT00771692
Flag-wt-FANCA
Westernblot
B74
N1128
67330557
A104
Struys
NFIencodedprotein
comigrating
phospho-degrons
Try557
activation47
Minelli
adenocarcinomas.20
RIT1-activated
paired-like
Fbw7-null
Matsuura
subunit-associated
cysticleiomyoma
vulva/vagina
al.9
RAS/BRAF
A871G
BICR3
Kerem
5¶-CTTGAGGGAACACATACTCG-3¶
=ns
pSINsi-hU6
–locus
R420P
E168K
13C-separated
mll1
NP_003308
protein·DNA
near-normal
566-571R
G275D
N127S
AdEasy
109:61–64
PTPN11-associated
hybridizationFormalin-fixed
TAATACGACTCACTATAGGGAGACCACCATGAACTACTCAGTGAAGAAGTGC
MgCl2/2.0
MYCL1
16KRAS
EIIa
27.5–52.0
Blimp-1/prdm1
systems19
.Singh
,9B
p.Q207D-c.a.
0.359
GCAGAGATGTTTGCTGCGGCGCCTCTCTTCTG
PopMusic
bisulfite-treated
Gly-477
OCLN
cysteine-tRNA
Li–Fraumeni
anti-Genentech
bone88
GI/S
p16—another
L125P
NcoI-EcoRI
urea-phosphate
◊
hVIN-1
thesamples
FLAG-NRASA146T
.1497A
GGGCAGAATTGGATTAAGCA
SMARCB1-regulated
particular195
54K
anti-poly
−977/−482
molecule.31
54+A199
reported25
2273
0.653
principle10
Ikzf1
.Tet1-KO_MA9+HOXA9
FGFR-VEGFR
L-82
14.87
1.0–1.9
GRB2-related
trial14
hypocellular
-CTGGAATTCGAGGGAATCCCTTACCTCGAGTCTGG-3
1×104/well
3-H-12
ninds.nih.gov
.Tentative
mut-KO
MUM2B
Alleleic
anti-PY20
Immunopurification
med.uni-heidelberg.de
nevomelanocytes
decloaking
SpectroDesigner
KIU/ml
Tyr74
CEBPα
survival/OS
39-primer
S205
individuals111
0.0299
epithelium–derived
PGK-neomycin-HSV
Multi-platform
GS1-440B14
anti-HA11
DEAE-NPR
V561A
activity18,32
Pit-2
5′-ACAgAgCgAACCAAgAATgCCTgT-3′
W1837R-R
regimens.17
14,16,17,18,19,20,34
retroviral-GFP
R-COP
.Step
Médico
.II.I.I.Il
Unconditional
Aurora-3
Sanchez-Beato
samnples
EPR14335-78
ovaryindependent
.Pópulo
D17S1307
GCAUUGAUCAAUUUGCAAAdTdT
APAAP
yahoo.com
sequencer-generated
RPTPs
D743R
p′c
ΔΔGbind=ΔGbindmut-ΔGbindWT
.AGS
euthanatized
LAG-1
PTEN-antagonized
COFS
233.3
activation19
CHPv2
siCryptic
TPSCTAYTSSFVFTYPEADSFPSCAAAH
269
1062
Wanguo
V294
XRCC3
domain,13,14
phosphoproteomic
multiple-effector
checkpoint38
RB/E2F1
Tyr280
cases.32
promoter15,16
5q35.1
fragmentation
uni-muenster.de
/DNA
isoform.9,10
H1047R-NIH3T3
9011
Vaco
12/38
DS-ALL
thoracentesis
CT/PET
278780
stimulatesuch
reported.8
proliferation-
Henriksson257
CGCCTGATGAGGACTGTACC
endoderm-like
hMSH2–hMSH6
-agtttggctgaggcaaaactc-3
R257Q
Smad4N
154/398
cGKIβ-mediated
.IGC
HAV12
phosphorylated-RPA
Lacrimo-auriculo-dento-digital
Glu185Gln
ΔBRIP1-pcDNA3.1/MycHis
Gln25His
88-128
centrifugations
17/243
2.67
matrix/scaffold
previously.8,24
5′-ACTGACCACACTGAGAACAGGCAAG-3′
20–51
DRB1'0405
8.
HEVHFLHEESILER
Tgfbr2+/−
SCD–FHA
MSH2-mutation
cancer7,10,13
APC/C
Dusp6
imposition
15,16,20,34–41
36-h
localiza
14.5–16.0
RCS
.Photosensitivity
members5
cancer55
dominantly-inherited
6030
Fas-FADD/
bcr1
anti-phospho-S6
TGF-β-Dependent
38-2005
analysis.21
Boston-type
SCALA56
N=42
monoubiquitinate
syngcneic
Stratakis,9
EWSR1/POU5F1
aldehyde
E299A
www.mutationtaster.org
inchanges
1-TRCN0000039974
Ufo
19-23
5.1-55.8
MDA-MB-468-IKBKE-Y88C
A.A
T3/ABN
354x
//frodo.wi.mit.edu
388
:kanMX
E24R1
~305
locoregionally
colony/burst-forming
S82T
0.147–0.602
nilotinib.16,17,54
BRD4-mediated
1,281–
/highwire/powerpoint/42251
ADP-ribosyltransferase
208–210
72C×30″
shNTC
muCi/gram
A_51_P377526
ΔGDH2O
diseasepredisposing
eti
Ggbele
L198A/L235A
.Combining
MEK111054
inresistance
/S
IGF1
co-altered
p.Gly317Asp
north-east
JBW902
Collapsed-Pocket
S252W
5′-ACATACTTATTGACTCTAAGAGGAAAGATGAA-3′
reads/tumor
agonist-versus-antagonist
expression.Activation
IL3-independent
59-CAC
Tyr418
70°
mutation.Figure
cryptorchism
18,191
5'-ATATGTGCTTCTTACCAGTC-3
TMLINK
Nmethylhistamine
35–36
T575
'12
.IPC-298
II/IV
diagnosis29
three-scale
270K
I642V
FC1
Atrophy
SRSTSPTFNK
AAAGTCATAACTGCCATTGT
gliomas4
130–198
IVS27–1G
63K
47-fold
probe-mutant
FLAG-AR-cofactor
Gly96Cys
anti-5-methylcytosine
1-95
62.7
no-coverage-search
199/502
P46L
1268
c.5511G
pMC1-
AIETDKEYYTVKDDRDS
protein/E2F
Msh6L1352Q/+
45
CRL4DCAF1-independent
.G270
Trans-
73.0
Sat2
1640/
Pbrm1+/−
Biotech.
Prf1
31–69
430KB
ovarian-type
S2–S4
382-395
P252
3ERT
R166W
40–80
gene-poor
C339T/CAA-TAA
1–24S15–P
degradation.16
μL/
hen
.Ground-state
14.500
7624
Sox17α
15/58
FCS/DMEM/0.5
L198A
.Parenthetically
A614
extra-follicular
5Oaa
.Critically
cases4–6
expression37
R272
GCTCTCTGTGGGCGACAAAAGACGACG
PRMT6
inha.ac.kr
antiGSK3β
Bethesda-negative
Bgl2/Not
EGFR-delL747_P753insS
6–18
H271
PKCɛ
*2403
Chr1
1.097–1.875
mutation/total
Wherlock
3.5-d.p.c
USP45
378-bp
underreported
Skp1/cullin1/F-box
23:2617–2629
EGFR.d
Smad4C266
MPNs,2
MS00041230
4,5-bisphosphate
lymphomagenic
RVL
transformedA
.D:32P-inositol
R1353P
genes18,19
erbB2-activated
Q=1.7×10−16
YCP50
ATGGUAAATAAAAT
EPHB2
Cys-X3
A121P
TÃŸR-lexpressing
acid-RQIKIWFQNRRMKWKKYSNLLDSTPLAPLVSVPKTLSPVAVP
RAB35S22N
//www.ensembl.org/index.html
worldwide.1,4
retrognathia
transcrptional
0/132
Fisher–Freeman–Halton
event-free-survivals
RP11–154J22
CTC→CTA
above.Cell
cycles*
PCRproducts
Hormone-independent
BRCA2-W31C
Ras-Raf-MEK-MAPKs
C-terminus.31
andERK2
_in-frame_
Assays—Isolated
H3-K4-HMTase
far-reaching
pCMV-Renilla
0.66–1.95
4.92
PECTMWT-1/P
G9A
onartuzumab
EGFR-related
Misidentifying
50.7
high-level
.NPS
StemElite
DPH5
1.Effects
HDQ-P1
activition
inculactosidase
FL-mut
C324Y/pCMV5
CEPF-CEPR
.Malformations
cancer143
Snf5inv/−/Mx-Cre
FA-32j
4.—
GST-AR-AF-2
trifluoroethanol
696X
H-RasC118S/K117C
//ftp-mouse.sanger.ac.uk
bN.K
muscle-like
Kdm6a
rhizomelia
AACCTCAACTGCTGCCCCTTA
LVH
damage-inducing
.CFC
.5,15
IMCE-derived
RA-sensitive
MLL-ENL–
GCAAGTCTAGCCAAGGGCTGCA
98.8
MEFs.K-rasV12-expressing
ΔHIF-2α-Y532C
1263–1377
Q354P
24–
ImmunoResearch
orthopantomogram
≈317,000
p=0·199
Nrf2–Keap1
1OL5
ependymoma7-14
.Historically
mutation-carriers
mMMgCI2Jfor
juvenile-type
pFlagSox9
mutation/SNP
ABC-DLBCLs
p.N486
Y279C/CD
601626
Berrozpe
4,28–42
.MEK1/2
Dominguez-Lopez
359P11
homoestatic
midnolin
5´-CGACCACCAAGCGAAACA-3´
antidifferentiation
response.19
ATAGACCCAACACAACCTCCTTATGATCACAAA
∼3
adenocarcinoma.9,21
D121
JM-Zipper
gctactacgccatgatgatcctgcggaagga-3′
TCEP-Neutral
Ras–Ras-GAP
present|
Foulstone
amplification-driven
.Well-known
proto-oncogene
calciumphosphate
non-transparent
12/106
3000-fold
2003
Caspase-8a
antisurvival
1−9.5FGD6FYVE
msh2-AD872p
TRCN0000015994
PTPN11.RAS
CFC77
86,813
ECEL1
GOF/COF
179617
CTAACTACCCATTTTCCTCCCTCAATTCCTAGAAAATATTTCAG
IFITM1-GFP
K860fs*43
c-abl1
Martínez
Floquet
dETV1-expressing
Q9HM14
postoperative
Akt/Erk1/2
transcription25
genomeDir
6.22
PrC
PLZF-RARA.28
37/45
.KIT/PDGFRA
0.4ke
SB203580-sensitive
cSerum
V800A
si-ASC
alÃ-eleswere
L858R/L704N/D837A-Myc
4-kb
quinolizin-1-yl
GSEN.FSRWPALCSQKDFLKECS
signaling-mediated
S2D–F
FA-D1
Bcr|
TGGGATTACAGGCGCACAT
.ACTTCACGGTGCCCGgtgagtctggcgggggcccctgcccggctctgctg-3
Tel/PDGFRβ
carcinomas.32,34,37
re-envision
instructions.Echocardiographic
fixation26
penetrance.21
SpectrumGreen
GAGGACTCGAGCTCAAGC
HSD-11β-type
4.5.3
18.7-fold
ΔU3
thatincreases
Guillouf
43-gil
HincII
one-way
KMT2D/MLL2
10,12,13,16,17,21,28
Myc-
withMSH2
–1.0
PI3K-AKT–mediated
vitromutational
204531
Bcl2/adenovirus
7.642287667
0.157
patients.15,21
Endoglycosidase
H-128
GCAAATG
genes7
7AAD-stained
JAK2.13
GGTGTTTGTCTCCTCTTCATTGTCA
Ruizeveld
EGFRΔ746-750
Gly281
x-ray-induced
TGGTGTTTTATTGTTTGGCTTTT
yPMS1
tube–specific
Gg1.3kb-Luc
Ikk1
4723
tolerance/immunity
antibodies.html
tinidazole
2.129077267
-99
R256G
G13
Cdk2
Tyr791Phe
ALK-TKI
EHE10
0.2-μm
.Ovarian
PABP-C1
TGCACGGAAGCGTCTCGTCTCAGTC-Texas
recurrence.In
CD180
ofobserved
,0.5
FMRP
pyrrolo-pyrimidine
Pro/
000535.5
R361H
seven-year-old
V-erbb2
NBT-II
shVHL
.Curiously
0.88–1.09
10,11
A564
N-lobe/C-lobe
leu2–Δ1
orMSI-LDSS107
SUPT3H
LS,29,30
date,22
I157T
1232
Lmo2
HA.~
E2921
Cre-induced
.Eight
QUASAR2
S1049CH*
5.3*
7C103
dovitinib-treated
PEBP2αA
HIF2-dependent
tetrapeptide
treated/P-ALK
seborrhoeic
cells.23
P848
forty-eight
Max=maximum
IVS15+1G→A
300ng
R173G
pRK5-PTEN
FL-tFL
2-pyridyldithio
11.I332V
screen.tThis
E1707
44-309
p70S6K-independent
.30,31
pGEM
R29Q
5'-CTCTCCCTGGAGCACCGAGATTCCTGA-3
12-567
polymicrogyria-postaxial
luciferaseandLacZ
Haluska
anti-BLIMP-1
1−117
10-18
F134Y
2Eh
INK4-
PDGFR/
fasting-induced
helicase-dead
splice-site
Levran
1151Tins
deoxyadenine
DLL-1
-based
I–K
*320
mIU/ml
striatin-Pdgfrα
K182E
Integrin/VEGFR2/TEM8-
denature
//cgap.nci.nih.gov/SAGE/DKViewHome
Q787R+L858R
33337
RET-activating
6G–6H
pericytes
1557-9190
PDSM
dition
hvr-mutant
PHTS
5976
myc–wild-type-CARD11–mCherry
n-iSH2
HT-29R
cross-contaminatingeach
TGBFR2
LSQC
CTLAAla
ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCG
'full
2-TATA-CAT
V570•••V559
-CGGTCCACTTCAGTCTCCT
G127E
follow‐up
.ERM
BMDP-2L
Flt3-ITD
–138/–139
FGFR2WT-V5-pcDNA3.1
HER2–afatinib
K592I
Cys220
L/h
Anti-TRKA-immunoprecipitated
retinoblasomas
Tyr29
c-mer
D572A
pathway/gene-set
SPARCL1
NM_001880.3
once-weekly
.Korshunov
criteria–positive
expression/absence
CD3+CD4−
AAG-9AAA
35.2
T7-coupled
3h–i
STXBP6
V1565I
agcttttccaaaaaTGGTGATCACTCCAGGTAGtctcttgaaCTACCTGGAGTGATCACCAggg
phospho-AKT–inhibitory
orofacial
non-overlaping
respectively.7
.P-TEFb
Thorstenson
multimer/DAB
tumours82
a._
Akt/NF-κB
Mus81-/-
Rotor-Gene
P152L,11
GeneTac
TCGATTTCTTCATTGATTCGGGT
Bouck
NCT01262027
2,186
PICOWER
S8–S9
Toso-Haas
V5-FLT3
f35
-4.0
blood–
.CSL
XLαs-M302V
9.8–11.5
.Prophylaxis
4-Iodophenyl
c.2500_2501del
MMR-deficiency
2.330
Brattlebro
.Death
days.Some
multiplicatively
KO-transplanted
Hy-Line
avidin–biotin–peroxidase
Raf-1/MEK
T1175S
.Phospho-Array
EW
genes2–9
phosphodiesterase-3
over-
ASTELLAS
2,597
92°
HG19
Thol
Luc-PB
Tariquidar
Gal4p
MESNA
enzymes.Cell
Altena12
SPIB
3RGF
age-standardized
theright
-CTG
3-carboxymethoxyphenyl-2-
C124/277S
TMPRSS259
lines38,39
Garami
.Infected
p.R143X
FLT3/ITD-expressing
H1722Y
Bcr-Abl+
multicentre
4×10−4
A636PhMSH2
program178
notch-4
μC18
1T46
ofrhabdomyosarcoma
T199M
.ResultsBCR-JAK2
spheroplast
identified.6
Y127C
Intron26
HCV+
Pulmonary/upper
90-
1.003
neuroblastoma42
TMRPSS2
Step-wise
V23TC21
SYT1-C12orf63
Ja¨rvinen
Hup-T4
IκBα
DD-SF3B1–tagged
FLT3-W51-expressing
pre-pubertal
2TABLE
C187Y
A290T
EBPalpha
EDTA-catalysed
Si3
Transgenes
Pusan
S2000
phospho-Ser217/221
subsetof
92037
.Figure.5
000038.2
Real‑time
screen18
stress20
1167
FISH-related
brca2ΔCTD
wHTH
709A+G719C
ExTaq
Src-
non-surgical
adjvuant
AtB′
meta-analysis
tree-like
KB1P
activation-associated
XSmad2C
oestrogen-stimulated
WWP1-C890A-myc
MetS•r
Tumor-bearing
downward-pointing
authors.5
.SCH
10u
2713C
Aissaoui
fundoscopy
Suppression
Br76
PRDM1,9,10
reactedwith
76,557
61.0
transitional31
p16-R2
TAATTACTCATGGGACATTC
5′-CCAGTATGACTCCACTCACG-3′
c.7379_7380delAA
EGF-ligand
BaF3-EPOR-shVHL
c.380A4G
EZH2-targeted
apoptosis.15
phospho-serine/proline
Phosphoamino
pre-entrectinib
9/53
0.59
substratification
.Dissected
three-state
precastration
D1067V-KD
107.7
14.67
40.8–67.3
row-action
3802
studyf
andleukemic
3x‑UAS‑TK
EBV−
anti-CD3–FITC
9.98326
AML.27
Fug-III/4
partial-penetrance
.Read
LRM
S252W-expressing
ab2
EMD/Calbiochem
differentNTRK1
950
IDO1/2
triphospate
D447A
CDK5R1
.MD
αA′
fluoro‑l‑thymidine
HRas-driven
LSL-N-rasQ61R
IRES-mediated
Alu-insertions
ODN
−35.7
RERTn+/ERT
well-plates
W19
VH10
70Z–mediated
GC.72
polycytidylic
super-imposed
CUL-4A-associated
seizure-prone
LifeScope
retinoblastoma.A
513G
ESE-dependent
M37K
Pgr=magenta
Molsoft
Benvenuto
carcinomas.26
E10.582
proteins47
sition
BCR–ABL129
.BEL-7404
A.G
3.8–4.0
.sample
10770
Oâ€
Sae2
presentation30,31
de-induction
synchronisation
Npm1-/-p53-/-
PeproTech
81.7
Lu135
Wingless/Wnt-dependent
sorbitol-induced
90–97
branch-point
D-cbl
.HGF
ACG
c.903G
.Consensus
mutaionsT790M
COX-1
9/66
26,29,30
Mug22
Bar-coded
1954G→A
46,27,3
Lyt10
granulocytes,4,10,29
Bowtie
miR-106b–25
Kleine-Kohlbrecher
Appleby
121–131
glycerol/5
antiMEK1/2
actin-forward
2,24,25
Assay—WT
c-Mpl/THPO
cc-11-4059-g2
Venkatesan
6858del141
Imgenix
CA16058
.KM12L4
3-hydroxypicolinic
trans-Inhibited
Harshman
37.5+
RASGAP
K84N
Rat1a
EGFR/ERBB2/ERBB3
5.837
HLA-A2
HBG1
Smo-resistant
.BAK-null
CU-rich
MsigDB
anti-PKB/Akt
SpectrumRed
intrabursal
Claudio
MITF-regulated
andafter
c.
K80A
Rtest
35.685
Y-585
family—apart
odd-numbered
p.Ala57Val
GPT
doi:10.1136/jmedgenet-2012-100965
p.Glu227
p.K117N
assessed.22,30
AdTet-ON
MaMel-48b
TSLPR
STRN-PDGFRA
KTLKLGTMMPEAFLQEAQI
Snf5inv/−
HLY1
member1
pGal
TACTTCAGGTTGCACGGTCTCAGTGTTAC
TrkB-T1
D57.2.2E
equivocal/discontinuous
nontarget
heptahelical
66.1
FOP-related
5′-CTCTTGGAAGGCTAGGATTGAC′-3
allreporters
expressingmutant
remodelling101
a=47.8
C/W-promoter
Prall
G-÷T
R.Treisman
cancer18
070
Dicer1
Δ14–15
confluentp53wt
3-hour
Cdkn1b-null
c-MAF
A8S
tier3
MYCN-specificity
–1.907
8/84
anti-p-Ser473
Lane1
.TTK/hMps
phospho-Tyr88
exons.19
0.01–0.06
patients.81
described.10,23
1~~~~~~~~~~~~~5
models38
u133plus2
25,14
pUC118
pDsRed1
llD
adenocarcinomas
SMID_BREAST_CANCER_LUMINAL_B_UP
5F⇓
ERCC1-ERCC4
G/T
Y223
DOA4
3834–3836del3
4284delGA
activity77
EHE2
Pem
immunoprecipitation-Western
Lipofectamine-2000
Residues*
theGSK-3B
plotsfor
CBL-B
A*0215N
.K63
:67.8–99.7
CT-PET
waspositive
anti-green
ATIC108
5T32AR07098-23
M/28
TGCCTCAGTTTCCAGTTTTG
pFLAG-PIK3CA
2CBL
H3K4me1/2
15:6791–6798
39/2334
=14*
axioplan
7727
Sena-Esteves
CHOK-1
Dup-2R,19
c.3491G4T
costaining
Aurora-A–TPX2
3,5,7
5′-cccacaccctactttctatcatttac-3′
D16S398
invasion/metastasis
nextgenerationsequencing
E267
Bδ2
receptor-type
E2F-Dependent
Thioredoxin
5/41.7
​Fig.7C
investigative
RABPT5-PDGFRβ
697
carboplatinum
L611S
73.7
peptide-substrate-binding
55,870,909
D4.12.9
WM852
subjectsb
pI-pC
5′-GCTGAGGGAGGCGTCCTCCTTTCTCCAGGATGG-3′
Gli-binding
meninges24
Tyr1284
.Lungs
1,834
CRG32
At+1j−A0j
VX-11e–
NET-N
paradigmatic
signaling26
Vol7No.11
E232
pOP-SRC-Ires-GFP-Puro
sc-179
Cys797
PTH-Cre-specific
0.3546
liquid-handling
Metabolic-Labeling
\J\..
.Insets
a-9
single-species
FBS-containing
–53
Sethumadhavan
.Gremlin-1
.Epoxomycin
TrkAC266S
shAKT1b
zlM
charge-inverting
1–323
CMV-LacZ
enteroendocrine
C2686T
spreadingtype
Dhrs6
Dohet
3.7m
JB12293
lipophilic
RP11-252A23
Amino-terminal
nonfermenting
//ajp.amjpathol.org
Ri~o.-'~ManitobaN
discarded10
BBMM
500-fold
3.1–11.6
inter-probe
AIIFTRI
L82P
N116H
ependymomas.19
Flk-1
Bmx
ALKG1202R
Zetasizer
volume/treated
J.H
.MutS
CCCL18
TP53–ATP1B2
SRSF2+/+
AKTJ
−4.28
PPi
macrodissection
Teitz
–,41
thods
ITMAT-Broad-CARe
R683
sufferers10
chloro-
11•5
Wat172
copy-dependent
.5a
un-irradiated
Nomenclature
capillariesABI3730
–Myc
Bonferonni
performed.Serum
β-chains
IGtranslocations.A
0.5-50
Phospho-mTOR-S2448
Akp
L265P-L265P
Loss/downregulation
Ambrosone
877–881
humanpapilloma
step-wise
RELAFUS2-RFP
T72721G
141.Box
5′-GCATTCTAGA­GATGAGCACGC­AGTCACTGC-3′
PREX2A
CK17
drug.4-7
SUPM2–derived
pUSE
p.Glu402SerfsX8
−2.24
RING-less
RG-15T
gi71017883
ACP1.17
β3-αC
L536G
●
2–6-fold
NCT00743938
L597R/S/Q/V
GnRH-II-induced
breast-tumor
Tet-op
1-2F/2-3R/2G
Q1756C
Elf3ΔC354
804-806
2.39
PBAC
Bergisch-Gladbach
XP11BE
PEBP2βCBFβ
Cell/Tissue
non-cerebellar
M680I
30,31,42,43
ETV1-high
Pre–crizotinib
CAGGACATGGGTCTTTCCAT
62,70⇓–72
I219V
5'gaacgtacgatgtttggtttcca
pancreatectomy
anesthetizing
.Absorbance
pCMV-3Tag-7
profiling3
waswashed
containssix
CLNK
gtatggtgt
Yin-Yang
c.8978_8991del14
p53H1299
95C°
counter-selection
94000
-Ciuar
middle-down
Arrigoni
fusiform
Restrictionendonucleases
mutagenesisof
1997a
pMC1-tk
pGAu
TFIIEβ
D1810
PEM-luc
T24A-Foxo1
GTGCCTGCCTTAAGTAATGTGATGAC
0.2595
KIT/chromosome
Brca1-deficient
AMPKα1
food/cage
genetically-engineered
R1703
Pre-B-ALL
c.3565C
kinopathies
axis15
T-cell–stimulatory
,t
Myh
P/P
17,18
r/rrtrovirrt//y
5′-TCCACGAAGACGACCAGAAT-3′
genes107
Anti-CD31
10-sec
Balbc
'Novel
FigFig2H2H
oligopolypyrimidine
.Second-generation
FA-inactivating
3.672
Qiazol
Histoclear
Hempsted
A767
co-localization
120K
polymerasechain
F2138
depletion–insensitive
/highwire/markup/117227/expansion
Ang-1
eector
+Tet
prewarmed
lXq41
pET28a
12-112
plasmidsbears
BCRA2
≈1.40
.Discovery
Waltenberger
saline–Na
145,146
Gln→Stop
allrelevant
rs200724560
-80jC
arrest/apoptosis
described9–12
HA-YAP
BilIN-like
32â€
OR=1.11
isothiocyanate-phenol-chloroform
K14cre/Brca2F11/F11/p53+F2-10
GSE6008
polysorbate
5A5A
Simcha
17.5,6,20–23
13a
S93L
KDR-mutated
Fig.3C3C
0.0251
10.6Acral
annexin-positive
K1003
APCgene.1
helicase-like
PD173955
.More-detailed
ACACAATTGG
KRAS-specific
bZIP
HxD-
COADREAD
Asn235
-GGACCTCACTGCATTAAA-30
.select_db=NF1_germline
issue.EGFR-TKIs
P28T
KIP
Glu-909-HER2
Apaf-1/Caenorhabditis
G229C
Rac/NADPH
α2-α3
ID14-3
chaperon
pEF6/TSC2
Transactivation
LtLvDLVdLcvDIskGcVYLerMHFIHRDLAaRNCLVSvkdytsprIVKIGDFGLaRDIYknD
336/180/80
EBNA2A
Spitaleri
ADP-Glo
MAPKα
involution.72
pUC18
ggt
endometrioid/serous
2-76
al7
cytokine-inducible
28·7
6/2012
447–753
Kukk
19,32
trade-oﬀ
75.5
CNL
2TK
J.D.M
D6
TGCTTAATGGGTGTAGATACCAA
C5_all
p.Gln629Arg
DEQ20130326477
nCounter®
114–116
ER–/PR–/HER2–
p.Leu819_Lys820delinsPhe
amoxicillin
LacI-CHERRY-NUT-transfected
Sau3A
KCTD11
NM_010708
5′-GCACCGTCAAGGCTGAGAAC-3′
interposition
ED14
.Arginine-903
~1.18
post-marketing
phospho-PDGF-Rβ
.Composite
E546Q
suppressors-the
adriamycin
DP8/9
overfilling
973-EGFR
hTRF
effec-
.Anti-Actin
Co23
mice32
post-pazopanib
NCT00199056
367
AFAP1–NTRK2
ANHL01P1
L57Q
GppNHp
Asn71Lys
mutations,14–16
CD43-
470-
transformation/focus
pMT3-based
S523T
trizol
0.338-1.458
Ø29
Supersignal
WHATIF
BALB-neuT
Hafizi
3/35
postpubertally
TCAACATCACCTACC-3
Arg337
100-nanosecond
.4517G
tlift
Full-length
non-verbal
mutation/rearrangement
MSH6-p.L1354Q
Bioruptor300
recurrencewas
phospho-ERK1/2-Thr202/Tyr204
Muchardt
Primary-tumor
Schmelzle
shRNA-Ptpn2-A
Xenotransplantation
0.49–0.99
16256
Allele
11Cancer
:439–49
Met626
5'-TCGGGTCCATCGGATCGGAGG-3
0.481
WT-L265P
5689
migration.—Tarcic
n=20
553969
phenotype.Msh2p-Msh6p
6.Cabozantinib
.CD34-deficient
CRC007
5–10-d
OX40-induced
P≤0.001
ofthis
cases1
I53T*
.Newer
sta
sarcomas/soft
rotamers
plus-strand
LIAI
TTTGGC
71-18-1-9
.ImageJ
Gaczynska
70/
reportsg
pcDNA4c-H2B-NUT
comma-shaped
+231
Beta1
~-PDGF-R
protease-sensitivity
GCCGTCGCCG
TGGAGAAGTTAATTGCTGCT
Tet−/−Mx-1+
FACT-depleted
HB9
.07
Jeol
challenging6,55,56
phenomenon.51–53
.Workfl
autoradiographed.Arrows
arthritogenic
3.267
apo-blue
2.8.1,18
Y842C–transfected
andTransfections
cell-rich
59-CCTCCACAGTGATCACACTC-39
Barbacid*
itcrtiorl
2-keto
MI-ONCOSEQ
p.Gln60Pro
Foxk2
Thr303/Asp304
sulfate-polyacryl
9.1–50
ex13–15
53BP1-PDGFR
radiolabeling
genes—ASB1
SLVL/SMZL
11/exon
respectively40
.Price
shPEAK1
sequencing.Representative
TACAACTTGTGCTTTATGG
P1087T
753KB
PRB
1.24
R106K
Australia,9
Berdasco
62y
c.6097G
Y340FY341
heterochromatin-rich
P0015
CCTTAGTTGCTGGCTTTGACC
Dpc4flox/flox
MuSiC45
IRTA21
VHL-defective
Arg49His
11AstraZeneca
S1172L
.DiscussionAbstract•
hu_p53s
signature27
HCG
K-digested
TGTGTGTGAAG
5/29/14
GM-6001
2Rα
FA/Brca
Fearnhead
Foxl2
D7Z1
BioEssays
F207
0:0
.Residue
Y861
MDS15,16
6×His-Flag-tagged
FTIR
3.5-5.5
.YACs
SMC1A
0.0356
D489N
end-product
317-276-1414
premRNA
p53-M246I
D–H•••A
KSR-MEK25
ab1791
12/20
KMT2D-associated
azimuthal
800–1400
aberration.The
apoptogenesis
population-scale
G-Sepharose
4/1
top100
nonsense-mediated
IL7R-mediated
phospho-GSK3α/β
PTPRQ
3112del
site-enhanced
α-active
Heselmeyer-Haddad
CD123+
Y367C
AGATp53-190
T11Q
PDGFRβ
pSS1
PCNSL
TGX-22120
pN-category
Cys3Tyr
LSL-Eyfp
75-94
Staufen
f25
I22M
Asepharose
84,753
.SETD2
.Principal
thisminimal
SEK1
NIN-1
5′-CAAGGCCTTCTAACCTTATAGG-3′
Dpy-30L1-RNAi
T286-phosphorylated
.ALK-related
Y295H
Gly772
MCC26
pGAD-byr2
testis/ovary
EDD-DYRK2-DDB1-VprBP
transwells
D1a
RMissense
'S
single-lesion
5′‐ACCCATTTTCCTCCCGCAATT
FSK
non-RER
dnETV1
M1293
PD7
mice.The
Hasselblatt
antly
solvent-exposure
hCDC4
tsc2−/−
ATM-mediated
8/140
BRCA-1–binding
EIEI
54.2
60-kb
oncogenesis35
Space-filling
MMP9
exon11mutations
activity6,7
capecitabine
Sjödahl
.Advantages
3:1
chloroform
Tetanus
fancc
3-bromine
tibia
F8**
5′-GACAGCGGCTCCGTGGAGG-3′
~23
phospho-tyrosin
8.35E06
225-mg
RBPJ
BARF1
Ex9R
post-neuregulin-1
¶Consists
Skp1-Cul1-F-box
and-6
16–23
CREST68
Nuclotide
mC7
p=1.2e-15
intron13
D77
211-230
0–2.0
.Molewaterplein
FIP1L1-PDGFRαT674I
viral-probe-reactive
yeast.DNA
IGIIV
∼10–30
Tc21
undertension
development.We
P379fsdelCT
biotinylating
enrichment/depletion
0•57–0•87
pertuzumab
epternber
fareflock
.Cullin
.Melo
acetyl-lysine-binding
30–41
COMN72
dimerization,39
antirabbit-horseradish
12,907
extinguish
.Closure
/Primer
Mre11nuc/-
containig
p53,6
MED12WT-like
Analysis—For
RPKM/PSI/PIR
50,050,261
8,9,17,31–33
software,22
L1407P
M0
goldFISH,27
PAB419
HM481
552709
3,350
decapentaplegic
HGRP
MB42
A200P
38182641
rpS6
Carcinoma
super-binding
intrasteric
Quantitations
fifth-leading
aCGH
WinNonlin
Campochiaro
complex.3,6
KRAS-wild-type/XPO1-inhibitor-resistant
latrunculin
RP11-1133O3
total3
CTTCTCCAGTTGGTCTCTGGAT-3′
1.Schematic
differentiation.7
Hap2
c.890delG
.R7
YAPC
.Salerno
.PF
mice.162
46–24
site.Table
21/42
postmicrodissection
1275–1281
.033
E353Q—Mutation
ΔΔGas
14,070
TIG1
Widschwendter
1290–2603
Hamaguchi
PV-treated
GGAGGACCGTCGCTTGGT
L923
Q556A
abnormalities.14
Wokolorczyk
al.,2003
m1L-3
BARD1-ΔAnk
transcriptionPCR
IARC-Thai
S6D
TrkA/B/C
EIF2C1
0P
kinase/AKT
88/131
.lumbar
0.0134
differ-
6Canonical
isrk=P
MyoD-AD
NS-neurofibromatosis
cattag/CAAACT
lymphoplasmacytoid
1960s
let-60gof
S241L
-18S
Immune-deficient
TGF-β/SMAD3-specific
591A
C-ERBB3
2−5.8HIST2H2AA3Histone
USP45-dependent
anti-oncogenicity
.190
18F‑FLT
MAP3K1-mediated
17-23
Msx1
-RFDSGLDSLKEDEY
ImmunoSEQ
bacpac.chori.org
HAFANCG
diffracting
C33a
carcinomas/adenocarcinomas
.Tumorigenicity
IP/Co-IP
defi
I314F
17pl3.3
6⇓A
Ser/Thr-kinase
0.020425
NTA-bound
1.85–5.65
Ank3
Chk2-reconsitituted
.Lancet
QS
5¶-TGCAAATGGATTCTGCTTCACCTACTTTGCAGGAA-3¶
35,40,41,42,43
H.R.B.
Suppl
Msh2-deficient
NM_011102
serially-diluted
progenitors28,29
557-8
degradation.2
EWSR1–ATF
p.o
PARK1N
HAWP
V45E
36799
Etv4
6/RAe3R
.STRAUCH/SCIENCE
signaling-pathways
Spector
GK1.5-injected
LN-229
.GSK1120212
resequences
double-barrel
internalization/degradation
L10P
.Dijkgraaf
Riobo
non-ampli®ed
disease41
NF00234
cancer4
homology-.
d'Avis
FLT3ITD-transduced
families3
.Integrating
S2D
Buganim
GDLG-18
Hong-Kong
0.880
Rozovskaia
S152N
1341-1446
≤0.05
76Â°Cfor
breaks.BRCA1–BARD1
T58A
ΔII
A266
on-board
0.6.1-r104-tpx
reports15
0.004*
R489L
LMB-treatment
enrichement
MTA1shRNA
PD4/neo
CTTTCAGCATTTTGACGGCAACC
P=.002
Rafl
EIAFm.2
p36.32
t-butyldimethylsilanol
.Bcl-x
pYES2
CD115+
Ret-MEN2B
Immulite
pcDNA3-EGFR
birth132
aTruncating
Non-hyperdiploidy
P165S
p.Ser2Gly
AccuMed
T-box
p34.1
ENST00000071246
125m
temperature-conditional
T1346
ROS-associated
WK557–558d
mis-incorporated
Cntn6
Monsonego-Ornan
Glu-62
SQCCs13
PMS2-coding
caspase-8-positive
CMV
HER-L726F
37–
HMGA1/HMGA2
development21
MPLW515K
knownfor
5-trisphosphate
RAC,8
.FLIP
molecule-like
1,095
3.46
p21−/−/TRAMP
hybrydization
malignancies7
Tyr35-OH
.Family-based
KTFSTYSDNQPGVSIQVYEGER
TATGTGTGTGCGTGTTTATG
Barbulescu
Blacked-in
Ig/TCR-based
D521–603
G117R
LC-MS-grade
1771
3731delA
P320T
antimitogens
sarcoma/primitive
569-fold
dataYes
IL-9-induced
2986
revealedthat
Trp53R172H
5′-TGAGATGTACGAGGTGCACACA-3′
U20824
GBM-T01
72–74
6.11×104
FGF3/FGF4-amplified
TRCN0000235890
2760
edgeR-test
F93C
CSD.KIT-mutant
2•0
001664.2
ligand-neutralizing
afatinibwere
HWE,15
patients46
Ras-GRF
t‐test
.Gli-luciferase
-N-
MKK4L/L
hyperplastic/dysplastic
osteotropic
a-cyano-bhydroxy-b-methyl-N-
diagnosisIn
.ErbB-2
50kD
CD6
erlotinib.1,27
41,47
Fig.3a3a
factor-acute
TrpThr
non-ionic
1,800
1.633
nonfunctional.30
pMSH2
anti-MICA-MICB
40.4
XK16/20
identified—55
P12/ICHIKAWA
pVHL172
2.4–15.0
Met37
twenty-four
Opioid
pregrown
51.0
MRE112/RAD502
.2959C
6Da
ERCC3-XPG
Stat3,21
11ew
R320H
Non-Langerhans
Fcγ−
ETV5_exon6_racer-r.
4.View
ISUABXIS
neuropathologist
p.Val25CysfsX3
pMALC-2
His188
ereas
methylase
carriers.1,5,13
thedetergent
G353D
1285
2A.ResultsIn
JMJD2C
PCGF2/MEL18
cod-
M099
V1247
Quaternary
G1382
centrosome–nucleus
Qiashredder
ANNOVAR36
∼1.2
Analysis—Anti-chicken
.Wrinkled
mutations.BCL10
22.23/11.97
reported.65
mostcommon
Targeting—Wild
E-box/GATA
Study..
−41.9
8.3/2
CAGGCTTATCTCCAGGATC-3
PDGF-β
ADT
T161A
41/1968
TTCTAGAGACGTCCACGATGCC
scores—RUNX1T1
pT2GIII
Indel
itself,45
α11
GgAGAAAR123
.Inversely
V768D770dupSVD
was…
forTFG
Pl3K
1′
Ex-vivo
BCA-4
phakt
MPN-like
6-year
imatinib.24,25
p53wt
loss,48
samtools.25
HA-D2
.1732
DAPI-based
pancreatitiswas
RAD21
resistance10
the-fold
Navaza
.Progenitor
Occlusion
CYP19A
QqTOF
CBP+/−
P1806AF
pathway–compromising
C217R
ICN1/2
9p.11
56˚C
Brca1-mutant
Intronexon
cancer,41
567-576
ERBB
Pold1
Del591
cells40
ClaI-digested
GA.
phosphoERK1T202/Y204/ERK2T185/Y187
28.0
14-Rb
CD3+CD57+CD8+TCRαβ+CD5dim
Wnt7a-labeled
Galabova-Kovacs
MCMCglmm
GSE12777
TELJAK2.13,18,25,26
therapies93
β-catenin-overexpressing
KRas-wildtype
limb-girdle
inter-Src
c.1288delG
c.-1114-
.Deficiency
government-funded
EZH2Y646F
Hi-fidelity
GST–D1
activity.21
expression-dependent
BimKO
PBS-T.
99.5
T20-TBS
approach16
propagermanium
stabil-
RRRCWWGYYY3
c.5346G
3H2EB
FYRC
2−8
p.Leu245Phe
tubulopapillary
4676
R643H
elongation-associated
MLH1,36,38
MET–HGF
edu/pph2/
SMARCA4-containing
836T
S810L
study,39
677T
Raf1–MEK1–ERK
MLL.24
8032
E2F1-mediated
TCAGGTCTTTTTGTGATGGGGATCCA-3
Visvanathan
-IRES-neo
melanocytoma6
K-Ras-G13D-bearing
129P2
GCN1
AAGACTTGTTAACCAGTGGAT
NCT01570036
NHA9-GLEBS
elements,99
I684
anti-PPAPDC1B
vol-
Abl/Rac
Tannehill-Gregg
MPNSTs.17
ER561
Cyclin-Cdk
factor7,8,9
.Photographs
aUPID
adapter-ligated
mutation.44
42·0
2184–1
supraglottis
binding/release
c.1651
promoter.Fusion
1-silencing
immunosuppressant
Carma1
FGFR-IIIc
74,000
Jaeken
driver-
0.44-0.81
169KKLR172
nihms710585u1
0-132
L-744,832
Kras-driven
C2-FGFR-2
//broadinstitute.github.io/picard/
HD-0292
DECAprimeTM
lymphoma/leukemia
G419R
VEGF165
previously.10,18
Galand
.6–.94
717-3298
59-AAGCACAGCCTGCATGTGTC-39
TDK
.SMADs
TBK1/IKBKE-regulated
inborn
TCATCTTGGTCAGGTGGTGT
–16.2
H1′
oncogenic-mutations
27.15
ERK1S74G
AAV-derived
FGFR1c
end52
0.809–0.935
Thr280
β2m-free
AA447835
3-dependent
117,971
pSG5-LNCaP
Runx1-ETO
neurofibromatosis–Noonan
Youan
SMART-pool
19–24
TACTGCTCCAG-3
interactions.21,22
POLR1C
Qpromoter
2.337
oa-helix
C′
0.28-0.73
early-lineage
.Dual-color
JJY
Hypereosinophilic
.MNX1
analysishas
VB5-transfected
Cbl-dependent
GDP/GTP
728.0
M134del
counsellor/geneticist
Hs68
-a
8.83
LNCaP-cxD2
src-homology
BCAM
FBXO4
weexamined
LK79
R2510L
CLOCK/BMAL1-mediated
TTTTATGG-30
Kamimashiki-gun
background78
pY694
.A1
psi-PIK3CA-C
∼0.1
leukemia-free
BRCT–BRCT
Pho81
SSCP-PCR
.Pilot
35.36
NP_004949.1
791small-bowel
unknown3
CTGAAATATTTTCTAGGAATTG
p53tet-R337C
1.18–2.33
GCCGCCTCAC
basal-like14
0.208‡
6-nucleotide
Neuregulins
primerdirected
Lys622
//www.pamgene.com
THPO
cytokine-independent
DP013
.FEIEKLKPED..
co–primary
vivo.39
G309E
FLT3-V592A-
FIDA
IgG/0.5
Bcl-Abl
tyrosine705
ribosome-sized
Zuccarello
rs3924917
D38nt
Kaghad
precancerouscells
Poly-pharmacology
ACCTATAGTCTAAATTATACCATCa
PRDI-BF1-RIZ
SNK
RAD4
1.17-fold
D-MEM-F12
RP11–49M9
PGEM
Smad2–
L.X.
harmartin
133D3
Blockage
AbERCC3
FISH.35
5′-TCGCGATTATCTTCTATATCTTCAG-3′
D1306
S9600330
N=55
172±123
32P-labeledhuman
2-15
5296de14
Pparγ
Hillion
λ-Phosphatase
1.2E-11
35.7
src-homology-2
Y628E-for/Y628E-rev
proline-substituted
Cbl-
META-PP
median-centred
4562-7
0.472
L38I
Cicchini
pCDNA3.1-Keap1-V5
controls.EWS/WT1
activity,25
gastroenterological
1.93—21.1
C2-embryonic
NH2-residues
Ser23
3-estradiol
PTT-based
onDNA
P2/cholesterol
c.2422C
APC11
D182A-expressing
3p21-22
*p=0.03
seconds/68C-1
neurobasal
2.5-min
1749
1,1
compartmental
nonchromatin
FLJ40165
Gurevich
201C
40/41
S1a
F44
colleagues5
blotting.Following
D835G
Acetyl-FoxO
14-fold
92/77
R177X
–have
10−36
RSISAKGAERVITLKMEIPGSMPPLIQEMLENSE
behavior.27
corepressors/coactivators
receptors.7
size-based
value,37
QiaQuick
single-genome
Giaccone
atropine-insensitive
cisplatin18
RP11-147O19
10-MV
134797
OBP2A
M13-tagged
NCT00939627
2.35–359
D551H
half-plateau
Serous/2
.EZAF
perithyroidal
2−6.3ANK3Ankyrin
exencephaly
leupaxin
GAGCTCCAGTGAGTCCAGCTCCTCTG
myeloid-derived
SloanKettering
CHK1*
exit97
AFRREWSPGKEAKK
Commonalities
K666T-SF3B1
p.G230X
Fil
anti-SMARCA4
hyper-ERK1/2
Jeselsohn
GST-BTG2
329
0.1–2.6
phospho-FGFR
TC-106
SF3B1MUT-sensitive
improvement.17
5.65
JCML
.A375/
activated6,7,9
luc-17/20a
1690–1695
phosphorylation-modulated
alpha1B-adrenergic
2.1289126
c.844_850dupTCATTAC
Q15K
double-
performed.29
IKBKE-overexpressing
n=22
p53mutantcancerNMRpeptide
.Impressive
ΔN3
PIK3CAG1049R
5′-GAGGTCCAAGGTGCCCTACAT-3′
C133W
inhibitedwhen
GTATAGACAAAAGA
5·2–73·4
findings,13,26
HCImage
GIST38
18/50
2430
R508W
anity-puri®ed
Brainarray
10.76
Bretsky
5'atggctttctgtgctaaaatgaggagctcc3
5′GGAACACCATGAGCAGGCCAGGCGG3′
activity3
Figure3
c.1277–6284_1386+4776del11170
MARCKS
AGA→ATA
.BMPR-I
4645
P146S
Disheveled35,36
.017
sevenwith
0.9573
10-year-censored
CRC29
0.866
2−6.5FBN2Fibrillin
3633BC
physiopathological
.Proteome
blot.H
GCCCGCCCGG
IC34
.Brm
imatinib-
26/281
I55
rs35958982
HER2-positivity
multi-probe
inexperienced
∗603254
610182
.Kidneys
.FCS
protein.64
Ala-627
manner8
G56R
3.3.5.
572630
reported2–8,27
calcein-AM-positive
45,46,48
complex-Rheb
leukemia.5
CAF13
Stevens-Kroef
.BLI
5′-TAATACGACTCACTATAGGGAG-3′
5′-CTTCGCCGCTACTCCTGTTC-3′
SH2B
enlargement,27
relapse143
Å
Gundem
phenylthiohydantoin
hybridising
nonseminomas
nature.comInactive
5′-GCTTCCGACGGTACACAATCATG-3′
PR143
c.-212C
32530
17-5
immnuoblotting
aSMA
2006-344
PC-12
..Performance
.Thomas
968
Uni/multivariate
Akt-T308D
RCT-D419
cellnÂ°281524102116141985027349683752329101826571489
c.373C
IDH1-mediated
125T
2.21
eyelid
MSCV–puro
helix-parallel
GAAGGAT-3
285
III.2
erbB2-targeted
135900
5123
flurescein
MLH1-PRO1F
R71L
DU4475
p-Erk1/2Thr202/Tyr204
tomography–or
ARfl
806del
Cancer—Geiersbach
homogenously
GFAT
.Methylcellulose
Hist1h1d
13469
hydrogen-bond
HMLE
GX15-070
.EBV-transformed
ridge.21
flut-
XH2
//www.genecards.org/cgibin/carddisp.pl
PP2A-B56δ
Koutsopoulos
AR-V567
227-amino-acid
Wnt3a-induced
7.64
.Costa-Guda
1.6×10−5
Peutz-Jeghers
decapsulated
CULLIN3
androgen-AR
Brakensiek
R52L
MDS-r-AMLd
therapy.29,36-38
LrrLUtLALI
R401H/A
ETV5d
FA104R
457–464
Gelucire
coinjected
NSE
PDAI12-R3
SacI/KpnI
17–30
TrkA/NGF
,17,18
X-100/50
G420R
Bossemeyer
PeakScan
errors.8
Vaske
KRASY71H
p-Trk
–FGFR1
.448C
lB2
n=131
m5C
4603G→T
2582
Glu265Lys
S1598F
co-structures
RodriguezViciana
thyrotropin-independent
c.1378
osteo
NTRVGTKRYMPPEVLDIâ
MEKis75
E799
RET51
1159
Sjalander
IEF
Yeast-based
pan-class
co-mutational
0.001696948
anti-EWS-FLI-1
NCT01349933
templateDNA
DUSP4/DOK2-codeleted
0/450
KFSM
C_724_G_5
3C5
R.H
plaque-like
p21/
Reexpression
D167H
ZipTip
p.Gly13Asp
S1524Q
pT1b
GST-ELK-1
266
Hypomorphic
Conjugate
Pms2−/−
p300-mediated
cells.8,21,31
pLVX-IRES-Puro
74.6±7.9
2—
mutations24,25
1.9-kb
CRF-immunoreactive
Thr118
SuperScript®
SY38
Monotherapy
P9424
C387A
supE/F
.Cytostasis
exon-capture
p=0.0007
880
Edlundh-Rose
ERBB2-positive
carfilzomib
detectedc
urokinase-type
isoforms.3,4
patient2
dual-labeled
vasculogenesis
7F–G
Y133C
tumorsuppressive
UPN-1
Ala205Thr
.Metaphase
treatment.28
nuArCInVIGIuGIyArgGlyLuGIuGlInAIdlyTrpIIeLouThrGIuLeuGIuCGI
//www.cbs.dtu.dk/services/SignalP/
E706X
consecutively31
gtt
D594E
27.0/10.2
integrins
.957
C15orf21_S
vemurafenib,14
DEK-NUP214
M947V
Ahlem
0.092222
18/17
HerceptinTM
risk-directed
proximate
//cbio.mskcc.org/tcga-generanker/
.Y1086
S5A–C
EHD1
F139S
LKB1/Hsp90
E10.5–E11.5
PDGRFA
GATA3-specific
17/135
3.97
ERBB3-Knockdown
99.912
L106F
NM_001042424
936E23
GGTGTGCACACCTCTTGCTCC
5a-DHT
TAZ45
LEF
deconjugating
T512I
2014-0024
50s
EADock
proteins24,25
pan-Trk
DEL5PB
442-patient
ratescored
MEIS1,33-35
Hoechst-counterstained
IR-mediated
thymidine-guanine-adenine
406_411
5′-tcgaggattggggaccctg-3′
1B6C
59-CAGCTAGATGCTGTTGTC-39
PDGFRA-D6842V
t.
K=3
.006548
DAF-2
steroid-responsive
L452I
1541
galectin
K369
r4
CC-to-TI
D'Avino
INPP4BhiPTENlo
canonical_and_isoforms
fibroblastoid/mesenchymal
anti–glyceraldehyde
S4
KIT-G565R
Satoko
GAGTCAACGGATTTGGTCGT
welldocumented
Asp816mutant
Zenklusen
proctocolectomy
Administration-approved
Y800X
precasted
Forshew
1.066
HumanMethylation450
GBD-Msh2
5-GGATTGGCTCGAAATATCATGAGTG
pGEX-4T1-Ntev-NF1-333
32.6±3.3
25−
Beatson
peroxiredoxins
PI3K/Pten
subclone-specific
mTOR-rapamycin-FKBP12
V702
R113Q
-20.8
Sukumar
setting.4
Y340FY341F
3.532
96:4319–4327
q32.1
3730×l
SBD
R38
three-probe
Sorafenib-RET
exchanges61
02118
Thr316
p.Cys241Arg
HR-2239
+201
EGFR/erbB3
complex.7
BetaPlate
F354L
.cDNA
//hapmap.ncbi.nlm.nih.gov/
Fig1M–O
MTBSTFA
N=21
par-4
Mob1
50.5–99.5
g2612a
siYap
.MM-121
P.E746G
Gly63Stop
BM-specific
Q-banded
phosphoglycerides
s921
-22
n=8
c.1381C
p53-reactivation
nonprocessed
Y52C
q/
NLS-PNA
−5.8
function25,26
.Interferon
ezrinT567
phospho-tyrosine–substrate
anessential
crystal-violet
p.E180Qfs*5
.7–9,20,34
MYOD1-expressing
*Thy1
anti-vimentin
111,171
ASD-Splicing
unblinded
Hs00175273_m1
1.00t
LEF-1-dependent
ac.jp/SnpDB
top/low
Sumihare
disease9
.Nutri-Cal
2⇑
333bp
chlorarnphenicol
MUM1p
EGFRprotein
leukemia/set-domain
Figure4C
anti-Bw6
VavCre+-Tet2−/−
c.1384_1388del
c.823_826delGAAG
H1047R-expressing
790–927
2dup
anti-phospho-c-Kit
miR125a
often-fatal
L305P
5′-CACAACTCCAGTGCCACTACAGGGAAGGGTGCGGTAT-3′
80K-
vimentin
Leu938
5684
Rajasegaran1,2
mitochondria5
elements,33
melanoma-derived
//www.xlab.unimo.it/GA_CDF
originalmutation
Vκ6
Leu-34
8*
TM2D2
M523V
line21
WICH,40
BARD1-expressing
double-edged
FBP1
RAGB
protein35
dra
1-kilobase
16q24
V600E-K-D
resistance.26
group23
pEJ6.6
382genetic
FBW7gamma
29-74
1.376
super-short
Array-comparative
C242R
I255D
BRCA2-specific
activity22,23
RET-derived
16,41
0.0006
anti-hCD34
pGEM4
14q21.3
Fig.6A.6A
non-DNA-bindingdependent
.CXXC
0-to-14-year
study.23
Othman
Nan
peptide-conjugated
6.View
Asp316
arrest129
defects.32
E930G
.Chao
Assays—ChIP
nitorosurea
.Procedures
R234C
q13
hMLHa
FA'Ua
E2-21K
V372C
p53.14
M7998
DYRK2
SRC-homology
G453C
anti-phospho-4EBP1
ras+/V12
RASL2
d9891
S18N
S5.5-8
S7N–O
.Inthis
Satzger
5α-reduction
jsp
TBI-Endoxan
28,51
subgroup-specific
5.04E09
IFAR824/1
44,670
IFNa-inducible
qll.2
pseudogene
T1-T2
Kotecha
form1
Sf3b1-mutant
c.811G
signifi-
V600K-M-D
Z3/6
C229/277S
p110/p85
SC-61
RNAiso
.PolyA
Radiolabel
P50.0139
25–35-fold
D-004937-03
pro-death
Biol.
.A461
HBL-100
PCR4/TOPO
bakerlab
cedric.lecaignec
23–26
Fig11
MDA‐MB‐231
sensitivityStarting
stage.27–29
eB1
L8A4
andSupplementary
Skp1/Cul1/Roc1/F-box
gefitinib.2
cross-complementing
Macrophage
1.17–3.75
pHisH3
Hrs-
anti-AcH4
PreAmp
types183
1134–1784
additive.51–55
Staal
non‐small
Affi-beads
Genomics-Based
anlage
Cpd
plasmablast
PTENK128T
125–226
D521N
KVEQEGYPQESSK
BAT-Ril
LacI-CHERRY-NUT-bound
pharmacologically-targeted
cancer.19-
72/72
OPK14
pUAST-ALK
v18
Ile57
si-scramble
Ser2215
D-53011
www.ncbi.nlm.nih.gov.ezp-prod1
Asp158
5-carboxylcytosine
7.5°-9°
pT2-4
KIT177
⁁
Statview
.Plant
Gleevec™
days/week
Hs380463_m1
polymerisation
HCC2429
crecursor
RTKIII
cytolysis
pT1–4
MGH-PO-l
BRCT-dependent
5D
a-Casein
relativeto
LGOGSFGMV
RP11-1122L13
BMT
andprocedure
form.164However
foci.72
and7
CCCTCAACATCTGGGTTTCT
glaucoma
anti-Mek1
dimerization3
MLPI
Lin−Sca-1+c-Kit+
palsy.17,18
T.J.
pathway.1-3
G468A-expressing
M0-AML
0.3–4.7
p.Ser3147CysfsX2
Q276
149×109/L
J-
Oncovirus
R7S
.Axin1
C.I.
4-week-old
c-MET-overexpressing
MG14R
pRS314-CX3
c.6677_6678delAA
unclear.84
bActin
FoxH1s
Abl-expressing
0.83–
Ser21
agouti
OR=0.39
EKB-569
0.829
single-bp
Ras…
.47426808C.G
_t_
pS6-S235/236
Myc-WPDGFR
Protamin-Cre
KILLER/DR5
HB-EGF/ErbB1
81/115
Zollinger-Ellison
.AntiphosphoErk2
PolyPhred
p=0.060
F/68
crosslink-dependent
5′-caaactccttggcaaggtaacctttggcaaagtca-3′
hybridizationFISH
ER16
97N
8q23â€
RUNX1–EVI1
AKT3-dependent
60–68
Wt1-null
24668
05/03
Iranian-born
immune-driven
E3d
Mll2+
PI3K/protein
E36K
G323V
Poly-
R2971
isomorphic
35–42
dye-flip
1q22-23
60y
months.10
3865
ERG400V
49,125
EWSR1–FLI1-transformed
proteins118
C.-F.
bis-acrylamide
Fuhrman
DME3+/MMR+
anti-Sox4
Claix
ERCC3/
morethan22
alteration48
18p11
31.6712.2
HC11-NeuT-induced
3193_3194insA
BIX-01294
Sutent
assay-specific
19/150
33y
Asp176
Iq
100V
p53-coding
.ARMS
OA2s
−920
1PEG
anti-Actin
insulin-stimulation
2timesSSC
TCCGGA
.BACH1
Biomédicale
.P3
11q
V710A
H.M.
YFP-Ets1
tumor.Patients
Dnmt3b-deficient
lymphoma11
haematopoietic-cell
MAS5
inter-observer
29923/B-03
Percentinhibition=100−
AYVM
Arf-deficient
BAF8
E76D
β10-β11
chronic-
Ribominus
NM_000141
NHBE5239
myc-CARD11
13·3
Keppler-Noreuil
L521I
NF-Y,40
Kurumizaka
zlj9990993630005
493K
p.Glu276Gln
DBI
PI3K-PDK1-AKT
NMI
DLCL-associated
Alterna
D'Azeglio
ofigonucleotide
triethylene
.§
NCT00656136
self-DNA
48/186
Ruland
POLE-induced
Akt3-WM278
Y801
doi:10.1371/journal.pone.0025021.t005
Kleer
C-kit-positive
damage3
untargeted
23.58
26/45
G228W
phenotypesTwo
.Morphologically
.Encounter
.Protein
.Haluska2
H3-K42
uc002ozu.4
pRc-CMV-Cyclin
G580
model,29
37.87±3.82
NCT00265759
EGFR-P848L
thymomas.
BBT
MPPLI
thrombocytic
KW-2449
145-2c11
.R273C
1,528–1,863
MIRB
.E3.5
K187T
5′-GGCGCGCTACGGCCGCCCCCcgg-3′
wild-typeDNA
ACCCAAAAAGGTGACATGGA
1187
C-CDK8/19
APC-
KS+
anti–p-STAT3
601
NP_000240.1
rereplication
2.8-
CLL27
ploid
enterocolitis
G-protein/cAMP
Splicinga
n.d
sc-98302
al.67
Groene
E2A-PBX1a
Q1537R
5'-CTCTTCCTCAGGATTGCCTT-3
T1022A
RP11-314P15
100K-SNP
ribbonjr
centrilobar
Schottelius
R19120
794
megakaryocyte-erythroid
MEL-
regions.6–11
TSQ-Vantage
amplification106
pre-exists
9,882/10,604
VHL-L158P
Rap2
Polyacrylamide
Retsch
4,3-c
RP11-799E21
phospho-PDK-1
menin-complemented
Fig.1,1
63°C
z.g6
image/gif
mutations.43
GST-Chk2FHA
-H-L-T
−1.74
.Release
2575G
MDM2SNP309
mutation.CSVDisplay
Del745-746
TRIP4
c.1386190_93del
RCC2,3
13/24
I157T-positive
Y268H
GSE37088
5′-CTGGGTAAGGGCAGGAGTC-3′
STAT3/STAT5
ccgctactatgccatgatgatcctcaagaaggagg
16q22.4
Pax2/5
Paid-end
pathways.26
C-19
CD35.7,10
|induced
.Hybridization
N205S
.Multifocal
.High
9p13.3
c.837+1G
+++++++++
patients4
7,8,9,10,11
FGF-1-producing
−1.55456
tumor-infiltrating
.Rad51
18–522
56770018
NE=not
cells/mm2
E271K
1–20
BCR-ABL20
CaCO2
FU-treated
well-resolved
3.Summary
G340W
malaria-endemic
tandem-duplication
mediasti
motif116
CubN
SW480-
TCGCCAGTCTCCCGAGC
-ATTCTGGTTGAAAGATGGCG-3
RAGD
54.6*
D777-MycT58A
26.8
0.3–
D13MIT67-R:5′ATCTTGCATAGAACCTTTGGATG3′
StainiÏg
S0500T
.5932G
CHEK2.ivs2
SN357
Beldjord
41.cER4.34
chr16:67416845–67424923
positro
S3H–I
2.3/NA
L7675
5′-UAGCGACUAAACACAUCAAUU-3′
V-ets
.2881C
gle-strand
.Cheng
extractability
CCR7+CD45RA+
Il2rgtm1Sug/JicTac
Circulatory
Smo-independent
19–56
vaccine9
FBW7-dependent
T5443G
plasmidfreestrains
pY674/675
bi-lobate
5.1-4
4.03
466X
H3K27.18
immunoadsorbed
0.18-fold
PTP1C
2AHX
547J11
CAACCGCCCGGCT
Myc-BS7
39791–40133
guments
37–38
GeneBank®
MDS.60
v-Akt/c-Akt
PtdInsP2
mutnomen/examplesAA.html
1.28E17
0.459
Prpf8
p.Ser282TyrfsX15
623
109/l
FBC
Y315
El-Deiry
myeloid-erythroid
ALK2-Smad
structures.14,15
LEAFLET
proto­
HPV-18
anti-PDGFRalpha
∼2.3
+BYL719
nihms646437f7.jpg
cases.4
IDH2-mediated
His-286
p.Arg134X
beiging
1100delC
ForDiscussion
FGFR3-encoding
domain/iSH2
notto
.HGF-induced
D8N
972/1042
v64
0.492
H3K4me2/me3
Accelrys
Hs01554635_m1
K558NP
AACGCACTGCC-3
TCGA-97-7554-01
virusevoked
L173
340–419
'effectors
range=4–140
PRMT5
hydrolysis-dependent
anti–phospho-Y705-STAT3
N195D
Ik
Asn535
FCS-DMEM
®ndings
AMIGO2
enzyme-inducing
p.Leu648Pro
β-5′-Mlu
rs11571833
/LPL
Garcia-Blanco
Ser32
FRIZZLED/LRP6
γ-irradiation-induced
RVKELEARIISLKNKKDEAQSVLDKVKNERDIQVRNKQK~ADINRLIDRFQTIYNEWDFEAKGFDELQTTIKELELNKAQMLE
c.1216C
29-31
BCR/PDGFRA
HEL-transgenic
12.5-fold
SUZ12P.5,7
43–50
.DAG
WT-JAK2
'251-labeled
1193–203
5µM
.5555
XSCALE
Mga‐dependent
diethylnitrosamine-induced
165217
Vilimas
diffuse-types
PMut
p21/WAF1/CIP1
RET-HSCR
mMachine
R505G/L
KIT-to-centromere
61-8
carcinoma,42
dTORC2
GDP7
G401V
A355P
2,5-dibromophenyl
Axiovision
4249C
GCN5
Gln251
4-methyl-piperazin-1-yl
transduction1
.Mutantmsh2
3791–4131
CNG–positive
n=28/132
demethylation
tumors—should
Bedtools
kit®
MN56B
U-SK
women.3
imatinib-responsive
Glu221
Men1-positive
Cx4
ARVO
Fischle
CPVCLQYFAEPMMLD-CGHNICCACLARCWGTAC
CPQ
NM_031550
miniprotein
VCB|
TRAF1-ALK
FusionPlex™
SV40-encoded
1BEN
5'-protruding
mutation.6,7
S8A–S8D
EstrogenResponsive
NF1-NS
R717W
007298
0.057-fold
Skyline29
polio-like
Bjarnegård
immunoprecipitation-MRM
collaboratively
5′-ATCTAATCACCTCCTACCAGTCTG-3′
0.84–0.92
Easyprep
Ikegaki
J.Q.C
demographically
MEKi-induced
Lats1-
analysis-based
micro-GIST
dihedral
Glu453Gln
NMRI
Srsf2Δ
.Endonuclease
Gibaud
K398A
2293Tfs2319X
HEC-1-Aand
Smad3-heterozygous
FIP1L1-PDGFRα-mediated
transactivity
S518D
mastocytosis.3,4
EGFR-driven
TA2
FigFig2B2B
1OTh
carcinomas.24
ART-27
anti-miRNAs
non-tissue-specific
ΔPDZ
Atm-knockout
NL-13
Montre´al/Institut
2-methoxyl-4-nitro-5-
2/33
waschanged
6259
1445
52.1
8q24.12
AGTGCAAACAATACATCATACTTCTTCA
pCMV3
c.1450_1461delAAGCACAATGGCp.K484_G487delNone
SAMtools37
histiocytoses
5.0-fold
10−20
p33ING1
context-dependency
NCT01708174
Fluor-555
LSC_DN
cctctatag
Skp-1-Cdc53/Cullin-F-box
28/25
5′‐CATTTTCCTCCCGCAATTGCTAGAAAATATTTCAGTGTCC‐3′
93.7
ASXL1-WT
A95
Ercc1-deficient
apoptosis/senescence
CD90
dysplasia.38
25-30
Q556H
.TSC1–TSC2
PanCancer
FLT3-ITD/TKD–expressing
94143-1330
lovd
p.H125P
tetramerization
p53-Y163C
Holm-Sidak
5-GTCCTGGAAGCCATTGAGCCA-3
PCA1-4
Bc1-2
mucosa*
E1B
visu
p53/T-antigen
Rikova
TrkB-induced
.GAP
IFITM1-induced
dual-injector
BR803
RP2574R
5'-GC-clamp-AAACTATGAAAACAAACTGACAAAC-3
3768
14.74
carboxylmethyltransferase
Sakakihara
p300-TFAP2A
1534/0/230
MCAK
****de
UBC9
±31
pCITE4a
2.CDK10
themsh2-AE859p–Msh6p
collagenase-1
5.44
r=0.79
∗
S34F/Q157R
1.511
fmahdi110
Flag-caspase-8-R413
NSHP
whole-genome-amplification
R283H.The
0.25=0.0000965
TCTCGCTGTGGTGACCTCTG
2604
Krangel
6°
9587
043
GAGCTAGACGTCCGGGCAG
1863aa
germline-activating
RIl
PAX5-JAK2+
25,500
R713Q
l0o
rearrangements/fusions
G617A
two-score
cryo-preserved
FigFig5M
Mill-Hill
p85–nSH2
5'-CTGAACTAGTCGTGGAATGGC-3
KIF5B–MET
0/76
MQ-003886-01
AACCCCCAC
oncogenic10
.Power
Asp208Asn
Tenen.16
FOK1
anti-CDK4
transcriptomal
Ziv
Tnf-α–induced
mRNA-overexpressed
80–20
U-Score
RG-4N
I996
.Kerr
HER2-IHC
HUH
RM2235
HNPCC.29
EGAS00001000775
Poulikakos
U133Plus2.0
MPCEWS-FLI-1
M134T
ERK1
T230M/E168D/N375S
mutations.10–12
0.29-0.53
p53–expressing
Calpains
D256
BRD3-
Figure22c
mouse/rabbit
0.590
11,119
breakpoints.15
cc-12-1598-g3
phosphatase–mouse
cgc
HGF/Scatter
Flag-MLLC180ΔF/SET
Nab2
ScRad54
∗∗∗P
MAPKKKs
201K
serologically
680LT
11-year-old
ME2-F
dextran/charcoal
casesadenocarcinoma
J009
RP11-90A8
Milliplex
streptavidine-peroxidase
Leu-196
prostate-specific
ZFHX2
K292T
b‑ga‑
CDK4-
IRSp53/MIM
c.534dupA
α–helices
30-76
chromatin12
anti-ÃŸ-catenin
anti-CD2
p=6.3E-05
PD184352-
demonstrated.50
describedby
Anorexia
1.02–4.06
UltraWash
Immunotherapy—boosting
C‐ter
pcDNA-Flag-ZBP-89
1.710–2.814
A41P
AF036760
5101
RP5-1099C19
hematopoiesis.28-31
93.4
11·1
NEHJ
ETV6/FLT3
p.M511I,25,39,40
J.A.F
.SF268
.SURVEYOR
:685–690
1/100
Oro
Intergroupe
NCI-H-
SU2C
Invitrogen
ROR1-Mediated
IIGFYNAVFVPAM
leucine-to-proline
geranylgeranyltransferase
MAPK9
right-pointing
1651-1863
hypoxia-independent
189NF-κB
​View
cranio-facial
Herblot
cx6
ASXL–BAP1
non-RhoAV14
71‡
XP_317619.4
significant.ResultsHigh
arginine/serine-rich
3/8
0.1˚C/sec
resonates
q12-13
Biochim
Bcl10-dependent
LDSb
Wnt/β−catenin
Ile472
O_sativa
*Age
LIN28
01223-746777
slow-cycling
GRSTFMEIJL
subtype9,27,28
Kornberg
puri®ed
Johann7
EBNA-2-3A
retinoblastoma-sensitized
Mock-
G376
R580W
p-RSK
59.96
aggressivebehavior
haplotye
S2S123
studies.Our
68-kDa
homodimers30
sortby=releasedate
Non-radioactive
frequent.55
Cuezva
L307P
nick-
1GFJR
CLICK-IT
TNFRSF10A
T529MBRAF
CCD-associated
Antitumour
−2.1
Differentiate
PDGFRA-mutated
myelo-/lympho-proliferative
Plk3
BamHI-NcoI
predisposition
≥2+
.PLAU
MIR143
surface12
difluoride
Limpet
CD74-E5F
W80R
19757
6-frame
p.Arg24Cys
D29B3
Bromodomains
neoplasia7
guidelines.10
Lats1/2
K805R
WWTR
XbaI-
cells.24,25
MKK6/p38
States5
S3023
FU/LV
NF1187
AII-2
Reavie
cells—the
IRA1
MLH1-specific
FPLC-purified
hCdc4
/22.5
RB1.20
.Epidemiological
64,770
RAS-less
Homogeneous
Anargyroi
c.-39C
Pharmacogenetics
p.Glu33Ala
pPGS-CITE-CMV-Neo
c.4097-11T
Survivin
3IO2
lines.Semiquantitative
5′-CACCGAGATTTCCTTCAAAC-3′
ACTN4-MLL
.UCSC
Skp1/Cul1/F-box
sh-1
30jC
Nederveen
Phe516
LN-RNHFQSYIMADMYSFGL
−2.71
freshly-frozen
.2–4
31·7
56–60
controversial,43,44
F-WT
h53BP1-reconstituted
melanogaster36
GAGCATGATTTTGAAGTCAGAGAAGA
abstr
.Protein–lipid
CCATTTGACC
cancer115
UVS1-derived
Genome–Phenome
p53-mutated
T327S
A062
bladder-carcinoma
H3K36me3/H3K27me3
FLJ13792
up-regulation/amplification
phoshpho-ERBB3
LLS
hypo–fatty-acidemic
regulators.49
18·7–33·7
proposed2,4
1464–1481
191-amino
over-growth
D319N
erb-b2
S1000
reticulocytosis
surface92
inyeastTotal
437–439
66,803
His1477Tyr
oncosystem
RUNX1–871F/Chr9–977R
Rosa26Pik3ca*H1047R
His1047Arg
cgtc
Pre-assembly
acid-rich
mHGA18
dissociation-resistant
7.65
linearization
2810
3518
expressivity.9
GTGTCAACAAGTGGTAGTTCA
ofIG
starvation.31
GGAA/T
LN405
FH-driven
65.95
K-RasT74P
Two-Sample
.Equivalent
PRC1
misfolded
May–Grünwald–Giemsa
Eluates
6115
5′-CATTTCCATCCTGCAGAAGA-3′
SeqCap
IPed
FBW7-inactivating
TGFR2
Bax/Bcl-2
EF-HASmad4

gene-depletion
Bdomain
.Yung
GFP-activated
P256R
NM_003194
Spritz
Microm
TEL/platelet-derived
MY22
Pten-/-
theorised
haploin-sufficient
wt‑P53
Hoechtlen-Vollmar
7339
TGF-–responsive
G4R
c-55G
SDS/
NHL801
425A
HS15
Germany19
programs.17
SP-49
p27kip1and
18−20
andwas
CS-F1R
13/71
~Schlitter
APC/32-microglohulinFrequencyHigh
12.5mM
dyshomeostasis
E2-responsive
2089
3/115
S1.4
134–137
2236–2250
IO4
SRP012682
14/29
CellTiter-GLO
rates.14
hospice/palliative
4-μl
30-mers
5′-cagcgcatcgccttctatcgccttcttgac-3′
patients.17
fusion,34
V750Pro
and2b
HCC9
cyclase
122–136
Msh2+PUR/Δ
NM_053056.2
cells/slide
inhibitors.10
Nanog
G112A
binding109
V1238l
NRR.18,43
.Biotinylation-based
E526Q-specific
GSK-3β/PTEN
Nmyc
A1948C/K650Q
Mad-4
twice/day
P1087R
gaseous
suprapharmacological
activation.74
Rat-401
337–415,1–41
β-4
MRPL47
D/CDK4-6
Pen-2
HA-Akt
RUNDC3B
Monoubiquitination
.distinct
HNSCC/normal
deregulated/aberrantly
cancer48
Il-3
Isotope-labeling
presymptomatic/prenatal
Chaetomium
Trp53
c.1176
never-smokers
MMSJ9
XPO
6B
.Sedimentation
locations24
tetramer-capable
currentlyavailable
si-Con
b37
Y850
CTC-549A4
tool.7
Sca-1+c-Kithi
Glu130
Scienze
5438delTGTG
BX-51
5′-CAAATGGGGAGAGGCTGGAC-3′
CMV/V5-HA/ER
response-to-injury
Pten/Dicer1
159,162,164
40–55
Lykke-Andersen
PRKAR1B
glutamine-rich
5′-AGGGTAGGTGTTGGGATAGC-3′
GEMIN3
Chemiluminescence
A173
responses.1-4
V–APC
+45
Garcia-Garcia
plakophilin-1
.Admittedly
phe116/9
I-Smads
557-560
cullin-2
4770
+u
D816Y
phospho-AKT2
poliovirus
Lapetina
.PFS6
monoubiquitinates
166K
RcaI
NADPH3.2HG
1.2–6.0
Q268H
.Antibodies
breast-ovarian
HSD17B10
than15
Hsl1p
carcinoma-like
orsteroid
Myc-DCAF1
del747–750
aminopeptidase
PSEN1
5′-GTAGGAGAGGGCCACAAGG-3′
biallelic
P308
DBM
p-Akt
double-amplified
≈35-Mb
gluten-sensitive
Drosophila.6
CARD11-nucleated
ARID1b
AMN-107
ERK1∕2
Migratory
NRA4A3
HomCs
sc-618
PMC42
dystrophy.7
CACAAAGAAGTTACATCTT
Q522R
non–phosphorylation-mediated
25C
.16,28
IIu
Ds-Red
F114V
R495G
−His
.Moderate
0.408–1.837
loss28
lectin-coated
cm−1
Four-Month
software.Bone
tumor-draining
Mekentosj
Crumbs-mediated
oeMaterialsand
13.5,18
HL-derived
CN_173550
CRK7
Tyr279Cys
CrossRef
Swoboda
F498
E4TF1-60
VBC-HIF1α
Gli2/3
96h
36/hg18
Com12.2
3224
MEK1-Q56
agents172
F-/SOCS-boxes
LacI-CHERRY-BRD4C-
TSC1/
described.17,18
Cre+
BDNF-binding
CYP19A1
Ala/Val
pan-Ace-p53
in10-cm
FGFR3.Focus
PtdIns-4-P
cancer53
CSVDisplay
meta-static
.Phosphorylation/activation
C.S
TNT®
20050203
–PDGFRalpha
0.05.
.H.
PRDM1.E7.32.F/
potential.8
motif-proximal
GFP-only
Reed-Sternberg
H187
G776V
g.3029C
p.Tyr537Ser
252-258
NCIH358
.00191
46+A259
co-stained
PTCL5
ELECTROPHORETIC
MG-B2GFP-6174delT
amplicon-negative
MELANOMA
XP1
method55
transrepressional
9q34.3
BPH
Intra-abdominal
17/21
683–1,235
andfour
.Collins
RING-BRCT
microenvironment/host
642.7⇓-9
leul
R362C
Scintific
D-loop
11A
.steroid
TrkAIII/TrkA
polymicrogyria,2
VERs/PVR
caspase-9s
2000.1
T503M
Ceraline
myeloid-restricted
GTGAGCCTGTCTCGGAGTCTTGGG
H-470
YTA
Try537Asn
DxxG60QE
2×105
IVS11
scaphocephalic
400C
p69trk4
8/64
-p53
nonmutation-associated
udarabinerefractory
Ournewly
agents28
PharMingen
differentiation23
Shp2K590R-SUMO1
levels,127leading
cgu
tissues.93
0:52143
.5,6,9,15,16
17q22
PKB3
5′-GGAAGGATGCCCAAAAG-3′
loopweremutatedinimatinib-resistant
28572
shown.Expression
DMX-600
−.67
Akpgenes
//www.cbioportal.org/public-portal/
14–59
FloJo
c-Src-mediated
Ago2-miRNA
1-7
shCDK8-1
phosphorylation4
pMIG/HahBRAFwt
c.6638delC
indel
3/4/05
5′-CATTTCAGCAACAGCAGCAT-3′
12148
receptor–positive
antigensafter
TFAP2CΔN220
Retinoic
TCGACGATAACGAATATGCCTGCCTCAAAGCC-3
TRC-Mm
re-organized
T286R
BRD4–NUTΔbr1
Takezawa
Naka-ku
1,027K
C.A.F.
130650
4LYF
PC-specific
3435
Four-Chamber
0•5
Bindereif
oncogene.1
T539C
differentiation21
3-helix
.Stealth
C11orf95-MAML2
4–171
cAMP-induced
.GATA3
Technolgies
73569
IL-2Rβ
EIF4G1
GGCATGGTCTCCCTGCTCAGTG
SNF5-deficient
:9731–9
gene-silencing
migratory
nonfounder
pTRIPΔU3-Mnd-IRES-EGFP
769e11
levels,44
Oncocytic
RAS23
TLK2
leukaemia19
2–11B
oncovirus
albumin-Cre
923
367This
Luria-Delbrück
8.5–8.8
Lys3
.E.
Naïve
diethylpyrocarbonate
PCR-initial
shorter/weaker
anti-PDL139
vera.53
ab1870
DAPI-stained
0.97949
P69A
SignalChem
.R248Q
astrocytoma/gliomatosis
groups11,15,16
150–189
R201
N-ethylmaleimide–sensitive
54:161–169
2Aa
Gâ
www.sanger.ac.uk/genetics/CGP/cosmic
ER17
c.101C
Kreb
kn
64°C
Feulgen-staining
auccucaaccucuauguagTT
non-PIK3CA
®nger-containing
19.1/25.9
.P27
AKT-P/L
22have
1–248
.Two-stage
M3=15
4–14
−r
described32
H3-K42me
.Genomic
G15A
Gómez-Lahoz
low-input
antiangiogenetic
treatment,1,18
17β-OH
Hex-labeled
Redundancyb
β-catenin-T
APC/beta-catenin
FcγRII/IIIlo
copy-numbers
GDC-0941/erlotinib
stainings.25
anti-phospho-NF-κBp65
threonine-to-methionine
cancersWe
ATRXmutated
.A–F
clear-cell
Pro-GluSer-Thr
26–85
non-CLL-like
schizoaffective
smaller-effect
gttagtccg
catastrophically
Tpo-c-Mpl
gene41
5-GGATGACGAGTTGGCCCTAGA
S2A–C
animals29
Nucifora
Sibanda
56-85
5′-CAGTGAGCATCTTTCCATCTT-3′
G50E
p.Phe1174
resistance–associated
TOF®
Gz
cancers46
region.9
7933
//www.genome.wi.mit.edu/cgi-bin/primer/primer3
−271GG/GA
248G
toEdmondson-Steiner
H1299/D281G
11f41
4-week
pNGFI-A-CAT
4',6-diamidine-2'-phenylindole
tethering8
complex/Tramtrack/bric-a-brac
E566
transcription.32
H68A
co-cultures
c.-32_29del
NL-22
790–797
FACT-dependent
.ANTIESTROOEN
0.5–1.8
3QS9
433–436
G833R
Lep
Intergene
+41
MSI-status
I1183T
0.5–2.5
cBioPortal
H3K36me1
sub-G0/G1
mutations.13,14
V59G
,5b
Cys384Tyr
1eAlaGl
C7916
T123R
p.Glu66fs
E-cadherinreverted
PTPases
496-517
multiexon
TIDCs
.T12
PathVysion
0•55
L229P
variant.For
non-CGA
HMG-CoA
U2AF35-
shBRAF-infected
16–30
complexesIn
co-incubation
FacsAria
C1021
RNA-ligase-mediated
113–116
Gynaecology
DNA-damage-response
Ser380
.PB-implicated
-ATGCCAGGGTAAGGATTCACACC-3
slideExamples
epitope-containing
L265P
CuKα
monopartite
348–630
Post-hoc
G201D
diazol
FGFR2-IIIb
Mis-sense
NCF2
83-274
entry-site
1099_1497del
156
Bettstetter
AEEEEYFELVAKKKK
MCN
.Y1714
TrxSki
c.307-2A
Y42C-induced
oscillate
2.04
5-1,000
Humana
.R821C
unclassifi
Gal4-DNA-BD-ERF
A1125
methyl-CpG-binding
500-mg
D9S1851
Myeloperoxidase
C.D.
Ready-To-Go
257-bp
Leu32−Ala34
†Not
p.Arg578ValfsX3
0·052
R301I
syndrome.4,5
Protein-antibody
L187V
0.00103
VEGF164
non-infant
C15
Ala814Ser
5-m
HLA-A2–positive
balb/c
siBAP1–3
BRAF/BRAF
Jenuwein
Karpas422
GAATTCTACCATGCGCTAG
.Shigematsu
doi:10.1042/BST0380217
immunoglobulin-gamma
P35127
R25A/S124Db
.Fulvestrant
mednet.ucla.edu
MRP-1
Rozenblum
pseudo-papillary
EnzymeKinetics
phosphoSQ/TQ
al.
0.144
D623A
differentially-methylated
ltk
C299-C311
group28
C110G
hyperdiploid/near-triploid
ACUGA
EBV-immortalizedlymphoblastoidcell
Flag-AS160–4P
143:288-299
M2
4–11-fold
L114
large-intestine
inhibitors.5
Brainswere
tumors13,14,15
tumors.19
factor-4
rs121434569
pFA2-c-Jun
G646WfsX12
GATA3-DBD
miss-matched
NTRK3-expressing
hyper-stabilization
Error-prone
1.7/MB
L493V2.
3795
category.9
Leitao
NFASC-NTRK1
Dell'Era
RAS-Q61
I2820T
DNMT3A
7j
.samples
13-3
blast-associated
-GGGAAGCTTGTCTTTTACCTCCCAGA-3
−13.3
.Gatekeeper
A1225C
observations16
2HGDH
5′-GAAATGGTTTCAGCTGAATCTGTAGAC-3′
binding.20
95–96
anti-p58a
RhoGEF
.Intratumoral
markers.12
B9-12-1
muM
αFLAG
G-75
Kmt2a,162–164
clinically5
loci.1-5
.Chemokine
c.2520+1G
PVFs
APC-Alexa
MKKLRHDKL
ter
CMV-CBP
J6
glycosylase/BER
p53-/-+S
3K-L
outReadsUnmapped
gac-3′
FGF3-amplified
.Age/sex
4048
11-c2
Ba/F3-hKIT-D816V
ERCC4-specific
E2A-deficient
P045B
DRB1'0403
reads/bp
chil­
Q613
shRNA222
His6-Ub
Anf
sulfate-15
variedin
HSD17B7P2
JAK2.20,21
p.T153N
Syndax
A216P
MDA-MB453
AlphaImager
.PharmacokineticsImatinib
Zhang_Targets_of_EWSR1
benzimidazole
Arg21Gln
LAMA5
dilutions1
recurrence12
0.3889222
∼180°
~100-fold
96-h
Diagn
marker-positive
and75
Taparowsky
tumour–stroma
Met-246
bipolar
backmutated
set-point
2.6-6.9
5′-ATTATAAGATCTATGAATCAGGAACTGCTCTCTGTGG-3′
Snf5Inv
pH7.6
.9.5
distinctively
∼900
ligation-dependent
CMPD.7,8
interaction.53
106–108
CRE-lox
c.494T
3.14
HED351A
strategies/agents
mSin3
metastasesTranscripts
R273H/P309S
respectively.Sequences
1.1.4,19
cytohesins
1−q
Rplp0
G132D
25-μl
anti-IGF-2
Nentedanib
11q24
motility.33
interleukin
M71
650-1214
14/33
TRK-T3cDNA
EWSR1-NR4A3
2.0nM
InVivo
SND1‐BRAF
TCF3-regulatory
connexin43
12:16
AIB-1513–813
2.STRN-ALK
residues24
disease‐free
DNC
128of
AGG3GGG
assayCells
GGG
c.9691_9695del5ins8
Trans-35S-label
c.5873C
56-h
Twenty‑nine
I445M
Q556_Q575del
susceptibility.3–6
LR02-064
FM11
1.4–5.0
A_52_P282058
GeneArt
multiorgan
KEAP-UM1
Q20
IV-5
vitro.6,8
Carr-Wilkinson
NM_009878
Nonmethylated
mutants.Figure
pCMV2-Flag
multi-well
Mantripragada
CD3+CD4-CD8-
methoxypiperidine
8/261
Y657
CDC42
kilobasesin
ERtranscriptional
rs139868331
others.9
1L3
527–536
+TAI
iCCA7,8,9,10
PSI-BLAST
HIF1B
N723D
124×
tumor/stromal
BamH1A
paradox-breaking
Arg-46
Stop-cassette
TCGA-B5-A11E-01
AR3-specific
P4HA1
Set1/Ash2
Haglund
T-allele
receptorPTPs
dihydroethidine
TATGAGCGCTGCTCAG
T.R.G.
threshold25
Selumetinb
immature/ETP-ALL
1018
/d
over-sampling
MRPIP-NTRK1
Gibco-Invitrogen
MDA-MB-361
mail.tains.tohoku.ac.jp
wheat-colored
1066
03Q
polyadenylation
.PLCɛ
42/85
//www.omicsoft.com/fusionmap/
6⇑B
5-azacytidine
PTEN-activating
recombination.39
10:8195—8203
oncogene-immortalized
Bioethical
baculoviruses
c-KitV750M
7p11–p14
SKES-1
XCorr
WNT3a
pY597/pY599
P616L
−42.4
.67delG
RPCI6
25/32
.Polycythemia
.Youich
blot.c.3610C
3ξ
QKGRKPRDLELPLSPSLL
1000-bp-long
carcinomas2
HBO1
5'-CTCTGGCTCC-TAGCACCATGAAG-3
0.793
.B-RAFi
DNAJB9
-internal
KPT-185
c.1411_1414delAAGA
cellulaire
5′TGFBR2
99228
14,16,23-28
co-opted
single-line
Chr3:71021758
GCCTCAGGCCGGAGCAGCCCCATC
Vermeij
corticoid-induced
D4-RLAA
.Ruderman
Xenogen
c.226_228dup
R234H
61,62
noisyData
p16INK4
sub-cm
U02509.1
extractedfrom
Bokoch
N-terminal-
neuroblastoma17,18
SASI_Hs01_00151612
CKMT1A
CTTCTT-GTT-3′
G446C
1:29
E210
chorioallantoic
nonoverexpression
579del
−31.3
migration-encoding
59-guanosine
thapsigargin
mixand
5-phosphatase
~3.4
EuroFins
PDGFA1
L1147F
1x1M
CEIC-IMAS2009/3515/
pathways16
oncogenecity
Y680
Alexa-488–conjugated
Scorpions®
onset19
4.18
656–661
instability.18
15K
48–142
il0
pEAA55
proliferating-cell
domain77
FOB
nucleus.47
HMGB-1
.Immunoprecipitaiton
MPL-W515A/R
recommendations.10
≥750
Y2124C
FIN-based
Stanchina
susceptibility.16,17
pT4bN3
clone-pooling
Vκ4
outcomes.8-10
KIT-imatinib
p70frk
.Gregory
NOD–Scid
Flybase
0.97838
37˚C
His6-
amajority
145-fold
EF6
.ES
surface-to-total
Foxo
5′-FAM-AAGCAGTTGAAGACCAGACTCATGGGTCCT-TAM-3′
.PHDs
V15F
castaneus
ISM1
REST-mediated
FADD+/−BIRC2
reincubated
functionalized
Gui,1
BMI-1.16
tagless
p.Thr200Ile
193
-100
c.1255_1257delGAC
4564
1.152274
HLA-low
cbt-15-768-g4
PgrCre
Nu18/SP4
Phosphorylates
B7–2
beta-domain
FLT338
SHB
5-1-5-4
0169-5002/
5,15
progression-related
SKNAS
B100,000
4.2-kb
Ptpn11/Shp2
miRviewer
DKO172
59/F
Xrs2
BAL
personalization
Mut5
1.39-4.82
patients—which
S4E
MicroBeads
CH-11
RUNX1+/-
lymphoproliferation
24F*
risk.1
G/L
2,578/4,153
Nsc
yeastYeast
reported5
erythromegakaryocyte
chimerism
ON12380
°C.e
p73-mediated
apoptosis.29,39,40
BEBM
Y62D
recovered.No
0.96
-Overlapping
ValAl1
anti-FGF
MZ
46Kanti-cdk6
Tahbaz
*Short
5′-biotin-GGTGCCATCCACTTCACA-3′
transcription10-13
CH3
charcoal/dextran-treated
Neuro-Oncology49
.OncoMap
Tsukita
astrocyte-like
outof
N377K
cancer,7,8
MDM2-induced
emblematic
z'rA
5′-ACCATCTCACAATTGCCAGTTAAC-3′
compromize
e-Bioscience
hypermenorrhea
SD26
sodium-dodecyl-sulfate
individualBRCA1
glands.Histological
PME
4873
FBXW7ΔF
F37
.Heavy
analyzedfurtherby
E330
5′-CAGCCTGACATCTGAGGACTCTGC-3′
patients.10,11
anti-PLC-γ1
HbH-containing
R2178H
pervanadate
TGC-9TTC
Xrcc2-knockout
HER2WT
CSNK1A1
0.0085
Guenard
6.02
A1303T
fmol/mg
∼1.5-fold
t4
.613G
breakage–fusion–bridge
BAF180-deficient
K42-specific
hNQO1-ARE-luciferase
CD4+
peer-review
0.320510883
3.01
3,5-8
Q206H
Larramendy
I704L
3'-fluorescence-labeled
PCRSSCP
shBRAF2
Activator-Like
Fractionations
Arg381Ser
procedures.9
V99D
2.162
Ayton
5/6.0
Ettl
=100
NA934V
10/49
EGFR/HER1/erbB1
.Neoplastic
biopsying
//doi.org/10.1371/journal.pone.0032451.g003To
signalling219
Megaplex
5′-AACTTCCCCCTGCTGATGTTTGCC-3′
S427G
.Substituting
NONISOTOPIC
genomic/
Leu115Pro-stimulated
CK2a
MET-WT
STAT5-inducible
cagcaaacccaga
recently.43
.N676K
ANC
.230
denude
affinity-based
GDP-Fucose
Wainstein
wt-p53
5′-TCCCCACAGTGCCAATG-3′
cells41
cells/section
BIBR1532
TLR‐mediated
FUS–ERG
bevacizumab
PGK
47nt
limits.6,7,15
CMV-6
Speci®c
shown.Control
NM_130398
AKTusing
FGFR1K-4P/5P
PIVE
0.001307–0.003510
TLX1-translocated
circumstantial
p.L13fs*10
BRG1/hBrm
gatk-somatic-indel
at-risk
WM1346
wt=wild
Figure1A
study.MLPA
P488S
p-p85/70
end-disease
HCC70
vitro–transcribed
Afinitor
v3.3
196-bp
ab9048
N.I.H
dMDS-r-AML
bio-marker
5′-TGCCCTACCTCAGGGTTCTCAAGGC-3′
6/379
I*
Ι
XP6BE
324–2094
pF5xUAS-SV40-puromycin
lymphomas30
1b-4
5416T4G
L131P
.S6a
U87MG.wtEGFR
Azumaya
Heiss,2006
S237
JM-B
T1N0M0
Myddosome
pCMV-RL
NGF
NKCC1
phospho-CREB
Tcf/Lef
2-6-3
P=0.12
factor-2
14-bp
Stem-Like
SLX4–SLX1
1Average
140.163.0.5
A439V
-TACGCGGAGCGTCGTGAAAACCAGGACCAAGTGTGCAG-3
CDK-inhibitors
pSPL3
Gly-X-Gly-X-X-Gly
children/infants
Ser939
4858L
polyhedral
-Cadherin
VM-CUB-2
PTTG1-binding
KMT2C-associated
AVA
ATR/ATM
Trk3
KITimatinib
ABL–PTK
Hightech™
18,25,26
MTA1-expressing
.Cerebrospinal
anti-Pim-1
α-FGFR3
0–27
Asn822Lys,37
Lys11
3/6
Fastx
events.1-3
5′-GGACTCAATACCATTCCATTGT-3′
XhoI/HindIII
D549G
mTORC1-mediated
p.S7F
943
TLR1/2
VHl-CCT
UAS-ALKF1174L
Ambio
R107
OLIG2−/FOXG1+
ED4SS
hypoadiponectinemia
GFP-Puromycin
PDE6δ
melanoma68
effect.36
positive−negative
anti-CD71
MDS/MPNu
duodeno–pancreatic
al.3
Thr58.16
clincancerres.aacrjournals.org
Asxl1fl/+
A79T
C62
IKKα
`C
Marfanoid
NS.4,5
anti-metabolite
P551A
R678Q
*The
c.897G
elucidated.8
C18Y
1,614
c.1610C4G
ο-nitrophenyl-1-thio-β-d-galactopyranoside
F537-K539delinsL
Ubiquityl-Histone
361–763
progression.49
B-ring
types.Recently
GQ60GK-mutant
DSB-repair
1000–4000
2.174328267
hetero-oligomers
AmpFlSTR
residues-e.g.
T771R
occurence15
electronic-PCR
RII
Gli-driven
.CRL1933
profiling30
EC.14
C131W
Ad-GFP
receptor-tyrosine
PVR
2.2.1
59-TACGGGGGGCGGTGCCT-39
judicious
PLCγ1/2
arginine-and-serine-rich
p38alpha+/+
S5.3
MAPK8IP2
.PCR
ENSEMBL
dephosphorylation
HIF-prolyl
Phe595Leu
Q580L
KIAA1549
6644
E353STOP
25/26
Paschen
Rosette-forming
wereBorrmann
Okorokov
gefitinib-senstive
0.025Gender
non-adherent
protein.76
5′-tcccaaacactcagtgaaacaaa
p.R1148H
100U/ml
KOH
KIT-K642E
ERBB2-K753M
anti-NUP205
arginine-for-leucine
molecule.2-4
TTACGTTGATTTCAGAGAATATG
//www.gdb.org/
CSR23,24
S707P
Lysine48
Hybridization-capture–based
GATTTTGGTCTAGCTACAGAGAAATCTCGATGGAGTGGG
phosphinositol-3,4,5-triphosphate
NRASG12V-independent
2F21
0808
:GAL1-lacZ
Tyr26
2236-2245
liposarcoma–C/EBP
efficien-
proteins.Loss
.Cross-linked
BCAT-F:5
Rexer
omeprazole
PYK2/
R25A/T450D
AGCATCCT
RUNX1-EVI1-expressed
NMD-insensitive
signals/nucleus
vivo15
CTGTAAACCAGGAGCCGTAC
3.12+0.02
.Displayed
.Ligand-induced
ATR-dependent
expression27
D1/1-233
7,9
anti-phospho-AKT-Ser473
RUNX1-EVI1
FLI-1-specific
OF3
19/187
pRC/p53
mutation,29
AG2020
melanomas2–6
G740R
NK-like
§kind
Ser21/9
p.E673X
coimmunopurified
EµSRa
Y628T-for/Y628T-rev
=0.0859
HIF-1αP564G
tissue—arising
S762Y
BRAF/ERK
Ref.22
0.5653
GST-FANCA1–271
GTX112066S
\70
Nontarget
SqCC/Y1
2007,1,2
d1X174
BRCA2/FancD1
16.1–37.4
pathologist-determined
5×/week
Co26
141C
HIF1α162,163
disrupted55
1.75–3.74
3,357
echocardiographic
A66dup
SLC34A2-ROS1
ARMS®
EGFR‐L858R/T790M
Apert-associated
CDK4–p15
'104
dual-speci
488–
arti
.Kan
0.250
mismatchwill
K-Ras4b-fwd
Barbosa
.0725
Lin−Sca-1−c-Kit+CD34+CD16/32low
cells107
Y674
1945A→G
lines23
1982a
468M
G13D-associated
Grb2/Sos
c.1867G
shRen
trk36
Y206*
dedifferentited
Isotopomer
Q701Stopa
ED25-ED90
DLD-1–transfected
Shq1p
raÃ-proteins
7,339
Q61K–mutant
ANKRD28
GFP–Fbw7
CTGCAAGTCCAGCCAGAGTGTT
∼60°
leukemia.8-10
Igα/Igβ
symptoms-free
neuron-like
.HER2/ErbB-3
Stype
GCAATAACAGCCTTTGTTGTGTC
Jet‑PEI
N457Y
chemo-radiation
Provean
Dox-induced
BIM-specific
Positive2,14,15
.Chang
Manival
function.4
32nd
RCGLD
.MDM
HBS-EP
/35
IVS515GrA
L216M
394.5
Smad4-reconstituted
pLKO-GFP
testis-restricted
91–99
mm2d
Helenius
.CD
Camptothecin
nontumorous
0.8713b
by-products
238,8
incontinentia
SoftBerry.34
5'ggctgttccttcaaccacct
pronuclei
pDsRed2
5Diii
EGFRvIII-G719S
seizures19
Homeodomain
antiphosphoserine
pCRII-TOPO
1.01–1.20
AML10
Hoh
G2812E
DSBs87
pVL1393-V5-His
Kruskal-Wallis
TCATGAAGTCGAC-39
EAT-2
Pre-Sequencing
CBF-AML.9,11
mutant-promoted
pathogenesis12
pCRFL319
49-year-old
ITD-mutant
reactionconditions
SCF-
pCDNA3.1-
Skp1-Cullin1
melanocyte-derived
COMPASS-like
acetyl-group
co‐transformation
tumors.Thus
intent.2
7-week-old
-165K
al.24previously
Phospho-RTK
L115P/R
alterations25,29,30
Asp-33
promoter-anchored
R158C
235-fold
anti-desmin
SC–His
R414
NIH3T3/neo
.Cyclins
free-cysteine-EGFR
al.13•
∼1.0
4621
3.124
39/66
-ACAAATGAAACCCAGGTAGGAG
1991b
PCRTotal
Capna-2
+P
505â€
Singal
pathway75
43,54
5.6*
deprivation‐induced
–PET
non-null
HETERONUCLEAR
inhibitors.Despite
TCP-1
keratinocyte-specific
−50.4
Kluijt
Ras/Raf/MAP
Gly271Val
Schroinger
.INSR
71-4
0.03*
snRNA-binding
Materials-35S-Labeled
PTTG1
shWWP1
ALL47
PreviousFigures
Schickwann
CMJO
A135304
Ras-GTP/
c.5468-10C
5′-CAGGTGTGCGCATCTACAAC-3′
criteria22
c.-32_-29del
GDLV-52
G74R
Pim1-E135K
—previously
syndrome23
tumor-initiating
Storkebaum
609310
pSFKs
MKLP2
Banerji
unpairedt
all.20,22,23
0/376
115-165
D18S460
646-3190
methods.7
17q24
SCN9A
11.580
non-ccRCC
60bp
2BR
5′-TCAGAAGCCTTTCACTGCCGCA-3′
Arg-371
signiWcance
InhibitorsCharacteristic
Tyr88
lineage-biased
Met-243
lipogenesis.4,21
L731F
corepressor/HDAC
.Logistic
//bacpac.chori.org
.Fig.3,3
transplant
54.7
//www.hgvs.org/dblist/glsdb.html
3145
165-167
2585
BsiWI
Conformational
lipoatrophy
TRIZOL
5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside
.Restaging
14×
shPAK1
p.Arg265Cys
variant.24
SPOP26
pAd/CMV/V5-DEST
CAAGAGACGCAGAGTCAGTTT
pGEX4T
50-kb
-GCATGTTTAATGAGGAACTA-3
caspase-8Table
bric-a-brac
juxtacentromeric
.40,41
−1.95
Mu¨nchen
tri-demethylase
HLH-mutant
.CTs
target.17
GALV
gene14
Raf-I
2237-2255
ng/L
rs1346044
2/190
highly-effective
AV-299
∆N
.STS
M/F
Phe37
pre-Tα
syngeneic
CCAC
SuperBioChips
M/46
loop-negative
cell-polarity
Ins10
PLAP1
L270P
D.W.E
.Organ
undruggable
R200C
PF-03084014
hemangiomata
instability57
mC-KITs
Cheng-Wen
A414V
heterotrimerize
microarrays,24
M1-P22
BNST
M_musculus
Ctcf+/−
allelesofRI
development22,23,24
vector.27
committee.ResultsAt
//mordred.bioc.cam.ac.uk/~sdm/sdm.php
.5E
-mmWw
JH1-7
.APC
0.09–0.21
C135/182S
retro-transcribed
20/67
deletions—suggesting
GCTTGGCTTCAAGTTGTC
3-15
tS-
Flip2
pre-surgical
ATMivs38-
Karyotypic
173K
RadSource
recessivemutations
Kensler
15N-HSQC
1629-2604
m-Tc-Sestamibi
trypsin–2.21
PI-metabolizing
LP90-032*
M14372
Signal-transduction
DEPDC5
misattributed
PEST–truncated
∼10-fold
cost-effectively
Targeting—We
1FPU
GenBankTMaccession
0.143838287
.Autoradiography
pClneo/FLT3-N841I
47/F
5′-TTCATGGACTACAAAGAC
Bac-To-Bac
c.1100del4C
S703L
//www.arup.utah.edu/database/MEN2/MEN2_welcome
Rad3-
PCR/reverse
regulation14
3983
chr7:116,099,682–116,225,676
22.5–43.5
p18-L21H
Pdgrα
.Immunoprecipitation—For
E746-T750
nucleus.1,2
.0028
TP53-mutant
Low-level
ho212
90M-1
FITC-labeled
Fast-Cycling
miR-34a
lymphoma–transformed
S4H–c
pcDNA3.11.Myc-U2AF2
maternal-derived
TGF-β-Mediated
gp70-H2Ld
1,660
Ser1613
Sarcoma-Like
.Vaco8-2
432-bp
pMSCV-IRES-GFP
processing,33
Equilibria
551/654
c1053C.G
GST–PPD
p.Y371
Lacronique
dimerization-dependent
0:11
IFNγRα
11/162
0.292‡
-MUT7
53*
SycP1Cre
ABD–Y321T
BamHI/XhoI
substrates6,7,8
myrAkt
17q25.3-amplified
0.6918
MDCK
S1486C
Ala60Arg
8.3-33.9
MulitSeq
22–72
Flag–LKB1
TRAP-2
PD173955.23
47–63
DNA‐binding‐independent
intermediately-sensitive
EDA-GDP-Atto488
10-bp
CGGCGCGCAG
3.70E+04
Spo11-bound
cells.thumbnail
PyT
UV-Stratalinker
catttcacag
∼75
SF188
CCT-bound
aged⩾18
.Hrs
.Flag-FANCA
MYC16
GSP99
BCR-ABL–dependent
.FIP1L1–PDGFRalpha-induced
AG-3′
BCR-FGFR1–
HEK293Ts
CHEK2.S428F
5′-CTCAATATGTTCTGTTCTGTTTCC
E.C
KRASG12C/A59G
pos-
nonsense-mutant
.BCL-U
LXSNAKT2-AS
PI3Ks
santpau.cat
475C
K65M
single-institutional
P022
11.8-fold
4562
SCCO-010
Stability-activity
V368G
K806Ea
.Oltipraz
0.006
BRCA15396+1G
33–73
Leftward-
anti-E2F
17-85
L130F
p55γ
hydrophobicity
Asp304/Ser306
puro-selected
ERCC1-p.Arg689Ala-XPF
98/91
performedwithout
phospho-STAT1
NIEHS
stress.19,20
53⇓⇓–56
DDR2-
80,798
sequences.Generation
K77Q
ε-amine–to-N641
21.16
p.S1411N
E4.5
AssayTo
dual-label
15-month-old
publication.22
Emu–Bcl2
gcGBM
monophosphate-dependent
protein-tet
strain22
Noha
10,0001
J.D
0/180
D319
W88
refLink.txt
S3E–I
YC
1/1000
CBLG375
c8
G219E
vehicle/rapamycin
B6-Ly5.1/5.2
H2B-tdTomato
post-release
S..
74-year-old
RE-specific
.Estrogen
.Vorinostat/ABT-263
S+G2
DMSO/90
ANLL
microtrauma
cTested
L490P
TCCCAAACACTCAGTGAAACAAA
GSI-induced
.NCI-H3255
BaculoGold
RNB
INI
previously1
HMC-1.2
6313
SBS
LXSN-TbRII-HA
1291–1673
Insulin-stimulation
Krasrare
I1719T
1-329
NM_005631
TFAP2CΔC413
cancers,5
Astuti
previously.11,15
RGC-containingreporter
277X
polyubiquitinates
Asp/Val
Ponatinib-FGFR4-KD
*IFN-g
Sequenom
CEBPADM
k/uL
CEP28122
valine
0.81–1.45
Varjosalo
intermediate-avidity
L197/201
37,39,34,35
TNT-DDB1
disease-susceptibility
aconitase
HLH-containing
cc-EpoR-II
agents.12,13
RASopathy-spectrum
ACACCTAAAGATGACAATTTGAGa
1386
-w
ERα_pCMV5_5KpnI
HR-associated
rad502TEV
.RYBP
32D-Flt3
1.03–1.83
non-carboxylating
TTF-1/NKX2.1
BamHI/SstI
starvation/re-stimulation
539
Notre-Dame
apoptosis.35,53
qMSP
197:238-244
109,725
STAT3,24
fivefold
primer.HUMAN
.HDACis
.093
.TRK
Langholz
L159M
stainingc
FU-based
Rasopatheis
E884K-COS-7
37.8
development9
mutationdependent
2:22
.SK-Mel
–75
L653L
L726I
Co-existence
o00
D816V/Y
9077
Matrix-Assisted
1.070
effects—specifically
tumour/cell
17873
233,000
MSI-L
S1613G/H1402Y
HER3-negative
K652E
Fig2E
1560-1863
0.4211356
functional/clinical
lines—it
R361S
target-specific
complex.PPP2R5D
.I2006
A−
HMC-1.17,18
DDK-tagged
1660–1779
.V43T
absorptive
10/217
-MGRNAprobes
C592
.Brd4-inducible
Yxxx
nite
12E7
G251Ea
apoptotic-response
P-Egfr
GDC910
growth.Figure
≤58
BEP
H-2Ld
CUL3.8
K590
A/T-rich
receptor-negative
~3–4X
analyses—as
R486C
NZM7
mechanisms—although
L-1236
gaagcgccgcactctcctta3
A_51_P290290
OR2T35
Reduction-sensitive
RKY1400
.Clonality
HeLaGFP-H2B
*Semiquantitative
20-nI1T1â€
Snf5-null
4:119–131
promiscuities
150-200
p.Gly23Asp
Korhonen
–25
S25A
PJS063
receptor–expressing
L4610
28572+
2:3
renatured
elute
ERBB2-S653C
30Â°C.PCR
MET-transduced
gynaecomastia
pluripotency36
ercc6
Homotetramer
.Crystals
p110γ134-136
L.C
Phe337
Anti-Total
DNAZap
607117
regulationby
AACAATG
25-ml
pNeh2E82G-GFP
.Gly434
kcat•GTP•
.Cruz
HeyL
FBXW7-mediated
ANKRD15
Pro755Phe
AID/APOBECC
N-GFP-MOCK
BAP1-mediated
Edamatsu
5.HER2
pro®le
glutathione-containing
Nym
5-rapid
GI50s
27.43
perimposition
beneficial.Similarly
c.350T
rs4266112
acidlocked
FACS-Star
pET28
Ruley
post‐transfection
S308A
12/19
Gelucire®
472
likethe
Granovsky
p.Arg389X
MCF-7-empty
AA417252
E286
propositi
Nussinov
Jun/Jun
Z4/7
activation-mutated
,4,4
fold-enhancement
11–mutated
5/2010
bone-inductive
keratinocytic
Urokinase
HMECsIn
-GCTCTGTAGAGAAGGCGT-3
3RCD
g-phosphate
demultiplex
Aaltonen
co-repressors38
gatekeeper-substituted
yTSC1
Krefeld
MCF2L
c-terminal
.109
SRC-3/AR
Ser98
5′-GGCAAGAUUCUUCUCGUUGTT-3′
recombinome
ZymoResearch
.Predicting
Multicenter
RET805
B/Research/Acembly/index.html
8–35
Y254RD256
V304I-positive
MP41
apoptosis26
Angiomyolipomas
Scg6
PvuII-NcoI
C678
dnAKT
190KB
∼4.0
expeditiously
withMMP
UbcH9
prominent54
S78/S82
CLL14
IRAKs.40,41
155-kilodalton
0-600
mutations1
Men+/+
frame-shifting
dephosphorylating/activating
β-catenin–p65
B-cell-receptor
.RG7204
AmpErase
3c
Beert
strain27,28
TTC
Meis1a–Transformed
close-up
Tyr1175
NM_001111067.2
PEBP2β/CBFβ
c.793C4T
prolactin-releasing
XX,11,11,17,17
calcineurin-dependent
8·5
delK745-A750insK
T121I
disquilibrium
CAnN.CgFoxn1
D11S4946
000222.2
4.28E20
Mmp15
8492
His-RAC1P29S
1,858
Hsp90/CDC37
96-plated
DP103
CBFB–MYH11
desmin
Fig2
ENmediated
48/59
218,281
Hodis
.Defining
al22
V38R-Ras
PPP2R1A
PLCɛ
MED13KD
C-RAFS427G
Figure1,1
TAP-GLI
sorafenib.6
30,990
Comtnrctiorl
µJ
IgM
.2B
frequency42
auerbac
146G
TGF-btreatment
CD34-positive
43,530
Y1356F
s/72
2.Primers
Basolo
IFS
postfertilization
Elkhart
.SF3B1MUT
dimethylthiazol-2-yl
Heat-mediated
HER2-K753
65/433
Typec
63/1.40
peroxidase-labeled
.RESTRICTION
nM-40
10664
N-19
22
HBQ1
CHEK2.P85L
WWP1-C890A
p.N385Vfs*7
miRNA138
BRAF-dimer
proteins8,11,12,13
p.Gly322Asp/p.Asp487Glu
yI
Co-transfecting
*As
X-10
triple-mutation
agents.12,22
BL21-CodonPlus-RIL
S319A
UAS-Hcf-RNAi
mice49
cribiform
epithe-
.Guided
GeneScan-500
G395
5′-GCCAGTGGACTCCACGAC-3′
α-glycerophosphate
T4339C
single-arm
TCS-SP/SP-AOSB
JH3
ACER3
chromaffin-cell
18m
195–255
5′-GCATGATGTGCATTATTG-3′
Hope20
FG/GLFG
K642Ec-Kit-expressing
P.C-B.
domain,12
EPYC
0.855
Stéphane
.Poly-
Hs00230877
GACACCAT
AR-target
CAGCCAGAAATATCCTCCTTACT
≥0.01
deficiency118
HCC1937-derived
ccRCC
CNS3
kb-downstream
DD-wtSF3B1
CASP2
αC‐β4
studies17,23
SW-480
–29
large-insert
expression.48
cleaved-Caspase
years.67
3-microglobulin
G325*
apolipoprotein
Asp-269
S87R
glycemic
7–9
P.S720P
05-495
stricture
polypeptide/trefoil
nonendometriod
polygonal
Tcf/
25/28
dehydroforate
Asp190/194
1411
WD409
digestion.28
S6K1T389
neo-
72*
chemotherapy-related
.CBFβ
cutpoints/thresholds
11/173
15-kD
FGFR-1
p35srj
BlP
Fbw7-specific
ipt
Mg2+/Mn2+
.Trastuzumab
vemurafenib/PLX4032-resistant
–24
.Rev
Ostrobothnia
L448P
1–F-box
HEI286
resistance.38
V306M
KITV559D
GFP-NRAS
Y279
100-base
non-physiologic
MLL3/MLL4-independent
Arg224
lariat
activation13
Hsp90a
G48V
RASGRF2
Rhabdomyosarcoma
2-hydroxyglutarate.26
.Photolysis
Kanto
anti-acetyl-p53
K2100–11
typeMGH-BA-1C
propane-1-sulfonamide
tumors.13
p.C134W
frontier.107
phospho-blot
CACATCCAGTCAGAAACCAGTGG
ValueTotal
18/694
therapy,3
435–441
receptor47
dFO-
PAMP
p71l'5
V391M
ular
pMEX
20/143
tumors.35,42
glomangiopericytomas
EGFmediated
Klijanienko
/mac1
half-lives.39
MEN2A-causing
pod-rtTA/tetO-Cre
triple-quadrupole
NPS1034
ATM–ATR
119547
TKI-sensitizing
M.Sc.
V8379
0.792
dual-IP
34,39,40
A859T
activation53
Leptomeningeal
EU/ml
-TL
Anti-HIF1α
=4
cisplatin.16
BL-CFC
8765delAG
Copynumber
J-Sm
min-segment-size
2019-27
ofapproximately
TGAGAGAATCTGGCTCCTTGAAC
14/16
HNF1α
Neuropilin
CTCCTTGGAGGCCATGT-3′
c.1813dupA
1240X
IIIb-D1713K
MC/
Kamada1
~28
littermates.4
Arg111
CYT387
SDS–proteinase
medulloblastoma/normal
Arg882
ALKR1275Q-expressing
p.Asn4614IlefsX5
BML
.1406G
1,129
development19,20
MAX/C-MYC
GLIR
0.842‡
residue-wise
vantetanib-treated
indolyl-β-d-galactopyranoside
.Vorinostat
I19E
65-6
Shaoul
TOP-FLASH
190-FF
p.K3326X
disadvantageous
VEGFR-3s
I418N
KIT-specific
28-kDa
G*NN/NS
D18Mit19
.hMSS
Pfu
pGLM4
juLSA
p691rk4
sequence.29
MMR-Deficient
turnover/repression
Hemminki,1,5
-1289
glucose-stimulated
C1-Reverse
non-OCCRs
H128
G145R
-untagged
p.Trp2725MetfsX3
aaaaaccggtATGAAAAGCAGCATACCGAACAATAAGGAGATCCC
.~
target.35,36
85.9–100
5bp
therapies43
performed.10
survival17
OmniGene
T380
higher48
M23632
182530
3q25–29
bHLH*
CSF3RE785K
Arg-465
~~~~~~~~~
.MutSα
.FRS2
MP6
r-
5V-gctcagccacgcacatttgac-3V
weobserved
Chipuk
LU-A08-14
13C,15N-labeled
L-deprenyl
3i2m
DNA-linked
WT-agonist
DLBCL+
.HSPs
affinity-binding
WGA2
609173
p16INK4A-resistant
p.S1514X
P=0.0037
2.285
Matthijs
p210mut
K789R
sight-threatening
endometrioid/mucinous
S257
EWSR1-ERG
-W-PDGFRA
.,1
3,4,5-dimethyl-2H-tetrazolium
receptor,33
11644807001
GTP-Rho-specific
1915C→G
.Inactive
763/852
placentas
hMSH3and
1.110
1.2-kb
5q31-q33
7p14
AR-Kpn_fwd
7B–C
haematoma
4.83
pmCherry-K-rasG12V-R164Q
∼1400
0.9-4.4
OII
anti-beta-actin
Lavrrar
Maulik
Cohorta
6700/2.3.-05
NSCLC.10Conversely
IgG-protein
Autophosphorylatioe
5'UTR
000141
A81T
EGkLVKIcDFGLaRDImrds-nYiskGST
phenotype.10
α-brain
.3H
α-IRS1
www.biomedcentral.com
5′-CCTCAGCCACAGCCCGCAGCAGTGAGAAGC-3′
Ple1
helix-turn-helixdomain
UniCAP
cells.FIG
//medgen.ugent.be/arrayCGHbase
UVB/UVC
NCI-H727
throughoutthe
V281I
parameters45
Axin-myc
5′-CACCTG-3′
Pro70
culture19
Bomholtgard
L341
Counklin
4.1-
cancer.16,26
rCTL
NM_000267
alpha-2b.8
FBS/
franeshift
SNCAs
5'-CGG
Feldser
RAD51C-AD
therapy-induced
LMO4
GCT/ACT
aprotinin/ml
Cdc4/FBW7
M1–M8
ZFYVE19
Genet.
rolein
Dicer1-deletion
mislocalised
mRNAsTo
X-100/bovine
platelet-specific
108,605,181
2882
defects1
PDLM
4,103
1Centromere
nilutamide100
normalization70
75235-9133
Sombke
triple-tyrosine
G697
Giannakis
06-297
thermostatted
insA
slit-like
HPLC-grade
c-19
1882
Nur
msh2-D860
3â€
β-d-galactoside
p.Y1003N
native-state
Non-Silent
DTT
CEBPA
1.93
C50Tumorigenicity
loop‐mediated
Dybedal
.Electrostatic
PK/PD/efficacy
genome4,5
p.G12V-
immunoaffinity
pCMV5-AML-1/ETO
5CpG|
PIK-85
S133
Mutant/WT
3.902
≤4:1
vitro11
ALKG1269S
16.3
abscess
Top-20
pE3-DBD
T45221
ezrin-radixin-moesin
7.9/150
−1469
cytoxan
Unconventional
MD903
MKP-3
R310H/K420A
Skoglund
.F2
analysis13
FMTC-RET
RE1
EWS/FLI-1
others,22
Sertie
G415V
10mers
p.Val133M
ssDNA.35
genes/tumor
LB1622-Mel
T393
5-ACACACTACACCTGGCTCAAT-3
1-593/pLG3
p.Q462X
66/M
S13S11S10
Hoxa2
pY1136
U-E4
c.A1_A495del
.KRas
GTCCCTGGTTG
c.1100delC
compartment.81
AG2964
aq-G207T
11Université
18a
5′-CACCCGTCCTGCCCCTTCACCTT-3′
Xenografted
RBM10‐RNA
0.440
UGGAG
immunomodulatory
immune-suppressive
embryos35
pMX-IRES-blasticidin
lethal152
1:2,500
Asp-838
mre11Δ
.PE‑1/METS
Double-
HER4/ERBB4
macrocephalic
EcoRI+HindIII
2446
N69
AGTRAP–BRAF
∼4.6
Asp1840
weeks-of-age
FLAG-NRAS
.Km
100C15
PLC-gamma
mutation.22
results4
3904T
MYCN177
E120K
SNuPE1699Rev
59INI1
Magnifications
GIST.15
Suzui
formation.39
SASI_Hs01_00056396
cellswasassessed6
CAL-101
NRAS/KRAS/FGFR3/BRAF
N=4,405
.3,9-11
R328C
RAS–CRAF
tumours121
adenocarcinoma.2
agonist/antagonist
EtOAc
Staphylococcus
GTTTCAAATGAAGCAGTCGACTACCGAGCTAC
1986a
I202N
-STAT3
M1783
anti-GATA
access_num
pVHL-elongin
WM98.1
OR10H3
.Caspase-3/7
Ohinata
0.0072
10.Proteomic
cogenic
CYSTEINE-RICH
Parsa
S-transferase–JNK1
SF3B1WT-
CCCACTCCATCGAGATTTCTCTGTAGCTAGACCAAAATC
G2-phase
pathway.12–14
56–80
A-A
kbp
RP11
Berlex
Repair-deficient
phenocopies
used.4
Ci/mol
0.409
Min26
Gr-Mac-positive
chemotoxic
G32R
AGAACATCTG
~50-fold
half-life.39
hyper-
cases.Finally
Sabbatini
testing.20
GAP3-The
focality
hem76
.MRI
recingiae
−18.5
MseI
cigar-shaped
activation-dependent
p=0.000720
KJ
Single-nucleotide
inanimal
ofexon
NID
UVB
D1778Yb
transactivating
Inappropriately
medullobastomas
Val-2284
aZNF198–FGFR1
G1phase
YFP-Jak2
status.7
diffuse.9
b-sandwich
deparaffi
775
Behrend
Cln2
E339Q
n=1
Interconnected
785
urticaria.8,18,19
3500XL
Thiazolyl
−936
factors.56
BRCA2/IVS23
inhibiton
monly
4NK9
59y
helix-turn-helix-motif
cancer116
FGFR2P253R
45·7
2.55/54,481
−a
pbabeH2BGFP
iDNA
p=0.353
caspase-8∼8h
ViewerPro
TRCN0000059090
TATGGGAGCCAGCCTTCT
positivities
S111A
administration75
Msh3-knockout
Fig6C6C
NUGC
Trans-Blot
Tyr-64
iframe=true
adiposity-related
GATA3_02
dithiothreitol/1
W0.05
HGPIN
EWSR1–ZNF444
FUSchimeric
genome-amplified
msh2-QG863
Cdc2/cyclin
MMR.18
sites/506
C-terminal
V11101
WG-6
proliferation25
gp140Protc'rk
histidinol
DDs.9-11
rictor
C.Ten
BAP1-nuclear
.Preoperative
IGBlast
1-174
R1331L
Nicolantonio
ubiquitination–proteasome
JAK/Stat
H3K4
0.305
958
MED12-Mutated
μM/L
7/338
2.43-fold
0.0348
tcatattcaatttcatcttcagag
a-cyano-bhydroxy-b-methyl-N
Pgr-dual
cancer.1
PGK1/Pgk1
Ahmadzadeh
HindIII/KpnI
nilotinib–Abl
.001
SEL-10
Hlli2R
Runx1f
4–6-week-old
.HER2-positive
kinase–interacting
186
TAATCAATCACTCAAAAAAAACCCT
myelodysplastic-type
.0128*
6-HEX
Cy5-dCTP
C634R/V804M
.Eighty
molecular-based
DeltaDeltaEMM
acetyltransferases.10,21
TTG-3
GPCR-dependency
SCE
TÃŸR-I.type
18,19,26
cytoprotector
035188
described,94-97
256
8/174
1/39
analysisFor
phosphoY15cdc2
LPA-Dbl-Rho
melanoma.3
529576
8333
NanoDrop
–eight-twenty-one
234–47
cancersonly
Balagurumoorthy
pcb.ub.es
general—and
1077_1475del
Sf31b1+/K700E
C3H/10T1/2
115–196
Ci/mmol
ELF3
HGF/c-MET
.Maxwell
.BRCA
Meyyappan
15/217
11,470
MDM2-amplified
aggregates/clouds
neuro-psychological
RARE-containing
3G209
DEENQQ
3.5–10-fold
tumor-containing
disease18
binding.42
Figure4b
TMPRSS2-ETV5
DNA/mRNA
343
Gentra
supershifted
725
MOLT-16
immunosurveillance
nucleotide—was
Psp0M1
BAG1
X-linked
X3-4
peripheral-blood
stereological
S7K
fewTP53
chabaudi
Hoeijmakers
G3602A
NM_133810
Tyr653
55Â°C
19q13.1-q13.2
5′-TTACCCAGAATCAGAAGGTGG-3′
Tsg101
MYOD1-mutated
-TCTTGCTCTCTGTGTATGTGT-3
10q22-23
106-μm
Q96RK0
.Janus-activated
529F4
PRPF40B
Ser615Phe
osmotic
LStype
TORC1/2
Ptenproficient
Lu-specific
p.Leu242_Leu243insFPGVC
IGF1R-mediated
CD381
T3NxM0
prediosition
CSF-arrested
β-strands
5313
sub-clonality
5′-GCATACACACTGCACGCCTCGTCAGC-3′
Gag-AKT
5¶-ATAGTAGTATGTGATACCGTG-3¶
phospho-ELK-1
features,6
gccggtgggctacccagagagcc-30
PstI-XbaI
Mischel
cttgtccagcttgacagtgaattgctgcaacatgattgtcatctt
S6G–S6I
Casesa
Census53
PD-180970
Smad4-induced
70950501
TRIB1
mTOR-complex
FLT3-WTalone
sc-177
.Mann-Whitney-Wilcoxon
2,8,9
Snf5floxed/+/Mx-Cre
61
.P-ERK1/2
weshowed
ctgttcacag
bindingthat
chromogenic–
iodoacetamide
I.D
G264W
R278-bridged
ARID1B2
TTGGTCTTGACCACTGTTGG
polyacrylarnide
transcription43
41yrs
Arg88Gln
identi®ed
D324N
units/reaction
ATCAAACCCTGTTTGCGTTT
transited
p.Thr343fs
ppErk
S1101L
culture77
SNP285
.V-GTTTGGCTGAACCATCACAG-3
1.3–1.9
78.64
glioblastoma24
linesMCF10A
mel*-NRASG12D
pcDNA3.1/His/LacZ
phosphorylation.1
MethodsPatient
1383
cytometry.21
receptor.48
S1436Sb
FBW7γ
flM
null1313Y
32-s-associatedand
Srsf2P95H
BCOR
Myc-p110
α-isoform
PF2341066
EffectsThumbnail
.3.5
Zemla
191
ab5644
56/EC
2.15.1
Phe1448
MRC1-expressing
NCBI/hg17
spin-echo
c.1534C
RNFwt
HG18
12.39
chromosomes—up
RBM-Binding
35–90
-grade
treatment.22
Table44
therapy167
Fbw7-associated
FCCTX
TGF-β1-induced
47C
Rap-RapGAP
4060–4069
FGFR4-N535K/D
23–39
Double-Hit
pointmutated
www.fdaapproveddrugs.us
c.4306A
Insuilin-like
.ACVR1Q207E
5′-GCAGCGGGTTACATCTTCTTTC-3′
FDR⩽0.05
microinfusion
Furochrome
phosphoALK
Mlh2
Y202/Y204
double-step
Challen
andwhite
5Vends
disease.36–42
Chibon
p.Trp267X
TCC™
59-regulatory
groups,6-8
Half-sibling
p.Pro2150ArgfsX2
AKT-DN
fluorescent-fusion
≈2
mantGppNHp
forms.36-39
WT1.2,4
Cisplatin/fluorouracil/trastu-zumab
63/M
LtβR
group.In
×29
C.a
912_929del
heat–shock
33-4-78-77-72-13
7810–7812
617
17–46
R882S
NCT00931645
finder†
NF-κB-mediated
phospho-Y1234/Y1235
Cdk4
S252X
RT-derived
−8.09
CSF3/G-CSF
Prime-It
12/B
MUT3B
Dnmt3afl/fl
p.Gly1707Arg
8q
H157
undetectablein
malignancies/
SYK/JAK
P44
Pellman
.Heterodimer
D80F5
Akt3-mediated
infarct
non-kinase-targeted
IT-293
CEH
S1101N
tRNAs
SOCS-
FLT3-ITD-transduced
hybridizationbuffer
Thirty-three
T233D
TCGA-CV-7421
1.581
inputting
pms1
Inhibition—Sorafenib
LS411N
POLD4
368-370
domain.34
D1739Y
4,6-diamidino-2-phenylindole
RBC
xenografting
sunitinib.17
99.175
cancers19
colleagues53reported
81.89
analyses22
.Utilisation
2987283
MES–SSF
Il-6
Cw*0501
NaF/1
anti-ER
tetramerized
0·004
FAT1-lacking
mMglutamine
Gli2R
.Ninety-one
Universite´
Fig.7C
p.Gln133X
19·4
//rnaseq.gersteinlab.org/fusionseq/
19-91
CTCAGCGGGTTACGTGGGTGACC
Glu-3OLys-31
SRP065600
5′-most
suppressor.15
neutralization
Watnick
wasproven
2.This
-H-L-T+F
deletions-one
somatosensory
Detachment-induced
1/84
α2′
p.R608K
WW2-WW3
stopl'6
kinase.10
c.1596dup
MET—the
status.47
D16S318
Suppl.1A
methyl-CpG
55.00
Blimp1CD19KO
PLX4032-induced
vSMCs
ENC
anti-HIF
-gdPTCL
TXT
Dana-Faber
pivotaldrug
CN-LOH
0.162
−2008A/G
-0.27
metabolically
gadolinium-enhanced
D172N
A178P
DGKH
reads.18
BCR/ABL1
fyn-related
Tbili
pollen
butyrate-mediated
effectp16/CDKN2A
3/74
GHE1287
Alw44I
2.942
CD34+/38−
K70
Antibody-reactivity
genotype.Protein
Epigenomics
Anti-Thy1.2
R491W
INK4C
slat
W176
Morente
low-grade/superficial
thesensitivity
Scadden
BRAFV600_K601E
22.5-fold
hyperfunctioning
4UWY
poly-L-lysine
1–600
I43R
carcinoma.23,24To
polymorphism'4
.David
ACTAGTGGATCCGTCGACtcagtctgagtcgagcccct
retainedexpression
monophosphate–phosphorylation
statusc
.AJCP
Kodaki
G1194D
KMS12PE
theRSV
NF1-REP-a
T511A
Cysteine
N=237
IGF1R−/−
CCACATAACGTGAAACCGG
HLLYQLLWNMFSK
129-derived
Y238A
Groet
cells20
.341
CMP
mandibulofacial
p.K499E
signalling2
Harif
shRNAs/ORFs
E-Cadherin-negative
Bevilacqua
biopsy,24
Ca–Cd
.0055b
V..
mb1
8004
6224
UMT
D761Y/N
N-20
p110-isoform
84,596
AGGCCC
.LPCX-Smad3
.C396R
Bardoxolone
AxioPlan
cyclin-like
412e10
.Just
.LKBI
Haematoxylin-and
monocytes/macrophages
underphosphorylated
CCL5/IL-6
Nobox
lysosome
IL-3–deprived
sulfurylase
Trastuzu-mab
10.1002/humu.20734
Rad51c-deficient
shRNA–mediated
Koiss
pan-CDKi
site-directedmutagenesis
colocalizing
morphologycally
2685
and3
Zondag
.CMRPG
forestomach
prosurfactant
Greider
Membrane-induced
Thr-75
.Enrolment
Pten-loss-driven
anti-NCK1
submembranous
PNES
PHTS-related
Pi3k
BiQ
usefulmodel
noncysteine
HA-FANCG
c.791_794delATCG
strain-matched
.Tg-GR201H
METD1228H
single-photon
B-resistance
performed35S-methionine
-MLL-ENL
theactivity
150-kDa
cytokine-
fertility84
SK-Mel173
pSRα
ApcS580/S580Ptendel/del
Engelman
LXFA
SV40-T
_TACC_-coding
5hmC/5fC/5caC
DDK
Intronic
plates13
pLp53
hemorrhage
Notch2ic
endoreplicating
1C
prescreening
Arg1744
pigmentosa.20,21,24
mutations.24,28
general.22
transamination
ATRXM40L
proteins.12
RAD51C-A126T
2991
Wieringa
oppositeto
±HLA
alvelolar
G505S
cH2AX-positive
omentum/peritoneal
imatinib.9–11
0.0008c
Sc-Rnt1
100µm
pan-aurora
NM_001013365
.PEST-Substitution
1604
right-tailed
844G
lines87
intiate
ApparentK
SV-40
β13
1–12
4,132
TCGA-66-2787-01
.Collective
S34X
35G→C
30G18.0
less‐characterized
NeoFuchsin
bonemarrow
.Dots
www.ncbi.nlm.nih.gov/dbEST
v-iiiT
G469L
EGFRvIII-specific
peripheral-nerve
Activin-responsive
NBS12
2.0.12
presumbly
azoo-
DD-wt-SF3B1
sperm-derived
patternsfor
Ileu87
6,20,23,24
leukaemia25
14T
-11p
mutationin
G515S
Col2a1-Cre/ERT2
SNuPE
paraformaldehydein
ofrecurrence
5′-GGCATGGTCTCCCTGCTCAGTG-3′
re-dissolved
F-Tu
F207I
CDC25Graphic
unclear18
resistance.32
nephroblastomas
0.0609
V113D
∼14-week-old
RAD9
anti-rabbit/rat
nontargeted
reading-frames
HAUSP/USP7
34432
cyclinA
A_52_P219473
GDP-RasY64A
.PDGFR-β
remainobscure
Z.
FANCA24
DNA-seq
ERBB3-
.Errfi1–/–
R368H
MRTs7,8
phospho-AKT-Ser473-specific
antiBrdU
TFSEARCH.html
C345Y
vehicle-control-treated
2739
C481S
5′-GACAGGGGCGGGATGGGAAGCAGC-3′
G5882
0.092
tcttttatag
fghiringhelli
NUP98-NSD1-positive
194–197
F71
rs28897728
months10
ARID1B-containing
3405
VavP-Bcl2
C.Bouchard
clonewas
ERα+PgR+HER2−
Q660E
phosphotidylinositol-3,4,5
analysis.36
21.8
L858R+R776H
immersion
2d–h
I1769
PML–RARα
Bcl10-deficient
Dassault
L535P—the
.Giving
ADP-ribose
c.3283delG
Nitroblue
NUT-amplified
4.0.4
2443
low-populated
.Ab
MPD
nick-directed
adhesion.10
4274
Hennighausen
sameconcentration
.Haploid-converted
survival=22
regions20-22
p.D727E
IgK
Soscat-mediated
4147
IV:8
-phosphorylation
100-µl
TAC-to-TAA
BRD4-NUT-mediated
ofNUP98
BTK-mutated
FGFRTACC_positive
q13q15
S59N
PCTL-NOS
pcDNA3.1-Ires-GFP
MYC93
5′-GTCAGGCTGGTCTGCCTCCG-3′
5′-CCCAGGTCAGTGGATCCC-3′
.1e
reported41
U24170
CHK-1
Neurologico
WT-KDR
fusion-induced
5′-GCGGGTGCATTCAGGCCAAGG-3′
Bui
SYT/SSX-1
Kansal
in-fection
MIG
MSL1
BCR-ABL-independent
nausea/vomiting
Q288VfsX10
ste5
CMV-VP16-CITED2
Oragene
drug-relevant
ERK2.20,31
isoleucine‐to‐valine
Abdomen
expected-size
ACTH
anti-importin-β
PR2034R
49:1
HIF-alpha
p+1
Ang-2
JAK14
PTIP-associated
helix–helix
AKT1/
BCR-ABL-positive
54b-ll
obsessive-compulsive
Celbio
20:2101–2108
D2-3
Allof
W638X
pG418-SCR
A619V
MAP3K1-deficient
FGFR-dominant
1/52
//www.mutationassessor.org/
G327R
≈302
Brembeck
.Blast-phase
Myc-nick-like
shRNA-Ptpn2-D
Ni2
TG-3
TGCGCTGCTCTGCCTTCT
lysate-stimulated
–FLAG
P/R-specific
debumping
PI-MECs
AXIN117
prephosphorylation
Sahni
SR-UL
9821/12153
shRNA-transfected
middle/SB2
controls.6
FFAR2
site,41
c.169T→G
residues.43,44
pcDNA3-Flag-VHL
mechanism26
a–n
R142K
difficult-to-classify
−53
NCIFCRDC
NCOA4
mouse-anti-rabbit
1,2-dimethylhydrazine
MAPKmut
H177N
p.1286
mTOR-silenced
disfavorable
Ser146
meG
preRNA
R40H
preponderance
n=7/10
Cα-Cα
BIM-γ
FamIly160
Dnase
hypo-methylation
G154V
Joo
Tyr751
323-361
Tyr15
V819
Biotinylated
gynaecological
5′-GAAGATGGTGATGGGATTC-3′
described18,54
I-based
RAD50S
.Fax
Korolchuk
CTCAGCCATGAGACAATAAATCC
intodistinct
Rab-dependent
66178
11828665001
cells.U2OS
5′-GACCTGTTCCAGCACAGCCG-3′
Pten-targeting
average±S.D
Ras-MAPK
TCF7L2−/−
6,541
tumor-inhibiting
BWA-SW39
.Thermal
13q12-13
β/SMAD
27/51
sc7392
ql4q21
Ebos
170-amino
Trimethylated
MEK1
ZNF493
interactions28
identity-by-descent
.S13
disease.31
lethargy
proliferate
18.9
F7αR
Keap1-DC-DLG
observations52
5-HT-mediated
14Thr670Ile
p53V157F
19–
7731
18/33
0-hr
H209Y
UbcH5c
17q21.31–q21.33
Migdal
man.Here
p.Glu23ValfsX17
A-R1
EYSGSSEKIDLLASDPHEALICKSDRVHSKSVESNIEDKIFGKTYRKKASLPNLSHVTEN
1398
methods.21
Diff-Quik
first-antibody
−7.9
Ccnd1-
Blood-derived
ggatag/GTATTG
TBNA
Msg1
.Mg-2
32.5x
EPZ
MYD88L265P-transduced
.A-C.
S1404Q
retrotranscriptase
Ballmaier
GCGGGGGCG
covalently-linked
arginine-
Hematology/Oncology
5541
SSBP2
WI2-1990K3
pCEFL-GSTneo
2.9-kb
.Bresnick
G17A‐RhoA
midostaurin
electrophoretic
ubiquitin-tagged
SH2D1A
transduction.5,6
guanine/cytosine
.S1–S7
282–437
cysteine–histidine-rich
alsofor
c.9257-10insT
MT-cyclin
latory
Fehling
probe-
pseudotype
c.262delCA
pCMV5-AR
transformation.54–58
Hs02339479_g1
antigensby
TGF-b3
Mean±s.d
D770_N771ins
OMM2.5
3xFLAG-ERG
2,640
E-MEXP-2197
GST-RSK-1
grey-white
o5724
HRG-beta2−7.3CNN3Calponin
Pdgfc
IHGSC
PcG-repressed
bioconductor.org
SNF-A
LC_C35
p≤6.6e6
LC_S19
leucine-free
massively-parallel
.Dose–responses
T198V
~10-
synthesis/replication
Stabillipan-2
Veigl
hEWS-FLI
autostainer
BBB
highly-significant
inHLA
BPC41
IKZF1+
cells54
cells119
9/F
N-glycosylated
P1729
Fig6A6A
sarcomas.56
pro-line-rich
KCNS3
months.2-4
D967
nonpaired
deletions/insertion
JA3
low-stage
PRC2.49
337GluFS-351X
.Epigenetic
systems-level
p.Arg342*
//exac.broadinstitute.org/
464–469
mildGardner
supplementation
-CTACACCCTGCGAGGCCTGTGCCCCTTCATGACCATCCG-3
changes11
anumber
FcγR−CD34−
D1304D/A1357A/P13821P
E69Q
0.01–0.25
neomycin-
approxi-
ALKF1174L/G1123D
One-step
rylation
MegaMUGA
studies26–28
segment59
nGl
1.823
findingsadditionally
receptor.26The
pCAGGS-FlpE-IRES-puro
8-12
6.52-
MCCT_29
time-dependently
ezrin–Ras
p-aminosalicylic
13.5-day
24-25
DDtag
Pro772_His773insProArg
hgmd0
CO.17
genome-informed
5′-ATCGAAGCCCTGCTGGAGTCAAG-3′
1C-D
Q61L–mediated
EJCs
55.6
RT-RQ-PCR
postzygotically
:21–29
protocols61
h.u-tokyo.ac.jpReceived
Mlh1–Pms1–Exo1
duplication/insertion
tumours29
glucuronosyltransferase
sarcoma-associated
Il7r
transglutaminase
Myc-ezrinT567D
10.1007/s10038-003-0037-z
lower-than-average
CCL20
*****
R320*
μCi/μL
18:22
off-diagonal
..LVEFGA
Kihoku
sensitivities
*Breslow
Distal
.DIPGs
200-aa
5*
whole-exome
5′-TGCAGGTGTTCTGCATAAGG-3′
Adrenocortical
AC002080
phoshorylation-dependent
andERF
Smad2/3-TIF1γ
SSPSmut-SSPSwt
G334S
1,112
16.9/2.8
factor-BB
Tollervey
PDFGRalpha
METHODSStrains
rll
template-based
.j
UP-REGULATION
cycloheximide-pretreated
Y223F
Hypertelorism
5q−
Zipfel
TP53–
Y1699F
1.38
growingcells
Smad7
.Wound
11.0+
chemoresistance
L182
796
C57Bl/6
deoxyuridine
40–100
CTGACT
ATP-containing
Strobl
R1699Q
medulloblastoma27,28
Trimethylation
2.731
DTpYVQHI
adenocarcinomas36
commercially-available
UPLC/ESI-TQD
TA10-R1
LC3B-I
19-exon
–isocitrate
Thr-68
Devoto
dmol
.40G
1.319
III–IV
A276D+WT
Nrf2-Keap1
pre-plasma
D-001210–01
C153Y
webfigure
ACD
G463V
3.4
OB1
III:17
2x4
Eissa
troglitazone-induced
0.666
Patmasiriwat
Arg26
Treatment-free
Lohuizen
pEFplink.6
p85α/p110
entity-defining
hormoneindependent
function.The
21Table
SKMEL
.Jeong
first-degree
deoxy-uridine
↑XAX
Thr235
HRG-b1
12q12-13
Ile201
TSLP
Supershifts
Cardarella
ridge—hereafter
5′-GGAGGAACCTCCCCTGCCATC
non-informative
FAD1
PTPRT-knockout
dystroglycan
5′-GAGGCCGGAGTATCTAGGCGTGGCG-3′
NSCLC.25
-PIKWTAPESLAYNKFS
plateau/
Barretina
alectinib-ALK
E-selectin
atoms—yellow
Yep181
cells1,4
2264–
NF-kappaB61
re-array
JNK-dependent
molecule-based
ATTBAASTT6ACTTCTSAA6AAT69AAZAiATTBAAAAArTIGAIrTCAACTT6TCT
mass.48
probes.14
refeeding
therapy-based
autoradiography.To
4275delT
EDC-RAF
V5/His
249T
cases.Table
FgfR2
Takagaki
thateven
70jC
425
Na2HPO4/1.5
~embryonic
biomacromolecules
telangiectasialike
SCC-associated
9503
.0023
proliferation/growth
Q1196-R2
Ibidi
KIT,4
3,341
MetastasesKIT
GCCTGGCGGG
Figure6d
ΔΔCT
hypoglycosylated
20-mmol/L
pCLxIP_MEK1-IRES-hmAG
⁎
reported32
A06Z
Autoinhibition
cases.15
0.1–5.0
562A8
Buchberg
R102S
.RKO
86–95
antiphosphorylated
leGl
Pdgfb-iCre
PTCs24
4.19
Blimp1fl
∼10−12
5•6–9•7
H193
G300E
781C-G
negative-charged
P63H
WThad
varianta
al.95
.Gordon
non-alcoholic
Clintec
WWP2
Ser24
003194
Sorafenib-induced
48.4
no/weak
21/24
FIP1L1–PDGFRalpha
helix-span-helix
fluorophore
0•39
1247_1358del
LIN-12/NOTCH
Jeuken
ade6
E99Q
syndrome,3,4
5′-AAAGGGAGCGAGTGCCTTTTA-3′
.Princeton
409–411
11K558N
HER2/HER3
10–100ng
Neh
PI3Kβ
0.4-13.0
C67E7
CagA-evoked
I173N
5′-CGGGATCCACTCAGCCACTGGATTTAAG-3′
CSF
CU110
N117S
P13
R40
Deltatas3
Biochrom
Wetering
0/96
IC+CRE
luciferase-labeled
mastermix
RAD51-coated
JAK2-positive
5¶-TCATATTGCAGATGTACGGTGTGGATTTAT-3¶
11-point
133.3/112.7
∼160,000
KOPTK1
CPT
5G–5H
⁎p
glycosylphosphatidylinositol
T1384
TACCCTGACACCAATCTCCTCAACG
V1804DF
7976
e2+3
Chemotherapy-naïve
cell–cycle
o~Y
I9_8_
4mM
ΔHIF-2α-L529P
chondrosarcomas
antitumorigenic
2515
TGF-bsensitive
ETV4a
LSAB2
CTCCAATGCAAGGAGTAGGG
helix-sheet-helix
≥200
DnaB
5′-GTTGAACGGTggCCACACCGGC-3′
1National
arcsinh-transformed
gonadotrope
Autogen
lesions6
Clean-Up
.ABMT
5'-AAAGAGGATACGAATGGGACTTG-3
F-generated
Lambret
S1.1-S1.3
TACCTFCCATGAGrFGTAGG
Post-capture
masculoaponeurotic
OP132
NDUFB5
bitbucket.org
Uterine
2237–2251
Cliby
IL-3–starved
6652-1
A-kinase
T256R
Sv129
WIP-CLO2
GCAGCATGGACAACTGACAT
10.9
Lats1-kinase
e82
pcDNA3.1Myc-His/BACH1
Fujisawa
sequence78using
17.9-fold
240
574
SacI/SalI
p-Jnk
gain-of-function/dominant-negative
28–28
CD24-PE
3.198
p.L73WfsX59/p.G196S
171-bp
ImmunStarTM
B.J.S.
38-Mb
.ILL
SiRNA-mediated
inTsc2−/−
Asn221
serumfree
77.06
false-discovery
platform35
p85α.17
BMDCs
siRNA/μl
mSin3a
TATTTTGGATTTTTGGAATTGT
activity.59
receptor–Smad2
0/107
613390
4182
347KB
amplification-positive
ConditionsFibroblasts
Asp419Del
3'RACE-PCR
TrkAIII/IP3K/Akt/NF-κB
460-nm
antiGLI
anti-p-p38
Fig.S6
.Granulocyte-macrophage
0.181
B7-H1
HRAS-knockdown
SFTPB
cm2
lateral-line
frame-shifts
HA-PMS2
α-V5
K612Q.H
D.A.S
Auto-phosphorylation
.8,16
Brown-purple
available.4
Bonnal
0.004–2.55
W399S
damage6,16
Gpx3
tract-binding
pBabe-derived
P379H
TIR-domain–only
TAGCAACTGGCACAAACAGC
iCAT
p.Phe45_Val51
F64
6/29/98
C.B
L452M
CD34-negative
dcc.icgc.org
.Hypothalamus
Siravegna
pGAD-STE11
administrationCrizotinib
2,3,48
RUNX1-deficient
papulopustular
practicable
nificant
RB43
p.M289R
site36
rk
NF-κB2-dependent
Ser473/474/472
cytoplasmic-restricted
rabbit–anti-mouse
ctt
expression.5,12
p-TrkA
51/80
Rhone–
MicroSpin™
MSH2missense
550–750
3,286
.constitutive
5′-GATCCACTCCCGAGACGGAAGTACCGTGGAGGGC-3′
c.4556T
906
50-145
FIP1L1-PDGFRα-positive
transformed.To
pGL3-1AP
BCR-ABL-associated
kinases.68-70
S.R.H.
MC38-OVA
204369_at
3-generation
1753–1760
pCATAbbreviation
A502_Y503
-Msh6p
plasmidto
111
+Tet1
Ala60Thr
ART3
3,47,62
FIGO
.Phe929
auxotrophs
`short
genome/whole
Tanshinone
PTEN110
L244P
iressa
K669
activation135
Co14
Bissler
lymphomas,13
MCF10ATK1
G*
565G
MB107
pEGFP-C1/DSS1
usingL-
Charcoal-stripped
fourinformative
Alaggio
-AAGGAAAGCCACGAGACAGA-3
.83
H107Y
Bergonie´
CoC
Ponasterone
Visualsonics
28-year-old
mutations.11
Mlh1–Pms1–Ntg2
∆C
thermocontroller
.Tnfaip3
3018m
trials6,7
1959
described37
T41
BRD2-4
cancers47
Kinase-inactive
profile.31
R672S
82.54
.Cytosines
-cDNA
Materials—α-Minimal
Flt3/ITD
Christoforides
ZMYM2
.Haematopoietic
XS
Cardiomyocyte
-competent
v-Maf
p16/Rb
0.00647
Bre
pcDNA3.1/Myc-HisA
disease-remitting
V-region
superhelical
.Cbl
non-smoking
2804delAA
K9
SHH–receptor
K224A
Co2+-NTA
−89
technical-scientific
NCT01001299
amino-acid
Fug-II/10
R60
adipose-specific
genes,4
5.55
inhibition.33
ITAMs
wtRhoA-expressing
I836MR
TTCATCCAGCATATCATGAAATCC
Factor/Scatter
Co-infection
supersede
VDR-responsive
SeyDey
intraand
UT-7/Epo
a-p85
short-lasting
349.0
VavCre+
CRTC1
progression7
whole-transcript
87-9663
nuclear-targeted
.Cdk4+/+
Pten-deficiency
L358R
pseudouridylase
88-3
21-23
RP11-285A1
25–64
procarcinogenic
A134
HMB
Tabone-Eglinger
1350-9047/16
LOH1p/19q
ba2
SectionDiscussionWe
chemiluminescence-based
SCC090
c.204delG
437,619
Sirohi
Bcl2-transduced
††To
hydromethyluracil
.Transversion
brca
Assessmentof
Myc
210-aa
1·25
AED
proteomics
1988–1991
potentiators
P217K
MMS-118P
Pece
resistance-like
p=0.032
precursors.2
=0.31
.Whereas
.FDC
BAT25
MAPK1-E322K
migration/invasive
ETV6a
1d-4
BA/F3
ERCC
EBV-TPl
EGFR-mutated
GST–Nck
p.V769L
R357W
mutantcombinations
R244P
Concurring
sub-diploid
Destabilizing
Bombesin
islands27
Leu403
18.1
p.S535C
six/ternary
Akv
.Integrated
manuscript.11As
Cul2-W117R
SK-HEP-1
1,220
.Approved
abnormalities24
.IDSs
null423L
R64Q
Rc/FGFR3-KMS18/IIIc
WT-p53
HUT-29
Sørlie
investigated.30
HA-mutant
humidi®ed
tumours—all
formation.153
insulin-sensitive
Retroscript
intrapeptide
AluS
TCS1-TCS2
5´-ATGGCCACAGGACTAGAACACCTGC-3´
β-TrCP-mediated
K.U
viscerosensory
ROCK∆3kd
limitations177
0.805–0.930
exponential
Arg57
Xp11-translocation
hSET1B
8037373
298-333
loss/inactivation
KH2PO4
37-38
F4/80+MRC1low/−CD11c+
~dash-dot-dot
HR=1.97
K382Q
Imoto
465
L/T
'e
S6.Figure
510META
IL-6/STAT3
mTOR/S6K1
Q799P
CorrelationsGenotype–phenotype
radiolabeledanti
Miltenyi
stalwart
His718Tyr
homeobox-genes
Met1775
KIT-mutant
1038
recurrences18
S532A
M340
NSCLC.38
86K
1,5,6
Y727H
atom=
stability.35
Fluorescein-Osu
glial-derived
TFA11
sj
1980
.mTOR
Chiarugi
OMM1.5
g-associated
1-771
30,31
1–29
IASLC
Envision+System–horseradish
ras/mitogen-activated
Pdk
2,3,5
mini-V
PHA/
EDTA–0.1
,51
p.Arg21Gln
CAAAGTGAGGATAAGGGCCA
Neuropathology
ETV6-GOT1
HRASG60A
7,598
Soenen
1:100,000
Myelodysplastic
BM-911453
Cullin-4A
dox
S226
Cbf5p-associated
AATF-STAT3
Hyperactivated
n=65
members.34
rearrangement4
K305M
D47A
non-carriers
Myc-nick-induced
pcDNA3.1-
overexpressed/overactivated
RO5045337
5'-CpG
all200
17/50
Unevaluable
Cip1/p21
Lys650Asn
ALK/ROS1/PDGFRβ
Osaka
2101
GGATGGCCT1TTAGAAAGTGG
NSCLCs,17
0.00009
3–independent
SHP2ΔSH2
0.576
.HD-LEC
Promoter—To
non-type
R1242L
LTC-initiating
1179–1187
Tyr1045
125.3
381–766
p-PKCα
6.43
regulons
break-apart
glycosilase/endonuclease
p=0.0359
96.95
trypsin-mediated
GGATTACAAGGATGACGACGA
5660
treatment20
3303
12h
TrkC
–PAGE
E2f4
11/29
.Plus
Incubate
V321M
potential.1
ORF/well
sequencer.RT-PCRFirst-strand
100094
-cxD12
overtreated
a-loop
91/167
hydroxydaunorubicin
LUN01
copresentation
E142D
Genomically
D272
.04
RNA2.7
.Subcutaneous
Cdk6-null
p53-speci®c
.Unadjusted
aIncluding
study,14
NGF-binding
Sonobe
Quikchange
rate.11
individuals3,4
Figure7D
clonogenicity
V297I
|CODD
LDS11
AVF
Bach1/FancJ
Q63fs
Lkb1-transfected
K5CrePR*
ARAF/RAF1
,12
ef9
112:217–227
motifs—may
3-kinase/AKT/mammalian
.STRUCTURE
sensorineural
MSH2–MSH6
I/Stu
CMV-stat1
dual-labelling
mMet
D1-D289/292A-
mock-injected
D16S539
135-bp
spot,14
.Transphosphorylation
D1067Y/
p-Smad2–positive
Hydroxystaurosporine
differentiation.11-13
receptors9
Garibyan
L680
TCACGGAACTTTGGGCGACTATCT
270–415
Gaspar-Maia
S4A–S4D
GNC
TGFbR-II
Figure2C2C
Lys1140
DiI
-Mediator
T48R
Appledorn
Shp
Thr87
R542W
half-life.80
UUCUCAAGCUCAUCUAACCGUCCUG
.lPage=11753
Ptf1a-Cre
thoraxa
D309
32133R-1
GTTCTCAGCCT
exudation
1228–1234
GIST–Regorafenib
Y174N
competition.Competition
6917–6925
A449T
months-38.1
Haar
V765G
Innovatis
-2-pyrrolidinemethanol
shRNA738
anti-prominin
myeloma-like
ei
co-immunoprecipitates
case-wise
p.Pro289fs
commonalities
Birtwistle
steady-state
18/239
S3J–S3K
cancer103
xDFG-aspartate
20–28,37,38
8988S
p.Gln474X
DMI6000B
GACTCCTGGG
S381Y
SCSsequence
ABCB7,23,24
biterminally
13-bpEREplus
21.8/26.4
pADH1p53L22E/W23S
2266G
pQE32-derived
ADT-induced
GenomeAnalyzerII
scaRNA
UGGUG-containing
Tsc1-
GRD.The
5′-CTTTCAAAATATACCCCCCTCCC-3′
//www-genome
Deiss
1717WGTPF
significant.Gene
bromophenolblue
5×10−2
coincident
1391
Xenopusembryos
cells,220-201-154-134-R1881
p=0.018
blockage
:cyclin
3-tandem
status.MUT
synaptic
LTR/+
11721
syndrome-derived
complex1
GENE-E.
RC20-Horse
cancer-sequencing
anti-glucagon
E554_N566del
p90RSK
GP+envAm12
mll2se
27/79
mutations.49
RCC-affected
MDM2
hematopoetic-origin
Calbiochem-Merck
N227S
exclusion/concurrence
outcomeOut
AlignGrantham
07-328
BINDNG
product8
4220-D
PD183805
MKK4-shRNA
mRNA.20
Powerblock
HA3
S477
13-kb
IRS137
pMEFLAG‐Mga
M541L
group3
apoptosis.33-37
Poyurovsky
of2.2
10/20
VEGF-targeting
VNTR
c.211_213delGAA
UltraVision
eubacteria
models12
hemi-inhibitory
EML4-ALK/NPM1-ALK/RANBP2-ALK
374–498
4′
−150/+150
hemangiosarcomas
Ral-A
tables11
0.0069
Gandara
A_52_P70949
clonality.Plasma
splice.pl
4E-H
NGFtreated
NF1-nondeleted
Gln938
1·1–7·6
Paalman
AML-M7
PLECKSTRIN
-CTCTGCACGATGCTGTTGAGAACGA-3
Trp99
TW-7
V615L
methylation177
Piccart-Gebhart
mBAND
novobicin
guanosine-5′-triphosphate-bound
EU693920
Vab
FIP-positive
,1
ß-actin
culturewere
ARUP
ubiquitin
−2All
MAP2K1/2-ERK1/2
thoracic-abdominal
cancer25
p.Gln61
186,260
Gorski
nihms5567f6.jpg
r~-3
c.490G
anti-H3K27me3
protocols52
CATCA
Ser6
XXXII
cells/L
non-GAG
int14R
mediated-apoptosis
N-β1
Scan-500
sites.EGFR
721–92,701
V——
signalling.29,30
5'-M13-TGGAATACTTITTCTTTTCTTCTT-3
αBRCA1
3.28/15,144
Y-linked
p.Q3066X
End_position
Beaujon
Xc
Kaneda
mFOLFOX6
12-yr-old
15.99492
CGCAAACGTTGCATTCGTACT
FGFR2N169Q
complementhas
3.65
tumor-producing
#
tomography/CT
8p22–23
haematoxylin-stained
Jak2
.XPF
Florenes
TGF-beta-responsive
gain-of-function
.FMTC
ruthenium
pWzlBlast
.Ser217
.2113G
GGTTCCAAGTCATTCCCAGTA
Rodenhiser
M/69
0.478
a-actinin
2358
.Immature
~85
Dasatinibbound
175Pro
pCB6p53mt
P=0.06
shP-A
.FusionSeq
Peshavariya
reads/germline
NSCLC7
.PEBP2β/CBFβ-MYH11
non-discriminatory
V560D/V654A
232274_at
.Flag–FBXW7
4.59
GHKL
GST-PAK1
Lfc
`wildtype
3′OH
I-10060
NZM20
cic
70-mm
co-expressed
c.910C.T
VIL
59.59
Pit-1
ligand-stimulated
familial/bilateral
Pro9733Leu
FL145
death63
metallophilic
ung
gained/amplified
HSM
48.7
experiment.Statistical
mutations/PTEN-null
AAAACGAGCAGTGACGTGAGC
RNA-induced
K562.52
Ca9–22
c-IAP2/HIAP-1
.TG
Degron-knockin
signal46
90.67
pZNaqQ209L
signal-specific
3.49
non-suspect
Dreyling
nuclease-assisted
MA9+shTet1-a+b
amplifications/
HindIII-Avr
PDGFs—SMCs
Anti-NF1
.4,28,29
AG06234
populations.18,19
NCOR
Q322A
Paragangliomas/pheochromocytomas
Del746-transfected
.Uniquely
Li–Fraumeni-like
0†
mice.11
G779F
23,24,30,42–44
phenocopied
Valbuena
6D-F
2–109
Loxo-101
induced-hepatocellular
DXXGQ
RBX-1
syndrome.6
14,22
phosphorylation-site
.GFP-Smad4
TGFbR2
ofhuman
1660
helseforskning.etikkom.no
.CDK
Tww-tk-Luc
.Equally
.Vaco400
T532M
First-dimensional
371-380
restriction-endonuclease
luc-F5
Orelli
.CapZIP
rs12255372
AG09391
NT_035113.6
tAML
Na-piruvate
DEAD/DEAH
more-effective
A695S
anliestrogens
S1524A
RalGDS-Ral
1.2–3.0
anti-CD31
0.730
ICRF-19318
S.B.
3882delGA
YR6
34-year-old
00001311
fromp53Y220S
SFA3a
F347L
μmol/L†
roscovitine
hypomyelination
S784Q
UTP-labeled
SNORA*
resourcefulness
ϵR
Procaspase
`+
241delAb
HCC/Del-T790M
GdotT
topoisomerases
Ship1
β2-
2-82
monophosphate-activated
disfavoured
SD1
Bcl-2-mediated
Letouzé
SLC45A3
p.Q519P
vemurafenib-naïve
Medium-sized
reported.63
TTD/XPD
3/55
SMARCA4-mutated
Ni-NTA-agarose
Merlin-independent
5700
46-bp
63,70,71
receptor-α
R137H
fusions70
Table3.3
rules.40
HN-K-rasG12DSmad4+/–
Neuro–cardio–facial–cutaneous
Thr77Pro
5-/j.m
LATS2-WT
Phosphorylated-ERK1/2
F35L
.18,19
triethanolamine-HCl
.EI
surgery.6
PDGFR-β-deficient
ICIG-7h
themultiple
Seromucinous
CCTCATGCCCGTCTTCTTC
Dacwag
months.3
_2589
35/31
heat-induced
intraobserver
pre-processed
crosslinker-induced
human-murine
RipE-cad
19•87
PI3Kα-selective
one-state
2§
SRC66
AdCMVGFP
D308E
Ago2high
anti-IL-10–neutralizing
stable-transfected
RKE-Ras
JCI
+601
Swiss-Prot
implementated
231579_s_at
Arg547
NM_145602
TnlO
anti-proliferative
morphology.3
IFAR1
phakomatoses
familialmalignant
c.974G
Southern−blot
sVEGFR-2
1522-8002/10/
described3
package,28
6–127
AGTRAP
releasemismatched
leukemogenesis.Materials
rpGInArg
anti-LYN
described.18,19
CD38-FITC
10m
weeks.85
A2825
non-reducible
Graphic-GraphicP
pcDNA3.1-based
multi-cyclic
02181-8
Early-onset
Figure3,3
TEL-AML1-mediated
c.5259
multi-drug
tumors.20-22
.Fast-flow
6Nucleo
E3*
V600-like
pCMVR8.91
ct.dons
^-i
FACStar
Glu-659-Phe-1248
RUNX1-RPL22L1
CytoStim
H219fsX272
fromFO-1
NKTCLs
SCFFBW7α
C2773R
SUM190
L426P
ossificans
rThrLmaL*uLeuVsILuAsnLy
0-46
.Intracranial
amitriptyline
60.8
multiband
vav
Lys51–Asp45
PI3K3CD
ERK2D318K
ab15597
–/1
deviation–centered
UHPLC-QqTOF-MS
cGGGCATGCCCg
∼28,000
reducing/denaturing
hydrolysis,11
mutations66
erythroleukemic
p.V600G
–600
PDGFβR/HIP1fusion
1-mediated
TRAM,15
Granulocyte/macrophage
CD34+/CCR1+
V1741G
co-immunofluorescence
54-bp
brain-restricted
GST-PKBα
INTEGRINS34
7PolymorphismG/T
Ser46
wX0XN
p.Ile682_Arg683insGlyPro
D17S635
4A-4B
c.1669
treosulfan
0.005M
growth.5
.Classon
competitive28
Burgt
1.97
pGEX-NF1-GRD
V115E
Rapidly—
Lentirviral
assaysTwenty-four
59-CTAATT
C268W
.Abdominal
GGA-3′
Kiewe
-linearized
V600EBRAF-positive
H1746N
benzyloxycarbonyl-Ile-Glu
probe/gene
DNASep®
Thermodynamics
Sharrocks
MDS/myeloproliferative
871–880
SuperCluster
BioOne
Chx10-cre
.Relaxation
c.463+43
I.M.S.
Oscier
FHIT
o_~
BeSO4
c.1790A
cysteine/serine-rich
1000-3000
.Established
Non-SHH
MCC13
rgGl
.Development
V1833E
T366
lymphomas61,71
project+
previously.5,6
H596
GST-Gli1ZF-K350A
.r6
Igh-V7183
well-defined
keratinocyte-deficient
pGL3-GLUT2
mutation.42
N-6
nucleotide-free–like
.PDGF-D
LAT599VKS-motif
1–250
MiR-483
DAK
mHprt1
site.58
PCNT
protocadherin
anti-CD135–PE
TY4r
DSRCT3
infectioncDNA
LyP
EnhammaMw
ImpromII™
Eppley
spectroscopy-based
3746
⩾60,3
Invasion/migration
18–25
c.1980G
BMS-833923
c.3800T
E2-EPF
loss-driven
triethoxysilan
Pigmetosum
dual-responsive
CD-95
Roch-Lefevre
stimula­
Lib-L
protein-negative
Fig.1A
Glu542
3/611
nano-HPLC-coupled
CXCR1
Schiering
8586–8599
PC9-BIMi2+/+
G102S
gemtuzumab
≥3.1
G324E
recombi­
Alk9
PDGFRA-R15
transferases
EGFR/CEP
−8.5cDNA
768.36
phospho-c-Jun
.Hepatic
Tyr-700
MLH1-2
growth-factor
Hutvagner
eitherhMSH2
Vectorette
Bromodeoxyuridine
Y.G.Chen
L1215
transmis
CLB-MA
.Asselain
Nf1−/−
Flavell
daunoxome
literature-based
0.033
Ras-family
SF3B1H662Q
carcinogen-dependent
erythropoiesis.53
PTEN-deficient
episome
8-hr
animals14
ikaros.49
A69S
anti–PD
lines133
described13
61°C
YesNoRefs
R752
Plaur
SKI606
puc
Pmut
Raf.C
mortality9
4/413
phosho-FGFR
.T-tests
controls.Signaling
I2XP2
TKI-insensitive
Akt-Myr
58.59
14–0112
medulloblastoma13
tv-a
-0.475
5′-TGCCTTTCCTAACTCACACCT-3′
SignalingIn
−6195
14-6077-82
α-TrkC
studies11,24,26
p53-/-/p210
-GCAGATTGATGACAATGAATA-3
ATP/protein
L481F
pathway.html
DLBL
3468Boissel
TGGAGAAACCTGCCAAGTATG
2211
Arg86-Phe55
.Bar=100
Triple-negative
Landesärztekammer
TSA
cells6,7
ERCC1–5
A354V
K580X
.LAM
ploidization
catCT421M
DOGS-NTA-Ni
msh6pproteins
GsqDLLnwcmQIAkGNsYLeDVRLVHRDLAaRNvLVk
C2-FGFR-3
hand-foot-skin
4C–4F
nm2/ms
www.appliedbiosystems.com
Syndrome–Associated
KanMX4
cancer39
GRM8
phenotype.Protein
20G11
AcCoA
0.1.18
gt/ag
THxID
anti–phospho-JAK2
HCT-15-TetOn-Wt-CHK2
Fig.6D,6D
Pdgfrb
ERRFI137
Fueyo
403-aa
overlap.5
5′-AGAAGGCTGCTTTGGACA-3′
ani
801bp
.Imatinib
prognoses1,2,3
hGAPDH
100bp
theprevious
PD‐L2
-tailed
Crohn's-like/lymphoid
Alk-3
event8
100-171
0.719
TKI-induced
OR/
740615
pS62
12/8/98
M081
14,28,38,39
.CD95
Kevwords
21.
4–7.3
3396-400
trials.12,15
KITN822K
EZH2.14
F81V
B/NK/M
PtenΔ
characterised.1
IM-resistant
TGATAGACGC
slideAssociation
D279N
Presentb
.Anexample
.16-20
E412K
GAAGGCAATCACGGAGGTGA
Recognition—We
red/yellow
cancer–derived
cotransfection
JHUEM
.wild-type
-p42MAPK2
C814-L815-S816-P817
previ­
anti-Aim-1
≈5.4
pathway-specific
VACO-235
tropomyosin-3
RP11-489L13
68352608
Bjornsson
Lin−Il7Ra+Sca1medcKitmed
.S102
W6
100:1.Frequency
1.22-9.90
Hochhaus
stroma-induced
6G-J′
exon13
c.692C
DASL
NewEast
Gastrointestinal
p=0.0375
3.8–32.3
non‐existent
NPRL2
T-Rex
p53DN
K650/652T
.Thermocycling
ssm
SNP-specific
Asn-850
factor-IL6
demethylase-1
FOXA1-directed
FOXO-stimulated
EGFR/ErbB2/ErbB4
clease
pVHL-binding
1.60
SHH/WNT-independent
RasQ61L-GppNHp
M928
Generacer™
G2195A
interchromatin
.PEST
seen.Figure
.Lists
dbj
PLINK
pCMV-NEO-Bam
Corp.
Smad4+/−
Hanlon
.select_db=ATM
P-0000208-T02-IM5
Kleihues
.Results—AR
T/null-cell
pCMV5-TGFBR1-HA-Flag
PhosphoImager
HMVII
complexes.The
129Sv/Jae
CD4+CD8−
PDGFRA-blockers
cancer78
W76G
Antibodies—
vitro3,4,7,12
'feedback
41.7
marrow-biopsy
5α-DHT
R53C
t-CMML
pathway12
1,356
RP11-350N15
8948
0.774
.Interpretations
13,403
GF003
SuperscriptTM
pEF
15-year-old
KIT-binding
MEK1S298
high-field
TGTAAAACGACGGCCAGTGATTATTCTCAAAATGTTGCTGTGCG
IV-7
substrate-site
GISTs,5
pylorieradication
heteroduplexing
CATGCATCAATTTTCGCACT
29-30
163.1
EGR–TKIs
dodecylsulfate-denaturation
.High-resolution
Ebf1-GFP
—results
.LPA
effusion-derived
NK/T-cell
Bilkent
regard.26
far.9
Snf5-heterozygous
horizontal/vertical
104-bp
magnetic-bead
harbinger
pCtBP
Jeb
Y823D
NM_011799
0/9
.RA-binding
Gβγ-mediated
NED
prognosis101
Lys59
2-methylphenyl
as.g.
activity.15
Pstl-Hincll
Enamel
phospho-l-serine
invasion-associated
CRLF1
O-glycosylation
0-3.9
decay23
.Suggestive
HOXA3
b-catenin–overexpressed
IZMSH3
p53-DO1
anti-Nras
FANCD2.15
ura4
Y826
intertumour
LPXN
phRL-TK
Cmp
7966
r=0.32
oligosaccharide
xenograft-specific
A072
0.001aCD4/8
\i'*\t*2
intestine.87
EndoH
lactotransferrin
GPD
tumour129
58,000/mm3
~100M
pcDNA3-VHL.HA
MgCl2/2
50/10HPF
0.51-0.63
.His-tagged
Majesky
−UV
70–138
pro-apototic
thymoma.43
1–820
50–65˚C
germinoma.44
kV
genetics.bwh.harvard.edu
0.339-1.652
Srcfl
Mono-ubiquitination
ß-f
RORα
Catalouge
14.03
disorders/myelodysplastic
STAG2
K-ras-2
Mesenchymal-type
ezrin–SOS–Ras
immunoblotting
BCThe
TIF1
Prp40
N-D-T.
S4–S6
spectrumOrange/CEP7
L815I
tropomyosingene
α-ketoglutarate-dependent
A138S
FFU/4g
ΔMH2
np16ex2r
2–10
APC–CDH1
D19S216
Fifty-six
CNT
PDGFRA-R3
amplicons7,8
ketone
Wetzker
AB5535
lineages.1
nM.59
1751–1754del
.Misprocessed
R134G
9-mer
Glu63-OE1
conditions.23
database85
melanoma-predisposing
DNMT3L2
0.4±0.5
6delTG
lp3l-32
conjugate
βc-associated
Li–Fraumeni-Like
chloride/5
Sub-stratification
-Methionine
37Codon
MER-type
.Akt
Lin−Sca-1−CD49fmed
mCcnf-Forward
H4/D10S170
autophosphorylation.20
KYSE-170
P13K/AKT
G101
289–1219
c.3008C
Matsushime
MADS-box/MEF2
proteins41–44
0.8G0.2
93-5
combination71
FISH—cyclin
Nihon-Kayaku
awaited.In
segmentwithin
NM_000038.3
myelogram
FU/LV/CPT-11/bevacizumab
5′-ACUGUACUCCUCUUGACCUGCU-3′
short-chain
pseudo-first-order
.DD-SF3B1
5′-GCCGTCAGGAACTGGAGTATGTTC-3′
multi-nuclei
Kac
reverse-cross-linked
c.4023G
U04847
parietooccipital
CTGCCGGGGC
G9A/GLP
acetonitrile/50
SNB19
.Intensity
H3K9Me1
renal
pcDNA3-wtp53
N166Y
148αα
K-1
5'-CAG
.Psychomotor
Src-induced
expression.84
Spain,12
I391
pCDNA6.2_murine
~D~lacproAB
.Subtype
gene-carrying
deacetylaces
BCR-ABL–independent
extragenic
Notch1-induced
rectal-sigmoidal
0.3–2.3
76/F
RSPO2
malignancies.38
proliferation36
PRDI-BF119
DCT/TRP2
Idkowiak
41×103/mm3
disaggregated
SKBr3
Aquacosmos
N1-ICT2133A
36/123
2/151
D4S1586
24/39
enhancer-like
Max-Planck-Institut
S266L
damage.12
-ETO
Map3k1Δ1/2
O'Reilly
Reverse-GAGATTCCATAAACTAACAAGCA
~12–15
7/47
Kao
Fig.1D1D
pri-
pipettor
dissection†
2-group
C135/141A
F307A
106-115
XP-correcting
Xia
G/A228
Arginine-to-Histidine
pLenti-CMV/TO-eGFP-Puro
NHRVGTKRYMAPEVLDDSIN-MKHFESFKRADIYAMGL
expression26
W757C
249–311
β3-α2
Br26
15q24
0-14
R134W
Nde1
Clínicos
TDII
NOTCH1-acti
responsi
10/18
=76
I1–3
non-mapped
1981Tins
7o
Herskowitz
events—the
FYQQQQQSELQPPAPSEDK
2012008
trkV345
methods.18,19
and2C2C
βE'-F
351-381
FANCC,24
cancers122
29bp
dis3DPuroR
Single-stranded
gbAF329273
R75Q
BSA/1
disease.FIGURE
p53RE–hCMV2–DsRedTo
0.60–1.16
¿E232
simplistically
p2lRasGTP
seqLogo
LAR
.ImmunohistochemistryDue
R271Q
NCT00549848
1,25-Dihydroxyvitamin
calnexin
di-methylation
Hs00153277_m1
inhibition/withdrawal
XB-1
71-3-7
D4.3
78000/mm3
regions1,4
space-filling
screens18
Korsmeyer
N-SH2/E76K
pharmacokinetic-pharmacodynamic
≤0.01
/Cys
.FRS
.OFFICIAL
Anti-CD8
PLX7486
Schlaepfer
~point
R379Q
headgroup
C9344/
CD25-negative
point-wise
GFP-RAC1P29S
R1947X
3004-504
CTC-554D6
pBabe–HA
CAGUAUUGCUCGUCCUCAAdTdT
2y-PFS=57.1
.Podocyte-specific
HDPR-1
circuitries
PDGFRB–positive
TrkB
8.00
j-th
2.7×10−4
004448
368–449
SPHF
c.2251G
CDKN1B-R1R
KidC
+82
nature.Although
.1973T
46480
R7Ras
.WlldType
KLHL6
INTACT-1
+Wnt
cyst
K26M
27–71
R164Q
LSC
bromide
Provisionally
CGAGACCGATCCTCAGCAGCTCCCAATGTGCAT
P95R-12
PtdIns-
5.3052078
.Relationships
G165E
and3B3B
GTC-*TTC
anti-14-3-3
NM_010939
anti-Snf5
-carbonyl
dataFigure
R-CACCTGCAAGGGAGAGAAAG
Ostergaard
TGF-ÃŸ-RII
71lF
intra-strand
.FIGURE
kcat/Km
Myc-p110α
gene.7
DuoSet
wtGSK–3β
sub-stoichiometric
Neurotransmitters
15q11-13
P-H2AX
Elk
441.2
.Maki
≥3000/μl
.Pro-525
.Mac-1
pFox01
collection.21
Partanen
C600R
82
L13
R761K
alterations1
KIRP
3-position
impedance-based
v1.10
PASLI-CD
oligospecific
QBEnd10
obfuscate
R214H
HS00418963
hemoglobinemia
1.08–6.08
BAP1-independent
Rajewsky
.Deposition
nature.comp53
Akt-p
Frizzled/LRP6
p15
NIS-element
MB4-1
cancers.Materials
Avastin
~100–1,000-
Garcı´a-Harna´ndez
DDR15
del2013-2024
CPICLELIKEPVSTK-CDHIFCKFCMLKLLNQKK
1,000cells
Polymorphism-ATA
21160301–22679000NM_016373
syndrome1
HER‐2‐mutant
0.488
pSPS
ESI-trap
DSS1/DNA
therapy24
MvlLu
pregnancy-related
gastrinoma
KIT/T670I
c.73G
TROSY-HSQC
354–371
re-supplemented
RASA3
T65P
0.67-fold
Phosphorylation-Enhanced
ProtK
mutant–positive
amplification/mutation
9C
p85α-mutant
shRNA-Ptpn2-B
TGFBRI
0.78694
0.6.2
Br54
GTGGTCATTCTG-3′
F958S
andmanipulate
S-795
≥10-fold
vemurafenib-naive
mucosa.33
N398
5'-TGTGAACATCATTCAAGGCGTAC-3
membrane-related
.Especially
FLAG-hRKIP
200kb
CD2
Stat5
GC-HBOC
Tischkowitz
.Sera
diseases.29,30
.Comutation
E29-913
Fig4D
spasm/hypsarrhythmia
karyotyped
SS_L1-23
Helleday
W3248R
papers,33
A59T
PLCyl
EcoRI/XbaI
3565-4347
.In-house
PDE4DIP-PDGFRB
Q40
fromATCC
N285H
D42
APC/GSK3β-mediated
Thr-681
Gly375Cys
.Histogram
CIN4
eumelanin
5′-GGAAAGACAACGGACAAATC-3′
13.37
criteria14
JAKs31
ERANGE
lines.Anchorage-independent
Kreike
BHY
PDGFB-driven
−2SD
detectionwas
observed.22,23
Del/Ins
double-label
.Chemical
rs67972878
GSE27832.Figure
/ETO
p53MT
anti-hPMS2
-mbq
35/223
Yoshiuchi
anti-p70rk
iodophenyl
supraoptic
clonotype
fludarabine-refractoriness
virus,1
Gly-1479
NVP–TAE684
A_52_P430886
74
.methods
P261T
13C2D2-iodoacetamide-labeled
J15–17
29/M
score+1.0475×∣∣thenumberofΔheavyatomsofsidechains∣∣–8.0548×theaccessibility
Meuer
CSD.1
4,5‐dimethylthiazol‐2‐yl
PTpy-
S5e–h
Nilotinib–Abl
thensequenced
.Y236F-p53′
0.128
VHL-expressing
aryl
GRIM-1
T32R
SBC1
fractionate
Patient-specific
M23720
B-lymphocyte
a-type
FH225V
Stat-3
IDH1MUT
Ras/Raf/MAPK
described.6,16,17
SHP2-expressing
.Canal
H3-K42M
GTCGCAGATGAAATAGGGCTGT
RΦΦNHSC
2010
T131L
Labimage
12,000g
RANGAP1-PVALB
Bars=50
Granta
Type-A
0.0432
H-RasV12G
Macherey–Nagel
AktE17K
11097601–11148500NM_017837
Jaju
sub­cloning
avariety
p.E443K
ELL
50–80
CTEN
NaB-induced
RERâ
BV13
BRD4–NOTCH3
Sabatakos
Iql3
Engelbreth
documented.10
protein-antibody
9.29
PROBE-FAST
perchlorate
113.7
mutimeric
c.1489_1490insC
activity10
anti-STAT3
University-Purdue
ALL-11
5′-gggatccccatggtttctaagctg-3′
S6F–S6H
//www4.od.nih.gov/oba/rac/guidelines/guidelines.html
Human–mouse
nitrocellulosein
ΔΔEvdw
FAM46C/MTF2
Mdm2-p53
LCX.5
2000-fold
Tiam1-Rac
resistance.Other
3+d/C+M
promoter-driven
hydrolysis/DNA
Tis28
574/1059
xenotransplants
Berlin-Frankfurt-Münster-Germany
non-standard
WTBRCA1
Vannucchi
senescence15
gammaR
Oldenburg
PALS1
PRR23C
intensity.
D.In
DUX4RTr2
Supt11
.Uninformative
RARA
53–57°C
R1881—suggesting
system,1
Lysophosphatidic
10Genome
Y827C
α-thalassaemia/mental
5′-LTR
GAL4-CBP
Denaturating
Methods.NMR
2.20
CX2CXGraphicCX2C
18–53
.KIT
AML/Evi-1
Calne
BamH1
genetic50
doi:10.1186/1747-1028-2-26
Gly423
P003
U2AF35
13-17
NCI-H128
.OCDfl/fl
ll'.â€
P6/7b
Histopathologically
non-DBD
2.5-fold
40–43
ProbeLibraryAssayDesignCenter
A1214G
.BWA
hematocytometer
phocytes
+39-11-6706582
Caspase-8
TetO-PIK3CAH1047R-IRES-luciferase
.Ebrahimi
al61
spectropolarimeter
KMT2D–ERα
domain/AF2
rearrangementproduces
KB1P-B11
anti-Collagen
β-aminoethylether
.864A
un-mutated
Over-represented
26,45,53
UniProtKB/SwissProt
D-03
RARS/-T
non-PMBL
methylation—levels
N564H
NTRK1/ch17
HLA-matched
L656S
anti-phospho-
BCR-PDGFRα
5Km
MSI.13
S7.Figure
co-occuring
Asp-316
85283
previously9,24
age-inappropriate
823
CCAATGCTTCCTTAAGCGGC
10/69
MOSCATO
P43
TDLLD
Q57L
TP53INP1
2.66Å
antiavidin
MSH2-PROF
N-acetylglucosaminyltransferaseV
QFQ
Th1-promoting
//ftp.genome.washington.edu/
Phosphorylation-dependent
0.272
−725
high-molecular-weight
5-class
PKA-CREB
61–64
.What
Cdk1/Cdk2
E91A
S253
26p.F506_F508dup**
0.033-1.790
No.sc
EGFRΔ768-expressing
R1589H
rsc2
~0.2
Phosphatidylinositol
tantly
α-selective
pseudo-gene
Ras-proteins
partic
SectionMethodsProtein
ofGISTs.We
7EGFR
non-responsiveness
domain.7,8
58–63
INK4-targeted
dimethylglutarate
genes.20
GATGCCCAGGGAAGACAG-3′
EWSNTD
,45
5'-AAT
S.5-
–26.8
SF1/HGF
Mydlo
brentuximab
methylomes
.K-ras
L142R
triplets.15
Friedrichshall
chromatin2
Robanus-Maandag
15nM
24.24
F246L
presentingwith
members.7-9
4-a
Sos1E846K
N-ros.
XTcf
brightener-dimmer
Karnitz
RBM10‐targeted
Wap
antibody12CA5
pY877
1T11-115
Sun-Whe
LN-KNHFQPYIMADIYSFGL
pBAXs-luc
pT3N1
MCC-1
×16
erythropoietin-secreting
A-GVGD-based
insufficiently
Sensitization
KRASV14I
TCGACACACGCAGGCTGAA
modi®cation
Gly63-Ser68
p53R273H.20,21
V3079I
p110δ/p85α-nicSH2
Mx1-Cre
l-
Ml3
-g.
25-wk-old
protein-A-conjugated
RanGTP
Tg-GWildor
manganese-
R93N
a-d
IVTT-hMLH1
CGTTTGGGTAGAAGAGATGCTTTAC
LSK_UP
39848594
p.Gln878*
~F
hyperplasia160
bothersome
clairf
D18Mit9
.Robert
leukemia.14-16
Roughened
lling
G1769R
werelabelled
ABL-T334I
TOB
Bani-Hani
osteodystrophy20
S235F
Hormone-Resistant
earlier,24
.Vital
CYT387/GSK1120212
dimer–defi
anti-CD19-PE
activation—before
dicale
.Splenocytes
rs1140475
Meduloblastoma
BM/PBMNCs
promoterassociated
P182S
1906-1885
30691501–30738500
MK2
c.3635dupT
PRDM1.3BR.F
subgroup.3
E504fs
al,28
386–509
proteolyt-
99615
acid–serine
ΔEGFΔLNR
UCS
cancerpredisposition
AnnV1
.Eczema
sequencing.The
drivetranscription
1i–j
pBTM116
J.L.
cells149
SPF45
ZTo
cuvets
Vi-cell
c.5438A
8A–C
Research-UK
Stk
Hs00739599_m1
dicates
705-096-147
+44
anti-TBL1XR1
cbio.mskcc.org
Regulation—The
Mismatch—We
16-wk
Eli
20h
D2365N
setting.10-13
1.148-3.82
apoptosis-signal-regulating
critoztinib
Bmi-1-mediated
HoxA11
5ʹ-PuACCPuCA-3ʹ
Val159GlyfsX10
.Gen
Hypermutated
.Best
.MAPKs
GCATGTAGCCCAGGCCCTCGCGACATATCTGG
exon-containing
C223R
3′-fluorescein–conjugated
0.077
.375
Val458
Shc-Ras-Raf-Mek1/2-Mapk
As-Au
1462−211A
SSChiB220+CD19+CD43−IgM+IgDhi/lo
.Exhaustion
WT1-DNA
appearedindistinguishable
Cells—rPLD1
anti-NKX2-8
96–122
53.82
.Unphosphorylated
pS/pT
C461Y
GTTAATAATTCAC
iuxtamembranous
ciliopathies
17h
797-843
1.11–6.93
transcription–quantitative
39/1280
H385P
GTGCAGGCCACA
Repair—To
GISTs.5,9
hem75
2T202
aza-dC
mechanisms.5-12
R418G
//210.60.98.19/IPTREEr/iptree.htm
rescue.48
specificity-switching
IB
SH2-JH2
MethodsPlasmid
Phototope-HRP
NRASG60E
EML1
RT-PCR-SSCP
tetO7
C-termini
PTENAtgFwd
reported.10
wingless-type
Q-T
Wistar-Furth
aweak
NCIH1975
deletion/L858Ra
Rad51-interacting
age31
Cy5-dye
CH165
.S15
A2911E
EpICD
AKT1-dependent
Tomlyn
Pro919Ser
endocytosis
method13
​and44
pericytes/vSMC
morphogenesis54
multiclonal
shRUNX1_2
50.88
sh-Myc1
sS~
BRAF-BRAF
hyper-proliferation
Â°Cfor
OSA1
BRCA2-linked
−90.3
HA-TGFBR1
BAF155
GACTGGAAGTGTCGCATCACCAATG
BRCA2/exon13
D3S2338
**a**
09-223
tL.A.Q
paper.20
dovitinib-resistant
S768_V769delinsIL
MgC
H*
double-chamber
FIIN-3
~~~~~~
Fig1b1b
RP11-572O17-GOLD
964
Towhom
Glu884Lys
4.8§
Tumor-rich
Five-fold
selenomethionine-substituted
45,281
−4.1
C-cadherin
5′-GGAGAATGAATACGGATCCATCCAGCACACGTACCACCTGG-3′
R784H
lymphomas.18
antsMSH2
S12.1
RCC4/VHL
TGGCTAAGGCGGCCAAATAA
627170
l8
Pelger-Huët
Cul3-dependent
RP-A
27.8:1
BRAFV600E/L505H-containing
1.5–2.9
p.L350SfsX4
formation/angiogenesis
n=300
Spliceogenic
structures,48
1.445
prognostic/
-URA3-hisG
ERK1/
A081
drug-addiction
de-convoluted
a-IRS-1
000/uL
del8
PI-424
Tnf-α/NF-κB
secondary-resistance
S4C
rst-generation
60614
mTOR-responsive
14.9–81.7
andelectrophoresed
Ink4b
c.197C
multi-immunoblot
USP48
Smad2+/+
.SNB19
265G
BTZ
0.71
Helmholtz-Zentrum
pembrolizumab
med.kindai.ac.jp
p.EY451del
p.S46I
8629InsertionGGG
BioVex
1/8,524
indolent,5
Tdt
MISSION®
pCMV6-iSH2p110a
misinsertions
7.3
Cardiac-
G0–G1
patients25
pC53-SN3-R249S/H168R/T123A
neuroectodermic
I-IV
SpectroTYPER
5′-TCGGTCTATGACGAGCAG-3′
FBP
Hsp16
6/11.3
signalrelated
241–248
W398V
DNA-PK/mTOR
7.0–8.5
.Treating
.1023T
TGTTGGACTCCGCAGGATTG
oligo-nucleotide
right-side
32-16-346210
Dajani
Cryptorchidism
Sakakura
PancreasPrevious
ID3/TCF3
CD38-positive
Delta266
INSRR
XV.34
v-crk
quadruplicated
C8360
C379A
'on-pathway
Q300R
1144C
restriction-enzyme
S6K1/Akt1
FOP-FGFR1-induced
tumors.21
S427Y
AU5-tagged
Ramnarain
10–15
GATTCAACTTGCGCTCATCTTAGGC
p11q24
BRE1
E2F-site
spinoparabrachial
Croquelois
V561D-PDGFRA-Ba/F3
Ferrando.8
Symes
VEGFA.4
Chromotek-GFP-Trap
histone–enzyme
−1.22
3,780
scoring21
repressor.The
.Fumihiko
Eadie-Hofstee
100μl
4.34
.Method
T9-1
End-repair
CAGAGCCTAAACATCCCCTTA
−10.5
SssI-methylated
psi-PIK3CA-WT
2930.20
AZD7762
W20G
corticotrophin-releasing
1/36
RT-PCR.The
D842V-transformed
59SS
Ala-66
No.Bilateral
p217/p221-MEK
IRF4-deficient
.5194delG
Cat.No
fruition
Akt-3
Djuzenova
c.770A→G
RP11-451F15
Hsp-90
reference-unirradiated
IBA
Usp18
tamine
Maccoux
malignancy4–7
Asp560
spi1
4,643
972-bp
ophthalmic
GDNF-GFRA-RET-RAS-MEK-ERK-ELK-SRF
2.1±0.1
kidney-cell
fDetailed
pMSCV-IRES-GFP-HA-CBL
immunopathology
pseudo-diploid
RSF,43
states39
β-counter
pEAC001
p.Gly20Arg
fibroblasts.23
K3-I-P-I-K
Thr-32
K14cre
GLP-1
GTPase-binding
LLC.
2′,3′-cAMP
anti-Tip60
M3231
eMC
.Movements
ISS
Tris-Acetate
10n
-MNDSNYI
G~~O-Q-A-K-K-K-K-L
.823
G719S/E709A
1060–70
8/31/98
cholangiocarcinogenesis
podocytes.5
SRM
Xie
BMPR‐II
p.Lys205Gln
232
103/150
0.690
Offield
Sequestosome-1–regulated
.7.1
R248K
mid/hindbrain
10/301
anapmet
BMS-690514
Guièze
Gly104
MIG-constructs
5′-TGCACCACCAACTGCTTA-3′
TTK
EGF-R
.MGA
.FACScan
providepossible
KCNJ8
phenotype18
onp53wt
S6K-mediated
immunoprecipitated-pellets
Sawaki
GFP-marked
instability.14,16,32,42
T195N
Kanehisa
.409dup
MED1
P708S
33285
p.V559A
Baylor
20,56
gene106
AWBF
GGT→AGT
hematopoietic-cell
Wortmannin
QIAshredder
R140Q-expressing
poorlycharacterized
promoter-bound
Gg1.0kb
MPZL2
15Å
Bargettoni
521–603
Adhesive
DaiichiSankyo
20-week-old
.Venn
models.6
Rad50-deficient
IL-10–containing
FGFR2bN550K
anti-PDGFRA
Rebiopsying
FGFR3TACC3negative
A160V
K1103R
pre-term
Glu147
reported,25
glyscosylated
MCRF-7
1.28
NCI-H1299
D3S1289
Age-related
344th
645,201
Chromatography—Mass
Thyrotropin
cases.40
3-exon
ADCY3
certam
MLL-AF4/T1G
merotelic
ATG8
4hrs
U462
H168P
SMO-W281
JAK2-R1
puroR
TE12
Comp.
erbB3
Non-synonymous
laG
13.1-41.8
c.986A
phospho-Y694-STAT5
.Neither
CREB3L1
.Redo
NTRK-rearranged
'VALIDATION
dark-stained
87-bp-long
R537G
c.9002G
Y822
78.0
SK-Mel
196-kDa
.statistical
H3K27me3-mediated
blood-born
0.12
.Cranial
7000
KIT-ITD
Ca2+-binding
α-Mcm6
0.0208
¶Cells
9CaseNo.Age/Sex
wtRhoA-transfected
USSAGU
PilotCE
F119S—yielded
HNF-
OAW
.ChIP-sequencing
CSF1R65
SSC:0.15
3.12
sets/59
SgrA
564-conjugated
Zic4
imM
p.Lys2950Asn
Irish/German
G779C
E102
12-14-17
small-molecule-mediated
anti-CD3/anti-CD28
-CCTCCTTTGGTCTTACTGGG-3
6-azauracil
Shyue
TCACCATTAGATGACGCT
M25277
on-set
2242A
SZX9
L94Q
3p21.3
pLXSN
instructions.The
mg/kg.We
.3T3
mRNA6,19
anti-jI
5′-TAG
V:15
gene16
intermediate-conformation
biologicalsignificance
n=330
orβ
ligand-expressing
APC-axin-GSK-3β
CC64
methyltransferases—dSet1
Below-average
or32P-labeled
Gly434
anti-DYKDDDDK-tag
~140
COALL97/03
effect.
subline
Y628E-rev
TAGAAGAGCCCAGCCAGTGT
ATM-ATR
11-1
comhomozygous
~1/3
intermediate-grade
Long-Range
EMM
EF-lacZ
–37
1A⇓
Gastro
non-Alu
pPRAS40
Sankyo-Lab
19,289
ERα-signaling
Cdk2AF
2z60
mutant23
GST-FKBP12
11q22-positive
18G4.2
promoter—C250T
.060
Shochat
β-catenin-mediated
Tyr568
1.074
spin-infection
GISTsThere
c.1709T
EBNA2-
ab23738
CCNH
-100a
2249
p4E-BP1
Wild-typeAA
Inter-University
G55D
6HR10/30
nucleotide–binding
TCF7L2+/−
S199C
rehydratation
proteins.13-17Thr58
complic
Fumitaka
merlin-EBP50
base-line
C4HC3
Inc.y
600-base
C-section
RB-sensitivity
PI3K-transfected
W224S
Ala502-Tyr503
5′-gcttggcctagtggggttttg-3′
397mel-mock–implanted
non-Smad
L405
EEN
5–10×103
S9B
-D281G-5
Argine
neuromodulators
μ
malignancies16–18
T1700A
Myo
AxioImager
IFITM1-overexpressed
1018G
NR-2
ribosomalorpseudogene
SU9518
dacapo
28/49
substantia
K8+K14−
19A10
place65
332
F10
C289
regulation50
093
-Alcian
id=69000052
.RAS-dependent
oversampled
35/0
inhibitor.50,49
R-axis
FLJ10261
A9V
phospho-S6-Ser235/236
cohesin—a
78.0±12.6
lineage.4
Pathlogy
histiocytomas.9
cells141,142
ubiquitin-conjugation
Xa
neuroactive
GMP.PNPHras
loss-of-function.8
ACCATG
AML,8
GTP-ty
NM_018761
Mcm3
e015
cyclooxygenase
sites.20
PTHR1
.076mPFS
22,27
86617
nature.comRepair
markers.44
Tomato-lectin
FAM72D
Tworkowski
GenScript
p.Ile131SerfsX2
TP53-NTRK1
1,765
8van
LR01-081*
c.2482_2483insA
mirasensitive
0.3–6.3
CARD11-mCherry-expressing
5.1-46.6
criticalgrowth-related
25/30
anti-phosphop70
DMSO-only
mutation32
EGFR/PI3K/mTOR
203,225
125°C
A–Sepharose
0.00207
NFKB1A
S353L
O/AO
Post-Translational
KRAS-associated
C8
CMV5
Ile538Val
3–12
p16/Δ
γ-ray-sterilized
VH3-23
C417R
0.0625
H3F3A.K27M
GTATC
11/54
5′-AAAAGCATTATTACATTTAAATTAGCTC-3′
mutations96
.Albeit
mCitrine-TIR
D16S3107
Tyr1162
β-blocker
65.8+0.5
p53/RYBP
c.1068_1075del
C78R
EP300
ERα3_ClaI
ESRRA-C11orf20
68301863
E498K
I-linked
39-kDa
TAP1/LMP2
detection38
immunofluorescence‐positive
S5–S7
Barrack
~200ng
inBCR-ABL
//www.chori.org/BACPAC
Ser-Gln
G-3″
1MB
model.24
dose–response
siROR1-teated
5′-GCAGACCCACGGCCAAGACC-3′
B362
.PC-9
.SERPINB5
cancer-
5'-GATCCTCGAGTCACAAGTTAGAGACAAGCCTGGG
F-actin-binding
C121S–positive
D1-AP1/dE
320-kDa
SERPINA11
3/64
Mll-
IDH2R172.18
D91N
Zealand-derived
Full-size
MST-2
Golgi.In
9656
CML4
FGF9
T1008I
assaysT-75
59/08/95
Migration/motility
fusions—including
residualDNA
Schaaper
.Amniocentesis
1,594/201,501
1.96
Rnl2
ARHGDIA
polycythemia.7,8
Baudat
-ATCGCTACTTGACATTGGACCA-3
———————
J/m
RNS
instability7
557
100-1500
5′‐CAGCTGTACCATCCATTCCA
H3K27me3-bound
Rcurrence-free
ChrX:24078360
Vousden
CapZIP
ge=31-38
Hu_
DLG-binding
c-jun
5′-GAG
.Papillary
-4.1
.Con-
non-HSPG
B8.4.B
samplesfrom
Lef
pyrosequencing
U-2-OS/Myc–Chk2
Ex-Cell
Kaluza
2001–2005
.Transduced
andthat
estradiol-independent
Echocardiogram
IL‐10
DBI-1
.SRC-3
GAAAGGGGCAGA
R506H
11+
PCRproduct
Schüler
R550G
heterodimerize
Graphpad
.IC50
34,43
Expression—GST
c.154A
7q35-q36.10
.Cos7
.BRCA1A
5′IDL1
.Bertholon
PAX3-FKHR
1,784
254KB
K539L-transduced
D347
c.1-
sc-7389
ΔGu
ATPcompetitive
GST-Raf
WNT/β-catenin
R325W
//www.mmtsb.org/
2QRV
post-surgical
12F–5′-CCA
JAK1-transformed
p=0.039
GIBCO-BRL
Notch2-
HRASVa8l12
2.2–2.6
DNM1
HCC827
mitosis/10HPF
1855STOP
M229
BCR-ABL1/ABL1
nontranslocated
bl2seq
plasmidpLS76
4291
.EWS-FLI1
stage-
T378P
p14
pNPP-
L113L
rearrangement3
Blimp1CD19WT
sapiens|gi:35213
vertebral
EcoRI-
/α−2
c.3810_3820delCATGCAGACTC
NNFF103
5′-GGACAACCCCCTCGTGTG-3′
hGFAP-cre-
1,159
mutant–mediated
melanoma—though
APMO
HC-
proteins­
superfamilies
MDM
Liebold
E1705D
81-3-5803-5820
GAFGs
AJ519932
SC-15334
Q367P
hormone-depleted
P100
pCDH–CuO–MCS–EF1–CymR–PURO
E.L
HER2YVMAA
465–469
Glu98
MAQ
described,15
rearrangement-associated
pGA-MTS1.c
PD-0332991
9596
2148
OX40L-positive
development/remodeling
.Aromatic
Neurologic
proliferation/metastasis-associated
r.p.m.
NP_524145
complex,27
.D1228N
overrepresented
PHLPP
A9/A9
40-day
pCDH-MCS1-EF1-puromycin
4.07
NSCLC.21
p.Ala603Profsx92
501–509
D61Y
cancer-containing
P311fs*4
High-throughput
clinicobiological
//www.broadinstitute.org/gsea/msigdb/index.jsp
4535delTTinsG
c-Mpl-mediated
G-CSF-induced
1-86
Tyr10Stop
S3D–G
symptom-onset
IRF3-binding
D22S303
21217-00
5′-GGGAGTTTGGCTCCAGAGTTT-3′
codon24
81g/L
D245/249
expression143
6.ATP
signaling.2
Alignment/Map
mispair-specific
.Abstracts
polyamine
GFP-SPA
4,608
African-American
conformation25
38G.A
Mucosa-associated
Forghieri
1.65+0.10
FcεR1−
DP20
.1592delT
mice27
expressionOverexpression
Lys482
Signaling—Does
GTTACTATT
MEG-PMG-MegaCC
Lys-NH3
moffitt.org
Bilke
post-ER
RIT1-mediated
TYMS
BCL-xL·ABT-737
-GGATAGGCGCGATACCTCA-3
RP11-418K16
genome.ucsc.edu
iodophenols
immunoglobin
methods.6
Wl
58,170,985
PCAF-dependent
Sprouty.55
5μg
Smad4‐interacting
Microarray-Cell
111A9
Leukoc
+E884K
/FGFR1OP-FGFR1
RHOA17
Truseq
99.947
Giraudier
V560L
Atr+/−Mlh1+/−
NPY/PYY
RCC/786-O
p27G177
SCD3
AKT112
U55763
NO3
IL-7–induced
129S4
FGFR1a
S220
drug-based
Sap-1
FLT3-JM-PMs
KIAA1524
FluF-induced
di-β-D-galactopyranoside
−54.5
00299804
0.00523
P-J
1.138−3.855
R34W
\/
638-gene
growth-regulatory
4894
lapatinibCharacterization
EGFR-CF
-V617F
Y17118–Y17126
FGFR4Gly388
test,12
**Acquired
mGM-CSF
tumor‐promoting
FA-pathway
GRα-mediated
8E9
Rad3—have
F/50
EXT2
hyper-IgM
5'-GATCCTCGAGGGGCAAGACCTGCCAAGCCTCTCGAG-3
HIAA
7-3-1
=9
p.Thr537Arg
Lys203
4-88
gene.Although
MILD-
K-29/32
Dysembryoplastic
antibodyFIG
347A
14q12
17-5132-01
2.6–3.92
EGFR-ERBB3-PI3K
4EBP
O'Toole
S-Score
Anti-BACH1
191117
ERBB2+ve
F691L
.Published
.Basal-like
P53protein
RUNX-mediated
20120228
dpc4
.Herceptin
neuroblastomas17–19
R420G
83-126
mTR
diaphragm
Q67R
chr6
//soap.genomics.org.cn
CUX1-14R1
.Empiric
AML.10
tumors14,15
M1737
Glu-876
pathway–associated
RAD51C-XRCC3
I+
1.373
4000B
G21VN-Ras
FGFR2C278F-transfected
J020
..D.N
¯uorography
surfactant-specific
021-314-3558
wtEGFR.21,33
Do1
leukaemia.Phosphotyrosyl
ieo.it
ChIP™
7SD
μcalpain
p=0.5365
Sos-dependent
dinucleotide
Two-dimensional
Fraction-PREP
c.6174delT
//www.insight-group.org/
PTEN-T319Δ
pDM58
domain-swapped
c.1277-7
.Severe
HSC7E769
5′-GCTAGCGGTTAGCAACCAGGTGTC-3′
unphosphoryFigure
System,68
TCACAAAAAGACCTGAATTG-3
1*,15*
non-bonded
AAAGAT/gtaagt
BLIMP
TAGGTGGAGAAACGGGAACCAG
SS18–SSX2
anti-guinea
stabilization.10
2.5-3.0
BRCT-BACH1
Spheroplasts
expression14,39
correlatedwith
man.68
mean±S.D
contradictory.11,12,18,19
jens.schittenhelm
H2228
6–16
cases.7,9
A*0303N
S6E–F
.Resected
E2F-1-associated
Fe3O4
PCP
b-glycan
.Novartis
LS180
146KB
4374G→A
omniMAX
foregut-derived
Cetuximab
Wnt3a-dependent
RPS6KC1
E131
Eα2
Stag-cyclin
S4M
induc­
p16INK4A/p19ARF
8-minute
Exon2
F642
8-
pseudohermaphroditism
S4D–J
11.068
.standard
level.8–10
87,88
technology155
0'12
Leu122Arg-induced
FANCE
c.798_799delTT
PDGFRbeta
-PET
v76
G11
76–121
R385A
JPred
dysmorphy
p46B
pantetheine
~33
A.T.S
FVNPSLPREEKEEKLETVKVSNNAEDPKDLMLSGERVLQTERSVESSSISLVPGTDYGTQ
23,26,33,34
RhoGEPs
development16,17,19–21
KIT.18
mutationsmight
1FLI
T67I
activation.22
5′-GTTTCAAATGAATCTGTCGCCTACCGAGCTAC-3′
correlational
ecta
TFA5c
Cter
1.43-fold
R311Q
Igκ2
410
sub-function
Mutation.
ENESTnd
101.3
L1564PF
preconditioned
C634F
JCRB0627
How-ever
Sytems
mice37
included18
Antinolo
HD-0304
20-76
Isotopic
CD74–ROS
PI258
anti-CD28–coated
F1745C
copy-number-driven
PIPKs
β-glucuronidase
isothiocyanate-cesium
37-F:5′CACGACGTTGTAAAACGACTCTGCCCAAACGTGCTTAAT3′
L1196M
criteria.32
5415R
SCC-13
pcDNAI
Dermatologists
HA-HRP
expressingeither
beta-binding
non–exon
HCC202
LTR-based
unadj
723-7843
PI3K/MEK
pCMVbeta-Gal
clone:1700019L09
locus35
Siow
thebiology
self-limited
seleno-methionine-substituted
Serotec
A300T
Kmt2dfl/fl
200mM
flies1
mutagenizing
TLR2/6
PBS-Glycine
Arg5
Chesi
Kabsch
tumors15
MA1ESILhRiYThQSDVWSYGVtVWELNTFGskPYdgIp-asEissiLekGerLpqPpiCtiDVYmIMvkCWmiDADsRpkFRELiieF
Engelsen
FGF2
pRip1Tag8
Dentistry
rad50D1241A
7545delCT
IVS11-8
TGFBR2R537P
proximity-based
204-bp
AAATATGGCAACCAACTAGG
DNATechnologies
.Circles
NAS
ptel-D3S1266-D3S3727-D3S1611
AKT/PKB
750mg
difﬁculties
retrosplenial/parietal
1127
S5a
522KB
modal
heterodimerizaton
Y553N
antisheep
brca2
OneCell
M.A.K.
mg/20
p-MET
Histopathological
free-of-disease
XhoI/AgeI
5307
10–200-μl
551
c.1178T
IMAGE:4489485
cross-contaminated
GTCAsp
Hamamatsu
imatinib-naïve
SCO2
5.5-6.5
describedvery
attL2
EGFPexpressing
L869R/
2.665149833
Hsp90-regulated
lines,58
4.4.1
Cys842Ala
Suite™
Gαi2
SAC
overexpressed-Srsf2
omentum,9,12
fist-line
ll/ml
c.4308C
syndrome11
.NF1+/−
ErlotinibT790M
clinicalbehavior
1.232
Chapiro
EGFRresulted
G-141Tc
FGFR2-RP11-62L18-orange
del96
4817A
Ets-related
end-labeling
Akervall
Emb
chaperonin
exon-4–specific
alleles.160
111–113
normal.11
Phe31Ile
threonine-
Thr-197
9/29
VariantBRCA1
H-M-MLV
H140Y
Extractsprepared
68352609
Y220C-containing
2045
JM-a
//www-shgc.stanford.edu
MacKerell,1998
Cancer-derived
CYCLIN
0.3762
Marañón
ppERK2
mUbRasK117
GTTGTAAGCCTTACATTCAACCG
formaldehyde–0.8
cytokineinducible
65.9
hepatoprotective
materialper
EI
LXSNAKT2-AS-3
Antigen
cancer-mutant-containing
Plk3-PBD
HCT116TP53−/−
.3–6
.Tryptophan
PDOC00100
CDK6-BLPDs
Molkentin
CCGGATCCTTACATAATTACACACTTTGTCTTTGAC
H2AK119ub
Muhandiram
63y
LSP
IVS+1
.55C
2−7.4NRG1aNeuregulin
FGFR1-induced
F1174L-expressing
Dsk7
rad3-related/FRAP-related
ERK-ERF
neuropathies
GIC
SPOP-M117V
Annenberg
69/178
A*02
c.213_215delAGA
proteins-a
P233R
receptors16
FLAG-MED12
o0.06
cancer.12
transformation.40-43
17q23.1q23.2
length/strength
dual-mutant
JB10085
2.5–20
∼250
polypurine
point.56
D340
website.Table
I–restricted
neg
ERK2A189V
HER2–EGFR
DAPPLE
0.68
anti-cytochrome
Schlacher
caspase-8-dependent
adenine
ion-coordinated
nonfixed
.0056521
-NIH3T3
SJRB001X
p.L73P
retrotranslocates
Domains—SETD2
76-3
3xT1010I
CP-690550
screening.EGFR
q44
16:14:47
Pro772_His773insGlnVal
426
mutations-mediated
Hyper-IgE
toTable
NCBI36
Svegliati
PVT1
IM13L
AGI-6780
erythroid-2–related
Met387
Cdk4-deficient
HVKI
His703P
Caniesille-Teijero
20,23,24,26
P780ins
TGAACCGCATCGCGGCGG
species.6
off-line
six-parameter
TCF-4/TCF7L2
EDFtVKIGDFGNtRDIYeTD
Rowitch
anti-EB1
VHL-targeting
35.5
~20×
72h
p185bcr/abl
isotope
Rictor-null
TRIM24-NTRK2
mTOR-S6K1-RPS6
.Bold
R-AXISIIC
46481
amegakaryocytic
649–701
KITV560G
Hemerly
LCTL
orsomatic
A281
ROCK58
Figure1B1B
.GFP-tagged
Urhammer
TCGA-BR-8363-01
I377
R342
Nutlin-3-stimulated
200–400
.Aurora
MAM
transplantation.13
lâ
chromoendoscopy-directed
Cyclin/CDK
Pharmacol
in.Â
IVS±3
252–315
TGCI
cancer79
Catania
1−51
FAM-GACCTGGA-TAMRA
anchor-based
5'-TGAGCTCGAGTCATTGCATAC-3
IVS14+1G
domain.12
werenormalized
95Â°C,45
81/81
Figure1F,1F
1129–1131
Amsterdam-criteria-fulfilling
variationdetected
A-2
diphtheria/tetanus/Streptolysin
A181E
Val643
leukemia-like
noncardiogenic
Bobscript
0–2,000
V600insT
FoxO3a
GFP–PTEN
156.9
AMCA
Smad2276–467
CM-1
byanalyzing
0.469
48/M
Affinity-purification
≈36
NRNRNRNR10-83
HBL100
TSHR
SB-216763
1.00–1.54
EXO1
FLT3-KD
Scintillation
.787A
inactivation22
replication.136
IIIb-dsRBD
chaperonin-mediated
PDGFRB-GOLGA4
23.0-
triphosphatases
RG-20T
CCGCCTGCCTCTGGGAACAC
c.1730dupA
5,6,11
.Contaminating
44-20-7153-5340
D-to-G
428A
1706
//www.taconic.com
FILIP1L
R466Q
PAX5,57
polyproline
∼210
manner.13
.Dominant-negative
TPM3–NTRK1
C162S
0-7
dup501-502c-Kit
thefrequency
PU4
43,75
2012
1.01–1.34
5′-TTCAGCACTCTGCTTGTGGTC-3′
E5/6+
ex14–ex18
Ellezam23
yeast-expressed
neutrophils.27–28
promotion27
MHC-positive
,40
N-D
GFP-TOP1
SKC01
V319D
EkFtVKVADFGLaRDMYdkE-
OE/KD
repeatswere
ΔCA
1418819
Wdouble
lipoblastic
1.636–105.9
ofAkt
GGCAGCTGAGTATCGAGAAATCATTAAACCAGACCTTATCCAGCTGAG
ASK1-diffuse
N616S/rad54
GI:30577617
mll
DMY3010
S138P
per-patient
PD6
multi-nucleated
5′AGGGCTGGATGGTATTG3′
charge-neutralizing
938mel
M85079
19-amino
V923Ef
Tao-1/
ErbB2s
E203A
Poel
VassarStats.html
100109
−1.80414
.CDK4
P9–13,282
D13318
0–44
significance-that
p53.11
CTGGCATTAGAATTATTTAAA
c.4232T
ALL,33
c.2888-5_2944del62
Haferlach
anti-α-actinin
his3-
TGCTTCTTGCTGATCTTGACA
D2/Mad-1/Myc/p27
chromothripsis21
1,435
peroxidase-positive
pseudo-positivity
IDL40
R132-mutated
tgggctccataactgctttc
impli
77,81,77°
.NOE
5′-TTGGAAGAGCCGTGTGTGC-3′
BEV
carbohydrate
.H184
De-identified
non-functional
CCDS14607
.Δ
Lyso-TSC2-expressing
α-Enolase
1462
Geneticin
-tcctgcaggggcatgttgttgatg
G294E
35–52
E542K-PIK3CA
P=0.0119
15-year
32,000
N417S
nilotinib.16,51,54
antagonist/killer
intracellu-
HygromycinB
/IIIB
BCCIPα/β
IntOgen
compartment57
TLR7
vorinostat-treated
p.G12V
neutrophil/plasma
neonatal
2-minute
M5.28
inhibitor12
receptor/Pi3K/AKT
ATCC*
approaches7,8,9,10,11,12,13,14
–1,500
Rictor+/-
pGL3-HNF4AP2
R149*
ERGa
60,000-79,000
report.32
K5+
—which
//www.olympusfluoview.com/java/colocalization/index.html
.Gradienta
CBR
KspI/ClaI
Orange/green
fluoresceinated
THOC4
6.8-
10-50
linker7
RAS/RAF/MAPK
micro-papillary
Inoperable
dx.doi.org
myelomagenic
R273H/T284R-DNA
activity90
Spo11-cleavage
phosphine
.Visceral
FMOD
-441
32D.41-43,45
15751737
SV40-transformed
'contact
3/14
.Cochran
6-13
overgrowthf
PIK3CAT1025T-expressing
Lobaccaro
IR2
GMCSFR-expressing
AAGGATCCTCAGTAGTGCTGTGGGGGATCTG
Ser17
W15R
Figure9B
m835016
41–44
125
±S.D
IGK-directed
home.php
asCR1–3
cells.104
S646A
CycD
.Le
.Summary
MII2
215Ser
A′
25,37,38
FSMD
T37Y
R555Q
T01
L370fs
transactivationregulating
Methods—Two
G7
Sik
identical,39
colon-derived
FLAG-FHL1
TGF‐β‐induced
Cys459
2-to-3-fold
transcriptase–polymerase
PVL1392
Chk2-dependent
.EGR-1
S385A
L6C
TCGA,24
tcA*
Ser327
APST
bettercompensate
T/DHT
AUC0
TC20
Tyr783
nonascorbate
pro-viral
C.Y.P
.Level-3
.SQ-20B
4•99
flutamide-dependent
AUC24ss
octomers
14/38
transphosphorylates
cell-type-
Ser333
Cys124
7/11
mwt
agents.24-27
tyrosyl-DNA
14q21.1-q32
Berulava
pfg023T
BRCA2-related
non–drug-bound
.Thirty-one
P008-B1
CR2
Clinopathological
trans-differentiation
G140A
p36.31
RasY64A·GppNp
CARMA1-transduced
Green™
FGFR1−/HR+
-ACAAGAAGTGGAAGGCTTAG-3
PRE2
anti-Erk
n=3±s.d
21/936
I1170S
.CDK2-cyclin
Boxshade
13•3
damage5
MR-1
microspeckled
DX-MS
.1,7
signaling.32,33
SSTR1
CCK-81
iQ5
CD74-TRKA
Smc
N143S
Break-/fusion-point
q23q27
V296
deﬁned
E164D
gastrectomies
TGACAAGTGGTGGAACAGTCAAG
FGFR3-mediated
26-508
16/42
quality-control
Kaetzel
years/F
errors.25,26
Myr-hp110β
activity36
.Phe85
gel-retardation
G299R
MSC
drivers.2,6
ABD—Arg38
Granta519
R196L
.Adaptor
4669
c-mycT58A-HA
5′-AAAGCCCCTTCTGAATATGAGCAAA-3′
R268A
.Pten+/-
~800,000
kinase-3ÃŸ
PALB2-BRCA1
//genome.uscs.edu
4279
Homeobox
increased27
twenty-two
domain-
0.55–1.00
Tuokko
Trans-ABySS
charged-to-alanine
recombination,31
M21850
M+3H
.Low-Copy
1843
pEAA61
AZD9496-
epitope-specific
1880
DomainCancer
PUMA28
~lg~irose
Makalowski
V143Amutant
pEGFPC3-Smad4
rate.16
p.E84E
GUS
,42
2193
102-103
Lausanne
9,11,13
p.Q883*
cancers.10
homozyogtes
therapy38
dscDNA
Essen.7
centroid-linkage
281–318/Pro-rich
672–862
v12
SF3B155
Rakoff-Nahoum
0.0276
97.1
wehave
nonoverlapping
S3B–C
domain.182
6930
fusion-expressing
WT^
antibodies.14
P149Q
disorder15,25
C231A
CD45RA
Q521R
ADSCC
psA
PanIn-2
81291
G48R
TGAGC
growth-factor-independent
members—EGFR
R738C
771insVDSVDNP
qpolymerase
SETD3
PI3K/mTOR/S6K1
Patisia
Gln61Oε
E04
K.K-K-R.K-V-E
orange/D5S721
S1653P
Kapitanovic
IL6ST-activating
12340166
RAF-centred
VEGF-induced
inactive/unphosphorylated
HEK-
apoptosis.37
S5I
M=male
pRsk-1
TOX
NP40
HIF-1β
313-833-7294
prefoldin
FANCC,18
1.25×1012
36.16
Salomon-Nguyen
AS6
processes.1,2
G427S
collision-induced
delA770insGY
G2505B
WGA
25-50
c.1108-1_11083delTAG
PARPi-induced
I544
CCACTAGTCCGCGGCCC
HER2/ErbB2/neu
metastasis40
resveratrol-induced
E1384K-bearing
LTβR
HDACs-1
603-
cancers10
p-Tyr-containing
Emmerson
antinucleophosmin
∼95-fold
COL09335−8.5IL18Interleukin
155348L22
proteins.2
CCTTCCTTCCTGGGCATGGAGTCCTG
ThfI
10D-E
Total-RNA
WHIM6
Sp.
0:2
Tooze
1–41
Tyr1035
28.L344P
TOYOBO
reactivator
de-cross-linked
R279C
sc789-G
5mCpG-DNA
TET-interacting
pri-miRNA
Dicer1wt/Δ
p85α-nicSH2
HiBind
p85α/β
Gene-Spec
NSCLC.12,17
NCT01566019
LMO2
.An
4c–d
characterizationof
CSB
apoptosis/IAP
alone.We
Interferon-induced
70,000
YDSRW582-586
169,011
pod-rtTA/tetO-Cre/Vhlflox/flox
RING1A/B
PTPRT/
Swaminathan
CD117-negative
AML-M4Eo
56/56
S3C–G
29/85
P39A
rs1551645
RAD502
3.22.11
9.6
activity12
BHLHB38
.CREDIT
assessment.25
1452R
Superiore
E40K
GFPi
.Perera
21.10,13,14
phosphadidylinositides
E-cadherin-mediated
FW1:5-TCTTCACCTGGAAGGGGTCCA-3
cellsby
.Ref1
167,191
Ccnd2
advantage98
Signalmethylated
deglycosylated
s-free
GACCTGTCCAGGCACCATGAAGTCCTGGGTGTA
Cytopathol
PAM3CSK4
KIU
15q26.1
E566A
SMARCA2/BRM
862G
SDH-related
//chromium.liacs.nl/lovd/
FAM58A-specific
non–GCB-like
testing,1
Lynch-syndrome–associated
CRL3-HIB
.A677G
150–280
c.1178A
50.8
dye‐termination
ΔP
Co22
D136H
FCS-containing
caspases-3
Sanver
Airik
afterpreoperative
Spoel
L7/L10
THR
anti-b-tubulin
6B–6D
tumours152
IB13026
present10,11
Andrieux
5-fluorouracil/leucovorin
con®rmatory
M7=1
RNA-Seq
differentiation.13–15
mulan.dcode.org
models16
ΔD1
.NGGCTs
P-00006559-T01-IM5
COOH-terminal
RT-PCR-based
.Indeed
cis-actingelements
rLouA
β-cateninflox
L1853
f100
saline–sodium
centres34
yS
chr14q23.1
Dihydroethidine
Ser245
U-2940
Ramalho-Santos
Co115
.27
protein–­coupled
GeneTitan1.1.ST
c.233234delAT
loss6,7
+/−7.2
.SKY
pC-Raf
D2723
Jeko-1
3.3.0-g37228af
V221M
​Table2
RP11–35D6
336.06
Mxd1/Max
p16INK4A-/-/p19ARF+/-
—appear
anti-AXL
2054
.Susceptibility
Dupont/New
FLJ44186
Elvehjem
second—often
P369S
Low-frequency
Alcian
leuke
nonrespiratory
.discussion
3.5-day-old
advantage95
355-nm
Gly1290Ala
B56δ-specific
p=0.001
complex—
footnotee
.Search
peptide-specific
-Thy1.2
PLX4032-resistance
ERK2P58L/S/T
IFG1R
TO-PRO-3
hRos-7
anti-P21Cip
//www.rcsb.org/pdb/home/home.do
1/560
BC021773
pMMTV–Luc
3/5/08
Runx1-25F
V444E
2-fold-higher
pcDNA™6.2/V5-DEST®
effects.3–5
E-Cadherin
types.16
DNeasy®
phospho­
MDM2–p53
imatinib
c.3640G
and—in
CD61+
Fundación
5'-GATCCTCGAGAAACAAGCCACCAACATGCTTCTCGAG-
mutations.19,20
controls.51
biopsy,26
150,000
SDS/PAGE
T21
844-bp
17q22â
QuikHyb
yeastClass222222212121111111211122222222122111111112Describedin
RAIG1
p21CIP1
pcDNA3/LKB1-L67P-myc
Crino
ME001
AMLCG-1999
transition-type
Srsf2fl/fl
.Anti-cdk6
1000μg/ml
published31
H-bonds
intraduodenal
NODN
receptor-SMADs
triplex
U57843.1
TNF-R1
anaplastic/pleomorphic
5'RACE
.F876L
.5386C
°e
data-freezing
FLAG-INPP4B
MET/Alk
Fig.4G,4G
A465V
A6G
PIK3CA/B
335,420
1618
anchorage-
protomer
38.6
Tyr481
silanized
Norbury
1.5-6.3
.Hep3B
IL3-starved
37-43
GSE8218
PgR-positive
CEM-C7
delL747-S752
14–2590×108
PDGFR-β45
Melan-A/MART-1a
Izrailit
DTT/0.5
p-phenylenediamine
Selenomethionine-derivative
leukemia-specific
GAD-fusions
5′-CCGCCACTGTGCTGGATA
ATMS
.Poly
TCATAGTTTCAGCTTCTTTTTTCTTCCTCGACCATCAGGTGCGCC
C241G
E680A
subchromosomal
acctttcag
.Chimaerism
PDGFbR-Po
EF-FLAG
19.62
ScaBER
Nieuwkoop
RING/BARD1-dependent
pCDNA3.0
yPH-p21
Weinberg31
AGACGCACTC
Anti-CD11b
.MMC-induced
19/41
.GSE42401
bitransgenic
Small-cell
estradiol-
Kmt2d-wild-type
deaths.1,2
.But
CMN
V5-tagged
~2.9
S129
Shi
E790K
9145
N203D
Ccng1
analysed.Focus
22065–22071
5q-
Illumina-specific
anti-APC
defensin
carcinoma-derived
IIIm
69–109
Heravi-Moussavi
IL-2Rγ
233K
0449
T4M1
PBCre4-Foxa1
Figure2c
Glabrescione
antisense
depigmentation
survival2
kinase-linker
RTK/PIK3CA
FastSNP
K492
5′-biotin-tagged
14/259
Shc
pBSFI
Biomediche
CS17
59-GTGCGTTCGCTACATACAAGGT-39
In01*
off-pathway
Calcium-
44,47
HCI
Hedlund1
87–94
chromatin-remodeling
electroencephalograms
U-STOP-C
BCL226
THERMOmax
20q13.33
thisrespect
32.0
33428251
Congruent
-pyrimidine
Gmolecule=Ggbtot+Egas−TSsolute
G/c.4061T
oncogene72
location-
0.48/0.39
1,860
3.7-fold
GNE/MNK
Y1092-phosphate-specific
T165M
mRNA-Decay
si-Mer-1
immunoreactivity
counted.RNA
translation206
pCDNA3-3MYCROC1
​and1D1D
L.I
.DDIT3-WT
R789
qPCRs
pre-32m
blood-brain
0.2–2
3–10th
theMET
68/380
CviKI-I
EGFR/PI3K/Akt/mTOR
primers/probe
c-H-ras.DISCUSSIONWe
pBK-CMV
QC~
anti-Involucrin
-,11
261M
traditionally
-FAM
GDP-Haras-p21
RUNX1-induced
Clear-cell
S71W
conditions—den
SKP1-CDKL3
TFRC
E186K
FOP-FGFR1-transfected
25:139–146
Goethals
Fenoglio-Preiser
EC50control=0.100
FGFR3TACC3-fusion
domainencoding
H98P
3,17
RARA/RXRA
PTEN73
acetylation-occurring
p-S473
−599
exist.1
3223
Maistrasse
-PET/CT
P-Ser473
35–350
32D-Kit
583-597
2-5-2
multisequence
CNNM2
Del-3
ball-and-sticks
18-basepair
III:24
F317L/I
aqQ209L
Retroviral-Mediated
sum149
ab14389
PDLIM5
FZR1-regulated
NCL-END
BRCA2-like
G598V
Gryfeet
Expr.
R669/675
anti-phospho-SHP2
Andrulis
Altmetric.com
Par3
Embryonically
HER2-pY-1248
120-kDa
AACAGCTATGACCATGGGGTGACTGTTTGGGAGTTGATG
RPMI8266
cdk1
Men1T
-ETV6/FLT3
BrdU-pulse
HSC41
investigatedmutationsof
STAT3/1
gov/molbio/proscan/
GLI-Kruppel
2388delG
Fgfr2flx
5′‐GGACACTGAAATATTTTCTAGCAATTGCGGGAGGAAAATG‐3′
1S
Pep3b/BoyJ
Pemetrexed/Cetuximab
6.5-
triciribine
.G469S
MITFR217Δ
MK-STYX
Immunogenet
×10−3
.Conservative
2008
individuals3
JM-V560G
areaswith
pre-culture
Heterozygotic
mitogenicity
nonpermeabilized
finaer
p.N486-P490del
RPMI-8402
IC90s
NeuNT
10−7
genes35
K230M
r.8755_8953del
10.62
L127R
DB-ID
SETOR.25
BglII
herpesvirus-2
postrecruitment
ETO-associated
D24
lymphoma27
35/103
WAP-Cre
Dll-1
disease.8,12
anti-WIP1
1.9E
targeted-capture
NM_011631
Olac
5−6
-l-hydroxyproline
FLT3-independent
A279T
E353Q/F461I/G442V
p.Arg398*
Pathogenesis
5′-FAM-CAAGCTTCCC
A43T
n-octyl-β-d-glucopyranoside
​We
PYGO1
−600
ID9
CCAACTAACAGGTCAAATTAAACAAACA
sub-confluence
.PRAS40
KCl/1
c.1927C
m/79
J061
www.nfht.nl
WG
PAX8-PPARγ1
5.1.22
lowerexpression
brachytherapy
MET-001
5/group
all_cancer.html
.NM_005228
D84V
p.Cys576Leufs*7
3211
Gly-89
C342Y-OB1
VE-cadherin
subunits10
CU110-shPDK1
EMBL
protein/protein
Dnmt3af/f
AD-EDAID
8,11,13-15
SK+for
ready-to-use
11B3−/Trp53−
.Dual-luciferase
115.6VASNVasorin15.1C2ORF32DKFZP566K1924
SORL1
al8
Wingless-type
models,1
WTMSH2
mitoxantrone+
C1164G
*VaIHIsNIsIILysArgArgAspI
TissueCorrelation
C33A
n1Pa
MMR-defective
homology-mediated
LKB1-associated
EVH-1
loss/mutation
p=0.0644
redundancies/cooperation
RA3
NAN8
354–551
OA/AOA
p53S
17,25,41–45
ACAATGTCATCACAGGAGG
.Tony
mutation3
Cα2
translationally
iPhemValCysThr
EUFA
ectomesenchymoma
intermediate-1
R.L.S
M144V
Cancro—ONLUS
cancer23
proteins.15
21591445
Electromobility
Cx
SwissPDB
adaptor-type
.Lineage-specific
HSCR.64
meidated
0.58–0.86
His/Myc
DR-GFP
I477S
p.T82M
vemurafenib.43
stress87
KT768091
36,38
TdotG
1191–1194del
4ZFΔPR-HA
14q
c-Raf
kappaB
n-
0.3343
1wd59
IKSDVWAFGVLLWEIA
RING-only
//www.tgen.org/research/research-divisions/genetic-basis-of-human-disease/scco-research-study.aspx
GCTGGACCGT
1,026
n=347
.Exogenously
2779
366363
Myxoid1Â°
Int'l
142-149
impermeable
GSK′212
Toxicities
ACi
Manthorpe
HC11
S10strand
RAS–RHO
triarylimidazole
U1C.79
TRAILinduced
4–fold
E804K
TableI
XP+
transformantwas
MLL3/ASC-2
antigen.24
tumors.17
5′-AGCTTCTGGGTTGTCTCCTCAGTGG-3′
Sox17α2
head-and-neck
CD36+CD71+
HCC-1143
A_51_P293087
23–357
.TGF-β–
formaldehyd
thatcould
msh2-PD865p–Msh6p
casp9
.Bromo
andTEL/PDGFβR
.17
NP_000526.1
-94
0–33b
tcgcagcacactgttttgaga
manufactuer
.THPO
Bonn–Cologne
sham-operated
RAD51C9
Q510
Tyr703
BRCA2D17
p.F506_F508ins.CUD
described31
Saretzki
eout
3–56
0.4–2
observed,1
homologue—hDIS3L2—does
Ell
Rembrandt
Reichert
chr19:42,805,880-42,808,040
Zoller
2547
bacterially-promoted
0.118613552
M623A
γ-phosphate20
studies.Immunohistochemistry
~100–300
Matusow
.Cases
HCC5-1318
K493.1
1.Several
c.4284_4285delAG
cancers25
c.1989
.Phenotypically
www.broadinstitute.org/cancer/cga/
DPC4/Dpc4
studies5,8
c.187_188delAG
MFG
1,700
W557C
H58873
15,22,23
del747
trials14
E/F
hTCF4
176–274
BAS1000
protein/inhibitor
Primer341
13–2
5/2223
Pin1-induced
BAF60
FeSO4
Anzick
0.0894
phospho-MAPK3/MAPK1
Phosphoinositide-3-kinase
P-loop
.S1d
end-sequenced
bindingwas
−1.907
a±gMutants
44,692
9.View
motif9
18,116,940
M808T
childhood.3
GCCATTAGCGCATCACAG
LIM1899
poly-dIdC
.IMMUNOSTAINING
DLBCL/
LYMPHOCYTOSIS
JOO300~~~~~~~~~~~3J~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~20
NM_007670
L166F
mTORC1-specific30
695-bp
26,280×109/L
Maiti
5′-CTTAGTGTCTGGGCTCAGTGGGATAGGTACGAGCGC-3′
anti-pH3
Mrc1****
TibMolbiol
tetramethylrhodamine
kemia-associated
SectionResultsHigh-Throughput
cases.1,2
ZF-3
.STABLE
Pricl
Autophosphorylation—We
p.Leu749Gln
.EBNA2
pLP-CMVneo
~1
MO435
THase
550429
0264488363
Invitogen
91-kDa
phosphoprotein
Hstological
genotype/phenotype
M688I
Glu-37-3Aspand
8077
GRL
EZH2-catalyzed
beta-galactosidase
SIFTS
APC-Cy7
604-675-8112
TTGGGCTT
100µl
antiHLA
300-1000
inhibitor31
iliac
Humangenetik
−1.11
Nontransfected
anti-αSMA
S5B
expressingRenilla
Hi-Seq
HMSH2
AKTE17K
SNT
.PI4K2A
=mean
10a–10c
P-C-Raf
30g
MnCl2-free
RNA-positive
Thr-Glu-Tyr
Interchim
68–361
grandchildren
1Df–j
GAP43
0.002.
women-years
15Asn
A056201
CCCA
pS6-negative
XPO1.1,3–6
Lac
−20
Rotkrenz
TAFII250
:GFP
Apperley
genotype-phenotype
'Others
HNSCC/ESCC
vincristine
progression.39
:CA5
CK7
MEK1P124
PHG0314
GAS6–AXL
66.92
FR3-GFP
.Italian
GRP94
ACVBP-like
PRKAR1a
S337
.Electron
82,365,280–106,601,691
CTD-1013N12
Soluble
Xentech
PE-
1.903
HPC20
sequence.21
2Ae
p110β-K230E
transition.34
ER81/ETV1
HNN
77—19
fromendogenous
CAAATGACAAAATGCCATGA
.RCC
Cys3HisCys4
9232/98
peptidyl-prolyl
1p12/FAM46C
Debiais
12.05
.HCC827
forkhead.45
expressionthroughout
Sheaff
IL‐8
x-ray
metastasis.25
Thr-126
NotchicΔR
TUNEL-labeled
∼0.3–0.7
four-point
HumDiv-trained
GFP-C-RAF1-330
Rev-5′-CATGTTTGAGAAAGAGCAGGAGCG-3′
.CD2-associated
algorithm72
238LeuFS-337X
GAAAACAACCAT-CAACTTACAGACC
HA-tuberin
p24.2
–PI3K
110/159
.Therapies
g2
NKX28
LÓPEZ-NEVOT
FLAG-Elf3Δ246
80,000
12.9/MB
2-times
chromotography
CGGGCGGCTGCAG
glucokinase/MODY2
hypocholesterolemia
10-min
104,105,106
.Verystrikingly
56–411
-2,5-diphenyl
Tacrolimus
Jak3-transfected
R465W
AG3970
leucine-for-serine
pcDNAI-wtER
NME1
pGST-FANCG480–622
amplification—and
P100/S420
S3B–D
Transducer
n=100
Arg167Trp
contexts22
//caintegrator.nci.nih.gov/caintegrator/
20-ml
non-tumorous
5q21.1-q21.3
n=1280
O~.
degradation.1,2
Gajiwala
1:7,500
development.2
R73H
​,44
c.1562C4T
Iliopoulos
peptide-BRCT
ex3-BRAF
W472*
01820364
Bard1
ATCTGTATCAAAGAATGGTCCTG
CAGTCGGAGACGTTGGAATG
ISEL
salutary
Internaliontil
pProLabel-p53WT
RaplAGppNHp
-,18
34/61
q1
phospho-Ser240/Ser244-S6
Institute–sponsored
G11R
substratechromogen
Kutler
Nanosep
genes—TP53
evolution.4
Salmena
Arnaudeau
*â€
3976
c.3649insA
.SU6668
xTCF-3
R101Q
resistance-causing
three-colored
Buffer®
DiMaio14
Scheimann
AML.25
c.9092_9097delAAGTGA
5′-CTGAATTGAAATGGTTCATGAAC-3′
4/108
Phosphorothiorate
MTA1/HDAC1
grant-in-aid
IGBMC
SUPT1
invasion125
HIV1
2564–2922
inactiveGAL1
control.Novel
COHU-CCD
Marcelli
8p12-p11.23
CAL-51
pCMV-I-SceI
32D/pLAM-LacR
C-RAF.7
Phe242
BRCA1/exon23
0.47±0.14
T3/ABN5
P=0.0019
1925-2002
response9
GTA/GTG
7−6.0ICA1Islet
CBLD390Y
SOX2
10.58
.Phosphoprotein
discs9
ElonginC-interacting
sug
MYD88L265P-driven
SequenceAnalysisPCR
117,654-117,833
RRRCA/TA/TGYYY
Fluorimetry
LR5PL
3/30
RQ
0.607
L845P
0-1.9
CDKN2A/B–deleted
.Chemically
Gln167-Q1863
Non-amplified
hmERCC3
Alox-targeted
PF4–firefly
BCL9L
110-PT72
VHL-Y98N
NM_005163
acidocaldarius
TGTG
RNA–binding
500-ps
Braf+/LSL-V600E
0.495
0.1-7.7
LNR/HD
28a
total-PTEN
70.86
exomes13
10p14
phenotype/pathology
18/119
PLA2G2D
TAGAAGGCACAGTCGAGG
regeneration•
catalytic-carboxyl
cancer,5,6
EVI
C.L.S.
Shih-Chuan
.Recommendations
C57B6/J
Phosphatidylinositol-3
catagen
APETALA2
polylysine-coated
re-classify
sRNA-sequence
Kleibl
transformation53
G266E
0.1.Figure
Brca1flex2/FH-I26A/p53LSL-R270H/+/Wapcre/+
promoter.37
CDK2-staurosporine
GS-525
***Significantly
fb
KOKKINIDIS
1-aminocyclo-propane-1-carboxylic
bivalently45
p110/niSH2
GTCTTCTGGGTGGCAGTGAT
RNA-editing
Bcl11b
tall-cell
homopolymers
JNJ42756493
ABCmethod
Microtetrazolium
MSI29
expan
76349-76369
480–520
CMV-vector
3′-truncated
.Equal
R248Wclass
iCCAs
.Ionic
Milyavsky
D49685
−647
purpleresidues
Asp142–Met157
.HCF-1C
8.Chromatin
process.Fig
alone.31
nucleosomal
ID10
Ptip
~see
reduction.A
Notch1-sensitive
colleagues12
seizure-free
R976H
5'-CCAAAGAAACACACCACATT-3
S1029A
c.4358-10C
¢lled
clinical-response
cells.8
sulfonylfluoride
2ING
1–409
C15orf21–ETV1
non-diabetic
recurrentchromosomalabnor
N478S
RNT-1
Hs00266705_g1
+6.7
L410V
S218D/S222DMEK1
V272C
2,3,6
BRCA1/8
RERFLC-MS
33.5
4q24–q31
IL-7R–mediated
acetate–10
Zanjani
Gj2
CYP1B1
senesced
region-
GATA1.8,9
ClustalW
4E-binding
pEGFP.N1
.Trypan
theTGFBR2
105/60-mm
1D5R
PDGF-Bs
Blogged
Krieken
612518
R181P
maystabilize
biochemical/reverse
neutralise
Cys769
4098
275.
FANCG/FANCAbinding
IX-FLA
sox9
μm/slide
unique-sequence
SquareDancer
828+829
LXSN-transduced
ctagaaaaagatatctgccacatagttctgtgaactatgtggcagatat
JAKI
Schinzel
6.51
HF7C
Sepp-Lorenzino
SPK
Carbohydrate-deficient
A243
risk-related
1.9-
membersof
EGR3
-rich
G12.2D
Frame-shift
p.Lys150Asn
lesions149
TGFβ-driven
demethoxygeldanamycin
203K
caspase-9b
p.Arg171X
serine-phosphorylation
52−137
β-selective
gene–ablated
.E26
RETV804M
Roncalli
SPOP-WT
recalculating
CRC312
42272
calmodulindependent
ins/del
J.Five-micrometer
EML4-ALKwt
642-base
SV40-rtTA
set42
mE2
10.1158/0008-5472.CAN-10-0207
CTGCGGGTGGCGGTG
26-68
GATA2
//perso.curie.fr/
/IIB
Val387
GISTc
R361A
I1275V
Gene/exon
Mixer-GSTSmad2C-DNA
bloc
C630
LURET
-GATGGGTAAAACC
homotetraoligomerization
Merlin-Mediated
AML1-ETV6
AsplOOTyr
Deconstruction
6Sos1+/EK
58951
ligand.10
8.45
41Z1
use,30–33
TM1–6
2B7A
G654A
8q13.3
pMMP-FANCA
PCa,3
DeltaEMM
528-2,190
L1951
results.116,117
Microchem
BCoR-RARα
Postdoc
V1809F-R
includingthe
a-Flag
CGGGGTGGGG
null496R
multiforme20
2217S
superinfecting
S225fsdelC
.Integrative
mesylate.21
05-389
CYBB
0-=
crisis34
11F
R14
SMO-W281C
FIP1L1-PDGFRA–negative
CASP8-mutant
Glioma-specific
GDC-0879
I.UbtAlaAlaPhestAspAsnProPhCGluPheAsnProI
pathway.37
HKLM
anti-SHP2
05-1000
Folberg
sequenclng
rheumatold
0.932
Y1003F-expressing
RA45
RNAseOUT
∼85
FGF8a
5′-GCCCCCCAGTATACTGGTAGGCTGACTTGT
.Underlying
63.22
GAS6-positive
methioine
D25E
Prostaglandin
2,947
0.22-1.00
G674
nucleus.61
Rosenbauer
PDGFR1
siRhoA
–1.4
JMJD1B
Anti-OX40
andkinase
Mutation-specific
100029
Serrador
.CtBP1
OTX2
T84
SPEN-regulated
K721R
Ba/F3-BCR-JAK2
metastasis/progression
enzyme-treated
Oler
motif-containing
IL-11
ATCTGCCTCTGCCCTGTTTA
proteins.23,24
I′
GCTTS
ATRX-DAXX
eu-egf
LXSN-AKT2-S-transfected
MED14
pro-apoptosis
E-stained
G89D
Mab-MsS-725-P
competitiveness
AY028848
BJ-EHT
MET/AXL
T-effector
80037A-T
'discrepancy
Stratakis.9
872G
JAK2-PAX5
−271AA
-CCTTACTGCCTCTTGCTTC-3
‡525GA
P264S
metalloproteinase-dependent
2fTGH
Cy3-dCTP
pGEX6P2
Tg2
DFCILU-011
desmoplastic/nodular
CO2
p.Q1554H
PRDM1-expressing
Stage*
37–77
break-inducing
two-species
JAK2182
65.84
p300-dependent
A.T.Y
Carità
Culture-Insert
treated-primary
p.E490_C491dup
Ulcerocancer
KMT2G
mUbRas
diBayes
NVSPI3
M1248T/L1193Vmu/+
2.15.2
kinase-C
30–75
R50P
Q331H
Trp53−/−
3975–2A→G
inv16
FGFR4/5q35.2
row/column
L611V/V617F-directed
NSj
C784
DNA6
neural-like
sub-entities
152-8
protein.16
phospho–ERK-1/ERK-2
pair-interaction
P=0.085
Meur
//www.ncbi.nlm.nih.gov/BLAST/
spontaneously-arising
t-cdk4
ERα36
duplication15
tgtggtttcactttaaaccctgga
D-2-hydroxyglutaric
Intrinsically
ZF-bound
é
Calonge
Koseki
BCL2-related
senescence22
high-risk/level
reported7
Blotting—The
anti-H3K4me0
0/102
HT1080
WT-c-Mpl-GFP
GAP-Related
_Eco_RI
614562
BRD8
domain-defect
.Yes
AAACATACCAAACCACCCACCTAACAAA
Q61KNRAS
.Cos
centrosome-clustering
9107
c.2107-
trans-activational
L1224F
Temozolamide
p53-D281G/L22Q/W23S
C3886
variants56
activities.5
23:267–277
DLL494
R951S
clone12CA5
≈3-mm
HEC1A_ENDOMETRIUM
FGFR-like
fosfestrol
45,497
0.00049
p.Val600Glu
vitro18
TCOF1
29,660
Tumors..
epithelial-expressed
blocks.fhcrc.org/sift/SIFT.html
rerlaive
NOTCH-responsive
〈I/σI〉b
LN40-ADPnP
A_52_P423810
c.1406G→A
RER-
Svärd
Tyrosine-containing
91-3
M466V
Mib1
BL=Burkitt
rv50
Meddeb
Klaulis
5,000/well
191.3
_A_TRX
.Hospital
TACAGAACATGTCTAAGCATGCTGGGG
Lys99
B220/CD45R−cells
Na3VO3
killing.7
gration
ATFl
0.9068
mutation.29
FADD.12
mutant/
Gr-1-phycoerythrin
DNA33
Brca1FH-I26A/−
Bcr-Abl–driven
anti-CD138-APC
C1156Y–L1198F
hormone-sensitive/hormone-refractory
MCF7-derived
SH2-kinase
R273Q
G870S
H418L
L193
proliferation141
31.04
324–355
.1381C
RNA/DNA-sensing
61.11/1954
mE2-C
Arg88
Tet2−/−
AE-insert
CEPH
time,15
t20
r.562_631del
.HA-tagged
re-expression
pre-occupies
neu–expressing
UV-dependent
406
i–l
includinghistological
Pol3-C462S
PTTG1IP
anti-Smo
Wartiovaara
P283L
0.5−0.6
60323401–60651300
prehybridized
EBM-2
90-120
5′-GGGAAGCCGUGAAUUCAGUTT-3′
1910
U87MG
8th
color-code
midi/
C759F
K650/652Q
13-16
pEGPF-C1
looked-for
HIFI
GnG
Fgfr1b
.Bu
Flow-scheme
2454–6556
W.A.
Mm00483243_m1
rmsf
Rochefordiere
single-nuclear
Nestin-expressing
rs17289589
LS-mimicking
15179
1084_1455del
1.01–1.89
.Intriguingly
CAGGGCACCTACAGATGAAT
HF7c
735delGTCCCGGCCCGGCA
-GGCTTTGAGGCAGGCATATTCGTTATCGTCGATCTGCAGCTCTTGGAAGGGC-3
p-CDK2
logM
Platanias
first-responder
891
findings44,78,79
.Staging
decamers
phosphorylated-Akt
CNTN3
low-androgen
molecularly-defined
¢rst
GSI-based
PEBP2β2
82.6
.Common
optionsOverall
Cys-Rich
GDC-0810
.Chase
PE-Cy5–conjugated
TFG-derived
individuals.3–8
Mac1+/lo
_green
strongly-activating
.VEGF-induced
TTGAGGGAAAACACAT
cancer-cell-autonomous
Unnur
PDGFR-α.19
side-deleted
Bosc-23
pone.0064364.e002.jpg
B*39:97N
NM_001001890
HapMap52
23,49
site.24
Sequenom-based
Y1067F
GIT2
Co5
TP53/BRCA1
PEG4000
5′-cctccttcttgaggatcatcatggcatagtagcgg-3′
patients.DiscussionNext-generation
vitro.50
-CDC25
μLC-MS
GSK-1120212
9154S
BRACO19
Y1173
8XGli-luciferase
S352F
74–82
co-segregated
//links.lww.com/JTO/A822
BCRABL1-negative
features*
.HER2-L726F
UX13
cotranscriptional
2Δ
HMG-box
MPLW515L-expressing
UBA3
0/319
pGEX-2T-huC-RAF-RBD
Caco
ysMetGl
.~Apparent
.U32446
MTSL
1559–1692
Pro157syn
YFP–ERK2
c-mycT58A
.FC-402-4001
RT-PCRTwo-hundred
36–44
Gaumann
cotransfected
protein-based
647-phalloidin
R1751Q
anemia,21
Gln286
.Migration
mutant,20
'simple
Lu-1566
P704S
IIb2
.Fusicoccin
BRAF-CRAF
KRAS-expressing
39/40
erlotinib-rescue
EBV-subtype
SU11274/IGF-IR
C-RAF-dependence
12.9
N771GY_delN771insGY
WT-BAP1-expressing
CTSC
nonmuscle
Gabrielli
.FGF-FGFR
S649L
0.021
S966
FIGLA
acute-phase
FA-J2
poor.2–4
.Polyglycol
5′-GAGGCTAAATAAATGTTTGC-3′
mg49361.f3
10p11.2
38.Q354R
p.P2515Rfs*4
286/Mb
TCGA-EK-A3GK-01
Katballe
p.Pro531Ser
58ºC
activation.We
non-overexpression
p.R553H
1510
.Neurological
.HE
12p12–12p13.1
gestation19
Shibanuma
Wroblowski
fibro
.1832delC
test.10
TMPRSS2–ERG2
.3A3A
Ser-473
F231L
β-catenin/TCF-responsive
.PDTC
Lys551
vitro-generated
:73–78
2×25
phospho-IGF1Rβ
9967/3
fastx_toolkit
S1512I-L
16/23
cullin–RING
DDR1a
seribantumab
58-CCTATGTGTCGCCCAGTAATTCTGT-38
inhibition.12
Ligand-stimulation
E96
n=192
B1321
samples148
Dunwell
Exon-spanning
0.953
disease,14-16
sc-55155
disease.2
1.17–7.43
chromatin-associated
NMorphology
GloMax-Multi
BIN2-PDGFRB
JNK-related
NAF1-dependent
Holland,41
rnethylmethane
0.000720
lysine-coated
:10417–27
13,31
GCTTAAGGC-F-5
17,24
T195I
AKAP9–BRAF
1c-1
ClustersProliferative
CD31+
25/36
inhibitors99
phosphorylation-AKT
-Y674/675
red-fluorescent
i32m
E768
here56
anti-chromatin-Ab
m/ml
Whsc1-deficient
Blotting—293T
Epicanthal
DerSimonian
.Bolzan
T1010I.Met-transfected
IL12p40
Fe3+
ade-ura
Non-Polyposis
shRNA-Mediated
fosmids
XRCC4
S6-pSer240/244
substantial170
Morikawa
immunoregulation
UVB/UVA–induced
CTL
genelarge
previously,29
ERK2E250K
MTOR
pathway-targeting
Brouillard
ninein
deletion–mediated
.Mutation
i.p.
BRDU
mad3−/−
GTCAGGCAGCTCATAGCTCT
IGFBP-3
Gupta-Rossi
STn
patients.1
activation49
inter-related
Mg–O
UBC13
ACOSOG
GENios
DHLPC
hMul
coli16
GST-p300
Anuradha
.Levy
cancer62
BCP1_HAEMATOPOIE…
Pzp53med
Kleymenova
ETV6-WW-PDGFRB
pGBDzNeh2
tissue-sarcoma.27
binding15
phosphothreonine
-v.0
0.300594087
SPT5/SUPT5H
-AGTAACTCAGCAGCATCTCAGG-30
shBCL6
Wntβ-catenin
5xkB.eGFP
Dpy-30L1
hemiprobes.15,16
521–543
HEK293-EGFP
SQSTM1-ALKG1202R
dut
AMPK-mTOR
TGFβRI
lymphomas/leukemias
homeodomain-derived
FGFR3TACC3-KD
nCi
85Lane
phosphorylation.24
JMML-typical
TCTTTTCCGCCTATTTTCAGTT
lB2-microglobulin
NP_116071.2
63/253
NSCLC,17
progressions*
study.19
NCT00084396
HSP90–p53
GAGGGGCAAGGAACTGAACT
2A-1
76/M
EGF-like
Bohling
non–hot-spot
Tyr-107
CUL5
.Milder
E2584
D211G
Friedlander
5q-deletions
-GATTGGGTCGTTTCTGCTGTG-3
K860
4153delA
28:138–144
interface-I
3xFLAG-tagged
S872
long-rang
tumours31
dasatinib-binding
5′-GCCTGTGCCAGGGACCTTAC-3′
Anti-CD117
Grb2–Sos
vasoformative
G2461V
angiogenesis194
Fug-III/12
tumoral
substrate/ligase
poly-Glu-Tyr
CATTGTGCCCACGCTTTCTGAACT
2217
CELLCYCLE
anti-phospho-MEK1/2
thatthey
STRATAGENE
2.571
IQCA1
Trp183-to-Ala
REAB
.Anti-CITED2
A375-conditioned
Progen
UX12
.Sixty-seven
Y260fs-ter573
and6b
photooxidation
cytometryApoptosis
Jak
–mediated
PKBTrp-80
mg/capsule
2-hr
Gly-511-Glu-Gly-Ala-Phe-Gly-
L620P
Amelogenin
pGR/α
Cancer-Thailand
2–21
D259S
siteselective
cytoplasm107
PCR-tested
430Av2
Wightman
clonallyderived
DAPT-treated
Affymetrix-based
3ug
F-box-containing
AP-3
5′-GCTTCGGCCAGTAACGTT-3′was
PIP2-containing
N10
PI3K/PKB/NF-κB
T738M
GAL1-based
Akt-expressing
TCRαβ-bearing
multiple-case
5′-TGCTTTTACCT
GMPs.54
NS/LS
pA3
87,749–482,715
EZH2+/+
large-
DS98000
derivatize
41/120
AP-1/ERα
C-CBL-like
35S-metabolic
gavage53
To-Pro3
serum/growth
α-phospho-JAK2
1·7
TIF1β
A-1
-ms
Non-CR
non-periductal
Lnk
anti-phospho-Erk
P2–P6
17-28
AB7900HT
activity.Table
spleen-derived
ErbB-2and
deacetylases-3
N1-N5
MuDR
P839L
HMT
SH3GLP2
SP-Sepharose
amp-hours
levels,20
welldifferentiated
PS/PtdIns
c.1440_1441insA
PICALM-AF10
nonpermissive
fold.18
NVE
photostation
P55*
loop.12
wu103
BRCA1/2-related
Kras4a
20.78
CTB-5M9
CAGGAAACAGCTATGACCCAACAGAAGTGCCCTCTCAA
CAAACACCATGAGCCCCATCCAGGAGTACTGAATGACAG
1.17
Arg378Ala
HGS-OV
c.241
G290R
LOC115548
TÃŸR-1-transfecled
N155D
v9.0
muCi
hematopoietic-restricted
0.0428*
finger-print
D314A
Software.35
FDG-avid
LDQIMMCSMYGICKVK
KCl/1.5
5-nt/4-nt
adenomas.50
Hijiya
105/well
hMSH6-infected
pDR/FANCA-GFP
1:1280
samples.2,17,18
ond
chromodomains
life‑threatening
.Platelet
Elf3ΔC363
5hmCpHs
mutated,8-10
P=0.25
n=1/8
murine-type
5kb
Villunger
.Patrick
OSI/Genentech
quality/quantity
SPEPLVLH
1,3,4
21841502
11VQWKV555-559del
4V,6-diamidino-2-
hipH
Duke-NUS
Acvr1Q207E
ETS-binding
Arg139
49/m
protein-containing
10564
protocols33
γH2AX
diversity.34
SK-Mel23
664-1030
pFC38
age-appropriate
RAD51D-specific
3-4x
Riboprobe
pGL-2
monomer
Buard
exon1-to-exon2
5q11
mU/L
Ile168
KRASG12D-transfected
.Retardation
5.5173
TD-mutated
2284delCT
SU-5402
control.84
t.I+
.Alveolar
conservatively
p12521
.Allconstructs
PF-02341066
MPLV
doxycyline-repressible
targetedBCR
DH*
mice23,24,25,26
Glu-107
f2m
Annexin-V/7-AAD–positive
factor-1
DNA*.CSVDisplay
KRAS-G13D-expressing
P30-CA008748
R69L
pK62R-FLAG-Fwd
Lys-48-mediated
H14
C-lect
C15orf5
82Glu
BSG-derived
Fbxw7R465C
45-kDa
FPBH
proteinitself
and16
form.38
IgG-purified
7.0+
Triscott
AMT
epiderminal
ubiquitinylation.Mice
Fig.22G
reviewed4,34
1:6.000
ATM/Rad3-related
Igκ+
14—causes
LMO1
Q=9.1×10−5
OIN
.1202T
G12-mutant
2-yl
.11D
9802
co-polymerized
inhibitor–dependent
proteins19
isotypematched
H273
104/mouse
hemi-allele
1961–1967
cells,19
c.7471C
RKIP_E4_R
Ärztekammer
cofactors35
3.8-kb
DSBs35
005235
.Conditioned
.NSCLCs
Bα-D197K
H3122-EML4-ALKL1196M
D-81675
37Â°Cfor
described.Treatment
Acetylated
.Eosinophils
/SSCPs
ITDWTNPM1WT
a2xb
PI3K-AKT-MTOR
.Ill
RNA32
DLCL.51
fusicoccin
I195
HEK-EpoR-Jak2
G-to-A
PCGF4
Stanmore
0.313
R556*
deletions-T790M
NTRK1both
.ROR1
1915C
.Detectable
indexNextAnalysis
chr22
seg-
2.54-
20pM
SAMD11
lower-molecular
iNOS
ATP1B1
BamHI-HindIII
assay—an
integration-site
A3232G/Glu1038Gly
level.16
Nikoloski
gefitinib39.The
Arg183
BRAFK601E
mg/mI
NTRK1/NTRK2/NTRK3
stablely
R329C
DCIS
glioblastoma,15
5'-CCCTTCATTGCTTAACACAT-3
Hippo/YAP
M237I
5′-CTGACTCCAATAAGAGCATCCATGTGTACAG-3
2Chighwire_embed
-p70ltrk
conservesome
.N-APC
pGL3-1APm
158C
cGKII
men.9
HBOC
Kardassis
Jade-1sh1
.Awide
Halazonetis
RAF265
.Extranodal
31-86
drug-inhibited
non-WGA
TSP
0/31
acid-RQIKIWFQNRRMKWKKLLSLDLPTSYTKSVAPNVVAPPSVLP
F105V
Comoglio
F229L
GAAAAATGCTCAATGAGCATG
Limpt
pY1173-EGFR
_t
BMP-2-untreated
n=35
ERK2D321G
2821
documented.The
Nutlin-3
lXq22q43
Ramsahoye
L515
N-glycan-dependent
2.329
cytometries
AC-40
RD841-842KI
B-C
//www.flintbox.ca/technology.asp
.T-ALLs
BRCA1/2-mutant
0.3618
Leu-61
1a-2
off-protocol
5′-CAGTTTCTGTCTGCTAGGAG-3′
V647
hypernasal
si08
c.154G
MMTV-Neu
.PRODH
RA1
K449
60.55
48109-0638
PEBPβ/CBFβ
Altmetric
structure−function
Y163H
multiple-neoplasia
trimer-interface
82.2-fold
JY/FANCC
IDH-induced
K052
reference.ADC
LGSGAFGTVYKGLW
receptor/Src/c-Abl
ICN-CBF1
non-proliferating
therapy58
.RNase
pET-28
29EGFR
HER-2–overexpressing
KinTek
Schreiber-Agus
cellular,26
RG-23N
GSK-3α
abTCR
LR04-078
mu-
Z-lyte
p.Leu486Ser
4,5-dimethylthiazol
15-yr-old
biotin-aminohexanoic
FosB
58·0
Neurodevelopmental
.C-scores
004985.3
±4100-fold
downslant
5.49
5′-AGGGAAGGATTTTCCTTTAGT
mutation.PIK3R1R348∗-
Jarvis-Patrick
p300-HAT-deficient
Brachyury‐
CRL-2610
8-position
Crossbreeding
GAP-associated
A276P
IWP-2
E453
Cdk1-Cyclin
Young-Onset
cross-links
cycle1
p190-
lympho-
cells/100
myc-epitope-tagged
Pharmacia-Amersham
DN30
29432674
immunological
EGFP–p53
70˚for
AJ131188
IFN-'y
pi-stacking
heterozy
Wiedemann
polyethyleneimine-impregnated
.DM
112.4°
tissues62
Complete™
well-tolerated
12•3
JAK2K539L
68Gallium-DOTA-Tyr3-octreotide
species-specific
8:1125–1128.10.1016/S0960-9822
3-118
4q22.3–q26
CARMA1-BCL10-MALT1
Dierick
7-12
PIP3-dependent
AA499
anti-SOX17
Y64G
red-green
analysisGenomic
1.580–2.689
​andC
V617F-negative
PONDR1
manifestation.29
FMTC.9
hFLI
V144M
6•9
mutations,4-6
NCT01172769
Pdef
6.11
cons46
R54Term
doi:10.1038/ng.2938
multiubiquitylating
c.8487G
TGFA
N29I
β-TRCP
substitution.4
ÃŸ-cateninmutations
B19
1.244–2.370
U80932
0-1.40E+116
palmitoylation
0,9
Ile332
syndrome9,11
utx-1
MAb
ETSfamily
KRas-GTP
RDint
.Early-passage
glioma46,47
Celgene
v-erb-A
his3–Δ200
others.28
269–46
Glu121
Sulindac
immunofluorescent
Cys136
16Pfx
pFLAG-BARD1
afatinib-treated
32P-radioactivity
5-GGGAGTCTCATTTGCACCGT-3
40*
subcluster
S42T7
A*0205
.LMO1
Q279E
mesophase
Leu-97
Plovins
ATG-3′
myloproliferative
Abagovomab
112.0f
isopropyl-b-D-thiogalactoside
phosphodegron-mediated
metastasis132
Foxo1-Δ256
expO/MILE
multiunit
BarnHl
Lichter
RARB
Ohnuki
M980T
G418R
.Immunotherapy
A_51_P408595
0.1–0.3
Ardlie
PDE11A
5′-ACTTCCTGAGCTTTTGCCAGTG-3′
Y*
LRH
pMSH6-N1
McBlane
Howel-Jolly
6842_6937del
Paradigm-Shift
supershifting
p.S241P
574PT
maleimidopropioryl
E2-luc
confocal
timine
FC2LisH
Cysteines
BTIC-enriched
neodynium-iron-boron
1100G→A
Wound-Closure
5'tggaaatcccatcaccatct
0–9.2
22Q
S15D
BsmBI-reverse
FUMI
SCALA
Zlotorynski
×3
//dx.doi.org/10.1530/ERC-10-0258
Otsuki
two-sides
≥16.0
PIK3CA/centromere
11,24,25
610938
41M
glucose-dependent
Amido-black
ribozymes
79.3
factors/10
.Structure
101000
cDNA—was
www.usbweb.com
DBD-coding
formaldehyde/PBS
nonaberration
Vaishnaw
B2SrnWP
CGGA_64
G118D
gIn
Krt19
EMSA
patricia.tonin
Fromentel
67KB
.020851
96-286
K555
1,265,133
CCGAGTGGCTGGACGGAGATTCTAGGGACTTAA-5
RNA-to-cDNA
CAM-SpongeAssay
GENMOD
S807/S811
Val-143
proteo-lipid
11-c3
ABMT
CDKN1B/KIP
.Add
E286D
ml0418
11/13
MDS_341
CLL05
A1066V-NHUC
A/C/T
40/49
p11.22q11.2
AKT1PH
4–6-fold
chimpanzee
EWSR1/CREB1
000×
M45A
∼77
g200
L549
IDH3
7/6/0
PBS/5
.2T
Glu-561
Phenol
9431
177-182
Coamplification
frontal
Ile219Val
lymph-node–negative
59-TGGGCTGAGGCAGCTGCCTT-39
50◦
c.2103G
43–55
KMT2D-null
Theprotected
.Anaplastic
pERK1/2/total
interleukin-21
analysis.2,16
optionsHistologic
malignancies6
3,10
//exon.cshl.edu/ESE/
fusion-encoded
GenePrint
CML34
21–86
elsewhere.31
2-646
p4E-BP1-T70
1.Figure
Δδav
CCS
Diaphot
EGFR-V851A
E996K
GTPγ
Y298A
RAS-neutralizing
Relapse-free
.Fortuitously
R658Q
,Rat
I78
pathway80–83
spectro-metry
169-kb
chemosensitizing
.Ferrando
TCGCGCATTTTCTTCAACC
pre-loaded
E228G
age/genotype
+36
genes.15
1:100–1:400
R173
LKB1/STK11
ABI3730
click-chemistry
n=185
5C5C
crizotinib-mediated
'mixed
25.44
ccRCCs
62aa
AR−
C/Wto
20Mb
5′-CCCTCCCAGAGGCCCACCTT-3′
ApcMin-dependent
inhibitor49
STA-NB-8
Calcification
Olah
c.1789_1790CT
K618A-related
complex/diaminobenzidene-peroxidase
4A4C
PI3-kinase/AKT/mTOR
caArray_GSKdata
.Enzymes
ARN-509–treated
sc-356
hetero-zygous
FIL1P1-PDGFRα
26–142
F1L1P1
-GSLLEFL
auto-inhibited
anti-Stat3
E-loop
5′-CACCCAGCAGTTTGGCCCTCCCAAAATCTGTGATCTT-3′
genes24
101–370
Th2/T
NM_182482
S179N
dimerization.24
Vehicle-treated
V824V
neuroblastoma180
P-0002050-T01-IM3
STK15-Phe31-Myc
5′-UCAGUAAGGUACGGAGUAA-3′
D17S1323
Pharamceuticals
tubes.C
E781D
1156
TRRAP-histone
1225
E525X
CSEP
phosphosite-specific
Tp63
Sweet-Cordero
pLenti6/GUS
S.-L.
manifacture
'Wallenius
157–170
forks40
p.Arg322Cys
v1.5a
mRFP-Gal-1
7-Tesla
Hypotriploid
re-normalization
.PHD
PALB2/FANCN
0.408
3153–3163
IPMN-like
panoramic
totalcell
TTG
6,28,59,60,65
R369
TGATGGTCCTATGTGTCGCCCAGTA
Hemacolor
SMAD4−/+/APCΔ716
'mini-gene
transcription-factor
anti-Akt1
myr-IKBKE
60,529
receptor29
.Explicit
Surh
.End
malignancy/to
1shows
LMNA–NTRK1
D454G
Hsp90/LKB1
A883
photolysis
v-Ha-Ras/RaplB
ERF/AP2
.qRT-PCR
chromatin-promoter
38,028
959
c-Myc/MYCN/L-Myc
5269
F1174I
CCGTG
3-to-49-day-old
miR-17∼92a
F2–R2a
positive/estrogen
K709E
FIP1L1/PDGFRA
transcription.17
4–6-month
18,225
80,000/mm3
IL-18
PAAKRVKL
mg49361.f1
leiomyoma-specific
.Modeled
5'gaacattgtaaacttgctggg
BRAF—a
11.5.1
18~23
anti-V5-E10
-p21*
melanomas.5
-midline
D226G
biologicaleffects
site-models
224-C10
sequencing.We
bcr
disease.1-6
Beppu
MEK1-ERK
Adenovirus-mediated
CFC75
Fig8D,8D
−0.26
.PK-8
HRASQ61L-mediated
malignancies.8-10
Wier
phospho-recognition
C176
ARK
patients—one
NRAS-4-F
CMAH
λex
RT4-truncated
angioleiomyoma
R1380C
Dnmt3a-HET
.A21049
RET-related
28â€
1.01–7.18
WHN
MF,5⇓⇓–8
oncogenesis178
Met30
goodness-of
RPTPζ
transforming-activity
​Figure2B
F359C/V
gut-specific
WT-driven
~M21
Analyses—For
26–30
Vemurafenib20
mutation175
responses.5-9
.CAV1
503-494-
anti-ERK-2
BsrBI
CDK4-containing
Kermorgant
−85◦C
isoleucine139
hybridization-captured
yPH-Bax
2.907
.441G
G5-E1B
10–41
GGCTAAGC
points13
homolog/mitogen-activated
EPHB3
ERK2IIp38IVERK2
2124
Q227R
GSE46948
BAALC
W748S
Canzian
.Identi¢cation
117–224
100mm
c.160C4T
fractionations
Pull‐Down
Baguski
binding8
microsatellite-unstable
HMCB
N161T
RBPJ-dependent
Zeta-Probe
p.However
lingual
NaOH/1
criteria/cutoffs
12p11.1
agonistbound
mock-transplanted
nonpalpable
Mantel–Haenszel
/0.25
b-mercaptoethanol
instabil
BTB-like-fold
33/19
12/18
C0C°
concept55
Parathath
allografted
Flag–Smad3
GDP-AlF3
A481F
cancer•
TKI.EGFR–RAD51
carcinogenesis.30
non-sequence
II:2
RAD51C-mediated
3a-3b
-irradiation
.L755P
SD/
phospho-S795
pPNT
Y821
-UTRWT
Startingblock
H1-FOXL2
moi
-CD2
anemia,27
E2F-1/
PC-gd-PTCL
CLARP/MRIT/Usurpin
Doxycyline-HCl
Spectrochip
0768
Hε
.NS527
205′–217′
1-757
CAG/Cre
Akt3-expressing
TEL.E1F2
shWWP1-1
DEJL
ure
S46R
S9WT
P.K860N
BRD4-NUT-acetyl-chromatin
proliferation.23
PilT
PLZR–BCR–JAK2
3′-guanosine
DR50
CTLA4Ala17
complemen­
~D351382
Lenti-Cre
cER4-2
Ig1
ST5a-2H2
R552G
10q25
D418Y
Emp2
PP5
Strouboulis
responses42
PANC-1
thehelix-turn-helix
order-of-magnitude
exoribonucleases
back-thinned
Rheb.32
AACAAG/gtgaga
M7195
Voronova
.Worth
GABPA
-QGLVVKIGDFG6SRDIYSTD-
S385
AG1-X8
3698
.7,8
hydroxyethylpiperazine-N
5'-CCTTACTGCCTCTTGCTTC-3
G13C
Bai
residue.15
1431–1737
.2404151
ΔID-L225LI
NH2-
erozygous
glicazide
BSÂ°
1,646–1,863
Fluciferase-r-
1495Aright
histidinol-resistance
pharmacologically
MSRB-3
Crystalographic
specimens11,12
cis-imidazole
B–C
794-796
E383K
Cdk6-knockout
NZM58
Asp241
pathway,37
|17
Ser-1655
p.N78
^3801
HER3/4
SET-1-like
BCM
tween-80
Vannini,1
AG17
infectednecrosis
g.67589663
CoDP
BAX-immunopositive
twenty-fold
D1-D2
N-myc
oncosuppressors
c.68T
GISTs6
−E2
AF049703
phosphate-buffered
MYCN-regulated
Trojani
Msh6P1085R/+
inversion-recovery
chemotherapy.16,17,23–25
cytarabine.132
I/II/III/IV
withlane
J21Graphic4E4
pathogenesis.2–4
MB1
14q32.33
MSH6/
c.857A
DNA1000
15/38
MLL-mediated
981
1/2a
435
942
MitoTracker
M/45
pApuro
thermosensitivity
sponses
anti-MutS
RBP
acid-amino
localization.7
MRCHolland
514-412-4315
BRAFS467A
stress-induce
occur.30
pTB701-FLAG-PLD1-D4
BFTC-905
serum-starved
On-Target
CIM
5′-TAATGACCTCAGGGAAAAGCTTC-3′
.Daudi
Lavau
D9S180
E627K
Lajoie
LAPTM5
4–deleted
NPM-ALK–transduced
TEL/PDGFβR
Insti-
0.742309
p-S6
,28
p.Met18Thr
5A3
FANCD2,18
n=33/279
mdm2-dependent
n=129
1.2+/−0.5
Mer
FuPa
1.29-3.14
G315E
Capo-Chichi
Molecolar
Calabresi
p.D277GfsX79/
L236P
RAS-guanosine
PREX2
T/P-conditioned
Koeln
S1B
5-GTTGGGCTTTTAAATACTCGTTCC-3
LFS-L
DNA/sample
shRNA-Blast
Ampli
MYCN-Lin28B-Let7
5/71.4
.DLD-1
Dot1
4702
counts/total
translation48
signals.2,3
6.57
~2,700
TEYCCYGDLLNFL
11q.18–20,22,23,33
Thr-387
.V730M
2RA
EΔCPD
Pro155
neurochemically
D4S127
Douchi
L/I
VQSR
uAsnArgAlaleut
M2a
I189T
stop-flow
−59.78
anti-HA1.1
patients.8,35
well.14,28
0.002
index.htm
Tukey-style
FA–A
S1108
20/177
ARTD7
fixed-model
unobtainable—presumably
2.61
IGC
.Arch
DNase
∼170
anti-his-tag
PIKKs
anti-pan-MKK4
c.283A
promyelocytic
hu_p53
PIK3CB-specificin
pCMV6-DSN1
ccG*
glfSomatic4,35
2008-136
L747-S752insQ
W290
1.987
LR12-389
ScXPO1
1–465
0.9–2.5
660
Medicilion
19.125
pre-leukemia
Biankin
_Helicobacter
inhibitors.69
Vuorenoja
GGTase
G1624A
al48
124L22
.26440374
.FIP1L1-PDGFRalpha
BSÂ
SDCBP2
tumors1,2,4,5
types138
HMAs
pineoblastoma
NM_001421
CCAAT
CAAGGTCACGGTGGCCACCCCG-TGAOCG
Ras-driven
.185
1242
entry2
retrotranscripted
ARHGEF13
ICSBP
Val57Phe
H4434
onogenes
c.1039-8
Heterodimers
al68
T481K
8q24-ter
Lestaurtinib—but
HhAntag-affected
2752C
1963
AJ519934A*6811N
teb
TROPOMYOSI
mutation–disease
deletion24
disomy
CCND3
Bueren
KEAP-DM1
18⇓–20
_EGFR_-TKIs
55th
R175H-induced
A168D
GRKKRR
.Anergy
JunAA
non-effective
–32/–29
TAP-HA-tagged
0.241
Ba/F3-
multifocality
1.46-kb
isoforms.23
Smpokou
Wet-mount
apoptosis-prone
3′GACTGTTACCACCATACAGG
Azienda
eosin-Y/well
K468N
UC.9
Trogerstr
6144
MDMX
switch.11,22
.Homo
.Perform
5′-TTCCATGAGGCAGGCTGAAC-3′
K-Ras-4b-UTR
mega-yeast
.Asp-450
-0.19
BAK39
HCT116-cells
Top-scoring
T71
protein–Dicer
ferentiate
SYBRÒ
136/256
mL/sec
PEA-15*
P24
LinesHER2
G49A
L627H
Ris1
al,38
%
QRSTpSTPNVH-COOH
GGTGTGATGCATGTATTACC
ICSI
counter-ions
five-tiered
2008–2012
W515
tumours.45
8770
c-MYC–expressing
EGF-alone
M23379
MEN-2
F735
32/91.4
profes-
3.2.1
trypsin/peptide
Ski7
COLO201-AR
TrkAIII
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
AsCNs
at141C
//structure.bioc.cam.ac.uk/symphony
actin-related
.Initially
cases10
T468M/CD
SC-2019
GRCh38
CFC/CS
Callén
LabChips®
008017
NM_000546.5
pool45
V599E-expressing
species=
IncubationnTreatment
DU-4475
triad—the
atdiagnosis
ErbB-2–specific
ExAc
43/101
K831R
figure9A9A
isoquinoline-7-one
RAM‐ANK/CSL/Mastermind/DNA
CTATCCTCGTGGACTGGTTAGTTG
MED29
LOC100505759
homozigosity
Gpa33
STK11-null
5′-gaaaatttagagtttgggaagg
pLenti6/V5-GW/lacZ
.Ultrasonography
values88
IVS10+8C→T
V299L-containing
26,32,33
Januszewicz
.1.5
CD3-PE/Cy7
eachlysatewas
SK-MEL
VII-3
HEPES-OH
E8-10
described.12,22
S144F
D2S2382
6/13
Bjornsson17
signaling43
4032
XL-184
A19
andalso
A234T
123I-MIBG
_1711+
D–G
neg.
thathave
MEN1-like
Y253F
M48T
NCT01207440
SBE13
hemoglobinopathy
I3412V
.Diaminobencidine
43–90
blottransferred
nondecalcified
GI:62857819
'hairy
23.87±3.04
RNL1
RUNX1mut
4494–503
C-CDK
5′GATCAGCGTAATCTGGAACATCGTATGGGTACAT3′
WTRhoA
Kincade
Figs.2
region.cTumor
.Kurtz
intron-6
phosphaterelease
sc-92
www.takeda.com/research/files/pipeline_20130204_en.pdf
.Untranslated
procedure.36
32:59-66
55/369
pTRE
ERBB3/PI3K/AKT
15q21.1-15q-terminal
sae2
.Manifestation
described.28,48,49
deletions/
.GFP–VHL
apoptotic/necrotic
report.1
JK1
oligometastatic
ATR-phosphorylated
rs56391007
GRANTA-519
6delAAGT
-M
0157
sucrose-1.2
ngers
phospho-STAT5-
Pfx50
pSG/Flag-D243
described79,80
YAP-
cancer-genome
bystanders.
ng/transfection
100893147-103364733
540
≤4.0
Siddique
codependent
GGGCTCTGGG
msh2p-AE859p–Msh6p
size-exclusion
BRCA1–I90T
conformation-flexible
G128V
TDI
D-boxes–containing
growth-restraining
19.35
EC11F5′AACTGGCTGGAGATTAATCCG-3′
TWEEN-20
Q22R
91/345
LSL-G12DPdx1
GTACC-3′
±40
Phe328
WT-EGFR-GFP
18-70
DRB1'0402
observed.24,25
FMS-Like
cerevisiae-expressed
Shelley-Hwang
.E-Cadherin
Tyrosine-Phosphorylated
86d
C1408
T790M.3
NF-kappaB60
SMA
WAP-rtTA-Cre
side-to-side
//annovar.openbioinformatics.org/en/latest/
CO2-incubator
D439A
S6B–S6E
1−ΔT/ΔC
5655
L2431
v/w
sub-categorized
cIAP2
N.C
NRAS/HRAS
LogMAR
1751–1863
YB
reduced.34
Snf5-deleted
mutation.1,6-11
27–28
bound.It
13C5-2HG
p.Lys27Met
2554A
TMTC2
phospho-platelet-derived
35/60
BH1-3
Cys342
mu1577F/mu1577R
lymphocyte-tumor
AS-chloracetate
Raf
phospho-EphA2
diseaseassociated
.NTRK1––encoding
S1887
+5mar
differentiation.11
Dsh-induced
1208
inhibitor–refractory
Bglll
BC038572
.16-28
CuZnSOD
Dik
microdeletion
notexceeding
axillary/subclavian
BFL1
3B–3C
GGACTGTGAGATCGAGCGAGAC
2.1–7.8
McIntush
Leu89
P383L
466-8560
268·3
G273E
X-4A
.Lineage
∼1.5−2
.CBFB-MYH11
Treatment1
transphosphatidylation
6/66
4W
464
H-rasG12V-D47A
gene.53
294002
GADD45/GAPDH
1p22.3–qter
.staining
SNP5
pGEX-2TK-AR-AF1
STK11-inactivating
Slot-blots
0.5mm
FO-IA
FluorImager
20·0
shLACZ
vivo5
,92
BACH1-ΔNLS1
streptavidin-linked-horseradish
level2,9,15
mtor+/-
.Hey
Adv-MKP-2
Nup133–GFP
Insitu
intron|exon
pCMV5-HA-Akt
MCC
relapse-specific
−2.9
.1,600
1.846
Gli-mediated
G370/372C
Multilabel
Petitjean
BRRS
dmol−1
ARF2
175Asn
Tso-Pang
Val370Asp17
tumour/control
NCT01252628
JAK2V617F-Y931C/L1026F
Deacetylation
BCL10-IGH
tyr204
3/59
161
p2lras
U-937-myc-6
50-cycle
cancer-exome
south-west
active.
C.-F
Tamrazi
Karolinska
ETO-related
Kn
mir-19
1697498
Launonen
PR-positive
I448V
65–94
C277–C275
N'Guyen
PTEN,24
2517
direction.16
Gab1-
DMSO-hypersensitivity
epd.html
-DRB1
.Letter
CH3OH
fc-MG
G3PDH
5′-CCTTAGTTGCTGGCTTTGACC-3′
.C‐terminal
E866K
activity.Since
GAGCTGATGTCGGTGGGTAT
Cancer-linked
S34F/Y
four-somite
Table11C
marker-expressing
OWBC
.SNVs
72C×7′
IRES-GFP
Saskatoon
KMT2Dfl/flCγ1-Cre
Dotzenrath
l4
MutSalpha
D-Cbl
malformations1
0.014/
10058-F4
Smad2-L
loss-offunction
5′-TAGAAGGCACAGTCGAGG-3′.Identification
multiple-sequence
730/1,631
Rottgers
lymphoma.42
23/23
‡Results
GST-hShp2WT
Zarghooni
tissue±3s.d
J.P.H.
Jinlin
1â€˜fltiswork
5′-ATAGTCGACTTCCAGCCCATCTGTTATGT-3′
65del22
N265Q
-intolerant
parathyroids12
nihms646437t12.jpg
S334P
141-bp
MFH
0.714
Germ-line
2,249
ITDMUTNPM1MUT
.iii
5.2.3
GH
Allione
5p15.1–15.2
B-Rafs
c-H-rastransformation
synteny
1014delGT
C1471Y
JQ-1
bowtie1
c5
R229Q
infection–appears
YAPWT-RFP
Image-Pro
HA-p130Δ21
post-UV
16-gene
fusions10
peptide/modification
kinase-inhibiting
0.885
Female/male
SEL
32/M
P=0.262
H292
bacilli
system12
transactivation.For
+/+/+
c983G
p21-R1
​Figure11B
described.2
.Until
7.40,41
8R
.In-vitro
1416
1,1,1
preblocked
Thirty-eight
FA.4
50Â°Cfor
4729
Anaesthetized
areable
T44A
NF-jB
TEAD4
tumour-serous
19.3
CTCLs
0041
H773R
ATCTGTTAC-3′
E1384K-mediated
sarcoma11
kinase-driven
INPS
|/RIhkl|Fo|
Vigneri
IFCT
consideredimportant
.10,38,39
12'5
nia
K751M,16
Pansini
terminus.B
procedence
Wnt3a
'Tet
ASLC1
AA609985
PhyloP
heter-
myr
temperature-equilibrated
Ala767_Val769dupAlaSerVal,27
inhibitor.8
.Mouse
Histopathology
5′-TAATACGACTCACTATAGGG-3′
G-loop
.Usually
agagggcatctg
ontogeny-defining
.Marynen
.Wnt/β-Catenin
protein-terminating
0.75
setpoint
–160
inter-day
1466insC
Staresincic
mBcl2-Reverse
2-2-5-8
16/61
5/39
repeat–driven
mixture22
differentiation,34
passage32
index.html
0.2–0.7
FISH-positivity
GTGATTG
BCL3.179
hot-spots
erly
Figures11
BRCA-truncating
ACTCTGG
W534
Cofractionation
Karpinich
tyrosine-
authors.20
Endocrinologia
Botta
agents39
wall/septum
Al-Ahmadie—MSKCC
trk22
Tyr326–Tyr337
GAGTGCTCTAATGACTGAG
phosphatidylinositides
SBNO2
.Takada
NMR-derived
PIG-U2AF1
70:315–320
anti–pEGFR-tyr1173
χ22
DCX
Daoy
c-CAS
.left
dimethylsulfoxide/PBS
972-8-9344125
AML1/EVI-1
Ba/F3-L858R-L747S
lymphoepithelial
bacteriophage
H727
1–349
4ZFΔPRΔTK-HA
3130×l
.074
advantageously
:leu2-bsteII
7–17
TTD6/4VI
.AG
VEGF-A–blocked
homotetramerization
31-gauge
Q-R2
.0001a
Sprague–Dawley
0021-9738/87/11/1512/04
.Ma-Mel-48c
β28-luc
0.8728
pmGFP-K-rasG12V
decay4
Puddu
phospho-Myosin-IIa
.Candidacy
Orlando/Paro
EGFR-KDD-dead
msh2-G317D
9559
227646
LEF-
14-0451
Wavelength
SMARDOVA
PDGFRA-amplified
His6-stathmin
delL747–S752+
BCL6-translocated
coreceptors
solvate
billiary
multi-alignment
oxidative-stress
spacefill
ORISTM
*Phosphorylation
SCGIO
CCTGGG/gtgagg
13.16
120+350=470
BARD1-mediated
11–13
Miyakawa
trypsin/1
S4H–b
Chihara
0.251
TMPRSS-ERG
myc-ETV6
unidimensional
reinduction
I504F
promoter132
≈1.6-fold
pMexTrkA
Receptor-DNA
.GRCm38
granulocyte–monocyte
183.17
L148
70Â°Cfor
.We33
GAAAAAAAGA
//www.ebi.ac.uk/Tools/
cbt-15-768-g2
Kutryk
G13.2V
hybridizationDNA
1181
E746-A750del
π-π
Rowland-Goldsmith
1p32.3
hit-and-run
DDR2-overexpressed
S14-15
p.Ser24Phe
Ras4
Left-dominant
coimmunoprecipitates
function21
PCR-RFLP
PIK3CG
5255–64
R482W
Ternary
exome
hgu133plus2
c.555+1G
Bio-serv
mth
.E238G
pa‑
94Â°C
anti-mouse-FITC
W=
Site-II/substrate
eight-bladed
Ciona
468
5-54
T185/Y187
HTB
15.1C4ORF34Hypothetical
G1788D
Mx1-Cre-
J.H.J.P
R27P
c.2808_2811del4
Patients/cell
L7
E2F1-regulated
+RH
GST-RhoB
muta-tion
0–50
D1-D289/292A
K650
foci/G418-resistant
c.476G4A
DNA.39
pseudoinclusions
approx2
p300AS
HD-0234
Solexa
.397C
.Selected
2010-
Tet2fl/fl
hypersprouting
E462G
trP1
schwannomatosis
36T
Vav-Cre+Tet2wt/f
C124R/G129E
Southern-blot
3delAb
.V12Ras
165-bp
p=0.0506
Buckinghamshire
non-allelic
21—24
EAPII
1.4.6
hasprovided
trangene
lines1
V599Ins
nonhypermutated
V110
druggable.
Spectral
Unslected
tosylate
nonhydrolysable
mutatorâ€•model
FGFR3-TACC3-negative
ATACCGAACTCGAACAACGAC
CAPRIN-1
metastasis-specific
HSV-1
–ACVR1
.098
knockdowning
c.400T→C/p.Y134H
gtgagttaa
calcitonin-producing
.Exome-wide
phosphodependent
discontiguous
HPCX
53,61,62,72,82
neovessel
Odero
–5.65297
mitochondrial-mediated
cross-striation
h224G11A
forward-transformation
ARID1B-2188
5J
Ile-59
GCATTTTCTTCAACCAGGAG
*Cells
Sperinde
.2192
delEx1-9
9.4
published.21
p.T1150A
pS660
I-deficient
3,12
24,334
telomerase-deficient
apo-mouse
45–54
MmAGAAAR13
IVS2-1G4A
RAF-MEKERK
mutation-rate-prediction
raloxifene-bound
CFP–MAPKK1
CD4+CD3−
M-Bcr
Fascin
281
5′-CAGTTGATCTGTGGGCGTGTTGGTGAAGG-3′
AHCYL
path—therapeutic
Abstract•
individuals.46
YRI
systems.48-50
Ditchfield
damage/DNA
toconfirm
TrkA-C266S
96°C
8970
68353893
Over-activation
A864Q
^l
GTGGATGGATGTGCAA-3
PerkinElmer
N826S
E346G
CFP-WT
E110K
leukemia,55
www.stratagene.com
domain.14
U2AF145
cacaaccgcaaccacgagtccgt
L833Va
-2-hydroxyglutarate
.ImmunohistochemistryThe
reported.32
Epidermolysa
C8orf54
6680
.Non-quantitative
antibody/input
.cluster
.Recessive
CARD11-Bcl10
NF1WT
Gly-245
Haematoxylin-counterstained
.Fan
si-RNA
R-AXIS
−1.94
+WT
Rumpold
1987b
fate1
6,7-3H
lineal
A19D
6.86
LEEKKVCQGTCVKKCP
neurotrophin
SOX17-M
abouta
Matsuo
Ac-pVLEGFFURPTPp
intraabdominal
R752Q
'25I-MAb
EWS-FLI1-repressed
previously,8
HSCR
D16S520
ependymal-specific
p.Cys275Tyr
siMLL-AF4
TCGA-AG-A002
MH1-deleted
CGGACATAGTCCAGGAGGGAGCCGAAGGGCATGAGC
T82M
.Abrogation
H214N
p.Leu1515Pro
A4956G
VavCre-AtmC
M/77
AE-expressing
RASSF5
pFRT/lacZeo
Exchange—ATP
iNine
p27Kip1RNA
AT-Rich
dH20
EWSR1-CF1
0.46a
doi:10.1007/s00401-013-1095-8
−65
BC083508
P=0.684
Asparagine-linked
EMT.5
types41
NUP98-NSD1-negative
30–95
Lectins
HIP1/PDGFΒR
â€˜ITt'AU
I344K
sc-100908
RESULTS—Missense
Fondazione
0–9
trx-mediated
−7.3
.KIF5B-RET
Flag-EZH2
c.1573C
500μg/ml
T1717
repair-specific
malignancies.54-56
activation,25
needed.1,2,4
8,21,22
D-FISH
life.5-7
thateach
rehybridi/ed
.IV
10Gy
-IIII
S10.2
betaP1
EVI2B
EP400
6.54E05
.52,154
survival90
mutations.31
cancers79
CD391
8,11-14
FAM46Cand
c.3038delA
POZ
'JJ
LacI-CHERRY-BRD4S-positive
P291fsdelC
Acvr1Q207D−c.a
Posthybridization
TolueneO
theexception
d-2HG–producing
1774
virus-transformed
80–129
BioRobot®
overexpressed14
Gain-and-loss
ch15:59.7-59.9
activity37
D17S1166
GEN1
high-degree
EWSR1–SMARCA5
Sarstedt
w22
α-Rpb1
IGF1R/pERBB2
chromatinstructure
Mhatre
sites—the
PPFIA1
pAktSer473
~120
tumors.9
deionizedformamide,10nu
Klumb
pre-casted
anti-Aurora
suppressors18
5a
17^31
3Eo
unspec
A_52_P193265
desmosomes
AlexX
Y92
p.Glu322Lys
Y17F
HCC827/Emp
anti-TRAP170
everyp53-responsive
∼1090
T528M
5′-GCACAATCATTTGAATTGGTTGTC-3′
arrow.https
Pronostic
cholecystectomy
Wiersdorff
dnSTAT5
Stat6
Conductin
13,43,44,62,70
chromatography-purified
Q157R-5
leukemiainitiating
Holo-EGFR
VHL1_1R
Prados21
5'-AAC
17:31095310-
ATB
VEGF-C
proteins44
ALK.13
TGAGCTGGGCGGATACAC
93.2–97.1
Schulz
14784-400
–22
21–66
microdissections
0.864
63675
C290Y
self-renews
58C
ACVP
H323R
ZTF
androgen-depleted
AGACAG/gtaaac
LDQNIMCAIYIYIRVK
BN
u-
contig-derived
NSCL
α/β-domain
seven-transmembrane
.Fig.6H,6H
carcinogen-treated
p53–ARF
3D-G
_C
patients.28
caspase-8L-mediated
.3c
transductions
subsume
available—for
CCCCAAGTTGCCAGTGTTTCT
telomeres
E884-R958
Dnmt3b−/−
N304+C243
-7f
α-carboxyl
A/T
secondary-resistance–conferring
discontinuity
S445fsdelAG
Tris-Glycine
cellular/tissue
unclear.Individuals
RP5–875H18
ATTATTATTCC
L.M.S.
HA-Hdmx-E
AGAAAAAGAA
1–146
TSC,25
RUNX1–ETV6
4810-30-K
Ile31.The
S37A
ıve
phosphatidylethanolamine
S602
RHOAwt-FAM
stage.32
EGFP–p53The
anti-motility
Ink4A/Arf
P+1
mutant-copy
L503V
ProLabel-tagged
cells.Analyses
75.42
Brca1SCo
Fig.2d
B-processed
1235
GCAAAGGATGCTGGGTGAC-3
CyC1
Ola
Δtrx1
SUM-52PE
PAK3
p62-dependent
CDC4/Fbw7-mediated
fibroblasts.35
molecule.39
myogenic-specific
.Biochem
Arid1b
Nutlin3
deuterium
ACC.13,37
23/248
taccaaaag
Pharmacodynamics
Val/Met
p.Ser587fs
GG-62
extrathoracal
9.40
4.5-9.8
1323
aK-Ras-based
Gln125
spectrometric
-7-methoxy-6-
S108L
A123E
Pilocytic
pG418-PDE4B-B
Depict
α-hMSH2-den
32,641.6
440g
P42T
TCF3-regulated
CDKN1A*
expression—a
leukemias11-13
online.6
sarcomas.14-18
phosphate/nitro-blue
TEL541
c.350C4T
10–100-fold
A127V
pCMV-VSVg
IR1–4
BRAFis30
Koukourakis
L790
.S27
E86A
1.288
clinically-relevant
FamilyThe
pregerminal
IC50=350
I/I
vitro19
1866G3A
best-scoring
toreveal
30∥
TTTTGCTAGCCTTTGTGCGGTTCGTGG
betaP1-betaB
Phosphoinisitide
c.1799–1800TG
V1810G
CDT1
607139
JAKV617F-negative
signaling.Neither
like1
pH7.8
suzanne.baker
H69CDDP
lgene
CAGGAAACAGCTATGACCGCCACAATGGTGAGTGCGTG
.Tyr314
CACCACAGGTTGGTGAC
PME/PBC
indicatethis
422T
IKBKE-expressing
T-5293
BRCA2-defective
p61V600E
Lys-162
16–40
Close-Up
ubiquitin-modified
G448D
epidermolysis
.Multiple
Bevacizumab®
Mdmx-deficient
p-nitrophenyl
ETV6-responsive
409-bp
phosphorlation.101
∗p
Puteaux
c.1504_1509dupGCCTAT
−1.64
22040
contexts,53
aberrations.26,27
Gupta21
P-bodies13
compartmentation
CMML/MPN
reversal
literature.107
beenidenti
.DHEA
5V-CTG
cancer–only
Raval
c.1513A
embryos15
pMM15
13BGCGCGGGTACCFGTAGGAA452
construct12
G/delG
5′-AATTTCTCGATTGAGGATCTTTTCT-3′
TBB
10.81
CA43703
Cl-moiety
FCSCOR
MSI.56
Kracker
pathways.The
plateaued
JHUEM7_ENDOMETRIUM
HSC7E1175
DHL
8700
272–354
321E
leukemia.50,51
rho-cDNA
−32
pSG5-RL
apoptosis.72
Leu790
49–52
65°C0:35
_1183+
D\
cytosine-5-methyltransferase
Bax-deficient
5-TGCTGCAGGAAGGTGTGTTTGTTG-3
Subcloning-Point
red/pink
85–179
Thr674
Zumbrunn
cancers/22
16PCR
andtwo
extra-helical
S2-3
extra-medullary
hyrdrophobic
buspended
.Co-crystal
downsteram
fective
sonidegib
full‐
cell-lineage–independent
K48
Ile31
.Approval
www.sanger.ac.uk/genetics/CGP/cosmic/
loss-of-function43
Medivation
single-positive
600nM
4WKQ
CGUAGAAAGUGUUGUAGUUGAUUGA
/N
37,40
THR202
YANG_BREAST_CANCER_ESR1_LASER_UP
Fgfr1a2
50–60
permeabilization/wash
Selak
HEK-EpoR-Jak2-WT
actin-myosin
.Diabetes
EBV-negative
MLL-AF4/4C
exogenou
octahedrally
Long-Distance
RasG12V
E950
interface35
FLAG-BAP1-Wt
.ACTIVITY
VDR
phospho-FGFR1-4
TopHat
per-allele
Eckner
AML1-target.20
–methionine
activators.27
TKIs,12
5′-methylcytosine→thymine
5.1.2
Golgi-marker
nihms774093f9
Cd105
C-amplification
.Peabody
Dellagi
CRI-2
Gprotein
dap
E37-skipping
guidelines21
populations.28,29
HDSN8455-848P
21160301–22679000NM_004432
RING-H2-type
EGFP-expressing
Ahmadiyeh
V-FITC/PI
hematoxylin-
smagarwal
tumors.21−23
Duke–National
l00
PHA-556752
Tumorigenicity/Metastasis
leiomyomas/sarcomas
JAK2C2624A
5′-CATCGGATCTCGTAACGTGGCT-3′
YAL
6.5–46.1
efficacyNext
ÃŸ-CATENIN
0-40
KDB-RAF
B-RAFV600E-expressing
chemotherapy.13,14
IKKα-mediated
p.1236
Skts13
11.0-
accordingto
3/185
trial13
versican
–0.5
hyperdiploidy
Banelli
menin-negative
S1-9
Mastercycler
P281fs*6
C117T1
20/34
1.33×108
C235R
Cascon
10.1593
E026
sequencing-based
managed177
NPM-ALK–mediated
BamHI–EcoRI
3,4,5
70.0
FBW7R465C
InB
position.32
p.V387
BRCA1–M1775R
CD8low
NCT01004224
Ajou
1.02E-2
CRC525
peridinin
H3-containing
5′-TCGAAAGTTGAAACTAAAAATCC-3′
K-Ras-G12C
log-transformed
Immunoreactions
MutSα-C697F
amplitication
lipid-bound
//sift.jcvi.org
.EGF-stimulated
I28
Ser235
TCTGGGCAGATTCTGC
pemtrexed
predictedfunctional
26.2
R-964E11
12-bp
MDM2-transactivating
5q33.2
III.B
DES-treated
TAE684-resistant
hRos-5
WM115mel
100nt
pGST-TCF4
GAAAGAACTGGAAATCCTGAACATTGG-3′
CGGAAACAGGAAAACGAGTCA
-59
e163
AGAGCAGAGCTTCTGGCACTCA
aspreviously
Seventy-four
e8a2
XAF1
studies84
BCR–ABL-negative
5.29
fluorouracil.13,14
Hebrok
800-225-6872
post-injections
-flanking
Used—MDCK
vating
CDDO
LMN
R723Q
haploid-insufficient
RNF115
TGT→CGT
pE3-VI
ResponseWith
K714N
eIF-4
play.209
CS5b
phospho-c-Kit
differentiation.66
59TTGAGAAGGAAGTCACGGAGCG39
non-brainstem
LRRTM2
MM/PBSA
472–478
Tzb
structure.To
9135
.Y17118–Y17126
ERBB2/HER2–positive
X-001
CD16/32
PLX4720-mediated
R265
.Classical
GPIbα
67-fold
0.5–1ml
lung/prostate/breast
808C
www.clinicaltrials.gov/ct2/show/NCT01351103
/PTEN
P68/p73
cetuximab-sensitive
exist15
p53-G245A-4Km
P=.04
pCMV-C/EBPα42
pBABE-puro-K-rasBV12
cytostatic
310–597
3T9
EGFRΔ746–750
HPI-1
ACAGAGTCAGACCCTGCCTCAAAG
Notch-mutated
28.97
kZZ
co-suppressing
pGBD-MSH2
first-in-class
PIK3C-mutated
Oricchio
ASK1
-DR
p.R359X
4′-6-diamidino-2-phenylindole
UM-SCC-10A
1602
558·86
.S6P
DEPTOR-centered
C1-carboxylate
MYC-complex
5′‐TCTGGATCACCTTCTGCTGG
V445M
BFB
receptor‐regulated
156301
HKR3
decay.cDNA
colleagues13
AxioCam
J087
K-120
Ciome
CS06
88–92
Cuad
somaticmutations-EGFR.org
596–601
.Mann–Whitney
PI3K–Akt–GSK-3β
CGH.7
.Fbxw7
Chipster
MultiTF
Tyr-to-Phe
8/no
TFA29
.CGH
promoter.18
DNAcopy19
T→A
telomeretelomere
N-RasG12D
kimdw
sequences3
.BCR-ABL1
HF-2
GI:18490281
//www.cancer.gov/clinicaltrials
V388M
classification.19
109.3
cm3\
becausewe
protein.18,19
methyltransferases,10,11
JNK2
NRAS-transformed
IMDM/20
.RESULTS
.D404GTbRII
mutations,36
DOK4–6
10-35
6.24
CD79α+p63+
R130C
R213T
loop.Figure
non-AER
CIEA
JMML8
calcium-independent
B1/B3
cells16
.Philippe
24,238
+81-22-7178139
I383
EVO
F15
SMARCA4−/+
Oligodendrogliomas
FBN1
GATA3-ext-induced
p.Ser78Ser
LC-MS/MS-based
`++
PIK75
Tiam1
genomes.29,30
myosin-heavy-chain
p.Val840_Cys843del
1i2R
10−8M
immunoabsorbentand
shAR3
S4D–4F
C618R/E543A
758.4
Sos1EK-targeted
L678P
subtype-associated
tetraparesis
25–60
172.
G13.1R
Covaris
Ig-folds
SCT
mol.f.u-tokyo
HG
.Web
GST-RNA
UIM-deletion
R167
RAPGEFL1
Non-specific
involved.In
astrocytomas27
Pro772_His773insX
specific-binding
method29
Levitus
Set1-related
767,1996
kitWT
CCT3
Ke
321A
NIC-GFP/lentiviral
caspase-8-R162I
undifferentiated/anaplastic
NP4O
affected/nonaffected
GT-11A
namelyBRCAJ
S840
HLA-1
pGBMs
225363_at
828–843
producedFull
transistor
986K
N116
SH3–SH2
c.601C
byselection
FFPE/Fresh
Isinger
+5.35
.TPO
2092C4
GAACAG/gtaata
22/22
GP+E86
arrest21
MSH2–ATR
Gallahan
PV-6001
5406
FGF23
32–40
2500–3098
colleagues1
stage-dependent
mock-expression
theEcl136
176K
gefi‑
2026–2171
reembedded
0.58-1.03
17,238
0.1182
m.-
mant-GDP
exon11
pentobarbital
542/545
.285a
65–90
GSK3.1
aTP53
pmGFP-N-rasG12V-C51Y
1.035
⩾50
Hdmx-E
p53-competent
α-NTRK3
Server33
n=4/4
protein-losing
Proteolysis—1
E-cadherin-dependent
crisis.3,12-17
.22,26
nt158T
morpholineethanesulfonic
H11–H12
25–50
transition.1
Ym1
Seventy-three
CDK6-targeting
2·4
Attiyeh
Dysregulation
P.M766_A767INSASV
.-L.
TE2000U
1453
MAP3K6
1MHT
12-hr
38.1
70kDa
2413–2991
MCL
250K
co-existed
mutation–induced
3730x1
.MEN
26/60
Pro151
MPN–
Lys-716
pEGFP–C3
myristoylated-IRS1
ΔKFS/M
developdifferent
Y443Ni
416-813-5974
138101301–138240900NM_001017975
23−5.5LETM2Hypothetical
Theproviral
lagging/bridging
.ERBB2
Q61.2L
15.00
HPRT-F
p89
FAK/AKT/mTOR
P=0.28
Arg177
40μM
59.06
pyrimidines/total
trs.str
.Removing
incentivize
benzenesulfonylfluoride⋅HCl
RBA
R209
clinicaltrial.gov
Cotswold
numbering/FGFR3b
804brate7
E868Ga
few-base
F11**
11/2010
G.A
IL-1–
20.000
Nevaldine
Nδ1
min..
Immunocompromised
spliceosome.5
catalytically-inactive
69/M
Fig.55
Y87N
osteosarcoma65,144
G59A/Y40A
287C
*‡
1.883
Ea21
NotI-EcoRV
.Humanized
6,8,9,30
.Cross-linking
S.K
fos-luciferase
Location/size
anti-cdk2
R1347
Arg86
tumors22
.Piccinin
118/250
reverse-sequencing
1770
protein-truncating
TieDIE
v5.0.1
reports10,11
25-cm2
mASXL1
//sourceforge.net/projects/denovogear/
MethodsTissue
.AKT-Thr308
subentities
JAK-STAT/Crkl
permount
23.7+0.3
E633K
BXPC-3
P21S
JAK2WT-transduced
neurofibromas.12
001810
50–400
5′-CCTAGTACTGTGAGGCACTAGGCTCCTGGCATCAGGA-3′
199/191
S62P
7.84
2-25
Gâ€
pRetro-blast
Intimal
2055
Tel1-dependent
NIH-3T3-transformed
1599del16
Cys393
GAGCAGGGCACCCTCTCATGG
species-
POLYTRON
German–Israel
82y
.2195
GNASwild
conductance
2134-bp
optionsWe
8q22–23
5427
tumor-enriched
CD25-expressing
.Triglyceride
ATATCTTATGGCGGCGGCG-3
scores.30
-propanesulfonic
cyclin-induced
HGNC
steroid-regulated
promoter-containing
inhibitor.21
−1,453
noncraniosynostosis
TTCTGCCGATGTCTTCGAG
R378C
Snf5floxed/−
20q11–q13
RB355
doi:10.1158/0008-5472.CAN-07-1587
o-
Pol3-C462N
MEF/PTEN
15-
diethylnitrosamine
CAAGCAGAAGACGGCATACGAGAT
mg/sponge
K-RAS4B-GDP
signalling30
.0167
.SDHD
UDP
AATAAACCAATTGTTCACTTGAAGG
35,168
inter-conformer
.INI1/hSNF5-mediated
0.682
DCS156
FGFR2-KCTD1
28F
GSE600839
Pfiefer
BRCA1-IRES-GFP
Glu326–Arg333
inant
.Names
clinico-pathological
.S9WT
PTEN/MMAC1/TEP1
Koskela
K526
1.3–23.4
vera,24
L63F
.Afatinib
Dox−/+
Zhang_targets_of_EWSR1_FLI1_fusion
HA-FLAG-BAP1
PDGFRβ74
GBM-021
Ser1396
T1977R
17q24.1
TrueSeq
Exo
Ser474
region,60
c.1151T
758
HN31-C2
Anti-kinase
IGK/CDK6
1/86,000
219534_x_at
R295A
38.48
T1046C
acZ
G364C
SPOPMATH-SBC
P106L-FLAG
Cul3-SPOP
proapopotic
µg–1
J.K.Sicklick
sporadic.11–13
55–63
A646D
leukaemia.6
Saint-Quentin
autokinase
CACNG8
progestagenic
p53R2
Gr-1dim
PEI
/LVDd
Y-shaped
photolyase
NA34
OCI
deaths1
0.25a
-4R
van-der-Waals
4a–b
D3S1262
RP11-154H23
caggaggccgttgcttcgta
543-conjugated
Tchou-Wong
≥6
CAGGAAACAGCTATGACCCTTCCTCTTTTTCTTTGAGG
1-5-5-3
embAJ011003
1.6-6.7
~Kahn
flow-through
cytotrophoblast
ARR2-PB-TMPRSS2-ERG
8.A
Pangenomics
ICN1-specific
Banin
GTPase37
V1
1j
I195T
bait-prey
Ikk2ΔPdx
TP-mediated
AL713790
FoxO3
Arg912
-14G
2-2
SA533
97.45
erythroleukemias
FireHose74
2.80–2.70
L92F
-H
UV-Type
.Baum
mTOR1/2i
TM-β1
Gln-207
E1187G
3.0–4.0
A354T
CTCTCACACTCTTGAGGGCCprimers
674–780
.Crystal
Con-
bcl1
925
c-RAF1
transmurality
47/60
Arg-1775
3'-hSNF5/INI1
//dx.doi.org/10.1136/jmedgenet-2014-102934
vector–mediated
.631G
α-glucosyltransferase
.Ofnote
long-running
NAa
criteria.14
41–138
leukemia,17,18,19
E/II-1
neuroblastomas111
PMCID
0.4325
13qdeletion
counterbalancing
pGT3/DLeu
postincision
cytosol18
phosphosites
Ba/F3-hKIT-Y568F-D816V
JEKO
alectinib
maximum-likelihood
2wd54H
technology.18,19
52,30
Assaya
formationNIH3T3
LKBÃŒand
I-Bgl
c.6631delTTAAATG
35975
NTRK1-004
huckebein
Hyal3
CA13
BrdU-positive
chemist
hand/split
614852
Sunyer
ERK-mediated
.Isogenic
proliferation7
TGCTTGATTT
K-Ras4A
Zupnick
4‐thiouridine
NG9
ubiquitination/receptor
wu102
IVS5^1_3delTAG
.143Activation
TLSMD
allele36–38
4/44
KYSE520
dephosphorylatesthe
Exo/SAP
seminoma.39,42⇓⇓⇓⇓⇓–48
_-v
//www.diagnosticpathology.diagnomx.eu/vs/1450529994118798
p=0.000550
sense:5′-GAACAGCAAGAGCAGGTTC-3′
v2.61
protein-unfolding
13.3
R261
hemangiopericytoma-like
129-Krasex3op
-C531R
.5D
ofimatinib
high-ranking
GOPC/ROS1
CEP14823
.ONCOCYTIC
main-tained
Heska
null129R
HAT.Figure
phenylalanine18
B72
1rc5
reverse-specific
pg/mL
ribosomal-depleted
hMSH2carriers
Amplex
lines.9-11
PREX1
Aquifex
Down-Regulate
MITF/DAPI
R1034Q
3,578
F30
8q23.3-q24.21
Msh6LQ
UACC558
end–binding
KMS11-TKO
patients.15,16
gianluca.spitaleri
TGL
597
cell-speci®c
cancer.2,23,24
operant
235-bp
c.1699G4A
S28
.Datasets
CCNG
Keff-ssDNA
YFP-FOXP1
anti-myosin-heavy-chain
R208L
MET/EGFR
4C–F
quadratic
1290
GGCGACTGGCGGCTTTTGCGGCGCCCAATGTTGTC
.379
6732–1736
MPRIP-
Nodular
pcDNA4c-BRD4-NUT
3GFT
Pro223
level/activity
GelCode
surface-bound
pDEST20
.Desmocollins
syrinx
31A335
Barnetson
wt-FLT3
508C
SOS1-transfected
siBAP1
mis-
PhyreEngine
MTA1-dependent
Rottmann
.793C
E528
7.18
18p.K484_G487del
structure—common
M232T
E317
ArgfsX11
Ser536
AVAVA
SignalStain
T779fs
CD4/CD8+
hSOS1
Hagemeier
GREB1a-specific
ULBP-2-Phycoerythrin
96
Ocidental
BoxB
adenoma–borderline–low-grade
D25H8
P=0.022
G34R/V-H3.3
2.Download
Conformation-sensitive
Electrophoresed
13A
CpC
T157A
.396
antinociceptive
pQE9-RUNX1
.6989
Y223C
5′-AGGGATAGGGCCTGGGCTTC-3′
GIu
KDD
Single-Use
74.8
SP142
2.20e
c.71G
antilipidemic
PF-3
f/89
0K
D13A2
aformentioned
N-domain
5′Phos-GTG
andD
GeLC-Mass
C.P.
XDP
1/32
beenlost
Δ768
Hyclon
Smad2Δ1
2455
4.54x
Runt–Tramtrack
Inter-American
4q11–12
CCNL1
4O1
PER-624
tsr
G2063E
8727
-GCTGCGAGCTCACCCAGAATGTCTGG-3
EXOME
21320
Baulcombe
LY67
GATCCCCTG
N-ras-E49K
Entrez-Protein
α-Helical
template-positive
.Perhaps
27/110
0.1
Ptgs1
W372
organization11,16,17,18
AATCCAGCTATATGCCGC
F57C/ΔS222+ΔS226
p=0.0701
RNA-18
wt-Flt3
fragment-based
NADPH-quinone
non-ubiquitylated
TMAO
JAK2WT-
LP2
1.092–2.063
A.F.A
digoxigenin-labeled
23/90
.Aurora2
IRF1
nonamer
db=gene
R1276
'mark
theconversion
preserved…
Pdgfrbredeye
BRCA1-containing
BPDE
687
LIF
gene_set
acryl-bisacrylamide
ELOB
91/125
75.
Abteilung
∼E8
//doi.org/10.1371/journal.pone.0032451.g006Primary
Brigatinib
ARFRP1
HA-TET1
xlOO
V760M
MED12
234C
pSG5-PMS2
G5144
activity1,2
ANKRD
Non-uniquely
pa-
Niccoli-Sire
trkl7
Q1218
deleted/substituted
RET/PTC1
mGluR
Y824
M10291
TransIT-L1
135-
.C-MYC
.Collected
sitestested
Re-establishing
Naoyoshi
G2–M
Pardanani,2008
migration/invasion
ReACp53
2-is-associated
.EBV=
50ng/ml
GAPp120
GST-MEK-1
ox-chymotrypsinogen
420099
AACATCTTGGCTGG*CTTGAGCCACTCC
wet-fixed
reproduce86
Watertown-Mass
non-consecutive
TβR-I–catalyzed
H3K4/K9
10q21•3
261835STOP
IGF-1R
1093-1233aa
Genitourinary
non–T
0.5272
glucosamine-6-phosphate
i1
MIRb
.Store
calicheamicins
Hopital
p.Lys22Arg
.SNaPshot
LiAC
48hrs
517T-GFP
FAK-B
11Val555_Leu576del/14Thr670Ile
anti-p85-Pl3K
Post-Irradiation
Discussion2.1
Microdeletion
2476
ATCAAAG
67/30/4
exonintron
NM_181690.1
swi2
Klezovitch
Melanoma
ligand-binding-domain
Safley
www.asbestos.com
co-inactivation
Rasmitogen-activated
S5P-CTD
2–85
elsewhere.22,23
COSM1294063
anti-PSA
Monomer
//www.kinexus.ca/KPSS.htm
hemoperitoneum
55-
IgG2b/~
SND1
W489
HSPA6
mono-ubiquitinylated
systems5
4.3–45.9
454-bp
Citifluor™
EUFA265
non-BAT-RII
Cdk1AF-expressing
JH126,34
RAB11FIP1
First-degree
Val302_X863del
Harousseau
93-kDa
Rad51–Brca2
MyoDE12
Simental
NCT01828021
gain-of-function/truncating
H458D
R374W
GADD45-containing
2267
TKIs9,23
=∑mg
phenotypes168
puro-transducing
guanadinium
0.13–0.48
Urano
study.12
pMD
HLA-A*03
weredissected
PuroR
50-amino
14q11.2
One®
1,64
studies10,11
2Y1N
samples3
Autònoma
high-dose
Blots—For
bTMP
c-Kit–PECy7
ribosomes9
.HIST1H1
.CsA
anti-p-FRS2
lymphoma36
L559R
phosphatidylinositol-3-OH
negative-binomial
.2,14–16
C9710
N-lobe
sub-class
.Other
ping-pong
P1386S
Tumor_
activatingthe
p.I252T
t-EGFR
HG-mediated
1.21-kbp
5-gcagttaaattgtgcgctgta-3′
.MRC
D661
5'-TGGACTGCATTCTATTATGC-3
1–415
PMAs-expressing
5′phosphate
described.4,11
Manola
E3-like
.HRP-secondary
non-granulosa
NF1-333-mediated
TFD
.Plasmid
paralog.14,25
M784V
812-
p110α29
non–full-length
//www.jbc.org
prebone
methyl-CpG–binding
Myc-CDK10/CycM-V5-6His
-D281G
Katayose
L54V
71·1
15•2
Protrans
λ-derived
1X=1.51×10−7
APRIL+
14×12
ligand-controlled
GLI1siRNA
E8.5.93
alphoid
MCSP-1b
and3.3
.downregulation
appropriately
1–456
.Strizheva
.GGCTGGGGTCACCCTgtaagtgccccgcccccccgggcactcaccacacg-3
.A.T.Y
DLS
anti-CDKI
70/69
phosphopeptides
MLL-TET1
CMD
transformation.27
NScausing
oursurvey
L-form
PRKG2
UPGMA
siNKX2-1-mediated
c.3045insC
IdentiCell
FoxA1-mediated
tata.PIK3CA
10838
replacment
5′-TGGCCCAGCATTCTCCACCCTT-3′
p.E153V
GAL4-AD
E30V
c.2547-_2548delTA
Downing14
T=tumor
gene-1
agents.4,5
+v-Ras
NCI-H2087
Greenblatt
thetrans-activation
Weak-to-moderate
Somatic/
minibodies
22Bri/J
FLIPI
38-300-fold
TGT-*TAT
FL-independently
cytokinesis11
2.01
+1-bp
T903
doi:10.1038/ng.778
CA50706
cRC220457
W183
Wieczorek
.026PD
genetic-predisposition
1.5min
ZEB1/2.2
haploinsufficent
inhibition39
leukemia.17
Arg249
ofmouse
​,33
.So
type.18
3q26–27
IRE2
DRH
siEX7
38–45
.Arterial
paraffin-sections
fengbi
ALK+/ALK−
p-BABE-puro
.NipR1
mant-GppNHp
2p24-amplified
best-understood
PMPCA
p10–31
Y537K
R224H
D68A
N476K
tSETD2
pSC101
activity6
photosensor
aCGH-based
rs16941
mitosis
0.7419
c.2024_2028del5
β-catenin-induced
Biostat
GIST-associated
dacarbazine65
PDGFRB-2b
1.013–1.101
TESTI20159625.2AKR1C3Aldo-keto
H3K9Ac
3.1Zeo
hand-flapping
ED10
Xijing
ASXL2
POLYPHEN2
MY47
I122K
-80°C
-Pro273
5a–b
limb.20
ARID1A-BRG/BRM
LMP2
.AC
02341066
re-amplified
metaphasic
234–268
leuTable
HCX
p3.1
Dontu
AmpliTaq
case,21
3′-GGGCCATGCTGGCTGCAGGCCCCAAACAATTTGATGACATGTGG-5
L89
2+d/M
FOPFLASH
1,370
Tris-EDTA
Fe-S
2.1.1.
LR11-153
COS1863429
Argc158
ITD/F691L
BAG956
aminopropylamino
0.0206
Xm
D-A2
2.3–8
eye-pointing
60–64
G836S
Japan.38
GCCCCGGCTCTCGGTTATAAGATG
L457
6xHis-tagged
:30
≈21–22
Xanthogranuloma
types.11-
D100A
add-on
anti-inflammatory
LB1622-
GST-linked
G-2607
54.3±20.8
respectively.3
non-dysregulated
38*
T47D-SPEN
WISp39
γ2A-Jak2-V617F
ab6672
Vav-cre+Asxl1fl/fl
//cabig.nci.nih.gov/caArray_GSKdata/
age.12
=0.03
-4-piperidinyl
second-ranking
R229P
F3
∼228
Iq41
2.61×109
GGGTCTAAAAAGGTCTGTGTTCC
TPR-MET-H446
geneticists/cell
TCRalpha
MPCEWS-FL1-1-T1
ST-EPN-YAP1
23/1293
normospermic
S4O
CSL-binding
non-dysplastic
logarithmic
IIH
EGR-1-binding
malignancy1
.Colors
Synapse
p16/p19
recurrences.6
//csbg.cnb.csic.es/mtserver/
.1681C
H2AK119Ub-containing
5-6
malignancies23,24
46.4-57.5
V53C
hexahistadine
RhoAspecific
T294P
Al1aâ4€4
Rachakonda,1
TTTTAACCCCGAGTCTGTGC
2,329
R537P
C6orf204–PDGFRB
40,42,96
.34
fear/anxiety
5−12
JB4
U12
18096
HER2receptor
Y1235D
IGF-R
S256
holotransferrin
.Supplementary
.T-
EVO_ECOL
EGFRvIVb-identified
,2b
Pleiotrophin
R659Q
F1223
p.Asn34fs
5′-CTCCATCCTGACCGTTGTTT-3′
L2035F
sequencing.26
leiomyosarcoma.15,16,19,20
SDS/polyacrylamide
.BCL2
1782
c-erbB3
Jun-N-terminal
miniMacs
minipigs
NM_008179
Rb-E2F
Y173C
4-stranded
LC480
tumors.11-13
hg
valine-to-tyrosine
debated73
ElonginB/C
Rb-mediated
cancer.Table
Trinucleotide
−66
D87/D90
v2.1
STAG2-corrected
**Results
7/304
GT1795-96AG
E1384K-expressing
structure.14
X-chromosome-linked
D/CDK6
45–55
2R2G
ERBB2-activating
FRS2–SOS–GAB1
Dia2
P110
Ha-RaslRaplB
R26
BRCA1-independent
dx47
BTB
Kmt2dfl/flCD19-Cre
cells8
48±8.3
motogen
sh-Contr
.Fibrosis
2fold
ab80
p.Gly207Glu
glucocorticosteroids
177-
10.Q331R
RESULTS•
mutants,11
promise192
444
genotype–treatment
PJS08
RUNX–ARF–p53
Multi-tissue
.94,139
PTEN-like
byflow
lociDinucleotideD2SI23D3S1067TGFÃŸRH
HDAC2-deficient
ZnF
XP-C
0.124
613707
siControl2
infection/transplantation
CCG1CCG
Druker
anti-Flag-antibody
gene–inter-gene
presentedwith
non-reference
33,672
metachronous
EcoRV-DNA
B-Type
Kawame
RP11-436J4
5′-GGGTGACACTTACGAAAAT-3′
Neonatal
SH-SY-5Y
IGR
I/thrombospondin
Absorbance
FAK/Akt/mTOR
evidence.4
45°C
mutant-p53
KK4702
nontransplanted
Surfact-Amps
fsinsC
stimulation-induced
HMTs
V1804A
0954-691X
.Rheumatoid
interrogation
KREATECH
4LV6
Granulocytosis
.TCF-4
meticulous
p.Thr599dup
tumors.1-3
T185
Morali
gp11OPrOtO-rk
RAP2A
L50P
sc-133
.Transductants
BCR-ABL1–driven
7he
glioblastomas30–32
aGenBank
Del-5
EGFR–PI3K
MED15
21914
AlP
1q21-q24
mg49361.f2
DuPont-New
WZ4002-resistant
WEHI-3B–conditioned
EPD23
^6071
Bouchlaka
UBE2A
estra
swi2/snf2
r-T
43.53
6.49
W.R
further-differentiated
15,19,20,21,22,23,24
BC233A
293T
PCR/RFLP
PBS/0.1
38.66
Fig3B,3B
11q14.3
Ltf
CDC73
Gutgemann
U/μg
Immunother
∼1.0–2.0
16.00
EGFR60
TRE-L2-CCTACCTTGACCAGTCGGTCCTTG
mc1–mc5
FRA7G
Cedars-Sinai
c.5216A
bHGVS
L469V
172–374
T1010IWT
Krasnewich
374-385
Lkb1-deficiency
Electrospray
16HBE14o–
GPLOTS
ddi476
8p12-p11
//portal.biobase-international.com/hgmd
ENDOU
gpj40Proto-frk
PIK3CA-driven
Duesbery
gluco-
desorption
Val1010
hyperfluorescent
apoptosis.68–70
tissue2
non-enriched
p.R273C
basophil
p.56_61QKQKVG
BaF3-cell
Non-recurrent
120,000-dalton
Flusberg
0.262
3.Detection
30295.
survival.3
Erratum
alymphocytic
1,469
to12.976.8
.Ser35
27.82
RMA-normalized
pCR2.1-TOPO
Ultracentrifugation
elsewhere.23,24
empirically.4,5
5′-FAM-ACCACTCCAAACGCCGGCTGATCT-BBQ-3′
-array
daily.7–9
GISTs.2,24As
TRAP170
α-subunits
PV/idiopathic
6.5±4.5
SKP1-CUL1-F-box
high-arched
100-amino
Kanamycin
phosphorylated
Immunohistological
BMK
Ikawa
.096
G158V
053
paraYn-embedded
:FUS1-lacZ
GraphicPOGraphic
RTJ1
SectionDiscussionGene
.CDKN1C/p57KIP2
VD858
.2646delGinsTTCT
CD83
I–positive
G93
71,000
and4E
gene.68
p.A18T
36004
micrometastasis
Holm-Šídák
0.9M5
GST-Cbl-RING
activityb
448-lagTA
PBS/
ÃŸ2-MGantisense
BCR-TK
nonanucleotide
Buparlisib
curve.Further
GCAAUCACGACUAUAAACATT
Notch1/c-Myc
*Five
RhoA-WT
L151
SequencingAll
MluI/BsrGI
toxicity172
WI.Serological
4a–d
IDH1mutation
10.3±3.4
Sos1-ex6-rev
white/pink
carboxy-
GGCATGAA-3′
WNT3a-mediated
TCF7L1–KIF1B
RasK104C
N-RAS-mediated
less-resistant
Seventy-nine
Non-idet
circumscribed
SeqLab
Ala-133
103K
F112S
M1286T
51–75
MEK1-C121Snegative
-extended_genotype
9.5±7.6
Woude
1-dl3
architecturally
Mahony
.Kedde
0.029/FDR
Âst°omach
network/canonical
15th
.E909G
CARMA1-expressing
anti-IRS1
non-gastric
translocation.9
D538G-ERα
ASP-64
E6
6,18,30
detected/counted
Thedominant-negative
FBXW7-mutant
L25A
CD19
anti-thymocyte
Ser473/Thr308
N269H
14.23
.Relevant
All-Stars
p85-binding
cullin1
no-drug
kinase-inactivated
6/306
anoikis-resistant
substantiating
H1α67
S784F
158808
inflexible
anti-phospho-H2A.X
three-dimensional
409†
5′-CCTAGTCCCAGGGCTTTG
9.9-21.9months
Martíneza
15–3.2
SY5Y-TrkB
.1096c
8-independent
525–560
FANCL-W341A
Glu642Lys
LacZse
toclarify
609-258-1704
493.2
2-mercaptoethanol/1
Shanafelt
Cartesian
K-RAS,6-10
ZR-75-30
P422L
Pickering
reported,16
benzamidine
tachyarrhythmia
MDS/
sensitive.30
anti–phospho-MAPK
semiconfluent
PJS055
M1659
AZD1152
BaF-3/Epo-R
.826
142
common/recurring
pEMH17
DYRK3
p.Q207E
Multi-Array
shCRAF2
0.1–0.15
L858R.9,29,30
S1457Q
LexA-hMLH1
binding14
X82786
at370C
β-linked
EWSR1/ZNF278
myeloid-repopulating
anti-phospho-c-Met
pLenti5.5-IRES-GFP
p27Kip1
NLS2wt
pLXSP3-puro-K-Ras
PCR/SSCA
acid-deoxycytidylic
DNASep
.Tab
GTGAATGG-3
ALB1
Debnath
v3.2.1
5′-CTTTCTCTTCCGCACCCAGCAGTT-3′
FANCJ-K52R
anti-NKX2-5
rs9916423
TP53.47
EWSR1-fusion-encoded
canonic
lossof
Q804H
motifs10
auto-inhibitor
open-reading
1.11–2.70
//telomerase.asu.edu/
performance-status
centrocyte
IR-stimulated
thefull-length
p38a
104–761
GRE-
hoge.txt
R56
KIT46
B220–Pacific
LMO-rearranged
.Definition
1835STOP
FIP1L1-PDGFRα.70
WHIM20
cgap.nci.nih.gov
A2Kio/J
CDC2/CDK2
3σ
and1C,1C
MERCK
SALE-EGFRL858R
Rab25
SFRS
interchangeability
5′-tgggctccataactgctttc-3′
.RASY71H
AR-non-specific
Twenty-four-well
4474004
90209651
Tirumani
.Scientists
pathway.24
d–e
Mb–DCC–0.19
1b-3
III-dsRNA.25
162del
StemCells
axin/conductin
IGF-1Rβ/IRS-1
Rbpj-
EBV+
TERT49
1,2-dioleoyl-sn-glycero-3-phospho-l-serine
SphI/XbaI
Enzinger
Garcia-Montero
300–600-bp
486
muta-genesis
pCRTM2.1
Gain-Ratio
17N,69N
9–35
NipRF1
R240A
age−
549–571
ketoxoglutarate
EMEM
MAP3K110
SNI61
2546
Hinderlich
His8-tagged
baculovirus
D.-W.
transgenic-mouse
pDEST12.2
TSC112
SGK2
Exogenous
cHiPLC
c.913G
−367C/T
5.0–6.7
samples,34
Alfred.Wittinghofer
ddH2O
polyadenylated
database75
consensus-related
L580R
Courtois-Cox
cisplatin23
Gancyclovir-resistant
scapular
synthesis.39
proliferin
CXCR4-dependent
LogEC50
lrz.tum.de
devascularization
MN–TEL
T-ALL81
AlCL
jaeyong
ALR
Serl
energysensing
motif-mutations
MPLW515L-transduced
0.0040
.Welch
RP11-444G7
Otolaryngologist
5.2-kb
.Myeloperoxidase
NM_053142
EFS=event-free
Glu99
activation.9,10
QuickChange
_FGFR3TACC3_
T1151K
ineffective.2-6
history.1–3
lysine-substituted
TGFJ3RII
c.2533G
O'Driscoll
Bcl10-coding
.uid
Guzmán
.Vicente
IκB-α-
KDfl
c.2271G
nonmethylated
.White-cell
PD-0325901/PD-901
IKK
elsewhere.22
GAAGCTGTCCTTGTTGCAGAGGCATCCAGGCGTTGTCC
651–656
deficiency111
I930M
26·9
p=0.055
BCLC
Ietraploid
265
.Bin-Bing
V139M
73.5
M18fs
NM_000435.2
tyrosine-823
fluorescein-labeled
2376
LGG
.Ala
*9A
C80
disease30,33–36
0.82-1.43
V545A
.11B
interphase/telophase
38/48
3-1-8
FBXW10
.Hardy–Weinberg
Broudy1
.Cytokine-independent
TPR–38
imatinib-specific
ampli‑
BRCA1-interacting
Her-2
Inpp4Bflox/flox
IH-300516-05
hoitntlnries
68.32–68.45
1094C
Ligand-activated
±15.5
.016Exon
Funakoshi-Tago
G796S
keratinocytes
pre-cleared
structure.24
HER2-PI3K-FoxO-survivin
N-terminal-truncated
BDLC
Asp870
Tighe
15/56
GenePattern44
phenylindole
N2912D
ExoSAP-IT
G686R
Martinsried
HIKRLR
12·8
LIN28A/B
-unresponsive
cbt-15-428-g4
RASU2
TSGs.11-14
GST-p16'NK4
melanoma.20
sense/antisense
.Hybridized
40.0-73.5
cytomorphology
80–82
R216C
.Products
MLL-AF9-mediated
mutatorphenotypes
Golsteyn
2Å
Myc—Fw
nonassessable
KIT-ΔWK557
PCR–RFLP
DNAzol
2656–3056
repair-defective
Axin2/cyclin
Gdf9
multifunctional
2.718
reexamination
Jeoung
BLASTP
A16-4
ysH
p.G13D
Diffuse-type
.Vpr-and
*2.5
low.37
pathway.123,124
U-13
testing—samples
pathway.5-7,22-26
Em-pim-1
KIAA0677
63x
genetic/phenotypic
U2af1
Y627
Axon
CACTAGGGTTTTCATTTCCATTG
16/46
FGFR3K
Neh4-Neh5
HPA015825
Tsc1fl
Ni2+
Ludes-Meyers
pN2
164-173
cancer20
PTEN.R189X
P53R2
e.g.Φ
straA
β-cas
folded-to-cleaved
plasmid-based
ELZINGA
4738
.Phosphatidylinositol-3-0H
CMV-Cre-dependent
E137G
Consanguinity
1309
156845
shown.Genetic
Q91715
IFN-γ–treated
TKI258
NM_011582
lomustine
61/75
L550P
segregant
poly-l-coated
models,24–26
3.1myc-His
plasmidsa
bow-tie
MD10
acetylcholinesterase
R289
Asp701P
hepatobiliary
areinduced
sclerosing
88800
p=0.793
cis-autoinhibition
HincII/EcoRI
PKB-PH
P.A840V
514–552
SMILLIE
10.1-fold
3891
0190
4',6-diamidino-2-phenylindole
.Pro124
n=9/9
examined.23
.305G
HiSeq2000
amplified.17
Treeview25
ΔS
core-binding-factor
.NHEJ
R574
DSBs19–21
Smad4-deleted
A*0243N
alaninate
L858R+L747V
5′-CAAGGGCATCCTCCCGCTCGTGCAGTTTCTC-3′
Let7
1BC8
SYBRgreen
POM121L12
Hth7
p.H169Q
3.13
pCR2.1
CAMK1DT6TP53
F328V
27/44
1,182,802
32-
loci22/6
HER2-based
areclearly
radiography
1-2002
CellCultureandTransientTransactivatlonAssays.HeLacellswere
a=47.7
Huotari
Liver-Biopsy
-GTTTATTCCGGAAACTAGTTTCAAGAGAACTAGTTTCCGGAATAAACTTTTTGGGCC
DDX1
0–29
NCT00958971
CAGCATGAAGTGCGAGAA
Mx-1-Cre+
broader.11
MDV+LEE
p21-5′
.EELS
PTEN-WT-expressing
sequence25,26
OGT.93
Segundo
d.
Asn1643
therapies3,5–7
p.Asn382His
Risk-associated
.TβRI
p53null-like
quality/depth
Leu-123
PDGFRA/r
1.78
Fluorescence-conjugated
hypothesizedthat
EBPα
resistance.ResultsA
electrophoretograms
Hydrogen/Deuterium
Thermodynamically
Arpino
Taxol-induced
PPNK
1PR
KRASG12V-initiated
-ERK2
1Y340DY341D
INI1/hSNF5
citrate/0.3
GCTAAAGCGCATGCTCCAGACTGCCTTG
T287A
all-in-one
1848
~64
c.2590GOA
counter-receptor
during-treatment
gtaagatgc
EcoRV-HindIII
1.22Å
kinase-insert
G440D
p.Arg596ProfsX23
algorithm51
Q1178X
Cawthon
rs104886013
XP–CS
WT-MEFs
W5b
nonphosphorylatable
pMD2G+pCMVdR8
WWC2
Lutchman
~~~~
VEGFR-3/NRP2
phenylarsene
3/89
HIFβ
5915
microinsertions
.Biomarkers
AMDeC
amido-black
2.9
development.12
A2/A3–restricted
CCC3CGC
iniinunoglobulin
.00780
KI
D6-hydroxyl
2007.1
plakins
anti-CD11b–PE
P=0.132
FIP1L1-PDGFRA+
intentionto-treat
G12/13
LHβ
16/80
hydrolyzed
.Hydrogen
P13S
Lkb1-SL8
42–67
-7-TRAP170
1.302
monotherapy,12,13
Ser236
0.015*
sarcopterygian
171400
D3S1029DIOSI97
SCID-Bg
L-21
Curry
HA/BrdU-positive
3μg
0.65-kb
CCTTAGCCCACACCATGAAA
stress.13
sc-85283
sample-size
METamp
13Val654Ala
noncategorized
FISH-mapping
Boehringer
precocity
.Perner
E55
N=2
disease28
signaling/cell
MDB-MA
JAK1-mediated
glioblastomas,3
AL132656
GFPlow
98.46
p.Ser230Leu
fracture13
.Rwork
266–267
forsingle-base-pair
.G390D—The
R-Hyper-CVAD
71103
p63high
CCD88A
1,037
RHO-binding
switch.9
GST­
K14+K18+
ADH1-based
Asp493His1
OX40-KO
1−9.6SFRP1Secreted
centro-some
19°C
.Blots
68,83,85Å
193300
Immunoreactivebands
Ser1028
ITDtransfected
2000–2006
Figure2B.2B
S1832P
24,30
ascending-graded
−229
ptata.PIK3CA
–Y
Flowscheme
c.631G
0.21-fold
ADAM5P
~Darmstadt
pEFm6
453delCCTT
0.156-0.351
p.Arg229X
identifi-
VE-7800
TGF-β–regulatory
.Dysgerminoma
0.8674
27.79
Endometrioid/3
self-healing
anti-Sox9
light–exposed
Seung-Woo
C.A.
loxp-stop-loxp-KrasG12D
∼135
clari®ed
phRL
FGFR3c-K650E
R389
GP2-293
GAGCCTGGTGGTCTAGGATG
202/295
Flt3-ITD.We
EGFR-Amp
Gln-
B220/CD45R
G761R
.Fusing
NES-bound
PR93
43/71
x10−11
344
vimentin-negative
EGFR-L858R+H870R
that—by
65
bFGF
.Arnt1b
1753del3
L44fsdelC
non-TN
Lehto
Sample012
.NB
integrase-targeted
.Approaches
.Soft-Agar
weight-average
non-AC-fulfilling
anti-phospho-VEGFR2
Tuveson
LCS041
size-ranges
CCATT/enhancer
n=520
Keam
Electrophoresis
RAB27A
0.058/s
pGEM3Z
en-
TableFull
boundary22
21/40
15002
1,14
SSC/1
Site-II
pat-
Klucel
tetramer-incompetent
CIC4120
CSF-1R.6
RET804
Qx200®
HR=2.723
D16S663
.Modes
™
GMR-GAL4
.GATCCGGCAGCACAGgtgagcggcccctgggggcagtggggccgaggctg-3
ADSS
GCAGC
Cytokine-dependent
antidimerization
Nfinal/Ninitial
Nakashima
mutS-KA622
12917
mouse.32
Ras-effector
15.11
hypothesis.3
GAT→GAA
pGL3-Basic
REDEDEIEW-NH2
tetranucleotides
protein3
proofreading-mutant
al.219
9/16
.Inability
1,000-fold
22-fold
surface-biotinylated
D419
Ex18
Aurora-2-adenosine
.Hormonal
gene.29
Southem-blot
x=.,2,3
V867G
Supek
Y185
crosstalk
dasatinib
sc1656
.Radioisotope
//www.ebi.ac.uk/arrayexpress
18–80
/injection
toluene/isobutylalchohol
deglycosylation
Neurocognitive
immunolabeled
*VU-ucl
Girardini
therapy21
1/335
c.1852_1853AA
Schro¨
terization
matrigel-coated
TGGCCTGAAACTGCTCTCTGACTT
self-governed
5792
DSGIS
ibility
ofBCL2
instability.Figure
L108P
6/23
NCT01772797
.18,24
Scl
cobas®
H1″
cbf2/ndc10
-hydroxysteroid
ΔMBII
anti-
.Baugher
gliomas,9
25-μL
Brunak
Euhus
SAM-to-BAM
TBL1XR1
Lingbeck
7.03/Mb
mouse.16
5′-CAAGATCTCCATCTCGGCATTTGTGGGTGACAGACGAGC
.90
F2.50
yH5BAEAAAAALAAAAAABAAEAAAIBRAA7
T790M/L858R
Notch2.39
bccrc.ca
site/type
28/36
3,102
5330
tonsillectomy
Gabay
ρ
2KR
24.0+
Giacca
S-adenosyl-L-homocysteine
hypermobility
.-H.S.
88:408–415
Chiraz
C334S
andEcoRI
Kauntz
pre-selection
0.89–1.45
NCT01520870
hobnail-shaped
Recur/progress
24624/24626
a12-wt
strong/diffuse
–Mdm2–p53
quenced
c.475C4T
time/activated
remitting
SATB1
missegregation
knock-down
.Lysine
therapy,44
Mitogen-stimulated
association108
1p36-linked
ACGTAGACGTTTTATTAGGGTCGC
PDGFRA-mutant
ErbB4sc
lusc
1.6:1
324
unL
|139
mycTiam1‐C1199
78–100
11q14.1-q25
3.193
variation.10,11
Co-A
5′ATR/3q23
CyChrome-conjugated
WTPTEN
40,43
loop-DFG
nSH2
short-limbed
D1739E
.HPA001906
1060
S6Kinase
B16
.Significantly
described.44
I365
Zn2+
ZEB1/2
.Error-prone
58C×30″
Seiyaku
.ETS1/PAX5
nuclear-localization
K018444a
SSC/70
53–60
double-immunofluorescence
interface.6
conformation12
DHAP
v.1.0
plescin
5′-CTTGGGCTACTCCTTTGGGTCTGCAGCGGCGTCCGGGGCAGTCAGAG-3′
procedures.30
RAS-mediated
10–98
Bouscary
nonsyndromic/unselected
non-covalently
EGFRΔ768-specific
TKI–naïve
971
NUP88
S71G
hyposecretory
BRCA1/2-associated
BCR-Fw-T
p.VGPKNS-to-NAAIRS
Antibody-chromatin
Medicine31
snRNAs
5018-5021delTCAA
∼12–26
c.6866delC
TAT47
.Gz2-K-R-K-R-K-S
.Stronger
S970073
5D2
classification2
eachcelltypewascomparedwiththatof
MSS/MSI-L
32–55
12/17/14
HSP20-like
Cys151
Luminal-mRNA-subtype
WM3862—harbored
change-point
I1858L
Gly-X-Gly-LysThr
I3XP3
S257P
110–1000
8/9/99
F4132
function.16,17
2,7,8
tubulo-papillary
2.6–3.3
respectively.5
Bombardieri
c.3610C
ERFm1-7-expressing
.ABSOLUTE
MmAGAAAR3
mice.28
Micecarrying
c.472delA
TETr–RB
2985
5′-regulatory
41cER4.34
5q23.2
50-177
S478N
10.32
Greffe
D556MED,27
T66T
1708,46
patientThe
SKMEL19
growth-inhibiting
13·8
49years
Brandford
Keap1-binding
loss–induced
al.39
pGP1
Figure2b2b
BimL
.8035G
111.0ANPEPAlanyl
PgR636
E92K
Inc.Peroxiredoxin
mutant-driven
Msh2pMsh6p.Consistent
CK14-negative
checkpoint-correlated
great-grandparent
Miescher
NF723
.Local
8A21
vcfutil
P190H
transcription–PCR-single
POODLE-S
—time-of-flight/mass
G-type
45Â
zaprinast
.HER
Tyr127
angiogenesis93
5′-TTTGGATCCGCCACCATGGGAGTGC-AGGT-3′
anti-phospho-IGF1R
Transgenomics
cKitwild-type
Glu1505
HDFtVKIGDFGMtRDIYeTD-
RAA.1
pT7-7-SOX9box
-hlt
d-2
150V
anti-HNF3α/β
membrane-dependent
556,183
KPGTMSPEAFL
c.4693+1G
miR-301b
glutamine-61
andFo
somatic-p-value
signals.5
=15-5-7
a:4N
www.biologia.uniba.it/rmc/
S-scores
studies2–9,27
IL-20
activation76
150000
C.G.K
1.00–3.42
HER2-overexpressing
Cytoscan
GGAGUGCGCUUAUACUACAtt
C634R/V804M-mediated
'pocket
GSE40989
BCL2-family
FLT3/604F
-426
1150
Biotik
N98
Anti-proliferative
Mutationa
6.7–5.4
interference21
ΔDeg2
multi/binuclear
RACE5
gastrectomy.4,38,39
0.01787
non-transgenic
2_790
E545K-NHUC
region14
∼800
S5.Next
PS00107
Tumorigenicityj
c.1939A
TCTCGAAGT
27–51
Carrano
IL-9Rα—ALL-associated
294–342
39/14
1KCl
5′-mouse
infiltration/aggressiveness
Rac1·Tiam1
Oligoastrocytic
930
Zyppy
reported.22
1–38
13.08
ATPa
Asn540Thr
Eschwege
hypermethylation5
de-acetylases
Melkunie
350–2,450
gene.16
Osnabrück
ERP001575
deubiquitinase
frugiperda
WDR5
anti–CD56-APC
bcl-1
gastroparesis
1.7Å
dye-primer
sc-21572
LREC
p.1259
V-positive
.O-GlcNAc
c.346A
.Calvin
foractivation
6H
66.9
/3-network
DEAE-dextran-chloroquine
subgenomic
actin-CreER
non-destabilizing
MEFs.A
cases.1-3
n=700
7-82
Divergent
ACTCAGAAGC-3
PRKCB
tumorigenesis.20
lanperisone
ALK88
moleculardefect
406–557
Brg1-deficient
codominance
nition
BRCA1-GFP
signalling28
284.4
APC1941Δ
resistance.51
*Percentage
multimers
15,16,23,27-30,33,34,36,37
Latsmediated
Resected
34–46
0.7926
208:66
21,000,000–25,500,000
RFP1
MLL-forward
caveolin-1
overestimation
KN-62
single-cell
glycogensynthase
5'-GATCCTCGAGGAACATGTCTAAGCATGCTGCTCGAG-
Il1b
22-Å
KIT-induced
VEGFD
-intolerance
I128N
5′-biotinylated
Affytmerix
anulvsis
.KATOIII
Mx1-cre
4,30
CGC→GTT
ntegemieDAo
164860
PlGF-2
0.336–1.099
Ink4
OCCC5
P640L
asssays
SM-AML
PEM
l2rgtm1Wjl/Szj
CTAD
IRD800-labelled
40.0–97.2
23-kb
71-18
dPCR
h3
Flag-INPP4B
interconverted
CDK4-MUT6
diseases,2-4
.Calf
230,000
SWI/SNF-like
SIFT39
single-guide
PAK1+PAK2
8pter-p12
Rethmeier
chr12:12,037,415
Schuster-Bockler
Δ4–8
pWPXLd
1.278–6.806
VAST47
/RARS
focus/106
neuroepithelium
cognitive-psychiatric
171,229
6.25X
'effector
pCMV5-Myc
detail.10
ICAD-DIFF45
rs10088218-G
97-64
untrasfected
21:60-65
ZFP36L2
V786M
C2709T
stimulation,2
U0031
MAP3K1-MAP2K4
unknown.1
urethane-induced
V14L
report,7,9
Pull-Down
homeologous
Kdx
median-overlay
GGCTGAGAGAGTCCTGTGTCC-3
precipitation.26
midsacral
cullin2
E928
PTENR233*
.181
pathogenicities
galactose-inducedBJ5464/pEAE20
zerumbone
everolimus/pazopanib
5'-AAATTGGTATAAGCCAGGAG-3
.S4F
TCR-Lck
complexes.44
transcripts.13⇓–15
.2000.3839
IyVa
BRCA1*IVS19-12G→A
J005
phosphorylate/
Fast-flow
Gly-484
CI-1033
selumetinib.11
tumor-Δ
bindthe
msh2-GD693-PD865or
Cell-survival
25-2007
0.307*
denileukin
GAT-for-GGT
L570H
5′-ETS
TAL1-
derstood
ATR–ATR-interacting
.Calypso
hydrolysis.16
1185
ALCL-related
monosome-containing
16104
140K
dinucleotides
A3529T
6.-Amino
ClueGO
2013-1-70
subgroups27–30
xmparaffin
50/49
95-kDa
KMG
TGGGATTCTGGTGCTGATG
cdk417
R12K
boxWith
GST-AR-AF1
252.5±145.6
Astocytoma
SK-Mel239
GI:450351
MERCHANT1,4
humans12,13
GxGxxG
paper.19
Gliosarcoma
SRD5A2+
valosin-containing
Dynabeads®
5′-GG
.C308
signaling4-7
KEAP1-CUL3
478–494
3.525
24624
c.1688G
CH-296
Erk/MAP
380-residue
study.29
2,048
PTH-Cre-negative
tumours35
neurofibromatosis.1
V5
analyzed.27⇓⇓⇓⇓–32
Bicine
Tsuneo
nt1
HA-Fbw7-expressing
CGAGGGCCGCCCCCTGCTCA
3044.0±311.9
N90I
2A91
Y1045*
.Properties
Akt8
factors31
IL-6–independent
p.Gly312Ser
Clayton-Smith
CD13
oftheB2m
.HT-DHL8
HIFα-regulation
MLL3–CHGB
P21and
Genephor
0.916
PBD12
slsn135
Gln412
rs104895438
Gro
reinstitution
wasPAX8
AspGraphic
.ATPase
E3-independent
animals/group
p.R418G
-hydrolyzing
329/672
MED12–Cyclin
P262
non-labeled
Jak2-
Tumors—β-Catenin
transMedical
–RT
AP2A2
S.Ellard
LOH/allelic
PC374
Lewandowska
TEL-JAK3-transformed
co-located
.ETS1/RUNX1
intestine29
A1A
v35
Eµ-Myc/Dnmt3b+/−
89.3
KEAP1-Mediated
hairless/LAG-1
follow-upThe
Anti-phospho
pan-tropic
HER2also
nitroxide
.QPCR
Anti-HER3
siRNA-resistant-WT
182.0
.His6-Ub-conjugated
G242fs
Meox2
I654V
Pro261
ErbB2-driven
1,556
p.Glu322Ala
protocols38
2-KG
0.514
∼30
500uL
Up-Regulated
6xHis-WT
51K
strand-rich
non-haematopoietic
.Intron
atheroprotective
targeted.8
pLentiPGKpuroDEST
NUT-BRD3
MACF1
11.47
absorbances
HLA-DR
missense-mutated
-IL-3
899
NUTM2A-CR2
double-tagged
5′-TATTAACTACCACCTGGTCCTC-3′
52‐year‐old
.F328L
Kelch‐peptide
11.14
Goksenin
Nakamori
v2.4
CRC328
T45M
anti-CD18-phycoerythrin
RAB35Q67L
P159T
intra-focal
Arg262
pLM6
N561
DR.
described2
IL3-driven
5'-AGCCAGTGTGCTGAGCTCT-3
azide-alkyne
tumour.Copy
368-1166
1p36.33
Hirschprung
β-helix
HERVK22q11.23
Fig.1a
L152M
leukemogenesis.The
.Redundant
–RBX1
.Actin
.Incorporation
lyser
p.G274S
orHIP1
miRBase27
DAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVG
10462
000059.3
biotin-coated
N425D
retroviruses31–33
E276D
expression.13
5′-ggct-3′
BM2
Ctl
RPE1
SHIP2
overexpression/active
SYBER
KEAP1–CUL3–NRF2
Anti-β-Actin
.VX-680
Glomeruli
destabilization49
Asp142
PIK4β
base–repeat
24·1
S60–S118
5′-GTGACCGCTGCCTGGCCATGG-3′
dermis12
Angioleiomyoma
PARsylation
TFAP2CΔN220C413
dXTP
.Regulated
1,305
slow-release
AlkB
Akt-derived
E315A
R1276P-NF1-333
Concentrator™-5
IVS26-20C→T
Arg-268
proteins,24
synaptopodin
H-21
interaction.10
Xnr5
601399
S5E
5′Fam-CTA
contact-dependent
cmd=rps
6827
Phe709
pET-21b
Ile836del
reciprocality
NM_007900
.Hematopoietic
gaactgtgtgcactcctatttg
IL-22-producing
indolinone
34.3
Filtermate
FcγRIIB
582+
1R2G
D.S.Where
CCTGCTC
N07
Vav-Bcl2
SUM229
XL-related
metastasis.88
micro-insertions/deletions
childhood-associated
I2005
mucus-containing
A787V
S8D
Cédric
BOX1-defective
159.3
K/D/D
Lucchesi
V915
frequentin
Streptavidin-Biotin
UPMM4
M13F
CDC2
Y1234Y1235
signalling1,2,11
kinase-signal
activated–NOTCH-1
Tesaro
1–526
G1-stage
L858R*
p18/CDKN2C
.SPAG9
Asynchronized
3.22–17.00
Pten-deficient
streptavidin-peroxidase
10q-22q24
ZC3H7B-1190F
NSCLC38
Leu-539
directionsAchievements
WT-Positive
rs139480
analysis.27-30
MLK/MKK/JNK
erosioninduced
knockdown.4,5
N-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-C
A3845
W844C
CHP100
a−c
1LF0
35/88
OCI-Ly18
TANGO47
Ref.16
DDB1
1796
5′-ATTACAAGCATGCGTCACCA-3′
2Alameda
P-box
E0411
J.-H.M.
GCAAAAATGTGGTCCCGGTGTTCGACCTGCTGCTGGAG
Fig.7B
mono-ubiquitylation
Kitl
Igh-V
estimates.33
adults.1-3
selection4
Biotinylation
SHC-Raf-MAPK
locus—one
3.9-fold
LaJeunesse
R642*
AR-TRAP220
/lymphoma
5′-GATCGAACTGACCGCCCGCGGCCCGT-3′
EWSR1–NR4A3
Vitry-sur-Seine
c.593_595delACT
anInk4A
//www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi
V1.2
TRiC-substrate
Tefferi10
position.31
adhesions.34
a/w
Maquat
Europe.12
-L-X
Conclusion325
sp.
antitrpE-trpE-GAP
16.3+
−4.42
orientation9
5′-TCGTCCATGAGGGCACCGTCTGAAG-3′
R89
/DP
g.90
Pim1+PLX-K063
c.1804-1814delAGACCCGAAAG
77.1
Yegnasubramanian
GAL4-DBD
anthracyclines
8219
R553H
HA-Merlin-S518A
L9R
8.85E-05
pBabeHygro
AUCSS0–12h
non-CSCs
adenosines
G663S
Kaplan–Meyer
indicated.Here
Calcium-activated
Gene*
STAT6
Yakumo
36-hours
10/9
DH-domain
Myc-tag-fused
.Setting
explant-associated
Pretet
cysteine–cysteine
gatekeeper-mutant
Carret22
XB11BE
Monomac-6
boronated
ActFGFR2-infected
oligosaccharides
non-inducibility
.codon
NF00437
endosomes.28
C235
thefeasibility
HER2-FISH.15
L428
pan-CDK
cells12
//david
9-mutatedcases
thyroids
investiga
3-hydroxy-picolinic
CUTADAPT
0.588a
.Neoplasia
CBDCA/VNR
46-85
tissue-independent
Annexin-V-allophycocyanin
Phe-864
GraphPadTM
Bead-immobilized
multi-year
.Certain
pGEX4T-2
Gag/Pol
FGFR3-targeting
L54R
leukemias.17
3T3/R1275Q
vemurafenib/dabrafenib
dehydrogenation
mutations3,28
109-1/5/6a
900–0
A170E
TGF-b1
.PDGFR-alphaDelta8,9
0.2317
:4040–5
NADPH-binding
SSCP-
100–2000
Torlakovic
0.98–1.51
wu117
EGR1
NIBR
N_crassa
TGGTATTCCTAATAGTTCAGAATG
NUP98-6
208–211
Raedt
Ras-associating
pSG5L
.DHPLC
RAS/mitogen-activated
//agvgd.iarc.fr/agvgd_input.php
T1–T13
HCC05
genomequebecplatforms.com
Frohman19
29In
IDH2–EGFP
Koussay
p.Leu386fs
LATS1-transduced
Tazarotene-induced
CT26-specific
CCCAAGACTTAGTACCTGAAGGGTG
'passenger
49.24
−2.82
R445C
canertinib
hubs31,32
Ta0057
Ac-H3/4
NOTCH1-activating
4464-65TC→AT
I1148T
Lys-63-linked
sequenceinformation
MN1–TEL
months.In
GST-SH2-PLC-γ1
26.
BRCAX
revolutionised
43Â°C.PCR-SSCP
behavior.1
N676
MM-6
354825
data-base
GDP-to-GTP
V3THS
phospho-proteins
multiplex
5′-CTGCGGTACCAAATATCAGCAC
c-KIT.78
5′-UAACGCUUCUUGACAAGUGdTdT-3′
rs3212723
PC4645
17q24-25
barcoded
Bochar
XP_001166213.2
NipR1-mediated
G515A
0.0044
I-1252
7q35-qter
AGCGGCAAGAAGAGTTACCTCAGCG
perfect-match
Shirouzu
PDAC-relevant
0.121
18-kbEcoRI
chordae
IP-western
P202
cell-
48-hour
tibility
IVS2+742
causality—more
pGVB2-DR5/−1188
data-collection
K656
www.liebertpub.com
5^8
N=95
20–87
Akt/PKB
S170
Bcl-2.25
.I2
DÃŒ7S250
48.Table
0.89–1.07
31/178
c.1475C4T
ETV6-NTRK3+
030621.2
laboratory202
HEK-V617F
5-8,21-25
multi-cancer
s-rRNA
31
nbs1
N1620S
20·2
103–105
Frauenklinikstrasse
great-aunts
RENAL
.HCT
qg
18-79
H870R
CTCGGGATCCATATGTGGTAA
SacII/BamH1
1715–1734
Y950
RAF1S338
7.63
activators166
STARD10
008
L927F
c-H-rascoding
M766
L1354
haematopoietic/lymphoid
TrkAII
p110δ-specific
7q35-36
ref1
26.5/31.6†
Polyadenylated
Ras-MAP
methylcellulose
A750P-EGFR
www.hgmd.cf.ac.uk/ac/validate.php
H68H
H299Y
pGEM4Z
6.7–9.5
5′-CCTAGGCTTCCCAAGGACTGCCTGC-3′
telomere-based
Me13
Weichselbaum
.Transition
μg
ml.After
c.653A4G
Y1230H
MessageAmp
p.Q56_V60del
5.1–9.8
pRb/E2F3-regulated
IμBcl6
12-13-15-17
465-
PC5-CD7
medium-mediated
c.1144+2
VassarStats
IGF-1R.69
HLHZip
p.V1394V
β-cellulin
NPM-ALK-induced
H1686R
peroxide/peroxidase
sVEGFR
amino‐acid
MGC:88103
reported.6,7
5′-GGGGTCATTG
IIb
μlon
spongiotrophoblast
HCV29
12-paired
elsewhere34
0.73mM
M1–M5
9,10,17,18
5B
cases.57
–Fig.6B
non-tropomyosin
αGSK3beta
R585_E587del
cfu/ml
break-induced
AMTXR41
megaprimers
mut+
glycine-to-alanine
50–600
pRL-TK
7-Hydroxystaurosporine
HA-pRBΔ22
Fifty-ml
18.75–300
TGTGAATACTCCTCGCACGGA
c-KIT-activating
f1MR1/f1MR3
ultracentrifuge
P1202H
mutations-induced
Guidelines,14
xi−xj
−TSC1
1556-0864/10/0510-0291
newly-synthesized
AG-
NPM–ALK-infected
69.9–83.4
AYins503
TRiC-loading
Superdex200
I442T
crystal-packing
.BAP1
PDVF
compound-specific
Thisfinding
b-strand
antiHsp90
localise
non-synchronized
K-RasV14I–Driven
INH
CsCl
S2G-S2L
.R106W
SGZ
6938_7007del
H6-Complementing
2.7-Mb
0.07–0.42
.PRDM16
F286
.Expand
20-times
Platelet-Derived
ubiquitin/proteasome-dependent
mutually-exclusive
1p32
E–F3
723–9
RP11-106N8
ORCA-ER
Neurooncol
Y426
16.8/23.0
carcinogens.34
.Nontumoral
2–4x
Rainin
TH17
n106–143
proreceptor
B55β
standard.30
c.691delG
gamma-stimulated
MRE11-associated
HR,2
GAS5
TL1
rearrangement12,17,21
ajplung.physiology.org
doi:10.1155/2011/697162
Freissmuth
5'-enhancer
YANG_BREAST_CANCER_ESR1_BULK_DN
trointestinal
respectively.10,11
kick-started
4593G
al.58
R2028P
AAGAACCTGTGCCAAACC
Nonsmall‐cell
5′-TGT
.Kinase
19.98
.Gland
ATAGGTTTTACCCATCTACTCACAAGCCGGGGG-3′
*R0
3A–C
Digoxin
≥71
FGFR2-amplified
L576
1122
P293L
regression-based
~83
Wimmer.4
apoptosis11,12
GIBCO/BRL
c.1459C
0.0464
–79.7
Benzodiazepine
GMPPNP
TWEAK-induced
MQRankSum
ECM/BM-associated
-30-fold
_IDH1_
normoplastic
-Fwd.
studied.12
cyst-forming
Abl/src
Transactivation-independent
B-Cell–Progenitor
99.96
E192V
S2–5
51.8
Trp-1023
TCGA-19-5947
579–580
FISH-amplified
.Hayward
IgM−
GTGGCT
5′-TACAGAACATGTCTAAGCATGCTGGGG-3′
alkylphospholipid
utations
excitation/emission
Mahadev
TRIM8
genome-forward
23–64
.Reexpression
AML2/CBFA3/PEBP2aC
telomerase-positive
.Whole-Exome
Cell-proliferation
.CD34+CD43+
subnanomolar
oncogenes.16
c.2488_2497dup10
c.1854C4G
3-Kinases
Talebian
p.D258H
pMIRB
CD5+
.Arg-transformed
subcarinal
clathrin-dependent
Vaterstetten
4250-050-K
post-confluent
GW441756
9994
Villigen
SHPS-1
0.283231056
1081
shC
p-nitrophenol
MYC-like
a–c
Gemtuzumab
–3􀁂
glutathioneS-transferase
1-octyl-d-2-hydroxyglutarate
.Level
CFU-GMs
tranformed
ATP-promoted
ICGT
KMM1
P780L
.0136
Frauenklinik
Glc1Man9GlcNAc2
'overdetection
DNMT3L-DNMT3A-DNMT3A-DNMT3L
N523K
S1653F2
M197
I282
U2AF35-transduced
Y366
MYOG
569/1,744
2.094
2258
by-stander
Neomarkers
Table1
OR=0.95
22,23,28
starryscattered
Arg-951
Asp493His
BRCA2–6174delT
6B-D
RNA-seq6
activity.17,29
ΔHuTm
phosphodegrons
Trp-64
.G831
62.1
.Adiponectin
GUANINE
.3,33,34
.Percent
near-gene
5′-GCTGCAGAAATGCATCAAGC-3′
Vega-Ruiz
.Nrf2
9700HT
0.4–0.5
Fbw7
37.5-
undifferentiated/primitive
pTL1-effector
FGF8
INPP4B-mediated
VL3
f=0.05
genome-sequencing
Estradiola
MPCEWS-FLI-1-T1.2
MutSigCV2
BAT-RI
differentiation.4,5
HPPS-associated
Wnt3-induced
blood.4
tumours5
receptors.7,8
immunoprecipitation.55
L245–E252
system.7
Sprague–
Bernried
autoregulated
salpinge
function/activity
interactions39
HEI10
.Q
46000
S.typhimurium
FMTC
Dickins
Tyr1242
53BP1-independent
arginine749tryptophan
RET27,36
Wülfing
NCT00684385
R369Q
E340Q
senescence-suppressor
D910A
−1.25
Glivec/Gleevec
shG9A_1
pTyr-2
BRAFWT/
Thr529
Bric-a-brac–Tramtrack–Broad
.AR-V7
GSM718288
1–124
PC-RET/PTC1
Cullin1-Rbx1/2
becaplermin
Sato2,3
.Blastp
p=0.031
v4.10.1
H24p53-14
ab150077
441/407
embryos6
SNL
ALK-GRB2
Weblogo
Brandhuber
Jeers
.Walter
Marchioninistr
A*0105N
cells,33
98/99
COSM51966
RPPA-based
4144
B-RAF
11.4a–c
11000delC
Tyr568–570
damage–inducible
PMS2.1
myelofibrosis.46
PB–X–PG
lac-Smad4
MEK–ERK–JUN
000148
rationalise
2455A
∼3.3
Xq25-q26.1
models13,14
11,17,18
655-conjugated
1,121
VavCre+AtmC/KD
IID
Roumiantsev
5′-GTGGGCCGCCCTAGGCACCA-3′/5′-CGGTTGGCCTTAGGGTTCAGGGGGG-3′
actiuity
H2O2/diaminobenzidine
RAD51-nuclear
prebound
cascade24
hydrocarbon-responsive
Krasnat
and5D
HR-/ERBB2-
4D4D
N935H
nevi.12c-abl
RRRAA
Disappointingly
391/396
n°1
RG-10N
UAS-Luc
Bigner
-373
non-HIF-mediated
HCC1143
197–205
.T3M
salivary
13,000
MetT990I
P1130L
ELR
INK4A-CDK4-CDK6
cancer.26
EML4-ALK-expressing
L290V
of32-L
lymphoma-laden
BMPR1A
Rho‐GTPase
423-amino
N2
T-A
T2511.56
28–67
Leu607Ile
C716F
GANT58
leading-strand
transcription94
pulverization
-B220
mitogen‐activated
ΔR/Rf
conditions.52
.6D
.Glioblastoma
celllineages
CAGCA
well1
one-tube
17841
Nitou
MatTek
MLL1
64.3
Y1230-interacting
pMLP-CAT
-GACACTCTCAGCATGGACGA-30
9q22.29
phosphodegron.29
518,828
561-562
ErbB1–4
Hustinx
IVS8+32
D1/BCL1
enhancerbinding
ActRIIB
case2
GRAF4WIN
W15
oligonucleosomes
110,000
−2.92
170-180
wtPIK3CA
Lenti-SYK
5′-TAGATATCCCTGCTCATGCCA
rs121913230
.RPTPp-dependent
QTR2
R374C
A8822G
pBAD
consanguinity
Esashi
CGS
Neuro-2a
63,64
RBM7
States.10
Keiyu
.JII
HindIII/Nar
5'-TCGAGCCTGCAGCCAAGCGACTCAAGGTGGATCAACGACGACGAGCACCTG-3
1gene
died26
Akp-stained
R426H
59ATAGTCGACTTCCAGCCCA
393-aa
duplexes4
HEN-1
M766_A767insA
survival.18
1.50–6.69
THAI10
super-complex
Kandoth
transaldolase
60kb
5′-CTGCGTGCAGCGCGTCAATG-3′
cycle.2
3.16.3
NM_011058
M-CSF.29,30
endocrine-related
aneutral
Willert
four-nucleotide
TGFbold
1U2N
.PCR/Sanger
151/200
-IEDNE
pcDNA5-FRT-TO
982
thyroidstimulating
K650/652M
1163T
s00439
80.2
bHLHZip‐binding
FLAG-BAP1
37ÆC
Natali
.RET
LDE225
WKVVE
strategy.52,154
Llobet
Leiomyoma-Linked
60-meric
0.1-10
A612T
transwell
p.Tyr640Phe
P-value=0.009
N38D
1,082
E-cadherin/catenin
p~
www.imgt.org
full‐length
F103
specifi
61jC
vemurafenib
TAL1-regulated
Gajjar13
non-quantifiable
M325R
D84H
c.731G
MGH-056-1
2,002
68.0
:1291–1300
NBMEL
5′-AAGTTGA
number-specific
cullin
phospho-FGFR1
TBLASTN
2347
Southhampton
.Butler
CACTCATGATAACTCGAGCC
G1788V-R
p.D781E
predispositions
LGPIN
hyperrecombination
deterred
Deacylated
106/915
cancer-type-specific
I196/200
age.1,2
α-helix-loop
fourchanges
tripartite
200–800
Furstoss
14-3-3/C-RAFpSer621
CD3E
C/l
*
Y1234∕Y1235
S:17
WT-kinase
ChimeraScan
0.600
.1174C
CARD-
IFNtreated
p.A77S
A723D
Herlyn
caspofungin
anti-FGFR3
Vκ1
Glu-24
Tris-HC1
leiomyomas42
−20bp
bClassified
324delCA
3′-terminus
Camptodactyly
2727
0.407
.RESULTS/CONCLUSIONS
genea
δ-koz-for/δ-rev
G103C
.Automated
â€oel
SPA-820
.S34
md.tsukuba.ac.jp
L2653
post-fibrillogenesis
promoter–containing
G356D
.TREAT
hard-wired
®nal
2004b
employed.15,17,20–26
CS-07
anti-CREB-1
shorther
4807
E638G
patient.5
elements.Table
3/498
Biotools
immunocomplex
001986.1
DiFi
anti-thyroglobulin
E54L
115–156
SGTd
described,3
belie
1.51*10-9
mammalian/mechanistic
oncogenes.32-34
Saldivar
glycosaminglycan
develops21
PLX4720-binding
Tyr3O98His
LPS-induced
pBabe-Puro-RasV12
CRAF-null
Cbl-c*
observed27
.Stable
X29A
840
BRCA1C61G
AA455929
58.2
1,200×
9200
DUV
data.11
S.G.
GEF-RhoA
5′-TCGCTCTGGTTCGGGAGGCT-3′
Unicancer
NRASS65C
aberrations71
HA-MEF2BΔMADSMEF2
D141
SIFT44
10h
S93G
N-rai
GeneScan/Genotyper
pleiomorphism
baf3
pdgfra
.High-power
heavy-chain
-tyrosine
quinonazoline
Grotel
X94207
theDNA
biclonality
thesplenic
ETV6-
reported,15
Sefar
CAU
wh
Fig5J–L5J–L
28/76
Myoepithelial
p.R144Cg
Ptenflox
Quizartinib
Yong-Hyun
CSSMAX
jig/
Dox-mediated
MOZ-p300
TableS1
0.698
5B′
hspl
5′-CCACCAUAGUCAAGAUACA-3′
2.482193867
CSU=cancer
matched-related
tag-SNPs
pathway-amplified
5p12–13
BH3-containing
3.30
single-domain
E166Q
V769dup
AN3CA
Lentivector
515
.208
Tsc2-expressing
detail.98
receptor−infected
OMS
chromosome.26
COLIA1
5′-ACAGTGAGCCTGGTCCC-3′
HEL-binding
Humain
restorative
0212
PT_BM
.Theclones
dFBS
cases—no
Smad2-6
chr2
1.2â€
Thr172
2′
S218A+S222A
D247II
122×
Cusmai
FBS/DMEM
7.C.1
.Particle
Desruisseau
t0c
resistance-associated
Tsc2+/–
0/10d
Smadl
CT10-2C-T1
disorder.19
GIST-affected
2,449
I–VII
RAT1
ELLESISNSVSYFPPPLFYICQNIYKVACEKFPDHAII
Vialou
59-AGCCCCTGTTTCATACTGAC-39
2–40
neratinib.82
.MDA-MB-134
785-7531
Alsner
9.4-kb
.Cumulative
Ashktorab
attribution
,19
18q12
VEGF-D.
syndrome.16
AGG-3′
leukemia-promoting
2/day
9Foundation
p.Y163D
granulo-monocytic
unclear.20
unadjusted†
PBD-binding
ATAD2
−2.03
spin-infected
12R5-5
DUS1L
pTyr+4
Cys-231
UM-SCC
12A
7-Aminoactinomycin
L73P
spacers.54
30470384
patients,10
49–87
p.R325Q
0.5–1×104
HuR
292
TRK-T1
PAK-independent
bi-weekly
703
MS-MS
,3D
ERK1K71R/ERK2K54R
20-residue
upregulating
32P-GST–CTD
S4a–c
assessed.8,11-13
IP/Akt/NF-κB
TNF-
1.492
R273H/T284
K935I—were
V6.5
.Ligand-Mediated
UTP
Cip/Kip
Met766
transcriptionalactivator
XNP107
p.Gln4882ProfsX36
geometrix
Ig3/64
PTP1B
.Phosphoinositide
Haslam
v-myc-containing
NM_016681
CRLDCAF1
Roissy
immunonegative
hepatocyte
MMR-induced
HCA-7
Arg-124
CYT387-treated
cancers25,26
34.8
shp53
PheGraphic
29-89
2014_07
TDA
radiation-induced
TRAILR3/TRID/DcR1
Riggi_Ewing_sarcoma_progenitor
leukemia-related
LTED
3.437
R132L
5361
M—designated
neutrophilia/monocytosis
SU11657
previously.25,26
Tumor/Non-tumor
4E–H
altemative
C-loop
Q158*
FusionHunter
BOSC-23
Latil
Z9600205
pET-MTS2
pIK6
421–548
ESS
.Single-stranded
western−blot
commun
66/6
//daphne.humgen.upenn.edu:1024/gaia/index.html
/31
multi-monoubiquitination
database.39Statistical
FGFR-driven
P299L
Ltine
Kritz
.Abolished
TAC
004304
STATA.As
1-6mar
LSAMP
4.16E05
introns43
c13
389–403
P8340
p.S1379L
.Deleterious
ARA-C
CLL.16,17
leukemogeneses
20892-1810.
African–American
Analysis31
c.358G4A
presentstudy
7541
PMI-F3
SectionDiscussionThe
.Mochizuki
oncogene24
methylcellulose/0.2
MMR46
Mll1f/f
lines25•26
CMV-β-gal
95·5
9227
sequence.Figure
E670
IDH2-mutated
Lanzara
melan-A
Cephalometric
JAK249
complexes1
S3.4
`Myc
phospho-ERBBs
many—and
Mehdipour
D572_P573del
response-rate
piloid
Linardopoulos
colonie
CD117+
257–278
1-814-443
n=410
.phase
Bach1
gene,18
Bromberg-White
on-rate
SRSF3
ATK
600281
highly-destabilizing
-130°C
Δ8,9
p.Gly52Arg
ETV6.4
11receptor
c.1768del
COOH
Gleevec
Ecotropic
Tyr1571
.PDGF-BB-induced
cancer—activating
mutations4
CASTp
c.119delG
V592G
χ²
FLAG-Gab1FF
132794901–135944600Because
5′-GGCTACATTGGTGTTGAGCTTTT-3′
I26A
diethylmaleate
element/IFN-regulatory
2B3
Tibshirani
Actinfilin
aPKC-ι
009898
pm1Sf
'false-positive
.Predominant
TATAGAL1
antiHis
N382S
E769
ER-fused
/extracellular
CD24+
TAT-fused
fluorophenyl
035
biotinylated-linking
Tris–acetate–EDTA
tz-
2.017729033
Koltin
TEV-treated
oligop73
5E⇓
del2013
T751
stress-inducing
–generated
phospho-TrkB
ankyrins
Kijima
RAF/MEK/ERK1/2
indicated.C
chains,23
150,000–400,000/µl
HEK293-pCMV
methanesulfonate-induced
c.387+5G
Ep300
substitu-tions
YEY
CUHK-NTE
~Sung
protein16
,2I
TranscriptasePCR
B-CLL
GTGAGTCTAC
HDAC1-dependent
G-Banding
development26
Δ230
spectum
OT2
pGW1825
Kaplan-Meier,25
post-PV
anti-LEF-1
overproduction
GTGTTGTCTCCTAGGTTGGC
results.24
P=0.11
mitogen-associated
sub-lethallyirradiated
R169Q
Smad4f/f
G670G
Tcf4/Tcf1-deficient
dorsomorphin
substitution3
RAD51C-mutant
//gdb.infobiogen.fr/
D1–/–
Thr573
-AGTTCAGAAGGTCAGCCTGC-3
TGCT
GIyArgAoICIuVa
.Phytohemagglutinin-stimulated
replication-defective
V1688del
H.D.
Rsc1
closed/tethered
.0521
.Living
≥1,500/μl
activation.36
445
extrapulmonary
Target-specific
underex
14-3-3δ
CBL-encoding
cells63
beta-dependent
mutations,4
RT-PCR2
J103
.Lats1-
2931
44–71
cancers7
weight/day
0.24–2.81
Dpc4flox/+
NGF-stimulated
19/209
C85Y
.Kaibuchi
28-nt
orT
protein/nucleic
11—del
SLL
transcriptionat
30,630,000–30,830,000
on-treatment
026
1a
.Bristow
mA621Raf
Centricon-30
dependent-manner
640,000
anti–phospho-ERK1
radii
isopropyl-β-d
R2=0.63
.Spry1
Lys-619
Thr202/Tyr204
outcome.27
6/104
Tweak-receptor
Zoanna
PBRM1-mutated
Enhanced…
at.
Stringent
98.02
mutated/amplified
.Fluorescence-aided
Schmucker
Transcriptional/epigenetic
microdeletions.18,19
results.30,31
substrate-conferring
SoxF
9800
-232
Ser31Stop
+1,773
162-0233
E18
*******
Coomassie
1060–1079
covalent-receptor
trk40
1429
TCG/CGA
subcompartment
2.6b
Nuclear-positive
.HBxAg
TFIID
187600
Lavagna-Sevenier
Hs99999908
monomerization
Enterococcus
Tyr1054
Cys–Cys–His–His
analaysis
PhiKan083
pSF91-IRES-eGFP
1D8
5′-gaccaaaccagcatgtttc-3′
.PLX47206
15–
Yes-associated
facio-cutaneous
KRASA59G
NaCl/50
lipomas39
p53-R337H
Northrhine-Westphalia
S190
D245
pathway.29,30,71
2a
//epi.grants.cancer.gov/documents/CFR/CCFR_BiospecimenCoreSOP_040607.pdf
.Strep
pSC-EGFR
overexpressed31,32
4,5-dimethylthiazol-2yl
TP53-R280K
OriGene
20.56
expression96
EWSR1/ETV4
Dnmts
28,29,32
Y928
DDR1A803V
pLKO-TRC005
9-131
eachof
0.016
sche
cDNA-R
301
.CD3+
236–245
4.3425
mutation–containing
prognosis.31-33
ubiquitin-proteasome-dependent
n=5/5
vitro.9
FHA2
CD41
therapy10
−.47
RNAi-depletion
I548
.10NRAS
V170G
E433D
loco-regionally
'myeloproliferative
G67-T368
.All
factors.6
retinoblastoma
BE299670
MAPP-MMR
C-RAF46
rates27
hMeindl
BCL-XL
mucositis/diarrhea/neutropenia
MSK-IMPACT
miR-199a/b
Xinhua
6602
HematologyOncology
D816V-Y568-Y570FF
polyerase
.Diploid
5′-GCUUGAAUCUCCCAAGAUATT-3′
c.3407delG
TBE-urea
overhang.9
postganglionic
non-frameshift
pancreatic-specific
Se´zary-like
Merieux
NCT00788775
cells/20
prolyl-hydroxylases
Affymetrix-provided
.Cos-1
theT3T
hydroxytamoxifen
60◦C
G1738EF
.S7A–S7C
.Fig.4B
DS-ALL-related
38.7±4.5
34342
0.000267
5.8s
gd-T-cell-derived
Inr-like
1,836
alpha-PI-3K
CancersThe
Low-Complexity
C2β5–β6
experiments17
anti-ERK1
6516
E0432
sites32
fluorescencemicroscope
CCTATTCAGAGCGTGCTTCC
Tween-20/0.01
MMP-13
Oligomer
TT-3′
Minato-ku
2wd58
irradiate
elongation-competent
R149
XLb1R
S291L
method.45
MAPK-redundant
remodelling134
per-protocol
adults.1–4
.Npm1+/−
p53-G245A
RT-CES
Bel-Art
pEµSRa
Flt3+/+
68,000
RAB26
L1765
SYK-targeted
.Laboratory
KLHL3
signall­
Sos1-ex6-fw
M74363
pY-recognition
KDQEGQDL
T1151R
sassDT1
ins_del
mt-SPOP
17/85.0
5768.36
23,38
p85α–p110δ
immunohisto-
cohorta
G776C/V777insCG
Zawel
chemorepellents
Whyatt
.Co-transfection
negative-control
amikacin
duke.edu
291-464del
11B3+/+
thrombocytosis.15
tissues.1,3,4,22
647-conjugated
p.His143Tyr
vivo.The
.Principal-component
hamartomous
DN2
5-200
epi
TLE4
pro-carcinogen
SRE-CAT
p110β84
/KRAS
EWSR1-SP3
SA495
saturated/optimal
L-trans-epoxysuccinic
lines.32,33
expression.47
Thereasons
V5-FGFR2–PPHLN1
517–533
SectionPatientsWe
367–372
Ile548
EED/EZH2
2293-2757
La,0
CHESS-F2
c-Myc17
J.A.E
NTB-2
A*11:01-C*04:01P-B*15:375N-DRB1*01:01:01-DQB1*05:01:01G
SEPT6
94ÆC
mutantsThe
chi2
∼10−13
PLC-γ1
p.Tyr537Ser/Asn
KU70
521-603
56-
G353S
acid127
36–78
loss/negativity
TopoIIα12,17,18,20
ploidy
5′-CGAGCAAGAACCTTTGGAAG-3′
MC2
Interleukin-2
76.54
K558__D572del
potency10-13
Inoki
P=0.032
1326
Anti-XXLαs
1−5.0FAM83AFamily
.670
.55−58
c.A3140G
DNA52,53.DiscussionMutations
MSI−
TIF-2/GRIP-1
Technologies/Bethesda
M54T
Her2/Neu
Gnad
250×g
6His-Ras
processes1–10
DeNovo
GGA
BRD4-NUT-positive
H658Y/R
2.24–2.20
CSQNTS
Saos2
G750D
StatusfAbbreviations
MLH1/MSH2
RAT1-
IL2RA
61,64,65
M25a
DR50/6H05
NIBP
'partial
0.25µg
anchorage-independent
48.5
disorder.6-8
Phosphorylation-independent
2**
.Exons
Mcl1
BRCA2,7
5–7.75
HGS-OvCa.Table
Li-7
CFP-AFFAQLQLDEQTGEFL
Histopathologic
P2-P4
methylation12,14
BCR-ABL1–Negative
MKK6+
LCN2
Brd4shRNA
c-KIT/SCF
glucagon-positive
919-681-0172
domi
ErbB1-KD
pBXG1
GSK3/FBW7-dependent
F151S
nonmutated
puromycin.Soft
BCR–JAK2-transduced
31⇓–33
Maximy
5'GGTAAAGGAGTTAGTAGAAGCCAGTCTGGATGCATGCTGG3
AKR
responses.8
ULTRAhyb
c.700G4T
BCR—BTK—NF-kB
Cancer-Specific
-2-fold
P14
Ly5.1
Disparate
pY204
Colo-829
Uderhardt
TKI-treatment
D1/91-295
//jcem.endojournals.org
EC-DII4
83.3
p.W534R
RBD-pulldown
DyeEx
phosphorylated/total
Salzberg
hydrodynamic
-stop
L95M
MEK2.14
.Martine
higher-dose
nonmutually
families.1
protoporphyria
RNR
0/233
circlesrepresenting
Smad2/Smad2/Smad4
μm.His6
pcDNA4c-BRD4
TCGA-AA-3715
T/c.2633T
rs115465194
5′-GGAGTCCTGTTTGCTTCTGG-3′
c.582
0.9.8
HPP1
14Clabeled
N210
Rho-Rock
8.09
sulforaphane
examined39
Puissant
−c2
.S6J
Naviglio
Wt1b
ORFeome
Y537Eretained
.5266dupC
-340
Demischelis
HGCLPEESASPAR
c.804-2A
non-adenocarcinoma
pNLS-Cre-EGFP
pleko
15–19,22
.Occurring
130.2
88.1
G325E
.Rockville
BRAF/CRAF-dependent
N-SVGSKRRR-C
unresectable
NF1-WT
GSE44860
27A-F:5′CACGACGTTGTAAAACGACCTATTGGATAAGTATGAGGTACTG3′
Brizuela
107,108
Oren,1996
.R.
5′-caagucuucggguggcuuu-3′
Avestin
HLA-A*01:11N
FAT1-expressing
Asp449
1k-CAT
7767-1
gpl4OtfA~-
NCP
Ceccon
geneswere
PHBS
gene-hallmark
pY100
Asp1033
L1012P
acetylation28
small-branched
//tcga-data.nci.nih.gov/docs/TCGA_Data_Primer.pdf
lentiviral-based
Hrefna
SPIC
L145F
mESC51
Revel
ERα-antiestrogen
7H2O
Sgt1
NS=rgrg+1
​and2,2
−Leu
Ser139
E2F2-
./nmol
0.974
circumstances71
G3464C
GSE19539
GSK-3β/β-catenin
eribulin
concatenating
self-renewal22
auxotroph
5′-TGTTCTCTCTCCAGAGTGCTCTAA-3′
DFG/activation
agglutinin
thrombocytopenias
Bolanos-Meade
2003a
Del-5-myc-luc
AAT
Hs371735_m1
mGTP
hPatients
10402580
AAPC/multiple
509–524
p.Q2503*
severe-Wishart
HN31-S19
CD74–ROS1–introduced
Gin
HRP-conjugated
IVS11+5
shortspace
co-dominance
11-147,000
MSI-NA
Kit-positive
canReceived
.CIT
7,26–29
S170R
peptide–pVHL–ElonginB–ElonginC
5′-AGT
8,41
KFYKL
ginseng
subcategories
p95HER‐2
slow-cooling
D-ring
glandcarcinomas.Some
90.9
Y307N
XXLb2
11E12
EGF11‐12
mld
IX71
989A
DGC26
polyA-enriched
5′-ATCAAGAGAGCAAGCTCATCAT-3′
HR=2.94
Overhauser
patient-tailored
Fourth-Line
histology22
Man-Ting
p.L926fs
.CAC
adenocarcinomas.1
indentify
ER-negativity
1-multi
EGAS00001000253
140-295
FancM
3/84-
transplantations
mMEDTA–10
Great-grandparent
TCTAgTgCT
Immunoblotting—Endogenous
ΔN
H-125
-2516
Conditionally
EGFR/ERRB2
+S
CGAGGAGGAGGAAGAGGAG
Linggi
METV1110I
.Disruptions
Wilkinson-Berka
HIV1-REV
individual-specific
4–49
10.8¡1.2
bitransgenics
59.3
5′-AATGTCTGGGGACCAGGAAGGTGGGC-3′
WS1
CATCTACGAGGGCTACGCC
471
TKI-resistant
cAMP/carbohydrate
migration.14,16,33
IGH/MYC/CEP
1.891–5.065
reported35
disease—indication
ENU-selected
failure.11
tenable
TCGA-FU-A3HZ-01
.Promoters
615-322-
Arg515Gly
1554.024
array-based
WHS
IW
32:1470–1480
PCR-Topo
'two
CCDC15
exonucleases
multifiltered
.1526G
314–397
tumours.Consequential
S.B.C.
J045
homopyrimidine
0.078-1.82
R102P-FLAG
individuals.8
amongpatients
blocker-PCR
768–770
10.1200/JCO.2003.10.066
genebank
leukaemias/lymphomas
pGL4.36-MMTV-luciferase
matrix.41
TLE1
A_52_P25599
1-Protein
1524–1661
5.852
RERTn+/ERT…Download
synaptic-related
R51G
Wound-healing
YEPD
Cre´teil
Boutain
STAT5.9–11
0.338685
NA26
PI3Kγ-dependent
.Fig.2B,2B
20:04
GGAGGCTGCG
Ramsdell
MDYPYDVPDYAGS
trans-repression
TrkB-BDNF
Kaidanovich
Family-History
HAT-dependent
G328-ACVR1
58.7
membrane,19
TJP3
l5Xq22
mice10
hepatospenomegaly
rs35151472
5-CGGGATCCGCCACCATGGACTTCAGCAGAAATC-3
.Spinal
33433451
4Oncology
shChk2-expressing
-40
Four-
Gonzalez-Barrera
c.864dupG
F1174V-mutated
SCL/Tal1
RUNX1/RUNX1T1
:6.7–100
receptor–induced
.Harlow
genes8
1694–1708del15
androstenediol
Plk2
GTP‐bound
Do-1
stroke-induced
non-wnt
CD3–B220–Ter119–
EPEG
C15orf55
samples.Standard
Glu23ABD
goodness-of-fit
slideA
acids10
activity49
p53-conformation-specific
3T3-transfected
AmPure
12/70
substitution/
17,93
5′-TCTCATGGTTCACACCCATGACGAACATG-3′/5′-AAGAAGATGCG
Nakayama
pre-cleaned
:685–700
2mg/kg
sequences.In
ccacatgaaatcaataaggttctcggtgag
1.1-kbPDGFβR
p22surrounding
N-vector
16/119
N/A-transfected
215C
P.W
Casero
S155R
GenePixPro
S21
protocols.9
400-kbp
A203V
AIF3
//genetics.bwh.harvard
TSC1variants
p.Thr616TyrfsX8
0.1-trypsin
Misssense
A179T
kinase-focused
.KLECKNER
ARID1A/BAF250A
ITD+F691L
posssess
gastrointes
desaturated
Jmj
-loaded
site—are
Sox-mediated
nonspecific.hMutSα
delTTC'7
v-erb-b
−2.39
I196
Fzr1–WD40
***Wooderchak-Donahue
Fiset4
.Ingastric
X-treme
Slingerland
132.7
Cd79a
Hospital–Weill
OB1/OB2/OB3
ARR2-Pb
J.-G.
mastermind-like
Gln497
Appropriately
T-ALL,24
Analysis—MCF7
siFAT1
FZR1
BioThermStar
v-fps
AVM/spinal
FLT3-840GS–expressing
E168
4188
RUNX1-dependent
MEK1-
H3
N546K–mutated
Neu-positive
Funnel
polyglycol
P569L
3D4Q
.CONCLUSIONS
c.3007T
Event-Free
REV1:5-Fam-TGCCACCTCCACTCCGTCTA-3
MEK1G276W
H-score
apoptotic/transformation
1192
alteration-derived
W583C
homologous
L744832
kinase–driven
10124â€
Gut
LCE3B
PDGF/PDGFR
Y578G
,1,800
q15q33
PGP-
c.3656C
VK
α=0.05/27
Valinluck
Drickamer
.EWS/WT1
GATA312
RFS-mycS62A
cicArg505Trp
G161V/E
development,12
~2kb
P427L
A315T
CD34−
5-drug
5′-GGACAGCCCAAGCTAGAGATGA-3′
/progenitor
.Prolonged
C2202Y
6.9-fold
3/9/98
S1982T
EcoR1
5-CAGGATATAGCAGCCGTAA-3′
ERK-MAPK
9,10,16–22
Lats1DN/DN
sub-lineage
H2AX-γ
KLF5-mediated
Lck14,1
oxygenases
siScr
22–28
AML.2,3
IKLE
KRAS/NRAS
SMMC
Dystrophy
Contesso
Carlabad
.PB
T-independent
H3K27-trimethyl
mismatches11
Chx10-immunopositive
receptor-based
LUC-shRNA
E65–E67
Y1794H
today10
Cullin-type
R529Q
34*05
2.9×2.5-cm
439-residue
478-Ser
22,826
C141/229S
pSP73-loxP-neo-tk
Kif23
F1888I
Canada,45
–1200
716-845-3044
respectively47,48
c-Jun/Fosl1
Yes24
N603D
tryptase+
D479Y
family6
②
I1171N-mutant
Br59
B72.3
SH2-C
Rosiglitazone
pIRESPuro
Ral
46-year-old
Flag-Jade
.Butterfield
ATCGGATCCATTAAGGTTGTTGATGTGGAG
Ito1
retainedwild-type
ID3-mutant
R361C
cdk4+/R24C
Mmol
3-methylcholanthrene
Gcn5p
Y2163C
9.183
.Thirty-seven
ALK5
L102P
5′-CAAGGAAGCAGGACACCAAT-3′
mNSg
KYSE220
colorimetric10
levels42
19:1
M205
HIF-ODD
.Genomatix
T58/S62
5′-TTAAGATGTCAC-CC
AGGTGTGGGTGGAGTAGGCTG
dichotomously
Gr1/Mac1
pone.0064364.e012.jpg≤−2.0
B-LBL
co-selected
.GELLES
BRCA1-mutation
MCF10A/HER2L869R/T798I
MOBIX
.Another
cells.6-9
37th
J.C.W
MutationsThere
markers43
120–150
PI9
forebrain-specific
3T3EML4
ETS/FOX
amc.seoul.kr
NSCLC-specific
UK_FOCSS
NCI-H82
SIK1
p.T901R
Next-generation
g.wells
0.32
previously1,2
p38alpha-/-
7S250t
HDAC2/cMyc
TTC6
.Anti-FLAG
medium.
280
invasiveness,25
p.S56I
RCC10,15,16,17
trkS
PE3700
BMP8A
'HIII/EV_pT81
Aressy
cytosolic-localized
M5gNeo
I-Block
22.5
Kuchenbauer
α-Musashi-1
CTGACAGACGCACTAGTCG
0.624909
:target
anti-phospholipase
B2mgene
.Precipitates
Met-mediated
Cisplatin-based
wt-CBL
D177fsinsG
56-kDa
.HLA-B*4423N
1.3-316
fibrosarcoma.14
ofantibody
Lees-Miller
HEPES
GNDF
A-11037
3437
awk
Tallquist
adrenalectomy
decycling
e.wn-inlron
E279S
.T7-VHL
-unlike
184–467
266-5193
control-siRNA-DOPC
'tor
nonCNS
FGFR3-targeted
p27/RhoA
αERK
middle-T-initiated
translocation/cyclin
CFC76
34,40
rebinned
Y321T
HEK-YFP-Jak2-WT
nomenclature
.HIF-α
K83E
+109
autocatalytical
-GAAGCCCTGATCATCAGCAAAGTCAACCACCAGAACATTG-50
nilotinib-induced
BIALLELIC
spliceosome-mutant
families61
4,266
complex-2
Vertebral
0.0498*
GATAAACTCAAGGA
IgH-related
ponatinib-containing
hematoxylyn
-,20
S89D/N
/ZMSH2
Kinase-dependent
S810A
AAG
W6/32and
0.0196
5′-to-3′
25-90
NF-κB80
RP11-117L6
.nd
acids.5
Sphera
CPE
low-molecular
CD2-Gata3
Aj-Al
4B2
360–393
GCGCCAATTGTCAGGTGGCCTGGTC
.Unscaled
PANJJE
Turcan
G59
YEGNARD
Hannak
0.365
melanoma,21
gengen9F:9R
-selected
EGF-regulated
.Free-floating
8548
mutations.11-16
Trenaunay
p110α-H1047R/K227E
steroiddepleted
tumors.92
.Implication
89.82
CBFβ45
DFGLARLLDIDETEYHADGGKVPI
CAF21
D132H
1-635
HACE1
p53/GAL4DNA
2.43
12–74
Tet2fl
Biomédecine
12q13.3-q14
IgSF
.pEAA39
S342C
Processivity
level.11
function.44,46,52
MSCV
antiHA11
21,015,386
.Transplanted
Tropomyoaln
47-year-old
3892
.C250T
MGdotMG
0.01237
lineage106
Tyr981
Rosa26-derived
Cali
galactose-based
RP11-1149J13
S19
BAR-1
ZBP-89
thissequence
Gab1/HASHP2
549–595
anti-hepatitis
5′-GAGAAACGATGTCCTTCCAG-3′
1–6
D-001100-01-20
350-kb
Variant_Classification
ΔsubG1
11:623–629
PLSTIRE
Yoshihara
3-93,900
D16S3407-D16S303-
GCACAGCATGCAGACTATGG
24·2
Lützen
melanoma.20,21
optionsMolecular-Cytogenetic
Queensferry
PI3KCA
Niehues
c.122G
Antibody-labelled
sec.
3NKX
Shcherbakova
GST-mouse
cytokine-dependent
317-433-4549
members.Top
22-45
70.4±40.0
.control
BPs13
protein-driven
p53-induced
dCTP-labelled
OIII
Met-790
KLHL9-overexpressing
23.51
.649
.~Díaz
SuperArray
ASXL1-deficient
56.8°C
orbit-sparing
loss9
speci®city
gravid
Yes-Associated
Tominaga
D223E
.Uhlenhaut
-CTTCCTCACCCCGTTTCC-3
PAC/BAC
/minute
M.B.
karyotyping
4M21
Asp835Gly
CCGGAA
Przylepa
C8orf4
S4f
deficiency–targeting
peroxide-induced
NM_033632
GISTs,28
AKAADGYVKPQIKQVV
ADAM-type
.5115A
three-four
T877A—is
PHEM
ARF1
value20,21
LUCC2
expressin
detected6
previously.4,5
30-
NPHP4
0.4×
KRASmut
dence
V256D
phosphor-JAK2
.G660D
MPPs36
transformantscontaining
anti-hDIS3L2
unspecifically
c-erbB-2
c.825_838del14bp
site-specific
352
3D5
cellulose
1.03–2.94
inhibitors.27
Cyp2f2
CBF-1
Roux-en-Y
Q1966
alone.MEF2C
c.4537C
al115
Rensland
differentiation.30
multidimensional
jgpark
shot-gun
Karyogram
prognosis.4⇓–6
587F11
SMARCA4
phosphomimic
CCTGGTGATGTCCGACCTGTT
A-T.
comprisinga
SMARCA2-containing
parallel81
example—we
Resistance-Conferring
right-sided
vitro6
1,579
ml–1
0.180
NPM1/5q35.1
G15S
lymphoma.7
I682delinsMPAP=2540del-C-ins-GCCCGCCCCT
.Mucosa
ACAGGGCCTGGGGCGACCAC
TA-16/24
Gulcher1
S-tagged
MSH6-p.S144I
allelesunder
outcome118
osteoblastogenesis
instructions9
610253
Src/JAK-dependent
sequencing.39
CanPredict
Â£and
Runx1-EVI1/+embryos
beendemonstrated
5′-GCCTGCTGGTGGTAAAGAAA-3′
muTect27
5-methylcytosine-containing
Kinematica
I/mTOR
PpuMI-forward
R867C
Ikura
CMV-p300-E2
4¶,6-diamidino-2-
repressor-corepressor
18·9
Expres­
RP11-379D20
temperature.Both
//www.bioinformatics.bbsrc.ac.uk/projects/fastqc/
Y-653/Y654
Graveley
15.8–36.3
p.M552
DLC1–PTEN
B56gamma1
INPP5E-mediated
Ih|/ΣhΣiIh
51jC
10−9-6.0
cis-regulatory
residuesb
cgr534
pIRESneo2
-ERK2E322K
enantiomerically
273–552
cystadenoma–borderline
1–727
3.5802
.MALT
pan-Akt
L409
STAT5B-WTand
HSC-6
withLi-Fraumeni
re-respond
.Xenograft
medium–10
Metastasis-free
AGACCAACTGCCTCAAATAGTAGG
CD74-
Q95X
shRAC1
anti-IgG1
−0.13
Villejuif
non-tumors
E265A
LQLDEETGEFLPIQ
p.V423Hfs*37
Maugard
2/12
100ug
/4
476
membrane-type-1
A870A
andDNMT1
others10
c.724_739del
.PRC1
RKIP.6
.Design
0–16
-,23
2723
Ser-Ser-X-Ser
Korn.28
AURKA-mediated
Runx1
Ehata
Agerstam
anti-PY719
Lys127
107:4090-4100
ARNT/AHR
cc-12-1598-g2
A1641T
observedtransactivation
delL747–S752
-11.5
1.8nM
D1S468
effect.4
SV40-PURO
activity.27
damage-sensing
P2–P5
FISH-validated
KAAD-Cyc-treated
AGTTCTGAGGATGGGGGAGCCAAGT
mab-3
520-amino-acid
10-week-old
nonviability
cells.Although
TFIIIA
0.0468*
ive
Z-leu-leu-NVA-H
.EGF
fl2m
38/61
.Titrations
0.952
GGATTTGTGTTTGCTTATGCC
non-Rb
snpEFF
C-to-T
Sequation
end,23
9438
E149K
K832R
c.2765
cell-survival
inter-repeat
5′-TGCCTTGACATTCTCGATGGT-3′
Fbxw7+/−
10−10
androgen-mediated
1p31.1
RBM-Mediated
N56S
bined
D1384V
CADO-ES-1
Protein/DNA
dislipidemia
CV-1/COS-1
Gal4/UAS
proline
Nonamplified
modifi
I42V
GeneCopoeia
al,8
vemurafenib/PLX4032
TAA
+PUR
physiology.med.cornell.edu
MEL290
.0001*
p3HAmtSox9
peroxidase-tagged
Native-polyacrylamide
PCRanalysis
underexplored
5′-GGTCCTCTTCACTCTTCATGAACAGC-3′
γ2a
25-bp
-dextran
49⇓–51
cleavage.It
avail-
mutations.Neuroblastoma
Effectd
cis-autoinhibited
SPORT6
4NQO36
cleophilic
.Anterior
Arg59
335–500
H889
Gleevec™/STI-571
K461N
Tyr1234
YAP1-active
3,914
*Unpaired
tolerance109
Ppgb
.R273H
L200P
RNEasy
M115T
analysis10
/Bmax
6q27
119.00KB
.Went
Detectionof
Snf2-ATP–coupling
6p12.1–q11.1
p.Pro246CysfsX3
c.3670C
8/
TdT
B.1
1305
bileduct
D1310N
D473
ll2R
FANCC-deficient
supernatants
ofall
Eae-1
76/1935
hMHL1
HID
229114_at
625
M13-derived
0.899
furiosus7
Ofradiolabelled
NMTS
0–1,000
TopHat11
patients'lymphocytes
10.1097/MEG.0b013e32830b0f76
cotrimoxazole
Naevus
'TCGA
GTAAAACGACGGCCAGTCCTGAGCAAGGAGCGGGT
0.378
phenotypes.20
H347
mutation.17
≈1,450
detergent
RESCIST
Spt6
anti-pFRS2
CRM1
oncoproteins41
c.2410G
753A
.Bandshift
re-spectively
solutions/media
CD8-APC
NMR-monitored
Dw
.Probes
Tyr/Phe
mg/dL
analysis24
Conclusions.Cells
DNA-fingerprinting
Farnesyl
pSMV-betaGAL
Porto
pcDNA-CRIK
Vaco8-2RII
1TAPhe
mechanisms233
.AR-mediated
column-wise
FGF8a/b
5'-CCAGTT
JAK1-transfected
97.4
Y803N
mycTargetDB.asp
pro-growth
LPHN2
c.837_842insC
structur‑
2.00E08
recommendations.Blots
.E2F-Dependent
translocations23suggests
SDVWSFGILLWEIFT1
◊IVS11+1g
p300–null
374–376
Flag-tagged-WT
overexpressionof
G468EB-RAF
AEGFR
4.5e−5
GST-G17A
.Motifs
anti-phospho-KIT-Y719
BHRF1
GAPS-dependent
EX3AF
structure8
GRIA3
BCOR-BCL6-binding
heterologs
13-month
Caslini
self-assembles
p.Tyr181X
Hs02507752_cn
Hernán-dez-Muñoz
C-α
non-elevated
TERT-to-MCTP1
*Li7
NCI-1975
S35-labeled
His206Asp-GFP
Mut
tumor‐derived
mildly/minimally
Gαq/11
CpG-island
.Dusa
Arg-to-Stop
I232
0.179
Ras-GTP-GAP
untilA
noninfant
dyserythropoietic
lyzed
mutation.12
Z.Z.
nucleus.11
5′-CAGGCTTGTGCCAAACATCTTC-3′
inflatum
0/166
T206I
Vanneti
SW-13
intracellularly
cdk4-binding
E10c
S-200
SLC26A4
Ala.
.Younger
E596QS
12.7-fold
Tyr1193
rhuMAb
∼4.5
0.31–8.05
mediatedby
tothat
5′-aag
GPCR-mediated
5′-CTAGAACAGGCAAATTCAGAGAAG-3′
NOTE.-Sixty-seven
Nonradioactive
Sasebo
824
CSDA
siROR1-mediated
GGGGTACCCCTGACTATTCTGCACACCATTTT
V:11
Sabadell
PCD24
-2266G
XIIIB
±0.54
W1211
TGF-ÃŸ-induced
immuno-phenotype
Msh2
aldolase
MDM2/MDM4
IGFRII
Pericytic
Six-year
contig
168A51-2
Y279C/C459S
4C9
D207D
SF3B1MUT/SF3B1WT
–20°C
Meera
MITF-P
CAAGATGCTGGGAAAGTCGT
p.367Q
NPM/ALK+
NIH/NCI
p120-
Co..
post-operativesurvival
720-1044
metabolism.15,25
CDK4/6/2
units/
EGFR/MAPK
Khelif
deletions.28
V821
LN+/all
delete-1-observation
59CCTGAAGCTGACAGCATTCG39
47.5
C634S-Cl
cancerb
.Inferred
BCR–ABL13
exon-search
sc-8185
KLF5*
G96V
GR-1
3433
sclerosis-like
Endolymphatic
A755T
RetroNectin-coated
end-result
KITV560del/N822K
¿
JVM-2
amplification.7,8
7.5/0.1
Mll–lacZ
.K14
L95-14
0.497
cells.19,20
n't
MATH-BTB
FacRad3
similar.The
12,559
Maghrebian
Ubfd1
Carney103
C-11
FeO4S-untreated
.Bettegowda
andS8
Hedgehog12,13
4â€
pcDNA-ERBB3
Gendler
41/404
approaches.To
CR14mot
1/13
11.0a
p-alpha
lentitransgenesis
γ-glutamylcysteine
RG205130
thioredoxin
35716
differentiation.1
∼660
syn-conformation
CO1686
Rhodependent
identi¢cation
1,752
C727T
anti-pRb
SUMOylated
Trp-393
.Fifty-eight
c.p.m./ml
56–78
Mutationalscreening
Mutants—Chromosome
4.956
52˚C
BL2
slanted10
Wigley
Wistar
domains63
overexpressors
migratory/invasive
.L/B
Myr-pBSFI
22.8
MLF1
−34.6
c/5-fluorouracil
acid-stimulated
EGFR-activating
Mo-DCs
H2265P
S2514E
37·5-mg
CN-AML,26
AZAP
N118K
Thr-34
Q158X
addictive20,32
72.3
Sigma®
R270C
21-41
t9
FAM179B
Tables2
270C
SHOC2–RAS–RAF-1
Web-prediction
aggres
12.5
TCATAAGCGTAGACCTGCCCCCCAT
genitography
−.17
WT*
carp
Ponzetto
A20E
model51
ENST00000318493
GPD1
vinorelbine
MacCSF
.Rev-Cdk12
/ErbB4
G674D
BRCA1/BARD1
AC2209
Quant-iT™
.ORR
MYO1E13,41
mutants.22
death.19
Hepatocytes
RR-01081
juxta-transmembrane
Sox2-Cre+/0
gp140Prto-'rk
c.1510delC
E481G
Bookstein
.SKMEL-19
T-16
Sachdeva
14q31â€
2kb-
.Contingency
S1761*
methylome
21Life
.Micrographs
enoLOGOS
shift.47
.Tropomyosin-receptor-kinase
.IVT
H-D281G
|/∑hkl∑i
SF3B1WT
survival.134
.Pharmacological
cells90
authors.Efficacy
hematomalignant
oncD4
p53WT-
PDGF–PDGFR
3–68
-transduced
.AF116268
D-11
AR-V5
published,11
M23477
–124/–125
12.45
â€¢¿Towhom
littermates.Several
activity.17
FASAY-tested
AGTGTGTCCACCGTGATCTG
R1835X
cDNA-complemented
17q21.32–q21.33
nger-BAP1
0.730–0.892
L64R
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F4.medium.gif
.IRS-2
R547G
ribosome-bound
V890M
6a–c
LoxP
APRIL-producing
collagen-binding
K57E
correBiochemistry
Alexa594
Viewer.25
.LN
S9-CT26
HeLa-derived
anti-HSP70
DDLPS
U29115
lines.50
I90M
pro-survival
TAL1
SF2
2.463538333
5'-GATAGAGGCAGTTTTGAAGAAATC-3
Y751
1⇓–3
MPN/MDS
Fenrick
Breast-conserving
4E26
S310F/Y
target.15
rehybridization
sections37
agents5
reexpressed
CMEMS
005465.4
helix-distorting
pSBE428
TGAGTTTTCCAGTCCAAGGGTG
Deprotonation
ATP11A
C-helix-out
Habener
∼10.5
OR8U8
CDK4-Y17F
target-identification
5,197-bp
phorbol
AKT-binding
.European
COL27A1
60219601–60273100
5′-GGAGGACAATGACTACGGC-3′
chemoembolization
138:1
K83N
1,820
Reverse-Transcriptase
purities
TheFGFR1
1528–1863
Rosa+/ERCRE
Rufini
P681L
tet-approved
C57BL6/J3Balb/c
CD3/TCRαβlow
10.580
PIK3CAthe
7,21
5/58
Lats22/2
SCEB
885-A
.Desmoid
p53-R172H
cells.Expression
CCND1-GSK3B
monospecific
.Tricribine
3'-gTTTACAGGGCGAGACctag-
.TheHIP1/PDGFβR
R121L
+E2
neurokinins
self-aggregated
DLBCLs12
.T98G
Ser298
3/44
//www.ncbi.nlm
O-764
PI3-Akt
FM-binding
G310S
IPSS-R
6x-His
His105Arg
Nowakowska
subtypes18
p.=
PH-like
pseudohypoaldosteronism
transcription.BCL2
MLL-SEPT6
justifications
15–37
15-fold
45.3
cancer8,9
II.10
disease19
G501S
64,66,67,69
Gayet
Hamiche
C481
histochemical
phosphoELK-1S383
Gly-12/Ala-59
gene.4,5
EGF‐like
HindIII/ClaI
367.3
R3.50Y
JMJD2
FLAG-Ezh2H689A
JBW301
Ala486
13/86
Yada
CTTCTTGATCTTATCTCCAGATTTGGTCTC
Intraluminal
L17P
proliferation14
risk-modifying
circumferential
months.22
1940s3
7aA044
pimozide
sc-764
pVHL-HIFα
EhIF
affinity/protein
βE3globin
elsewhere.4
Favallier
33,39,62Å
cystine-rich
TGCCTTTTCTCACCTGCATTC
.7007G
c.3845A
USP28
CTCACAGGACAAGGATGCGGTTTGTCA
sc-8989
CA77467
2,102
anti-CD8-PerCP
numer-
.044333
1,028
autoimmune-based
5′-GGCAGACCAGCATGACAGATT-3′
TGF-alpha
SBE4-lux
P=0.751
HLA-DR.
EMBL3-SP6/T7
permutation-based
7350
pTrc10Gly11
SH3-mediated
FLT3-ITD-mediated
.BrdU-incorporated
Oncotator9
5′-CCAUGAGGAAAUGAGAGAAAUGCUU-3′
//www.hgsc.bcm.edu/sites/default/files/documents/Illumina_Barcoded_Paired-End_Capture_Library_Preparation.pdf
miR-34
ERBB2-
non-steroid
.Mll3
HER2-
ACCAGCAGCTCCTACACC
Kaldis
trP1-Exon27R
MIAPaCa
G|
.AXL
Eychene
metastases.100
EcoR
algorithms1
a-10
thrombospondin-1
P435L
0.45-um
Wittinghofer
Huesca
Gallegos-Ruiz
product/corresponding
localised
recognizedby
clinically-related
Waldner
BRAF—G442S
CAUGGUAGUCACUAACAUAdTdT
10m—began
ETV1-1c
Luger
alteration.4
pEGFP-C2
NCT01324479
Rajeshwari
Titer-Blue
M/76
p,0.001
−157/+24
.MMTV-Wnt1
.Unmodified
3008TrA
AZD8931
15N-labeled
A_51_P463765
ERCC3_F1
73·3
Ercc1Δ
FGFR1.21
.Mcl-1
01/2002
3−7
GISTs41
MuGAPDH-1S
E18.5
linesCell
memprin/A5/PTPμ
.Stylianos
pAD4-ras
6f
HCT8/HCT15
pYNZ22
chp.edu
2.38
.Transcriptomic
studies12–17,19,21
R299P
luteus
Megalencephaly-capillary
phosphorothioate
pEAA295
Cul3
.8,42
CL/F
Alimandi
211421_s_at
RTS
GC.Tumor
7.92
identified.12
Nawshad
2.5µg
v9.2
p.W308L
.Fastq
Atm+/KD
MLL-11q23
.11,18,19
COV318
104cells
Ba/F3-cells
emerge5,6
Y.-M.Y.
N-region
beneficial.23
1616
assays.72
CAGAGCCAGC-3′
0.83
Disease-Associated
described.27
CD8m/CD8T
Cleavage-stimulation
Stancovski
–31
BEAS‐2B
weeks.6
NCT02499614
www.pjbpubs.com/pharmaprojects/index.htm
M160I
amountsof
SPOPBTB/3-box
I566_D578del
Rasgenes
G-helices
Fmoc
αP-p70S6kinase
238–249
SFRPs
70–166
Lucitanib
R253
violet-acetic
MSX1
neoplasms.23
TG−
.Cordon-Cardo
FGFR4–Y367C
anti-biotin
facio-cardio-dental
Gar1p
on-house
catenin
.Including
PTCL59
NHM16
androgen-liganded
p27G177×
CMV-Neo-Bam
bi-allelic
Medicale
lipofuscinosis
53.Despite
172,173
methods.19
Co-immunoprecipitated
TUBGCP2
computationally
1a-3
lines13
4484del
COL6A1
cow,26
RhoA-associated
3–5,9
age3
5′-UTR-WT
1503_1520del
GAL10-MSH6
ERα,30
Spry1/2
Arg140
.Oligonucleotide
pC53
5597G→T
cocultured
pY+4
.Different
2318
∼150-fold
pGBT10
Ras-GAP
debate.1
F470I
SPT
deprivation40
procedures.
Maycroft
Cytopathology
MEK1-mutated
chromatinmodifying
320-
MLCom
501–510
5'-AGGCATGTCT-3
-2174
0.7947
R273C/T284R-DNA
amber99sb
CDK6-specific
activated…
Castro-Rivera
2,5-diphenyltetrazolium
2.2-4.8
07–627
single-mutant
85-PT78
GGAGTTAGGCAGGTTAGGGG
HHT
S985
kinase-AKT-mTOR
P1034L
agtcgagttccaaccttcg
E697-L1017
BRCA1/RAD51/hUBC9
pSp65
FRS2a
AZD6244-mediated
min-coverage=10
477b
SWI/SNF-A
Columnar
RB-P
apo–protein
1780
Strains—Yeast
marrow.93
.Break
0.13-6.20
Sephacel
5alpha-androstane-3beta,17beta-diol
Ser37/33
DNAseq
WIPF2
study.10
E228K
13B3
Tabuchi
ofviral
five-nucleotide
16.37
ER+PR+HER2+
PK6101
GSE19180
Agonist-liganded
/DbpA
signaling23
Cohesion
.Hata
mutations38-40
Ismaninger
401–406
14/14
rs7903146
IVS19–2840
TCGAGCCCCCACAGAAGAAGATAAAGAGCG-3
thermolysin
YesNoRefs.28
COLO741
PowerPlex16
5′‐GACACTGAAATATTTTCTAGCAATTGCGGGAGGAAAATGGG‐3′
0·67
presentation2
oren.becher
LumB
CyQUANT®
CTGACCACGAAAGAAGAAGACA
8.0/0.9
IVS9+536C-T
G0109
F270S
SCP
HCC827-HGF
mice17
N+
3-hybrid
HaeIII-cleaved
pathway.19
10990
FUNPEC-RP
motifs93-95
pR26-Pik3ca
c.59G
drug-susceptible
GFP-VHL172-positive
plagiocephaly
AD1-AD2
Conspicuously
F595I
HLA-A*2409N
sequestosome
rupture†
expression.MDM2
Thr230Pro
GenMAPP
Intensity/Sigma
ligand–dependent
tumour-producing
controls.21
bacmids
346/698
subcategorized
rs267603578
NOVARTIS
XL-2000
IL21R
mutagenesis33
Effector-Binding
Pro-197/Phe-198
.Excessive
BRAFG469-mutated
5′CTGGGGTATCAGGTAGGT3′
CSF1R/39
svn1hcsi.s
Schleutker
s00441
loci.49
554
69Carboxyl
KITV654A
steroidogenesis
co-evolved
.Dishes
DHPLC/DNA
0-65
ATR-Chk1
ATPphosphate
3.612
Mac-1+/Gr-1+
measurability
culture35
P224S
-homeodomain
Encyclopaedia
E9.5-E13.5
.AII_1
decomp
71,238.0±11,382.0
73.4±8.0
22p.A502_Y503dup8z
c.876delG
LBP
cells/reaction
co-cluster
17/61
pepsin-digested
C618R/E543X
pneumomediastinum
E054
HER2for
K476E
R411Q
biotinylatedfragmented
ThermoScript™
4FVR
family.6
Time-response
RPMI-8226
PN5
processes/ribosomal
unfolding-refolding
¯anked
performed.The
Haematocrit
R-Smad-binding
SEC31A109
informatics-based
0.2mM
E143K
Akt-driven
79/130
swab
13-nucleotide
TheEdmondson-Steiner
NF1-driven
346A
TRC0000072243
eGl
p.Y772_A775dup
ccaaactgaattatttgtgccatc
A501T
235K
mTOR-G6862A
colon-responsive
EGFR/ErbB2-KD
AML.43
75.2
ymsh3
e.g
GelMount
B–elongin
A_gambiae
Rheb-GTP
cy5/cy3
Mmp11
resistance-generating
coimmunopurification
−EGFR
R174Q,4
Skin-related
f/48
P-ERK1
Â¡i\of
IKKβ
.PTH-Cre-positive
CD40-mediated
JSI
transmissible
Horb
C3H/He
mutations.42
Q238R
3500HT
nine-alanine
skin-derived
element19
14,999
.6H
Kovall
98.3
EWSR1-FEV
GLP-1-induced
brca1
–http
R1513
TOR
GGGGTACCCCCTGCTCCGAAATAAACA
nonseminomatous
oocytes/section
24.2–27.5
B31
-gaaagcagccaatgggagttc-3
f/38
Antennapedia-
V600E/KB-RAF
GAN
FGF-pathway
Q1382R
sc-9137
p≤4.6e10
half-brains
.Bead-bound
p.A11
Fig.3e
Type-B
IRES/PURO
0–57
RA-mediated
1/30.000
R188I
Non-GCB
post-Chernobyl
15T
humangastric
mutant-like
approx0.5
MAP3K1,22
transcription-independent
MDM2-null
acid-sensing
analysis17-18
whetherchanges
γ-phospho-exchange
TfÃ¬R-Ã¬lgene
PKN1/ROCK–
withfilled
_n_=6
2-phenylaminopyrimidines
SDSerence
RAD51-promoted
0.211797223
FcγRIIIa
47469–47475
T716
pMSCV-HA-CBL
c.1068_1077del10
.Poulain
LRP5L
complex40
GGTAGTAGGTATTTA
lower-MW
.LGK974
54.6
PGBKT7
Glu762
p53175P
ETV6-TTL
Ennabli
2−6.3EST384910
S1774TOur
2/230
Polyhydramnios
Perez-Oliva
M239I
5′-TGAGTCAGTATCAGAGACG
HLA-associated
Bao
v.13
MAP2K1/MAP2K2
160.00KB
Tyr503insAlaTyr
anti-CD13
arrest.40-42
−138/−139
institution-approved
po0.005
www.dovepress.com
variant.8
segment30
TpC
R2=0.37
EcoRI–XhoI
.Combination
5′-ttaaagtttggcctgagctagtttggccttc-3′
nonorthodontic
Myc‐BRCA1
+/+/1.5
Costa-Guda
AXIN1/2
sunitinib.16
HN-Smad4+/–
0.2–1μg
DMRT1
L622P
Pose-Clustering
100000
BRIP
slit-diaphragm
MNU13
selectin
M.spretus
.BAC
pGPD-TRX1
EGM-2
E368K
NBD-ATP
EGFR-RAS-MAPK
MDM2-Luc
UM-UC14
∼1000-fold
Leukopenia
TTGGAGAGCGCGGCCGA
used.27
D829
Ser243
∼150
tomography/magnetic
SS-34
°C-10
0.0456
protocol44
lysosomes.10
.Sports
Buonamici
.Tight
DDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASI
types.28–31
Zeocin™
p/
amplification-refractory
BCAC
Tcf
I1293I
1/3rd
Fig.44A
N.J
Kressel
1base
McWhirter
~66-67kb
F36
//www.stratagene.com
GFP-alleles
q=0.065
ioPh*Th
ELREA
DFG-aspartates
.Substantial
patients.2
MmAGAAAR35
Immunodepletion
5′-CATCATCATTGTGGCTGAGG-3′
siteto
Lys51–Asp54
EWSR1–ERG
isoforms.4,5
Glu-975
V166I
Dermatologic
S-1A
b-catenins
ABComplex
.WM266.4
p.Glu227_Ser295del
SamplesFrom
.aEighty-five
miceA
ductal/no
200-µm
mMNaCl
NF1-REP-c.
g/daily
ETV6-PDGFRβ–transformed
therapies*
Caldes
melanomas64
phospho-SRC
c.9876G
Figure2d
/2KA4
vitro1,2
heterozygosityand
1,930
RFS-MycS62A/Wap-Cre
HSPA2
LVIME1
groups.Prioritization
RTKs,8,9
oridonin
K422
6-MV
SLBP
CENvectors
.L861Q
PMB1
antip19
34.0±17.8
8-anilinonaphthalene-1-sulphonic
pSMAD
haemato-poietic
Mgat3
Kononen
5′GTGGTGGTGAGGCTGTAGCC3′
47-57
leukemiaderived
Axioskop-2+
FH-912
Mowiol
Tet1-
0.14482608
receptors33
.Ion
mononu
550–561
interation
JAK2V617F-Y931C/I1018W
.Eric
phosphatebuffer
FGFR/CEP
3097
1.493
nog
Ishikiriyama
GBCA
0–126
pH3+
L-V
PGAM2
pathways.14
−325
Dijke
⩾2
al.,4
5d–f
5′-CCTAGAGTTCTGAAGCACGCGGTTCTCAGT-AAGCG-3′
R375P
pLXSN-Neo
3.9-5.4
mut-positive
.Casein
mBRAF
C634R/Y806E
TRAIL-induced
W42
iTRAQ
439.12
Bonferroni-Dunn
RG214069
.Ledel
cells.20-22
.Examining
K-M.
354V
1140–2683
cancer2
clear-2
Akt12
pg/ml–1,000
BCA™
targets/
endothelial-to-mesenchymal
Co8
16–31
cells/6-cm
0.869
miRNA-regulated
erlotinib/gefitinib
carboplatin/paclitaxel
phospho-AKTS473
109/liter
BRAF-mutant
9.61
,700
pSRGN-derived
.HCT-116
FBS+1mM
chaperone
effectordomain
Pyruvat
TEL/PDGFRbeta
Martinez-Barbera
recombinase/loxP
.2125C
GCACGGAAUUUGAACAGUAUCUGCA
2.5-3.7
99/1383
CHK2-like
CMV-Cre−/−
12-5
MDA-MB468-IKBKE-Y88C
CGAGTATTGTTAGTAATACG
Econo1
pre-equilibrated
58/F
JHOC5
.subset
v1.5
bipopulation
SFA7
months—not
Taïeb
GD855
v10.0
expression.10
MSI/p53-
exogeneous
.Engelman
5′-GTGTTAGTAATTTGGGGGAAAGTTT-3′
4-
.Pfister
French-Belgian-Swiss
93060
TGF-β–mediated
~dash-dot
BCR–ABL-induced
FGFR1-amplified/HR-positive
Surface-to-total
SEPT9
PAb1801
Single-organoid
Lopez-Ilasaca
40.Male
Flag-MLH1-ΔNLS
RIP140733–1158
streptavidin-biotin
Beas2b
CPT-SIOP-2000
1446del
levels.18
147.9
Interferin
c.2007−117t
G88E
-approved
746H5-hybridizing
Fio
H110R
0.00046
6X
Autoradiograms
P53ΔE5
mislocalize
N554H
HIII2R
K402
c.44_45insT
FoxO-binding
.8524
Arg142
pS9-GSK3B
taneous
chromosomes.28,35
0.567
1R–3R
1/35
26–
/Golgi
1806C
c-Myc-transduced
date,19–21
D3073G
Diliberto
tristetraprolin
p.Arg337X
K-rasV12-expressing
sheet-loop
IE84
819
.NPHP4
DLBCL14,45
bisulfite-modified
SJCRH
F239V
-Venus
93.3
anti-Thr172
PKCα
FLX
T666M
15,841
casesOther
34N-morpholino
0.32-0.62
p.R108K
to20
Ungureanu
.GSEA
SmarcB1
GATGGACGCCAGACAAGC
seven-in-absentia
AUA
shRNALentiviral
.Occult
Genuardi
97–99
8-amino
20-ng/ml
7764–7774
SNPdetector36
BRCC
1-457
deletion/
BFL
overlapping/fused
mActin
.Phosphorylation
once.
component-binding
Neu/HER2
H-roi
PTENdeficient
Ge´raud
pY653/Y654KD
shMll3-expressing
T7-JAK2
.Medium
onlyinhibited
theCIC–DUX4
1–353
K2003I
S3b
∼95th
9:3
Battaglioli
Fig.44B
leukaemias16
Multimodality
transactivation/repression
K-RasG60_A66dup
​Table44
823c
IITAT
lymphokine-mediated
recharging
PTEN-K62R
G325
q34.3
Translocase
C–14
12,000x
ATC88ATA
CCTCAAAAGCGTATTGAGTGC
Calibur
//tux.embl-heidelberg.de/
p=0.000622
:177–183
5c–f
uncertain.In
50-nM
//rsb.info.nih.gov/ij/index.html
5'-TGGAGTTCCACTGCAAGGTGTA-3
.Far
B-RAF-MEK
AKT2E17K
.384C
p110γ-R1076H
stratifi
hACTB-Forward
puro-H-Ras
87.25
ubiquitylation15
IFN-g
S709F
p.Leu36Pro
Ba/F3-hKIT-D816V-IRES-EGFP
1q12
S473
anti-V5-HRP
.Blood-derived
spheroid-like
Drosten
EcoRv
day-off
specialed
recapitulating
Hyperresponsiveness
hematoxilyn-eosin
604167
Nanocluster
25×
signal/noise
forward-
ssk
466|
DG10S478
p.Ser1841Ala
p.Arg24Gln
.MATERIAL
NUP214-ABL1-positive
Ipo7
Kazemi-Esfarjani
RARα-expressing
L1267S
ACATCAAGGAACTCGATCGTATCATTGC
2J0L
Cdc6
1.11∼1.66
100/200
genotype-clinical/radiographic
Pharmaprojects
estradiol-stimulated
AL-F.M
NCT00932893
l0-pi
hMLH1account
X-Ray
Díaz
1.0011
exccpt
Y589/Y591/Y597
31-35
cassette28
haplo
E5.0
Bt12
screeningThe
.7023
2.10∼3.08
.Lozenge
FLAG-StrepTagII
Neurooncology
.Pathogenesis
489T
FIP1L1-PDGFRA–transduced
finding25⇓–27
iron–sulfur
Capmatinib
26–39
model.The
EGFR-ICDs
5/113
MAPK-mediated
/TG\
KVVEEI
199.1
LMP-2
Crebbp-HA
aminority
W22
1.95Å
p=0.013
GADD45by
54-4
MetaXpress
pheomelanin
anticipate.
8A245
Ba/F3/FLT3-ITD
death200
p.Arg381Ser
.KS
2mL
signaling.12
mRNAs.Intriguingly
Moroianu
Gln1360*
174–371
P044
1'3
.6-fold
gefitinib.15
p110-specific
AJ277845B*3925N
ER-negative/progesterone
Tel/PDGFRβ-F2
SCide
FH-negative/2SC-positive
colonoscopic
BTB-MATH
p27G177X
assaydifferent
HFM1
8-month-old
Historyc
GSK3ß
54.80
,5B
nt3014G→AR976H
ERG-defined
temperatures.From
AAGGGACCAGTACAG
1,047
Tris-borate–EDTA
COSM42898
CTTGAAATTCTGcAG*CAGTCGAATGGCATA
noncarrying
7th
C-ring
TGGCGAGGAGTTTGAATTCACCCTCTCGGCGC
DN1-DN2
Acommercially
pcDNA6A
MitoProbe
R337L
electrophilic
p=0.0005
BCR-specific
neurofibromin‐1
CCL1
Melzner
LHR
3/53
SMO-V321
WD40-repeat-containing
7.37E06
12,866
17/320
W406A
transrepressed
Oct-1/Runx2
8087
Ac-NPV
RG6-NUMB
Rad50S
SEI
Tyrosine-phosphorylation
DELFIA-based
overexpression–mediated
WOD
MCF-10
AVGSAMFLRFINPAIVSPYEAG
GCG-3
tttctagtaactcagcagcatctca
Myc.Fig
gene-dependent
JQ413994
962del4
KMnO4
−1188
Maunakea
PhosphoALK
TP53R337H
32D3
1673
pS112
Intrafamilial
T58I
Xirodimas
10−41
2/31
536
PF-502/PD-901
sample-dependent
V713L
P2456S
SPOPN-MATH-BTB+
.Suspect
e83380
IT-1
10.0
69–76
macro-complexes
ΔKpnI
LSI–WCP
H-
brokenline
3,063
gi42552104
I2017T
P51
Innova
shRNA-hairpins
F325
NCT00818441
experiments,15
post-reaction
S1B–C
IMR-
Eischen
Teflon-covered
I-04
BApoptosis
HBV/HCV
MPG/GBF
c.187delG
APL204
phospho-Y570
Medioambientales
retransformation
antimouse-peroxidase
0.7:1
lamellipodium
locomotor
MYD88wildtype
models.a
Tsujimoto
H1047Y/K111N
S4C–S4F
Dirupting
SPARC-like
assays.35
HEK293-DDR2
68-271
Co-crystallization
Pierga
139/183
Leu460
Y.-L.
Thr652-X3-Ser656-X3-Gly660
AR9961
c.815G4A
HPaII
7a
pBD-GAL4-Cam
-QVAQGMAFLASKNCI
p≤3.0e15
Npy
N-RasG60E
Kuo
issue36
E1A-binding
carcinogenesis22
G4l8-resistant
mechanistic/molecular
LSL-IDH2
Oberdoerffer
4b–c
68-year-old
postprocessing
mutation-screening
Inhorn
VBMCP±INF-α2
S6k
1.0.1
TGFβTo
activity.26
SYT-SSX1
CTGGGCTAGGCCAAAGGT
ATH
S111C
melanoma-affected
c.4067A
R2505Q
anti-P-AKT
1gene20
50g
G100
3·8
biotin–free
B/T
GAGGAG
TGCTTCTGTACTGCCAGTGGATGTGCA
Asp214
T77
AML1/CBFA2/PEBP2aB
.Wildtype
lymphocytes31
complex/cyclosome
IL2
c.982G
16e19
tuberin-deficient
gigaxonin
19280
Raychaudhuri
=λ0
touch-down
F4,25
GATCCTCGAGAGGCT
Ravichandran
MvA
oxidative-stress-mediated
*Time
Thirty-seven
AKT/AKT1
costimulated
Melanogenesis
DCAI
20-column
25-mm
Lower-grade
CGAGGGAGCrGCAGGGAGCG
Duchenne
Strasberg-Rieber
.MMS
P3k-Induced
row-
mutant.As
Pac10
pLZR–IRES–EGFP
Bcell
Serine/arginine-rich
EGFR/ErbB
NPAT/p220
15989
①
kallikrein
202,401
24-county
TRIP/ΔU3–EF1-α–TAL1
ATGCACTTGGTGTTCACG
3-aa
EGFR21F3
C/DGDP
.RBy50
CCDC6-
MOZ-B
M1a/b
previously.9,11,25
c.861_864del
.Wnt7b
rg=∑Ii=1rigi∑Ii=1gi
ERBB-directed
pFLAG-CMV5.1
204887_s_at
evolution.1
.GDC-0941
model.17
line38
Saturno
Wadayama
BJG-398
q-value=0.001
PVH-IVH
5′-CAGTTCTCGCTTCAGCACGATG-3′
Ago-subfamily
0.47
Tyr764-Val765insHisHis
continuously-cycling
pCMV-Neo-Bam
Thr598
correspondingly
9/121
115:239–240
*11
J6-M2
catalysed
pCS2-TGFBR1*6A
2133
NIC-GFP-transduced
Delbruck
reverse-phase
ACGT/
micro-environmental
G1596V
tcoffee_cgi/index.cgi
Hepatotoxicity
breakpoint-region
Dsk1
11,12,41
g.340C
K101M
n=333
6809G
GST–SH2–SH3–SH2
1309Δ
NonfunctionalFunctional/partiallyfunctionalBreast
Angiopreventive
signalling176
Golstrup
Gln22
2249ins9nt
benefit4
Grigoriadis
normal/cancer
ng•h/mL
IgG-Sepharose
PDFGRβ
anti-rodent
HV
KIT-P
H1124
triple-negative
4-anilinoquinazolines
Vindelov
Anti-HER2
poly-pyrimidine
acid-washed
R/TACCRCA
STRN3–JAK2
pET-cdk4
48*
10-01
resistance.9
I332S
20S
Obsil
10.3–80
SPA-1
.See
D186A
2–156
L163
Towbin
.Martignetti
GNE
types—small
OS9
screening.Allelic
NPM-ALK–expressing
TiTv
Crb3
df=2
cells.Ba/F3
Cα1.76Rearrangements
-CAT
Aunt/uncle
anti-BAD
Map3k2
RacGAP1
mGAPDH
L-X
Pituitary
consensus-type
15I–5′-GTC
-1α-mediated
DCM3
respectively.14
Clincopathological
//bioinformatics.mdanderson.org/OOMPA
C634R/Y806F
35-kD
6.48
FLAG-type
Jackset
disease-free-survival
CCTCTCGATGACTGTGGTCGCCTGCAGG-CAGCGTATG
D575Y
DNA-stimulated
.Download
32/88
.Although
M-280
growth-factor-dependent
gene-expression-profile
post-modifications
.PND
rue
4,784
A_51_P204153
thenvisualized
–0.1
G1266R
components.Recent
PVN
2012-07-20
p.Ile2664Ile
PH/WT-KD
Skiv2l
mutations—all
activity,28
curve-fitted
99.941
–114.5
Rreduced
contentof
4•
oligonucleotide-
mg/day.15
Gronbaek
proteins.Identification
1774-5148
Transfectants
Anti-H3K27me3
neuroblastomas70
3*-kinase-protein
levels.5
RUNX–CBF
0.108294
15+ve
S459F
myristoyl-transferase
meta-analyzed
CBX4
ME16C
RB1
KRAS-WT
36/F
1601
co-clustering
Polyscan
K-Ras→Raf→Mek
particu
53/411
F/61
Dominant-negative
temsirolimus
G759R
Glu67Stop
mutantCabozantinib
'KEGG
vetting
polyG-tract
kinase5
~12
35S-methionine-labeled
Mavrakis
rs1137101
new-born
TCGA-19-2619
.D404
Δ576Pc-Kit
non-NSCLC
lestaurtinib
Gardembas
ancestry-matched
S5L
.Nonparametric
platin-based
BAP1-carrying
3762_3763insAG
R562P
0.5191
includeTP53
FHDLRECAGEHFPSNREV
OTTHUMT00000280548
L2688P
functions.51
rhotekin-RBD
GDC-0879–mediated
SPRED
'calcium
.NER
VUSb
P-TEFb
Tabara
Y791A
pEGFP-SPA-1
linesThe
.H3.3K36
GRASP70
hypercholesterolaemia
p.E490G
C586
-generating
In-vitro
SHIFT30
multiplicative
I62V
Immobilization
ASH2L
S256T
43.1
C198R
58,900
KA622
GGCCTA
0.1.4
FHL-mediated
.FBS
ab1191
IVS14-2A
S804F
MSCVIRES-EGFP
III.11
Ser326
Gimelli
FA-73
1−5.5ADAM23A
fusion.6
DISC.7
GTGagarose
ARCN1
pCMV-tag2A
Maltham
'2P-labeled
.4L
Chloride
GACATC
p110γ-K832R
0.320.000148
Kaibuchi
7,16
CP-associated
2.3–2.2
UUGUCUACCUUCUCGGUCACACUCA
LSm12
ofGIST
Ndg1
Bostick
3·0–11·1
MF-ChemiBIS
p=0·0309
0.94022
.Aiming
FRT19A
*D835Y
Immunodeficiency
Proteomics
9/2014
missplicing
P.G874Se
327-bp
53BP1
MaxEnt
1Y
PIK3CAH1047R-independent
pGL2-754TR
C0
71229
.24,25
L744F
5-fluororotic
ARccr-binding
Y764
leuprolide
oncogenesbut
parametrial
NF1-loss
D620E
Benlloch
eosinophilia.45
23.5±6.4
//snpeff.sourceforge.net
stacked-pentamers
p.Lys328_Lys329insVal
2.0–2.5
WBP7
1.4–4.2
Val82−Phe90
Maheshwar
likelihood-based
loss.20–23
.Dicer1Δ
BcrAblT315I
Chromatograph
2.22.0
p53-transfected
Lupron
NIK
.Anti-ERα
0.41*
K333E
haploinusufficiency
S1651F
PRISM®
613-347-1938.
uGGAGu
Pasche
glutathione-S-transferase
non-fluorescent
437–445
cancers44
p=0.358
pIS2
2134
hsc-70
10–24
cancer45
120,121
DSRCTs
native-IP
UHR/HBR
15-19
anti-Stat
spininfection
c.2075C
trials.13
equipping
5q-syndrome
50,399.24
Ser111
1q24
neurofibro
RR-2500
FANCJ
cells.Abnormalities
HEPI-RAB
hyper-recombination
.Joint
pathway8
DHR123
www.hgvs.org/mutnomen
v3.3.3
wide-set
Albihn
MCSFR
imatinib43
1p32-Amplified
methyltransferase-treated
VEFGR2
181-52-744-
mMessage
Pharmacia-LKB
linitus
10.
AML.15,23,27
Eco47III
ATG-*TTG
F/R
AdoMet-bound
Changmeng
Dose-responses
patient-informed
CDCA2
/66.6
Morphogenesis
.Knijn
30,000
45–82
near-confluency
17p13.1–p13.3
dehydrogenase22
Set1/COMPASS
SP71
.−PV
β-Alanine
exons.11
v11.2
SceI
10-year-old
26p.F506L
pZNa
Whittaker10
MCF10CA1h
Akt-E40K
East-Asian
P179L
293FT
397melb-cateninS37F
SCDencompassing
thr202
FIR
5′-ATATGAAGGTGAAGGGCGAGG-3′
mesenchymal/invasive
dsh
427692Transversionâ€˜ITI
andMsh2
L2-domain
.Rip1E-cad
mutation.PowerPoint
R617C
f/64
p.Ile2315Val
Mm6.6kb-LacZ
hMSH3mutation
previously2
0.0020e
FA-53
5´106
anhydride
fetal/or
D-glucose
SNF96.2
ER/cis-Golgi
CreERT2/RMCE
BRCA-tumour
AGACCCTGTTATGCTGTGGG
DNAladder
D259G
electronic_applications
microfiltered
tg-3′
malformatifs
anti-MMP-9
Itahana
-EGFR
Neurobasal
DOWN-REGULATION
p.Glu619Lys
levels1
IL-3βR
1995.7
lesion-specific
Mouse-Cy3
//scansite.mit.edu
7558
1568
W628R
SOS-enhancing
demonstrative
97.47
44–319
respectively8
loop–phosphorylated
2/423
gene19
pmol/μg
DNAMini
Endothelial-cell-specific
HEPES-KOH
AMLCG.19
PK7209
polyI/polyC-activated
Figure4,4
139:1315-26
agents40
5'-TGCATTGTTCAAGAGTCAAG-3
CreER™
relevantfor
10128
S37Ab-cat.
P2*
HPV-39
Y503dup
mGFP-tH
P1859R
H-antp16mut
16–24
trigging
Alb
Hypochondroplasia
G34E
GloMaxTM
HA-Ub
Mm768bpΔAGAAAR/ΔGGAA-
Δ12–13
ARF=0.14plusminus0.03
crizotinib,2
R226W
ACVR1Q207D−c.a.-mediated
1–1863
L826M
Co15
Tgfb
particular—exert
.Imai
DLBCL7
history.We
ANBL0032
_N_A_TU_R_E
TTCCAGCAGTCACTAGGC
61x
CBFbeta-SMMHC
0.0–9.2
Kinderpoliklinik
whereasonly
.Ser45
❚Image
G347V
2466
Anti-cdk6
Vainshnavi
10.1182/blood-2002-03-0953
M918T
members.3,17,18
Allander
ErbB-null
Zur
hgLiftOver
literature50
.Carraway
40682
castration-sensitive
erlotinib.35,36
*Leads
mesendodermal
3769
T290S
HCC.15,18-20
adamalysin
FGFR4-Dovitinib
CD45.1+/CD45.2+
.M.M
MCF10A-HER2
RAD1901
.Fifty-three
.Ten-thousand
1q21.2
receptorand
quadruple-negative
Ly6A
GGGACACCACGGACCAGACCT
Partial-Responders
Cos-7
UAS-LPT-RNAi
PI3K-α
0.166
SF3B1,26,28
Double-hit
BristolMyers
RPS11
CBT
functional-impact
5′-GATGGG
1.2–17.1
PTP
CCNL2
NITISS
80PC
pathway8–10
10b
AMKL.22
Loenarz
.Phenol
monoclonality
1–39
JHUEM7
DNA-staining
tract.1
D11S535
CFC110
rit
thepatient
receptor-FTP
1aleuGl
ratio:1:0.5+0.5
erties
.Q3d
nity
128,145,146
6874
.YAPC
self-association.4
Daser
T157A/L198/L235A
274.5
Facility.22
85.7
A306T
Vitae
MDA-MB-435s
Cytometrics
IDH1/G-CIMP
Glu52
3468
PBRM14
gamma-induced
.RESULTSHisto-pathological
STAG2-mutant
Ab16918
anemia.1,2
invivo
E007
toFig
5174
-LYS
nontumor
171–564
+82-2-7603380
ASXL1-MT2
low-proliferative
thoracoscopic
kinase.2
P=0.18
H3K27me3-marked
anti-H3K36me3
exonucleaseVII
membranes.27
SMO,4
NUP98-rearranged
novemcinctus
L42R
pre-imatinib
PIK3R1E160∗
ALK-expressing
muaion
blood-derived
IFNα-stimulated
.SSCV
Rmsd
LiCI/6
MnTMPyP
ubiquitination
KpnI-BamHI
p.557_558del
JEKO-1
D194N
IGH–EPOR
granzymB
PCR4
ETV6–JAK2-positive
E-associated
black-¢lled
PRKCB-driven
right/ascending
spliceosome
PIK3CA-
D–F
Polyphen-2
12,15,17
complex.52
hIL7R_cP2s
6-histidine-tagged
1/97
Methylthiotetrazole
p.Val590fs
H98R
Venio
Ar9SerHlsGlyProAspAlalyslC
un-neddylated
two-plasmid
2895
Marlborough
eIF-2B
twp
I-L
25–84
ZIPneo
Glu501/Lys483
SLC45A3-FGFR2
May-Grünwald-Giemsa-stained
KDMC5
H3R8me2s
V1065
MG-B2
anti-mitogenic
5'-AACACGTAGCAGCTCGGATCG-3
8p11
VariantsThe
0.025
anti-CDK8
10.53
RT-Sf1
NMD-mediated
MGprobe.Fig
833
mispair
SPOPMATH-BTB+
SIAH2
E734Q
.Café-au-lait
individuals.23
G2813E
BAQ
.Sk-Mel-28
HER2E-mRNA-subtype/HER2-protein
B56δ-regulated
endometroid
26/55
.Instead
.H3K27
breast7
E545G/M793T
ν
BT11
LBH-positive
tumor-unique
.Be
ng/
serum-250
z90
nihms646437t19.jpg
phosphoserines
Novaplus
deficiency.34,47
180-182
B*07-specific
shRNA-2
methanol
0.197–3.174
stop1'71
whole-human-genome
-CCCATAGTGGTAGCCTGAGGACT-3
PCC–PGL
c.4879A
**lacks
Gr-1+CD11b−
Hh-signaling
K8−K14+
D594ABRaf-expressing
diaphyseal
1:10.000
thelatter
proliferation.15
eholerae
p16.33
H671
BIDMC
.Fo
anti-MEK1/2
VAV1
HMW
unknown51
D137N
37.7
483KB
HIP2372F
E125G
mutations,55
49.8
19.25
Superose-12
glutathione‐beads
Multiplicom
one-stage
Kras+/LSL-G12DIkk2fl/flPdx1-cre
0.28Gene
1.3e−25
GPSQCPLCK
D.F.
NCI-H661
9/59
genemutation
Glu659-Phe12
H280
snR10
chromosome-negative
pro-plus
St.Giles
.Littlepage
28.29
I2500M
Clone4
13,425,865
1475A
Kisseleva
function-l
Leu61
GSK2118436-resistant
pro-migratory
DK-
Tasmania
V89M
left-truncation
isencoded
.Crystallization
E266∗
.E18
5′CCDC170
cytocidal
imidazoleconcentrations
chickenβ
PTEN/
−y
doseresponsively
56C
PIK3CA/PTEN
point-
pKT3
KRAS2
2373
GP369
​Figure9B
oligo-nucleosomes
lymphokines
.4185G
B-other
Fibromyxoid
MIG-Bcr-Ablwt
550291
Flag-β-TRCP1
.0032
REF
c.3179A
ab58641
invasion33
sialotransferrin
hyposignal
.Unliganded
ENVISION+
frequencies,13,14,15
fms-like
Arg-405
BBRC
B-overexpressing
4ς-positive
phenotype.2
.Ets2
functions2
MINIPREP
P522T
191/+94
9167
1–188
a-12P
receptor–like
MLC
//www.genet.sickkids.on.ca/˜ali/splice
DELTEX
epoetin
studiescDNAs
Pals1
LVEF
2/helix
absorbance
5′-GGCTTCATCCACCACATACAGG
immunochemotherapy
Bcl2L11
p.C61G
anti-CD23
.Array-based
tumors.24
2451
YUSIT1
rad51d
anti-TbRII
μg/m
expression.27
*Asp
cells,26
ERα72
genome-maintenance
si08ResPPP6CWT
6/37
SNU-324
Dermatological
R249S/T123A
initiation/progression
JAK2.33
17-hydroxyprogesterone
MassARRAY®
RPA2
856
development.7-9
charge–charge
falsenegative
gel-selected
short-tailed
anti-pFOXO1/FOXO3A
EGFR-knockout
1201
Y1021F
pLenti-ErbB4,16
0.40–0.60
SRSF4
obesity-resistance
Kajita
75-bp
hydrolysis.30
S4–S11
model.15
2β
Holtkamp
TACATC
earlier.13
Cyc
PRDM6
CAGCTCCATCTGCATGGCTTG
cascade.18-26
+P16
→TGA
L834R/T766M
WI2-1114H9
enhancerless
.6I
T37/
Workup
β-RII
33-38
THPO-independent
β-decarboxylating
RP3
1st-
YH
.R248T
6.41
54b
p.M1_E165del
Djabali
BCR-ABL,24
PC2
4267
pCDNA3-HA/ER
tissues67
23/24
.KITM541L
-MKHFDSFKC
frame-shift
LDK
KNN
promotersequence
6Department
5/20
FOXA3
preferentially
0.402711757
Podocytes
p53-defective
2104–2076
RG-28
alone*
BRCA2/10
mismatch-specific
paraffin-embedded
S1506L
SF3B1MUT-associated
301040
Fbw7-SBD
PBTC-001
7.161872625
EpoR-
FZR1-mediated
5'-CAGCAGATCCAGAGCCATAGAGAA-3
7S1327
C2HC
DUG
multi-step
Ile246
−1.29
pre-annealed
Leukemogenesis
Third-party
789
pan-Myc
KRAS-mutant/FSTL5-wild-type
toV774
3k
inhibitor,17
iNtron
Asp792
APEH–SHISA5
Phe157
partners11
R605P
N239D
.Accrual
profilingBroad
DeBerardinis
CIMF
0.03–1.59
Osx-GFP-Cre+
pEAE39
honoraria
LR01-081
Gli3
leucine-rich
ER1656
10o
ER-positive
48129
MCF10AL869R/T798I
stimulation.9
imageTo
Y371H
L536E
MET16
Mac-1/CD11b
gigabases
lmFit
51-79
characteriza
Gleason-score
Assay-on-Demand
assays.11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,35
date.2
testicular
68878224
type-restricted
Yukinari
466
XP_003122293.3
146255
//www.sanger.ac.uk/cosmic
ofourknowledge
envelope.18,23
Ala57Val
Fermentas-Thermo
U4
800-conjugated
ABC-1
T-ALL-derived
R675Q
brivanib
120-752
GCG-Rich
minimax
q14
culture-associated
MG132-treated
p=0.08
Ectodomain
.HNF-1α
H36P
Gly17
tyrosine-to-lysine
GRIA2
splicing-related
ΔBRAF-MYC
ZsGreen−CD45+F4/80+
10859A
Manuscript
Valasani
phenotype
q-RT-PCR
immunoblotted
ON01910
5-TAMRA
p=0.206
histone-DNA
uAl
GDP-Fuc
gene–
ferrochelatase
Niewolik
SW1463
XRCC1–DNA
MMR-deficient
pGW1811
GFP–LKB1
Raf-1-
8:22
PAPSS1
phospho-S6
Smoking-related
30.9
FOXO1-DNA
29S9
T529M
20q13.3
D135G
α-synaptophysin
C17ORF37
EphA4
.Cha
ADP-depleted
pSTAT1/3/5
HotStarTqa
KE–CDK4
TGC3GGC
A34D
P.0
X-100/20
F.B
cadherins
MYC-repressed
pEF-BOS-puro
RT4
His1047Tyr
527,325
22.1
q21.3q23.1
BCL2-
POLG2
paraganglia.7
v-FLIPs
Rnd1
8/119
.PTPN11/Shp2
pBabe-Puro
cytoskeleton-disrupting
0/30
case–
TGACGACGGGAGAGGAAG
phatase-1B
CDP-Star
RasGAP-334
receptor,3but
refSeq
.Wallace
2-regular
RFG
low-back
Phospho-antibodies
-'3
.HEL-specific
5/77
Agnelli
c.2500G
61/125
28–105
c.341-11T
summa‑
.NSE
protein.10-12
inhibitors1,4
Polyethylenimine
C396R
deregulation191
Qiaquick
2−ΔCt
//about.jstor.org/terms
FGFR
SRY-F
.Cohorts
7/8.3
trk6
ofHaCaT
hyperactivates
lymphnode
boxplots
Q2223K
previously21
STAT5B-mutant
construct.9
vago-vagal
9•
.137
Rwork
Ohkura
Geiman
0023
low/very
2-HG
BRCA1-producing
1144del21
cancer.4
P814S
TP73-AS1
P-LRP6S1490
high-levels
5E3
SMO-CA
P88R
p.N659K
.Cheng*
v51
AACATCAT
.Remove
68,67
Second-line
Glu-906
β1-integrins
p.R462H
beta-2-
GBM17
profilingMechanistic
CS03
EN-K380N
c.226
Haurani
33–82
0.1292
Schmidlin
calcium-regulated
isothyocyanate
Gluto-Lys
anti-LATS1
10e−22
BamHI-Q
1K2P
described11,12
FOP.1
pCLE
TGF-beta/Smad4
GT239
HGGs,6
AgarTo
criteria4
Fug-II/16
5484G4A
Figure4E
5'-ctcctgctcagtgattttagagagaggatctcgtg-3
A042
microarray
acid-labeled
Mumby
trials.12–14
-RLPQLVDMAA-
147,500,000–147,900,000
.Trimming
EJ-RAS
L1820F
R807Q
program18
1Figure
U*S*VT
PIK3CAin
annotation1
interestingto
cVector
37–86
SCH772984
2A–B
storage.6His-ETS2
intertwined,3
PPP1R1
123–126
settings18
0–25
Ynization
∼7,200
TCAGAGCTTTGAGCAGGTAGTG
binding45
thescientific
FAM46A
20.2
ofmismatch
m/71
Post-therapyNumber
MicroBeta
dell3
oncocytes
Franceschi
P/Na
pab1801
-TAAATCATAAGAAATTCG-
Xpress-tagged
studies.5–7
G418-supplemented
.LATS1-mediated
TUBULIN
p=0.016
box-driven
Implicate
hexamer
control86
197K
Iwahara
S2591
Lys1731*
ASXL1/2
NP_005334
cooccur
c-Myb-mediated
PTPN6
D32G
.50,000
Asn-923
3—figure
gctgcggcagaaggtcaagt
siMYC
94–292
Mlst8
32649–32657
Bax1
Met1783
PP1δ
CASP1
DNMT3L\
VHL+/+
Rac–p110β
other.Figure
p.R29W
interlexA
Arg276
3:10
milk/PBS
.Lentiviruses
3',5'-monophosphate
1.272
Pre-scission
phenotype.13
L63Xc
allorecognition
5′-CCAGCTCTGAACAGATCATG-3′
values.39
LiOAc
DQB1
12Y
allospecificities
subunit-related
rhebGAP
apoptosis-sensitizing
organisms,47
MXD1/MAX
MEK/
vitro.30
medicine.nature.com
Asp1203
E010
SPDGHE566-571K
Ficoll-Conray
SERPINE1
Sambuughin
5′-ccagggaagatgcggggtag-3′
helixturn-helixmotif
Plaschke
T1-T4
95Â°C
substrate-signaling
MARTÍNEZ
type–Glu17Lys
548–646
U12819
samples.60
well-delineated
KRAS-G12V
glycan-binding
H412Y
.Serum-starved
1.099
ZFP36
KMT2D-
C−terminal
www.ensembl.org/Homosapiens
ΔHSV
0.3840
BRCA-mediated
exposure.15
p.M224R
BTB-proteins
6/349
hydrolyzed/molecule
RAS-V12
L-plastin
2112
P16–2
PCAT2
higher-resolution
template25
H662
APR1–APR2
pCDNA3-NLbh
AACTGTCTCCCTCCTTCCTTG
non-cardiac
Aα—two
instability53
1.10-2.17
376
sf9
R675/669
Autoradiographic
IL-5–dependent
con¯icting
pLNCX-HA-AKT1
deficiency.5
CMV-Mad
2ITZ
γ-koz-for/γ-rev
8a2
phytohaemagglutinin
RAD51/52
5′-ACGAGGACGACGACAGAGAT-3′/5′-TCCCGGCAAAAACAAATAAG-3′
G.N
S375F
exosites
gastrulation.9
SC9976
counterregulatory
gtaagatcct
GAAAGGGAAAAGACCCAGTG
5762
already-present
14-3-3s
Shiozawa
Dicer1Δ/Δ–transplanted
53,273
Jak2-T875N
0-44
Asp842Tyr
Fig2H
TdZ
p-STAT1
metastatic/progressive
N792
nucleotide–MutL
PLCγD
CASR
.Destabilized
Unfavourable
1684
runt-family
R287SfsX19
Cycletest
Neoadjuvant
germinoma.11
1//////////|
PIK3CAH1047R-mutant
FL3-H
astrogenetic
TCF7
Cell-Type-dependent
carcinomas.19,23
KIT-low/negative
lrb1
G9R
PUF60
syndrome/stem
gsf.de
T670I–transfected
∼4-weeks
KLK12
Inuzuka
YM201636
F6,6
GDP-L-fucose
vector-base
c.5113G
KB43
metaphase-chromosomes
GST-ERK
re-stimulation
GST-Mek
γ-radiation
.PDGFRA
loci1,2,12,13
Dedd2
TSC2-LAMP1
A_52_P120037
Aldape4
Mg-containing
2.2e-16
BCR-JAK2-bearing
CGT
5'-GGCACCCGCTTCCGCGCCATGGC-3
algorithm47
DiscoveRx
TβRIIE526Q
.Protoc
K445R
175−595
BIRB-796
phosph-STAT5
host-derived
L-010194-00-0010
ECsamples
S31R/ss4388499
SRPK2
FZD10
PE56
FIP1-like
one-second
–RAF–CRIB
no-change
models10
previously,5
locationwithin
5′-CACGGGAGTCAGGGACTTTG-3′
43·2
great-aunt
CA140575
CS-12
E746–A750
XGC
Tyr340/
RPMI/FBS
960/958
pDM17probe
CDMF
amplification35
1.524
heterodimerization.18
kinaseinhibitor
ATRX.29
nuclease-type
Flag-caspase-8-G366H
P290R
ITD-
.Isis
11q22.2-22.3
C1167T
BSA-treated
imprecise
D3U4C
four-copy
structure-specific
146va1
Seetharam
CFTL
neuro-cardio-facial-cutaneous
phosphoserine-specific
oligo-pigmented
TbRII
cancer.13,20,21
Gleevec-based
MLN4924
1474–1479
R505
tomography–guided
redoxsensitive
SS/EE
Dindel33
Lig1
p44MAPK1
LiCOR
4.0.2.Upon
68-71
c.546
mÃ©tastases.In
14.5∗
FLT3/Y842
YFP-SOCS3
SQRT–PCR
Disease‐associated
embryonoc
.CFU
r.t
Sc-633
216
S-labeled
2713
previouslyreported
microvessel
intra-protein
TME
AF078165
DUSP9
MKK4-
Tannheimer
Sec7
β-stands
6.2
T1328A
124–466
APCmin/+
Pleura
effector-occluded
tuberin–hamartin
bromochloroindolyl
Tet2−/−VavCre+
AB15
43–72
DAMTS10
CLB-GA
infection.114
K618R
Ser295del
A118E
Autogizer
E1163V
7.273.2
sun-exposure
C/imm
non-hematopietic
HA-Flt3
system28,29
described.14,16,32,41
7/8wΔ9
Q701H**
636–650
5-AAC
T-lymphoma
sequencingbut
mTORS2215Y
ETV6/ABL.39
EF-FLAG-Smad2
ASXL1-MT–expressing
phenylmethylsulfonyl
Met340
31610
NrasG12D/+-derived
controlcell
1µg
GTCATCTAATGGTGA-3
GATA-3-infected
—localization
counterscreening
94551-0808
TPT
ENU-damaged
0.360
So-called
CRPDX
D835Y/H
29443631
Cer-BCL-xL
Serova
hepatoblastoma.184
PIK3CA-inducible
9585s
MKK7
Becausehuman
pGEMhp53-282A
GSE3021934
LTX/plus
invarious
fibroxanthoma
Mika.Tirkkonen
imatimib-resistant
pOZN-BRD4S
FRMD4A–PFKP
TCCCGCCCTCCAAAATAAGG
Unaccompanied
TAT-3
concentration-independent
apoB-100
Y823D.4,17,18,26-30
use131
17,55–57
Variant_Type
71,72
multiarray
vasculature.11
58949
oxalated
−0.5
.Gl
Adli
22,11
post-
1-bp
Weunambiguously
bronectin
367×
Fanconi-like
plasminogen
4057
proteins.Initial
Hs00175892
BBD
mTOR-G6871A
TNCGCY
'normalized
S1893
myotubes/microscopic
1135insA
8.5/500
R8781
7779
treatment12,13
EPOR
706
.7242A
3020
5′-AGCTGTTTGCAGGGTCCTAA-3′/5′-GTCCTCCCACCACCCTCT-3′
biphenotypic.20
rs121913434
Dhomen
ATPγS
GCCTGCAG
DNAand
+−−−
S222R
73,671
PDGFR-targeting
PciI
THR180/TYR182
5'GGCTCGAGCCACACCCTAACTGACACAC3
NT_022184.15
NMR32
signalling5
Toride
WT-Flt
mixed.
density-arrested
RCF
Belani
RP11-315I17
G.C.B
71–73
L206Pd
1/4/5/1
LMNA-TRKA
Val5Glu
250nM
2,414
-tVqLVtQlMpyGcLldhVR-eNrg
PBAP
Reagents/Human
ETV6.Fluorescence
re-classification
Lg−j
1,2,3,5
Δtrr1
10/9/08
Asn166
alized
EMT.81
JCEM
1388A
undeterminable
SUMO3
GTCGATGAATGGTCG
itor
_1896
G288R
anities
Dedifferentiated
five-
39/60
Octane
P-STAT5
immortomice
Sequence-specific
.R841K
T-to-A
-CAAAAGGAGGCCTCTCAGAT-3
EPIGENETIC_COMPLEXES
.Sections
PTCL-not
D38A
lymphedema-linked
S.t/I
seconds/56C-30
T232A
S145
Wakeling
.Repeat
BRCA1188del11
GADD153
Roge
Polesskaya
Fluidigm-enabled
pWZL-blast-HA-MITF
Hemorrhage
Herceptin-treated
NCT01979865
PACA-CA
/CRISPR-associated
rep15
TUNEL-labeling
5-CTTGATTAGCAGGTCAAAAGTGAACTGAGTCAGCTCTCT-3
G13.1C
computer-generated
51,55
adjacent-normal
:975–985
ROS-induced
5-Fluoroorotic
5.9-69.0
.Pparγ
MIFS
70-wk-old
N.P.S
.Constructs
PNGase
Material.1
Immunoblotted
iXon
15/3/0
KGRH
Plate-based
N962
chemi-luminescent
CytoSoft
5′-AGCTAGTAGAGCGAACATGTCCcAACATGTTgGCGTGCTGCAGC-3′
5′-GGAAAGCTAGAAGGTTGTACAGTTAACTCCCAGGGTGTAACTCTAAACCATACAACCTACTACCTCCTATAGTGAGTCGTATTACAT-3′
Densities—Contact
kinases.33
ERK-5
MEK1-coding
BP/LR
15q26.2–q26.3
.Physicians
ARGHDIB
wasgenerated
CAG-Cre-ERT2
gtatttcac
299–329
BU-32
p.Arg789
sgRNA
vivoFor
R380W
hotspot,15
ison
hsRon
PB-Cre
lmbc
BP1OO-GL2
.Thermodynamic
c.3439-16C
7288
.How-
.Dramatic
mutationnegative
FusionSeq
tryptase-positive
Hennekam
zlj9991055910005.jpg
D614A
2254
apo-enzyme
S7B
negativeregulators
S59R
C61G
Fq
5′-CCTTCCTAAGTCCGCTTCTG-3′
pSer217/221
Receptor-Ligand
EGFR‑TKIs
BaF3-EML4/ALK
3/0/1
cycle.HeLa
16/18
world—is
proliferating-cell–nuclear-antigen-like
freezing-thawing
CSS12h
mTORR2505P
q22q35
M133T
/highwire/markup/117342/expansion
MLL-MLLT10
UNC84A
Abnormalities
registrants
2323
His-66
Variant-level
noxA22
-ATP
sulforhodamin
full-length
PuGPuCA.TGPyCPy
.OSCC3
2.00+0.06
R.A
N-nitroso-N9methylurea
previously.26,36
α-H3K27ac
864G05
V561D-PDGFRA
EMP1
80del
Figure3B3B
TIE2
38–41
05-185
:863–70
1128.10.1016
8.84
Chr9-320R
8·2
2-ml
L1353W
EMBL/Genbank/DDBJ
7.12-dimethylbenz
BAAframeshift
platinum-refractory
nitrosoureas
NeuNT-induced
.Laura
investigators.10
PX-866
FKBP1A/FKBP12
Cancerbackup
GCAACGCCACAGCATCAAGGATGTGCACGCCCGGCTGCAAGCCCTGGCCT
hFig-34
mid-cerebellar
action21
CATCCATCTTCAGTGTGACTCGATTG
GISTs.However
36-58
G23V
CRC26,27
688–982
5′-GGGGGCCCTCCACTTGCTGCTGG-3′
autoactivation
IVS4
ASOH
72.0
9101
-GCTGGGGTTGTCATCTTTGT-3
Ligand-receptor
.Imunoblotting
RUNX
58-kDa
pBluescript-KS
Muranen
BRAFV600D/R
p.E746–751
arisen
p-value=0.56
CT6
BRN2
re-isolated
SBF2
135-414
decapping
Casciano
Elf3ΔN270I279P
32/30.2
OCM-3
10B
Δ8
integrin/Rab-coupling
//www.gene-regulation.com
HT374
Genetyc
melanoma53
.Tyr591
10.1158/0008-5472.CAN-10-4351
faster-migrating
precatalytic
CAATGGCTCAGTTTTGCTGAATAA
Bendel11
3.43+0.18
LR13-109
p.E886G
5'-CTGTCATGAAAGTTGCAGTGAAG-3
SH2-domain-containing
N56T
q-2
diseases.6
AGRN
Single-drug
969
Gli-dependent
5.30E+04
pGL2M4T2
PCC-associated
4α
OND0
GMS
Thirty-five–nucleotide
BRAL
63.47
ME1-R
Nimblegen
G74D
91355
p53-response
DVL2
/F-12
∼1–10
disease.39
MAPK1
density–dependent
pRb
PI-103
0.00283
-CATCTTCGGC
Goldenbridge
phleomycin
HA-MAPK
SOX11-positive
Wnt-1-conditioned
p.Lys803Thr
TXLNA
L1490
09M/10F
phenorangement
//research.nhgri.nih.gov/projects/
instruc-tions
phosphatidyle-inositole
⩾0.05
GFP-EZH2Y641
T977C
0.415
4'-
ARE3-
powerpointFig
island-containing
anti-ACVR1
9p23-24.1
1620–1862
Ser592
Kit-8
c.5123C
1.Top
.S6E
=Polymorphism
R176Q
jobid=netgene2
AA/nucleotides
orange/green
P=0.950
Santos-Rosa
.CMV-CBP
cancers7–10
Percesepe
center-derived
9.0/165.0
cancer,7
Glu29
chr2:61703069–61767418:2p15
D19N
15639
cells73,74
Phenopedia
Innsbruck
650â€
myelodysplasia24
trials.28
thioester
p.T41A
56-59
C3831G
11B3
-R382W
2×10−4
c.1801
KEMEAESISSSEEIVPNSVQEK
embryo13
uninj
Fakultaºt
Taqman-based
R321
Tadokoro-Cuccaro
Figure3L
Nf2-mutant
ABCG2-deficient
G288C
AML1RTF3
oncogenic/growth
H355A
2497
gene-targeted
-GGTCGTTCCTTCACAATC-3
endogenousgenes
Polybromo
M-LC84
radiation8
multilayering
7-16
18,507*
HpaII/MspI
T/T
islet-tumor
SYT-SSX1-V5
SHQ1-unique
FBW7-intestine-deficient
Thijn
3820
myc-Pdx1
individuals.19,21
YFP-fused
desphosphorylates
Mootha
0.000278
16.8DIRAS1DIRAS
Itf
www.nature.com/reviews/cancer
species20
46482
complexes.142
CATCCCCCCC
Q738
pRSVNeo-Stat5AΔ749
GGGlTCCACTTClTCACA-3
misannotation
I53F
PKCepsilon
T276M
1,343
4.8-fold
ubiquitin-like
.DiffExprOutlier
β-catenin.15
E353Q/G390D
heterogeneity.To
TGCCCCTCGAG-3
mechnaism
95/96
units/cell
substrates12,13,14
11.67
incancer-related
Screen-CH
K398
nonmutation
cohesion-associated
SCCRO
D603G
AML-M4eo
BAT3-SLC44A4
ofplcVNK4
pCMV6-XL5
described.35,39
trisomies
.NMs
GGCAGCTGCTTTGCTCTC
CTH
GRID2
SSO
CD71+/Ter119-
106cells
p=
_y-32PIGTP
developed6,7
inhibtion
F338S
LLPLDKDYYVVREPGQK
553–558
IGF-1-antiapoptotic
aMean
∼400-fold
Kadyrov
gggcag/CTCTGC
RiboLockTM
people.Figure
Lys12
LNCaPabl
leftmost
A875
TMZ-resistant
Z-13825
2p12
.Toledo
NFKB1
c.1767_1768insA
Intra-orbital
.L-2-hydroxyglutarate
p21GFP
Caxo
domain-located
202S
152–155
c.5641_5644del4
SE-AX
5q11-23
77–80
models,13
LRT,28
Optiphase
NF-κB-specific
5′-ttcactgtagagctggaagaggacgaac-3′
BRAF.5
NODP
→ter
673
36B4
cases.6
-malate
MMP.Mutational
c-Kit.Parental
SUM149PT
S382L
.Ig
al.7
p.Arg188His
.Liquid
9904
AP2416353
samples.24
ON-TARGETplus
pFA2-ELK1
α-ATR
511139
219delC
SalI/ApaI
summarising
polypropylene
forks22
Kamangar
R3b1.1
Missenses
typewould
lW6
3,6,20
E1978X
Autoionize
90020
Fbxo22
input-corrected
D71V
Faderl
nonmucinous
35–59
SCWRL
XhoI/NotI
AML-related
Hygromicin
120-aminoacidregion
S23
Germany—the
NRASwild-type/BRAFmut/cKitwild-type
CCCACAAACAAGAAAGGCAAT
itpresented
lymphocytes.10,13,24
T2aN2M0
2.8–9.7
expectancy,5–9
rabaptin5-binding
receptor–ligand
Hulit
Three-hundred
TGF-β/SMAD3-induced
PTC-like
patients.MATERIALS
ENC1
neuromouse
BiBr39-42
p.R498W
G1232D
ATATCGGTCATTGGGTGAGTT
231006
.JEG-3
mcl-1
BYR2-RBD
Poa
binding-coupled
TSC-causing
27/61
Flag-ETO
end-organ
p.Val142Gly
Ras-GppNHp
.1D
14.0-fold
monomer-only
Kortylewski
5'-TTTTATTGTAAGGCCTGCTG-3
pYXXM
CO-132
rapid-binding
mutation-imposed
Krt1-13
.Y-linked
7676
E448K
inhibitor–sensitive
E534
LabChip
Bohring-Opitz
Cyclophilin
His-95
bk514C6
expression-driven
recently.16
pofeffitin
Cdc25A16
AG/GTACA
p.R1204G
lamina-associated
1299
H835La
NR6.EGFR
–/1.3
BLIMP1β
CGTCCTTTCCACAAGATATATAA-3
Arg575
.Y-axis
PCR-introduced
FLJ39179
suscep-
LNCap
63G10
type-1-expressing
**indicate
enzastaurin-mediated
S44L
translation.3
Bf1
JNK/SAPK
G13.2D
689
Wyeth-Ayerst
Raf-induced
Tyr42
YUMAC-BRAFV600K/L505H
HCC1937/BRCA1
V157A
weresubstituted
TriFast
47/93
NhRL229/ChRL230
Longgang
CONSERTING
pOPALI/
InVitro
beads47
17.96±5.39
24,537,000
R132H-Myc
non–ErbB2-mediated
H3K27me1
JCRB0077
EGFR-C797S
EOC,18
4×104
V359M
187l3
pasteur.rns.tn
Fernandez-Escamilla
WTMEK1
0.1114
therapy—peptide
.Idh1-R132Q
Yingbin
Pcr1
predispose
he/she
topGO
9a–d
DOK2-deleted/DUSP4-intact
S985A
DMEM/10
G1302R
5′-GCCTTGAGAACCCTGAGGTAGGGCA-3′
corecruitment
c-KIT14
±0.08
N457T
A03
Mll2F
CXP-26
comcal
1.2kg
TheBgl
DetectionDNA
Caspase-9
Ser441
Evi1
Ep/sp
COSM22226
ex3op
NM_003403
problems.2
Zoomer
G308
S120R
.Assessing
survival-promoting
HT-29R1
AdCRE-treated
p.R657W40
functionally.11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,35
100-ms
nM-range
767
disease.9
allele.17,18
cycle-coordinated
P1116
states42,43
E407K
surface-TCRβ/CD3
M5a
S0410T
+180
55242467
CGC3TGC
RLT
GAAGATGGAAGGGCATGAAA
ical
γ-subunits
S+
0.543±0.38
PMS2-specific
28.1–51.2
CGGGIGT
KIT816-unmutated
HCT116TP53+/+
thesmaller
30-3
p3300MCK-CAT
0.540
re-examined
NCI-H1666
RAD51-single-stranded
cou
.Identical
YUGEN8
.TH/MYCN
real-world
septa
RT-PCR/PCR
and2.5
report,23
multiple-hypothesis
vWF
AATGTTTA
MSCV-Cbl-IRES-Venus
protease-activating
3×102
amino-acid-changing
0.4.0
J-catenin
TS543
gtaagttta
cocultivated
leukemia.19
11E7
.021314
G831E
antiandrogen
MjHSP16.5
nonsense-mediate
1Dj
UNG2
SU10991
FGFR1K-3F-2P
Correale
c.mathew
anti-Pan-Ras
BrafLox-D594A
Ura−
Pvull
lipid-based
shMll3-induced
Lessdominant
CT/TT
//www.cran.r-project.org
TGT
FR3-G370C
.Activation/expression
gp96
.Y44D
1.1-fold
4d–f
Results—Sixty-two
32606
201–227
themouse
/SRα
CellBank
snp.ims.u-tokyo.ac.jp/
cafe-au-lait
RASP34L
1–145
XFoxH1a-dependent
G1139K
SPARKY
Rad50Δ/−
R122L
p50/p50
161:348–356
p53N236S
modeling-derived
wound-healing
Non-phosphorylated
consensus.44
U2AOS
M/68
F1061W
19/36
aLozano
Leu-97to
patients.27
E50034
antibody–enhanced
specificitiesthat
D464G
2Western
APC/CCdh1
14/19
LCH-27
cpm/fmol
TCTAGACGGCAGGTCAG
Ba/F3-ETV6-NTRK3
MERIT40
9,16-18
G2238D
T1036M
0.87–2.43
P190A
Pubblica
V937
Saethre–Chotzen
Ectopic-myc
CRC012
S6M
8.33
Telomerase
Ar151
pcDNAp73β
AGGTCA
CTNr
U/m2
cases.2-7
DFNA5
452-bp
noncytoskeletal
tuberin-hamartin
Granulopoiesis
Multi-site
2543
highdensity
M11667
GATATCATGAGTGATTCCATCTATGTTGTCAGGGGCA
k22
NCOR2
.Urgency
5′-gc
pseudoautosomal
G827R
al77
I.M.A.G.E
.Premature
P24a
growth-limiting
high-powered
14-gene
Eching
F341V
47/260
expression.54,55
.Trans-well
TRCB
BX
Cut-off
growth.12
12:2944–2950
611964
ultraviolet-dependent
DR3
Rheb-mTORC1
7808C.Recombinant
p.Lys656Glu
F25A
N=85
Y795F
Colleran
silencing-resistant
abundance–
.Clone
exocyst
4/2
D/CDK4,6
Nfi
China7
N676S
2197
BC015129
observations21,22
HSP90
-Vii
Oikawa
Bmi1+/+
IGF-1R–dependent
medullaiy
Vx-001
polysaccharide
*Stomach
.PF-2341066
extraarticular
FLT3-L
retMEN2B
LBH-overexpressing
jagged1/2
Rmsds
5′-TGAAATTGAACAGCGAGCTAAAT-3′
GCTGAGGAAGAACCTGTG
S127R
44,000–115,000
MIM218040
S0539T
squa
0.25–2.29
wild-type/wild-type
repeatedfourtimes.Dataare
XP_417614.2
.0
14-h
6/74
DHov
p.Gly722Val
IGF2/IGF1R/IRS2
Extrapolating
Go¨ttingen
cells—tumor
TFPI2
11q22.1–q24.2
Craniofacial-Severity-Index
mCD3
G356W
1118A4G
series,36
R280T-mediated
141-kD
Ca922
ditions
-STOP
AT7LA-pMAT1
Hemangioblastoma
slow-scanning
D1226N-2mu/mu
RhoA‐specific
clinical-neuroimaging
FLAG-KEAP1
mutant.39
U73343
cytoDetection
Mx1-Cre+Srsf2+/+
W340R
MeV2.2
MPLWT-transduced
BCL1locus
I66L
11-6
SU11274-induced
c.1425+1
E380Q-
E836K
SEGA-like
BMYCN
S518
hyperreflexia
cytokine-driven
N355S
AGCGCTTAAGCCGTTTTCA
GNETs
phenotype24
Bilroth
845
R108X
e83395
HMGA1
I565
TCF-4-mediated
dideoxynucleotides
ultra-pure
PDTC-MSK
R404C
reports.18,22,23
TCTACACGAGATCCTCTCTCTGTAATCTC
T799fs
cancer-naive
05-257
F-BCL-xL
differentfibroblast
thecassette
Finlin
pCR
CD15high
cross-tabulation
Kuzminov
Guazzarotti
Kibra
FGFR2-CIT
24740
susceptibility-weighted
epiphysis
RIMBP2
5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCAAT-TGGGCAGTATCTTTCCAGCAAC-3′
10–11
HSPA9B
KinBase
14/70
.Bakkenist
cell^.^
Keratin14
558
EGFRcellsstablyexpressingtheplacentalAkp
D880E
FFCD
ACTTGAGTGACATTGGCACCA
TCS
S7.3
blastocoel
CCL12
age-specific
NM_005656.2
p.Gly591Val
foregoing
GNPAT1/Emeg32
Lats1-deficient
Microcystic
p.Arg117fs
Pten/p110β-deficient
1R
Swedishfamilieswithhereditary
detail.17,18
Tlr2
P-81
.Flt3
dabrafenib26
Â£roRI-////idlll-digestedpMV7
stop-mutations
lymphoma5
misrepair
colleagues33
T620I
Inpp4b+/Δ
0.236
Fbw7-dependent
α-2-
JV
SPHK1
AJ316067.1
c.1589C
9/17
most-frequent
ø
I-subset
E76G
OncoChip
2-log
Nrf2‐related
.Microscopically
Stehelin
NM_004364.1
G1050S
carcinomas.7–12
ImmunoblottingFor
P10–P14
matched-pairs
sunitinib-KIT
L23F-6
epithelial-specific
-hump110β
2308-2309
C110rf95-RELA
CCL-185
Tyr-774
Bonferroni-adjusted
P.B.L.s
NIRCA
miii
binding–
stain-extracted
c.3024del
non-C5
GST-Tas3
cancers42
neglible
paxillin-binding
p.Arg630Glu
IA-2
self-reactive
Agaram
benzylamino-9-isopropylepurine
4F-H
C46R
Y1003F-V5
revolutionise
7636del9
unresponsiveness
toPAX8
Rb-positive
gtatgtttg
328
myeloma155
eachflask
ER+/HER2−
ETV1-locus
L-Wnt3a
G409R
Shewchuk
suppressors3,6–12
.MMPs
1.228
c.3984_3987dupGTCA
Jae-Sik
hyperplasia67
KMS-2
.EFS
L449P
6q25.1
Horn,1,2
high-probability
g–h
R213
anti-goat
GFP-fusion
neurite-carrying
15138z
sh-LATS2-RNA
3.0Å
andlog-rank
2I–2K
made4
downregulatory
ILC-score
P0007
RET/V804G
v0.1.19
mitochondria-independent
44-94
N-Ras-G12V
HindIII­
2/171
WM1158
C135S-p53′
2801
PP1B
STAT3/pSTAT3
coadministered
5,6,7
Macrophage-associated
0.0001.
~~~~~~~~
NK92
HCC827R2
GFP/R175H
families.Despite
Machiels
MDM-X
PATZ1
NSCLCs.12
.Defect
vSMC
vesicle-related
progress/transform
DNArepair
GGATTGGCTCGAGAGATCATGAGTG
paraspinal
ARSH4-
protein‐protein
LR11-068
ABT-737-treated
-0.03
GTTATCCCATCTGCATCAGCATCTGG
EMD1214063-sensitive
pregnancy†
.Mitogen-inducible
Lentivirus-mediated
17-ID
m3
250-900
pCB6+p53
BBDS
protein-G
NF-κB,14
2252
c-neu
59567
G648
FUS–
retardation.39
microscopy16
chr11
R161/K163/K164
G54A
=1.55
PYK
propidium
chicken29
leukemogenesis,16
−2.34
conformation.12
properties.Biological
pFAG9
MLL4
.Tsao
assays190
HVP
overamplification
u95a
AV/DY
nocodozole
2.31
L304P
Y720F
GTPase24
brigatinib
consideration.3
TAGLN3
Botrugno
Knebelmann
BEL-1
ovariancarcinomas
.Visualization
development15,16
V923E:15.776.1
BCR/ABL-positive
FANCC.19
G-Box
PDE6
205-bp
Kurzawska
COU
Huddinge
BiBr40-51
FADU
86420
P1711S
models.10,11
CIB2
H1299/mp53
P272S
PBS++
MG-B2GFPΔ3270
genome-wide
shG9A_2
diagonal-hatching
NF-κB-dependent
91T
Tomita8
Accrual
//rana.lbl.gov/EisenSoftware.htm
studies,16,18-28
'Smad
best.Table
Ala178Thr
autophosphorylation.14
.Irnr
ATGGAGCCTTCGGCTGAC
apoBTK-KD
self-associate
RUNX1-I42R
ureter/renal
J.G.H
V166fs
months.17
.NPLs
SNU-769B
078
B.Vogelstein
ATR–ATRIP-dependent
DakoCytomation
NM_002609.3
10,11,20
2.1.4
.Stabilized
pEAE30
www.cbioportal.org
Cys848P
Izutsu8,9
A-Barcode-Exon22R
DD/estimated
NCI-H596
BRG
activity140
Cκ
urea/formamide
3N-O
−1.5°C
V412L
SNPEFF_IMPACT
scores34
60.1°C
606
acetyltransferase23–25
TTAATAGACTGGGCCACCC
MITF-low
overexpressed-1
Yasumi
22/85
K608E
luminal-restricted
800–2490
4b–i
.Thrombohemorrhagic
0.59–1.01
K211N
'Â
M1360I
VHL-negative
FBXW7-depleted
5′-GTCTGCCTGTG
co-immunoprecipation
receptors.10,14
p.R206H
Asp123
929–935
DCS-11
ACPP-PIK3CB
site/frameshift
pEVRF2
andRaf-1
VUS.27
GAL11
T790M.41,84,85
sh-PDK1
199.7
KB1PM
19/
-phase
w.
Notch1-13
McLure
PIK3R1-derived
Mgat4a
Ala29SlThr
α
Rheb-GAP
straightforwardly
Muramatsu
226G
p.F76del
Iqspccific
proteins/ATP
FLPe-mediated
Spera
.0157
.ECadherin
change*
.CEVDPQKLGNVS
5'-GTTTTCTTTTCTCCTCCAAC-3'/5'-TGCAGGACTGTCAAGCAAGCAGAG-3
144
interaction,54
C.L.C
HCVþ
tumorigenesis36
paediatric
'illegal
kinase/
.Lines
Tpo-Mpl
B2m
Ret
Genica
Abl-SPOP-F102C
ICHICAWA
pRc/CMV-HA-VHL
previouslyshown
09T
R342P
13.59
mutation—a
p120v-Abl-IRES-Myr-AKT1
648T
117,338-117,438
harmonization
interaction-induced
stereoscopically
antibiotic-resistance-altering
gefitnib
HD-0377
lyon.fnclcc.fr
Kaisaki
.Ternary
.f
S2C
thalassaemia.14
protein-serine/threonine
Anneka
p.G12D
-FANCF
c.68-80insT
signals,16
H2311.36
growth/apoptosis
0.1mM
2.In
BX41
reseeded
Ryczko
RUNX1-
M492V
radiotherapy—allowed
5′-GGAGGACCGTCGCTTGGT-3′
Antwerp
2–91
T300A
senescence,14-17
Tyr1135
238/138
5–74
=1.2-4.8
bag-of-worms
IL-9Rα-mediated
.HEG0
235-239-240
CCTGGTCACGGCCTCTCCCT
103779
1878
pariental
28/137
locus.The
population.The
Vilkki
Bedikian
CD150+CD48−Lin−Sca-1+c-kit+
LMP‐7
736E11
FCS/PV
ras-containing
85–106
TotalRasGTP
f1MR
inwhich
918
1796insCTA
​High-grade
AS-604850
myeloma48
BamHIrestricted
RP5–1060P11
androgenindependent
.NM_001105.4
NC_000002.10
fi-nally
HER3-Lys-907
characterised
Spry1
.Exploration
.fluorescently
0/sum
2.53
Geneset
ab67221
RP11–547P13
c.1202T
0tfk
MeCN-0.1
individ-
FigFig2P–R
P65S
CD56−CD64−
960-983
U2940
Smad-dependent
DFVe
outcome.37
0031
.IGF2
42/50
withthat
Biotin-CGA
CK19
1970
DSRCT
Tsuzuki
Y701
1631
E353Q
nonresponsive
P35
FITC-CCA
sc-7199
oncogene.—Alamo
low-birthweight
104–105
thesemutants
1∶5,000
rs11552758
CDK5RAP2-PDGFRA
W719
CAGTTCTGGCCCATTGTTGAC
Leu62Pro
EµSRa/HA-TEL-JAK2
Cw*0409N
described110
3′‑deoxy‑3′‑
pWWP-Luc
BAX205
67474
p-
6/99
mBrca1+
7279
HA-RUNX1_R139X
cardiopathies
megakaryoblastic
13.24
TEL-PDGFRβ–mediated
0.001.
Alamar
exposure.3
autoinhibitory
118.4
spinocellular
Herceptin-bound
RCC-47e
granulocytes.21
Leu/Gln
77×108
functions16
CA→TG
170–194
resistance90
tumors.33,34
93–140
formation9
Schrecengost
GST-PTB-SHC
pcDNA3.1+2XMycKRAS4B
below.Immunofluorescence
D1H2
AGR2
GQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQES
GCAAAAATGTGGTCCCGGTGTCCGACCTGCTGCTGGAG
delAAAGA
MLK3-MKK7-JNK
g-32P
1262–1628
Jochum
-120
Afro-American
GSK690693-bound
+TN+FP+FN
cyclophosphamide+
G465R
Biosym
HIF-1|
36a
single-board-certified
knockdown/JAK2
vol.27
mini-max
retinoblastomas
593–622
UKCCSG
Pre-invasive
binaural
only.1
2ng/mL
Pinto
LR04-373
coloredwhite
recombination54
.Mnt
Type1
RMH3954
sTn-antigen
p-mTORSer2448
I-Sce1–expressing
IG
BRCA-allele
E2A-Pbx1
-GATTCGTGGAGCCCAACA-3
Ghouzzi
CTCGACGAAGGCGAAGTTTTTG
interleukin-9
aArgGl
=39
721
NPH1
subG0/1
ccRCC-relevant
645
CACACCCATTCCTGTACCTCAG
0.310073033
ligand-specific
AS16
_b
cipitates
hCP38872
56–57Mb
Vav-tTA–driven
88.3
25/35
.Stimulating
37-R:5′GTTTCTCCTGCCTGGGCTAAAATAGA3′
FMA
Oesophagus*
C20orf74
002000700000101015412644320555328478602806170
Vidali
.Non-T790
Bcl-2-associated
NFE2–
309/309
end-helix
24/35
22-25
pHA-BAP1
5.48
phosophorylation
eosinophils/μL
3-21
malignancies,42-44
Fig5B,5B
0.0061
virus.25
P36507
157–48
K22
ClinicalTrial.gov
157/2013
RUNX3
system,17
T/p.P214L
.0289
C462N
c.9501+4A
size104
tetracycline-controlled
5′-CACTGTTCTCTGTTCCCAGG-3′
effector-binding
P-RPS6K
Ankyrin
explana-
temsirolimus-containing
47,215,315
pol30-52
±7.0
37–81
triggeringp53-
Callbiochem
methods.Biostatistical
HER2independence
imidizole
.Toexclude
CD163
—caused
pXP2
71.19
Y806
anti-total-Akt
mTORC1-directed
ZC3H18
-O-
935
.15–.39
34/35
5/HPF
v-P3k
11-yr-old
7.5A
STL
R401H
down33
AKT1/PKBα
14,29
rVaGIaInVa
sort-purified
interactionof
kinase-related
AR-V1
newtumor-promoting
BMMPC
cells,40
35482
WT/Y88F
DP3
4490
.Bidirectional
93/299
bones28
67911
ETGE
β7/α1
0.36512
Provocatively
.Predictably
processedfor
G719/E709
endoribonucleolytic
figs.5F5F
18/132
TGGCTCAGCC
rationalization
V181
resistance.13
AVM/facial
5′-GAATCCCCAGAATGGCAGGAA-3′
Figure7A
MACHβ1
post-lymphedema
PALB2-1
gambiae
5-ACTGTTCAAGTGGCAGACAAA-3′
3p14.2
GTL16R3
MVAC
-85°C
884C
j.lungcan
mutants—including
._1145+
CAT-TAMRA
KIT816
1.0.7
hydroxy-dabrafenib
gi3821282
825.8
SNU1196_BILIARY
CIMP16
dys-regulation
SAMtools28
43/115
Ras-GTP/GDP-binding
R348
information-based
GST-GRB2
.DT40
1:1.1
women.38
Cluster-Buster†-
D1*
single-file
/2.5
MSI-H.
10/413
Sznajer
50,000–70,000
Niitsu
FlagRHOA
c.621
.Stepped
posthybridization
32/65
protocol.14
.Guinea
c.100-22_102del25
GL3B
MLBCL
DR4
nonaffected
Aci
STI-571-resistant
HSC7E222
T-p53C-V143A
5′-CAGACGGTGAGGTGCACAG
TM4SF13
EBP
5.27:1
themterminated
supression
aneuploitdumors
5′-ATTAAT
1890s
3.95
METwt-expressing
R397C
H-J
NBDG
Sepagene
Beavo
PIK3C-increased
R96
848
P=0.60
KD-CARD11
mation
ROSA26-M2
non-adhesive
IDA-MS/MS
EX2R
StuI/XbaI-digested
10560
QuikChange™
survival.‡ORR
.Neutrophils
refolded
MS5
eosin-stained
pathologi-
NCT00975819
tumours97
B*07:02
OHF
E2A-PBX1
Pol30/PCNA
co-migrates
06a
melanocyte-lineage
GST·pVHL·ElonginC·ElonginB
αTRK
SapI
0.9b
malformed
447A
15687
sideroblasts
TCR-dependent
Calbiochem
0/64
toll-like
fentomole
CA125
EGFR-WT
A_51_P116940
dimerizatlon
littermates30
Macville
GIST18
G158
fokI
Il2rg
CMG
37–89
C463G
EX3–8del
fine-needle
Flox
1×71
5′-GAAGGTGTGTTTGTTGCGGT-3′
50ul
5′-GATGCGGCCGCCATTTCTTTCATCCAGCCATG-3′
//www.ncbi.nlm.nih.gov/protein/
FOXA
prognosis-associated
209
CTGGAGC
oligonucleotide5'-TCGACCTTGCCTGGACTTGCCTGGCCTTGCCTTTTTCGA-3'with
Dye-generated
imatinib,30-39
ALL,4,6
CAATGGTTTTTATGCTTTGAATCC-3′
p.Gln2384ArgfsX7
pEBG
transplantahle
K244E
MS2
restricted,25
FACS®-purified
Nakagawa
8–31
V834I
recombinase-induced
2-year-old
hRos-9
−6.55
3,9,10,46,47
goosecoidpromoter
pCB6+Bax
GADD45A19
indicated.
U87MG.WtEGFR
14:759–67
alÃ-ele.As
relevant.The
tracheostomized
44-kDa
rSegspLVVLpYNKHGDLrnFIR-neth
1-24
RSESGSPSAGGH
*Department
NUT-directed
Texas-Southwestern
431–437
Rstitution
CYC1transcription
Masterpure
hierarchic
cell-permeable
1Ba
EnVisionFlex
BAP1-HCF-1
Tap42/alpha4
RPMI-1640–HEPES
IG-like
HIII
S100A
leukaemia23
alÃ-eleis
17608
anti-5-hmC
p.P491S
hydrophobic
45.9
HBV-mediated
B-Raf.11
G280R
4424
programs.177,178
110KD
pMSCV-blast
shRNA-targeting
ACTAGT
2010–February
c.1136C4A
cholangioacrinoma
reoriented
fluences
arrow-
BRCA1–BRIP1
PI3K-targeted
Ras–Ras–GAP
PHKG
FA178
clinically-significant
14th
CREB3L2-PPARG
4-methyl-N-
Luijt
-TCR
reverse-transcription
activation42,43
non-infectious
low-levelexpression
mass—growth—with
1·5-
HiSEQ
Haraguchi
26,000
PowerPlexR
cancerdevelopmentof
proliferation.65
.8,8
P=4.657.10-6
anti-NICD1
GSE
.ETS
diathesis
Ferrigno
TRIM24-BRAF
.Interphase
p53-dependent
5′-CAAGCACCTCACAGATTCCA-3′
sarcomas/mesenchymal
NH4+
T141M
Sudol
Hirotani
assayNCI–H1299
characterising
0–6-month-old
antibodyTGN1412
hematopoiesis,24,25
Sankyo
IHC+
RTGABnnnGCR
autodimerization26
anti-pY1173
R780/R847
mutationd
Preparati
vitrowith
phosphodiesterase
SHPTP1
FGFR2s
ERG-expressing
56ºC
.COMET
RGP
G797R/S
3′/5′
.GTPgS
RUNX2-mediated
FGF2-FGFR1c-heparin
acrylamide-bisacrylamide
FGFR2N550Kexpressing
MAPK2K1
MfeΔ
27-
242–493
AnalysisTo
Squamous-cell
210
siRNA-mediated
`PXXP
Y490
Ras23
R98X
PKCϵ-binding
Stradal
β1–β4
anti-Brg1
siRNA7
Database=http
Length-adjusted
arise1
Brd4
R128Q
Quant1
5.Download
P117L
Hh-activated
addgene
3pat
P3l6-N.K-K-K-R.K-L
XFoxH1s
co-transfected
Sc-489
anti-V5
E79K
indrectly
c-mpl
L87V
AceView
68–75
PLIN3
NEMO-independent
MAP1B
SNV/INDEL
V79
G3930C
0.6642
PF-EPN-A
paraben
0211H
glioblastomas1
R76W
N200
BOC-D-fmk
CCCTCTGGCTATTCAATGGCAGGG
germline.5
p.Asn146Lys
superimposable
erythroblasts,39
RET/V804M
endonuclease-deficient
HLA-B*08
TMPPP
2002–03
transcription30
789a
hydroxymethyl
PROSC
MLL-transformed
samtools-0.1.18
TRADD
transfeclion
Mycn
U1285
Verviers
precartilaginous
FANCE,26
MgOA
pCMV2
ERÃŸmay
GGUCUUCACCUCAGACACUtt
RunX1
Yl3-2S9
.Keyomarsi
G37
Rho-specific
VDRC
18.6
PRDM1/Blimp-1
P146
intron.11
CLS
HBB-bH1
CCGGGGGCGG
TGF
V600E+K601del
c.325C
P0039
OCT4
2bio
GAGCCTGGAACTGTAGGAAAT
IDH2MUT
Ser45
others,34
CTLA-4AlleleG
MmAGAAAR15
enroled
lines.136–138
07A
MSCV-BCR-ABL1-IRES-GFP
renin–angiotensin
thatwas
TURBT
L351P
hygro-expressing
E1513
DC290
models.To
9.53
2142
determined1,19
FMTC-associated
andMaterials
.Breakpoint
recombinant-based
Fundamentally
Msh6P1085R
10-88
Carney
Asp419del
pRS314-PGK-SN
PIK3R1R348∗
MNU-induced
plant-derived
D174nt
site‐specific
PDGF-stimulated
.CASP8
5′-CGTCAACATTGAGAGATGG-3′
p.Asp191_Ile210del
studya
Ser218Asp
p-mercaptoethanol
T3wt+T3/ABN5
auto-inhibitory
MBD-containing
Stojanova
ezrin–SOS
.SAOS
Whitlock-Witte
.FIP1L1-W-PDGFR
TERT-HME
Transcript/Peptide
Immunodysregulation
GSK21118436
mutations—missense
.PDGF-C
S249A
-e-
Rheb-WT-implanted
.SMARCA4
G216A
startingat
Rivera4
96-Well
11-day-old
LEUKEMIA
7-encoded
p.K642R
.Hazard
Reverse-transcribed
.DMSO
basc
p.Ala75Pro
.Meenhard
GS600
ALDR1
syndrome8
.234T
cag
Quickchange-XL
R599
144G
Hematopoietic-Specific
Ctcalibrator
phosphatase-conjugated
128–134
MNP
APCFZR1
PMP22
Somatically-Acquired
tamoxifen-sensitive
case45
non-SMAD
CTNNB
F129
Bcells
amplification/activating
97.66
S502
acceptor/donor
G101R
250mg/day
.Pinter
2030/6889
U133A2.0
ChIP-PCR
C1156Y/L1198F
294–309
SWISS-MODEL
Clinicopathological
elastin-rich
prognosis91
NOTCH1—an
.Adjacent
pCpGL
SIOP/UKCCSG
Ala502–Tyr503
8−10
micro­phthalmia-­associated
endoprotease
2430T
described.19
GTP-conformations
O.OSo
D-Cdk4/6
HCF-1N-binding
SCF-starved
6–25
LC_C7
non-genomic
=DR
Papagerakis
L600P
hkyonsei
ÃŸ-Catenin
Yesm
Meindl
stress-sensing
mutations.4,25,26
MKK1-mediated
1458
si-knockdown
H1299-TO-p53
CTACCAC
orthodenticle
J.R.Bischoff
279-kb
Log-normal
.S14A
Skirball
gag-myb-ets
9Biostatistics
c-MET.16
risk-estimation
Rad16
7q-terminal
L125V
DM5000B
=1.2
c.526166G4C
thewild-type
Ser150
Sequist
60-Å
A/ID
prostate13
domain-mutant
N4
immunoprecipitationThe
RP5
anti-TATA
EGFR/ERBB
:URA3RBy41
RAD52-dependent
hydroxytoluene-induced
tuberinhamartin
partnering
.Follow-up
mIL-3-stimulated
Hybri-Care
AQ-AAA
CD65s+
cAMP-responsive
Ec-RNase
Nrf2-WT
pBL5
ubiquitin-speci®c
Q209L
5C-E
p.E9X
PLCitalic
anti-UCP
1–15
γ2A
chicken,27
.Degradation
PEG10
Bouillet
described.21–23
caspases.14
cAMP-protein
Brca2+/+or
151I21
stoichiometrical
AMER1
MEK2L46F
L980
.Freedman
TG
TGFβ1-induced
per-exon
TPβ–induced
Hacohen
.Antibodies—The
explicit-solvent
inhibitors.7,16
.PyMol
RD-CBFβ
2p16.1-2p15
LU-A08
overex
MT-2
aq
values.The
respectively.28–30
83.5
Bioconductor/R
cancer,24,25
CCND1−/−
SD116
RBM10‐binding
72–97
His6-c-FosEE
E-proteins
p.G52R
29432565
TUSC3
Ser621
myometria
49413009
Ginsburg
pathway15
0.7712c
COL1A1
Scheel
B-RAFi-resistant
-N505I
p.Gly44Cys
MGH021-4
Honjo
KDYRMERPE
GFP+KuOr+
GM03542
inhibitors.35
amplicon-specific
liposarcomasCase
aggregation-promoting
3,067
L117fs
HLA-B*39:01:01:01
Look-Locker
and55B
A.Self
v3.0
40–130
assembly.9
GTAACCAAGGTGAAGCTGTG
1466
0.9796
cancers2
U3-1287/AMG
451,18
D1228N
Gly89−Asp92
T910M
1282
α-Mek1/2
drug-targetable
down-modulated
Choet
export-defective
4.60
1/66
pre-AVM
paraformaldehyde/PBS
HPVstatus
0.000508
his3-200
mismapped
Rafidi
2.0.2
epigenomes
313
-0.137
.A246P
cells15
activation.44
V-FLUOS
203A
prognosis43
60389701–60414200
islands-5
iGGTC-3
physiologically
NSCLC.67
T-PBS
,2D
Calmette–Guerin
Three-Dimensional
post-virus
5¶-GTTGGTTAATTCTCTTCCTGTCCA-3¶
APHP
Warthin
602KB
Vaco8-2
.MATERIALS
N-TAD
2/18/98
Thr315
pBluescript
~4000-fold
c.580G.A
Pinyol
Optiquant
.153
//www.ncbi.nlm.nih.gov/gap/
Tapestation
malignancies.In
regressivechanges
1-phenyl-3-H-8-oxa-2,3-diaza-cyclopenta
SASI_Hs01_00340497
progression.14
A775
CTAG
Arg132
caC
D816V,2
CycD–Cdk4-overexpressing
co-associate
semi-synthetic
.Petrini
shRNA-containing
Ala399
5′-CAGGAAACAGCTATGACCTGGATCATATTCGTCCACAAAA-3′
EGFR/HER2–TKIs
.5,16,17,18
Karpinnen
A004
BAF60A
1D/E
p-ROS1
.4,9,21,22,27,28,30
veriWed
partnermediated
huPO
2024del5
D810-F811-G812
D65N+GAP
ERK-to-EGR1
96AI
.Consensual
pCAS
BRM-positive
5'-GAG
COMIRB
206–421.12
R733W
F1054S
90.1
p27Kip
ΔΔGbind=αΔΔEvdw+βΔΔGsolv+γΔSAmut+εΔΔGBM+λΔΔGFD+δ
TPM53-NTRK1
full-text
782
Tubulointerstitial
BRACAnalysis
proliferation.19,23⇓-25
Friedler
Germinal-center
Tyr-Tyr-Arg-Gln-Gln-Arg-Lys-Leu-Val-Glu-Glu-Ile-Gly-Try-Ser-Tyr-Thr
*Â¿gof
IVS5-2A→G
TYK2P1104V
lymphoma21
Phospholipid
chromatography-electrospray
FluF
serine–
P=0.000193
H305Q
signalingTo
fludarabine-refractory
patients19
3637
PHL-Akt1-GFP
RERF-LCAd2
E1799
presumptive
5′-TGAGAGAATCTGGCTCCTTGAAC
mechanism.67
anti-TBP
-36
1172
Kastanet
subcohorts
I135K
Giannina
Con-A
762â€
+5′
Centricon-10
NK2
reduced.117
GSK3β-β-catenin
p.1073_1075LQS
c-kitgrew
Bcr-AblT315I
p.a
V29G-Y32W
signaling.4
R243A
D626K
90-3
EML4-ALK—K589M—failed
Onderzoekacties
.Electromobility
ED-rich
pS235/6
NoRisk/Very
SMO-D473G
imagequant
.Bond
UCRC
Medulloblastoma
mitochondrial-specific
GenotypingAll
Hematoxylin-stained
SIFT.33
EGFR-targeted
anti-pT68
p.N435S
differentiation94
miR-200c
LuCaP
­inactivation
pSHP2
12.6–13.3
P587
–ALK132
Kruijer
C_945_H_1
M32K
1,4,11–13,15,22
non-esterified
U87MG-
M83
Nalorac
Lys2717
HOC313/v_1
p.Ser531Thr
cells.35,37,39
Cys-CysHis-His
George23
NELF-A
carcinomas57
monteia
Mohapatra5,6
11.93
372O17
theproviral
cancer3
N.A
oncocytomas
GATA-type
IPHC
0=benign
I-form
O*O
R174
R1263C
p.G128D
activation22
treated=0.256
methionine-labeled
SVZ-B
④
V307L
Lys1029
BAP1hi
synergise
KIAA0146
points.50
.Pre-adipocytes
2100TR
F461I
RAF-RBD
GFP-specific
sooner.16
BMS-785807
A249E
S196
G15
Johji
44,74
Hex
C113R
86–9766
.Plots
cds-synon
ETV6R418G
anti-TRAP220
TT55
568-conjugated
glutathione-agarose
1-kb
C293
anti-hRAD51
imidazole-HCl
trial.34
MS4A1/CD20
hypophosphatemia
trials.84
14727
Valine599Lysine
NG_001333.2
Basosquamous
non-focal
.Q61
c.2444C
sequence9
Arnt/Hif1b
GCAAGGGAAAAGGGAGTCTT
anti-phospho-Ser473
3/12.0
ARH03
7630
environment48-51
Lys298
caspase-8/a-h
c.1681C
β-MHC-Cre
Galacton
families.29
RAD51A
A.G.L.
AcralMucosalCSDNon-CSD
Akt-S473-P
trial.16
pubs.acs.org/biochemistry
kDa-like.
8⇓⇓–11
F516
ifthere
ECadherin
Constitutive
myelodysplastic/
cGy
788–915
TOT-binding
P=0.752
3.Although
Foldinductionby
393P-shZ
Holt
NR3C2
pLIX
smaller-sized
cloning.6
MTA1-knockdown
P5
Analysis—The
∼1.5
.Balloon
c.1666_1698+15del
1lowMac
–MEK
Bcl
37°Cwith
Yale-New
747–752
autoregulation37
p53-Ser46
S2–S6
P=0.0180
dUTX
TGGTTACACT
.Clinicopathologicand
50HPF
56774214
accumulation/abnormal
approval,9
androgen-responsive
0.125
delected
LBD-localized
0.6∗
Papoulas
Dhalluin
Gray-Schopfer
DrugBank
dIAP—resides
.generate
www-jpred
Q40L
MMR.16
perfect-match/mismatch
GGGCCCCGAGAAC
with…
HKC
WAF1/CIP1
++/+
T529N
spl~ce
sc7268
Jak-family
RAK
NB7-α3L
rare,11-16
AZD3463
Nakat-suru
ACCTGATGATTTCCTGCTGC
B-Raf-MKK1/2-ERK
arrest.TGFβ
6cI.3
5′-GTGCCAGCAGAAAAGACTT-3′
growth.1
region35
pairing/recombination
Schwechheimer
hhc.eisai.co.jp
L687E
D3S1609
potential.16
improvements16
LIM-domain
CU159
PDGFR-β-dependent
Tyr125
MO_1167
contact,8
granddaughter
L838-R808
rs1042522
GTFACGCAGTGCTAAC
Cdc42
NT217
5'-CC
FLAG-LNR-
.ESR1/YAP1
DM15
GC/
Thbs4
antivimentin
DCLRE1A
b2a2
/T-cell
921–979
49-bp
AGCGCGCCGT
described.1–4
cvff
5155
Scacheri
GST-MEK1
Lys650Asn/Gln
.Solid
and12
E566G/A
0.05â€
5.6
FAM55B
pc-ΔC2
2074
anti–phospho-AKT
q-terminal
insulin-like
pc-CARD11
.C643
TA-Cloning
leukemia20
p53-silenced
patients13
16–37
p.Y130C
ARV/AR-FL
0.0066
insulinlike
chr16ms4
ARshRNAb
50.2
T-cell–acute
NP_000258.1
MycER
damage,39
frans-hydroxytamoxifen
Brx-like
W23S
FBS/RPMI
12.3
R2076L
HA-GST-Akt1
R278X
host-mediated
005163-26
Alu-negative
active-EGFR
≈4-fold
months-18.2
proteins20
124O11
transformation.Deregulation
pluripotency.12
16q12.1
0.45–9
Silhavy
shp16
pHA
5′-TCCCAGGCTGTCAGAAATGC-3′
non-heritable
PDGFR-a
0.183
A3140T
ALKL1196M
1602.6
cyclin–p27
NODNRef.767778798088l8288384858640794040793233,793131313444,794549525254515252878843JTumorBladder
-AAGCTTA
anti–rabbit
MK410
EWSR1/FLI1
R-PTPK
16,42,43
models60
Thr187-independent
NADPH-producing
.Pharmacokinetic
+0.5μg/ml
9-month-old
Glycine-to-serine
VBC-CUL
BamHI/PstI
resistant.123
41.17
.Abolishing
carriers.48
5236SeqR
.6341C
V1120E
assays,4
TSC1/2/RHEB
Mll1+/−
suppressor.1,5–11
Calabretta
F‐Smad2
SLIDGVFTNHSDVWAFGVL
.Accumulation
.529
C9orf102
amplification23
Pf=Plasmodium
M91T
biology25
1:40
Q264X
Universitaºt
factor-supplemented
One-fiftieth
TFO
/ml
BACH-WT
contact.34
104-S.
leucine-858
10.1–13.7
NrD
hospitalisations
methylnitrosourea
additive-synergistic
hyperresponse
pBabe-puro-hTERT
.CN
.A-C
5171
p110γ
/DEL+PM
overexpress-
R301L
RhoA.V14
cbt-15-1239-g5
tuberin-Dishevelled
BATTLE-1
Guoren
GDNF/neurturin
MET-ligand
RNAi-mediated
log-risk
.Hh
RP11-18J23
human-A
del747–751
expression.58
c.1204delG
0.140215
5'-CGTAAT
glioblastomas.59,60
AML,13
little-known
G65
evs.gs.washington.edu
PolyPhen2
IGFa
D351E
*Study
1:2:13
.Pathologic
.Nterminal
30,439
//bowtie-bio.sourceforge.net/bowtie2/index.shtml
35th
phosphorylated.6
c.646-3_654del12bp
Gli-
E33D
Y32S
×107
pMKO
NGAL
414‑588
Fgfr1-deficient
residue37
-CCATTAATAGTGATGTCTGGTCATAT-3
1.3G0.4
7F*
R273L
anti-oestrogen
chrY
haematopoiesis47
neuro-blastic
hormonally-induced
Yes1
LC-Gadd45
K159R
IC50=40
non-contact
domain,19
impaired.8
.Erythropoietin
15.02
animals.28
Hypothyroidism
1–298
FGF-receptors
11.9×
understandably
yPH-bax
.Eligible
319–551
271-bp
H00057492
muA
rate=0.089
expression,25
L755S/P
thymoma.49
N-phenylthiourea
RKIP_M_R
Verti
N1-ICΔ82
K38N
Det1-COP1
:1117–34
β-values
P110βΔ
10D
rear-end
C-findings
0.75–5.64
P403S
chromsomes
RP11-880O16
−2.23
13q32.1-13qter
E/CDK2
C16:0
lines.H2O2
.Temozolomide
529
comprehnsive
progression.6,8
within-subjects
2.5:1
D-TOPO
SH3-domain-mediated
:2552
c.9118-2A
1=tolerated
one-somite
FGF19-amplified
Adenoc
//string-db.org/
KFSHRC
.Thin
solubilization
MKN1*
ALK-related
human–mouse
Bümming
ASK1-negative
P70S6
dimethylthiazol
H694R
Fanconi-Anemia
osin
RUNX-gene-dependent
N-Terminal
2of
prime-derived
I*GI
v0.99rc6
HA•Chk2
tctatgcag
40–50
.018a
TSC2-RNF216
supratentorial
2435
3p21-p22
27·3
,2B,2B
SJHGG003
19–21
cell/100
HADC1
Topiramate
-Wnt1-transgenic
10R
t=13
.RCC-1
andperformed
antibody4
Flt3−CD34−
Flt3-Y589F
improves.8
ofcell
P-0005044-T01-IM5
87.2°
11q22.23
Mlh1ko/ko
23FQNLF27
50–63
L398R
32/29
ACCAAACTGTTCTTATTAC-3′
Set1b
Haenszel
chromatid35
DENinduced
PLA
S608/611
NSHL
glucose-inducible
GSNAP-mapped
PRCC
1PES
RPM1
CDIO
'back
and.the
1153
.Haplotype-based
Ex17-F
~stopped
T312A
CENPJ
retinoblast
inhibition.We
Non-genetic
phenotype',10
facilitate27,28
Venus-NPM1
.ASXL1-MT
papillary–mucinous
CGGGATCCATGGACTACTTTGATGACGACGACAAGATG
www.sciencedirect.com
1,150–1,200
2–31
Y68C
031550
imidazole-HCI
phospho-Y1092-specific
CD49f
143-2M
bar=200
avid
VHLmediated
WAD
anti-Shh
.Melton
PanIn-1A
45/185
1058
Met-938
LSID7S522
1a-d
Dacomitinib-induced
PHARMA
5258
defined55
SI00715932
5261
.Physiologic
counterstained
C8161
GGT→GtT
banal
Arg205
20–26
5′-gctgcacaaacgagggaagtacatcaagacctg-3′
RAS-Binding
15/55.6
anti-sera
Abdulkadir
364-
Non-propellor
hemicorporal
protrusions19
3.mRNA
Cytospins
1.7-kb
SALL1
C266S
C2C2
13.5-year-old
NM_001145306.1
LDC1267
myristoyl
processSomatic
+.-
MSH2/MSH2
N1219S
Characterisation
.MAPK
2454
S'-untranslated
c.1731G
meningioma-associated
Single-copy
DHT
mast9
cGMP-dependent
ComparativeMarkerSelectionViewer
609insS
BTB-POZ
Tie2-Cre
c.425G
MycT58A-expressing
RC218460
.NCI60
fulvestrant
16/3/25/18/46Age
family–associated
PMLRARα
Tris•Cl
FGF/FGFR
pGIPZ
5â€
D4
maxi-prep
crystallography-based
osteosarcoma.2
PAX-5,14
.Ley
membrane-associated
C1.7
Rejto
PMS2-Related
state.14-16
hyper-dysplastic
C447A
T315I
not.5
MC63
E673
involvement.18,35–38
≥5
ABP
OX40-agonistic
CATAAATACCACAGAGGCCCACAGC
in-silico
p=0.2
I448Vand
immunopuri®edp53
//links.lww.com/JTO/A823
p19INK4D
cSCC
Creu
LGGGQYGEVYEGVWKKYSL
assayf
arecultured
type-like
CNC-C
D831-K721
A74G
Genemapper
recombination-dependent
T331
05/05/2015
K650Q/N/M/E
PC12/MEN2B-cl.7
EZH130
T67T9
Rapalogs
SLB1
monozygosity
pharmokinetics
high-normal
2.09
NT_005403
HD-0263
5′-gctcgaagaggcgctcatagtcctggttgtagaag-3′
MarrowMax
33434081
975–988
ligands34•37•38
Lys-104
GSK3-ß
fosmid
ribonucleic
1043
phosphorylation-driven
Gly2Ala
ndings
Olaparib-resistant
.D839
apoptotic-inducing
propor
2HG/glutamate
unit/μl
Sorlie
prosomere
SH3-SH2-kinase
.G-protein-coupled
BCL6+/MUM1+
PIK3CB_S12
ASXL1
Accustain
ΔBRIP1
.Anti-emetic
andTissue
f+
a.a.1–a.a.172
0.150
cross-resistance
p.S819P
macrophage-associated
domain.53
L402P
.Fig.2G
SNP-A
5451
4,6.To
sequenase
PM3
CMV-GAL4-TFAP2A
Houvras
-1221/1222
NM_001654.4
absCN-seq51
.Endocrine-Related
360K
Volgestein
I1054F
SOHLH1
echogenicity
770_771insVDSVDNP
SpeIClaI
pT4N1
forreview
transformational
RAF-specific
.NOVEL
SJHGG016
histocompatibility
G-361
4826
TET3
HKR1/T7
Karg
nucleus.thumbnail
laparoscopically
1st
P96Q
microassay
GENOTYPERTM
H-4-2013-FSP-082
SA501
.Binarized
LRP6
nonmammary
PD168393
67.9
.Arg
A457P
1846
22.44
Cell-free
Genscan
GGAXCA
IP2
ofFO-1
hapli-insuffiency
150-450,000
R383W
A174T
53.0
oligodendrocytic
//dx.doi.org/10.1136/jmedgenet-2014-102912
MerlinS518
W-III-04T
3TPLux
PI3-K/Akt
anti-rabbit-conjugated
ITD3
effective,2,3
Asp22
immunoprecipitation-chip
sequencing27
Gly3Trp
D408E
hAgo
HSPCs20
cytoarchitecture
Shojaei
EC5
hyperplasia-driven
PI-4,5-P2
CS-1s
HPN
–17.8
cancer90
IKK2
Syriam
E148V
glucose/g
ACCEDE
AF032985
anti-Stat5
apoorer
HER2-EGFR
harmonic
Cochran–Mantel–Haenszel
H509Y
V–propidium
.Lox-K-rasG12D
1873R
1086-1
High-efficiency
.Linda
delE746-A750
Inserm
Fig2D–F2D–F
BA-12
26492527
predic­
c.−154C
W582C
18-kd
IL9R
Bycomparison
Nausea/vomiting
NFE2L2.27–30
.Prepublished
cerevisiae,25
CDK4-ΔG
Myc/Bcl-2
MuLV
MachineTM
mesodermally
re-cloned
A33P
G719CþS768I
.1731
chorioretinopathy
1848R
98.27
CML/acute
G285C
Ft-BCOR
MYC-N.
seimpaired
PPM1D-D314A
miR-17-5p
AML.1⇓⇓⇓-5
H1047
Ruschoff
Muchmore
FischerVize
S3H
Kabbinavar
XRCC3+RAD51C
WNK3
‰
0.83225
NES=2.05
trancriptions
D2148N
radiotherapy-induced
CA166
L723
7242A
Q781R
001210
R291W
aects
CDKN2B/p15
TEL.E5F
PI3K/AKT-dependent
centirays
rIC
BioGEM
cosuppression
5′-AGAGTATGTGAAGAGATGGAG-3′
94°
Stivala
12F8
I691
frameshit
∼20–110
.Semenza
Apcin
TRANSDUCTION
.5074
locus-controlled
.FGF2
1st-degree
58,800
ART.10
gene.80
andFGFR-3
ACVR1-BGH
QMSP
-delP449-455
RAGBGDP
SWLKNN
KYM-1
0.2/field
miR-TOP1
.Chromatographic
SUV
k12•K1•
R961W
Enfermedades
.D835H
9012
tumor-supporssor
self-activation
−80C
ubiquitin-proteosome
R522H
Eck
Germaneto
p.P26_Q31delinsE
del=deletion
553142
glucosteroids
growth-phase
5'-GGTTATTCCTCCCATCAGCT-3
MMTV-Polyoma
n=51
droog.gs.washington.edu
chemoattractants
.Surrounding
62K
Lys351
131:333–340
NPMþ
RSC2
SCC35/61/294/151
10−101
DUSP4-GFP
c3
nonmutagenized
cohort-wide
Brd3
wavelength
RTK-induced
L360P
pCGN
5′-CGCACGCTCTGCTGAATG-3′
ffgmx
.Tx
RHxNΦΦLFMG
mGppNHp
ALL.16,18-29
TGTAAAACGACGGCCAGTGCCAGAAGACTTGGAATTGTTTATTTG
Ba/F3Kit
Δ1–33Neh2/ETGE
BMP-2-downstream
D4736.55
331–1200
collagenoma
GI191E/A8
phosphor-ERK1/2
1.5–2.5
TRegs
sagittal
232×10−6
CFC96
E7080
8-wk-old
Fk
gynecological
Gli2-R
p89/4x48
VHL-deficient
transcription-induced
197Cys
Phe185
/EGFP
−684/−677
MLM2
Bα-binding
zileuton
Topo-isomerase
0·1
SectionAmplification
3.27E05
hyperkeratinisation
Flag-Cul3
-800
.Senescence-Associated
Stupack
dihydroorotase
ESR1
wile
Persistent/recurrent
MEF/pcDNA3/His
.Provean
content.springer.com
criteria.2
McGiffert
anti-CSL
GAC→GGC
D470V
catalytically
VPREB
gd-PTCLs
2000.
areshaped
Cell/KIRC
cCalculated
RAS-cooperative
paxillin
deamination10
anisopoikilocytosis
III-4
ΔD-Fbw7
pSmad2
cFUGW
AldAla
5′-CATCTATGGTACCGGGGCATCAGGTCTTCACCAA-3′
64-,70-,76-
R41A
G759E
100,000x
XXL
kDaPEA-15*PEA-15
Phe
Cisplatin-Based
-0.028
240–243
cells7
irnmunosorbent
TCR-α
uAspProl
P.S768Ia
fossa.27
chromatin/DNA
doman
Demehri
grand-aunt
1μg/ml
22-only
AGS/siRhoA
CMV-T7-hOsa1
p300
Miyaki
CD74–ROS1–addicted
cancer.35,36
LeufsX7
.9118A
p.Val530Asp
carboxyterminus
0.562
co-deleted
75-µg
D904E
.Secretion
13C6,15N4
.022
Ub
EWSR1-ZSG
TW-24
C–C
1238
Sharp1.52
1.43NPM1
50K
medulloblastoma10
DNMT3A.4
GAAGTGTACATACATTGTGAACGACCA
melanomas.9
Mci
ERCC2-mutated
3066del
F5-6814
PermaFluor
ATM/ATR-like
PRAD1
19,66
double-reporter
GCAGGA
cbt-15-428-g3
1796dup
NB1
A_52_P58558
TOPBP1
2–269
VVI
AMPK-regulated
R415W
9±0.2
p.Arg180SerfsX30
R6867
depletion-mediated
Cys515Ser
TP53INP1-amplified
LDD
10,11,12
.DMV
6-phosphate
75-fold
involved160-162
MMPTumorsâ€•BAX
Rossant
miR-200
26°C
report40
n=198
10-pI
.PDL
104:2867-2872
EVI-1-tansfected
Cul1/Cdc53
AAGAGGAAGAACTCCACGGAC
V560A
Ermington
Nasir3
Shrunken
FYN
-tcagccaactaatctcgcaac-3
.add
Pro-Apoptotic
ulated
ULS-2
TEGM
pericytic
.680
2116
16.52
-GTA
5′-gcgcaatTGTAATACGACTCACTATAgcgcAGGAGGgtttttaccATGgaaggtgaatgcagtcgaagccattgtg-3′
G1097D/S
5'-TCGACGGACATATTTCA-3
obtainedon
PIK3CA-110
–CSF,23myeloperoxidase,24
exon7/8
LIGHT-RESPONSE
SMYD3
.Stop
BM/PB
Skafar
Dtk
E2-bound
RNF144B
L726F
Sba1·Hsp82p·ATP
22/
streptavidin-based
-Cbl
benzyloxy-carbonyl-Val-Ala-Asp-fluoro-methylketone
mutations.29,33,34
Brg1L
multicapillary
ERαLBDCam3R
Bcr-Abl-positive
MSH2-6
structure—exhibit
.Tamura
v2.1.071
hERα-testosterone
S207,212A
FUS–FEV
1.51
anti-activated
F52
1397-1398delTC
TheAPC
2/panel
10S
BSID-II
PGCTYS-05
reaction.Despite
high-/intermediate-risk
Variation_2294
KCL22
Δ118
mAmps
5′-GCACAAAGATTGTATATCTTG
54:461–468
STAk
3516-bp
6800
EVSA-T–expressing
v.1.12.4.2
.2,31
Life-threatening
Catalytically
.Rash
outcome42
K23E
Stat1
mortality1,2
cells52
1387
AstrocyticTumors
patients.ChIP
V600E–mutated
Genemark
Jong-In
primer3
CD45+
.Daly
L979P
survival.20
adenomaMicroMacroSeminomaMelanomaSarcoman
4-mo-old
−6.4KIAA1257KIAA1257
BCR-ABL46
CDH12
EGFR-TKI.14
Chute
mechanism-driven
118450
beta1-integrin
acinar/neuroendocrine
15,18,32,62
gluconeogenesis
Diff-Quick™
C-MAF
H508
integrin
NM_005898
p.Thr196fs
gi55733310
factors93
.Interferon-g
real-time
subclone
cyclin-D-CDK4/6-Rb/p107/p130
pBSK+IGF1R
DC200
7PIK3CAWT
PRSS1
delAsn771insGlyTyr
late-exome
59:1427-1434
1/1/2/0/0/0
Hidalgo-Curtis
.glioblastomas
anticentromere
H303N
SRC-homology-2-domain-containing
Reconsidering
pan-B-cell
G719/L861Q
StrepTactin
fluorescenceacquisitions
.Rosa-Stop-lacZ
Brca65
AHL
65,66
ilv1-
.Ras-related
.Theirfrequency
protein23,24
ARF-null
Silver-stained
boxB-luc
pcDNA3.2/V5-DEST
interleukins
Neur
isoschizomer
mo-old
7.2-fold
ALKwt
deletion/substitution
sample-derived
world-wide
-Smad2
0.1–10
-TGAATGGA-30
LNCaP-AR
−1.89
Prettybox
.Rat-1
P436T
3–10-fold
350O14
1577
ATM-S1981
gert.matthijs
interstitial
Hg
CML52
AIYAAPF
o45
mgfap
Elutions
Brookmeyer
.C57/BL
R310H
33-260014
1045
b/a
PLCγ-PKCα-mTOR
COSM20405
RAS-exchange
nonordered
inorganic
=63
proliferatively
5′‐GGACACTGAAATATTTTCTAG
StrataScript
rs1551641
1.0013
genes.2
HBV-
Ikk3
5–23
94:662–669
inescapable
figs.5B5B
Pro766
hepatosplenomegaly
GSTNF1
RIRTQFSFSLQERQLRG
􀁂-catenin
pCA57
BCR/JAK2
CSF1RD1—D3
decision-tree
RABGAP1L-NTRK1
55242469
-GGU
pre-excision
extradomain
3q25–26.3
www4
lines.20,21The
93.14
TCGA-KIRC
SETD2/Set2
cancers12,13
C200
antirabbit–horseradish
assaysProliferation
3.491
genes91
1.9-2.9
P3-ARE
S297F
Velcade®
5′-GCCTGAATGTTCATCCGTTT-3′
www.cancer.gov
R546–R551
HSC43
-corrected
.Timing
re-hydrated
TuScan
lacZ-expressing
aminoethyl
66/151
AG3971
MTS1R1
subcultured
20,718
pZF1
Myc-ICN1
2Proliferation
785.3
cancer.2-4
leukemia.25,31,33
NC2
II-F
5BFIGURE
panendoscopic
34–374
VM-CUBII
internally-developed
T117
μkcat
2,299
.MPCs
HA-p53G245D
MPL-mutated
K45N
10.1158/2159-8290.CD-16-1431
acid-precipitable
homologe
129Rb-pur
Nrf1-null
38/50
salpingo-oophorectomy
waselectrophoresed
over-production
mised
serine/
pIDT‐SMART
25/82
mater
adenoma-to-carcinoma
Pro-Thr
.Evaluations
V11A
architerctural
Lgr5/stem
NT-4/5
6736
SARNP
sensitivity/specificity
determiningmutation
ZnF1
79.1
Men1/D
KrasA
Y764_V765insHH
Drosophilavirilis
Ink4a/Arf-deficient
recur.2
oncogene46
.Much
pure-colour
Abcam-ab32081
5q33.3
iKC1
.Ser37
Gastroesophageal
Incheon
211KB
,11,12
10.56
Diasorin
mL/
activational
.—ED
iNPicated
Thr58/Ser62
965–969
Beghini
P316S
diplotypes
UDS
NCT00346164
Ras/Neu
EGFR-T790M
Asp-539
12,24
Akt/ERK
Y901
.MEL-26
p.Asn615Metfsx45
.Cumulatively
D835NF
p.Arg297Cys
765×
–85.4
AX
VHL-silenced
Cooper.1
p~~~~~oCR
found.7-11
pcDNA-Dup
TEL-mediated
B/pointed
47.0719.5
RaflMAPK
reverse—5′-GGTTTTACTCTCCTGCTGGTACT-3′
EZR-ROS1WT
pSCB
Sora
pMCV-E1A12S
c-Cbl+/-
stimuli.16
anti-AnnexinV-PE
5′terminal
Fornace
-III
101-base
****S.
9p21.3-p21.2
slideFlow
DEXD/H
0.21-6.56
.2131C
1mMEDTApH8.0
H3K36me3.20
MKN1
113
c.3076G
Y535C
receptor-like
.EPIDERMAL
/Mb
-D281G.54
FH0007
​Figure4C4C
pY785
BUBR1
Truncating*
0\0L
3+
dovitinib
CAF22
HLA-DRA
Arhgap19
CDC45
EP4
RAS–B-RAF–C-RAF–MEK–ERK
Brca1tr
Indolent
trafficking40
proteasome-induced
GLUL
3/91
TPR-MET
Kothare
NS-associated
Bric-a-brac
VCaP-siERG
neuroblas
TRM-
chromothripsis-like
p.Ser445fs
HLA-B7cDNA
H-Thy1
GACGTACCTTATCTATAAGAGGACCGAC-3′
MDDcontroltumor-bearinganimals
raÃ-alÃ-elein
NOTCH1/Lin12
process.134
HRm
FH1
0.205–0.788
analysis.Transfection
BACH1.Interestingly
T277M
Apc1−/−
Dll1
0.5340
AMP-regulated
bialleleic
Anatomic
5'-hSNF5/INI1
al36
C57B6
Twenty-two
model35
Anti-GPNMB
bevacizumab/oral
neutrophils/mm3
GCLc
mask-file
R391H
M-R
D336
polyadenine
Apo-One
midrange
pCLxIP_MEK1
oligodendroglioma
+33-478782821
QuÃ©bec.H3A
M18
Lipid-binding
1.05–2.00
5′-TGATGCGTCGACACTGATACTGCTGGGTA-3′
tubulin-specific
pQCLIN–enhanced
6601delA
1,646
APCFZR1-promoted
p.Deletions
28–92
TSC2-mutant
dose-escalation
sh-AXL
approaches.3
NRG3
non-ICL-chemotherapeutics
50–200
probeswere
CDC25Mm
9–136
RAS-binding-deficient
Tran1
C‐domain
applied.5
TLR10
ALL18
enhancer-bound
.Seventy-nine
W.R.H.
gels.To
9mutants
INK4a-ARF
UTMC2
348–353
Fig.5A5A
140481275-140481298
QTR1
-308a/g
survival=23
astrocy­
375X
1––was
more-prominent
GST-fusions
anti-PCAF
18~11.2
RAF-1/mitogen-activatedprotein-kinase
VUS-carrying
withan
TrkAIII/TrkAI
better-known
Br37
pTSAd-fe_
endurance
Vκ-directed
A2–C2
ortho-
localization.In
His6
3/20/19
FKBP1A-myc
96×
.Penicillin
olfactory/taste
8-well
c.1106G
signaling.99
cyclopamine-like
NANOG/TET1
TNE
SPOP-Cul3
Naruse
galactose-binding
MNC
//www.targetscan.org
limited-
YAP1–TEAD
3OOI
complex–mediated
sample-specific
E260K
FSC-H
decidualization
behavior.9
p53-pT-REx-
Inpp4b+/+
J-associated
HLA-1-
cdc28
inhibitor-1
−147SRYP
K/sodium
HER2-containing
8H
q15q22
pGEX
CS1USAU
Glu659-Phe1248
L-myc/pim-1
Pik3cae20H1047R/+
CI=42.95–64.03
ozogamicin
Flag-SPA
ARIAD
5′-TGGGCTGAGGCAGCTGCCTT-3′
.Determinants
2-methylcarbamoyl
DEC.
cancer-like
5′-GCTAAAGCGCATGCTCCAGACTGCCTTG-3′
Loss‐of‐function
Qo-T16V
toxicity136
leafy
InducesNeoangiogenesi
marrow19
EGFR‐mutant
26-R:5′GTTTCTCTGCGAGAAGGTACTCACCC3′
damage.13
11,14,15,25
4.3-fold
anti–Gr-1
Papanicolaou
−.48
S7b
Setd1
5'-gtttatttcactcgaggcc-3
R455*
suppressors.24
1.03–2.12
E2663
.Fasting
Ar9GlyCysTrpGlnAr9GluProSerAs11AlaThrAlaSerAr9Mo
Glu453
normally43
8/162
target-innervation
2.8−3.5
BMMR-D
5′-TGTCAAATACTTACTTGGCAGAGG-3′
co-occurring
Int7G24A
//www-p53.iarc.fr/P53main.html
pcDNA5/FRT/TO
CRC-CLM
M649T
67.60
mGATA-3
ftp.genome.washington.edu
directionality
UMR5641
78.7
gene5
STAT5B-mutated
proteins—PDGF-C
pCDNA3
629–630
7oa
8/132
.Mild
32/
278740
S80R
203fs
CH3OH:2.5
3604
3.1-ZBP-89-FL
P161S
5′-ggatcctaatacgactcactatagggagaccaccatgtcgttcgtggcaggg-3′
p69'rk4
tRNACys
1527–1863
XP_536047.2
thatare
TLR2,16
p-Values
45-μm
MLLT10
'64
SrivasGENES
117N
p68TRK-T3
Parvovirus
R394
12/118
EEHVpY118SFPN
platyspondyly
T-3V
G2089A
TCCATTCCATGAAGTCAGCGATA
S3.12
53,472
R1285Q
300-nm
structure.A
-CELL
.Spreaders
CDK-Activating
Accesskeys
promoter-specific
90-104
p.Gln2285X
GTG
3Adverse
=412
.Lamin
*P≤0.05
30-86
Q286R
~180,000
RET-dependent
21938036–21938724
pREX-IRES-CD4
Y46S
Cad-
ERK2-p38
.Follow-Up
N-dimethyl-ethanamine
thin-layer
1.5–2µM
3.FIGURE
IRF4/
Asp-92
2-aminothiazole
-ccgtcctggggcttctggtcatcc
GBD-MSH2
V114I
//www.pharmatechs.com
.SRC-3-dependent
Metastasis-prone
170–6516
pVHL–peptide
INF-
cytoreductive
300T
highly-specific
EZH2WT/EZH2Y641F
.Section
Lavenius
N458I
.O
effects,8-10
generated.21
TSC1–2A
II-CD4
Kasumi
vossKühler
Kinase-Driven
2q33-34
NFkappaB
Paciga
analysis.20
1168
5-Component
un-coupled
NR4A3,4
GST-FERM-A211D
testing.6
Epo-induced
PMA/ionomycin
methyl-cytosine
muliplex
1.13-2.61
approaches20
Vikneswari
lineage−Sca1+c-Kit+
FACSorter
probe-based
EGFR-G719S
hTCF-4b
re-review
1.999
L555P
Elements-based
col-
MEK-dependence
Pdx1-Cre-driven
monotherapy4,6
eosinophilia.16
Immunoreactive
recombinase-mediated
9803
ultra-mutated
acti
14.5/14.5
Rabaptin-5/PDGFbR
30.2–
tamoxifen-treated
.Haematological
methods.26
Fig.1a1a
88-90
familya
RCC-41
anti-Jag1
levels.4
NAT9
Ricerche
5′-GAAGACAGAAAAGGGGAGGG-3′
HATs.Figure
482KB
/total
-monomer
date.We
maltose
Bbeta
Aut
GS-5'-enhancer
Arg188His
human/yeast
BioCare
Figure.4
flutamide-activated
RTTPSYVAFTDSER
Raznahan
ficiency
maccaca
.How
translation.4
3612
megakarocytes
bulk-selected
observed.thumbnail
Native-PAGE
K113K
E723
anti‐HER
5′-cttctccagccaggtag-3′
anti-Mdmx
p.Gln1579Pro
asCN
Biotag-TCF3
S1I–S1O
reporterstrains
5′-caaagtcagtgatcttcatgtggccatctttgtcca-3′
BM.34
.Spontaneous
ST-turn
Neural-specific
.Six
p=0.433
E216V
pSTAT3-positive
StablesImmunohistochemical
.Cavalloni
tumor/cell
p.D153V
T854A
~15nM
20p12-pter
ERCC2-wild
Flag-MLLC180
endometrial59
faintly+/negative
domain/section
MDS.6
as-R201
k-mers
3C–3E
Multiplication
phenotype10–15
H94Y
aporeceptor
1p/
3ERD
Furuse
respectively.emerged
54/502
sc-6533
G882S
.Trans
mutations9–11
pCEFL-
R443P
L-540
p.Arg342
1E2
Thiopentax
DEPDC1
time=
carboxyl-terminal
postulat-
842
A_52_P229536
mutantA
ready-reaction
49-fold
backcrossed
0.07159
15/67
R2323C
both203
-helix
members14,15
Lys745
5′-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3′
Leu576Pro
T/p.P154L
-mutated
NotI-Smurf1-R
P623L
anti-CD56
SMO-S533N
TC-PTP
G248Vl
SDS™
2218G
E142
carcinoma.74
EGFRhigh
area/
phenol/chloroform/isoamyl
88bp
Glu768Asp
metastasis.11
benigntumours
Perozzi
neuro–cardio–facial–cutaneous
al.,2006a
protein-oligonucleotide
.FZR1
dierently
patients.5,34,35
first-diagnosis
51306
ICR
Repligene
broblast
DNA-dependent
5α-androstene
TTTTAAGCTT
RAG2
kinase-specific
pseudosubstrate-like
14–66
Sall-Xhol
SDF-1α-induced
activator–sensitizer
Okami
41.cER4.30
.1puro
20–42
combinationfor
TSHZ2-SLC35A1
Roulland
K806-
LB-IPTG/XGAL
R144C
11nM
CS-L
17790
proubiquitin
FGFR1.
832037F
anti-cytotoxic
pUHD10.3
97:3
LP96-057
CTTTCCAGGATTCGCACAAT
,75
N.A.G
III:10
dnRas
RAF-inhibitor
iPatients
Full_KD_Fwd
S157C
promoter/enhancers
S6-kinase
BRCA1-knockdown
fects
orally/daily
SCH66336
Ballarino
PPP
p.Phe595Leu
non-core
.Dulbecco
C-terminus.4
monocytic/macrophage
29,32
Pierre-Robin
+mar
ACAGCACCGACT
PAH
GSE50022
self-ligated
DSBs.28
concordant
G1/G2-phase
.Ezh2Y641F
pSG424
84,85
FANCA-NLS
2012-04-16
SX.18MV
Leu128
R+Ras
Stat5-dependent
GeneTools
1,894
Arg-885
1:1/4
Kras-p53
.14,15
exons.17,20
±10.2
Asp65–Leu72
.Rapidly
.Highlighted
GISTsTable
2HCl
www.uniprot.org
S446
2946
AM38
Nakagawara68
test.26
RRRCWWGYYY
self-ligation
nonlymphocyte
c.1944A
NHLBI
FGFR1OP
primaryresistance
.Tumor/normal
2749
5′-CATGAGGCAGAGCATACGCA-3′
1291insC
A218V
spholipase
cohort37
4-year-old
.Dingwall
hbrm-associated
anti-Erk2
YFP+
cosegregate
anti-FGFR-2
Macias‐Silva
Hec1
CSMD
NBD-GTP
C-FMS
.Duplication/deletion
1093
Diamidino
glycogen-associated
3EWS/WT1-KTS
.Btk
MFGR1877A—3
pCβASceI
20089
FC500
puriWcation
E-Z-Em
Dyserythropoiesis
≤0.8
single-nuclei
GTP-loading
therapy106
myb-like
radiologist/pulmonologist
.Mutants
ERCP
development3
Chmielecki
36-38
F299C
Koltun
.LC-2/ad
ASK1-focal
pN1
p-STAT3-positive
M571T
p.P85L
R110G
Qo
T491I
arms.Full
–Ura
IRF-bound
/fl
MLL-AF9–transduced
*Po0.05
VHL2_2F
nonneuronal
15.
withinthis
carriers.7
TATCCTGGAGTTGGATGC
.Eker
GPd5
bling
2.64
reporter-gene
116K
hyperactivity.2–5
Leu127
Jeste
3,769
non-overlapping
H101R
q13q14
3/70
D374N
c.2904insCCCC
A92T
target1
CA37754
slideDetails
-158
.Ba/
-TTCACAGCCCTGCGTAAA-3
*TRPS1
cancer.40
GCAAGTCATTATTAT-*GCAAGTCGTTATTAT
pEGFPC1-PTENΔCAT
proliferation5
R-CHOP-like
CFP-E78P
antistress
counter-stained
paired-SCLC
non-exhaustively
cells/100-mm
Thiffault
N-acetylglucosamine
Δ16HER
MGH056
Y55H
–Exo1-fragment
DNCH2
MVC
IVS1-8
holoEGFRs
deriva
A075
NRASG12/13-mutant
LS200
P638L
MNNG
LA2
CNstates
6.2-
1665
0-02M
2310
AUUUA
strain-dependent
andgreen
stage-for-stage
achondroplasia/hypochondroplasia
sub-classes
CohortsWe
694,000
haplotype-based
c.2519_2530del12
DEGSeq
B-RafV600E/3x/S729A
tel1/mec1
lentivirus-expressed
HCA
caa
report,22
c.2439–2A
.Wurtz
Aminoalkylamino
Glu3342ter
1.00-5.58
T118M
invasion111
trypsinGiemsa
3230
described39
EORTC/MSG
RpTPp
58•
V143A31
sequence-homologous
RNA-tethering
TRAS
SNF1
HGF-treated
target.Because
HIP1
G12V‐H‐Ras
KRASS65N
F749
.Sixteen
Myc-SPOP
p53-S15
MEK1-transduced
HIF1a
Buschbeck
HER296
RBPSUH
3.9-4.8
A607T
Abbreviations—–Pt
CFP–Dicer
activation20
polyp/adenoma
allele.29
22400-071
GR5
75-amino-acid
Biomeda
splenectomized
B-site
ter3015
NF1Q1174*
125â
5FU-based
Carcinosarcoma
M504
status.29
non-index
S598
D820E
incisional
16q-
18–78
Calbiochem-Novabiochem
3-phosphoinoistides
pLP2
245-bp
OCDfl/fl
NOL11
Para-formaldehyde
FOXJ1
Meetei
3330-fold
.Overt
gradient-gel
5′-CTTCTGCCAAAGCATGATGA-3′
TSC2.6
BCL-xLΔLΔC
A301-046A
GTCCCTCCCCAGCACGC
'~-~5
re-immunoprecipitated
RELAFUS2-RELAFUS7
FPKM
5′-GAGGCGAGGTTTGCTGGGGTGAGGCA-3′
P329207
Saracatinib
Qcolor
cases.1–4
complex-mediated
L37
IBI
antirat
xwx
cancer-predisposing
IGROV1
Ψ
Red640-CAGAGCCACAGCCTGCTGCCCA-p-30
TP5323
D276S/E279S
18.7-ms
STC-1
box-type
16.88
SPDHE
P=0.07
aAmino
.Elimination
TGTCCTTGGAGGAAGTGGGAG
Xiaoet
TGFβ38
Glu316
mIU/mL
650g
Akt-regulatory
AZD6244-induced
collagen-dependent
–80°C
typeIHCimmunohistochemistryLOHloss
OncoMethylome
4.8-4.6
Hv
A763V
:5
Ras/B-Raf
p.C625S
mycoplasma
cells/l00
super-killer
T6AAAAFABA
medium-
EWSR1–ATF1
Q24171
MLL-PTD
anti‐Keap1
Infinium
profilingTumor
-DHFR
J′
5-day-old
kinase-interacting
c.1526G
5′-GGCCAA-
'All
jimmunol
Ercc4-null
multi-head
activity35
HIB
hyposegmented
66°C
1MUO
4.6-
237–239
LSI®
-activated
ER-LBD-biotin
M1775V
databaseof
/LV
c.119G
DeepView-SwissPDB-Viewer
protocols35
7,8,12
shown.32
CTGTCATTCAGTACTCCTTGATGGGGCTCATGGTGTTTG
SW872
S216M
p.Gln178Pro
SP-1-binding
HER2E-mRNA-subtype/HER2-positive
Schlessinger
GATA-3fl/fl
E1776*
59-CAGCAGACCACGTAGAAGAA-39
29/3
anti-H3K4me3
R.P.
3/28
TRK-SHC
KDfl/+
PRMT7
Gly-rich
12.0.1
SASI_Hs02_00339757
Balss
M-CSFR
UoC-M1/FA
141A-C124
HER2‐driven
R400
pdgfrb+/+
226002_at
3523–3531
464del
FLT3-overexpressing
subdomains11
pE1E2SUMO1
interchromosome
CFPNrf2
receptor-oncogenic
12•17
intra-PDX
pBabepuro
15Clinical
c.1702_1703del
.Craniosynostosis
1.59-5.34
Non-catalytic
CB17SC-M
Singlestranded
G35V
PURB
unphosphorlated
cell.52
PBS/1
Pluk
.PAX5-JAK2
GlnAl•GluAlaGluValAlaSerleuAsnAr9Ar9IleGlnleuV
,8,9,10
0.960‡
hamartin-mediated
Fgfr2/3
RW2982
pJG4-5
HRAS-expression
Futscher
A1099T
chemotherapy66
FACsCalibur
31.3±3.6
Δlinker
4366
Antennapedia
1−Pindel
p21/Waf1
EEINGNNYVYIDPTQLPYDHK
P302L
5/118
6.96E05
0.00019
BLAST-homology
V769
rs28897675
pDel-5-myc-luc
protocol1
carcinomas.22
CC73T
ofMyoD-Max/E12
Fermentas
EMILIN2
–pp-dol
1•6–2•1
25/55.6
lines.11,16,60
.Locus
–LAG1
FLT3-mediated
m1–M44
tuberin-
LKRE
Q61LNRAS
levels174
cancer1
P153A
Tyr341
granulocytic
IGF-evoked
SU-11464
Fibronectin
1623
⋯
Ba/F3-KIT-D816V-Y568-Y570FF
treatment.48
Hardy-Zuckerman
+/Mild
Shc-Ras-MAPK
WCP22
IL4
Ln-transformed
CD4+CD25+
population2
71.6
dpf
malformation-polymicrogyria
brotic
SAETEKEMANMKEEFEKTKESLAKAEAKRKELEEKMVALMQEKNDLQLQVQAEADS~AE-ERQDLIKTKIQLEAKIKEVTERAED
.Asp
D1S128
Avellino
phospho-RP-S6
.GFP-ABD
phosphorylating
//www.arup.utah.edu/database/MEN2/MEN2_welcome.php
Subependymal
NCI-H2452
68301872
L262V
Bioneer
5′-tacacaaattacacaagtctgagaattccccgatatcgcctcga-3′
dis3-G766R
33P
chain.32
GCCTCTGTTCCACATAC-3′
VEGF-receptor
Gachon
Spi1
32P-labeIedantisense
2389
19.66
p.S553
5′-TCATGAAGAAGTCCCGCTCT-3′
​Fig.2.2
mitogenesis3
//research.nhgri.nih.gov/bic/
HA4-tagged
13-aa
transducer-1
proline-glutamic
ITD505−508
,7–15
Phe-Gly-Leu-AlaThr
BRAF-positive
9,10,35
ERK/Akt
mapped.39
genotoxins,11
urolab
4620
3148
WT+EV
EGRF
225
p-40
CODD–pVHL
04/03
DLD-1
10-ml
-CCAGTGCTGTCTCTAAGG-3
.Cartoon
one-codon
5/25/89
.Tyr
events32
deubiquitinates
portant
761Y
SCGJO
.ERα+
Lauth
PIK3CAM1043I
GID380–404
G438E
¶Leads
IDH1R132H-overexpressing
Lu¨cke
4810-bp
RP2433R
7G
Licchesi
UUC
CIN-
0.9-kb
alpelisib
Demonstrating
.Mothers
S1613P
33/M
27A355
DM4
10.058
Asp816Phe
R34
*Signifies
gAACAGAACAAACA
anti-N-cadherin
3.467
NCoR
semiquantifiable
.Harvesting
AG/GTAAG
pUSEamp
/KO
cysteine-substitution
Berlin-Brandenburg
G270R
3T3-L1
levels43,44
5-CCCAAACTCAGCAGCCTAAG-3
–16.6
FGFR3/A391E
N384S
S2Gg3
non-HIVassociated
drug,11
AMY-1
Q350X
TGF-j3
Real‐time
Y1092
M53
phenol-choloroform
GeWtinib
peri-menopausal
n=0/4
phospho-S6S235
tyrosine-to-phenylalanine
∧Individual
ab3825
H3K9me1/2
Coot43
green/molybdate-based
5′-GCATGTGAGGATCCTGGCTC-3′
pLenti-CMV-TetR-Blast
Co1
www.jci.org
PI3–Akt
thyrocalcitonin
-14A
deaths.1
R153Q
F317
553T
rFANCC
P98A
2.7
ModLoop
RhoA‐interacting
5q31-35
AlaProGlyPrQ
ng/AL
RE-Hygro
9.99
10868–10881
–NF-κB
I494T
rearrangement.12,29
c.2459-12A
described52
2521A
0.02–0.20
S127N
O.T
P196L
Reference_Allele
macrophage-like
Fifty-four
RhoA-NipR1
Etl1
XPF–ERCC1
Cma2
anti‐rabbit
D1246
RhoB
CRF-containing
TRCN0000000369
TGF‐β/SMAD
WTB-Raf
KSR
II-restricted
α4β1
Wnt/β-
15/34
R419P
Sinnamon
4,567
FGF-FGFR3
post-genomic
o7
heterochromatin-mediated
C92Y
®nger
JMML.8⇓-10
Malchoff
lines=0.2
CD10-
Molofsky
Bivona
0.25μg/ml
.Categories
IL-1
CBL–FBXO2
C6
2p25.3
tyrosine-related
Smad4–/–
2-oxoglutarate-dependent
Slx4
p120GAP-stimulatedGTPase
microhomology
.ChIP-PCR
o63
p.Pro715Leu
carcinoma10
pseudo-energy
.Concentration
3.5†
–49
FA62
8.1-fold
-2-epimerase/N-acetylmannosamine
A_51_P453909
9.15
p16.41
Vif
activation/deactivation
c.1–26C
RAC
Kruppel-type
69–122x
Celltiter96
PstI-HindIII
Q157P-5
Ghannam
Theretransformed
osteolyses
5163
Caco-2
-309
Manoranjan
p110γ-specific
cohorts.1,2
neuropilins
anti-SS18
8q11.23
growth.33
SNP-arrays
FGM
5′-CAG
S44
Budinger
donne´es
E159
46KFIG
Duplex-PCR
147.3
imatinib16
2488
described.4
deletiona
ASXL1-MT
F159I
Mek2−/−
GRCm38
bromodomains5
97-7
.Seventy-two
Proteasome-mediated
c.1676
2232L
1.88×105
86–91
Alizadeh
0.571
inter-exon
octamers,27
BRCA1–PALB2
pcDNA3-NOTCH1
non–age-stratified
5′-AAGCATCTTGACGGCCACTTTCA-3′
2q33.1
hIL-11
HSC-7
6/21
Y893
5′-GAGGCGGGCAGTTGTTATGCAGGCATCC-3′
site,15
c.1989G
W274E
un-phosphorylated
3,5-Difluorophenacetyl-L-alanyl
141.7
ZAP-
1722
pathways.59
Quiagen
594/781
Nfinal
F393L
well-structured
rhoA
domain-domain
Baylin
Genomics21
missense/in-frame
0.281
gene/mutation
p.Thr408LeufsX40
EGFR-T790I
Drug-Binding
CNR1
.Exon-intron
CFCS-associated
//www.ebi.ac.uk/Tools/clustalw2/index.html
activity.5
EAIYAAPFAKKK
Phe147
GGCCCGCGGC
pKI
.min
PLXNC1
coactivators/histone
EGFR–driven
.Whilst
TGF-β/SMAD4
anti-sense
ubiquitin-labeling
12p11.1–q11
Tassabehji
1800–1805
34a
jirovecii
Radek
AGACAG/gtatgg
NSTS
GAGCGCAAAUGUACCCAAUUU
ofdifferent
Pgk1
44820273
36–68
fruitfly
C-G
Arg531
44K
NHEJ
Gazdar
A-conjugated
µlof
Protein—Although
GGATTTACATTATGAAAGTCACAGG
Dharmafect-1
β-GT+MspI
EZH2
SRC1
phosphoryla.se
+24
termedSCS
5228CrT
SERPINB1
countries.114
heat-killed
Yaf2
gtgtgtaaa
HSB-2
exome-level
hygromycin
c.379C
Three-nucleotide
Thoenes
polypeptide-1
retinoblastoma-associated
Sh4
RP11-480O8
4687
XDS
Futamura
TEV-cleaved
redocking
hTERT
F39I
QIAamp®DNR
phosphate.51,52
HT29/CX1
4EBP1
dif­
D1114G
41395
pCEV29.1
CCR7-null
GADD45G
47,29
dose-levels
al34
magnifi-
-pulsed
1–281
L327P
DHEA-induced
388-gene
H2*
92-nt
wereunstable
∼20-
glycine–serine
p.Asp1248Asn
GraphicRas
NP40/1
Schwarz-Romond
S647F
Tsc2/
2:342–350
1·0
CDKN1Bgene
BRAFi-insensitive
process26,27
melanoma.10
H-R273H-14
ERK1G186D
AKT-3/chromosome
t003There
p21/TRAMP
1735
1,27,28
.Immunoblotted
H4531
Merlin/Nf2
3.4Figure
cKit+Lin−
R121H
ATPLite
SNU283
leucine-zipper-genes
688.70
BRG1-binding
lapatinib-resistance
.Grilley
mutations94
RAD52
identificationNext-generation
0.1206
104,176
good-prognosis
HEPII
Nony
5:1,295,228
PLC-γ–specific
micro-
arthritis45
NFKB140
1.34–7.91
MNG/
.Hetero-dimerization
transgenic-cre
AvrII–AflII
Ect2
5′-GTAGGAGTACTCAGGAAAACACACCATGTGAATATCCTACTCT-3′
damage10
non-androgenic
GEF-H1/RhoA
G982D
TGF-beta
q14.2
AP-081088
.BAT-26
–GFP
fidelity19
330T
NLF-TrkB
MRD14
5-week-old
accidental/therapeutic
V2389_splice
PN4
annuallyb
R175K
ex6/7
4107
35–82
Mti=max
SNTG1
moiesin
Asp-920
spindle/epithelial-mesenchymal
studies.9
Macrophages
inverse-Wishart
CCTCTGCCTAGGAAA
pBabe-Puro-Flag-PAK1
DAF
.Platforms
phospho-immunoblots
Phoenix-AMPHO
n=14
Anti-HSP60
0.0427
cryotome
5′-GCTATCACCCGTACTGTGTCAACA-3′
2246
V2THS-260806
~upper
acid-stimulation
Amsen
NM_152274.2
C819
HER3-neutralizing
lq+
0/14
PBS-T
pEGFPC3
2106–2125
Post-operative
residues37
ATCG
Pt3
nonindependence
BCCs.2
.4987
5′-TGAACTACCACTTGTTGACAC-3′
P22
Ser2448
ensembl.org
ggctctctgggtagcccaccggc
Glu-659-AC
nontransgenic
.PP2
Lellouch-Tubiana
36/42.9
R-Smad/Smad4
metastasis.62
MinCyR
STAG2/RAD21/SMC3
BeŁrard
Typhoon
anti-Skp2
HERPUD1-ERG
NF-κB–targeted
5′-CAGCTG-3′
ATPasedomain
5/6/02
'With
PHD6.49
3–32
membrane-anchored
MEK-IGF
2,007,694
1,30,31
.FLAG-B-Raf
Glu88′
IFAR781
LEDGF/p75
Drug-Related
5′-GGCCGGGACCTGACTGACTAC-3′
Met1652Ile
Chevere-Torres
single-strandedDNA
ESCC-148T
gatgcagggatgatgttc
COL11A2
evolution174
WDLPSs
26-86
Phosphatidylinositol-3-Kinase
13Table
5¶-AAGTGATTGGTGCTTCTGTGGATTCTCACT-3¶
321–440
GTF-binding
polyadenylic
36.1×
Y76
PTB
0.38-0.76
events,4
6.5.1
D258A
c.1159G4A
cpm/pmol
.Growth-factor-receptor
androgensensitive
v-kit
cell/
Type-3
Mutant-enrich
FLJ11196
Rapamycin
CAGGTGCGGTGAAGTCGCTTTCCT
c.1411G
ccttcgaacata
anti-Smad2-Smad3
inter-domain
al26
66.5
12.9581
L211M
ATM-dependent
22,15
c.920-43G
U138
GISTs.3,4
30,31,49
25F*
adeca
subculturing
3.04–54.86
IL-10–independent
p≤0.029
YAC-DNA
0.2/NA
.Microscint
DFG/β9
Smad-ablated
cells.16,28
16–21
number2
,6d
.Structural
19–364
–54
1.12
hBrm
Neiman
amphipathic
CL2
dominantly-acting
Kohlbacher
2ln
C257G
.Dual-specificity
SSV-transformed
Sequence-read
H2195
15b
TGGGAGAAGGGGGATTCTAT
OX86-untreated
−5.49
509T
competition-binding
featuresFigure
p.V1671I
G102V
ABCYS
shRNA1
F1576
Acontaining
g.149503842A
cdc2
CD64
classi®cation
Ha-Ras-specific
GHR
86.9–87.4
TAU-5
Mishra
-CD8
patientsTo
Leu+Trp+
mast-cell–enriched
exon20
approach42
model17
lymphomas.To
Stat3+/+
K712Q
GGCAGCACCUCACAUUUGAUU
credential
§PDB
ULN—for
fe-p53
p53.20
imatinib-mediated
75010
3-kinase-like
median=2.1
lymphomas.1
24/45
ectodomain-
L560F
3.2-kb
11/27/08
GCTGGGAGCC
M1-like
inhibitors.
TKD-encoding
.OSCC
HspBP1
Piknotic
13,16,23
.00160729
ATP/tyrosine
Gln-10
CARMA1—NF-κB
disease-containing
phosphoMek
encom­
phosphothreonine-containing
volumeof
healing133
V1180L-alectinib
pattern.28
+4mar
70-Millipore
non‐constitutive
DharmaFECT1
Y414D
sstProAsnAlaS
anti-RAD3
-GAGGGTACCCCTTACCCGGAATCTGGAATCAG-3
BRCA227
.C−F
proliferations
Kamizono
DNA/CBFβ
8955delGTTinsAA
octreotide.21
R482Q
*Four
MSigDb
BU
Intron-exon
Keap1-dependent
CoverWell
ZBP-89/p53
DN-Src
keratoderma
EC109
anti–glyceraldehyde-3-phosphate
relocalize
BRCA1+
Anti-phospho-ERK1/2
GDP→mGTPγS
methodology.12
washing.3
anti-CD4-FITC
IP/Akt/NF-κBA
trans-compound
Oη
carC
PENST
Bq
11–50-
6-8,15,16
Wnt-activation
0.78–1.12
Loop—Genetic
A600
9De´partement
.A1C
amide
PV.3
EGFRdependent
2375
380
P291
D661V
programs40
N-glycosidase
Anenhanced
proliferation.5
5′-AAAGCCCTTGAAGGATGGGC-3′
microplates
RFTPp
non-tumorigenic
daunorubicin-induced
􀁂-catenin.51
sensitive.38
BMS-536,924
fERΔ
S/G2/M
59-GACCACGCGTATCGATGTCGAC-39
Chk1
thrombocythemia.15
APC25
isoform–specifi
expression.34-37
PLAGL2–HCK
PTEN-negative
Figure5,5
continuum13
Smad4-overexpressing
p.N71K
lymphocyte/tumour
Chr9-236R
CD4+/−/CD8+
Cilloni
178,000
NR-mediated
www.xlab.unimo.it
xa
coselection
CP-D814
8-plex
ESR1YAP1
Actidione
S464
alleles—but
GCAGTGAGCA
recurrent/progressing
contaminat
1642–1863
N-RAS10
28°C
18,19,20,21
Alox15b-Trp53
controls.130
immunopreciprather
5-GCTGGGAATGGTGGCATGTG-3
R218Q
Y32F
Ala→Val
domain29
Raf-1R401H
thienodiazepines
2R+
Th'ng
.CD34+
Ref.24
BRAFV600E/PIK3CAP449T
hybrization
RNA-Lentivirus
SK-Mel-30
1281
non-FGFR-expressing
5′-AGATTTAGGTGACACTATAGGAGCTGCTCCAGTTCACTGA-3′
proteinaltering
293Ts
Ceacam
chemilumigrams
H738fs
R85H
ACCAG
malformations.4–6
GGTT
publications.15–19
Fig.6B,6B
werecoprecipitated
T6199
Mut4
MCSP-1
2419
H-280
18.8
Kovaret
v.8.4.6
pathway-related
Fig.2L
C.ES
Taspase
WW3-GST
pCEP4-HA-CA-Mek1/2
cancers13,16-18
translationproduct
Martinez-Torrecuadrada
Asp66Asn
loss/retention
.Strong
TCT6raTTTCArcCATCC
9p24.3–p24.1
Short-read
HLA-positive
HIF-1α-myc
1.5-1.7
non–M3
BR2-9-RT-R
.Del.
inFig
cancer.8,9,22-
​Manual
CMX-NCOR
STXBP5
F2108L/M2327I
71.94
transcriptionalregulatory
Z-VAD
levels.39
phospho-dependent
HCTI
MAPKAPK2
R834-R865
highest−ranked
C8′
C356G
HBA2
M552_Y553del
thromobopoietin
PCR-single
9/14
19.7±8.0
Ser20
Men1-deficient
CGLS
421/Mb
cofactors
model6
leukemias.46
6620
msh2-AE859
WEX
RB.5,6
heterophilic
CBTE
myeloid-
R1459C
Holm-Šidák
Assays-on-demand
nonactive/nonphosphorylated
LCE3C
R816W
.044
Gly200
DNMT3B7-expressing
QTR3
midforearm
Interactions—To
5/4/00
WpsBM
BAC-DNA
AGAGAAAAAATGGAAAAAAAA
p53-wild-type
9131
individuals1
−35
antiphosphotyrosine-specific
Globisch
pJHGT3'lnFAM
Glu285-Arg1744
Bγ
isoform145
Akr1p
FAT1-positive
5249
NH4CL
molybdate
cells.21,42
D.S.L.K.
MSCV-Flag-Bio-DOT1L-Puro
formation,29,30
gtragtkttt
Azadmanesh
doi:10.1126/scitranslmed.3003316
transthoracic
FIREPol
C108F
532-8686
p.Gln409ArgfsX7
anti-CD41
AB07
5-fluoro-2′-deoxyuridine
models.Concomitant
~2.2-Mb
Irpino
Rfreed
non-aversive
figs.5A5A
+MMS
48/90
5′-CTGGCTGCCAGGACCT-3′
CD30-
C277S-p53′
XM_009898
Petruk
IRES-LacZ
erythroid–myeloid
CS12
rejection-induced
CAGGAAACAGCTATGACCCCACATCAGAGCCACCAATG
R251H
Na+/H+
GPI1
centrosome-targeting
Bluescript
5.6–10.1
15,000-20,000
Birchmeier
exon/gene
MS-MLPA
,4-6
anti-SHC
Fuente
atrophic/degenerative
A570
nude-Foxn1nu
15–20-fold
anti-STAT5a/b
dehydrogenase-2
.Apart
ethamsylate
®brosarcomas
.EGFRT790M
X‐linked
10×103
bp.19
.D835
Hox9/Meis1
failure-to-thrive
4420
a-Tubulin
Co-treatment
Sox17iECKO
membrane-associ
5.10^7
p.Val1234GlnfsX8
1751G
hmsh2
0.66/0.63
.Deleted
www.ejcancer.info
alleles.17
deduplication
β–catenin/Armadillo
non-zinc-coordinating
HES
female-male
Cross-Correlation
274–317
apoptosis8
sequencinghas
6–12
CCDC6-RET-driven
H-DHT
nonrandomly
MCG224
.736
S768D770dupSVD
green-α-mouse
Adereth
FGFR1−/FGF3+
2,039
tVkDLIGfG6
probe18
≥2.8
PDGFRα/β
c.6949C
22-24
Lys-655
differentiation,28
Thomas-Tikhonenko
accumulation44
EGFRvIII30,31
effects34,35,36,37
A557T
anti-NF-κB2
.Droplets
low/intermediate
t16
1p22.3
snpeff.sourceforge.net
46929367–46930658
PRDM15
PeptideProphet
.14,26
413
myc-his-tag
CD1a1
0.0877
CTNNBl
91K
P1054R
heparin-agarose
imageWe
FGFR2-BICC1
Nefedova
S111P
0.54–0.91
.4B4B
elucidated171
erythroid-derived
RCDM-RS
113-117
II.2
Danielian
OGT
lesion,17,18
MLH1-PMS2
Virchow–Robin
.Errfi1
jority
ER+PR−HER2−
73-100
Up-Regulation
plasmids/siRNAs
p.Glu24fs
EUFA262
domain.22
Loupakis
cells,18
Mm00435546_m1
9/L
K1452
Endog
T220M
Chemokine-induced
HRG1
interindividual
Mericskay
followingmismatch
8.77931525
Tyro12
dysmorphologists
D1-CDK4-CDK6
p21pΔ1.1
allellic
Suwon
HIPK2-BRAF
prognosis124
10829018
5E–H
190450
Mlh1-CTH
L596R
APTAMER
TRK-A
methodologydescribed
1998-1999
2033delC
assayForty-eight
mice43
134.27
types4,5,6
PCM35/2+
0.080
L2C
tumor.47
JRJ
FRT-sitespecific
D1270
Mimori-Kiyosue
60−70
and15
methylcholanthrene-induced
Tumorscape
JEM-1400
Transarterial
al65
Hyperpigmentation
upper/active
His911
trinucleotide
2.6.2
20/26
∼4-
hotspots,9,10
EGFP-tagged
development.50
CTB-46E9
A573V
CGGACAAAACTACCCAGAGG
P203
4EXP
.Soluble
byEMSAMost
HD-0169
I156R
Asp641
R-280
/Z
253J
biologigc
38:35:10:2:15
D276S
β2-microglobulinsample/β2-microglobulincompetitor
complexes.7
Aph-1
Zn21
HNF
Cristofanilli
4,9–14
446·90
116-kD
EZR-ERBB4-
delG106-R108
A_51_P230382
TGAGOTCTC
neo-vascularisation
V600–mutated
MCF10A-control
single-strandconformation
0961/3694086
cgibin
Arg369Gln
3620
sequencing.Cell
.Cdc2
//dx.doi.org/10.7554/eLife.14709.014
NPM1/ALK
L108R
AssayA
p.His1047Leu
pathogenity
using30
autoactivates
1XSSC
pFA2
506
1p12
wk-old
d'Ulm
UltraScan
spongiotic
cluster192
study-based
nano-spray
1766
UUC-3′
P=2.35e–75
yPMSJ
14694
mutations.Figure
0.4543
isobutylmethylxanthine
Plasmid-linked
anti-c-Myc
microadenoma
anti-RAF-1
0-19
pathogenesis11,14,15,16,17,18
791-0295
1747
41.0
Fluorodeoxyglucose
Asp-281
Phenotypically
,140,141
Solvak
pErk1/Erk2
TNS3-C2-T323A
BFU-Es
haploinsufficiency
colorectal-
947519
LMP2-
277-281.Eighty-three
Trp-722
170325
20q12
⩾60
0.6G0.8
Gly52
epitopes,32
533.3
sIAG
75788
5′TTCACGCTAGCGTCTAAGGCCCCAAATCCAAACGAG
5′-CGGGATCCCAGGTCATCTTCTGC-3′
55282
EUFA423
synergizing
Bas.Sub
pan-tissue
24ENDT
box–mediated
R799W
1,871
METHODSCell
3678
c-Myc-His6-Ub-conjugates
fludeoxyglucose
Ras/p53R175H
WW45
N-Tcf-4
figure2B
ATP-catalyzed
Max/Max
Szymczak
T-to-U
36.5±6.3
alcohol-abuse
pcDEFp300Q1874X
p.Asp370Gly
DNaseI
Petrukhin
129S1/Sv-derived
.AK030489
22.22
Eurobio
GST-ERK2wt
â€˜â€¢
Beug
NM_005188
ofhistopathological
ANR10-INBS-09-08
40kDa
Glu-766–Arg-868
.SCLC
Myc-nick-expressing
Pul
EUFA349
Fahraeus
D'Angelo
TFA2
Cys528
KVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTE
Hattersley
mutations.87
8266
predose
.N676
repeatsequences
YAP-negative
restric
D1002A
D-Cdk
coculture
carbon-5
1,412of
non-differential
.Post-transcriptional
OAII
NUDCD3
.315
Blimp1fl/+
SMAD-binding
Bodvarsdottir
imatinib/sunitinib-refractory
5'-GCCTCAGCCACCTACTACAGGAC-3
epidermis.34
286-291
.E19290
CAG-LSL-GNASR201H
stimulation.6
Hypocellularity
in®ltrates
COS-
signature15
84.09
Bamshad
custom-built
Electropherogram
R461X
Abdelhak
earlier.20
31-90
receptor–negative
.Phosphorylation-dependent
described.38
Medsystems
E93
BTF2/ITFIIH
IIIB/IV
GST-RAF
Flag-caspase-8-R413G
CCCCTTTGAAACAACAAAGAGTGTAC
Model-base
previously3–5,15
Epidemiological
-and
I-Mutant2.0
non-EPAS1
.alignment
cohort
M551
Bcl-XL
hormones.1
INI1–4
SHEP1
apoptosis-linked
pretherapeutical
combination-treated
6315
immunopreclpitated
1q31.3
ARMC10
ER/cyclin
synatophysin−
yGIuGIyAlaPheGIyLysVaIPhLeu
intra-cytoplasmic
//www.microrna.org
tumors.11,12
–90
Galeazzi
1.4E
Steinman
HER3-phoshoinositide
endometrium–serous
.CDK4-MUT3A
FK-FRK
1036–1040
1-193
interactions—the
LRB
136del4nt
ligase-mediated
pSTAT3/STAT3
EFO-27
ESR1-negative
Promyelocytic
LR11-230
KYSE-150
emerge.18
MeDRA
Fernandez-Valle
miRNA-expression
17,109
Pellagatti
expression.30,47
VCX
5′-CGGCAGAGAATTCCACGTGAT-3′
–MLH1
GACCTGGA-39
_MET_
Val→Asp
LNS
available.This
MLLT6
RAS27
AG=
pCDNA3-6myc-Smad2
MLTC-48a
PSN
RNF11
Ser39
-type
355K
carcinoma.14
CEP110-FGFR1
cIn
I1yAspPhCIeGyUetSerArgAspII*TyrS.rThrAspTyrTyrArgVClGlyGlyArg
SPOP-S119N
pFastBac/hMSH6/KR
Bhangoo
ml.Whole
AK72
status.That
effector/target
GloMax
anteroflexion
V300A
pY572
Hiseq
Hyashi69
88-3a
Wnt-dependent
DIMH
antiRas
post-mitotic
lrg-sequence.org/
~189
U87MGcells
Maastricht
5′-CTTCTCGAGCACTTAGACGCCAGCAGC-3′
.Spliced
MDr
Szymonowicz
anti-fibronectin
ineective
.Gata3
pCB6p53mtVl73E
EDD
0.909
MUTLuc
DNA3,9
Stratagene®
Q556
3'=predicted
'two-factor
S2A
DNMT-dependent
M1652T
Genbank.8
Fig.8A,8A
PIK3CA+MEK1/2
11876
precastrated
carcinomas50
TseI
c.9463_9467del5ins8
LSL-rtTA
B1310
RUNX1-AMP19
αN
FRG2
Snail-mediated
Q1409L
11-mutated
GDNF-mediated
previously.24
B-
anti-H3K36me2
.Lys256
ective
O:105
AR-S647A
2.0.24
8.3∗
–138
ThermoQuest
,55
GTCCAC
YAP1-positive
described.8,15,16
C104F
proto-oncoprotein
subconfluence
steroid-depleted
nevus-rich
15990
CDKN2A/homo
annexin-/PI−
E‐box‐binding
MIRAS
pEMH7
190K
mutation.21
2022
p.Gly44Arg
deoxy-uridine-5-triphosphate
PI-0.5
1991
Trr—have
leukemias17
71-yr-old
stages.Outcomes
Arf-dependent
site50
423X
AGgt
.41,42,46
.NSD1/NSD2/NSD3
12,759,639
DNA.10
−875
phospho-contact
5′-AGTCTCGAGCATGATGAGGATGATAAG-3′
far,8
Protein-G
fibroblastsThe
U14680.1/NP_009225.1
:883–890
medaka
M40T
Tlr9
TRAMETINIB
Shridar
D532H
TCCACCACCCTGTTGCTGTA
glsdb.html
detected1,3,5
11/15.5
12–72
degreer3
leukemia.22
//www.genesilico.pl/index.php/home.html
Heemskerk
MDSR
E369K
SK-Mel119
rs28897754
NSD1
G12C-bearing
+tras
16,873
22.05¡0.7
mutant-Renilla
ligand-induced
Glu76
WHIM14
Perjeta
chromosomeloss
chondrocranium
straight-forward
steamer-cooker
macro-oligomer
0.01560313
cancer,6
.Suggested
138PEA
ARSZ
TLS-CHOP-specific
K177Q
AC00.1222
P50.03
virus-free
EMY56-5D
55–59
M1149
MEK-specific
Akiyoshi
Galacto-Star
.LB373
One-tenth
4423
3,12–16
G.E.L
heterozygousity
E413D
.9‡
W140G
BARD1-ΔBRCT
RPT2
Lysine-HMTases
1–10
D2LIC
ViewPlates
90-base
DSP-IP
Tumourclassification
F171S
SF3B1Y623C
H19-H21
NCT01202591
STAT/DNA
154.1
Maranchie
Met/ATG
S44F
PMA/lonomycin
acetylated
Yakobori
7â€
FGFR3b-Y375C
D910
IkBepsilon
theXho
VNQSFICDPDDETFIK
GTTAACTACGAATCTTCGACC
p.I49S
prostaglandin
down-regulator
51-201
IDH.24
EWS2020
long-range-PCR
mediators/proteins
.Τhe
R354P
mutations65,66
Bertulli
D5S421
K100R
R1275
Hematoxylin–Eosin
S.D.
13271A
uracil-transformed
nucleophosmin-ALK–
176,334
Doxorubicin
fractionation.In
pcDNA6-ACVR1-V5
LAS3000mini
somaticcell
PRJEB14813
Hemizgyous
.535
decremental
spermatogenesis.23,24
alkylating
Gene-E
mesothelioma11
-Trp
007
rearrangements.2
pGL5-STAT3S727A
11.1.1
96.0
.SPEN
.Fig.2
Rb1
27,964
.Sunitinib
//www.ch.embnet.org/software/COILS_form.html
KEx15BEx9
FEC
sorafenib-induced
disease,29
H2.3A
Leu113Leu
number–
months-24.2
653_654del
JH2Δ-Jak3
D33E
K836-V810
J1
dark-green
Through-out
C2-7
colon_cancer
bbrc.1999.0237
previously.11,15–17
MolBrowser
.Beginning
2471
gbAF036382
20p12
5′-ATCTTGTTACATCACCACACAT-3′
5-GCACTGGACGAGGCAGCTGCGTAC-3
covariates.41,42
www.fruitfly.org/seqtools/splice.html
Anti‐HA
Tet2w/w
celll
Hresko
Val126Asp
5D–5G
TL
P57S
p.Recent
Y90H
JAK-signal
ROX1
sc-29130
D7S2418
2.5m
481–688
0.220
NQETGE
HEK293-RETS891A
18/130
parafibromin-β-catenin
CACGGAAACAATTTTTATCGAA
non-PTC
GCT-15
.JAKs
611-CTF
trastuzumab-containing
MSH6.67
C620G
CRL3-KLHL20
Mutant–Expressing
AMG706
CD40
G98S
end-sequencing
.Cytogenetic
PDGFβR-induced
Q-test,23
motif.162
GAL1-inducible
injectionsb
GATGAGATGCCTTGGGACTT
PET-avid
10/17.5
U34070
100-3425B
GXXXXGK
criteria.1
Proteotoxic
gov/SNP/
Anti-BrdU
Pneumocystis
MC/9
factor-D
PTEN-deletion
anti-Yap
5325
sub-numbering
TP53gene
w32
MMR-D
581–593
28-34
embryos22
DN-Akt/Ad-infected
Five-month-old
Orimo
transformationwith
11–48
IDIBELL
Dijk
.Malignancy
IDATLTR
Cytospin3
pRS316-p53RE-LacZ
250kD
cullin-RING
Figs.3A3A
genomic/expression
Microdissection
NUT-midline
Y1230C
C557S
D539A
V453
694
912
SmartSpec
Prism5
GAGGCGGTGGT
self-associates
signaling27,38
598C
MYBL2
TRCN0000121068
2084
2o8j
2010CB912802
816T
0.734242
V8012
~48
free-energy
C1F27
1,9
PAX5locus
Cdkn1b/
.NCI-H1703
CK1D
25/29.8
BRCA1-D11
100°C
.Neuwald
21–403
PCR­
state18
bio-statistical
model.43
6046
pt1
cdk4R24C/R24C
p.K315E
Pusat
6059
300448
S4D–E
p53-knockout
pre-miRNA
Pardali
-CTTGGGAGGTTTCCACTGGA-3
1.41–4.17
RBM
CeSNF5
Pichon1
100×100
nomodel
wild-typeAML1
.Bengtsson
BRD2
pathway-level
9/8Δ
BCL2/
trk34
.HA.C
FL-3B
Fbxw7Δ
612-656
1a–c
416b
LacI-CHERRY-NUT-positive
P656L
miRNA-mRNA
VavCre-
1477
cancerView
62˚C
CFC
4.14
Collagen-1
ty-
sampe
HCS—may
19.63
F159
u-Ha-Ras
ACAGGGGTATTG-3′
4^6
Runx1-/-
blastidicin
cases.166
9211S
.PI3K-C2α
Blimp1Cγ1KO
G4449A
AR-dependent
/highwire/powerpoint/139515
Biophys
N-deacetylase
anti-keratin
mutations.108
usedfor
KU812
304–361
Wapcre
GPyPyPy-3
KPT-185-ScXPO1*-HsRan-ScRanBP1
teratogen
603254
.Enzyme
Lys56Arg
.Oral
phospho-signals
5′-FAM-AAGACTGGCGAGGACGGTTCGAATC-TAM-3′
cells,53,56
C2β7–β8
M1Rb
allylaminogeldanamycin
ofgroups
pCMV5-TrkA
TWEAK-mediated
EWS-FLI1-
Flt3−lin−Sca-1+c-kit+CD150+CD48+CD34−
V447I
Fgf/FgfR
p.1100delC
cytokeratins
Z-heotad
minichromosome-speci®c
1H-2-indolyl
S113R
hepatolithiasis
agglomeration
I744V
K270M
α-ETV6
radiation38
Ni7
5′-GAGAGGAGACAGACGACGAG-3′
Widjaja
−20.4
SalI-XbaI
hormonebound
S1A-C
pY657
Assays—To
donor/
osteonectin
GPR37
EGFRΔ746
syndromes.16–18
pN1_PMS2
Rho-dependent
NVP-TAE628
point.Multiplex
Mfd4729
Ets1
HaellI-HaelI
184-bp
NM_0049δ5
near-triploid
25963434
33b
R1321G
T1181
JAK1-V658L
Weinstat-Saslow
patients,1
V92M
SK-MEL-28
0·091
YMVA
52.0°C
ZM-expressing
anti-CDC2
gamma-actin
Br41-Sar73
11q12.2
0.1–0.7M
5'gagctcctggagggaaaaac
R206H-ACVR1
HA-PI3K–expressing
Fig.44b
p=0.0456
S366
histonc
3-based
organ-matched
methylthioadenosine
blotting,53
inception
oncoprotein.37,49
592
3e-10
5′-CCGGATCCTTACATAATTACACACTTTGTCTTTGAC-3′
~2
200-400
right\
lymphadeno-pathy
GST-effector
PDGFRB-GPIAP1
746H5-speci®c
∼48
Glu300
neversmokers
0,46
CALCA
acinar-to-ductal
RbBP5
carcinogeneticmechanisms
SHP2-T468M
destabilize
DRAF
746delELREA
low-estrogen
V301I
KPC1/2
Glu2281_Gly2313del
896–903
256.00
VR
.Anti-BACH1
71-11
activity.Haploinsufficiency
G396D
mice,25
D281G-clone
investigations.11-16
NCBU
BigDye3
778r
HHUA
karyotyped22
2026R273P10
25-
.Purity
autoubiquitylation
L70P
4388
FACS/Calibur
.RU-SKI
tumorigenesis.11,15,35
pathway11,12
hypercellular
33–45
201-bp
secretase
Myc/IgH
Hep3
n=1622
Tsc1wt/mut
CD11b+/Gr1−
5,38
matcu2
VE-Cadherin
p85α–PTEN
substitutionally
R601W
pRad50R83I
WW2
Dyer
Parthenolide
Bj
CRKR
TGTCCCAACCAAGGCCGACA
-suppressive
D1a/cyclin
Ctrough
E1501
pGLIK12
syn
0.23–1.2
R683T
ILC/IDC
.Colonic
Niklinski
35.6
.Downmodulation
15-gene
.Mucin
BRafV599
KYSE70
platelets,19,20
2332
W290R
550_576del
low-quality
eTables
auto-deubiquitinase
bTwo
amonafide
NNSplice,31
R161G
PP-1/PP-2
AML-MLD
J1-1
AUAUAAUAGUGACUUCACCAUUCCC
MO_1129
L285F
Y21H
CBF-leukemias
RP23–23D5
:131–135
W406R
envelop
two-layered
Gln536
immunoglobulinG
FLAG-mTORSL1+IT
His6P110/p85α
R.ERG
Suraweera
photoreactivation.Determination
Méditerranée
11GF-IIR
XG
61.7∗
KpnIXhoI-digested
counterscreen
3532866
60.1
0.92–1.96
Methylation-Specific
rs984896
GST-fused
tibia-pseudarthrosis
CGACCUUCAGAGCAAAUGU
region.1,2
anti-phosphoY1062
Hs00372378_m1*
C-15
metabolism.36,37
∼16
Ala-353
chromosome23
neurite-length
GC-resistant
counterpart.54
S.r.l
Pho8l
1F
gene-methylation
frequencies—one
HO1-U1
.Gel-filtration
homozy-
thedatabase
SOCS3-WT
500–540
HER2-Targeted
1.98
L397M
5′-GACCCAGATCATGTTTGAGA-3′
shRNAs—sh374
.PROMPTs
trk2l
EcoRI-Smurf2-F
5,16,17
NDIb
levels9
E2-conjugating
Sh002
VGENH
Krasex3op/nat
P152A
μm-wide
R18W
ETV6-RUNX1-positive
Knocking-down
pathways11
TAM-
Kras-G12D-driven
MAP2K1-mutation
EN/IGF1R
hedgehog-driven
RAS/MAP-kinase
linesFurthermore
Y869
expression–defined
LYL1-positive
c.583_584ins73bp
GACTCCAGATAAGAGAGCTG
2009ZX10004-903
13e
highwire_figures
SFA16
Alagoz
20/29
peak-associated
5′-GCGCATTTTCTTCAACCAGG-3′
W5e
allelespossess
52/68
SLC25A26
M+5
substitution.18
suppression.3
Thematrix
0.0076
ADP/min/mM
1038–1048
Msh6RH/RH
401-
p50α
349.6
IVS14
D68
c.676C
highaffinity
proliferation/viability
KHM11
EnVision™
papulosis
path­
t-AML.6
24.5/10.7
Mll3
FLT3.113⇓⇓⇓⇓–118
motifs5
BCR/FGFR1
Lys1423-
I1240T
oncogenes7
.TRFA
.final
mutant-p53-expressing
ethanesulfonic
breast.20
andobservational
1801_1812del
MALX10
mononu­
Ghiorzo
68–78
0.14
non-transfected
Scilimage
PKC-driven
H1047R/niSH2
Q74P
17.877.6
.Fig.77C
NM_007616
li7
Donkey-anti-mouse
EISMEDEATTLFRATTLASTLMEQYMK
KPT-185–enforced
ultramutated
ftp.genethon.fr
P-40/PBS
Ptc-lacZ
analysis,8
ɛ-amino
COLO201
N.P
nickase
pGVB2
Heemers
G618R
8G4
Tif
amyloid-forming
800CW
FGFR2/-VT
887/1231
AMPPCP
BRAF-AS
499610
…Download
B-RafCAAX
retainsselective
family-specific
high-energy
110-PT65
Buchdunger
anti-Cdk9
riction
Neuro2A
FileBuilder
Y1239H
p.M173I
nudemice
GGTAGTAGGTATTT
∼0.4
f'J
prespliceosomal
ligand.4
GCB-type
antimetabolite
4.01-fold
.BEZ
396-420
FIP1L1-PDGFRA
immunofluorescently
Kα3
RSV-Rev
andrechecking
loops36
.Formation
TGFBR2-
infratentorial
Glucotrend
probability39
pYNH24
79-year-old
coli-expressed
.Conditional
KDfl/fl
to100
Blue-red
lines28
e8.2
35S-Methionine-labeled
non-invading
F-domain
hemimethylated
tumortypes
salt-inducible
ATGCCCAGCCCCACATCCAG
Cytogenet
Dzierzak
.Recent
AREG
pMEK/MEK
R401
c.326A4C
sheet–like
-TGTGTTGAGATGGACGCCTA-3
dysfunction.2
Ferlay
acid-Schiff-stained
Q227
3D-collagen
162R
cancers12
Sebra
.Anti-pan-Trk
5′Fam-CTC
schematicrepresentation
ARBS2a
nature.comIn
Grm
chromophobe
1–377
C73Y
453-amino
Q643R-
AXL/CEP19
shGFP
c.8536G→A
Del746–750/T790M
HumanOmni1-Quad
Phe-156-WVal
J-003014
peptide-MHC
TbR-II-deficient
ENST00000396950
Desmoglein
sc-5273
non-drug-bound
L270R
mTOR-G6850A
22/165
ModerateLowBiallelic
Arg8973Gln
BamHI-fragment
1.3–3.7
E12a
tool18
strategy37
GGGGAATTCAAAAAGCACTGCTACTCTT
177-179
p24.1
Fast-component
—
siEGFR-1
.Five-milliliter
CFC-associated
dMyc
Tyr1023
trans-phosphorylate
epithleium
1.97-fold
l.3
_1076
INSULIN-DEPENDENT
FOM104
BCOR-CCNB3-positive
bromo-domain
anterior-posterior
2520
prenylation
H3K4me2/3
Phospho-JNK
REV-GFP
TK-GFP-Luciferase
jcem.endojournals.org
p.S480X
re-cutting
SignatureChipWG™
.Solution
NSCLC11
GDP.Strikingly
flex2
.Foci
biloba
GDP-p21
soton.ac.uk
3p22-24
5'-GAA
Jain10
E-cadherin
RAL-GDS
0/118
P=0.10
nutrient-limiting
IL12RB2
−11
lysozime
effect.40
-0.11
mg/mL.20
pRRL-EF1_MCS-PGK-GFP
cancer.13
Taghian
al.,2009
EGFR-ERBB3-mediated
−b
acidsSynthetic
P2-MG-PSADMNT
BRK20
ISM2
N61
D316A
5906
methylation35
/j.1of
19/56
p.V617F
elsewhere5
LR00-016a1
Helix-turn-helixdomain
NCT01514864
204.4
Ink4A
AML.40
Dot1l19,30,58,59
10,108
cooperatively
B-RafD594A/R509H
—Wnt2
53BP1+/+
Anti-MAP
p.W1306
pmGFP-H-rasG48R
FXFG
OR51E2_S
7/46
spindle-cell
P.P
.Kancha
PKC8
11q23.3
G310D
1+f/C+M
regulators.22
vorinostat-induced
0/0/0/4
G12F
C47*
5907
NM_029495
tamoxifen-induced
Tyr1056
MDC1
polyethyleneimnine
non-FA-A
Palangie
XG4
Lipofectamine™
prelevation
stat-IR
A300-123A
0018896
MCL-tumors
expressions.36
ECOG-sponsored
Septum
GSK3/Axin
lines.21-38,40,41
18.0PGCPPlasma
high-scoring
ER–
p.P1412R
1–175
His+
Notch1/Gal4
Ligand-Mediated
pDM71-
transluminator
GP1ib
Beerm
Na2PO4H
Srsf2
Dayananth
binding.35
0.5μg/ml
5′-AGCACCTCGCGGTAGTGG-3′
non-irradiated
pHRE-Luc
LDS-like
16864T
Cebpa
glycyl-histidyl-lysine
Atomique
paramagnetic
Vect/Vect
3–13
-methionine-labeled
H-T-H
Ras15
MG-B2GFPΔ3263–3385
30·8
m/59
−48.9
0.584205
wild-type/heterozygous/homozygous
∼220
chromosome-arm
G524D
s24
RapaLink
GSE1852
FGFR-4
G.C
HA-FLAG
KMS-9
Cul3‐associated
5′-AGCGGATAACAATTTCACACAGG-3′
a-b
GGT-*GAT
p.Ile1347*
8.93
autoimmune-like
R179R
213-13
Autotaxin
Degenhardt
BRCA1/RAD52
αTubulin
CCAGCAGCAAGTGGAGGGCCCCC
72-74
7-AAD
.1634A
S8
DISCUSSIONThere
tumoriDNA
c-Kit–MAPK
Agg/ml
srtictly
KIT20
PLCG2
TetR
modified.27
exon/intron
5-Azacytidine
0.5197
–4.9sox10
+10μg/ml
Figure33E
hydroxycinnamic
1137
p22.3
9,29
c-Met
tumorigenesis.2
22Rv1
diaminopyrimidine-based
68878147
306G
R233H
metastasis4
TASR
LPTPPLSP
CD45.2-positive
CH1
appearsto
CMV-expressing
MIR145
melanoma7
BCAP
electroporation
GST-NRF2-Neh2
TrkAIIIA
down-
2,812
32GTP
29.7
309
R958Q
Ten-Eleven
p800luc
G1788V
b2m-transfected
Sixty-seven
interferon-g.
bronchioalveolar
signal.33
AKR1C3
STAT3.Each
rtom1916
receptor-interacting
.Centroblasts
ultraviolet-crosslinking
PIK3CA-encoded
hypertelorism
F156LC
depalmitoylation
TGen
7.5/44
RCSD1–ABL1
2.1
cDNAsynthesis
HYRYS
Koschmieder
pTB
.Pf=Plasmodium
wu20/wu102
doi:10.1038/ng.3037
≥600
P392L
C/GGNG
Line-Derived
Nf2−/−
SDS/40
SOCS1-cooperative
mice,28
GDLV-11
NF-027
Figure22
MACROD1
Fgfrs
pathway-activating
89–301
Craf
72-77
methyltransferases.50
|xi
S345
Trastuzumab-resistant
R564
61K
EZH2-expressing
point.29
well-investigated
/FUS
division.18
297
miR-95
mar­
waveform
H4K4me2
5′-GAGCAGGGCACCCTCTCATGG-3′
1014–1020
AmpliSeq™
.OA5D5
4,000,000
GTYPE
CBLWT
20–1.80
aberration-positive
receptor-mediated
electropheresed
pCMV-FGFR2M391R-FLAG
HA.Akt
GTPHRAS
C778T
hMYH
TÃŸR-Iin
182–227
11.79
D1-YFP
.Pearson
≈77
17q23-24
SPC+
LUX-Lung
5-CCTAGAGTAAGCCAGGGCTTT-3′
gp'40ttk
flow,3–6
F.C
2218_2243del
.NO1-CO-56000
inother
Summarisation
pCR3-HA-VHL
22,25
50-bp
bi-phasic
SPOP/CKI
E270G
NLK
-galactosidase
Glu-25
pSuper.retro
10473
c-Cbl.53-55
173–278
VP2
.Each
ARAF-
region,19,20
Burbelo
hamartin-bound
VIC-prelabeled
al.,1
CLL09
CBP-
-7
anti-beta
736–739Langabeer
E7–7.5
non-microdissected
How-
emerging.8'-
Ser222
promoter–HIS3
Menn
resistance.5
§1734
phospho-FRS2-Tyr196
DH225A
mononucleotids
.BrdU
F5-
GU-rich
.6,10,15
Acvr1Q207D−c.a.
ALK-
-*-*
RAW264
NTRK1-3
notsignificantly
740-180
6a
wild-type-length
591-pY599-605
5′G/T
~2–5×
borosilicate
↔/↑
IGF-II
74-222
43.6-fold
C-ι/λ
literature.14–17
microbiologic
tosurvive
gastroenteritis
7q21.11–q21.3
5'-GTTCTCGTTCTGAGAAAGAC-3'/5'-CTTCCATAACTTTGGCTATC-3
M22
transblotted
fibroblasts,9–11
p21waf1-mediated
Plenary
Autographa
λj
lymphoma/T-ALL
E1311D
10−13
R133W
HS_6
HA–Smad3
SYPRO
occur-
al.40
57
LMB-dependent
T1685A
non-cyclin
1547
RHOC
,6a
orWHSC1,33
.8D
BRAFV600E-wildtype
RAD51B
30/40
Immobilon-P
PTP1B-interacting
SNVs—a
Pea
EGFR19F3
−32SRYP
a3
1°C/cycle
c1687G
treatment.2
subependymal
2–34
dopaminergic
cAch
55–82
CELSR2
Ninkina
behav-
AF132500.1
null330W
detergent-containing
mice.212
mutation/variant
v1.90
mean-2SD
tract.56
r=0.737
Akt2-mediated
abnormalities3
constituatively
HER3-HER3
N-methylhisFIGURE
OVCA5
EWS/ERG
897
.Physiological
anti–HLA-A
matrix-bound
SHGC-3245
M837
Fe-
agonist-like
363–371
Arg768
kvd02101
FLT3-non-ITD
cell.28-30
PKB-mediated
thiol-reducing
DLL4,29
NMS
RVP*Stop
012345
99.6
Brg1T910M
Copie-Bergman
MKP1/2/3
K299R1
TFAP2CΔN353C430
RFP-tagged
MPCEWS-FLI-T1.1/T1.2
TRC0000001066
MAP-kinase
HEG0
TRCN0000196795
grand-mother
RAD51-binding
Δ8.9
wouldpresumably
coil-containing
.Meaning
Hh-Gli–activated
8022
described9
KSII+
3318
2d–g
assays.36
optionsTo
biotin-16-dUTP
splicing2,19
0.008/FDR
tumorigenesis.1-3
.Preformed
NotI-WWP1-R1
HNX
R599b-4
erythropoietin-independent
Myomegalin
2-3F/2-3R/2G
HEK/293
A_52_P540219
IL-4/IL-5/IL-13
anti-GRP94
earlier-mentioned
neuroblastoma
r2=0.054
AAGGCGGGCCCGGGA
.One-hundred
alanine-coding
STAT3-Y640F
neoplasms.17
instabilities
erlo‑
EBNA3B
550–592
26/99
.Poeta
15140122
2413-236/nt
A46T
.Surrogate
S2514
p=0.0723
described.63
His/RH-tagged
follicular
genotyping/iPLEX
Marczylo
non–lymph
Mrstandards
71–18
0.1494
FLJ35294-ETV1
scores9
H1793
Terminator-Mix
RYBP/YAF2
GATATC
xenoantiserumR5996-4
S3B-D
leukemias.75
workup
CSMD1
RBM5/RNA
CDKN2A8
47–132
T305A/S472A
MucycD-2A
+KIT
pPGK-hygro
beta‑galactosidase
PKCβII
p=0.019
interaction-network
QMPSF
48.6
Goktas
KIT-expressing
CTCCAGACT-3′
promoters/transcriptional
TAATACGACTCACTATAGGGTTGTTGTGAGCATGGAGGAG
TCATAAGCGTAGACCTGCCCCCCAT-39
.Over-
Arcturus®
Y1110
Becauseit
pseudo-chondroid
D65E/N
delTn
LSL-KrasG12D-driven
T.T
CTLA-4-deficient
FLAG-tag
aa150
cotransfccted
fourth-line
bServicio
c.983G
proof-reading
CSK-mediated
Soussi
immunotherapies.Targeted
71/M
G-to-C
belongsto
do-main
athanogene-1
ARQ197
pan-TGFβ
Fixman
TPC-1
MYH10
Shigematsu
sorting10,11
RPMI-7951
PT02
HIF-2α—Cells
ML3
G2359R
-induced
C540ins
Balmain
TLS-ERG
27:397–407
5′–UUUUAAUGGAAACCUUCCUCGAU-3′
NCT00787267
1–102
.1.3.1
E2K
DDR2-mediated
Hhresponsive
width/2
AneusomyIn
.S6B
leukemia.10
variant-to-total-read
Breakage
97-24
lymphangiectasia
59-TAC
vinorelbine.13,18
V-PE/7-AAD
Double-stain
Xq22
ever-increasing
pCB6pS3wt
RELA-proteins
acids205
.Schematic
docking-defective
demethyltransferases
Proof-of-concept
Duvallet
ST88-014
OTOXXX10.1177/0194599815569709Otola
plasticity.36
MAP2K1/2
7.4-fold
eight-
GST–Raf–Ras-binding
_Aligned.sam
HSSRB
Pindel
ad-hoc
U87MG-PTEN-G20E-1
pZNctj2-Q205L
Wü
supra-wild-type
RanGTPase-dependent
mut
Non-malignant
pLHCX-EGFRvIII
dbSNP87
MSCV2.2
Metzeler
DMEMsupplemented
elementreporters
FGFR3-TACC3–positive
pMC41
AFM070xb11
T790M-directed
0.9-2
pCSC-SP-PW-GFP
Cγ1-Cre28
//genetics.bwh.harvard.edu/pph
inhibitor,30
s3
inlanes
temperature29
formamide/4×
5′-GATGCCTTCCAAAGCCTACCTGCAGAAG-3′
Controlcells
PNT-Domain
80Â
Non-hematologic
Glu-286
NFkB2-TYK2
anti-SYK
ubiquitin-ligase
P2465S
.Relapse
PI3KγRBD
AstreZeneca
QIAKGMNYLEDRRLVHRDLAARNYL
method.27
DNA-directed
cancers66
c.518G
Indelocator
4.272.641
82/85
occur15
xenografts.62
.Crude
Gonzalez-Hormazabal
glucosylation
IL23R
§Splicing
coupling/decoupling
R102P
.Non-shaded
4.63
×100
62°C
.MLPA
+33-478782781
G1706AR
meth.
co-workers
Y519C
mutationson
Celtrix
kinaseδ
BENTA-associated
PLA2G6–CRYBB1
.fourfold
Pico-Green
HSF
012-000-120
*R
Atelocollagen
MutSigCV22
pcDNA3.0
Avogadro
Vrouwe
MAB374
M484L
5p15.1–
pathology4
:155–162
VO4
Pre-adipocytes
V404
E2020K
agent/placebo
Lineage-negative
2565BA
D277H
VHL-Jade-1
4E–binding
p30/32MIC2
103–106
-GCAGGGTATCATAGGTGGCAG-3
aâ€¢
Sensodyne
tumor.18
c-onc
activation.14
CD1a+
EglN2
10p12.1
69-year
3.8213841
inguinal/axillary
'FOP-flash
//cancer.sanger.ac.uk
contemporaneous
Ohlstein
Kamikubo
phyloP
orange=NRG
C2-R2/C382D
3T3-Vec
N335K
A2092T
signaling.16
oncogene.3
MutSa
resistance.
DSC2
with,9
H1-H3
browser1
8.0+
adenomyoepithioma
EAP1
reaction–single-strand
ms00008708
Rechavi
thiocyanate
ArgGluPhe
M309G
R181L
.KIT-directed
INI1−/−
Hesson
S3D–E
MSigDB
PPQKKIKS
Nanri
Mm768bpΔAGAAAR
.D.J
imatinib-BCR-ABL
OpenBiosystem
.113
C86S
HPRCCs
proteasomal-mediated
pathways135
formalin-fi
.Fibronectin
transform-
adeno-carcinoma
loge-transformed
.Shaw
biotin-free
.Phosphatases
17–49
1H-13C
8/10-matched
tm1Par
expressionof
patienta
Multifunctional
P454R
−30°C
arabinoside
His→Arg
CtBP-mediated
2All
Gly63
T117M
beneficiaries
1094
DD-R625G–mutant
eosinophlia
B42
nCoR
s.e.m..
74/M
JARID1B
MSIG1.1SK/BRCA1
fast-growing
dissociate
P1009S
D69
10-20-fold
D13
13C-enriched
β1,4
S-Transferase
1942C
c.520C
CancerIn
NOE
tag10
216-cell
HLA-A02/03
2-kilobase
Cɛ
.Wap-Cre
.0019
metabolism34,52
Wohlgemuth
H1860X
wellcharacterized
c.-54+500T→C
45/114
dabrafenib9
3′,5′-monophosphate
QD
TCGA-D1-A16X
ZnCl2
b-Galactosidase
α3A
Oncologique
glucointolerance
RU-SKI
variant.Compared
imagesImages
N351S
ADVL0912
karyotyping.19
rdh54
DN-Akt
dichloroplatinum
c.1450_1461del
anti-V5-horseradish
N546K-expressing
TELJAK2
IkBalpha
GlaB/GST
.Aggregate
GGTGCCCCTCAAAGATCTGCTGCTGG
.Weigel
30-μl
Franssila
D22
Gylfason1
43/44
2ffl
HEK293-pGL4.36
3c–f
F-183W
35,46
Y27632
3277
Scheidtmann
inaccessibility
994
.Assays
c.1126A
ethylenedimainetetraacetic
AoPlGuVaITyrAI*IIeUetArgGI
BCOR-3860R
follicle39
7ul
immunocytohistochemical
hSNF2H.31
medio-lateral
FAM150
Raft
IL-3.9
rs1801270
.NUP93
Samtools
rate=30
0.01472
p=0.0077
c.532-18C
Wesel
gcccttgtggatgcctaaga
G405R
kinases11
C843G
P29S
GGATACCACACAATAGGTCCAG
astroctyomas
dimerization33
Thr57
5.08
15,17,18,35
kinase-anchoring
CDK2–cyclin
TRCN0000040123
36/518
carriers33
Δ557-558
ATM-p53
c/w
differentstages
n≥4
GFPpos
c.2970delAAT.9
FL-LG
NIH3T3-transforming
hedgehog-induced
753
Luhrmann
G−748/E−738
1–101
IKZF1,44,45
5′-CTTGGTGTCTGGGCTCAGTGGGATGGGCACTGGTGC-3′
Smad2–4
150-
G423
Juillard
evaluation88
B/C•CUL2
CHRAC,41
18–24
−245
c.559_560insG
p70/85S6K
Asp820Tyr
YAVV-PEEP
K299AR300A
K627R
Zbu1
assays.In
isodisomy
13,25
immunocytofluorescence
'c
Huzarski
30aMVD
1,156
αp16
recognising
RxL
type—specific
MUC4
TGF-ÃŸon
Akt2-YFP
6-mo
Nobs/Nunique
U114
000.1,2
8+4
~4–7
Itgα5Pdgfrb-cre
001001890.2
p=3.0E-06
induciblility
immunoglobulin-micro
Bcl-xL-transfected
98–897
V173G
GST-tag
lineage-committed
nm/min
FOS–JUN
ABL-1
Coufal
non-VHL
4,5-b
AB21
WHW/c-myc
myc-epitope
:211–25
Scheithauer
Reichrt-Jung
ubiquitin/proteasome
TRCN0000134715
30×
A1798G
NTRK1cDNA
signaling-competent
cryosections
Tyr412
G700C
mtp53-R273H
amplification-mediated
p16+
lorlatinib
RAD51C
BALBk
vpGQLVANlqgIAsGMnYLsnhNYVHRDLAaRNiLVn
DLBC
Cooper6
receptor.75
narrowband
well-appreciated
NM_033360.2
544K
Springer-Verlag
S5H–S5I
E6–immortalized
PHTSs
pT2a–c
L2647P
.Haematol
T1021
p16.48
Dehydrogenase
1990s
11/36
mei
A276V
D803G
α-klesin
Lys69
juxtamembrane-mutated
ETV6-FCHO2
HT-29R9
5fC
variant–expressing
0.43
R40L
4–
TP2
8BJ
AFM198wc5
Beijesbergen
CCCAGCTTTCTTCGCTGCTGTTGCTGCTGCTCGTGGACTTAA-5
Bicistronic
E3724K
LIM
Ring6a
MÁ
.22DCR
11q22-q23
MEL1
MND-IRES-GFP
V-*F
culture91
pathway23,39
CD69−CD8+
Rsc4
detergent.Control
50-μL
637
α2β1
−5.76
transduction/transplantation
GnRHs
MMTV-LTR
FLK1
location.5
Bachoo
galactosidase
MORN4
degradation,9
AKT1-activated
SDC4-ROS1
7~4
HpaII
p31.3
CGH,7
JM-Proximal
EPR-T681I
Table22
Stagea
ACTL6B
.Unreduced
c.1649T
methyl-methanesulfonate
DGC12
F-box-like
20-75
Met-726
slideValidation
c-Jun-amplified
microvascularization
22,910
c.2970-2972
P=0.72
15.We
Bioluminescence
KD-Akt
rs11568799
QIAampDNABlood
PDGFRAD561V
.Sarcomatoid-Specific
Flk-negative
21,015,386–24,537,119
K125128R
n=263
molecule,44
N256S
Grünwald
closely.
non-orthologous
TFG-ROS1
vagal-sympathetic
WT-positive
0.0437
tumors/condition±s.e.m
L837
carcinogens-induced
.first
CARD14
artefactual
TGF-βR2
anti-IKK
NM23
D3A7
4,592
papillomata
D84G
MIP-1α
5′-Bromo-2′-Deoxyuridine-5′-Triphosphate
TTCTGCCATCTCTCTCCTCC
animals/genotype
0.001787
S62D
G513D
D1031V
modestamount
D289
anti-bromodeoxyuridine-FITC
.IKK-β
B2M
L483P
RAS.10,11
a‐RBM10
703185
616C
SignalSlide
nonmutational
ITD-alleles
COL01781−7.5CD24CD24
NaCl/2
RSS.8
MerCreMer
4:2
G581S
Farnesyltransferase
BRCA15396
0.7718
J100
phenotypes90
DNA-ligase
.2,3
DNAlevel
TC21Leu
p.Asn40_Phe45
NM_020630
PTEN.23
1-5-4-4
0227R
signallingmight
ml71
Q379K
Keap1‐CBD
5'-GATACAATGCTGGATTTCGTTTGCTA-3
progenitor–expressing
-incompetent
D571N
Cytosine-to-thymine
Openbiosystems
20·5
trial.19
192090
XSFM
P127fs
5′-AGTGACGACCAGAGCCAGAC-3′
R290H
.Combinatorial
mutant-splicing
Chk2delCr
ÌM
Besmer
beta-TrCP
.Pakistani
1817
mix-up
transition.11
endof
XPO1-E571K-mCherry
4-containing
.2002A
5′-GCU
cancer.Previous
Shuntaro
αGLT
D5S2002
evolution.10
YLDSGIHSGATTTAPSLSG
nature.comRAS
HR=0.734
Abl-SPOP-F133V
14C-labeledchloramphenicol
thymidine-to-cytosine
PIK3CA-addicted
shNf1-shMll3-transduced
4506
Zp3-Cre
/progesterone
.EN
R499C
ÃŸ-cateninlevel
USF-1
.Blockade
fluoro-phenylethoxy
962–966
turcica
bond-mediated
Constantinou
SrR
serpentine
2A1
Y1045W/*
approximately5-
H94R
Val1741Gly
PIP3in
PC4590
p-STAT5a/b
436
&
vasopressin-immunoreactivity
Hairpin
factor–serum
lines14
Amanatullah
7B
60:1021-1030
approx52
cancerogenesis
5,8–10
FITC-labelled
−795
LIF/IL6
S193P
Multile
R528S
EGFR31
tumors,35
Witkin
6–8,17,23,27
.AF4
10:20:0.2
3121
0.016*
single-group
CellGenix
orInk4A/Arf
antibody-labeled
M356T
inCEBPA
PG-21
T1-E4
RasGDP
anti-phospho-Ser10
Phaeochromocytomas
Prostate-Cancer-Associated
31.A347G
.FANCE
Insome
1mMEGTA
adherant
Lobachev
M44
5′-TACCCACTGGAGGATCGAGA-3′
Haemagglutinin
P=0.67
c.1277−1180_1386+2226
pGEX-GP1/3
Ile-798
Δ99
.Polymorphonuclear
Ccr9
02/2003
ATP-induced
ARID1B-deficient
10.1097/CMR.0000000000000188
.Communicates
Grivennikov
selectedfrom
R282S
0°C
YYYYYYYYYYNCAG/G
BET-family
0.0084
Mitsudomi
1290–1863
2,20
p.Arg201Trp
0.65-47.4
pSmad3
700-kb
CAGGGGAAGAGAAACCCGACT
radioactively
.myeloid
P-Erk1/2
f.a.
FGF-1
15.6°
0–77
AKT-tail
intraprostatic
NB2107
.Epidermal
exons/regions
anti‐HA
telomere-lengthening
FGFRL1
MutShomologues
flap
3.65E−8
Trp332/Tyr340/Arg74
polybrene.33
CHCl3/CH3OH/H2O/NH4OH
EST14_S
15,315
GSE26566
Nguyen-Khac
ddNTP
NCI-H2073
2000/well
.Newborn
cryptic/alternative
TxRed-TGGGGAAGGTGAAGGTCGGA-IAbRQSp
22q12
A879-R865
F335L
TGGT
pLenti6-TR
1NVV
EGFR–SEPT14
IDH
dFMGEN
flavopiridol
imatinib.In
Sixty‐one
ENST00000340107
nihms703640f10.jpg
anti-14–3-3
dUSD2
KitD60N
CRM1-mediated
pCY4B-FLAG-BAP1-Wt
Kaffman
21–
origin.9
R245W
FHA
16–39
.Skin
MPL.44–46
gene,30
V310I
A347D
GELCOUNT
phosphoepitopes
24138/E-01
10M3
MAP2K1-
v-Ha-rastransformants
pmGFP-K-rasG12V-R164Q
.Panel
p.Asn127Ser
Rheb-WT/-Y35N
62.9
GAL4-DNA
patrick.ma
tumor-supressor
IPEGEKVT
.Replication
0.015–0.32
anti-androgens
Sangiorgi
V429M
9139
B*0819N
bevacizumab-treated
k1
Methods•
controls.18,20,22
p53-suppressed
3.52+0.18
2662A
OLM
Hoffmeyer
HIF-2α-derived
E16.5
YVDFRE
anti-IKKɛ
p.Glu35Stop
disintegrated
WAPAL
50-kd
Anecdotal
RUNX1–ETO-expressing
S11
.Surprisingly
orthopedic
0.37-0.76
retinoblastoma-1
preprepared
MYC1
.SPTBN1
56–75
sex.Age
17/25
215–233
Vanio
extreme.
c.2607_2616dup10
Asn771_His773dupAsnProHis
Fz-related
DNMT3B7-positive
varFilter48
gtatgtgtg
5Qo
1,353
10−3
A296T
r=0.84
PCR-amplification
AmpDESTER
NPRL3
Cell‐tek
.Testicular
Anderl
pT-stage
60.2
10.1007/s00251-002-0429-9
OXY
S703I
intermarriage
p110Δ/Δ
repair14
1Only
high-oxygen-affinity
//imgt.cines.fr
features.13,14
competing-risk
cells84
132,12
cortisol-producing
SK-BR-3
chromosome-based
1.46r
cGKIα
FBXL20
Otolaryngology-Head
499KB
progesterone-liganded
bindingligand-binding
Polα
c-Mpl-expressing
INK4aΔ2,3
Bcr-Abl1
MIZ1
BOX1
.EasLetters
p19ARF+/-
lentivirus-expressing
MB3
isp53-
.N
1-step
GDC-0879–treated
coh.org/mdm2
Kii
STAMBP
2.63–4.39
IQGAP
TEMRA
-deficient
mutations.23
T127
.2547
PRDM1.3BR.R
6.7
6p-terminal
phospho-threonine/tyrosine
phosphorylation.14-16
Khong
5′Fam-T
MLTC
1,389
QUIKCHANGE1
hydrolysis6,8,9
G.F.
interactions.Figure
CMMRD
Liposome-binding
c.9631delC
P.J.Hurlin
Bonavia
1882-bp
.518G
unequivo
cost-effective
RANBP2–ABL1
34450
SNU-C2B
gacaactactggtttgggggggacaaaagctgtg
309–433
Cardiovasc
FANCCs
Radiobiology
*e
activated,5
18,28
stress-susceptible
First-line
phospho-Y490
mBcl2
p.Leu729GlnfsX6
non-autoinhibited
HR-CGH
α-solenoid
Lubbert
E39D/A44V
2–54
6–amino
transfections,29
phosphorylated-ERK1/2
82.23
GOLGA4-PDGFRβ
8A-R
Nrf2-ARE
15,000–20,000g
.Open-access
130-fold
Auto-inhibition
S210–D217
RP11-334L22
+84
R201Q
MELmiRNA-108
carcinomas,18
IDO‐mediated
EKR
O96017
Pro772_His773insAspAsnPro
Brachman
ETNK2
tablePerspective
AB032598
signature.15
7–15
5h–i
hydroxypropylmethylcellulose
1-nearest
membrane-filopodia
−3228
lectin
LA-Taq
~30-40
MmeI
c.998G4A
T392fsdelA
N-SET
Q137A
E5/PDGFβR
Zp3
RemoveNoncanonicalUnannotated
G12V/E37G
CK5+/CK18+
SP-D
150±9
TUMOURS
0.5–3.0
Z/AP
WI2-3011D5
metal–ligand
NB251
Sites®
3269
anti-phospho-JNK1
JAK2V617F-mediated
UASGAL4
Aasland
SWissDock35
3ACC
102–112
hamster-human
\0.01
BLIMP-1+
-400
RHDSGLDSMKDEEY
Breakapart
R260C
OPM-2
pathway,26,32
ÃŸgalactivity
Drosha
PMS1/MLH3/PMS2-interaction
VBC-CUL-2
AA609602
ab8226
0.000588
475b
trophoectoderm
R266K
Directional-construct
PRMD1
AAC
pGADT7
post‐treatment
GERP++,31
R122H
P1099L
Sep-Pak
iB
bifidobacteria
V:4
repositioning
frequencya
anti-A11
gene82
EWSFLI1
p.Gly353Val
L158S
TGF-β-driven
3.31–421.60
assays.3,4
RB-related
.Good
sucrose/1
1112
c.3103G
py
sc-8032
levels.Chromosomal
18Esophagus
valve-sparing
39SS
System-HRP
Mareels
G1C-rich
L115W
microsystem
1.255-3.677
44.0°C
β28-Luc
4,6,11
p.Tyr214X
cKOs
MLL-AFF1
c.8141_8145del5
2.299
Tyr426Ala
p.His147Arg
Four-μm
anti-pEGFR-tyr1173
HEK-YFP-Jak2
5′-GATTTTTGTGAATACTGGGAACTATGA-3′
MG-B2–6174delT-GFP
E209K
.Depletion
PVT
cmax:145
receptor−associated
//sift.bii.a-star.edu.sg/
Sjursen
5xUAS‑TK
MTI-MMP
Met1Lys
,4b4b
doi:10.1158/1078-0432.CCR-08-0575
MutSavariants
BiBr40-53
LS270
LETSIFTP
0.1/NA
FDXR
methylpiperazin
TACGACAGG
PIK3CβD1067V/A/Y
AM105
FLT3-Asp835
–intolerant
Rb7/7
5/232
Onset
4Z
IGR-39
affordability
p-Stat3
c465C
Imunologia
V45A
STE7+
HBsAg
Borello
mutation/overexpression
Micale
cancers6
patient-mimicking
Fludarabine
D538G-TOT
cases.8
FLT3-Y842C
ampli®ed
study96
SHEP-21-N
ATIC
package45
92.3
ANTII
interac-
189th
CCAACC
ppp
used.14
Brzovic
2,772
443-492
V*e
anchorage-dependence
Figs.1A1A
Pro-x-x-Pro
560
group.1
substratemix
TAF2N
HGS-OvCa
4.6-fold
Mobility-Shift
KCOOH
interest.40
helixloop-helix
pertuzumab-binding
TCRB-NOTCH1
deciduae
Chalamalasetty
Sciclone
strategiesIn
ets-induced
Ozturk
pulse-labeled
BeckmanCoulter
co-electroporated
mSrsf2
6.5-fold
targeted.The
non-ASXL1-mutated
G325R
comprehensively.62
BIRC3-unmutated
SET1B
trk2
5,7-13,17
PF-04449913
NPM1/FLT3
S910P
54,55,56,57
L607H
sults
WaveMetrics
8.70
1,039
pcDNA3–myc-EGFP–LKB1
.35
Smad-specific
c.129_130delCCinsA
rate=14
p=2.6e-4
.034
Immunostar
TAE-684
anti-CD33
sarcoma.11-14
AC005631
3β-containing
factors53
7.3e-4
haemogenic
NSD1-1
thanthree
Cy5-
340–351
LXSN-HPV
T2D
ERK/JNK
MSS
zCiof
-.When
7.44
Q223R
Leu236_Tyr268
AmpliTaq™
lished
T37/46
cascade8,11,12,13
aurothiomalate
FGFR3ex18
2.8
A5T
Extracellular
57–75
300V
BRCA1-induced
2483
proteins.37-39
CCT
neuroblastomas17
pVP16-CYR1
thiocyanate-sodium
A-to-C
EGFR.20
c-H-ras.A
.Huntingtin
1081C
RBP-J/CSL
Cunnick
Protein/RNA
p.Gly322Asp-p.Asp487Glu
CI=0.36–0.98
ABCF1
11111
non-DIPG
Y1820
goat–anti-rabbit
FRT
c.8397_8400dup4
41bW4
24/37
SMARCA4-mutant
SPU
anti-p110β
524,827
sympathetic-like
141A
Prohits
carcinoma26
Ull-011
.L.M
deletion/UPD
RB7-RT-se
EGFPmid
V843I/L858R-3T3
crossreacts
5µm
phosphorylation8
C135Y
4-c
R1514H
ROX
gastroduodenal
10Center
alide
tumors.5,6
RP11–6C14
G1065T
H928
various17,18,36,37
antibody15,34,39
SW156
lentivector-transduced
Second-Hit
Nox4-derived
PAb1620-
DNMTi
depolarization
two-metal
tsforming
apo-RXRα
.6547
adipocyte-
Pomerance
FM9
Lys-52
IL-1A
REPLI-gTM
5′-TTGGCGCTTCTCAGGCTC-3′
12-13-14-17
MaMel
anti-Met
59-63
17p.16
Methods.
immunity12
p537
pSV2neuNT
GSE17855
bone-specific
probasin-Myc
N372H
IRanges
35Slmethionine-labeled
MCL-derived
GFP-BAF180
enzastaurin
PMF-purified
10-200-fold
HA-GST-tagged
underlyingthe
c.2354C
starvation-induced
clinvar
SKBR-3
TET1-FL
4361
nihms646437f6.jpg
sia
9215
anti-p50
.Pre-existent
Jothy
Rrp41–46
R1742K
Muta-Gene
heatedto
HIF-1α-expressing
BLC
I301T
pRS414GPD
antiMMTV-c-erbB-2
Joa˜o
29443695
deamination18
Ishov
itwas
tables•
Axins
epitope
Curatolo
RhoA-regulated
phospho-Stat3
paraffin
.Underpinning
B-RAF-specific
deletionb
ResolverTM
//www.cbcb.umd.edu/software/GeneSplicer
ERBB3-mediated
Gln-353
t44
Kuriyan
USP16
5′-AGTCGGAATTCTCTGCAGATAGTTCTACC-3′
p.Pro1749Arg
Bodrug
TSC1-TSC2-GSK3-Dsh
16p12.1–p11.2
cytofluorometry
Ehlers-Danlos
states.31
674–870
androgenliganded
Int11
targetedagent
//databases.lovd.nl/shared/variants/STK11
alphaC
Scala
​Fig.44C
0.2μm
Y578C
5-GGATTGGCTCGAGCTATCATGAGTG
GAL-PGK-6His-rad54
interphase60,61
ATP2B3
22318
2Memorial
XP_419364.2
TSG101
W557__E562del
Two-compartment
E24G
5/40
PTPλ
pcΔID
block72
Ccl2
lines12,19,20
T35S
fast-moving
Five-micron
2061del
KITDNA-F
218/411
neuromuscular
n=148
alternativeigna
ND10/POD
ZAP
Ih|lllhi
2delA
C-II
progression.25
9G10
0.970
4q31.3
S1B-E
HDM2/p53
Apc-deficient
mutation-detection
pTCF
P.L858R
Philadelphia-
p=2.3e-5
Y267N
Rco
hypopigmentation
Komori
14q23
30600/4-05
centric/acentric
477-1039
pFLAG-CMV-5b
mg/12
Quantifi
al,45
IC87114
MI.MATERIAL
bandshift
ultrasound
BMC
BerlinBuch
//cancerdiscovery.aacrjournals.org/
Shah
CL4B
I549T
TGGCATCACAAGTTTTTAAGCA
-65
S463P-expressing
M158I
ts0
FailSafe
IPA-3
immunomagnetically
AR-binding
SOS1_00027
Thiriet
DK50654
rapamcyin
putrescin
121–300
before.5
S118
periphery
.Chimeric
QTL
Differentiates
7627
ARP32188_T100
4/33.3
CD115
Cajal.1,2
Merkhofer
partners.org
Zahler
5'-GACCGTGTCCTTACCGTGAC
NaCL
30/30
W515L,14
39-HRYKme2PGTVAL-48
pan–human
D25
FGFR3–transforming
468/497
del/p.Gly24Arg
/GSK3β1-binding
segregation15
MLL-rearrangements
BMS-354835
firstline
p.A573V,41
Genetix
ternational
forVX680
site,12
M1=3
neurblastoma
apoptosis.16,19,20
pLenti-BRF2
21,35
MHDS844-847
JCJ
inhibitors.Table
ccA
Jacakl
PDGFRα-
16A
p32∼
Peptide-specific
human-IL-6
macronucleoli
FKHRL1
CI=54.9-92.3
atom-model
4710-243
CBL_i7f
pathways.15,16,25
.Order
//www.uniprot.org
Perkin-Elmer
www.broadinstitute.org/msigdb
tracheoesophageal
pharynx-defective
debated.31,32
oligomerization23
//consig.cagenome.org
superinfected
5'-CCAAGGAGACCTTCCATCCC-3
and6B,6B
A393E
©2004
angiogenesis73
pcDNA3WT1−/−
H179
:Myc-DDK
5/7
MUM2
expression-based
ligandbound
.Firstly
1003C
APSTs
Cited2−/−
byandrogen
L718Pa
leukemia
Ayadi
Brodeur66
respose
419.4
Two-tailed
CodonPlus
CAGGAAACAGCTATGACCACACAAACACACACACATGGCAGTAG
.Megalencephaly-postaxial
nonavailable
Asn546
5′-CCATCTCAGATCTCCACCATG-3′
interaction/binding
100-μg/mL
T58M
.Pancreas
1801delTGA
sub-micromolar
RasMol
uterine-specific
mPMBL
5.48×1010
-Hoxb8
99.94
C-958
pTau
-CTGCCGCTGTACCAATC
CLL9
633-nm
ABL-Ib
00811-3
5′-fluorescently
Dichotomous
515L
wereinactive
BRAF-directed
Yamagata5
EAF2
Promix
KV558-559N
N756Da
well.19,25,26,28,29
Intra-Cellular
E180-R181
synaptonemal
Control-infected
acetic-acid-coated
cancer.8,9
m5CpGdotm5CpG
6G
EGF12
factors.2
PAX3-
siRYBP
LIMK-mediated
colleagues15,57
896
9,31
5-nucleotide
p45
IL1
HHF2
IIF
PT-35
.Yamazaki
years/M
U-Test
32/84
1741Aright
Cε
stori-form
20–
GIST.16
.2368A
Arg687Trp
BALB/cA
C160Y
c.1499-
Myc/Max/Mad
AATGGG
2,081
6KCAAX
APCΔ716
8A–F
compression/fracture
GJA
9,034
.Polytenes
0.59-1.04
SWI
−3.54
-quinolin-4-yloxy
liver-function
MTAP
neurofibromin-catalyzed
CD31+CD45RA+
4m–o
rabbit-anti-MYC
310bp
E884K—coexisted
Arp
acid–locked
.FAB
IKZF1,13
e-mail
cancer-implicated
JNK.6,7
TGFbeta
.Menin
Arg87Pro
Tyr202
095570
G123D
alpha4
1C1Y
MET-encoded
sporadicmelanoma
zig-zag
CD74-NRG1
.Hypotonia
DEL+PMs
BRCA1-M48
lys2–801
9·1–61·4
GST-ubiquitin
antibiotic/antimycotic
-TCCCCAGCCTTTGACGAAGCTC-3
H-Ras-V12
HER-TKIs
K666T
.TBK1
rCD2p110
Involution
Young-onset
24ploxp
PTEN-mutated
Lin−Sca1−C-Kit+
.Reporting
psiCHECK
sham
.ITDs
DHT+CHX
-Cy5.5-conjugated
46–70
LR06-220
protein/pull‐down
KANK1-PDGFRβ
pre-adipocytes
polyvinylchloride
Cycin
HMECsA
p110δ147
0.5uM
250K_Sty
–containing
0¶
BCOR-RARA/RXRA
Mrstop
pBatem
Taxotere
.BAP1-mediated
Val777
~i
c.38G→A
β-catenin,13
HCC25
ex15
6d
Seizinger
~a
2316
DIA
KIT–expressing
RUNX1-unknown
.Acceptance
radionormal
FOXO4-exon
tissues24
pHER2/total
FractionPREPTM
standard.indels.b37.vcf
exomes
Antiapoptotic
lengthof
activation7
Sanger-based
338C
E10–10.5
Max-von-Laue-Str
EWSR1-nonETS
CAGCTTGGACACGGCTTTAC
effluent
.Tissue
histology-specific
31.1
TTF1-PAX9
resultsin
locus30
F7425
-mediatedcell
substrate-binding/phosphorylation
IgK-HIV-kB-driven
W32G
rs34661876
BGAL1L
deficiencies43
epileptic
HPBCD
c.967A4C
p.D76V
AG3057
indicator156
Kelch/DGR
92.21
CTP34B4a
Met434'â€¢â€
.75
SteadyLite
ISX
ALL-Berlin-Frankfurt-Munster
GeneGel
58˚C
buildup
diallelic
2.16.2
223Leu
Sef
ΔGfoldWT
B80
pyrimidine-based
let-7.40,41
Ser-240/Ser-244
non-basal
HQ2
mineral-
Rosa,3
Bay11-7082
23
EPIGENETICS
c.7699C
MPCEWS-FLI-1-T1/T2-derived
broad/specific
MLL-AFF1/AF4
ligand.36
D1115H
efforts—both
A634D-induced
mutations.15,41
fluoropyrimidine-
ApoB
.Phylogenetic
S12
88.5
CDGE
R413Q
variants.
KIAA1509
KITD816V/N
Ref-Seq
4T-1
Hoxb1
chromothripsis17
PHOX2b
GzW-N-K-A-K-R-Q-R
101.42
36:10
KX
domain44
streptavidin-Cy5
KP-4
Mu¨nster
1.76+0.02
pcBRCA1–385
AA845432
PP-K9218
mutation/copy
anisotropic
ZfhX3
Hs00229805
.Bim
BL-specific
M2009-011
p.Ala1922CysfsX2
Reina-San-Martin
SPOPL
GeneSet
growth-related
KRASG13D
5′Fam-ATC
TEB
224–1366
T674I-mutant
culturemedium
KRas-mutant
GGCTGGGATCACCAC
TAG-3
2437
5.573
5P01AR050440
H+-transhydrogenase
syndromechronic
CCD-1300-Y
.Cell-free
unit-less
a-thioglycerol
FERM/JH2
CD66
370C
uracile
Cph
refSeqStatus.txt
.PI335
Entry-NFIA-FLAG
GGGGAATTCCTTCTGATTCCTGAATGG
8-fold-lower
Koivunen
0623
lapatinib-induced
HRG-positive
A-T—including
Dreusicke
0.24*
20q13.2–13.3
SacII
D315N
68:6822–6830
Thr790Met.27–30
.Coronal
bronchopneumonia
A26
Figure7E7E
odd-chain
RPN1
107K
Cys2-His2
ligand
ETV6–PDGFR-B
SOX10
Onkologie
.TOBACCO-RELATED
CBFA1/RUNX2
pathway.16
1,582.2
SERMS
homotetramers
n=5/13
response.Patient
26-1
-GAGCGAGGAGCTGGTGGTGGAGACTGAGGAAGACGTTCC-3
GCATGTCTCACAAGACAACCA
C87Y
C283Y
V-1E
TSGs,33
isoforms-2
accrue
pEBFP
Ras-GTPase
Texas-red-conjugated
PTEN-CC
Ruttledge
antiHA
170–220
TC32
anti‑DP103
GIST-derived
theextracellular
re-orient
5′-GTGCAGCAGAAGATGGTGAA-3′
50.5–100.0
DIPG6,7
CC203TT
TRIF,14,15
anti-STK11
ofpathogenicity
fibroblastomas
4-methoxypiperidine
69163500
Rictor–TOR
Ophthalmological
postembryonic
Dausset
unclear2
B0.005
15q21
CD79α
Mll3/Mll4–COMPASS-like
.Abundant
92.5-
4767
Cypriot
protocol.20
IL-16
Y845-R812
.RESULTSGenome-Wide
.TI
several15–24
20/43
.rad54
A294P
L-15
K36
DCSupplemental
tumours.Distinct
5′-CTGGCCCAACGATGGCGA-3′
c.-329C
8–477
c.482T4A
anti-p84
significant.Extracellular
Androgen-sensitive
QNPG
DSBs.17
8.46-fold
corroborate
ju.1
RET17
Ovariectomy
4q28.3
Haematology
1581.9
endogenous
730–43
chemotherapy.2,3
.UVB
G173R
8826
961478-2
P95-to-R102
trp1-289
Southern-
P278F
CBP/p300-binding
tkg
PTK5
endoV
QPCR
formation77
0.8/6.7
GlideScore
concentrations.10
0.746–0.912
investigations.8
ily
129-Krasnat
survival-associated
cancer,11
mutant28
prefoldin-mediated
CrkII
R1138A
chemopreventative
anti-NRG1
Fig.4D4D
Ju
Lys-858
S664Q
5Z
warwick.ac.uk
p110α-kinase
borderline-malignant
back-grounds
α-carbon
subunit-β
Receptor-ligand
Asp771
evi-
Chst10
NRP-152-sh-LacZ
tests.The
Ser2Gly
5'-GACTTCAGCAGACATCCTAC-3
YGRRP~QVMMM~~SARVAEMLLHIEICA~PA
protein.29
S.W.
deacetylase-2
ZNF384
6-kDa
described.9
R76Q
UPMD1-2
ephrin/Eph
ZNF-217
213-11T→G
emergedin
pEGFPspectrin
CAG→TAG
XIIIA32
.Livers
phosphate-EDTA
skeletal-muscle
Be-
GnRH
shRNA-5
c.8390delA
0-82.5
endoxan
10124â
.RS
upshifted
c‐MYC
T720I
141–156
R90H
syndrome47
Gd3+
effec
10p15.Figure
XenTech
polarization-based
PEST-mutant
4,839
D925-D932
-8L
yutakawa
319KB
Ni-NTA
Bignell
82/82
HSU1468O
p.N642H
KRISHNAN1
D/E
AIF
sites.178
MiniSOX9
CD44'OW
database38
pCMV6-Entry-EGFR
2.75-kb
SCCHN—with
ng1571
P-erbB3
FancA/B/C/D1/D2/E/F/G/J/L/M
Tropepe
respectively.23
respectively.32
Cdk12-F-containing
0.486
223–763/p53−/−
5938
kinase43
ErbB2_ex24-27.R
3,19
R336Q
Fbxw7-null
canplay
PTP1B·EGFR/pY992-peptide·
LED225
Caarlsbad
screening.9
MMTV-infected
5'-GTG
A−F
4,5-dimethyl-2-thiazolyl
activity.The
pCMV-53–337H
89,223,174
6-10
1650–1736
disproportionally
485_1283del
BOK
TKI
555-1G
GSK436
ENSP00000362294
homology-modeling
argi
CP66
hormone-driven
F893
HER2relevant
anti-FancD2
factor-β-induced
neoplasms.1
Δ66–75
GST-GSK-3β
Smad2-dependent
p.Gln448*
R988C.Met-Rat1
degrons.24
grade.7–12
.Northern
ZMYND12
subtype-1
tumor-bearing
G221C
S1290A/Y1295A
.RARa
girls.34
pancreaticoduodenectomy
differentialplot—is
RCC.44,45
68K-
target-prediction
Repli-G
n°2
GAA-GAAA
2,673-bp
.n.d
.Reconstitution
K390N
erlotinib.22
Raptor114,115
KRAS/NRAS/BRAF/MEK1
therapy,62
p.H1204P
Harbin
R832Ha
undulate
705–960
Arg749Cys
Seqwncirlg
p.D347A
Flag-Aurora
8wks
p70s6K
syk
2820
490K
20Â
FB12
CCCGCATAGATGCCACGGAAGGTCCC
.Sporadic
5′-GATGGTGGGGGCCCTCCTCTT-3′
MAPK-reactivating9,10
H11/12
P390
P102L
French-Canadian
end-diastole
13.0-fold
PRUNE2
J-041170-06-0002
4q+
22-67
n=17/17
//www.activemotif.com
GISTs53
Cyclohexmide
kit-fluorescein
repair.1–3
2102
individuals.25
phospholipids28
CSGE,16
24-48
Q546E/R/K/P
Chk2-pVHL
Brca2ex27
sucient
N676K-mutated
Co-operative
196–208
Flag-α-Fbxw7
53/88
c.218T
464-8681
Rearrangements
LFS/LFL
109CRT
Arg186*
UUGUGUUGAUUUGUCACAACUCAUG
V:23
YAP1-TFE3
.Thrombocytopenia
mono-methylase
tissuewas
D748Y
Phe572
Sox17GFP
K526E
fandaim
DUOX1
CACTGTACATAATGATTGTTGTTAC-3′
50nM
RNF2
S6N
Thr-315
H3K36Me3
humancancers
p54
Blackfan
anti-CBFβ
d-aspartate
S4P
hematepoietic
.In
CIN25
CRL1933
GBM39
0.5ug/ml
K-K-R-S-K-A
MutLβ
46-47
Tet-op-K-Ras4bG12D
S0140
Yong-qiang
iodide-based
EWS/WT1-KTS
CMV-Max
pCMV5-ERα
SKMEL23
S9600206
pY-phenyl
CagAevoked
2AC0
HRASG12V-mediated
pR54.N616S.1
antibodyH1299
pE3-Wr
S473-
AHC
5'-end
apoptosis.45
-VTGT
NES1
DN-MAML1
.Birth
H585D
MO25
GGWG
HPCs0
pCEP-Zeo/RII
Kamibayashi
phospho-tyrosine-specific
8.3/75
22–75
bookmarking
GFAP-cre
OR=0.99
demonstated
allele.7,8
s13058
www.jco.org
//www.cls.ioe.ac.uk/studies.asp
SWI/SNF-based
clones25
4R
LSM510
ADP/min
AC004518
FGFR2′s
BRAFV600E-mutant
nucleofection
pBind
PIK3CAN345K
SnoN-binding
mg/m²
11–263
.9,11,13,14,23
SF3B
S626
1160-27
D835del
Calpastatin
ino
Ptpn11D61Y
OX86-induced
enhancer-binding
octamers23
Fig.3A
GMP-E
Nedd4L
R838R
a-phosphoMek1/2
vitrotranslated
l-lysine-
7.87
RBM8A
laser-capture
g-rays
uropathologists
SK-CO-l
LGR5
3424
E45
Aben10,11
F157S
5′‐ACGGCAGGACCTCCTTCTG
acetyltransferase
mutantpolypeptides
vB5
FBXW7α
0.4–3.5
ACT1
MII2–/–
13-valent
strand—TRE-U1-CTGCCAGCCCCCTCAC
11-dUTP-labeled
megalencephaly-perisylvian
T308A/S473Ad
CLONET
LRRC31
shRNA/dsRed2
report41
Weigelt
40mg/kg
to—yet
Q2265R
total-RSK
Feinberg
lymphocytes/L
p21s-luc
4358_4675del
Hosaka
As3-104
TSC16–8
24:203–216
R334Q
32P-gamma-dCTP-labeled
0.323
UV-stimulated
2,5,6
MPCEWS-FLI-1-T2.2
68.8
.Megakaryocytes
Waveform
Streubel
BRAF-active
V523M
TER119-positive
rpS6-dependent
18/22.5
colocalizations
Pyknotic
CMML5,6,8,18–20
cMET-addicted
anti-pSer
labeling-index
functions.19
800–1,000
.LKKE
flBRD4
5-flanking
172–1019
1−11
.002Exon
NFNS,18
pair11,32
pSV-Sport-1
U87MG.Lux-LacZ
ligandactivated
Freq.
GGGCAACAGACCAAGACTCTGTCTC
40S
alphavb3
I7
17-amino-acid
SDC4-E2F
HER2E-mRNA-subtype
Asp816Val
C4II
oligonucleotides
MCL1—were
Nao
Bonifaz
N-terminal-folded
MEKK3
Leukocytopenia
delta12-BRCA2
Beuzeboc
lesion
P-MEK1/2
794G
types6–12
Gr-Mac
LC/MS-MS
22–43
650C
inflammation.6
ACTN4
geneswerealsopresentin
4,7,19,23,24
GAL-
0.0387
modiﬁcation
A-Barcode-Exon26F
Montagut
cdc42
Tyr196
Y809
GTT→GAT
293
MAPK1/2
.KMS11
.D.G.G
41.E358D
GnRH-I
Dulbeccos
.I852M
Axio
M-1
'absolute
mobility-shifted
39-years-old
Pro-Orbitrap
ILouTrpO
32212
.L1460
spliceosome-WT
Toji
p.Ala501Thr
BR12F1/
E-Bcl2
HHF1
mucopolysaccharidosis
Actb
V600E/K/M/R/D
α-NKX3.1
assaying.Finally
5′-CCTGGGGTTATGTGAAGCTG-3′
.Flanking
.F328V
F547L
DZ-induced
5800
Q698E
.Sea
Collagenase
anti-phosphotyrosyl
c-FLIP
485G
o5666-o5706
CRAF56
Vpr
594-conjugated
Rap1-GAP
S29P
β-catenin/TCF-dependent
described,32
R1231Q
TET2-
CODPL
Src.52,53
LightScanner
Movva
bB62PW
middle-high
KLHL327
12th
negative/atypical
studies.3–5
mutation—R882
PCa_ERG_1
GSE20196
Tet-op-PI3KCA
R168P
4198
.Hsp104-GFP
7–40
ID2
non-RefSeq
reasonablethat
optionsT790M
tumours36
10–10
domain-dependent
C57BL/6NCR
fractions.Assessment
Y220C-specific
transcription.79
S229E
XL-647
flow-cytometric
TGCGGACAGG
p.R53X
μm
drug-saturable
F132143151159172179
genes—NF1
outcome147
EWSR1–SMARCA5-transformed
GTGTGACG
signaling37
R.B.S
MutationTaster=0.987
TO-PRO
97to
S27
β-catenin/TCF/LEF
Csf1
CAAGCCTGCATTTCTGTGGCAGAT
contextual
9/133
Overproduction
prostress
Tyr570
website.Retroviral
.Ubiquitinated
U133a
micro-environment
MDM-2
Col2a1-Luc
CGC
c.4225A
'active
temperaturesensitive
apoptosis-defective
MBD4–DNA
phorylate
analysis.9–11
formation11
166–168
thatproposed
Whole-mount
NCT01808573
KRAS-V12
AZD
AKT1-E17K+E49K
Y74
Ni2+-nitrilotriacetic
ANKRD22
Universität
5′-M13-GGCCGATTCGACCTCTCT-3′
novelKIT
254–257
RAS/MEK/MAPK
log2/
Y311C
RTK-Ras-ERK
amino-termin
phosphorylation1
Igβ
.3Mutations
agarose/DMEM
Population-doubling
29F
PI222
9q343
pHR′CMV8.2ΔR
hydroxyflutamide
transloca
p.Arg271Trp
melanomagenesis
mutations.7,9
pCRC
BioPat
fashion.16,17
1.3–1.7
GSE46190
vibratome
year-olds
D2S367
P.V717A
R266W
2.824
pone.0064364.e010.jpg
deoxycytidine
//gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi
Tnfaip3lsv
558–560
240.3
CEN6/ARS4
miR-301a
L2143M
overBAP1
DICER120
-TGTTC
Imatinib-bound
A.T.
4NST
.Excision
ATP.Second
wIpdgEnvKIpVAIKvLREntSpkAnkEIldEAyVMagV-gspyVsRLLGIC1
hepatotumorigenesis
progenitors.57
RAD51-5
e14.5
representative.578IMAI
P573_L589
AMOTL1
μgofthe
A302-590
c.1658C
withother
DNAsequencing
WXXXS
PI3K/AKT/TOR
Braunschweig
G596RB-RAF
NRASWT
17-Allylamino-18-
DRB4*01
trans-autophosphorylation
inhibitors28
loss-of-imprinting
A715V
caattacag
preleukaemia
9368
cycloheximide-based
SPRN1D
phenotype.Inhibition
Geletot
wmi.usyd.edu.au
0.0055
SU11274-treated
79.2
59*
growth/survival
BSG022
FLAG-PI3K–p85
genome-wide12,13
H3F3A/NF1
population-enriched
Scapula
BK-14
MycWW-PDGFR
5′-CCTCCCTGGTCTCCGTGTA-3′
c.1153_1253del
Tet-op–Kras
gttgttaag
vec
Flag-KRAS
.EMSY
LCM-purified
Flt3-ITD1
Alac
.Jak-family
ΔΔ
N400D
prodomain
mean-sized
L485F
48–96
T-*A
in1,5
RNAisolated
5′-human
BC.1⇓–3
Nonrelevant
lost14
appreciated32
Rreference
siderocytes
proteins.4,7,20⇓⇓⇓⇓⇓⇓⇓-28
P430fs*63
2°antibody
mTet1-shRNA-5
MxCre+
.Nanoclustering
.Increased/decreased
.CtIP
c.1758+32C
G278D
significant.DiscussionWe
GFP-Trap
ScintiSafe
TCF-4E
cMET.61
Gly300
HMLE-PAK1
EGR2-
5′-TCGAGAAAAAAAAGTAATAGTGGTTACCACTCTCTCTTGAAGAGTGGTAACCACTATTACA-3′
ATATCCAC1TFG-3
I273F
CTGGCCCCTGTCATCTTCT
'built-in
anti-CD3-fluorescein
Welfare/Ethics
TCGA-USA
7708C.T
monophalangism
Precisionc
Overrepresented
100mM
Gradec
p19Luc
6.609*
5′-TTAGAATCATTCTTGATGTA-3′
triple-kinase
32P–end-labeled
SDS-100
C-F
CUL2-dependent
.Christian
anti-Vimentin
GEE
DNA-microarrays
1906C
Tris-EDTAbuffer
YXX
2Arg
1–479
interexperiment
tail-vein
phenyl-glycine
TKIs-based
κ-B
−482
KpnI
HRAS-driven
HMG1
Wilcoxon-Mann-Whitney
0.5ºC/sec
leukemia-retinoic
Ultracel
I836L1D
5′-GATCCCAATGCATTTACAGT-ATG-3′
Figure6D6D
2141
IdU
lentivector
Coffin-Siris
Trophectoderm
Ghanbari
~30-35
accumbens
phosphoribosylglycinamide
40†
12q14.16,17,22
butdisplayed
RET/PTC-2
.Fourteen
Core-binding
-turn
neutrophils36
caspase-3/CAD
//clincancerres.aacrjournals.org/content/clincanres/21/14/3307/F2.large.jpg
D281G-4
2013.0801
DS62
−285
C138R
newcomer
pheno
5.66-10.34
p4
Pavletich
DSRCTOur
pGEM-HA-TRAP220
CC1452TT
cx32P
XR
IR1
2α
D9E
reinterpreted
Codenaturation/hybridization
responsec
Kibutz
response22
ALK/MYCN-driven
G12D–driven
reported,47
morphologicallysimilar
signaling,5
gp140Proto-
318,313
nonneoplastic
W999C
Y6A
Nucleolin
S-Plus
Arlot-Bonnemains
microbeads
.Average
9q34.1
Myc-Cap
protocol.Quality
p.Gln2491X
5′-CCAGGTGTGATCATCAGT-3′
pCDNA4/TO
p.L274P
48C
Osheroff
RAD51L1
co-crystallize
IVS18-13A→G
2993
1064
V48A
CD19+/IgM+
1816ins
CTGAGGGACCTTCCGCG
TrCP1
brca2ΔBRC
NCOR1/2
3-kinase-AKT-mTOR
RO1CA92312
Sorval
vagally
EGFR-Y1068
3791
LEF1—
152×108
0.21inv
PT03
granulocyte/monocyte/macrophage
StatView®
Ref.11
gemcitabine-platinum
two-to-four-fold
HSP16.9B
0.283
trypsinisation
A_52_P220573
MSH6-NM_000179.2
Glivec®
Nonidet-40
DP72
V1223L
AKT1-
Y376C
tyrosine-phosphorylated
Snf5inv/inv
isoprena­
EGFRΔ747-749
Asxl1-deletion
8.1j
17q22–24
bNot
DAD1
.Additionally
Dicer1fl/wt
NZM56
D65A
KIT6,4
Institut
S6d
n=10/25
Transplantations
Hsc70
Smad3+/–
tcaccatcttccaggag-3′
XPLN/Arhgef3
caller21,72
myopericytoma
cardiomyocyte-dependent
,6,7
hPP
F595Y
Apc+/ApcMin
techniques33
tSNPs
tissues.21,22
helper-inducing
p13.2p11.2
GNAI2
mm3
T-ALL.18
ym.edu.tw
p.V717M
CDB3
R683E
snRNA
NFkB2.49
Khochbin
readFilesCommand
TGGTGCAGATGAACTTCAGGG
SPOPWT
E57K
F1245V
∼235
.630
gonadoblastoma
Ser24N
OMA1
M837G
m/62
X-535
AKT-independent
macro-oligomers
mesenteric
RUNX-gene
Epitect
μM,17
pCMV-
translation-independent
ΔG‡
HCC-bearing
microsampling
KDa
Conze
TRE2
Rmsangle
c008000900000100503322444047501378493755360020500438190Method
ASPH
NCT01874665
donors16
extra-pancreatic
MBI
c-Met-overexpressing
RANBP17
SCL25A10
Suv
others,30,35
re-examine
Tyr-CreERT2BrafV600Ezh2Y641F/+
MC3R
2542G→A
7.8BX098660
.HPI-1
Synergistic/antagonistic
Fgf-1
FRS2-Tyr196
Kelch-binding
shA673-pTER
frame.29
56.65-fold
protocol-specific
1583
RIPA-coIP
gp70-env
vitromethylation
53-responsive
SMM
T100
−79.5
761–775
min-
cytokinesis.35
SRB10
carcinoma33
Theprotein
LNH03
AGS3
atroom
5′-ACAGACUUCGGAGUACCUG-3′
D820E/Y
SUMOylation
protocols22,23
PTEN233
Rho‐GTPases
2003c
Phe216
Blnk
pathology-based
78.47
848del4/ins9
74.7
nucleus-positive
H1770
P50L
1,838
Met560
M536
Ti-U
0.801–0.963
1A8
concentrationof
G382V
cross-regulatory
Adeno-CRE
25·0
DnaK
I.as
recombinant-mutated
1ISN
384KB
.Gain
traD36
multisite-directed
positon
catch-all
RT100
Jun-B28
4775-bp
.HNPCC
loop'10
carcinomaFollicular
RA2-independent
977R
NCT01184326
.TRANSFORMATION
517C→T
.693G
*TuVICIGyGInGlyLeuVaIVaILysII
1375
CAGTCAACCAAGAAAAGGGAAA
.Subsets
Noncanonic
methods58
Drosophila—dSet1
pathways.16
+v-Ras/Y527FSrc
stretch-induced
014669.4
BioView
PGL1
diBarbiano1/10,40136
S303
.RNA-seq
co-localises
D6M9S
10.8×103/mm3
cases9
3.3e16
39142
REDD1-mediated
α-catalytic
one-twentieth
1.162x10-04
808
sizeTo
μl−1
I457T—have
cancers5,28
HM32,34,35,36
TGF-β–Smad
80-90
4–6,7,12–17
de-glycosylation
ORF
Afatinib
Felsenfeld
NP_000236.2
rituximab-based
72-79
sequencing.13
Prdm1
0.947-1.341
intradermally
transcriptioninitiation
split-mapped
metabolise
493C
4340
CDK4-Arg24Cys
P353L
rlmfnmf-rlm
3/1/00
lymphoma/leukemia.26
R810W
Enhancer-of-zeste
5′-GACTCCACGACATACTCAGC-3′
pro-mutator
V130D
211/441
E3–ubiquitin
S-type
CDKN2A-binding
TGAGCACTTCATGCTGTAGG
PLC-γ–PKC
Pax6-immunopositive
Hardy–
v601
A006E25
3.HER2
uu
Samduk
I114T
R2228L
1Ai
NM_005656
Sawyers39
-TCCTGATGGAC-GAAATCAGA-3
oligogucleotide
ASRRcGTMSSLSGADDTVYMEYHSSRSKAsSKHVHPL
−1.91
apurinic
β-catenin-luciferase
insulin-mimetic
D84A
31-20-
1.11–2.13
3-portion
PA20
37jC
elsewhere.21,22
non-recurrently
aac-3
5′-AACGCCGCTGCGCGAGATGTTG
Ser-592
PAPPA2
—IRF4
18.5±11.8
www.snps3d.org
2,160
b-strands
FL393
comorbidities
-_-iP-S
guanidinium-isothiocyanate/CsCl2
3532
WTmu/mu
L658P
C/CDK8
D27
Viewer53
screened6
5TC
EZH2.1,24–27
A1064V
.FBXW7-mediated
Mapk1
1.In
Duthu
T-FISH
Heme™
25/65
Rolipram
67.0–89.4
E29Q
FJ627786
1.22×10−4
n=38/132
scintigram
cholangiocarcinoma,10
ligand–SCF
1–295
PG-luc
autoradiographed
VI-1
emPCR
.Histologically
59–67
clones/144
gpg5trk5
SEPP1
RecA11
HinfI
β6–β9
trials95
anti-lysine
6.825398375
TMD8
Muc2
.589G
rs26279
BSA/TBS/Tween
temperaturesensitivity
GD/GVa
1.1G719S
comparability
.20070872
9p21.47
Barberá
-broad-min-quality
8953del
nonsyndromic
genes151
pTet-On
met.Data
20q11-qter
ATM–Chk2
RAC1-mediated
IKK-related
H393D
Phospho-SHP2
Barski
SHARP58
parathyroid-specific
19/46
Lkb1-SL8/pAHC
10−9M
GALNT11
pCMV-Ras
S363Q
Barcoded
∼40-kb
andgerm
FGP
pEAA163
nihms484665ig1.jpg
t8
13C9
arid1a
168.
thelevels
IDH114
|T
LNCaPcxD2
3771S
analysisGainsLossesAmp1pDt'lq
antireceptor
antibiotic-unresponsive
gpl40Proto-rk
Inukai
30,37
R401Q
co-recruited
736C4T
sequence34
DDR2-ERK
Thermolability
CCAGAGCATATGTGCATGTACC
A_51_P497332NM_008709
V218G
lymphoma25
E168D
5′-ACAGTCTACAAGGGCATCTGGA-3′
TRAP-Mediator
PI3K/AKT/mTOR
posttraining
27–35
~Y32WQ61H
XXXIII
Epithelium-specific
10,16,17,26,27
GM-CSF–stimulated
glycosylase-sensitive
.2,34,42
zbe
*04
DiscoverII
3−16.3AMIGO2Amphoterin
E3-bound
investigating
CLTCL
:92–8
In-cell
T319
Plk1.40
deg
P135
2-associated
-CH2F
CGTGAGCGTGTAACCTGAAA
v-ErbB
COX-2-independent
AGGGTGTGTTAGATGCTGGAA
2878
PF-0521384
elusive.ResultsCluster
gene,1,2
MYC-amplified
P34
PPM1D-WT
FuGene6
con®rmed
-noncompetitive
DM2500
E2-11
TGCTTGCCACAGGTCTCC
2‡
Glu-770
UBC-9
ANKHD1
CDK4I
GST–Grp1-PH
intracytoplasmic
IVS+5
LIGAND
programs,18
complex-dependent
12-48
HLA-negative
C‐terminus
0.9-1.0
red-brown
1000genomes
MEK1-WT–positive
20.25
16-22
9715
.PRCs
854
three-day
p.Ser32Tyr
tumor-predisposing
Hs01547250_m1
5′-GATCATTTGGAACAGTCTGCAAGGGAAAGTGGCATGGT
10/15/99
vRas
Y71H
XM_935390
Nuclear/nucleolar/cytoplasmic
.Ottenho
F39.4.1
1.143
AML.4,5
fluorescein-12-UTP
isopropyl-β-D-thiogalactoside
anti-FGF-2
Single-amino-acid
Ptch1
gtnagt.lt
F55
.SSCP-PCR
106/well
Smad2Δexon3
1863-residue
johinaz.cgen
W4
acatag/GGCCGT
1.22–20.9
Ligands
336-66bp
I-abd
1145
agonistdependent
Pancreas-specific
0.28–0.95
SRY-R
Lys-36
TCAGCAGAGGGTCCTCTGGCACC
18-09/DR-GFP-4
FCS+G418
H179Y
JH4–JH7
c-Myc-responsive
​Finally
HCC827R1
loss/maintenance
493_864del
Mononucleosomes
48BTGCGCTTCGCATFCVFACCTGG1096
tumours13,14
Niida
PFU
co18d+oSn4J51331â€
cleaved-PARP
Ac-pVLExJ
States.7,18
p.Arg1183Glyfsx7
pareffin
L1065P
tively
mcr
CC223
C-score
NM_002524
OCC
Q590R
Keap1/Ikkβ
.Fifty-six
Nicchitta
Cdc4
12These
1.—
54:1–8
RET/PTC2–8
22•
alphaAcrystallin
crosspeaks
IVS7+83
LPL.77
J35
12K
L1854
738.St/Int
K601E-mutant
series.8
rmed
79.53
BCoR-RARa
c.164-2A
semitransparent
Fehon
G284V
Tris-Base
break-through
17,606/1003
49,260
2184/56
pT3E5Aand
TÃŸR-I.S387Y
NKX2-8
CCAATTGTGTTTGTGCAG
Abbondanza
Y849S
previously10
5′Rapid
25-nt
4-digit
agent.Our
URT
instabilityThe
E1282V
Bárcena
390A
.Fang
nucleus/chromatin
HCC-1569
D487E
Anti-parafibromin
targetsAbstract
anti-CD15
RETV804L
Monoranu
ab85454
V467L
D.N
transplantion
SW-60
19,21
analysis.24
V617F/STAT5-mediated
4/781
FLT3-R644K
CCND1/FGF19-amplified
Immunohistologic
type1
Methanol
MAC-1/2A/2B
HA-PMS2-ΔNLS
microhomology-mediated
p.Gly13
P081/P082
pMMP-puro-DEST
374-384
binding14,21
anti-AKT3
EphA-ephrin-A
treatment.24
Y527FSrcexpressing
DP-LOH
Hsp90-mediated
doi:10.1093/hmg/ddl136
.Escherichia
Zactima
algorithm30
23q
RMC20C001
U-178
methyl-CNV
sc-277
0.5–5
1649R
1•96
10-week
'double
//www.selleckbio.com
//jmg.bmj.com/supplemental
Genefind
dexamethasone-induced
5′-TGCTTTGAATGCGTCCCAGAG-3′
17,27
diVerences
33.4
​,2A,2A
1,100-nucleotide
W1057R
NP_984921.1
Nontransformed
p.Leu332Pro
withanti-HLA
CD4-Cre.21
A10S
unexplained12
dual-repeat-interaction
recognition/hinge
4058S
isrelated
RAD54L
I1122V
superinduction
1/52,000–1/36,000
sc-1751
School-Dana
2ata
bylowercase
PlasmoTest
0.001669125
Tsc1−/−
2476A
1418
nihms646437t9.jpg
CAOV3
models18,19,21,42
ceGAP
.ResultsExpression
Non-classifiable
270–282
Smad2-N
Blackhall
715K
9,11–16
D2723H
proto-oncogenepreceded
IgG+
TNFstimulation
P.G719UNKd
CREB53
mammaglobin
cyclin-associated
Anticdk6
insG
–8
Pertschuk
c.1177-8
DAX-1
kinase-ordered
.DLL1
CATGACTTTGTGTG
TPX2
P312L
10,000-50,000
β6-
JRG
Ivanovic
Yaseen
beindicative
COSM268315
α5
GCGGATCCTCACAGGTAGGTGTCC
HER1+
SLCT/Sertoli
.Sorafenib
AN3
RGC-containingreporters
β-catenin.33,36
3/7
cios.to.cnr.it
Protein–lipid
AML1-MTG8/ETO
hepatoxicity
wasspecific
Tris·HCl/1
523_528del
V161D
euGlnGl
Anti-Tyr
-p27T198V
Rebhun
3591
co-purification
Smad4-dependent
matrigel/MCF7
DR5G
saracatinib
.Incorporated
2rgn
deleterious/neutral
C311-C326
Rho-depleted
K-rasV12
Arg653Trp
pla2s
15.8⁎
L232A
Lys1423
sic-Src
c-FLIP–long
adenocarcinoma.In
R175H-p53
.Dotted
NF-κB,13
Hypertrimethylation
RAD21T11TP53
animals3
estrogen-independent
'G
Seventy-two
p.Arg301Cys
tctgcctatGCCTATtttaac
10-3/4
c.404delA
rectosigmoidal
Fig.6B
69/70-year
1980s24
B-lympoid
c.538-3C
.Reconstituted
100-mg
//agvgd.iarc.fr/agvgd_
40–
FLJ36835
J029
23–520
SeaSun
Nox4-dependent
elastosis
exon-4–containing
P50.02
non-chronic
CDH1–APC
Recklinghausen
34196–34550
A-to-D
462M
10−269
p110α
Raf-Ras-binding
T1621M
0.249–2.683
V443I
65-1
PI3K-like
Keyan
HTR3B
D816V/Y/F
pirif
0.140991412
3438
220-kDa
indispensably
pSTAT3
antigensand
G385D
SMO/MET
SOS-dependent
GREB1a
90º
medullary-type
Athough
F3T3
29,701,173
gcccag/GAATCC
FLAG-Elf3ΔC354
Kan-Mitchell
6,11,16
G623D
cancer-preventive
surveyedwere
MEK1P124-mutant
Osoegawa
|pVHL
spirocycles
p-JAK2
Ki-67-labeled
,9MYC
pcDNA-p73α
U/ml
000g
Detera-Wadleigh
c.440A4G
/highwire/powerpoint/139509
signal-transducing
EPO-treated
K-ros
Thr308/309/305
≤0.4
SF59
paraffin-blocks
MEK2-WT
8-546
cmRT–PCR
popula-
MES4305
1263delF
DU145-derived
30/12
phosphoryaltion
C2/helical-nSH2
OMIM132800
639–685
pathogenic.25
-CD34
transitions39
46.4–2.0
c.162311G4A
Arg-12
defined3
dolichocephaly
Ago-containing
US-based
1758
pelvic
Chr3:71027059_71027060
Single-probe
2114insA
45-bp
DDR1c
4-mers
Duisburg
manner92
.Sudden
sys-
HGFR
isopropyl-1-thio-β-D-galactopyranoside
anti-PDGFC
290mm3
Bioresource
5′-GGGCCTGAGGTTCAGAGCCA-3′
pRb/E2F2-
pH1-plasmid
CollapseDataset
tumorigenesis.23
93,900
S4R–S
TOM-1
B-sites
COL2A1
RA/RARS/RCMD/RCMD-RS/5q/MDS-U
23–66
AmplitaqGold
sub-telomeric
Red-conjugated
Ub-VS.
BRCT1-
2.2Mb
MGH-U4
0.7819
methanol-glacial
20,800
2.949
SCC-10B
K409Q
mutant-ERs
137c7
4.16
6-9
1.0-5.5
A/C/G
c.686G4C
HSP70-PK
ATCAAGTGGA
RING-H2
.Exon-specific
mutant-expressingstrains
3523
−25
non–cross-resistant
structure.Figure
c52G
PT98
WT-KEAP1
T9I
HER2′s
degradation166
12670
anti-CD38
PTEN-363
p300Δex15
rare4
.Berger
stress—while
thrush
Malkin29
19q12
P=0.024
∼40-fold
Electrostatic
MDM2-specific
DODx
tumorignesis
973
agar,20
rliang
Fuyuhiko
neuroblastoma18,19
knocking-in
K142A
Scansite
progression1
7q31.1-q35
K14-cre
chemostatin
L-368
//www.benaroyaresearch.org/bri_investigators/atm.htm
15q22
TRK-speci®c
ERα-positive
D486G
cyclin/CDKs
p.1432
metal-chelate
SKP1/CUL1/F-box
5'-GATCCTCGAGCAGCATGCTTAGACATGTTCCTCGAG-3
DeMatteo
p.Lys601Glu
NM_008714
397melb-cateninS37F–implanted
5′-GAGAGUGGAUUAUGUUGUU-3′
5´-CCTCTTCAACCTCAGCAGCATCC-3´
TbetaRII
Angeloni
V246fsdelGT
F338I
V11
SK-Mel-239
Miedzybrodzka
q32-34q34
N94I
R836R
22,400
.Percentage
.F4
pre-symptomatic
acetylation/de-acetylation
databases35
lymphoma24
B-associated
pEBG-2T
combinatorial
B′
-fused
identi®ed`hot-spot
p.V612del
co-aggregate
non-Down
HDT
receptor.8,9,10,11
51:54–65
833-fold
YAP-positive
l-5
4.0.1
amplicon-containing
ETS-negative
pathway.70
Magnevist
N-D-T30
trifluoromethyl
immunobloted
leaky
diluant
.Ad
studies.4,5
CCDC170
carcinogen-specific
EWSR1–1667R
sensitivetransactivation
14q31–32
102-3
.Cancer-Associated
–RUNX1
DS-AMKL.40
Ins58L
thymocytic
of32P-labeled
ALK-TKI-naïve
development,6
LIPID
Aected
5′-ACCTCTTAACCTGTGGCTTCTC-3′
/f
c.389A→G
cleavage/activity
G−697
FLAG-NRF2
HDX
ultradeep-sequencing
U95A
Shiraishi
non-BL
physio.mcgill.ca
display.31
-Pro257
evaluated/monitored
Traenckner
pcDNA3.1/ZNF198-FGFR1
lacZ-sorted
neoplasms35
SYT-SSX
25/27
VZ
29-day
and6a
CtCDKN1B
EIF4A
lymphocytes*
lymphoid-associated
~~~~~~~L6C
direction46
Hs700T
Stat3–/–
NF-κB/RELA
CREBBP/Crebbp
vemurafenib.6
AmershamCorp.
sc-459
Holoenzyme
ETS-driven
Frizzled1
STAT5B-RARA-rearranged
.5438A
cyclin-GDK
Hisright
L'Arbresles
Keap1‐mediated
CD7+
Koide
long-postulated
2A-G
1–1712
.Forshew
sSNVs
S783
-islet
DERKD334N
anti-VSV
S1423Q
EVSA-T
γ/δ
c-Mpl–minigene
5′-gctgcggcagaaggtcaagt-3′
BCR-PDGFRA
Membrane-Associated
2.382
FL-induced
H109P
mutation20,21
.Deeply
Esa1
AZD6244-resistant
p.A1708E
R67W
Hagemeijer
197/328
pVHLHyp564
BRCA1/2-unrelated
USP21
11.
DIS3
PTEFB
kinase-active
ACCGGAGCGCGAGCAGT
RTKs—
FANCD2-S.
161:267-80
mice30
Aurora-A
antagonist-like
unipolar
High-Risk
t-test
G1l
deletions/amplifications/translocations
Blimp1
partners43
5′-TGTCACAGACA-AGTAATGTCGATAAA-3′
b-cateninLEF-1
RA/JRA
hematopoiesis.16⇓–18
A704G
.Meigs
described42
NUTM2A-exon
623dupT
2900
mechanotransduction
G35
NAV2
Noh
K5.Smad2f/wt
gene/protein
7-pound
P667L
ARID1A17
p21WT
CCAGACTGTGTTTCTCCCTT
med.osaka-u.ac.jp
2759T
10-10.5
36-year-old
EnVision-FLEX
K12GGA
Amperase
BRCA1–abraxas–RAP80
region–containing
NUMB-Low
PRDM1a
RPMI
FLJ21816/LOC79728
GS1-119P5
RAF-targeted
inno183
genes/ESTs
GLI2
F/49
3-keto
PYK2
S16b
0.0392
Crizotinib-treated
≤30
homeostasis25
Osifchin
50min
Krieger
RP11-231A23
therapy.72,73
5′-CCCUGACCCGUCUAAUAUAdTdT-3′
89.5
4,6,8,10,12
pups/litter
MPL515-WT
N3
development31
message.23
Kinsse
30KB
RP11-3H20-SO
Shirokanedai
ZNF198-FGFR1-transformed
Smad4Lox
3-metho
binding-pocket
L120F
transversion-low
NM_011053
F667Y
1569
Calif.
JUP
recombination.13–15
+0.7
disconnection
R193X
sc-364162
calb
T790M-negative
MDA157
D17S786
P1087H
L1240A
wu20
c.220G4T
p.Gly409Ala
hemopoiesis.38
Myc-Skp2
0.300
VisualSonics
K373ac
Thr648
hypovolemic
15/50
Ascertainment
Bergsagel
≥7
Point-mutation
MY64
30,44-47
CDC25C
p.Tyr341*
892
Metallo
N47717
Calabuig-Fariñas
S549I
.Dutasteride
EcoNI
.SFIHE
776-1095
arrays/immunohistochemistry
2000g
longer-lived
to-S
chemiluminescent
difference8
GT19
druggable10,11
CrG
1.75
36,600
anti-IKK1/2
64260
Δ557-558/T670I
P=0.36
V658F-
Arg574
N299∗
p.Leu819
resistance49
Lys48-
GSK-3ß
3TP-lux
p.Met535Val
described.21,22
.Lysed
2p23.2
ARP/wARP54
Deoxyribonucleic
Cell-cycle-checkpoint
20.6
pSV3gptH
p/2
SPRY227
ablation-associated
cells29
Lkb1G163D/pAMC
S.E
FancC-FancD2
PMS2CL-specific
oligodendrogliomas
hematopoiesis43
∼175
vivo.18
Hif1a
Hlil2R
P=0.24
acc=GSE53350
3,7
mismatch-induced
.V600EBRAF-
KBM5
p=5.3e-2
T7-VHL
pretherapeutic
04/02
6-h
10-09
.show
protein-truncation
andk
G–T
Omega39
Ala756
migration.18
.Trafficking
1405
10–16
6C-D
873
drugs.39
RET16
CytoVision
p.SOX9
5-ACTACCCAGTTCCTGACCCC-3
pessimism
GCAGACCCGGGAGAAAGATG
homeostasis50
NCT00149162
29/121
9.0–329.0
I–V
Tgfa
q14·1
proteins.5
000050.2
data•
whole-exome-sequencing
M1043I-NHUC
2576delC
5′-GAAGATCTAAGCTT
types.8-12
9,484
SW41
R447C
Stout,2
α-mouse-horseradish
TTGAAGACTGGGCTTGTCCC
3998
.11,12In
Input-Myc
E198K
5'-CTTTCGTGGAGGAGGCTCACTAC-3
Swinnen
PCFG3
18b
FBW7R479Q
antiamnesic
TRPV6
.NKX2-1
NF2-except
56772359
NRP-152-shRNA
ralph.tiedt
NM_020910.1
XM
H3K4-me3
BAP1-F170I
GeneBank
1049–1809
G100531R-8
MEI
NCI-H3122
4.3–44.4
.Pelletier
4397
D446V
CellTiterGlo
⩾4
Q211P
SC-35
bladder-specific
CFCS-related
V245A
1,183
ALK‐dependent
FLT3-amplified
MAV203
Histagged
samples.Genetic
misinserted
.caveat
12·6
endonucleasePstI
GIST—if
eﬁciency
nuclei.28
28391047
co-segregating
Mutation-Positive
p.V600delinsYM
N357
4•63
Drosophila1
LCGreen
212–217
CAATGCACTGAGCGTTTGTT
TNM-Staging
Gata3-deficient
E-activated
BCOR-3196F/ZC3H7B-1714R
oxoGdotA-specific
R243P
A17
pCA3
Tg/luciferase
GST-IVTT
SRP028594
approx200
Enge
USP32
//www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi
Shiose
mastocytoma
CLONTECH
3′ss
RAD50/MRE11/NBS1
59-ACAAGTAGCTGATATTGATGGACAG-39
CMRPG
SQCC-derived
–62
low-depth
rhodamine-EGF
activity.25⇓⇓-28
rundown
1046-1067
c.3109_3112del
BRCA1/13
2261-2284
phosphatidyl­
macrophage/dendritic
pCMV-Neo-Bam-PPM1D
uroplakins
DFHCC
Pheonix
2237-2251
inhibitors54,55
immunocomplexed
.Toxicity
position28
mutant39
GTP-regulated
5′-CGTCCAAAGGTCTTGCGTTGT
NOTCH-mediated
TAT-bound
ME1
non-myristoylated
NM_017590
.Fourth
L295P
379-384
S2F–K
59-CTT
5′-CCTCAACAACCTTCCCCTGTACTTCATACATG-3′
Abi-1
BRCA1–BRIP134,35
pcDNA6-V5/His.b-ARID1A
RTK.1,61,63⇓–65
chromatography-quadrupole
FIP1L1-PDGFRα-induced
.PoPMuSiC
Pepinh-MYD
p.Thr195Pro
.AZD6244-resistant
8·7
probes.31
4ng/ml
maximum-tolerated
.PE/CA-PJ34clone12
1,872
cancer94
D7S648
FLEX+
Met1076
Hyris
K675A
Elk-1
profiles76
erolotinib
de-represses
OE19
carboxymethylation
Blimp1-null
477G4A
87.4
Achong
Gholami
PKUCH
1,000–2,500
sail-boat
72C
vitro34
melanoma.7,8
.Embryologic
G521C
Sarcoma/Primitive
overinclusive
.119
Schro
leiomyomas7
PCyR
SMA/MAD
molecularsize
m/rn
250/358
CBL.18–23
__K558del
LTR-
5236SeqF
1-30
KRas-mutated
Met-343
p53-L344P
Shh-associated
ELAM-luciferase
hepatogenesis
DNA-shuffling
maturate
/Arg
NHD13
Erivedge
Bii
DI7S588InterpretationMSI-H
p.Trp2788X
100–3.3
29,111
.Midguts
p.A1141T
KNUDSON
48-mul
MANIATIS
KIT-acquired
stress…Download
heterozgosity
Elf3Δ246–250
LR09-006
ation-stage
AP-1-dependent
permeabilising
6824
.Ring
gefitinib,32-34
D556N
therapy6
inhibition130
invasion,16
2,224
tantalising
72.99
analysis31
3e–g
undersample
protein/well
non-EZH2
wash.
PF-502
MITFS473A
DDX420
p53Y220C
array-CGH
NEO4
platinum‑based
TTF-1−
.Anti-cyclin
sc-138
Rho-GEFs
reinforcement
2.1–192.7
REX-1
obser-
NACI
c.434C4T
chloroacetamide
9.65
Pen/Strep.Transient
promoter130
6.667
.Programs
zygocity
NIH
12–167
33430296
data-dependent
AluSx–AluSp
–BRAFV600E
not18
CNC-bZip
EID-1
genetic/epigenetic
Gammacell
35-68
Oligodendrocytes
p.R625L
E30/K31
UvrA
side-effect
Divecha
527-549
73y
www.biologia.uniba.it
GCCTCAGGCCGGAGCAGCCCCAT
4300
ABCC1
0.706a
RHDSGLDSMKDEDY
6-oligonucleotide
chromatin.Figure
CBFB/
...
Dina2–4
oncogenic.42
Agarose-bound
.71T
bands.Panel
oArg
25
.Liposome
double-minutes
ERE3-TATA-CAT
N0-N1M1
2.Twenty-five
morphologicappearance
REACTOME
RUNX1–EAP
mucin-filled
ofgreen
PLD1-D4
P-bodies
V289F
pGAL4-ELK-1
-catenin-mediated
68/F
19p13.78
Hox
5′-CGATTACGAAACCAATCAGCA-3′
BCL2/18q21
9.46
R546W
DNA.Generation
cancer.16
uta.fi
2,341,066
Rydstrom
A-Barcode-Exon23R
formamide/6
PBS/BSA
A_51_P368012NM_010783
.E-MEXP-2197
bHLH–LZ
autoregulate
Rad51-ssDNA
Nutlins
Klingler-Hoffmann
JGFJJR
NC7
developed139
E346Q
pre-transcriptional
Laminin
cell/epitheloid
wide-scale
P.Sung
EGFR/ErbB1/HER1
-0.33
162072007
GI:71987419
9/41
sc-612
structure181
mTOR/PI3K
10.47
rafl
AGACACAGGTAGCTCACTCA
spectrometryGene
HS3ST3A1
defects,6,7
SequencingHRM
disease-propagating
//www.nfdht.nl
non-reducing
RG-20N
9018
pattern.4
C8orf53
71.7±8.0
BN-PAGE
TLR1
non-Jewish
Notch-related
ponatinib-selective
approxpH
C360A
Desm
121:4359-68
mutationfrequency
.H6
D1517N
melan-a
C2030T
BIX101294
19.99
GLI-ElA
SV40ER
sc-585
Met243-Phe1695
FIP1L1-PDGFRA7
H1047R–expressing
24–33
nonreceptor
6083G
5′-
merlin-deficient
CL207
NK4
TPR-fused
D61V
centrifugation
9c
ercc3
MDA-MB361
S15B
Group-box
nt2757
PKWS
MST3
SMO-binding
multi-turnover
RG-24T
drugs.33
alone.12KRAS
L788
61.5–69.1
www.broadinstitute
2A–2C
AdCRE
335–605
obscurred
.Santa
96-10-P308
A–E
repulsion
study.Horizontal
process.Box
EFE184
Pathania
phospho-p90RSK
R249S/H168R-DNA
aarrow
227
Gebbink
WT-
∼84
profile17
lymphomaShown
nt−23
pCAGGS-Etv1
well‐understood
TLTKAKTKLEQQVDDLEGSLEQEKKIRMDLERAKRKLEGDLKLAQETSMDIENDKQQLDEKLKKLEFMTNLQSKIEDEQALM
CCTACGCTTACTTGAACGCGTC
RUNX1-EAP
34773CM
2,766
megalencephaly
32D/FLT3
Figure.7
spectrometer
Geiersbach
Peaper
Antisense-ESX
FOP-LisH
​Fig.1.1
CD74-ROS1
TTCAGGAGACAGACAACTCACTC
midgestation
PHA-stimulated
rrcrrrrErA
DLL4-blocking
WO2008120004
50°
.Vhl-null
high-purity
5′-CCGGCGGCTCCATCATCAATGACATCTCGAGAT-GTCATTGATGAT-GGAGCCGTTTTTG-3′
cdk6-cyclin
1988–1992
Yes39
±lipid
allelicimbalance
deficit-hyperactivity
P-STAT1
P408
ATP/ADP
pEAA310
Card10
CMF
protein–substrate-binding
PDGFRA-F3
4447
9q12-31
molecules18
P=0.090
InbreedingCoeff
Hutchison/MRC
genomicrearrangements
FLT3.E12F
reported6,17,21,23–27
.Refs
c.6014C
patient-identified
plexus-specific
ODC
18-month
IgG-APC
.Lucchina
polyubiquitylating
*P≤0.0018
d.p.c
SOX17-U
Quarmby
homolo
E-Box
10a–
growth,13-17
54880
12q14-q21
commonp.A502_Y503dup
4120
31.7
-stain-negative
spinoculated
Dispensable
H3K27me3.4
.MEN2A
RipTag
Dorschner
neo-proliferation
EGFP-B56δ-E198K
≥4-fold
hydroxycarbamide
9030
Zandwijk
AKAP9-BRAF
E985K
6p25.1
non-stop
therapy-associated
®ber
hypertranscription
Raf-bound
A1*'
interpediculate
αT3-1
E746K
44/72
ESE-2
IVS15-7C→T
U-251
anti-IGF-1R
thatmight
Pdgfra
counterbalanced
peptide.22
M/2·7
42,000/μl
.Dalton
T232K
cyan\
andsusceptibility
801
RPS29
supertransfected
shNF1a
kinase–Ras–phosphoinositide
4544
H171
328K
G168E
4q35
IgIIIc
L497P
Y597
R598H
PAX53
182delA
II-III
SPOP-independent
cells.118
H-RAS
2,740
Anti-hsp90
rai
Cancer/
2954
2002a
p.Lys577fs
R1076C
136-bp
unchanged.80
ZNF216
XG6
.572T
Breslow–Day
CD40L
CentriMo25
tissus
intensity-fold
E255V
TKO
20–152
GST-DP103
c.213-11T→G
p53DBD
5′-CAAGGTGGACAACCTGACCT-3′
6/8/89
beta-interferon
3q26.3–
models27
1.636
05/patient
52–64
USP34
GAP-Arg789
Serandour
POVRAY
PECAM-1
sensitivity.10
PH-in
c.1035G
Immuno-Lite
NEUROD1
miRNA-380-5p
.Re-sequencing
bemediated
.Ctr
p.Ser142Phe
Ciriello
0–8
V138F
GEF-catalyzed
.73–.93
RAD51C-009
proplatelet
139×
IIα
0·3–3·0
68,611
Kilpivaara
IL-3–conditioned
Cys1097
318™
645ASSTT649
93.2
G12VRAS
20:5n-3
L48S
D93
K.Furthermore
repressors.8,20,21
S646F
1JM7.pdb
Xhol
D1Δ-18
UPMD2
DMSO-treated
promotersof
partner.3,9,10
1096-1077
conc=concentration
Chiariello
subtyperequires
.PATIENT
transformation.46
Billaud
ITLLRELGQGSFGMVYEGNARDII
0.04–0.32
3b
asynchronously
1540
wingless-Wnt
=∑Lgj=qg
Brc-Abl
1000–5000
.Disease
GTAGG
different.23
xDFG-phenylalanine
R319C
.98456520
.MUTATIONAL
190,000
IFig
647–780
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic
Ov
Génome
,4A
pNTAPb
601581
890–893del
V559__V560del
23–27
C646
16/40
2-carboxy-ethyl
PMS2-N45A
HrasG12V
3-CAS
Anti-pan-Trk
p21—the
substrate-Fbw7
6/24
VIC-MGB
tail.6
theoccurrence
CRAF-specific
OE21
300200
PI226
interleukin-4-mediated
c.503G4C
nonameric
Q2716H
SMARCA2
Billack
entrectinibWe
bA375E1.3
feedback-loop
full-size
C-MYC.46
Protein–protein
:p53WT
.3193
.Results
lof
AFM
colonyforming
Veeriah
tcga-generanker
Semiatutomated
k+1mut
codonsare
therapies.8
32P-ortho
Bio-Rad®
ς-A
RMSF
SUV39H1
glyco-engineered
Sample005
‡P
3/10/09
//www.genego.com/metacore.php
Ser516
www.bjcancer.com
Glivec/STI-571/imatinib
gfor
Ran-RanBP1
row-wise
60417401–60457100
80Â°C
motor-skill
154/160
rbf+/+
damage.6
immunoprecipitates106
tumorigenesis78,83–86
FHCRC
328/543
SFII
AM949727
Nystrom-Lahti
Permeabilization
POL10
62/2,669
S1898
17-mers
Fasano
4G–4J
sh-PCM1-JAK2
VEGF-VEGF
JustBio
2GS6.PDB
0.0158
1.3–1.6
31–72
Kcal/residue
K1307-specific
F3336
hybrid-selected
MPL-Y252H
members32
2–22
RCC-43d
c.1A
1serine-threonine
pGBT9
primers/probes
morphogen
859/G
30/3
collagen-
cytoplasm52
TCGA-C8
9–14
Geuns
TTCGGGACTTTTGCTCTCAC
NdeI–BamHI
ISREC
autophosphorylated
.CBL
EGFRvIVa
H393L
–3.7
FGFR3-S249C-expressing
A-Trisacryl
183-fold
bK514C6
Inghirami
bioreductive
.8,10,12,13
Akt3/PKBγ
.GATA-3fl/+
Giemsastained
〈I/σ
Ts/c
therapy—the
flk1
WWP1
D17S798
Mixer-GSTSmad2C
D22A
KITD816N
RETV804M-
stabilise
EWSR/FLI1
network18
SLC35E3
Br58**
5′-ATTGGT
IGFRI+
G113C
CDK8-KD
ectodomains
277.4
c.2145,6
.Threonine-875
gonadotrophins
dp-ERK
R870W
.M32
revisited.56,57
-Myc/pBabe
CyQuant
c.1792
breast-derived
G161V
olaparib-sensitive
estimable
cytoplasmHCV
TAZ109
acid-L-tyrosine
affectedby
HCC827-GR
ab101430
mug/mul
XNP84
cell-matrix
SRBC
RP11-434C1
97-1
0.022
LMWPTP
1.475
non-viable
MPL
E64P
glycine12
CD33-PE
EcoRI/blunt
Skp1-Cullin-F-box
⩾20:1
mutations.zIncluding
Ala502_Tyr503
BCL-NOS
-33P
EA2506
Anti-CT
.CBC-RARA
TET/JBP
bLZ
BST0380217
.BAF57
W16
ATXN3
EGFR-TKI-related
development116
Gab1-specific
hexane
81.95
nucleus,30
homomultimerization
3/ErbB
BamHI-EcoRIfragmentfrom
N3T3ODNODN
inhibitor,74
YUGEN8-BRAFV600E/WT
5′-gcaguuucuucagagcagguaucuu-3′
Tyr284
Stoecklein
p=0·05
.STMN2
K6R
P01.019
94080
CENP-B
exaggerated/prolonged
5069C
influx25,26
D1016G
AY028850A*2409N
tovarying
+/+-6
K390
ubiquitin-proteasome
LH−hypogonadotropic
lial
C12ORF5
WPD-loop
LOVD-IARC
González-Pérez
tissue.14,16,42
ALKF1178L/ALKF1174L
P*-ds17-
8941–8944delTATGb
reptin
D57Y
L585I
monomer,24
DDIT3-4ST/A
Kovar
expression5
2−3
thepolymorphic
adenoviral-cre
A309S
thyrocytes
37-week
173A
Lamballe
ProteinsWe
V560G19
Novelc.4067A
fulllength
20–79
chemotherapy.1,2
ctatggaatccccaccatcttc
631–637
E041
VE-CADHERIN
Zeocin-lacZ
495/518
kinase–dependent
cells—DMEM
M23403
gtg
R190Q
determined216
5-ethynyl-2′-deoxyuridine
TTAAGAACACATCTGTTTGCG
-GNLLDYL
61–121
paraformaldehyde/2
D-14
PPP1R1A
RSLRPEAENNPGRPPPTL
LMP1-RNA
80×
hybridization.23
1AWC
11.A
IVS40-1050ArG
p.On
CD69+
MAGI2
MSCV-U6miR30-PIGdeltaRI-PTEN
1hr
S222D
STC
depleted56,57
N487S
5ꞌ
SN2
Ong1,2,12
IHCCs1,3–5
004360.3
MPN.12–14
6.72
-HIS
MO_1185
thatTRK-T3
.AnnexinV
size-control
withoverexpression
.RESULTSExpression
protein-G-agarose
1.26-fold
1,104
5′-AGGAGGCGAGTGATAAGGATCC-3′
Dicer1-deficient
aWe
1q21.3–q22
3.43
v-erb
13Hematology/Oncology
NRAS,13
Rmergea
PI-dependent
p.Arg399Cys
p53gene
GAP-related
assessments/measurements
helix-12
5′-AGTGCTGCCCATAAGGAGTCAC-3′
50–154
KIT/V654A
iPTree-STAB
packed-to-the-C-lobe
5'-GA
advantageCase
LMD
HER2-APC
3BIY
Enzon
ZNF639
NF1-ERK
goat-antimouse
system.19
96–98
GST-FANCG480–622
3q24–28
DR-U2OS
Meis1
Zn2þ-
/MHY11
Akt-Myr-Δ11–60
co-produced
Tyr674/675
17,19–22
BCAN-NTRK1
1,635
Subcloning-In-frame
R960–25
cancers,13
IFNg
D1028N
Changchun
BTX
H520
s-801
.A775_G776insYVMA
DNTM3A
D1–CDK
-TATA-chloramphenicol
MathJax
promoter-Luciferase
PI3K-independent
Lo-Coco
doi:10.1006/excr.2000.5131
FigFig4B
AGC-3′
p.R180C
D2-D3
KTxxxW
Orsetti
5758
126:443–451
thirty-three
.PD-0332991
5871
hematopietic
FAM91A1
Chempartner
491.5
84.2
readyto-use
Faletto
proteins.https
.Colorimetric
Ildikó
evade
Kam
IsGIyGInGlyProLuAlsaHi
PTEN-regulated
GTCCGCGAAGATGACAAAATTG
MaeI
.Am
Mlh1-null
1489
XFoxH1a
p.G13C
R248W
Ikonen
breakpoints.18
alÃ-ele
TMEM14Cswap
54jC
CLL/B-NHL
p-FKHRL
anti-TAP1
98G26.9
D1103
c-KIT.48
7q32
1627A.T
hypernickability
Flinn
c.656
mutation-carrying
223.00KB
med.kuleuven.ac.be
targets10
3.7-
Neutron
2.69
nt+68
7–8-fold
E2-
nucleophosmin/B23
104/213
L870
Cytotoxicity
26-76
BAFF/Blys
vitA2ERE-TK
superextended
Lechward
N3a
p3xFLAG-CMV14
translocation4
yVa
Nucleospin
13z
MAPK-based
Macroscopically
42.7
27–86
macrofollicular
Microfluidics
5-Aza-2'-deoxycytidine
Se-Met,53
Fraizer
0.395
p=1.2E-06
BglIIBamHI
3-hydroxyl
pVHL19
LiCl/1
Koto-ku
250,000,000:1
dextrose-based
TCGCTCCATCTTTGG
B1-CDC2
293CONT
9INSERM
5.0ng/ml
2–15
//www.clinicaltrials.gov
S18
Bartkova
CtBP/TCF-4
melanoma,31
GSE17247
pCMV-IKBA-40G
5′-GTAAAAGACCTCAGTCTAAAGATTGTGGGTCTGCAATCGGCATGG-3′
Gold®
Gimenez-Roqueplo
CD26
transrepressors
Nye
5075G4A
0.001.We
flt3
insCAAA
nucleatum
1L95
NBsusSR
pProLabel-C
tyrosine–protein
Chronology
43768
16.74
P2
score=0.01
Aditi
HAL-B5
p21waf1
3,913
Phospho-p44/42
Batf
MAP2K1–MAP2K7
stress18
GST–BTG2
One-nucleotide
chromosome3
HOP-62
Asnafi
301–320
expression.Figure
interaction,40
pZlPneo
0101
58.3
β-interactions
trimethoprim-sulfa-methoxazole
quizartinib-resistant
Amaya
RK3ERAS
HIFs.48
withhematoxylin
F1174L-positive
II-3
Vrij
Bourillot
cytoplasmicprotein
BRCA-mutation
/NPM1-RARA
Y164
92.7
sequons
OTT-
cancer46
lymphomas5-7
PTPRN2
s10911
Rhotekin–Rho
Ijichi
seen.2
YY-1
Ambion/Life
Src-homology-2
FLT3-ITDNPOS
consolidating
D-
//tcga-data.nci.nih.gov/docs/somatic_mutations/tcga_mutations.htm
al.,2004
PTPRT+/−
VHL-DHFR
re-express
CDKs10
case5
R358Q
Gly538/Ser537
GGSGGS
12,13,34,35
GCET-1
Tzoneva
R265C/K618A
V599ins
KDM4A
C1229Y
.S16a
α-C
p130+/-
≥10
McCune-Albright
ser/thr
Phe-134
PIAS1
I2333M
81-kb-long
P=0.013
B.
constructs.56
BAF170
inefficacy
CDH2
2HG-octyl
30.1997
mAb108.1
.15
GTATTGATCCCCATAAGCATGATGACCTATGATGATAGGTTTTAC
promoterand
.Uncovering
induction/repression
kSik
EVI1-mediated
BPSP-qPCR
Ixempra
p.Ala1320_SerfsX5
R+EN
.MYCN-induced
mitomycin
Y527FSrc
9/6
IFNγ-producing
BACH1
auto-induction
outcome.K-RAS
SETD6
12.0–95.4
mC-KIT-carrying
Arg8733Gln
4/49
Lin−c-Kit+Sca-1+CD135−CD34−
.Urothelial
.Positively
C-RAF53
tumours20
LCT-Premier
NCT00660920
//www.genome.ucsc.edu
nonquantitative
was202
11/730
GGC
64.15
5′-CTTCACTCAGCGCTACAAC
3.547
//www.ebi.ac.uk/gwas
helical-OB1
G894S
.Disclosure
remethylated
basic-leucine
p.D67N
GSE25016
red-cell
Aurora/Ipl1p
MEFs.4
M13912
TCR-Graphic
ACOX1
TTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPM
PT3K
dimer-capable
6.5–32.1
Sprr2f-Sox17cKO
F211S
Purification—PCR-generated
RepairPDB
C490F
GSE1747
variant3
W131C
SUM-225
AMH
Hom
scaffold/adaptor
p.Y98H
.Saraswati
4.8±0.4
Roche/Genentech
-which
.Hydrophobic
825delC
cancer-prone
NEN/DuPont
20-28
BioJava
J.G.P.
protein36
.Tumor
.Fosl1
Mis-splicing
Hoxc8
near-
kdGSK-3β
.Inheritance
explicable
mBAP1
decalcification
37/96
c.3395C
7/18
bi-
T425M
GOG
p.Arg1010X
Eμ-TCL1
114K
p53274Phe
NGQN
MyD88
genes.18,21
18K
250-03
transfer—for
ubiqutin-dependent
AZD9496
GGACAGAGACATAC
NKX2-1-transfected
HNF-1β
CMN-associated
non-relevant
TRP1/CEN
S6A–D
multiforme.5–9
p.Asp254Asn
re-seeded
.S6.1
PHRED34,35
ter958
ITD-positive
Selectionfor
progression.27,28
UV–cross-linked
transcriptome-wide
Inv
D93G
HA-Ezrin
:GAL1-HIS3
0.64-fold
.Crucially
protein–ligand
3553–3562
Alower
carcinoma4,22
PDGFRα
HCF1-binding
system.Cells
Weigelt25
aa2
87/33/6
~e.g.
NFI-associated
CHD1del
17/30
BRCA2–6174delT-GFP
1,433
run.The
MUM-133
G633R
caveolin1
p=9.9e-5
.IDH1/2
L858R/S768I
pSer-x-x-Phe
BACH2
DICER16
Pindel48
Reproducibility
dephosphorylations
.024894
2947
835.3
HER4/ErbB4
john.exton
region.15,30
Garrigue-Antar
A4502
CRC237
β-adrenergic
FACT25,26,32,33
_2589+
1.0R
oligosaccharyltransferase
CYT
depression-like
​Mice
5-carboxylate
dimethylate
TCCAATCAAAGATCTTCTTCCAA
Pabo
67–70
II5
MSI.26
GAGAACTGGGAGGGACAGC
Duet™
trP1-Exon23F
asparagine-linked
Glut2
HA-AKT3
Polyphen2=0.993
56.5-63.7
ABC-C
486E
marfanoid
translocations.4
nonmutant-bearing
263f
−2.85
Siah-interacting
131.0
Kettering-
32,433
Y290
43–78
Hedenfalk
.WDR82
12-o-tetradecanoylphorbol-13-acetate
FIO
manner35
1852_1853AA
P-Tyr
5′-GGCACAGCCTCTATGGAGAA-3′
super-shifted
rTh
Bar-Ilan
families.4
TX1
pBabe-E804G
NEG
AAD–positive
erbB3/PI-3
NFT
gtgCtgatt
G697R
APC/C-mediated
R841H
N254
Methyl
ICIG
MgaA2*
p.Gln466X
GISTs.21
FGFR1-mutated
N323K
thyroidhormone-receptor-associated
340mM
-lowering
p.R132C
0.371*
CD11b+
MultiImager
69795
mutation-carrier
cells/plate
thatFO-1
gencode.annotation.CCDS.gtf
EBPdelta
ysleul
153K
PALB2-dependent
ASXL1/cohesin
www.correlator.com
S249,254A
22c
fl-galactosidase
percent.6
1954
10Comprehensive
COL4A5
Perez-Pinera
1425.19
Elsevier
HyClone
=14
Schuetze
silver-stained
year-OS
'pan-inhibitor
PIK3CA15
g3140a
W515S
T7-1
1.55E-07
6−10
220–8
unknown.Other
brown/red
5′-TTAGGAGATTCAGAAGGCAA-3′
Tgfb1
0060090
GFM3434
1.01.08
MSCVGFP
Cre/Flp
f/39
Forty-four
10.1158/1541-7786.MCR-14-0157
Ang1
populations.35
Ch2/3r
CTLL
M.uteus
r.l.u.
Mlh−/−
R353L
NBT
integrin-PI-3
Tp53R172H
86.2
Ex11-F
silane
Q205P
PKB/AKT-dependent
range=89-149
Fgf
Akt/
10–amino
cohort.Table
.Near
119K
AML,36
61,000-sample
RP11-946D14
cancer.43,44
anti–phospho-Erk1
splicing8
.Caspase-9
antigen-G
TL7
246–250
5-2
oncogenes.18
204886_at
pRSFDuet
HWE
fectants
toEGFR-mutatedNSCLC.11-13
695–696
Antibodies—Mouse
IBiD
a-LEF1
W.J.M
different.Sex
rTRct1
Carter-Su
Huh
SCLC31
.N304
G2032R–
5′-TGACCTAAAGCCACCTCCTT-3′
mGFP-
I398N
R560del
.R1391S
MMFF94s
C1024G
51/50
low-resting
.ERK2
44/52
aa1236-1325
anti-cRaf
Feger
Chk1/2
Bellezza
protein-nucleic
USP16-
GCCGCCCCTCGACTCTGAA
318–400
CONDEL40
samples36–40
Pro-259
OncoCarta
KIT-A502_Y503dup
F/62
c.471C
fusions/translocations
TGF-ÃŸpathway
MYC-targeting
Zn-binding
Cause-specific
Mass.
34–42
+39.0382.986397
ZC3H7B-1214F/BCOR-3860R
c.716_736del
42–55.6
5'tggatcccggccatgtcggccggcgag
.C-KIT
p74Raf-
p.Gln573*
p.I1307V
10,000,000
K299Q
megakaryocytes
-4-methyl-4′-
NSCLC.5
Idh1WT/WTVavCre+/WT
RP11-647D11
965–970
respectively52
nsi
hooks—mediate
IRF4/MUM1
Ac-pVLhFL
70-mer
function-1
F1007A
oxindoles
reviewed261
K.C
BCL2-anatagonist
Minowada
6B2
0.02a
Mayatepek
1-carrying
well-validated
stage-IV
500×
Alessandro2,16
c.7586delG
74.33
damage.11
2-diphtheria
40.3/15.6
Sox2
RG-6N
11.91
Kaighn
DNT
middle-linker
Phe204
ETGE-containing
impaired,31
Anit-ragweed
cbioportal
-TGACGTCG
Imject
5qter
5'-AGCACGGTAACGTAGGGTGT
393–327
47/M
S259
HER2-transformed
-GCCACATCTTTTCCTGAGA-3-3
3,728
IRB100-11-010
10–135
1.5-mM
mg5
setting.82
Co-Smads
G373R
OBJECTIVE—The
shTet1-b
M737I
.BLM
tumor-autonomous
vascularization.18
1–1807
level-3
2809
Smad4-/-
one-year
K581E
.IMBALANCE
anti-CD11b-fluorescein
Tyr319
W80
1,000–5,000
Hirosumi
14.6-Mb
0M
Y877-F899
well.10–12,19
5′-CTGGTCCCGCGGCAGCTCCCACGTGGA-3′
611–881
N.GA
FlowJo
1–induced
D5S107
indvda
D7S481
60·0
CGCCAGGGGAGAAGAGAAAGA
degradated
SCCOHT-specific
Gln282
human–hamster
p53R175H
c.5042_c.5043del2
759
Randerath
Janin
16q21–q23
Flag–FBXW7
beingpresent
Myc-Cdc20
rAsplysleulysGl
FlexStation
M263
5′-GCAAGCTGACCCTGAAGTTCAT-3′
-CRY2/CRAF-CIBN
49-patient
N1L1601P-T2512A
0.3–5.0
MIR143-NOTCH2
BRaf/NRas
0.6X
JB12360
.FITC
Bam
iscapable
188−bp
25,27,28
degradation/pVHL
Lim1,2,12
S1A–S1C
HD-MY-Z
pseudogene-specific
GTTGGTACAGGTGACCGGCTC
POL13
.S6A–S6D
tumors38,39
.Preventing
χ2-test
debatable5,6
S312L
Garcia-Echeverria
Nf1+1+
647–1043
H16
polyubiqitylation
9.9-13.6
PIC1/
non-skin
R262
non-acetylatable
dysrhythmia
D835V/Y
recentrifuged
antibodies.In
GBM32,33
80,780
previously-described
.Sister
phosphorodiamidate
1:34.000
.siRNA-mediated
Alpha-secretase
809-831
10:1.27
Re´gion
810KB
cancers32
.F9
21.8–27.0
GFP-C-RAF1
34-bp
3.5-kb
spatial-temporal
Biosci
NSCC
h-CD
5,402
E–CDK2
induced-cell
β-subunit
1–181
.5548dup
peritumoral
in-silico/in-vitro
Δex4
S768R
cells.6
Gly-Gly
pluripotency/self-renewal
C225/12
cancers.27
Alk
HCC2998
1151T
R1784L
~50,000,000
MspA1
Arg214
1143
R119G
FKBP12
HDC101
keywords=E-NCMF-2
decreasedexpression
Hasegawa1
FISSR-PCR
GTCATGATGATGGGCAGC
anti-breast
erythocytosis
GAGCGAACAGTTTCCATCTGGTA
3298
Erg-FLAG
Dieumegard
T.J.L.
MCF10A/
YFP‐BARD1
anti‐myc
LRP5/6
T1010I.Met
R504
BAH
Cell-Sorting
aberrations*
R158Q
AmBion
Hökfelt
pairmate
suninduced
existence-might
immunodominant
microsatellites.42
nejm.org
foe
Moruzzi
keratoacanthoma-like
c.1569C
0.843–2.407
intrafollicular
KltIT
p.R5
Karunagaran
PvuI/KpnI/SacII
FITC-fluorescence
//www.insightgroup.org
G95R
Tyr-129
OCI-MY5
Amo1
previously.9
.October
AMLCG2004
0.19
20p
PI3K/Akt-independent
ATP-labeled
21q21
800-1200
Antisense
RhoA-ROCK-mediated
transfectionmedium
p-ERK2
c.-112
CDK6-
localizationFor
W515–mutated
Coverglass
32-91
Scc2-Scc4
phenylmethylsulfonylfluoride
DNA-contacting
cells48,49,50
L63V-expressing
CAP-accredited
.3598C
wererequired
LNEY
GGCTGGATCCTCACAGAGCTGGA
6.7–9.0
P145L
development.21
activity.19
Jiaotong
β–DNA
mannose-
MMTV-CreNLST
J-N
commoncancers
G-L
Tyr503
mutations.mRNA
5-CTTCTGAGGTGATCCGTCGAC
c.15785-238_16168del2425insTTGTATCTCAA
ri-
JAK9
TEV-mediated
47out
tumors.4–7
K086
.Owing
anti-PLCγ
Treatments—Human
Joosten
95C×10′
mmn
S5F
EZH2ΔSET
Assessor
0.5mg/mL
Tietze
L-2HGA
-propenamide
1h
EpH4-EN
MFE319
.Uterine
rendering.High
.Hyperglycemia
AR-responsive
F1387
SCGlO
AGT3GGT
microarraysThe
CD34+CD38-
Y551F
errorprone
A.G.
liganddependent
podocyte4,5
Jyllingy
imatinib-bound
PBMR1
77
ALK-fusion–positive
.GA
​Fig.3B.3B
:43–62
ERLIN2T5TP53
ExtractionFor
†P
gel-eluted
cctcaacaagatgtttcgccaa
jugulare
compared.39
Condel16
MPD→AML
Legless/BCL9
activin-BMP
Cdk/cyclin
high-titer
bromphenolblue.TABLE
IRF4
therapy—chemotherapy
VEGF-B
TT-39
1913
lucifcrase
.Those
H1693
185.3±2.9
CUB
CtoG
dermis.E
Toshihiko
3.405
DinG
p.Thr528Ile
ALK6
6,8,10
pancreasectomy
50×103
Immunosuppressive
NM_001024139
.IARC
101:2720–2729
reaction-single
BCVA
Gbx2
FVII
C47G
Ldb1
hMutsα
PTEN-C2
p=0.024
SNVs/INDELs
CD133/1
farnesyl-transferase
34,38
MDS,1
2,281
GSE27692
PIKK
1532–1541
heparin/heparan
128-139
'1717300137538404192250631927195670282726261100170501101800000Method
9-subunit
~3D
.Contradictory
A056
ETV6WT
1Wt
428-465
c.4427T
−21
TCTACG-39
non-pseudo-hypoxic
MPLV.3-5
957–968
873–83
DQ
NPM-ALKI1171Nmutants
3896
G2-arrested
Kuball
-inactivating
761
ezrinT567D/R40L
20.8
5'-TTTAGCGATATTTTTTGAGATACGA-3
ΔCTsize
RIPAE
13C/15N
Laemmli
thesecond
J074
AKT3-
profilethat
CWCH2
GATCTCACTATGTTGACAAGGC
anti-correlated
pLZR-mock
40-80
5b–g
dyspoiesis
T.he
pRV2
Sakaue
V374I
Balb-NeuT
design24
nifty.ne.jp
Cre-specific
.FOXM1
2-hydroxyglutaric
products,25
L909S
c.3259C
oncogenein
post-HGF
inadvertently
EUFA232
11q13-14
K-HA
p7311
co-stain
extramacular
genes—BRAF
5′-TCCGTCTTCTCACCTTC-3′
PDGFB130
L1575P
phosphoserine/phosphothreonine-binding
MAPD
K.
A.d.M.
Tdel
RAS44
.Fig.1C.1C
Fig.33B
-conjugating
a16
I,19
state32,35
Barlesi
diminished.36Because
Tyr1278
ATX/SMG1
siGli1/Gli2-knocked
IMab
D17S1290
ChromoTek
SU2C-PCF
2168
HG-U133-PLUS2
activin-responsive
mechanics/Poisson
123243211
back-tracked
flippase-recognition
Gln95
6–39
Sartelet
.Baltimore
Gly719Xaa+Leu861Gln
β-substituted
600-mg
I-loss
∼1.3
BRAFV600E-inhibited
myelodysplasia-related
Na2HPO4
tirucalli
M/B
.Spectra
pEYFP-C1
47–56
60–65°C
pT3N0
c2323C
race-matched
EGFRtumors
.Necrotic
HER2/EGFR
L153P
330.5
nicotinate-nucleotide
ERK-independent
THRB
Sp1-mediated
KlURA3
neurosphere/stem-like
0.28Mean
617-735-2069
PerkinEmler
v5.2
D-10
CO2–humidified
nM.14
normalization31
glutaryl-CoA
Non-responder
−271G/A
prelayered
14-3-3ε
S2PY—Smad2
villus.22
5p15.1
2/201
Tet-R172K
75–90
Deconvoluting
SgraI
repressors.16-19
Desmoplastic
rs2112527
lesions.Figure
pCMV6-Entry
mCherry-overexpressing
MREC
dimer.30,32⇓⇓⇓⇓⇓-38
ZNF384/CIZ/NMP4
5x‑UAS‑TK‑lucifer‑
RS.12
5′-GGACTGCCGGCACAGGCCTCCACAGTGG-3′
Ab-124686
dox-treated
IVS15+3097
anti-Bax/NT
1.325
169,290
057
Suc1
sets.24
microsatellite-instabile
'Basal-like
BsaB
BRCT-targeted
81-3-3814-0021
erythro
KCNJ11
150024
4,225
Roussel-Uclaf
day,19
DualGlo-Luciferase
21.2
PC12/MEN2A
reporterat
RasY32F
222999_s_at
PRDM2/RIZ
18F-deoxyglucose
lesions/aberrations
receptor10
78A
2110
PCR/SSCP
OX3
paired-reads
mCcnd3-Forward
casesbetween
AML-1/ETO
METΔ15-expressing
Tyr845
Big-Dye
CASP8-mediated
C/EBPα.Mutant
two-cycle
A.X
pLg
.CDKN1B
V373F
–1000
59-4
004333.2
cardiomyopathy
C307
4/106
∗P
BAT-4O,5'-ACA
Fig5C
regulation54
gefitinib/erlotinib–resistant
respectively.22
R96W-PH/WT-KD
adrenally
TGF-bRII
anti-PKCϵ
1c–e
5′-end
84.55
.Bioplex
EGR-1-like
Napolioni
troublesome148
Figure1F1F
JB9640
bAbnormally
p.E746–750
70–95
G118
rearrangements/deletions
CtBP1/2
‐2H‐tetrazolium
lymphomas.44
3,65
Theprimers
6-month
TCGA-B0-5691-01
1Latency
ethnicities.30
telomere
rs1799725
1.09–1.76
LacI-CHERRY-BRD4L-positive
Btk/Tec
RAS-related
9.677.5
A2C
fusedin
03/02
6*
7p11.1-q11.1
Yukiko
.Der
4381
R77C
−3.07
cells164
p110γ-
WW6
X66365
c.2325+5G
Gateway-selectable
.Tokita
inhibitors42
oeMo
CANC
.Triplet
LX1
cellbased
COX-2/VEGFR2
approach.16
alternative-spliced
DAPI/antifade
15a
endosperm
.C-Maf
VLM
3q12.1-q12.2
G1269
R265H
SCFFBW7
p≤7.0e6
Kendzior
JmjC
Exome-wide
Co-affinity
deteriorating
l‐glutamine
Gil
αpMAPK
Asp870P-Arg547M
PI3K-p110α
Propidium
cornGENES
Hes1-positive
BCR-ABL-negative
inhibitors—dasatinib—was
p.Cys378Tyr
lysosomal
Inhibitor
,2a
p.D1344H
Croyle
noncolorectal
HBM-like
Smad2/APC
LXSN
con­
Immunolabeling
BL-derivative
FLT3-ITD/FLT3-WT
Magendantz
EMT15
ttggaatag
NCALD
__UM
27.63
μm–1
Lefty1
5′-CCA
PI3KCγ
5′-AGGCCACCAGTGATGATGTAACTCT-3′
catalysis.14
YMESO
DyeDiDeoxy
Preinitiation
postdamage
inguino-abdominal
117309
.Crystallographic
Deh
homology-directed
Ressourcenzentrum
platedand
NP_001070679.2
gpt
TGFβ-responsive
Ala/Ala
4432
R949
progenitorsA
DLBCL-associated
J1-6
GGAGTGGTGGCCTGTTTGGATTCA
KRAS-dependence
consequences.mRNA
glycine-34
Tyr1150/1
Gab1orGab1FF
Y242del
94.9
DP2-BSW
371bp
7/7
5′-ATCCTCCAGGTAGCTCATCC-3′
L114A
immunoprecipitateswith
Sperimentale
MLH1c
1552
X−5.1RNF128Ring
.S4O
n≥7
haematochimaeric
hematopoietic/endothelial
cavum
1,050
1-carboxylate
marks—H3K4me3
.CD34
CATGTTGCTCAAAGAACCATATAGGAAGT
1333
RTK-RAS-MAPK
S6KT389
cross-peaks
T790M.91
23888
0.4036
25–95
.Film
MM1.s
n=664
d-30
175-nt
R24G
KGE005
PTEN–p85α
HPM
100.The
tumors24,26,27
Tanji
121IKLAPPPKKA130
respectively6,7
M667V
18–19
RhoA‐GEF
1To
FGF1-mediated
.P16
L64P
213T
ERK-T202/Y204
target.14
plasmid29
SH-TAP
5475â€
A-F
disorders.30,31
−176
5′-FAMggagaaaaattccgggt-3′
sh-LacZ
KCl/0.4
Keap1-Cul3
A1C
Shp-2Δ46–110
ccaccactgcatcaaattcatg
661
Protein*
patients,59
Plk
06-056
518
A2103
-GAGGAGCTGGTGGTGCAGACTAAAATTTCAGCTCCATCCA-3
.Edmondson
inter-helical
criteria.12
ATGGGAATGGCC
FGFR4.32
Flag-14-3-3α
7/152
279/310
reaction-assisted
si-SPOP1
Clarification
arole
N-oxalylglycine
MM5.1/2
matrixin
D813-R817
CWR22Pc
R290
alleles.3,11
HJ-specific
RAF-ERK
K568
712-714
targeted-sequencing
883G
0.87
complex.25,26
-R175H-72
PF-12340166
1E-16
miR17
.Host
anti-Thr308-pAKT
Missense_Mutation
profiling,16
signals/tumor
Size-ranges
//www.ncbi.nlm.nih.gov/omim
macroH2A1.1
LR03-260
ENST00000440486
GGH
APG5L
drug-
ITDMUTNPM1WT
KIT-NEGATIVE
12ER
half-decrease
'Alberta
RAD51B-Gal4
69.63
Brystol
5.2.6
5.3
0.990319
2–18
DNA-damage-driven
Retroperit
FPB
eluting
Ser463Pro
multiprotein-containing
pcBRCA1
I109N
neural-crest
MDS/AML.25,26
T2-
37-3
Eμ–Myc
Kmt2dfl/flCγ1-Cre
andÃŸ2-MGRNA
BRCA-1
anti‐RBM10
ADRB2
T7-Enhancer
76.9
fluoro
AKD
C328R
IL-3
Mt-BCL6
RB7-RT-as
c.332_340+1del10
T778
timing4
//bioinf.uta.fi/PON-MMR
EPD12
adenoviral-mediated
K-RAS4B-GMPPNP
CRL4DCAF1-Dependent
gbAD000671
D560Y_N564D
p85α-myc
PIK3R1/PIK3R2
Pde4b
N1468H
2:26
FC2S
phospho-serine/threonine–binding
8312
myeloblast/promyelocyte
DQA1*0501−
lOx
concentrations—Rb
nonkeratinocyte
elongated/fibroblastic
.Post-confluent
activation3
AF-l
enhancer-mediated
p.G357W
transforXBHX
Sagittal
Analyte
2O8B
MPCEWS-FLI-1-T2
approx40
E203K
Fine-needle
sc-98299X
5′-CGGACGCAACAGAGAAAGACTT-3′
2331280
Free-floating
anti-B1
SF80
ExSite
destabilizationof
42⇓–44
p.Val380fs
Coincidentally
DFC300
.539T
tumor—mainly
di¡erence
carboxypeptidase8.0TNFAIP2Tumor
5q-deleted
ab2/2
retardation,15
Yrkesuagen
−−/+−
cabozatinib
tctacttag
c.185A4G
I167N
319K
3,13-15
TGFBR2E526Q-mutant
shy
AKT/PI3K
R952Q
132:854–867.10.1002/ijc.27713
//genome.ucsc.edu/cgi-bin/hgGateway
.Gastrointestinal
.CD8þ
IκBα/β
BioLT-Drugbank
www.R-project.org
E842G
high-tumor
cells/stem
K4me3
phosphorylation/activation
p-S
AY-insertion
shRNAs/enzyme
421–1793
p185neu
ITD-type
grade/stage
GH/IGF1
24,28,30,34–36
Thr790Met+Gly719Xaa
5′-ACCAAGATCCAGACGAGACT-3′
supernatent
deleterious—12
STAT5B-RARA
NOR-1
proto-oncogenes2
UC-specific
blocks.fhcrc.org
D137G
Single-color
**Bam1a/**Universal
TET1-MLL
I-
3627
.Ezh2
2688
59LTR
LR08-018
D1-Cdk4
carcinoma21
2.169
HNPCC3
GST•Chk2
.CDK4/CDK6
PFKFB2
0.7
BioCarta
deathII-2
Nelipepimut-S
Michaelis−
end-labelled
V600L
non-canonical
Koleske
anti-neuron-specific
mitosis12,17
HER2-dependent
Skp1−Cul1−F-box
;
Stat5/Bcl-xL
CGGGTGCAAATGGCGCGCTACGGCCGCCGGGGACCGCCACCCCGCAGGTACGGGG
myc-His
Soleimani
Raptor+/-
al.89
IGF1R/EGFR/pERBB2
0.73-2.64
ERBB3-WT/ERBB2-expressing
V1293I
NOTCH1/TRB
1.38-8.06
lrg-sequence.org
galactose-inducible
aptomer
0.530
Danver
tggaccaccaactgcttag
PHF23
oligodeoxyribonucleotides
cancer56,57
minipreps
neuro-fibromin
pCMV–HA
Ly-6G−
R515S
.16-19
resid
RGLKLMSKILQSIAN
radiation.5,9,20
Notch/Delta-like
5'-CCTGGGTGGGCTGCAAGATACTCA-3
geneindicated
c-kit,2
GNAS—the
c.65T
histomorphologically
S:18
hyperacetylation
11/108
p.N1643S
MPL..
patients.3,4
FGFR2WT-pcDNA3.1
JAK/
Smad4-depedent
7,500
ligandmore
5190
AP-1-luciferase
cross-section
48.21-110.23
Bocker
14/57
computer-guided
Non-tumor
dithiothreitol-d1o/5
S.A.A
5′-proximal
.c-MET
osteosarcomas64
MMP
samplethe
FBXW7-Aurora
c.1670GC
16294
boundto
survival=37
2e
TET-ETS
CICDUX4
pcDNA3-Myc
D5S2057
mel*
G162R
anonymized/de-identified
lines1,2
48-96
forK-Ras4bG12D
849KB
1,124
LVUH-shp53
free-radical
ectodomains62
859.4
.Korsmeyer
174,349,350
MAST1
β-catenin/CTNNB1
SB590885-treated
G719AþL833VþA882G
0.93-
delN771insGF
HR†
Y279C-Shp2-expressing
L488P
Δ576c-Kit-
regionimpair
ROS1D2033N
.Structure−Function
mutants.11,12,26,27
43–224
BCR-Abl
MATH-BTB-BACK
LTR-ERK2wt
coimmunoprecipitationassay
database54
5'-TTCTAGATGAGGTAGATG-3
ETh
T168I
4182-90
gmail.com
hMutLα
beryllium
p21-targeted
0.5–12.6
6:1
3-hydroxy-kinase.18
DMRT2
.Suppressor
LacZexpressing
qPCR95
74–98
1-C
cdk2–cyclin
TβR-kinase
DNA.16
EZ-Zyme
NIH-3T3
.Dickson
tissue-related
fourth-filled
TCC/TGACA
163-195
36.0003
R2251Q
LIN-12
protocols3,5,10-14
.PAKs
figure.High
1880-kb
5807
c.2111-2112delCA
KPD
2.42579
nmol/mg
GTCCACC
.G-361
D-Raf
GAA-3′
orienta-
.MUTYH
TARGETS_UP
polyclonalrabbit
domain/nuclear
notable.34
E526K
RAF
39.
Mycos
.G162R
PEBP2β/CBFβ-MYH11
NORE1
G328W*
HCC4011R
Y14
-15A
medecine.unige.ch
Gleich
.14⇓-16Genome-wide
2068
0.28
MLL3Δ
tumors.42
al.,1990
PHRF1
20-50
485/20
therapy.FGFR1/2/3
KIF5B-exon19F1
9.1-
microenvironmentally
riginally
di-methylates
vitro.2
disease6
Supernumerary
.Dividing
D96nt
.Phospho-MET
signature33
p.Glu804Lys
4B–D
c-Metnull
echocardiographer
ASH2
1905
GTP–p21ras
carboplatin/pemetrexed
2869
AR-AF
6.89E−6
A_51_P444447
Anti-MKP1
p.V89L/c.281
genesdev.cshlp.org
loop/β8
multimodular
5'-TCACAAGTTAGAGACAAGCCTGGGCGTGGGCTATATTG-3
K-rasV152G
KMS28
125I-SCF
V995M
104.6
CTCTGGCTAAGCTCCCTGT
infiltrates.Statistical
R113W
comprehension
jelly-roll
Epstein-Barr–encoding
.CtBP=0
log2-scaled
coimmunoprecipitated
anti-Mouse
solution–fixed
retMEN2
NdeI/XhoI-cleaved
UoCM1
N235K
c.1216-
differentiation.24,25
LAN-5
Ala502-Phe506
4G
CD44LOW
well.18
N810Y
.jnci.oxfordjournals.org
ternary
.Asymptotic
erlotinib+MET
leukemia.33,36,38–41
.Adenoviral
WT-2
miRNA-ZEB1
p.G242E
MycN
islet-enriched
Ins20
RCC-predisposing
NPC
PKB-regulated
CEN8
c-METtransfected
water-insoluble
.Medline
Jaboin
SPOP-CRL3
GATA3-shRNA
5′-TGAAGGTCGGAGTCAACGGATTTGGT-3′
tetramer,22
computed-tomography
116/20
ab1971
geminin
1:30,000
Chr3:71021785
F647S
criteria.16,29
822–873
CDK-activating
EK/EK
oligomeric
disease.46
H570R
R-ICE
7=wild
CGGAAGGAATATTCACTTCTAA
β-D-glucose
Bprocessed
p3xFLAG-CMV-mutant-CHK2
Wnt1
Romainville
D816V/H/Y/N
EN-expressing
BMS-754807
palmo-plantar
ETV6-PER1
relapse3
core.TRK-T3
5′-GTATTTGCTTTTTCTGTAAATCATCTG-3′
F564
G,6,7,8,9,10,11,12
G12V/PIK3CA
absense
R202S
pY1230/1234/1235-MET-positive
25-Leu-Leu-Pro-X-Gly-ϕϕ-31
BASCs
SMARTpools
.RDA
mechanism.37
Ac-p53
500
NAMB-1
p.A1789T
0.8–1.0
triazolopyridazines
62–393
SU11274-
W279
zeste-white3
.TRANSLATIONAL
pF1KE0668
palpable
Bi-directional
G12S.20
2.5-252
T/H
May-Gru¨mwald-Giemsa
V529M
C107A
—BCL9
Susini
macrocephaly-capillary
T-lymphotropic
EGFR-delL747_T751+R776H
T766R
Gln61–Arg789
JGI_4.2
−28.9
ActR-IIA/ACVR2
silibinin-induced
E-protein
NUT-transfected
Microarray-based
colour-coded
cancer/normal
castration-associated
.8,24
DP1/APC
V302M
3179–3193
0.99rc6
exonucleolytically
vide
.Kasper
FGFR2C278F/PLCγD
E1024
huntingtin/elongation
BOSC23
ZBP89
c-sis
Diploids—Rates
l−1
Abdollah
±4.8†
kanamycin-resistance
reported.6
615-
Msh2pMsh6p
co-stimulate
1150T→C
V600E16
3.77t
replica-plated
R206H-overexpressed
P8-10
anti-Elk
631-1277
.4388C
58-CACTTGAGCACGATGTC-3
hLKB1
4–11
A588V
p.L550P
WDR48-PDGFRβ
pJET1.2
0.709
B-ALL
20-
conditions.Cell
Ultrascan
28/30
1.1:0.6:1
p44Erkl/p42Erk2
R-spine
GISTIC2
'AJ
0.0660
Figure6B6B
proliferation9–12
S707
-PDGF
.S15B
2,578
Trithorax-domain
PVT-1/MYC
Unresponsiveness
.Accessible
FGF10
Contacts*
chains48
KYSE-220
BRAFWT
3T3/
c.431G
Biotechonology
imageIdentified
.576
uPA
high-ranked
G189R
Mateu
Lorsbach
17q21.3-
Università
GCGGCGGGGC
67.3
p3xFLAG-CMV-10
GlaB-treated
leukemogenesis.1
PIUP4K2A
hIL7R_cP2a
nonisotopically
Ce-Drosha
—are
.2A–B
Quaresima
Hypertelorism`
subdivison
sunitinib-insensitivity
.CYP17A1
0.28WT1
IA–C
hDIS3L
Mut-tetO-KAT
fetal-specific
134375086
Cockroft
G/ml
Thesecond
30–45
E10.5–11.5
disease-bearing
60:20:23:18:11
Hematopoiesis
84.6nM
.RhoA-mediated
p46
NRasQ61K
Y1234∕1235
MSCV-neo
8.24/106
AMG-888
periostin
types12–14
CDC4
telomestatin
KMS-7
annexin-/PI+
megakaryopoiesis.15,16
mechanisms.In
LIM2551
NCT01064921
Ba/F3-G2032R
breast,129
O-911
D16S496
lnH
LAMTOR1
17-02-1-0093
2,347
U29112
DLA
adult-type
MG-B2GFPΔ3263–3380
E40Lc
KRAS-
Smo-dependent
transcriptions,4
Himmelbach
msh2-D6
Pax2
s/cycle
M453T
CML-like
50–150
269–467
gareth.morgan
Socho-gu
BAP170
stimulation.17
cr_Mll3
tumor-suppressor-gene-deficient
Kaplan-Meiermethod
NuMA-RARA
–binding
FOXL2-mediated
G484X
Alk-5
.55A
.Matrix
10010
AKR/J
SA532
electrophysiologic
GeneElute
RG-24N
STAT3.34
FC=1.72
poly-D-lysine
0.2–128.0
.Distinct
–36
Figure5E
loss-of-transactivation
S4I–S4K
trichloroacetic
frGFP
c.448C
intron–
Overactivation
ofPDGFβR
787.2
packages.44
2,576
A169T
UAS53
RP11-81P15
Poloxin
AF086904
D/7–9
cggcgactcgaagctggcgacgacgc
pCMV-SPORT6
culture119
591C
6:1140–1149.10.1158/1940-6207.CAPR-13-0216
1030–43
2D-NMR
S1D–E
4-time
HLA-B*07-specific
250–300
Haarlem
2−5.2XISTX
BCOR-unmutated
R94P
kDA
MASTOCYTOSIS
/C×100
TY6
CCCGAGGAGGGGTGGTCTGAA
F25
G464V
M146I
REX1
p.Asp495ThrfsX26
p.Q613X
norvegicus
Szabowski
reports,18,19
TβR-II
UM-UC-14
372H
105/10-cm
catenanes
v12.1
cancers77
MB468
G1201E
case,34
10g
153–156
.Portions
Jle36
liganding
transformation.1
.Immunoexpression
benchmarks.17
helmut_friess
Associazione
DDR2-specific
D-243
5′-GCAAGTCTAGCCAAGGGCTGCA-3′
Snf2_N
CRC2
kinases/AKT
241850
prototrophs
M-CSFR+
59-89
0-2.0
.DESMOPLASTIC
10–7
AKT2-associated
A.E.Photos
-ttgacaaatgtcagaactggaaa-3
'D
.IKZF1
HPI-4
SESN1
DYEnamic
G305R
CACGTG‐binding
19/836
PPP6C-depleted
alphacarbon
abusive
300o
medulloblastoma27
EGFR-Septin14
CC1st
AT/RT35
+0.02μg/ml
human-mouse
BCL11B-driven
44.57
translationbased
2.08Å
17.7
Ma-Mel-86a
0·01–10
DTC
252*
CAMA1
super-elevation
bindingrunt
NB200–592
nuclease-hypersensitive
Cebpa-Cre
pS3
Y1045
CMV-Renilla
3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL
ÃŸ-cateninfrom
K-mer
5′-CUCUCUGGUUGCAUCUGUC-3′
TableII
smoking-
80Â°C.Thin
WR2721
NM_019945
FLT3genom-r
600C
calcium-biding
mutagen-treated
constructs—insFQEA
Glutamine-61
3Moderate
MUT7
Corradini
non-stressed
previously31
P-CGAGGGCGCGCAGGTCTCCTCCG
383–390Langabeer
MTase
Zn2+-bound
08193
XAR-5
I1171N/T/S
MédiMabs
39/37
PAK1-CCND1
95°C-
un-stimulated
process137
KDM2
Piacibello
AACAAAG
5,530
Figure4G
25-kb
497T
.058
ASXM
mir
.Animal
1388
Ontogeny-based
Fluidigm
N551K
Reverse-phase
.X-axis
I105T
construction.To
streptavidin-bound
p.G449V
p.A592T
FoxO-induced
E121
anti-GAPDH-HRP
AG409
signaling17
R261Q
Overrepresentations
tocomplement
pathway.57
kinase83
K602
.MST
VSN
Mre11Nuc/-
activities42
Val1001
70468-3
23e
anti-p38
concentration=1
aminoallyl-UTP
Cul2-Jade-1
CellsAlthough
GTP-associated
NRAS-BRAF-MEK-ERK
BaF3/TpoR
28046
treatment-resistant
Nitrocellu-
TNG
ZSTK474
Gly171Asp
1993b
Filippova
Ser99Phe
therascreen
145–151
HS6ST2
agaATcatc
life-sparing
GFP-BAP1
DCTN1
SW780
0.18–7.7
fifty-two
1-82
wassubject
ProKinO
IDC-enriched
PIP3-activated
000009
81852
Lin–Sca
SnaBI–MroI
mk
-2A
serum-stimulated
5′-GAGGAAGTCGGTGAAGAACG-3′
5′-CTAAAGCGCATGCTCCAGACT-3
-fold
613670
.85C
.Cancers
​Figure6C
lacI
anking
6AU
M.D.
54h-2
Tyr314
.Twenty-eight
2B23
aligand-independent
hydroxiurea
25:1
61817
ReciprocalRB
www.broadinstitute.org/tumorscape
BCORL1–ELF4
Lin−/IL7Rα−/Sca-1−/c-Kit+/FcγRhigh/CD34+
Hs99999908_
3GQI
.Descending
anti-actin–polyclonal
mTOR/p70S6K
N1297K
controlTumour
128-amino
RP11-642K17
KARPAS-299
0.205
3,355
mTβR-II
Rad-51
polypeptide/
nit
13–17/18
anti-MAPK1/2
RAS-RAF
.Recruitment
I1709T
001001890
V843I-specific
32456
BRAF11
Asp277Tyr
1Ee1
In-vitrogen
.HDACs
progenitors-specific
cells/data
Myc–p300
gene,4
Y397F
phenotype.81
25TK
GT3TKB
SYT/SSX1
3.14-11.12
cholangiosarcoma
year.19
Tan-IIA
G543
trial.64
+Wnt-1
0.36
-0.140
c.231T
CagA/SHP2
zeocin
86745
pRSET-His6-MRE11
BRCA1-BRCA2
apoptosis.22
c.2150C
IVS17+1G→A
disease.Theoretically
1703
hydrocortisone
~2.6-fold
proteinstructure.In
Cowden-disease
1:4
toimmunofluorescence
44–46
Y591
κB
≈450
–225
1P4Q
12149
density/time
heteronuclear
ANLN
SVTCTYSPALNK
Prol637Leu
pancreatic8
-V4
G2032R-mediated
Est14
C57BL/6+129S1/SVImJ
amplification28
RARb2
75bp/75bp
5′-CAAAGGAGACTGCACCATCCGT-3′
TNFRSF10B
Clinical-pathologic
ABBS
MACS1.4
.COS
Rad51/
/10th
pro-malignant
.SNIP1
H1373
promoter74
FGFR2C278F-expressing
ripheral
LGX
axoneme
anti-ERG
7824
1H8
Q-FISH
2/200
intronic
..TT
AML-1B-
2.3-kbp
.Arginine
T466M
morphology.6
emissionfilter
.Wappenschmidt
pluripotency
LZTR-1
+1/–1
Quick-change
NM_001037134
IRAK-4
RP11-278J17
RP11-460H18
polymorphism10
EPR3864
ETV6–FGFR3
D314
7163
.Unbiased
Undifferentiated
FLI1-mediated
Proviral
D114E
benign/possibly
Azechi
R15A
Flag-LKB1
nucleosomes
GFP-C-RAF
Tyr268
patients.35
2/1
BD1000G1
patients158
p85α-inter-SH2
10-cm
rolling-six
allele-targeted
NKLVPFITAVADL
G12D∼A146T∼G60E
TAL1–expressing
p.His1047Tyr
luminol/
X-114
cellSquamous
anti-phospho-PDGFRalpha
JCI85271DS1
TGFβ-receptor
ICDK4
SGT
TOR-dependent119
transactivatioan
\uis
Proviruses
bar=50
ATXR6
Velichutina
Â°5
UPII
NEDD9
Cpuromycin
Aarnio
.Polarity
Codon-Containing
cgi-bin
QMIR
D67E/Y
riskfactor
-sorted
ACTTCGTCGATTCCC
VIII-1
ZNF57
FGFR/Neu
COV504
GSK-3B
94-10
MutationsWe
430
31K
BRCA1-p53
AF064564
0.5-kb
phosphatase–conjugated
BamHI-NEDD4-1F
performance-validated
proteins-the
Lentigines
thanonce
Q4
EP3008
S261N
pSP72
.NC
P37A
-D319N
6934
anti-IRS2
Ac-Lys-NH2
GFP-K-Ras
A1-dependent
APOI1
ab68141
840×
.702G
cancer54
V920A
/xypage/worksmart/tsp000/68480f/41
288
XL-A
AIB1
GLI-responsive
amplification15
ER-repressed
basepair-level
GSEA6
138,050,000–138,300,000
.Neuregulins
q11·2
cascade.22
300K
29-82539041
U6/
Theconcentration
shTAL1-
bindingby
HR.42
1/166
GTPγS-bound
2507–2508
CMV-driven
0.28-0.86
v1.1
Schleif
disease—and
degrons
clinicopathologicalfeatures
Billerrica
worrisome
ERG–MAb-based
F-L
0.00079
oil-immersion
cis-diammine-dichloro-platinum
5′-CCCAACAGGTTGgCCACGTTCAGGTG-3′
5′-GTTAACA
463−k∗
phosphorylates
26-46
4B–4F
DVL
TSC22D1
acetyltransferasepVHL
c-CRK
aacagccctttaaattcagctatgga
PDGFRβD1–D3
.Chromosomes
status.6,15,16
.Switching
Rac
vitro.2,3,10
CTM-2988653
2015a
0.1/
1:90
novo–derived
8•
case1
Pdgfbret/+
DebCav
revealedaltered
.Copeland
S1d
PADMORE
0.5322
.Pure
Jiricny
T9TP53
Gly117
MYCN80
pSPI-luc2
p≤0.031
Histo-Line
pcDNA3.1-vector
GCACAAACTCTCCTACTATGA
T353M
SLX4
Post-transfection
ﬁve
His773_Val774dupHisVal
1–80
HRASV12-
Hematoxylin
ab13847
3–17
PvuII/NcoI
KITV560del
Langmead
Y216/279
SOLiD™
5.91
RAD51C-deficient
S741C
short-spindled
17-81
anergy,1
sc-28698
del/T790M
1984–2004
A229T
MYCL1-amplified
//www.karger.com/WebMaterial/ShowPic/252153
P0042
CACTTOCCT
R6865
Sjoblom
exonuclease
501-
7.39–1126
rL*uGlIyLouTh
melanoma8
c.35
significantfraction
R1076
FOXO1-binding
R552
ALK-Y1604
p.W557G
FDG-PET–CT
Arg531Gly
1792G
receptors/cell
I-SceI-induced
45–80
loss-of-NUMB
4693delAA
Tyr542
g.39,347,347_39,348,479
T5326
MOC
5/80
C634R
.Trp-277
1632
K344E
232–238
.LJM716
hierarchically
FTI
anti-p19ARF
B6.SJL
mechanism—upregulation
Slu7
.BMP7
212-
Knudson2
2987–2989
cancer22
De˛bniak
Breast-175
17544
0.0905
Phospho-S6-Ribosomal
296/617
−170°C
Synchronization
AA/AT
al.,1997a
Rabbit-Alexa
stratifications
Fig.8E
myc-TSC1
.FGFR3-TACC3
pCHl10
ced
50–75mer
S1G–J
HER2T798I/L869R
1,092
Erba
Delta557–558
Penicillin/Streptomycin
99.2
as-yet-unidentified
downsampling
909
+3
1,439
Pro-1776
GFP-RAC1
.150
^9391
3H-I
CMML-1-n
175–225
IBM-compatible
Sykkinase
CMxRos
studies,5,16,17,18
5′-CCCTATGAGATCCGAGTCCA
b-casein
.CgGal4
fi-
E362H
Topoisomerase-2α-mediated
virally
imageThe
TbR-I–HA
56.1-66.9
sunitinib.9
PI3-kinase-Akt-mTOR
two‐tailed
Tazi
31–38
Nordeen
NIH-H1975
V550E
amplification/development
56–83
CRC-16
PTEN189-expression
MEK1-internal
preamplification
Hakai
F476
1895011
FASAY-identified
FBXW7-knockout
9523192
L1750Afs254.4
.DAPI
UCCAG
NCT01945021
1q41-43
SSBP2–JAK2
Mll2+/+
ALK-M1166R
Cavet
red-dUTP
CCGCTCGGCC
switch-II
Phosphorimager
10.1038/ncomms3185
interaction36
Hdmx-E.
0.5370
bacto
EP300-mutated
R493H
H-R175H-72
quasi
Bethanis
∧GTGT
PI3K-PTEN-AKT-upregulating
HD100CAU
V91fs-ter94
Ub-OEt
ERK1/2-MAPK
4.5-kb
ZMYND8
leiomyosarcoma15
ROKβ/ROCK1
.Reprints
HSC/HPCs
2.28μM
lymphoma-2
IL2RG-JAK-STAT
tableClinical
transcriptase-PCR.5
NM_004521
B38-91
flat-cell
23/25
D1304
.20,83
NSD1-NUP98
S934
genes49
NFE2L2G31V
â€¢C..*1
c.6409
syndrome29
FGC
-shLacZ
pGEX-4T1-huNF1-333
HED351V
MYLK
GSE9891
G102E
1257delGAC
tumor-regrowth
Men1F/T
Rheb1
decamer
2697
n=203/279
Multiangle
HiPrep
siently
brain.8
​SIGNIFICANCE
doi:10.1158/1078-0432.CCR-05-0976
NSCLC136
EC1-5
pNOF
ICN1-mutant
ANGUAA
P-H2AX–positive
helical-bundle
.Centromeric
Speckle-type
transprocessing
110,894
plasminogen-related
nitriltriacetate
M199
31year-old
human-in-mouse
TGF-β–
msh2-GD693-VD862p–Msh6p
D849V
Montagna
BamHI/AflII
bisulfite-converted
anti-PDGFR
372–411
E543A
Glu336
HER2-Mutated
gapless
3663–71
p.As
NU-DHL
Barjesteh
bi-nucleated
GCTTTTTCCACTTCCTGTGGCACTCTCCAACAAACAATG
FGFR1•AZD457
563.7
.Cen
mutation.38
∼10
SequiTherm
PMS1/PMS2/MLH3
15,200
ATP-based
ERTOHT
less-than-optimal
pharmaprojects
western-blotting
L147F
hybridization10
directly37
1509
11-week
S2D–
TCEB3B
R31
ASX-Calypso
.CT
‐3
N1228D
pathogenic-or-not
.KRAS-mutant
80–273
MKN74
phosphospecificity
c.del159C
p.D327V
DCS-127
Trovo
signaling.6
PDX-1
mesentericography
w/w
F1174S
bromphenolblue
2413-2435/nt
L63X
disintegrin
.q
BCOR-disruptive
P383S
c.472A4T
A10
PFT
S2.4
reaction.1
pY1135/pY1136
X.50
L52_A174del
Dep
hypoglycemina
PDGFR-like
30.5-gauge
pCDNA3myc-6xhis
GTP/GDP
.Impediments
anti-CXCR4
N-myristoylation
Flag-epitope
.Cell-Based
Westfaelische-Wilhelms
9:550–559
signalling114
BC100/Nonidet
ABF
4,5,20
vivo41
apoptosis.44
1071–1082
W-M
Double-stranded
857
within-group
-AGGGGCAAAAAGGTGCTC-3
finidings
6xhis
c.891
followingthree
sp3
ATMivs38-8T
L597R/Q
ERBB1/ERBB2
-excisional
42-43,64-68
p.R132S
225insA
29:1
psittacii
Ras/Raf//MEK/ERK
CUX1-FGFR1
506–509
K57T
D552N
ARB
described.1
BRD3–NUT
mutations—R249S
Str.
Dδ2
p53-Dependent
C.S.Hill
Knockout
2.5mM
Ank1–Ank4
.adenocarcinoma
ANNOVAR
PDGFR-
R24A
non–lung
PVF
Tyr1253
0.6852
indel/rearrangement
LS-SHP2
NP_524891.1
signaling.19
g/liter
R1124
eachplate
K104C
Hoxa10
factors—F-box
miR-99a
PARP-1-specific
TKIs-induced
tinib,17
-5Finland
C-13
RYBP–MDM2
Bieche
reports23,30
-pRS6-his3D30
burgelab
–HER2
tenascin
p.M1_S8trip
SNF2α
.lpage=5175
26,3
3730-XL
CpHpG
Serine/arginine-Rich
V774dupHV
GGGACAGAAGGAGAAATACAC
12variants
pcDNA3-Myc-TGFBR2
WM983C
10.1172/JCI39703DS1
0.5°C/cycle
NOTCH1−/−
PLX-K031
mini-exon
dimerizationcompetence
5B-nF
Roghi
0.05.ResultsTable
transduction.2
PDGFRβ-F2
.‡P
TElow
cholangiocarincomas
Microfollicular
0.455
Simoneau
.MMP
colony-stimulating-factor
Tet-free
medulloblastomas13,23
SYT/SSX
Glu-207
Nup9349
G487del
hyper-pigmented
5′-CTAGCCATGATGTGCTGCTTCC-3′
categorising
mutated/WT
5-aza-2'-deoxycytidine
EBF1+
phospho-Myc
003225
leukopenia
cancers.22,23
/MLL-MLLT4
58881
Wright–Giemsa
stimulatory
study8
V617F–only
5–63
phospho-Mek1
.05–.81
FANCA-null
c-KIT-negative
7-day
leu2-3
LB940
cAMP/PKA-mediated
His68His
ºthe
IDH1/2-mediated
APC,8
AA398237
Asp1625
miR-34c
overexpressed.32
TGF-b1-resistant
troponin
JAK2/20
HA.AKT21
224–258
non-G-CIMP
phenyl‐2
Arg80-
59-GAAACTATTTGAAATAACTG-39
sarcomas.18-22
.Intact
Gly328Val
Biocomputing
homoand
V463del
IDH1-mutation-induced
28,000
Sup.
hyper-sensitivity
System/HRP
.Zooming
DNAMaster
D579del
1795_1796insA
pCIG
withy
b-catenin–accumulated
plate-wide
suppressive41
30.5
304−595
radioprotection
cholesterol-sensitive
model15
E62A
ethyleneglycoltetraacetic
trimethylase
TKIs.34
870–875
FGF1–FGF10
pFA2-cJun
60ºC
Courtaboeuf
Duolink
SF3B1MUT-containing
5′-TGTCACCTGAGCTGGCATTAC-3′
Vigna
extrapolation
carcinogenetic
AGCA
-3ß
degeneration181
factor.9
p.Asp219Val
spe
background-level
48138
D.L
p21-L2/p21-R2
partby
HIFα
CBL-C384R-expressing
759-1061
Endocytosis
TYGMSPYPG
Kristinsson
'troublemaker
FII/6
Nanozoomer
longitudinally
Glu385
19/102
Glucagon
SNF2-N
Biomol
pSV-β-galactosidase
Asp-Ile-Lys-Leu-GluAsn
EcoRIand
cells/debris
TCF/beta-catenin
1/6
basilar
Ncstn
MYC-epitope
PA12
Mef2
sd=9
Q261X
data.Table
re-assigned
11q22-23
LN-18
Xq13.3
transposons
13-
3B–3E
ERp57
NCT02864992
-chains
W563L
∼1.9
feasible45
MYC/BCL
p.E526Q
G-tetrad
lrasl
13.92
Δ1
line-screening
featuresin
EGFR/pY992-peptide·VO4
Val804
c.922A
AR-specific
FPRC
eﬀect
C-CBL-IRES-Kusabira-Orange
G5544T
Suv39h1
adventitial
EGF-dependent
TProfessional
F198
12–120
HCC-transformed
3-3-gamma
c.6463_6473del
F265L
mastermind
AER
GCAAGCTGACCCTGAAGTTCAT
active-Akt3
.Heatmaps
ExoSAP
//www.med.mun.ca/MMRvariants/
Graziani
Ptprj
Mec1-
Chinen
LCPlanFL
0005.01.003
fibrosarcoma26
527
amplifications—onto
thyroidectomy
985–996
4.2-5.5
bCell
electrocardiographic
1.023
.Enrolled
.Immuno¯uorescence
Amol/L
–Tris-Borate-EDTA
R577L
TÃŸR-Iand
108.8
789plusminus4745
transcript.34
0C
56802458
ras-associated
712R-BD
PD-L1expression
3.2–7.9
cc-11-4059-g5
Daitoku
E365K
dasatinib.48,49
C1483Y
G52K
significanly
fast-spoiled
PBegg
pathohistologic
HCC1500
3′-dUdUCCCGCACCGACAGGAGUUA-5′
chromatin-immunoprecipitation
mutations103
EcoRI
anti-Phospho-PLCγ1
C10H15NO8P–
C-14
F4/80
T‐box‐containing
O1
abnormalities.1
−19.5
Ramucirumab
test.30
15-μl
IC50≈350
Funakoshi
N387P
28,30,31
SupM2
L858R-substituted
gene11–14
///
CAGGAAACAGCTATGACCAGTTTAAGTTCTCTTAGCG
homo‐oligomers
Figure5B
LAN-1
l-54
4′,6′
G1404
TK-RL
co‐activator
RFP-RET
L-X2-L-X3–5-L-X3–5-L
Tsichlis
high-order
WM1791C
NM_002529.3
J.T
pathways.4
factor-starved
UPH
q23–
DEAH-box
Krauter
c.173C
46x
structure‐based
mutations—causes
BND
p.Cys217
PALB
LDS-OECs
A556T
crosssectional
CU127
delCTTC
,61
non-Scottish
Kmt2c
29,825
1LFD
V752A
714506
5B–D
Met-1775.E
rs2289657
EPCAM
Val878Ala
KRASG12C-mutant
K210R
KLHL22
cohort.32
anti-pFGFR
5.
PR-negative
C389G
'mutational
0.29–0.84
1,455
AutoSol
anti-pERK1/2
2.5×103
72/50
reinitiated
c.3290G
S.J.B
KPT-185-ScXPO1*-Ran-RanBP1
phenotype31
FusionMap
Br60-Sk62-64**
0.04*
L348
RhoA-expressing
1000–10
EPIGENETIC
lumilight
D1203
result19
AGGCA
E1Alike
3/26
ERRB2
c.2753C
c.1795delC
p63lo
0.64–2.27
δ
BCR–ABL1–positive
536KB
crizotinib-sensitive
0.01–90.0
R443Q
allele.5
hemagglutinin-ubiquitin
annexin-V-FITC
W71C
leukemias.5–7
I789
M1326T
/extracellular-signal-regulated
substitution.9
.Inducibility
Grothey
L'Arbresle
//www.appliedbiosystems.com
Rheb
Ba/F3-Y568-Y570FF-
9331S
-half
R625G
RXL
Del19
141-222
ampli¢ed
HOXD10
predisposition.27
4.5y
Serum-free
3454_1
.Alignments
//dx.doi.org/10.1053/j.gastro.2013.10.020
.MSH2∷HA
+0.9
5.102
CA-ALK5-induced
KaryoMax
headgroups
shAXL
Tyr1021
diabetes-induced
pro-B-lymphocyte
phenotype28,29
Fcalc|/ΣhklFobs
Yq
tropomy­
32D-FLT3-Y842C
hBRCA1+
LMO2-related
Ponatinib-DDR1
10−12
Linding
Mirtazapine
​Fig.3d
1611
MHH-CALL-4
LGX818
PRKG2r/2
G197R
I360
1841
12q21-q22
Glu64
BAC-derived
KIT/FLT3
types.1
p=0.0167
1.619
HAtagged
MMR18
RC-K8
M.A.R
hyperkeratotic
H1781
C-YL
10.1002/humu.20
Gipf-Oberfrick
Glu158
in¯uenced
0.05M
MIG-BAwt
10.7554
p308AKT
T123
p110δD911A
MnCl229
6.465.4
D1304A
enzyme/min
.FGFR
factor-
894.7
Tet1+/+
.XPLN
.S5
ErbB2-independent
c.708C4T
S1A-E
EpiQuikTM
BrU
4895S
p85αdelR574-T576
modest-frequency
4373
1-min
Metachronous
fluvastatin
patients.5-12
dimerised
MC3T3E1
Pro-B-cell
105:335-340
–80ºC
anti–green
9–mutant
604321
1700.5
1,19
Asp-184
LIFR
HPC4
mpileup
www.emea.europa.eu/
C890A
15·0
ETV6–NCOA2
Holbro
14.32
.Polyubiquitination
phosphorylation-induced
Tapscott
cancer22–25
p.Asp206Tyr
Superpositions
2ivu
Gästeiger-Hückel
Cochrane–Armitage
GGACCTCGATGACTTTAGAAGACGT
ecting
Val654
WT/dis3-D171N
trametinib16
JC8
.6464T
Kinectin
40-48
resistance.We
95–100
1109
autoactivated
SLIT2
.Tsafrif
CD61
9173
masscorresponding
QBend10
inter-Ig-like
IHC.69
Gln1313
S-nitrosylation
p3X
SSNG
Dicer1-mediated
Marsischky
recombination-based
20ug
Asp293
6-O-sulfotransferase
5′-ATCTCACCATTCGGATGAGTCT-3′
Hepa1
fludarabine+
migration/motility
regions—the
humans2
CycM-V5
transformation33
iQ-SYBR-Green-Supermix
Deanehan
PHKG2
1241–1784
Sulphorhodamine
AAV
c.38G
∆26–31
501-502
Hexamers
CAF27
D294H
5421
activation18,47
6/28/00
stathmin/p27
StatMate
c.670+8C→T
CCR1+
p105
30μM
adulthood111
www.med.mun.ca/mmrvariants
trastuzumab-resistant
BW6
www.switchdb.com
CL1-5
Pink1
5,036
ndez
−1.48
TK2
.IGFBP2
FGFR-specific
2,820
.SCNAs
homeostasis
Total-myc
Sequencing.For
2–
.TGFbeta
Gomez-Segui
SRBCT
pBI
5'-TCGTCCATGAGGGCACCGTCTGAAG-3
.1076
calcium/lipid-binding
mRad50Brdm1/mRad50Brdc1
PI-4–P
co-operates
anInk4A/Arf-deficient
Shintani
XbaI/SmaI
Y563N
Rat-1A
5'-ATCCTGGAGTCCACCATGAATGGCCAGCCAAGACC-3
aatcctga
V572L
9180
OsteosarcomaWe
Tbx2
CM–AVM
502-Ala
e3
p53-R280K-treated
pFOPFLASH
singleagent
6s
PLZFRARA.28
26-2
RNAs.12,13
therapeutical
previously5
¨
pLNCX-HA-AKT1-W80A
motif13
3042
non-tolerance
BRCA1-1
C255Y
TCGA-A8-A06Z
SHISA6
tyrosine1068
Gne
pathophysiologic
ID8
GMP–dependent
CDD
G-418
α-GFP
previously.34
Blue-stained
HER3/erbB3
Fop-flash
L777F
MT-MMPs
M848T
Xp21.2-p21.3
b-e
glandular
.P-AKT
L141P
283.69
Full‐exome
thermostated
MAP3K1.60
Yaniv
D594ABRAF
1290–1620
191-146-166-115-198-110
RC20
33445598
EGIL-BII
aggregation-suppressing
D10S532
home-treatment
Collaborazione
mutants34
bound1
conditional-mutant
Nateri
5′-ACGGAATCCCGTAACTC-3′
OVCAR3-positive
_O-_
uorescent
CRAF-B
797-913
10-nucleotide
TGTCATGC
sgRNA-2
RAD51C-
5′-CATGA-GCTATGTCTCCATCG-3′
0.00004
Chr2:29432664
MYCdriven
GTTAACTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC
52
predominated.11
pyrimidine-rich
2-GABPA
lys2z202
neurodegenerative
vector-derived
-independent
method.Prediction
K32
GFP-BRD4
U07343.1
between-replicate
0.159943
NM_007742
post-gastrula-stage
nihms646437t8.jpg
2.2−fold
10-mer
ldh-a
164–172
phosphorylation.27
L147P
NHEJ-initiated
119.3
Y1035C
therearranged
H374R
.CR:18
CBLe7F
plasmiddependentmutation
4,7
pGEX5′and
.Single-cell
1982T
SIM-interacting
nonexchangeable
9451S
cGKIβ6
beta-mercaptoethanol
.Mitsuyoshi
ECnR1
Fluor-S
membrane.7
indexNextWe
SMC
ofR1881
Serviddio
G248R
162°
TBST/5
resuspended
21q21-22
form22
null189Y
HIP1gene
.Chiari
A1
D1–CDK4
.DUSPs
in-appropriate
CCGCCGACTC
Gualco
models7
cells3
p.Tyr2920ArgfsX3
KIT.4Unresectable
E3002
.T58
.Evolutionary
extracellular-domain
G678V
5′-CTGACTCATCCACCTGCTTC-3′
​Fig.3,3
distin-
12144
T239
Omnibank
cleavage26
termini.1
CMV-Mad∆N
.SNU-213
You-Prime
insults.8,9
.Sf9
14-3-3/PMA2
7,27,28
/AF
≥2.2
phenformin
7006.2008.00782
IGFBP-1
3.1-kilobase-pair
E478G
MAG/GTRAGT
C430G
IFAR983/2
pp46
CD30-positive
reported.9,12,13,14
andhomeostasis
Krt
contexts.25–29
.Ishii
0.002686
Schwerzenbach
2.002
'7
over-replication
aldosterone
Segalen
ER71
VAMedical
Imatinib-sensitive
second-leading
T+5
10.1093/abbs/gmv103
p=3.3E-09
5'-TCATAATGCTTGCTCTGATAGGA-3
0.0128
SMARCA4-K798R
immunomodulating
trio-based
PDC
.Immunoblotting
C140R
patients.24
'll
repair.37
nyumc.org
p.Gly914Arg
Nutrilab-CR1
AN-21
affinity-labeling
cellu­
Nishimoto
DMRTA1
complex.However
2y-PFS=33.3
DLBCL14,15,16
syndrome/
Al-Saleem
2,415
.Sohn
transitionmutation
48,52,57
Depakote
error-free
379–396
Anti-b-actin
4.6–9.4
79574
FIII
Grp75
PBK
3D-image
andionizing
H2O2-induced
'bottom
17-hydroxylase
GRCh37.62
NCC-Japan
c1117A
treatment21
V1736A
GST1AF
30.8
-958
HA-HIF2α
Dehm
Leucine
Exon1.3
.Cancer-naive
G719S/C/A
ThermoFisher
Medrano
intermediate-I-risk
EGF-suppressible
334-bp
6j
TRAP150
Xkid
8p11.21–8p11.23
R135W
cancer86
//dcc.icgc.org/web/
signalingA
1934dupG
Artfadilo
Fig4B,4B
transposon
1.9σ
2725
ACNS0121
Squamous-Cell
34-amino-acid
predisposition13
0.0239e
5′-CGCGGATCCTCCTGTCCATCAGTGCCATA-3′
GX
anti-phosphoSer19-MLC
C3ORF10
Ser538
mutations.3,17,18
FIRC
Beckman–Coulter
pcDNA3.1-WIP1-mut-458
R83C
DraIII-EcoRI
trypsin-0.02
−329
Ulnar-Mammary
MEK1-ΔN1
protein–ATP–agarose
aSee
cytometry-coupled
10.1172/JCI43304DS1
erlotinib-sensitizing
multiclonality
sc-94
catholic.ac.kr
type-switching
P=.01
T319E
ACS2,17
tumori-
trkS345
WW3.Fig
luciferaser
pSBE4-dependent
amidite
Q354
promoter.34
IL-3–depleted
attenuate
phosphastase
.4G
AGA-3
Ficoll-Triosil
carboxymethylcellulose/0.25
5-GGGGTCAGGAACTGGGTAGT-3
K198
Olafsson18
E2-9
1792C
Å3
129/Sv
Familial
H83Y
H/R/Y254
proplatelets
M1c
30nM
RoXaN
GTTGCTGACAGTGATGGCTGG3
PR1785F
B583/300
protease-treated
CPGPLOT
allele31.No
GT12-A
Thr197/202
D10S541
Y98H
X/H
59-to-39
complex-mTORC1
RAS-mitogen
MALDI3
428–449
6-PTEN
–15.1
.Coactivator
siRNA-knockdown
CBCANH
534
single-point
EM-
constructs6,7
WHIM5
H213R
Nonpolyposis
glial-cell-line-derived
.Brd4
miR-124-binding
wild-type73-bpPCRproduct
andautoradiography
DHPLC/Surveyor
G464
mutant-biased
FLT3-ITD–diseased
E‐box
excitotoxic
holo-complexes
177Lu-DOTATATE
fication
.MYELODYSPLASTIC
exposure.13
rs11554137
Met1043IIe
FGF17a
HgdP441L
.GenBank
CAGCCAAATTCAG-3′
p.Thr521Ile
His–caspase
intensity×
epidermal-growth-factor–like
KuukasSupported
L983F—demonstrated
Ser68
cells125
HERV
strategyWe
MutRHOA-2A
B-RAF–C-RAF–MEK–ERK
polycistronic
.1.6
context-related
RAS–ERK
HNO3
unacknowledged
pharmacogenomic
p.D61Y
Met/Cys-free
Cyclin
10.Carcinogen-induced
TCGA-19-5958
transplants.16
λTriplEx-CITED2
11q13-q14
trials,57
positive/PI-negative
RcCMV
R481/R509
SHC002
BCOR-RARA/BCL6
0.683
..~~~~~~~~~~~~~~~~~~~~~~~~~~~
.26
Bα-E27R
sHSPs
-treated
pHA-1
NFE2L2G31A
V271
Asp933
atherogenesis
Lopez-Knowles
Hovestadt
cycle31
GPX2
.VEGFR2
N549K
EGFR/pcDNA3.1
TGM1
Annexin-V+/7AAD−
tumorigenesis.9
30703701–30810200NM_001024847NM_004021
acg
-TTGTGCCCCCAAAACCAAG-3
.Dose-dependent
S0392T
CCATAAGGTTTCGTTTCTGTACTCGAGTACAGAAACGAAACCTTAT
SCRIB
3.31
SMAD4-deficient
HMO
crcatcci
dyade
Hossain
GCAGACATTTTAAAGCTGGTTGG
sorafenib—with
33Codons
Tet1-depleted
AAGAATCCAAGTTTGGTATA
+H
NM_176795.2
.Cleavage-stimulation
p-EGFR–negative
MYM
V310E
p110α/p85α-iSH2/PIK-108
Leu-Ala-Val-Ala-Ser
AF-2
372KB
Purandare
nutlin
p=0.27
V832M
postgraduate
pre-viously
CTCACG/gtatgt
study,15
simvastatin
R508H
18-20
proliferation31,32
IRS1
phospho-Smad1/5/8
best‐studied
NRAS-mediated
pepstatine
Yaffe2
HRA
¥
S151D
kBq/ml
/-7
.Binding
1646–1859
4050
adeno-associated
145–300
p16INK4a/pRB
althoughthis
p19/ARF
.EEF1A1
wild-type—is
C121S/G128D
microlitres
Sanchez-Elsner
Tyr754
ACCTGTTGGCGAAGCATTAC
relapse.13
752-bp
HSCs/progenitor
Red–coupled
PAX5-JAK2–expressing
7.49
P.S
status.Bim
280°C
Hughest
11/4/04
IDH2R140Q–t/Flt3ITD
apotential
FOXE1
f:804brate7:0
-GAT
MMP27
EGR2-H384R
endoreduplication
Coinfected
Marcucci
489–491
10−22
prolyl-isomerase33,34
Rosenström
BRE-Luc
H036-1.1
.7351
.6792C
P815
.Skp2
sprouty-related
R256S
HAFA
Flag-Dsh
acids28
52–56
.Runx1m/+
1/80
Alexandrow
RUNX3–cyclin
ab97437
JAK2-L611V
facultative
3-1-3
AGGTTAACTCGAGatgcaggagccgccgttgga
manner20
ATM,7
Akt/tuberin/p70S6K
11.685
CD45.1+45.2+
17,47⇓⇓⇓⇓⇓⇓–54
HIFα-independent
.Scattering
H6908
//www.cancer.gov/cancertopics/types/melanoma
H3K36
1.2N
CUCUGAA
cyIg+
38,60
AACAGTCTACTCAGGTTAT
1–442
domain-coding
p53-Y220C
2035
TrxSARA
8/86
oligohistidine
GeneBridge
—of
p27+/−
r~~~~~~~~~
221m13
06–750
neurofibromasa
Pat.4
5′-AGGCAGCTTGGACACGGCTT-3′
flexibilities
genes.5
Msh2pfrom
OM-1
AML1/promoter
perinatal
GTPgSbound
wasidentified
BRCA1-profi
crizotinib-resistant
kin-cohort
CGP41251/Midostaurin
trametinib.3
markers.26
.Nomination
p.E1172X
haploin-sufficiency
NUP98-HOXA11
IL-5R
CH-4031
Ile100
drug/ATP-binding
Invivogen
A098
Smad3Δc
IgG-negative
L•uGlnH
A-to-I
1×10−8
fertilization
ATR-interacting
frans-activation
immu-
cancer57
glycine-
D619G
sacral
A502_Y503dup
U/L
7.3.1
immunopositivity
interface.27
3-cluster
E1274K
CARMA1-BCL10
SV40T-antigen
counted45
anti-p-ERK1,2
TIL1362
HCC1937EcoR+puroR
G/p.R418G+p.N385Vfs*7
chromatin-mediated
E671
death.2-4
184352
*Patient
2544
RETC634W
Thr1462
phenotypeA
LET-23
2507–2508delAGb
.Q510E-Shp2
r=0.3840
unliganded
M3548
.Stark
18*Thirteen
Martinsson62
5′-gctcagagcctggcatgaa
.5277
testspecific
20-67
Chlamydomonas
shGATA3_2
therho
ESE2
FYB-120/130
margins64
anti-transferrin
.Lysine-935
16.39
leukemia.31,57
E586KBRAF
Bekri
4143
analysisTable
pZNaq-wt
_so
CFU-granulocyte
cycle/PI
ZWINT
3'-diaminobenzidine
pCMV9
variable-width
A389V
chloroacetate
92.20
progression4,5
PIG3/β-actin
Althoughp120GAP
acro-osteolysis
−57
Bioworlde
R6775
G250E
MKN45-
inhibitor4,17,18
.Radioisotopes
V192L
sys­
0,5
CCl4
atthe
PI3Kα-specific
1A
Hypoacetylation
notbeen
MYH11-rearranged
a-32P-labeled
mTOR-targeting
technitium
BEH300
//rulai.cshl.edu/tools/ESE
HA‐Nrf2
-coupled
Green–
E627
P639S
.Macrodissection
.Blastocysts
−a2
μCi/tube
D648N
■R335W
mRNA.26
αPALB2F4
Constructions—V658F
-FANCC
poly-T
Seliciclib
NINPDGFRB
heterodimerizing
100,000AR
90–250
Pi3K/AKT
p.Arg1077
G12C/G12V
145–155
-CAG
5′-CTCAGTGACCTGTTTTGG-3′
-RHDSGLDSMKEEEY
7741
325-648
1074
58-GGGAAGGGAAGCCCATCAACC-38
FISHa
A189V
mechanisms.12
GAGGATGGCCACAAATTAGC
HRE-luc
2/44
7.14
monomolecular
7.59
asymmetrically
data,17
Picksley
1362
.Evidence
neuroblastoma/neuroepithelial
matrigel-matrix-coated
Houdayer
His-Lys-Asp
Imatinib*
0.001t
460.6
c.1484_1488
GW572016
Daumke
TRANSPLANTATION
Verweij
step.37
C~
cell/fat
A259Raf-1
KAP-1
.p
84.6±
p.F57V
hormone-bound
TGF-b2
Saharinen
IgG-conjugated
Comparatively
algorithm.28
hematopoietic—perturbations
G775A
supertrans
41μM.hr
G1971E
gag-pol
Olympus-Meridian
SNU-769A
Kazuto
12,000xg
R245S
amplification.9–11
K27M-mutated
21×109/L
retinomas
Setd2
8.18353425
Dysmegakaryopoiesis
Structure-Based
-TGTTCCTCTAGAATTCATCCAAGGGGGGCCCT
IL-3-stimulated
second-best
//zk.bwh
B56δ
authors.23
J715
Qiao
I744-
SWItch/Sucrose
invasion.23
immunprecipitation
Nrf2‐dependent
BNIP1
multi-kinase
Minipreps
Two-millimeter–diameter
Sequence-verified
30000g
D13S319
bothat
generacer
G1770V
.4794
Seventy-seven
21/22
U83845
test-one
S268W
+664
histone-like
268D21
19–26
hlt
FLT3-WT*
oemutator
N626D
LA1-55n
ELK–SRF
Hata
EGFR-ligand
insertion-deletions
His3w
±0.5
CS07
∼30–40
1/4000
54–59
Okla.
minutes.29
RBM23
Gln61–3O
.Conquering
0.725
ATPfurther
IRES-firefly
.Nausea
`hotspots
pathophysiologically
H1838
latest.6
279V
development,51
3-kinase-PKB/Akt
WWP1-ΔWW
5'-ATTCTATGCAATATGCCTGG-3
CATTTGCTCCAAACTGACCA
transfusional
16.7+
ΔR616
43
PU.1/CEBPα
CCDC6–RET
BRAF/RAS-WT
40/37
12,946
myelofibrosis
Tera1
±14.5
b–h
770_771ins
molura
mdanderson.org
non-SBC
carriers.10
Three–five
myopia
QRT–PCR
viz.
10inversions
c-myc.48
G7rade
allelelic
BMI143
Mixosarcoma
IVS1811G
733–1158
cut-off-filter
.It
2F3307.atom
function17
50mm3
0.85146
279–1315
Tiainen
FIP1L1-PDGFRA/T674I
ROR1/2
DosageWe
Mole´culaire
10.1002/humu.20569
CEV14
2.748
UCGUCGAUCGUCGA
8-4
C15310100
Meletis
SP5
15-hour
SQCC.Significantly
2012-029
www.mwg-biotech.com
neurofibromin
proteosomally
10–54
P-strand
flutamide-LHRH-agonist
PQCXIH-p53S
novo.
CDUhigh
Sid2
cells—but
Post-PCR
20×/0.30
pSBE4
malignancy22
Replatings
Savino,2
database27
,3b
RK5C1
Valcárcel
Hs00195988
133-145
WT-Flt3-32D
TGFRB2
BamHI-Nhel-digested
PRE-Guided
SA496
therapy.9
clear-cell-like
23These
Sirard
inhibitors.Mutant
2J13/98
Ser63
YPEL2
CA-Mek1
+47
GTPbound
cotrans-fected
diagnostic/preoperative
Mel249
gation
SFTPA
~18,000
tetracycline-resistant
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
908delG
MethodsPatientsFamilies
2B2B
-3.3
transferase–mediated
88-year-old
Vibra
Gammie
specification/induction
CCGGTGACGCGATCGCTCCA-3′
//swissmodel.expasy.org/repository
Sturzbecher
32-34
interaction33
hot-
ϵC
8.2/10
matrix-dependent
Cynomolgus
=obstructive
two-nucleotide
Raf-mediated
IDH1-induced
p.Ala116Val
V136A
4983
cyclirl
targetcells
doi:10.1007/s00428-015-1747-2
Nearest-neighbor
700g
850–869
Abl-SPOP-W131G
BRCA1.5382insC
Isotope-Labeled
3,274
MSH6-p.G566R
Y568/570
Ruark
−4.81
caspase-8a/FADD
Group2
AFF1/AF4-MLL56
assays.21
crypts.We
ScanScope
interleukin-17
methionine-depleted
Figs44
*20C
acetyl-H3
.Actuarial
.Downstream
P388/CPT45-GFP-TOP1
sc-17841
parvalbumin
Da.36
c.944_945insA
hASXL1
PEX12
Hdm2-specific
~10-fold
lncRNA
c.1661+12
pYFP-BRCA1-
carcinomas7
2008–January
WA31
tumour3
antiBRCA1
AF071538
343.5
luciferaseactivity
c.770
ERBB2+
1–1365
Monache
.Plot
co-IPs
D4S1548
mMmagnesium
97.53
C336R
KNOCKOUT
non-transactivating
BF683
FPP2-RPP2
years±11.0
ring-binding
mannose-terminated
DMR1881
Procedures.Human
1-TRCN0000074283
.Regulators
left-lower
VA13
PDGFβR
WDR48
AAX92675
pmCFP-H-rasG12V
32,34-36
glomeruli
1.5×
immunotherapeutic
11L
4,7,8
Kucejova
Hippo-independent
ALK
Laufey
Pasteur-Cerba
i~~~~~~~-
theremaining
rescaled
GCATC
Raf-RBD
TTG-GGC
AGATTTAGGTGACACTATAGGAGCTGCTCCAGTTCACTGA
QiAamp
Saiki
K28
Fluoroblok
pY1252/1253
therapy.135
Khani-Hanjani
TFMB-
R24
NURF
ERG11
5405
Oncostatin
VAL193ILE
MPD,5,53,55,56
733O21
89–92
TGCTCACCCG
Oermann
GATA-3fl/+
CCATGGAGCT
.16,17
RPA-T8
α-5
glutamate-oxaloacetate
KIT/Delta559/T670I
pre-coupled
59-GCCCAACGCACCGAATAGT-39
approaches20-22
LAU618
5′-CCT
Saccharomyces
1742-10T
SG-L
monocyte-enriched
Focus-Formation
foreshortened
VRK1-depleted
G4T
3–40
TNFRII
multi-purpose
CDKN2A/p16INK4A
P-AKTS473
4g10
arrowT
bead-based
//research.nhgri.nih.gov/projects/bic/index.shtml
c-Met-specific
cactggccgagggag-3′
++++++-_-
RNAbinding
S636F
pVHLS65L·HIF-1α
Leu-206
SPOP-substrate
Cullin-5
D820A/E/G
heterogeneite
Argi-
Frohling
0.2−7.8
AACCCTTGTCCTTACCAGAACGTTG
JAB1
75.01
PPARγ/retinoid
E413K
pTyr705
AnalysisPFS
Omnigene
41–70
hMSH6Human
ERG-positive
OD420
RFQ-3
Tallini
hTERT-immortalized
50pmol
0.037MLL-PTD
pCDM8
*Alternative
warmspots
18/11
85-90°C
38,42,46
drug-specific
S144
sunitinibdose
chromium-labelled
BR2
72,781
0.135304137
M.J
Thyroid-Specific
AICl3
BCR-ABL7
Brn
DMS-153
.Male
ERK-MEK
0007646
G2032
interpolation
.Gleevec
0-79
SERPIN8B
crizotiinib
translocations.7
Molecular/Vysis
25FXXLF27
shLUC
D737N
1.55-5.34
0.844
chorioallantois16
G.M.
granulocyte/monocyte
PAX5–JAK2
≤1,8
AUC
off-centre
ALK.15
4801
*Quantitative
defect.65
E391K
7/19
H2Bub
ESRP1–RAF1
-IRES-EGFP
.Nucleofection
agaroseformaldehyde
categories1
MAST1/MAST2
Focus/colony
effector-like
−271A
siSAPS/PPP6R
leucovorin
cancers.4,5
NPM-ALK
ICA
.Restoration
HA-M-RAS
embryological
ErbB2/Neu.28
YCe
.Carney-Stratakis
G1249E
superenhancer
anti-centrosome
transformative
Y801Ca
Alk-5-induced
epidemiological
describedin
do-
AMACR
Liyayon
.Breast
AACAAATTGGACTAATCGATACG
protein-equivalent
MET-HGF
0.4816
26,31,32,36,37,39,40
oligomerization-inducing
BCL11B
chr9:5450559-5468477
PT09.2
E8-I9-E9
pan-erbB
.Adorno
Kit-
asbestos-induced
Mowry
Grandori
EIIa-Cre
p.Ser786Phe-XPF
LDS2A
ras-dependent
matrix-activated
−2.5446
.S3D
Shinya
CUCON
antigen-immortalized
Sample009
v-Abl-induced
3-prime
11-c1
Ras-regulatory
Born.9
NCT00854152
rate-liming
PMS2-CL
RAS-GTP.14,16
Sébastien
Focus-Forming
1700bp
L-shape
.‡NIH
InsS
.Residues
.Band
rs121913464
c.526G
Dideoxy
Read-Pairing
intactp16/CDKN2A
R1939Q
1,067
motif.31
0.85–1.15
1.5.0
1701–1743
pGR
GeneProduct
cytokinesis22
T.H
Rad3-related
9235
.FastSNP
Val716Met
ase
Higashimoto
ver.2
models—one
Data|V
carlos.arteaga
Brd4±
MgC12
R448Q
pLX304-blasV5
Esplit
∼38.6
K18E
Leu-540
shrinkage147
FUOV-1
2.5.1
30614–30623
.0802655105
Heatmap
2000–2009
Fig.3d
found.Currently
8-year
.Receptor
airdrying
Hillan
n=3/4
—the
S33F/Y
p.Gly2Ser
cancer.7
Reznik
morphology,39
pBABE-HIF2α
Gln783
A_51_P110301
0–4
Kriaucionis
coding-joint
//repeatmasker.genome.washington.edu
D5
procaspases
V2932
events45,46
riskclassification
MPNs18
G553R
SCF129
set39
Asahimachi-dori
205′
.R
GSK3-dependent
Chest-wall
L747-T751
ERK/mTORC2
condel
1.6–3.9
oo0
26582
E747G
.KPT-185
HCGCCCTCAGCA
56404
ALCL-2
RNA-dependent
MAB7419
protocols60
chemotherapy-refractory
p110α-delP449-L455
Δ552-559
intermediate-power
gastro-jejunal
two-colour
BCOR-3196F/BCOR-3954R
Aveyard
CACGCCTAGATACTCCGGCCTC-3′
19/61
Sixma
specified.2
LEIOMYOMAS
Asia.14-28
RPMI-10
1010–1390
1γ
BRCA2-containing
cells103
IL-3.thumbnail
460
N525S
25a
2-min
1.41-7.58
pseudo-locus
1–17
Pms2
ID29
brosarcoma
Pierce/Thermoscientific
5′-gacctcgcggggctccgtcga-3′
4184de14
5′-CGCTCCGTCTCTATCATGCA-3′
immuno-staining
MDS
sc-5298
8-Oxoguanine
Anti-RhoA
Carboplatin
26094
splicing.17,18
misconception
S6kinase
Asxl1Δ
q21.3
co-activators
R277K
Nicke
D4GDI
RG-29T
cases.7
pcDNA3/His-tagged
childhood149
B2N60
GUSBP11
13.5
23,26,29
Pten+/-mtor+/-
0.851
mucin-positive
fusion—echinoderm
exon.cshl.edu
non–chronic
p70S6
HEAGFPPSDDEDEEGEEFVLDYVEH
473T
5′-gga
Lippincott
OMM
PDGFRA+
R86L
stimulator-responder
Rosa26LsLmBcorA
VIMENTIN
p53-H179Q
SIGLEC10
RAS–guanosine
Dct
9321
Leusden
231481_at
3730x
serumstimulated
pGEX4T-1
Med12
Gly751Arg
noninflammatory
1292A
sitting-drop
AATGGTTCCATCGGCCTAAT
Piskurich
Table11
*9A.30
receptor‐type
340Â
Amplirase
Cryostream
6.12
1636
ARID1A/BRG1
16G8.5
Ehlers–Danlos
−4.26
ANKHD1-EIF4EBP3
NCOR2-ROS1
IGHV4
KRAS–expressing
w2
Xq28-targeted
hereditability
RTK-
TLX3
GABAergic
gene/GAPDH
ER−/PR−
C-C4a
non-potent
IndelGenotyperV2
p110β–Rac1/2
Fifty-microliter
.PPB-FTDS
GGCA-3
HIP13071R
Akt
CH5126766
Akt-overexpressing
.4,7,8
Cottin
origin30
DSG1
T352N
wereshown
m–o
Dpc4/Smad4
Phe1734Ser
B–F
survival112
TCTTTTTGGTGGGTTTCTCTG
acid-0.005
BTK-KD/Dasatinib
7A4G
PIK
TCCTTTTAGGACTT
βGal
ATR-C1
12–15.28
.wIncluding
FASEB
LOC-CNV
expressionFollowing
deadenylate
Flag-M2
melanogenic
concentra-
EWSR1-FLI1-
MicroImaging
321-amino-acid-long
mLats1
Q23R
p.E685
H3224N
1-15
Mg2+
non-Ewing
A:50
13–
Bi1
MLLT11/AF1Q
study.27
MYBPC1
signaling.30
BC†
1,288
Y323
PJS06
colleagues53
frequencies10,20
progression‐free
.Runx1
c.5077_5080
11268
neurotrophins
14.40
potential.Previous
UKO
high-specificity
Leu576del
FIGH-CT-
tumors,4-6
MM57
Clopidogrel
FISH.Spectral
Chk2-
jaundice
1431X
18751
K125Q
458-
inhibition.46
mis-classified
myeloma-associated
rapamycin-sensitive
sc-22778
.graphical
'gene'-transfected
fibronecrotic
activity69
pcDNA3β
desmin-positive
R181Q
pTa
threonine-phosphorylated
RXA2
FGF1−/−
al.12
AGCAGCCCCGTCTGTGTCCT
N25
transcarbamylase
Q53
GBMs––albeit
domain23,24
GCACAAAC
GGCTTCCCACGTGCGCAGCAGGA
MetaSystems
2.7×10−37
I5307.50
UHM
R1872H
rs290487
motif-bin
.W.
161-0380
RUNX1.31
8.92
Ultrasound-guided
Phosphoflow
RAT1-MycER™
.CON
Nb2HP
Y877
Carinci
transactivation-dependent
11,18
TC-30
kinase/lactate
sequence.Fig
A85E
eIF-4A
D1S2449
COSMIC13
HW
7110
−0.617WTNNSplice
rearrangement.26-28
NCT00949455
−.88
MPBT
metachrone
oncogenesis.Our
BRAF-dependent
1.3e
MCL.20,25
TOP1-dependent
GAS6
-JAK-STAT
dbcAMP
0.00144
DCS-5
TAX1BP1
oligo-CGH-arrays
1H–I
307-358
Schroedinger
G215S
23408T/G
cetuximab-binding
oestrogen-responsive
14q24
AY036887
C14
SEC22B-NOTCH2
pDNR-Dual
Ligplot
overpredict
IgM-
specimens7
fibroblasts91,92
incubatingwild-type
CRAF10,12
ElonginCB/Cul2
10–50
thymus-1
-2-butanol
Liver
.Cdk6
47.8–49.3
pRevTRE-V14RhoA
9Rα—ALL-associated
cells.Cells
ABH2-dsDNA
C775insHV
tricho-rhino-pharyngeal
Cys-Ser-Ser-Met-Ser
F4/80+CD11clow/−MRC1+
161C
.Autism
Stukenberg
IRF112
first-response
.ResultsCharacterization
6V
Bristol-Meyers-Squibb
MaxArray
Spry-Grb2
Non-overlapping
less-abundant
One-base
MPR
Kangaspeska
NM_006908.4
Leu13
rs6005863
loci55
.Mutationally
JNK1
ATHB6
Asmentioned
JAK2-V61724
S222D+S226D
S360G
.Venous
KD1
c.1636_1639delGACA
Boehringer-Gasse
M4b
medium-expression
C618G
AD-FANCB
pRK5-SMO
12−14
Tarnier
32P-αCTP
P454S
.Myc-WW-PDGFR
MON702
1.36b
2,837
Rrp44
1and
doxycycline-induced
monosynaptic
ARAF23
.Estrogen-Independent
BLM.23
VAS
4e–f
L34P
130-bp
elonginB/C
cycle.51
AML-1/ETO-mediated
HOXA9-induced
6-histidine
.Ponceau
Pitié-Salpitrière
tacrolimus
wildtype.TABLE
1.07–2.90
bychromatography
mispaired
pTL1
6,169
Accelerat-
142–485
PDGFR—Src–c-Abl
X60152
CODOXM
Lymphoblastic
helix-turn-helixmotif
patients4,5,6
538G-ER
−3.82
mock-infected
patients-derived
46-0092
.N.
AP1-EBS
p.Glu155*
L45
NaOAc
25:2625–2633
5′-AGTTCAGAAAAGGATGGGCG-3′
-456_-453delCCTT
Fast-3/Foxh1b
GCAGCAGCCATCAGGTATT
BNTB
NS/LAH
~1997b
II-18
Sausen
TRIS/HC1
7q21.1-q21.3
c.G3052T
Changea
MLH1-17
Y905
proteindomains
thedeletion
treatment-continuation
p≤0.027
816–823
II..I
C
well-characterized.2,26
10ul
glycine-HCl
c.705+1G
Miyano4,18
effectively.Preventing
TGAAGCAAATTGCCCAAGAC
3.3.5
Spergel
cdx4
Lu5
PIKR1
PR72
8644
14/M
BCAS1
HxD-histidine
Polyribosomes
/CTG
de-Bruijn
E343A
.Anchored
Plasmid-safe
LYMPHOID-SPECIFIC
ITD-containing
.Immortalized
21/27
GTTCAACATCGGCACCAAAT
CAR,24
PCRproductsof
C236F
ss44
AD-FANCA
conceptualization
Okano
p53-Y220C+/+
Predisposing
MET-26RP
www.macrogen.com
pCR2.1-ras
1144
leukemia.20
top-sequence
NM_153207
PCR/direct
Hivep1
cells.According
/1.30
ATCC-CRL
hyperosmolarity
previously,22
Tyr790Met-driven
tumors1-4
affinity-regulating
E/N
oncoprotein-expressing
CATCCTCCCC
Rayasam
Gain-of
IVS16
SKUT2
1465
,12,13
nuclease-free
76,100
profiling1
11.57
4.4-4.8
www.nfdht.nl
molecular-mass
K5.Cre*PR1/Smad2f/wt
HUVEC
GSM718287
Nucleotrap
E689
IAP
non-POLE-exo*
~60,000
PRC3
disease.10
Ahmann
C697F
huntingtin-elongation-A
GenJet
cells–clinical
described.3,4
75235
1q23.1
ECV-mediated
4C10138b
Fin-00014
Sources.—This
CRISPR/Cas9-mediated
1899–5276
found.4
F401G
Ara-C
Fornerod
12.89
HNF6
BRAFV600E.First
.PDGFR-α-null
.Coupling
non-V600-mutant
SKP1-like
noncoding/coding
cancer,9
ERα-binding
β-cells50
4184delTCAA
Three-color
inheritance.3,4
lysine-20
non-deletion
1.07–5.13
acrylate
iSH2p110a
D183G
GdotU
59-O-
CLB94002
Q1071P
andabsence
Val104Leu
220°C
prostase
A17S
Thr382
progression‑free
cells,28,29
progression.38
HGMDs
SRP048759
150–480
N-dimethyl
1-hour
Arg-156
kbp-
M8001
Jorissen
5′GGTCCCGTGGACAGTGAGCA-3′
A013
PtdIns-4,5-P
T7280
-2H-
GAAGGCGCGG
Y872
elsewhere.13
173.3
Cd79b
AAAATCACATTATTGCCAACATGAC
skin107
CstF/BARD1/p53
K196R
CSF1RD1–D5–CSF1
pRCC15,16,17
~7-fold
arrest.49
lyticase
synthetase
Anoikis
Arg172
SETD1
immunoprecipitate
Gcn5/PCAF8
c-Kit.We
ASC
Kuraoka
mice81
N-lobes
268S259D
Otolaryngology
297th
M2i8BR
CD4lowCD8
'rich
0.609
life6
tumor–T-cell
+c
COS-7-transfected
microhomologous
transformingactivity
FLT3-ITD/51
Mxd4
anti-rictor
Cl-10
TGCACTCTAGACTCTACTGCC
features-
YAC1
R90Q
PKP4
PCI-32765
28626789
W.G
LEI
18/18
Hnf4a1
anti-emetics
274–331
modifications.9,10
23.7+0.7
I132T
E1238G
exchange.25
withone
nonconservative
IL-9/JAK
Proteins—F9-differentiated
EGFR-A763_Y764insFQEA
pFR
N5
W73F2
withKpnI
mutations—three
RBi2
c.613A
M2057I
mutation.About
double-variant
5′-GGAG
FLAG-FBXW7
GST-3XCTD
cdc7/ASK
D835A/E/G/N
antagomirs
retransformed
hamartoma
p.Glu207Lys
motif.68
2072
MTB/HR-2239
Asp65Oδ1,2Y35A
Nmyc/pim-1
+4
pseudomyogenic
FLT3-transduced
INC280
type.Cotransfection
ErbB2_ex11-19.R
V600-
CLL-patients
p277-G-K-R-K-K-E-M-T-K-Q-K-E-V-P
NetworkMyc
group4
5′-CCTCAGATAATGAGTACTTCTTCGTTGATTTCAG-3′
FCAMR
rabbit-anti-EGFR
Fbxw7−/−—but
L216F
BRD–NUT
E-positive
EBV-CIMP
Yap65
leucine
I2
Pdeδ-KRas
gene,12
HPV-driven
hSWI/SNF
1/22/4
Rediprime
572635
GGGCCGGTGA
COPADM
F929A
anti-ABL
M3234
calcineurin-nuclear
2,250
others15,20,25
R273H-expressing
λex=
2761G
Lau-
PRODH
pCL-Ampho
AREG55
|log2
.WrightGiemsa
suspendedin
FAM-AGGCATGCTATCCACAGGTGATTG-IABlkFQ
CGdotCG
examined.88
ACCGTCAGTACGTGAGATATCCTT
Kix
g_hbond
140,000-dalton
IBC1-3
MSH6-germline-variant
MYCN-transgenic
cost.2
quences
T210.1–T210.8
.TSC1-null
Axiovert
EML4-ALKG1202R
.TGF-beta
0.019
StrepII-CycM
neuro-oncologist
analysed16,17
Y913C
.Tyr576
D16S3026-
E165del
STYXL1
LBH-expressing
12·5
S329P
A_51_P437240
reverse-transfected
EF.RhoA.V14
15–70
Transfast
clonesharbored
GDLM-9
RKTG
A335
p21waf-1
209-times
.Maintenance
TCGA-HB-A43Z-01
re-treated
39/106
myc-Jade-1
9,733
mM,21.2715.0
genes—SF3B1
13q-
1.96×103
.8754
7q11.2
2J
1.64-fold
6-17
Gulino
CCAAAAAAGCCAGATTATGA
anti-Smad2/3
gelatin-coated
immunuoprecipitated
.Fibroblasts
AMAXA
Single-cell-derived
IGL
mDNA
5RSDA2
40000-1
5′-CAGCTAATAAGCCAGCCTGTCTCATAAGC-3′
biochemicaldata
ERBB3/PI3K/Akt
myelofibrosis6
R2150L
isoAbbreviations
L313M
.SCR
thereactions
H1112H
toKOH-treated
n\
inter-vention
CRM-1-dependent
//gene.gmi.ac.kr
1.078
RTK-target
PMS2ΔC-ΔNLS
Tor1aip2
dexamethasone17
hsdS
D29
phospho-kinase
2,38
30-35
71.3
post-initiation
p.Met1_Arg359
Howell-Jolly
Aalpha
UC-rich
Sex
damage7,19,20
Intrathymic
pedigrees.10Heterozygous
Rooij
259015
66-year
terminated.Properties
3.869e
-interacting
Protein-A
203/10/41/42/0/4
simulat
.Tuning
67,000
aFGF
5f–j
PLK-1
centromerically
GSE13429
homology3
Yilmaz
Fibrous
differentiation.13-15
RET-KD-P·PP1
PTPN5
G417P
5'tgagagcttgtttttcactgga
BRAF-inhibitor
auxotrophic
bispecific
CDK4/6
tumour-cell
submicromolar
0.771
RÃ©f.49
00
trisphosphate-dependent
Q527
GIT2/f2
1.40–4.99
del738-75
NCOA1
SLC38A10
I332T
levelsTrizol
.Mutant
multi-hit
phenotype.4
one-binder
C441F
heavily-pretreated
diameter2
BRD4-NUT-negative
439–471
Euromedex
Variousc
12,718
lymphomas.23
Meignan
10.1002
q22q23
campomelic
1.717
1.2-Mb
Pretreatment-Solution
V413L
HCM14
A=38.5
anti-ret
co-occupies
SD=stable
Immunoblots
293-EBNA
unit–erythroid
TGCTGTAGCCGTAT-3′
AAACTCGAGTCAGACTGTGGCAGGGAAA
Selkoe
exclusive.9
conﬁrmed
maytansine
4K–M
31F12
BRAF-targeting
ComNet
Intra-patient
YUMAC-TIM
.Wash
Runcorn
two-water
Arg1107Val
AACAATAGTTGGCCGGCGAG
TTACTCTCGCCCAAGCGAG
5q14
N-methyl-N
RMPI-1640
mutation22
V55L
ApReceived
c.529dupC
pCMV6-Entry-FLAG
P-0005214-T01-IM5
952
3,3′diaminobenzidine
low-dose
double-blocked
p52-deficient
MLH1–PMS2
radio-sensitivity
101.2
somaticchanges
proteins.Subcellular
Ly6
PBF-specific
1490
R292C
involvepE3-WT
falciforme
1INSERM
positive/
Mtb
acumen
Elisei
Leu245ThrfsX19
proviruses
14/1248
log-linear
rearrangement.5-7
dome-like
pDM10-1
subconfluent
3640
mutants-expressing
.3788
D21S211
Asp-354
GISTsbeing
p=2E-05
'open
DdeI
G1633A
1:20
Rad51.Fig
EGFR.The
E1155*
Ser43
p27CK−
IGF-IRβ
Warzecha
2Cand
4=,6-diamidino-2-phenylin-dole
domain-lacking
Zeocin
pQCXIN/TrkB
Interstitial
PD‐L1
PO1
aQuant-iT
CTGCAACTCATGTTTCCTTGTC
D814H
D761N
ligation10
.Ready-to-use
−1.85
microvillar
dimerization28
R183Q
617-871-
Polybrene/ml
512_931del
Hägerstrand
anti-p34cdc2
ApaI-digested
.561
macrometastases
.G525
trials.32,33
Thermoflow
ysPh..
28,40
Tyr1003
haploid
37535
amplification30
m13-tailed
step-down
question—Are
0*
v.8.8.7
family.3
background21
100‐fold
W179R
4ml
EGFR/erbB-1
.APOI1
www.endocrinology-journals.org
Fig.1A–F1A–F
38–49
PAX2
BamHI-XbaI
OCUM‐2M
IDH1-mutated/G-CIMP+
uni-
persephin
GFP-TOP1-expressing
antiangiogenic
gplotrk
JAK2V167F
colonies/cm2
'90
bioluminiscence—7
HCH
animportant
Cowherd
NOS
mesylate24
typically-presenting
OLIG1
Val131
.81264825
dideoxy-chain-termination
cAMPPDE
HLHS
-99.5
Drosophila17-20
A1459P
Millipede
1619del25
Zymed-Invitrogen
8×60k
p3X-
rs10525052
m−2
.79
Ser719Ile
34–64
.MES
AT7LA
GCCTTGACGGTGCCATGGAATTTG
env
S6S235/236
1-10
PgR+
NAF1
15q15
sequestring
Cocalico
Karni
5.0–12.0
Guidoboni
**
mMTris-HCl
G1–3
Rangatia
33,35
CTTGACAATGTGTACG
PolD1
fromhttp
pCMV5-TGFBR1*6A-HA-Flag
2-21
6823
T‐domain‐containing
B-cell–progenitor
RETE805K-
p.I219V
heterocyclic
Semagacestat
TATGGGGCCAACTTCTGC
c.6409delTT
//www.bioconductor.org
cells/non-stem
pagetoid
XNP139
F39L/C20R
X4
Preparatory
anti-CD40
phosphotyrosine-associated
C39
Flk2+
manner70
E746_T751
17·0
E12
Perbal
self-responsibility
33.3–45
octyl-esters
I151
F341C
casesThe
UNC-LCCC
ATCCATCAGGGCACGGTAGAAGTT
NPXpY
serial-replating
cDNA-based
MRD2
.Han
KODN
Re1
loop10
lapatinib.25
H201R
GST-Jun
M-dependent
T556A
iCluster13
T1977
Cdc73
R14W
high-concentration
V13L
score0.5
CFP-AFFAQLQLDPETGELL
Classes…
nonmosaic
Stevenage
26-week-old
Folylpolyglutamate
Garcia-Martinez
2110–2117
Porcupine
0.5–6.6
‐furanone
12511-3
Glu685Val
NCI-H2122
brucei
12q15
High-level
EEF126–8
ncomycin
1561delAG
SUP-M2AR500A
Pro/Arg
Zhimin
'Fragmented
VBP
//doi.org/10.1371/journal.pone.0103021.g003
Footprinted
Linden
nuclear-cytoplasmic
A-rich
anti-p70frk
methylation-high
7*
Introgen
radioanalytic
2/38
-CD16/56
0.69–1.28
pedigree/uninformative
A344P
HBEGF
pattern41
5X
clonesRP11-74L18
Colcemid
quality-score
leiomyomas.20
phospho-Smad2
TERT-BRAF/RAS
2262_2263insG
KIT–imatinib
Lazaris-Karatzas
Classon
AdNeg
rs138213197
TRMP
1.7-2.5
leukemiaConsidering
RLuc
testing13
Kras-mutated
P=0.042
Larger-scale
CRL4DCAF1-mediated
.MSI-H
water.Mutation
NotI/SmaI
instructions.Survival
001195132NM
p.T82I
pE1A
envelope–specific
others5,6
KIT-low
R20
Pab246
co-precipitating
SMC2structural
KRAS-inducible
cohesion/chromatin
SLC2A12
47.8
.Yoshitaka
I941R/D837A
Ser144Ile
Cytometric
pSRa/MSV/TKneo
*not
human-rodent
NT_007731
hMutSα·Mismatch
Tris-acetate/3-8
14.6
2J1X
MEK1-driven
TAQ
biomarker-selected
Gender/age
CTLA4Ig
population-level
study,52
.V5-catCS428C/D486N
.Heterozygous
harmatoma
p16INK4a-inactivating
β-catenin-TCF/LEF
//app1.bioinformatics.mdanderson.org/tcpa/_design/basic/index.html
IL-2R–FAT-IC
subendothelium
Y72H
.Chromatogram
dsRNAs
Fibrolamellar
D21099
AXL-mediated
CD19-cre
overex-pression
80.6
A488
cytoxin-associated
p21-dependent
Skp2
pWzl-Neo-Myr-Flag
Asxl1
C-4
NPCBX3
mutation.2,4,8,20,26,29
GCTGAGAA
21/53.8
fibroblasts.5
Homologue
P-LC34T
domain7
PET112
Annovar
NaCitrate
3pLOH
13443
Dll4flox/flox
AAATACTGGGAGGAGGAGGAAGG
Nrc31
Gli-luc
MYOD
Jinling
R228G
p.Ala626Glu
C-RAF-mediated
Henikoff
manner.NIH
tissue-containing
Yes−/−
2G–2K
Vav-cre–mediated
9361
onlySample
effector-loop
4232
0-34
POLE1-mutated
N0TRK1
Y408
centrin-2
G380
c.803T4C
MFM
37.5–85.4
single-breakpoint
FOXO1a
ID:3H9R
wereexcluded
835G
nephroma
1,203
three-axes
diC8-phosphatydilinositol
ARE-CAT
0.937
5,688
ABI3100
c.1794_1795insGTT
post-Nutlin
.FASAY
isointense
manner.30,34
.Prevalence
Beg
78·0
/N30
8.338e
Ro-31-8220
INCB018424
prefractionated
16p
S290F
3396
Touton-like
kinases30
937A
0.56TBE
0/47
non-cirrhotic
miR-146b
TCFL1/VPS72
C15orf55-002
patients.10
E219
Y371D
K531
KPT-SINE
P.H.T
N581I
4p16
forvarious
~50,000
Δ1–1526
10/5
GCTGTTTCAAATGCCTACCTCT
ImmunohistochemistryMore
12,18
-CGCGTCCGCGCCATGAC
665752
650–657
kinase-YT
heterozygos
000
−X
benzonase
piperazine-N
PBEQ-Solver
Nuclear-confined
S55F
I22T
42,160
tenuous
1SM2
activity.53
Brauchburg
GTCGT
disease–neuroblastoma
bronectin-coated
0.02-2.02
TRRAP-independent
the32P-labeled
.8,11,12
.Lethally-irradiated
nonfasting
theβ
cyclins44
vismodegib-treated
c-Kit+/lineage−
calcium-
1566
E250K
2/lane
E478KCRAF
IVS22-15delTTC
1.4
127.7
Wordeman
Bensaad
A088
YAC927G5
0.9–1.0
.T286
indeterminate
anti-CD19
deoxynudeotidyl
Elomri
201010
Lys601_Trp604del
B-RafV600E
1:250-1:1000
hChk1
LDKPdnCPdmLFeLNRmCWQyNPkmRpSFl
4q12–13
c-17
BssSI
.Misdiagnosis
311900
.Gray
SQ-20B
40,068
MBs.3
SH2Bb
reconfirming
Mst1
N=75
0.117
'classical
//www.icp.ucl.ac.be/vikkula/VAdb/home.php
GK1.5
directly.16
Calnan
TKIs.8,11,15
PI3kinase
Akt2/PKBβ
mels*-BRAFV600E
Asn-116
Lin−/IL7Rα+/Sca-1low/c-Kitlow
carboplatin/gemcitabine
9q22.3
PMS2-WT
ROSANotch
13.0+
misfolding
anti-phospho-P15
Bergonie
p.Arg267His
Pbx3
neutrophils,37
v9
BLN22,23
FLT3-ITD-NPOS
pathway.16-19
.Antibody-reactivity
E4a
EF-plink
p.T1052M9
Nall-l
dynamics-Rho
11/81
1.50–12.20
MED12_WT
N635S
000-25
2Fs10120-013-0298-y/MediaObjects/10120_2013_298_Fig1_HTML.gif
SSCP
Igκ
wnt
Amplitaq
differentiation.14,15
neurofilament-positive
350-bp
1/114
0.0635e
R282G
U2OS
double-stand
0.2550
158.5
.Pten
NM_007633
ITGA8
GIST.8-10
Bcr-Abl-expressing
immunoprecipitates
90-day
NBP1-01032
Bloom-Richardson
IVV
HRASG12D
DHX9
XL1-Red
44/F
post-injection
T399I
Solution-hybridization
Laconi
1.802
cyclin/cdk2
pSCW367
package70
pT3/4
TPR-MET–transformed
2194A15
0.2705
Azami-Green–negative
HSP70/RET
BRCT-M1775R
TATGAGGAAGAAATCAAGA
sirtuin
mg33258
.Ferrone
UMD-BRCA1d
100W
inour
CHOP.17
bilayered
p-akt
3.2.3
509
.Organoid
.I24N
magna
Fairfax
11,633
Efstathiou
Activation…
28,141
219-fold
BSRBI
61·0
BCR-ABL-induced
R158R
hepatobilliary
,2-4
.Pull
p=0.0002
GATA3-enriched
GFLs110
15.8
2.98+0.10
1.5–12.5
R510Q
Kleefstra
SRC-3-regulated
Y88C
0/25
Fig.1A–B
autophosporylation
rs16892766
haveconcluded
pyrograms
Centromeric
S815L
PEBP2alphaC/CBFA3/AML2
ReddUTP
Wilms-tumorassociated
.Unauthorized
nonmodular
HR-/ERBB2+
Subclavian-artery
Luh
jordi.surralles
mayfail
Table11B
p120-GAP-catalyzed
KIAA0876
TLR
semi-adherent
.Retrovirus
6.73
nihms820730f8.jpg
pRL-null
helix–loop–helix/leucine
5EGFR
.Disturbed
Ser-22
Seewald
Dovitinib-resistant
inositol-3-kinase
Strataprep
10-10
HAC
estrogen-inducible
VCB-Cul2
Groden
Pcorrected=0.006
15,31-33
G331C
Wijker
AAF47691
vitro.18
SX21
Arg248
fivepositive
SPOPMATH-BTB
p16-131R
I89T
.Plasma
Adv
distributedwith
Abbreviations—–CISH
72.1±6.6
ofoligonucleolidcprimers
n=3/3
Wardelmann
cancer6,10
0.0742
site29
Ser1000
56–258
D146nt
4A-C
Non-targeted
SMHC
p16a
jengelman
2149
AX-70
leupeptin/mL
T7-18
RBI
β2m
MMS-derived
electrofocusing
n=68
hydroxylapatite
4277
-L2
D22S689.214
Pena-Llops
Carboplatin/Paclitaxel
trk37
V1838E
Mollehaven
SPSSv16.0
50.5/Mb
cyclindependent
–PCR
Bousset
486–487
IL-4Rα
.Low-quality
recruited.39
S6B
261
20-amino-acid
TRE-MET
Ror2
pCDH511b
nonhematologic
pMSCV-ETV6
Elior
R202H
q12q21
+-
tumor-microenvironment
Blahnik
p.Gly191Asp
intersomitic
5′-cagtggaccactgtcatcgaagccaccttccatgtg-3′
LTK-14
≥18
4370
fastermigrating
Twenty-microliter
.455
NM_024556
NAP57-interacting
Almholt
7.16.4
−2.18
Pluripotency
kinase-mediated
T4d
56801448
1,667
2929
v-H-Ras
103~4
caspase-8-negative
cohort19
Myc‐like
anti‐apoptotic
Tgfbr1fl/+
CT.22
Hs.496943
sequence17
S-adenosylmethionine
nanoliter
CE-
4880–4890
interactions20
bitransgenicp53
FLJ11036−5.1GLS2Glutaminase
p-Chk2
anti-CSF1R
dance-like
dodecylsulfate
J48+KNN
domain.21
genetic/molecular
ΔΨm
SRC-1
c.91_92delinsTG
0.7-17.0
Ala767
residue.2
J6I/JXI
TGTTAGTCTCACCTCCAAGTCC
L/MED
2:1
4.5-ml
hShp2K590R
K-Ras4bRNA
PP1
61-10
TREM-1
Argonaute
patients.48
a′
C124A
T1340C
19:594–600
pRad50K22M
parafi
phosphorylationn
seromucinous
HCV-positive
or-
2478C
21666668
5p13.2
TRF2
modifications.Table
AACAGCTATGACCATGGGCTGGA
T315I/Y253H
s-KB
Neurospora
posttransplant
Nucleotide
45.91
​and4L
PTEN/p53
p4-p9
features.DiscussionHere
.Bacterial
0,99
HER3
±0.9
co-stimulation
α–GATA-3
studies153
G665X
.Anti-pMEK1/2
35-55
79D7
HD-0246
K232R
Intestinal-specific
.S2H
c.93delG
total-drug
non-observed
Piwi/Argonaute/Zwille
vitroPI3Kα
alteration/in-frame
thrombospondin-J
59•
Meuwissen
KEAP1-
Sermet-Gaudelus
gvs.gs.washington.edu
G224A
mTERT
permeabilised
raÃ-alÃ-eleand/or
cellularity16
Phe84
Asxl1-bound
31,874–31,630
X29
MLN120B
carboxy-terminally
SA536
sc-135651
Nck
5-GAAGGGCACTTCAAACCAGTG-3
c.118_135del18
eleven-nineteen
Caux-Moncoutier
FAB-based
EWSR1-DDIT3
6A–E
2.3–20.8
M397
domains.173
KuOr
SK-OV
S40110
proximal/distal
non-cognitive
−0.11176
V600B-RAF
Winterpacht
WT-NHUC
Yardena
S577P
5-ranking
:75.5–98.2
G2/M-phases
5'-TCCCCAGGTCCTCACAGAT-3
o5724-o5703
strand-cleavage
pcDNA3-C/EBPβ
163N
pH.7.9
MET-D1246N
.Overlays
Croonquist
3′-ends
TTGAGGATCCCGCCAGGCCAGTCCCTACTAC
myelogenic
​Figure3B3B
AURKA–INPP5E
PU10
RealignerTargetCreator
21,19
5′-TTTGAACTCTTTGTTTTCATGTCTT-3′/5′-TGAGACAATGGCAGGATTG
safran
one-water
cytokine-binding
MC3T3
837
chemica
PARP14
Wtsi
doi:10.1172/JCI78782DS1
pGEM-T-Easy
fo-
–51
NM_010207
PTK-encoding
cis-prolines
Alterations*
Y877-unphosphorylated
AXL
500-kb
Ser9/21
genesWe
cytotoxicity.HSC536N
T2/FLAIR
thiol-ester
48-derivatives
polychromasia
gfap
five-stranded
anti-BrdU-POD
4-E-BP1
atttag/CGGCAG
2.18
exon21
snphosphatidyl
NVB
2.5–2.7
Lv-GFP
5′-AAGACTGCCAACTAATAGTCACGT-3′
14q24.3
Y517F
Hot-spots
DLBCL15
C12orf26
Gli-targeted
www.oncomine.com
ZAP70
D609G
AML1-ETO-induced
W557_V559delinsC
AUY922
Jürgen
0.005045
R18F
pBG2.8
0.002791424
193,000
miR-98
Mlh1-knockdown
anti-STAT5a/
S11A
patients.93
CHOP.16,17
non-JAK2
LUC14
89.36
prolactin-secreting
FLT3JM-S
McCune–Albright
lyo-philized
Arg-87
DNA/6
P539S
EN-Y513F
IGF-1/2
aBglII
SDC4–ROS1
C–F
hERa-Y537N
instigate
foci.A
MSH6-24
B-findings
pp53
LIIGAFVSEPQIIQERPLTNKLKRKRRPTSGLHPEDFIKKADLAVQKTPEMINQGTNQTE
.72.7
9-fold
Uptake
D1-T286R-KE
.XRCC2
.PANC1
intron-length
1,2-dioleoyl-sn-glycero-3-phosphocholine
SMO-L412F
STK11/KEAP1
DRBl*04-
.29,30
GTAGGTTTCTAAACATCAAGAAAC
pCDH511b-G328V-ACVR1
50-mm
Literature-derived
2eb1
gene–disrupted
metastasis65,101
p338CRAF
study-specific
190-amino-acid
.T.
Corradetti
noprecipitates
Elf3-cooperating
mutation,4
.Chvostek
interaction39
2.4–13.8
IDDM2
S3C–S3E
tivities
ophthalmology
described.51
intronic/exonic
erm1000
c.14252-6_14252-5insGAAA
cial
207-kb
.Increasingly
.All-trans
promoted/repressed
.PBMC
Ser-8
Y605S
Aulmann
α1-adrenergic
.Brightfield
binomical
non-classifiable
12/L
test.16
ggaatgcaagctcattgtga
1−9.7FGFBP1Heparin-binding
dermatopathologist
0.06-1.03
cacgagatcctctctctaaaatcactgagcaggag
Nu/SP43-1
180K
Figures5,5
19946
:743–8
p.G12S
hMSH6ver
co-repressors125
340A
TRIS-acetate
TIR-domain
family.5
apamin-sensitive
Hypersecretory
constitutively-active
GST–merlin
transplantable
Mslow-pair
S3F–G
11.63
∼53
PDGFRαJ/J
12.7160675
Ser47Thr
0.345
-EF7
.IPC
nitrotyrosine
40.0
endoderm.32
resectable
MG-B2GFPΔ2889–3418
P262T
galactose-containing
methylphenidate
7Altered
FOP-plus
I90T
7C
D5S436
A007
c.519G
p.K382E
hyper-ECL
self-care
I216S
3F-G
MK2206
mid-loop
WT8…
1,527
OR=0.93
6.243485125
BC-proband
3′-flanking
signif
_+++NDNDND+NDNDNDNDNDBands
32.96
ddCt
Ragulator/RAG
UTR/Exon1-2
Sadanandam
Gripp
sc-69879
1.29-16.62
~1,100-kb
SNP3D
Arid1a
T681I-
others39
mantGDP
DDR2-driven
973-235-
4/11
C135/229S
pLL3.7
yetother
WT-ERG
þþ
Co-inhibition
Y-MESO-25
MPL-W515K
NODD
ABC-derived
V122M
p59xDR-GFP6-
isomerase45
domain-TSC2
MDM2-positive
Ser15and
activation4,5
INPP4B-2
pAd/
epi/genetic
MPNs.27
A.T
DO3
intussusceptive
G423V
observa­
308–309
aneuploidies.Figure
xb
less-effective
RhoAinduced
13,15,17,18,35,44
1345–1368
eld
5′-AAAATGGCGTCCACGGATTAC-3′
NDL
14.26
E1F
19-22
06029
proliferation.63
Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-AlaAla-Arg-Gly
T7-amplified
1284–1669
PHx
JAK-1/2/3
Genome-edited
dermal-like
Fbw7/PKC
Mac-1/Gr-1
described29
-93
SNaPshot14
qRTPCR
pCR4/TOPO
FAF
Jnk1
1.480
K54
c1
NUP
G70220
earlier.16
BCL-XL226
Wtsi/+
CHD1−/
histomorphology
disease.15
3O
.Contribution
PIK3CBA1048V
FLT3-ITD/F691
G333C
0-192
5′-32P-labeled
HBEC
calcification-prone
729–731
Somaticmutations
start=1
ZR-75
mutant.MMS
.IntOgen
5'-ATCTAATGTAATGGGTCCAC-3
MigR1
A21E
ATP-driven
CuffDiff
-GGC
p.Gly2281_Asp2312
ATGCAAAT
4724
2,8,18
Hammet
FGS
D-dependent
analyses-ARID1A-MAST2
TCF7L2/TCF-4
rs61758784
.703
moreinteractions
clusters.10
leupeptin.The
F-box/WD
Bev
ampullarycarcinomas
Myr-removed
††P
receptor-β
IP-on-IP
myelofibrosis.58
ofwild-type
p-EGFR-positive
Asp354
proxim-
G-proteins
p116
different.b
respectively.12
CCTCAG/gtaaca
.Transgene
NM_173745
10-s
p.S815L
.JIKÃŽS
Neutrophils/granulocytes
57.9
P=0.242
W10
inter-SH2
fusions7
al.,1995
WHIM2
V387M
p.S140A1H143A
Cl-
cells.55-57
non-encapsulated
TTTAGGATTTCTTTCACGCTGT
C387
Neuroradiology
CD45RA−CCR7−
2012Youngs
sc-7148
4,11,28,29,53,58-67
DNA6103
`atrogenes
ELK-I
R468Q
3'-dephospho-Lys-CoA14
58-89
WM3152
.Precancerous
gene-2
AKT1-expressing
RasGrp3
Casper/I-FLICE/FLAME-1/CASH/CLARP/MRIT/Usurpin
Mitochondria-rich
PTEN-PI
RPN1-JAK2
blasticidine
42,74,75
clinicoclinicopathological
L1407
MEK1WT
.Strain
response24
25.7–44.2
min-flanking-quality
needed.As
c.1995
IGF1R-independent
sub~loning.~
A56T
abnormalities*
IL35
R183G
pGL2BTCF4
K85A
GFP/YFP+
CstF2
WEHI-free
2683-2711
11.92
10nm
33P-ATP
FDG-PET/CT
.Q120E
3p21.2-p21.31
Gilad
K758*
K935
67–100
*Analyzed
50-kD
V76
Ras-isoform-specific
EIAF/PEA3
pCAGGS-FLPe
partners24,25
sonidegib102
2032–2035
Watson13
Funahashi
CTD-2303L4
403-amino
SMARCB1−/−
value.37–39
p11·3
3000–5000
resolution.4
papulopustules
Fluoride
PXK
5′-CCTCCCACCATTGAACTGTT-3′
PT3004
.Focus-Forming
14,24-27
JAK1-induced
gpl4Ot'k
TKI-bound
MSCV-derived
TMPRSS2/ERG
Hs233648
69061259
88.77
B56δ-Aα-R182W
deformability
CBFB-MYH11
771_773
Asn-268
Transcripter
1078-1083
F54
QIA
SNU-878
–ARE
unligated
Smaill
MMP-7
CX1/HT29
2551
IVS10-6T
Cullinan
Sigma-Aldtrich
bacu
1195–1658
AZD6244-Resistant
10q11.2
patirnts
gene-targeting
Audard
hFGFR3-expressing
figure4A4A
.Microphotographs
HumanOmni2.5-8
22-57
ubiquitination-mediated
p.Ala148Trpfs*26
Characteristically
632-648
.Mismatch-binding
antigen‐peptide
Ujiie
21/910
Met1411Thr
Mga
156–158
p.Y652H
ex4-6del
SP53
V136I
9-18
cell-level
CMMR-D.
BRCA15
craniofacial-severity-index
APC-deficient
.T790M
serine-9
700bp
MutationsSequencing
transformation/protein
Jak2/STAT5
RAC–GAP
454-Titanium
4993C
.Stripping
EcoRI­
NSCLC.7-10
siRNA-bound
138:629-35
Brca2-Deficient
pGEX6p-2
MSH2-PROR
.217wild-typeFIG
61:2912–2923
UCSC23
-Phe151
IL-2/3
1980s
G3
PTP1B·EGFR
598
Emeryville
p85/pl
RKIP_E3_R
statusa
18.7/21.2
no.27
pET-26b
observed.We
andyet
sc101199
CP-257042
N345I
Japan,33
Technologies-Invitrogen
746777
ARHGEF12
Exp.
GFP/YFP+Mac1+
allelespecific
Busslinger
HCT-15-derived
Saucedo-Cardenas
398
0.62–2.14
Ma¤tya¤s
S2and
NT_022853
FIP1L1-WW-PDGFR
Msh6p
arrest24
R1276P-NF1
UTY
CD8-APC-Alexafluor700
611H4
Jacquinet
board-approved
kinase.32
BAwt
mastocytosis-associated
ADSQ
I255T
T4N2M1
MPD.73
.A569T—The
p.N580D
NOD2
ABC-subtype
IDO‐expressing
S3Ee1–S3Ee3
ERG-WT
S2215F/P
Immunoprecipitation/Western
intrinsicGTPase
erbB2/erbB3-targeting
xenografts.36
specic
cswl.3
G106S
surveillance167
CTCL8
line.4
BioPulverizor
.Supernatant
Src-I5
MCF7.C
PASW
publicly-available
TSERN~CLOU
model.45
RAF-mediated
Frasca
real-life
APCR
detectable/not
3516–3517delTTb
Luongo
f32m-like
SIRT1-specific
vivo.47–49
anti-CD28
3-kinases
degradation.21,24,25
μm2
F5-II-2
described,9
99th
p.T315M
FAN1
medulloblastoma49
GATA-3–TAL1
R853C
MM96L
Neutra-avidin-agarose
Tyrosine-751
Gayther
Superbiochips
SafeClear
KIT-Δ557
disease14
5′-AATTGAAGGAGAGGACGCTGTCTG-TCGAAGGTAAGGAACGGACGAGAGAAGGGAGAG-3′
Lys1147
HCC25-0705A
CRL-2615
1q21
test14
/rtTA
delE750-K758
c-MET.34
A524P
FLK2
CTAG1
two-rather
breast-cancer-specific
1921
Non-Targeting
2-MDa
c.1450_1461delAAGCACAATGGC
IU.-*
RhoA-immortalized
V110I
heart28
cis-Alu-repeats
15,34,72
neo­
1940delC
FGFR2-BICC1-positive
Se-
2.35
143-bp
receptor-deficient
20b
6p11.1
Y537
hormone-resistant
10C4
FANCO/RAD51C
0.000420777
5-or
Quebec.19
cyclin-B1-Cdk1
P-D-thiogalactopyranoside
development.2–4
ZKSCAN5
bronchiectasis
orig-
EZH2-induced
UVP
11-deficient
Gly356Asp
1.05×105
Wt1
ubiquinated
MDM2/p21/14–3–3t
TrkA-expressing
Flag-MLLN320/C180
RET–PTC3
nonpathogenic
5´-CTTCCTTCTTCATGCCAG-3´
INTESTINAL
RLAA-His-BRAF
256S
Actin-like
Lazo
42MAPK
YB5.B8
137-amplicon
Chumakov
9–19
V122R
FAF506-508
standard-
activated-NOTCH-1
HGMIC-containing
p.L191H
proteomic-genomic
0.688
G776LC
ς
565–933
CHIR-258
thanF
MV4-11
AA8
D10S583
.Fixed
CD3ε−B220−Mac1−
0.007433
2.545
−507516
TRAIL-resistant
lymphocytes,38
Epithelial-to-Mesenchymal
.9,16
burgdorferi
26–34
Ni-bead–purified
primarytransformant
C39S/L
-5q
D448V
3q26.3
R372P
Starczynowski
SRP
RNeasy®
0/46
8/125
JALSG21-23
hFLI-1
background.91
alÃ-eles.These
/49.5
Asp399Asp
36mer
Non-Tumor
junction-associated
ARVIND1*
pre-mRNAs
ETV6′
CArcATAcTCCAAABATATEAr7TTAcTcACrTcAtrAAWAI16ArAATMEAAnTr6
dA-addition
.Fig.4A,4A
CAKI-1
discohesiveness
A-T-rich
'determinant
yloxy
gtaagtagt
E239A
3.379
686-bp
SCOR
Ci/mmole
CD4+CD45RA+CCR7-
48–58
11,882
Mitsuishi
P716R
Vaco703
289–293
metastasize.1
PLXNB3
language-published
deletion/substitutions
pmol/L
2x2
AID-
L1947R
zincbinding
HER2−
Shubbert
NSCLC.11-13
single-colour
TCCCATTAAAGCCCTGTCTG
157-bp
pEGFR-tyr992
BstNBI
11q22.1
Villin-Cre34
Kmt2g
71237
4.5e
ALK-rearranged
TPO.15
consanguineous
gastro‐oesophageal
59-GATGGATTGCACGCAGGTTC
anti-phospho-IκBα
1,976
Pepcb/BoyJ
nonultramutator
19.9×14.7
complexes3
Biomarkers
OncoPrint
Mei
5′-CTGCTCCGTGCTGCCTACGCACTG-3′
instability.Adenocarcinomas
KIGDFGMSRD
PPOX
Colo-38
TM-transgenic
4-amino-5-
5685
pathway29,30
R18R
F28L
11/20/97
tau1/2
colransfected
318C
Ala146Thr
4.02285
c.-55_-64delCACGCGGTGGinsGC
7D–E
Pharmenigen
Q252L
7/8Δ6
target-based
Fgf4
4q22
19/37.3
structurally-unrelated
ligand-indepen-dent
H3K27me0/me1
βB
domain49
Asn580
substrate-binding-site
phospho-specificity
v.2.3
Olfm2
CD144
R-DICE
0.797
Alk-x/Smad1/5
Fig.33a
mV/3.0
poxvirus
GCAGCAGCCACTAAAGAAGG
doxycycline-dependent
Neg.PMS2
10.67
1/200
E.R.
Fig.33D
recognition.Mismatch
1,000
PTPc
14.08
SYBR®
non-thyroidal
100,866
lines.4-13
uchc.edu
AZA-treated
Lew
TMEM45A
0.13-0.87
PanIn-1B
aal560-1863
BRCA1185delAG
prolyl-peptidyl
UCT
therapy30,31
NM_000051.3
33428015
55-100
phase.25
rat-2
R684
ARBS3
A563T/A563V
surface‐bound
n=74
TCACTGTGAAGCTGGAAAGGGACGAACTGGTG-3′
gland–specific
WT.To
tomography-CT
10798535
ER=estrogen
tαˆi
phospho-STAT1-
SiteDirected
CA-USA
high-binding
mutations2,14,16
UCI101
0.47–2.19
lines.3,5
p.Arg263His
anti-mutagenic
D419,9
R2a
RP11–34N19
NFIX-MAST1
CTGAAATCAACGTAGAAGAACTCATTATCTGAGG
ofAKI2
ERK1I48N
5′-ggcaggggagggagaga
4',6-Diamidino-2-phenylindole
genes1
limited.3,4
StdDev
SOX11-negative
RecA
Tolvaptan
pRetrosuper
jmomand
enriched/not
co-relation
eosinophil-derived
abrogationof
10,20,21
IRD-800
SphI
loxP-
0•0022
c.1249C
carcinomas3
Microorganisms
Ser768
HNF-1-binding
1p34-p36.1
kcal/mol•M
1034
α-INI1
Hyperfilm
.Albumin-Cre
cDNA-derived
123-bp
Prlpn1
PRDM1.E2.Probe.R
G189C
min-coverage-tumor
728A
Pseudo-Pelger-Huet
9-ethylcarbazoles
.IRS
Anti–promyelocytic
.ACTIN
3,370
isoprenoid
//bioinformatics.wustl.edu
proteinaseK
:447–56
recom-
NKTCL
P670L
RC3
Tyr185
.C3H10T1
anti–phospho-Erk1/2
M1411T
Besta
RANBP2-fused
factor—is
04-046
epifluorescent
Shilatifard
tumorigenesis.24
Elf3ΔN270R331P
Thr188
.Fraction
observed28
Nagahawatte1
3'-noncoding
high-definition
activation.75
RACE1
6/NT
8+
-CCGGAATTCGGATCCTGGGGCGCTCTGAGCCCGGG-3
Xq25
signaling.6,8
7,8,11,13
minimal-deviation
proximal-inflammatory
.V299L
U87MG.Δ2-7
PDZK1IP1
//www.hgmd.org/
V1713A
Danielsen
TGFbeta-induced
5′-GGATTTAAACATATTTCCCTGTGG-3′
orfractions
RSEM-generated
Lyubynska
CDK4-MUT3D
daunorobucin
PCPT
.CCL5
ACCACCATCTGCCGTATGAGTCAACCACCTTGACTGACCA
Germinal
thediminished
R265S
8/40
4q11-q12
.Kit
N414K
Actin-binding
.Bertolli
INCB01842
.Bernard
0.08–0.42
nic
peri-implantation
Hedgehog-specific
morphology.18
PHA665752
B/C-Cul2
delpletion
1254/12032
E897K
//provean.jcvi.org/index.php
echocardiography
-GACCAGATCTGTTATACCTTTGCCCTGAGA
1,015
ST6GALNAC1
1.17.20
mB−
ND10
A89V
39,52
28.2
UniRef100
A716T
IgH
MAPK-targeted
GSK3β-dependent
Qiagen-purified
SKM1
.MSH2
.GPI
INP
AGACCAGCAAGAAGATCACC
H718Y
9027
SRNS.8-10
aAccording
260–325
Arg49His*
differentiated
C620-C628
YFF
anti-phospho-Aurora
1470-bp
125I-TGF-β1
theprimary
.SH-SY5Y
E1167-K1150
AF083322
R93Q
origindependent
filâ€¢K^n
HA-RUNX1_wt
haboring
7Q
Asxl1-binding
.CYCHP
behavior.91,95,99
c.184_198dup
ACCGAATCTAGCAACTGAT
WPMY-AR
L.E
23/27
Nup49
cancer—EGFR–RAD51
ras-transfected
Tay2
Shc-EGFR
normal-length
AK1
SDS-RIPA
CTGATGGTCTCAGGGACAGGC
sex
.Stem
27y
5′-CAGGCAGCTCGAGCTCGG-3′
p.R158Xd
activity/substrate
SW50
asbestos-exposed
patient.To
stainedwith
TTCCGATC
multi-component
Luc-reg
N82
5′GAATAAGCCTTACGGGAAA3′
L553F
F.C.
5636
sh-miRNA–mediated
EF2
CD3-positive
FL393-G.
SDS-12
PLKO.1-puro
Belo
antiphospho-tyrosine
HA-TrkA-P203A
gcagaagtatactctgaaatTCAAGAGatttcagagtatacttctgcTTTTTTGGGCC-3′
HNSCC-PI3K
D18S46
technology13
21q22.35
lymphokine-dependent
Caenorhabditiselegans
non-medical
open/extended
Three-fourths
TNS3–ABD-N
MLL3Δset
ventralize
co-operate
F958
SDHA62
7g–i
Sca-1+c-kit+
chr10:123,224,100-123,398,498
NP_004603
IV-
RLIDAITSSIDDFPIELVDICKTIYNAASVNFPEYAYI
cKit+
uncharacterised
beta-catenin/TCF
DynDom
1,806
FIG.6
E611
1.924
R-I
loss-of-heterogeneity
NZM36
event-free
614008
spinotelencephalic
MSCV-EBF1-PDGFRB-IRES-GFP
RasGRP3
016
.MCF10ATk1-YB-1
Genotype^Phenotype
Estrogen-Responsive
oliqonucleotide
cross‑linked
sibility
77.3/82.2
alterations29,30,31,32
Diebold
N375
GDLG-20
Exon1/Exon2
MRC-5
Gli1-K340A
1406
PI-3-P
–tagged
~1–5
leukemia.42
Cre-conditional
1,106
RafEmpty
mono-nucleotide
negative,12
phenotype.Biochemical
.Pazopanib
leukemia.12,13
S46I
Soh
.Y-axis=normalized
Methyltransferase
605925
E934
9-mutatedGIST
Etchison
.Umezono
alpha-GRB2
MeOH
poly-alanine
Src64WT
gcrma
ROCK-1
.study
vitro,13
eight-arm
0.1388
KFFHAIISSSSEFPPQLRSVCHCLYQVVSQRFPQNSIG
26886
chemotherapy.In
caldesmon
GPR180
Rneasy
5.1-63.7
phpshorylation
-A
CGGGCCGAGGCGGCCGTCGTCATCATCATCGGCCGTAATGGCC
.Nakanishi
4987C→G
IVS9-19
NOD-scid
PID_WNT_Signaling_Pathway
FIPIL1-PDGFRA
CGTGCCTGCCCACC
∼100–amino
Double-knockout
Snf5-targeting
DAB
6.46
324-362
-2.1
212-717-3203
3-2-4-3
p110β-CAAX
c-myb.Int1.ProbeF
capacity,16
pZero-2
0.00003
A13
Czyzyk
phenotype/genotype
IVRFFGVCTEGR-
BCR-ABL-expressing
H-cortisol
Srsf2P95H/WT
sub-centimetric
alone.81
5B–5D
SC-67
GI:2317721
.0031
Pro-Rich
0.264
p120v-Abl-IRES-GFP
Bae2
129/Ola
Glu171
nondenaturing0.5X
KDM6A
EMBL4
trastuzumab.51,73–77
resultedinmoderateimatinib
R207W
H-83
cancers22
Medyouf
anti-CD16
D667H
pathways.7
.Johswich
non–
GST-Cbl-3-TKB
37C
LightningPlus
positivity.43
Agents—Colony
Rachagani
predeveloped
0.582
F-TSC2.ex14
28.2±5.9
Vorinostat-mediated
many-fold
QuickAmp
anti-JunB
Real-Time
780–781
734
N19RhoA-mutant
p.Lys54SerfsX80
anti-FOXA1
Dis3exo
fidelity.92,93
Boeh-ringer
lactose
F78
practice/approved
nonexpressed
P582fs
1807
TGF-ÃŸl
anti–E-cadherin
R1341Q
CFP-
sensitises
mis-expressing
50-400
2/58
FLAG-Elf3ΔC363
HNPGLs
RP11-266N13
by3H-thymidine
head/tail
.GRID—a
BMAL1
5′-CUCAUUGGUUUCACAAGUC-3′
.Screening
NUT-fusion
MYC128
1/427
cross-resistant
BLAST2
Immunostains
P1637L
asd-srv
Daniotti
NSCLC,28
strand27
Kirschner
multinational
andjuxtaposed
vitro16
3A-D
leukemia141
A216
antitumour
EGFR–VSTM2A
→3
//www.kconfab.org/epidemiology/1eligibility.asp
HEC-1
P36897
site49
3.10
GTTTTCCCAGTCACGACACTTGACCATGATCATGTAGAC
A203
low-resolution
NO2
AIRWAY
Set1a
implications.20
22/37
0.4×10−5
Ser727
chromosome10
uorescence
c.4267A
substrates37
lobulo-alveolar
DNA/60-mm
vivo.20,41,42,50
Glu-851
SlideBook
NSCLC196
p16INK4a-induced
Thr202/204
CRL4DCAF1.8
R-Spondin
higher-order
CNAs.Genetic
substantiated
6.8-cm2
positives.8
stressAntioxidant
TβRIIR537P
TGFβ/Smad3
NF1186-
patients.4–9
14.0–38.0
NHLBI-ESP
Gurel
collagen-encoding
NfJ-1-
Gβγ115
Leu872
5′-TCTGAAGCAAGGCGGTGGAC-3′
I691T
Taatjes
18,24,26
M5=10
antihRRP6
c.1105_1106
Par1
TEL-TYK2-
Tumorigemcity
Nontransforming
non-stem
2/MTC-associated
h-R3
sequence-encoded
14.27
hMutSα.3
Oligos
sedentary
MatrigelOverlay
1832G→A
c-KIT-mutated
0.50–0.83
amplifications/155
Fig.4F
RAS–GTP30
ciliogenesis
Thr340Ala
additionare
MEK–ERK-independent
TH01
5′-GCTCTCTGTGGGCGACAAAAGACGACG-3′
review.22
3∼4
X-AR
Arg71Gly
Gr1+
NEG-772
L12P
finger-
nonacinar
non-classified
disease.55
induced/selected
arrestWe
.S2.4
ctr9Δ
AML,21
cytoplasmic/plasma
sensorgram
S612T
HFKs
.S7F
.BCR-Abl
wtRUNX1
Kispert
mostfrequently
chr2:29447265
S252W/D626A
Ti/Tv
6A–B
Q1591P
C951G
differencein
AF-239-NA
Shigdar
threedimensional
P38
363.
1:25
pre-disposed
DNA-glycosilase
10.1158/2159-8290.CD-14-1096
butyrate-induced
ARID1A-regulated
selection28
5HIU
P19CL6
.Cantley
di-
BCR-Abl/T315I-mediated
Thr305
non-transforming
35‡
Asn-x-Ser/Thr
The18-kb
P=0.0017
Rasdependent
2361
MPNST
M5.50
FM209427
10•7
splicing,2
MutL-ADP
primarly
Cancer-1
BRAFV600K-mutant
4200-319
Thussbas
CO.
23.22
DHPLC
3398delAAAAG
non-sister
gene-rich
pBlueScriptllKS
phospho–NF-κB
Keto-N-
A57S
Amp-
NaPPi
p.G642fs
anti-MSH6
aZeiss
mTOR-signaling
AKT1-K179M
NCT01309633
4839
RanŸGppNHp
–H2B
base-pair
underrecognized
.RPPA
5′-region
NCT01791985
hPMS2-135
//nchgr.nih.gov/Intramural_research/Lab_transfer/Bic/
KIAA0228
Nbs1
leave-one-out
Tyr340/341
del25–26
preosteoblast/osteoblast
anti-melanoma
Cluster25
activator-like
BRCA1wt-expressing
C-elongin
C105Y
S5–6
hMOB1
.S4G
PC-3/pcDNA3
ATCATCACAC
p.G10
.HD-0288
H89
P10
Protein-1
P18.4F
32/22
n=0/8
custom-formulated
P.P772S
Fig.2G
Ltmc
ALK35
2390–2392
HLA-A*010101
EBF1-PDGFRB+
demonstrateda
–S6
531–536
pedigree.17
V560_Y579del
.S12
EGFR-E19F
BCL-xL18–20
662160
TAGC
thebreast/ovarian
0810
III.C
Lys507Gln
microscopy-grade
PITPNA
HCC06-0606
Vladimirova
.Brent
CC-2586
.20We
IGF-1R/erbB2
siINPP5E
V664L
mammary/breast
608716
30-60
DHH
Figure9
1.44–5.96
R137W
.+MutLα
_IDH2_
www.genecards.org
Degron
QIAampl
affinity-tagged
amc.uva.nl
Pim1-N82K
c.812G4A
0.32-0.81
EGFR-L858R-T790M-HA
HisTrap
GDNF-responsive
NIK-expressing
Gln69
GRASP.46
H281A
Y165D
a-c
GeneProfiler
.Vismodegib
LM3D-induced
S637G
2098
described.55
patients,36
Cdk12fx/+
ANK
5′-GGAGACAGAGATACACTGACTGTG-3′
anti-caspase
KYSE-410
GST–caspase-8
Glostrup
17:56768103–17:56802458
RKIP_E2_R
.Karyotype
pCW57.1
Metabolite
252a
.Dll4
.Pediatric
anti-HEL
KYSE450
N-MYC-ampli®ed
photomicrographic
4E
activated/rearranged
RBX1
1205-1232
11394
azoxymethane-induced
3992-4578
SpacePAC
ARG13
pI6lNK4
CaCo-2
2mm
sphingolipid
.1207179
V599EΔB-RAF
ZD6474
PGK-Neo
p21VEGF
deuterostomes
barnase
.Idh1-KI
L88P
38–43
protein-protein
cells35
HR=0.608
P230S
1.0.6
rs1802683
rearrangement
C135R
capacity.8
Exon10F/10R
.Star
Ultra-low
L858REGFR/NIH3T3
GRCh37/hg19
V224E
.§Score
36:1
NTF-3
fragmentographic
5uM
cleavage-specific
AGT-3′
PDGFβRprimers
undercontractwith
©2014
TP1
1Gl
Glu180
269K
PMDLg
V726M
multi-factorial
Myc-Q63L
Hochschule
α-α-Tub
Avdievich
investigated.13-17
Anne-Sophie
D86
Bordey
adenovirus-mediated
MycER™
F189Y
tumors.29,30
re-synthesis
1440
hetero-dimerize
75-78
deficiency33
/B7H1
Frankfurt/Main
GSHSepharose
123/78
mutation-appropriate
o/e
E2F1-5
offoci
growth-signaling
Mien
abstention
Vκ
193-gene
trithorax-related
GFP-moesin
.Downloaded
WRAP53
.hMSH2
Val617
320,192
Kyong-Ah
BRCA1-specifi
immunoprecipated
podVhl
A41P/S/T
AGGTGGAACAAAACAAAGG
500K
deletions.15
CDK4-MUT3A
−1.21
-nickel
RAS–RAF
7q21.3
+TMAO
immunoprecipitated
R=2−ΔΔCtR=2−ΔΔCt
∼170-fold
N2206S
CTNNA1
Annu
interception
R101W
ubiquitin-His-green
.Beside
Noonan-type
Heaphy
non-malarial
177
GCCCGGCCCT
degradationin
.SI04158049
~43
unknown.2
A-+G
Heusden
GCGCGTCATAAAGCTCGAGCTTTATGACGCGCACGTT
theproportion
TX-100
F119S
153
Ducd
Hyal1
interaction-networks
factors50
.Q472H
3667
×63/1.3
s2
non-V600
pLH30
activity.14,31–34
23–271
SOX/Q6
.Previouslypub
Spliceosome-mutant
V274
DDR/tumor
XhoI
Cavum
.Reva
HRP-anti-rabbit
mappmmr.blueankh.com
ABC/NC-DLBCL
**p≤0.01
17-611
36/65
inactivation.10
others.13
family.12–17
q11.2–13.1
Acro-osteloysis
pCB6p53mtR273H
.Degassed
.Reactive
.Thymic
α-shaped
.1321155111i14
Domaina
129SV/C57Bl/6
.1408C
Arg58−Ala68
A9251
GATTTGTATTCTGTAAA
2SO4
PIK3CA6
8x60
abnormalities5,6
Hoogsteen
mutant-derived
Arntflox
P-O
Smadja
varum
slit-lamp
92°C
genes73,74
×
81-29-847-5291
ovary.9-12C/EBPα
VPS34-VPS15
receptor‐activated
FGFR2Y376C
.Velichkova
5-tiered
'basket
DRB1'0404
13.53
/F-box
BCL1
p.Ala1708Glu
ctgtgtcag
known.16
Korinek
spontaneously.23–25
RAS-deficient
ab10799
U-698
TBE-polyacrylamide
apps1
.18760
Tri-Methyl-Histone
4/20b
ΔDNMT3B1
f100-fold
l7q21
Stat1-Stat3
s/72jC
Analysis—RET-KD-0P
3-bromophenyl
HIF-independent
329–903
4,122
n≥3
4,1-3
537–1689
PACH
G-score
.Inadvertent
131550
quartile
D13S171
6647
Pientenpol
0.2-ml
~280
GIT
pGEMTeasy
ofsingle
R3052W
MYC-thymidine
CT-b/CYT-2
ERP001058
www.ambion.com
L.A.G
37,47
deoxythymidine
K5.Smad2-knockout
V14RhoA-Swiss3T3
RINGH2
KLHL9
androgendependency
intrapatient
.82–1.04
16-expressing
0.983
DC1
-Tyr278
Hosoi
FLT3WTNPM1MUT
Fas-suppressing
described,14
F2202L
Dok2
RUNX1-EVI1-meidated
3,928
Paired-End
ab001
hypothesizing
CIC-
75.9
sc-32762X
inconstant
RALD
T17-2
C1837R
PP1-sensitive
single-clone
ECOG
bcr/abl
−670/−664
Rahnenfuhrer
HNF1G
Mendell
5′-GAACAGCTCCTCGCCCTTGCTCACCCTAGGTTTTTGATGAAACAGAAGCTTTTTGAT
anti-Smad5
pCI-Neo
p52–HDAC1
neck.Figure
peroxidase–goat
Demiroglu
W31C
CEP-14083
wnt1
550474
M7858
c.1588G
destabilizes
YAP1r
MEWO
array-scanner
.Transduction
3.3±2.5
Aftab
fibrin
Gly1269
CCSLGT
Verbeek
substrate-specificity
nonkinase
Espoo
.28,29
T96
D1S2134
G442V/F461I
.Model
E285G
1.3–16
/IKK
TACCGGG
epithelium14,15
CD41CD82
06-570
5′-nuclease
3–20
FGFR2-TACC3
498-base-pair
Liu
probands
pSV7d-NR4A3
Foxn1nu
colocalize
.7,26
P95H/WT
D10S189
ED40515
.MPL-W515L/K
Transfectam
K173E
2-mm
COLO205
CCL-243
hFAST-1-or
IVG
forward—3
substantially1
.Biallelic
ence
67:1
A326V
Fig.1C.1C
apoptosis1
.31,32
100–300
Wnt/beta‐catenin
homologues
MFG-RII-infected
L30P
Botchan
anti-TRAP100
PKB-Thr308
∼4-13-fold
thrombocythaemia
ITD-negative
00/19
-u8
Z-138
1jfz
VCB/VCB-Cul2
CFTR-cystic
FLT3/TKD
A.E.COS7
core-amplified
.Three-day
Missouri-Columbia
20.16-fold
∼47-
CDK-4/6
non-peptidic
5′-TGCGAGTGTCAGTCGGCTCT-3′
M+L
pSuper
27.0–29.2
Tel-test
A‐14
1.7-
DNBRG1
AML1-PEBP2Β
0.0428
L344
Phe518/Phe519
587
analyses,26-28
E2F-driven
BM28
Forgermline
equipotent
β-structured
Inveon
9q22.17
binding23
anti-active-caspase-3
1+
Pro-x-Glu/Asp
.Experience
NaOH/0.5
Abl9
CCTTCATGACACACTTGGG
AnalysisAll
.CUTLL1
HSR
3.2±0.23
manifestingmigrationshifts
32–74
1253
respectively.5,9,12,16⇓-18
Trapnell
fusion–overexpressing
Asp/Asn
q35
group-based
IKKβ-depleted
CD74
LIF-mediated
OncogenicitylAnti-oncogenicity
«
108-8639
S14
neoplasms.4
respectively50.Figure
D1159A
LVPW
286O18
immunohistochemistry.6,8-12
P=0.44
62-year-old
.PDGFRα-activating
T480A
anti–Lamin
SMCC
squamous-like
used.43
3606
study.15
D2S116
J28
Ccnd3
0.299
1,295,229
AAACAG/gtaggg
705-1013
CD15+cells
deletion-insertions
,1d
89-I-006
7/82
FIP1L1-PDGFα
Namalwa
hours5
tox‑
positive-negative
p19ARF-encoding
Planegg
15–46
0.72−6.07
LC–MS/MS
Ref.c
KRASP34R
core-axial
γ-secretase-dependent
hybridizationChromosome
rLP-sQDcktVAIKtLKDtspgGqWwNF1
LEF-responsive
Disease-free
mg∕ml
W326A
284â€
EWS-NTD
3,25
Lymphocyte-depleted
0490683700
BTK-KD-Y551E
74–54
siMyc
PEP3
MSCV-Meis1-IRES-Puro
laboratory-evolved
S9D-E
keratinocytes19
PECTMWT-1
Cax
▶
-396-LYN
HR-independent
48-49
pSG5-hPMS2
5q13
'pBatem
ab65834
c.1591T
deparaffmized
125-bp
Ariol
dysgueusia
V181F
.Pires
GCGAAGAACCTCAACGGAG
E.Figure
Kashiwa
AKTT308
-0.28
21–37
adults.6
R669H
intra-cutaneous
ETV6-CDX2
2407
pmol/reaction
caggatctcctcacgcagac
0/579
A427V
Interleukin-6
cancer70
ERBB2/3
Colon26
types—revealed
aAsterisk
104-S
duke-nus.edu.sg
GUCUCAAGCCCAAAGAGCATT
Hannover–Minsk
0.030
Q152X
.CD45
7.3–13
×20
-Arg
Cul1
O-linked
.23.3
TβRI/TβRII
GNAQwt
antibodies54
1385
Y350
FA/FU
GRF-stimulated
sex-adapted
B-3001
mg/well
A109T
R1263H
andhMLH1
RV560-561
I151S
68.7
544–581
4909
Ca++-
short-reads
HRASV12-induced
RET/PTC9
non-Wnt
-control
phospho-Histone
transposons.9
.MEF
35.9
RABGAP1L
scMutSα–DNA
biphosphoryl
foci-forming
SOST10
huh6
NCI-H1725
DIAPH1
P172S
Ser-990-phosphorylated
.HCLv
Zerial
coiled-coils
uninterrupted
recently.37
charybdotoxin-sensitive
Shwachman-Bodian-Diamond
FGFR-dependent
LUC7
LDL-receptor
Phe-404
Q9E
Tossicologia
NOTCH1-A465Tmutation
PDGFR,19
126.5
CN-AML–associated
SNP-FASST2
ΔHIF2α-A530V
Sigma-aldrich
Pharmacological
84.06
Gly736
6-1474llBCCAGAGATGCCTCACCTCAT1548
Clean-up
Dextrose
understood.29
639V
4,5-Dimethyl-2-yl
andNSD1-NUP98
2b—area
Type-1
NCT00075725
3-benzimidazole-quinolinones
32:2230–2236
and1010C
5′-aza-cytidine
c.2131C
pRL
×80
Gsα-subunits
Pik3c2b
heatmaps
FLTITD
doi:10.1038/ng.2936
BRCA1unclassified
herringbone
rGADL1
19q-arm
1064P9
.BIOL
ERK5
TLX
pre-B–ALL
IL-9
S770a
11lGluGluGluleuAspAr9AlaGlnGluArgleuAl
GST/
aaltonen
IP3K
TEMHEAD
bcl-3
a+b
G649R/K929E
pTOPFLASH
multitargeting
pancreatric
FLT3-ITD–driven
DuPont/New
Itgax
39/42
described.24,25
ubiquitin-dependent
SLOVACKOVA
17/58
mutants,3,4
99a
−4.85
lysatesor
pVal133Met
TdT+
5´-CGATGAATCCAGAAAAGC-3´
shNKX3.1-expressing
near-infrared
Tyr221
abdominus
.Accession
14,801
.Jouve
5HI
2513
P33S
Gly101Trp
signals.15
Arg428
overestimating
incorporation.Solid
MCF7cells
29–313
S5J–L
2-d
exon-3
Val74
anti-PTCH
D444H
AF032986
Figure3K
cell-transforming
inTable
22-kDa
counter-secretion
COLTHERES
pMT3
n=143
50HPFs
Figure6H
Xillix
2-4,7,19,23,24
dis3-
ctgtgggaagaacgaagtgt
a-HLH-ETV6
C618Y
AML14
2.16–3.22
0.0633
GSE11263
nonsurrounding
tumors11
0/84
moderate-
2-1309
2.807
bic/
erythropoiesis.2,3
Ori
INI1-mediated
-GAGACCTCAAGTGCTTCCTCCGAGAGACCCGCC-50
different-sized
.Tetracycline-inducible
.Higher-expressed
Ewing-family
FAST-1-Mediated
0.539
b-Raf
isunwarranted.Once
Co18
sensitivity.24,28
.Somewhat
FA-38i
ELISA-based
NCD80
p53ΔE5-6-positive
first-described
peroxidase-antiperoxidase
apoptosis.38,40,41
0.66-2.05
NM_002011
Iysine-48
mitosis-like
nonesterified
-CTGTCTAGATGCCAGACTGTCTGCCTC-3
.Meningiomas
structures-biosynthesis
.Misfolded
76543-76526
L232
double-membrane
BC/AP
n.f
S6F
assaySee
lymphoma.15
Nfatc3
methods.3
6I-J
hypopigmented
path.33,34
CEP4c
R831C
cocrystallized
anddemonstrated
1.0000b
prediabetic
Chr4
ab10646
2ITT
E166fsX223
Andrechek
21,35,36,41,42
S3I-201
27/88
alÃ-eleof
a-HA
Proteases
FLT3.2–8
pre‐spliceosomal
5′-CATCAGCCTCCAGTTCCGCAAGGGGTCATAGAC-3′
WW3∶S7PY
Hanada
DSS/ASS
BRMS
BRCA1-reconstituted
HERVK
ELISAPLUS
IPNB
0.092834945
complex56
p53/MDM2
Dead‡
glypican
high-capacity
LOXO-101.47
Top-1
III.3
sitedirected
.HCT-15
carcinoma,9
2027–2033insC
55/781
tumorpromoting
SFNCILYDH
useless30
gammopathies
.Phenylalanine
coliMitosisCentrosomeGenetic
HO-1
meta-COPA
heparin-like
rereview
GDP-mannose
211421
A502-Y503a
p.F2482Ffs*2
270
P542R
Newcastle-upon-Tyne
leukemia.23
E51D
Tyr900
.GFP–VHL213
V342I
EML4-ALK-dependent
anti-C/EBPα
0.3304
.1795
.187
sc-753
BCRxL
Wallac/Perkins
L25
Dam/J
released—to
R919G
NM_058216
0.5–45.0
ER-binding
⟨I⟩/σ
G12
Perubatan
S8-S10
PN701021
W398X
AD-IL-17F
underexpressing
//vbase.mrc-cpe.cam.ac.uk
5′-GUCACUCUUUGUUCGAAUATT-3′
JOBNAME
.Allele-Specific
JM-Z
.ETV5
5′-ggatcctaatacgactcactatagggagaccaccatggagcgagctgagagc-3′
SVL
.Washes
αG-helices
Ctoplsma
BRCA2/FAND1
//mappmmr.blueankh.com/
WILMS
NPM1,11
SEM.Consistent
S594R
Progenesis
receptor34
PFDN4
phases—namely
Y583
c.C2312G
ubiquitin-specific
SDHx
translocators
15–amino
p32
De´partement
162.4
ALLELELINKS
functions.5,13
K1193
MODY2
Vicari
pGEX2T
.Well-designed
chr2:29443486
pBabe-GATA3-R367L
5'-TGCCACAGGTCTCCCCA-3
mutLhomolog
intestinal
42/F
yGlyS
activities.16
SR-EBP
anti-FGFR1
SCFFBW7-mediated
LM-PCR
.1832G
C28R
3962delG
RKO-E6
select_db=ATM
CLL.53
Myelodysplasia
-173
Ral-GDS
backmutating
hexadimethrine
BCR-ABL-like
V-like
HindIII-blunted
A355T
Akt3-transduced
/RAe3R
p53-L157F
populations3
IBD
P-0000645-T01-IM3
83.85
setback
T-ALL.Experimental
RAS-GEF
non-selective
Brca1-
20–3.2
deprivation29
1801del
R181E
/highwire/markup/42272/expansion
Zymolase
mutationallyspecific
.Balbas
contumorigenesis
intmed1.med.kyushu-u.ac.jp
165-fold
nutlin-3
NCT01820364
T161
Maria-Mercè
Fig.S7.1
MLL-7S
GTCCAGCTAATACAGTGCTT
S4d–f
54/
depletion/AKI
XSE4
5'-ACCAGCAGCTCCTACACC-3
NG_007524.1
PAPILLARY
60-63
Spom
date,8
TGAA
gene.17
kt
2imt
microcytic
thepDM56
3K-M
RP11-152O23
ACC-MESO-1
YKL221W
p.His91Pro
139·8
flow-sorted
ÃŸ-cateninbecause
signalling11
gene-level
1–131
methyltransferases20
N1046-02
pim1-
c/g
Sarnow
β-cateninflox/flox
WT/K1003A
32,8
confluency
42.6
.Address
24-36
HA-Smad4
2146-2162
0.011
CDK4R24C-expressing
Androgen-Dependent
elutions
Leu858Arg+Glu709Gly/Val
FRT/TO
types.Mutations
53y
pan-TrkA
GSE18828
SEC61G-EGFR
RQ1
T138M
FDCP-EpoR
327/506
M.M.
bK143F12
CYP1A1/GAPDH
S9F
G294R
TSC210
35-mm–diameter
megakaryocyte/erythroid
YFP-GlyAla17
Y114C
shNF1a-e
NCT01111058
inhibitors,26
cancers.19
function.Figure
7p22
T13
analysis20
CWR-22
AZD2461
intron/exonic
systemMutagenesis
ethylenebis
R155Q
-tcctgttctgtgccaacaatatgcaag
qtRT-PCR
CWF19L2
BaF-3/EpoR
Simoes-Correia
guideline,8
Maccioni
AAT44835
0.1597
Tgfbr2
58,616
inhibitors83
D2723A
p.A148Tg
S.F.
FLT3D1
2920
respectively8,9,35–37
16:11
.Transforming
lPage=11753
surface.26
6.36
//RasCentral.org
Ser1655
.Fgf17
-shaped
PI3K-Delta
662G
GAPl
28⇓–30
.curie.fr/curie/sm/brcal
TLR9
T118
difficult/atypical
.GL
Asp208
E551K
Cys-124
cells10-12,16
glycosylases
Des+
sc441
25.0
M64
PDGF-Rac
2Dd
P088
per-chip
AR-directed
shown.The
'private
p.R640G
II1
n=6/7
Hogness
fovea
.Recurrent
100∼1000
anti-Hdmx
C8orf78
D–F3
anti-self
WZ-4002
h.Gels
1.008
8795
DNP-induced
checkpoint-mediating
Somatic-mutation
SRa-promoter
ETV6-JAK2
G.H.
Datar
L187Pc
ALK-2
8.79
patient.Prognostic
BRCA-/-
ofan
WNT3a/β-catenin
1055
ras-associating
PDGFRA-expressing
mapping,4,5
BALB-NeuT
Y0ci
Fig.3H
.Precipitated
al.4
CML9
Asn581Ser
cleavage12
pone.0056521.e015.jpg
TNS3–PI3K
transactivators,62
I798
anthracycline/taxane
platelet-associated
Jeong
genes.13
shRNA2
cells.Ba/F3-mock
16100
LY8
proteins.11,23
7+NGF
p-EGFRs
1SZP.PDB
Thrombolysis
-157
GCY
Mgat5-deficient
tablet/50
E9-I9NoAG-E10
eachanalysis
RPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRC
myc-null
erent
Egfr-expressing
2BIN
mini-puberty
pEAE75
4/151
.Prenatal
pGreenFire1-Sox2SRR2-mCMVEF1-
BH3-mimetizing
D16S520-
Chondrogenesis
nihms820730f6.jpg
tub.
Yersinia
triplemutant
19A/B
Asp7ff
Least-squares
15N-TROSY
K601
Stiftung
TCR-CD28
34.7
1O0W
v6.0
224217_s_at
Pre-2000
mutant12
S838G
Ricciardone
-S646F
phenotypes76
Anti-IL-6
Aurora2
O-NBD-GTP
.Squamous
BEL-7402
tranorming
H1c–histone
D–I
MAPK-reactivating
negative/1+
Subline
TC21Leu-72§
Phe568fs
agarose
③
A509D
al.,2006
0258
minielute
0.007
.EPR
Smad2-null
61-yr-old
Arg367
RTS13
α-Kar2p
3´
16B
SJHGG003_A
CGGGGGTGTCTTCTTCTATTTCTCGCTTAA-5
Ci/Gli
g/m2
transformation32,34
diVerently
188delAG
AMPPNP
■
nonsmokers.5
301,430,531
PTPRT-specific
287.3
34y
596-616
AAGAGTCCTGT-3′
computer-based
Figure4C4C
anti-GAPDH
d–l
316-319del
PIWI
ajplung
.Mock-H446
H1047R-induced
2qH4
genedysfunction
3516–3517
p.385-418del
5′-CTG-
–cell
JAK200F
RP11-454N6
Y34A
immunoediting
C-46
α1-helix
PLAT-E
microvascular
80.7
XP_691964.2
PDE4B-B
NSD1-2
drugs.6,7,25
BRRS/CS-overlap
BTLA/CD200
PTRAJ
proliferation.47
NLS-unmasked
leukemia/chronic
case-by-case
gi4151103
protein–expressing
pLenti
L229
Exon-8
2,220
q24.21
β3-deficient
A146T
CEBPAMUT
GST-T3
Masback
rs1801133
P844L
degraded6
multi-fragment
Emanuele
E633K-p110β
WT-Flt3-
Caseno
degradation-resistant
FLAG-Elf3ΔC235
re-expansion
androgenresponse
non-competitive
G-quadruplexes
apoptosis124
GR201H
phospho-protein
cross-hybridized
R788C
LacZ-transduced
WTERF-
gefitinib-related
23/66
3/24
fusion-cancers
IyLouProS
.Mitotic
I870M
Jean-Yves
thrombocytosis.1
EI-6917
disease.Materials
35S-labelled
10min
Dierences
55-031-PB
anti-CD24/HSA
pyrazolopyrimidine
heat-shocked
CH-4005
MEKi/AKTi
AluSx/Sp
H/
alteration42Sâ€
autoactivate
CMV-promoter-driven
Macherey-Nagel
HTB-14
earlier-onset
21–44
isoprenoids
Phosphatidyl-Inositol-3-Kinase
invasion/metastasis-promoting
T64S
ERSPC
D351
13/21
25-29
Bhartur
Ce-Dicer
rnaseq.gersteinlab.org
.00146
centers,50
detectbinding
G465
209-fold
IDH4
GTAAGATCTGCCTGCCAAAAGC
placebo11
l-glutamine/100
panitumumab—was
Constitutively
nM.3
S.-H.
1.4.0
factor–independentTo
nevi,9,10
T130I
-CD19
component-tumor
Locht
RBy159
imatinib-refractory
21:244–249
GTG-3′
tumor-prone
TKI=tyrosine
L188Q
WTBRAF
6,799
49Consistent
neointima
UF
T1–2
.EFFICACY
12721
57.80
SAGEmap
N-Tcf4
FGFR3-IIIb-R248C
Bioregulation
SAHF
CDKL3
F71K
Y1278H
373/447
4/21
controls38
anisomycin-mediated
.YCpLG-myc-p110β-wt
clonespecific
D603Y
transurethral
Group/Response
A186T
3F
.200
HCC17
4◦C
10/30
N540K
AGCCCTGCTCGGGGAACT
pUC19/IL7R
chromatin-binding
associatedwith
QT-PCR
VdW
Virgen
Glu-epitope
OBT0030
39729127
D551A
Chromoplexy
670QPIF673
M11037
OCT-embedded
microtubule-depolymerizing
3:2
Assays—E
Thirty-four
stromal/microenvironmental
QED
Tet1-KO_MA9+HOXA9
immunolocalization
Vernersson
–MEK1
11R
CK−
SRC-1/ACTR
anti-BCL6
G442R
MUC2
EGFR-Del
gene15
probe.2
Syndrome-1
literaturea
155-294
.FMTC-RETS891A
H1047R–induced
5,042
high-bioavailability
leukaemia24
Cbl-b
gata1+
Red–conjugated
K295E
distinguishable
73.796
sex-specific
ThxID
U=218.5
TRIP13
EZH2-mutated
743-995
R208H
Yaptarget
Fyn
∼500-fold
271-
p53-H179L
MSH2-deficiency
n=0
CD28/B7
SRC-3−/−
assays.45
62A
anti-c-erbB-2
9-36
-target
1948
8D
observed.5
Caveolin
EGFP-Ires-CREERT2
1832
Ser555
//www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim
carbohydroxylate
chromatin-IP
Peczkowska
Hypertetraploid
Ser118-dependent
Spen
and10
Harel
p53G245D-mediated
Q327K
mutation-introduced
FLT3-activating
TGF-β.DISCUSSIONIn
FPα.9,16
al,44
kvd12904
l.
byeither
antigen-processing
0,28
SJDOS006
signal-to-noise
H2355R
EWS-FLI-1-infected
Cre-mediated
Marmorstein
XPF/ERCC1
footprinting40
9.42270525
A300-170A
4,965,192
5–18
periglandular
.ERF-Mediated
ERG–MAb
2/27/08
14–17
7q36
5′-cgatgacagtggtcgcctgcaggcagcgga-3′
LTPSPESP
WLSTGLWHNLELVK
tight-fitting
Ca2+-
study.Fusion
24hr
430.2
2.5–3
ra.v
LA1
epitope-retrieval
biodistribution
PET/CT
Cy1
56/66
re-shapes
unclear.33
hypervascular
064
multiplication
Cav-1
H870R+L858R
.2b
Givol
COL18A1
cycloadenines
v-Ha-Ras-
Q256K
TheLNCaP
pFGFR1A
.Rabaptin-5/PDGFbR
D769H/Y
Fig2F2F
hydrogen/
Phospho-MET
regionencoding
shRictor2
ZBTB7A
JST003692
sensitive−to−hormone
Familiesa
5–intron
SKH1
PAKYEP
CH1/TAZ1
andR249S
mice,4
anti-Stat5b
.Simulation
Phosphoryated
68kDa
livers26
Sevenless
dynamin-
MDS-specific
qPCR™
unclear73
Kunliang
882230H
adipocytes.13-15
c.4235C
7+9
pMSCV-WTKIT-IRES-GFP
.0558
Luc-reg16mut
interactions.14
Inducibility
10.1007/s10120-013-0298-y
19.00
P.K860E
Boldin
autoradiography
MSI/BRAF
low–risk
.Intrachromosomal
lethally-irradiated
particle-mesh
Finland.PALB2
LAU50_2
33–66
xg/mlHoechst
Umanoff
mitogen-dependent
SA-β-Gal
.GNAS
S1278
18/71
.CRAF
examined.Figure
Y64/SII
AAAAGC
−83.9
20m
.6C
homogenization
p21has
forward24
RAC/CDC42-
Viock
AlignGVGD46
2010a
−PV
immunosuppressive5
Cysteine-rich
R-SMAD
.Signifi
inXuenced
N′-methyl-N′-nitro-N′-nitrosoguanidine
tumor8
galectins-1
Conformation-Sensitive
.JCRB0834
HR25
VhlR
Sekimezu
non-essential
.Long-range
10-07
2−5.4FGFR2Fibroblast
PfuTurbo
R135
Q283P
HMS-101
discriminator
leukemogenic
Kuperwasser
3.46E−05
3/200
high-leukemia
110-fold
G13E
Mdm2-dependent
rapalog/FKBP
GGAGGAGCA
stimulators/inhibitors
BCR-JAK2-expressing
19mer
literature.16
+901
1.88-fold
SK-MEL-28-E
GENEEDITOR-produced
Mensink
wu116
pCS2
viewerDownload
v-Rasexpressing
conc
pLPC
pAD–TAg
acceptor.
Anti-phospho-PTEN
5/49
TSC129
adaptor‐ligated
CTGGGCATCAAGGTGAAGAT
53BP
G12VN-Ras-expressing
.PIK3CAE542V-and
MSH2-A834T
-GGA
HSPA8
NALM1
LBE
uent
518–533
CRCc
sclerosis
G277
S947X
folding-reporter
SRP72
VEGFA-amplified
–20ºC
anti-Asxl1
/Total
TTGGCCCCGC
​,3B,3B
pY1248
AGGTTGTGAGGAGA
Mlox–Alox
ALK-tyrosine
mRNA/18s
.13
KM012
Saemundsson18
63-69
MCF1.fgf-4
described.31
.Interpersonal
MSH2-G674A
profiling/sequencing
docking‐defective
MP3
FuGENETM-6
Myd88WT
-benzamide
shown20
/3-globin
D-Cdk4
T409I
development6,46
Jumonji-C
5′-CAACAATTGGTGTTTGTCTCCTCTT-3′
06–134
5′-GCATTCTAGA­GAAGGTCCAAG­TAGTATGAC-3′
I770V
Alexa488
2-liter
MCV-negative
Miz-1
heteromer
atcctgtag
PCCL3
multidrugresistant
flicts
Claessens
rearrayed
GGNG
//dx.doi.org/10.1136/gut.2008.159137
Pcut
V44D
co-transcriptional
26/31
515/612
GAGGAGAGCCTGAT
2578
anthracycline
syndrome.Cyclin-dependent
transformation.28-31
consensus-based
p.R1276Q
Meselson
Miyakoshi
p210BCR-ABL
mutation96
.Performance
p16INK4A-deficient
Megalencephaly-postaxial
L471
TCCCGAGACTCCTGTAACCTT
ibrutinib.8,24
ABT888
R192Q
Sh1
inconsequential
¿51position
anti-TGFα
tether
mJ/cm2
R216L
//yellow.nist.gov:8444/dnaAnalysis/primerToolsPage.do
3•49
5′-GAATCAGCTAGCGTCTTGAGTCTCCAGGAAGAGATT
TEL2
D3S3527
77.2–
E69V
Trp53+/−
AGCGGTGAGT
single-quantum
MCPH3
carcinoma15,16
n/seq_tools/splice.pl
Ins13/E37G
N-myristoyltransferase
EAFQins
GyrA
G37E
Coimmunoprecipitated
±14.7
1.23-2.421
5′-CCACATAACGTGAAACCGG
sequencing-directed
Co-mutations
.GIST-T1/829
.C50
CBF1-VP16
.MYD88
kdr
Non-haematological*
SLIIB
.Isotype-matched
~91-95
MES4487
Nigg
6–48
Hnf4a7-9
ERK15
MEK.19
—genetic
SignalIP
C3H10T½
ONPG,29
cervicomediastinal
129S6
TTGV-172
E545E
contrast-enhancing
pseudo-merohedral
ag/gt
deleterious/high-risk
GISTs66
0.4–0.6
p85-p110
CAAGAG/gtttgt
.Ayadi
Overall/individual
dNF
risk16
cardio-facio-cutaneous
13C5-labeled
previously.23
5440delTGTG
.Gain-of-function
BGR1-associated
p.G1483D
α-Actinin-positive
interval-level
theimportance
RINGB1
.Round
SETD4
UPN1333
sc-398
Innotec
eectively
6,251
Ultragaps
pre-exist
-310
.Funding
keratinization.23
gactgtcttataaagattatgattttgggcactcc
above-cited
30.73
AID-directed
11.18,19
mBcl2-Forward
2,629
inhibitor74
αIIbβ3
protein–mediated
M23239
www.ingenuity.com
relapse40
H3S10P
GCATTTATAGTCCAGCAGTGTGATGATCACATGG
phospho-Tyr-FGFR
XhoI-BamHI
ARID1
cancers6,28-30
R422C
Met160Val
pRETRO
BRCA1–expressing
Ser269
//www.broadinstitute
7-85
9.8622
pLAM-LacR
pIRES-EGFP
GISTsKIT
Src42K10108
S7.1
MKK3
ffu/pmol
BRD4–NUT-containing
0·5–NE
FOXO3
BAT-I3
TCAATCACAGCTGCCAGTGTGTATC
sc-
Hahm
K‐Ras
genotypic–phenotypic
pecentile
ETS1-mediated
amplification-
1G-J
Kancha
VILO™
pre-abiraterone/enzalutamide
.0201
6-mers
alamarBlue
myelo
Tie2Cre
Oligonucelotide
AGGTGGCTGGGGCCAAGGCT
coding…Download
pGL4-Luc2P-NRF2-RE-Hygro
pCYC1-28C
Desmoplasia
ImmPACT
189
halogenated
mec1
EOFreceptor
Behzadnia
phosphotidlyserine
5'-CAGUGAGACUGCAGAAGUAtt-3
antibody/Sepharose
study.28
IIO
66K
1762T/1764A
1q21-23
+BAP1-transduced
cDNA-capture
cancers,9,12,16
P214L
APC-catenin
4.62
IRF4-mediated
.£
blast-phase
cancer.29–32
Pungchanchaikul
process.175,176
metastasised
pCDNA3.1-hygro
Caspases-3
Apc2lox14/+
KIT-receptor
999del5
R248Q
5–216
defects.In
oxidation-resistant
.Mounting
Lin12/Notch
Hsp104–GFP-positive
Orgiana
sulfate-concentrated
A164IT
Smad2-Smad3
light-chain
α-STAT5
CAAAGGAGACTGCACCATCCGT
MutSigCV,40
Foretinib
0.97-2.56
S9E
fine-tuning
p.Leu64Arg
functionalproperties
MA1-91878
2.3b
3-AKT
www.ensembl.org
Ala205
Hs06336027_cn
SH-EP
70-80
arrest.7,8
pCNDA4
Ukraine130
67NR
tumors,39–43
ERÃŸAF2
17.16
days.https
SD-093
H-labelled
16/17
Pigny
anti–IL-10
deletions.There
morpholinoethoxy
408C
genetics.bwh.harvard
245
Kuwata
members—7
CATCCATGTGCTCTCAGGAA
JAK2.48
71100
mahogany-brown
autotransplantation
anti-Gal4
deubiquitinases
SpiC
PH-out
gpcr2
13/37
KITlow
E1384Kfourmutants
4475
CS02
Calpain
THYRO10000728.8LOXL1Lysyl
translocation-independent
blotting.1
P388T
anti–CD14
ERG.We
base-called
p.G634G
pAPN-HA-HCF-1
p-RB
293Tcells
cancer91
13I6
153-bp
Flag-MKK4/pLHCX
Krox24
D473G
PBRM1−mutated
DNA4,9,10,23,45
20910
MCCT_17
non-
Ptenfl/+
holoprosencephaly15
3′-GG
L214P
rearrangements.14
HCT116+TGFBR2
.ICM
AZ9496
F174L
histostains
Pro-531
EGF52,53
S208F
nucleusFour
453-kDa
28,33
UV-irradiation
64–84
Val1060
al.,2002
5YR
classI
LM-LECs
diagnosis*
Brd1
25K
L1433
RP11-138H3
Aa-Al
.Semi
5′-GGTACTCCTG
265-279
0.55–0.99
AAGAGCAACTTCTCCACATGT
anti-CD3–
MB-102
Karplus
Haploinsufficiency
Zabludo
R-IB
AutoQuant
de-regulated
Tyr62
,3-5
LUC12
F170L
FruitFly
gene-ranked
membrane-permeable
anti-p-AKT1
R280K
ibrutinib-resistant
R291H
Sulman
NPM1_ex12for
DABP-GTP
P2-P5
NB0308-D
T674I7
0545
DNMT3A/DNMT3L
pDSred_C1_PMS2
rCGIuS
metamorphosis
rs55737335
Msh2-ATP
X87175
anti-H
1,210.8
¯uorescein
c.1277–1180_1386+2226del3516insCATTCTCTTTGAAAA
Log-rank
modelSox17
MPM23
GGAATCTGCTTTTCAAGTATGCCA
enzalutamide
CAA
fancg
HMC1
AmpF
RMH3952
VegfamRNA
DOK1
ILVGERL
0.077-
CD3ε−B220−Mac1lowcKit+
p=0.35
femorogluteal
D448D449
calcify
I-coated
IGC2
sites106
G12E
.MFS2
6609–6620
protein14.5cDNA
Cys→Arg
NG_023199.1
U01–573
PROSITE
extra-cranially
microdissector
non‐familial
Ifi204
9·5
Chromatin-immunoprecipitation-sequencing
papillomaviral
1-202
Cytokine-Independent
N935S
reported.8,11,19,27-
pathwaysAbstract•
Pui
RETand
p300-p53
Miltiorrhizae
III.1
eIF
p-EGFR/t-EGFR
5′Pso-TACAGCTACTTGTTCTTGAGTG-3′
1q
collinear
c.9117G
CAS-1
M1317
RNAiMAX
AnnexinV-FITC
risk.19,20
Glu446
739–744
CDKN2A/p16
Multiz
expression.13,15
events.9,12,13,19,27,30,31
110
GGGGTCGGCG
CBF-AMLs
VEP
process44
BCP-ALL
8713S
c.7271T
muscle,18,19
VEGF
single-punch
5′-CTCCTACCATCCCCTTCCTC-3′
hydrocloride
conditionsin
cells.After
N318S
Lys889
MARK2
-Hoover
Morcos
350031
c.476-9dup
hSNF5/INI1
Ggbtot
NUPAGE
p.R366W
80.62
G367A_F
SCF-containing
m3-18Raf-1
I1855X
Growth-Inhibitory
2124–2130
.SM
reports12
CCTAGG
R246C
ends–polymerase
2455T
PCR26
ACC-LC-48
.ALK-positive
.ACC
T3/DN
cells.54
Kisielow
QI
40,6-diamidino-2-phenylindole.FISH
oncoretrovirus
Debaryomyces
12.9a
S34F
TTCTCTGGGGGAAAGAAAAGAGTGG-3
c.6935A
Cul3-Interacting
C422G
X-100/1
P-Frk
Fukuuchi
CYVD-FREYE
Boussouar
zeste
ABgene
p19ARF/p53
DKCL
DEFG
S6H
1-nucleotide
R2042C
2.4–5.8
αc
Hietakangas
L210R
206–368
CD200
Asn-616
SuperScript™
.105
37.Q354E
718T
G1202
108/153
56809885
His231
inacti-
promyelocyte
ultrafiltration
PAX6
Fig.22C
300-fold
CIN+
TFA6c
p18INK4c
34023
Sap-2/Net
trations
transfecting
AF363013
Fgfr2+/Y394
CDK4-T172A
.Murdoch
ASD
30/289
BC112
progressiveBCR-ABL
4448489
WH0051755M2
88.6
prognosis9,10
G1771D
HrasQ61L
41.3
SETD2-depleted
1–3•5
Bolzan
IL-less
studies.45–47
speciesspecific
RING-PHD
Pol2-dependent
3.45
-Leuplates
cryo-stabilization
B56gamma
cohort.20,22
syndrome.13
non-cisplatin
mant-nucleotides
32,34
217G
0.0673
C57BL6/MF1
0701
T.S
Borkham-Kamphorst
RP11-466H15
.Proof
c-Mpl-P106L-GFP
Xq11.2q12
Ex-Taq
peroxisome
KU19-19
⁎confirmation
GML
p110α3
AML1-rearranged
0.33–0.71
.Pyrograms
Cool-interacting
HDACS
POLE2
pnas.1321155111i1.jpg
RARA-PML
60˚C
Coradini
Glu1042Lys
pbabe-hTERT+p53DD
22.2
PtenloxP/loxPRictorloxP/loxPPB-Cre+
2.1–6.5
HLA-restricted
sc-2033
Tet-op-K-Ras
leukemia.28
3EQC
authorSchematic
eIF4A
3.73–3.60
610827
roLouLouffitV
Soulez
R94Q
43-9006
panSF3B1
TAL1-induced
immunocomplexes
A527V
PTPRT–p-Tyr
6h
EM11
D594V
estdab
amounts—105
Bertozzi
V386A
5534
INPP5E-dependent
2118-1
12.5–16
AKTThr308
ERK1/2-independent
151.6
clasto-lactacystin-β-lactone
11/
.39,40
pore-dependent
toDX
V617I
KRASG12D-induced
D5-D5
immuneinterferon
B1ΔCC2
22,49
F617
TAT3GAT
ZMSH2
alpha4-binding
2/3rds
Lyn-
inter-center
Pstl
ReMOAT
M1211L
A190-131A
membrane-associ­
ΔΔGfold
noncysteine-rich
Val-Glu
tumours15
AGCACTCTGCATCTGCTTTTAAAGTC
p.K57T
.Uncontrolled
y-H2AX
HA-GATA-3
C-Cdk3
genetic-linkage
.chest
14-18
ccle
differentiating
Arnt1b
AG/
leiomyomas.7
non-survey
EGFRE884K
haploinsufficiency.Dominant-negative
mMMgCI2-0.5
Y.Z
Hisafe
RC161
E1283
2106-bp
D1682H
Fas-sensitive
V1144L
MM21
GAP-mediated
γ2
81-3-5449-5433
Houldsworth
CDKN2A/B32,33
5′-ACAGAAAGCACTGGCTTGGT-3′
H68Y
5′-CGCAGAAGTTCACCACCAAGTC-3′
RBP1
2156G
withdrawal13
defrozed
VrG
-CAC/T
CCTTTTCACTTGGCCAAAAA
S-5
treatment16
inhibition203
AmpliSeq23
∼1
pCR2.1®-TOPO®
8/25
shRNAi
pathway-targeted
glomerulosclerosis
2-5-2-3
FcγR+CD34+
428b
.Adv
d'ITP
p.Met1043Ile
7q.9
3ZME
well-characterized
zebrafish-based
RTs113
.0419
2A-3A-4A-5A
3026
Ly-5.2
shMll3-2
anti-RFC-140
associations—UV
Heterogeneities
13,35,36
TTTCTATC
pEGFP-Flag-SPA-1
IP05
Bandaranayake
Rit
−0.392
-TTCCCAGGAACATGCTTG
lymphedema-associated
HOC313/v
GLYAT
DFGLATVKSRWSGSHQFEQLSGSI
Optronix
R1594
re-linearized
EGFR148–150
ETV6-JAK2.20,21
TP16
r2=0.04
60–621C
E732E
ATA-27
10C
neutropenia31
rs2066827
migration10
sively
D871
Muc4
TIS1
∼21
6a−c
tumors.9-12
proteins.22
NP–CGG
RG-6
neuroblastoma15
220.6
OX40-mediated
3773delTT
1160
BAG4
T81Y
0.3274
1a-i
Axiom
Ser114
4444964
KIT-V559D–expressing
35S-methionine–labeled
0.989–1.077
G12D.HP
PTPRD-FLAG
CG-1945
Asn998-Phe1008
andCEV14/PDGFβR.11
.Rad51–Brca2
three-hybrid
-/
ATRA-resistance
.SNU-2535
1.019±0.08
control.We
P=.001
medium-sized
5/T
0·15
Guillosson
B-RafE586K
cytokine-induced
doi:10.1056/NEJMoa1508887
AMI4404
myxoid–vascular
stimuli205
Maeno
Bapat48
co-translocates
Nathke
.MDA-MB468
germ-line
ON*
14/51
G.S.
Leonard15
progression39
10-8
SDF-1-
Bond-III
nding
serous-like
PD153035
sc-9571
anti-NPM
SF-1
omim
ISI
second-site
aga-3
54–61
5Bb
exportin5
11/35
chromosomal-scale
Endonuclease-based
0.7–42.4
HIC
management.figureFig
222–227
.Catalytically
K71R
c.474G4T
A325
this.In
pEAA304
TOP/FOP
D1010Y
MSH2-G162R
SA3
OVCA429
75°
458c
/protein
CD95L
migration—a
S84
.Guerrette
5′-AAAAGGTGGGCCTGAGGTTCA-3′
774_776
31-kDa
ITK
PCR-specific
vimentin-positive
Phospho-IGF-I
Grb7
S494
Lethe
rehybridized
post-progression
SNL2
p27KIP1
70-year
.IPs
M3542
.S1
C'.A
332†
15,987
Arg130
1GXC.pdb
Thongprasert
57C
3.39
CTB-85C5
Anti-EGFR
min.width
bHLHLZ
.Genotyped
D1–7
independently-derived
Gallou
NCI-H520
Neuroscienze
subunit15
A.F.
A475P
S129F
RA-binding
.Nucleotide
ERG-only
Ly3
1368.0±192.3
DSB-associated
Half-Life
sequencing-
933124
Oncoprotein
SFA5
SJRB001-2
cFLT4
3,417
XIIIB33
.t
FP1020
c-cbl-/-
R182W
129/SV
0.7-11.0
p-HER2
.BAY43-9006
studies36,37,38
.High-salt
G13D
receptor-b
microfollicular
embryonic-lethal
1992b
RP11-476D17
nextgeneration
HSCs.14
265–271
cleavage.11
ZSCAN29
PKAa
HCCS
W2
I-104
459844
K122G.D
RAF-dependent
sample_data
lin
CEPBA
R378Q
oligomerisation
BAF250a/b
L117R
NEURON
Ecadherin
immunonohistochemistry
genomes.31
AGACCGAGCGGAC*TATGAGGATGAAGA
d+54
Gly14
mutations.26,47
to85
f-
p85f3
tissue.34
Mandahl
Q5
survival.37
MU/day
β-catenin-
N659
**e**
5'-uCCAGu-3
SDSpolyacrylamide
Burrows–
bevacizumab-failing
Saraiva
v-H-ras.Previous
adenocarcinoma24
GTTTTCCAGAGTGAA-
cell.Gene
3p13–14
10.1369
M1041T
SMG-1
ji
core20
variantsa
S229A
upper-strand
Asp-38
BHK
D9S61
BamHI/EcoRI
CYP3A4
SOSTDC1
AL161450
CD2-GATA3-transgenic
13q21.1
Y150C
10μl
possiblilty
Smc2l1
A549
0–20
ERcontaining
Fakharzadeh
1.935
Karyotypically
274,351
V128del
Myelofibrosis
Fig.5A
Y187
Phaeochromocytoma
D–Cdk
myxofibrosarcomas
VATER
pcDNA3-FOXO1
4.Correlation
G201E
Q-RT-PCR
11.6
prolyl-hydroxylase
.Mammospheres
pspMyc0/1
withandrogen-depleted
//agvgd.iarc.fr
wtBRCA1
F359C
c.-34G4T
SNF5/INI1
Con-C
.ETU
T376C
Asn-847
CC64T
whole-organ
3879
described28
Gly-46
protein-interaction
variant/classic
G197C
re-grew
quantificationa
LMYC
smartpools
speci-
AmpliSeq
Dicerfl/fl
plasmacytoid
S7.11-15
JMML
2336
N-terminus.18,19
V255M
C265Y
single-gene
VEGFA-gain
sc-479
FAT1e
samples.4
60,706
Chromosom
al73
llleu
5161
double-blinded
chronic-phase
=26
gamma-inducible
P=0.56
ATPase-inactive
v1.6.2
.LN40
HNCACO
Voron
FACScanto
Loftstrand
Silverscan
onehour
SETD2-H3K36
~~~~~~~~~~~~~~~bo
DHT-induced
T-2001-01
GGC-3′
Ljungman
binding–dependent
MLLT3/
CHX-chase
TGTAAAACGACGGCCAGTCTGTTCTCTTCAGGAAGGTC
35,339
.Anti-MAPK
Ser/Ile
FISH9696
Hotspot3D
TCNGA
5'-TATACTCTACCCTGCGATTT-3
KitV558Δ
Asp612
g3
gynandroblastoma
S119N
CS-10
Kmt2dfl/flCγ1-Cre/VavP-Bcl2
5806
005557
.Gene-internal
M13-R
Q443P
carcinoma71
H1904R
COSMIC27
79.01/6695
IKBA-transfected
rearrangements13
bsteII
isoform.22,26
0.953–1.593
53BP1-p53
P-1020
phenocopying
//pfam.sanger.ac.uk/search
-p27G177X
192mM
ABD-N
.Nonselective
Fourie
.Neoplasma
beta-glucuronidase
Mazzanti
0.017
P569R
NM_177274
doi:10.1172/JCI87033DS1
+0.6
5,456
Appert
RP11–864G05
min/day
transgelin
GDP-clusters
.-R
Y375/373C
triflouro-amine
ages.1,8,9
30,36,45
C.Z.
Molrep
S3.3
2633
green=mammary
RAS/RAFWT
YM024
7545–7556
avidity-based
FAM-CCCGCCCTGCTCACACCTCG-TAM
blue-labeled
M6
mightimpairtransportof
pcDNA3-dETV1
JH1-JH7
A829P.35,36
mRNP
DePinho
gluco-intolerant
larvae
5′-GTGCTGGGTCTTGTTGGTTT-3′
.Uniting
histomorphologic
expression.78
SexAI-NotI
p53-activating
Glinsky
lysozyme-M
HRASA146V
PEBG
into…
Deletion-specific
c.768-770delGAA
CACGCATTTCTCAGCATCATG
polyubiquitination
MEL22
MLL-EPS15
Co15Co16Co17
SIRT-1
NLRP1
substitution—we
nras-injected
research-purpose
DLDL
Swi/Snf-regulated
0.0148
47883
isolated.To
LAX1
ofmagnitude
Rad27
c.2438+1G
NB-1
epithelial-derived
ARHGAP10
140481298
colonies.25
H179R
548
apoptosis-stimulating
▲
SW1990
1239dupCC
control-treated
r.517_631del
hematopetic
Thr9′
DMZ
Y236F
c.1886A
SQCCs32
E171X
S262I
HER2VC
HDGC.14–16
zinc-ion
z-axis
A1948G
.Orientation
type-dependency
4146G
v3.0.8
KIF5A
inher-
GSE74442
tat
half-life
1656
erythroblasts,10
RNAZOL-B
dSet1
CellTiter-96
Ctcf+/+
.TSQ-Vantage
SGK
Fernandez-Cancio
mouse49
D300N
ubiquitylated
11–20
RNASEH2B
KIT-D816V–transduced
9.41–14.24
reflector
ETV4b
150mMNaCl
Thr230
self-contained
−1.86
protein,16
I1170N/S
reinstatement
Bio-informatique
2643
pappalysin
self-association.2,3
NSD1−1R
999
constitutivedimerization
supermolecular
inactivation3,81,82
L=
Ivell
LR03-034
Smarcc1
FLAG-BRD4
c-Jun,11,12
.BCRP1
1/55
intermediary
15-50
XRCC3-
effect.3
OAW-28
diameter/2
trypan-blue
Q358E
Fig1B1B–E
Zojer
analysis.Targeted
D5C5Z
L452
al.130
333–625
D594BRAF
pALK-Y1604
events/sample
non-receptor-tyrosine
G590S
Arg-Phe-Ser-Ile-Arg-Gln
Malagola
6K-L′
D9W2I
BUB3
reflections/no
NSH2
Asp156
HIT3α
MSCV-IRESGFP
R882H-induced
486C
c.3611-9_3611-34delinsCC
Ser-20
500–1000
DTX880
contraindicated
MIY
CRAL/TRIO
FAM58A
GenePhor
613-616
CANGTG
kinase-A
c3332
143-1870
Follow-up
1001020
p.Ala311Asp
P274L
D17S1800
ε-amine
penicillin/streptomycin
PP2A-mediated
humans,38
13851-3
YFYVDFRE
.524G4A
GKTSE
inhibitor-progressors
MNNG-transformed
GAATCGGAGCTCAGAGCGTTGCTTCG
RING-finger-containing
18+6+19+13+1+7=64
relapse/refractory
A4416
Arg99Pro
RPA
humans.77-79
Nu43/1
S438P
1.096
OD41
57/3
C334
Ct1
p.R273H
REFSEQ
polyglutamic
CRL-1629
T334
Noonan-associated
FLK-3
V600E-dependent
2434–2439
tumours48
factor/R
a-f
P05622
.RBMs
supportedby
DFG-in
7/8
2J13
A392Q
polyps.7
γ-counter
Endometriosis
R1677Q
self-dimerisation
−10.9
.MGH-U3
4/5
polyGluTyr
r=0.83
H2A.X
.Coordinates
X2-based
Stillman21
25-µl
gamma-signal
.Beta-actin
258-
leukemia/lymphoblastic
V823D
loop16
6q15-27
713.5
CD41a+
enhancer—is
polymorphism–polyacrylamide
B220−
ofthree
AB589
Boehringer–Mannheim
R1/R9
±30
thermostabilized
FGFR1-nonamplified/HR-positive
30:1
0.0–25.6
GGGTTAACGC
c.2970_2972delAAT
non-quantitative
aIn
rs41396448
p.G8R
PHA-665752–resistant
V599D
p2335A-1
snacking
CGAGGGAGCGCAGGGAGCG
p.R103C
apyrase
.Reuther
date.35
contralateral
3×
47.01
I401M
Flag-RUNX1
AnalyzedThe
1β–induced
P616R
toluene
-ΔCt
1-hydroxyanthraquinone
ERG-TLSIFUS
.Hum
Phenotyping
FLOW-CYTOMETRIC
CATCCGGCCCTGCTCACCCT
F522C
300–360
caspase3
L22-like
Ait-Si-Ali
hand-traced
.Densitometric
KEAP1-associated
5′-CCCTATACTGTATATTATATACAGTAATCCC-3′
anti–guinea
casapse
1−2μ
IuII
NP_005667
α-phosphotyrosine
.ABI
Hematoxylin–counterstained
.miR-130b
bequenued
7:3
stages.We
receptor.1
Piedmonte
0•005
4469496
3-meC
90,109,90°
HJMD
C135G
38.8
Proxcon
77731
NKX-2.8
17q22-2413AcycDh
Pik3r2-/-
pathway.35
AXL-induced
1RA
leukemia.29,30
.NIH
MLH1expression
p=0.036
S37Aβ-cat
0.782
polyhistidine
signaling.7
26,47
5,19,20
V1616fs
+Control
Micro-vessels
described.19,22,25,26
RAF1-p-ERK-β-catenin
cytoplasms
mutations88
EGFR-RAS-MAPK-dependent
-remodelling
Damage-Binding
I684T
//www.umd.be/VHL/
FCS-deprived
homotypically
39delinsAG
.WST
p=4.68e-08
HIR
sc-81
0.702
SNF5-mutant
203/160
far-fetched
MIY-EGFR
D.S
TCF-β-catenin
disease.Genotype-Phenotype
16/60
TÃŸR-1und
62/12
anti-STATS
R910-25
c.503_504insA
−124
HEK293T17
DOT1L
MLH14
neuroblastoma.9
IGCLC
FIP1L1-PDGFRα.35
IKKγ
1.01–1.69
gpllOProto-Irk
1–136
splicing,12–15
3B‐F
four-day-old
-2.2
DN89b-catenin
hsMet
ATP1B-PRKACB
inmunostained
heterozygously
imatinib/day
L28P
–19.9
sphingosine-1-phosphate
multinuclei
ND2000
0.7–1.6
anti-pY576
pThr308-Akt
Bosselut
AP23848
72/193
37–72
proliferate.So
S4A–S4F
Del5A
MSS/no
activation39
H4-D10S170/PDGFbR
070201
L290
NCATc2
works.
P871Lb
1xD820Y
8.17
Abcam
nodal
subtype22
A397P
PENSTP
sporad
16m
10A-derived
PDGFR-positive
R599e
Drotschmann
Importin7
R632X
Spiotto
Mll4
described73
ϕX
95–97
sub-clone-specific
68°C
.FLT-3
MALDI-TOF-TOF
57.4
h-glycerophosphate
XL1
4X
flexural
-..
HER2/neu–expressing
interarray
A-253
STK3/4
Dibb
risk-factors
60.88
1:24
mutation8
androgenresponsive
TCGACTTCTCATCGGTTCT
p=0.0062
NRASQ61R
instability.62,63
EcoRI–SalI
735–767
CryoTube
Jaisser
computer-aided
SSP
hyluronic
PF-12341066
FGFR2C278F/-VT
DNAdamage
c-Kit.Total
markers.96
HER1/2
LKB1-STRADα-MO25α
2–16
.Epstein-Barr
7590863.7571720
.BAC-DNA
geranylgeraFIG
KB45
Leu858
68,69
p56Akt2
AR-expression
∼29
S2231W
q-ter
Jääskeläinen
10463
cBot
KE-T286A
BCL2
ΔCtcalibrator
.IRES-LacZ
rec.html
10q22–23
luciferace
6.024
0.0039
PolyPhen-2
MEN-2A
McLeskey
L833F
Drug-sensitive
EGFR.1,8,9
H4706.52
complexed
McNight
LR13–109
5035
SMO-D473R
9.66
SU5614-resistant
20GAP
analysis9
SignaGen
hyperoxia-induced
++/−−
ever-growing
32-microglobulin
germinal
CRISPR
current-smokers
.Effects
6^14
early-mutated
509r1
6.0/5
NF1-REP-d
co-electroporation
collection.In
c.9023A/C
TAF4B
glycosylase9
double-charged
5′-GTCGCTTTGCTGAGGTCTATAAGG-3′
Pompidou
carcinoma64
ICKGCVYLEKMRFI
1,140/2,164
IFITM1-caused
ofmessages
E-cadherin–β-catenin
mam-
www.hgvs.org/rec.html
oligoribonucleotides
SUZ12-binding
antigen-recognition
4-day-on
pan-inhibitors
microinjecting
E6.5–12.5
PLCE1
15–63
Val-158-
BP-ALL
Flag-Mre11
C=0.496/T=0.504
185insA
.Narumiya
.CTGF
Y1604
genotoxicity
TIA,13,14
caspase-8-specific
MCF10ATP53
TMEM14Cmut3
79.5
Consang
AR-V3
5254
TEL.E7R
pPGS-CITE-CMV-Tcf4dN
hypothalamic/thalamic
Siderius-type
substrates.10-12
M1166R
GTPg
T354M
P.D761N
V582A
Cotta-Ramusino
.9,29,30
1988b
sample.15
Aph
p.Lys581X
Tfx
PCR-TRAP
BRAFV600E/PTENnull
Hepatosplenomegaly
FMC
FGFR135
containsthe
Pawar
TURE108,109
MTAP–C9orf92
MTC.3
.Apoptosis
Runx1+/-
tagged-antibodies
AMPK-dependent
CEA
�
Brd4/mcap
Myc-BRCA1
Banpo-dong
IκB-ε
150-ng
0.126
194/2010
Smad4-DNA
mg/d.16,17
E931G
angstrom
Nδ
R732Q
biotinconjugated
pS1
APOL637
bio-marker-selected
BIDMC2009-P-000182
S473-PNo
family,14
SLC34A2-
Ser232Pro
K62R
Col15a1
Val1092
potency62
23–25,45,46
G-CIMP+
M1b
βc-specific
ERK1G54A/S
—Kong
R625
NM_015760
SuFu−/−
SHPC
5′-TCCATTCCTCCAGTGGTGAAGG
c.164–2A
DNE
trans-Reporting
survival=32
oligoastrocytic
/pLysS
2014-03-10
mutant/imatinib
102.3
Emtol
m–p
mutationswas
c.3223delG
MMR-debilitating
Lox
5′-TGCCCCTGACAACATAGT-3′
theconnector
100-μm
D1520H
Hwa-Ryeon
PAR4
2B8-biotin
p.Thr392fs
HBZ
Immunoglobulin-like
cases.62
1762
γ-phosphoryl
18/34
.SCCs
LC-MS/MS
criss-cross
L1240R
Ras-GTP
866–916
-CCGCCAGGGCCTCCCCTCACCGAGGAAGACGTTCCAGGAG-3
.GENOMIC
4-Hydroxytamoxifen
SIFT-analysis19
PI-3K-dependent
tumors,14
29.7X
ASH2L–DPY30
1.27-fold
1Bc
PALB2/BRCA2
HERα
6,18,30-32
IκBα–mutant-expressing
2-Step
M-positive
.Graphical
6·3
factors.16
.Anti-Bim
c.1687_1700delAACCTCACGGAGCT
E589G
200X
KI-67
.41,46,53,124
Bidirectional
.Profiles
pyrido
12,13,53
OV1063
R2336H-encoding
—cyclin-dependent
NIN-6
resistance31
HGF-mediated
signaling.34
LSL-BrafV600E
Thiede
ALK5-induced
chaperone-mediated
Hypodiploid
multiple-mutant
0•75
124K
andβ
Fgfr2+/Y394C
10d
BC80
390/µL
MCF10A1
al.,7
EF-Tu
.Cohort
phosphor-FGFR
assay.20
40-µl
sequencingShort
Figure55D
Val109Gly
b-glycerophosphate
349±107
L27P
pGBKT7-p53/pGADT7-T
CIC-CF1
RET-KD-P·ZD6474
mm.Photographs
.IRF4
≤50
microdeletion/microinsertions
81-2108
Npm1+/-Eµ-Myc
frameshift-causing
W3B
factor—contacts
203/1902
DNA/reaction
ATR-B
þT674I
LH
r12
+pertuzumab
B-lymphoblastoid
Kashishian
Bioanalysis
.Hydroxylated
roles10
.Translational
immunophenotypes
SK18
TGAGTATTGCTCTCTTGCTATCTTG
1.6
low-serum
N=10
shRNA-induced
8q12q24
H319Q
.Dewaele
510-nm
3bp
exportin1/CRM1
pathogenic,23
kocytes
31.38
tumor-cell
Ligand-ERK2
ARID1B-1777
isothiocyanatephenol-chloroform
PAX8-PPAR
R898A
/lookup
multi-threaded
Rho-ROCK
Ins770SVD
Plasmablast
AA-V600EB-Raf
1644-1665
differentiation,1,2
9.5-
Activitiy
MEK1-K97M
thec-myc
A442
delP95R-R102
damage-associated
.PNT-Domain
PHD-containing
Plus-70
suppressor.13-15
ponatinib-KIT
Meprin
IgH/MMSET
HS729
Medience
//www.rcsb.org/
L139P
TSS-2000
p53*
1,520
H1299/R273H
Homoligomerization
TPHPARIGL
methodologies.14
CBDCA/GEM
3808
.MYD88L265P
Lassle
E554K
Schmekel
million1
`intrinsic
postinjection
GTTGTAAACCAGACAAGGC
.Electroporated
Steenbrugge
SNUH
460–490
range=108–167
A871T
Buhard
93·4
oncogenesis216
METHODSMSH2
samples.12–18
546
RP11-754J8
RET-fusion
Szanjert
Kinase-defective
0.696348
3,4-Diaminobenzophenone-phosphoramidate-GTP
large-amplitude
UV-specific
A4623
Gunma
.MLN8054
mg/3
pAD/CMV/LACZ
pCMV-VSVG
LeRoith
PIK3CACAAX
1.Inhibition
cAMP-controlled
5′-CCGAATGAAGAACACGACCAA-3′
DEDΔ
.TranscriptCluster
TGF-β-
S-18
60.9
proband
T599_V600insT
27/35
mant-dGDP
1,540
D831
mutation/amplification
RapamycinInhibitory
.CI-1033
39
syndromes.12
drug-resistant
Binding—HIF
Egg-laying
59-TAGATGGGTCCTCCTTTGGTG-39
TATA-EBV
2007.
Aspreviously
TFSearch
tetR
LOC441179
J.If
PTCH1-S616G
.term=lgk974
FIP1L1–PDGFRα
25-pound
forms.31
Fluorochrome-labeled
°C.DNA
​and6E
respectively54,55,56
tetramer-associated
pGEMhp53
018664
TrkA-I
arescattered
​and6C
Mdmx+/−
45-nt
CA102774
GST-RhoA
S53
pMSCV-IRES-EGFP
PDGFRA-overexpressing
Pinsky
hallmarks.1
Stella/Dppa3
−PTEN
BAFF-mediated
R544
0.276
20Division
CP01
Asp-739
163:1721-1727
1–99
1512
ERRBS
NLS2-Ala
N-C
motif.9
hMLH3
5′-ATTCTGCTCGTGGAGACTTC
N771INSSVD
Trp53-mutant
C102S
G-PROTEIN-COUPLED
Aebi
Q343R
HER2-related
HERVK17_S
fascin
alkylated
Wagenmakers
.K-RasV14I–mutant
PUREGENE™
Inflammatory
CHD-family
reversetranscription–polymerase
interspecific
Lipfectamine
5'-CAGTATGGAAAGAAATAACTC-3
manner.177
MYH9
Alpha-thalassemia/mental
0.1-50
V328-329ins
hemorrhage.6
Y1384C
1,525–1,770
177as
¢40
denaturation/renaturation
newly-reported
V600F
HDR-dependent
L10-120
1§
Brca1SF/SF
KRX0401
.71
n.d.
≈40
TrKA
tct
p.Asp1213GlyfsX2
ago.66
chloroform-saturated
µl
TAAD/LDS
Fig.4D
89.9
capillary-gel
self-sensing
5-GGA
PrEC-ERG
subjectedto
Thermofluor
p-TYR
lineage-positive
S744I
Gly2
TrkA-dependent
W131G
.Phasing
16.R335H
GFLs
biomarker
adverse=25
halluces
Amy-1
58-end
DEXDc
TCF25
Flag–D1
−78.2
D12S1581
Area/
3~
.Interacting
J053
G64V
ln=PIK3CA
megabase
p.R487Q
Ado-trastuzumab
Exonuclease
CAG1TFCATACCAAGUCCF
5'-CAGGC
Y6044C
.Friedlander
fibroblast-type
1,248
p.Leu159Glyfs*20
p537/7
I278V
Giebler
29†
5′ATCTGGCACCACACCTTCTAC3′
CD23
..*
Osthus
phase.20
IL-9Rα/γc
Lab-Becton
0/281
Tyr589
anionexchange
cancers.31-34
A458T
Roock
-p
RD2
use.4
RUNX1/AML1
disease.14
5′-GAGATGGGGGTAAAACAGAAGAGTG-3′
UAS-CycD–Cdk4
0.0417
A‐agarose
H-235
W2065R
0.9-213
pT24-transfected
cadaverine-Alexa
Hypertensiona
egtazic
E482K
pRc/CMV-A339V
Autoantibodies
abovebut
.B-RAF
telomeres6
7/31
747–753insS
A728V
No.sc-8312
mL3
Extranodal
receptor‐interacting
Viewer82
suppressor,60
Gfplow
HiSeq-2000
1155
genein
kidney-associated
SOCS-mediated
select_db=NF1
34585
anti-phosphospecific
means±SD
SPAG9-JAK2
TNFα-activated
RFS-MycWT/Wap-Cre
.Flag–D1
Raf/MAPK
BCLAF1.33
22,25,26
249
19·0
patho-biochemistry
activity82
pathway2
T/3R-I
interaction-blocking
development21,22
Faraone
β-glucosyl
Tonin
components—F-box
5mCpA
20-ul
/c-myc
GCCACCCAGAAGACTGTGGATGGC
IP6
V2THS
G47
L536-HEG0
methylxanthine
noncoding
AAATACAGAATCATGTCTTGAAGTa
triple-band
oxygen-dependant
hyper-methylated
469–471
promoter-luciferase
R791
observed32,33
first-
BRCC45
Tgf-TβRII
Kiese
hTert
NRXN2
A_52_P680941
microtubule-kinetochore
.Overexpression
≈557
L61P
29.1
SNF2-related
APOBEC-mediated
G861
ETV1-mediated
Smad4.52
Godfraind
NS-mutant
DEL/DEL+PMs
expressextremely
FBXW7-associating
-specific
regulation29
K607T
expression5,76
pnas.1321155111i9.jpg
Kco15
jg/ml/1
GSE57194
.Afterwards
A623S
MetI
EN-driven
TR-target
damage-inducible-α
LYSA
cancers61
AKT2-I289M
histone-methylating
DSC1
CD9I
2039
1r2
cis-correlation
assay.8
occasionalshaking
mo_p53
BRCT-N/BRCT-C
reported9
S101
method.28
Ser220/Ser225
NSCLC124
Sensograms
non-myr
eitherstroma
residuesfound
pleural-based
446MMP+
ProTrpTyrGInLeuSerAsnThrGIuAIII.AsIIeThrGInCIyArgGluL-uCIuArgProArgA
S12-23181-TP-NT
TY4
K623
5181del3
lipofectin
Thr488
deletlon
'*-Â
HFFs
METHODSMaterials
RBM10
M537V
P151A
trastuzamab
p217
medulloblastoma15
MB36
High-tech
20-year
Temperature-Sensitive
exit35
pCUB79
5671
quizartinib2
micro-tip
coverslip-embedded
haematologica/the
ARHGAP6
Cre-positive
.N233
capability.Definition
72515_72517
NCT00965250
Lex
antitransforming
binding.2
c.1764delT
Y589/-
kinase-encoding
pack–years
Vav-KI
Pro4309Ala
G34
bortezomib-induced
T1669G
81.1
2Rß
0.7–42.3
p.Glu4882ProfsX36
CBP/p300
Cogenics
2128
Myelome
MGC13040
Leulliot
TP536
Ga1
Histology*
Bric-a-Brac
Policlinico
147920
medullablastomas
pUHD10S
GRAALL03/GRAALL05
NF1–Noonan
bcl2fastq
PD20
Bi/multinucleated
I-induced
NM_0000546.4
Puromycin-sensitive
//dx.doi.org/10.1530/EJE-11-0929
gene,1
morphogenesis17
2Center
UPN2
73.2
p.F508_K509insFAF
bases-i-+++++++++n.s.n.s.CytoplasmNucleus
f/74
synthesisand
.S4c
PSMB1
IVS10+12A
4897
c.-74insC+c.-456_-453delCCTT
Avance-800
3,040
G267D
increaseddensity
18/20
6q14–15
.HTLV
33428245
T6557
AlCl3
V1346M
18q21.3
journal.pmed
+51
products—the
A775_G776insYVMA
-CRLF2
rng/ml
AGS/neo
betweexi
.Contract
fatenir
HIF-2
D148Y
monotonous
Notch-centered
Ã²r10~8
A2466V
ash-leaf
»
Lys569
-cell-specific
1,750
BRAFK600E
109,110
CAGGAGCGCC
'Hippo
C.H.U
theexperiments
MONO-MAC
GMEPS
Blastp
DKO
Y11306
onc/1205250
577-582
Immunoprecipitation
.Goat
helpfulin
S49C
.Irradiated
BCC44
D543N
c.2563T
p=0.87
\0.001
4B5
.SAV1
797del
Q448E
LKB1-mutant
bear-
1Hi
D283
Cirillo
retinopathy-like
self-interactions
p.Glu71del
8RG
NBS-HGG
c-KIT.20
RNP-CS
R1339C
693
JR2355
xa/xb
50μg
SLC35A1
5H1
LB9501
fructose
.Nanostring
GAAACACAGAGAACACCACG-3
R213X
mephrins
wtBRIP1
rs17879961
5q13.1
.7Furthermore
trpE
Gal
ubiquitin-associated
proliferation47
Fat1
p.R171S/p.G196S
cystatin-related
B′/PR61-γ1
~twofold
Pan-p85
pp70
T41N
16/F
Surralle´s
viability15,16
Martirosyan
RG-4T
5527
9131S
Phe442
dual‐specificity
unradiolabeled
C1F
haematoxylin-counterstained
.FL1
32P-ubiquitin
dsRNAspecific
defined27-29
Levine5,6
cover-slipped
GC-experienced
Francke
entially
over-fitting
pentapeptide
Abcb7
anti-tumor
NTRK-1-related
Xenopusvitellogenin
Merck-Millipore
PAb1620-reactive
PAX
CD34+CD16/32highLK
Proliferative
xenoantibodies
Nagaike
ichtyosis
camptodactyly
ttgcag/ATTGGA
GTGG
.Reasoning
proto-TRK
K'R
.374Never
67–135
PNT-domain/MAP-kinase
entity.1
EcoRI-PvulI
1.41
Photobleaching
PD901
JAK2V617F-induced
Ser65
2807.0±364.8
p*mel
pathway2,4,5,6,7,8,9,10,11,12
estimates.21,31,32
copy-ratios
CTTGGC-3′
5′-G
ATCTGTTAC
40/97
Chromothripsis-Driven
chr17:34846173-34846521
CBL-WTorV5
genes.25
PSA-luc
SH2B3
anticariogenic
p7ork
microfocus
sesquiterpene
Probe-level
MN61
N161K
RB2-RT-MGB
analysesThe
poisons.25
1.2.2
deteced
3–61
—only
PRC2-driven
PAK-mediated
553–559
unit–spleen
Bosotti
‐4‐
HIF-target
N-18
CRL4CSA
ISPB
replication.7
Arid1aflox/flox
concen-
pathways1,2
S3k–l
A102D
deacetylases,4
200mm3
21702
anti-Brg
Thr-59
Ig-I
-supplemented
4539T→A
1S5K
H202
ofNSD1
tσ
BWH
sensitivity24
Ile
Bordetella
caspase-independent
Lpl
0.001211
.18q
N-phosphonacetyl-l-aspartate
P501T
primersequences
YY1–1018F
CSGE
clinic—not
SETMAR
miceSnf5+/−
−3.24
dimer–Cul3
described.29Clonogenic
mentale
3.Association
pT538
characterized14–17
OPM2
*10A
Fig.8C
//www.compbio.dundee.ac.uk/www-jpred/
=32
events8
NPM-
KDR/VEGFR-2
//www.sanger.ac.uk/genetics/CGP/cosmic/
HSXB9
133/289
multi-subunit
69–72
5′-TATCTCCTCAACATCCTTCCACTGTACTTC-3′
exon-specific
Efferent
Runx1m/+
bHLH/Zip-type
sc-23921
32highLK
suprathreshold
NCT01283945
Low-intensity
MEFsa
/e
poly-d-lysine/laminin-coated
al.,25
αHA
3cen-p21
5′-TGTAAAACGACGGCCAGTTGTGTGACATGTTCTAATATAGTCAC-3′
cpm/ml
andPI3Kγ
Dose-effect
∼35-80
Brca1Delta223
4,5,13–15
WM266
HER2MUT
5′-CTCCAACCTCGCCTTTTGC-3′
EGR2
Glu-993
RG7204-treated
G5373C
HuGene
R06
.Retrograde
M1166
CCTGA
XPC–RAD23B
Thr204→Asp
A232V
PD9
.Nonrandom
lysine-
glioma18
Vesicular
ErbB1-4
N62Y
p.Phe232Cys
cell-depleted
pseudopapillary
IHVl69Acell
KU58948
nonhaplotype
pcDNA3-wild-type
30.8721.0
TM1-TK2
.Increase
cancer,21,22
rhabodomyosarcoma72
Fig2G2G
signaling.21,22
1.33-4.54
DDR-deficient
DP-2976
Takasaki
WNT-pathway
Leu333
SEC31A-F1
17,31
IL-1RA
.PCVs
_Pwo_
Mitoferrin
dasatinib.17,47⇓⇓⇓⇓⇓⇓–54
.Fig.22C
tests—Spearman
7FF4
.WT8
2210
C169Y
177–243
STAT3β14
18,31,32
Carna
c417–46
5′-ATTTTCTAGGAAAGAGCTAGC-3′
5′-ACC-CTT-TTT-GGA-CTT-CAG-GTG-GCT-GGA-GT-3′
substrates15
EBV-lymphoblastoid
099
parallel-displaced
R468C
1,539
5-11
Lkb1-SL26-transfected
0950-9232/05
LinesTo
p.Asp86Asn
anticorrelated
p27KIP
Eμ-TCL1-SCID
hydrolyse
suppressor43
RB1up-RT-se
TNF-α–related
VEGFR2-signaling
G348E
4281
CA57208
0.26–0.79
PH-LIKE
*S.R.B
training-validation
C318Y
87,410
PDGFRA/RP11-24O10-SO
CCATTTTCCGCCGGCAATTG
domain176
Bremen
30,988
multiwell
EML4-ALK
K-E-T
446K
MPLW515L—the
LowModeMD
Cdh5
T-Cell
breast,3,4
SHGC-33468
IFD
bCDK6
C-pEGFR
NBS.5
JAK2-TELtranscripts
g.3100
Wollnik
pPAX2
Flag-Med12
characterized.To
observational
viable28,29
endonuclease-based
2587X
Numis
glioblastoma,28
11Val555_Leu576del/17Asp820Gly
S257A/T261A
al.,1994a
.FAT4
Myc-SPOP-WT
Fig.1D,1D
.DNAs
TRU
CBF-AML—at
CMK3
IIIb-E1813A
5′-TTAGGGCTTCCTCTTGGAGAAGATCA-3′
TTGTTTAC
Half-filled
complimentarity
PROGRESSION/SURVIVAL
dierentiation
peFigure
Epitheliolid
1790
Quantifiler®
KITD816H
nemission
A1948C
Yamashiro
X10
1.6–16.7
.Gyory
P-Src
tumour-initiating
PLD1
118–120
sc-6396
pQCXIN
instability-high
derepressed
80,000-Da
T725
young-onset
TET1-mediared
SLC3A2
p.E545A
1770_1795dup26
co-operatively
phosphodiesterases
S241F/+
thosecausing
p.Thr2681CysfsX11
.3B3B
p120GAP-stimulated
all-heterozygous
.Lats1DN/DN
c.426delC
1,3-5
CrkL
Akt2E17K-GFP
823_1113del
mmp9+
documented13
LF1
M745
phosphatidylinositide
anti-CD144
choreographed
.Donors
Mutant-containing
latency.15
Gly346Glu
.Species-specific
mammosphere-derived
239del3
1195
p=0.105
mll2
stage–dependent
T790M.86
AML-MRC
1897
PRIP
F0
human-C
exon-spanning
pSIC.PRDM1.3′
S277N
activity.41
59-TGA
log2-ratio
anti-pJAK2
JAK200Rbio
FRA-45l
database*
org=human
genomicdeletion
SectionPatient
cancer121
determing
3954R
lieu
977
lenging
BET-bromodomain
.0626
r=0.68
R1275Q-ALK
.Anti-ERK
1H-I
p-Tyr654
PGN-SA
164008
Val2006
SigmaD
pp90RSK
eGFP-expressing
pRbmediated
lumenal
EGFR/Ras/MAPK
cotransfections
6repeat
R374Q
SCCOHT1
SPOP-AR
MSH6Combined
Msh2pMsh6pinteractions
12R5-1
Romidepsin
1–106
0.23-fold
5′-AGATGG
seereferences
urine-based
150-mm
pT1N0Mx
rkramer
al.,1985
909–979
0.881
Captisol
1576
Dual-colour
11q-aUPD-positive
TLX1-overexpressing
Rheb2/RhebL1
Butti
MuStab.13–15
Thursberg
3733–41
SNP-array–based
MEL-UKRV-Mel-20
=~
587T
TrkAI-transfected
NM_008815
Mod.diff
HA-Akt1/PKBα
Fig.5B
10~*
ndicate
T286R-KE
G897A
R187P
brc13
complexes31
L3T4
∼2.5-fold
Bcl-xL–tubulin
qRT-PCR
pGL3-Tg
0411B
2745
EfficiencyBecause
c.847+1G
Fab
SK-MES-1
∼54,600
24.7
TVCDYT
T-20
-CATCATTGCGACCCTGGAGGTCATT-3
N1358H
RETY791F
EPHa2
counterselectable
Y441S
R175
EVEKLDNDHLMFRGNTLATKAMESFMK
TPS6KB2
MUM-1
579-base
.6325T
.55B
KRAS-induced
bleomycin-induced
dideoxy-based
.MALDI-TOF
p.S347C
Refs.1-4
tumors—in
-GTGGTGCACTCGAGTGCTGGTGCAGGGAGG-3
FGFR2-C342Y
A20-type
ATTCTCTCAGGGCCAGCAGTTCTAAGC
Wapcre/+
0.733–1.264
0·64-0.94
14p.A502_Y503insSAy
single-extended
Biotinylation—Transfected
93/102
c.1226_27delAG
T6E
0.1x
X=305
'long-lived
−0.1
IVS9-19b
un-spliced
IRneo
G1381E
-CATGACCGTAAGTATTCCGTGAG-3
I-kB
C817A
tMffTf
identified10
N318D
starvedfor
100-fold
C3H/HeJ
Leu62casp-8-transfected
cell-growth
meta‐analysis
.Immunochemistry
coherenceppm
.Wentink
aIuTyribtArgH
HIV-MND
D761Y-containing
mitogens
fmding
Gna14
RNA.23
94°C/20
0•33–0•47
c-j
theAmsterdam
GenomeStudio
1p21
R776C
re-elevated
44U
5′-GCCTCCATCTTCGGCACCGA-3′
ribozyme
.Enzyme-linked
3,913/2,852
16600
cancers.42-44
R395C
Chandrasekaran
8326
PoPro3
signal-responsive
HSC7E113
5.a
detected.5
non-G12C
280–400
Cnopf
h/0
MPN/PMF
D217
nanoflow
.NUMB
Hes1GFP
NCBI37/mm9
chromosome–like
hand-in-hand
GABPA/B
vein.3
ERCC2/XPD
30-wk-old
RAD50-dependent
Dynameomics
1O
keyevents
11-mutatedcases.7,8At
A384T
5084
differentiation.12
scratch-wound
anti-RNA
JX013981
600185
APR-246
1.5-2-time
DEN–PB-injection
Con12/23
CDDP-resistant
R183H
.db
deglycosyolated
far-Western
ficient
culture.21
NCBI36/hg18
NdeI–NdeI
3,4,5-dimethylthiazol2,5-diphenyltetrazolium
c.a
S67P
656–680
IgG1-PE
75-nucleotide-long
FIV
1.80×104
Augenlich
V3THS-380110
59-CATTGTA-39
.Histo-morphological
.Testosterone
S1186L
Saarikangas
ex10-BRAF
2-methoxy-4-nitro-5-sulfophenyl
1e−3
p.S635
Rajagopalan
28–72
0–6021
gene179
BRCA1.The
30,83–86
18.33
S2088F
ERG-3D
Haelens
0.172
——
eosinophila
16.12
pOPI3CAT
CD4‐dependent
5/34
TGGACCCCTCCAAGAAGCTGGC
M54V
.Discarded
diseases—the
.Tet1-deficient
C.and
HapMap
2129
Crevier24
87m17
118.5
fac
–10
.CSC
4,933
PBS-1
GFP–VHL172-positive
intraepidermal
HER-mark
anti-CBP
E412V
VAIK
SGK1
waf-Jlcip-1
pG418
78,200
butwithout
ATF1
K196
Data|M
adenoidectomy
311-347
32.38
S6K–S6M
50kb
lines136
STS-1
pLS76
gene.4
Sprouty-related
.Exploratory
L74
KRT14/5
EGFRT790M-containing
Tyr112His
ENST00000367145
noncerebellar
56772504
periodic-acid-Schiff-positive
SJHGG004_D
hoc
NPM1-RARA
13m
size-matched
IFL
Narishige
.African
single-
-nonamplified
Dualcolor
~0.7
Fengmin
intuitionisticily
fibroblastsor
angiopoietins
more-complete
P101-B1
mutation.45
RXDX
FLAG-IKKγ
SKOV3
06-760
T507
GawB
6+
MM5-101R
100ng/mlrecombinant
*Present
DelE709_T710insD
p-value=0.01151
DDR1-binding
lobule-alveolar
E2014K
CytoSelect™
839/μl
RP11-726I20
P08069
A_51_P204454
exome–capture
cancer.32
RPS
inhibition—nucleotide
H3F3A
Lent-shRNA-SOX17/Lent-shRNA-control
polyubiquitylates
cáncer
I254F
dnERG
anti-ElA
CACTTGGGCTGGAGTGATTT
.Co-localization
D1–3T3
peroxidase—conjugated
Cdc20-activated
occur.39
Y214
4I–L
CATATAACGCGTTCTCTAGTG-3′
C-H
.33C
K16A
1387delGTG
BARD1-
mg/M2
213342_at
co-repressor
.Dierence
HVEM
20560291
TBC1D10
pLenti-6/V5-DEST
.Anti-Thy1.2
c.1940insC
Ligation-Dependent
5′-CAACAAGATGAAGAGCACCAA-3′
ECFP-MyD88/L265P
21-specific
rotor
636–base
DGGE
Figure.8
FGFR3Y373C
Kiapp
KTN
KIT/V564A
granulomatous
soft-shell
MYCBP
Leu-7
pathways31
NVAMP-1
RDHD1
Neo-resistant
3βR
NM_053262
Lkb1/
-attgcctgtgttggaagacagc
downregulator
carboxamide
W290C
PU-1
P0013
D143Q
N-benzoyl-staurosporine
panobinostat
19:2607–2611
previously.15,19
Y1022
genotype*
transferFADDFas-associating
3.1–96
28580
pRsc2-D540G-myc
85-amino-acid
tumours=7.5
delachapelle-1
p-MAPK3/MAPK1
p74Raf
input_SNPListAnalysis.jsp
34,37,34,36
66G4C
5′-atggccggctatctgcgggccgtgagc-3′
Carson-Jurica
R139K
Isw1b
0.185
823-843
.TaxolÒ
AKT-expressing
SOCS3-YFP
benzimidazol-2-yl-carbamate
Arid1aflox
SUM159
CFA6
incorporating
5′-GACAGAGCGGGACAAGGATG-3′
TEL-tyrosine
RP5-839B19
epimutation
.Size-exclusion
CREB,2-4
si07
4·8
PP2
PDGFR-β-expressing
.Non-negative
L175R
0.0247
35-year-old
iView
3.7×
neurohypophysis
KIT-Y823D
apoptosis,33,34
30.64
α-Erk1/2
54/f
.Graft
PT06.2
I2672
GpA
45/75
2.36
p16/MTS1
BAP1-ASXL1
AntiphosphoAkt
1606delT
DOK3
S464X
HSD17B
phenotype14
12q14.3-q15
buparlisib
MCM10
22Q/23S
sublines
.GAACGTGGTACCCCTCTTCGACCTGCTGCTGG
HX
.6-13
mutS+
studiesindicated
understandingthe
vector-containing
self-referred
.FLI1
0.0527
S2AB
E6-AP
.Accelerated
non-aggressive
methylsulfonylethylamino
Notch1–4
5′-GCACCAGTGCCCATCCCACTGAGCCCAAGCACCAAG-3′
10µg
anti-p27
CTAGGTAGGGGATCGGGACTCT
null19
non-anonymous
Trastuzumab/paclitaxel
.Ueda
Klift
.Log2
.QRT-PCR
function.Previous
NUP98/HOX13
11207750910
.Informa­
cases.7,10
mutations.1,2
pack-years
PA-associated
C342A
5′-CATGCTCCAATAAATTCACTGCT-3′
p.D446N
SEC31A
Ba/F3-TEL-JAK2-treated
moderate-to-severe
4087197
phospho-Chk2
EWSR1/ETV1
S47R
didnot
NF-κB/IKK
end=1069
GST-PMS2
sizeFive
kidney-sparing
p-p70S6K
.Trigeminal
CTTAATGTGCCCGTCCTTGT
Asp892–Ala919
V157F
MG-132
4-09.Case
c-raf-/-
TAATACGACTCACTATAGGGTCGATTCATCACCAACAGGA
metastasis.27
enzymes6
TBS/BSA
Ser33Tyr
ΔH287–Q289
TNFRSF1B
RIP2/CARDIAK
intermedia
35A
AX10
XG3
death-inducing
call-able
816
megakaryocytic-erythroid
αC-glutamate
Sdha
studies4–7
VAV3
Nkx2.1
FMT
T573S
cAPC2
threoninc
SO2CH3
SCCOHT
COBEA
RnaseP
_MAP2K1_
saline-TBS-Tween
de®ciency
KIT-amplified
1785
FAB-M3
EPOR-shVHL
pLX304
lineage-survival
G171R
7×/week
sodiumacetate
methyl-specific
.Once
sequence.14
P/A
L539A/L540A
S672R
phopsho
I.2
C-CDU
Bioplates
.2804
Cebpe
S37Y
onset.50
Phrap.14
–7
pBabe-GATA3-WT
c.C3736T
R2c
F/45
BCORwt
SND1–BRAF-transformed
529KB
david.goodrich
BCR1
MLL-deficient
Ser436LysfsX22
fusions.1
K14-creER
.GC-MS
T1130M
13,14,39
HGF-positive
41.5
44–81
Avalanche
.J6E/JXE
non-promoter
tissue-microarrays
6p22–p24
del829-88
ubiquitin-binding
4005
Gemin4
SUC2
hypochondroplasia
hydroxyanisole
ETV4_3VUTR-f
PBase
Ras-Raf-1
R-CHOP-21
128.00
32,36
7/466
Q207
high-volume
null262Q
D699N
P1311T
Mito+™
Thesolid
andmismatch
DHL1
mcf3-encoded
oncogene-transduced
neI
−900
representation…
213/852
receptor−expressing
BOTSTEIN
ORC2
9.62
twodimensional
RAB11
.Scattered
signalling151
p.Arg1076Cys
C277G
IGEPAL/NP-40
QRSTpS259TPNVH-COOH
p110-C2
E668K
1,4,11
W741L
1R-CGCTCTCCCTTACTCAAGCTA
C268Y
spindle/squamous
98.4
L330H/P/R
4I
FA104
re-excision
A219D
GeneOverlap
Hdf2
D16S3121-D16S3026
Raf/MEK/Erk
III-reverse
.M1R
P15INK4B
1488
lumphatic
∼60.0
4H4
162.2/Mb
Klupa
transformation37,38
4:124–133
cMET-positive
α-phospho-Akt
transient.12
cell-cultures
rs9600079
7–49
7.DISCUSSIONThe
CML.30
RNaseA
p53-luc
23.
CD45-Percp-Cy5.5
c.943
TERT-HME1
Hs00427621_m1
intraperitoneous
.8,11,15
1.1–1.8
ALU
experimentalconditions
function-specific
cancer.Advanced/metastatic
0Neoadjuvant
c.7976G
5′-TCCACCACCCTGTTGCTGTA-3′
p.M389I
d'Evaluation
DS-AMKL
homeotic/Hox
KCNQ1OT1
SG11
pGL2-Id2/E
Hs00183486
require-
Protean
2921-3991
.40
CTM
deviation.Chromosome
zationsimplyendorsementby
SLA2
FLAG-Krasnat–transduced
​STAT5
.WT1
Trp53LSL-R172H
Damage-induced
capture69
.Tetanus-induced
8-μm
reported,4
GST-α-Fbxw7R465C
105/60
M43
29563
respectively.Studies
DNA.67
Gymnopoulos
—in
Tomkiel
pRLTK-Luc
Zn-coordination
anti-STAT5
ARHGAP18
Cismasiu
α-β-catenin
S4A–B
2606T
,5C
E217K
ELN33
KLURA3
FIH1
4380
miRNA-mediated
cluster-based
35219
.MC
.Output
IVS2-1G
K.Sushia
gata1
episodes/patient.year
q11.2
protein.The
KIT+KRAS
P389-A1
MGC:35174
D-phosphatidylinositol
Institute-Common
post-synaptic
forms.1–3
∆CB
c.802C
0.4425
data,12,13
12q21-qter
cryptochrome
AH006664.To
C250T
W741C/L
6/40
Vaxillaire
mutationsconsisting
mechanistically-based
Rad51chromatin
.EZR-ROS1
GATA3_03
15,106
stathmin43
6217
397-806
5′-CGCTCCGGCTTAGGTAACCGCT-3′
28–31
differencesin
Noc/Yese
13/13
+Prop
hACTB-Reverse
3–20-fold
94608
Inthis
R100G
Cdc20-mediated
1c
patients166
.Lys73
GATCCTCAAGAAGAAGAAG-30
L-carnitine
atggccgcggccggctggcgggacggctccggccag
Akt-T308A
38-amino
.Integrin-mediated
ETV6.Fusion.Ex6.1F
thermophoresis
T2133
genes5–13
lymphocyte-enhancing
ERG-D39
Ei
benefi
carboxyterminal
CellTiter
1.45*
COS-1/HeLa
great-grandparents
FP14
V9M
`F8
20-221
14C-labeled
L.M.K
specificity.17
5.82893
29/154
Robertsonian
1976
R-TSC2.ivs22
£ank
0.025215827
B27
Caenorhab-
FISH/chromogenic
indirectly.36
Asp46
1156insA
melanomagenic
15-wk-old
T373I
autografted
ctactgcttgcccagagctctgtccagg
Geisser-Greenhouse
b-cateninS37
pTRIP
Erb-A
insulin/C-peptide
PP6
γH2AX-ChIP
reported.40,41
9-nF
aspartatic
.Flank
gd-T-cell
.S0516T
EWS-FEV
tumours8,9
PLX4032-Sensitive
retro.puro
.Clurman
TpLN61R
N1522S
functionalloss
.MCMCglmm
V617F
NCT01121393
IDH1-R132H-expressing
N981I/T
​andE
Comassie
pseudogenes
ALPS-like
.SRNS
R175H/L344P
Calcium-flux
892-894
0.812
Aberrant
mir-19b
37×
+85.052764
intraprotein
LVKVADFGLSRL
HydrolinkMDE
minus-DNA
3′-UTR
HCC78CR3
0.946
phospho-ATM
G321S
Yushima
4138
3108-1
anti-NOTCH
MG↔U
Noi
26/41
RNI
7p12.2
K5.Smad2+/+
.NT_011362
0.536
K125R
non-carrier
μM.18
n=92
E-
2.00+.40
mM-1
5-CTC
Fig5B
Kirsten-
Dis3
chemokines
decameric
32.378*
methionine-for-threonine
PT66
AKT1
L159F
tetra-acetylated
Hefei
sc-47694
DAC6
mastocytosis.9
R240C
pVHL-HA
BRCA1-truncated
SRP049005
60,61
.4627C
SWI/SNF
4.5.4.package
pMiw-caFGFR2
4H-benzo
Histidine
LexA-I68N
Referencesc
width=1000
Fattoroso
immunostaining18
Puc1-390
nt+44
Pharmacologically
A58-89
green/blue
cramp
TKI-dependent
MIP-2α
Haematologic
D281A
CD29+CD61+
studies49
breaks/secondary
C.-H.
.6
RCO1
tumor,32
com/doi/abs/10.3109/10428194.2012.723706
Ets2
p.G288R
2.138
Trp22
supercompetent
BUB1
René
Heidel
,5A
software.For
NCT01393730
genomic/transcriptomic/proteomic
â€¢.â€¢-
T3wt
PBRM1-immunostained
antigen84
beenscreened
MLP
5C3
ESE-1
Ulm
0.825–0.83
37Â°C.All
HUH-6
results.31-34
X‐100
0254
60–73
sequencing-by-synthesis20
.Regulation
FREM1
31S/IVS2
Ala156Val
16respectively
hyperphosphorylate
adex
P480L
pcDNA4C-NUT
14-dATP-labeled
p.R249
Kpn1/Acc651
ETS/TCFs
97-18
GGTTGGGTGGATACCAGATCCT
probe23
lack-of-growth
5′-CTCTCAGGCATAA-
andWestern
126–95
Smad2–Smad4
tumorigenesis91
alcian
0,4
TCGA-BT-A0YX-01
34-kDa
SEPT5
D226
33.30
8.19
destabilised
MSCV-PGK-NEO
mutation,22
H1672
PEO-1
malignancies.13,26-28
Met/hepatocyte
Pim1neo/neo
Anbi-pTYR
I171T
=132
PDE4
S125L
pcDNA3-myc-EGFP
CD3-mediated
acid-based
.U04847
XM_194344
3726
786-VHL
590402
MDS/MPN,7
dimers.7,8
NRID
GST-hBAP1
VAC
STK36
IU/liter
95-4
–11.21928
0.2-micron
F40
antibodies53
use39
4AG12D
scale13
.Double-strand
thioguanine
Rap1-GTP
hypermethylations
7.D.1b
H1299-p53-R175H-clone
c.1114C
Domestication
subgroups1
hypermethylated.K-Ras
HCHO
Mx1-Cre+Srsf2+/−
SCCa
p.Y42F
RTPS2
MØ/DC-1
10.8
CV-l
pepcoil
TGCAAA/gtaagt
Figure2O,2O
3U32
dissociation-of-function
pGPD-TRX2
.Wijnen
24-hours
masto-cytosis
N-termini
KUPIEC
α-32P
5′-ACTGTTCATCATACCTGTTGACTGC-3′
92.62
study182
147,633,067–147,754,364
5′AGAGCCTGCGGAACTGCGCG3′
Measurements—An
Core-amplified
nucleus9
0.33–0.96
Immunofixation
0.14-fold
Lats1+/DN
kinases/phosphatases
PHF8
Fig.66A
anagen
prodrug
loco-regional
08-01-98
F1761
cells.Patients
PGE2
ƒÓX
lip13q22-3416
Y1289
GCCTAT
5068C
sulfate
59/M
Biobank
BCOR-3954R
16,17,20
.Howman
42–84
adenocarcinomas.Materials
theTyr537AsnERmutantpossesseda
oligomerization–transactivation
3′-diaminobenzidine
theAPC
G81
Phospho-FLT3
theMLL-CBP
P-p38T180/Y182
mutation+/HER3¡
Orius
43.7±7.4
I1855
tumor-propagating
c-MycER™
Tryggvadottir2,3
Darmstadt/Germany
ATERIALS
phospho-FoxO1
Non-transfected
32P-phosphorylated
CAGCAGCTGAAC
Omenn
anti-pERK
tumours41
separately19
Gene-internal
KRASG12C-GTP
miR-99a/U6
hPMS2-134–MutSα
p.Thr377Ile
.§A
3.6-fold
P56
miR-142
Anti-Ras
mature/immature
5′-CGCAGCGTGACCGCTACACT
One-P
Kit-negative
al51
.Yun
apoptosis11
anti-9E10
.0665
in-utero
c.1267_1268del
R6862
FLAG-Elf3Δ237-241
BT-483
1:49
non–dominant-negative
Chr9
talin.27
MAPK1-specific
AssayFertilized
transcription-translation
103/
1518
.CHO
XPA
-ROC1
HoxA9
3011D5
nuclearpore
A40
330KB
W1497
ansonin-1
scorea
excretion
mev.html
JNK-specific
TFAP2AΔN165
17B
RASTER3D
others,41
geographically-distant
women.54
paired-ends
0.703
EGFRL858R
CEB
F595K
ER-LBD
nonpretreated
Noninformative
comedication
EGFR25,26
.UUT
FACS-based
3969
CellsDirect
protein-phosphoprotein
Brancati
hFANCD2
77/M
Y364
E1367K
China2
P148S
EWSR1-2
lines,14-16
αRAG2
T5002C
miR-9
Δ12
c-Met-H446
common-SMAD
Clec5a
V560D/G
TTTCCT
early-middle
ssDNA69
NMD-Sensitive
TACC3ex13
Magna
function—particularly
7'4
HBS+/glycerol
anti-p-GSK-3β
A204E
36–59
D911A
32P-consensus
OCTA
0.1.13
R534Q
1031
752–1044
noncovalently
5′-CAAGCACTAGTCCATCTCTTGG3-′
ÃŸ-cateninactivation
ICG-001
recombination-prone
-Rb-hSWI/SNF
30ug
.Anti-Gab1
Abl-phosphorylation
-ERK
o500
LIGPLOT
Roe,1
-28S
V600EBRAF-postive
I423T
shRNA-treated
cKit+subset
346–593
0.3552
CD19+-sorted
Â®1eÂ®
Hoxa9-null
0.49-1.021
LKBt
ALGGs
8p11-q24
APL.28
rs3822214
13202
XPC-RAD23B
GRGES
D564A
Tyr772
33-year-old
15sec
4670
21.39
Q546P
Mdr2
PDGFRαK/K
GST–Rhotekin
MSIG1.1SK/HA-BRCA1wt
andhMSH6
osteo-sclerotic
CD5
tumors39,40
c-Src-transfected
57-fold
PBCre4/Tomato
Ni-binding
multi-wavelength
LGsGAFGtVYkG1
G487R
Lapunzina
C161F
-tetrahydro-5-oxofuran-2-carboxylic
long-chain
CBL-
.Ret
R272P
ERα-negative
p21/WAF1/Cip1
quintupilicate
ciprofloxacin
binding.78
‐tagged
couch.fergus
control7
5,9
BAI1
leucine‐to‐valine
PRODH-reverse
systems2
ATR-associated
IHCb
.FLP-rescued
,10–12
°C/30
BLM
c.1159G4C
5′-GACCTACCAGTTGAAGATTCCG-3′
31:692–701
Y1902
cord1
/PAb240
mouse29
0.0032
ΔD
thenincubated
1,792
40.0°C
monocyte–macrophage
erlotinib,12–14
right-sized
YLW
CATGTG
Pgp-mediated
kg-1
CTFC
8085
A_52_P232637
Clopper-Pearson
_1302+
R86C
Montero-Conde
F/73
ADSC
p.T2722R
11–12ba
near-triploidy
Rafl-X
Haploinsufficient
MUC5A/C
sc-631
RAS-like
far.6
M+G+
c.815C
Vemurafenib
lobule-restricted
c-Akt-E40K
Tsuta
FAMILIAL
3895
63,000-79,000
.Homeobox
stressor
.http
Oxcarbazepine
.Acetylation
PB1
family9
rimentales
scanning132
p21Cip
EMT17,22
D189Db
CD65
CC-3249
184L6
8G
formamide/5
NUP98-PHF23
1/2000
Y34F
GGCTGTCAGTGGGGAACAAGAAGT
.Proteasomes
MLL-11A
TTACCTCTTCCATTGCCGGG
CD34+
E82
test.Given
GCB-cell
4.1/NA
PbCre
activity155,160
.Values
9365
Leu32
c.7706
284.1
VHL1_1F
E3-containing
AML.4
protein-16
Ltda
.Silent
pT185/pY187
wereanalyzed
mitogen-activated
50–52
A_51_P449878
11,56
al88
trpl-289
0.061
eitherwild-type
tool33
*10-7
Rasa1
.Lemischka
electrophoregrams
RANBP2
aminosalicylic
adminstration
αEF-β12
signaling30
whileincubation
deficienthuman
GI/S-phase
TGFbIIR
SpeciesSecondary
6/185
.Braf+/Lox-DA
P22AS
RUNX1-corrected
sensitivity,30
5′-GGATCCACACATAAATAAACAAAATGCCAAAGAAGAAGCCAACGCCAA-3′
myelogeneous
binding-p53
Melan-A/
AAALAC
EED
database51
RTK-SH2
FTOC
chemoprotective
V664Q
GAPDH_SybrG
anti–cyclin
G662E
RERTn+/ERTOHT
RSVneoNi
CD14highCD15low
CS27
2Aa–c
GTGGTATAATCATGTGGG
described,31
312-438
p.Q367P
−14.7
FOXL2
indicatethat
/guanosine
Ca-2°
gene-related
SRL
Met-344
FAM86A
pBABE-Puro-HA
others.1
genotype–-phenotype
GGTGCTAATGACAGCAGTAATTAAG
L469P
NM_019932
probasin/
super-repressor
tumour-mediated
nonframeshift
Herbimycin
11-5′
dephosphorylates
years.1
Sibling
//www.ebi.ac.uk/arrayexpress/
absent.66
SIEm67
adenocarcinomas39
110,000-dalton
SC-03
indicat
5'-TTCCAGGGAGGTTATATTCA-3
SCCT1-3
Boncinelli
602-fold
survival.36
MRE112/RAD502/NBS12
58,59
groups.16–23
BRAFi115
Tnfr
Phe317
.Gastric
PmII
0.000202464
3238
T518S
SU12662
55/107
iXGXXgXGKSXXXxxi
−4.7
Hh-unresponsive
.Surveying
3720
-CTGAGAAAGCAGGC
sub-domains
Cutadapt
amplification-associated
cell–extracellular
non-trapping
HPV-59
AML-like
trypan-blue-positive
post-receptor
ÃŸ-cateninexpression
rs6435074
5′-terminal
approach64
observed.6,7
pLXSN-EWS/WT1
49/57
determined.15
Oct3/4
shUCP
Lab.
ROR1-c-Src
DLD-1a
.EBV+
3-phosphates
translation27
T790M/AEE788
radiosensitizes
MelanomaStudy
c.4956G
5′-TGGTCAAAGGCTGTATCCCATCGG-3′
TSSC2
ecules
GGTCAGTGTGGCAACCAGAT
changes.29
c.2081_2087del
NVP-TAE
5479599
autochthonous
7/25,873
granulocytes\
G660D
unampli®ed
LYST
8q23.3
therapy4
.N750
Myc-ΔBRIP1-transfected
S4T-U
Third-Line
Three-week-old
endothelial/subendothelial
1863-amino
5′-triphosphate
777.0
seminomas/dysgerminomas
hyperkeratosis
1124
9.3×10−10
AEE778
S62
LUCC8
non-HNPCC
P124L/D1017H
PEAK1/Src-dependent
87-gene
04-103
pmGFP-H-rasG12V-R128A
ProbandsOR
CCTGAA
G831D
haploinsuffi-
PTEN21
780-nm
-RHDSGLDSMKDEDY
1–134
dATP
0.1742
c.1490G
Ficoll-based
WT+GAP
R1046H
function.9
.Generally
cause.4–7
H2AX17–19
formaldehyde/phosphate-buffered
P197_F198delinsL
L1201F
T413N
L468F
ubiquitin–proteasome-dependent
4379
pimecrolimus
School/Partners
FGFR2-AHCYL1-positive
Orthologue
23/55
pRsc2-H458P-myc
onoff
._1896
0–81
pY823
RhoGTPase
phenol
Ij
α-Jnk
proteolytic
development.1
ChangesA
PHOX2B-related
BsmI
geneset
Sprick
psoares
pMSCV-PDGFRAD842V
solution.RT-PCR
VHLR/R
TTCCAC-3'2
ASXL1aa401–587
DACT1
givenB*1817N
PIK3CAH1047R-driven
1494
TCRβ/CD3low
polymerase
CML123
7p11
4*
HCT
sc-44233
IC557
c.3492_3493insT
asfalse
AC-30
'MSKCC
-Xaa-Ser
EPAS1-mutation-negative
2:5
Arg294Cys
pGMBs
nup153
ttaaag/GTTCAG
Smarca2−/−
LR2
10-µg
ATAD5
NPHS1
.BRCA1-mutated
C5–C6
translocase
pERK/ERK
Z-axis
1.219
287-5353
NOTCH-CSL
GCCTCGTGTGCATTCTCTG
Microarrayer
Characterizing
pk-in-24ploxp
0.3849
10p12.33–p12.2
G1779E
Pan-Asia
.Number
Mg-ATP-binding
373a
P.N
CMV-p300-myc
1a-5
.Unlikely
promoted-mammosphere
γc
EWS-ets
59.6
30.7±3.4
loading154
205.78
'T-cell
ATR−/−
AM989467
3-phosphoinositide-specific
Sasai
parm99
GIST,31
Arg74
AML4
pmGFP-tH
before14
′13,000
H233fs
pNKY47
.Bgl2-Smurf1-F
frameshift/nonsense
MINT2
0.91
Ultra-view
phosphorylation33
non-GCB
rearrangementproducing
mislocalized
Suppl.2
V717A
Port0
development12
O2−
E1900
200~299
±12.5
5-CTGTCATTCAGTACTCCTTGATGGGGCTCATGGTGTTTG-3
André1,2
.Eischen
nihms646437t20.jpg
mutantmsh2p
DEseq33
p.G566R
ras-effector
RAPGEF5
resuscitation
Fn3
head-start
7563
Sox17-mediated
'functional
fre-
manipulable
con-
In-Young
PBRM1-deficient
UPS-mediated
carinatum
CD33
imatinib10
'in
Supplem
659–749
1-15/100,000
Smads1/5/8
α-PLAP
T-+C
Molecular-dynamics
miR-199a
MET/CEP7
NIH/Olac
∼60–70
insertion-mediated
v.1.0.3
phase.40
tr-FRET
U266Y373C
BRCA1-defi
platelets/L
1:52000
B23-positive
T1623I
107Raji
5,006
FANCG.24
-TAG
c.657del5
18-gray
5'-AAA
Pair-wise
N130S
nihms703640f9.jpg
C277Q
Finnzymes
variant20
pGL3-5′-UTR
nonoscillating
inhi-
P53-positive
DeltaNTD
1×10−2
D136
-D835V
CBFB-SMMHC
nitro-blue
ZAP-70
nM,11
D245G
Kurokawa
shAHR_4
www.broad.mit.edu
PCR-buffer
Na4P2O7and
2.0:1
CIPA
R77Q
0.004-2.74
DA872508
-bio-AGA
+1.5*
'on-target
mass-weighted
mut/amp
A*0111N
Nimes
.36,38,40
Smad3-binding
0.36-0.79
p.371Y
non-radiographic
UPN1125
anti-CUL-2
unifocal-onset
MYPT1-PP1δ
MYCN6
complexes129
-CCATCTCATCCACACTGTTC-3
spectrophotometrically
DCPS
LS7500
anti-IgM-PE
Tris—pH
V119G
.Ye
hydrophopic
21–27
risk.4,12–17
anti–phospho-STAT5a
Ser73
neutropenia
results29,31
2239-2253
Whole‐mount
P0011
Commassie
7.82
mutÃ¢t
PBX3
mg/d7
22/8
pEAA288
action-dependent
N-Morpholino
genes.45
f−
BTK-specific
†All
P=0.40
coldspot
366nm
4I23
TEV-expressing
SMAD2
˜2-fold
pnas.1321155111i6.jpg
K255E-mutated
mutations21,22
0.875‡
activity–deficient
EZ-Red
80-kD
Non-radioisotopic
-_
Antibodies-Antiserum
GGACCCT
–438
≤55
Balbc/nude
AlaTyr
∼50×
521KB
CCAAGGCCCGCCATGCCACT
Apaf
485delAGA
catalysis.36
NBD
PIK3CA-Bearing
3573
Gly
G1073D
Bap1−/−
GGACTACAGGCCTGCACC
57HCCs
promoter19
CS-FBSor
M/53
D67
FBXW7-AuroraB
K714-E715-T716
3914
TRIBUTE,48
microg
2194–2175
Porse
.Anti-
57jC
muTect
kidneys.1
5'-GATCCTCGAGCAACATGTTGGGACATGTTCCTCGAG-3
2-containing
0.5-1.5
HSC7E-YACs
Harel-Bellan
pC53-SN3
www.nci.nih.gov
Novo
A1141T
5′-ATTTGGAGGCCTCCAACTT-3′
1OL7
pfg341T
occiput/brachycephaly
p10/p18
KSYL
LRRTM4
Alk7
nevi/melanomas
3.36
GI:532526
seqanal
Geisen
mutant-
ACACA
c.49G→A
Optiphot-2
two-3-fold
thymidine
virilized
human-cancer-derived
411
2272
medial-lateral
hmC+
supposition
HindIII/XbaI
11798014
Bottino
MS9-DLD-1
St-DEGEETF-OH
pro-survival/proliferative
Kahlert
rates.A
~t
FANCD2**
p21Waf1/Cip1-deficient
a.l
MAS1L
cyclin-mediated
2.10.1
NIH-3T3-MSCV-puro
Tcf4
2.08
mox1
validated,47
SCC-1
PIK3CA-activating
TACCTAACGCGACCTAAACG
V.N
GraphicE4
Q58_E62del
Tyr182
1.PK/PD/efficacy
Bla
interleukin-5-
SOX9-induced
I870
Covance
.Mapping
–194
26588
ASP2215
sublocalised
CSRWe
Ha'Emek
86-year-old
R79Q
stable-phase
resistance163
Y849C
WWP1-induced
.Non-hematologic
1.8-2.8
PCA3-4
CCDC149-ALK
IRCCS
GST-ELK
A.M.
FHTP
Pik3r1
=2−ΔCt
AATC
C11ORF95
Neuroblastoma
.Operators
RBy377
13C/13C
p.Pro106Leu
PstI-
cl.5
degradation16
48930
5′-GCCACCAACCAAATACCAAATCTC-3′
EagI
≥100μm
QoD
E50088
rceptorPTPs
age2
clonesshown
D420Y
phospho-RB
yeast13
5′-UTR-MUT
single-aminoacid
Modela
intravasated
kinase1
.Castro
Shp1
MSH2-WT/MSH6-WT
CD99
Thr-
42–45
1/700
CtBr
TP+FP
zdock
1.6–66.2
***The
NMD-Irrelevant
Tuscany
4jC
siCONTROL
16/14
W244L
Dawlaty
1751
31/77.5
Foxa1loxp/loxp
50from
HD-0180
NM_002648
Keap1–Cul3–E3
de¢ned
.Modulation
+236
monochemotherapy
5′-GATCCTGTGGACTCCATCTGCTGGAA-3′
at…
p.A889P
BamHI/NsiI
P53S
DIX-domain
biclustering
FIP1L1-PDGFRA–positive
CCGCTGAGGG
Brd4-SPA-1
neuronal/glia
transcripts.17
CRS
Pgr-Sox17and
phophorylation
23544
SpiB
.KMT
cc-13-834-g7
29,553,478insC
p.D587H
V43I
SMO33
0.968MUTMES
spliced/truncated
targeting136
p.G464E
GISTIC10,11
G6n~tique
reported.29
−1p
02142
haematologica
β-NGF
AAC-3′
.Injected
lymphomas.12
GFP-V5
.25,17
ST6GALNAC1-8
//cs.brown.edu/people/braphael/software.html
330K
Derivatized
hy-
guanosine-to-thymidine
twice/week
spliceosomal
p.R571W
-GCGCGAATTCTGTATGGTCTGTCTGTTTC-
EBPα42
1–939
•SV40
5′-CTCTGGAATGCCAGAACTAC-3′
byvortexing
PTL
36-4
NCT00406445
cancers18,19
osteosarcoma134
3236374
Furstenberger
cancersTo
R1201
2S219P
evaluated.
N.D.K
YAP–TEAD
Reactive-like
dacarbazine,11
Rad50Δ
11-13
382×
Berardi
.May-Gru¨nwald-Giemsa
I332V
Adenovirus-CRE
E-S-P
.4b
2B,2F
three-stage
p73alpha
Figure4c
PTEN-M3M4
S2.3.2
glycosaminoglycans
Sall-Eco
E545G
93.95-94.38
Affigel
AG′-centred
cardiomyocyte-specific
p110γ-K255E
CE1
First-step
SPTBN1
ancestry.17
Orbitrap
125a
amplification67
mutant-transduced
polymerase/Taq
Pienta
CU404
non-fusion-containing
shRNAs/open
E138
V272
032
Hortsch
OncoImmunin®
Nf12
pMD2.G
.LV
synostosis8
MS-256-P1
.V923E
panel‑
Lu-165
Beecham
80°C
.Nerve
p.Phe489fs
Intringuingly
Aprataxin
E622V
3.2-32.5
elucidated.7,8
described.24
150mg
/12
WTC-RAF
MYC-rearranged
IHAs
cells89
COS-1/PC-3
N568D
PIK3CA/PIK3R1-mutated
Upd/IL-6
c.1556C4T
N676K-expressing
2p24.3
NB0175
cerebro-oculo-facio-skeletal
30.
SP62
//p53.curie.fr/
c.928-937delTTAAGCCAG
0.17334682
5′-CGCTCCGTGGCCTTAGC-3′
VMCM
arise.47,48
.Contrast-enhancing
Fe2+.15
Y473C
described.5
1608
M338T
Woerden
5′-TTCCATCAGAACAAGACAGGTAT
p53-D281G
intra-individual
PDGFRAD842VMutant
12.67
putative
BRCAl-predisposing
A29
67K
NALM6
TRβ2
28-74X
Fig.2D2D
Gibco
TERT-low
c.-146C
pre-let-7c
Low-energy
2728
R0622
136.3
flox/+
CUX1-FGFR1-expressing
non-fluorescently
ab26046
BaculoGoldTM
MAPKKK1
VWA
0.21
Coinjection
DCregs
inversus
Tyr86Stop
47/272
H3–H4
8212
Possner
48b
PU1
10.42573163
block-NM
–125.3
IFN-activated
malignancies.33
anti-HER2–targeted
PRAD1/Bcll
Abdul-Nabi
angiomotin
yA*pLouAsnArgPhoLouArgSrH
insertion–mutated
malignancy.14-17
S1G
16β
transcriptional-mediated
CLU
types,19–21
Lin28
MREC/01/2/18
OR5T1
T75P
2.5–fold
kinase-coding
H_sapiens
62/2
pZNaq-Q209L
ERQRRNELKRSF
NS-causing
Cardio-Thoracic
loop.4
26-a
Jones7
theGADD45-containing
whether/which
9438/14928
GTCCCCCAATC-3
positive/no
4476206
MM-PBSA
ovoalbumin
PDGFs
anthropometric
prediluted
CRC382
.Proteinuria
MORC4
epithelialization
30159
11-18R
account.12
D1692Y
Hyperdiploid
progression17,18,19,20,21
Grap
pituitary
X-chromosome
63E
PyClone4
MLN8357
pMSG-CAT
approx15
605481
pGBT9RhoA
co-immunoprecipitate
pseudoschisis
SI-NET
over/under-expressed
p.Gln250X
Aldape
H3K9Me3
RQGAKF
Anti-C-FGFR1
100
MPCBcl-2
hav‑
p21by
Brca2+/−
pVH213
particular2
α-PARP-1
Williamset
H3F3A-Mutated
=0
n=168
Chène
−1.84
non-mutants
disorder.2–4
14-3-3/C-RAF
HD-0394
0.0404
cascade.7
24776∼
reorientates
.IL-3-independent
liver.1
Y384A
individuals.75
CDK2
5440delTG-encoded
.Suchcomplexes
Supermix
+TSC1
Miracco
TSC2-associated
=q
q75
5′-TAACAGAAGGAAGTGAGAGGCTGCC-3′
Optima
T291R
Hs01013371_m1
Y211C
127,128
cold-methanol/acetone
.ROSA26-M2
pJade
1.Foretinib
T790M-mutant
5′-GACAGTGGAGTTTGAGACCTACTC-3′
RUNX1
Figures55
filaments14
Ascomycota
tumor.68
protein/ERK
C-to-U
h-
elsewhere.2
Anisotropy
Regaud
CAGGAAACAGCTATGACCTTGCTTCCTATTAAGTCACTGGCTG
.Elucidating
Dharmarajan
WDR5-RbBP5-ASH2L
interferon-italic
.Amplicons
insFQEA
A421V
3,3′-diaminobenzidine–specific
M/54
situation8
SU6655
Hadjihannas
FLT3-N676K
71-73
nucleus.9
AMPK-WT
antimerlin
S36A
/5
NM_003482.3
behaviour32
27:179–192
0/17
S-168.16
carcinogenesis.41-43
Sox17-Wnt
c.C1110G
neurotransmitters/modulators
~350–500
9.6-
HA-pRB
TCRVβ3
RNAwas
speifically
DIM-5
GGCCTTGTTCCTCCTCTGAT-3′
mutated-EGFR
0.17–0.85
fusionmap
401–403
14,16
PfuUltra
14°C
8402
Myr-AKT1
p.Thr241Pro
Temperature-induced
924-1588
trichostatin
Biocsciences
TATA-Luc
.Reaction
1C—source
NM_010097
othermutations
WGCQSRRKSRF
witheither
Hs00174029
3-18Raf-1
~5Å
Vredeveld
0–17
Gab
foretinib-treated
autophosphorylation50
160–552
37/hg19
D19S891
p110β-selective
4B-C
524625
D151N
AnnV+/7AAD–
//doi.org/10.1371/journal.pone.0005137.g005
.Age/
Protease
3138471
Brg1G1232D
H4-PDGFRβ28
mRNAlevel
597aa
2.5-µm
80000
59–39
H1047R-Dependent
hasa
mg/24
2•75
SOCS1
withacute
EXELTM
tumorigenesis9
c.6427_
K1419Q
sBL
1/98
RBM10-expression
pathway.PIK3R1R348∗
HoxA9+IDH1wt
***P≤0.0003
AML1-deficient
wildtypep53
proteins.41–45
I–treated
1601B
BTK7
Unterschleissheim-Lohhof
n=116
pspMycC,16respectively
pSer473-Akt/Akt
non-PI3K
82.1
41-57
004119
myristylation-defective
S1715
ofHIP1
Flag-ETS2SASA
p-S6PT240
ingressing
//github.com/boyangzhao/targetID
C448Y
methylprednisolone
cancers.17
NSlike
26,32
pRCC10,11,20,15,16,17
100:75:25:15
TOPFlash
1.5–2
Limb-bud
RAG-1–deficient
MorphologicSubtypeRiskClassification
TGFβR2
3T3/WT
Sekishindo
myb,11
lysosome/phagosome/proteasome
Patched3,4
glioblastoma1
C-Met/SE7
non-matching
64911
syntenic
β-common
FG10a
pIS0
FAM55A
1.413
members—EGFR/ERBB1/HER1
Frank-Vaillant
1L–N
MgCI
development22
López-Nevota
D254N
Δexon
gpllOS345
stability75
10q25-q26
137,800
Frame_Shift_Ins
Astek
3.34
phemomenon
TPM3-ROS1
BT549
eosinophilia.5
.Modern
pico-ECL
0.740
abnormalcies.23
SPRR
cases128
mL/L
CK40
PRKD1
scansite.mit.edu
.3005
mild-transforming
Bouche´
finalconcentration
assay16
.Adenocarcinoma
Marinkovic
Cis-acting
5′-TGCCAACAACATCAACCACAA-3′
transcripts.15
U133
anti-M
phenotypy
:3032–41
14,16,106
.Details
EGFR-L861Q
SWI-SNF
mant-labeled
dnFLI1
MRT.15
3190
Myc-BS6
0.057153719
EBV-B
substrates.11
nonboiled
CLL22
Rahimov
1p36
OR†
UCP2
1-Tables
C→T
EndoHf
Lokker
α-synuclein
TM3
runMode
ET2.1
5751
Alf
LC-Laboratories
53/F
nonserine/threonine
rebiopsy
macro-
p.R790*
YAC781B12
magnoid
pBABE-puro-NF2
R905
amplificaiton
andvalidating
c.1513C
D213G
Lu65A*
Kristjansdottir
15-μL
chordoma
TE7
His206Asp-FLAG
DAB+
family30
BR99-0207
metastasis.4
CDR3
I154F
Tumor-Specific
152K
5¶-TAGCTGGATGGTAGGTAAGT-3¶
Torrezan
0.1-45.0
23,45,46
59.27-60.20
PKB-independent
millionWT
K/R
Apo-FGFR4-KD
Y641H
acomplex
missense-mutation
pseudotyped
p.Thr4511Ile
FANCA12,13,24,29
ZR-751–
1989–2001
cells4,12
c.2355_2396del42
non-oxidizable
/150
p.T383A
L845F
anti-phospho-p44
8/44
prepared16
17783
0.024-1.531
≈7.5
M238
12q13-q15
Y231
literature6
anti-CD1a
complex-type
BAG-1
​Fig.4D,4D
malignancy.140,188
//www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi
spindle-type
oncogene.91-93
78–93
NAP1L3
.overexpressing
fewareas
Nexin
0.25–0.79
AG3969
DESbound
adenylated
pCS2-TGFBR1
cullin4A
forties.24
//dx.doi.org/10.7554/eLife.08905.001
Brca1F/F
PFR
Tyrosine
2307N
3.94
78.4
Gly17del
FLT3-D835
four-well
8036943
∼364
.Cyclin-D2
0.00037
Fbxw7-Deleted
HR10
p.K700E
swinging-bucket
c-mycand
R468L
theBamH1
JCI70196DS1
108.0
pGEX-EcoRV-Sac1
3146
13,14
483-729
described.22,30
7RI-1
AJ519933
498delT
d'Ivoire80
BC129121
6-R
Pik3ca-driven
ATMex39
gggaaaggaaaacaccgtcctttgaataac
3984
analysis/immunoblotting
DNA-Binding
pET42c
S-35
.Weverified
p.His117Arg
2012aa
Xterra
.DePinho
JB10115
α3-deficient
YN-C-RAF1-330
—cyclin
751
Furuta11
PMA-dependent
Tarcic
−138
106–143
4/51
5′-ATGGACGGGGCCGTGCTGGACGGCCGCGAGCTGCGGGTGCAAATGGCGCGCTACGGgCGCCaCCCaGACTCACACCACAGCCGCCGGGGACCGCCACCCCGCAGGTACGGGGGCGGTGGCTAC-3′
mutation25
H2B–GFP
uAI
high-ARF/low-INK4A
Anti-c-Jun
heterozygous22
Immunoblot
D278A
p110α37
Thermofisher
Trx2–/–
−c1
Assay-On-Demand
pCMV-ZsGreen/TagRFP-derived
Lgals9
hAR3973
+1
erbB3-specific
-335
Tip50
0.04–0.29
Jun-B
10–13,16
33433488
⩽0.05
0.0001.DiscussionJust
2F6
BACH1-ΔNLS1-GFP
pBS302
7433
Sin1p
.9A
K550
pENTR1A
∼10,000
H297N
glucocorticoid/androgen
ND*
dacomitinib-
Rue
20.3/26.6
hepatomas15
E695K
Y222C
cancer.Left
LSL-Fbxw7flox/flox
factor–catalyzed
pGM4
Mg2+-GDP
.Invasion
10ZFΔPR/MSCV
SK-OV3
markers12
KEL
KIT-W557_K558
pRC-CMV-RETWT
ADRBK1
Moavero
EWS-rearranged
E758G
shRictor1-
C,4A
3676
isotope-labelled
0.3-1
malignancies.3
debate5
ECTM
8.11
cuta
Y791F-RET
3187–3703
Ran-spindle
CG/CC
ROS-specific
hemagglutin
.Knockout
NPRVGTKRYMAPEVLDETIQ-
ATTTTTAGGTACTTCTCGCTTG
Ba/F3-expressing
growth,12
GxxxxGKS/T
igr.fr
1H/15N
MSMS
RESCUE-ESE
Corporation/Molecular
×155
G1/S/G2
0.61–1.04
dissociation-enhanced
Antiestrogen
tomodensitometry
LFA
hHTMNM-1
Nrf2-deficient
ACI
dif
polyanionic
Martuza
-64
p57k1P2
tumors.4-12
beeninvolved
R1960Q
LR+EK
Rad51-/-
1294
RI-B
ACCAAATGGCACCATACGA
HIST1H3C.K27M
AMP-PCR
8.7-10.1
E762
BBC3/PUMA
S99fs
Il6
Flag-UCP
MN27
−1.76
RHD-CBFβ-DNA
Anti-B-Raf
ceRNA
karyograms
3H3
IGV15
neuroblastoma30
Trp248
3μM
D.A.P
cells.1,2,3,4
FL-associated
.Re1
SNU-5
Thr935
07/Q0702/69
ATMKD
Yamagunchi
.7805G
c.739T
P-40/1
HA–sBRD4
p38β
2.33
anisomycin-induced
PACH-33c22
636
BATTLE-2
co-represses
CRC-
3/244
7/25.9
Domain—Our
wild-type–like
Crosslink
chromagen
Lipofectamine-based
9/38
GSE69624
Ca2+/calmodulin
pH3-positive
RAF1–RBD
Fig7H
44.0
.Guangzhou
Leu799
.NM_005898
mal
R280T
-style
size/bp
FGFR4-specific
F123
3′-dUdUCAUUCUUCGGUCUACAATT-5′
tolerogenic
sepharose
.high-grade
LC3-II
Y67H
EGFR-mutations
.Densely
v2.22.0
caspase-8.12
.NMS-E628
Phe527
multitf.dcode.org
wtBRCA2
H-K
FANCA13
944
CAGAAGACAGGAGAGGGAAC
30-120
FRT/TO-FLAG-BRD4-NUT
S34F-affected
C843Y
skin-photosensitive
0.01881
log2-transformed
PACS1
88.73
WT344A
Tris⋅HCl
Canto
2461
Lumenera
RALT
.Third-party
pcx4
4470
BAP1.72
None,2
serum-rich
superfrost
CHOP-variant
GATA1s.24
TCCAGGGTTGTTTCTATTTGC
KRas4b
2.193070567
KIT.21-23
software.21
CKYS
Dostert
Iranscriptional
.Atomic
ab15050
6,39,40
n=403
c.2021G4C
5'-ATAGATGACAGAGCAGCCCGGCTA-3
Lck-cre/Brca1f5-6
606–615
5′-CGGGCCATTACGGCCGATGATGATGACGACGGCCGCCTCGGCC-3′
5.0b
17–51
Erf-mediated
PDGFRAΔ8,9
OCCCs
target-by-target
.Helper-free
demography
FFPE/fresh
E160A
T1G
Glu472
finger-like
GGTG
R669
CD74–ROS1–G2032R
posi
1175
0.05-fold
status—the
ref.5
55538
repair.7
~160
5q35.3
PTPRT+/+
p85α-R274A
pre-steady-state
mainlyconcerned
Workfl
.Noted
GTP-analog
p=0.10
clodronic
kinase/RAS
2830
D9S942
SBA
S2.12
A3JUN
POLD1-exoD316N
S436
Fourquet
1695
p.E1978X
F1378
SPDGHE566-571
CMP6
PI3K-activating
90–217
7SL_F
P13K
lethality.Sos1
.Activities
Gata-3
T267I
//www.ensembl.org/Homo_sapiens
MLL-AF9neg
TAL1/LMO2
36931
cell-associated
his-tagged
Pan-mouse
Q218E
pleuro–pulmonary
39-residue
anti-SRSF2
PtenΔ/Δ-derived
MSH
CDKN1A84
malignancy88
p-RELA
chemoresponsiveness
cell5
Y1022/Y1023
therapy-naïve
5'-AGGTCTCCTG
NM_030220
seven-blade
early-on
Is…
ii–v
protocols.Linkage
cells/48
RFS-myc
bcl-2family
C.A
Phospho-KIT
Alencar
,AGCATTCoO6CC6AOATcrcTCOCrcc6TsOccTTAOrTGrG
171
EGFR-L858R+A871G
CBFA1
GSK3β-meidated
.MC3T3
institution/consortium
Hs01019589_m1
G4920
alr1
2‑hybrid
SMM-7721
9Okinaka
Wu1,15
7,900
GhQPYpahS-Nl
non-NBL
Fgf8/17/18
p.Arg20Gln
E-64
bilineal
.Cytogenetics
221.28
Post-radiation
1443
AmpliTag
5′-GGTTTCCTTCATCAGTCCATTGG-3′
collagen-rich
-L
p110δ-selective
Gly727
receptor-expressing
p44/42
27-30
5-month
67.4
cells.10–12
allele.41,43,44
co-precipitates
./vol
CCDC148
4/45
Wnt-mediated
VHL+/−
phospho-PKCζ
MRC-AML-12
COL8A1
gene44
12709-11
146/181
XL2-Blue
T1385G
Lotem
13.29
PIR
entiation
9/11/98
49.8×109
//genetics.nature.com/supplementary_info/
years.
sensitivity-resistance
55–72
membrane,76
12–43
3J
TTACATGCCACAAAAGGAA
CF-1
510-513
witha
EFO-21
D10S1779
kinasespecific
steady‐state
LNCaPcxD12
Sclerosing
2374
fluorometry
maps,4
TIA1
analysis.Total
SMRT/HDAC1-associated
ecotopic
flutamide
effect.NVP-BYL719
P831A
EGFR/RP11-231C18-SO
5a–f
deacetylases
W73G
.3,8
over37
FH-ERα
two‑sided
PLX7904
.Rameen
190080
lq22qâ€
PMS2ΔC
KRASMTtumor
32D-FLT3-
Endocnne
cdk
838
N444
FGF2-FGFR2c
STAT-mutations
C10orf90
advantage1
*~uICUICVI
Karthigeyan
Acetyl-Ile-GluThr-Asp-p-nitroaniline
FLAG-ZBP-89
glucocorticoids
Δ82–100
0.975
5-CAAACACCATGAGCCCCATCCAGGAGTACTGAATGACAG-3
61L/156L
.In‐frame
1\
membrane-anchoring
IFN-ytreatedFO-1
T155I
Porimin
.Memorial
blue–negative
-CGAGGGCGGGGGCGATTTAT-3
transformation.1,3,4
lineages.22
98.5
Tyr142
Anke
=19
F468
Y1794C
membranes33
.interphase
CRISPR/Cas9
95°
17q23.2
7-d
.Around
pSCEGFR
thatC277Y
K39A
Becker-Catania
p.Gln6X
transcription17
mendation
mutations55
Laemly
one-site
co-regulatory
−3.5
availabilities
C12F2
R1204G
Kinase…
alignment–based
N=82
pCAT3′L
gadolinium-diethylenetriamine
5B3
2/1353
ALKF1174L-expressing
EC3-4
KIT-independent
Toolkit37
MolProbity44
p.Val678Leu
499,887,339,249
↔Primary
.IDH
KO–neo
.Circulating
12D-2
fedratinib-mediated
V272F
substrates.The
I-SceI-generated
stability6,16
Ex12-F
W3A
AF2
signaling.15,16
4–107
promoter-mutation
30-55
..D.AIV
DNA-protein
marmorata
non-crystallographic
GDP-cluster
malign
0.4/NA
1.659
trypsin/2.21
159-181
mispairsand
Thermoscientific
Gujral
protransforming
Ser32Ile
Catalytic
0–5
processes/pathways
TreeView
TÃŸR-Igene
pWZL-blast
Sf9cells
ΔCFTL
.Hayashi
.HFKs
ODM
Neurophysiological
His-524
long-size
EGF-to-EGR1
pGW1
Cells—Cells
genes8,18
Col2c1
NIH3T3/v-ras
TGF-beta1
.H1048
cell-to-cell
9Rα-mediated
1Cii
patients.26,27,29,33,34,37
pT3pN1M1
2002-03234
PRKD3
Goumnerova12,13
factor-free
R184H
IJ-
anti-U2AF35
Ras·GDP·AlF3·RasGAP
KCTD5
.RKIP
FLAG‐HA‐tagged
-X
tozasertib
.SDC4
hER-specific
exposure101
MyoD1
recommended,16
Tsukasaki
Shp2K590R
BMP2
edu/fanconi/mutate
suggested9
histiocytoma––previous
Bishop1,7
phospho-PRAS40
6q14.3
K730-V745
mis-localization
.Martinelli
30,34,36
S476
onlineat
Flp
12–35
FLAG-Caspase
Perturbation
mutagenesiswere
+DMSO
Ilei
59–177
evoluFigure
gp130
S/MED
Golgi-resident
CIT
50.3
SFTPA2
.Interferon-α
SIV
MLLT1
m-ris1
catalyticdomain
1,749
LeuGlnGlnG
inflow
5-hydroxymethyluracil
H3K4Me3
14Days
p.Arg709*
SOLVE.42
103/well
melanoma6
RUNX1-PRDX4
GPR149
b-d
CTG-39
subreads
ovary-K1
72160
O073f
Assay—Tissue
57o
vemu
methylases/demethylases
Glu520
co-alteration
EZR-ERBB4
tomography-guided
SVM_BP
truEXTRAC
homeostasis.1
challenging—it
M980
0.35±0.03
.Equilibration
5-GATGCCGCGGGCGGCCGCCTGGGTGTGGAAATAGATGGGCTTGAC-3
/6
mRNA-expression
5·3
.Lens
ErbB2_ex17-25.SR2
exon-16
CPRG
KITamplification
418–419
437/565
anti-Cdc37
GSE36006
1GJO
imatinibsensitive
L814P
8/678
.M95936
Neuroradiologic
9-27
outcome59
cancer.69
213-amino-acid
Cockayne
volume.47–49
ofheavy
individuals.21
.Ultrasensitivity
amidoblack
.Also
andY35N
35762
D397-MG
1999
spike-formed
of4l
c.571G
hypo-phosphorylation
RG-26
555-conjugated
5´-RACE
69/F
rs11894252
0.7940
650nm
5′-GGACTCTCCCAGCTCGCTGTG
Eeghen
/D
A636P
TRGBRII
CACNA1D
AF363014B*4022N
Chp1
eachsample
Genotoxic
R83H
5/73
NM_006206
Malkova
SLCT/OSCST
anti-IL17A
Glu-659/Phe-
colleagues.13
54b-2
gi68441231
base.12−14
.Schiffman
.Sensitive
Arg-1835
HBS-MgCl2
CD5-negative
cMET-amplified
vacuolated/signet
A259V
5′-TTGAGCAAGACTGATACCACCTG-3′
LEEKK
I1307
migration1
age.1–7
.Corroborated
6207
pseudosymmetric
N=140
Phospho-MEK1/2
c.1342C
Zacksenhaus
741-782
CDG-IId
5′-CATTAAAAATTAAAAGGCAATAAAGTG-3′
TÃŸR-I.Two
G148
`Transcription
hTrx-pBlue
//www.nature.com/authors/editorial_policies/license.html
examined.Statistical
q4d
fold-back
HeNe
H3K27Ac
mg/ddose
Guardant360
selectiveat
6/6
EGFR.Report
GCTGTCTGGCTAGGTTGGAC
32:1–12
Semi-quantitative
size-fractionation
fast-track
Trp4
ACVR1-transfected
3rd
3600dell1
TGGAGGGGAC
5905
E9486
T155S
601–612
Dominant-Negative
LS-affected
Palbociclib
C20F4
CRC.12,15,27
//informahealthcare
S1P2-deficient
Pai
amplification8
NB-1643
chr14:74358911-74360478
MGZL
60Â°C
metastasis30
Irish/German/Scottish/Danish
4E–K
p53L22E/W23S
p53amino
Icmt
.scrambled
RP11–348A21
0.758
c-Myc-associated
KRAS-G12D
circumvent-specific
theretroviral
−i
stability.48
AY519501
G1529R
FIP1L1-PDGFRA-T674I
KpsI
3‐carboxymethoxyphenyl
GGC-tGC
leukemia.16
Lc-1sq
mTOR-interacting
Fasciclin
NTRK1-derived
DLFEIR
iHEM
cellularity,52,53
SKBR3
phospho-HER2-Tyr877
Kohonen-Corish
isothermalisobaric
Streisinger
min/72
yellow/CPK
localization-dependent
gse3960
PTEN.R233X
Serpine
postmitotic
Qubit
ERK-β-catenin
studiedfor
KDR-mutant
¯at
61-265-2889
S32A/S36A
..REA
PE-mouse
2.0–5.9
pPM231
4053GrC
1-384
A549-G12D-K-RAS
p53RE–hCMV2–DsRed
Ciotti
reshaped
+C
Karnieli
gamma32-P-incorporation
19280-bp
Luminosity
transplantation-based
pMXs-puro
p.Pro291fs
PACC
Cytochem
anti-metastatic
no-overexpression
deduce
Glutamax-I
B-lymphocytic-related
EcoRI-NcoI
M9–M14
.Abundances
M.Brouns
CP31398
An~erindian.-'~Hong
10774
RUNX1-MACROD1
TBS-1
g7
NM_005633
OncoTargets
S307P
5′-CC
20892-4470
D7S531
P-T58
C463S
granulomonocytic
GAACATGTCCCAACATGTTG
qRT
Fig2M,2M
albumin-containing
types2,3
4/29
FRS2β
pBabePuroconstructs
mutation44
14:300–308
1e–m
p.C392*
time-controlled
anti-Erk1
markerfor
8749
unaected
RP11-117E8
FLT3mf2
FGFR2-mutation
T321P
p.Glu17Lys
selectins
DcR2
FNJIJ
TTCACACACAAAC
p70
A289X
Higashino
5'-CGAACAGTGAATATTTCCTTTGAT-3
TGF-b-resistant
/recurrence
GloMax®-Multi
11/88
S221/S225
ARIDIA
+–
C12-FDG
AAACTGGCCAAG-3
AF110184
]
HSA-PBS
P=0.00063
0.20–0.75
life-long
RasGAP–
p.Gln7X
scientifically
112.7
PAX-PPARγ1
GST-RSK
npr1
blasts.25
Tortola
c.7976+35
neurocircuits
clitoromegaly
lysateGAP
age-dependent
Flag-mTOR-expressing
p34cdc2/cyclin
11⇓⇓⇓⇓–16
3108
86.01
well-designed
Keratoacanthoma
cells.29
destabilize/degrade
GCCAAGCAGC
score=5
DataBank.29
.1100delC
RNAsol
immunotagged
propsho-Chk1
S10F
msh2D
Bacp-37
MYCN4
membrane16
.BRAFwt
anti-RhoGDI
D425N
6F9
A008
NM_032637
A_51_P353221
FGF-4-producing
approx9
deficieny
TLSIFUS-ERGchimerictranscriptby
expressed.100
1195–1673
BMF-depleted
MRm
domains.12
resequenced
.Flow-cytometric
kD.37
1.8139
.Autophosphorylation
antiangiogenesis
qPCR—ChIP
0.9646
CDK5
P.H773_V774INSAH
treatement
Rai
.soft
D1010H
.Microinjection
D770
VGLL3-treated
Fluorophore
irrtrorlrcc.rc/
previously36
EVOLVE
year.2
629
VHL.HA
rmIL-3
L536H
DNA–database
PROTOR/PRR5
,46
instrains
non-superbinder
19/58
236-amino-acid
.Iwashita
1715
32×22×48
−.33
OCCR
cell-lethal
mt=CtFt
Thr-341
GSI
HeLa–SSA
.I-Mutant2.0
A932V
GAL10
TAC272TAT
5.04
cFLIPL
MMR-mediated
cyclophosphamide–methotrexate–5-fluorouracil
AnatomÃ-a
.Organization
1653–1736
40-day-old
associaA
RAS/RAF/MEK/MAPK
C628Y
465insT
amifostine
Müller
Semiquantitative
4-fluorophenyl
tumors7,8
−1.00
665–737
LSL-KRASG12D
14–31
V765M
TOPIIA
differentiated/dedifferentiated
11.8
recently-identified
Spradling
SDH-gene
myxohyalinale
3q12.1
375^387
chler
5′-CCTCGAACCCCA
ISKGRVPYPGMNNREVLEQV-EHGYHMPCPPGCPASL
P417A
domain24
nonpathogenicity
41824
extensively.3
carcinoma.4,5
damage80
CS-causing
COL3A1
0/0/0/1
5053
EGFFURPTPp
c.3061G
4185G
Mb–
complex83
0–15
non-tumourigenic
p110α-E545K/p85ni
individuals47
31-38
P574H
Merok
antibody–mononucleosome
2069
non-ERK-dependent
al118*
Jak323
c-Jun/EN-EpH4
RhoA-selective
complex–RNA
times500
cell-type–specific
p110γ-RAS
.multivariable
14-year-old
T357,526A
treated/
FGF18
HTB-82
PDGFRβ.41
W509C
0.142–1.835
c.365T
8.72
.Microarray
Erastin
5′-TGGCAGTAGGTGGAGTACAG-3′
PowerVision
chromoanagenesis
2/22
99904995
GGAAATCCTCTATGAAGCCTA
ducto-lobular
mutation.27-30
M-199
E.9.5
variant.31
5'-GGGGGATCCCAAGGTCGGGCAGGAAGAGGGCC
.Anti‐HA
transcription-coupled
l-cysteine
Gly1738
deletions/amplifications
7α
C145Y
cells.26,27
collagenase-disaggregated
.1D–F
apoptosis2
~0.9
R249H
PL14
1,4-dioxane
tru-cut
p21CIP/WAF1
Mpl
lyArgArgAsn
degra­dation
PLX-K063
7.D.3
hypo-myelination
2000–8000
Rdd
.2344
Brca1flex2/flex2/p53flex7/flex7/Wapcre/+
6–4
frataxin
TOP1-binding
ARN
R132H/G/C
.FRET-imaging
SMMC-7721-shShp2
.Exclusion
CD8þ
justification
Rbg76819se
Co‐staining
islands/promoters
leukemia,153
BCL-6
synchronously
untransfected
Extensive/NA
//www.gatc-biotech.com/en/sanger-services/lightrun-sequencing.html
NM_207323
ENSMUSP000000xxxxx
2.—
FA-causing
content.springer.com/image/art
PF-06463922-treated
methyltransferase/demethylase-inhibitors54-56
histotype
phosphorylation/oligomerization
pre-organize
rearrangementfusing
TP/
predisposing
disease-association
Xiaoyan
H271Q
2064-2065delTG
25–67
IPI/aaIPI
non-MSI
E7107-
LuCaP35
MSH2-p.A834T
pESC-URA
2-amino-1-methyl-6-phenylimidazo
R830K
generations29
FDR=17
CrebbpΔflox/Δflox
Mdouble
proliferation18
BrgGD
-K111E
BclI-digested
3'-2
c.1420delC
ConSig
rs267603579
α-tubulin-FITC
Tan7
FGFRgenes
c.1553_1555delTCCinsA
activitites
tumorigenesis.11–14
A128V
phase-2
S1140G
12-24
SCF-occupied
guanine-nucleotide-exchange
7384–7385insTb
ERBB2amplification
S1031
IL18R1
.Swapping
hydrochloride
above.In
DeŁpartemental
pENTR_L5
conditions.50
BAP1-
Dnmt3a/Dnmt3b-mediated
C240F
pretherapy
GeneCluster
104-R.001
Rad9/Rad53
calipersSubsequent
D-001810-01-20
membrane96
angiogenesis19
K464R
AF292567
c.70_71delGA
WT-Ala
endocervix
.0002
pathway-proficient
Fbxw7−
.Metastases
cancer*
81-3-3542-2511
1.6–105
G-361-TrkA
EBV=
sporulated
Ontology
pGAD–PKN.N
htcohen
ligationdependent
non-proteinaceous
552
pSer473-Akt
VMCUB
CH3Cl
8/37
rabbit-anti-Pro-SP-C
ACKNOWLEDGEMENTS
24–42
Further-
c.843delC
Sato14
identified.5
NI-ESR
morgan.med.utah.edu
c.1798_1799GT.AA
A_51_P249957
Yesi
∼85×
119±29
rs17336988
chaperone-like
relapse-associated
2-month
NKX2–3
apoptosis-deficient
BIOCARTA
Tel1/Mec1
genome.4,5
dwarfism36
G1261S
c-myc/GAPDH
vemurafenib-bound
NS,12
400bp
activities.DNE
Tip60-mediated
mitoxantrone
guanidinium-HCl
1z2c
SUMO-deficient
Wnt-related
Superfect
0.711-2.423
c.3927
phism
LR08-361
14/80
mutatedFANCC
Valtorta
E.EE
5557G/A
†
BRAFD594
StemCell
phosphotyro
Somasiri
Up-regulation
.Wounds
Hif1α
IKZF145
Rel/nuclear
Gynecological
tumors,105,106
c.1738G
11-4
webtable
beproduced
4Avii
.8
-cell
lOOI
years.6
pCMH6K-Trp53bp1
21231
ERL536P
ERCC4-encoded
EWSR1/SP3
CCAGCGGCCACTGACACTAGCAATGTCTGA
Investigaciones
R1347G
S2I
.EXEL-7647
rules23
CD123
cancer106
development55
MKN455
R5A
FGR
bcl–abl
Schraml
.Forty
primarylesions
0.1–100
60–75
TT60
GPII
higherproliferation
NRAS-3-F
.5558
RG-8N
Intra-focal
–c-abl
pCMV-6-entry-ERRFI1
HiTrap
non-rescue
Upstate-Millipore
p35.3
1251I
Met.34
immunopreci­
JAK2-SSBP2
10,15
c.2657A
osteoarthritis
CR61LI
cell-movement
Guertel
epithelium70
under-represented5
nonsignificant
I867S
G1306E
CCCTGTCTCCTGCTTCCTCTA
anti-phospho-Tyr1068-EGFR
Δ3381
anti-ki-67
GRB-2
GCCTTGAAGTTCAGAAACCAA
sub-section
CYT-2
,3K
y-taka
NMSE628
PTP-U2S,12
follow-
E545G-NIH3T3
p53R283H
domainin
HumCore
multicomponent
fortherapy
tttttgcag
106-3
low-moderate
KRAST58I
G1567D
1971
.When
DEADG
anthropometry
Rampino
keratocysts
Pro-134
non-translocated
FRO
Xp11.23
Tyr123
HER2YVMA-transfected
s.Table
0732-183X/03/2101-60/
H11A
SEC31A-JAK2–transformed
M7a
28,869
Fumagalli
UbiAl
7-19
IVS23
E545G/A1066V
WM88
844-1946
SH2-linker
920–amino
ZP
G348C
SK-LC
MgCl2,1U
biogenesis38
E.E
E602V
five-gene
485k
.Arg420Del
plasmidwas
TruSeq™
pHAGE
edp53
Wessex
bisulfite-sequencing
612111
Buchhagen
activating-FGFR3
95.8
238KB
micro-kit
acral
45jC
1103–1113
355-377
pseudofollicles
596-602
His-Smad2
precipitationwith
11668027
rad50L1240F
4282–94
L493P
Panc05.04
SVCOC
vonHochstetter
perturbation-sensitive
.Annotated
.KIT-WT
0.74–5.83
13-cis-retinoic
partiallymatching
8tract
Y1248H-targeting
/1L8C
192/88
.Mutating
**FANCD2
models13
SUDHL
patiens
+T3/3L-V
probethat
HUMDISEASE
FDR≤0.05
StatSpin
.Date
BamHI-EcoRI
1197
re-emerge
GlutaMAXTM-I
c.1799T.A
Satoh
anti-p-Akt
cell-substratum
3A1–2
0.59±0.08
atrioventricular
8–intron
UPlan-Fl
CXCL12-dependent
4-OH
gene-based
Polycomb
44020102S
BLAST-querying
.d
CD79b
fitinib40,41
Nonreplicating
anti-BCL-2
MOLT-3
MEK1–KSR2–B-RAF
10.1182
5′-AAGGACTGTAGGAGTGGACGAT-3′
withMSH6
endothelial-cell
itspathogenicity
Ala159
coimmunoprecipitate
kinase-initiated
27–90
ErbB4-specific
H168R
13778-150
Buiting
615-322-6494
sodiumpyruvate
c.2166_2167
+71
5′-TCCCAAACACTCAGTGAAACAAA-3′
–40
S5d
Overgrowth-birth
ch11:46.6-46.8
92005
.Broader
Gly189
plasmids.A
2.17–26.75
7.40
NCT01171924
restriction-fragment-length-polymorphism
0.0486
thyroid-hormone
:181–189
2-TRCN0000009850
MLH1-p.E633_E663del
CTCTCTGTGGGCAGCAGAAGACGACGAACTGG
Eg5
–95
.Labeling
125.9
IIβ
CD11b-PE
Christofori
0.01–30
0.4-fold
TGT3TAT
ofplasmid
9819
SVZa1
wiccmail.weizmann.ac.il
1.Distribution
Ser795
-HEX
pITR-TCE-Ins-UTR33,34
concurring
EGFR.1
12q14–15
H58N
Proteostasis
three-month
BMP2K
www.invitrogen.com
second-strand
BrdU
MiTF–M
Sertoli-Leydig
Thearrow
deletion=630
myc
|lm
3,622
DEST30
genotype-based
AML.2
Brady-Kalnay
K-RASG12D
68Gallium-DOTA-Tyr3
paracrine
C-terminuscontains
IDH1and
tuberin/RAS
INS502AY
heregulin
Runx1−/−
ubiquitylation32–34
2,3,3,4,4
insACCAAC
0:07306
Glu-37-.AspS5
p.Thr10Met
.S9C
Xcorr
0.285
NCT00850382
reported,19
pLenti-puro-LacZ
MicroStrips
ClassTo
.Inserts
.00251
15J
detection,12
spinomesencephalic
Senturk
*Nucleotide
G272
JIM-3
mut/loss
non-MO
high-granulocyte
nonhereditary
//www-p53.iarc.fr/
.UTR
Xq11–13
Wnt7a-Lmx1b
HCC366
miR-200c.5
.Hydroxyflutamide
~dashdot
N616S/rad54Δ
Kurek
T-cell-selective
top-ranking
Deltex
8-µm
p.N822H
chRCCn=
myelofibrosis-like
RhebTyr35
HsXPD
PPB-related
ß-cateninaccumulation
n=210
cerebellum.F
PD325901
ofco-infection
p-Tyr653
Halegoua
S311A
implementable
CAGTGTGGCCTCACGGAAAGGGTGTGCCTGGACTTCTGTGA
Dz
E-Biosciences
IDH1-mutant
p27QF
anti-MYC
non-diffuse-type
R320Q
gastroenterologists
0457
v7
48K
c.2413C
GIST,28
Ptgs2
group34,35
P=0.0095
p.Leu230Pro
MCF-7.fgf-4
E291K
.DX
rhabdomyo
4836
delayed-type
MSD1-EVII
BL1921
filopodial
subcohort
lysine-to-threonine
Umbilical
CAGGAAACAGCTATGACCCCAAAGGGCTACTAAGATAAAAGCGAG
gDNAs
GA-3
phosphatase-β
G101W
TCAGTCTGAG
P531A
recto-sigmoid
Y537S/N/C
NKY278
pageResultsComparison
Q279R
93/239
C634R-Cl
~5.9
BLBP
Lyser
F/M
pERK1
proliferationindex
-n3
Si23
2.9066167
hemangiopericytic
signaling.Next
R166T
0/43
5.26
§P
c.5857
structure-nonspecific
560–576
domain.54
circularity.Statistical
GAAGT
cells.149,150
79071–79072
keratin-stained
lines—UM-SCC
kth
manner.20
.Using0.4
Hidefumi
M12.49
Forty-nine
3,323–3,487
ER–agonist
1py5A
WebLabViewer
plink
pineoblastomas
R-free
Chrivia
FLAG-HCF-1C
EGFR-G719A+S768I
trafficked
MMAC1,21
F4/80-
ninefold
p.R297S
Aertgeerts
S384
CS-11
fusion17,18
NM_001105.4
lymphoma.34
-Q510E-Shp2
2113
55–120
L•uk•rrti•
DNA/dish
G137R
purinerich
H-Ras27
implications76
0.53410234
264.6±4.3
Pharma
Scarisbrick
5.5.1
affinity.11
E452K
Ehninger
miR-16-1
overlap26
R468W
HPV-68
c.806−2A
BLIMP-1−ABC-DLBCL
Glu71Lys
multigated
v.3
Ala-276
DTT/100
1711
KMS-1
TGF-TGF-β1
–JAK2
S614R-mutated
Elf3R331P
anti-EGFR-TKIs
geneSRY
12,13,18,35,36
cytoplasm-predominant
Gata1-Cre
WIP1
colinearity.41,42
heteroalleles33
11G
Attachment–mediated
mini-kit
ΔS‡
Rciss
pan-SF3B1
H369R
F150S
6/435
heterochromatin-
151:1107–1111
94-kDa
NM_008017
.AKR
04/21
115258944-115258921
apoptosis51-55and
H1451
MORAS
5′2
heteromerization
CAF39
.Repeated
12D7
mUbRasK147
GC/SM
protein/phospho-protein
PKC412-treated
signaling47
FBW7-NOTCH1
.CHR
and0.1
.Antisense-E1AF
TEL-PDGFβR.10
BCRABL1
Ser1613Cys
wu103/wu21
atom-mediated
.102
200-bp
.INK4
Ivry-sur-Seine
.Neuronal
.FA-A
orGab1FF
p-Y
arrows.The
Leu-64
T91A
suYcient
Arg-815
ofprotein-bound
300–500
respectively.42
.Maintaining
Anti-hMet
195.1
HRG-β1
E7389
88/817
EWS-ERG-expressing
Tris/pH
IPMNs.1
D/Cdk4-dependent
D448H
TEAD-independent
c.1700T
X-100/0.5
co-amplication
0.498
driver-negative
.Maeshima
β4-β5-loop
earlier.24,37
0.26-16.26Metastasis
.Typing
C542Y
.These
Low-MC/NMC
antileukemic
CD23+
×0.5
T785
GA-mediated
activity,110
yellow/blue
PD-0325901
curved-edge
90–94
GSE57002
8×105
.Polygons
TNT-translated
drug-sensitive
UL14
publication12
.Spearman
WT1-KTS
kvd12902
178.7
Hingorani
analysis,39
extractionGenomic
dehydrocortisol
2.399
Figs1B1B
19.89
treatment-naïve
Bepler
245,248
G1324S
RER+
truncating-mutation
.large
site44
proliferation.24
Urashima
Eect
S8A–S8C
respectively11
thanhalf
NKX2-5/BCL11B
1030
mice35
GCTCTACGTTGATTTCAGAG
NOD-SCID-IL2-γ-null
5.4–4.7
strategies.14
5K–N
neratinib-sensitive
repeatedwith
BRG1-expressing
19F
21-residue
Waalwijk
tomography–computed
RHOA-driven
.S3G–S3I
1we
Gly1375
brachydactyly
1845-2002
PDFGRB
1–252
MO_1051
Y268LfsX31
4:499
LiVolsi
units.52
LD-PCR
61.84
TAAGTTTAACCTGAAGGTGG
129-strain
N-terminal/C-terminal
allele68
class-IA
P0040
www.hgmd.cf.ac.uk
AML-MRC,17
marrow–
RhoA.V14-
5-19
Mre11-/-
M1267T
conditions.Thus
M.A.P.
Arg258Gly
16B-reverse
+2.1
0.7–10
B36
91.0–92.0
533–536
M921
.28,43,44
therapy-response
g.26440374_26472747
8q24.11-13
//www.mutationtaster.org/
2.00+0.03
co-ampli®cation
Petek
30-fold
0.000194
BRAFP
smoothened
immunostaings
ILT-
5′-CAATGTGTATCTGGCACGGTCTCGG-3′
6Flow
VAMP2-NRG1
N-methyl
inhibit/over-ride
diabetes-associated
aflatoxins.17
p53CON
CBLDexon8/9
1753
10−8m
L869R/T798I
exptype
22/87
Ena
Porta-Pardo
10964–10973
Ser15-phosphorylated
TTCCTCCAGGATGT
Pallan
pBabe-puro-GATA3-WT
Asp-130
postreceptor
Cre/loxp-based
mutantRas
94–103
KRAS-G13C
A767V769dupASV
levels.11–15,23,24
PLX-treated
L350A
SCneo.Figure
Vilber
families.9
carcinomas,31
breakapart
N520Y
AR-ins58L
PCDH19
D935N
pREP41-GFP-VHL
p.R790
cancer10–13
167-bp
Yrich
HES1
perifosine
THYROID
RLA
B_H580
Xp21
pT198
S1290
310
wild-type-derived
Notch1-
antiEGFR
path-scan13
31/1/8
Miz1
1/573
5.8:1
S1025C
T-ALL165
differentiation.31
ACR
lineages.11
GW-182
59.5
caserepresents
patterns26–28
pCMV-3tag-1A-SF3B1WT
pEGFP–p53–ΔTD
DiscussionGenomic
RiboJuice
p.I32R
5,8,9,11
~63
H3K27-methylation
ELF
46/59
AGI-6780-treated
5,782
50/97=
INPP5E–AURKA
connect-
thestrategies
left-ventricular
translocations6–9
Maruoka
KLK3
STROG|
10:597–601
TGFBR2E526Q
L344R
Collaboratory
Intramucosal
C149
Post-IP
S2.7
Asn414
inSDS–polyacrylamide
S-5′adenosyl-L-methionine
Mucaj
Gazit
x40
I98M
MINPP1
OR5L1
low-tumor-content
774_775insHV
metastasize66
lymphomas,45
expressedand
R683K
p.R528C
four-log
.represents
17/23
STAR*FISH
co-transduction
R249S
T94-phosphorylated
chondrocyte-terminal
15N/13C
AS41
profilingThe
HIF1α-mediated
NM_001164273.1
trafficking6
jannaschii
germlinemutation
32,41
sc-58
Sitedirected
CGTG-3′
erlotinib–EGFR
anti-N-Neu
M2G3
c.677A
.Measurement
fastprotein
∼1.1
check-point
5′-AACCTGAGTGTGAATGTTGAAAA-3′
BRCA1-null
b-actin
A192V
albeitwith
S10wt
domain37
KFCfl/+
Gibco/Life
São
FLT3-L.
Smith-Waterman
LfsX7
//mct.aacrjournals.org/content/molcanther/12/2/220/F2.medium.gif
r0.6d
Deupi
5′GGATCCTAATACGACTCACTATAGGAACAGACCACCATGG
phosphoERK1/2
LAVTVKS
141.9
leupeptin-sensitive
-vector
Autorad
Ser768_Asp770dupSerValAsp§
15Université
anti-XXLαs
.Quantitative
unremarkably
LGQGsFGmVYeGnardIIk-GEaetrVAVKtVnEsAS1
KRT7
2-induced
+12
pSTAT5A
eye.1
3C–F
conc=concentrationFurthermore
alone.5
gamma-32P
hydroxytamoxifen-liganded
R171W
RTU
0007417
Cbl-R420Q
p.R304W
BRAFWT/RASWT
MCS
mainstay,3
Tumors—in
basal-cell
secretion.4
oncD-derived
buffer-B
EmSRa
HA-ID-GST
allotransplant
4i–k
.KANK1
study38
.Hypomelanotic
UV-laser
MiSeq™
Phe-764
nantly
Instituut
anti-MYC-coupled
G72S
//www.roche.com
3Argsubstitution
tumor–prone
thecrosshybridizing
539–1/pGL3
Q79
BCR/ABL1-negative
c.1592C
copy-loss
S6272.We
TG101209
.an
ECM-driven
MALT1-
S1008
c.773T4G
67–85
mutant-p53-dependent
Additionnal
Ubiquitination—Degradation
-200
5'−AACAAGACCCTGCCCATCGCTTTC−3
-EGrkMKISDFGLSRDVYeeD-sYvKrSqg
p.Gln649*
46.5
T584C
XL019
.UV–cross-linked
.IFN-γ-activated
GT6
1213
1.1b
al29designed
GCCGCCCGCC
CHEK1/2
EPIGENOMICS
∼125,000
phospho-Erk-1/2
H1421Y-U2
cholangiocyte
gefitinib22
.Inducible
.ROS1
D1-P287A
Y-705
pCS21
per-cell
7P
anti-nestin
TA-KE-3T3
Beau-Faller
c.730G
Thangaraju
ΔEGSSS
syndromal
C1483R
membrane-docking
3730_l
Kovacina
MDH
36-44
phospho-T389-S6K1
neuropsychological
repeat-dose
3481
competitive-alternative
Ser41
S720P/F
used.Cloning
E33del
L392V
antibodies35
five-helix
transfor
1–1530
DLG
Dissemination
polyphosphate
≥8×
0.0029
210–216
PML-B2
Prosperi3
SHELXS
21/50
goterm.R
RCAS/PDGF
,3a
disease.A
1i
0.3082394
W50
0.335
.Raf-1
unfolding/denaturation
Tomtec
'off
mL89Raf-1
R-roscovitine
Oncolytics
8.081077125
Acrylamide
1PPP2R1A
82.8
hus.fi
tomatidine
Aggregation-dependent
L135F
Bagot1–3
S.H
argon-ion
TANK-binding
I68V
PRODH-forward
K213
vivo.I2
0·29–0·83
TCF/b-catenin
Kaestner
pMAL-PHD1
blue-gray
RhoA‐regulatory
nonerlotinib
269-bp
RP11-231C18
D1/CDK4/CDK6-Rb
FCCM
dependent.A
.Investigators
MAF≤0
AtoG
AI745526
SGK-1
325-355
2136–amino
months.20
Y375C-
AS-PCR
.Rac
SMG6
V400M
al'7
here.31
impetiginized
SpeI-SwaI
high-EGFR
2Ef
antibodies-
p.F57C
S550N
Y1003
splice-3
IVS13-2A
hindrance
PKB/AKT
M173I
PHF21B
8003
0.2-cm
7907
methoxy
ZSTK474/GDC-0941
20.06–
minisequencing
2.125057033
-CAATGGGTCTTGCTCATCCATGCAGAGAGCCTCCCACGCCCATTG-3
362.9/146.6
47,48
undervirilised
5-GGATTCTGCCCCAGGC
Parellada
MgSO4
formation.14
8–10
DOP
tests.28
prognosis.18
29,60,62,70
calvarial
protoporphyrin
breathhold
day.12,14
Dali-lite
1153×
6:6025
p.Gly1366Asp
GLARL-
600678
.TEP1
10/14/2014
GCTCATGCCCTTCGGCTCCCTCCTGGACTATGTCCG
11836170001
mutation¡/HER2+
Yeastgrown
Sugimoto
Co60
semiquantitative
L536K
fgf-5
593–599
.shown
−Δδ
vivo232
transcription18
5'-M13-GTCCCCTCACGCTTCCC-3
R780K
77c
f32
SDHX
glycosylation-dependent
shLuc-expressing
Kurume
IR-specific
indexNextTo
disease135
CD4+IL-17+
process=home
3Arg
intersample
CREB1-binding
*Complete
4,700
C″
Vihko
663
Wilq-Liss
.0014
X0902
453A
40–180
5′-AATGTTTCAGTGCAGAGCC-3′
.13,16
+19
NaVO4
PIK3CA.16
L446P
FANCD2-S/L
.blinded
WT1–U2AF65
HS00869981
µF
dataset28
co-silenced
6.45
-irrelevant-F
1It
QPSMT/SE
41016
3/21/03
BAP1-only-transduced
pEGFP-ΔC
HRG1-β3
Neaples
Addenbrooke
10415
GC-related
25,97
Gas6-mediated
stimuli38
N2=13
children40
Leu484
responsivereporters
Kaplan–Meier
KpnI/EcoRI
-CATCCTGCTGGAGTTCATGGCGGGGGG-3
HS00418963_m1
2.521
Ultrafree
teh.bin.tean
trans-hydroxytamoxifen
WST-8
10.1056/NEJMc1309091
10s
populations5,24,35
QuantiT
cells.46,48,86
bysequential
CTGGGCT
pre-ranked
1–318
colonies6100
c.5309G
p.Thr495Asnfs*6
D3S1029
reinvestigation
colony–forming
E1756K
Tyr65
TrkAIII-negative
paragangliomas.14
My16
describeunknown
19.33
agents35
Y243N
heterotetramer
coamplified
A2213G
E739K
,16
271–282
.HIF1A
E542K/E872K
5632
pick-up
33/48
imatinib.11
74.82
ACAATCAAAGGACCGAGAAGGA
MSCV-Bcr-Ablwt
phenotype20
High-magnification
Burrows9
NR4A2/Nurr1
phosphorlyated
45,600
1,025,590
0.53–0.95
.HMTase
WW3
anti-immunoglobulin
92.1
isoforms17
25c
50.1±13.5
tcl
sonications
JAK2-V617F-addicted
ATRX-based
143–154
BRAFV600E/L505H
N-myc-p110α
glioma-relevant
fusion-protein
11596–11604
pv-9000
2.5388139
2680
Ottaviani
Nrf2-based
372-bp
proteolytically-resistant
VFGFPVHYTDVSNMSHLAR
non-aqueous
88K
Mm00441724_m1
productsare
P3in
1,785
first-in-human
CC/CA
H218O
L41P
bly
pathways—like
aggregation-nucleating
cell-intrinsic
protein57
//www.molpathol.org/data/
Fbxw7-overexpressing
CD71low
theecacy
03
andrs1165049
p53si
28.3
dendogram
0.15:1
.Controlled
iodide-negative
kras2
200nM
.ESTern
-MUTY17F
4um-thick
Bruker
.0087113
agCca1955agTca
tested.Effects
hereinafter
puromycin-specific
14105
Tyr699
IRF4+BLIMP1−
SGOL1
0–56
PPxY
posttransfection
imatinibresistant
F-TSC1.ivs17
tamoxifen-dependent
antimicrotubule
5′-TGAACGCCTTCATGGTGTGGGCAAA-3′
5GeneRacer
3‐D
ARID3A
.Multiplication
and4C,4C
Adematous
/CBFB-MYH11
743_1111del
STAT5.19
5′-CCTGCCATGGGTAGATTTCT-3′
pCEP4HA-ERK2
291-294
ID23-1
airway
RASG60R
transcriptase-dependent
28:3061-3068
1−Pg
690K
MMTV-activated
.Dose-limiting
pp1.The
non-colonie
SOS1-mutated
accumulating.1
19664
GG-3
STI-571–treated
99.3–100
4463
HN
loxp-flanked
3.1-V5
UNK
MET-D1246H
mononucle
S-related
.AY303970
.In5
V710
post-transcriptional
A432G
.Thereafter
29.3
0.026
.Incomplete
.Symptoms
Sox9–DNA
resultsBecause
5'-GC-clamp-TTGAACATGTAATATCTCAAATCTGT-3
P383R
multi-stage
Hnf1
Met-221
and6C
59NTRK1-39TFG
fourwell
Over-representation
manufacturer-recommended
neuro-trophin
40±+
Runx2‑deficient
5′-CTGCATACACACAGCCCGCCTC-3′
S32
854T→G
5′-TTCTGCCGGAAGTTCAGTTT-3′
samples5
.CNVs
prereplication
R859Q
4A2C7
missense/nonsense
c.97+25_+39dup15
2–5X
N857S
Asp-876
Hajra
p.R457*
25:125–134
composedof
ANS-fluorescence
AVCR1
contra-indicated.22
p.D337fs
pre-marriage
box-deleted
re-ran
CGCGCCCCGC
.GENE
c.-228A
Phe-187
–8.4
c.435T
regress
2535
,1E
1,2
DN-MAML1/pBabe
phosphorylable
MEK—or
control.Middle
Sicinski
subsite
craniosynostotic
BRelative
Lys83
TCL1A/B
p1.7XhAT13
EthicsThis
GIuProGInGInArgHisSerIIeLyvsAspVaIHisAaArgLouGInAIaL
gyrata
SMAR1
respectively.8
c.1324C4T
droplet-accumulating
..9
17RA
37/42
119.2
p84
intermediate-risk
re-annotated
WWW-hgc.lbl.g~v/projects/
ellipsoid
≥9
K1250K
muscarinic
21q22.1-22.2
phospho-ERK5
which-in
A1096V
2D–F
DOG-1
AKT1myr
pac10
000875
Akt/survival
unlabeleddCFPto
3111–3130
,14,17
hyrogen
M172K
0.25
diffuse-type-specific
H.-P.
ST7–CTTNBP2
8,38
Hand–foot
.Gly
4HA-BAP1
Primers/probe
K255E
5′-TGGCTGCCAGGGCGCGGTGCACC-3′
dual-specificity
Ottenho-Kal
V.1.1
cancer,18,19
p110β-dependent
8.1months
F53_Q58delinsL
HEI
ploidies
anti-polyhistidine
proliferation56
APCCdh1
suppressor.Top
E1271K
BMI-adjusted
135
stim­ulate
DOTAP
NEMO-deficient
13±4
TGF-f3
mutations.17
49-nt
Blumberg
exon-deficient
gi66361202
.AR-FL–expressing
BCRABL1–positive
FoaR
Ras-GDP-like
43AXIN2
activationin
CBD‐tagged
cells—one
CLDN7
Mel270
1,706
Mutsα
PPARG-dependent
150/2
Electrophilic
thyroid27
Solit
Pepstatin
mimickers.11-13
and2a
Jambaque
5-fluorouracil–treated
Y641N
AMLCG
c.736_741del6ins11
HES7
123I-MIBG-avid
progression.102
544–547
QuickChange®
acc=GSE48850
Jnk
RCT-D782
.Keam
.Toschi
M86R
Anti-p53
1439
GATCTTGGCAGGATTGAAGC
OTT
S425C
CD44
HR=1.3
110kDa
STX8
conformational
PKCa
2+d/C+M
.Tuberculosis
ERK2-wt
FGFR3=fibroblast
K14−
F450S
–type
S3.10
Val57
CMV-miR-17
proteasome-mediated
transected
HER2‐mutant
p/CIP/AIB1
reports9,10
chromosome-positive
∼0.024
case.1,3,4
untranslatable
msh2-VD869
Calbindin
M282L
Okayasu
DR104
5'-uCGAGu-3
453x
hTopoIIα
11–28
pathway.61
Raf-transformed
degrad-
PCa-specific
D1-degrading
G472R
0.4M
Mantel–
mitosis/high-power
www.ncbi.nlm.nih.gov/genome/sts/sts.cgi
.G12V
Nonsynonimous
PJS050
wi.mit.edu
transcription.13
Cac8I
SBE
-61
Ave.
clusters/subtypes
Hartl
3611
228V
tetrazolium-based
to125
mutationinKITexon11
cancer12
BRA2
1–888
G.B
sprouty
research.nhgri.nih.gov
q=1.9E-14
p.C121S
disease-causing
5′-ACGTGGGGGTTGCCGGGGTTGTCCACGCTGGCC-3′
Escusa-Toret
and8.8
H3-positive
aTotal
59-GGTTTTGATAACTTTCACATA-39
del/+
extrusion
0.215
mid-brain
pool106.Resistance
RP11-1137N1
c.1976delC
1Department
.Positive
Adelmant
DEK-
v.9
NZM46
602759
1181A
Parafin-embedded
iix
1-TRCN0000195502
triphosphate–dependent
OpenBiosystems
GLUT2
FISH9226
TEAB
HRASF28L
in47
LUC7L2
Mx1-Cre-negative
pro-apoptotic
KIAA1797-p16INK4
phosphoserine-S1981
70-
Giampietro
DNAmp
rad50vsc+h
5–8
8520
213–250
1796–1863
Kâ€
ligands67
R2784Q
A127E
8/29
TCPA
aminopropyltriethoxysilane
beclin-1
Imgenex
SAV1
.LATS2
methods11
C11orf68
TTCTGAGATATGGTGTCCAGG
~0.5mm
RAS.14
T3/T4
CausalityLLRGene
GRM3
LacZ-positive
P123
Bosse
.IC50s
non-induced
detectedin
S-21
'-TGTCAAGCAGAGAATGGGTACTC-3
qPCR
L747-P753insS
N-CAM
609–615
ECL2s
IRE-reporter
Q1579P
E1a
TÃŸR-lin
D1046K
PBX1
11Division
theC-MAF
185-bp
°-
3844
1:3,333
reaction-single-strand
Gln528
myeloidlymphoid
Ty-82
RING1-
TCGA-06-5411
successfullyexpressed
NZM11
hTERT-NHUC
interleukin-10.18
angiomyofibroblastoma
Perrimon
S2.Table
F4799
6.00E05
s80
T-cell-independent
K223E
splice-enhancer
PACH-211K24
11,551
Arg373His
GFP-fused
M1R
Taspase1-mediated
X66947
Townes-Brocks
F9
radiochemotherapy10
S251N
anti-FGFR-3
receptor-T
measurementThe
.JAB34
G1075T
biocenter.helsinki.fi/dali_server/
disease.14-17
T-ALLs100
AK045226
6-54
1.3–21.4
H213
tumors31,32
A1626
c.1702–1G
21-26
Fig8F–H
Anti-SPA-1
Crude-cell
2J1Y
METPRC
focus-targeting
.Q207D
oxidant
c.1554
PCNA-forward
kinase-inhibitors
Ki
Gly325
MDA-231
signalling86
IC501μM
pAKT-positive
18/51
TSC2/PKD1
Belve´de`re
carboxylated
//dx.doi.org/10.1371/journal.pmed.0040315
Pro96
mice-
RP3-508I15
chr7
DFS/RFS/
1.15,17,18,20–26
mice/group
machine-learning
kVp
.IRX2
Foroni
CYS
GISTs.4
G.Mohi
8,11
siRET-transfected
Skp1-Cul1/Cdc53-F-box
NCI-H1975
RhoA—We
3.771
Igλ
Lonardo
11*
8R–11R
p.R1443X
Blm
ATGGAGCCTTCGGCTGAC-39
V=1
leftIII-2
BglII-rearranged
R636H
trP1-Exon25F
occurin
TFA10
intronMotif
GENEEDITOR
TCGA-A3-3347-01
FLAG-CHK2
.Weidong
types7,50
V600K-mutant
H-DHT-binding
Kistner
V33T
TG-30
Dysregulates
D469G
5.904
re-populating
Matrigel-PBS
BARD1-B202
Jak/STAT
conditio
53.
3434
UVRAG
isotope-dilution
AqcNCQOCC
1770–1800
5Sequencing
functions7
E230fsdelGA
fusion-
ERK-activated
/pw
ACAGTGTGTGAACTGCTTTCAAGT-3′
pVDL-1393
investigators.25,26
Cre-ERT2
R|F=
ELDLETPAPYIPMDGEDFQ
≥25
31.8
7358–7363
literature7,19,20
1kzy
L99M
cells48
§Present
~35
MDA-BO2
TR1-6
rk4
2:1:2
1–462
528K
Cbl-b,20-24
-Brd4
AGVD
21.9
afterinitial
R321H
.PON-MMR
R2319S
HOMER2
BAP1.18
K179M-AKT
5′-CTGGTGGATGAGCAGCAGGAGGTCAGAACCATCTCTGC-3′
co-amplifications
range=9.9–29.8
Hennig
8.77
gene-amplified
bil
Miyazono
2y-PFS=62.5
progenitor/precursor
Akt-GFP
Ci/ml
FGFR3/MMSET
PD98059-treated
MAPKKK
stabiliza
5,51
SW3
NMDA-induced
Haplotype-based
2p13
GST–GBD-
HT376
murine-specific
reestablishment
Aaltonen13
pGEM7Zf
co-expressed104
p14.1
Pedegree
//dx.doi.org/10.7554/eLife.12792.001
2.486337
EcoRIdigested
15−20
T674I
β-thalassemia
2–35
40/113
aminolevulinate
AGGAAGAGCTAATAAATCTCTTCTTTGCTG
17-allylamino-18-demethoxy-geldanamycin
twenty-six
='1/4th
anchorage-dependency
Masuda
o1.5
Spheroid
c.1495A→G
−24.97
cells.18To
NUT-containing
DMEM-15
treatment19
TMPRSS2/PLAP
P68S
H184A
1849
risks—that
FQ868–869del
Circumventing
R619G
c.1439del
K650E
PLD1-insensitive
GNPAT1
RETY791Fand
.positive
c2191G
Schuuring
T1-weighted
range=32–125.9
ErbB2_ex11-19.SR1
men6,7
209.3
0.02*
Polyubiquitination
mutations.35
5′-TCTTTGGGATCCTCATCAAG-3′
Skarin
CYP2J6
immuneprecipitated
MEK–ERK-dependent
D18S481
V3.0
SNU-407
p/CAF
Mikuta
5′-TGTTACCTGGCAACTCTGCTGAA-3′
CK600
CTTCTTGATTATCAA-+CTTCl
.Hepatology
Q25
selumetinib102
nucleus-negative
Ly-6G+Dicer1Δ/Δ
.80,90
Stockhausen
dimerization19
L349P
AmpliTaqGold
BRAF76
1,2,3,4,5,6
0.6-fold
Asn505PheAlaPhe
TPG
MultiScreen
SSPNN
T334A
SRP056295
000-28
gel-shifted
VVSGFIFLRFFAPAILGPKLFD
Mu-En
chr18:36613976-36614714
phospho-mimetic
-R201
D770_N771
TR-KE
I39M
KLHL1128
.Hodgkin
V5/Dest
Joutel
Three-state
17130—several
AZD0530
CDDP
byionizing
elegans
577K
transfusion-dependent
Nrf2-pathway
3879insT
Nκ-kB2
D16S3025
nonlesional
GST-cyclin
lli'il
//imgt.org
R140Q
MEL-26
//www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi
F60L
germ-free
contextualized
UHR
WSU-HN6
1.1–1.7
CT26
dose–dependent
oncology.wisc.edu
APAX8-containing
pCAGGS-Cre-IRES-puro
HMLH1
D166nt
anti-PLCL2
12q15-24,14q31-32
EWS–DUX4
Chaker
0.370
.N-terminally
PC-associated
GST-BRMS1
scdl
V3841
post-SU
phosphorylated-Erk1/Erk2
FoxP3
.Stability
epiphysal
diphenyloxazole
Paratrabecular
fluorese-cent
289/367
RAC1Q61L-expressing
.Scepter
wild-type-sized
Msi
ATP1B1-PRKACB
rearrangement.19
polyploidization
Thr183
ALK-I117S
method30
0.0465
.Mailing
A_52_P498241
ofdetection
Age1/Mlu1
bromodomain
D802Q
SalI/XhoI-digested
BNIP358
agec
Tran-35S-label
epithelially
81–100
Met120
assembly-based
SMADS
phosphoryl-
W748R
GRGDS
LAPC9
pcDNA3–PTEN–V5
Shh1
Duh
MDA-MB435s
methods.22
15,000-25,000
OG1
non-structural
.CUX1-FGFR1-expressing
formazan
48-residue
.Existing
27164
5557A/A
Second-
65˚C
Phosphorlmager
1,163
pDONR223
UbcH7
c.537+17a
Rosa26-LSL-rtTA31
SPC216
SuperScriptII
C-Raf-1
800-MHz
lucitanib
stomach-restricted
.SOX17-overexpressing
tel/PDGFbR
TANGO17
4M
L342P
oncocytoma9
SASR
double-mutation
sulfide
sequencing.Drug
Afro-Caribbean
non-specifically
BostonBiochem
APC/β
rare.14-16
SFA24a
G-CSFR
2790
cRRS4
.Phosphatase-Independent
Nras12
PTEN-351
S0464T
V431
bilization
V-shaped
CAMK1D
RDS
Asp1778
TCTGCATTTTAACTATGGCTC
Abgent
4a
variant.https
disorders.77-79
9232/99
5′-RNA
5′-tgtggtttcactttaaaccctgga-3′
Garcia-Espana
R179
RTR
WS.9
splicesomal
hematoxylineosin
pY187
DLBCL.10,12,14
5456
1⇑
hyperpolarization
INTAS
IDPotential
hetero-oligomerisation
+/0
GbSTFM
G111
SLIDER*
0.135
20.1
Vans-activation
1.0SÂ°IICE
Thr41
G691
2,203
MED23
cells/wells
13.6/1.4
4B-R
NCT00815295
B*4423N
walls.16–19
2-like
Nar1
HuGene1.1STv1
antagonist138
105-114
300291
ofsecondary
SF1/HGF-specific
TP53-G244D
L729V
mam
CGACTTAAGGCGCATTGTCTGG
ab77400
Krankenhausstr
Matlab™
D422Y
5′-CATGCGAAGCCACACTGACGTG-3′
30973436
Bcr-Ablwt/Bcr-AblT315I
conc=concentration.Second
.Working
ATTGTGCCATTGCATTCCAA
GATGCTGCGGCTTGCGCTGCTAGCGCTGAGACGGAG
disialoganglioside
S970074
Figure1A,1A
.KrasG12D
Tctex-1
obtainedin
hygromycin-selected
PI3K–p85
patient-level
CX-5461
.Ceritinib
S508
Sox17
I~JM
modules15
.Gli1
deletions.3
k0
Gln453
SDS/proteinase
algorithm35
activation37
DNAbinding
sonicating
D190V
malignancy.27–29
1922del
Green-dUTP
.MLS/RCLS
activation.33,48,49
proteasome1
CX-1
X53
.Work
3.82±0.07
Δ4-11
Mourikis
up-regulated
GppNp
c.4517G
Cold-shock
9.22
Cdkn2a+/+
Cy™3-conjugated
nascent
MKN28
BAF180-dependent
23-33
Nrp
ABHD11
T27
p53fl
Y1853X—were
S142F
Glu101
raf-J
5-μL
trp-1
model47
CERFE
nuclear-to-cytoplasmic
JAG1
Keap1‐Y334A
MED12-mutant
cylinD1-YFP
.Metabolites
UF2
0.288plusminus0.036
PDGFRA-positive
semi-digested
treatment-failure
telomerase-independent
controls26
one-nucleotide
Rebaı¨
single-transfectant
accessionan.d
Zinc-finger
EGFR/PTEN/PI
Y641
1LM
10b–e
A302-080A
LATS1K734M
–24.59
Dual-GLO®
prokaryote
history1
YZ
myc-p110α
TGF-bs
0.87±0.29
p110β/p110δ-selective
proteins.8
models.19
co-
I/II–IV
3.50+0.20
5909
NLS-dGFP
-48c
hTPO
S702G
E33A
0006
38/295
Naidoo
disorders.11-16
bydisrupting
photoconversion
2682â€
18-51
.IDH1mut
Q42Term
trimethylation
TTTCCTCTCCTCCCAGTTG
formationwas
HRD-targeted
anti-microtubule
c.501-
gene-
pigment
p7o'rk
Smad4-Flag
microtubule-severing
Hs00420495_m1
.Blimp1
F1323
887/812
.Seventy-six
S0168
−2.40
hypaesthesia
0.681
HT-1376
antoantigen
Nucleoporins
35P
and4
BAF53
97.3
Arf-/-
E565G
cSCC6,16,17
QuickExtract
J014
−g
.S-21
dioctanoyl-PtdIns
cytosolic/nuclear
D1733
HBUILD
Eμ-Bcl3
rst
ALK-G1269A
1.030–5.529
phospho-SQ/TQ
TGFBIIR
L1195
10−32
Immunitaires
receptors.31
.eMC
cancerdiscovery.aacrjournals.org
.Inferring
ARY005
∼6-
tube-like
Guarente
HCC21-0208
L688X
2.50
cycle-time
families,8
Arg24His
0.000077
7,339–567,685
HS294T
anti-BRCA1
B150
79.61
p.R524VfsX1
D861Y
E-G
Arg784His
.Having
acinar-cell
cross-tabulations
a-phosphate
CellTiter96
usingBamHI
penchant
1i3
ChIP–PCR
50bp
erlotinib-resistance
Anti-mitogenic
HGDM
GCACA-5′
5507
732.8
CCTACGATAATACTGCGAGTC
10.1054/
A.CTC.TCT.C
ISWI2
FOXA1-binding
radiofrequency
2,950-bp
PIK3CA-Related
responses,8
0-218
splanchnopleural
_FGFR3_
S13N
19-positive
ACAGTTCGGAAATACTACA
n=880
TrkC-specific
Lys-237
rs6723097
CRAF-dependent
GSTERK1
tumorigenesis33,34,35
Holland-Letz
34f
karyotypically
IDH2R140Qt
USH
non–phosphorylated
Amino-acid
JRA
DNA-independent
83.32
nonsquamous
//tcga-data.nci.nih
NF2
EZ-Cytox
1p36.23-33
53BP1-negative
Y537Y537F
D1-D289A-3T3
anti-βactin
NCI‐H1993
panitumumab
Nsd3
complex41
Asp-863
anti-EGFP
BglII-
AGCTCATCATGCAGCTCAT-3′
Coot/REFMAC
TGTCCTACTTCAAATCTGTGCAGAAGGAGGT
deaminase-2
DRB1*07
criteria—including
EGF-related
Lindahl
5-mer
controls.116
Ku70/Ku80
A/G/T
MlC2
p.P281R
3p14.1
D538G-E2
JEG
sc-8396
V543
2f–h
36-53
CoA
MCF10A-GATA3-ext
NHR
non-BTICs
MLL-AF4pos
C379
units=intensity
cross-study
mutation4
AKT/ERK
hydrate
EDTA/Na3VO4
Ad-Myr-AKT1
DNA-damageresponse
Sicheri
delN480
Nigro
enterobacteria
.IKK-mediated
partial-genome
NF1G1166
leverdomains
10m7u
CDKN4
TIMP-2
.KFC
hIL7R5′BglII
.Probabilities
~57
−/−ArafMEF
sc-20682
coimmunostaining
dup501-502KIT
thrombocythemia/primary
DRAM1
S211R
28–79
10,12,13
BPGM
q33q33
.hMSH6
K601E/I/N
≈3-
nitro-N-nitrosoguanidine
RasGAP–p190-
toTransactivation
intereference
HTLV
imatinib-treated
fqr
284
EMT.Figure
5'-M13-TGAGATCTTTTTIII
V44E
KIT-W557_K558del
dermal-LEC
deletion-encoding
4O
TKI-naive
Trichostain
27/PKCθ
Welm
PAX5-JAK2–transformed
10–intron
.Synopsis
HUT102
E717K
CDHI
KITD816N/Y
para-meters
pSH18-34
∼180
High-molecular
WC-I
tileSize
6C-E
VEG
lymphomas106
Vottero
F113L
Activated-XTT
Catovsky
p37
85X
20.1/10.5
PCa-associated
32D-Flt3-KD
+497
GACACTCGATGTGTT
450^690
IGV82
Commun
psoralen
Da40
PHD-finger-containing
BERF1
4q31.1-3
7.85
NCT01909453
261,894
pT1N0
.PH
e9
.Genome-edited
p19/CDKN2D
NOD/SCID/IL2rγ−/−
ICL-
pl6/CDKN2A
Tmprss2-ETV1
cirles
Radicicol
P-MET
mechanoreceptors
5′-GATA-3′
cRSS3-cRSS1
24G
19.41
studies23
anti-CTLA-4
low/little
TFS
Arcuturus
LD50
GST-CDC25
2011-814
81.47
Prom1
M12.53
99728
Sudbecket
astocytoma
8994-9007.
I462M
WTKIT
0.31-1.17
RIN
S957
UMODL1
PRKCB2
Biotinylation-based
proteins.27
.DGC
ISUP
T150
Sin3p
Loserth
LATS1
locations.17
de®ne
Bcl-2-null
prognosis.24,25
Myc-ubiquitin
mesylate-sensitive
12/17
BRAF35
Kcat/KM
V626F
c.2276dupA
Msh2−/−
-BPfinder
–induced
probands'parents
41.10
.0012a
cycle-regulatory
R198
UBB
29–70
controversies
ura3
2A-2
aCGHSmooth
gray/min
C124/135/141S
non-G12/G13
'weak
NSML
Moses,1995
kilo-
CD122-PECy5
0.475
Fridlender
PeutzJegher
16.6⁎
TranScreen
E2-induced
Mol6culaire
lobular-specific
HIRSCHSPRUNG
Illkirch
boost/nest
calpain-2
CL-2B
I853Ta
H-US
1,25
Eye-bleeds
susceptibilty
.Adenoma
50x
PK2
Berchuck
WT-transfected
of60
50101
Sec5
HPV-32
RG206047
affectedproband
MEK1P124S-mediated
β-gal-expressing
COOH-terminally
A.6–8
Asp769
PLX4032/vemurafenib
dose-and
Q510E-Shp2-encoding
AGGGTAAGGAGCCCAGACAG
*68
containedmutations
A_51_P493649
oxygen-regulated
FuGENE
0.07294–0.1085
G77R
imatinib-naBve
HECT-domain
D816V-containing
NRTKs
rosiglitazone-treated
pT3E5A
G0
SS*MS*
T783
BRCA1-methylated
.NICD
9G2
BAIAP2L1-targeting
calbindin
p-Akt*
Smad3-Foxl2
Transrectal
tissue-microarray
.1G
1,671
43.8
fingers/toes
His115-containing
-0.002640254
Korchynskyi
DA460061
-CTTCCTGCTTCCACCTTGTC-3
respectively15,16
binding–independent
K42me
0.01-10
2166
3.74
T369I
12p11–p12
pS-p53
A510V
GS-392R
5-CACCTCCATCTTACGGTCG
PIK3CA-GEMM
F460L
PRDM1.E4.60.R
D17S938
TEL-TRK
Arg361Cys17
3,5,7,9,11
W1456R
FA-58i
tested,22
14-3-3-binding
230−248
misidentified
p53/Gata3
Q271
S2d
cds-indel
2FIGURE
1-219
Q493X
sequence.23
2Sequential
.GTPg
Heat-induced
macromolecule
protocols5
RC161/2QW
Karpas1106
3′-partner
valine-based
CAP20
B2201
9q13
Helicobacter
isopropyl-L-thio-BDgalactopyranoside
R263H
yeastWe
1798
FGFR1N546K
restreaking
nine-gene
glioma-derived
positional-cloning
TC-3′
p/sec/cm2/sr
1.0010
mechanisms.44–47
11TEFMTY
CellTiter-Glo®
3-isobutyl-1methylxanthine
lymphocytedepleted
VMRC-LCP
RAS-mant-GMPPNP
Kmt2d+/+
H-15
CDC4-K63
S296
.4867112
bowtie41
Naf1p
bcr-abl
in-trans
10q23b
_P278S
presenilin-GSK3β-β-catenin
TATTTAGGTGACACTATAG
^16951
Iheavy
Sunaga
K117N
1531l
caALK2
anti-angiogenic
c.2203G
Superimposing
15N/1H
KSR2
p=0.159
RAD51C-G153D
DIM842-844
n=16
MMCA
AKITlentiviralshort
12-time
TGAACTACCACTTGTTGACAC
Nop30
72jC
corticosteroids
.47
R2227C
0.992
AGAATGCCACTTGATTTCTTTTC
Val197
xVent2
∼2.8-fold
1.2–56.7
Dlg1
.Exclusive
monomer/monomer
anti-sheep
C278
2-oxoglutatrate
NBSHGGs
12–296
nonglial
U2-
PMF–mutated
TSC,30
c.1038G
PEX1
Immunoprecipitation–Western
pADBRCA1∆242
neural-type
FLAGZBP
PI3K-PKB
tumors25
BME-coated
.ARccr
Ory
mutantFANCC
KPS
Venus1-tagged
-5
T131S
3.60
BrafV600ETgfbr1fl/fl
.Brca1FH-I26A/+
.LH
classificationA
d-Rhodamine
VWLNF
yet-to-be-identified
MycHis-BRMS1
spline
UbcH10
Mechanistically
c.2950G
classification5
ARID1A-mutant
15,300
0·0–52·2
530A
.ETV6-RUNX1
.Critial
www.mrc-holland.com
clinicalpathological
circumvention
R443L
RAF-1
cancers7,8
283KB
CYC1
V-based
2k
5′-GGGAATAAGTGTGATTT
sequencing.17,26,31,37,38
CTCGCTTGGGCGAGAGTAA
E798
370
c.2008-2011delTACT
.Staining
L3-loop
RAF1-activating
H3K36me3
K650E-FGFR3
Tyr118
cells.4
S/L
H2Aub1
c.2457_2460delinsT
μA
Ala763_Tyr764insPheGlnGluAla†
F1*
5′‐GAGGCTCTTTAGCTTCTTAGGAC‐3′
methionine/cysteineHsp90/Cdc37
hMSH6.After
fusions—the
leukemogenesis40
.Miscellaneous
Tyr490
superinduced
0.08548
HBL2
36-73
Phenylmethylsulfonyl
z-Vad-fmk
EF1-α
29.94-31.04
HUC
P5-speci®c
S396L
pT3pN2
JCRB0252
NOD.Cg-PrkdcscidIl2rgtm1Wjl
−48,359.45
.425G
elucidated38,41,43,44
pCMV-HA
-2,5
Stilgenbauer
1100deC
ARshRNAc
stability/subunit
triple-resonance
.Actively
.L536P-HEG0
non-adenocarcinomas
c-erbB2
pep4
over-all
entropic
non-dominant
gsp
HER4-G785S
5′-CAAAGTAAGCAATGGAATACCAATACTCAGGAGCAGG-3′
Xiangming
big-dye
.Strategies
Striatin
www.hgmd.cf.ac.uk/
Thr1572
Arg297fsX38
Cellulaire
antiERK
mutantsare
μM—with
HeLa-deficient
52/295
ecular
alteration1–5
9,600
correspondingfragment
p50
autophagy9
COSM317523
0.0132
Chr.15
-smoothed
GCAAGT
TKD
enzymatic
T-G
Novelc.4225A
1/183
phaeochromocytoma5
families,22,23
Quick-Coupled
plant-specific
3.23±0.33
A177D
BCC3
13,200
R593C
Jeb-
FE9
flag-4KR
ln2/λ
S7c
IVS2-52T→G
effectors11,12
hlots
dacomitinib
T-cell-based
SUDHL4
dependence39,44,45,46
0.327
P533R
P263T
StDPETGEL-OH
V224A
R174K
AL121790
0.11-1.00
e.g.SERM-bound
tumours.32
gpll0Proto-
megencephaly
dose‐dependent
1.15–9.59
n=234
hematopatholigists
Vav-Bcl2-Tg
elsewhere.21
34/935
Polysyndactyly
methodsStrains
'O.l6
.-H.M.
lymphocyte-associated
s.c
37.7–52
5′-CACCATGGCGGCGCTGAGCGGTGGC-3′
X02231
ql3
TRAP170/DRIP150
-CTCCCAGAATTTGCTCCAG-3
gadolinium–diethylenetriamine
R382L
phospho-akt
Karimi
private.22
HeLa-TK−
Fms-like
E2F-response
uhnresearch.ca
anti-hnRNP
3,073
tabDownload
KITM541L
0.1722
c.423
Rem-Cdc25
​Indeed
single-step
hairpain
T318M
TAM-injected
dermis/subcutis
strainsStrain
pVHL-defective
PDGFR-alpha
5'-CCCAGTAATGTACCTAGAAA-3
AL040312
~218-kb
RUNX1-CBF
65/F
deproteinization
GIST-related
siRictor
12,200
.DESeq
proteinwith
PR110
sub-functional
MerlinHippo
8/24
94^103
MLL-related
P340L
Y537D
AB3
CCCTGCTTCCCTATCACTGT
R547A
metabolism7,8
symbolise
others,42,43,45,48-50,82,83
MCF-7
P1-P2
EWS–fli-1
929
Plougastel
H1966Y
.Calabretta
.052Women
HBO
NHA9-induced
ZFP-dependent
ECOG=Eastern
:62–74
D168_R300del
Bcl-x-
anti-pSTAT3
pDEST-V5-FGFR2/PPHLN1
ionic
2070WT
Kloor
Q500MC
FP8
c.3302G
7.16
5′-CAC
exhibitedby
QQ-plots
skp1-24
IKZF1-deleted
trials.gov
frameshift-mutated
HLAmatched
33.9–37.9
KMS-18
0.29043
p=1.81E-29
3500
Pro-Long
proposed78
Val559Gly
W1487
S204P/F
CDKN1B-encoded
Dynazyme
BRIP1-knockdown
Multiglandular
apocrine
c.3443G
Sp3
proglucagon
/mL
copurify
c.1984C.T
collaboration.28
SSCP/heteroduplex
UBE4A
.DFCILU-011
Nestin-tv-a
1ir3
leukoencephalopathy
.FGFRTACC
scar-like
PCA-based
.Denaturation
0.37–1.08
superhelix.Figure
Borealin
Douillard
ab75984
D-resistant
deacetylase-independent
234This
c.1238_1239dupCC
previously,3
__W558del
+Y527FSrc
G→A
5´-GTATGCAATGCCTGCGGCCTCTA-3´
lymphocyte/lymphoblast
1.67
Prostate
C26S
carcinoma.21
.ACL-4
FGFR3-S249C
re-analyzing
arterial-specific
microprocessing
CUG
Mx1-
reported.19
Phoenix-ECO
Mcl
3q26-27
immunoprofiles
15‐fold
LB1622
modulatingthe
Allele-Specific
S-Adenosylhomocysteine
myeloma.Derivative
NM_021140
Dnmt3L
170,000
87/140
~87
Waghorn
NRF2-specific
reported51
.EGFRvIII
lines3
IGH-BCL2
miR-16
NR6
Segatto
v1.26.0
1.6.1.
BRCA1–Met-1–expressing
S45Y
Co-crystals
lumican
CIMP−
MDM2-mediated
pnas.1321155111i10.jpg
MMP2/MMP9
Fanconi
E-cadherin-associated
SOX2-amplified
LUC
high-efficiency
pNKY1070
extracullar
V839
2014.
EML4-ALK14
TGF-beta18
−TEV
therapy-refractive
A_51_P214197
TAO
D-317
β-tubulin
brain-stem
Kegg
K652E=Wildtype=Control
ARHGAP20
apraxia.8
amphothericin
70:27–56
GAFG
K641
Flag-caspase
R465
NRasQ61R
V217F
escapefrom
Forêt
R100W
before.21
milk-secreting
CTG-3′
3344
spinal-cord
Naevi
cell–rich
laLeuAspS
Nilotinib-mediated
Apoptome
PD846
8/34
1257–1419
3•43
procaryotic
ACATCTGGGTTTCTGTCTC
ogenic
ab68348
transcription2,117
8,9,10
D631A
Adgene
E80K
Bioanalyzer
Microsatellite-Based
autoradiography.Transcriptional
4bp
antagonist-bound
v1.0.0
16α-methyl
O5
79-fold
GFP–VHL213-P86L-expressing
Fig.7B7B
1.90–12.9
p21CDNK1A
~3000
CRC/C
SurvivalCharacteristic
FA-32
nonerythroid
CIC-binding
N1/3
Zipursky
phospho-BAD
M37
Seeburg
Kuismanen
PlanApo
diethylstibesterol
CUX-FGFR1
ESEm
HLA-A*02
PMT-E565
MSSh
bioinfo.genotoul.fr
NSCLC—both
CLIP1
carryingthe
estradiob
Chelix-out
SF3
5'-GCCTGTGTCAAACTGTGT-3
2.189329533
PMA-stimulated
‡‡
S6A–C
1.71
6067
∼16-fold
V106M
DRBI
Leu-Xaa-Xaa-Leu-Leu
Tyr537Ser–Asp351
TK1-TK2
pcDNA3.1-human
R210A
CCR4
penicillin/streptomycin-free
Flip1
G418-positive
CGATAATACTAGCAATGACC
Edg4
Foxo1
todate
R784
Zenz
KC12
p53RE-driven
FIGC§
suivi
virus-producing
categories:14
5753010
colony-forming
χ2=49.53
50◦C
.0202*
lymphblastic
110b
certiWcation
fusions.4
HR=1.32
15c
IL-9Rα
grade.18
deIC
57,60
MMS22L
1.2mg/m2
OncoBAC
.Eμ-Myc/DNMT3B7
Ser-365
WO2009/093032
C672Y
5′-NPM
FGFR2-fusion-expressing
heavychain
pcDNA3.1-hygro-3×FLAG
182KB
methods46,59
c.4182C
–+–+–+–+
overhauser
GENESCANTM
379.00KB
228K
Hupki
R17T
supplementedwith
gels37
dasatinib-insensitive
0.4±0.1
250V
Stastical
hyperproliferation
.Overhangs
.Agilent
pSV-Sport
AGATCTATGACCGCACCTGCAATAAAG
XXLαs
SK-MG
rosetting
goseq42
GFP–Fbw7-SBD
/Sertoli
non-Gaussian
P15L
drasticreduction
CATGGGGATATAAGCTGCCAGTGTCTC
histone/chromatin
-untreated
GRα-
fractioning
1q21.3
controversially
complex,16
RASopathy
FLT3-WT-expressing
.JE
cyclopamine
YFP-MS2
MSH2-L173P
Arg1024Gln
Prepotech
S765
zlj9990993630005.jpg
silentnucleotide
=∑nj=1K
HPMF-CT-2001-01330
-45
V419E
21R4
subG0
bone.8
∼3.5
.7b
KDRA1065T
pFastBacI
RNA/protein
SceGFP
tetradimerization
PCR-SSCA
60–65
T75-cell
3.00/0
M-003132-04
.S17C
24/135
acetic
PTCL33
PTENRad51
fTwo
FANCJ-transfected
N1303H
55–80
PIK-E20F
XhoI/SpeI
pGEX-KG
pCEFL
.Mutation-based
2nd
β-spectrin
BCR-Rsa
ggcgcctatggtttccattt
TRCN0000025258
Phycoerythrin-conjugated
searchand
5310
−CAS
sensitivityTo
gagGG
ERBB2-dependent
0.78–10.72
controls,6
Ras‐mediated
M53I2
BiBr52
.more
Mizuta
BRCA136-
afatinib.24,26
.Non-phosphorylated
.Site
rhabdoid-shaped
rate–adjusted
355345
missensemutationsdetectedin
M.M.S.
studieshave
171,900
metabolomic
holo-RARg
CpGdotUpG
//www.python.org
αβ+B220+CD4−CD8−
pLenti-BAP1
III-mutated
.CT-PET
KPT-185–bound
COSY
reprogramming204
2241
PA1
T24T
Pre-mRNAs
Y472C/R509HBRAF
UAS-Cdk4
respectively.6-14
Baleja
alteration9
COsegregation
erlotinib.6,7
aminomethane
forced-expression
scale-up
G13.1S
c.34G4A-positive
progression.25,27
MT–transduced
TrkA-kinase
5′-AUAUAAUAGUGACUUCACCAUUCCC-3′
Bc-CML
1434
MEK1-binding
rhBMP-2
quasimonomorphic
SPOP
Q869P
CIBIO
whichwere
R882P
V569G
V658L
Re-probing
MutSdependentATP
∼0.9
More-detailed
LDS5
153,000
Ser602
isolateactivating
BRCA1-mediated
investigatethe
Colorgrams
AB2553_E11
g001
TGFβ2
SD*
∼60–100
D–CDK4/6–RB
k11
c.183a
H530R
complex108
32/44
mouse-model
MutS/min
®eld
.Performing
.ResultsNVP-BYL719
R114I
PSEN2
TSP1
microphysiometry
suchsubstitutions
73/74
FSBA
charge-stabilized
75.7
Pluquet
1594
p.G596R
G992R
P13AS
combination.49
insults.28,29
MOLSCRIPT.22
Lin–Sca1+c-Kit+
799
TAACT
PmlI/BglII
number.EGFR
PU
PTEN1/1
nontriad
melan
mulata
−7.81
UEM-1
cell-FN
rearrangements,19
lines171
−3.59
1845–1826
PCR/454
Cys608
zZ
dimethylbenz
non-exchangeable
1745
35,47
mp3
20,27p.F508_K509insYFAF
2833
CSF-1R
melanomas.24
487X
α-isoform–specific
273–332
R1896
underlined.Rat2
69Kgpl
His36
5′-CAGGAGCTGAGGTCTGAAC-3′
PEAR1
32-amino-acid-long
Sptizoid
profiles.16
Blm-/-
AANAT
WT-EGF
R1881-treated
BugBuster
commercialproducts
1476del
kinase-kinases
−7.47
survival99
staining6
G382D-IIIc
7308
/CGTG
93-97
ERα-1
N™
rs143021252
eph
novagen
outwhen
TGTCCCGC
CDKN2A/hemi
c.402_403dupTG
.Embedded
cholerae
virus–internal
NAPESIFnsl
D-17
L101H
therapy.PIK3R1
zif/268
Grompe
studies.33
used14
ERα+
pentagonal
.Tuberous
MHC‐peptide
noncoated
c.524G4A
endocrine-drug-resistance
resistance38
25-^tl
mutant18
Fink
46–115
57-76
140,000
anyof
382M-18
sunlight-induced
−221SRYP
ssDNA-bound
BRAFis159
.PDGF
non-arginine
HEC-88
TD,2
GraFit
locus.12
2–80
Ashrafian
A003
fusion17
129–159
0.8-μm-wide
nSH2/phosphotyrosine-peptide
95.03
att-site
mg/m2
2.2-fold
translocationsThe
R634Q
156.5
pPGK-puro-loxP
10/28
15.38
pCTV1B
p.G646Wfs*12
anti-RFTPp
Gsα-subunit
H6pital
I100
0.5g
ALK-transfected
SP12
juxtamembrane
V851A
17,454
E1664G
χ2-tests
RET/PTC-Ras/Raf/ERK1/2
F1P1L1-PDGFRα
SK-Br3
0.1961
GGTGCCCGGG
log-odds
appendage
podocyte-Fat1
'One
protein-tyrosine-kinase
PRK7-TSC1/−TSC2
Mahadevan
-STAT
PCLO
M246I
zinc-hook
308:205–214
S.Z
CRAF,9
1358
Thr-17
nonseminoma
-CDK6
motifs93
Y3301*
2172–2173insG
A_52_P18267
QuantaSoft
Rakheja
defects39
†These
re-refinement
h-CAP-C
read-length–1
oligomerization-defective
S–G2
G415S
HLAdeficient
ishighly
Arid1A
Monoubiquitinated
IP/Akt/NFkB
TG101348-treated
4.40×108
encephalo-myocarditis
macrocephaly.12
R26hBRCA1
GA/AA
SPH
RCB1129
risk-adaptive
Gorina
30-bp
intestine8
scRNA
p53WT
728C
c.347C4T
hepatocarcinoma
lymphocytosis.17
.VIEW
55.3-65
600901
95–091
cycle−regulated
−T/L/H/A/X
colocalized
Glu629
.TEL
GSE51274
GTCATCTAATGGTGA
MLH1c.793C
Waymouth
ALL-prep
R65G
panda-like
interven
BaseRecalibrator
chance5
//snpper.chip.org/mapper/mapper-main
MPPH-like
Gln-64
.Hansen
Smad2f
.ERa
mechanism—by
noninvading
bChronic
11.2-fold
.GC
tumours.3,15,26
TINF2
.CUL-1
IL-8
G164R
816delGT
.2096C
23/36
.Janne
GraphPAD
43.94
1:27
eosinophilia.15
BCL6B
inhibitors13
HGF-targeting
p.Trp194X
Rad9-Rad1-Hus1
Kruppel-Like
Ampneg
CCACACAGTCACTCGTAACTC
.Romano
controversial.21
CU579
gamma-mediated
anti-BrdUrd
1.21–2.98
2μg
betaP2
MYRIP
PIK-2E9MR
S734L
PIK3CAT1025T
.B7‐H1
GACATGAGCCACGGGAAG
cancers13,45
ESCRT-I
ins/trn
1KTS
ES/PNET
His6-c-Fos
approach85
G380R/WT
4-542
AJ006290
anti-53bp1
long-suspected
TSS
GDP/GTP-binding
.Establishment
development,7
05–671
downregulate
misfold
R46L
MEK1/2and
.8,14
92.4
.CT-guided
Kilberg
hpo-mutant
EGR-1
.Glomerular
CD62Llow
Quik5236F
1951
U87MG.AEGFR
regulators63
3.8343365
2364
G63S
5′-CGAACGCACCGGAGCTCAGCACTTTGATCTT-3′
carbonamide
doi:10.1172/JCI75746DS1
T608I
Q1893*
E2F5
kidney60
S.ENo
EGF-ERK-ERF
beta-chain
MUM2C
semi-supervised
anine
tumors,47
M/80
MEFp53−/−
Ly8
dihydrotestosterone-treated
87-171
auto-dimerize
11–intron
16,403
K125/128
methanol/CHCl3
p.Gly67_Asn71del
Balkwill
c.2631
CR90-1
A215T
U2AF35-mutated
31.11
1.26–3.26
.MDA-MB453
RXRA
6835
neurodevelopment
0.6783
92.8
.Benign
5'-CACTCCCTAACCTCTAATTAACCAA-3
//doi.org/10.1371/journal.pone.0103021.t001
2.1.
Figure6D.6D
K836
MM48
site.14,16
7.4/0.1
187KB
Met-102
competitor–type
effect.Previous
TrkA-1q23.1
.Hygromycin
v.1.3.3
.Abnormal
arrest7
30Å3
RNF139
Knoepfler
15–21-fold
9A6A
//www-bio.llnl.gov
pCNDA4/TO
proteins35,59
tive
Mtbp
MSH3
19-73b
5.34E09
Lebowitz
H127P
RAD55
diarylurea
CCATCTCCTAACGGCTTTTG
468-504
348:1201–1214.David
group.112
retrovirus-associated
LAMP1
number-based
serosa-infiltrating
D837A
59-GCGTGGGAGT-39
kyungpook.ac.kr
Y860
Sertoli–Leydig
Trp-926
activity114
pVSV.G
FH
PI3K/TOR
10413
SMO-N219D
immune-mediated
K426R
HER‐2‐T798M
ERCC1-deficient
v4
pHA-BAP1-GFP
2499
7q21-q31
5″
FGF-soaked
oestrogenic
58-TAATATGGAAGTCCAAGTT-38
MDS/acute
non–HCM-associated
Nrf2-dependent
R282Q
shRNA-Smad2
235–260
2-μ
1×10−16
polycomb-group
lax
expanded-access
BH
Peková
CCDS55072.1
Diaz2,3,15
Thr-positive
crossvalidation
nonBRCA1-mutated
apoptosis,49
src-transformed
/MgCl2
3/
.Entrectinib
N514
Arg466
fold38
235/236
.RNAi
FGFR3IIIb
p130
dehydrogenase
RP11–4C17
vr-class
autism-associated
defarnesylation
11q22–23
/AGACCTCCTTTTCTTTCCGGAGG
EGFRvIII+
5′-AAAATGACTGAATATAAACTTGTGG-3′
3q22-26
UAG
Ex11
MYCN-independent
retroviralvector
280ARC
5′-GCAGAAGACAGGGATGAAGAGAAG-3′
epimutations
Gata2
kinsase-4
α-14C
plant-homeodomain
Klann
FGF19-expressing
q-score
88.20
TMPRSS2-ETV1a
lapatinib.23
TG101209-treated
treatment9,10
TFA8c
CGGGCCGGGG
pIII
Colombo-Benkmann
intrasplenically
'not
001145306
mutants.Marin
ΔEcoRI
18.7/25.6
769-P,51
immunohistopathology
79.4
ATTACTGACATCTC
inhibitor.It
Smad4/DPC4-/-cell
colitits
yellow-green
25,809
0·45
hydro-
high-metastatic
TβR‐I
.Sorted
p-iodonitrotetrazolium
.Second-strand
ofmsh2
fusions7,8
hemi-
min-•
Soas-2
GSE54140
CA35494
4Ad-f
12-13-14-15-17
p.Glu1587Lys
20independent
/PCM1-JAK2
origin55
F5/8
CBFβ-deficient
MLL-AF4–positive
8301
documented.36,37
CRC
62.4
activity—stronger
NM_001664.2
5'-GCCGGTACCCGGCCGCGCCCCGCCGCCGCCG-3
ATXN2
Gas6/AXL-induced
0.651-2.548
.Texas
CTGCCTTGGCCAATCAG
mutant2
motor/personal/social
Snf5floxed
IntelliGenetics
l7q
/46
Oncomap
responsible138
gal4
postpartum
A_52_P213932
Δexon3
sawmill
Lbh
RNT
Myc-XSmad2
0.38–4.54
Polyubiquitinated
IMC-C225
.9,21,22
10.1172/JCI38854DS1
co-regulator
0.3-kb
F317L-BCR-ABL
latency.Our
ipilimumab
q=0.008
androgen–insensitive
DNA—for
VBC-associated
GCAATATTAATGTGTCTTTCC39
.Third
-0.23
GATCCTAATCTCATCAGTG
tClass
NCr-Foxn1
stimuli.1
NIBC
samemutation
−1039
PKI
erythropoiesis14
2,3-bis
UACC257
tumour-suppressor
huW671X
I508L
G85E
04217903
tumors,7
NLS1-dGFP
pDMl
p53Lox
sonication
//p53.free.fr/
ESS1
oncogeneA
,300
tumours1.Figure
apoptosis.12-15
PBF-depleted
irritant
.Cos-7
Nakagawara
21.05
.Reliable
ACTB-tdTomato
neuroprotection
0325901
quencing
H213Y
CNRS
erloitinb
Apc-specific
p.A414T
LK1
c.2881delA
loxPRictorloxP
CALB2
TGTCAAGCAGAGAATGGGTACTC
.FOX
APAAP-complex
8,000
extractionOf
TNFR1
totalhands-on
-N-acetylgalactosaminide
22/40
Juberg-Marsidi
3661T
.TKIs
pEGFP-N1-IDH2R172G
αH
animal†
ExoProStar
LEF8
V12-expressing
anti-hexokinase
.Y537
P567P
Arflox
pre-diluted
RPTPrho
exons—3
LSM780
Fattahi
Degradation—
H524D
.PodArnt
60-62
W226L
gtgggtgctt
EGR
11-22
TRP-1
4-Hydroxy-3-nitrophenylacetyl
PEG3
2uL
SuperSignal
0.06⁎
ZNF14
−124/−125
PTEN-F21A-C124S
Witsch
.Noticeably
nucleofector
ofmost
reoxygenated
Q305_E309del
tumorsTo
cephalopelvic
familiesAltogether
amyotropic
L826P
reference41
2q34-q35
,2
-3-
1969a
p85αR301X
proline/arginine
G12D/+
GAU
MER2
Gatzemeier
VSV-tagged
LSDBs
.ANNOVAR23
CD-domain
uc003xdo.3
Ca-922
''Not
S122R
Yamakage
I3A
74566
well-differentiated/dedifferentiated
ITPK1
vitro30
C634S
K483MBRAF
.Recapitulation
sorafenib-resistant
noncancer
near-complete
Flt3−lin−Sca-1+c-kit+CD150-CD48+
.3G
00114
Daktl
Bergamaschi
Lys|
anti-OX40
p.N676K
Gesu
small-to-medium
amplification‐negative
PR-4240
0.2-μm-thick
sequencing15
95-3/4a
stick-model
5A-F2
Scroogle
MAP4
Pro-kineticist
carbon-branched
2341066
GTDC1
Akt1-3
M599I
R420H
10i
D802R
.MPL-K39N
HCC515
.Substitutions
CDKinteracting
COX2-dependent
//emb1.bcc.univie.ac.at/embnet/tools/bio/PESTfind
H189
XC
OCDfl
1520–1529
.SMO-WT
VUB
five-level
N261Y
ALK-mutant
PIDD
41/48.8
29,584
27599-3280.
CR1–CR3
AGAATCGAGACCGAGGAGAG
Extragenic
Logistic
8,43
Deshpande,1,2
Rummelt
proteinbinding
Polycythaemia
RBM5-responsive
7.4/0.05
.CNT
P/I
c.4850-1G
Domain-Mediated
oped
median-normalized
A-2468
INK4-deficient
G1738
030662
p.Tyr573Asn
CDK4-bound
.Enrichment
mutants.11
5'-AGCATTGGGTCAATCCTAATGT-3
insAA
SMS-KCNR
4970
MutationTaster,29
17,19
1-8
CI=0.85–1.45
439-bp
T389-phosphorylation
Ets2ΔN331/DNA
6Dd–6Dl
478.8
miR-223
rehydrated/washed
single-span
c.790G
modifyingtheir
VEGF-dependent
RSC18
L=low
59-178
Dobrzycka
26,27,57
JAK2.26
635-654
CDK6-BLPD
A329V
Li-Ping
hypermethylated
14,38,39
p.Figure
α-α-helical
488-tagged
p=0.7683
59.1
0.60–74.8
thecomas
5329
suppressor18
5'-M13-AAAGGAAGATAATTACCTTATATGC-3
.Parameters
spinning-disk
.ElA
omentum.9,10,12
OCM
50.1
SCFkkit
hypodense
Sør
744,832
H1299cells
.BCOR-RARA
SCaBER
AR-mediated
ETO–HDAC-1
90-fold
promoter-
L507P
ONPG
RAD51D-deficient
20.4
hard-to-find
Sijbers
P29S-mutant
.EWSfusion
His-BRAF
5′-GCAGATATAGACCATCAACAT
receptor115
1,000U/ml
306–311
Pediatr
statisticalevaluation
development75,76
bioconductor
'hit
oncogenesis7,9,33,34,49
Committee.Statistical
pDEST-IRES-Thy1.1
15.91
HLA-ABC
effector-to-target
fossa28
.HR
andmsh2-GD855p–Msh6p
nocodazole
Co-activation
lipopolyamine
repressor-lac
nonfunc
ACCRCA
Calvarial
D4nt
CLDN4
Kowloon
melanoma120
Plasmids—pcDNA3.1-HIF-1α
c.295_296delAA
.245A
OMIM*162300
HLA-DRB1*01
HS00703603
pyrazolopyrimidines
RAS7
heterozygocity
R283Q
CGCGGAGCTTG-39
assaysBalb/c
.Xenografts
/RAC
puromycin-resistant
Ficoll-Paque™
right-adjacent
inhibitor23
dithiothreitol
PTEN65
125–179
Azami-Green–
c.523G
D342Y
mineralization
4−103
MSIG1.1SK
transm
v0.5.9
Puijenbroek
Gfi1
cGKIβ
EGFRcells
.T212
5′-AAACATTATTGCTATGGGATT-3′
18F-labeled
GDNF-stimulated
G236W
5′-GCC
.Heterotrimers
JB12452
remission.109
BRAF-V600E-specific
S37C
multi-mono-ubiquitylation
p.Gly35Val
adenine-deficient
compositional
ATGGAATAC
non-gynecologic
V75A
necessitate
activity-dependent
1323–2564
LI-COR
IMD-0354
m2-18Raf-1
GAA
×120
GOLGA5-RET
forlanes
patients.3
andcytoplasmic
growth4
Cattoretti
F595A
-Fold
Figure.2
NH2terminus
NCI‐H1299
Flag-HA-tagged
±2kb
Jundt
FANCA,22,23
Dialysis
Dontje
organisms.1-5
sub-populations—or
OVCA3
HDAC-2
0.169aOncogenesTAL1
UAS-CycE
D83V
deprotected
2526
MEK-IGF-1R-mediated
AAATAAC
cellmorphology
allele-freq
1088–1101
Axioplan2
exofacial
construct29
T-even
L112
0·4
Sox2-Cre+/o
Asxl1+/Δ
45–50
.AJs
0.468
Imab-1
515K/MPL
p300-specific
study66
CLL.3,7
EBF1-PDGRFB
1.03-1.47
Trahey
.G719S
AML1.26
T790M-EGFR
95
D-02
tissues16
B2PH
switch-I-loop
C.M.
Hey1
cells60
cytochemically
GDC0449
phospho-Rb
anti-cdc2
c.521A
BR12F1
pulse-chase
invasive-like
respectively.We
15-cM
HAhB-RafinsT
166-bp
V205M
containg
tumor-matched
RAF-kinase
less-specific
pV2-2
B-RafV600E/R509H
PEG-asparaginase–induced
9·1
2126
W6/32
CTCT
pA308
1754del
4E-F
elicit.20
Atg7
4BG12D
TUB2
regimens.6
SpeI/XhoI
p21ras–GDP
5A-D
methanol-extracted
detach
HCXXGXXR
Migone
short-range
D3S1298
Ser180
MDS1/EVI1
HGF-specific
PGA2
587-592
EGFRΔ768
G122R
|0.5|
CD61−
karyogram
dwarfism.5,16,17,18
proteins/pathways
Mlh1–Pms1
imatinib.3
M19
trans-reporting
5′-AAACACTAAAATACCCCGAAAACTACG-3′
incubationon
T144
Hepato
episomally
.ERCC6
TRK/NGF
T-24
13q31-q32
SK-Mel37
.Digoxigenin-
1794
Gläser
G533C
TIGR
1800–1848
CD56−
.UCP
THRAP4
reportedb
Tet250
SHQ1-NAP57
H/ACA
Koradi
indexWe
NOD/scid
receptor-driven
byanti-HLA
FP-1039
21–39
GGGGGTCTTTCA
FC-104-4002
p.D551H
I.P
Wallac
NM_013641
2,861
ab109394
PFGRA
hybridised
PIK3CA-H1047
NMS-E628
medulloblastomas5,6
c.1221delG
RUNX|
syn­
serum-responsive
hemizygous/homozygous
models164
Frame-shifts
E2wt
656
p.Lys614X
5′-ggTgACCgCTCTgCA
-0.1
DD/EDC-RAF
k1-3
reinduction/reconsolidation
764–783
c.4600G
MMR+
COT69
differenti­
Val3Met
−14.9
FIP1L1-PDGFRA-negative
.Difference
re-evaluations
Phe596
7190
gplloPr°r
R4674G
c-Kit+CD25+
L1POSARCOMAS
metSummary
S-transferase
stopt`'4
Alk4
post-immunization
Flag-Rheb
IVS6211GrA
lac-Smad3
CSCC-derived
80-92
5′-ATGGGCAAAAGAGACCGAG-3′
.Metabolic
osteoclastogenesis10,11
follistatin
310–400
RFS-mycS62A/Wap-Cre
Val437+4266â€
Figures6B6B
20,212
Thr-79
13.4-fold-higher
EP2109Y
12812
AGTTCTGAGGATGGGGGAGCCAAGT-3
.Rescreening
L-20
243/368
PCR−based
oligo
analysis.Red
.Post
S451R
prophylactically
SH-PTP2
ClustersRelative
Tet2-/-
than0.1
p110δ-D910A
↑
field-of-view
castrate-sensitive
c-Jun/ATF-2
shatter-and-stitch
S2–S5
1-phenyl-2-thiourea
'1ViL=====JI
5′-CGGAATTCCAACTGGAATGGATGGTA-3′
394–678
anti-LKB1
.Nosingle
Kanatsu-Shinohara
ERG2
N≥10
11K
3XFLAG
Analytik
5'-TCGTCAACACCTGTCTTGTC-3
+801
hysteroscopy
.Asp-33
spike-in
,7,8CDKN1A
S15A
β-Catenin/TCF
Gsα
392F
genotype‐phenotype
59-TACAGTCAAAAGGCC
FLIP-specific
Yagasaki
13C6-lysine
4′,6-diamino-2-phenylindole
TgB
CAPN2
gefitinib
Ezoe
1.516
0.319‡
GFRa1–GFRa4
Qiagen-PCR
c.901A
additive/synergistic
NCI-H838
.PF-EPN-A
239-248
PO9936
observed.Fig
26/4/05
GS1-165I4
Dicer1/Pten
Mukaiyama
Shp2-
16.33
MKK7.p85α
ACER1
D647
pPaxillin
A–tagged
3F/R
isotope-labeled
KLF2
course.24
RNA‐seq
transcriptomically
types65,66
9186
32D-Flt3-ITD
ESR1-positive
5'-gct
120.
Dual‐Light
UPN266395
D2093G
40/68
8.831538875
Scharenberg
c.977C
tested-negative
1737–2414
CD79a+
.Fluoroshield
ACL-4
.6C–E
1.05–1.93
I.0
TRIFAST
Fine-mapping
HRASA59G
p53loxP
delity
survival=26
super-physiological
SmaI-digested
Medhurst
483_802del
303-311
EpiTect
Oncogene`se
59RACE-PCR
v2.1-8-g5efb575
function1,141
Thr66
Joerger
17q23.3
c.199G4A
specificmutagenic
c.2077C
EG‑
.Qualitative
erlotinib.19
FIP1L1-PDGFRA-induced
HS68
∼50th
12-gauge
pSV40β-gal
777-amino
P-05-06
.AF4-MLL
Δ3263–3418
5.00
5–30
conformation42
real-time-PCR
-stand_call_conf
3925
Polymorphisme
IDIA
pTRX2
tpqhVKItDFGLaKlLgaeEkeYhAEGG
11/64
5'-gcctgacaggcgccactgcttctgggcgtttgcagCTGGTTCCGGAAGAA..
S273A
Advantage-2
IMWG
CAAGTGGCTCCTGACCTGGAGTC
SLC36A4
UM-PCGP
Eso
p.G369V
SNDX-275
crystallographically
//www.cbioportal.org/publicportal/
P594
6–1132
STAT5A_01
binding/ATP
pMV7
p.Cys217∗
CDC25-bound
1.4–2.3-fold
gp12o0rks
HER2/Neu
.Histagged
line47
16/24
BRCA1–T37R
telangiectasia
pE3-K-
percent,7
intensity-modulated
prognosis.Among
3937
1-302
CSL/ICN1
excavatum
1.263
GIBCO®
11-26
Rpatient/Rreference
-D835V/Y
WWP1-ΔWW-myc
108/179
lymphonodal
Toyo
1p36-p34
p.Lys442Asnfs
PI16
+CA-ALK5
EMR202600
G719C/S
BspMI
MMR-dependent
28780
v1.6.0
nominations5
Post-irradiation
36.00
23–25
NaF/1×
H-1299
0.045MUTSSF
anti-β
required.23
Genasense
hGFAP-cre
bound-2
Promoter-Associated
amplification—a
Fluor-549
syndrome.1
—MUM2/MUM3
ptp-2
06030
mutation.4
CTGATTTGATGGAGTTGGAC
39,48
phaseAcute
receptorlike
p16INK4a
progression.15,34
non-affected
Neurofibromatosis–Noonan
HD-
3,420
5′-AGTGAGAAGTGTCTGCCCG-3′
Muyrers-Chen
1.06–4.32
Interbreeding
TLS-ERG-infected
Egr1
VD858p
C*
c.229G
JME
pcDEFCBP
P2-binding
B-Algo
triphosphate–binding
ERBB2-L755P
E689K
IIe
2.014
AGL
10-cycle
gp95
Figure2B2B
COSM351040
non-NF2
JAK2-JH2
•heterduplex
pre-calcification
S0530T
pLXSN-V12HRAS
PIK3Cs
Debye
pre-disposition
0.0312
Oedema
2H7
Meyerson
Discoidin
63.4
Multi/binuclear
TAATACGACTCACTATAGGGAGACCACCATGTGTACCCCCCGGAGAAGGAT
Met-340
5'-GGTATTGGTGACAAGGTAGG-3
criteria:1
DSRCT.MethodsEthics
29238
HN-K-rasG12DSmad4
1150X
anti-murine
44,45
nonaggressive
Figure44F
SK-N-AS
TGCTCGTAGTAATCGTTCGCAC-3
ERT
n=83
MLP-CAT
resus­
.RRM
ankyrin-type
E640
17-AAG
erlotinib.4
loci22/5
carcinoma27
D104A
molecular-editing
neoplasia84
5′-CGCCTAAAGAAGAGGCTGTG-3′
hNRG-1
encouragment
etiopathogenic
.Cosegregation
ER-mutant
procaspase
0.32/0.36
c.7805G
Novabiochem
substoichiometric
T790M—were
nglml
.She
Oncotype
chromatin1
Entensity
advanced-disease
samples36
427
5′-TCATAGTTTCAGCTTCTTTTTTCTTCCTCGACCATCAGGTGCGCC-3′
Colo357
pHK102
free-cysteine
mutationsPolymerase
Tris-borate
androgen-associated
CDG-I
10−3–10−4
anti-c-erbB
.Estrogens
ra-
Microsatellites
c-SRC-T341M/I
p.Arg2Gly
p.S214/RAF1
reinstate
PI3K-triggered
PAX8-PPARγ
nontemplate
Fig1I
'monomeric
Roc1
tumorgenicitiy
4757
BamHIand
.siRNA
E583K
HLRCC
TCRVβ9
DMBA-induced
1.799
KG-1
c.156–157
−45.48
Trp-Leu-His
pro–B-cell
B220+PNAhi
.MPL-A519T
Myeloid-specific
.AG-G
growth190
S6G–J
Δ291
Niwa
hepatocyte–endothelial
32/60
allcases
HATPase
L-methionine
Livingood
22.937
carcinoma22
Pten-phosphatase
BSA-1
PTEN2/2
.—Universal
4:0
breast-ovary
al,24
Sorafenib-treated
Grasso
oncogenicactivation
9.5Gr
CR115
electromagnetic
coordinaVOL
Livak
Cambrex
López
WT+/+
GATCTAGGGCACCCTTTGAAGCTCT
GDP-AlF4-
SVs27
P66
R23T
quaternary
1B1B
MAP2K1-targeting
j.jonkers
H4-RET
I332N
LV-Let
T99N
8–10.Analysis
p13.1q22
phosphohistone
Aug.
Velculescu
D1G6
QIAFilter
.BMC
ActiveBiochem
L1597H
RHOAmut-VIC
G227E
.Duplex
upregulated
OX86
D28E
14-month-old
21,100
.Subsequent
Pdgfbret/ret
Hox5
SoftWoRx
Gamma-catenin
5′-ATACACTCCCCACACGGAAC-3′
SPSYVYHQF
S2F–H
phaeochromocytoma7
9,1995
eighty-six
SRA
and9
RPN1–JAK2
Hybrite
c.598C4G
5′-TTTCATGCAACACCCAACACT-3′
80Â°C.For
diseases.16
Naturally-occurring
point-mutations
Multi-level
L101P
4351–63
=∑iwiOi∑iwiEi
5′-GTCCGACCTAGACCCACAAA-3′
Bead-antibody
2000–2004
P-40/10
14-17
G108D
CRL-5803
exten-
p473AKT
Tandem-Tudor
5′-CCTAAGAGGCAACTTGGTTGAATC-3′
Mdm4
.that
MAPK13
singe‐site
d–h
bristol.ac.uk
V351fsdelG
3-inhibitor
R79
NP-specific
BRCA1/11
pathway.7
Yap2
bipartite
counterparts6–9
0.667–2.392
CHMP2B
pLKO.1-Chk2
IL-7–deficient
kinaserelated
HSC-related
V38S
TRCF
158,050,096
HM40-3
PM-MM
T2294A
6.69
E762Q_insFQEA
GSK-3β-depleted
antibody.17
EGFP/Bcr-AblY253H
Leul•uV
kinase,35
reading-frame
SC323288
577C
Glutathion-S-Transferase
5′-TCT
doxycycline-untreated
ChemiluminescentSubstrate
q34-35
melanoma9
OHT
Mazhab-Jafari
NPHS2/podocin
pBabe-Puro-MEKDD
Triton-X
Vill-Cre
BAF60b
1,194–81,172
KrasLSL-G12D/p53flex7/flex7/Pdx1-cre/Brca1
DNA-associated
Basidiomycota
Tumbarello
pathways,54
MS-stable
AGAAGA
SF3B1MUT-insensitive
5′-GCAGAATTCGGCTTCACAAGCTAGCGTAATCTGGAACATCGTATGGGTATCCATCTCCCATCCGTTGATGTGGC-3′
PBAF-BAF180
g-i
.Mesothelioma
NCI-H520.X1-shPAK1
RG-16T
205225_at
42Â°Cfor
smad5
NM_000179.2
PEO1
glycosylphosphatidylinositol-membrane-anchored
differentiation.107
NCI-H1993
JAK2-Dependent
84/188
1.8.2
Ink4a/Arflox
leukemias10,11
C.d
A716S
HDAC-GloI/II
near-triploid13
/CEN1p
Gadd153
YRGRHLVPRKCRGWCQGPQG
c.726G
kinase23
weak.4
LCNEC
0.647144
Coimmunoprecipitations
broad-specificity
Assay—Saos-2
CITED2-independent
epithelial-
ONL
Kusakabe
FUUthOF
polycythemia.72
rearrangements.8
NBL16,17
malignancy.16
Waksman
I1233N
lost.Therefore
PB-Cre+
S6F–G
598–599
AVANIYAPURAM
.MYC-mediated
development–associated
ammonium-chloride-potassium
genesDNA
appropriateness
Heuckmann
ras'3T3ODNODN7RMC*ODNODNRFLP7ODNODNODN3T33T33T3ODNRMC*ODNODN
__radiolabeled
D835ER
E2F-1-binding
07-641
V290M
2.1-
KEx16BEx9
300-350
EZH2Y641F-expressing
.K-means
COX
207116
.Phaeochromocytoma
p.L861Q
S988
Hardy–Weinberg
individual.8
Background-adjusted
85-fold
M142K
15q21.2
p110β-specific
I-03
76.86
TGX-
LC71
Kakizuka
no.7
acutely-transformed
Hh-interacting
48106
mean7SD
SacIIsite
Gefitinib-Resistant
337.
Reagent®
pEGFP-C3-IκBα-NES-Mut
staining.12
3-19
Immunohistopathological
Manuscrit
129×
XXIX
**treated/**control
hPMS2.25
R43W
HBG
regimens.1
3e
SMG
1–350
pathogenetically
non-Reactive
STRADβ
.Y220C
D243
SOX17-His
set-wide
Pim1-neo
R1n
.982G
PAXgene
MethodsEthics
phospho-MAP
.JAK2-L611V/V617F
68352686
and6F
216L13
CUCRC042
more-included
wave-like
.Amino-acid
3–16-year
84.9
CFU-GEMM-derived
anti-P-ERK1/2
FLT-4
1–432
pVHLmediated
phosphor-4E-BP1-Thr37/46
9267
BLPD-associated
risk-group
.CD381
GGGCTGTGGCGGGCACTC
ET-affected
ryanodine
Co-Occurrence
25–53
S4686.50
SGI
specific.13,31
dual-
Coe
32.3
1.PCR-SSCP
-GGAGT-GCAGTATCTCTCCTCTCT-3
phosphatidylinositol-dependent
.Perpetuating
tumorogenity
MQM
H3K4me
G79R
Glu339Ala
ALL.9
.MKN74
medulloblastoma.31
6-50
1,300-kb
Bluc
βD
inter-residue
andIGFIIR
GSSEr-BP
S6c
SEK1/MKK4/JNKK
Diehn
2p23
5,6,8–11
y-
CYT-dependent
TCF7L1
Netrin
FMR1
arteriolovenular
Quivoron
2519
TRCN0000005322
SKEMPI
1891
p-c-Met
chr16:67328695–67328844
model.9
Analtech
Noetzli
al1
6046-1
3Di
3-kb
g32
51-wk
NCT00428558
discretization
p=0.0633
21:247–269.10.1146/annurev.cellbio.21.020604.150721
NK-cell
BRD4-interacting
LRP12
integrins5
BZS
seventy-two
±M
TSR-/
.ErbB4
+/A636P
D259
FLT3/ITD
TCAATCAGAAGGGAAGACAA
mice.15
39/44
AF3925
GFI1
signaling.18,23,24
Cum
pGL2-basic
Pompeu-Fabra
GOLGA4-PDGFRB
gamma-irradiation-induced
Cdk12
DNA-modifying
Grosshadern
factor-induced
.Remodelling
HACL1–RAF1
stability.Six
Q79R-Shp2
ofPAX8
CTCF-only
L893V
www.ncbi.nlm.nih.gov/projects/SNP/
5D–I
recently18
.Liver
GTP17,18
alleles.13
PDGF-like
293/HA-FANCG
Wilson6
p.P1497L
posttransduction
ELF4
1Characteristics
FOXP1C
wt-2
SRE-Luciferase
control.The
build131
SWI/SNF-mediated
FIGURE4
2468
PTK.31
relapse.12
gilberto.fronza
IGF-1-resistant
DDIT3-E95A
5'-GGGGAATTCAAAAAGCACTGCTACTCTT
.Bender
structure/function
SignalP
fertilisation
ExtrAvidin
6.19
cdc6
5′-GCGCTATTACTGTTTACACC-3′
alleles10
8–20
MDA-MB
anti-Tyk2
rstdescribed
I886V
senescence,25
97.6
1Aa
STAT3-Dependent
Hayflick
months2
acetone
98K
29-mer
5′-AA-
Kyse
IDH1-mutated
Q=4.2×10−3
S5A–S5C
rs12947788
5-9
LlLlSCHKlS
SV40.Luc
Sf3b1
C-variants
.A301-591A
9E1
EWSR1such
15,17
lane31
metabolic-based
masto-cytosis.21
OCCC33
Rimerman
—BCL8
RP11–328P13
combined-type
wererun
400
191–291
derepressing
Digest–ALL
.Methylation-specific
Hai
553000
tumours19,20
17/PDGFRA
H1112L-derived
Ras-Raf
nCounter
LysM-Cre
aP2-Cre–mediated
ectiveness
myofibroblastic
PolyDhan
lowgrade
Hegi
5′-GAGGTTGGTACATCAGAAACACC-3′
HA-3B
P440
and.-Src
Semi-nested
temperature-independent
.ARTICLE
ERÃŸtyrosine
NOTCH1-driven
.Junop
8.1.3
5-aza-2′-deoxycytidine
TCATCTTTGGAGCAGGAACAAT
Roach
D486N
TGF-β-independent
wavemaker
D18S51
mm–diameter
V157L
BCP-ALL.1⇓-3
122222
-300
Circumstantial
to-Y
Fas/CD95/APO-1
60ng
domain-CBFβ-DNA
0169
Hs00371735_m1
30,691,560–30,738,500
outcome.7
4.65-fold
RAC1/CDC42
GFP-Elf3A312P
PTEN/C2-T319/321A
×469
7D–7H
protein.11,12
TCGA-C5-A1BM-01
msh2-VD862–Msh6p
Ba/F3-EGFRvIII-based
Yat-Sen
GAS-LUC
S645Q
CLDN18–ARHGAP26
A-19
www.taconic.com
fuel-partitioning
4316C
Y1228Cmu/+
ER—When
6.1.3
PAX9
metastases.https
Smad
V348L
TyrKC
0.304–0.938
stromal-epithelial
.Sizes
-CCAGTACATCAT
short-/long-range
juxtamembrane-type
LTX
33p9
HRM
MSCV-p210Bcr-Abl-internal
kanamycin
SphI-XbaI
−4.4
coeffi-
LUC13
28-3
seven-residue
breakage
.Conditions
500–1,000
5′-CTTATCAAGTCCTTTCTGCACAGCTATGGCCCTTGCTGCTAG-3′
M-BCR-ABL
//doi.org/10.1371/journal.pone.0087113.g001
PEBP2alpha
ponasterone
1.00-1.79MVD
HD-0193
p16INK4a_F
Dye
.AL
R100L
,2,4
redigested
www.genet.sickkids.on.ca/∼ali/splicesitefinder.html
−4.88
YopH-pCDF
51.20
153622
25.51
follicles.34
CXXC6
stability22,35
p.Glu203Gln
A148G
3751
101•
Myc-BS5
Waltham
preproinsulin
Gleevec-resistant
culminate
ALLM
notshown
1761
StrainsConditional
V742Aa
AR-transcriptome
50,000,000
2473
l-arginine-
R528C,3
Karreth
K-Ras-4b-UTR-
25,140
P2Y
Spectropolarimeter
member-2
methylcytosine
ENEPFDEDQHTQITKV
pcDNA3.1-HNF-1α
/.1D
wnt-10b
.1124delG
33P-labeled
BrgTM
747−750
cases28
thrombocythemia-associated
postdexamethasone
Tyr-572/574
PDGRF-α
U-test
.Cytokine
R268C
haemangiosarcoma
1.5–31
L844F
CD27+CD19+
targets.26,27
me1
L79K
FcγIIIR
modiWcations
factor-I-dependent
MPN-U
JAK12−
25-kg
0.0468
1502
SF3B1-wild-type
let-7c-5p
102GRA
FITC+
alter-
pPCR-Script
rs2746462
G90D
0732-183X/06/2429-4764/
cell-line-
100,000×
noninvasively
Tp53
pVHL·HIF-1α
EZRIN
-CD14
MutLα11
DRBlC04XXa
P1849/R1737
Fluorescein-avidin
FA-J/GFP-tagged
2OG-binding
5′-ATGTGGCACCATCTCACAATTGCC-3′
anti-Rabbit
binding95
Biological/clinical
K42L
.CMV-p300ΔCH1-E2
-48
-Luciferase
.Del746–750
subunit-containing
RP1-240G13
5′-CCACCAACCTCATTCTGTTT-3′/5′-AGACATGGTCCCTGAGTATA-3′
Ser1086
1501–1503
Tyr1188
fluorescein-di-β-d-galactopyranoside
P212R
E19
CC73
Hughes-Davies
patients,29
.Intracellular
repression.83,84
SDS-resistant
CIN2
=0.003
RAD502/MRE112/NBS12
Gefitinib-inhibited
EcoRI-Smalfragment
BaF3.FGFR2
1169
cancer.4-9
/siRNA
HQ645LP
α-tubulin
Metasystems
1641
Fbw7α-S10A
instability.45
E→Q
ipates
jnci.oxfordjournals.org
.Excised
TP53.13
972±457
c-Fos
K539L
proof-of-mechanism
d-g
mTORC1
NM_006197.1
N-Plan
mRNAsWe
RAScan™
17.47
4.3.1
0.3–210
12,14,15,17
telomerase-related
Hybridizations
pigmenti
tumor20
electrocompetent
leukemia.Pedigree
tactile
7–42
ramidal
Bio-Rad
GST-Smad4C
F8S
pre-complexed
5′-ccugcaagagucgaauguucucuau-3′
4p12–q13.1
IDC-score
misincorporated
7-exon
hormones,38
900-residue
.43,44
.Histopathologic
p=8.3e-9
.Reynisdottir
mice.4
1:2274
GSE32036
.Alteration
.compilation
Eµ-myc-induced
overstaining
polysome-containing
Sau96I
GTGATCTGTCACCACATAATTACCTTTCTT
144/218
579-bp
wild-type-carrying
W960R
Platinum-based
Gln-to-Lys
k–1
.Seminomas
BothTEL-JAK2
particularities
H3.1
QPSMT
Theorell–Chance
5′-tca
.Filopodia
3607_3610delCATG
2078
auto-tresholding
treand
401-444-9038
SPEN-sh1
platinum-containing
3i–n
314TCS
Bjerrum
2.5982837
anti-Elk-1
pMMP
EUFA1341
dren
singleton
7-R1
K31E
V769_D770insASV
p.Gly35Ala
Septin14
ligand‐induced
picomolar
cyclin/cdk
8.Analysis
C/45s
CBF-1/Su
LKB1–AMPK
53558-93-3
GM8437A
0.3311i
invadopodia22
P=0.164
reverseprimer,5'-ATGGUAAATAAAAT
DNAploidy
Rafl-GAD
TQ
Lsm1
BentiresAlj
PBCre4-mediated
FLJ21816
35–350-CFL
1670
AALE
Zou
cancer-driver
NCI-H2196
GT1795-96AA
HCT-15-TetOn-K373E-CHK2
1/00
dox-dependent
GAL-TEV
26603
supraceliac
n=420
BRCA1-S988A
i.p
ETV5c
3,33
MeFE
A-Raf-independent
×500
proportionally
0.8-2.5
Sancak
Hypertranscription
Germline-inactivating
236B4
S32I
RARS/-T.9
c.571
Hyp4
1995
Gag2
R.W.
tobase
Blk
of15
CHK2-deficient
R680X
1·00
Leu802
SCCHNs
least1000
GCAGGAAGCAGGAATGGAAC
CCCGCCCGGAAGCAAGAGGC
MAPK7
1915
phosphothreonine-binding
Ha-ras-encoded
Amary
1.5-7.3
ARY001
~16°K
c.3109C
P29S-mutant–expressing
Deschênes
SacI-XbaI
expression.5
.Akp
Varscan
development.Hotspots
chr2:42495163
H-RasK117R
12P-labeled
Obsessions/compulsions
A2241
D5-phosphorylated
EFM
SKmel173
AML-
3HA-tagged
eGFP-N1
GTT→ATT
5′-ACCTGCTCAACTGGTGTGTGCAGATCG-3′
lines14•15
.305
RNazol
BCOR-CCNB3–positive
.Dierent
retrotransposons
16,42
2.435
p-c-Jun
LNR
statusWe
GBM3
GTMSIN9
anti-glioma
intemucleosomal
BRAF31
PGR
LT-2
C141S-p53′
Scheurlen
Ras/Raf
.Monolayers
496-8350
BRCA1-specific
sensitivity21
occurrences.The
leukemia.1
pooled-sequencing
bX2
agonist-liganded
specific68
Ptpn11Y279C/+
Miraoui
TGTAAAACGACGGCCAGTATTTTAAGGGAAGTTTGCC
1p34–p36
Alk-x
Δ45
Sweden,7
pSirenRetroQ
.Kaplan–Meier
RNU2
5′-methylcytosine
MultiLabel
MAP2K6
HNF3-dependent
pRK5F
KIT-selective
OCT1
1,148
phospho-Tyr
crystal-
ASXL1-MT1
CUCU
duplicates.High
Ludlow
Denovo
Tnf-α/Hes1–driven
p53flox
21.7
1aArgGl
.Juvenile
T704
DCN1
T194A
II-ALY
cdc2leads
ARX-related
Lys101
MGT16
K141N
proteins.TOP1-associated
451–456
deleted78
320–360
p.R692X
3456delACTC
mfa2-Δ1
55B11
D1–RB–E2F
oftopotecan
M13mpl9
untransplanted
pNENs
73.22
Intrivogen
bulk-tumor
S6Ks
Fig.The
iss=2
SOX9
/5:1/5-/21
12/40
Y260X,35
GAGCAGGTTTCTGCAACGAT
B1BE2
U41220.1
SRE-Dependent
NM_004020NM_004023NM_004022NM_004006NM_004009NM_004010NM_000109NM_004007NM_004011NM_004012NM_004013NM_001033087
Gly719Xaa+Thr790Met+Leu858Arg
expression12,13
previously38
.Preferential
neuroblastoma/N-myc
solvent–solute
H732Y
FBS/0.5
Q60P
gene…
study22
Bhowmick
IC50approximately1000
21-year-old
83.9±11.7
Q-Exactive
I-stained
18–24m
therapyPrimary
1–45
p.P86S
tumorcell
SKmel28
7/10/2012
Trp15
R204Q
∆CC
5′-AGGTAAGGGCCATCTGAAAACT-3′
GATTAAACAGCAAGCAACATTGTTTG
//endo.endojournals.org
.NMR-monitored
sulch
β-secretase
an32P–end-labeled
RNA-levels
benzoquinoid
21,30,31
⩾15
nonirradiated
0.982
5′-AATTCACGCGTAAGCTTATCGATGTCGACGGGCCCGGCCGCCTCGGCCGTAC-3′
3130x/Genetic
hyperactivating
89–194
DISHQC
5′-FAM-TCACCACTATTGCTGGAGTCATGA-BBQ-3′
Bralten
p.Pro101Leu
anti-CD3-APC
91.2
cross-tested
0.020137
EZR–ROS1
endoscopical
Molt4
transplantation.5
Debelenko
TCCGACAACCGATGCTCCAG
poly-adenosine
protein/C2
Lasorella
0004376
NT_039211
.S18C
NDC80
3'ss
63-100
TACTGGGAAAAGGGGAAGTG
HCC1937/WTBRCA1
pRevTRE
lyzer
port-wine
DKFZ
0.238
RsSSJmethionine/cysteine
chromosome-wide
cisplatin/gemcitabine
E-targeting
B2M-transfected
MEK1-ERK1/2
.RESNICK
cells66,143
Smad3W406A
5-21
BRG1-based
exons/gene
examined.99
MCF10A-Q61H
Proapoptotic
1−Pmut
LPA-treated
lymphangiomyomatosis.30
subset-directed
pT3N2M0
6~~~~~~~0
.Myc-induced
1217
population-specific
31.66
www.seer.cancer.gov
62•87
CD68
Shapiro–Wilk
de‑
2D05
Pastorino
radio-iodine
AstroKIT
Ref676852697032717273747J767778
E542
vp2
I2142
bindingsubunits
1-1.5
Minuti
described7,8,26,27
16.96
Ushio-Fukai
Glu1694
one/two-hybrid
factor-related
tracellular
recurrence.TABLE
www2
ucsd.edu
NEBNext®
NPM-ALK+lymphomas
metasulfite
acetyltranferases
R130Q/E201
Gowher
fasciculate
megakaryocyte-erythrocyte
VMLAVQEGIDLLTFPPAPGSPEPPH
min-1
III:6
Genotyper45
//www.biomedcentral.com/1471-2105/12/122/additional
18187013
pseudo-BRCA1
24472
FigCC–E
EEF
66-1
PS00108
euG
RS2
175,249
2,6-dichlorophenyl
TFA4b
TLS/FUS−/−
GeneAmp
JMP7
pMMP-FANCA-H1110P
//www.switchdb.com/motifs
NUT-bound
5′-AGCTTGTGGAGCCTCTTACACC-3′
24F
GRCm38/mm10
2-3/1,000
MB-SCs
thecorresponding
laboratory.DiscussionIdentifying
25-basepair
TCRb
GCGGACTCTGAACCTCAAG
Y905F
//www.ncbi.nlm.nih.gov/geo/
3,098
FACSanalysis
anxiety-related
cancer-suppressor
//research.nhgri.nih.gov/bic
2°
melanomas16
re-folding
2003-2010
205393_s_at
A559T
.Degron-KI
493
Attisano
sites/682
wd
ChIPd
TGFBR1p.S387Y
M231
gemcitabine13
.Boxed
363–366
EN-Y628T
POMC
−1.66
GSE9829
RE-dependent
protein—the
MacTH1
cross‐presentation
Note—In
IVS4411GrA
SIM-binding
370A
I-mI
vivomismatch
GST-Mek-I
≥1.5
Wiesmuller
8years
8-point
24–73
dephoshorylate
2.499
LR3′
UR2
cadherin/catenin
I646V
ttattttag
pected
ACC2
HNSCC-derived
.Rylaarsdam
Rotkreuz
1900X
zeae
ABT-737
Wavemetrics
−Tet
L869Q
29,62,70
69,728
TTCTGTCAAATGGGCACTC
trans.21
B80-TERT1
insignificantly
account,52
7R–mediated
FLT3-
Milliporc
ERK-inhibiting
S-transferase-Jun
.S6A
∼7.5/s
coamplification
themutants
RU486-treated
Průková
day-of-life
-competitive
EFGFR-TKIs
-CDK2
microtubule-mediated
RT-PCR-amplified
T393A
EGF-independent
provirus
N-methyl-N′-nitro-N-nitrosoguanidine
neoangiogenesis
expression.24
non-silencing
66–75
mut3
thetumor
50–61
mIU/L
.Coinhibition
Proneural
Cellstripper
RPL13a
Population-Based
ZD6474-resistant
94.6
chorioepithelioma
HOXC
NM_133330
//www.sanger.ac.uk/genetics/CGP/Archive/
piecharts
MWs,46
.SDS-polyacrylamide
Mcph1
hyperadrenergic
SDS/10
19/28
trial.2
genes.8,30
SWI-SNF5
germinomas
40ng
PyMOL
immunosandwich
33/242
oligo-dT-primers
BCL-XL/BIM
21,655
5′-CCTTCATGACACACTTGGG-3′
pefabloc
Co-hybridization
CAGGTCAA-GGCGATC1'TCAAGTAG
139C
S505P
dexamethasone-treated
Smad-Smad
72Â°C.A
QlAquick
anti-Cdx2
NM_032006
PMC2686526
restoration194
α-subunit
//www.ebi.ac.uk/asd-srv/wb.cgi
8/16
D835/836
hypo-diploidly
14,753
58-GAAGTTGTCATTTTATAAACCTTT-38
oxygen-depleted
R249W
DNA-religation
dermatomyocytis
non–mast
GSE33218
a-gal
tumours25
subphenotype
R-cadherin
FLT3ITDNPM1MUT
88–90
Mac1
.086
RNA-synthesis
L1017F
TGX™
p1303.0
Arg385
post-partum
Universiteit
Extra-JMD-W
Fersht
1–182
BCR-ABL/T315I
E1197-CO
NB0308
studies.25–27
ICM-Molsoft
Y806G
3220
ATXR5
anti-NKX2
EC90
406II
.Should
120:251–256
Tantigen
MDA-N
J2
25–
.WNT
Glycine-1
G-7
p.Pro40
KIAA0495
Limbergen
subtypes105
.736G
M13-Kin1
T847Ia
mL/min
sMof
PEVATPESEEAFTLPLLNDPEPK
C_880_B_7
light23,24
tetramerization-independent
NSPC1
CRAF-independent
pyridazin-3-ylmethyl
002729
8.2.2
pY589
GCATTTAATGTGCCAACTACCAA
CAGGCATTTTGGACAACACA-3′
.2590GOA
4·3
Rushworth
898C
SKI−/+
W2=4
1p32-pter
​As
Greenland
ultrastructural
NF1_01012
MSP
TEL/AML1
humans.3
theEcoRI
1.29–3.38
FancA
probe.PCR-SSCP
INCENP48
exit,23
HIS4-LEU2
other.37
sc-1615
0•65
ATL-engrafted
Predisposition
FKBP5
pyelonephritis
per-sample
7/16/02
Anti-Rabbit
miR-31-5p/3p.7,8,11–14
mTOR-PI3K
R39Q
gp140'rk
humanRef-8v2
deubiquitylases
33/28
.Vehic
Gabrilovich
Cbl-b,7
18-gauge
CD130
A*0201
133K
mutant-mediated
DSS346
antibody-treated
Co-localize
HCC13-0109
incubatedunder
irreproducible
.MYC/BCL2
NEEDLEMAN-WUNSCH
AS–PCR
©2007
J-13
transduction.3,33
analysis.40
LUA/ALF
L42P
3beta
p.Arg272fs
.Significance
dysphagia.5
Gli1/GlaB
.DEV
Mac1−B220−CD3ε−CD8+CD4+
PWWP2A-ROS1
Acinetobacter
.Embryo
Q510E-Shp2
28,36
p.Phe53Leu
JAK2V67F
iNHA
AZ12908010
5′-GAATCAACTAGTCTCAGTGGCCAGTCGAAGAATGAAG
T2151
marker.MEFs
β-catenin/
CD19-negative
.Inherited
5′-AGCAGCAGTAGTGGTCCTCG-3′
1024
69–71
smallportion
CyQuant®
FAK-promoter
net-positive
studies14
—Abbreviation
H-166
FGFR4-Y367C
Q60K
M947R
Yamao
21–73
anti-GATA3
c.392G4A
∼50–55
MAP/microtubule
R249S-transfected
S847I
bell-shaped
11-fold
MEN2B-like
035113.6
NF1expressed
methionine-free
reactionsingle
−3.25
TIRF
compartments.24-625
UTERINE
V600E-specific
invasion/metastasis/EMT
19/22
anchorage-independence.25
5′-ATGGTGGTGAAGACGCCAGT-3′
0.908-1.215
Ligation-dependent
68.4
VX
NCIH446_LUNG
.RAD3
pFastHTB
wildtypeand
Lin
FGFR2-S342C
1209
Indian.-l6CzechosIovakia
PIC3CA
SPo
FGFR-independent
Hartman8
c-myb.altE1.98.F
p.R460H
0/27
Id2-mediated
Ncap
8−14
SalI-linearized
XF
αM-β2
V769La/Ma
tables.Kaplan–Meier
first-generation
sequence.82
S433A
basal-specific
CRISPR/CAS9-stimulated
l-1L-glutamine
aberrantbandby
Mesri
TTTTTCTAGATCAGCAAACACAAACAGTTTTC
0/63
209KB
aacr.org
penetrance75
0.405–589
BE2C
Pplus
CCH
purificationof
Y1278
.NS
.dM
Anti-pTyr
area.34
gggttcatcttgcttcctta
amplified/overexpressed
cells27
cancer/
–87
pCMV-HA-KMT2D
5/65
406KB
LS50B
c.1647+48A
R45K
RMSFXray=3B/8π2−−−−−−√
www.bloodjournal.org
AshkenaziJewish
FVB.129-Trp53tm1Brn–MMHCC
RB–E2F
.Pyrexia
5′-CACCTCTGTACAAAAGACAAT
C238F
re-entry
GSSG
5'-GTCAGCTCAACTGAAAGCCG-3
p53-stabilising
HAT-activity
pair-level
homoduplexoligonucleotide
1DD1,1
Smarcb1
alkali-labile
SNF2-like
24–35
NOK6
ADP-bound
129-50
ERα-M2
vascularisation
pTSTEPQpYQPGENL
ERa4
11WK557-8del
J.W.S
19-month
.226
p.Gly12Val
position-specific
hsRBP4
calculatedby
Bap1
WAF1/
pCMV-KIT
GDP-Ha-ras-p21
ncubated
mutation-overexpressed
5Å
mediator-associated
4S*p.gs
.Age-related
www.baystreet.ca
Qu
S180N
GAADDLAS
.Multiplatform
0–6
RMA
KRAS+KIT
Angpt2
.WHIM12
G463
92/227
pCS2nrf2ΔN4N5
MAX-MAX
CRISPR/Cas-generated
T42
H184
A339V
G2505C
Asn664
1.2Table
EXT1
plasmid-dependentrecessive
HNC
degradation51
duct-lobular
jxM
benzene-sulfonamide
.Dedifferentiated
GFP-siRNA
12Royal
11.27
1909G→T
.AVected
l-methionine
ETV1-only
28/72
pUG35
L90P
.138
mock-H446
Y897S
p53Y220Sfibroblasts
TGF-α–specific
polyvinylidine
receptor-1-specific
OS.20,23,27,28
GTP-active
.LDSb
p110α162
transphosphorylating
650
anti-H3
4–27
MEK1/MEK2
100–172
Labortories
M/32
RASL-seq
9086
26/32
pMEK1/2
PGTVALR
L373R
kinase30
non-genic
FluoroEnhance
Thr791
TopNotch
BiBr45–60
72,223
differentiation.82
I/r
variantsT33P
over-55-year
2135A
ALK+
streptavidin-APC-Cy7
GD693
Kunfolding
H833V+L858R
delL747–T751insS
KMT2D-truncating
Favata
Cdk12-siRNA
22mastocytosis,24
5q21–22
c-Myc-GFP
DecisionSite
world.1-3
SEC63
IB1O
mutationstested
7.7-
expression.38,39
BCL6+MUM1+
Clalit
extra-cerebellar
described7
Genomic-based
poststimulation
RNAseP
//archive.uwcm.ac.uk/
V617FJAK2-positive
TRCN0000010025
Pascual-Garcia
H132
.combination
2O8OinsA
AnnexinV-/PI-
97.9
98-74
-,3
511–520
Yesb
94-base
5,48
factors.1,7,8
FGFR2-BICC1-expressing
polymorphisms.Statistical
FP/540-20/590-20/590-20
α-phosphate
PE-Cy5.5-conjugated
GTACAAGGCCGCGGATCCCCACAG
p.Ser1013Thrfs
co-expressing
HEM
gemcitabine-cisplatin
525_526insC
P111L
phenylbutyrate
cdk5
MEK-ERK-β-catenin
GluC
97,299
myeloid/T-cell
leukemia-derived
2/138
10–37
O091
sc-81149
Homo-/hemizygous
Firpo
R649W
loop‐dependent
TDA/enzyme
.SUP-T1
.7-10
strain.Fig
534G
q15q34
lex/lex-4
bi-transgenic
MDS/MPN.6-12
Kashuk
5′-GGGGAAGCGCTGACACTCAC-3′
vivo.21-23
Y806F
p16INK4A-mediated
Y551E
27–94
4D5
6–304
Leu-130
c.572A
immu-mount
HFBA
802G→A
I326T
7066
10q21.3
meayamycin,38
Krivtsov
scoreo60
Finder30
MutationTaster45
non-BRCA
alvaro.monteiro
effector-type
DIRC2
trans-allelic
V179
GATA3-null
FRET-based
Gelstar
FASN
guanidinium/cesium
Microarry
1,036
.39,43,44
-/acZ
SMURF1
chr9:5404875-5581849
recip
functions109
tissue157
mechanisms.37,38
NER-mediated
COL1A1-PDGFB
4.41
SJNB12
+PTEN
IRE-mut
non-mammalian
5′Fam-ACT
uGl
5′-CGTTAGCTGTTGTTTTCACTG-3′
AAB04680
405.00KB
3-pixel
III54
Wnd
PMS2—cause
812
genotypically
and33C
.586
slideGenes
tumor-causing
pre-dose
HA-RUNX1
q31q33
∼350
51-base
2-1807
–99.9
PGAAHY
Arg134X
GW5057
±500
respectively.5,8
P310R
2843
autophosphorylates
/σ
flag–STRAD
≥35
803–934
miR-424,17
Aalpha–B56bold
P183T
antiestrogens
Mirzoeva
Hawthorn
inhibitor-type
antimutagen
SD142
D.R.F
misssense
platinum-taxane
Y26F
10−3G719S
regulation.14,19
domains28
121:24–33
aorta-gonad-mesonephros
elements—in
1–606
//www.cbs.dtu.dk/services/NetGene2/
2.46±0.91
new-onset
LCIS
p300-2S
T2N2M0
CAA→TTA
sun-shielded
.PCH
GAP/Ras
Gp2D
16-kDa
PrL
filled-in
itself.In
derived—i.e.
fx/–
and-specific
Hoxc9
–1,077-bp
Tissenbaum
Tdt+
MEK-dependent
10q25.3
trans-activators
BIMS
HBS
GST-HEG0
1147
ATCGAGAACCCACAATACTTCAGTGATGCCTGTGTTCACCACATCAAGCGCCGGGACATCGTGCTCAAGTGGGA
hpv-positive
pEGFPC1-PTEN-C2
cpm
48–60hr
DQB110302
PDGF-
V600E/K/D/R
284fs
MAG|GTRAGT
reshaping
10.33
5'-TACCTFCCATGAGrFGTAGG-3
m/69
TKITreatmentDFS
DN-MKK4-ES
NF2families
1–1670
hyperplasia78
G670E
2500-ROX
thesefour
Hospitalar
lineage-based
www.controlled-trials.com
GATA-3/DNA
EWS-FLI1-regulated
features.1
Leu542
CAAACCGAGT-3
GCTGGGCCTGCTACTGTTATT
L876
immunoglobulins.10
TCCCTG/gtaagc
Shen-Li
Unità
itf
N346
p21-L2
C890A-myc
thymidine/
V1220I
pcDNA3-FLAG-Myc-wt
tMEK
p.R2637fs
Lenferink
MODY3-causing
multivariable
y-of-age
9.21-fold
GRB2-associated-binding
PD-168393
amino-acid-sequence-identical
supernatant/polybrene
Fig.1A,1A
UDP-glucuronosyltransferase
1111
Nonlymphocytic
1516
λhp300-2
8.40
BAF170/BAF155
seconds/68C-2
4-methoxypiperidine-1-carbonyl
V/cm
c.903delG
CML-BC.16
Priebe
181
1.022
68-90
tgg
type-II
second-round
EMR
V-myc
PTP1B·EGFR/pY992-peptide·VO4
.Project
RP11–567O16
inter-genic
ninein35
K31
TGGGGCCTGGGG
fusions–particularly
*Upstream
.SLX4
nonisogenic
cyclosporin
50:192–202
BAP-deficient
.Hybrid
Microscopy
anti-rabbit-PO
1927C
electrophillic
C204Y
2002c
region.A
K608M
M133L
fMRI
METAVIR
518–813
gene–specific
.9,26,54,55
9,10,11
1049
WT-GFP
myristylated
H3K9me2
ERK1-
H-1404-072-572
p53-H179Y
GREM1
.NF-kappaB
E608D
59-CACTGTGACTGAGAAAAGACAA
39/45
residual31
activity.A
differentiation.50
somatically-acquired
responses.44
postive
ML1
200-mm
reversible
E40We
COX‐2
A353V
36/73
.SeeGH
WNT-mediated
isView
2ΔCtsample
erbB3/HRG
anti–Ki
1.17-5.54
S170N
0.48713
progression.21
Asn166Chk2/Asn107Rad53
R659P
60-cycle
pACT2
-myristic
0.023
CDK4-MUT17
V617-negative
R-CHOP+MTX+
.Cosset
RBBP5
Fig.3F
Ac73-bp
75410
12.1
34,060
H119P
disorder/attention
Ala34−Ala36
expected.10,11
ligand12
CloneID6510019
5′-CCTTCACCAACAGGCCCACAGATCAACTG-3′
114–119
interphasic
Smad3ΔPY
CD29
P577_K581dup
CEP17
logFC
MSI-targeted
mitosis19
monotonically
metabolismCullin
L53P
gliomagenic
Rspondin-based
MIGAADINIYKIGRSTFMIEoL
PstI-BamHI
F41
c.1866G
.FoxO
multidrug
and4C
functions.14–18
development.19
9,12,13
buffer/well
Z≤−3→3
95.0
AR-C
.A11034
ThymomaThymic
rs717962
EVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLF
52-57
DDEE
E1346K
Ambis
−85
p.T333A
T116P
G/G-genotype
legsb
R367H
28-31
C117S
R1–R7
82.7-fold
JNX1.pdb
BioSearch
xenografts157
SUP
T19N
FIG–ROS-Driven
91•2
BLIMP1-null
E684
of-the
63Â°Cfor
Eksigent
GST-FANCG83–622
All-India
pro–B
B159
5′-GGCAGTACCAGTGCCAGCAATA-3′
Ras/Raf/Mek/Erk
characterized8,9
0.66-8.43
p.T458A
SMARCA2,40
diagnosis4
refrozen
–1667
NSLCLC
Fractionsof
loratadine
.Fig.3B3B
IVT-HIF
AdvancedBiosciencesLaboratories
HELF
×10–60
performedin
days.ImmunofluorescenceSee
ProteinSimple
coin­
30–400
Drohat
SMO-D473E
Map3k9
400.While
JB9639
anti-ASC-2
granulocytic-monocytic
5′-CTGGCTACCAGGACCT-3′detecting
effect45
latent
.GSI
.Cdh1-activated
B-RAFV600E/loss
BASF
p.Arg1515
.Ultrastructural
chromosome-22
R420Q
M6989
11/109
N304K
L348F
Keap1-Mediated
E2–25K
colleagues79
murineCD4
2800-fold
MCV+
Onto-Express
21-month-old
CEPF-F9
R1004G
endogeneous
cytosolic-predominant
aneuploid/polyploid
proteins1
E235G
D346H
L747_S752del
vs.84
ultra-high-risk
LongAmp
0.000622
.Fold
formazam
-58
relapse78
c.602-c.631
_FGFRTACC_negative
e-blot
−146C
sc-377567
M450
development.83
pBABE-puro-K-rasAV12
1,697
.AKT-dependent
RAS/RAF/mitogen-activated
ciliary-targeting
NF1/2
hMMR
80T
Comutation
∼7-fold
R273Cmutant
theidentification
Amarsham
water/acetonitrile/acetic
Src-T341M-Y530F
SC-20
estrogen-sensitive
R1825H
machinery21
Borghaei
0-30
GSE14879
AMBIS
AG471
1LWD
PDGFRA-CDK2RAP2
ID021850
D5S82
.Day
R1737
LSH
pSK-K-ras
3285
91-23
TERT-high
binding.2,19−21
types10,14,15
609-258-
SDS/25
endonu­
homophilic
Ras-transformed
Lineweaver
extrascheletric
Keumsung
.Ohh
dual-staining
5517
//www.genet.sickkids.on.ca/chromosome7/
TtoC
BRAFD594A
H3K27me3-specific
NFKBIE-mutated
86.5
SKW-EGFP
importin7
Grbovic
regions28
N140*
5′-CAACCTCAGCCAGACAAGGTTGTTGAC-3′
≥0.25a
BTIC
135-8550
39/M
.Remaining
18750
CDK-dependent
proteins65
C-subunit
L1951R
inmediately
CCSLTGT
annexin-V/7-AAD
TGTCACAGACA-AGTAATGTCGATAAA
diode
.N71S
transfec-
204-3-1
ng/µl
NCT02192697
kinase-deficient
Genetica
.AO4
p=0·1193
45·8
PCR-4
each6,7
started.18
tcacgctgaccatggccaag
checkpoint-guided
L428R
.SLC45A3
A124T
IGF/IGFRI
Cuenin
regression132–134
tumorbiopsy
ABI1
to0.05
.PTPN13
syndromes.13
3.96
V611
54–57
ERK/MEK
2118
S860L
CTC-3
D~~D1
ASXL1,15
mice19
N822
CCCATAGTGGTAGCCTGAGGACT
MT-p44
3186
mycp110α
NH4
72Â°C.For
65/f
forcefield
RASSF9
V-DJ
Gal4-UAS-system
A/i
FLJ33320
Lastella
TRKC
G776insV_G
Levantinib
93–110
targets.45
20-µm-thick
Biospecimen
5-GATGAAAAATCCTAGGAAGG-3
Bsr
butyl
p73β
A491V
F12
0.94–1.42
KIF9
second-most
NHbonds
R776C/Ha
HT-29/EGFP
Gli-responsive
CI=26.8–73.2
vignette
Beta-galactosidase
non-haematological
Netsurf
VIb
n52
resource-poor
KPDfl/fl
crizotinib-related
S7.2
anti-T-cell
RP11–100O5
hlack
MEK2—require
Lierman
S240N
ADAR1
APC-b-catenin-c-myc
state.1,2
p27kip1cytoplasmic
721-1372
subfamily34
TGFβ/SMAD
3-CTP
RCC4/
nucleotide-positioning
MALT-lymphoma
13.28
.FLT3
p110α/p-S6
profiling21
Inr
N-myc-p110δ
teratogenic
-RAS-PI3K
Tumor-predisposing
delinsL
Mg2Cl
mediatingthe
studies,33-35
Q643R-NHUC
1ESE
Trp53L
BI-3C5
function.36
16.72
Figure9F
Wilcoxon/Mann-Whitney
FoxO1/3
diagnosis-relapse
53,946
Ex8
Smad4-deficient
BRMrnai
Variation_5006
Unstable—p53
FA-F
EGF/PDGF
leucogenys
18SFigure
Quant-iT
oxygen-free
time–course
D′Eloop
c.1960G
.CMV-VP16-CITED2
0.058657388
19/126
MEF/
46F
C93F
71.43
3.1.2
81-95-849-7304
.Ser46Ile
F219S
~750
GGGCTTTAGAAATAGAGAATGCTG
1A–H
TP533–10
STI-
oncogeni
c.614A
bdf1
G302R
3-carboxymethoxyphnyl
Asp814
T2Onc
S121C
two-week
G171V
ERC1
keratin-positive
migration90-92
882.3
KIT-transfected
crossresistant
pCMV-β-gal
domain,14
cells/ml
KYS3-450
MSCV-Hoxa9
Suzuki-Takahashi
virus–transformed
N=4
Prc-PKN-AL
ezrin–radixin–moesin
agnostic
NaH2PO4·H2O/0.75
NAO
S2.6.1-
c.325
Up-
1,234∕1,235
NRIP3
.Exploiting
Hs00195664_m1
AMG-337
BRCA2:8765delAG
S9.1
H816
Tkachuk
CHARMM27
Simulconsult
perfluoroalkyl
3400/muL
0.39–0.72
D1017H-
MPN.4
,8R
ARAR0332
Th17
744081
pre-cursor
//www.interscience.wiley.com/jpages/0022-3417/
NB2870T
non-Mk
RP24-174O22
Gjc1
FGFR1.7
caspases-8
Non–Pgp-mediated
Gershenson
15q15.1
hue
lagging-
G34S
symptomatic-palliative
PRKACA
9:3674-3678
S1285F
Ba/F3-L858R
11q14.1
HN31-shp53
oxoglutatrate
569.7
Δ39
D16S3123
0.40
20/10
Glu116
Q176X
EML-ALK
neurosurgical
Fmo2
665772
PDP-based
5′-TATGAGCTCTTT-
velcade
EIKRAARSDDILRRNSCATRALSLYTR
pZEROtg
−2455T/A
disease34–37
.q13
lysine-120
p52
Alterationa
fluorescence=green
rap1GAP
0.00002644
Fbxw7R482Q/+
A20P
rs16986145
Tzivion
angioedema
nihms
LR12
failure–associated
tramtrack
Lines—Subconfluent
pan-cadherin
¼33.2
p.R462P
variant.19
Ruijin
i.
/-..-..
105/286
Mohaghegh
His-myc-Rbx1
TTGGCAGTGGGTGGGTCTTCATAGG
7.4–7.5
RBP–RNA
.Noteworthy
R703W
.SP
TGTCTCA
.HaCaT
p80Proto-trk
A293T
8991del14
27.59
Gene-Disrupted
Gaddl53
tumorigenesis2,15,16
+1155
4VIB
2,000
resistance.33
EcoRI–KpnI
Δ9/10d
TyrS37Asn
qt-RT-PCR
C-dependent
ppâ€
2.032
300A
T89.1
G209V
1mM
S784Y
G514C
.Whole-exome
RAF1-RAS
Translocation-Positive
Awild-type
FLAG-Kelch
sc-1703
BRCA2-GFP
ab52893
fluorescenceactivated
4993C→T
iso/ano
β-catenin–activated
SD:29
GRAPHPAD
channel.19
ELDLETLAPCIPMDGEDFQ
TP53,25,26
PGI2
|â€
debated30
S106R
CUL3-KLHL11
1.037–5.372
BRAFWT-expressing
29,421,819–29,722,897
CEBPADMDNMT3AMUT
I268T
PD173074-mediated
RP11-1089B2
pancreatobiliary
whichenable
Pre-Developed
atrogin-1
102,103
position-12
manner.22
BACH1-deficient
Eschenchia
Σ\I–
CCTTTTCCACTTCGTCTGAG
P202-B1
T2173I
.B-cell
HSS110905/sip53-1
.IL-9Rα-mediated
HSC7E161
erlotinib175
43,000
FSTL5–YAP
Cotransformants
vitro-produced
Leu74
1.916
1356–1334
1013
-ribose
BRC25
P445H
adriamycine
2,763
c.1859C4T
Wnt-1
0.0035
synthetically
.Ionizing
Check1F
20-23
104-1,104-R.and
anti-HPC4
Cγ1-Cre
59GCGGTCGA
.Tamanoi
α-Cut
GDC-0032
5′-GTGCATCGCTGGTAACATCC-3′
–mutated
K99fsdelAA
6830
INTRODUCTION/RESULTS/DISCUSSION
SP174
H123P
subchromo
downsampled
subclassification
P110α
KITD816H/Y/N/N
spectrometry10
2073
c.1044_1049del
CG2083
region,41,42
BRAF28
.Pdgfrbredeye
35x
12/per
0h
deletions,18
M224R/G1035S
131/4,402
e15640
p67'rk2
.17,21,24–27
GAP-catalyzed
JB12292
V*
Calcitonin
Niguarda
pGST-FANCA1–271
I246L
used.17
C182
KF
MRAIL
pQE9
.Colonoscopy
.FBXW7-null
5′-GAAACGGCTTTCAGTTGAGC-3′
promoters.27
.Considerable
lin-12
Ras/p53H179R
.LASSO
light-dark
CHROMATIN_MODIFIERS
5.5m
17q2l
P-0004798-T01-IM5
TRCN0000197134
notproduce
pathway86
placental-like
ICL-hypersensitivity
mouseATRX
72.7
5߰
ura3–52
outcome.2,3
Nomdedeu
CAAATGGCGCGCTACGGCCGCCACCCGGACTCACACCACAGCCGC
W38*
KRAS-EV
8I
C630S
molecules—ambushing
Lgr5CREER
colleagues9
VHL/SDH-like
DP1/E2F
trklO
S449F
cosediments
Cen
SMG-
Kuttler
.Phosphorylations
losses.11,28,29
END0
P551_V559del
Binom
147,148
library17
dehydrogenase-dependent
c.1495A
19,38-42
9.9-kb
translocations.37
caspase-7
377
G2637A
15°C
ACGCTCGACA
p15-wt
protocols.21
Eker-derived
chemiluminescence
CGCGACTGTGATGCGCTAATG
heptad-helical
embryologically
Ser-245
wu113
Harvard-BIDMC
G466C
type/transfectant
50*
381delAAC
Leu410
c.529_530insG
trp1D63
step-by-step
anti–PD-L1-PE
SPOPMATH-Puc
P379R
Cappelletti
-1.61
Rehybridization
LEF/
ABCB4
WaxFree
HCLc2,4
anti-Her-2
Tyr-371
CRP
assay17
420A
hyperactivation
dnFoxO3
1p110α
AGC3
5′-CAGAGAAGTGGGAATAACAG-3′
SPOPMATH
SMAD3-specfic
resuspending
50.6
frequencies.4
_____
Ser588
Merck-Serono
mass-forming
state.47-49
Figure5E5E
CATGTTCCAGTATGACTCCACTC
gene-176C
zinc-stabilized
.Neural
57.0-68.6
106-kb
GGATACTGACGAAACGCCTGCC
205024_s_at
cytokines102
203967_at
A391/393E
1,271–1,288
7or
cells158
SF3B1-specific
Ins770G
Doorn-Khosrovani
Ascierto
potential198
42:149–152
M2b
5′-ATTAGGTGGGAACTGTAGAACC-3′
676–1255
PRKAR1A-
.SCFs
Y1463
Xrcc2+/−cells
STAT5.24
SectionResultsSmurf2
Plx-1
membrane18
0.705
aberrations.MethodsAbstract•
withPvuII
genes28,29
NFKBIA/IκBα
erbB2-induced
.Meyer
dup
al114
2.Expression
HPV–
J4
HTLV-1
53.7∗
S-fraction
α-RBM10
5′-TCTGAGTCACCTGGACAACC-3′
c.5058T
Wequantified
factor13–15
paralogue
Lys114
Leadbetter
Fluorescence-based
Gorre
cedures
S218A
PCR-mediated
1.34.0
V54M
GIST-T1/829
.Rate
T-p53C-T123A/H168R/R249S
modifyp21
worked-up
5′-TGAGCCGCTTGAGGTTG
tobiological
1487–96
Mobitec
Abl-specific
previously30
unglycosylated
H3K36Me2
thompson14
yves.engelborghs
D2
2.8-4.1
5'-TGTGTGCTGAGAGATGTAAT-3
pFlag-Jade-1
G669R
C1-C4
Collard
abolish/reduce
Isnard
D1-T286A-dependent
92-3
15s
Y32A
.B
2/disabled
isfemoral
anti-Fbw7
IV:34
GSM459015
pPLC-γ1
PCRKIT22as
013986
Sprr2F
protein19,20
XtalView
.PCR/RFLP
K42Q
patient-paired
c.1621
NOTCH-specific
message16
112C
histopathology
Cys/His
pathway–induced
richard.gibbons
multivulva
cytokine/chemokine
insertion.Missense
hasalso
.They
Prx1
anti-EBV
β-phosphate
GTGCATCGCTGGTAACATCC
CPT-induced
CFU-Cs
Mei-41
2279
ng/nl
.Autoradiographs
A111G
lΔ
GST-pl61NK4
PhosporImager
found.29
respectively112
Y272D
ATM82-13601A02
immuno-therapeutic
.BothTEL-JAK2
FLAG-SMAD4/wild-type
3d-f
BL-like
endothelium-derived
pancytopaenia
GAGG
δ-5′-Mlu/δ-3′-Cla
4—6
32D-Y589F-Flt3
SVDFDSLTVR
phosphoindependent
21.4/24.7
tyrosines
mutation.14
resultingin
P379L
intrigu
►
aneurysm†
Y64
Class2
Sviderskaya
BMS-
Truong-An
Video-capsule
phospho-AS160
29-32
his3-Δ200
0.35-1.15
subsequentSanger
8p12-p11.2
α2-domain
30000
8,240
K236
.18,25,26
mg/d38
V599
igure
ADP/min./gM
Sharan
CycD–Cdk4-expressing
BCR–ABL-positive
E52K
Cullins
F56
CAGA12-Luciferase32
.Arrow
142/1,028
co-infection
5.39
0.98-4.25
Lats2-KD
12–37
937
three-base-context
rs1136201
RUNX1-637F
N181A
3-G
Skp2/p27/pRb
stomach.31–33
motif35
Gu6k
monoblasts
AUGinitiated
SW1088
loss48
Ruiz‐Cabello
M/50
Pirh2
TNF-treated
disulphide-fragment-based
pX458
≤4
72Â°C,5
PhosphoSitePlus
SCC-bearing
34th
chaintermination
rat-embryo
.1798delinsTACA
95-3
GFP-RA
exacerbate
JUNQ
0.0375
puisieux
PF-04691502/PF-502
and55A
P=.02
FGFR3-IIIb-K652E
treatment,5
.Lymphopenia
25μM
34–68
3A10.1007
U.D
PAAKRVKLDQRRRAP
2,747
24-hour
T/
Baybis
PTEN-R233X
Rad50+/+
Arg911Stop
Schalm
cancer76
microcapillary
.Risks
59/89
G.O.H
trk25
L389S
mRNA25,26
S338
.G418-resistant
pGL3ti-BRE
exon4
D276V
Schnittger
Raschella
intein
base-substitution
HCOOH
R37XM40L
ERK1R84
S301
AA4.1+
JAK–STAT
umds.ac.uk
origin.24
GSE67388
genomes—a
c.9435_9436del2
KIT+
N16
FACSArray
1164-amino-acid
sec−1
activation.41,42
E6-immortalized
anti-CDK10
LIG4
Fbw7-dimerization
residues.1-3,9
0.02911
NSCLC.18
studies19
Putative
R457Q
CUTO
multi-read-correct
57-71
Trp-79
V/975
polycystin
siEGFR1
AAGGTAGTCTGCCGCCTCCG
over-diagnosis
seeCordon-Cardo
SCSG
CDKN27
A300-171A
CDK2-associated
M572K
p.Met1_Arg69del
v-mil
Collagenolytic
13.2-kb
protein-conjugated
074
RikuRator
APC/c
G831
<
T7271G
L-glutamic
1784
Kagaya
fibrosis,6
S2P-CTD
miR-3127-5p-c-Abl
E252L
Nr3c1
mutationsduring
LT/YF
Ziekenhuis
JMJD1C
Miettinen
determinethe
pVHLQ145H
late-replicating
IBRUTINIB
8.6-
.T1691I
SNON−/+
CI=
/5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside
artefacts.Histological
L1649R
recombinations
YCC11
kallikreins
.2527G
38-80
phospho-JAK1-
0.266
27,44,45
Hhregulated
125I-EGF
R28H
Que´bec
chr6:67272228-67272863
'false
TRIM71
Ala114
p-glycoprotein
Follow-up1
ALK-fusion
geographic/ethnic
Immunoflourescence
BamHIsite
Y285C
TCTGTTATGT
24:3397–3408
Minisequencing
T+4
MTV-CAT
4060S
11/11/98
USA.36
V565
IRS1-4
Bapta
5′-ggc
GTAAAACCTATCATCATAGGTCATCATGCTTATGGGGATCAATAC
oligoprobes
posttranslational-inactivating
microdissect
NK-cells
AL142
EcoR+
4901–14
-AMCA
ΔSAmut
G-sepharose
autism–spectrum
LC51
pcDNA4/HisMax
c-KITs
SAP49
mutation.67
RTK-pathway
PRKCQ
64-year
,31
and183
61AML
pLX302
Src-deficient
Hs03714372
80mM
L1546N
Grp1
neuropeptides
A70F
leukemia.27,30,31
S1002R
GxxxxGKS
ras-association
mutationally-activated
R461I
D-enantiomers
spermatogenesis
Proteins—F9
TNF-stimulated
50-99.9
bound-paclitaxel/bevacizumab
d-glucose-13C6
L5P
antipain
Radixin
pGEX-4T-3-GST-VHL-ElonginB
AACCATGCTTGCAAACCACT
immunophenotyped
.S4R
28576∼
myofibres
Hg18
10−9
106139
FAM-forward
TCTGCTGACCCCAAGAATG
RING-bearing
.c.3038_3054del
Promoter-associated
2.4.1
2TA
focusforming
domain.16
UVC
1911
RN7SL
5Vand
PTC-Ras
33†54
NVB-HER
KIT/PDGFRα
.Gallagher
HindIII-labeled
.Cetuximab
GraySchopfer
Raf-1wt
Q61R-mutant
VRL
BWA,8
CTCCAGAATGCCCAGTGAAT
required.Some
interfollicular
D1225N
s922
Low-stringency
0.1237
3.1.3
MCG758
kip1.5
DEC-1
Glul541Stop
PIK3CA11
cytoplasm,30
H=34.13
fouradditional
.Sixty
pI-12-MUT
.Various
gg/mI
non-receptor
WT1-BINDING
sc133
pCEP
-mmf-min-quality
c.1648-5_1672del
PDGF-BB-induced
p.E685V
KPβ.9
sequence.38
17-80
Clichy
PTK2/FAK1
OCM8
terl307
Protein-ligand
.ETV6
PDGFRA-exon13/14R2
PD0325901-injected
NUP98-NSD3
1Th
lines177
foci68
.Altstock
autoglobus
S6.1
Asp-38-
Cdk-interacting
recently32
GenBank/DDBJ
Methanobacterium
RETE805K
Msh2Y165D/Δ
1−3
T58I-expressing
Re-biopsy
Lifr
gefitinib-based
.AR6
20.0μM
∼870
N288S
ACINAR18
Rustgi
MMP9-dependent
anti-TNS3
.S8–S10
CACCATCCGGGATGAAAGTGAGAT
D.A.T
type-TCF-4
3-kinase-generated
database41
Palavalli
6i
Combinatorial
2867–
independently-associated
XPD-causing
MED24
DLX2
0.000400403
aged-matched
932f3
848/732
Helicases
–0.05
ArrayTools
GATA1
MscI–EcoRV
methylation.100–102
CMP/GMPs
†14
XVI
studied,15
P1-P3
Aslanian
ViiA™
H.These
SNP309
Kit-KD
'negative
L38C12
Peutz–Jeghers
STAT3α
32/167
Y696
quadriceps
hematopoietic-specific
Lentiviral
enzymes—
O:100
Emu-T286A
conditions.We
intra-exon
C=N
AATF
del2
0.028
vitro/in
9.7–14.4
155–189
ALKi
Abnor-
F39
ependymoma—to
puromycintreated
.CDK10
49/82
c.8165C→G20
3730
JAK1-overexpressing
6601
Flowjo
M166
R279W
0.000967
endocrine-therapy
D482N
p.Leu833X
95/0849
Zap-70
1392dupCAGT
TUBB6
DxETGE
A_51_P449171
L792R
pTZ19R
status11–14
J.RT3
noted.24
1Staining
4-wk
HNPCC-causing
77-year-old
173
N-KRRRTGGSLRGN-C
.GM-CSF
GST–Empty
ScanAlyze
Japan.84,85
β-geo−
homodimerisation
Brodbeck
A-purified
ALK-wild
S30A
nonsynchronized
ATPase-binding
moderate-tohigh
SNU1
D9S176
lymphocytes26
phosphoinositide-3
12kDa
chromokinesin
spheroplasting
A*010101,020601
delL747_T51+R776S
T198D
pre-hybridized
TCR-negative
births.7
temperature-induced
fluorescence-activated
EWSR1–SMARCA5-MIEG3
1.911
5′-CCAGTGAGCAGAGTGACG-3′
44a
β-mediated
anti-BACH1
calcium/
1.02∼1.52
algorithm52
.Tel
S1699
Nisson
S1.Apoptosis
beenproposed
1.4–1.6
5-GGATTGGCTCGAGAGATCATGAGTG
MutSigCV—Broad
-_-~
Lu1
14-25
ditluoridc
23:332–339
0.277
B/X
28,438
circum-
p300/cyclic-AMP
GtoA
protein–carbohydrate
promiscuously
Klekner25
∼0.4-0.8
glycine-to-cysteine
population.11
AWT
P98175-1
p85-related
p53-sensitive
Kovr
Stress-related
geneshMLH1
3,135
370/1112
L626Q
metastatic-associated
Lats1−deficient
2a–c
g/ml
Transplantation
lymphoma.38
fast-tracking
GST-RSK-D2
non-H1047R
pAAU
H22Y
IL-4
BHT101
normal-karyotype
p.P34L
r5-bp
PIK85
K104
HMMs
Anschutz
Topcount
c-FOS
4MET
mechanism.14
GST–β-catenin
mutation197
tNIH
Exportin-1
elsewhere26
Flag-tel-jak2a-injected
self-masking
FGFR2/Fgfr2
Kreiborg
31/54.4
H1b
SK-4800
p.S46N
.1321155111i2
His-x-Asp
V600–mutant
factor-betas
pRL-Renilla
Ocular/visual
available.We
58/M
mHGA34
D1733GF
5-TCCCCCGGGCACCATCAATCAGAAGGG-3
94551
11,12,13,15
17-61
143,925
cbt-15-428-g5
4-case
−58.5
Alava
cellswasimatinib
c.4270C
construct.17
E40Wc
TCGCGGGTGA
.Commonly
D11S1343
iCCA-HCC
CCLE17
TÃŸR-IImutant
​Figures1B1B
hSET1A
429
0950-9232/06
influorescence
L219Q
ScSet1.3
thentreatedwith
h-Tert-immortalized
P203A
pro-interluekin-1β
-70'C
RNAi-injected
Schekman
antibody.HMECs
Lkb1/Kras
hypoxic/ischemic
mutations.24
10563
BstEII
OCT4+
189.3
previously.15
q11∼12
Lehnertz
~Y32W
p.Ile618Met
Plotter.11
NUP214-ABL1–activated
serosal
Advantage®
G735S
tumorigenesis.14
q13q32.33
non-GCB/ABC
.RING-less
Haukeland
Val560
Taqman
jochan
.S.O
0.02664
types,16
Immunotools
p110γ-mediated
5¶
CD1b
5′-biotin-GGTTATTGCGGATAAAGGAACCAC-3′
1454C3A
~
non-activatable
OV
53,267,127
ACTCGCTCAGCTTCTTGGTG
G-coupled
demultiplexed
DHX32
Ajuba
time.37
14-3-3/QRSTpST-COOH
Insertion/Deletion
Svetnik
F7αF
4-VO
20–3.20
15-cm
2338J
5′-ATCTCTTCGCCAGCTCCAACA-3′
17b
TRK-derived
plastic-bound
ubiquitin–conjugating
.S4A–D
occurrences.4–6
I-Pst
TCT/AGA
3′-modified
KITD4
duct-like/glandular
Cyntellect
81675
D-value
Tyr185Phe
NRF
kinases—budding
HER‐2
P227L
transphosphorylation
kcal/mole
S4A
XK469
p.Gln1654*
p.Tyr1414Cys
co-inhibitory
First-Strand
tetraploidy8,22,23
2JIU
FGFR2-S354C
B02
GGCACCCTGGGTAAGATTTC
5′-AAGCACAGCCATCAGGATTCA-3′
FBW7mut
range=1–16
PLX-4720
w70
TP53-targeted
Swiss-model
rs1563828
Germ-cell
N-benzoyl
/CDKN2B
Myc-TGFBR2
A8081001
Lyonnet
.XPB
www.nature.com/onc
p.Lys831_Lys835del
Long-term
RASAL3
138G6
G79E
n=158
NCBD
G319S
siPPP6R
7.5m
pH8-FLAG-B-Raf
4.008
like-domain
Sample003
P.J.
complex–dysregulated
groups:13
race/ethnicity
V731F
RALGDS–RBD
low-incident
interactionsbetween
phophatases
MIB-1
TGF-β-2
Pho8lp
392–658
R689Q
Kaganovich
hMLH1-hPMS2
MSH2-p.N127S
sc-9007
-leukemic
phospholipid
cold-shock
binant
EGFR-dependence
2RU
GTGGTGCCCCTCGCAGATCTGCTGCTGGAG
D300H/K420A
WR1065
ERK2.7
ß-human
Ser139-phosphorylated
Charames
.Anti-human
FastTrack
3-ml
.3558insG
1-oleoyl-lysophosphatidic
12−24
1858–1859
L13616
PAX8-PPARg
27.08
1-cell
c.1852_1854delAAG
liposomal
missence
suggested.8
TD-20/20
hepatocyte-specific
D593VB-RAF
Vanaja
RPL32
S4e
provident
therapy,17
anti-SLUG
LC/MS
1612–1673
TGCATTCTAGTTGTGGTTT
Arg117→Ala
Indian-born
LDTPISYSLKYSDEQ
MEN2A-type
3.319
I-Smad
TnI
55–63aa
32Dcl3/Flt3-ITD
Phenomenex
vis­
families92
62C
FRAP-ATM-TTRAP
1448
E385Q
Shc/Enigma/Frs2/IRS1-2/Dok4-5
ERF-associated
Figures1B,1B
Trafficking
NA10851
Val-659-Phe-1248
.Castle
tumors10
neurotransmitter/neuromodulator
intestinal-
predominantlyas
PLC-γ
H3K9ac
structurefunction
v-erbb
cDNA-VP16
FLJ25409−5.5PDPNaPodoplanin
glycosylasesensitive
6.2–17.9
dithioerythritol
TTGGATTCCCTCTTGGACAC
2G–2I
tumour249
17.1/22.2
.R-283
andmatching
desmoglein-4
14/10
.Passaging
8138_8142del5
3455
_EGFRvIII_
EPGN
.Careful
MS-5
differentiation-related
tsalliance.org
3'-kinases
anti-estrogen-resistant
.Yes-associated
6q21,26
GAAGATCAGGGGCTGGCAGA
c-FLIPS
P617S
doi:10.1038/sj.onc.1206177
.ALT
D15S209
background27
promoter–driven
esophago-manometric
beta3
7q21-31
250mg
perme-abilized
TGTAAAACGACGGCCAGT
p.G12C/c.35G
−0.05987
_â
DMBA/TPA-induced
etoposide-induced
5408
SmgGDS
L.L.C
−241
CLL147
micrograns
'antibody
NCT1237236
5.850
carry­ing
pT638/641
R1362X
5′-CCTCCTTGCATAGTAAGCGTT-3′
Rehovot
∼5-
AlleleSEQR
6–10
q=0.035
K700
domain-encoding
I7ÃŸ-estradiol
arginine-scanning
adenocarcinoma.11–13
17,50,51
ScaI-based
−271GA/GG
//www.ensembl.org
0.6022
pUCFAC-D1
4837
normal.95,96
low/normal
1,2,30
Comprehensible
cancers.75–78
Ser-2
4-level
L-3
methylation-driven
-S-adenosyl-methionine
us.expasy.org
hTERT/CDK4R24C/p53DD
BCR-ABLfusion
chain-like
465:119–133
PAX8and
.LS
lw
structure-based
ANGPTL4
GGAAAGTTGTAGTAGTCGCGACTCTG
P47S
.L104M
.Discriminant
c.837G
wasreplaced
Sklenar
activation—as
p.F368L
SPFH2
het
αE
.Immunosubtypes
Ser/His/Tyr
small-insert
Kusch
Gasi
1–309
Asp30-O
KPL
Pelger-Huet
malignancies.22
ViraPowerTM
Temodar—TMZ
del6q
c.5536C
4-μm
activation/repression
factordependent
2143
CAGGAAACAGCTATGAC
4th
BCR-induced
lesion.44
anti-CD39
PTEN9
MAP2Ks
14q32.12q32.2
AtmC/KD
glycerolphosphate
tranFIG
R654W
.35S-Labeled
2-ethanesulfonic
Ragimov
n=500
V1155
2.5y
.Cohen
WHIM8
A534E
Let-7-5p
geriatric
tet-operator
:DNA
activation91
zlj9990993630006.jpg
carcinomas44
method.23
Gh
Ser746FS
pre-
Chiba4
PT-31
-o._
A/CDK
FoSTeS
N=154
BRAF-wildtype
pLNCX
–Akt
3U/mL
non-repeat
non-LFS/non-LFL
MUTZ5
Antennapedia-tagged
PTEN-C
POLE1
GAA-to-AAA
.1730dupA
.ZAP-70
5′-ACTCTGGGCTGATGCTGTCT-3′
e18
Soufir
nonoperated
-morphologic
His/Pro
5′-ACCAGGAAACAGCTATGACCAACCTCTGACAAGTGACCACCA-3′
Hll
insertions/duplications
p.Glu365Lys
0.08898
surgicalspecimensfrom
Moazed
1223405-08-0
5′-GACGACCTCAACGCACAGTA-3′
Arg91
.Deviation
O'Donnell
.ATP
liver-directed
eGFP.We
Suprec
14q11.1-q12
pDN6
gel.Protein
Rho-binding
pre-capture
Trp557_Lys558
data-driven
AACGUUAGCUUCACCAACAUU
F129/134
PANC8.13
TGGTCTCACAGGACCACTGATT
Valarmathi
Calbiochem/Merck4Biosciences
FGFR2-ERK
MASv5
otherwise.38
UACC812/LR
functionin
mid-nanomolar
0,7
'raÃ-gene
~30
DNA24
BTB-TPR
L345Q
F656S
EdU-positive
YUMAC-
Gas-6
SC-718
9/1000
WHO-defined
GATA3-peaks
CCR7-KO
guidelines48
V370D
leukemia.37
tissue5,40
19±11
2.0Å
normal/tumour
3.2.5
pSG/Flag-D146–186
EN-Y560F
S270P
VHL/SOCS1
Quizartinib-Resistant
Genetics.3
TN=triple
tyrosinase–Cre
.VC
-GDP
0–34
–PTEN
S7PY.To
B/B55/PR55
BRAC1
Co-crystal
li-Ili
family142
L72Q
//doi.org/10.1371/journal.pbio.0050109.g003In
q23q25
tool.2,4,19Imatinib
NFLA
Hôpital
.Heparin
Laatiri
B-cell–lineage
pathway-activated
2,903-bp
Nu/SP24
fruitflies32
39/50
Phospho-STAT5-positive
2707
stage46
HIV-LTR–caspase
Pathogen
ALGG
TEL-PDGFRβ.9,16
6·1
DEN–PB
//www.ensembl.org/Homo_sapiens/Info/Index
CGGA_D64
ALKG1269A
144700
.Bayard
558-560
Kawamoto
chemical-induced
Brca2
GADL1
.1778
Cobaleda
c.2590G
L-T
.U2OS
5256
digoxigenin-11-UTP
NCOA7
3–16
64/108
findings,8
R206T
low5
Alucifcrase
.Fpg
CELL-FIT
2430–2450
mutations—E160*
GST-MAP
kcal/mol
CAGAC
T198A
death-ligand
13.69
ZNF262
proline–serine–threonine
4-phenyl-3-
RNA‐binding
hypothetically
3327
expected29
Sty1
.Lutz
indiscriminate
CDC2/Cyclin
hpf
–approved
dye-labeled
S47–S59
Flaig
4.21
E1197
CD2-Gata3/TCR
nuclear-receptor-interacting
incultured
arrest/slippage
allincluded
gi:28559089
//cbioportal.org
Polyubiquitilation
isogeneic
18,826
GBM-cell
ArcturusEngineering
R-IVAC
CC1m
receptor-tyrosine-kinase
±1.5-fold
nArgGIuAICI
pan-PI3K
tumorgrafts
2-18
Gfp+
Glutaraldehyde
27.0
4G5J
AGCCAAGCTGGAAAAGACA
2-bp
7.2d
mutants—loss
S2807
8.67
TEL-Jak2-
epithelium.The
R6872
A-peroxidase
Koonin
PDGFR-β
waterbath
p73-knockout
marianum
H-2
c.976-15G
receptor.2
65-
corerpessors
2The
structure10,11
P27kip1
Phospho-SMAD1/5/8
cascade.12
NcoI-XbaI
D17S795
WI2-2194A15
shown31
AJUBA
Nfat5
BTBD12
V54
HG-U133-plus2
EagllBsml
anti-HIF2α
E221G
Miao,1
non-charged
p=0.017
NFT2
7985
HGF-stimulated
6TG-
system.6
SEQ-2
Hs-Drosha
110Eμ-Bcl2
promoter27
site57
UMUC15
GPS1
JQ1.23
p-SFKs
cohorts*
EIIa-cre+Tet2−/−
c.8257_8259del
cloxacillin
RIT1-mutant
FosHA
P73L/P63
.Pole
HA-FLAG-tagged
93,94
cp5
presenilin
3.19
carry.MethodsGeneration
adjuvant/neoadjuvant
G2032R-mutated
104.7
progressivedisease
pDONR201
Electroporated
TRCN0000006556
proper/stable
pY861
.CHAP31
193189
D–cdk4
GEN/284/12
p.H306Y
P157R
BFM-98
4B
pCY4B-FLAG-BAP1
17ÃŸ-estradiol
V782
clinopathological
knockdown/inhibition
.C1
WEHI-3
phsophorylated
anti-cytokine
364–393
200518-5
F109
RARS.36
Tramtrack
DUSP6
cdk4.24,28-30
BATF
peptides,1
Smad4-Smad2
WEE1Hu
in-parallel
3199
del2239–2256
interaction.39
dielectric
5′-GGACTTGCACGCTAATGAC-3′
abnormal/alternative
Suv39h
−95
GTACAAGGCACGTGCTCCCGCCAGTGGCCAC
.Gel-purified
.AU1-tagged
0.00000001
maturation41,42
E12/E47
R583C
pOZN-H2B-E2TA
insertion.Statistical
//doi.org/10.1371/journal.pone.0019059.g001Expression
areas.Locus-specific
\66
CRABP
Tsarovina
BRAF-initiated
11.78
c.999A4G
Cys443
αH1047R-K227E1/αH1047R-K227E2
4967
1008
IVS12a+1G
misinsert
12,16-18
557445
17.85
Hannemann
tetracycline-repressible
9102
submicroscopic
.G1128S
5′-TGTAATACGACTCACTATAGGGCAAGATGAGCGAGGCGTT-3′
HTA2
P00761
Guex
Genotype-phenotype
Foxo1-stimulated
genome-average
TEAD/TEF
mmHg
210-kDa
D57N
kinetochore-microtubule
G1069E
ICI
311−360
leukemia.7-9
Production—The
pathway-inactivating
toexon2
Kusafuka
tensin2/C1-TEN
TC-32
lenvatinib
Valdecilla
messengers.57,87
previously.23Cells
breast27
JL
GNEFs
12CA5
Flt1
proteins.1,44
5.63
12,20
proliferation148
nonequilibrium
T‑ALL
Ex17-R
K420E
Figure3B
Zuniga-Pflücker
Visvader
D–H
domain.1,2
6239–6247
mock-IRES-Kusabira-Orange
462/330
Δ8.91
0.98-1.13
transducting
G697C
turn-down
A722T
A047
HHML
AML1/MTG8
2202G
dehydrogenase15
BrdU-APC
and4F
Muerkoster
D22S301
20,500
ATCAATG
14–16
antigen-presenting
imbalance/loss
A/E-CDK2
Men1/F
NSP
Discrepancies
5′-TTCCAGCAGTCACTAGGC-3′
S432L
R131Q
Filtermat
self-tissues
.N540
Adenoma-carcinoma
R965H
atypia
Sudhl-1
OPSCC
OsteosarcomaOur
Jâ€
mamallian
2164
NM_011414
6.02b
BMH
p300-1667
mutant-type
O–GTP-O3
-Predominantly
RET
autopod
329-bp
no-discordant
18q11.2
.Newly
45-year-old
AML41
T3wt+T3/ABN11
Falcou
Mx-Cre
AGTCGGCATCGTTTATGGTC
C243
26.21
R-1B
CTTATGACTCAAGATGGGAG
skipping.12
AAGTGGAAGGAACCCCTCGA
western-blot
FTase
1.3–3.6
cellIa
alr33
missense-group
mutations.29-
hDIS3L2
months-34.7
PIK3A
TRKoncogenes
Nakada
4Aa
trasfection
lipotoxicity
k-1
PDGFRAex18
1.CDK10
rad3
.Composed
TMEM127
86662C7
Roskam
EoT
membrane-linked
malignancies5
TTF
A_51_P345649
*i
Q.
-4.1kb
BR00-0365
Fig.1c
11·4–187·7
4-hydroxy
1.1–4.7
DI3SI53
t=test
half-site.
20–77
Arg1775
DLC1-specific
G328R/G328W/G328E
pSUPERIOR.neo
Kahari
SMO-C469
.Sandal-gap
*363
fat1
Y780
.7,22
Gln711
20-nt
line-by-line
myc-antibody/protein
QIAexpressionist
FACSdiva
Gelatinase
pretranslational
FITC
LexA5
B*3540N
monomer-driven
gain-of-function/neomorph
LEF-1
A636V
availabilityaCGH
−.07
1,850
VH4-39
Fcalc
APOFTOTIC
TCS1
Oligoclonality
toa
formylcytosine
Bim-regulated
dramaticallydecreases
LATS1-myc
Atri
R171H
Amersham-Biosciences
,2C
IRAK1-
rapamycin-FRB
S.M.L
phorbol-ester-induced
Sox17fl/+
receptor-binding
AÊ
y.
NCI-N87
Seminested
Gz2-K-R-K-R-K-S
sc-365916
YAC-
T994I
-fusion
Base-pair
14-3-3-family
biotin-16-2'deoxy-uridine-5'-triphosphate
Py-5′-CACTCACGTTGGTTGTC-3′
1/76
5506
14:7773–7780
al.203
ionomycin
modification43,44
24,211
μm-pore-size
2.Protein
TIP60-mediated
R209A
down-regulation.46
caspase-3/7
313200
mBAT37
EWSR1–ETV1
R674H
25C
48.99
S34-associated
1/1,200
control-
winged-helix
nonsynonymous/synonymous
5′-TCTGAGTTAACAGATTCTGCCTC3-′
osteoclastogenesis.26
INI1-expressing
Bornstein
TKI–resistant
A25P
VP16-activating
.Fig.2C2C
Fig.9
arteriovenous
pcDNA3/
R226L
K939A
MG-B2GFPΔ1
113/187
BC-binding
Sezary
ApcΔ716and
pMSCV-ETV6-NTRK3
L-2-HGA
NSH2/PTP
.0208
activatedmemory
JAK2-cases
Y341A/KD
PDGFRI~
proteins.4
1/95
73.1–97.0
2XY
mismatchbinding
tel-jak2a
p.Q61L
pericytes—to
—were
Kim,3
functions41
.5–8
withIPI-504
diseaseand
Ala-119
Kolomietz
GTAAGCTTCCGCAGCGCAGGACAGTT
D835delF
instability-associated
nick-end
9e
P-site
‡Int
p.K546K
non-insulin
Guerrette
ARF
M/42
Δ235–270
haploinsuffiency
Bioarray
EKG
6th-8th
Wtsi/+mice
5′-TAGGCTTCATAGAGGATTTCC-3′
MnCl2-containing
AKT-mTOR
BTKKD
D2512H
E1A/RAS
P52
LSL-N-RasG12D/G12D
ErbB2-expressing
ETV6-NTRK3-transformed
RP11–52C8
P=0.0031
24,2
mTORC1-independent
E92
low-concentration
1,023
TCTT
NSCL/P-associated
allophyco-cyanin-conjugated
FDC-P1
BLIMP1-positive
SKRVAKRKL
Asp90
pro‐oncogenic
Oncology/Pathology
66.1–70
//woldlab.caltech.edu/rnaseq
CHIC2/BTL
81377
structures.4–6
Xq22-qter
22-78
OR=4.9
PD199
α-Ketoglutarate-dependent
TRC0000039714
1212
K507
carcinoma6–9
5mins
1-506
revertants
models.28
OriginPro
.Ages
neurofibrosarcoma
1–3.5
EGAPP
M297L
FGFR3-BAI1-associated
LiCl/
LeFranc
pMBl
Anti-pS111
PDGFRα-D842V
5-139.5
Reinjection
mini-BEAM
2q33–34
cells28
BamHI
Fatatis
hTERT—hereafter
transition.20
described.23,24
CD34/Flk2
0.001450265
40–47
postcompletion
50,51
doi:10.1038/sj.onc.1210704
centroblast-restricted
D280Y
CTGGACTCTGGAATCCTGG
61–110
4294
Epo-R
CUL3-BPM
4375
A1613G
1.683
R1-R2
Rb−/−
Gatza
A1948T
Sindrome
Borrello
Poorey
overlap10
.25,29
Wiltu-1
Ex20
HCC13-0212
3,225
R275W
TCGA-A6-6141-01
eightamino-acid
ileo-rectal
CD2/CD25
PKNOX1
LS+
p.Ser442Argfs*59
S518A
NRASQ61H
single-codon
1-9
Nanmoku19
Kusuhara
.Cross-validation
'at•GTP
Vitro—We
mutationassociated
.ZFHX3
V716M
R300X
study.2
stress-regulated
compartment-specific
pediatric-onset
inadequate.2,3
BRIP1
SH3D19
disease-linked
WGDs
15×10
6.17865
DAPI/pseudocolor
CYP7A1
HRP-labeled
Q23*
1QZJ
R177
S563
dasatinib/AZD
MST
GST-wild
broadinstitute.org/cancer/cga/indelocator
RAD51C-T287A
5B-F2
coronal…
Oligofectamine™
.Y71H
Serum-starved
gfeng
74.0
GM-130
ErbB4/EGFR
65.5721.8
G0262
pCDNA3-Cul1-HA
mutant7
DNA-contact
//dx.doi.org/10.1136/jmg.2007.056895
81202107
EM8
TFAP2CΔN220C430
Z9503098
Sf3b1+/
gefitinib.4
.Trametinib
c.1138T
Ligand-independent
water-filled
.Did
Identifcation
pleomorphic/anaplastic
diurnal
IGKV7-3
βTrCP1
mutation.2,42
c.1541A4G
4184del4
pre-organized
ESFT-like
D4344H
SK-HEP-l
published19
ROK
immunostains
1232–1712
RAC-GTPase/RAC
pThr-Gln
40–172
osteochondrodysplasia
V84L
medium-1640
–2.5
TFG-β
548KB
-212C
Fg/ml
6,25
damage—unlike
Delta3
UAS-trr-RNAi
,7H
/CBFB-MYH11.21,34
TheY-axis
pylori_
Discovery-Rate
manner.19
respectively.Effect
described10
.Sox17flox/+/Cdh5
11D4.1
.Effectively
2–13-fold
Hyp-binding
170,171
pBlueScript-derived
genetically-targeted
p.There
SKW3
HER2-L726F-expressing
Brieger
_FGFR3ex18-TACC3ex4_
HER21
lines.13,14,22
C8166
STAT-binding
CCATGAGCAGTGGTGACACTT
ATCTCTCTCAGTTTG-l-ATCTCTCAGTTTGAA
*6AK10
α-helical
D102N
PI3KiA/D
flexibility.51
Tgfbr1fl/fl
receptor,2-4
2201
137Cesium
diering
D17S1325
ΔH‡
Rubnitz
AVMa
1,323-bp
outsidethe
inhibition96
.Kotoula
bistable
thehMSH3
490nm
23.7-
*p
b2m-associated
collagenase
1.10∼1.36
.Wnt3
vemurafenib,11,14,21
WT-H3.3
K78I
Dlx5/6
Y220C-PK7242
Atm−/−
anti-T389
yAT-iGAL
tranforming
346A→C
Bottinger
Ubiquitin-Proteasome
FDR≤0.0005
∼2.8
IGL/CDK6
Rossella
non-cystic
full-exome
WIF-1
A72L
P-KIT
590-3856
.2.0
A2951T
p.S144I
C-terminus
FANCL-E340A
64.7
Phe143ValfsX12
cap-independent
Visco-Young
sites.26,39
NimbleGen
c1688C
origin.25
62434
P=0.9
568G
genotypes.Based
X-irradiation
Microplate
Kittur
14.41
B-treated
42.E358K
reported.13-20
PE-401-3001
GST-CrkL
33K
9360
co-immunoprecipated
DH5α
40×109/L
published3
bioluminescent
1,5,7
tumors31
10suggesting
F1734S
.MAP4K3
c.1508C
binding12,13,15,17
GCTGTTCAACGGTAGCCTTA
Trigiante
0.000532
.Same
cell/xenograft
15p.S476I
kinase/CDK8
reportedonly
Hedgehog-dependent
bilayer
Puisieux
conformations
protein-blotted
≥3rd
NF1-Noonan
3FIGURE
≈
FGF10-
WT1-null
Four-hours
activity139
Kaniskas
JetPRIME
RA53T
.6935T
leukemias,7,8
3cm
59-CATGGTCGGATCACAAAGAT-39/59-ATTATGAAAGTCACGGAAAC-39
1.713
cases24
Immunosuppression
E/I
786-V155A-expressing
MSD-L
forBCR-ABL.1
F-BCL-xLΔC
CACTATTCTGCCCCAGGAGA
YPH
Thierry.Soussi
inhibitor.43
K-rasG12D…
FGF1–FGF23
select-
RAD51CG773A
CD4−
5′-ACTGCCCATTGCCCAAACAC-3′
E405
XP-543464.1
EGFP-expression
hydrolysisdefect
mutation.Co-Occurrence
0.61^
DICER-deficient
TYK2WT
KRAS-driven
images.39
rad21
sGBMs
A1/A2
CLL.40
Myeloid/lymphoid
si-Rheb
1258–2225
placebo-controlled
282,291
myc-RUNX1
tissues.41
145K
analyte
ThePro-34
1-1201
.CRLF2
.IC.,0xF20W8/32IC
DUSP-10
2852
elsewhere.16
Mv1Lu
-1,4-dimethylpiperazine
LNA-mediated
SGC
CDCD581
MLL-GAS7
R132H/3DN
0.036*
c.812G
erlo
.1989
K239-100
chemotherapy5
domain.3
LNCaP-CSS3
800–1300
EURHAB
5′-GGAATATGGGACTACTTCGCG-3′
FOSL1
damage-modified
pombe4—and
0.51–1.60
Homer–Wright
D25N
16,33,34
metastatic—
N-Tcf4-negative
Ligon6,13,30
AML.Figure
MGdotTG
c.2140A
p.Val617Phe-negative
29.2
Cdk2/cyclin
HER‐3
anti-epidermal
G-CIMP-positive
.Membrane-induced
R2015M
H214Y
6/28/04
0.6mm
Intersectin
20,24
patients.49
BASC
MUM1+/SOX11–
—a
0.00088
12–71
www.ncbi.nih.gov/index.html
Glu-874
Phe-6
150+120
transposition
transactivationand
rcy
Q207D-overexpressing
P110αΔ/Δ
nnnol/L
−2.21
A/c.8755-1G
antihistamines
p53–MDM2–ARF
ALL-10
IRES-YFP
`hot
R208C
MEK/c-Raf
IVS5-l
936-3524
WT-Cbl
Microinjection
ncicgap
Semin
ficoll
.529dupC
TLR421
373XL
lowaffinity
MXD
Smad2CΔ207-259
C223
discohesive
LS6500
hexa-
5,7,9,12
inductionof
9/3
JH1
.Mammalian-Two-Hybrid
G4924
S1808N
VH-64
three-fourths
06h3
hTMNM-1
TNFRSF9
hormonereleasing
anti-4E-BP1
mechanisms91
angiosarcomatous
CGACCCACAGAAATGAAAAGGCAGCAAACT
10/86
CTGGAAGTGGGTGACTTAGAGG
events7,8,9,10,11,12,13,14
powersc
292–329
Meijering
-methionine-labelled
Time-of-Flight
mimietics
.Xia
construct9
0.15–0.90
3=exon
tissue-specificity
STAT3/STAT5B-mutant
32P-4E-BP1
Glu69Gly
​Shown
C656
32-16-347218
1K8R
PCM28/2+
119P5
.Ki
.ALK-activating
R423P
p=1.99e–7
56.65
differentiated/Gleason
.E2419
nggenomic
43/285
anti–CD3-FITC
solid-phase
INl
Y589F
Â¿IMeach
A455S
predictivefor
3•0
1840A
.Splice
NR24
curated
5348delAA
S240R
PCR-direct
.Filters
Idh1WT/WTLysMCre+/WT
C265R
HMSH3
229K
8337
HPV-negative
2-PN
type^
Saraswati
3QTI
-Ps
below/equal
1.4–160.0
Taufkirchen
kinase-basal
EF583852
Smad2dex2
spe-
p.G13V
B-Cell
H3K4me3/H3K27me3
.CD55
U2932
5510545
P28L
Met118
Horikoshi
12-kb
BRAFG596R
ATRX-deficient
MTC-TT
f/80
miR-19
SAβ-gal
mellitus26
cancerGastric
K253A
MYC-directed
N-MYC
subgroup.14
29·9–80·2
R422Q
EndoFree
5′-AGCACTGTGTTGGCGTACAG-3′
PGDx
impaired.Binding
L326P
PTPRD-regulated
immunocytochemistry
.Amplified
membrance
FK-mutations
NF-κ
Baldinger
calcium-phosphate
PrimeSTAR
.Arm-level
7,8,9,10
X-receptor
pKo-c-myc
Hnfa1-6
11q12-14
SW480.7
pcDNAWT1−/−
RP11-665O2
KNCKKRR
S167
3329A
36,293
death-resistant
45Comparison
FOXO3A
hyperactivation-driven
.Excellent
OXY-containing
postcastration
proliferator–activated
0•76
14/8514
fn2m
Myofibromatosis
18/68
Y-L
mice,20
2514
Smad3/Smad4-mediated
DNMT3A-introduced
high-grade
Thr19Asn
Perdew
553986
L836Ca
BDCA
gradient-recalled
1.75–11.4
Funseq
p.W290C
ACT-3′
positions—Arg5
caspase-3
PIK-E9F
Ariad
binding=1
MAP2K2
Oestrogen-receptor-positive
915+93
0/212
cells.46
CommentsIntegrated
Minigeshi
eachparental
8/70
MGT
Heisterkamp
in-frame/single
TRiC/CCT-mediated
TBS-T.
CREB-regulated
.Rheb-WT
1/6‐99‐006
pRev-TRE
Aguilar-Salinas
Saos/U2OS
progression,8,9
RPGN
described.9–11Fluorescence
8006
.Catalogued
1.5–12-fold
Lfng
cytokine-directed
CVCL
110K
Anti-α-tubulin
cells.B
SALL4
1.867
+/fx
98.4∗
10.4:1
TSC2-WT
phospho-286
MAML2
Roche-Boehringer
s.e.m.
Bnp
CRL3-MEL26-dependent
studies11
AATAA
AML-lym
AAV-mediated
round-shaped
p.Y71H
black-red
TTAAACTTAAGCTTGGTACCATGGAGAGCAAGGTGC
anti-receptor
TEAD-mediated
aKpnI/XbaI
0.82–0.91
Altered-length
1.61
.S4C
VHL-CCT
rulai.cshl.edu
0.0068
GGGATGGAGAGTGGAGGATT
K4500
chemosensitization
thecalcium
PF4
1-43
Aguda
specimens—Heidelberg
CREB3
.ANS
~100
Notides
CEL-files
skin-invasive
Akf
24/124
physicochemical
hyperganglionosis
tumors39
5months
46,47,48,49,50
active/phosphorylated
0.445–1.526
'research
532
D993
-y1
1420
photomultiplier
TGCAGATTGACTCTG
Microattribution
C3H10T1
sets/19
Consed17
b2m-Me18105
171-
27:602–613
U20S
G105D
CL0.0
GIST.13,16
L1679P
cancer101
JAM2
Arg-107
Cbl-PTB
M572
silver-staining
p16q24
TIS
functions11–13
D842V-PDGFRA-Ba/F3
Arg767
effects.4
Gap2
lower-sized
nonDLBCL
EPOR-specific
D5358G
progressing/relapsed
leukaemia22
BRCA1/exon20
p-MEK1
pathogenesis1
phosphoprotein-binding
grb2
HRAS-specific
T/N
.R162*
F4-R4
70·0
R768W
25.
ga/80-538
survial
G4654T
methodsCell
D1029Y
P07333
ill-understood
reverse-ACAGAAAGCCCTGTAGAGCATCCA
CMPD-associated
SOCS1-dependent
RET-directed
S3020
non-homogenous
Biniou
aspartic-acid
I563A
R2659T
.PCR-generated
discontinuities
1OX
K351Ter
g37228af
HA1E-M
theV597A
conBiotechnology
JUN-NH2
-γ1
11-base
glutamate-gated
FANCD2.The
FL-triggered
dysregulated
gp95WrI
Rex
Hammoudeh
CCGCCTCAGCCACCTAC
PLD1-selective
HER3/ErbB3
666-1013
k+1wt
S.A.
tumors.1,10,11
.Spectrum
59-GAAATGCTGTTAGTT-39
H1–H3
p.Glu284X
B.S
NP_005391
4,405
CDH13
M837G/S838R/
508–517
PINK1
signal‑
t-SNE
df=56.3
S6A–B
Crebbp+/−
therapy5
stages.29
Braekeleer
P3k
mice.Lower
instabilityBub1BubR1
P2g
G198D
EED-EZH2
Rad51-dependent
compound-bound
pSC
Friedrichsen
aCGH-Smooth
c-kit/CD117
1,935
15-2
Puc
virus,2–4
.CDK5RAP2
TopoIIα-deficient
equilibrating
LIS1
glutamic-acid
LVSd
5412
Fig.7D,7D
—two
G74V
c.2007−4g
Kakinuma
Y583/Y585
accepled
TGACT
D61A
∼8-fold
GST-vector
22-yr-old
5′-ggcctggcttttgggttagg-3′
activity15
3.25
LC-MS.
8/181
interommatidial
SNU738_CENTRAL
Godleski
EGTA-containing
coincubation
Novagen
melanomas.7
SCS-containing
features.Figure
hr10-D
94-HG-0193
c.1332G
RRSO
.Phosphopeptide
Dou
CAF-1p150
Less-cropped
U73122
types.10,11
TCCTTTACTTACACCTC
Emmergence
interleukin-7–dependent
XL-880.15
N-SVGpSKRRR-C
pdgfr
WMM1175
only.15
133.33
retrotranspositional
500-530
Cohort―Response
altered.31
14-14
DH5a
.CV-1
VU
anti-CD3
Wps/Wps
serum/Dulbecco
C0543
Bruges
repair–deficient
microscopy/spectroscopy/flow
1.06–2.58
mistmatch
EGFR–Stat-3
Quiaquick
TPCK
55·5
PKC-B
TAK-632
p.Q699H/p.K700E
5′-CTCTATTGTTGGATCATATTCGTC-3′
p.Tyr480*
59-GACTCTCAAGCTGTTGAGAC-39
NovoCraft
RET-Men2A
homologs.We
185–260
Kötting
I.CJPMFNT
.BRAF-mutant
one-base
0.374–0.909
H617D
elegans31
Species-Related
GST–cMyc
.Delitto
E2A-mediated
0.1.200808
11-heavy
data.Effects
phospho-ERBB3
7.1
5464
p.Anti-ERK1
morial
L74P
p.P49Q
1.99
scissor
Hoeven
co-target
MLN8237
J.S.Seo
Li-Fraumeni–like
.Sequence-verifi
XPE
G65V
hypercontractility
F€orster
M.Eilers
FANCP
1099K
.RNAseq
models.13,14
Bcl2l11
Lavallée
.9870
untreatedFBS
MAC1+Ly6G–Ly6C+
-UUGCUGCUGCUG-3
1F–1H
Patgiri
UA
E2-saturated
.Type
PALIBN
fine-mapped
5′-ACGCAAACACTTCCCTAGCT-3′
RET-inhibitors
NB2885T
TG+
TRIM29
Subpopulation
bright-field
XP_420447
anti-matrix
cotransformants
Ile654Val
Cell-Autonomously
Brca11700T
5′-ggatcctaatacgactcactatagggagaccaccatgatgtttgatcacaatgg-3′
8q12.1
13q
ZHFX3
fibril-like
toxicity.functional
Procaspase-8
monoubiquinated
1.768
Q185
rs1037364
K104Q
PCR/MS-based
Kitsiou-Tzeli
SDS/Tris-EDTA
gab1
lines34
BCR–ABL1
re-plating
T9
+21
ACTH-secreting
Preferential
C5024T
.Cho
T85I
kinase2
IL-3-dependent
5q31–33
39.37
1853insA
F615S
Lae¨nnec
3381–3385
c.199G4C
pharmacokinetics
A3854
Patients*
.PP6-H114Y
genes3,4
nonhydrogen
Bentires-Alj
49/85
.Greulich
14,147
c.68_69del
Merlet
CATTACCACCTATCCGCCCTATG
HM
xypyrrolidin
F788C
T-p53-G245S
Schymkowitz
ΣiΣi|Ii
Basic-domain
.Chromas
infraumbilical
blasts.34
0.17b=0.11
tri-nucleotide
Codeletion
06030-3101
//www.umd.be/VHL/W_VHL
5′-CATGTACGTTGCTATCCAGGC-3′
GBC-SD
MetaXPress
Uhrbom
Ser269X
,5H5H
c.378delT
High-income
MgCU
Myeroff
p=0.02
`L
.476
Kapeller
Kourmouli
ALKBH3
Mx-1+
cytapheresis
Barbosa-Tessmann
ALK-binding
monitoring.3
sixty-seven
Rheb-60K
Horiba
9.41E05
TSC-like
c.16C
.Hereditary
andSCS
D673N
.Ile1171
Riken
.265
5-bromo-4-chloro-3-indolyl
Israel-Deaconess
12-O-tetradecanoylphorbol-13-acetate
H+E
disease62–64
isopropyl-1-thio-b-D-galactopyranoside
Notch/CSL
Pwt
repeat-luciferase
accumulation99100101110143171192214222203Codon
assay.51
Q267E
0.0008
Down's-syndrome-crucial
6,343:16,116
3A
H2AK119.18,20
S113L
nE6
LC3-I
DNA-replication
.Metastasis
PD1/B7‐H1
.Fig.33A
.MAMLD1
overexpression.11
3.69–3.4
EWSR1-FLI1–modulated
DDB1–2
ÃŸ2-MG
analysis37
prechondrogenic
.Am80
CXCL12-CXCR4
MMP-3
CD74–ROS1-rearranged
levantinib
DDDDK
MM34
gpllOProtot-rk
6885insT
23,31,32
progeny.24
Myc-Max-Mediated
pRSVNeo
14.G334W
AffiniPure
R297C
Kong/PRC
SHP2-E76K
1.20–7.85
β3
mutations—one
Bdnf
44.1-175.5x
45.6
Erlotinib3
analysisDescriptive
RETV804M/E805K-transformed
'BH
c.588
17q12-2l
c.736G→C
p63/p73.52
Cell-Adhesion
BRCA1–Met-48
e.g.R100T
siPLK1
cRPMI
prognosis.58–61
0.9814
puro-K-Ras
CSL-HA
LFT
Hep3B-G245D
anti–Grb-2
anti-HIF1α
non-causative
phosphotransferase
coxae
24a
S21/9
Rap1a
RING-deficient
KD-wt
.FGF8a
T798I–expressing
H179L
neomycin-resistant
RBD-binding
inter–Src
tated
12q23
anisotropically
Mann-Whitney
Thr74
receptor15,16
5′-CTCCCTGCAGCTGTTCCTGT-3′
GRIN2B
Fluroskan
low-level-transcribed
Plink
12.6-
alone13,14
610621
Arg1012
207-nm
trichostatin-A
cytoplasmn.s.Nucleus
E445/K430
MDA69637
FGF-R1
spleen–derived
29234
CFU-Meg
fusion.However
siRNA-depleted
1101
30/145
.3d
linear-trend
–NRAS
3-238
SOS1
samples/class
mality
STAT1/CXCL9–10
supra-
7776
pDsRed2-N1
4J
spQ24742
11Val555
p50-2Luc
R113S
c.264-6C
NcoI/SalI
Kreisler
CRC477
wellestablished
late-developing
*-
SoftWorx
5′-GCGACAGAGCGAGATTCTG-3′
Cxcr4
wild-type.12
in-tandem
A395D
EIEKSSRPTDILRRNSCATRSLSMLAR
HTLF
HLA-I
T798M
subtype-specific
.405
MNNG-induced
Kraulis
effector-recognition
I443V
Phospho-Dependent
N1651S
6-bladed
Silvennoinen
B.9
_q_
59Rabaptin
mmll4
5′-CCCAAATCTGCTATGCAACACTGTCCATTC-3′
S8′
TCR-transgenic
ranucleotide
ISC
1.42-12.6
Lourmat
kcal/mol.EGFR
Elk-1-mediated
NF-κB–inducing
4058
1.52-fold
Thorac
GST-TCF4
p-Erk1/2
.Jain
261.3OLFML2AOlfactomedin-like
ERG-
activities6
SMCX
one‐way
pSP73
anti-anillin
MAPKphosphorylation
CTCAGGTTCCGAGCCTAACAG
ErbB-2genetic
multichambered
single-nucleus
19–35
HOX
GGAACCUGUCUCCACAAAG-dTdT
Phe771
midline-associated
5–43
Rougier
.Side
Spreadex
221±95.3
prurigo-like
0.404bWBC
P496L
and13
KM-H2
Rhone–Alpes
XbaIFO-I
Ser108Stop
ZNF198/FGFR1
sporadicbreast
methylated
ChIPseek24
R168G
residence-matched
Diccianni
SKNDZ
Eμ
1696
melanoma1
exon3/4
WHV
0.006aCD1
PI-3
divisible
S34F/WT
GAACCT
D20S894
K505E.lh
UV-light
report.2
anti-LexA
21.6/24.2
Ala-1617
EGFR21R3
water-treated
Ch157f
ErbB2-Y877
II-III-IV
PROX1
anti-PDGFR-α
countries.3
1.52
MURUGAN1
HL71207
4750923
dual-pass
MMG1
FANCD2
I145M
103/μL
Cys135Arg
Bateup
2000–2007
PowerGene
L62M
1017
FL-393-G
oligopyrimidine
RKIP_M_F
intermediaries
S1G-K
J.K.V
1.3/0.7
100-ml
HMMer
genes24,25
W/O
c-H-Ras
1760
MAP3K8
HPC4-tags
SPDBV_4.10_PC
p16L/L
prognosis.2
9.4-11.3
carbamoyl
standa
F958-
.Even
15.0–2.7
Glu643
.Natl
factors.61
MF12,13,14
1820•
NFAT
tuftelin-interacting
29,067
KRAS/PIK3CA
pRSETb-p53
TCF
.M322T
D230N
BRAF–RAS
mutation—as
.INI1
oncogenes.1
Metabion
GST-Cdc25C
c.5894insCA
.RT–PCR
and6D
APC-labeled
2p22.2
postcoital
in.22
GISTs.KIT
2175
Nikaido
PHRED
rs3222244
KITD816N/H
development19–21
PI3K-Akt-ribosomal
CCAGCATGCATCCAGACTGGCTTCTACTAACTCCTTTACC3
exosome-mediated
Ink4a-encoding
SNU-colorectal
07/2001
anti-GSK-3β
Npm1
.Germ
lymphoma–derived
D842V-PDGFRA-associated
E711–T712
hyperIgE
andf
89-week-old
r=0.13
.Pik3ca
G270
100–115
356O9
G551S
Durocher
aminoalkylamino
CFP
IHC-positive
6.15
.Zymed
-4
K-Ras4B
discovery7–10
anti-pSmad1
38–119
blot­
Nox1–5
.L755S
P=0.186
Gln19
Rigaku
proteins.11–13
contraction/expansion
2TEV829
II-4
2108
23–84
defects.24
immmunoblotted
pocket20
6..
TESK2
transformationfrom
Effectene.Mutagenesis
∼154
30°C.Construction
138ins
WAF
post-screening
Dok
β-catenin173
promotility
NFG
.Ile-Gln-Leu-Ile-Gln-A~-His-Phe-Val-A~-Gii
NF1P1323L
250–640
Gln184Stop
C/EBP-δ
CDK4/Cyclin
:44
functions.17–21
ARHGAP24
10/7/98
Hif2
anti-FGF19
CACTAGGCGCTCACTGTTCT
Whole-Genome
re-organization
hnRNPA1
anti-gene
shCntrl
Nedd-8
Δ
knocked-out
Q~IA
promoter–activator-specific
.Unstimulated
Akeo
Rat-2–stable
confi-
75×35
0.021C
-F
Missense/truncating
5p13.2-p12
S729C
~39
insightful
Molenaar16
T1010I
ImmunohistochemistryDeparaffinization
K658insY
4.Increased
target-of-rapamycin
.Fig.3B,3B
scores51
form2
gene6
ApCEV29
Men1l/l
G-R-K-K-R-R-Q-v-E-R-A-P
p.S1286T
998-1057
differentiation,1,3,5
E11.5
5′-ACCGCCATGTCGAAACCTC-3′
Counterstained
low-intermediate
Cancer-associated
outcome25
cells.42-48
HA-tagged
Neuroectodermal
GSK-3β
OMap
p.P364A
A35
Petti
266–334
K634R
E4–0.5
MRK
B-Raf-expressing
.Talin
JB10114
5′-GTCGACATTTCCCGTAAATC-3′
−3.86
p.T387A
cell-impermeant
antrum-localized
synoviocytes
pETHis6ERK2
pN3
5277+78G
RP11-95I21
ETV2
.BROCA
mice6
/StrepII-cyclin
membrane–cytoskeleton-associated
TCCACGAAGACGACCAGAAT
1b.19
Gadgeel
Iannis
anti-oestrogen-resistant
62–198
EGFR-
.GlaB-treated
43–76
Autschbach
14d–h
5,000-fold
TGFβRII
EFNA1
U*
208′–214′
cGKI
L1196M,37–39
ETS-DBD
pre-menopausal
NM_177603
PDGFRα−/K
detected—amplification
DDBJ/EMBL/GenBank
5′-TTGGGAGCCTATTTGTTCATC
Asc1
Histiocytoses
//www.biodiscovery.com/software/nexus-copy-number/
A_51_P452629
M/47
CED-4
.Heteroduplex
tubulocystic
EGFRvV
G367A
gatekeeper-mutated
chimaeric
pGAL4B
R2169H
0.625
7.5–9
PCR-enriched
555K
transcription.1
GCTTAAAGGATCACACCATCCTTGC
days.40
PTATA-CAT
PI3KH1047R
HACL–RAF1
p.I427M
Ink4a/
.Identified
mucins.47
56.6
Yassaee
p.A636P
9308
17-92
.Soft-agar
b-cell
Yokogawa
't
Notch/Hes1
GA/GG
∼6
−8.47
HCC/Del
RG-27T
Location-specific
p.Val2985
Fig.3D
Geldanamycin
GNAQ/GNA11
Table2,2
TCGGTTGGAGATATCAGAGTGCAG
5547G
.Problems
intraperitoneal
Koetz
P62942
EDITORTM
5538
TCF7L14
A694E
fluorodeoxyuridine
872-
repeats41
vitro.18,21
Telencephalic
Asxl1-deficient
68–108
.476G4A
IVS25+3A→T
Desmoid‐type
C76Y
S64
Ala-213
re-emphasized
20q13.2–q13.3
5A–5D
cyclinA/Cdk2
5'-ACTTACCAGATTACATTATA-3
G–Sepharose
Rad50SK22M
Pg-stimulated
Bcl-X
V/A
Label-free
193K
M.Z.
Grinsberg
0.875
∼51-kDa
othercase
UVA–induced
77-year
n=610
L474S
RET/V804L
ectoloops
†21
acidarmanus
Clapperton1,3
syndromes.1,2,4
10–14
WEHI3B-conditioned
–competitive
c.350C
hKMT2D-Reverse
NPM-ALK-
C261F
28–78
science.sciencemag.org
P525A
++++++++++++
.Runx1-
PTEN8
non-negative
Non-conservative
mismatchspecificity
Thr90
aging-specific
,142
AA209914
MutS
GDC-0449–resistant
T.A
Tudor
pflag-Smad3R373H
Hygros
-GTCCAGATCTG
gpllOPr'ot-ork
Q144X
YEAMEQTWRLDPE
Jak2-WT
P53overexpression
PQS-rich
Mutantmsh2
cells70
.Apoptotic
worldwide.On
2900-bp
R2/C382R
DNAJB1-PRKACA
//www.iarc.fr/p53/polymorphisms
members1
P.I706T
manually/automatically
DNAsequence
pro-oncogenic
glycin
Tolypocladium
40,49
parapharyngeal
p-nitroanilide
Sex/age
mg/day.49
non-Axin
non-CD44+CD24−/low
T196fsdelCCAAa
P†
PDGFRA/PDGFRB
C-RAF73
348–361
HCF1-Not-R
.Digestions
α-Rip
26/230
P7
−20°C
function-2
peptides.50
.651
.Noi
7264
nihms646437t1
problematical
microM.High
Sox17flox
Br/Ov
c.517G
.AP-1
ERα-WT
delE709
Bjorge
5382insC
284K
.Smaller
GJM
Epub
ciiib
98-kDa
radio-labeled
Lys4
polyI-polyC
Gln767
.Disordered
software.32
Q479E
MCM6
A16T
MTS1-L1
.Accepted
Shime
Q475H
AKI
q25.3
78/M
5′-TTG
Y-LW
pathway94
90-bp
IV:2
/emission
Cytologically
157–188
HSB-
Acvr1Q207D
O095
0.286*
al.69
CD19+CD27+
15months
GISTsa
cently
LNCaP104-S.
671
activation27
expected17
tmor
Raf‐1
Cambridgeshire
RCSD1
9p22-p23
ERK2D321N
A21049
K4Fe
-methanone
25/67
SK-Mel-28
stromadependent
5-like
3–kinase-like
Bax-mediated
tet-regulated
A1708EF
pS9
exclusionary
Maehema
4Vanderbilt
Met-associated
ER/EB
GSEA19
.Importance
CG-rich
14060-2
5′-deleted
Temozolomide
T237R
1231
fold*
embryonic/fetal
7q21–q22
V171M
1tsr
SVZ-OPCs
48nM
18-year-old
hyper-activity
Â°55
calipcr
DNA119
dispersive
determined/not
V.01
beta-catenin–mediated
∼5–10
P124L
.4-6,8,9,57-62
MluI
activity23
H3122-derived
ggctccttcccagcctgggcatc
hmsh6
PDGFRB-2
Hokland
550–586
Anti-VEGF
YBR040W
G521R
Mini-Protean
11/107
breaks36
p=0.79
X/Y
0.595
4,917
.LEF-1
171del
-qPCR
0.9793
Montluçon
36–83
2bp
MAFB
Celdyne
mTORC2-dependent
Ni2+-NTA-bound
cancer.14,15
.Repressive
Brca1fl/5382stop
BARD1.A
Spo
D1-luciferase
.Prior
α-N-INI1
expression,38
K89R
EPD19
determination2
mutagen
TEL.33
5′-CAATCAGCCCAGATGGACGTGAATATATTTATGTGG-3′
nickel-resin
~47
S8a
Syndrome17
R243H
T581
AGK–BRAF19
pcxn2
vdw
HC11-NeuT
coli18
aurora-kinase
Table6
isocitrate-binding
Rho–Rho
276/484
RO-induced
5′-atctccagggactgaatctagggc-3′
transformation124
Â°Â¿Â°^Â°i
OVCAR-5
holo-EGFR
A153V
52*
CHRF-288-11
.cloning
PHD-like
co-in
5305–13
.Rat2
Gallie
AGGGTCCCCAGGCCTCTGAT
Affymetrix-GE
shown.•=
39–48
HNF4α-negative
BTKC481S
ofTGFb-RII
HME
population-matched
24:885
15.5–30
.K562
75–90th
Nucleofection
nevic
Ser116
Cxcl1
004333.4
SRP015003
Mg2+-
Lwoff
pBL3
GACC
−10.6
mCRC.9,35,36
phycoerythrin-conjugated
p.Glu276Asp
10-9
15407
31–84
type-I
Inter-WW
HCC06
anti-pYAP1
Kit-1
GBC-normal
M1199
C220
pRL-CMV
PC-PTC1
26-kd
50,60,61
Brca1fl
570±29
cancer-susceptibility
RAF/RAS
A1347V
66-year-old
CD21/CD23
PDGFRA-Rc
andinfluence
8071C
9q33
arachnodactyly
expressionsof
c-nyc
p.Arg133
NAF1-RNP
W674stop
T303M
ECL/autoradiography
GDP-dissociation
.Merlin-Mediated
GISTIC-identified
ERK1/2-regulating
Y235C
well-monitored
tetramers.15
403–463
YPH-p21
600375
Arg34
Met/
liver-specific
c.1600C
Sox-TCF
JAK2,7–13
FLT3ITD-WTNPM1MUT
.R262
PtenL/L
cell.1
133520
Tumorsa
ACCTCG
382–659
TSC2GAP-Mediated
50-3a
performed.Cell-cycle
*Mean
V889M
FLAG-Elf3Δ235
d887–d912
FLAG-SMAD4
Broudy
tissues+
19,22
22A
Tle
Y709
p.Asn45Ser
g395a
5′-GCAGAAAGGACTTGATAAGCTTCCTAGAGGATGGGGTCACGATG-3′
phospho/total
multiforme
.KMT2D
ofamino
differentiative
173g
4I0
Antiproliferative
BRCA1/IVS6
pLX
Thyroid
IgG1-Pe-Cy5.5
Gata3-lacZ
P448L
FGFR3-IIIb
DNMTL
tA5
ovaire
.BAX
Sel-10
0.7868
NPM1-mutated
Dsh
regulation.9
β-selection
5.247
5′-ATAGGAGATAAAGAACAAAGAGCTGCTTTTG
630×
Tnf
inTris-ethylenediamine
.Orthologs
ITGA6
31-20-4448293
Gab1-immunoprecipitates
slide-scanning
BCOR-expressing
Y15
1.7–1.6
70-μm
1∶2,000
176807
MM45
glassbeads
ch11:47.1-47.3
RP11-248I17
p53-773
Zn-fingers
p.N171A
.I.as
260KB
244,400
A375PF11
indelible
Y806E
3350
PCA1
32P-99-mer
ÃŸ-catenin-Tcf
discoveredin
oc-
AndreuttiZaugg
S7–S9
.Blockage
FA/BRCA
leukemia.29Blood
54-58
T6074
Rougeon
A72IT
WT-FBXW7
R547K
analogue-peptide
anti-Akt
ECG
QLQ
MUS81
1776
ESCC146
Figure1A1A
Ikediobi
E40N
-V567es
3-9
E2-occupied
P42S
5I0
3/82-2/83
.Extrapolating
DNAsextracted
respectivelyFull
1.03–1.21
IP-
Sk-Mel-2
seven-week-old
P-value=0.001211
HER2+
Hsp70-interacting
by*
Jeck
flies.31
4/32
mTOR-FLAG
4719
Ser188
QM
intraclonal
PROTO-ONCOGENE
processing/splicing
targeted-agent–naive
RepeatMaskerFilter
anti-EGF
34.13
antisensetreated
17/24=
5mC/5hmC
www.few.vu.nl
K666
29.4
fate23
GST-RalGDS-RBD
STAT-specific
v2.3.9
proliferation76
hemagluttin
Akt1/2
D1865N
T2643R
andinserted
PhoSTOP
DFG-out
toperfectly
v-Ras5
M/F=1.2
4-OHT–treated
ERβ
straddle
RAF/mitogen-activated
04880594
R995
Ile24
al.180
Y44C
~3.5-fold
RP11-103F10
.RAF1
-1H-pyrrol-2-yl
raÃ-p21
173KB
EN-EpH4
G843D
200–500
64-fold
.34G
-2
Morpholinos
Arg628Stop
.RT-PCR
activationinduced
phospho-Akt1
.9098A
71.66
ADM
indrance
ttcagaagcttctccctgacat
SIE-reporter
75.3
5′-CTTCGCTTGGGCTTAGCGGCGGCCGCGTTCTGTCCGTTCAT-3′
paraformaldehyde-frozen
lymph-
Glu-dO/Lys-
nucleoporin
high−magnification
664–1014
p.A678V
42–82
Boggon
pEntry
GCCTGGAGCTAATCAGAATGC
Ba/F3-Epo
JHDM
γRα
adrenalectomies
14,24
deterioration
1b/2
\x\
hyperplastic/adenomatous
MZ1580
IFN-ytreatedB
groupedaccording
9-72
square_
disentangling
907
GAGCTG
oncopanel
Luoh
c.1447A
K459
.Non-specific
development.28
.Flag-Sox9
subnuclei
2439G
lane10
miR-30d-3p
data.Examination
CD8
553043
Aladjem
HNF4α15
S125X
damage-independent
RAF-KSR
NCT01196390
AlfIII
A107
CD99-negative
Bazedoxifene
CMV-based
ultra-spectral-microscope
.BCC
.0036
PTEN−/−
Bacher
IV-3
5.4-fold
hTERT/5q
triturated
neurogenin
Roderik
phic
life.1
phosphatase,26
L2026M/K2003I
cycle.4
D-6429
pcDNA-Cond-ΔDIX
F3T3-KD
7.20
n=119
EML4-ALK-translocated
Notch-driven
IGF1R/ERBB2
43·3
Spt6p
25-bed
Q209X
pMSCV2.1
EHE9
29231
HR=2.79
KLH-coupled
ableto
NUP98−5F
3222
OP40
3292
13.74
ZNF750
Jose¤
K386
analy
provider/genetics
\80
amplificationis
rs121913431
stat1
.Pull-down
6–1442
hormone/insulin-like
BRD-encoded
vehicle-only
D333G
376G
Rag2−/−
AGPC
Mann-Witney
TGF,3R11
.37
1.339
.Peptides
.Corless
duplication25
figure4
non-tumor-containing
vivo.50-52
//www.cephb.fr/cephdb/
mutSKA622mutation
5.326
Taylor4
1–70
transgene-encoded
38.60
immune/inflammatory
pMyc-p110α
.Pentapeptide
chr7:116,411,300-116,415,300
.Profound
AGAP
NCT00660816
Exo1
Precastrated
iodobead
terminus-truncated
overexpression
L730Fa
C1000
E81G-mutated
RT–PCR
H-HCA
electrophoresis21
Mollinari
non-amplified
~hedicine
RP1–80K22
Put3
F2-R8
E2221K
etiology.3
5-P2
TβR-I
Neurog1
0.27–2.41
protein.15
CLL-mutant
Flt31
Type-B2/3
.PAK1
SSRP1-ChIP
HER2signaling
S299
6-day
2822
.PPARγ1-P
BCIP
Gencode17
Shavlik
dUTP
Ser229
Glutamax/1
O/mumps
demethyation
CREM
shNF1b
27-year-old
ALK-targeting
2.6-kb
04906837001
q=0.2
GCTACTACAGTG
previously20
GxGK
7.4/150
algorithm13
7.25-11.15
p27T187-198A
pre-incubation
AGA-3′
PLC-d1
Q824E
.Inflammation
E18.5–/–
BRM/BRG1
9386
Ki-67/Mib-1
5′-TTGGTATGCGTCTCAACTTC-3′
CBX4-ubH2A
ischemia/FO
CEP250/CNAP1.25
tRNAPhe
progression.1
response/repair
deoxycytosines
anti-β-galactosidase
SNF-BRG1
No.andReported
intensity—can
R170H
phosphatidic
BPG
mug/l
130×
lipotoxicity-related
anti-phospho-MEK1
55.42
RP11-165B4
NUAK2
SectionDiscussionOne
Jijoye
piecewise
α-glucosidase
hCDC4/FBW7
r.l
cosegregation-based
WAF-1
posttranslationally
≤5
E663del
rab5
chain-specific
cyclin-E-associated
:lacZ
F4/80+
HN_62699
M788V
24A
anti-PHF20
SNVs.Generation
expression-subtype
proliferationThe
aurora-
M2-Flag
Garraway
co-staining
.49G
Phe795
.Batch
15.38±3.16
//www.ncbi.nlm.nih.gov
TRIpure
haploinsufficiency.4
5B–C
Na251CrO4
5'-CTATTATACATGCAACACTGAAC-3
sinopulmonary
Shigetsugu
-luciferase
32D-FLT3
I04-I
p.P470S
T389I
Gly-328
CD34+CD10−CD19−
Bjorkman
0.047530595
D1246H/N
OD600
ERK2-substrate
amember
0.22–1.34
mid-face
NF00358R1
GG4AA
V+/DAPI−
−54G
Peppel
Fanc/Brca-deficient
5′-GACAAAATGCTCAAGGAAGAGG-3′
InhibitorsHaving
iPIK3CAH1047R
7q21.11
B220lowMac1low
1OL6
pathology-diagnosed
JAK2s
1.2-kilobase-pair
0.6:1
12.1.4
L626V
Ltk−/−
deamination/DNA
random-priming
.EGFR-L858R
cytokine/serum-free
KIT-D816
11α-cortisol
doi:10.1006/mgme.2000.3109
5′-GCTACTATGCTGAACGGTGC-3′
.9C
5′-ATGTCAAACGTGAGAGTGTCTAAC-3′
−809
Erdogan
mel-BRAFV600E
MYO18A-FGFR1
activation.51
Hs00179843_m1
locus24
types45–50
BsaBI
OCT4-2A-EGFP-PGK-puro
unphysiological
megabases.21
Saint-Aubin
11.Analysis
stroma-poor
198A
alkali-denatured
clone.16
anti-X-press
MULTALIN
PolyFect
D561G
A750P-EGFR/
GSE56449
v−1
Totaln
S5F–G
corpuscular
Mad-1
Leu505
._Mol
Abankwa
volasertib
36.3
VIL2/ezrin
anti-HER3-blocking
anneal
6q22–
P.D855V
cancer.17,18
F57C/S222A+S226A
439Mean
multible
107–110
substrate-containing
MCG10
Dietmaier
RNA-expression
tor
extremeties
179delGTGAinsT
G244D
SRBC-immunized
III-6
Pt6
302–310
40–49
SK-MG-17
717-722
EDTA
1065–1860
Co39
1X5
ML309
7.13×10−4
correlatations
MNNG-resistant
Sma
detectKIT
cll
=35
moderate*
centrocyte-rich
anti-SPA-1
.FLI-1
incontrovertible
outcome—namely
Vafa
recombination–deficient
EML4–ALKG1269S
Methionine
71187
RP11–316L14
Smarca2
RAD7
8.3–19.5
Pan-AML
tet-operators
p.I300_Q302del
W480
-pCRAFS338
92.5
pVHL160
CACNA1G
L122fs*4
R1004A
RNAse-III
2List
TableTable11
imidazo-
malignancy.80,90,94,96,97
Optimax
-146b
E.M.V.A.
LTM
.Pulmonic
RIP-TRKA
ganciclovir-administration
R382W/Q
HCC13-
*_3
TRIM24-BRAF–transduced
V1059A
Y127F
1,396–1863
6·5
Dbl-homology
Dickkopf1
ACCAA
AnalysisTumours
4135
interbreeding
polyacrylamide/SDS
F/35
CDR
Assay—Cells
sequence—GAACAAAUACAUGGGAUUAUU
.BT20
ATP-binding–site
guanine-nucleotide
ROS1.11-13
SUP-T1
pcDNA3-ALK1464STOP
de-identified
.Methods
Pro404
immunobeads
p=0·5492
secretion-filled
.FasL
IPASEISSIL-EKGERLPQPPI
5′-CAGCATCAGGAAGTTCATCT-3′
PBS-5
mean7SEM
17-nts
01/03
Radioinert
group–
578/607
m/41
manner1
5′-ACCGAGAUCUCAAGUCUAAUU-3′
Y580
3Cardiac
2XB7
dir.molonc.mcgill.ca
AD-plasmid
Integrin/laminin
-GUS
SCN5A36
women4
1.908
ALK-1
mutp53.34
5′-GTCCGGTGCCTTGAACCAT-3′
NM_005896
.-X
ligand‐independent
Figure77
c.2327G
.BRCA1-BACH1
6319-26
Leu22
TFC
mutation+/HER3+
www.flowjo.com
Fig.2
p.Q76dup
V443D
PNKP
4076
W23
eMethods
E690
N1128I
D539
9–18
1-145
HIP1301F
L1019V
.Melan-a
p53.6
alteration/gain
helicase-encoding
L306V
10–14,44
+2.04
​​​​
distinctmutants
syndrome–causing
co-regulate
594-
polyclonality
.PARP
.Speckled
sensitised
electrode
mutations,5–9
KPSS
Nelen
MTB/TetO-PIK3CAH1047R
oncogenes-have
lyophilization
R838H
XP42RO
D2S44
doxorubicine
7Division
www.dmbr.ugent.be
3.546
inactivation.27
T315N
657del5,42
0.71-1.39
embronic
contacts.29
E1A/HPV
cancer.9
c.208G
pval
signalling127
9-14
Tuefferd
c-62C
alignment28
2730–2731
SIR74Wa
TP53-Penta
RAB1A
pY1248/1252/1253
cell-collagen
11.97
preadipose-like
RP11-1148G1
reported59
1dsy
Mantel–Haenschel
6,570
counter-selectable
disease2–4
med.niigata-u.ac.jp
alpha-fetoprotein
n=205
p16/INK4a
Hua
14,500
chymotryptic
.Merrimack
antipeptide
vemurafenib.6,17
136K
mActb-Reverse
myelosis
JBP1
311×
5¶-TAGCAAGCGATCACAAGTACA-3¶
40300
K868N
R0004
natural-history
RP11-188A17
non-synonymous
Z-score
pp38
monochromosome
liver.16
−4.5
AG2991
mass-related
76.5
c.828G
al46
MO25α
1,3,27,28
PAX5.9,10
.Mock-transfected
0·58
Fotodyne
Cy5-dUTP
7,000
169/2355
E114/118
94.5–100
Malocclusion
SDS‑PAGE
mutant-catalyzed
NM_013605
radioimmunotherapy
BRCA2-CTD
Womer
OGG1
nonmyristylated
α2
cIncludes
sets/96
polymer-based
Ubc
.1621
iBET152
2170
U1752
1H/15N-heteronuclear
Gaithersburg
BioLegend
510–512
4.4–5.3
.11,112–114
1001-1250
Myelo|
cancer.38
Matsuno
0.218-kb
dissemination35
c.3386_3388del
Cre-recombinase
toimmunopuri®ed
~450
inelastic
Figure.3
RG-23T
L60M
promoter5
pear-like
426KB
NHA9-GLFG-1
cancer–multivariable
Tubulin-tyrosine
*Active
tryptophan-dominated
NRG-1β
α-corrected
//genetics.bwh.harvard.edu/pph2
:142–146
RhoA—As
Cdk4/INK4
6-myc
Figure11c
ILHR
−Ade
RAB35Q67L-expressing
proteosome-mediated
PDGF-treated
0.2μM
pEGFP-C2-SSRP1
177-183
MX3000P
factor-restricted
v3.2.3
patients.7,8
Because645ASSTT649
WSU-NHL
.Sox
N628
gmlI
.Gamma-secretase
5'-tcaagcggctccgccagcgg-3
D1/
SKNSH
RSP
N.S
Polymerases
electroporator
Slowfade
PV3314
MLL*.29
differentiation36
.LSD1
UO
pLXSN-EGFR
n=5/36
PROR
K45E/T/N
results.9
PDGFRA
molecule,7-9
Flpmediated
63.1
anti-p-KIT
5.28
7q7
cq
SC-170
c1068
mutants.MethodsCell
ALK-G1202R
1128
88.8
UBCH5
D874
.Calorimetric
paradoxically
months,31
log2Cy3
second-step
TURBOTM
GGCGCCGTGG
TEL-JAK3-
c.875C
D6S291
p.Thr1738IlefsX2
ACU
3181
∼1–100
PCRwas
Gata-1
promoter-distally
neuroblastomas.18
99
pellet
T420
PI3K/AKT-independent
complexes.49,50
Xrcc2+/+
MBPpRb
2.075
15,28
MLK2
preimmobilized
detectable/non-detectable
STRUC
.Biophys
Shh-mediated
PCRbased
BRAFi14F
Q188R
cancers8
E/Cdk2
T-p53C
BR-0279
1706A
.Carbon
steroid/nuclear
cells.PD4
depletion-addback
O-prenyl
restimulated
p.I330del
14q21.1
μm2/s
NOTE.—The
H550
–42
rÃ©Ã©valuationof
hot-spots'5
STAT1
3550
Cisplatin
6.77
casp
humans.20
YOUSSOUFIAN
033
.SETD7
p53-/-/Brca1+/+
anti-β2-glycoprotein-I
'RESULTS
genes32
HA-pVHL–Cullin-2
KIPVAI
L858R-bearing
NABTC
15–9.6
3.93
misinterpretation
S214P
dephosphorylate
split-reads
DKs-8
Nc\JFIG
Bechan
secondgeneration
S2215F
approx20
Mel-Juso
yIG397
pone.0056521.e014.jpg
202/285
Witman
Gothenberg
∼46
recombination12
non–tumor-bearing
5′-GCTCACAAAGACACCAAAGTTTC-3′/5′-ACCTTGAC
864-980
856A→G
Delta1–96
0.001832
b+
Xba131
HER2+/PIK3CA-mutant
siRNA/shRNA-transduced
unconventional
s'Ctransition
bosutinib
BRCA1185delAG-mutant
HSC72
kα9
8-s
MLH1c.2263A
6-16
QiAmp
antiphospho-AKT
Bassi
Cataliotti
activating36
Mutagenized
SCL45A3-ERG
Time-line
COP9
micromegakaryocytes
I617R
His87
FLT3-ITD/F691I
A.D.D
Hattier
transforming.9,12,13
Eco47
Circos41
TPM3
5′-CTGGAAGTGGGTGACTTAGAGG-3′
neuroblastoma2
HSP90/HSP70
PU11
Asnaghi
ambulatory
17,25
translesion
protein-intrinsic
Unblinding
p.M37K
7403
permeabilization/blocking
PTEN-351and
600-bp
glucocorticoid-based
growth-inhibition
P-ERK1/2T202/Y204
PREDDIMER
F251S
Bcl-6
aGI
Histomorphologic
Lys120
Set7/9
Hensin
pY10-p53
KrasG12D-expressing
2085
COVAR
MLL-MLLT1/ENL
−0.93
prognostically
GAGCTCCCACCAGAAGGAAGAAACTCC
MDS-L
T1151M
2/46
N.Y.
213931_at
3′
EGFR-TL
Myeloblastosis
H-Twist
Val104
6438
jprat
MET‐amplified
7270
sc-23948
pRetro-Puro
.642PR
pS2/TFF1
HU133
sister-chromatid
2.429
.†Cell
18–40
cMLH1-D761-kPMS1-K822
I616I
PE/CA-PJ34clone12
IVBe
2,050
P53
S647A
S05-31806-TP-NT
featureCounts
FLJ21683
solvent-accessible-surface-area
weakened7
mid–upper
A276Da
spliceform
/MPD
Genetyx
Stroobant
LKE1
pRb-E2F
CrmA
MIRAX
mutanl
+der
644–650
CNBP
di-phosphorylated
1,581
re-addicted
misfolded/blocked
//ca.expasy.org
reditary
MLL-9S/p300-8A
xylen-cyanol
.0.011
des~ribed
11815091001
top-100
de-paraffinization
P89
pRS2
GTEx
44.2
DNA-gyrase
2-'4-associated
link_type=CLINTRIALGOV
lysine-specific
y/
Agtll
pBL2
ICR_FBCS
Tyr259
p.Ser238Thr
Myocardial
RNA-seq–based
Shortt
multi-arm
amino-terminally
p5324,25
CFU-monocyte
G03
alpha5
A-II
T1977I
Stancato
report18
R174Q/+
SOX9-binding
mutations.9,10
CDC25Mm-mediated
eYcient
recutting
.021
PT3/PT6
L107P
sc-10736
itCysThrPrQGlyCyslysProTrpProAr9Hi
4.79
Abe
G91R
Morphology…
Organization1
shSCR
p73.2
Y234
.Arg531
u/mL
616
Mammonium
helices42
SYNM
Transposon
1,123
size104–107
Ser-Asp-Val-Trp-Ser
T-6557
2.272
DeletionsChromosome
Rapid-Capture
PCRd
SW780FUS
products.19
0.69–1.44
—inv
4446
C1837G
Bd-XL
rolipram
immunoprecipitatethe
8,10-13
MG63
STRADα
benefit.Inhibition
V2746
4664–4674
5D3
pZNa0
571C
8q8p
anti-V
physical-chemical
Flag-antibody
.TET
markers.11
Schulman
D21S65
effect.42,43
RAS-stimulated
D-targeted
RFS-mycT58A/Wap-Cre
Cordon-Cardo
pSG/Flag-D317
NHERF
RMT
HER4
multicenter
membrane–
GS543
+86.21.5080.6600
R303Q
studies.16,38
280Ile–601Met
D16S3057
HA-GST
_EGFR_-mutant
245S
v1.07
kinases.25,26
I/C
P/J
36-87
transformation.10
7/0/0
PD174074
cellmay
hypoxia-mediated
sequences7
TTTCTCTTCCTCTTCTTCACG
bcl
Prestained
c-Myc-deficient
EUFA173
pGLT2
proportional-hazards
n.c.p.cross
p.Arg299Gln
NSCLC.12-14
rs339331
thefunctions
complexes.36
SART3
pT3
MVO
Sapkota
PDAC
GFP–PKCζ
set63
GCAAAGACACAAGTGGGGAAATC
-AGAATGCCACTTGATTTCTTTTC-30
n=76
therapeutics13–16
GSTpVHL
F691L/I
significantlycorrelated
D594ABraf-induced
extract-peptone-dextrose
Woodring
6-cm-diameter
69.0
GFP-Elf3I279P
chr8:134407748-134408779
sizec
T1165
//genome.ucsc.edu/ENCODE/
E388X
gefinitib
Perillo
gtttag/GTCCTG
reported,5
.Infertile
TSC1-specific
SM1645
TEL-JAK2transcripts
CDKN2afl/fl
RAS-GTPase–activating
FinchTV
1.MAP2K1
pFC36
tsc2
AXIN-associated
JH2-containing
AB/BB=1
.KMT2B
2.140,41
E521K
W5357.55
anti-Ret
RUNX2,18
.Open
Arg133
PP4
CDK-independent
hot-spot-activating
DICER1-related
SHR
HYPB
OPL
0.008aCD3
Oligodendroglioma
voltage-gated
.SV
.1806
.Densitometry
samples.A
signal-mediated
Zn2+A
miR-106a/b
.TRKA
Margency
Tasaka
Luminal/HER2E
β‐actin
Mixed-phenotype
Nieminen
C99Y
ankyrin-binding
H3K36me2
pmCit-N-rasT50I
interface45
translocation/maturation
typhimunium
G→G
PNK
Raf-MEK-ERK-TCF
E2A−/−
F57
Patholv.159
~Laue
antiphospho
SQSTM1
–N
.NIH-3T3
.Multisample
Lefkovsky
P340
24.70
Kalluri
NP40/Na3VO4
E768D/
MENIN1/LEDGF/MYB
neuroblastomas6–9
G338R
RByl61
Tropomyosin
p.I668V
multiple-step
53-year
Petrini
pGEXpl6
HAP1
p-adducin-γ
titrating
theHIP1/PDGFβR
197nM
ATGGGATGAGATCTG*CTTGAAATTCTGGAG
Hoa
abnor
PI-3K-Akt
Anti­
A546-2G
T421NCRAF
3773
thermodynamical
C135S
F185
S139F
DVC
cis-element
1-115
SPC-rtTA
baboon
.O-
GST‐beads
.Discussion
counterintuitive
p.N581D
5672
anti-p42
//doi.org/10.1371/journal.pone.0019059.g002Expression
ratios18
Graphic30
M57732
state-of-the-art
Hypertriploid
regional/ethnic
q36.1
150pi
densitiy
CGGGAATGACTTCTTTTAGTTTGTTCTTAA
.S3I
D425Med
Ikk2fl/fl
work-up
Botton
Reneker
Asp537
5′-GCCTAAGCTAAATCGAGAGAA-3′
WT1-associating
H144P
0.207
.Nishio
6,7,12,14
leukemogenesis
3.ratio
described.3
Fig7C7C
pCMV-3tag-1A
3,593
f900-fold
GAPDH-specific
99bp
1805
EBV-encoded
RasMAPK
downstream—might
previouslypublished
93.9
microcentrifuge
CFPCTLAAla17
E250Q
Nrf2-over-expression
re‐ventilation
Asuragen
0.055
optionsUltimately
.Jessen
TCRBJ2S4
ascendens
293XTs
cancer,8
MEK-1
T432A
LMP2/7
SIFT/PolyPhen-2/Provean
Vem
stage/epigenetic
karyopherins
P169R
U24
GAGGCCAGTGCTGTCTCTAAGG
Anti-inflammatory
R118H
164–383
ischemia-induced
transcription/repressor
erence
function,39
Riveiro-Falkenbach
3p21-
1-log
time-window
INK4A-CDK4
sub-chromosomal
.Ethnic
U-118MG
PGAL10
mutation-bearing
times300
TAGCGGCCGCATGGAGGAATTTAATTCG
Sharrard
NTRK1NTRK2
saline+
.Context-dependent
V617FJAK2
neurite-specific
LOH-15
marks43
T-3
.Apoptosis-competent
interactions.27,28
CGA→TGA
260-nM
LC3/MAP1LC3A
−9.02
Tek
FLAG-BRD4-NUT-inducible
γ-phosphate-binding
/NCr-Balb/c
CAA-3
538G-ERα
23-72
survival48
.equation
β-catenin–dependent
cytomegolavirus
Balasubramaniam
Qi-Ming
090572
helix-turnhelixmotif
CCDN1
more-indirect
Ligand/solvent
models44
35–63
heterezygously
RTC13
GST-merlin
c.475+1G
RIKEN
K1724E
miR-17/20a
13,23
.Meanwhile
respectively.Cotransfection
RAF-CIBN
0.070–0.243
ARID1A/BRG1/p53
SMARCB1-mutant
intellectual-disability
.Kelch-like
.SK-Mel-28
gefitinib-unresponsive
pTL-unspecified
TORKis
microarrays
D162G
HD-0288
Cep
30-42
.024
erb-A
RAD51C8
blood-filled
CAGCTTGCCCACCCATGCTC
colonies/well
rs7253447
factor-driven
cancers200-202
Akp-positive
pathway.3
treatment.19,51,67–71
described12
ProteinTech
F82
-63-linked
-.The
2404.0±397.3
SMO-A459V
aruplab.com
RasGEFs
Max‐network
102934
59-TTTTTTTTCAAGGGATAATAAA-39
2+/3+
cycle-related
CGCCACAGACACCGAGAAUUU
7:00
4.35–7.05
voice-web
FUBP
IgG–H
mMdCTP
anti-H2AK119Ub
Flag-PCAF-expressing
not—consistent
PKP2
.Patterns
Cytoge´ne´tique
lymphopenia82
fine-map
Brca1fl/C61G
G106
A333V
12q14.3–15
LXXLL
suppression/inhibition
staining.31
185-kDa
.Zygosity
FN
−3.35
astrocytoma-related
g=max
695b
3C3
5′-GATATCATGAGTGATTCCATCTATGTTGTCAGGGGCA-3′
Sahlgrenska
-14.6
5′-CAGGAAACAGCTATGACCCGTGGTGGTCCCGGCCGCC-3′
.B′-γ1
n.1
.WM793
.MACH
1:15,000
c.9663_9664delGT
events21,22
10,14-19
pharmacoresistant
.837
Acrylamide/Bis-Acrylamide
Karyotype*
Hypophosphorylated
Leukemogeneic
tumors38
NHEJ.Figure
A455E
intratracheally
610151
DuPont-NEN
Plesmanlaan
MPP4
pC53-SN3-T123A
α-35S
+−
Reverse-transcription
PathDetect™
focus-density
1822GVPLH
transcrip­
Messiaen
TP53-tumour
used.8
seen.Recurrence
Wwtr1−/−
Q1634*
IgM-expressing
segment–pVHL
-ITD3
patients51
5p:3p
pEBB-HA-ID-GST
3μCi
52–54
pGL-Basic
ORF2
arginine–glycine–glycine
f.
80.46
months.9,11,18
pCYC1
SK7
importin
omentum58
tioned
RCSD1-ABL1
PKCβ,28
p.Asn40_Ala50
vorinostat-low
micromolar
datasets.57,59⇓⇓⇓-63
EIF4G2
calcium-sensing
.PanIN
chymotrypsinogen
.Backbone
99.7
1260_1677del
Leu861Gln+del19
'ItI
MEK2WT
previously.6
HEK-Jak2-K539L
R-249
51.355
SFA6
TCF/LEFs
V22insHPI
.Breakapart
68.55-68.62
215-228
Hibi
SamplesViably
.Lanes
1:6000
l-α-phosphatidylinositol-4,5-bis
GLT21.T
UM-UC
LTR-3
Adsq
Brg/Brm-associated
-2.5
clone-specific
EORTC-ISG-AGITG
complexion
.Clearly
passage84
5'-CGTATATCTACATTCGAAACGA-3
1433Å2
functionally-validated
hepatocellular
769_770insASV
TT2
genomes.34
2416
.Colons
onantibiotics
23,25-28
protein/S
EasyCyte
criteria23
pZNctj2
contradictory
F47
mutations/variants
327,137
modi-
showedremarkable
Origina
Reintroduction-Expression
rearrangment
Multi-Institutional
tomography
pTN24
oesophagogastric
specimens—Cambridge
pQCLIN-SMAD4
p.F154L
SEC31A-JAK2–
infection.4
Erk-2
informatic
1000nM
RGB
patients24
4/9
Pdgfbret
TRRAP
Band-shift
3p25
Y75XfsX0
anti-CDKN1C/p57KIP2
sclerotic
large-focussed
'structural
1455
MPDs.1
103-fold
tumors/adenomas
radish
binding29
Ciampi
COSMIC26
cc-12-2656-g4
Spectrum-Orange
1455–1863
W587S
offamilial
aWilcoxon
Rahimi
//psort.nibb.ac.jp
.Colorectal
sc-13576
Extrapolation
C210Y
.Baculovirus-infected
1C–E
UBP3
G1–S
IL-3/ml
Superdex-200
580W
Fig.2B
1650–1723
p.Arg200Gln
Wodarz
genes.60
CTAGAAGCATTTGCGGTGGACGATGGAGGG
Gly508
AML,13,34,35
50:50
5B-nR
Ser981
RP11–320J20
mispairings
perilobular
FCHSD1-BRAF
Genecopoeia
Ser473-phosphorylated
P008
1.3–1.5
methodsSite-directed
De-regulation
^0.90
140452668-140452690
TCGA-AZ-6598-01
metacarpal–phalangeal
pre-crizotinib
35.70
metaFig
A-032
27/61.4
BC001g71
survival36,37
0.5-fold
Phorbol
Stanfiwd
Objective.—To
V790M
×1
Gln61-
silibinin
GAGT-3′
shRNA
ESErescue
ventriculomegaly
inhibition91
5′-CCACCCATGGCAAATTCCATGGCA-3′
B1.5
E339K
LB96V
BRD4S-
genemaps
–Ras
TRCN0000081781
bosutinib.5–6
E6201
−49°
medulloblastoma22
Activity—In
p53-independent
47-kDa
1562
TIG-ER
G2032R-bearing
Hematopoiesis-specific
-γ2
.BaF3
.107C
285K
1658
60–120
c.1888delG
N423Y
PNA
60mg/liter
NADSYN1
mice28
110–175
BC012846.1
D264V
.Cooperating
100gg
AB_397455
Ontogeny
15449
SJLGG039
drug-target
L206
1or
changes12,20
instable
strategy27
0.001baThe
NMC.28
nitrocellulosefilters
W1837R
variants46
patients—surgical
pathway.33-37
Sakata-Yanagimoto
PC3M
Laffaire
proto-oncogenewith
DEC.11
NCI-H211
delocalization
ubiqutination
TK-II
s-KEx16BEx9
p21-induced
development54
SflÂ£-/lwas
TTCA
sinpRRL-PGK-GFP
CK19-positive
defects44
Würzburg
KIT.4
Lab-Tek
Zia
c.370
1cUAS53
c.1569delT
0.000982
81029941
IgIIIb
5666
rs304270
p73betaIn
Tuber-like
BACH1/FANCJ
α3–α4
49412898
1.9–2.1
439KB
Gly400
TGFβ/activin
9-E12
SaOS2
367T
obtrusive
Chfr
92:1173–1179.Lierman
TGF-b-mediated
c.5095
Tyr190
P1114L
.Spry1/2
126of
ijA
exome21
AdenoCA
lineage-restricted.16
.Reduce
2.98×104
PROTOR1
clone-stimulating
BRCA18
purine-rich
DRB1'0407
SI02100902
ACC-CTT-TTT-GGA-CTT-CAG-GTG-GCT-GGA-GT
Formalin-Fixed
p.Asp351Gly
A33T
.Lambert
RAS–BRAF–ERK
924
CCL-64
s.e.m
Gombart
TTTCATGCAACACCCAACACT
__L576del
HKR1
IGF-1-mediated
underrepresented
S424
carboxyl-terminus
leukaemias26
Tat
81183
MYD88–IRAK
aneu
levels.thumbnail
*Higher
~4
time.50
HD-0167
three-codon
p110α-ABD
Trib2
MEFs-injected
half-denaturation
wingless-related
Pax
Shahmoradgoli
14/122
steroid-resistant
Hisx6
Ras/glutathione
0.158192173
TGFBR1*6A-HA
miR-24
Four-point-one
twohit
Rdh54/
40–200
al.,1995a
Ago2-miRNA-containing
Dufner
P-0003073-T01-IM5
14q32/IgH
DBL-homology
Q10A
sub-
HNPCC.2-4
TRCN0000361331
Palos-Paz
Anti-hypothalamic
MEF2B
interface.34
RAS/MAPK-related
manner22
OptoCRAF
−318
-DM
published.30
.P.M1_E165del
RasGTPase
2-hydroxyethyl
ERK1/2.5,35,38,46
doi:10.1056/NEJMoa1400029
S215I
D19S565
mMMgCl2
EdgeSeq
MEFp53+/+
200-kilobase
activation57
forward-primer
Trypsin-treated
64/71
liver11
R80W
study,7
P1-9
Ischemin
V2THS_237948
144–147
CTAAGGCCAACCGTGAAAAGA
.1994
p.G268_M270del
TR-TRAP-Mediator
.Low-dose
Cyclophosphamide
K860fs
enkephalins
Lu140
Lin−Sca1+c-kit+
1mL
M351L
102×
factorκB.2
EconoPac
F311
SMC1-S957
del1434-6
Sma-3
RUNX1-4F
Pgk-Neo
reaction-sequence-specific
CD28
oestrogens
G12R/C186S
mutation.The
FITC-Avidin
V-6
Men1Δ
signaling15
NSCLC=non-small-cell
0.6-30.0
CRC344
double-coded
siRNATarget
3:13
15.8±3.3b
thromobocytopenia
I571-L576
subclones.34
ATATCTTATGGCGGCGGCG
pRetroX-TetOne
K-RasV12
N.D.
ATP/Mg2+
fibroblasts.Analysis
GTP-contacting
RNAzol®RT
Yap
formation/stability
DZIP1
+3.5
apoptosis2,3
S135L
DCRAF
35–43
Hernández-Muñoz
2/48
.IC50values
E-CDK
allele31,32
cytosine-to-thymine
del557-558
polypeptide-like
498-514
SNuPE1708F
GGG-30
defective.19
-|theprogram
Mll-AF9
SDS-PAG
Q236H
GSEA-P68
3•2
Del696–701
non-repetitive
anti-titin
areshown
8E4
GFP-ABD
45.3cDNA
Notch–altered
D.P.S.
.Concentrated
c-myc,31
ROCK11
dav
mantGppNHp-bound
~Figs
fundamentaldierence
I-I-I-I~I~I~I~I
Cytovision
p53-RE
29Some
P8
.Mathieu
15·3–21·6
pET14b
UBC.11,13
ome
3D.AFosHA
levels20
pS473
arti®cialhigh
mutations104
62-patient
5′-GGUGAUGUUUGGGUCAGGUGCCUUA-3′
0.269MUTNNSplice
V1809F-F
mucosae
A.A.
43/51
MEK2Q60P
ng/dl
W1718C
EGFR21-AS1
RSK-mediated
5′-GCCAACAACTTACATCTCAGTCACTCC-3′
D835delR
.Luminescence
proteins.26
,155
determined14,24
.ACTN4
4.PTEN
biventricular
Palaskas
significance.PIK3CA
E-CAD
S5N–O
0.6-kb
Arg399Cys
D.M.L
single-pathway
messengers30,67
Terracciano
cleavage/polyadenylation
9/p300
promot‑
three-center
Ex8A
+4°C
induced-RAF1
R562G
pMCG26
.TGF-TGF-β1
described.35,36,66
E585
env-sea
S3.7-S3.9
hypoacetylation
49–
≥28
SU6656
p.Thr287Ala
AGT→GGT
N-liked
Lbh-specific
previously,19
LRP1
whowere
G1201
ABSOLUTE35
Interferon-γ
phytochrome
G358R
isothiocyanate/phenol/chloroform
cellstransfected
I63V
pHT385
Meraldi
survival.2-10
Mitsiades
ATCTTCCACCATTTCCACATCAGAA
pGL3-PD-L1
.Similarities
fibroblastsinduced
gemistocytic
.Somatic
/RUNX1-RUNX1T1
translocations.5-12
DICER1.19–21
years-MFS
non-porous
Joung
phenothiazine
0.00405
MgSO
cyclin-depen
MDS19
p21/WAF1
HR16–18
expression.93
4364031
PRGFRA
CADASIL
permmatswap
Phospho-Y705
doxorubicin-inducible
HTH
AR-nonspecific
cAMPresponse-element-binding
540.0
2Mutations
HL-like
Axin.32
XPCS2BA
DO09126
Orfao
2433
basal/squamous-like
F350C
.random
GDC-0449-resistant
59-TACCCCGGTTCCATCTACC
pCMV-based
Val-559
Aldrich
Ala9
SOS/Ras
3-amino-9-ethylcarbazole
TPβ-mediated
CR2-domain
reports8
AfeI
D3S1300
DAK-H3
CCL75
Val-
Cot-1
0.00021
D569
frogs4
Pelengaris
AgR
Ser79
species.22
mGli1
COPL
SQSTM1-NTRK1
M24682
D19S883
switch-off
7/1
C1142F
Bgl2-WWP1-F
esophagogastroduodenoscopy
EMS-like
HOX11
factor–β-induced
T172A
R102P-GFP
3.5±1.7years
TP53-R273H/DNA
RS2.0
Germantown
mutation.50
A1CT
hypermutation.8
5′-ACCGTCACCGTGGATGTGCT-3′
ab37837
β-Act
autophosphorylation.18
1*5
.Warmer
AML-1B-C/EBPα
b-4
eAustralian
4RWI
2.771
27
AGGGGACAAGGGTATGAACA
740–52
PRDM1.E5.575.R
1016C
396301
1Â°Karyotypc46
Sulforhodamin
0.0067
RP4–686C3
I-1
193/193
X100-soluble
-could
mSWI/SNF
GBM1-GBM19
°Cin30
55-amino-acid
=13
46.7
hypoglycemia.24
DPVB+110DAB
RET-mediated
72ÆC
D0j+1
ΔE
87.44
streptavidine-biotin-peroxidase
.Forward
F92
studies.In
0.32–2.34
secretory-like
medain
described46–49
Gata-2
thefollowing
1989–2007
8.30
Focusd
BRCT−ligand
P35A
R73C
cancers1,2
3,504
IVS8-17G→T
AMS
9.72
//www.broadinstitute.org/gsea/index.jsp
0.60.9
SGK269
mutations48
compartments29
Logsdon
Chr9-1226R
melanocytoses
TGACACGGACTCAATTAAC
BMMPCs
.Conducting
HRPO
≤5-fold
FGFR-KD
Brd4+/−
H115N
EML4-RET
anti-αβTCR-PE
15–28
SNP-transfected
H3-K36A
Flt3ITDneo
R-TSC2.ex10
lumc.nl
Lox-K-rasG12V-IRES-BGeo
GFPBsd
heterogenousparental
Westem
HA-ERK2
ASC-2+/−
Br2
R2081W
assesswhether
TRKT3
Arrays—Arrays
EWS-Ets
D38
pBMN-CCND1-HA-IRES-Hygro
6–60
human-8
1.28–2.17
P1I
TATGAGCGCTGCTCAG-3¢
soonsoo21c
+49-931-2015756
Trp53fl/fl
4-TOPO
mutations118
D816V/F/Y
125–500
GENESCAN™
hormone-response
9165
.11
EGFL7
hSNF5/INI1/BAF47
intrachain
CA03
Toyoshima
2755
–GppNHp
respectto
SimplePCI
Cloning®
65-ns
dnFADD
HoxB4
–6
theIGH
IDEAL,52
IUPAC
ANTI-FLAG
alÃ-eleratio
lordosis
158,760
Y527FSrcG2A
mean-centered
non–hotspot
re-screened
.Keratinocyte-specific
CpG-site
IDEXX
2family
years-old
WM3248-GFP
binding.31
CGAGGTTCAGTGGCAGTGGAT
0.288494197
AML.13
FGFR2+/FGFR1−/HR+
mutations2
p300-interacting
Zn-chelating
//ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
pfg103T
Interincisal
pSNVs
EUFA330
310-helix
UJ13A
Y496
Il7rα−
MOL
proteinwas
53,000
.552678
rerio
abnormality.14,18,19
ACCATGCCAA
.Discrepancy
absenceof
3710
mix-
miR-222
D256N
p.Thr244-Ile245insCysProThr
TGFbeta-responsive
pET-28a
Lee-Hoeflich
K444R
1561
CHIR258
XRCC11
K167N
GSI-resistant
Applecross
non-activating
R634W
5Department
D.F.O
Pro291fs
regulation21
S_HBV848r
AbD
32-fold
involved23
−448
PTPRT-regulated
ligand-contacting
25.6/5.5
schizophreniform
PH-GRP1-GFP
FIPL1-PDGFRα
D1058S
co-precipitate
NOMO1
Seongnam
Heterocomplex
5′-CCGCCTCAGCCACCTAC-3′
78—December
P–C
Q-CD-OPH
receptor-alpha
9R-1
NaCl/0.1
UTX/KDM6A
AXINI
129S1/SvImJ
PI3Ki-A/D
GGT-sTGT
FANC
1,960
7/14
PLVX-BRAF
R72P/rs1042522
dierentiation-speci®c
nucleus,12,13
0.31–0.81
Rosenblatt-Rosen
Brigaudeau
disease.34
zfan
V112
PI3K/mTOR/S6
T'llGGCCCUITACATCGAC-3
hypotetraploid
ZC3H7B-1214F
.853C
TGFBR1*9A
ETV6–NTRK3
HT-1080
A8837
carcinoma.b
Fox-Chase
good-quality
protein-dishevelled
interactor5.8DPTDermatopontin5.6cDNA
.second
10–6
Protein-Alpha
MRE11/ATM
Allo-SCT/TBI/Cy
ΔF508
p=0.0419
prei
186.3±27.1
L93R
intraventricular
Physiological
wu7/wu21
mRNA/DNA
-TRAP100
leucoerythroblastic
Phosphorylation
Katholieke
KT-44
54/340
END0.1993
A279S
L77
.Nguyen
V/V
five-codon
access-
www.futuresoft.org
7-drug
organism-specific
CGACCAAGCACTAGTCCATCTC
c.1480dup
retro­
Gr-1
2.87´105
etically
ENU-based
1015G
HS-578T
94–95
5′-CCAGCAGCAAGTGGAGGGCCCCC-3′
232,090
Multiplatform
acycline
182780
C.1.2.C
Xrcc2-Knockout
Loundou
Thr753
g-o-f
SYBER-Green
.Immunodepleted
gamma1
A104P
Trk-driven
14430
1p12-p21
re-evaluated
Kantarjian
A293V
10.84
eYcacy
RAF/14-3-3
Tamnip-Dong
epidermis10
hypothesise
H118P
mesylate,4
doxycyclineinducible
platelet‐derived
single-nucleotidesubstitution
full-genome
pRB-defective
re-calibrated
.Surface-density
5-CCTCTTTCAGCTCCAAGGCA-3
116M11
CD48–
.GPCRs
PIK3R2.7
RUNX1–ZFPM2
A2056V
III:3
3Vto
ACVBP
Cells—Human
post-anchorage-independent
contemporaneously
11/43
Y279C/R465M
matory
497-8
187C
269.10.1146
.FIM-FGFR1
.28Mice
inter-breeding
T210.8
~GDP-BeF3
.Fig.1C
binding21
154534
BRCA1−/−-
nature.2
HLA-A31
3180G20
peptidebinding
54C
Translesion
5M
Photonics
pBSKS1
4858
.Figures
S222/S226
VSV-pseudotyped
Miltenberger
34-81
Golgi-mediated
A*33:03:03Q
embryogenesis.22,24
382delC
semi-thin
del.755–759
W391
PTEN-F21A
a/.8
KRas-driven
WZR6
D218/D396
S151A
1,15
uridyl
Cells—The
FastQ
a-2
mice.37,38
5′-TGCTAGGGACCCCTCACATT-3′
2888-16_2888-3del14
J.M.G.
virallyor
cis-autoinhibitory
Hprtb-m3/EshJ
factor.15
NDRG1
7.4/1.5
hemoglobins
74-week-old
.TLS
KIT/PDGFRα-mutant
o66
Jura
agr3PGK
Seongnam-si
GCTTCTATAGATCCTGCC
1.0–75.0
anti-H3K27me2
3420
dominant/recessive
coprecipitations
min–1
0.0870
centrosomal-associated
cocrystallize
KIT/CD34
PREDIR
GST-3X-CTD
MSCV-IRES-GFP
R77H
162N14
Espérance
0.49/9.8
heterodimers22
Feilotter
EWSR1–986F
vTR
CommentsLung
12-year
SUDHL-1
4,5-f
identiFIG
ligand,15
1451
U87MG.ΔEGFR-
2.995
p=4E-4
Cys303_Asn383
cancers.15,26–33
P.O
L1196MþD1203N
development117
S821F
MYC-specific
pairs9
5912–5919
G669D
.D130A
Merlin-insensitive
1.10×106
Tumor-volume
Nrf2-Ub
NM_005235
0.007a
15q14
respectively.2-4
3S5
PLC/Prf
pcDNA3-H17Y
320R/HΦΦNHSC326
Cys136Arg
IQGAPs
holoendemic—eg
.C634W
negative.The
07/38
Enx1
immunobloting
nanopublication
rhophilin
Duiven
5′-VIC-CAGCAGGCGCGCAAATTACCCA-TAM-3′
months5.The
T-ALL/LBL
Malattie
D648V
PDL-1
Mangoura
cccatgccctcaagtgtgcagattg
inhibitors39
G1979V
HNRPA2B1-ETV1
cytokine-supplemented
-SPA-1
supratentorium
15·9–29·9
PSK-J3
hFLm
anti-Flag
HKY661
signaling19
.Along
V600E/K-secondary
KITD816H/Y/N
Authenticated
TITAN19
Alk-positive
1–166
−0.06225
30_402del
5U
MDS/MPNs
B7N37
Streptavidin-alkaline
610041
red+green=yellow
fluorophore-linked
15
HGSOC
PPP6
R135G
CD138+
EDTA,10
Ras/membrane
α-CBP
1390del2
enterochromaffin
91,119–121
transcripts.21
pY2-peptide
586A2
snp
pipetting
R882C
4·1
442
Highdose
pcDNA3-Smad5
PolyPlus-Transfection
MES-A
3.551
.McConnell
F-5
K5.Smad2+/−
p.R776H
302,176
armb
retrovirus-expressing
Q474X
nonsense-variant
25–base
nontransmissions
306-bp
p53mutants
Myc-nick-facilitated
NanoEn
1862
toR1881
signaling28
0.271
9/97
Overrepresentation
Alexa-conjugated
61.3
repairdefective
1,349
-Q227L
Hibbard
ccRCC.18
E-19
bis-benzimide
RNA-recognition
CAGCCATAAGTCCTCGACGTGG
bition
Clz
PER3
bypassthe
42–73
postopera‑
Trp-998
SFRS4
für
al60
LV-Let-7d
Max-Lebsche-Platz
promoter–tetracycline
dysmyelination
TGFBR1/2
p210Y253H
rs121913466
Keap
E286G
mours
survival.16,17
RNMT
Asp154
duligotuzumab
anti-panTrk
replication-incompetent
H303Y
Bi/multinuclear
actin-myosin-dependent
NACA2
.14643
Asp-Leu-Pro-stop
13–20
10-18-07
P169
elements.15
acinar-neuroendocrine
MACHα3
X-expressing
.MASK
peroxynitrites
classes—those
Gig1-258
BRAF-G469R
2,833
5′-TTCCTGGAGGGGTGACCCAAACACT
5′-triphosphate–binding
breastovarian
n=27/37
CD31+/Podoplanin+
functional.46
71delGA
dendrimer
H1229
.Again
BRAF–wild-type
39-45
Brca2lex
humans.1
panniculectomy
co-stimulatory
anueploidy
6-FAM
CRC.2,29,30
E619D
Two-month
-UTR-WT
TGAGGGAGAAAGGC
4×10−42
0.039
kinase–signaling
91852801–91853100
ATM+/−
F309S
iGFIIR
p.Thr18_Ala19dup
N-Ras-T50I
Kras/Tp53-mutant
pN0
transver-sions
blasts.4
phospho-p44/total-p44
D16S265
PCNA-positive
â€¢_
1988§*
.Kinase-dead
Bacto-Agar
months.1
supernatant-treated
Anti-Bim
CRBP1
demethylases2-4
well-understood
G289Rx2
MECA-32
c-Kit+/Flk2−
poly1
Dtrk
misidentification
S415N
p.R1032X
product109
auto-feedback
PDGF-induced
Passeron
Pro2699
~~~~~~~~~O
non‐consanguineous
PTEN314
10/16
67/79
3q26.3–29
Y87C
SHP2-knockdown
criteria-fulfilling
IL-24
pos.
BMTH9
Fellström
I590L
inhibitorTo
40.9
factor-reduced
hypochondrium
Nt.BstNBI
antiflag
dopamine-b-hydroxylase
7–9-fold
experi
-SPOP
225-490
0.358
7–89
Myc-EGFP–PTEN
simulation.14
H27Y
12332-1-AP
models25–27
Ptpn11D61G
NM_008371
2xl04
abnormalities—rather
Zweibaum
G1041R
properties.20,27
TRK–T3
51.16
Isl
3.5-day
sav
G9a9
precise,15
.DiscussionSomatic
AMP/protein
3575
EML4-ALKG1269A
0.406
HAhB-RafV600E
region5,19,20,21,22,23,24,25,26,27
Propellor
nGlyleuGl
STAT5A_02
traceable
invitro/in-vivo
two-stage
pathway-regulated
0.013*
disorders23
histomorphological
cis-linked
BCL-xL-sequestered
-o-
infrequent1,4,5
Telatar
hypoxia-induced
.3_7976
UVAGGCAATCCTG
.Sarcomatoid-specific
150.5–152.0
FANCM-deficient
377XL
Plan-neofluar
Serologically
Neuropathologica
K423
PDGFRA-T674M
Ser-516
Phi-mediated
anti-PDGF
tumorwasfunctionally
//www.rii.com/publications/2002/vantveer.html
fullReverse-transcription
1406Gright
LFS/LSL
P=0.26
anthropologically
factors.44
P128
A656fs
lymphoma.128
exportin
ffu
.Allogeneic
T8
.275
pBabe-puro
GRB2.17
Constantinescu
Notchic-ER
−1938SRYP.pGL3
k5at
NextGENe
non-point
Kluwe
Cul3‐dependent
CDKN1B-negative
missense/splicing
RQ515,516AA
NM_022435
immunostaining-negative
rs-coded
£D
Polyp-induced
9,727
E382K
m-EGFR
−43.7
F2742.50
63·8
Leu3Met
svr
sys‑
2TK-AR-AF1
5′-CpG
J-041171-10-0002
rebiopsied
anti-RARα
vcf2maf
chromatography–electrospray
Tyr-17
2Fbloodjournal
E17K
/3P57
early-phase
-*5
olaparib-treated
cc-11-4059-g1
−19.6
repair82
probandus
spindle‐shape
Czermin
GD-103-4001
122–125
411.1.5-1.3-E2kbX
R236Q
effi-
pre-apoptotic
BMMR-D.
q26.2
fos-luc
Biochip
Enhancer-ofzeste
magnetic-resonance
-mmf-max-hq-mismatches-xt-u
5'-AGAAAGGAAGGGCCAAGAAA
unkinked
NPM-ALK,11
Brinck
RAD53
T1142M
PTEN-CAT
F153
5′-TTCATACC
kinase4
Merlinat
cross-reactive
AF011468
appropriately-derived
NC5
subambient
ASC-2-null
haematopoiesis22
Muller-Tidow
G3867A/GAG-+AAG
V580I
PuriJicatiorz
Sos-catalyzed
CD34+CD16/32medLK
models75
amplifications66
v37
pEXV-wtRhoA
GAL4-BD
electrophoresison
17776
Dose-cytarabine
hSNF2H
Goedbloed
E687
c.802_803insT
HEK-EBNA
157,000
STGC
Near-uniform
multiparameter
amplifying/progenitor
431,000,000,000
15,17,18
N616S
CD74–ROS1-expressing
Leung-Pineda
dimerization-impaired
D842Vmutant
pathogenic.10,11
E18-93
−3.19
Bis-Tris
Pieper26
RSF1
28.
GTCT-3
752
2008a
Biomax-30
Q506P
transAuthor
p.Ala530Val
5′-AAAGTGTCTCGAGCGTGAACAGTA-3′
sequencing.31
LFM-A13
anti-MED1
furrowing/corrugation
M76V
M1008I
RTK/ras
bysemiquantitative
Errfi1–/–
the…Download
eightfold
p=0.7
£at
JAK2-cytokine
L1224
mutationswereasfollows
receptor.47,48
resealing
CBFA2T1
ShRNA-mediated
RasQ61L
Raeve
Anti-ERBB3
markers18
Cys1438
I1227L
allele21
HCT116p53−/−
c.400C
EEL
5.1-24.5
¯uorochromes
625/489
F20
spottedoligoarray
1,22,23
ME180
.E7107
1.43E−07
NP_001269551
SPI
μF
non-response
ImaGene
14c
unclear.55
mesylate.7
30X
L536A
ribonuclear
Hohest
14196
Fig.3
AIHW
siNC
IDH1/2-mutated
//www.drugbank.ca
4q11-12
demo.istat.it/altridati/natid1d2/index.html
embolitic/ablative
.BC043399
0.534
time-dependent
HEPG2
anti-pVHL
non-Phase
approx36-kDa
IKAROS,22
GGGGAAAATAATACCTGGCTTC
MANEA
I427M2.
pathway.22
BD-Pharmingen
molecular-level
fgfr1b-MO
.Mini-gene
CDX1
BCR-JAK2-mediated
BRCA1-deficiency
Dheda
CIP2A
//somaticmutations-egfr.org/NSCLC.html
ctk
EGFR.31–33
FBXW7-silenced
length-dependent
T200A
L27
55221
10,000–1,000,000
p53-P250L
Smad3−/−
Promega/ATCC
ABI7900
Matakidou
P65L
N454D
Her-2-positive
growth-prone
conductin
2.5times
screening143
pcDNA3
F893L
b-galactosidase
Nu24/SP2
50-^tl
yeast.58
B53
C5orf39
negative-regulatory
TP53–/–
±36.3
uz.kuleuven.ac.be
3,12,14,15,26,28
inhibition30
0.98-1.67
tetracycline-tested
22-base
13,622
L241fsX313
M4NDATE
H3-K27
Xq13.1
−2.08
fields/section
ΔC-box-
N319T
.Hematoxylin-stained
.Limited
30–33,38,57
pericentriolar
T2119C
CBFA2/CBFA2T1
leukemogenesis17
Kducation
50-aa
R487W
Affi-Rad51
10215
c.774delT
line.16
embl-heidelberg.de/PolyPhen/
Ampliqon
epigenomic
toIGHS
CCTCCTCTCCTTCTTCCCCATTACCC
88/257
Nicotinamide
13.094
polyps.9
agarose–2.2
HIF-1/2α
-173g/c
Lys116
FACSAria
TCF-LEF
metanephrine
stochastically
129K
URA3,2p
cause-and-effect
K642N
picard.sourceforge.net
Al59lG
299-319
Ambedkar
Parafibromin
3875de14
p.F508
0.7–1.3
Jeelall
inactivation15
p.R132G
serum-inducible
carcinomas.3
320-328
P.T854Id
machinery.20
FIP1L1-PDGFRα-negative
LPS+
pS592
.Armadillo
DFCI076
t-test.The
vsv-g
HA-Fbw7
activity14
.089
NF1-1
mPanIN
DROSHA
common.121
nutrient-poor
Leboeuf
.Diagrammatic
R172
'promiscuous
24–86
dual-repeat
CULLIN-RING
CHRAC
J.Binding
gene.31
5′-GGAA-3′
RAC1Q61R
Roux-en-y
pathway.33,48
X-Ray–Induced
pin-pointed
reported.12
PC-3/PTEN-c11
six-replica
5B2
EWSR1-POU5F1
816–831
D537Y
double-band
0015-0282/03/
non-progression
R183-mutated
MspI
◇
18/35
moderate-strong
multi-target
KAR300B
HT-29S1
Y234C
disregulation
pCaSpeR3
17-nt
BAP1-associated
compound–deficient
24/31
GIST-T1/816
Eick
D16S303-D16S3121
.Ba/F3-L858R
-CATCACAGTCGCGTCTCAGC-FL-30
Biochimica
non-monoubiquitinated
.Dovitinib
-1β
ZC3HAV1–BRAF
plug-in
AR–LBD
trans-genes
NF00358F1
C4-2
0/274
Asp400
10.1007/s10875-013-9906-1
FLT3–internal
.ARaf
lineinto
BCR-ABL/SRC
MSCV-HoxA9-PGKneo,25
studies7,12
c.189C
A796T
Doffinger
checkpoints6
~600
70–100
Virshup
1.6e
I670
His773Tyr
Q331K
deptor
81-52-764-
BRAFV600D+FGLAT601-605ins
ARY-HH0225
Caspase3
GI:348620
P.V
c.2554T
Asp190
UV-Light
17,068
RT-Lr1
Inefficiently
pSGTLS-ERG
A621Raf
Asp300
:7165–75
deconvoluted
co-factor
.Nuclear-cytoplasmic
solvent-facing
1.Analysis
-GCTACAAAAGTTGCTTTCCGGG-3
pyrazolo-pyrimidine-based
CCTCTCTTATACACAGCAGAT
black-and-white
SETD2-wild-type
chronology
pro-caspase-8
deoxyuracil
.GMP
pLH20
.Chauveinc
failure.18
HIV-based
RPL24
RHO/RAC/CDC42
LR4
glycopolymers
K303R
markers.32
B–G
D13S153
BRCA1.23
HA-p110αH1047R
others44
p.Thr462Profs*3
phosphorylation86
0/190
210720
myc-transfected
Shq1p-GFP
Hematopoietic/Endothelial
carboxypeptidase
CD19/pcDNA
G13K
Nareyeck
3-m
tophat-fusion38
n=367
Igλ–MYC
DSS1-OB1
IL5
kg−1
PPM1D-mutated
X76184
5′-AGGTCATCAGGGATCTTGCAG-3′
Negr1
5′-GCAGCTGCTCTCACAGAATG-3′
Themolecularmechanisms
13q12–31
o5725
pCITE-7.1
Vec
phosphatase-2
.Cullins-2
Men1T/T
OVCA432-Luc
NSOFC
c-Met-expressing
Eighty-seven
Hietpas
CASP6
​Table1
Tetanus-induced
macro-dissected
CytoScan
1.8–2.1
CLEC3B
XFE-affected
0.041450744
3,850-bp
K120A-12
factorrelated
.Zeiss
PDGFR-downstream
Asp-25
MMPâ€
15.9
-2-
rasoncogenes
three-cluster
chromic
Progetto
CCGCCTCCCGCGGTCCCCTCAG
bioenergetic
translation-immunoprecipitation
A-TLD
K-RasV14I/V14I
A40T
K942
+I
E2F-responsive
anti-chicken
F265C
30mer
Breast-Ovarian
PIK-2E9R
myelofibrosis.2
established3
5'-AAAGGAAGCCACTGGAGTTCC-3
JCB1117
Kusy
4~~~~~~~~~1
Cefl
D473H
cancer.32,33
Tarrytown
R280G
64.6
LSL-KrasG12D/+
Nu-PAGE
.715C
Gastro-intestinal
T2–T4
5'-CAGACCTCCCCAAGTAGAGAA-3
EHE1
162/263
high-activity
c.2218_2219insG
L247P
9172
motifs.14,34
VelocImmune
.Cour
GST-AKT-PH/Linker
TAP1-Luc
G418-selected
4/190
UTS2
NEO3
BARD1-K619A
SLAM-family
Capicua
.Amongst
mathematically
26,27,29,48
Al-Hajj
here10
769-P
1063G
kinases6
XtremeGene
PCA2
R1881-stimulated
fromcultured
R119C
LDH
203EGSSS207
dnCul1
NCT02122913
LOVD2
R509Q
tSTAT3
mutation–overexpressed
8.43
Asxl1-null
5′-GCGGGGGCG-3′
124,125,127
pKT3-Wr
expression-negative
.KLK3
Lys8-Trp99
strategies9
.Calcitonin
Preter
Leu1086
MEN-2B
Departm
T674
Topflash
R844L
kinase-α
protocol.24
BZLF1
Iaisa
LBR
20–75
7/1,560
Screen—The
MYRA-B
PMD2.G
107-106
ERBB2-mutants
n=8/8
AWG
114–117
5′-GCATGATTCGAACTCTGTGTCGAAAGGCAG-3′
allsearches.RE
.Rowan
landscape8,9
MY32m13
phthalazin-1
.Hierarchical
WNT/β-catenin-mediated
potential.7,8
p.Arg285
1-ethyl-3-
Khotaro
4-parameter
andtransferred
NCN
R322P
.PC3M
pCR2.1-TA
S288c-derived
CK1γ1
antiHER3
ASF/SF2
C293–C304
meyloproliferative
Leu201stop
Anti-phospho-ALK
Tyr630M
ZKCyclinD1p1-R
29443696
Eyfp
region,3
trabeculations
growth/viability
NSCLCs21
.SUBCELLULAR
maleylated
red-herring
PDB1BI7
1927
A159T
SLC45A3-ETV535
-italic
6/109
TXN`
-33
33-44
Ret16R
groups.Cytogenetics
upper-
nullizygotes
tissue,5
CellLymphomas
PolE2
www.ebi.ac.uk/ega
diamidino-2-phenylindole
2p11
5′-cctcattctgacagaccagagcca-3′
.SMYD2
DERMATOL
N-Myc
Cre/loxP
cre-recombinase
i+1
components,58
PDGFRADDIM842
+1/−1
K700E-10
H193R
8173
.Means±s.d
TCF4-associated
BRAF/RAS-mutant
Paraffin-sections
IGF-BP3-derived
//www.endocrinology-journals.org
builtthe
0.8μg/well
Ras-compound
CD3+CD8+
F-TSC1
factorization
∼2-
transformation/mesenchymal
RPα
0.106
5′-CUACGACUCUCUAGACAAGUU-3′
HPMC
9/22/94
1.9–14.1
melanoma95
Autolumet
0.825
HGOC
T798I-induced
upslanting
.Anti-ACTIN
connexin-43
G34-H3.3
AA4
32:909-912
S1255P
Sera-Mag
double-minute
n.TABLE
PDP
02/19
.GV
Microchemistry
-2-hydroxyglutaric
antidigoxigenin-rhodamine
Mixte
338X
.R1523C
presence/absence
0.5–1µM
double-strain
2p-directed
Quehenberger
RET/M918T-transformed
vERE-TK
S1F–G
c.5894
Dojindot
2.49
factors/hormones
pCDNA1amp
.MEDLINE
2:74–83
Immunohistochemisry
CD14−
WEHI-independence
07-396
non-isoform-selective
angiopoietins/Ties
6,18,30,32
GVMs
'de
2079
TLS-mediated
2p13-p21
2.65-fold
EBRT
Lys99′
turned-over
μCi/mL
7.2±0.8
090
Fig.1a,1a
Lent-control
L1493
k.
Mathsoft
pZeo
2,000-bp-long
I11T
D1733GR
PEG300
B-Raf-IRES-GFP
Leiomyomsarcomas
flammeus
2μg/ml
Val170
model14
CCA/Ph+
0.900
truncatus
phosphorylated-AKT
rAAV
.24891
chemotherapy.34–38
.Cores
S.T
couldstill
progression-specific
CATCCTCCCCTGCATGTGT
NHA9
GIST.10
K445
0.157150487
Nhe1-Eag1
DPP6
pRB-MI
91.6°
2.2–3.8
ofmsh2-GD693p–Msh6p
neuro-
557_559del
poorly-differentiated
MEF2A-D
MAPK-inhibited
Notch-induced
NER-deficient
*Hill
5-mg/kg
n=60
Hist1h2bc
0.136
12/18/2014
ATRAresistant
48a
pRLTKluc
left-gaze
9–18-fold
.Synthesis
EGFRexerts
2299
2,247
induc
αs
IDHM
=15
357del4
D351-L540
Nippongene
TEV-cleavable
.N-Ras-T50I
10–100
trastuzumab-DM1
GSE21273
CCD-based
N-stage
DSB-inducing
˚C
-IEDNEYNP
Lys618Ala
R163Q
MMC-resistant
thepatients
PIK3R1
m001
MassEXTEND
FLT3-N841
escalate
100-mL
12/271
10.07
STAT5B-
.Radioactivity
CD8m/T-cells
.Denaturing
tissues10
rassignalling
speckle
N1819Y
Pro-B
T103
proliferation—a
β-catenin-specific
64.64
S222Q+S226Q
R610Q
5'-GTGCCCCT
BCC1
Y190
laGlu
Neigeborn
method,37
p.R509Q
GCCCAAATAAGCAGCAATGT
JAB1/MPN/MOV34
Coreceptors
2b/2c
Gunnarsson
Y279C-
'w
doi:10.1007/s00401-013-1156-z
snRNP-containing
Sc-878
Chandarlapaty
1978-82
HoxA4
analog-loaded
GAGCTTCA
E1794D
Tet1/PRC2-cobound
.HMB
BTB-containing
BrdUrd/BrdUrd
R302C
Positionsof
Caltag-Medsystems
CI=0.32–2.97
II-associated
treatment-naive
EML4-ALK-driven
C458.2H
Seichi
Pro-405
anti–murine
s-modified
rheb-GTP-dependent
tumor-feeding
therapy.Although
6H2.1
K482MB-RAF
E661
lters
well-behaved
Fig.9C,9C
Schramke
oncomine
Lys558Arg
S5B–S5D
.Infiltration
18/23
smart.embl-heidelberg.de
exportins
Woerner
short-coming
429–539
SmIg
T338
1980s–1990s
SortMeRNA
1.82
M532V
//itsa.ucsf.edu/~urolab/methprimer18
hippocalcin-like
studies4
ten-year
trastuzumab-induced
bic
0.06.
3-wk-old
Khare
214-241
experiments117
centrosomal
n=
,14
foci/
-enantiomer
.SCCH-196
N2a
-100b
87.14
AXIN2
Badalian-Very
bindingdomain
FLAGZBP-89
OSI-774
E82V
E001
Penix
AP3M2
Asn11′
N205H
63†
5′-CCTCACGCGCAGTTGCCCAT-3′
0000
Tyr-823
c.1295C4G
spino-solitary
myopericytomas
trametinib-resistant
D846Y
~67
99.954
2146
breast-cancer-derived
NF1-mediated
PDGF-R.
prednisone
,10
5′-TGCCAGTTAACGTCTTCCTTC-3′
E268K
Myc-overexpressing
lymphomas11
72-hrs
proteinwhich
6/144
DNA-recognition
themismatch
0.033‡
Smad2/3/4
MPLW508S
9,10,53
HIF-responsive
pattern-finding
delEx5
Intermolecular
p.Ala589ProfsX2
tumours86
tumor-transforming
5x‑UAS‑TK‑lucifer
lowest-frequency
roche.com
32,445
partner-mediated
Phe1174
SRXN1
18487A
p.E257X
ckit+
A_51_P426096
GPI-linked
5′gagggcgagctgcatgat3′
function/gene
XPO1-E571G-mCherry
6.7-fold
1975
GLI1-driven
Msh2+/Δ
R25A/S124D/T450Db
R228H
restoration132–134
p.G12A/c
PVDF-Fl
peroxiredoxin1
EasyMag
.BATTLE
1⇑B
_884+
A2B
Flag-Ubc9/His-SUMO1
LISSSIFLRFLCPAILSPSLFN
50-ju.l
myc-Jade
L1000
transgene-specific
â€oeMateriaalsnd
.CRE-dependent
allele-specific
V:25
4,6,7,27
.Ligand-Dependent
cytoskeleton3
601990
ERα128
activation.15
SETBP1
c.4987-3C
SpringBioscience
MDS-associated
AFM025TG9
pGEX-2T
Gbx2/Otx2
interferon-β
TRIO–TERT
.Transmural
Blegen
R7Ha-Ras
IRS-1/2
pCR3-HA-pVHL
±SE
.Alonso
bladder48
UUT
D194A
elsewhere.20
platelet/endothelial
S:16
Bβ
0/20
HindIII-XhoI
R465Q
retrotransposon
mechlormethamine
N-~4-nitrobenzo-2-oxa-1,3-diazole~aminocaproyllphosphatidate
occludens
2.9/MB
pEAE51
HPC2-Ubinuclein-1
conflicting.4,5
82–87
M156
DLL
.BD
Ferrarini
EGFR/KRAS/ALK-negative
CCDC14
Quantity-One
Keratin8
delV559V560
mGDP
59-AACTGGTGCGGCCCTTGCAG-39
3,944
rewspended
–polymerase
triple-hit
TEM/TEMRA
.P53
analy/.ed
vector-transformed
293a
ttttag/GCACTT
PrimeScript
150–151ins6
simplex
Ser-779
1-54
1Met
thalassemia.14
RAS-RAF-ERK
b–d
genes—IL-8
1–187
PTCL3
deubiquitinated
cells/well
'd
1/2-site
B28
505
FRK-activating
substrate-independent
tSmad3
992-1006
H3K36me3-negative
WlW10
213-232
Ap-1
1042
TSGprotein
26-30
H441Q
uid
registry-based
A96G
∼600-kb
transcript—C300Y—still
dodecylsulfate-polyacrylamide
ERBB2/EGFR
65-80
MSCV-G418
nickel-Sepharose
2,892
17-
DHSBH
Photophysics™
L211W
242–251
430-fold
.IFN-γ
423–431
12q13
CLTC-ALK
FZD2
ID3-deficient
phosphorylation219
anti-SR
−5.12
KYSE-110
SG152
DNA-minikit
Russian/Asian/Australian
c.4077delT
Gli1-dependent
1573
PI-3,4,5-P3
0358
K299AR300
LNCaP-C-42
0.52–1.70
E800
HPV
5.23*10−6
delG106
Figure8C
Stat5-target
17/129
A2–E5
Smurf2-myc
lymphotropic
51–100
1N8Y
MAPK-dependent
R-2-hydroxyglutarate
.Reduced
Y652C
3119304
al.24
Gene-ontology
MCF7.fgf-4
gcgaagcttgc
01/01
D107N
unclear.67,74
10,11,33–38
codon-optimized
HindIII/Not1
q35.3
Gustav
mUbRasK104
15,659
ASPP2
GTTTAACAACCCGTAAACTCG-3′
Bayarsaihan
Puncta
Findley
Roe
N-methylhistamine
Malecki
shRNA3
cNormalized
TET2-wild-type
exome-
9.3/100
studies32
p.Pro447Leu
0.22–
GPL10558
single-letter
cholangiocarcinomas
MR112
pRS316-TINV
NM_030917
.CK1
Pan-PI3K
12a–c
X3F
Srsf2-mutated
CCSP
alpha-thalassemia
STAT5-mediated
HDM
PF-8
Non-unique
aâ€œfoundereffectâ€•
40/364
1,223
A01
SUDAAN15
44/p42
Δ369
G/G
BlpI
El-Osta
G372C
A630P
conformation-independent
3196
0–0.9
prometastatic
CALN
Ikcda
nucleus133
z-scores
c-Kit
p12p13
.Becauseit
MRC1+
51−54
Strathern
Lys1195
ERα+SMA+
kα1
thatour
NFl-like
locusAbstract•
+216-1-791833
1-associated
bcl-XL
assays.60
120GX
9312
common.1
FLJ10385
DNA/polyethylene
.Masitinib
transcripts13
ERBB3-ERBB2
Glu285
I2285V
232.3
428
OperonTechnologies
yieldsobtained
Pisitkun
FISHb
418–421
Lysine-1423
NP_003233.4
GST–p300
3762_3763insG
VAKI
metastasis15
anti−N−terminal
.Nutlin-3
P-M600
PT06
doi:10.1007/s10875-013-9906-1
function.Interestingly
TaqMan
Anexin-V
XX,3q+,7q−
least-expressed
17/1629
ING2
FLIP-1
gHMSH2
dimethyl-sulfoxide
late-temporal
639-8975
Y599F-Flt3
four-state
epoxy
TGGCCCAGCATTCTCCACCCTT
DIS3-knockout
GradeBorderline
Dnmt3af
.IL7R
multinuclearity
prescreen
N-CoR-mSin3
0.125mM
H2347
FastPrep24
NM_005656.3
GSE6338
Q120E
.Desmoplasia
~1/6000
findings.9
receptor—but
16.3/25.6
-21R
Bialkowska
1∶1∶0.1
∼5,680-fold
YLIRR
8–
control-infected
DELeteriousness
Ter-119
.Plotting
SSX5
oe-
OP115
PLOIDY
phospo-T58-MYC
TPT1
LB9507
ERBB2_HUMAN
Garcia-Closas
resistance.50
pYAP
T240R
cdc37/Hsp90
pathogenesis28
colonies40
5′-CGT
Plasminogen
chemotherapy-resistant/relapsing
D1/c‐Myc
.Tuberin
truncations+BAP1
Massague,1990
51:54–65.Anterior
GS-expression
148,526,024
Q648Q
D425A/C459S
ATG7–BRAF
12/01/08
clustering–based
G435R
HA-Mer
K753E
0.673
countervailing
AlÃ-eleAre
granulo-macrophage
0.16
chitinase
mice102
nanospheres
Kadcyla
218/531
16–20
Carcinomatous
pAD4-Ha-Ras
SB1.3
Y1230D
4.0e7
WA26
Asp874
Pbrm1−/−
5p13.3-p13.1
0H00
TAK-733
co-segregate
Glendening
Rustandi
unfractionated
A_52_P796682
-34
Thr125
complex14
L528
anti-caspase-9
G614
out-flanking
re®ned
30×103
81.6
CTTCTATGGAGGTAAACCAAGTC
Ub-H2AK119
35-
AMI..
P596L
Hreidarsson
data4
5′-CCGCACACTCCATAGAACTTGAC-3′
T629A
D2016G
GW5074
ofboth
LGS
33327
GCB
Boramae
Smad3/Smad4-containing
YC-HRas
BCL6-mediated
.Successful
.Four-month-old
D860
95Â°C.45
Rebay
Runx3-null
244
9K2
Novocraft
ALLEGRO42
tropomyosin-derived
ZEB2
reports19
W545
polyethylenimine23
DIPD*
NM005228
alpha59
tg
BsteII
significancea
BcL-xL
p414GPD–p53
n-DX/n
CS-02
.Langdon
p787A
UCCAG-containing
2460–2479
habours
Universidad
NM_009250
p53-reconstituted
S6272
Hueber
practices19
wtEGFR-bearing
SULT4A1
c.283A4C
S267insSTVVGGD
2F–H
regulator7,8
luciferase-promoter
E746-A750
Q63L‐RhoA
rhabdomyosarcoma.8
p.P34R/P34L
GTT-3′
5′-GTGAATTGCAGTCCTTCC-3′
HCF-1
PICALM
Eif5a
acid-binding
C1084
mutantshows
K539L/F595A
p34.2
43K
DEC-consult
3q26.3–27
54°C
B538
CIC-CR2
0.35–
BrdU+ve
G/T-Fam
radio-therapy
airflow
RUS08/
heminested
nucleus,44
pCDNA3-Bio-Smad3
MPV
TESD
lanes15–18
5E1
cSNP
23-27
adenoviral
development14
OB1-OB2-DSS1
spindle-defective
40-90
10-y
0.64*
DIG-Nick
homeodomains
R167T
Battista
Bmpr
c-Kit+
3015
U34032Types
NMC
cytidine-to-thymidine
RB-
Arg2691
XGAL
pSer675
STRN.Fusion.Ex6.1F
Myc-systems
.BRCA2−/−
9100
1cen-p31
histogenesis/line
Val470
3q25.1
Oligonucliotide
inheritance1,2
RasK117R
L785F
High-risk
crotonamide
multi-cellular
Technologies.9
partial-gene
reorganizedin
7MW
NRK
1449
c3496G
Shc/ENIGMA/FRS2/IRS1–2/Dok4–5
z-transformed
two-drug
mutated-AML
P449T
Mangiarini
pMSCV-puro
pLKO.1puro-KIT
12-566
.Wray
cancers3,19
NKX2-8-PAX9
MAB1264
Figures1,1
GenTarget
Christner
k1H2O
Jaw
2/2,105
Pterygopalatine
V599DB-RAF
66°C/45
un-liganded
KPi
H3.18
Assays-on-Demand
Shortlisted
9.3amp
Gadolinium
~lower
PSM
F_EB_R_U_ARY
phospho-MAPK-specific
score/median
K/ml
conceptualizing
99.0∗
kinase–BRAF
pseudo-glandular
Troester
BRAFQ257R
NI-ESS
mucocellulare.Upon
age-of-onset
carcinomas65
EFV
dpm
1,602
R603Q
21.15
p.N581S
targeting2,3,4
c.655AG
GNPDA
3/62
recrystallise
Egfrwa2
Josef-Schneider
1.871
Smad3-defi-
byapplying
915
MutSα-V161D
6.41−2.71
CAGCAGCAGCAA
convertase
previously14
P=0.00089
Rat-2
S112
Lackner
1188
610Q
eYcacious
unpubHelix
213,4
HMGA2
survival.11
tomography81
observations3,4
98.9∗
FGFR2IIIb
9.47
α/β
p120GAPtype
Mg+2
AGTGACCAAGAACCTGCGAC
response.3
EWS
0.4–29.3
A594
NIH-Image
symptoms—shortness
SRC/receptor
.Cooperativity
interlobe
gustaveroussy.fr
myeloma—is
81
sorafenib-specific
-mmf-max-hq-mismatches
0.12–0.55
T286A
immunophenotyping
hMSH6/BluescriptSK
probehead
membrane-P
.S6H
exp3alr
.FA-D2
thiol-containing
R99Q
pTRK
drugs.12
c.292C
classified.4-11
Δcul1
CYC1terminator
bsd.uchicago.edu
.Baker
.Gaiddon
Hospital/Harvard
NGEF
Arg258
mutation9,32
immunocompetent
Recloning
P648L
gatccccTGGTGATCACTCCAGGTAGttcaagagaCTACCTGGAGTGATCACCAtttttggaaa
76/972
Inchinnan
anti-U2AF1
types74
domains.37
P490-Q494
©IRL
respectively21
Ptch.Constitutive
GAGTCATTTCCTTCGTACCCAC
AD_ALT
infraclavicular
004064.3
CCACCAATGGAAAAGGTTCA
5′-GCCTGATCCTCTGTGAAACCC-3′
p27WT
Europe,15
siPRKCA
061
G231V
1D-IEF
p.Q602
DpnI-treated
651
2F*
Discussion•
TPM4–ALK
Y376A
sequencing23
others4,13,24,25
anti-SREBP1
phosphoimager
mSIN
2,20,21
pathophysiologies
mimosine
FNIII
0.15µg
Kitakyusyu
8878
PDGF-CC
Xeloda
Daiming
K51Q
4.84
aminoallyl-dUTP
Fgf17/18
glycopolypeptide
MSK538
.Making
oil-free
tumour-inhibitory
.1-
HSB2
222–231
6llATCTCFGCGCATfCAGGAGTG214
2,268
9w
MN31
background-specific
C490
/Akt/mammalian
9621
VPS13A
,0.0001e
-CT
4MKC
αC-helices
A375
9q34.13
I-set
66/140
CTD
Exon1
pre-plated
anti-PTPRD
cistrome.org
19-mer
~50–500
Group/Cooperative
Y969
AM129B
POG8704
D415N
approach.9-12
MSCV-NUP214-ABL1-IRES-GFP
exon–intron
6240
cific
619
.GBM6
functions.23
v56
erbB3-mediated
Q3141X
cells153
Δ480
RAG
286th
Ataxia-Telangiectasia
RSXpSXP19
seaplaque
UniSTS
R644S
.Homo-
carcinogenesis.36
−22.1SPRR1BSmall
ALK-fusion-positive
GSEA62
p21/CDK/PCNA
Y1349/1356F
representativeclasses
vitro-phosphorylated
Intravasation
.1E
Mx1-Cre+
Mg-ATP
HLH-deletion
p55α-
146bp
AMEL
TCACAGCAGGGTCTTCTCTGTTT
22-2S
E208/212
marks13,14
cullins
off-treatment
EGFR.27,28
001025577
Y40C
pRB-containing
322delG
approach35
Y65C
Xcalibur
Willmore-Payne
ultraspiracle
19/32
data-processing
p.V559G
high.10,11
trametinib-treated
streptavidin-biotin-horseradish
melanoma-related
Purification—Human
c.1424C
IP-kinase
betaB
E676G
S293
REB
Ma-Mel-100a
TEL-JAK-transfected
185‐kPa
c.211G
1-meA
ZHAO1
HCC19-1010
Rheb-WT-mediated
5′-CCAGACGGGTTTCATTATTAT-3′
Cfor
siPOR™
117
ER.29
SC-227
Y440X
miRNA-binding
pAD-BRCA1∆2
117.00KB
553311
mammalian
sequencing.1
lenalidomide-treated
pDONR221
HA-tag
1442
knockdown,25
non-ligand-induced
FCγr+
Zeb1
ULSa
CRL3-NPH3
neoplasms.5⇓-7
−11.6
2-cyano-3,12-dioxoolean-1,9-dien-28-oic
andmsh2-AD872
TBS-T
NC_000007.12
T386A
GDC-concentrations
0.91^0.98
ubiqui-tin-proteasome
i.e.chromatin
c.1059_1062delACTGinsCAATAA
donkey-anti-rabbit
Transcription-PCR
T.C
IPF1T
controlThe
atposition
Ile-Glu-Thr-Asp–P-nitroanilide
TTGCTTAATGGGTGT-3′
reverse-transcriptase
cytomegalic
5′-CAGAAACTCTGTGTGCCTATAAGAGCCATGC-3′
I1062T
anti-small
Rebaı
53-162
31F
.SND1
.Ligase
cascadic
pX330
rnaseq
proteases
bombing.Adapted
gammadelta
H4
Komatsuzaki
SRC-2/GRIP1
Gelfoam
Inhibitor…
Cdc24
PDGFRA/
attrib-
TIE1
subtype8
activation14
KIT5
4Molecular
CpG-interacting
GATGATATCATGCGACCCTCCGGGAC
anti-phospho-STAT5
MultiGauge
4M1T
V-18
NDE1
dNMPs
c.2040_2041insTT
9351S
I540–548
R410W
A_52_P925197
Recessive
113,510
disorders.8
p24–25
described62
0.00738
RasG12D
GeneChipTM
3X-FLAG
IRF4+/BLIMP1
CCDC33
Smad4/Dpc4
p21cip1/waf1,11
4.51E05
neoplasm-associated
hMSH3
p.Gln2325
∼2500
58.5°C
Tyr-
DERKD334N/sem
UROD
248–467
reticulum
heterodimerization
BRCA1C
S29
progression.32
osteosclerosis
7p12
tropomodulin
mutation.15
MCYTOMAG-70K
OncoScan
Retransplantation
fifty-three
40~~~~~~
C152R
Lkb1-SL26
.7,15–21
.N-Ras
HLH-domain
SNIP1/SkIP-associated
originates.3
ABySS85
2,818
mutations1–5
pathologically
B‴
55b
13-day-old
.Monocytes
non-Amsterdam-criteria-fulfilling
c.-138^2641
2A-Puro
29/44
HER2.rtTA
.Jews
Path-scan
bonemarrowcellsof
RHO
Kamata
.PLC-γ
Leukemia/lymphoma
Four-month
Togashi
*T
nology
Rdd-BRCA1
pY10
NM_058216.1
E-cadherin-expressing
0.21c
AP-HP
Lux
p–signal
p.P1132L
MUC21
concentration-time
CAG-3
.Knock-down
echogenic
cells.30
DeltaVision
EMM1002-5800626
Universitario
01/38
EGFRis
0.39–1.00
P1614S
5′GCTATAACTCACATAATGT3′
DME2
.Fig.5,5
RET-KD-P
Vectoshield
disease-causative
tofunction
HI-1
.S478N
KMT2E
D1546Y
EWS-ATF-1
FAT1-siRNA
5/71
enterohepatic
E061
0.172261585
**Po0.05
pTyr1045
7.4557
8.13
Q347_A3438del
site-speci
infre
Pi3K-driven
0–16.6
.NSHP
IC99
E10fsX35
WT-PIK3CA
Tor2
LV-LIN28A
liposarcoma–associated
Yesce
nontransformed
0.4846
DuCaP
A3421V
Olfm1
TGF-β/SMAD3-dependent
CAMTA1
S4J
cells23
Cys278Leu
GCATTAAACCAGACCTTATCCAGCTGAAAGACGAGAGACCAATACTTG
TGX
10417–1-AP
320×
.Recombinant
FMR1-201
0.437
bone-morphogenic
C1787S
0.7683
V84D
p.Ala573Val
E-GISTwith
dchip
M.O.M
383–390
FANCF-
424-445
.William
MSCV-ETV6-PDGFRB-IRES-GFP
spine/back
anti–phospho-ABL-Y412
T1010I.MetBaF3
receptor-defective
regulation/
KO52
EZH2–β-TrCP
Adi
2207
granulosa-luteal
BCR-Abl/T315I
GTG.CC.GCG.C
lacZ+
trophoblast-specific
function5,6
116.4
Ascano
INI1-1
pl6-Arg87Pro
anti-b
NciI
sub-cellular
c-H-rasfrom
2Rβ
Exon28
de-tected
†Host
pGL4.17-basic
dCTP
6A-C
WT1-mutant/CTNNB1-mutant
gastric/
Odin-deficient
β-aggregates
reports5
CAAACAAAGCTTCAACAATTTAC
THY1
C275S
Hoxa1
temozolomide––provides
.Washed
HIP301F
7.DNA
E2F4/p130
patients61
69.88
30-pg
.III
S7I–S7K
levels16
AUCinf
Pinol
L460A
C162Y
8mer
Barthel
randomisation
CLONALITY
cholangiopancreatography
ADK
XLIV
.fuller
Barczak
Cdkn2b
.Depicted
K61A
Fulga
hDIS3
.FK506
0.0287
10-46
activation.A
therapeutically
e5
target-recognition
14*,10*
1261
5′-AACGCCTTCCATCCGTCTGG-3′
EDTA/1
IL-3–containing
S648A
IFNGR2
UTRMUT
phosphorylation/expression
gland44
77/F
RBy33
820
binding–folding
R2784W
D915N
E326
hairpin
25/110
mH1a
studies,19
Pro-253
mono-methylation
mice16,17,69,89
targetthe
W/V
domain.42
positively-
exemples
0.0005*
Del603
chromoso
promotor.42
OSDROOFWKroCAQTOGCCA-
adenoacanthoma
.557T
88100
5′-GCACTCTCGTCGGTGACTGTT-3′
Quickprep
Neh5
HEK-293T
Gentien
Eastman-Kodak
FirstChoice®
GGGCTTTTTCTCC
CEP85L–ROS1
.CCND1-HA
p.51
711-136-152
³5
28-bp
GBM-derived
gi39973949
Jae-Seok
D16MIT4
instability1
20,23,25
development8
.CCT
ubiquitin-HA
genomicSuperDups.txt
3373
BbvCI
NBS1
cohort.We
MAN1B1
X-tile
∼0.5–1.5
28177
.Upstate
PEST-mutated
|Fo
granulocyte/
644–859
pathways193
al.,10
HPNE
CS09
interleukin-1β
A89
Tyrosinase-related
Thiobarbituric
research.20
VDS
CK20
exona
patients.Histopathological
cycle/cell
nullizigosity
FOLFIRI
RUNX1tr
PCR5pD
B5
blot27
EPD13
High-molecular-weight
liposarcomas/atypical
forprogression.These
2p15-21
aprotinin
I57T
1×10−5
5′-cctgtgacagagcccctcac-3′
Fridericia
complex–bound
mutant-bearing
.dsRNA
tumor-type
1214
BRIM7
Navelbine
.LBD
cDNA3
conformation10
protein.21
+Torin1
v10.1.0.0.0
EGFR-inhibition
polymerase-mediated
P=0.019
IVS24–6C/G
11–3
T670E
anti-tubulin
Fe3
Hs578T
48-60
palate
0.0018
described46
TGAAGAGGGCCAAGATGGACAAGT
Xp21.1
Leu350
MSK921
c.1349delA
500mM
:248-253
ERα-target
GnRH/GnRHR
MEK1-C121S–expressing
blastic
Rigid-body
0–9.1
p.Val112Glu
S1206R
causedby
Supra-additive
chaperones
10/6
731st
30-nm
progression.33
0.069Mean
TUMORIGENICITYCONFERRED
ArrayStudio
P230A
NPM-ALK-R1192P
Xylene
non-responsive
^CCT
Two-class
q21.1
self-ligands
G674Amutation
refametinib
CytoScanHD
2/49
hannonlab.cshl.edu
neurofibromas.10
Recombinant…
0.968
zligRII
R175H/I254R
2.77
005027.2
n=106
MIAME-compliant
2071883699/82579
RGI
20:315–326
Counter-intuitively
MSD
method17
.Truncations
−5.6
.Novel
40mM
R356W
CAGGAAACAGCTATGACCATGAATACCAGCCCCAGTTC
site17
c.3756_3759del4
'-thiotriphos-
FA-J
ΔΩnit
D-I
oncogeneinduced
15-3
2A2A
Tel/PDGFRβ-mediated
Plasterk
investigated.13
Parkland
wts/lats
PSG
04
Â¿igof
trans-dominant
c.174C
Seishi
antiActRIB
.AML
.Gapdh
Val599
TCCGGGAACACAAAGACAATA
EGFR/ERBB2
BMSCs
PBS–10
ESBP-2
pI-12-WT
I182T
BCR-ABL–amplified
psycho-oncologist
.Null
paralogues
loci.28
anti-phospho-RNA
450-nm
31368
−6.2
permeabilize
homodimerization
Brethon
TCGA-AA-A00K-01
phospho-SMAD2
EBNA2-R3
cbl.2364
10–95
​and4G
p.Lys158X
Fig4E4E
software9
GST–EGR2-WT
S145S
4-based
.Partially
type-1
GTL-16
IVS7–1129
MFGR1877A—0.3
dilatation
interdispersed
bMSI
Roeder
9662
disease/gene
nt805C
.HAT
R905Q
Boffetta
0–700
G607S
R1737E
co-sedimented
pCB6p53wt
R26CreERT2/RMCE
Albumin-Cre
Identifiler
GFP-control
adenoviral-based
Pharmacea
grid-based
polydeoxyguanine
cDNA.4,17,18
formation.33,40,41
.02.
Twenty-meric
Casp9
'Mutations
BA=BCR-ABL1
Arrowheads.positionof
Protein-extending
mutated–would
.Time
3H-all-trans
current/former
.BEZ-235
ataxiatelangiectasia
Uden
Q61.1E
μs–ms
33.8-57.5
V1.1
cycle.19
WNT–β-catenin
S1H-L
Walunas
Ekholm-Reed
IL3RA/CSF2RA/CRLF2
gene.37
Br55-Kd67
detail69
E048
N127I
106K-ras+/V12
555–558
.Kin-
Parafibromin/CDC73
phenotype.33
IFN-γ-producing
inter-tumoral
TFAP2A-mediated
BX-60
8a–c
10μM
non-ubiquinated
MSCV-HoxA9-GFP
ter49
sh1–sh4
.§Family
14–40
MSCV-I-GFP
Y471S
~125,000
frequent11,12
.Hes1
anti–phosphop42/p44
24.10
RTV
GeneCodes
BL21-competent
20–36
68331840
Yoshiura
R127W
LFNG
.013*
KIT-activating
§Consists
α-hemagglutinin
Hy-
E1036K
3′-phosphoinositides
silane-coated
5′-TCTTCTCCACAGACACCACA-3′
125–350
Dubowitz
Akt-negative
MRIP-NTRK1
ROS1S1986F/Y
H445Y
tumorigenesis.16
e15
Ex38
-AAATACTGTCC-ACATTGACCTC-30
doxorubicin–ifosfamide
T725T
T598
.463
Fig.1b1b
anti-centrin-2
mCP1483
COSM159405
85.2
'uncertain
Thr790Met,64
EWS-ATF1
p89/4x48-Luc
CENP-C.
A25T
25uM
BAK
retronectin-coated
RAG-induced
anti-cyclin
3,131
D1155H
115.9
Probe.F
a32P-labeled
RP11–208F13
fibroblasts.6
-Log
CK1α1
1:1
cells/lane
bi-lobectomies
25†
-Q510E
chaperone.32
Craf/Rok-α
lizing
A1024
ICT2133A
day,13
transgene-derived
CRL3-MAB1
.S2.1.1
MIGII-KIF5B-ALK
raicontaining
drugs.33,34
bicinchonic
mutantion
0.295
TAp63α
antiFLAG
CEP290
central/eastern
p53-downstream
CDK8-FLAG
PAXgene™whole
phospho‐
497K
theTRK-T3
thiocyanate–phenol
KAB
Akti-resistant
iCCA
I1628T
R417C
STAT3-mediated
phosphoERBB3
phenotype-ataxia
marker-negative
MRPL45
phospho-Erk-positive
scription
CCL‐110
PNMU
Col2a1
7.0–24.9
domain.42,89
EWSR1/CHN
.PI3-K
G.1
1Table
root-mean-square
G334R
GTGCAGCCCTCAGGGAGTACTCCCTGAGGGCTGCAC
CI=0.84–1.12
SKP1–cullin
2.532
understood1
0.4397
chromium.liacs.nl
.Fibrodysplasia
W170R
potential.11
2HYY
pgpl40Ok
3Tag
inferior-prognosis
RAC-mediated
diagnosable
Present/not
RPS6KB1-TMEM49
A.B.G.
Pulser
145-
Tumorigenic
RBL1
vector-alone
DLK1
BCLXI
FIP1L1-PDGFRA–overexpressing
5–8.Soft
CD8−ckit+CD25−
Mono-Q
Bax-derived
CD68-positive
residue76
H-marked
aminoactinomycin-D
Lagadec
C243S
patients176
99.921
//www.cbs.dtu.dk/cgi-bin/
Hong-Gang
AKT-targeting
Blast-phase
↓WM
UK,19
1037
HA-SOCS1
morpholinepropanesulfonic
0.0186
_in
-L-glutamine
maspin
Nassif
23A8
th-
YesAbbreviations
.SAOS2
Mitosis/
A-loop
31.3
clarification
Supplementray
D19S894
FluoroImager585
.TheBgl
v3.1.1
P163L
Figure2d,2d
LGS/SB
604–605
4u
35/58
.Meta-analysis
rGADL1gene
transfections
53-7.3
Tokumo
Cross-breeding
RG-26T
ACTG1
c.5238C
S2F-M
GTP-cluster
CTGTCCCCCTTGCCGTCCCA
preplating
.Tuberin–hamartin
H2
1p36.23
well-packed
012
CAGGCCCAGCAGAACAT
GST-Cep-1
Pik3cae20H1047R-driven
uniplex
doi:10.1371/journal.pone.0025021
9qA1
carcinomatosis
Q408P
Genomewide
c-DX/c=1.20
P18
L1255
lysosome-like
R1495M
Grilley
E439K
Ampliseq
0.0111
dimer–promoting
T-cell–
BioMuta
factors51
S7PY.Alternative
KASLEEAQI
MEK-
BacPAK
1016delA
One-hundred-nucleotide-long
RD841
LIKFYNTIYVGRV
S435F
protein.7
d5
2q29
.Hyperphosphorylation
3Polymorphisms
Tsygankov
Keap12Nrf2
TRAP-Mediator-like
2ez6
.Coincubation
LxxLL-like
ZFPs
CACTCTTCCCGGATCTTGTTTTTCT
Cre-recombinase/LoxP-Stop-LoxP
234×108
RG-9T
EORTC-CLG
20/15
FluorChem
V344G
.Rainer
R189T
BALB
SIFT33
117,654
Hollsteinet
pAD–BRCA1
p.Note
06463922
H1094
20q12-q13
0.452
Antley–Bixler
cell–ECM
.PATIENTS
N1-IC
JAK2/STAT5
anti-hemagglutinin
pDM8
Anti-Sox4
Tse
GSP781-783ins
domain84
.Illustration
2330
c.7977-7C
ABC-type
denervation-induced
p53si-1
FOXO1—Our
.Asp1002
≫
Val59Gly
12,14,15,24-27
pathogenicity
GTTGCCTTCTGCTTTGATAAAACTT
p48
KrasLSL-G12D/p53flex7/flex7/Brca1flex2/FH-I26A/Pdx1-cre
p21ras·GTP
SCF/CRL1
.Coamplification
Combaret
Plasmacytic
finalised
+43
S2–S2
/49
144–228
thiazole-5-carboxamide
59-CCAGAGAAACAGAGAAC-39
genotype-matched
Vierstra
substrates.30-32
P327L
Tec
K125/128R
Y443S
138–145
structure.52
R505Q
3.2519368
Gln470
anti–T-cell
Aml-1/Runx1
T312S
Q61.2R
Mammospheres
f/55
CO2-humidified
ΔLNGFR
25,26
1.Cellular
L2576
Nmi
P202A
QuikChange®
pragmatic
mm2
R96W
1.44E
anti-BARD1
RP11-58H17
subunit13
IRESSA
Akt-
Sf3b1+/K700E**
CF5116
D252G
blottingStandard
CK5/6
19-day
Goldeneye™20A
codenatured
S6K1
8/94
SGK1-mediated
outFilterIntronMotifs
18-base
42/41
SP4
2/A
10-14.9
noncontrast-enhanced
10St
C515
CENPK/FKSG14
0.60abnormal
Sall-Sacl
c.105_107delGTA
6116
–m
3p25.2
†Intestinal
Anti-phospho-γH2AX
.PIK3CA-KD
K101MMEK2
Necropsies
r=0.9978
domain-exchanged
H1069Q
786-0-PRC
97309311C
Ml-M12
33–74
NUP98-HOXA9
–/–
Cdkn2a+/–
+216-1-789608
28-
oocytes
AML11
maria.debiec-rychter
Ins-LacZ
1OPJ
6/419
O-phosphotransferase
LXT
_y-32P
Fe–S
d-rhodamine
sequencing11,14,15
counts/ml
14/26
993
14/25
−0.29
Smad2/3
45-47
2003.
Glu659_Phe1248
pcDNA3-Flag-TSC2
MedB1
Poly-ubiquitinated
16-year-old
1061
1p22
ETS-positive
4032/4720
26–55
subcarcinogenic
V867M
pathoResearch
RP11-163D23
VHL-wt
L2016R
60Co
Hitchcock-Dartmouth
cellullar
-acetate
Z-regular
5'-flankingregion
VHL-dependent
14,18,19
pENTR/Directional-construct
TD2
Zn-SOD
treatment.21
FLAG-Peptide
'overexpressed
Podocyte-specific
patients.BRCA1The
seconddegree
homology-1
Blimp1-deficient
cycle-type
ERCC3-derived
0.00
15,109
cells––cells
FDG-PET
5001–6000
Assays—300
T49.3
nonreconstituted
1:2:22
374400
Botany
IL-3–mediated
−2.38844
ninety-one
reaction–based
Smad–Smad
doi:10.1186/s13073-016-0393-x
.Genotyping
coregistration
3-carboxymethoxyphenyl
CS,21
q=0.039
rearrangements.34
radio-sensitive
genotype-cell
IVS16-14T
1,096
DMIRE2
HA-HIF
sunitinib/SU5614
Y568-Y570FF-D816V
NUP98
.Comparable
anti-pAkt–specific
.Pentanucleotide
P1082S
Max‐mediated
partially-degraded
mouse–anti-human
IGFBP4
sequenceGC
N-Cadherin
response6
pCDH_EF1
.Isoforms
,41
Lymphoma.10,11
1–prior
CUL-1
EGFP+
®lter
T1148
3611-MSV
G-TCCCTGGTTC
ofampullary
.Lyubomir
barrel-shaped
E353Q/G390D/G442V
cyclirn
IVS1b
perspectives•
Kadel,1,2
Completenessb
Amundson
proliferativeresponse
Trp135
61-3-9656-1247
reported14
c.3008-1G
Isoform-Specific
WT/CD
S795
CAR-PAC-TRAS
.S22
FGFR2S252W
18,5
5′-CCATCTTGTCGTCTTCGGAAATGTTATGAAGC-3′
15/M
ljmedeiros
neoR
BioTICLA
A741V
59-39
/MTCP1TG
C706Y
806C
CRISPRv2
PTEN-401
G430
UPMM1
described50
PBAF-dependent
H383
DISCUSSIONBased
5′-TTACCATCTTTGCTCATCTTTTCTTTAT-3′
R188137.712.3272Relativeluciferaseactivity76
TGFf3RII
.Dasatinib
~1.45h
p.S241L
GAB
protein-disrupting
T417Δ
growth-factor-mediated
proteinYFPyellow
Com61.2
p53F/F
-7R
CD45RA−
cyclin/Cdk
anti-PDGF-BB
c.206T
EGFR-ERBB3
AR-V11
rare13
4–410
4˚C
BRAF-inhibitor-induced
O-5′
55C6
cells.DISCUSSIONIt
Anti-Mouse
phosphodegron.18,37
.4575delA
Leu609
M+H
dumbbell
5′-TTTGCCTGGAGTTGTGGATC-3′
2013b
Non–Small
compactin-treatment
16q21-qter
Forty-eight
tracheobronchial
doi:10.1038/sj.onc.1209873
Ezh1
-exon
FoxO3A
GGCTGGGTACGATCTCAGTT
R178H
hyper-recombinogenic
TFIIB
-15SK
worldwide10
Medulloblastomas
FLT3-ITD/F691L-AL
free-form
6e
damage–inducing
CCTAGAGTTCTGAAGCACGCGGTTCTCAGT-AAGCG
E542V
MEK-independent
cytoskeleton-
agaTacatc
.IGF1Rβ
LEDGF,21
Means±s.d
light-insensitive
under-reporting
≥0.25
CD4‐mediated
.Snf5
Re-challenge
120–201
c-SRC-T341A
98×108
method74
multityrosine
cells46
COS‐7
fluorodeoxyglucose-positron
Bodmer
JMSU-1
1–15/16
TTTACTCATGGAGGGAAGC
aZ.
WNT5a
586459
9°/eul-32
membrane/cytosol
A937V
FLT3-D839
mucicarmine
drug-gene
5¶-CATCCTGGCTACATGGCTTT-3¶
CDB38
1.5-mlpolypropylene
Co9
integrin-evoked
IDC
.Joan
Biscardi
anidentical
Cd11b+
60−kD
.Acrylamide
8755—several
1YWT
4/490
Absorbances
121–126
T161A/T161A
singlecopy
×100Percentinhibition=100−
22,000
GGAAATGAATGGGGTTGGTAATG
α6β4
molecular-genetic
9–31
2919
anti-TFIID
.2H
Lbh-expressing
Wat'75
occurconcomitantly
Syndrome/Li-Fraumeni–Like
Leu871
identified81
al,9
.K.
resection.5,6
n=53
IHD1
1,169
R89LC-RAF
3144–3150
1769
S1826
codonand
Carolina.8
5′-GGCTGTTCCTTCAACCACCT-3′
KM12C
Endogenous
c.394G4A
Orthovoltage
pcDNA3.1-Flag-VHL
certinib-
0016-5085/01/
135–414
NM_018130
14.1×103
DNE.
ncRNA
possibil-
testosterone-producing
THUKRAL
5′-gggatcctcacaacttgtgccggaag-3′
ruxolitinib-mediated
p-rpS6S235/236
BSA-PBS
Mnt/Rox
L-368—anti-human
3262
44:16246–16256.H1299
66-69
.Author
SKMEL-239
Surg
correspondingdomain
.7-9,17,18
PPV
230-
drugs.12-14
59-CATGGCATAAAGCCCTACAG
6/55
V397A
ARID1B-mutated
haptenized
.Jose
LC802a
'androgen
colonies/mg
grade.79
10MF/10HPFs
p21-23
.ΔNterm
invasion/migration
CLB-PE
K413E-transfected
E561A
Y280C
.Forced
WebsiteThe
∼10–20
7271
p.S257P
^534
TXT-MASA
senescence-associated
Serizawa
5549
A175-180
19/23
DSB-Repair
trans-well
b-subunit
**Hershkovitz
bis-benzimidazol
AAGGGCCCTGTGTTTACTGTCAGATTTGAGGATTC
43a1
TP53-negative
neurotized
non-DNE
261–270
log2-coverage
R303H
protease-associated
GATCCTCGAGGGTCAAGTTGGGACACGTCCCTCGAG
erlotinib-mediated
.V617
Suc1-associated
transactivated
EcoR+puroR
Douarin
.BRCA1-deficient
BRAFR509H
E11.0
L747F
cleavedPARP
gig/Tsc2
β-casein
.Chp
LTR
C569Y
17q11.1-q11.2
RPS3
TGGACACCATACTTGAGCAG
myelofibrosis.26
R209T
CCTGCCTGGTGTCTGAAGTT
.mutations
2235-2249
chemoattractant-induced
nonproductively
2303
rhIGF1
VSV-G–pseudotyped
uab.es
T-LBL
ETV5
ProteinPack
AT-CMML
13–19
geftinib
c.1754T
Fisher-exact
p210
L209A
D1/Cdk4
5′-aaagtcatcctggtgtgggagaaggccactg-3′
1,307
AROG
62/63
M/9·6
1901–1928
dom-
S5O
50§
phosphatidylinositol-3-kinase/AKT
NM_011202
respectively.Clinical
strand.10,11
Eμ/MYC
Phe1241
TrimGen
16/37
RC/A
G289E
22.7
Q209
Lindmo
VSV-G
pre–crizotinib
R265C
−1.38
ets-like
HSF2
7,260
12p12.1
.Unconditional
c.48C
-4B
themedium
f/52
TKI–naive
Dharmawardhane
manner52
intermediate-expressed
treatment86
pcDNA4/myc-HisA
eutz-Jeghers
H3-K42me-specific
p.R625H
specific/CpG
73-bp
AAC36493
andTAFII60
NKX3-1+/−
IGF2-amplified
13,15,16
collagen-producing
cetuximab-treated
NGF-activated
GR-11146
245-571
fusions—NPEPPS-EPHA6
advantage,42
11e
Y98N
tni
R.D.C
A1708E
Haplo.Stats
rs1914
vitro14
I406V
aImpact
c-MycWT
genes.10,11
1815nM
tiinalund
p=0.158
study,46
30°60
lymphomas.1,2
polysaccharides
delinsKLN
0278-0240/04/
G446E
pRB-associated
optimalinduction
VUCS
Vivo
replicationcompetent
resuspensed
G463R
CSK
Asp1213Gly
2772–3969
TCGA-KM-8441-01
NFL398/CFL394
S179R
c.1976delG
si-p65
33521
R970
G1202RCrizotinib
short-course
Thr408LeufsX40
50–1.6
pG418-CRAF-B
FB312FB
analysisAll
PDFGRA
TTD
homeostasis.25
by/with
dpsnp137
owczarzaki
mll2−/−
co-overexpression
M20537
NS-derived
.Transiently
437^445
S1B–E
nihms646437f5.jpg
NSD1.30
Myc-LZTR-1
functional.11
full-term
L747_A750delinsP
CRNDE
Snf5fl/fl
70Z/
shepherdin
2-DG
aromatic/hydrophobic
ARAF-RBD
andsPGL
DDtagged
∼2,000
Kiyoi
light-induction
5′-CACCTGGACACATTCCATGA-3′
Fig.4A,4A
non-cytogenetic
Hypercalcemia
GAAATGCTGTTAGTT
heteroduplexesor
1DC3
5e−4
1.674
-WT
B-CLLs
Hilgen
segment6
hepatoblastomas.20
Q442X
ChemiDoc
35.4
17-5,898
checkpoint91
-tagacctcattcacgagtctgc-3
L363
MDA-MB-134IV
ttcatttcag
c.1454C
2.9.2
5¶-GACCATCGCACACCGGCTTAACACTATCATGGA-3¶
Ito
LFS-related
.Gender
5′-GCAGAGATGGTTCTGACCTCCTGCTGCTCATCCACCAG-3′
L344P
C8ORFK23
mechanics/Poisson-Boltzmann
552–558
tertiles
pcDNA3-transfected
Capan-2
type.7-10
NXS2
.Retrovirally
ErbB2-V659E
V9-2b
3.1×
forward/reverse
pCRll
H496L
dysmotility
groups.We
T45
36p6
//smart.embl-heidelberg.de
H371R
Sauerbrey
some4
P2–5
1530
TTGCTTAATGGGTGT
KRASQ22R
C615R
.DMs
BCL-xL34
Brca1FH-WT
J.-O
c4
GFPpos/mCherrypos
trkl3
c.828del
provenance
TopCount
Figure1A1A–1B
p15Ink4B
821–837
RNA-splicing
ÃŸ-cateninabnormally
G-csf
C106
BLIMP-1−
p.A597D
exVR
1394
.Specimens
8189A
Empore
polydactyly-polymicrogyria-hydrocephalus
Leu-104
2KTS
ACCGCTTCCCTCTGAGAGGC
cells.35-37
T2
.Diane
cDNA-expressing
.Merlin-S518A
08N43-030
bimodally
Smad3+/−
ras/effector
​andd
EWSETV1-expressing
.HS1
Grubmüller
P–Cb
Cdk/Cyclin/p16
37.9
element–coupled
.WZ-4002
transcription-profiling
R186C
.FGFR2-AHCYL1
c.34G4A
.primary–secondary
0.716
NeuNT-evoked
4-HT
25-kDa
53,55
1011
Degenkolbe
activity,6,41,42
samdeleted
Verhaak
3.24
DITpYADLNLPKGKKPAPQAAEPNNHTEpYASIQTS-NH2
3.15
therapies.3,4
.PET/CT-scan
MFI
2.095
AGAGGA
CD74–ROS-harboring
`just
TIDC
13C,15N-isotope-labeled
TTGAGAAGAGAAATACCCACT
Mm00436960
E336
60-day-release
mammary-gland
.Growth
H2Ax7,8
253K
Asp737
EC-differentiated
miR-125
2-pyridyl
LNZ308.ΔEGFR
immune-incompetent
Dax-1
pcDNA3.1-SOX17
Zeste
.Hypochondroplasia
delEx6
0.012*
4A-B
ubiquitinspeci®c
1°
p53-Y220C-
association—Barplot
Brca1flex2
16§
CS-32
MORF-CBP
.Sampson
F∗∗∗
apoptosis-specific
l-α-phosphatidylinositol
Y806-containing
.4229
BC-His6
PAb1620-specific
TRIzol®
n=159
pET-27
7.6/0.1
pMyc-FAST-1
Gualberto
N339fs
penicillin/0.05
LEICA
3-kinaseδ
H65Y
suppressor,5
cER4-34
EGFRK721R-GFP
mutations.89
TPTDVRDVDI
Smc3
de2-7EGFR
CONSTITUTIVE
227K
actin-bundling
H254R
Jurnak
→
GI-related
domains—a
mood-stablilizing
86
gene51
EGFR-based
gpl4otrk
Anti-phosphorylated
ApaI-SacI
17-allylamino-17-demethoxygeldanamycin
cooledto
rearrangement/inversion
nm-fluorescence
antiphospho-MAP
melanoma-suppressing
His114
59,60
F3-EpoR
aaagtcatcctggtgtgggagaaggccactg
Witcher
XpYXXXØ
EIF1AX-RAS
Luciferase-Reporter
reprobed
ErbB2_ex11-19.SF1
QJ
cDNA.11,22
p.E1099K-mutant
sequence5
formation.12
Me1
//browser.1000genomes.org
W1020C
triacylglycerol
HN-Smad4–/–Smad3+/–
FA55
ltrating
stroma—and
Pms1
5′-TACTGAGGTA­CCAAGTGCCCC­CAGAAAGGCAA-3′
4/Exon
FLT3-WT-
onco-proteins
data9,10
11q13.3-amplified
41.
p=0.0003
ATRX-ADD
OGCTs
DIP2C
11-activating
.Roper
Canr
986
expressFigure
32-40
coactivator-binding
context.MiceAll
12045
Tsc2
201579_at
β6
−/−BrafMEF
melanomas1
16A-reverse
DEXA
.PubMed
EML4-ALKI1171T
Benitah
G343R
IL-6-deficient
f20
ex7R
HAGST-S6K1
.Tomizawa
ExJ
13/56.5
domain28,29
HURTHLE
P1b
420-kb
CASP8+/−HRAS
anti-total-MET
70.5
23-25
IH3T
65/M
S5.1
CAUSAL
Massachussetts
ACVR1Q207D−c.a
BGS
ESS-1
A492
0.180708637
Jβ2
MycS71W
-TTCCTCACATCCTCCTTCTT-30
48/107
1270–1900
.2040
S75
Troelstra
Y1128C
GCTGAGGAGCCCCATATTCC
IU/l
isoform-selective
L485-P490
1•99–19•87
transgene19
Westwick
Retrograde
REU
585-bp
0.01-370
Tyr-1173
Visel
JB6504
p.Leu61GlnfsX13
anti-FLI1
10.000
APOPTOTIC
PCI-13-A161S
H2882
Hirama
R198Q
KRF-2005-015-E00064
Salivary
pCMX
factor-alpha
A171V
pVHL-CUL2
c.2276-
Poisson-Boltzmann
pTα
Wound-Healing
S8C
Bajek
Y252H
infinitum
KLF1
cord-like
M/72
\D
osteocytes
Itk
S99
5′-CGCTCAATGACT-GTGGTCGCCTGCAGGCAGCGGATG-3′
Cdk2-inhibitor
v-sis
jaxtamembrane
Fn14
90-d
1.IC25
1b
corroborative
44_694del
3,970
JAK/TYK2
Hep3B-TR
1349
nonphosphospecific
C169
tumor.1–3
retinoblastomas12
.9,11,12
hTERT/CDK4R24C/p53DN
A375M
Wnt-
pCBWT1−/−
MPM.69
pN1a
p.V722I
Finetek
Med-
gene‐3
2,710,000
0.39b
CA10
NRF2-target
Healtcare
INK4
VIN-HER
−216G/G
60jC
Svendsen
.16–.28
RASBRAF
S3-AS1
polysome-associated
Hertfordshire
NFlg
IVS11-1G→A
TACC2
15/602
DeAngelo
tj
D9S916
31–37
27/66
found,9
RFS-mycT58A/WAP-Cre
CA74
2,529
Ras-signaling
p.R718G
5′-GAGAAAGCCCTCTCCATGTG-3′
3950
–27.0
Jak2–β-TrCP–EZH2
4047
l•GluAsnPrQGlnTyrPh.
translocations
Papaionnou
0.6b
trichloracetic
NR5A2
Small-RNA
receptors.15
spi1-expression.40-42
gefitinib-resistant
PLCγ-1
trans-repressing
ETS1/RUNX
pLRNL
P-1020-pGL3
56-58
myelodysplastic/myeloproliferative
Mm99999915_g1
Gyapay
3.0081877
183R
aSomatic
anti-h-actin
Ylisaukko-oja
BAZ
Micro-vessel
Liopfectamine
61:1359–1371
HeLaDNA
.068
European/Native
activity26
2.739
tcc
models14
2,2,3,3
≦60
D425A
ASXL1-specific
FLT3-V592A-expressing
Cowtan
5qSTS
2266delNF
pG418-
T-20926
.Resequencing
αβ-heterodimers
Zerp
H61R
.Polyadenylate-enriched
M635R
keap1
mutation-negativity
sorafenib+everolimus
proteome
.Roche
FRE-independent
BRCA1-∆11+BAP1
Igk
growth.4,9,10
S465
000245.2
ry-
343AA
V378
Val2424Gly
Sce
66.6°C
5′-ATGGCAAAGCAACCTTCTGATG-3′
V5-PAX5
22245C
NUP90-NSD1
CTTCCACAAGTCAGCCTACCAGTATA
14,28
Lukin
1−8
.Bollag
non-tethered
AY138246.1
fibrillogenesis
66.72
.Non-germline
8.View
transcription-permissive
l1
v.3.0
Y53G8AR.2
alTable
.Anticipation
GeneEraser
PAI-1-luciferase
SNF2_N
GST-Gli1ZF-K340A
deacetylation
−4.2
Erk-mediated
c.2184_2185del
STAT1-independent
populations.2-4
1.515–2.954
Egfr-mediated
alÃ-elesize
anHRM
53BP1−/−
licate
anti-TP53
Weetem
v-src-mediated
NRG-3
Sarkosyl
activation.50,51
hypermethylator
−58.1
phenylalanine
.34C4T
Laudet
MEK/CDK4,6
nonmicrosatellite
CBL-b
β-catenin
.Usable
.BCOR-CCNB3
GDF11
cdc37
0.912
p53transactivated
T1799
9362
Mrózek
non-PHTS-associated
TopHat2
-E2
angiotensin-II
4-OHT-mediated
Na-EDTA
H191D
c.3558insG
www.insight-group.org
1.32
.052305
loci21/2
dysgermimoma
4.3
gcagttaaattgtgcgctgta
S966Q
PIK3/AKT
MAS5.0
Cosedimentation
−1.32
non-penetrance
1.03-3.51
IVS5911del4nt
intradomain
.Roth
N441I
.5,6,11
www.perkin-elmer.com
Ca2
srs2Δ
.time
c.1761_1762insG
setting.14
adenosyl-L-methionine
erythrocyte-depleted
13q12.11
cre-
NCT01480479
vivo,61
//science.sciencemag.org/
Aspand
phosphatidylinositol-linked
.LIBRARY
future.15
phenotype.Metabolic
homoscedasticity
Asp-86
6/67
.Invest.
Coregulators
H119L
1867423
viscerofugal
C58
7631
K427
Val19
LSD
anti-RB
M623K
alterations,40
95ºC
Mo7e
occurrence.33
Albitar
tissueswas
258
‡Cells
501–820
proteins,48,49
MASTR
2.2-4
codon-altered
.Tartaric-acid
Lomedico
SMO-E518K
up-regulated.6
p.E180_Q235del
unexplained1
P-450
GST-METS
G169R
562,772
themutator
Ras/MEK/ERK
Shld
RNasin
EGFR-Tyr1068
Phospho-FGFR
pregnancy-associated
pCDNA3.1/ZNF198-FGFR1ΔC-myc
2245
ever-improving
GCbox30
DR100-102
BAT-lOA
MLL-shRNA
cAch/12
65/111
M–G1
Noc
ARR2
2-OG
described1
RCC52
Thr35
C234Y
anthracis
Amakye
TC21wt
bestatin
lineAlterationPredicted
GGGGCTGTACTGCTTAACCAG
Hpy8I
C.-I
1´106
15,700
Astrophysics
TP53-depleted
S3E
ETV6–RUNX1
HCC78
Nellhaus
300147
leukemia22
expressive
pcDNA6-V5/His.b
thismutation
co-fractionate
2660
5-120
R328A
CYP27B1
6E-F
GI:178897-178904
CA-PJ34
.On
5XSRE-CAT
AGGCTGC-3′
11F.S
c.1277−1180_386+2226del3516insCATTCTCTTTGAAAA
Tetramerization
63/65
1.08±0.09
L536R
10.1172/JCI69766DS1
BAP
pp-dolichol
AATGTCTCACCAATGCCAGAGT
a02
cc-12-2656-g1
pcDNA3/GFP
1744
HIST1H3B.K27M
DS-R
10/18/2007
Schonheer
highlightingthe
P0038
I596T
p16Ink4a-Rb
HSPADSFSSMGSPVNAQDFCTDLAV-
p.L722I
HER2L869R/T798I-induced
NM_017392
repair.1
Cre/LoxP
agagcgacctgacgatgtcc
SMO-WT–transfected
37,000
3.72
ΔPQA
p.Q324VfsX8
TRAAIL-R1
UDP-6-N3-glucose
p.Leu44fs
Nipped-B
theRET
well-correlated
NGF/TrkA-downstream
ligand/co-receptor/RET
-25.3
matrix25
NuPAGE®
P284
S387L
p.Q27_E33del
CD8-postive
Munchen
A65
split-hand
50e
AS-mediated
N2B27
Wigler
agarose-formaldehyde
Htt
ATRA-resistant
4D–G
27/54
Dikic
RAS-regulated
RET/papillary
V7I5M
1799-1816
acetylation/deacetylation
FAT1a
3-month
F460V
13-13-22-A-8-A-25
U95Av2
Katzenellenbogen
Imaging—Stained
ErbBs—Myc
high-ARF
distal-site
TEAD1
breakpoints,17
non-transmitted
.Dwarfism
Position2
densitometry
TBJ
360486
Colo38
regimen.19
tight16
HistoMark
EN-mediated
lysis-LiCl
.I1855X
4860
Q207D-c.a
0422
0-6.40E+116
.Altiratinib
GST-c-Cbl
A65V
SphI-SpeI
Indiana-
Arg9His
AR-V
P551__E554del
culture–derived
.TSC2-N
566
‖Three
0.7-660/nL
Smad-transcription
Suc-LLVY-AMC
C971R
C57BL/6JJ
Songyang
H929
R469W
small-intestinal
.Cautions
mutantcomplexes
μs
RASA1/R-Ras/Ral-A
0.00319
viv
Salcido
.VAN
M7b
forL22E/W23S
3.5–8.5
whichhad
EWSR1/WT1t
∼11.4
//www.umd.be/
histidine
midplane
E868K
ΔC
doi:10.1007/s12032-011-0074-y
pY65C-FLAG
*A
1×antibiotic-antimycotic
phenotype.29
lysine-36
IeValLysS
E71X
Shirodkar
5′-CAUCACUGAGAUUAAAACU-3′
RecurrenceWe
Microsystem
KDM6A.23
hyperactivation.21,22
genes.34–41
1:600
phosphorylation.25
Noguera-Troise
Leu-281
EnVision+System
above.RESULTSThe
R948K
42,000
P98AH2
S-adenosyl-methionine
07342
AG-dependent
GIST.19
c-Fms
box.
513-777-6889
β-catenin/Sox17
truncations.9,10
Meis1a-YFP
subspectrum
3/27
ErbB-2immunoprecipitates
0.433
SRF-binding
internalization
predictions4-5
.Flow
Cranor
3172ins5
P305L
twice-weekly
hSNF2α
//projects.tcag.ca/variation/
phospho-Raf1
208/222
63×
NPPIK3CANP
600899
CML-T1
P057
Postprint
LUCC1
F1174V
K1718
panel.Full
GI:47215436
gout12
N924T
BUBR1A/FilaminA/BCCI
fat-pad
EGFWRPTPp
linesAlthough
F1245C
c.561
FANCA.22
Omniscript™
tissues.27
slidePNG
NTC-transfected
23–33m
Haq
0•32–0•46
micronucleated
liquid-chromatographic
pre-metastatic
T648A
W557R
NTRK3-containing
f2-M
W217G
PmlI-BglII
p.P26L
μl
occipitofrontal
1729
NCT01283516
5V-CGT
substitutions.44
−3.18
application—we
germline-inherited
.071
2.3×10−6
pGRE2
IDH1-R132H
daily.7,8
Pantaleoni
metaphase-spread
tyrosinephosphorylated
genes.16
chromatin
21-month
.Phosphatase
Fibrosis
non-cancer-associated
–keep-dup
AqueousOne
RP11-79G16
210/572
IYIVI
Agell
16.42
:582–591
10p15
micropreparation
ARY007
5cm
Ret13R
0,8
Nimnual
His-to-Tyr
Smad4+/-
Bj˛rk
2q31-q33
inyellow
michael.reiss
non-B-non-C
5'-TTTACAAGCGCACGCAACTG-3
F525L
GSK-3ÃŸ
A_51_P293401
Multi-chip
double-positive
GFP-VHL213-expressing
30.3
41–
-blocking
glioblastoma68-70
exploratively
Tunicamycin.26
-B41
tubule-specific
11/27/00
SHP2-GST
270-kb
short—estimated
L301
PALB2-associated
quartile—adjusted
mismatch-binding
n-DX/n=0.51
PL2XR
Martinez-Ramirez
MEK1P124Q
5542
TCATTGTCAAGTTTCATTATTTTAGAG-39
119X
co-defining
1k
TERT-H.
Cy2-conjugated
monitoring.22
.Important
p.Gly31Asp
2818
Beta2-microglobulin
standard-PCR
2-phenylaminopyrimidine
19981
antisera46
Autocorrelation
Foxp2
c-MYC
phospho-NDRG1
McEarchern
Fifty-five
U.S.
TNF-RI
NTRK3-associating
tyrosine-protein
TFIIF
ACCCATCCTGGCATAGCTC
Q107L
spnhVKItDFGLaRlLdidEteYhADGG
Superscript™
Wnt-induced
PCTK3
.AITL
.NALM-6
TCTGAAGCAAGGCGGTGGAC
CD9
four-fold
1Multiple
respectively22
gliomas22
237–250
TSR-011
A266_S267insSTVVGGD
Wiley-liss
DDR2-containing
CS16
BrdU-incorporated
dik2002
NheI-EcoRV
Neh2
245/762
UPMD1
ofMMP+
380/402
AGCGGGAAATCGTGCGTG
CEQer
β7-β8
7-aminoactinomycin-D
-99.6
phosphocreatine
©
msh
Maemondo
rBGH
AKT1—due
E8
ΔM4
half-time
6.562
enzymelinked-immunosorbent
.18,23
GFP–
.Sian
switchability
cells.Several
25.R342P
virus-immortalized
V59M
5C-F.
SAP1
SOX5
Bergerat
inter-plate
correlationbetween
Loehne
SCF-Binding
C-Myb
`F3
3.8-9.2
BETAmatic
TRAIL-R4
McMacken
Intra-Thoracic
‡PDB
-ork
150–200
BIII
19961
p.P281L
R-Smad-dependent
N50
P-M-D-D
SIK2
333:1
doxorubicinhydrochloride
Picagene
Tet2-IRES-CD25
Immunoprecipitaiton
//www.gist-france.org
11–encoded
Dorsomorphin
Hras-driven
established11–13
T541
4,295
.Trends
L..
.Gly2Ala
BRCAassociated
40-year-old
R1a
Aspl
myelotoxic
––––
326KB
Activationz
poor-risk
tumourigenesis27
KOdakBiomax
analyses5,6
specialisations
96.7
GDNFR-α
PKC-
corecruited
Nde-Intr14-R
-domain
10−3T790M
M.J.M
L652P
bidmc.harvard.edu
TP53-R273G
LTQ
Starburst
NUT-BRD4
.2617
rBRIP1
.FAM46C
isoprenylcysteine
syndrome/Cockayne
100–8
Dlg
Mohebiany
.Fresh
G661V
564Lys
pyrophosphorylase
immunodeficient
C1265S
7–75
R928
20.Whole
.Auto-deubiquitinated
44–48
2A-C
Irino-TMZ
10/64
q26.3
0.0161
33.7-68.6
Q6N021
mRNAWe
dephophorylation
28/348
94°C-1′
cytokine-1
anilinoquinazoline
hRARγ
mice5
remission.24⇓⇓⇓–28
.Fertilized
S.E.diff
PKCζ
116,099,682
pcDNA
CAPAN-1cell
17q21.1-q21.2
HIP1/PDGFβR
580–668
12,005,749
HIP-1/PDGFbR
q22,4
Jadayel
RNAseA
Spdef
de-differentiated
AKT8-transformed
MONOMAC
SMAD4-mutated
R65P
P56T
back-cloned
153245
ansatz
Myc-transduced
RTK/RAS/
L43S
STI571
strain-derived
D-5-phosphorylated
NVP-TAE684
Glu79
Δ576c-Kit-transformed
86T
F3**
Brca1Δ5
CACNA1A
Twenty-four-hour
.LGX818
p=0.0910
K689X
juxtamemebrane
fscherichia
cγ
CD25+
MV/IFDI
anti-p-BTK
Derré
stability,21
SPCC
molecular-guided
Osteolineage
Ryohei
wasthe
Vantaa/Finland
SalI/SmaI
ARID5B,10
p16Ink4A
F403V
GCRm38
TTCTCAGAA
/33
Cotransfected
Ligation–Dependent
Leu+Trp+colonies
.ESPOSITO
P1011
anti-LTβR-treated
ligand-orphan
RITA-induced
Marone
T3
cMET.4
Fig.5E
ZBP-89-induced
BP-ALL.59
-Rac1
.Tpr-Met-transfected
MDA468
193–421
TCCCGCCCAACATGTTGGGACATGTTCAACCAGC
GIST_KIT
61-7
c.1784T
181–185
usage.20
AMAGs
/computed
11.65
6,838
NES-PIK3R1R348
post-siRNA
line±s.e
ox-
CHEK2
Ras/GAP
29*
∗2
pSVneo
classification–based
Keshet
development178
Morito
natriuretic
Frangioni
E7.5–E10.5
45-Mb
epsilon-amino
anti-Chk2
1/1,019
spongesadsorbed
5083
Lin−Sca1+C-Kit+
.R1881-
mgrl/ml
Valenica
.Demetriou
R111P
Yesd
unidenti
N453S
A603A
K4Q
1982-2920
-SAM
uncurable3
indicatingthe
32
Motamed
hallucinations
hetero‐dimerization
32643
domain—specifically
//cbio.mskcc.org/prostate-portal/
c.-11C
re¯ected
E1/E2
Ras-Sos
ends.57
breakpoint.6
transcriptional-adaptor
inhibitors.37
Ba/F3-ZNF198-FGFR1
Ossipova
H1d–histone
vesicle-specific
F3165
R776G
NM_009621
regions.48
'hook
fI2
.HPV
Sprouty2
D544
IVS2-14
qPCR-based
2/42
GCGTGGACA
R1276A
RP11-164O7
CUC
GDC0980
macrophages39
PEA-15-induced
unhydroxylated
insipated
Neu-
69–84
EGFR‑mutated
OX40+
1–5×103
97,101
ENSG00000171862
mechanism.materials
Bacani
'loose
2521
.Ideally
-1100/+580
33,34
not,37
T‐Cell
Int.
AY131971.1
C/D
158.8
S58
mutations.51
protein-related
~30,000
Leu34Leu
KIAA1468-RET
c.3212A
tyrosine­
retroviruses24,25
LQ
2.54–12.05
AZD8941
del577-578–579
M640
MAbTP25.99
Blimp1FF
9q34.2
iCycle
.Discordant
Com61.3
iuxtamembrane
described.17–19
CL-Xposure
12.G334L
2.KRAS
LN40-ADP
Baculoviruses
−2.52
Nf1–/–
Fuc
mutants.21
TGCCGTCCGACGACAGG
STAT3/5
Nestin+/GFAP−/Olig2+/CD133−
Differentiation-induced
HP1α
hyperediting
54-56
c.2719C
identified27
p53CT
Tajima
anti-kinase
people,1
10.38
L194P
5'-TCATTACACCAGTTCGT
contribution24,28–31
p-Tyr542
+–+–+–+
—engineered
factor–reduced
IRAK1/4
Peterlongo
C2183S
resistance23
p.Lys540fs
Sedman
activity8,9,10
clustalw
anti-intercellular
Medullay
NaFl
pTB701
msh2-GD855
cellsSix-
1071ins1‡
y-bridging
colorimetrically
CVCL_0236
FLJ39181
hypereosinophilia.8
anticaspase-8
iNaCI
—BCL6
vivo31,32
OpenMS
P90L
literature.8,10,12,13
0.8-32.0
P=ns
341–595
transcript.32
02-s
CDK8-driven
live-born
66·7
HA–Cdc25A
hypocelullar
Fig.2b
ACSL1
p.Val3040MetfsX20
Immunoprecipitation—Inducible
10‑12
IDH2R140Qhm-t
//www.sequenom.com
MAPK/Erk
gabactosidase
atemozolamide
zinc-finger
bThis
epicentres
effects.22,23,29
'TMPRSS2-Ex1-nest
27-87
Asp1521Ala
role.6
S.A
p110δ-
c.6341C
–70.7
pone.0056521.e016.jpg
K299CR1
SC-1616-R
SCC25
31-20-5122050
non-phosphorylated
semi-annually
p.C9S
expression24
CycD-dependent
GGP04172
LIP-1
FLAG-Elf3ΔN173
5C1-5C3
melanomas.1–3
EPCAM-MSH2
14-amino
H0
Y220C-dependent
Q207D
D404GHA
IN'SQedicine
6145
11/21
patient.The
TGFβCell
invertebrate
Clappier
H351Y
patients.15
TFG-
BAS
115,256,529
NAMPT
trxE3
n=3/36
D1865Y
f2+
T681I,18
iNtRON
Intrel
equivalents.32
figures33
tumors.12-14
S462Y
chondrocyte-derived
p.Gly74Ala
50:25:10:0:15
⇓=
mixed.15,16
Karyomax
390-8621
10p11
aminoguanidine
GAGCTGAGAAATGCTACCGCAGC
WT-p53-expressing
phospho-p70S6K1
797TRex
weight-of-evidence-based
mid-S-phase
p.Pro124Gln
2314
EcoRI/MaeI
Asp47
.Skin-related
non-R882
DAP12
lymphoadenopathy
32/90
p-FoxO1/p-FoxO3a
min-var-freq=0.02
cup-like
anti–HLA-B
4S
GIST74
PUF
leukemia.7
time-points
38.33
LS-fam
105,448,183
chickenpox
substitutions—
GATGACGACGACAAGATGGCTGGCCATCCGGAAG
.PI98
E–G
kinase.8,10,12
samelittermate
GACTCGAGATGAATAAGGGCTGGCTGGAGCTGGAG
Ohkubo
analyzethe
Ser319
45–90
RH-Fox1rnu
N241Q
21.1716.3
N3124
andpEAE20
DeOme
LKB
N-GFP
0.25-fold
1.15–34.6
correlation-based
GISTs.2
CCSP-rtTA
residue—is
transcriptionally
FGFR3/Neu
∼2-kb
MMRd
25/51.0
ATP1mM
cathecholamines
Mclustalw-aln
1244-1249,1997
ATR-C2
198–206
11–42
overexpessed
mutations.40
Flag-CDC4
5.0-cm
L783F
F1403C
bythe
RhoAV14-induced
293T/dish
CTTTGAT
acci
BAF180-depleted
D-3-
pLenti6.3/V5-DEST
-7-fold
anti-SRC-1
results.1
arrayexpress
rpA
AGAGGT
PTPμ-mediated
Tgfb1+/−
1.8–1.7
4472T
E748*
:URA
anti-phospho-Erk1/2
18020
chr1:179835004-179846373
open-and-shut
2191
exome-deep
image-left
3-min
.Coincidentally
GIT2-PDGFRβ
IPI
ms00008687
1245
E14K-derived
+X
ofFO-
.582
RAS–RAF–MEK–ERK
.Thioredoxin
self-caring
fam.
G34-mutated
Mice/D171N
×106/ml
AML-1-interacting
5′-ccagcgggagatggtggacaccacgggtc-3′
2923
CUL3-RBX1
Jsco
HRDLAARN
disease-
limelight
Accuprime
multiple-tissue
model53
CD11b-magnetic
mastocytosis.6
TC15-12F12.2
CpG
13–21
35,000–45,000/mm3
V600E,10
Vétérinaires
p-CrkL
45,951
31.5
cytometry
4-morpholinepropanesulfonic
Gullo
bullosa
5′-TAATACGACTCACTATAGGGAGCTTGTCCTTTTC-3′
RAF1S259A-induced
UHRF1
L386fsinsA
PRC1.1-PRC1.6
trial8
.IFD
p=0.429
D207
97-patient
hydroxypropyl
context.31
Arg337Ser
Rosai
.0114
Rad50/MRE11/NBS1—all
theFGFR3
//swift.cmbi.ru.nl/servers/html/index.html
Patz1
AUGCACAAUUAGUUCGAGAUU
APC-independent
marker-selected
DST1
TE4
.Possible
allele–specific
monotherapy-treated
0.018
Rothberg
energetically
CATTGTA
80.67
4‐Thiouridine
AIB1/ACTR/NCOA3
green-to-red
thymine-to-adenine
AZ5104
mutant-p53R273H-dependent
PCR-DHPLC
Ddx20/
Npm1hy/hy
p53E258V/I254R
5/32
nonpleomorphic
∼60–80
0.11-
E355G
237–276
MMTVyCre
5′-CCATGCCCAGGCACTCATTTTCA-3′
0167
U87MG.DK-
0.004678
trpl-1
Motchoulski
.S8
CBLK382E
p.Asp532Glufs*17
73.79
factors.13
deletionappears
wild-type-overexpressing
A-allele
p53,1
shRNA-specific
TATGGGCAACCGAGCAGCTATGGA
ERBB2/ERBB3
0.00333
65,88,89,113,114
M/26
tricho-rhino-phalangeal
PKIα
dichlorophenyl
post-transplant
E132D
cohesion-dependent
RRL−
andJ.D.B.
Gleevec/Glivec®
Gtg
Turnhout
ER-negative
complexesby
nature.comMost
fea-
pTCF-4
MHL1
100,101
–17.7
splicing.33
ANTXR2
cellulo
//dx.doi.org/10.1007/s10120-013-0298-y
.Repetitive
Cd19
30/358
32Pend
10.1093
Pye
alpha-32P
Trnková
Trancriptional
endometriotic
His6-c-Myc
HiPi
5'-AGGTTACCCCATGGAACTTACCA-3
Surveyor®
anti-phospho-Y845-EGFR
compaction.8
GGGCACCTCCTTCTT
1675delA
C311R
interaction,64-66including
early-passage
r­
onchromosome
impact1
NI*
Lys469Glu
pre-Bleukemia
SK-N-DZ
sc-1058
His387
established.19
pathogenecity
BrdU-PE
0.88
Giemsa-like
868,596
fusion.27
Llanberis
1,382
NF1_00398
Y443A
afterdrug
208
mode.28
ACS5
RP24
1wdmet61
2710
anti-annexin
2.71
subtype6
2·2
investi-
Ubiquitination
c.38_39GC
cofactors.73,74
p300-7.5A
SALE-YAP15SA
E412
.14,26–28
D'Amico
HT-29S
PI3K/Akt/mTOR
previously,16
c.1145GA
methylphenyl
CD3−/CD16+
Luciferace
exo1Δ
αAKT
quantum-210
TCGA-28-5216
sorafenib…
VHL-related
Fig.7E,7E
AA-linked
Genetique
KRAS-transformed
Met-237
cellextracts
Q61V
over-expression
c.380
signal-transduction
C5173T
1–1758
ICMT
∆16HER‐2
0.5–1.5
KMT2D–ER
4b
c.-113C
broad-based
homodimer-
T24/EJ
Human610-Quad
anoikis,44
30–72
survival,6
centromereassociated
1/59
Matsumoto
HA-MKK6
GCCAACCTCTCGAACAGTATTC
M1268T
2.0.9
snpEff
RNPS1
~170,000
9p.11,12
protected.35
sterile-alpha
anti‐HER‐2
androgen-independence
C29R
cephdb
R26H
Geome
four-subunit
Hist1h3a
DNA—short
SMARCB1/SNF5/INI1/BAF47
KU006
medgen.unizh.ch
CCND1
ICN
g.26473245_26492527
kinase-domain
poor.3
tumors33–39
5′-TCCGTACTCCAGCTGCTCTT-3′
madillo/f-catenin
patients28,29
α-phospho-STAT5
PhenoPath
N1-methyladenine
10−207
PNL
al31
0019887
anti-CD4-PE
Predominantly
43–
msh2-GD855p
66258
health-care
myelofibrosis.32,37-40
pSG5-AR
pErk1
Ras-medi
6,10,11indicates
1.5–3
pre-leukemic
TopHat-Fusion
can1-100
non-detectable
0.800
homodimerize45
-SYT1-PAWR
Legeai-Mallet
Flag-M2-coupled
dismal-related
PaperClip
-AGA
syndromes175
27.71
Alberto
.Bearing
Bond-max
23-spacer
120K-
sc-8408
reticulum/cis-Golgi
61/male
N550H/K-expressing
q12
Fanc/Brca-defective
—M————W
p.D301N
.MLL1-Dependent
GGTGACCCGAGAGCGGGTGTT
CP70
RU486-inducible
JSI‐124
2-cluster
stricking
anti-cMet
V+Va
R175C
VEGF/VEGFR2
Krascommon
types.6
B⇓
immunohistopathological
mutation.23
pFL-mDia1
DYG
.Presumptive
R318H
H229R
//rb1-lsdb.d-lohmann.de/
BCRT
c-Cbl-Induced
Scrima
.EFTs
G286S
.Kagawa
Y754
F157
invasion.6,7,35-37
thyroglobulin
LI7
NM_010959
0.243–1.023
samples6
integrin-dependent
52/55
1.5418
12nM
−11.08
obliterate
base-calling
PRIZM
cancer-induced
EGFR-TKI
33428022
NM_004304
Shp2−K590R
GGCATGCAAGTGTGAGACAG
DDR2-Transformed
MAST2-shRNA
vitro.Figure
−.61
nuclear-stained
appraise
.MB-SCs
TNT-AR
recombinational
96144
271±186
phenyl-sulfonamide
R873
Anti-c-Cbl
GraB-specific
FGFR1–ZNF198
p≤0.020
transfer.10
.82
A148
scrib-dlg-lgl
Nicolli
MCDB-131
PPARγ-depleted
EPR-expressing
Dedon
BCRABL1–negative
Arg-438-Arg-439
10G4
wild-
valine/threonine
drivers.16,27
CstF/BARD1
sites/176
1560
controls.77
TP-promoting
pAS-cdk4
A31C
Puri¢ed
1N
FGF-
KRASG12R/G12R
BMP-mediated
NKX2-5-BCL11B
Biosystems-Life
.036
MyoD.14
-32/-29
Met-positive
BEL-7404
,51–54
allelotype
tryptophan.3
H479A
oncogene.13
p.Gln1447X
bbrc
P106L-GFP
8672del115nt
HNF4AP2
Corepressor
pathway—has
prosurvival
inject‑
itary
119-bp
p221-3
Y795C
FLAG-RhoA
solubilized
P098
E3810
Microporator
public-portal
p414GALNVP16
protocols.16
0.0169
*6A
G34R/G34V
intratumorally
RCR
LexA5′-fused
HTb
dissociation-induced
positively-charged
.Endo
t-Butyl
D441G
methylguanosine
DT3
GSE51176
J82
C620F
15Aâ€
E217G
1/50–100/50
0.333
region122
543x
pTM898-neo
II-negative
HeLa-DR13-9
08-262A
.Re-establishing
HCOONH4
pRK5-HA-ubiquitin
PBS−/−
TEL-PDGFβR
2.2–5.5
1.665
ChemDoc
2580delA
visceral-muscle
RHOA19
-Cat
p63
//cancer.sanger.ac.uk/accessed
O.S
Consortium,2010
61,57
5-bromo-4-chloro-3-indolylphosphate
BREAK-MB
CA62924
p.Tyr657X
Convergent
Lysine
56.1
pathways.17
HIF2A
CRM-1
avidin-biotin-peroxidase
kDa
Kogyo
PRPF19
Theisen
co-injecting
AP–HP
∼120
.Q99
IPSS
yeastTo
Enhtmcasnw
NEPA21
L847P
Baseloid
regimen3
1p39
non-selected
DIA-H09
.Synergistic
1C–D
SMAD3-dependent
Zp3-cre
2.58-kb
—another
dbSNPs
HOC313/c8_3
Wa2
8269del150nt
AA399674
ller
m–1•min–1
p.E321K
Terskikh
Four-micron
.DMSO=vehicle
asite-specific
M|
Lachmann
recessivep53
A563
479del107
Nakajima
0.00195
transcription-repressive
BDC
3383
Two-month-old
Tpr-Met-BaF3
meaningless.The
anal/rectal
β-G
S2-S5
RSXpSXP
Mono-allelic
31-f35
msh1
Tyr-X-X-Met
D-2-HGA
TCCTGACTGTTGAGGAACTCAC
keratinoytes
TCCTACAGCCACTTCGAGAAC
embryos14
Glycan
R577Q
deplete
pENTR™/D-TOPO
569–576
pVHL30
satiety
CONCLUSIONS—These
Lübbert
PEG400
mechanism.36
H446/97
GFP–PHD
phosphoEGFR
G111R
pre-GC
49,6-diamidino-2-phenylindole
E-null
0.1491
p53-MDM2
Jan09
Mb–D18S487–0.44
TACTCGAGATGGCTTCGGCCGTGTCGCCCGCCAACTT
.GSK3
hypercellularity
Archaeoglobus
Ubc9
ClinicalTrials.gov
Twenty-sixmucosal
3.61
5.9-fold
Gal4-driven
P51L
fCre-ERT2
f/68
NM_010049
LKLLGVCLLNEPQYLI
pyridopyrimidine
DHSa
.AZD3463
pathogenesis40
misclassified
ERKis
REINSTEIN
virilization
biCEBPA
3182
phRL-SV40
Cre-negative
AML,25
Wnt-1-expressing
miR-14619
Neu/ErbB2
R401A
fusions15
GSK2118436-treated
1A4O
c.2726A
Legnano
anti-androgen
-are
.R175C
pCMV-dR8.2
5′-GCCCCTAACCTCAAAATCTAC-3′
expression160
employschemically
W88S
ultrahigh-performance
Graphic-tagged
G217R
protein-coupled
neurofibromatosis+Noonan
isoforms27
RAS–GRD
Pharmingen
–0.44
−.9
5′-CCCTCGAAGACACCTCTATTGGGAGGC-3′
pLenti-CMV-puro-Luc
XA90
pACE-Cre-pGK-Neo
homo‐oligomerize
5′-TGGCGGGAGGGGAAGGGTTT-3′
TÃŸR-I.whereas
56774146
anti-p110α
96C
reducedGTPase
2.6–45
WM266mel
dose/actual
Pokfulam
Chem.
Ser140
Q565E
phoshporylation
2.1–4
Ponssen
conformation
GST-XPLN
MUM+
Cul1/Rbx1
IFITM
U14680
15d
LKE2
PPP2R1A-WT
BMMC
CTCAGCTGGATAAGGTCTGGTTTAATGATTTCTCGATACTCAGCTGCC
264-
IKZF1−
Blondeau
asPersonal
04/patient
RhoGEFs
TP25
EWR1
splicedexon
prediction10
83.18
lymphoma130
TECR–PKN1
receptor—tyrosine
YAP1-FAM118B
lipogenesis-regulating
1687
Na3VO4,1mM
MYCN-transduced
cointegrate
c.592_593insT
//doi.org/10.1371/journal.pone.0032451.g005Nude
PDGFRA-downstream
TAGGCTAATGAGGTTTATTTCTCAAGAGAAAATAAACCTCATTAGCCTTTTTTTTTC
Brno
p±24
GCGAAGCTTAGTACTCCATGTATACAGTGTC
.ECL2
.582del25
RSmad
-GTT
thr
Raben
3q12.3-q13.31
spliceostatin
ALTD
SectionThe
Ras.GTP
129SV
DCAL
MIP-1β
epithelial-to-mesenchymal
R21Q
eupoloid
method38
GDFGLAROI
Wernig
Pro70lies
FAK2
non-G12
AEE788.31
Idh1LSL
findings.20
53BP1-associated
MET-N375S-Fc
0.694-4.908
surgery.Patients
www-p53
.Evol
c.4987-5T→A
L430P
7.5–17
−125°
d.f
osteoblasts64
HGF/MET-mediated
GM-CSF–transduced
1303C
250,000:1
G468A-induced
GGGCGTCGGCTGTCGGG
ab16898
R177ter
Tateishi
mean±SEM
mitogenically
CFA2
differentiation.11,20,21
Ins2
1101_1508del
0.32–1.02
A489D
by15N-1H
Oceania
//snpanalyzer.uthsc.edu/
M-1s-1
.Conclusion/future
asilent
PNPP
p85α-mediated
0.0025
59FDRs
5′-GACATGAGCCACGGGAAG-3′
ErbB2/EGFR-KD
melanoycte
S7e
inactive-EGFR
:2779–2788
LNCaPhr
V.15.0
PI3K-HTRF
-TCCTTCCCTGCACATGTCCGC-FL-30
.Inter-observer
M180
MEF2D-DAZAP1
226–228
05-678
HEK-T875N
TP53/ATM
3q21.3-q22
AAATGGA
47-3
P=0.036
XX,222
program-induced
thelargest
A099
5′-ATAGCATTGCA-TTCCCTGTG-3′
BioMol
STNM2
TCL
cells.12,13
-X-pT/pS-P-
chr3
LDLRA
multiforme,4
COSMIC.27
.Gata-3
CTA-39
GGAGCCTGCAGAGACCCTA
≥5-fold
leukemias.26
WT-PH/D323H-KD
isoforms.13,14
RETSIEMEESELDAQYLQNTFKVSKRQSFAPFSNPGNAEEECATFSAHSGSLKKQSPKVT
ALK4
p53G242A
Ser643Gly
23-plex
Agaimy
ARAF-mutant
S4.1
1p21.3
D276
S100-immunonegative
=0.33
E64A
EPHA2
-Ba/F3
Parsimony
B3C4
Co32
Individual/Family
Immunophenotype
EDM-associated
HTLF-3
19,36
molecule-specific
RP11-295I5
Src64
inter-kinetochore
analysisTwo-hundred-fifty
.Filtered
.Larger
0.456
2/61
ALK+AlCL
0.0613
stanolone
Pc-G
biopsies68
Y69
CSP-associated
Mg2+is
FGFR3-coding
therapy.20
3Binding
9.04
ALK9,10
SPROC
EPAS1
de\elop
RAP1A-dependent
BRAFV599Ins
solid/trabecular
non-redundant
1.01–2.34
71-1500
E293A
002524
+2.5
561
signs/words
33.1
dUTPs
.1.2.4
c.670+6
pool8
FGFR3-IIIc-G372C
BamH1/Sal1
p.Y112H
.Wei
TBLB
proteins.14
4D-E
prognosis21
differentiation,3
rareexample
4-mm
Flag-FBW7α
exon-12
TrkA-MAPK
Diasonics
−2.79
biopsy/aspiration
Padgett.6
.Ruling
given.A*0104N
M123
Danhauser-Riedl
gene-therapy
Forward-ATCACTTCTTCCATTGCATC
153P4
VEC-dependent
catal-
Markerloci
c.543delT
H426
.NADPH
Fbw7-ΔNF
CL-387785
R89G
∼60
RagA/B
021924
toAKTJ/RAC
§Fifteen
P110βΔ/Δ
vertebrate*
pY589/pY591
GGGACTTAGAAGTC
M328T
pEAE37
Brennetot
pI-pC–induced
26.113*
~1.7
IIV-qm
6.36E16
3'-terminal
R-INT
3μm
PI-stained
.Relatively
22/50
M211I
007194.3
enhancer.88
24th
polymorphnuclear
66.5°C
233–245
ELFR
non-TNBC
ratio=2.992
pEGFR-tyr845
NMD-prone
Directions/Concluding
R776H/G719A-expressing
Asn236
Figure4a4a
EGFR–Stat
anti-STAT5b
.Bead
LS-3
found.39
CMV-USF
range=38.7–50.1
Trp-741
Mediated-PCR
gagggccccggcctcacaaactcggtgaag-3
HCCs.In
∼100,000
BMI1
genes—ACVR1
medium/F-12
LUCC1-LUCC8
growth-stimulating
SEM-NSD2sh1
F341Y
Bac-to-Bac
SSEA1
α-sense
T338I
n=17
al.110
FNAC
Pontén
SK-Mel-217
Bubnoff
GACACTGAACGGTCCCCGAGG
0.50–2.55
GFP-targeting
miR-2–mediated
Asp-160
R330W
Heerding
exclusive8
6-tag
μmol/L¶
Q61-mutant
SC-30
96.5:3.5
K169R
g.90delG
fully-tryptic
Brash
ICL-associated
2.16
ofclones
plakoglobin
fsX2
Fig.6A,6A
diaminobenzophenone-phosphoroamidate-GTP
dPBS
gtgggcaac
.Erg-expressing
←min⎧⎩⎨0
Ring6a/MBLR
Karyopharm
anti-pEGFR-tyr992
.0.0032
Haffter
centroiding
.SMARCB1
apoptosis/growth
MMR-abrogating
p-value=0.0465
HER2:369–377
haploinsufficiency.14-17
11/33
nearGene-5
SHP-Q510E
p.H1047R
K860I+L861Q
CAAATGAGCTGGCAAGTGCCGTGTC
Weeraratna
usedby
rule-based
GMean
–80
9–mutated
TATTTCC-3
R1236H
efferent
4Bc
lyGlALl
DNAmanipulations
TE-I
Cancer.28
18–20,24
S217/S221
S7.10
10-14
.Customized
5′GTGTTATGCTATTTTGCTCTTC3′/5′-GAGGTTTATCTCATGTACATTTTAG-3′
DNA/normal
sterility.26
caspase-8–mediated
S33N
anticlotting
92K
effectorfunction
streptavidin-biotinylated
retinoic
Lee65
23–41
29,553,477_29,553,478insC
G1788V-F
insulin-sensitizing
0.77
andV923E
LXSN-AKT2-AS-3
5′-CACAAAGCCCCCTGTAGACAAAGC
caspase-8-frameshift
papil
ROKα/ROCK2
GTD-/GTP-binding
22/96
.Fig.10D,10D
ATM/ATR-dependent
3p-arm-specific
SF1126
imatinib-synergistic
Asp→Tyr
GTG-*GAG
TEM814,33-35
3,429
C-Cbl
FLT3-ITD–transduced
CACGACGATGCCCCTCAACGTGA
L11910
3′-MLL
Methods.Yeast
tyr705
Y35N
hypogranular
D-thiogalactopyranoside
92:205-216
GGTGACCAAGTTCATGCTGTG
UCUCA
N3T3
region.27
one-turn
report11
Bouvattier
MAP/SAP
BCL-xL1,4
curvesforNRAS-mutant
phosphopeptide-induced
.EMT-like
+5.5
diagnosis.41,44
pore
Q1500P
GCCTTGTCTGGTTTACAAC
acids.55
Br66
.Cluster
isothermal-isobaric
.Target
L186D
G101S
IVS11-11T→C
pRSVL
T32-CA009135
SNU308
MSK543
Oosthuyse
KrasG12D-initiated
Adamts4
NP-KLH
HA-p85-dsRed
carcinoma,45
1244
S585S
IIa
confounders.30,31
to2-fold
HDAC6
anti-R172K
08e
CFU5
nanoclusters
Arg515
HCC-2998
iSriptTMcDNA
.D-FISH
G__
16p13.13
H3122EML4
Arg335
Lab-on-a-Chip
EXV∆NRaf
5′-GGCGGGGTGGAAAGCAGCTCGAA-3′
2Y
5′-GATAGCCATTTACCGCATAGGGGTC-3′
pPNET
Nairz
L65
GPR98
32.
CARD11-associated
NBS-HGGs
tumours.11
4352042
Vα11.1
CBC
inhibition-based
beta-lactamase
C00-840L10
FA-58
iden
myelofi
.Mechanisms
Renriction
SCFD2
I-A
FSCOR
p.Glu245Gly
atrophic
84.0
Calsbad
described.20Statistical
5′-CGGCAGAGGAGAGCGGGACAGAGG-3′
p53BP1
recultured
TxNxM1
dichloroflorophenyl
ARMC9
antigens.The
JM-binding
T3/
Me98923
10966018
c.4007A
faint/weak
-34.1
aspar-tate
Jurica
EcoRI-Pstl
95-bp
tetraploidization
VAV2/3-deficient
0.059
cycle.5
therapy.11–13
messanger
:3244–50
eluant
gene,14
9p/9q
G12D/R10
FAP
immunohistological
Brca2flox/-/Wapcre
ascyclin
-TGGAGACTCTCAGGGTCGAAA-30
EGFRoverex
1-39
38MB
Inprostate
//www.hgvs.org/
c-MET-H446
E355A
EVI2A
545-951
polyps.27
C1483F
expressor
.midline
rs1801132
GCTACAGTG
adoptive
93.38
.1.27
HMS
Overexpressed
P.Modrich
Betsholtz
0.0079
to0.045
foundthat
Sox4
PD-1
oligoribonucleotide
EPF
neurons.4–12
SMO95
IDH1-
Dysfunctional
NTRK1preceded
HSC7E131
5′-ACTCACGTACATAATAACGAAAATCCG-3′
1389
Nhe
mÃ©tastases.We
Asn822
D1-T286A-expressing
proteinWe
37/67
anti-p-STAT5
25:402–408.10.1006/meth.2001.1262
with/comprised
7RP
.Text
AnalysisAn
G1500
1–934
56-yr-old
NRAS-4-R
TSGs.7
cooperativity-dependent
Urothelial
Delta8.2
post-extension
WDHD1
45.10
prepa­
KO_MA9
3.044
MMPâ
13mp2
CRC042
.7
simultanous
.Hyperactivation
anti-MDM2
system.Examples
2289.0
estrogen-dependent
P.J
data—to
1g3n
p53—G1
.Ctcf
CPP-ACP-FV
.Well
I789_L792del
pAcHLT-c
epistatically
1001-
HSC7E116
R132H-transfected
protein.5
TORKi6–8
Nicla
RNA-
×150
characterized.24
glycine–0.0375
1834
GC-poor
Glu-717-HER3
HRSP12
6085
.017208
E586
460b
strepavidin
S136C
tyrosine-based
Taz
Flip-out
8B
PRDM1.E2.75.F
B3.6
840GS
Akt1WT
c-kit+Lineage−CD48−
Scaruffi
A614D
time-limited
T232
1997
cMET
5510
EGFR-induced
239/269
postischemic
proliferationactivated
.Crosslinked
Red‐avidin
His–caspase-8a
RHMAPPER
FIPL1-PDGFRalpha
12R8
cdc10
Post-selection
forvard
recommenced
AQueousOne
Family-as-Unit
polycomb-associated
pcDNA3-ERF
post-resection
well-established29,30,31,32,33
wtEGFR.21
1,569
WNK
E409G
903delG
loss-of
ylXtV
inDrosophila
severe—apparently
617-735-2065
classification.MATERIALS
91405
microscopy.Cells
megalencephaly39–41
0.04–0.87
DR103
1.29–2.71
retroperitoneum.24,26-33
mutation.yIncluding
enthalpic
obser
W248C
GST-CDK4-MUT5
-EGFR-L858R-T790M-HA
,0.05
SUDHL10
AML1/ETO-positive
centrilobular
multi-molecular
8505C
Endo-GluC
A1733
57.99
35SMethionine-labeled
PAX5,64
abundantthan
Men1−/−
S3I–S3K
signal–containing
7*sigma
pBRAF-S729
pH1
0.0516
neuregulin-1
Uropath
hyalinizing
10/101
TA™
206–208
ZDHHC16
15/108
mCherryhigh
p.Met622Ile
13,581
2ZVA
-6-
inadequacy
acti‑
Complementary
BRAFE600-induced
3′-RACE
gtatgtagc
89,165,786
complex135
Wap-Cre
nonradiolabeled
differentially
AGG-3
Quik-Dip
18q23
A4158G/AGA-*GGA
G300V
PIG3d
p.Glu205Gln
kcat/K
.Gly67_Asn71del
63.2
5,680
.R175
0.2621
A508G
Leu515Phe
pB42AD
JetPEI™
Y551E/Dasatinib
.8E
4′,6′diamedino-2-phenylindole
stimulation12
pcDNA-HA-ARv567es
MC1RV60L
1993–1997
semi-automated
MSH2-20
risk.Mutation
3-trifluoromethyl-4-chlorophenyl
expressingc-H-ras
prestarved
p.1272
5'-GAGAGCGGCCCCACAACAAAAGA-3
Dianova
S6I–J
IDHl-expressing
G519R
amphiphatic
EcoR1/Sal1
RIPK1
+TGFBR2
V769_770insASV
motility28,29
doi:10.1172/JCI77627DS1
E1904K
–associated
pcDNA-p73β
hepatoblastomas
D-box–dependent
I-SET
extracts26
and3A
K171R
DNAdamage-response
XL-880
Dephosphorylated
31R/IVS2
dominant‐negative
c.2032C
Munush
.Preneoplastic
7235G→A
pianissimo
217–222
microanalysis
774delT
MUS
0.586
∼7.0
antibodies38
described.32
Raf-1-14-3-3
SOD
WT1-replete
.Parallels
12544
4bp‡
EGAS00001000348
.Sox17=green
12790
Molinolo
EMT-associated
CCTTACTGCCTCTTGCTTC
types5
Rad54-homologous
drug-targeted
Tet2loss
yeastexpressedp53
E69K
CD44-positive
Beier
pS473-phosphorylated
PyMOL.Clinical
RAinsensitive
c896
371-aa
C302R
pcDNA3.1-FLAG-tagged
GXL-Taq
V232I
1478
~Pai
polynucleated
–––––
p.S526S
methylated-regions
E0φ
50μl
Clincal
gpIRES
myelencephalon
L412F
Tumor-Suppressor
WDLPS/ALT
EYPSPTNA
intersubunit
F49L
2888-16_2888-13delTTCT
promoter‐proximal
modimerization
Cardio-facio-cutaneous
BRCT1749
11.275.1
0.25-
.SMO-A459V
GTPbinding
paragangliomas.5,25
months.8
∼16–18ns
60X
17986
D433H
defect-associated
μg/dl
61/724
predisposi-
GOF-induced
Brook-Carter
S.U./ml
IyArgf
F/76
Ser687
exsanguination
N540T
2/97
V20T
NS29I
LNCaP/AR–Luciferase
anti-serum
mutant/wild-type
NM_027208
here.11
mammals21
0-1+
models.71
SA2-depleted
K42me-specific
B-factors
impeccable
FANCD2,25
CADO-ES1
HDCC114
denaturation27
.Figure.4
0.076
C250
yumc.yonsei.ac.kr
Sox17GFP/GFP
processes.5-7
Furuta
NKAML
GTP30
imageFigure
431–443
SH2-Bbeta
histones.45
.Counterbalancing
Umkirch
.Recombination
p385-BRCA1
lacZ-hygro
â€˜I
pEAA291
Tgfβ3
cancer23,24
cycle/apoptosis-related
4.4E-4
leukemias,45
DCGR8
MMRdeficient
Arg→Ile
p21.Attempts
7.5,10
RASGEF
2AF/2AR
GPS2
nonconsequential
KD/C
BRCA2-truncated
mutation.16
Totoki
CRAF
SEGDVPGSLAGAYRGRHLVPRK
immunotherapies16
60–85
analysis27
CAG-9TAG
.FGFR2-IIIb
size—that
PBS-0.5
l•uAsnl
SNU638
Phoenix-Ampho
CCATGACAACTTTGGCATTG
F467CB-RAF
TFAM
BAF53b
Subfunctionalization
K373
BRCA2/FANCD1
immunofluoroscence
selumetinib-treated
NRAS-mutated
AA1370
Sleptsova-Friedricha
dysmorphologya
20.2–21.6
3′-GTCAACGCGTCGGACTTACCGC-5′
.714791
hormone–related
angiogenesis89
kinase/extracellular
marker24
3′-OH
ciliopathy
autodock
.002
V321
co‐segregation
STRADα/β
-FZR1
Eol-1
\0.001*
IPD-IMGT/HLA
D594H
G139V
LinesGenes
Myelum
S2-1
exon7
non-mutated
pAD4
1.6.0
TagRFP
Cortazar
auristatin
b-catenin-dependent
E10del
Gastric/12
~0.5
//www.synapse.org/
.USA
OVI-P
H3K27me3
OR=2.12
Dox
2774
C'l
6C–E
K22A
CCACCACAGCCAGTATAGGTG
Fig.6E
260/439
308/462
.Pham
.G273Stop
UI/ml
3/135
M14
exome22
Hirohide
GGCTATTTTCCTACAATTAGC
282-595
RNA/cDNA
H-test
Zagano
Hydro-RP
V8
phospho-Y417
Pro933
3611S
.Repair
18q21.1
2B11+PD7/
6/53
pY1604
ProteoQwest
IPF1
cells.12
61,43
BRCT-N
hVUS
0.962
.WM278-NIC-GFP
homeodomain
PTPRF
Uscn
GSYVPAI|H
MTOR-interacting
Sarantaus
NPM/ALK
p42-p44
studies13,14
families/
.†Compared
Zuo
519K
13q14.2
cata-
7
GATAD1
4485_4675del
24⇓⇓–27
R1513*
phenotype112
P304R
Z-value
LY2157288
—FGFR3
17q11â€
.73
7,430
ser53
allele30
F.rubripes
D19S1166
F133
GCGCT
EGFP-vector
allophycocyanin-labeled
ΔKD
HTLV-I
CBX7
described.37View
York-Presbyterian/Columbia
BiBr47*
5q33
.~Due
IsProGI
cancerres.aacrjournals.org
DS-red
stongly
mechanisms.21,22
p.T165I
bladder_
Rebbeck
43-316-385-4086
4.95
CD3/CD4
p′-DDD
gefitinib.8
90K
receptor12
pGL3-PSA-luc
13/504
Y320C
∼2–3-fold
p.Gln146Lys
D308
2001-2008
non-NMC
vitronectin
F/80
gggatccccatggtttctaagctg
/mammalian
pBabe-puror-FLAG-SNF5
9/95
M/83
200-time
82-
068
wortmannin/PX-866
Bio-Dot
SRC-dependently
NP_000050.2
5-hmC
state26
5′-CTTCCACAAGTCAGCCTACCAGTATA
iSH2
M1211
myeloma.6
//picard.sourceforge.net/
Fig.2f
2008.33
30th
ab93684
TGAGAACATGCAGTGTTTGGTTT
cardiomyocytes206
N1
Fgf-2
y-old
281-2
20°C/s
FOXP1-related
JAK2-translocation
.Sacramento
E39A
NRASA146
6n
CCNE2
5′-GGAGTGCAGTATCTCTCCTCTCT-3′
CEPH-YAC
D1449
MC1–neo
kMeindl
pE12R
SET-domain
receptor,52
A-J
500–1,500
4.5kb
CD31-positive
rs3891921
anti-OGT1
F450
1312–1328
MarkDuplicates
dN/dN
Cytochemistry
.DLD
Cos1-LV1
leukemia.6-9
oligomerization,13,15,16
p-value=0.82
self-ubiquitination
HMB-45–positive
5-nt-long
phosphoinositol-3
Alphelys
kinases.1,3
non-extremity
standard.Cell
Ingelheim
Melanoma-only
1849G
NIH-
inter-clone
.G719AþL861Q
cell-conditioned
PI020145
NB1224
II2
α1β1
glioneuronal
BIRC
N806
mutation21
Ptc+/−
1/ecotropic
San-Chung
dimethyltransferase
.Relatives
Fasinduced
BCR-ABL1-Positive
weak/diffused
DlICDK4
.Fbw7ARG/+
cancer.2
pHK1
513/1,363
PMM
XXVII
gatccCCCGCGCGCAAAGGG-3
receptors.7-10
lymphoma7
Chicago,36
Wrd
36D10
CO115
PRDM1-
polyclonal-resistant
luciferase-transfected
4.705
5C–F
6F
al,11
imatinib.27
ADIYAMGL
pCMV-Flag
Tyramide
Callorhinchus
2h–j
medschl.cam.ac.uk
Immunoblotting—Cell
NuGEN
C402G
.vcf
agent.31
MIDN-SBNO2
//www.broadinstitute.org/igv/
V600R/D
Mdm2
-10-8
Adipoq
CHD6
receiver-impairing
HVP26
AMP-19
AG1010
Tyr-CreERT2BrafV600EPtenL/L
2,533×
p.Arg109*
Runt-domain
2p22
leptomycin-sensitive
dysregulation—and
Msh2+PUR/
cleavage-resistant
c.9254_9258delATCAT
nonsmall-cell
oncogene14
4B-nR
15,18,19,21
*-.r4t2t+4.
figure2C
inB2m
one-letter
rs116057045
reported.37
L584F
Phe53
Khatlani
adults.33-36
Vennström
t2:3
co-evolution
*0408
Polyplus
deparaffination
finger/BR–C
33-45×106
I538
Delta27
overepressing
M13mp8
0.0353
←
v2.0.8b
ONCOCYTIC
cancer.18
Medcalc
50â€
knowledgebase
LP95
motif1,12,17
Tumor-Promoting
MFG-CAT-
fashion.39
G773A
c.1617_1618delAG
wereterminated
p-Value
risk,19,20
1/72
p-p
PMAIP1
homozygous
p.N71I
flash-frozen
9202
friable
46537
.ETV6-NTRK3
.CDKN2A
antioxidant-responsive
growth-factor-receptor
8Impact
complexes14
re-biopsy
miRBase
MEK1F53Y
DRB4*0201N
CCGC
1.03–1.05
-GCCAGGTAGCACTGAACACC-3
122–32
LAU108
.Py
F540
Spry2
SHOC2/SUR-8/SOC-2
~97
HCTp53+/+
kinase.2,3
BAP1-Xho-F
TNFaþCD8þ
//www.ncbi.nlm.nih.gov/geo/query/acc.cgi
3-Kinase-Dependent
NF2-WT
mg/day.63
TI-loops
patients.87
PI=3-P
pathogenic.15
mean=17.4
AML.103
translocator
ampicillin-resistant
treshold
24.2-Mb
residues6
37,061
H4-12K5R/K12R
1q2233
TGFβRIIpA
donor-specific
genome.cse.ucsc.edu/cgi-bin/hgGateway
R1262
IGKY
board–approved
McConville
V842A
bHLH–PAS
200-300ng
112–115
noncodon
c.4097G
V559V560
CLIP2
TÃŸR-Iserinethreonine
arrowindicates
.0003
,33,34
L.L.
Immunonstaining
NF1-deficient
Y177F
Conclusion—Activation
phospho-Mek
p.T779fs
.5062
B220-positive
Immunological
≈80
speciWcity
P179L/P179R
5′-CACGTG-3′
alsoshows
functions.43
Phe447E
5.56
max.-min
24,25,26
19,25,26
informationMouse
8·3
't'-test
50.4
S2M
5′-GTTATCCCATCTGCATCAGCATCTGG-3′
andBoiocchi
pCMV-Tag2-BRAF-WT
H3K27-specific
counterbalances
progression.5-7
Immunochemicals
Mll
.Trying
intestine23
fgfr1b
Alagille
reudction
cyclinD-CDK4/6
×100/total
E3.582
S222A
021
,37
cyclohexane-carboxamide
10-71
5'-TGAGTGAGAACAGGTGTCACC-3
ΔD3
promoter–associated
NUP214-ABL1–positive
1122–1141
1.67–19.65
A1102G/ACA-+ACG
methylation.99
target-capture
T/U
31/88
focus-assay
switching-off
Leivonen
binding12–15
3.914
p.Gln1388GlufsX2
GAGGCAAAGCAAATCCATTCG
RPCI1,3
//www.cancercell.org/cgi/content/full/5/4/375/DC1
01223-333634
quantitated
V1773
ERBB3/PI3K
3.7.0
MSH6/MSH6—with
CD5-positive
p53.Figure
∼2-fold
.Pat.1
E675D
.Excitation
36836067
subtype26
FGF16-FGF23
p21Kip1
Zbar
interpretedto
SNP-based
SNU484-LPCX
CCGTTGATGAACTCATTGGTT
7.5–10X
medulloblastoma/infratentorial
.Side-by-side
Caspase-8-expressing
LAU165
MUT-promoted
.Twice-daily
ZNRF3
D276G
locations19–21
C164
:ura4
249/168/123
PE-anti-human
K208M
41–77
11/19
1992
lys2-801
anti-ERBB3.2
Br45
p85αK511VfsX2
1×10−6
BATF3
34·3
L1732
ETV1b
melanoma8,9
'molecular
Aliquot
M224R—were
9E
I82
mTOR/p70S6K/rpS6
del13q14
Fig.2,2
glycogen
Srsf2flox/flox
transformation79
lodogen-coated
promoter-tagged
α-helices/β-strands
Bcr-FGFR1
.Euclidean
493±19
V5/SHP2
C-JUN
54906–55221
.AR3
pGEM5Zf
200×g
Sry-related
BSA-T-TBS
P418H
follow–upStandard
CUO26
anti-4EBP1
tramolecular
PCI-13-G245D
BCR-ABL.20
Smurf2-independent
475
T1996M
S4B–C
vectorthat
7q31.2–q31.31
5′-GGAACAATCAATCGACCAACTCC-3′
.Initial
CTATTTTTCCCTTTCTCCCC
IVS17-12
FANCD1/BRCA2
MAHALINGAM1
cynomolgus
regrown
EGFR–phosphoinositide
pLenti7.3/V5-DEST
deletionlskipping
TGTAAAACGACGGCCAGTACTTGCCATACTCCTTTTGG
G203A
chemoattraction
near-diploid
I715Sa
314–403
mesylate.6
µl/well
R47Q
denovo
Anti-phospho-p38
I21M
transgenic
epithelium29
phosphotidylinisitol-3-OH
GolgiPlug®
BRCT–
G72E
.Three-hundred
9A/9A
316–319
FLT3-ITDs
56_61QKQKVG
Merelbeke
5′-GAGGACTCGAGCTCAAGC
WT+MYCN
A111P
06-599
autopsy8
H3K79
configuration141
HER2/Neu-negative
−295
PI3
,4·3–77·7
Q.Z.
3736
Danieau
B=9.5
panitumumab.65
LEF/TCF
4244.0±382.5
j32m
B2P2
p16/p19ARF-null
ganglioglioma
GFC
however,21
RIGUI
.RAD54
follicular-variant
Drpnrtment
CD48+
†Very
4097
TCCCGCGCCC
gene.32,33
GSE17958
lTCTATCTTCAAGGGACTAGGAG-3
15,25
phosphatidyl-inositol
Theother
p53.61
-EGFR-L858R-T790M-C797S-HA
isvaluable
protein55
38.3°C
Andre´
93VU147T
p-Erk*
Cyp2j6
Blumenthal
side-chains
Cremophor
SMYD
ApaL1
V104M
vacuum-dried
FGFR2-IIIb-dependent
-71-276115
CY5
Pyk2
2·9–11·4
​Fig.44
pMD.G
HBS-Ca2+/30
BVU972
MDM2-expression
NM_013986
CldU-labeled
NFκB1
deoxy-NTPs
YesClones
pair/hydrogen
isotherm
1937A3G
includThe
carboxymethylated
T1700A-U
42/70
ALK-5′
Lys-538
anti-VEGFR
.Cellular
Asp351His
pXJ40-HA-PakCAAX
Tyr1017
75.27
IκBα-mutated
R1800G
ERBB28–10
Ras-GRP3
GAGCTGGCAATCGAACGACT
D1026Y
6q22–6q23
Y32W
surmount
neoplasm.11
target12
98.1
18-year
389–491
P256
1621-1
1:40,000
pseudopodium-enriched
integrin-binding
Pro104
non-gaussian
machineries19
3A-C
B-beads
progressionfree
bipotent
patients36,37,38,39
GAP-Since
Leu31
anti-Histone
Mulligan
AMP46
4C167d
BRAFV600K/R
1A–E
GFP-Ets2
integrity.Domain
−3.88
I167L
//weblogo.threeplusone.com/
1.5-25.0
coinhibitory
-CGTGAGGTCTGAAGGCCCC-30
1,260
9183
D821N
β-folding
5.96
Hs00184728_m1
seeTable
HEK293-ebna
Lys309-Arg309
IGH-CDK6
Immunopre
b-galactosidase-positive
Thr-37/Thr-46
blue/yellow/red
N489D
FANCD270
CAGGUCAAGAGGAGUACAGUUA
proteins5
carcinoma36
metapla
ATP-Mn2+–dependent
9/35=26
theory-based
AnalysisGene
non-normally
genes26–29
TBLASTN.27
CHK2
inactive/
.Disagreements
Dicer–PPD
whenbound
PSAwas
Nested-PCR/SSCP
e¡ect
p.L493V
36–41
RAS-bound
mutationconfers
Microanalysis
.Zweibaum
resistance39
reports/series
IM-50
chemotherapy,3
8-Cohort
STSVL
68°C.31
c.7913_7917del5
FLT3-LM
XAV939
p-β-catenin
p-GSK-3β
603467
Cell–cell
W860A
snR30
PRKAR1A-ALK
Tyr-Leu-Lys-Arg-Phe-Leu-Ala-Cys-Ile-Gln-Leu-Leu-Leu-Cys-Val-Cys-Arg-Leu
RETV804M/S904C
≈791
glucose-lowering
SNR_green
hMOFΔHAT
R552S
INPP5B
2L
Aindicate
desthiobiotin-ATP
Exon9-MLH1
c.5763dupT
instability.17
5′-FAM-CCCGCCCTGCTCACACCTCG-TAM-3′
pone.0064364.e005.jpg
MirusBio
811
moderate/weak
A.H.
p.Asn478Ser
carcinoma.8
NF-κB–driven
AKT2-transfected
15–450
Sham
Asp521
DABCO/Vectashield
maISSN
0094
Met1
64.0
binuclear
electroporated
GFP/KO
F876L–expressing
K170A
whole-arm
ATG→GTG
Alk-knockout
TCTGGGACACGAGCTATTCC
61.93
hypermethylation,4-6
microirradiation
Tris-borate-EDTA
tablets/week
.ERBB2T798I
M49
87:284-292
G418V
.Littermates
119–288
-TTGGGTGGATGCTCACACTG-3
Met35Asn
theSOX9
16·4–NE
KIF4A
ferrocyanide/5
c.2zF
258–368
KKEEEEYMMMM
Y2430C
PCR/fluorescence
T730S
InterPro57
Flag-SPOP
related-HMG
High-dose
Aa-RNase
pLXSN-neo-EGFR
A-III-3
Br51
p115
pAb
GC/metastasis-specific
3.53
.Therefore
N186D
nucleus.16
c.843C
843–846
.1730dup
ARv7
F909
.13–.25
C624-C636
Gln510Glu
Proliferation/cell
107–108
2854C
Minigenes
.Healy
UBC-Cre-ERT2
villae
-332a/g
integrin-linked
4275
UniSTS:156301
UnitedStates
MSK352x
472-474
Tanaka1
targetd
authenticated
Hypergeometric
IMC-A12
7.9/10
10.1182/blood-
Left-
SQLCOther
anti-p21/WAF1
82-kDa
.IL-7
p.1423
Down-Regulated
1287
3087–93
p.Ala370Thr
S-checkpoint
.Pro-Rich
.Loss-of-heterozygosity
.Motions
contactin
ICE-like
Vitanza
Btk
c-MYC−/−
IL-6R
Ser366
lineage20
ERG-Δ39
5′-CCCTCTCCGTTAAACCCATT-3′
metaplasia-dysplasia-carcinoma
c-Met-null
45°
GTTAACCATGCCGGCGTTGGCGC
I124V
CTLA4-deficient
AGAA
seq_tools
Takasawa
Western-blot
HPC2
NCT01133678
G17V
transrectal
fibroproliferative
mutation-focused
E542K
Hnf4a1–6
Subclones
BRAC1/BARD1
p.K666
induction23
H31L
Thesemutant
RAB34
DH‐PH
β-islet
p.128delV
wu20/wu101
90.15
SDF1/CXCL12
predifferentiated
MYCN-mediated
–70
Minami-Ohtsuka
SERPINB5
Molrep39
DMBA4
.Triplex-DNA
dichlorofluorophenyl
pSRGN
598/682
Cbl-Cool-1-tyrosine
forkhead-associated
MDA-MB435
18,61
q-scores
StageTips
globlin
GASTROENTEROLOGY
.1799
cholangiocar-cinoma
GXGXXGXV
0.001‡
PDGFRA-S3
H1047R/D933A
G12VKRAS
116-126
NMYC
Pim-1−/−/Pim-2−/−/Pim-3−/−
12.24
84.5
EX3
anonymised
1059
Ifo/J
CML.43
EZH2-promoted
pmCherry-N-rasG12V-C51Y
pter
RP11-80K5
CKII
A-172
p.Glu261Lys
TRA/D-TCL1
Y239C
bottomrow
1.3b
characterized14
//cbl-gorilla.cs.technion.ac.il/
pCMV-FLAG-5b
HD-0371
-enhancing
I448VC-RAF
1186
16–27
R289L
MUTTTTTTGAGAGTGC
.Copy-number
Regression-associated
non-contiguous
Venus–Raf
_FGFR3TACC3_-negative
N1380
HPV16/E6E7-immortalized
p53dinp1
guanidium-thiocyanate
c.511C4T
analysis.In
STAT3-independent
MCF7-inducible
TER119-expressing
anti-receptor-interacting
spermatocytic
8,48,49
12/44
vertebrates5
re-screen
3-hydroxy
ProCyte
D1.7
Transcriptomic
Keeton
ltration
0.035
anti-Akt/PKB
0.40–1.85
W137P
propria
MCP-1
//www.ncbi.nlm.nih.gov/projects/SAGE
46nt
K202
N368Sa
5-reverse
transcriptionally-active
metaplasia41
19p12
CS-600
c.476-2A
Kuhlenbaumer
Sudbeck
MiSeqDx
F856
pcDNA5/FRT
Tpo
.0014b
119804
.Inhibiting
TKI–treated
ependymoma-associated
Birc5
platinum-free
polyornithine
LME
.737G
rates30
evanescent
process78
RUNX1-CPNE8
Female/Male
cases.22-24
Y1007
0.16-1.73
Chusid
single-platform
BMT.70-72
Ninety-three
andReceived
CATGCCGAGG
RP11-59K17
cSingle
6TG/puromycin-resistant
instability.19
67,9
30–39
GSE2109
.Alkaline
68,69,70
Figure3E3E
1434L39
2091
Smad4-initiated
.ChIP-Seq
Pryzchodzen
marsupial
MYCN/EZH2
activity43
phospho-p42
active.29
5′-GAACACACCCGGGATGGTAGTGTTCAATGGCCTTC-3′
578
Tyr672
never-smoking
Sca1-
stage32
I789_L792
≥50,000
genes.The
.436G4A
sample‑
RG-6T
IκB-α
12146
272:10957–67
59-GCAATTTCTCGGCCCCTTTCC-39
IKBKE-amplified
activation202
ac.jp
5′-Rapid
syndrome69
E746_A750del/T790M
9211
TTTGAGGGACAAACCAGATAGG
GST-p110
thelithium
HR/DSBR
IgG-Cy3
11/318
AACGTGGTGCCCCTCTGTGACCTGCTGCTGGAGAT
monoclonals
day-3
Pietrak
GFP-TNRC6B
E627L
RDLQGEEIKSQNSQ
3812–21
Mdm1
PD0325901-treated
OR=1.19
Kras.We
R319Q
IFITM1-stabilized
Acvr1Q207D−c.a.-overexpressing
Janicki
System—To
1257
gender-specific
AA=0
3a-d
314690
20q12-qter
LNCaP/mAR-V4
SF1
out.8
NCT01362296
NAD+-
S296R
Accili
pLKO.1-puro
syndrome.14,33,34
–coding
19–23
phoshorylated
ARNT-ta
TFBS
laborintensiveand
anisomycin-stimulated
CB-17
120/112
×5000
v5.11
MYB
2624
J2-4/NOTCH1
c-MET-specific
K1101N
hystero-oophorectomy
Holz-Schietinger
Anti-ERBB2
insert.3
V=volume
Zwaan
//earray.chem.agilent.com/earray
N-cad
10710
L115E
CAN/Nup214
C-spine
HELIOS-Klinikum
analyzeda
micro-RNAs
20/0.50
utilising
melanoma10
Â¿Â°-
lymphomagenesis.51,52
p63.27-31
Chloramphenicol
suc1-associated
pCSUACG
PFGE
Figure6b,6b
Usp28
Q-promoter
p.Y60
homogeneous
Nagaoka
P14ARF
Tabela
overexpression/gene
raf-1
Myc–Max
2.4–5.1
S3-S4
phospho-deficient
pan-ERK
SNP-
Monrad
AAGGCCACTGTGGTTGAATTG
pcDNA5-Frt-TO
p.A246P
Bethesdaguidelines
p,0.05
–and
Fig1A–D
Pdgfrbredeye/+
1-1,000
rs6339
Q145H
505â
K-ras-R164Q
Sundström
438
diagnosis.4
43-154
FO-mediated
.II
glioblastomas.27
City.-'China
gene.26,27
0.0799
non-exhaustive
Beh
gastrointestinalstromal
OTUB1
RT-F
.TGF-beta1
Lagnaet
ATP-phosphate-binding
hPMS2-interaction
C901
signaling.28,48
dihydrofolate
TGF-β-treated
p110α-bound
BRCA2-deficient
assciation
pGAD–ROCK-I
Coomassie-stained
acidSchiff
Miknyoczki
immunoreactivity38
Memorial-Sloan
Å.
sites20
GTAGATACAAGTAGAGAAT
231
anti-p120-Gap
L-shaped
Vasioukhin
Ballmer
e009
KIT-Y568-Y570FF-D816V
EBNA3A–C
LMO–Ldb1
2-TRCN0000010397
CTM-5990506
c.1396G
CTACATAAGGCGGCCGGTAATCCGG
.I2005
Paragangliomas
low-toxicity
10q26.11
D292
-0.15
re-imaged
≤1•5×normal
process-level
4,5,23–27
PCA17
MIR765
10.1016
GC-specific
2Z60
Biologie
sensorgrams
HLH-Zip
Hydrophobic
Fgfr1a-mediated
osteoblasts11
GTPase220
discontinuations
wesuspect
*M
Siah/SIP/SCF/Ebi
P128L
3-associated
BT7
NSCLC23
prescreened
TÃŸR-H
.Hypoxia
endonucleolytically
6.5±3.9
C149T
7217
p-GSK3β
BRD4C
c.268C
self-renewal55
studies3–9
IKK-induced
CKO1
access_num=301040
Cks1
3,500
135-137
trastuzumab-mediated
Tannock
MEM–10
.Contacts
PA18
thisdata
BMS-345541
GST/T3
strains45
a12.5-kb
−13.9
metastasesProteins
minima
αvβ5
110–1100
features.9
JAK2T875N-expressing
TEL-ARG12
R248-L1847
Thedata
94–312
status55
KrasG12DTrp53
ß-cateninexpression
Cuningham
iron-overload
Targ
Thioflavin
E-PREDICT
S6-
expression3
.3902T
Papadopoulou
non-obese
15–25-fold
peptides.
R228Q
Q669X
attB5r_MEK1
Kolvenbag
NUS
ARID1A4
Th1/Th2
RhoA-G14V
C123S
pcDNA3.1D/V5‐His‐TOPO
-PCNA
H00003845-M01
NPMc+
low-glucose
MEK1L115P
anti-MLL1
normal/germ-line
ASXL1–BAP1
dialysate
.Ability
Lu165
GRB1
Junyaku
4q24
pejorative
anti-Trk
KS+/−
SIFT21
59-CGC
oxyphil
47/48
Radprime
GSE14960
C-terminally-truncated
metastatectomy
H4-12K5R/K12R/K8Ac
ASCAT
demonstrated.24,25
28.02
Sufu
-TGAATGAA-30
σˆ2a/
concurrently,50
AMPD3
M321
8642
chr19:41773142-41774065
splice-acceptorsite
12/90/71
preparationThe
cen.
1.34–5.99
particular—due
F148Y
KRASG12V-expressing
BSA
4Q21
Gain-of-function
pcDNA3/HA
INNO-LIPA
5′-CACTCAGTGTGGTGTAGAGG-3′
Holgado-Madruga
fusionpositive
mice.Cardiac
Myc-DH
themselves94
Oxo
ERK1G54A
torsion
5.38
withknown
Thr-654
−272
553
5A-C
BcI-2
II/2
17.34
47483801G
PRDX
IMHD843-846
3–1274
N913S
Picard-tools
Precursor-B
AMP-response
.0026
PLD-interacting
upregulation,19
bonafide
outcome.Materials
AmpCGH
-GTACACGATGTCTTTGGCAGA-3
JUN/FOS
diVerentiated
β-CATENIN
48.8Colorectal
0.00106
.Ub
AD-HIES9–11
NVP-BEZ235-AN
Tomizawa
BWA47
'neurofibromin
2c–e
AKT1/2/3
Asp-161
HER2-immunohistochemistry
Notch4
IVS27AAAT2.1
797TRex-flag-omomyc
2×10−1
dysplasia.7,9
SpeedUpTM
E67A
,8E
clinicopathologi-
317E13
P2A
∼80nM
kindred73
GTGGGACCAGCGAGGATG
C277S
obtainedfromWilliam
X-100-150
RUNX1c
WT1-
r.4097_4185del
MIR143/145
progeny-derived
P.M
His6-tagged
61.6
1-1-1
1523T1C
ATPase/DNA
A_52_P584302
tumor-forming
LMP2-transfected
sequencing9
S189/S207
rPLDl
jiroveci
imatinib.Figure
1525–1770
statusCytogenetic
targets17
47/1632
−/1+
144-fold
lobe.3
435Illmer
clinically-achievable
Cnossen
5′-TAAAATTGATTCCAATGCCATCC-3′
2.110
NBL18,19,20,21,22
fold-change
Arg1331X
phosphorylated-specific
Inhibin
mega-
Neuroradiologist
beta-naphthoflavone
0.726
12p13
autophagy-deficient
D351Y
single-cell-specific
NMR
.MAPK-signaling
7660
35S-met
LogP
USA.22
X-PDGFRB
phospho-p42/p44
twenty-fourth
1906G
×10−5
19th
2295
2662
CACO
NCCNCS
Harpaz
toolkit,24
3+d/M
600409
JQ1143
IVS3+3A
Q34K
EF1vsCT
arginine-DNA
M1400V
Pigmentosa
tal
Variation_1197
BRAFE600-transformed
Illumina/Solexa
F/75
5′-GCTGAAGTACTTGGCTGGTC-3′
Tables66
activity54
COP1-mediated
family21
sites.44,45
Eμ-MYC-transgenic
A-11,032
N=1
G60A
BioRobot
5.34
7.55
PHG0126
SCDs.We
GASTROINTESTINALCANCER
222-bp
Neu/ErbB-2
0.865
Fig.1C,1C
PBRM1
0.2–42
PDGFRADDIM842-844
cancer.37
formamide/7
\0.1
.AA
MYCC
aresensitive
ENST00000519973
0.0458†
∼200,000
19–22,24,27
L.uLeuAlsAlaAsnProPhIGlyGInAlaSerAlaSerI
transpupillary
S7-S8A
del22ter64
.Daxx
Q30
tc6
4D4
.Megakaryoblastic
N-glycoform
pFKHR
5.6-fold
REFLINK
M134L
bevacizumabtreated
TSC1-dependent
ubiqitin
R42P
p16INK4a−/−
NCL-p53-CM5P
.Available
Immunoblottings
QHP
fat1-knockdown
D2D6
ATCTTGAACTTCAACACAAGC
levels.31
MLL-negative
H478Y
substrate-binding
testis-specific
Vangala
61–3606
studies2
3056
.Ibuprofen
G249V
Fosl1
endoscopically
Haapasalo
29/35
88.81
S6282
6/165
site‐dependent
self-seeded
26,188
AVMb
FJ627787
soil9,10
+rescue
R815
arachdonyl
GDC-0879–resistant
refocusing
angiogenesis138
APC-mediated
4.25
analysis11,12
ALK-based
Receptor/isoform
immuno-compromised
Westmead
prevalance
GFP+CD45−lin−CD31−
BRCA2/18
specificity.11
viously
.PDGFR
P596
PtenloxP/loxPPB-Cre+
One-letter
18/556
MBS-540215
.Non-parametric
abnormalities
monoalleliclly
CCTGGGACAGCACTTTTGATGC
www.r-project.org
IRK3P
non-synonymous/splice
advance-stage
Oxiod
Virginina
06/01
DakoAb
300–800
470/40
Stolt
.NSD2
rate-limiting
D835HF
Arg224His
Pms1-deficient
p14ARF-regulated
THADA
far-upstream
pTyr694
R93L
vary17
eration
vectorcontains
status.12-14
WRINKLED1
FGFR3-TACC3-positive
−5.7
Asxl3
WT-R249S
.Haematoxylin
39·8
M552A
Enteropancreatic
141X
A172V
13C
unincorporated
genotypes/haplotypes
FMSlike
RGC-Luc
-5.2
.5x
Gisli
~~~~~eNN
ARE-regulated
UVS1.cER4.1
enhancers.45
cAMP-PKA
non-R206H
F75
Long-rank
GZL
p-interaction
Deuterium
CP690550
FAM72B
starvation/aphidicolin
EGFRvIII-based
protein.Reaction
0.3.3
Primersequences
p21-GTPyS
ERBB2IP–MAST4
Ser473
G345E
AutoDockTools
average25
1B–1D
1096
jid
acinar/ductal
NGF-TrkA
DH5α/P3
eBio4E3
GTCCCTGCGC
produc­
DharmaFECT4
1470–1862
IKAROS,26
phages
57e
TBJ10
desorption/ionization
CFP-T80K
Aulnay
GCCCGCCGCC
co-dependent
=∑Lgj=mg
pseudopseudohypoparathyroidism
12-base-pair
.Chick
CHEN_HOXA5_TARGETS_UP
cell-certified
DNeasy™
.patient
lipid-modified
MDS.9
GSE42401
Raster3D
estradioland
c.117A
3,346
754807
3-kinase/AKT–mediated
2.86–13.85
Katritch
Rab5-positive
3,5-bisphosphate
RQ1Dnase
Gefitinib-Responsive
2,5-diphenyloxazole
P=0.037
1,2,3
jil
amplifications/overexpressions
7184
4230
T790M-specific
BRCA1/2-mutated
removal.24
pGT3.4
1000-
HDMEC
.§The
theMann–
F1174L
9/9/98
PFAM
.DU145-derived
S6k1/2
TCR-CD3–mediated
intr2
E190K
5362
Cullin1
HR=0.39
lqâ
mutated-like
Pax6-positive
135.2
SCS
Mre11-interacting
Q575_D579dup
Thr37/46
Flowgen
FA1b
K-Ras+/V14I
P0009
28.7
Small-pool
arginines
Lyt-10-7
Table55
IGFBP7
0.537
p.R687W
Gal4-B2N60
.Autophosphorylated
incorporation
11,205
CTGCGC1TFGCACTATFGGG
LOX-IMVI
SmB
RAS–MAPK
anti-phospho-Akt1
anti-p62/SQSTM
ΔRAD51C-DT40
TACCCCCATCTCTCCTCCTC
300~400379
Woodage
red/brown
Ras-mutated
100íl
5.60
PBRM1.18
MAP3Ks31
NKAIN2
71*
Köhnke
p.Glu720ArgfsX6
profile/distribution
–Curie
zlj9990993630008
DNMT3A-DNMT3A
VEGFF
approx65-kDa
X8
R132H
−136
S751
p300-CBP
amperage
Context-specific
mRNA.1
elsewhere9
BR0019
anti-rabbit-Texas
37-bp
breast.16
GFP–VHL160-expressing
AMPK-activating
p.Thr196Ala
692–701
32373
—was
TBq
SKGNEYLIRTLQPLLKKIIQNRDF
motif/Pointed
signalling,53
5′-TGTGGAATGTAGAGATTGGAGAATGTATA-3′
calcein-AM-labeled
PD03259019
Groucho-related
tcctag/GGGGCT
MSN-ROS1
brain–independent
pFlag-CMV2
R702Q
μU/ml
nontyrosine
terminus15
12-13
-derived
InDel
presymptomatically.9
IKK-β
TNFa
IHPM
3.Y327S
c.1181G4A
4.38E-03
Alexa568-conjugated
*Twenty-one
genes.21
RP11–457E6
R181→E
phenotype,33
29/60
66245
.Fragment
TEL-Jak1-expressing
signaling.60
A-B
iuGlyGluGlyAlil
DMEM/HAM
spheroid-containing
NM_178596
TGGAAGATCTGACCCGAATCAA
0.827-4.696
IRES-dependent
ab65258
.CEN
.BBD
23-50
8.78
binding43
HCC.22,24
1to
212-4729471
translocationassociated
family.26
Leu790Phe
2-295-
Loop–sheet–helix
mbt-like
NF-κβ
T474M
Senescence-Associated
T-cell–inflamed
.pDpc4
5q14.1
www.ebi.ac.uk/msd-srv/ssm/
D1-D289A
14.00
3'-ATCTGTAACGGGAGCTCCATGGTACCTAGGCTACAGYTGGAGTTTGGATCT
Npm3-ps1
I˙stanbul
cell-independent
characterization3
GSE39793
Perseptive
GIGAXONIN
GFP-fusions
hormone-treated
38.03
Fbw6
Mutation/Overexpression
Q182H
h-urine
P=0.200
PA42
Emulsiflex
CD45.2+
mayven
HA-AKT2
166/168
hrthe
Ephrins
CTMP
p.C459G
G298S
F6A
relocalized
retrovirus-derived
PEN2
'e~~~~~-~~~~-
.G1738E
platelets.1
Sowter
Pahlman
––
CRE-2-TTTGGGCTCTGCCCCTCGCTGCTC
double-transfected
ALK+samples
MAP3K118
arrest.58
non-stoichiometric
L57
residues1–10
zVAD-fmk
embryogenesis,15
Nowakowski
con®ned
PDX-unique
progression.56
Serous/3
21,585
nomutations
TNFRSF10A/B
siRNA-RhoA
35,41
1/4JHN
80K
.line
destabilizedthe
23,5
F1245
activation,38
HRASV12
∼10-5-10-7
ARF-p53
staining.23
.IMAs
E7.75
JFCR
172T
G502
exome-sequenced
horseshoe-shaped
c.241C4A
Genotype–Phenotype
N54S
Time-course
mwald-Giemsa
CGA9TGG
Plust
GM6914/wt-FANCA
.Tracheomalacia
F1174L-mutated
werethe
S.2
Naumovski
RP11-927H16
rPhSI
bioMérieux
H319Y
Hall-Jackson
JCRB0401
SRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFH
3446
SDS2.1
S403F
491T
TAAD
28-33
0.6789
HTSeq-count60
–90.9
rap2B
FLT3-JM-PMs.15,16
copiesof
cER4-40
.Theother
GFC-transfection
post-Tet
molecular-cytogenetic
SEQUENCHER
GIuAsnProGInTyrPheSerAspAl
5.5-9.0
.Annu
Vasquez
D770_N7719nsSVD
ScienceSlides
FGFR4≈34
MEK1-BRAF
TRKC1059
15.4–17.6
tumor–dysplasia
BCR-ABL1-like
TMPRSS2_F
ψ0
MEM-alpha
LacI-SHQ1
/0.1
alleles.Prospective
wormannin
396K
As2O3
-glutamine
c.4131-4156del26bp
vector/well
culty
Tofacitinib
RPTPp-dependent
0.05/numbers
pMDL-RRE
Proline124
hetero-trimer
CLEC5A
.3,17,18
alone99
D419A
drug/adenosine
v11.5.1
conditionsfor
.22,23
just-enough
6.23
resistance/sensitivity
PUFD
L32
SC-9420
.DNMT3AMUT
synchondrosis
Anaemia/
factor,63platelet-derived
.SNF2_N
T1368M
N41A
F284
PPP2R1A-indepent
SLCT-19
Q56_V60del
revealedthe
FANCA-specific
T57I
Immunoprecipitation—For
autoradiogram
.4,5,6,7
Ala654
4.23+0.02
www.aacrjournals.org
1,613
.Library
Bortner
F125V
bromine-derivatized
bindingreactions
1374–1550
pS6K1
PROTON-BEAM
2493-2467
anti–IL-10–neutralizing
CCACCCATGGCAAATTCCATGG
baculovirus-produced
Brca1-knockout
SCCIC1
R1204W
91-94
Pten+/–
K-Ras-4B
Hartsuiker
Texas-red
FLAG-FANCA
0-5
www.ncbi.nih.gov
transcription.Finally
G88S
3.04
G719S+E709A
N345H
4.9–5.2
postconception
truncationtest
613583
Genome-level
.MiRNAs
RTLTLISKTIQIIGN
1725
byethidium
54th
10–12-wk-old
tV.alPhoGluTyrMotM9Hi
CT-26
pOPI3
www.biochemj.org
GGCAGACAGAAGTTAGCTCGGT
co-opt
Â
co-activate
STEMCCA
Mammalian-Two-Hybrid
1.10969
c.1738A
3=0.0299plusminus0.0216
Embi
pT202/Y204
Foxp1
.Smad4
p53-mdm2
T309I
myc-p110β
deletions,20-22have
case-reports
c.107C
H,32
OPEC
AGC/TCC
Q8UVR8
C1-C3
SNP309-associated
genomicrearrangement
Bcl-2–interacting
VL2
'driver
two-hybrid-based
K157N
Takai
3.1/V5-His-based
UT=49.9
gluconeogenic
-CATCGGGGATTGTTCAGATT-30
E17K-PH/WT-KD
gp11OPro'-trk
transphosphorylated
Inhibitor-1
www.genome.washington.edu
sarcomatous-like
c.677
enzalutamide-resistant
c.142delG
.Ultimately
FLT3-WT-Ba/F3
BCR.Materials
tumors99
Ala1268
CCACTGCTCCGACATG
GFP–VHL213-
PH3
addiction.
3.1-
0.5–1.5×106
H246R
Nugc-4
4336
61·4
RNU1A1
EID
time-resolved—FRET
13Cα/13Cβ
SCC-15
15B
480-bp
XPCS1CD
1β
1,300
∼5.5
activation.8,20
V378A
AACCACGT6ACTTTBTC1C
L185P
haematopoiesis4,10,11
PAM50
1.22
TCS-SP2
D1709
birth.Statistics
thought,2
11-35
Socolovsky
methodsMore
sample—suggesting
Two-colour
shRNAmir
.Position
Glu73
Cdc37/
Elf
Tumeurs
−71C
CB.17
KD1077
≈18
cancers3
somatostatinoma
nonskewed
D4MIT27-F:5′GCACGGTAGTTTTTCCAGGA3′
ttccag/AAGGAG
tBI
clinicopathological
FGFR-aberrant
.PIK3R1R348∗
T384M
receptor-y
pBabe-zeo-H-Ras
G301C
D-CDK4/6
RP11-9E13
pTS76
anti-p53-specific
Spitzner
intention-to-treat
desensitizing
carcinogenesis
peroxisomes
BRCA1.185delAG
genes.91
alterations2,3
wiley.com
Stauber
cycles16
¢lters
PshAI
Rap1A
GFP/E1384K
.2449
NPM-ALK-dependent
1d–f
Nevzorova
described19
15N−1H
degradation/turnover
MMRCS
Ercc1tmJhjh
Ser259
uke.uni-hamburg.de
SUVi
pre-cold
MiTF-high
1Met–89Leu
e13.2
DO4
1554
rearrangedin
.Improved
T544M
5'-GTGTCCTTGATCCACTTCCG-3
diverticulitis
wu118/wu120
PTF
retinoblastoma-family
EZH2-
Cbl-70Z.15,28
chemiluminescense
.Autoactivation
95-110
19q13-qter
SPEN-overexpressing
557_558
Noort
c-Myb,4
0·3
Patient-matched
CFP-Peptide
MagAttract
homospecific
Divlsion
E1-E2-E3
5′GCTGCCGAGAGAGGACGCG-3′
telomerase-immortalized
rag1
LNCAP
surface36
SSPSwt
Figure6B
5′-GCAGAAGCCTGCTATGTCCA-3′
tobramycin
factor.6In
R1751X
NSCLC.28,29
ancestry9
Phaselock
Chimeric
pY1096
5′-GGGCGUGGCUGUCCUCAAUdUdU-3′
CACTGGAAAGTCCCAACACC
GAAGATGGTGATGGGATTTC-3′
LKB1-interacting
8464
.Truncated
SUMO-site
0.6971
2-TRCN0000074285
katherine.geiersbach
acid–based
small-needle
+N
.DAX1
NTD-PAZ
-ggctctctgggtagcccaccggc-30
10.1007/s10549-011-1599-7
5′-TGCTGTCGCCGAAGAAGTTA-3′
CFP1-interacting
c.8035G
4:1
20-mer
10,13,15
Sengong
35-150
S2B–S2D
564–578
EN-Y518F-expressing
ALDH
methods25
BRCA115
intra-genetic
Fungizone
I669T
PPRC
.OX86-induced
Stata
p42/44
anterioposterior
MOLMOL69
U01-051
Electroperu
LN40–ATP
−51.8
467N23
DSP-
cross-staining
Kip1
≤64
sc-12911
.S8A–S8C
FGFRTACC
eciency
M-01
postradiation
ETV6-FLT3
17–28
RUFY2-RET
I2008
5′-TCACATTCTCCCCATCAGGGATCCA-3′
163/248
Eblaghie
408
3782
GST-SRC-1
phenanthroline
-S36A
1.091
DENND1
.SKN
/phenylalanine
1560–1863
.9,63,79,87
2043
protein-Fbw7
and2B,2B
273–293
www.interscience
Leu209
that–when
BRAF1
pseudo-electron
NEDD8
RescueESE
.1003749
c.365C
pCMV-Tag2
His-Flag-BRCA1
.Indications
0.5
.SCF/Kit-induced
GAG-GCG
Ser505Asn
AAAGAAATTGATACCAGTACCAAAGTTG
9.81
pLRD21-
testis-like
tumor–microenvironment
120.3
5-TGCCTGTGGAGGAACTTTTCA-3
SCCH-196
dyscalcula
36/M
23:111–116
543delT
RPMS1
50–57
.Multifactorial
TAT-1
GISTs.In
theKd
c.4660_4661insA
anti–Melan-A
O6meG
M3434
Doddroe
pyramidal
1475
BCR-ABL/G6PD
87.91
110–160
187953
.Extracellular
BRCA1-RING
CYP2E1
basal-myoepithelial
sequenc­
Arg680
pE3-111
Sekiguchi
non-mutation
PIC1/SUMO-1
oncogenic33–37
offocus-forming
rs2430561
SGC7901
Mec1-dependent
fluorescent-based
umin.ac.jp
anaemia156
antisense-oligonucleotides
Histomorphological
Bdf1
rabbit-anti
13.32
TAATCTACTTT6AG
8µm
T157A/D319N
double-digested
CBFβ
vector18
Erg10
JRSGC
major-phosphorylated
2,3-d
S2L
.Heritable
twoalpha
Y281H
sc-508
non-isotopic
ERBB4s
documented11,12
wet-transfer
H.-L.
CtGUSB
//www.upstate.com
10·8
Shiota
A_52_P472324
PTPRD-Binding
host-protecting
DCS-6
1996,11
retroviruscarrying
cascades.6
mutant.26
S404
ABI/Prism
6.95
Peukert
1.267–8.083
S384F
0.9nM
PROS-A
c.10095delCins11
antisense-treated
pVHL213-overexpressing
E711K
modulatemismatch
6829
Bfivefold
c.1224dupT
NCI-H1155
21,23
//foldx.crg.es/
HS/PCs
NM_025393
3Dcoffee
TMS-treated
P031
R168
S1898F
pGBM
.Mapped
8,5′-3H
fo–fc
.Rabaptin
catalysis,32
Ben-Shachar
PI3K-Akt-dependent
NM_007929
Serl613Gly
genome-wide21–25
C175R
Nellist
FLT3-ITD–
RCCn=
anti-IL-3βR
pαGT-RII
p.R369Q
.341G
0.082
www.thelancet.com
p.G216_splice
NM_001262.2
Moinova
P322S
0,0013
WNT3
s-KIAA1549
v0.8
87.89
oxygen-air
D7nt
ERGpositive
wu95/wu21
R249S+FL-CDB3
Dumaz1,2
…S10
RPCI11
10–81
1752
antibiological
.Tumorigenic
90:10
therapy-assignment
104–108
pC53-248
Grignani
dideoxy-DNA
PtenΔ/Δ+PTX
36–39
spirinolactone
Asn58
Orthologs
EUROHEAR
CFSElow
TAZ-mediated
hybridoma
-R-K-K-R-R-Q-R-R-R-A-P
.Cigarette
98kb
MEN2A-RETC634W
polIII
.Anti-β-actin
aggressive.30
proximal/
RosaLSL-RFP
U87MG.ΔEGFR-KD-Akt
HGF-induction
1.00–1.02
831
Honavar
CBL-Y371
P16–3
RAS–MEK–ERK
.Reintroduction
Hydroxylation-dependent
c.3028+1G
toproduce
p53Δ
Oligofectamine
activity30
T-transgenic
Rintala-Maki
pool-mediated
.Thevariants
I1074F
Pro445H
FGF3/FGF4
MLL–MLLT1
FGFR3−/−
GATA-3+
N169Xc
GCK
cases.2
Nkx2.5
ofHCC
AGTCCTCTCTCCGGATG
5T32
R899P
​Figure11
Kouki
long-bone
94-mm
l-901/eu2-3,112
.DNA–protein
SATB
TJ
C4323T
acetate/TE
Stylianos.Antonarakis
CD4-allophycocyanin
L19F
​,5B
caspase-10
scavenger-receptor
A.F.O
R479G
GH3
R410
JMP
PI103/PI3Kα
21–35
C224
A_52_P482897
CIC-FOXO4
cyteine-rich
454-nucleotide
L2427R
Tyr204
anti–phospho-ALK
.6438
Ustun
DrosophilaHopscotch
S326A
IBC
onlypatients
Ex12-R
Monolayer—In
-CATATCCCCATGGCAAACTCTTGC-3
4.8e
5'-CGTCATGGAGGCCAGCATAT-3
37l-bp
Döhner
High-power
FITC-rat
MACROLIDE
pseudoprogression
pCMVbeta-gal
p-MAPK
ratsAll
phopho-ERK1∕2
G8
allele31
AAG-3V
non-transmembrane
KIT-V654A
Heterogeneity
1906
p.Q61H
3,520
Dimer_
Virchows
KYTE-DOOLITTLE
translocations2
thymidine-arrested
.-O
BRCA1/20
URA3-marked
Lats1-mediated
Solute
NM_022160
H.R
Bach1WT-FH
profile105
κ=0.95
sarcomatoid-specific
Ki-67-immunostained
NMDc
CCAAGGCCAACCGCGAGAAGATGAC
C44R
coli—Each
.RAD51D
adenocarcinoma11
Thr-308
A56220
Sumazin
P250L
9/172
4NKA
c-Cbl-binding
L15F
Stelter
10:3
458
1–235
33428300
0.258
aredivided
series24–32
Elk4
Emmert-Buck
breakinduced
Trempat
providedgenerously
0.5−1.0
DiGiammarino
241,248
RTJ.2
24/54
membranes.113-115
SP-A
E545
EglN
.Y905
11S*
.28,48
EcoRI-HindIII
K652Q
GPA
rad50hook
4/16
Drost
D1-D292A
repair156
Tsp-1
hypercalcemic
NSEP
KRAS-2F
immunophenotypically
Met-923
_________________________K
x-100
746-752
tumors,25
52–149
CD36+/GpA-
CHTOP
.U73122
Brca1SCo/Δ
G-C
AKTi
.NotI-Smurf1-R
neoplasms32,33
-GAA
76.5°
HH-specific
H-U.S.
RAF176
98/168
.2364
RnaseH
.IGF-II
yLFM-based
ETV6-W-PDGFR
discriminate
16:1207–1212
.Translesion
MLL-NRIP3
TLS-
10q26.3
growth-arrested
Xuan
M1652
edge59,60,61
n=1128
taxol
‑264/-40
gil
NM_000535
sunlight-exposed
NSD1-3
14–24
2Division
assay40
SHP2/A461T
GFP–PKCα
R1190W
shRNA-hASXL1
713
185300
67425126
expression.Statistical
Md.
AD-HIES13
GST-MLH1
5′-CTGAAGCAACACGTCCTTCTGAT-3′
mMK3Fe
DTCS-Quick
EML4-ALK-I117S
p.A77P
Vismodegib-Dependent
69KB
CArcATAcTCCAAABATATEAr7TTAcTcACrTcAtrAAWAI16ArAATMEAAnTr6*ATTTrCn
0.5761
GJA-1
25.0–63.4
192K
GDP-RasD38A
DQA1*0501+
1,157
R499H
NFlg26
Smad2−/−
∼2000
c.9118A-2
.†Tests
N540→K
R284Q
pan-BCR-ABL
64°
K320
13qter
c-H-ras
SLEC
50ng/μL
www.nhgri.nih.gov
NCI-H678
line-containing
.S2.8
MEK2-P298L
p.D591*
precur
STAT3.6
2.6.1
geNorm
MG-B2GFPΔ3263–70/Δ3381–85
PP2A-specific
C.P.S
conformatiomal
pathway-mediated
R192W
Albcre/Tgfbr2f/f
Ts−
tissue9
N412S
..We
H3K36me3-deficient
-Cre-ERT2+
electrolyte
Myl2
Roux-Dosseto
'stemness
ÃŸ2-MGprobe.Fig
//bioconductor.org/packages/release/bioc/html/limma.html
www.povray.org
P79L
0.005-2
never-smokers109
SWI–SNF
pathway.Figure
statement24
T286A-dependent
bowtie2
1870
p.K1423E
trr-RNAi
cule
CPT-stalled
U.S.A
assay/enzyme-linked
moreslowly
supplementing
interest.35
Scheffzeck
-ethyl
0.040513812
Rosteck
FL-CDB316
speciesto
-11-
Merlin96
COSMIC-FG1
8.96–24.58
XLI
2854A
24/29
33–37
physiology.1,2
Haemato-oncology
36-month
ALOX
1,4d
.NONISOTOPIC
10–5
GCTTAAGGC-F
SAMtools81
HxY
CD5dim
gamma-H2AX
30–31
investigation.BRCA1B
Bioioinformatic
TGAGTTGCCTGAGTTTCG
proteins.73
list40
amino-termin­
17p13.3
AGI-5027
Glu-766
9079
method.50
QV-OPh
Noran
BAT-RIl
rearrangedfragment
NES.37
Non–Hodgkin
Baf170
HLA-B*56
R237Q
2Aj
39f
.Organs
760-500
Nfkb2
UNC337
2FERC-stop
phosphate⋅DNA
-CCTTAAAAGCCACTGGGGATG-30
activity.106
EWS2017
ΔΔCq
malformations.6
PI-88665
Palmitoylation
GGTGAGG
FL-1H
Immunocytometry
Iwabuchi
amplification,22
single-target
5′-JAK2
NCL-p53
pIRES2-DsRed
PD033299,1
ZNF-198-FGFR1
translocation-containing
Spred
EDTA,110
Docetaxel
0.063–0.074
CD45R
DNA/chromatin
protein.27
pRS425GALMEK
2444
FGFR1ex16-FW
Protein–DNA
3,527
0.010
.Sensitivities
NMS‐E628
IIalpha
.295C
Frobenius
//browser.1000genomes.org/Homo_sapiens/Gene/Variation_Gene/Table
Daneshmand
.H2–H12
R272C
429-442
L611V/V617F
28/115
109/1-1
GDC-0941–resistant
TATGTGAACAGAAAAGAGGCAAAG
667
mutantswith
.NS597
re-plated
bHLH-LZ
Arg-273
neddylation-dependent
biotechology
A–G
AG656
.HT-29R
1020–9
0.519
38–
TTCTTTGAA
anti-phospho-GSK-3β
Raf-l.
CCR9
EML4-ALKL1196M
ΔGbind
nutrient-starved
anti-CAR
Asp153Tyr
MUTYH/MYH
simiincluding
PRO47ALA
methylene-based
Q558
differentsizes
pauciarticular
Kif11
//www.umd.be/BRCA2/
Zar
0-4°C
58.5∗
ubiquitn-like
SKOV-3
SH30003.03
Erase-a-base
Leu265Pro
thekinase
Genecodes
G766R
PCa-positive
JAK2V617F-Y931C
2.024
CAPONY
3.53–45.9
K118N
antigenexpression
Myc-LZTR
.N233K
Lightcycler
single-hit
1b/
9B11
26p.G510del
13266
anti-HER2
gelelectrophoresis
0.000007
cancer,33,34
lymphoma
41,42,66
.Heterogeneous
Moch
.Oct-1
373KB
155–174
pcbi.1003545.e003.jpg
anti-acetyl-histone
Osajima-Hakomori
hMSH6-P1087
SOX17-null
hCDC4/NOTCH1
PhasePrep
Brixton
late-onset
46,49,50
Pack-year
Raf-isoforms
1×105/well
aaIPI
BCR/ABL-induced
acttac
CAAATCAGGGACTCCTGCGT
MFE296
E022
V802F
21.Transfections
smallbowel
+140
studies.80
2.5–10
μg/mL
p=0·007
pcDNA3/PTEN
thymidine/nocodazole
V326A
Anti-MYC
2.148
dn-Raf
BTK-ibrutinib
criteriaa
comparison.To
Y3092S
Craniosynostosis
al.11
MAPKK
Lys949
Co33
organs12
MSI-based
Klion
RCURE1
D3–CDK11
infections8
5′-CATTTGAACATTGTAAGCTTGCTGGGAGCCTG-3′
D-09
c.862G4T
ARHGAP23
Glu100
PRSS3
D1–dependent
Brca2flox/-/Wap-cre
5′-ATC
XP295BE
coimmunostained
0.00097
8405
.AGAGAAGCAGAAAATatatcctttccggtgttgggaccgcggggcctccg-3
Ariumi
p110δ−/−
PRKCBvsCT
NRAS.13
CII
ray-induced
Deep-seated
cancer88
gplloProtot-rk
wall.34
UAS-TK-LacZ
C2110T
L435P
FGFR4/FGFR1
cancer7,8
NU7441
SQSTM19
38:461–466
-G106R
RFS-c-myc
null154R
Arg186
.NRAS
6405insTT
N-Ras
TLS
67-year
3p
5′-GACTCCAGATAAGAGAGCTG
receptor-encoding
denatured-form
35S-Methionine–
13q32
.SRC
M11802
2H-tetrazolium
27/500
Hyperdiploidy
NRNR0/97
1000-fold
five-residue
STAT3-WT
Arid1a+/flox
Wicoxon
X-inactivation
c.-74insC
29/178
4,8,16
tetrahydrofuran/water
RUNX1/CBF
Eventsa
H773_V774insH
UCH
Anticyclin
0.7519
AGCCTGAAGAAGGAGGATGTGAGG
Sp-Dicer
patient—an
24694
oligo-astheno-teratozoospermic
noprognostic
Salesse
2Rγ
KURY
M74088.1
Anti-mouse
KMT2D
RP11-
KLPQL
coactivated
_FGFR3TACC3_positive
.Trp268
J060
3dhotspots.org
occipitocervical
734-647-2944
CML.3
Asn705
HindII/SmaI
lower—not
utr
perturbations
S5b
DALI46
del747-P753insS
anti-therapeutic
vivo.13,14
496
N901-07A
CCFCGTCGG
Cavailles
63.6
chaotropic
G145A
-dCTP-labeled
pCyclinA-Luc
MicroRNAs
function11–15
-l-piperazineethanesulfonic
far.1,2,4,5
Microinjections
acids26,27
Ready-to-Go®
v4.1
I/σI
//www-stat.stanford.edu/~tibs/SAM/
.Eighteen
Kerbel
285A1
demonstrated.23–25
bphuron
pRb/E2F2
Howev-
.TGF-
MGC29506/MZB1
.Chemoinvasion
1-methyl-2-pyrrolidinone/90
carcinomas,4
osteoclast-like
therapyBased
K35A
ZvLSSILISPI
.R139X
octocysteine
\16
PTPL1
vitro86
pGEMhp53wtB
.Highly
ET.E..
.695
1-s
RAF—ARAF
Schreiber‐Agus
PIM4973g
TAATACGACTCACTATAGGGGCGCTGGCATCCACTTCCATCGTCG
p.Thr3941Hisfs*4
762-782
p.S365A
.Efficient
tumors.14,26
4,6-diamino-2-phenyl-indole
P154L
normalFANCC
RG-19
d887
MLL-Rearranged
8xDBE
D43968
disproportionate
5hmCpGs
648‐CTF
PPPY376
901,779
MUT+
AMPK-α1-T174D
microdeletions.5
AGGF1
pjanne
negative-stain
genes.4
.0113
Leu87
ATTGCTTTTGGCTTCTTTAGCC
16–61
234T
Fbw7ARG/+
functions110
trophoresis
1Y6
αq
cytoskeleton,29
moderate-sized
.7785
differentiation92
Leu97Arg
Igll1
3834–3836
redeposited
tested.The
2-OH-estradiol
SAVI
T-switch
.MEK/AKT
aspartate-816
IL-10–producing
P-actin
NheI-sensitive
∼0.6
1−5.1SCN4BSodium
5′-CTACCAGATACCTACCAGTATCTCCGTACTATCTTGTC-3′
BCL2-driven
Trp-227
and4c
glycosyl
CMX-ÃŸgal
antsBoth
Ras–GRD
v9.10
MoMSV
0.211-1.098
Univalent
HD-0172
YM
–stimulated
511fs
1307
methytransferases
oligomerized
Rab7-positive
â€oemutatorthat
P753S
presentation.6,7,9,10
ARE3
results,13
TGGCCGT
PMC0035
HGAs
CMV-Gal
.Andrechek
and-
170-0005
55-year
MIZUKI
E84E
Apoptosis—During
180435
I130T
yeast.20
V129M
carboplatin-paclitaxel
Lys16
USH-associated
3H
survival-shortening
V2.5
epithelial-stromal
pre-exisiting
50/56
0667
sizeDiscussionMany
Srsf2-mutant
Lin−c-Kit+Sca-1+CD135+CD34+
K5.Smad2f/f
X3C-5
smad3
snRNP-associated
transportation.29
protein–interaction
TCF8
R1262A
expectedto
p16INK4a–cyclin
non-Caucasians
.Glucocorticoid
35S-pulse-labeled
C1275Y
–69.6
PML-RARa
MUC5AC
Broniscer
IL1B/CDK2
7.6/150
251061661914336864202536+*21430211320113235714657571538100103206000020
3,200
S430
antiJNK1
5,200
UroCor
p.Tyr506Leufs
C3H/10T/2
P2158A
HS683
two-phase
MCF-7-luc-F5
SOTARRAY
3.5-Å
Fig.8D8D
7.5–25
Suela
Thyroid-specific
CCU-3′
Cie
piperidin
APMIS
5-aza-cytidine
Bgn
4141
I0LL
Etv6-NTRK3
4.40-
33446143
shock-freezing
Conacci-Sorrell
Kavuri
19–amino
infralimbic
EGFRL861
Gfi
G56S
MscI
-IRES-hmAG
QuikChange
44.The
mutant/WT
CRE-L1
Hf7C
www.ncbi.nlm.nih.gov/SNP
49–60
Anti-emetic
strategies.11
sn-1,2-diacylglycerol
Asp770_Asn771insSerValPro
HGG
RCT-E473
NRF2-mediated
F40L
37/47
G34V
protein-p53
β-catenin-T-cell
2,3,4,5,6,7,8
14-69
gamma-dependent
pFlt3
H168R-DNA
doi:10.1371/journal.pone.0025021.g004
malignancy17
81-3-5841-4778
D'Alessandro
44,1:1,000
Hyperproliferative
TFE3-rearranged
gadobutrol
p.G245
user-friendly
RLL
cilia-based
HRASK147E
coprecipitation
pT1G2
PCRamplifiedfor
samples.106
.MutPred
77.2
Loughrey
54.597
Miccadei
mÃ©tastasescarried
1Bb2
RenderByAttribute
post‐transcriptional
Thr-specific
7/TET1
1404–1423
FGFR2
neurofibromatosis/NSlike
32S
LSL-G12DTnfafl
amino-terminal
8.20
0.0.7,8
179L7
.7‡
t-tests
carcinomas.5,12,13
.Hwang
Su-DHL-2
aconthosis
thePolyPhen
RET/C634R-
32P-dCTP/tube
was-c-myc
Swi2
cells.Lin-
3/196
.Clinico-pathological
AAsp-25
SC-
-ATGAATTCTAGAGGAACA-3
pCDH-Vector
tamoxifen-stimulated
MicroScint-PS
pBabe-Puro-Myc
A49T
geranylgeranylprenylation
IUE
5q21-22
others1,4-6
cells39
variants40
167–187
c.2382G
RNA/small-molecule
5utr
Soslow
TGFBR2/TβRII
spindle-assembly
pCMV6-entry
HEPH
electrocardiogram
4,40,41
.Charge
Exon-by-exon
V-4758
.Using
K12
TGFB1–SAE1
HGF-transgenic
42-70
.Merkhofer
.of
HPRC3
mgrg
LOH-negative
.PP58-induced
sera
241–244
inhibitionThe
p-p90RSK
ischaemic
c.425C
Trp-994
nongranulosa
DII4
SF3b
leu2
target-mediated
MLL-ENL-ERtm
3A–3C
S1570L
6,14,15
reconstruction.4
T342M
MEK2-Q60P
PMA-free
acidification
anti-phospho-BAD
stroma51
FP1
Vectormediated
RP11-148D21
NCT02141828
diseaseAbstract•
CRE-bound
0.41308348
129-143
.Intestinal
Thesleff
.EURHAB
glutathione-horseradish
4OHL
RAS/PI3K
andtransactivation
HIF-β
TCTCCCAAAGCACCAAGTCT
YAP194
corpora
3-kinase/protein
.Cyclosporine
b4
PI3K-Ras
TPC
N78S
55jC
2,320
TU-02
phosphotidylinositol
D299G
ϕB
Fig7
LVId
SH3-proteins
.Sladek
19-BM
cPTPRD–Asp1521Ala
PMS2-NOT
Bone/soft
p.R203C
sequence.17
non-resectable
vectorsK-ras
C107R
E2F3
GT-3
FGFR2-3x
tactic
juxtamembrane-transmembrane
Mistou
2p33
cellclones
D300H/R310H
P531AA
activation44
P208′–P210′
Pettinato
L-PCR
Mice.53BP1−/−
HrasG12V/
p27
NEH2
Dean-Jett-Fox
Epsom
0.35±0.04
A017
N432T
22–355
R438C
R332H
Funabiki
biological/targeted
103cells/well
5/18
FC=5.6
p.A502_Y503dup-mutated
201566_x_at
HPC1
L133H
CGATGAAGAGATCATCAAGGGC
HED351G
Fcc-receptor-mediated
Schardt
39-3
Mmp1a
8-proline-stretch
Hs36
viglietto
.Left
3.5–5.0
GAPstimulated
groups87
ispossible
553712
.Repopulation
ETV6–ABL1
SOS-catalysed
NaDodSO4
/IIA
*None
pGK-neo-bpA
.Capping
bindingsurface
57K
Ad5-ZBP-89
480b
E12.5
seminoma/dysgerminoma
sequence-dependent
D142G
hadbeen
Yancik
MECOM
W3
T599/S602
CDK12
Bouchalova
15125
Fifty-three
c.866T
.Ethical
PI3KR3
G168–728
hemEC2
Nonhematopoietic
cells.18,19,21,25
phdm2-Luc
E67-52
6c–f
interrelations
Lys49
Proxeon
Thr-202/204
tumour-node-metastasis
Cbl-UbcH7
77MDM2
LNCaP-cxD12
PGL2
Gly-12
.MH2
PTEN-centromere
4.63–7.06
.PCM
mL89
Ts65Dn
mis-incorporation
C*03
K-Ras-driven
formaldehyde/0.2
v-SRC
Elf3Δ237
chr2.hg19
RAB39
ANNOVAR47
P=0.9556
Ecopac
T54I
soy
75.0
_FGFR3ex18-TACC3ex13_
Isoform
E.g
L114R
A347
1791
M-to-A
Muniyappa
Univeristy
leukaemia50
W942C
undermasculinization
0.798–1.866
isocitrate-metal
4.18E-15
anti-YAP
22263
.RAD51C-R214C
4803delCC
mediaAll
129/OLA
1085-9195/00/33/53–62/
Chimaerism
8/26
non–cell
.Cholera
temperature-dependency
PAK4–6
ofPro
low-expressed
Tween80
DNA-mini
Asp816Tyr
C-C1a
K299AR300D
ALL.34
alÃ-elesfor
Poullet
CGC-
*Six
c-Mpl-R102P-GFP
oligo-d
drawtree
.3,13
20α-hydroxysteroid
D5S299/APC/L5.71
biofunctions
Fig.4B4B
PEG6000
Antibiotic-Antimycotic
pT7Blue
BstBI
cases.In
p53RE-bound
0.97887
59Thr
T202
46
5C–E
men/14
described.7
Ct2
.H3.3
.4.1
TEL-PDGFR,6
nitrobenzo
TAPUR
HSC536
SH2-PI3-kinase
.Swensen
Balsara
387
Awada
CBCC
V600R-M-D
p.Leu354AsnfsX4
Martinez-Moczygemba
multiple-gated
respectively3
hypoxia-driven
p-MAPK1/2
S0389
DePex
cells.19–21
RTQELEIELPSEPR
000o0
251-2A
.Engraftment
2−ΔΔCt
177H
5q21–34
LC32
activation.20
non-aligned
Mre11
MFGR1877S
1-3
1.043
PB-SMART
I748T
types10
Crouzon-linked
-CTGGCATTAGAATTATTTAAA-3
10-8-15.HEK293T
p.W257C
IL3-independence
–321d
r2012
V57
Anti-CD24-PE
553927
V155A
Panton-Valentine
5q31.3
miceTable
/h
Koutras
976A-G
DPC4
pEFP
Cpb
.181G4A
p16/Ink4a
Co-activator
oxyethylenenitrilo
basic‐helix‐loop‐helix‐leucine
HERPUD1
psychotropic
1❚
eukaryotes3,4
lines,6,12,13
.Dysgerminomas
lomonocytic
1ViL
apoptosis/cell
15NH4Cl
granulo-monocytes
previously.28
p-ter
V345L
MDA-361
GAGAFG
1,328
IKAROS.17
0.0009
shRAB35
W276S
pGEX-6P
c.787_790dup
polarisation
sub-sites
In-Fusion®
S455A
smokersa
Sollievo
Gata1
2PSQ
AR-p160-CBP
multi-label
vectorfrom
Homotrimer
males.1,2
coverage42
Y174D
Leg-length
MSH2c.2087C
H305
taqpol
PCl
Thecells
ceritinib/crizotinib
B-Raf-mediated
.GST-tagged
38210
eight-cell
11,12,13
tttgctgtctcatcctcacagITPLACCTTGATGATACTTCCC
mutanta
ERBB-1
PAb240
T3-T4
LR06-069
1,505
acetyl-lysine
LDE-225
.3.0-fold
SPR.27–
beta−5.1TMEM40Hypothetical
11lGlulyslysAspGluThrPrQPheGlyValSerValAlaValGlyleuAl•ValPh•AlaCysleu
LNR‐C
Varscan2
000548
94℃
non-TKI
yMLHI
transformable
8195
0.060
.ETS1
2639
COHORT
*0102
P1749R.BRCA1
p53tet-R337H
cells6
//www.jhc.org
Rad51cko/+
AIIIFVPVPQLK
19/M
frame-duplications
45-54
microtubule-disrupting
HCTp53−/−
hAgo—is
'-10-fold
mutations/amplification
WT-AAC
PKH67
subre-
Walantus
Rho-GTPases
HlsLeuGluLeuArgAspLeuArpglyLeuGlyGluLeuArgAsnLeuThrl
3,565
≥0.00
MES4490
PRE2005.LNCC/FD1
M286V
16.2
Arg-48
cell1
predis-
Microscope-based
Methylation-specific
Brca1fl/185stop
R2=0.016–0.299
55242468
Crepaldi
1.03–5.33
mTOR-activating
dyskaratosis
78/309
GIST46
proto-oncogenes.16-18
C66-230
calcium-mediated
AUL
single-site
cancer.Stable
P53-specific
NGFinduced
ETV1/chromosome
818A
76+76bp
3'RACE
Halevy
FIG-ROS1
CycD–Cdk4
,56
dithio-disulfide
retention.18-20
C118R
IRES-Thy1.1
P-loops
ofN-methylanthraniloyl
chromosome1q21.MUC1
1/48
arthritis87
AAGCATAAGAATATCATCATCAA-3′
//imagej.nih.gov/ij/
xDFG-backbones
p.Arg31Cys
GFPbased
nonstem
NP_000042
gene.2,3
MKK
pipettes
Stratagcne
p53and
DAPI-banded
Deptor
0·9
β.6,9,10
2.0c
promotor-driven
FDR=10
BCFR
MgADP
DRAQ5
.Close-up
T6–T9
J6E
Beas2B
Bmi1-null
17Ras
TRFA
N219Y
236-251
TCGA-A6-4105-01
1:30
mTORC1-activating
25,600
FFBE
L636P
H19/IGF2
60-year-old
Karpas1272
P252R
D60A
hidradenoma
WT1/EGR-1
C/p.G114D
Godin-Heymann
SETD2
14/203
multigland
≤40
NBS1/Xrs2
439ins15del310
FZD7
41-year
Kaer
guanidinium-phenol/
pCB6WT1
85/1070
HRasV12-induced
mutation‐L726I
RBM6
dominant-negative–
strategy52
dyskeratosis,30
SPOP-dependent
PI3K-binding
Rb1654
pNFκB
VAMT
eAll
PE-labelled
38/42
0/1a/1b
C–F1
NCoA-1
patient,48
.181T
batchwise
-SH2
deacetylases17
loss,38
assayedfor
AA6TTACTTCAGAArG6AAiAATTSAAATMCATTCAMCTTOTCTTT
NF-κB2–Cα1
A337P
0.191*
//dx.doi.org/10.7554/eLife.08905.002
augmentation
parsimoniously
5e
β-catenin/Tcf-binding
20104
microarray30
donor-site
5′-CTCTTCACAGGTGAGGCCATTAT-3′
T582P
I84S
approach,6
FPα.23,27
ALKR1275
pre-MegE
∥
splenocytes14-16
French,28
+1550
naphthoylated
pureDNA
ofβ
Parolini
pVhl
.Unexpectedly
chemo-therapies
17S
.C-RAF
collagen-1
p.G116A/p.R117A
1.904
dimethylbenzanthracene
European-origin
1809del
HbHcontaining
Q90Ga
ALG13
GGT→GAT
AKNS1A
31-91
GeGAGcAGT
565/1,631
f1MR1/MR3
first-dimension
Mapk/Erk
Grb2-
Na–Hepes
5′-GCGCTCGTACCTATCCCACTGAGCCCAGACACTAAG-3′
.Fig.1A,1A
proteintruncating
transgene-expressing
HER3-associated
treatPC12
hemidiaphragm
flatbottomed
p145
8:13
ProTran
Gorringe
gleu
400009
.Two
T670M
1.17–14.5
used.w2
TTGTGAGTAC
12/15
Abbreviations—–yr
R2-C278F
kination
.Anti-phosphotyrosine
neu–overexpressing
GAGTGGGGAGCATAGTGCTAG
c-Sea
FQ868
CTG
Histiocytosis
lux
Immunoblotting
anti-vascular
crizotinib-relapsed
Transconjugant
RET-∆6
pSer473
Quick-hyb
amplifi
750-bp
H-rasV12
p120GAPand
not.4
ERBB3-ligand
Ortica
5′-tct
IGFBP2
anti-actin
030810
types.27
G12V/A
inhibition.Similarly
T149A/+
www.broad.mit.edu/mmgp
A–D
A-coated
PDGFAB
PLG
CTGTGGGCCATGGCTGTGGTTTG
VK256-257V
AML1/RUNX1
CDK6
Rui
InTFG
Flag-Ubc9
carboxy­
RAPTOR-sensitive
Ni-TA
7,17,20
high-information-content
D-022211–01
NRSApSEPSL
thiopeta
phenylmethylsulphonyl
kinase.38Other
Gln738
Phenol-red
MST1R
.Lakshmi
earlier.2
NLS2-dGFP
analysis.9
AF355273
10/262
0.25mg/ml
11722
.ERE
Moldenhauer
a-keratin
59-CTGTTTCTTCAGAGGAGAGCG-39
GM-CSF·GM-CSFR
Hes1-specific
5′-GAATCAGCTAGCGAAGAGCTGTTCTACCAGATACTC
.PDGFs
immunoglobulin
cells.11
AP1-like
.HTLV-1-infected
log2-fold-change
Non-infected
glesatinib
10/65
A_52_P64356
activity.38
.LTK-14
.Preponderance
II.I.I.Il
GISTs.16
H-102
aggregation-associated
D594G-BRAF
NM_001626.3
Gd3+-conjugated
pEAA286
TCAGTGATGT
5,000
87
lymphoid-primed
.Smad3−/−
activity.24,25,32,34−36
7.0±4.7
gamma-treated
reconsolidation
PEBP2αA/CBFA1
HepG2-shSUMO1
LSL-N-RasQ61R
Debrauwere
ARAF1
cM–long
A338
Voytyuk
RA49LT
//www.simulconsult.com/run/index.html
1–23
Porri
Thirman
μg/ml
0.61–1.21
aecting
Ret15F
DLBCL/PMBL
BAF47
MLC20
crystallization
siRNA-resistant
Fig.11
~for
criteria.6,7
0.05.Finally
ACAGGAAGT
Csk
P=0.0086
Ackrill
D19S209
pRSET
GNAS
-0.8
NSCLC4
rabaptin-5/PDGFbR
receptor185
HECOG
Fyn−/−
H63D
/GST-pl
7498
RNA-24
084
guanidinium-phenol
H773_V774dupH
Hatzi
rearrangementcreates
N47K
16q23.2
CTTGAGGGAACACATACTCG
GeneMarker®
Theclones
ser465/467
beamline
Q3
1,289
His773_Val774insHis,27
sub-classify
mTOR-induced
PAI
GAACATGTCCCAACATGTT
fulllengthNTRK1
NM_018881
Volocity®
chemo
Hs00269212_m1
R173C
13-mm
Chi-squarebased
A196V
Ex13-R
U6/siRhoA-2
-CD33
AGGCACTGAG
hematologic/nonhematologic
.AF078776
Cxcr2
microstrabismus
8.3–20.0
61.4
Tsubouchi
E.132Additionally
NROB1
TC7
1-666
74–79
ofIGH
transcripts.89
15·9
pre-assembly
P400T
Tris/Boric
J.A
D1228H
F595A/V617F
Tecfidera
K..
.G418
s-PSA
-349
RYDLKPEN
2¼
SARL
.VEGF-C
Sm3CAC-L
Be21
Sa˜o
147–185
-PAGE
-ΔI
Vibhuti
thio-β-d-galactopyranoside
trigonal-bipy-
p.Val133Met
Tet1-mediated
tumours81
3908
pep2
A/M
Smad4-
SvEv
1922
.YWHAB
circumventing
uct/hgmd
815–816
RT-qPCR
Tm=53°C
.Assignment
inactive18
.T411
V600E-mutated
postmortem
post-NGS
B-actin
WT1cause
Variation_30190
Fig.4d
cord–stromal
nonHodgkin
28,434,853–31,065,330
first-pool
.Hicklin
K5.Cre
triple-knockout
QL
e21
LacZeo
T310R
3443
MutLa-variant
.Gly96Cys
cells59
sumbucosal
anti-Ki
P=0.491
transistion
248and
//dx.doi.org/10.7554/eLife.12792.002
DyeDeoxy
P48-Cre
LiFraumeni
Ag/mL
−/nd
hematoxylin–eosin
non-cerebral
Q61
DeepView
Cocrystallization
GSE50021
Bw4
goldenrod
Jomar
Encyclo-
Skottke
C01
1XTQ
Ubc5c
148K
pentostatin
dNTP/2.5
ME-PCR
Diepoxybutane
FDC
28,34
PCR-2
FANCG.24,28
paracortical
Tip49
Isakoff
abdomen/pelvis
Aff
Cl−
concentrating
3,3-dimethylglutarate
.Snap
discoloration
SFB-tagged
H68
S-Transferase–tagged
tissueswhere
Lag3
P2A-DD
FOXO6
MEN4-associated
partiallycaused
Inda
TNFalpha
7-derived
030917
p50/p52
antidigoxigenin
22q11-q13
TrisiHCl
CCNB2
ARCM
molecule-R-phycoerythrin
co-precipitation
pseudonormal
HNF1A-inactivated
mechanisms7
TFBSs
Polyadenylate-enriched
CPG-activated
non-analyzed
S37
pellet-1
2ul
STAT1–IFN-γRα
miR-155
MSA
1532/0/187
receptor-blocking
13∼15
VPMLDMKGDIKYADIE
4·1–15·2
nohybridizing
S142
missenses
estradiol−estrogen
NFIC
2080
11Ar9L
4.3*
proteinby
hydroxymethylation
survival.7,8
ob-
4.Table
D835VF
p3TP-Lux
MluI-
replication85
41.1-fold
charged-to-Al-
Tsuchihara
L63
Figure6A
A1207
Never-smokers
c.693C
adrenocortical
.29-
Hypokalemia
anti-FIG
FGFR4Arg388-expressing
oligodeoxynucleotides
Pro150ES
DIGIFTR
−688
CFP-CTLAThr17
twenty-nine
Phospho-AKT1
GSE841
4.44
RTC14
15q22.31
rela-
r.1153_1253del/p.N385Vfs*7
C.For
A300-810A
22161
Ammirante
H1734
proline-rich
CWR22Rv1
.H3
Zorbax
530T
0.32-0.86
54.9-fold
TPR-Met
Dojindo
K42me2
K43me2
3-phosphoniositides
Menzel-Glaeser
Supernatant
RTK-associated
Structure-activity
Giessen
−2.06
Fig.4e
08/15/2011
5′-CAATTTTTTAAAGTAACTATCTGA-3′
smoking-related
ectual
genes.7,8
VV559-560
Egfrmediated
5′-CTCCTTAATGTCACGCACGAT-3′
Lane2,4
I852
0–265
gene.Mutated
TAp73α
305-8571
CCG→TCG
liver.1,7
*McNemar
cytokinesis-regulatory
.Alk9
Spreds
Y628
malformation-arteriovenous
.Ninety-seven
r.9118_9124del
2.27–15.44
Dnmt3a
137.94
1.91–7.78
GST-CDK10-
p21-p53REs
BPDE-induced
RASA2
pre‐mRNA
synthetase/aspartate
.Anecdotally
n=322
016-510-084
Y527F
yAr
EμPNA
PATHOGENESIS
electron-spray
anti–b-catenin
7qBCR
.Silver-stained
p.R167
5′-CTCTCTGGTTCTAAGGTAGAGTG-3′
PC130
FOXO-3A
2Unità
nihms646437t15.jpg
interactions.13
PCR-DNA
LeGO-C2
v20
withBamHI
reassayed
p-ATM
p.P215A
haematoxiylin-eosin
p21.Analysis
5′-TCTGGGCTTGGGGAAGCTGTC-3′
11VYIDPTQL569-576del
Onwuazor
desmin+
36-37
personalized-medicine
ERK/MAPK
substrates.3
MFGR1877A—1
568K
TP6317
Investigation/American
trypsin-like
erlotinib.11,12
5′-AACTCCACACATCACTCTGGTG-3′
room-temperature
protein/GAPDH
abnormalities2
V715M
G369D
wt12
.POLE
S714C
H-Meso
Goydos
evaluation.Two
91.03
1,153
chickens3
38–50
140-kb
PF04449913
2314C
279R
activity/Renilla
low-
pAAU-Ha-ras
BFCOL1
Piti-Salptrire
SK+
Sp/ep
Avantaggiati
73-4506
ChemBridge
18-hydroxycorticosterone
.UGG
pVHLS111R
size-determined
wide-spread
discriminating
phospho-Y1604
cysteine–aspartic
pFR-luc
excitotoxicity
back-of-the-envelope
life.10,13-15
conjunctivitis
non-UV-treated
dolichostenomelia
MDS_314
5′-AAGCTGTGCATGATTCTGGG-3′
R198C
0.5x
.4J
K650K
Neurology
ACATCCAGCAGCAGCAAAG
37–75
S-tag
FMCBioProducts
6-Nf
GSE847
lag
aca
EGFR-E18R
ER-induced
threonine-308
Materialsand
RAD51-ssDNA
P1657L
//pierotti.group.ifom-ieo-campus.it/suppl/epd.html
.Structure-based
.Optimization
1–352
Y1730C
Sboner
D76N
.Neoadjuvant
tissue/cell-type-specific
∼57,000:1
ciD
Agents/Circumstances
Calypso-interacting
.I496V
androgen-unresponsive
arylpyridine
O-nitrophenyl-galactopyranoside
VPS34
396
.Eaton
abiraterone-resistance
RETA833F
896a8
R-domain
assays10
effect.8
SOO
622–781
IGR1
M792
Vrielink
low-pass
.Fat
V166F
NUP20531
23–87
anti-p21/CDKN1A
Genemap
rs55986863
pY1045
8/5
SK-N-MC
binding6
anti-Topo1
17q11.2-12
P86H
YFP-Jak2-T875N
PV-like
100mg/ml
Hipskind
sc-8017
.PTCH1
7.74-14.86
METHODSYeast
fusion-transformed
.0015
Sub-domains
Eberharter
Hif1b
c.1789–1790CT
q-Q209L
P-STAT5A
4.9-133.6
taxane
FDR=0.01
time.21
2813±1197
S–P
account.8-11
~105
INF/NF3b-associated
H597Y
myelodysplasia/myeloproliferative
TCGA-27–1837
Fig4
3451
incessant
guanidine
principalcomponents
FgfRs
JCV
Heidenreich
A1625G
2001–2014
+uu
NuPAGE
MED12KD-like
JMM
DMS
ad-Cre
FLT3-ITD-W51
.select_db=SOS1
nihms646437t14.jpg
E663G
kinase-inducible
inhibitor67
071
3,6,7
vesicle-associated
MCPH9
adenoma–carcinoma
PK-6105
p.Y646C
14q11
KMS-3
9/15
Bim-dependent
0.58–0.98
n=173
HNF3α-specific
FGFBP1
described.33
sc-40
leukemia42
phospho-Ser15
arenot
VCS2
lymphoma-specific
Twelve-week-old
295
5'-TTCCTATGAGTCCGTAGACT-3
tw
LELMEGGDLLSYL
p.E501G
98–280
.Reprinted
globular
TATGCCACATCCCAAGTG
17016070
W113R
I1171T-alectinib
tritium
B1,24
phosphotungstic
7-1-
R.O.B.
CDK-binding/inhibitory
dissociation-ion
AF363682
PYY3–36
.72A
SMP410
PC-Brca1
DeltaFosB
Abelson-related
.G24R
fgf-8
A_52_P533809
domestica
pFC-MEK1
Amol
Smallbowel
.2227
Asp119
491–498
microphthalmia/anophthalmia
BAF180+/+
kinase/Akt
eachother
BM8
VetEquip
JAK/STAT-dependent
osteodystrophy
bound.22
al16
4.0,23
A31T
'non-malignant
MPHOSPH8
Rac/Nox
saltingout
304−554
.Mode
Palucka
.TRiC-mediated
v2.0.4
.Protection
FWHM
1.947
Laser-MicroBeam
transducers4–6
cyclin-box-fold
LoxP-flanked
Site–directed
8Dâ
TSC1/TSC2-mutated
7p22.1
GSE53350
shAHR_1
cull
low-expression
FITC-
FMG
ER/FOXA1
H-RasC118S
p.L761X
.Perturbation
rate.33
mitfa
6/20
−24.20
CTD-2131H15
p.S34F
.Purple
IKK-α
PI335
K69R
p815
SC-Ura
R98H
G518D
68·2
RP11–
byIFN-'y
Adenomas
W78
monolayered
α1/β3
icPTPRD-3X-FLAG
D291V
Akt2-null
ex14
2×104
c.219T
AGGCG
h.p.f.
Tnfsf10
R1138Q
∼2.0
.FU
RG-21T
23.8
DNA-bindingcarboxyl
cDNA-pJP1520
395–800
Dajee
c.3170_3174del5
T1203K
activity–independent
561483
sunitinib+everolimus
CAGCTTCGCGCATCGGTTCGCCTTCGACCTTAA-5
liver-fluke
L293
59–157
EversusBT
K1724-R181
and—on
PTP-SL
p110γ-D964A
NFE2L2_REV
sigificant
∼200–300-fold
Insightful
ILeuTy
1p22.3–p22.2
αI
E262K
AML1-mediated
rs16260
HGGs5
95jC
p.L1872P
EGF11
.ASP3026
Arg447
ACTINFILIN
RARS-T.
1μM
Tyr223of
Y472C
CAIS
PCR-SSO
p53-specific
IL-17A
.Small-molecule–based
E.B.L
46968–47246
F216S
N433A
Q626*
agents.1
Gleevec/STI-571/imatinib
.A23
anti–HGF-cMET
.N-T
.PTENINACTIVATION
'Ewing-like
GTAAG
MSCV-FIP1L1
doi:10.1158/0008-5472.CAN-05-0471
0.839
37-149
QSY7-3′
-transformed
HTLF-4
erbB-2/neu
responses43
–––
≤3×
vemurafinib
-6
Elf3K320E
GGAGGG
tumours28
hand.38
NRASA146T
Factors/Serum
.Smooth
-0.459
Src-SH2
p.Gln1037X
Rbm10
sub-Saharan
U04045
mTR−/−
4627C
PCR-directed
t003
counts21/5
®lm
Hamaratoglu
PRDM110–16
OB2/OB3
structures27
205879_x_at
c.9403delC
ΔB-RAF
osteolineage
cellshave
10.The
chromatin-prebound
20/121
life.22
29–41
pIGF
NOD.Cg-Prkdcscid
ChIP-reChIP
Gil-Perotin
Pro1749Ala
monotherapy
I335M
0.56-1.01
I574
G623
C-GFP
buprenorphine
20071
Glu→Lys
IgGI
D1/bcl-1
coilin
co-transcriptionally
myc-p110
FCHSD1–BRAF
thePAX8
PIK3/Pten
TTTTTGAGAGTGCGAGAGAGGCGGTCGTGCAGACCCGGGAGAAAGATG
KYPVQPFTESQSLTLTDVENLH
metastaseswere
P-Met
K.A.R.
Keersmaecker
Ly5.2+
S1b
10.3±3.1
anti-phospho-Stat3
T-stage
–39
Oliviera
.Ba/F3-BCR-JAK2
study,42
Mek2
FigFig1L1L
E748
DLeu
72–75
GlideXP
sulfate/polyacrylamide
M483R
BMP/Activin
defects.NS
Plusagarose
E326K
.IVT/translation
n=591
29–52
Stat5a
S1E–H
transdifferentiate
1270–1272
L662P
189.7–193.9
Spearman–Rho
lymphomagenesis26,27
dysgerminoma/seminoma
D1384
ErbB2-catalyzed
BCL2-modifying
Gligand
3,208
Myc-wtBRIP1-
Katowice
F176S
.Emergent
WT-ERF
2,145
oncochip
single-tumor
StyI/EcoRI
KIT-D816V-positive
DNA-derived
IL-3–carboxymethylcellulose
described.35
R1800H
,16,51,53,54
128KB
unit-granulocyte/monocyte
Fig.33A
GAGGTTCAGAGCCATGGACC
410950
anti‐PD1
2/56
D298A
polyubiquitylate
1649–1859
Methods.b
ZBP-89-mediated
CHEK2-dependent
Shayeghi
pcDNA3-H179Y-mutated
.Short
56774080
FU/LV/irinotecan
Pofut1
MZBCH
G0–S
cm/year
.CHEK2
kobsH2O
approaches21
1A-2
trplA63
IL-7Rα17
1.014–15.099
damage-dependent
lanesçthe
SETD22
Weidemann-Steiner
MPL-T487A
.Ungual
multi-national
cRSS-mediated
Pette
tumors.16
Ab-reactivity
encephalomyocarditis
Tgfbr1fl
alectinib-resistant
1.29-6.69
SETD2/Ku80
.ADE2
Ethnicity*
Gln336
AFF1
c.8169_8172dup4
H69-CDDP
nptII
Jackknife
gefitinib.15,17–19
ExomeDepth
M.V.Fig
416-bp
LS-50b
P50H
MMC-triggered
Millauer
protein-serine-threonine
biopsy/plasma
5′-CAACACGACACCGGATAAACC-3′
H2544
genome.16
0.717893341
TaKaRa
Speir
REARRANGEMENTS
S378P
types.4
syndromes—Noonan
0·018
WM1789
sub-G0
female-specific
0.386
Centricon-I0
region.15
Jo¨rg
factor,60
AKT1/3
NP-
AGS/U6
Alk-7
S0397T
pcbi
.TITANIUM
tumor‐bearing
system44
fluorescence-aided
/streptomycin
Avidin-HRP
100,000/mm3
.4A
NCT01336634
GeneMap
Hoxa9/Meis1–induced
hepatocyte/HCC
J40
3911
AY428536
0.008-0.067
Europe/SAS
amp/gain
Gln61-NE2
13,15
2–LacZ
KNAUS
G2A
8.04E-39
homologousyeast
L122V
imidazolo
estrogen-respon
non-PIK3R1R348∗
H2126
0.37–2.49
Hrs-positive
1107
2,596
0/0
vehicle-control-only
10-chloro-4-oxo-3-phenyl-4H-benzo
-Tubulin
S5G–S5I
SH2B322
pulsed-labeled
HUTS-21
c.34A
A157V
Kong1
Pro1115ThrfsX41
.DISCUSSIONIn
Exelixis
DNA-extraction
JB11738
Allderdice
Petach
A057
+4–5
yAG|r—the
cell–context-specific
M37K-mutant
KasI
clinic-pathological
0.72
7310
p300-promoted
Galon
22/34
6.5/54
5-times
methyl-nucleotides
A775insYVMA
155-
.Today
.Bosc23
©2013
N642H
LRP5
.shows
cluster96
instability-12
GCB-like
5′-TCCCGCCCTCCAAAATAAGG-3′
ward.D2
TGAGTGGGGTCTCCTGAACATA
8400_8401ins4
actin-filament
Lck–Cre30
.IM
MDX-010
Eco31I
195,000
TRIM24–NTRK2
tissue-type-dependent
c.1169_1170ins20
BAF
epigallocatechin-3-gallate
6AU—such
4538C
starry-sky
anti-oxidation
ReportsPatient
00×
pTre2hyg
~27
APKN
XPO1-E571K/G-mCherry
N324
pCR-TOP0
cyclin-
InvPCR
aMSH/
01223-333345
41/285
pCNX2
α-G
flex-points
anti-RUNX1
Cul3–SPOP
Tub-C
NUP98-HOXD13
foci.18
prognosis102
36,37
100*
anti-XIAP
L116V
3×104
sequencingMicrodissected
glycosylase-like
BACH1/FancJ
IRF4hi
EDA-GppNp-Atto488
Y'-C
Immunoblots—Preparation
17-22
5′-CAATACTCGGTTTTAGCAGTC-3′
5′-AGGATGGAAGTGCAGTTAGGGCT-3′
DOSPER
markedNRS
L701H/T877A
Fambrough
antagonising
Nsegbe
formation76
replisome
MGC16044−7.6FAM83BcDNA
oval-shaped
FA–G
neverbeen
M1842I
BC043399
RIE
1TUP
M-CSF
D−/−mice
H4K16
R156Q
71.7
inter-individually
polylinkerfragment
C96Y
BREAK-2
amplifications
sites.30
G55fsdelGGGAG
function53,54
mp1
.n-
cases.4-
Swi
bromin
STK11/LKB1-HA
SDS/4–
−4.6
minigemistocytes
Rappold
10-HG-0065
1.6-
theinduction
pSmad2/3
~100-400
PPA-574
CTCK
TDRD1
538–548
MET28
AKT1R370C
slow-moving
downregulation,15
OD450nm
127.3–128.4
2007,16
MSH6in
4044
neurofibromatosis.51
.Kostzin
PRDM1.E4.52.F
129S7/AB2.2
JAK2-Rv-T
-CCACCACCAGCTCCTCGCTC-3
M1/70
TGFBR1p.M318R
GDP-GTP
AML-BFM
19/224
4,540
p.Pro219Ser
GGCAAGAGACCGAGGAC
M.SssI
theTGFb-RII
α-phospho-MAPK
amphiregulin10,11
pLenti6.3/TO/V5-Dest
SNP-Fast
UCVA
.Undefined
Berglund
GSE47701
CBFbeta-knockout
DOPS
genes25
31/36
K/Akt-dependent
C1156F
Versteeg64
MPN.44
p27T187A
K171E
2421
memory-disruptive
BCR-ABL–harboring
H3K4-methylation
SC271
C91S
=5
Galectins
5p14
Natrajan
400mg/day
0.25íM
ongoing.64
-13
indicatingthat
described.26-28
c.-138^27841
LKB1-interaction
Ser/Thr-Pro
719G
11349
.PNGase
IX51
C299
PDK1/PRK-2
reticulolysates
c.762_763delTG
Biogenex
extratumoral
J021
RASG60
30-day-old
O-6-methylguanine
suhulee
Tonsil
elbow-like
46-49
SPOPBTB
WT-R1
ras-raf-MAPK
62.02
betweenFGFR1
co-treated
202–509
Immunolocalization
CyQUANT
â€¢Â°.Â°2
acquisition/preparation
1600
Cdk-inhibitors
ACGATACTACATTC
abnormalities.a
par­
K150N
CancerQuest
proteasome11
/stable
/63.6
fibroblast‐like
2.1/1.1
2.3–435
Asp76
pLFACSN
depthCopy
extra-long
population.2
thiopurine
hepatosplenic
ALDH1
124,488
Southernblot
cancer-specific
E29
tenfold
P126-K.K-K-R.K-V-E
52-55
polymerised
2–4
.Jung
AGGCAAGGCTACAGAGGACC
nature.7-9
E267A
DNA…
NNK-induced
mutation,1
BAP1-BRCA1
Leu124
4i
phospho-Ser727STAT3
.4E
space-occupying
TSC2/tuberin
lysine-4
OCI-Ly4
1-cM
D1Δ-956
3.036
4-chloro-3-bromo-2-indolyl-β-d-galactopyranoside
5′-TCAGCCCATCTTCTTCCAGA-3′
7·8
RING1A/RING1B
NL-203
crlls
7S855
=10
c.361G
p53—the
157680
development.23
LS-SNP
SPN
MSH6-11
p.K618A
NM_001004140
mice9
E40K-
C1/CHOPWT2.2
.Recurrence
rs3138601
NZM31
median=22
5'acctggtgctgatctttctgat
SuperscriptII
Seiryo-machi
34.9
tritium-labeled
CTGGCATGGCCTTC
ETV4_exon4-r
katanin
8q24.6
.Met-1775
35,58-60
M.C.
Azcoitia
pDM22
Double-targeted
200–5000
80–89
profile,8
south-east
Inpp5e−/−
pipobroman
59–61
Ghadirian
5′-cacgatggaggggccggactcatc-3′
V3/V4
Leu-139
chronological
-directed
MBOAT1
midportion
S31R/
.+
deparaffinized
lucem
5'-AGAT
PDGFbR-specific
Short-hairpin
reclosure
A327
depurinated
inhibitor.51
RecJ
MspI-
MutagenesisThe
G216R
12q21.33
adenocarcinoma4,14
MiniJanus
electrophysiology
CycD–Cdk4-driven
Bierie
centromer-specific
.GBMs
inthis
cBreast
TRIM4-BRAF
arginase1
glyceraldehydes
G-domains
Ten-micron
074-15-061
H204R
IV:21
MDGA2
OD2
Bcr-Abl-mediated
—c-MAF
34,40,43,46,47
L-70K
plusminuss.d
remarkablerelationship
DiBiase
gravida
construct22
PanIN1A
pPKCδ
AAPC
1,391,319
eIF4A2
14,49
45.83
tumorigenesis38
3B-C
3′-limit
phy-
haplotype-insufficiency
excisionrepair
diabetic/severe
-GCLLDYV
100-bp
Y100C
K975
VEGFR1–VEGFR3
GSM718289
FLAG-TAK1
homozygocity
1.2-439
FIP1L1-PDGFRα.9
5′-ATGGCTGAACCACACAGCTTCA-3′
hook-hook
Id2–overexpressing
5'-TTTAGTGATATTTTTTGAGATATGA-3
BeadChips
HT-DHL8
E3002D
cancer.34
Allagio
RCC4/pVHL-WT
VYQLTRMCTIRMSFVKGW
mutants.4,7,8
0.0451
SOCS-containing
0.446
.ECL3
.UV-induced
described16
inhibitor-IV
TTGAGTGAAGGACTGAG-3
post-natally
Rosenwald
R.C.K.J
−944
Tet1/2/3
***p
Ad-Cre
≈1
tmix
L~~~~~
transcription/chromatin
promyelocytes
b-Actin
G421S
NUGC-4
Ipl1/A1
8p,8,14
6q22
PG1
CD150+CD48+
T68-Q-E-L
side-mounted
α-TRK
Fo−Fc
0002-9297/97/6005-0003
thereafter.10
TCACATGCATAGATTTGTTGAGTTC
W1314X
.NMyc
i12
non-Long
MEK–ERK
thrombopoietin-Mpl
Me6
C121S-negative
1/90
polyhydramnios
Alamut
0.062
sensitisation
EML4-ALK–Positive
4.Effects
means±S.D
instabilityPCRPolymerase
c-CBL-related
c.206A4G
.Dermatological
procaspase-8L
Trk-specific
E0.5
recognizesdenatured
601650
CSN6
0.00206
Y:15
.0369
5–11
rs143081574
metrioid
M/79
FAK
pNFκB-luc
/STAT1
.ABSTRACT
NP28761
sentially
CTNNB1-exon
F124
genes.24,25
S1029
C197C
high-density
.Component-specific
enzyme-based
-,5
duplexoligonucleotide
transfectionThe
AAGTTGATGTGATTGCCGGCTCCTC
LOM
6594
M1258
BMH71-18
liberated4
HA-myr-AKT-GFP
Compendia
^ACT
slope.To
116.3
55,368,995-55,370,994
Assays—All
DDR2-dependent
C618
pen-
cells.41,51
general-pedigree
pvakt/1
DP-1
C1221R
wtEGFR-3T3
DIAP1
MCPH6
IVS20+1G→A
49.9
M-003324-03
FLIII
anti-GSK-3
.Indicating
proarrhythmic
repeat-
RAC-driven
SDS-containing
Il2rgtm1Wjl
128050332
5′-ATCACGCAGCTCATGCCCTT-3′
1349/1356
Mandai
polycytosine
multievent
protein/ezrin/radixin/moesin
5,6,9,10
TRAFs
domain.25
systom
Villaverde
miRNA-imposed
0.06–0.45
F594L
disassociation
CTATTCTTATAAACTTCAACTCTATACT
short-read
Spi
596KB
P=0.0045
C620R
LoxP-STOP-LoxP
CODD|
HIF-mediated
17p11.2
PAX8-
intramembranous
Flag–Akt2W80A
4/271
124,125
Homogenously
KinaseProfiler
SCL45A3
4664
Plasmacytomas
Ja-Lok
bold.Four
leukemia.14
50.03
UTR-WT
vectorial
97763
C609F
del-ins
pDM56
control20
triaged
.Uni-
.32325117
Prism6.0
D8S1800
tested—MSH2/MSH2
c.-469C
R688A
one-size
syndromes.20,21
models18,19,20
MBq/kg
7.30
H1047R-transduced
Pt_009
immune-modulatory
Epo-stimulated
Re´seau
MSH6/MSH3
*Infiltrating
gene-set
Kosei
2-TRCN0000025258
R3/G380R
Hsp90/Hsp82p
CD45−lineage−CD31−
.PLCγ
.Outside
Q.-Y
Vo
.WZR
G419A
SAX
rearrangementin
9
HS01235235_cn
DAPI-containing
31–225
shLacZ
low-throughput
retinoic-acid
.CL-387
ISHC
Y694F
13/M
domain4
tumour–dysplasia
1,2,3,4,9,10
0.1–0.47
CBLDexon8
Raf-
PBS+/+
cocrystal
anti-cMyc
Mellinghoff
1141
concentration=0.5
membrane–associated
cascades.3,4
Nordenstadt
RKK-PTP
RASSF2
bromine
p.Arg388Trp
34mer
Consugar
v-P3K
I682F
Pasqualucci
.Exceptions
c.914delA
MAVER-1
1E–005
//www-p53.iarc.fr/index.html
Adenocarcinomas_variants.txt
lineage11,21
NeuroD1
mBcl2l1-Reverse
CEBPαmut
database,12
5H
7A–E
K714
.solution
sc-633
PtA
tumorigenesis-related
SDS/3-8
335–1027
decompression
centrosomes.84
Trimmomatic27
ligand-independence
Y1003F-V5/His
6E
Myc-ΔBRIP1
30·0
MIG-R882H
IIIJ
.Uptake
Treestar
III-B
vulgas
5'-gagggccccggcctcaaactcggtgaag-3
Cdkn1b
|CD40
Hajime
poly-dI-dC
L726F-expressing
Pro1008
DW
28/47
–59.0
I656V
LMW-DSP2
5′-fluorescein
+5.6
μl/tube
atcodon
CBL-UbcH5B-S
40-μm-thick
Transport—Given
EN-DeltaHLH
G363
5KpnI
simple-hit
Figure2B,2B
NGF/TrkAI-induced
145-mm
Emergent
.Dried
α-β-actin
Yancopoulos
cytokines.11–18
d-2-hydroxyglutaric-2,3,3,4,4-d5
dce41.nci.nih.gov
WT1-containing
gMYCN
L91F
108.10
receptor—has
pre-antral
94Â°Cfor
c.989-
10.25
anti-Ki-67
1.0
2ady
F12L
AIII
Stk6
.sion
1.28Å
GCAAUCACGACUAUAAACATT-3′
F1003
96-gene
havenot
EGFRTKD
methallothionin
4485
FGF2-induced
HPV-7
tendon
valuea
complete/
Marrivoet
D3Z2G
sus-
.226C
S768_V769insVAS
Stossi
NRF-2010-0018896
−5.35
37.2
Yb
7-F1
NXA931
RBF
later-passage
.Quantitatively
Gr-1+Mac-1+
P253
E37
Y299
T3N1bMO
1r
cleavage43
EVOLVE-1
D693N
Recombinants/Meioses
.Ligand-stimulation
DAAAGMEYLESKCC
splaying
Rat1-myr-p110α
clonal-specific
dimer-defi
anti–Grb
hyperinsulinaemia
weekly–monthly
jSeven
Faculte´
,22
D384
clinical-stage
Epalinges
B-ALL13
hyperosmotic
Q61KN-RAS-driven
gentamicin-induced
PTCL
.Presence
0002-9297/96/5902-0008
2.3.
RET/V804L-transformed
897dupTT
1099-1936
L16464
P5D2
KIT-D816V-mediated
Signagen
FunctionModel
BB/tubes
IHCA
Progression9
q13.4
TCCAAGGGTAGCCAAGGAT
.prostate
NGF––is
CCG
Disomy
JAK2-WT
∼600,000
overfitting
S-19
Japanese29
P=0.3363
130.4°
sig‑
HSV
Coatasome
0.342
Phosphoimaging
.Essentially
MFGE8
10.5-kb
Heterotrimeric
Granta591
_Hinf_
maintainingthe
pre-T-lineage
RP11-63G10
PCRT3
.Adding
Lamotrigine
C‑Terminal
N-rasG12V
mammalian59
Gypsies,6
CAATTTTGCAGAGATGAGCATAAATAC
5′-AACTGACTGGAGCCATAACTTCTGG-3′
MgCl2,1mM
K618K
HN_00361
1.626
POP5
α-dUTX
S6K1-dependent
gene—influence
n=149
Tris/borate/EDTA
CDK2NA
.Antagonistic
nuclei.9
Bcl11B
Venus–Raf-1
patient-specific
Sucker,2
FujiFilm
elsewhere.7
differentiation-inducing
carcinoma–causing
–c
PBF-transfected
A19T
malignancy126
E60K
1487
10−40
His6-ubiquitin
3.84
5058
5/50
Epifluroescent
1h–j
S25Q
GR4
unclear.28
Cys-His
H-HCAs
Fbw7αΔBD1
pCS2nrf2
.Danish
68–83
/CACA\
EGF-inducible
vÃ
Y81A
Soder
trans-elements
3E1
system7
CSE1
SEC31A-JAK2–derived
A2643G
L'informatique
C611F
rate-determining
lymphoma,39
PHERAstar
.S4P
StuII
D218Y
671GRA
NM_130859
2-wk
tumour-infiltrating
9.80
Leuven
PC12/RET-wt-cl.9
.S259
SUDHL2
13–17
OD620
L777Ga
MS-PCR
.1136
Marchenko
17–80
annexin-V
.pombe
GCTGATGTTTGGGTGCCAGG
Pan‑Asia
co-ordinately
ttttag/AACATT
-CD36
.Scatter
3/130
Epigenetic
-KTS
p=0.55
L245P
PON-MMR
9/45
NCT01602315
ABC/non-GC
www.har.mrc.ac.uk
Co-115
Uroplakins
V658F/F958C
12p12
antifading
urchin175
alone30,31
CD74-NTRK1
36/38
Proteinspresent
tccacagctaccgaggtcac
MNES-GrG
c.892_893insC
186del146nt
Ley
.Vemurafenib
pGEX2TK
pGBT9-based
≅7–10-fold
signi-
bResults
syndrome.1–6
Met16Thr
p=0.022
Subcloned
paraffin‑embedded
CS/Hsp20-like
considered.35
Radioactivity
EML1-ABL1
OC316
1:5,000
PLD1-mediated
mg⋅kg−1⋅d−1
FAM71B
1508G
kinase-9
242
four-generation
Italy.15
233314_at
13–mutated
mainmetabolite
T42A
47BCGAAGCI'TCACTGAAGGGTC1023
leptomycin
CS-FBS104-S
pB4XCAT
Δ3270–3418/K3266T
CAV1
epitope-tag
Table2.2
SJRB004
7434
BAK42
cancer1,2
Enterobacter
G274D
G4650A
A2780M
mitomycin-treated
non-hot-spot
.N-TAD
control/p53
Gaslini
apoptosis.2
2200
Hopfl
S846I
precursor-ion
KITD820Y
5′-AACCCAACCATCACCACA-3′
H–I
F15020
S46N
Gly719Ser
SA600
Gln171
SASI_Hs02_00333382
Olink
ligand/receptor
70.79
400KB
P016
.MMC
R2178L
sarcoma142
anti-TCF4
14,16—18
Q90E
Akt/GSK-3β/β-catenin
1102mel
H-281G-5
Argyrin
0·2
Fruman
54.9
Y42C
cancers.94,95
128-amino-acid
Heinrich-Heine-Universitat
beta-tumour
L151P
expressed—together
ITGAL
STK33-
C56R
paranitrophenyl
glucosinolate
eOne
GFPuv
4a-d
polymorphism-mediated
Nghiem
pASII-ETO
rs45511291
variant-positive
70Â°Covernight
plasmoblastic
psammomatous
CA46274
malignancies.107
.TDA
T537R
PHA-induced
Ras/RasGAP
retention223
Results—We
.First-generation
pET-21a+
polII
serieswe
responses.1,6
7E-F
C11orf95RFP
106a
TEL-induced
491M
PRDM1β
.KDM5A
CRL1–TIR1
Mst1−/−Mst2−/−
5'-GTGATCAAGCAGGCTGACTATGTG-3
sidechains
min.9,30,31
xenograft
24.46
half-lifeof
Stathmin
RB-K
.Duckworth
cT2a
51
K51E
5′-CTCTGGGTTCTCTGCCGTAG-3′
P.G719Ab
PKCζ/λ
Dinucleotides
c.400+1G
1st–3rd
gene.28,30
mutation.PDGFRA
MEGAP
5′-CTAGAAAAAATGGACTTCAGCAGAAATCTTTCGAATTTTTTCCAAAGATTTCTGCTGAAGTCCA-3′
institutional-approved
333nM
10–150
.Interpreting
1Downregulated
.Futreal
lonov
.1A–C
GFRα3
Consortium10
pstate
.Duplicate
Xiaotu
MA1-840
—ED
S449F,1
pLVX-IRES-tdTomato
FOX-related
S288C
Curated
190-kb
Ophthalmologische
−3.74
SRFc
study9
IL-18R
Epirubicin
tripsinized
Ligand-dependent
Post-hybridization
Pellet
signal/input
5′-GGAGCCTGCAGAGACCCTA-3′
1H-15N-TROSY
4,17,27
53bp1+/−
leukemia,15,16
.Disease-free
Gibcus
MLH3
fkabbina
675-850
ZO1
S998T
al24
mycWT
HSC7E506
setting.41,46,53,124
EGFRvIII-I853T
p.P572fsX3
PLB1
I.O.L.N
GST-parafibromin-His
Imatinib-Resistant
box-binding
CRE-dependent
.Strikingly
S.S
tumors.
S3–4
Lemonnier
.2023
5′-CCATCCACGCTGTTTTGACCTC-3′
pcDNA3-asGal-1
RNA-sequence
PCR—Total
5′-GGAAAGCTTCATTCTCCTTGTTG-3′
ab-cat
dye/antibodies
LMO3
α-acetyl
DLBCL.20
individuals/families
fire-polished
treatment.27
.Anti-c-Jun
R897Q
Lys-831
3Université
T-ALL17
PFDN6
sequence–altering
Immunogenetica
.PTPμ
Tasocitinib
YWBC
receptor44
WHOLE-GENOME
26–68
molecular-targeted
18–35
CXXC4
cerevisiue
2010.31
cases.15–22
phospho-SER276
FA-A+FANCA
hgg1
5034
outgrowth.43–45
theGPCR
gain-of-function.18,21
XapI
.5-fold
neuroblastomas175
Phosphatidyl
H-3255
BRG1-associating
carcinogeneses
Ten.
Domain—These
SuperScriptTM
MutSβ
Rac-dependent
Guo,1
oxaliplatin
Yang,1
andPro
ADPKD
line.60
69165000
18–171
26–76
1/plateletderived
non-inhibitory
WT-Ovation
FGF-receptor
CLCL10
OSCC3
p.A563S
TPβ-expressing
lymphoblastoidcells
16,20–23
codon-independent
dell'Adulto
760-4378
c.1053delG
pressure.SOS1EK
Hs00257977
saline–Tween
theYP
tumordoubling
Asp-814
DNA-Female
estrogen-induciblegenes
VWRPY
.H1975
NSCLC.66
HDA
1,300,000
≥pT2
pFastHTBhuman
homo-DNMT3A
2-A-free
PHD3
A67T
50,52
c.2361_2364del
mutations16
M157V
chondrodysplasia
6KR
.Overcoming
Kit™
.Anti-IL
9013
SHP2-Y279C
G833R-pA
G17del
Thr766
1300-fold
liquid-phase
4-hydroxybutyl
5′-GTTTCAAATGAATCTGCAGACTACCGAGC-3′
GGGTCCCCGG
evidence30⇓⇓⇓⇓⇓⇓⇓–38
2010|
self-limiting
L.L-C.
55-y-old
2D–E
•GI
-GGTACCGGTACCCCACCTTAAGGCCGCGCTCG-30
060233.3
R280D
p.D28_E33del
p.Pro379His
CH-1011
X-only
5'-CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTTTTTTTTTTTT-3
96K
intron2
TGGCGAGGAGTTTCCTGTTTCCCTCTCGGCGC
mTOR-T2813C
GGTTCC
0.0313
P=0.162
18S-~
Corriell
LUMICAN
foodstuff
88M19
.S7
R89LRaf-
GDP-Man
.ECGs
μm×200
site-dependent
5′-GCCGATCGATGTAGGAAACTGGGTGAATGGC-3′
PDX
sigmoideum
JAK1-mutated
B220+/CD19+
9544001–9932300NM_018847
c.527C4T
1399-1406
Smad3-expressing
15.0/1.8
Y987
.8B
p.Ile18Val
2−6
non-homozygously
Immunosorbent
Self-Association
EWS-FLI-1
IKZF1-mutated
TGAGGACTAGTTAACCTGGAGGA
302–1863
bothDaudi
1,3,5
V654L
allo-
leukemia16
Helix/Turn
Nonsteroidal
Poteete
AC-II
pipeline.25
DA868984
T529NBRAF
BRG1-interacting
dARBR
92.9
SMAD-interacting
.s
Me18
//blast.ncbi.nlm.nih.gov/Blast.cgi
NUT–p300
TritonX-100
Expe´rimentales
6396
AYK1
erlotinib-sensitive
FNII-2
pCR-TOPO
C30
5242C
36.0
±755
VTHAHD.R
32Pg
α-H
defect.Our
Dickkopf
.11A
M707I
variants.https
alterations.1
PDA-R1
RhoA.V14-WT
GDP-preloaded
thatFO-l
OVCA
prmga2
E5.5
umino
IVS13+5
anti-Cyclin
activ‑
I5500
.TLS/FUS
LBD-disrupting
2.274
replicates/treatment
PIK3CD
−1.3
CFLAR
0.401
Corticosterone
591F
44,334
ITD+D835Y
anti-CDK6
PI3K/Pdk/Akt
A859
phosphoribosylaminoimidazole
daughter-strand
cancer75
p230
4.686056867
V559I
PDGFR-targeted
Gsolv=Gelec+Gne
J.E.P.
p190-containing
R74
TIRKKONEN
gefitinib/erlotinib,60,61
V-FITC/propidium
uncommon.22
R188120
membranelocalized
phospho-ligands
S42T7/AS42SP6
1-ligand
ATP–protein
D22S689
andchilled
Brij35
7.5–10
A353P
activi
0.83±0.21
T380M
G346
FUSCC
Non-expressed
co-introduction
6–23
RO5424802/CH5424802
4.70
R90C
|A|
B38-42
FCHSD2
β-propeller
.Sitting
20q11.21-13.33
7561-7
FBW7+/−/p53+/−
v-Sis
19:429—439
.FIP1L1-PDGFRα
M701B
mutant.20
Baryawno
Thermocycle
R3-pRARE2
−44.0
shRictor1
R174X
ATTTAGGGGGTGAGGTGGAG
7q32-q36
Trp23
MSI,3
.MMR
ethanol/glacial
citrate-buffer
PPP2R1A-associated
pAXL
241-269
CAFQLDTGLEYANSYNFAK
1849delACTC
.Brachyury
W557__V559del
cointegrator-2
CGTTGTGAGT
Akt.200
deconvolutes
123–133
secrete
L243P
.Conversely
2398delC
//www.chlc.org:80/
44-888G
F/P-negative
Prominin
Ben-Amitai
Nde
traits—self-sufficient
FKBP1A-transfected
ERBB2-L755S
M1L
MM.We
15.87
Arg601Gln
CD150−CD48+
AG′—were
pCMV-Sport1
XCCAGCACTCGAGTGCACCACCAGTGGGC-3
TACTCTCAAAAAGAAGATAAATATGAGGAAGAAA
E429A
2520–3056
EWSR1–YY1-encoded
50units/ml
Nup93_FL
shRNAs-targeting
pGalactosidase
Pik3ca
c.1–154
440,170aa
.S7G
p.adjust
.LUC
mutations,13
P9/10
mastocystosis
1526
Arg135
digoxigenin
Reamplified
p=8.5e-4
annexin
NGF-independent
Facility.Immunoprecipitations
anti-pan-Ace-p53
GSE14833
dimethyl-modified
b-CATENIN
GIST-T1
mutSRSF2
everolimus23
0.317
Buttke
Epileptic
4-capillary
S6A-L
1135_1394del
analysis15,17–20
or≥15
α-positive
UV-triggered
TEL–AML1/RUNX1
43-93
1.221
β4
diagnosis,14,31
p53negative
1.0475
V1-
metastasis-promoting
GS-1101
10.1007
18/155
HIPK
cancers.7,8
outcome.3
array-CGH572d
0.674
9/415
HAL-B4
skeinoid
0.37–1.65
Ilql3
Postmortem
adaptor-specific
gemcitabine/cisplatin
.02090328
.ImmunoblottingCellular
95-2
NM_000179
total/Ser5-P
.Tiedt
2477
-GTGGTGAATGTTTATCAGAG-3
Na-pyrophosphate
non-KRAS
cord-stromal
onKIT
Sample002
Krüppel-type
isotope-editing18
2Figure
.Consecutively
Reintroducing
Locasale
c.436G4A
RET/PTC-1
hematopoeitic
wild-type-likemutant
R26-Pik3ca
Rosenzweig
www.pnas.orgcgidoi10.1073pnas.0601192103
EPH
BSA-soaked
p.S65
types1,2
IRF-E
AE859and
582:2093–2101.10.1016/j.febslet.2008.04.039
32,779,983–32,908,796
1.87–3.99
PyMT
vivo.69–71
Apoprotinin
G-band
-chloramphenicol
Context-dependent
androgen-deprivation
VTI1A
self-tolerance
IIb1.194
cooccurred
378-625
RB17-RT-as
3–1,079
ψKxE
Software—Clinical
lines,36
tumours96
Ser722
.Dworakowska
streptavidin·DNA
Superarray
D9S283
WM3060
Knock-down
previously.36
Msh2-like
40×/1.3
.425

1,8
.M-category
of0.05
progrowth
NM_00433
TGTTGAGCCTTTTCCCTCTTT
Leu−
−507669
glycans
noncomplementary
A/II-1
p.Arg285*
CDKN1B/KIP1
Multi-genome
12.476.2
RXDL-deleted
positive/PI
90-kD
AzamiGreen
HybridizationFluorescence
p.A133V
p70S6K-T389
c.1106-1109delAGAG
p110α-p85
R702W
BRAFV619E
p21vHras
3.500
rs41494749
het.
CLLU1
CDK1
Hughes1
core-domain
.Marchetti
.Short-term
strepavidin–HRP
KITK641E
mesna
etiology
entrectinib-acquired
oestrogen
R348∗.p85α
11p/q
DNA19
.Accompanying
re-ligated
Rad54B
doi:10.1158/1541-7786.MCR-06-0172
11of
phosphorylation41
5418
MLL2-mutation-negative
pCR2.1–
2HGA
Ba/F3-mutant
surgically-corrected
Msh6-ATP
10~8
pathway31,32
antiepileptic
Dbl
.Paired-End
2.18.1
methionine-
KAI3
Lawrenceville
cells130
F621V
MAC-2A/2B
ROR1-sustained
731-bp
HUS
LOC2018955.0Genes
41
0.07–1.23
ATL-Engrafted
5′-CCATGCTCCTTTCTCCTGCCCA-3′
cholangiocarcinoma4
5'-catgtttgagaaagagcaggagcgag-3
S80
allele.3
α-RC2
ki-67
neomycin-resistance
Hydbring
untranslocated
9–77
activation.46
I/II/III
.Fig.11
stathmin
midipreps
inIG
dysovulation
dTumors
branching-defective
α-methylacyl-CoA
Titus-Ernstoff
post-transduction
ig/ml
S.EAnchorage-independent
RU58,668
D1222
ymsh6
Famfly
post-reproductive
Physical-chemical
mutants—as
Origene
Tenovin
Heavy/light
/independent
arginine-finger
Hinzpeter
microbiota-brain
c.1-381_207+606del
Kölliker-Fuse
mg33258.f3
Me15
241Δ246
68/199
Zafrani
1–110
pRRLsin.PPTs.hCMV.GFPwpre
TUNEL
studies15,18,19,20,21,22,23,27,28,29
APCn
BCOR-3256F
cells.27,28
-DR103
caspase-8-knock
pseudo-hypoxic
1M6B
RASbinding
RAF1c
A_52_P433889
l-3
domain-specific
guish
p.S35T
perk-negative
PRK7-TSC1/PRK7-TSC2
.Fbw7β
Apc+/+Smad3+/−
Phages
.HOT
m/72
receptorif
TGAATCCGGCCTCAGGTAGTT
55Â°C.The
retruded
Calcusyn
negative/weak
L597
permg
CASP8-induced
19/7
H168N
B-CDC2
BAT-21
doi:10.1186/s12885-015-1791-y
Prestel
gression
2q34-35
Xbp1
Gly180
5-15
cBIO
vitroubiquitylation
InhibitorsCOS-7
CLB95052
.Squares
K539
PD0332991
Arg826
Del1001
Immunohistochenistry
11/16/98
nuclease-dead
5′-TAAAACACTAAAATACCCCAAAAACTACA-3′
IFN-induced
MGH021-5
refSNP
GST-SHP2
0.434560079
al-
c.725G.A
Tube-O-DIALYZER
SEF
18-day
BSA/TBS-T
1Laboratory
p-TYK2
1q23.3
mouse/rat
Pedigree/
RankViaContact
p27-G9R
≥age
rearrangement.20
5AAB
driven-CAT
ubiquitin/ATP-dependent
.IFITM1
CH17-408M10
Src-T341M
x/y
Yun
/phospho-RELA
BRCA2-dependent
microfuge
−50.3
L858R+H870R
Carcinogenic
S548R
proteins.However
c.3418A
cores/slide
BRAFV600-mutated
attR1
G365R
Interleukin
mulate
GATA-3-mediated
DeltaGNP=italic
Asp-871-HER3
6001
.Xiong
G328E
6.8-12.8
24/61
HG-U95A
ubiquitination15
N1860S
A.i
nucleocytoplasmic
insulin-secreting
DVC1310
aei
SCFFbw7regulates
689-1588
ascompared
4,19–24
FGFR1genes
p53R172H
Anti-RFC-140
507451
pKP22+
LLC17
Y2581
models85
Iwanaga
cases23
P120RasGAP
Blimp-1
acidsb
1.5–2-fold
invasive-metastatic
p.Q22R/Q22E
PHZ
casesDistribution
method.30
Cdkn1B
stop'16
www.ONCOMINE.org
cagaatgggtagtcaaggaag
AKT-pathway
Seoane
cancer-linked
macrophage+granulocyte
tissuesanalyzed
γ-R1076H1/γ-R1076H2
HGAs—the
dabrafenib-only
.possible
NZM24
chondrocyte-specific
Met789
others30
repertoires42
AAGTCGCCACCTACCACA
A96fs
79–108
pBr1
14CNRS
5′-CCAGATAGCAAAGATATAACAG-3′
r=11:108093211-108239829
P497332
NM_004972
nondepleted
13–21a
RP11-1059G13
argimne
1E,5
.Bub1
Thr269
6/5/03
S2.1,2
2183–2189
Q145
0612
.1514G
chromobacteria.30
stimulation-dependent
i.e.However
metabolite-specific
Takenoshita
.Cisplatin-resistant
Low-Medium
me3
DISUCSSION
Y118
ERK-­phosphorylated
KPT-185-treated
transactivator
MOI
PDGFR-inhibiting
.1235A
54.5°C
Nalla
molecular-surface
81/111
transformation.69
cdc2c
E71del
effects.38
senescence-like
TTGATTTAGCCAG-TCCACGA
Pansorbin
7C-E
low-titer
54†
18G
YpVNVYp
ARV-expressing
Y1029
ER.73,75
cancer,25-
nitrogen/oxygen
leukemia45
derepression/up-regulation
39,312
chromatids30
RARy
Sox17-siRNA
29/34
0.072
Overdispersion
polyacrylamide-SDS
.TAE-684
D816I
CDK2-dependent
Plus-agarose
GSK212
Chromatographic
20
studies97
K81X
BRAF-containing
.0050
nanospray
.FRTL-5
3006
delberg
Dadiani
FLT3-W78
c.6734C
step22
K862E
IVS13-2738
Detec
RFX-DNA
adenosine
10.1158/1535-7163.MCT-14-0768
protein-expression
WDLPSs/ALTs
osteocalcin
BRAFV600K/L505H
DCA1
ORL
GST-Box
phosphate–DNA
Hepes/pH
chromatin-targeting
week-old
10.7
≥20
EvaluationThe
cotransfectant
uniquely-mapped
3q25
albumin
c.2249G
endodermally
Langabeer
N1-ICΔ162
FA-Q
tko
pRc/CMV
Bellamy
aZNF198
ZSGB
Cytofix/Cytoperm
9104
compartments.2,3
TIMP-1
2450T
20-μm
collagenase/hyaluronidase
ASK-1
Colagenomas
Mdr2−/−
studies.9–17
hemocytometer.Xenograft
ATM-disrupted
KIN193-treated
JAK1–HIVEP3
34K-
Punctual
Cancer—and
.3975
Zr
genes/proteins
11.0.1
clonogenic
,23
supernat
PLCγ
.960398
2.96
615007
origin.51
Zimp10
frame-shifted
28,37
lentigines
averageHMEC
1823.9SDC2Syndecan
7,15,17
GPR20
iSH2-contacting
proteins.1
DMBA-TPA-treated
PKN
2911
P0001
SpectrumRed-dUTP
−−/−−
wIpegEkvKIpVAIKeLREatSpkAnkEIldEAyVNasV-DNpHVcRLLGICltS
tuberin-bound
activity—poor
at948C
c.1115_1118delTTGG
7–specific
ARR2PB-c-MYC
occlude
Cdc53
.Wan
CRL1658
neurofibroma-derived
R569W
S320N
3×2
.19,51,67
Stirewalt
174-1
studies12,37,38,39
GRP1
p.F615S
49/64
two17
INF/NF3b
roomtemperature.Sectionswererinsedin
36/42
WM3248-NIC-GFP
100/100,000
GKSTjYjMRjQJL
proteins.5,38
Belvederesi
attaag/ATTATA
GIST.8
p.G776_777insVC
n=286
SDS–7.5
0–1.1
cross-contaminationoccurred
MetaGIST
M340K
W34A
rs17851657
P-Smad2Δ1-240
G674Avariant
Ras/PI3K/Akt/mTOR
c.7541_7542delCT
c-Myc–Max
REGlSTRlES
MAPK—p38
3-kinase/Akt/mTOR
miRNA/mRNA
5-bisphosphate–binding
respondbetter
129/Black
Quantitative-PCR
Mayordomo20
colleagues.25
chr1-chr22
K11-13
somatic-cell
N311S
p16INK4a-mediated
BioGene
2995delAAGA
.HERVK17-ETV1
R441H
Cys278Phe
Cy-5.5
6Identification
Multiple-sequence
mutation,9,13,30
3H-uridine
N-myristoylated
HER2T798M
97.52-98.27
2,175
Thy1+
1.4×105
p85–p110
proteins.13
Satou
.G361
Spi-B
mutationb
20-fold
IRF1gene40
protein-promoter
polycistronically
Ala72
0.0244
Gab1/pY589
PIK3CAVM-CUB-3
1Mb
nodularity
Shq1
RoboSeq
TCH
bleomycin
Lumingen
chromatin-protein
WAF1/glyceraldehyde-3-phosphate
ETV026
whole-genome-binding
crizotinib.In
FFPE-microdissection
Adsay
derl
X-α-gal
p.Arg802*
pHAGE-EF1α
50–67
leukaemias44
pSmad5
beta-TrCP-mediated
GLI
CGCTCCGGCTTAGGTAACCGCT
.Clean-up
subunit-sharing
MART-1-Me18105
Raf-301
Fc-Block
trastuzumab+neratinib
|-end
Br67
phosphorylation-defective
SCF-binding
p.Lys332dup
fibroblast-specific
2.113
R1597W
co-transfecting
PMA/Ionomycin
12p11.2–12
//bio-bwa.sourceforge.net/
A22V
inflammation.36
Cul4-B
FUS-CREB3L1
F158S
nM/mL
Glu578_
T-lymphopoiesis
Tet-inducible
R263L
SM-EGFR-DB
124-bp
ScRad3
ovarian-like
5-color
S'-cccagctgacaggctcctcgccggcttctcctcagGGATGCTTGAGTACG..
R453C
I41
N701S
malignancies.17–20
5′-GA
2990
compound–null
N38A
109-kDa
Polo-box
TNF-α.18
TTCCTCATCCTTGATTTGATG
Msh2Delta7n
Stat5A
Dual-color
P412L
19p13.2
A219V
4.2–23.2
89–96
melanoma.23
.183a
del.755–759*
extravesical
D24E4
CpB′
militate
Dephosphorylation
cases,12,13
D839H
ERK2Y131N/H/F/C/S
Phe102′
GMPPCP-bound
14,331
D473H102
CMP/GMP
B140
chemotherapy.3,4
GLI1-specific
openreading
analysis.Genotype–Phenotype
3.1C5.18
.Physical
Rat1-myr
standard-dose
191–193
STS26T
486T
preadsorption
linkage36
Ford,2003
12.95
HOTNET
pFOP-FGFR1K259
Ranade
Val126
.1009C
SUP-M2AR300B
Susceptibility
reached.26
q13.2
5922034
atrogin-1/MAFbx
PKC412-induced
L702H
Raf-stimulated
CCGGGACTGG
AAC-3
c.3927_3931del
PC4644
malignancy.35
3.1/Myc-his
M95712
enzyme-Lys-NH3-AdoMet
decrease5
pcDNA-CRIK-KD
ourcohort
Calmette-Guérin
54
60-second
pMEGIX
OSM
67,645,330
60.4
NWASP
poly-A-enriched
.FGFR4-KD
S317Q
f1MR1/f1MR1
368C
c.4171T
Keap1-DC
Arg/Gly
Smad2‐HA
FoundationOne™
deacetylation.7
TTBS
6884
T751del
Fig.7C7C
pY701
c.4308T
scintiscan
Glutamax
Astonishingly
BLC1501
demethylating
Arg145
N35K
RG-20
.GTGCCAGGCCCACGGgtgcgtgcgcggggcaggggccagggtggggcggg-3
rate18
contransfectantion
R4187C
Burset
Homology-based
Asp835deletion
Mek-Erk
p140met
386-
259K
P1b/2
85y
GCB-
GIST.103
f8
repeatmasker.genome.washington.edu
well42
12/27
S7-S8
1Ae
ATG-start
Drash
ERCC2-DEL
M7003
COX2
V637L
PALFBA
0.5–35
JAK2.29
.55E
ROR1-silenced
rubripes
3025–3034
Paez-Ribes
NMR-predicted
G267R
.p27
O.43
anti-phospho-RET
CB10
.Anti-HCF-1N
lowmelting-temperature
studies25
1.3.17
further10
−2.31
OCCC-like
hall-
III1
12514-6
dbNSFP
Myr
B-RAF83
Anti-flag
OCS
c.1329G
Hatachi
T314A
cancer.15
POC1B
CGG→CAG
AP-1-
preimatinib
RoboCycler
studies.35,41
mice,25,40
TGGTGT
eluent
V1306I
GCTTCTATGGTGCGTTCTACA
sulfate/sonicated
assigned10
NIN-PDGFRB
Hilenski
V–positive
p95
rhodamine-
.Missing
domain25
HR1
re-affirmed
ACVR1Q207D−c.a.
T58A-immortalized
H2N
Poulat
4,775
ΔDeg1+2-mediated
fusions24
same-sense
tttcag/GTGTGT
T2722R
5′-ggagaactctaactccaccatggagtcgg-3′
P960S
cross-referencing
Bmp4
Glycosylation-deficient
c.5152+5G
used.20
2-/A
T1220I
c-MYB
Tnfafl/flMx1-cre
rVista
4,728
Sulfo-NHS-SS-Biotin
−903
ovary-independent
B-ALL/NHL
Arg12l
Anthracycline
described.41-43
73–103
83–165
ARID1A-MAST2
shRNAs/pool
E384–E393.10.1073/pnas.1321510111
Universityof
039
Local-type
7—figure
E-instigated
+14
perspectivesThe
GAP-sensitive
5′-GGAAATCCTCTATGAAGCCTA-3′
transwell-invasion
treatment.This
al.35
death-receptor-
.Combinations
THC2316750
MGH-BA-I
importins
prostate.20,23
.KP
1465-1166insC
lacZ-marked
labor-intensive
anti-NTRK1
10−204
.Taqman®
lledTARGET
hotspotsfor
p300/CREB-binding
5′-GGTGTGCACACCTCTTGCTCC-3′
sc32322
gefitinib/erlotinib-resistant
GPF
JAK3A572V-expressing
pERK-T202/Y204
237-bp
2001.26
Ras-Raf-ERK
V599R
C238S
resistance.Compared
RP11-350O14
LSL-K-rasG12D
G293R
4-inhibitor
deletions.6
//r2.amc.nl
RAB3GAP1
10296-010
XPO1-inhibitor-sensitive
Stocco
acid-761
Caruana
136–138
16q23.103
Bulletkit
R323G
21,742
PDGFRα+/J
Splice-site
M58I*
arginase
pCDNA6.2-N-GFP-MOCK
.Cell-of-origin
immunocytometry
clinicopathogic
Q157G
exon-4
Vitro
EGFR-pcDNA3
MEI-1
connective-tissue
+2003
_FGFRTACC_positive
HLA-B*15
225-241
truncatedDNMT3B
G129R
≥2.00
331327
Fifty-fold
C57BL/6-Ly5.1/Ly5.2
94bp
5′-TGGAAGGCCGAGAGATCATT-3′
MuGAPDH-2A
insert-free
Heidecker
S1/S3/S1
TC-BER
Medicine/Hematology
TreatmentWe
three-to-four
8.2-fold
non-HIF
D/2
EF1a
andinverted
top-300
1338y
20/31
design30
gaggattcgtgacttggaagagggtcactttggg
Sinari
MiR
Sungkyunkwan
R1334Q
CSNK2A1
IX81
V645F
anti-PDGFRβ
currence
zinc-coordinating
B–D
LysS6Arg
phosphorylated,162
FANCF-FLAG
immunopuri®edoryeast-expressed
DENN/MADD
ÃŸ-cateninaccumulation
CUA
www.cbs.dtu.dk
.R988C.Met-H446
platinum-pretreated
SBRCT-related
GDC-0449–
Mailand
124.5
mutations.11,12
al41
type=7
Febbo
5457
EWS/ATF-1
months11
5188-5340
05–668
ddATP
p.Glu1163Lys
NKX2
c.252A
657del5
CELLQuest
KRAS4–7
Signal-dependent
KSR2KD
D1-responsive
p.Arg987Trp
BCR-ABL.41
RING-TKBD
Lent-shRNA-SOX17
positive-ionisation
GSE19429
Podocyte-selective
322−333
identified23
PDGF-DD
146/183
Atrophin
Immunopre-
127–215
pAG55
A121G
20q12–q13
40-kDa
M133L/V203A/N239Y/N268D
melanoma.8-13
3403del174
5V-ttgtggacataggggtttgc-3V
.STAG2-negative
pre-pro-B-cell
complex.4
SOCS-boxes
0.697
27/57
pErk/Erk
1788n
0–316
biphosphoglycerate
188a
pmGFP-N-rasG12V-T50I
Michaelis-Menten
SRS
flash-cooled
FANCAAND
ofTGFBR2
SMO+
EHneo
~squares
g.8097_22733del14637
nihms703640f8.jpg
cul2
Lys-147
iodacetamide.Lysates
thalassemias
Yuneva
T68
subcellcular
z5.keio.jp
V550M
approach2
MSSE/Ferguson-Smith
Gly328Asp
−105
Yamanouchi
soft-clip
L1593P
oncogene-infected
2/0
10y
5′-ATTACTGACATCTC
MEK1-mediated
IIIb–IV
mayo.edu
MUM1+
lymphovenous
Stat5-responsive
MLV
stem-cell
LAMTOR3
−13
RBS6KB1-TMEM49
upstream-nontranslated
eeeooeooo
53.8
F53SMEK1
Adenine
Q266
85940
GCAATGCCAGGGTACATGG
NHSCR
//hgdownload.cse.ucsc.edu/goldenPath/hg19/database/
minigene14
HR+/ERBB2+
VAV2/3
RP11-551D4
E346V
21–25-nt
RG-7N
PDX230
Δ4
ATP-operated
151K
mantle-cell
fibrosis29
MycW-PDGFR
pustulosis
Ex4-3seq
5'-cap
Cerebellum_B_1
non-signalling
years.8,9
.Alternate
FcγRIII
.Dephosphorylation
Roessle
U43746
V1577E
Karanjawala
Fushimi
Soucek
imatinib.21
CYP2D6
R129
GTTTTCCCAGTCACGACCTGAATGACAAGGTAGCGCTG
anti–phospho-SFK
acetylH3K27
H3K36me3/H3
.Rather
Ser240/244
CPK
17.4+
1–393
0/60
655V
non-P124
ER-splicing
12K5A
ShRNA
Anti-p85a
MYC-Mediated
25896
AITLa
function135
epithelium-specific
aprotinine
Ubc5a
NRASG12V-dependent
TGA-39
5.3.2
3XFLAG-epitope-tagged
authorLoss
firststrand
67782324
role27
23,51
rs28384376
~104–105
RPCI-11
A217
cleft-wall
Kcal/mol
N-terminal-specific
Co34
Habegger
1PZN
∼23-
Hoischen
Nb.BsmI
non-proliferative
-processing
mpileup2snp
12000
Doublecortin
cbioportal.org
pCBL-E2-S
negativefor
proliferation.40
cluster31
CrafRBD
two-hybrid
J-056843
137.
.Disruptive
Onar-Thomas7
Vlierberghe
MCP-2
TIMPS
44.1
.A339V
pGL2-Basic
adipoctye
BRCA1
.K-Ras+/V14I–mutant
RAD51C-001
Hap3
cer-predisposing
Tyr-394
TC-797
MET37
II:5
5′-ttgcttgtaatctgccagatgtggt-3′
NAMB-l
octreotide
~perhaps
chromatinSince
29,879
NNFF
ESF
6174delT-GFP
hydrocephalus
0.80-2.56
decapentaplegic-3
Skin/hair
TATA-associated
BCR-ABL1-translocated
0.114
6,412
c.1558+5G
793.6
toTet-op-K-RasG12D
γ-secretase-mediated
Tyr34
and1010B
DNA–p53
.K-
61.6∗
4n
1.5-kilobaseEcoRI-Wi/idIII
.Y806C
c.2411_2412del2
site,43
BRD4.12,13,18,19
3839–3815
GPd5+/d6+
.3B
TumorF.ndomelrialF.ndornetrialOvarianFndometrialGastricGastricGastricCervixBreastSkin
6792
method62
Loo
vitro36
Veracini
autism
onesituated
4q11–q13
Bsu36I-
Ala-1708
Ser29
FLT3-tyrosine
oncology.1–3
Gq18
puri-
mtations
mate-std-dev
KAAD-cyclopamine
perthat
0245679
100/1885
1´PCR
H190
AGTTTTAAAGTACTAAAAATTGCCATC
.OC316
enterocytes
DEL3PB
endocrinologically
allGISTPredominantlyspindle
Phe993
781–786
confirmed8,9,10,11
8.9–16.3
LWH
five-carbon
2.377
mutations,20
AATGAGATC
SNNTE
P0002
Mlh1p
oligonucleosome
modi®ed
de-ionized
penetration.31–34
6xL576P
L274H
6/290
progression57
S226Q
.Study
Ser118
JADE-1
BYL719
.Annex/PI
Xho-F
471–598
Smad4-initial-IP
pXR2
I1307K
outgroup
PET-1
NLRP7
.Peroxide
progenitors24
Olschwang
Rappsilber
I2006
H132P
Hurko
cytoplasmic/perinuclear
P=0.122
FA-affected
Sulcova
0.5320
Bmp15
MutSdependentmismatch
lesion44
Co13
heparin-binding
cells,7
2-4.View
replicate10-12
5μM
EWS/exon7
CP-868596
Tyr1289
non-RAS
NPR2
p-p85
P.R831C
RP11-417J8.6
structures14
p70-S6K
∼80-fold
F706S
1-sided
Noonan-syndrome-associated
T16
415,38
245–225
T-p53C-F270L
criteria.4
PhastSystem
0.037
heteroduplexed
N564D_D560Y
apoAl
wnt-1
antihost
Cys1129_Val1130
USP2
Folate
dabrafenib
pathogenic.Of
rgl
D110H
SKP2
-mediated
zf
CdotC
V581F
yIG468
resultsplusminusstandard
NaCl–0.2
IL-1β
4857
Transfection—Cell
CXR
analysis.12
stimulus-regulated
HIST1H3B
occur,18
Roosendaal
55℃
118–121
.TVs
1417–1424
NP_004976.2
micro-injection
YTHDF2
Tyr-742
-G207T
EGFRon
BCL11b
V1122
76-year
SEPT11
clonality
2Chemotaxis*6h16,416
scleroderma-related
Jeliken
High-penetrance
cataatgtccagactttgatta
hormones11
gure.The
loss-of-contact
.REF52
g.3100C
E1997
1859
NSCLC-linked
G254
B-cells
0804-4643
database17
Utt
brahmarelated
Ultradeep
4.53
fusion-bridge
aptamers
H305A
0.122
61-11
NUP98/HOXD13
unsatisfactory
.Gefitinib-induced
mutations.14
29KB
P.R-V.
MET-E34K
16,25–28
enteropancreatic
-CCTTCCCTGGAGTAAAAATC-3
thanclass
.12–17
anti-HER
−4
expression70
692
theleft
−.97
12d
damage42,43
.Mll2
CTGGCCG
associa-
D92G
olaparib-induced
//www.dnalc.org/bioinformatics
cHL
Vitari
sensitivity-conferring
5'-CTTCGGAATTCTGCCTCT-3
RAC1WT-expressing
3829delT
Alk-5-independent
height=600
criteria.58
3.9Complete
50/57
Axioscop2
1.170
RNF43-mutant
ZNF780A
URA31
c-mycS62A-HA
0.0413
bevacizumab.2,3
acetate-responsive
JH-MMSET
NCT01712217
281–338
Coimmunofluorescence
V.M
5′-AAGCACCTGATCCTAGTACCT
stain/PBS
−659/−653
IDH1-transduced
Ademonstration
213q
ΔJH2-Jak2
gene-expression-based
cells13
DTI
18-76
Gln1424*
Glu746
chloramphenicolresistant
ATCTCCAGCAGCAGGCCATAGAGGGGCACCACGTT
TCRαβhigh
of1
nanoclustering-response
Legube
GGTCTG
300751
.Cross-talk
IFITM1-myc
Carracedo
Fig.5D
mice13
trypsin-digested
-DERKE335K
HPV-infected
EBI3-expressing
galectin-1
up-/downregulated
VavCre+/WT
Pik3caH1047RPtendel/del
1-way
ortho-pervanadate
PC-3M
ATGTATGAGC
1.4.4
Tyr265
CA-PJ34clone12
Bisulfite-modified
refractory.34
apaf1
pKH199
PTC/MNG
1:45
Tet3-deficient
c-3
sarcoma/mitogen-activated
5′-cacaatggattttgccagtctcc-3′
GUE
differentiation4
hMSH6-deficient
deletions/mutations
NRasG12D/EV
lip—E
Fortini
achondroplasia
CD117
SacI/EcoRI
NM_000245.2
APO-1/Fas
G42R
c.1990-16_1990-2del
28*
c.3197+9dupA
5000
pEYK3.1
Nov.
spectramax
0.55
//doi.org/10.1371/journal.pone.0005137.g002
post-hormone
wt-SPOP
re-expression150
14.3-
1330
2/100
Puromycin-selected
.Suppressing
1,818
L1-S2/S2'-L2
activation2
models=20
11:8441–8448
ERLIN2-FGFR1
ChromasPro
nucelosomes
1.3–4.7
D19S1872
70F/62M
Narumiya
KAF
conditions.9
ligand-dependence
activation23,24
G454R
8q24.13-q24.21
4725
5522–5527
D2-Ub
monomyelocytic
Histofine
Bedfordshire
98-kD
CASP8AP2
Venkatramani
5′-GCAGACATTTTAAAGCTGGTTGG-3′
26–41
MP-CAFEE
CGCTCAATGACT-GTGGTCGCCTGCAGGCAGCGGATG
zhuangp
TIITLE
sensitivity.31
Gly2032Arg
previously.59
pT1a
HR+/ERBB2-
translational/posttranslational
cases.19
214–233
1.0–1.5
Co43
481/484
/ZNF198-FGFR1
collagen-based
26105
E515K
±200
5'-GCCATTACAACTCTCCACAAC-3
pcDNA3.1/V5-SOX17-His
TSC10–13
PAR-dependent
CCL9
mesylate
NZM3
3E2
13-fold
4000–6000
overenrolled
dNRARA
T465P
GC-Rich
55.9
i-Mutant
3.5–24
pGBT9Keap1
*Data
CRL-1441
61–65
Radioligand-binding
−106
NUP98−6R
179,938
Val50′
2239–2247
5'gtcttctgggtggcagtgat
1353
pCDH-MCS1-EF1-Puro
L834R
resistance14
Q603X
P960-targeting
LUC961
anti-IGF1Rβ
93°C
n=33
PTPRM
Pre-
Varella-garcia
100-mg/ml
81.9
33–55
motifs.4–6
non-Zn2þ-binding
G331H
Lys-330
Posttranslational
study—C121S—has
CT2
L167P
sub-phases
1895016
.Moon
5/70
NB2
pre-clinically
mutant-infected
TSC2.27
Tau
Abl-1b
JB10091
L540R
webtool
CCCTTCCATTTGGCATAGCAC
transitionTo
5AAC
.Lifetime/cumulative
pYXXXP
neoplasms.41
subgroupings
18/21
sevenamino
Tyr-657
C-23
TOR-mediated
35/63
Sal1
di-methyltransferases
pSer/pThr
Anti-psychotic
CAU-tailing
Y1282
presentedin
Na51CrO4-labeled
**p
Kawamura-Saito
overgrowth-associated
Vétérinaire
VMD
LCS
Bioruptor
66.38
FGFR1-TACC1
ATTTCTATC
r.p.m
vitro-derived
38–52
GAGTGAGGTCGGTGGACTTCAGGT
C/EBPα-null
MCC14
4,20-22
carboxy‐terminal
SNARF-1
transformingversions
FRALLE
CTGGTATGGAAATATTACAGTCCTG
Ad12E1A
MØ/DC-2
bindingproperties
K120N
TPP
5.10
OncoSign
.Recognition
P871L
total—would
Xg
cell.Bottom
μg/g
H2B-green
Oct-4–positive
156L
pR54.1
p16/Δ1–8
schwannomas
47–62
-GGCGCTTTGTTTTGTTCGG-30
mMyb-Reverse
NHA9/MLL1
IgG-enriched
preparationscontained
MMR-proficient
range=3–39
modification/stabilization
4180K
P491S/L
IKTE
astrocytic/oligodendroglial
E1679K
14.29
strepavidin-Alexa598
U-H01
2.316
.Only
D10
607–1099
Glu386
Glu659-Phe'248
810,000
plate-based
5′-AGCTGGATTGAAGGAACAGG-3′
.Goat–anti-rabbit–horseradish
growth,5
array-CGH9577
p85-p110β/δ
adenocarcinomas12
JB10092
OVCAR-3
S240/S244
-Box
Gly468
variant.17
structures32
Hematopoietic
lines.51
D816E
cytometolic
ectopically
Excel-based
novelNTRK1-derived
ZF3
pp1.
pCMV-3Tag-1A
P=0.116
7g
−0.08
BCR-JAK2-rearranged
554132
nuclearlocalized
vivo31
q2
9–10
IV:1
K1420-1
MinimumNQSCovariate
coregulated
ATR-X-associated
BRD4-independent
90,000-shRNA
X-P
Costello/CFC
C176S
BCR-ABL–transformed
pPDGFRA
itprobably
MSH2-E749K
Spred-2
.R282W
//www.chem.agilent.com/Scripts/PDS.asp
c.182_183delTG
dâ
KRAS4B
DEK/CAN
Ret11F
protein-forming
E2F1–E2F5
rs17336191
mid-level
RAF1/MEK/ERK
p300,12respectively
−.04
CU110-SCR
HCC-56
2-and
ERK2/MAPK1
BARD1
HLA-A2–
receptor‐binding
p85α-iSH2
Eynde
AML29
V158Q
immunoblotters
ALFA-9802
tyrosine-phosphate
81–83
SRa
44also
SQ20B
doses.15
conWrm
S104ON
tumorigenically
APC-induced
819/906
gpl40rk
.NM_004119
AID/APOBEC
10,20
peptide–tagged
NKT
A829V
Hsp47
LGE
A-8-A
P209L
T-LBL/ALLs
5′AGATCGGAAGAGCACACGTCTGAACTCCAGTCACNNNNNNATCTCGTATGCCGTCTTCTGCTTG/3′ddC
N854
D–CDK4
RANBP2-ALK–positive
TAM/AXL
S.-F.
not74
.Ng
glucokinase
PHLDB1
59portion
Spektor
10,26
L869R
actin-mediated
F68L
R503C
a6c
carcinoma.6,24
I0.5
_1896+
detailsin
Stat5-β-casein
15q21-q22
EFHA-Smad4
D814V
CX-1/HT29
GAL4-based
122/118
anti-PTK
-=â€¢100-C
C/EBPα.20
AAUUGUGAUUUUUUUUUUUCCCCAG
precancers
delGlu746
Q466X
p531
59–65
14d
20/27
3–99
elutepolypeptides
LMCD1
05-321
100gg/ml
Goumans
.Debiec-Rychter
N-G-loop
PI3Ks.Consistent
cell–derived
.Karger
haploinsuficiency
NUP153
0.2–5.5
GTCCAGGCTCTGAGCCACAC
A_52_P329197
extracutaneous
www.softgenetics.com
RAM34
EP2367Y
holoenzyme
0.0274
geranylgeranylated
detail.21
3·2–100·0
¯asks
1178
41/F
c.3028C4T
ΔGH2OU-I
46929367
5′-GCAGGACTGTCAAGCAGAGGA-3′
3364s1c1
St-DEETGEFOH
-cyclopamine
A167_K302del
neoplastic-tissue
18°C
linewith
1/5/15
9p24.3
FLO-1
0.2-mL
heterotrimers
//cellbank.nibio.go.jp/~cellbank/cgi-bin/search_res_det.cgi
CBP-mediated
7p-q
EGFR/HER1/ERBB1
TCT
similarity/distance
X-PDGFRA
Hodskinson
Lineageneg
anti-PI
Sidrón
12‑01
QIAQuick
s.d.
/C
subfragment
PTEN–membrane
diseases.4,45,46
H592R
infl
Nabili
c.339G4A
FLAG-Smad4
cue
methanol/l
94◦C
21/120
TWEAK-stimulated
1xV560D
//doi.org/10.1371/journal.pbio.0050109.g004We
.NSD3
determined.14
RP11-721K11
.MOLSCRIPT
SMAD7
D835-Mt
.Placental
controls.24
1:10
Lapatinib-induced
Glu303
MutationsThe
.Inter-observation
H72L
cEnrichment
endo.endojournals.org
phe
THP1
.S3J–S3K
Tokodai
anti–phospho-MEK1
cancer.9,21
proline/glutamine/serine-rich
ESFT
time-of-flight
7FF2
III.10
W65461
v0.1.16
to0.4
8w
p.Asp153Val
pMX-menin
268/207
ava
H123-to-Y
S864
RP11-107F6-
cytokeratin
pS6S240/244
c1615g
uninvestigated
tocolytic
High-MC
.RFLP
2F-G
E6.5-E9.5
.Miettinen
A755G
BDF1
cancers.3,9,10
www.dnalc.org
lines–derived
32/45
422
cancer-initiating
caspase-8/FADD
UCCC
224-fold
Cβ
B2–E
reports13
3A1B
isotype-matched
F590
syndromes.15
pCMV-HyPBase
000017.10
B7-1
L145Q
∼6000
1829
Jennifer_Clark
TTYH2
H4K20
CDKN2A,66
MSI3
VHLΔC
LL6=LUX-Lung
.MG-B2GFPΔ1–2886
isobolograms
4393insA
Arg341
expression_manual.affx
9/248
ubiquitin98
pre-cancerous
Amsterdam-like
150,227
AZD6482
inclusions,9
productsTable
four-micron
of10
Rrp4
pE3-V
predominate.2
cytobands
117,833
,7,7
ZC3H7A
Groton
-peptide·VO4
CysWild
1238±605
.Amount
HER2+/PI3K-mutant
MmAGAAAR135
BuildModel
DNY612LV
L320
suppressor/cytotoxic
.1995
MLKs31
:5548–57
17/48
studies.57
Goudie1,16
paclitaxel-induced
non-complex
55970
insertion/
MCF-7-shRNA-SPEN
Phe62
lipopolysaccharides
correlations.8,10,12,13
notypes
.SDHA
0.5559
5′-GCTACTTACCATCATAGCAGCACTACCACCTGG-3′and
‐conjugated
performed3
i.m
HRPlabeled
SAS-5
immunodeficiency5
E1447
Signifi
investigated.CONCLUSIONThe
Ras/ERK-mediated
variant.Prediction
CD117/Kit
L245R
cases.A
+3.8
.Jak3
Smad4ΔC
dual-kinase
Henri-Mondor
Fig1C,1C
cholangiocarcinoma
Op8
v~vo
2,393
p.A776T
24-46
.Nuclear
250K_Nsp
16R6-4
controls,9
HI100
neoplastically
tumors/15
ARF876L
Domain—Regions
staphylococcal
n=154
protein-expressing
HER2growth
XPO1-RFP
TI-1
1,7–9
keratoadenoma
bioinformatic
16·4–26·9
LB953
FGFR1–FGF2
//www.ebi.ac.uk/~zerbino/oases/
sc-101760
interchangeably
-6A
Leu298
0.0104
fgf3/int-2
MASAMITSU
3Ser
patients.5
BrafWT
G245
TBRI
17,795
MYO5A
.Measuring
Cdk4–p27
speciWc
Annstrong
atsub-physiological
Ser308–Lys318
231–233
translation.The
-l4L0s
ANNOVAR23
CCAATT
.Creation
FB2
bcl1/JH
ilar
mCitrine
GTPaseTo
Resau
J013
Del9
2.PPM1D
®vealleles
let-7
GRK-interacting
23S
V310M
/SSPSwt
1:1.38
lethality180
adhl
KIT/Delta559/TV654A
WT≫Y641F
H-12
Cterminal-epitope
59poly-A
c.1735_1737delATG
15-to-55-year
Dharmafect1
T603Q
Toshyuki
Segmentation71,72
rTRα1
Hs_FGFR4_5
nm/280
Yazaki
missensemutations
back-exchange
p.Gly2919fsX3
+CHX
12-403
etoposide/cisplatin
.Spliceosomal
FLT3-JM-PM-expressing
p120GAP.Since
non-transitioning
a02-wt
°C.Homozygous
E554D
L.
Mean-centered
5570
RAS/MAPK/ERK
Cancer-predisposing
Y97C
Krawczak
goiter.7
31C
anti-ubiquitin
44–
Carbohydrate
CGGTCAGTTGAAATGTCAG
mLst8
6.8–19
1913076−7.2TRIM29Tripartite
Kollermann
oncoprotein-activated
.BRAFL505H
A72-Q506
Suemitsu
IVS1412TrG
0.1–2
97-29
4159
described24,29,44
I-9
colony−formation
Live/Dead
comutated
K562
K171
subtype.4,5
2.846
cells.21
SUGEN
prominence.10
hDIS3V504G
neuroaxis
D1/1-145
damage–mediated
VHL-mutation
5′-GGATCAACTAGTTCTGAATATTTCCAGATTTTCTATCAG
1.5plusminus0.3
Luciferase32
mm-sized
anti-CCSP
CCCCAGGAAGGAGCACTTAC
Ensembl50
mgz
=3.3
Rad50−
.I157T
K37
CAGAGCCCTTAACC
Thr1068
Val481
R808
nccRCCs
modimers
BCL/ABL
3-month-old
double-distilled
Aksoy
Non-invasive
.TET2
K.U.Leuven
Stat5AΔ749
TrkA-L92VL95V
allo-HCT
gccctttcctggcgctgggtctttsacacgcccaCOOCTGGrsly
orp53
I,36
50462-1
1.77*10-9
6xOSE2-Luc
affinity.Previous
EFA
NRG2
10-PT98
0.463
counting.qRT-PCR
BFTC909
late-arising
CCTGCTTCACCACCTTCTTG
TPM3-TRKA
9·3
CCNG1
72ºC
ADCK2
.4136C
10–25th
Arnhem-Nijmegen
non-mutational
943ins10
Nras–/–
NUP358
Beyotime
15-28
TGGTCAACAAAGCAGCTATGGGCAG
ICI182,780
R29W
5q23.3
inhibitor20
end-labeled
HIV-associated
ataxia–telangiectasia
.S4A
Taqm
gliomas36
KIT80
CCCCCGGCTTGTGAGTAGATGGGTAAAACCTAT-3′
1003/μl
086690
Chond
Vpr-and
02115
Min/+colon
CTCR–OV01
KCl
paragangliomas
thenormal
carcinoma.56
Farma´cia
melanomas12,33
14-nt-long
p110β
G54E
1.121
20,31
N705S
BRAFV600K
3054
NQO1-ARE
IMCE
IDH2Wild
selection,34
10-0505
//www-stat.stanford.edu/∼tibs/SAM
c.4327C
NHL-BFM
CAF
activity.ResultsHuman
f/78
creativecommons.org
broncho-pulmonary
Sugimachi1
Arg278
pVHL-S111C
AML-1
17,45
1x106
RASSFIA
cP0
Twodimensional
ability.11
c.5334T
K1727R
anti-phospho-JNK1/2
non–R882-mutated
1344
A364V
Sepharose
80jC
12/group
advantage.Y589F
Gene-Marker
HA-Jade-1
mid-to-lower
C278F
.Brown
ATP6C1V1
osberved
CT‑guided
CR-CLL
AML,3,5
artery-specific
MCM2
mutation.ResultsClinico-pathologic
somatic/germline
SPA17
InVo
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1102282
.Smad4/DPC4
PIK3CA-genetically
Nrf2.The
C1483R/W/Y
single-end-mode
142433
needed.The
Group-3
cancer3,4,6
N96
Thismodel
Danlos
190b
Z-5
G391
204.9
S35C
ScanArray
Ligation-mediated
Nocd
c.8389_8390delAA
R1114P
.Tonic
mechanisms.26–30
–Cre
centrosome-binding
field—0.74
D117nt
Oft
lung,26
GSTSmad2C
cell26,27
Aavikko13
Pard6b
PMS2/MSH6
blasts.70
.Wps/Wps
.SPSS
.Grade-3
Denys–Drash
respectively.8,9
MK-STYX/STYXL1
NCI-H1693
JAC/6
T1781-1798
Zygosity
guanine-HCl–containing
PMS2-E41A
murineK-Ras4bG12D
FA-specific
Billeria
Kasyapa
MLL–E2F
c.G1633A
phenotype3
WJ
.resultsETV6-NTRK3
RG-9N
L597S-mutant
extra-nodal
p.Leu585Ile
GC-MS.
PF00299892
pcDNA5/FRT/TO/Myc
G1588A
517–534
NM000535
.FRAP/TOR
II/I
5′-CACATGGTCTGATGCAGTGGAA-3′
BCOR-probe
278.4
5′-GTAGATACAAGTAGAGAAT-3′
Gachard
W50R
10.1158/1078-0432.CCR-12-0625
Tresini
0.294
SWI2/SNF2
Tihan
anti-phospho-c-KIT
fluorescensce
313–320
SYGOOS
.Alterations
1p13-q31.1
OPN
Image-Gauge
pET-MTS1/Δ1−8
HN-Smad4+/-
andCUO27
tumors13
HELYDLDVTAPEDPNEEAVSQIFPDS-
Q303H
tumors5,6
5′-ATGGAACAGAAACTCATCTCT-3′
Insertion-deletion
NaH2PO4–0.6
disease.1–3
Blmhelicase-deficient
Rubin16
RNA-Seq-based
FGFR1+/HR+
p100
alpha_beta
Gal-Yam
Cell–Cell
wt/del
co-transduced
bk143F12
rs2151280
Deshaies
ACGCT
Medular
Deoxycholate
458.0
al17
579/581
.CUX1
¢70
RÃ©f.45
chemically-crosslinked
ATP.20
Jetquick
PTEN2
.Arrowheads
OR=0.40
R257P
Fernandez-L
I941
YAP–β-catenin–TBX5
hyperactivated
intragenetic
FigFig5A,5A
95Â°C.PCR
fgf-1
stability18
TotalPrep
GFPpos/mCherryhigh
cancers51
protein-tagged
500nM
1817–1819
Shankaran
Durie-Salmon
diagnosis.16
accumula
CEPH-Généthon
populations,3,8,9
elucidated.First
V362F
DNA-damage-inducible
31312
gacaactactggtttggggcggacaaaagctgtg
bronchography
factor.Figure
.MDC1
R337C
deep-sequencing
ERBB2-Tyr1221/1222
staining.Immortalized
E2F/pRb
M3628
5.0.14
IPRO13507
BMPR-1A
described20
pmCit-N-rasG12V
5V-gcccacgctcttctcactca-3V
cycle.BACH1
Cases/controls
Phospho-AKT
DeltaDeltaGbind
CD117-bearing
overexpressed.10-12
erlotinib.40,109,111,114–119
M1248T/L1193V
Gpx1/2
15/118
WHIM13
myelo-erythroid
co-recruits
Jade-1
C-terminal–truncating
bcr–abl
benefit.42
'spike
c-225
21,26
Arg-375
Pbrm1
'ol
DRB1*08
F328
2•99
.Ulceration
ETV1-overexpresssing
43-237
K550_Q556
RxxLx
pothesis
S373C
S462
CEP7
nervegrowth
R1024W
NM_007940
pathway/network
HPA026441
Ras-associated
SOX6
PRKAA1
forty-seven
Cell-conditioned
p.Cys44Phe
hCD19
cytokines.3
stem/progenitors
FE-11
1,2,3.
possi-
1times104
3q24-qter
.Wilson
IL-21
PDGF-Rα
WISP3
CD/ED
dynamin
5.5±5.1
//www.sanger.ac.uk/genetics/CGP/CellLines/
004449
N8
Sox17-β-catenin
39,43,88Å
634-640
.Wild-type
translocation/gene
Gutternigg
nonspliced
off-set
AAAGTC
GRCh38/hg38
.Excitingly
invasionc
ERK1D338N
sc-2053
HAhBRAF
areas.1
Met466
superficially
5.7
P=0.663
antigenically
associated-adverse
NMF
Glu/Lys
NVP-BEZ-235
.Noninvasive
Pheochromocytomas
D211V
chemotherapeutics
18FDG
R1437Q
LXSNAKT2
patients13,29,30
colchicine-untreated
cell-free
TWEAK-treated
all-heterozigous
ilS
174T
CstF/p53
Concanamycin
Vogelstein36
T875
PDB-codes
pCAR-IF
βPDGFR
mg/1.5
intracelluar
GCTCAAGCTTGCCATCTCTT
gastrointestina1
PAI1/SERPINE1
levoleucovorin
rs7901695
AML1-ETO.32
L396M
.Menarche
0.6503
xenogeneic
Fig.2A2A
Pestell
FNB56
R397W
100ng/ul
P521L
//www.iarc.fr/p53/Index.html
non-fibroblastic
D04
m-thick
ERK2P58L
P=0.007
ETV1_AS1
Craf+/D486A
.Formula
37.82
K39N
ReniliÂ
H1047R-NHUC
population.9
A-I-4
3.2–4.6
GISTs.26
TGC/CGC
64/f
1.542
.Oligonucelotide
C329R
MLPA-negative
WillmorePayne
MassachusettsGeneral
interpretative
.Two-tailed
lmer
KCl/0.246
Y453D
K753A/ErbB4
ETV6/RUNX1
HSC7E802
.00776131
ezrin
normallydeveloped
TNFSF6
wtGSK-3β
ΔBID
WPD
5x104
pET28A
1999b
D89N
.1799T
5.15–221
5-CGTGAAGATGCTGAAAGACGATG-3
cells.66,67
.Freissmuth
γC
v-yes-1
1M52
E85E
Ly6C+
HaloPlex25
FV1000
5´-GGCAGACCACAAACTGAGGATTG-3´
Tyr572/574
mutation.2
NM_003797
line/tumor
.Diagnosis
LINC00290
5′-TCG
macrocyclic
DCS
79G16
TKI1,2,3
Vojtesek
pTyr
SM2702
König
21/23
39–49Mb
TCAATTTTGGGGTTTTGTTTTG
d–f
R913Q
bbrcg
post-fertilization
iuGl
established19
729–736
40s
antipoly
18.61
Arr
13776-9
642C
72.8
D12S366-D12S86-D12S321-D12S76-HNF1A/M1-UC39
M1689R
023
Ex7F
FIII/6
Fumo
activating34–36
L858R-EGFR.47
P34Q
2×5
TAATACGACTCACTATAGGGGCCAGTGTGTCCAAGTGCTATGCCC
64-year-old
60203001–60306200
ter1678
TCGAGC
5′-CGAGCTCAATAAAAGAGCCCACAACCCC-3′
G420E
1055B8
E037
AR-FL–mediated
p110α-H1047R
cells.17,18
3-32P-labeled
DEN-induced
real-space
R1192P
49°C
colon10q11.2
aSilent
5′-CTCTCTGTGGGCAGCAGAAGACGACGAACTGG-3′
.Vogelstein
speci®cally
Watermann
.1731G
275-280
JV18
S1819
activation.3
protein/DNA
EDTA/0.2
Asxl1-F3
mimetics
CAK
Skp1–Cul1–Rbx1/Roc1
adenocarcinoma5
H-1
RPS6K
MutSαWT
.84
308a
NS-patients
cryovials
L687P
anti-FANCG480
-CCNDs/CDK-Rb
residues.20
PDS
QGlnAr
Evi1–/–
7-methoxycoumarin
analysis.7,15
ZNF
Wallich
microcephaly26–28
oncogene-mediated
Asn486
EEC
Zabrze
1×107
Tosei
FAM-CACAGTTCCTAAGAACGCCAACAGGT-TAMRA
0.0769
acttacTTCTTCgac
C598T
burden.20
Z/AP-positive
GCATCTTCAATACTTTCTGCACAG
H3K27me0/1
mPI
p53-R267P
3O96
E670D
SB1
smMIP
grade.1
CultureBa/F3
goseq.html
Q99R
nESI
69°C
5′-GAGATGATGGTGGAGCACCAC-3′
GGTGCCCCTCGAGGACCTGCTGCTGG
suppres-
allelic-imbalance
Spindled/Intermediate/Epithelioid
TaqIpolymerase
.Statistical
imunostaining
P=0.0024
gtatttgtt
eicosapentaenoic
3.6-Å
RPTKs15
ERK-1/2
BL1672
Thiazolidinedione
WTwas
c.587_590delCCAA
monomers110
//clinicaltrials.gov
C117Y
p.Q373P
kinase-downstream
prednisolone
types24
pcDNA3.1/Zeo
Mlalign-id-pair
F311L
KRAS-2R
lig­
hetero-trimerization
machinery204
Gene-Scan
2312-14
icecold
senescence82
chondrosarcomas5
domains60
3.352
0.53-fold
Fip1l1–Pdgfrα
N-16
RIT1-mutated
N308S
beta-globin
IndelDetector37
Lys247
5q31-33
immunogen.Luciferase
Sigmaaldrich
genetics-driven
ectivity
E-mail
P.A763_Y764INSFQEA
YAP1/TEAD1
59,62
intrathyroidal
aArgGInAspPhoGI
2.9684
2-3H
−6.46
Q1826
Fig2A–B
S3E–F
C.S.
5438delTGTG-derived
shAlox15b.1252
it17–20
fibroblast-like
61.59
R59W
GAPDH_SybrG_REV
EPHA7
151101
L164P
pDM71
Kurdoglu
−2.48
R40L/T567D
Selectivemedium
TRX2
drug-discovery
11.54
.Glycoproteins
.Alternative
.GFP–VHL160
.Peak
ion-pair
Weissenbach
-containing
9.2
p.Leu1930TyrfsX33
.1747C4G
967248240
Tan1,2,12
v.4.22
ERBB2-independent
MHH-CALL-3
5q22
GCTTTGTAGGATTCG
CSR.Figure
4204
p.Ser32Ile
RhoBTB1
smartpool
cross-contamination
Transfections
mutations25,26
PI3-K-independent
mice20
K07C11.2
leukemias,11
cell–skewed
no.30
\400
shGLP
W557_559delinsPF
Zn2+-
.KrasLA2
zug
.Inspired
AspS5
AGCTGTAAGTGCGTCCCCGTGGTProduct
oncogenomics-based
III9
Trk-Met-expressing
GFP-DH/PH
Mehine
AML.16,18-29,37,64
Transfections/Luciferase
non-lymphopenic
RNApolymerase
H479
AGGTAGAAACTGAAAAAGACATGC
2-5-4-7
469
969_972delCTAT
//fokker.wi.mit.edu
CGGA
BRAF/MAPK
CDCREL1
epigenome
N-ras-nanoclustering
3/13
fusion-gene/targeted-agent
Proteins.GST-CDK10
PFS
Fry
sposterior
9-11
mutation.7,8
SIRT1
exon3/3b
MEF2B-V5
Pathscan35
leukaemias.2
α-OH-substituted
sex-neutral
overall-survival
91–281
Bergethon
H3/H4
26,406
NSAIDs
anti-phospho-BRAF
subunits14
A.M
DNMT3
two-coin
652N
ETVl
-Smokers
.TβR-I
DTA
silverstaining
gordon.chan
Bioconductor
BRC-2
Prdm1−/−
auto-phosphorylation
activity75
.Over-represented
APC-conjugated
donor-derived
patient.45
parainfluenza
MD-286
P=2.6e−4
ATPases
0/66
PanINs—except
fgfr1a2
haemozoin
BLOSUM
variant.10
h.Western
ASXL1-mediated
AATCCTTTAGCCCCCTGAGA
38.5±14.4
Steenweg
factors.20
5221
InsituPro
tcatttcag
FHD
split-Venus
Charbonnel
//pngu.mgh.harvard.edu/purcell/plink/
phenotype.15
.Caveolin1
TGGGGAGA
NM_031965
CDDO-Im
third-stage
0.006b
2000s
1.05-3.80
Pin1-mediated
RhoAlibrary
iPTreeSTAB
Tris-Hcl
pEF-Bos-myc
33–121
V1607D
RP11–140H23
S12C
C1697R
ScienCell
N233Y
select_db=SOS1
sc-8007
MGUS
C381
DeltaGbind
ARID1A26
Eyfjord
.Negatively
5'-GATGGGCTCTTTACTCGGGTCGTAAT-3
COG
Tet-U6-pLKO
Utada
≥NN3
8g–i
anti-TRP
.Inside
H111OP
1,478
ATGCCTGGCCAGGGGCCGT
CLB-Car
V1110
c.1118A
R1314W
consolidation.35,36
0.3761
8/17
virus2
3sS-labeled
.Viral
function.21
Zochbauer-Muller
Tyr43
protocol.13
HA-ERK1-
Calbo
MY31m4
SHCBP1
S320F
MET-gene
shLacZ29
B-RAF–mediated
myofibromatosis
testedabove
NPRVGTKRYMAPEVLDE
mU/mg
C20R
transformation.18
pPKCα
membrane.44,45
PI-3K-phosphorylated
.39,41,42
V14RhoA
Asef
RAF-MEK-ERK
insulin-receptor
I34
DDX3X-RNA
MLLN320
F57C
PHA739358
factors.14
.160
AGO1
re-ligation
more-reliable
pDM2LacZ
109C4T
Vector\
SNP5.0
Borkin
yeastand
summarise
Kamijo
R97P
Spi-1/PU.1
Elzen
G39R
Formation—During
Y705-phosphorylated
allelotyping
2965
toprecede
model.11
9R-2
PE/CA-PJ49
Dm-Dicer-2
-KIT
25-mer
RNase-treated
RIZ1
Kreso
Mll-fusion
-EGFR-L858R-HA
attenuance
dephospho
NF1-
PARGKK
pGAD–PKN
Yoh
LMP2-deficient
hydronephrosis
High-grade
p.Cys61Gly
9611
Signaling—To
244A
φ-π-S-S/T-S/T
P95
13/46
60/61
ofeither
RUNX1-ETO
ChIP-qPCR
pGL2-ARFpro
reportsh
unilineage
Gandarillas
10/21
TGFBR1*6A
1Adjusted
5.50
6Myc-Lats1
EGFR-fusions
p-MKK7
therapeutic-naïve
defectivein
Sanger/454
months.27,28
p1=0.066
0035
LSL-R172K
2-methoxyl-4-nitro-5-sulfophenyl
biochemotherapy
RBD§
CA102662
F359V
R380
ARE-ARR3-luciferase
Novartis/Broad
Polyprep
R2323H
Honkaniemi
MDAMB361
susceptibility.5
localization.62
Wnt-APC-β-catenin
proximity-induced
D.J.
hMsh2
12.3-
SAPS1/2/3
R137C
Eluent
Arg268
AB005048A*29010102N
switch.76,77
'type
42.8
EK
ER-α-responsive
downstream-cistron
2540/μL
R67147
A.cal
SMO-V321M
YAP224
αvβ3
SRSF2-dependent
nucleaolar
c.C1270G
nonpolarized
Me12
2.2-Kb
50–1.94
C831L
cytokine
ubiquitination.9
CFP-E78P/F83L
.Rad50S/S
vitro.1,2,17,28,49
Exon-capture
stage.9–11
oestradiol129
MRC5
Cardio–facio–cutaneous
anti–phospho-Histone
4.20+0.16
fancc/brca2ΔCTD
E709A+G719S
MSPPrimer
–8.9
.A.L.F
Cdc42GAP
18322/14928
6,12
low-sensitivity
Biosystems
Bcell–like
sc-483
development—germinal
Cytosines
collapse/consolidation
mutation-to-drug
30,37,68
Msh2pMsh6pcomplex
TargeGen
CRISPR-edited
S1329L
22.5Brain
.b
1.47–10.93
Lats1tm1Tx
-tris-phosphate
contact-inhibited
High=3
-neu
protein.9
gp110Prt
FDCP2
-22-fold
subfecundity
dye-terminators
proteins—ezrin
D10S170
transformation55
5′-tcagacttgtgtaatttgtgtatgctgatcttcatcaaaagg-3′
C42G12
HCC-initiating
E2147
web-service
1.5x
MGH0NZ
PCPG
Figure1E,1E
0.8–15.2
addedfor
.Anti-phospho-p38
Retronectin-coated
Bösmüller
R1025C
HA1E
Y1853X
S259A
p53-targeted
MCL-1
xenografts137
C/EBPε
E157K
p.1279
multi-reader
Li-Cor
.NLS
BFM-G
.TNS3
read-strand
ID5
samples.Samples
AFMC010ZC9
anti-ROS
~61
low-melting-point
p.E542G
p.N550H
54–135
milk/TBST
rearrangedNFKB2
compartmentalizes
290-bp
site67
Georges-François
G322D
WNT-induced
Fbw7−/−
/Hsp70
iMeindl
0.5´10-9
D277+S310F
1.06–1.95
.-.p-Y
.brief
trial.14
work16
thatthere
Twenty-five
proposed.46
RG-12N
anti-phospho-CHEK2
cases,36,40,41
pathways.3–7
Nonsense_Mutation
mid-stage
described.56
RhoA-GDP
IKKα-null
GFP–VHL213-P146A
5′-GCACCACCACCCACGGAATCG-3′
maximalstimulation
.RCSD1-ABL1
sequences/conditions
CIEBP
mPEG5000
Molecolare
injections/mouse
2C–D
Δ227
Cbl-mediated
.ΔCt
.Nevertheless
Elf3Δ237–241Δ246–250
1/CIP1
post-primary
958C
.BM
pTrcHisB
Ba/F3-WT-c-KIT
EJ5GFP
22,145
91CCCCC92
13â€
605ins
IMAGE:5170293
1.20×1011
9122S
C2-like
Srcfl/fl
317,000
Burrow–Wheeler
bitemporally
Phe735
55,832
E-4
nucleophilic
.HECT-type
−2.72
8/8
prognosis.15–24
region.39,41
SCFCdc4
Nanog-proximal
16.57
Colomba
shAXLCl
interaction29
translocation,6
AE859pand
EGFR–TKIs
lysine263
phosphorylation—and
Flag-BAF200
Rb-/-
retinal-vein
thatPientenpol
TLR4
JC-1
EWS101
Δ368
5′-AGGTGTCTCCCCCTGTAAGCC-3′
88:408–415.Transfection
Hoxa9/Meis1a
wild-typeADH-p53gene
recombinationin
HTML.gif
~50
Asl
LR/TI
Endo-H
analysis–PCR
17missense
900-bp
www.landesbioscience.com/journals/cc/article/18096
.D84H
Usingthese
6000IC
0.089
EGFR-Thr790Met
Ze-Hong
Phospho-ALK
3305
di-nucleotide
Ultramount®
Hs233648_m1
.Advancement
inhibitor–derived
35,37
.VMs
VEHIV
TSC2−/−
mRNAs.26-28
TCCTGAGTGTGTGGCAGGTA
e2020
www.cancerregistry.fi
52-4
5'-ATAACTCATCTCTGCATGACCT-3
SCF
hyperbilirubinemia
ice–hexane
CTTCGGGGAGCAGCGATGCGAC
1401
calculable
23−26
pVHL/HIF-α
WSTF-SNF2h
D219G
HOC313
AGGGACACACTGGGAAACAG
CD28.2
medium.gif
jb2-specific
medium/5
shFBXW7
hospital-based
Lin–Sca1–c-Kit+
MAPK1-targeting
Walke
AA-30
serine-for-alanine
C3219T
K1183R
3-mum
min/kb
practice.figureFig
Malynn
types,179,180
AssaySix-week-old
Ortenberg
pathway.10
T321A
C-I
receptor/proliferation
35S‑labeled
R436W
63-66
pEAE60
microRNAs.1,2
:44–9
GAGCGTATGAAGACTGAGGCTG
B_1394
FANCA-NLS-Mut2.33
Y-28
S133T
MSCV-BCR-ABL1
KLF5
centile=54.5
c.5406+8T
3'f-gGGGCGCGCGTTTCCCctag-
MG-B2GFPΔ3263
326V-+A
1,5
lkb
714-1047
54,020
Events..
RP11-82E23
12.25
exon14
c.26G
.Right
IRS-I
S23G
p=0.440
differentiation27
kurokawa-tky
heighten
phosphatidylinositol-4,5-
1E–F
ChK
79665
Ala161Glu
tenand
SoftMax
p.Arg172Ser
Genes/Proteins
serine-709
E1-E3
ligand‐activated
5B-R1
ab53712
25-gauge
consitutively
pemetrexed153
TAL1-mediated
0.099
−513
EPD22
cMet
TV1
Sensitive*
phospho-Ser780
p.Tyr273*
A210P
9275S
MOV10
Wellesley
c.4154delA
.UPN
19,825/1139
Zymark
1fgi
Q798E
caseA
phosphogluconate
G466V
.-.s
siU2AF65
13Breakthrough
p-kit
synthetase-1
q10
1jnx
HER-II
.Between
V217N
Dual-Luciferase
noninterfering
iodoacetamide-modified
991delM
G-25
Genesearch
pY1173-EGFR-positive
FGFR2wild-type
Sample011
123.6
210K
-CATT
–48
Sawey
Wertelecki
anti-FADD
1.2-bppRyc
oligoclonal
intron7/exon8
abl
Terminal-deoxynucleoitidyl
.Futhermore
BRCA2.MethodsSource
5-CTGCATCCAGGTCCTTCTGG-3
F590GY591D
L930067C06
progression38,39,40,41,42
A750del
—by
Rat2cells
IB3010-01
4308
.S4D–S4E
1A–C2
selec
pre-mRNA66
.1H
bMutation
pRcCMV/wtMyoD
PBS-buffered
10.3-fold
Sévenet
'SAR
-21.46
primerpairnumber3
arrayCGH
lacrimo-ariculo-dento-digital
Pim1-L193F
TG+GG
PLCγ1-binding
leukemia:4
RETE768D
FASAY
Taschner
buffered-saline
ÃŸ2-MGprobe
Downmodulation
di/oligomeric
cylcophosphamide
BRAFV600delinsYM
34/46
p-FGFR
NI=6
348–479
CD29-FITC
Valent
CXCL9
low-coverage
crisis22
Smad4+/+
c.2119T
pY516
RET-A919V
1.5e
10e9/L
7,28
cIAP1/2
1.24–13.1
A1235
Shimakage
ECM/BM-related
freeze/thawed
Arg589Trp
breast/ovarian-cancer
S217P
BC3
11093070910
c.716C4T
EDTA/5
pcDNA/TrkAI
PDB-deposited
vitro13,15,35,41,42,43
P63085
//www.ncbi.nlm.nih.gov/BLAST
Gleichen
cytokines18,49
c.494C
2276X
Topogen
S3I
adenocarcinomas.15
immunocytoma
6540
D480N
.Prevalent
UoC-M1.11
RafDD
.Tumours
NonSmall-Cell
517–552
.Counts
2.5-11.2
d-4
0.6-mm-diameter
qd
βB-βC
Like-1
412
1–2.20
780-492-2136
r-make
Flag-PCAF
.PolyDhan
restriction-length
screen-derived
TP53-Dint
CEP12q
HLA-A1-restricted
Pesquisas
.Microfocus
FGFR1-CUX1
leukemia.12,14
underloading
IκB
K-INH
CCCCAAGTGTACCAGGACAG
T308R
52a
−.42
NRXN3
pcDNA3.1+IGF1R
Y-27632
Shchelochkov
G458V
5′-CAA
V5-cGKIβ6
I414G415
ttk
RAM‐ANK
TGACATTTCTCCAGGGATGC
pPM231.6His
20–50
Gotil
shTet1-a+b
Non-AR
.Von
P384R
EGFR-specific
12pWT
p.a.
other18,24,27,35
voltage-sensor
T4
Internalization-dependent
F317L/V/I/C
AAV-targeting
invitrogen
anti-Pak1
awild-type
differ­
activation,86
RNF168
.Searching
C-+G
1.0-fold
p53–Ras
TL-125-AL
246-residue
5-0
10/27
Msh6+/+
Rottapel
nerve-growth
TOPOP
IDH1R132H-IDH1WT
shRNA-INPP4B-2
CW22R
T1685I
exten
5′-CAGCTCTGGCTCACACTACCAG-3′
pathway-compromising
I919
Ki-S5
Ha-rasp21
stereoview
.Misregulation
methionine-minus
G180R
Ser99Tyr
°C-40
Q1196
dry-ice
within-slide
A126G
30′
T699M
rockefeller.edu
Jak1-Jak2
4.56
PDB:3I60
.Microplate
progenitor-enriched
Egr2.26
BCL2-mediated
FGFR3-TACC3
A504
∼41
high-mobility-group
ARACne
Tra2β
Shappell
analyzed1
6Myc-tagged
l2
BRCA-dependent
CGGATTATTCATACCGTCCC
14-50
1FGK
3F–3G
phosphospecific
KDEYACRVNHVTLSQPKIVKWDRDM*
-0.110
pT3–4
melanoma,45,46
4957
timelengths
precultured
radiomimetic
pYpeptide
1K
1intron
Let-7-5p-family
pgk
RACK1
silibinin-mediated
MLL-AF9–transformed
T10
py99
ago4
assaysParental
9865
Me9923
automodel
EFHASmad4D537Y
1412
2/36
25918
.PDGF/VEGF
//www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf
TET1
BrCa10040
Go24
deoxycytidines
uninodular
2,468
λ5
Jasin
5′-TTCCATCATCCTTCATGCAAT-3′
thestudied
annexinV
ALK-negative
Skp2+/−
R665W
Homodeletion
D92N
CpCpN
HER/2-neu
growth1-3
.BJG-398
264090
FGFR2-skeletal
studied17,27,28
YIERMNY
Decal
stereoelectronic
.Myc-epitope-tagged
Leukemia-free
Ohnmacht
61328–61626
\j
TAATACGACTCACTATAGGGCCGTAGCGTCCACAAAAGTT
r2
cell106
117T-R
T-47D
'alternative
complete.1
pEF-
​Fig.6C6C
kinase.48
.Post-hoc
A*STAR
Cooccurrence
Val43–Val48
`h
least-squares
ICT2484A
varFilter
V272M
Manoir
days.Apoptosis
patients39
HMC-1
M-bcr
SHGC-144275
MPL-A519T
Gal4–firefly
disease,21-23
expression/amplification
paran-embedded
/STAT
Y1853C
D64
R1753T
1166
TCTCAAAGTCCTCATCATCCTCGT
p=0.0147
20-gene
long-standing
BerEP4
Cidea
CACCTGGCCTTCATACACCT
II-7
FBW7-associated
c.1670C
291–371
.Ly
β-galactosidase–positive
Self-Ubiquitination
cy3-labeled
p48,10
CRIP2
EFLacZ
.Limitations
B*0808N
.Difficulties
SDCCAG1
5′-CACUUGUCAAGAAGCGUUAdTdT-3′
P25L
.U87MG.I
FGFR3.28,46
CNR
7062
FGFR-signalling
f/50
5′-GGAATTCCATATGCCACACAGCTAAGCATCCTACT-3′
S5-
1106
p21/Cdkn1a
CD40L-IL4-TGFβ.Full
BRCA1-deficient
XP_616782.3
SilverQuest
126–8
Hoxa9/Meis1/Pbx3
SAPK2
portions2,3
PEBP2β/CBFβ−/−mice.53
GSK1363089
Control-transfected
cyclopropyl
placebo.6,7
P85
puromycin-containing
Tyk2
palmitoylated
group,35
RhoA-2A
status2
Pescarmona
Rad1-Rad10
αRet
inhibition9
NGF42
EVP
2a11
CD5–
q11q13
SRAEGRAPNPARKAC
inmethionine-free
HMGA2-
-q
Garcia-Bassets
TRAP220
.Corresponding
GR-mediated
plotsAll
End-systolic
3-3
2/high
chemotype
PIK3CA-mediated
Nude-Foxn1nu
p.Arg867Gln
buffer®
Eskandarpour
–30
Anti-FGFR3
.Triple
pCMV6-Entry-NFIA-FLAG
E2-E6
phospho-p38α9
67328695
500-kDa
JNJ-42756493-treated
p70S6K—demonstrated
DAH
YUGEN8-BRAFV600E/L505H
ongo
540–847
356–385
Δ=−0.039
21.57
47.2
LacZas
interactions42
V4045.43
methionine-labelled
FGFR3/TACC3
5,666
re-stricted
Transgenesis
A2V
.Ba/F3-KPβ
surface19,20
H1688
AZD9291
154838U22
tonote
11q23
2.96×107
folliculitis-like
Biotex
OUMS23
Asp-520
Ch2/3f
Ser363
BstNI
pseudokinase-like
JAK2/STAT
.Longitudinal
2-ΔΔCT
8/27
p.R9H
183–185
412-414
pCR-Blunt
Destabilization
TSC1-deficient
MLH1/PMS2-deficient
WT-NICD
Anti–Ki
Mar345
formation37
one-dimensional
C229fs*10
N-acetylneuraminic
mAU/ml
Minotech
45h
Shh-induced
separation23
pirarubicin
sNaOH,0.25
E39D
EHT1864
H12A
.BT474
23/156
S6RP
N2C
NH3-terminal
MDR
SNF5-associated
elsewhere.12
treatment141
Transfac
study11
G3129T
500–2,500
+1/+2
protein-solvent-phosphate
448.1
R264H
causation
pancreatoblastoma
HC-20
IKBKE-WT
−3.84
.Diffraction
AGGGACTGCCTATCT
genomeRNAi
315
YNB
AP26113-resistant
p27-cyclin-Cdk
747-751
*.vV~~~
D.P.
c.601
2p16–22
ITGA2B
log2ratios
pYDLK
FcεR1+
non-tumor-bearing
ubiquitinconjugated
A198V
.Endogenously
TGF-beta-mediated
FP9-1
S395Q
CDKN2A/CDKN2B
Karnoub
20q13
MEI-9
H1047R–CCSP-rtTA
E879E
enzyme-catalyzed
16000
A2034V
C696Y
.Notwithstanding
receptors,31
16,365
.BOX
-hybridization
5'-GCT
HD-VP16
half-life.6
pBS-myc-BirA
MLH1/MSH2/
Institute-Navy
Q527*
19–29
.Interaction
BRAF-CRY2/CRAF-CIBN
Pleuropulmonary
ATP-consuming
EED–EZH2
less-charged
aminoglycoside
survival.43,44
ARAF-induced
2038
Ini1-null
L43V
TSC-mTOR-protein
Administration.16
19-base-pair
subsitution
RUNX1-810F
R-CHOP.49,50
carcinoma/normal
dÂ°'50
rearrangementappears
TGFBR1-mediated
ligand-response
Goemans
models.43–51
Cbfa2+/−
Bcl11b53
cbt-15-1239-g1
-cys
13/130
TLR2
QFQbanded
ERK-targeted
kinases-1
Hygromycin
anti-CD58
UNC0638
R259P
animalslacking
.HMEC
c.2935C
cDNA.A
imatinib-sensitive
V773L-activating
SNU-1
K10+
kcal//mol
Pdgfb
CTC-307M15
15/17
xenotransplant
Ezh2
5′-ATGCTGTTTTGTGACTTTG-3′
Laemli
ERK2-Y261A
HLA-A01/25
.VHL-Mediated
Bonferroni–Dunn
p.K666N
RO4987655
N333
isoform1b
pyridin-3-yl
K650→E
ofSDS-PAGE
proteins4
identity9
TGFβ1-mediated
al20
co-primary
other17
E¡ects
anti-RasGAP
4693
control.10
143
I405S
612-gene
ctDNA-based
.Cotransfection
06/patient01
sc-130656
U0124
CTACAGCCGCTCGAAGTCTC
R403C
Figure5D
.1288delG
c.1998G
non-puromycin
Mb-tel
paediatric-type
GSK-3beta-interacting
30-90
∼158
P-GSK3αS21
881
af-
Vi11
pmaxGFP
oligodendroglioma-derived
Lynp56
40–66
1.44:1
.8.8.7
74103
M1124D
4.
hmC
Thirtyeight
Cardio-Facio-Cutaneous
.CT26
KIT/18s
elucidated.We
HCT116-derived
MutSaG162R
P798L
damage-response
LFS-causing
ASLK
8259del
pmiR-ABL1_3′UTR-Mut
melanoma.31
Posttranscriptional
agonist-switch
Nodal
sensitivity.11
P=0.19
22p
12q23.1
thelowest
0.0285
0.50**
α1,3-galactosyltransferase
39-4
realistically
anti-VEGFA
Con/shCon
FKBP12-based
proximal
G719C
Chlorambucil
.Stephens
post-incubated
Cotransfection
prolinerich
tobacco-related
ATP-requiring
MCNsWe
L−1
10.1007/s00439-008-0542-4
27.4:1
.S20
mutations/SH2
T529
Studiesf
Ryckaert
PTKIs
RAF-driven
SK-L3
19,20,21,22,23,24,25,26,27
demyelinating
Pertz
anti-PI3Kinase-p85
applicability
216/333
dark-®eld
H00002033-M01
Arg240
miR-155-5p
c.1177G
autocrine-produced
Garlisi
I0o
PF04691502
rocally
αRAG2−/−
Pem1-Ad2-GFP
54/M
Fanconia
microvessels
distance-PCR
.BTK
Fedratinib
C1orf4
partner-specific
08-522
CX8CX5CX3H
women.17
diagnosis.1
113.1
1−6.6LAMB3Laminin
delivery+IL-2
CTLAThr17
adverse-effect
three-amino
depurination
F1593S
positionlies
.GIST48
R243C
A_51_P220062
Phospho-SMAD1
'coldspots
anastomosis
CTAATG/gtaaga
subunit5
cells22-24
15213
9•30
c.1564A4G
L1764P
studies3,4
RG-4
748
p=0.0081
c.780_781insAGT
DLBCL13,14
amplification/deletion
U68161
C3H/1OTh/2
394G
Pulverer
KIT136
c.291-1G
.Schafer
3.07
c/Apaf1/caspase-9
imatinib-resistant/intolerant
group—the
Glu-45
mechanism107
cancers.27,30,33,34
38/38
DICER1
GG-NER
non-seminomatous
1998c
ACTGinsCAATAA
K2173
non-sequence-speci®c
E-box-like
//doi.org/10.1371/journal.pone.0032451.g002BCR-JAK2
Y463KD
4.4
ATRIP–ATR
C6orf97
tcacc
GGGGCAGGA
SCC-25
PTKC
DNA.27
C-CDK8
G71R
dispase
,19,20
Hicke
P415
747–753
disease‐associated
Wip1-deficient
A368D
disorders2
~13,000
abnormaliFigure
S17C
non-mesenchymal
Sox3
A11034
Jun-/-
time-PCR
CCDC6-RET-suppressed
HCR
DES-bound
DsRed
HER2kinase
non–cancer
EZH2-amplified
tumor.32
CpC-containing
Y220
control.Figure
shRNA-transduced
unusual.7,15
ATP‐binding
0.142
P=0.00417
CTL1
inactivation.20
p-loop
Mek
PLX47206
caspase-
R234Q
tubulovillous
PKCy
PAb246
levels.23
immune-compromised
spinoculation
nucleotide-sequencing
28/63
TrkB/BDNF
Trp-729
e2.1
M199del
MSH-free
D1181E
Stransky
26.0+
AIM-V
HA-positive
IBM/BCX
Rev-ACCACTTGCCCAAAGCAA
5,338
607,559
αGS2
vaginally
kinase-deleted
NR3C1
FOImelanoma
M410
GTGATCAAGCAGGCTGACTATGTG
housekeeping-type
stoichometrically
chr15_g.66729153T
WlldType
HODs—at
n=200
Al-Mulla
anti-FLIP
G171S
Thr–Glu–Tyr
Xenobiotic
.Strobl
p=0.029
better.View
BC-CUL-2
Ki11
GST-1α
TKI-258
5′-CTGAATGCCACTGAGAATGC-3′
spliceome
αvβ5-dependent
Nishikawa1
:2142–51
FLAG-
GATA1.05
0.0064
p.Y336N
c.2566T
In-depth
Lyssenko
.c.1494_1495dup
163–268
p300-1956
chondrocytes.3,4,5
pathways.11
INPP5E
EZN-3920
458,000
promonocytes
PMSA
transferase-positive
K/N-Ras
precipitating
.Transformed
7,26
daunorubicin
CA-genotypes
immunogold-labeled
Benedito
Mir-19a
Y1294
NSHLs
Glu-211
σ2a
somuis0
Lys506
gammaR1
H1083R
Msh2p-Msh6pcomplex
Li2l
MDS,4
pDMl0-1
neuronal
Szoka
.RUNX2
E1813
p=0.026
R988C.Met-H446
29,702,381C
oestrogendependent
Pbd
P=0.070
69061228
'homogeneously
2.464996233
T432K
hydroxylating
0.0446
serumstimulation
TP53-p300
24,28,29,35
Fredersdorf
extra-extra-long
2137
tumorigenesislikely
EZ-ChIP
GGAGTGCAGTATCTCTCCTCTCT
8/172
M13-reverse
Lineweaver-Burk
Growth/Viability
.C-II
5–40
SP6-1
Arg151
'inter'-molecular
pE3-C42
9–174
NT_011362
tumor27
F14
GSTNF1-R1391S
1732C
helicase/adenosine
35
q22-23
BICa
nitrocelluose
1018F
P=.05
YCE1086-1SB
control.Flow
1663G
c-myclq
1433
fluorescein-AggCCCAggACggCg-P
larger-sized
Bmpr2
RAC1F28L
2.24E08
iso-orotate
surg.med.kindai.ac.jp
-MUT12
Ig-II
con®rmation
recombination36
Ushiro
2FLU
06/06/09
YCpLG-myc-p110α-wt
S2.6.3
nonsteroids
rhodamine-goat
9.8–12.4
c.780delC
YDIpSQVFPF
EEF1A1
rad50coils
1.2-fold
B-DNA
Rosa-Rosa
Cbl-overexpressing
~-galactosidase
U14860.1
TSC2-null
763
study.43SUGGESTED
c.409dup
DNA-fragment
GSK-3β2
CH11
Bigdye
dPTEN
Glomset
PTH-Cre-negative–Z
SP-IHC
GAB2
65-5
node-positive
Targetability
35-mm
anoncogene
0.23–1
PAM250
.4,17,18
244F9
GMI
2:2:2
complex,8
PA2
c.1961C
G80V
chr3:178932477-178939690
pBabe-based
Bead-level
CEP110-5′
Asp59-Met157
Mastermix
p.N375S
0.86-1.27
49/600
software37
CACGACGTTGTAAAACGAC3
.Chimeras
autoradio-graphed
K196T
D13S263
SB590885
neurofibromas.14
+2137
MSH2from
MLL.5
spinal/skeletal
Rab5.14,15
5306
breakpoints.29
BlottingIn
Hauschild
Anthracyclines
5/23
AlamarBlue
Br41
1,646–1,858
L771Lb
p53/BARD1/CstF-associated
8.3μL
pp6OSrc
cetuximab10
studies13
CTNNB1-driven
C/T
transmbembrane
rofibromin31
1-12
SYBR-green
P=0.47
CTB-171P15
erlotinib.25
ofinsertion
Shp2hep
I26N
conditionsemployed
1R01
.PflM
sub-clones
121–150
c-ERG
SWO-38
kinases.29
75C
rheb.8,9
DDX3X/beta-catenin
C788
confered
291–300
R‐1B/L17
ALCL
Genepharma
cells/mil
B220+CD43+CD19−
ALLN
R259Q
giant-sized
God
=-
1022G
D9S287
516K
outcome.41
.Seong
Ala43
prognosis.8,9
wa2/wa2
PhC151
.002Nonsmokers
//dx.doi.org/10.1136/jclinpath-2012-201345
5′-GCTGTGTCTGAACATCAGCTACT-3′
12-43
0.01548
MPL-K39N
transformation.1,16
C3orf20
C–E
5′-TGTAAAACGGCCAGT-3′
~2I
cells.7
0.45-μm-pore-size
1614
LC-Red640-TCATTATCTGAGGAGCCGGTCACCT-P
lanelevel
4E-BP
21/82
behaviourally
transcription-mediating
ZPSI
C21
cytometry-based
15.58
1.433
crystallographically-observed
pressures.12
rutuximab
François
-32P
.Starting
EGAS00001000447
cavity/the
ΔPEST
phosphatylinositol
Basecaller
12023
thousand-fold
.D842V
Apc
L983F
YUROB
therapies1–3
MassaguÃ©
PRDX1
VMELVQGGDFL
25–40
macrometastatic
C/EBPα−/−
sanger.ac.uk/genetics/CGP/cosmic
approx12
25000
MY-LA
FLAG-wtRhoA
800-μl
SOCS3-ΔBox
.-U
donuclease
analyses15
pT4bN1bM1
Skp
TRE-U2-ACGCTCACGAATTCAGTCCCAGGG
S/G2
gi67972282
GF07
IL-6-responsive
LMV
UBTF
Karpas620
disappearance
GST-S6
240/244
C145
Biotechnol
.HRP-conjugated
multi-ring
Assays—For
QIAxcel
GNAQ-Q209L
0·09
DDIT3/CHOP
.AML-1
NSCb
IPI-matched
-3T3
G1–G3
q.
3331S
Elfilali
313–367
anti-phospho-Stat5
Y414C
site.40
175Cys
aneuploidy.14
.Robust
CBL-directed
Phospho-PKB
asGal
activation.29
by0.1
.Gene
p-values
Peprotech
anti.Akt-CT
FoxA1-low
Brezin
​Full
microarrays.nki.nl
DDR1e
CD45RA+
369–443
ÃŸ-cateninmonoclonal
autophagosomes
Br37-Mel40
BCG
HLA-A2+
Dose-limiting
.Sadovnik
μU
p.T670K
ataxia-telangiectasia-like
NCT00488150
Vitolo
CellNTec
confluence-induced
.Sobrinho-Simões
L179F
.Binary
Ctgf
T→I
Rogakou
RP23
Traditionally
.Location
coumadin
Adachi
gene/chromosome
literature.25
JunAA/JunAA
bp/helical
V617JAK2-positive
Kadonaga
IGF-I1R
BamHI/Not
Neo-deleted
Tolstykh
Spivak
paraffin-based
vWA
murineCep110
inflammation20
1193G
GFP-trapped
acetate-induced
activity.63
p.Q56
g_mdmat
21–40
r2003
X87838
bax25
two-compartment
protein/cell
gbU13875.1
'H-'5N
www.urogene.org/methprimer/index1.html
genome-sequenced
1N6L
A232D
embryos/animals
4.9
MPN-associated
.0069*
274–278
assayColony-forming
v8
30–80
SV-
7-nitrobenz-2-oxa-l,3-diazol-4-yl
Myc-null
assayAmino
.Agar
low-melting-temperature
spectroscopy–based
activity.46,47
alteration4
WT-ALK
//www.broadinstitute.org/cancer/cga/mutect
B50
Stanglmaier
Suz12
22-3
phospho-mimicking
2007–1007
Bcl-6.9
FASTACT-2
retrorsine-treated
sc-481
ZDHHC18
RASY71H
TRK-C
MEKDEKVRENS-RMINLIKEKELTVSEIESSLT-QKQNIDDSIRSKRENINDIDS
13R
LeuGluGl
2439
­confirmed
Smad2-negative
nonresponsiveness
antivinculin
CytoSpin
E9.5-10.5d
271
tttctttag
described47
D258
D594ABraf
1–76
JCML41
.6679C
Habour
CDK/CCN
TGEN
.DMR1
antiandrogen-induced
T790M-selective
21.47
G13F
ΔC1
pCDF1-MCS2-EF1-Puro
Kulaeva
NVP-LDE225
16/22
K.R.IdentificationofCDK4sequencesinvolvedincyclin
1:3
5′-GGCCGCTCATAATTATTGTTGGTT-3′
Saci
J.Q
0L
.Di
AMELY
ASPSCR1-TFE3
po0.0001
Five-hundred
factors41,42
1•1
n=0/9
EBMNAI
15/19
mid-1990s
5′-TTGAACCAGGCGGCTGCGGA-3′
1.3–91.9
Pik3caH1047RPtendel/WT
autoinhibition
transactivation/inhibitory
9541
P86N
A1671
T-ALL–derived
contraceptive
PI3K/PKB
MMTVpA3LUC
non‐identical
10.7/15.3
F1141
1536–1542Meshinchi
21•22
export.15
CT-402-4001
RTW
4132
Y.Z.
B-RafEVKD
GS-expressing
l-KIAA1549
.Harvest
GSE12992
EGFP-TEV-B56δ
myc-WT
3.66
Asn-131
Stennard
treatment,14
.Radiological
V263G
202K
FoxA1-inhibited
caccatggggagcagcaagag
–ALK—as
MYC-simple
and44
PharmDx
antibiotic-containing
CRISPR-Cas9
1860
TCCc
p21/CDK-interacting
vitro.22
homodimerization19
N612Q.H
MPN.6–10
important4
H3k4me3
p2335A
Redon1–3
FADD/MORT1-mediated
samples14
enzyme-conjugated
D438Y
PpuMI-reverse
type.Full
ggatctggag
Fluor488-conjugated
MKK1/2
III10
.STK15
G90S
protein.19-21
factors.
005898
WT1-binding
complex72
PrCa
NM_000267.1-8627s1c1
suppression.10,11
retroviruses31
J.-Y.S.
signaling—such
variants137
16T
GTGTACAAGGCATGCGATCCCCACAG
5′-AGTCCAGGAAGCTCCGAGGACTCTGATGTGGAAATGGTG
.Computational
CCND2
G576D
co-bound
Dnmt3
populations.8
Agonist-bound
genotype-specific
RXA2-fluorescence
type,5
.Somatically
protocol.Independent
STS-based
9.16
attB-attP
cep7
Pro1749
.Grades
Cycloheximide
FRG1B
EGFR/ERBB3
StudiesExponentially
MB8
43-46
pFA-Elk1
retransplanted
DUSP12
assays,44,45
R671Q
p53-binding
activity20,33
BACH1-mediated
P208S
H69
13q22
.Geographic
C190S
E339
1,191
TableSanger
//www.hgvd.genome.med.kyoto-u.ac.jp/
variation6
5′-TTCCATGGGAAGGTTCGTACA-3′
solid/micropapillary
236-255
Population-level
N265I
∼550
D18S69
Gp70-H2Ld
Δ1–108/E545K
5′-TGAGCTGTTCCTCTGGCA-3′
5′-ccttgccgtcccaagcaatggatgat-3′
GFP/Ly-5.1
responses86
p.Q215K
SVS5
c.8754+3G
​Here
underepresentation
.Globally
Lys119
analysisfor
.18,21
IC050
C341
TERF1-interacting
_hg18_
homology-deduced
6A1
463
never-smokers.11-13
EPHX2
1.6–58.4
K4011
aswhite
MF20
5′-CATTGCCAGCCATCACAGTGAC-3′
ap‑
H4K20me2
2701
scirrhous-type
R1493W
nanodisc-conjugated
plates/treatment
cancer.73
vumarray
Wnt3a-deficient
−0.04
tumor31
.Specificsized
LANCL2-SEPT14
TGGAACGTACCCCATTCAGT
16.8–42.4
cancer,27
S2.3
tTransformed
0.75uM
.Geneticand
NM_016418
SU4984
6.5-mo-old
hemorrahgic
5/16
patients.8
×18
Supple­mentary
2XP2
described53
-TGGATGGAGCTGAAATTTTAGTCTGCACCACCAGCTCCTC-3
IL-31
Nazaryan
drop-out
.B16-F1
Tsc1fl/mut
.SNAIL1-induced
Foxg1-Cre
INPC
MiGR1-ERBB2
thespeci®city
D1045
xenografts14
AC-74
cell-types
neovasculature
Mcm6
phospho-Tyr1062RET
p.1lel8Vala
EGFR-KDD-transformed
491
bidpo
compressible
rigin
epifluorescence
.Blocks
2logfold
GAGGT
dysregulate
posttranscriptionally
GAMG
SVZ-C
P316T
IL1beta
fgfr1at3R705H
I11-2
.ΔNMEK1
family,37
ACVR1Q207D
NHERFs
.1403T
family.17
1764
toD
R226X
.Ancillary
assay.Interestingly
pathways.34
132±87
beta-receptor
DCCMs
5′-CGGGATCCACCTGTGCCAAGG-3′
Kopra
R748P
888–1249
n=293
10.7–11.0
NBPF10
J-774
phalloidin-Oregon
rs1466445
tetraspanin
277
pTaG1/G2
ETS-family
Asp435
ATP-hydrolysis
mucosa-associated
super-induction
5'-p-fluorosulfonylbenzoyladenosine
71175
CCT-assisted
dutasteride
RUNX1-25F
.Evasion
95.2
5341T
multi-tumor
0.352
JDP
510–514
HBV-infected
5′-TGCCCCTGACAACATAGATGGAATCACTCATGATATC-3′
Multiscan
1–19
novo_
pre-requisite
Eurogentec
4.04
.SAS
Chelix
5′-catcaccatgccactttcccttgt-3′
BTRC
0.0472
BMP-2
Bax-luc
-GCGTGGGAGGCTCTCTGCATGGATGAGCAAGGAC-3
13/16
RAC1/RAC2
avidin-blocking
GG-3′
3+ifosfamide
+chemo
NB4-R2
SAPS1
.09
ZNF700
mHEI8GF
fluorescein
ima-tinib.38,39
NF861-
−2.7
.Ubiquitylated
537F
LVS
'looping
fusion‐driven
M1149T
EGFR-derived
Ab-17
CARMA1
PDGF-A/C
10247528
MacVector
cancer.42
XXLαs-R844H
threonine-serine
5′-ATGTAATACGAC
2-type
18022
whenoverexpressed
1A–1D
incorporatedinto
slowing-down
CSMD2
-BRCA2
RegistryCologne/Bonn
martin.dreyling
autophagosome
vitro.29
Birindelli
GGAAGCCCAGCCATTTCTA
KpnI-ClaI-digested
XPCS1/2BA
5′SPARC/5q33
CASPASE-8β
nihms646437t17.jpg
INC.
ney
preheating
CBFL
autophagy–lysosome
pMEGIX-GFP
F691L-AL
EGFR.Tumors
phase.2
190.3
VNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCERTLKYFL
KRAS/ALK
deletion.25,26
NICD–Rbp-j
.470T4C
MYC/Ig
32–56
Flag-ETS2
.SV40
-YYRVGGRT
enthalpy
mD814V
Sednterp
XTT-assays
mouse-human
p13
ab85893
63••
HA-high
4.08
c.2768T4A
polyvinylidiene
222.00KB
E526Q/Smad4
nonmethyl
cytokine–cytokine
delAsn771insGlyPhe
24–51
mTORC2-independent
EpCAM
R1448C
C447
pCSK-LacZ
//umr976.simdif.com/team_2__n__dumaz.html
biotin-16–2-
FBXW7-shRNA
33433487
//www.cbrc.jp/research/db
Nexins
ERBB2-overexpressing
shL5
staining–positive
PinDel6
p13.3
Mll3/Mll4
138-736
complex-karyotype
MPL-P106L
library39
Vav-Cre+Srsf2+/+
Microretrognathism/PierreRobin
cebpa
MAPQ
YPDA++
10Département
D341MED,26
1538del4
TGATCCTAGTACCTT
ZFHX4
HQPA
concentrations8
CSF1/M-CSF
0.064
conformation.9
promise40
HMLEs
.Disruption
shRNA-3
.predicts
Gietz
75-min
grou
intraerythrocytic
PIK3CAare
.Brattain
SMAC
non-membrane
Low-activity
dorsal-ventral
1997b,1998,1999
-promoter
IGHV4-34-
S2
p.Asn1403His
S218L
ctggtcattttgagatgcttgcaat
IMG-5019A-1
microscope.Confocal
Deep-Sequencing
Delatre
PDGFRA-targeting
Xq28
inmismatch
3·4
8787
1.424
Tween-20/TBS
hPMS1
visualizations
gi:37360980
ERG,26
Val559Asp
0.994
Asp842
Mlh1
gpl10Pro
the6
G776VC
KRAS-mutant-positive
p27CK−/T198V
Andreasson
FoxG1
DI=1.43
delTYD
X5R
genomon.hgc.jp
CD48-PE
domain11,12
Dalerba
Map2k2−/−
nonclefted
PANC-10-05
454-sequencing
FAM114A2–BRAF
H82N
NM_026840
129-131
Y125H
.Shq1p
TNFα-treated
1,488
.CSVDisplay
isoforms.5
mJAK1
Ras/MAPK
3,112
described.58
c–h
1450529994118798
TEL-PDGF
M257
____________________++
AKR1C1
'luminal
GTPboundp21
Phospho-STAT3
p16-156R
.Changing
disease.33–35
activities.13
rate33
PMF–
.MN1
4f~
ARHGDIA16
.List
-PCR-sequencing
Maurici
318-6-11
ROSA26-M2+/−
1,180
R758Q
Eble
HBEC3KT
Trr/MLL3/4-independent
P=0.0067
0.4g
R1589P
Hesseling
3Institute
MSCV-HoxA9
taatag/CAAATG
kataegis
togenerate
circular-binary-segmented
delE161
Y450N
GH-releasing
forward7,20,21
unrecognizable
CMOP
adenenocarcinoma
GFP-NUT
HA–SnoN
Interstrand
15/89
subdiploid
UACC-893
HPV-specific
c-KIT-coding
miR-451/Let-7d-5p
hepatocytes.G
survivin,46
0.339
CIITA-Luc
0006-291X/99
DMIKKɛ
c.6delG
775–777Cairoli
RASWT
intravenously
Predilute
MetfsX17
well-accepted
33,36,38
—or
T24A
IgH-MMSET
5.67
TDG-depleted
Chakroun
8/33
251–257
KSA
analysisCell
.Transcriptionally
dimerization/DNA-binding
T334I
4f38
53–88
An60
D720
analysis/Transcript
2-butanol
L/H
anti-phospho-active-Akt
1CRR
.SHP
Glu767
remodelling128
p.Ala40Glu
F876L/T877A-
G-*A
Glu-Glu-tagged
co-occupying
unv
anism
survival32
E2Fs7
14/288
0.494
70,71
MPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLS-
pSRalpha-AR
GGAAATAAACACAAAGAGAATCCTAC
ofBdF3
≈400
GeneRead
0.35×10−4
cases5
0.20-0.78
enhancers41,42
2.362
.BTK-KD/B43
490_779del
g/d
Subpopulations
10–18
guidelines.6
pmCit-N-rasC51Y
N62S
HEK293A
RSEQtools
Met160→Val160
3639
factor-a
–50
Urist
Gariboldi
hairpin-resistant
LSDB
GGATCCTAATACGACTCACTATAGGGAGACCACCATGGTTGAGGACTTTGTCATGAT
9.59
GIMP†
~95
PolySciences
G912R
5mMMgCl2
300–310
Lenzen
back-flowed
INTERSTITIAL
system-specific
GST-FANCG480
non-nullmutant
anti-GAL4
1333R
BT54
pGC-2
androgen-ablation
c.476−2A
ligation-assisted
IGFRI7
data.24
KIAA0892
1BG1.pdb
WASF2–FGR
SUP-M2-TS
44/220
Bcl-x
largestknown
Lys-147-*GluS17
Morimatsu
COL3A1+/-
ATS2
NCI-H1173
system93
1d–i
SNON
GTBP
E318K
-GGTGCCTGGAAGTAGATGCT-3
0.0049
recurred
substrate/kinase
well-duplexed
.Histopathology
E1B-Luc
Retrovirally
3999
NLS-deficient
FLT3D835/836
AITL-specific
G12V-
melanoma81
205/250
h30.914
50C
0.00125
arestill
acetonide
linsitinib
lossof-function
Cornolti
QMCEAPVVTREWVLDSVALYQCQELDTYLIPQIPHSHY
G442E
FLT3.58
GACTACTACCAAGTT
8541â
-ACAGGCCTCGCAGGGTGTAG-3
3183
sitravatinib
Papkoff
osteoblastoma
38,000
YSI-Copper-His
G574S
causep53-independent
sequence—siHIF-2α
MDS1/Evi1.43
p53-positive
Shp2E76K-expressing
E-cadherin20
solvent-treated
RAS-dependent
R778L
46+A249
DN2R
tethers
head-position
5.58
.Lys117Asn
androstenedionc
AP3B1
60522601–60564900
panitumumab-containing
NELL1
.1984
GATA3-binding
MEL202
25/507
doi:10.1007/s10689-010-9372-3
Proangiogenic
581A
K20A
C_932_D_12
.Impairing
.TD
modulatedby
33-kDa
BRAF-inhibitors
202–204,10
DPPIV−/−
Prves
p.N263T
2Aiii
DNA-motor
V282
Double-digit
tein–protein
Screen®
Annariikka
ÃŸ-ctileninmutatinns
Pro124
GGAGCGCCGCCTGGAG
836,791
P307840
demethylases
iGFP
3p26.3
BVD-523
scatter–high
anti–CTLA-4
Bcl2-mediated
p.Ci/ml/33-mm
acid/1
HEK239A
methods.6,9
P=2.8×10−19
164/178
15–74
NDA
LOWESS
5′-GGGTGCAGCGAACTTTATTGATGG-3′
base64
.Reversal
L191H
disease.108
CARD11-mediated
transduction.38–45
bPredictions
91.6
Ile326
K171_R306del
NGS-predicted
2.5-6.2-fold
redistributing
p53-V143A
pleiotrophin
NaCl.For
GABPA-
vector-mediated
20μL
-10,13q
radiation/temozolomide
E1317
I/HindIII
alterations-
.Chi-square
A4573
c.890C
0-250
absolute.Previously
PDGFR-rearranged
S5L-M
73-year-old
.TGFBR1
._2174+
.FGFR2-mutant
AmpFlSTR®
Merlin-DCAF1
11aR
nononcogene
G719X
Pericyte-coverage
ERCC2–complemented
0.5758
.method
SRO1-SRO3
E346K
Kubbutat
.Muta
NGF-mediated
RING1B-mediated
pg/kg
Ostrander
391/291
-benzene-sulfonyl
kinases39
homodimer
alr25N
ACCCGGGTCC
nondysplastic
capicua
GFP–VHL160
ΔS222
premotor
NUMB-PRRL
.3F
ARSH4
twohealthy
TTGGGGA
HBCx-3
.NCOA2
.Group-specific
HAP
Sequenceanalysis
RGS.His
1,688
.TOPflash
T315
32:389–399
Browd17
BRAF49
CLDN18–ARHGAP
Asp-538
activity20,21
.Multinucleated
97.20
KRIBB-AEC-14024
22q13
=Non-conserved
8–48
.7235G
NKX3.1
44-20-7153-5510
.Wee
Burtani
receptors.54
δN-IκBα
LPU015
I21V
687delT
tissue‐specific
intrachromosomal
complex-specific
melanoma.12,13
5′-UUGUCUACCUUCUCGGUCACACUCA-3′
umol
PCR-validated
5-CCACAGACGCACAGGATTCTAAGTC-3
.Dimers
Anti–insulin
12-14,16
NQRVGTKRYMAPEVLDI
21–24
zsgreen
fractionation
amino-lobe
KCNQ1
M7240
mutations/patient
ice-filled
NIH-OVCAR3
66A-B
.0128115
0/56
fomed
S406N
759–769
Lgr5CreER
pathways.55
aforementioned
SSC/0.1
MBIP
multiplatform
Me14
ablation-independent
V1206
Stein
heparin-induced
myofibroma/infantile
Sox17-positive
patients.19–27
5′-CAAACATGATCTGGGTCATCTTCTC-3′
progression.5
Lys656
pGA-MTS1/ΔΔ52−144,1
hsp90
SKY-FISH
Smad2–TGF‐β
Serine118
0.419
.Rearrangements
RNF8/RNF168
1399
pTM898-neo-KPβ
5′-ACGTGGCCGAGAATTTCACC-3′
Tbx3
3.067
IGsequences.20
Wiskott—Aldrich
Parvalbumin
∼1250
JAK-STAT
.BCR–JAK2
non-duplicated
1.51–7.80
.provocative
CCDC6-RET-positive
PanIN/PDAC
PRa
J.Gilbert
TGG-3
40K
80-160
pTRIPZ-SRSF2
double-fusion
AS.
Moscatelli
0.813
90–95
Medicine/
HEMIZYGOUS
disease33
1.411
ELP4
3OOI.pdb
4018
o.59
Ets2ΔN331
Zeosin
GGGCG
661W
p53-inactive
5.5.11
35-37
J.W.C.
.5F5F
ER13
PDGFRA-MT
HSC7E162
p.Tyr506Leufs*13
Universitat
Yap/
1op
non-prostatic
NrasLSL-G12D
purple\
-CGA
NHA9-bound
loss-induced
V3–V4
interleukin-3–independent
1052G
Osm
Lennartsson
4.85
2600
5′-GGGACTGTCCAAATGCTTA-3′
1q31
Hybridization—In
10.1159
L320G
5′-TCCAAGAGGCATACTCCTCATAGG-3′
ACAT
//bioinfo-out.curie.fr/projects/freec/
GGATGCAGGGATGATGTTC-3′
CFX384
5D-5F
Evi1-IG
0.610
Folpe
5VUTR
sc-59
EB1-related
5′-CCTTCCCTGGAA-ctggga-ATAGTGGGTGAGATAGTG-3′
FOXO4-
c-Cbl-associated
Tashiro
NF-IL3
mutations/tumor
23.4
RP11-91O21
tetranucleotide
ofmammalian
vitrification
FL-Conductin
Xplor
–61
SULF2
Gefitinib-Treated
EWS-FLI1
MASC
.Noncavitated
H3K27methylation
D1031N
1027
polymerized
cells…
Hypersensitive
ANK/CSL/MAML‐1/DNA
918-fold
multipoint
pMMP-FAG
detrimental.16
digoxigenin-11-dUTP
KIT-mutation
p.P577–D579del
gaggtacagattgcccgaaag
Immunohistochemically
972-8-9342696
93-133
BaF3-N/A
R612
2JAM
​Analyses
phospho-Shp2
ofa
.could
PLCB1
7q33–q34
dideoxy-sequencing
gpll0Proto
choreoathetosis
UniRef90
survival.2
CDYL
SPOP-ΔBTB-expressing
3A3A
phosphocellulose
.3.0-
FGFR1-3F-2P
sequencingwith
0.1230
22.3
5′-CCCCAAGTGTACCAGGACAG-3′
rs2981578
wereligated
lmost
1089
four-color
anti-C-terminal
14·3
A506T
ILVGENL-
I117N
PrDOS
=no
thecore
499C
Glu-31
D15S1007
kinase.38Moreover
Dup2P
Ghetu
ProR
3.2–13.1
-TTGCTGGGAGTTGTGAATGCT-3
Smad-mediated
CFU-S8
compli
SerS11
101•10
extra-3q
1342
microcancer
hotspot,14,15,32,33
anti–phospho-Akt
-J
Substrate-binding
.2008.057943
05–101
KIT-D816V-positive/AML1-ETO-positive
lines21
tumors12
25.14
42,790,756
filling-in
FHL-induced
Froguel
model.117
1447–1452
R277X
DLCL.74
Asp-406
HLA-
TableTable1.1
vectorswas
548G
5′-GTAGGTGGACCCTAGCTTT-3′
atomic-level
Figure3F
Brain
Mec1
gadolinium
hME
ΨKXE/D
shNKX3.1
G1138A
cell–cell
3Q4U
5′-GGGGGATCCCGGGTACCTGGTACTGATTATGGC-3′
c.94+7G
times80
extract-treated
MDS1/Evi1
inhibitors.Figure
Basham
p=0.025
303/304
1.41–
R1021W
AGY28
red.DiscussionThe
486.9
K650N
2J6M
p-BTK
ResultsTable
binding.37
L3loop
6•2–7•0
,3F
F1-R2
lineages60
K259/A
591.5
NSL2
KIF15
Elemento
L1201R
ccc
Histogene
L168S
SUPM2AR500B
Propagermanium
26121818
Lyn,50
0.3462
Orita
3398
1856
MAPK8I1
47.62
BAF250B
5α-reduced
1.32-2.68
956
ACK2
CATCAGTTTGCCAGTTGTGC
DeltaG
Src-dependent
transformationin
37-5
receptor14
Mre11/Rad51/Nbs1
.Schubbert
proliferation.69
C57BL
Cytoplasmic/perinuclear
.PDGFR-α
Br48
M1652K
347:481–487.These
anti-Ly6G–FITC
1.078-63.881
bax
mouse-trap
anti-whole-Mek1/2
NCT01775930
.Wolkenstein
23–28
MIG-Bcr-AblY253H
Q64L
Cimbora
+701
.Bishop
GAATCCGATGTCCCCAGCACA
0.660
functions.29
NFKPSPSKNKGMFPGFK
versionU41206.1
sub-libraries
GAPDH
ofvalue
Tip60-
3q11-12
CAAGAGATGGCCACGGCTGCT
V316D
30–20
Loss-
`empty
TGFBR2-rGADL1
exit.9
HIS-tag
C45Y
samples.Data
Cellstar
20–32
.Haploid-Conversion
GVHD
pC53-SN3-R249S
14.75
1987§
XXI
TNF-related
wtBRIP1-pcDNA3.1/MycHis
c.4759G
c.211A
.BLAST
G1408R
3V04
12.36
S742
0/37b
GTGAAGATCTGTCTGGCTTTA
48•
preinitiation
5′-CCTGATCGAGAAACCACAACCT-3′
G172D
CreERT2-mediated
perMb
ATP-Binding
.22a
L858Q
5′-TAGAAGGCACAGTCGAGG-3′
diseases3,4,5,16,18
.52,53
half-maximal
oncogenes.82
Honoraria
E2423G
Thermo
15/27
PMTV
WIDR
1276
resolved.3
UPD
Y155C
Her4
observed34
ARF–MDM2
homodimer25,26
leiomyomas.3
cancer–like
5.5.8
5′-ccgctactacgccatgatgatcctcaagaaggaag-3′
.Homozygousdeletionswithinhumanchromosome
α-helix5
anti-BAF47
dose-reductions
immunoglobulin.2,3
nonresectable
purvalanol
ofROSI
5.5amp
0.822–0.937
.Treatment-Related
KAAD-Cyc
ubiquitin–protein
Renkonen
8q24
hypopituitarism
values42
tissuespecific
Macroscopic
Nonidert
MEN-causing
78-nucleotide
anti-p-MEK1/2
Tyr-1234/1235
cancers.4
M.C.D.
3p12–p14
.Arg1004
Mgat4a/b
Epitope
c.533A
LY3009120-induced
Pab1620
andCHEK2H371Y
drugtreated
defective/sucrose
pPSH
seconds/cycle
HOXB3
IDH1mut-transduced
Blacklow
wild-typeWT1
metastatis
p.Gln573
independence.16
Chamber13
PI3K1
9/22/98
anti-IgD-FITC
gefitinib/PF2341066
shortlisted
-l7
gefitinib.16
500–508
COL4A5-COL4A6
TEL-EVI1
54b-llwd
D1238H
11827
NSYGQQS
melanoma.5PTKs
5′-GAGGTTCAGAGCCATGGACC-3′
/Tβ
1226R
264.7
3/10
AU-rich
disease9–14
disease,2
V5-tag
Oncotator
.Clonal
0.02–P
1240delCter375
yph-p21
tumour-suppressing
52°
CHIR265
p.787A
CIC-DUX4–positive
SNF2/SWI
9*
MEF2B2
tTR-shRNA
years.2,3
A4F
non–Ph-like
K509I
variance-fixed
474
consensus-like
Colo829
plastica
FIMO
68-fold
rs304269
MEGAscript
10/0.30
S3.Expression
/Mort-1
Carboplatin/gemcitabine
PU9
Physiologically
SRO
α1
MDN
HCC14-0910
252K
8Université
lower-expression
c.605G
TRAF2
c.7807G
GRB7
146.9/128.8
intramuscular
S2lists
L430F
Twiddy
ab5535
FOXP2
50KB
Bardet-Biedel
≤0.0005
p=0.0255
8.955-1495.680
p53tet
amplification,24
//www.dsmz.de
sterility.125
VC+siROR1
FLT3/D835Ymice
P151S
Zea
co-IPed
Marqueurs
.DLC1
Gli
5'-CACACCCAGCAATACGAA-3
Tgfβ1
mRNAbinding
B130018P07
sites16
classiWed
glycated
Zauberman
IgG-PE
Feitelson
0.237
​fig1
NM_183417
rs66944506
Hot-start
differentiation-matched
FIAU
P199A
S-methionine
One-way
.8755
14001A
Mx3000P
stricter
populations,3
c.485G
pathway,4
cryo-protectant
.TERT
NCT00949702
42517
FGFR8+
mutants29
29–69
R=−0.04
KITV560D
c-KIT
-regulated
byATP
.De
α-Trx
5′–CATTCATGCGTCTTCACCTG-3′
12/12
.D14S72
NHI
hom3-10
74.91
Beveren
MSH6-MSH2-DNA-ADP
exo1
.0361
.Advanced
chemosensitivities
URE
2−4
GST-pulldown
chromoplectic
Restaging
PHGDH
Ret10F
Sumoylation
D835EF
ammatory
14q34–24
tEGFR
N.H.
.Neurofibromatosis
L862Y
1.64–6.07
RAD21T12TP53
abil‑
ELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSD
TRK-T3oncogene
Jak3-Stat3
exome/low
E4TF1A
Attribution-NonCommercial-NoDerivs
.GATA-3-infected
MAPK/ERK1/2
pEGFP-N1-EGFR
environment-related
Gloyn
rs143479220
80S
BMP-Smad1/5
FGFR4-silenced
pBluescriptR
CAAGGACAAGGTGTACAGTTATGTGACT
PI3K/Akt/GSK3β
carriers.MATERIALS
CAATTGCCAGTTAACGTCTTCCTT
.Detached
PRDM1.E2.1.F
.TABLE
p.Tyr1853X
35,58
Qiaprep
GSE10196
Shalloway
Dicer1fl/+
Trunzer
c-Myc-driven
,5
mERÃŸ-Y443F
A®fth
I20
Mm768bp-LacZ
R217T
14.8
.Early-onset
p21rai
Multiscreen
.Finn
BLIMP-1β
Drug-related
cross-institutional
.S16C
T28
928mel
CTD-2057D4
NfJ+I+
NF-κBin
.HCV29
IL-4R
sc-376257
ASPC-1
5′-CTTCCACCCAGATTTCAATTC-3′
Dyslipidemiab
Rappaprt
TKI-Induced
MYPT1
TnfaΔPdx
mbr
1.056
Msh2G759E/Δ
CTD-3184H13
J04102
phosphate–
BAT-1OA
transformation.27,32
ROS1-rearranged
397–412
FACScan
–AKT
NM_010288
G114R
discriminativity
MTC2
larva
v63
group26
pET-MTS1
.Images
TFactS
876KB
Phalloidin
­doubled
Sprr2f-Sox17
.Confluent
TGAAGGAGGATGAGCCTGACC
RP11-59H1.Karyotypes
progression156
116/746
lines41,42
4/37
Arg117
PRB-432C
capaa
.KEAP1
000–62
S15Q
net-like
.D769Y
c.1139T
pTRE-Hyg
Y204C
5'-GATCCTCGAGAGACCTGCCCGGGCAAGCCTCTCGAG-
Kisker
method7
method76
SOR
SH2-binders
76°C
6/exon
PAIS/MAIS
factor/lymphocyte
mice.DiscussionWe
RalGEF
.Hematoxilin/eosin
=A
Arylsulfonamide
described51
Merbl
Spo11-DNA
–ataxia
MYST1
0.338
E36A
ΔF-β-TrCP
a15
L783
activation.25
≤G2
LMO2.1
Rheb-Y35N
photosensitizer
39-fold
1.07∼2.34
d.IF
hypomelanotic
II1-7
1–3
BSA-C
phosphorylation172
E730X
COL3
neuritecarrying
4ÃŸ
D13MIT139-R:5′TTGTTTGTTTGTTTGAAGTAGAACG
NCT00180921
C135
Phe-1704
0•045
94/100
KIM_WT1_TARGETS_UP
CUPSAT
Chk2-deficient
AmbionX
38.2
Y32W-Q61H
intra-observer
7636
1K79
progressions/salvage
1359
.004‡
activated-tumors
scholastic
Asp569
8q24.13
Ptchþ/
5646
noninterventional
tumor.14
ZBTB16
D3S3691
HOXD13
25,235
SI04194498
65°
STL,14
9B
68/73
M-C.
Small-molecule–based
5′-AGGTCAGGTTTCACACCG-3′
BRCA2.10
F1092
melanocytes8
GLUT4
signal.Interest
PTK
FJK-16S
p53-trimer
7–2
cytokine–RTK-III
corticosteroid-binding
13.88±0.40
TGFBR1-null
1.5-3.0-fold
Wild-Type
VHL-TRiC
non-significantly
W210C
cancertopics
kindred12
≈0.3
Y251H
HT-1197
trialed
anti-phospho-ERK1
I665N
-GGGGCTGTACTGCTTAACCAG-30
Notch-4
Istruzione
≈22-kb
higher-stringency
GFP–VHL213
hinge/linker
optionsThe
K111N
E-cadharin
——V
Lowinger
VEGFE
Crtc1-nuclear
1.10−5
e006
8f
K232E
Schemat
PC-3
0.971
phospho-FRS2
neurite-like
AACCATTCAACATTTTTAACCC
R-*T
Keshelava
.Seventy
Miz
B.G.N.
Supescript
above33
PARP-dependent
.Val133
pathway22
.TCF
niclosamide
59-ATTCCACAGAAGCGCTATGC-39
.Bracket
non–phoshorylated
p.Asn127Ser+p.Ala328Pro
oxo
RAD51C,19
5,6,8
B220-IgM–positive
5-AGGGACACACTGGGAAACAG-3
Rac–GTP
CUL3–BAZF
sternal
`hot-spot'p53
pGreenpuro
E211D
a-phosphoryl
p.Ala1685Ser
FHA–SCD
1.01We
flavination
M2M
expected7,11
Matrigel™
2.0-kilobase
reported100
mannose-6-phosphate
R337Q
5′-TGGAGGAAGTGGAAGTCGAG-3′
P-β-cateninS33/37/T41
sheet-containing
tetracycline-like
TPPPEPET
RELEELNVPGEIVESLSSSEESITR
RT-PCR–SSCP
wildtypeactivity
androgen-sensitive
W78B2
pany
Kd=1.1
72-h.p.f
splicing/processing
Stratagenc
56.4
39.94
heterochromatic
Trypsinized
SHCLNV-NM
sh3
mice.n
IGHtranscriptional
9p21.3
Lüscher1
c.199G
properties10
Gershtein
0.978
K108T
I252T-Fw
min/58°C
non-triple
R386P
nonhaematopoietic
Genotype‐phenotype
80.27
RGQ
ttt
protein.34,35
5/119
Rad51d-null
BglII-BamHI
ANAES
pRC/CMV
crosschecked
Pro34
c.131C4T
DTT/bromophenol
before.18
Nephrotic
mice13,15,16,17
intergenerational
reverse—2
KITD816H/Y/N/V
involved.It
multi-polar
vitro/animal
c.2168C
adenocarcinoma117
remission.12,13
2,974/7.2
cAMP–signaling
PGL5
1419
R445H
Iolascon
c.3770_3771delAG
inhibitor37
mice91
mid-parental
.Oncogene
Co‐immunoprecipitation
delivery28
2++
Hes4
PD/PR
U2AF
/relapse-free
ALL1
vasculitis.26
SFRP4
genomes23
N4002S
.Tumor-associated
P780-Y781insertionGSP
Frasor
ml/dish
Asn45
TACC3ex11-RV
TNXB
Cullin-3/RBX-1
A206T
intron–exon
macrophage
disease—especially
chromatography–purified
.1326
0.5–2.0
.Diminished
MDS.19
P6522
HBV-positive
CPH
H147R
SPOPMATH-substrate
gland-forming
Anti-pErk
first-cycle
proteincomplexes
Pik3r1-null
ERBB2-negative54
phosphoSTAT3
9.55
.Pictures
Eya1
HACL1-COLQ
.PIK3CAI391
cDNA-transfected
TRAPP–GCN5
adenoma-carcinoma-sequences
shA673-B5M3
C2755T
.Interstitial
p.R718
​Somatic
Mxi1−/−
en~u
7·5–24·6
HNF-1α–deficient
Fast-Flow
L-
4Cardiac
remodellers53
188
TERT-altered
phosphatase-deficient
ACN
82,479
33/38
SDS-Proteinase
phospho-PDGFRβ
Am-Ao
pre-release
Arg1275Gln
0.0859
p.Thr620Ile
R173P
Fraumeni
WT-CBL
003131
inositides
pyrazolo-pyridine
c.904–1533
lightface
IPA-identified
sc-7221
frequency*
SFRP5
p27Y74F-T198A
.1A–F1A–F
Ras­
MFP
pLI800
a-actin
K2049-1
WO
ofPDGFβR.22
Madin-Darby
.Demonstrating
history,34–39
RasN17
TCTCTTATCACCAGCATTTTTGAGG-3′
.Continuous
35-38
Ileum
N–SH2
4×
direct-readout
100–110
1.09–5.10
WHIM4
P–O
non-processive
case.edu
α-Helix
GISTsIn
resistance–conferring
N8080234
SNU-484-LPCX
www.interscience.wiley.com/jpages/1059-7794/suppmat
SNU-761
rs35550267
D2Jau1
kinase‐defective
cancers,19
LOF
−3.94
BRAFV600E/L505H.In
4.2
forprogression.Summarizing
R1150H
learning/memory
family60
Hnf4a1-6
p.Arg258Ser
Alepee
.NOA-04
B.L.W
JAK2/STAT5/Bcl-xL
-Phase
3.06
.HPRT
myc-A
Cramlington
no.1
8·4–NE
sub-type
Ile8
protein/lane
Gene-dosage
NER
ss4388499
97.2
23,27,28,29
Grb2-Sos
LSAB
129/SvEv
E52DEL
Monney
Machine™
1p31.3
–124
SHH-driven
ICBP
erlotinib.14
SequencingAnalysis
α3′
5′-GCTCTTCGTCATCTGACCAGCC-3′
S100B
.H446
side-specific
455–822
MAGI3-AKT3
5.0–16.0
UV-cross-linked
slideSchematic
valueplusminusstandard
p-interaction=0.45
0.52–210
EZH1
HSP90A
pT3pN2aM0
prophase-like
A_52_P558401
www.broadinstitute.org/cancer/cga/chainfinder
p-fluorosulfonylbenzoyladenosine
Ckap2
.Point
.E–G
.Infants
p.CEYCFD-to-NAAIRS
Thrombocytopenia
'excess
52Expression
Rpl19
mutations6
1/236
.TIS/FUS.ERG
SLC34A2–E4F/ROS1-E34R
PDGFRA-CDK5RAP2
TetOn-K373E-CHK2
2-5-2-2
Falchook
hilar
16–66
P2-positive
1−200
CRABP2
563-849
GCAGCTGTTTGAAGGCTGGAT
PVR/VERs
pBabe-Hygro-E1A
MDS.10
L1977F
deletional
hypoketotic
pCMV-K-ras
488
SMARCA3
stressand
.PALB2
32±5
0.001–P
estrogen-occupied
elfin
ofalternative
.Defects
e25021
CtBP1
MMS-101R
Q79K-PH/WT-KD
α1–α3–β-sheet
.Me
190182
Ivisual
Darnell2
.IL-6
Lys141
Kupffer
condensate
GLUTag
485H23
hemi-homo
K1324
pericyte/vSMC
potency70
non-founder
Hs01060648_m1
cgh
2-A
previously9,10
HAT3.1
Microarray
wu7/wu111
myocardium
41-45
HNSCC17
54.3
negative/dnFoxO3
1545
I.However
0.168
polyinosinic-polycytidylic
91.0
ARS853
helicase/ATPase
F187
G601V
immunopurified
M1043I-
P=0.0894
ACVBP/R-ACVBP
CAF26
J710
5-P3
LSL-N-RasQ61R/Q61R
ZNF3
6/35
-633-conjugated
≈60
−29.8
5′-GGGRN
LUCA-15/H37
K-2
RasV12
K42M
KWTAPEAAL
SKM-1
Craniofacial-SeverityIndex
calcium/calmodulindependent
synthesis97
71.47
0.503
μM.49
thecoding
6410
anti-Tyr653/654
p.S1
L701
dose,19⇓⇓–22
HDSN845-848R
ATGCTGGTCTGCCGCCGTT
thermo
.Zou
.0590
213
.IGF-I
AXL-targeted
breakage24,25
AB_10695538
pY721
GCLLSG
.Articles
peroxidase-coupled
p7otrk
redox-inactive
Syto60
MEKis27
WH
-transferase
Col2a1-Cre
11–65
5.123
β-MHC
pIS-ERα-1-WT
Molitor
nonpathologic
.Measurements
.Knowing
Y1253
1,404
300,341,259
NCT01639508
2,432
CK18+/vimentin+
p.G305V
11bp
L330H
120h
E2284
CA630
340Â¿
aminopyridine
pBABE-puroERBB4-JM-aCYT-2HA
.ResultsOther
LKB1
4/6a
0x
11–15—with
EGFR-P
radio-resistant
Smad4/PTEN
5′-GGGAATAAGTGTGATTTGCCT-3′
~900
cross‐linking
M23066
M/NK
distin
V3-20ii
protein.39
TKI-pretreated
small-sized
.NO
.Traditionally
75±31
+NGF
Sulis
PDGFR-deficient
nontransmembrane
SNRK
nucleus.MKK1
vacuole
Arlinton
.G12D
MCT
chemotherapeutics,53,54
£L
2
UMUC10
demethylation30
5p
self-antigen-induced
RABL3
1480
Alu-Alu
p.Indeed
Wnt-responsive
8321
7S855t
1−10.0Full-length
∆∆Ct
failure.102
ETV6-TrkC
0.83–1.49
Met541Leu
CP-724714
dasatinib.At
34-3
DS-bla-084
C29F4
HUN
misexpression
GSE16619
name-sorted
mAb31
non-reversible
.Hprt
EGFR-E21F
68878180
E152K
disease.6
PR48
Aviii
CIC-negative
21,13,14
CMA301
isoform-signaling
Bim-induced
p.Glu14X
R.L
G355V
ATG-translation
T1561IF
EWSR1-
Vitrogen
PF00299084
Szudek
1.1±0.1
.CIC-DUX4
E5
.SVSs
models.36-38
2000bp
FBS/mTPO
Nur77-/-
Met54.4
Ras/Rap
S453fs
codons.32
CCCGCTGTCTTGGAGACATTT
EWS-WT1
G.A.B.
Patj
FOXP3+
toform
GTCTAGAC
S6,7
p.E490
~unaffected
2532
–16.4
correspondent
S492R
cancers26
3994
T348
R901H
Speci
AA4345-4363
169/200
CAAGTTCCGCCACTGAACATTGGAA
article.Table
S4c
.ORAOV1
Sequencher
.Restricting
-0.4
NCI-sponsored
immunohisto
.Photos
99.0–2.80
tumor-repopulating
ATTCCATGGCAGTGAGAAGG-3
00256
Izeradjene
p.A598_T599insT
28E1
CK8
derepress
Mutation–Negative
TreatmentA
H-1437
trifluoromethylbenzamide
heterohexamer
p=0.5556
2breast
Neu4
FLT3-ITD/WT1mut
18.31
Namaiwa
D556
Tyr-CreERT2BrafV600PtenL/+Ezh2Y641F/+
0:1
4A-F
Idh1LSL/WT
-Y35N
Signalway
Gumbiner
TACCTTCATTCCATTACTGG
NCI-H620
4•5
MITO+
15.2+
p110-activity
NM_007439
TSC2/TSC1
-234/-40
.Hilbert
390X
5′-CGCGTAGCAGTGTGAGGTAA-3′
CT‑guid
cells.TransfectionsThe
72-hour
H648
-chloromethyl-2′,7′-dichlorodihydrofluorescein
60/101
Transgenic
pl20
5′-TCTTGGAATCCAGTGGAGGCATAAA-3′
6-hour
cryocrystallography
tumours7
212238_at
AF5
SP5-II
CRL-136
XFKH1
10–21
BAF200
proliferationTable
KKEEEEYMMMMG
M375
9.96
cell-specific
5–15
Tris⋅Cl
non-DNA
-GGGAA
pcDNA3.1_MLH1
45.54
0.2246
Expression—Endogenous
p27/CDK
4/54
DRBl
auto-inhibits
c.2191G
50mM
VectaShield
Br53
0.000005
T199
57.48
.158,159
208305_at
IFN-γ–induced
histones15
BrdU-uptake
Buriedness
ERK-1
S.O
Vleugel
5′-ccg
TAATACGACTCACTATAGGGAGGAAAGCCATACCAAACGACGAGC
GGGTGGTTAATTTAGAGTTTCGAGAGACG
hormone-inducible
pax2.1
pUAST
blotIntroductionA
N-glycosylation
5′-GAGAGTCTGGACACGTGGGCATTAAGCCG-3′
214–279
GSK2849330
CJW
MPCEWS-FLI-T2
FM7
Ser37,27
to0.19
dlc1
.546
Loh
apoptosis.21,22
Ph−
Brachyury‐binding
850-kb
non-migrated
BZ-8100
.Enhancing
GTGATCCATTGCAGTGCG
LINE‐1
Pre-treatment
S619W
exons1
IMT158
convolved
p.R2450*
3051
mutantsthus
13.1
tuberin.21,22
1760–1863
GPC5
1944A
TBL1XR1-PIK3CA
Rasbard
Bellusci
hydrocortisone+10
D258N
4-wk-old
HBV-associated
non–FV-PTC
PYEARS
hair-bearing
.VCS2
'251I-anti
EP1674Y
CGCGGUAUAUUACUGCAACUAUCCU
TRA1
140,141
immortal…
K5
byWestern
Cullin-2
5V-gacacctagcggagcgatgc-3V
.-ERG
lattice-forming
FOP-flash
ACGCGGAACTTGCCACACGTGC
mg/6
gly-A
TheARID1A
ETV6-SYK
M96T
C1396
.Lentivirus
K562.8
escargot-gal4
22,39,40
neuroepithelial
32.48
L-Gln
Reactionswere
on-
ABL1.89,94–106
multiple-site
Fig.33H
BCP-ALLs
Neuhausen
charcoal-dextran
Brunin
BORR
EJ-ras
Mateyak
delEx1
thiazolidinedione
3.4414
bAllowed
Sakuma
epoxide
H3K4me.110
AF295024
E.A.B
59-GATCTATTTTTCCCTTTCTC-39/
FGF-specific
1.4:1
40,000
hormone-unresponsive
SBE4-dependenl
GCATGGCTCTTATAGGCACACAGAGTTTCTG-3′
Pik3cae20mwt/e20mwt
1|
871–873
.V600EB-RAF-bypass
orientatioin
p53TDs
P-GSK3α/βS21/9
Brown/Hazel
GTGAACTGGATGGCCC
2p16
Gorlich
CTL‐mediated
5.0e7
//www.infosci.coh.org/mdm2
adsorption
69304
Bartusel
suprabasal
non-methylated
glycosylation-deficient
mitosis3
Glu279
c.1159delT
P=0.0043
Smads2/3
single‐agent
thirty-two
254–311
hIL-3
.Anti-CD117
β-cells
right-upper
RapaLink-3
anti–Jak-1
8,21
ras-genes
c.2707C
TGF-a
.PML–RARA
GeneRulerTM
miR-194/192
Nft+
7.View
.T47D
PCRwere
bioavailable
Q31K
D-box
anti-p-FGFR3
T599
rheb-dependent
vitro43
​and4
mCdk6-Reverse
adriamycin-stimulated
v2.3.3
MENX-affected
0.746
.Induction
dose-corrected
14–23
/dsRed-positive
B4GALNT1
5′‐TCTTCCTCAGGATTGCCTT‐3′
L792del
P=0.32
z-scored
R408C
ash2-RNAi
NECDIN
pY396-LYN
cell-autonomously
630–659
TGGTACCCACTAGACATTCAATAAGC
2.304
-GTGCAGGACCATTCTTTGATACAG-3
hydrolysis
hypertriploid
VITRO
1593G-C
RBD/Ras
Mock-H446
±11.6
F.II.1
stromogenesis
Y553_K558del
488K
–CUL1
Lievre
anti-hSNF2H
12–20
Miled
HUCH
conditional-null
XB
pVP16Rhophilin
phospho-p38γ
¸2.5
ESR1-Y537S-positive
anti-Gaq
BRAF−/−
1.0mL
.Carol
KITD816
antigen-retrieval
R1945C
-GCAATTGTGGGAAGAGAAGGGTGAC-3
R.J.G
References∗
4.670
elsewhere.29
8.75
mutation-mediated
isclearly
P180S
KIT-V560
DeltaNp73
RMSDs
ACAGGGCATAGCCCTATTGA
06800
independence.16,22,32
Immunobloting
APOBEC19,20
684
Δ551
3.2.6
MKK2
propionate-2,2,3,3−d4
F/70
.Acid-extracted
NFL-c-Myc
I-3
MPL515
,26-30
5A–F
.676G
uMeach
PYXXQ
urinary-methylhistamine
-sample
PIK3CBmutant
Li-538
9.7–10.0
domainby
CGT3TGT
Fig.22E
HGU133P
STS
TOP-flash
QRT-PCR
exons/20
501-Fc18
~400–600
pathogen-free
DN-like
sc-5546
F958C-positive
malignancies.19,20
3þ
GWAS-identified
RP11–535A5
mutation-insensitive
melanoma15
K2950N
pathway-
CGH-smooth
TCGAGGGTCGAAAGAAGCGACGACAAGTTGAGCGAGCACCTG-3
51402007
Arg112
3·5
loss‐of‐function
JCR
mass-spectrometry-based
epithehal
./-/-/
gains139
5′-ACCAATACCTATTCCGTTACAC-3′
.U
3EQG
controls.4
cases.Variant
CD34-APC
sc-20733
−5.28
Swiss-Protein
normal.26
rs3208856
acid-activatable
Onyx/Bayer
Wolf-Hirschhorn
Ikk2-mediated
H55R
5CpG
ualized
high-expressing
2,295,239
p1.5RXT2
ab57311
5′-CGGGCCAA-AGTGACCATGAACGATTTCGACTATCTCAAACTCC-3′
NF-E2
Noji
NOTCH1-induced
4,476-bp
.343G
Mut469
AY033606
X1-24
breakpoints15
mcf-3
551.3
EGFR–targeted
tumors.58
North-American
Clinico
85,000
A1752PF
1,2-dioctanoyl-PtdIns
doselimiting
i.e.
Y705F
.Detection
HGSOC.8,42
folylpolyglutamate
31.5–42.1
FTA
leu2–1
al26,41
6.009
hTMNM
CD74–ROS1
D41
K424R
A127G
.GI50
0.425
Z60
cases.DiscussionWith
Lowenfels
5′-TCCCTGGAGATCCTGTCTTC-3′
5′-CTTACGCUGAGUACUUCGA-3′
E/I-3
F1174L-mutant
p115RhoGEF
Fig.4a
signal-log-ratio
c.306dupA
clusterin
20733
G776S/G778D
.NotI-WWP1-R
∆∆CT
BRAF/V600D+FGLAT601-605ins
character—show
1/500
distribution111-113
semiconductive
LKB1-wild
NCT00717210
30–33
effects.9
−2.17
TpT
–multiple
221–234
WHO-grade
5′-NH2
KIT-positive
GGGCGGCGGG
86.0
SRF-mediated
–28.6
ATTTATCTGCTCTT
512–653
.RT1
19pl3.3
≈24
MO-nrf2
Kuczyk
c.118C
G57
T63
Fig.7E
resolution.4,10,12,15
mutations.9
M504V
12-96
oncogene29,30
—also
GenomeAnalysisTK-1.2-58-gc1329c4
.Jak323
D87
shPLC-γ1
CBFbeta
p.N597T—are
excessdouble-stranded
Touhara
ETV6-RUNX1-mediated
RRB1
TH/MYCN
SCC17B
4ST
β-Cells
0.4–35
mice.27
misunderstanding
Isselbacher
Dnmt3a/c-Kit
schedules,2
GOLLA
.High-fidelity
cancers20
MLL-AF4-expressing
melanoma.32
1:150
Gonadoblastoma
FLT3D1–D5–FLT3L
NUSAP1
**d**
.Sonicated
D2–D3
5′-TACAGGATCA
Ex13-F
25-year-old
AVX901
cell.3–6
pMiw-Fgfr1N546K
RAS–RAF–MEK-ERK
pDM2-LacZ
ng/ml.Whole
home.html
kDa.14
M581I
24.20
pre-DN1
28-329
trastuzumab+lapatinib
Postganglionic
CD45RA+CCR7+
13-15-26-A-8-A-24
48-hr
.190T
NM_005026
TCF4-specific
U/μl
Challagundla
Tumor-type
IYI
majority-vote
L1564P
p.Pro534Leu
1265
demineralization
MTOC
5μm
KKKPTPIQLNPAPAGSAVNG
states20
CAG-CAT-Q510E-Shp2
Anti-VHL
41.0±7.4
D404GTbRII
wild-type–expressing
visualise
M.R.S
FRS2–SOS–GRB2
65-95
zlj9991036390003.jpg
FIP1L1-PDGFRα–transduced
DOC-TRAS
primer-extension
mutations71
microsomy
.Delayed
CBF1/Su
inappropriately
62-66
Tg.26
p.Arg150Cys
thrombospondin
weretherefore
.Tet
EIB
nl-1
range=1.72–7.34
HER‐2‐containing
ERK1Y81C
ng/μl
−T/L/H
ySet1
.RT-PCR–SSCP
Reagents—Cell
AGtt
/highwire/powerpoint/42290
‑120/+4
30•31
lines.The
BL107
immunoreacitivity
character.12
M1043V
level.5
www.modernpathology.org
AHTakt
AMLCG99
P81
zer
MRF4
±standard
HNPCC-Like
P3/P5
Cdk4-mediated
CCTCTGTGCTGGATGCCCTCGA
NP_203524.1
1166insC
K351
2LKZ
PC-γδ-PTCL
C91S/ΔHBM
100-kilobase
4472395
R273P
α-loop
5′-GAGGCAAGTTTCCCGTGTTGACCAGCATTTCACTA-3′
rare.2
Cullin3-based
MiniprepDNA
anti-HA-agarose
Categorization
YF-
€
FEV
.From
half-site
Voena
micro-molar
repeat-containing
SectionInvasive
MouseChick
microarrays13
wu38
FigureFigure1G,1G
NPM–ALK
MutSα-A834T
3.57943
betweenmutants
p0
744A15
Energie
E224K
HRECs
Polysciences
51-year-old
1734
RCAMO
ESR1/CCDC170
caveolae
PI5P-and
Charite
Leu348
codes•
proteindestabilization.Deletion
clinic.10
.Voron
rserGl
PCR/MiSeq
neuroblastomas.Cancer
STI571/Gleevec
GNE-692
561-nm
TENN
Villa-Morales
HEK293-WT
unquantifiable
microfoci
93-58
0/15
HER‐4
S210
Y137
CS.9
group/mean
S7L
S140N
H870Yc
puncta
proportion-like
re-initiation
ADP-binding
Gel-filtration
3-basepair
Schwann
pBABE_EGFRWT
pS2—Fw
CCTCC
amplified33
WTX
break-
Stem-cell
400–450
chr22:40003155-40184294
leukaemia-initiating
sc-965
E/P
MAPK-YT
NaCl–1
Tyr321
wild-type–independent
chr8:134441414-134442401
methylazoxymethanol
II–III
Gr-1+/Mac-1+
IV.2
PLC-γ-defective
Tris‐HCl
IL-6Rs
S53342
FISH-obtained
2Df
Ras/MAP-kinase
5′-AGTTGCAGTAATATACCGCGGAGC-3′
Zucman
357A/390A
Osornio-Vargas
19K
with/
Fig.5,5
H846-R865
HA-11
expressedinefficiently
substrate18
Grisworld
P379fsdelCC
re-challenged
Shaulsky
CDK6-GST
syndrome–like
17.33
sequence8
59RACE
v-myc-expressing
Microglobulin
FERM-SH2-pseudokinase
Ready-Reaction-Premix
.Too
MSCV-PGKneo,25
CD74–E5F/ROS1-E34R
50–70
M517
NEC-1
presum­
18F
cafe´-au-lait
353,362,403
4893T
68331826
CCarcinoma
-shControl
autophagy30
R161Q
DNase-hypersensitive
AAS
YAP102
61-065-RO
followingidentical
6–20-fold
.G12
THSD1
α-Lkb1
5211
BID007
anti-phospho-FAK
¸90
Myc-Dnmt3a/Dnmt3a2
924GrT
NP_075259.2
C‐loop
TGF-binducibilty
ÃŸ-catenin.Inomata
HRAS.22–24
.Mst1/2
stage-I
populations1,2,3
nonfunc-
p53RE–DsRed
definitive,28
200x
depletion.4
SLC1A2
HA.Gene
26557884
1393G
c.1565A
Electromax
.Outcomes
500-ml
recombination-DNA-repair
GIST.26,107
208892_s_at
FGFR2–BICC1
activity.21–23
nucleus-cytoplasm
p190-related
CSC-mediated
.p53
DiffExprOutlier
twice.9
Tokuyama
1186G-C
AlNen
indisputable
Flag-positive
118K
L618/M623
CAL-148
8repeat
type-liganded
-T202/Y204
Q24
RIN1
NSC
22q12.2
.CEP110
LA-N-5
pEGFP-VHL
disgerminoma
Myeloproliferative
AG/GT
schizophrenia.141
11/39
GTTGGTGCGGAGCTCTCGGTAGTGG
TGF-βR
shortfall
5'-TTGAGCTGGTCAAGTTCAGACACGTTC-CGAAACTGCAGTAAAAGGAGTTAAGTCCTGACTTTGTCT-CCAGCTC-3
InvivoGen
B2222
Tyr1467
≈247
.MDA-MB-468
AA135289
site.9
600×
twodifferent
infobiogen.fr
OPLS
0·053
cysteinerich
themean7standard
TCF3–PBX1
contain­
non-pathological
/nat
Perbio
Apoptosis-competent
T-cell–specific
methacarn-
oruntreated
p.Glu533fs
fluoroscopically
Alterna-
Hybridization
Jak/STAT3
NDUFA1
136,137
Immunohistchemistry
L22E/W23S
NB88
D1810A
MSSE2,4,6
Thr/ACT
SG274
HA-Shp2-SUMO1
cancer.17
Smad4C294
Lipkowitz
inheritedRUNX1
82–93
989,000
Noesel
/MLL
259348
transposon-dependent
DEF-domain-interaction
n=110
Fluoruracil–treated
5′-GTCAGGCAGCTCATAGCTCT-3′
D502E
YdNoYesYes
Fgf10
GST-FHL1–3
XPE/DDB2
Man18
manner.44-46
N°42
NM_010284
P246L
6.145
CFE
Mmp9
Thr-2294
dominantmutations
6,893
3832–3837
models5,9
−2.51
phosphotyrosine-specific
p.Arg561Cys
P42A
GC1
Pa/512
oxoglutarate
.TFIIF
Ohue
L100V
IU/m2
AlkPhos
differentiation32
Anti-PAR
locations19
425-600
ARID1A-induced
Collisson
WBC=white
rosiglitazone-induced
doi:10.1006/bbrc.2000.2841
587,498
4EBP141,142
A159V
.1888delG
76y
activation21,22
T2515I
RHOA-GDP
Mm768bpΔAGAAAR/ΔGGAA
Ser1210
permutation-derived
Sck
MSTO-211H
polyacry
.Cytometric
7762
inactive.14
p21+/−/TRAMP
L196P
GTPgS-loaded
FAM-TGGAAATAAG­ATCATCATGCC­CACTTGAGAC-TAMRA
21,130
E31K
NCI‐H1781
1649–1736
-defective
DED1
His926
pCMV10-Flag
LDcHL
S364
intra-lesional
fashion19-23
T181A
*c.
.5C
ab46540
S599Q
rs28384375
CY5-dCTPs
forty-four
LCLC
jet-PEI
p.Leu65dup
IL-13
CEYCFD-to-NAAIRS
BRCA1−/−
CromRCC
Cancer-causing
myeloma169
PRC2.8-10
SSEA-4
fusion29
tional
NEO-transduced
Glioma-bearing
5′-CGATATTCCTCAGGTACTCC-3′
T7–oligo
RNA-ISH
sc-7020
pretreated
anti–Melan-A/MART-1
Macabeo-Ong
77845
16,19,23,24,49
.4F
∼3-
Mg2+-dependent
Firelfly/Renilla
CRC98
tumorigenicity.17-20
HER3-driven
I1802
10,983
receptors.8
S-adenosyl
T1940C
LAG
H396P
EWSR1–YY1-positive
pGSK-3β
.B43
ActN1-infected
ARafDDCAAX
ALKT1087I
.ROS
www.asterand.com
Na/No
inconceivable
MMG3
p21-
.G–I
1835
155273L23
T338M
IP/Akt
PRKCB-inhibition
IIGF
model-phased
R2/ATP7
previously9
11q14.1qter
molecule.13
gonadotrophin
MODY6
76-year-old
27*
CD16/CD32
Mapreads
8050-bp
cells,23published
ERK1Y81C/
Weisner
pMEK-1/2
24776
NR4A3-containing
sixty-eight
metastasis-initiating
c.58G4C
V89/CC
ntroduction
P261S/S621A
CACGACGTTGTAAAACGACTTGCTGAATTGGTGAGCTTC3
glioblastomas.10
1.View
Sca-1−c-Kit+
node-negative
Diyana
F151L
c.3788_3790delTCT
.Bronte
.High-molecular
HA-TSC2
11/46
vitro.52
PMM-deficient
T248_N249delinsX
ysAspGluGl
PD162
CPT45
exon19del
BTB-BACK-Kelch
n=710
FLT3-N676K-ITD
B7.3
cells.35
Juxtamembrane
86.59
p3k-induced
7-hydroxylase
KMT2-family
5FU
PI-90
JP1536
RAS-expressing
functionalTRK-T3
HER29
Makela
9146
Leu19Phe
blood,12
80.4,5
Elbein
AluSz6
previously.37
NGGCTs
p.Phe1218Ile
•Attenuates
.Custom
domain34
approach.29
Ctransversion
R348∗/Cdc42/Rac1/MLK3/MKK7/JNK1/JNK2
.S37A
pCI-ML24
Luccarini
pCDNAJ
TrkB-transfected
accumulationof
SJL
METHODSPreparation
x3
Chr9–187
intrinsically
_D_NMT3
GST-p53
Mickelson
tumor-stroma
G503
conWrmed
Facolta
non‐Sptizoid
interactions.27
ABL1-positive
W118R
D418E
lestaurtinib—but
metastasis/
RP11-153M24
Apc1322T
translation12
Wnt5a
XPO1C528S
ERK1Y53H/ERK2Y36H/N
Dowrick
B-5-1-2
lineage,2
Ex12R
Pagenstecher
predictions—after
level.The
chrom18
CustomSeq
ACL4/FBS
A–H
G35D
1.061–2.472
c.949C
PTCH-regulated
Rheb-GMPPNP
individuals.22
Avioli
hyperelongation
c.1474A
co-repressive
BCR-ABL1−
0.7186
RAD51D-mutation–positive
R.K.
genotype-adjusted
concise.maf
patients,32
5′-CCCTGCATGTTCTTCCACA-3′
cases.11–13
globocan
PD3
P39
c.374_375delCT
TPM3-
GIn61
Tahirov
funnel
.Site-direct
N1185
crypt-columns
No.1
acetyl-transferase
.Anti-phospho-STAT5
8/18
transfectedby
YDLKWEF
Precore
151-193
189,980
air/10
positively-stained
Hebsgaard
mutants/RTK
MCL160
D387V
PHRC
pAKT-S473
TUJ1
LRP
E2-DNA
non-overexpressing
1,000-
miceCrosses
toestablish
p.M918T
RB-E
cystathionine-β
fatigue.28
RUNX1-binding
AML.15
H70
growthAnchorage-independent
bronchioloalveolar-type
Ser1248
.07a
D110G
X-chromosome–encoded
2.53´105
Q71P
21June
.Alanyl
97.8
CD11b
P-0005355-T01-IM5
Hachitanda
/3-phosphate
Na382
JE6B
Grieselhuber
mutations67
assemblies66
L330R
mAR-V1–4
TAcloning
variant.28
gain-of-­function
activation.16
anti–bcl
c-kitmutants
22:151-153
leukemia29
767C
R420A
MYC-positive
B-Raf/Raf-1-deficient
.Center
PeakPicker
13-day
SID-2
Multiparametric
5/47
HR-deficient
Chou-Fasman
0.5236
ALK-deregulated
MEN2B-specific
Flo-Jo
rTRcv1
types24,25
86-29-83373974
T172
PCa_ETV1
Groudine
734-647-8153
significantly.22,23
Amyere
Q264
10A–D
R306Stop
carbonyldiimidazole
transhydrogenase
.Exonic
WM1361A
WT/G1125A
C/EBPβ
143.51×
-3′
under-expression
dATP.Binding
5-GCTGCTAGTAGAGCCAATGG-3
M536I
binding132
benefıt
191K
leptin12
0.036/100,000
OR:0.51-
GC23,24
In-
studies5–7
.Loss-of-function
5-bromo-2-'deoxyuridine
self-applications
NCT01028222
Ser523
suramin
DHF
24/34
Bonferroni-corrected
778–780
charcoal/dextran
3.08×103
NG15
immunostainer
couldacquire
.Lipids
federica.dinicolantonio
MICROARRAY
p.Q79L
cellpellet
immunocytochemically
0.00008
hRAD54
Bgl2
G810Sa
RP11–488L1
D3S1597
R175P72–74
respectively135
Mesothelioma
EDTA-based
p95ERBB2
exceptfor
EWSEIAF
CTGF208
dysregulation.14,21–25
1p36.33-p36.32
ACVR1-WT
D.M.-Z.
Co25
HER2-activated
.4662G
P-40/20
pro-NOTCH1
Theresults
crizotinib-unrelated
Yki
99.969
GSTM1
809
241–462
∼47
335–430
AML/MDS/Evi-1
78/NA
MDAPS
786–0
.S8A
K416E
1/8
-strand
lrseg
c.3337C
MnCl
5′-GGGACCGGCTTAATCCATAG-3′
radiation26
years.2
bicinchroninic
TLVM
GCCCGGTGCC
serotype
EfficiencyAbbreviations
BLK
speation
EIF3C
antagonistically
1675:1
TGF-β1-responsive
6/4
S34F-mutant
1,268
p.T58I
Trans-Repression
Thr790Met
i′
V272G/M
Heineman1
craniosynostosis.3,6,7
SEC31A–ALK123
Molecular-targeted
J016
Transfected
flCγ1
.HERVK17
586
BCORL1
.Whole-Transcriptome
23-nucleotide
G110V
genes.33,34
–39.6
analysis.17
12-29
preeclampsia
CALCR
947
1.5-4.1
μl/dish
92:194–197
SDF-1α
basal-level
dicroism
DNA-mismatch
SHEP21N
pseudo-first
miscalculation
inhibitor-naive
BACH1,8
7/4
Pc=0.01
17q1
Glu78
L71Q
1A/D
clone-sc338
contransfected
itself.57,87
Ligand-binding
BaF-N
HA-TGF-βR2
comigrate
1–300
4615C
p53,31
Ena/Vasodilator-stimulated
p≤0e0
Maixin
Mx1-cre+
5-AAGCCCATCGTAGAGGCCCCA-3
6.2-8.3
neighbor-based
Goorden
TCPTP
DRBI'04.Xb
-24
2.3.1
non-competitively
family-wise
.Lethality
PDGFRI
IgD−
Bochringcr
streptavidin-covered
CFP-CTLAGlyThr17
18–22
Buetow
PDGFβR-dependent
mastocytosis.32
lo5
MiniPrep
0.2°/sec
condi‑
immune-surveillance
R438L
-2102
2603
3′untranslated
.EGFRK721R
Val769_Asp770insAlaSerVal‡
-12.7
41/CRC
.HA-FANCG
4B10
D842
rapamycin-resistance
PTPRs
.N.s.
bglycerophosphate
features.181
5′-CTGTCCCCCTTGCCGTCCCA-3′
colonoscopies
c.1677_1678insA
.ATRX
linker-p53
K252
68,758–72,236
p.Glu218Lys
18/292
checkpoint.Figure
99–135
EDA-ID
retrovirus-transduced
5′-AAGGGCATGAGCTGCGTGAT-3′
.Histochemical
P-selectin
shChk2
MTA3
pG8
SAR
1c-h
.Biopsies
metformin/phenformin
Ser221
-1.73148
Arg1835
PCNA+
Hyper-mutation
post-replicative
Mulrow
Fig7G,7G
TACC3ex9-RV
Y2174L
E-MEXP-3997
TRK-T1oncogene
Val506Stop
changea
Na-Deoxycholate
tique
therapy-resistance
25-95
examined.15
TGGTA
FLAG-Rad53
TDT
MgCl
p.S214
blood-brain-barrier
.Dax-1
thrombocytopenia22
48.9
EZ-CHIP
ER-marker
GSK-3β-
large/GCMN
c.697G4T
K-ras
log-relative
4HJO
semiselective
−22
variants.35
Pin1-depleted
Calbiochem/Millipore
18:0
genes.17
EGFR-G719C
DDX5-ETV4
0.01–0.03
Fgf15
M38
Rho-kinase-induced
SF5
specificity.12
.DUSP6
M1628TF
MultiExperiment
FLAG-affinity
05-516
GU
MTX/ASCT
ATTGGGTGGTTAATTTAGAGTTTTGAGAGATG
4,26
IL-3-mediated
GAGGGGGGTG
kDa-like
10W
IGL-CDK6
Ochiai
HMG-domain
517
Thr252
quadrupole
Treffers
.MED17
RET/C634R
1.8–13.2
long-read
.Byrd
P225L
echo-guided
non-significant
5221801
CUY5
F-statistics
10−18
Stereoview
I5
SLP-65
paucicellular
Three-micrometer
syndrome,10
Jaksic
pTRE-tight
490
methodologies
earlierin
ESRP1-CRAF
GGCCACGC-3′
5′-CGCAGGGCACATCCAACTT-3′
IL-17-producing
ATGCGATCTGGGACACAGG
variants—differences
recombination-mediated
tonsillitis
1,045
6595
13INSERM
Q61.3Hb
6–22
proline-glutamate-serine-threonine-rich
45.48
-ROS1
-catenin.13
+O
Lynch.5
non‐polyposis
R718W
.Is
//doi.org/10.1371/journal.pone.0005137.g001
340.6
shTet1-a
microphthalmia
caspase-activating
W2248C
Me2SO
L858R-L747S
PBF
5403
OCI-AML5
TAATACGACTCACTATAGGGAGACCACCATGCGGCGGCTGGACGAGACAGT
described.20
vector-transduced
2-megabase
5¶-TATTTGAATCCCCATTTAGCAGATAAGGAAGCTGA-3¶
CTGTGGGCCATGGCT
hyperactivity
family.Deletion
PSA/β2-
.AI
0.0209
mg/mE2/d
//dx.doi.org/10.7554/eLife.14709.010
pRNDM
Comparison.a
isocitrate-dependent
Monoclonal
1992–2000
2.5×109
Profuse
HLA-DR1
.1321155111i12
molecules11
Figure6C,6C
RNFmut
0.169
.endogenous
and…
Hippocrate
clonescontained
Parametrial
5'-GGACCCGGCTCTCAGTGCT-3
JH6-7
F786
L34A
BCR–RET
A_51_P170807
Hirano
−441
Recurred
N550H
cucurbitacin
WD-40
.PDGFRα−/−
whole-genomesequencing
analysesrevealed
ensue26
0/158
factor-β1
0037
dimer26
immunoprecipitationof
latterreagent
Tubby-like
4508A
G212R
L792Pa
SCA
165J16
5′-GAAACACCGGTCACCGTCTGTG-3′
T37K
helix-loophelix
ligase-dead
52/116
forms/blasts
Y579del
Immunoblotting-For
.Exoribonuclease
gatekeeper.
anti-integrin
6-diamidino-2′-phenylindole
erythropoietic
HeLa-ERE3/EBV
565/430
FP7
T7-Pro
thermalization
10,19,24,26–28
Amano
Polygonal
His93
tumors6
P258
Kras+/LSL-G12DPdx1-cre
U/PI
E805K-expressing
AOCS
sc-418
40–48
28•29
FBXW7-WT
Cdk4+/+
341
Y654KD
Smad2f/f
C_
granulosum
BioMek
0.0037
Bronchioloalveolar
small-caliber
D538G
G112E
252–256
293-EGFP-CtBP/Dox
02
MPD.36
2239
bInteraction
.ARID1
I-BamHI
tgtcaagctggacaaggacgaactggtgtaatgatatgtgcata
activity.34
management91
volume/growth
W3654.50
20p+q
Agilient
AKT1-PH-EGFP
Ektachrome
91320
SX
5-TCTATGGCGCTGAGATTGTG-3
elec
CEP
MyD88-IRAK
−3.99
TOR2
dedifferention
hMECs
Ubiquityl-histone
intra-exonic
Asp630
found13
AKT3-specific
WBM
WWOX
tumours.2
transformation.6,17
ETV6-TRK3
.Microsatellites
.FISH
98–912
H3K4/H3K27
anti–Stat5-b
54/F
allele25
del434-6
alteration.30
MAPP-based
0.6562
Thr-rich
TGCCTCAACCGTGGACAATA
NG_015859.1
patient.6
photocoagulation
supressors
allele.18
anti-CD36
bardoxolone
480-fold
Microcon-100
Stanbrough
C820005J08
I181S
38.6–61.4
.c-CBL
mTOR-Raptor
:ADE2
figs.5A,5A
CO2-containing
results.9,43-
RXF393
9p11-q11
NB100-122
.Michel
p-Tyr–binding
XHO1
SLC–ROS-driven
.MPL
BCL9
Acuson
Arg-823
90-95
ClipR-59
tamoxifen-activated
N-methyl-N8-nitro-N-nitrosoguanidine
S-shaped
p.D1853N—have
RNAlater
MedB-1
Ohgaki
Goo
17q11.2-deleted
5¶-AGCTGGGCAACAGAGCGAGACCTTGTTTCTAA-3¶
Helsinki.Immunohistochemistry
128.8
terl
SEColonies
c-MET-transfected
Ross-Innes
myelofibrosis.4,10,11
Goswami
BglIIIXhoI
l322F
RNF43
PIK3R1WT-expressing
.2707C
UPR
model,15
triiodothyronine
V730D
BEDtools54
0.466
proteolyisis
dark-field
B1.7
Myc-infected
systems29
nℳ
c.4185G
H1299/R175H
kT/e
170.
Suk-Chul
13,36
FGFR3Ach
1812
W.S.
TFE3-TFEB
U133A–based
regions46
LPS
V239M
H874Y-mediated
PTEN-G129E
mg/kg/day
Ã§
lurzoprPcil
Plk2-PBD
WNTs10,11
pcDNA3.1-LacZ
phenotype.Computational
Gregorieff
5695.
MMR-wild-type
ERCC5
pTx
.KIT-D816
.Norris
GASTROINTESTINAL
-suppressed
studies.64
Carattere
−3.11
100.50-101.66
semipurified
anti-PUMA
BR-04126
immunoprecipitating
Flk2−
EWSR1-ATF1/EWSR1-CREB1
andshowed
MCF7-specific
P=0.026
tttcag/CGATGT
Asn-X-Thr/Ser
-imidazo
GEF-H1
129-Krasex3op/ex3op
Flt-4
in-series
CC-223
structurally-related
2-78
L323
amplicons
50X
PU5
hivBL
antiRet
start-methionine
60-mm2
pyridinone
cysteine→tyrosine
D816V-c-Kit-negative
WGA-Sepharose
c.842G
ex9
macrophages.23
AKXD
GSE12241
Gab1FF
U-bottom
KLHL9-expressing
PS**
cbl
5′-GGCAGGGACA
‐2‐
H4/
R138C
1c1c7
3.63±0.10
115-bp
cellularity/femur/body
.Nu
grayish-yellow
Apo-2-structure
Hsd
Pten+/-Rictor+/-
C3H/HeJ-gld
K-S
oligo-based
Zyxin
MYOCD
epithelial-specification
Thermosequenase
MDS1-EVI1
6.99
p.Arg200Trp
PDGFRAD842V-transduced
CLw
DPC4/SMAD4
post–C
transmembrane
3'-TAG-5
K-phenol-chloroform
V2.IIA
8/M
accentuate
Rfactorc
Fos11
6-μm-thick
7/six
ofc-myc
adhesion-independent
4.55
trans-phosphorylation.5
n=25/129
of2O
D561E/V/N
5.77
5′-CAAGCTTCTGGAGGGTGAG-3′
-N′-
//dx.doi.org/10.1136/jcp.2011.090498
v.0.1.1616
disulfide-induced
53°C–66°C
disease116
standardisation
MRC-600
MGH
pEGFP-ΔI
68
resistance.2
601Met
.TACC3
alfa-2b26
Dhanasekaran
×109
I682-D686del
response.†Progression-free
.4,12
30,703,763–30,810,239
33433448
R102C
agar145
grossRB1gene
.Evans
7D.2
p.D176N
ρi
tumours3
myoepithelial-like
CCCGCGTCCC
Il7−/−
ADL=2.93
c.589G
Met769
DSP-cross-linked
*Statistically
NM_007194.3
CNstate
p-ERK/ERK
transduced
Maljaars
PIK-108
lines.MCF-7
NOTCH-1-mutated
92,304,395
p68
R834
.Correspondence
foot-and-mouth
A121E
2.73
37-amino
II:7
Highermetastatic
Link+
ectodomain-mutants
categorised
-CD45
BC007333
0.002*
in-phase
AmplificationWe
p.S675C
GISTsClinical
CHEK-dependent
Demory
99T
C_940_a_12
Hollink
Babraham
Figure6F
r-ras
HIF2A/EPAS1
methyltranserase
moderatelypoorly
−2.93
G12.1C
protocols.1-
T49.8
1showed
5242
//www.proteinatlas.org/
Etemadmoghadam
β-γ-bridging
5255
LP95-025*
His-TCF4
M276K
effectene
D417H
Gln319
filterplate
packs/y
genome18
lineage-related
biostatistical
ACAGCACCCACAACCACCAGAA
7088.
anti-RUNX2
E´tude
K-mTOR
pGEX-4T-1
1H4
I41T
V774M
R282/I254R
Arg112His
SCC–matched
BMDM
8966-70
frequen-
Designation†
450
mutation¡/HER2+/HER3+
mut/fusion
www.karger.com
syndrome17
ERLDAQTS
MGC-5172
516.869
chain37
de-crosslinked
0.309
Zz
NHU
46·8–145·1
p=6×10−6
.Rogers
Madin–Darby
steroid-screening
.S1G
Fresh-frozen
V354E
908
1R401H
thisdatabase
∼7.3
SEF99
RCT-C658
tumorigenesis1
Diagenode
Coregulated
non-medulloblastoma
S8-S9A
NeutralityBRCA1
Ezh2Y641F
B.F.
Hep3B
ninety-six
PTCH1-P681L
H2170
Hir/-HhaI
NT_007592
activity.p53
carcinoma.30-32
0.5–2
MTS2-R
NSCL-not
NSP3
pHK101
lines.Analysis
GST‐G15A‐RhoA
1:1,000
vimentin-caged
Contrast-enhanced
.PKN1
3'-RACE
Mandelker
1.3–2.0
Multidomain
CEP110mRNA
0.814*
−1.7
LPS-treated
Jeltsch
allele—in
p=7.1e-3
Futreal
mutagenesisThe
12/101
1157bp
//creativecommons.org/licenses/by/3.0/
glyoxal/dimethyl
transcriptionmachinery.Another
A¡ect
p-AktSer473
SMS-CTR
expression.73,74
932–936
P=0.363
Ishtobi
leukemia.38
level-dependent
/KD
.Clinical-pathologic
V420I
BstUI
Ewsr1
baso-lateral
METPRC-induced
CAATAAATCC
published41
byNheI
26592
Pro379
unbeknownst
Referencec
duplicationp.A502_Y503dup
c.37G→T
ERK2-resistant
factors65
M408V
K623M
malignancies,40
4751–4755delT
YAF2
group.49,50
p.E1554fs
64.49-fold
M01
I-Sac
10-ng
UTP-Li2
polysome
OX-7
Thecostsof
tEulerian
Hilum
anti-EphB4
.Microarry
cytoplasmic.19-22
Pletscher
GFP-BAP1-ΔUCH
1840
non-cognate
MKP
AML1-ETO-positive
PamStation
C1354A
5α1
upfront-verified
Nox4-
Bio-imaging
